20102380-6	RESULTS: Age was negatively associated with free <compound-id="6013">testosterone</compound-id> (r = -0.399, P &lt; 0.001 in 2002; r = -0.458, P &lt; 0.001 in 2007) and <protein-id="Q06520,A8K015">DHEA-S</protein-id> (r = -0.233, P = 0.02 in 2002; r = -0.336, P &lt; 0.01 in 2007) but not with total <compound-id="6013">testosterone</compound-id>, while the 5-year changes of free <compound-id="6013">testosterone</compound-id> and <protein-id="Q06520,A8K015">DHEA-S</protein-id> levels were not significant and showed no associations with major cardiovascular risk factors.	testosterone__DHEA-S__no_interaction
21627143-1	The interaction between CdSe nanocrystals (NCs) passivated with <compound-id="65577">trioctylphosphine oxide</compound-id> (TOPO) ligands and a series of Ru-polypyridine complexes-[Ru(bpy)(3)](PF(6))(2) (1), [Ru(bpy)(2)(mcb)](PF(6))(2) (2), [Ru(bpy)(mcb)(2)](BarF)(2) (3), and [Ru(tpby)(2)(dcb)](PF(6))(2) (4) (where bpy = 2,2'-bipyridine, mcb = 4-carboxy-<compound-id="11019291">4'-methyl-2,2'-bipyridine</compound-id>, tbpy = <compound-id="4249187">4,4'-di-tert-butyl-2,2'-bipyridine</compound-id>; dcb = 4,4'-<compound-id="20094891">dicarboxy-2,2'-bipyridine</compound-id>, and BarF = tetrakis[3,5-bis(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]<compound-id="26574">borate</compound-id>)-was studied by attenuated total reflectance FTIR (<protein-id="Q13535">ATR-FTIR</protein-id>) and modeled using density functional theory (DFT).	trioctylphosphine oxide__ATR-FTIR__no_interaction	borate__ATR-FTIR__no_interaction	dicarboxy-2,2'-bipyridine__ATR-FTIR__no_interaction	4'-methyl-2,2'-bipyridine__ATR-FTIR__no_interaction	trifluoromethyl__ATR-FTIR__no_interaction	4,4'-di-tert-butyl-2,2'-bipyridine__ATR-FTIR__no_interaction
18985232-1	Subjecting furan to <compound-id="5360545">sodium</compound-id>-mediated magnesiation via the new heteroleptic alkyl-amido reagent [(<compound-id="8037">TMEDA</compound-id>).Na(CH(2)SiMe(3))(<protein-id="P54849,A0A024RAT0">TMP</protein-id>)Mg(<protein-id="P54849,A0A024RAT0">TMP</protein-id>)] produces the remarkable dodecasodium-hexamagnesium molecule [{(<compound-id="8037">TMEDA</compound-id>)(3)Na(6)Mg(3)(CH(2)SiMe(3))(2,5-C(4)H(2)O)(3)(2-C(4)H(3)O)(5)}(2)], built upon a bridge network of 10 monodeprotonated and 6 twofold-deprotonated furan ligands.	TMEDA__TMP__no_interaction	sodium__TMP__no_interaction
19082062-2	The ligand [2-((<compound-id="97257">2-hydroxy-</compound-id>3-(((2-hydroxyethyl)(pyridin-2-ylmethyl)amino)methyl)-<compound-id="137548">5-methylbenzyl</compound-id>)(pyridin-2-ylmethyl)amino)<compound-id="176">acetic acid</compound-id>] (H(3)L1) and two Zn(ii) complexes have been prepared and characterised as [Zn(2)(<protein-id="P07306,Q6FGQ5">HL1</protein-id>)(CH(3)COO)](PF(6)).H(2)O and Li[Zn(2)(<protein-id="P07306,Q6FGQ5">HL1</protein-id>)](4)(PO(4))(2)(PF(6))(3).(CH(3)OH).	2-hydroxy-__HL1__no_interaction	acetic acid__HL1__no_interaction	5-methylbenzyl__HL1__no_interaction
23438291-3	RESULTS: Serum <protein-id="P02765">fetuin-A</protein-id> levels were significantly associated with QT-d (r = 0.289, p = 0.044), P-d (r = 0.39, p = 0.005), total <compound-id="5997">cholesterol</compound-id> (r = 0.526, p = 0.000), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (r = 0.456, p = 0.00), triglyceride (r = 0.360, p = 0.011) and highly sensitive C-reactive protein (hsCRP) (r = -0.347, p = 0.030).	cholesterol__fetuin-A__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__low-density lipoprotein cholesterol__no_interaction
7756530-2	The fluorescence decay traces were analyzed with global compartmental analysis yielding the following values for the rate constants at room temperature in aqueous solution with <compound-id="104751">BAPTA</compound-id> as Ca2+ buffer: k01 = 1.2 x 10(9)s-1, <compound-id="1715">k21</compound-id> = 1.0 x 10(11) <protein-id="P09758">M-1 s-1</protein-id>, <compound-id="16122638">k02</compound-id> = 5.5 x 10(8) s-1, <protein-id="Q99456">k12</protein-id> = 2.2 x 10(7) s-1, and with <compound-id="6207">EGTA</compound-id> as Ca2+ buffer: k01 = 1.4 x 10(9) s-1, <compound-id="1715">k21</compound-id> = 5.0 x 10(10) <protein-id="P09758">M-1 s-1</protein-id>, <compound-id="16122638">k02</compound-id> = 5.5 x 10(8) s-1, <protein-id="Q99456">k12</protein-id> = 3.2 x 10(7) s-1.	EGTA__k12__no_interaction	EGTA__M-1 s-1__no_interaction	k02__k12__no_interaction	k02__M-1 s-1__no_interaction	k21__k12__no_interaction	k21__M-1 s-1__no_interaction	BAPTA__k12__no_interaction	BAPTA__M-1 s-1__no_interaction
8482332-1	The observation is reported that in low-passage human keratinocyte colonies cultured under conditions that allow full epidermal differentiation (i) the basement membrane protein <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein, identified by the mAb <protein-id="Q9NPC4">GB3</protein-id>, is codistributed with <compound-id="44342165">laminin</compound-id> and collagen type IV as well as with the bullous pemphigoid antigen in footprints deposited by growing and migrating colonies; (ii) the integrin heterodimer alpha 6 beta 4 is codistributed with the same molecules suggesting its spatial association with basement membrane components; (iii) the distribution pattern of alpha 6 beta 4 and <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein underneath individual cells is identical and is characterized by a typical "leopard skin" pattern complementary to the distribution of submembraneous F-actin microfilament network; (iv) a rabbit polyclonal antiserum to <compound-id="32518">kalinin</compound-id> (R4012) used in double-label immunofluorescence staining with mAb <protein-id="Q9NPC4">GB3</protein-id> shows that this protein has the same distribution as <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein and this suggests that they are identically located; and (v) immunoprecipitation with mAb <protein-id="Q9NPC4">GB3</protein-id> to <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein and <compound-id="3352881">BM165</compound-id> to <compound-id="32518">kalinin</compound-id> shows identical bands suggesting that nicein and <compound-id="32518">kalinin</compound-id> represent the same molecular entity.	laminin__BM-600__no_interaction	laminin__GB3__no_interaction	BM165__BM-600__no_interaction	BM165__GB3__no_interaction	kalinin__BM-600__no_interaction	kalinin__GB3__no_interaction
8890720-5	Twenty patients had hyperPRL (serum <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> 331 (223-1120) mIU/l (median, range) in men and 932 (660-3927) mIU/l in women): urinary free cortisol excretion (p &lt; 0.03) and peak serum cortisol in response to IIH (p &lt; 0.02) were lower in hyperPRL than in normoPRL patients; peak serum cortisol after <protein-id="P06850">hCRF</protein-id> was not different between groups but occurred later in hyperPRL patients (at 60vs 30 min, p &lt; 0.03); urinary <compound-id="44626398">H4S</compound-id> excretion and <compound-id="6128">androstenedione</compound-id> response after <compound-id="4174">metyrapone</compound-id> were lower in hyperPRL than in normoPRL patients (p &lt; 0.05 for both): 60% of hyperPRL patients and 15% of normoPRL patients had an abnormal <compound-id="44626398">H4S</compound-id> response (p &lt; 0.025): central hypothyroidism (overt + subclinical) was present in 74% of hyperPRL and in 60% of normoPRL patients (NS); 78% of hyperPRL and 55% of normoPRL patients had gonadotrophin deficiency (NS): <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> (GH) deficiency was present in 83% of hyperPRL and in 89% of normoPRL patients (NS); 73.3% of 75 evaluable pituitary hormone axes were abnormal in hyperPRL patients compared to 53.8% of 78 hormone axes in normoPRL patients (by <compound-id="4174">metyrapone</compound-id> test to examine adrenal function, p &lt; 0.025); and no significant differences in tumour grade and stage distribution were found between hyperPRL and normoPRL patients.	metyrapone__PRL__no_interaction	metyrapone__hCRF__no_interaction	metyrapone__growth hormone__no_interaction	H4S__PRL__no_interaction	H4S__hCRF__no_interaction	H4S__growth hormone__no_interaction	androstenedione__PRL__no_interaction	androstenedione__hCRF__no_interaction	androstenedione__growth hormone__no_interaction
11196864-5	Reactions of <compound-id="123195">diazene</compound-id>-diazonium complexes 13-17 with the metal hydrides M2H2P'4 and M2'H(CO)5-nP"n afforded the heterobinuclear <protein-id="O95817">bis</protein-id>(aryldiazene) derivatives [M1(CO)<compound-id="86208116">3P2</compound-id>(mu-HN=NAr-<compound-id="449336">ArN</compound-id>=NH)M2HP'4](<compound-id="1125">BPh4</compound-id>)2 (ReFe, ReRu, ReOs, MnRu, MnOs) and [M1(CO)<compound-id="86208116">3P2</compound-id>(mu-HN=NAr-<compound-id="449336">ArN</compound-id>=NH)M2'(CO)5-nP"n](<compound-id="1125">BPh4</compound-id>)2 (ReMn, MnRe) [M1 = Re, Mn; M2 = Fe, Ru, Os; M2' = Mn, Re; P = PPh2OEt, PPh2OMe; P',P" = P(<compound-id="6324">OEt</compound-id>)3, PPh(<compound-id="6324">OEt</compound-id>)2; <compound-id="9549877">Ar-Ar</compound-id> = 4,4'-C6H4-C6H4, 4,4'-C6H4-CH2-C6H4; n = 1, 2].	Ar-Ar__bis__no_interaction	3P2__bis__no_interaction	BPh4__bis__no_interaction	OEt__bis__no_interaction	diazene__bis__no_interaction	ArN__bis__no_interaction
16422962-4	RESULTS: A statistically significant improvement in all eight parameters was observed as a result of <compound-id="5212">sildenafil</compound-id> administration: number of erections from 3.1 +/- 0.7 to 4.0 +/- 0.7 (P &lt; 0.05), erection time 22 +/- 3.5 to 34.2 +/- 5.9, minimal base tumescence 8.2 +/- 0.8 to 8.7 +/- 0.8, maximal base tumescence 12.1 +/- 0.7 to 14.2 +/- 0.7, base rigidity 75.6 +/- 3.1 to 81.6 +/- 3.6, <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> rigidity 70.6 +/- 1.5 to 75.9 +/- 3.1, minimal <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> tumescence 5.9 +/- 0.5 to 6.5 +/- 0.6, and maximal <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> tumescence 8.6 +/- 0.6 to 11.7 +/- 0.7 (P &lt; 0.0001 for each of the last seven parameters).	sildenafil__tip__no_interaction
2004445-2	The dialysis patients displayed a moderate hypertriglyceridemia (1.94 +/- 0.12 vs 1.09 +/- 0.11 mmol/L in controls, mean +/- <compound-id="5289348">SEM</compound-id>; P less than 0.001), <protein-id="P02656,A3KPE2">apo CIII</protein-id> concentrations were also increased (130.2 +/- 2.1 vs 108.4 +/- 0.7 mg/L; P less than 0.001), whereas apo CII (34.5 +/- 0.5 vs 36 +/- 0.5 mg/L; P less than 0.05), <protein-id="P02649">apo E</protein-id> (22.7 +/- 0.3 vs 27.9 +/- 0.2 mg/L; P less than 0.001), and <protein-id="P02647,A0A024R3E3">apo A-I</protein-id> (1.18 +/- 0.05 vs 1.31 +/- 0.04 g/L; P less than 0.05) were decreased.	SEM__apo CIII__no_interaction	SEM__apo A-I__no_interaction	SEM__apo E__no_interaction
21447733-6	Presented in the order of vector control, <protein-id="A6NDG6">P-gp</protein-id>, <protein-id="Q9UNQ0,A0A024RDD4">BCRP</protein-id>, and <protein-id="Q92887">MRP2</protein-id> knockdown Caco-2 cells, the P(app,B-A) values (×10(-6), cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for <compound-id="60823">atorvastatin</compound-id>; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for <compound-id="3403,446155">fluvastatin</compound-id>; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for <compound-id="446157,656606">rosuvastatin</compound-id>, respectively.	atorvastatin__BCRP__no_interaction	atorvastatin__P-gp__no_interaction	atorvastatin__MRP2__no_interaction	fluvastatin__BCRP__no_interaction	fluvastatin__P-gp__no_interaction	fluvastatin__MRP2__no_interaction	rosuvastatin__BCRP__no_interaction	rosuvastatin__P-gp__no_interaction	rosuvastatin__MRP2__no_interaction
8342613-8	A cross-reaction of <compound-id="27991">dDAVP</compound-id> with an <compound-id="439302">oxytocin</compound-id> (OT) receptor can be excluded since 1) the specific OT agonist [Thr4,Gly7]OT (10 nM) increased only slightly [Ca2+]i (delta-[Ca2+]i = 20 +/- 5 nM, n = 11); 2) the <compound-id="27991">dDAVP</compound-id> response was not altered by the specific OT antagonist [1-(beta-mercapto-beta,beta-cyclopentamethylene <compound-id="1032">propionic acid</compound-id>),2-(O-methyl)<compound-id="90983769">tyrosine</compound-id>,<compound-id="11094586">4-threonine</compound-id>, 8-<compound-id="6262,91481091">ornithine</compound-id>,9-tyrosylamide]<compound-id="24774,44285264,68649">vasotocin</compound-id> [d(CH2)5(1),O-Me-Tyr2,Thr4,<compound-id="6057">Tyr</compound-id>-NH2(9)]OVT; 3) it was insensitive to V1 antagonists but was totally blocked by the V1/V2 antagonist [d(CH2)5(1),O-Et-Tyr2,Val4]<protein-id="P01186">AVP</protein-id> ([delta[Ca2+]i = 18 +/- 4 nM, n = 6).	dDAVP__AVP__no_interaction	propionic acid__AVP__no_interaction	ornithine__AVP__no_interaction	4-threonine__AVP__no_interaction	oxytocin__AVP__no_interaction	vasotocin__AVP__no_interaction	Tyr__AVP__no_interaction	tyrosine__AVP__no_interaction
9182472-10	Responses to <compound-id="2585">carvedilol</compound-id> were greater than those to <compound-id="2249">atenolol</compound-id>, as follows: increase in total <compound-id="206,5793,64689,79025">glucose</compound-id> disposal, 9.54 mumol/kg of body weight per minute (95% CI, 7 to 11.9 mumol/kg per minute); decrease in plasma <compound-id="206,5793,64689,79025">glucose</compound-id> response to oral <compound-id="206,5793,64689,79025">glucose</compound-id>, 61 mmol/L x 180 minutes (CI, -101 to -21 mmol/L x 180 minutes); decrease in <protein-id="P01308,I3WAC9">insulin</protein-id> response to oral <compound-id="206,5793,64689,79025">glucose</compound-id>, 6.2 nmol/L x 180 minutes (CI, -9.8 to -2.6 nmol/L x 180 minutes); decrease in triglyceride level, 0.56 mmol/L (CI, -0.75 to -0.37 mmol/L; P &lt; 0.001); increase in high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level, 0.13 mmol/L (CI, 0.09 to 0.17 mmol/L; P &lt; 0.001); and decrease in lipid peroxidation, 0.25 mumol/L (CI, -0.34 to -0.16 mumol/L).	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction	atenolol__insulin__no_interaction	carvedilol__insulin__no_interaction
11229829-8	Principal results as mean differences (95% CI) between GO and placebo are: pulse, 2.9 beats/min (-0.8 to 6.7), P = 0.12; systolic BP, -4.5 mmHg (-10.8 to 1.9), P = 0.16; plasma total <compound-id="5997">cholesterol</compound-id>, 0.01 mmol/l (-0.34 to 0.37), P = 0.95; plasma triglycerides, -0.20 mmol/l (-0.43 to 0.03), P = 0.09; plasma TAS, 45 micromol <compound-id="40634">Trolox</compound-id> equivalent/l (-35 to 124), P = 0.26; LDL density, 0.0019 g/ml (-0.0005 to 0.0043), P = 0.12; LDL triglycerides/protein, -0.078 mg/mg (-0.149 to -0.007), P = 0.03; LDL <compound-id="5997">cholesterol</compound-id>/protein, -0.24 mg/mg (-0.69 to 0.22), P = 0.3; LDL TAS/triglycerides, 29 nmol/mg (11, 68), P = 0.15; <protein-id="P00734">prothrombin</protein-id> time, 0.99 s (-0.36 to 2.35), P = 0.14; partial thromboplastin time, 3.0 s (-1.0 to 7.1), P = 0.13.	Trolox__prothrombin__no_interaction	cholesterol__prothrombin__no_interaction
2441054-1	A series of pseudopeptide analogues of the C-terminal heptapeptide of <protein-id="P01355">cholecystokinin</protein-id> in which each peptide bond, one at a time, has been replaced by a CH2NH bond were synthesized: Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id>-Nle-Asp psi-(CH2NH)Phe-NH2 (1), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id>-Nle psi (CH2NH)<compound-id="7016047">Asp-Phe-NH2</compound-id> (2), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id> psi-(CH2NH)Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (3), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-Gly psi(CH2NH)Trp-Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (4), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle psi-(CH2NH)<compound-id="102763">Gly-Trp</compound-id>-Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (5), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id>-Nle-Asp psi (CH2NH)Phe-NH2 (6), Z-<compound-id="6057">Tyr</compound-id>-(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id>-Nle psi (CH2NH)<compound-id="7016047">Asp-Phe-NH2</compound-id> (7), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id> psi (CH2NH)Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (8).	Gly-Trp__cholecystokinin__no_interaction	Asp-Phe-NH2__cholecystokinin__no_interaction	Tyr__cholecystokinin__no_interaction
3271096-1	<compound-id="5413">Tetraethylammonium</compound-id> tribromo[2-(2- acetoxystyryl)<compound-id="7222">benzothiazole</compound-id>]platinate(II), [(C2H5)4N]-[PtBr3(C17H13NO2S)], Mr = 860.4 monoclinic, <protein-id="P38936,A0A024RCX5">P21</protein-id>/c, a = 11.230 (9), b = 19.333 (4), c = 13.685 (6) A, beta = 101.06 (4) degrees, V = 2916 (4) A3, Z = 4, D chi = 1.96 g cm-3, lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, mu = 90.3 cm-1, F(000) = 1648, T = 296 K, final R = 0.047 for 3384 unique observed reflections.	benzothiazole__P21__no_interaction	benzothiazole__Mo K alpha__no_interaction	Tetraethylammonium__P21__no_interaction	Tetraethylammonium__Mo K alpha__no_interaction
11194238-6	The mean values for NGT, IGT, and <compound-id="65103">DGT</compound-id>, respectively, and analysis of covariance P values, adjusted for age and sex, are as follows; intra-abdominal fat area by CT 69.7, 95.0, and 101.1 cm2 (P &lt; 0.0001); total CT fat area 437.7, 523.3, and 489.8 cm2 (P &lt; 0.0001); fasting triglycerides 1.40, 1.77, and 1.74 mmol/l (P = 0.002); fasting HDL <compound-id="5997">cholesterol</compound-id> 1.56, 1.50, and 1.49 mmol/l (P = 0.02); <protein-id="P01308,I3WAC9">C-peptide</protein-id> 0.80, 0.90, 0.95 nmol/l (P = 0.002); systolic BP 124.9, 132.4, and 136.9 mmHg (P = 0.0035); diastolic BP 74.8, 77.7, and 78.2 mmHg (P = 0.01).	DGT__C-peptide__no_interaction	cholesterol__C-peptide__no_interaction
17250655-3	Transiently expressing intact HEK293 cells, transfected with increasing amounts of <protein-id="Q01959">DAT</protein-id> cDNA, displayed increasing levels of surface <protein-id="Q01959">DAT</protein-id>, binding of the <compound-id="446220">cocaine</compound-id> analog [(3)H]<compound-id="6918292">2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane</compound-id> ([(3)H]CFT), and uptake of [(3)H]DA, [(3)H]N-<compound-id="39484">methyl-4-phenylpyridinium</compound-id> ([(3)H]<protein-id="P25189">MPP</protein-id>(+)), [(3)H]norepinephrine, and [(3)H]<compound-id="5202">serotonin</compound-id>.	serotonin__DAT__no_interaction	serotonin__MPP__no_interaction	cocaine__DAT__no_interaction	cocaine__MPP__no_interaction	2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane__DAT__no_interaction	2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane__MPP__no_interaction	methyl-4-phenylpyridinium__DAT__no_interaction	methyl-4-phenylpyridinium__MPP__no_interaction
10052021-5	Plasma vitamin C concentrations increased significantly (p &lt; 0.005) only in the group supplemented with vitamin C. Lipid peroxidation measured by breath <compound-id="8003">pentane</compound-id> output (BPO) (C: 7.5 +/- 1.4 vs P: 7.0 +/- 1.3 pmol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>) and plasma HPLC-separated <compound-id="10964">malondialdehyde</compound-id> (MDA) (C: 0.58 +/- 0.05 vs P: 0.47 +/- 0.05 nmol.ml-1) were not significantly different between the 2 groups at baseline and did not change after four weeks of vitamin C supplementation (BPO: C: 5.3 +/- 0.9 vs P: 5.5 +/- 0.9 pmol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; HPLC-MDA: C: 0.50 +/- 0.07 vs P: 0.42 +/- 0.07 nmol.ml-1).	pentane__min-1__no_interaction	malondialdehyde__min-1__no_interaction
15793560-2	The key cellular signaling pathways include 1) ER/coactivator interaction, 2) AR translocation into the nucleus, 3) ER/NO/sGC/<compound-id="24316">cGMP</compound-id>, 4) <protein-id="P62993,B0LPF3,Q14451">ER/Akt, 5) ER/Src, 6)ER/Src/Grb2, and 7</protein-id>) ER/Ca2+/CaM/CaMK pathways.	cGMP__ER/Akt, 5) ER/Src, 6)ER/Src/Grb2, and 7__no_interaction
11961081-2	We examined several small molecule inhibitors of alpha4beta1/<protein-id="P29533,Q3UPN1">VCAM-1</protein-id> interactions with in vitro potencies (IC(50) values) ranging from 0.52 nM (<compound-id="9828124">CP-664511</compound-id>; 3-[3-(1-[2-[<compound-id="13516411">3-methoxy</compound-id>-4-(3-O-tolyl-ureido)phenyl]-acetylamino]-3-methyl-<compound-id="68006705">butyl</compound-id>)<compound-id="11725766,25676">isoxazol</compound-id>-5-yl]-<compound-id="1032">propionic acid</compound-id>) to 38.5 nM (CP-609643; 3-[3-methyl-1-[2-[4-(3-O-tolyl-ureido)-phenyl]-acetylamino]-<compound-id="68006705">butyl</compound-id>)-<compound-id="11725766,25676">isoxazol</compound-id>-5-yl]-<compound-id="1032">propionic acid</compound-id>).	CP-664511__VCAM-1__no_interaction	3-methoxy__VCAM-1__no_interaction	butyl__VCAM-1__no_interaction	propionic acid__VCAM-1__no_interaction	isoxazol__VCAM-1__no_interaction
19175617-12	The concentrations of <protein-id="P01270">PTH</protein-id> and beta2-MG were significantly reduced by HPHD in comparison with <compound-id="221493">CHD</compound-id> (<protein-id="P01270">PTH</protein-id> 119.27 +/- 8.41 vs. 165.18 +/- 9.37 pmol/L, P = 0.01; beta2-MG 3.39 +/- 0.76 vs. 5.92+/- 1.58 g/mL, P = 0.012).	CHD__PTH__no_interaction
20601983-1	The directed assembly of N,N-<compound-id="5259992">bis(benzimidazol-2-yl-methyl)amine</compound-id> (BMA) with Cu(II), Mn(II), Ni(II) and Zn(II) salts based on <compound-id="80295">dicyanamide</compound-id> (<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca) and <compound-id="7489">terephthalate</compound-id> (mu-ta) linear bridging ligands, respectively, leads to four novel compounds: [Cu(BMA)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)(ClO(4))](n) (1), {[Mn(BMA)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)(CH(3)OH)] x ClO(4) x C(10)H(9)N(3)O x CH(3)OH}(n) (2), {[Ni(2)(BMA)(2)(mu-ta)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)] x ClO(4) x CH(3)OH x H(2)O}(n) (3), and {[Zn(2)(BMA)(2)(mu-ta)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)] x ClO(4) x CH(3)OH}(n) (4), which were characterized by single-crystal X-ray diffraction, elemental analysis, IR, fluorescence spectroscopy, and magnetic measurement.	bis(benzimidazol-2-yl-methyl)amine__mu(1,5__no_interaction	dicyanamide__mu(1,5__no_interaction	terephthalate__mu(1,5__no_interaction
24383924-10	Baseline <compound-id="5950">alanine</compound-id> aminotransferase and <protein-id="P19440">gamma-glutamyl transferase</protein-id> (GGT) levels (71 ± 31 vs 47 ± 22, P &lt; 0.001 and 49 ± 39 vs 36 ± 28, P = 0.027, respectively), baseline mean fibrosis stage (2.2 ± 0.7 vs 1.9 ± 0.7, P = 0.018) and histologic activity index (6.3 ± 1.9 vs 4.3 ± 1.6, P &lt; 0.001) were higher in the TF group compared with the TN group.	alanine__gamma-glutamyl transferase__no_interaction
8006337-5	A distinct <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> episodic release was observed in all groups (follicular phase: 5.5 +/- 0.5, luteal phase: 6.5 +/- 0.6, postmenopause: 5 +/- 1, hyperprolactinemic women: 4.2 +/- 0.8, men: 4.8 +/- 0.4, agonadal before <compound-id="6013">testosterone</compound-id>: 6 +/- 1, agonadal during <compound-id="6013">testosterone</compound-id> administration: 5.3 +/- 0.3 peaks/6h), but mainly the computation of ISR allowed to demonstrate that the duration of the lactotropes secretory events was constant in all groups studied.	testosterone__PRL__no_interaction
15161652-4	The sequential infiltration and activation of effector cells correlated with the histopathological development of cutaneous GVHD and was accompanied by up-regulated expression of many chemokines and their receptors (CXCL-1, -2, -9, and -10; CCL-2, -5, -6, -7, -8, -9, -11, and -19; <protein-id="P51675,Q8BVW4,Q8BMH9">CCR-1</protein-id> and <protein-id="P51682">CCR-5</protein-id>), adhesion molecules (<protein-id="P13597,Q3U8M7">ICAM-1</protein-id>, <protein-id="P50284,B2RRV3,Q8BJV0">CD18</protein-id>, <protein-id="P26011">Ly69</protein-id>, <protein-id="Q3TA56,Q8C265">PSGL-1</protein-id>, <protein-id="P29533,Q3UPN1">VCAM-1</protein-id>), molecules involved in antigen processing and presentation (<protein-id="P21958,Q3TBA3,Q3U6V4">TAP1</protein-id> and <protein-id="P36371,Q792S7">TAP2</protein-id>, MHC class I and II, <protein-id="Q00609,Q549R2">CD80</protein-id>), regulators of apoptosis (<protein-id="P04187,Q3TZH4">granzyme B</protein-id>, <protein-id="P97864,Q4FJQ4">caspase 7</protein-id>, <protein-id="O08734">Bak1</protein-id>, <protein-id="Q07813,Q544Z6">Bax</protein-id>, and <protein-id="P10417,Q6NTH7">BclII</protein-id>), interferon-inducible genes (<protein-id="Q8C3V4,Q8CFQ1,Q99K94,A0A087WSP5,Q8C8M3,Q8C497">STAT1</protein-id>, <protein-id="P15314,Q5SX13,Q3U5M1">IRF-1</protein-id>, <protein-id="Q9QZ85,J7NNX8">IIGP</protein-id>, GTPI, <protein-id="Q9DCE9">IGTP</protein-id>, <protein-id="Q9R002">Ifi202A</protein-id>), stimulators of fibroblast proliferation and matrix synthesis (interleukin-1beta, transforming growth factor-beta1), and markers of keratinocyte proliferation (keratins 5 and 6), and differentiation (small <compound-id="145742,57240853,614,8988">proline</compound-id>-rich proteins 2E and 1B).	proline__TAP1__no_interaction	proline__TAP2__no_interaction	proline__caspase 7__no_interaction	proline__STAT1__no_interaction	proline__IIGP__no_interaction	proline__CD80__no_interaction	proline__PSGL-1__no_interaction	proline__CCR-5__no_interaction	proline__BclII__no_interaction	proline__Bax__no_interaction	proline__CCR-1__no_interaction	proline__granzyme B__no_interaction	proline__VCAM-1__no_interaction	proline__IGTP__no_interaction	proline__CD18__no_interaction	proline__Ifi202A__no_interaction	proline__ICAM-1__no_interaction	proline__Bak1__no_interaction	proline__IRF-1__no_interaction	proline__Ly69__no_interaction
2898330-2	By using GC/MS methodology and synthesized regioisomeric standards, we showed that three of the four possible monophenolic metabolites, alpha-[3-([2-(3,4-dimethoxyphenyl)<compound-id="23134249">ethyl</compound-id>]methyl-amino) propyl]-<compound-id="13516411">3-methoxy</compound-id>-4-hydroxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)<compound-id="8794">phenyl-acetonitrile</compound-id> (2), alpha-[3-([2-(3,4-methoxyphenyl)<compound-id="23134249">ethyl</compound-id>]methyl-amino) propyl]-3-hydroxy-4-methoxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)phenylaceto nitrile (3), and alpha-[3-([2-(<compound-id="13516411">3-methoxy</compound-id>-4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]methylamino) propyl]-3,4-dimethoxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)<compound-id="16227014,345685">phenylacetonitrile</compound-id> (4) were formed.	3-methoxy__alpha-(1__no_interaction	phenyl-acetonitrile__alpha-(1__no_interaction	phenylacetonitrile__alpha-(1__no_interaction	methylethyl__alpha-(1__no_interaction	ethyl__alpha-(1__no_interaction
12498906-3	In <protein-id="P08183,A4D1D2">MDR1</protein-id>-transfected Madin-Darby canine kidney, MDCKII, cell monolayers, <compound-id="2724385">digoxin</compound-id> secretion was reduced by the <protein-id="P08183,A4D1D2">MDR1</protein-id> inhibitor cyclosporin A, whereas no inhibition was seen in the presence of <compound-id="5281888">MK-571</compound-id>, 3-([(3-(2-[<compound-id="521963">7-chloro-2-quinolinyl</compound-id>]<compound-id="23134249">ethyl</compound-id>)phenyl]-[(3-dimethylamino-3-oxoprphyl)-thio)-methyl]-thio) <compound-id="1032">propanoic acid</compound-id>, a Multidrug Related Protein (MRP) inhibitor.	MK-571__MDR1__no_interaction	7-chloro-2-quinolinyl__MDR1__no_interaction	digoxin__MDR1__no_interaction	propanoic acid__MDR1__no_interaction	ethyl__MDR1__no_interaction
8174273-3	Analysis of the sugar chains by high performance liquid chromatography in combination with exoglycosidase digestion revealed an increase of a biantennary complex-type sugar chain with a fucosylated trimannosyl core; Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6(Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3) Man beta 1-4GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>(<protein-id="P04066,B5MDC5">Fuc alpha</protein-id> 1-6)GlcNAc in 7 of 13 cancer patients and an increase of a sugar chain with a fucosylated trimannosyl core and bisecting <compound-id="11861101,24139,439174,899">N-acetylglucosamine</compound-id>; Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6(GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>) (Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3)Man beta 1-4GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>(<protein-id="P04066,B5MDC5">Fuc alpha</protein-id> 1-6)GlcNAc in one of the 13 cancer patients.	N-acetylglucosamine__Fuc alpha__no_interaction	N-acetylglucosamine__beta 1-4__no_interaction
16106048-2	After adjustment for maternal polymorphisms, newborn <protein-id="P06858">LPL</protein-id>*S447X was associated with lower triglycerides (-21 +/- 9 mg/dl), lower LDL-<compound-id="5997">cholesterol</compound-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>; -12 +/- 5 mg/dl), lower <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (-14 +/- 4 mg/dl), higher HDL-C (5 +/- 2 mg/dl), and higher <protein-id="P02647,A0A024R3E3">apoA-I</protein-id> (9 +/- 4 mg/dl) in their mothers; newborn <protein-id="P06858">LPL</protein-id>*N291S was associated with higher maternal triglycerides (114 +/- 31 mg/dl); and newborn <protein-id="P02649">APOE</protein-id>*E2 (compared to E3E3) was associated with higher maternal <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (14 +/- 6 mg/dl) and higher maternal <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (14 +/- 5 mg/dl).	cholesterol__APOE__no_interaction	cholesterol__LPL__no_interaction	cholesterol__apoB__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__apoA-I__no_interaction
18549246-1	Site-specific insertion of <compound-id="3081165">5-(3-aminopropyl)-2'-deoxyuridine</compound-id> (Z3dU) and 7-deaza-dG into the Dickerson-Drew dodecamers 5'-d(C (1)G (2)C (3)G (4)A (5)A (6)T (7)T (8)C (9) Z (10)C (11)G (12))-3'.5'-d(C (13)G (14)C (15)G (16)A (17)A (18)T (19)T (20)C (21) Z (22)C (23)G (24))-3' (named <protein-id="P13647">DDD</protein-id> (<compound-id="53301832">Z10</compound-id>)) and 5'-d(C (1)G (2)C (3)G (4)A (5)A (6)T (7) X (8)C (9) Z (10)C (11)G (12))-3'.5'-d(C (13)G (14)C (15)G (16)A (17)A (18)T (19) X (20)C (21) Z (22)C (23)G (24))-3' (named <protein-id="P13647">DDD</protein-id> (2+<compound-id="53301832">Z10</compound-id>)) (X = Z3dU; Z = 7-deaza-dG) suggests a mechanism underlying the formation of interstrand N+2 DNA cross-links by <compound-id="947">nitrogen</compound-id> mustards, e.g., <compound-id="460612">melphalan</compound-id> and <compound-id="4033">mechlorethamine</compound-id>.	melphalan__DDD__no_interaction	nitrogen__DDD__no_interaction	Z10__DDD__no_interaction	5-(3-aminopropyl)-2'-deoxyuridine__DDD__no_interaction	mechlorethamine__DDD__no_interaction
11015191-5	The presence of tertiary structure of purified ImmE1 in a solvent of mixed polarity, <compound-id="6212">chloroform</compound-id>/<compound-id="11686950,887">methanol</compound-id>/H(2)O (4:4:1) was demonstrated by (i) the constraints on <compound-id="6057">Tyr</compound-id> residues shown by the amplitude of near-UV circular dichroism spectra in the wavelength interval, 270-285 nm; (ii) the correlation between the near-UV <compound-id="6057">Tyr</compound-id> CD spectrum of single and double Cys-to-X mutants of the <protein-id="Q3ZU31">Imm</protein-id> protein and their in vivo activity; (iii) the upfield shift of methyl groups in a 1D NMR spectrum, a 2D- HSQC NMR spectrum of ImmE1 in the mixed polarity solvent mixture, and a broadening and disappearance of the <compound-id="798">indole</compound-id> (1)H <compound-id="1038,5460653">proton</compound-id> resonance from Trp94 in H3 by a spin label attached to Cys16 in the <compound-id="783">H2</compound-id> hydrophobic domain; (iv) near-UV circular dichroism spectra with a prominent ellipticity band centered at 290 nm from a single Trp inserted into the extended hydrophobic domains.	indole__Imm__no_interaction	H2__Imm__no_interaction	chloroform__Imm__no_interaction	proton__Imm__no_interaction	methanol__Imm__no_interaction	Tyr__Imm__no_interaction
16562956-2	[Cu(I)(R-PYAN)(<compound-id="6342">MeCN</compound-id>)n]B(C6F5)4 (R-PYAN = <compound-id="85985944">N-[2-(4-R-pyridin-2-yl)-ethyl]-N,N',N'-trimethyl-propane-1,3-diamine</compound-id>, R = <protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>, OMe, H, and Cl) (1R) vary over a narrow range in their Cu(II)/Cu(I) redox potentials (E(1/2) vs Fe(cp)2(+/0) = -0.40 V for 1(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>), -0.38 V for 1(OMe), -0.33 V for 1H, and -0.32 V for 1Cl) and in C-O stretching frequencies of their carbonyl adducts, 1R-CO: nu(C-O) = 2080, 2086, 2088, and 2090 cm(-1) for R = <protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>, OMe, H, and Cl, respectively.	MeCN__NMe2__no_interaction	N-[2-(4-R-pyridin-2-yl)-ethyl]-N,N',N'-trimethyl-propane-1,3-diamine__NMe2__no_interaction
10454466-1	The 5-hydroxytryptamine(1B/1D) (<protein-id="P28564">5-HT(1B</protein-id>/1D)) antagonist 2'-methyl-4'-(5-methyl-[1,2,4]<compound-id="10197612">oxadiazol</compound-id>-3-yl)-biphenyl-4-carboxyli <compound-id="8563">c acid</compound-id> [4-<compound-id="91066389">methoxy-</compound-id>3-(4-methyl-<compound-id="91216341">piperazin-1-yl</compound-id>)-phenyl]-<compound-id="2826723">amide</compound-id> (GR 127935) and <protein-id="P19327">5-HT(1A</protein-id>) antagonist N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)<compound-id="23134249">ethyl</compound-id>)-N-(2-pyridinyl)cyclohe xanecarboxamide (<compound-id="5684">WAY 100635</compound-id>) were used to assess whether hyperactivity induced by 3 mg/kg (+)-3, 4-<compound-id="1615">methylenedioxymethamphetamine</compound-id> [(+)-MDMA] is mediated by <protein-id="P28564">5-HT(1B</protein-id>/1D) and/or <protein-id="P19327">5-HT(1A</protein-id>) receptors.	methoxy-__5-HT(1B__no_interaction	methoxy-__5-HT(1A__no_interaction	piperazin-1-yl__5-HT(1B__no_interaction	piperazin-1-yl__5-HT(1A__no_interaction	amide__5-HT(1B__no_interaction	amide__5-HT(1A__no_interaction	c acid__5-HT(1B__no_interaction	c acid__5-HT(1A__no_interaction	oxadiazol__5-HT(1B__no_interaction	oxadiazol__5-HT(1A__no_interaction	WAY 100635__5-HT(1B__no_interaction	WAY 100635__5-HT(1A__no_interaction	methylenedioxymethamphetamine__5-HT(1B__no_interaction	methylenedioxymethamphetamine__5-HT(1A__no_interaction	ethyl__5-HT(1B__no_interaction	ethyl__5-HT(1A__no_interaction
9714526-4	When compared with placebo, <compound-id="4674">pamidronate</compound-id> treatment was associated with: (a) marked decreased osteoclastic resorption rate (0.86+/-0.59 microm/d vs. 5.7+/-5.0 microm/d, p=0.002), and diminished activation frequency (0.20+/-0.18 yr(-1) vs. 0.72+/-0.55 yr(-1), p=0.014); (b) compensatory reduced volume referent bone formation rate (0.17+/-0.21 yr(-1) vs. 0.71+/-0.54 yr(-1), p=0.007), but unaltered mineral appositional rate; (c) neutral (-0.66+/-5.6 mm) vs. negative (-2.15+/-2.2 microm, p=0.013) bone balance per remodelling cycle; (d) higher trabecular bone volume (21.0+/-6.2% vs. 13.0+/-3.7%, p=0.01); (e) suppressed urinary excretion and serum levels of some of the biochemical markers of bone metabolism; and (f) significant reduction of circulating soluble <protein-id="P08887,A0N0L5,A0A087WTB5">interleukin-6 receptor</protein-id> (IL-6sR) (25.9+/-4.1 ng/ml vs. 32.1+/-6.6 ng/ml, p=0.04), and (g) a uniform tendency of lower serum and marrow plasma levels of IL-6, <protein-id="P01584">IL-1beta</protein-id>, and <protein-id="P01375,Q5STB3">TNFalpha</protein-id>.	pamidronate__IL-1beta__no_interaction	pamidronate__TNFalpha__no_interaction	pamidronate__interleukin-6 receptor__no_interaction
15855434-10	RESULTS: <compound-id="54675783">Minocycline</compound-id>-treated macaques had less severe encephalitis (P = .02), reduced CNS expression of neuroinflammatory markers (major histocompatibility complex class II, P = .03; macrophage marker CD68 , P = .07; T-cell intracytoplasmic antigen 1, P = .03; <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P13500">monocyte chemoattractant protein 1</protein-id>, P = .001), reduced activation of <protein-id="Q16539,L7RSM2,B4E0K5,A0A024RD15">p38</protein-id> mitogen-activated protein kinase (P&lt;.001), less axonal degeneration (beta-amyloid precursor protein, P = .03), and lower CNS virus replication (viral RNA, P = .04; viral antigen, P = .04).	Minocycline__p38__no_interaction	Minocycline__monocyte chemoattractant protein 1__no_interaction	CSF__p38__no_interaction	CSF__monocyte chemoattractant protein 1__no_interaction
15907124-1	Coordination compounds with a <compound-id="11109901,23092711,87362681,87362782">4,4'-azobis</compound-id>(pyridine) (azpy) ligand, {[M2(azpy)6(H2O)5] x 4PF6 x azpy x H2O}n (M = Ni(II) (1) or Co(II) (2)) (0-dimensional (0-D) dimer), {[Zn(azpy)3(H2O)2] x 2PF6 x 2azpy x <compound-id="70679364">4H2O</compound-id>}n (3) (1-dimensional (1-D) fishbone-type chain), {[Ag(azpy)] x <protein-id="Q6Q759">PF6</protein-id>}n (4) (1-D linear chain), {[Mn(NCS)2(azpy)2] x azpy}n (5) (2-dimensional (2-D) grid sheet), and {[Ni(NCS)2(azpy)2] x 3toluene}n (6) (2-D grid sheet), were synthesized and structurally characterized.	4H2O__PF6__no_interaction	4,4'-azobis__PF6__no_interaction
21141136-9	The expressions of NF-kappaB protein (0.2315 +/- 0.0624, 0.3213 +/- 0.0740, 0.4729 +/- 0.0839) and mRNA (0.4370 +/- 0.0841, 0.5465 +/- 0.0503, 0.6443 +/- 0.0538) in all the lead exposed groups continuously increased compared with correspondent control groups; Group I was decreased obviously compared with group F. The expressions of FN protein (0.4243 +/- 0.0595, 0.4917 +/- 0.0891) and mRNA (0.8650 +/- 0.0880, 0.8714 +/- 0.0980) in group E and F increased compared with group B and C, but the expressions of FN protein in group I significantly decreased compared with group F; The expressions of FN mRNA in Group H and I significantly decreased compared with group E and F. CONCLUSION: The <compound-id="4875">potassium iodide</compound-id> can ameliorate renal ultrastructure and degrade expression of nuclear factor-kappaB and <protein-id="F1LST1,A0A096P6L8">fibronectin</protein-id> induced by lead. 	potassium iodide__fibronectin__no_interaction
8549614-4	The use of subtype selective muscarinic receptor antagonists (10(-7) to 10(-5) M), <compound-id="4848">pirenzepine</compound-id> (M1 &gt; M3 &gt; M2), AF-DX 116 (11-([2-[(diethylamino)-methyl]-1-piperidyl]acetyl)-5,11-dihydro-6H- pyridol[2,3-b][1,4]<compound-id="134664">benzodiazepine</compound-id>-6-one base; M2 &gt; M1 &gt; M3) and <compound-id="3602">HHSiD</compound-id> (p-fluorohexahydro-siladifenidol hydrochloride; M3 &gt; or = M1 &gt;&gt; M2) revealed that the negative inotropic effect of <compound-id="187">acetylcholine</compound-id> in atrial as well as the positive inotropic effect in ventricular trabeculae were best antagonized by AF-DX 116 and not by <compound-id="4848">pirenzepine</compound-id>, suggesting the involvement of the <protein-id="P08172,A4D1Q0,Q86SJ1,Q6SL56,Q6SL59">muscarinic M2 receptor</protein-id> subtype, possibly linked to different second messenger systems.	HHSiD__muscarinic M2 receptor__no_interaction	pirenzepine__muscarinic M2 receptor__no_interaction	acetylcholine__muscarinic M2 receptor__no_interaction	benzodiazepine__muscarinic M2 receptor__no_interaction
24049617-5	Pearson correlation coefficient between <protein-id="P02741">CRP</protein-id> and the other risk factors in case group showed that only ferritin, serum <compound-id="23925,67172434">iron</compound-id>, waist circumference, and <protein-id="Q14746,B1ALW7">LDL-c</protein-id> significantly correlated with <protein-id="P02741">CRP</protein-id> (r = 0.32 with P &lt; 0.001, r = 0.29 with P &lt; 0.05, r = 0.41 with P &lt; 0.01, and r = 0.36 with P &lt; 0.001, respectively).	iron__CRP__no_interaction	iron__LDL-c__no_interaction
9666272-5	<compound-id="446220">Cocaine</compound-id>'s in vitro effects on (a) permeability, (b) immune cell migration, (c) adhesion molecules, and (d) cytokine expression were investigated in a blood-brain barrier model constructed with brain microvascular endothelial cells and fetal astrocytes with the following results: (a) <compound-id="446220">cocaine</compound-id> and <protein-id="P16599">tumor necrosis factor-alpha</protein-id> (<protein-id="P16599">TNF-alpha</protein-id>) increased the model's permeability to <compound-id="18772499,24763">inulin</compound-id> similarly in a dose-responsive fashion; (b) <compound-id="446220">cocaine</compound-id> (10(-4) to 10(-8_ M) enhanced monocyte migration across the barrier with the maximum increase, approximately 100%, by 10(-5) M <compound-id="446220">cocaine</compound-id>; (c) <compound-id="446220">cocaine</compound-id> treatment also increased the expression of endothelial adhesion molecules, <protein-id="Q00238">intercellular adhesion molecule-1</protein-id> (<protein-id="Q00238">ICAM-1</protein-id>), <protein-id="P29534">vascular cell adhesion molecules-1</protein-id> (<protein-id="P29534">VCAM-1</protein-id>) and <protein-id="Q3SWT0">platelet/endothelial cell adhesion molecule-1</protein-id> (<protein-id="Q3SWT0">PECAM-1</protein-id>); (d) although the <compound-id="446220">cocaine</compound-id> in vitro effects on cytokine production by mononuclear cells have been difficult to assess due to a heterogeneity in the degree of responsiveness between individuals, the data suggest that mononuclear cells from <compound-id="446220">cocaine</compound-id> addicts are sensitized to in vitro <compound-id="446220">cocaine</compound-id> challenge with hypersecretion of inflammatory cytokines.	cocaine__platelet/endothelial cell adhesion molecule-1__no_interaction	cocaine__tumor necrosis factor-alpha__no_interaction	cocaine__vascular cell adhesion molecules-1__no_interaction	cocaine__PECAM-1__no_interaction	cocaine__intercellular adhesion molecule-1__no_interaction	cocaine__VCAM-1__no_interaction	cocaine__ICAM-1__no_interaction	cocaine__TNF-alpha__no_interaction	Cocaine__platelet/endothelial cell adhesion molecule-1__no_interaction	Cocaine__tumor necrosis factor-alpha__no_interaction	Cocaine__vascular cell adhesion molecules-1__no_interaction	Cocaine__PECAM-1__no_interaction	Cocaine__intercellular adhesion molecule-1__no_interaction	Cocaine__VCAM-1__no_interaction	Cocaine__ICAM-1__no_interaction	Cocaine__TNF-alpha__no_interaction	inulin__platelet/endothelial cell adhesion molecule-1__no_interaction	inulin__tumor necrosis factor-alpha__no_interaction	inulin__vascular cell adhesion molecules-1__no_interaction	inulin__PECAM-1__no_interaction	inulin__intercellular adhesion molecule-1__no_interaction	inulin__VCAM-1__no_interaction	inulin__ICAM-1__no_interaction	inulin__TNF-alpha__no_interaction
19143962-5	RESULTS: Serum hsCRP level was positively correlated with BMI (r = 0.512, P &lt; 0.01), RW (r = 0.438, P &lt; 0.05), systolic and diastolic BP (r = 0.498, P &lt; 0.01), serum <protein-id="P41159,A4D0Y8">leptin</protein-id> levels (r = 0.457, P &lt; 0.05), but not with serum lipid, <compound-id="206,5793,64689,79025">glucose</compound-id>, fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, plasma hcy levels or <protein-id="P01308,I3WAC9">insulin</protein-id> resistance indexes.	glucose__leptin__no_interaction	glucose__insulin__no_interaction
23611092-10	Compared with control group, in "stage" group, <compound-id="612">lactic acid</compound-id> (Lac) was significantly lowered (1.50±1.08 mmol/L vs. 2.93±1.09 mmol/L), and pH, mixed venous <compound-id="977">oxygen</compound-id> saturation (SvO2), <compound-id="977">oxygen</compound-id> extraction ratio (O2ER), cardiac index (CI), <compound-id="977">oxygen</compound-id> delivery (<compound-id="160603">DO2</compound-id>) were significantly increased (pH:7.29±0.05 vs. 7.20±0.05, SvO2: 0.75±0.18 vs. 0.66±0.17, O2ER: 0.32±0.06 vs. 0.25±0.06, CI: 113.36±13.34 ml×s(-1)×m(-2) vs. 83.35±13.34 ml×s(-1)×m(-2), <compound-id="160603">DO2</compound-id>: 840±170 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2) vs. 630±171 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2), all P&lt;0.01).	DO2__min(-1__no_interaction	lactic acid__min(-1__no_interaction	oxygen__min(-1__no_interaction
1388945-1	(1) 1,2-<compound-id="74971">Naphthalenedicarboxylic acid</compound-id>-<compound-id="3283">diethyl ether</compound-id>, C12H8O4.nC4H10O, M(r) = 216.19, tetragonal, I4(1)/a, a = 22.086 (3), c = 9.463 (3) A, V = 4616 (2) A3, Z = 16, F(000) = 1792 (without ether), F(000) = 1873 (with 2.7 molecules of ether per unit cell), Dx = 1.24 g cm-3 (without ether), Dx = 1.31 g cm-3 (with 2.7 molecules of ether per unit cell), lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, T = 296 K, mu = 0.88 cm-1, R = 0.052 for 1130 unique reflections having I greater than 3 sigma I.	Naphthalenedicarboxylic acid__Mo K alpha__no_interaction	diethyl ether__Mo K alpha__no_interaction
15618238-12	In univariate analysis, DeltaCCA-<compound-id="447041">IMT</compound-id> correlated positively with age (R = 0.32, P = 0.03), BMI (R = 0.29, P = 0.05) and mean concentrations of <protein-id="P02741">CRP</protein-id> (R = 0.37, P = 0.01), <protein-id="P01375,Q5STB3">TNFalpha</protein-id> (0.52, P = 0.0002), but inversely with HDL-<compound-id="5997">cholesterol</compound-id> (R = -0.37, P = 0.01).	IMT__CRP__no_interaction	IMT__TNFalpha__no_interaction	cholesterol__CRP__no_interaction	cholesterol__TNFalpha__no_interaction
12025913-6	The results showed that plasma levels of <protein-id="P02741">CRP</protein-id> are significantly higher in patients with UA than those in patients with SA and control subjects (5.1 +/- 1.4 mg/L vs 1.7 +/- 0.4 mg/L and 1.3 +/- 0.2 mg/L, p&lt;0.01, respectively) with no difference between the latter two groups (p&gt;0.05); the total incidence of clinical events during in-hospital follow-up was higher in the group A (p&lt;0.01); the scores of coronary stenosis are significantly higher in patients with SA than those in patients with UA (4.9 +/- 2.1 vs 3.4 +/- 1.4, p&lt;0.05); there is no correlation between plasma levels of <protein-id="P02741">CRP</protein-id> and serum total <compound-id="5997">cholesterol</compound-id> (TC) as well as high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) in both groups (p&gt;0.05 respectively); there was no correlation between plasma levels of <protein-id="P02741">CRP</protein-id> and severity of coronary stenosis was found in patients with UA (p&gt;0.05) but a significant positive association in patients with SA (p&lt;0.001); and the patients with persistent, severe, treatment-unresponsive UA had significantly higher <protein-id="P02741">CRP</protein-id> levels as well as incidence of clinical events than patients with treatment-responsive UA (7.4 +/- 1.8 mg/L vs 2.6 +/- 1.3 mg/L, p&lt;0.01; 0 vs 22.2%, p&lt;0.05).	cholesterol__CRP__no_interaction
20339887-2	In particular, log beta values for the formation of (VO)<compound-id="6914579">hTf</compound-id> (13.0 +/- 0.5), (VO)(2)<compound-id="6914579">hTf</compound-id> (25.5 +/- 0.5), (VO)HSA (9.1 +/- 1.0), (VO) (2) (d) HSA (20.9 +/- 1.0), cis-VO(<protein-id="Q12882">dhp</protein-id>)(2)(<compound-id="6914579">hTf</compound-id>) (25.5 +/- 0.6), cis-VO(<protein-id="Q12882">dhp</protein-id>)(2)(HSA) (25.9 +/- 0.6), (VO)<compound-id="6914579">hTf</compound-id>(lact) (14.5 +/- 0.8), (VO)(2)<compound-id="6914579">hTf</compound-id>(lact)(2) (28.5 +/- 0.8), (VO)<compound-id="6914579">hTf</compound-id>(pic) (15.6 +/- 0.8), and (VO)(2)<compound-id="6914579">hTf</compound-id>(pic)(2) (30.4 +/- 0.8) were determined.	hTf__dhp__no_interaction
23646229-22	Comparing patients with liver cirrhosis but without active <compound-id="10982484,702">alcohol</compound-id> consumption (n = 11), we also found significant lymphopenia (1.3 × 10(9)/L ± 0.6 × 10(9)/L vs 2.1 × 10(9)/L ± 0.5 × 10(9)/L, P &lt; 0.0001) and decreases in populations of CD3(+) (945.5 ± 547.4/mm(3) vs 1523.0 ± 364.6/mm(3), P = 0.003), <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>(+) (745.2 ± 389.0/mm(3) vs 992.4 ± 274.7/mm(3), P = 0.032), <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>(+) (233.9 ± 120.0/mm(3) vs 478.9 ± 164.6/mm(3), P &lt; 0.0001), and <protein-id="P15391">CD19</protein-id>(+) (150.8 ± 76.1/mm(3) vs 264.6 ± 88.0/mm(3), P = 0.001).	alcohol__CD4__no_interaction	alcohol__CD8__no_interaction	alcohol__CD19__no_interaction
17305237-7	Two methods of sample preparation, derivatization, and analysis were used on aqueous standard mixtures of, respectively, (i) eight beta-adrenoceptor ligands, including five beta-antagonists (<compound-id="1978">acebutolol</compound-id>, <compound-id="2119">alprenolol</compound-id>, <compound-id="2249">atenolol</compound-id>, <compound-id="4171">metoprolol</compound-id>, <compound-id="4828">pindolol</compound-id>) and three <protein-id="Q13562">beta2</protein-id>-agonists (<compound-id="2083">salbutamol</compound-id>, clenbuterol, terbutaline) and (ii) seventeen diuretic drugs (<compound-id="1986">acetazolamide</compound-id>, <compound-id="2122">althiazide</compound-id>, <compound-id="2315">bendroflumethiazide</compound-id>, <compound-id="2471">bumethanide</compound-id>, <compound-id="13789">canrenone</compound-id>, <compound-id="2720">chlorothiazide</compound-id>, <compound-id="2732">chlortalidone</compound-id>, <compound-id="2804">clopamide</compound-id>, ethacrinic acid, <compound-id="3440">furosemide</compound-id>, <compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="3647">hydroflumethiazide</compound-id>, <compound-id="3702">indapamide</compound-id>, <compound-id="3715">indomethacine</compound-id>, <compound-id="5833">spironolactone</compound-id>, <compound-id="5546">triamterene</compound-id>, <compound-id="5560">trichloromethiazide</compound-id>) and one masking agent (<compound-id="4911">probenecid</compound-id>).	canrenone__beta2__no_interaction	trichloromethiazide__beta2__no_interaction	indapamide__beta2__no_interaction	furosemide__beta2__no_interaction	probenecid__beta2__no_interaction	acebutolol__beta2__no_interaction	bumethanide__beta2__no_interaction	althiazide__beta2__no_interaction	acetazolamide__beta2__no_interaction	alprenolol__beta2__no_interaction	pindolol__beta2__no_interaction	atenolol__beta2__no_interaction	chlorothiazide__beta2__no_interaction	salbutamol__beta2__no_interaction	triamterene__beta2__no_interaction	clopamide__beta2__no_interaction	spironolactone__beta2__no_interaction	chlortalidone__beta2__no_interaction	bendroflumethiazide__beta2__no_interaction	hydrochlorothiazide__beta2__no_interaction	hydroflumethiazide__beta2__no_interaction	metoprolol__beta2__no_interaction	indomethacine__beta2__no_interaction
11511232-1	<compound-id="702">Ethanol</compound-id> adducts of <protein-id="O95817">bis</protein-id>(3-R-penta-2,4-dionato) <compound-id="935">nickel</compound-id>(II) have been prepared by recrystallization of the corresponding <compound-id="935">nickel</compound-id> bisacetylacetonate species from <compound-id="702">ethanol</compound-id>, and their crystal structures have been determined by X-ray diffraction: R = methyl, C16H30NiO6, a = 5.177(1), b = 9.326(1), c = 9.649(1), a = 95.39(1), beta = 100.04(1), gamma = 97.16(1), space group Ponebar, Z = 1; R = hex-5-enyl, C26H46NiO6, a = 5.176(1), b = 9.677(1), c = 14.458(1), a = 92.333(3), beta = 93.945(4), gamma = 96.011(6), space group Ponebar, Z = 1; R = phenyl, C26H34NiO6, a = 27.399(1), b = 5.349(1), c = 19.827(2), beta = 117.410(7), space group C2/c, Z = 4.	nickel__bis__no_interaction	ethanol__bis__no_interaction	Ethanol__bis__no_interaction
9809851-1	The aim was to study firstly, the motor effects of a new <protein-id="P19327">5-HT1A</protein-id> antagonist, <compound-id="6420188">NDL</compound-id>-249 [(R)-3-(<compound-id="12487536">N-cyclopentyl-N-propylamino</compound-id>)-8-fluoro-3,4-dihydro-2H-1-benzopyra n-5-<compound-id="11960529">carboxamide</compound-id> hydrochloride] and of the reference <protein-id="P19327">5-HT1A</protein-id> antagonist WAY-100 635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))<compound-id="23134249">ethyl</compound-id>)-N-(2-pyridinyl) <compound-id="14283">cyclohexanecarboxamide</compound-id> trihydrochloride], in comparison to the <protein-id="P19327">5-HT1A</protein-id> agonist (+/-)-8-OH-DPAT [(8-hydroxy-2-(di-N-propylamino) <compound-id="8404">tetralin</compound-id>, hereafter 8-OH-DPAT], in rats acclimatised to the automated activity cages; secondly, to study whether the behavioural effects of <compound-id="6420188">NDL</compound-id>-249 and 8-OH-DPAT are sensitive to the <compound-id="5202">5-HT</compound-id> depleting effects of <compound-id="4652">p-chlorophenylalanine</compound-id> (PCPA); thirdly, to characterise the nature of the antagonist-induced activation seen in the automatic activity cages with the aid of a behavioural observation analysis; fourthly, to examine the interaction between the <protein-id="P19327">5-HT1A</protein-id> receptors mediating the behavioural effects and <compound-id="681">dopamine</compound-id> (DA) receptors.	carboxamide__5-HT1A__no_interaction	NDL__5-HT1A__no_interaction	5-HT__5-HT1A__no_interaction	cyclohexanecarboxamide__5-HT1A__no_interaction	p-chlorophenylalanine__5-HT1A__no_interaction	tetralin__5-HT1A__no_interaction	N-cyclopentyl-N-propylamino__5-HT1A__no_interaction	dopamine__5-HT1A__no_interaction	ethyl__5-HT1A__no_interaction
18070344-13	The 2 hour postoperative plasma <protein-id="P80188">NGAL</protein-id> levels strongly correlated with change in <compound-id="588">creatinine</compound-id> (r = 0.46, P &lt; 0.001), duration of AKI (r = 0.57, P &lt; 0.001), and length of hospital stay (r = 0.44, P &lt; 0.001).	creatinine__NGAL__no_interaction
15131536-4	Such trials included: the Belegian Netherlands Stent Study (BENESTENT) II, Optimal Coronary Balloon Angioplasty With Provisional Stenting Versus Primary Stent (OCBAS), Balloon Optimization vs Stent Study (BOSS), Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT), Optimum Percutaneous Transluminal Coronary Angioplasty Compared With Routine Stent Strategy (<compound-id="107901">OPUS</compound-id>-1), French Optimal Stenting Trial (FROST), Angioplasty or Stent (AS), and Doppler Endpoint Stenting International Investigation (DESTINI) trials for de novo coronary artery lesions; the Stent vs Percutaneous Angioplasty in Chronic Total Occlusion (SPACTO), Total Occlusion Study of Canada (TOSCA), Stent or Angioplasty after Recanalization of Chronic Coronary Occlusions (SARECCO), and Mayo-Japan Investigation for Chronic Total Occlusion (<compound-id="6440583">MAJIC</compound-id>) trials for coronary occlusions; the Primary Angioplasty Versus Stent Implantation in Acute Myocardial Infarction (<protein-id="A0A0A0MT80">PASTA</protein-id>), Gianturco-Roubin in Acute Myocardial Infarction (GRAMI), Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO), Immediate Coronary Angioplasty with Elective Wiktor Stent Implantation Compared with Conventional Balloon Angioplasty in Acute Myocardial Infarction (STENTUIM-2), Stent Primary Angioplasty in MI (Stent-PAMI), Zwolle, and Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (<compound-id="6468">CADILLAC</compound-id>) trials for acute ST-segment elevation myocardial infarction; and the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries (ISAR-SMART), Park, Stenting in Small Arteries (SISA), and Bestent in Small Arteries (BESMART) trials for small vessels.	OPUS__PASTA__no_interaction	MAJIC__PASTA__no_interaction	CADILLAC__PASTA__no_interaction
17333738-2	The mean <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P00813,F5GWI4">ADA</protein-id> values for the different groups were: 39.44 +/- 41.46, 13.00 +/- 7.43, 34.20 +/- 40.81, 3.17 +/- 4.82, 10.03 +/- 9.23, 8.67 +/- 13.60, and 2.58 +/- 2.90 U/I, respectively.	CSF__ADA__no_interaction
15118266-7	There were significant positive correlations between serum BPA and total <compound-id="6013">testosterone</compound-id> (r = 0.391, p&lt;0.001), free <compound-id="6013">testosterone</compound-id> (r = 0.504, p&lt;0.001), <compound-id="6128">androstenedione</compound-id> (r = 0.684, p&lt;0.001), and <protein-id="Q06520,A8K015">DHEAS</protein-id> (r = 0.514, p&lt;0.001) concentrations in all subjects.	testosterone__DHEAS__no_interaction	androstenedione__DHEAS__no_interaction
23990706-4	Afterwards, continuous infusion of <compound-id="36339,6338045">etomidate</compound-id> emulsion and <compound-id="60815">remifentanil</compound-id>, respectively (E1: 10 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.1 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>); E2: 15 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.2 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>); E3: 20 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.2 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>)), and <compound-id="4943">propofol</compound-id> (P group: 6~10 mg · kg(-1) · h(-1)) were administered.	etomidate__min(-1__no_interaction	remifentanil__min(-1__no_interaction	propofol__min(-1__no_interaction
15137766-1	<compound-id="24523">Deuterium</compound-id> kinetic solvent isotope effects for the human alpha-<compound-id="90470996">thrombin</compound-id>-catalyzed hydrolysis of (1) substrates with selected P(1)-P(3) sites, Z-Pro-Arg-7-amido-<compound-id="11833">4-methylcoumarin</compound-id> (<compound-id="9920436">7-AMC</compound-id>), N-<compound-id="12623186,18362414,87576829">t-Boc</compound-id>-Val-Pro-Arg-<compound-id="9920436">7-AMC</compound-id>, <compound-id="23056">Bz</compound-id>-<compound-id="4096934">Phe-Val</compound-id>-Arg-4-<compound-id="61191">nitroanilide</compound-id> (pNA), and H-D-Phe-L-Pip-Arg-pNA, are (DOD)k(cat) = (2.8-3.3) +/- 0.1 and (DOD)(k(cat)/K(m)) = (0.8-2.1) +/- 0.1 and (2) internally fluorescence-quenched substrates (a) (AB)Val-<compound-id="133189">Phe-Pro-Arg</compound-id>-<compound-id="21285384">Ser-Phe</compound-id>-<compound-id="6992563">Arg-Leu</compound-id>-<compound-id="5962">Lys</compound-id>(<compound-id="54058300,57080304,57201203">DNP</compound-id>)-Asp-OH, an optimal sequence, and (b) (AB)<compound-id="139506">Val-Ser</compound-id>-Pro-Arg-<compound-id="21285384">Ser-Phe</compound-id>-Gln-<compound-id="5962">Lys</compound-id>(<compound-id="54058300,57080304,57201203">DNP</compound-id>)-Asp-OH, recognition sequence for factor <protein-id="P10176,Q53XN1">VIII</protein-id>, are (DOD)k(cat) = 2.2 +/- 0.2 and (DOD)(k(cat)/K(m)) = (0.8-0.9) +/- 0.1, at the pL (L = H, D) maximum, 8.4-9.0, and (25.0-26.0) +/- 0.1 degrees C. The most plausible models fitting the partial isotope effect (<compound-id="1038,5460653">proton</compound-id> inventory) data have been selected on the basis of lowest values of the reduced chi squared and consistency of fractionation factors at all substrate concentrations, assuming rate-determining acylation.	Phe-Val__VIII__no_interaction	Val-Ser__VIII__no_interaction	Lys__VIII__no_interaction	thrombin__VIII__no_interaction	proton__VIII__no_interaction	Deuterium__VIII__no_interaction	t-Boc__VIII__no_interaction	7-AMC__VIII__no_interaction	DNP__VIII__no_interaction	nitroanilide__VIII__no_interaction	Phe-Pro-Arg__VIII__no_interaction	4-methylcoumarin__VIII__no_interaction	Arg-Leu__VIII__no_interaction	Ser-Phe__VIII__no_interaction	Bz__VIII__no_interaction
11606774-5	Mesenteric arterioles of <protein-id="Q91WT9">CBS</protein-id>((-/+))/<protein-id="P11352">GPx-1((tg-)) mice</protein-id> showed vasoconstriction to superfusion with beta-<compound-id="1993">methacholine</compound-id> and bradykinin (P &lt; 0.001 vs. all other groups), whereas nonhyperhomocyst(e)inemic mice [<protein-id="Q91WT9">CBS</protein-id>((+/+))/<protein-id="P00435">GPx-1</protein-id>((tg-)) and <protein-id="Q91WT9">CBS</protein-id>((+/+))/<protein-id="P11352">GPx-1((tg+)) mice</protein-id>] demonstrated dose-dependent vasodilation in response to both agonists.	methacholine__GPx-1((tg-)) mice__no_interaction	methacholine__CBS__no_interaction	methacholine__GPx-1((tg+)) mice__no_interaction	methacholine__GPx-1__no_interaction
16295739-6	Among them 30 patients completed at least 6 months of therapy, majority (27 patients) showed improvement in liver function with decrease in serum ALT from mean (+/- SD) 118.8 +/- 106.5 to 50.2 +/- 57.1 U/L (p &lt; 0.001), decrease in serum <compound-id="5280352">bilirubin</compound-id> from 73.9 +/- 80.5 to 44.7 +/- 62.9 micromol/l (p = 0.129), increase in serum albumin from 26.2 +/- 4.2 to 33.2 +/- 3.4 g/l (p &lt; 0.05), decrease in <protein-id="P00734">prothrombin</protein-id> time from 8.3 +/- 4.0 to 3.9 +/- 2.9 seconds prolonged (p &lt; 0.05) and reduction in child pugh score from 11.0 +/- 1.7 to 7.0 +/- 1.3 (p &lt; 0.001).	bilirubin__prothrombin__no_interaction
15285676-1	The nature and dynamics of the lowest excited states of <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(I)(L)(CO)(3)(phen)](+) and <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(I)(L)(CO)(3)(5-NO(2)-phen)](+) [L = Cl(-), 4-<compound-id="23134249">ethyl</compound-id>-<compound-id="1049">pyridine</compound-id> (4-Etpy), <compound-id="795">imidazole</compound-id> (<compound-id="444499">imH</compound-id>); phen = 1,10-<compound-id="67473">phenanthroline</compound-id>] have been investigated by picosecond visible and IR transient absorption spectroscopy in aqueous (L = <compound-id="444499">imH</compound-id>), acetonitrile (L = 4-Etpy, <compound-id="444499">imH</compound-id>), and <compound-id="887">MeOH</compound-id> (L = <compound-id="444499">imH</compound-id>) solutions.	phenanthroline__fac__no_interaction	imH__fac__no_interaction	pyridine__fac__no_interaction	MeOH__fac__no_interaction	ethyl__fac__no_interaction	imidazole__fac__no_interaction
14735233-3	This issue focuses on the following selection of drugs: Abetimus <compound-id="5360545">sodium</compound-id>, adalimumab, alefacept, alemtuzumab, <compound-id="123606">almotriptan</compound-id>, AMGN-0007, <compound-id="90470007">anakinra</compound-id>, anti-<protein-id="Q28090,Q71AW3">CTLA-4</protein-id> Mab, L-<compound-id="6322,90867653">arginine</compound-id> hydrochloride, <compound-id="179337">arzoxifene hydrochloride</compound-id>, <compound-id="2247">astemizole</compound-id>, <compound-id="148192">atazanavir sulfate</compound-id>, atlizumab; Belimumab, BG-9928, <compound-id="9576912">binodenoson</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, bovine <protein-id="P24627,B9VPZ5">lactoferrin</protein-id>, BufferGel; <compound-id="5486792,2826718,468682,66577042,71295847">Caspofungin acetate</compound-id>, <compound-id="6918155">ciclesonide</compound-id>,<compound-id="151170">cilomilast</compound-id>, <compound-id="9853710">ciluprevir</compound-id>, <compound-id="119182">clofarabine</compound-id>, CVT-3146; Darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="73303">doripenem</compound-id>, <compound-id="208898">dronedarone hydrochloride</compound-id>, drotrecogin alfa (activated), DT388-GM-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id>, <compound-id="60835">duloxetine</compound-id> hydrochloride, E-5564, efalizumab, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="9568614">esomeprazole</compound-id> <compound-id="5462224">magnesium</compound-id>, <compound-id="157050">estradiol acetate</compound-id>, ETC-642, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="5472495">exisulind</compound-id>, ezetimib; <compound-id="134018">Febuxostat</compound-id>; <compound-id="5360835">Gallium</compound-id> <compound-id="8369">maltolate</compound-id>, <compound-id="16130957,16130966">ganirelix acetate</compound-id>, <compound-id="124093">garenoxacin mesilate</compound-id>, <compound-id="123631">gefitinib</compound-id>; H11, HuMax; <protein-id="Q28028">IL-15</protein-id>, IDD-1, IGIV-C, <compound-id="5291">imatinib mesylate</compound-id>, ISIS-14803, <compound-id="216295">ITF-1697</compound-id>, <compound-id="132999">ivabradine hydrochloride</compound-id>; KRN-5500; L-365260, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="3033825">levosimendan</compound-id>, <compound-id="133021">licofelone</compound-id>, <compound-id="441401">linezolid</compound-id>, <compound-id="3037609">LJP-1082</compound-id>, <compound-id="92727">lopinavir</compound-id> <compound-id="151166">lumiracoxib</compound-id>; MCC-478, <compound-id="896">melatonin</compound-id>, <compound-id="5288826">morphine hydrochloride</compound-id>, <compound-id="5360621">morphine-6-glucuronide</compound-id>, <compound-id="16760141,71312368,86287400,91506576,9571036,9604461,9832912">moxidectin</compound-id>; <compound-id="9903482">N-Acetylcarnosine</compound-id>, natalizumab, NM-702, <compound-id="5278688">NNC</compound-id>-05-1869, NSC-703940; <compound-id="216456">Ocinaplon</compound-id> OM-89, omalizumab, omeprazole/ <compound-id="767">sodium bicarbonate</compound-id>, <compound-id="219020">OPC-28326</compound-id>, <compound-id="3036505">ospemifene</compound-id>; PEG-filgrastim peginterferon alfa-2a, pegsunercept, <compound-id="40632">pirfenidone</compound-id>, <compound-id="6852372,6918245">pralmorelin</compound-id>, <compound-id="5486971">pregabalin</compound-id>; Recombinant <compound-id="16133831">glucagon-like peptide-1 (7-36) amide</compound-id>, repifermin, <compound-id="9930049">RSD-1235</compound-id>; S-8184, <compound-id="3082555">selodenoson</compound-id>, <compound-id="6597">sodium dichloroacetate</compound-id>, <compound-id="5311">suberanilohydroxamic acid</compound-id>; TAS-102, <compound-id="5405">terfenadine</compound-id>, teriparatide, <compound-id="54682461">tipranavir</compound-id> <compound-id="151173,454194">troxacitabine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; YM-337.	Ocinaplon__IL-15__no_interaction	Ocinaplon__CTLA-4__no_interaction	Ocinaplon__lactoferrin__no_interaction	ospemifene__IL-15__no_interaction	ospemifene__CTLA-4__no_interaction	ospemifene__lactoferrin__no_interaction	Febuxostat__IL-15__no_interaction	Febuxostat__CTLA-4__no_interaction	Febuxostat__lactoferrin__no_interaction	maltolate__IL-15__no_interaction	maltolate__CTLA-4__no_interaction	maltolate__lactoferrin__no_interaction	lumiracoxib__IL-15__no_interaction	lumiracoxib__CTLA-4__no_interaction	lumiracoxib__lactoferrin__no_interaction	glucagon-like peptide-1 (7-36) amide__IL-15__no_interaction	glucagon-like peptide-1 (7-36) amide__CTLA-4__no_interaction	glucagon-like peptide-1 (7-36) amide__lactoferrin__no_interaction	astemizole__IL-15__no_interaction	astemizole__CTLA-4__no_interaction	astemizole__lactoferrin__no_interaction	OPC-28326__IL-15__no_interaction	OPC-28326__CTLA-4__no_interaction	OPC-28326__lactoferrin__no_interaction	garenoxacin mesilate__IL-15__no_interaction	garenoxacin mesilate__CTLA-4__no_interaction	garenoxacin mesilate__lactoferrin__no_interaction	troxacitabine__IL-15__no_interaction	troxacitabine__CTLA-4__no_interaction	troxacitabine__lactoferrin__no_interaction	bosentan__IL-15__no_interaction	bosentan__CTLA-4__no_interaction	bosentan__lactoferrin__no_interaction	morphine-6-glucuronide__IL-15__no_interaction	morphine-6-glucuronide__CTLA-4__no_interaction	morphine-6-glucuronide__lactoferrin__no_interaction	lopinavir__IL-15__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__lactoferrin__no_interaction	melatonin__IL-15__no_interaction	melatonin__CTLA-4__no_interaction	melatonin__lactoferrin__no_interaction	exenatide__IL-15__no_interaction	exenatide__CTLA-4__no_interaction	exenatide__lactoferrin__no_interaction	morphine hydrochloride__IL-15__no_interaction	morphine hydrochloride__CTLA-4__no_interaction	morphine hydrochloride__lactoferrin__no_interaction	ciclesonide__IL-15__no_interaction	ciclesonide__CTLA-4__no_interaction	ciclesonide__lactoferrin__no_interaction	ivabradine hydrochloride__IL-15__no_interaction	ivabradine hydrochloride__CTLA-4__no_interaction	ivabradine hydrochloride__lactoferrin__no_interaction	dronedarone hydrochloride__IL-15__no_interaction	dronedarone hydrochloride__CTLA-4__no_interaction	dronedarone hydrochloride__lactoferrin__no_interaction	sodium__IL-15__no_interaction	sodium__CTLA-4__no_interaction	sodium__lactoferrin__no_interaction	licofelone__IL-15__no_interaction	licofelone__CTLA-4__no_interaction	licofelone__lactoferrin__no_interaction	cilomilast__IL-15__no_interaction	cilomilast__CTLA-4__no_interaction	cilomilast__lactoferrin__no_interaction	NNC__IL-15__no_interaction	NNC__CTLA-4__no_interaction	NNC__lactoferrin__no_interaction	RSD-1235__IL-15__no_interaction	RSD-1235__CTLA-4__no_interaction	RSD-1235__lactoferrin__no_interaction	pirfenidone__IL-15__no_interaction	pirfenidone__CTLA-4__no_interaction	pirfenidone__lactoferrin__no_interaction	estradiol acetate__IL-15__no_interaction	estradiol acetate__CTLA-4__no_interaction	estradiol acetate__lactoferrin__no_interaction	esomeprazole__IL-15__no_interaction	esomeprazole__CTLA-4__no_interaction	esomeprazole__lactoferrin__no_interaction	suberanilohydroxamic acid__IL-15__no_interaction	suberanilohydroxamic acid__CTLA-4__no_interaction	suberanilohydroxamic acid__lactoferrin__no_interaction	pregabalin__IL-15__no_interaction	pregabalin__CTLA-4__no_interaction	pregabalin__lactoferrin__no_interaction	ciluprevir__IL-15__no_interaction	ciluprevir__CTLA-4__no_interaction	ciluprevir__lactoferrin__no_interaction	enfuvirtide__IL-15__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__lactoferrin__no_interaction	ITF-1697__IL-15__no_interaction	ITF-1697__CTLA-4__no_interaction	ITF-1697__lactoferrin__no_interaction	sodium dichloroacetate__IL-15__no_interaction	sodium dichloroacetate__CTLA-4__no_interaction	sodium dichloroacetate__lactoferrin__no_interaction	CSF__IL-15__no_interaction	CSF__CTLA-4__no_interaction	CSF__lactoferrin__no_interaction	clofarabine__IL-15__no_interaction	clofarabine__CTLA-4__no_interaction	clofarabine__lactoferrin__no_interaction	terfenadine__IL-15__no_interaction	terfenadine__CTLA-4__no_interaction	terfenadine__lactoferrin__no_interaction	gefitinib__IL-15__no_interaction	gefitinib__CTLA-4__no_interaction	gefitinib__lactoferrin__no_interaction	LJP-1082__IL-15__no_interaction	LJP-1082__CTLA-4__no_interaction	LJP-1082__lactoferrin__no_interaction	atazanavir sulfate__IL-15__no_interaction	atazanavir sulfate__CTLA-4__no_interaction	atazanavir sulfate__lactoferrin__no_interaction	Gallium__IL-15__no_interaction	Gallium__CTLA-4__no_interaction	Gallium__lactoferrin__no_interaction	arginine__IL-15__no_interaction	arginine__CTLA-4__no_interaction	arginine__lactoferrin__no_interaction	selodenoson__IL-15__no_interaction	selodenoson__CTLA-4__no_interaction	selodenoson__lactoferrin__no_interaction	sodium bicarbonate__IL-15__no_interaction	sodium bicarbonate__CTLA-4__no_interaction	sodium bicarbonate__lactoferrin__no_interaction	tipranavir__IL-15__no_interaction	tipranavir__CTLA-4__no_interaction	tipranavir__lactoferrin__no_interaction	linezolid__IL-15__no_interaction	linezolid__CTLA-4__no_interaction	linezolid__lactoferrin__no_interaction	Caspofungin acetate__IL-15__no_interaction	Caspofungin acetate__CTLA-4__no_interaction	Caspofungin acetate__lactoferrin__no_interaction	arzoxifene hydrochloride__IL-15__no_interaction	arzoxifene hydrochloride__CTLA-4__no_interaction	arzoxifene hydrochloride__lactoferrin__no_interaction	ganirelix acetate__IL-15__no_interaction	ganirelix acetate__CTLA-4__no_interaction	ganirelix acetate__lactoferrin__no_interaction	N-Acetylcarnosine__IL-15__no_interaction	N-Acetylcarnosine__CTLA-4__no_interaction	N-Acetylcarnosine__lactoferrin__no_interaction	doripenem__IL-15__no_interaction	doripenem__CTLA-4__no_interaction	doripenem__lactoferrin__no_interaction	Ximelagatran__IL-15__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__lactoferrin__no_interaction	imatinib mesylate__IL-15__no_interaction	imatinib mesylate__CTLA-4__no_interaction	imatinib mesylate__lactoferrin__no_interaction	exisulind__IL-15__no_interaction	exisulind__CTLA-4__no_interaction	exisulind__lactoferrin__no_interaction	moxidectin__IL-15__no_interaction	moxidectin__CTLA-4__no_interaction	moxidectin__lactoferrin__no_interaction	diflomotecan__IL-15__no_interaction	diflomotecan__CTLA-4__no_interaction	diflomotecan__lactoferrin__no_interaction	almotriptan__IL-15__no_interaction	almotriptan__CTLA-4__no_interaction	almotriptan__lactoferrin__no_interaction	desloratadine__IL-15__no_interaction	desloratadine__CTLA-4__no_interaction	desloratadine__lactoferrin__no_interaction	magnesium__IL-15__no_interaction	magnesium__CTLA-4__no_interaction	magnesium__lactoferrin__no_interaction	anakinra__IL-15__no_interaction	anakinra__CTLA-4__no_interaction	anakinra__lactoferrin__no_interaction	pralmorelin__IL-15__no_interaction	pralmorelin__CTLA-4__no_interaction	pralmorelin__lactoferrin__no_interaction	binodenoson__IL-15__no_interaction	binodenoson__CTLA-4__no_interaction	binodenoson__lactoferrin__no_interaction	levetiracetam__IL-15__no_interaction	levetiracetam__CTLA-4__no_interaction	levetiracetam__lactoferrin__no_interaction	levosimendan__IL-15__no_interaction	levosimendan__CTLA-4__no_interaction	levosimendan__lactoferrin__no_interaction	duloxetine__IL-15__no_interaction	duloxetine__CTLA-4__no_interaction	duloxetine__lactoferrin__no_interaction
22170388-7	<compound-id="702">Ethanol</compound-id> solvate 3 with a dimer motif shows field-induced single-molecule magnet like behavior below 2.5 K. The exchange coupling constant J within the dimer propagated by π-π interaction is -0.14 cm(-1) by fitting the susceptibility data χ(M) T (20-300 K) with the <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> Hamiltonian H = -2J S(A) S(B) + β(S((A)g(A)) + S((B)g(B)))H. The present studies open a new way to construct SCMs from anisotropic magnetic single-ion units through weak intermolecular interactions in the absence of bridging ligands.	Ethanol__spin__no_interaction
10565441-6	Mean concentrations (X(g) x DF) were as follows: <protein-id="P11182">E2beta</protein-id> (bpl) 31.1 (1.16), (spl) 24.2 (1.42) pg ml(-1); E1 (bpl) 143.3 (1.21), (spl) 117.7 (1.53) pg ml(-1); <compound-id="57336492">E1S</compound-id> (bpl) 157.3 (1.44), (spl) 2.92 (1.42) ng ml(-1); T (bpl) 570.6 (1.43), (spl) 23.1 (1.68) pg ml(-1); A (spl) 17.9 (1.39) pg ml(-1); DHEH (spl) 12.4 (1.51) pg ml(-1); 5alpha-DHT (spl) 9.7 (1.29) pg ml(-1).	E1S__E2beta__no_interaction
16990846-3	Our results are summarized as follows: (i) a recombinant HSV (M012) was constructed in which both copies of the gamma(1)34.5 gene were replaced with the bacterial CD gene, under the control of the cellular promoter <protein-id="P08046,Q544D6,Q8CAT6">Egr-1</protein-id>; (ii) M012-infected cells in vitro efficiently convert <compound-id="3366">5-fluorocytosine</compound-id> (5-FC) to 5-<compound-id="3385">fluorouracil</compound-id>, thereby enhancing cytotoxicity of neighboring, uninfected cells; (iii) both direct and bystander cytotoxicity of murine neuroblastoma and human glioma cell lines after infection with M012 were demonstrated; (iv) direct intracerebral inoculation of A/J mice demonstrated lack of neurotoxicity at doses similar to G207, a gamma(1)34.5-deleted HSV with demonstrated safety in human patient trials and (v) intratumoral injection of M012 into Neuro-2a flank tumors in combination with 5-FC administration significantly reduced tumor growth versus tumors treated with <compound-id="706845">R3659</compound-id> combined with 5-FC, or treated with M012 alone.	5-fluorocytosine__Egr-1__no_interaction	R3659__Egr-1__no_interaction	fluorouracil__Egr-1__no_interaction
2077810-11	5) When the bilateral vertebral arteries arising from the respective subclavian artery are found in the above 2), 3) and 4) "2" postfixed "C" and the prime mark "', as type G'2, type <compound-id="447253">C2G</compound-id>, type <protein-id="Q9H330">CG'2</protein-id>, type <compound-id="447253">C2G</compound-id>', type <compound-id="447253">C2G</compound-id>'2, type H'2, type C2H, type CH'2, type C2H', type C2H'2.	C2G__CG'2__no_interaction
17923273-5	<protein-id="P41159,A4D0Y8">leptin</protein-id> showed a positive correlation with BMI (r = 0.851, p &lt;0.0001), waist-to-hip ratio (r = 0.692, p &lt;0.0001), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.441, p &lt;0.001), HOMA-IR (r = 0.412, p = 0.002), fibrinogen (r = 0.387, p = 0.004), <compound-id="1175">uric acid</compound-id> (r = 0.293, p = 0.033), hematocrit (r = 0.394, p = 0.003), systolic (r = 0.504, p &lt;0.0001), and diastolic blood pressure (r = 0.363, p = 0.008).	uric acid__leptin__no_interaction	uric acid__insulin__no_interaction
11149424-1	Evaluation of <compound-id="444795">retinoic acid</compound-id> receptor (RAR) subtype-selective alpha and gamma agonists and antagonists and a retinoid X receptor (RXR) class-selective agonist for efficacy at inhibiting both induction of <protein-id="P00860">ornithine decarboxylase</protein-id> (<protein-id="P00860">ODC</protein-id>) by the tumor promoter 12-<compound-id="18633279">O-tetradecanoylphorbol</compound-id>-13-<compound-id="176">acetate</compound-id> (<compound-id="122634,22833501">TPA</compound-id>) in mouse epidermis and rat tracheal epithelial cells and the appearance of papillomas in mouse epidermis treated in the 2-stage tumor initiation-promotion model indicated that (i) RXR class-selective transcriptional agonists, such as MM11246, were not involved in <protein-id="P00860">ODC</protein-id> inhibition; (ii) RAR-selective agonists that induce gene transcription from RA-responsive elements (RAREs) were active at low concentrations; (iii) RAR-selective antagonists that bind <protein-id="Q9D0I9">RARs</protein-id> and inhibit AP-1 activation on the collagenase promoter but do not activate RAREs to induce gene transcription were less effective inhibitors; and (iv) <protein-id="P18911">RARgamma</protein-id>-selective retinoid agonists were more effective inhibitors of <compound-id="122634,22833501">TPA</compound-id>-induced <protein-id="P00860">ODC</protein-id> activity than <protein-id="P11416,Q3U3R3,Q3U5E7">RARalpha</protein-id>-selective agonists.	O-tetradecanoylphorbol__ornithine decarboxylase__no_interaction	O-tetradecanoylphorbol__RARs__no_interaction	O-tetradecanoylphorbol__ODC__no_interaction	O-tetradecanoylphorbol__RARgamma__no_interaction	O-tetradecanoylphorbol__RARalpha__no_interaction	retinoic acid__ornithine decarboxylase__no_interaction	retinoic acid__RARs__no_interaction	retinoic acid__ODC__no_interaction	retinoic acid__RARgamma__no_interaction	retinoic acid__RARalpha__no_interaction	TPA__ornithine decarboxylase__no_interaction	TPA__RARs__no_interaction	TPA__ODC__no_interaction	TPA__RARgamma__no_interaction	TPA__RARalpha__no_interaction	acetate__ornithine decarboxylase__no_interaction	acetate__RARs__no_interaction	acetate__ODC__no_interaction	acetate__RARgamma__no_interaction	acetate__RARalpha__no_interaction
7769797-7	RAS activation was confirmed by 24-h urinary <compound-id="5360545">sodium</compound-id> excretion (screen, 142 +/- 74 mmol/24 h; prestudy, 66 +/- 33, 59 +/- 41, 78 +/- 4, 73 +/- 30 mmol/24 h) and increase in plasma <protein-id="P00797">renin</protein-id> activity (PRA) (screen, 0.8 +/- 0.3 ng <compound-id="15942654">AI</compound-id>/ml/h; before dosing, P, 6.5 +/- 3.1; 30 mg, 8.2 +/- 3; 100 mg, 9.4 +/- 5.7; 300 mg, 6.5 +/- 2.4; 600 mg, 5.2 +/- 2; 1,000 mg, 6.2 +/- 4.4 ng <compound-id="15942654">AI</compound-id>/ml/h).	AI__renin__no_interaction	sodium__renin__no_interaction
24005498-1	The reaction of <compound-id="9559">tetrapropylammonium</compound-id> bis(acetylacetonato)<compound-id="23985">gold</compound-id>(I) with alkyne derivatives of the <compound-id="5243808">tris(pyrazolyl)methane</compound-id> and 1,8-<compound-id="66491">naphthalimide</compound-id> functional groups yielded two new compounds, both bridged by the linear C[triple-bond]C-Au-C[triple-bond]C spacer, namely <compound-id="9559">tetrapropylammonium</compound-id> bis{3-[2,2,2-<compound-id="6503">tris</compound-id>(1H-pyrazol-1-yl)ethoxy]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-1-yl}aurate(I), (C16H28N)[Au(C14H13N6O)2], and <compound-id="9559">tetrapropylammonium</compound-id> {η(2)-μ-3-[2,4-dioxo-3-azatricyclo[7.3.1.0(5,13)]trideca-1(12),5,7,9(13),10-pentaen-3-yl]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-yl}bis{3-[2,4-dioxo-3-azatricyclo[7.3.1.0(5,13)]trideca-1(12),5,7,9(13),10-pentaen-3-yl]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-1-yl}digold(I) <compound-id="71583">deuterochloroform</compound-id> disolvate, (C16H28N)[Au2(C15H8NO2)3]·2CDCl3.	tris(pyrazolyl)methane__prop-1__no_interaction	deuterochloroform__prop-1__no_interaction	tetrapropylammonium__prop-1__no_interaction	naphthalimide__prop-1__no_interaction	gold__prop-1__no_interaction	tris__prop-1__no_interaction
11894121-8	We found that: i) pretreatment with <compound-id="53232">lovastatin</compound-id> (5-30 microM) induces apoptosis in HT-29 cells significantly only at high concentrations (&gt; or = 20 microM) but not at low dose levels; ii) similarly, pretreatment with <compound-id="2662">celecoxib</compound-id> produced apoptosis in colon cancer cells at high concentrations only (&gt; or = 75 microM); iii) <protein-id="P42574">caspase-3</protein-id> protein expression was moderately altered by the treatment with <compound-id="53232">lovastatin</compound-id> or <compound-id="2662">celecoxib</compound-id> at lower concentrations; however, a significant increase (1.6 to 4-fold) in <protein-id="P42574">caspase-3</protein-id> expression and activity was found in HT-29 cells exposed with 20-25 microM <compound-id="53232">lovastatin</compound-id> and/or 5-125 microM <compound-id="2662">celecoxib</compound-id> and iv) importantly, in tumor cells exposed to low doses of (5 or 10 microM) <compound-id="53232">lovastatin</compound-id>, combined with 25-75 microM of <compound-id="2662">celecoxib</compound-id>, apoptosis induction rose 2.5 to 10-fold, <protein-id="P42574">caspase-3</protein-id> expression was 2.3 to 8-fold higher, and enzyme activities were 1.5 to 5.5-fold elevated.	lovastatin__caspase-3__no_interaction	celecoxib__caspase-3__no_interaction
16130178-3	As part of a program aimed at the design of selective agonists for the human V(1b) receptor, we recently reported the human V(1b), <protein-id="P30560">V(1a</protein-id>), V(2) and OT receptor affinities of the following position 4 substituted analogues of [deamino-Cys(1)] <protein-id="P01185,X5DQP6">arginine vasopressin</protein-id> (dAVP)-(1) d[Leu(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (2) d[Orn(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (3) d[<compound-id="5962">Lys</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (4) d[<compound-id="123895">Har</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (5) d[Arg(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (6) d[Val(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (7) d[Ala(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (8) d[Abu(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (9) d[<compound-id="824">Nva</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (10) d[Nle(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (11) d[Ile(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (12) d[Phe(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (13) d[Asn(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (14) d[Thr(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>: (15) d[Dap(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>.	Har__V(1a__no_interaction	Har__arginine vasopressin__no_interaction	Har__AVP__no_interaction	Nva__V(1a__no_interaction	Nva__arginine vasopressin__no_interaction	Nva__AVP__no_interaction	Lys__V(1a__no_interaction	Lys__arginine vasopressin__no_interaction	Lys__AVP__no_interaction
12365017-5	RESULTS: The current study data demonstrate that 1) <protein-id="Q04206,A0A087X0W8">RelA</protein-id>/NF-kappaB activity is activated constitutively in Hep3B cells, as determined by electrophoretic mobility shift assays; 2) <protein-id="Q04206,A0A087X0W8">RelA</protein-id>/NF-kappaB reporter gene activity is inhibited specifically by dominant-negative mutants of <protein-id="P25963">IkappaB(alpha</protein-id>), <protein-id="O15111">IKK1</protein-id>, <protein-id="O14920">IKK2</protein-id>, <protein-id="Q13233">MEKK1</protein-id>, and <protein-id="Q99759,J3QRB6,J3KRN4">MEKK3</protein-id> and it is activated by overexpression of wild-type <protein-id="Q99759,J3QRB6,J3KRN4">MEKK3</protein-id>, suggesting that upstream kinase cascades induce phosphorylation of <protein-id="P25963">IkappaB(alpha</protein-id>) and activate <protein-id="Q04206,A0A087X0W8">RelA</protein-id>/NF-kappaB in Hep3B cells; 3) overexpression of the HBV x gene fails to activate NF-kappaB in HepG2 and Chang cell lines; 4) The NF-kappaB-inducible gene, <protein-id="Q07817,Q5TE63">bcl-xl</protein-id>, is overexpressed in Hep3B cells and is inhibited by the proteosome inhibitor <compound-id="387447">PS341</compound-id>, which prevents <protein-id="P25963">IkappaBalpha</protein-id> degradation and <protein-id="Q04206,A0A087X0W8">RelA</protein-id>/NF-kappaB activation; and 5) inhibition of constitutive <protein-id="Q04206,A0A087X0W8">RelA</protein-id>/NF-kappaB activity by <compound-id="387447">PS341</compound-id> sensitizes Hep3B cells to <compound-id="31703">doxorubicin</compound-id>-induced apoptosis.	doxorubicin__IKK1__no_interaction	doxorubicin__IKK2__no_interaction	doxorubicin__MEKK1__no_interaction	doxorubicin__MEKK3__no_interaction	doxorubicin__IkappaBalpha__no_interaction	doxorubicin__IkappaB(alpha__no_interaction	doxorubicin__bcl-xl__no_interaction	doxorubicin__RelA__no_interaction	PS341__IKK1__no_interaction	PS341__IKK2__no_interaction	PS341__MEKK1__no_interaction	PS341__MEKK3__no_interaction	PS341__IkappaBalpha__no_interaction	PS341__IkappaB(alpha__no_interaction	PS341__bcl-xl__no_interaction	PS341__RelA__no_interaction
19219304-4	<compound-id="4266">Muscimol</compound-id> reduced the effects of BVE on <compound-id="5360545">sodium</compound-id> excretion (isotonic: 2.4 +/- 0.3 vs vehicle: 4.8 +/- 0.2 and hypertonic: 4.0 +/- 0.7 vs vehicle: 8.7 +/- 0.6 microEq.100 g-1.40 min-1); urinary volume after hypertonic BVE (83.8 +/- 10 vs vehicle: 255.6 +/- 16.5 microL.100 g-1.40 min-1); plasma OT levels (isotonic: 15.3 +/- 0.6 vs vehicle: 19.3 +/- 1 and hypertonic: 26.5 +/- 2.6 vs vehicle: 48 +/- 3 pg/mL), and <protein-id="P01161,B0BMW5">ANP</protein-id> levels (isotonic: 97 +/- 12.8 vs vehicle: 258.3 +/- 28.1 and hypertonic: 160 +/- 14.6 vs vehicle: 318 +/- 16.3 pg/mL).	sodium__ANP__no_interaction	Muscimol__ANP__no_interaction
24579358-4	Cholera toxin B-subunit conjugated horseradish peroxidase (CB-HRP) containing 1.0% HRP was respectively injected to acupoint "Chengman" (<protein-id="P15709,A0A0G2JYC0">ST 20</protein-id>), "Liangmen" (ST 21), "Guanmen" (<compound-id="171434">ST 22</compound-id>), "Taiyi" (ST 23), "Huaroumen" (ST 24), "Tianshu" (ST 25) and "Wailing" (ST 26) of the Stomach Meridian, and "Ganshu" (BL 18), "Danshu" (BL 19), "Pishu" (BL 20), "Weishu" (BL 21) and "Sanjiaoshu" (BL 22) of the Bladder Meridian, and "Daimai" (GB 26), "Wushu" (GB 27), "Weidao" (GB 28), "Juliao" (GB 29), "Huantiao" (GB 30), "Fengshi" (GB 31), "Zhongdu" (GB 32), "Xiyangguan" (GB 33) and "Yanglingquan" (GB 34) of the Gallbladder Meridian (for labeling preganglionic neurons), and the celiac ganglion and superior mesenteric ganglion for labeling sympathetic preganglionic neurons.	ST 22__ST 20__no_interaction
16718631-6	<protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> concentration correlated inversely with HbA (1c) (r = - 0.43, p &lt; 0.05), <protein-id="P01308,I3WAC9">insulin</protein-id> concentration (r = - 0.38, p &lt; 0.05) and triglyceride concentration (r = - 0.42, p &lt; 0.05) but positively with <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (r = 0.38, p &lt; 0.05).	cholesterol__HDL__no_interaction	cholesterol__insulin__no_interaction	cholesterol__adiponectin__no_interaction
16455291-4	The pK(a) values determined with this procedure were as follows: H(4)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)=H(3)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(-)+H(+), pKa1 (6-H)=6.52+/-0.06; H(3)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(-)=H(2)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(2-)+H(+), pKa2 (3-H)=7.97+/-0.06; H(2)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(2-)=H(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(3-)+H(+), pKa3 (7-H)=9.44+/-0.04; H(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(3-)=(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>)(4-)+H(+), pKa4 (1-H)=12.10+/-0.01; where it has been considered <compound-id="12306736,5281647,5358385,5464041">mangiferin</compound-id> C(19)H(18)O(11) as H(4)(<protein-id="P21583,A0A024RBC0,A0A024RBF5">MGF</protein-id>).	mangiferin__MGF__no_interaction
22460931-12	It should be noted that the expression of CCN3 was already reported to repress <protein-id="P50282">MMP9</protein-id> (Benini et al., Oncogene 24:4349-4361 2005, Fukunaga-Kalabis et al., Oncogene 27:2552-2560 2008) and the roles of CCN3 in inflammatory processes has been extensively documented in the past few years (Bleau et al., Front Biosci 10:998-1009 2005, Lin et al., J Biol Chem 280:8229-8237 2005, Perbal, Cell Commun Signal 4:6 2006, Hughes et al., Diabetologia 50:1089-1098 2007, Lin et al., J Cell Commun Signal 4:141-153 2010, Pasmant et al., J Neuropathol Exp Neurol 69:60-69 2010, Shimoyama et al., Thromb <compound-id="54690394">Vasc</compound-id> Biol 30:675-682 2010, Lemaire et al., J Invest <compound-id="16683000">Dermatol</compound-id> 130:2517 2010, Chen and Lau, J Cell Commun Signal 4:63-69 2010, <compound-id="7009630">Le</compound-id> Dréau et al., Glia 58:1510-1521 2010, Rittié et al.	Vasc__MMP9__no_interaction	Le__MMP9__no_interaction	Dermatol__MMP9__no_interaction
22460931-15	Implication of CCN3 in cognitive functions (Su et al., Sheng Li Xue Bao 52:290-294 2000) and the possible involvement of CCN3 in the regulation of pain was already suggested almost a decade ago (Perbal, Expert <compound-id="78673847">Rev</compound-id> <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">Mol</protein-id> Diagn 3:597-604 2003, Perbal et al., <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">Mol</protein-id> Pathol 56:80-85 2003) with the demonstration of cell-specific effects of CCN3 on intracellular <compound-id="22044544,5460341">calcium</compound-id> stores and inhibition of anionic channels by CCN3 (Li et al., <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">Mol</protein-id> Pathol 55:250-261 2002, Lombet et al., Cell Commun Signal 1:1 2003, Perbal, Expert <compound-id="78673847">Rev</compound-id> <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">Mol</protein-id> Diagn 3:597-604 2003, Perbal et al., <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">Mol</protein-id> Pathol 56:80-85 2003).	calcium__Mol__no_interaction	Rev__Mol__no_interaction
23749259-1	The complexes [PtMe2(NN)], NN = 2,2′-bipyridine = bipy, 1a; NN = di-<compound-id="10439">2-pyridylamine</compound-id> = dpa, 1b; NN = di-2-<compound-id="88065">pyridyl ketone</compound-id> = <protein-id="O00180,A0A024R3T2">dpk</protein-id>, 1c, NN = 4,4′-bis(ethoxycarbonyl)-2,2′-bipyridine, bebipy, react with <compound-id="70297">m-chloroperoxybenzoic acid</compound-id> to give the <compound-id="23939">platinum</compound-id>(IV) complexes [Pt(OH)(O2C-3-C6H4Cl)<compound-id="13847">Me2</compound-id>(NN)], NN = bipy, 2, or [Pt(OH)(OH2···O2C-3-C6H4Cl)<compound-id="13847">Me2</compound-id>(NN)], NN = bipy, <compound-id="2981881,91293124">3a</compound-id>; dpa, 3b; bebipy, 3d, or [Pt(OH)<compound-id="66414">2Me2</compound-id>(dpkOH)]3[Pt(OH)(OH2)<compound-id="13847">Me2</compound-id>(dpkOH)][H(O2C-3-C6H4Cl)2]·2MeOH, 43·5·2MeOH.	platinum__dpk__no_interaction	2-pyridylamine__dpk__no_interaction	2Me2__dpk__no_interaction	m-chloroperoxybenzoic acid__dpk__no_interaction	Me2__dpk__no_interaction	pyridyl ketone__dpk__no_interaction	3a__dpk__no_interaction
23146795-7	The malaria parasite density in symptomatic HIV infected participants was negatively associated with <protein-id="P00390,V9HW90">glutathione reductase</protein-id> (r = -0.906, P&lt;0.01), <compound-id="124886,20725278">glutathione</compound-id> peroxidase (r = -0.719, P&lt;0.01) and total antioxidant status (r = -0.824, P&lt;0.01).	glutathione__glutathione reductase__no_interaction
1578483-2	This series of compounds includes [R-(R*,R*)]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2- [[(tricyclo[3.3.1.1] <protein-id="Q9C0J9,Q8TAT1,A0A024RAV8">dec-2</protein-id>-yloxy)carbonyl]amino]propyl]amino]-<compound-id="137551">1-phenylethyl</compound-id>]amino]- <compound-id="1112">4-oxobutanoic acid</compound-id> (CI-988, 1, Figure 1), the first rationally designed non-peptide antagonist of a neuropeptide receptor.	1-phenylethyl__dec-2__no_interaction	4-oxobutanoic acid__dec-2__no_interaction
19590499-10	Consistently, along with the increase in sCD40L, a worsening in <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity was observed, which was expressed as homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (HOMA%S: 99 +/- 52, 77 +/- 43, and 72 +/- 35, P &lt; 0.05), composite <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity index (ISIcomp; Matsuda index: 5.11 +/- 2.65, 3.61 +/- 1.98, and 3.28 +/- 1.87, P = 0.025), or oral <compound-id="206,5793,64689,79025">glucose</compound-id> <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (OGIS) index (OGIS: 421 +/- 67, 386 +/- 90, and 362 +/- 72, P = 0.004).	glucose__insulin__no_interaction
22392462-9	After administration of H(2)O(2), <protein-id="Q16625,A8K3T2">occludin</protein-id> and <protein-id="Q07157,G5E9E7,G3V1L9,A9CQZ8,B4DZK4,Q6MZU1">ZO-1</protein-id> proteins were restored by <compound-id="5372374,78350454">Cur</compound-id> (<protein-id="Q16625,A8K3T2">occludin</protein-id> 175.67 ± 29.50% vs 53.67 ± 24.19%, P &lt; 0.05; <protein-id="Q07157,G5E9E7,G3V1L9,A9CQZ8,B4DZK4,Q6MZU1">ZO-1</protein-id> 139.67 ± 33.71% vs 36.00 ± 15.88%, P &lt; 0.05) and this effect was blocked by <protein-id="P09601,Q6FH11">HO-1</protein-id> inhibitor, ZnPP (<protein-id="Q16625,A8K3T2">occludin</protein-id> 54.67 ± 10.02% vs 168.33 ± 36.47%, P &lt; 0.05; <protein-id="Q07157,G5E9E7,G3V1L9,A9CQZ8,B4DZK4,Q6MZU1">ZO-1</protein-id> 50.00 ± 15.13% vs 117.67 ± 38.81%, P &lt; 0.05).	Cur__occludin__no_interaction	Cur__HO-1__no_interaction	Cur__ZO-1__no_interaction
21951627-8	Intracoronary <compound-id="2083">salbutamol</compound-id> demonstrated significant dose-response Δ<protein-id="Q9BRV3,Q5SR67,A0A087WXX5">SLV</protein-id> and Δ<protein-id="Q03701">CBF</protein-id> from baseline, respectively (0.15 μg/min: 3.5 ± 1.3%, 28 ± 14%, P = 0.04, P = NS; 0.30 μg/min: 5.5 ± 1.4%, 54 ± 17%, P = 0.001, P &lt; 0.0001; 0.60 μg/min: 4.8 ± 1.6%, 66 ± 15%, P = 0.02, P &lt; 0.0001), with Δ<protein-id="Q9BRV3,Q5SR67,A0A087WXX5">SLV</protein-id> responses further exemplified in low vs. high plaque burden groups.	salbutamol__SLV__no_interaction	salbutamol__CBF__no_interaction
21864288-2	The molecular basis for anthocyans pharmacological activity includes the regulation of plethora of mechanisms mainly involved in: (1) suppression of the inflammatory response through targeting the phospholipase A2 and PI3K/Akt and NF-κB pathways, (2) protection from cardiovascular disease by exerting (i) antihypertensive and endothelium-protective activity through targeting the Akt/eNOS and ACE pathways (ii) antiatherogenic activity through targeting NF-κB mediated VCAM and ICAM expression, (3) growth/differentiation control and tumor suppression by exerting (i) anticancerogenic activity through targeting the EGF and HGF signaling pathways (ii) tumor anti-invasive activity through targeting the VEGF signaling pathway and ECM degrading enzymes (iii) cell cycle arrest and induction of apoptosis through the JNK/<protein-id="P46108,L7RT18">p38</protein-id> MAPK mediated caspase activation (iv) modulation of chemotherapeutic efficacy by affecting resistance to anticancer drugs, (4) reduction of diabetes incidence through modulation of <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity and <compound-id="206,5793,64689,79025">glucose</compound-id> utilization, (5) neuroprotection through amelioration of oxidative stress and Aβ deposition, and (6) hepatoprotective activity through interference with TNF-α and TGF-β in the liver.	glucose__p38__no_interaction	glucose__insulin__no_interaction
22751962-7	Compared with the monophasic group, participants with a biphasic response exhibited lower HbA(1c) (5.4 ± 0.3 vs. 5.6 ± 0.3%, P &lt; 0.01) and lower <compound-id="206,5793,64689,79025">glucose</compound-id> AUC (14,205 ± 2,382 vs. 16,230 ± 2,537 mg ⋅ dL(-1) ⋅ h(-1), P &lt; 0.001) with higher <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (5.4 ± 3.2 vs. 4.6 ± 3.4, P ≤ 0.05), higher <protein-id="P01308,I3WAC9">insulin</protein-id> secretion (2.1 ± 1.3 vs. 1.8 ± 1.3, P = 0.05), and better β-cell function (10.3 ± 7.8 vs. 6.0 ± 3.6, P &lt; 0.001).	glucose__insulin__no_interaction
2253863-3	The following MCA have been described: MCA <compound-id="69867">ICO</compound-id>-87 against common T-cell antigen <protein-id="P09564,Q29VG3,J3QLC7">CD7</protein-id>, <compound-id="69867">ICO</compound-id>-33 and <compound-id="69867">ICO</compound-id>-80 against common T-cell antigen <protein-id="P06127">CD5</protein-id>, MCA <compound-id="69867">ICO</compound-id>-10 against <protein-id="P04216,B0YJA4">Thy-1</protein-id> antigen of early thymocytes, <compound-id="69867">ICO</compound-id>-44 against <protein-id="P29017">CD1c</protein-id> antigen of cortical thymocytes, MCA <compound-id="69867">ICO</compound-id>-90 against CD3 antigen of mature T-lymphocytes, MCA <compound-id="69867">ICO</compound-id>-86 against CD4 antigen of T-helper/inductor cells, MCA <compound-id="69867">ICO</compound-id>-31 against CD8 antigen of T-suppressor/cytotoxic cells, MCA <compound-id="69867">ICO</compound-id>-1 against nonpolymorphic antigens of HLA II class, MCA <compound-id="69867">ICO</compound-id>-12 against <protein-id="P20273,Q0EAF5">CD22 antigen</protein-id> of B-lymphocytes, MCA <compound-id="69867">ICO</compound-id>-30 against mu-chain of human IgGM, MCA <compound-id="69867">ICO</compound-id>-66 against <protein-id="P11049">CD37 antigen</protein-id> of B-lymphocytes, MCA <compound-id="69867">ICO</compound-id>-88 against antigen of activated T- and B-cells, MCA <compound-id="69867">ICO</compound-id>-35 against lymphoblasts, MCA <compound-id="69867">ICO</compound-id>-88 against CD38 antigen of thymocytes and activated cells.	ICO__CD1c__no_interaction	ICO__CD37 antigen__no_interaction	ICO__CD5__no_interaction	ICO__Thy-1__no_interaction	ICO__CD7__no_interaction	ICO__CD22 antigen__no_interaction
15540129-4	The phenyldiynylphosphine complexes 2a, <compound-id="2981881,91293124">3a</compound-id> and <compound-id="69255155">4a</compound-id> react with [Pt(<protein-id="Q9UNA4">eta2</protein-id>)-C(2)H(4))(PPh(3))(2)] to give the mixed-valence Pt(II)-Pt(0) complexes [((C(6)F(5))(2)<compound-id="7965">LPt</compound-id>(mu-1kappaP:2eta2)-C(5),C(6)-PPh(2)C[triple bond]CC(6)H(4)C[triple bond]CPh))Pt(PPh(3))(2)](n)(L = tht 6a, CN 8a and PPh(2)C[triple bond]CC(6)H(4)C[triple bond]CPh 9a) in which the Pt(0) fragment is <protein-id="Q9UNA4">eta2</protein-id>-complexed by the outer fragment.	3a__eta2__no_interaction	LPt__eta2__no_interaction	4a__eta2__no_interaction
18052758-11	Higher serum <protein-id="P41159,A4D0Y8">leptin</protein-id> and <compound-id="45100492">FLI</compound-id> and lower <protein-id="O00300">OPG</protein-id> levels were shown in the OA group (<protein-id="P41159,A4D0Y8">leptin</protein-id>: 31.22 +/- 6.4 versus 26.50 +/- 9.27 ng/ml, p &lt; 0.001; <compound-id="45100492">FLI</compound-id>: 3.20 +/- 1.02 versus 2.50 +/- 0.95, p &lt; 0.05; <protein-id="O00300">OPG</protein-id>: 4.75 +/- 1.97 versus 6.96 +/- 2.75 pM, p &lt; 0.001), whereas lower serum OC and higher urine DPD were noted in the OP group (OC: 16.45 +/- 8.45 versus 13.06 +/- 6.25 ng/ml, p &lt; 0.05; DPD: 10.83 +/- 7.12 versus 15.29 +/- 6.65 nM BCE/mM Cr, p &lt; 0.001).	FLI__leptin__no_interaction	FLI__OPG__no_interaction
14994184-5	AP-1:activator protein-1 CCR1:chemokine receptor 1 <compound-id="23994">CINC</compound-id>-1:cytokine-induced neutrophil chemoattractant 1 COX:cyclooxygenase EGCG:(-)-epigallocatechin gallate ELAM-1:endothelial-leukocyte adhesion molecule-1 ERK:extracellular signal-regulated kinase GRO:growth-related oncogene HUVEC:human umbilical vein endothelial cells ICAM-1:intercellular adhesion molecule-1 IFN:interferon IL:interleukin iNOS:inducible <compound-id="145068">nitric oxide</compound-id> synthase IRA:the natural interleukin receptor activation JAK:janus kinase JNK:c-Jun <compound-id="6329">NH2-</compound-id>terminal kinase LPS:<compound-id="11970143">lipopolysaccharide</compound-id> MAPK:mitogen-activated protein kinases MCP:monocyte chemotactic protein MHC:major histocompatibility complex MIP:macrophage inflammatory protein MMP:matrix metalloproteinases MPO:myeloperoxidase NF-kappaBnuclear factor kappa B NO:<compound-id="145068">nitric oxide</compound-id> PAF:platelet aggregation factor PGEE:<compound-id="285703,6145931">prostaglandin</compound-id> PK:protein kinase <compound-id="122634,27924,4792">PMA</compound-id>/<compound-id="22833501">TPA</compound-id>:<compound-id="18633279">phorbol myristate</compound-id> <compound-id="176">acetate</compound-id> RANTES:regulated upon activation normal T-cell expressed and secreted <protein-id="P01137">TGF-beta</protein-id>:transforming growth factor-beta TNFalpha:tumour necrosis factor <protein-id="P19320">VCAM-1</protein-id>:<protein-id="P19320">vascular cell adhesion molecule-1</protein-id>	TPA__vascular cell adhesion molecule-1__no_interaction	TPA__VCAM-1__no_interaction	TPA__TGF-beta__no_interaction	CINC__vascular cell adhesion molecule-1__no_interaction	CINC__VCAM-1__no_interaction	CINC__TGF-beta__no_interaction	acetate__vascular cell adhesion molecule-1__no_interaction	acetate__VCAM-1__no_interaction	acetate__TGF-beta__no_interaction	prostaglandin__vascular cell adhesion molecule-1__no_interaction	prostaglandin__VCAM-1__no_interaction	prostaglandin__TGF-beta__no_interaction	PMA__vascular cell adhesion molecule-1__no_interaction	PMA__VCAM-1__no_interaction	PMA__TGF-beta__no_interaction	phorbol myristate__vascular cell adhesion molecule-1__no_interaction	phorbol myristate__VCAM-1__no_interaction	phorbol myristate__TGF-beta__no_interaction	nitric oxide__vascular cell adhesion molecule-1__no_interaction	nitric oxide__VCAM-1__no_interaction	nitric oxide__TGF-beta__no_interaction	lipopolysaccharide__vascular cell adhesion molecule-1__no_interaction	lipopolysaccharide__VCAM-1__no_interaction	lipopolysaccharide__TGF-beta__no_interaction	NH2-__vascular cell adhesion molecule-1__no_interaction	NH2-__VCAM-1__no_interaction	NH2-__TGF-beta__no_interaction
11477890-5	(2) Lowest <compound-id="977">oxygen</compound-id> saturation during sleep was significantly correlated with the level of <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>(r = -0.659, P &lt; 0.05) and <protein-id="Q10586">DBP</protein-id>(r = -0.677, P &lt; 0.01) in awake, the baseline of <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>(r = -0.777, P &lt; 0.01) and <protein-id="Q10586">DBP</protein-id> (r = -0.590, P &lt; 0.05) in NREM sleep and that of <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>(r = -0.585, P &lt; 0.05) in REM sleep.	oxygen__DBP__no_interaction	oxygen__SBP__no_interaction
2189770-4	<compound-id="206,5793,64689,79025">Glucose</compound-id> disposal by lean body mass was markedly reduced both at baseline (11.7 +/- 1.1 vs 15.6 +/- 0.6 mumol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; p less than 0.05) and during clamp (15.0 +/- 1.1 vs 34.4 +/- 2.8 and 26.7 +/- 3.9 vs 62.2 +/- 2.8 mumol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; p less than 0.01) Oxidative (12.2 +/- 1.1 vs 17.8 +/- 1 and 16.1 +/- 1.1 vs 51.1 +/- 1.7 mumol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; p less than 0.05-0.002) and non-oxidative <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism (3.9 +/- 1.1 vs 15.0 +/- 2.8 and 12.8 +/- 3.3 vs 38.2 +/- 2.2 mumol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; p less than 0.01-0.001) were impaired.	glucose__min-1__no_interaction	Glucose__min-1__no_interaction
8712445-8	<compound-id="5206">Sevoflurane</compound-id> decreased the acute hypoxic ventilatory response in the absence and presence of noxious stimulation: C = 0.69 +/- 0.20 l.<protein-id="P13987,Q6FHM9">min-1</protein-id> (% change in arterial hemoglobin-<compound-id="977">oxygen</compound-id> saturation derived from pulse oximetry [SpO2])-1, C + P = 0.64 +/- 0.13 l.<protein-id="P13987,Q6FHM9">min-1</protein-id>.%SpO2(-1), S = 0.48 +/- 0.15 l.<protein-id="P13987,Q6FHM9">min-1</protein-id>.%SpO2(-1) (P &lt; 0.05 vs. C and C + P) and S + P = 0.46 +/- 0.21 l.<protein-id="P13987,Q6FHM9">min-1</protein-id>.%SpO2(-1) (P &lt; 0.05 vs. C and C + P).	Sevoflurane__min-1__no_interaction	oxygen__min-1__no_interaction
15998033-3	The reactions between M(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2 x xH2O; M = Cd(II), Cu(II), and Co(II); x = 3-6 and Cu(<compound-id="73706">hfac</compound-id>)2 x H2O [<compound-id="73706">hfac</compound-id> = bis(hexafluoroacetylacetonato)] with L1 afforded the following one-dimensional zigzag chain structures: [Cd(C20H12N2)0.5(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)(CH3OH)]n (1, monoclinic, C2/c; a = 7.586(1) A, b = 23.222(1) A, c = 13.572(1) A, beta = 92.824(1), Z = 4); [{Cu(C20H12N2)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2(CH3OH)} x CH3OH]n (2, orthorhombic, P2(1)2(1)2(1); a = 8.589(1) A, b = 15.766(1) A, c = 17.501(1) A, Z = 4); [Co(C20H12N2)2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2(H2O)2] (5, triclinic, P1; a = 7.493(1) A, b = 8.948(1) A, c = 14.854(1) A, alpha = 100.427(1), beta = 97.324(1), gamma = 110.901(1), Z = 1); [Cu(C20H12N2)(<compound-id="73706">hfac</compound-id>)2]n (4, monoclinic, C2/c, a = 18.828(1) A, b = 14.671(1) A, c = 13.427(1) A, beta = 90.447(1) degrees, Z = 4).	hfac__NO3__no_interaction
15998033-6	The reactions between M(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2 x xH2O; M = Cd(II), Cu(II), and Co(II); x = 3-6 and Cu(<compound-id="73706">hfac</compound-id>)2 x H2O [<compound-id="73706">hfac</compound-id> = bis(hexafluoroacetylacetonato)] and L2 were dependent on the nature of the metal center and resulted in the formation of four different interpenetrating and noninterpenetrating compounds (6-10): [Co(C20H12N2)1.5(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2]n (6, triclinic, P; a = 14.172(1) A, b = 15.795(1) A, c = 18.072(1) A, alpha = 115.380(1), beta = 101.319(1), gamma = 93.427(2), Z = 4), which consists of T-shaped building blocks assembled into three-dimensional interpenetrating polycatenated ladders; [Cd(C20H12N2)2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2]n (7, monoclinic, I2/a; a = 11.371(1) A, b = 20.311(2) A, c = 15.240(2) A, beta = 100.201(2) degrees, Z = 4), which adopts a two-dimensional noninterpenetrating square-grid motif; [Cu(C20H12N2)(<compound-id="73706">hfac</compound-id>)2]n (8, monoclinic, I2/a; a = 11.371(1) A, b = 20.311(2) A, c = 15.240(2) A, beta = 100.201(2) degrees, Z = 4), composed of three sets of distinct one-dimensional linear chains; [Cu(C20H12N2)(<compound-id="702">EtOH</compound-id>)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] [Cu(C20H12N2)1.5(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] x 2EtOH (9, triclinic, P; a = 12.248(2) A, b = 13.711(3) A, c = 18.257(4) A, alpha = 108.078(4) degrees, beta = 97.890(4) degrees, gamma = 103.139(5) degrees, Z = 2) and [Cu(C20H12N2)(<compound-id="887">MeOH</compound-id>)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] [Cu(C20H12N2)1.5(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] x 2MeOH (10, triclinic, P; a = 12.136(1) A, b = 13.738(2) A, c = 17.563(3) A, alpha = 107.663(3) degrees, beta = 94.805(4) degrees, gamma = 104.021(4) degrees, Z = 2).	EtOH__NO3__no_interaction	hfac__NO3__no_interaction	MeOH__NO3__no_interaction
12732361-4	The rank order of potency for catecholamines and known beta-AR agonists was <compound-id="5403">terbutaline</compound-id>(3.31 nM)&gt;<compound-id="3779">isoproterenol</compound-id>(8.31 nM)&gt; or =<compound-id="3343">fenoterol</compound-id>(15 nM)=<compound-id="5816">epinephrine</compound-id>(16.2 nM)&gt;<compound-id="439260">norepinephrine</compound-id>(77.5 nM)&gt;<protein-id="O95696,A0A024R4W4,A0A024R4V5,Q59G93">BRL</protein-id>-37344 [(R(*),R(*))-(+/-)4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxy acetic acid, <compound-id="5360545">sodium</compound-id> salt] (1000 nM)&gt;<compound-id="36811">dobutamine</compound-id>(1770 nM)&gt;CGP12177 (4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-<compound-id="162542">2H-benzimidazole-2-one</compound-id> hydrochloride) (inactive).	isoproterenol__BRL__no_interaction	fenoterol__BRL__no_interaction	sodium__BRL__no_interaction	2H-benzimidazole-2-one__BRL__no_interaction	epinephrine__BRL__no_interaction	norepinephrine__BRL__no_interaction	terbutaline__BRL__no_interaction	dobutamine__BRL__no_interaction
12732361-7	In addition, <compound-id="3779">isoproterenol</compound-id>-activated luciferase expression was blocked more potently by ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-<compound-id="7219">inden</compound-id>-4-yl)oxy]-3-[(1-methylethy) amino]-<compound-id="6568">2-butanol</compound-id>], a <protein-id="P07550">beta(2)-AR</protein-id> antagonist than by ICI 89,406 [(+/-)-N-[2-[3-(2-cyanophenoxy-)]-2-hydroxypropylamino]<compound-id="23134249">ethyl</compound-id>-<compound-id="91358256">N-phenylurea</compound-id>], a <protein-id="P08588">beta(1)-AR</protein-id> antagonist, giving K(B) values of 1.07 and 161nM, respectively.	isoproterenol__beta(2)-AR__no_interaction	isoproterenol__beta(1)-AR__no_interaction	ethyl__beta(2)-AR__no_interaction	ethyl__beta(1)-AR__no_interaction	2-butanol__beta(2)-AR__no_interaction	2-butanol__beta(1)-AR__no_interaction	N-phenylurea__beta(2)-AR__no_interaction	N-phenylurea__beta(1)-AR__no_interaction	inden__beta(2)-AR__no_interaction	inden__beta(1)-AR__no_interaction
22093558-7	There were negative correlations between TF/<protein-id="P10646">TFPI</protein-id> ratio and TAC (r = -0.518, P &lt; 0.01), <compound-id="124886">GSH</compound-id>-PX (r = -0.454, P &lt; 0.05), PaO2 (r = -0.511, P &lt; 0.01) respectively and a positive correlation between TF/<protein-id="P10646">TFPI</protein-id> ratio and the percentage of neutrophils (r = 0.379, P &lt; 0.05) in AECOPD patients before treatment.	GSH__TFPI__no_interaction
20356498-9	When PANC-1 cells treated with 1.0, 2.5, 5.0, 10.0 mg/L <compound-id="60750">gemcitabine</compound-id> for 72 h, the level of miR-155 (2.21 +/- 0.40, 1.86 +/- 0.03, 2.47 +/- 0.04, 3.24 +/- 0.05) also higher than that of the control (1.11 +/- 0.09, P &lt; 0.05), while no change was observed when the cells only treated for 48 h. Further study showed <compound-id="60750">gemcitabine</compound-id>-induced <compound-id="8110">BIC</compound-id> RNA up-regulation was inhibited by <compound-id="312145">wortmannin</compound-id>, a specific <protein-id="P42336">PI3K</protein-id> inhibitor, the expression levels of <compound-id="8110">BIC</compound-id> RNA of 1 micromol/L <compound-id="312145">wortmannin</compound-id> + 5 mg/L <compound-id="60750">gemcitabine</compound-id> group and 10 micromol/L <compound-id="312145">wortmannin</compound-id> + 5 mg/L <compound-id="60750">gemcitabine</compound-id> group were 5.34 +/- 1.11 and 1.26 +/- 0.07, lower than that of 5 mg/L <compound-id="60750">gemcitabine</compound-id> group (11.82 +/- 3.11, P &lt; 0.05).	wortmannin__PI3K__no_interaction	BIC__PI3K__no_interaction	gemcitabine__PI3K__no_interaction
15508718-3	These strains were classified into 6 genotype patterns and MIC90 values for <compound-id="6249">ampicillin</compound-id> (ABPC): (i) <protein-id="Q6A253">beta-lactamase</protein-id> nonproducing, ABPC susceptible (BLNAS) strains and lacked all resistance genes (27.7% of isolates; MIC90, 0.5 microg/ml); (ii) <protein-id="Q6A253">beta-lactamase</protein-id> producing, ABPC resistant (BLPAR) strains (12.9%, 16 microg/ml); (iii) <protein-id="Q6A253">beta-lactamase</protein-id> nonproducing, ABPC resistant (Low-BLNAR) strains with a Asn526Lys amino acid substitution in ftsI gene encoding PBP3 (31.2%, 2 microg/ml); (iv) <protein-id="Q6A253">beta-lactamase</protein-id> nonproducing, ABPC resistant (BLNAR) strains with Ser385Thr and Asn526Lys substitutions in ftsI (17.2%, 8 microg/ml); (v) <compound-id="33613">amoxicillin</compound-id>/clavlanic acid resistant (BLPACR I) strains, having <protein-id="Q6A253">beta-lactamase</protein-id> gene and a Asn526Lys amino acid substitution in ftsI (9.2%, 32 microg/ml); and (vi) <compound-id="33613">amoxicillin</compound-id>/clavlanic acid resistant (BLPACR II), having <protein-id="Q6A253">beta-lactamase</protein-id> gene and ftsI substitutions as for BLNAR strains (1.9%, 64 microg/ml).	amoxicillin__beta-lactamase__no_interaction	ampicillin__beta-lactamase__no_interaction
7726130-6	The recommendations are as follows: (1) Total serum <compound-id="5997">cholesterol</compound-id> (TC) and high density lipoprotein-<compound-id="5997">cholesterol</compound-id> (HDL-C) are presently the recommended screening tests for dyslipidemia in the general population; (2) The National <compound-id="5997">Cholesterol</compound-id> Education Program (NCEP) recommends measuring TC and HDL-C in adults with a single sample at 5-year intervals beginning at age 20; (3) The NCEP recommends measuring TC in children with at least one parent having TC &gt; or = 6.24 mmol/L (&gt; or = 240 mg/dL); (4) The NCEP recommends a lipoprotein analysis consisting of a 12-hour fasting TC, HDL-C, triglyceride, and estimated <protein-id="Q14746,B1ALW7">low density lipoprotein-cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) in adults with the following results: (a) TC &gt; or = 6.24 mmol/L (&gt; or = 240 mg/dL); (b) borderline TC of 5.20-6.23 mmol/L (200-239 mg/dL) and HDL-C &lt; 0.91 mmol/L (&lt; 35 mg/dL) or two or more risk factors; (c) desirable TC of &lt; 5.20 mmol/L (&lt; 200 mg/dL), but HDL-C &lt; 0.91 mmol/L (&lt; 35 mg/dL); (5) The NCEP recommends a lipoprotein analysis in children with documented <compound-id="221493">CHD</compound-id> in a parent or grandparent, or in children that have a TC of &gt; or = 5.20 mmol/L (&gt; or = 200 mg/dL); (6) Two or three separate lipoprotein analyses should be done to confirm the <protein-id="Q14746,B1ALW7">LDL-C</protein-id> result before therapeutic intervention.	Cholesterol__low density lipoprotein-cholesterol__no_interaction	Cholesterol__LDL-C__no_interaction	CHD__low density lipoprotein-cholesterol__no_interaction	CHD__LDL-C__no_interaction	cholesterol__low density lipoprotein-cholesterol__no_interaction	cholesterol__LDL-C__no_interaction
23554700-3	Our results showed that the over-weight group had higher blood pressure [(130.15±19.01) mmHg vs (123.66±18.70) mmHg] and higher levels of blood sugar [(7.09±2.89) mmol/L vs (6.21±2.59) mmol/L], triglyceride [(1.93±1.19) mmol/L vs (1.44±0.85) mmol/L], total <compound-id="5997">cholesterol</compound-id> [(4.26±1.06) mmol/L vs (4.09±0.99) mmol/L], <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) [(2.56±0.75) mmol/L vs (2.39±0.72) mmol/L], and <protein-id="P04114,Q7Z7Q0,Q59HB3">ApoB</protein-id> [(0.83±0.27) mg/L vs (0.78±0.23) mg/L], and a higher <protein-id="P04114,Q7Z7Q0,Q59HB3">ApoB</protein-id>/<protein-id="P02647,A0A024R3E3">apoA1</protein-id> ratio (0.83±0.27 vs 0.75±0.25) and lower levels high-density lipoprotein <compound-id="5997">cholesterol</compound-id> [(1.10±0.26) mmol/L vs (1.21±0.31) mmol/L] and <protein-id="P02647,A0A024R3E3">apoA1</protein-id> [(1.04±0.20) mg/L vs (1.08±0.22) mg/L] than those of the normal weight group (all P &lt; 0.05).	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__ApoB__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__apoA1__no_interaction
16508258-6	Higher levels of the mentioned biochemical parameters were found in Greek mothers versus their newborns (<compound-id="5997">cholesterol</compound-id> 5.20 +/- 0.98 mmol/l, TG 2.37 +/- 0.62 mmol/l, <protein-id="Q14746,B1ALW7">LDL-C</protein-id> 3.40 +/- 0.85 mmol/l and VLDL-C 0.48 +/- 0.13 mmol/l vs. <compound-id="5997">cholesterol</compound-id> 1.55 +/- 0.31 mmol/l, TG 0.56 +/- 0.20 mmol/l, <protein-id="Q14746,B1ALW7">LDL-C</protein-id> 0.65 +/- 0.15 mmol/l and VLDL-C 0.12 +/- 0.01 mmol/l; p &lt; 0.001) and Albanian mothers versus their newborns (<compound-id="5997">cholesterol</compound-id> 7.1 +/- 0.78 mmol/l, TG 2.55 +/- 0.60 mmol/l, <protein-id="Q14746,B1ALW7">LDL-C</protein-id> 4.1 +/- 0.88 mmol/l and VLDL-C 0.52 +/- 0.13 mmol/l vs. <compound-id="5997">cholesterol</compound-id> 1.6 +/- 0.40 mmol/l, TG 0.59 +/- 0.15 mmol/l, <protein-id="Q14746,B1ALW7">LDL-C</protein-id> 0.70 +/- 0.21 mmol/l and VLDL-C 0.12 +/- 0.01 mmol/l; p &lt; 0.001).	cholesterol__LDL-C__no_interaction
6339539-5	Compared to group C (O-T response, 5.97 +/- 0.54 ng ml-1 h-1; Furo-T response, 6.71 +/- 0.82 ng ml-1 h-1; mean +/- <compound-id="5289348">SEM</compound-id>), <protein-id="P06703">PRA</protein-id> response to both tests was blunted in group P (O-T: 2.48 +/- 0.46, P less than 0.001; Furo-T: 3.02 +/- 0.53, P less than 0.001) and remained so in F (O-T: 2.18 +/- 0.40, P less than 0.001; Furo-T: 2.52 +/- 0.28, P less than 0.001), In group F + T, the response to both tests was greater than in P and F (O-T, 6.61 +/- 1.19; Furo-T, 4.36 +/- 0.44; 0.001 less than P less than 0.05).	SEM__PRA__no_interaction
17035015-1	We hereby report the synthesis of four <compound-id="105162">fluorine-18</compound-id> labeled <compound-id="6057,90983769">tyrosine</compound-id> derivatives, 3-(2-[(18)F]fluoroethyl)<compound-id="6057,90983769">tyrosine</compound-id> ([(18)F]1, [(18)F]ortho-<protein-id="Q9QX79,Q6IRS6">FET</protein-id>), 3-(3-[(18)F]<compound-id="9998">fluoropropyl</compound-id>)<compound-id="6057,90983769">tyrosine</compound-id> ([(18)F]2, [(18)F]ortho-<compound-id="3000505">FPT</compound-id>) O-methyl-[3-(2-[(18)F]fluoroethyl)]<compound-id="6057,90983769">tyrosine</compound-id> ([(18)F]3, [(18)F]MFET), and O-methyl-[3-(3-[(18)F]<compound-id="9998">fluoropropyl</compound-id>)]<compound-id="6057,90983769">tyrosine</compound-id> ([(18)F]4, [(18)F]MFPT).	FPT__FET__no_interaction	tyrosine__FET__no_interaction	fluoropropyl__FET__no_interaction	fluorine-18__FET__no_interaction
2487452-1	Based on a study of the larvae from two helminth species parasitizing the crab Cyrtograpsus angulatus <compound-id="65309">Dana</compound-id>, 1851 (Microphallus szidati Martorelli, 1986 and Falsifilicollis chasmagnathi Holcman-Spector et al., 1977), from <protein-id="P10914,Q6FHN8,X5D3F6">Mar</protein-id> chiquita lagoom (Argentina) together with the analyses of their life cycles and rates of prevalence, intensity and association coefficient (compared in definitive and intermediate host) the following conclusions have been reached: a) C. angulatus suns to be an excellent intermediate host in the life-cycles of the studied helminths; b) the size of the crabs and the occurrence of natural amputations in the females (Spivak &amp; Politis, in press) appeared correlated with prevalence; c) in the studied crabs the prevalence for F. chasmagnathi is higher in males than in females; d) the intensity did not appear correlated with size and sex of the intermediate host; e) M. szidati and F. chasmagnathi are closely associated with the intermediate host; f) C. angulatus and Himantopus melanurus Vieillot, 1817 (Aves; Recurvirostridae) are reported as new intermediate and definitive hosts, respectively, for F. chasmagnathi; g) Chasmagnathus granulata <compound-id="65309">Dana</compound-id>, 1851 (Crustacea; Brachyura) is reported as a new intermediate host for M. szidati.	Dana__Mar__no_interaction
17786291-5	Multivariable logistic regression analyses and stepwise forward selection procedures revealed that seven different polymorphisms were significantly (P&lt;0.005) associated with MI in individuals with low or high serum concentrations of HDL- or LDL-<compound-id="5997">cholesterol</compound-id> or of TG: the 190T --&gt; C (Trp64Arg) polymorphism of <protein-id="P13945,A8KAG8">ADRB3</protein-id> in individuals with low HDL-<compound-id="5997">cholesterol</compound-id>; the 1018C --&gt; T (Thr145Met) polymorphism of <protein-id="P07359,L7UYB8">GP1BA</protein-id>, the A --&gt; G (Ile646Val) polymorphism of <protein-id="O43572,E7EMD6">AKAP10</protein-id>, and the -55C --&gt; T polymorphism of <protein-id="P55916">UCP3</protein-id> in individuals with high HDL-<compound-id="5997">cholesterol</compound-id>; the -603A --&gt; G polymorphism of F3 and the -11377C --&gt; G polymorphism of <protein-id="Q15848,A8K660,B2R773">ADIPOQ</protein-id> in individuals with low LDL-<compound-id="5997">cholesterol</compound-id>; the 1018C --&gt; T polymorphism of <protein-id="P07359,L7UYB8">GP1BA</protein-id> in individuals with low TG; and the 4G --&gt; 5G polymorphism of <protein-id="P05121,A0A024QYT5">PAI1</protein-id> in individuals with high TG.	cholesterol__PAI1__no_interaction	cholesterol__GP1BA__no_interaction	cholesterol__ADRB3__no_interaction	cholesterol__AKAP10__no_interaction	cholesterol__UCP3__no_interaction	cholesterol__ADIPOQ__no_interaction
18438563-5	Means(SD) were as follows: Carbonated drink: elastic modulus decreased from 111.6(14.5) to 62.3(10.3) <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, nanohardness decreased from 4.62(0.67) to 1.28(0.46) <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, roughness increased from 5.30(2.39) to 6.86(2.56) microm, and the pH changed from 2.69(0.35) to 2.29(0.24); Orange juice: elastic modulus changed from 115.15(12.94) to 92.11 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id> (13.83), nanohardness from 5.54(1.48) to 3.18 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id> (0.64), roughness from 5.26(2.27) to 6.73(2.25) microm, and pH from 3.46(0.20) to 3.03(0.14); <protein-id="O75369">tap</protein-id> <compound-id="962">water</compound-id> (control): elastic modulus changed from 117.87(22.3) to 107.91(20.05) <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, nanohardness from 4.35(1.66) to 4.28(0.93) <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, roughness from 5.76(3.11) to 6.11(2.65) microm, and pH from 7.97(0.28) to 8.11(0.21).	water__tap__no_interaction	water__GPa__no_interaction
9139249-10	Significant difference was found between diabetic patients with (n = 315) and without (n = 618) abnormal urinary <protein-id="P02768">albumin</protein-id>/<compound-id="588">creatinine</compound-id> ratio regarding age (64.3 +/- 0.7 years vs. 61.4 +/- 0.5 years; p &lt; 0.001), duration of diabetes (10.3 +/- 0.5 years vs 7.9 +/- 0.3 years; p &lt; 0.001) systolic blood pressure (151 +/- 1 mmHg vs 146 +/- 1 mmHg; p &lt; 0.01), serum <compound-id="588">creatinine</compound-id> (99 +/- 2 mumol/l vs 88 +/- 1 mumol/l; p &lt; 0.001) and blood <compound-id="206,5793,64689,79025">glucose</compound-id> (10.4 +/- 0.2 mmol/l vs 9.4 +/- 0.1 mmol/l; p &lt; 0.001).	creatinine__albumin__no_interaction	glucose__albumin__no_interaction
8808492-8	Serum free <compound-id="5997">cholesterol</compound-id> from diabetic and control subjects correlated with <protein-id="P11597,B4DMZ5">CETP</protein-id> activity measured using endogenous lipoprotein assay (r = 0.77, P &lt; 0.001 and r = 0.82, P &lt; 0.001), and also with LCAT activity (r = 0.76, P &lt; 0.01 and r = 0.79, P &lt; 0.01).	cholesterol__CETP__no_interaction
2476588-4	Chronic administration of E2 resulted in a significant decrease in: (1) pancreatic weight (0.96 +/- 0.04, T vs 1.142 +/- 0.046 g, C); (2) total pancreatic DNA content (5.74 +/- 0.37, T vs 6.81 +/- 0.16 <compound-id="445507">mgs</compound-id>, C); (3) total amylase content in pancreata (2081 +/- 307, T vs 3795 +/- 442 I.U., C); (4) absolute value of basal amylase release (6.57 +/- 1.4, T vs 11.8 +/- 1.9 I.U./incubate, C); and (5) absolute value of amylase release stimulated by increasing doses (0.01-1000 nM) of <protein-id="H0VR95">CCK</protein-id> in T vs C animals.	mgs__CCK__no_interaction
22528041-3	Similarly the basic <compound-id="2826723">amide</compound-id> in 2 was protonated with a variety of other weak acids to form the complexes [(<protein-id="P13497">PCP</protein-id>)Ni(2-Me-<compound-id="795">imidazole</compound-id>)] (4), [(<protein-id="P13497">PCP</protein-id>)Ni(<compound-id="11686,14740173">dimethylmalonate</compound-id>)] (5), [(<protein-id="P13497">PCP</protein-id>)Ni(<compound-id="9255">oxazole</compound-id>)] (6), and [(<protein-id="P13497">PCP</protein-id>)Ni(CCPh)] (7), respectively.	oxazole__PCP__no_interaction	imidazole__PCP__no_interaction	dimethylmalonate__PCP__no_interaction	amide__PCP__no_interaction
15772926-8	RESULTS: Hb was 11.1 +/- 1.2 g/dL, Hct 34.4 +/- 3.7%, CHr 32.7 +/- 3.8 pg, <protein-id="P02787,Q06AH7,A0PJA6">Transferrin</protein-id> 170 +/- 31 mg/dL, <compound-id="23925,67172434">iron</compound-id> 60.2 +/- 25.9 mg/dL, TSAT 30 +/- 18%; ferritin 204 +/- 219 ng/mL, <compound-id="6037">folate</compound-id> 4.2 +/- 1.0 mcg/L, vitamin <protein-id="O43676,A0A024R413">B12</protein-id> 0.58 +/- 0.15 mcg/L, and s-TfR 1.94 +/- 0.83 mg/L.	iron__Transferrin__no_interaction	iron__B12__no_interaction	folate__Transferrin__no_interaction	folate__B12__no_interaction
17487968-1	Eight members of the <protein-id="A0A075B762,O95994,Q4JM46">Ag/1,2,4</protein-id>-<compound-id="67516">triazole</compound-id>/polyoxometalates (POMs) hybrid supramolecular family, namely, [<compound-id="44201383">Ag4</compound-id>(dmtrz)4][Mo8O26] (dmtrz=<compound-id="139001">3,5-dimethyl-1,2,4-triazole</compound-id>, 1), [<compound-id="25181326">Ag6</compound-id>(3atrz)6][PMo12O40]2.H2O (3atrz=<compound-id="1639">3-amino-1,2,4-triazole</compound-id>, 2), [<protein-id="O95994,Q4JM46">Ag2</protein-id>(3atrz)2]2[HPMoVI10MoV2O40] (3), [<protein-id="O95994,Q4JM46">Ag2</protein-id>(dmtrz)2]2[HPMoVI10MoV2O40] (4), [<protein-id="O95994,Q4JM46">Ag2</protein-id>(trz)2]2[Mo8O26] (trz=1,2,4-<compound-id="67516">triazole</compound-id>, 5), [<protein-id="O95994,Q4JM46">Ag2</protein-id>(3atrz)2][<protein-id="O95994,Q4JM46">Ag2</protein-id>(3atrz)2(Mo8O26)] (6), [<compound-id="44201383">Ag4</compound-id>(4atrz)2Cl][Ag(Mo8O26)] (4atrz=<compound-id="11432">4-amino-1,2,4-triazole</compound-id>, 7), and [<compound-id="44201382">Ag5</compound-id>(trz)4]2[<protein-id="O95994,Q4JM46">Ag2</protein-id>(Mo8O26)].<compound-id="70679364">4H2O</compound-id> (8), were synthesized through hydrothermal reactions of 1,2,4-<compound-id="67516">triazole</compound-id> or its derivatives with appropriate <compound-id="23954">silver</compound-id> salts and molybdates.	4H2O__Ag2__no_interaction	4H2O__Ag/1,2,4__no_interaction	triazole__Ag2__no_interaction	triazole__Ag/1,2,4__no_interaction	3,5-dimethyl-1,2,4-triazole__Ag2__no_interaction	3,5-dimethyl-1,2,4-triazole__Ag/1,2,4__no_interaction	4-amino-1,2,4-triazole__Ag2__no_interaction	4-amino-1,2,4-triazole__Ag/1,2,4__no_interaction	3-amino-1,2,4-triazole__Ag2__no_interaction	3-amino-1,2,4-triazole__Ag/1,2,4__no_interaction	Ag6__Ag2__no_interaction	Ag6__Ag/1,2,4__no_interaction	Ag5__Ag2__no_interaction	Ag5__Ag/1,2,4__no_interaction	Ag4__Ag2__no_interaction	Ag4__Ag/1,2,4__no_interaction	silver__Ag2__no_interaction	silver__Ag/1,2,4__no_interaction
12602117-8	Low serum <compound-id="22044544,5460341">calcium</compound-id> was associated with elevated <protein-id="P01270">PTH</protein-id>- (r = -0.75, p = 0.001), serum cross laps- (r = -0.61, p = 0.01), <protein-id="P02818">osteocalcin</protein-id> levels (r = -0.49, p = 0.05), was an independent predictor of femoral neck bone mass (r = 0.57, p = 0.02) and accounted for 36% of this variance.	calcium__osteocalcin__no_interaction	calcium__PTH__no_interaction
12602117-12	Serum <protein-id="O00300">OPG</protein-id> was, however, significantly correlated to serum cross laps (r = 0.71, p = 0.003), <protein-id="P02818">osteocalcin</protein-id> (r = 0.63, p = 0.01), serum parathyroid hormone (r = 0.61, p = 0.01) and serum <compound-id="588">creatinine</compound-id> levels (r = 0.53, p = 0.04) and showed only a weak and non-significant correlation to femoral neck Z-scores (r = -0.38, p = 0.16).	creatinine__osteocalcin__no_interaction	creatinine__OPG__no_interaction
16278259-9	Predictors of log <protein-id="P10082">PYY</protein-id> were nutritional markers, including body mass index (r = -0.62; P &lt; 0.0001), fat mass (r = -0.55; P = 0.0003), and REE (r = -0.51; P = 0.0006), and hormones, including GH (r = 0.38; P = 0.004) and <compound-id="5920">T3</compound-id> (r = -0.59; P = 0.0001).	T3__PYY__no_interaction
7486211-3	Plasma immunoreactive <compound-id="44284481">endothelin</compound-id> (22.07 +/- 7.06 vs 13.80 +/- 1.43 pmol/L, P &lt; 0.011), urinary excretion of NO2- (0.28 +/- 0.10 vs 0.15 +/- 0.02, mumol/mumol of urinary <compound-id="588">creatinine</compound-id>, P &lt; 0.01) and <protein-id="P41271,A0A087WTY6">NO3</protein-id>- (0.17 +/- 0.07 vs 0.09 +/- 0.02 mumol/mumol of urinary <compound-id="588">creatinine</compound-id>, P &lt; 0.011), and forearm resting blood flow (FRBF) (6.67 +/- 1.69 vs 4.30 +/- 0.38 mL/m'/100 mL, P &lt; 0.005) were increased in patients with Bartter's syndrome in comparison with normal controls (C).	endothelin__NO3__no_interaction	creatinine__NO3__no_interaction
8153143-5	Compared with untreated rats, IRFI-016, in particular the dose of 200 mg/kg, caused a reduction of the necrotic zone whether the necrotic area was expressed as a percentage of the area at risk (55 +/- 4% in the MI/R vehicle group and 24 +/- 2.5% in the MI/R treated group; p &lt; 0.001) or as a percentage of the total left ventricle (23 +/- 3.4% in the MI/R vehicle group and 8 +/- 2.1% in the MI/R treated group; p &lt; 0.005), reduced the myeloperoxidase activity, an index of neutrophil infiltration in the necrotic area (from 4.8 +/- 0.8 to 1.6 +/- 0.4 U/g tissue; p &lt; 0.005), reduced the serum levels of <protein-id="P16599">TNF-alpha</protein-id> (from 216 +/- 13 to 45 +/- 7 U/ml; p &lt; 0.001), blunted the rise of the ST segment of the ECG (from 0.47 +/- 0.13 mV in the vehicle group to 0.3 +/- 0.18 mV in the treated group; p &lt; 0.001), reduced the loss of CK (from 220 +/- 15 to 88 +/- 13 IU/ml of blood; p &lt; 0.001) and improved the depressed <compound-id="445997">PRI</compound-id> (from 56 +/- 4% to 78 +/- 3% mm Hg/beats/min; p &lt; 0.005).	PRI__TNF-alpha__no_interaction
16930226-3	The presentations were as follows: (1) Effects of Ethanol on Immune Response to Hepatitis C Virus by Jack R. Wands, (2) <compound-id="10982484,702">Alcohol</compound-id> and Alveolar Macrophage Dysfunction: The Role of Chronic Oxidant Stress by Lou Ann S. <protein-id="P07147,Q3UFS3">Brown</protein-id>, (3) T Cell Responses to Listeria monocytogenes in Mice on a Chronic Ethanol Exposure Protocol by Robert T. Cook, (4) Mechanisms of Acute and Chronic <compound-id="10982484,702">Alcohol</compound-id> Consumption on Severity of Viral Infections by the Liver and Pancreas by Thomas R. Jerrells, (5) Acute and Chronic Effects on Macrophage Ectodomain Shedding: Implications for Lung Host Defenses by Jay K. Kolls, (6) Increased Susceptibility to Pseudomonas Infection of Burn-Injured Mice Given <compound-id="10982484,702">Alcohol</compound-id> Before Injury by Elizabeth J. Kovacs, (7) Regulation of Tumor Necrosis <protein-id="Q8VHT7">Factor alpha</protein-id> Expression in Macrophages by Chronic Ethanol by Laura E. Nagy, and (8) Hepatitis C Virus Infection and <compound-id="10982484,702">Alcohol</compound-id> Use by Gyongyi Szabo.	Alcohol__Brown__no_interaction	Alcohol__Factor alpha__no_interaction
11440279-7	<compound-id="638015">Retinal</compound-id> photocoagulation influenced neither the intraocular concentration of the permeability marker <protein-id="P02768">albumin</protein-id> (PDR+: 253.2 +/- 46 mg/dl; PDR-: 256.4 +/- 66.5 mg/dl) nor the levels of IGFs (PDR+: IGF-I: 1.2 +/- 0.1 ng/ml; p = 0.38; <protein-id="P01344,E3UN46">IGF-II</protein-id>: 34.8 +/- 2.2 ng/ml; p = 0.1; <protein-id="P17936,B3KPF0">IGF-BP3</protein-id>: 75.7 +/- 9.7 ng/ml; p = 0.27; PDR-: IGF-I: 1.1 +/- 0.2ng/ml; <protein-id="P01344,E3UN46">IGF-II</protein-id>: 29.3 +/- 5.2 ng/ml; <protein-id="P17936,B3KPF0">IGF-BP3</protein-id>: 61.5 +/- 18.3 ng/ml).	Retinal__IGF-BP3__no_interaction	Retinal__albumin__no_interaction	Retinal__IGF-II__no_interaction
8102225-6	Significant Spearman's rank correlations (<compound-id="7021454">rs</compound-id>) were demonstrated between serum ALP2 level and the respective values of ALPt (<compound-id="7021454">rs</compound-id> = 0.9128, p &lt; 0.001), <protein-id="Q7L266,A0A024R573">ALP1</protein-id> (<compound-id="7021454">rs</compound-id> = 0.4443, p &lt; 0.001), <protein-id="P05187,B2R7C7">ALP3</protein-id> (<compound-id="7021454">rs</compound-id> = 0.5898, p &lt; 0.001), gamma-<compound-id="6830">GTP</compound-id> (<compound-id="7021454">rs</compound-id> = 0.2903, p &lt; 0.001), LAP (<compound-id="7021454">rs</compound-id> = 0.3093, p &lt; 0.001), IgA (<compound-id="7021454">rs</compound-id> = 0.2299, p &lt; 0.01), <protein-id="P29965">IgM</protein-id> (<compound-id="7021454">rs</compound-id> = 0.1773, p &lt; 0.05), RAHA (<compound-id="7021454">rs</compound-id> = 0.2420, p &lt; 0.01), <protein-id="P02741">CRP</protein-id> (<compound-id="7021454">rs</compound-id> = 0.3532, p &lt; 0.001), ESR (<compound-id="7021454">rs</compound-id> = 0.4006, p &lt; 0.001).	GTP__ALP3__no_interaction	GTP__ALP1__no_interaction	GTP__IgM__no_interaction	GTP__CRP__no_interaction	rs__ALP3__no_interaction	rs__ALP1__no_interaction	rs__IgM__no_interaction	rs__CRP__no_interaction
9435206-7	SB 207499 inhibited the activation of a variety of immune and inflammatory cells in a concentration-dependent manner: (1) <compound-id="774">histamine</compound-id> release in basophils [-log IC25 = 6.6 +/- 0.3 vs. 8.0 for (R)-<compound-id="5092">rolipram</compound-id>], (2) lipopolysacchride-induced <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> formation in monocytes [-log IC50 = 7.0 +/- 0.1 vs. 7.2 +/- 0.1 for (R)-<compound-id="5092">rolipram</compound-id>], (3) <compound-id="443295">fMLP</compound-id>-induced degranulation in neutrophils [-log IC15 = 7.1 +/- 0.2 vs. 6.4 +/- 0.5 for (R)-<compound-id="5092">rolipram</compound-id>], (4) house dust mite induced-proliferation of peripheral blood mononuclear cells [-log IC40 = 6.5 +/- 0.3 vs. 6.4 +/- 0.3 for (R)-<compound-id="5092">rolipram</compound-id>] and (5) ragweed-induced production of <protein-id="P01579">interferon-gamma</protein-id> [-log IC50 = 5.4] and <protein-id="P05113">interleukin-5</protein-id> [-log IC50 = 5.0].	rolipram__TNF-alpha__no_interaction	rolipram__interferon-gamma__no_interaction	rolipram__interleukin-5__no_interaction	histamine__TNF-alpha__no_interaction	histamine__interferon-gamma__no_interaction	histamine__interleukin-5__no_interaction	fMLP__TNF-alpha__no_interaction	fMLP__interferon-gamma__no_interaction	fMLP__interleukin-5__no_interaction
14630620-4	After antigen challenge, <compound-id="90470996">thrombin</compound-id> activity also showed significant correlations with <protein-id="P05113">interleukin-5</protein-id> (r = 0.66, p = 0.002), transforming growth factor beta1 (r = 0.70, p &lt; 0.001), <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id> (r = 0.85, p &lt; 0.001) and <protein-id="P13726">tissue factor</protein-id> (r = 0.55, p = 0.03) levels in lavage fluid.	thrombin__fibronectin__no_interaction	thrombin__interleukin-5__no_interaction	thrombin__tissue factor__no_interaction
6361449-4	Increasing WHR was accompanied by progressively increasing fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> levels (r = 0.47, P less than 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> and <compound-id="206,5793,64689,79025">glucose</compound-id> areas after <compound-id="206,5793,64689,79025">glucose</compound-id> challenge (r = 0.53, P less than 0.001; r = 0.50, P less than 0.001, respectively) and fasting plasma triglyceride concentrations (r = 0.48, P less than 0.001).	glucose__insulin__no_interaction
18719290-8	This stretch-activated response was significantly diminished by the stretch-activated cation channel blocker <compound-id="23982">gadolinium</compound-id> (10(-3) M), the L-type Ca2+ channel blockers <compound-id="4485">nifedipine</compound-id> (2 x 10(-6) M), <compound-id="39186">diltiazem</compound-id> (10(-5) M), and <compound-id="2520">verapamil</compound-id> (10(-5) M), the sensory neurotoxin <compound-id="1548943">capsaicin</compound-id> (10(-5) M), and the <protein-id="P21452">neurokinin (NK)(2) receptor</protein-id> antagonists MEN 10376 ([<compound-id="6057">Tyr</compound-id>(I),<compound-id="9060">d-Trp</compound-id>(6,8,9),<compound-id="5962">Lys</compound-id>(10)]-<compound-id="5311311">NKA</compound-id>(4-10)) (10(-5) M) and <compound-id="104974">SR48968</compound-id> (N-[(2S)-4-(4-<compound-id="178">acetamido</compound-id>-<compound-id="69873">4-phenylpiperidin</compound-id>-1-yl)-2-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="68006705">butyl</compound-id>]-N-<compound-id="11954">methylbenzamide</compound-id>) (3 x 10(-6) M).	nifedipine__neurokinin (NK)(2) receptor__no_interaction	NKA__neurokinin (NK)(2) receptor__no_interaction	capsaicin__neurokinin (NK)(2) receptor__no_interaction	dichlorophenyl__neurokinin (NK)(2) receptor__no_interaction	Lys__neurokinin (NK)(2) receptor__no_interaction	diltiazem__neurokinin (NK)(2) receptor__no_interaction	SR48968__neurokinin (NK)(2) receptor__no_interaction	4-phenylpiperidin__neurokinin (NK)(2) receptor__no_interaction	d-Trp__neurokinin (NK)(2) receptor__no_interaction	verapamil__neurokinin (NK)(2) receptor__no_interaction	butyl__neurokinin (NK)(2) receptor__no_interaction	gadolinium__neurokinin (NK)(2) receptor__no_interaction	acetamido__neurokinin (NK)(2) receptor__no_interaction	Tyr__neurokinin (NK)(2) receptor__no_interaction	methylbenzamide__neurokinin (NK)(2) receptor__no_interaction
8334804-8	Blood pressure-corrected aortic distensibility was found to correlate inversely with age (r = -0.67, P &lt; 0.001), low-density lipoprotein-<compound-id="5997">cholesterol</compound-id> (r = -0.37, P &lt; 0.02) and the low-density lipoprotein-/high density lipoprotein-<compound-id="5997">cholesterol</compound-id> ratio (r = -0.33, P &lt; 0.05) and positively with <protein-id="P05019,Q5U743,Q13429,Q59GC5">insulin-like growth factor-I</protein-id> (r = 0.47, P &lt; 0.01).	cholesterol__insulin-like growth factor-I__no_interaction
22137662-1	<compound-id="114789">Carbon-11</compound-id>-labeled arylpiperazinylthioalkyl derivatives, 2-((4-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)<compound-id="68006705">butyl</compound-id>)thio)<compound-id="9228">benzo[d]oxazole</compound-id> ([(11)C]5a), 2-((4-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)<compound-id="68006705">butyl</compound-id>)thio)-5,7-dimethylbenzo[d]<compound-id="9255">oxazole</compound-id> ([(11)C]5c), 2-((4-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)<compound-id="68006705">butyl</compound-id>)thio)<compound-id="7222">benzo[d]thiazole</compound-id> ([(11)C]5e), 2-((6-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)hexyl)thio)<compound-id="9228">benzo[d]oxazole</compound-id> ([(11)C]5g), 2-((6-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)hexyl)thio)-5,7-dimethylbenzo[d]<compound-id="9255">oxazole</compound-id> ([(11)C]5i), and 2-((6-(4-(2-[(11)C]methoxyphenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)hexyl)thio)<compound-id="7222">benzo[d]thiazole</compound-id> ([(11)C]5k), were prepared from their corresponding <compound-id="996">phenol</compound-id> precursors with [(11)C]CH(3)OTf through O-[(11)C]methylation and isolated by a simplified solid-phase extraction (SPE) method using a Sep-Pak Plus <protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C18</protein-id> cartridge in 50-60% (n=5) radiochemical yields based on [(11)C]CO(2) and decay corrected to end of bombardment (<compound-id="9547937">EOB</compound-id>).	oxazole__C18__no_interaction	piperazin-1-yl__C18__no_interaction	EOB__C18__no_interaction	benzo[d]thiazole__C18__no_interaction	benzo[d]oxazole__C18__no_interaction	butyl__C18__no_interaction	phenol__C18__no_interaction	Carbon-11__C18__no_interaction
18305842-1	Seven new <protein-id="P36544,Q494W8,A0A0A6YYA8,A0A0G2JMC1">d10</protein-id> metal coordination polymers with isomeric benzenedicarboxylates and <compound-id="2797657">3-(2-pyridyl)pyrazole</compound-id> ligands, [Zn2 L2(1,2-<compound-id="446612">BDC</compound-id>)(H2O)]n ( 1), {[Cd2(H L)2(1,2-<compound-id="446612">BDC</compound-id>)2] x H2O}n ( 2), [Cd(H L)(1,2-<compound-id="446612">BDC</compound-id>)(H2O)]n (3), [Zn(H L)(1,3-<compound-id="446612">BDC</compound-id>)(H2O) x 3H2O]n ( 4), [Cd2 L2(1,3-<compound-id="446612">BDC</compound-id>)(H2O)]n (5), [Zn(H L)2(1,4-<compound-id="446612">BDC</compound-id>)]n ( 6) and [Cd(H L)2(1,4-<compound-id="446612">BDC</compound-id>)]n (7) (<compound-id="446612">BDC</compound-id> = benzenedicarboxylate, H L = <compound-id="2797657">3-(2-pyridyl)pyrazole</compound-id>), have been synthesized and structurally characterized by elemental analysis, IR and X-ray diffraction.	BDC__d10__no_interaction	3-(2-pyridyl)pyrazole__d10__no_interaction
17002932-3	RESULTS: On admission, a 33-year-old African American woman had the following laboratory findings: serum ionized <compound-id="22044544,5460341">calcium</compound-id> 3.8 mg/dL (0.95 mmol/L), venous pH 7.26, <compound-id="767">bicarbonate</compound-id> 20 mEq/L, <compound-id="312">chloride</compound-id> 111 mEq/L, alkaline phosphatase 1,192 U/L (20.26 microkat/L) (normal, 40 to 136 U/L), <compound-id="5283731,6433735">25-hydroxyvitamin D</compound-id> &lt;5 ng/mL (&lt;12 nmol/L) (normal, 10 to 60 ng/mL), <protein-id="P01270">parathyroid hormone 1</protein-id>,620 pg/mL (165.2 pmol/L) (normal, 10 to 60 pg/mL), <compound-id="5839">aldosterone</compound-id> 68.4 ng/dL (1,894.7 pmol/L) (normal, 4.5 to 35.4 ng/dL), supine plasma <protein-id="P00797">renin</protein-id> activity 19.8 ng/mL per hour (5.35 ng/L per second) (normal, 0.5 to 1.8 ng/mL per hour), and aminoaciduria.	calcium__parathyroid hormone 1__no_interaction	calcium__renin__no_interaction	25-hydroxyvitamin D__parathyroid hormone 1__no_interaction	25-hydroxyvitamin D__renin__no_interaction	aldosterone__parathyroid hormone 1__no_interaction	aldosterone__renin__no_interaction	chloride__parathyroid hormone 1__no_interaction	chloride__renin__no_interaction	bicarbonate__parathyroid hormone 1__no_interaction	bicarbonate__renin__no_interaction
20584222-6	NT-proBNP significantly correlated with cardiac index (R = -0.44, p &lt; 0.001), right atrial pressure (R = 0.40, p &lt; 0.001), pulmonary arterial wedge pressure (R = 0.38, p &lt; 0.001) and <protein-id="P02768">albumin</protein-id> (R = -0.52, p &lt; 0.001), and total <compound-id="5280352">bilirubin</compound-id> with right atrial pressure (R = 0.59, p &lt; 0.001).	bilirubin__albumin__no_interaction
11414660-1	We have investigated the pharmacological properties of B8805-033 [(+/-)- 1,3,5-<compound-id="4245325">trimethyl-</compound-id>6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-<compound-id="136071">1,4-benzodioxin-5-yl</compound-id>)-1-piperazinyl]propyl] amino]-2,4(1H,3H)-<compound-id="1174">pyrimidinedione</compound-id>], a new <protein-id="P43140">alpha1A-adrenoceptor</protein-id> (AR) selective antagonist.	1,4-benzodioxin-5-yl__alpha1A-adrenoceptor__no_interaction	trimethyl-__alpha1A-adrenoceptor__no_interaction	pyrimidinedione__alpha1A-adrenoceptor__no_interaction
18063533-3	Along with magma and steam (H2O), the following gases surface in the environment: <compound-id="5462310">carbon</compound-id> dioxide (<protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id>) and <compound-id="1119">sulphur dioxide</compound-id> (SO2), <compound-id="281">carbon monoxide</compound-id> (CO), <compound-id="402">hydrogen sulphide</compound-id> (H2S), <compound-id="5462310">carbon</compound-id> sulphide (CS), <compound-id="6348">carbon disulfide</compound-id> (<protein-id="P0DML3,B1A4H9,A6NIT4">CS2</protein-id>), <compound-id="313">hydrogen chloride</compound-id> (HCl), hydrogen (<compound-id="783">H2</compound-id>), <compound-id="297">methane</compound-id> (CH4), <compound-id="14917">hydrogen fluoride</compound-id> (HF), <compound-id="260">hydrogen bromide</compound-id> (HBr) and various organic compounds, as well as heavy metals (mercury, lead, <compound-id="23985">gold</compound-id>).Their unfavourable effects depend on the distance from a volcano, on magma viscosity, and on gas concentrations.	hydrogen chloride__CO2__no_interaction	hydrogen chloride__CS2__no_interaction	hydrogen sulphide__CO2__no_interaction	hydrogen sulphide__CS2__no_interaction	gold__CO2__no_interaction	gold__CS2__no_interaction	H2__CO2__no_interaction	H2__CS2__no_interaction	hydrogen fluoride__CO2__no_interaction	hydrogen fluoride__CS2__no_interaction	carbon disulfide__CO2__no_interaction	carbon disulfide__CS2__no_interaction	carbon monoxide__CO2__no_interaction	carbon monoxide__CS2__no_interaction	hydrogen bromide__CO2__no_interaction	hydrogen bromide__CS2__no_interaction	carbon__CO2__no_interaction	carbon__CS2__no_interaction	sulphur dioxide__CO2__no_interaction	sulphur dioxide__CS2__no_interaction	methane__CO2__no_interaction	methane__CS2__no_interaction
20137536-7	<compound-id="2214">Apocynin</compound-id> significantly reduced <compound-id="5884">NADPH</compound-id> oxidase activity (P &lt; 0.05), upregulated SERCA2a, <protein-id="Q29621">RyR2</protein-id> and <compound-id="5289162">PLB</compound-id> mRNA expressions (SERCA2a/GAPDH: 0.63 +/- 0.11 vs. 0.34 +/- 0.08, <protein-id="Q29621">RyR2</protein-id>/GAPDH: 0.23 +/- 0.04 vs. 0.17 +/- 0.06, <compound-id="5289162">PLB</compound-id>/GAPDH:1.28 +/- 0.13 vs. 0.95 +/- 0.09, P &lt; 0.05), downregulated NCX mRNA expression (NCX/GAPDH: 0.67 +/- 0.10 vs. 0.95 +/- 0.12, P &lt; 0.05), and improved cardiac function [LVEF: (60.06 +/- 10.07)% vs. (38.87 +/- 3.31)%, LVFS: (30.12 +/- 6.56)% vs. (17.40 +/- 2.45)%, P &lt; 0.05] in rabbits with HF.	NADPH__RyR2__no_interaction	Apocynin__RyR2__no_interaction	PLB__RyR2__no_interaction
16842009-1	Nonanuclear cluster complexes [<compound-id="11371378">Ru9</compound-id>(mu3-H)2(mu-H)(<protein-id="Q9H0R1,A0A024R654,E7EQ45">mu5</protein-id>-O)(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-ampy)(mu3-Hampy)(CO)21] (4) (H2ampy = <compound-id="15765">2-amino-6-methylpyridine</compound-id>), [<compound-id="11371378">Ru9</compound-id>(<protein-id="Q9H0R1,A0A024R654,E7EQ45">mu5</protein-id>-O)2(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-ampy)(mu3-Hampy)2(mu-CO)(CO)20] (5), [<compound-id="11371378">Ru9</compound-id>(<protein-id="Q9H0R1,A0A024R654,E7EQ45">mu5</protein-id>-O)2(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-ampy)(mu3-Hampy)2(mu-CO)2(CO)19] (6), and [<compound-id="11371378">Ru9</compound-id>(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-O)(<protein-id="Q9H0R1,A0A024R654,E7EQ45">mu5</protein-id>-O)(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-ampy)(mu3-Hampy)(mu-Hampy)(mu-CO)(CO)19] (7), together with the known hexanuclear [<compound-id="22489155">Ru6</compound-id>(mu3-H)2(<protein-id="Q9H0R1,A0A024R654,E7EQ45">mu5</protein-id>-ampy)(mu-CO)2(CO)14] (2) and the novel pentanuclear [Ru5(<protein-id="O00189,C9IZL5,C9JC87">mu4</protein-id>-ampy)(2)(mu-CO)(CO)12] (3) complexes, are products of the thermolysis of [Ru3(mu-H)(mu3-Hampy)(CO)9] (1) in decane at 150 degrees C. Two different and very unusual quadruply bridging coordination modes have been observed for the ampy ligand.	2-amino-6-methylpyridine__mu5__no_interaction	2-amino-6-methylpyridine__mu4__no_interaction	Ru9__mu5__no_interaction	Ru9__mu4__no_interaction	Ru6__mu5__no_interaction	Ru6__mu4__no_interaction
17140222-1	Reactions of [WES3]2- (E = S, O) with <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> (X = NCS, CN, I) in the presence of bix (bix = <compound-id="1257389">1,4-bis(imidazole-1-ylmethyl)benzene</compound-id>) in DMF or CH3CN resulted in the formation of two novel 2D --&gt; 3D interpenetrating coordination polymers [S2W2S6Cu4(bix)2]n (1) and {[WS4Cu4(NCS)2(bix)3].CH3CN}n (2), a noninterpenetrating 3D polymer {[<protein-id="P56693,A0A024R1N6">WS4Cu2</protein-id>(bix)].DMF}n (3), and two 2D sheet polymers [WS4Cu3(CN)(bix)]n (4) and {[OWS3Cu3(bix)2][I].DMF.2H2O}n (5), depending on the reaction temperature and the reagents used.	1,4-bis(imidazole-1-ylmethyl)benzene__WS4Cu2__no_interaction	1,4-bis(imidazole-1-ylmethyl)benzene__CuX__no_interaction
3191256-3	In three instances, protein binding parameters are greatly affected by isotopic substitution, namely for: <compound-id="2153">theophylline</compound-id> and 1-C(2H3)<compound-id="2153">theophylline</compound-id> with isotope effects on total binding site concentration (N), affinity constant (Ka) and extent of HSA binding (%) respectively, equal to: NL/NH = 0.51; KaL/KaH = 1.78; %L/%H = 0.96 (L (light) and H (heavy) represent the unlabelled and labelled analogue respectively); <compound-id="4763">phenobarbitone</compound-id>/-5-(phenyl(<compound-id="7191875">2H5</compound-id>]<compound-id="4763">phenobarbitone</compound-id>, NL/NH = 1.72; KaL/KaH = 0.56; %L/%H = 1.26; <compound-id="4763">phenobarbitone</compound-id>/1,3-15N;2-13C <compound-id="4763">phenobarbitone</compound-id>, NL/NH = 2.95; KaL/KaH = 0.44; %L/%H = 1.32, together with a change from one (saturable) to two (saturable + non-saturable) families of <protein-id="P02768">albumin</protein-id> binding sites in the latter case.	2H5__albumin__no_interaction	theophylline__albumin__no_interaction	phenobarbitone__albumin__no_interaction
8062515-5	The concentrations of glyoxalase metabolites, methylglyoxal, <compound-id="119450">S-D-lactoylglutathione</compound-id> and <compound-id="61503">D-lactate</compound-id>, were increased in diabetic patients, relative to normal control subjects: methylglyoxal [median, range (n) pmol/g], <protein-id="P01308,I3WAC9">insulin</protein-id>-dependent patients, 470.7, 85.6-1044.3 (42), P &lt; 0.001, non-<protein-id="P01308,I3WAC9">insulin</protein-id>-dependent patients, 286.8, 54.7-2370 (105), P &lt; 0.001, control subjects, 79.8, 25.3-892.9 (21); <compound-id="119450">S-D-lactoylglutathione</compound-id> [mean +/- SD (n)pmol/10(6) erythrocytes], combined diabetic patients, 3.37 +/- 0.85 (24), control subjects 4.76 +/- 1.95 (8) P &lt; 0.05; <compound-id="61503">D-lactate</compound-id> [mean +/- SD or median, range (n)nmol/g], <protein-id="P01308,I3WAC9">insulin</protein-id> dependent patients, median 18.3, 5.7-57.4 (42), P &lt; 0.001, non-<protein-id="P01308,I3WAC9">insulin</protein-id>-dependent patients, 20.0 +/- 8.9, 2.6-48.4 (105), P &lt; 0.001, control subjects 9.7 +/- 4.3, 1.8-19.7 (21).	D-lactate__insulin__no_interaction	S-D-lactoylglutathione__insulin__no_interaction
17200026-8	Compared with normal saline group, <protein-id="P05503,Q8HIC9">COX-1</protein-id> mRNA expression of the groups (Ia, Ib, Id, IIa, IIb and <compound-id="6540267">IId</compound-id>) increased (0.384 +/- 0.031, 0.354 +/- 0.026, 0.753 +/- 0.049, 0.366 +/- 0.035, 0.381 +/- 0.036, 0.766 +/- 0.401, P &lt; 0.001) while <protein-id="P00406,Q8SEZ5">COX-2</protein-id> mRNA expression of the above groups decreased statistically (0.483 +/- 0.056, 0.448 +/- 0.046, 0.461 +/- 0.050, 0.479 +/- 0.032, P &lt; 0.001).	IId__COX-1__no_interaction	IId__COX-2__no_interaction
17887755-2	Via the use of derivatized <compound-id="6350">oxime</compound-id> ligands and bulky carboxylates we show that it is possible to deliberately increase the value of the spin ground state of the complexes [Mn6O2(Me-sao)6(O2CCPh3)2(<compound-id="702">EtOH</compound-id>)4] (2), [Mn6O2(Et-sao)6(O2CCMe3)2(<compound-id="702">EtOH</compound-id>)5] (3), [Mn6O2(Et-sao)6(O2CPh2OPh)2(<compound-id="702">EtOH</compound-id>)4] (4), [Mn6O2(Et-sao)6(O2CPh4OPh)2(<compound-id="702">EtOH</compound-id>)4(H2O)2] (5), [Mn6O2(Me-sao)6(O2CPhBr)2(<compound-id="702">EtOH</compound-id>)6] (6), [Mn6O2(Et-sao)6(O2CPh)2(<compound-id="702">EtOH</compound-id>)4(H2O)2] (7), [Mn6O2(Et-sao)6{O2CPh(Me)2}2(<compound-id="702">EtOH</compound-id>)6] (8), [Mn6O2(Et-sao)6(O2C11H15)2(<compound-id="702">EtOH</compound-id>)6] (9), [Mn6O2(Me-sao)6(O2C-th)2(<compound-id="702">EtOH</compound-id>)4(H2O)2] (10), [Mn6O2(Et-sao)6(O2CPhMe)2(<compound-id="702">EtOH</compound-id>)4(H2O)2] (11), and [Mn6O2(Et-sao)6(O2C12H17)2(<compound-id="702">EtOH</compound-id>)4(H2O)2] (12) (Et-saoH2 = <compound-id="101121">2-hydroxypropiophenone</compound-id> <compound-id="6350">oxime</compound-id>, Me-saoH2 = 2-hydroxyethanone <compound-id="6350">oxime</compound-id>, <protein-id="P30519,A0A087WT44,B3KSE0">HO2CCPh3</protein-id> = <compound-id="68992">triphenylacetic acid</compound-id>, HO2CCMe3 = <compound-id="6417">pivalic acid</compound-id>, HO2CPh2OPh = <compound-id="75237">2-phenoxybenzoic acid</compound-id>, HO2CPh4OPh = <compound-id="75182">4-phenoxybenzoic acid</compound-id>, <protein-id="P30519,A0A087WT44,B3KSE0">HO2CPhBr</protein-id> = <compound-id="11464">4-bromobenzoic acid</compound-id>, HO2CPh(Me)2 = 3,5-dimethylbenzoic acid, HO2C11H15 = <compound-id="9238">adamantane</compound-id> <compound-id="11229316,91179806">carboxylic acid</compound-id>, HO2C-th = <compound-id="6918">3-thiophene carboxylic acid</compound-id>, <protein-id="P39900">HO2CPhMe</protein-id> = <compound-id="7470">4-methylbenzoic acid</compound-id>, and HO2C12H17 = <compound-id="519973">adamantane acetic acid</compound-id>) in a stepwise fashion from S = 4 to S = 12 and, in-so-doing, enhance the energy barrier for magnetization reorientation to record levels.	4-phenoxybenzoic acid__HO2CCPh3__no_interaction	4-phenoxybenzoic acid__HO2CPhMe__no_interaction	4-phenoxybenzoic acid__HO2CPhBr__no_interaction	2-hydroxypropiophenone__HO2CCPh3__no_interaction	2-hydroxypropiophenone__HO2CPhMe__no_interaction	2-hydroxypropiophenone__HO2CPhBr__no_interaction	triphenylacetic acid__HO2CCPh3__no_interaction	triphenylacetic acid__HO2CPhMe__no_interaction	triphenylacetic acid__HO2CPhBr__no_interaction	oxime__HO2CCPh3__no_interaction	oxime__HO2CPhMe__no_interaction	oxime__HO2CPhBr__no_interaction	4-bromobenzoic acid__HO2CCPh3__no_interaction	4-bromobenzoic acid__HO2CPhMe__no_interaction	4-bromobenzoic acid__HO2CPhBr__no_interaction	3-thiophene carboxylic acid__HO2CCPh3__no_interaction	3-thiophene carboxylic acid__HO2CPhMe__no_interaction	3-thiophene carboxylic acid__HO2CPhBr__no_interaction	pivalic acid__HO2CCPh3__no_interaction	pivalic acid__HO2CPhMe__no_interaction	pivalic acid__HO2CPhBr__no_interaction	EtOH__HO2CCPh3__no_interaction	EtOH__HO2CPhMe__no_interaction	EtOH__HO2CPhBr__no_interaction	2-phenoxybenzoic acid__HO2CCPh3__no_interaction	2-phenoxybenzoic acid__HO2CPhMe__no_interaction	2-phenoxybenzoic acid__HO2CPhBr__no_interaction	carboxylic acid__HO2CCPh3__no_interaction	carboxylic acid__HO2CPhMe__no_interaction	carboxylic acid__HO2CPhBr__no_interaction	adamantane__HO2CCPh3__no_interaction	adamantane__HO2CPhMe__no_interaction	adamantane__HO2CPhBr__no_interaction	4-methylbenzoic acid__HO2CCPh3__no_interaction	4-methylbenzoic acid__HO2CPhMe__no_interaction	4-methylbenzoic acid__HO2CPhBr__no_interaction	adamantane acetic acid__HO2CCPh3__no_interaction	adamantane acetic acid__HO2CPhMe__no_interaction	adamantane acetic acid__HO2CPhBr__no_interaction
20799970-6	RESULTS: Of the 152 infants investigated had a significant positive association of high-density lipoprotein <compound-id="5997">cholesterol</compound-id> with hemoglobin (P &lt; 0.001), hematocrit (P &lt; 0.001) and total <compound-id="5997">cholesterol</compound-id> (P &lt; 0.001) and a negative significant association with reticulocytes (P = 0.046), leukocytes (P = 0.015), monocytes (P = 0.004) and platelets (P = 0.005), bilirubins [total <compound-id="5280352">bilirubin</compound-id> (P &lt; 0.001), direct <compound-id="5280352">bilirubin</compound-id> (P &lt; 0.001) and indirect <compound-id="5280352">bilirubin</compound-id> (P &lt; 0.001], <compound-id="23925,67172434">iron</compound-id> (P &lt; 0.001), aminotransferases [<compound-id="5960">aspartate</compound-id> aminotransferase (P = 0.004), <compound-id="5950,602">alanine</compound-id> aminotransferase (P = 0.035)], <compound-id="612">lactate</compound-id> dehydrogenase (P &lt; 0.001), <compound-id="1176">urea</compound-id> (P = 0.030), <protein-id="P01009,E9KL23">alpha 1-antitrypsin</protein-id> (P &lt; 0.001), very low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (P = 0.003), triglycerides (P = 0.005) and hemoglobin S (P = 0.002).	alanine__alpha 1-antitrypsin__no_interaction	bilirubin__alpha 1-antitrypsin__no_interaction	cholesterol__alpha 1-antitrypsin__no_interaction	urea__alpha 1-antitrypsin__no_interaction	aspartate__alpha 1-antitrypsin__no_interaction	iron__alpha 1-antitrypsin__no_interaction	lactate__alpha 1-antitrypsin__no_interaction
19927783-7	In univariate analysis the factors associated with a high risk of liver involvement were a higher level of <protein-id="Q9BX51,D3DW46">gamma-glutamyl transpeptidase</protein-id> (44.5 + 36.8 IU/l vs 23.3 + 9.28 IU/l p = 0.005), a higher level of phosphatases alkalines (233.9 + 96.6 IU/l vs 189.4 + 49.9 IU/l p = 0.03) and a lower level of <compound-id="5997">cholesterol</compound-id> (1.22 + 0.2 g/l vs 156 + 0.3 g/l p &lt; 0.0001).	cholesterol__gamma-glutamyl transpeptidase__no_interaction
16801985-4	gamma-globulin, <compound-id="132999">ivabradine hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; <compound-id="219078">Lacosamide</compound-id>, <compound-id="767">lanthanum carbonate</compound-id>, <compound-id="216326">lenalidomide</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="6047">levodopa</compound-id> <compound-id="9958101">methyl ester hydrochloride</compound-id>/carbidopa, <compound-id="6047">levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, <compound-id="9911821">lidocaine/prilocaine</compound-id>; <compound-id="3002977">Maraviroc</compound-id>, mecasermin, <compound-id="23497">melevodopa hydrochloride</compound-id>, <compound-id="56603701">mepolizumab</compound-id>, mitumomab; Nesiritide; Omalizumab, oral <protein-id="P01308,I3WAC9,P01270">insulin; Parathyroid hormone</protein-id> (human recombinant), <compound-id="448013">patupilone</compound-id>, <compound-id="56603655">pegaptanib</compound-id> <compound-id="5360545">sodium</compound-id>, PEG-filgrastim, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, photochlor, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="468595">posaconazole</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="6918456">prasugrel</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="4906">prilocaine</compound-id>, <compound-id="11430856">PRX-00023</compound-id>; <compound-id="60866">QS-21</compound-id>; Ranibizumab, <compound-id="153948,9953887">ranirestat</compound-id>, <compound-id="65218">rhodamine 123</compound-id>, <compound-id="9938933">rotigaptide</compound-id>; <compound-id="1088">Sarcosine</compound-id>, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498">sirolimus</compound-id>-eluting stent, <compound-id="216235">sitaxsentan sodium</compound-id>, <compound-id="154059">solifenacin succinate</compound-id>, Staphylococcus aureus vaccine; <compound-id="110635">Tadalafil</compound-id>, <compound-id="3036289">talactoferrin alfa</compound-id>, <compound-id="5486799">talaporfin</compound-id> <compound-id="5360545">sodium</compound-id>, Taxus, <compound-id="158795">tecadenoson</compound-id>, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">temsirolimus</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, teriparatide, <compound-id="9938840">terutroban sodium</compound-id>, <compound-id="208901">tesaglitazar</compound-id>, <compound-id="108092">tesmilifene</compound-id> hydrochloride, <compound-id="10427712">TG-100115</compound-id>, <compound-id="54686904">tigecycline</compound-id>, torcetrapib; <compound-id="16132416">Ularitide</compound-id>; Valproic acid, <compound-id="5360545">sodium</compound-id>, <compound-id="71616">voriconazole</compound-id>; <compound-id="23375907,52945214,53398674,91450784,9876378">Zotarolimus</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>-eluting stent.	TG-100115__insulin; Parathyroid hormone__no_interaction	tigecycline__insulin; Parathyroid hormone__no_interaction	QS-21__insulin; Parathyroid hormone__no_interaction	melevodopa hydrochloride__insulin; Parathyroid hormone__no_interaction	solifenacin succinate__insulin; Parathyroid hormone__no_interaction	tecadenoson__insulin; Parathyroid hormone__no_interaction	zotarolimus__insulin; Parathyroid hormone__no_interaction	sodium__insulin; Parathyroid hormone__no_interaction	talactoferrin alfa__insulin; Parathyroid hormone__no_interaction	prilocaine__insulin; Parathyroid hormone__no_interaction	lanthanum carbonate__insulin; Parathyroid hormone__no_interaction	sirolimus__insulin; Parathyroid hormone__no_interaction	ivabradine hydrochloride__insulin; Parathyroid hormone__no_interaction	PRX-00023__insulin; Parathyroid hormone__no_interaction	rotigaptide__insulin; Parathyroid hormone__no_interaction	tesaglitazar__insulin; Parathyroid hormone__no_interaction	rhodamine 123__insulin; Parathyroid hormone__no_interaction	pregabalin__insulin; Parathyroid hormone__no_interaction	methyl ester hydrochloride__insulin; Parathyroid hormone__no_interaction	entacapone__insulin; Parathyroid hormone__no_interaction	Ularitide__insulin; Parathyroid hormone__no_interaction	sitaxsentan sodium__insulin; Parathyroid hormone__no_interaction	Lacosamide__insulin; Parathyroid hormone__no_interaction	voriconazole__insulin; Parathyroid hormone__no_interaction	tenofovir disoproxil fumarate__insulin; Parathyroid hormone__no_interaction	ixabepilone__insulin; Parathyroid hormone__no_interaction	tegaserod maleate__insulin; Parathyroid hormone__no_interaction	pegaptanib__insulin; Parathyroid hormone__no_interaction	pimecrolimus__insulin; Parathyroid hormone__no_interaction	pemetrexed disodium__insulin; Parathyroid hormone__no_interaction	mepolizumab__insulin; Parathyroid hormone__no_interaction	prasterone__insulin; Parathyroid hormone__no_interaction	ranirestat__insulin; Parathyroid hormone__no_interaction	telithromycin__insulin; Parathyroid hormone__no_interaction	tesmilifene__insulin; Parathyroid hormone__no_interaction	posaconazole__insulin; Parathyroid hormone__no_interaction	lenalidomide__insulin; Parathyroid hormone__no_interaction	talaporfin__insulin; Parathyroid hormone__no_interaction	Sarcosine__insulin; Parathyroid hormone__no_interaction	patupilone__insulin; Parathyroid hormone__no_interaction	levocetirizine__insulin; Parathyroid hormone__no_interaction	levodopa__insulin; Parathyroid hormone__no_interaction	Zotarolimus__insulin; Parathyroid hormone__no_interaction	terutroban sodium__insulin; Parathyroid hormone__no_interaction	Maraviroc__insulin; Parathyroid hormone__no_interaction	lidocaine/prilocaine__insulin; Parathyroid hormone__no_interaction	Tadalafil__insulin; Parathyroid hormone__no_interaction	prasugrel__insulin; Parathyroid hormone__no_interaction	temsirolimus__insulin; Parathyroid hormone__no_interaction
8923153-4	RESULTS: Serum <compound-id="1175">uric acid</compound-id> concentration showed positive associations with BMI (r = 0.24; P &lt; 0.0001), WHR (r = 0.19; P &lt; 0.0001) and serum triglyceride levels (r = 0.19; P &lt; 0.0001); it was also significantly correlated to systolic (r = 0.08; P &lt; 0.01) and diastolic (r = 0.11; P &lt; 0.001) blood pressure, fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.11; P &lt; 0.001), total (r = 0.12; P &lt; 0.001) and LDL <compound-id="5997">cholesterol</compound-id> (r = 0.10; P &lt; 0.01) plasma concentrations.	uric acid__insulin__no_interaction	cholesterol__insulin__no_interaction
21132575-6	Age &gt;65 years [adjusted relative risk, 2.303 (95% confidence interval, 1.551-3.418), P &lt; 0.001], low platelet count [3.086 (1.997-4.768), P &lt; 0.001], high <compound-id="5960">aspartate</compound-id> aminotransferase value [3.001 (1.373-6.562), P &lt; 0.001], high <protein-id="P02771">AFP</protein-id> level [≥10, &lt;20 ng/mL: 2.814 (1.686-4.697), P &lt; 0.001; ≥20 ng/mL: 3.405 (2.087-5.557), P &lt; 0.001] compared to &lt;10 ng/mL, and high <protein-id="P02771">AFP</protein-id>-L3% level [≥5, &lt;10%: 2.494 (1.291-4.816), P = 0.007; ≥10%: 3.555 (1.609-7.858), P &lt; 0.001] compared to &lt;5% were significantly associated with an increased incidence of HCC on multivariate analysis.	aspartate__AFP__no_interaction
11932880-10	Both measures were correlated to a similar degree with disease duration (r = 0.51 for each measure), grip strength (r = -0.49 for <compound-id="73441651">NDJ</compound-id>, and r = -0.51 for <protein-id="Q96T58">Sharp</protein-id>'s score), walking velocity (r = -0.44 for <compound-id="73441651">NDJ</compound-id>, and r = -0.45 for <protein-id="Q96T58">Sharp</protein-id>'s score), the timed button test (r = -0.62 for <compound-id="73441651">NDJ</compound-id>, and r = -0.57 for <protein-id="Q96T58">Sharp</protein-id>'s score), and the Modified Health Assessment Questionnaire (r = 0.38 for <compound-id="73441651">NDJ</compound-id>, and r = 0.38 for <protein-id="Q96T58">Sharp</protein-id>'s score).	NDJ__Sharp__no_interaction
19056675-7	In vivo, NB-1691 tumors in CB17-<protein-id="P97313">SCID</protein-id> mice treated with the combination of <protein-id="P01574">IFN-beta</protein-id> and <compound-id="5394">temozolomide</compound-id> had lower <protein-id="P26187,Q4VA39">MGMT</protein-id> expression and a significantly reduced tumor burden, both localized [percent initial tumor volume: 2,516 +/- 680% (control) versus 1,272 +/- 330% (<compound-id="5394">temozolomide</compound-id>), P = 0.01; 1,348 +/- 220%, P = 0.03 (<protein-id="P01574">IFN-beta</protein-id>); 352 +/- 110%, P = 0.0001 (combo)] and disseminated [bioluminescent signal: control (1.32e10 +/- 6.5e9) versus <protein-id="P01574">IFN-beta</protein-id> (2.78e8 +/- 3.09e8), P = 0.025, versus <compound-id="5394">temozolomide</compound-id> (2.06e9 +/- 1.55e9), P = 0.1, versus combination (2.13e7 +/- 7.67e6), P = 0.009].	temozolomide__IFN-beta__no_interaction	temozolomide__SCID__no_interaction	temozolomide__MGMT__no_interaction
1663527-5	The 50% inhibitory concentrations (IC50 in molarity) of the four local anesthetics for chemotaxis were as follows: <compound-id="5411">tetracaine</compound-id> = 4.1 x 10(-4), <compound-id="3676">lidocaine</compound-id> = 3.2 x 10(-3), <compound-id="4906">prilocaine</compound-id> = 3.6 x 10(-3), <compound-id="4914">procaine</compound-id> = 4.9 x 10(-3), those for SOA production induced by <protein-id="P21462">FMLP</protein-id> were: <compound-id="5411">tetracaine</compound-id> = 3.1 x 10(-4), <compound-id="3676">lidocaine</compound-id> = 5.9 x 10(-3), <compound-id="4906">prilocaine</compound-id> = 1.9 x 10(-2), <compound-id="4914">procaine</compound-id> = 1.2 x 10(-2), those for SOA production induced by <compound-id="122634,22833501,27924,4792">PMA</compound-id> were: <compound-id="5411">tetracaine</compound-id> = 1.1 x 10(-3), <compound-id="3676">lidocaine</compound-id> = 1.2 x 10(-2), <compound-id="4906">prilocaine</compound-id> = 1.5 x 10(-2), <compound-id="4914">procaine</compound-id> = 2.5 x 10(-2), and those for release of <compound-id="445463">BGL</compound-id> were: <compound-id="5411">tetracaine</compound-id> = 1.6 x 10(-3), <compound-id="3676">lidocaine</compound-id> = 5.3 x 10(-3), <compound-id="4906">prilocaine</compound-id> = 2.8 x 10(-2), <compound-id="4914">procaine</compound-id> = 1.2 x 10(-1).	procaine__FMLP__no_interaction	tetracaine__FMLP__no_interaction	BGL__FMLP__no_interaction	PMA__FMLP__no_interaction	prilocaine__FMLP__no_interaction	lidocaine__FMLP__no_interaction
14669934-6	Mean serum <compound-id="23978">copper</compound-id> and <protein-id="P00450,A5PL27">ceruloplasmin</protein-id> concentrations were within the normal range and did not differ significantly among the controls (117 +/- 22 microg/dl, 445 +/- 122 mg/L) and cross country track (98 +/- 17 microg/dl, 312 +/- 59 mg/L), tennis (140 +/- 84 microg/dl, 424 +/- 244 mg/L), softball (95 +/- 30 microg/dl, 310 +/- 77 mg/L), swimming (98 +/- 25 microg/dl, 312 +/- 40 mg/L), soccer (93 +/- 15 microg/dl, 324 +/- 54 mg/ L), basketball (85 +/- 10 microg/dl, 280 +/- 62 mg/L), and gymnastics (96 +/- 21 microg/dl, 315 +/- 68 mg/L) teams.	copper__ceruloplasmin__no_interaction
11836328-5	At baseline (saline injection), older, compared with young, men maintained: 1) similar serum total T, <protein-id="P08833">IGFBP-1</protein-id>, and <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> but reduced IGF-I concentrations, namely, mean (+/- <compound-id="5289348">SEM</compound-id>) IGF-I 160 plus or minus 15 vs. 280 plus or minus 18 microg/liter, (P &lt; 0.001); 2) reduced GH secretory burst mass (0.68 +/- 0.09 vs. 1.2 +/- 0.20 microg/liter, P = 0.031); 3) more disorderly GH release patterns (approximate entropy 0.501 +/- 0.058 vs. 0.288 +/- 0.021, P &lt; 0.001); and 4) blunted 24-h rhythmic GH output (nyctohemeral amplitude 0.25 +/- 0.05 vs. 0.47 +/- 0.08 microg/liter, P = 0.025).	SEM__IGFBP-1__no_interaction	SEM__IGFBP-3__no_interaction
17062890-12	According to histology, levels of <protein-id="P41159,A4D0Y8">Leptin</protein-id> and <compound-id="45100492">FLI</compound-id> increased as steatosis (<protein-id="P41159,A4D0Y8">Leptin</protein-id> from 11.9 +/- 6.3 in score 1 to 17.4 +/- 6.9 in score 2 (P = 0.01) and 22.2 +/- 6.8 ng/ml in score 3 (P &lt; 0.001); <compound-id="45100492">FLI</compound-id> 2.56 +/- 1.40, 3.57 +/- 0.34, 4.45 +/- 0.64 respectively (P = 0.05)); ballooning (from 13.7 +/- 6.7 in score 1 to 17 +/- 7.5 in score 2 (P = 0.001) and 22.1 +/- 7.1 ng/ml in score 3 (P = 0.01); <compound-id="45100492">FLI</compound-id> 2.81 +/- 1.50, 3.40 +/- 1.65, 4.57 +/- 1.67 (P = 0.01 between 0 and 2)); fibrosis (from 14.3 +/- 7 to18.3 +/- 6.9; P = 0.03; <compound-id="45100492">FLI</compound-id> 3.03 +/- 1.57 vs 3.92 +/- 077; P &lt; 0.05) and NAS score (score 1-2: 12.9 +/- 6.9; score 3-4: 17 +/- 6.9 (P = 0.01); score 5-7: 22.9 +/- 7.5 ng/ml (P = 0.03); <compound-id="45100492">FLI</compound-id> 2.70 +/- 1.53, 3.12 +/- 1.53, 4.58 +/- 1.57 P = 0.01 and P = 0.05 between 1-2 vs 3-4 and 3-4 vs 5-7 respectively) worsened.	FLI__Leptin__no_interaction
19622649-6	The other cyanobacterial clades that can now be identified and circumscribed in molecular terms by using these signatures include a deep-branching clade (clade A, corresponding to the subclass Gloeobacterophycidae), consisting of Gloeobacter violaceus and two diazotrophic Synechococcus strains (JA-3-3Ab and JA2-3-B'a) (15 aa insert in EF-G); a clade comprising all other cyanobacteria except those from clade A [18 aa insert in DNA polymerase I (Pol I), 2 aa insert in the DnaX protein, 4 aa insert in TrpRS and 4-5 aa insert in <compound-id="57175189,6305">tryptophan</compound-id> synthase beta subunit]; a clade (clade C, corresponding to the subclass Synechococcophycidae) of various marine unicellular Synechococcus and Prochlorococcus cyanobacteria (12 aa insert in Pol I, 3 aa insert in RpoB, 2 aa insert in KgsA, 6 aa insert in TyrRS, 2 aa insert in tRNA-mG1 transferase <protein-id="P59328,E9QPB3">and 1</protein-id> aa deletion in the RpoC protein); a clade of the low-B/A ecotype Prochlorococcus strains (5 aa deletion in LeuRS <protein-id="P59328,E9QPB3">and 1</protein-id> aa insert in the Ffh protein); a clade consisting of the Nostocales species/strains (subclass Nostocophycidae; 4 aa insert in the <compound-id="19042">PetA</compound-id> protein and 5 aa insert in the ribosomal protein S3); a clade of the order Chroococcales (1 aa insert in RecA); a clade comprising the orders Nostocales, Oscillatoriales and Chroococcales [19 aa insert in DnaE, 13 aa insert in <compound-id="18396">GDP-mannose</compound-id> pyrophosphorylase and 22-27 aa insert in <compound-id="5886">NADP</compound-id>(H)-<compound-id="4650">quinone</compound-id> oxidoreductase subunit D].	tryptophan__and 1__no_interaction	GDP-mannose__and 1__no_interaction	NADP__and 1__no_interaction	PetA__and 1__no_interaction	quinone__and 1__no_interaction
11187466-2	In each complex, the pendant amine is trans to the bridging CN ligand, as determined by spectroscopy and X-ray crystallography: Na(trans-[L14CoIIINCFeII(CN)5]).8H2O, monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/c, a = 15.58(1) A, b = 19.797(4) A, c = 19.830(6) A, beta = 91.62(4) degrees, Z = 8; trans-[L14CoIIINCFeIII(CN)5].<compound-id="70679364">4H2O</compound-id>, monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/m, a = 9.9690(9) A, b = 13.316(1) A, c = 10.1180(8) A, beta = 90.720(6) degrees, Z = 2; [L15CoIIINCFeIII(CN)5].<compound-id="70679364">4H2O</compound-id>, triclinic space group P1, a = 9.454(1) A, b = 9.778(1) A, c = 9.865(2) A, alpha = 60.37(1) degrees, beta = 62.60(1) degrees, gamma = 65.82(1) degrees, Z = 1.	4H2O__P2(1__no_interaction
9004793-4	RESULTS: Serum <compound-id="44342165">laminin</compound-id> was higher in cirrhotic patients belonging to Child's C group and, in cirrhotic patients, it significantly correlated with Pugh's score (r = 0.32, p &lt; 0.01), <protein-id="P00734">prothrombin</protein-id> activity (r = 0.23, p &lt; 0.05), serum albumin (r = -0.35, p &lt; 0.001) and <compound-id="5280352">bilirubin</compound-id> (r = 0.30, p &lt; 0.01), and also with the degree of fibrosis (r = 0.49, p &lt; 0.001).	laminin__prothrombin__no_interaction	bilirubin__prothrombin__no_interaction
8552453-9	Elimination serum half-life (5.86 +/- 1.13 h versus 3.85 +/- 0.40 h) and serum trough concentrations (46 +/- 14 mg/L versus 23 +/- 7 mg/L) of <compound-id="6857980,54197">CAZ</compound-id> were significantly (p &lt; 0.001) increased in the asphyxiated newborn, whereas total body clearance of <compound-id="6857980,54197">CAZ</compound-id> (128.4 +/- 25.1 mL/h versus 205.7 +/- 55.4 mL/h), <compound-id="6857980,54197">CAZ</compound-id> clearance per kg (40.9 +/- 6.1 mL/h/kg versus 60.8 +/- 8.3 mL/h/kg), and the <protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> expressed in mL/min (3.14 +/- 0.43 versus 4.73 +/- 0.89) were significantly (p &lt; 0.001) decreased in the asphyxiated newborn.	CAZ__GFR__no_interaction
23197888-13	For the 18F-<protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id>-negative (n = 22) and -positive (n = 19) groups, there were no differences in the male to female ratios (10/12 vs 4/15, P = 0.186), patient age (63.6 ± 2.4 years vs 60.1 ± 2.6 years, P = 0.323), presence of histopathological grade 1 vs 2 (20/2 and 17/2, P = 1.000), follicular dendritic cell pattern (duodenal/nodal: 13/5 vs 10/3, P = 1.000), mitotic rate (low/partly high, 14/1 vs 10/3, P = 0.311), clinical stage according to the Ann Arbor system (stages IE and <compound-id="6540268">IIE</compound-id>/other, 15/7 vs 15/4, P = 0.499), clinical stage according to the Lugano system (stages I and II-1/other, 14/8 vs 14/5, P = 0.489), soluble interleukin-2 receptor levels (495 ± 78 vs 402 ± 83, P = 0.884), LDH levels (188 ± 7 vs 183 ± 8, P = 0.749), hemoglobin levels (13.5 ± 0.3 vs 12.8 ± 0.4, P = 0.197), bone marrow involvement (positive/negative, 1/8 vs 1/10, P = 1.000), detectability by CT scanning (positive/negative, 1/16 vs 4/13, P = 0.335), and FLIPI risk (low risk/other, 16/6 vs 13/6, P = 0.763), respectively in each case.	IIE__FDG__no_interaction
22938660-6	RESULTS: eGFRs calculated by SCysCAC, Arnal-<compound-id="536770">Dade</compound-id>, Larsson and Rule formulae always were close to those of <protein-id="P01589,Q5W005">Tc-GFR</protein-id> and that were 37.96±32.65 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 33.69±25.24 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 34.16±33.65 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 33.02±30.88 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2) vs. 36.21±31.16 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2) in RFI group, 112.99±39.26 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 101.86±72.29 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 102.69±71.78 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2), 99.12±69.54 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2) vs. 110.54±48.98 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×1.73 m(-2) in <compound-id="56593152">RFN</compound-id> group (all P&gt;0.05).	Dade__min(-1__no_interaction	Dade__Tc-GFR__no_interaction	RFN__min(-1__no_interaction	RFN__Tc-GFR__no_interaction
22171090-7	<compound-id="5287955">CN2</compound-id>-Cbi synergistically enhances <protein-id="P20595">sGC</protein-id> activation by NO-independent regulators 3-(4-amino-<compound-id="53694593">5-cyclopropylpyrimidine</compound-id>-2-yl)-<compound-id="12018214">1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine</compound-id> (BAY41-2272), 4-[((<compound-id="7991">4-carboxybutyl</compound-id>){2-[(<compound-id="139727">4-phenethylbenzyl</compound-id>)oxy]phenethyl}amino) methyl [benzoic]-acid (<compound-id="9808022">cinaciguat</compound-id> or BAY58-2667), and 5-chloro-2-(5-chloro-<compound-id="21846493">thiophene-2-sulfonylamino</compound-id>-N-(4-(<compound-id="8083">morpholine</compound-id>-4-sulfonyl)-phenyl)-benzamide <compound-id="5360545">sodium</compound-id> salt (ataciguat or <compound-id="213037">HMR-1766</compound-id>).	1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine__sGC__no_interaction	5-cyclopropylpyrimidine__sGC__no_interaction	CN2__sGC__no_interaction	4-carboxybutyl__sGC__no_interaction	thiophene-2-sulfonylamino__sGC__no_interaction	sodium__sGC__no_interaction	morpholine__sGC__no_interaction	HMR-1766__sGC__no_interaction	4-phenethylbenzyl__sGC__no_interaction	cinaciguat__sGC__no_interaction
9467535-6	Serum sIL-6R significantly correlated with urinary <protein-id="Q02318">CTx</protein-id> (r = 0.190, P &lt; 0.05) and serum <protein-id="P05187,B2R7C7">ALP</protein-id> (r = 0.209, P &lt; 0.05) and serum <compound-id="5757">estradiol</compound-id> with intact osteocalcin (r = 0.309, P &lt; 0.0005) and serum <protein-id="P05187,B2R7C7">ALP</protein-id> (r = 0.181, P &lt; 0.05).	estradiol__CTx__no_interaction	estradiol__ALP__no_interaction
10736974-5	The genes coded for proteins that may be assigned to four different groups: 1) proteins implicated in the regulation of vascular functions (thrombospondin-1, 20 kDa myosin regulatory light chain; relative increase of rHuEPO induced mRNA levels: 155.2%, P = 0.043; 137.6%, P = 0.046, respectively); 2) gene products involved in gene transcription and/or translation (<protein-id="P22392,Q6FHN3,F6XY72">c-myc purine-binding transcription factor PuF</protein-id>, <protein-id="P23381,A0A024R6K8">tryptophanyl-tRNA synthetase</protein-id>, <protein-id="P39019,B0ZBD0">S19</protein-id> ribosomal protein; increase of mRNA levels: 126.4%, P = 0.032; 150.9%, P = 0.012; 134.9%, P = 0.038); 3) subunits of mitochondrial enzymes related to energy transfer (<compound-id="439153">NADH</compound-id> dehydrogenase subunit 6, cytochrome C oxidase subunit 1; increase of mRNA concentrations: 141.7%, P = 0.007; 140.3%, P = 0.01); and 4) regulators of signal transduction (protein <compound-id="6057,90983769">tyrosine</compound-id> phosphatase G1, increase of transcript level: 160.3%, P = 0.016).	NADH__tryptophanyl-tRNA synthetase__no_interaction	NADH__S19__no_interaction	NADH__c-myc purine-binding transcription factor PuF__no_interaction	tyrosine__tryptophanyl-tRNA synthetase__no_interaction	tyrosine__S19__no_interaction	tyrosine__c-myc purine-binding transcription factor PuF__no_interaction
6325690-2	The excitatory effects of the 3- <compound-id="9964065">isoxazolol</compound-id> amino acids (<compound-id="7021454">RS</compound-id>)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5, 4-c]pyridine-7-<compound-id="11229316,91179806">carboxylic acid</compound-id> (4, 7- <protein-id="P84076">HPCA</protein-id> ), (<compound-id="7021454">RS</compound-id>)-alpha-amino-3-hydroxy-5,6-dihydro-4H- cyclohept [1,2-d] isoxa zole - 8-<compound-id="1032">propionic acid</compound-id> (8, 8- AHCP ), (<compound-id="7021454">RS</compound-id>)-alpha-amino-3- hydroxy-7,8-dihydro-6H- cyclohept [1,2-d] isoxazole -4-<compound-id="1032">propionic acid</compound-id> (12, 4- AHCP ), and (<compound-id="7021454">RS</compound-id>)-alpha-(methylamino)-3-hydroxy-5-methyl- 4- <compound-id="18331929">isoxazolepropionic acid</compound-id> (15, N-Me-AMPA) were shown to be sensitive to (S)-<compound-id="73961">glutamic acid diethyl ester</compound-id> (GDEE), an antagonist at quisqualic acid ( QUIS ) receptors, and insensitive to (<compound-id="7021454">RS</compound-id>)-<compound-id="1216">2-amino-5-phosphonovaleric acid</compound-id> ( 2APV ), an antagonist at N-methyl-(R)-<compound-id="424,57268516,5960">aspartic acid</compound-id> (NMDA) receptors.	glutamic acid diethyl ester__HPCA__no_interaction	2-amino-5-phosphonovaleric acid__HPCA__no_interaction	RS__HPCA__no_interaction	propionic acid__HPCA__no_interaction	isoxazolol__HPCA__no_interaction	isoxazolepropionic acid__HPCA__no_interaction	carboxylic acid__HPCA__no_interaction	aspartic acid__HPCA__no_interaction
17132759-8	RESULTS: After adjustment for age, BMI, <compound-id="588">creatinine</compound-id> clearance, and mean visceral fat no statistically significant association was observed between <compound-id="6013">testosterone</compound-id> (total, bioavailable), <protein-id="Q06520,A8K015">DHEAS</protein-id>, and <compound-id="5757">estradiol</compound-id> (total, bioavailable)levels with natural log tHcy (beta = -2 x 10(-3); 95% confidence intervals (CI) -9 x 10(-3); 5 x 10(-3)), (beta = -4 x 10(-3); 95% CI -18 x 10(-3); 9 x 10(-3)), (beta = 3 x 10(-3); 95% CI -6 x 10(-3); 12 x 10(-3)), (beta = -9.3 x 10(-5); 95% CI -1 x 10(-3); 1 x 10(-3)), and (beta = 0.00; 95% CI -3 x 10(-3); 2 x 10(-3)) respectively.	creatinine__DHEAS__no_interaction	testosterone__DHEAS__no_interaction	estradiol__DHEAS__no_interaction
12553836-7	At low pH and total NP concentration (pH &lt; 3, [NP]/[<protein-id="P22681">Cbl</protein-id>(II)] approximately 1), the cyano-bridged successor complex [<protein-id="P22681">Cbl</protein-id>(III)-(mu-NC)-Fe(I)(CN)(3)(NO(+))](-) (1(s)()) is the final reaction product formed in an inner-sphere electron transfer reaction that is coupled to the release of <compound-id="768">cyanide</compound-id> from coordinated <compound-id="11963622">nitroprusside</compound-id>.	cyanide__Cbl__no_interaction	nitroprusside__Cbl__no_interaction
12830457-5	Plasma <protein-id="Q9HD89">resistin</protein-id> levels correlated significantly with GFR (r = -0.82; P &lt; 0.0001), plasma <compound-id="778,91552">homocysteine</compound-id> concentration (r = 0.68; P &lt; 0.001), and age (r = 0.42; P = 0.05), but not with fasted plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.34; P = 0.12), <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.25; P = 0.19), and <compound-id="90470904">leptin</compound-id> (r = -0.24; P = 0.21) concentrations; body mass index (r = -0.06; P = 0.75), waist-hip ratio (r = 0.09; P = 0.63), or <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (r = -0.05; P = 0.79).	leptin__insulin__no_interaction	leptin__resistin__no_interaction	homocysteine__insulin__no_interaction	homocysteine__resistin__no_interaction	glucose__insulin__no_interaction	glucose__resistin__no_interaction
20837565-3	To examine whether <compound-id="3028194">lithium</compound-id> affects the expression of genes regulating the circadian <protein-id="O08785,A0A0J9YU61,Q6ZQD6,Q8C9W6,Q3UWG6">clock</protein-id>, cultured NIH-3T3 cells were synchronized by serum-shocking, and the relative expression of the <protein-id="O08785,A0A0J9YU61,Q6ZQD6,Q8C9W6,Q3UWG6">clock</protein-id> genes Period1 (<protein-id="O35973,Q6A060,Q5BJ30">Per1</protein-id>), <protein-id="O54943,Q3TW41,Q8C8R0">Period2</protein-id> (<protein-id="O54943,Q3TW41,Q8C8R0">Per2</protein-id>), Period3 (<protein-id="O70361">Per3</protein-id>), <protein-id="P97784">Cryptochrome1</protein-id> (<protein-id="P97784">Cry1</protein-id>), <protein-id="Q9R194">Cryptochrome2</protein-id> (<protein-id="Q9R194">Cry2</protein-id>), <protein-id="Q9WTL8,Q3UHZ2">Brain and muscle aryl hydrocarbon nuclear translocator-like 1</protein-id> (<protein-id="Q9WTL8,Q3UHZ2">Bmal1</protein-id>), <protein-id="O08785,A0A0J9YU61,Q6ZQD6,Q8C9W6,Q3UWG6">Circadian locomotor output cycles kaput</protein-id> (<protein-id="O08785,A0A0J9YU61,Q6ZQD6,Q8C9W6,Q3UWG6">clock</protein-id>), <compound-id="78673847">Rev</compound-id>-Erb-α (<protein-id="Q3UV55">Nr1d1</protein-id>), RAR-related orphan receptor α (Ror-α), <compound-id="439177">Glycogen</compound-id> synthase kinase-3β (Gsk-3β), Casein kinase 1-ε (<compound-id="447955">CK1</compound-id>-ε; Csnk1ε), <protein-id="O08750">E4 binding protein 4</protein-id> (<protein-id="O08750">E4BP4</protein-id>; Nfil-3) and albumin D-binding protein (<protein-id="Q60925,E9Q3E4,Q3USN7">Dbp</protein-id>) was examined for three consecutive days in the presence of <compound-id="3028194">lithium</compound-id> (20 mM) or vehicle (20 mM NaCl).	CK1__Bmal1__no_interaction	CK1__clock__no_interaction	CK1__E4BP4__no_interaction	CK1__Dbp__no_interaction	CK1__Cry1__no_interaction	CK1__Cry2__no_interaction	CK1__Per3__no_interaction	CK1__Per2__no_interaction	CK1__Per1__no_interaction	CK1__Period2__no_interaction	CK1__Circadian locomotor output cycles kaput__no_interaction	CK1__E4 binding protein 4__no_interaction	CK1__Cryptochrome2__no_interaction	CK1__Nr1d1__no_interaction	CK1__Cryptochrome1__no_interaction	CK1__Brain and muscle aryl hydrocarbon nuclear translocator-like 1__no_interaction	lithium__Bmal1__no_interaction	lithium__clock__no_interaction	lithium__E4BP4__no_interaction	lithium__Dbp__no_interaction	lithium__Cry1__no_interaction	lithium__Cry2__no_interaction	lithium__Per3__no_interaction	lithium__Per2__no_interaction	lithium__Per1__no_interaction	lithium__Period2__no_interaction	lithium__Circadian locomotor output cycles kaput__no_interaction	lithium__E4 binding protein 4__no_interaction	lithium__Cryptochrome2__no_interaction	lithium__Nr1d1__no_interaction	lithium__Cryptochrome1__no_interaction	lithium__Brain and muscle aryl hydrocarbon nuclear translocator-like 1__no_interaction	Rev__Bmal1__no_interaction	Rev__clock__no_interaction	Rev__E4BP4__no_interaction	Rev__Dbp__no_interaction	Rev__Cry1__no_interaction	Rev__Cry2__no_interaction	Rev__Per3__no_interaction	Rev__Per2__no_interaction	Rev__Per1__no_interaction	Rev__Period2__no_interaction	Rev__Circadian locomotor output cycles kaput__no_interaction	Rev__E4 binding protein 4__no_interaction	Rev__Cryptochrome2__no_interaction	Rev__Nr1d1__no_interaction	Rev__Cryptochrome1__no_interaction	Rev__Brain and muscle aryl hydrocarbon nuclear translocator-like 1__no_interaction	Glycogen__Bmal1__no_interaction	Glycogen__clock__no_interaction	Glycogen__E4BP4__no_interaction	Glycogen__Dbp__no_interaction	Glycogen__Cry1__no_interaction	Glycogen__Cry2__no_interaction	Glycogen__Per3__no_interaction	Glycogen__Per2__no_interaction	Glycogen__Per1__no_interaction	Glycogen__Period2__no_interaction	Glycogen__Circadian locomotor output cycles kaput__no_interaction	Glycogen__E4 binding protein 4__no_interaction	Glycogen__Cryptochrome2__no_interaction	Glycogen__Nr1d1__no_interaction	Glycogen__Cryptochrome1__no_interaction	Glycogen__Brain and muscle aryl hydrocarbon nuclear translocator-like 1__no_interaction
15017138-4	A number of different versions are given for in-phase to in-phase (II-COS: S (-) \\ to I (-)), in-phase to anti-phase (IA-COS: S (-) \\ to 2 I (-) S (z)), in-phase to <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-state-selective (IS(3)-COS: S (-) \\ to 2 I (-) S (alpha /beta)), anti-phase to in-phase (<compound-id="15942654">AI</compound-id>-COS: 2 I (z) S (-) \\ to I (-)), anti-phase to anti-phase (AA-COS: 2 I (z) S (-) \\ to 2 I (-) S (z)), anti-phase to <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-state-selective (AS(3)-COS: 2 I (z) S (-) \\ to 2 I (-) S (alpha /beta)) and <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-state-selective to <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-state-selective (S(3)S(3)-COS: 2 I (alpha /beta) S (-) \\ to 2 I (-) S (alpha /beta )) coherence transfers.	AI__spin__no_interaction
21561882-4	The expressions of α-internexin intermediate filament (α-IIF), <compound-id="5957">ATP</compound-id> synthase D chain (<compound-id="5957">ATP</compound-id>-SD), heat shock protein (Hsp)-70, truncated <protein-id="Q5T442">connexin-47</protein-id>, <protein-id="P10809,A0A024R3X4">Hsp-60</protein-id>, mitogen-activated protein kinase-activated kinase-5, <compound-id="936">nicotinamide</compound-id> <compound-id="190,57060554">adenine</compound-id> dinucleotide dehydrogenase <compound-id="71819732">24k</compound-id> chain precursor, <compound-id="108157,5313888">platelet-activating factor</compound-id> acetyl hydrolase 1b-α2 (PAF-AH 1b-α2), and <protein-id="P60880">synaptosomal-associated protein-25</protein-id> (<protein-id="P60880">SNAP-25</protein-id>) were altered in the substantia nigra and <compound-id="936">nicotinamide</compound-id> <compound-id="190,57060554">adenine</compound-id> dinucleotide- specific <compound-id="1198">isocitrate</compound-id> dehydrogenase, <protein-id="P30086,D9IAI1">phosphatidylethanolamine-binding protein-1</protein-id>, <protein-id="P35232,A8K401,Q53FV0">prohibitin</protein-id>, protein disulfide isomerase-endoplasmic reticulum 60 protease, <protein-id="P16949">stathmin</protein-id>, and ubiquitin-conjugating enzyme in the striatum along with motor impairment, decreased <compound-id="681">dopamine</compound-id> and TH-IR, and increased microglial activation after <compound-id="2912">cypermethrin</compound-id> exposure.	cypermethrin__stathmin__no_interaction	cypermethrin__prohibitin__no_interaction	cypermethrin__Hsp-60__no_interaction	cypermethrin__SNAP-25__no_interaction	cypermethrin__synaptosomal-associated protein-25__no_interaction	cypermethrin__connexin-47__no_interaction	cypermethrin__phosphatidylethanolamine-binding protein-1__no_interaction	adenine__stathmin__no_interaction	adenine__prohibitin__no_interaction	adenine__Hsp-60__no_interaction	adenine__SNAP-25__no_interaction	adenine__synaptosomal-associated protein-25__no_interaction	adenine__connexin-47__no_interaction	adenine__phosphatidylethanolamine-binding protein-1__no_interaction	isocitrate__stathmin__no_interaction	isocitrate__prohibitin__no_interaction	isocitrate__Hsp-60__no_interaction	isocitrate__SNAP-25__no_interaction	isocitrate__synaptosomal-associated protein-25__no_interaction	isocitrate__connexin-47__no_interaction	isocitrate__phosphatidylethanolamine-binding protein-1__no_interaction	24k__stathmin__no_interaction	24k__prohibitin__no_interaction	24k__Hsp-60__no_interaction	24k__SNAP-25__no_interaction	24k__synaptosomal-associated protein-25__no_interaction	24k__connexin-47__no_interaction	24k__phosphatidylethanolamine-binding protein-1__no_interaction	nicotinamide__stathmin__no_interaction	nicotinamide__prohibitin__no_interaction	nicotinamide__Hsp-60__no_interaction	nicotinamide__SNAP-25__no_interaction	nicotinamide__synaptosomal-associated protein-25__no_interaction	nicotinamide__connexin-47__no_interaction	nicotinamide__phosphatidylethanolamine-binding protein-1__no_interaction	platelet-activating factor__stathmin__no_interaction	platelet-activating factor__prohibitin__no_interaction	platelet-activating factor__Hsp-60__no_interaction	platelet-activating factor__SNAP-25__no_interaction	platelet-activating factor__synaptosomal-associated protein-25__no_interaction	platelet-activating factor__connexin-47__no_interaction	platelet-activating factor__phosphatidylethanolamine-binding protein-1__no_interaction	ATP__stathmin__no_interaction	ATP__prohibitin__no_interaction	ATP__Hsp-60__no_interaction	ATP__SNAP-25__no_interaction	ATP__synaptosomal-associated protein-25__no_interaction	ATP__connexin-47__no_interaction	ATP__phosphatidylethanolamine-binding protein-1__no_interaction	dopamine__stathmin__no_interaction	dopamine__prohibitin__no_interaction	dopamine__Hsp-60__no_interaction	dopamine__SNAP-25__no_interaction	dopamine__synaptosomal-associated protein-25__no_interaction	dopamine__connexin-47__no_interaction	dopamine__phosphatidylethanolamine-binding protein-1__no_interaction
12482890-6	Consistent with the possibility that changes in the activities of HCO(3)(-)-dependent, <compound-id="5281951">DIDS</compound-id>-sensitive mechanisms contribute to the steady-state pH(i) changes evoked by the PKA modulators, in neurons with initial pH(i) values &lt; or = 7.20, Rp-<protein-id="D3KR63">cAMPS</protein-id> concurrently inhibited Na(+)-independent Cl(-)-HCO(3)(-) exchange and stimulated Na(+)-dependent Cl(-)-HCO(3)(-) exchange; in contrast, <protein-id="D3KR63">Sp-cAMPS</protein-id> concurrently stimulated Na(+)-independent Cl(-)-HCO(3)(-) exchange and inhibited Na(+)-dependent Cl(-)-HCO(3)(-) exchange.	DIDS__Sp-cAMPS__no_interaction	DIDS__cAMPS__no_interaction
20610164-2	In our continued effort to develop appropriate PET <protein-id="P31645,B2R7Y7">SERT</protein-id> radioligand that can be labeled with either C-11 or <compound-id="105162">fluorine-18</compound-id> (F-18), two new C-11 labeled analogues of HOMADAM, [(11)C]-N,N-dimethyl-2-(2'-amino-5'-fluoro-4'-hydroxymethyl-phenylthio)<compound-id="408153,7504">benzylamine</compound-id> ([(11)C]-(2)) and [(11)C]-N,N-dimethyl-2-(2'-amino-4-fluoro-4'-hydroxymethyl-phenylthio)<compound-id="408153,7504">benzylamine</compound-id> ([(11)C]-(3)) have been synthesized and evaluated along the previously reported [(11)C]-N,N-dimethyl-2-(2'-amino-5-fluoro-4'-hydroxymethyl-phenylthio)<compound-id="408153,7504">benzylamine</compound-id> ([(11)C]-(1)).	benzylamine__SERT__no_interaction	fluorine-18__SERT__no_interaction
9358293-6	The ABD scale was significantly (p &lt; or = 0.001) associated with the POSIT <compound-id="44216753">AOD</compound-id> scale (r = 0.46), the 22-item <compound-id="44216753">AOD</compound-id> drug screen (r = 0.57), the <protein-id="Q86TM3">CAGE</protein-id> questions (r = 0.39), the sexual risk behavior scale (r = 0.39), and the POSIT physical health (r = 0.34), mental health (r = 0.51), family relations status (r = 0.37), peer relations (r = 0.57), educational status (r = 0.44), social skills (r = 0.31), and leisure/recreation (r = 0.16) scales.	AOD__CAGE__no_interaction
11854151-7	High-affinity inhibition was seen for <protein-id="P05177,P04798,A0N0X8">CYP1A2</protein-id> (<compound-id="5318">sulconazole</compound-id> and <compound-id="5482">tioconazole</compound-id> K(i), 0.4 microM), <protein-id="P20813">CYP2B6</protein-id> (<compound-id="4189">miconazole</compound-id> K(i), 0.05 microM; <compound-id="5318">sulconazole</compound-id> K(i), 0.04 microM), <protein-id="P33261">CYP2C19</protein-id> (<compound-id="4189">miconazole</compound-id> K(i), 0.05 microM; <compound-id="5318">sulconazole</compound-id> K(i), 0.008 microM; <compound-id="5482">tioconazole</compound-id> K(i), 0.04 microM), <protein-id="P11712,S5RV20">CYP2C9</protein-id> (<compound-id="5318">sulconazole</compound-id> K(i), 0.01 microM), <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> (<compound-id="4189">miconazole</compound-id> K(i), 0.70 microM; <compound-id="5318">sulconazole</compound-id> K(i), 0.40 microM), <protein-id="P05181">CYP2E1</protein-id> (<compound-id="5482">tioconazole</compound-id> K(i), 0.4 microM), and <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> (<compound-id="2812">clotrimazole</compound-id> K(i), 0.02 microM; <compound-id="4189">miconazole</compound-id> K(i), 0.03 microM; <compound-id="5482">tioconazole</compound-id> K(i), 0.02 microM).	miconazole__CYP2C9__no_interaction	miconazole__CYP1A2__no_interaction	miconazole__CYP2D6__no_interaction	miconazole__CYP2B6__no_interaction	miconazole__CYP2E1__no_interaction	miconazole__CYP2C19__no_interaction	miconazole__CYP3A4__no_interaction	sulconazole__CYP2C9__no_interaction	sulconazole__CYP1A2__no_interaction	sulconazole__CYP2D6__no_interaction	sulconazole__CYP2B6__no_interaction	sulconazole__CYP2E1__no_interaction	sulconazole__CYP2C19__no_interaction	sulconazole__CYP3A4__no_interaction	tioconazole__CYP2C9__no_interaction	tioconazole__CYP1A2__no_interaction	tioconazole__CYP2D6__no_interaction	tioconazole__CYP2B6__no_interaction	tioconazole__CYP2E1__no_interaction	tioconazole__CYP2C19__no_interaction	tioconazole__CYP3A4__no_interaction	clotrimazole__CYP2C9__no_interaction	clotrimazole__CYP1A2__no_interaction	clotrimazole__CYP2D6__no_interaction	clotrimazole__CYP2B6__no_interaction	clotrimazole__CYP2E1__no_interaction	clotrimazole__CYP2C19__no_interaction	clotrimazole__CYP3A4__no_interaction
9798978-10	In contrast, OVRAD adjusted for age and BMI still exhibited statistically significant associations with FVII:C activity (R = 0.38, p = 0.05), triglyceride (R = 0.51, p = 0.008), LDL-<compound-id="5997">cholesterol</compound-id> (R = 0.45, p = 0.02) and <protein-id="P28845,X5D2L1">HDL</protein-id>/Total <compound-id="5997">cholesterol</compound-id> ratio (R = -0.63, p &lt;0.001).	cholesterol__HDL__no_interaction
3211711-3	When determined with 4.0 nM labelled hormone, the distribution of specific binding sites (expressed as 10(-18) mol [125I] <protein-id="P01308,I3WAC9">insulin</protein-id> bound per glomerulus or mm tubule length) was as follows: glomerulus, 2.5 +/- 0.3; proximal convoluted tubule (PCT), 12.6 +/- 0.6; pars recta (PR), 4.0 +/- 2.6; thin descending limb (<compound-id="6518187">TDL</compound-id>), 0.6 +/- 0.2; thin ascending limb (TAL), 0.6 +/- 0.2; medullary thick ascending limb (MAL), 0.8 +/- 0.1; cortical ascending limb (CAL), 2.1 +/- 0.1; distal convoluted tubule (DCT), 5.6 +/- 1.1; cortical collecting tubule (CCT), 3.2 +/- 0.3 and outer medullary collecting tubule (MCT), 2.3 +/- 0.1.	TDL__insulin__no_interaction
6347489-2	We found (1) RA spontaneous plaque-forming cells were significantly reduced (RA 344 vs normal 627 PFC/10(6) MNC, P less than 0.002); (2) RA spontaneous IgG and <protein-id="P29965">IgM</protein-id> (but not IgA) elaboration was significantly diminished (IgG RA 339, normal 776; <protein-id="P29965">IgM</protein-id> RA 255, normal 869 ng/ml, P less than 0.001; IgA RA 87, normal 124); (3) RA stimulated IgG and <protein-id="P29965">IgM</protein-id> production (but not IgA) was also decreased (IgG RA 2434, normal 3862, P less than 0.06; <protein-id="P29965">IgM</protein-id> RA, 1676, normal 3323, P less than 0.005; IgA RA 1859, normal 2315); (4) reduced RA Ig elaboration was not clearly due to altered numbers of T or non-T cells, age, medications, clinical features of disease, or response kinetics; (5) relative improvement of RA in vitro IgG, but not usually <protein-id="P29965">IgM</protein-id>, secretion followed removal of adherent cells, addition of <compound-id="3715">indomethacin</compound-id> or addition of <compound-id="5746">mitomycin C</compound-id>-treated T cells; (6) MNC from synovial fluids, but not bone marrows, exhibited spontaneous Ig production in excess of stimulated synovial fluid cellular or peripheral blood Ig elaboration.	indomethacin__IgM__no_interaction	mitomycin C__IgM__no_interaction
20736053-3	We found that: (1) intradermal injection of both the endogenous ligand for the Ret receptor, glia-derived growth factor (<protein-id="Q07731,A7UGJ1">GDNF</protein-id>), and the ligand for the tropomyosin receptor kinase A (TrkA) receptor, nerve growth factor (NGF)-which are present on distinct populations of nociceptors-both produce mechanical hyperalgesia; (2) DOR agonist 4-[(R)-[(2S,5R)-4-<compound-id="8252">allyl</compound-id>-2,5-<compound-id="7818">dimethylpiperazin</compound-id>-1-yl](3-methoxyphenyl)methyl]-<compound-id="15542">N,N-diethylbenzamide</compound-id> (SNC) but not MOR agonist [D-Ala2, N-MePhe4, Gly-ol]-<protein-id="P04094">enkephalin</protein-id> (DAMGO) inhibit <protein-id="Q07731,A7UGJ1">GDNF</protein-id>-induced hyperalgesia; (3) both DAMGO and SNC inhibit NGF hyperalgesia, even in rats pretreated with isolectin B4 (IB4)-saporin, a toxin that destroys IB4-binding neurons; (4) co-administration of low doses of DAMGO and SNC produce enhanced analgesia, and; (5) repeated administration of DAMGO produces cross-tolerance to the analgesic effect of SNC.	dimethylpiperazin__GDNF__no_interaction	dimethylpiperazin__enkephalin__no_interaction	N,N-diethylbenzamide__GDNF__no_interaction	N,N-diethylbenzamide__enkephalin__no_interaction	allyl__GDNF__no_interaction	allyl__enkephalin__no_interaction
21289246-5	RESULTS: For both antidepressants, treatment was associated with rises in aldosterone [sertraline: baseline, mean ± sd, 243 ± 34; 2 wk, 256 ± 33; 6 wk, 267 ± 34 pmol/liter (P &lt; 0.01 by <protein-id="Q9UNW9">ANOVA</protein-id>); escitalopram, 261 ± 36, 269 ± 38, 282 ± 40 pmol/liter (P &lt; 0.05)], <compound-id="150345">DRC</compound-id> [19.5 ± 2.2, 33.5 ± 2.0, 39.0 ± 2.4 mU/liter (P &lt; 0.001); 24.5 ± 2.4, 34.0 ± 2.7, 42.8 ± 2.4 mU/liter (P &lt; 0.001)], and PRA [2.24 ± 0.21, 2.58 ± 0.26, 4.68 ± 0.42 ng/ml · h (P &lt; 0.001); 4.31 ± 0.22, 5.57 ± 0.36, 6.42 ± 0.53 ng/ml · h (P &lt; 0.001)].	DRC__ANOVA__no_interaction
16685733-2	T(1) and T(2) relaxation times (in milliseconds) were determined for the major prostate metabolites and an internal <protein-id="P07996">TSP</protein-id> standard, and used to optimize the acquisition and repetition times (TRs) at 11.7 T. At 1 degrees C, polyamines (PAs; T(1mean) = 100 +/- 13, T(2mean) = 30.8 +/- 7.4) and <compound-id="311,17938267">citrate</compound-id> (<protein-id="O14578">Cit</protein-id>; T(1mean) = 237 +/- 39, T(2mean) = 68.1 +/- 8.2) demonstrated the shortest relaxation times, while <compound-id="1123">taurine</compound-id> (Tau; T(1mean) = 636 +/- 78, T(2mean) = 331 +/- 71) and <compound-id="305,57080826">choline</compound-id> (Cho; T(1mean) = 608 +/- 60, T(2mean) = 393 +/- 81) demonstrated the longest relaxation times.	taurine__TSP__no_interaction	taurine__Cit__no_interaction	citrate__TSP__no_interaction	citrate__Cit__no_interaction	choline__TSP__no_interaction	choline__Cit__no_interaction
16685733-4	<compound-id="1014">Phosphocholine</compound-id> plus <compound-id="439285">glycerophosphocholine</compound-id> (PC+GPC), total <compound-id="305,57080826">choline</compound-id> (tCho), <compound-id="612">lactate</compound-id> (Lac), and <compound-id="5950">alanine</compound-id> (Ala) concentrations were higher in prostate cancer ([PC+GPC](mean) = 9.34 +/- 6.43, [tCho](mean) = 13.8 +/- 7.4, [Lac](mean) = 69.8 +/- 27.1, [Ala](mean) = 12.6 +/- 6.8) than in healthy glandular ([PC+GPC](mean) = 3.55 +/- 1.53, P &lt; 0.01; [tCho](mean) = 7.06 +/- 2.36, P &lt; 0.01; [Lac](mean) = 46.5 +/- 17.4, P &lt; 0.01; [Ala](mean) = 8.63 +/- 4.91, P = 0.051) and healthy stromal tissues ([PC+GPC](mean) = 4.34 +/- 2.46, P &lt; 0.01; [tCho](mean) = 7.04 +/- 3.10, P &lt; 0.01; [Lac](mean) = 45.1 +/- 18.6, P &lt; 0.01; [Ala](mean) = 6.80 +/- 2.95, P &lt; 0.01), while <protein-id="O14578">Cit</protein-id> and PA concentrations were significantly higher in healthy glandular tissues ([<protein-id="O14578">Cit</protein-id>](mean) = 43.1 +/- 21.2, [PAs](mean) = 18.5 +/- 15.6) than in healthy stromal ([<protein-id="O14578">Cit</protein-id>](mean) = 16.1 +/- 5.6, P &lt; 0.01; [PAs](mean) = 3.15 +/- 1.81, P &lt; 0.01) and prostate cancer tissues ([<protein-id="O14578">Cit</protein-id>](mean) = 19.6 +/- 12.7, P &lt; 0.01; [PAs](mean) = 5.28 +/- 5.44, P &lt; 0.01).	lactate__Cit__no_interaction	glycerophosphocholine__Cit__no_interaction	alanine__Cit__no_interaction	choline__Cit__no_interaction	Phosphocholine__Cit__no_interaction
18031163-7	Serum <compound-id="160907">carnitine</compound-id> levels were correlated with age (r = 0.35; p = 0.02), type of response (r = - 03; p = 0.04), duration of disease (r = - 0.8; p = 0.0001) and high-density lipoprotein <compound-id="5997">cholesterol</compound-id> levels (r = 0.43; p = 0.005) after completion of <protein-id="P01562,L0N195">IFNalpha</protein-id> treatment.	carnitine__IFNalpha__no_interaction	cholesterol__IFNalpha__no_interaction
25258390-8	<compound-id="2733526">Tamoxifen</compound-id> and primary metabolites completely inhibited cell growth regardless of the <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> genotype in all cell lines (mean fold induction ± SD vs vehicle control: MCF-7 = 1.57 ± 0.38, P = .54; T47D = 1.17 ± 0.23, P = .79; BT474 = 0.96 ± 0.2, P = .98; ZR-75-1 = 0.86 ± 0.67, P = .99).	Tamoxifen__CYP2D6__no_interaction
19248814-3	In untreated control rats serum <compound-id="612">lactate</compound-id> and non-esterified fatty acids (NEFA) increased on attaining T(rec)23 degrees C with decreased blood enzyme activities hexokinase (HK), phosphofructokinase (PFK), <protein-id="Q8VHF5">citrate synthase</protein-id> (CS) and <protein-id="P05370">glucose-6-phosphate dehydrogenase</protein-id> (<protein-id="P05370">G-6-PD</protein-id>), on attaining T(rec)23 degrees C and T(rec)37 degrees C. Decreases were also observed in liver and muscle tissues HK and <protein-id="P05370">G-6-PD</protein-id> enzyme activities and liver <compound-id="439177">glycogen</compound-id> and CS on attaining T(rec)23 degrees C and recovery; muscle PFK during recovery; muscle CS on attaining T(rec)23 degrees C. Single and five doses of extract administration restricted increase in serum <compound-id="612">lactate</compound-id> values of rats on attaining T(rec)23 degrees C and maintained blood NEFA in single dose extract treated animals, indicating improved utilization of NEFA as energy fuel.	glycogen__citrate synthase__no_interaction	glycogen__G-6-PD__no_interaction	glycogen__glucose-6-phosphate dehydrogenase__no_interaction	lactate__citrate synthase__no_interaction	lactate__G-6-PD__no_interaction	lactate__glucose-6-phosphate dehydrogenase__no_interaction
8708169-9	Compared to control and nasogastric suction periods, after <compound-id="3001055,9883333">ranitidine</compound-id> mean gastric <protein-id="P06744,B4DE36">pHi</protein-id> was higher (control 7.22 +/- 0.08; nasogastric suction 7.23 +/- 0.07; after <compound-id="3001055,9883333">ranitidine</compound-id> 7.31 +/- 0.06, p &lt; 0.001) mean gastric PCO2 lower (control 6.4 +/- 1.3; nasogastric suction 6.5 +/- 1.3; after <compound-id="3001055,9883333">ranitidine</compound-id> 5.3 +/- 0.9, p &lt; 0.001) and pH gap lower (control 0.18 +/- 0.08; nasogastric suction 0.17 +/- 0.05; after <compound-id="3001055,9883333">ranitidine</compound-id> 0.09 +/- 0.06, p &lt; 0.01).	ranitidine__pHi__no_interaction
23589614-3	We then subdivided the Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)Sca-1(-) cells into three groups--Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(-)CD4(-), Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(-)CD4(+) (CD4(+) <compound-id="16007060">LTi</compound-id>-like cells), and Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(+) (<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(+) ILC22 cells)--and showed that the Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(-)CD4(-) cells produced the highest level of <protein-id="Q9GZX6">IL-22</protein-id> protein after IL-1β, <protein-id="Q9NPF7">IL-23</protein-id>, or IL-1β and <protein-id="Q9NPF7">IL-23</protein-id> stimulation.	LTi__IL-23__no_interaction	LTi__IL-22__no_interaction	LTi__NKp46__no_interaction	LTi__c-Kit__no_interaction
23589614-7	Taken together, these findings indicate that the IL-7Rα(-)CD34(+)β7(int) and IL-7Rα(-)CD34(int)β7(hi) populations are mast cell progenitors, and the IL-7Rα(+)CD34(-)β7(int) (CD4(-) <compound-id="16007060">LTi</compound-id>-like cells) and IL-7Rα(-)CD34(-)β7(int) populations within Lin(-)<protein-id="P10721,A0A024RDA0">c-Kit</protein-id>(+)<protein-id="O76036,A0A0A0MTU0,A0A0A0MQZ0,A0A0A0MR94">NKp46</protein-id>(-)CD4(-) cells may control intestinal homeostasis and provide intestinal protection by producing high levels of <protein-id="Q9GZX6">IL-22</protein-id> and α-defensins, respectively.	LTi__IL-22__no_interaction	LTi__NKp46__no_interaction	LTi__c-Kit__no_interaction
22807059-3	In the presence of <compound-id="53675528,6325">ethylene</compound-id> and Ni(<protein-id="P14678,Q66K91">COD</protein-id>)(2)  or B(C(6) F(5) )(3)  co-catalysts, these complexes along with their monometallic analogues [2-<compound-id="90937099">tert-butyl</compound-id>-6-((2,6-(3,5-dimethylphenyl)phenylimino)methyl)-<compound-id="996">phenolate</compound-id>]-Ni(II) -methyl(trimethylphosphine) [(CH(3) )FI-Ni] and [2-<compound-id="90937099">tert-butyl</compound-id>-6-((2,6-(3,5-ditrifluoromethyl-phenyl)phenylimino)methyl)phenolato]-Ni(II) -methyl-(trimethylphosphine) [(CF(3) )FI-Ni], produce polyethylenes ranging from highly branched M(w) =1400 oligomers (91 methyl branches per 1000 C) to low branch density M(w) =92 000 polyethylenes (7 methyl branches per 1000 C).	ethylene__COD__no_interaction	phenolate__COD__no_interaction	tert-butyl__COD__no_interaction
15298350-8	However, <compound-id="3108">dipyridamole</compound-id>-stimulated flow and coronary vascular resistance were blunted in diabetic patients with retinopathy (2.9 +/- 0.9 ml x g(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 34.1 +/- 11.3 mmHg x min x g x ml(-1)) when compared to diabetic patients without retinopathy (4.0 +/- 1.3 ml x g(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), p=0.04 and 24.6 +/- 7.5 mmHg x min x g x ml(-1), p=0.03) or non-diabetic subjects (4.5 +/- 1.4 ml x g(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) p=0.008 and 22.2 +/- 8.7 mmHg x min x g x ml(-1), p=0.01).	dipyridamole__min(-1__no_interaction
19307624-5	The data provide evidence that 1) DMI (18%), BW (17%), and BF (5%) together explained 40% of the variation in plasma <protein-id="P50595,G8BLB4">leptin</protein-id> concentrations (r(2) = 0.396); 2) unlike the acute postprandial increase in plasma <protein-id="A5PJB2">insulin</protein-id> as a result of increased nutrient density (H 1.42 +/- 0.09, M 1.02 +/- 0.09, L 0.68 +/- 0.11 ng/mL), plasma <protein-id="P50595,G8BLB4">leptin</protein-id> concentrations did not respond acutely with a distinct postprandial profile; 3) although plasma <protein-id="P50595,G8BLB4">leptin</protein-id> concentrations increased with age, <protein-id="P50595,G8BLB4">leptin</protein-id> at puberty did not differ among treatment groups (H 5.63 +/- 2.48, M 4.28 +/- 0.55, L 4.12 +/- 0.72 ng/mL) and there was no evidence of an abrupt transition in prepubertal plasma <protein-id="P50595,G8BLB4">leptin</protein-id> concentrations; 4) plasma <protein-id="P50595,G8BLB4">leptin</protein-id> concentrations may not be a critical trigger for puberty in rapidly growing heifers, but are apparently essential for puberty in heifers with normal or restricted growth rates; and 5) plasma concentrations of <protein-id="A5PJB2">insulin</protein-id> (H 0.59 +/- 0.07, M 0.43 +/- 0.09, L 0.30 +/- 0.09 ng/mL), <protein-id="P07455,F2X2F3,F2X2F0,F2X2F1,F2X2F2">IGF-1</protein-id> (H 151.08 +/- 16.47, L 82.51 +/- 17.47 ng/mL), and <compound-id="206,5793,64689,79025">glucose</compound-id> (H 81.35 +/- 3.39, M 73.59 +/- 2.34, L 68.25 +/- 3.39 mg/dL) reflected nutrient density, whereas GH (H 1.82 +/- 0.23, L 5.87 +/- 0.45 ng/mL) and NEFA (H 209.54 +/- 50.83, L 234.93 +/- 48.97 microM) were inversely related to the plane of nutrition.	glucose__leptin__no_interaction	glucose__insulin__no_interaction	glucose__IGF-1__no_interaction
23646463-17	Concomitantly and consistent with the hypothesis, we observed, from the pre-Olympics to the during-Olympics period, statistically significant (P &lt; or = 0.05) or marginally significant (0.05 &lt; P &lt; 0.1) decreases in HR (-1 bpm or -1.7% [95% CI, -3.4 to -0.1]), SBP (-1.6 mmHg or -1.8% [95% CI, -3.9 to 0.4]), <compound-id="73318">8-OHdG</compound-id> (-58.3% [95% CI, -72.5 to -36.7]), FeNO (-60.3% [95% CI, -66.0 to -53.6]), <compound-id="368250">EBC</compound-id> <compound-id="946">nitrite</compound-id> (-30.0% [95% CI, -39.3 to -19.3]), <compound-id="368250">EBC</compound-id> <compound-id="10313259,943">nitrate</compound-id> (-21.5% [95% CI, -35.5 to -4.5]), <compound-id="368250">EBC</compound-id> <compound-id="946">nitrite</compound-id>+<compound-id="10313259,943">nitrate</compound-id> (-17.6% [95% CI, -28.4 to -5.1]), <compound-id="368250">EBC</compound-id> <compound-id="783">hydrogen</compound-id> ions (-46% [calculated from <compound-id="368250">EBC</compound-id> pH], or +3.5% in <compound-id="368250">EBC</compound-id> pH [95% CI, 2.2 to 4.9]), sCD62P (-34% [95% CI, -38.4 to -29.2]), sCD40L (-5.7% [95% CI, -10.5 to -0.7]), and <protein-id="P04275">vWF</protein-id> (-13.1% [95% CI, -18.6 to -7.5]).	nitrite__vWF__no_interaction	nitrate__vWF__no_interaction	hydrogen__vWF__no_interaction	8-OHdG__vWF__no_interaction	EBC__vWF__no_interaction
10344354-6	A significantly positive correlation was found among blood concentration of PAF and heart rate (r = 0.4193, P &lt; 0.017), serum <compound-id="588">creatinine</compound-id> (r = 0.3671, P &lt; 0.038), serum <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.5475, P &lt; 0.005) and urine excretion of <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (r = 0.3984, P &lt; 0.044), whereas a negative correlation was present with the number of circulating platelets (r = -0.4285, P &lt; 0.018).	creatinine__IL-6__no_interaction	creatinine__IL-8__no_interaction
21387753-2	The study included a total of 99 patients: 44 (44.4%) women with mean +/- SD age of 42 +/- 11.9 years and 55 (55.6%) men (43 +/- 12.2) treated for chronic hepatitis C. RESULTS: Levels of several markers changed significantly after 3 months of treatment (with interferon alpha and <compound-id="37542">ribavirin</compound-id>) comparing to values on admission to hospital: we observed statistically significant differences of ALT: 32.6 +/- 15.7 vs. 61.5 +/- 35.6 (U/l), p&lt;0.001; <protein-id="Q9NRA2">AST</protein-id>: 34.1 +/- 11.1 vs. 48.2 +/- 26.5 (U/l), p&lt;0.05 and total <compound-id="5997">cholesterol</compound-id> concentration: 4.0 +/- 0.4 vs. 4.9 +/- 0.9 (mmol/l), p&lt;0.01 in women; <protein-id="Q9NRA2">AST</protein-id>/ALT ratio in both men (0,8 +/- 0,3 vs. 0.69 +/- 0.25; p&lt;0.05) and women (1.2 +/- 0.4 vs. 0.84 +/- 0.24; p&lt;0.001) and age/<protein-id="Q02083">PLT</protein-id> score: 0.4 +/- 0.3 vs. 0.28 +/- 0.12 (p&lt;0.01) in men.	ribavirin__PLT__no_interaction	ribavirin__AST__no_interaction	cholesterol__PLT__no_interaction	cholesterol__AST__no_interaction
17171555-10	While PP levels were significantly associated with <compound-id="9827862">IAF</compound-id> (r = 0.16, p = 0.031), WHR (r = 0.30, p &lt; 0.001) and age (r = 0.37, p &lt; 0.01), they were not associated with <protein-id="P21583,A0A024RBC0,A0A024RBF5">SCF</protein-id> (r = 0.02, p = 0.829).	IAF__SCF__no_interaction
10200996-9	RESULTS: Continuous <protein-id="P20096">IL-4</protein-id> treatment (experiment 1) significantly (P = 0.001) reduced proteinuria (3 +/- 1 mg per 24 hr vs. 56 +/- 7), fibrinoid necrosis (0.06 +/- 0.04 quadrants/glomulus vs. 1.2 +/- 0.1), macrophage infiltration (6.7 +/- 2.6 cells/glom vs. 33 +/- 2.5), CD8+ cells (1.5 +/- 0.6 cells/glom vs. 6.2 +/- 1.1), inducible <compound-id="145068">nitric oxide</compound-id> synthase positive cells (0.04 +/- 0.04 cells/glom vs. 3.7 +/- 0.6), proliferating cell nuclear antigen positive cells (3.2 +/- 1 cells/glom vs. 15 +/- 2.3), and glomerular intercellular adhesion molecule-1 expression.	nitric oxide__IL-4__no_interaction
15280523-5	<compound-id="447041">IMT</compound-id> progression was significantly and positively correlated with age (r = 0.37, P&lt;0.01), log-transformed <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>; r = 0.33, P&lt;0.01) and log-transformed <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>; r = 0.22, P&lt;0.04), but inversely correlated with blood <compound-id="588">creatinine</compound-id> (r = -0.36, P&lt;0.01) and albumin (r = -0.24, P&lt;0.02).	creatinine__C-reactive protein__no_interaction	creatinine__CRP__no_interaction	creatinine__interleukin-6__no_interaction	creatinine__IL-6__no_interaction	IMT__C-reactive protein__no_interaction	IMT__CRP__no_interaction	IMT__interleukin-6__no_interaction	IMT__IL-6__no_interaction
23474641-4	The results indicate that reported childhood sexual and physical abuse is high in all three settings, also among men, and shows strong relationships with a range of sexual risk behaviors, including age at first sex (OR -0.6 (CI: -0.9, -0.4, p &lt; 0.003)-among men, OR -0.7 (CI: -0.9, -0.5, p &lt; 0.001)-among women), <compound-id="10982484,702">alcohol</compound-id> (<protein-id="Q6IF00">OR 1.43</protein-id> (CI: 1.22, 1.68, p &lt; 0.001)-men, OR 1.83 (CI: 1.50, 2.24, p &lt; 0.001)-women) and drug use (OR 1.65 (CI: 1.38, 1.97, p &lt; 0.001)-men, OR 3.14 (CI: 1.95, 5.05, p &lt; 0.001)-women) and two forms of partner violence-recent forced sex (OR 2.22 (CI: 1.66, 2.95, p &lt; 0.001)-men, OR 2.76 (CI: 2.09, 3.64, p &lt; 0.001)-women) and ever being hurt by a partner (OR 3.88 (CI: 2.84, 5.29, p &lt; 0.001)-men, OR 3.06 (CI: 2.48, 3.76, p &lt; 0.001)-women).	alcohol__OR 1.43__no_interaction
12177691-1	DPC423, 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[<compound-id="7095">1,1'-biphenyl</compound-id>]-4-yl]-<compound-id="21990846">3-(trifluoromethyl)-1H-pyrazole-5-carboxamide</compound-id>, is a synthetic, orally bioavailable, competitive, and selective inhibitor of human coagulation factor Xa (K(i) [nM]: factor Xa, 0.15; trypsin, 60; <compound-id="90470996">thrombin</compound-id>, 6000; plasma kallikrein, 61; activated protein C, 1800; factor IXa, 2200; factor VIIa, &gt;15,000; chymotrypsin, &gt;17,000; urokinase, &gt;19,000; <protein-id="P00747,Q5TEH5">plasmin</protein-id>, &gt;35,000; tissue plasminogen activator, &gt;45,000; complement factor I, 44,000 [IC(50)]).	thrombin__plasmin__no_interaction	3-(trifluoromethyl)-1H-pyrazole-5-carboxamide__plasmin__no_interaction	1,1'-biphenyl__plasmin__no_interaction
22321710-12	<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> mRNA, <protein-id="P10145,A0A024RDA5">IL-8</protein-id> mRNA, TNF-α mRNA and protein in cold stimulation + <compound-id="9929425">BCTC</compound-id> group [0.42 ± 0.09, 0.52 ± 0.13, 0.52 ± 0.12 and (72 ± 8) ng/L, (92 ± 14) ng/L, (68 ± 11) ng/L], cold stimulation + <protein-id="Q7Z2W7,W8DTH1">TRPM8</protein-id> shRNA group [0.41 ± 0.10, 0.49 ± 0.08, 0.50 ± 0.08 and (60 ± 12) ng/L, (89 ± 14) ng/L, (68 ± 11) ng/L] and cold stimulation + <compound-id="2533">calphostin C</compound-id> group [0.40 ± 0.07, 0.44 ± 0.09, 0.47 ± 0.08 and (69 ± 9) ng/L, (86 ± 15) ng/L, (61 ± 10) ng/L] were significantly lower than those in cold stimulation group (t = 2.47 - 4.21, all P &lt; 0.05).	calphostin C__TRPM8__no_interaction	calphostin C__IL-6__no_interaction	calphostin C__IL-8__no_interaction	BCTC__TRPM8__no_interaction	BCTC__IL-6__no_interaction	BCTC__IL-8__no_interaction
23864776-11	Compared with the control group, in the IgAN group, the structure of the tight junction became obscured and the dotted crystal structures had disappeared; the fluorescence of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> was uneven and weaker (5.37 ± 1.27 vs 10.03 ± 1.96, P &lt; 0.01; 4.23 ± 0.85 vs 12.35 ± 4.17, P &lt; 0.01); the mRNA expression of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> decreased (0.42 ± 0.19 vs 0.92 ± 0.24, P &lt; 0.01; 0.40 ± 0.15 vs 0.97 ± 0.25, P &lt; 0.01); protein expression of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> was decreased (0.85 ± 0.12 vs 1.98 ± 0.43, P &lt; 0.01; 0.72 ± 0.15 vs 1.38 ± 0.31, P &lt; 0.01); and the ratio of urinary <compound-id="11024312,11333,16217605,16760534,3872">lactulose</compound-id>/<compound-id="6251">mannitol</compound-id> increased (3.55 ± 0.68 vs 2.72 ± 0.21, P &lt; 0.01).	mannitol__occludin__no_interaction	mannitol__ZO-1__no_interaction	lactulose__occludin__no_interaction	lactulose__ZO-1__no_interaction
23864776-12	In the <compound-id="10168">Rhein</compound-id>-prevented and <compound-id="10168">Rhein</compound-id>-treated groups, compared with the IgAN group, the intestinal epithelial tight junctions were repaired; fluorescence of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> was stronger (11.16 ± 3.52 and 8.81 ± 2.30 vs 5.37 ± 1.27, P &lt; 0.01; 10.97 ± 3.40 and 9.46 ± 2.40 vs 4.23 ± 0.85, P &lt; 0.01); mRNA of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> increased (0.81 ± 0.17 and 0.64 ± 0.16 vs 0.42 ± 0.19, P &lt; 0.01; 0.82 ± 0.22 and 0.76 ± 0.31 vs 0.40 ± 0.15, P &lt; 0.01); protein expression of <protein-id="F1M4A0">ZO-1</protein-id> and <protein-id="Q6P6T5">occludin</protein-id> was increased (2.07 ± 0.41 and 1.57 ± 0.23 vs 0.85 ± 0.12, P &lt; 0.01; 1.34 ± 0.21 and 1.15 ± 0.17 vs 0.72 ± 0.15, P &lt; 0.01); and the ratio of urinary <compound-id="11024312,11333,16217605,16760534,3872">lactulose</compound-id>/<compound-id="6251">mannitol</compound-id> decreased (2.83 ± 0.43 and 2.87 ± 0.18 vs 3.55 ± 0.68, P &lt; 0.01).	mannitol__occludin__no_interaction	mannitol__ZO-1__no_interaction	lactulose__occludin__no_interaction	lactulose__ZO-1__no_interaction	Rhein__occludin__no_interaction	Rhein__ZO-1__no_interaction
21300674-8	RESULTS: Treatment effect was sustained at 24 months in the intervention versus control group for BMI z score (-0.16 [95% confidence interval: -0.23 to -0.09]), BMI (-2.8 kg/m(2) [95% confidence interval: -4.0-1.6 kg/m(2)]), percent body fat (-4.2% [95% confidence interval: -6.4% to -2.0%]), total body fat mass (-5.8 kg [95% confidence interval: -9.1 kg to -2.6 kg]), total <compound-id="5997">cholesterol</compound-id> (-13.0 mg/dL [95% confidence interval: -21.7 mg/dL to -4.2 mg/dL]), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (-10.4 mg/dL [95% confidence interval: -18.3 mg/dL to -2.4 mg/dL]), and homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (-2.05 [95% confidence interval: -2.48 to -1.75]).	cholesterol__insulin__no_interaction
21814755-4	One hundred twenty-nine patients followed up in our vasculitis clinic were reclassified according to CA in different categories (ACR or Lanham criteria in "1" for Churg-Strauss Syndrome (CSS); ACR in "2a"; CHCC-Wegener's granulomatosis (WG) in "2b"; CHCC-microscopic polyangiitis (MPA), So-WG in "2c"; So-WG, <protein-id="P24158">proteinase 3</protein-id> (<protein-id="P24158">PR3</protein-id>) or myeloperoxidase antineutrophil cytoplasmic antibody (MPO ANCA) serology in "2d" for WG; clinical features and histology compatible with small vessel vasculitis without So-WG in "<compound-id="2981881,91293124">3a</compound-id>"; So-MPA, <protein-id="P24158">PR3</protein-id> or MPO ANCA serology in "3b" for MPA; CHCC-classic-polyarteritis nodosa (<protein-id="O76075,Q96P73,B4DZS0">c-PAN</protein-id>) or typical angiographic features in "4" for <protein-id="O76075,Q96P73,B4DZS0">c-PAN</protein-id>; unclassifiable in "5").	3a__proteinase 3__no_interaction	3a__c-PAN__no_interaction	3a__PR3__no_interaction
20670237-5	RESULTS: Unlike BS-G1, administration of <protein-id="P42857,B2R5R8">NS-G1</protein-id> produced mild hyperchloremic acidosis (base excess BS-G1 vs <protein-id="P42857,B2R5R8">NS-G1</protein-id>, baseline 1.9 +/- 1.7 vs 2.9 +/- 0.9 mmol.l(-1), study end 0.2 +/- 1.7 vs -2.7 +/- 0.5 mmol.l(-1), P &lt; 0.05, <compound-id="312">chloride</compound-id> BS-G1 vs <protein-id="P42857,B2R5R8">NS-G1</protein-id> baseline 102.4 +/- 3.4 vs 102.0 +/- 0.7 mmol.l(-1), study end 103.4 +/- 1.8 vs 109.0 +/- 1.4 mmol.l(-1)P &lt; 0.05).	chloride__NS-G1__no_interaction
19837795-6	RESULTS: i) In HR versus EU: (a) arterial <compound-id="206,5793,64689,79025">glucose</compound-id> was similar (AUC(0-360) 2087+/-57 vs 2010+/-43 mM x min), but <protein-id="P01308,I3WAC9">Insulin</protein-id> was increased (AUC(0-360) 17 267+/-2447 vs 10 331+/-666 microU/ml x min, P=0.01), (b) homeostasis model assessment (HOMA) was increased (2.3+/-0.4 vs 1+/-0.1 kg/m(2), P=0.007), (c) arterial NEFA were increased (AUC(0-360) 136+/-18 vs 89+/-7 mmol/lxmin, P=0.03), (d) arterial <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL6</protein-id> (2+/-0.3 vs 0.9+/-0.1 pg/ml, P=0.0009) and <protein-id="P01375,Q5STB3">TNFalpha</protein-id> (4.2+/-0.8 vs 1.5+/-0.2 pg/ml, P=0.003) were increased, and (e) <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL6</protein-id> production from the subcutaneous adipose tissue (AT) was increased (18+/-6 vs 5+/-1 pg/min per 100 ml tissue, P=0.04).	glucose__IL6__no_interaction	glucose__TNFalpha__no_interaction	glucose__Insulin__no_interaction
18818166-5	Urinary <protein-id="P81172">Hepcidin</protein-id>, as log(intensity per mmol/L <compound-id="588">creatinine</compound-id>), was correlated with log ferritin (r = 0.33, p &lt;0.001), the <protein-id="P02786">transferrin receptor</protein-id> index (r = -0.22, p = 0.007), and log alpha-1 acid glycoprotein (r = 0.20, p = 0.01), but not hemoglobin (r = 0.07, p= 0.40), log <protein-id="P02786">transferrin receptor</protein-id> (r = -0.07, p = 0.41), log <protein-id="P01588,G9JKG7">erythropoietin</protein-id> (r = -0.01, p = 0.88) or log <protein-id="P02741">C-reactive protein</protein-id> (r = 0.06, p = 0.48).	creatinine__transferrin receptor__no_interaction	creatinine__C-reactive protein__no_interaction	creatinine__Hepcidin__no_interaction	creatinine__erythropoietin__no_interaction
2056445-1	In order to confirm the structure of three fecal metabolites, <protein-id="E9PU01">M-I, M-II and M-III</protein-id>, of a new <compound-id="22044544,5460341">calcium</compound-id> antagonist, (+)-3,4-dihydro-2-[5-<compound-id="91066389">methoxy-</compound-id>2-[3-[N-methyl-N-[2-[(3,4-<compound-id="79015">methylenedioxy</compound-id>) phenoxy]<compound-id="23134249">ethyl</compound-id>]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1,4- benzothiazine (SD-3211), in rats, (+)-3,4-dihydro-2-[5-hydroxy-2-[3-[N-methyl-N-[2- [(3,4-<compound-id="79015">methylenedioxy</compound-id>)-phenoxy]<compound-id="23134249">ethyl</compound-id>]amino]propoxy]phenyl]-4-methyl- 3-oxo-<compound-id="3088997">2H-1,4-benzothiazine</compound-id>((+)-I), (+)-3,4-dihydro-2-[5-hydroxy-2-[3-[N- [2-[(3,4-<compound-id="79015">methylenedioxy</compound-id>) phenoxy]<compound-id="23134249">ethyl</compound-id>]amino] propoxy]-phenyl]-4-methyl-3-oxo-<compound-id="3088997">2H-1,4-benzothiazine</compound-id>((+)-II) and (+)-3,4-dihydro-2-[5-<compound-id="91066389">methoxy-</compound-id>2-[3-[N-[2-[(3,4-<compound-id="79015">methylenedioxy</compound-id>) phenoxy]<compound-id="23134249">ethyl</compound-id>]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1,4- benzothiazine((+)-III) were synthesized.	methylenedioxy__M-I, M-II and M-III__no_interaction	calcium__M-I, M-II and M-III__no_interaction	ethyl__M-I, M-II and M-III__no_interaction	2H-1,4-benzothiazine__M-I, M-II and M-III__no_interaction	methoxy-__M-I, M-II and M-III__no_interaction
24127691-5	Among genotype 1-infected patients, characteristics that were negatively associated with SVR independently included baseline HCV viral load &gt;2 million IU/mL [adjusted odds ratio (AOR) 0.41, 95% CI 0.2-0.7], Black race [AOR 0.56 (0.3-0.96)], diabetes [AOR 0.42 (0.2-0.9)], baseline anaemia [AOR 0.42 (0.2-0.97)], serum <compound-id="5960">aspartate</compound-id> aminotransferase/<compound-id="5950">alanine</compound-id> aminotransferase ratio ≥1.2 [AOR 0.48 (0.2-0.97)] and use of <compound-id="35370">zidovudine</compound-id> [AOR 0.41 (0.2-0.9)]; characteristics positively associated with SVR included a starting dose of <compound-id="37542">ribavirin</compound-id> ≥1000-1200 mg/day [AOR 2.0 (1.1-3.7)] and <protein-id="P01588,G9JKG7">erythropoietin</protein-id> use during treatment [AOR 2.9 (1.6-5.0)].	ribavirin__erythropoietin__no_interaction	alanine__erythropoietin__no_interaction	aspartate__erythropoietin__no_interaction	zidovudine__erythropoietin__no_interaction
21699147-1	This investigation presents the syntheses, crystal structures, magnetic properties, and density functional theoretical modeling of magnetic behavior of two heterobridged μ-phenoxo-μ(1,1)-azido dinickel(II) compounds [Ni(II)(2)(L(1))(2)(μ(1,1)-N(3))(N(3))(H(2)O)]·CH(3)CH(2)OH (1) and [Ni(II)(2)(L(2))(2)(μ(1,1)-N(3))(CH(3)CN)(H(2)O)](ClO(4))·H(2)O·CH(3)CN (2), where HL(1) and HL(2) are the [1+1] condensation products of <compound-id="8991">3-methoxysalicylaldehyde</compound-id> and 1-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8082">piperidine</compound-id> (for <protein-id="P05162">HL(1))/4</protein-id>-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8083">morpholine</compound-id> (for HL(2)), along with density functional theoretical magneto-structural correlations of μ-phenoxo-μ(1,1)-azido dinickel(II) systems.	piperidine__HL(1))/4__no_interaction	2-aminoethyl__HL(1))/4__no_interaction	3-methoxysalicylaldehyde__HL(1))/4__no_interaction	morpholine__HL(1))/4__no_interaction
18786299-11	Compared to <compound-id="4369359">sitagliptin</compound-id>, <compound-id="45588096,53396299,56927919">exenatide</compound-id> improved the insulinogenic index of <protein-id="P01308,I3WAC9">insulin</protein-id> secretion (ratio <compound-id="45588096,53396299,56927919">exenatide</compound-id> to <compound-id="4369359">sitagliptin</compound-id>: 1.50 +/- 0.26, p = 0.0239), reduced postprandial <protein-id="P01275">glucagon</protein-id> (AUC ratio <compound-id="45588096,53396299,56927919">exenatide</compound-id> to <compound-id="4369359">sitagliptin</compound-id>: 0.88 +/- 0.03, p = 0.0011), reduced postprandial triglycerides (AUC ratio <compound-id="45588096,53396299,56927919">exenatide</compound-id> to <compound-id="4369359">sitagliptin</compound-id>: 0.90 +/- 0.04, p = 0.0118), and slowed gastric emptying (<compound-id="1983">acetaminophen</compound-id> AUC ratio <compound-id="45588096,53396299,56927919">exenatide</compound-id> to <compound-id="4369359">sitagliptin</compound-id>: 0.56 +/- 0.05, p &lt; 0.0001).	sitagliptin__glucagon__no_interaction	sitagliptin__insulin__no_interaction	exenatide__glucagon__no_interaction	exenatide__insulin__no_interaction	acetaminophen__glucagon__no_interaction	acetaminophen__insulin__no_interaction
19764896-4	METHODS: Fifty-two single-rooted teeth had their crowns sectioned at the cementoenamel junction and were randomly divided into four groups (n = 13): G1: conventional preparation (CP) + irrigation with <compound-id="56620595">EDTA-T</compound-id> + <compound-id="6695">rhodamine</compound-id> B dye solution associated with <protein-id="Q00604">NDP</protein-id> (<compound-id="9400">dexamethasone phosphate</compound-id>, paramonochlorophenol, polyethylenoglycol) (Rhod-<protein-id="Q00604">NDP</protein-id>); G2: CP + <compound-id="56620595">EDTA-T</compound-id> + Er,Cr:YSGG laser irradiation 0.75 W + Rhod-<protein-id="Q00604">NDP</protein-id>; G3: CP + <compound-id="56620595">EDTA-T</compound-id> + Er,Cr:YSGG 1.5 W + Rhod-<protein-id="Q00604">NDP</protein-id>; G4: CP + <compound-id="56620595">EDTA-T</compound-id> + Er,Cr:YSGG 2.5 W + Rhod-<protein-id="Q00604">NDP</protein-id>.	rhodamine__NDP__no_interaction	dexamethasone phosphate__NDP__no_interaction	EDTA-T__NDP__no_interaction
21409278-5	Upon reaction of bimptz with two equivalents of MnCl(2)·4H(2)O, CoCl(2)·6H(2)O and [Ru(<compound-id="679">dmso</compound-id>)(4)Cl(2)], the dinuclear complexes [Mn(2)(bimptz)(µ-Cl)(2)Cl(2)] (1), [Co(2)(bimptz)(CH(3)OH)(2)(µ-Cl)(2)](<protein-id="Q6Q759">PF(6</protein-id>))(2) (3) and [Ru(2)(bimptz)(<compound-id="679">dmso</compound-id>)(2)(µ-Cl)(2)](<protein-id="Q6Q759">PF(6</protein-id>))(2) (4), respectively, were isolated.	dmso__PF(6__no_interaction
21215232-8	HGF decreased I/R- and GdCl(3)-induced apoptosis [GdCl(3) + HGF: (11.8 ± 1.89)%, GdCl(3): (25.36 ± 2.60)%, P &lt; 0.05] by suppressing <protein-id="P55213">Caspase-3</protein-id> (GdCl(3) + HGF: 1.12 ± 0.23, (GdCl(3): 1.93 ± 0.28, P &lt; 0.05; GdCl(3) + HGF + <compound-id="3973">LY294002</compound-id>: 1.87 ± 0.31, GdCl(3) + <compound-id="3973">LY294002</compound-id>: 3.86 ± 0.47, P &lt; 0.05) and promoting <protein-id="P49950">Bcl-2</protein-id> (GdCl(3) + HGF: 2.56 ± 0.54, GdCl(3): 0.82 ± 0.18, P &lt; 0.05; GdCl(3) + HGF + <compound-id="3973">LY294002</compound-id>: 1.68 ± 0.28, GdCl(3) + <compound-id="3973">LY294002</compound-id>: 0.68 ± 0.13, P &lt; 0.05) and <protein-id="D3ZFJ0">PI3K</protein-id> phosphorylation expression (GdCl(3) + HGF: 2.87 ± 0.21, GdCl(3): 0.61 ± 0.07, P &lt; 0.05; GdCl(3) + HGF + <compound-id="3973">LY294002</compound-id>: 2.01 ± 0.14, GdCl(3) + <compound-id="3973">LY294002</compound-id>: 0.44 ± 0.10, P &lt; 0.05) in accordance with downregulation of CaSR mRNA expression (GdCl(3) + HGF: 1.46 ± 0.37, GdCl(3): 4.46 ± 0.62, P &lt; 0.01).	LY294002__Bcl-2__no_interaction	LY294002__Caspase-3__no_interaction	LY294002__PI3K__no_interaction
6233132-1	Using microsomes isolated from term human placentae kinetic analyses of each of the enzymes involved in estrogen synthesis from <compound-id="12594">dehydroepiandrosterone sulfate</compound-id> have been carried out and the following parameters were found: <protein-id="Q5FYA8">sulfatase</protein-id>, Michaelis-Menten constant (Km) = 16,000 +/- 5,000 nM, maximum velocity (Vm) = 2.0 +/- 0.5 nmol X min-1 X mg protein-1; 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD), Km = 15 +/- 3 nM, Vm = 1.8 +/- 0.4 nmol X min-1 X mg protein-1; <protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">aromatase</protein-id>, Km = 14 +/- 4 nM, Vm = 0.12 +/- 0.02 nmol X min-1 X mg protein-1.	dehydroepiandrosterone sulfate__aromatase__no_interaction	dehydroepiandrosterone sulfate__sulfatase__no_interaction
15770721-5	The frequencies of NAT1 genotypes <protein-id="Q9GZZ1,E7EQ69">NAT1*3</protein-id>/*3, <protein-id="Q9GZZ1,E7EQ69">NAT1*3</protein-id>/*4, <protein-id="Q9GZZ1,E7EQ69">NAT1*3</protein-id>/*10, <protein-id="P25440,X5CF57,A0A024RCR5">NAT1*3/*14B</protein-id>, <protein-id="Q8WUY8">NAT1*4</protein-id>/*4, <protein-id="Q8WUY8">NAT1*4</protein-id>/*10, <protein-id="P25440,X5CF57,A0A024RCR5">NAT1*4/*14B</protein-id>, NAT1*10/*10, NAT1*10/*<compound-id="259834">14B</compound-id>, and NAT2 genotypes NAT2*4/*4, NAT2*4/*6, NAT2*4/*7, NAT2*6/*6, NAT2*6/*7 and NAT2*7/*7 also had no statistically significant difference between the two groups (chi(2) = 11.86 and 2.94 respectively both, P&gt;0.05).	14B__NAT1*4__no_interaction	14B__NAT1*3/*14B__no_interaction	14B__NAT1*3__no_interaction	14B__NAT1*4/*14B__no_interaction
21144566-3	The base media contain different <compound-id="22044544,5460341">calcium</compound-id> concentrations, so that five experimental groups were obtained: TCM/FCS (TCM 199 + 20% fetal calf serum (FCS), [Ca(2+)] 9.9 mg/dl); PBS/FCS (Dulbecco <compound-id="1061,167704,644102">Phosphate</compound-id> Buffered Saline (PBS) + 20% FCS, [Ca(2+)] 4.4 mg/dl); PBS(CaMg free)/FCS (PBS without Ca(2+) and Mg(2+) + 20% FCS [Ca(2+)] 2.2 mg/dl); PBS/BSA (PBS + 0.4% <protein-id="P02769">bovine serum albumin</protein-id> (BSA), [Ca(2+)] 3.2 mg/dl) and PBS(CaMg free)/BSA (PBS without Ca(2+) and Mg(2+) +0.4% BSA, [Ca(2+)] 0.4 mg/dl).	calcium__bovine serum albumin__no_interaction	Phosphate__bovine serum albumin__no_interaction
18599971-2	bis(4-<compound-id="8640">aminonaphthalene</compound-id>-1-sulfonato-kappaO)bis(<compound-id="342157">4,5-diazafluoren-9-one</compound-id>-kappa(2)N,N')<compound-id="23978">copper</compound-id>(II), [Cu(C(10)H(8)NO(3)S)(2)(C(11)H(6)N(2)O)(2)], (I), and poly[[[diaquacadmium(II)]-bis(<protein-id="O00189,C9IZL5,C9JC87">mu-4</protein-id>-<compound-id="8640">aminonaphthalene</compound-id>-1-sulfonato)-kappa(2)O:N;kappa(2)N:O] <compound-id="3039108">dihydrate</compound-id>], {[Cd(C(10)H(8)NO(3)S)(2)(H(2)O)(2)].2H(2)O}(n), (II), are rare examples of sulfonate-containing complexes where the anion does not fulfill a passive charge-balancing role, but takes an active part in coordination as a monodentate and/or bridging ligand.	copper__mu-4__no_interaction	4,5-diazafluoren-9-one__mu-4__no_interaction	aminonaphthalene__mu-4__no_interaction	dihydrate__mu-4__no_interaction
8043308-3	The concentrations of <compound-id="8370">hexachlorobenzene</compound-id> (HCB), alpha <protein-id="P43699">BHC</protein-id>, beta <protein-id="P43699">BHC</protein-id>, gamma <protein-id="P43699">BHC</protein-id>, heptachloride, <compound-id="12310947,2087,222548,24860538,61103">aldrin</compound-id>, heptachloride epoxide, pp'<compound-id="3035">DDE</compound-id>, <compound-id="12358489,16211853,222547,3048,60963,6478437,71316037,969491">dieldrin</compound-id>, op'DDT, pp'DDT were found as 84 +/- 23, 96 +/- 20, 522 +/- 120, 156 +/- 20, 198 +/- 130, 47 +/- 9, 11 +/- 4, 2389 +/- 280, 6.7 +/- 3, 70 +/- 12, 410 +/- 60 micrograms kg-1 milk, fat, respectively, measured by gas chromatography (GC) method.	dieldrin__BHC__no_interaction	DDE__BHC__no_interaction	aldrin__BHC__no_interaction	hexachlorobenzene__BHC__no_interaction
22610190-8	Endotoxemia had no influence on mean arterial pressure (95 [74-103] mm Hg vs. 92 [78-104] mm Hg; p = .75), but increased cardiac output (8.3 [6.1-9.5] L·<protein-id="P13987,Q6FHM9">min(-1</protein-id>) vs. 6.0 [4.5-8.2] L·<protein-id="P13987,Q6FHM9">min(-1</protein-id>); p = .02) through an elevation in heart rate (82 ± 9 beats·<protein-id="P13987,Q6FHM9">min(-1</protein-id>) vs. 63 ± 10 beats·<protein-id="P13987,Q6FHM9">min(-1</protein-id>); p &lt; .001), whereas arterial <compound-id="280">carbon dioxide</compound-id> tension (37 ± 5 mm Hg vs. 41 ± 2 mm Hg; p &lt; .05) and middle cerebral artery mean flow velocity (37 ± 9 cm·sec(-1) vs. 47 ± 10 cm·sec(-1); p &lt; .01) were reduced.	carbon dioxide__min(-1__no_interaction
2161298-8	At 0400 h plasma <protein-id="P01189,Q6FHC8">ACTH</protein-id> (mean +/- <compound-id="5289348">SEM</compound-id>) was 758.4 +/- 298.1 vs 380.2 +/- 166.6; 0600 h, 795 +/- 288.7 vs 477.8 +/- 191.7; 1200 h, 266.8 +/- 106.2 vs 187.0 +/- 80.3; 1400 h, 470.0 +/- 239.0 vs 302.0 +/- 135.9; 1600 h, 548.6 +/- 262.5 vs 394.2 +/- 178.5 ng/l (P less than 0.05).	SEM__ACTH__no_interaction
14716833-9	RESULTS: <compound-id="5757">Estradiol</compound-id> treatment in both ovariectomy and sham ovariectomy groups reduced liver levels of ALT (from 658 +/- 220 nkat/L to 311 +/- 146 nkat/L and 540 +/- 252 nkat/L to 314 +/- 163 nkat/L, P&lt;0.05) and AST (from 697 +/- 240 nkat/L to 321 +/- 121 nkat/L and 631 +/- 268 nkat/L to 302 +/- 153 nkat/L, P&lt;0.05), increased serum <compound-id="145068">nitric oxide</compound-id> (NO) level (from 53.7 +/- 17.1 micromol/L to 93.3 +/- 24.2 micromol/L and 55.3 +/- 23.1 micromol/L to 87.5 +/- 23.6 micromol/L, P&lt;0.05) and hepatic <compound-id="145068">nitric oxide</compound-id> synthase (NOS) activity (from 1.73 +/- 0.71 KU/g to 2.49 +/- 1.20 KU/g and 1.65 +/- 0.46 KU/g to 2.68 +/- 1.17 KU/g, P&lt;0.05), diminished the accumulation of hepatic collagen, decreased centrolobular necrotic areas as well as the inflammatory reaction in rats subjected to <protein-id="P50230,G3V7I1">CCl4</protein-id>.	nitric oxide__CCl4__no_interaction	Estradiol__CCl4__no_interaction
10852463-8	Older and younger subjects had similar fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (5.3 +/- 0.1 vs. 5.2 +/- 0.1 mmol/L), IRI (83 +/- 8 vs. 76 +/- 9 pmol/L), PI (8.9 +/- 0.8 vs. 10.6 +/- 2.0 pmol/L), and PI/IRI ratio (12.3 +/- 1.3% vs. 13.9 +/- 1.6%; all P = NS) despite a 50% reduction of <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (SI, 1.94 +/- 0.21 vs. 3.88 +/- 0.38 x 10(-5) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)/pmol x L; P &lt; 0.001) and in B cell function [SI x fasting IRI, 139 +/- 18 vs. 244 +/- 24 x 10(-5)(P &lt; 0.001); SI x AIRglucose, 0.75 +/- 0.13 vs. 1.70 +/- 0.15 x 10(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (P &lt; 0.001); SI x AIRmax, 3.63 +/- 0.53 vs. 6.81 +/- 0.70 x 10(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (P &lt; 0.001)] in the older subjects.	glucose__min(-1__no_interaction	glucose__insulin__no_interaction
22260227-4	Reduction of [κ(3)-Ar(Tol'(2))]Ta(<protein-id="P04080,Q76LA1">PMe</protein-id>(3))(2)Cl(2) with KC(8) in <compound-id="241">benzene</compound-id> gives the <compound-id="241">benzene</compound-id> complex [κ(3)-Ar(Tol'(2))]Ta(<protein-id="P04080,Q76LA1">PMe</protein-id>(3))(2)(η(6)-C(6)H(6)) that is better described as a 1,4-<compound-id="21296230">cyclohexadienediyl</compound-id> derivative.	benzene__PMe__no_interaction	cyclohexadienediyl__PMe__no_interaction
17003017-5	In comparison to controls (group II), the offspring of <protein-id="P62633">DM2</protein-id> subjects (group I) had higher fasting serum triglycerides (mean +/- SD 2.25+/-2.08 vs. 1.6+/-0.8 mmol/L, p&lt;0,05), lower HDL <compound-id="5997">cholesterol</compound-id> (0.96 +/- 0.2 vs. 1.1 +/- 0.2 mmol/L, p&lt;0.001), higher total <compound-id="5997">cholesterol</compound-id> (5.5 +/- 1.1 vs. 5.1 +/- 0.8 mmol/L, p &lt; 0.05), higher <protein-id="P04114,Q7Z7Q0,Q59HB3">Apo-B</protein-id>-lipoprotein (133.2+/-34.3 vs. 125.5+/-30.5 mg/dl, p&lt;0.05), higher LDL-C (3.7 +/- 0.8 vs. 3.2 +/- 0.6 mmol/L), higher gamma-GT (28+/-10 vs. 17+/-5.6 iu/L, p&lt;0.01) higher <protein-id="P01308,I3WAC9">insulin</protein-id> in the Area Under the Curve (204.7+/-140.8 v. 153.1 +/- 63.0 microU/ml, p&lt;0.05) and higher HOMA-IRI (2.84+/-1.39 vs. 1.67+/-0.77, p&lt;0.001), higher serum ferritin concentrations (98.3+/-57.7 vs. 62.0+/-41.1 ng/ml, p&lt;0.01), higher serum <compound-id="23925,67172434">iron</compound-id> concentration (20.2+/-6.0 micromol/L vs. 14.5+/-4.3, p&lt;0.001) and higher <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation index (31.3+/-8.4 vs. 22.6+/-7.3, p&lt;0.0001).	iron__DM2__no_interaction	iron__transferrin__no_interaction	iron__Apo-B__no_interaction	iron__insulin__no_interaction	cholesterol__DM2__no_interaction	cholesterol__transferrin__no_interaction	cholesterol__Apo-B__no_interaction	cholesterol__insulin__no_interaction
11311734-3	Infusion with the opioid antagonist naloxone hydrochloride significantly increased systolic blood pressure (SBP) in hypoxemic-hypercapnic (182.0 +/- 3.2 versus 205.1 +/- 3.0 mmHg; P &lt; 0.01), hypoxemic-normocapnic (149.3 +/- 1.8 versus 169.1 +/- 2.2 mmHg; P &lt; 0.01) and hypoxemic-hypocapnic (147.3 +/- 1.3 versus 166.8 +/- 2.2 mmHg; P &lt; 0.01) patients, <compound-id="439260">norepinephrine</compound-id> in hypoxemic-hypercapnic patients (3583.2 +/- 371.8 versus 5371.3 +/- 260.0 fmol/ml; P &lt; 0.01), and reduced <protein-id="P01160">ANF</protein-id> in hypoxemic-normocapnic (18.3 +/- 0.8 versus 11.9 +/- 1.0 fmol/ml; P &lt; 0.05) and hypoxemic-hypocapnic (18.1 +/- 1.2 versus 12.1 +/- 2.1 fmol/ml; P &lt; 0.05) patients.	norepinephrine__ANF__no_interaction
22025009-4	The experimental results show that the surface coverage Γ(m) for C(12)SH-SAMs-Au by the five pretreatment methods are: <compound-id="62687">aqua regia</compound-id> pretreatment (8.0 × 10(-10) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> cm(-2)) ~ reductive annealed pretreatment (7.8 × 10(-10) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> cm(-2)) &gt; UV/O(3) pretreatment (5.0 × 10(-10) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> cm(-2)) ~ piranha reagents pretreatment (4.1 × 10(-10) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> cm(-2)) ~ simple polishing pretreatment (4.0 × 10(-10) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> cm(-2)).	aqua regia__mol__no_interaction
16239354-2	The mean (+/-<compound-id="5289348">SEM</compound-id>) <compound-id="4594">omeprazole</compound-id> hydroxylation index in CLD patients with homozygous extensive metabolizer (EM) genotype (*1/*1, n = 8), heterozyous EM (*1/*2, n = 11; *1/*3, n = 6) genotypes and poor metabolizer (PM) genotypes (*2/*2, n = 3; *3/*3, n = 3) were 17.15 +/- 2.12, 20.02 +/- 2.63, and 26.04 +/- 3.15, respectively, which were significantly higher compared with control subjects with the corresponding <protein-id="P33261">CYP2C19</protein-id> genotypes (0.81 +/- 0.09, 1.55 +/- 0.20, and 15.5 +/- 1.52).	SEM__CYP2C19__no_interaction	omeprazole__CYP2C19__no_interaction
24057291-6	<protein-id="Q8NAU1">irisin</protein-id> was associated negatively with <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (r = -0.4, P &lt; .001) and positively with body mass index (r = 0.22, P = .008), systolic (r = 0.17, P = .04) and diastolic (r = 0.27, P = .001) blood pressure, fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.25, P = .002), triglycerides (r = 0.25, P = .003), and homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.33, P &lt; .001).	glucose__irisin__no_interaction	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
12819136-4	Using a combination of public (NCBI) and private (RIKEN) databases, we compared the repertoire of apoptosis and NFkappaB-inducing genes in humans and mice from cDNA/EST/genomic data, focusing on the following domain families: (1) Caspase proteases; (2) Caspase recruitment domains (CARD); (3) Death Domains (DD); (4) Death Effector Domains (<compound-id="447358">DED</compound-id>); (5) <compound-id="5478838">BIR</compound-id> domains of Inhibitor of Apoptosis Proteins (IAPs); (6) Bcl-2 homology (BH) domains of Bcl-2 family proteins; (7) Tumor Necrosis Factor (TNF)-family ligands; (8) TNF receptors (TNFR); (9) TIR domains; (10) PAAD (<protein-id="Q9JJ26,Q32MT0,Q32MT1">PYRIN</protein-id>; <compound-id="445779">PYD</compound-id>, DAPIN); (11) nucleotide-binding NACHT domains; (12) TRAFs; (13) Hsp70-binding BAG domains; (14) endonuclease-associated CIDE domains; and (15) miscellaneous additional proteins.	BIR__PYRIN__no_interaction	PYD__PYRIN__no_interaction	DED__PYRIN__no_interaction
12679947-3	RESULTS: The incidence of epithelial nucleoplasmic ratio &gt;1, lobulated nuclei, inter-chromatin aggregation of granules, nucleolar hypertrophy, and the content of DNA, Zn, Cu in nuclei and serum <protein-id="P22079">LPO</protein-id> of each group were showed as belows: normal control group (0.0, 0.0, 6.7, 0.0, 12.6+/-2.7, 7.6+/-0.4, 58.4+/-0.3, 2.6+/-0.6), <compound-id="15216946">CSG</compound-id> group (5.7, 2.9, 7.4, 2.9, 15.2+/-3.1, 8.1+/-0.5, 58.9+/-0.5, 4.2+/-0.7), CAG group (31.3, 29.7, 45.3, 42.2, 16.5+/-3.1, 8.6+/-0.4, 59.3+/-0.5, 4.5+/-0.6), CA group (100.0, 100.0, 72.2, 50.0, 30.7+/-8.2, 8.8+/-0.3, 59.5+/-0.4, 6.8+/-1.6), <compound-id="5957">ATP</compound-id>(++) group (61.5, 38.5, 23.1, 38.5, 23.5+/-8.9, 8.3+/-0.4, 59.1+/-0.4, 5.1+/-1.2), IM(++)+<compound-id="5957">ATP</compound-id>(++)group (77.8, 55.5, 33.3, 44.4, 25.1+/-7.2, 8.4+/-0.5, 59.5+/-0.4, 6.5+/-1.1), IM(+++)+<compound-id="5957">ATP</compound-id>(++) group (100.0, 100.0, 75.0, 62.5, 28.5+/-9.1, 8.9+/-0.5, 59.7+/-0.4, 7.6+/-0.7), IMII(b) group (100.0, 62.5, 75.0, 50.0, 27.3+/-10.3, 8.6+/-0.3, 59.5+/-0.4, 6.1+/-0.9); whereas the content of Zn, Cu in mitochondria and <compound-id="6076">cAMP</compound-id>, SOD in gastric mucosa, and (3)H-TdR <compound-id="537952">LCT</compound-id> of each group were showen as belows: normal control group (9.2+/-0.5, 58.3+/-0.3, 15.9+/-1.5, 170.5+/-6.1, 1079.7+/-227.4), <compound-id="15216946">CSG</compound-id> group (8.6+/-0.5, 57.8+/-0.3, 14.6+/-1.8, 163.3+/-5.6, 867.3+/-240.5), CAG group (8.3+/-0.4, 57.5+/-0.3, 13.4+/-1.8, 161.2+/-4.3, 800.9+/-221.8), CA group (8.9+/-0.4, 57.1+/-0.3, 10.2+/-3.9, 152.2+/-3.8, 325.7+/-186.8), <compound-id="5957">ATP</compound-id>(++) group (9.1+/-0.4, 57.0+/-0.3, 12.4+/-1.8, 161.5+/-3.8, 642.9+/-174.3), IM(++)+<compound-id="5957">ATP</compound-id>(++) group (8.6+/-0.4, 56.9+/-0.3, 12.0+/-2.3, 152.2+/-2.5, 326.3+/-160.3), IM(+++)+<compound-id="5957">ATP</compound-id>(++) group (8.5+/-0.3, 56.8+/-0.2, 10.4+/-0.9, 147.4+/-2.6, 316.1+/-170.7), IMII(b) group (8.6+/-0.3, 56.9+/-0.3, 11.9+/-1.9, 150.0+/-2.8, 318.9+/-145.8), there were significant differences between groups (P&lt;0.05-0.01).	CSG__LPO__no_interaction	cAMP__LPO__no_interaction	LCT__LPO__no_interaction	ATP__LPO__no_interaction
16364499-4	Furthermore, <protein-id="O95399,A0AVP6">UII</protein-id> correlated significantly with Big-<compound-id="11395145">ET1</compound-id> (r = 0.32, p = 0.03), <protein-id="P16860">BNP</protein-id> (r = 0.42, p = 0.005) but poorly with Nt-proANP (r = 0.28, p = 0.07).	ET1__UII__no_interaction	ET1__BNP__no_interaction
23840141-10	When the incubation time was extended to 12 h (0.33 ± 0.05, 0.32 ± 0.03 and 0.25 ± 0.03 vs 0.69 ± 0.01) and 24 h (0.31 ± 0.01, 0.29 ± 0.03 and 0.25 ± 0.01 vs 0.63 ± 0.01), <compound-id="6323417">MS1</compound-id> cell activity decreased in all <protein-id="Q9QUK6,L0CL36">LPS</protein-id> concentration groups compared with the blank control (P &lt; 0.001).	MS1__LPS__no_interaction
8725178-8	This clone expresses alpha 1 type (I) procollagen mRNA and secretes type I procollagen C-peptide at both temperatures, although the levels were slightly elevated at 40 degrees C. The cell line expresses alkaline phosphatase activity at 34 degrees C, and the basal level of this enzyme increases 2- to 6-fold at 40 degrees C. Alkaline phosphatase activity is induced 4- to 8-fold by 1 alpha,25-dihydroxyvitamin D3 (vitamin D3) at both temperatures, but <protein-id="P01137">transforming growth factor-beta 1</protein-id> (<protein-id="P01137">TGF-beta 1</protein-id>) suppresses enzyme expression &gt; 90% at 40 degrees C. Vitamin D3 also induces a 10-fold increase in <protein-id="P02818">osteocalcin</protein-id> secretion when the clone is maintained at 34 degrees C, and this induction is enhanced &gt; 8-fold at 40 degrees C. <protein-id="P01270">Parathyroid hormone</protein-id> and <compound-id="47936">forskolin</compound-id> stimulate a 4- to 6-fold increase in the production of intracellular cyclic AMP (cAMP) by the cells at 34 degrees C, and this stimulation is enhanced 2- to 4-fold at 40 degrees C. In contrast, <compound-id="285703,6145931">prostaglandin</compound-id> E2 stimulates a 7- to 8-fold increase in cAMP only when the cells are maintained at 34 degrees C. This cell line secretes <protein-id="P01137">TGF-beta 1</protein-id> and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>) at 34 degrees C, but only the basal secretion of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> increases 70% at 40 degrees C. Finally, <compound-id="6293">alizarin</compound-id> red-S histochemical staining demonstrates that these cells produce mineralized nodules at both temperatures.	forskolin__IL-6__no_interaction	forskolin__osteocalcin__no_interaction	forskolin__transforming growth factor-beta 1__no_interaction	forskolin__Parathyroid hormone__no_interaction	forskolin__TGF-beta 1__no_interaction	forskolin__interleukin-6__no_interaction	alizarin__IL-6__no_interaction	alizarin__osteocalcin__no_interaction	alizarin__transforming growth factor-beta 1__no_interaction	alizarin__Parathyroid hormone__no_interaction	alizarin__TGF-beta 1__no_interaction	alizarin__interleukin-6__no_interaction	prostaglandin__IL-6__no_interaction	prostaglandin__osteocalcin__no_interaction	prostaglandin__transforming growth factor-beta 1__no_interaction	prostaglandin__Parathyroid hormone__no_interaction	prostaglandin__TGF-beta 1__no_interaction	prostaglandin__interleukin-6__no_interaction
18831354-6	In control group, the basal HR was 82.06 +/- 8.07, <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> 111.95 +/- 8.23, DBP 76.8 +/- 6.42, EMG 4.08 +/- 2.99, <compound-id="127716">EDG</compound-id> 9.77 +/- 3.29, RR 15.60 +/- 3.77 and T was 97.86 +/- 0.63.	EDG__SBP__no_interaction
1910630-1	The crystal structure of <compound-id="57476835,60961">adenosine</compound-id>, C10H13N5O4, Mr = 267.24, has been refined by full-matrix least-squares methods using single-crystal neutron diffraction data (<protein-id="Q9NVU0,A0A0C4DH01">sin</protein-id> theta/lambda less than 0.79 A-1) measured at 123 K. Crystal data at 123 K: monoclinic, P2l, Z = 2, a = 4.7885 (8), b = 10.240 (2), c = 11.772 (2) A, beta = 99.59 (2) degrees, V = 569.2 A3, lambda = 1.0402 (1) A, Dn = 1.559 Mg m-3, mu = 191.1 m-1, F(000) = 175.72 fm, R(F2) = 0.044, wR(F2) = 0.055, S = 1.13 for 2450 reflections with F2 greater than 0.0.	adenosine__sin__no_interaction
20150840-9	RESULTS: <compound-id="5282263">8-iso-PGF2alpha</compound-id> levels were significantly higher in ACS compared to CAD patients (363.2 +/-45.94 vs. 328.2 -/+31.96 pg/ml, P = 0.011) and correlated with venous plasma levels of <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-sel</protein-id> and <protein-id="P02775">beta-thromboglobulin</protein-id> in the ACS (r = 0.66; P = 0.0005 and r = 0.62; P = 0.001, respectively) and CAD groups (r = 0.46; P = 0.02 and r = 0.49; P = 0.01, respectively).	8-iso-PGF2alpha__P-sel__no_interaction	8-iso-PGF2alpha__beta-thromboglobulin__no_interaction
20140276-1	[Methoxy-(11)C]PD-153035, <compound-id="66414">2-Methoxyestradiol</compound-id>; Adalimumab, Adecatumumab, <compound-id="60871">Adefovir dipivoxil</compound-id>, <protein-id="P07327">ADH-1</protein-id>, ADX-10059, Aflibercept, AIR-human <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id>, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="76935">AMG</compound-id>-221, <compound-id="2162">Amlodipine besylate</compound-id>/<compound-id="130881">olmesartan medoxomil</compound-id>, <compound-id="151165,21923359,53660666,6918365">Aprepitant</compound-id>; Bavituximab, Bevacizumab, <compound-id="82146">Bexarotene</compound-id>, BIBW-2992, BMS-690514, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, Briakinumab; <compound-id="60953">Capecitabine</compound-id>, Certolizumab pegol, Cetuximab, <compound-id="10883523,22811020,25127095,2735,44281724,5280795,5283710,5283711,5353527,5363362,54253998,57484195,6221,6432644,9821465">Cholecalciferol</compound-id>, <compound-id="64929">Choline fenofibrate</compound-id>, Chorionic gonadotropin (human), Cixutumumab, <compound-id="60606">Clopidogrel</compound-id>, <compound-id="9926791">CP-690550</compound-id> <compound-id="311,17938267">citrate</compound-id>; <compound-id="216210">Dabigatran</compound-id>, <compound-id="9953592">Dacetuzumab</compound-id>, Daclizumab, <compound-id="9887712">Dapagliflozin</compound-id>, Darbepoetin alfa, <compound-id="3062316">Dasatinib</compound-id>, Denosumab; <compound-id="64139">Efavirenz</compound-id>, <compound-id="9855343">Elisidepsin</compound-id>, <compound-id="57199466,772">Enoxaparin</compound-id>, <compound-id="176167">Enzastaurin hydrochloride</compound-id>, <compound-id="11354606">Eribulin mesilate</compound-id>, <compound-id="176870">Erlotinib hydrochloride</compound-id>, Everolimus, <compound-id="45588096,53396299,56927919">Exenatide</compound-id>; <compound-id="162834">Fenobam</compound-id>, <compound-id="6917781">Figitumumab</compound-id>, <compound-id="54708673">Filibuvir</compound-id>, <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, Fresolimumab; <compound-id="123631">Gefitinib</compound-id>, Golimumab, Golnerminogene pradenovec; <compound-id="3690">Ifosfamide</compound-id>, <compound-id="5291">Imatinib mesylate</compound-id>, Ipilimumab, <compound-id="132999">Ivabradine hydrochloride</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; <compound-id="208908">Lapatinib ditosylate</compound-id>, <compound-id="216326">Lenalidomide</compound-id>, <compound-id="1549000">Levocetirizine dihydrochloride</compound-id>, Liposomal <compound-id="5978">vincristine</compound-id>, Liraglutide; M-118, <compound-id="10074640">Masitinib mesylate</compound-id>, <compound-id="4091">Metformin hydrochloride</compound-id>, <compound-id="477468,6602291">Micafungin sodium</compound-id>, <compound-id="152946">Moxifloxacin hydrochloride</compound-id>; <compound-id="9915743">Neratinib</compound-id>; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="6918251">Ofatumumab</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="100427">Palifosfamide</compound-id> <compound-id="57449,5962,866">lysine</compound-id>, Panobacumab, <compound-id="6918837">Panobinostat</compound-id>, <compound-id="448013">Patupilone</compound-id>, Peginterferon alfa-2a, Pegylated <compound-id="6322,90867653">arginine</compound-id> deiminase 20000, <compound-id="9801640">Piclozotan</compound-id> <compound-id="21885828">hydrochloride hydrate</compound-id>, <compound-id="134019">Pixantrone maleate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">Prasterone</compound-id>, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5865">Prednisone</compound-id>, <compound-id="5994">Progesterone</compound-id>, <compound-id="3052762">Prucalopride</compound-id>, pVGI.1 (VEGF-2); <compound-id="121892">Retigabine</compound-id>, rhFSH, Rituximab, <compound-id="9875401">Rivaroxaban</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>; Salinosporamide A, <compound-id="10127622">Selumetinib</compound-id>, Sipuleucel-T, Somatropin, <compound-id="216239">Sorafenib</compound-id>, <compound-id="11347895">SSR</compound-id>-244738, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="2733525">Tamoxifen citrate</compound-id>, <compound-id="16139605">Teduglutide</compound-id>, <compound-id="3081362,6918703">Telavancin hydrochloride</compound-id>, <compound-id="65999">Telmisartan</compound-id>, <compound-id="65999">Telmisartan</compound-id>/amlodipine, <compound-id="65999">Telmisartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">Temsirolimus</compound-id>, <compound-id="5481350">Tenofovir disoproxil fumarate</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="216237">Tolvaptan</compound-id>, Trastuzumab, Trastuzumab-MCC-<protein-id="Q09013,E5KR05,E5KR06,E5KR07,B4DM55,B4DZE2,I6L989">DM1</protein-id>, <compound-id="5282226">Travoprost</compound-id>, Tremelimumab; <compound-id="60846">Valsartan</compound-id>/<compound-id="2162">amlodipine besylate</compound-id>, <compound-id="60846">Valsartan</compound-id>/<compound-id="2162">amlodipine besylate</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="60846">Valsartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="3081361">Vandetanib</compound-id>, <compound-id="5311">Vorinostat</compound-id>.	Fenobam__DM1__no_interaction	Fenobam__ADH-1__no_interaction	Fenobam__growth hormone__no_interaction	Erlotinib hydrochloride__DM1__no_interaction	Erlotinib hydrochloride__ADH-1__no_interaction	Erlotinib hydrochloride__growth hormone__no_interaction	Teduglutide__DM1__no_interaction	Teduglutide__ADH-1__no_interaction	Teduglutide__growth hormone__no_interaction	Filibuvir__DM1__no_interaction	Filibuvir__ADH-1__no_interaction	Filibuvir__growth hormone__no_interaction	Figitumumab__DM1__no_interaction	Figitumumab__ADH-1__no_interaction	Figitumumab__growth hormone__no_interaction	Elisidepsin__DM1__no_interaction	Elisidepsin__ADH-1__no_interaction	Elisidepsin__growth hormone__no_interaction	Gefitinib__DM1__no_interaction	Gefitinib__ADH-1__no_interaction	Gefitinib__growth hormone__no_interaction	Micafungin sodium__DM1__no_interaction	Micafungin sodium__ADH-1__no_interaction	Micafungin sodium__growth hormone__no_interaction	amlodipine besylate__DM1__no_interaction	amlodipine besylate__ADH-1__no_interaction	amlodipine besylate__growth hormone__no_interaction	Dacetuzumab__DM1__no_interaction	Dacetuzumab__ADH-1__no_interaction	Dacetuzumab__growth hormone__no_interaction	olmesartan medoxomil__DM1__no_interaction	olmesartan medoxomil__ADH-1__no_interaction	olmesartan medoxomil__growth hormone__no_interaction	2-Methoxyestradiol__DM1__no_interaction	2-Methoxyestradiol__ADH-1__no_interaction	2-Methoxyestradiol__growth hormone__no_interaction	Aliskiren fumarate__DM1__no_interaction	Aliskiren fumarate__ADH-1__no_interaction	Aliskiren fumarate__growth hormone__no_interaction	Vorinostat__DM1__no_interaction	Vorinostat__ADH-1__no_interaction	Vorinostat__growth hormone__no_interaction	CP-690550__DM1__no_interaction	CP-690550__ADH-1__no_interaction	CP-690550__growth hormone__no_interaction	Fondaparinux sodium__DM1__no_interaction	Fondaparinux sodium__ADH-1__no_interaction	Fondaparinux sodium__growth hormone__no_interaction	Pixantrone maleate__DM1__no_interaction	Pixantrone maleate__ADH-1__no_interaction	Pixantrone maleate__growth hormone__no_interaction	Panobinostat__DM1__no_interaction	Panobinostat__ADH-1__no_interaction	Panobinostat__growth hormone__no_interaction	hydrochlorothiazide__DM1__no_interaction	hydrochlorothiazide__ADH-1__no_interaction	hydrochlorothiazide__growth hormone__no_interaction	SSR__DM1__no_interaction	SSR__ADH-1__no_interaction	SSR__growth hormone__no_interaction	Capecitabine__DM1__no_interaction	Capecitabine__ADH-1__no_interaction	Capecitabine__growth hormone__no_interaction	Ifosfamide__DM1__no_interaction	Ifosfamide__ADH-1__no_interaction	Ifosfamide__growth hormone__no_interaction	Amlodipine besylate__DM1__no_interaction	Amlodipine besylate__ADH-1__no_interaction	Amlodipine besylate__growth hormone__no_interaction	Clopidogrel__DM1__no_interaction	Clopidogrel__ADH-1__no_interaction	Clopidogrel__growth hormone__no_interaction	Tolvaptan__DM1__no_interaction	Tolvaptan__ADH-1__no_interaction	Tolvaptan__growth hormone__no_interaction	Ixabepilone__DM1__no_interaction	Ixabepilone__ADH-1__no_interaction	Ixabepilone__growth hormone__no_interaction	Tipifarnib__DM1__no_interaction	Tipifarnib__ADH-1__no_interaction	Tipifarnib__growth hormone__no_interaction	Neratinib__DM1__no_interaction	Neratinib__ADH-1__no_interaction	Neratinib__growth hormone__no_interaction	Lapatinib ditosylate__DM1__no_interaction	Lapatinib ditosylate__ADH-1__no_interaction	Lapatinib ditosylate__growth hormone__no_interaction	Cholecalciferol__DM1__no_interaction	Cholecalciferol__ADH-1__no_interaction	Cholecalciferol__growth hormone__no_interaction	Levocetirizine dihydrochloride__DM1__no_interaction	Levocetirizine dihydrochloride__ADH-1__no_interaction	Levocetirizine dihydrochloride__growth hormone__no_interaction	AMG__DM1__no_interaction	AMG__ADH-1__no_interaction	AMG__growth hormone__no_interaction	Eribulin mesilate__DM1__no_interaction	Eribulin mesilate__ADH-1__no_interaction	Eribulin mesilate__growth hormone__no_interaction	Sunitinib malate__DM1__no_interaction	Sunitinib malate__ADH-1__no_interaction	Sunitinib malate__growth hormone__no_interaction	Choline fenofibrate__DM1__no_interaction	Choline fenofibrate__ADH-1__no_interaction	Choline fenofibrate__growth hormone__no_interaction	Dabigatran__DM1__no_interaction	Dabigatran__ADH-1__no_interaction	Dabigatran__growth hormone__no_interaction	Oblimersen__DM1__no_interaction	Oblimersen__ADH-1__no_interaction	Oblimersen__growth hormone__no_interaction	Valsartan__DM1__no_interaction	Valsartan__ADH-1__no_interaction	Valsartan__growth hormone__no_interaction	Prasterone__DM1__no_interaction	Prasterone__ADH-1__no_interaction	Prasterone__growth hormone__no_interaction	Imatinib mesylate__DM1__no_interaction	Imatinib mesylate__ADH-1__no_interaction	Imatinib mesylate__growth hormone__no_interaction	lysine__DM1__no_interaction	lysine__ADH-1__no_interaction	lysine__growth hormone__no_interaction	Enzastaurin hydrochloride__DM1__no_interaction	Enzastaurin hydrochloride__ADH-1__no_interaction	Enzastaurin hydrochloride__growth hormone__no_interaction	Moxifloxacin hydrochloride__DM1__no_interaction	Moxifloxacin hydrochloride__ADH-1__no_interaction	Moxifloxacin hydrochloride__growth hormone__no_interaction	Enoxaparin__DM1__no_interaction	Enoxaparin__ADH-1__no_interaction	Enoxaparin__growth hormone__no_interaction	Ofatumumab__DM1__no_interaction	Ofatumumab__ADH-1__no_interaction	Ofatumumab__growth hormone__no_interaction	Bexarotene__DM1__no_interaction	Bexarotene__ADH-1__no_interaction	Bexarotene__growth hormone__no_interaction	Paclitaxel__DM1__no_interaction	Paclitaxel__ADH-1__no_interaction	Paclitaxel__growth hormone__no_interaction	Lenalidomide__DM1__no_interaction	Lenalidomide__ADH-1__no_interaction	Lenalidomide__growth hormone__no_interaction	Dasatinib__DM1__no_interaction	Dasatinib__ADH-1__no_interaction	Dasatinib__growth hormone__no_interaction	Patupilone__DM1__no_interaction	Patupilone__ADH-1__no_interaction	Patupilone__growth hormone__no_interaction	Sorafenib__DM1__no_interaction	Sorafenib__ADH-1__no_interaction	Sorafenib__growth hormone__no_interaction	Tamoxifen citrate__DM1__no_interaction	Tamoxifen citrate__ADH-1__no_interaction	Tamoxifen citrate__growth hormone__no_interaction	Adefovir dipivoxil__DM1__no_interaction	Adefovir dipivoxil__ADH-1__no_interaction	Adefovir dipivoxil__growth hormone__no_interaction	Rosuvastatin calcium__DM1__no_interaction	Rosuvastatin calcium__ADH-1__no_interaction	Rosuvastatin calcium__growth hormone__no_interaction	Prucalopride__DM1__no_interaction	Prucalopride__ADH-1__no_interaction	Prucalopride__growth hormone__no_interaction	Masitinib mesylate__DM1__no_interaction	Masitinib mesylate__ADH-1__no_interaction	Masitinib mesylate__growth hormone__no_interaction	Efavirenz__DM1__no_interaction	Efavirenz__ADH-1__no_interaction	Efavirenz__growth hormone__no_interaction	Rivaroxaban__DM1__no_interaction	Rivaroxaban__ADH-1__no_interaction	Rivaroxaban__growth hormone__no_interaction	Progesterone__DM1__no_interaction	Progesterone__ADH-1__no_interaction	Progesterone__growth hormone__no_interaction	Vandetanib__DM1__no_interaction	Vandetanib__ADH-1__no_interaction	Vandetanib__growth hormone__no_interaction	Prasugrel__DM1__no_interaction	Prasugrel__ADH-1__no_interaction	Prasugrel__growth hormone__no_interaction	Dapagliflozin__DM1__no_interaction	Dapagliflozin__ADH-1__no_interaction	Dapagliflozin__growth hormone__no_interaction	Retigabine__DM1__no_interaction	Retigabine__ADH-1__no_interaction	Retigabine__growth hormone__no_interaction	Travoprost__DM1__no_interaction	Travoprost__ADH-1__no_interaction	Travoprost__growth hormone__no_interaction	Telavancin hydrochloride__DM1__no_interaction	Telavancin hydrochloride__ADH-1__no_interaction	Telavancin hydrochloride__growth hormone__no_interaction	Tenofovir disoproxil fumarate__DM1__no_interaction	Tenofovir disoproxil fumarate__ADH-1__no_interaction	Tenofovir disoproxil fumarate__growth hormone__no_interaction	Telmisartan__DM1__no_interaction	Telmisartan__ADH-1__no_interaction	Telmisartan__growth hormone__no_interaction	Bortezomib__DM1__no_interaction	Bortezomib__ADH-1__no_interaction	Bortezomib__growth hormone__no_interaction	Temsirolimus__DM1__no_interaction	Temsirolimus__ADH-1__no_interaction	Temsirolimus__growth hormone__no_interaction	sodium__DM1__no_interaction	sodium__ADH-1__no_interaction	sodium__growth hormone__no_interaction	Metformin hydrochloride__DM1__no_interaction	Metformin hydrochloride__ADH-1__no_interaction	Metformin hydrochloride__growth hormone__no_interaction	vincristine__DM1__no_interaction	vincristine__ADH-1__no_interaction	vincristine__growth hormone__no_interaction	Selumetinib__DM1__no_interaction	Selumetinib__ADH-1__no_interaction	Selumetinib__growth hormone__no_interaction	Piclozotan__DM1__no_interaction	Piclozotan__ADH-1__no_interaction	Piclozotan__growth hormone__no_interaction	Olmesartan medoxomil__DM1__no_interaction	Olmesartan medoxomil__ADH-1__no_interaction	Olmesartan medoxomil__growth hormone__no_interaction	Bosentan__DM1__no_interaction	Bosentan__ADH-1__no_interaction	Bosentan__growth hormone__no_interaction	Ivabradine hydrochloride__DM1__no_interaction	Ivabradine hydrochloride__ADH-1__no_interaction	Ivabradine hydrochloride__growth hormone__no_interaction	hydrochloride hydrate__DM1__no_interaction	hydrochloride hydrate__ADH-1__no_interaction	hydrochloride hydrate__growth hormone__no_interaction	arginine__DM1__no_interaction	arginine__ADH-1__no_interaction	arginine__growth hormone__no_interaction	Palifosfamide__DM1__no_interaction	Palifosfamide__ADH-1__no_interaction	Palifosfamide__growth hormone__no_interaction	Aprepitant__DM1__no_interaction	Aprepitant__ADH-1__no_interaction	Aprepitant__growth hormone__no_interaction	citrate__DM1__no_interaction	citrate__ADH-1__no_interaction	citrate__growth hormone__no_interaction	Exenatide__DM1__no_interaction	Exenatide__ADH-1__no_interaction	Exenatide__growth hormone__no_interaction	Prednisone__DM1__no_interaction	Prednisone__ADH-1__no_interaction	Prednisone__growth hormone__no_interaction
12731460-3	This issue focuses on the following selection of drugs: AAV-CF, adalimumab, <compound-id="34756">ademetionine</compound-id>, <compound-id="9941008">afeletecan</compound-id> hydrochloride, <compound-id="82148">agomelatine</compound-id>, alemtuzumab, <compound-id="123606">almotriptan</compound-id>, <compound-id="124088">amdoxovir</compound-id>, <compound-id="44152164,5459174,56928089,9812534">aplidine</compound-id>, <compound-id="208900">aranose</compound-id>, <compound-id="44144609,44151616,6328537">arsenic sulfide</compound-id>, <compound-id="148192">atazanavir</compound-id>, atlizumab; <compound-id="5311027">Bimatoprost</compound-id>, <compound-id="101524">BMS-181176</compound-id>, BMS-188667, <compound-id="387447">bortezomib</compound-id>, <compound-id="16760328,22524140,433902,44277532,5280757,5458769,5477635,6473739">bryostatin 1</compound-id>; <compound-id="5351387">Combretastatin A-4 phosphate</compound-id>; Darbepoetin alfa, <compound-id="177236">darusentan</compound-id>, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="124087">desloratadine</compound-id>, DTaP-HBV-IPV/Hib-vaccine, <compound-id="3082555">DTI-0009</compound-id>; Eculizumab, edodekin alfa, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, epoetin, <compound-id="4594,9568614">esomeprazole magnesium</compound-id> <compound-id="123619">etoricoxib</compound-id>; <compound-id="1727">Fampridine</compound-id>, <compound-id="5288209">fenretinide</compound-id>, FR-146687; Galiximab, gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="16130957">ganirelix acetate</compound-id>, <compound-id="123631">gefitinib</compound-id>, Gemtuzumab <compound-id="9942071">ozogamicin</compound-id>, <compound-id="9577124">gimatecan</compound-id>; HEA125xOKT3, <protein-id="P35225">hIL-13</protein-id>-PE38QQR, HSV-2 theracine, Hu14.18-IL-2, human gammaglobulin; <compound-id="57391680">Idraparinux sodium</compound-id>, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="216326">IMiD3</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P05112,D4HNR6,Q5FC01">interleukin-4</protein-id>, <compound-id="148189">irofulven</compound-id>, <compound-id="6918486">ISAtx-247</compound-id>; JT-1001; <compound-id="5284583">Levetiracetam</compound-id>, <compound-id="3033825">levosimendan</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, liposomal <compound-id="11957715,3717450,5978,62313,45356936,5388993,71752952,6324671">vincristine sulfate</compound-id>, <compound-id="172997">lixivaptan</compound-id>, <compound-id="92727">lopinavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>; <compound-id="6398761">Maxacalcitol</compound-id>, <compound-id="896">melatonin</compound-id>, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="3038522">MLN-518</compound-id>; <compound-id="71237">Neridronic acid</compound-id>, nesiritide, <compound-id="9884642">nitronaproxen</compound-id>; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, oregovomab; PEG-filgrastim polyglutamate <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>, rotigotine hydrochloride; <compound-id="444389">SGN</compound-id>-30; T-1249, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, teriparatide, <compound-id="15057856,3086655,49800038,5487427">tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="54682461">tipranavir</compound-id>, <compound-id="213039">TMC-114</compound-id>, <compound-id="108150">trabectedin</compound-id>, transdermal <compound-id="26757">selegiline</compound-id>; <compound-id="3002977">UK-427857</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">valganciclovir hydrochloride</compound-id>, <compound-id="110634">vardenafil</compound-id>, <compound-id="151194">vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="11957715,3717450,5978,62313,45356936,5388993,71752952,6324671">vincristine sulfate</compound-id> TCS; <compound-id="92400">Zofenopril calcium</compound-id>.	trabectedin__interleukin-4__no_interaction	trabectedin__insulin__no_interaction	trabectedin__hIL-13__no_interaction	tipranavir__interleukin-4__no_interaction	tipranavir__insulin__no_interaction	tipranavir__hIL-13__no_interaction	agomelatine__interleukin-4__no_interaction	agomelatine__insulin__no_interaction	agomelatine__hIL-13__no_interaction	deferasirox__interleukin-4__no_interaction	deferasirox__insulin__no_interaction	deferasirox__hIL-13__no_interaction	gimatecan__interleukin-4__no_interaction	gimatecan__insulin__no_interaction	gimatecan__hIL-13__no_interaction	afeletecan__interleukin-4__no_interaction	afeletecan__insulin__no_interaction	afeletecan__hIL-13__no_interaction	Valdecoxib__interleukin-4__no_interaction	Valdecoxib__insulin__no_interaction	Valdecoxib__hIL-13__no_interaction	etoricoxib__interleukin-4__no_interaction	etoricoxib__insulin__no_interaction	etoricoxib__hIL-13__no_interaction	Neridronic acid__interleukin-4__no_interaction	Neridronic acid__insulin__no_interaction	Neridronic acid__hIL-13__no_interaction	melatonin__interleukin-4__no_interaction	melatonin__insulin__no_interaction	melatonin__hIL-13__no_interaction	ademetionine__interleukin-4__no_interaction	ademetionine__insulin__no_interaction	ademetionine__hIL-13__no_interaction	Levetiracetam__interleukin-4__no_interaction	Levetiracetam__insulin__no_interaction	Levetiracetam__hIL-13__no_interaction	nitronaproxen__interleukin-4__no_interaction	nitronaproxen__insulin__no_interaction	nitronaproxen__hIL-13__no_interaction	valganciclovir hydrochloride__interleukin-4__no_interaction	valganciclovir hydrochloride__insulin__no_interaction	valganciclovir hydrochloride__hIL-13__no_interaction	SGN__interleukin-4__no_interaction	SGN__insulin__no_interaction	SGN__hIL-13__no_interaction	sodium__interleukin-4__no_interaction	sodium__insulin__no_interaction	sodium__hIL-13__no_interaction	vatalanib__interleukin-4__no_interaction	vatalanib__insulin__no_interaction	vatalanib__hIL-13__no_interaction	lixivaptan__interleukin-4__no_interaction	lixivaptan__insulin__no_interaction	lixivaptan__hIL-13__no_interaction	lumiracoxib__interleukin-4__no_interaction	lumiracoxib__insulin__no_interaction	lumiracoxib__hIL-13__no_interaction	selegiline__interleukin-4__no_interaction	selegiline__insulin__no_interaction	selegiline__hIL-13__no_interaction	bromide__interleukin-4__no_interaction	bromide__insulin__no_interaction	bromide__hIL-13__no_interaction	vardenafil__interleukin-4__no_interaction	vardenafil__insulin__no_interaction	vardenafil__hIL-13__no_interaction	bortezomib__interleukin-4__no_interaction	bortezomib__insulin__no_interaction	bortezomib__hIL-13__no_interaction	IMiD3__interleukin-4__no_interaction	IMiD3__insulin__no_interaction	IMiD3__hIL-13__no_interaction	TMC-114__interleukin-4__no_interaction	TMC-114__insulin__no_interaction	TMC-114__hIL-13__no_interaction	pregabalin__interleukin-4__no_interaction	pregabalin__insulin__no_interaction	pregabalin__hIL-13__no_interaction	atazanavir__interleukin-4__no_interaction	atazanavir__insulin__no_interaction	atazanavir__hIL-13__no_interaction	enfuvirtide__interleukin-4__no_interaction	enfuvirtide__insulin__no_interaction	enfuvirtide__hIL-13__no_interaction	esomeprazole magnesium__interleukin-4__no_interaction	esomeprazole magnesium__insulin__no_interaction	esomeprazole magnesium__hIL-13__no_interaction	Zofenopril calcium__interleukin-4__no_interaction	Zofenopril calcium__insulin__no_interaction	Zofenopril calcium__hIL-13__no_interaction	UK-427857__interleukin-4__no_interaction	UK-427857__insulin__no_interaction	UK-427857__hIL-13__no_interaction	amdoxovir__interleukin-4__no_interaction	amdoxovir__insulin__no_interaction	amdoxovir__hIL-13__no_interaction	emtricitabine__interleukin-4__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__hIL-13__no_interaction	Maxacalcitol__interleukin-4__no_interaction	Maxacalcitol__insulin__no_interaction	Maxacalcitol__hIL-13__no_interaction	darusentan__interleukin-4__no_interaction	darusentan__insulin__no_interaction	darusentan__hIL-13__no_interaction	gefitinib__interleukin-4__no_interaction	gefitinib__insulin__no_interaction	gefitinib__hIL-13__no_interaction	Bimatoprost__interleukin-4__no_interaction	Bimatoprost__insulin__no_interaction	Bimatoprost__hIL-13__no_interaction	DTI-0009__interleukin-4__no_interaction	DTI-0009__insulin__no_interaction	DTI-0009__hIL-13__no_interaction	aplidine__interleukin-4__no_interaction	aplidine__insulin__no_interaction	aplidine__hIL-13__no_interaction	vincristine sulfate__interleukin-4__no_interaction	vincristine sulfate__insulin__no_interaction	vincristine sulfate__hIL-13__no_interaction	irofulven__interleukin-4__no_interaction	irofulven__insulin__no_interaction	irofulven__hIL-13__no_interaction	Oblimersen__interleukin-4__no_interaction	Oblimersen__insulin__no_interaction	Oblimersen__hIL-13__no_interaction	tiotropium__interleukin-4__no_interaction	tiotropium__insulin__no_interaction	tiotropium__hIL-13__no_interaction	ganirelix acetate__interleukin-4__no_interaction	ganirelix acetate__insulin__no_interaction	ganirelix acetate__hIL-13__no_interaction	fenretinide__interleukin-4__no_interaction	fenretinide__insulin__no_interaction	fenretinide__hIL-13__no_interaction	prasterone__interleukin-4__no_interaction	prasterone__insulin__no_interaction	prasterone__hIL-13__no_interaction	imatinib mesylate__interleukin-4__no_interaction	imatinib mesylate__insulin__no_interaction	imatinib mesylate__hIL-13__no_interaction	arsenic sulfide__interleukin-4__no_interaction	arsenic sulfide__insulin__no_interaction	arsenic sulfide__hIL-13__no_interaction	ISAtx-247__interleukin-4__no_interaction	ISAtx-247__insulin__no_interaction	ISAtx-247__hIL-13__no_interaction	Combretastatin A-4 phosphate__interleukin-4__no_interaction	Combretastatin A-4 phosphate__insulin__no_interaction	Combretastatin A-4 phosphate__hIL-13__no_interaction	paclitaxel__interleukin-4__no_interaction	paclitaxel__insulin__no_interaction	paclitaxel__hIL-13__no_interaction	bryostatin 1__interleukin-4__no_interaction	bryostatin 1__insulin__no_interaction	bryostatin 1__hIL-13__no_interaction	almotriptan__interleukin-4__no_interaction	almotriptan__insulin__no_interaction	almotriptan__hIL-13__no_interaction	midostaurin__interleukin-4__no_interaction	midostaurin__insulin__no_interaction	midostaurin__hIL-13__no_interaction	tenofovir disoproxil fumarate__interleukin-4__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	tenofovir disoproxil fumarate__hIL-13__no_interaction	aranose__interleukin-4__no_interaction	aranose__insulin__no_interaction	aranose__hIL-13__no_interaction	doxorubicin__interleukin-4__no_interaction	doxorubicin__insulin__no_interaction	doxorubicin__hIL-13__no_interaction	desloratadine__interleukin-4__no_interaction	desloratadine__insulin__no_interaction	desloratadine__hIL-13__no_interaction	Rosuvastatin calcium__interleukin-4__no_interaction	Rosuvastatin calcium__insulin__no_interaction	Rosuvastatin calcium__hIL-13__no_interaction	ozogamicin__interleukin-4__no_interaction	ozogamicin__insulin__no_interaction	ozogamicin__hIL-13__no_interaction	MLN-518__interleukin-4__no_interaction	MLN-518__insulin__no_interaction	MLN-518__hIL-13__no_interaction	Idraparinux sodium__interleukin-4__no_interaction	Idraparinux sodium__insulin__no_interaction	Idraparinux sodium__hIL-13__no_interaction	BMS-181176__interleukin-4__no_interaction	BMS-181176__insulin__no_interaction	BMS-181176__hIL-13__no_interaction	lopinavir__interleukin-4__no_interaction	lopinavir__insulin__no_interaction	lopinavir__hIL-13__no_interaction	Fampridine__interleukin-4__no_interaction	Fampridine__insulin__no_interaction	Fampridine__hIL-13__no_interaction	succinate__interleukin-4__no_interaction	succinate__insulin__no_interaction	succinate__hIL-13__no_interaction	levosimendan__interleukin-4__no_interaction	levosimendan__insulin__no_interaction	levosimendan__hIL-13__no_interaction
20658502-1	Ten [C(8)C(1)Im](+) (<compound-id="21321822">1-methyl-3-octylimidazolium</compound-id>)-based ionic liquids with anions Cl(-), Br(-), I(-), [NO(3)](-), [BF(4)](-), [TfO](-), [PF(6)](-), [Tf(2)N](-), [Pf(2)N](-), and [<protein-id="Q12884,B4DLR2">FAP</protein-id>](-) (TfO=trifluoromethylsulfonate, Tf(2)N=bis(trifluoromethylsulfonyl)imide, Pf(2)N=<compound-id="2779028">bis(pentafluoroethylsulfonyl)imide</compound-id>, <protein-id="Q12884,B4DLR2">FAP</protein-id>=<compound-id="6503">tris</compound-id>(<compound-id="137907">pentafluoroethyl</compound-id>)trifluorophosphate) and two [C(8)C(1)C(1)Im](+) (<compound-id="21321828">1,2-dimethyl-3-octylimidazolium</compound-id>)-based ionic liquids with anions Br(-) and [Tf(2)N](-) were investigated by using X-ray photoelectron spectroscopy (XPS), NMR spectroscopy and theoretical calculations.	bis(pentafluoroethylsulfonyl)imide__FAP__no_interaction	pentafluoroethyl__FAP__no_interaction	1-methyl-3-octylimidazolium__FAP__no_interaction	1,2-dimethyl-3-octylimidazolium__FAP__no_interaction	tris__FAP__no_interaction
15681117-5	The affected genes encode a wide range of apoptosis-related proteins, including death receptors (<compound-id="5326889">NTF</compound-id>-R1, <compound-id="5326889">NTF</compound-id>-R2, <protein-id="B1AWN9,Q8VD70">DR3</protein-id>, <protein-id="Q9QZM4">DR5</protein-id>, <protein-id="P50284,B2RRV3,Q8BJV0">LTbeta-R</protein-id>, <protein-id="O35714,Q540M6">GITR</protein-id>, <compound-id="9962786">P57</compound-id> TR-1) and their adaptor and regulatory proteins (MASGE-D1, <protein-id="P39429,Q3U8L1,Q8C6X9">TRAF-2</protein-id>, <protein-id="O54926">SIVA</protein-id>, MET, <protein-id="O35732,Q5U4G3,Q812G4">FLIP</protein-id>, <protein-id="Q9WUD8,D3Z3C1">FAIM</protein-id>, IAP1, ATFA), members of transcription regulatory pathways (JNK, NF-kappaB, <protein-id="P02340,Q80ZA1,Q549C9,Q3UGQ1">P53</protein-id>), members of BCL-2 family of proteins (<protein-id="P70444">BID</protein-id>, <protein-id="Q61337,Q3U9H3">BAD</protein-id>, <protein-id="Q07813,Q544Z6">BAX</protein-id>, <protein-id="O70337">BIK</protein-id>, <protein-id="O54940,Q91VL0,G5E8U9">NIP21</protein-id>, <protein-id="O55003">NIP3</protein-id>, <protein-id="Q9Z2F7,Q91Z78">NIX</protein-id>, BCL-2), DNA damage sensor (<protein-id="Q921K2">PARP-1</protein-id>), caspases and their substrates and regulatory proteins (<protein-id="P70677">caspases 8, 4, 9, and 3</protein-id>, <protein-id="Q9JIX8,Q52KR6,Q80TU6,B8JJ91,Q7TSL7">ACINUS</protein-id>, <protein-id="O70302">CIDE-A</protein-id>, <protein-id="O70303,Q3V4D3">CIDE-B</protein-id>, <protein-id="P11862">GAS2</protein-id>), mitochondrially released factors (cytochrome c, AIF, <protein-id="Q9JL95">PRG3</protein-id>), specific endoplasmic reticulum- and oxidative stress-associated factors (<protein-id="P97303">BACH2</protein-id>, <protein-id="P00520,Q3SYK5">ABL1</protein-id>, <protein-id="Q9DBE8">ALG2</protein-id>, <protein-id="P35639,Q3V405">CHOP</protein-id>), members of cell survival <protein-id="P31750">AKT</protein-id> and HSP70 pathways (PIK3GA, <protein-id="O08586,Q3UUT8">PTEN</protein-id>, HSP70, <protein-id="Q60739,Q9CUY1">BAG1</protein-id>, <protein-id="Q91YN9">BAG2</protein-id>), and others.	P57__BAG2__no_interaction	P57__BAG1__no_interaction	P57__LTbeta-R__no_interaction	P57__ALG2__no_interaction	P57__caspases 8, 4, 9, and 3__no_interaction	P57__BAX__no_interaction	P57__AKT__no_interaction	P57__BAD__no_interaction	P57__PRG3__no_interaction	P57__GITR__no_interaction	P57__ABL1__no_interaction	P57__NIP3__no_interaction	P57__BIK__no_interaction	P57__BACH2__no_interaction	P57__BID__no_interaction	P57__ACINUS__no_interaction	P57__FLIP__no_interaction	P57__CHOP__no_interaction	P57__TRAF-2__no_interaction	P57__NIP21__no_interaction	P57__PARP-1__no_interaction	P57__SIVA__no_interaction	P57__FAIM__no_interaction	P57__CIDE-A__no_interaction	P57__CIDE-B__no_interaction	P57__DR3__no_interaction	P57__DR5__no_interaction	P57__PTEN__no_interaction	P57__NIX__no_interaction	P57__P53__no_interaction	P57__GAS2__no_interaction	NTF__BAG2__no_interaction	NTF__BAG1__no_interaction	NTF__LTbeta-R__no_interaction	NTF__ALG2__no_interaction	NTF__caspases 8, 4, 9, and 3__no_interaction	NTF__BAX__no_interaction	NTF__AKT__no_interaction	NTF__BAD__no_interaction	NTF__PRG3__no_interaction	NTF__GITR__no_interaction	NTF__ABL1__no_interaction	NTF__NIP3__no_interaction	NTF__BIK__no_interaction	NTF__BACH2__no_interaction	NTF__BID__no_interaction	NTF__ACINUS__no_interaction	NTF__FLIP__no_interaction	NTF__CHOP__no_interaction	NTF__TRAF-2__no_interaction	NTF__NIP21__no_interaction	NTF__PARP-1__no_interaction	NTF__SIVA__no_interaction	NTF__FAIM__no_interaction	NTF__CIDE-A__no_interaction	NTF__CIDE-B__no_interaction	NTF__DR3__no_interaction	NTF__DR5__no_interaction	NTF__PTEN__no_interaction	NTF__NIX__no_interaction	NTF__P53__no_interaction	NTF__GAS2__no_interaction
8864697-2	The rank order of their potency in inhibiting <compound-id="47936">forskolin</compound-id>-stimulated adenylyl cyclase was found to be: (S)-2-amino-2-methyl-<compound-id="2773805">4-phosphonobutyric acid</compound-id> (<protein-id="Q5M7W5,A0A0G2JW88">MAP4</protein-id>) &gt; (2S,1'S,2'S)-2-(2-carboxycyclopropyl)<compound-id="45934207,750">glycine</compound-id> (<compound-id="1271">L-CCG-I</compound-id>) &gt; (1S,<compound-id="21439199">3S</compound-id>)-1-<compound-id="2906">aminocyclopentane</compound-id>-1,3-<compound-id="867">dicarboxylic acid</compound-id> (1S,<compound-id="21439199">3S</compound-id>-<compound-id="1310">ACPD</compound-id>) &gt; (1S,3R)-1-<compound-id="2906">aminocyclopentane</compound-id>-1, 3-<compound-id="867">dicarboxylic acid</compound-id> (1S,3R)-<compound-id="1310">ACPD</compound-id>) &gt; (2S,1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl)<compound-id="45934207,750">glycine</compound-id> (<compound-id="5310979">DCG-IV</compound-id>) &gt; (S) -<compound-id="444578">2-methylglutamate</compound-id> ((S)-MG) &gt; L-<compound-id="23327,33032,611,57109091">glutamate</compound-id> &gt; (2S,1'S, 2'S)-2-(2-carboxycyclopropyl)<compound-id="5950,602">alanine</compound-id> (<compound-id="5311457">MCCG</compound-id>) &gt; L-<compound-id="2207">2-amino-4-phosphonobutyric acid</compound-id> (<compound-id="179394">L-AP4</compound-id>) &gt; L-<compound-id="5951">serine</compound-id>-O-<compound-id="1061,167704,644102">phosphate</compound-id> (<compound-id="194658">SOP</compound-id>).	aminocyclopentane__MAP4__no_interaction	DCG-IV__MAP4__no_interaction	2-methylglutamate__MAP4__no_interaction	alanine__MAP4__no_interaction	glycine__MAP4__no_interaction	3S__MAP4__no_interaction	4-phosphonobutyric acid__MAP4__no_interaction	MCCG__MAP4__no_interaction	2-amino-4-phosphonobutyric acid__MAP4__no_interaction	ACPD__MAP4__no_interaction	SOP__MAP4__no_interaction	forskolin__MAP4__no_interaction	L-CCG-I__MAP4__no_interaction	L-AP4__MAP4__no_interaction	phosphate__MAP4__no_interaction	dicarboxylic acid__MAP4__no_interaction	glutamate__MAP4__no_interaction	serine__MAP4__no_interaction
19248186-2	3-(2-phenylethenyl-E)-NH-<compound-id="798">indole</compound-id> (1), 3-[2-(<compound-id="119211">4-nitrophenyl</compound-id>)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (2), 5-bromo-3-[2-(<compound-id="119211">4-nitrophenyl</compound-id>)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (3), 5-<compound-id="91066389">methoxy-</compound-id>3-[2-(<compound-id="119211">4-nitrophenyl</compound-id>)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (4), 3-[2-(4-<compound-id="7505">cyanophenyl</compound-id>)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (5), <compound-id="73321644">3-[2-(4-cyanophenyl)ethenyl-E]-N-ethylindole</compound-id> (6), 5-bromo-3-[2-(4-chlorophenyl)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (7) and 5-<compound-id="91066389">methoxy-</compound-id>3-[2-(4-chlorophenyl)<compound-id="123166">ethenyl</compound-id>-E]-NH-<compound-id="798">indole</compound-id> (8) with <protein-id="P02769">bovine serum albumin</protein-id> (BSA) was examined by UV-vis and steady-state fluorescence spectroscopy.	indole__bovine serum albumin__no_interaction	methoxy-__bovine serum albumin__no_interaction	4-nitrophenyl__bovine serum albumin__no_interaction	cyanophenyl__bovine serum albumin__no_interaction	ethenyl__bovine serum albumin__no_interaction	3-[2-(4-cyanophenyl)ethenyl-E]-N-ethylindole__bovine serum albumin__no_interaction
7910716-5	Upon SC <protein-id="P17108">rIL-2</protein-id>/rIFN-alpha combination therapy, we observed mild decreases in plasma protein and albumin levels (mean nadir +/- standard deviation, 67 +/- 5 g/L and 38.8 +/- 3.9 g/L, respectively), minor albeit significant increases in serum total <compound-id="5280352">bilirubin</compound-id> levels (mean peak +/- standard deviation, 7.8 +/- 3.1 mumol/L), serum <compound-id="5960">aspartate</compound-id> aminotransferase (25.9 +/- 9.9 U/L), <compound-id="602">alanine</compound-id> aminotransferase (42.0 +/- 45.9 U/L), alkaline phosphatase (301 +/- 255 U/L), <compound-id="612">lactate</compound-id> dehydrogenase (230 +/- 64 U/L), <compound-id="193305">gamma-glutamyl</compound-id> transpeptidase (147 +/- 141 U/L) activities and triacylglyceride (2.6 +/- 0.9 mmol/L) concentrations.	bilirubin__rIL-2__no_interaction	alanine__rIL-2__no_interaction	aspartate__rIL-2__no_interaction	gamma-glutamyl__rIL-2__no_interaction	lactate__rIL-2__no_interaction
20459031-9	In PN21 and PN14, integrated optical density average of <protein-id="P15791">CaMK II</protein-id> in <protein-id="B0BNN3">CA1</protein-id>, <protein-id="P14141">CA3</protein-id> and DG regions of the hippocampus in <compound-id="807">iodine</compound-id> deficient group [PN21: (26.05 +/- 4.98), (30.79 +/- 3.22), (26.40 +/- 2.63); PN14:(25.48 +/- 4.87), (44.17 +/- 5.91), (26.41 +/- 3.01)] and 15 mg/L groups [PN21: (17.02 +/- 2.68), (24.57 +/- 6.62), (20.18 +/- 4.05); PN14:(20.66 +/- 3.51), (34.94 +/- 5.09), (27.32 +/- 4.97)] were significantly lower than those of controls [PN21: (57.75 +/- 13.22), (65.03 +/- 6.20), (49.39 +/- 8.41), P &lt; 0.05; PN14: (54.08 +/- 12.00), (71.04 +/- 5.07), (78.52 +/- 12.42), P &lt; 0.05].	iodine__CA3__no_interaction	iodine__CaMK II__no_interaction	iodine__CA1__no_interaction
23158666-10	And the following factors were relative to recurrence: elevated D-dimer (1.77 (1.34 - 2.36), P = 0.000), idiopathic PTE (1.82 (1.61 - 2.05), P = 0.000), right ventricular dysfunction (<compound-id="46934007">RVD</compound-id>) (persistent <compound-id="46934007">RVD</compound-id> vs <compound-id="46934007">RVD</compound-id> regression (8.71 (2.38 - 31.91), P = 0.001); persistent <compound-id="46934007">RVD</compound-id> vs non-<compound-id="46934007">RVD</compound-id> (2.45 (1.26 - 4.76), P = 0.008), short anticoagulation duration (1.73 (1.32 - 2.28), P = 0.000), increased endogenous <compound-id="90470996">thrombin</compound-id> generation capacity (1.89 (1.39 - 2.56), P = 0.000), elevated factor <protein-id="P10176,Q53XN1">VIII</protein-id> (1.96(1.40 - 2.74), P = 0.000), positive antiphospholipid antibodies (5.64 (4.09 - 7.77), P = 0.000), anti-<compound-id="90470996">thrombin</compound-id> defect (2.45 (1.26 - 4.76), P = 0.008) and males (1.47 (1.06 - 2.03), P = 0.020), etc.	thrombin__VIII__no_interaction	RVD__VIII__no_interaction
20009917-7	Although total (6.5 vs. -6.7%, P &lt; 0.0001) and low-density lipoprotein (LDL) (8.6 vs. -9.1%, P = 0.004) <compound-id="5997">cholesterol</compound-id> increased significantly in the abacavir/<compound-id="60825">lamivudine</compound-id> group relative to the <compound-id="464205">tenofovir</compound-id>/<compound-id="12043008,60877">emtricitabine</compound-id> group, we found no significant changes in the biomarkers: CRP (-3.9 vs. 0.0%), <protein-id="P13500">MCP-1</protein-id> (5.9 vs. 4.0%), <protein-id="O00300">osteoprotegerin</protein-id> (5.1 vs. -2.8%), IL-6 (0.0 vs. 0.0%), <protein-id="P22301,Q6FGW4">IL-10</protein-id> (0.0 vs. 0.0%), <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (0.0 vs. 0.0%), <protein-id="P05362">ICAM-1</protein-id> (6.6 vs. 5.2%), <protein-id="P19320">VCAM-1</protein-id> (0.02 vs. -0.01%), <protein-id="P16581">selectin E</protein-id> (-0.4 vs. 7.8%), <compound-id="4929">selectin</compound-id> P (4.6 vs. 12.6%), <protein-id="P01308,I3WAC9">insulin</protein-id> (-2.5 vs. 8.8%), <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (-2.2 vs. 15.4%), and D-dimer (0.0 vs. 0.0%) (P &gt; or = 0.12 for all comparisons).	lamivudine__insulin__no_interaction	lamivudine__selectin E__no_interaction	lamivudine__IL-10__no_interaction	lamivudine__adiponectin__no_interaction	lamivudine__VCAM-1__no_interaction	lamivudine__osteoprotegerin__no_interaction	lamivudine__ICAM-1__no_interaction	lamivudine__TNF-alpha__no_interaction	lamivudine__MCP-1__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__selectin E__no_interaction	emtricitabine__IL-10__no_interaction	emtricitabine__adiponectin__no_interaction	emtricitabine__VCAM-1__no_interaction	emtricitabine__osteoprotegerin__no_interaction	emtricitabine__ICAM-1__no_interaction	emtricitabine__TNF-alpha__no_interaction	emtricitabine__MCP-1__no_interaction	selectin__insulin__no_interaction	selectin__selectin E__no_interaction	selectin__IL-10__no_interaction	selectin__adiponectin__no_interaction	selectin__VCAM-1__no_interaction	selectin__osteoprotegerin__no_interaction	selectin__ICAM-1__no_interaction	selectin__TNF-alpha__no_interaction	selectin__MCP-1__no_interaction	tenofovir__insulin__no_interaction	tenofovir__selectin E__no_interaction	tenofovir__IL-10__no_interaction	tenofovir__adiponectin__no_interaction	tenofovir__VCAM-1__no_interaction	tenofovir__osteoprotegerin__no_interaction	tenofovir__ICAM-1__no_interaction	tenofovir__TNF-alpha__no_interaction	tenofovir__MCP-1__no_interaction	cholesterol__insulin__no_interaction	cholesterol__selectin E__no_interaction	cholesterol__IL-10__no_interaction	cholesterol__adiponectin__no_interaction	cholesterol__VCAM-1__no_interaction	cholesterol__osteoprotegerin__no_interaction	cholesterol__ICAM-1__no_interaction	cholesterol__TNF-alpha__no_interaction	cholesterol__MCP-1__no_interaction
23290114-10	The <compound-id="16219094">CCK-8</compound-id> results showed that cell proliferation increased with the treatment of <protein-id="P42830,Q6I9S7">CXCL5</protein-id>, but no significant difference existed (F &lt; 1.00, P &gt; 0.05), cell numbers of migration of 0, 0.1, 1.0, 10.0 nmol/L <protein-id="P42830,Q6I9S7">CXCL5</protein-id> groups were 29 ± 3, 56 ± 16, 113 ± 7 and 130 ± 15 (F = 51.94, P &lt; 0.01), while cell numbers of invasion 17.3 ± 1.8, 33.0 ± 3.2, 65.7 ± 4.4 and 94.3 ± 3.5 respectively (F = 104.13, P &lt; 0.01).	CCK-8__CXCL5__no_interaction
21713545-7	Patients with idRTA had significantly higher 2-h fasting and 24-h urine pH (2-h urine pH: 6.6 ± 0.4 vs. 5.2 ± 0.1, p = 0.001; 24-h urine pH: 6.1 ± 0.2 vs. 5.3 ± 0.3, p = 0.001), 24-h urinary <compound-id="22044544,5460341">calcium</compound-id> excretion (7.70 ± 1.75 vs. 5.69 ± 1.73 mmol/d, p = 0.02), but significantly lower 24-h urinary <compound-id="1176">urea</compound-id> excretion (323 ± 53 vs. 399 ± 114 mmol/d, p = 0.01), urinary <compound-id="311,17938267">citrate</compound-id> levels (2.32 ± 0.82 vs. 3.01 ± 0.72 mmol/d, p = 0.04) and renal <compound-id="1061,167704,644102">phosphate</compound-id> threshold normalized for the glomerular filtration rate (<compound-id="10541">TmPO</compound-id>(4)/<protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id>: 0.66 ± 0.17 vs. 0.82 ± 0.21, p = 0.03) compared to non-<protein-id="O43251">RTA</protein-id> patients.	phosphate__GFR__no_interaction	phosphate__RTA__no_interaction	calcium__GFR__no_interaction	calcium__RTA__no_interaction	TmPO__GFR__no_interaction	TmPO__RTA__no_interaction	urea__GFR__no_interaction	urea__RTA__no_interaction	citrate__GFR__no_interaction	citrate__RTA__no_interaction
20058619-9	CC-<compound-id="447041">IMT</compound-id> was positively correlated with BMI (r = 0.489, P &lt; 0.05) , TC (r = 0.429, P &lt; 0.05), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (r = 0.426, P &lt; 0.05) and HOMA-IR (r = 0.428, P &lt; 0.05).	IMT__low-density lipoprotein cholesterol__no_interaction	IMT__LDL-C__no_interaction
11510783-5	The relative abundance of the different PLA2 transcripts were <protein-id="P30041,V9HWC7">aiPLA2</protein-id> &gt; X approximately = IVA &gt; IIA approximately = <compound-id="6540268">IIE</compound-id> approximately = IVB approximately = VI &gt; IB approximately = <compound-id="6540267">IID</compound-id> approximately = III approximately = IVC approximately = VII approximately = <protein-id="Q9NP80,A0A024R746">iPLA2-2</protein-id>.	IIE__iPLA2-2__no_interaction	IIE__aiPLA2__no_interaction	IID__iPLA2-2__no_interaction	IID__aiPLA2__no_interaction
12788878-7	As expected also, circulating <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> was significantly associated with waist to <protein-id="Q06141,Q53S56">hip</protein-id> ratio (r = -0.28; P = 0.013), diastolic blood pressure (r = -0.25; P = 0.027), fasting plasma high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.35; P = 0.001), triglycerides (r = -0.37; P = 0.001), and <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (r = 0.30; P = 0.011).	cholesterol__hip__no_interaction	cholesterol__insulin__no_interaction	cholesterol__adiponectin__no_interaction
17460145-5	<protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> from month 6 (mean +/- <compound-id="5289348">SEM</compound-id>: 54.3 +/- 1.6 versus 53.9 +/- 1.5 ml/min per 1.73 m(2); P = 0.83) to month 72 after transplantation (49.5 +/- 2.2 versus 47.3 +/- 2.4 ml/min per 1.73 m(2); P = 0.50); <protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> slopes (mean +/- <compound-id="5289348">SEM</compound-id>: -1.10 +/- 0.56 versus -1.23 +/- 0.31 ml/min per 1.73 m(2) per year; P = 0.83); and 72-mo patient mortality (4.0 versus 4.0% [P = 0.95]; HR 0.96; 95% CI 0.28 to 3.31; P = 0.95), graft loss (6.8 versus 6.1% [P = 0.82]; HR 0.89; 95% CI 0.32 to 2.46; P = 0.83), incidence of persistent proteinuria (25.0 versus 27.4%; P = 0.72), late (&gt;6 mo after transplantation) rejections (25.3 versus 21.2%; P = 0.53), and adverse events were similar on <compound-id="2265">azathioprine</compound-id> (n = 124) and MMF (n = 124), respectively.	SEM__GFR__no_interaction	azathioprine__GFR__no_interaction
21349479-8	Acute <compound-id="2519,57106085">caffeine</compound-id> ingestion significantly increased FMD (patients with CAD 5.6 ± 5.0% vs 14.6 ± 5.0%, controls 8.4 ± 2.9% vs 18.6 ± 6.8%, p &lt;0.001 for all comparisons) but not NTG (patients with CAD 13.0 ± 5.2% vs 13.8 ± 6.1%, controls 12.9 ± 3.9% vs 13.9 ± 5.8%, p = NS for all comparisons) and significantly decreased high-sensitivity <protein-id="P02741">C-reactive protein</protein-id> (patients with CAD 2.6 ± 1.4 vs 1.4 ± 1.2 mg/L, controls 3.4 ± 3.0 vs 1.2 ± 1.0 mg/L, p &lt;0.001 for all comparisons) in the 2 groups compared to placebo.	caffeine__C-reactive protein__no_interaction
17216399-9	In phase 2, comparing midpoint to discharge levels in the three variables again favored <protein-id="Q15181,V9HWB5">P/F over F/P and P/P</protein-id> (&gt;0.001): QN (P/F +16.00 -/+ 8.35* F/P -13.27 -/+ 11.40), <compound-id="170325">QL</compound-id> (P/F +8.71 -/+ 4.75* F/P -6.55 -/+ 5.59), and PU (F -9.29 -/+ 4.39* P -18.00 -/+ 5.27) (*p = &lt;0.001).	QL__P/F over F/P and P/P__no_interaction
10706078-5	Statistically significant correlations were also found between steady-state blood <compound-id="77620543">CFU</compound-id>-GM and peak numbers of CD341 cells (r = 0.68, p = 0.001), numbers of day 4 CD341 cells (r = 0.52, p = 0.005), <compound-id="77620543">CFU</compound-id>-GM (r = 0.63, p = 0.002), and <protein-id="Q06124">CFC</protein-id> (r = 0.61, p = 0.003).	CFU__CFC__no_interaction
17211243-6	RESULTS: The maximal percentage of flow-mediated dilatation was reduced in detoxified alcoholics (10.1 +/- 4.6 versus 14.9 +/- 7.4, P &lt; 0.001) who also showed significantly higher blood pressure (systolic 127.5 +/- 12.9 versus 118.2 +/- 10.7 mmHg, P &lt; 0.001; diastolic 79.4 +/- 7.1 versus 74.6 +/- 6.4 mmHg, P &lt; 0.01; mean 95.4 +/- 8.2 versus 89.1 +/- 7.3 mmHg, P &lt; 0.001), <compound-id="1175">uric acid</compound-id> (5.0 +/- 1.1 versus 4.4 +/- 0.8 mg/dl, P &lt; 0.05), high-sensitivity C-reactive protein (2.1 +/- 2.0 versus 1.0 +/- 0.9 mg/l, P &lt; 0.01), <protein-id="P05305,Q6FH53">endothelin-1</protein-id> (0.38 +/- 0.11 versus 0.17 +/- 0.10 pg/ml, P &lt; 0.001) and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (10.4 +/- 4.5 versus 5.6 +/- 1.6 <compound-id="15947593">muU</compound-id>/ml, P &lt; 0.001) with abnormal homeostasis model assessment index of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (2.3 +/- 1.1 versus 1.2 +/- 0.4, P &lt; 0.001).	muU__endothelin-1__no_interaction	muU__insulin__no_interaction	uric acid__endothelin-1__no_interaction	uric acid__insulin__no_interaction
21900198-3	Survival curves of all FcγR single nucleotide polymorphisms were superimposable after <compound-id="2907">cyclophosphamide</compound-id>, doxorubicin, <compound-id="5978">vincristine</compound-id>, and <compound-id="5865">prednisone</compound-id> (<protein-id="P35638,Q53YD1">CHOP</protein-id>); but after <protein-id="P35638,Q53YD1">CHOP</protein-id> with rituximab (R-<protein-id="P35638,Q53YD1">CHOP</protein-id>), event-free survival (EFS) and progression-free survival (PFS), but not overall survival, of FcγRIIIa 158 F/F had a trend to be lower than those of 158 V/F and 158 V/V: 3-year EFS: FcγRIIIa 158 F/F: 64.5%, 158 V/F: 70.2%, 158 V/V: 76.9% (log-rank test: P = .224 F/F vs V/V; P = .285 F/F vs V/F + V/V); 3-year PFS: FcγRIIIa 158 F/F: 68.3%, V/F: 76.1%, V/V: 80.5% (log-rank test: P = .233 for F/F vs V/V; P = .185 for F/F vs V/F + V/V).	cyclophosphamide__CHOP__no_interaction	vincristine__CHOP__no_interaction	prednisone__CHOP__no_interaction
15035826-3	After treating cells with gradually increased O(2)(-), generated by the <compound-id="57266239">hypoxanthine-xanthine</compound-id> oxidase system, it was found that: (i) the proliferation of hepatoma cells firstly increased at 1-2 microM O(2)(-), then decreased markedly as the concentration increased; (2) at 8 or 16 microM O(2)(-), re-differentiation of hepatoma cells was induced, as indicated by the indices relating to cell malignancy or differentiation, such as cell surface charge, <protein-id="P02771">alpha-fetoprotein</protein-id>, gamma-glutamyltranspeptidase, <compound-id="6057,90983769">tyrosine</compound-id>-alpha-<compound-id="51">ketoglutarate</compound-id> transaminase, <protein-id="P49913,J3KNB4">cAMP</protein-id>, and the tumor's clonogenic potential; (iii) at 16 microM O(2)(-), accompanied by the re-differentiation of cells, cell apoptosis was also simultaneously induced as indicated by the appearance of apoptotic bodies, detached cells, and other apoptotic morphological features, as well as specific DNA fragmentation; (iv) at the highest concentration of O(2)(-) (32 microM) in this study, cell necrosis was dramatically induced as shown by <compound-id="5904246,5479131,6364561,5473556">Trypan blue</compound-id> exclusion; (v), an increase of intracellular Ca(2+) ([Ca(2+)](i)) was observed at all concentrations of O(2)(-) treatment, and this [Ca(2+)](i) increase was found to be involved in the regulation of O(2)(-) on the cellular processes.	Trypan blue__alpha-fetoprotein__no_interaction	Trypan blue__cAMP__no_interaction	hypoxanthine-xanthine__alpha-fetoprotein__no_interaction	hypoxanthine-xanthine__cAMP__no_interaction	ketoglutarate__alpha-fetoprotein__no_interaction	ketoglutarate__cAMP__no_interaction	tyrosine__alpha-fetoprotein__no_interaction	tyrosine__cAMP__no_interaction
12794907-3	The Mn(I)Mn(I) compound (1(-)), the mixed-valent Mn(I)Mn(II) (1), and the oxidized <compound-id="27854">Mn(II)</compound-id>Mn(II) form (1(+)) have been characterized by various analytical and spectrosopic methods, such as electrochemistry, variable-temperature EPR spectroscopy, IR spectroelectrochemistry, and UV/Vis/<protein-id="Q9Y3T9">NIR</protein-id> spectroelectrochemistry as well as by DFT and TD-DFT calculations.	Mn(II)__NIR__no_interaction
19826726-3	The molecular structures of the acetonitrile/<compound-id="962">water</compound-id> adducts 1a(NCMe)(2), 1b(NCMe)(OH(2)) and 2(NCMe)(4) reveal that L(tripp) acts as a <protein-id="O95817">Bis</protein-id>(tridentate) ligand that can support a range of structural motifs for the cationic units including [(L(tripp))CoCl(mu-Cl)CoCl(NCMe)](+), [(L(tripp))CoBr(2)CoBr(OH(2))(NCMe)](+), [(L(tripp))CoBr(mu-Br)CoBr)](+) and [(L(tripp))NiCl(NCMe)(mu-Cl)NiCl(NCMe)](+).	water__Bis__no_interaction
18722776-2	Biaryl <compound-id="795">imidazole</compound-id> ([4-(imidazol-1-yl-phenyl-methyl)-phenyl]-<compound-id="931">naphthalen</compound-id>-2-yl-amine (8), IC(50)=0.5 microM; [4-(imidazol-1-yl-phenyl-methyl)-phenyl]-<compound-id="10326">indan</compound-id>-5-yl-amine (9), IC(50)=1.0 microM) and heteroaryl <compound-id="795">imidazole</compound-id> derivatives ((1H-<compound-id="5798">benzoimidazol</compound-id>-2-yl)-{4-[(5H-imidazol-1-yl)-phenyl-methyl]-phenyl}-amine (15), IC(50)=2.5 microM; <compound-id="90934628">benzooxazol-2-yl-{4-[(5H-imidazol-1-yl)-phenyl-methyl]-phenyl}-amine</compound-id> (16), IC(50)=0.9 microM; <compound-id="90862014">benzothiazol-2-yl-{4-[(5H-imidazol-1-yl)-phenyl-methyl]-phenyl}-amine</compound-id> (17), IC(50)=1.5 microM) were the most potent <protein-id="O43174">CYP26</protein-id> inhibitors.	benzooxazol-2-yl-{4-[(5H-imidazol-1-yl)-phenyl-methyl]-phenyl}-amine__CYP26__no_interaction	indan__CYP26__no_interaction	benzoimidazol__CYP26__no_interaction	benzothiazol-2-yl-{4-[(5H-imidazol-1-yl)-phenyl-methyl]-phenyl}-amine__CYP26__no_interaction	naphthalen__CYP26__no_interaction	imidazole__CYP26__no_interaction
6872936-4	The protein that binds [3H]<compound-id="5757">estradiol</compound-id> in uterus differed from that in pancreas in a number of ways: 1) in the range of 10-20 X 10(-9) M [3H]<compound-id="5757">estradiol</compound-id>, specific binding of the hormone to uterine sites was saturable, and Scatchard analysis indicated a single class of binding sites, (approximately 0.5 pmol/mg protein) having an apparent Kd of 3 X 10(-10) M; 2) the rate constants of dissociation of the [3H] <compound-id="5757">estradiol</compound-id>-bound complexes in pancreas and uterus were 3.1 X 10(-4) <protein-id="F1MAG9">sec-1</protein-id> (t1/2, 37 min) and 8.7 X 10(-5) <protein-id="F1MAG9">sec-1</protein-id> (t1/2, 134 min), respectively; 3) the molecular weight of the estrogen-binding protein in freshly prepared uterine supernatant fractions appeared to be at least 240,000; this was unaltered regardless of whether protease inhibitors were present during initial homogenization of the tissue; and 4) when uterine supernatants prepared in the absence of protease inhibitors were kept at 8 C for 24 h and then analyzed by Sephadex G-200 chromatography, a second peak of [3H]<compound-id="5757">estradiol</compound-id>-binding activity appeared at the same eluate volume as the low molecular weight binding fractions of pancreas.	estradiol__sec-1__no_interaction
14688036-1	To examine the hypothesis that combined treatment with tracheal gas insufflation (TGI) and partial liquid ventilation (<compound-id="447949">PLV</compound-id>) may improve pulmonary outcome relative to either treatment alone in acute lung injury (ALI), saline lavage lung injury was induced in 24 anesthetized, ventilated juvenile rabbits that were then randomly assigned to receive (n = 6/group) 1) conventional mechanical ventilation (CMV) alone, 2) continuous TGI at 0.5 l/min, 3) <compound-id="447949">PLV</compound-id> with perfluorochemical liquid, and 4) combined TGI and <compound-id="447949">PLV</compound-id> (TGI + <compound-id="447949">PLV</compound-id>), and subsequently ventilated with minimized pressures and tidal volume (Vt) to keep arterial Po(2) (Pa(O(2))) &gt;100 Torr and arterial Pco(2) (Pa(CO(2))) at 45-60 Torr for 4 h. Gas exchange, lung mechanics, myeloperoxidase, <protein-id="P19874">IL-8</protein-id>, and histomorphometry [including expansion index (EI)] were assessed.	PLV__IL-8__no_interaction
7965709-2	To gain a better understanding of the roles of <protein-id="P25101">ET-A</protein-id> and ET-B receptors in nociceptive information transmission in the spinal cord, this study evaluated the effects of <protein-id="P05305,Q6FH53">ET-1</protein-id>, <protein-id="P14138,Q4FAT2">ET-3</protein-id>, <compound-id="16132429">Sarafotoxin S6c</compound-id> (an ET-B receptor-selective agonist) and (R)2-[(R)-2-[(S)-2-[[1- (hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl]amino-4-methyl-pentanoyl]amino-3- [3-(1-methyl-1H-indolyl)]propionyl]amino-<compound-id="564292">3-(2-pyridyl)propionic acid</compound-id> (<compound-id="107810">FR139317</compound-id>, an <protein-id="P25101">ET-A</protein-id> receptor-selective antagonist) on the agitation behavior evoked by <compound-id="712">formaldehyde</compound-id> solution injection and on the thermal nociceptive test.	1H-azepinyl__ET-A__no_interaction	1H-azepinyl__ET-3__no_interaction	1H-azepinyl__ET-1__no_interaction	FR139317__ET-A__no_interaction	FR139317__ET-3__no_interaction	FR139317__ET-1__no_interaction	formaldehyde__ET-A__no_interaction	formaldehyde__ET-3__no_interaction	formaldehyde__ET-1__no_interaction	Sarafotoxin S6c__ET-A__no_interaction	Sarafotoxin S6c__ET-3__no_interaction	Sarafotoxin S6c__ET-1__no_interaction	3-(2-pyridyl)propionic acid__ET-A__no_interaction	3-(2-pyridyl)propionic acid__ET-3__no_interaction	3-(2-pyridyl)propionic acid__ET-1__no_interaction
9037439-1	Metabolic studies of <compound-id="53942694">pioglitazone</compound-id> (CAS 105355-27-9, AD-4833), a new agent, in rats and dogs using liquid chromatography/tandem mass spectrometry and 1H-nuclear magnetic resonance led to characterization of the following metabolites; the parent compound, (+/-)-5-(p-hydroxybenzyl)-2-4-<compound-id="5437">thiazolidinedione</compound-id> (M-I), (+/-)-5-[p-[2-(5-<compound-id="23134249">ethyl</compound-id>-2-pyridyl)-2-hydroxyethoxy]benzyl] -2,4-<compound-id="5437">thiazolidinedione</compound-id> (M-II), (+/-)- 5-[p-[2-(<compound-id="90846000">5-acetyl-2-pyridyl</compound-id>)ethoxy]benzyl]2,4-<compound-id="5437">thiazolidinedione</compound-id> (<protein-id="E9PU01">M-III</protein-id>), (+/-)-5-[p-[2-[5-(1-hydroxyethyl)-2- pyridyl]ethoxy]benzyl]-2,4-<compound-id="5437">thiazolidinedione</compound-id> (M-IV), (+/-)-5-[p-[2-(5- carboxymethyl-2-pyridyl)ethoxy]- benzyl]-2,4-<compound-id="5437">thiazolidinedione</compound-id> (M-V), and (+/-)-5-[p-[2-(5-carboxy-2- pyridyl)ethoxy]benzyl]-2,4-<compound-id="5437">thiazolidinedione</compound-id> (M-VI).	thiazolidinedione__M-III__no_interaction	5-acetyl-2-pyridyl__M-III__no_interaction	pioglitazone__M-III__no_interaction	ethyl__M-III__no_interaction
7490159-4	Blood pressure values were normal in both groups (obese subjects: 109.2 +/- 4.9/68.2 +/- 2.7 mm Hg; lean control subjects: 108.2 +/- 4.1/60.7 +/- 3.8 mm Hg), but in addition to a marked increase in body mass index (38.5 +/- 0.8 versus 23.1 +/- 0.9 kg/m2, P &lt; .01), obese subjects showed a slight and nonsignificant increase in heart rate (71.1 +/- 3.2 versus 66.7 +/- 3.3 beats per minute, P = NS), increases in left ventricular wall thickness and left ventricular mass index (121.5 +/- 4.8 versus 103.4 +/- 3.3 kg/m2, P &lt; .01), no changes in plasma <protein-id="P00797">renin</protein-id> activity and plasma norepinephrine (compared with normal values), and a marked reduction in total body <compound-id="206,5793,64689,79025">glucose</compound-id> uptake (<compound-id="206,5793,64689,79025">glucose</compound-id> clamp technique).	glucose__renin__no_interaction
24801553-7	Analyses identified <protein-id="P14780">MMP-9</protein-id> p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.31-0.94; P = .029) as a significant confound discriminating between control vs slow-growth AAA, <protein-id="P14780">MMP-9</protein-id> D165N (OR, 0.49; 95% CI, 0.26-0.95; P = .035) and <protein-id="Q07954,Q59FG2">LRP1</protein-id> (OR, 4.99; 95% CI, 1.13-22.1; P = .034) between control vs aggressive-growth AAAs, and <compound-id="19754076">methyltetrahydrofolate</compound-id> reductase (OR, 2.99; 95% CI, 1.01-8.86; P = .048), <protein-id="P14780">MMP-9</protein-id> p-2502 (OR, 2.19; 95% CI, 1.05-4.58; P = .037), and <protein-id="Q07954,Q59FG2">LRP1</protein-id> (OR, 4.96; 95% CI, 1.03-23.9; P = .046) as the statistically significant confounds distinguishing slow-growth AAAs vs aggressive-growth AAAs.	methyltetrahydrofolate__MMP-9__no_interaction	methyltetrahydrofolate__LRP1__no_interaction
15619727-1	Three new unsymmetrical compartmental dinucleating ligands, 4-bromo-2-(<compound-id="7818">4-methylpiperazin-1-ylmethyl</compound-id>)-6-[{2-(1-piperidyl)<compound-id="23134249">ethyl</compound-id>}aminomethyl]<compound-id="996">phenol</compound-id> (<protein-id="P07306,Q6FGQ5">HL1</protein-id>), <compound-id="12131906">4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(morpholin-4-yl)ethyl}aminomethyl]phenol</compound-id> (<protein-id="P07307,Q7Z4G9">HL2</protein-id>), and <compound-id="12131907">4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(thiomorpholin-4-yl)ethyl}aminomethyl]phenol</compound-id> (<protein-id="Q14204">HL3</protein-id>), have been synthesized in order to model the active site of type 3 <compound-id="23978">copper</compound-id> proteins.	copper__HL3__no_interaction	copper__HL2__no_interaction	copper__HL1__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(morpholin-4-yl)ethyl}aminomethyl]phenol__HL3__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(morpholin-4-yl)ethyl}aminomethyl]phenol__HL2__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(morpholin-4-yl)ethyl}aminomethyl]phenol__HL1__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(thiomorpholin-4-yl)ethyl}aminomethyl]phenol__HL3__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(thiomorpholin-4-yl)ethyl}aminomethyl]phenol__HL2__no_interaction	4-bromo-2-(4-methylpiperazin-1-ylmethyl)-6-[{2-(thiomorpholin-4-yl)ethyl}aminomethyl]phenol__HL1__no_interaction	phenol__HL3__no_interaction	phenol__HL2__no_interaction	phenol__HL1__no_interaction	4-methylpiperazin-1-ylmethyl__HL3__no_interaction	4-methylpiperazin-1-ylmethyl__HL2__no_interaction	4-methylpiperazin-1-ylmethyl__HL1__no_interaction	ethyl__HL3__no_interaction	ethyl__HL2__no_interaction	ethyl__HL1__no_interaction
22849630-1	Variation of the reaction conditions with AgC≡CR (R = Ph, C(6)H(4)OCH(3)-4, (t)Bu), (t)BuPO(3)H(2), and <protein-id="Q16222">AgX</protein-id> (X = NO(3), BF(4)) as starting materials afforded four new <compound-id="23954">silver</compound-id>(I) <compound-id="6326">ethynide</compound-id> complexes incorporating the <compound-id="312546">tert-butylphosphonate</compound-id> ligand, namely, 3AgC≡CPh·Ag(2)(t)BuPO(3)·Ag(t)BuPO(3)H·2AgNO(3) (1), 2AgC≡CC(6)H(4)OCH(3)-4·Ag(2)(t)BuPO(3)·2AgNO(3) (2), [{Ag(5)(NO(3)@Ag(18))Ag(5)}((t)BuC≡C)(16)((t)BuPO(3))(4)(H(2)O)(3)][{Ag(5)(NO(3)@Ag(18))Ag(5)} ((t)BuC≡C)(16)((t)BuPO(3))(4)(H(2)O)(4)]·3SiF(6)·4.5H(2)O·3.5MeOH (3), and [{Ag(8)(Cl@Ag(14))}((t)BuC≡C)(14)((t)BuPO(3))(2)F(2)(H(2)O)(2)]BF(4)·3.5H(2)O (4).	ethynide__AgX__no_interaction	tert-butylphosphonate__AgX__no_interaction	silver__AgX__no_interaction
1916215-7	Relative in vivo biological activities, calculated from dose (30-100 ng)-response curves of mGnRH-I, cGnRH-I, <compound-id="16130955">cGnRH-II</compound-id>, [Ile8]<protein-id="P01148">LHRH</protein-id>, [D-Ala6]<protein-id="P01148">LHRH</protein-id>, [Ala4]<protein-id="P01148">LHRH</protein-id>, [Leu8]<protein-id="P01148">LHRH</protein-id>, [Ile5]<protein-id="P01148">LHRH</protein-id>, [Ile7]<protein-id="P01148">LHRH</protein-id>, [Phe3]<protein-id="P01148">LHRH</protein-id>, and [Phe2]<protein-id="P01148">LHRH</protein-id> were 1.00, 1.40, 1.81, 1.50, 4.59, 1.90, 1.28, 1.56, 0.57, 0.67, and 0.57, respectively.	cGnRH-II__LHRH__no_interaction
18201799-6	Other peptides readily predicted from the genome of T. castaneum include two AKH/HrTH peptides (Trica-<protein-id="A3RE76">AKH-1</protein-id>; pELNFSTDWamide and Trica-<protein-id="A3RE77">AKH-2</protein-id>; pELNFTPNWamide), the second of which is identical to Pyrap-AKH, an AKH-related peptide (Trica AKH-L; pEVTFSRDWPamide), two CRF-related diuretic factors (Trica-DH 37 and Trica-DH 47), the latter identical to Tenmo-DH 47, a putative antidiuretic factor (Trica-ADFb; LYDDGSYKPHVYGF-OH), two sulfakinin-like peptides (Trica-SK-1; pETSDDY(SO(3))GHLRFamide, and Trica SK-2; GEEPFDDYGHMRFamide), a potential allatostatin-C (Trica-AS; pESRYRQCYFNPISCF-OH), six allatostatin-B/myoinhibitory peptides (Trica-AST-B-1,2,3,4,5 &amp; 6; DWNKDLHIWamide, GWNNLHEGWamide, AWQSLQSGWamide, NWGQFHGGWamide, SKWDNFRGSWamide, EPAWSNLGIWamide), an <compound-id="71311646">allatotropin</compound-id>-like peptide (Trica-<compound-id="9841438">ATL</compound-id>; GIEALKYHNMDLGTARGYamide), four '<compound-id="47346">CAPA</compound-id>'-related peptides (Trica-<compound-id="47346">CAPA</compound-id>-1,2,3,4; NKLASVYALTPSLRVamide, RIGKMVSFPRIamide, PGANSGGMWFGPRLamide, SENFTPWAYIILNGEAPIIREVHYSPRLamide), <compound-id="123786">proctolin</compound-id> (RYLPT), a potential SIFamide (Trica-SIFa; TYRKPPFNGSIFamide), an <compound-id="6322,90867653">arginine</compound-id>-vasopressin-related peptide (Trica-AVP; CLITNCPRGamide) and an <protein-id="A3RE85,A3RE86,A3RE87">ITP</protein-id>-related peptide (Trica-<protein-id="A3RE85,A3RE86,A3RE87">ITP</protein-id>).	ATL__AKH-2__no_interaction	ATL__AKH-1__no_interaction	ATL__ITP__no_interaction	allatotropin__AKH-2__no_interaction	allatotropin__AKH-1__no_interaction	allatotropin__ITP__no_interaction	CAPA__AKH-2__no_interaction	CAPA__AKH-1__no_interaction	CAPA__ITP__no_interaction	arginine__AKH-2__no_interaction	arginine__AKH-1__no_interaction	arginine__ITP__no_interaction	proctolin__AKH-2__no_interaction	proctolin__AKH-1__no_interaction	proctolin__ITP__no_interaction
16967087-1	The investigations included: 1/ Establishment of culture systems that would maintain the three-dimensional structure of bovine intact early <compound-id="35864">antral</compound-id> follicles (EAF) or isolated cumulus-oocyte-granulosa complexes (COCGs) and increase the resulting portion of cumulus-oocyte complexes (<compound-id="24836920">COCs</compound-id>) with normal morphology for subsequent in vitro maturation (IVM) and in vitro fertilization (IVF), 2/ Quality assessment of IVM bovine oocytes and resulting day-8 blastocysts produced in TCM199 medium supplemented with fetal bovine serum (FBS), fatty acid free bovine serum <protein-id="P02769">albumin</protein-id> (fafBSA) or <compound-id="6917">polyvinylpyrrolidone</compound-id> (PVP40), 3/ Testing the polymorphism of the genes: <compound-id="445354">retinol</compound-id> binding protein (<protein-id="P27485">RBP4</protein-id>), epidermal growth factor (EGF), <protein-id="O62698,F1MNI5">prostaglandin-endoperoxide synthase 2</protein-id> (<protein-id="O62698,F1MNI5">PTGS2</protein-id>), <protein-id="P07456,B8QGI3">insulin-like growth factor 2</protein-id> (<protein-id="P23695,G9BFT5">IGF2</protein-id>), <protein-id="F1MEV4,A5PJE7">amphiregulin</protein-id> (<protein-id="Q9BDH4">AREG</protein-id>) and <protein-id="P01239">prolactin</protein-id> (<protein-id="P01239">PRL</protein-id>), and their effects on reproductive traits in swine.	antral__IGF2__no_interaction	antral__PTGS2__no_interaction	antral__albumin__no_interaction	antral__amphiregulin__no_interaction	antral__PRL__no_interaction	antral__prolactin__no_interaction	antral__RBP4__no_interaction	antral__insulin-like growth factor 2__no_interaction	antral__prostaglandin-endoperoxide synthase 2__no_interaction	antral__AREG__no_interaction	COCs__IGF2__no_interaction	COCs__PTGS2__no_interaction	COCs__albumin__no_interaction	COCs__amphiregulin__no_interaction	COCs__PRL__no_interaction	COCs__prolactin__no_interaction	COCs__RBP4__no_interaction	COCs__insulin-like growth factor 2__no_interaction	COCs__prostaglandin-endoperoxide synthase 2__no_interaction	COCs__AREG__no_interaction	retinol__IGF2__no_interaction	retinol__PTGS2__no_interaction	retinol__albumin__no_interaction	retinol__amphiregulin__no_interaction	retinol__PRL__no_interaction	retinol__prolactin__no_interaction	retinol__RBP4__no_interaction	retinol__insulin-like growth factor 2__no_interaction	retinol__prostaglandin-endoperoxide synthase 2__no_interaction	retinol__AREG__no_interaction	polyvinylpyrrolidone__IGF2__no_interaction	polyvinylpyrrolidone__PTGS2__no_interaction	polyvinylpyrrolidone__albumin__no_interaction	polyvinylpyrrolidone__amphiregulin__no_interaction	polyvinylpyrrolidone__PRL__no_interaction	polyvinylpyrrolidone__prolactin__no_interaction	polyvinylpyrrolidone__RBP4__no_interaction	polyvinylpyrrolidone__insulin-like growth factor 2__no_interaction	polyvinylpyrrolidone__prostaglandin-endoperoxide synthase 2__no_interaction	polyvinylpyrrolidone__AREG__no_interaction
22178778-5	The final model consisted of seven independent predictors of ORFs: [lowest quartile (Q(1)) vs highest quartile (Q(4))] physical activity score (Q(1) vs Q(4): ≤12.61 vs ≥15.38); relative risk estimate [RR], 2.87; (95% confidence interval [CI]: 1.88-4.38); age≥60 years vs age&lt;60 years (RR=2.43; 95% CI: 1.49-3.95); hand grip strength (Q(1) vs Q(4): ≤13.88 vs ≥17.28 kg) (RR=1.88; 95% CI: 1.15-3.05); BMD total <protein-id="P47914">hip</protein-id> (Q(1) vs Q(4): ≤0.784 vs 0.973 g/cm(2)) (RR=1.86; 95% CI: 1.26-2.75); dietary <compound-id="22044544,5460341">calcium</compound-id> intake (Q(1) vs Q(4): ≤391 vs ≥648 mg/day) (RR=1.66; 95% CI: 1.08-2.53); serum 25(OH)D (Q(1) vs Q(4): ≤17.9 vs ≥45.1 nmol/L) (RR=1.63; 95% CI: 1.06-2.51); and past year history of falls (RR=1.61; 95% CI: 1.06-2.48).	calcium__hip__no_interaction
3142396-6	The results show: 1--A similar antihypertensive effect for MD and <protein-id="Q9GZY6">LAB</protein-id>, but significantly less for ACE (initial <compound-id="19805081,5492869">PAD</compound-id>-37th week <compound-id="19805081,5492869">PAD</compound-id>: MD +/- 18.8 +/- 2; <protein-id="Q9GZY6">LAB</protein-id> = -17.9 +/- 3; ACE = - 8.2 +/- 2.7 mmHg, p less than 0.02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or <protein-id="Q9GZY6">LAB</protein-id> (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; <protein-id="Q9GZY6">LAB</protein-id> = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645.	PAD__LAB__no_interaction
15853419-3	From the respective one-electron oxidation potentials collected in aqueous solution at pH 6.4 for <compound-id="1175">uric acid</compound-id> (E = +0.686 vs normal <compound-id="783">hydrogen</compound-id> electrode, <protein-id="Q4G0N8">NHE</protein-id>), <compound-id="1188">xanthine</compound-id> (E = +1.106 vs <protein-id="Q4G0N8">NHE</protein-id>), and <compound-id="790">hypoxanthine</compound-id> (E = +1.654 vs <protein-id="Q4G0N8">NHE</protein-id>), the overall free energy changes for electron transfer from the quencher to the triplet-excited <compound-id="493570">riboflavin</compound-id> are as follows: <compound-id="1175">uric acid</compound-id> (DeltaG(o) = -114 kJ mol(-1)), <compound-id="1188">xanthine</compound-id> (DeltaG(o) = -73.5 kJ mol(-1)), <compound-id="790">hypoxanthine</compound-id> (DeltaG(o) = -20.6 kJ mol(-1)), and purine (DeltaG(o) &gt; 0).	riboflavin__NHE__no_interaction	hypoxanthine__NHE__no_interaction	hydrogen__NHE__no_interaction	uric acid__NHE__no_interaction	xanthine__NHE__no_interaction
11600523-11	Moreover, after <compound-id="4091">metformin</compound-id> therapy, hyperandrogenemia and hyperinsulinemia were normalized, and <compound-id="206,5793,64689,79025">glucose</compound-id> utilization improved [obese before: total T, 0.9 +/- 0.15 ng/ml; fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, 22.2 +/- 12.1 U/liter; <compound-id="206,5793,64689,79025">glucose</compound-id> utilization, 2.15 +/- 0.5 mg/kg.min; obese after: total T, 0.5 +/- 0.2 ng/ml; fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, 11.6 +/- 6 U/liter; <compound-id="206,5793,64689,79025">glucose</compound-id> utilization, 4.7 +/- 1.4 mg/kg.min 9P &lt; 0.003, P &lt; 0.006, and P &lt; 0.002, respectively); nonobese before: total T, 1 +/- 0.5 ng/ml; fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, 15.5 +/- 7.6 U/liter; <compound-id="206,5793,64689,79025">glucose</compound-id> utilization, 3.4 +/- 0.7 mg/kg.min; nonobese after: total T, 0.8 +/- 0.5 ng/ml; fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, 9 +/- 3.8 U/liter; <compound-id="206,5793,64689,79025">glucose</compound-id> utilization, 6 +/- 1.7 mg/kg.min (P &lt; 0.04, P &lt; 0.02, and P &lt; 0.0008, respectively)].	metformin__insulin__no_interaction	glucose__insulin__no_interaction
10510546-2	METHODS: In 33 pregnant women where based on the <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test (75 g <compound-id="206,5793,64689,79025">glucose</compound-id>) GDM was revealed, repeatedly <protein-id="P02675,V9HVY1">fibrinogen</protein-id> values were assessed (FBG 4.38 +/- 0.98 g/l), the <protein-id="P01008,A0A024R944">antithrombin III</protein-id> activity (<protein-id="P01008,A0A024R944">ATIII</protein-id>% 103.83 +/- 14.9), <protein-id="P00750">t-PA</protein-id> Ag(4.82 +/- 3.35 ng/ml), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> Ag (158.04 +/- 57.7 ng/ml), D-dimer (234.99 +/- 455.36 ng/ml), plasma proteins-orosomucoid (ORM 0.506 +/- 0.14 g/l), <protein-id="P02741">C reactive protein</protein-id> (1.34 +/- 0.96 g/l), <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> (3.77 +/- 0.79 g/l), prealbumin (1.86 +/- 0.83 g/l) and <protein-id="P01023">alpha-2-macroglobulin</protein-id> (A2M 2.01 +/- 0.62 g/l) and cytadhesive molecules sICAM-1 (230.8 +/- 57.76 ng/ml) and sE-<compound-id="4929">selectin</compound-id> (35.50 +/- 16.55 ng/ml).	selectin__ATIII__no_interaction	selectin__alpha-2-macroglobulin__no_interaction	selectin__fibrinogen__no_interaction	selectin__t-PA__no_interaction	selectin__transferrin__no_interaction	selectin__antithrombin III__no_interaction	selectin__C reactive protein__no_interaction	selectin__PAI-1__no_interaction	glucose__ATIII__no_interaction	glucose__alpha-2-macroglobulin__no_interaction	glucose__fibrinogen__no_interaction	glucose__t-PA__no_interaction	glucose__transferrin__no_interaction	glucose__antithrombin III__no_interaction	glucose__C reactive protein__no_interaction	glucose__PAI-1__no_interaction
9626116-5	Despite comparable <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations, both OH and OB groups had significant hyperinsulinemia (OH &gt; OB), both basally and after iv <compound-id="206,5793,64689,79025">glucose</compound-id> stimulation, as compared to LN controls (basal <protein-id="P01308,I3WAC9">insulin</protein-id>: OH, 252 +/- 52 pmol/L; OB, 145 +/- 41; LN, 60 +/- 9, P = 0.009 OH vs. LN; peak <protein-id="P01308,I3WAC9">insulin</protein-id>: OH, 2052 +/- 417; OB, 1109 +/- 127, LN, 480 +/- 120, P = 0.0009 OH vs. LN).	glucose__insulin__no_interaction
16024716-6	<protein-id="P06850">Corticotropin-releasing hormone</protein-id>-induced cortisol and <protein-id="P01189,Q6FHC8">ACTH</protein-id> AUC were not different in C vs. R after the sixth R&amp;R. There were no differences among treatments in <protein-id="P00738,Q6PEJ8,A0A0C4DGL8">haptoglobin</protein-id>, <protein-id="P02675,V9HVY1">fibrinogen</protein-id>, and concanavalin A-induced interferon-gamma after the first, third, and sixth R&amp;R. <protein-id="P02768">Albumin</protein-id>, <compound-id="1176">urea</compound-id>, and <protein-id="P80303,V9HW75">NEFA</protein-id> were greater (P &lt; 0.05) in R than C steers after the first R&amp;R. beta-Hydroxy-<compound-id="264">butyrate</compound-id> and <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations were greater (P &lt; 0.05) in R than C, whereas no changes in the protein and globulin concentrations were found in C vs. R after the sixth R&amp; R. White blood cell, differential and total count, red blood cell, and platelet numbers did not differ in C vs. R after the first and third R&amp;R. Lymphocyte numbers and mean corpuscular volume were greater (P &lt; 0.05) in R than C steers after the sixth R&amp;R. Monocyte numbers were greater (P &lt; 0.05) in R than C steers following first R&amp;R. There was no difference in the overall ADG in C vs. R; however, there was a tendency (P = 0.10) for lesser ADG by R than C steers following second R&amp; R. In conclusion, steers exposed to R&amp;R responded with increased plasma cortisol, <protein-id="P02768">Albumin</protein-id>, <compound-id="1176">urea</compound-id>, and <protein-id="P80303,V9HW75">NEFA</protein-id>.	butyrate__Albumin__no_interaction	butyrate__NEFA__no_interaction	butyrate__fibrinogen__no_interaction	butyrate__haptoglobin__no_interaction	butyrate__ACTH__no_interaction	butyrate__Corticotropin-releasing hormone__no_interaction	urea__Albumin__no_interaction	urea__NEFA__no_interaction	urea__fibrinogen__no_interaction	urea__haptoglobin__no_interaction	urea__ACTH__no_interaction	urea__Corticotropin-releasing hormone__no_interaction	glucose__Albumin__no_interaction	glucose__NEFA__no_interaction	glucose__fibrinogen__no_interaction	glucose__haptoglobin__no_interaction	glucose__ACTH__no_interaction	glucose__Corticotropin-releasing hormone__no_interaction
19349670-6	RESULTS: After modified super-long down-regulation, (1) in endometriosis patients, the average gonadotropin (Gn) used was (32.33 +/- 15.11) ampoules, duration of medication was (10.57 +/- 1.88) days, the <compound-id="5994">progesterone</compound-id> (P) level on <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id> day was (0.78 +/- 0.44) microg/L, and the clinical pregnancy rate (CPR) was 73.8%; (2) in PCOS patients, the average Gn used was (28.57 +/- 12.07) ampoules, the duration of medication was (11.71 +/- 2.07) days, the P level at <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id> day was (0.65 +/- 0.39) microg/L, and the clinical pregnancy rate was 65.7%; (3) in insufficient down-regulation patients, the average Gn used was (26.22 +/- 12.07) ampoules, the duration of medication was (10.01 +/- 1.77) days, the P level at <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id> day was (0.71 +/- 0.50) microg/L, and the clinical pregnancy rate was 72.7%.	progesterone__hCG__no_interaction
9237784-4	<protein-id="P01308,I3WAC9">C-peptide</protein-id> levels were significantly (P &lt; 0.05) correlated with systolic (r = 0.21) and diastolic blood pressure (r = 0.19), BMI (r = 0.21), high density lipoprotein (HDL) (r = -0.22), non-HDL-<compound-id="5997">cholesterol</compound-id> (r = 0.23), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.29), log of triglycerides (r = 0.39) and <compound-id="1175">uric acid</compound-id> (r = 0.35).	uric acid__apolipoprotein B__no_interaction	uric acid__C-peptide__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__C-peptide__no_interaction
18271959-7	The serum levels of <compound-id="5997">cholesterol</compound-id> (97.00+26.02 vs. 114.78 +/- 37.72 mg/dl), TG (153.41 +/- 80.39 vs. 324.39 +/- 134.9 mg/dl; p &lt; 0.01), HDL (20.45 +/- 5.14 vs. 55.15 +/- 17.47 mg/dl; p &lt; 0.001) and <protein-id="P60042">somatostatin</protein-id> (1.32 +/- 0.31 vs. 1.59 +0.37 mg/dl) decreased, whereas LDL (37.83 +/- 15.39 vs. 16.77 +/- 6.81 mg/dl; p &lt; 0.001) and LBP (308.47 +/- 194.53 vs. 60.27 +/- 42.96 ng/ml; p &lt; 0.001) increased.	cholesterol__somatostatin__no_interaction
18399713-10	RESULTS: Factorial ANOVA revealed an independent impact of the <protein-id="P11712,S5RV20">CYP2C9</protein-id> genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the <protein-id="Q9Y6L6,Q05CV5,A0A024RAU7">SLCO1B1</protein-id> genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p&lt;0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p&lt;0.01) on disposition of <compound-id="41781">torasemide</compound-id>.	torasemide__CYP2C9__no_interaction	torasemide__SLCO1B1__no_interaction
19642374-7	The total protein was (76.4 +/- 5.0) g/L vs. (78.4 +/- 5.6)g/L (t = 3.83, P &lt; 0.01), <protein-id="P02768">albumin</protein-id> was (45.7 +/- 3.1) g/L vs. (47.3 +/- 2.9)g/L (t = 5.24, P &lt; 0.01), serum <compound-id="23925,67172434">iron</compound-id> was ( 10.3 +/- 4.1) micromol/L vs. (12.7 +/- 4.6) micromol/L (t = 5.48, P &lt; 0.01), and saturation of <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> was (19.0 +/- 7.6)% vs. (23.1 +/- 9.1) % (t = 4.90, P &lt; 0.01), respectively.	iron__albumin__no_interaction	iron__transferrin__no_interaction
21488144-5	RESULTS: The Spearman coefficient between serum <compound-id="5462224">magnesium</compound-id> and the first and second phases of <protein-id="P01308,I3WAC9">Insulin</protein-id> secretion showed a significant positive correlation in the overall (r = 0.265, p &lt; 0.0005; r = 0.541, p &lt; 0.0005), normal <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (r = 0.369, p = 0.001; r = 0.618, p &lt; 0.0005), impaired fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.320, p = 0.02; r = 0.449, p = 0.001), and impaired <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (r = 0.129, p = 0.37; r = 0.522, p &lt; 0.0005) groups.	magnesium__Insulin__no_interaction	glucose__Insulin__no_interaction
9112243-6	Compared to the anterior compartment mass, the posterior compartment mass displayed stronger relationship with <protein-id="P01308,I3WAC9">insulin</protein-id>-mediated <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (Rd) (r = -0.44, p = 0.009, and r = -0.76, p = 0.0001, respectively) as well as with residual hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> output during the 40 mU.m-2.min-1 <protein-id="P01308,I3WAC9">insulin</protein-id> infusion (r = 0.39, p = 0.02, and r = 0.53, p = 0.001, respectively).	glucose__insulin__no_interaction
21463548-7	RESULTS: Arterial and venous concentrations of all factors analysed showed no statistical difference (all p values &gt; 0.1); <protein-id="P41159,A4D0Y8">leptin</protein-id> A: 39 ± 16 vs. V: 42 ± 18 ng/mL; total <compound-id="44576256">ghrelin</compound-id> A : 0.86 ± 0.27 vs. V : 0.76 ± 0.35 ng/mL; <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> A: 7.7 ± 3.3 vs. V: 7.7 ± 3.6 μg/mL; insulin A: 17.9 ± 9.7 vs. V: 18.6 ± 10.5 μU/mL; <compound-id="206,5793,64689,79025">glucose</compound-id> A: 8.3 ± 2.1 vs. V: 7.9 ± 2.2 mM; NEFA A: 0.98 ± 0.93 vs. V: 0.89 ± 0.38 mM ; hs-CRP A: 10.17 ± 7.68 vs. V: 10.27 ± 7.30 μg/mL and NT-proBNP A: 54.3 ± 47.9 vs. V: 54.7 ± 49.3 pg/mL.	ghrelin__leptin__no_interaction	ghrelin__adiponectin__no_interaction	glucose__leptin__no_interaction	glucose__adiponectin__no_interaction
24929766-5	RESULTS: Among 33 clinicolaboratory characteristics, receiver operating characteristic (ROC) curve analyses selected 12 characteristics with recommended cutoff values such as HCO(3)(-) (≤19.8/&gt;19.8; mEq/L), base excess (≤-5.35/&gt;-5.35; mEq/L), diastolic blood pressure (≤48/&gt;48 mmHg), mean arterial pressure (≤73/&gt;73 mmHg), pH (≤7.29/&gt;7.29), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (≤19,150/&gt;19,150 pg/dL), prothrombin time-International Normalized Ratio (PT-INR; ≤2.05/&gt;2.05), predictive value of Acute Physiology and Chronic Health Evaluation II (APACHE II; ≤0.4/&gt;0.4), <compound-id="1060">pyruvate</compound-id> (≤1.82/&gt;1.82 mg/dL), APACHE II score (≤21/&gt;21), <compound-id="176">acetate</compound-id>/<compound-id="1060">pyruvate</compound-id> ratio (≤19/&gt;19), and <compound-id="176">acetate</compound-id> (≤44.8/&gt;44.8 mg/dL) on the basis of large area under the ROC curves for 28-day mortality.	pyruvate__interleukin-6__no_interaction	acetate__interleukin-6__no_interaction
15847025-10	Small dense LDL showed a positive correlation with fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.252, p = 0.023), HbA1c (r = 0.281, p = 0.012), total <compound-id="5997">cholesterol</compound-id> (r = 0.443, p &lt; 0.001), triglycerides(r = 0.685, p &lt; 0.001), LDL(r = 0.342, p = 0.002), total <compound-id="5997">cholesterol</compound-id>/<protein-id="P28845,X5D2L1">HDL</protein-id> ratio (r = 0.660, p = &lt; 0.001) and triglycerides/<protein-id="P28845,X5D2L1">HDL</protein-id> ratio(r = 0.728, p &lt; 0.001) and a negative correlation with <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (r = -0.341, p = 0.002) and QUICKI values (r = -0.260, p = 0.019).	cholesterol__HDL__no_interaction	glucose__HDL__no_interaction
3537630-4	Fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (FPG), immunoreactive <protein-id="P01308,I3WAC9">insulin</protein-id> (IRI), and C-peptide were significantly lower in AN as compared to NC (84.3 +/- 1.5 v 91.5 +/- 1.7 mg dL-1, 9.3 +/- 1.0 v 13.5 +/- 1.4 microU mL-1, and 0.26 +/- 0.03 v 0.41 +/- 0.02 pmol mL-1) (P less than 0.05).	glucose__insulin__no_interaction
3537630-5	During the <compound-id="206,5793,64689,79025">glucose</compound-id> clamp, the <compound-id="206,5793,64689,79025">glucose</compound-id> metabolized (M), the metabolic clearance rate of <compound-id="206,5793,64689,79025">glucose</compound-id> (MCRg), and the <compound-id="206,5793,64689,79025">glucose</compound-id> metabolized per unit of <protein-id="P01308,I3WAC9">insulin</protein-id> (M/I ratio) were all higher in AN as compared to NC (M, 8.7 +/- 1.2 v 6.9 +/- 0.6 mg min-1 kg-1; MCRg, 9.9 +/- 1.5 v 7.4 +/- 0.6 mL min-1 kg-1; M/I ratio, 8.6 +/- 1.6 v 5.0 +/- 0.3 mg min-1 kg-1/microU mL-1 X 100), but only the M/I ratio attained statistical significance (P less than 0.05).	glucose__insulin__no_interaction
21162838-4	RESULTS: (1) Compared with exposure group, the GLB in control group was higher (β = -0.16, t = -2.30, P = 0.02), but the A/G in control group was lower (β = 0.14, t = 2.09, P = 0.04); (2) Compared with the persons who carried <compound-id="7010588">QQ</compound-id> genotype, the accumulative symptom scores were lower in the persons who carried RR genotype (t = -2.78, P = 0.006); (3) Compared with <protein-id="P30711,A0A0G2JRN4,Q4W251,A0A0G2JRQ5,Q4GZS9">GST T1</protein-id> carriers, non-carriers' GLB (β = -0.20, t = -3.01, P = 0.00) and IgG (β = -0.20, t = -3.01, P = 0.00) were higher, but the A/G was lower; (4) The abnormities of cardiograms among people who had been exposed to pesticides were higher compared to people who did not expose to any pesticides (β = 1.147, P = 0.042).	QQ__GST T1__no_interaction
19258676-6	RESULTS: there were significant differences between case and control group for BMI (body mass index) (30.2 +/- 4.1 vs 26.9 +/- 4.7 kg/m2), waist circumference (93.5 +/- 7.9 vs 84.4 +/- 11.5 cm), triglyceride (207.4 +/- 101.8 vs. 119.3 +/- 71.5 mg/dL) , HDL <compound-id="5997">cholesterol</compound-id> (48.6 +/- 9.4 vs. 59.9 +/- 11.8m g/dL), systolic blood pressure (132.8 +/- 17.9 mmHg vs 120.6 +/- 13.5 mmHg) and diastolic blood pressure (83.8 +/- 8.5 mmHg vs. 79.4 +/- 10.7), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (128.3 +/- 40.8 mg/dL vs. 100.7 +/- 29.4 mg/dL), HOMA index (6.7 +/- 17.4 vs. 2.0 +/- 2.0) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (3.8 +/- 1.4 vs. 5.9 +/- 2.5), respectively.	glucose__adiponectin__no_interaction	cholesterol__adiponectin__no_interaction
7491996-5	RESULTS: Unpacking resulted in a significant increase in CI (3.1 +/- 0.4 to 4.2 +/- 0.6 L/min/m2), <compound-id="160603">DO2</compound-id> (539 +/- 41 to 689 +/- 43 mL min/m2), <protein-id="Q99999,A0A024R1D7">CST</protein-id> (26 +/- 6 to 36 +/- 4 mL/cm H2O), and PaO2/FiO2 (162 +/- 44 to 237 +/- 53 cm H2O), as well as a significant decrease in PAP (47 +/- 9 to 29 +/- 6 cm H2O), MAP (34 +/- 4 to 27 +/- 3 cm H2O), PCWP (21 +/- 4 to 13 +/- 3 mm Hg), and SVR (1,239 +/- 162 to 887 +/- 130 dyne/<compound-id="5327073">cm5</compound-id>).	DO2__CST__no_interaction	cm5__CST__no_interaction
21581166-1	The title compound, [Fe(C(10)H(20)O(5))(H(2)O)(2)][Fe(2)(C(4)N(2)S(2))(4)]·2C(10)H(20)O(5), consists of an [Fe(II)(<compound-id="36336">15-crown-5</compound-id>)(H(2)O)(2)](2+) cation, sandwiched between and O-H⋯O <compound-id="783">hydrogen</compound-id> bonded by two additional <compound-id="36336">15-crown-5</compound-id> ether mol-ecules and two independent [Fe(III)(mnt)(2)](-) anions, where <compound-id="36336">15-crown-5</compound-id> ether denotes 1,4,7,10,13-penta-oxacyclo-penta-decane and mnt denotes <protein-id="Q9NSE2">cis-1</protein-id>,2-dicyano-1,2-<compound-id="23134249">ethyl</compound-id>-enedithiol-ate.	15-crown-5__cis-1__no_interaction	hydrogen__cis-1__no_interaction	ethyl__cis-1__no_interaction
24063409-1	Three seven-coordinate lanthanide(III) sandwich-type mononuclear complexes with π-conjugated <protein-id="Q15669,Q6ICP4">TTF</protein-id>-<compound-id="86573619">Schiff base</compound-id> ligand H2L (L(2-) = 2,2'-((2-(4,5-bis(methylthio)-1,3-dithiol-2-ylidene)-1,3-<compound-id="12246284">benzodithiole</compound-id>-5,6-diyl)bis(nitrilomethylidyne)bis(<compound-id="4684">4-chlorophenolate</compound-id>)) and the tripodal ligand L(<compound-id="6324">OEt</compound-id>)(-) (L(<compound-id="6324">OEt</compound-id>)(-) = [(η(5)-C5H5)Co(P(═O)(<compound-id="6324">OEt</compound-id>)2)3](-)), [(L(<compound-id="6324">OEt</compound-id>))Ln(L)]·0.25H2O (Ln(3+) = Dy(3+), 1; Tb(3+), 2; <protein-id="P49590,B4DDN8">Ho(3+), 3</protein-id>), have been synthesized and structurally characterized.	Schiff base__Ho(3+), 3__no_interaction	Schiff base__TTF__no_interaction	benzodithiole__Ho(3+), 3__no_interaction	benzodithiole__TTF__no_interaction	4-chlorophenolate__Ho(3+), 3__no_interaction	4-chlorophenolate__TTF__no_interaction	OEt__Ho(3+), 3__no_interaction	OEt__TTF__no_interaction
7713154-3	Results indicate that <compound-id="2419">BMY 7378</compound-id> is selective for the <protein-id="P23944">alpha 1d-adrenoceptor</protein-id> subtype (pKi: hamster alpha 1b-adrenoceptor 6.2 +/- 0.03, human alpha 1b-adrenoceptor 7.2 +/- 0.05; bovine alpha 1c-adrenoceptor 6.1 +/- 0.02, human alpha 1c-adrenoceptor 6.6 +/- 0.20; rat <protein-id="P23944">alpha 1d-adrenoceptor</protein-id> 8.2 +/- 0.06, human <protein-id="P23944">alpha 1d-adrenoceptor</protein-id> 9.4 +/- 0.05) and has high affinity (pA2, 8.9 +/- 0.1) for rat aorta alpha 1-adrenoceptor.	BMY 7378__alpha 1d-adrenoceptor__no_interaction
22992795-2	The penetration hardness derived from fundamental crystallo-chemical data (confirmed by experimental determinations) proved to be far lower in MS(2) (M = Mo, W) than in <compound-id="5462310">graphite</compound-id> and hexagonal BN, both for H(max) (H(graph)/H(MoS2) = 3.85; H(graph)/H(<protein-id="O75030,Q8WYR3,A0A087WXU1,B4DNC7">WS2</protein-id>) = 3.60; H(hBN)/H(MoS2) = 2.54; H(hBN)/H(<protein-id="O75030,Q8WYR3,A0A087WXU1,B4DNC7">WS2</protein-id>) = 2.37) as well as for H(min) (H(graph)/H(MoS2) = 6.22; H(graph)/H(<protein-id="O75030,Q8WYR3,A0A087WXU1,B4DNC7">WS2</protein-id>) = 5.87; H(hBN)/H(MoS2) = 4.72; H(hBN)/H(<protein-id="O75030,Q8WYR3,A0A087WXU1,B4DNC7">WS2</protein-id>) = 4.46).	graphite__WS2__no_interaction
20371226-3	In our study we evaluated the role of a non-specific mGlu receptor agonist ((1S,3R)-<compound-id="1310">1-aminocyclopentane-1,3-dicarboxylic acid</compound-id>; 1S,3R-ACPD), mGlu5 receptor agonist or positive modulators ((<compound-id="7021454">RS</compound-id>)-<compound-id="1800613">2-Chloro</compound-id>-5-<compound-id="20468917">hydroxyphenylglycine</compound-id>;CHPG; [(3-<compound-id="10008">Fluoro-phenyl</compound-id>)<compound-id="123164">methylene</compound-id>]hydrazone-<compound-id="68009">3-fluorobenzaldehyde</compound-id>; DFB; 3-Cyano-<compound-id="4156919">N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide</compound-id>; <compound-id="11245456">CDPPB</compound-id>) and a mGlu2/3 receptor agonist (2,2,2-Trifluoro-N-[4-(2-methoxyphenoxy)phenyl]-N-(3-pyrdinylmethyl)ethanesulfonamide hydrochloride; <compound-id="9825084">LY-487379</compound-id>) on performance in a cognitive <protein-id="O14649">task</protein-id> (Active Allothetic Place Avoidance) after sub-chronic administration of 5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)-cyclo-<compound-id="11610">hepten</compound-id>-5,10-imine; <compound-id="1207">MK-801</compound-id> .	3-fluorobenzaldehyde__task__no_interaction	RS__task__no_interaction	N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide__task__no_interaction	LY-487379__task__no_interaction	CDPPB__task__no_interaction	MK-801__task__no_interaction	hydroxyphenylglycine__task__no_interaction	2-Chloro__task__no_interaction	1-aminocyclopentane-1,3-dicarboxylic acid__task__no_interaction	Fluoro-phenyl__task__no_interaction	methylene__task__no_interaction	hepten__task__no_interaction
12690090-9	In the obese group, plasma ratios of <compound-id="173183,23424736,312822,5283637,6428659">campesterol</compound-id> correlated inversely with VLDL-<protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> secretion (r = -0.359, p &lt; 0.05), VLDL-<protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (r = -0.513, p &lt; 0.01) and IDL-<protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (r = -0.511, p &lt; 0.01) pool size, and plasma <compound-id="65728">lathosterol</compound-id> ratio (r = -0.366, p &lt; 0.05).	lathosterol__apoB__no_interaction	campesterol__apoB__no_interaction
11327896-1	Disulfide-bridged dinuclear <compound-id="23950">ruthenium</compound-id> complexes [[Ru(<compound-id="6342">MeCN</compound-id>)(P(OMe)(3))(2)](2)(mu-X)(mu,<protein-id="Q9UNA4">eta(2</protein-id>)-S(2))][ZnX(3)(<compound-id="6342">MeCN</compound-id>)] (X = Cl (2), Br (4)), [[Ru(<compound-id="6342">MeCN</compound-id>)(P(OMe)(3))(2)](2)(mu-Cl)(2)(mu,<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta(1</protein-id>)-S(2))](CF(3)SO(3)) (5), [[Ru(<compound-id="6342">MeCN</compound-id>)(P(OMe)(3))(2)](2)(mu-Cl)(mu,<protein-id="Q9UNA4">eta(2</protein-id>)-S(2))](BF(4)) (6), and [[Ru(<compound-id="6342">MeCN</compound-id>)(2)(P(OMe)(3))(2)](2)(mu-Cl)(mu,<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta(1</protein-id>)-S(2))](CF(3)SO(3))(3) (7) were synthesized, and the crystal structures of 2 and 4 were determined.	ruthenium__eta(1__no_interaction	ruthenium__eta(2__no_interaction	MeCN__eta(1__no_interaction	MeCN__eta(2__no_interaction
9845654-7	RESULTS: <protein-id="P01308,I3WAC9">insulin</protein-id> stimulated VSMC growth at <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations more than 0.2% (0.4% <compound-id="206,5793,64689,79025">glucose</compound-id> with no added <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 13,073 +/- 336 cells/mL, 0.4% <compound-id="206,5793,64689,79025">glucose</compound-id> with 100 ng/mL <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 16,536 +/- 1175 cells/mL, 0.4% <compound-id="206,5793,64689,79025">glucose</compound-id> with 1000 ng/mL <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 17,500 +/- 808 cells/mL, 0.6% <compound-id="206,5793,64689,79025">glucose</compound-id> with no added <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 14,167 +/- 1062 cells/mL, 0.6% <compound-id="206,5793,64689,79025">glucose</compound-id> with 100 ng/mL <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 18,984 +/- 1265 cells/mL, 0.6% <compound-id="206,5793,64689,79025">glucose</compound-id> with 1000 ng/mL <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 20,450 +/- 1523 cells/mL, 0.8% <compound-id="206,5793,64689,79025">glucose</compound-id> with no added <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 15, 853 +/- 1650 cells/mL, 0.8% <compound-id="206,5793,64689,79025">glucose</compound-id> with 1000 ng/mL <protein-id="P01308,I3WAC9">insulin</protein-id> resulted in 26,302 +/- 1919 cells/mL; P &lt;.05 compared with <compound-id="206,5793,64689,79025">glucose</compound-id> with no added <protein-id="P01308,I3WAC9">insulin</protein-id>).	glucose__insulin__no_interaction
12766167-4	Treatment of rat osteosarcoma UMR 106 cells with 3 microm, 300 nm, and 30 nm PGE2 increased the steady state levels of <protein-id="A0JPM6">BSP</protein-id> mRNA about 2.7-, 2.5-, and 2.4-fold after 12 h. From transient transfection assays, the constructs including the promoter sequence of nucleotides (nt) -116 to +60 (pLUC3) were found to enhance transcriptional activity 3.8- and 2.2-fold treated with 3 microm and 30 nm PGE2 for 12 h. 2-bp mutations were made in an inverted CCAAT box (between nt -50 and -46), a <protein-id="G3V8S9">cAMP</protein-id> response element (CRE; between nt -75 and -68), a <protein-id="P13109">fibroblast growth factor 2</protein-id> response element (<compound-id="656999">FRE</compound-id>; nt -92 to -85), and a pituitary-specific transcription factor-1 motif (between nt -111 and -105) within pLUC3 and pLUC7 constructs.	FRE__fibroblast growth factor 2__no_interaction	FRE__cAMP__no_interaction	FRE__BSP__no_interaction
6588243-1	The following conclusions and speculations can be tentatively drawn from the changes in lipoprotein composition and metabolism: (1) The presence of <protein-id="P04114,Q7Z7Q0,Q59HB3">apo B</protein-id>-48 in serum VLDL and the high serum apo A-IV concentrations indicate a greater than normal contribution of alimentary remnant particles to the hypertriglyceridemia of uremic patients, (2) The presence of <protein-id="P02649">apo E</protein-id> and C in triglyceride-enriched serum LDL, together with the triglyceride enrichment of all lipoproteins, probably stems from a deficiency of <protein-id="P06858">lipoprotein lipase</protein-id> (<protein-id="P06858">LPL</protein-id>) and <protein-id="P11150,A6H8L5">hepatic lipase</protein-id> (HL) activity, (3) The decreased ratio of serum apo C-II/C-III in VLDL is at least in part responsible for the depressed activity of <protein-id="P06858">LPL</protein-id>, (4) The accumulation of lipoprotein particles with distorted apoprotein and lipid patterns (particularly beta-VLDL with enrichment in <compound-id="5997">cholesterol</compound-id>) could be associated with an increased atherogenesis because a recent study has demonstrated a strong association between raised serum IDL and VLDL concentrations and the degree of coronary atherosclerosis, (5) The increased <protein-id="P02649">apo E</protein-id> content of VLDL and HDL in uremic patients could particularly point to a disturbed <compound-id="5997">cholesterol</compound-id> metabolism because such lipoproteins could interact with LDL at <protein-id="P04114,Q7Z7Q0,Q59HB3">apo B</protein-id>, E receptors, (6) The decrease in serum HDL-<compound-id="5997">cholesterol</compound-id> has been shown to be strongly associated with atheromatous vascular disease, and this could also hold for uremic patients; however, it is probable that low serum HDL-<compound-id="5997">cholesterol</compound-id> together with a diminished capacity to form <compound-id="5997">cholesterol</compound-id>-rich, <protein-id="P02649">apo E</protein-id> containing HDL represents a decrease in the antiatherogenic defense of the organism rather than an increased atherogenic potential [21].	cholesterol__apo B__no_interaction	cholesterol__LPL__no_interaction	cholesterol__hepatic lipase__no_interaction	cholesterol__apo E__no_interaction	cholesterol__lipoprotein lipase__no_interaction
21241520-7	Furthermore, significant correlations were found between <compound-id="447361">RDR</compound-id> and eosinophil numbers (r = 0.71, p = 0.001), level of <protein-id="P12724">ECP</protein-id> (r = 0.72, p = 0.001), <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (r = 0.57, p = 0.015) and <protein-id="P05164">MPO</protein-id> (r = 0.64, p = 0.007) in sputum collected after <compound-id="6251">mannitol</compound-id> challenge.	mannitol__MPO__no_interaction	mannitol__IL-8__no_interaction	mannitol__ECP__no_interaction	RDR__MPO__no_interaction	RDR__IL-8__no_interaction	RDR__ECP__no_interaction
20166418-2	Shear bond strengths were determined following treatment of flat ground human enamel and dentin surfaces (4000 grit) with 11 adhesive systems: 1) AdheSE One Viva Pen-(ASE), 2) Adper Prompt L-Pop-(PLP), 3) Adper Single Bond Plus-(SBP), 4) Clearfil SE Bond-(<compound-id="6326983">CSE</compound-id>), 5) Clearfil S3 Bond-(<compound-id="49769870">CS3</compound-id>), 6) OptiBond All-In-One-(<compound-id="444764">OBA</compound-id>), 7) OptiBond Solo Plus-(<protein-id="P41159,A4D0Y8">OBS</protein-id>), 8) Peak SE-(PSE), 9) Xeno IV-(X4), 10) Xeno V-(X5) and 11) XP Bond-(XPB) using recommended treatment times and an extended treatment time of 60 seconds (n = 10/group).	CSE__OBS__no_interaction	CS3__OBS__no_interaction	OBA__OBS__no_interaction
24311484-1	As part of our search for catalytically active Ru(II)-<compound-id="166653">hydride</compound-id> complexes, we have synthesized and crystallographically characterized three different <compound-id="23950">ruthenium</compound-id> species, namely dihydrido[(SR)-(10,11-η)-N-(pyridin-2-ylmethyl-κN)-<compound-id="208163">5H-dibenzo[a,d]cyclohepten-5-amine</compound-id>](<compound-id="11776">triphenylphosphane</compound-id>-κP)<compound-id="23950">ruthenium</compound-id>(II) <compound-id="8028">tetrahydrofuran</compound-id> monosolvate, [RuH2(C21H18N2)(C18H15P)]·C4H8O or (SR)-[Ru(II)(H)2{N-(pyridin-2-ylmethyl)tropNH}(<protein-id="P60510,A0A024R625">PPh3</protein-id>)]·THF, (1), chlorido{(1SR,<compound-id="72163596">2RS</compound-id>)-N,N'-bis[(10,11-η)-<compound-id="208163">5H-dibenzo[a,d]cyclohepten-5-amine</compound-id>]<compound-id="3301">ethane-1,2-diamine</compound-id>-κ(2)N,N'}hydridoruthenium(II) <compound-id="8071">dimethoxyethane</compound-id> hemisolvate, [RuClH(C32H28N2)]·0.5C4H10O2 or (1SR,<compound-id="72163596">2RS</compound-id>)-[Ru(II)(H)(Cl){tropNH(CH2)2HNtrop}]·DME, (2), and chlorido{(1SR,<compound-id="72163596">2RS</compound-id>)-N,N'-bis[(10,11-η)-<compound-id="208163">5H-dibenzo[a,d]cyclohepten-5-amine</compound-id>]<compound-id="428">propane-1,3-diamine</compound-id>-κ(2)N,N'}hydridoruthenium(II), [RuClH(C33H30N2)] or (1SR,<compound-id="72163596">2RS</compound-id>)-[Ru(II)(H)(Cl){tropNH(CH2)3HNtrop}], (3), where trop is <compound-id="67492">5H-dibenzo[a,d]cycloheptene</compound-id>.	dimethoxyethane__PPh3__no_interaction	tetrahydrofuran__PPh3__no_interaction	ruthenium__PPh3__no_interaction	triphenylphosphane__PPh3__no_interaction	5H-dibenzo[a,d]cyclohepten-5-amine__PPh3__no_interaction	hydride__PPh3__no_interaction	5H-dibenzo[a,d]cycloheptene__PPh3__no_interaction	propane-1,3-diamine__PPh3__no_interaction	ethane-1,2-diamine__PPh3__no_interaction	2RS__PPh3__no_interaction
15651082-1	Novel radiolabeled <compound-id="4578">O(6)-benzylguanine</compound-id> (O(6)-BG) derivatives, 6-O-[(11)C]-[(<compound-id="140104">methoxymethyl</compound-id>)benzyl]guanines ([(11)C]p-O(6)-MMBG, 1a; [(11)C]m-O(6)-MMBG, 1b; [(11)C]o-O(6)-MMBG, 1c), 2-amino-6-O-[(11)C]-[(<compound-id="140104">methoxymethyl</compound-id>)benzyloxy]-9-methyl purines ([(11)C]p-O(6)-<compound-id="451880">AMMP</compound-id>, 2a; [(11)C]m-O(6)-<compound-id="451880">AMMP</compound-id>, 2b; [(11)C]o-O(6)-<compound-id="451880">AMMP</compound-id>, 2c), 2-amino-6-O-[(11)C]-[(<compound-id="140104">methoxymethyl</compound-id>)benzyloxy]-9-benzyl purines ([(11)C]p-O(6)-<protein-id="P02760">AMBP</protein-id>, <compound-id="2981881,91293124">3a</compound-id>; [(11)C]m-O(6)-<protein-id="P02760">AMBP</protein-id>, 3b; [(11)C]o-O(6)-<protein-id="P02760">AMBP</protein-id>, 3c), 2-amino-6-O-benzyloxy-9-[(11)C]-[(methoxycarbonyl)methyl]purine ([(11)C]ABMMP, 4), and 2-amino-6-O-benzyloxy-9-[(11)C]-[(4'-methoxycarbonyl)benzyl]purine ([(11)C]ABMBP, 5), have been synthesized for evaluation as potential novel positron emission tomography tumor imaging agents.	AMMP__AMBP__no_interaction	3a__AMBP__no_interaction	methoxymethyl__AMBP__no_interaction	O(6)-benzylguanine__AMBP__no_interaction
8666137-5	Concentrations of fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (CDP571: 10.0 +/- 0.8, 10.1 +/- 0.8, 10.0 +/- 1.0; placebo: 8.5 +/- 0.6, 8.1 +/- 0.5, 8.7 +/- 0.8 mmol/l at baseline, day 1, and week 4, respectively), fasting serum <protein-id="P01308,I3WAC9">insulin</protein-id> (CDP571: 21.2 +/- 2.8, 21.0 +/- 2.8, 24.8 +/- 3.3; placebo: 19.0 +/- 2.8, 20.8 +/- 2.9, 17.5 +/- 2.2 pmol/l, respectively), and C-peptide remained unaffected by the type of treatment throughout the study.	glucose__insulin__no_interaction
17636046-4	Although differences in kinetic parameters were observed between the parent enzymes and chimeras, <protein-id="P22310">UGT1A4</protein-id>-3((45-535)) and <protein-id="P22310">UGT1A4</protein-id>-3((45-154))-4 [but not <protein-id="P22310">UGT1A3-4</protein-id>((45-535)) and <protein-id="P22310">UGT1A3-4</protein-id>((45-154))-3] retained the capacity to <compound-id="94715">glucuronidate</compound-id> LTG and TFP.	glucuronidate__UGT1A4__no_interaction	glucuronidate__UGT1A3-4__no_interaction
23537505-4	OBJECTIVES: Because available immunosuppressive therapies cause unacceptable side effects after long-term use or are not always effective in inducing remission, novel biological agents directed against the following targets might be options for future therapies in MG: 1) T cell Intracellular Signaling Pathways associated with T cell activation, such as monoclonal antibodies against <protein-id="P31358,V9HWN9">CD52</protein-id>, <protein-id="P01589,Q5W005">Interleukin 2-receptor</protein-id> (<protein-id="P01589,Q5W005">IL-2 R</protein-id>), co-stimulatory molecules or compounds inhibiting Janus <compound-id="6057,90983769">tyrosine</compound-id> kinases <protein-id="P23458">JAK1</protein-id>, <protein-id="O60674">JAK3; 2</protein-id>) B cells, against key B cell-surface molecules or trophic factors B cell activation factor (BAFF) and a proliferating inducing ligand (<protein-id="Q92688">APRIL</protein-id>); 3) Complement, against C3 or C5 that intercept membranolytic attack complex formation; 4) Cytokines and cytokine receptors, including <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, IL-17, the <protein-id="Q92974,D3DVA5">p40</protein-id> subunit of IL12/1L-23, and <protein-id="P04141">GM-CSF; and 5</protein-id>) Lymphocyte migration molecules.	tyrosine__CD52__no_interaction	tyrosine__GM-CSF; and 5__no_interaction	tyrosine__IL-6__no_interaction	tyrosine__IL-2 R__no_interaction	tyrosine__APRIL__no_interaction	tyrosine__JAK1__no_interaction	tyrosine__p40__no_interaction	tyrosine__JAK3; 2__no_interaction	tyrosine__Interleukin 2-receptor__no_interaction
12132915-2	Reaction of the beta-<compound-id="438531">diketimine</compound-id> H(<compound-id="122669">Dipp</compound-id>)NC(Me)CHC(Me)N(<compound-id="122669">Dipp</compound-id>) (<protein-id="Q9NZJ9,A0A024RBD0,A0A0C4DGJ4,A0A024RBG1">Dipp(2</protein-id>)N(wedge)NH; <compound-id="122669">Dipp</compound-id> = C(6)H(3)-2,6-Pr(i)(2)) with M[N(SiMe(3))(2)](2) (M = Mn or Co) gave <protein-id="Q9NZJ9,A0A024RBD0,A0A0C4DGJ4,A0A024RBG1">Dipp(2</protein-id>)N(wedge)<compound-id="14181">NMN</compound-id>(SiMe(3))(2) (M = Mn, 1; Co, 3) while the reaction of Fe[N(SiMe(3))(2)](2) with Ar(2)N(wedge)NH (Ar = <compound-id="122669">Dipp</compound-id>, C(6)F(5), Mes, C(6)H(3)-2,6-Me(2), or C(6)H(3)-2,6-Cl(2)) afforded the series of <compound-id="23925,67172434">iron</compound-id> complexes Ar(2)N(wedge)<compound-id="5195770">NFe</compound-id>[N(SiMe(3))(2)] (Ar = <compound-id="122669">Dipp</compound-id>, 2a; C(6)F(5), 2b; Mes, 2c; C(6)H(3)-2,6-Me(2), 2d; C(6)H(3)-2,6-Cl(2), 2e).	NMN__Dipp(2__no_interaction	Dipp__Dipp(2__no_interaction	NFe__Dipp(2__no_interaction	iron__Dipp(2__no_interaction	diketimine__Dipp(2__no_interaction
18786322-3	Real-time polymerase chain reaction (real-time PCR) were used to evaluate the mRNA expression levels of TLR2, TLR4, myeloid differentiation primary response gene 88(MyD88), interleukin-1 receptor-associated kinase 4 (IRAK-4), tumor necrosis factor receptor-associated factor 6 (TRAF6), TAK1-binding protein 2 (TAB2) transforming growth factor-beta-activating kinase 1 (TAK1), interleukin-1 receptor-associated kinase 3 (<protein-id="Q9Y616">IRAK-M</protein-id>), <compound-id="23994">zinc</compound-id> finger protein inhibiting nuclear factor-KappaB (Triad3A), protein associated with Tlr4 (PRAT4B) and signal-transducing adaptor protein-2 (STAP2), and the levels of mRNA expression and production of pro-inflammatory cytokines [tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and IL-6] were measured by real-time PCR and enzyme-linked immunosorbent assay (ELISA).	zinc__IRAK-M__no_interaction
12181176-3	Our data in support of this conclusion can be outlined as follows: 1) incubation of Caco-2 cells with <protein-id="P60880">SNAP</protein-id> (500 microM) for 30 min resulted in approximately 50% inhibition of <compound-id="5281951">DIDS</compound-id>-sensitive 36Cl uptake; 2) soluble guanylate cyclase inhibitors <compound-id="3976">Ly-83583</compound-id> and (1,2,4)<compound-id="10197612">oxadiazolo</compound-id>(4,3-a)quinoxalin-1-one significantly blocked the inhibition of Cl-/OH- exchange activity by <protein-id="P60880">SNAP</protein-id>; 3) addition of <compound-id="104767,16760331,1915">8-bromo-cGMP</compound-id> (8-BrcGMP) mimicked the effects of <protein-id="P60880">SNAP</protein-id>; 4) specific <protein-id="Q13976">PKG</protein-id> inhibitor <compound-id="108152">KT-5823</compound-id> significantly inhibited the decrease in Cl-/OH- exchange activity in response to either <protein-id="P60880">SNAP</protein-id> or 8-BrcGMP; 5) Cl-/OH-exchange activity in Caco-2 cells in response to <protein-id="P60880">SNAP</protein-id> was not altered in the presence of protein kinase A (PKA) inhibitor (Rp-cAMPS), demonstrating that the PKA pathway was not involved; 6) the effect of NO on Cl-/OH- exchange activity was mediated by PKC, because each of the two PKC inhibitors <compound-id="411938">chelerythrine</compound-id> <compound-id="312">chloride</compound-id> and <compound-id="2533">calphostin C</compound-id> blocked the <protein-id="P60880">SNAP</protein-id>-mediated inhibition of Cl-/OH- exchange activity; 7) SO/OH- exchange in Caco-2 cells was unaffected by <protein-id="P60880">SNAP</protein-id>.	8-bromo-cGMP__SNAP__no_interaction	8-bromo-cGMP__PKG__no_interaction	Ly-83583__SNAP__no_interaction	Ly-83583__PKG__no_interaction	chelerythrine__SNAP__no_interaction	chelerythrine__PKG__no_interaction	oxadiazolo__SNAP__no_interaction	oxadiazolo__PKG__no_interaction	calphostin C__SNAP__no_interaction	calphostin C__PKG__no_interaction	DIDS__SNAP__no_interaction	DIDS__PKG__no_interaction	KT-5823__SNAP__no_interaction	KT-5823__PKG__no_interaction	chloride__SNAP__no_interaction	chloride__PKG__no_interaction
23728361-1	The reactivity of the unusual d(8) <compound-id="18648447">trigonal-bipyramidal</compound-id> systems [MX(<compound-id="4879">PP3</compound-id>)]X (X = Cl: M = Pd(1a), Pt(2a); X = Br: M = Pd(<compound-id="2981881,91293124">3a</compound-id>), Pt(<compound-id="69255155">4a</compound-id>); X = I: M = Pd(5a), Pt(6a); <compound-id="4879">PP3</compound-id> = <compound-id="6503">tris</compound-id>[2-(<compound-id="70017">diphenylphosphino</compound-id>)<compound-id="23134249">ethyl</compound-id>]<compound-id="24404">phosphine</compound-id>) in CHCl3-CH3OH, the square-<compound-id="18648446">pyramidal</compound-id> compounds [MCl(NP3)]Cl (M = Pd(7a); Pt(8a); NP3 = <compound-id="604074">tris[2-(diphenylphosphino)ethyl]amine</compound-id>) in CD3OD-DMF and the distorted square-planar mononuclear [MX(<protein-id="P00491,V9HWH6">PNP</protein-id>)]X (M = Pd: X = Cl(10a); M = Pt: X = I(10b); <protein-id="P00491,V9HWH6">PNP</protein-id> = <compound-id="434330">bis[2-(diphenylphosphino)ethyl]amine</compound-id>) and the heteronuclear [PdAu2X4(<compound-id="4879">PP3</compound-id>)] [X = I(9a), Cl(<compound-id="657007">14a</compound-id>), Br(<compound-id="10036366">15a</compound-id>)] and [MAuX2(<compound-id="4879">PP3</compound-id>)]X [M = Pd: X = Cl(16a); M = Pt: X = Cl(17a), Br(<compound-id="72187586">18a</compound-id>)] species in CDCl3 with <protein-id="P60510,A0A024R625">PPh3</protein-id> + <protein-id="O60749">SnX2</protein-id> has been explored to establish the factors that influence the nature of the products.	15a__PNP__no_interaction	15a__SnX2__no_interaction	15a__PPh3__no_interaction	diphenylphosphino__PNP__no_interaction	diphenylphosphino__SnX2__no_interaction	diphenylphosphino__PPh3__no_interaction	18a__PNP__no_interaction	18a__SnX2__no_interaction	18a__PPh3__no_interaction	trigonal-bipyramidal__PNP__no_interaction	trigonal-bipyramidal__SnX2__no_interaction	trigonal-bipyramidal__PPh3__no_interaction	bis[2-(diphenylphosphino)ethyl]amine__PNP__no_interaction	bis[2-(diphenylphosphino)ethyl]amine__SnX2__no_interaction	bis[2-(diphenylphosphino)ethyl]amine__PPh3__no_interaction	pyramidal__PNP__no_interaction	pyramidal__SnX2__no_interaction	pyramidal__PPh3__no_interaction	PP3__PNP__no_interaction	PP3__SnX2__no_interaction	PP3__PPh3__no_interaction	tris[2-(diphenylphosphino)ethyl]amine__PNP__no_interaction	tris[2-(diphenylphosphino)ethyl]amine__SnX2__no_interaction	tris[2-(diphenylphosphino)ethyl]amine__PPh3__no_interaction	14a__PNP__no_interaction	14a__SnX2__no_interaction	14a__PPh3__no_interaction	phosphine__PNP__no_interaction	phosphine__SnX2__no_interaction	phosphine__PPh3__no_interaction	3a__PNP__no_interaction	3a__SnX2__no_interaction	3a__PPh3__no_interaction	ethyl__PNP__no_interaction	ethyl__SnX2__no_interaction	ethyl__PPh3__no_interaction	tris__PNP__no_interaction	tris__SnX2__no_interaction	tris__PPh3__no_interaction	4a__PNP__no_interaction	4a__SnX2__no_interaction	4a__PPh3__no_interaction
23728361-5	Although complex 9 was also prepared by interaction of the heteronuclear <compound-id="105054,30165">iodide</compound-id> 9a with <protein-id="P60510,A0A024R625">PPh3</protein-id> + <compound-id="25138">SnI2</compound-id> in CDCl3, the use of the neutral and ionic heteronuclear chlorides and bromides (<compound-id="657007">14a</compound-id>-<compound-id="72187586">18a</compound-id>) as starting materials afforded the distorted square-planar ionic systems [MAuX'(<compound-id="4879">PP3</compound-id>)(<protein-id="P60510,A0A024R625">PPh3</protein-id>)][<protein-id="O60493">SnX3</protein-id>]2 [M = Pd: X = Cl, X' = SnCl3(-)(14); X = Br, X' = SnBr3(-)(15); M = Pt: X = Cl, X' = SnCl3(-)(17); X = Br, X' = SnBr3(-)(18)] containing M-<protein-id="O60493">SnX3</protein-id> and P-Au-<protein-id="P60510,A0A024R625">PPh3</protein-id> functionalities.	PP3__SnX3__no_interaction	PP3__PPh3__no_interaction	SnI2__SnX3__no_interaction	SnI2__PPh3__no_interaction	18a__SnX3__no_interaction	18a__PPh3__no_interaction	iodide__SnX3__no_interaction	iodide__PPh3__no_interaction	14a__SnX3__no_interaction	14a__PPh3__no_interaction
22388798-9	<compound-id="2732">Chlorthalidone</compound-id> (A): NOS3 rs3918226; <protein-id="P16581">SELE</protein-id> rs5361; <protein-id="P05362">ICAM1</protein-id> rs1799969; AGT rs5051; <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">GNAS</protein-id> rs7121; ROC comparison, P=0.004; <compound-id="2162">Amlodipine</compound-id> (B): <protein-id="P03956,Q53G95,B4DN15">MMP1</protein-id> rs1799750; Factor5 (F5) rs6025; <compound-id="128898">NPPA</compound-id> rs5065; <protein-id="Q08499">PDE4D</protein-id> rs6450512; <protein-id="P14780">MMP9</protein-id> rs2274756; ROC comparison, P=0.006; <compound-id="5362119">Lisinopril</compound-id> (C): AGT rs5051; <protein-id="P27169">PON1</protein-id> rs705379; <protein-id="P39900">MMP12</protein-id> rs652438; F12 rs1801020; <protein-id="P07359,L7UYB8">GP1BA</protein-id> rs6065; <protein-id="Q08499">PDE4D</protein-id> rs27653; ROC comparison, P=0.01; <compound-id="3157">Doxazosin</compound-id> (D): F2 rs1799963; <protein-id="P05121,A0A024QYT5">PAI1</protein-id> rs1799768; <protein-id="P09237">MMP7</protein-id> rs11568818; AGT rs5051; ACE rs4343; <protein-id="P08253,A0A024R6R4">MMP2</protein-id> rs243865; ROC comparison, P=0.007.	Amlodipine__MMP12__no_interaction	Amlodipine__GNAS__no_interaction	Amlodipine__SELE__no_interaction	Amlodipine__PON1__no_interaction	Amlodipine__MMP2__no_interaction	Amlodipine__GP1BA__no_interaction	Amlodipine__ICAM1__no_interaction	Amlodipine__MMP9__no_interaction	Amlodipine__MMP7__no_interaction	Amlodipine__PAI1__no_interaction	Amlodipine__PDE4D__no_interaction	Amlodipine__MMP1__no_interaction	Chlorthalidone__MMP12__no_interaction	Chlorthalidone__GNAS__no_interaction	Chlorthalidone__SELE__no_interaction	Chlorthalidone__PON1__no_interaction	Chlorthalidone__MMP2__no_interaction	Chlorthalidone__GP1BA__no_interaction	Chlorthalidone__ICAM1__no_interaction	Chlorthalidone__MMP9__no_interaction	Chlorthalidone__MMP7__no_interaction	Chlorthalidone__PAI1__no_interaction	Chlorthalidone__PDE4D__no_interaction	Chlorthalidone__MMP1__no_interaction	Lisinopril__MMP12__no_interaction	Lisinopril__GNAS__no_interaction	Lisinopril__SELE__no_interaction	Lisinopril__PON1__no_interaction	Lisinopril__MMP2__no_interaction	Lisinopril__GP1BA__no_interaction	Lisinopril__ICAM1__no_interaction	Lisinopril__MMP9__no_interaction	Lisinopril__MMP7__no_interaction	Lisinopril__PAI1__no_interaction	Lisinopril__PDE4D__no_interaction	Lisinopril__MMP1__no_interaction	Doxazosin__MMP12__no_interaction	Doxazosin__GNAS__no_interaction	Doxazosin__SELE__no_interaction	Doxazosin__PON1__no_interaction	Doxazosin__MMP2__no_interaction	Doxazosin__GP1BA__no_interaction	Doxazosin__ICAM1__no_interaction	Doxazosin__MMP9__no_interaction	Doxazosin__MMP7__no_interaction	Doxazosin__PAI1__no_interaction	Doxazosin__PDE4D__no_interaction	Doxazosin__MMP1__no_interaction	NPPA__MMP12__no_interaction	NPPA__GNAS__no_interaction	NPPA__SELE__no_interaction	NPPA__PON1__no_interaction	NPPA__MMP2__no_interaction	NPPA__GP1BA__no_interaction	NPPA__ICAM1__no_interaction	NPPA__MMP9__no_interaction	NPPA__MMP7__no_interaction	NPPA__PAI1__no_interaction	NPPA__PDE4D__no_interaction	NPPA__MMP1__no_interaction
22522369-1	A series of α-aminopyridines in the form of (2,6-C(6)H(3)N)(R(1))(CHR(2)NR(3)R(4)) (R(1) = R(2) = H R(3) = H R(4) = (i)Pr (<compound-id="6914630">L1a</compound-id>), R(4) = (t)Bu (<compound-id="6914631">L1b</compound-id>), R(4) = Ph (<compound-id="25210468">L1c</compound-id>), R(4) = 2,6-Me(2)C(6)H(3) (<compound-id="25210469">L1d</compound-id>), R(4) = 2,6-(i)Pr(2)C(6)H(3) (<compound-id="44223999">L1e</compound-id>), R(1) = R(2) = H R(3) = R(4) = Et (L1f), R(1) = H R(2) = <protein-id="A2PYH4">Me R(3) = H R(4) = (i)Pr</protein-id> (L2a), R(4) = Ph (<compound-id="15991540,16048584">L2c</compound-id>), R(4) = 2,6-Me(2)C(6)H(3) (<compound-id="56955958">L2d</compound-id>), R(4) = 2,6-(i)Pr(2)C(6)H(3) (L2e), R(1) = Me R(2) = H R(3) = H R(4) = 2,6-(i)Pr(2)C(6)H(3) (L3e)) and β-aminopyridines in the form of (2-C(6)H(4)N)(CH(2)CH(2)NR(1)R(2)) (R(1) = H R(2) = (i)Pr (<compound-id="69255155">4a</compound-id>), R(2) = (t)Bu (L4b), R(1) = R(2) = Et (L4f)) have been prepared.	L2c__Me R(3) = H R(4) = (i)Pr__no_interaction	L2d__Me R(3) = H R(4) = (i)Pr__no_interaction	L1d__Me R(3) = H R(4) = (i)Pr__no_interaction	L1e__Me R(3) = H R(4) = (i)Pr__no_interaction	4a__Me R(3) = H R(4) = (i)Pr__no_interaction	L1a__Me R(3) = H R(4) = (i)Pr__no_interaction	L1b__Me R(3) = H R(4) = (i)Pr__no_interaction	L1c__Me R(3) = H R(4) = (i)Pr__no_interaction
17922073-1	[<compound-id="5462099">111In</compound-id>]-<compound-id="121841">DOTA</compound-id>-cG250, [<compound-id="167195">131I</compound-id>]-Metuximab injection, [<compound-id="161046">177Lu</compound-id>]-<compound-id="121841">DOTA</compound-id>-cG250; Anatumomab mafenatox, AP-12009; BIBW-2992, <compound-id="3037617">Biricodar dicitrate</compound-id>; <compound-id="9933475">Cediranib</compound-id>, <compound-id="176873">Cilengitide</compound-id>, <compound-id="153994">Clevidipine</compound-id>, CNTO-528, CNTO-95, CP-870893; <compound-id="6913176">Disufenton</compound-id> <compound-id="5360545">sodium</compound-id>, DNK-333A; Ecallantide, <compound-id="176167">Enzastaurin hydrochloride</compound-id>, <compound-id="193962">Etravirine</compound-id>, <compound-id="151115">Exatecan</compound-id> mesilate; <compound-id="107970">Fingolimod hydrochloride</compound-id>; Human <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="24728612,24759,3084050,453618">Hyaluronic acid</compound-id>; <compound-id="216468">Indisulam</compound-id>, Inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine, Ipilimumab, Irofulven, <compound-id="9824145">Ispronicline</compound-id>, <compound-id="214907">ITF</compound-id>-282; J591; <compound-id="56603678">KAI-9803</compound-id>; L-<compound-id="6322">Arginine hydrochloride</compound-id>, <compound-id="9867642">Laropiprant</compound-id>, <compound-id="9909438">LY-518674</compound-id>; Matuzumab, MB-7133, <compound-id="5361918">Methylnaltrexone bromide</compound-id>, MVA-5T4; <compound-id="6918348">Nemifitide</compound-id> ditriflutate; <compound-id="11244031,46930997,45356963,66751253">Obatoclax mesylate</compound-id>, Oral <protein-id="P01308,I3WAC9">insulin</protein-id>; P-276-00, <compound-id="11713159">PF-562271</compound-id>, <compound-id="1018">Picolinic acid</compound-id>; <compound-id="5280343">Quercetin</compound-id>; R-109339, R-547, <compound-id="9875401">Rivaroxaban</compound-id>, <compound-id="153999">Ruboxistaurin mesilate hydrate</compound-id>; <compound-id="160355">Seliciclib</compound-id>; <compound-id="476861">Terameprocol</compound-id>, <compound-id="132862">Tilarginine hydrochloride</compound-id>, <compound-id="216237">Tolvaptan</compound-id>, <compound-id="1174,90983865">Uracil</compound-id>; <compound-id="5978">Vincristine</compound-id>.	111In__insulin__no_interaction	Laropiprant__insulin__no_interaction	Etravirine__insulin__no_interaction	Exatecan__insulin__no_interaction	PF-562271__insulin__no_interaction	Tolvaptan__insulin__no_interaction	177Lu__insulin__no_interaction	Tilarginine hydrochloride__insulin__no_interaction	Seliciclib__insulin__no_interaction	Hyaluronic acid__insulin__no_interaction	Biricodar dicitrate__insulin__no_interaction	Indisulam__insulin__no_interaction	Picolinic acid__insulin__no_interaction	Arginine hydrochloride__insulin__no_interaction	131I__insulin__no_interaction	Uracil__insulin__no_interaction	Ispronicline__insulin__no_interaction	Quercetin__insulin__no_interaction	Disufenton__insulin__no_interaction	Vincristine__insulin__no_interaction	Terameprocol__insulin__no_interaction	DOTA__insulin__no_interaction	Rivaroxaban__insulin__no_interaction	Ruboxistaurin mesilate hydrate__insulin__no_interaction	KAI-9803__insulin__no_interaction	Enzastaurin hydrochloride__insulin__no_interaction	ITF__insulin__no_interaction	sodium__insulin__no_interaction	Clevidipine__insulin__no_interaction	Cediranib__insulin__no_interaction	Nemifitide__insulin__no_interaction	Fingolimod hydrochloride__insulin__no_interaction	Cilengitide__insulin__no_interaction	Obatoclax mesylate__insulin__no_interaction	LY-518674__insulin__no_interaction	Methylnaltrexone bromide__insulin__no_interaction
22825450-4	We discuss genes encoding several types of proteins: macrophage receptors, such as the <compound-id="206">mannose</compound-id> receptor (MR, <protein-id="P22897">CD206</protein-id>), <protein-id="Q9NNX6,M0R0P0,B4E2A8,X6RB12,B2R907">dendritic cell-specific ICAM-3-grabbing nonintegrin</protein-id> (<protein-id="Q9NNX6,M0R0P0,B4E2A8,X6RB12,B2R907">DC-SIGN</protein-id>, <protein-id="Q9NNX6,M0R0P0,B4E2A8,X6RB12,B2R907">CD209</protein-id>), <protein-id="Q9BXN2,Q68D78,A0A024RAN9">Dectin-1</protein-id>, Toll-like receptors (TLRs), complement receptor 3 (CR3, <protein-id="P11215">CD11b</protein-id>/<protein-id="P36941">CD18</protein-id>), <protein-id="Q9Y239,G3XAL1,A0A024RA73">nucleotide oligomerization domain 1</protein-id> (<protein-id="Q9Y239,G3XAL1,A0A024RA73">NOD1</protein-id>) and <protein-id="Q9HC29">NOD2</protein-id>, <protein-id="P08571">CD14</protein-id>, <protein-id="Q99572">P2X7</protein-id>, and the <protein-id="P11473,F1D8P8">vitamin D nuclear receptor</protein-id> (<protein-id="P11473,F1D8P8">VDR</protein-id>); soluble C-type lectins, such as <protein-id="Q8IWL2,A0A024QZP2,B4DNP6">surfactant protein-A</protein-id> (<protein-id="O43866">SP-A</protein-id>), <protein-id="P23415,Q14C71">SP-D</protein-id>, and <protein-id="P11226">mannose-binding lectin</protein-id> (<protein-id="P11226">MBL</protein-id>); phagocyte cytokines, such as tumor necrosis factor (TNF), interleukin-1β (IL-1β), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P22301,Q6FGW4">IL-10</protein-id>, IL-12, and <protein-id="Q14116,A0A024R3E0">IL-18</protein-id>; chemokines, such as <protein-id="P10145,A0A024RDA5">IL-8</protein-id>, <protein-id="P13500">monocyte chemoattractant protein 1</protein-id> (<protein-id="P13500">MCP-1</protein-id>), <protein-id="P13501,D0EI67">RANTES</protein-id>, and <protein-id="P02778,A0A024RDA4">CXCL10</protein-id>; and other important innate immune molecules, such as inducible <compound-id="145068">nitric oxide</compound-id> synthase (iNOS) and <protein-id="P49279,A0A024R474">solute carrier protein 11A1</protein-id> (<protein-id="P49279,A0A024R474">SLC11A1</protein-id>).	mannose__VDR__no_interaction	mannose__IL-8__no_interaction	mannose__dendritic cell-specific ICAM-3-grabbing nonintegrin__no_interaction	mannose__IL-6__no_interaction	mannose__DC-SIGN__no_interaction	mannose__CD209__no_interaction	mannose__solute carrier protein 11A1__no_interaction	mannose__CD206__no_interaction	mannose__MBL__no_interaction	mannose__surfactant protein-A__no_interaction	mannose__monocyte chemoattractant protein 1__no_interaction	mannose__SLC11A1__no_interaction	mannose__Dectin-1__no_interaction	mannose__NOD1__no_interaction	mannose__NOD2__no_interaction	mannose__SP-D__no_interaction	mannose__vitamin D nuclear receptor__no_interaction	mannose__SP-A__no_interaction	mannose__mannose-binding lectin__no_interaction	mannose__CXCL10__no_interaction	mannose__IL-18__no_interaction	mannose__P2X7__no_interaction	mannose__IL-10__no_interaction	mannose__nucleotide oligomerization domain 1__no_interaction	mannose__CD14__no_interaction	mannose__CD11b__no_interaction	mannose__RANTES__no_interaction	mannose__CD18__no_interaction	mannose__MCP-1__no_interaction	nitric oxide__VDR__no_interaction	nitric oxide__IL-8__no_interaction	nitric oxide__dendritic cell-specific ICAM-3-grabbing nonintegrin__no_interaction	nitric oxide__IL-6__no_interaction	nitric oxide__DC-SIGN__no_interaction	nitric oxide__CD209__no_interaction	nitric oxide__solute carrier protein 11A1__no_interaction	nitric oxide__CD206__no_interaction	nitric oxide__MBL__no_interaction	nitric oxide__surfactant protein-A__no_interaction	nitric oxide__monocyte chemoattractant protein 1__no_interaction	nitric oxide__SLC11A1__no_interaction	nitric oxide__Dectin-1__no_interaction	nitric oxide__NOD1__no_interaction	nitric oxide__NOD2__no_interaction	nitric oxide__SP-D__no_interaction	nitric oxide__vitamin D nuclear receptor__no_interaction	nitric oxide__SP-A__no_interaction	nitric oxide__mannose-binding lectin__no_interaction	nitric oxide__CXCL10__no_interaction	nitric oxide__IL-18__no_interaction	nitric oxide__P2X7__no_interaction	nitric oxide__IL-10__no_interaction	nitric oxide__nucleotide oligomerization domain 1__no_interaction	nitric oxide__CD14__no_interaction	nitric oxide__CD11b__no_interaction	nitric oxide__RANTES__no_interaction	nitric oxide__CD18__no_interaction	nitric oxide__MCP-1__no_interaction
19099443-1	A series of luminescent cyclometalated <compound-id="23924">iridium</compound-id>(III) polypyridine <compound-id="798">indole</compound-id> complexes, [Ir(N--C)(2)(N--N)](PF(6)) (<protein-id="P22894,B4E0I2">HN--C</protein-id> = 2-<compound-id="13887">phenylpyridine</compound-id> (Hppy), N--N = 4-((2-(indol-3-yl)<compound-id="23134249">ethyl</compound-id>)aminocarbonyl)-4'-methyl-<compound-id="1474">2,2'-bipyridine</compound-id> (bpy-ind) (1a), N--N = 4-((5-((2-(indol-3-yl)<compound-id="23134249">ethyl</compound-id>)aminocarbonyl)pentyl)aminocarbonyl)-4'-methyl-<compound-id="1474">2,2'-bipyridine</compound-id> (bpy-C6-ind) (1b); <protein-id="P22894,B4E0I2">HN--C</protein-id> = <compound-id="9191">7,8-benzoquinoline</compound-id> (Hbzq), N--N = bpy-ind (2a), N--N = bpy-C6-ind (2b); and <protein-id="P22894,B4E0I2">HN--C</protein-id> = 2-phenylquinoline (Hpq), N--N = bpy-ind (<compound-id="2981881,91293124">3a</compound-id>), N--N = bpy-C6-ind (3b)), have been synthesized, characterized, and their photophysical and electrochemical properties and lipophilicity investigated.	phenylpyridine__HN--C__no_interaction	indole__HN--C__no_interaction	2,2'-bipyridine__HN--C__no_interaction	iridium__HN--C__no_interaction	7,8-benzoquinoline__HN--C__no_interaction	3a__HN--C__no_interaction	ethyl__HN--C__no_interaction
22009699-2	Treatment of dimeric metal complexes [{Cp*M(μ-Cl)Cl}(2)] (M = Ir, Rh; Cp* = η(5)-C(5)Me(5)) with a solution of one equivalent of nBuLi and a carboranylamidine produces 18-electron complexes [Cp*IrCl(<protein-id="P56537">Cab</protein-id>(N)-DIC)] (1 a; <protein-id="P56537">Cab</protein-id>(N)-DIC = [iPrN=C(closo-1,2-C(2)B(10)H(10))(NHiPr)]), [Cp*RhCl(<protein-id="P56537">Cab</protein-id>(N)-DIC)] (1 b), and [Cp*RhCl(<protein-id="P56537">Cab</protein-id>(N)-DCC)] (1 c; <protein-id="P56537">Cab</protein-id>(N)-DCC = [<compound-id="12358846,5316647,54610010">CyN</compound-id>=C(closo-1,2-C(2)B(10)H(10))(NHCy)]).	CyN__Cab__no_interaction
18249202-9	At the multivariate regression analysis, waist circumference, high-density lipoprotein <compound-id="5997">cholesterol</compound-id>, <protein-id="P02741">C-reactive protein</protein-id>, and <protein-id="O00300">OPG</protein-id> were predictors of carotid mean <compound-id="447041">IMT</compound-id> (beta = 0.55, P = .001; beta = -0.14, P = .001; beta = 0.16, P = .001; and beta = 0.14, P = .05, respectively) and age, <protein-id="O00300">OPG</protein-id>, low-density lipoprotein <compound-id="5997">cholesterol</compound-id>, and brachial diameter of brachial <compound-id="53313342">FMV</compound-id> (beta = -0.13, P = .05; beta = -0.25, P = .001; beta = -0.14, P = .024; and beta = 0.48, P = .001, respectively).	FMV__C-reactive protein__no_interaction	FMV__OPG__no_interaction	IMT__C-reactive protein__no_interaction	IMT__OPG__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__OPG__no_interaction
23720457-5	Ex vivo cultivated human PVSMCs were preincubated with the <compound-id="44284481">endothelin</compound-id>-A-receptor selective inhibitor <compound-id="6918493">ambrisentan</compound-id>, with the <protein-id="P24530,A0A024R645,A0A024R638">endothelin-B-receptor</protein-id> selective inhibitor <compound-id="5311032">BQ788</compound-id> [<compound-id="5360545">sodium</compound-id> (2R)-2-{[(2S)-2-({[(2R,6S)-2,6-<compound-id="3016856">dimethyl-1-piperidinyl</compound-id>]carbonyl}amino)-<compound-id="11062343">4,4-dimethylpentanoyl</compound-id>][1-(methoxycarbonyl)-<compound-id="16758211">d-tryptophyl</compound-id>]amino}<compound-id="8892">hexanoate</compound-id>], or with the dual blocker <compound-id="104865">bosentan</compound-id> before stimulation with smooth <protein-id="O14896,G0Z349">LPS</protein-id> (S-<protein-id="O14896,G0Z349">LPS</protein-id>), rough <protein-id="O14896,G0Z349">LPS</protein-id> (Re-<protein-id="O14896,G0Z349">LPS</protein-id>), or a mixture of long and short forms (M-<protein-id="O14896,G0Z349">LPS</protein-id>).	d-tryptophyl__endothelin-B-receptor__no_interaction	d-tryptophyl__LPS__no_interaction	sodium__endothelin-B-receptor__no_interaction	sodium__LPS__no_interaction	hexanoate__endothelin-B-receptor__no_interaction	hexanoate__LPS__no_interaction	bosentan__endothelin-B-receptor__no_interaction	bosentan__LPS__no_interaction	ambrisentan__endothelin-B-receptor__no_interaction	ambrisentan__LPS__no_interaction	endothelin__endothelin-B-receptor__no_interaction	endothelin__LPS__no_interaction	dimethyl-1-piperidinyl__endothelin-B-receptor__no_interaction	dimethyl-1-piperidinyl__LPS__no_interaction	BQ788__endothelin-B-receptor__no_interaction	BQ788__LPS__no_interaction	4,4-dimethylpentanoyl__endothelin-B-receptor__no_interaction	4,4-dimethylpentanoyl__LPS__no_interaction
19545008-6	The average anoxic <compound-id="167704,644102">phosphate</compound-id> uptake rate was 32.68 mg/(L x h) in the early 30 min during anoxic phase when <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) was as electron acceptor, and every 1 mg <compound-id="1061">PO4</compound-id>(3-)-P uptake would consume 1.14 mg <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-)-N. In the process with NO2(-) as electron acceptor, the average anoxic <compound-id="167704,644102">phosphate</compound-id> uptake rate was 17.66 mg/(Lx h) in the early 30 min, and every 1 mg <compound-id="1061">PO4</compound-id>(3-)-P uptake would consume 1.57 mg NO2(-)-N. In conclusion, ORP and pH can be used as control parameters for simultaneous phosphorus and <compound-id="947">nitrogen</compound-id> removal in an anaerobic/anoxic process, and the system with <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) as electron acceptor is superior to the system with NO2(-) as electron acceptor.	PO4__NO3__no_interaction	phosphate__NO3__no_interaction	nitrogen__NO3__no_interaction
20563525-6	RESULTS: The comparison of students of medicine and physical education, respectively, showed a higher frequency of individuals presenting: low level of physical activity (55% vs 15.0%; p = 0.008); pre-hypertension measured by SAP (80% vs 25.0%; p = 0.000) and by DAP (45% vs 5.0%; p = 0.003); overweight (50% vs 10.0%; p = 0.006); increased abdominal circumference (25% vs 0.0%; p = 0.017); increased total <compound-id="5997">cholesterol</compound-id> (165 +/- 28 vs 142 +/- 28 mg/dl; p = 0.015); increased <protein-id="Q14746,B1ALW7">LDL-c</protein-id> (99 +/- 27 vs 81 +/- 23 mg/dl; p = 0.026); increased glycemia (81 +/- 8.0 vs 75 +/- 7.0 mg/dl; p = 0.013); lower cardiorespiratory fitness (48 +/- 8.0 vs 56 +/- 7.0 ml/kg/min; p = 0.001).	cholesterol__LDL-c__no_interaction
21294443-8	Before surgery, tumour MVD correlated significantly with serum NO, <protein-id="P01375,Q5STB3">TNFalpha</protein-id>, <protein-id="P09038">bFGF</protein-id> and <compound-id="23978">copper</compound-id> (r = 0.458, P = .011; r = 0.379, P = .039; r = 0.513, P = .004 and r = 0.613, P = 0.000, respectively).	copper__TNFalpha__no_interaction	copper__bFGF__no_interaction
11596935-3	Key data are as follows: [(eta5-C5H4(CH2)6CH=CH2)Re(NO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)-(CH3)], intermolecular metathesis (95 %); [(eta5-C5H5)Re(NO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)(E(<compound-id="123136">CH2CH=CH2</compound-id>)2)]+ TfO (E=S, <protein-id="P04080,Q76LA1">PMe</protein-id>, PPh), formation of five-membered heterocycles (96-64%; crystal structure E = <protein-id="P04080,Q76LA1">PMe</protein-id>); [(eta5-C5Me5)Re(NO)(PPh((CH2)6CH=CH2)2)(L)]n+ nBF4-(L/n = CO/1, Cl/0), intramolecular macrocyclization (94-89%; crystal structure L= Cl); fac-[(CO)<compound-id="49852675">3Re</compound-id>(Br)(PPh2(CH2)6CH=CH2)2] and cis-[(Cl)2Pt(PPh2(CH2)6CH=CH2)2], intramolecular macrocyclizations (80-71%; crystal structures of each and a hydrogenation product); cis-[(Cl)2Pt(S(R)(CH2)6CH= CH2)2], intra-/intermolecular macrocyclization (R=Et, 55%/24%; tBu, 72%/ &lt;4%); trans-[(Cl)(L)M(PPh2(CH2)6CH=CH2)2] (M/L = Rh/CO, Pt/C6F5) intramolecular macrocyclization (90-83%; crystal structure of hydrogenation product, M=Pt); fac-[W(CO)3(PPh((CH2)6CH=CH2)2)3], intramolecular trimacrocyclization (83 %) to a complex mixture of <compound-id="139510">triphosphine</compound-id>, <compound-id="139283">diphosphine</compound-id>/ monophosphine, and <compound-id="6503">tris</compound-id>(monophosphine) complexes, from which two isomers of the first type are crystallized.	triphosphine__PMe__no_interaction	triphosphine__PPh3__no_interaction	3Re__PMe__no_interaction	3Re__PPh3__no_interaction	diphosphine__PMe__no_interaction	diphosphine__PPh3__no_interaction	tris__PMe__no_interaction	tris__PPh3__no_interaction	CH2CH=CH2__PMe__no_interaction	CH2CH=CH2__PPh3__no_interaction
16216550-5	Analysis showed that, compared with WT mice, <protein-id="O35704">Sptlc1</protein-id>(+/-) and <protein-id="P97363,Q542D6">Sptlc2</protein-id>(+/-) mice had: (1) decreased liver <protein-id="O35704">Sptlc1</protein-id> and <protein-id="P97363,Q542D6">Sptlc2</protein-id> mRNA by 44% and 57% (P&lt;0.01 and P&lt;0.0001, respectively); (2) decreased liver <protein-id="O35704">Sptlc1</protein-id> mass by 50% and <protein-id="P97363,Q542D6">Sptlc2</protein-id> mass by 70% (P&lt;0.01 and P&lt;0.01, respectively), moreover, <protein-id="O35704">Sptlc1</protein-id> mass decreased by 70% in <protein-id="P97363,Q542D6">Sptlc2</protein-id>(+/-) mouse liver, while <protein-id="P97363,Q542D6">Sptlc2</protein-id> mass decreased by 53% in <protein-id="O35704">Sptlc1</protein-id>(+/-) mouse liver (P&lt;0.001 and P&lt;0.01, respectively); (3) decreased liver SPT activity by 45% and 60% (P&lt;0.01, respectively); (4) decreased liver ceramide (22% and 39%, P&lt;0.05 and P&lt;0.01, respectively) and <compound-id="31270,5280335">sphingosine</compound-id> levels (22% and 31%, P&lt;0.05 and P&lt;0.01, respectively); (5) decreased plasma ceramide (45% and 39%, P&lt;0.01, respectively), <compound-id="5283560">sphingosine-1-phosphate</compound-id> (31% and 32%, P&lt;0.01, respectively) and <compound-id="31270,5280335">sphingosine</compound-id> levels (22.5% and 25%, P&lt;0.01, respectively); (6) dramatically decreased plasma <compound-id="5280613">lysosphingomyelin</compound-id> (17-fold and 16-fold, P&lt;0.0001, respectively); and (7) no change of plasma sphingomyelin, triglyceride, total <compound-id="5997">cholesterol</compound-id>, phospholipids, and liver sphingomyelin levels.	lysosphingomyelin__Sptlc2__no_interaction	lysosphingomyelin__Sptlc1__no_interaction	sphingosine-1-phosphate__Sptlc2__no_interaction	sphingosine-1-phosphate__Sptlc1__no_interaction	sphingosine__Sptlc2__no_interaction	sphingosine__Sptlc1__no_interaction	cholesterol__Sptlc2__no_interaction	cholesterol__Sptlc1__no_interaction
16205934-6	RESULTS: In the order of <compound-id="181579,25245095,441664,448437,5281243,5368396,6433159">lutein</compound-id>&gt;Trigonella&gt;<compound-id="1548900,1742129">vitamin E</compound-id>&gt;Teucrium, all four compounds were effective in preventing <compound-id="638015">retinal</compound-id> damage by I/R, as (1) they significantly decreased the formation of MDA (8.83, 16.48, 17.24, 18.5 nmol/100 mg tissue wet weight, respectively) compared with I/R without protection (23.29 nmol/100 mg tissue wet weight; controls: 8.0 nmol/100 mg tissue wet weight); (2) they significantly inhibited the activation of <protein-id="P55213">caspase-3</protein-id> [0.01, 0.02, 0,02, and 0.04 arbitrary units (AU), respectively, versus control, 0.0, and I/R, 0.08 AU]; and (3) they significantly decelerated the loss of GSH (from control levels of 36.04 nmol/100 mg tissue wet weight) to 30.4, 15.98, 18.1, 15.02 nmol/100 mg tissue wet weight, respectively (<compound-id="181579,25245095,441664,448437,5281243,5368396,6433159">lutein</compound-id>, Trigonella, <compound-id="1548900,1742129">vitamin E</compound-id>, Teucrium), compared with unprotected I/R (12.84 nmol/100 mg tissue wet weight).	lutein__caspase-3__no_interaction	retinal__caspase-3__no_interaction	vitamin E__caspase-3__no_interaction
22539464-6	RESULTS: There were significant differences between cases and controls: body mass index (kg/m(2) ) 27.4 ± 5.6 vs 23.9 ± 3.6 (p = 0.013), waist circumference (cm) 85.2 ± 12.9 vs 77.5 ± 9.0 (p = 0.017), metabolic syndrome (WHO definition) 14.6% vs 0% (p = 0.012), metabolic syndrome (NCEP-ATPIII definition) 22% vs 0% (p = 0.002), low HDL 36.6% vs 9.5% (p = 0.024), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (mmol/L) 5.4 ± 0.6 vs 4.9 ± 0.2 (p &lt; 0.001), <compound-id="206,5793,64689,79025">glucose</compound-id> 120' oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test (mmol/L) 5.8 ± 1.7vs 4.7 ± 0.8 (p = 0.007), fasting insulin (μU/mL) 13.4 ± 8.1 vs 8.4 ± 4.3 (p = 0.004), HOMA index 3.3 ± 2.3 vs 1.8 ± 1.0 (p = 0.002), HbA(1c) (%) 5.4 ± 0.2 vs 5.2 ± 0.2 (p = 0.021), <compound-id="1175">uric acid</compound-id> (mg/dL) 4.1 ± 1 vs 3.5 ± 0.6 (p = 0.009), <protein-id="P41159,A4D0Y8">leptin</protein-id> (ng/mL) 32 025.5 ± 19 917.3 vs 20 258.9 ± 16 359.9 (p = 0.023), respectively.	uric acid__leptin__no_interaction	glucose__leptin__no_interaction
14739216-6	Lower plasma <compound-id="5997">cholesterol</compound-id> in MX1Cre(+)LRP(flox/flox)-LDLR(-/-)APOE(-/-) mice coincided with increased plasma lipoprotein <compound-id="5474737">lipase</compound-id> (71.2 +/- 7.5 vs 19.1 +/- 2.4 ng/ml, P =.002), coagulation factor VIII (4.4 +/- 1.1 vs 1.9 +/- 0.5 U/mL, P =.001), von Willebrand factor (2.8 +/- 0.6 vs 1.4 +/- 0.3 U/mL, P =.001), and <protein-id="P11214">tissue-type plasminogen activator</protein-id> (1.7 +/- 0.7 vs 0.9 +/- 0.5 ng/ml, P =.008) compared with controls.	lipase__tissue-type plasminogen activator__no_interaction	cholesterol__tissue-type plasminogen activator__no_interaction
21125190-11	Patients with <protein-id="P05186,A0A024RAG0">A-LPL</protein-id> and A-OXLDL &gt; 0.40 (n = 12) showed coronary risk correlations of: <protein-id="P05186,A0A024RAG0">A-LPL</protein-id> x LDL-Trig = 0.7008, P = 0.0111; bilateral ultrasound vs total <compound-id="5997">cholesterol</compound-id> = 0.62205, P = 0.0308; LDL-Trig vs myocardial infarction (MI) = 0.76562, P = 0.0037; total triglycerides vs MI = 0.78191, P = 0.0027); LDL-Trig/LDL-<compound-id="5997">cholesterol</compound-id> vs MI = 0.80493, P = 0.0016; A-OXLDL vs USBL = 0.71930, P = 0.0084.	cholesterol__A-LPL__no_interaction
9186844-5	Compared with placebo-treated cirrhotic rats, <compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> caused increased urine <compound-id="5360545">sodium</compound-id> excretion (-10 +/- 4% vs. 13 +/- 8% from baseline values, p &lt; 0.05) and systemic vascular resistance (2.6 +/- 0.1 vs. 3.3 +/- 0.3 mmHg.min.100 g.ml-1, p &lt; 0.05); and decreased plasma <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id> levels (166.7 +/- 24.8 vs. 234.0 +/- 19.2 pg/ ml, p &lt; 0.05), <protein-id="P08424">renin</protein-id> activities (2.45 +/- 0.49 vs. 4.36 +/- 0.53 ng.ml-1.h-1, p &lt; 0.01) and <compound-id="5839">aldosterone</compound-id> concentrations (290.2 +/- 40.0 vs. 483.3 +/- 82.6 pg/ml, p &lt; 0.05).	aldosterone__atrial natriuretic peptide__no_interaction	aldosterone__renin__no_interaction	octreotide__atrial natriuretic peptide__no_interaction	octreotide__renin__no_interaction	sodium__atrial natriuretic peptide__no_interaction	sodium__renin__no_interaction
15464043-6	The introduction of di-peptide <protein-id="P06881,P01258">CGRP</protein-id> receptor antagonists, namely <compound-id="6918509">BIBN4096BS</compound-id> (1-<compound-id="72887">piperidinecarboxamide</compound-id>, N-[2-[[5-amino-1-[[4-(<compound-id="12594992">4-pyridinyl</compound-id>)-1-piperazinyl]carbonyl] pentyl] amino]-1-[(3,5-<compound-id="34264">dibromo-4-hydroxyphenyl</compound-id>) methyl]-2-oxoethyl]-4-(<compound-id="361199">1,4-dihydro-2</compound-id>-oxo-3(2H)-quinazolinyl)-, [R-(R*,S*)]-), is a breakthrough in <protein-id="P06881,P01258">CGRP</protein-id> receptor pharmacology and can be used as a tool to investigate the role of <protein-id="P06881,P01258">CGRP</protein-id> in migraine headaches.	1,4-dihydro-2__CGRP__no_interaction	dibromo-4-hydroxyphenyl__CGRP__no_interaction	piperidinecarboxamide__CGRP__no_interaction	4-pyridinyl__CGRP__no_interaction	BIBN4096BS__CGRP__no_interaction
11241353-2	Myocytes were exposed to <compound-id="25249">stanozolol</compound-id> (<compound-id="2733335,7067772">STZ</compound-id>), <compound-id="9416">testosterone enanthate</compound-id> (TE) and <compound-id="6013">testosterone</compound-id> (T) (0.1 micromol/L, 1 micromol/L, 10 micromol/L, and 100 micromol/L) for 20 h. The percentage of myocytes undergoing apoptosis was determined by <protein-id="Q5EB91">terminal deoxynucleotidyl transferase</protein-id>-mediated nick end labeling (TUNEL) and was found to be increased when compared to control myocytes at <compound-id="2733335,7067772">STZ</compound-id> 10 micromol/L 12 +/- 2% (mean +/- SD), <compound-id="2733335,7067772">STZ</compound-id> 100 micromol/L 42 +/- 3%; TE 1 micromol/L 11 +/- 2%, TE 10 micromol/L 21 +/- 3%, TE 100 micromol/L 62 +/- 2%; T 10 micromol/L 11 +/- 2%, T 100 micromol/L 40 +/- 3% (P &lt; 0.001 vs. CTL 2 +/- 2%).	stanozolol__terminal deoxynucleotidyl transferase__no_interaction	testosterone enanthate__terminal deoxynucleotidyl transferase__no_interaction	testosterone__terminal deoxynucleotidyl transferase__no_interaction	STZ__terminal deoxynucleotidyl transferase__no_interaction
9764576-2	To substitute the autocrine activity by a single physiological component, 28 cytokines, growth factors and biomodulators were tested [<protein-id="P08831">interleukin 1alpha</protein-id> (<protein-id="P08831">IL-1alpha</protein-id>), <protein-id="P09428">IL-1beta</protein-id>, <protein-id="P05016,B2BB68">IL-2</protein-id>, <protein-id="P49875">IL-3</protein-id>, <protein-id="P30367">IL-4</protein-id>, <protein-id="P26892">IL-6</protein-id>, <protein-id="P43480">IL-10</protein-id>, IL-11, <protein-id="Q28132">stem cell factor</protein-id> (SCF), platelet-derived growth factor (PDGF), acid fibroblast growth factor (aFGF), <protein-id="P03969">basic fibroblast growth factor</protein-id> (<protein-id="P03969">bFGF</protein-id>), insulin-like growth factor (<protein-id="P07455,F2X2F3,F2X2F0,F2X2F1,F2X2F2">IGF-1</protein-id>), <protein-id="P07456,B8QGI3">IGF-2</protein-id>, insulin, macrophage colony-stimulating factor (M-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id>), <protein-id="P35833">granulocyte colony-stimulating factor (G-CSF</protein-id>), <protein-id="P11052">granulocyte-macrophage colony-stimulating factor</protein-id> (<protein-id="P11052">GM-CSF</protein-id>), oncostatin, <protein-id="O97919">RANTES</protein-id> (<protein-id="O97919">regulated on activation normal T cell expressed and secreted</protein-id>), angiogenin, <protein-id="Q27956">leukaemia inhibitory factor</protein-id> (<protein-id="Q27956">LIF</protein-id>), <protein-id="P48617">erythropoietin</protein-id> (<protein-id="P48617">EPO</protein-id>), interferon alpha (INF-alpha), INF-gamma, <protein-id="Q29443">transferrin</protein-id>, tumour necrosis factor alpha (<protein-id="P01375,Q5STB3,Q06599">TNF-alpha</protein-id>, <protein-id="P01374,Q5ST95,Q6FG55,Q5STV3">TNF-beta</protein-id> and bovine serum albumin for control reasons].	CSF__LIF__no_interaction	CSF__erythropoietin__no_interaction	CSF__IL-4__no_interaction	CSF__regulated on activation normal T cell expressed and secreted__no_interaction	CSF__IL-2__no_interaction	CSF__IL-3__no_interaction	CSF__EPO__no_interaction	CSF__TNF-alpha__no_interaction	CSF__interleukin 1alpha__no_interaction	CSF__basic fibroblast growth factor__no_interaction	CSF__granulocyte colony-stimulating factor (G-CSF__no_interaction	CSF__leukaemia inhibitory factor__no_interaction	CSF__stem cell factor__no_interaction	CSF__IL-1alpha__no_interaction	CSF__bFGF__no_interaction	CSF__IL-6__no_interaction	CSF__GM-CSF__no_interaction	CSF__IGF-1__no_interaction	CSF__IGF-2__no_interaction	CSF__TNF-beta__no_interaction	CSF__granulocyte-macrophage colony-stimulating factor__no_interaction	CSF__transferrin__no_interaction	CSF__IL-10__no_interaction	CSF__IL-1beta__no_interaction	CSF__RANTES__no_interaction
21264540-5	Among 96 tumor tissues, promoter hypermethylation of the <protein-id="P24530,A0A024R645,A0A024R638">EDNRB</protein-id> gene was correlated with tumor infiltration (T1: 47.4 ± 7.31% T2:48.2 ± 9.17% <compound-id="5920">T3</compound-id>:52.9 ± 6.48% T4:53.2 ± 10.45%), lymph node metastasis (N0:45.4 ± 6.99% N1:49.0 ± 9.10% N2:52.0 ± 8.40% N3:53.7 ± 9.92%), and distant metastasis (M0:48.9 ± 6.99% M1:53.9 ± 11.98%) (P &lt; 0.05), but it was not associated with other clinicopathological characteristics.	T3__EDNRB__no_interaction
10587312-1	We report the solid phase synthesis and vasodepressor potencies of the novel hypotensive peptide [1(-beta-mercapto-beta,beta-<compound-id="9253">pentamethylene</compound-id> <compound-id="1032">propionic acid</compound-id>)-2-<compound-id="57020015">O-ethyl-D-tyrosine</compound-id>, 3-<compound-id="6322,90867653">arginine</compound-id>, <compound-id="22796635">4-valine</compound-id>] <compound-id="6322,90867653">arginine</compound-id> vasopressin, d(CH2)5[D-<compound-id="6057">Tyr</compound-id>(Et)2, Arg3, Val4]<protein-id="P01186">AVP</protein-id> (A), its related Lys3 (B), <compound-id="6057">Tyr</compound-id>-NH(9)2 (C), [Lys3, <compound-id="6057">Tyr</compound-id>-NH(9)2 (D) analogs and in a preliminary structure-activity study of positions 2-4 and 7-9, 24 analogs (1-24) of A-C. Peptides 1-6, 9-14 have the following single substituents at positions 2, 3, 4, 8 and 9 in (A): 1, D-<compound-id="6057">Tyr</compound-id>(Me)2; 2, L-<compound-id="6057">Tyr</compound-id>(Et)2; 3, Orn3; 4, N-Me-Arg3; 5, Glu3; 6, Arg4; 9, D-Arg8; 10, Eda9; 11, Arg-NH(9)2; 12, Ala-NH(9)2; 13, desGly9; 14, desGly-NH(9)2.	pentamethylene__AVP__no_interaction	propionic acid__AVP__no_interaction	O-ethyl-D-tyrosine__AVP__no_interaction	arginine__AVP__no_interaction	4-valine__AVP__no_interaction	Tyr__AVP__no_interaction
11026072-6	RESULTS: In the groups studied (A, B, and C) <compound-id="22044544,5460341">calcium</compound-id> serum levels were 9.1 +/- 0.3; 9.6 +/- 0.4; 9.3 +/- 0.6 mg/ml, respectively; osteocalcin levels were 14.8 +/- 4.6; 13.0 +/- 2.5; 11.9 +/- 3.4 ng/dl; the type I collagen carboxyterminal telopeptide (ICTP) levels were 19.6 +/- 16.5; 14.2 +/- 15.4; 13.0 +/- 18.3 micrograms/l; the <protein-id="Q5VZB9">DMO</protein-id> levels were 0.67 +/- 0.06; 0.68 +/- 0.06; 0.69 +/- 0.06 g/cm2; and the CMO levels were 1,158.8 +/- 217.4; 1,106.4 +/- 256.1; 1,176.5 +/- 240.5 g, respectively.	calcium__DMO__no_interaction
15381966-3	<compound-id="57024563,957">Octanol</compound-id>, 1.2 x 10(-3) M, a gap junction inhibitor, significantly reduced Jw (expressed as mg.20 min(-1)) in isolated toad urinary bladders (a model of the distal nephron) subjected to a transepithelial osmotic gradient and exposed to agents mimicking the <protein-id="P01185,X5DQP6">vasopressin</protein-id>-triggered mechanism: <protein-id="P01178,X5D7M6">oxytocin</protein-id>, 50 mIU.mL(-1) (from 185.3 +/- 28.0, P &lt; 0.001, to 69.0 +/- 23.6, P &lt; 0.05; Pdiff &lt; 0.01, n = 6), and cyclic AMP, 2.5 x 10(-3) M (from 98.0 +/- 32.6, P &lt; 0.02, to 31.0 +/- 13.9, NS; Pdiff &lt; 0.05, n = 12), without altering the effect of <compound-id="11286230,16219709,6420032,44424838,49867935,5311331,53486448,5702099,60196358,6433272,71308475">nystatin</compound-id>, 450 U.mL(-1), which increases Jw via a mechanism unrelated to apical aquaporin insertion (163.2 +/- 16.3, P &lt; 0.001, in controls vs. 150.3 +/- 10.4, P &lt; 0.001, in <compound-id="57024563,957">octanol</compound-id>-treated bladders; Pdiff: NS, n = 6).	nystatin__oxytocin__no_interaction	nystatin__vasopressin__no_interaction	Octanol__oxytocin__no_interaction	Octanol__vasopressin__no_interaction	octanol__oxytocin__no_interaction	octanol__vasopressin__no_interaction
1528029-6	While CO blockade had no effect on PCA induction by <protein-id="Q9QUK6,L0CL36">LPS</protein-id> (without INDO 30 microM 446 +/- 131, with INDO 30 microM 546 +/- 193, mU/2 x 10(6) cells, n = 4), <compound-id="688035">NDGA</compound-id> caused a dose-dependent inhibition (IC50 = 3 microM) without affecting cell viability (without <compound-id="688035">NDGA</compound-id> 3 microM 446 +/- 131, with <compound-id="688035">NDGA</compound-id> 3 microM 191 +/- 67, mU/2 x 10(6) cells, n = 6, P less than 0.05).	NDGA__LPS__no_interaction
7669269-3	The order of stability is 5'-d-A-(G-A-)2G + 5'-d-T-(C-T-)2C-(T-)4C-(T-C-)2T &lt; 5'-d-A-(G-A-)2G + 5'-d-T-(mC-T-)<compound-id="165390">2mC</compound-id>-(T-)4C-(T-C-)2T approximately 5'-d-A-(G-A-)2G + 5'-d-T-(C-T-)2C-(T-)4 mC-(T-mC-)2T &lt; 5'-d-A-(G-A-)2G + 5'-d-T-(mC-T-)<compound-id="165390">2mC</compound-id>-(T-)<compound-id="24180710">4mC</compound-id>-(T-mC-)2T at <protein-id="Q9NXG6">pH 4</protein-id>.	2mC__pH 4__no_interaction	4mC__pH 4__no_interaction
7998584-5	Patients underwent M-mode and 2-dimensional echocardiography as well as Doppler and peripheral pulsed Doppler flowmetry, determination of plasma <protein-id="P01160">atrial natriuretic factor</protein-id> (<protein-id="P01160">ANF</protein-id>) levels and renin activity (<protein-id="P06703">PRA</protein-id>), and of 24-hour urinary electrolyte and <compound-id="588">creatinine</compound-id> excretion in control conditions (systolic/diastolic blood pressure, 148 +/- 3/102 +/- 1 mm Hg), 4 weeks after blood pressure normalization (131 +/- 2/84 +/- 2 mm Hg; p &lt; 0.01), after 1 year of satisfactory antihypertensive treatment (142 +/- 3/90 +/- 1 mm Hg; p &lt; 0.01) and, finally, 1 month after therapy withdrawal (155 +/- 3/106 +/- 2 mm Hg; difference not significant [NS]).	creatinine__ANF__no_interaction	creatinine__PRA__no_interaction	creatinine__atrial natriuretic factor__no_interaction
23360186-7	In the diabetes group <protein-id="Q04760,X5DNM4">GLO1</protein-id> correlated with HbA1c (r = 0.33, p &lt; 0.01) and <compound-id="65359">oxidized glutathione</compound-id> (GSSG) (r = - 0.34, p &lt; 0.01) and in the control group with <compound-id="124886">GSH</compound-id> (r = 0.37, p &lt; 0.005) and fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.26, p &lt; 0.04).	GSH__GLO1__no_interaction	oxidized glutathione__GLO1__no_interaction	glucose__GLO1__no_interaction
19425567-1	<compound-id="5359967">Indium</compound-id> <protein-id="O95817">bis</protein-id>(phenolato) complexes [In(L)R(<compound-id="8028">THF</compound-id>)(n)] (L = 1,4-dithiabutanediylbis(4,6-di-tert-butylphenolato) (etbbp), R = Cl, n = 0, 1; L = 1,3-dithiapropanediylbis(6-<compound-id="90937099">tert-butyl</compound-id>-4-methylphenolato) (mtbmp), R = Me, n = 1, 2; L = 1,4-dithiabutanediyl-<protein-id="O95817">bis</protein-id>(6-<compound-id="90937099">tert-butyl</compound-id>-4-methyl-phenolato) (etbmp), R = Me, n = 0, 3; L = etbbp, R = CH(2)SiMe(3), n = 0, 4; L = 1,4-dithiabutanediylbis{4,6-di(2-phenyl-2-propyl)phenolato} (etccp), R = CH(2)SiMe(3), n = 0, 5) were prepared from <compound-id="24812">indium trichloride</compound-id> or from the corresponding <compound-id="6503">tris</compound-id>(alkyl) complexes and 1 equiv of tetradentate 1,omega-dithiaalkanediyl-bridged <protein-id="O95817">bis</protein-id>(<compound-id="996">phenol</compound-id>) LH(2).	tert-butyl__bis__no_interaction	indium trichloride__bis__no_interaction	phenol__bis__no_interaction	THF__bis__no_interaction	Indium__bis__no_interaction	tris__bis__no_interaction
11114931-6	Four lines of evidence indicate that <protein-id="Q56685,Q5DYI1">HvnA</protein-id> and <protein-id="Q9F0R5,Q5E182">HvnB</protein-id> mediate <compound-id="6322">polyarginine</compound-id> <compound-id="6022">ADP</compound-id>-ribosylation not by ARTase activity, but indirectly through an <compound-id="5893">NAD</compound-id>(+)-glycohydrolase (NADase) activity that releases free, reactive, <compound-id="192,44415180,445794">ADP-ribose</compound-id>: (i) like other NADases, and in contrast to the ARTase cholera toxin, <protein-id="Q56685,Q5DYI1">HvnA</protein-id> and <protein-id="Q9F0R5,Q5E182">HvnB</protein-id> catalyzed ribosylation of not only <compound-id="6322">polyarginine</compound-id> but also <compound-id="162282">polylysine</compound-id> and polyhistidine, and ribosylation was inhibited by <compound-id="787">hydroxylamine</compound-id>; (ii) <protein-id="Q56685,Q5DYI1">HvnA</protein-id> and <protein-id="Q9F0R5,Q5E182">HvnB</protein-id> cleaved 1, N(6)-<compound-id="46936401">etheno-NAD</compound-id>(+) and <compound-id="5893">NAD</compound-id>(+); (iii) incubation of <protein-id="Q56685,Q5DYI1">HvnA</protein-id> and <protein-id="Q9F0R5,Q5E182">HvnB</protein-id> with [(32)P]<compound-id="5893">NAD</compound-id>(+) resulted in the production of <compound-id="192,44415180,445794">ADP-ribose</compound-id>; and (iv) purified <protein-id="Q56685,Q5DYI1">HvnA</protein-id> displayed an NADase V(max) of 400 mol min(-1) mol(-1), which is within the range reported for other NADases and 10(2)- to 10(4)-fold higher than the minor NADase activity reported in bacterial ARTase toxins.	ADP__HvnA__no_interaction	ADP__HvnB__no_interaction	NAD__HvnA__no_interaction	NAD__HvnB__no_interaction	polylysine__HvnA__no_interaction	polylysine__HvnB__no_interaction	polyarginine__HvnA__no_interaction	polyarginine__HvnB__no_interaction	hydroxylamine__HvnA__no_interaction	hydroxylamine__HvnB__no_interaction	etheno-NAD__HvnA__no_interaction	etheno-NAD__HvnB__no_interaction	ADP-ribose__HvnA__no_interaction	ADP-ribose__HvnB__no_interaction
12396096-3	This in vivo study of recovery time-course from 15 mins of cerebral ischemia indicated specific biochemical assessments of functional meaning: (a) <compound-id="923">Na+</compound-id>K(+)-ATPase of synaptic plasma membranes in adult and aged animals is stimulated by ischemia; (b) this "hyperactivity" is more markedly related to adult than to aged animals; (c) these abnormalities still persist after 72 and 96 h during the recirculation times, indicating the delayed postischemic suffering of the brain; (d) specific Mg(2+)-ATPase enzyme system possess a lower catalytic power in aged animals than in adult ones, but remained unaltered in adult animals by ischemia and reperfusion; (e) Mg(2+)-ATPase is stimulated in aged animals by ischemia, further increasing during reperfusion up to 72-96 h, indicating the delayed hyperactivity of hippocampus; (f) the increased metabolic activity of hippocampus is indicated by the increased activity of cholinergic system; (g) integrity of synaptic plasma membranes seems not to be altered by 15 min ischemia to a critical extent to compromise their catalytic functionality during reperfusion; (h) <protein-id="P37136">AChE</protein-id> activity increases in both adult and aged at some survival times.	Na+__AChE__no_interaction
16082422-3	This issue focuses on the following selection of drugs: <compound-id="9821849">Abiraterone acetate</compound-id>, <compound-id="16137348">acyline</compound-id>, adalimumab, <compound-id="57476835,60961">adenosine</compound-id> triphosphate, <compound-id="10297043,11578515">AEE-788</compound-id>, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, <compound-id="2088">alendronic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt, <compound-id="16197724">alicaforsen sodium</compound-id>, <compound-id="2118">alprazolam</compound-id>, <compound-id="124088">amdoxovir</compound-id>, <compound-id="76935">AMG</compound-id>-162, <compound-id="137">aminolevulinic acid hydrochloride</compound-id>, <compound-id="157922">aminolevulinic acid methyl ester</compound-id>, <compound-id="2153">aminophylline hydrate</compound-id>, <compound-id="90470007">anakinra</compound-id>, <compound-id="111332">anecortave acetate</compound-id>, anti-<protein-id="P16410">CTLA-4</protein-id> MAb, APC-8015, <compound-id="60795">aripiprazole</compound-id>, <compound-id="2244">aspirin</compound-id>, <compound-id="148192">atazanavir sulfate</compound-id>, <compound-id="54841">atomoxetine</compound-id> hydrochloride, <compound-id="60823">atorvastatin</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="159594">atrasentan</compound-id>, <compound-id="16070039">AVE</compound-id>-5883, <compound-id="9933475">AZD-2171</compound-id>; <compound-id="21800">Betamethasone dipropionate</compound-id>, bevacizumab, <compound-id="5311027">bimatoprost</compound-id>, biphasic human <protein-id="P01308,I3WAC9">insulin</protein-id> (prb), <compound-id="387447">bortezomib</compound-id>, BR-A-657, BRL-55730, <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id>, <compound-id="2478">busulfan</compound-id>; <compound-id="5288783">Calcipotriol</compound-id>, <compound-id="9832804">calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="6006">calcium folinate</compound-id>, <compound-id="60953">capecitabine</compound-id>, <compound-id="1783">capravirine</compound-id>, <compound-id="2578">carmustine</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">caspofungin acetate</compound-id>, <compound-id="6915944">cefdinir</compound-id>, certolizumab pegol, CG-53135, <compound-id="2708">chlorambucil</compound-id>, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="5280754,5284373,5497195,57123750,6435893,73896891">ciclosporin</compound-id>, cisplatin, <compound-id="119182">clofarabine</compound-id>, <compound-id="2806,60606">clopidogrel hydrogensulfate</compound-id>, <compound-id="2818">clozapine</compound-id>, co-trimoxazole, <compound-id="15228060,9821217">CP-122721</compound-id>, <compound-id="586">creatine</compound-id>, CY-2301, <compound-id="2907">cyclophosphamide</compound-id>, cypher, <compound-id="6253">cytarabine</compound-id>, cytolin; D0401, darbepoetin alfa, <compound-id="444031">darifenacin</compound-id> hydrobromide, <compound-id="10446567">DASB</compound-id>, <compound-id="2995">desipramine hydrochloride</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="125017">desvenlafaxine</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="5743">dexamethasone</compound-id>, <compound-id="50599">didanosine</compound-id>, <compound-id="148197">diquafosol tetrasodium</compound-id>, <compound-id="148124,54277830">docetaxel</compound-id>, <compound-id="31703">doxorubicin hydrochloride</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine hydrochloride</compound-id>, <compound-id="6918296">dutasteride</compound-id>; Ecallantide, efalizumab, <compound-id="64139">efavirenz</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="57199466,772">enoxaparin</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="259329">estramustine phosphate sodium</compound-id>, etanercept, <compound-id="5991">ethinylestradiol</compound-id>, <compound-id="6917715">etonogestrel</compound-id>, <compound-id="6917715">etonogestrel</compound-id>/<compound-id="5991">ethinylestradiol</compound-id>, <compound-id="11758093,17571827,3310,439525,45356822,50989217,5284558,59360017,6419930,6610299,6708815,90657341,9916469">etoposide</compound-id>, <compound-id="45588096,53396299,56927919">exenatide</compound-id>; <compound-id="3324">Famciclovir</compound-id>, <compound-id="1727">fampridine</compound-id>, <compound-id="134018">febuxostat</compound-id>, filgrastim, <compound-id="30751">fludarabine phosphate</compound-id>, <compound-id="6215">fluocinolone acetonide</compound-id>, <compound-id="3385">fluorouracil</compound-id>, <compound-id="444036">fluticasone propionate</compound-id>, <compound-id="5353627,446155,1548972,3403">fluvastatin sodium</compound-id>, <compound-id="3035403,17854871,71316924">fondaparinux sodium</compound-id>; <compound-id="3448">Gaboxadol</compound-id>, gamma-hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">gefitinib</compound-id>, gelclair, <compound-id="60750">gemcitabine</compound-id>, <compound-id="3463">gemfibrozil</compound-id>, <compound-id="3488">glibenclamide</compound-id>, <compound-id="56842993">glyminox</compound-id>; <compound-id="3559">Haloperidol</compound-id>, heparin <compound-id="5360545">sodium</compound-id>, HPV 16/HPV 18 vaccine, human <protein-id="P01308,I3WAC9">insulin</protein-id>, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="57017735,6918173,71364,86583335">Icatibant</compound-id>, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="5359967">indium</compound-id> 111 (111In) <compound-id="74890578">ibritumomab tiuxetan</compound-id>, infliximab, INKP-100, <compound-id="807">iodine</compound-id> (I131) tositumomab, IoGen, <compound-id="43232,25897919,3746,5702074,73440752">ipratropium bromide</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; L-870810, <compound-id="60825">lamivudine</compound-id>, <compound-id="208908">lapatinib</compound-id>, <compound-id="54677946">laquinimod</compound-id>, <compound-id="5311221">latanoprost</compound-id>, <compound-id="13109">levonorgestrel</compound-id>, licochalcone a, liposomal doxorubicin, <compound-id="92727">lopinavir</compound-id>, <compound-id="92727">lopinavir</compound-id>/<compound-id="392622">ritonavir</compound-id>, <compound-id="3958">lorazepam</compound-id>, <compound-id="53232">lovastatin</compound-id>; <compound-id="3002977">Maraviroc</compound-id>, <compound-id="471161">maribavir</compound-id>, matuzumab, MDL-100907, <compound-id="460612">melphalan</compound-id>, <compound-id="126941">methotrexate</compound-id>, <compound-id="6741">methylprednisolone</compound-id>, <compound-id="5746">mitomycin</compound-id>, <compound-id="4212">mitoxantrone hydrochloride</compound-id>, <compound-id="4369359">MK-0431</compound-id>, <compound-id="9893228">MN-001</compound-id>, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, <compound-id="4271,5281078">mycophenolate mofetil</compound-id>; <compound-id="64143">Nelfinavir</compound-id> mesilate, nesiritide, <compound-id="6505803">NSC-330507</compound-id>; <compound-id="4585">Olanzapine</compound-id>, <compound-id="130881">olmesartan medoxomil</compound-id>, omalizumab, oral <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="219077">osanetant</compound-id>; PA-457, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id>, paroxetine, <compound-id="43815">paroxetine hydrochloride</compound-id>, <compound-id="16155604">PCK-3145</compound-id>, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, <compound-id="10819">perillyl alcohol</compound-id>, pexelizumab, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="5282452">pitavastatin calcium</compound-id>, <compound-id="13116,244989">porfiromycin</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="6918456">prasugrel</compound-id>, <compound-id="54687">pravastatin sodium</compound-id>, <compound-id="5865">prednisone</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="466151">prinomastat</compound-id>, <compound-id="8420">PRO-2000</compound-id>, <compound-id="4943">propofol</compound-id>, prostate cancer vaccine; <compound-id="3052776">Rasagiline</compound-id> mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, <compound-id="37542">ribavirin</compound-id>, <compound-id="6451164">rilpivirine</compound-id>, <compound-id="392622">ritonavir</compound-id>, rituximab, <compound-id="11396600">Ro-26-9228</compound-id>, <compound-id="12136802,446157,6436659,6439133">rosuvastatin calcium</compound-id>, <compound-id="6239562,4979943">rosuvastatin sodium</compound-id>, <compound-id="472335">rubitecan</compound-id>; <compound-id="3082555">Selodenoson</compound-id>, <compound-id="54454">simvastatin</compound-id>, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">sirolimus</compound-id>, <compound-id="216235">sitaxsentan</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="216239">sorafenib</compound-id>, SS(dsFv)-PE38, St. John's Wort extract, <compound-id="18283">stavudine</compound-id>; <compound-id="445643,90726579">Tacrolimus</compound-id>, <compound-id="110635">tadalafil</compound-id>, <compound-id="115358">tafenoquine succinate</compound-id>, <compound-id="9857256">talaglumetad</compound-id>, <compound-id="12001323,177347,6918336">tanomastat</compound-id>, taxus, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, <compound-id="137994,549976">tempol</compound-id>, <compound-id="464205">tenofovir</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, <compound-id="9416">testosterone enanthate</compound-id>, TH-9507, <compound-id="5426">thalidomide</compound-id>, <compound-id="54686904">tigecycline</compound-id>, <compound-id="168613,33624">timolol maleate</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, torcetrapib, <compound-id="108150">trabectedin</compound-id>, <compound-id="5282226">travoprost</compound-id>, <compound-id="5282226">travoprost</compound-id>/timolol, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate, <compound-id="170361,5310966">varenicline</compound-id>, VEGF-2 gene therapy, <compound-id="5656">venlafaxine hydrochloride</compound-id>, <compound-id="11077541,24848920,6918537">vildagliptin</compound-id>, <compound-id="11957715,3717450,5978,62313,45356936,5388993,71752952,6324671">vincristine sulfate</compound-id>, <compound-id="71616">voriconazole</compound-id>, <compound-id="11963530">VRX</compound-id>-496, <compound-id="5743186">VX-385</compound-id>; Warfarin <compound-id="5360545">sodium</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; Zanolimumab, <compound-id="35370">zidovudine</compound-id>.	didanosine__CTLA-4__no_interaction	didanosine__insulin__no_interaction	osanetant__CTLA-4__no_interaction	osanetant__insulin__no_interaction	olmesartan medoxomil__CTLA-4__no_interaction	olmesartan medoxomil__insulin__no_interaction	Valdecoxib__CTLA-4__no_interaction	Valdecoxib__insulin__no_interaction	PCK-3145__CTLA-4__no_interaction	PCK-3145__insulin__no_interaction	rubitecan__CTLA-4__no_interaction	rubitecan__insulin__no_interaction	capravirine__CTLA-4__no_interaction	capravirine__insulin__no_interaction	ciclesonide__CTLA-4__no_interaction	ciclesonide__insulin__no_interaction	varenicline__CTLA-4__no_interaction	varenicline__insulin__no_interaction	calcipotriol/betamethasone dipropionate__CTLA-4__no_interaction	calcipotriol/betamethasone dipropionate__insulin__no_interaction	febuxostat__CTLA-4__no_interaction	febuxostat__insulin__no_interaction	chlorambucil__CTLA-4__no_interaction	chlorambucil__insulin__no_interaction	acyline__CTLA-4__no_interaction	acyline__insulin__no_interaction	talaglumetad__CTLA-4__no_interaction	talaglumetad__insulin__no_interaction	desipramine hydrochloride__CTLA-4__no_interaction	desipramine hydrochloride__insulin__no_interaction	melphalan__CTLA-4__no_interaction	melphalan__insulin__no_interaction	fludarabine phosphate__CTLA-4__no_interaction	fludarabine phosphate__insulin__no_interaction	zidovudine__CTLA-4__no_interaction	zidovudine__insulin__no_interaction	capecitabine__CTLA-4__no_interaction	capecitabine__insulin__no_interaction	Selodenoson__CTLA-4__no_interaction	Selodenoson__insulin__no_interaction	VX-385__CTLA-4__no_interaction	VX-385__insulin__no_interaction	fluorouracil__CTLA-4__no_interaction	fluorouracil__insulin__no_interaction	gemcitabine__CTLA-4__no_interaction	gemcitabine__insulin__no_interaction	travoprost__CTLA-4__no_interaction	travoprost__insulin__no_interaction	etoposide__CTLA-4__no_interaction	etoposide__insulin__no_interaction	fluvastatin sodium__CTLA-4__no_interaction	fluvastatin sodium__insulin__no_interaction	aminolevulinic acid hydrochloride__CTLA-4__no_interaction	aminolevulinic acid hydrochloride__insulin__no_interaction	Tacrolimus__CTLA-4__no_interaction	Tacrolimus__insulin__no_interaction	DASB__CTLA-4__no_interaction	DASB__insulin__no_interaction	Olanzapine__CTLA-4__no_interaction	Olanzapine__insulin__no_interaction	ipratropium bromide__CTLA-4__no_interaction	ipratropium bromide__insulin__no_interaction	calcium folinate__CTLA-4__no_interaction	calcium folinate__insulin__no_interaction	sorafenib__CTLA-4__no_interaction	sorafenib__insulin__no_interaction	enoxaparin__CTLA-4__no_interaction	enoxaparin__insulin__no_interaction	glyminox__CTLA-4__no_interaction	glyminox__insulin__no_interaction	paclitaxel__CTLA-4__no_interaction	paclitaxel__insulin__no_interaction	atomoxetine__CTLA-4__no_interaction	atomoxetine__insulin__no_interaction	mitomycin__CTLA-4__no_interaction	mitomycin__insulin__no_interaction	voriconazole__CTLA-4__no_interaction	voriconazole__insulin__no_interaction	clozapine__CTLA-4__no_interaction	clozapine__insulin__no_interaction	tafenoquine succinate__CTLA-4__no_interaction	tafenoquine succinate__insulin__no_interaction	amdoxovir__CTLA-4__no_interaction	amdoxovir__insulin__no_interaction	pitavastatin calcium__CTLA-4__no_interaction	pitavastatin calcium__insulin__no_interaction	etonogestrel__CTLA-4__no_interaction	etonogestrel__insulin__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__insulin__no_interaction	Ro-26-9228__CTLA-4__no_interaction	Ro-26-9228__insulin__no_interaction	indium__CTLA-4__no_interaction	indium__insulin__no_interaction	pravastatin sodium__CTLA-4__no_interaction	pravastatin sodium__insulin__no_interaction	prasugrel__CTLA-4__no_interaction	prasugrel__insulin__no_interaction	laquinimod__CTLA-4__no_interaction	laquinimod__insulin__no_interaction	treprostinil sodium__CTLA-4__no_interaction	treprostinil sodium__insulin__no_interaction	bortezomib__CTLA-4__no_interaction	bortezomib__insulin__no_interaction	methylprednisolone__CTLA-4__no_interaction	methylprednisolone__insulin__no_interaction	alicaforsen sodium__CTLA-4__no_interaction	alicaforsen sodium__insulin__no_interaction	methotrexate__CTLA-4__no_interaction	methotrexate__insulin__no_interaction	ribavirin__CTLA-4__no_interaction	ribavirin__insulin__no_interaction	diquafosol tetrasodium__CTLA-4__no_interaction	diquafosol tetrasodium__insulin__no_interaction	alendronic acid__CTLA-4__no_interaction	alendronic acid__insulin__no_interaction	Yttrium__CTLA-4__no_interaction	Yttrium__insulin__no_interaction	propofol__CTLA-4__no_interaction	propofol__insulin__no_interaction	anecortave acetate__CTLA-4__no_interaction	anecortave acetate__insulin__no_interaction	creatine__CTLA-4__no_interaction	creatine__insulin__no_interaction	AMG__CTLA-4__no_interaction	AMG__insulin__no_interaction	alprazolam__CTLA-4__no_interaction	alprazolam__insulin__no_interaction	perillyl alcohol__CTLA-4__no_interaction	perillyl alcohol__insulin__no_interaction	vardenafil hydrochloride__CTLA-4__no_interaction	vardenafil hydrochloride__insulin__no_interaction	venlafaxine hydrochloride__CTLA-4__no_interaction	venlafaxine hydrochloride__insulin__no_interaction	vincristine sulfate__CTLA-4__no_interaction	vincristine sulfate__insulin__no_interaction	darifenacin__CTLA-4__no_interaction	darifenacin__insulin__no_interaction	atrasentan__CTLA-4__no_interaction	atrasentan__insulin__no_interaction	MN-001__CTLA-4__no_interaction	MN-001__insulin__no_interaction	clofarabine__CTLA-4__no_interaction	clofarabine__insulin__no_interaction	anakinra__CTLA-4__no_interaction	anakinra__insulin__no_interaction	gefitinib__CTLA-4__no_interaction	gefitinib__insulin__no_interaction	Betamethasone dipropionate__CTLA-4__no_interaction	Betamethasone dipropionate__insulin__no_interaction	ixabepilone__CTLA-4__no_interaction	ixabepilone__insulin__no_interaction	MK-0431__CTLA-4__no_interaction	MK-0431__insulin__no_interaction	90Y__CTLA-4__no_interaction	90Y__insulin__no_interaction	ethinylestradiol__CTLA-4__no_interaction	ethinylestradiol__insulin__no_interaction	dexamethasone__CTLA-4__no_interaction	dexamethasone__insulin__no_interaction	CP-122721__CTLA-4__no_interaction	CP-122721__insulin__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__insulin__no_interaction	telithromycin__CTLA-4__no_interaction	telithromycin__insulin__no_interaction	maribavir__CTLA-4__no_interaction	maribavir__insulin__no_interaction	sodium__CTLA-4__no_interaction	sodium__insulin__no_interaction	bimatoprost__CTLA-4__no_interaction	bimatoprost__insulin__no_interaction	carmustine__CTLA-4__no_interaction	carmustine__insulin__no_interaction	tempol__CTLA-4__no_interaction	tempol__insulin__no_interaction	caspofungin acetate__CTLA-4__no_interaction	caspofungin acetate__insulin__no_interaction	efavirenz__CTLA-4__no_interaction	efavirenz__insulin__no_interaction	AVE__CTLA-4__no_interaction	AVE__insulin__no_interaction	succinate__CTLA-4__no_interaction	succinate__insulin__no_interaction	PRO-2000__CTLA-4__no_interaction	PRO-2000__insulin__no_interaction	cyclophosphamide__CTLA-4__no_interaction	cyclophosphamide__insulin__no_interaction	Abiraterone acetate__CTLA-4__no_interaction	Abiraterone acetate__insulin__no_interaction	NSC-330507__CTLA-4__no_interaction	NSC-330507__insulin__no_interaction	trabectedin__CTLA-4__no_interaction	trabectedin__insulin__no_interaction	exenatide__CTLA-4__no_interaction	exenatide__insulin__no_interaction	busulfan__CTLA-4__no_interaction	busulfan__insulin__no_interaction	VRX__CTLA-4__no_interaction	VRX__insulin__no_interaction	Nelfinavir__CTLA-4__no_interaction	Nelfinavir__insulin__no_interaction	dutasteride__CTLA-4__no_interaction	dutasteride__insulin__no_interaction	tigecycline__CTLA-4__no_interaction	tigecycline__insulin__no_interaction	prinomastat__CTLA-4__no_interaction	prinomastat__insulin__no_interaction	pregabalin__CTLA-4__no_interaction	pregabalin__insulin__no_interaction	gemfibrozil__CTLA-4__no_interaction	gemfibrozil__insulin__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__insulin__no_interaction	aspirin__CTLA-4__no_interaction	aspirin__insulin__no_interaction	AEE-788__CTLA-4__no_interaction	AEE-788__insulin__no_interaction	vildagliptin__CTLA-4__no_interaction	vildagliptin__insulin__no_interaction	tenofovir__CTLA-4__no_interaction	tenofovir__insulin__no_interaction	porfiromycin__CTLA-4__no_interaction	porfiromycin__insulin__no_interaction	tipifarnib__CTLA-4__no_interaction	tipifarnib__insulin__no_interaction	lorazepam__CTLA-4__no_interaction	lorazepam__insulin__no_interaction	ritonavir__CTLA-4__no_interaction	ritonavir__insulin__no_interaction	ciclosporin__CTLA-4__no_interaction	ciclosporin__insulin__no_interaction	Calcipotriol__CTLA-4__no_interaction	Calcipotriol__insulin__no_interaction	Icatibant__CTLA-4__no_interaction	Icatibant__insulin__no_interaction	lovastatin__CTLA-4__no_interaction	lovastatin__insulin__no_interaction	docetaxel__CTLA-4__no_interaction	docetaxel__insulin__no_interaction	prasterone__CTLA-4__no_interaction	prasterone__insulin__no_interaction	imatinib mesylate__CTLA-4__no_interaction	imatinib mesylate__insulin__no_interaction	Haloperidol__CTLA-4__no_interaction	Haloperidol__insulin__no_interaction	Rasagiline__CTLA-4__no_interaction	Rasagiline__insulin__no_interaction	aminolevulinic acid methyl ester__CTLA-4__no_interaction	aminolevulinic acid methyl ester__insulin__no_interaction	lapatinib__CTLA-4__no_interaction	lapatinib__insulin__no_interaction	thalidomide__CTLA-4__no_interaction	thalidomide__insulin__no_interaction	calcium__CTLA-4__no_interaction	calcium__insulin__no_interaction	desloratadine__CTLA-4__no_interaction	desloratadine__insulin__no_interaction	Famciclovir__CTLA-4__no_interaction	Famciclovir__insulin__no_interaction	aripiprazole__CTLA-4__no_interaction	aripiprazole__insulin__no_interaction	adenosine__CTLA-4__no_interaction	adenosine__insulin__no_interaction	fluocinolone acetonide__CTLA-4__no_interaction	fluocinolone acetonide__insulin__no_interaction	iodine__CTLA-4__no_interaction	iodine__insulin__no_interaction	cytarabine__CTLA-4__no_interaction	cytarabine__insulin__no_interaction	testosterone enanthate__CTLA-4__no_interaction	testosterone enanthate__insulin__no_interaction	rilpivirine__CTLA-4__no_interaction	rilpivirine__insulin__no_interaction	atorvastatin__CTLA-4__no_interaction	atorvastatin__insulin__no_interaction	cefdinir__CTLA-4__no_interaction	cefdinir__insulin__no_interaction	fampridine__CTLA-4__no_interaction	fampridine__insulin__no_interaction	mitoxantrone hydrochloride__CTLA-4__no_interaction	mitoxantrone hydrochloride__insulin__no_interaction	tadalafil__CTLA-4__no_interaction	tadalafil__insulin__no_interaction	sitaxsentan__CTLA-4__no_interaction	sitaxsentan__insulin__no_interaction	tiotropium bromide__CTLA-4__no_interaction	tiotropium bromide__insulin__no_interaction	clopidogrel hydrogensulfate__CTLA-4__no_interaction	clopidogrel hydrogensulfate__insulin__no_interaction	sirolimus__CTLA-4__no_interaction	sirolimus__insulin__no_interaction	mycophenolate mofetil__CTLA-4__no_interaction	mycophenolate mofetil__insulin__no_interaction	fondaparinux sodium__CTLA-4__no_interaction	fondaparinux sodium__insulin__no_interaction	lamivudine__CTLA-4__no_interaction	lamivudine__insulin__no_interaction	simvastatin__CTLA-4__no_interaction	simvastatin__insulin__no_interaction	tanomastat__CTLA-4__no_interaction	tanomastat__insulin__no_interaction	duloxetine hydrochloride__CTLA-4__no_interaction	duloxetine hydrochloride__insulin__no_interaction	estramustine phosphate sodium__CTLA-4__no_interaction	estramustine phosphate sodium__insulin__no_interaction	prednisone__CTLA-4__no_interaction	prednisone__insulin__no_interaction	budesonide__CTLA-4__no_interaction	budesonide__insulin__no_interaction	emtricitabine__CTLA-4__no_interaction	emtricitabine__insulin__no_interaction	stavudine__CTLA-4__no_interaction	stavudine__insulin__no_interaction	atazanavir sulfate__CTLA-4__no_interaction	atazanavir sulfate__insulin__no_interaction	latanoprost__CTLA-4__no_interaction	latanoprost__insulin__no_interaction	tegaserod maleate__CTLA-4__no_interaction	tegaserod maleate__insulin__no_interaction	paroxetine hydrochloride__CTLA-4__no_interaction	paroxetine hydrochloride__insulin__no_interaction	pimecrolimus__CTLA-4__no_interaction	pimecrolimus__insulin__no_interaction	aminophylline hydrate__CTLA-4__no_interaction	aminophylline hydrate__insulin__no_interaction	doxorubicin hydrochloride__CTLA-4__no_interaction	doxorubicin hydrochloride__insulin__no_interaction	ibritumomab tiuxetan__CTLA-4__no_interaction	ibritumomab tiuxetan__insulin__no_interaction	glibenclamide__CTLA-4__no_interaction	glibenclamide__insulin__no_interaction	rosuvastatin sodium__CTLA-4__no_interaction	rosuvastatin sodium__insulin__no_interaction	tenofovir disoproxil fumarate__CTLA-4__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	Gaboxadol__CTLA-4__no_interaction	Gaboxadol__insulin__no_interaction	rosuvastatin calcium__CTLA-4__no_interaction	rosuvastatin calcium__insulin__no_interaction	desvenlafaxine__CTLA-4__no_interaction	desvenlafaxine__insulin__no_interaction	Maraviroc__CTLA-4__no_interaction	Maraviroc__insulin__no_interaction	timolol maleate__CTLA-4__no_interaction	timolol maleate__insulin__no_interaction	levonorgestrel__CTLA-4__no_interaction	levonorgestrel__insulin__no_interaction	eletriptan__CTLA-4__no_interaction	eletriptan__insulin__no_interaction	fluticasone propionate__CTLA-4__no_interaction	fluticasone propionate__insulin__no_interaction	AZD-2171__CTLA-4__no_interaction	AZD-2171__insulin__no_interaction
16831357-5	Eighty-five PCOS patients were diagnosed; PCOS accounted for 97.65% (83/85) in &lt;or= 35 years old population groups; (2) Clinical manifestations were different between PCOS groups and controls in each age stage (P &lt; 0.05); Menstruation, body hair Ferriman-Gallny (F-G) score, acne, ovarian follicle numbers decreased with aging among PCOS groups, and menstruation cycle was longer, <compound-id="6013">testosterone</compound-id> (T), free androgen index (FAI) and ovarian follicle numbers were higher, sex hormone-binding globulin (SHBG) was lower than control groups of the same age respectively (P &lt; 0.01); (3) Homeostasis model assessment-<protein-id="P01308,I3WAC9">insulin</protein-id> resistance (Homa-IR) index in infertility PCOS group was higher than in fertility group (1.49 +/- 0.73 vs 1.31 +/- 0.66; t = 2.058; P &lt; 0.05); fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> in obesity PCOS group was higher than in non-obesity group (8.50 +/- 3.46 vs 5.7 +/- 2.3, t = 2.984; P &lt; 0.01, 5.45 +/- 0.54 vs 4.88 +/- 0.45, t = 2.891; P &lt; 0.01), in contrast, <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity index was lower in obesity PCOS group than in non-obesity group (0.025 +/- 0.015 vs 0.044 +/- 0.026; t = 2.292, P &lt; 0.05).	testosterone__insulin__no_interaction	glucose__insulin__no_interaction
18820765-2	Oral administration of <compound-id="25750,3032604,3033834">phosphamidon</compound-id> (1.74 mg/kg), an organophosphate insecticide, increased serum <compound-id="10964">malondialdehyde</compound-id> (3.83 +/- 0.18 vs 2.91 +/- 0.24 nmol/mL; P &lt; 0.05) and decreased erythrocyte <compound-id="5359597">superoxide</compound-id> dismutase (567.8 +/- 24.36 vs 749.16 +/- 102.61 U/gHb; P &lt; 0.05), <protein-id="P04762">catalase</protein-id> activity (1.86 +/- 0.18 vs 2.43 +/- 0.08 U/gHb; P &lt; 0.05) and whole blood <compound-id="124886,20725278,745">glutathione</compound-id> levels (1.25 +/- 0.21 vs 2.28 +/- 0.08 mg/gHb; P &lt; 0.05) showing <compound-id="25750,3032604,3033834">phosphamidon</compound-id>-induced oxidative stress.	phosphamidon__catalase__no_interaction	glutathione__catalase__no_interaction	malondialdehyde__catalase__no_interaction	superoxide__catalase__no_interaction
10611439-1	We investigated, in ferret trachea in vitro, the binding characteristics and the inhibition of non-adrenergic, non-cholinergic (NANC) neural mucus secretion of four tachykinin receptor antagonists: the non-peptide tachykinin <protein-id="P25103">NK(1</protein-id>) receptor antagonists CGP 49823 ((2R,4S)-<compound-id="192342">2-benzyl-1</compound-id>-(3, 5-<compound-id="34224">dimethylbenzoyl</compound-id>)-4-(<compound-id="7047">quinolin</compound-id>-micro-ylmethyl amino) piperidine), CGP 55000 ((2R,4S)-<compound-id="192342">2-benzyl-1</compound-id>-(3, 5-bistrifluoromethyl-benzoyl)-4-(quinolinyl-methylamino)piperidine ) and <compound-id="105083">CP 99,994</compound-id> ((+)-(2S,<compound-id="21439199">3S</compound-id>)-3-methoxybenzyl amino)-<compound-id="103020">2-phenylpiperidine</compound-id>), and the peptide tachykinin <protein-id="P20366,Q9Y494">NK(2</protein-id>) receptor antagonist <compound-id="6438356">MEN 10,627</compound-id> (cyclo(<compound-id="7009610">Met-Asp</compound-id>-<compound-id="4427709">Trp-Phe</compound-id>-Dap-Leu)cyclo(2beta-5beta)).	CP 99,994__NK(1__no_interaction	CP 99,994__NK(2__no_interaction	3S__NK(1__no_interaction	3S__NK(2__no_interaction	Trp-Phe__NK(1__no_interaction	Trp-Phe__NK(2__no_interaction	2-phenylpiperidine__NK(1__no_interaction	2-phenylpiperidine__NK(2__no_interaction	MEN 10,627__NK(1__no_interaction	MEN 10,627__NK(2__no_interaction	quinolin__NK(1__no_interaction	quinolin__NK(2__no_interaction	Met-Asp__NK(1__no_interaction	Met-Asp__NK(2__no_interaction	2-benzyl-1__NK(1__no_interaction	2-benzyl-1__NK(2__no_interaction	dimethylbenzoyl__NK(1__no_interaction	dimethylbenzoyl__NK(2__no_interaction
15848720-9	PD effects at C0h/C2h (% expression +/- <compound-id="5289348">SEM</compound-id>, all P &lt; .05) were IL-2, 18 +/- 3/10 +/- 2; <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>, 12 +/- 2/7 +/- 1; <protein-id="P12004">PCNA</protein-id>, 8 +/- 1/5 +/- 1; <protein-id="P01589,Q5W005">CD25</protein-id>, 26 +/- 4/13 +/- 2; <protein-id="P25445,Q59FU8">CD95</protein-id>, 23 +/- 4/11 +/- 2).	SEM__PCNA__no_interaction	SEM__TNF-alpha__no_interaction	SEM__CD95__no_interaction	SEM__CD25__no_interaction
23322993-17	However, over-expression of <protein-id="P00406,Q8SEZ5">COX-2</protein-id> was significantly suppressed by <compound-id="5372374,78350454">CUR</compound-id> (77.52 ± 1.68 vs 100 ± 0.00, P &lt; 0.001), HHC (71.33 ± 3.01 vs 100 ± 0.00, P &lt; 0.001), 5-FU + <compound-id="5372374,78350454">CUR</compound-id> (76.25 ± 3.32 vs 100 ± 0.00, P &lt; 0.001) and 5-FU + HHC (68.48 ± 2.24 vs 100 ± 0.00, P &lt; 0.001) in the treated groups compared to the vehicle group.	CUR__COX-2__no_interaction
23322993-18	Moreover, <compound-id="5372374,78350454">CUR</compound-id> (77.52 ± 1.68 vs 95.79 ± 1.60, P &lt; 0.001), HHC (71.33 ± 3.01 vs 95.79 ± 1.60, P &lt; 0.001), 5-FU + <compound-id="5372374,78350454">CUR</compound-id> treatments (76.25 ± 3.32 vs 95.79 ± 1.60, P &lt; 0.001) and 5-FU + HHC (68.48 ± 2.24 vs 95.79 ± 1.60, P &lt; 0.001) markedly decreased <protein-id="P00406,Q8SEZ5">COX-2</protein-id> protein expression more than 5-FU alone.	CUR__COX-2__no_interaction
15063517-3	<compound-id="40539">QUS</compound-id> parameters of <protein-id="Q06141,Q53S56">hip</protein-id> (AdSos = 1806.2 +/- 104.6 m s(-1); UBPS = 0.22 +/- 0.13) or spine fracture (AdSos = 1774.4 +/- 90.0 m s(-1); UBPS = 0.19 +/- 0.10) were not significantly lower than controls (AdSos = 1819.1 +/- 111.9 m s(-1); UBPS = 0.25 +/- 0.17), and BMD of <protein-id="Q06141,Q53S56">hip</protein-id> (spine: 756.0 +/- 138.9 mg cm(-2); femoral neck: 583.6 +/- 61.8 mg cm(-2)) and vertebral (spine: 727.4 +/- 120.4 mg cm(-2); femoral neck: 592.8 +/- 82.1 mg cm(-2);) fracture was lower than controls (spine: 829.2 +/- 167.6 mg cm(-2); femoral neck 665.0 +/- 108.9 mg cm(-2)) (p &lt; 0.001).	QUS__hip__no_interaction
18089463-4	RESULTS: Twelve months after renal transplantation, significant differences were found between Group I versus Group II in plasma levels of <compound-id="123831">asymmetric dimethylarginine</compound-id> (ADMA) (3.65 [SD +/- 0.47 micromol/L] versus 2.01 [SD +/- 0.36 micromol/L], P &lt; .01), <protein-id="Q15848,A8K660,B2R773,Q8K3R4">adiponectin</protein-id> (<protein-id="Q15848,A8K660,B2R773">ADPN</protein-id>) (15.4 [SD +/- 6.6 microg/mL] versus 22.3 [SD +/- 8.2 microg/mL], P &lt; .01), <protein-id="P50596">leptin</protein-id> (51.3 [SD +/- 11.2 ng/L] versus 21.3 [SD +/- 9.2 ng/L], P &lt; .01), soluble <protein-id="P50596">leptin</protein-id> receptor (24.6 [SD +/- 8.4 U/mL] versus 46.1 [SD +/- 11.4 U/mL], P &lt; .01), <protein-id="Q8K4J7">resistin</protein-id> (20.8 [SD +/- 10.1 microg/mL] versus 14.6 [SD +/- 6.4 microg/mL], P &lt; .025), and triglycerides (3.9 [SD +/- 1.6] versus mmol/L 2.8 [SD +/- 1.6 mmol/L], P &lt; .01).	asymmetric dimethylarginine__leptin__no_interaction	asymmetric dimethylarginine__resistin__no_interaction	asymmetric dimethylarginine__ADPN__no_interaction	asymmetric dimethylarginine__adiponectin__no_interaction
19400561-1	A series of five-coordinate <compound-id="5359268">aluminum</compound-id> complexes supported by o-phenylene-derived amido <compound-id="139283">diphosphine</compound-id> ligands, [N(o-C(6)H(4)PR(2))(2)](-) ([R-<protein-id="P00491,V9HWH6">PNP</protein-id>](-); R = Ph, (i)Pr) and [N(o-C(6)H(4)PPh(2))(o-C(6)H(4)P(i)Pr(2))](-) ([Ph-<protein-id="P00491,V9HWH6">PNP</protein-id>-(i)Pr](-)), have been prepared and structurally characterized.	diphosphine__PNP__no_interaction	aluminum__PNP__no_interaction
22342968-5	In the present study, tracheobronchial-projecting AVPNs (T-AVPNs) were retrogradely labeled from the trachea wall; fluorescently labeled T-AVPNs in the eNA were recorded with whole-cell voltage patch clamp; and the effects of <protein-id="P19327">5-HT(1A/7) receptor</protein-id> agonist (±)-8-Hydroxy-2-(dipropylamino) <compound-id="8404">tetralin</compound-id> hydrobromide (8-OH-DPAT) (1 μmol L(-1)) and 5-HT(2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-<compound-id="6363">2-aminopropane</compound-id> (DOI) (10 μmol L(-1)) on the synaptic inputs were examined.	2-aminopropane__5-HT(1A/7) receptor__no_interaction	tetralin__5-HT(1A/7) receptor__no_interaction
19435828-6	RESULTS: The area under the curve divided by time (AUC(0-360 min)/360 min) in obese vs. nonobese was as follows: 1) arterial <compound-id="206,5793,64689,79025">glucose</compound-id> was similar 6.04 +/- 0.2 vs. 5.67 +/- 0.1 mm), but <protein-id="P01308,I3WAC9">insulin</protein-id> was increased (65.5 +/- 6.6 vs. 28.7 +/- 1.7 mU/liter, P = 0.0004); 2) BF was decreased (3 +/- 0.2 vs. 4.4 +/- 0.3 ml/min per 100 ml tissue in M, P = 0.002 and 1.8 +/- 0.1 vs. 3.7 +/- 0.3 ml/min per 100 ml tissue in AD, P &lt; 0.0001); 3) <compound-id="206,5793,64689,79025">glucose</compound-id> uptake was decreased (0.9 +/- 0.1 vs. 2.3 +/- 0.4 micromol/min per 100 ml tissue in M, P = 0.002 and 0.45 +/- 0.1 vs. 1.1 +/- 0.17 micromol/min per 100 ml tissue in AD, P = 0.01); 4) fractional <compound-id="206,5793,64689,79025">glucose</compound-id> extraction was decreased in M (5 +/- 1 vs. 9 +/- 1%, P = 0.03), but was similar in AD (3 +/- 1 vs. 3.6 +/- 1.4%); 5) <compound-id="206,5793,64689,79025">glucose</compound-id> uptake (per total fat mass) was increased (0.275 +/- 0.04 vs. 0.12 +/- 0.02 mmol/min, P = 0.027).	glucose__insulin__no_interaction
23702664-9	Multivariate analysis confirmed that the SVR was significantly associated with genotype (OR: 13.40, 95% CI: 1.73-103.58, P = 0.013), baseline HCV RNA (OR: 0.19, 95% CI: 0.06-0.59, P = 0.004), BMI (OR: 0.73, 95% CI: 0.56-0.96, P = 0.022), and <compound-id="3037877">EOT</compound-id> <protein-id="O15524,Q4JHT5">SOCS-1</protein-id> methylation (OR: 1.71, 95% CI: 1.11-2.62, P = 0.014).	EOT__SOCS-1__no_interaction
12931846-11	The following biomarkers were analyzed: * polymorphisms in genes involved in BD metabolism (Prague and Burlington); * urinary concentrations of 1-hydroxy-2-(<compound-id="54311034">N-acetylcysteinyl</compound-id>)-3-<compound-id="7844">butene</compound-id> and <compound-id="91528795">2-hydroxy-1-(N-acetylcysteinyl)-3-butene</compound-id> (M2 [refers to an isomeric mixture of both forms]) (Amsterdam); * urinary concentrations of 1,2-dihydroxy-4-(<compound-id="54311034">N-acetylcysteinyl</compound-id>)-<compound-id="7843">butane</compound-id> (M1) (Amsterdam); * concentrations of the hemoglobin (Hb) adducts <compound-id="54358626">N-(1-[hydroxymethyl]-2-propenyl)valine</compound-id> and N-(<compound-id="97257">2-hydroxy-</compound-id>3-butenyl)<compound-id="6287">valine</compound-id> (HBVal [refers to an isomeric mixture of both forms]) (Amsterdam); * concentrations of the Hb adduct N-(2,3,4-<compound-id="18970792">trihydroxybutyl</compound-id>)<compound-id="6287">valine</compound-id> (THBVal) (Chapel Hill); * T cell mutations in the <protein-id="P00492">hypoxanthine phosphoribosyltransferase</protein-id> (<protein-id="P00492">HPRT</protein-id>) gene (autoradiographic assay in Galveston with slide review in Burlington; cloning assay in Leiden with mutational spectra determined in Burlington); and * chromosomal aberrations by the conventional method and by fluorescence in situ hybridization [FISH]), and cytogenetic changes (sister chromatid exchanges [SCEs] (Prague).	valine__hypoxanthine phosphoribosyltransferase__no_interaction	valine__HPRT__no_interaction	2-hydroxy-1-(N-acetylcysteinyl)-3-butene__hypoxanthine phosphoribosyltransferase__no_interaction	2-hydroxy-1-(N-acetylcysteinyl)-3-butene__HPRT__no_interaction	N-acetylcysteinyl__hypoxanthine phosphoribosyltransferase__no_interaction	N-acetylcysteinyl__HPRT__no_interaction	N-(1-[hydroxymethyl]-2-propenyl)valine__hypoxanthine phosphoribosyltransferase__no_interaction	N-(1-[hydroxymethyl]-2-propenyl)valine__HPRT__no_interaction	butane__hypoxanthine phosphoribosyltransferase__no_interaction	butane__HPRT__no_interaction	2-hydroxy-__hypoxanthine phosphoribosyltransferase__no_interaction	2-hydroxy-__HPRT__no_interaction	butene__hypoxanthine phosphoribosyltransferase__no_interaction	butene__HPRT__no_interaction	trihydroxybutyl__hypoxanthine phosphoribosyltransferase__no_interaction	trihydroxybutyl__HPRT__no_interaction
17346805-8	Our findings indicated: (1) 100 microg of P2 peptide 57-81 and 200 microg of P0 peptide 180-199 may induce an acute <compound-id="6432248">EAN</compound-id> and 200 microg of P2 peptide 57-81 may induce a chronic <compound-id="6432248">EAN</compound-id>; (2) Lewis rats were more sensitive to P2 peptide 57-81 than P0 peptide 180-199; (3) clinical disease had nothing to do with a change of relative CD4+ T cells number in lymph node MNC; (4) frequencies of CD4+CD25+ T cells and levels of <protein-id="P17246">TGF-beta1</protein-id> secreted by lymphocytes negatively paralleled clinical <compound-id="6432248">EAN</compound-id>, while levels of <protein-id="P01581">IFN-gamma</protein-id> secreted by lymphocytes roughly paralleled clinical <compound-id="6432248">EAN</compound-id> at the acute phase; (5) sciatic nerve sections from the chronic <compound-id="6432248">EAN</compound-id> rats didn't show any inflammatory cells, but showed remaining segmental demyelination and axonal collapse at the chronic phase; (6) self-limitation of acute <compound-id="6432248">EAN</compound-id> may owe to the rising levels of <protein-id="P20096">IL-4</protein-id> and <protein-id="P29456">IL-10</protein-id>, while a longer duration of chronic <compound-id="6432248">EAN</compound-id> may owe to the decreasing levels of <protein-id="P20096">IL-4</protein-id> and <protein-id="P29456">IL-10</protein-id>.	EAN__IFN-gamma__no_interaction	EAN__IL-4__no_interaction	EAN__TGF-beta1__no_interaction	EAN__IL-10__no_interaction
18811153-1	Four tetranuclear heterometallic compounds, [(Tp)<compound-id="115022">Fe(CN)3</compound-id>]2[<protein-id="Q9UHG0">Ru2</protein-id>(DMBA)4] (1), [(<compound-id="75318">MeTp</compound-id>)<compound-id="115022">Fe(CN)3</compound-id>]2[<protein-id="Q9UHG0">Ru2</protein-id>(DMBA)4] (2), [((i)BuTp)<compound-id="115022">Fe(CN)3</compound-id>]2[<protein-id="Q9UHG0">Ru2</protein-id>(DMBA)4] (3), and [(PhTp)<compound-id="115022">Fe(CN)3</compound-id>]2[<protein-id="Q9UHG0">Ru2</protein-id>(DMBA)4] (4) [DMBA = <compound-id="91559053">N,N'-dimethylbenzamidinate</compound-id>, Tp = (<compound-id="53708583">hydrotris(pyrazolyl)borate</compound-id>, <compound-id="75318">MeTp</compound-id> = (methyltris(<compound-id="1048">pyrazolyl</compound-id>)<compound-id="26574">borate</compound-id>, (i)BuTp = (2-methylpropyltris(<compound-id="1048">pyrazolyl</compound-id>)<compound-id="26574">borate</compound-id>, and PhTp = (<compound-id="6503">tris</compound-id>(<compound-id="1048">pyrazolyl</compound-id>)<compound-id="78412">phenylborate</compound-id>)] were prepared from the combination of <protein-id="Q9UHG0">Ru2</protein-id>(DMBA)4(NO3)2 and an appropriate [(<compound-id="122108">RTp</compound-id>)<compound-id="115022">Fe(CN)3</compound-id>](-).	MeTp__Ru2__no_interaction	N,N'-dimethylbenzamidinate__Ru2__no_interaction	borate__Ru2__no_interaction	phenylborate__Ru2__no_interaction	RTp__Ru2__no_interaction	hydrotris(pyrazolyl)borate__Ru2__no_interaction	pyrazolyl__Ru2__no_interaction	Fe(CN)3__Ru2__no_interaction	tris__Ru2__no_interaction
11579433-3	In the last five years, specific mutations have been defined in Lafora disease (gene for <protein-id="O95278,H0UI04">laforin</protein-id> or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (<protein-id="O14773">CLN2</protein-id> gene for <protein-id="O14773">tripeptidyl peptidase 1</protein-id> in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (<protein-id="O75503,A0A024R644">CLN5</protein-id> gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (<protein-id="Q13286,Q2TA70,A0A024QZB8,B4DFF3,B4DMY6">CLN3</protein-id> gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in <compound-id="984">palmitoyl</compound-id>-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA <compound-id="5962">Lys</compound-id> mutation in mitochondrial DNA).	palmitoyl__laforin__no_interaction	palmitoyl__CLN5__no_interaction	palmitoyl__tripeptidyl peptidase 1__no_interaction	palmitoyl__CLN3__no_interaction	palmitoyl__CLN2__no_interaction	Lys__laforin__no_interaction	Lys__CLN5__no_interaction	Lys__tripeptidyl peptidase 1__no_interaction	Lys__CLN3__no_interaction	Lys__CLN2__no_interaction
20965535-7	Compared with wild type mice, <protein-id="Q06186,Q5FW64">HB-EGF</protein-id> transgenic mice had significantly decreased histologic injury (mean injury grade 2.79 ± 0.84 vs 3.88 ± 1.43, P = .02), apoptosis indices (mean apoptosis index 8.77 ± 5.23 vs 17.91 ± 13.23, P = .03), and mucosal permeability (<compound-id="18730">FITC</compound-id>-<compound-id="4125253,5460037">dextran</compound-id> 4 clearance 13.06 ± 5.67 vs 20.03 ± 7.81 nL/min/ m(2), P = .02) at 3 hours of reperfusion.	FITC__HB-EGF__no_interaction	dextran__HB-EGF__no_interaction
1806362-4	In <compound-id="477579">MyD</compound-id> patients SI was reduced (p less than 0.01) by 71% to 1.4 +/- 0.3 x 10(-4) <protein-id="P13987,Q6FHM9">min-1</protein-id>/(microU/ml), whereas in controls it was 4.85 +/- 0.77; SG was within the normal range: 0.044 +/- 0.012 <protein-id="P13987,Q6FHM9">min-1</protein-id> in <compound-id="477579">MyD</compound-id> patients and 0.036 +/- 0.017 <protein-id="P13987,Q6FHM9">min-1</protein-id> in controls; <protein-id="Q96C90">phi 1</protein-id> increased in <compound-id="477579">MyD</compound-id> patients (7.4 +/- 1.3 min (microU/ml)/(mg/dl) versus 4.1 +/- 1.2 in controls); phi 2 increased in <compound-id="477579">MyD</compound-id> patients (126 +/- 47 x 10(4) <protein-id="P13987,Q6FHM9">min-2</protein-id>/(microU/ml)/(mg/dl) versus 17 +/- 6 in controls; p less than 0.05).	MyD__min-2__no_interaction	MyD__phi 1__no_interaction	MyD__min-1__no_interaction
7996680-2	These are; <protein-id="Q14576">ple21</protein-id> in limbic encephalitis; PCD17, <protein-id="Q01850">CDR62</protein-id>, <protein-id="P51861">CDR34</protein-id>, and CZF in paraneoplastic cerebellar degeneration; one of the anion transporters band 3 in chorea-acanthocytosis; visinin-like substance in cancer-associated retinopathy (CAR syndrome); <protein-id="P02686,A0A024R384">myelin basic protein</protein-id> (<protein-id="P02686,A0A024R384">MBP</protein-id>) and <protein-id="P60201,A8K9L3,B4DI30">proteolipid protein</protein-id> (<protein-id="P60201,A8K9L3,B4DI30">PLP</protein-id>) in acute disseminated encephalomyelitis; <protein-id="P02686,A0A024R384">MBP</protein-id>, <protein-id="P60201,A8K9L3,B4DI30">PLP</protein-id> and myelin-oligodendrocyte glycoprotein (MOG) in multiple sclerosis; <compound-id="23327,33032">glutamic acid</compound-id> decarboxylase in stiff-man syndrome; GM1 ganglioside in amyotrophic lateral sclerosis; peripheral nerve K+ channel in Isaacs syndrome; synaptotagmin in Lambert-Eaton syndrome; <compound-id="187">acetylcholine</compound-id> receptor in myasthenia gravis; GM1 ganglioside in Guillain-Barré syndrome; GQ1b ganglioside in Fisher syndrome; myelin-associated glycoprotein in IgM paraproteinemic neuropathy; <protein-id="P26378,B1APY9,B1APY8">HuD</protein-id> in paraneoplastic sensory neuropathy; and tRNA and <protein-id="P10809,A0A024R3X4">HSP65</protein-id> in polymyositis.	acetylcholine__HuD__no_interaction	acetylcholine__PLP__no_interaction	acetylcholine__myelin basic protein__no_interaction	acetylcholine__proteolipid protein__no_interaction	acetylcholine__CDR62__no_interaction	acetylcholine__CDR34__no_interaction	acetylcholine__ple21__no_interaction	acetylcholine__MBP__no_interaction	acetylcholine__HSP65__no_interaction	glutamic acid__HuD__no_interaction	glutamic acid__PLP__no_interaction	glutamic acid__myelin basic protein__no_interaction	glutamic acid__proteolipid protein__no_interaction	glutamic acid__CDR62__no_interaction	glutamic acid__CDR34__no_interaction	glutamic acid__ple21__no_interaction	glutamic acid__MBP__no_interaction	glutamic acid__HSP65__no_interaction
18580988-2	Reactions of ligand precursors <compound-id="160754">HON</compound-id>(Me)Ph(OMe), <compound-id="160754">HON</compound-id>(Me)Ph(<protein-id="P62304">SMe</protein-id>), <compound-id="160754">HON</compound-id>(Me)C(OMe) or <compound-id="160754">HON</compound-id>(Me)C(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>) [<compound-id="160754">HON</compound-id>(Me)Ph(OMe) = (2-OMeC6H4CH2)N(Me)(CH2-2-HO-3,5-C6H2((t)Bu)2); <compound-id="160754">HON</compound-id>(Me)Ph(<protein-id="P62304">SMe</protein-id>)= (2-<protein-id="P62304">SMe</protein-id>-C6H4CH2)N(Me)(CH2-2-HO-3,5-C6H2((t)Bu)2); <compound-id="160754">HON</compound-id>(Me)C(OMe) = (MeOCH(2)CH2)N(Me)(CH2-2-HO-3,5-C6H2((t)Bu)2); <compound-id="160754">HON</compound-id>(Me)C(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>) = (Me2NCH2CH2)N(Me)(CH2-2-HO-3,5-C6H2((t)Bu)2)] with 1.1-1.3 molar equivalents of (n)BuLi in <compound-id="3283">diethyl ether</compound-id> solution afford (LiON(Me)Ph(OMe))(2) (3), (LiON(Me)Ph(<protein-id="P62304">SMe</protein-id>))2 (4), (LiON(Me)C(OMe))2 (5) and (LiON(Me)C(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>))2 (6) as dinuclear <compound-id="3028194">lithium</compound-id> complexes.	HON__SMe__no_interaction	HON__NMe2__no_interaction	lithium__SMe__no_interaction	lithium__NMe2__no_interaction	diethyl ether__SMe__no_interaction	diethyl ether__NMe2__no_interaction
12031977-9	In group 1 plasma <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> was negatively associated with the basal (r = -0.65, P = 0.003) and positively associated with the fold increase in IR <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation (r = 0.69, P = 0.001) before and after the adjustment for percent body fat (r = -0.58, P = 0.01 and r = 0.54, P = 0.02, respectively).	tyrosine__adiponectin__no_interaction
23493435-10	Patients with PHPT who had active sarcoidosis had higher serum ACE levels (60.9 ± 38.1 vs 20.2 ± 14.0 U/L, P &lt;.0001), lower <protein-id="P01270">PTH</protein-id> levels (60 ± 24 vs 96 ± 41 pg/mL, P = .01), and lower <compound-id="1061,167704,644102">phosphate</compound-id> levels (2.7 ± 0.6 vs 3.2 ± 0.5 mg/dL, P = .02).	phosphate__PTH__no_interaction
1828801-10	We conclude: (a) measurement of Pi-protectable Na(+)-[14C]PFA binding determines numbers and affinity of Na(+)-Pi symporters in renal BBMV; (b) the affinity of PFA for Na(+)-Pi symporter is similar to apparent affinity for Pi (KmPi), as determined from measurements of Na(+)-gradient-dependent 32Pi uptake by BBMV; (c) both Na(+)-Pi symporter and [Na+]<compound-id="79025">D-glucose</compound-id> symporters are present within renal BBM in a similar range of density; (d) <protein-id="P04089">PTH</protein-id> decreases the number of Na(+)-Pi cotransporters in BBMV commensurate with the parallel decrease of Na(+)-gradient-dependent Pi transport, whereas the affinity of Na(+)-Pi symporters for Pi is not changed.	D-glucose__PTH__no_interaction
1367999-3	Cultures supplemented with 2% CO2 showed higher <compound-id="10313259,943">nitrate</compound-id> (5.0-7.0 mM d-1) and carbohydrate (3.3 g l-1 d-1) uptake rates and biomass production (mu approximately 0.24 d-1, yield approximately 0.33 g dw g <protein-id="E9Q5G3">CHO-1 and 7.4 g dw L-1</protein-id>) as compared to air (3.6 mM d-1, 2.1 g l-1 d-1; 0.20 d-1, 0.25 g dw g <protein-id="E9Q5G3">CHO-1</protein-id> and 5 g dw l-1) and 5% CO2 (2.0-3.6 mM d-1, 2.0 g l-1 d-1; 0.11 d-1, 0.20 g dw g <protein-id="E9Q5G3">CHO-1</protein-id> and 5 g dw l-1) cultures and as reported previously for suspension cultures.	nitrate__CHO-1 and 7.4 g dw L-1__no_interaction	nitrate__CHO-1__no_interaction
16428601-2	<compound-id="784">Hydrogen peroxide</compound-id> accumulated in the leaves of tobacco (Nicotiana tabacum) defective in <protein-id="P06258">ndhC</protein-id>-ndhK-ndhJ (DeltandhCKJ) at 42 degrees C and 4 degrees C, and in that of wild-type leaves at 4 degrees C. The maximum quantum efficiency of PSII decreased to a similar extent in both strains at 42 degrees C, while it decreased more evidently in DeltandhCKJ at 4 degrees C. The parameters linked to CO(2) assimilation, such as the photochemical efficiency of PSII, the decrease of nonphotochemical quenching following the initial rise, and the photosynthetic O(2) evolution, were inhibited more significantly in DeltandhCKJ than in wild type at 42 degrees C and were seriously inhibited in both strains at 4 degrees C. While cyclic electron flow around PSI mediated by NDH was remarkably enhanced at 42 degrees C and suppressed at 4 degrees C. The <compound-id="1038,5460653">proton</compound-id> gradient across the thylakoid membranes and light-dependent <compound-id="5957">ATP</compound-id> synthesis were higher in wild type than in DeltandhCKJ at either 25 degrees C or 42 degrees C, but were barely formed at 4 degrees C. Based on these results, we suggest that cyclic photophosphorylation via the NDH pathway might play an important role in regulation of CO(2) assimilation under heat-stressed condition but is less important under chilling-stressed condition, thus optimizing the photosynthetic electron transport and reducing the generation of reactive <compound-id="977">oxygen</compound-id> species.	oxygen__ndhC__no_interaction	ATP__ndhC__no_interaction	Hydrogen peroxide__ndhC__no_interaction	proton__ndhC__no_interaction
14737474-4	The detection limits for these compounds obtained with PDMS/DVB/<protein-id="P10644,B2R5T5">CAR</protein-id> fibre and GC/FID were: <compound-id="241">benzene</compound-id> (15 ng L(-1)), <compound-id="1140">toluene</compound-id> (160 ng L(-1)), <compound-id="7964">monochlorobenzene</compound-id> (54 ng L(-1)), ethylbenzene (32 ng L(-1)), <compound-id="7929">m-xylene</compound-id> (56 ng L(-1)), <compound-id="7809">p-xylene</compound-id> (69 ng L(-1)), <compound-id="7501,90712699">styrene</compound-id> (35 ng L(-1)), o-<compound-id="7237">xylene</compound-id> (42 ng L(-1)), <compound-id="10943">m-dichlorobenzene</compound-id> (180 ng L(-1)), <compound-id="4685">p-dichlorobenzene</compound-id> (230 ng L(-1)), <compound-id="7239">o-dichlorobenzene</compound-id> (250 ng L(-1)) and <compound-id="6895">trichlorobenzene</compound-id> (260 ng L(-1)).	benzene__CAR__no_interaction	p-dichlorobenzene__CAR__no_interaction	styrene__CAR__no_interaction	o-dichlorobenzene__CAR__no_interaction	trichlorobenzene__CAR__no_interaction	xylene__CAR__no_interaction	monochlorobenzene__CAR__no_interaction	m-xylene__CAR__no_interaction	m-dichlorobenzene__CAR__no_interaction	p-xylene__CAR__no_interaction	toluene__CAR__no_interaction
19127197-4	RESULTS: After 12 months of exercise, significant effects were observed for total body fat [EG: -1287 g vs CG: +484 g; P = 0.001; confidence interval (CI) = -2787 to -744 g], trunk fat (-1070 vs -203 g; P = 0.005; CI = -1460 to -274 g), <protein-id="Q06141,Q53S56">hip</protein-id> circumference (-2.1 vs +1.0 cm; P = 0.001; CI = -4.8 to -1.3 cm), triglycerides: (-24.1 vs -0.3 mg dL(-1); P = 0.021; CI = -43.9 to -3.7 mg dL(-1)), total <compound-id="5997">cholesterol</compound-id>: (-19.8 vs +0.2 mg dL(-1); P = 0.008; CI = -34.6 to -5.5 mg dL(-1)), and HDL-C: (+3.8 vs -0.2 mg dL(-1); P = 0.036; CI = 0.3 to 7.6 mg dL(-1)).	cholesterol__hip__no_interaction
16741030-7	Compared with the banded groups, debanding significantly decreased pulmonary preproET-1 mRNA, pulmonary <protein-id="P22388">ET-1</protein-id> (sham, 210 +/- 12 pg/g protein; <compound-id="86580354">AOB</compound-id>(1-28), 242 +/- 12 pg/g protein; <compound-id="86580354">AOB</compound-id>(1-49), 370 +/- 49 pg/g protein; and <compound-id="86580354">AOB</compound-id>(1-28)/DeB(29-49), 206 +/- 1.9 pg/g protein), and plasma <protein-id="P22388">ET-1</protein-id> levels (sham, 10.1 +/- 1.5 pg/ml; <compound-id="86580354">AOB</compound-id>(1-28), 13.4 +/- 2.0 pg/ml; <compound-id="86580354">AOB</compound-id>(1-49), 15.4 +/- 2.0 pg/ml; and <compound-id="86580354">AOB</compound-id>(1-28)/DeB(29-49), 10.3 +/- 0.9 pg/ml protein).	AOB__ET-1__no_interaction
1418812-1	(4R)-3-[(2'R,3'R)-2'-Bromo-3'-(<compound-id="29030">phenylbutanoyl</compound-id>)]-4-(<compound-id="123147">phenylmethyl</compound-id>)-2 - oxazolidinone, C20H20Br-<protein-id="P41271,A0A087WTY6">NO3</protein-id>, M(r) = 402.30, monoclinic, P2(1), a = 11.542 (2), b = 7.625 (1), c = 11.667 (1) A, beta = 113.97 (1) degrees, V = 938.2 (2) A3, Z = 2, Dx = 1.42 g cm-3, lambda(Mo K alpha) = 0.71073 A, mu = 21.8 cm-1, F(000) = 412, T = 296 +/- 1 K, final R = 0.028 for 2369 observed reflections.	phenylmethyl__NO3__no_interaction	phenylbutanoyl__NO3__no_interaction
18322625-1	Group 4 metallacycles [eta5:sigma-Me2C(C5H4)(C2B10H10)]Ti[eta2-N(Me)CH2CH2N(Me)] (1a), [eta5:sigma-Me2C(C5H4)(C2B10H10)]Zr[eta2-N(Me)CH2CH2N(Me)](<compound-id="674">HNMe2</compound-id>) (1b) and [eta5:sigma-Me2C(C5H4)(C2B10H10)]M[eta2-N(Me)CH2CH2CH2N(Me)] (M = Ti (2a), Zr (2b), Hf (2c)) were synthesized by reaction of [eta5:sigma-Me2C(C5H4)(C2B10H10)]M(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>)(2) (M = Ti, Zr, Hf) with MeNH(CH2)(n)NHMe (n = 2, 3).	HNMe2__NMe2__no_interaction
15005094-10	In the latter one, eight categories of medical doctors are discussed according to their moral degrees: <protein-id="Q14190">sim</protein-id>'<compound-id="16222096">eui</compound-id>, sik'<compound-id="16222096">eui</compound-id>, yak'<compound-id="16222096">eui</compound-id>, hon'<compound-id="16222096">eui</compound-id>, kwang <compound-id="16222096">eui</compound-id>, mang'<compound-id="16222096">eui</compound-id>, sa'<compound-id="16222096">eui</compound-id>, and sal'<compound-id="16222096">eui</compound-id>.	eui__sim__no_interaction
12209103-5	HLA data analysis revealed significantly increased phenotype frequencies for <protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (<compound-id="57326580">DQ8</compound-id>; 91/189 [48%]) and <protein-id="P13762,X5D2U9">DRB1*04</protein-id> (<protein-id="P13762,X5D2U9">DR4</protein-id>; 102/189 [54%]) in <compound-id="16131133">hevein</compound-id>-positive HCWs with latex allergy compared with the 80 <compound-id="16131133">hevein</compound-id>-negative HCWs with latex allergy (<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302: 16/80 [20%], corrected P value [P (c)] = 7.1 x 10(-4); <protein-id="P13762,X5D2U9">DRB1*04</protein-id>: 23/80 [29%], P (c) =.01) and with control subjects (<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302: 16/89 [18%], P (c) = 1 x 10(-4); <protein-id="P13762,X5D2U9">DRB1*04</protein-id>: 22/90 [24%], P (c) = 3.2 x 10(-4)).	hevein__DQB1__no_interaction	hevein__DRB1*04__no_interaction	hevein__DR4__no_interaction	DQ8__DQB1__no_interaction	DQ8__DRB1*04__no_interaction	DQ8__DR4__no_interaction
7816186-5	The responses of TSH (2.0 +/- 0.3 vs 12.3 +/- 2.2 microlU/ml, p &lt; 0.01), <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> (15.3 +/- 2.3 vs 46.4 +/- 8.8 ng/ml, p &lt; 0.01), <compound-id="5920">T3</compound-id> (178.0 +/- 16.4 vs 248.7 +/- 21.1 ng/dl, p &lt; 0.001), T4 (7.9 +/- 0.4 vs 9.6 +/- 0.5 micrograms/dl, p &lt; 0.001), and <protein-id="P60568,Q0GK43">IL-2</protein-id> (45.6 +/- 7.8 vs 79.9 +/- 16.4 fmol/ml, p &lt; 0.05) in TRH test were noted.	T3__PRL__no_interaction	T3__IL-2__no_interaction
16557449-2	Several consequences can be drawn from these studies: i) women anticipate postoperative pain more realistically and it occurs more often than in man; however, pain intensity and analgesic consumption are not different; ii) placebos elicit psychological phenomena (e. g. expectation) that trigger neurobiological processes (e. g. activation of endogenous opioid system); iii) <protein-id="P00403,U5Z487">COX-2</protein-id> inhibitors increase the risk for thromboembolic complications (e. g. myocardial infarction, apoplex, pulmonary embolism) and perioperative mortality in patients undergoing aortocoronary bypass surgery; iv) NSAID as supplement to postoperative PCIA with opioids reduce the risk for PONV and sedation; v) preoperative administration of <compound-id="3446">gabapentin</compound-id> reduces preoperative anxiety and postoperative pain; vi) epidural catheters situated at the site of major spinal surgery are promising approach to provide efficient postoperative analgesia; vii) in the literature contradictory results have been reported regarding the effect of perioperative acupuncture on intra- and postoperative consumption of anesthetics or analgesics; acupuncture appears to decrease the incidence of PONV, but no reduction in the postoperative use of antiemetic agents has not been shown yet; viii) laparoscopic versus open colectomy in patients with colon carcinoma results in prolongation of surgery, reduction of postoperative pain and analgesics, earlier mobilization and a reduced hospital stay, if conventional systemic opioid-based pain therapy was used postoperatively.	gabapentin__COX-2__no_interaction
15492278-3	The cDNA-oligoarray analysis and reverse transcription-PCR verification indicated common changes in gene expression in <compound-id="6137,84815,876">methionine</compound-id>-dependent cell lines to include up-regulation/induction of <protein-id="P24385,Q6FI00">cyclin D1</protein-id>, mitotic arrest deficient (<protein-id="Q05195,B7ZLI7">MAD)1</protein-id>, <protein-id="P42857,B2R5R8">p21</protein-id>, growth arrest and DNA-damage-inducible (<protein-id="P24522,A5JUZ3">GADD)45 alpha</protein-id>, <protein-id="O95257">GADD45 gamma</protein-id>, <protein-id="O75807">GADD34</protein-id>, breast cancer (<protein-id="P24385,Q6FI00">BRCA)1, 14-3-3sigma, B-cell CLL/lymphoma (BCL)1</protein-id>, <protein-id="P01137">transforming growth factor (TGF)-beta</protein-id>, TGF-beta-induced early response (<protein-id="Q13118">TIEG</protein-id>), <protein-id="Q99717,Q68DB7">SMAD5</protein-id>, <protein-id="O15105,B3KYA8">SMAD7</protein-id>, <protein-id="Q15796,B7Z5N5,Q53XR6">SMAD2</protein-id>, insulin-like growth factor binding protein (<protein-id="Q16270">IGFBP7</protein-id>), <protein-id="P31995">IGF-R2</protein-id>, <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">vascular endothelial growth factor</protein-id> (<protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id>), <protein-id="P50591,Q6IBA9">TNF-related apoptosis-inducing ligand</protein-id> (<protein-id="P50591,Q6IBA9">TRAIL</protein-id>), <protein-id="P78536,B2RNB2">TNF-alpha converting enzyme</protein-id> (<protein-id="P78536,B2RNB2">TACE</protein-id>), <protein-id="P50591,Q6IBA9">TRAIL</protein-id> receptor (<protein-id="P50591,Q6IBA9">TRAIL</protein-id>-R)2, <protein-id="O75509,A0A024RD71">TNFR-related death receptor (DR)6</protein-id>, <protein-id="Q9BWF2">TRAF interacting protein</protein-id> (<protein-id="Q92844,Q6NW12,B2R7S3">I-TRAF</protein-id>), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="Q13007">MDA7</protein-id>, <protein-id="P29466,A8K257,A8K249">IL-1B convertase</protein-id> (ICE)-gamma, delta and epsilon, <protein-id="P10914,Q6FHN8,X5D3F6">IRF1</protein-id>, <protein-id="Q13568,A0A024R763,B7Z1M2">IRF5</protein-id>, <protein-id="Q92985,M9RSF4,A0A024RCA2">IRF7</protein-id>, <protein-id="P01579">interferon (IFN)-gamma and receptor</protein-id> components, <protein-id="P05161">ISG15</protein-id>, p65-NF-kappaB, <protein-id="P17275,Q5U079">JUN-B</protein-id>, positive <compound-id="108194">cofactor</compound-id> (PC)4, C/ERB-beta, <compound-id="892">inositol</compound-id> triphosphate receptor I, and <compound-id="6137,84815,876">methionine</compound-id> adenosyltransferase II.	methionine__cyclin D1__no_interaction	methionine__TRAF interacting protein__no_interaction	methionine__TNF-alpha converting enzyme__no_interaction	methionine__SMAD5__no_interaction	methionine__IL-6__no_interaction	methionine__SMAD7__no_interaction	methionine__TIEG__no_interaction	methionine__SMAD2__no_interaction	methionine__p21__no_interaction	methionine__MAD)1__no_interaction	methionine__GADD34__no_interaction	methionine__transforming growth factor (TGF)-beta__no_interaction	methionine__TNFR-related death receptor (DR)6__no_interaction	methionine__VEGF__no_interaction	methionine__ISG15__no_interaction	methionine__GADD45 gamma__no_interaction	methionine__GADD)45 alpha__no_interaction	methionine__IL-1B convertase__no_interaction	methionine__MDA7__no_interaction	methionine__BRCA)1, 14-3-3sigma, B-cell CLL/lymphoma (BCL)1__no_interaction	methionine__IGFBP7__no_interaction	methionine__TACE__no_interaction	methionine__IRF1__no_interaction	methionine__IRF7__no_interaction	methionine__IRF5__no_interaction	methionine__JUN-B__no_interaction	methionine__interferon (IFN)-gamma and receptor__no_interaction	methionine__TNF-related apoptosis-inducing ligand__no_interaction	methionine__TRAIL__no_interaction	methionine__vascular endothelial growth factor__no_interaction	methionine__I-TRAF__no_interaction	methionine__IGF-R2__no_interaction	inositol__cyclin D1__no_interaction	inositol__TRAF interacting protein__no_interaction	inositol__TNF-alpha converting enzyme__no_interaction	inositol__SMAD5__no_interaction	inositol__IL-6__no_interaction	inositol__SMAD7__no_interaction	inositol__TIEG__no_interaction	inositol__SMAD2__no_interaction	inositol__p21__no_interaction	inositol__MAD)1__no_interaction	inositol__GADD34__no_interaction	inositol__transforming growth factor (TGF)-beta__no_interaction	inositol__TNFR-related death receptor (DR)6__no_interaction	inositol__VEGF__no_interaction	inositol__ISG15__no_interaction	inositol__GADD45 gamma__no_interaction	inositol__GADD)45 alpha__no_interaction	inositol__IL-1B convertase__no_interaction	inositol__MDA7__no_interaction	inositol__BRCA)1, 14-3-3sigma, B-cell CLL/lymphoma (BCL)1__no_interaction	inositol__IGFBP7__no_interaction	inositol__TACE__no_interaction	inositol__IRF1__no_interaction	inositol__IRF7__no_interaction	inositol__IRF5__no_interaction	inositol__JUN-B__no_interaction	inositol__interferon (IFN)-gamma and receptor__no_interaction	inositol__TNF-related apoptosis-inducing ligand__no_interaction	inositol__TRAIL__no_interaction	inositol__vascular endothelial growth factor__no_interaction	inositol__I-TRAF__no_interaction	inositol__IGF-R2__no_interaction	cofactor__cyclin D1__no_interaction	cofactor__TRAF interacting protein__no_interaction	cofactor__TNF-alpha converting enzyme__no_interaction	cofactor__SMAD5__no_interaction	cofactor__IL-6__no_interaction	cofactor__SMAD7__no_interaction	cofactor__TIEG__no_interaction	cofactor__SMAD2__no_interaction	cofactor__p21__no_interaction	cofactor__MAD)1__no_interaction	cofactor__GADD34__no_interaction	cofactor__transforming growth factor (TGF)-beta__no_interaction	cofactor__TNFR-related death receptor (DR)6__no_interaction	cofactor__VEGF__no_interaction	cofactor__ISG15__no_interaction	cofactor__GADD45 gamma__no_interaction	cofactor__GADD)45 alpha__no_interaction	cofactor__IL-1B convertase__no_interaction	cofactor__MDA7__no_interaction	cofactor__BRCA)1, 14-3-3sigma, B-cell CLL/lymphoma (BCL)1__no_interaction	cofactor__IGFBP7__no_interaction	cofactor__TACE__no_interaction	cofactor__IRF1__no_interaction	cofactor__IRF7__no_interaction	cofactor__IRF5__no_interaction	cofactor__JUN-B__no_interaction	cofactor__interferon (IFN)-gamma and receptor__no_interaction	cofactor__TNF-related apoptosis-inducing ligand__no_interaction	cofactor__TRAIL__no_interaction	cofactor__vascular endothelial growth factor__no_interaction	cofactor__I-TRAF__no_interaction	cofactor__IGF-R2__no_interaction
23196336-7	In multivariable analyses, theta was associated with brain atrophy (OR 2.6, p = 0.020), theta/delta with intracerebral hemorrhages (<protein-id="O76002">OR 6.8</protein-id>, p = 0.005), FIRDA with past cerebrovascular accidents (OR 2.7, p = 0.004), TWs with liver or multi-organ failure (OR 6, p = 0.004; OR 4, p = 0.039), and delta activity with <compound-id="10982484,702">alcohol</compound-id>/drug abuse with or without intoxication, and HIV infection (<protein-id="Q8NHB7">OR 3.8</protein-id>, p = 0.003; OR 9, p = 0.004).	alcohol__OR 3.8__no_interaction	alcohol__OR 6.8__no_interaction
19879766-2	Among them, (4R,6S)-6-[(E)-2-(2-cyclopropyl-6-fluoro-4-(4-fluoro-<compound-id="90475853">thiophenyl</compound-id>)-<compound-id="7047">quinoline</compound-id>-3-yl)-<compound-id="123166">ethenyl</compound-id>]-3,4,5,6-<compound-id="10396821">tetrahydro-4-hydroxy-2H-pyran-2-one</compound-id> (1d), (4R,6S)-6-[(E)-2-(2-cyclopropyl-6-fluoro-4-(<compound-id="13516411">3-methoxy</compound-id>-<compound-id="90475853">thiophenyl</compound-id>)-<compound-id="7047">quinoline</compound-id>-3-yl)-<compound-id="123166">ethenyl</compound-id>]-3,4,5,6-<compound-id="10396821">tetrahydro-4-hydroxy-2H-pyran-2-one</compound-id> (1f) and (4R,6S)-6-[(E)-2-(2-cyclopropyl-6-fluoro-4,7-di(<compound-id="13516411">3-methoxy</compound-id>-<compound-id="90475853">thiophenyl</compound-id>)-<compound-id="7047">quinoline</compound-id>-3-yl)-<compound-id="123166">ethenyl</compound-id>]-3,4,5,6-<compound-id="10396821">tetrahydro-4-hydroxy-2H-pyran-2-one</compound-id> (1q) showed potent <protein-id="P04035,A0A024RAP2">HMG-CoA reductase</protein-id> inhibitory activity comparable with <compound-id="5282452">pitavastatin</compound-id>.	pitavastatin__HMG-CoA reductase__no_interaction	tetrahydro-4-hydroxy-2H-pyran-2-one__HMG-CoA reductase__no_interaction	thiophenyl__HMG-CoA reductase__no_interaction	3-methoxy__HMG-CoA reductase__no_interaction	ethenyl__HMG-CoA reductase__no_interaction	quinoline__HMG-CoA reductase__no_interaction
21595704-8	On the day of admission, S-<protein-id="P17405,Q59EN6">ASM</protein-id> activity correlated positively with levels of carbohydrate-deficient <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> (r = 0.410, p = 0.034) and high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.440, p = 0.022) and inversely with body mass index (r = -0.509; p = 0.007), <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.480; p = 0.011), triglycerides (r = -0.592; p = 0.001), and large unstained cells (r = -0.526; p = 0.017).	glucose__transferrin__no_interaction	glucose__ASM__no_interaction	cholesterol__transferrin__no_interaction	cholesterol__ASM__no_interaction
21409896-11	<protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) was not significantly correlated with waist circumference (r = 0.24), BMI (r = 0.16), triglycerides (r = 0.22), HDL <compound-id="5997">cholesterol</compound-id> (r = 0.18) and HbA1c (r = 0.35) but showed moderate correlation with fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.44).	glucose__insulin__no_interaction	cholesterol__insulin__no_interaction
22244813-3	Compared with sham treatment, I/R treatment induced severe lipid peroxidation injury in rat myocardium: plasma <compound-id="10964">malondialdehyde</compound-id> (MDA) content and myocardial LDH activity was increased by 34% and 85% (all P&lt;0.01); Mn-<compound-id="5359597">superoxide</compound-id> dismutase (Mn-SOD) and catalase (CAT) activity was reduced 80% and 86% (all P&lt;0.01), respectively, and the protein levels of the <compound-id="5884">NADPH</compound-id> oxidase complex subunits gp91(phox) and <protein-id="Q63413">p47</protein-id>(phox) were markedly increased, by 86% (P&lt;0.05) and 95% (P&lt;0.01), respectively; <compound-id="795">IMD</compound-id>(1-53) treatment ameliorated lipid peroxidation injury: plasma MDA content and myocardial LDH activity was decreased by 30% (P&lt;0.05) and 36% (P&lt;0.01); Mn-SOD and CAT activity was elevated 1.0- and 4.3-fold (all P&lt;0.01), respectively; and the protein levels of gp91(phox) and <protein-id="Q63413">p47</protein-id>(phox) were reduced, by 28% and 36% (both P&lt;0.05), respectively.	NADPH__p47__no_interaction	malondialdehyde__p47__no_interaction	superoxide__p47__no_interaction	IMD__p47__no_interaction
17278008-2	The concentrations of the parameters in the river <compound-id="962">water</compound-id> samples ranged in the following order: pH (5.6-6.9), temperature (26.90-28.60 degrees C), turbidity (23-63 <compound-id="446223">NTU</compound-id>), electrical conductivity (52-184 mus/cm), DO (5.4-7.2 mg/l), <protein-id="O54918,Q542N5,Q3U7X3,Q6PEB3,Q3TR86">BOD</protein-id> (21-57 mg/l), TDS (6.0-217 mg/l), <compound-id="1061">PO4</compound-id> (3-) (0.19-1.72 mg/l), SO4 (2-) (25-36.8 mg/l), <protein-id="Q61477">NO3</protein-id> (-) (20.3-28 mg/l), Fe (6.07-15.71 mg/l), Zn (0.04-0.24 mg/l), Pb (0.01-0.17 mg/l), Ni (0.01-0.13 mg/l), Vn (0.01-0.20 mg/l) and Hg (0.001-0.002 mg/l).	water__BOD__no_interaction	water__NO3__no_interaction	PO4__BOD__no_interaction	PO4__NO3__no_interaction	NTU__BOD__no_interaction	NTU__NO3__no_interaction
17156680-5	The levels of <protein-id="E9PWB6">MUC5AC</protein-id> mRNA, <protein-id="E9PWB6">MUC5AC</protein-id> protein, and <protein-id="P07750">IL-4</protein-id> mRNA of the asthma group were 0.5341 +/- 0.303, 0.1906 +/- 0.0008, and 0.6265 +/- 0.0932 respectively, all significantly higher than those of the control group (0.1994 +/- 0.0128, 0.1194 +/- 0.0007, and 0.2389 +/- 0.0289 respectively, all P &lt; 0.01), and those of the asthma + <compound-id="5743">dexamethasone</compound-id> group (0.2729 +/- 0.0345, 0.1456 +/- 0.0003, and 0.2424 +/- 0.0260, all P &lt; 0.05).	dexamethasone__MUC5AC__no_interaction	dexamethasone__IL-4__no_interaction
1910063-9	The PINI was positively correlated with <protein-id="P02741">CRP</protein-id> concentration (r = 0.72, p = 0.0001) and negatively correlated with PA concentration (r = 0.56, p = 0.0004 and <compound-id="947">nitrogen</compound-id> balance (r = -0.51, p = 0.0018).	nitrogen__CRP__no_interaction
9840403-6	The results were that the mean MVC was 412 (<compound-id="5289348">SEM</compound-id> 90) N and 304 (<compound-id="5289348">SEM</compound-id> 85) N in fresh and fatigued muscle, respectively; during tests 1 and 2 the mean EMG rms increased from 0.403 (<compound-id="5289348">SEM</compound-id> 0.07) mV to 0.566 (<compound-id="5289348">SEM</compound-id> 0.09) mV and from 0.476 (<compound-id="5289348">SEM</compound-id> 0.07) mV to 0.63 (<compound-id="5289348">SEM</compound-id> 0.09) mV, respectively; during test 1 the mean <compound-id="11544170">MMG</compound-id> rms decreased from 9.4 (<compound-id="5289348">SEM</compound-id> 0.8) mV to 5.7 (<compound-id="5289348">SEM</compound-id> 0.9) mV; in contrast, during test 2 constantly lower values were observed throughout contraction; during tests 1 and 2 the EMG f declined from 122 (<compound-id="5289348">SEM</compound-id> 7) Hz to 74 (<compound-id="5289348">SEM</compound-id> 7) Hz and from 106 (<compound-id="5289348">SEM</compound-id> 8) Hz to 60 (<compound-id="5289348">SEM</compound-id> 7) Hz, respectively; during test 1 the <compound-id="11544170">MMG</compound-id> f increased in the first 6 s from 19.3 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>.4) Hz to 23.9 (<protein-id="Q9NS98">SEM 2</protein-id>.9) Hz, falling to 13.9 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>.3) Hz at the end of contraction; in contrast, during test 2 the <compound-id="11544170">MMG</compound-id> f declined continuously from 18.7 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>) Hz to 12.4 (<compound-id="5289348">SEM</compound-id> 0.8) Hz.	SEM__SEM 1__no_interaction	SEM__SEM 2__no_interaction	MMG__SEM 1__no_interaction	MMG__SEM 2__no_interaction
1972176-2	Our experiments explicitly show that: (a) crosslinkage of TCR with the <protein-id="P08920,Q549Q4">CD2 antigen</protein-id>, and not independent crosslinking of TCR and of <protein-id="P08920,Q549Q4">CD2 antigen</protein-id> or crosslinking of either protein with the <protein-id="P46630">CD4</protein-id> or <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id> antigen induces significant proliferation independent of co-stimulatory signals (e.g., accessory cells, recombinant lymphokines, or tumor promoter), (b) F(ab')2 fragments of mAb directed at the TCR and F(ab')2 anti-<protein-id="P06729,Q53F96">CD2</protein-id>, crosslinked with F(ab')2 fragments of rabbit anti-mouse IgG, promote the proliferation of highly purified T cells, (c) a prompt and sustained increase in intracellular free Ca2+ concentration results from crosslinkage of TCR with the <protein-id="P08920,Q549Q4">CD2 antigen</protein-id>, (d) T cell proliferation induced by this novel approach is curtailed by <compound-id="6207">EGTA</compound-id> and by direct or competitive inhibitors of PKC, (e) crosslinkage of TCR with the <protein-id="P08920,Q549Q4">CD2 antigen</protein-id> results in the transcriptional activation and translation of the gene for IL-2 and in the expression of IL-2 receptor alpha (<protein-id="P01590,Q544I2">CD25</protein-id>), (f) anti-<protein-id="P01590,Q544I2">CD25</protein-id> mAbs inhibit T cell proliferation initiated by crosslinkage of TCR with the <protein-id="P08920,Q549Q4">CD2 antigen</protein-id>, and recombinant IL-2 restores the proliferative response.	EGTA__CD4__no_interaction	EGTA__CD8__no_interaction	EGTA__CD2 antigen__no_interaction	EGTA__CD25__no_interaction	EGTA__CD2__no_interaction
19452241-3	METHODS: To clarify the factors influencing the prognosis and survival of patients with diabetic nephrosclerosis, we carried out a retrospective follow-up study of 166 cases (age, 55.6 +/- 1.0 years; male/female, 110/56) by simple and multifactorial analyses of clinical data recorded at time of renal biopsy, including survival after diagnosis of diabetic mellitus (months), body mass index (BMI) (kg/m(2)) [body weight/(body height)(2)], age (years), mean blood pressure (mBP) (mmHg) [diastolic BP + (systolic BP - diastolic BP)/3], serum levels of <protein-id="P02768">albumin</protein-id> (mg/dl), <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (BUN) (mg/dl), serum <compound-id="588">creatinine</compound-id> (s-Cr) (mg/dl), total <compound-id="5997">cholesterol</compound-id> (mg/dl), triglyceride (mg/dl), and fasting blood sugar (FBS) (mg/dl), hematocrit (%), HbA1c (%), urinary protein secretion (g/day), <protein-id="P01308,I3WAC9">insulin</protein-id> resistance, BP control (good, &lt;140/90 mmHg or poor, &gt; or =140/90 mmHg) after biopsies, and pathomorphological parameters at the biopsy.	creatinine__albumin__no_interaction	creatinine__insulin__no_interaction	urea__albumin__no_interaction	urea__insulin__no_interaction	nitrogen__albumin__no_interaction	nitrogen__insulin__no_interaction	cholesterol__albumin__no_interaction	cholesterol__insulin__no_interaction
24411287-8	NLR, <compound-id="95687">PLR</compound-id>, and <protein-id="P02741">CRP</protein-id> levels were significantly higher in patients with PVT than in controls (3.2 ± 2.1 vs 2.2 ± 0.8, p &lt;0.001; 163 ± 77.5 vs 114.9 ± 37.3, p &lt;0.001; and 1.97 ± 3.02 vs 1.02 ± 1.22, p = 0.01, respectively).	PLR__CRP__no_interaction
21903023-11	RESULTS: Subjects with anorexia nervosa versus healthy controls had lower mean ± <compound-id="5289348">SEM</compound-id> <protein-id="P01178,X5D7M6">oxytocin</protein-id> levels (14.3 ± 1.5 vs 31.8 ± 5.1 pg/mL, P = .003), <protein-id="P41159,A4D0Y8">leptin</protein-id> levels (2.7 ± 0.5 vs 11.4 ± 1.1 ng/mL, P &lt; .0001), bone mineral density (anterior-posterior spine: 0.83 ± 0.02 vs 1.04 ± 0.03; lateral spine: 0.63 ± 0.02 vs 0.81 ± 0.02; total hip: 0.79 ± 0.03 vs 0.97 ± 0.03 g/cm², P &lt; .0001), and fat mass (8.8 ± 0.6 vs 19.7 ± 0.9 kg, P &lt; .0001).	SEM__oxytocin__no_interaction	SEM__leptin__no_interaction
23560213-6	RESULTS: Post-60 seconds exercise heart rate after 3-minute test (R60 heart rate) was correlated with age (r = -0.21, P = 0.02), education (r = 0.17, P = 0.04), body mass index (r = 0.23, P = 0.01), waist circumference (r = 0.28, P &lt; 0.01), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.28, P &lt; 0.01), HOMA-IR (r = 0.25, P &lt; 0.01), low density lipoprotein-<compound-id="5997">cholesterol</compound-id> (r = 0.28, P &lt; 0.01), high sensitivity C-reactive protein levels (r = 0.22, P = 0.02), and baseline heart rate (r = 0.56, P &lt; 0.01).	cholesterol__insulin__no_interaction
23346909-1	The highly efficient asymmetric total syntheses of (-)-Δ(8)-<compound-id="16078">tetrahydrocannabinol</compound-id> ((-)-Δ(8)-<protein-id="P42768,A0A024QYX8">THC</protein-id>) (13 steps, 35%) and (-)-Δ(9)-<compound-id="16078">tetrahydrocannabinol</compound-id> ((-)-Δ(9)-<protein-id="P42768,A0A024QYX8">THC</protein-id>) (14 steps, 30%) have been developed by using <compound-id="23950">ruthenium</compound-id>-catalyzed asymmetric hydrogenation of racemic α-aryl cyclic <compound-id="114522">ketones</compound-id> via dynamic kinetic resolution and intramolecular S(N)Ar cyclization.	ruthenium__THC__no_interaction	ketones__THC__no_interaction	tetrahydrocannabinol__THC__no_interaction
17347912-4	In all, 212 cases were diagnosed (6.6%) including 92 (43.4%) with amino acids disorders (48 with phenylketonuria, 12 with <protein-id="P00480">ornithine carbamoyltransferase</protein-id> deficiency, 7 with tyrosinaemia type I, 9 with maple <compound-id="11162923">syrup</compound-id> urine disease, 5 with citrullinaemia type I, 8 with citrullinaemia type II, 2 with homocystinuria, and 1 with argininaemia); 107 (50.5%) with organic acid disorders (including 58 with methylmalonic acidaemia, 13 with propionic acidaemia, 6 with isovaleric acidaemia, 7 with glutaric acidaemia type I, 6 with <compound-id="439869,9549326,99">3-methylcrotonyl-CoA</compound-id> carboxylase deficiency, 2 with <compound-id="445127">3-hydroxy-3-methylglutaryl-CoA</compound-id> lyase deficiency, 10 with multiple carboxylase deficiency, and 5 with beta-ketothiolase deficiency); and 13 (6.1%) with fatty acid oxidation disorders (including 1 with <compound-id="85">carnitine</compound-id> palmitoyltransferase deficiency type I, 1 with <compound-id="85">carnitine</compound-id> palmitoyltransferase deficiency type II, 1 with short-chain acyl-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> dehydrogenase deficiency, 5 with <protein-id="P11310,Q5T4U5,B7Z9I1,B4DJE7,Q5HYG7">medium-chain acyl-CoA dehydrogenase</protein-id> deficiency, 3 with very long-chain acyl-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> dehydrogenase deficiency, and 2 with multiple acyl-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> dehydrogenase deficiency).	CoA__ornithine carbamoyltransferase__no_interaction	CoA__medium-chain acyl-CoA dehydrogenase__no_interaction	carnitine__ornithine carbamoyltransferase__no_interaction	carnitine__medium-chain acyl-CoA dehydrogenase__no_interaction	3-hydroxy-3-methylglutaryl-CoA__ornithine carbamoyltransferase__no_interaction	3-hydroxy-3-methylglutaryl-CoA__medium-chain acyl-CoA dehydrogenase__no_interaction	syrup__ornithine carbamoyltransferase__no_interaction	syrup__medium-chain acyl-CoA dehydrogenase__no_interaction	3-methylcrotonyl-CoA__ornithine carbamoyltransferase__no_interaction	3-methylcrotonyl-CoA__medium-chain acyl-CoA dehydrogenase__no_interaction
17319473-10	The mean values of various lipid parameters (mg/dL) at baseline, and at weeks 4, 12, and 24 respectively were: total <compound-id="5997">cholesterol</compound-id> 233.9 +/- 27, 206.3 +/- 27, 189.8 +/- 31, and 174.9 +/- 27 mg/dL; LDL <compound-id="5997">cholesterol</compound-id> 153.4 +/- 22, 127.3 +/- 21, 109.2 +/- 27, and 95.1 +/- 23 mg/dL; triglycerides 171.1 +/- 72, 159.5 +/- 75, 149.2 +/- 45, and 135.2 +/- 40 mg/dL; HDL <compound-id="5997">cholesterol</compound-id> 45.6 +/- 7, 48.9 +/- 7, 51.6 +/- 9, and 53.9 +/- 10 mg/dL; lp(a) 48.5 +/- 26, 40.1 +/- 21, 35.4 +/- 21, and 26.9 +/- 19 mg/dL; and <protein-id="P02647,A0A024R3E3">apoA1</protein-id>/<protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> ratio 0.96 +/- 0.7, 1.04 +/- 0.4, 1.17 +/- 0.5, and 1.45 +/- 0.5 (p &lt; 0.01).	cholesterol__apoB__no_interaction	cholesterol__apoA1__no_interaction
9785215-4	STUDY DESIGN: The occurrence of antibodies directed against three linear antigenic and immunogenic regions in each of the nucleocapsid (N): N3 (Thr11 to Gly30), <compound-id="4218">N25</compound-id> (Ser231 to Ala250) and N39 (Thr371 to Leu391), and the phospho-(P) proteins of respiratory syncytial virus (RSV), subgroup A: P49 (Pro91 to Asp110), P56 (Ser161 to Lys180) and <protein-id="P32780">P62</protein-id> (Glu221 to Phe241), were analyzed in ELISA with (a) 32 paired sera from humans with recent or previous RSV subgroup A and/or B infection diagnosed by conventional ELISA, detection of antigen in nasopharyngeal aspirates and measurement of antibody avidity change; and (b) 40 RSV antibody-positive sera (HCS) obtained from patients during their convalescence from RSV infection and possessing clearly demonstrable titers of RSV IgG in conventional enzyme immunoassays (EIA) based on whole RSV antigen.	N25__P62__no_interaction
3290588-7	Evaluation of stroke work index after 60 minutes of recovery (as percent of control) was performed using the isolated, blood perfused, working heart preparation in all groups: Group I (Stanford cardioplegia, saline storage, normal blood reperfusion) had a recovery of 11%; group II (Stanford + <compound-id="22044544,5460341">calcium</compound-id>, saline, normal blood) 8%; group III (Stanford + <compound-id="22044544,5460341">calcium</compound-id>, saline, modified blood, <compound-id="5359597">superoxide</compound-id> dismutase 35,000 U/L, <protein-id="O62839,F1SGS9">catalase</protein-id> 35,000 U/L) 37%; group IV (Stanford + <compound-id="22044544,5460341">calcium</compound-id>, Sacks II, modified blood, <compound-id="5359597">superoxide</compound-id> dismutase 35,000 U/L, <protein-id="O62839,F1SGS9">catalase</protein-id> 35,000 U/L), 47%; group V (Stanford + <compound-id="22044544,5460341">calcium</compound-id>, Sacks + <compound-id="206,5793,64689,79025">glucose</compound-id>, modified blood, <compound-id="5359597">superoxide</compound-id> dismutase 35,000 U/L, <protein-id="O62839,F1SGS9">catalase</protein-id> 105,000 U/L) 89%; group VI (Stanford + <compound-id="22044544,5460341">calcium</compound-id>, Sacks + <compound-id="206,5793,64689,79025">glucose</compound-id>, modified blood, <compound-id="5359597">superoxide</compound-id> dismutase 150,000 U/L, <protein-id="O62839,F1SGS9">catalase</protein-id> 150,000 U/L) 107%; group VII (Sacks + <compound-id="206,5793,64689,79025">glucose</compound-id>, Sacks + <compound-id="206,5793,64689,79025">glucose</compound-id>, modified blood, <compound-id="5359597">superoxide</compound-id> dismutase 35,000 U/L, <protein-id="O62839,F1SGS9">catalase</protein-id> 105,000 U/L) 115%.	calcium__catalase__no_interaction	superoxide__catalase__no_interaction	glucose__catalase__no_interaction
22070627-1	On the basis of evidence that opioid compounds with a mixed μ agonist/δ antagonist profile may produce an antinociceptive effect with low propensity to induce side effects, bifunctional opioid peptides containing the μ agonist H-Dmt-<compound-id="71070">d-Arg</compound-id>-Phe-<compound-id="5962">Lys</compound-id>-NH(2) ([Dmt(1) ]<compound-id="122222,14444332">DALDA</compound-id>; Dmt = <compound-id="124247">2',6'-dimethyltyrosine</compound-id>) connected tail-to-tail via various α,ω-diaminoalkyl- or <compound-id="17842493">diaminocyclohexane</compound-id> linkers to the δ antagonists H-<compound-id="6057">Tyr</compound-id>-TicΨ[CH(2) -NH]Cha-Phe-OH (TICP[Ψ]; Cha = <compound-id="12003067">cyclohexylalanine</compound-id>, Tic = <compound-id="95489">1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid</compound-id>), <compound-id="44292391">H-Dmt-Tic-OH</compound-id> or H-<protein-id="P03999,Q0PJU0">Bcp</protein-id>-Tic-OH (<protein-id="P03999,Q0PJU0">Bcp</protein-id> = 4'-[N-((4'-phenyl)phenethyl)<compound-id="713">carboxamido</compound-id>]<compound-id="6140,71567,89654470,994">phenylalanine</compound-id>) were synthesized and pharmacologically characterized in vitro.	1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid__Bcp__no_interaction	Lys__Bcp__no_interaction	carboxamido__Bcp__no_interaction	DALDA__Bcp__no_interaction	phenylalanine__Bcp__no_interaction	diaminocyclohexane__Bcp__no_interaction	d-Arg__Bcp__no_interaction	2',6'-dimethyltyrosine__Bcp__no_interaction	H-Dmt-Tic-OH__Bcp__no_interaction	Tyr__Bcp__no_interaction	cyclohexylalanine__Bcp__no_interaction
22358916-10	Using this strategy in the 500 L reactor, we predict that dissolved <compound-id="977">oxygen</compound-id> and CO(2) levels can be maintained in the range to support maximum productivity (40% DO, 76 mm Hg pCO(2)) for a culture at 10(7) cells/mL, and with a minimum sparge rate of 0.006 vessel volumes per minute.A = volumetric agitated gas-liquid interfacial area at the top of the liquid, 1/mB = cell broth bleeding rate from the vessel, L/minCER = <compound-id="280">carbon dioxide</compound-id> evolution rate in the bioreactor, mol/min[CO(2)] = dissolved CO(2) concentration in liquid, M[CO(2)](*) = CO(2) concentration in equilibrium with sparger gas, M[CO(2)](**) = CO(2) concentration in equilibrium with headspace gas, <compound-id="447055">MCO</compound-id>(2)(1) = dissolved <compound-id="280">carbon dioxide</compound-id> molecule in <compound-id="962">water</compound-id>[C(T)] = total carbonic species concentration in bioreactor medium, M[C(T)](F) = total carbonic species concentration in feed medium, MD = bioreactor diameter, mD(I) = impeller diameter, mD(b) = the initial delivered bubble diameter, mF = fresh medium feeding rate, L/minH(L) = liquid height in the vessel, mk(A) = <compound-id="280">carbon dioxide</compound-id> transfer coefficient at liquid surface, m/mink (<protein-id="P01571">infA</protein-id>)           (supO) = <compound-id="977">oxygen</compound-id> transfer coefficient at liquid surface, m/min.	MCO__infA__no_interaction	carbon dioxide__infA__no_interaction	water__infA__no_interaction	oxygen__infA__no_interaction
15538546-3	This issue focuses on the following selection of drugs: <compound-id="3081349">101M</compound-id>, <compound-id="124761">166Ho-DOTMP</compound-id>, <compound-id="9571836">3-AP</compound-id>; Abatacept, abetimus <compound-id="5360545">sodium</compound-id>, ACR-16, <compound-id="60871">adefovir dipivoxil</compound-id>, alefacept, AMD-070, <compound-id="6433083">aminolevulinic acid hexyl ester</compound-id>, anatumomab mafenatox, anti-<protein-id="P16410">CTLA-4</protein-id> MAb, <compound-id="3032556">antigastrin</compound-id> therapeutic vaccine, AP-12009, <compound-id="74787553">AP-23573</compound-id>, APC-8024, <compound-id="60795">aripiprazole</compound-id>, <compound-id="9952916">ATL-962</compound-id>, <compound-id="54841">atomoxetine</compound-id> hydrochloride; Bevacizumab, <compound-id="5311027">bimatoprost</compound-id>, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, <protein-id="O14625">BR-1</protein-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="156419">cinacalcet hydrochloride</compound-id>, <compound-id="2794">clofazimine</compound-id>, <compound-id="6167">colchicine</compound-id>, cold-adapted influenza vaccine trivalent, CRM197; <compound-id="124087">Desloratadine</compound-id>, <compound-id="447865,6918680">desoxyepothilone B</compound-id>, <compound-id="60702">diethylhomospermine</compound-id>; Edodekin alfa, efalizumab, <compound-id="108059">elcometrine</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="153941">entecavir</compound-id>, EP-2101, <compound-id="443872">eplerenone</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="123619">etoricoxib</compound-id>, everolimus, <compound-id="9916058">exherin</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="134018">Febuxostat</compound-id>, <compound-id="44152039,70697664">fluorescein lisicol</compound-id>, <compound-id="131536">fosamprenavir</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="77992">frovatriptan</compound-id>; Hemoglobin raffimer, HSPPC-96, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine, <protein-id="Q9BZI1">IRX-2</protein-id>, <compound-id="5311037">istradefylline</compound-id>, IV gamma-globulin, <compound-id="6445540">ixabepilone</compound-id>; <compound-id="44587015,56928091,6436220">Kahalalide F</compound-id>; L-759274, <compound-id="6047">levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, <compound-id="133021">licofelone</compound-id>, <compound-id="148195">lonafarnib</compound-id>, <compound-id="92727">lopinavir</compound-id>, <compound-id="60956">lurtotecan</compound-id>, LY-156735; MAb G250, mecasermin, <compound-id="896">melatonin</compound-id>, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="206044">muraglitazar</compound-id>; Nesiritide, <compound-id="9884642">nitronaproxen</compound-id>; <compound-id="4578">O6-Benzylguanine</compound-id>, <compound-id="130881">olmesartan medoxomil</compound-id>, <compound-id="130881">olmesartan medoxomil</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="656629">omapatrilat</compound-id>, oral <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="119828">Parecoxib sodium</compound-id>, <compound-id="16155604">PCK-3145</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ <compound-id="37542">ribavirin</compound-id>, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, peptide YY3-36, PG-CPT, <compound-id="219100">phenoxodiol</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="468595">posaconazole</compound-id>; <compound-id="3052776">Rasagiline</compound-id> mesilate, rDNA <protein-id="P01308,I3WAC9">insulin</protein-id>, RG228, <compound-id="104850">rimonabant hydrochloride</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">rosuvastatin calcium</compound-id>, <compound-id="59227">rotigotine hydrochloride</compound-id>; S-3304, <compound-id="131682">safinamide mesilate</compound-id>, <compound-id="158789">salcaprozic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt, <compound-id="65015">SDZ-SID-791</compound-id>, <compound-id="444389">SGN</compound-id>-30, <compound-id="24978490,6918315,70687327">soblidotin</compound-id>, <compound-id="72495">squalamine</compound-id>; <compound-id="65999">Telmisartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="6013">testosterone</compound-id> gel, TF(c)-KLH conjugate vaccine, TH-9507, theraloc, <compound-id="159324">tipifarnib</compound-id>, tocilizumab, <compound-id="5282226">travoprost</compound-id>; <compound-id="6918572">ValboroPro</compound-id>, <compound-id="119607">valdecoxib</compound-id>, veglin, <compound-id="71616">voriconazole</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>.	Imatinib mesylate__IRX-2__no_interaction	Imatinib mesylate__CTLA-4__no_interaction	Imatinib mesylate__BR-1__no_interaction	Imatinib mesylate__insulin__no_interaction	eplerenone__IRX-2__no_interaction	eplerenone__CTLA-4__no_interaction	eplerenone__BR-1__no_interaction	eplerenone__insulin__no_interaction	clofazimine__IRX-2__no_interaction	clofazimine__CTLA-4__no_interaction	clofazimine__BR-1__no_interaction	clofazimine__insulin__no_interaction	Ximelagatran__IRX-2__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__BR-1__no_interaction	Ximelagatran__insulin__no_interaction	squalamine__IRX-2__no_interaction	squalamine__CTLA-4__no_interaction	squalamine__BR-1__no_interaction	squalamine__insulin__no_interaction	Febuxostat__IRX-2__no_interaction	Febuxostat__CTLA-4__no_interaction	Febuxostat__BR-1__no_interaction	Febuxostat__insulin__no_interaction	phenoxodiol__IRX-2__no_interaction	phenoxodiol__CTLA-4__no_interaction	phenoxodiol__BR-1__no_interaction	phenoxodiol__insulin__no_interaction	bortezomib__IRX-2__no_interaction	bortezomib__CTLA-4__no_interaction	bortezomib__BR-1__no_interaction	bortezomib__insulin__no_interaction	travoprost__IRX-2__no_interaction	travoprost__CTLA-4__no_interaction	travoprost__BR-1__no_interaction	travoprost__insulin__no_interaction	Kahalalide F__IRX-2__no_interaction	Kahalalide F__CTLA-4__no_interaction	Kahalalide F__BR-1__no_interaction	Kahalalide F__insulin__no_interaction	olmesartan medoxomil__IRX-2__no_interaction	olmesartan medoxomil__CTLA-4__no_interaction	olmesartan medoxomil__BR-1__no_interaction	olmesartan medoxomil__insulin__no_interaction	bosentan__IRX-2__no_interaction	bosentan__CTLA-4__no_interaction	bosentan__BR-1__no_interaction	bosentan__insulin__no_interaction	166Ho-DOTMP__IRX-2__no_interaction	166Ho-DOTMP__CTLA-4__no_interaction	166Ho-DOTMP__BR-1__no_interaction	166Ho-DOTMP__insulin__no_interaction	exherin__IRX-2__no_interaction	exherin__CTLA-4__no_interaction	exherin__BR-1__no_interaction	exherin__insulin__no_interaction	fluorescein lisicol__IRX-2__no_interaction	fluorescein lisicol__CTLA-4__no_interaction	fluorescein lisicol__BR-1__no_interaction	fluorescein lisicol__insulin__no_interaction	etoricoxib__IRX-2__no_interaction	etoricoxib__CTLA-4__no_interaction	etoricoxib__BR-1__no_interaction	etoricoxib__insulin__no_interaction	ribavirin__IRX-2__no_interaction	ribavirin__CTLA-4__no_interaction	ribavirin__BR-1__no_interaction	ribavirin__insulin__no_interaction	melatonin__IRX-2__no_interaction	melatonin__CTLA-4__no_interaction	melatonin__BR-1__no_interaction	melatonin__insulin__no_interaction	levodopa__IRX-2__no_interaction	levodopa__CTLA-4__no_interaction	levodopa__BR-1__no_interaction	levodopa__insulin__no_interaction	erlotinib hydrochloride__IRX-2__no_interaction	erlotinib hydrochloride__CTLA-4__no_interaction	erlotinib hydrochloride__BR-1__no_interaction	erlotinib hydrochloride__insulin__no_interaction	rimonabant hydrochloride__IRX-2__no_interaction	rimonabant hydrochloride__CTLA-4__no_interaction	rimonabant hydrochloride__BR-1__no_interaction	rimonabant hydrochloride__insulin__no_interaction	colchicine__IRX-2__no_interaction	colchicine__CTLA-4__no_interaction	colchicine__BR-1__no_interaction	colchicine__insulin__no_interaction	elcometrine__IRX-2__no_interaction	elcometrine__CTLA-4__no_interaction	elcometrine__BR-1__no_interaction	elcometrine__insulin__no_interaction	sodium__IRX-2__no_interaction	sodium__CTLA-4__no_interaction	sodium__BR-1__no_interaction	sodium__insulin__no_interaction	lonafarnib__IRX-2__no_interaction	lonafarnib__CTLA-4__no_interaction	lonafarnib__BR-1__no_interaction	lonafarnib__insulin__no_interaction	fosamprenavir__IRX-2__no_interaction	fosamprenavir__CTLA-4__no_interaction	fosamprenavir__BR-1__no_interaction	fosamprenavir__insulin__no_interaction	licofelone__IRX-2__no_interaction	licofelone__CTLA-4__no_interaction	licofelone__BR-1__no_interaction	licofelone__insulin__no_interaction	SDZ-SID-791__IRX-2__no_interaction	SDZ-SID-791__CTLA-4__no_interaction	SDZ-SID-791__BR-1__no_interaction	SDZ-SID-791__insulin__no_interaction	cinacalcet hydrochloride__IRX-2__no_interaction	cinacalcet hydrochloride__CTLA-4__no_interaction	cinacalcet hydrochloride__BR-1__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	PCK-3145__IRX-2__no_interaction	PCK-3145__CTLA-4__no_interaction	PCK-3145__BR-1__no_interaction	PCK-3145__insulin__no_interaction	tipifarnib__IRX-2__no_interaction	tipifarnib__CTLA-4__no_interaction	tipifarnib__BR-1__no_interaction	tipifarnib__insulin__no_interaction	rosuvastatin calcium__IRX-2__no_interaction	rosuvastatin calcium__CTLA-4__no_interaction	rosuvastatin calcium__BR-1__no_interaction	rosuvastatin calcium__insulin__no_interaction	SGN__IRX-2__no_interaction	SGN__CTLA-4__no_interaction	SGN__BR-1__no_interaction	SGN__insulin__no_interaction	valdecoxib__IRX-2__no_interaction	valdecoxib__CTLA-4__no_interaction	valdecoxib__BR-1__no_interaction	valdecoxib__insulin__no_interaction	aminolevulinic acid hexyl ester__IRX-2__no_interaction	aminolevulinic acid hexyl ester__CTLA-4__no_interaction	aminolevulinic acid hexyl ester__BR-1__no_interaction	aminolevulinic acid hexyl ester__insulin__no_interaction	Rasagiline__IRX-2__no_interaction	Rasagiline__CTLA-4__no_interaction	Rasagiline__BR-1__no_interaction	Rasagiline__insulin__no_interaction	Parecoxib sodium__IRX-2__no_interaction	Parecoxib sodium__CTLA-4__no_interaction	Parecoxib sodium__BR-1__no_interaction	Parecoxib sodium__insulin__no_interaction	enfuvirtide__IRX-2__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__BR-1__no_interaction	enfuvirtide__insulin__no_interaction	ATL-962__IRX-2__no_interaction	ATL-962__CTLA-4__no_interaction	ATL-962__BR-1__no_interaction	ATL-962__insulin__no_interaction	101M__IRX-2__no_interaction	101M__CTLA-4__no_interaction	101M__BR-1__no_interaction	101M__insulin__no_interaction	rotigotine hydrochloride__IRX-2__no_interaction	rotigotine hydrochloride__CTLA-4__no_interaction	rotigotine hydrochloride__BR-1__no_interaction	rotigotine hydrochloride__insulin__no_interaction	3-AP__IRX-2__no_interaction	3-AP__CTLA-4__no_interaction	3-AP__BR-1__no_interaction	3-AP__insulin__no_interaction	Calcipotriol/betamethasone dipropionate__IRX-2__no_interaction	Calcipotriol/betamethasone dipropionate__CTLA-4__no_interaction	Calcipotriol/betamethasone dipropionate__BR-1__no_interaction	Calcipotriol/betamethasone dipropionate__insulin__no_interaction	diethylhomospermine__IRX-2__no_interaction	diethylhomospermine__CTLA-4__no_interaction	diethylhomospermine__BR-1__no_interaction	diethylhomospermine__insulin__no_interaction	entacapone__IRX-2__no_interaction	entacapone__CTLA-4__no_interaction	entacapone__BR-1__no_interaction	entacapone__insulin__no_interaction	voriconazole__IRX-2__no_interaction	voriconazole__CTLA-4__no_interaction	voriconazole__BR-1__no_interaction	voriconazole__insulin__no_interaction	safinamide mesilate__IRX-2__no_interaction	safinamide mesilate__CTLA-4__no_interaction	safinamide mesilate__BR-1__no_interaction	safinamide mesilate__insulin__no_interaction	O6-Benzylguanine__IRX-2__no_interaction	O6-Benzylguanine__CTLA-4__no_interaction	O6-Benzylguanine__BR-1__no_interaction	O6-Benzylguanine__insulin__no_interaction	ezetimibe__IRX-2__no_interaction	ezetimibe__CTLA-4__no_interaction	ezetimibe__BR-1__no_interaction	ezetimibe__insulin__no_interaction	ixabepilone__IRX-2__no_interaction	ixabepilone__CTLA-4__no_interaction	ixabepilone__BR-1__no_interaction	ixabepilone__insulin__no_interaction	Desloratadine__IRX-2__no_interaction	Desloratadine__CTLA-4__no_interaction	Desloratadine__BR-1__no_interaction	Desloratadine__insulin__no_interaction	istradefylline__IRX-2__no_interaction	istradefylline__CTLA-4__no_interaction	istradefylline__BR-1__no_interaction	istradefylline__insulin__no_interaction	ValboroPro__IRX-2__no_interaction	ValboroPro__CTLA-4__no_interaction	ValboroPro__BR-1__no_interaction	ValboroPro__insulin__no_interaction	hydrochlorothiazide__IRX-2__no_interaction	hydrochlorothiazide__CTLA-4__no_interaction	hydrochlorothiazide__BR-1__no_interaction	hydrochlorothiazide__insulin__no_interaction	entecavir__IRX-2__no_interaction	entecavir__CTLA-4__no_interaction	entecavir__BR-1__no_interaction	entecavir__insulin__no_interaction	pimecrolimus__IRX-2__no_interaction	pimecrolimus__CTLA-4__no_interaction	pimecrolimus__BR-1__no_interaction	pimecrolimus__insulin__no_interaction	AP-23573__IRX-2__no_interaction	AP-23573__CTLA-4__no_interaction	AP-23573__BR-1__no_interaction	AP-23573__insulin__no_interaction	testosterone__IRX-2__no_interaction	testosterone__CTLA-4__no_interaction	testosterone__BR-1__no_interaction	testosterone__insulin__no_interaction	lurtotecan__IRX-2__no_interaction	lurtotecan__CTLA-4__no_interaction	lurtotecan__BR-1__no_interaction	lurtotecan__insulin__no_interaction	pemetrexed disodium__IRX-2__no_interaction	pemetrexed disodium__CTLA-4__no_interaction	pemetrexed disodium__BR-1__no_interaction	pemetrexed disodium__insulin__no_interaction	frovatriptan__IRX-2__no_interaction	frovatriptan__CTLA-4__no_interaction	frovatriptan__BR-1__no_interaction	frovatriptan__insulin__no_interaction	salcaprozic acid__IRX-2__no_interaction	salcaprozic acid__CTLA-4__no_interaction	salcaprozic acid__BR-1__no_interaction	salcaprozic acid__insulin__no_interaction	posaconazole__IRX-2__no_interaction	posaconazole__CTLA-4__no_interaction	posaconazole__BR-1__no_interaction	posaconazole__insulin__no_interaction	atomoxetine__IRX-2__no_interaction	atomoxetine__CTLA-4__no_interaction	atomoxetine__BR-1__no_interaction	atomoxetine__insulin__no_interaction	bimatoprost__IRX-2__no_interaction	bimatoprost__CTLA-4__no_interaction	bimatoprost__BR-1__no_interaction	bimatoprost__insulin__no_interaction	midostaurin__IRX-2__no_interaction	midostaurin__CTLA-4__no_interaction	midostaurin__BR-1__no_interaction	midostaurin__insulin__no_interaction	calcium__IRX-2__no_interaction	calcium__CTLA-4__no_interaction	calcium__BR-1__no_interaction	calcium__insulin__no_interaction	nitronaproxen__IRX-2__no_interaction	nitronaproxen__CTLA-4__no_interaction	nitronaproxen__BR-1__no_interaction	nitronaproxen__insulin__no_interaction	desoxyepothilone B__IRX-2__no_interaction	desoxyepothilone B__CTLA-4__no_interaction	desoxyepothilone B__BR-1__no_interaction	desoxyepothilone B__insulin__no_interaction	adefovir dipivoxil__IRX-2__no_interaction	adefovir dipivoxil__CTLA-4__no_interaction	adefovir dipivoxil__BR-1__no_interaction	adefovir dipivoxil__insulin__no_interaction	antigastrin__IRX-2__no_interaction	antigastrin__CTLA-4__no_interaction	antigastrin__BR-1__no_interaction	antigastrin__insulin__no_interaction	soblidotin__IRX-2__no_interaction	soblidotin__CTLA-4__no_interaction	soblidotin__BR-1__no_interaction	soblidotin__insulin__no_interaction	aripiprazole__IRX-2__no_interaction	aripiprazole__CTLA-4__no_interaction	aripiprazole__BR-1__no_interaction	aripiprazole__insulin__no_interaction	Telmisartan__IRX-2__no_interaction	Telmisartan__CTLA-4__no_interaction	Telmisartan__BR-1__no_interaction	Telmisartan__insulin__no_interaction	lopinavir__IRX-2__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__BR-1__no_interaction	lopinavir__insulin__no_interaction	muraglitazar__IRX-2__no_interaction	muraglitazar__CTLA-4__no_interaction	muraglitazar__BR-1__no_interaction	muraglitazar__insulin__no_interaction	eletriptan__IRX-2__no_interaction	eletriptan__CTLA-4__no_interaction	eletriptan__BR-1__no_interaction	eletriptan__insulin__no_interaction	omapatrilat__IRX-2__no_interaction	omapatrilat__CTLA-4__no_interaction	omapatrilat__BR-1__no_interaction	omapatrilat__insulin__no_interaction
16954336-3	We studied 29 total parenteral nutrition-fed neonatal piglets infused intravenously with either saline (control) or human <protein-id="Q06606,P01275">GLP-2</protein-id> (420 micromol.kg(-1).h(-1)) for 1, 4, or 48 h. <protein-id="Q06606,P01275">GLP-2</protein-id> infusion increased small intestinal weight, DNA and protein content, and villus height at 48 h, but not at 1 or 4 h. Intestinal crypt and villus apoptosis decreased and crypt cell proliferation and protein synthesis increased linearly with duration of <protein-id="Q06606,P01275">GLP-2</protein-id> infusion, but were statistically different from controls only after 48 h. Before the morphological and cellular kinetic changes, <protein-id="Q06606,P01275">GLP-2</protein-id> rapidly activated putative <protein-id="Q06606,P01275">GLP-2</protein-id> receptor downstream signals within 1-4 h, including phosphorylation of <protein-id="A1L1M0">protein kinase A</protein-id>, protein kinase B, <protein-id="P21708">extracellular signal-regulated kinase 1/2</protein-id>, and the transcription factors <compound-id="6076">cAMP</compound-id> response element-binding protein and <protein-id="P12841">c-Fos</protein-id>.	cAMP__protein kinase A__no_interaction	cAMP__GLP-2__no_interaction	cAMP__c-Fos__no_interaction	cAMP__extracellular signal-regulated kinase 1/2__no_interaction
8665485-4	NCF analysis was able to distinguish terminally differentiated epithelial cells (DMEM/<protein-id="P00748,Q8IZZ5">F12</protein-id>/NaCl) from those less differentiated cells (<compound-id="11300413">KGM</compound-id>, DMEM/<protein-id="P00748,Q8IZZ5">F12</protein-id>/FCS) in several emission (lambda ex 340 nm, lambda em 360-660 nm; lambda ex 365 nm, lambda em 400-700 nm; lambda ex 420 nm, lambda em 440-800 nm) and excitation scans (lambda ex 200-360 nm; lambda em 380 nm, lambda ex 240-430 nm; lambda em 450 nm, lambda ex 250-460 nm, lambda em 480 nm; lambda ex 270-500 nm, lambda em 520 nm).	KGM__F12__no_interaction
24351532-24	Compared with those of group B [0.50 ± 0.07, (69 ± 10) µg/mL, (26 ± 11) µg/g, (0.672 ± 0.145) U/mL], the contents of <compound-id="187">acetylcholine</compound-id> and intestinal mucosa protein were increased significantly, <protein-id="O35078">DAO</protein-id> activity decreased significantly in group B+P (with P values all below 0.01); the contents of intestinal mucosa protein was increased significantly, <protein-id="O35078">DAO</protein-id> activity decreased significantly in group B+G (with P values all below 0.01); the contents of <compound-id="187">acetylcholine</compound-id> and intestinal mucosa protein were increased significantly in group B+LPG (with P values all below 0.01); the intestinal propulsion index, the contents of <compound-id="187">acetylcholine</compound-id> and intestinal mucosa protein were increased significantly, while the <protein-id="O35078">DAO</protein-id> activity obviously decreased in groups B+<protein-id="D3ZEM0">MPG</protein-id> and B+HPG [0.66 ± 0.07, 0.68 ± 0.05; (163 ± 24), (168 ± 15) µg/mL; (57 ± 7), (57 ± 7) µg/g; (0.203 ± 0.070), (0.193 ± 0.068) U/mL, with P values all below 0.01].	acetylcholine__MPG__no_interaction	acetylcholine__DAO__no_interaction
21283059-11	<protein-id="Q13162,V9HW63">peroxiredoxin 4</protein-id> correlated with the sepsis marker procalcitonin (r = 0.61, P &lt; 0.0001), the inflammatory markers C-reactive protein (r = 0.65, P &lt; 0.0001) and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin 6</protein-id> (r = 0.62, P &lt; 0.0001), and antioxidant blood compounds total <compound-id="5280352">bilirubin</compound-id> (r = 0.37, P &lt; 0.001) and albumin (r = -0.54, P &lt; 0.0001).	bilirubin__peroxiredoxin 4__no_interaction	bilirubin__interleukin 6__no_interaction
23252893-1	As an overview of the structure of the neuromuscular junction, three items are described focusing on cooperative mechanisms involving the synapse and leading to muscle contraction: (1) presynaptic <compound-id="187">acetylcholine</compound-id> release regulated by vesicle cycling (exocytosis and endocytosis); the fast-mode of endocytosis requires a large influx of external Ca(2+) and is promoted by the activation of G protein-coupled receptors and receptor <compound-id="6057,90983769">tyrosine</compound-id> kinases; (2) postsynaptic <compound-id="187">acetylcholine</compound-id> receptor clustering mediated by the <protein-id="O15146,A0A087WSY1">muscle-specific, Dok7-stimulated tyrosine kinase</protein-id> (<protein-id="O15146,A0A087WSY1">MuSK</protein-id>) through two signaling mechanisms: one via agrin-<protein-id="O75096">Lrp4</protein-id>-<protein-id="O15146,A0A087WSY1">MuSK</protein-id> (Ig1/2 domains) and the second via Wnt-<protein-id="O15146,A0A087WSY1">MuSK</protein-id> (Frizzled-like <compound-id="5862,90793998">cysteine</compound-id>-rich domain)-adaptor Dishevelled; Wnts/<protein-id="O15146,A0A087WSY1">MuSK</protein-id> and <protein-id="O75096">Lrp4</protein-id> direct a retrograde signal to presynaptic differentiation; (3) muscle contractile machinery regulated by Ca(2+) -release and Ca(2+) -influx channels, including the depolarization-activated <compound-id="11317883,27439,441753,5114,6326656">ryanodine</compound-id> receptor-1 and the receptor- and/or store-operated transient receptor potential canonical.	ryanodine__MuSK__no_interaction	ryanodine__Lrp4__no_interaction	ryanodine__muscle-specific, Dok7-stimulated tyrosine kinase__no_interaction	acetylcholine__MuSK__no_interaction	acetylcholine__Lrp4__no_interaction	acetylcholine__muscle-specific, Dok7-stimulated tyrosine kinase__no_interaction	cysteine__MuSK__no_interaction	cysteine__Lrp4__no_interaction	cysteine__muscle-specific, Dok7-stimulated tyrosine kinase__no_interaction	tyrosine__MuSK__no_interaction	tyrosine__Lrp4__no_interaction	tyrosine__muscle-specific, Dok7-stimulated tyrosine kinase__no_interaction
15920060-7	In a univariate analysis, <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> was positively associated with <compound-id="588">creatinine</compound-id> (r = 0.41; P &lt; 0.0001), AER (r = 0.33; P &lt; 0.0001), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (r = 0.22; P = 0.002), systolic blood pressure (r = 0.22; P = 0.004), HbA(1c) (r = 0.17; P = 0.02), total <compound-id="5997">cholesterol</compound-id> (r = 0.16; P = 0.03), and <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (r = 0.16; P = 0.03) and negatively with estimated glomerular filtration rate (GFR; r = -0.52; P &lt; 0.0001) and waist-to-hip ratio (WHR; r = -0.16; P = 0.03).	creatinine__HDL__no_interaction	creatinine__interleukin-6__no_interaction	creatinine__adiponectin__no_interaction	cholesterol__HDL__no_interaction	cholesterol__interleukin-6__no_interaction	cholesterol__adiponectin__no_interaction
21281788-5	The most significantly elevated analytes in tumor were checkpoint kinase (<compound-id="656923">Chk</compound-id>) 1 <compound-id="5951">serine</compound-id> 345 (S345), <compound-id="656923">Chk</compound-id> 2 <compound-id="66545740">S33</compound-id>/35, <protein-id="P06730,X5D7E3,D6RBW1,Q32Q75">eukaryotic translation initiation factor 4E</protein-id>-binding protein 1 (<protein-id="Q13541">4E-BP1</protein-id>) S65, protein kinase C (PKC) ζ/ι <compound-id="194239,6288">threonine</compound-id> 410/412 (T410/T412), <protein-id="Q15831">LKB1</protein-id> S334, <protein-id="P25963">inhibitor of kappaB alpha</protein-id> (IκB-α) S32, <protein-id="P06730,X5D7E3,D6RBW1,Q32Q75">eukaryotic translation initiation factor 4E</protein-id> (<protein-id="P06730,X5D7E3,D6RBW1,Q32Q75">eIF4E</protein-id>) S209, <protein-id="Q15796,B7Z5N5,Q53XR6">Smad2</protein-id> S465/67, <protein-id="P35568,A0A024R499">insulin receptor substrate 1</protein-id> (<protein-id="P35568,A0A024R499">IRS-1</protein-id>) S612, mitogen-activated ERK kinase 1/2 (<protein-id="Q02750,A4QPA9,B4DFY5">MEK1/2</protein-id>) S217/221, and total PKC ι.	Chk__eukaryotic translation initiation factor 4E__no_interaction	Chk__IRS-1__no_interaction	Chk__Smad2__no_interaction	Chk__eIF4E__no_interaction	Chk__insulin receptor substrate 1__no_interaction	Chk__inhibitor of kappaB alpha__no_interaction	Chk__MEK1/2__no_interaction	Chk__4E-BP1__no_interaction	Chk__LKB1__no_interaction	S33__eukaryotic translation initiation factor 4E__no_interaction	S33__IRS-1__no_interaction	S33__Smad2__no_interaction	S33__eIF4E__no_interaction	S33__insulin receptor substrate 1__no_interaction	S33__inhibitor of kappaB alpha__no_interaction	S33__MEK1/2__no_interaction	S33__4E-BP1__no_interaction	S33__LKB1__no_interaction	serine__eukaryotic translation initiation factor 4E__no_interaction	serine__IRS-1__no_interaction	serine__Smad2__no_interaction	serine__eIF4E__no_interaction	serine__insulin receptor substrate 1__no_interaction	serine__inhibitor of kappaB alpha__no_interaction	serine__MEK1/2__no_interaction	serine__4E-BP1__no_interaction	serine__LKB1__no_interaction	threonine__eukaryotic translation initiation factor 4E__no_interaction	threonine__IRS-1__no_interaction	threonine__Smad2__no_interaction	threonine__eIF4E__no_interaction	threonine__insulin receptor substrate 1__no_interaction	threonine__inhibitor of kappaB alpha__no_interaction	threonine__MEK1/2__no_interaction	threonine__4E-BP1__no_interaction	threonine__LKB1__no_interaction
20979831-8	(2) total <compound-id="5997">cholesterol</compound-id> (TC) and fasting insulin (FINS) of FC group were lower than those of HF group [TC, FC group: (1.37 ± 0.39) mmol/L vs HF group: (2.01 ± 0.26) mmol/L, P &lt; 0.05; FINS, FC group: (3.03 ± 1.37) mU/L vs HF group: (4.76 ± 2.75) mU/L, P &lt; 0.05] while insulin sensitive index (ISI) and <protein-id="Q5GAM5">angiotensin II (AngII</protein-id>) of FC group were much higher than those of HF group [ISI, FC group: (58 ± 12) × 10(-3) vs HF group: (29 ± 9) × 10(-3), P &lt; 0.05; <protein-id="P01015">AngII</protein-id>, FC group: (61 ± 11) mmol/L vs HF group: (52 ± 10) mmol/L, P &lt; 0.05].	cholesterol__angiotensin II (AngII__no_interaction	cholesterol__AngII__no_interaction
21903990-5	RESULTS: In unadjusted analyses, <protein-id="Q9GZV9">FGF23</protein-id> correlated with serum <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.66, P &lt; 0.001), residual renal function (r = -0.37, P = 0.002), dialysis vintage (r = 0.31, P = 0.01), and renal <compound-id="1061,167704,644102">phosphate</compound-id> clearance (r = -0.38, P = 0.008).	phosphate__FGF23__no_interaction
11861502-7	Recombinant <protein-id="P08842">ARSC</protein-id> as well as human placenta microsomes hydrolyzed <compound-id="22833547">iodothyronine</compound-id> sulfates with a substrate preference for 3,3'-<compound-id="70682628">diiodothyronine sulfate</compound-id> (3,3'-T(2)S) approximately T(3) <compound-id="1117">sulfate</compound-id> (T(3)S) &gt;&gt; rT(3)S approximately T(4)S, whereas human and rat liver microsomes showed a preference for 3,3'-T(2)S &gt; T(3)S &gt;&gt; rT(3)S approximately T(4)S. <protein-id="P08842">ARSC</protein-id> and the tissue microsomal sulfatases were all characterized by high apparent K(m) values (&gt;50 microM) for 3,3'-T(2)S and T(3)S. <compound-id="22833547">Iodothyronine</compound-id> <protein-id="Q5FYA8">sulfatase</protein-id> activity determined using 3,3'-T(2)S as a substrate was much higher in human liver microsomes than in human placenta microsomes, although <protein-id="P08842">ARSC</protein-id> is expressed at higher levels in human placenta than in human liver.	Iodothyronine__sulfatase__no_interaction	Iodothyronine__ARSC__no_interaction	diiodothyronine sulfate__sulfatase__no_interaction	diiodothyronine sulfate__ARSC__no_interaction	iodothyronine__sulfatase__no_interaction	iodothyronine__ARSC__no_interaction	sulfate__sulfatase__no_interaction	sulfate__ARSC__no_interaction
9704757-6	The laparoscopic hysterectomy group had a significantly lower postoperative <compound-id="5288826">morphine</compound-id> consumption (median 5.5 vs 14 mg, P &lt; .05), lower febrile morbidity rate (15% vs 45.8%, P &lt; .05), and shorter hospital stay (median 4 vs 6 days, P &lt; .001) and demonstrated a less intense stress response in terms of serum <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (median 50.6 vs 73.9 pg/mL x hour x 10, P = .01), <protein-id="P02741">C-reactive protein</protein-id> (median 28.1 vs 44.7 mg/L x hour x 10(2), P = .005), <compound-id="5754">cortisol</compound-id> (median 23.4 vs 27.2 mg/mL x hour x 10(3), P = .04), white blood cell count (median 59.5 vs 69.8 10(9)/L x hour x 10, P = .009), 24-hour urinary excretion of <compound-id="5754">cortisol</compound-id> (median 34.8 vs 44.2 nmol/L x hour x 10(3), P = .02), and <compound-id="439260">norepinephrine</compound-id> (median 80.8 vs 132.4 nmol/L x hour x 10(2), P = .001).	norepinephrine__C-reactive protein__no_interaction	norepinephrine__interleukin-6__no_interaction	morphine__C-reactive protein__no_interaction	morphine__interleukin-6__no_interaction	cortisol__C-reactive protein__no_interaction	cortisol__interleukin-6__no_interaction
23534516-6	The results of DNA microarray analysis showed that 9 genes associated with apoptosis (murine double minute 2, heat-labile enterotoxin B subunit, lymphotoxin B receptor, tumor necrosis factor ligand superfamily 7, tumor necrosis factor receptor superfamily 21, tumor necrosis factor receptor superfamily 1A, myeloid cell leukemia-1, <protein-id="P70677">caspase3</protein-id>), 13 genes associated with cell proliferation and cell cycle (cell division cycle27, cell division cycle37, CDC28 protein kinase 1B, cycling B1, <protein-id="Q9D4H8">cullin 2</protein-id>, <protein-id="Q9JLV5,Q9CTE0">cullin 3</protein-id>, <protein-id="Q3TCH7">cullin 4A</protein-id>, growth arrest and DNA damage-inducible 45A, meiotic recombination 11 homolog B, forkhead box M1, minichromosome maintenance 7, antigen identified by monoclonal antibody ki 67, <protein-id="P17918,Q542J9">proliferating cell nuclear antigen), and 11</protein-id> genes associated with cellular stress and toxic reaction (<compound-id="124886,20725278">glutathione</compound-id> peroxidase 1, metallothioneins, <compound-id="5359597">superoxide</compound-id> dismutase-1, heat shock protein <compound-id="5327090">A1A</compound-id>, heat shock protein A2, heat shock protein A4, heat shock protein A5, heat shock protein 9B, heat shock protein CA, <protein-id="P34884,Q545F0">macrophage migration inhibitory factor</protein-id>, plasminogen activator inhibitor)were up or down regulated more than 2 folds in tumors treated with <compound-id="84046">Bleomycin A5</compound-id> compared with controls.	Bleomycin A5__proliferating cell nuclear antigen), and 11__no_interaction	Bleomycin A5__caspase3__no_interaction	Bleomycin A5__macrophage migration inhibitory factor__no_interaction	Bleomycin A5__cullin 3__no_interaction	Bleomycin A5__cullin 2__no_interaction	Bleomycin A5__cullin 4A__no_interaction	glutathione__proliferating cell nuclear antigen), and 11__no_interaction	glutathione__caspase3__no_interaction	glutathione__macrophage migration inhibitory factor__no_interaction	glutathione__cullin 3__no_interaction	glutathione__cullin 2__no_interaction	glutathione__cullin 4A__no_interaction	A1A__proliferating cell nuclear antigen), and 11__no_interaction	A1A__caspase3__no_interaction	A1A__macrophage migration inhibitory factor__no_interaction	A1A__cullin 3__no_interaction	A1A__cullin 2__no_interaction	A1A__cullin 4A__no_interaction	superoxide__proliferating cell nuclear antigen), and 11__no_interaction	superoxide__caspase3__no_interaction	superoxide__macrophage migration inhibitory factor__no_interaction	superoxide__cullin 3__no_interaction	superoxide__cullin 2__no_interaction	superoxide__cullin 4A__no_interaction
8821773-7	Patients with acute myocardial infarction (AMI) had increased serum levels of soluble <protein-id="P16581">E-selectin</protein-id> (sE-<compound-id="4929">selectin</compound-id>; AMI + urokinase = 312 +/- 20 ng/ml; AMI + <compound-id="4510">nitroglycerin</compound-id> = 334 +/- 15 ng/ml) and soluble <protein-id="P05362">ICAM-1</protein-id> (sICAM-1; AMI + urokinase = 629 +/- 30 ng/ml; AMI + <compound-id="4510">nitroglycerin</compound-id> = 655 +/- 25 ng/ml) compared to both patients with chronic angina (sE-<compound-id="4929">selectin</compound-id> = 67 +/- 10 ng/ml; sICAM-1 = 230 +/- 20 ng/ml) and healthy control subjects (sE-<compound-id="4929">selectin</compound-id> = 53 +/- 15 ng/ml; sICAM-1 200 +/- 16 ng/ml).	nitroglycerin__E-selectin__no_interaction	nitroglycerin__ICAM-1__no_interaction	selectin__E-selectin__no_interaction	selectin__ICAM-1__no_interaction
16636723-3	This issue focuses on the following selection of drugs: <compound-id="167195">131I</compound-id>-labetuzumab; <compound-id="441300">Abacavir sulfate</compound-id>, abatacept, adalimumab, <compound-id="34756">ademetionine</compound-id>, adjuvanted influenza vaccine, alefacept, alemtuzumab, <compound-id="2162">amlodipine</compound-id>, <compound-id="5280965">amphotericin B</compound-id>, <compound-id="90470007">anakinra</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="2244">aspirin</compound-id>, <compound-id="6450551">axitinib</compound-id>; <compound-id="21800">Betamethasone dipropionate</compound-id>, bevacizumab, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="16219006,443289,52943236">BQ-123</compound-id>; <compound-id="6006">Calcium folinate</compound-id>, <compound-id="156414">canertinib</compound-id> dihydrochloride, <compound-id="2568">carboplatin</compound-id>, <compound-id="2578">carmustine</compound-id>, <compound-id="2678">cetirizine hydrochloride</compound-id>, cetuximab, <compound-id="10883523,22811020,25127095,2735,44281724,5280795,5283710,5283711,5353527,5363362,54253998,57484195,6221,6432644,9821465">cholecalciferol</compound-id>, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="5280754,5284373,5497195,57123750,6435893,73896891">ciclosporin</compound-id>, <compound-id="156419">cinacalcet</compound-id> hydrochloride, cisplatin, <compound-id="84029">clarithromycin</compound-id>, <compound-id="2794">clofazimine</compound-id>, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, <compound-id="444031">darifenacin hydrobromide</compound-id>, <compound-id="6529858">DB-289</compound-id>, <compound-id="124087">desloratadine</compound-id>, Dexamet, <compound-id="3042">dicycloverine hydrochloride</compound-id>, <compound-id="637568">dimethyl fumarate</compound-id>, <compound-id="148124,54277830">docetaxel</compound-id>, <compound-id="100208,54600749,56840947,9810929">dolastatin 10</compound-id>, <compound-id="68873">drospirenone</compound-id>, <compound-id="68873">drospirenone</compound-id>/<compound-id="5757">estradiol</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>; Ecogramostim, <compound-id="151078">edotecarin</compound-id>, <compound-id="122335">efaproxiral sodium</compound-id>, <compound-id="5388962">enalapril</compound-id> <compound-id="444266">maleate</compound-id>, epoetin beta, <compound-id="5282411">epoprostenol sodium</compound-id>, epratuzumab, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="5757">estradiol</compound-id>, etanercept; <compound-id="3365">Fluconazole</compound-id>, <compound-id="30751">fludarabine phosphate</compound-id>, <compound-id="3385">fluorouracil</compound-id>; <compound-id="123631">Gefitinib</compound-id>, <compound-id="60750">gemcitabine</compound-id>, <compound-id="44576256">Ghrelin</compound-id> (human), <compound-id="3488">glibenclamide</compound-id>, <compound-id="3476">glimepiride</compound-id>, GTI-2040; <compound-id="3559">Haloperidol</compound-id>, human <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="636398">hydrocortisone probutate</compound-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="216468">indisulam</compound-id>, influenza vaccine, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, <protein-id="P01308,I3WAC9">insulin</protein-id> glulisine, <protein-id="P01308,I3WAC9">insulin</protein-id> lispro, <compound-id="60838">irinotecan</compound-id>, <compound-id="9824145">ispronicline</compound-id>; <compound-id="60825">Lamivudine</compound-id>, <compound-id="60825">lamivudine</compound-id>/<compound-id="35370">zidovudine</compound-id>/<compound-id="441300">abacavir sulfate</compound-id>, <compound-id="208908">lapatinib</compound-id>, <compound-id="3902">letrozole</compound-id>, levocetirizine, <compound-id="3950">lomustine</compound-id>, <compound-id="148195">lonafarnib</compound-id>, <compound-id="151166">lumiracoxib</compound-id>;<compound-id="24083">Magnesium sulfate</compound-id>, MD-1100, <compound-id="460612">melphalan</compound-id>, <compound-id="4091">metformin hydrochloride</compound-id>, <compound-id="126941">methotrexate</compound-id>, <compound-id="4168">metoclopramide hydrochloride</compound-id>, <compound-id="121891">mitiglinide calcium hydrate</compound-id>, monophosphoryl <compound-id="9877306">lipid A</compound-id>, <compound-id="5281040">montelukast sodium</compound-id>, <compound-id="151071">motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>, <compound-id="4271,5281078">mycophenolate mofetil</compound-id>, <compound-id="446541">mycophenolic acid sodium salt</compound-id>; <compound-id="115355">Nitisinone</compound-id>; Omalizumab, <compound-id="656629">omapatrilat</compound-id>, ONYX-015, oxaliplatin; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id> nanoparticles, panitumumab, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/<compound-id="37542">ribavirin</compound-id>, pertuzumab, phosphatidylcholine-rich phospholipid mixture, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="4829">pioglitazone hydrochloride</compound-id>, <compound-id="16132446">pramlintide acetate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>; QR-333; <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, ranolazine, <compound-id="3052776">rasagiline mesilate</compound-id>, RFB4(dsFv)-PE38, <compound-id="37542">ribavirin</compound-id>, <compound-id="6323490">rifabutin</compound-id>, <compound-id="5073">risperidone</compound-id>, rituximab, <compound-id="5090">rofecoxib</compound-id>, <compound-id="77999">rosiglitazone maleate</compound-id>, <compound-id="77999">rosiglitazone maleate</compound-id>/<compound-id="4091">metformin hydrochloride</compound-id>, rotavirus vaccine; S-236, <compound-id="56801">salmeterol xinafoate</compound-id>, <compound-id="6918388">sarizotan hydrochloride</compound-id>, sildenafil, <compound-id="5212">sildenafil citrate</compound-id>, <compound-id="5329102">sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="5394">temozolomide</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, teriparatide, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="108150">trabectedin</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="3081361">Vandetanib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate, <compound-id="151194">vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>, virosome influenza vaccine, <compound-id="71616">voriconazole</compound-id>; <compound-id="35370">Zidovudine</compound-id>.	escitalopram oxalate__insulin__no_interaction	clofazimine__insulin__no_interaction	letrozole__insulin__no_interaction	abacavir sulfate__insulin__no_interaction	gadolinium__insulin__no_interaction	Lamivudine__insulin__no_interaction	ciclesonide__insulin__no_interaction	erlotinib hydrochloride__insulin__no_interaction	melphalan__insulin__no_interaction	131I__insulin__no_interaction	fluorouracil__insulin__no_interaction	gemcitabine__insulin__no_interaction	epoprostenol sodium__insulin__no_interaction	cholecalciferol__insulin__no_interaction	Magnesium sulfate__insulin__no_interaction	Vandetanib__insulin__no_interaction	pioglitazone hydrochloride__insulin__no_interaction	rasagiline mesilate__insulin__no_interaction	paclitaxel__insulin__no_interaction	enalapril__insulin__no_interaction	voriconazole__insulin__no_interaction	anakinra__insulin__no_interaction	sildenafil citrate__insulin__no_interaction	bortezomib__insulin__no_interaction	temozolomide__insulin__no_interaction	salmeterol xinafoate__insulin__no_interaction	montelukast sodium__insulin__no_interaction	methotrexate__insulin__no_interaction	Fluconazole__insulin__no_interaction	sarizotan hydrochloride__insulin__no_interaction	ribavirin__insulin__no_interaction	lomustine__insulin__no_interaction	rosiglitazone maleate__insulin__no_interaction	rofecoxib__insulin__no_interaction	Gefitinib__insulin__no_interaction	desloratadine__insulin__no_interaction	hydrocortisone probutate__insulin__no_interaction	estradiol__insulin__no_interaction	amphotericin B__insulin__no_interaction	vardenafil hydrochloride__insulin__no_interaction	indisulam__insulin__no_interaction	cinacalcet__insulin__no_interaction	Betamethasone dipropionate__insulin__no_interaction	pramlintide acetate__insulin__no_interaction	Paclitaxel__insulin__no_interaction	carboplatin__insulin__no_interaction	clarithromycin__insulin__no_interaction	canertinib__insulin__no_interaction	carmustine__insulin__no_interaction	mycophenolic acid sodium salt__insulin__no_interaction	succinate__insulin__no_interaction	lonafarnib__insulin__no_interaction	darifenacin hydrobromide__insulin__no_interaction	drospirenone__insulin__no_interaction	bosentan__insulin__no_interaction	DB-289__insulin__no_interaction	rifabutin__insulin__no_interaction	Tadalafil__insulin__no_interaction	aspirin__insulin__no_interaction	Imatinib mesylate__insulin__no_interaction	maleate__insulin__no_interaction	edotecarin__insulin__no_interaction	tipifarnib__insulin__no_interaction	risperidone__insulin__no_interaction	ciclosporin__insulin__no_interaction	amlodipine__insulin__no_interaction	dicycloverine hydrochloride__insulin__no_interaction	Zidovudine__insulin__no_interaction	Ranelic acid distrontium salt__insulin__no_interaction	docetaxel__insulin__no_interaction	prasterone__insulin__no_interaction	Haloperidol__insulin__no_interaction	motexafin__insulin__no_interaction	ispronicline__insulin__no_interaction	lapatinib__insulin__no_interaction	irinotecan__insulin__no_interaction	Ghrelin__insulin__no_interaction	fludarabine phosphate__insulin__no_interaction	aripiprazole__insulin__no_interaction	omapatrilat__insulin__no_interaction	Calcium folinate__insulin__no_interaction	trabectedin__insulin__no_interaction	vinflunine__insulin__no_interaction	metformin hydrochloride__insulin__no_interaction	BQ-123__insulin__no_interaction	dolastatin 10__insulin__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	ademetionine__insulin__no_interaction	efaproxiral sodium__insulin__no_interaction	vatalanib__insulin__no_interaction	tiotropium bromide__insulin__no_interaction	mycophenolate mofetil__insulin__no_interaction	lamivudine__insulin__no_interaction	dimethyl fumarate__insulin__no_interaction	Nitisinone__insulin__no_interaction	duloxetine hydrochloride__insulin__no_interaction	cetirizine hydrochloride__insulin__no_interaction	axitinib__insulin__no_interaction	sunitinib malate__insulin__no_interaction	tegaserod maleate__insulin__no_interaction	pimecrolimus__insulin__no_interaction	treprostinil sodium__insulin__no_interaction	metoclopramide hydrochloride__insulin__no_interaction	lipid A__insulin__no_interaction	glibenclamide__insulin__no_interaction	mitiglinide calcium hydrate__insulin__no_interaction	lumiracoxib__insulin__no_interaction	Abacavir sulfate__insulin__no_interaction	glimepiride__insulin__no_interaction	zidovudine__insulin__no_interaction
18008059-5	RESULTS: In participants with high [median 12.0% (interquartile range 5.7-18.5%)] vs low [2.0% (1.0-2.0%)] liver <protein-id="P16671,A4D1B1,E9PLT1,B7Z6C3">Fat</protein-id>, fasting serum triacylglycerols (1.6 +/- 0.2 vs 1.0 +/- 0.1 mmol/l, p = 0.002) and fasting serum <protein-id="P01308,I3WAC9">insulin</protein-id> (55 +/- 4 vs 32 +/- 2 pmol/l, p &lt; 0.0001) were increased and serum HDL-<compound-id="5997">cholesterol</compound-id> (1.26 +/- 0.1 vs 1.48 +/- 0.1 mmol/l, p = 0.02) and fasting serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (9.5 +/- 1.2 vs 12.2 +/- 1.2 microg/ml, p = 0.05) decreased.	cholesterol__insulin__no_interaction	cholesterol__Fat__no_interaction	cholesterol__adiponectin__no_interaction
21717743-3	Using <compound-id="977">oxygen</compound-id> utilization rate method, following kinetic parameters were measured: heterotrophic yield coefficient <compound-id="7020181">YH</compound-id> = 0.693, autotrophic yield coefficient Y(A) = 0.263, heterotrophic decay coefficient KdH, = 0.108 d(-1), autotrophic yield coefficient KdA = 0.089 d(-1), specific maximum <protein-id="P14678,Q66K91">COD</protein-id> removal rate v(mS), = 1.94 mg x (mg x d)(-1), half saturation constant for <protein-id="P14678,Q66K91">COD</protein-id> removal K(S) = 34.6 mg x L(-1), specific maximum <compound-id="222">ammonia</compound-id> removal rate vmN = 0.18 mg x (mg x d)(-1), half saturation constant for <compound-id="222">ammonia</compound-id> removal K(N) = 1.06 mg x L(-1).	YH__COD__no_interaction	ammonia__COD__no_interaction	oxygen__COD__no_interaction
18956642-5	RESULTS: In <compound-id="5288643">IPO</compound-id> group, Compared with I/R group, antioxidant systems such as the levels of SOD, CAT, GPX, and <compound-id="124886">GSH</compound-id> of <compound-id="5288643">IPO</compound-id> Group were (41.4 +/- 4.4 ) U/mg, (19.5 +/- 1.6) U/mg, (168 +/- 13) U/mg, and (1.72 +/- 0.26) U/g, all significantly higher than those of I/R Group [(19.6 +/- 2.8) U/mg, (8.4 +/- 0.8) U/mg, (72 +/- 8) U/mg, and (0.89 +/-+/- 0.07) mg/g respectively, all P &lt; 0.05); and the levels of XO, <protein-id="D3ZGE2,A0A0G2K1A2">MPO</protein-id>, and MDA of Group <compound-id="5288643">IPO</compound-id> were (50 +/- 6) U/g, (5.0 +/- 0.5) U/g, and (0.91 +/- 0.08) nmol/mg respectively, all significantly lower than those of I/R Group [(83 +/- 8) U/g, (7.6 +/- 0.7) U/g and (1.58 +/- 0.17) nmol/mg respectively, all P &lt; 0.05).	GSH__MPO__no_interaction	IPO__MPO__no_interaction
21521770-7	The imidazole- and <compound-id="67516">triazole</compound-id>-containing inhibitors [S-(R*,R*)]-N-[4-[2-(dimethylamino)-1-(<compound-id="795">1H-imidazole</compound-id>-1-yl)propyl]-phenyl]<compound-id="8706">2-benzothiazolamine</compound-id> (R116010) and (R)-N-[4-[2-<compound-id="23134249">ethyl</compound-id>-1-(<compound-id="9257">1H-1,2,4-triazol</compound-id>-1-yl)<compound-id="68006705">butyl</compound-id>]phenyl]-<compound-id="8706">2-benzothiazolamine</compound-id> (R115866) were the most potent inhibitors of <protein-id="O43174">CYP26A1</protein-id> with IC(50) values of 4.3 and 5.1 nM, respectively.	triazole__CYP26A1__no_interaction	1H-1,2,4-triazol__CYP26A1__no_interaction	1H-imidazole__CYP26A1__no_interaction	butyl__CYP26A1__no_interaction	2-benzothiazolamine__CYP26A1__no_interaction	ethyl__CYP26A1__no_interaction
12778880-3	Group I: 52 (62.3%) cases with standard oral hypotensive drugs alone and control of other cardiovascular risk factors (mean age 53 years old, sex m/f 50/50%, race white/no-white 75/25%, mean known hypertension follow-up 10.2 +/- 10 years, mean SBP 208 +/- 30 mmHg, mean DBP 123 +/- 17 mmHg, mean serum <compound-id="588">creatinina</compound-id> 1.62 mg/dl and increase peripheral plasma <protein-id="P00797">renin</protein-id> value in 61.6% of patients) and group II: 31 (37.7%) cases treated with revascularización procedures (<protein-id="Q6ISU1,A0A087WTE9,Q6ZNR1">PTA</protein-id> or surgery) or nephrectomy in selected patients (mean age 50 years old, sex m/f 68/32%, race white/no-white 16/84%, mean known hypertension follow-up 8.5 +/- 8.6 years, mean SBP 214 +/- 32 mmHg, mean DBP 1.31 +/- 16 mmHg, mean serum <compound-id="588">creatinina</compound-id> 1.85 mg/dl and increase peripheral plasma <protein-id="P00797">renin</protein-id> value 78.3% of patients).	creatinina__PTA__no_interaction	creatinina__renin__no_interaction
11093772-5	Kinetic studies identified <compound-id="90478331">3A7</compound-id> as the most active P450 in the formation of three of the metabolites: for <compound-id="6438629">4-OH-retinoic acid</compound-id>, <compound-id="90478331">3A7</compound-id> showed a V(max)/K(m) of 127.7, followed by 3A5 (V(max)/K(m) = 25.6), <compound-id="72206642">2C8</compound-id> (V(max)/K(m) = 24.5), <protein-id="Q63HQ0,A0A024RDK6,A0A024RDI1">2C18</protein-id> (V(max)/K(m) = 15.8), 3A4 (V(max)/K(m) = 5.7), <protein-id="Q9UMX9,A0A076YGN1,D6RGY6">1A1</protein-id> (V(max)/K(m) = 5.0), and 4A11 (V(max)/K(m) = 1.9); for 4-oxo-RA, <compound-id="90478331">3A7</compound-id> showed a V(max)/K(m) of 13.4, followed by a 10-fold lower activity for both <protein-id="Q63HQ0,A0A024RDK6,A0A024RDI1">2C18</protein-id> and 4A11 (V(max)/K(m) = 1.2); and for 18-OH-RA, <compound-id="90478331">3A7</compound-id> showed a V(max)/K(m) of 10.5 compared with a V(max)/K(m) of 2.1 for 4A11 and 2.0 for <compound-id="72206642">2C8</compound-id>.	2C8__1A1__no_interaction	2C8__2C18__no_interaction	3A7__1A1__no_interaction	3A7__2C18__no_interaction	4-OH-retinoic acid__1A1__no_interaction	4-OH-retinoic acid__2C18__no_interaction
19507910-2	DFT computations find that the Fe-Fe bond in the Fe(I)Fe(I) diiron models is thermodynamically favored to produce the mu-oxo or oxidative addition product, Fe(II)-O-Fe(II); nevertheless, the <compound-id="402">sulfur</compound-id>-based HOMO-1 accounts for the experimentally observed mono- and bis-O-atom adducts at <compound-id="402">sulfur</compound-id>, i.e., (mu-pst)[Fe(CO)(2)L][Fe(CO)(2)L'] (pst = -S(CH(2))(3)S(O)-, 1,3-propanesulfenatothiolate; L = L' = CO (1-O); L = <protein-id="P60510,A0A024R625">PPh(3</protein-id>), L' = CO (2-O); L = L' = <protein-id="P04080,Q76LA1">PMe</protein-id>(3) (4-O)) and (mu-pds)[Fe(CO)(2)L][Fe(CO)(2)L'] (pds = -(O)S(CH(2))(3)S(O)-, 1,3-propanedisulfenato; L = <protein-id="P60510,A0A024R625">PPh(3</protein-id>), L' = CO (2-O(2))).	sulfur__PMe__no_interaction	sulfur__PPh(3__no_interaction
9836526-8	There were significant correlations between <protein-id="P28845,X5D2L1">HDL</protein-id> <protein-id="P02647,A0A024R3E3">apoA-I</protein-id> FCR and the following parameters: <protein-id="P28845,X5D2L1">HDL</protein-id> <protein-id="P02647,A0A024R3E3">apoA-I</protein-id> (r = -0.902, P &lt; 0.001), <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (r = -0.797, P = 0.001), plasma triglycerides (r = 0.743, P &lt; 0.01), <protein-id="P28845,X5D2L1">HDL</protein-id> triglycerides (r = 0.696, P &lt; 0.01), and <compound-id="5997">cholesterol</compound-id> ester transfer protein activity (r = 0.646, P &lt; 0.01).	cholesterol__HDL__no_interaction	cholesterol__apoA-I__no_interaction
20391574-6	Similarly, the reaction of mercury <compound-id="5047209">thiolate</compound-id> Hg(SC(6)F(5)) with Ga(<protein-id="O60220">ddp</protein-id>) (2 equiv) produced the bimetallic homoleptic compounds anti-[{(<protein-id="O60220">ddp</protein-id>)Ga(SC(6)F(5))}(2)Hg] (<compound-id="2981881,91293124">3a</compound-id>) and gauche-[{(<protein-id="O60220">ddp</protein-id>)Ga(SC(6)F(5))}(2)Hg] (3b), respectively, with a linear Ga-Hg-Ga linkage.	3a__ddp__no_interaction	thiolate__ddp__no_interaction
9045686-1	The pivotal discovery that <protein-id="Q13158">Fas-associated death domain protein</protein-id> (<protein-id="Q13158">FADD</protein-id>) <protein-id="P29466,A8K257,A8K249">interleukin-1beta-converting enzyme</protein-id> (FLICE)/<protein-id="Q14790,A0A024R3Z8">MACH</protein-id> was recruited to the <protein-id="P25445,Q59FU8">CD95</protein-id> signaling complex by virtue of its ability to bind the adapter molecule <protein-id="Q13158">FADD</protein-id> established that this protease has a role in initiating the death pathway (<compound-id="10154">Boldin</compound-id>, M. P., Goncharov, T. M. , Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815; Muzio, M., Chinnaiyan, A. M., Kischkel, K. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827).	Boldin__interleukin-1beta-converting enzyme__no_interaction	Boldin__CD95__no_interaction	Boldin__FADD__no_interaction	Boldin__MACH__no_interaction	Boldin__Fas-associated death domain protein__no_interaction
16847310-3	In mice, <compound-id="11970143">lipopolysaccharide</compound-id> produces a rapid, marked decrease in mRNA levels of nuclear hormone receptors [<protein-id="P37238,Q6GU14,M1VPI1">peroxisome proliferator-activated receptor gamma</protein-id> (<protein-id="P37238,Q6GU14,M1VPI1">PPARgamma</protein-id>), <protein-id="Q9Z0Y9,Q91X41">liver X receptor alpha</protein-id> (<protein-id="Q9Z0Y9,Q91X41">LXRalpha</protein-id>) and <protein-id="Q60644,Q8BP65">LXRbeta</protein-id>, thyroid receptor alpha (TRalpha) and TRbeta, and <protein-id="P28700,Q6LC96,A2AJP1,Q3UMU4">retinoid X receptor alpha</protein-id> (<protein-id="P28700,Q6LC96,A2AJP1,Q3UMU4">RXRalpha</protein-id>) and <protein-id="P28704,Q3TWJ1,Q8VCR0">RXRbeta</protein-id>] and receptor coactivators [<compound-id="6076">cAMP</compound-id> response element binding protein, <protein-id="P70365">steroid receptor coactivator 1</protein-id> (<protein-id="P70365">SRC1</protein-id>) and <protein-id="Q61026,E9PV80,Q8CE59,Q8C961,Q8CAG7,Q8CBM5,Q8BN74">SRC2</protein-id>, thyroid hormone receptor-associated protein, and <protein-id="P37238,Q6GU14,M1VPI1">peroxisome proliferator-activated receptor gamma</protein-id> co-activator 1alpha (<protein-id="O70343">PGC1alpha</protein-id>) and <protein-id="Q8VHJ7">PGC1beta</protein-id>] along with decreased expression of target genes (adipocyte P2, <compound-id="1005">phosphoenolpyruvate</compound-id> carboxykinase, <compound-id="24759880,753">glycerol</compound-id>-3-<compound-id="1061,167704,644102">phosphate</compound-id> acyltransferase, ABCA1, <protein-id="P08226,Q3TXU4">apolipoprotein E</protein-id>, sterol-regulatory element binding protein-1c, <protein-id="P14142">glucose transport protein 4</protein-id> (<protein-id="P14142">GLUT4</protein-id>), malic enzyme, and <protein-id="Q62264,Q543J4">Spot14</protein-id>) involved in triglyceride (TG) and carbohydrate metabolism.	phosphate__PPARgamma__no_interaction	phosphate__PGC1beta__no_interaction	phosphate__apolipoprotein E__no_interaction	phosphate__retinoid X receptor alpha__no_interaction	phosphate__LXRalpha__no_interaction	phosphate__LXRbeta__no_interaction	phosphate__RXRbeta__no_interaction	phosphate__RXRalpha__no_interaction	phosphate__SRC2__no_interaction	phosphate__PGC1alpha__no_interaction	phosphate__SRC1__no_interaction	phosphate__glucose transport protein 4__no_interaction	phosphate__peroxisome proliferator-activated receptor gamma__no_interaction	phosphate__GLUT4__no_interaction	phosphate__steroid receptor coactivator 1__no_interaction	phosphate__Spot14__no_interaction	phosphate__liver X receptor alpha__no_interaction	lipopolysaccharide__PPARgamma__no_interaction	lipopolysaccharide__PGC1beta__no_interaction	lipopolysaccharide__apolipoprotein E__no_interaction	lipopolysaccharide__retinoid X receptor alpha__no_interaction	lipopolysaccharide__LXRalpha__no_interaction	lipopolysaccharide__LXRbeta__no_interaction	lipopolysaccharide__RXRbeta__no_interaction	lipopolysaccharide__RXRalpha__no_interaction	lipopolysaccharide__SRC2__no_interaction	lipopolysaccharide__PGC1alpha__no_interaction	lipopolysaccharide__SRC1__no_interaction	lipopolysaccharide__glucose transport protein 4__no_interaction	lipopolysaccharide__peroxisome proliferator-activated receptor gamma__no_interaction	lipopolysaccharide__GLUT4__no_interaction	lipopolysaccharide__steroid receptor coactivator 1__no_interaction	lipopolysaccharide__Spot14__no_interaction	lipopolysaccharide__liver X receptor alpha__no_interaction	cAMP__PPARgamma__no_interaction	cAMP__PGC1beta__no_interaction	cAMP__apolipoprotein E__no_interaction	cAMP__retinoid X receptor alpha__no_interaction	cAMP__LXRalpha__no_interaction	cAMP__LXRbeta__no_interaction	cAMP__RXRbeta__no_interaction	cAMP__RXRalpha__no_interaction	cAMP__SRC2__no_interaction	cAMP__PGC1alpha__no_interaction	cAMP__SRC1__no_interaction	cAMP__glucose transport protein 4__no_interaction	cAMP__peroxisome proliferator-activated receptor gamma__no_interaction	cAMP__GLUT4__no_interaction	cAMP__steroid receptor coactivator 1__no_interaction	cAMP__Spot14__no_interaction	cAMP__liver X receptor alpha__no_interaction	glycerol__PPARgamma__no_interaction	glycerol__PGC1beta__no_interaction	glycerol__apolipoprotein E__no_interaction	glycerol__retinoid X receptor alpha__no_interaction	glycerol__LXRalpha__no_interaction	glycerol__LXRbeta__no_interaction	glycerol__RXRbeta__no_interaction	glycerol__RXRalpha__no_interaction	glycerol__SRC2__no_interaction	glycerol__PGC1alpha__no_interaction	glycerol__SRC1__no_interaction	glycerol__glucose transport protein 4__no_interaction	glycerol__peroxisome proliferator-activated receptor gamma__no_interaction	glycerol__GLUT4__no_interaction	glycerol__steroid receptor coactivator 1__no_interaction	glycerol__Spot14__no_interaction	glycerol__liver X receptor alpha__no_interaction	phosphoenolpyruvate__PPARgamma__no_interaction	phosphoenolpyruvate__PGC1beta__no_interaction	phosphoenolpyruvate__apolipoprotein E__no_interaction	phosphoenolpyruvate__retinoid X receptor alpha__no_interaction	phosphoenolpyruvate__LXRalpha__no_interaction	phosphoenolpyruvate__LXRbeta__no_interaction	phosphoenolpyruvate__RXRbeta__no_interaction	phosphoenolpyruvate__RXRalpha__no_interaction	phosphoenolpyruvate__SRC2__no_interaction	phosphoenolpyruvate__PGC1alpha__no_interaction	phosphoenolpyruvate__SRC1__no_interaction	phosphoenolpyruvate__glucose transport protein 4__no_interaction	phosphoenolpyruvate__peroxisome proliferator-activated receptor gamma__no_interaction	phosphoenolpyruvate__GLUT4__no_interaction	phosphoenolpyruvate__steroid receptor coactivator 1__no_interaction	phosphoenolpyruvate__Spot14__no_interaction	phosphoenolpyruvate__liver X receptor alpha__no_interaction
11290568-5	CKs fell into four categories: a) type-1-dominant (gamma-interferon-inducible protein (<protein-id="P17515,Q548V9">IP-10</protein-id>), <protein-id="P18340">monokine induced by INF-gamma</protein-id> (<protein-id="P18340">MIG</protein-id>), <protein-id="P10889,Q3U1J5">macrophage inflammatory protein-2</protein-id> (<protein-id="P10889,Q3U1J5">MIP-2</protein-id>), <compound-id="11970143">lipopolysaccharide</compound-id>-induced chemokine (<protein-id="P50228">LIX</protein-id>), rodent growth-related oncogene homologue (KP), macrophage inflammatory protein-1alpha (<protein-id="P14097,Q5QNV9">MIP-1alpha) and -1beta</protein-id> (<protein-id="P14097,Q5QNV9">MIP-1beta</protein-id>), <protein-id="P47993,Q542T1">lymphotactin</protein-id>), b) type-2-dominant (<protein-id="P48298">eotaxin</protein-id>, <protein-id="Q9Z121,Q149U7">monocyte chemotactic protein-2</protein-id> (<protein-id="Q03366,A9Z1Z1">MCP-2) and -3</protein-id> (<protein-id="Q03366,A9Z1Z1">MCP-3</protein-id>), <protein-id="O89093,Q54AI7,Q642U4,F8WHA7">liver and activation-regulated chemokine</protein-id> (<protein-id="O89093,Q54AI7,Q642U4,F8WHA7">LARC</protein-id>), <protein-id="P10146,Q0VB35,B1AVL8">T cell activation protein-3</protein-id> (<protein-id="P10146,Q0VB35,B1AVL8">TCA-3</protein-id>), c) type-1 and type-2 co-dominant (<protein-id="P10148,Q5SVU3">MCP-1</protein-id>, <protein-id="Q62401,Q545B5">MCP-5</protein-id>, monocyte-derived chemokine (MDC), thymus and activation-related chemokine (TARC), <protein-id="P27784">C10</protein-id>), and d) constitutive (lungkine, <protein-id="P84444">secondary lymphoid-tissue chemokine</protein-id> (SLC), <protein-id="O70460,Q548P0">EBI1-ligand chemokine</protein-id> (<protein-id="O70460,Q548P0">ELC</protein-id>), fractalkine, <protein-id="P51670,Q3U9T8">macrophage inflammatory protein-1gamma</protein-id> (<protein-id="P51670,Q3U9T8">MIP1-gamma</protein-id>), and stromal cell derived factor-1alpha (SDF1-alpha).	lipopolysaccharide__monokine induced by INF-gamma__no_interaction	lipopolysaccharide__monocyte chemotactic protein-2__no_interaction	lipopolysaccharide__MIG__no_interaction	lipopolysaccharide__C10__no_interaction	lipopolysaccharide__LIX__no_interaction	lipopolysaccharide__MIP-2__no_interaction	lipopolysaccharide__MIP-1alpha) and -1beta__no_interaction	lipopolysaccharide__TCA-3__no_interaction	lipopolysaccharide__MIP-1beta__no_interaction	lipopolysaccharide__ELC__no_interaction	lipopolysaccharide__IP-10__no_interaction	lipopolysaccharide__secondary lymphoid-tissue chemokine__no_interaction	lipopolysaccharide__MCP-2) and -3__no_interaction	lipopolysaccharide__T cell activation protein-3__no_interaction	lipopolysaccharide__macrophage inflammatory protein-1gamma__no_interaction	lipopolysaccharide__liver and activation-regulated chemokine__no_interaction	lipopolysaccharide__macrophage inflammatory protein-2__no_interaction	lipopolysaccharide__MIP1-gamma__no_interaction	lipopolysaccharide__EBI1-ligand chemokine__no_interaction	lipopolysaccharide__eotaxin__no_interaction	lipopolysaccharide__lymphotactin__no_interaction	lipopolysaccharide__LARC__no_interaction	lipopolysaccharide__MCP-5__no_interaction	lipopolysaccharide__MCP-3__no_interaction	lipopolysaccharide__MCP-1__no_interaction
11926007-5	RESULTS: A significant linear correlation with peak <compound-id="977">oxygen</compound-id> consumption was found at <protein-id="Q13127">rest</protein-id> for: mean pulmonary artery pressure (<protein-id="Q9QWY8,E9QMJ1,H3BKE6,H3BL41,Q3TXY1,Q3UJA5">mPAP</protein-id>, r = -0.56), right atrial pressure (RAP, r = -0.42), pulmonary wedge pressure (PWP, r = -0.53), and total pulmonary (TPR, r = -0.53) and <protein-id="P15151,A0A0C4DG49,A8K4I1,A0A0A0MSA9">pulmonary vascular resistances</protein-id> (<protein-id="P15151,A0A0C4DG49,A8K4I1,A0A0A0MSA9">PVR</protein-id>, r = -0.45); after 1 min of exercise for: cardiac index (CI, r = 0.49), <protein-id="Q9QWY8,E9QMJ1,H3BKE6,H3BL41,Q3TXY1,Q3UJA5">mPAP</protein-id> (r = -0.57), RAP (r = -0.60), PWP (r = -0.45), and TPR (r = -0.67) and <protein-id="P15151,A0A0C4DG49,A8K4I1,A0A0A0MSA9">PVR</protein-id> (r = -0.38); at peak exercise for: tidal volume (r = 0.63), CI (r = 0.63), RAP (r = -0.43), TPR (r = -0.65) and <protein-id="P15151,A0A0C4DG49,A8K4I1,A0A0A0MSA9">PVR</protein-id> (r = -0.43).	oxygen__mPAP__no_interaction	oxygen__PVR__no_interaction	oxygen__pulmonary vascular resistances__no_interaction	oxygen__rest__no_interaction
11926007-6	A significant linear correlation with peak <compound-id="977">oxygen</compound-id> consumption was found, for the increment between <protein-id="Q13127">rest</protein-id> and 1 min of exercise, for RAP (r = -0.58) and CI (r = 0.42) and, for the increments between <protein-id="Q13127">rest</protein-id> and peak exercise, for tidal volume (r = 0.79) and CI (r = 0.61) and, for the ratio between the increment between <protein-id="Q13127">rest</protein-id> and 1 min of exercise/increment between <protein-id="Q13127">rest</protein-id> and peak exercise, for <protein-id="Q9QWY8,E9QMJ1,H3BKE6,H3BL41,Q3TXY1,Q3UJA5">mPAP</protein-id> (r = -0.42), RAP (r = 0.51) and CI (r = -0.54).	oxygen__mPAP__no_interaction	oxygen__rest__no_interaction
17284019-2	Loss of Cl following photolysis of <protein-id="P13236">CCl4</protein-id> and NaCl was used to determine k(Cl + C6H6) = 6.4 x 10(-12) exp(-18.1 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) over 578-922 K and k(Cl + <compound-id="71601">C6D6</compound-id>) = 6.2 x 10(-12) exp(-22.8 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) over 635-922 K. Inclusion of literature data at room temperature leads to a recommendation of k(Cl + C6H6) = 6.1 x 10(-11) exp(-31.6 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) for 296-922 K. Monitoring growth of Cl during the reaction of phenyl with HCl led to k(C6H5 + HCl) = 1.14 x 10(-12) exp(+5.2 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) over 294-748 K, k(C6H5 + DCl) = 7.7 x 10(-13) exp(+4.9 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) over 292-546 K, an approximate k(C6H5 + C6H5I) = 2 x 10(-11) cm(3) molecule(-1) s(-1) over 300-750 K, and an upper limit k(Cl + C6H5I) &lt; or = 5.3 x 10(-12) exp(+2.8 kJ mol(-1)/RT) cm(3) molecule(-1) s(-1) over 300-750 K. Confidence limits are discussed in the text.	C6D6__CCl4__no_interaction
16478779-7	However, plasma <protein-id="Q9HD89">resistin</protein-id> in cirrhosis was negatively associated with hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> production (r = -0.47, P &lt; 0.01) and positively with circulating free fatty acids (FFA; r = 0.40, P &lt; 0.01) and <compound-id="4348752">ketone</compound-id> bodies (r = 0.48, P &lt; 0.001) as well as hepatic <compound-id="4348752">ketone</compound-id> body production (r = 0.40, P &lt; 0.01).	ketone__resistin__no_interaction	glucose__resistin__no_interaction
22933439-8	Baseline HFF correlated with 2-h <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.38, P = 0.001), whole-body <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (r = -0.405, P = 0.001), <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (r = -0.44, P &lt; 0.001), <protein-id="P05783,A0A024RAY2">CK-18</protein-id> levels, (r = 0.63, P &lt; 0.001), and disposition index (r = -0.272, P = 0.021) at follow-up.	glucose__CK-18__no_interaction	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
22785385-3	Two <protein-id="P47898,A4D2N2">5-HT5A</protein-id> antagonist ligands, SB-699551-A (<compound-id="11168182">N-[2-(dimethylamino)ethyl]-N-[[4'-[[(2-phenylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclopentanepropanamide dihydrochloride</compound-id>) (3-60 mg/kg, intraperitoneally) and A-843277 (N-(2,6-dimethoxybenzyl)-N'[4-(4-fluorophenyl)<compound-id="9256">thiazol</compound-id>-2-yl]<compound-id="3520,87210844">guanidine</compound-id>) (3-30 mg/kg, intraperitoneally), were examined in the open-field test, in a foot-shock-induced ultrasonic vocalization test, in the forced swim test (FST) and in the <compound-id="3007">amphetamine</compound-id>-induced and <compound-id="6468">phencyclidine</compound-id>-induced hyperlocomotion tests to examine their effect on general behavioural patterns, and their anxiolytic-like, antidepressant-like and antipsychotic-like properties, respectively.	guanidine__5-HT5A__no_interaction	amphetamine__5-HT5A__no_interaction	N-[2-(dimethylamino)ethyl]-N-[[4'-[[(2-phenylethyl)amino]methyl][1,1'-biphenyl]-4-yl]methyl]cyclopentanepropanamide dihydrochloride__5-HT5A__no_interaction	phencyclidine__5-HT5A__no_interaction	thiazol__5-HT5A__no_interaction
16278810-10	<compound-id="31703">Doxorubicin</compound-id>-exposed hearts also contained the highest levels of <compound-id="5359597">superoxide</compound-id> (p &lt; 0.001, compared to controls), which correlated negatively with the mtDNA-encoded respiratory chain activities, such as the <protein-id="P21912">COX/SDH</protein-id> ratio (r = -0.57, p = 0.02) and the <protein-id="P21912">NADH/SDH</protein-id> ratio (r = -0.52, p = 0.04), as well as with the mtDNA content (r = -0.69, p = 0.003), and correlated positively with the frequency of the 'common' deletion (r = 0.76, p &lt; 0.001) and the MDA levels (r = 0.86, p &lt; 0.001).	Doxorubicin__NADH/SDH__no_interaction	Doxorubicin__COX/SDH__no_interaction	superoxide__NADH/SDH__no_interaction	superoxide__COX/SDH__no_interaction
16209232-13	In case of women, whose parents were affected with IS, higher levels of the following indicators were detected: BMI (24.3 +/- 3.9 kg/mz vs 21.5 +/- 2.3 kg/m2), total <compound-id="5997">cholesterol</compound-id> (5.1 +/- 0.7 mmol/l vs 4.4 +/- 0.5 mmol/l, LDL <compound-id="5997">cholesterol</compound-id> (2.7 +/- 0.6 mmol/l vs 2.1 +/- 0.4 mmol/l), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (1.0 +/- 0.1 g/l vs 0.8 +/- 0.1 g/l), lipoprotein (a) (0.3 +/- 0.2 g/l vs 0.2 +/- 0.1 g/l) and triglycerides (1.0 +/- 0.4 mmol/l vs 0.7 +/- 0.2 mmol/l).	cholesterol__apolipoprotein B__no_interaction
1764021-2	We now report that human myocardial cytosolic Ca(2+)-independent <protein-id="P04054">PLA2</protein-id> is modulated by ATP through mechanisms which are independent of protein phosphorylation, since: (1) ATP and its non-hydrolysable analogues reversibly augment the initial rate of crude (but not purified) human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> activity 3-4 fold; (2) ATP and its non-hydrolysable analogues dramatically attenuate the rate of thermal denaturation of human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> activity; (3) ATP and its non-hydrolysable analogues alter the sensitivity of human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> to mechanism-based inhibition by (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-<compound-id="68154">2H-pyran-2-one</compound-id>; (4) <compound-id="190,57060554">adenine</compound-id> nucleotide triphosphates are more potent than <compound-id="764">guanine</compound-id> nucleotide triphosphates in activating and stabilizing human myocardial cytosolic <protein-id="P04054">PLA2</protein-id>; (5) <compound-id="57476835,60961">adenosine</compound-id> 5'-[beta gamma-<compound-id="123164">methylene</compound-id>]triphosphate is more potent than its <compound-id="6802">guanosine</compound-id> counterpart in protecting an essential thiol residue(s) in human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> from covalent modification by 5,5'-<compound-id="132740,3009841">dithiobis</compound-id>-(2-<compound-id="11087">nitrobenzoic acid</compound-id>); and (6) ATP-dependent activation and stabilization of human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> are mediated by a cytosolic protein(s) which can be functionally reconstituted with purified human myocardial cytosolic <protein-id="P04054">PLA2</protein-id> catalytic polypeptide.	adenine__PLA2__no_interaction	dithiobis__PLA2__no_interaction	nitrobenzoic acid__PLA2__no_interaction	guanosine__PLA2__no_interaction	guanine__PLA2__no_interaction	adenosine__PLA2__no_interaction	methylene__PLA2__no_interaction	2H-pyran-2-one__PLA2__no_interaction
20535794-8	Circulating cytokines were significantly higher in patients who had experienced relapses (mean +/- <compound-id="12631">SD 25</compound-id> +/- 39 versus 10 +/- 11 pg/ml; P = 0.04 for <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and mean +/- SD 34 +/- 15 versus 25 +/- 11 pg/ml; P = 0.042 for <protein-id="P01375,Q5STB3">TNFalpha</protein-id>).	SD 25__IL-6__no_interaction	SD 25__TNFalpha__no_interaction
23884539-1	Hydrothermal reaction of a tripodal bridging ligand, 5-(4-carboxyphenoxy)<compound-id="8496">isophthalic acid</compound-id> (H3cpia) with <compound-id="22372">cobalt salts</compound-id> modulated by N-donor neutral ligands leads to the formation of six novel coordination networks formulated as {[Co(1.5)(cpia)(o-bix)](H2O)(1.5)}n (1), {[<compound-id="280">Co2</compound-id>(cpia)(μ-OH)(m-bix)]H2O}n (2), {[Co(1.5)(cpia)(m-bix)]}n (3), {[Co(1.5)(cpia)(p-bix)(0.5)(H2O)]H2O}n (4), {[Co(2.5)(cpia)(Hcpia)(4,4'-bpy)(2.5)](H2O)3}n (5), and {[<compound-id="767">Co3</compound-id>(cpia)2(<protein-id="O60687">bpp</protein-id>)2]H2O}n (6).	cobalt salts__bpp__no_interaction	isophthalic acid__bpp__no_interaction	Co2__bpp__no_interaction	Co3__bpp__no_interaction
11372412-7	There was a negative linear correlation between <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> positive rate in syncytiotrophoblasts and the values of <compound-id="5496796">UmA</compound-id> PI (r = -0.52, P &lt; 0.001), RI (r = -0.43, P &lt; 0.01), S/D (r = -0.40, P &lt; 0.01).	UmA__VEGF__no_interaction
17164573-5	RESULTS AND DISCUSSION: Molecular analysis of the <protein-id="Q16678,Q53TK1">CYP1B1</protein-id> gene showed the following molecular defects: (1) a novel single-base pair deletion within codon 370 (1454delC) that produces a substitution of <compound-id="6106">leucine</compound-id> instead of <compound-id="145742,57240853,614,8988">proline</compound-id> and a premature stop codon 57 amino acids after the last original amino acid; this family also harbored a novel polymorphic variant of the cytochrome <protein-id="Q16678,Q53TK1">P4501B1</protein-id> with six single-nucleotide polymorphisms (142C--&gt;G; 355G--&gt;T; 729G--&gt;C; 4326C--&gt;G; 4360C--&gt;G and 4379C--&gt;T); (2) a novel single-base pair deletion within codon 277 (1176delT) that results in a premature stop codon; (3) a novel single-base pair deletion within codon 179 (880delG) that produces a substitution of <compound-id="6322,90867653">arginine</compound-id> instead of <compound-id="5950,602">alanine</compound-id> and a premature stop codon 17 amino acids downstream from the last original amino acid, and (4) a duplication (or insertion) of ten base pairs within codon 404 (1556dupATGCCACCAC) that results in a premature stop codon 26 amino acids after the last original amino acid.	leucine__P4501B1__no_interaction	leucine__CYP1B1__no_interaction	alanine__P4501B1__no_interaction	alanine__CYP1B1__no_interaction	proline__P4501B1__no_interaction	proline__CYP1B1__no_interaction	arginine__P4501B1__no_interaction	arginine__CYP1B1__no_interaction
9324100-6	The increase in dietary <compound-id="5360545">sodium</compound-id> from low to high did not result in significant differences in fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (6.0 +/- 0.2 v 5.8 +/- 0.1 mmol/L, P = .20) or <protein-id="P01308,I3WAC9">insulin</protein-id> (72.5 +/- 7.8 v 69.9 +/- 12.4 pmol/L, P = 0.71) levels or in the <compound-id="206,5793,64689,79025">glucose</compound-id> (374.0 +/- 50.8 v 493.2 +/- 45.0 mmol/min/L, P = .12) and <protein-id="P01308,I3WAC9">insulin</protein-id> (43,783 +/- 10,278 v 44,110 +/- 12,392 pmol/min/L, P = .96) areas determined during the oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test.	glucose__insulin__no_interaction	sodium__insulin__no_interaction
16735760-7	It correlated well with age (r = 0.56, P = 0.006), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.8, P = 0.003), fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.95, P = 0.00001), total units of blood transfused (r = 0.52, P = 0.005), serum ferritin (r = 0.4, P = 0.02) and splenomegaly (r = 0.51, P = 0.004).	glucose__insulin__no_interaction
24341473-1	There were new dinuclear Zn(II)-Ln(III) complexes of general formulas [Zn(μ-L)(μ-OAc)Ln(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] (Ln(III) = Tb (1), Dy (2), Er (3), and Yb (4)), [Zn(μ-L)(μ-<protein-id="P41271,A0A087WTY6">NO3</protein-id>)Er(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2] (5), [Zn(H2O)(μ-L)Nd(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)3]·2CH3OH (6), [Zn(μ-L)(μ-9-An)Ln(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2]·2CH3CN (Ln(III) = Tb (7), Dy (8), Er (9), Yb(10)), [Zn(μ-L)(μ-9-An)Yb(9-An)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)3]·3CH3CN (11), [Zn(μ-L)(μ-9-An)Nd(9-An)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)3]·2CH3CN·3H2O (12), and [Zn(μ-L)(μ-9-An)Nd(CH3OH)2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]ClO4·2CH3OH (13) prepared from the reaction of the compartmental ligand N,N',N″-<compound-id="4245325">trimethyl-</compound-id>N,N″-bis(<compound-id="97257">2-hydroxy-</compound-id>3-<compound-id="10351751">methoxy-5-methylbenzyl</compound-id>)<compound-id="8111">diethylenetriamine</compound-id> (H2L), with ZnX2·nH2O (X = <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) or OAc(-)) salts, Ln(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)3·nH2O, and, in some instances, <compound-id="2201">9-anthracenecarboxylate</compound-id> anion (9-An).	methoxy-5-methylbenzyl__NO3__no_interaction	2-hydroxy-__NO3__no_interaction	diethylenetriamine__NO3__no_interaction	trimethyl-__NO3__no_interaction	9-anthracenecarboxylate__NO3__no_interaction
18780391-4	In compounds [[Ag(4-pia)][X]]n (1 supersetX; 4-pia=<compound-id="3758644">N-(4-pyridyl)isonicotinamide</compound-id>; X=<protein-id="Q6Q759">PF6</protein-id> -, ClO4 -, BF4 -, and <protein-id="P41271,A0A087WTY6">NO3</protein-id> -), [[Ag(4-pmia)][X]]n (2 supersetX; 4-pmia=N-(pyridin-4-ylmethyl)<compound-id="15074">isonicotinamide</compound-id>; X=<protein-id="Q6Q759">PF6</protein-id> -, ClO4 -H2O, and <protein-id="P41271,A0A087WTY6">NO3</protein-id> -H2O), and [[Ag(3-pmia)][X]]n (3 supersetX; 3-pmia=N-(pyridin-3-ylmethyl)<compound-id="15074">isonicotinamide</compound-id>; X=<protein-id="Q6Q759">PF6</protein-id> -, ClO4 -, BF4 -, and <protein-id="P41271,A0A087WTY6">NO3</protein-id> -H2O), each chain is aligned parallel to neighboring chains, but adjacent chains run in the opposite direction.	N-(4-pyridyl)isonicotinamide__NO3__no_interaction	N-(4-pyridyl)isonicotinamide__PF6__no_interaction	isonicotinamide__NO3__no_interaction	isonicotinamide__PF6__no_interaction
18780391-5	Particularly in [[Ag(3-pmia)][<protein-id="Q6Q759">PF6</protein-id>]]n (3 supersetPF6 -), [[Ag(3-pmia)][ClO4]]n (3 supersetClO4 -), and [[Ag(3-pmia)][BF4]]n (3 supersetBF4 -), <compound-id="2826723">amide</compound-id> moieties of 3-pmia ligands are complementarily <compound-id="783">hydrogen</compound-id> bonded to <compound-id="2826723">amide</compound-id> moieties in neighboring chains, as in the beta-sheet motif in proteins.	hydrogen__PF6__no_interaction	amide__PF6__no_interaction
17703659-12	The means and standard deviations of the derived elastic coefficients were: c33 = 29.9 +/- 5.0 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P17516">c11</protein-id> = 21.9 +/- 2.1 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, c12 = 9.2 +/- 1.5 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P31276">c13</protein-id> = 9.7 +/- 1.6 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, and <compound-id="23657803">c44</compound-id> = 6.7 +/- 1.2 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>.	c44__c13__no_interaction	c44__c11__no_interaction	c44__GPa__no_interaction
21678503-1	Addition of the amine-boranes <protein-id="P68431">H(3)B</protein-id>⋅NH(2)tBu, <protein-id="P68431">H(3)B</protein-id>⋅NHMe(2) and <protein-id="P68431">H(3)B</protein-id>⋅NH(3) to the cationic <compound-id="23950">ruthenium</compound-id> fragment [Ru(xantphos)(PPh(3))(OH(2))H][BAr(F)(4)] (2; xantphos=4,5-<compound-id="86658749">bis(diphenylphosphino)-9,9-dimethylxanthene</compound-id>; BAr(F)(4)=[B{3,5-(CF(3))(2)C(6)H(3)}(4)](-)) affords the η(1)-B-H bound amine-<compound-id="5462311">borane</compound-id> complexes [Ru(xantphos)(PPh(3))(<protein-id="P68431">H(3)B</protein-id>⋅NH(2)tBu)H][BAr(F)(4)] (5), [Ru(xantphos)(PPh(3))(H(3) B⋅NHMe(2))H][BAr(F)(4)] (6) and [Ru(xantphos)(PPh(3))(<protein-id="P68431">H(3)B</protein-id>⋅NH(3))H][BAr(F)(4)] (7).	ruthenium__H(3)B__no_interaction	borane__H(3)B__no_interaction	bis(diphenylphosphino)-9,9-dimethylxanthene__H(3)B__no_interaction
17993762-7	The relative risk of <compound-id="221493">CHD</compound-id> was significantly increased for male patients [odds ratio (OR): 1.6; 95% confidence interval (CI): 1.1-2.2], patients with age &gt; or = 66 yr (OR: 1.8; 95% CI: 1.3-2.5), body mass index (BMI) &gt; 30 (OR: 1.5; 95% CI: 1.1-2.1), waist circumference &gt; 88 cm for females and 102 cm for males (OR: 1.5; 95% CI: 1.0-2.1), proteinuria &gt; or = 30 microg per min (OR: 1.6; 95% CI: 1.1-2.3), LDL-<compound-id="5997">cholesterol</compound-id> &gt; or = 100 mg/dl (OR: 2.1; 95% CI: 1.5-3.0), glycated hemoglobin &gt; 7% (OR: 1.6; 95% CI: 1.1-2.3), <protein-id="P01308,I3WAC9">insulin</protein-id> therapy (OR: 1.9; 95% CI: 1.3-2.9), and ABPI &lt; 0.90 (OR: 3.7; 95% CI: 2.2- 6.2).	CHD__insulin__no_interaction	cholesterol__insulin__no_interaction
2800633-1	For determination of the endurance limit range, 8 healthy male probands aged between 20 and 26 years loads had carried out for one hour on a bicycle ergometer at an ambient temperature of +20 degrees C, +28 degrees C and +35 degrees C. Staying in an ambient temperature of 35 degrees C leads to a decrease in the physical endurance limit in an order of magnitude of 10 W. At 20 degrees C, in the endurance range the following values result (mean +/- s): load 68+/- 10.3 W, heart rate 113.6 +/- 5.8 beats per min., <protein-id="P41970,A0A024RBE2">net</protein-id> heart rate 31.8 +/- 2.4 beats per min., <compound-id="977">oxygen</compound-id> uptake 1340 +/- 170 ml per min., auditory canal temperature 36.5 +/- 0.24 degrees C, sweat rate 275 +/- 143 g. At 35 degrees C, the endurance limit is attained at the following values: 57 +/- 10.6 W, heart rate 125 +/- 11.8 beats per min., <protein-id="P41970,A0A024RBE2">net</protein-id> heart rate 27.4 +/- 3.6 beats per min., <compound-id="977">oxygen</compound-id> uptake 1210 +/- 130 ml per min., auditory canal temperature 37.2 +/- 0.3 degrees C, sweat rate 577 +/- 96 g.	oxygen__net__no_interaction
22745575-7	Particularly, we observed that TNF (tumor necrosis factor) gene is significantly associated with both beef marbling score (P=0.0016) and <compound-id="985">palmitic acid</compound-id> (C16:0) (P=0.0043), <protein-id="Q3ZBP4">RCAN1</protein-id> (<protein-id="Q3ZBP4">regulator of calcineurin 1</protein-id>) with rib-eye area (P=0.0103), <protein-id="Q08DV6">ASB3</protein-id> (ankyrin repeat <protein-id="Q08DV6">and SOCS box-containing 3</protein-id>) with backfat (P=0.0392), <protein-id="Q4TTZ1,F1MG24">ABCA1</protein-id> (<protein-id="Q4TTZ1,F1MG24">ATP-binding cassette A1</protein-id>) with both <compound-id="985">palmitic acid</compound-id> (C16:0) (P=0.0025) and <compound-id="445639">oleic acid</compound-id> (C18:<compound-id="11843159">1n9</compound-id>) (P=0.0114), SLC27A1(solute carrier family 27 A1) with <compound-id="445639">oleic acid</compound-id> (C18:<compound-id="11843159">1n9</compound-id>) (P=0.0155), <protein-id="Q95MI6">CRH</protein-id> (<protein-id="Q95MI6">corticotropin releasing hormone</protein-id>) with both <compound-id="5280934">linolenic acid</compound-id> (OMEGA-3) (P=0.0200) and OMEGA 6:3 RATIO (P=0.0054), <protein-id="F1MQP2">SLC27A2</protein-id> (<protein-id="F1MQP2">solute carrier family 27 A2</protein-id>) with both <compound-id="5280450">linoleic acid</compound-id> (OMEGA-6) (P=0.0121) and FAT (P=0.0333), <protein-id="P63214">GNG3</protein-id> (<compound-id="764">guanine</compound-id> nucleotide binding protein gamma 3 with desaturase 9 (P=0.0115), and <protein-id="A2VE41">EFEMP1</protein-id> (<protein-id="A2VE41">EGF containing fibulin-like extracellular matrix protein 1</protein-id>), PLTP (phospholipid transfer protein) and <protein-id="F1ME12">DSEL</protein-id> (<protein-id="F1ME12">dermatan sulfate epimerase-like</protein-id>) with conjugated <compound-id="5280450">linoleic acid</compound-id> (P=0.0042-0.0044), respectively, in the Wagyu x Angus F(1) population.	linoleic acid__DSEL__no_interaction	linoleic acid__and SOCS box-containing 3__no_interaction	linoleic acid__dermatan sulfate epimerase-like__no_interaction	linoleic acid__ASB3__no_interaction	linoleic acid__RCAN1__no_interaction	linoleic acid__solute carrier family 27 A2__no_interaction	linoleic acid__ATP-binding cassette A1__no_interaction	linoleic acid__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	linoleic acid__regulator of calcineurin 1__no_interaction	linoleic acid__EFEMP1__no_interaction	linoleic acid__GNG3__no_interaction	linoleic acid__ABCA1__no_interaction	linoleic acid__corticotropin releasing hormone__no_interaction	linoleic acid__CRH__no_interaction	linoleic acid__SLC27A2__no_interaction	oleic acid__DSEL__no_interaction	oleic acid__and SOCS box-containing 3__no_interaction	oleic acid__dermatan sulfate epimerase-like__no_interaction	oleic acid__ASB3__no_interaction	oleic acid__RCAN1__no_interaction	oleic acid__solute carrier family 27 A2__no_interaction	oleic acid__ATP-binding cassette A1__no_interaction	oleic acid__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	oleic acid__regulator of calcineurin 1__no_interaction	oleic acid__EFEMP1__no_interaction	oleic acid__GNG3__no_interaction	oleic acid__ABCA1__no_interaction	oleic acid__corticotropin releasing hormone__no_interaction	oleic acid__CRH__no_interaction	oleic acid__SLC27A2__no_interaction	1n9__DSEL__no_interaction	1n9__and SOCS box-containing 3__no_interaction	1n9__dermatan sulfate epimerase-like__no_interaction	1n9__ASB3__no_interaction	1n9__RCAN1__no_interaction	1n9__solute carrier family 27 A2__no_interaction	1n9__ATP-binding cassette A1__no_interaction	1n9__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	1n9__regulator of calcineurin 1__no_interaction	1n9__EFEMP1__no_interaction	1n9__GNG3__no_interaction	1n9__ABCA1__no_interaction	1n9__corticotropin releasing hormone__no_interaction	1n9__CRH__no_interaction	1n9__SLC27A2__no_interaction	guanine__DSEL__no_interaction	guanine__and SOCS box-containing 3__no_interaction	guanine__dermatan sulfate epimerase-like__no_interaction	guanine__ASB3__no_interaction	guanine__RCAN1__no_interaction	guanine__solute carrier family 27 A2__no_interaction	guanine__ATP-binding cassette A1__no_interaction	guanine__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	guanine__regulator of calcineurin 1__no_interaction	guanine__EFEMP1__no_interaction	guanine__GNG3__no_interaction	guanine__ABCA1__no_interaction	guanine__corticotropin releasing hormone__no_interaction	guanine__CRH__no_interaction	guanine__SLC27A2__no_interaction	linolenic acid__DSEL__no_interaction	linolenic acid__and SOCS box-containing 3__no_interaction	linolenic acid__dermatan sulfate epimerase-like__no_interaction	linolenic acid__ASB3__no_interaction	linolenic acid__RCAN1__no_interaction	linolenic acid__solute carrier family 27 A2__no_interaction	linolenic acid__ATP-binding cassette A1__no_interaction	linolenic acid__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	linolenic acid__regulator of calcineurin 1__no_interaction	linolenic acid__EFEMP1__no_interaction	linolenic acid__GNG3__no_interaction	linolenic acid__ABCA1__no_interaction	linolenic acid__corticotropin releasing hormone__no_interaction	linolenic acid__CRH__no_interaction	linolenic acid__SLC27A2__no_interaction	palmitic acid__DSEL__no_interaction	palmitic acid__and SOCS box-containing 3__no_interaction	palmitic acid__dermatan sulfate epimerase-like__no_interaction	palmitic acid__ASB3__no_interaction	palmitic acid__RCAN1__no_interaction	palmitic acid__solute carrier family 27 A2__no_interaction	palmitic acid__ATP-binding cassette A1__no_interaction	palmitic acid__EGF containing fibulin-like extracellular matrix protein 1__no_interaction	palmitic acid__regulator of calcineurin 1__no_interaction	palmitic acid__EFEMP1__no_interaction	palmitic acid__GNG3__no_interaction	palmitic acid__ABCA1__no_interaction	palmitic acid__corticotropin releasing hormone__no_interaction	palmitic acid__CRH__no_interaction	palmitic acid__SLC27A2__no_interaction
2066980-2	Nine of the following analogues were designed by replacement of each of the nine residues in ANTAG with an L-<compound-id="57175189">tryptophan</compound-id> residue: [Ac-<protein-id="Q9QX01,A0A0G2K7J3">Trp1</protein-id>,D-<protein-id="Q9R283">Trp2</protein-id>,Val6,Arg8]OT, [Pmp1,<protein-id="Q9R283">Trp2</protein-id>,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Trp3,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,<protein-id="Q91ZM1,Q91ZM0">Trp4</protein-id>,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Trp5,Arg8]OT, [Aaa1,D-<protein-id="Q9R283">Trp2</protein-id>,Trp6,Arg8]OT, [Aaa1,D-<protein-id="Q9R283">Trp2</protein-id>,Val6,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Ica7,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Trp7,Arg8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Trp8]OT, [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Arg8,Trp9]OT (11), [Pmp1,D-<protein-id="Q9R283">Trp2</protein-id>,Arg8,Trp(For)9]OT (12).	tryptophan__Trp2__no_interaction	tryptophan__Trp1__no_interaction	tryptophan__Trp4__no_interaction
2855220-5	Peak increase in plasma ACTH (<protein-id="P01178,X5D7M6">oxytocin</protein-id> 266 +/- 54 ng/l; saline 281 +/- 43 ng/l, mean +/- <compound-id="5289348">SEM</compound-id>) was at S + 10 min while peak plasma <compound-id="5754">cortisol</compound-id> (<protein-id="P01178,X5D7M6">oxytocin</protein-id> 680 +/- 47 nmol/l: saline 656 +/- 40 nmol/l) was measured at S +/- 60 min, peak GH (<protein-id="P01178,X5D7M6">oxytocin</protein-id> 96 +/- 17.8 mU/l; saline 106 +/- 18.6 mU/l) at S + 60 min and <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> (<protein-id="P01178,X5D7M6">oxytocin</protein-id> 1332 +/- 239 mU/l; saline 1242 +/- 273 mU/l) at S + 30 min.	SEM__oxytocin__no_interaction	SEM__prolactin__no_interaction	cortisol__oxytocin__no_interaction	cortisol__prolactin__no_interaction
15319345-0	In vitro metabolism of <compound-id="151183">MK-0767</compound-id> [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-<compound-id="14114096">2-methoxy</compound-id>-N-[[(4-<compound-id="6373">trifluoromethyl</compound-id>)-phenyl] methyl]<compound-id="2331">benzamide</compound-id>], a <protein-id="Q07869,F1D8S4">peroxisome proliferator-activated receptor alpha</protein-id>/gamma agonist. II. Identification of metabolites by liquid chromatography-tandem mass spectrometry.	2-methoxy__peroxisome proliferator-activated receptor alpha__no_interaction	trifluoromethyl__peroxisome proliferator-activated receptor alpha__no_interaction	MK-0767__peroxisome proliferator-activated receptor alpha__no_interaction	benzamide__peroxisome proliferator-activated receptor alpha__no_interaction
15319345-1	The in vitro metabolism of <compound-id="151183">MK-0767</compound-id> [(+/-)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-<compound-id="14114096">2-methoxy</compound-id>-N-[[(4-<compound-id="6373">trifluoromethyl</compound-id>)-phenyl] methyl]<compound-id="2331">benzamide</compound-id>], a novel 2,4-thiazolidinedione (<compound-id="124687">TZD</compound-id>)-containing <protein-id="Q07869,F1D8S4">peroxisome proliferator-activated receptor alpha</protein-id>/gamma agonist, was studied in rat, dog, monkey, and human liver microsomes and hepatocytes, as well as in recombinant human <protein-id="P08684,Q6GRK0">CYP3A4</protein-id>-containing microsomes.	2-methoxy__CYP3A4__no_interaction	2-methoxy__peroxisome proliferator-activated receptor alpha__no_interaction	trifluoromethyl__CYP3A4__no_interaction	trifluoromethyl__peroxisome proliferator-activated receptor alpha__no_interaction	MK-0767__CYP3A4__no_interaction	MK-0767__peroxisome proliferator-activated receptor alpha__no_interaction	benzamide__CYP3A4__no_interaction	benzamide__peroxisome proliferator-activated receptor alpha__no_interaction	TZD__CYP3A4__no_interaction	TZD__peroxisome proliferator-activated receptor alpha__no_interaction
21493287-8	Alterations specific to the polyp tissue included downregulated genes, <protein-id="P12273">prolactin-induced protein</protein-id> (fold change 377.2 ± 169.0, P &lt; .0001), and <compound-id="23994">zinc</compound-id> α2-glycoprotein (fold change 72.1 ± 26.5, P &lt; .0001), as well as upregulated genes, met proto-oncogene (fold change 2.5 ± 0.7, P = .029), and <protein-id="Q15063,A0A024RDS2,B1ALD9,A0A024RDT5">periostin</protein-id> (fold change 7.5 ± 3.4, P = .003).	zinc__periostin__no_interaction	zinc__prolactin-induced protein__no_interaction
19368529-5	We investigated the basis of oxime resistance of phosphoramidyl-<protein-id="P06276,D3DNN4">BChE</protein-id> conjugates by determining the kinetics of inhibition, reactivation (<compound-id="107688">obidoxime</compound-id> {1,1'-(oxybis-<compound-id="123164">methylene</compound-id>) bis[4-(hydroxyimino) methyl] <compound-id="1049">pyridinium dichloride</compound-id>}, TMB-4 [1,3-<compound-id="6351">trimethylene</compound-id>-bis(4-hydroxyiminomethylpyridinium) dibromide], HLö 7 {1-[[[4-(aminocarbonyl) pyridinio]methoxy]methyl]-2,4-bis-[(hydroxyimino)methyl] pyridinium dimethanesulfonate)}, HI-6 {1-[[[4-(aminocarbonyl) pyridinio] methoxy] methyl]-2-[(hydroxyimino)methyl]<compound-id="1049">pyridinium dichloride</compound-id> <compound-id="1488787">monohydrate</compound-id>} and aging, and the crystal structures of <protein-id="P06276,D3DNN4">hBChE</protein-id> inhibited by different N-monoalkyl and N,N-dialkyl <compound-id="6500">tabun</compound-id> analogues.	trimethylene__BChE__no_interaction	trimethylene__hBChE__no_interaction	monohydrate__BChE__no_interaction	monohydrate__hBChE__no_interaction	obidoxime__BChE__no_interaction	obidoxime__hBChE__no_interaction	pyridinium dichloride__BChE__no_interaction	pyridinium dichloride__hBChE__no_interaction	tabun__BChE__no_interaction	tabun__hBChE__no_interaction	methylene__BChE__no_interaction	methylene__hBChE__no_interaction
7499784-6	Hepatic venous <protein-id="P05305,Q6FH53">Endothelin-1</protein-id> was significantly correlated with the hepatic venous pressure gradient (r = 0.61, p &lt; 0.00004), serum <compound-id="588">creatinine</compound-id> (r = 0.35, p &lt; 0.03), diastolic blood pressure (r = -0.31, p &lt; 0.05), central and arterial blood volume (-0.36, p &lt; 0.05), central circulation time (r = -0.41, p &lt; 0.02), and serum <compound-id="5360545">sodium</compound-id> (r = -0.56, p &lt; 0.00002) in the patients with cirrhosis.	creatinine__Endothelin-1__no_interaction	sodium__Endothelin-1__no_interaction
12933668-8	MCH (1 micro M) increased the release of the orexigenic neurotransmitters neuropeptide Y (37.8 +/- 6.0 fmol/explant vs. basal 30.2 +/- 4.3 fmol/explant; P &lt; 0.05) and agouti-related peptide (4.1 +/- 0.6 fmol/explant vs. basal 2.4 +/- 0.2 fmol/explant; P &lt; 0.05) and decreased the release of the anorectic neurotransmitters <protein-id="Q8K422">alpha-MSH</protein-id> (41.7 +/- 6.8 fmol/explant vs. basal 65.9 +/- 11.0 fmol/explant; P &lt; 0.01) and <compound-id="446220">cocaine</compound-id>- and <compound-id="3007">amphetamine</compound-id>-regulated transcript (112.3 +/- 12.4 fmol/explant vs. basal 167.4 +/- 13.0 fmol/explant; P &lt; 0.001).	cocaine__alpha-MSH__no_interaction	amphetamine__alpha-MSH__no_interaction
8816035-11	GVSDS was correlated with serum <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> (r = 0.22, P &lt; 0.01), FT4 (r = 0.321, P &lt; 0.01) and inversely with basal GH (r = -0.362, P &lt; 0.01) concentrations, but was not correlated with <compound-id="5754">cortisol</compound-id> levels or peak GH concentrations in response to <compound-id="2803">clonidine</compound-id>.	clonidine__IGF-I__no_interaction	cortisol__IGF-I__no_interaction
3441302-1	Spinal serotonin1 (5-HT1)(labelled by [3H]<compound-id="5202">5-HT</compound-id>), <protein-id="P19327">5-HT1A</protein-id> (labelled by [3H]8-hydroxy-<compound-id="90285">2-(di-n-propylamino)tetralin</compound-id> ([3H]8-OH-DPAT)), mu- (labelled by [3H]<compound-id="6057">Tyr</compound-id>-<compound-id="6992371">D-Ala-Gly</compound-id>-(Me)Phe-Gly-ol ([3H]<compound-id="5462471">DAGO</compound-id>) and [3H]naloxone) and delta-opiate (labelled by [3H]<compound-id="6057">Tyr</compound-id>-D-<compound-id="7009644">Ser-Gly</compound-id>-Phe-Leu-Thr [( 3H]<compound-id="107847">DSTLE</compound-id>] receptor binding sites were studied in adult rats using quantitative autoradiography after either neonatal treatment with <compound-id="1548943">capsaicin</compound-id> or unilateral cervical dorsal rhizotomy.	DAGO__5-HT1A__no_interaction	capsaicin__5-HT1A__no_interaction	DSTLE__5-HT1A__no_interaction	5-HT__5-HT1A__no_interaction	D-Ala-Gly__5-HT1A__no_interaction	2-(di-n-propylamino)tetralin__5-HT1A__no_interaction	Ser-Gly__5-HT1A__no_interaction	Tyr__5-HT1A__no_interaction
11839533-3	" This hypothesized mechanism is supported by the following experimental data: 1) <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulates the de novo synthesis of surfactant phospholipid by both fetal rat type II cells (400% x 100 ng(-1) x ml(-1) x 24 h(-1)) and adult human airway epithelial cells (85% x 100 ng(-1) x 24 h(-1)); 2) <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> is secreted by lipofibroblasts in amounts that stimulate type II cell surfactant phospholipid synthesis in vitro; 3) epithelial cell secretions such as <protein-id="P12272,Q53XY9,A0A024RB29">parathyroid hormone-related protein</protein-id> (<protein-id="P13085">PTHrP</protein-id>), PGE(2), and <compound-id="5743">dexamethasone</compound-id> stimulate <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> expression by fetal rat lung fibroblasts; 4) <protein-id="P13085">PTHrP</protein-id> or <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulate the de novo synthesis of surfactant phospholipid (2- to 2.5-fold/24 h) and the expression of <protein-id="P22355">surfactant protein B</protein-id> (<protein-id="P22355">SP-B</protein-id>; &gt;25-fold/24 h) by fetal rat lung explants, an effect that is blocked by a <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> antibody; and 5) a <protein-id="P13085">PTHrP</protein-id> receptor antagonist inhibits the expression of <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> mRNA by explants but does not inhibit <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulation of surfactant phospholipid or <protein-id="P22355">SP-B</protein-id> expression, indicating that <protein-id="P13085">PTHrP</protein-id> paracrine stimulation of type II cell maturation requires <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> expression by lipofibroblasts.	dexamethasone__SP-B__no_interaction	dexamethasone__Leptin__no_interaction	dexamethasone__surfactant protein B__no_interaction	dexamethasone__parathyroid hormone-related protein__no_interaction	dexamethasone__PTHrP__no_interaction
8606641-6	In NS, <compound-id="444913">ACX</compound-id> failed to significantly potentiate the GH response to either <protein-id="P01286">GHRH</protein-id> (1,371.9 +/- 425.2 v 1,001.8 +/- 229.0 micrograms/L x min) or <protein-id="P01286">GHRH</protein-id>+ARG (3558.4 +/- 1,513.7 v 3,045.9 +/- 441.8 micrograms/L x min), while in OB patients it increased the GH response to <protein-id="P01286">GHRH</protein-id> (797.6 +/- 277.3 v 353.8 +/- 136.7 micrograms/L x min, P&lt;.01) and did not modify the response to ARG+<protein-id="P01286">GHRH</protein-id> (1,010.5 +/- 253.1 v 821.1 +/- 222.0 micrograms/L x min).	ACX__GHRH__no_interaction
15651855-1	The reaction of (<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))<compound-id="5460531">AuCl</compound-id> with the low valent <compound-id="5360835">gallium</compound-id> compound Ga(<protein-id="O60220">DDP</protein-id>) (<protein-id="O60220">DDP</protein-id> = 2-((2,6-<compound-id="11345">diisopropylphenyl</compound-id>)amino-4-((2,6-diiso-<compound-id="7668">propylphenyl</compound-id>)imino)-<compound-id="5326160,5326161">2-pentene</compound-id>) yields the insertion products [{Ga(<protein-id="O60220">DDP</protein-id>)}Au{Ga(<protein-id="O60220">DDP</protein-id>)Cl}] (1) and [(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))Au{Ga(<protein-id="O60220">DDP</protein-id>)Cl}] (2), the first examples of molecular compounds with Au-Ga bonds.	propylphenyl__DDP__no_interaction	propylphenyl__PPh(3__no_interaction	AuCl__DDP__no_interaction	AuCl__PPh(3__no_interaction	gallium__DDP__no_interaction	gallium__PPh(3__no_interaction	diisopropylphenyl__DDP__no_interaction	diisopropylphenyl__PPh(3__no_interaction	2-pentene__DDP__no_interaction	2-pentene__PPh(3__no_interaction
10193650-3	Furthermore, the anxiolytic-like effect was antagonized by co-administration of the potent <protein-id="P07808,F2W8A6">neuropeptide Y</protein-id> Y1 receptor antagonist ((R)-N-[[4-(<compound-id="90777035">aminocarbonylaminomethyl</compound-id>)-phenyl]methyl]-N2-(diphen ylacetyl)-<compound-id="2234">argininamide</compound-id> <compound-id="6422">trifluoroacetate</compound-id>) 3304, but not with the inactive enantiomer ((R)-N-[[4-(<compound-id="90777035">aminocarbonylaminomethyl</compound-id>)-phenyl]methyl]-N2-(diphen ylacetyl)-<compound-id="2234">argininamide</compound-id> <compound-id="6422">trifluoroacetate</compound-id>) 3457.	aminocarbonylaminomethyl__neuropeptide Y__no_interaction	argininamide__neuropeptide Y__no_interaction	trifluoroacetate__neuropeptide Y__no_interaction
24513870-2	Here we describe the activity of a novel, inhaled, bifunctional, small molecule (R)-6-[(3-{[4-(5-{[<compound-id="97257">2-hydroxy-</compound-id>2-(8-hydroxy-2-oxo-1,2-<compound-id="5231402">dihydroquinolin</compound-id>-5-yl)<compound-id="23134249">ethyl</compound-id>]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-<compound-id="11910">8-methylquinoline</compound-id>-3-<compound-id="11960529">carboxamide</compound-id> (GS-5759), which has specific β(2) agonist and <protein-id="P27815">PDE4</protein-id> inhibitory activity.	2-hydroxy-__PDE4__no_interaction	carboxamide__PDE4__no_interaction	ethyl__PDE4__no_interaction	8-methylquinoline__PDE4__no_interaction	dihydroquinolin__PDE4__no_interaction
19192257-6	Other comparisons (mean +/- SD) between cryoprecipitate and FFP, respectively, were as follows: coagulation <protein-id="P00451">FVIII</protein-id> activity, 133 +/- 37 and 265 +/- 83 U per bag; <protein-id="P02675,V9HVY1">fibrinogen</protein-id> content (Clauss kinetic assay), 183 +/- 44 and 725 +/- 199 mg per bag; <protein-id="P04275">VWF</protein-id> antigen content, 181 +/- 53 and 218 +/- 70 U per bag; <protein-id="P04275">VWF</protein-id> ristocetin <compound-id="108194">cofactor</compound-id> activity, 168 +/- 34 and 221 +/- 65 U per bag; <protein-id="P04275">VWF</protein-id> collagen-binding activity, 164 +/- 40 and 208 +/- 71 U per bag; and fluid (plasma) volumes per bag, 21.3 +/- 2.7 and 245 +/- 29 mL.	cofactor__VWF__no_interaction	cofactor__fibrinogen__no_interaction	cofactor__FVIII__no_interaction
10912908-4	In the in vitro biological assays a remarkable agonist activity to the opiate receptor mu in guinea pig ileum (GPI) relative to Leu-<protein-id="P22005">ENK</protein-id> was shown by the following: Leu-<protein-id="P22005">ENK</protein-id>, 100; [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (I), 8.1; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (VI), 26.2; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (VII), 2.9; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (VIII), 4.7; and [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (X), 5.6.	CH2OH__ENK__no_interaction	NOH__ENK__no_interaction	Tyr__ENK__no_interaction
10912908-8	The analogues: [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (I), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2H)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (II), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (III), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2H)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (IV), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CONH2)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (V), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (VI), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (VII), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (VIII), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=NOMe)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (IX), [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (X), [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (XI) and [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (XII) under testing had no significant agonist activity to the enkephalinergic receptor in mouse <compound-id="6323535">vas</compound-id> deferens (MVD).	CH2OH__ENK__no_interaction	NOH__ENK__no_interaction	Tyr__ENK__no_interaction	vas__ENK__no_interaction
11555526-15	The mean (+/- SD) variables that were significantly different between desaturators (10 patients) and nondesaturators (3 patients) were FEV(1) (70.1 +/- 9.1% predicted vs 98.1 +/- 15.1% predicted, respectively; p = 0.002), resting PaO(2) (61.8 +/- 16.1 vs 90.3 +/- 2.3 mm Hg, respectively; p = 0.001), alveolar-arterial <compound-id="977">oxygen</compound-id> pressure difference (P[A-a]O(2)) (40.5 +/- 20.5 vs 12.2 +/- 7.2 mm Hg, respectively; p = 0.048), resting <protein-id="P22079">SpO</protein-id>(2) (91.6 +/- 5.4% vs 98.7 +/- 2.3%, respectively; p = 0.038), and walking <protein-id="P22079">SpO</protein-id>(2) (83.8 +/- 9.3% vs 95.3 +/- 1.2%, respectively; p = 0.002).	oxygen__SpO__no_interaction
16676966-2	Treatment of 1a with <compound-id="82050">LiBr</compound-id>/1,4-<compound-id="9261">pyrazine</compound-id> (1,4-pyz), pyridine (py), <compound-id="433294">LiCl</compound-id>/py, or <compound-id="11107">4,4'-bipyridine</compound-id> (4,4'-<compound-id="1474">bipy</compound-id>) and treatment of 1b with 4,4'-<compound-id="1474">bipy</compound-id> gave rise to a new set of W/Cu/S cluster-based compounds, [Li[((eta5-C5Me5)WS3Cu3(mu3-Br))2(mu-CN)3].C6H6]infinity (2), [(eta5-C5Me5)WS3Cu3(mu-CN)2(py)]infinity (3), [[<protein-id="O14649">PPh4</protein-id>][(eta5-C5Me5)WS3Cu3(mu3-Cl)(mu-CN)(CN)].py]infinity (4), [<protein-id="O14649">PPh4</protein-id>]2[(eta5-C5Me5)WS3Cu3(CN)2]2(mu-CN)2.	4,4'-bipyridine__PPh4__no_interaction	LiBr__PPh4__no_interaction	bipy__PPh4__no_interaction	LiCl__PPh4__no_interaction	pyrazine__PPh4__no_interaction
24900171-2	We report here the discovery of the first potent and selective inhibitor of <protein-id="Q02224">Centromere-Associated Protein E</protein-id> (<protein-id="Q02224">CENP-E</protein-id>) <compound-id="97584">3-chloro-</compound-id>N-{(1S)-2-[(N,N-<compound-id="10197622">dimethylglycyl</compound-id>)amino]-1-[(4-{<compound-id="91272666">8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl</compound-id>}phenyl)methyl]<compound-id="23134249">ethyl</compound-id>}-4-[(1-<compound-id="275736">methylethyl</compound-id>)oxy]<compound-id="2331">benzamide</compound-id> (<compound-id="46898058">GSK923295</compound-id>; 1), starting from a high-throughput screening hit, <compound-id="22597728">3-chloro-4-isopropoxybenzoic acid</compound-id> 2.	GSK923295__CENP-E__no_interaction	GSK923295__Centromere-Associated Protein E__no_interaction	dimethylglycyl__CENP-E__no_interaction	dimethylglycyl__Centromere-Associated Protein E__no_interaction	methylethyl__CENP-E__no_interaction	methylethyl__Centromere-Associated Protein E__no_interaction	8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl__CENP-E__no_interaction	8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl__Centromere-Associated Protein E__no_interaction	3-chloro-__CENP-E__no_interaction	3-chloro-__Centromere-Associated Protein E__no_interaction	benzamide__CENP-E__no_interaction	benzamide__Centromere-Associated Protein E__no_interaction	3-chloro-4-isopropoxybenzoic acid__CENP-E__no_interaction	3-chloro-4-isopropoxybenzoic acid__Centromere-Associated Protein E__no_interaction	ethyl__CENP-E__no_interaction	ethyl__Centromere-Associated Protein E__no_interaction
11867949-12	In rHuEPO-treated CAPD subjects <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and <protein-id="P08833">IGFBP-1</protein-id> correlated positively with serum CrossLaps (r = 0.61, p &lt; 0.05 and r = 0.64, p &lt; 0.05, respectively), whereas in hemodialyzed patients without rHuEPO a significant negative correlation between <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> and serum CrossLaps was found (r = --0.69, p &lt; 0.001) as well as between <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> and <compound-id="5359268">aluminium</compound-id> (r = 0.51, p &lt; 0.05), <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and ICTP (r = --0.43, p &lt; 0.05).	aluminium__IGFBP-3__no_interaction	aluminium__IGF-1__no_interaction	aluminium__IGFBP-1__no_interaction
14689705-9	The stepwise regression analysis discovered correlation between plasmic ASUP and end-diastolic volume of the left ventricle (r = 0.62; p = 0.01), dopplerographic index (r = 0.52; p = 0.001), left ventricular ejection fraction (r = -0.66; p = 0.002), velocity of early diastolic filling (r = -0.84; p = 0.001), plasmic pool of norepinephrine (r = 0.66; p = 0.001), endotheline-1 (r = 0.70; p = 0.03) and <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin-II</protein-id> (r = 0.55; p = 0.02), daily dose of <compound-id="3440">furosemide</compound-id> (r = 0.80; p = 0.001), heart rate (r = 0.64; p = 0.02).	furosemide__angiotensin-II__no_interaction
9181456-3	The main observations were as follows: (a) The mean encapsulation efficiency, as determined by bioassays, was 49-79%, depending on the formulation, for <protein-id="P01587,Q5SX78">GM-CSF</protein-id>, and 48% for <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>; (b) some of the entrapped cytokine preparations displayed high stability at 4 degrees C, with &lt; 30% loss of biologic activity during a 4-month period; (c) release of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>, but not of <protein-id="P01587,Q5SX78">GM-CSF</protein-id>, from the liposomes was required for their biological activity in vitro; (d) plasma half-lives (t1/2 alpha, t1/2 beta) and the area under the curve (AUC) of the entrapped cytokines were 10-20 times greater than those of the soluble cytokines; (e) the toxicity of liposomal <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> was one-third and one-seventh that of soluble <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> in normal and tumor-bearing mice, respectively; (f) administration of liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> (5 x 10(4)-2 x 10(5) U, one to five times) to normal and <compound-id="3385">5-fluorouracil</compound-id>-treated mice led to a two- to fourfold increase in the absolute number of peritoneal and spleen leukocytes and of GM colony-forming cells in the spleen, as compared with the levels obtained using soluble <protein-id="P01587,Q5SX78">GM-CSF</protein-id>; and (g) under the experimental conditions used, neither free nor liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> significantly increased the absolute number of blood leukocytes, although liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> markedly (threefold) enhanced the level of blood granulocytes.	5-fluorouracil__TNF-alpha__no_interaction	5-fluorouracil__GM-CSF__no_interaction
14632755-4	Regardless of the total lymphocyte count the <compound-id="67184">NBS</compound-id> patients showed: (1) profound deficiency of CD4+ and CD3/CD8+ T cell subsets and up to fourfold increase in natural killer (NK) cells, almost lack of naive CD4+ T cells expressing CD45RA isoform, unchanged percentage of naive CD8+ cell subset (CD8/CD45RA+) but bearing the CD8 receptor of low density (CD8low); (2) normal expression of CD45RA isoform in the <protein-id="P13591,A0A087WWD4">CD56</protein-id>+ lymphocyte subset, profound decrease in alpha beta but up to threefold increase in gamma delta-T cell-receptor (TCR)-positive T cells; (3) shift towards the memory phenotype in both CD4+ and CD8+ lymphocyte subpopulations expressing CD45RO isoform (over-expression of CD45RO in terms of both the fluorescence intensity for CD45RO isoform and the number of positive cells); and (4) an increase in fluorescence intensity for the CD45RA isoform in NK cells population.	NBS__CD56__no_interaction
23598081-2	To explain the role of <compound-id="5951">Ser</compound-id>(1) and Pro(4) residues of <protein-id="Q9VIP4">Neb</protein-id>-colloostatin in the pro-apoptotic activity of this peptide, the synthesis of a series of analogs was performed, such as: [Ac-<compound-id="5951">Ser</compound-id>(1)]- (1), [d-<compound-id="5951">Ser</compound-id>(1)]- (2), [Thr(1)]- (3), [Asp(1)]- (4), [Glu(1)]- (5), [Gln(1)]- (6), [Ala(1)]- (7), [Val(1)]- (8), [<compound-id="8988">d-Pro</compound-id>(4)]-(9), [Hyp(4)]- (10), [Acp(4)]- (11), [<compound-id="187">Ach</compound-id>(4)]- (12), [Ala(4)]- (13), [Ile(4)]- (14), and [Val(4)]-colloostatin (15).	d-Pro__Neb__no_interaction	Ser__Neb__no_interaction	Ach__Neb__no_interaction
15975960-5	Number/cm(2) liver section, mean area (mm(2)) and percent liver section area occupied by total (persistent + remodeling) placental <compound-id="124886,20725278,745">glutathione</compound-id> S-transferase (<protein-id="P04906,B6DYQ7">GST-P</protein-id>) positive PNL was reduced (P &lt; 0.05) in AtRA (107 +/- 13; 0.12 +/- 0.06; 13.9 +/- 3.9), 9cRA (71 +/- 12; 0.12 +/- 0.06; 6.8 +/- 2.2), ROL (96 +/- 13; 0.11 +/- 0.22; 6.8 +/- 2.0) and betaC (106 +/- 13; 0.08 +/- 0.03; 10.8 +/- 2.5) groups compared with CO group (166 +/- 14; 0.18 +/- 0.09; 28.6 +/- 5.2).	glutathione__GST-P__no_interaction
23579233-1	DFT calculations of the mononuclear Fe(II) <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover complexes [Fe(L)](2+) (L = ({bis[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7852">3-aminopropyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine})), ({[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7852">3-aminopropyl</compound-id>][N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="57481262">2-aminoethyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine}) and ({bis[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="57481262">2-aminoethyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine}) abbreviated as (66), (56) and (55) have been performed in order to explain the observed <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> transition temperature differences.	2-aminoethyl__spin__no_interaction	2-pyridylmethyl__spin__no_interaction	3-aminopropyl__spin__no_interaction
7923820-15	There was a significantly (P = 0.0014) greater increment of GH secretion after <compound-id="4991">pyridostigmine</compound-id> and <protein-id="P01286">GHRH</protein-id> analogue compared with <protein-id="P01286">GHRH</protein-id> analogue alone (difference in AUC of <compound-id="4991">pyridostigmine</compound-id>+<protein-id="P01286">GHRH</protein-id> analogue and <protein-id="P01286">GHRH</protein-id> analogue alone 6348 (696-12856) mU/l controls vs 542 (120-1340) mU/l in the irradiated group) and significantly (P = 0.033) greater suppression of GH secretion after <compound-id="4848">pirenzepine</compound-id> and <protein-id="P01286">GHRH</protein-id> analogue compared with <protein-id="P01286">GHRH</protein-id> analogue alone (difference in AUC of <protein-id="P01286">GHRH</protein-id> analogue alone and <compound-id="4848">pirenzepine</compound-id>+<protein-id="P01286">GHRH</protein-id> analogue 1644 (222-15205) mU/l in controls vs 479 (469-1623) mU/l in the irradiated group) in the control population compared with those who had received cranial irradiation in childhood.	pirenzepine__GHRH__no_interaction	pyridostigmine__GHRH__no_interaction
20142002-12	Vessel-wall <protein-id="Q5BKB0">IL-1 beta</protein-id> was reduced only in the <compound-id="54671203">DOXY</compound-id> group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, <compound-id="54671203">DOXY</compound-id> = 6 +/- 3 pg/mg protein, n = 4-6, p &lt; 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, <compound-id="54671203">DOXY</compound-id> = 0.8 +/- 0.20, n = 4-6, p &lt; 0.05).	DOXY__IL-1 beta__no_interaction
8127099-2	The mean maximum constrictor responses, expressed as percentage of maximum <compound-id="5462222">potassium</compound-id> depolarization, were as follows: <compound-id="114873">thromboxane</compound-id> analog <compound-id="5311493">U46619</compound-id>: native vein 147.0% +/- 10.5%, distended vein 251.2% +/- 29.1%, short-term graft 174.6% +/- 33.8%, long-term graft 220.9% +/- 21.7%; 5-hydroxytryptamine: native vein 115.6% +/- 6.1%, distended vein 129.9% +/- 13.3%, short-term graft 80.0% +/- 15.0%, long-term graft 95.1% +/- 12.1%; <protein-id="P05305,Q6FH53">endothelin-1</protein-id>: native vein 126.5% +/- 22.1%, distended vein 138.1% +/- 24.7%, short-term graft 120.7% +/- 43.3%, long-term graft 171.4% +/- 26.0%; <compound-id="3907,44563898,5280493,5283121">leukotriene C4</compound-id>: native vein 49.9% +/- 8.7%, distended vein 78.9% +/- 11.8%, short-term graft 90.8% +/- 39.1%, long-term graft 7.4% +/- 5.0%; and norepinephrine: native vein 127.0% +/- 9.3%, distended vein 155.0% +/- 17.8%, short-term graft 61.6% +/- 11.3%, long-term graft 80.1% +/- 7.7%.	potassium__endothelin-1__no_interaction	leukotriene C4__endothelin-1__no_interaction	thromboxane__endothelin-1__no_interaction	U46619__endothelin-1__no_interaction
21950243-3	All remaining compounds adopt the hexagonal ScAl(3)C(3)-type structure (Pearson symbol <protein-id="O95059">hP14</protein-id>, space group P6(3)/mmc, Z = 2; a = 4.1772(7)-4.1501(2) Å, c = 20.477(3)-20.357(1) Å for REZn(3)As(3) (RE = Ce, Pr, Nd, Sm); a = 4.4190(3)-4.3923(2) Å, c = 21.4407(13)-21.3004(8) Å for RECd(3)As(3) (RE = La-Pr)) in which [M(3)As(3)](3-) layers (M = Zn, Cd), formed by a triple stacking of nets of close-packed As atoms with M atoms occupying <compound-id="57180004">tetrahedral</compound-id> and trigonal planar sites, are separated by La(3+) cations.	tetrahedral__hP14__no_interaction
19545664-5	RESULTS: Compared with control livers, <protein-id="P01256,P01257,A0A0G2JSX2">CGRP</protein-id>-treated organs showed significantly decreased <compound-id="5950,602">alanine</compound-id> aminotransferase (ALT) and <compound-id="53776235">glutamate-lactate</compound-id> dehydrogenase (GLDH) leakage and portal venous pressure (2.0 +/- 0.3 vs 4.0 +/- 0.4 mmHg; P &lt; .01), with significantly increased bile production (8.56 +/- 0.76 vs 3.34 +/- 0.68 microL/g/45 min; P &lt; .01), <compound-id="977">oxygen</compound-id> consumption (5.14 +/- 0.4 vs 2.57 +/- 0.2 microL/g/min; P &lt; .01), and total <compound-id="190,57060554">adenine</compound-id> nucleotides (TAN) (11.1 +/- 0.71 vs 7.02 +/- 0.53 micromol/g; P &lt; .01) upon reperfusion as signs of recovered viability.	glutamate-lactate__CGRP__no_interaction	alanine__CGRP__no_interaction	oxygen__CGRP__no_interaction	adenine__CGRP__no_interaction
23268605-2	Analogous treatment of 2 and 3 with 1 equiv of pyridine, <compound-id="76009">2,6-dimethylphenylisocyanide</compound-id>, <compound-id="23577">tert-butylisocyanide</compound-id>, or <compound-id="11776">triphenylphosphane</compound-id> gives the ionic compounds [(L)M{(μ(3)-NH)(3)Ti(3)(η(5)-C(5)Me(5))(3)(μ(3)-N)}][O(3)SCF(3)] (L = py, M = Cu (6), Ag (7); L = CNAr, M = Cu (8), Ag (9); L = CNtBu, M = Cu (10), Ag (11); L = <protein-id="P60510,A0A024R625">PPh(3</protein-id>), M = Cu (12), Ag (13)).	2,6-dimethylphenylisocyanide__PPh(3__no_interaction	tert-butylisocyanide__PPh(3__no_interaction	triphenylphosphane__PPh(3__no_interaction
3499193-3	The results demonstrate that 1) increased release of <protein-id="P01587,Q5SX78">granulocyte-macrophage colony stimulating factor</protein-id> (<protein-id="P04141">GM-CSF</protein-id>) in vitro from pokeweed mitogen stimulated mouse spleen cells and from human mononuclear blood cells occurred at lowered O2 tension, and that human mononuclear blood leukocytes were more sensitive to the LF-induced suppression of <protein-id="P04141">GM-CSF</protein-id> release when cells were cultured at 5%, compared to 20%, O2 tension; 2) LF administered intravenously (IV) to mice pretreated with sublethal intraperitoneal dosages of <compound-id="2907,9554281">Cytoxan</compound-id> decreased the cycling status of marrow and spleen granulocyte-macrophage (<compound-id="77620543">CFU</compound-id>-GM), erythroid (BFU-E-2 and BFU-E-1) and multipotential (<compound-id="77620543">CFU</compound-id>-GEMM) progenitor cells and the absolute numbers of these progenitors; these effects were most noticeable if care was taken to deplete endotoxin from the LF samples prior to testing LF in vivo and if the control medium was endotoxin free; 3) endotoxin-depleted LF decreased the cycling status of marrow and spleen <compound-id="77620543">CFU</compound-id>-GM, BFU-E, and <compound-id="77620543">CFU</compound-id>-GEMM and the numbers of these progenitors in the marrows of mice previously untreated with <compound-id="2907,9554281">Cytoxan</compound-id>; these effects were most apparent when assessment of progenitor cells and their cycling rates were evaluated in vitro at lowered (5%) O2 tension; 4) purified natural human <protein-id="P09603,A0A024R0A1">CSF-1</protein-id> increased the absolute numbers of marrow <compound-id="77620543">CFU</compound-id>-GM and the cycling status of marrow <compound-id="77620543">CFU</compound-id>-GM and <compound-id="77620543">CFU</compound-id>-GEMM in mice pretreated with LF; and 5) purified recombinant murine <protein-id="P01586,Q5SX77">IL-3</protein-id> stimulated proliferation of day 8 and day 12 <compound-id="77620543">CFU</compound-id>-S (colony forming unit-spleen) in mice not previously treated with <compound-id="2907,9554281">Cytoxan</compound-id>.	CFU__CSF-1__no_interaction	CFU__granulocyte-macrophage colony stimulating factor__no_interaction	CFU__GM-CSF__no_interaction	CFU__IL-3__no_interaction	Cytoxan__CSF-1__no_interaction	Cytoxan__granulocyte-macrophage colony stimulating factor__no_interaction	Cytoxan__GM-CSF__no_interaction	Cytoxan__IL-3__no_interaction
3585175-7	During these tests, the expected <compound-id="24759880,753">glycerol</compound-id> appearance rates were successively 5.03 +/- 0.33, 7.48 +/- 0.39, 9.94 +/- 0.34, 7.48 +/- 0.39, and 5.03 +/- 0.33 mumol +/- kg-1 X <protein-id="P13987,Q6FHM9">min-1</protein-id>, whereas the corresponding isotopically determined appearance rates were 4.62 +/- 0.45, 6.95 +/- 0.56, 10.85 +/- 0.51, 7.35 +/- 0.34, and 5.28 +/- 0.12 mumol <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>.	glycerol__X kg-1 X min-1__no_interaction	glycerol__min-1__no_interaction
2848453-3	In contrast, there were several ligand-dependent differences in the mouse <protein-id="P30561,Q3U5D9">Ah receptor</protein-id> complexes formed after incubation in low salt buffer and these include: <compound-id="5988">sucrose</compound-id> density gradient analysis of the 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex gave a 9.5 S specifically bound peak and a 2.6 S nonspecifically bound peak whereas the corresponding 2,3,7,8-[3H]TCDD receptor complex gave a single 9.6 S specifically bound peak; <compound-id="5988">sucrose</compound-id> density gradient analysis of the two major peaks eluted from a Sephacryl S-300 column chromatographic separation of the 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex gave two specifically bound peaks at 9.2 and 5.1 S. The molecular properties of the rat hepatic cytosolic receptor complexes incubated in high salt (0.4 M KCl) buffer were ligand independent with one exception, namely the significant difference in the sedimentation coefficient of the specifically bound disaggregated 2,3,7,8-[3H]TCDD receptor complex (6.8 S) and the corresponding 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex (5.0 S).	TCDF__Ah receptor__no_interaction	sucrose__Ah receptor__no_interaction
22088246-6	RESULTS: Compared to control group, patients with SCF were younger [(57.8 +/- 10.7) years vs. (59.8 +/- 8.2) years], rate of smokers (59.3% vs. 46.4%) and diabetes mellitus (49.3% vs. 30.7%), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (FBG) level [(7.8 +/- 2.8) mmol/L vs. (6.2 +/- 2.0) mmol/L, P &lt; 0.05] and triglyceride (TG) level [(2.11 +/- 1.93) mmol/L vs. (1.67 +/- 1.01) mmol/L, P &lt; 0.05] were higher, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) level [(1.05 +/- 0.35) mmol/L vs. (1.42 +/- 0.74) mmol/L, P &lt; 0.01] and <protein-id="P02647,A0A024R3E3">apolipoprotein A1</protein-id> (<protein-id="P02647,A0A024R3E3">apoA1</protein-id>) level [(1.10 +/- 0.19) mmol/L vs. (1.31 +/- 0.31) mmol/L, P &lt; 0.01] were lower.	cholesterol__apolipoprotein A1__no_interaction	cholesterol__apoA1__no_interaction	glucose__apolipoprotein A1__no_interaction	glucose__apoA1__no_interaction
15130378-9	RESULTS: (1) The levels of serum LH (15.8 +/- 2.8) U/L, LH/FSH 2.8 +/- 0.6, T (4.3 +/- 0.9) nmol/L, FIN (25.2 +/- 3.8) mU/L and HOMA IR (1.56 +/- 0.25) in group A were significantly higher than those of group B (13.9 +/- 1.9) U/L, 2.3 +/- 0.4, (3.6 +/- 0.4) nmol/L, (13.4 +/- 3.8) mU/L, 0.87 +/- 0.28 and control group (7.3 +/- 2.1) U/L, 1.3 +/- 0.3, (0.9 +/- 0.2) nmol/L, (9.5 +/- 2.6) mU/L, 0.50 +/- 0.30 (all P &lt; 0.05); (2) The protein expression and <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="P35568,A0A024R499">IRS-1</protein-id> in group A (690 +/- 19 and 528 +/- 72 respectively) were significantly lower than those in group B (892 +/- 31, 801 +/- 64) and control group (988 +/- 29, 1139 +/- 124) (P &lt; 0.05, and P &lt; 0.01 respectively).	tyrosine__IRS-1__no_interaction
10792332-7	RESULTS: PHP patients had higher concentrations of <protein-id="P02763">ORM</protein-id> (0.80 +/- 0.25, vs. 0.61 +/- 0.20 g/l; P = 0.05), FBG (3.22 +/- 0.48, vs. 2.57 +/- 0.47 g/l; P = 0.001), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> Ag (97.12 +/- 33.23, vs. 44.11 +/- 21.40 microgram/l; P = 0.001), sE-<compound-id="4929">selectin</compound-id> (72.42 +/- 28.35, vs. 42.	selectin__ORM__no_interaction	selectin__PAI-1__no_interaction
10792332-9	After 12-month rhGH replacement the patients showed an increase of TRF (2.64 +/- 0.84 g/l, P = 0.037) and decrease of soluble adhesion molecules (sE-<compound-id="4929">selectin</compound-id> 57.98 +/- 27.04 microgram/l, P = 0.01, sP-<compound-id="4929">selectin</compound-id> 121.74 +/- 50.42 microgram/l, P = 0.007; and sICAM-1 279.95 +/- 88.32 microgram/l, P = 0.005), which then, similarly to the <protein-id="P02763">ORM</protein-id> (0.	selectin__ORM__no_interaction
22535877-6	Twenty genes were downregulated (↓) and two upregulated (↑), including angiogenic growth factors/receptors (↓placental growth factor), adhesion molecules (↓angiopoietin-like-3; ↓collagen-18A1; ↓endoglin), proteases/matrix proteins/inhibitors (↓<compound-id="188982,448397">alanyl</compound-id> aminopeptidase; ↓collagen-4A3; ↓heparanase; ↓plasminogen, ↑plasminogen activator urokinase; ↓platelet factor-4; ↓plexin domain containing-1; ↓tissue inhibitor of metalloproteinases-3), transcription/signaling molecules (↓heart and neural crest derivatives-2; ↓DNA-binding protein inhibitor; ↓NOTCH-4; ↓ribosomal protein-L13a1; ↓<protein-id="P05386,A0A024R608">ribosomal protein large-P1</protein-id>), cytokines/chemokines (↓interleukin-1B), and miscellaneous growth factors (↓<compound-id="90470904">leptin</compound-id>; ↓platelet-derived growth factor-α); ↓transforming growth factor (TGF-α; ↑TGF-β receptor-1).	leptin__ribosomal protein large-P1__no_interaction	alanyl__ribosomal protein large-P1__no_interaction
15788127-5	RESULTS: The content of <protein-id="P49913,J3KNB4">cAMP</protein-id>, <compound-id="5359597">superoxide</compound-id> dismutase (SOD), Zn and Cu in gastric mucosa, and the content of Zn and Cu in mitochondria decreased progressively in order of groups: healthy control (HC), spleen Qi deficiency without organic lesion (F-<compound-id="448048">SQD</compound-id>), spleen Yang deficiency without organic lesion (F-SyangD), disease without symptoms group, spleen Qi deficiency with organic lesion (G-<compound-id="448048">SQD</compound-id>), spleen Yang deficiency with organic lesion (G-SyangD), spleen Yin deficiency (SyinD) and spleen deficiency with Qi stagnation (SDQS), chronic spleen deficiency gastritis (<compound-id="15216946">CSG</compound-id>) and chronic atrophic gastritis (CAG); decreased in order of HC, intestinal metaplasia (IM)Ia, IMIb, IMIIa and IMIIb, P &lt; 0.05.	CSG__cAMP__no_interaction	superoxide__cAMP__no_interaction	SQD__cAMP__no_interaction
20193771-6	However, strains JGS1714 (enterotoxigenic genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), human food poisoning), JGS1936 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), bovine neonatal enteritis), JGS4142 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), bovine jejunal hemorrhage syndrome), JGS1473 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), chicken normal flora), JGS1070 (genotype C, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), porcine hemorrhagic enteritis), JGS1882 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), porcine neonatal enteritis), JGS1120 (ATCC 13124, genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), gas gangrene), JGS4151 (strain 13, genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), canine), and JGS4303 (SM101, enterotoxigenic genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), human food poisoning) failed to produce disease.	neg__cpb2__no_interaction
17175269-9	Expression of <protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">osteopontin</protein-id> (22.5 +/- 2.6-fold <compound-id="8987">DCD</compound-id> vs 7.7 +/- 1.7 LD; P &lt; .001), chemokines (CCL4 4.4 +/- 0.7 vs 2.5 +/- 0.3; P &lt; .01), (CCL2 6.0 +/- 1.3 vs 2.8 +/- 0.5), <protein-id="P09341">CXCL1</protein-id> (9.5 +/- 0.4 vs 2.0 +/- 0.2), and <protein-id="P19875,A0A024RDD9">CXCL2</protein-id> (16.7 +/- 5.3 vs 4.8 +/- 1.3; P &lt; .05), adhesion molecule (ICAM-1 4.7 +/- 0.7 vs 2.5 +/- 0.4; P &lt; .05), and heat shock proteins (HSPA1L 6.7 +/- 0.7 vs 1.6 +/- 0.3, <protein-id="P0DMV8,P0DMV9,A8K5I0,B3KTT5">HSPA1A</protein-id> 17.7 +/- 2.6 vs 2.4 +/- 0.5, <protein-id="P0DMV8,P0DMV9,A8K5I0">HSPA1B</protein-id> 13.3 +/- 0.2 vs 3.0 +/- 0.7, <protein-id="P11021,V9HWB4">HSPA5</protein-id> 6.7 +/- 0.8 vs 3.2 +/- 0.3, <protein-id="P04792,V9HW43">HSPB1</protein-id> 2.9 +/- 0.2 vs 1.0 +/- 0.1, and <protein-id="Q92598,A0A024RDQ0,A0A024RDS1,B4DY72,A0A0A0MSM0">HSPH1</protein-id> 19.4 +/- 3.0 vs 5.9 +/- 1.1; P &lt; .001) were up-regulated in the kidneys from <compound-id="8987">DCD</compound-id>.	DCD__CXCL1__no_interaction	DCD__CXCL2__no_interaction	DCD__HSPH1__no_interaction	DCD__HSPA5__no_interaction	DCD__HSPB1__no_interaction	DCD__osteopontin__no_interaction	DCD__HSPA1B__no_interaction	DCD__HSPA1A__no_interaction
9145775-1	We have examined whether 4-<compound-id="6360">tert-butyl-</compound-id>N-[6-(<compound-id="97257">2-hydroxy-</compound-id>ethoxy)-2,2'-bipyrimidin-4-yl]-<compound-id="241">benzen</compound-id> esulfonamide (<compound-id="104865">bosentan</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(A/B) receptor antagonist) and (R)2-[(R)-2-[(S)-2-[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl] amino-4-methylpentanoil]amino-3-[3-(1-methyl-1H-indoyl)]prop ionyl]amino-3-(2-pyridyl) <compound-id="1032">propionic acid</compound-id> (<compound-id="107810">FR 139317</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(A) receptor antagonist) inhibit contractions of human airway smooth muscle induced by <protein-id="P05305,Q6FH53">endothelin-1</protein-id> or Suc-[Glu9,Ala(11,15)]enthothelin-1-(8-21) (<compound-id="16130933">IRL 1620</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(B) receptor agonist).	1H-azepinyl__endothelin-1__no_interaction	propionic acid__endothelin-1__no_interaction	endothelin__endothelin-1__no_interaction	benzen__endothelin-1__no_interaction	bosentan__endothelin-1__no_interaction	tert-butyl-__endothelin-1__no_interaction	FR 139317__endothelin-1__no_interaction	2-hydroxy-__endothelin-1__no_interaction	IRL 1620__endothelin-1__no_interaction
14629173-1	Six supramolecular complexes incorporating <compound-id="8651">benzil</compound-id> as a guest, CMCR*<compound-id="1474">bipy</compound-id>*<compound-id="8651">benzil</compound-id> (<protein-id="P25100,B0ZBE0">alpha) 1</protein-id> (CMCR = <compound-id="3952517">C-methylcalix[4]resorcinarene</compound-id>), CMCR*<compound-id="1474">bipy</compound-id>*<compound-id="8651">benzil</compound-id> (beta) 2, CMCR*2bpe*<compound-id="8651">benzil</compound-id>*<compound-id="702">ethanol</compound-id> 3 (bpe = trans-1,4-bis(pyridyl)<compound-id="53675528,6325">ethylene</compound-id>), CMCR*2bpe*<compound-id="8651">benzil</compound-id>*2H2O 4, CMCR.2bpeh*<compound-id="8651">benzil</compound-id>*<compound-id="702">ethanol</compound-id> 5 (bpeh = bis-(1-pyridin-4-yl-<compound-id="59061983">ethylidene</compound-id>)-<compound-id="9321">hydrazine</compound-id>), and CECR*2bpe.<compound-id="8651">benzil</compound-id> 6 (CECR = C-ethylcalix[4]resorcinarene), have been synthesized by hydrothermal and conventional methods and characterized by X-ray diffraction.	ethylene__alpha) 1__no_interaction	benzil__alpha) 1__no_interaction	bipy__alpha) 1__no_interaction	ethylidene__alpha) 1__no_interaction	C-methylcalix[4]resorcinarene__alpha) 1__no_interaction	hydrazine__alpha) 1__no_interaction	ethanol__alpha) 1__no_interaction
6363874-6	At each increment of <protein-id="P01308,I3WAC9,P01315">insulin</protein-id> infused, steady-state <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rates for porcine <protein-id="P01308,I3WAC9,P01315">insulin</protein-id> were 1.12 +/- 0.22, 1.90 +/- 0.59, 4.28 +/- 0.61, and 9.37 +/- 0.66 mg/kg/min compared with 1.27 +/- 0.42, 2.38 +/- 0.20, 4.25 +/- 0.43, and 8.87 +/- 0.67 mg/kg/min for semisynthetic human <protein-id="P01308,I3WAC9,P01315">insulin</protein-id>.	glucose__insulin__no_interaction
2180818-4	It was specific, as the pressor effect induced by other unrelated peptides was similar during the infusion of either vehicle or kinin antagonist (angiotensin II, 25 +/- 4 vs. 26 +/- 2 mm Hg; <compound-id="5280360">prostaglandin E2</compound-id>, 48 +/- 3 vs. 47 +/- 8 mm Hg; <compound-id="439260">norepinephrine</compound-id>, 17 +/- 2 vs. 18 +/- 2 mm Hg; <compound-id="6106">leucine</compound-id>-enkephaline, 15 +/- 2 vs. 16 +/- 1 mm Hg; <protein-id="G3V6J4">neurotensin</protein-id>, 18 +/- 2 vs. 19 +/- 1 mm Hg; substance P, 19 +/- 2 vs. 19 +/- 2 mm Hg).	norepinephrine__neurotensin__no_interaction	leucine__neurotensin__no_interaction	prostaglandin E2__neurotensin__no_interaction
7572973-5	<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex hormone-binding globulin</protein-id> was significantly inversely correlated with body mass index (r = -0.53, p 0.001), glycosylated hemoglobin (r = -0.34, p &lt; 0.001), and diastolic blood pressure (r = -0.25, p &lt; 0.001), and positively correlated with high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL <compound-id="5997">cholesterol</compound-id>) (r = 0.31, p &lt; 0.001), and HDL <compound-id="5997">cholesterol</compound-id>/total <compound-id="5997">cholesterol</compound-id> (r = 0.31, p &lt; 0.001).	cholesterol__sex hormone-binding globulin__no_interaction
20825003-4	The results show that the pollutants concentration often exceeds state criterion except <compound-id="947">nitrogen</compound-id> oxides, O3 concentration in summer and autumn is higher, averaged hourly maximum concentration (O3-<protein-id="P61244,Q8TAX8,A0A024R682">Max</protein-id>) is (177.2 +/- 63.0) and (105.8 +/- 61.7) microg x m(-3), the concentrations of NO and NO2 are (4.5 +/- 4.0), (32.7 +/- 12.4) microg x m(-3) and (21.5 +/- 16.9), (60.5 +/- 16.9) microg x m(-3) respectively, SO2 concentration is (72.0 +/- 27.5) and (92.0 +/- 44.4) microg x m(-3), PM2.5 and PM10 concentrations reach to (102.3 +/- 47.6), (153.3 +/- 58.3) microg x m(-3) and (95.8 +/- 50.0), (147.4 +/- 67.0) microg x m(-3).	nitrogen__Max__no_interaction
16732984-5	Duration of diabetes [(66.09 +/- 72.51) months vs (143.71 +/- 93.27) months vs (174.30 +/- 81.91) months, P = 0.00], systolic blood pressure [(131.95 +/- 47.20) mmHg vs (138.71 +/- 21.36) mmHg vs (147.58 +/- 24.10) mmHg, P = 0.01], urine <protein-id="P02768">albumin</protein-id> [(32.79 +/- 122.29) mg/L vs (190.96 +/- 455.65) mg/L vs (362.00 +/- 552.51) mg/L, P = 0.00], glycated hemoglobin (HbA1c) [(8.68 +/- 2.26)% vs (9.42 +/- 1.84)% vs (9.42 +/- 1.96)%, P = 0.04], <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) [(3.19 +/- 7.37) mg/L vs (6.36 +/- 23.59) mg/L vs (3.02 +/- 4.34) mg/L, P = 0.03], high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) [(1.23 +/- 0.37) mmol/L vs (1.33 +/- 0.35) mmol/L vs (1.24 +/- 0.33) mmol/L, P = 0.01], <compound-id="1175">uric acid</compound-id> (UA) [(288.51 +/- 90.85) mmol/L vs (300.29 +/- 101.98) mmol/L vs (337.57 +/- 115.09) mmol/L, P = 0.00], <compound-id="588">creatinine</compound-id> (CREA) [(84.22 +/- 16.31) micromol/L vs (89.35 +/- 27.45) micromol/L vs (103.28 +/- 48.64) micromol/L, P = 0.00], blood urine <compound-id="947">nitrogen</compound-id> (BUN) [(5.62 +/- 1.62) mmol/L vs (6.55 +/- 2.74) mmol/L vs (8.11 +/- 3.60) mmol/L, P = 0.00] were statistically different among the three groups.	creatinine__C-reactive protein__no_interaction	creatinine__albumin__no_interaction	creatinine__CRP__no_interaction	uric acid__C-reactive protein__no_interaction	uric acid__albumin__no_interaction	uric acid__CRP__no_interaction	nitrogen__C-reactive protein__no_interaction	nitrogen__albumin__no_interaction	nitrogen__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__albumin__no_interaction	cholesterol__CRP__no_interaction
18357530-7	After 90 days in group A treated with ALC, we observed a significant decrease in <protein-id="P00734">prothrombin</protein-id> time (P &lt; 0.001), <compound-id="5280352">bilirubin</compound-id> serum levels (P &lt; 0.01), AST (P &lt; 0.001), fasting NH(4) serum levels (P &lt; 0.001), Trail Making Test-A (P &lt; 0.001) and Trail Making Test-B (P &lt; 0.001), and a significant increase in albumin serum levels (P &lt; 0.005), MMSE test (P &lt; 0.001), Symbol Digit Modalities Test (P &lt; 0.001), BDT (P &lt; 0.001), AVL long-term test (P &lt; 0.001) and AVL total test (P &lt; 0.001).	bilirubin__prothrombin__no_interaction
9773399-11	Low-density lipoprotein diameter correlated inversely with concentrations of serum triglyceride (r = -.61, P &lt; .0001), apo B (r = -.66, P &lt; .0001), <compound-id="5997">cholesterol</compound-id> (r = -.53, P &lt; .001), LDL <compound-id="5997">cholesterol</compound-id> (r = -.45, P &lt; .005), and <protein-id="P02647,A0A024R3E3">apo A-I</protein-id> (r = -.39, P &lt; .02).	cholesterol__apo A-I__no_interaction
15879357-4	RESULTS: The patients were androgen deficient compared with controls (median, range), <protein-id="Q06520,A8K015">dehydroepiandrosterone sulphate</protein-id> (<protein-id="Q06520,A8K015">DHEAS</protein-id>): 185 (99-7800) nmol/l vs 4400 (820-13,000) nmol/l, P=or&lt;0.001; <compound-id="6128">androstenedione</compound-id>: 0.5 (0.1-7.1) nmol/l vs 4.3 (1.6-8.8) nmol/l, P=or&lt;0.001; <compound-id="10635">dihydrotestosterone</compound-id> (DHT): 0.13 (0.09-0.54) nmol/l vs 0.55 (0.09-0.89) nmol/l, P=or&lt;0.001; <compound-id="6013">testosterone</compound-id>: 0.28 (0.09-1.56) nmol/l vs 1.1 (0.71-2.24) nmol/l, (P=or&lt;0.001); free <compound-id="6013">testosterone</compound-id>: 0.004 (0.001-0.030) nmol/l vs 0.016 (0.001-0.030) nmol/l, P=or&lt;0.001.	dihydrotestosterone__DHEAS__no_interaction	dihydrotestosterone__dehydroepiandrosterone sulphate__no_interaction	androstenedione__DHEAS__no_interaction	androstenedione__dehydroepiandrosterone sulphate__no_interaction	testosterone__DHEAS__no_interaction	testosterone__dehydroepiandrosterone sulphate__no_interaction
23383498-4	The chromatographic separation was achieved on a reverse-phase <protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C18</protein-id> column by gradient elution using 0.01 mol/L <compound-id="1004">phosphoric acid</compound-id> (adjusted to pH 3.6 by <compound-id="8471">triethylamine</compound-id>) and acetonitrile, detected with a diode array detector (DAD) at 228 nm for 2-amino-9H-pyrido [ 2,3-b] <compound-id="798">indole</compound-id> (AaC) and 2-amino-3-methyl-9H-pyrido [ 2,3-b] <compound-id="798">indole</compound-id> (MeAaC); 253 nm for 2-amino-<compound-id="97555">3-methylimidazo[4,5-f]quinoline</compound-id> (<compound-id="53462">IQ</compound-id>), 1-methyl-9H-pyrido[3, 4-b] <compound-id="798">indole</compound-id> (<compound-id="5281404">Harman</compound-id>), 9H-pyrido[3,4-b] <compound-id="798">indole</compound-id> (<compound-id="64961">Norharman</compound-id>); 263 nm for 2-amino-<compound-id="151877">3,8-dimethylimidazo[4,5-f]quinoxaline</compound-id> (<compound-id="62275">MeIQx</compound-id>), 2-amino-3,4,8-<compound-id="69976">trimethylimidazo</compound-id> [4,5-f] <compound-id="7045">quinoxaline</compound-id> (4, 8-DiMeIQx), 3-amino-1-methyl-<compound-id="13347754">5H-pyrido</compound-id> [4,3-b] <compound-id="798">indole</compound-id> (Trp-p-2); 321 nm for 2-amino-1-methyl-6-<compound-id="69591">phenylimidazo</compound-id> [4,5-b]pyridine (PhIP).	phenylimidazo__C18__no_interaction	indole__C18__no_interaction	quinoxaline__C18__no_interaction	trimethylimidazo__C18__no_interaction	IQ__C18__no_interaction	MeIQx__C18__no_interaction	phosphoric acid__C18__no_interaction	triethylamine__C18__no_interaction	Harman__C18__no_interaction	Norharman__C18__no_interaction	3,8-dimethylimidazo[4,5-f]quinoxaline__C18__no_interaction	5H-pyrido__C18__no_interaction	3-methylimidazo[4,5-f]quinoline__C18__no_interaction
18252895-7	The most susceptible haplotypes are the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0301-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0501-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0201 (odds ratio [OR] 3.64) and the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0405-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302, <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<compound-id="5326974">DQB</compound-id>*0302, and <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0402-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 haplotypes (ORs 11.37, 8.39, and 3.63), followed by the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0404-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (OR 1.59) and the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0801-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0401-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0402 (OR 1.25) haplotypes.	DQB__DQB1__no_interaction	DQB__DRB1__no_interaction	DQB__DQA1__no_interaction
19875056-1	PURPOSE: The response of 2-amino-4-([(14)C]methylthio)<compound-id="264">butyric acid</compound-id> ([(14)C]Met) uptake and [(125)I]<compound-id="15284370">3-iodo-alpha-methyl-l-tyrosine</compound-id> ([(125)I]<compound-id="447041">IMT</compound-id>) uptake to radiotherapy of <protein-id="Q9NYD6,Q53XI4">C10</protein-id> glioma cells was compared to elucidate the intracellular reactions that affect the response of 2-amino-4-([(11)C]methylthio)<compound-id="264">butyric acid</compound-id> ([(11)C]Met) uptake to radiotherapy.	butyric acid__C10__no_interaction	3-iodo-alpha-methyl-l-tyrosine__C10__no_interaction	IMT__C10__no_interaction
20364816-4	Values for some of the more important parameters (r(g)/A; angle(alpha)/deg) of the C(s) form are r(C=C) = 1.337(21), <protein-id="Q9HC52">r(C1-C4</protein-id>) = 1.496(8), r(C2-C3) = 1.501(8), r(C3-C4) = 1.567(12), r(C1-O) = 1.318(12), r(C2-O) = 1.340(12), r(C3-F) = 1.375(4), r(C4-F) = 1.368(4), angle(<compound-id="16070039">ave</compound-id>)(C=C-C) = 94.4(4), angle(<compound-id="16070039">ave</compound-id>)(C=C-O) = 133.5(12), angle(<compound-id="16070039">ave</compound-id>)(C-O-C) = 119.6(13), and angle(<compound-id="16070039">ave</compound-id>)(F-C-F) = 104.4(7).	ave__r(C1-C4__no_interaction
14703492-7	The cDNA library contained oxidative metabolic genes in mitochondria (<compound-id="439168">triose phosphate</compound-id> dehydrogenase, NADH4, <compound-id="644102">pyrophosphate</compound-id> synthase, 16S rRNA ribosome, <compound-id="1110">succinate</compound-id>-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> ligase and <compound-id="5957">ATP</compound-id> synthase 6); transcriptional and translation genes poly (A) binding protein, t-RNA-<compound-id="764">guanine</compound-id> transglycoslase, <protein-id="P62831">ribosomal protein L23</protein-id>, ribosomal protein S15A, <compound-id="59918034">eukaryotic translation initiation factor 3</compound-id>, Rab interaction protein 5, splicing factor-<compound-id="54451667">arginine serine</compound-id> rich 5, and <compound-id="6022">ADP</compound-id>-ribosylation factor-like 6 interacting protein), <compound-id="190217">oxide</compound-id> stress related genes (ferritin high chain and <protein-id="P17741">high-mobility group protein 2</protein-id>); protein activating and signaling pathway related genes (casein kinase, serine kinase 2 and <compound-id="16738692,53477912">phosphatidylinositol</compound-id>-four-<compound-id="1061,167704">phosphate</compound-id> adaptor protein-1-associated protein); cell differentiation and apoptosis associated genes (NB4 cell apoptosis related protein and myeloid differentiation primary response protein) and five genes with unknown function (KIAA0092, CGI-147protein, GCI-35, nucleolar phosphoprotein Nopp34 and Mus muscular partial mRNA for hypothetical protein), as well as a novel gene unmatched to the sequence in GenBank.	pyrophosphate__high-mobility group protein 2__no_interaction	pyrophosphate__ribosomal protein L23__no_interaction	ADP__high-mobility group protein 2__no_interaction	ADP__ribosomal protein L23__no_interaction	triose phosphate__high-mobility group protein 2__no_interaction	triose phosphate__ribosomal protein L23__no_interaction	phosphatidylinositol__high-mobility group protein 2__no_interaction	phosphatidylinositol__ribosomal protein L23__no_interaction	arginine serine__high-mobility group protein 2__no_interaction	arginine serine__ribosomal protein L23__no_interaction	guanine__high-mobility group protein 2__no_interaction	guanine__ribosomal protein L23__no_interaction	eukaryotic translation initiation factor 3__high-mobility group protein 2__no_interaction	eukaryotic translation initiation factor 3__ribosomal protein L23__no_interaction	CoA__high-mobility group protein 2__no_interaction	CoA__ribosomal protein L23__no_interaction	oxide__high-mobility group protein 2__no_interaction	oxide__ribosomal protein L23__no_interaction	phosphate__high-mobility group protein 2__no_interaction	phosphate__ribosomal protein L23__no_interaction	ATP__high-mobility group protein 2__no_interaction	ATP__ribosomal protein L23__no_interaction	succinate__high-mobility group protein 2__no_interaction	succinate__ribosomal protein L23__no_interaction
20401425-1	The structures and magnetic properties of a family of new octanuclear heterometallic 3d-4f complexes [Mn(III)(4)Ln(III)(4)(mu(3)-OH)(4)(mu(2),eta(1)-X)(4)(O(2)CBu(t))(8)(t-bdea)(4)]·solv, where X = N(3)(-), Ln = Y (1), Eu (2), Gd (3), Tb (4), Dy (5), Ho (6); X = <protein-id="P02818">OCN</protein-id>(-), Ln = Dy (7); X = NO(3)(-), Ln = Gd (8), Tb (9), Dy (10), Ho (11), Er (12); solv = <compound-id="6342">MeCN</compound-id> or <compound-id="1140">toluene</compound-id>, are reported.	MeCN__OCN__no_interaction	toluene__OCN__no_interaction
22378230-1	Six inorganic-organic <compound-id="5359367">bismuth</compound-id> <compound-id="10367">2,6-pyridinedicarboxylate</compound-id> (pdc) compounds, [Bi(2,6-pdc)(3)]·3(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 1, [Bi(2,6-pdc)(3)]·3(<protein-id="Q31604,Q6ICR9">dma</protein-id>)·2(H(2)O), 2, [Bi(2,6-pdc)(2)(dmf)]·(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 3, Bi(2,6-pdc)(2,6-pdcme)(<compound-id="887">MeOH</compound-id>), 4, [LiBi(2,6-pdc)(3)(H(2)O)]·2(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 5, and Li(5)Bi(2,6-pdc)(4)(H(2)O)(2), 6 (where <protein-id="Q31604,Q6ICR9">dma</protein-id> = dimethyl <compound-id="223">ammonium cation</compound-id>, dmf = dimethylformamide and 2,6-pdcme = 6-methyl-oxycarbonyl <compound-id="1049">pyridine</compound-id> 2-carboxylate) have been synthesized under solvothermal conditions and their structures determined by single crystal X-ray diffraction.	pyridine__dma__no_interaction	bismuth__dma__no_interaction	ammonium cation__dma__no_interaction	2,6-pyridinedicarboxylate__dma__no_interaction	MeOH__dma__no_interaction
19099859-8	Compared with the group treated with traditional medicines, plasma concentration of <protein-id="P16860">BNP</protein-id> [(403 +/- 216) ng/L vs. (219 +/- 87) ng/L] significantly decreased, the clinical symptom was significantly improved, cardio-thoracic ratio (CTR) (0.60 +/- 0.05 vs. 0.54 +/- 0.06) (P &lt; 0.05) and heart rate [(115 +/- 20) bpm vs. (90 +/- 14) bpm] (P &lt; 0.01) decreased, ejection fraction (EF) (46.6% +/- 13.4% vs. 54.5% +/- 12.9%), fractional shortening (21.6% +/- 8.1% vs. 24.1% +/- 7.5%), mean velocity of circumferential fiber shortening [(0.8 +/- 0.5) cir/s vs. (0.9 +/- 0.4) cir/s] were significantly increased (P &lt; 0.01), left ventricular end-systolic dimension [(34.0 +/- 8.6) mm vs. (32.2 +/- 9.1) mm] (P &lt; 0.05), left ventricular mass [(65.9 +/- 34.1) g vs. (65.9 +/- 34.1) g], interventricular septal thickness at end-systole [(6.0 +/- 1.0) mm vs (5.5 +/- 1.1) mm] were notably decreased (P &lt; 0.01) after treatment with <compound-id="2585">carvedilol</compound-id>.	carvedilol__BNP__no_interaction
22098258-5	Estimates for the enthalpy of vaporization of EMIM(+)Br(-) and, by comparison, <compound-id="2734162">1-butyl-3-methylimidazolium</compound-id> bromide (BMIM(+)Br(-)) from molecular dynamics calculations and their gas phase enthalpies of formation obtained by G4 calculations yield estimates for the ionic liquids' enthalpies of formation in the liquid phase: ΔH(vap)(298 K) (EMIM(+)Br(-)) = 168 ± 20 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, gas)(298 K) (EMIM(+)Br(-)) = 38.4 ± 10 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, <compound-id="15942667">liq</compound-id>)(298 K) (EMIM(+)Br(-)) = -130 ± 22 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, gas)(298 K) (BMIM(+)Br(-)) = -5.6 ± 10 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, and ΔH(f, <compound-id="15942667">liq</compound-id>)(298 K) (BMIM(+)Br(-)) = -180 ± 20 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>.	liq__mol__no_interaction	1-butyl-3-methylimidazolium__mol__no_interaction
9666933-5	In women, <compound-id="40539">QUS</compound-id> data correlated significantly with age (r = -0.297), body mass index (BMI) (r = 0.403), <compound-id="22044544,5460341">calcium</compound-id> (r = 0.220), <protein-id="P01270">PTH</protein-id> (r = -0.296), 25OHD (r = 0.298) and alkaline phosphatase (AP) (r = -0.170) for broadband ultrasound attenuation (BUA), and with age (r = -0.195), BMI (r = 0.208), <protein-id="P01270">PTH</protein-id> (r = -0.174), 25OHD (r = 0.140) and AP (r = -0.130) for speed of sound (SOS).	calcium__PTH__no_interaction	QUS__PTH__no_interaction
15883813-3	RESULTS: Here we show that (1) <compound-id="46173706">beta-glucan</compound-id> had cytotoxic effect against human ovarian cancer HRA cells, but not against murine Lewis lung cancer <compound-id="86580376">3LL</compound-id> cells, in vitro; (2) <compound-id="46173706">beta-glucan</compound-id> promotes p38 MAPK activity for suppressing HRA cell proliferation and amplifying the apoptosis cascade; (3) <compound-id="46173706">beta-glucan</compound-id> stimulates translocation of the proapoptotic protein, <protein-id="Q07813,Q544Z6">Bax</protein-id>, from the cytosol to mitochondria, cytochrome c release, and subsequent <protein-id="Q8C3Q9,A2AS93">caspase-9</protein-id> activation; (4) treatment with <compound-id="176155">SB203580</compound-id>, a p38 MAPK-specific inhibitor, suppresses <compound-id="46173706">beta-glucan</compound-id>-induced effects, indicating that activation of p38 MAPK is involved in the suppression of cell proliferation and mitochondrial activation-mediated cell death pathway; (5) in mice, oral supplementation with <compound-id="46173706">beta-glucan</compound-id> reduces pulmonary metastasis of <compound-id="86580376">3LL</compound-id> cells and peritoneal disseminated metastasis of HRA cells and inhibits the growth of these metastatic tumors in lung or peritoneal cavity, in part, by suppressing uPA expression; and (6) in an in vivo experimental metastasis assay, however, the oral supplementation with <compound-id="46173706">beta-glucan</compound-id> after i.v.	beta-glucan__caspase-9__no_interaction	beta-glucan__Bax__no_interaction	3LL__caspase-9__no_interaction	3LL__Bax__no_interaction	SB203580__caspase-9__no_interaction	SB203580__Bax__no_interaction
6616041-3	For cells treated with 3H-<compound-id="5789">thymidine</compound-id> at 01 h, T = 24.3 h, ts = 6 h, <protein-id="P21981">tG2</protein-id> min = 1.5 h, <protein-id="P21981">tG2</protein-id>+ 1/2 M = 2.9 h and <protein-id="P21981">tG1+/2</protein-id> M = 15.4 h; for those treated with 3H-<compound-id="5789">thymidine</compound-id> at 13 h, T = 25.6 h, ts = 8.4 h, <protein-id="P21981">tG2</protein-id> min = 1 h, <protein-id="P21981">tG2</protein-id>+ 1/2 M = 2.2 h, tG1+ 1/2 M = 15 h. Cells labeled at 01 h proliferated more actively for a long period of time as compared to those labeled at 13 h. The synchronism in undergoing several successive mitotic cycles was greater for cells labeled at the peak radioisotope index.	thymidine__tG2__no_interaction	thymidine__tG1+/2__no_interaction
8647820-3	Seven <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)-derived triple-helical peptides (<compound-id="41478">THPs</compound-id>) were synthesized based on charge clustering (<protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)256-270, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)385-396, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)406-417, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)415-423, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)448-456, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)496-507, and <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)526-537).	THPs__alpha 1__no_interaction
21917315-5	RESULTS: <protein-id="P00813,F5GWI4">ADA</protein-id> activity and <protein-id="P02778,A0A024RDA4">IP-10</protein-id>, IFN-γ, and <protein-id="P27487">DPP4</protein-id> levels were significantly higher in <compound-id="445181">TPE</compound-id> than in non-<compound-id="445181">TPE</compound-id> (88.9 ± 62.7 U/L vs 18.1 ± 16.2 U/L, P &lt; .05; 147.5 ± 117.3 ng/L vs 24.9 ± 19.7 ng/L, P &lt; .05; 627.2 ± 345.3 ng/L vs 152.6 ± 71.4 ng/L, P &lt; .05; and 560.6 ± 451.2 vs 56.8 ± 57.7, P &lt; .05, respectively).	TPE__IP-10__no_interaction	TPE__DPP4__no_interaction	TPE__ADA__no_interaction
22112436-8	These had a mean ± SD reduction in weight (6.8 ± 6.9 kg, P &lt; 0.001), waist circumference (6.1 ± 7.3 cm, P &lt; 0.001), <compound-id="206,5793,64689,79025">glucose</compound-id> (4.5 ± 29.6 mg/dL or 0.25 ± 1.64 mmol/L, P = 0.009), triglycerides (26.4 ± 58.5 mg/dL or 0.30 ± 0.66 mmol/L, P &lt; 0.001), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (LDL) (7.9 ± 25.1 mg/dL or 0.2 ± 0.65 mmol/L, P &lt; 0.001), hemoglobin A1c (HgbA1c) (0.20 ± 0.64%, P = 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> (3.8 ± 11 microU/ml or 26.6 ± 76.4 ρmol, P &lt; 0.001) and ultra sensitive <protein-id="P02741">C-reactive protein</protein-id> (US - <protein-id="P02741">CRP</protein-id>) (0.9 ± 4.8 mg/dL or 7.3 ± 40.2 nmol/L, P = 0.012), an increase in mean high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL) (3.7 ± 8.4 mg/dL or 0.1 ± 0.22, P &lt; 0.001), and decreased use of medications.	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction	cholesterol__CRP__no_interaction	glucose__C-reactive protein__no_interaction	glucose__insulin__no_interaction	glucose__CRP__no_interaction
18940877-9	RESULTS: After 12 wk <compound-id="60823">atorvastatin</compound-id>, there was a significant reduction (mean +/- <compound-id="5289348">sem</compound-id>) in total <compound-id="5997">cholesterol</compound-id> (4.6 +/- 0.2 vs. 3.4 +/- 0.2 mmol/liter, P &lt; 0.01), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (2.9 +/- 0.2 vs. 1.8 +/- 0.2 mmol/liter, P &lt; 0.01), triglycerides (1.34 +/- 0.08 vs. 1.08 +/- 0.13 mmol/liter, P &lt;0.01), high-sensitivity <protein-id="P02741">C-reactive protein</protein-id> (4.9 +/- 1.4 vs. 3.4 +/- 1.1 mg/liter, P = 0.04), free androgen index (13.4 +/- 0.6 vs. 8.7 +/- 0.4, P &lt; 0.01), <compound-id="6013">testosterone</compound-id> (4.1 +/- 0.2 vs. 2.9 +/- 0.1 nmol/liter, P &lt; 0.01) and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance as measured by homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) (3.3 +/- 0.4 vs. 2.7 +/- 0.4).	atorvastatin__C-reactive protein__no_interaction	atorvastatin__insulin__no_interaction	sem__C-reactive protein__no_interaction	sem__insulin__no_interaction	testosterone__C-reactive protein__no_interaction	testosterone__insulin__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction
21813378-3	RESULTS: 1) In SB vs. SF unstratified OM biomarkers were statistically unchanged, but the majority of patients was overweight; despite, in SB vs. SF urine pH, total and non-albumin protein concentration were elevated, fractional urinary <compound-id="1175">uric acid</compound-id> excretion and blood <compound-id="767">bicarbonate</compound-id> decreased, whereas urine volume, <compound-id="5360545">sodium</compound-id>, supersaturation with CaOx and CaPi (as <compound-id="14781">hydroxyapatite</compound-id>) were unchanged; 2) upon variation of OM markers (strata below and above median) numerous stone parameters differed significantly, among others urine volume, total protein, Ca/Pi ratio, pH, <compound-id="5360545">sodium</compound-id>, <compound-id="5462222">potassium</compound-id>, plasma Ca/Pi ratio and parathyroid hormone, blood pressure, renal excretion of non-albumin protein and other substances; 3) a significant shift from SF to SB patients occurred with increase of urine pH, decrease of blood <compound-id="767">bicarbonate</compound-id>, and increase of diastolic blood pressure, whereas increase of plasma <compound-id="1175">uric acid</compound-id> impacted only marginally; 4) in both SF and SB patients a strong curvilinear relationship links a rise of urine Ca/Pi to urine Ca/Pi divided by plasma Ca/Pi, but in SB urine Ca/Pi failed to correlate significantly with urine <compound-id="14781">hydroxyapatite</compound-id> supersaturation; 5) also in SB, plasma Ca/Pi and urinary <compound-id="10313259,943">nitrate</compound-id> were negatively correlated, whereas in SF plasma Ca/Pi ratio, <protein-id="P01270">PTH</protein-id> and body mass index correlated positively; 6) multivariate regression analysis revealed that <protein-id="P01270">PTH</protein-id>, body mass index and <compound-id="10313259,943">nitrate</compound-id> together could explain 22 (p = 0.002) and only 7 (p = 0.06) per cent of variation of plasma Ca/Pi in SF and SB, respectively.	sodium__PTH__no_interaction	potassium__PTH__no_interaction	bicarbonate__PTH__no_interaction	nitrate__PTH__no_interaction	hydroxyapatite__PTH__no_interaction	uric acid__PTH__no_interaction
21341784-4	The <compound-id="123195">diimine</compound-id> [(Me(2))(C(6)H(3))Xanthdim]H(2) was treated with CuOtBu in the presence of acetonitrile, <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), and PMe(3) to yield the corresponding complexes [(Me(2))(C(6)H(3))Xanthdim](Cu(L))(2) (L = CH(3)CN, 1, <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), 2, and PMe(3), 3) that proved to be stable and were fully characterized.	diimine__PPh(3__no_interaction
17893771-2	Reactions of or with <compound-id="180">acetone</compound-id> oxime , cyclic <compound-id="6350">nitrone</compound-id> (-)O(+)N = <protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>(2)CH(2)C[upper bond 1 end]Me(2) or N,N-<compound-id="19463">diethylhydroxylamine</compound-id> give access, in moderate to good yields, to the unsymmetric mixed ligand oxadiazoline and/or imine complexes trans-[PtCl(2)(oxadiazoline-a)(imine-a)] , trans-[PtCl(2)(oxadiazoline-a)(oxadiazoline-b)] [oxadiazoline-b = [upper bond 1 start]N[double bond, length as m-dash]C(CH(2)CO(2)Me)O[lower bond 1 start]NC[upper bond 1 end](H)CH(2)CH(2)C[lower bond 1 end]Me(2)], trans-[PtCl(2)(imine-a)(imine-b)] [imine-b = NH = C(CH(2)CO(2)Me)ONEt(2)] or trans-[PtCl(2)(imine-a)(oxadiazoline-b)] .	nitrone__CHCH__no_interaction	diethylhydroxylamine__CHCH__no_interaction	acetone__CHCH__no_interaction
18633161-5	Blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (BUN) in <protein-id="Q60760">Meg1</protein-id> Tg mice (19.6 +/- 1.2 mg/dl) was significantly lower than in controls (22.0 +/- 0.8 mg/dl), while plasma triglyceride, insulin, <protein-id="Q60994">adiponectin</protein-id>, and <protein-id="Q99P87,Q5BMX4">resistin</protein-id> levels were significantly higher (202.0 +/- 23.4 mg/dl vs 146.3 +/- 23.4 mg/dl, 152.4 +/- 16.3 pg/ml vs 88.1 +/- 16.9 pg/ml, 74.4 +/- 10.9 microg/ml vs 48.3 +/- 7.0 microg/ml, and 4.0 +/- 0.2 ng/ml vs 3.6 +/- 0.2 ng/ml, respectively).	urea__resistin__no_interaction	urea__Meg1__no_interaction	urea__adiponectin__no_interaction	nitrogen__resistin__no_interaction	nitrogen__Meg1__no_interaction	nitrogen__adiponectin__no_interaction
10588341-9	For the determination of a mixture of <compound-id="11568">3-aminophenol</compound-id>, <compound-id="7245">2-chlorophenol</compound-id>, <compound-id="6947">2-nitrophenol</compound-id>, <compound-id="980">4-nitrophenol</compound-id>, <compound-id="335">o-methylphenol</compound-id>, <compound-id="342">m-methylphenol</compound-id>, <compound-id="2879">p-methylphenol</compound-id>, <compound-id="8449">2,4-dichlorophenol</compound-id>, <compound-id="7771">2,4-dimethylphenol</compound-id>, 2,4-<compound-id="1493">dinitrophenol</compound-id>, 2,4,6-trichlorophenol, <compound-id="10698">2,4,6-trimethylphenol</compound-id>, <compound-id="7808">4-bromophenol</compound-id>, 3-methyl-<compound-id="4684">4-chlorophenol</compound-id>, <compound-id="992">pentachlorophenol</compound-id>, and unsubstituted <compound-id="996">phenol</compound-id>, the calibration graphs for most phenols were linear over the range of 10-1000 microg <protein-id="Q9NTI2">ml(-1</protein-id>) and the mass detection limits were in the ng range based on three times standard deviation of seven measurements of the lowest peak that could be detected.	p-methylphenol__ml(-1__no_interaction	2,4-dichlorophenol__ml(-1__no_interaction	dinitrophenol__ml(-1__no_interaction	2,4,6-trimethylphenol__ml(-1__no_interaction	2-chlorophenol__ml(-1__no_interaction	o-methylphenol__ml(-1__no_interaction	2-nitrophenol__ml(-1__no_interaction	m-methylphenol__ml(-1__no_interaction	phenol__ml(-1__no_interaction	4-chlorophenol__ml(-1__no_interaction	4-bromophenol__ml(-1__no_interaction	pentachlorophenol__ml(-1__no_interaction	3-aminophenol__ml(-1__no_interaction	2,4-dimethylphenol__ml(-1__no_interaction	4-nitrophenol__ml(-1__no_interaction
15374490-5	Our data show that <protein-id="P01308,I3WAC9">Insulin</protein-id> resistance calculated by the <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rate during a euglycemic hyperinsulinemic <compound-id="206,5793,64689,79025">glucose</compound-id> clamp procedure is significantly correlated with the <protein-id="P01308,I3WAC9">Insulin</protein-id>-mediated net decrease in erythrocyte Na+ content (r = 0.58, P &lt; 0.05), as well as with net increase in erythrocyte K+ (r = 0.64, P &lt; 0.05) and Mg2+ (r = 0.67, P &lt; 0.01) content and to basal diastolic blood pressure (r = -0.63, P &lt; 0.05).	glucose__Insulin__no_interaction
20531239-7	RESULTS: Adalimumab treatment significantly decreased serum amylase activity (AP, 2778.25 ± 298.80; AP + ADA, 2143.13 ± 221.69; control, 1541.00 ± 148.39; ADA, 1143.00 ± 256.30 U/L; P &lt; 0.001), <compound-id="612">lactate</compound-id> dehydrogenase activity (AP, 2978.37 ± 364.65; AP + ADA, 2582.75 ± 164.23; control 931.25 ± 135.93; ADA, 582.62 ± 99.37 U/L; P &lt; 0.001), <protein-id="D3ZGE2,A0A0G2K1A2">myeloperoxidase</protein-id> activity (AP, 1.44 ± 0.20; AP + ADA, 0.86 ± 0.01; control, 0.60 ± 0.17; ADA, 0.41 ± 0.00 U/g of wet tissue; P &lt; 0.001), <compound-id="10964">malondialdehyde</compound-id> activity (AP, 16.94 ± 3.98; AP + ADA, 7.66 ± 2.27; control, 9.07 ± 1.00; ADA, 3.58 ± 0.30 nmol/g; P &lt; 0.01), and total histopathologic scores (AP, 2.75 ± 0.16; AP + ADA, 1.50 ± 0.19; control, 0.00 ± 0.00; ADA, 0.00 ± 0.00; P &lt; 0.001).	malondialdehyde__myeloperoxidase__no_interaction	lactate__myeloperoxidase__no_interaction
9225998-5	In this article, we summarise recent studies demonstrating that (1) chronic HIV-1 infection of human myelomonoblastic <compound-id="5289162">PLB</compound-id>-985 cells leads to constitutive NF-kappa B activity, activated in part due to enhanced <protein-id="P25963">I kappa B alpha</protein-id> turnover and increased NF-kappa B/<protein-id="Q04864">Rel</protein-id> production; (2) HTLV-1 Tax protein physically associates with the <protein-id="P25963">I kappa B alpha</protein-id> protein in vivo and in vitro and also mediates a 20- to 40-fold stimulation of NF-kappa B DNA binding activity mediated via an enhancement of NF-kappa B dimer formation; (3) casein kinase II phosphorylates <protein-id="P25963">I kappa B alpha</protein-id> at multiple sites in the C-terminal PEST domains and regulates <protein-id="P25963">I kappa B alpha</protein-id> function; (4) transdominant forms of <protein-id="P25963">I kappa B alpha</protein-id>, mutated in critical <compound-id="5951">Ser</compound-id> or Thr residues required for inducer-mediated (S32A,S36A) and/or constitutive phosphorylation block HIV LTR trans-activation and also effectively inhibit HIV-1 multiplication in a single cycle infection model; and (5) the amino-terminal 55aa of <protein-id="P25963">I kappa B alpha</protein-id> (<compound-id="3250092">NIK</compound-id>) interacts with the human homologue of dynein light chain 1, a small 9-kDa human homologue of the dynein light chain protein involved in microtubule and cytoskeletal dynamics.	NIK__I kappa B alpha__no_interaction	NIK__Rel__no_interaction	PLB__I kappa B alpha__no_interaction	PLB__Rel__no_interaction	Ser__I kappa B alpha__no_interaction	Ser__Rel__no_interaction
24189104-3	Based on comprehensive surveys of the nine Cree Territory (Eeyou Istchee) communities in this region during the period 2002-2009, blood plasma concentrations are presented of <compound-id="38018">Aroclor 1260</compound-id>, <protein-id="P11498,A0A024R5C5">PCB</protein-id> congeners 28, 52, 99, 101, 105, 118, 128, 138, 153, 156, 163, 170, 180, 183, and 187, <compound-id="12310947,2087,222548,24860538,61103">Aldrin</compound-id>, ß-HCH, α-<compound-id="5993">Chlordane</compound-id>, γ-<compound-id="5993">Chlordane</compound-id>, oxy-<compound-id="12303020">Chlordane, trans-</compound-id><compound-id="23275328">Nonachlor</compound-id>, cis-<compound-id="23275328">Nonachlor</compound-id>, <compound-id="3036">p,p'-DDT</compound-id>, p,p'-<compound-id="3035">DDE</compound-id>, Hexachloro <compound-id="241">benzene</compound-id> (HCB), <compound-id="16945">Mirex</compound-id>, <compound-id="158629,5289112">PBB</compound-id> 153, PBDE 47, <compound-id="36159">PBDE 99</compound-id>, <compound-id="154083">PBDE 100</compound-id>, <compound-id="155166">PBDE 153</compound-id>, <compound-id="5284469">Toxaphene</compound-id> 26, and <compound-id="5284469">Toxaphene</compound-id> 50.	Chlordane, trans-__PCB__no_interaction	benzene__PCB__no_interaction	PBDE 100__PCB__no_interaction	PBDE 99__PCB__no_interaction	PBDE 153__PCB__no_interaction	PBB__PCB__no_interaction	p,p'-DDT__PCB__no_interaction	Toxaphene__PCB__no_interaction	Chlordane__PCB__no_interaction	DDE__PCB__no_interaction	Nonachlor__PCB__no_interaction	Mirex__PCB__no_interaction	Aroclor 1260__PCB__no_interaction	Aldrin__PCB__no_interaction
11783633-4	Measured rate constants (in cm3 molecule(-1) s(-1) units) are OH radical reactions [OTNE, (9.85 +/- 0.88) x 10(-11); <compound-id="157326,6440618">acetyl cedrene</compound-id>, (7.7 +/- 1.6) x 10(-11); <compound-id="91497">HHCB</compound-id>, (2.6 +/- 0.6) x 10(-11); and <compound-id="96266">isochroman</compound-id>, (3.7 +/- 0.6) x 10(-11)], <protein-id="P41271,A0A087WTY6">NO3</protein-id> radical reactions [OTNE, (1.71 +/- 0.19) x 10(-11) and <compound-id="157326,6440618">acetyl cedrene</compound-id>, (4.1 +/- 1.0) x 10(-15)], and O3 reactions [OTNE, (2.1 +/- 0.5) x 10(-18) and <compound-id="157326,6440618">acetyl cedrene</compound-id>, &lt;2.2 x 10(-18)] where the error limits are two least-squares standard deviations.	acetyl cedrene__NO3__no_interaction	isochroman__NO3__no_interaction	HHCB__NO3__no_interaction
11714907-3	([R-(R*,R*)]-4[[2-[[3-(1H-<compound-id="798">Indole</compound-id>-3-yl)-2-methyl-1-oxo-2-[[tricyclo[3.3.1.1(3,7)]- <protein-id="Q99PV5,Q6L8F5,D3Z2G6">dec-2</protein-id>-yloxy)carbonyl[amino]propyl]amino]-<compound-id="137551">1-phenylethyl</compound-id>]amino]-<compound-id="1112">4-oxobutanoic acid</compound-id>) (CI-988; 100 nM) inhibited the ability of 10 nM <protein-id="P09240,Q8R041">CCK</protein-id>-8 to elevate cytosolic Ca(2+) in 1-[2-(<compound-id="16340557">5-carboxyoxazol-2-yl</compound-id>)-<compound-id="19959504">6-aminobenzofuran</compound-id>-5-oxy]-2-(2'-amino-5'-methylphenoxy)-<compound-id="6324">ethane</compound-id>-N,N,N',N'-<compound-id="57175139">tetraacetic acid acetoxymethyl ester</compound-id>-loaded NCI-H209 cells.	Indole__dec-2__no_interaction	Indole__CCK__no_interaction	5-carboxyoxazol-2-yl__dec-2__no_interaction	5-carboxyoxazol-2-yl__CCK__no_interaction	tetraacetic acid acetoxymethyl ester__dec-2__no_interaction	tetraacetic acid acetoxymethyl ester__CCK__no_interaction	ethane__dec-2__no_interaction	ethane__CCK__no_interaction	6-aminobenzofuran__dec-2__no_interaction	6-aminobenzofuran__CCK__no_interaction	1-phenylethyl__dec-2__no_interaction	1-phenylethyl__CCK__no_interaction	4-oxobutanoic acid__dec-2__no_interaction	4-oxobutanoic acid__CCK__no_interaction
8970998-6	However, further analyses revealed that (i) the EHV-1 <compound-id="56671814">vhs</compound-id> homolog gene, <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id>, was transcribed and translated into a 58-kDa protein in infected cells; (ii) the <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> protein was packaged into viral particles in amounts detectable in Western blots (immunoblots) with monoclonal antibodies; (iii) in cotransfection <compound-id="56671814">vhs</compound-id> activity assays, transiently-expressed <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> protein had intrinsic <compound-id="56671814">vhs</compound-id> activity comparable to that of wild-type HSV-1 <compound-id="56671814">vhs</compound-id>; and (iv) this intrinsic <compound-id="56671814">vhs</compound-id> activity was ablated by in vitro site-directed mutations in which either the functionally inactive HSV-1 vhs1 UL41 mutation (Thr at position 214 replaced by Ile [Thr-214--&gt;Ile]) was recreated within <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> or two conserved residues within the putative poly(A) binding region of the <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> sequence were altered (<compound-id="6057">Tyr</compound-id>-190, 192--&gt;Phe).	Tyr__ORF19__no_interaction	vhs__ORF19__no_interaction
24648846-3	ASM cells from people with and without asthma were stimulated with IL-1 β , TNF- α , and/or IFN γ and treated with <compound-id="774">histamine</compound-id> (1-100  μ M) ± <compound-id="2725,716121">chlorpheniramine</compound-id> (<protein-id="P35367">H1R</protein-id> antagonist; 1  μ M) or <compound-id="3001055,9883333">ranitidine</compound-id> (<protein-id="P25021">H2R</protein-id> antagonist; 50  μ M) or tryptase (1 nM) ± <compound-id="3033938,3910,439527,5284408,72429">leupeptin</compound-id> (serine protease inhibitor; 50  μ M), heat-inactivated tryptase, or vehicle for 4 h or 24 h. Human lung mast cells (MC) were isolated and activated with IgE/anti-IgE and supernatants were collected after 2 h or 24 h. The supernatants were added to ASM cells for 48 h and ASM cell <protein-id="P02778,A0A024RDA4">CXCL10</protein-id> production detected using ELISA (protein) and real-time PCR (mRNA).	chlorpheniramine__CXCL10__no_interaction	chlorpheniramine__H1R__no_interaction	chlorpheniramine__H2R__no_interaction	leupeptin__CXCL10__no_interaction	leupeptin__H1R__no_interaction	leupeptin__H2R__no_interaction	histamine__CXCL10__no_interaction	histamine__H1R__no_interaction	histamine__H2R__no_interaction	ranitidine__CXCL10__no_interaction	ranitidine__H1R__no_interaction	ranitidine__H2R__no_interaction
12074830-10	The levels of AuAb-oxLDL in patients were found to correlate with TAS, total <compound-id="5997">cholesterol</compound-id>, <protein-id="Q14746,B1ALW7">LDL-C</protein-id>, lipid <compound-id="784">hydroperoxide</compound-id> and erythrocyte <protein-id="P00441,V9HWC9">SOD</protein-id> activities (r = -0.62, p &lt; 0.01; r = 0.64, p &lt; 0.01; r = 0.55, p &lt; 0.01; r = 0.81, p &lt; 0.01; r = -0.63, p &lt; 0.01, respectively).	hydroperoxide__LDL-C__no_interaction	hydroperoxide__SOD__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__SOD__no_interaction
16352707-4	Here, we address the issue of physical dependence by comparing the <protein-id="P62812,Q544F7,Q3URD4">GABA(A)-alpha1</protein-id> affinity-selective drug <compound-id="5732">zolpidem</compound-id>, the novel compounds 7-(1,1-dimethylethyl)-6-(2-methyl-2H-<compound-id="9257">1,2,4-triazol</compound-id>-3-ylmethoxy)-3-(2,5-<compound-id="9706">difluorophenyl</compound-id>)-<compound-id="577392">1,2,4-triazolo[4,3-b]pyridazine</compound-id> (L-838,417) and 6-fluoro-9-methyl-2-phenyl-4-(<compound-id="31268">pyrrolidin</compound-id>-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one (<compound-id="9908378">SL651498</compound-id>) with functional selectivity for certain non-alpha(1) GABA(A) receptors, nonselective partial agonists [<compound-id="107926">bretazenil</compound-id>, 1-[1-[3-(3-pyridyl)phenyl]benzimidazol-5-yl]<compound-id="177">ethanone</compound-id> O-ethyloxime (NS2710), and 5-furan-3-yl-1-(3-imidazol-1-phenyl)-1H-<compound-id="5798">benzoimidazole</compound-id> (NS2664)], and nonselective full efficacy benzodiazepines, in a rapid precipitated withdrawal assay using the inverse agonist N-methyl-<compound-id="13129465">beta-carboline-3-carboxamide</compound-id> (FG-7142).	1,2,4-triazol__GABA(A)-alpha1__no_interaction	bretazenil__GABA(A)-alpha1__no_interaction	pyrrolidin__GABA(A)-alpha1__no_interaction	beta-carboline-3-carboxamide__GABA(A)-alpha1__no_interaction	benzoimidazole__GABA(A)-alpha1__no_interaction	difluorophenyl__GABA(A)-alpha1__no_interaction	SL651498__GABA(A)-alpha1__no_interaction	ethanone__GABA(A)-alpha1__no_interaction	zolpidem__GABA(A)-alpha1__no_interaction	1,2,4-triazolo[4,3-b]pyridazine__GABA(A)-alpha1__no_interaction
22967099-8	Increased LF was significantly associated with <compound-id="18283">d4T</compound-id> (P = 0.006) and didanosine (<compound-id="50599">ddI</compound-id>) use (P = 0.007), months on <compound-id="18283">d4T</compound-id> (P = 0.001) and on ARV (P = 0.025), duration of HIV (P &lt; 0.0001) and HCV infections (P &lt; 0.0001), higher HIV (P = 0.03) and HCV loads (P &lt; 0.0001), presence of lipodystrophy (P = 0.02), male gender (P = 0.02), older age (P = 0.04), low nadir (P = 0.02) and current CD4(+) T-cells (P &lt; 0.0001), low gain of CD4(+) T-cells after HAART (P = 0.01) and higher <protein-id="P08253,A0A024R6R4">MMP-2</protein-id> (P = 0.02) and <protein-id="P16035">TIMP-2</protein-id> serum levels (P = 0.02).	ddI__TIMP-2__no_interaction	ddI__MMP-2__no_interaction	d4T__TIMP-2__no_interaction	d4T__MMP-2__no_interaction
11927221-8	Patients with partially decompressed ventricles (n = 13, LVEDD = 4.8 +/- 1.0 cm) as compared to those with fully decompressed ventricles (n = 10, LVEDD = 3.0 +/- 0.3 cm) demonstrated significant improvements in: peak <compound-id="977">oxygen</compound-id> consumption (16.8 +/- 4.3 versus 12.8 +/- 3.0 ml/kg.min), native left ventricular index during exercise (2.5 +/- 1.4 versus 0.8 +/- 0.8 liters/min.m(2)); ability to exercise with the device weaned (10 of 13 versus 1 of 10 patients); resting myocardial blood flow (0.55 +/- 0.11 versus 0.21 +/- 0.13 ml/g.min); and myocardial <compound-id="977">oxygen</compound-id> consumption (0.04 +/- 0.01 versus 0.02 +/- 0.001 <protein-id="P13987,Q6FHM9">min-1</protein-id>) (all p &lt; 0.05).	oxygen__min-1__no_interaction
19489246-6	RESULTS: Compared with group C [size of area at risk (41.5 +/- 1.0)%, infarct size (45.5 +/- 1.0)%, expression of <protein-id="P55213">Caspase-3</protein-id> (5.87 +/- 0.29), percentage of apoptotic cardiomyocytes (26.8 +/- 1.3)%, level of phosphorylated Akt (10.8 +/- 1.9)%], <compound-id="4943">propofol</compound-id> 1 mg/kg and 2 mg/kg significantly reduced the size of area at risk and infarct size [size of area at risk (38.3 +/- 1.0)% and (37.3 +/- 1.2)%; infarct size (33.8 +/- 1.2)% and (30.2 +/- 1.7)%, P &lt; 0.05], inhibited the expression of <protein-id="P55213">Caspase-3</protein-id> (1.50 +/- 0.36 and 1.48 +/- 0.30, P &lt; 0.05), decreased the percentage of apoptotic cardiomyocytes [(16.3 +/- 1.2)% and (16.5 +/- 1.0)%, P &lt; 0.05] and promoted the phosphorylation of Akt [(68.7 +/- 4.0)% and (58.3 +/- 2.8)%, P &lt; 0.05].	propofol__Caspase-3__no_interaction
7991622-5	Antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-28) <compound-id="213604">Agm</compound-id> (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-28) <compound-id="213604">Agm</compound-id> (MZ-4-243), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-29) NH2 (MZ-4-169), [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGH RH-(1-29)NH2 (MZ-4-181), and [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGH RH-(1-28)<compound-id="213604">Agm</compound-id> (MZ-4-209) inhibited GH release at 3 x 10(-9) M. Among these peptides, MZ-4-243, MZ-4-169, and MZ-4-181 were also long acting in vitro.	Agm__hGHRH__no_interaction
20598432-6	No significant between-group differences were observed at the brachial, or axillary, artery for FMD (brachial: <protein-id="P49747">COMP</protein-id>: mean (SD) 6.2 (3.1)%, NONCOMP: 6.1 (3.5)%, p = 0.967, axillary: <protein-id="P49747">COMP</protein-id>: 8.0 (5.5)%, NONCOMP: 9.0 (3.6)%, p = 0.602), CADC (brachial: <protein-id="P49747">COMP</protein-id>: 10.4 (3.4)%, NONCOMP: 10.4 (5.4)%, p = 0.999, axillary: <protein-id="P49747">COMP</protein-id>: 9.6 (4.2)%, NONCOMP: 8.5 (3.2)%, p = 0.492), GTN-induced vasodilation (brachial: <protein-id="P49747">COMP</protein-id>: 17.9 (5.1)%, NONCOMP:14.1 (7.2)%, p = 0.173, axillary: <protein-id="P49747">COMP</protein-id>: 9.5 (4.3)%, NONCOMP: 7.7 (3.1)%, p = 0.302) or <compound-id="447041">IMT</compound-id> (brachial: p = 0.084, axillary: p = 0.581).	IMT__COMP__no_interaction
3887103-5	<compound-id="206,5793,64689,79025">Glucose</compound-id> uptake during the last 30 minutes of each clamp were consistently lower in uremic patients pre-dialysis than in controls (2.3 +/- 0.3 v 6.6 +/- 0.8 mg X kg-1 X min, 7.8 +/- 0.6 v 13.2 +/- 1.1 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id> and 9.6 +/- 0.7 v 15.5 +/- 1.0 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>, all P less than 0.001).	Glucose__X kg-1 X min-1__no_interaction
22247364-10	Age at onset of AS (p = 0.001), Bath AS Disease Activity Index (p = 0.002), AS Disease Activity Score (ASDAS) erythrocyte sedimentation rate (ESR; p = 0.047), ASDAS C-reactive protein (<protein-id="P02741">CRP</protein-id>; p = 0.012), Bath AS Functional Index (p = 0.008), global spine visual analog scale for pain (p = 0.000), Schober index (p = 0.039), Bath AS Metrology Index (p = 0.028), modified Stoke Ankylosing Spondylitis Spine Score (p = 0.035), and high ESR (p = 0.001) and <protein-id="P02741">CRP</protein-id> (p = 0.000) were correlated with high <compound-id="447041">IMT</compound-id> in patients with AS.	IMT__CRP__no_interaction
6349384-6	With the preprogrammed insulin infusions used to normalize plasma <compound-id="206,5793,64689,79025">glucose</compound-id> profiles to the intraduodenal <compound-id="206,5793,64689,79025">glucose</compound-id> load, all hormonal and metabolic responses were normalized during intraportal infusion (IRI, 72.5 +/- 4.2 microU/ml; <protein-id="P29794">glucagon</protein-id>, 66 +/- 10 pg/ml; <compound-id="612">lactate</compound-id>, 1.06 +/- 0.10 mmol/liter; <compound-id="5950">alanine</compound-id>, 0.251 +/- 0.042 mmol/liter; <compound-id="24759880,753">glycerol</compound-id>, 0.043 +/- 0.013 mmol/liter; NEFA, 0.24 +/- 0.03 mmol/liter; and <compound-id="441">3-hydroxybutyrate</compound-id>, 0.012 +/- 0.007 mmol/liter) but marked hyperinsulinemia (103.2 +/- 6.1 microU/ml) and depressed <compound-id="24759880,753">glycerol</compound-id>, NEFA, and <compound-id="441">3-hydroxybutyrate</compound-id> responses at 2 h (0.056 +/- 0.005, 0.52 +/- 0.10, and 0.019 +/- 0.010 mmol/liter, respectively) resulted during peripheral infusion.	lactate__glucagon__no_interaction	alanine__glucagon__no_interaction	glycerol__glucagon__no_interaction	3-hydroxybutyrate__glucagon__no_interaction	glucose__glucagon__no_interaction
1317517-4	Scatchard analysis of competitive inhibition of 125I <protein-id="P05305,Q6FH53">Et1</protein-id> binding gave the following results (m +/- <compound-id="5289348">SEM</compound-id>, n = 3): isolated glomeruli, Kd = 4.2 +/- 2.1 x 10(-10) M, Bmax = 8.1 +/- 1.2 x 10(10) sites/mg protein; mesangial cells, Kd = 5.2 +/- 1.5 x 10(-10) M, Bmax = 1.87 +/- 0.49 x 10(4) sites/cell; epithelial cells, Kd = 7.2 +/- 1.5 x 10(-10) M, Bmax = 2.46 +/- 0.15 x 10(4) sites/cell.	SEM__Et1__no_interaction
16318777-2	METHODS: Cultured HSC-T6 cells were randomly divided into 7 groups: Sham control group, <protein-id="P05305,Q6FH53">ET-1</protein-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id>), <compound-id="16219006,443289,52943236">BQ-123</compound-id> group [1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id>, a selective <protein-id="P25101">endothelin receptor A</protein-id> (<protein-id="P25101">ETRA</protein-id>) antagonist], <compound-id="5311032,44283453">BQ-788</compound-id> group [1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>, a selective <protein-id="P24530,A0A024R645,A0A024R638">endothelin receptor B</protein-id> (<protein-id="P24530,A0A024R645,A0A024R638">ETRB</protein-id>) antagonist], <protein-id="P05305,Q6FH53">ET-1</protein-id> + BQ123 group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id>), <protein-id="P05305,Q6FH53">ET-1</protein-id> + <compound-id="5311032,44283453">BQ-788</compound-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>) and <protein-id="P05305,Q6FH53">ET-1</protein-id> + <compound-id="5311032,44283453">BQ-788</compound-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id> + 1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>).	BQ-788__endothelin receptor A__no_interaction	BQ-788__ET-1__no_interaction	BQ-788__endothelin receptor B__no_interaction	BQ-788__ETRA__no_interaction	BQ-788__ETRB__no_interaction	BQ-123__endothelin receptor A__no_interaction	BQ-123__ET-1__no_interaction	BQ-123__endothelin receptor B__no_interaction	BQ-123__ETRA__no_interaction	BQ-123__ETRB__no_interaction
1835351-4	MAIN RESULTS: 1) The relative wall thickness (h/r) shows a normal distribution: mean = 0.39; SD = 0.08; 1st quartile = 0.33; 3rd = 0.43; 2) The septal/posterior wall ratio (ST/PWT) shows also a normal distribution: mean = 1.14; SD = 0.24; 1st quartile = 1; 3rd = 1.3; 3) Among patients with LVH (Devereux's criteria, n = 65) the 6 patients with h/r less than or equal to 0.33 are significantly different from the 18 patients with h/r greater than or equal to 0.43 for age (44 +/- 8 vs 51 +/- 10; p less than 0.03), casual (146 +/- 7 vs 166 +/- 13 mmHg; p less than 0.05) and ambulatory <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> (135 +/- 19 vs 146 +/- 16 mmHg; p less than 0.05), peak systolic stress (280 +/- 15 vs 187 +/- 31 Dynes/cm2; p less than 0.001) and E/A ratio (1.17 +/- 0.01 vs 0.94 +/- 0.27; p less than 0.05) but not for <compound-id="3337">ponderal</compound-id> excess.	ponderal__SBP__no_interaction
16784955-4	In these patients, the serum <protein-id="P23560,A0A0E3SU01">BDNF</protein-id> level showed positive correlation with the body mass index (r = 0.535, P &lt; .01), the percentage of body fat (r = 0.552, P &lt; .01), the subcutaneous fat area based on computed tomography scan (r = 0.480, P &lt; .05), the triglyceride level (r = 0.470, P &lt; .05), the fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> level (r = 0.437, P &lt; .05), and the homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance score (r = 0.506, P &lt; .05), whereas it showed a negative correlation with age (r = -0.486, P &lt; .05).	glucose__BDNF__no_interaction	glucose__insulin__no_interaction
7768892-3	As <protein-id="P04638">apoA-II</protein-id> was progressively substituted for apoA-I in HDL3 (A-II:A-I+A-II percentage mass: 29.5, 47.6, 71.5, 97.4, and 98.9%), the rate of <compound-id="5997">cholesterol</compound-id> efflux from Fu5AH hepatoma gradually and significantly decreased after 2 or 4 h of incubation at 37 degrees C (<compound-id="5997">cholesterol</compound-id> efflux: 30.4 +/- 0.8, 24.1 +/- 1.0, 19.8 +/- 1.2, 15.7 +/- 1.4, and 13.4 +/- 1.3%/2h, respectively; 38.4 +/- 1.5, 29.2 +/- 0.9, 27.0 +/- 0.2, 20.4 +/- 0.4, and 17.5 +/- 1.0%/4h, respectively) (p &lt; 0.01 with all A-II-enriched HDL3 fractions as compared with non-enriched homologues).	cholesterol__apoA-II__no_interaction
18040531-1	(-)-Epigallocatechin gallate, [<compound-id="167082">188Re</compound-id>]-P2045, 12B75, 89-12; <compound-id="441300">Abacavir sulfate</compound-id>/<compound-id="60825">lamivudine</compound-id>, Abatacept, <compound-id="9821849">Abiraterone acetate</compound-id>, ABT-869, Adalimumab, Ad-rh Endostatin, <compound-id="15942654">AI</compound-id>-700, Alemtuzumab, <compound-id="5488548">Alvimopan hydrate</compound-id>, <compound-id="3035016">Amrubicin</compound-id> hydrochloride, AP-12009, <compound-id="72231">Apomab</compound-id> 7.3, <compound-id="3083544">Arformoterol tartrate</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, AS-1404, <compound-id="9444">Azacitidine</compound-id>, <compound-id="10302451">AZD-0530</compound-id>; Bevacizumab, BHT-3009, <compound-id="71340">Biapenem</compound-id>, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, <compound-id="9941379">Bremelanotide</compound-id>; <protein-id="Q16790">CA9</protein-id>-SCAN, Calcitonin gene-related peptide, <compound-id="156414">Canertinib dihydrochloride</compound-id>, Cannabidiol, <compound-id="108144">Carboxyamidotriazole</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">Caspofungin acetate</compound-id>, <compound-id="60734">Celgosivir</compound-id>, Certolizumab pegol, <compound-id="156419">Cinacalcet hydrochloride</compound-id>, <compound-id="73115">Clevudine</compound-id>, CP-751871, <compound-id="969516">Curcumin</compound-id>, Cx-401, <compound-id="9962928">Cypher</compound-id>; <compound-id="213039">Darunavir</compound-id>, <compound-id="451668">Decitabine</compound-id>, <compound-id="11520894,23724531,53486198,71296108,71752077,72734349,74787553,86289926">Deforolimus</compound-id>, Dexamet, <compound-id="3108">Dipyridamole</compound-id>/<compound-id="5755">prednisolone</compound-id>, <compound-id="68873">Drospirenone</compound-id>, <compound-id="68873">Drospirenone</compound-id>/<compound-id="5757">estradiol</compound-id>, DTPw-<compound-id="4177956">HepB</compound-id>-Hib, <compound-id="60835">Duloxetine</compound-id> hydrochloride; Efalizumab, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="176870">Erlotinib</compound-id> hydrochloride, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="969472">Eszopiclone</compound-id>; Ferumoxtran-10, Ferumoxytol, <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="219090">Fosaprepitant dimeglumine</compound-id>; gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">Gefitinib</compound-id>, <compound-id="5280961">Genistein</compound-id>, <compound-id="44576256">Ghrelin</compound-id> (human), <compound-id="9577124">Gimatecan</compound-id>, <protein-id="P04141">GM-CSF</protein-id> PMED, Golimumab, <protein-id="P40967">gp100</protein-id> PMED; <compound-id="5291">Imatinib mesylate</compound-id>, Immunoglobulin intravenous (human), IV Gamma-globulin; <compound-id="56842232">LA-419</compound-id>, <compound-id="9867642">Laropiprant</compound-id>, L-<compound-id="15991548">BLP</compound-id>-25, <compound-id="6047">Levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, <compound-id="9911821">Lidocaine/prilocaine</compound-id>, <compound-id="11980957">Lopinavir/ritonavir</compound-id>, <compound-id="151166">Lumiracoxib</compound-id>, LY-2076962; <compound-id="56603701">Mepolizumab</compound-id>, <compound-id="5361918">Methylnaltrexone</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="121891">Mitiglinide calcium hydrate</compound-id>, <compound-id="4272">Mycophenolic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt, <compound-id="531641">Myristyl nicotinate</compound-id>; Natalizumab, Nesiritide, <compound-id="53232">Niacin/lovastatin</compound-id>; <compound-id="71587613">Oblimersen sodium</compound-id>, <compound-id="6918251">Ofatumumab</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, Ozarelix; <compound-id="6337614">Palonosetron hydrochloride</compound-id>, <protein-id="P01270">Parathyroid hormone</protein-id> (human recombinant), <compound-id="10113978">Pazopanib hydrochloride</compound-id>, <compound-id="158786">Pegaptanib octasodium</compound-id>, Pegfilgrastim, Peginterferon alfa- 2a, Peginterferon alfa-2b, Pegvisomant, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, Pexelizumab, <compound-id="7975">Picoplatin</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="468595">Posaconazole</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, PRO-1762, <compound-id="12419,169870">Progesterone caproate</compound-id>, <compound-id="65947">Prulifloxacin</compound-id>; <compound-id="208902">Ramelteon</compound-id>, <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, <compound-id="9838712">Reparixin</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">Rosuvastatin calcium</compound-id>; <compound-id="59227">Rotigotine</compound-id>; <compound-id="6918220">Satraplatin</compound-id>, Sertraline, Sipuleucel-T, SLIT-cisplatin, <compound-id="4261">SNDX-275</compound-id>, <compound-id="154059">Solifenacin succinate</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="5311424">Talnetant</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, Taxus, <compound-id="5362436">Tegaserod maleate</compound-id>, <compound-id="65999">Telmisartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="5282497">Tenofovir disoproxil fumarate/emtricitabine</compound-id>, Teriparatide, tgAAC-94, <compound-id="5487427">Tiotropium bromide</compound-id>, Tocilizumab, <compound-id="216237">Tolvaptan</compound-id>, <compound-id="5578">Trimethoprim</compound-id>; <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>, <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="10629256,157688,6918295">Vinflunine</compound-id>, <compound-id="71616">Voriconazole</compound-id>, <compound-id="5494449">VX-680</compound-id>; XL-880; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>.	Clevudine__CA9__no_interaction	Clevudine__gp100__no_interaction	Clevudine__GM-CSF__no_interaction	Clevudine__Parathyroid hormone__no_interaction	Gefitinib__CA9__no_interaction	Gefitinib__gp100__no_interaction	Gefitinib__GM-CSF__no_interaction	Gefitinib__Parathyroid hormone__no_interaction	Cinacalcet hydrochloride__CA9__no_interaction	Cinacalcet hydrochloride__gp100__no_interaction	Cinacalcet hydrochloride__GM-CSF__no_interaction	Cinacalcet hydrochloride__Parathyroid hormone__no_interaction	Genistein__CA9__no_interaction	Genistein__gp100__no_interaction	Genistein__GM-CSF__no_interaction	Genistein__Parathyroid hormone__no_interaction	Fondaparinux sodium__CA9__no_interaction	Fondaparinux sodium__gp100__no_interaction	Fondaparinux sodium__GM-CSF__no_interaction	Fondaparinux sodium__Parathyroid hormone__no_interaction	Rotigotine__CA9__no_interaction	Rotigotine__gp100__no_interaction	Rotigotine__GM-CSF__no_interaction	Rotigotine__Parathyroid hormone__no_interaction	Ranelic acid distrontium salt__CA9__no_interaction	Ranelic acid distrontium salt__gp100__no_interaction	Ranelic acid distrontium salt__GM-CSF__no_interaction	Ranelic acid distrontium salt__Parathyroid hormone__no_interaction	Tolvaptan__CA9__no_interaction	Tolvaptan__gp100__no_interaction	Tolvaptan__GM-CSF__no_interaction	Tolvaptan__Parathyroid hormone__no_interaction	sodium__CA9__no_interaction	sodium__gp100__no_interaction	sodium__GM-CSF__no_interaction	sodium__Parathyroid hormone__no_interaction	Pegaptanib octasodium__CA9__no_interaction	Pegaptanib octasodium__gp100__no_interaction	Pegaptanib octasodium__GM-CSF__no_interaction	Pegaptanib octasodium__Parathyroid hormone__no_interaction	Sunitinib malate__CA9__no_interaction	Sunitinib malate__gp100__no_interaction	Sunitinib malate__GM-CSF__no_interaction	Sunitinib malate__Parathyroid hormone__no_interaction	Tegaserod maleate__CA9__no_interaction	Tegaserod maleate__gp100__no_interaction	Tegaserod maleate__GM-CSF__no_interaction	Tegaserod maleate__Parathyroid hormone__no_interaction	Niacin/lovastatin__CA9__no_interaction	Niacin/lovastatin__gp100__no_interaction	Niacin/lovastatin__GM-CSF__no_interaction	Niacin/lovastatin__Parathyroid hormone__no_interaction	prednisolone__CA9__no_interaction	prednisolone__gp100__no_interaction	prednisolone__GM-CSF__no_interaction	prednisolone__Parathyroid hormone__no_interaction	Levodopa__CA9__no_interaction	Levodopa__gp100__no_interaction	Levodopa__GM-CSF__no_interaction	Levodopa__Parathyroid hormone__no_interaction	Picoplatin__CA9__no_interaction	Picoplatin__gp100__no_interaction	Picoplatin__GM-CSF__no_interaction	Picoplatin__Parathyroid hormone__no_interaction	Drospirenone__CA9__no_interaction	Drospirenone__gp100__no_interaction	Drospirenone__GM-CSF__no_interaction	Drospirenone__Parathyroid hormone__no_interaction	Olmesartan medoxomil__CA9__no_interaction	Olmesartan medoxomil__gp100__no_interaction	Olmesartan medoxomil__GM-CSF__no_interaction	Olmesartan medoxomil__Parathyroid hormone__no_interaction	Bosentan__CA9__no_interaction	Bosentan__gp100__no_interaction	Bosentan__GM-CSF__no_interaction	Bosentan__Parathyroid hormone__no_interaction	Dipyridamole__CA9__no_interaction	Dipyridamole__gp100__no_interaction	Dipyridamole__GM-CSF__no_interaction	Dipyridamole__Parathyroid hormone__no_interaction	Tadalafil__CA9__no_interaction	Tadalafil__gp100__no_interaction	Tadalafil__GM-CSF__no_interaction	Tadalafil__Parathyroid hormone__no_interaction	Vardenafil hydrochloride hydrate__CA9__no_interaction	Vardenafil hydrochloride hydrate__gp100__no_interaction	Vardenafil hydrochloride hydrate__GM-CSF__no_interaction	Vardenafil hydrochloride hydrate__Parathyroid hormone__no_interaction	Satraplatin__CA9__no_interaction	Satraplatin__gp100__no_interaction	Satraplatin__GM-CSF__no_interaction	Satraplatin__Parathyroid hormone__no_interaction	90Y__CA9__no_interaction	90Y__gp100__no_interaction	90Y__GM-CSF__no_interaction	90Y__Parathyroid hormone__no_interaction	Tiotropium bromide__CA9__no_interaction	Tiotropium bromide__gp100__no_interaction	Tiotropium bromide__GM-CSF__no_interaction	Tiotropium bromide__Parathyroid hormone__no_interaction	HepB__CA9__no_interaction	HepB__gp100__no_interaction	HepB__GM-CSF__no_interaction	HepB__Parathyroid hormone__no_interaction	Ramelteon__CA9__no_interaction	Ramelteon__gp100__no_interaction	Ramelteon__GM-CSF__no_interaction	Ramelteon__Parathyroid hormone__no_interaction	Vatalanib__CA9__no_interaction	Vatalanib__gp100__no_interaction	Vatalanib__GM-CSF__no_interaction	Vatalanib__Parathyroid hormone__no_interaction	VX-680__CA9__no_interaction	VX-680__gp100__no_interaction	VX-680__GM-CSF__no_interaction	VX-680__Parathyroid hormone__no_interaction	Arformoterol tartrate__CA9__no_interaction	Arformoterol tartrate__gp100__no_interaction	Arformoterol tartrate__GM-CSF__no_interaction	Arformoterol tartrate__Parathyroid hormone__no_interaction	Pregabalin__CA9__no_interaction	Pregabalin__gp100__no_interaction	Pregabalin__GM-CSF__no_interaction	Pregabalin__Parathyroid hormone__no_interaction	Eszopiclone__CA9__no_interaction	Eszopiclone__gp100__no_interaction	Eszopiclone__GM-CSF__no_interaction	Eszopiclone__Parathyroid hormone__no_interaction	Azacitidine__CA9__no_interaction	Azacitidine__gp100__no_interaction	Azacitidine__GM-CSF__no_interaction	Azacitidine__Parathyroid hormone__no_interaction	Yttrium__CA9__no_interaction	Yttrium__gp100__no_interaction	Yttrium__GM-CSF__no_interaction	Yttrium__Parathyroid hormone__no_interaction	Prulifloxacin__CA9__no_interaction	Prulifloxacin__gp100__no_interaction	Prulifloxacin__GM-CSF__no_interaction	Prulifloxacin__Parathyroid hormone__no_interaction	Methylnaltrexone__CA9__no_interaction	Methylnaltrexone__gp100__no_interaction	Methylnaltrexone__GM-CSF__no_interaction	Methylnaltrexone__Parathyroid hormone__no_interaction	AZD-0530__CA9__no_interaction	AZD-0530__gp100__no_interaction	AZD-0530__GM-CSF__no_interaction	AZD-0530__Parathyroid hormone__no_interaction	SNDX-275__CA9__no_interaction	SNDX-275__gp100__no_interaction	SNDX-275__GM-CSF__no_interaction	SNDX-275__Parathyroid hormone__no_interaction	estradiol__CA9__no_interaction	estradiol__gp100__no_interaction	estradiol__GM-CSF__no_interaction	estradiol__Parathyroid hormone__no_interaction	Mepolizumab__CA9__no_interaction	Mepolizumab__gp100__no_interaction	Mepolizumab__GM-CSF__no_interaction	Mepolizumab__Parathyroid hormone__no_interaction	Cypher__CA9__no_interaction	Cypher__gp100__no_interaction	Cypher__GM-CSF__no_interaction	Cypher__Parathyroid hormone__no_interaction	Darunavir__CA9__no_interaction	Darunavir__gp100__no_interaction	Darunavir__GM-CSF__no_interaction	Darunavir__Parathyroid hormone__no_interaction	Lumiracoxib__CA9__no_interaction	Lumiracoxib__gp100__no_interaction	Lumiracoxib__GM-CSF__no_interaction	Lumiracoxib__Parathyroid hormone__no_interaction	BLP__CA9__no_interaction	BLP__gp100__no_interaction	BLP__GM-CSF__no_interaction	BLP__Parathyroid hormone__no_interaction	Voriconazole__CA9__no_interaction	Voriconazole__gp100__no_interaction	Voriconazole__GM-CSF__no_interaction	Voriconazole__Parathyroid hormone__no_interaction	Pazopanib hydrochloride__CA9__no_interaction	Pazopanib hydrochloride__gp100__no_interaction	Pazopanib hydrochloride__GM-CSF__no_interaction	Pazopanib hydrochloride__Parathyroid hormone__no_interaction	Caspofungin acetate__CA9__no_interaction	Caspofungin acetate__gp100__no_interaction	Caspofungin acetate__GM-CSF__no_interaction	Caspofungin acetate__Parathyroid hormone__no_interaction	Decitabine__CA9__no_interaction	Decitabine__gp100__no_interaction	Decitabine__GM-CSF__no_interaction	Decitabine__Parathyroid hormone__no_interaction	Escitalopram oxalate__CA9__no_interaction	Escitalopram oxalate__gp100__no_interaction	Escitalopram oxalate__GM-CSF__no_interaction	Escitalopram oxalate__Parathyroid hormone__no_interaction	Progesterone caproate__CA9__no_interaction	Progesterone caproate__gp100__no_interaction	Progesterone caproate__GM-CSF__no_interaction	Progesterone caproate__Parathyroid hormone__no_interaction	Curcumin__CA9__no_interaction	Curcumin__gp100__no_interaction	Curcumin__GM-CSF__no_interaction	Curcumin__Parathyroid hormone__no_interaction	succinate__CA9__no_interaction	succinate__gp100__no_interaction	succinate__GM-CSF__no_interaction	succinate__Parathyroid hormone__no_interaction	Alvimopan hydrate__CA9__no_interaction	Alvimopan hydrate__gp100__no_interaction	Alvimopan hydrate__GM-CSF__no_interaction	Alvimopan hydrate__Parathyroid hormone__no_interaction	188Re__CA9__no_interaction	188Re__gp100__no_interaction	188Re__GM-CSF__no_interaction	188Re__Parathyroid hormone__no_interaction	Fosaprepitant dimeglumine__CA9__no_interaction	Fosaprepitant dimeglumine__gp100__no_interaction	Fosaprepitant dimeglumine__GM-CSF__no_interaction	Fosaprepitant dimeglumine__Parathyroid hormone__no_interaction	Abiraterone acetate__CA9__no_interaction	Abiraterone acetate__gp100__no_interaction	Abiraterone acetate__GM-CSF__no_interaction	Abiraterone acetate__Parathyroid hormone__no_interaction	Amrubicin__CA9__no_interaction	Amrubicin__gp100__no_interaction	Amrubicin__GM-CSF__no_interaction	Amrubicin__Parathyroid hormone__no_interaction	Mycophenolic acid__CA9__no_interaction	Mycophenolic acid__gp100__no_interaction	Mycophenolic acid__GM-CSF__no_interaction	Mycophenolic acid__Parathyroid hormone__no_interaction	Gimatecan__CA9__no_interaction	Gimatecan__gp100__no_interaction	Gimatecan__GM-CSF__no_interaction	Gimatecan__Parathyroid hormone__no_interaction	Reparixin__CA9__no_interaction	Reparixin__gp100__no_interaction	Reparixin__GM-CSF__no_interaction	Reparixin__Parathyroid hormone__no_interaction	Myristyl nicotinate__CA9__no_interaction	Myristyl nicotinate__gp100__no_interaction	Myristyl nicotinate__GM-CSF__no_interaction	Myristyl nicotinate__Parathyroid hormone__no_interaction	Lopinavir/ritonavir__CA9__no_interaction	Lopinavir/ritonavir__gp100__no_interaction	Lopinavir/ritonavir__GM-CSF__no_interaction	Lopinavir/ritonavir__Parathyroid hormone__no_interaction	bromide__CA9__no_interaction	bromide__gp100__no_interaction	bromide__GM-CSF__no_interaction	bromide__Parathyroid hormone__no_interaction	Celgosivir__CA9__no_interaction	Celgosivir__gp100__no_interaction	Celgosivir__GM-CSF__no_interaction	Celgosivir__Parathyroid hormone__no_interaction	Deforolimus__CA9__no_interaction	Deforolimus__gp100__no_interaction	Deforolimus__GM-CSF__no_interaction	Deforolimus__Parathyroid hormone__no_interaction	Pemetrexed disodium__CA9__no_interaction	Pemetrexed disodium__gp100__no_interaction	Pemetrexed disodium__GM-CSF__no_interaction	Pemetrexed disodium__Parathyroid hormone__no_interaction	Imatinib mesylate__CA9__no_interaction	Imatinib mesylate__gp100__no_interaction	Imatinib mesylate__GM-CSF__no_interaction	Imatinib mesylate__Parathyroid hormone__no_interaction	Mitiglinide calcium hydrate__CA9__no_interaction	Mitiglinide calcium hydrate__gp100__no_interaction	Mitiglinide calcium hydrate__GM-CSF__no_interaction	Mitiglinide calcium hydrate__Parathyroid hormone__no_interaction	Posaconazole__CA9__no_interaction	Posaconazole__gp100__no_interaction	Posaconazole__GM-CSF__no_interaction	Posaconazole__Parathyroid hormone__no_interaction	Bremelanotide__CA9__no_interaction	Bremelanotide__gp100__no_interaction	Bremelanotide__GM-CSF__no_interaction	Bremelanotide__Parathyroid hormone__no_interaction	Rosuvastatin calcium__CA9__no_interaction	Rosuvastatin calcium__gp100__no_interaction	Rosuvastatin calcium__GM-CSF__no_interaction	Rosuvastatin calcium__Parathyroid hormone__no_interaction	Oblimersen sodium__CA9__no_interaction	Oblimersen sodium__gp100__no_interaction	Oblimersen sodium__GM-CSF__no_interaction	Oblimersen sodium__Parathyroid hormone__no_interaction	Canertinib dihydrochloride__CA9__no_interaction	Canertinib dihydrochloride__gp100__no_interaction	Canertinib dihydrochloride__GM-CSF__no_interaction	Canertinib dihydrochloride__Parathyroid hormone__no_interaction	Duloxetine__CA9__no_interaction	Duloxetine__gp100__no_interaction	Duloxetine__GM-CSF__no_interaction	Duloxetine__Parathyroid hormone__no_interaction	Pimecrolimus__CA9__no_interaction	Pimecrolimus__gp100__no_interaction	Pimecrolimus__GM-CSF__no_interaction	Pimecrolimus__Parathyroid hormone__no_interaction	Tanespimycin__CA9__no_interaction	Tanespimycin__gp100__no_interaction	Tanespimycin__GM-CSF__no_interaction	Tanespimycin__Parathyroid hormone__no_interaction	Talnetant__CA9__no_interaction	Talnetant__gp100__no_interaction	Talnetant__GM-CSF__no_interaction	Talnetant__Parathyroid hormone__no_interaction	Ghrelin__CA9__no_interaction	Ghrelin__gp100__no_interaction	Ghrelin__GM-CSF__no_interaction	Ghrelin__Parathyroid hormone__no_interaction	hydrochlorothiazide__CA9__no_interaction	hydrochlorothiazide__gp100__no_interaction	hydrochlorothiazide__GM-CSF__no_interaction	hydrochlorothiazide__Parathyroid hormone__no_interaction	Telmisartan__CA9__no_interaction	Telmisartan__gp100__no_interaction	Telmisartan__GM-CSF__no_interaction	Telmisartan__Parathyroid hormone__no_interaction	Solifenacin succinate__CA9__no_interaction	Solifenacin succinate__gp100__no_interaction	Solifenacin succinate__GM-CSF__no_interaction	Solifenacin succinate__Parathyroid hormone__no_interaction	Erlotinib__CA9__no_interaction	Erlotinib__gp100__no_interaction	Erlotinib__GM-CSF__no_interaction	Erlotinib__Parathyroid hormone__no_interaction	LA-419__CA9__no_interaction	LA-419__gp100__no_interaction	LA-419__GM-CSF__no_interaction	LA-419__Parathyroid hormone__no_interaction	Trimethoprim__CA9__no_interaction	Trimethoprim__gp100__no_interaction	Trimethoprim__GM-CSF__no_interaction	Trimethoprim__Parathyroid hormone__no_interaction	Laropiprant__CA9__no_interaction	Laropiprant__gp100__no_interaction	Laropiprant__GM-CSF__no_interaction	Laropiprant__Parathyroid hormone__no_interaction	Biapenem__CA9__no_interaction	Biapenem__gp100__no_interaction	Biapenem__GM-CSF__no_interaction	Biapenem__Parathyroid hormone__no_interaction	Palonosetron hydrochloride__CA9__no_interaction	Palonosetron hydrochloride__gp100__no_interaction	Palonosetron hydrochloride__GM-CSF__no_interaction	Palonosetron hydrochloride__Parathyroid hormone__no_interaction	lamivudine__CA9__no_interaction	lamivudine__gp100__no_interaction	lamivudine__GM-CSF__no_interaction	lamivudine__Parathyroid hormone__no_interaction	Carboxyamidotriazole__CA9__no_interaction	Carboxyamidotriazole__gp100__no_interaction	Carboxyamidotriazole__GM-CSF__no_interaction	Carboxyamidotriazole__Parathyroid hormone__no_interaction	entacapone__CA9__no_interaction	entacapone__gp100__no_interaction	entacapone__GM-CSF__no_interaction	entacapone__Parathyroid hormone__no_interaction	Apomab__CA9__no_interaction	Apomab__gp100__no_interaction	Apomab__GM-CSF__no_interaction	Apomab__Parathyroid hormone__no_interaction	Ofatumumab__CA9__no_interaction	Ofatumumab__gp100__no_interaction	Ofatumumab__GM-CSF__no_interaction	Ofatumumab__Parathyroid hormone__no_interaction	AI__CA9__no_interaction	AI__gp100__no_interaction	AI__GM-CSF__no_interaction	AI__Parathyroid hormone__no_interaction	Aripiprazole__CA9__no_interaction	Aripiprazole__gp100__no_interaction	Aripiprazole__GM-CSF__no_interaction	Aripiprazole__Parathyroid hormone__no_interaction	Lidocaine/prilocaine__CA9__no_interaction	Lidocaine/prilocaine__gp100__no_interaction	Lidocaine/prilocaine__GM-CSF__no_interaction	Lidocaine/prilocaine__Parathyroid hormone__no_interaction	ibritumomab tiuxetan__CA9__no_interaction	ibritumomab tiuxetan__gp100__no_interaction	ibritumomab tiuxetan__GM-CSF__no_interaction	ibritumomab tiuxetan__Parathyroid hormone__no_interaction	Vinflunine__CA9__no_interaction	Vinflunine__gp100__no_interaction	Vinflunine__GM-CSF__no_interaction	Vinflunine__Parathyroid hormone__no_interaction	Bortezomib__CA9__no_interaction	Bortezomib__gp100__no_interaction	Bortezomib__GM-CSF__no_interaction	Bortezomib__Parathyroid hormone__no_interaction	Abacavir sulfate__CA9__no_interaction	Abacavir sulfate__gp100__no_interaction	Abacavir sulfate__GM-CSF__no_interaction	Abacavir sulfate__Parathyroid hormone__no_interaction	Emtricitabine__CA9__no_interaction	Emtricitabine__gp100__no_interaction	Emtricitabine__GM-CSF__no_interaction	Emtricitabine__Parathyroid hormone__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__CA9__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__gp100__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__GM-CSF__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__Parathyroid hormone__no_interaction
12895207-5	RESULTS: There was no significant difference observed in the allelic and genotypic distribution between the BPAD and control groups for cPLA2 (genotype: chi2 = 0.8, 2df, p = 0.6; allele chi2 = 0, <compound-id="15527939">1df</compound-id>, p = 0.9), <protein-id="O60733,B7Z6K3,A8K460">iPLA2</protein-id> (genotype: chi2 = 1.7, 2df, p = 0.4; allele: chi2 = 0.3, <compound-id="15527939">1df</compound-id>, p = 0.6), and <protein-id="P14555,A0A024RA96">sPLA2</protein-id> (allele: chi2 = 3.6, 6df, p = 0.8).	1df__sPLA2__no_interaction	1df__iPLA2__no_interaction
15319344-0	In vitro metabolism of <compound-id="151183">MK-0767</compound-id> [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-<compound-id="14114096">2-methoxy</compound-id>-N-[[(4-<compound-id="6373">trifluoromethyl</compound-id>) phenyl]methyl]<compound-id="2331">benzamide</compound-id>], a <protein-id="Q07869,F1D8S4">peroxisome proliferator-activated receptor alpha</protein-id>/gamma agonist. I. Role of cytochrome P450, methyltransferases, <compound-id="2016">flavin</compound-id> monooxygenases, and esterases.	2-methoxy__peroxisome proliferator-activated receptor alpha__no_interaction	flavin__peroxisome proliferator-activated receptor alpha__no_interaction	trifluoromethyl__peroxisome proliferator-activated receptor alpha__no_interaction	MK-0767__peroxisome proliferator-activated receptor alpha__no_interaction	benzamide__peroxisome proliferator-activated receptor alpha__no_interaction
15962959-1	The 1H NMR spectra of <compound-id="23925,67172434">iron</compound-id>(III) 5-ethynyl-10,15,20-tri(p-tolyl)porphyrin [(ETrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5-(phenylethynyl)-10,15,20-tri(p-tolyl)porphyrin [(PETrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5-(<compound-id="11355482">phenylbutadiynyl</compound-id>)-10,15,20-tri(p-tolyl)porphyrin [(PBTrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5,10,15,20-tetra(phenylethynyl)porphyrin [(TPEP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 1,4-bis-[10,15,20-tri(p-tolyl)porphyrin-5-yl]-1,3-<compound-id="9997">butadiyne</compound-id> {[(TrTP)Fe(III)X(n)]2 B}, and <compound-id="70653959">5,10,15-triphenylporphyrin</compound-id> [(TrPP)Fe(III)X(n)] have been studied to elucidate the impact of meso-ethynyl substitution on the electronic structure and <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> density distribution of high-<protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> (X = Cl-, n = 1) and low-<protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> (X = CN-, n = 2) derivatives.	5,10,15-triphenylporphyrin__spin__no_interaction	butadiyne__spin__no_interaction	iron__spin__no_interaction	phenylbutadiynyl__spin__no_interaction
17967187-4	RESULTS: Serum <compound-id="5950">alanine</compound-id> aminotransferase (ALT) and <protein-id="Q9NRA2">aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) were associated with <protein-id="P01308,I3WAC9">insulin</protein-id> resistance in univariate analysis (R = 0.54, p &lt; 0.0001 and R = 0.36, p = 0.001, respectively) and after adjustment for age, gender and waist circumference (partial R = 0.43, p = 0.0001 and partial R = 0.37, p = 0.001, respectively).	alanine__insulin__no_interaction	alanine__aspartate aminotransferase__no_interaction	alanine__AST__no_interaction
16580903-6	RESULTS: Oral <compound-id="4192">midazolam</compound-id> clearance decreased after pretreatment with <compound-id="3823,456201,47576,5702077">ketoconazole</compound-id> (from a geometric mean of 25 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 12-57 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)] to 2.7 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 1.2-8.5 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)], P &lt; .001) and increased after pretreatment with <compound-id="24871024,25141428,5381226,5458213,5702112,57032154,6243627,6913622">rifampin</compound-id> (to a geometric mean of 203 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 125-371 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)], P &lt; .001).	rifampin__min(-1__no_interaction	midazolam__min(-1__no_interaction	ketoconazole__min(-1__no_interaction
23801867-10	Compared with the conventional group, <compound-id="5469318">FTS</compound-id> shortened the duration of flatus (79.03 ± 20.26 h vs 60.97 ± 24.40 h, P = 0.000) and duration of defecation (93.03 ± 27.95 h vs 68.00 ± 25.42 h, P = 0.000), accelerated the decrease in white blood cell count [P &lt; 0.05 on postoperative day (POD) 3 and 4], alleviated pain in patients after surgery (P &lt; 0.05 on <protein-id="O43680">POD 1, 2 and 3</protein-id>), reduced complications (P &lt; 0.05), shortened the duration of postoperative stay (7.10 ± 2.13 d vs 5.68 ± 1.22 d, P = 0.000), reduced the cost of hospitalization (43783.25 ± 8102.36 <compound-id="446491">RMB</compound-id> vs 39597.62 ± 7529.98 <compound-id="446491">RMB</compound-id>, P = 0.005), and promoted recovery of patients.	RMB__POD 1, 2 and 3__no_interaction	FTS__POD 1, 2 and 3__no_interaction
9727056-3	Using murine osteoclast-like cells (OCLs) or their mononuclear precursors (pOCs), generated in a coculture of bone marrow and osteoblastic MB1.8 cells, we show: (a) <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> upon ligation of beta3 integrins or adhesion of pOCs to serum, <protein-id="P29788">vitronectin</protein-id>, <protein-id="P10923,Q547B5,F8WIP8,Q3UBR1">osteopontin</protein-id>, or <protein-id="P11276,B9EHT6,A0A087WR50,A0A087WSN6,Q3UHL6,B7ZNJ1,Q3UZF9,Q3UGY5,Q3UHR1,A0A087WS56,Q3UH17,Q3TBB4">fibronectin</protein-id> but not to <compound-id="44342165">laminin</compound-id> or collagen; (b) coimmunoprecipitation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> and c-Src from OCLs; (c) <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> binding to the SH2 domains of Src; (d) marked reduction in <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation and kinase activity of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> in OCLs derived from Src (-/-) mice, which do not form actin rings and do not resorb bone; (e) <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> phosphorylation by exogeneous c-Src; (f) translocation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> to the <compound-id="5590">Triton X-100</compound-id> insoluble cytoskeletal fraction upon adhesion; (g) localization of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> in podosomes and the ring-like structures in OCLs plated on glass and in the sealing zone in OCLs plated on bone; and (h) activation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id>, in the presence of MB1.8 cells, parallels the formation of sealing zones and pit resorption in vitro and is reduced by echistatin or calcitonin and <compound-id="24978555,30956,5458428,5476249,60159013,6433799,71308181,71308557,71699760,90479773">cytochalasin D</compound-id>. Taken together, these findings suggest that Src-dependent <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> is involved in the adhesion-induced formation of the sealing zone, required for osteoclastic bone resorption.	Triton X-100__osteopontin__no_interaction	Triton X-100__fibronectin__no_interaction	Triton X-100__vitronectin__no_interaction	Triton X-100__PYK2__no_interaction	laminin__osteopontin__no_interaction	laminin__fibronectin__no_interaction	laminin__vitronectin__no_interaction	laminin__PYK2__no_interaction	cytochalasin D__osteopontin__no_interaction	cytochalasin D__fibronectin__no_interaction	cytochalasin D__vitronectin__no_interaction	cytochalasin D__PYK2__no_interaction	tyrosine__osteopontin__no_interaction	tyrosine__fibronectin__no_interaction	tyrosine__vitronectin__no_interaction	tyrosine__PYK2__no_interaction
7657737-4	The mean (+/- SD) age (34.01 +/- 4.42 versus 34.81 +/- 4.00 years), mean total dosage of HMG (61.25 +/- 26.87 versus 56.17 +/- 25.18 ampoules), mean daily dosage of HMG (4.74 versus 4.94 ampoules), duration of HMG stimulation (12.91 +/- 3.68 versus 11.31 +/- 3.46 days) and <compound-id="5757">oestradiol</compound-id> concentration on the day of <protein-id="P01215,Q6I9S8,A0A087WYZ4">HCG</protein-id> (10,082 +/- 8007 versus 9440 +/- 7840 pmol/l) were similar in both groups but the mean total number of injections (GnRH and HMG) (13.55 +/- 3.35 versus 55.37 +/- 31.92) was significantly lower in group I.	oestradiol__HCG__no_interaction
12679161-5	RESULTS: Plasma Se (microg/L) levels were 47.11 +/- 11.61 in sg 1, 38.69 +/- 13.22 in sg 2, 43.53 +/- 11.73 in <protein-id="Q86UP2,A0A024R663">cg 1</protein-id>, and 48.71 +/- 9.39 in <protein-id="Q9H330">cg 2</protein-id>; plasma <compound-id="124886">GSH</compound-id>-Px (U/mL) levels, were 0.15 +/- 0.04, 0.14 +/- 0.04, 0.16 +/- 0.04, and 0.18 +/- 0.03, respectively; and erythrocyte <compound-id="124886">GSH</compound-id>-Px (U/g of hemoglobin) levels were 13.97 +/- 4.27, 13.16 +/- 3.85, 14.25 +/- 3.84, and 14.35 +/- 3.35, respectively.	GSH__cg 2__no_interaction	GSH__cg 1__no_interaction
16207394-4	The measured parameters included forced vital capacity (FVC), forced expiratory volume in one second (FEV(1)), FEV(1)/FVC, maximal ventilatory volume (MVV), residual volume (RV), total lung capacity (TLC), RV/TLC, inspiratory capacity (IC), thoracic gas volume (TGV), peak expiratory flow (PEF), total airway resistance (R(aw)total), diffusion capacity for CO of lung (D(L)CO), diffusion capacity for CO of lung/alveolar volume (D(L)CO/V(A)), 6 minute walk distance (6MWD), partial pressure of <compound-id="977">oxygen</compound-id> in arterial blood (PaO(2)), alveolar-artery <compound-id="977">oxygen</compound-id> gradient [P((A-a))O(2)], <compound-id="977">oxygen</compound-id> saturation in arterial blood (SaO(2)), partial pressure of <compound-id="280">carbon dioxide</compound-id> in arterial blood (PaCO(2)) and mean pulmonary arterial pressure (<protein-id="Q9QWY8,E9QMJ1,H3BKE6,H3BL41,Q3TXY1,Q3UJA5">mPAP</protein-id>).	carbon dioxide__mPAP__no_interaction	oxygen__mPAP__no_interaction
8548495-4	The individual values of the <protein-id="P38646">CSA</protein-id> of the left and right quadriceps femoris (QF) correlated (p &lt; .05-.001) with the individual values of maximal unilateral knee extension forces in M50 (r = .87 and r = .87), M70 (r = .61 and r = .80), W50 (r = .79 and r = .58), and <compound-id="73010356">W70</compound-id> (r = .56 and r = .54).	W70__CSA__no_interaction
20486179-6	RESULTS: At baseline, there was stronger correlation between sTfR and markers of hemolysis and erythropoietic drive, including hemoglobin (Spearman's r = -0.67, P &lt; or = 0.001) and reticulocyte count (Spearman's r = 0.59, P &lt; or = 0.001), than with markers of <compound-id="23925,67172434">iron</compound-id> metabolism, such as <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (TS; Spearman's r = 0.33, P = 0.02) and ferritin (Spearman's r = 0.17, P = 0.26).	iron__transferrin__no_interaction
12924877-4	Specifically, several new monoanionic <protein-id="O95817">Bis</protein-id>(<compound-id="139579">phosphino</compound-id>)borates are detailed: [Ph(2)B(CH(2)PPh(2))(2)] (25); [(p-MePh)(2)B(CH(2)PPh(2))(2)] (26); [(p-(t)BuPh)(2)B(CH(2)PPh(2))(2)] (27); [(p-MeOPh)(2)B(CH(2)PPh(2))(2)] (28); [(p-CF(3)Ph)(2)B(CH(2)PPh(2))(2)] (29); [Cy(2)B(CH(2)PPh(2))(2)] (30); [Ph(2)B(CH(2)P[p-(t)BuPh](2))(2)] (31); [(p-MeOPh)(2)B(CH(2)P[p-(t)BuPh](2))(2)] (32); [Ph(2)B(CH(2)P[p-CF(3)Ph](2))(2)] (33); [Ph(2)B(CH(2)P(BH(3))(Me)(2))(2)] (34); [Ph(2)B(CH(2)P(S)(Me)(2))(2)] (35); [Ph(2)B(CH(2)P(i)Pr(2))(2)] (36); [Ph(2)B(CH(2)P(t)Bu(2))(2)] (37); [(m,m-Me(2)Ph)(2)B(CH(2)P(t)Bu(2))(2)] (38).	phosphino__Bis__no_interaction
9061303-4	Suppression of <protein-id="P01308,I3WAC9">C-peptide</protein-id> during low-dose [2 pmol kg-1 min-1 (20 mU kg-1 h-1) for 90 min, plasma insulin approximately 120 pmol L-1 (20 mUL-1)] and high-dose [8 pmol kg-1 h-1 (80 mU kg-1 h-1) for 90 min, plasma insulin approximately 450 pmol L-1 (75 mU L-1)] insulin infusion under euglycaemic conditions [plasma <compound-id="206,5793,64689,79025">glucose</compound-id> 4.4-5.0 mmol L-1 (80-90 mg dL-1)] and during high-dose insulin infusion under hypoglycaemic conditions [<compound-id="206,5793,64689,79025">glucose</compound-id> 2-2.2 mmol L-1 (40-45 mg dL-1)] was evaluated by radioimmunoassay (RIA).	glucose__C-peptide__no_interaction
22976988-1	The acidity constants of twofold protonated, antivirally active, acyclic nucleoside phosphonates (ANPs), H(2)(PE)(±), where PE(2-)=<compound-id="60172">9-[2-(phosphonomethoxy)ethyl]adenine</compound-id> (PMEA(2-)), <compound-id="451477">2-amino-9-[2-(phosphonomethoxy)ethyl]purine</compound-id> (PME2AP(2-)), 2,6-<compound-id="76988">diamino</compound-id>-9-[2-(<compound-id="53689411">phosphonomethoxy</compound-id>)<compound-id="23134249">ethyl</compound-id>]purine (<compound-id="64988">PMEDAP</compound-id>(2-)), or 2-amino-6-(dimethylamino)-9-[2-(<compound-id="53689411">phosphonomethoxy</compound-id>)<compound-id="23134249">ethyl</compound-id>]purine (PME(2A6DMAP)(2-)), as well as the stability constants of the corresponding ternary Cu(<protein-id="P14550,V9HWI0">Arm</protein-id>)(H;PE)(+) and Cu(<protein-id="P14550,V9HWI0">Arm</protein-id>)(PE) complexes, where <protein-id="Q9UK76">Arm=2</protein-id>,2'-bipyridine (bpy) or 1,10-<compound-id="67473">phenanthroline</compound-id> (phen), are compared.	phosphonomethoxy__Arm=2__no_interaction	phosphonomethoxy__Arm__no_interaction	phenanthroline__Arm=2__no_interaction	phenanthroline__Arm__no_interaction	diamino__Arm=2__no_interaction	diamino__Arm__no_interaction	2-amino-9-[2-(phosphonomethoxy)ethyl]purine__Arm=2__no_interaction	2-amino-9-[2-(phosphonomethoxy)ethyl]purine__Arm__no_interaction	PMEDAP__Arm=2__no_interaction	PMEDAP__Arm__no_interaction	9-[2-(phosphonomethoxy)ethyl]adenine__Arm=2__no_interaction	9-[2-(phosphonomethoxy)ethyl]adenine__Arm__no_interaction	ethyl__Arm=2__no_interaction	ethyl__Arm__no_interaction
19050789-3	In the 1 : 1 molar ratio reactions, single C-O bond cleavage occurs, resulting in formation of alkyl <compound-id="312">chloride</compound-id> and of the complexes [upper bond 1 start]<protein-id="P07954">MCl</protein-id>(4)[O(R)CH(R')CH(2)O][upper bond 1 end] [M = Nb, R = Me, R' = H, <compound-id="2981881,91293124">3a</compound-id>; M = Ta, R = Me, R' = H, 3b; M = Nb, R = Et, R' = H, 5; M = Nb, R = R' = Me, 6; M = Nb, R = CH(2)Cl, R' = H, 7; M = Nb, R = (CH(2))(2)O(Me)NbCl(5), R' = H, 8], which have been characterized spectroscopically.	3a__MCl__no_interaction	chloride__MCl__no_interaction
20839916-5	In univariate analysis, <protein-id="Q15848,A8K660,B2R773">Adiponectin</protein-id> was inversely associated with <compound-id="447041">IMT</compound-id> (r = -0.16, P &lt; 0.0001) and directly with FMD (r = 0.12, P &lt; 0.0001) and carotid elasticity (r = 0.20, P &lt; 0.0001).	IMT__Adiponectin__no_interaction
12577838-3	RESULTS: <compound-id="3157">Tonocardin</compound-id> treatment lowered systolic BP (from 159 +/- 19.83 to 136.57 +/- 17.43 mm Hg; by 14.5%), diastolic BP (from 93.38 +/- 12.98 to 79.12 +/- 11.69 mm Hg; by 15.28%), fasting glycemia (from 9.32 +/- 1.61 to 7.05 +/- 1.51 mmole/l; by 24.36%), glycosylated hemoglobin <compound-id="15942654">Ai</compound-id> (from 9.63 +/- 1.86 to 8.59 +/- 0.98%; by 10.8%), total <compound-id="5997">cholesterol</compound-id> (from 6.09 +/- 0.57 to 5.4 +/- 0.4 mmole/l; by 11.4%), triglycerides (from 2.11 +/- 0.57 to 1.88 +/- 0.52 mmole/l; by 11%), glycemia after 30-min <protein-id="P01308,I3WAC9">insulin</protein-id> load (from 9.32 +/- 1.61 to 5.77 +/- 1.57; by 39% and from 7.05 +/- 1.51 to 4.2 +/- 1.25 mmole/l; by 44% at the beginning and end of the follow-up, respectively), <protein-id="P01308,I3WAC9">insulin</protein-id> resistance index (from 9.87 +/- 2.45 to 6.57 +/- 1.99; by 33.5%).	Ai__insulin__no_interaction	Tonocardin__insulin__no_interaction	cholesterol__insulin__no_interaction
15319815-3	This issue focuses on the following selection of drugs: <compound-id="3081349">101M</compound-id>; Adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, <compound-id="57476835,60961">adenosine</compound-id> triphosphate, albumin <compound-id="1345">interferon alfa</compound-id>, alefacept, alemtuzumab, <compound-id="6433083">aminolevulinic acid hexyl ester</compound-id>, autologous renal tumor vaccine, <compound-id="9571004">azimilide hydrochloride</compound-id>; <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, <protein-id="O14625">BR-1</protein-id>; C340, cantuzumab <compound-id="71301226">mertansine</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">caspofungin acetate</compound-id>, CGP-36742, CHAMPION everolimus-eluting coronary stent, <compound-id="9962928">cypher</compound-id>; Dalbavancin, darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>, <compound-id="6918296">dutasteride</compound-id>; Efalizumab, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="219078">erlosamide</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, everolimus, <compound-id="150311">ezetimibe</compound-id>; <compound-id="57347">Flesinoxan hydrochloride</compound-id>, <compound-id="131536">fosamprenavir calcium</compound-id>, <compound-id="5352062">FR-901228</compound-id>, <compound-id="77992">frovatriptan</compound-id>; <compound-id="9919137">Gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, gadomer-17, galiximab, gamma-hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">gefitinib</compound-id>; HuOKT3gamma1(Ala234-Ala235); <compound-id="12000240">IDN-6556</compound-id>, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="807">iodine</compound-id> (I131) tositumomab, <compound-id="16131103">iseganan hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; Keratinocyte growth factor; <compound-id="6480442">LB-80380</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, <compound-id="16760536,6917907">LMB</compound-id>-9, <compound-id="92727">lopinavir</compound-id>, <compound-id="92727">lopinavir</compound-id>/<compound-id="392622">ritonavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>, <compound-id="60956">lurtotecan</compound-id>; Mecasermin, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="5288826">morphine hydrochloride</compound-id>; Natalizumab, <compound-id="64143">nelfinavir</compound-id>, nesiritide, <compound-id="53232">niacin/lovastatin</compound-id>; <compound-id="6918509">Olcegepant</compound-id>, omalizumab, oregovomab; <compound-id="119828">Parecoxib sodium</compound-id>, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ <compound-id="37542">ribavirin</compound-id>, <compound-id="115368">perospirone</compound-id> hydrochloride, pexelizumab, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="466151">prinomastat</compound-id>; <compound-id="159603">Resiquimod</compound-id>, rhIGFBP-3, rhIGF-I/rhIGFBP-3, <compound-id="5074">ritanserin</compound-id>, ro-31-7453, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">rosuvastatin calcium</compound-id>; <compound-id="9871074">SCIO-469</compound-id>, <compound-id="65015">SDZ-SID-791</compound-id>, SU-11248, <compound-id="5311">suberanilohydroxamic acid</compound-id>; <compound-id="110635">Tadalafil</compound-id>, taxus, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, TER-286, <compound-id="151174">tezosentan disodium</compound-id>, TH-9507, <compound-id="159324">tipifarnib</compound-id>, <compound-id="54682461">tipranavir</compound-id>, <compound-id="216237">tolvaptan</compound-id>, <compound-id="33741">tramadol hydrochloride</compound-id>/<compound-id="1983">acetaminophen</compound-id>, <compound-id="5282226">travoprost</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>, <compound-id="55223">tucaresol</compound-id>; <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="6918726">val-mCyd</compound-id>, <compound-id="110634">vardenafil hydrochloride hydrate</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>, <compound-id="71616">voriconazole</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>, XTL-002; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>.	tramadol hydrochloride__BR-1__no_interaction	vinflunine__BR-1__no_interaction	erlosamide__BR-1__no_interaction	iodine__BR-1__no_interaction	voriconazole__BR-1__no_interaction	SDZ-SID-791__BR-1__no_interaction	ertapenem sodium__BR-1__no_interaction	90Y__BR-1__no_interaction	travoprost__BR-1__no_interaction	val-mCyd__BR-1__no_interaction	bosentan__BR-1__no_interaction	perospirone__BR-1__no_interaction	midostaurin__BR-1__no_interaction	Valganciclovir hydrochloride__BR-1__no_interaction	ribavirin__BR-1__no_interaction	FR-901228__BR-1__no_interaction	interferon alfa__BR-1__no_interaction	morphine hydrochloride__BR-1__no_interaction	IDN-6556__BR-1__no_interaction	pimecrolimus__BR-1__no_interaction	frovatriptan__BR-1__no_interaction	sodium__BR-1__no_interaction	desloratadine__BR-1__no_interaction	tezosentan disodium__BR-1__no_interaction	SCIO-469__BR-1__no_interaction	dutasteride__BR-1__no_interaction	suberanilohydroxamic acid__BR-1__no_interaction	acetaminophen__BR-1__no_interaction	azimilide hydrochloride__BR-1__no_interaction	aminolevulinic acid hexyl ester__BR-1__no_interaction	vardenafil hydrochloride hydrate__BR-1__no_interaction	enfuvirtide__BR-1__no_interaction	iseganan hydrochloride__BR-1__no_interaction	101M__BR-1__no_interaction	duloxetine hydrochloride__BR-1__no_interaction	mertansine__BR-1__no_interaction	tipifarnib__BR-1__no_interaction	tolvaptan__BR-1__no_interaction	lurtotecan__BR-1__no_interaction	Olcegepant__BR-1__no_interaction	emtricitabine__BR-1__no_interaction	Parecoxib sodium__BR-1__no_interaction	ritonavir__BR-1__no_interaction	gefitinib__BR-1__no_interaction	nelfinavir__BR-1__no_interaction	ezetimibe__BR-1__no_interaction	tipranavir__BR-1__no_interaction	ixabepilone__BR-1__no_interaction	Yttrium__BR-1__no_interaction	prinomastat__BR-1__no_interaction	ibritumomab tiuxetan__BR-1__no_interaction	niacin/lovastatin__BR-1__no_interaction	tucaresol__BR-1__no_interaction	treprostinil sodium__BR-1__no_interaction	imatinib mesylate__BR-1__no_interaction	Flesinoxan hydrochloride__BR-1__no_interaction	cypher__BR-1__no_interaction	Ximelagatran__BR-1__no_interaction	telithromycin__BR-1__no_interaction	Bortezomib__BR-1__no_interaction	lumiracoxib__BR-1__no_interaction	fosamprenavir calcium__BR-1__no_interaction	LB-80380__BR-1__no_interaction	tenofovir disoproxil fumarate__BR-1__no_interaction	levocetirizine__BR-1__no_interaction	doxorubicin__BR-1__no_interaction	adefovir dipivoxil__BR-1__no_interaction	rosuvastatin calcium__BR-1__no_interaction	Resiquimod__BR-1__no_interaction	caspofungin acetate__BR-1__no_interaction	adenosine__BR-1__no_interaction	lopinavir__BR-1__no_interaction	LMB__BR-1__no_interaction	Tadalafil__BR-1__no_interaction	Gadofosveset__BR-1__no_interaction	ritanserin__BR-1__no_interaction
16968464-11	Flow-mediated dilatation (FMD) was negatively related to hsCRP (r = -0.512, P = 0.015); <protein-id="P05305,Q6FH53">ET-1</protein-id> was positively related to free androgen index (r = 0.27, P = 0.05) and negatively to sex hormone-binding globulin (r = -0.465, P = 0.022); sVCAM-1 was positively related to total <compound-id="6013">testosterone</compound-id> (r = 0.431, P = 0.036); hsCRP was positively related to BMI (r = 0.647, P = 0.001), and negatively related to FMD (r = -0.512, P = 0.015), quantitative insulin sensitivity check index (QUICKI) (r = -0.499, P = 0.018), and MATSUDA index (r = -0.445, P = 0.038).	testosterone__ET-1__no_interaction
22791215-6	A binding preference for 9-ethylguanine (<compound-id="95189">9-EtG</compound-id>) compared with <compound-id="7">9-ethyladenine</compound-id> (9-<protein-id="P25101">EtA</protein-id>) was observed for [(η(6)-p-cym)Ru(bpm)Cl][PF(6)], [(η(6)-hmb)Ru(bpm)Cl](+), [(η(6)-ind)Ru(bpm)Cl](+), [(η(6)-thn)Ru(bpm)Cl](+), [(η(6)-p-cym)Ru(phen)Cl](+) and [(η(6)-p-cym)Ru(bathophen)Cl](+) in aqueous solution at 310 K. The X-ray crystal structure of the <compound-id="764">guanine</compound-id> complex [(η(6)-p-cym)Ru(bpm)(<compound-id="95189">9-EtG</compound-id>-N7)][PF(6)](2) shows multiple <compound-id="783">hydrogen</compound-id> bonding.	9-EtG__EtA__no_interaction	9-ethyladenine__EtA__no_interaction	hydrogen__EtA__no_interaction	guanine__EtA__no_interaction
22552303-1	Although it has not proved possible to crystallize the newly prepared <compound-id="64964">cyclam</compound-id>-methylimidazole ligand 1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id> (<protein-id="P48742,Q58F18">L(Im1</protein-id>)), the trans and cis isomers of an Ni(II) complex, namely trans-aqua{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>) <compound-id="1488787">monohydrate</compound-id>, [Ni(C(15)H(30)N(6))(H(2)O)](ClO(4))(2)·H(2)O, (1), and cis-aqua{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>), [Ni(C(15)H(30)N(6))(H(2)O)](ClO(4))(2), (2), have been prepared and structurally characterized.	nickel__L(Im1__no_interaction	monohydrate__L(Im1__no_interaction	1H-imidazol__L(Im1__no_interaction	perchlorate__L(Im1__no_interaction	cyclam__L(Im1__no_interaction	tetraazacyclotetradecane__L(Im1__no_interaction
22552303-2	At different stages of the crystallization and thermal treatment from which (1) and (2) were obtained, a further two compounds were isolated in crystalline form and their structures also analysed, namely trans-{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}(perchlorato)<compound-id="26158">nickel(II) perchlorate</compound-id>, [Ni(ClO(4))(C(15)H(30)N(6))]ClO(4), (3), and <protein-id="Q9NSE2">cis-{1,8</protein-id>-bis[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>) 0.24-hydrate, [Ni(C(20)H(36)N(6))](ClO(4))(2)·0.24H(2)O, (4); the 1,8-bis[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id> ligand is a minor side product, probably formed in trace amounts in the synthesis of <protein-id="P48742,Q58F18">L(Im1</protein-id>).	nickel__cis-{1,8__no_interaction	nickel__L(Im1__no_interaction	nickel(II) perchlorate__cis-{1,8__no_interaction	nickel(II) perchlorate__L(Im1__no_interaction	tetraazacyclotetradecane__cis-{1,8__no_interaction	tetraazacyclotetradecane__L(Im1__no_interaction	perchlorate__cis-{1,8__no_interaction	perchlorate__L(Im1__no_interaction	1H-imidazol__cis-{1,8__no_interaction	1H-imidazol__L(Im1__no_interaction
15978869-6	The visible absorption spectra of Mn2+:glasses have shown a broad absorption band at 520 nm (6A1g(S) --&gt; 4T1g(G)); with <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>+ ions one absorption band at 605 nm (<compound-id="25165666">4A2</compound-id>(4F) --&gt; 4T1(4P)) and another at 1450 nm (<compound-id="25165666">4A2</compound-id>(4F) --&gt; 4T1(4F)); and for Ni2+:glasses three absorption bands at 420 nm (3A2g(F) --&gt; 3T1g(P)), 805 nm (3A2g(F) --&gt; <compound-id="72206629">1Eg</compound-id>(D)) and 880 nm (3A2g(F) --&gt; 3T1g(F)) have been observed.	1Eg__Co2__no_interaction	4A2__Co2__no_interaction
10463859-3	These studies demonstrated that (i) the quiescent state is characterized by the absence of cell-associated virus, capsids, and viral antigens; (ii) HS (43 degrees C, 3 h) efficiently activated virus from quiescently infected Nd-PC12 (QIF-PC12) cells; (iii) the rate of virus production was significantly greater following HS than <compound-id="47936">forskolin</compound-id> treatment, and the rates of both were dependent on MOI; (iv) <compound-id="47936">forskolin</compound-id> and HS appeared to affect pathways of viral activation from a quiescent state as they did not enhance viral growth in Nd-PC12 cells; (v) viral alpha4 gene and host <protein-id="P0DMW0,P0DMW1">HSP72</protein-id> gene transcription were rapidly induced in QIF-PC12 as soon as 3 h post-HS initiation; (vi) induction of the viral alpha27 gene followed that of representative beta and gamma genes, U(L)30 and U(L)18, respectively, and (vii) HS induced asynchronous HSV-1 replication from QIF-PC12 cells with 1:400 to 1:22000 positive foci detected as rapid as 24 h post-induction when established at MOIs of 30 and 3, respectively.	forskolin__HSP72__no_interaction
23353941-12	RESULTS: Key recommendations and suggestions, listed by category, include: early quantitative resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm a potential source of infection (UG); administration of broad-spectrum antimicrobials therapy within 1 hr of recognition of septic shock (1B) and severe sepsis without septic shock (1C) as the goal of therapy; reassessment of antimicrobial therapy daily for de-escalation, when appropriate (1B); infection source control with attention to the balance of risks and benefits of the chosen method within 12 hrs of diagnosis (1C); initial fluid resuscitation with crystalloid (1B) and consideration of the addition of <protein-id="P02768">albumin</protein-id> in patients who continue to require substantial amounts of crystalloid to maintain adequate mean arterial pressure (2C) and the avoidance of hetastarch formulations (1C); initial fluid challenge in patients with sepsis-induced tissue hypoperfusion and suspicion of hypovolemia to achieve a minimum of 30 mL/kg of crystalloids (more rapid administration and greater amounts of fluid may be needed in some patients) (1C); fluid challenge technique continued as long as hemodynamic improvement, as based on either dynamic or static variables (UG); <compound-id="439260">norepinephrine</compound-id> as the first-choice vasopressor to maintain mean arterial pressure ≥ 65 mm Hg (1B); <compound-id="5816">epinephrine</compound-id> when an additional agent is needed to maintain adequate blood pressure (2B); <protein-id="P01185,X5DQP6">vasopressin</protein-id> (0.03 U/min) can be added to <compound-id="439260">norepinephrine</compound-id> to either raise mean arterial pressure to target or to decrease <compound-id="439260">norepinephrine</compound-id> dose but should not be used as the initial vasopressor (UG); <compound-id="681">dopamine</compound-id> is not recommended except in highly selected circumstances (2C); <compound-id="36811">dobutamine</compound-id> infusion administered or added to vasopressor in the presence of a) myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output, or b) ongoing signs of hypoperfusion despite achieving adequate intravascular volume and adequate mean arterial pressure (1C); avoiding use of intravenous <compound-id="5754">hydrocortisone</compound-id> in adult septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (2C); hemoglobin target of 7-9 g/dL in the absence of tissue hypoperfusion, ischemic coronary artery disease, or acute hemorrhage (1B); low tidal volume (1A) and limitation of inspiratory plateau pressure (1B) for acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure (PEEP) in ARDS (1B); higher rather than lower level of PEEP for patients with sepsis-induced moderate or severe ARDS (2C); recruitment maneuvers in sepsis patients with severe refractory hypoxemia due to ARDS (2C); prone positioning in sepsis-induced ARDS patients with a PaO2/FIO2 ratio of ≤ 100 mm Hg in facilities that have experience with such practices (2C); head-of-bed elevation in mechanically ventilated patients unless contraindicated (1B); a conservative fluid strategy for patients with established ARDS who do not have evidence of tissue hypoperfusion (1C); protocols for weaning and sedation (1A); minimizing use of either intermittent bolus sedation or continuous infusion sedation targeting specific titration endpoints (1B); avoidance of neuromuscular blockers if possible in the septic patient without ARDS (1C); a short course of neuromuscular blocker (no longer than 48 hrs) for patients with early ARDS and a Pao2/Fio2 &lt; 150 mm Hg (2C); a protocolized approach to blood <compound-id="206,5793,64689,79025">glucose</compound-id> management commencing insulin dosing when two consecutive blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels are &gt; 180 mg/dL, targeting an upper blood <compound-id="206,5793,64689,79025">glucose</compound-id> ≤ 180 mg/dL (1A); equivalency of continuous veno-venous hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding in patients with bleeding risk factors (1B); oral or enteral (if necessary) feedings, as tolerated, rather than either complete fasting or provision of only intravenous <compound-id="206,5793,64689,79025">glucose</compound-id> within the first 48 hrs after a diagnosis of severe sepsis/septic shock (2C); and addressing goals of care, including treatment plans and end-of-life planning (as appropriate) (1B), as early as feasible, but within 72 hrs of intensive care unit admission (2C).	epinephrine__albumin__no_interaction	epinephrine__vasopressin__no_interaction	dobutamine__albumin__no_interaction	dobutamine__vasopressin__no_interaction	hydrocortisone__albumin__no_interaction	hydrocortisone__vasopressin__no_interaction	norepinephrine__albumin__no_interaction	norepinephrine__vasopressin__no_interaction	dopamine__albumin__no_interaction	dopamine__vasopressin__no_interaction	glucose__albumin__no_interaction	glucose__vasopressin__no_interaction
15721346-4	The relative reactivities of OH-groups were determined by GC-MS as: Me alpha- and beta-Glcp, <protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;<protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;HO-6, Me alpha- and beta-<compound-id="16133813">Galp</compound-id>, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;HO-6, Me alpha-Manp, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;HO-6, Me beta-Manp, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;HO-<compound-id="90684367">4HO</compound-id>-6&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>, Me alpha-Rhap, OH-3&gt;OH-2&gt;OH-4; Me alphabeta-Fucp, OH-2&gt;OH-3&gt;OH-4, and Me alphabeta-Xylp, OH-2&gt;OH-4&gt;OH-3.	4HO__HO-2__no_interaction	4HO__HO-3__no_interaction	Galp__HO-2__no_interaction	Galp__HO-3__no_interaction
24024772-10	RESULTS: Oatmeal, higher in fiber and protein but lower in sugar than the <compound-id="23931">RTEC</compound-id>, resulted in greater increase in fullness (AUC: p = 0.005 [120 minute: p = 0.0408, 180 minute: p = 0.0061, 240 minute: p = 0.0102]) and greater reduction in hunger (AUC: p = 0.0009 [120 minute: p = 0.0197, 180 minute: p = 0.0003, 240 minute: p = 0.0036]), desire to <protein-id="Q07820,C8YZ26,A0A087WT64">eat</protein-id> (AUC: p = 0.0002 [120 minute: p = 0.0168, 180 minute: p &lt; 0.0001, 240 minute: p = 0.0022]), and prospective intake (AUC: p = 0.0012 [120 minute: p = 0.0058, 180 minute: p = 0.006, 240 minute: p = 0.0047]) compared to the <compound-id="23931">RTEC</compound-id>.	RTEC__eat__no_interaction
23394103-10	There was a positive correlation between <compound-id="1175">uric acid</compound-id> and inflammatory markers, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.30, p = 0.01), <protein-id="P02741">CRP</protein-id> (r = 0.37, p = 0.003), TNF-α (r = 0.40, p = 0.001), <protein-id="P05362">ICAM-1</protein-id> (r = 0.53, p = 0.0001), and <protein-id="P19320">VCAM-1</protein-id> (r = 0.45, p = 0.0001).	uric acid__ICAM-1__no_interaction	uric acid__IL-6__no_interaction	uric acid__VCAM-1__no_interaction	uric acid__CRP__no_interaction
14762098-3	To target thrombosis in a new way, we have identified and optimized a phosphinic acid-containing inhibitor of <protein-id="P19223">CPB</protein-id>, EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxyphosphinoyl]methyl]<compound-id="8094">heptanoic acid</compound-id>] and determined both the pharmacological profile and pathophysiological role of <protein-id="P19223">CPB</protein-id> in rat thrombolysis.	heptanoic acid__CPB__no_interaction
15117561-1	This study included the following experiments: (1) effects of <compound-id="107526">dextrose solution</compound-id> (250 mL of <compound-id="962">water</compound-id> containing 75 g of dextrose) or honey solution (250 mL of <compound-id="962">water</compound-id> containing 75 g of natural honey) on plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level (PGL), plasma <protein-id="P01308,I3WAC9">insulin</protein-id>, and plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> (eight subjects); (2) effects of dextrose, honey, or artificial honey (250 mL of <compound-id="962">water</compound-id> containing 35 g of dextrose and 40 g of fructose) on <compound-id="5997">cholesterol</compound-id> and triglycerides (TG) (nine subjects); (3) effects of honey solution, administered for 15 days, on PGL, blood lipids, <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>), and <compound-id="91552">homocysteine</compound-id> (eight subjects); (4) effects of honey or artificial honey on <compound-id="5997">cholesterol</compound-id> and TG in six patients with hypercholesterolemia and five patients with hypertriglyceridemia; (5) effects of honey for 15 days on blood lipid and <protein-id="P02741">CRP</protein-id> in five patients with elevated <compound-id="5997">cholesterol</compound-id> and <protein-id="P02741">CRP</protein-id>; (6) effects of 70 g of dextrose or 90 g of honey on PGL in seven patients with type 2 diabetes mellitus; and (7) effects of 30 g of <compound-id="5988">sucrose</compound-id> or 30 g of honey on PGL, plasma <protein-id="P01308,I3WAC9">insulin</protein-id>, and plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> in five diabetic patients.	homocysteine__CRP__no_interaction	homocysteine__C-reactive protein__no_interaction	homocysteine__insulin__no_interaction	homocysteine__C-peptide__no_interaction	water__CRP__no_interaction	water__C-reactive protein__no_interaction	water__insulin__no_interaction	water__C-peptide__no_interaction	sucrose__CRP__no_interaction	sucrose__C-reactive protein__no_interaction	sucrose__insulin__no_interaction	sucrose__C-peptide__no_interaction	cholesterol__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction	cholesterol__C-peptide__no_interaction	dextrose solution__CRP__no_interaction	dextrose solution__C-reactive protein__no_interaction	dextrose solution__insulin__no_interaction	dextrose solution__C-peptide__no_interaction	glucose__CRP__no_interaction	glucose__C-reactive protein__no_interaction	glucose__insulin__no_interaction	glucose__C-peptide__no_interaction
12165891-6	The results point out that well controlled and regulated HT does not reduce but increases the plasma levels of <compound-id="23327,33032,611,57109091">glutamate</compound-id> (means and SD; <protein-id="Q16518">RP 20</protein-id> +/- 8 micromol/l, HT I 34 +/- 11 micromol/l), <compound-id="5961">glutamine</compound-id> (RP 489 +/- 155 micromol/l, HT I 634 +/- 113 micromol/l) and BCAA (<compound-id="6287">valine</compound-id> RP 164 +/- 54 micro mol/l, HT I 283 +/- 58 micromol/l, <compound-id="6306">isoleucine</compound-id> <protein-id="Q86SQ9">RP 59</protein-id> +/- 20 micromol/l, HT I 101 +/- 24 micromol/l, <compound-id="6106">leucine</compound-id> RP 88 +/- 32 micromol/l, HT I 142 +/- 35 micro mol/l).	leucine__RP 20__no_interaction	leucine__RP 59__no_interaction	isoleucine__RP 20__no_interaction	isoleucine__RP 59__no_interaction	valine__RP 20__no_interaction	valine__RP 59__no_interaction	glutamate__RP 20__no_interaction	glutamate__RP 59__no_interaction	glutamine__RP 20__no_interaction	glutamine__RP 59__no_interaction
10210917-10	The following antigens were determined [cluster of definition (CD)]: <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">leukocyte common antigen</protein-id> (<protein-id="P09496,C9J8P9">LCA</protein-id>) (B220, T 200, Ly-5), <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>; LPS-R (<compound-id="11970143">lipopolysaccharide</compound-id> receptor), <protein-id="P08571">CD14</protein-id>; found on all T cells, CD3; <protein-id="P06729,Q53F96">LFA-2</protein-id> (<protein-id="P06729,Q53F96">lymphocyte function associated antigen, T 11</protein-id>), <protein-id="P06729,Q53F96">CD2</protein-id>; coreceptor for MHC class II molecules, found on helper T cells, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>; coreceptor for MHC class I molecules, found on suppressor/cytotoxic T cells, <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>; B4, found on all human B cells, <protein-id="P15391">CD19</protein-id>; <protein-id="P13591,A0A087WWD4">NCAM</protein-id> (neural cell adhesion molecule), <protein-id="P13591,A0A087WWD4">CD56</protein-id>; <protein-id="P05107,B4E0R1">integrin beta2</protein-id> subunit, associated with <protein-id="P20701,B2RAL6">CD11a</protein-id> (<protein-id="P05107,B4E0R1">CD11a/CD18</protein-id>, <protein-id="P05107,B4E0R1">LFA-1</protein-id>, alphaLbeta2) and <protein-id="P11215">CD11b</protein-id> (<protein-id="P05107,B4E0R1">CD11b/CD18</protein-id>, <protein-id="P05107,B4E0R1">Mac-1</protein-id>,CR3, alphaMbeta2), <protein-id="P05107,B4E0R1">CD18</protein-id>; alphaL, alpha subunit of integrin <protein-id="P05107,B4E0R1">LFA-1</protein-id> (alphaLbeta2, <protein-id="P05107,B4E0R1">CD11a/CD18</protein-id>), <protein-id="P20701,B2RAL6">CD11a; alphaM, alpha subunit of integrin Mac-1</protein-id> (CR3, alphaMbeta2, <protein-id="P05107,B4E0R1">CD11b/CD18</protein-id>), <protein-id="P11215">CD11b</protein-id>; <protein-id="P05362">ICAM-1</protein-id> (intercellular adhesion molecule), <protein-id="P05362">CD54</protein-id>; H-CAM, <protein-id="P16070">Hermes antigen</protein-id>, <protein-id="P16070">Pgp-1</protein-id>, <protein-id="P16070">CD44</protein-id>; AIM (activation inducer molecule), early activation antigen, <protein-id="Q07108,Q53ZX0">CD69</protein-id>; T-cell receptor gammadelta, TCR gammadelta.	lipopolysaccharide__CD56__no_interaction	lipopolysaccharide__CD54__no_interaction	lipopolysaccharide__integrin beta2__no_interaction	lipopolysaccharide__Hermes antigen__no_interaction	lipopolysaccharide__CD2__no_interaction	lipopolysaccharide__CD8__no_interaction	lipopolysaccharide__Pgp-1__no_interaction	lipopolysaccharide__NCAM__no_interaction	lipopolysaccharide__lymphocyte function associated antigen, T 11__no_interaction	lipopolysaccharide__CD45__no_interaction	lipopolysaccharide__CD44__no_interaction	lipopolysaccharide__Mac-1__no_interaction	lipopolysaccharide__CD69__no_interaction	lipopolysaccharide__CD11a/CD18__no_interaction	lipopolysaccharide__leukocyte common antigen__no_interaction	lipopolysaccharide__CD4__no_interaction	lipopolysaccharide__CD11b/CD18__no_interaction	lipopolysaccharide__CD14__no_interaction	lipopolysaccharide__CD11b__no_interaction	lipopolysaccharide__CD11a; alphaM, alpha subunit of integrin Mac-1__no_interaction	lipopolysaccharide__LCA__no_interaction	lipopolysaccharide__ICAM-1__no_interaction	lipopolysaccharide__LFA-2__no_interaction	lipopolysaccharide__LFA-1__no_interaction	lipopolysaccharide__CD11a__no_interaction	lipopolysaccharide__CD18__no_interaction	lipopolysaccharide__CD19__no_interaction
22738259-4	In the liver, we measured (i) <compound-id="5884">NADPH</compound-id> oxidase activity, and gene and protein expression; (ii) protein carbonyl groups, <compound-id="124886">GSH</compound-id> and TBARSs (<compound-id="2723628">thiobarbituric acid</compound-id>-reactive substances); (iii) catalase, <protein-id="P07632">CuZn-SOD</protein-id> (<compound-id="5359597">superoxide</compound-id> dismutase) and Mn-SOD expression; (iv) liver <compound-id="439177">glycogen</compound-id> and lipid content; (v) GK (glucokinase), <protein-id="P43428">G6Pase</protein-id> (<protein-id="P43428">glucose-6-phosphatase</protein-id>) and G6PDH (<protein-id="P05370">glucose-6-phosphate dehydrogenase</protein-id>) activities; (vi) FAS (fatty acid synthase), GPAT (<compound-id="24759880,753">glycerol</compound-id>-3-<compound-id="1061,167704,644102">phosphate</compound-id> acyltransferase), <protein-id="P43428">G6Pase</protein-id> and G6PDH, IL-1β (interleukin-1β), <protein-id="P20961">PAI-1</protein-id> (<protein-id="P20961">plasminogen-activator inhibitor-1</protein-id>) and TNFα (tumour necrosis factor α) gene expression; and (vii) IκBα (inhibitor of nuclear factor κB α) protein expression.	glycogen__glucose-6-phosphatase__no_interaction	glycogen__G6Pase__no_interaction	glycogen__plasminogen-activator inhibitor-1__no_interaction	glycogen__CuZn-SOD__no_interaction	glycogen__PAI-1__no_interaction	glycogen__glucose-6-phosphate dehydrogenase__no_interaction	thiobarbituric acid__glucose-6-phosphatase__no_interaction	thiobarbituric acid__G6Pase__no_interaction	thiobarbituric acid__plasminogen-activator inhibitor-1__no_interaction	thiobarbituric acid__CuZn-SOD__no_interaction	thiobarbituric acid__PAI-1__no_interaction	thiobarbituric acid__glucose-6-phosphate dehydrogenase__no_interaction	NADPH__glucose-6-phosphatase__no_interaction	NADPH__G6Pase__no_interaction	NADPH__plasminogen-activator inhibitor-1__no_interaction	NADPH__CuZn-SOD__no_interaction	NADPH__PAI-1__no_interaction	NADPH__glucose-6-phosphate dehydrogenase__no_interaction	phosphate__glucose-6-phosphatase__no_interaction	phosphate__G6Pase__no_interaction	phosphate__plasminogen-activator inhibitor-1__no_interaction	phosphate__CuZn-SOD__no_interaction	phosphate__PAI-1__no_interaction	phosphate__glucose-6-phosphate dehydrogenase__no_interaction	glycerol__glucose-6-phosphatase__no_interaction	glycerol__G6Pase__no_interaction	glycerol__plasminogen-activator inhibitor-1__no_interaction	glycerol__CuZn-SOD__no_interaction	glycerol__PAI-1__no_interaction	glycerol__glucose-6-phosphate dehydrogenase__no_interaction	GSH__glucose-6-phosphatase__no_interaction	GSH__G6Pase__no_interaction	GSH__plasminogen-activator inhibitor-1__no_interaction	GSH__CuZn-SOD__no_interaction	GSH__PAI-1__no_interaction	GSH__glucose-6-phosphate dehydrogenase__no_interaction	superoxide__glucose-6-phosphatase__no_interaction	superoxide__G6Pase__no_interaction	superoxide__plasminogen-activator inhibitor-1__no_interaction	superoxide__CuZn-SOD__no_interaction	superoxide__PAI-1__no_interaction	superoxide__glucose-6-phosphate dehydrogenase__no_interaction
11374224-5	Blood pressure was monitored for 24 hours with Spacelab tonometer (SBP: 161 +/- 29 mmHg, DBP: 98 +/- 12 mmHg versus SBP: 168 +/- 21 mmHg, DBP: 103 +/- 9 mmHg; plasma <protein-id="P00797">renin</protein-id> activity was 8.1 +/- 5.6 versus 0.3 +/- 0.4 ng.ml-1.h-1, p &lt; 0.001; recumbent plasma <compound-id="5839">aldosterone</compound-id> level was 98 +/- 31 versus 358 +/- 103 pg.ml-1, p &lt; 0.001, normal value till 150 pg/ml, serum <compound-id="5462222">potassium</compound-id> was 3.9 +/- 0.4 and 3.5 +/- 0.6 mmol/l).	potassium__renin__no_interaction	aldosterone__renin__no_interaction
17142315-4	The mechanism is now defined by binding of N-linked glycan having multiple <compound-id="24139,899">GlcNAc</compound-id> termini to GM3 through carbohydrate-to-carbohydrate interaction, based on the following data: (i) <protein-id="P00533">EGFR</protein-id> (molecular mass, approximately 170 kDa) has N-linked glycan with <compound-id="24139,899">GlcNAc</compound-id> termini, as probed by mAb (J1) or lectin (<protein-id="P51159,A2RU94">GS-II</protein-id>); (ii) <protein-id="P51159,A2RU94">GS-II</protein-id>-bound <protein-id="P00533">EGFR</protein-id> also bound to anti-<protein-id="P00533">EGFR</protein-id> Ab as well as to GM3-coated beads; (iii) GM3 inhibitory effect on <protein-id="P00533">EGFR</protein-id> <compound-id="6057,90983769">tyrosine</compound-id> kinase was abrogated in vitro by coincubation with glycan having multiple <compound-id="24139,899">GlcNAc</compound-id> termini and in cell culture in situ incubated with the same glycan; and (iv) cells treated with <compound-id="51683">swainsonine</compound-id>, which increased expression of complex-type and hybrid-type <compound-id="871">glycans</compound-id> with <compound-id="24139,899">GlcNAc</compound-id> termini, displayed higher inhibition of <protein-id="P00533">EGFR</protein-id> kinase by GM3 than <compound-id="51683">swainsonine</compound-id>-untreated control cells.	glycans__GS-II__no_interaction	glycans__EGFR__no_interaction	swainsonine__GS-II__no_interaction	swainsonine__EGFR__no_interaction	GlcNAc__GS-II__no_interaction	GlcNAc__EGFR__no_interaction	tyrosine__GS-II__no_interaction	tyrosine__EGFR__no_interaction
7565768-9	The following results suggest that JNK activation in rat liver epithelial cells is at least partially Ca(2+) dependent: (i) norepinephrine and vasopressin hormones that increase <compound-id="55310">inositol 1,4,5-triphosphate</compound-id> stimulated JNK; (ii) both <compound-id="49926">thapsigargin</compound-id>, a compound that produces an intracellular Ca(2+) signal, and Ca(2+) ionophores stimulated a dramatic increase in JNK activity (up to 200-fold); (iii) extracellular Ca(2+) chelation with <compound-id="174">ethylene glycol</compound-id> <compound-id="176">tetraacetic acid</compound-id> (<compound-id="6207">EGTA</compound-id>) inhibited JNK activation by ionophore and intracellular chelation with 1,2-bis-(o-<compound-id="5483936">aminophenoxy</compound-id>)-<compound-id="6324">ethane</compound-id>-N,N,N',N'-<compound-id="176">tetraacetic acid</compound-id> tetraacetoxymethyl-ester (<compound-id="2293">BAPTA-AM</compound-id>) partially inhibited JNK activation by <protein-id="P01015">Ang II</protein-id> or <compound-id="49926">thapsigargin</compound-id>; and (iv) JNK activation by <protein-id="P01015">Ang II</protein-id> was inhibited by pretreatment of cells with <compound-id="49926">thapsigargin</compound-id> and <compound-id="6207">EGTA</compound-id>, a procedure which depletes intracellular Ca(2+) stores.	EGTA__Ang II__no_interaction	thapsigargin__Ang II__no_interaction	aminophenoxy__Ang II__no_interaction	BAPTA-AM__Ang II__no_interaction	tetraacetic acid__Ang II__no_interaction	inositol 1,4,5-triphosphate__Ang II__no_interaction	ethane__Ang II__no_interaction	ethylene glycol__Ang II__no_interaction
8784086-6	No change was observed in other metabolic parameters, including <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity index (0.76 +/- 0.21 x 10(-5) <protein-id="P13987,Q6FHM9">min-1</protein-id>/pM on therapy; 0.76 +/- 0.19 x 10(-5) <protein-id="P13987,Q6FHM9">min-1</protein-id>/pM off therapy), acute <protein-id="P01308,I3WAC9">insulin</protein-id> response to <compound-id="6322,90867653">arginine</compound-id> (225 +/- 37 pmol/L on therapy; 225 +/- 40 pmol/L off therapy), acute <protein-id="P01308,I3WAC9">insulin</protein-id> response to <compound-id="206,5793,64689,79025">glucose</compound-id> (10 +/- 6 pmol/L on therapy; 5 +/- 4 pmol/L off therapy), <compound-id="206,5793,64689,79025">glucose</compound-id> effectiveness at zero <protein-id="P01308,I3WAC9">insulin</protein-id> (0.0127 +/- 0.0007 <protein-id="P13987,Q6FHM9">min-1</protein-id> on therapy; 0.0119 +/- 0.0009 <protein-id="P13987,Q6FHM9">min-1</protein-id> off therapy), and iv <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (0.85 +/- 0.05%/min on therapy; 0.71 +/- 0.07%/min off therapy).	arginine__insulin__no_interaction	arginine__min-1__no_interaction	glucose__insulin__no_interaction	glucose__min-1__no_interaction
14635503-25	Abbreviations' list: <compound-id="5920">T3</compound-id>--triiodothyronine, T4--<compound-id="853">thyroxine</compound-id>, FT4--free <compound-id="853">thyroxine</compound-id>, <compound-id="644280">rT3</compound-id>--revers triiodothyronine TSII--Thyroid Stimulating Hormone Type I lodothyronine 5'deiodinase = type I 5'deiodinase = 5'DI = DI Type II <compound-id="22833547">Iodothyronine</compound-id> 5'deiodinase = <protein-id="Q92813,Q9HCP7,A8K845">typeII 5'deiodinase</protein-id> = 5'DII = DII E.S.S.--Euthyroid Sick Syndrome, hDII = human type II <compound-id="22833547">iodothyronine</compound-id> deiodinase HDII-b, hDII-c = two novel splice variants SCC--Squamous Cell Cancer, A--adenocarcinoma, BMI--Body Mass Index BSA--Bovine Standard Albumin, <compound-id="439196,446094">DTT</compound-id>-1,4 Dithio-L-treitol, PTU--Propylothiouracil <compound-id="6421">TCA</compound-id>--Tricholoroacetic Acid, TNM--Tumour Nodule Metastases (class.	thyroxine__typeII 5'deiodinase__no_interaction	iodothyronine__typeII 5'deiodinase__no_interaction	T3__typeII 5'deiodinase__no_interaction	rT3__typeII 5'deiodinase__no_interaction	Iodothyronine__typeII 5'deiodinase__no_interaction	TCA__typeII 5'deiodinase__no_interaction	DTT__typeII 5'deiodinase__no_interaction
21043597-4	Our results indicate that: (a) the mean steady-state fluorescence polarization (p) of both <compound-id="15590,5376733">1,6-diphenyl-1,3,5-hexatriene</compound-id> (DPH) and 1-anilino-8-naphthalenesulphonate (ANS) in membranes from diabetic subjects were significantly greater than for control subjects, thus indicating reduced membrane lipid fluidity in diabetic platelets in various membrane regions; (b) the significantly higher [(3)H]NaBH(4) reduction, indicating the increased attachment of <compound-id="206,64689,79025">glucose</compound-id> to protein amino groups, was attributed to the proteins extracted from diabetic platelet membranes; (c) <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id>-positive resting platelets were not significantly more abundant in diabetic patients; (d) basically, unaltered amounts of PADGEM-140 membrane antigen (<protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id>) copies were detected in resting diabetic platelets; (e) significantly higher numbers of membrane glycoprotein β(3) were found in diabetic platelets; (f) <compound-id="90470996">thrombin</compound-id>-induced elevations in the expression of <protein-id="P05106">CD61</protein-id> (β(3)) and <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id> (PADGEM-140) occurred to much higher extent in platelets of diabetic patients, thus pointing to more profound activation of diabetic platelets by <compound-id="90470996">thrombin</compound-id>; (g) the total amounts of platelet membrane glycoprotein β(3) was significantly reduced in platelet lysates from diabetic subjects.	thrombin__CD62__no_interaction	thrombin__CD61__no_interaction	1,6-diphenyl-1,3,5-hexatriene__CD62__no_interaction	1,6-diphenyl-1,3,5-hexatriene__CD61__no_interaction	glucose__CD62__no_interaction	glucose__CD61__no_interaction
8785138-9	The mean population pharmacokinetic values for <protein-id="Q9NSE2">cis</protein-id>-<compound-id="47319">atracurium</compound-id> were: volume of distribution (V) = 21,900 (<compound-id="5289348">SEM</compound-id> 416) ml; clearance (Cl) = 549 (79) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of <compound-id="47319">atracurium</compound-id> isomers were: <protein-id="Q9NSE2">cis</protein-id>-<protein-id="Q9NSE2">cis</protein-id>, V = 15,100 (720) ml, Cl = 449 (42) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 23.4 (1.2) min; <protein-id="Q9NSE2">cis</protein-id>-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 5.8 (0.4) min.	SEM__cis__no_interaction	SEM__min-1__no_interaction	atracurium__cis__no_interaction	atracurium__min-1__no_interaction
21981776-13	<protein-id="Q99969,A0A090N7U9">chemerin</protein-id> mRNA expression in EAT was also positively correlated with BMI (r = 0.305, P &lt; 0.05), waist circumference (r = 0.384, P &lt; 0.01), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.334, P &lt; 0.05) and negatively correlated with <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> mRNA expression in EAT (r = -0.322, P &lt; 0.05).	glucose__chemerin__no_interaction	glucose__adiponectin__no_interaction
15072129-7	The significant results from the present study were: 1) serologically, a significant increase in HLA A2, A11, B40 and <compound-id="57345898">Cw7</compound-id>, while a decrease of A28, <protein-id="O43676,A0A024R413">B12</protein-id>, <protein-id="O95168">B15</protein-id> and Cw3 were observed among the leprosy patients when compared with the controls; 2) molecular subtyping in multibacillary leprosy patients revealed a significant increase in frequency of HLA A*0203, A*0206, A*1102, B*1801, B*4016, B*5110, Cw*0407 and Cw*0703 while a decrease in the frequency of HLA A*0101, A*0211, B*4006, Cw*03031, Cw*04011 and Cw*0602 leprosy patients was observed when compared with the controls; 3) further haplotypes A*1102-B*4006-Cw*1502; A*0203-B*4016-Cw*0703; A*11-B*40 was significantly increased among the multibacillary leprosy patients when compared with the controls.	Cw7__B15__no_interaction	Cw7__B12__no_interaction
8836619-5	The ultrapotent <compound-id="1548943">capsaicin</compound-id> analogue <compound-id="104826,44564218,5148108,5702546,57090162,6324660">resiniferatoxin</compound-id> (100 micrograms/kg s.c.) was discovered to be highly emetic and comparative studies showed that <compound-id="89594">nicotine</compound-id> and <compound-id="104826,44564218,5148108,5702546,57090162,6324660">resiniferatoxin</compound-id> induced the most intense responses with episodes (retches and a vomit) occurring every 10-15 s. The retching response to mechanical stimulation in the anaesthetised Suncus was not blocked by a 5-HT3 receptor antagonist (<compound-id="17572266,3510,5284566,86287410">granisetron</compound-id>, 1-5 mg/kg s.c.), a tachykinin NK1 receptor antagonist (<compound-id="105083">CP-99,994</compound-id> 20 mg/kg s.c. dihydrochloride salt (9+) -(2S,<compound-id="21439199">3S</compound-id>)-3-(<compound-id="81292">2-methoxybenzylamino</compound-id>)-<compound-id="103020">2-phenylpiperidine</compound-id>) or <compound-id="5288826">morphine</compound-id> (2 mg/kg s.c.) but was blocked by the <protein-id="Q6XXX9">5-HT1A receptor</protein-id> agonist 8-hydroxy-<compound-id="90285">2-(di-n-propylamino)tetralin</compound-id> (8-OH-DPAT 100 micrograms/kg s.c.).	2-phenylpiperidine__5-HT1A receptor__no_interaction	nicotine__5-HT1A receptor__no_interaction	capsaicin__5-HT1A receptor__no_interaction	3S__5-HT1A receptor__no_interaction	granisetron__5-HT1A receptor__no_interaction	2-(di-n-propylamino)tetralin__5-HT1A receptor__no_interaction	CP-99,994__5-HT1A receptor__no_interaction	resiniferatoxin__5-HT1A receptor__no_interaction	morphine__5-HT1A receptor__no_interaction	2-methoxybenzylamino__5-HT1A receptor__no_interaction
23961489-14	In newborns with <compound-id="56841631">VDD</compound-id>, serum <compound-id="22044544,5460341">calcium</compound-id> levels were correlated significantly with 25OHD (r = 0.597, P &lt; 0.001), Mg concentrations (r = 0.436, P &lt; 0.001) and negatively with <protein-id="P05187,B2R7C7">ALP</protein-id> concentrations (r = -0.451, P &lt; 0.001).	calcium__ALP__no_interaction	VDD__ALP__no_interaction
23961489-15	Serum <protein-id="P01270">PTH</protein-id> concentrations were correlated significantly with serum Mg (r = 0.78, P &lt; 0.0001) but not with serum <compound-id="22044544,5460341">calcium</compound-id> (r = -0.103, P = 0.3) or 25OHD (r = -0.03, P = 0.7) concentrations.	calcium__PTH__no_interaction
8684837-4	The genes include: (i) Scl-2 (mouse chromosome 4/human chromosome 9p; candidate Janus <compound-id="6057,90983769">tyrosine</compound-id> kinase 1) controlling a unique no lesion growth resistance phenotype to Leishmania mexicana; (ii) Scl-1 (distal mouse chromosome 11/human 17q; candidates <protein-id="P35228">Nos2</protein-id>, Sigje, <protein-id="P32246,Q5U003">MIP1 alpha</protein-id>, <protein-id="P13236">MIP1 beta</protein-id>) controlling healing versus non-healing responses to L. major; (iii) the 'T helper 2' cytokine gene cluster (proximal murine chromosome 11/human 5p; candidates IL4,5,9) controlling later phases of L. major infection; (iv) the major histocompatibility complex (MHC: H-2 in mouse, HLA in man: mouse chromosome 17/human 6p; candidates class II and class III including TNF alpha/beta genes); and (v) <protein-id="P49279,A0A024R474">Nramp1</protein-id>, the positionally cloned candidate for the murine macrophage resistance gene <protein-id="P41251">Ity</protein-id>/<protein-id="P41251">Lsh</protein-id>/<protein-id="P41251">Bcg</protein-id> (mouse chromosome 1/human 2q35).	tyrosine__Nramp1__no_interaction	tyrosine__Nos2__no_interaction	tyrosine__MIP1 beta__no_interaction	tyrosine__Bcg__no_interaction	tyrosine__Lsh__no_interaction	tyrosine__Ity__no_interaction	tyrosine__MIP1 alpha__no_interaction
9428458-6	Predialytic serum <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> was significantly correlated with serum <protein-id="P02768">albumin</protein-id> (r = -0.4, P = 0.006), cholinesterase (r = -0.51, P = 0.001), body weight change for 3 years (r = -0.48, P = 0.001) and <compound-id="8948">MAMA</compound-id> r = -0.39, P = 0.05).	MAMA__IL-6__no_interaction	MAMA__albumin__no_interaction
21063874-5	Serum <protein-id="P15090,E7DVW4">A-FABP</protein-id> at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.53, P &lt; 0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein <compound-id="5997">cholesterol</compound-id>, triglyceride, and CAVI.	cholesterol__A-FABP__no_interaction	cholesterol__insulin__no_interaction
23238775-1	A dinuclear <compound-id="23930">manganese</compound-id>(III) complex (1) of an N-(carboxymethyl)-N-[3,5-bis(α,α-dimethylbenzyl-2-hydroxybenzyl)]<compound-id="45934207,750">glycine</compound-id> (HDA) ligand (L) binds a <compound-id="23930">manganese</compound-id>(II) species through displacement of its solvating ligands by appropriately dispositioned carbonyl groups of a dinuclear complex {[Mn(2)(L)(2)(OH)(OCH(3))][Mn(H(2)O)(3)(CH(3)OH)(3)], 2, triclinic P1, a = 13.172(3) Å, b = 15.897(3) Å, c = 19.059(4) Å, V = 3461.9(13) Å(3)} leading to a trinuclear complex {3, monoclinic <protein-id="P38936,A0A024RCX5">P21</protein-id>/n, a = 11.7606(8) Å, b = 21.3505(8) Å, c = 26.7827(17) Å, V = 6722.7(7) Å(3)} with cyclization of two of the carboxy groups through the doubly-carboxy group coordinated Mn(2+) ion.	glycine__P21__no_interaction	manganese__P21__no_interaction
23214255-4	RESULTS: After 12 weeks of treatment, the IIEF-5 scores were significantly improved in both the trial and the control groups as compared with the baseline (19.5 +/- 4.1 vs 13.0 +/- 3.8 and 16.4 +/- 3.7 vs 13.7 +/- 3.5, P&lt;0.05), the level of serum <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> was remarkably decreased ([156.07 +/- 26.31] vs [478.35 +/- 62.28] mIU/L and [164.73 +/- 28.58] vs [445.26 +/- 57.83] mIU/L, P&lt;0.05), while the level of serum <compound-id="6013">testosterone</compound-id> was markedly increased ([15.34 +/- 5.27] vs [3.80 +/- 1.09] nmol/L and [12.02 +/- 2.36] vs [4.07 +/- 1.25] nmol/L, P&lt;0.05).	testosterone__prolactin__no_interaction
19482015-6	The different abnormalities of the alpha chain were located either in the G helix: Hb Bronovo alpha103(G10)His--&gt;Leu, Hb Sallanches alpha104(<protein-id="P49842">G11</protein-id>)Cys--&gt;<compound-id="6057">Tyr</compound-id>, Hb Oegstgeest alpha104(<protein-id="P49842">G11</protein-id>)Cys--&gt;<compound-id="5951">Ser</compound-id>, Hb Bleuland alpha108(G15)Thr--&gt;Asn, Hb Suan Dok alpha109(<compound-id="447467">G16</compound-id>)Leu--&gt;Arg and as yet undescribed alpha109(<compound-id="447467">G16</compound-id>)Leu--&gt;Gln, in the GH corner: Hb Foggia alpha117(<compound-id="163897">GH5</compound-id>)Phe--&gt;<compound-id="5951">Ser</compound-id>, or in the H helix: Hb Groene Hart alpha119(<compound-id="783">H2</compound-id>)Pro--&gt;<compound-id="5951">Ser</compound-id>, Hb <compound-id="71494">Diamant</compound-id> alpha119(<compound-id="783">H2</compound-id>)Pro--&gt;Leu, Hb Utrecht alpha129(<compound-id="448724">H12</compound-id>)Leu--&gt;Pro.	GH5__G11__no_interaction	Diamant__G11__no_interaction	H2__G11__no_interaction	H12__G11__no_interaction	G16__G11__no_interaction	Tyr__G11__no_interaction	Ser__G11__no_interaction
9439541-7	NE infusion produced approximately a threefold increase in plasma NE, associated with (1) a significant reduction in <compound-id="206,5793,64689,79025">glucose</compound-id> disposal ([KG] SAL v NE, 0.73 +/- 0.06 v 0.61 +/- 0.06 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05), (2) no reduction in Si (2.33 +/- 0.8 v 2.62 +/- 0.9 x 10(-4).<protein-id="P13987,Q6FHM9">min-1</protein-id>/mU/L, NS), (3) a reduced mean second-phase <protein-id="P01308,I3WAC9">insulin</protein-id> secretion rate (1.21 +/- 0.19 v 1.01 +/- 0.16 x 10(-3) pmol/kg/min per mmol/<compound-id="53782688">L glucose</compound-id>, P &lt; .05), (4) a significant increase in Sg (0.89 +/- 0.08 v 1.63 +/- 0.2 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05), and (5) a corresponding increase in <compound-id="206,5793,64689,79025">glucose</compound-id> effectiveness at zero <protein-id="P01308,I3WAC9">insulin</protein-id> ([GEZI] 0.55 +/- 0.13 v 1.30 +/- 0.33 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05).	L glucose__insulin__no_interaction	L glucose__min-1__no_interaction	glucose__insulin__no_interaction	glucose__min-1__no_interaction
16625256-1	The thioethers <compound-id="91407362">4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane</compound-id> (tBu-L3) and <compound-id="91407362">4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane</compound-id> (tBu-L4) react with <protein-id="Q8N4E4">PdCl2</protein-id>(NCMe)2 to give the dinuclear <compound-id="23938">palladium</compound-id> <compound-id="10909502">thiophenolate</compound-id> complexes [(L3)Pd2Cl2]+ (2) and [(L4Pd2(mu-Cl)]2+ (3) (HL3= <compound-id="91270987">2,6-bis((2-(dimethylamino)ethylimino)methyl)-4-tert-butylbenzenethiol</compound-id>, <compound-id="10130163">HL4</compound-id> = 2,6-bis((2-(dimethylamino)<compound-id="6341">ethylamino</compound-id>)methyl)-<compound-id="75454">4-tert-butylbenzenethiol</compound-id>).	2,6-bis((2-(dimethylamino)ethylimino)methyl)-4-tert-butylbenzenethiol__PdCl2__no_interaction	HL4__PdCl2__no_interaction	thiophenolate__PdCl2__no_interaction	4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane__PdCl2__no_interaction	ethylamino__PdCl2__no_interaction	palladium__PdCl2__no_interaction	4-tert-butylbenzenethiol__PdCl2__no_interaction
16625256-2	The <compound-id="312">chloride</compound-id> ligands in could be replaced by neutral (NCMe) and anionic ligands (NCS-, N3-, CN-, OAc-) to give the diamagnetic Pd(II) complexes [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(NCMe)2]3+ (4), [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(NCS)2]+ (5), [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(N3)2]+ (6), [{(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(mu-CN)}2]4+ (7) and [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(OAc)]2+ (9).	chloride__Pd2__no_interaction
20525986-3	<protein-id="P17931,A0A024R693">Galectin-3</protein-id> levels were associated with older age (r = 0.26, P = 0.006), lower <compound-id="588">creatinine</compound-id> clearance (r = -0.42, P &lt; 0.001), and higher levels of N-terminal-proBNP (r = 0.39, P &lt; 0.001).	creatinine__Galectin-3__no_interaction
9352247-5	Urinary albumin excretion showed a significant positive correlation with systolic (r = 0.46, P &lt; 0.005) and mean blood pressure (r = 0.38, P &lt; 0.05), serum <compound-id="1175">uric acid</compound-id> (r = 0.43, P &lt; 0.005) and triglyceride values (r = 0.36, P &lt; 0.005), and a significant negative correlation with plasma <protein-id="P00797">renin</protein-id> activity (r = -0.34, P &lt; 0.05).	uric acid__renin__no_interaction
12969144-14	<protein-id="P27548,Q0VEI3">CD40L</protein-id> blockade significantly reduced tubulointerstitial injury as well [tubular diameter microm), group 3, 42.5 +/- 6.9 vs. group 2, 66.3 +/- 13.7, P &lt; 0.001; and group 1, 37.3 +/- 5.7, P &lt; 0.01; tubular cell height microm), group 3, 16.3 +/- 1.7 vs. group 2, 11 +/- 1.8, P &lt; 0.01; and group 1, 18.2 +/- 1.9, P &lt; 0.01; interstitial volume (%), group 3, 13.9 +/- 5.1 vs. group 2, 26.2 +/- 4.9, P &lt; 0.001; and group 1, 1.3 +/- 0.7, P &lt; 0.001; proteinuria (mg/24 hours), group 3, 1.8 +/- 0.6 vs. group 2, 4.3 +/- 0.8, P &lt; 0.001; and group 1, 0.7 +/- 0.2, P &lt; 0.05; and <compound-id="588">creatinine</compound-id> clearance microL/min), group 3, 75 +/- 4 vs. group 2, 35 +/- 2, P &lt; 0.001; and group 1, 82 +/- 4, P &lt; 0.01] were also improved by <protein-id="Q8HWB0">MR1</protein-id>.	creatinine__CD40L__no_interaction	creatinine__MR1__no_interaction
9524781-7	Simple regression analysis showed that LVMI was correlated with 48-hour pulse pressure (r = 0.52, p &lt; 0.00033), 48-hour systolic BP (r = 0.37, p &lt; 0.05), <protein-id="P01270">PTH</protein-id> (r = 0.31, p &lt; 0.04) and inversely with serum <compound-id="22044544,5460341">calcium</compound-id> (r = -0.29, p &lt; 0.05) and hemoglobin (r = -0.33, p &lt; 0.03).	calcium__PTH__no_interaction
19711899-7	When compound 2 was heated to reflux in an <compound-id="356">octane</compound-id> solution, it was converted to two new compounds: cis-Re(4)(CO)(16)(mu-BiPh(2))(2)(mu(4)-BiPhBiPh), <protein-id="O75159">cis-6</protein-id> and trans-Re(4)(CO)(16)(mu-BiPh(2))(2)(mu(4)-BiPhBiPh), trans-7 and a small amount of 1 (3% yield).	octane__cis-6__no_interaction
23806067-5	Eight genotypes of Hb variants were found, including Hb E [β26(B8)Glu→<compound-id="5962">Lys</compound-id>, GAG&gt;AAG; <compound-id="5792">HBB</compound-id>: c.79G&gt;A], Hb J-Bangkok [β56(D7)Gly→Asp (<compound-id="449471">GGC</compound-id>&gt;<protein-id="O94925,Q68D38">GAC</protein-id>); <compound-id="5792">HBB</compound-id>; c.170G&gt;A], Hb G-Coushatta [β22(4)Glu→Ala (GAA&gt;<protein-id="P28676,H7BXD5">GCA</protein-id>); <compound-id="5792">HBB</compound-id>: c.68A&gt;C], Hb Queens [α34(<protein-id="O95168">B15</protein-id>)Leu→Arg (CTG&gt;CGG) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.104T&gt;G (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)], Hb I [α16(A14)<compound-id="5962">Lys</compound-id>→Glu, AAG&gt;GAG (α1); <protein-id="P69905,D1MGQ2">HBA1</protein-id>: c.<compound-id="445535">49A</compound-id>&gt;G], Hb Beijing [α16(A14)<compound-id="5962">Lys</compound-id>→Asn (AAG&gt;AAC or AAT) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.51G&gt;C (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>) or 51G&gt;T (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)], Hb <compound-id="16125102">Ube</compound-id>-2 [α68(E17)Asn→Asp (AAC&gt;<protein-id="O94925,Q68D38">GAC</protein-id>) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.205A&gt;G (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)] and Hb G-Taipei [β22(B4)Glu→Gly (GAA&gt;GGA); <compound-id="5792">HBB</compound-id>: c.68A&gt;G].	Ube__GCA__no_interaction	Ube__HBA1__no_interaction	Ube__B15__no_interaction	Ube__GAC__no_interaction	Ube__HBA2__no_interaction	HBB__GCA__no_interaction	HBB__HBA1__no_interaction	HBB__B15__no_interaction	HBB__GAC__no_interaction	HBB__HBA2__no_interaction	49A__GCA__no_interaction	49A__HBA1__no_interaction	49A__B15__no_interaction	49A__GAC__no_interaction	49A__HBA2__no_interaction	GGC__GCA__no_interaction	GGC__HBA1__no_interaction	GGC__B15__no_interaction	GGC__GAC__no_interaction	GGC__HBA2__no_interaction	Lys__GCA__no_interaction	Lys__HBA1__no_interaction	Lys__B15__no_interaction	Lys__GAC__no_interaction	Lys__HBA2__no_interaction
23329150-8	There was no correlation between iPTH and <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.04, P = 0.70) and AS progression was associated with <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.42, P = 0.009), but not with iPTH (R = 0.10, P = 0.55) in patients with normal <compound-id="5280795,5283711">vitamin D</compound-id> levels, whereas it was associated with iPTH (R = 0.47, P &lt; 0.001) and not with <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.04, P = 0.73) in those with low <compound-id="5280795,5283711">vitamin D</compound-id> levels, especially if mild renal insufficiency was present (R = 0.61, P &lt; 0.001).	vitamin D__osteocalcin__no_interaction	vitamin D__CTX__no_interaction
18540596-2	The subsequent rate of <compound-id="1038,5460653">proton</compound-id> transfer depends markedly on the nature of L. Stopped-flow kinetic studies show that <compound-id="1038,5460653">proton</compound-id> transfer from [pyrH] (+) to [Fe 4Y 4Cl 4] (2-) { (S) k 4 = (2.1 +/- 0.5) x 10 (4) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1); (Se) k 4 = (8.0 +/- 0.5) x 10 (3) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1)} is increased by prior binding of L = <protein-id="P10071">PhS</protein-id> (-) or Bu ( t )NC to form [Fe 4Y 4Cl 4(L)] (n-) ( (S) k 7 (L) approximately 1 x 10 (6) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1)), but prior binding of L = I (-), Br (-), or EtS (-) to the clusters inhibits the rate of <compound-id="1038,5460653">proton</compound-id> transfer {e.g.	proton__PhS__no_interaction	proton__mol__no_interaction
7709007-7	RESULTS: The 95% confidence limits of means for the most important variables were as follows: estimated ELF content 0.42-0.74%; total cells in <protein-id="P43652">ALF</protein-id> 76.6-143.0 x 10(6) l-1; distribution of inflammatory cells on filter and CCF slides: macrophages 74.9-83.6 and 81.4-90.1%, lymphocytes 13.1-22.5 and 8.1-16.4%, and neutrophils 1.0-4.1 and 0.7-2.7%, respectively; distribution of lymphocyte subsets: CD3+<protein-id="P06729,Q53F96">CD2</protein-id> 85.6-90.6%, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id> 44.3-53.1%, <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id> 26.9-35.8%; concentration of solutes in <protein-id="P43652">ALF</protein-id>: total protein 44.8-61.3 mg l-1, <protein-id="P02768">albumin</protein-id> 15.4-22.2 mg l-1, IgA 1.8-3.4 mg l-1, IgG 3.1-6.1 mg l-1, IgM 0.05-0.26 mg l-1, <compound-id="24728612,24759,3084050,453618">hyaluronic acid</compound-id> 8.8-11.1 micrograms l-1, <protein-id="P12724">ECP</protein-id> 0.19-0.77 micrograms l-1, PCP 0.005-0.58 micrograms l-1, <protein-id="P61769,H0YL18">beta 2-microglobulin</protein-id> 62.2-81.5 micrograms l-1.	hyaluronic acid__ALF__no_interaction	hyaluronic acid__beta 2-microglobulin__no_interaction	hyaluronic acid__CD4__no_interaction	hyaluronic acid__CD2__no_interaction	hyaluronic acid__ECP__no_interaction	hyaluronic acid__albumin__no_interaction	hyaluronic acid__CD8__no_interaction
21619011-1	The work in this paper presents the syntheses, structures, and magnetic properties of three end-to-end (EE) azide/<compound-id="540">cyanate</compound-id>-bridged <compound-id="23978">copper</compound-id>(II) compounds [Cu(II)L(1)(μ(1,3)-NCO)](n)·<compound-id="447474">2nH</compound-id>(2)O (1), [Cu(II)L(1)(μ(1,3)-N(3))](n)·<compound-id="447474">2nH</compound-id>(2)O (2), and [Cu(II)L(2)(μ(1,3)-N(3))](n) (3), where the ligands used to achieve these species, <protein-id="P07306,Q6FGQ5">HL(1</protein-id>) and <protein-id="P07307,Q7Z4G9">HL(2</protein-id>), are the tridentate <compound-id="86573619">Schiff base</compound-id> ligands obtained from [1 + 1] condensations of <compound-id="6998">salicylaldehyde</compound-id> with 4-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8083">morpholine</compound-id> and <compound-id="13516411">3-methoxy</compound-id> <compound-id="6998">salicylaldehyde</compound-id> with 1-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8082">piperidine</compound-id>, respectively.	cyanate__HL(1__no_interaction	cyanate__HL(2__no_interaction	copper__HL(1__no_interaction	copper__HL(2__no_interaction	2nH__HL(1__no_interaction	2nH__HL(2__no_interaction	3-methoxy__HL(1__no_interaction	3-methoxy__HL(2__no_interaction	Schiff base__HL(1__no_interaction	Schiff base__HL(2__no_interaction	morpholine__HL(1__no_interaction	morpholine__HL(2__no_interaction	2-aminoethyl__HL(1__no_interaction	2-aminoethyl__HL(2__no_interaction	piperidine__HL(1__no_interaction	piperidine__HL(2__no_interaction	salicylaldehyde__HL(1__no_interaction	salicylaldehyde__HL(2__no_interaction
22944276-9	After a pretreatment of antibodies of <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">ErbB2</protein-id>, <protein-id="P21860">ErbB3</protein-id>, inhibitors of p38MAPK, <protein-id="P28482,Q1HBJ4,Q499G7">ERK1/2</protein-id>, <protein-id="O75582,Q9UG98">MSK1</protein-id> and antibody of <protein-id="P16220,Q53X93,Q5U0J5">CREB</protein-id> and a stimulation of <compound-id="440005">NRG</compound-id>-1β, the expression of <protein-id="P98088">MUC5AC</protein-id> decreased (0.221 ± 0.033, 0.238 ± 0.044, 0.386 ± 0.021, 0.352 ± 0.022, 0.294 ± 0.017, 0.252 ± 0.019) versus the <compound-id="440005">NRG</compound-id>-1β group (0.650 ± 0.134).	NRG__ErbB2__no_interaction	NRG__ErbB3__no_interaction	NRG__MSK1__no_interaction	NRG__ERK1/2__no_interaction	NRG__MUC5AC__no_interaction	NRG__CREB__no_interaction
12740739-6	Similarly, no significant effect of physical training was observed on studied parameters between these two groups during either follicular phase (TG: 1.96 +/- 1.00 nmol x mmol C -1; <compound-id="46943433">ETG</compound-id>: 1.97 +/- 0.70 nmol x mmol C -1; TG/<compound-id="46943433">ETG</compound-id> ratio: 0.66 +/- 0.05 and <protein-id="O75800">FLU</protein-id>: 11.31 +/- 3.73 nmol x mmol C -1) or luteal phase (TG: 1.93 +/- 0.86 nmol x mmol C -1; <compound-id="46943433">ETG</compound-id>: 3.19 +/- 1.23 nmol x mmol C -1; TG/<compound-id="46943433">ETG</compound-id> ratio: 0.69 +/- 0.33 and <protein-id="O75800">FLU</protein-id>: 9.52 +/- 3.86 nmol x mmol C -1).	ETG__FLU__no_interaction
10585525-1	The role of <compound-id="681">dopamine</compound-id> D(1) and D(2) receptors in the control of <compound-id="187">acetylcholine</compound-id> release in the dorsal striatum by endogenous <compound-id="681">dopamine</compound-id> was investigated by monitoring with microdialysis the effect of the separate or combined administration of the <protein-id="P21728">Dopamine D(1) receptor</protein-id> antagonist, <compound-id="107930">SCH 39166</compound-id> ¿(-)-trans-6,7,7a,8,9, 13b-exahydro-3-chloro-<compound-id="97257">2-hydroxy-</compound-id>N-methyl-5H-benzo-[d]-nap <compound-id="444397">hto</compound-id>-[2, 1b]-<compound-id="6451476">azepine</compound-id> hydrochloride¿ (50 microg/kg subcutaneous (s.c.)), of the <compound-id="681">dopamine</compound-id> D(2)/D(3) receptor agonist, quinpirole (trans-(-)-4aR, <compound-id="69255155">4a</compound-id>,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo-(3,4-g)-<compound-id="7047">quinoline hydrochloride</compound-id>) (5 and 10 microg/kg s.c.), and of the D(3) receptor selective agonist, PD 128,907 [S(+)-(4aR,10bR)-3,4,<compound-id="69255155">4a</compound-id>, 10b-tetrahydro-4-propyl-2H,<compound-id="22361982">5H-[1]benzopyrano</compound-id>-[4,3-b]-1,4-<compound-id="12313776">oxazin</compound-id> -9-ol hydrochloride] (50 microg/kg s.c.), on in vivo <compound-id="681">dopamine</compound-id> and <compound-id="187">acetylcholine</compound-id> release.	acetylcholine__Dopamine D(1) receptor__no_interaction	5H-[1]benzopyrano__Dopamine D(1) receptor__no_interaction	hto__Dopamine D(1) receptor__no_interaction	oxazin__Dopamine D(1) receptor__no_interaction	SCH 39166__Dopamine D(1) receptor__no_interaction	azepine__Dopamine D(1) receptor__no_interaction	dopamine__Dopamine D(1) receptor__no_interaction	2-hydroxy-__Dopamine D(1) receptor__no_interaction	quinoline hydrochloride__Dopamine D(1) receptor__no_interaction	4a__Dopamine D(1) receptor__no_interaction
17291221-1	We developed methods for prolonged (12 h), sterile, normothermic perfusion of rat kidneys and screened compounds for renal preservation including: mitochondrial transition pore inhibitor (<compound-id="2971">decylubiquinone</compound-id>); caspase inhibitor (Z-VAD); <protein-id="P37230">peroxisome proliferator-activated receptor-alpha</protein-id> (<protein-id="P37230">PPARalpha</protein-id>) agonists (<compound-id="3463">gemfibrozil</compound-id>, WY-14643); antioxidants (<compound-id="40634">trolox</compound-id>, <compound-id="5280445">luteolin</compound-id>, <compound-id="5280343">quercetin</compound-id>); growth factors (HGF, PDGF, EGF, <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-1</protein-id>, VEGF, <protein-id="P12346">transferrin</protein-id>); <protein-id="P27321,A0A0G2JSY2,D3ZL24,F1LPH1">calpain inhibitor</protein-id> (<compound-id="72430">Z-Val-Phe-CHO</compound-id>); calmodulin inhibitor (<compound-id="5681">W7</compound-id>); K(<compound-id="5957">ATP</compound-id>) opener (<compound-id="4201">minoxidil</compound-id>, <compound-id="4203">minoxidil sulfate</compound-id>); PARP inhibitor (<compound-id="1645">3-aminobenzamide</compound-id>); <compound-id="22044544,5460341">calcium</compound-id> channel blocker (<compound-id="2520">verapamil</compound-id>); V(2) agonist (<compound-id="27991">DDAVP</compound-id>); diuretics (<compound-id="1986">acetazolamide</compound-id>, <compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="3440">furosemide</compound-id>, <compound-id="6251">mannitol</compound-id>); peroxisome proliferator-activated receptor-beta agonist (L-165041); <compound-id="681">dopamine</compound-id> agonist (<compound-id="681">dopamine</compound-id>); essential fatty acid (<compound-id="5280934">linolenic acid</compound-id>); <compound-id="5893">beta-NAD</compound-id>; <compound-id="1176">urea</compound-id>; <compound-id="1175">uric acid</compound-id>; and <compound-id="5839">aldosterone</compound-id>.	minoxidil__calpain inhibitor__no_interaction	minoxidil__transferrin__no_interaction	minoxidil__peroxisome proliferator-activated receptor-alpha__no_interaction	minoxidil__PPARalpha__no_interaction	minoxidil__IGF-1__no_interaction	3-aminobenzamide__calpain inhibitor__no_interaction	3-aminobenzamide__transferrin__no_interaction	3-aminobenzamide__peroxisome proliferator-activated receptor-alpha__no_interaction	3-aminobenzamide__PPARalpha__no_interaction	3-aminobenzamide__IGF-1__no_interaction	luteolin__calpain inhibitor__no_interaction	luteolin__transferrin__no_interaction	luteolin__peroxisome proliferator-activated receptor-alpha__no_interaction	luteolin__PPARalpha__no_interaction	luteolin__IGF-1__no_interaction	furosemide__calpain inhibitor__no_interaction	furosemide__transferrin__no_interaction	furosemide__peroxisome proliferator-activated receptor-alpha__no_interaction	furosemide__PPARalpha__no_interaction	furosemide__IGF-1__no_interaction	trolox__calpain inhibitor__no_interaction	trolox__transferrin__no_interaction	trolox__peroxisome proliferator-activated receptor-alpha__no_interaction	trolox__PPARalpha__no_interaction	trolox__IGF-1__no_interaction	ATP__calpain inhibitor__no_interaction	ATP__transferrin__no_interaction	ATP__peroxisome proliferator-activated receptor-alpha__no_interaction	ATP__PPARalpha__no_interaction	ATP__IGF-1__no_interaction	dopamine__calpain inhibitor__no_interaction	dopamine__transferrin__no_interaction	dopamine__peroxisome proliferator-activated receptor-alpha__no_interaction	dopamine__PPARalpha__no_interaction	dopamine__IGF-1__no_interaction	acetazolamide__calpain inhibitor__no_interaction	acetazolamide__transferrin__no_interaction	acetazolamide__peroxisome proliferator-activated receptor-alpha__no_interaction	acetazolamide__PPARalpha__no_interaction	acetazolamide__IGF-1__no_interaction	linolenic acid__calpain inhibitor__no_interaction	linolenic acid__transferrin__no_interaction	linolenic acid__peroxisome proliferator-activated receptor-alpha__no_interaction	linolenic acid__PPARalpha__no_interaction	linolenic acid__IGF-1__no_interaction	gemfibrozil__calpain inhibitor__no_interaction	gemfibrozil__transferrin__no_interaction	gemfibrozil__peroxisome proliferator-activated receptor-alpha__no_interaction	gemfibrozil__PPARalpha__no_interaction	gemfibrozil__IGF-1__no_interaction	aldosterone__calpain inhibitor__no_interaction	aldosterone__transferrin__no_interaction	aldosterone__peroxisome proliferator-activated receptor-alpha__no_interaction	aldosterone__PPARalpha__no_interaction	aldosterone__IGF-1__no_interaction	Z-Val-Phe-CHO__calpain inhibitor__no_interaction	Z-Val-Phe-CHO__transferrin__no_interaction	Z-Val-Phe-CHO__peroxisome proliferator-activated receptor-alpha__no_interaction	Z-Val-Phe-CHO__PPARalpha__no_interaction	Z-Val-Phe-CHO__IGF-1__no_interaction	DDAVP__calpain inhibitor__no_interaction	DDAVP__transferrin__no_interaction	DDAVP__peroxisome proliferator-activated receptor-alpha__no_interaction	DDAVP__PPARalpha__no_interaction	DDAVP__IGF-1__no_interaction	urea__calpain inhibitor__no_interaction	urea__transferrin__no_interaction	urea__peroxisome proliferator-activated receptor-alpha__no_interaction	urea__PPARalpha__no_interaction	urea__IGF-1__no_interaction	verapamil__calpain inhibitor__no_interaction	verapamil__transferrin__no_interaction	verapamil__peroxisome proliferator-activated receptor-alpha__no_interaction	verapamil__PPARalpha__no_interaction	verapamil__IGF-1__no_interaction	minoxidil sulfate__calpain inhibitor__no_interaction	minoxidil sulfate__transferrin__no_interaction	minoxidil sulfate__peroxisome proliferator-activated receptor-alpha__no_interaction	minoxidil sulfate__PPARalpha__no_interaction	minoxidil sulfate__IGF-1__no_interaction	mannitol__calpain inhibitor__no_interaction	mannitol__transferrin__no_interaction	mannitol__peroxisome proliferator-activated receptor-alpha__no_interaction	mannitol__PPARalpha__no_interaction	mannitol__IGF-1__no_interaction	beta-NAD__calpain inhibitor__no_interaction	beta-NAD__transferrin__no_interaction	beta-NAD__peroxisome proliferator-activated receptor-alpha__no_interaction	beta-NAD__PPARalpha__no_interaction	beta-NAD__IGF-1__no_interaction	quercetin__calpain inhibitor__no_interaction	quercetin__transferrin__no_interaction	quercetin__peroxisome proliferator-activated receptor-alpha__no_interaction	quercetin__PPARalpha__no_interaction	quercetin__IGF-1__no_interaction	decylubiquinone__calpain inhibitor__no_interaction	decylubiquinone__transferrin__no_interaction	decylubiquinone__peroxisome proliferator-activated receptor-alpha__no_interaction	decylubiquinone__PPARalpha__no_interaction	decylubiquinone__IGF-1__no_interaction	W7__calpain inhibitor__no_interaction	W7__transferrin__no_interaction	W7__peroxisome proliferator-activated receptor-alpha__no_interaction	W7__PPARalpha__no_interaction	W7__IGF-1__no_interaction	calcium__calpain inhibitor__no_interaction	calcium__transferrin__no_interaction	calcium__peroxisome proliferator-activated receptor-alpha__no_interaction	calcium__PPARalpha__no_interaction	calcium__IGF-1__no_interaction	hydrochlorothiazide__calpain inhibitor__no_interaction	hydrochlorothiazide__transferrin__no_interaction	hydrochlorothiazide__peroxisome proliferator-activated receptor-alpha__no_interaction	hydrochlorothiazide__PPARalpha__no_interaction	hydrochlorothiazide__IGF-1__no_interaction	uric acid__calpain inhibitor__no_interaction	uric acid__transferrin__no_interaction	uric acid__peroxisome proliferator-activated receptor-alpha__no_interaction	uric acid__PPARalpha__no_interaction	uric acid__IGF-1__no_interaction
15539964-3	In a 24-week, open-label, multicenter trial, men and women aged &gt; or =18 years with fasting levels of total <compound-id="5997">cholesterol</compound-id> &gt; or =200 mg/dL, HDL <compound-id="5997">cholesterol</compound-id> &gt; or =45 mg/dL, triglycerides 200-800 mg/dL, and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> &gt; or =110 mg/dL were randomly assigned to one of four treatment groups: <compound-id="446157,656606">rosuvastatin</compound-id> 10-40 mg, ER <compound-id="938">niacin</compound-id> 0.5-2 g, <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg plus ER <compound-id="938">niacin</compound-id> 0.5-1 g, or <compound-id="446157,656606">rosuvastatin</compound-id> 10 mg plus ER <compound-id="938">niacin</compound-id> 0.5-2 g. Daily doses of <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg monotherapy reduced low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> and non-HDL <compound-id="5997">cholesterol</compound-id> levels significantly more than did either ER <compound-id="938">niacin</compound-id> 2 g monotherapy or <compound-id="446157,656606">rosuvastatin</compound-id> 10 mg combined with ER <compound-id="938">niacin</compound-id> 2 g. Addition of ER <compound-id="938">niacin</compound-id> 1 g to <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg did not further reduce total or non-HDL <compound-id="5997">cholesterol</compound-id>.	niacin__apolipoprotein B__no_interaction	rosuvastatin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
18331609-8	Serum 25-OHD was negatively associated with %TBF (r = -0.28), <protein-id="Q96LC9">BMF</protein-id> (r = -0.36) and TBF (r = -0.33), all P &lt; 0.001, and positively associated with dietary <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.10) and pack years of smoking (r = 0.11), both P &lt; 0.01.	vitamin D__BMF__no_interaction
20738599-4	The basic diploid chromosome number (2n), in all mahseer species, was observed to be 100; however, the karyotype formula varied among the species, which were recorded as: 20m + 14sm + 22st + 44t (fundamental arm number, FN = 134) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> khudree; <compound-id="9547940">22m</compound-id> + 24sm + 24st + <compound-id="86346631">30t</compound-id> (FN = 146) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> mussullah; <compound-id="5225083">12m</compound-id> + 22sm + 14st + 52t (FN = 134) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> putitora; 20m + 24sm + 24st + <compound-id="25271551">32t</compound-id> (FN = 144) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id>; 20m + 30sm + 24st + <compound-id="77620531">26t</compound-id> (FN = 150) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> chelynoides; 20m + 20sm + 20st + 40t (FN = 140) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> progeneius; and 20m + 18sm + 14st + <compound-id="70698415">48t</compound-id> (FN = 138) in Neolissochilus hexagonolepis.	22m__Tor__no_interaction	30t__Tor__no_interaction	12m__Tor__no_interaction	32t__Tor__no_interaction	26t__Tor__no_interaction	48t__Tor__no_interaction
16954340-4	All five acute interventions caused significant increases of PRC in both <protein-id="P00405,Q7JCZ1">COX-2</protein-id>+/+ and -/- mice, but the response was consistently less in <protein-id="P00405,Q7JCZ1">COX-2</protein-id>-deficient mice (e.g., DeltaPRC in ng <protein-id="Q3UTR7">ANG I</protein-id> x ml(-1) x h(-1) caused by <compound-id="3440">furosemide</compound-id>, <compound-id="3779">isoproterenol</compound-id>, <compound-id="3637">hydralazine</compound-id>, quinaprilate, or <compound-id="2541">candesartan</compound-id> 4,699 +/- 544, 3,534 +/- 957, 2,522 +/- 369, 9,453 +/- 1,705, 66,455 +/- 21,938 in 129J WT, and 201 +/- 78, 869 +/- 275, 140 +/- 71, 902 +/- 304, 2,660 +/- 954 in 129J <protein-id="P00405,Q7JCZ1">COX-2</protein-id>-/-).	isoproterenol__ANG I__no_interaction	isoproterenol__COX-2__no_interaction	furosemide__ANG I__no_interaction	furosemide__COX-2__no_interaction	hydralazine__ANG I__no_interaction	hydralazine__COX-2__no_interaction	candesartan__ANG I__no_interaction	candesartan__COX-2__no_interaction
19087721-2	METHODS: Human HSCs of the line HSC-T6 were cultured and randomly divided into 6 groups: negative control group, <protein-id="Q9UID3">Ang II</protein-id> group treated by Ang II10 micromol/L for 15 min, <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="3749">irbesartan</compound-id> (<protein-id="Q9UID3">Ang II</protein-id> receptor inhibitor) group, exposed to <compound-id="3749">irbesartan</compound-id> for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="448042">Y27632</compound-id> (<protein-id="Q13464">Rho kinase</protein-id> specific inhibitor) exposed to <compound-id="448042">Y27632</compound-id> for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, <protein-id="Q9UID3">Ang II</protein-id> + <protein-id="P16260,B4DPV4">ML-7</protein-id> (myosin light chain kinase specific inhibitor) + saturo (protein kinase C specific inhibitor) group exposed to stauro for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, and <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="448042">Y27632</compound-id> + <protein-id="P16260,B4DPV4">ML-7</protein-id> + stauro group, exposed to <compound-id="448042">Y27632</compound-id> and stauro for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment.	Y27632__Rho kinase__no_interaction	Y27632__Ang II__no_interaction	Y27632__ML-7__no_interaction	irbesartan__Rho kinase__no_interaction	irbesartan__Ang II__no_interaction	irbesartan__ML-7__no_interaction
7512696-7	On guinea-pig isolated bronchi, the potency order of contractile agonists was: [Lys5,MeLeu9,Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; <compound-id="5311311">NKA</compound-id> &gt; or = NP gamma &gt; or = [Lys5,Tyr7,MeLeu9, Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; or = <compound-id="119137">septide</compound-id> = BHNKA &gt; or = [Lys5,<compound-id="6057">Tyr</compound-id>(I2)7,MeLeu9,Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; or = [Sar9,Met(O2)11]-SP &gt; or = <protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> = [Pro9]-SP &gt; or = SP &gt;&gt; <compound-id="108147,5079497">senktide</compound-id>.	NKA__NKB__no_interaction	senktide__NKB__no_interaction	Tyr__NKB__no_interaction	septide__NKB__no_interaction
1844449-9	There were significant positive correlations between the LVMI and ASBP (r = 0.51, p &lt; 0.005), the SHI (r = 0.49, p &lt; 0.005), CSBP (r = 0.47, p &lt; 0.01) and RSBP (r = 0.41, p &lt; 0.05), however, there were no significant correlations between the LVMI and <compound-id="126488">ADBP</compound-id>, the <compound-id="114683">DHI</compound-id>, CDBP, <protein-id="P18615">RDBP</protein-id> and age.	ADBP__RDBP__no_interaction	DHI__RDBP__no_interaction
1844449-10	There were significant positive correlations between the A/R and <compound-id="126488">ADBP</compound-id> (r = 0.44, p &lt; 0.01), age (r = 0.40, p &lt; 0.02), CSBP (r = 0.38, p &lt; 0.05) and <protein-id="P18615">RDBP</protein-id> (r = 0.38, p &lt; 0.05), however, no significant correlations between the A/R and ASBP, the SHI, <compound-id="114683">DHI</compound-id>, RSBP and CDBP.	ADBP__RDBP__no_interaction	DHI__RDBP__no_interaction
2343775-3	During lactation the significant findings were (1) a selective reduction (7.1%, P less than 0.03) in BMD at the ultradistal site containing 60% trabecular bone, but not at two more proximal, chiefly cortical bone sites; (2) increased bone turnover affecting bone resorption [fasting <compound-id="269023,5810">hydroxyproline</compound-id> excretion, Lac 2.22 +/- 0.12 mumol/liter GF (mean +/- <compound-id="5289348">SEM</compound-id>), Con 1.19 +/- 0.04, P less than 0.001] and affecting bone formation (plasma alkaline phosphatase, Lac 81.9 +/- 2.5 IU/liter, Con 53.5 +/- 2.7, P less than 0.001, and serum <protein-id="P02818">osteocalcin</protein-id>, Lac 14.0 +/- 0.7 microgram/liter, Con 7.3 +/- 0.4, P less than 0.001); and (3) renal conservation in the fasting state of both Ca and inorganic <compound-id="1061,167704,644102">phosphate</compound-id> (Pi) with a resultant moderate increase in plasma Pi but not in plasma Ca (total or ionized).	SEM__osteocalcin__no_interaction	phosphate__osteocalcin__no_interaction	hydroxyproline__osteocalcin__no_interaction
18843972-3	RESULTS: 1) Serum <protein-id="P61769,H0YL18">beta2-microglobulin</protein-id> (beta2-MG) &gt; or = 3.5 mg/L was an independent adverse prognostic factor for overall survival (OS), and serum <protein-id="P02768">albumin</protein-id> &lt;35 g/L predicted for time to progression (<compound-id="64968">TTP</compound-id>), 2) In the 58 cases having cytogenetic data, chromosome 13 aberration (Delta 13) was the only independent adverse prognostic factor for OS; 3) Factors significantly related to serum beta2-MG were serum <compound-id="588">creatinine</compound-id>, 24h urinary protein,body mass index (BMI) and performance status (PS); and those related to serum <protein-id="P02768">albumin</protein-id> were hemoglobin level, percentage of bone marrow plasma cells, <compound-id="612">lactate</compound-id> dehydrogenase(<compound-id="45382306">LDN</compound-id>), fever, PS, class of <protein-id="P54296">M-protein</protein-id>, serum phosphorus and BMI; 4) All traditional prognostic factors had no statistical difference between ISS stage II and III excepting for serum beta2-MG and <compound-id="588">creatinine</compound-id>, and 5/6 Delta 13 patients were classified to ISS stage II; 5) The median OS of ISS stage I, II, III were 69, 23 and 26 months (m) respectively, being no statistical difference between stage II and III; for DS system, 89.5% of patients were classified in stage III, being no statistical difference for OS between the stage I/II and III; while for <compound-id="447607">IFM</compound-id> system, the median OS of low-, intermediate- and high-risk group were 69, 40 and 8 months respectively, being statistically different between high-risk and intermediate/ low-risk groups.	IFM__albumin__no_interaction	IFM__beta2-microglobulin__no_interaction	IFM__M-protein__no_interaction	creatinine__albumin__no_interaction	creatinine__beta2-microglobulin__no_interaction	creatinine__M-protein__no_interaction	TTP__albumin__no_interaction	TTP__beta2-microglobulin__no_interaction	TTP__M-protein__no_interaction	LDN__albumin__no_interaction	LDN__beta2-microglobulin__no_interaction	LDN__M-protein__no_interaction	lactate__albumin__no_interaction	lactate__beta2-microglobulin__no_interaction	lactate__M-protein__no_interaction
9826215-4	Compared with six normal-weight subjects (BMI, 21.0+/-0.9 kg/m2), all obese subjects exhibited basal hyperinsulinism (fasting plasma <protein-id="P01308,I3WAC9">Insulin</protein-id>, 16.0+/-1.4 v 9.8+/-1.3 microU/microL, P &lt; .001; fasting plasma C-peptide, 1.4+/-0.2 v 0.5+/-0.2 ng/mL, P &lt; .001), hypofibrinolysis (euglobulin lysis time [ELT], 378+/-29 v 222+/-31 minutes, P=.01; <protein-id="P00750">tissue plasminogen activator</protein-id> [<protein-id="P00750">tPA</protein-id>] antigen, 7.8+/-0.9 v 4.2+/-0.5 ng/mL, P=.04; <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor type 1</protein-id> [<protein-id="P05121,A0A024QYT5">PAI-1</protein-id>] activity, 22.2+/-2.5 v3.9+/-0.6 AU/mL, P=.004), and marked <protein-id="P01308,I3WAC9">Insulin</protein-id> resistance (M value, ie, the maximal <compound-id="206,5793,64689,79025">glucose</compound-id> disposal rate, 9.1+/-0.6 v 18.6+/-0.8 mg/(kg x min), P &lt; .001).	glucose__PAI-1__no_interaction	glucose__plasminogen activator inhibitor type 1__no_interaction	glucose__Insulin__no_interaction	glucose__tPA__no_interaction	glucose__tissue plasminogen activator__no_interaction
24171493-2	Here we present a series of 26 novel <compound-id="2155">2-aminothiazole</compound-id>-featured <compound-id="5694">pirinixic acid</compound-id> derivatives as dual <protein-id="P48999">5-LO</protein-id>/<protein-id="Q9JM51,Q8BNP8">mPGES-1</protein-id> inhibitors with improved potency (exemplified by <compound-id="46936266">compound 16</compound-id> (2-[(4-chloro-6-{[4-(<compound-id="931">naphthalen</compound-id>-2-yl)-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]amino}pyrimidin-2-yl)<compound-id="5460613">sulfanyl</compound-id>]<compound-id="379">octanoic acid</compound-id>) with IC50 = 0.3 and 0.4 μM, respectively) and bioactivity in vivo.	octanoic acid__5-LO__no_interaction	octanoic acid__mPGES-1__no_interaction	2-aminothiazole__5-LO__no_interaction	2-aminothiazole__mPGES-1__no_interaction	thiazol__5-LO__no_interaction	thiazol__mPGES-1__no_interaction	pirinixic acid__5-LO__no_interaction	pirinixic acid__mPGES-1__no_interaction	compound 16__5-LO__no_interaction	compound 16__mPGES-1__no_interaction	sulfanyl__5-LO__no_interaction	sulfanyl__mPGES-1__no_interaction	naphthalen__5-LO__no_interaction	naphthalen__mPGES-1__no_interaction
18211669-9	Moreover, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (R2 = 0.338, p = 0.001) and not <protein-id="P22301,Q6FGW4">IL-10</protein-id> was a predictor of low <compound-id="5920">T3</compound-id> levels with only a borderline significance for T4 (R2 = 0.082, p = 0.071).By subgroup analysis, the proportion of patients with subnormal <compound-id="5920">T3</compound-id>, T4, and TSH levels was highest in the MI patients (70%, 70%, and 72%, respectively) who displayed the greatest <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and <protein-id="P22301,Q6FGW4">IL-10</protein-id> concentrations (192.5 +/- 45.1 ng/L &amp; 122.95 +/- 46.1 ng/L, respectively) compared with CHF (82.95 +/- 28.9 ng/L &amp; 69.05 +/- 44.0 ng/L, respectively) and CRI patients (40.05 +/- 28.9 ng/L &amp; 30.4 +/- 10.6 ng/L, respectively).	T3__IL-6__no_interaction	T3__IL-10__no_interaction
9047091-6	Maximal plasma <compound-id="612">lactate</compound-id> levels during exercise (<compound-id="4091">metformin</compound-id>: 4.1 +/- 2.6 mmol l(-)1, placebo: 4.5 +/- 2.6 mmol (l-1)), areas under the plasma <compound-id="612">lactate</compound-id> curve (207 +/- 121 vs 222 +/- 133 mmol l(-1) h(-1), blood <compound-id="1060">pyruvate</compound-id> levels at the end of exercise (0.06 +/- 0.04 vs 0.07 +/- 0.04 mmol l(-1)), <compound-id="612">lactate</compound-id>/<compound-id="1060">pyruvate</compound-id> ratio (65 +/- 41 vs 60 +/- 36), serum <protein-id="P01308,I3WAC9">insulin</protein-id> (25.4 +/- 8.9 vs 32.3 +/- 13.0 pmol l(-1)), and plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (4.4 +/- 0.3 vs 4.5 +/- 0.3 mmol l(-1)) did not differ significantly between <compound-id="4091">metformin</compound-id> and placebo administration.	pyruvate__insulin__no_interaction	glucose__insulin__no_interaction	metformin__insulin__no_interaction	lactate__insulin__no_interaction
19951500-6	01); the level of <protein-id="P10145,A0A024RDA5">IL-8</protein-id> in sputum was significantly higher in severe asthmatics [2907.78 (331.67 - 3457.93) ng/L] than mild-moderate asthmatics [287.58 (130.75-656.84) ng/L] and healthy control subjects [179.2 (58.55-346.59) ng/L] (P &lt; 0.01); the percentages of neutrophilic apoptosis respectively cultured with <protein-id="O14896,G0Z349">LPS</protein-id> [(10.57 +/- 1.97)%], severe asthmatics supernatant [(11.82 +/- 2.96)%], <protein-id="P10145,A0A024RDA5">IL-8</protein-id> [(10.47 +/- 1.93)%], <compound-id="5743">dexamethasone</compound-id> [(9.93 +/- 1.95)%], severe asthma supernatant + <compound-id="55245">mifepristone</compound-id> [(12.15 +/- 2.86)%] in vitro were lower than that cultured with <protein-id="P30536,O76068">PBS</protein-id> [(17.98 +/- 2.27)%], healthy control supernatant [(17.37 +/- 2.50)%], mild-moderate asthmatics supernatant [(16.35 +/- 3.26)%], <compound-id="55245">mifepristone</compound-id> [(17.89 +/- 2.38)%], and <compound-id="5743">dexamethasone</compound-id> + <compound-id="55245">mifepristone</compound-id> [(17.06 +/- 2.59)%] (P &lt; 0.01).	mifepristone__LPS__no_interaction	mifepristone__IL-8__no_interaction	mifepristone__PBS__no_interaction	dexamethasone__LPS__no_interaction	dexamethasone__IL-8__no_interaction	dexamethasone__PBS__no_interaction
17519026-9	Correlations between inverse of <protein-id="P61769,H0YL18">B2M</protein-id> and CrC (r = 0.477) and between inverse of <protein-id="P61769,H0YL18">B2M</protein-id> and Schwartz (r = 0.697) were better than correlations between inverse of <protein-id="P01034">Cystatin C</protein-id> and CrC (r = 0.390) or Schwartz (r = 0.586) and better than correlations between inverse of <compound-id="588">creatinine</compound-id> and CrC (r = 0.104) or Schwartz (r = 0.442).	creatinine__B2M__no_interaction	creatinine__Cystatin C__no_interaction
19095599-6	<protein-id="P07225">PSA</protein-id> concentrations were positively related to age (r = 0.34, P&lt;.001), total <compound-id="6013">testosterone</compound-id> (r = 0.29, P&lt;.001), free <compound-id="6013">testosterone</compound-id> (r = 0.17, P = .02), and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex hormone-binding globulin</protein-id> (r = 0.22, P&lt;.001) and negatively related to body mass index (r = -0.28, P&lt;.001).	testosterone__PSA__no_interaction	testosterone__sex hormone-binding globulin__no_interaction
14635202-7	Plasma levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (8.27 +/- 0.74 [9.65, 0.90-13.32] pg/mL versus 2.64 +/- 0.66 [1.80, 0.10-11.86] pg/mL, P &lt; 0.001), <protein-id="P02741">CRP</protein-id> (45.57 +/- 9.92 [21.00, 1.34-330.00] mg/L versus 1.96 +/- 0.50 [1.05, 0.19-8.03] mg/L, P &lt; 0.001), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> (7.40 +/- 0.67 [5.57, 2.40-31.80] IU/mL versus 4.73 +/- 0.65 [3.60, 2.32-11.00] IU/mL, P &lt; 0.01), <compound-id="45480165">GFC</compound-id> score (1.90 +/- 0.02 [2, 1-3] versus 2.50 +/- 0.14 [3, 1-3], P &lt; 0.001) were increased compared with controls.	GFC__IL-6__no_interaction	GFC__CRP__no_interaction	GFC__PAI-1__no_interaction
23094669-2	These compounds, (Hbpi)[(UO(2))(H(2)O)(HL)]·H(2)O (<protein-id="P11684">UP-1</protein-id>), represents 1D structure, (Hbpi)[(UO(2))(H(2)O)(HL)] (<protein-id="O00526">UP-2</protein-id>), (H(2)dib)(0.5)[(UO(2))(H(2)O)(HL)] (UP-3), and [(UO(2))(H(2)O)(H(2)L)]·2H(2)O (UP-4) feature 2D architectures, (H(2)bipy){[(UO(2))(H(2)O)](2)[(UO(2))(H(2)O)(2)](L)(2)}·2H(2)O (UP-5), and (H(3)O)(2){[(UO(2))(H(2)O)](3)(L)(2)}·2H(2)O (UP-6) adopt 3D networks (bpi: 1-(biphenyl-4-yl)-<compound-id="795">1H-imidazole</compound-id>, dib: 1,4-di(1H-imidazol-1-yl)<compound-id="241">benzene</compound-id>, bipy: <compound-id="1474">2,2'-bipyridine</compound-id>).	benzene__UP-1__no_interaction	benzene__UP-2__no_interaction	2,2'-bipyridine__UP-1__no_interaction	2,2'-bipyridine__UP-2__no_interaction	1H-imidazole__UP-1__no_interaction	1H-imidazole__UP-2__no_interaction
23663343-5	RESULTS: Hypoxia significantly increased the expression of <protein-id="P04961">PCNA</protein-id> (0.528 ± 0.028), p-<protein-id="P21708">ERK1</protein-id>, 2 (1.12 ± 0.05, 0.91 ± 0.06), <compound-id="6035">BrdU</compound-id> incorporation (143.3 ± 4.2) and cell proliferation index (12.5 ± 0.9) (all P &lt; 0.05, versus control group, 0.243 ± 0.025, 0.47 ± 0.03, 0.40 ± 0.03, 100.0 ± 5.4, 7.5 ± 1.2).	BrdU__PCNA__no_interaction	BrdU__ERK1__no_interaction
1635058-4	Among the more active compounds synthesized are tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[2-[[2-[[(3-hydroxy-5-isoxazolyl)acetyl]-amino]-2- phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl+ ++]<compound-id="277">carbamate</compound-id> (15), tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-[(1-oxo- 3-sulfopropyl)amino]-2-phenylethyl]amino]-<compound-id="23134249">ethyl</compound-id>]<compound-id="277">carbamate</compound-id>, <compound-id="5360545">monosodium</compound-id> salt (27), and tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1- methyl-2-oxo-2-[[2-[[(1H-1,2,4-triazol-5-ylsulfinyl)acetyl]a mino]-2-phenylethyl]amino]<compound-id="23134249">ethyl</compound-id>]carbamic acid (34) which have <protein-id="P32239">CCK-B</protein-id> binding affinities of IC50 = 2.6, 1.3, and 1.7 nM, <protein-id="P32238">CCK-A</protein-id>/-B ratios of 650, 780, and 550 and pK(a) values of 6.5, less than 1, and 7.0, respectively.	monosodium__CCK-B__no_interaction	monosodium__CCK-A__no_interaction	ethyl__CCK-B__no_interaction	ethyl__CCK-A__no_interaction	carbamate__CCK-B__no_interaction	carbamate__CCK-A__no_interaction
17115712-7	In contrast, the <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id>-catalyzed hydrolysis of N-alpha-Z-<compound-id="71070">D-Arg</compound-id>-Gly-Arg-pNA.2HCl (S-2765) and H-D-Ile-<compound-id="151004">L-Pro-L-Arg</compound-id>-pNA.HCl (S-2288) is most consistent with two-<compound-id="1038,5460653">proton</compound-id> bridges forming at the transition state between Ser195 OgammaH and His57 N(epsilon)2 and His57 Ndelta1 and Asp102 COObeta- at the active site, with transition-state fractionation factors of <protein-id="Q96C90">phi1</protein-id> = phi2 = 0.57 +/- 0.07 and phiS = 0.78 +/- 0.16 for solvent rearrangement for S-2765 and <protein-id="Q96C90">phi1</protein-id> = phi2 = 0.674 +/- 0.001 for S-2288 under enzyme saturation with the substrate at pH 8.40 and 25.0 +/- 0.1 degrees C. The rate-determining step(s) in these reactions is most likely the cleavage of the C-N bond and departure of the leaving group.	proton__FXa__no_interaction	proton__phi1__no_interaction	L-Pro-L-Arg__FXa__no_interaction	L-Pro-L-Arg__phi1__no_interaction	D-Arg__FXa__no_interaction	D-Arg__phi1__no_interaction
2157439-8	With aldehyde as the varied substrate the specificity ratios were: <compound-id="5278">statil</compound-id> less than <compound-id="133677">ICI 105552</compound-id> less than <compound-id="2120">alrestatin</compound-id> less than <compound-id="53359">tolrestat</compound-id> less than <compound-id="5280343">quercetin</compound-id> less than CCA less than <compound-id="337359">sorbinil</compound-id> less than <compound-id="4763">phenobarbital</compound-id>, and with <protein-id="Q16698,A0A024R9D7">NADPH</protein-id> as the varied substrate, <compound-id="133677">ICI 105552</compound-id> less than <compound-id="5278">statil</compound-id> less than <compound-id="2120">alrestatin</compound-id> less than <compound-id="53359">tolrestat</compound-id> less than <compound-id="5280343">quercetin</compound-id> less than CCA less than <compound-id="337359">sorbinil</compound-id> less than <compound-id="4763">phenobarbital</compound-id>.	ICI 105552__NADPH__no_interaction	quercetin__NADPH__no_interaction	phenobarbital__NADPH__no_interaction	tolrestat__NADPH__no_interaction	sorbinil__NADPH__no_interaction	statil__NADPH__no_interaction	alrestatin__NADPH__no_interaction
16934042-5	RESULTS: <compound-id="36811">Dobutamine</compound-id> dose-dependently increased ventilation (placebo 6.7 +/- 0.5 vs. D2.5 7.8 +/- 0.4 vs. D7.5 8.7 +/- 0.4 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.005) during normoxia, enhanced the ventilatory (placebo 14.4 +/- 0.6 vs. D2.5 17.3 +/- 0.8 vs. D7.5 22.5 +/- 1.9 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.0001) and sympathetic (placebo + 215 +/- 31 vs. D2.5 + 285 +/- 19 vs. D7.5 + 395 +/- 50% of baseline, P &lt; 0.03) responses at the fifth minute of isocapnic hypoxia and enhanced the sympathetic response to apnoea performed after hypoxia (increase after 5 min of hypoxia: + 290 +/- 43% for placebo vs.+ 360 +/- 21% for D2.5 vs. 537 +/- 69% for D7.5, P &lt; 0.05).	Dobutamine__min(-1__no_interaction
1528982-1	Using the direct measurement of the photosensitized luminescence of singlet molecular <compound-id="977">oxygen</compound-id> (<compound-id="44593851">1O2</compound-id>) the rate constants (<compound-id="196305">kq</compound-id>) have been determined for <compound-id="44593851">1O2</compound-id> quenching by the monomeric molecules of the following phthalocyanines and naphthalocyanines in <compound-id="6212">chloroform</compound-id>: tetra-(4-<compound-id="90937099">tert-butyl</compound-id>) <compound-id="5282330">phthalocyanine</compound-id> (I); octa-(3,6-butoxy) <compound-id="5282330">phthalocyanine</compound-id> (II), tetra-(6-<compound-id="90937099">tert-butyl</compound-id>)-2,3 <compound-id="5748311">naphthalocyanine</compound-id> (III), <compound-id="5359268">aluminium</compound-id> tetra-(1-tert-phenyl)-2,3 <compound-id="5748311">naphthalocyanine</compound-id> (IV), tri-(n-hexyl-siloxy) derivatives of <compound-id="5461123,6329105">silicon</compound-id>- (V), <compound-id="5352426">tin</compound-id>- (VI), <compound-id="5359268">aluminium</compound-id>- (VII) and <compound-id="5360835">gallium</compound-id>- (<protein-id="P10176,Q53XN1">VIII</protein-id>) 2,3 <compound-id="5748311">naphthalocyanine</compound-id>.	phthalocyanine__VIII__no_interaction	aluminium__VIII__no_interaction	1O2__VIII__no_interaction	oxygen__VIII__no_interaction	gallium__VIII__no_interaction	chloroform__VIII__no_interaction	tert-butyl__VIII__no_interaction	tin__VIII__no_interaction	silicon__VIII__no_interaction	kq__VIII__no_interaction	naphthalocyanine__VIII__no_interaction
17256846-1	A series of protonated and methylated Anderson-type molybdoperiodates as well as the unprotonated [IMo6O24]5- have been synthesized and structurally characterized as <compound-id="16028">tetra-n-butylammonium</compound-id> salts: [(<compound-id="137616">n-C4H9</compound-id>)4N]5[IMo6O24] [monoclinic, space group C2/c, a = 33.6101(3) A, b = 15.2575(1) A, c = 24.0294(2) A, beta = 126.9569(3) degrees , Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]4[IMo6O23(OH)] [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/c, a = 9.5587(1) A, b = 24.1364(2) A, c = 18.2788(2) A, beta = 90.1562(5) degrees , Z = 2], [(<compound-id="137616">n-C4H9</compound-id>)4N]3[IMo6O22(OH)2].2DMF [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/a, a = 17.6105(4) A, b = 15.5432(5) A, c = 29.3316(9) A, beta = 91.475(3) degrees , Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]4[IMo6O23(OMe)].3H2O [orthorhombic, space group Pbca, a = 17.0679(4) A, b = 25.6998(6) A, c = 20.7428(4) A, Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]3[IMo6O22(OMe)2] [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/n, a = 10.4009(1) A, b = 14.6658(3) A, c = 23.5395(4) A, beta = 100.324(1) degrees , Z = 2].	n-C4H9__P21__no_interaction	tetra-n-butylammonium__P21__no_interaction
21122208-5	The hemodynamics after using ECMO was much improved than before ECMO [mean arterial pressure (mm Hg, 1 mm Hg=0.133 kPa): 78.13±8.01 vs. 47.75±5.21, central venous pressure ( mm Hg ): 11.03±3.21 vs. 19.36±4.51, cardiac output (L/min): 4.93±1.01 vs. 3.50±0.81, cardiac index (L×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2)): 2.71±0.51 vs. 1.91±0.40, pulmonary artery wedge pressure ( mm Hg ): 12.72±6.52 vs. 20.22±6.91, venous <compound-id="977">oxygen</compound-id> saturation: 0.66±0.13 vs. 0.54±0.07], and the amount of using inotropic drug was significantly reduced compared with that before ECMO [<compound-id="681">dopamine</compound-id> (μg×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)): 5.05±0.85 vs. 14.20±5.05, <compound-id="5816">epinephrine</compound-id> (μg×kg(-1) ×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)): 0.05±0.01 vs. 0.24±0.04, all P&lt;0.05].	epinephrine__min(-1__no_interaction	oxygen__min(-1__no_interaction	dopamine__min(-1__no_interaction
9855050-7	The levels of <compound-id="23978">copper</compound-id> were positively correlated with the C3C (r = 0.41, P &lt; 0.0005), C4 (r = 0.38, P &lt; 0.001) and <protein-id="P00450,A5PL27">ceruloplasmin</protein-id> (r = 0.44, P &lt; 0.0005), whereas <compound-id="23994">zinc</compound-id> was correlated with C3C (r = 0.32, P = 0.0005) and ANA (P = 0.01).	copper__ceruloplasmin__no_interaction	zinc__ceruloplasmin__no_interaction
7806089-6	No differences were observed in SEpo levels (pre-<protein-id="Q9UHK6">race</protein-id> = 19.8 +/- 4.1 U/L, 6-hour = 21.2 +/- 4.9 U/L and post-<protein-id="Q9UHK6">race</protein-id> = 21 +/- 4 U/L), but UEpo increased following the <protein-id="Q9UHK6">race</protein-id> (pre-<protein-id="Q9UHK6">race</protein-id> = 15.4 +/- 9.6 U/L, 6-hour = 26.1 +/- 6.2 U/L and post-<protein-id="Q9UHK6">race</protein-id> = 14.1 +/- 6.5 U/L) (p &lt; 0.0001) and this UEpo increase was related to urine <compound-id="588">creatinine</compound-id> changes (<compound-id="7021454">rs</compound-id> = 0.79, p &lt; 0.00001).	creatinine__race__no_interaction	rs__race__no_interaction
24066833-1	The complexes (BDI)<compound-id="10111">MgX</compound-id>(<compound-id="8028">THF</compound-id>), where X = Bu(n), <protein-id="Q05519">NEt2</protein-id>, and OBu(t), are shown to undergo <compound-id="8028">THF</compound-id> exchange at low added concentrations of <compound-id="8028">THF</compound-id> by a dissociative mechanism: X = Bu(n), ΔH(#) (kcal mol(-1)) = 13.4 ± 0.4 and ΔS(#) (cal mol(-1) K(-1)) = 6.3 ± 1.6; X = <protein-id="Q05519">NEt2</protein-id>, ΔH(#) (kcal mol(-1)) = 15.2 ± 0.5 and ΔS(#) (cal mol(-1) K(-1)) = 11.4 ± 2.3; X = OBu(t), ΔH(#) (kcal mol(-1)) = 16.4 ± 0.3 and ΔS(#) (cal mol(-1) K(-1)) = 9.5 ± 1.3.	THF__NEt2__no_interaction	MgX__NEt2__no_interaction
1515102-1	(III): [4 alpha,6 beta(E)]-(+-)-6-(2-[2-(4-Fluoro-3-methylphenyl)- 4,4,6,6-tetramethyl-1-<compound-id="8079">cyclohexen</compound-id>-1-yl]<compound-id="123166">ethenyl</compound-id>)-4-hydroxytetrahy <compound-id="25113117">dro</compound-id> <compound-id="68154">pyran-2-one</compound-id> (<compound-id="22451705,6436001">RG-12561</compound-id>) <compound-id="6344">dichloromethane</compound-id> solvate, 2C24H31FO3.CH2-<protein-id="O95490">Cl2</protein-id>, Mr = 857.94, triclinic, Pl, a = 11.7413 (5), b = 13.0279 (5), c = 16.2332 (9) A, alpha = 99.456 (4), beta = 94.217 (4), gamma = 101.893 (4) degrees, V = 2381.9 (4) A3, Z = 4 [four molecules of (III)+two molecules of solvent per unit cell], Dx = 1.195 g cm-3, Cu K alpha, lambda = 1.54178 A, mu = 16.69 cm-1, F(000) = 912, T = 293 K, final R = 0.053, wR = 0.060 for 4031 reflections with I greater than 3 sigma(I).	pyran-2-one__Cl2__no_interaction	dichloromethane__Cl2__no_interaction	cyclohexen__Cl2__no_interaction	RG-12561__Cl2__no_interaction	ethenyl__Cl2__no_interaction	dro__Cl2__no_interaction
11907637-14	Treatment with 40 mg/day <compound-id="3403,446155">fluvastatin</compound-id> caused a significant decrease in total <compound-id="5997">cholesterol</compound-id> (patients: 5.47 +/- 1.32 mmol/L vs. 7.30 +/- 1.83 mmol/L; controls: 4.69 +/- 0.64 mmol/L vs. 5.81 +/- 0.72 mmol/L), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (patients: 3.28 +/- 1.25 mmol/L vs. 5.00 +/- 1.85 mmol/L; controls: 2.58 +/- 0.63 mmol/L vs. 3.50 +/- 0.70 mmol/L), and triglycerides (patients: 1.99 +/- 0.77 mmol/L vs. 2.50 +/- 1.00 mmol/L; controls: 1.24 +/- 0.46 mmol/L vs. 1.72 +/- 0.67 mmol/L) in both study groups, whereas HDL-C was not significantly changed (patients: 1.29 +/- 0.35 mmol/L vs. 1.17 +/- 0.32 mmol/L; controls: 1.55 +/- 0.30 mmol/L vs. 1.53 +/- 0.26 mmol/L).	fluvastatin__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
24180413-6	We show that i) <protein-id="Q8N414">PGBD5</protein-id> was first domesticated in the common ancestor of the cephalochordate Branchiostoma floridae (<compound-id="5287660">aka</compound-id> lancelet or amphioxus) and vertebrates, and is conserved in all vertebrates including lamprey but cannot be found in more basal urochordates, hemichordates, or echinoderms; ii) the lancelet, lamprey, and human <protein-id="Q8N414">PGBD5</protein-id> genes are syntenic and orthologous; iii) no potentially mobile ancestral <protein-id="Q8N414">PGBD5</protein-id> elements can be identified in other more deeply rooted organisms; iv) although derived from an IS4-related transposase of the RNase H clan, <protein-id="Q8N414">PGBD5</protein-id> protein is unlikely to retain enzymatic activity because the catalytic DDD(D) motif is not conserved; v) <protein-id="Q8N414">PGBD5</protein-id> is preferentially expressed in certain granule cell lineages of the brain and in the central nervous system based on available mouse and human in situ hybridization data, and the tissue-specificity of documented mammalian EST and mRNA clones; vi) the human <protein-id="Q8N414">PGBD5</protein-id> promoter and gene region is rich in bound regulatory factors including the neuron-restrictive silencer factors <protein-id="Q13127">NRSF</protein-id>/<protein-id="Q13127">REST</protein-id> and <protein-id="Q9UKL0,J3KN32">CoREST</protein-id>, as well as SIN3, <protein-id="Q13263">KAP1</protein-id>, <protein-id="P40763">STAT3</protein-id>, and <protein-id="P49711">CTCF</protein-id>; and vii) despite preferential localization within the nucleus, <protein-id="Q8N414">PGBD5</protein-id> protein is unlikely to bind DNA or chromatin as neither DNase I digestion nor high salt extraction release <protein-id="Q8N414">PGBD5</protein-id> from fractionated mouse brain nuclei.	aka__PGBD5__no_interaction	aka__STAT3__no_interaction	aka__KAP1__no_interaction	aka__CoREST__no_interaction	aka__REST__no_interaction	aka__NRSF__no_interaction	aka__CTCF__no_interaction
19781220-2	METHODS: Human monocytic cell line (THP-1) was induced into macrophages by 160 nmol/L <compound-id="4792">phorbol myristate acetate</compound-id> (<compound-id="122634,22833501,27924">PMA</compound-id>) for 48 h, and were randomly allocated into four groups: negative control group (50 microg/ml LDL for 48 h); positive control group (50 microg/ml ox-LDL for 48 h); <protein-id="P15169">C.pn</protein-id> infection group (50 microg/ml LDL plus 1 x 10(5), 4 x 10(5), 5 x 10(5) and 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 48 h or 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 0, 24, 48 and 72 h); ACAT <compound-id="5327347">inhibitor 58</compound-id>-035 plus <protein-id="P15169">C.pn</protein-id> infection group (1, 5, 10 microg/ml ACAT <compound-id="5327347">inhibitor 58</compound-id>-035 pretreatment for 1 h, 50 microg/ml LDL and 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 48 h).	inhibitor 58__C.pn__no_interaction	phorbol myristate acetate__C.pn__no_interaction	PMA__C.pn__no_interaction
18550542-6	Here we show that (i) upstream regulators, PIK and <protein-id="Q15118,B7Z7N6">PDK1</protein-id>, are not the target(s) of the <protein-id="P49913,J3KNB4">cAMP</protein-id> inhibitory action; (ii) constitutively active Akt and <compound-id="11029486,179202,2534,44338867,44351042,46936510,49786999,5459084,54608024">calyculin A</compound-id>-stimulated Akt are resistant to <protein-id="P49913,J3KNB4">cAMP</protein-id> inhibition, suggesting the action of a phosphatase; (iii) <protein-id="P49913,J3KNB4">cAMP</protein-id> increases the rate of Akt dephosphorylation, directly implicating an Akt-phosphatase; (iv) Epac- and protein kinase A (PKA)-specific analogs synergistically inhibit Akt, indicating the involvement of both <protein-id="P49913,J3KNB4">cAMP</protein-id>-dependent effector pathways; (v) H89 and dominant negative Epac 279E block <protein-id="P49913,J3KNB4">cAMP</protein-id>-inhibitory action; (vi) Epac associates in a complex with Akt and <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id>, and the associated-phosphatase activity is positively modulated by <protein-id="P49913,J3KNB4">cAMP</protein-id> in a PKA- and Rap1-dependent manner; (vii) like its action on Akt inhibition, PKA- and Epac-specific analogs synergistically activate Epac-associated <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id>; and (viii) dominant negative <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id> blocks <protein-id="P49913,J3KNB4">cAMP</protein-id>-inhibitory action.	calyculin A__PDK1__no_interaction	calyculin A__cAMP__no_interaction	calyculin A__PP2A__no_interaction
23375594-8	Our results show that (i) MU-PH1 cells expresses the Müller cell markers Vimentin, S-100, <compound-id="5961">glutamine</compound-id> synthetase and the progenitor and stem cell markers Nestin, <protein-id="Q9UNQ0,A0A024RDD4">Abcg2</protein-id>, <protein-id="P50553">Ascl1</protein-id>, α-tubulin and β-III-tubulin, whereas lacks the expression of <protein-id="P12271">CRALBP</protein-id>, GFAP, <protein-id="P58304">Chx10</protein-id>, <protein-id="P26367,F1T0F8,Q66SS1,D1KF47">Pax6</protein-id> and <protein-id="P46531">Notch1</protein-id> markers; (ii) MU-PH1 cell line stably express the photoreceptor markers recoverin, transducin, <protein-id="P08100">rhodopsin</protein-id>, blue and red/green opsins and also melanopsin; (iii) the presence of opsins was confirmed by the recording of intracellular free <compound-id="22044544,5460341">calcium</compound-id> levels during light stimulation; (iv) MU-PH1 cell line also expresses the <compound-id="896">melatonin</compound-id> MT1 and <compound-id="25011735">MT2</compound-id> receptors; (v) MU-PH1 cells express <protein-id="O60603,B3KWR9">TLR1, 2, 4 and 6</protein-id> mRNA; (vi) MU-PH1 express <protein-id="O60603,B3KWR9">TLR2</protein-id> at cell surface level; (vii) Candida albicans increases <protein-id="O60603,B3KWR9">TLR2</protein-id> and TLR6 mRNA expression; (viii) C. albicans or TLR selective agonists (Pam(3)CysSK(4), LPS) did not elicit morphological changes nor TNF-α secretion; (ix) C. albicans and Pam(3)CysSK(4) augmented MU-PH1 neurospheres formation in a statistically significant manner.	MT2__Abcg2__no_interaction	MT2__Ascl1__no_interaction	MT2__Notch1__no_interaction	MT2__rhodopsin__no_interaction	MT2__TLR2__no_interaction	MT2__Pax6__no_interaction	MT2__CRALBP__no_interaction	MT2__Chx10__no_interaction	MT2__TLR1, 2, 4 and 6__no_interaction	calcium__Abcg2__no_interaction	calcium__Ascl1__no_interaction	calcium__Notch1__no_interaction	calcium__rhodopsin__no_interaction	calcium__TLR2__no_interaction	calcium__Pax6__no_interaction	calcium__CRALBP__no_interaction	calcium__Chx10__no_interaction	calcium__TLR1, 2, 4 and 6__no_interaction	melatonin__Abcg2__no_interaction	melatonin__Ascl1__no_interaction	melatonin__Notch1__no_interaction	melatonin__rhodopsin__no_interaction	melatonin__TLR2__no_interaction	melatonin__Pax6__no_interaction	melatonin__CRALBP__no_interaction	melatonin__Chx10__no_interaction	melatonin__TLR1, 2, 4 and 6__no_interaction	glutamine__Abcg2__no_interaction	glutamine__Ascl1__no_interaction	glutamine__Notch1__no_interaction	glutamine__rhodopsin__no_interaction	glutamine__TLR2__no_interaction	glutamine__Pax6__no_interaction	glutamine__CRALBP__no_interaction	glutamine__Chx10__no_interaction	glutamine__TLR1, 2, 4 and 6__no_interaction
22012979-1	Six assays were evaluated in this study to determine their suitability for the diagnosis of acute dengue infection using samples from 259 Sri Lankan patients with acute fevers (99 confirmed dengue cases and 160 patients with other confirmed acute febrile illnesses): (i) the <compound-id="84098">Merlin</compound-id> dengue fever IgG &amp; IgM combo device (<compound-id="84098">Merlin</compound-id>), (ii) the Standard Diagnostics Dengue <protein-id="O60229,C9IZQ6,J3QSW6">Duo</protein-id> nonstructural 1 (NS1) antigen and IgG/IgM combo device (Standard Diagnostics, South Korea), (iii) the Biosynex Immunoquick dengue fever IgG and IgM (Biosynex, France) assay, (iv) the Bio-Rad NS1 antigen strip (Bio-Rad, France), (v) the Panbio Dengue <protein-id="O60229,C9IZQ6,J3QSW6">Duo</protein-id> IgG/IgM Cassette (Inverness, Australia), and (vi) the Panbio dengue NS1 antigen strip (Inverness, Australia).	Merlin__Duo__no_interaction
10841001-8	Peak <protein-id="P01308,I3WAC9">insulin</protein-id> and <protein-id="P01308,I3WAC9">C-peptide</protein-id> concentrations were as follows (<protein-id="P01308,I3WAC9">C-peptide</protein-id> concentrations are given in parentheses): for patients (n = 12): meal, 277 +/- 42 pmol/l (2,181 +/- 261 pmol/l); <protein-id="P01275">GLP-1</protein-id> (2.5 nmol), 390 +/- 74 pmol/l (2,144 +/- 254 pmol/l); <protein-id="P01275">glucagon</protein-id>, 329 +/- 50 pmol/l (1,780 +/- 160 pmol/l); <compound-id="206,5793,64689,79025">glucose</compound-id> plus <protein-id="P01275">GLP-1</protein-id>, 465 +/- 87 pmol/l (2,384 +/- 299 pmol/l); for control subjects (n = 12): meal, 543 +/- 89 pmol/l (2,873 +/- 210 pmol/l); <protein-id="P01275">GLP-1</protein-id>, 356 +/- 51 pmol/l (2,001 +/- 130 pmol/l); <protein-id="P01275">glucagon</protein-id>, 420 +/- 61 pmol/l (1,995 +/- 99 pmol/l); <compound-id="206,5793,64689,79025">glucose</compound-id> plus <protein-id="P01275">GLP-1</protein-id>, 1,412 +/- 187 pmol/l (4,391 +/- 416 pmol/l).	glucose__GLP-1__no_interaction	glucose__glucagon__no_interaction	glucose__insulin__no_interaction	glucose__C-peptide__no_interaction
20045992-4	Twelve novel single nucleotide polymorphisms (SNPs) (<protein-id="P00492">HGPRT</protein-id>: IVS6-12C&gt;A (frequency:0.003); <protein-id="Q9BY32">ITPA</protein-id>: 569T&gt;C (Phe189Phe, 0.003); <protein-id="P20839,Q6ZNB1,B3KRZ3">IMPDH1</protein-id>: IVS8-<compound-id="46840165">15C</compound-id>&gt;A (0.003), IVS9+227A&gt;G (0.003), IVS17+115C&gt;T (0.003), and 930C&gt;T (Thr310Thr, 0.005); <protein-id="P12268">IMPDH2</protein-id>: IVS1+<compound-id="86277907">50G</compound-id>&gt;T (0.003), IVS2+<compound-id="66575094">15G</compound-id>&gt;A (0.010), IVS3-<compound-id="71815954">20G</compound-id>&gt;A (0.003), 609C&gt;T (Arg203Arg, 0.003), and 1534C&gt;T (Arg512Trp, 0.003); and <protein-id="P49915">GMPS</protein-id>: 1563T&gt;C (Gly521Gly, 0.003)) and 7 known SNPs (<protein-id="Q9BY32">ITPA</protein-id>: 94C&gt;A (Pro32Thr, 0.005), 138G&gt;A (Gln46Gln, 0.586), and 563G&gt;A (Glu187Glu, 0.433); <protein-id="P20839,Q6ZNB1,B3KRZ3">IMPDH1</protein-id>: 987G&gt;C (Leu329Leu, 0.113) and 1575A&gt;G (Ala525Ala, 0.620) and <protein-id="P49915">GMPS</protein-id>: IVS5-7T&gt;C (0.153), 993A&gt;G (Thr331Thr, 0.153)) were identified in 200 Japanese subjects.	50G__ITPA__no_interaction	50G__GMPS__no_interaction	50G__IMPDH1__no_interaction	50G__HGPRT__no_interaction	50G__IMPDH2__no_interaction	15C__ITPA__no_interaction	15C__GMPS__no_interaction	15C__IMPDH1__no_interaction	15C__HGPRT__no_interaction	15C__IMPDH2__no_interaction	20G__ITPA__no_interaction	20G__GMPS__no_interaction	20G__IMPDH1__no_interaction	20G__HGPRT__no_interaction	20G__IMPDH2__no_interaction	15G__ITPA__no_interaction	15G__GMPS__no_interaction	15G__IMPDH1__no_interaction	15G__HGPRT__no_interaction	15G__IMPDH2__no_interaction
11372388-5	(2) When graded concentrations of <compound-id="5717">zafirlukast</compound-id> (0, 10(-12) mol/L, 10(-10) mol/L, 10(-8) mol/L, 10(-6) mol/L) were added to the <compound-id="5280493">LTC4</compound-id> cultured 16-HBE and ASMC, a significant inhibition of <protein-id="P05305,Q6FH53">ET-1</protein-id> production was observed in both groups cultured with 10(-8) mol/L or more <compound-id="5717">zafirlukast</compound-id> [(12.7 +/- 1.3) ng/L vs (5.5 +/- 2.6) ng/L 16-HBE, t = 4.693, P = 0.019; (7.5 +/- 1.0) ng/L vs (4.4 +/- 0.9) ng/L ASMC (t = 5.003, P = 0.007)].	LTC4__ET-1__no_interaction	zafirlukast__ET-1__no_interaction
2909737-2	These peptides are as follows: 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>]-<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)<protein-id="P01185,X5DQP6">AVP</protein-id>), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)<protein-id="P01185,X5DQP6">AVP</protein-id>), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)DAVP), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)DAVP), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)VAVP), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)VAVP), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)<compound-id="171113">VDAVP</compound-id>), and 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)<compound-id="171113">VDAVP</compound-id>).	4-valine__AVP__no_interaction	4-valine__vasopressin__no_interaction	VDAVP__AVP__no_interaction	VDAVP__vasopressin__no_interaction	O-methyltyrosine__AVP__no_interaction	O-methyltyrosine__vasopressin__no_interaction	ethyltyrosine__AVP__no_interaction	ethyltyrosine__vasopressin__no_interaction	arginine__AVP__no_interaction	arginine__vasopressin__no_interaction
21891868-5	In fact, <protein-id="Q92692">Nectin-2</protein-id> (NC-2); <protein-id="P02649">apolipoprotein E</protein-id> (<protein-id="P02649">APOE</protein-id>); glycoprotein carcinoembryonic antigen related cell adhesion molecule-16 (<protein-id="Q2WEN9">CEACAM-16</protein-id>); <protein-id="P20749">B-cell lymphoma-3</protein-id> (<protein-id="P20749">Bcl-3</protein-id>); translocase of outer mitochondrial membrane 40 homolog (T0MM-40); complement receptor-1 (CR-l); <protein-id="P10909">APOJ</protein-id> or clusterin and C-type lectin domain A family-16 member (<protein-id="Q2KHT3">CLEC-16A</protein-id>); <compound-id="44134894">Phosphatidyl inositol</compound-id>- binding clathrin assembly protein gene (<protein-id="Q13492,A0A024R5P1,A0A024R5L7">PICALM</protein-id>); <compound-id="5957">ATP</compound-id>-bonding cassette, sub family A, member 7 (<protein-id="Q8IZY2,B3KUJ3">ABCA7</protein-id>); membrane spanning A4 (MSA4); <protein-id="Q9Y5K6">CD2 associated protein</protein-id> (<protein-id="Q9Y5K6">CD2AP</protein-id>); cluster of differentiation 33 (CD33); and <protein-id="P21709">ephrin receptor A1</protein-id> (<protein-id="P21709">EPHA1</protein-id>) result in a genetic signature that might affect individual brain susceptibility to infection by the herpes virus family during aging, leading to neuronal loss, inflammation, and amyloid deposition.	ATP__Nectin-2__no_interaction	ATP__B-cell lymphoma-3__no_interaction	ATP__apolipoprotein E__no_interaction	ATP__CLEC-16A__no_interaction	ATP__CD2 associated protein__no_interaction	ATP__APOJ__no_interaction	ATP__EPHA1__no_interaction	ATP__CEACAM-16__no_interaction	ATP__ABCA7__no_interaction	ATP__APOE__no_interaction	ATP__ephrin receptor A1__no_interaction	ATP__Bcl-3__no_interaction	ATP__CD2AP__no_interaction	ATP__PICALM__no_interaction	Phosphatidyl inositol__Nectin-2__no_interaction	Phosphatidyl inositol__B-cell lymphoma-3__no_interaction	Phosphatidyl inositol__apolipoprotein E__no_interaction	Phosphatidyl inositol__CLEC-16A__no_interaction	Phosphatidyl inositol__CD2 associated protein__no_interaction	Phosphatidyl inositol__APOJ__no_interaction	Phosphatidyl inositol__EPHA1__no_interaction	Phosphatidyl inositol__CEACAM-16__no_interaction	Phosphatidyl inositol__ABCA7__no_interaction	Phosphatidyl inositol__APOE__no_interaction	Phosphatidyl inositol__ephrin receptor A1__no_interaction	Phosphatidyl inositol__Bcl-3__no_interaction	Phosphatidyl inositol__CD2AP__no_interaction	Phosphatidyl inositol__PICALM__no_interaction
11372387-6	RESULTS: At 1, 2, 4, 6 h after therapy, FEV1% [(43 +/- +/- 5)%, (50 +/- 5)%, (57 +/- 5)%, (67 +/- 6)%], PEF% [(47 +/- 5)%, (55 +/- 6)%, (62 +/- 7)%, (69 +/- 7)%], clinical index (5.1 +/- 0.8, 4.3 +/- 0.6, 3.5 +/- 0.6, 2.5 +/- 0.4) in <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id> group and FEV1% [(42 +/- 5)%, (44 +/- 5)%, (45 +/- 5)%, (45 +/- 5)%], <protein-id="Q03431,A0A024R2Z8,Q0VGD7">PFE</protein-id>% [(46 +/- 5)%, (47 +/- 5)%, (49 +/- 6)%, (49 +/- 6)%], clinical index (5.3 +/- 0.7, 5.0 +/- 0.5, 4.9 +/- 0.7, 4.8 +/- 0.7) in control group were difference markedly compared with before therapy [<compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id> group was (35 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.0, and control group was (33 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.1, respectively], all (P &lt; 0.01).	budesonide__PFE__no_interaction
9520478-1	In this study, we demonstrate that: (i) injection of an adenovirus (Ad) vector containing the <protein-id="P23363,A0A0G2K624,A0A0H2UI28">brain-derived neurotrophic factor</protein-id> (<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>) gene (Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>) into the vitreous chamber of adult rats results in selective transgene expression by Müller cells; (ii) in vitro, Müller cells infected with Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> secrete <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> that enhances neuronal survival; (iii) in vivo, Ad-mediated expression of functional <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> by Müller cells, temporarily extends the survival of axotomized <compound-id="638015">retinal</compound-id> ganglion cells (RGCs); 16 days after axotomy, injured retinas treated with Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> showed a 4.5-fold increase in surviving RGCs compared with control retinas; (iv) the transient expression of the <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> transgene, which lasted approximately 10 days, can be prolonged with immunosuppression for at least 30 days, and such Ad-mediated <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> remains biologically active, (v) persistent expression of <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> by infected Müller cells does not further enhance the survival of injured RGCs, indicating that the effect of this neurotrophin on RGC survival is limited by changes induced by the lesion within 10-16 days after optic nerve transection rather than the availability of <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>.	retinal__brain-derived neurotrophic factor__no_interaction	retinal__BDNF__no_interaction
11755153-5	Compared to other <protein-id="Q64077">tachykinin NK(1) and NK(2) receptor</protein-id> agonists, the order of potency was: <compound-id="108147,5079497">senktide</compound-id>&gt;<compound-id="5311312,55583">neurokinin B</compound-id>=[Sar(9),Met(O(2))(11)]substance P=[betaAla(8)]<compound-id="13561815,5311311,55582">neurokinin A</compound-id> (4-10)=[MePhe(7)]<compound-id="5311312,55583">neurokinin B</compound-id>&gt;<compound-id="13561815,5311311,55582">neurokinin A</compound-id>&gt;substance P. The potentiation by [MePhe(7)]<compound-id="5311312,55583">neurokinin B</compound-id> of <compound-id="774">histamine</compound-id>-induced microvascular leakage was abolished by the tachykinin NK(1) receptor antagonist <compound-id="108167,5311450">SR140333</compound-id> ([(S)1-(2-[3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)-1-(3-iso-propoxyphenylacetyl)<compound-id="8082">piperidin-3-yl</compound-id>]etyl)-<compound-id="142810">4-phenyl-1-azoniabicyclo[2.2.2]octane</compound-id>, <compound-id="312">chloride</compound-id>]) or the tachykinin NK(3) receptor antagonists <compound-id="219077">SR 142801</compound-id> ([(R)-(N)-(1-(3-(l-benzoyl-3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="8082">piperidin-3-yl</compound-id>) propyl)-<compound-id="69873">4-phenylpiperidin</compound-id>-4-yl)-<compound-id="6582">N-methylacetamide</compound-id>]) and SB 223412 ([(S)-(-)-N-(alpha-ethylbenzyl)-3-hydroxy-<compound-id="185680">2-phenylquinoline-4-carboxamide</compound-id>]).	4-phenylpiperidin__tachykinin NK(1) and NK(2) receptor__no_interaction	2-phenylquinoline-4-carboxamide__tachykinin NK(1) and NK(2) receptor__no_interaction	dichlorophenyl__tachykinin NK(1) and NK(2) receptor__no_interaction	piperidin-3-yl__tachykinin NK(1) and NK(2) receptor__no_interaction	senktide__tachykinin NK(1) and NK(2) receptor__no_interaction	SR 142801__tachykinin NK(1) and NK(2) receptor__no_interaction	chloride__tachykinin NK(1) and NK(2) receptor__no_interaction	N-methylacetamide__tachykinin NK(1) and NK(2) receptor__no_interaction	SR140333__tachykinin NK(1) and NK(2) receptor__no_interaction	neurokinin A__tachykinin NK(1) and NK(2) receptor__no_interaction	neurokinin B__tachykinin NK(1) and NK(2) receptor__no_interaction	4-phenyl-1-azoniabicyclo[2.2.2]octane__tachykinin NK(1) and NK(2) receptor__no_interaction	histamine__tachykinin NK(1) and NK(2) receptor__no_interaction
22229838-1	Three coordination polymers of [(NiL(1))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (1), [(NiL(2))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (2), and [(NiL(3))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (3) have been constructed using azamacrocyclic Ni(II) complexes [NiL(1)](ClO(4))(2)/[NiL(2)](ClO(4))(2)/[NiL(3)](ClO(4))(2) and <protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>(3-) as building blocks (L(1) = 3,10-bis(2-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12-<compound-id="11084806">hexaazacyclotetradecane</compound-id>; L(2) = 3,10-bis(3-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12-<compound-id="11084806">hexaazacyclotetradecane</compound-id>; L(3) = 3,10-bis(4-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12- <compound-id="11084806">hexaazacyclotetradecane</compound-id>; <protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>(3-) = tri(4-carboxy-benzyl)amine).	hexaazacyclotetradecane__TCBA__no_interaction	fluorobenzyl__TCBA__no_interaction
15644641-6	MEASUREMENTS AND MAIN RESULTS: Baseline plasma levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id>, <protein-id="P10145,A0A024RDA5">interleukin-8</protein-id>, and <protein-id="P22301,Q6FGW4">interleukin-10</protein-id> were each associated with an increased risk of death in both logistic regression analyses controlling for ventilator group (odds ratio 1.63 per log-10 increment, 95% confidence interval 1.33-1.98; odds ratio 2.33 per log-10 increment, 95% confidence interval 1.79-3.03; odds ratio 2.02 per log-10 increment, 95% confidence interval 1.47-2.76, respectively) and multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, <compound-id="588">creatinine</compound-id>, platelet count, and vasopressor use (odds ratio 1.63 per log-10 increment, 95% confidence interval 0.93-1.49; odds ratio 1.73 per log-10 increment, 95% confidence interval 1.29-2.34; odds ratio 1.23 per log-10 increment, 95% confidence interval 0.86-1.76, respectively).	creatinine__interleukin-8__no_interaction	creatinine__interleukin-10__no_interaction	creatinine__interleukin-6__no_interaction
7589203-1	The effects of two new non-peptide angiotensin receptor antagonists, irbesartan (SR 47436/<compound-id="3749">BMS-186295</compound-id>, (2-n-<compound-id="68006705">butyl</compound-id>-4-spirocyclopentane-1-[((2'-tetrazol-5-yl)bipheny l-4-yl)methyl]2 - <compound-id="504">imidazolin-5-one</compound-id>) and SR 47155A (2-n-<compound-id="68006705">butyl</compound-id>-4-spirocyclopentane-1-[((2'-carboxy)biphenyl-4-yl)methy l]2- <compound-id="504">imidazolin-5-one</compound-id>, <compound-id="6422">trifluoroacetate</compound-id>), on <protein-id="P01015">angiotensin II</protein-id>-induced pressor responses were studied in the pithed rat in comparison to <compound-id="3961">losartan</compound-id>, EXP 3174 and [Sar1,Val5,Ala8]<protein-id="P01015">angiotensin II</protein-id>.	losartan__angiotensin II__no_interaction	imidazolin-5-one__angiotensin II__no_interaction	butyl__angiotensin II__no_interaction	BMS-186295__angiotensin II__no_interaction	trifluoroacetate__angiotensin II__no_interaction
2850820-2	Increasing dietary Na at the lower Ca intake caused significant (P less than 0.05) increases in <protein-id="P01270">parathyroid hormone (PTH) and 24</protein-id>-hour cyclic AMP excretion that were associated with significant (P less than 0.01) increases in erythrocyte intracellular <compound-id="22044544,5460341">calcium</compound-id> (from 5.4 +/- 0.7 to 11.1 +/- 3.7 microM), Ca-ATPase (from 37.2 +/- 2.4 to 42.2 +/- 2.1 pmol/min/10(6) cells) and intracellular <compound-id="5360545">sodium</compound-id> (from 220.5 +/- 7.4 to 262.0 +/- 8.3 micrograms/mL) and decreases (P less than 0.05) in Na/K-ATPase (from 1.90 +/- 0.55 to 1.48 +/- 0.47 pmol/min/10(6) cells) and intracellular <compound-id="5462224">magnesium</compound-id> (Mg) (from 52.4 +/- 3.5 to 43.8 +/- 2.4 micrograms/mL).	calcium__parathyroid hormone (PTH) and 24__no_interaction	magnesium__parathyroid hormone (PTH) and 24__no_interaction	sodium__parathyroid hormone (PTH) and 24__no_interaction
11598880-2	The glucan <protein-id="Q9UKR8">TM8</protein-id> in <compound-id="679">DMSO</compound-id> was fractionated by nonsolvent addition method into ten fractions, and the solution properties were studied by size exclusion chromatography combined with multiangle laser light scattering (SEC-MALLS) and viscometry in <compound-id="679">DMSO</compound-id> at 30 degrees C. The dependencies of intrinsic viscosity [eta] and radius of gyration [(s(2)(1/2)(z-2)] on weight-average molecular mass M(w) for this glucan were found to be [eta] = (9.24 +/- 0.2) x 10(-2)M(w)(0.51 +/- 0.02) (cm(3)g(-1)) and [(s(2)(1/2)(z-2)] = (3.67 +/- 0.3) x 10(-2)M(w)(0.56 +/- 0.02) (nm) in the range of M(w) from 1.07 x 10(4) to 77.4 x 10(4).	DMSO__TM8__no_interaction
24570606-5	There was no significant effect of measurement time on session-<protein-id="Q96AT9">RPE</protein-id> values following easy (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 1.3 ± 1.0 Arbitrary Unit (AU), %Heart Rate Reserve (HRR) = 49.5 ± 11.1, and ∆Blood <compound-id="612">lactate</compound-id> = -2.3 ± 16.3%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 1.7 ± 1.0 AU, %HRR = 51.3 ± 10.8, and ∆Blood <compound-id="612">lactate</compound-id> = 0.7 ± 25.2%), moderate (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 2.7 ± 1.6 AU, %HRR = 67.2 ± 10.8, and ∆Blood <compound-id="612">lactate</compound-id> = 2.2 ± 19%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 2.5 ± 0.9 AU, %HRR = 67.2 ± 5.9, and ∆Blood <compound-id="612">lactate</compound-id> = 24.5 ± 17.1%) and hard (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 5.7 ± 1.0 AU, %HRR = 88.1 ± 6.3, and ∆Blood <compound-id="612">lactate</compound-id> = 146.3 ± 87.9%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 5.8 ± 1.9 AU, %HRR&gt; = 83.3 ± 8.0, and ∆Blood <compound-id="612">lactate</compound-id> = 91.6 ± 39%) sessions.	lactate__RPE__no_interaction
2146429-4	Patients with AGN and NS had comparable edema (AGN 2.8 +/- 0.53 kg; NS 3.36 +/- 0.47 kg; SE) and urinary Na excretion (mean +/- <compound-id="5289348">SEM</compound-id>: AGN 0.97 +/- 0.11 mEq/hr; NS 1.06 +/- 0.16 mEq/hr), but AGN patients had five times higher <protein-id="P01160">ANF</protein-id> (AGN 27.2 +/- 4.06 fmol/ml; NS 5.51 +/- 1.02 fmol/ml; P less than 0.001) and six times lower PRA ng/liter.sec levels (AGN 0.187 +/- 0.047; NS 1.144 +/- 0.222; P less than 0.001) than NS patients.	SEM__ANF__no_interaction
14970995-6	RESULTS: To yield the best-fit weight formula for each fetal gender we employed step-wise regression analysis based on fractional polynomials with the biometric parameters biparietal diameter (BPD), head circumference (HC), transverse abdominal diameter (<compound-id="124886">TAD</compound-id>), abdominal circumference (AC) and femur length (FL): estimated fetal weight for girls (g) = - 4035.275 + 1.143 x BPD3 + 1159.878 x <protein-id="Q08828,C9J1J0,Q8NFM5,Q59FG4,Q08462,Q71UM8">AC1/2</protein-id> + 10.079 x FL3 - 81.277 x <compound-id="446134">FL2</compound-id> [in cm]; estimated fetal weight for boys (g) = 43576.579 + 1913.853 x log10BPD + 0.01323 x <compound-id="65094">HC3</compound-id> + 55.532 x AC2 - 13602.664 x <protein-id="Q08828,C9J1J0,Q8NFM5,Q59FG4,Q08462,Q71UM8">AC1/2</protein-id> - 0.721 x AC3 + 2.31 x FL3 [in cm].	TAD__AC1/2__no_interaction	HC3__AC1/2__no_interaction	FL2__AC1/2__no_interaction
21896912-7	The CYP2B6*6 allele, <protein-id="O15439,A8K2Q2">multidrug resistance-associated protein 4</protein-id> (<protein-id="O15439,A8K2Q2">MRP4</protein-id>) 1497C → T, and <protein-id="Q9BX51,D3DW46">gamma-glutamyltranspeptidase</protein-id> (GGT) were identified as major factors influencing the apparent <compound-id="64139">EFV</compound-id> oral clearance (CL/F), reducing the initial interindividual variability by 54.8%, according to the model CL/F = (12.2 - 0.00279 · GGT) · 0.602(CYP2B6*6 [G/T]) · 0.354(CYP2B6*6 [T/T]) · 0.793(<protein-id="O15439,A8K2Q2">MRP4</protein-id> 1497C → T), where CYP2B6*6 [G/T], CYP2B6*6 [T/T], and <protein-id="O15439,A8K2Q2">MRP4</protein-id> 1497C → T take values of 0 or 1 to indicate the absence or presence of polymorphisms.	EFV__multidrug resistance-associated protein 4__no_interaction	EFV__MRP4__no_interaction	EFV__gamma-glutamyltranspeptidase__no_interaction
8230672-6	The amounts of cyclic AMP produced by the stimulation of membranes with GTP, GTP+(l)-<compound-id="3779">isoproterenol</compound-id>, <compound-id="54215836">guanylimidodiphosphate</compound-id> (<compound-id="36735">Gpp(NH)p</compound-id>) or <compound-id="36735">Gpp(NH)p</compound-id>+(l)-<compound-id="3779">isoproterenol</compound-id> were significantly lower in 10 mM <compound-id="784">hydrogen peroxide</compound-id>-treated groups than those in controls (GTP: control 57.6 +/- 5.6 pmol <protein-id="G3V8S9">cAMP</protein-id>/mg protein/min vs H2O2 46.4 +/- 6.9, GTP+(l)-<compound-id="3779">isoproterenol</compound-id>: control 83.9 +/- 10.2 vs H2O2 67.7 +/- 10.3, <compound-id="36735">Gpp(NH)p</compound-id>: control 77.5 +/- 8.8 vs H2O2 61.0 +/- 8.6, <compound-id="36735">Gpp(NH)p</compound-id>+(l)-<compound-id="3779">isoproterenol</compound-id>: control 105.0 +/- 13.1 vs H2O2 83.9 +/- 12.2, <compound-id="47936">forskolin</compound-id>: control 223.2 +/- 13.8 vs H2O2 182.8 +/- 18.4).	isoproterenol__cAMP__no_interaction	Gpp(NH)p__cAMP__no_interaction	forskolin__cAMP__no_interaction	guanylimidodiphosphate__cAMP__no_interaction	hydrogen peroxide__cAMP__no_interaction
15579544-2	The present study demonstrated that regardless of whether pre-exercise muscle <compound-id="439177">glycogen</compound-id> content was at a habitual resting concentration (412 +/- 30 mmol (kg dry muscle)(-1)) or depleted (60 +/- 3 mmol (kg dry muscle)(-1)), the increase in PDC activation from its resting value (5.46 +/- 0.96 and 3.67 +/- 0.34 nmol <compound-id="444493">acetyl-CoA</compound-id> <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (mg protein)(-1), respectively) during 10 min of exercise at 75% of the maximum rate of <compound-id="977">oxygen</compound-id> consumption (VO2max) (delta12.82 +/- 1.72 and delta13.24 +/- 1.42 nmol <compound-id="444493">acetyl-CoA</compound-id> <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (mg protein)(-1), respectively) was the same, despite pyruvate accumulation during exercise being 3-fold lower in the <compound-id="439177">glycogen</compound-id> depleted state (delta0.34 +/- 0.04 and delta0.11 +/- 0.06 mmol (kg dry muscle)(-1), P &lt; 0.001).	oxygen__min(-1__no_interaction	acetyl-CoA__min(-1__no_interaction	glycogen__min(-1__no_interaction
7554525-5	After switching from <compound-id="25244226">Sandoparin</compound-id> to unfractionated heparin we observed significant decreases in total <compound-id="5997">cholesterol</compound-id> (from 168.6 +/- 42.2 to 154.4 +/- 41.9 mg/dl, p &lt; 0.02), LDL <compound-id="5997">cholesterol</compound-id> (from 106.4 +/- 35.2 to 89.9 +/- 32.3 mg/dl, p &lt; 0.005), triglycerides (from 148.7 +/- 85.0 to 121.4 +/- 88.8 mg/dl, p &lt; 0.05) and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (from 100.0 +/- 35.3 to 89.9 +/- 30.4 mg/dl, p &lt; 0.05) and a significant increase in HDL <compound-id="5997">cholesterol</compound-id> (from 32.8 +/- 12.5 to 37.7 +/- 17.5 mg/dl, p &lt; 0.02).	Sandoparin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
19274289-1	The new mononuclear [Cu(Hbdea)(2)].2Hdnba (), dinuclear [Cu(2)(mu-Hbdea)(2)(N(3))(2)] () and [Cu(2)(mu-Hbdea)(2)(pta)(2)].2H(2)O (), and 1D polymeric [Cu(2)(mu-Hbdea)(2)(mu-<compound-id="122634,22833501">tpa</compound-id>)](n).<compound-id="447474">2nH</compound-id>(2)O () <compound-id="23978">copper</compound-id>(II) compounds have been prepared by self-assembly, in aqueous alkali medium and at ambient conditions, from Cu(II) <compound-id="176">acetate</compound-id>, <compound-id="7620">N-butyldiethanolamine</compound-id> (H(2)bdea) and the corresponding auxiliary reagents, 3,5-dinitrobenzoic acid (Hdnba), <compound-id="33557">sodium azide</compound-id>, <compound-id="7470">p-toluic acid</compound-id> (<protein-id="P14210">Hpta</protein-id>) and <compound-id="7489">terephthalic acid</compound-id> (H(2)<compound-id="122634,22833501">tpa</compound-id>), respectively.	copper__Hpta__no_interaction	2nH__Hpta__no_interaction	tpa__Hpta__no_interaction	p-toluic acid__Hpta__no_interaction	N-butyldiethanolamine__Hpta__no_interaction	acetate__Hpta__no_interaction	sodium azide__Hpta__no_interaction	terephthalic acid__Hpta__no_interaction
18411413-1	In the present report, we evaluated the effect of the novel acid pump antagonist <compound-id="9833312">7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine</compound-id> (CS-526) and 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-<compound-id="5798">1H-benzimidazole</compound-id> (<compound-id="3883,9578006">lansoprazole</compound-id>) on rebound gastric acid secretion, using an intragastric dialysis membrane perfusion model and on the serum and <compound-id="35864">antral</compound-id> <protein-id="P04563">gastrin</protein-id> level after a 14-day treatment in rats.	lansoprazole__gastrin__no_interaction	antral__gastrin__no_interaction	7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine__gastrin__no_interaction	1H-benzimidazole__gastrin__no_interaction
19044958-6	Combining the VUV-<compound-id="54688400">PFI</compound-id>-PE and VUV-IR-PIRI measurements, 17 fundamental vibrational frequencies of trans-CH(2)[Double Bond]<protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>[Double Bond]CH(2) (+) have been determined, including nu(1) (+)=182+/-3, nu(2) (+)=300+/-3, nu(3) (+)=428+/-3, nu(4) (+)=514+/-3, nu(5) (+)=554+/-5, nu(6) (+)=901+/-3, nu(7) (+)=928+/-5, nu(8) (+)=994+/-3, nu(9) (+)=1008+/-5, nu(10) (+)=1094+/-5, nu(13) (+)=1258+/-3, nu(14) (+)=1293+/-3, nu(16) (+)=1479+/-3, nu(18) (+)=1620+/-3, nu(19) (+)=2985+/-10, nu(22) (+)=3030+/-10, and nu(23) (+)=3105+/-10 cm(-1).	PFI__CHCH__no_interaction
18036385-4	The calibration curves of analysed compounds are linear within the range of concentration: 45-825, 0.2-15, 16-225, 12-285, 0.1-32, 15-235, 0.1-12, 0.1-12, 10-205, 0.02-12, 0.1-24, 0.01-10 and 0.01-8 nmol mL(-1) for GLN, <compound-id="123895">NOHA</compound-id>, CIT, <protein-id="Q9P2R6,B1AKN3,A0A024R4E9">ARG</protein-id>, NMMA, <compound-id="232">HARG</compound-id>, ADMA, SDMA, ORN, PUT, <compound-id="213604">AGM</compound-id>, SPERMD and SPERM, respectively.	NOHA__ARG__no_interaction	HARG__ARG__no_interaction	AGM__ARG__no_interaction
15167345-10	Corrected <compound-id="588">creatinine</compound-id> clearance negatively correlated significantly with both <protein-id="P01034">cystatin C</protein-id> and <compound-id="588">creatinine</compound-id> levels (r = -0.622, P &lt; 0.001; r = -0.346, P = 0.045, respectively) before chemotherapy and also 1 month after chemotherapy (r = -0.577, P &lt; 0.001; r = -0.45, P = 0.009, respectively).	creatinine__cystatin C__no_interaction
23633364-19	<compound-id="44223986">FGS</compound-id> versus alpha-glucosidase inhibitors showed statistical significance in favour of <compound-id="44223986">FGS</compound-id> for adverse events (RR 0.63, 95% CI 0.52 to 0.76; P = 0.01; 2 trials; 246 participants; HRB) and for drop-outs due to adverse events (RR 0.28, 95% CI 0.12 to 0.67; P = 0.004; 2 trials; 246 participants; HRB).Second-generation sulphonylureas (SGS) versus <compound-id="4091">metformin</compound-id> (RR 0.98, 95% CI 0.61 to 1.58; P = 0.68; 6 trials; 3528 participants; HRB), thiazolidinediones (RR 0.92, 95% CI 0.60 to 1.41; P = 0.70; 7 trials; 4955 participants; HRB), <protein-id="P01308,I3WAC9">insulin</protein-id> (RR 0.96, 95% CI 0.79 to 1.18; P = 0.72; 4 trials; 1642 participants; HRB), <compound-id="3033769">meglitinides</compound-id> (RR 1.44, 95% CI 0.47 to 4.42; P = 0.52; 7 trials; 2038 participants; HRB), or incretin-based interventions (RR 1.39, 95% CI 0.52 to 3.68; P = 0.51; 2 trials; 1503 participants; HRB) showed no statistically significant effects regarding all-cause mortality in a random-effects model.	meglitinides__insulin__no_interaction	metformin__insulin__no_interaction	FGS__insulin__no_interaction
23270831-5	These compounds could be grouped as follows: alkaloids, 25.23% (<compound-id="5311218">TB1</compound-id>), 25.67% (<protein-id="Q00765">TB2</protein-id>), and 21.91% (TB3); phenols, 24.19% (<compound-id="5311218">TB1</compound-id>), 23.08% (<protein-id="Q00765">TB2</protein-id>), and 29.91% (TB3); <compound-id="947">nitrogen</compound-id>-compounds, 11.79% (<compound-id="5311218">TB1</compound-id>), 11.25% (<protein-id="Q00765">TB2</protein-id>), and 13.39% (TB3); hydrocarbons, 10.96% (<compound-id="5311218">TB1</compound-id>), 10.37% (<protein-id="Q00765">TB2</protein-id>), and 11.37% (TB3); <compound-id="114522">ketones</compound-id>, 10.34% (<compound-id="5311218">TB1</compound-id>), 6.58% (<protein-id="Q00765">TB2</protein-id>), and 8.22% (TB3); furan, 5.40% (<compound-id="5311218">TB1</compound-id>), 4.06% (<protein-id="Q00765">TB2</protein-id>), and 2.33% (TB3); <compound-id="10982484,702">alcohol</compound-id>, 3.30% (<compound-id="5311218">TB1</compound-id>), 4.16% (<protein-id="Q00765">TB2</protein-id>), and 3.34% (TB3); fatty acids, 2.80% (<compound-id="5311218">TB1</compound-id>), 4.03% (<protein-id="Q00765">TB2</protein-id>), and 1.42% (TB3); esters 2.17% (<compound-id="5311218">TB1</compound-id>), 0.99% (<protein-id="Q00765">TB2</protein-id>) and 2.35% (TB3); and amines 1.61% (<compound-id="5311218">TB1</compound-id>), 2.81% (<protein-id="Q00765">TB2</protein-id>), and 0.86% (TB3).	TB1__TB2__no_interaction	ketones__TB2__no_interaction	alcohol__TB2__no_interaction	nitrogen__TB2__no_interaction
11561072-6	The rank order of potency at <protein-id="P47824,Q9JIF8,B7U2F3">rP2X1</protein-id> was <compound-id="5957">ATP</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = Ap6G &gt; or = Ap5G, and rank order of efficacy was <compound-id="5957">ATP</compound-id> &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; Ap5G &gt; Ap6G, whereas at <protein-id="P49654,Q9R1K3">rP2X3</protein-id> the rank order of potency was <compound-id="5957">ATP</compound-id> &gt; Ap5G &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; or = Ap6G and the rank order of efficacy was <compound-id="5957">ATP</compound-id> approximately Ap5G &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> approximately <compound-id="123694">Ap6A</compound-id> &gt; or = Ap6G.	Ap6A__rP2X1__no_interaction	Ap6A__rP2X3__no_interaction	Ap5A__rP2X1__no_interaction	Ap5A__rP2X3__no_interaction	ATP__rP2X1__no_interaction	ATP__rP2X3__no_interaction
1592393-2	A large panel of antibodies was applied that included, for frozen tissue, Leu-6 (<protein-id="P06126">CD1</protein-id>), <protein-id="P06729,Q53F96">T11</protein-id> (<protein-id="P06729,Q53F96">CD2</protein-id>), Leu-<compound-id="2981881,91293124">3a</compound-id> (<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>), <protein-id="P06127">Leu-1</protein-id> (<protein-id="P06127">CD5</protein-id>), Leu-2a (<protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>), J5 (<protein-id="P08473">CD10</protein-id>), My7 (<protein-id="P15144,A0A024RC61,Q59E93">CD13</protein-id>), Leu-11 (<protein-id="P08637,M9MML0">CD16</protein-id>), B4 (<protein-id="P15391">CD19</protein-id>), B1 (<protein-id="P11836,A0A024R507">CD20</protein-id>), B2 (<protein-id="P20023">CD21</protein-id>), Tac (<protein-id="P01589,Q5W005">CD25</protein-id>), <compound-id="16741230">My9</compound-id> (<protein-id="P20138,Q546G0">CD33</protein-id>), <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">T200</protein-id> (<protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>), <compound-id="9362340">NKH</compound-id>-1 (<protein-id="P13591,A0A087WWD4">CD56</protein-id>), kappa and lambda chains, beta F1, Ki-67, HLA-DR, <protein-id="P14151,A0A024R8Z0">TQ1</protein-id>, and keratin, and for fixed tissue, leukocyte common antigen (<protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>), <protein-id="P61254">L26</protein-id> (<protein-id="P11836,A0A024R507">CD20</protein-id>), <protein-id="O14832">LN1</protein-id> (CDw75), LN2 (<protein-id="P04233">CD74</protein-id>), LN3, LN4, <compound-id="44176361">LN5</compound-id>, <protein-id="P11912">MB1</protein-id> (CD45R), <compound-id="74766010">MB2</compound-id>, <protein-id="P04731">MT1</protein-id> (<protein-id="P16150,A0A024R629">CD43</protein-id>), <protein-id="P49286">MT2</protein-id> (CD45R), <protein-id="P09936,V9HW74">UCHL1</protein-id> (CD45R0), <compound-id="444703">BM1</compound-id>, Ki-1 (<protein-id="P28908,A5D8T4">CD30</protein-id>), Leu-M1 (<protein-id="P22083">CD15</protein-id>), <protein-id="P61626,B2R4C5">lysozyme</protein-id>, KP1 (<protein-id="P34810">CD68</protein-id>), actin, S100, neuron-specific enolase, <protein-id="P08670,V9HWE1">vimentin</protein-id>, and keratin.	My9__CD74__no_interaction	My9__CD56__no_interaction	My9__CD30__no_interaction	My9__CD33__no_interaction	My9__CD4__no_interaction	My9__CD5__no_interaction	My9__CD1__no_interaction	My9__CD2__no_interaction	My9__CD8__no_interaction	My9__T11__no_interaction	My9__MT2__no_interaction	My9__MT1__no_interaction	My9__vimentin__no_interaction	My9__L26__no_interaction	My9__T200__no_interaction	My9__TQ1__no_interaction	My9__CD45__no_interaction	My9__CD21__no_interaction	My9__CD20__no_interaction	My9__LN1__no_interaction	My9__CD25__no_interaction	My9__CD68__no_interaction	My9__CD43__no_interaction	My9__Leu-1__no_interaction	My9__UCHL1__no_interaction	My9__MB1__no_interaction	My9__lysozyme__no_interaction	My9__CD16__no_interaction	My9__CD15__no_interaction	My9__CD13__no_interaction	My9__CD10__no_interaction	My9__CD19__no_interaction	NKH__CD74__no_interaction	NKH__CD56__no_interaction	NKH__CD30__no_interaction	NKH__CD33__no_interaction	NKH__CD4__no_interaction	NKH__CD5__no_interaction	NKH__CD1__no_interaction	NKH__CD2__no_interaction	NKH__CD8__no_interaction	NKH__T11__no_interaction	NKH__MT2__no_interaction	NKH__MT1__no_interaction	NKH__vimentin__no_interaction	NKH__L26__no_interaction	NKH__T200__no_interaction	NKH__TQ1__no_interaction	NKH__CD45__no_interaction	NKH__CD21__no_interaction	NKH__CD20__no_interaction	NKH__LN1__no_interaction	NKH__CD25__no_interaction	NKH__CD68__no_interaction	NKH__CD43__no_interaction	NKH__Leu-1__no_interaction	NKH__UCHL1__no_interaction	NKH__MB1__no_interaction	NKH__lysozyme__no_interaction	NKH__CD16__no_interaction	NKH__CD15__no_interaction	NKH__CD13__no_interaction	NKH__CD10__no_interaction	NKH__CD19__no_interaction	LN5__CD74__no_interaction	LN5__CD56__no_interaction	LN5__CD30__no_interaction	LN5__CD33__no_interaction	LN5__CD4__no_interaction	LN5__CD5__no_interaction	LN5__CD1__no_interaction	LN5__CD2__no_interaction	LN5__CD8__no_interaction	LN5__T11__no_interaction	LN5__MT2__no_interaction	LN5__MT1__no_interaction	LN5__vimentin__no_interaction	LN5__L26__no_interaction	LN5__T200__no_interaction	LN5__TQ1__no_interaction	LN5__CD45__no_interaction	LN5__CD21__no_interaction	LN5__CD20__no_interaction	LN5__LN1__no_interaction	LN5__CD25__no_interaction	LN5__CD68__no_interaction	LN5__CD43__no_interaction	LN5__Leu-1__no_interaction	LN5__UCHL1__no_interaction	LN5__MB1__no_interaction	LN5__lysozyme__no_interaction	LN5__CD16__no_interaction	LN5__CD15__no_interaction	LN5__CD13__no_interaction	LN5__CD10__no_interaction	LN5__CD19__no_interaction	BM1__CD74__no_interaction	BM1__CD56__no_interaction	BM1__CD30__no_interaction	BM1__CD33__no_interaction	BM1__CD4__no_interaction	BM1__CD5__no_interaction	BM1__CD1__no_interaction	BM1__CD2__no_interaction	BM1__CD8__no_interaction	BM1__T11__no_interaction	BM1__MT2__no_interaction	BM1__MT1__no_interaction	BM1__vimentin__no_interaction	BM1__L26__no_interaction	BM1__T200__no_interaction	BM1__TQ1__no_interaction	BM1__CD45__no_interaction	BM1__CD21__no_interaction	BM1__CD20__no_interaction	BM1__LN1__no_interaction	BM1__CD25__no_interaction	BM1__CD68__no_interaction	BM1__CD43__no_interaction	BM1__Leu-1__no_interaction	BM1__UCHL1__no_interaction	BM1__MB1__no_interaction	BM1__lysozyme__no_interaction	BM1__CD16__no_interaction	BM1__CD15__no_interaction	BM1__CD13__no_interaction	BM1__CD10__no_interaction	BM1__CD19__no_interaction	3a__CD74__no_interaction	3a__CD56__no_interaction	3a__CD30__no_interaction	3a__CD33__no_interaction	3a__CD4__no_interaction	3a__CD5__no_interaction	3a__CD1__no_interaction	3a__CD2__no_interaction	3a__CD8__no_interaction	3a__T11__no_interaction	3a__MT2__no_interaction	3a__MT1__no_interaction	3a__vimentin__no_interaction	3a__L26__no_interaction	3a__T200__no_interaction	3a__TQ1__no_interaction	3a__CD45__no_interaction	3a__CD21__no_interaction	3a__CD20__no_interaction	3a__LN1__no_interaction	3a__CD25__no_interaction	3a__CD68__no_interaction	3a__CD43__no_interaction	3a__Leu-1__no_interaction	3a__UCHL1__no_interaction	3a__MB1__no_interaction	3a__lysozyme__no_interaction	3a__CD16__no_interaction	3a__CD15__no_interaction	3a__CD13__no_interaction	3a__CD10__no_interaction	3a__CD19__no_interaction	MB2__CD74__no_interaction	MB2__CD56__no_interaction	MB2__CD30__no_interaction	MB2__CD33__no_interaction	MB2__CD4__no_interaction	MB2__CD5__no_interaction	MB2__CD1__no_interaction	MB2__CD2__no_interaction	MB2__CD8__no_interaction	MB2__T11__no_interaction	MB2__MT2__no_interaction	MB2__MT1__no_interaction	MB2__vimentin__no_interaction	MB2__L26__no_interaction	MB2__T200__no_interaction	MB2__TQ1__no_interaction	MB2__CD45__no_interaction	MB2__CD21__no_interaction	MB2__CD20__no_interaction	MB2__LN1__no_interaction	MB2__CD25__no_interaction	MB2__CD68__no_interaction	MB2__CD43__no_interaction	MB2__Leu-1__no_interaction	MB2__UCHL1__no_interaction	MB2__MB1__no_interaction	MB2__lysozyme__no_interaction	MB2__CD16__no_interaction	MB2__CD15__no_interaction	MB2__CD13__no_interaction	MB2__CD10__no_interaction	MB2__CD19__no_interaction
15809706-4	Our results showed that (i) treatment with <protein-id="P48023,Q53ZZ1">FasL</protein-id> increased <protein-id="Q14790,A0A024R3Z8">caspase-8</protein-id> activity (maximum at 4 h) and apoptosis (maximum at 8 h) in both <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) and <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (ii) <protein-id="P48023,Q53ZZ1">FasL</protein-id>-induced <protein-id="Q14790,A0A024R3Z8">caspase-8</protein-id> activity and apoptosis were significantly greater in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells compared with <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (iii) <protein-id="P48023,Q53ZZ1">FasL</protein-id> treatment increased cell surface expression of Fas receptor in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells to a greater extent compared with <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (iv) increased cell surface expression of Fas in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells was not blocked by an inhibitor of protein synthesis (<compound-id="6197">cycloheximide</compound-id>), but was completely abrogated by <compound-id="24123450,2430,5351204,5353446,6364669,6436187,71308166">brefeldin A</compound-id>, an inhibitor of post-translational protein trafficking to the cell surface, and (v) <compound-id="24123450,2430,5351204,5353446,6364669,6436187,71308166">brefeldin A</compound-id> inhibited the increased sensitivity of <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells to <protein-id="P48023,Q53ZZ1">FasL</protein-id>-induced apoptosis.	brefeldin A__caspase-8__no_interaction	brefeldin A__MUC1__no_interaction	brefeldin A__FasL__no_interaction	cycloheximide__caspase-8__no_interaction	cycloheximide__MUC1__no_interaction	cycloheximide__FasL__no_interaction
21059972-5	Compared with the control group, supervised exercise produced significant improvements (mean difference [95% confidence interval]) in physical fitness; HbA(1c) level (-0.30% [-0.49% to -0.10%]; P &lt; .001); systolic (-4.2 mm Hg [-6.9 to -1.6 mm Hg]; P = .002) and diastolic (-1.7 mm Hg [-3.3 to -1.1 mm Hg]; P = .03) blood pressure; high-density lipoprotein (3.7 mg/dL [2.2 to 5.3 mg/dL]; P &lt; .001) and low-density lipoprotein (-9.6 mg/dL [-15.9 to -3.3 mg/dL]; P = .003) <compound-id="5997">cholesterol</compound-id> level; waist circumference (-3.6 cm [-4.4 to -2.9 cm]; P &lt; .001); body mass index; <protein-id="P01308,I3WAC9">insulin</protein-id> resistance; inflammation; and risk scores.	cholesterol__insulin__no_interaction
1377308-5	After 3 months of treatment, we found (a) significant decreases in systolic (147 +/- 18 vs. 166 +/- 16 mm Hg, p less than 0.001) and diastolic blood pressure (90 +/- 8 vs. 107 +/- 8 mm Hg, p less than 0.0007), triglycerides (107 +/- 47 vs. 120 +/- 49 mg/dl, p less than 0.0007), and <compound-id="5997">cholesterol</compound-id> (236 +/- 4 vs. 257 +/- 44 mg/dl, p less than 0.00075) in blood, and in K excretion (50 +/- 19 vs. 46 +/- 19 mEq/g of <compound-id="588">creatinine</compound-id>, p less than 0.0007) and excreted fraction of K (49 +/- 6% vs. 8 +/- 5%, p less than 0.0012) in urine; (b) significant increases in <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (65 +/- 13 vs. 58 +/- 13 mg/dl, p less than 0.001) in blood, and in Na (115 +/- 73 vs. 109 +/- 69 mEq/g of <compound-id="588">creatinine</compound-id>, p less than 0.0007) in urine; and (c) no significant change in the remaining biochemical parameters, or in heart rate.	creatinine__HDL__no_interaction	cholesterol__HDL__no_interaction
18520077-3	Among them, compounds with substituent at the 3-position on the central <compound-id="241">benzene</compound-id> ring represented by (N-{4-[1-(<compound-id="140746">acetimidoyl</compound-id>)<compound-id="79341">piperidin-4-yloxy</compound-id>]-3-chlorophenyl}-N-[(E)-3-(3-<compound-id="2332">amidinophenyl</compound-id>)-<compound-id="123136">2-propenyl</compound-id>]sulfamoyl)acetic acid dihydrochloride (<compound-id="42628077">45b</compound-id>) and (N-{4-[1-(<compound-id="140746">acetimidoyl</compound-id>)<compound-id="79341">piperidin-4-yloxy</compound-id>]-3-carbamoylphenyl}-N-[(E)-3-(3-<compound-id="2332">amidinophenyl</compound-id>)-<compound-id="123136">2-propenyl</compound-id>]sulfamoyl)acetic acid dihydrochloride (45j) exhibited potent <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id> inhibitory activities with IC(50) values of less than 10 nM in vitro.	benzene__FXa__no_interaction	piperidin-4-yloxy__FXa__no_interaction	2-propenyl__FXa__no_interaction	amidinophenyl__FXa__no_interaction	45b__FXa__no_interaction	acetimidoyl__FXa__no_interaction
9088909-1	Routine postmortem examinations and the pathobiological features revealed by systematically designed studies have shown several pathologic phenotypes that are often characteristic enough to differentiate among the various <compound-id="34756">SAM</compound-id> strains: senile amyloidosis in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, -P7, -P9, -<protein-id="P08207,Q3TC45">P10</protein-id>, and -P11; secondary amyloidosis in SAMP2 and -P6; contracted kidney in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, -<protein-id="P08207,Q3TC45">P10</protein-id>, and -P11; immunoblastic lymphoma in SAMR1 and -R4; histiocytic sarcoma in SAMR1 and -R4; ovarian cysts in SAMR1; impaired immune response in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, and -P8; hyperinflation of the lungs in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>; hearing impairment in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>; degenerative temporomandibular joint disease in SAMP3; senile osteoporosis in SAMP6; deficits in learning and memory in SAMP8 and -<protein-id="P08207,Q3TC45">P10</protein-id>; emotional disorders in SAMP8 and -<protein-id="P08207,Q3TC45">P10</protein-id>; cataracts in SAMP9; and brain atrophy in SAMP10.	SAM__P10__no_interaction	SAM__SAMP1__no_interaction
10447673-5	Several properties clearly distinguish cdkX, and its associated HMG-I kinase, from known anti-PSTAIRE cross-reactive cdks: (a) cdkX migrates, in SDS/PAGE, in a position intermediate between prophase phosphorylated <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id> and metaphase dephosphorylated <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>; (b) in contrast with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>, cdkX and associated HMG-I kinase activity do not decrease following successive depletions on p9CKShs1-<compound-id="11966311">sepharose</compound-id>; (c) cdkX and associated HMG-I kinase activity, but not <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>, decrease following depletions on immobilized inhibitor; (d) cdkX is expressed during the early development of sea urchin embryos; in contrast with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>/cyclin B kinase, the p15cdk-BP-bound HMG-I kinase is active throughout the cell cycle; compared with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id> it is active later in development; (e) p15cdk-BP-bound HMG-I kinase is essentially insensitive to powerful inhibitors of cdk such as <compound-id="448991">purvalanol</compound-id>, <compound-id="160355">roscovitine</compound-id>, <compound-id="4592">olomoucine</compound-id>, <protein-id="P38936,A0A024RCX5">p21cip1</protein-id> and <protein-id="Q8N726,P42771,K7PML8,G3XAG3">p16INK4A</protein-id>; HD is only moderately inhibitory.	olomoucine__cdk1__no_interaction	olomoucine__p16INK4A__no_interaction	olomoucine__p21cip1__no_interaction	roscovitine__cdk1__no_interaction	roscovitine__p16INK4A__no_interaction	roscovitine__p21cip1__no_interaction	purvalanol__cdk1__no_interaction	purvalanol__p16INK4A__no_interaction	purvalanol__p21cip1__no_interaction	sepharose__cdk1__no_interaction	sepharose__p16INK4A__no_interaction	sepharose__p21cip1__no_interaction
8006137-8	A decline in sperm motility from 0 to 4 h incubation was noted for all the <compound-id="4740">pentoxifylline</compound-id>-treated samples, under both test tube conditions (<protein-id="P18206,A0A024QZN4,V9HWK2,B3KXA2">VCL</protein-id>: 102.77 +/- 14.4 versus 73.16 +/- 4.6 microns/s, P &lt; 0.005; VSL: 27.2 +/- 10 versus 10.66 +/- 2.2 microns/s, P &lt; 0.005; LIN: 23.65 +/- 7.1 versus 11.86 +/- 1.8%, P &lt; 0.005) and HZA conditions (<protein-id="P18206,A0A024QZN4,V9HWK2,B3KXA2">VCL</protein-id>: 100.04 +/- 13.1 versus 76.00 +/- 7 microns/s, P &lt; 0.005; VSL: 26.40 +/- 8.7 versus 9.14 +/- 4.5 microns/s, P &lt; 0.005; LIN: 26.2 +/- 12 versus 11.05 +/- 4.3%, P &lt; 0.005).	pentoxifylline__VCL__no_interaction
17332736-5	<compound-id="3973">LY294002</compound-id> (a PI3K inhibitor) attenuated high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced cell cycle-dependent (G(0)/G(1) phase) hypertrophy at 72 h while attenuating high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced p21(WAF1) gene transcription and protein expression at 36-48 h. <compound-id="3973">LY294002</compound-id> also attenuated high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced binding of p21(WAF1) to the cyclin E/cdk2 complex, whereas attenuating high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced TGF-beta bioactivity, <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> phosphorylation, and <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> DNA-binding activity at 36-48 h. We concluded that PI3K is required for high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced cell cycle-dependent hypertrophy, p21(WAF1) transcription and expression, p21(WAF1) binding to the cyclin E/cdk2 complex, TGF-beta bioactivity, and <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> activity in LLC-PK1 cells.	LY294002__Smad2/3__no_interaction	glucose__Smad2/3__no_interaction
18426992-6	Renal medullary tissues of 2K1C rats showed greater levels of <protein-id="P08424">renin</protein-id> protein (CK: 1.4+/-0.2; <compound-id="24963056">NCK</compound-id>: 1.5+/-0.3), <protein-id="P08424">renin</protein-id> mRNA (CK: 5.8+/-2.0; <compound-id="24963056">NCK</compound-id>: 4.9+/-2.0), angiotensin I (CK: 120+/-18 pg/g; <compound-id="24963056">NCK</compound-id>: 129+/-13 pg/g versus sham: 67+/-6 pg/g), <protein-id="P01015">angiotensin II</protein-id> (CK: 150+/-32 pg/g; <compound-id="24963056">NCK</compound-id>: 123+/-21 pg/g versus sham: 91+/-12 pg/g; P&lt;0.05), and <protein-id="P08424">renin</protein-id> activity (CK: 8.6 microg of angiotensin I per microgram of protein; <compound-id="24963056">NCK</compound-id>: 8.3 microg of angiotensin I per microgram of protein; sham: 3.4 microg of angiotensin I per microgram of protein) than sham rats.	NCK__angiotensin II__no_interaction	NCK__renin__no_interaction
11510352-7	During the first 3 h of <protein-id="O15381,B4DF43">NVL</protein-id>, <compound-id="977">oxygen</compound-id> delivery increased from 371.3 +/- 84.9 to 443.9 +/- 92.7 gm/m2 and <compound-id="977">oxygen</compound-id> consumption from 123.9 +/- 35.9 to 173.5 +/- 34 m/m2, <compound-id="977">oxygen</compound-id> alveolar-arterial difference decreased from 400.8 +/- 165.3 to 210 +/- 57.5 mm Hg, pulmonary shunt from 41.8 +/- 11.9 to 19 +/- 7.9%, PaO2/FiO2 from 140.4 +/- 210 +/- 84.9, left-ventricular stroke index increased from 38.2 +/- 14.9 to 50.6 +/- 21.8 ml/m2, left-ventricular output index from 37 +/- 19.5 to 47.4 +/- 23.7 gm/m2, and heart rate decreased from 119.2 +/- 17.5 to 111.4 +/- 23.8 <protein-id="P13987,Q6FHM9">min-1</protein-id>.	oxygen__NVL__no_interaction	oxygen__min-1__no_interaction
10376199-8	For plaque size, univariate and multivariate analyses demonstrated that diabetes mellitus and hypercholesterolemia were independent predictors for greater plaque (13.5 +/- 5.72 versus 10.17 +/- 4.6 mm2, P = 0.015, for diabetic versus non-diabetic patients; 12.0 +/- 5.35 versus 9.03 +/- 3.76 mm2, P = 0.010, for hypercholesterolemic versus normocholesterolemic patients) and <compound-id="21313">EEM</compound-id> <protein-id="Q13216,B3KPW7,B4DGZ9">CSA</protein-id> (17.16 +/- 5.81 versus 14.3 +/- 5.1 mm2, P = 0.033, for diabetic versus non-diabetic patients; 16.57 +/- 5.49 versus 12.25 +/- 3.8 mm2, P = 0.001, for hypercholesterolemic versus normocholesterolemic patients) at the target lesion.	EEM__CSA__no_interaction
20979757-10	The level of plasma Hcy, and the content of <compound-id="5356750,6913958">Evans Blue</compound-id> leaked out brain tissue and the expression of <protein-id="P33436">MMP-2</protein-id> mRNA of the intervention group was significantly lower than those of the model group (12.5 +/- 1.4 vs 32.2 +/- 1.3, 3.42 +/- 0.45 vs 6.67 +/- 0.54, 0.118 +/- 0.052 vs 0.372 +/- 0.088, P &lt; 0.01).	Evans Blue__MMP-2__no_interaction
1518006-6	Anti-ZP3 titres developed in all treatment groups and correlated with carbohydrate content (peak per cent [125I]-labelled ZP3 binding by radioimmunoassay: SIZP 71.9 +/- 1.2, ZP3 70.0 +/- 2.5, <protein-id="Q07287">ZP3 alpha</protein-id>-EBGD 60.9 +/- 5.3, <protein-id="P42098">ZP3 beta</protein-id>-EBGD 56.4 +/- 5.0, <protein-id="Q07287">ZP3 alpha</protein-id>-DG 56.4 +/- 4.0, <protein-id="P42098">ZP3 beta</protein-id>-DG 53.5 +/- 4.3) (means +/- <compound-id="5289348">SEM</compound-id>).	SEM__ZP3 beta__no_interaction	SEM__ZP3 alpha__no_interaction
14605381-1	The title compounds, chlorotris(<compound-id="1068">dimethyl sulfide</compound-id>-kappaS)<compound-id="23939">platinum</compound-id>(II) <compound-id="9886">hexafluorophosphate</compound-id>, [PtCl(C(2)H(6)S)(3)]<protein-id="Q6Q759">PF(6</protein-id>), and bromotris(<compound-id="1068">dimethyl sulfide</compound-id>-kappaS)<compound-id="23939">platinum</compound-id>(II) <compound-id="9886">hexafluorophosphate</compound-id>, [PtBr(C(2)H(6)S)(3)]<protein-id="Q6Q759">PF(6</protein-id>), are isomorphous and are composed of [PtX(dms)(3)](+) complex cations (X = Cl and Br, and dms is <compound-id="1068">dimethyl sulfide</compound-id>) and <protein-id="Q6Q759">PF(6</protein-id>)(-) anions.	platinum__PF(6__no_interaction	dimethyl sulfide__PF(6__no_interaction	hexafluorophosphate__PF(6__no_interaction
8269792-8	RESULTS: Comparing data at the end of placebo and <compound-id="44093">captopril</compound-id> treatment, <compound-id="44093">captopril</compound-id> resulted in: lower blood pressure (systolic 154 +/- 2 vs. 163 +/- 3 mmHg and diastolic 93 +/- 2 vs. 101 +/- 2 mmHg); greater <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity in hyperglycemic conditions (total amount of <protein-id="P01308,I3WAC9">insulin</protein-id> infused and time of <protein-id="P01308,I3WAC9">insulin</protein-id> infusion required to reach euglycemia, 1.73 +/- 0.54 vs. 2.08 +/- 0.60 U and 58 +/- 8 vs. 70 +/- 11 min, <compound-id="44093">captopril</compound-id> and placebo, respectively, P &lt; 0.05); greater <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity in euglycemic conditions at liver level (hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> output 4.11 +/- 0.55 vs. 5.2 +/- 0.4 mumol.kg-1.min-1, step 1 of the clamp), muscle level (rates of <compound-id="206,5793,64689,79025">glucose</compound-id> disappearance 26.1 +/- 2.3 vs. 23.8 +/- 2.1 mumol.kg-1.min-1 step 2 of the clamp), primarily attributable to approximately 29% increase in nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism, and adipose tissue level (plasma free fatty acid 0.185 +/- 0.03 vs. 0.24 +/- 0.02 mM and lipid oxidation 1.9 +/- 0.3 vs. 2.21 +/- 0.04 mumol.kg-1.min-1 in step 1); and lower HbA1c (6.7 +/- 0.2 vs. 7.3 +/- 0.2%, P &lt; 0.05).	captopril__insulin__no_interaction	glucose__insulin__no_interaction
18799592-2	We describe two novel, potent <compound-id="242643">oxybenzylglycine</compound-id> <protein-id="Q07869,F1D8S4">PPARalpha</protein-id>-selective agonists, BMS-687453 [N-[[3-[[2-(4-chlorophenyl)-<compound-id="528411">5-methyl-4-oxazolyl</compound-id>]methoxy]phenyl]methyl]-N-(methoxycarbonyl)-<compound-id="45934207,750">glycine</compound-id>] and <compound-id="16727109">BMS-711939</compound-id> N-[[5-[[2-(4-chlorophenyl)-<compound-id="528411">5-methyl-4-oxazolyl</compound-id>]methoxy]-2-<compound-id="10008">fluorophenyl</compound-id>]methyl]-N-(methoxycarbonyl)-<compound-id="45934207,750">glycine</compound-id>], that robustly increase <protein-id="P02647,A0A024R3E3">apolipoprotein (Apo) A1</protein-id> and high-density lipoprotein <compound-id="5997">cholesterol</compound-id> in human <protein-id="P02647,A0A024R3E3">ApoA1</protein-id> transgenic mice and lower low-density lipoprotein-<compound-id="5997">cholesterol</compound-id> and triglycerides in fat-fed hamsters.	5-methyl-4-oxazolyl__apolipoprotein (Apo) A1__no_interaction	5-methyl-4-oxazolyl__ApoA1__no_interaction	5-methyl-4-oxazolyl__PPARalpha__no_interaction	fluorophenyl__apolipoprotein (Apo) A1__no_interaction	fluorophenyl__ApoA1__no_interaction	fluorophenyl__PPARalpha__no_interaction	glycine__apolipoprotein (Apo) A1__no_interaction	glycine__ApoA1__no_interaction	glycine__PPARalpha__no_interaction	BMS-711939__apolipoprotein (Apo) A1__no_interaction	BMS-711939__ApoA1__no_interaction	BMS-711939__PPARalpha__no_interaction	cholesterol__apolipoprotein (Apo) A1__no_interaction	cholesterol__ApoA1__no_interaction	cholesterol__PPARalpha__no_interaction	oxybenzylglycine__apolipoprotein (Apo) A1__no_interaction	oxybenzylglycine__ApoA1__no_interaction	oxybenzylglycine__PPARalpha__no_interaction
15945636-3	Results obtained using the CASSCF [multiconfigurational complete active space (SCF--self-consistent field)] method, with active spaces ranging from (9e/9o) to (15e/<compound-id="72201006">12o</compound-id>), followed by second-order perturbation theory [CASPT2 and MS-CASPT2 (MS--multistate)] with polarized 6-311G(d,p) and natural orbital (ANO-L) basis sets reveal the following: (i) both <protein-id="Q8N5C8">TAB3</protein-id>+ and TMB (D3h) have a quartet <compound-id="69255155">4A</compound-id>"1 ground state with doublet-quartet <compound-id="73010387">2B1</compound-id>-<compound-id="69255155">4A</compound-id>"1 energy gaps of 8.0+/-2.0 and 12.4+/-2.0 kcal/mol, respectively; (ii) in the neutral N series, the quartet state remains the electronic ground state, irrespective of the number of N atoms, but each with slightly reduced gap, 11 kcal/mol for C8H8N (<compound-id="69255155">4A</compound-id>"), 10 kcal/mol for C7H7N2 (<compound-id="25165666">4A2</compound-id>), and 9 kcal/mol for C6H6N3 (<compound-id="25165666">4A2</compound-id>); and (iii) the ground state of monoamino cation and <compound-id="76988">diamino</compound-id> dication is a low-spin doublet state (<compound-id="73010387">2B1</compound-id> for C8H9N+ and <compound-id="50937462">2A2</compound-id> for C7H9N2 2+) and lying well below the corresponding quartet state by 10 and 12 kcal/mol, respectively.	4A2__TAB3__no_interaction	diamino__TAB3__no_interaction	2B1__TAB3__no_interaction	12o__TAB3__no_interaction	2A2__TAB3__no_interaction	4A__TAB3__no_interaction
17003923-6	Variants of coagulation factors [factor V 1691G&gt;A (factor V Leiden), factor V 4070A&gt;G (factor V <compound-id="16220139">HR2</compound-id> haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G&gt;A, prothrombin 20210G&gt;A], coagulation inhibitors [<compound-id="38003">tissue factor pathway inhibitor</compound-id> 536C&gt;T, thrombomodulin 127G&gt;A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G&gt;A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to thromboembolic diseases [apolipoprotein E2/E3/E4, <protein-id="Q13201">glycoprotein Ia</protein-id> 807C&gt;T, <compound-id="21889576">methylenetetrahydrofolate</compound-id> reductase 677C&gt;T] were included.	methylenetetrahydrofolate__glycoprotein Ia__no_interaction	tissue factor pathway inhibitor__glycoprotein Ia__no_interaction	HR2__glycoprotein Ia__no_interaction
20100409-6	RESULTS: In elective and emergency aneurysm repair, D2max (26, standard deviation [SD] 3, mm v. 30.7 [SD 3] mm), D5a (16 [SD 4.7] mm v. 19.3 [SD 5] mm), D5b (15.3 [SD 4] mm v. 18.1 [SD 3.6] mm), H1 (25.6 [SD 8.6] mm v. 18 [SD 2] mm), H4a (173 [SD 22] mm v. 189.5 [SD 22] mm) and <protein-id="P62805,B2R4R0">H4b</protein-id> (174 [<compound-id="12631">SD 25</compound-id>] mm v. 190 [SD 14] mm) were significantly different between the 2 groups (p = 0.001, p = 0.006, p = 0.007, p &lt; 0.001, p = 0.05 and p = 0.01, respectively).	SD 25__H4b__no_interaction
16903746-1	New mono- and dinuclear <compound-id="23947">rhenium</compound-id>(I) tricarbonyls, of formulas [Re(bpy)(CO)3(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)]+ (1), [(bpy)(CO)<compound-id="49852675">3Re</compound-id>(I)(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)Re(I)(CO)3(bpy)]2+ (2), and [(bpy)(CO)<compound-id="49852675">3Re</compound-id>(I)(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)Ru(II)(NH3)5]3+ (3) (bpy = 2,2'-bipyridine, <protein-id="Q9Y5Y0,B2RB38">PCA</protein-id> = 4-pyridinecarboxaldehydeazine), have been synthesized as <protein-id="Q6Q759">PF6</protein-id>- salts and characterized by spectroscopic, electrochemical, and photophysical techniques.	rhenium__PCA__no_interaction	rhenium__PF6__no_interaction	3Re__PCA__no_interaction	3Re__PF6__no_interaction
23154546-4	RESULTS: Pathway activation mapping of NSCLC revealed distinct subgroups composed of epidermal growth factor receptor (ERBB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (<protein-id="P70424">ERBB2</protein-id>), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (<protein-id="Q61526">ERBB3</protein-id>), <protein-id="Q61527">v-erb-a erythroblastic leukemia viral oncogene homolog 4</protein-id> (<protein-id="Q61527">ERBB4</protein-id>), v-akt murine thymoma viral oncogene homolog 1- mammalian target of <compound-id="16760631,478951,49652385,5040,5284616,5358081,53627520,5374464,60150249,6436030,70789198,71296106,71308609,86583604,91454826,9854380">rapamycin</compound-id> (AKT-<protein-id="Q9JLN9">mTOR</protein-id>), protein kinase, AMP-activated, alpha 2 catalytic subunit (<protein-id="Q9Y478,A0A024RBN1">AMPK</protein-id>), and autophagy-related signaling, along with transforming growth factor-beta-signaling protein 1 (SMAD), <protein-id="P08069,C9J5X1">insulin-line growth factor receptor</protein-id> (<protein-id="P08069,C9J5X1">IGFR</protein-id>), <protein-id="P07949,Q9BTX6,A0A024R7T2">rearranged during transfection proto-oncogene</protein-id> (<protein-id="P07949,Q9BTX6,A0A024R7T2">RET</protein-id>), and activated CDC42-associated kinase (<compound-id="101812">ACK</compound-id>) activation.	ACK__ERBB2__no_interaction	ACK__ERBB3__no_interaction	ACK__ERBB4__no_interaction	ACK__AMPK__no_interaction	ACK__insulin-line growth factor receptor__no_interaction	ACK__v-erb-a erythroblastic leukemia viral oncogene homolog 4__no_interaction	ACK__RET__no_interaction	ACK__mTOR__no_interaction	ACK__IGFR__no_interaction	ACK__rearranged during transfection proto-oncogene__no_interaction	rapamycin__ERBB2__no_interaction	rapamycin__ERBB3__no_interaction	rapamycin__ERBB4__no_interaction	rapamycin__AMPK__no_interaction	rapamycin__insulin-line growth factor receptor__no_interaction	rapamycin__v-erb-a erythroblastic leukemia viral oncogene homolog 4__no_interaction	rapamycin__RET__no_interaction	rapamycin__mTOR__no_interaction	rapamycin__IGFR__no_interaction	rapamycin__rearranged during transfection proto-oncogene__no_interaction
22863558-7	In patients with ACS, there was a negative correlation among serum <compound-id="1176">urea</compound-id> (r = -0.377; p &lt; 0.001) and <compound-id="588">creatinine</compound-id> (r = -0.232; p = 0.024) levels and <protein-id="P02765">fetuin-A</protein-id>, and a negative correlation among WBC (r = -0.156; p = 0,132), ESR (r = -0.214; p = 0.037), hs-CRP (r = -0.220; p = 0.032) levels and <protein-id="P02765">fetuin-A</protein-id>.	creatinine__fetuin-A__no_interaction	urea__fetuin-A__no_interaction
20347721-6	<compound-id="16122568,16750043,4369303,448383">CSF</compound-id> Cbl levels were significantly higher (RR patients 27.9+/-9.7 pg/ml, p&lt;0.0001 vs. C; SP patients 25.4+/-8 pg/ml, p&lt;0.02 vs. C), and <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> and EGF levels significantly lower in the patients with the <protein-id="P01375,Q5STB3">RR (TNF-alpha</protein-id> 28.3+/-23.4 x 10(-3) pg/ml, p&lt;0.0001 vs. C; EGF 129.9+/-44.8 pg/ml, p&lt;0.02 vs. C) or SP (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id> 20.5+/-20.5 x 10(-3) pg/ml, p&lt;0.001 vs. C; EGF 116.5+/-24.8 pg/ml, p&lt;0.05 vs. C) clinical course than in controls (Cbl 21+/-4.6 pg/ml; <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> 75.6+/-34.7 x 10(-3) pg/ml; EGF 170.2+/-54.8 pg/ml).	CSF__TNF-alpha__no_interaction	CSF__RR (TNF-alpha__no_interaction
20079222-6	RESULTS: In the group NDM, ED and T-STD were prolonged [(546.04 +/- 103.78) s vs (617.52 +/- 106.96) s, P &lt; 0.05 and (378.64 +/- 92.34) s vs (436.84 +/- 91.25) s, P &lt; 0.05], STDmax was shortened [(2.06 +/- 0.37) mm vs (1.75 +/- 0.41) mm, P &lt; 0.01] and RPP was increased [(173.77 +/- 34.73) beatsxmin(-1)<compound-id="5289587">xmm</compound-id> Hg(-2) vs (199.23 +/- 37.07 beatsxmin(-1)<compound-id="5289587">xmm</compound-id> Hg(-2), P &lt; 0.05] as the parameters during EX2 were compared with those during <protein-id="Q96NE9">EX1</protein-id>.	xmm__EX1__no_interaction
19131510-3	Results are summarized: 1) E(2), the nuclear membrane-impermeable estrogen, estrogen-dendrimer conjugate, and the plasma membrane-impermeable estrogen, E(2)-BSA conjugate, all stimulated <protein-id="P01148">LHRH</protein-id> release within 10 min of exposure; 2) whereas the estrogen receptor antagonist, <compound-id="104741">ICI 182,780</compound-id>, did not block the E(2)-induced <protein-id="P01148">LHRH</protein-id> release, E(2) application to cells treated with pertussis toxin failed to induce <protein-id="P01148">LHRH</protein-id> release; 3) <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> mRNA was expressed in olfactory placode cultures, and <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> protein was expressed in a subset of <protein-id="P01148">LHRH</protein-id> neurons; 4) pertussis toxin treatment blocked the E(2)-induced increase in [Ca(2+)](i) oscillations; 5) knockdown of <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> in primate <protein-id="P01148">LHRH</protein-id> neurons by transfection with small interfering RNA (siRNA) for <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> completely abrogated the E(2)-induced changes in [Ca(2+)](i) oscillations, whereas transfection with control siRNA did not; 6) the estrogen-dendrimer conjugate-induced increase in [Ca(2+)](i) oscillations also did not occur in <protein-id="P01148">LHRH</protein-id> neurons transfected with <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> siRNA; and 7) G1, a <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> agonist, resulted in changes in [Ca(2+)](i) oscillations, similar to those observed with E(2).	ICI 182,780__GPR30__no_interaction	ICI 182,780__LHRH__no_interaction
25005608-9	RESULTS: In <compound-id="1983">APAP</compound-id> group, <protein-id="Q8QZR5,Q566C3">ALT</protein-id>, hepatic MDA and the number of IL-12 and <protein-id="P70380,Q2PMY2">IL-18</protein-id> positive stained cells were significantly increased when compared to control group (1210.50 ± 533.86 vs 85.28 ± 28.27 U/L, 3.60 ± 1.50 vs 1.38 ± 0.15 nmol/mg protein, 12.18 ± 1.10 vs 1.84 ± 1.29%, and 13.26 ± 0.90 vs 2.54 ± 1.29%, P = 0.000, respectively), whereas hepatic <compound-id="124886">GSH</compound-id> was significantly decreased when compared to control group (5.98 ± 0.30 vs 11.65 ± 0.43 nmol/mg protein, P = 0.000).	GSH__ALT__no_interaction	GSH__IL-18__no_interaction	APAP__ALT__no_interaction	APAP__IL-18__no_interaction
25005608-10	The mean level of <protein-id="Q8QZR5,Q566C3">ALT</protein-id>, hepatic MDA, the number of IL-12 and <protein-id="P70380,Q2PMY2">IL-18</protein-id> positive stained cells, and hepatic <compound-id="124886">GSH</compound-id> in Aloe vera-treated group were improved as compared with <compound-id="1983">APAP</compound-id> group (606.38 ± 495.45 vs 1210.50 ± 533.86 U/L, P = 0.024; 1.49 ± 0.64 vs 3.60 ± 1.50 nmol/mg protein, P = 0.001; 5.56 ± 1.25 vs 12.18 ± 1.10%, P = 0.000; 6.23 ± 0.94 vs 13.26 ± 0.90%, P = 0.000; and 10.02 ± 0.20 vs 5.98 ± 0.30 nmol/mg protein, P = 0.000, respectively).	GSH__ALT__no_interaction	GSH__IL-18__no_interaction	APAP__ALT__no_interaction	APAP__IL-18__no_interaction
3516657-2	The mechanisms subserving this facilitative interaction included the following: 1) insulin's synergism with LDL was profoundly attenuated by covalent modification of <compound-id="6322,90867653">arginine</compound-id> residues in LDL by 1,2-<compound-id="13006">cyclohexanedione</compound-id> treatment; 2) insulin increased by 2- to 6-fold the number of specific high affinity LDL receptors on granulosa cells, with no change in apparent binding affinity; 3) insulin augmented rates of [125I]iodo-LDL internalization and degradation without enhancing nonspecific bulk fluid-phase pinocytosis (assessed with [125I]iodo-polyvinylpyrollidone); 4) insulin increased by 2.5- to 3-fold granulosa cell content of free and esterified <compound-id="5997">cholesterol</compound-id> (measured by fluorometry) in response to treatment with unlabeled LDL; 5) insulin stimulated the intracellular accumulation of free [3H]<compound-id="5997">cholesterol</compound-id> and [3H]cholesteryl ester, and amplified [3H]<compound-id="5994">progesterone</compound-id> secretion by granulosa cells exposed to [3H]<compound-id="227041,22833537,46936301,5287939,54100202,54609098,57314933,6379755,6538325">cholesteryl linoleate</compound-id>-labeled LDL; and 6) insulin action was specific in that it was not mimicked by desoctapeptide insulin, epidermal growth factor, fibroblast growth factor, or <protein-id="P01348">relaxin</protein-id>.	cholesteryl linoleate__relaxin__no_interaction	progesterone__relaxin__no_interaction	arginine__relaxin__no_interaction	cyclohexanedione__relaxin__no_interaction	cholesterol__relaxin__no_interaction
23534942-1	New <compound-id="23947">rhenium</compound-id>(VII or III) complexes [ReO3(PTA)2][ReO4] (1) (PTA = <compound-id="143061">1,3,5-triaza-7-phosphaadamantane</compound-id>), [ReO3(<compound-id="656710">mPTA</compound-id>)][ReO4]I (2) (<compound-id="656710">mPTA</compound-id> = N-methyl-<compound-id="143061">1,3,5-triaza-7-phosphaadamantane</compound-id> cation), [ReO3(HMT)2][ReO4] (3) (HMT = <compound-id="4101">hexamethylenetetramine</compound-id>), [ReO3(η(2)-Tpm)(PTA)][ReO4] (4) [Tpm = hydrotris(pyrazol-1-yl)<compound-id="297">methane</compound-id>, HC(pz)3, pz = <compound-id="1048">pyrazolyl</compound-id>], [ReO3(Hpz)(HMT)][ReO4] (5) (Hpz = pyrazole), [ReO(Tpms)(HMT)] (6) [Tpms = <compound-id="6503">tris</compound-id>(pyrazol-1-yl)<compound-id="6395">methanesulfonate</compound-id>, O3SC(pz)3(-)] and [ReCl2{<compound-id="5288874">N2C</compound-id>(O)Ph}(PTA)3] (7) have been prepared from the Re(VII) <compound-id="190217">oxide</compound-id> <compound-id="123106">Re2O7</compound-id> (1-6) or, in the case of 7, by ligand exchange from the benzoyldiazenido complex [ReCl2{<compound-id="5288874">N2C</compound-id>(O)Ph}(Hpz)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2], and characterized by IR and NMR spectroscopies, elemental analysis and electrochemical properties.	rhenium__PPh3__no_interaction	hexamethylenetetramine__PPh3__no_interaction	methanesulfonate__PPh3__no_interaction	N2C__PPh3__no_interaction	oxide__PPh3__no_interaction	mPTA__PPh3__no_interaction	pyrazolyl__PPh3__no_interaction	Re2O7__PPh3__no_interaction	1,3,5-triaza-7-phosphaadamantane__PPh3__no_interaction	tris__PPh3__no_interaction	methane__PPh3__no_interaction
19265213-1	The title complex, <protein-id="O95817">Bis</protein-id>[mu(3)-cis-N-(2-aminopropyl)-N'-(2-carboxylatophenyl)oxamidato(3-)]-1:2:4kappa(7)N,N',N'',O:O',O'':O''';2:3:4kappa(7)O''':N,N',N'',O:O',O''-<protein-id="O95817">Bis</protein-id>(2,2'-bipyridine)-2kappa(2)N,N';4kappa(2)N,N'-dichlorido-1kappaCl,3kappaCl-tetracopper(II) <compound-id="3039108">dihydrate</compound-id>, [Cu(4)(C(12)H(12)N(3)O(4))(2)Cl(2)(C(10)H(8)N(2))(2)].2H(2)O, consists of a neutral cyclic tetracopper(II) system having an embedded centre of inversion and two solvent <compound-id="962">water</compound-id> molecules.	water__Bis__no_interaction	dihydrate__Bis__no_interaction
18605990-8	Plasma <protein-id="P01160">ANP</protein-id> concentrations positively correlated significantly with pulmonary artery pressure (PAP) (r = 0.74, p &lt; 0.05) and <compound-id="656964">3DE</compound-id> measurements of cardiac volumes (right ventricular end-diastolic (r = 0.50, p &lt; 0.05) and end-systolic volume (r = 0.50, p &lt; 0.05) and negatively correlated with RVEF (r = -0.38, p &lt; 0.05).	3DE__ANP__no_interaction
18822124-6	In COPD with <compound-id="2148">PAH</compound-id>, linear regression analysis showed good correlation between <protein-id="P05305,Q6FH53">ET-1</protein-id> in <compound-id="368250">EBC</compound-id> and <compound-id="10214">PaPs</compound-id> (r = 0.621; p = 0.031), and between arterial levels of <protein-id="P05305,Q6FH53">ET-1</protein-id> and <compound-id="10214">PaPs</compound-id> (r = 0.648; p = 0.022), while arterial levels of <protein-id="P05305,Q6FH53">ET-1</protein-id> inversely correlated with FEV1%, (r = -0.59, p = 0.043), and <compound-id="10214">PaPs</compound-id> negatively correlated to PaO2 (r = -0.618; p = 0.032).	PAH__ET-1__no_interaction	PaPs__ET-1__no_interaction	EBC__ET-1__no_interaction
22218706-1	A series of germylene, stannylene and plumbylene complexes [η(2)(N,N)-Me(2)Si(DippN)(2)Ge:] (<compound-id="2981881,91293124">3a</compound-id>), [η(2)(N,N)-Ph(2)Si(DippN)(2)Ge:] (3b), [η(2)(N,N)-Me(2)Si(DippN)(2)Sn:] (4), [η(2)(N,N)-Me(2)Si(DippN)(2)Pb:](2) (5a), and [η(2)(N,N)-Ph(2)Si(DippN)(2)Pb:] (<compound-id="18445697">5b</compound-id>) (<compound-id="122669">Dipp</compound-id> = 2,6-iPr(2)C(6)H(3)) bearing bulky <protein-id="O95817">bis</protein-id>(amido)silane ligands were readily prepared either by the transamination of M[N(SiMe(3))(2)](2) (M = Sn, Pb) and [Me(2)Si(DippNH)(2)] or by the metathesis reaction of bislithium <protein-id="O95817">bis</protein-id>(amido)silane [η(1)(N),η(1)(N)-R(2)Si(DippNLi)(2)] (R = Me, Ph) with the corresponding metal halides GeCl(2)(<compound-id="31275">dioxane</compound-id>), SnCl(2), and PbCl(2), respectively.	Dipp__bis__no_interaction	3a__bis__no_interaction	dioxane__bis__no_interaction	5b__bis__no_interaction
20964312-2	X-ray diffraction data of these complexes indicate that (PPh(4))(2)[Fe(CN)(5)<compound-id="795">imidazole</compound-id>]·2H(2)O crystallizes in the triclinic space group P1 with a = 9.8108(15) Å, b = 11.1655(17) Å, c = 23.848(4) Å, α = 87.219(2)°, β = 85.573(2)°, γ = 70.729(2)°, and Z = 2, while its precursor Na(3)[Fe(CN)(5)(en)]·5H(2)O crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n with a = 8.3607(7) Å, b = 11.1624(9) Å, c = 17.4233(14) Å, β = 90.1293(9)°, and Z = 4.	imidazole__P2(1__no_interaction
16390154-7	The rates of photoisomerization of these complexes, [((Z)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-bpy)Ru(bpy)(2)](PF(6))(2) (2Z) and [((E)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-bpy)Ru(bpy)(2)](PF(6))(2) (2E), were compared to those of their untethered analogues, (Z)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-OTBS (1Z) and (E)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-OTBS (1E), where <compound-id="23950">ruthenium</compound-id> sensitization occurred through an intermolecular pathway.	ruthenium__bis__no_interaction	ethene__bis__no_interaction
19061343-7	The rate constants for the low-energy channels given in units of cm(3) molecule(-1) s(-1) can be represented by the following: k(1)(<compound-id="448829">LM2</compound-id>) = 1.51 x 10 (15)T(-8.72) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-2531/T) at 300-1500 K in 760 Torr N(2); k(2)(H+NCNO) = 5.54 x 10 (-14)T(-0.97) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-3669/T) and k(3)(HCN+NO) = 7.82 x 10 (-14)T(0.44) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-2013/T) at 300-2500 K, with the total rate constant of k(t) = 3.18 x 10 (2)T(-4.63) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-740/T), 300-1000 K, and k(t) = 2.53 x 10 (-14)T(1.13) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-489/T) in the temperature range of 1200-2500 K. These results are recommended for combustion modeling applications.	LM2__exp__no_interaction
16357953-3	This issue focuses on the following selection of drugs: (Z)-<compound-id="449459">4-Hydroxytamoxifen</compound-id>, [18F]-FPS; Adalimumab, alefacept, alemtuzumab, alfimeprase, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="54841">atomoxetine</compound-id> hydrochloride; Belatacept, <compound-id="387447">bortezomib</compound-id>; C340, <compound-id="5486792,2826718,66577042,71295847">caspofungin acetate</compound-id>, <compound-id="6433095">clazosentan</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="9962928">Cypher</compound-id>; Darbepoetin alfa, <compound-id="6529858">DB-289</compound-id>, <compound-id="451668">decitabine</compound-id>, <compound-id="208898">dronedarone hydrochloride</compound-id>, <compound-id="60835">duloxetine</compound-id> hydrochloride; <compound-id="77993">Eletriptan</compound-id>, <compound-id="153941">entecavir</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="146570">escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, <compound-id="969472">eszopiclone</compound-id>, <compound-id="123619">etoricoxib</compound-id>; <compound-id="3448">Gaboxadol</compound-id>, <compound-id="9919137">gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, galiximab, <compound-id="9571107">gemifloxacin mesilate</compound-id>, <compound-id="5961">glutamine</compound-id>; Human <protein-id="P01308,I3WAC9">insulin</protein-id>; I-131 ch-<compound-id="8376">TNT</compound-id>-1/B, <compound-id="6450813">indiplon</compound-id>, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="72231">isatoribine</compound-id>; <compound-id="6322">L-Arginine hydrochloride</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, <compound-id="11980957">lopinavir/ritonavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>; <compound-id="24083">Magnesium sulfate</compound-id>; Natalizumab; <compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="656629">omapatrilat</compound-id>, OncoVEX (<protein-id="P04141">GM-CSF</protein-id>); rDNA <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="133017">rupatadine fumarate</compound-id>; <compound-id="216239">Sorafenib</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="16139605">teduglutide</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">temsirolimus</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate.	escitalopram__insulin__no_interaction	escitalopram__GM-CSF__no_interaction	ertapenem sodium__insulin__no_interaction	ertapenem sodium__GM-CSF__no_interaction	bortezomib__insulin__no_interaction	bortezomib__GM-CSF__no_interaction	4-Hydroxytamoxifen__insulin__no_interaction	4-Hydroxytamoxifen__GM-CSF__no_interaction	Valdecoxib__insulin__no_interaction	Valdecoxib__GM-CSF__no_interaction	DB-289__insulin__no_interaction	DB-289__GM-CSF__no_interaction	etoricoxib__insulin__no_interaction	etoricoxib__GM-CSF__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	tenofovir disoproxil fumarate__GM-CSF__no_interaction	aprepitant__insulin__no_interaction	aprepitant__GM-CSF__no_interaction	gadofosveset__insulin__no_interaction	gadofosveset__GM-CSF__no_interaction	Olmesartan medoxomil__insulin__no_interaction	Olmesartan medoxomil__GM-CSF__no_interaction	dronedarone hydrochloride__insulin__no_interaction	dronedarone hydrochloride__GM-CSF__no_interaction	sodium__insulin__no_interaction	sodium__GM-CSF__no_interaction	tiotropium bromide__insulin__no_interaction	tiotropium bromide__GM-CSF__no_interaction	indiplon__insulin__no_interaction	indiplon__GM-CSF__no_interaction	oxalate__insulin__no_interaction	oxalate__GM-CSF__no_interaction	glutamine__insulin__no_interaction	glutamine__GM-CSF__no_interaction	eszopiclone__insulin__no_interaction	eszopiclone__GM-CSF__no_interaction	TNT__insulin__no_interaction	TNT__GM-CSF__no_interaction	Cypher__insulin__no_interaction	Cypher__GM-CSF__no_interaction	teduglutide__insulin__no_interaction	teduglutide__GM-CSF__no_interaction	Magnesium sulfate__insulin__no_interaction	Magnesium sulfate__GM-CSF__no_interaction	lopinavir/ritonavir__insulin__no_interaction	lopinavir/ritonavir__GM-CSF__no_interaction	entecavir__insulin__no_interaction	entecavir__GM-CSF__no_interaction	temsirolimus__insulin__no_interaction	temsirolimus__GM-CSF__no_interaction	Eletriptan__insulin__no_interaction	Eletriptan__GM-CSF__no_interaction	isatoribine__insulin__no_interaction	isatoribine__GM-CSF__no_interaction	Sorafenib__insulin__no_interaction	Sorafenib__GM-CSF__no_interaction	clazosentan__insulin__no_interaction	clazosentan__GM-CSF__no_interaction	atomoxetine__insulin__no_interaction	atomoxetine__GM-CSF__no_interaction	rupatadine fumarate__insulin__no_interaction	rupatadine fumarate__GM-CSF__no_interaction	lumiracoxib__insulin__no_interaction	lumiracoxib__GM-CSF__no_interaction	L-Arginine hydrochloride__insulin__no_interaction	L-Arginine hydrochloride__GM-CSF__no_interaction	gemifloxacin mesilate__insulin__no_interaction	gemifloxacin mesilate__GM-CSF__no_interaction	Gaboxadol__insulin__no_interaction	Gaboxadol__GM-CSF__no_interaction	doxorubicin__insulin__no_interaction	doxorubicin__GM-CSF__no_interaction	vardenafil hydrochloride__insulin__no_interaction	vardenafil hydrochloride__GM-CSF__no_interaction	caspofungin acetate__insulin__no_interaction	caspofungin acetate__GM-CSF__no_interaction	aripiprazole__insulin__no_interaction	aripiprazole__GM-CSF__no_interaction	decitabine__insulin__no_interaction	decitabine__GM-CSF__no_interaction	Tadalafil__insulin__no_interaction	Tadalafil__GM-CSF__no_interaction	omapatrilat__insulin__no_interaction	omapatrilat__GM-CSF__no_interaction	duloxetine__insulin__no_interaction	duloxetine__GM-CSF__no_interaction
22431488-11	PG-PS-injected rats treated with 100 mg/kg <compound-id="445154,5056">resveratrol</compound-id> had lower inflammatory cytokine mRNAs (IL-1β [3.50 ± 1.08 vs. 10.79 ± 1.88, P = 0.005], <protein-id="P20607">IL-6</protein-id> [17.11 ± 9.22 vs. 45.64 ± 8.83, P = 0.03], <protein-id="P16599">tumor necrosis factor alpha</protein-id> (TNF-α) [0.80 ± 0.14 vs. 1.89 ± 0.22, P = 0.002]), transforming <protein-id="P62775">growth factor</protein-id> beta 1 (TGF-β1) mRNA (2.24 ± 0.37 vs. 4.06 ± 0.58, P = 0.01), and histologic fibrosis score (6.4 ± 1.1 vs. 9.8 ± 1.0; P = 0.035) than those treated with vehicle.	resveratrol__tumor necrosis factor alpha__no_interaction	resveratrol__IL-6__no_interaction	resveratrol__growth factor__no_interaction
9442572-4	On the other hand, subchronic <compound-id="24633">cadmium chloride</compound-id> administration for 14 days, increased plasma levels of GH (13.39 +/- 2.74 vs. 6.71 +/- 1.3 ng/mL, p &lt; 0.05), TSH (27.8 +/- 4.42 vs. 6.65 +/- 1.15 ng/mL, p &lt; 0.001), LH (11.1 +/- 1.3 vs. 5.18 +/- 0.28 ng/mL, p &lt; 0.001) and FSH (53.16 +/- 3.66 vs. 12.51 +/- 1.45, p &lt; 0.001), whereas plasma <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id> levels decreased (6.86 +/- 1.38 vs. 16.2 +/- 2.7 ng/mL, p &lt; 0.01).	cadmium chloride__prolactin__no_interaction
10871558-10	Positive, significant correlations were found between plasma <protein-id="P11597,B4DMZ5">CETP</protein-id> and total (r = 0.3868, P &lt; 0.0001) and LDL (r = 0.4454, P &lt; 0.0001) <compound-id="5997">cholesterol</compound-id> and also between changes in <protein-id="P11597,B4DMZ5">CETP</protein-id> concentrations and those of total (r = 0.4543, P &lt; 0.0001) and LDL (r = 0.4554, P &lt; 0.0001) <compound-id="5997">cholesterol</compound-id>.	cholesterol__CETP__no_interaction
1326946-10	Four Bn receptor antagonists had a higher affinity for the <protein-id="Q8R1I2">GRP</protein-id> subtype ([D-Phe6]Bn-(6-13)<compound-id="23134249">ethyl</compound-id> ester (500 x), [D-Phe6][psi 13-14,Cpa14]Bn- (6-14) (70 x) (where psi 13-14 refers to the replacement of the -CONH- peptide bond between Leu13 and Met14 by -<compound-id="142005">CH2NH2</compound-id>) [psi 13-14,Leu14]Bn, [D-Phe6]Bn-(6-13) <compound-id="6578">propylamide</compound-id> (30 x)] and two had a higher affinity for the <protein-id="D4A1W6">NMB</protein-id> subtype on C-6 cells and transfected cells ([D-Pro4,D-Trp7,9,10] substance P-(4-11) (9 x) and [Tyr4,D-Phe12]Bn (18 x)].	CH2NH2__NMB__no_interaction	CH2NH2__GRP__no_interaction	propylamide__NMB__no_interaction	propylamide__GRP__no_interaction	ethyl__NMB__no_interaction	ethyl__GRP__no_interaction
19506561-4	MEASUREMENTS: Adipocyte diameter (by microscope technique; n=29), expression of candidate genes (by quantitative real-time PCR) in freshly isolated adipocytes (<protein-id="P13500">monocyte chemoattractant protein (MCP) 1</protein-id> and <protein-id="P80075">MCP2</protein-id>, <protein-id="P10147,A0N0R1">macrophage inflammatory protein (MIP) 1alpha</protein-id>, <protein-id="P13236">MIP1beta</protein-id> and <protein-id="P19875,A0A024RDD9">MIP2</protein-id>, <protein-id="P14174,I4AY87">macrophage migration inhibitory factor</protein-id> (<protein-id="P14174,I4AY87">MIF</protein-id>), tumor necrosis factor alpha, interleukin (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL) 6</protein-id> and <protein-id="P10145,A0A024RDA5">IL8</protein-id>; n=22) and cultured preadipocytes (<protein-id="P13500">MCP1</protein-id>, <protein-id="P10147,A0N0R1">MIP1alpha</protein-id>, <protein-id="P14174,I4AY87">MIF</protein-id>, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL6</protein-id> and <protein-id="P08253,A0A024R6R4">matrix metalloproteinase 2</protein-id>; n=33) from subcutaneous abdominal adipose tissue (by aspiration biopsy, n=34), body fat by dual-energy X-ray absorptiometry, <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance by 75 g oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test and <protein-id="P01308,I3WAC9">insulin</protein-id> action by euglycemic-hyperinsulinemic clamp (<protein-id="P01308,I3WAC9">insulin</protein-id> infusion rate 40 mU m(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) (all n=34).	glucose__MCP1__no_interaction	glucose__MCP2__no_interaction	glucose__matrix metalloproteinase 2__no_interaction	glucose__MIP1alpha__no_interaction	glucose__macrophage migration inhibitory factor__no_interaction	glucose__monocyte chemoattractant protein (MCP) 1__no_interaction	glucose__macrophage inflammatory protein (MIP) 1alpha__no_interaction	glucose__IL6__no_interaction	glucose__min(-1__no_interaction	glucose__insulin__no_interaction	glucose__MIP2__no_interaction	glucose__MIF__no_interaction	glucose__MIP1beta__no_interaction	glucose__IL8__no_interaction	glucose__IL) 6__no_interaction
10770971-9	Among pre-HD patients, serum sulfite was positively correlated with serum <compound-id="588">creatinine</compound-id> (r = 0.714, P &lt; 0.0001), and negatively with serum <protein-id="P02768">albumin</protein-id> (r = -0.407, P = 0.0188), hematocrit (r = -0.524, P = 0.0017), and total <compound-id="5997">cholesterol</compound-id> (r = -0.375, P = 0.	creatinine__albumin__no_interaction	cholesterol__albumin__no_interaction
21340764-16	Table 1 Specificities and Sensitivities of Enzyme-Immunoassays Specific for Intact <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>(EIA-1), Free <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>β(EIA-2), and β-CF(EIA-3) First antibody Second antibody Cross-reactivity (%) Sensitivity Intact Free Assay Code Epitope Code Epitope Specificity (ng/ml) <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id> <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>β β-CF EIA-1 No.277(MoAb) β-<compound-id="6176">CTP</compound-id> No.224(MoAb) hcGa Intact <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id> 0.01 100 15 1.0 EIA-2 No.209(MoAb) <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>β No.115(PoAb) β-core Free <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>β 0.01 1.9 100 1.9 EIA-3 No.229(MoAb) β-core No.105(PoAb) β-core β-CF 0.01 3.3 100 100 MoAb: monoclonal antibody.	CTP__hCG__no_interaction
22701386-6	Key variables generated by PSG and Watch-<protein-id="O60664">PAT</protein-id> correlated well over a wide range, including the apnea-hypopnea index (AHI, r = 0.76, p &lt; 0.001); respiratory disturbance index (RDI, r = 0.68, p &lt; 0.001), mean <compound-id="977">oxygen</compound-id> saturation (r = 0.94, p &lt; 0.001), and minimum <compound-id="977">oxygen</compound-id> saturation (r = 0.88, p &lt; 0.001).	oxygen__PAT__no_interaction
10481820-3	For the positional isomers t4, t5, t6-8, t9, <protein-id="P28907">t10</protein-id>, <protein-id="P06729,Q53F96">t11</protein-id>, t12, <protein-id="Q6UB99">t13</protein-id>, <protein-id="P26842">t14</protein-id>, t15 and <compound-id="16740934">t16</compound-id> contents of 0.02, 0.02, 0.21, 0.37, 0.32, 0.68, 0.23, 0.15, 0.18, 0.09 and 0.14 wt% were established, with <compound-id="122325,5281127,5282761">vaccenic acid</compound-id> being the predominant isomer.	t16__t14__no_interaction	t16__t10__no_interaction	t16__t11__no_interaction	t16__t13__no_interaction	vaccenic acid__t14__no_interaction	vaccenic acid__t10__no_interaction	vaccenic acid__t11__no_interaction	vaccenic acid__t13__no_interaction
7595065-7	<protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> action was consistent with a protein kinase C (PKC)-mediated pathway in that: 1) the effect of <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> on TGS was mimicked by 1-10 nM <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> (<compound-id="4792">PMA</compound-id>), a potent activator of PKC; (202% <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> vs. 178% <compound-id="4792">PMA</compound-id> stimulation); 2) the effect of <compound-id="4792">PMA</compound-id> and <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> were non-additive with respect to TGS; 3) <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> (50 nM) and <compound-id="2396">GF109203X</compound-id> (bisindolymaleimide) at 1 microM, both competitive inhibitors of the <compound-id="5957">ATP</compound-id>-binding site on PKC, inhibited both <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> and <compound-id="4792">PMA</compound-id> stimulation of TGS (-59% and -65% for <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> and -84% and -99% for <compound-id="4792">PMA</compound-id>, respectively); 4) <compound-id="2533">Calphostin C</compound-id> (0.8 microM) which interacts with the regulatory domain of PKC also inhibited the <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id>- and <compound-id="4792">PMA</compound-id>-mediated stimulation of PKC (-76% +/- 11% inhibition for <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> and -99% +/- 20% inhibition for <compound-id="4792">PMA</compound-id>), although in all cases the inhibition of <compound-id="4792">PMA</compound-id>-stimulated triglyceride synthesis was greater; 5) <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> caused a time-dependent increase in intracellular <compound-id="6026790">diacylglycerol</compound-id> accumulation; and finally 6) stimulation by <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> caused an increase in PKC activity and a time-dependent translocation of PKC (maximal effect at 30 min) from the soluble intracellular compartment to a membrane-bound fraction (basal activity 22% in the membrane-bound fraction, <protein-id="P01024,V9HWA9,B4DR57">ASP</protein-id> 54%, P &lt; 0.05 and <compound-id="4792">PMA</compound-id> 69% P &lt; 0.0025).	staurosporine__ASP__no_interaction	phorbol 12-myristate__ASP__no_interaction	acetate__ASP__no_interaction	Calphostin C__ASP__no_interaction	PMA__ASP__no_interaction	ATP__ASP__no_interaction	diacylglycerol__ASP__no_interaction	GF109203X__ASP__no_interaction
7968598-6	In diabetic patients (n = 30), plasma O2- levels correlated with basal MLF (r = -.59, P &lt; .005), basal MPM (r = -.84, P &lt; .001), fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> level (r = .51, P &lt; .004), WBGD (r = -.53, P &lt; .002), and nonoxidative (r = -.45, P &lt; .01) <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism.	glucose__insulin__no_interaction
6373827-4	Plasma glucagon (area under the curve [AUC] above base line, 12 +/- 3 vs. 23 +/- 3 mg/ml X 12 h in nondiabetics, P less than 0.05), <compound-id="5754">cortisol</compound-id> (AUC 2.2 +/- 0.5 vs. 4.0 +/- 0.7 mg/dl X 12 h in nondiabetics, P less than 0.05), and <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> (AUC 1.6 +/- 0.4 vs. 2.9 +/- 0.4 micrograms/ml X 12 h in nondiabetics, P less than 0.05) responses in the diabetics were decreased 50% while their plasma <compound-id="439260">norepinephrine</compound-id> responses (AUC 49 +/- 12 vs. 21 +/- 5 ng/ml X 12 h in nondiabetics, P less than 0.05) were increased twofold (P less than 0.05) and their plasma <compound-id="5816">epinephrine</compound-id> responses were similar to those of the nondiabetics (AUC 106 +/- 17 vs. 112 +/- 10 ng/ml X 12 h in nondiabetics).	norepinephrine__growth hormone__no_interaction	epinephrine__growth hormone__no_interaction	cortisol__growth hormone__no_interaction
22121785-3	The main pharmacokinetic parameters t(1/2) of <compound-id="5329">sulfamethoxazole</compound-id> in PH, <compound-id="50937458">HNH</compound-id> and <protein-id="Q92766,A0A024QZU8">HNT</protein-id> were, respectively, 9.30 +/- 1.11, 10.99 +/- 1.23 and 10.44 +/- 1.05 h; tmax were 1.4 +/- 0.3, 2.0 +/- 1.1 and 1.8 +/- 0.4 h; Cmax were 94.42 +/- 15.26, 89.33 +/- 7.67 and 87.43 +/- 11.61 micro x mL(-1); AUC(0-t) were 1202.5 +/- 238.3, 1 434.7 +/- 193.9 and 1302.8 +/- 103.0 microg x h x mL(-1); AUC(0-infinity) were 1240.7 +/- 255.3, 1511.5 +/- 211.9 and 1363.9 +/- 116.5 microg x h x mL(-1); CL were 1.01 +/- 0.22, 0.81 +/- 0.12 and 0.89 +/- 0.08 L x h(-1) x kg(-1); V were 13.27 +/- 1.73, 12.81 +/- 2.15 and 13.28 +/- 1.20 L x kg(-1).	HNH__HNT__no_interaction	sulfamethoxazole__HNT__no_interaction
23973842-5	<compound-id="25058126">Cephalosporin</compound-id>-resistant isolates were further screened by PCR for genes encoding <compound-id="33613">AmpC</compound-id> (bla(FOX), bla(<compound-id="16058609">CMY</compound-id>), bla(MOX), bla(LAT), bla(BIL), bla(DHA), bla(ACC), bla(MIR), bla(ACT)), ESBLs (bla(TEM), bla(SHV), bla(CTX-M), bla(PER), bla(VEB), bla(<compound-id="6367215">GES</compound-id>/IBC), bla(OXA)) and integrases (<protein-id="Q209K2">intI1</protein-id>, intI2, intI3).	Cephalosporin__intI1__no_interaction	AmpC__intI1__no_interaction	GES__intI1__no_interaction	CMY__intI1__no_interaction
19860395-1	Circularly polarized luminescence (<protein-id="Q9BQS7,A0A0C4DG76,E7ES21">CPL</protein-id>) of Eu(III) complexes with point- and axis-chiral ligands, [Eu((R/S)-BINAPO)(D-facam)(3)] ((R/S)-BINAPO, (R/S)-2,2'-bis(<compound-id="6327869">diphenylphosphoryl</compound-id>)-<compound-id="11789">1,1'-binaphthyl</compound-id>; D-facam, <compound-id="521351">3-trifluoroacetyl-d-camphor</compound-id>), [Eu(BIPHEPO)(D-facam)(3)] (BIPHEPO, 2,2'-bis(<compound-id="6327869">diphenylphosphoryl</compound-id>)-biphenyl), [Eu(<compound-id="13097">TPPO</compound-id>)(2)(D-facam)(3)] (<compound-id="13097">TPPO</compound-id>, <compound-id="11776">triphenylphosphine</compound-id> <compound-id="190217">oxide</compound-id>), and [Eu((R)-BINAPO)(hfa)(3)] (hfa, <compound-id="73706">1,1,1,5,5,5-hexafluoropentane-2,4-dione</compound-id>) are reported.	1,1,1,5,5,5-hexafluoropentane-2,4-dione__CPL__no_interaction	1,1'-binaphthyl__CPL__no_interaction	triphenylphosphine__CPL__no_interaction	oxide__CPL__no_interaction	TPPO__CPL__no_interaction	diphenylphosphoryl__CPL__no_interaction	3-trifluoroacetyl-d-camphor__CPL__no_interaction
19860395-3	The dissymmetry factors of their <protein-id="Q9BQS7,A0A0C4DG76,E7ES21">CPL</protein-id> (|g(<protein-id="Q9BQS7,A0A0C4DG76,E7ES21">CPL</protein-id>)|) at the magnetic-dipole transition of [Eu((R)-BINAPO)(D-facam)(3)], [Eu((S)-BINAPO)(D-facam)(3)], [Eu(BIPHEPO)(D-facam)(3)], and [Eu(<compound-id="13097">TPPO</compound-id>)(2)(D-facam)(3)] were as high as 0.44, 0.34, 0.24, and 0.47, respectively, while [Eu((R)-BINAPO)(hfa)(3)] exhibited a relatively smaller dissymmetry factor (|g(<protein-id="Q9BQS7,A0A0C4DG76,E7ES21">CPL</protein-id>)| = 0.03).	TPPO__CPL__no_interaction
23097971-4	RESULTS: The <compound-id="1195">IPP</compound-id> showed a good correlation with the prostate volume (r = 0.61) and serum <protein-id="P07225">PSA</protein-id> (r = 0.48); p = 0.0000, free uroflowmetry (r = -0.27; p = 0.004), as well as the determinants of urodynamic obstruction: bladder outlet obstruction index-BOOI (r = 0.36; p &lt; 0.0001), and ICS and Schaefer obstruction class nomograms (rho = 0.33 and rho = 0.39, respectively; p &lt; 0.001), while the BWT showed only a statistical correlation with age (r = 0.23; p = 0.02) and serum <protein-id="P07225">PSA</protein-id> (r = 0.4; p = 0.0000), regardless of an significant correlation with the <compound-id="1195">IPP</compound-id> (r = 0.45; p = 0.0000).	IPP__PSA__no_interaction
14606091-11	RESULTS: Enhanced colonic mucosal injury, inflammatory response and oxidative stress were observed in the animals clystered with acetic acid, which manifested as the significant increase of CMDI, HS, <protein-id="D3ZGE2,A0A0G2K1A2">MPO</protein-id> activities, MDA and NO levels, PGE2 and <compound-id="5283137,5461">TXB2</compound-id> contents, as well as the expressions of <protein-id="Q06518">iNOS</protein-id>, COX-2 and NF-kappaB <protein-id="P21707,Q707P0">p65</protein-id> proteins in the colonic mucosa, although the colonic SOD activity was significantly decreased compared with the normal control (CMDI: 2.9+/-0.6 vs 0.0+/-0.0; HS: 4.3+/-0.9 vs 0.7+/-1.1; <protein-id="D3ZGE2,A0A0G2K1A2">MPO</protein-id>: 98.1+/-26.9 vs 24.8+/-11.5; MDA: 57.53+/-12.36 vs 9.21+/-3.85; NO: 0.331+/-0.092 vs 0.176+/-0.045; PGE2: 186.2+/-96.2 vs 42.8+/-32.8; <compound-id="5283137,5461">TXB2</compound-id>: 34.26+/-13.51 vs 8.83+/-3.75; <protein-id="Q06518">iNOS</protein-id>: 0.365+/-0.026 vs 0.053+/-0.015; COX-2: 0.296+/-0.028 vs 0.034+/-0.013; NF-kappaB <protein-id="P21707,Q707P0">p65</protein-id>: 0.314+/-0.026 vs 0.039+/-0.012; SOD: 28.33+/-1.17 vs 36.14+/-1.91; P&lt;0.01).	TXB2__MPO__no_interaction	TXB2__p65__no_interaction	TXB2__iNOS__no_interaction
17982511-1	12B75, 274150; <compound-id="441300">Abacavir sulfate</compound-id>/<compound-id="60825">lamivudine</compound-id>, Abatacept, Ad2/<protein-id="A0JND0">HIF-1alpha</protein-id>, Adalimumab, <compound-id="60172">Adefovir</compound-id>, <compound-id="60871">Adefovir dipivoxil</compound-id>, AGN-201904-Z, AIDSVAX, Albinterferon alfa-2b, Alemtuzumab, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="5488548">Alvimopan</compound-id> hydrate, <compound-id="2162">Amlodipine besylate</compound-id>/<compound-id="60823">atorvastatin calcium</compound-id>, <compound-id="2162">Amlodipine besylate</compound-id>/<compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="15251598">Ammonium tetrathiomolybdate</compound-id>, <compound-id="2165">Amodiaquine</compound-id>, <compound-id="5813717">Apaziquone</compound-id>, <compound-id="151165,21923359,53660666,6918365">Aprepitant</compound-id>, <compound-id="5359596">Arsenic</compound-id> trioxide, <compound-id="105031,16394563,49769200,53486426,5464098,60196289,65664,6917864,9821433">Artesunate</compound-id>/<compound-id="2165">Amodiaquine</compound-id>, <compound-id="54670067">Ascorbic acid</compound-id>, <compound-id="148192">Atazanavir sulfate</compound-id>, Atazanavir/<compound-id="392622">ritonavir</compound-id>, <compound-id="54841">Atomoxetine</compound-id> hydrochloride, Atrigel-<compound-id="657181">Leuprolide</compound-id>, <compound-id="6450551">Axitinib</compound-id>; Bevacizumab, <compound-id="9576912">Binodenoson</compound-id>, <compound-id="387447">Bortezomib</compound-id>, Bovine <protein-id="P24627,B9VPZ5">lactoferrin</protein-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="6918474">Carisbamate</compound-id>, Certolizumab pegol, <compound-id="6918155">Ciclesonide</compound-id>, <compound-id="151171">Conivaptan</compound-id> hydrochloride, CP-690550, CP-751871, <compound-id="9962928">Cypher</compound-id>; <compound-id="214347">Dapivirine</compound-id>, Darbepoetin alfa, <compound-id="213039">Darunavir</compound-id>, <compound-id="3062316">Dasatinib</compound-id>, <compound-id="445801">del</compound-id>-1 Genemedicine, Denosumab, <compound-id="124087">Desloratadine</compound-id>, <compound-id="9578005">Dexlansoprazole</compound-id>, DiabeCell, <compound-id="68873">Drospirenone</compound-id>/ethinylestradiol, DTaP-<compound-id="4177956">HepB</compound-id>-IPV, <compound-id="60835">Duloxetine</compound-id> hydrochloride, <compound-id="6918296">Dutasteride</compound-id>; Eculizumab, <compound-id="6918141">Eldecalcitol</compound-id>, <compound-id="77993">Eletriptan</compound-id>, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="153941">Entecavir</compound-id>, <compound-id="6912404">Eritoran</compound-id> <compound-id="21226136">tetrasodium</compound-id>, <compound-id="150610">Ertapenem sodium</compound-id>, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="179344">Eslicarbazepine acetate</compound-id>, <compound-id="4594,9568614">Esomeprazole magnesium</compound-id>, <compound-id="157050">Estradiol acetate</compound-id>, <compound-id="969472">Eszopiclone</compound-id>, ETEC vaccine, <compound-id="123619">Etoricoxib</compound-id>, <compound-id="45588096,53396299,56927919">Exenatide</compound-id>, <compound-id="150311">Ezetimibe</compound-id>; <compound-id="24847878,9854489">Fluticasone furoate</compound-id>, <compound-id="572">Fosmidomycin</compound-id>, <compound-id="572">Fosmidomycin</compound-id>/<compound-id="2786,29029,44421072,446598,45357041,52944314,53245639,9812677">clindamycin</compound-id>; <compound-id="5961">Glutamine</compound-id>; Heat Shock Protein 10, Hepatitis B hyperimmunoglobulin, HIV vaccine, Hochuekki-to, Human Albumin, Human papillomavirus vaccine; Immune globulin subcutaneous [human], <compound-id="72941955">IMP-321</compound-id>, Interferon omega, <compound-id="44564108">ISIS-301012</compound-id>, <compound-id="9841834">Istaroxime</compound-id>; Japanese encephalitis virus vaccine; <compound-id="5311221">Latanoprost</compound-id>/<compound-id="168613,33624">timolol maleate</compound-id>, <compound-id="216326">Lenalidomide</compound-id>, <compound-id="16158208">Linaclotide acetate</compound-id>, <compound-id="151166">Lumiracoxib</compound-id>, <compound-id="9939865">LY-517717</compound-id>; Malaria vaccine, MAS-063D, Meningitis B vaccine, <compound-id="56603701">Mepolizumab</compound-id>, <compound-id="5361918">Methylnaltrexone</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="477468,6602291">Micafungin sodium</compound-id>, MK-0822A, Morphine <compound-id="5281877">glucuronide</compound-id>, <compound-id="5288826">Morphine hydrochloride</compound-id>, <compound-id="446541">Mycophenolic acid sodium salt</compound-id>; Natalizumab, Nesiritide, <compound-id="13752005,62930,6537152,91454290,9568628">Norelgestromin</compound-id>/<compound-id="5991">ethinyl estradiol</compound-id>, NT-201; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, Omalizumab, <compound-id="5496659">Otamixaban</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, Panitumumab, <compound-id="6918837">Panobinostat</compound-id>, Parathyroid hormone (human recombinant), <compound-id="119828">Parecoxib sodium</compound-id>, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pegvisomant, <compound-id="56603685">PI-88</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, Pneumococcal 7-valent conjugate vaccine, Pneumococcal 9-valent conjugate vaccine, Pneumococcal conjugate vaccine, <compound-id="24751">Poloxamer</compound-id>-188, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, <compound-id="65947">Prulifloxacin</compound-id>; R-109339, <compound-id="5362129">Ramipril</compound-id>/amlodipine, Ranolazine, Rasburicase, rHA influenza vaccine, Ro-50-3821, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>, Rotavirus vaccine, <compound-id="59227">Rotigotine</compound-id>, <compound-id="153999">Ruboxistaurin mesilate hydrate</compound-id>; <compound-id="158348">Satavaptan</compound-id>, SC-75416, <compound-id="154059">Solifenacin succinate</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="6918585,70693550">Sugammadex</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>, Synthetic conjugated <compound-id="3001028">estrogens</compound-id> B; <compound-id="110635">Tadalafil</compound-id>, <compound-id="5311424">Talnetant</compound-id>, Taxus, <compound-id="5362436">Tegaserod maleate</compound-id>, <compound-id="159269">Telbivudine</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">Temsirolimus</compound-id>, <compound-id="5481350">Tenofovir disoproxil fumarate</compound-id>, <compound-id="3025803">Tetomilast</compound-id>, <compound-id="15057856,3086655,49800038,5487427">Tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="9896267">Tofimilast</compound-id>, Tremelimumab, <compound-id="5578">Trimethoprim</compound-id>; <compound-id="6918523">Udenafil</compound-id>, <protein-id="Q96RP3">Urocortin 2</protein-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="9930049">Vernakalant hydrochloride</compound-id>; XP-828L.	Morphine hydrochloride__Urocortin 2__no_interaction	Morphine hydrochloride__HIF-1alpha__no_interaction	Morphine hydrochloride__lactoferrin__no_interaction	Ciclesonide__Urocortin 2__no_interaction	Ciclesonide__HIF-1alpha__no_interaction	Ciclesonide__lactoferrin__no_interaction	Eldecalcitol__Urocortin 2__no_interaction	Eldecalcitol__HIF-1alpha__no_interaction	Eldecalcitol__lactoferrin__no_interaction	Parecoxib sodium__Urocortin 2__no_interaction	Parecoxib sodium__HIF-1alpha__no_interaction	Parecoxib sodium__lactoferrin__no_interaction	Tofimilast__Urocortin 2__no_interaction	Tofimilast__HIF-1alpha__no_interaction	Tofimilast__lactoferrin__no_interaction	Valdecoxib__Urocortin 2__no_interaction	Valdecoxib__HIF-1alpha__no_interaction	Valdecoxib__lactoferrin__no_interaction	Aliskiren fumarate__Urocortin 2__no_interaction	Aliskiren fumarate__HIF-1alpha__no_interaction	Aliskiren fumarate__lactoferrin__no_interaction	Rotigotine__Urocortin 2__no_interaction	Rotigotine__HIF-1alpha__no_interaction	Rotigotine__lactoferrin__no_interaction	Esomeprazole magnesium__Urocortin 2__no_interaction	Esomeprazole magnesium__HIF-1alpha__no_interaction	Esomeprazole magnesium__lactoferrin__no_interaction	sodium__Urocortin 2__no_interaction	sodium__HIF-1alpha__no_interaction	sodium__lactoferrin__no_interaction	Dapivirine__Urocortin 2__no_interaction	Dapivirine__HIF-1alpha__no_interaction	Dapivirine__lactoferrin__no_interaction	Conivaptan__Urocortin 2__no_interaction	Conivaptan__HIF-1alpha__no_interaction	Conivaptan__lactoferrin__no_interaction	Sunitinib malate__Urocortin 2__no_interaction	Sunitinib malate__HIF-1alpha__no_interaction	Sunitinib malate__lactoferrin__no_interaction	Alvimopan__Urocortin 2__no_interaction	Alvimopan__HIF-1alpha__no_interaction	Alvimopan__lactoferrin__no_interaction	Pimecrolimus__Urocortin 2__no_interaction	Pimecrolimus__HIF-1alpha__no_interaction	Pimecrolimus__lactoferrin__no_interaction	Vernakalant hydrochloride__Urocortin 2__no_interaction	Vernakalant hydrochloride__HIF-1alpha__no_interaction	Vernakalant hydrochloride__lactoferrin__no_interaction	atorvastatin calcium__Urocortin 2__no_interaction	atorvastatin calcium__HIF-1alpha__no_interaction	atorvastatin calcium__lactoferrin__no_interaction	Atomoxetine__Urocortin 2__no_interaction	Atomoxetine__HIF-1alpha__no_interaction	Atomoxetine__lactoferrin__no_interaction	Desloratadine__Urocortin 2__no_interaction	Desloratadine__HIF-1alpha__no_interaction	Desloratadine__lactoferrin__no_interaction	Eslicarbazepine acetate__Urocortin 2__no_interaction	Eslicarbazepine acetate__HIF-1alpha__no_interaction	Eslicarbazepine acetate__lactoferrin__no_interaction	Binodenoson__Urocortin 2__no_interaction	Binodenoson__HIF-1alpha__no_interaction	Binodenoson__lactoferrin__no_interaction	Ruboxistaurin mesilate hydrate__Urocortin 2__no_interaction	Ruboxistaurin mesilate hydrate__HIF-1alpha__no_interaction	Ruboxistaurin mesilate hydrate__lactoferrin__no_interaction	Prasugrel__Urocortin 2__no_interaction	Prasugrel__HIF-1alpha__no_interaction	Prasugrel__lactoferrin__no_interaction	Temsirolimus__Urocortin 2__no_interaction	Temsirolimus__HIF-1alpha__no_interaction	Temsirolimus__lactoferrin__no_interaction	clindamycin__Urocortin 2__no_interaction	clindamycin__HIF-1alpha__no_interaction	clindamycin__lactoferrin__no_interaction	Otamixaban__Urocortin 2__no_interaction	Otamixaban__HIF-1alpha__no_interaction	Otamixaban__lactoferrin__no_interaction	Drospirenone__Urocortin 2__no_interaction	Drospirenone__HIF-1alpha__no_interaction	Drospirenone__lactoferrin__no_interaction	Olmesartan medoxomil__Urocortin 2__no_interaction	Olmesartan medoxomil__HIF-1alpha__no_interaction	Olmesartan medoxomil__lactoferrin__no_interaction	Carisbamate__Urocortin 2__no_interaction	Carisbamate__HIF-1alpha__no_interaction	Carisbamate__lactoferrin__no_interaction	Dutasteride__Urocortin 2__no_interaction	Dutasteride__HIF-1alpha__no_interaction	Dutasteride__lactoferrin__no_interaction	Etoricoxib__Urocortin 2__no_interaction	Etoricoxib__HIF-1alpha__no_interaction	Etoricoxib__lactoferrin__no_interaction	Tadalafil__Urocortin 2__no_interaction	Tadalafil__HIF-1alpha__no_interaction	Tadalafil__lactoferrin__no_interaction	Aprepitant__Urocortin 2__no_interaction	Aprepitant__HIF-1alpha__no_interaction	Aprepitant__lactoferrin__no_interaction	Udenafil__Urocortin 2__no_interaction	Udenafil__HIF-1alpha__no_interaction	Udenafil__lactoferrin__no_interaction	ethinyl estradiol__Urocortin 2__no_interaction	ethinyl estradiol__HIF-1alpha__no_interaction	ethinyl estradiol__lactoferrin__no_interaction	Tiotropium__Urocortin 2__no_interaction	Tiotropium__HIF-1alpha__no_interaction	Tiotropium__lactoferrin__no_interaction	HepB__Urocortin 2__no_interaction	HepB__HIF-1alpha__no_interaction	HepB__lactoferrin__no_interaction	Glutamine__Urocortin 2__no_interaction	Glutamine__HIF-1alpha__no_interaction	Glutamine__lactoferrin__no_interaction	Pregabalin__Urocortin 2__no_interaction	Pregabalin__HIF-1alpha__no_interaction	Pregabalin__lactoferrin__no_interaction	Eszopiclone__Urocortin 2__no_interaction	Eszopiclone__HIF-1alpha__no_interaction	Eszopiclone__lactoferrin__no_interaction	Prulifloxacin__Urocortin 2__no_interaction	Prulifloxacin__HIF-1alpha__no_interaction	Prulifloxacin__lactoferrin__no_interaction	Methylnaltrexone__Urocortin 2__no_interaction	Methylnaltrexone__HIF-1alpha__no_interaction	Methylnaltrexone__lactoferrin__no_interaction	Atazanavir sulfate__Urocortin 2__no_interaction	Atazanavir sulfate__HIF-1alpha__no_interaction	Atazanavir sulfate__lactoferrin__no_interaction	Latanoprost__Urocortin 2__no_interaction	Latanoprost__HIF-1alpha__no_interaction	Latanoprost__lactoferrin__no_interaction	Fosmidomycin__Urocortin 2__no_interaction	Fosmidomycin__HIF-1alpha__no_interaction	Fosmidomycin__lactoferrin__no_interaction	Mepolizumab__Urocortin 2__no_interaction	Mepolizumab__HIF-1alpha__no_interaction	Mepolizumab__lactoferrin__no_interaction	Cypher__Urocortin 2__no_interaction	Cypher__HIF-1alpha__no_interaction	Cypher__lactoferrin__no_interaction	Darunavir__Urocortin 2__no_interaction	Darunavir__HIF-1alpha__no_interaction	Darunavir__lactoferrin__no_interaction	Dexlansoprazole__Urocortin 2__no_interaction	Dexlansoprazole__HIF-1alpha__no_interaction	Dexlansoprazole__lactoferrin__no_interaction	Lumiracoxib__Urocortin 2__no_interaction	Lumiracoxib__HIF-1alpha__no_interaction	Lumiracoxib__lactoferrin__no_interaction	Telbivudine__Urocortin 2__no_interaction	Telbivudine__HIF-1alpha__no_interaction	Telbivudine__lactoferrin__no_interaction	Sorafenib__Urocortin 2__no_interaction	Sorafenib__HIF-1alpha__no_interaction	Sorafenib__lactoferrin__no_interaction	Adefovir dipivoxil__Urocortin 2__no_interaction	Adefovir dipivoxil__HIF-1alpha__no_interaction	Adefovir dipivoxil__lactoferrin__no_interaction	Oblimersen__Urocortin 2__no_interaction	Oblimersen__HIF-1alpha__no_interaction	Oblimersen__lactoferrin__no_interaction	Micafungin sodium__Urocortin 2__no_interaction	Micafungin sodium__HIF-1alpha__no_interaction	Micafungin sodium__lactoferrin__no_interaction	Ammonium tetrathiomolybdate__Urocortin 2__no_interaction	Ammonium tetrathiomolybdate__HIF-1alpha__no_interaction	Ammonium tetrathiomolybdate__lactoferrin__no_interaction	Escitalopram oxalate__Urocortin 2__no_interaction	Escitalopram oxalate__HIF-1alpha__no_interaction	Escitalopram oxalate__lactoferrin__no_interaction	Norelgestromin__Urocortin 2__no_interaction	Norelgestromin__HIF-1alpha__no_interaction	Norelgestromin__lactoferrin__no_interaction	Ramipril__Urocortin 2__no_interaction	Ramipril__HIF-1alpha__no_interaction	Ramipril__lactoferrin__no_interaction	ISIS-301012__Urocortin 2__no_interaction	ISIS-301012__HIF-1alpha__no_interaction	ISIS-301012__lactoferrin__no_interaction	Ertapenem sodium__Urocortin 2__no_interaction	Ertapenem sodium__HIF-1alpha__no_interaction	Ertapenem sodium__lactoferrin__no_interaction	Arsenic__Urocortin 2__no_interaction	Arsenic__HIF-1alpha__no_interaction	Arsenic__lactoferrin__no_interaction	Ascorbic acid__Urocortin 2__no_interaction	Ascorbic acid__HIF-1alpha__no_interaction	Ascorbic acid__lactoferrin__no_interaction	Artesunate__Urocortin 2__no_interaction	Artesunate__HIF-1alpha__no_interaction	Artesunate__lactoferrin__no_interaction	tetrasodium__Urocortin 2__no_interaction	tetrasodium__HIF-1alpha__no_interaction	tetrasodium__lactoferrin__no_interaction	IMP-321__Urocortin 2__no_interaction	IMP-321__HIF-1alpha__no_interaction	IMP-321__lactoferrin__no_interaction	Estradiol acetate__Urocortin 2__no_interaction	Estradiol acetate__HIF-1alpha__no_interaction	Estradiol acetate__lactoferrin__no_interaction	Adefovir__Urocortin 2__no_interaction	Adefovir__HIF-1alpha__no_interaction	Adefovir__lactoferrin__no_interaction	Amodiaquine__Urocortin 2__no_interaction	Amodiaquine__HIF-1alpha__no_interaction	Amodiaquine__lactoferrin__no_interaction	Apaziquone__Urocortin 2__no_interaction	Apaziquone__HIF-1alpha__no_interaction	Apaziquone__lactoferrin__no_interaction	Dasatinib__Urocortin 2__no_interaction	Dasatinib__HIF-1alpha__no_interaction	Dasatinib__lactoferrin__no_interaction	Satavaptan__Urocortin 2__no_interaction	Satavaptan__HIF-1alpha__no_interaction	Satavaptan__lactoferrin__no_interaction	Leuprolide__Urocortin 2__no_interaction	Leuprolide__HIF-1alpha__no_interaction	Leuprolide__lactoferrin__no_interaction	Ezetimibe__Urocortin 2__no_interaction	Ezetimibe__HIF-1alpha__no_interaction	Ezetimibe__lactoferrin__no_interaction	bromide__Urocortin 2__no_interaction	bromide__HIF-1alpha__no_interaction	bromide__lactoferrin__no_interaction	Tegaserod maleate__Urocortin 2__no_interaction	Tegaserod maleate__HIF-1alpha__no_interaction	Tegaserod maleate__lactoferrin__no_interaction	Trimethoprim__Urocortin 2__no_interaction	Trimethoprim__HIF-1alpha__no_interaction	Trimethoprim__lactoferrin__no_interaction	Lenalidomide__Urocortin 2__no_interaction	Lenalidomide__HIF-1alpha__no_interaction	Lenalidomide__lactoferrin__no_interaction	Rosuvastatin calcium__Urocortin 2__no_interaction	Rosuvastatin calcium__HIF-1alpha__no_interaction	Rosuvastatin calcium__lactoferrin__no_interaction	Mycophenolic acid sodium salt__Urocortin 2__no_interaction	Mycophenolic acid sodium salt__HIF-1alpha__no_interaction	Mycophenolic acid sodium salt__lactoferrin__no_interaction	Eletriptan__Urocortin 2__no_interaction	Eletriptan__HIF-1alpha__no_interaction	Eletriptan__lactoferrin__no_interaction	Duloxetine__Urocortin 2__no_interaction	Duloxetine__HIF-1alpha__no_interaction	Duloxetine__lactoferrin__no_interaction	LY-517717__Urocortin 2__no_interaction	LY-517717__HIF-1alpha__no_interaction	LY-517717__lactoferrin__no_interaction	Talnetant__Urocortin 2__no_interaction	Talnetant__HIF-1alpha__no_interaction	Talnetant__lactoferrin__no_interaction	Poloxamer__Urocortin 2__no_interaction	Poloxamer__HIF-1alpha__no_interaction	Poloxamer__lactoferrin__no_interaction	del__Urocortin 2__no_interaction	del__HIF-1alpha__no_interaction	del__lactoferrin__no_interaction	hydrochlorothiazide__Urocortin 2__no_interaction	hydrochlorothiazide__HIF-1alpha__no_interaction	hydrochlorothiazide__lactoferrin__no_interaction	Solifenacin succinate__Urocortin 2__no_interaction	Solifenacin succinate__HIF-1alpha__no_interaction	Solifenacin succinate__lactoferrin__no_interaction	PI-88__Urocortin 2__no_interaction	PI-88__HIF-1alpha__no_interaction	PI-88__lactoferrin__no_interaction	Linaclotide acetate__Urocortin 2__no_interaction	Linaclotide acetate__HIF-1alpha__no_interaction	Linaclotide acetate__lactoferrin__no_interaction	estrogens__Urocortin 2__no_interaction	estrogens__HIF-1alpha__no_interaction	estrogens__lactoferrin__no_interaction	Amlodipine besylate__Urocortin 2__no_interaction	Amlodipine besylate__HIF-1alpha__no_interaction	Amlodipine besylate__lactoferrin__no_interaction	Tipifarnib__Urocortin 2__no_interaction	Tipifarnib__HIF-1alpha__no_interaction	Tipifarnib__lactoferrin__no_interaction	Axitinib__Urocortin 2__no_interaction	Axitinib__HIF-1alpha__no_interaction	Axitinib__lactoferrin__no_interaction	Entecavir__Urocortin 2__no_interaction	Entecavir__HIF-1alpha__no_interaction	Entecavir__lactoferrin__no_interaction	lamivudine__Urocortin 2__no_interaction	lamivudine__HIF-1alpha__no_interaction	lamivudine__lactoferrin__no_interaction	Istaroxime__Urocortin 2__no_interaction	Istaroxime__HIF-1alpha__no_interaction	Istaroxime__lactoferrin__no_interaction	Sugammadex__Urocortin 2__no_interaction	Sugammadex__HIF-1alpha__no_interaction	Sugammadex__lactoferrin__no_interaction	Fluticasone furoate__Urocortin 2__no_interaction	Fluticasone furoate__HIF-1alpha__no_interaction	Fluticasone furoate__lactoferrin__no_interaction	ritonavir__Urocortin 2__no_interaction	ritonavir__HIF-1alpha__no_interaction	ritonavir__lactoferrin__no_interaction	Eritoran__Urocortin 2__no_interaction	Eritoran__HIF-1alpha__no_interaction	Eritoran__lactoferrin__no_interaction	Calcipotriol/betamethasone dipropionate__Urocortin 2__no_interaction	Calcipotriol/betamethasone dipropionate__HIF-1alpha__no_interaction	Calcipotriol/betamethasone dipropionate__lactoferrin__no_interaction	Paclitaxel__Urocortin 2__no_interaction	Paclitaxel__HIF-1alpha__no_interaction	Paclitaxel__lactoferrin__no_interaction	Tetomilast__Urocortin 2__no_interaction	Tetomilast__HIF-1alpha__no_interaction	Tetomilast__lactoferrin__no_interaction	Tenofovir disoproxil fumarate__Urocortin 2__no_interaction	Tenofovir disoproxil fumarate__HIF-1alpha__no_interaction	Tenofovir disoproxil fumarate__lactoferrin__no_interaction	glucuronide__Urocortin 2__no_interaction	glucuronide__HIF-1alpha__no_interaction	glucuronide__lactoferrin__no_interaction	Bortezomib__Urocortin 2__no_interaction	Bortezomib__HIF-1alpha__no_interaction	Bortezomib__lactoferrin__no_interaction	Panobinostat__Urocortin 2__no_interaction	Panobinostat__HIF-1alpha__no_interaction	Panobinostat__lactoferrin__no_interaction	Abacavir sulfate__Urocortin 2__no_interaction	Abacavir sulfate__HIF-1alpha__no_interaction	Abacavir sulfate__lactoferrin__no_interaction	Emtricitabine__Urocortin 2__no_interaction	Emtricitabine__HIF-1alpha__no_interaction	Emtricitabine__lactoferrin__no_interaction	timolol maleate__Urocortin 2__no_interaction	timolol maleate__HIF-1alpha__no_interaction	timolol maleate__lactoferrin__no_interaction	Exenatide__Urocortin 2__no_interaction	Exenatide__HIF-1alpha__no_interaction	Exenatide__lactoferrin__no_interaction
11401417-7	Furthermore, <compound-id="5281037">eprosartan</compound-id> inhibited <protein-id="P01015">angiotensin II</protein-id> receptor binding in discrete brain areas, which express exclusively, or predominantly, AT1 receptors both outside and within the blood-brain barrier, such as the paraventricular nucleus ( 180 +/- 47 and 130 +/- 18 vs 545 +/- 99 dpm x mm(-2)of <protein-id="Q9EQZ8">CTRL</protein-id>; P&lt; 0.05), the subfornical organ ( 106 +/- 26 and 112 +/- 17 vs 619 +/- 256 dpm x mm(-2)of <protein-id="Q9EQZ8">CTRL</protein-id>; P&lt; 0.05), and the organum vasculosum laminae terminalis ( 461 +/- 110 and 763 +/- 136 vs 1033 +/- 123 dpmx mm(-2)of <protein-id="Q9EQZ8">CTRL</protein-id>; P&lt; 0.05).	eprosartan__angiotensin II__no_interaction	eprosartan__CTRL__no_interaction
24215309-3	A systematic search of Pubmed was performed using the key words: "<protein-id="P01308,I3WAC9">insulin</protein-id> analogue", "<protein-id="P01308,I3WAC9">insulin</protein-id> derative", "<protein-id="P01308,I3WAC9">insulin</protein-id> homologue", "<compound-id="44146714">glargine</compound-id>", "Lantus", "degludec", "tresiba", "NPH", "lispro", "<compound-id="16132438">humalog</compound-id>", "detemir", "<compound-id="72941722">levemir</compound-id>", "glulisine", "<compound-id="72941761">apidra</compound-id>", "aspart", "<compound-id="16132418">novolog</compound-id>", "<protein-id="P01308,I3WAC9">insulin</protein-id> treatment", "diabetes treatment", "<protein-id="P01308,I3WAC9">insulin</protein-id> therapy" or "diabetes therapy" combined with "neoplasia", "tumor", "cancer", "carcinoma", "malignan*", "carcinog*" or " mitoge*".	novolog__insulin__no_interaction	humalog__insulin__no_interaction	levemir__insulin__no_interaction	apidra__insulin__no_interaction	glargine__insulin__no_interaction
18499743-2	In this study, we describe a small molecule <protein-id="Q9EPK8,Q9HBA0">TRPV4</protein-id> channel activator, (<compound-id="23630211">N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide</compound-id> (GSK1016790A), which we have used as a valuable tool in investigating the role of <protein-id="Q9EPK8,Q9HBA0">TRPV4</protein-id> in the urinary bladder.	N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide__TRPV4__no_interaction
8852837-2	Strains of Saccharomyces cerevisiae were constructed that possess combinations of gene disruptions at the <protein-id="P37292">SHM1</protein-id> [mitochondrial serine hydroxymethyltransferase (SHMTm)], <protein-id="P37291">SHM2</protein-id> [cytoplasmic SHMT (SHMTc)], <protein-id="P09440">MIS1</protein-id> [mitochondrial C1-<compound-id="91443,9826590">tetrahydrofolate</compound-id> synthase (C1-THFSm)], <protein-id="P07245">ADE3</protein-id> [cytoplasmic C1-<compound-id="8028">THF</compound-id> synthase (C1-THFSc)], <protein-id="P48015">GCV1</protein-id> [<compound-id="45934207,750">glycine</compound-id> cleavage system (GCV) protein T], and the GLY1 (involved in <compound-id="45934207,750">glycine</compound-id> synthesis) loci.	THF__GCV1__no_interaction	THF__ADE3__no_interaction	THF__SHM2__no_interaction	THF__MIS1__no_interaction	THF__SHM1__no_interaction	glycine__GCV1__no_interaction	glycine__ADE3__no_interaction	glycine__SHM2__no_interaction	glycine__MIS1__no_interaction	glycine__SHM1__no_interaction	tetrahydrofolate__GCV1__no_interaction	tetrahydrofolate__ADE3__no_interaction	tetrahydrofolate__SHM2__no_interaction	tetrahydrofolate__MIS1__no_interaction	tetrahydrofolate__SHM1__no_interaction
9284740-6	Cross-correlation analysis revealed: 1) peripheral blood LH and <compound-id="6013">testosterone</compound-id> concentrations correlate positively at lags of 40-120 min with LH increases preceding <compound-id="6013">testosterone</compound-id> increases, viz., feed-forward (P &lt; 0.001); 2) LH and <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> concentrations in peripheral blood are positively correlated in simultaneous blood samples, as well as when <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> lags LH by 20 min (P &lt; 0.01); 3) unexpectedly, LH and <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> concentrations in peripheral blood are inversely related at a lag of 80-100 min (P = 0.002) and 0.004, respectively) where LH lags <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>; 4) LH and <compound-id="6013">testosterone</compound-id> concentrations in the spermatic vein show strongly positive correlations at lags of 80, 100, and 120 min (P = 0.002, 0.004, and 0.021, respectively); 5) spermatic vein <compound-id="6013">testosterone</compound-id> concentrations correlate negatively with peripheral blood LH concentrations 20 or 40 min later (P = 0.012 and 0.05, respectively), which indicates autonegative feedback; and 6) in contrast, <compound-id="6013">testosterone</compound-id> levels in the spermatic vein correlate negatively with <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> values in the periphery 100 and 120 min later (P &lt; 0.01), indicating more delayed negative feedback of <compound-id="6013">testosterone</compound-id> on serum <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> concentrations.	testosterone__FSH__no_interaction
9284740-7	Discrete pulse coincidence analysis disclosed: 1) a total of 30 <compound-id="6013">testosterone</compound-id> pulses in the spermatic vein and 25 <compound-id="6013">testosterone</compound-id> pulses in peripheral blood, with 28 LH and 29 <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> pulses in the periphery; 2) individual LH and <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> peak concordance was significantly nonrandom for <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id> pulse maxima lagging LH pulse maxima by 20 min (P &lt; 0.05 vs. randomness), with 6 observed coincidences vs. 2.9 +/- 1.5 (SD) expected; 3) peripheral LH pulses and spermatic vein <compound-id="6013">testosterone</compound-id> pulses were strongly nonrandomly coupled at an 80-min lag, with 8 events observed vs. 3.0 +/- 1.5 events expected (P = 0.004); and 4) LH peaks in peripheral blood followed <compound-id="6013">testosterone</compound-id> peaks in the spermatic vein by 40 min in a nonrandom manner, specifically, n = 11 observed vs. 3.0 +/- 1.5 expected (P &lt; 0.001), indicating possible LH escape from <compound-id="6013">testosterone</compound-id>'s negative feedback.	testosterone__FSH__no_interaction
20716917-4	RESULTS: We found (a) abundant tissue <protein-id="P16599">TNF-alpha</protein-id> and ASK1 expression throughout all layers of the intestine in neonates with NEC, suggesting that <protein-id="P16599">TNF-alpha</protein-id>/ASK1 may be a potential source (indicators) of intestinal injury in neonates with NEC; (b) <protein-id="P16599">TNF-alpha</protein-id>-induced rapid and transient activation of JNK/<protein-id="G3V617,Q56A33">p38</protein-id> apoptotic signaling in all cell lines suggests that this may be an important molecular characteristic of NEC; (c) <protein-id="P16599">TNF-alpha</protein-id>-induced rapid and transient ROS production in <compound-id="11656602">RIE</compound-id>-1 cells indicates that mitochondria are the predominant source of ROS, demonstrated by significantly attenuated response in mitochondrial DNA-depleted (<compound-id="11656602">RIE</compound-id>-1-rho) intestinal epithelial cells; (d) further studies with mitochondria-targeted <compound-id="8679">antioxidant PBN</compound-id> supported our hypothesis that effective mitochondrial ROS trapping is protective against <protein-id="P16599">TNF-alpha</protein-id>/ROS-induced intestinal epithelial cell injury; (e) <protein-id="P16599">TNF-alpha</protein-id> induces significant mitochondrial dysfunction in intestinal epithelial cells, resulting in increased production of mtROS, drop in mitochondrial membrane potential (MMP) and decreased <compound-id="977">oxygen</compound-id> consumption; (f) although the significance of mitochondrial autophagy in NEC has not been unequivocally shown, our studies provide a strong preliminary indication that <protein-id="P16599">TNF-alpha</protein-id>/ROS-induced mitochondrial autophagy may play a role in NEC, and this process is a late phenomenon.	antioxidant PBN__TNF-alpha__no_interaction	antioxidant PBN__p38__no_interaction	RIE__TNF-alpha__no_interaction	RIE__p38__no_interaction	oxygen__TNF-alpha__no_interaction	oxygen__p38__no_interaction
20418485-3	Suggestive signals for association with 25(OH)D were also observed for SNPs in or near three other genes involved in <compound-id="5283711">vitamin D</compound-id> synthesis or activation: rs3829251 on chromosome 11q13.4 in <protein-id="Q6IA69">NADSYN1</protein-id> [encoding <compound-id="936">nicotinamide</compound-id> <compound-id="190,57060554">adenine</compound-id> dinucleotide (<compound-id="5893">NAD</compound-id>) synthetase; P=8.8x10(-7)], which was in high LD with rs1790349, located in <protein-id="Q9UBM7,A0A024R5F7">DHCR7</protein-id>, the gene encoding <compound-id="172,25201813,439423,44135503">7-dehydrocholesterol</compound-id> reductase that synthesizes <compound-id="5997">cholesterol</compound-id> from <compound-id="172,25201813,439423,44135503">7-dehydrocholesterol</compound-id>; rs6599638 in the region harboring the open-reading frame 88 (<protein-id="Q9H8K7">C10orf88</protein-id>) on chromosome 10q26.13 in the vicinity of <protein-id="P45954">ACADSB</protein-id> (acyl-<compound-id="44216777,44246472,444624,445126,448506,5326877,6816,6914636,87642">Coenzyme A</compound-id> dehydrogenase), involved in <compound-id="5997">cholesterol</compound-id> and <compound-id="5283711">vitamin D</compound-id> synthesis (P=3.3x10(-7)); and rs2060793 on chromosome 11p15.2 in <protein-id="Q6VVX0">CYP2R1</protein-id> (<protein-id="Q6VVX0">cytochrome P450, family 2, subfamily R, polypeptide 1</protein-id>, encoding a key C-25 hydroxylase that converts vitamin D3 to an active <compound-id="5283711">vitamin D</compound-id> receptor ligand; P=1.4x10(-5)).	Coenzyme A__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	Coenzyme A__NADSYN1__no_interaction	Coenzyme A__DHCR7__no_interaction	Coenzyme A__C10orf88__no_interaction	Coenzyme A__ACADSB__no_interaction	Coenzyme A__CYP2R1__no_interaction	NAD__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	NAD__NADSYN1__no_interaction	NAD__DHCR7__no_interaction	NAD__C10orf88__no_interaction	NAD__ACADSB__no_interaction	NAD__CYP2R1__no_interaction	adenine__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	adenine__NADSYN1__no_interaction	adenine__DHCR7__no_interaction	adenine__C10orf88__no_interaction	adenine__ACADSB__no_interaction	adenine__CYP2R1__no_interaction	vitamin D__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	vitamin D__NADSYN1__no_interaction	vitamin D__DHCR7__no_interaction	vitamin D__C10orf88__no_interaction	vitamin D__ACADSB__no_interaction	vitamin D__CYP2R1__no_interaction	nicotinamide__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	nicotinamide__NADSYN1__no_interaction	nicotinamide__DHCR7__no_interaction	nicotinamide__C10orf88__no_interaction	nicotinamide__ACADSB__no_interaction	nicotinamide__CYP2R1__no_interaction	cholesterol__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	cholesterol__NADSYN1__no_interaction	cholesterol__DHCR7__no_interaction	cholesterol__C10orf88__no_interaction	cholesterol__ACADSB__no_interaction	cholesterol__CYP2R1__no_interaction	7-dehydrocholesterol__cytochrome P450, family 2, subfamily R, polypeptide 1__no_interaction	7-dehydrocholesterol__NADSYN1__no_interaction	7-dehydrocholesterol__DHCR7__no_interaction	7-dehydrocholesterol__C10orf88__no_interaction	7-dehydrocholesterol__ACADSB__no_interaction	7-dehydrocholesterol__CYP2R1__no_interaction
8060375-6	The univariate analysis showed that plasma levels of <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> were significantly associated with body mass index (BMI) (r = 0.37, P &lt; 0.001), waist/hip ratio (WHR) (r = 0.26, P &lt; 0.01), serum triglycerides (r = 0.47, P &lt; 0.0001), HDL/total <compound-id="5997">cholesterol</compound-id> ratio (r = -0.35, P &lt; 0.001), fasting and 2-h <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.27, P &lt; 0.01 and r = 0.34, P &lt; 0.001) and <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations (r = 0.25, P &lt; 0.05 and r = 0.28, P &lt; 0.01).	glucose__PAI-1__no_interaction	glucose__insulin__no_interaction	cholesterol__PAI-1__no_interaction	cholesterol__insulin__no_interaction
18427423-5	RESULTS: At the end of the 12-week period, HF-Sed rats exhibited higher body weight (means +/- standard error [SE]: 492+/-40 vs 432+/-21 g; P&lt;0.05), liver weight (16.21+/-2.23 vs 9.92+/-1.14 g; P&lt;0.05), serum <compound-id="5950,602">alanine</compound-id> aminotransferase (73.62+/-36.11 vs 27.16+/-4.62 U/L; P&lt;0.05), aspartic aminotransferase (AST; 198.87+/-120.16 vs 120.16+/-19.09 U/L; P&lt;0.05), nonesterified fatty acids (NEFA; 897.48+/-133.62 vs 437.5 micromol/L; P&lt;0.05), triglyceride (0.92+/-0.1 vs 0.56+/-0.04 mmol/L; P&lt;0.05), <protein-id="P16599">tumor necrosis factor (TNF)-a</protein-id> (21.74+/-2.93 vs 16.57+/-3.53 pg/mL; P &lt; 0.05) as well as liver <compound-id="10964">malondialdehyde</compound-id> (MDA; 5.3+/-1.45 vs 3.48+/-0.94 nmol/mg protein; P&lt;0.05) and NEFA (305.47+/-69.23 vs 204.56+/-64.26 micromol/mg protein; P&lt;0.05) than SD-Sed rats.	alanine__tumor necrosis factor (TNF)-a__no_interaction	malondialdehyde__tumor necrosis factor (TNF)-a__no_interaction
20190014-5	CP-900691 treatment increased plasma high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p &lt; 0.001) and <protein-id="P68292">apolipoprotein A1</protein-id> (96 +/- 5 to 157 +/- 5 mg/dL, p &lt; 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p &lt; 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p &lt; 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p &lt; 0.001), decreased body weight (p &lt; 0.01) and <protein-id="G7NWB4">C-reactive protein</protein-id> (<protein-id="G7NWB4">CRP</protein-id>) (1700 +/- 382 to 304 +/- 102 ng/ml, p &lt; 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p &lt; 0.001) compared with baseline.	cholesterol__apolipoprotein A1__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__CRP__no_interaction
1892247-4	Gene nomenclature: <protein-id="P28271">ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase</protein-id>; <protein-id="Q5EC55">AMH</protein-id>: antiMüllerian hormone; ARA 1: murine sarcoma 3611 viral (v-raf) oncogene homologue 1; CASB: beta-casein; <protein-id="O70589,B9EJ23">CASK</protein-id>: kappa-casein; <protein-id="P17182,Q5FW97">ENO 1</protein-id>: <protein-id="Q00612,Q790Y8">enolase 1 (alpha); G6PD</protein-id>: <compound-id="5793,64689,79025">glucose</compound-id>-6-<compound-id="1061,167704,644102">phosphate</compound-id> dehydrogenase; <compound-id="16131086">GALA</compound-id> (or GLA): glactosidase (alpha); GAPD: <compound-id="751">glyceraldehyde</compound-id> -3- <compound-id="1061,167704,644102">phosphate</compound-id> dehydrogenase; GPI: <compound-id="5793,64689,79025">glucose</compound-id> <compound-id="1061,167704,644102">phosphate</compound-id> isomerase; <protein-id="P47791">GSR</protein-id>: <compound-id="124886,20725278,745">glutathione</compound-id> reductase; HBG: haemoglobin gamma; HPRT: <compound-id="790">hypoxanthine</compound-id> phosphoribosyl transferase; <protein-id="O88844">IDH 1</protein-id>: <compound-id="1198">isocitrate</compound-id> dehydrogenase 1 (soluble); <protein-id="P05017,Q4VJC0,Q8CAR0,E9Q138,Q4VJB9,E9PU89,Q547V2">IGF-1</protein-id>: insulin growth factor 1; <protein-id="Q9D892,Q60I30">ITPA</protein-id>: <compound-id="6021">inosine</compound-id> triphosphatase; KRTA: keratin (acid); KRTB: keratin (basic); <protein-id="P09462">LALBA</protein-id>: alpha-lactalbumin; <protein-id="P06151,Q564E2,G5E8N5">LDHA</protein-id>: <compound-id="612">lactate</compound-id> dehydrogenase A; <protein-id="P16125">LDHB</protein-id>: <compound-id="612">lactate</compound-id> dehydrogenase B; <protein-id="P08249">MDH 2</protein-id>: <compound-id="525">malate</compound-id> dehydrogenase <compound-id="5893">NAD</compound-id> (soluble); ME 1: malic enzyme (soluble); MPI: <compound-id="206">mannose</compound-id> <compound-id="1061,167704,644102">phosphate</compound-id> isomerase; NP: nucleoside phosphorylase; OLA: ovine leucocyte antigen; OTC: ornitine carbamoyltransferase; <protein-id="Q9DCL9">PAIS</protein-id>: <compound-id="57263867">phosphoribosyl amino</compound-id> <compound-id="795">imidazole</compound-id> synthetase; <compound-id="6603828">PEPA</compound-id>, PEPB, PEPC: peptidase A, B, C; PGD: phospho <compound-id="10690">gluconate</compound-id> dehydrogenase; PGK: phosphoglycerate kinase; <protein-id="Q9CYR6,Q8BWW3,Q8BLS4">PGM 3</protein-id>: phospho glucomutase 3; <protein-id="P52480">PKM 2</protein-id>: <compound-id="1060">pyruvate</compound-id> kinase (muscle); PLP: proteolipid protein; PRGS: phosphoribosyl <compound-id="69020">glycinamide</compound-id> synthetase; <compound-id="449097">RCP</compound-id>: red cone pigment; SHMT: <compound-id="57223026">serine hydroxymethyl</compound-id> transferase; <protein-id="P08228">SOD 1</protein-id>: <compound-id="5359597">superoxide</compound-id> dismutase 1 (soluble); <protein-id="O88935">SYN 1</protein-id>: <protein-id="O88935">synapsin 1</protein-id>; <protein-id="P17751">TPI</protein-id> l: <compound-id="439168">triose phosphate</compound-id> isomerase 1.	NAD__AMH__no_interaction	NAD__SOD 1__no_interaction	NAD__GSR__no_interaction	NAD__IGF-1__no_interaction	NAD__synapsin 1__no_interaction	NAD__IDH 1__no_interaction	NAD__SYN 1__no_interaction	NAD__PKM 2__no_interaction	NAD__CASK__no_interaction	NAD__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	NAD__enolase 1 (alpha); G6PD__no_interaction	NAD__ITPA__no_interaction	NAD__PGM 3__no_interaction	NAD__MDH 2__no_interaction	NAD__ENO 1__no_interaction	NAD__PAIS__no_interaction	NAD__TPI__no_interaction	NAD__LDHA__no_interaction	NAD__LDHB__no_interaction	NAD__LALBA__no_interaction	inosine__AMH__no_interaction	inosine__SOD 1__no_interaction	inosine__GSR__no_interaction	inosine__IGF-1__no_interaction	inosine__synapsin 1__no_interaction	inosine__IDH 1__no_interaction	inosine__SYN 1__no_interaction	inosine__PKM 2__no_interaction	inosine__CASK__no_interaction	inosine__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	inosine__enolase 1 (alpha); G6PD__no_interaction	inosine__ITPA__no_interaction	inosine__PGM 3__no_interaction	inosine__MDH 2__no_interaction	inosine__ENO 1__no_interaction	inosine__PAIS__no_interaction	inosine__TPI__no_interaction	inosine__LDHA__no_interaction	inosine__LDHB__no_interaction	inosine__LALBA__no_interaction	RCP__AMH__no_interaction	RCP__SOD 1__no_interaction	RCP__GSR__no_interaction	RCP__IGF-1__no_interaction	RCP__synapsin 1__no_interaction	RCP__IDH 1__no_interaction	RCP__SYN 1__no_interaction	RCP__PKM 2__no_interaction	RCP__CASK__no_interaction	RCP__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	RCP__enolase 1 (alpha); G6PD__no_interaction	RCP__ITPA__no_interaction	RCP__PGM 3__no_interaction	RCP__MDH 2__no_interaction	RCP__ENO 1__no_interaction	RCP__PAIS__no_interaction	RCP__TPI__no_interaction	RCP__LDHA__no_interaction	RCP__LDHB__no_interaction	RCP__LALBA__no_interaction	serine hydroxymethyl__AMH__no_interaction	serine hydroxymethyl__SOD 1__no_interaction	serine hydroxymethyl__GSR__no_interaction	serine hydroxymethyl__IGF-1__no_interaction	serine hydroxymethyl__synapsin 1__no_interaction	serine hydroxymethyl__IDH 1__no_interaction	serine hydroxymethyl__SYN 1__no_interaction	serine hydroxymethyl__PKM 2__no_interaction	serine hydroxymethyl__CASK__no_interaction	serine hydroxymethyl__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	serine hydroxymethyl__enolase 1 (alpha); G6PD__no_interaction	serine hydroxymethyl__ITPA__no_interaction	serine hydroxymethyl__PGM 3__no_interaction	serine hydroxymethyl__MDH 2__no_interaction	serine hydroxymethyl__ENO 1__no_interaction	serine hydroxymethyl__PAIS__no_interaction	serine hydroxymethyl__TPI__no_interaction	serine hydroxymethyl__LDHA__no_interaction	serine hydroxymethyl__LDHB__no_interaction	serine hydroxymethyl__LALBA__no_interaction	hypoxanthine__AMH__no_interaction	hypoxanthine__SOD 1__no_interaction	hypoxanthine__GSR__no_interaction	hypoxanthine__IGF-1__no_interaction	hypoxanthine__synapsin 1__no_interaction	hypoxanthine__IDH 1__no_interaction	hypoxanthine__SYN 1__no_interaction	hypoxanthine__PKM 2__no_interaction	hypoxanthine__CASK__no_interaction	hypoxanthine__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	hypoxanthine__enolase 1 (alpha); G6PD__no_interaction	hypoxanthine__ITPA__no_interaction	hypoxanthine__PGM 3__no_interaction	hypoxanthine__MDH 2__no_interaction	hypoxanthine__ENO 1__no_interaction	hypoxanthine__PAIS__no_interaction	hypoxanthine__TPI__no_interaction	hypoxanthine__LDHA__no_interaction	hypoxanthine__LDHB__no_interaction	hypoxanthine__LALBA__no_interaction	PEPA__AMH__no_interaction	PEPA__SOD 1__no_interaction	PEPA__GSR__no_interaction	PEPA__IGF-1__no_interaction	PEPA__synapsin 1__no_interaction	PEPA__IDH 1__no_interaction	PEPA__SYN 1__no_interaction	PEPA__PKM 2__no_interaction	PEPA__CASK__no_interaction	PEPA__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	PEPA__enolase 1 (alpha); G6PD__no_interaction	PEPA__ITPA__no_interaction	PEPA__PGM 3__no_interaction	PEPA__MDH 2__no_interaction	PEPA__ENO 1__no_interaction	PEPA__PAIS__no_interaction	PEPA__TPI__no_interaction	PEPA__LDHA__no_interaction	PEPA__LDHB__no_interaction	PEPA__LALBA__no_interaction	glycinamide__AMH__no_interaction	glycinamide__SOD 1__no_interaction	glycinamide__GSR__no_interaction	glycinamide__IGF-1__no_interaction	glycinamide__synapsin 1__no_interaction	glycinamide__IDH 1__no_interaction	glycinamide__SYN 1__no_interaction	glycinamide__PKM 2__no_interaction	glycinamide__CASK__no_interaction	glycinamide__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	glycinamide__enolase 1 (alpha); G6PD__no_interaction	glycinamide__ITPA__no_interaction	glycinamide__PGM 3__no_interaction	glycinamide__MDH 2__no_interaction	glycinamide__ENO 1__no_interaction	glycinamide__PAIS__no_interaction	glycinamide__TPI__no_interaction	glycinamide__LDHA__no_interaction	glycinamide__LDHB__no_interaction	glycinamide__LALBA__no_interaction	superoxide__AMH__no_interaction	superoxide__SOD 1__no_interaction	superoxide__GSR__no_interaction	superoxide__IGF-1__no_interaction	superoxide__synapsin 1__no_interaction	superoxide__IDH 1__no_interaction	superoxide__SYN 1__no_interaction	superoxide__PKM 2__no_interaction	superoxide__CASK__no_interaction	superoxide__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	superoxide__enolase 1 (alpha); G6PD__no_interaction	superoxide__ITPA__no_interaction	superoxide__PGM 3__no_interaction	superoxide__MDH 2__no_interaction	superoxide__ENO 1__no_interaction	superoxide__PAIS__no_interaction	superoxide__TPI__no_interaction	superoxide__LDHA__no_interaction	superoxide__LDHB__no_interaction	superoxide__LALBA__no_interaction	glucose__AMH__no_interaction	glucose__SOD 1__no_interaction	glucose__GSR__no_interaction	glucose__IGF-1__no_interaction	glucose__synapsin 1__no_interaction	glucose__IDH 1__no_interaction	glucose__SYN 1__no_interaction	glucose__PKM 2__no_interaction	glucose__CASK__no_interaction	glucose__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	glucose__enolase 1 (alpha); G6PD__no_interaction	glucose__ITPA__no_interaction	glucose__PGM 3__no_interaction	glucose__MDH 2__no_interaction	glucose__ENO 1__no_interaction	glucose__PAIS__no_interaction	glucose__TPI__no_interaction	glucose__LDHA__no_interaction	glucose__LDHB__no_interaction	glucose__LALBA__no_interaction	triose phosphate__AMH__no_interaction	triose phosphate__SOD 1__no_interaction	triose phosphate__GSR__no_interaction	triose phosphate__IGF-1__no_interaction	triose phosphate__synapsin 1__no_interaction	triose phosphate__IDH 1__no_interaction	triose phosphate__SYN 1__no_interaction	triose phosphate__PKM 2__no_interaction	triose phosphate__CASK__no_interaction	triose phosphate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	triose phosphate__enolase 1 (alpha); G6PD__no_interaction	triose phosphate__ITPA__no_interaction	triose phosphate__PGM 3__no_interaction	triose phosphate__MDH 2__no_interaction	triose phosphate__ENO 1__no_interaction	triose phosphate__PAIS__no_interaction	triose phosphate__TPI__no_interaction	triose phosphate__LDHA__no_interaction	triose phosphate__LDHB__no_interaction	triose phosphate__LALBA__no_interaction	glyceraldehyde__AMH__no_interaction	glyceraldehyde__SOD 1__no_interaction	glyceraldehyde__GSR__no_interaction	glyceraldehyde__IGF-1__no_interaction	glyceraldehyde__synapsin 1__no_interaction	glyceraldehyde__IDH 1__no_interaction	glyceraldehyde__SYN 1__no_interaction	glyceraldehyde__PKM 2__no_interaction	glyceraldehyde__CASK__no_interaction	glyceraldehyde__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	glyceraldehyde__enolase 1 (alpha); G6PD__no_interaction	glyceraldehyde__ITPA__no_interaction	glyceraldehyde__PGM 3__no_interaction	glyceraldehyde__MDH 2__no_interaction	glyceraldehyde__ENO 1__no_interaction	glyceraldehyde__PAIS__no_interaction	glyceraldehyde__TPI__no_interaction	glyceraldehyde__LDHA__no_interaction	glyceraldehyde__LDHB__no_interaction	glyceraldehyde__LALBA__no_interaction	pyruvate__AMH__no_interaction	pyruvate__SOD 1__no_interaction	pyruvate__GSR__no_interaction	pyruvate__IGF-1__no_interaction	pyruvate__synapsin 1__no_interaction	pyruvate__IDH 1__no_interaction	pyruvate__SYN 1__no_interaction	pyruvate__PKM 2__no_interaction	pyruvate__CASK__no_interaction	pyruvate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	pyruvate__enolase 1 (alpha); G6PD__no_interaction	pyruvate__ITPA__no_interaction	pyruvate__PGM 3__no_interaction	pyruvate__MDH 2__no_interaction	pyruvate__ENO 1__no_interaction	pyruvate__PAIS__no_interaction	pyruvate__TPI__no_interaction	pyruvate__LDHA__no_interaction	pyruvate__LDHB__no_interaction	pyruvate__LALBA__no_interaction	isocitrate__AMH__no_interaction	isocitrate__SOD 1__no_interaction	isocitrate__GSR__no_interaction	isocitrate__IGF-1__no_interaction	isocitrate__synapsin 1__no_interaction	isocitrate__IDH 1__no_interaction	isocitrate__SYN 1__no_interaction	isocitrate__PKM 2__no_interaction	isocitrate__CASK__no_interaction	isocitrate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	isocitrate__enolase 1 (alpha); G6PD__no_interaction	isocitrate__ITPA__no_interaction	isocitrate__PGM 3__no_interaction	isocitrate__MDH 2__no_interaction	isocitrate__ENO 1__no_interaction	isocitrate__PAIS__no_interaction	isocitrate__TPI__no_interaction	isocitrate__LDHA__no_interaction	isocitrate__LDHB__no_interaction	isocitrate__LALBA__no_interaction	GALA__AMH__no_interaction	GALA__SOD 1__no_interaction	GALA__GSR__no_interaction	GALA__IGF-1__no_interaction	GALA__synapsin 1__no_interaction	GALA__IDH 1__no_interaction	GALA__SYN 1__no_interaction	GALA__PKM 2__no_interaction	GALA__CASK__no_interaction	GALA__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	GALA__enolase 1 (alpha); G6PD__no_interaction	GALA__ITPA__no_interaction	GALA__PGM 3__no_interaction	GALA__MDH 2__no_interaction	GALA__ENO 1__no_interaction	GALA__PAIS__no_interaction	GALA__TPI__no_interaction	GALA__LDHA__no_interaction	GALA__LDHB__no_interaction	GALA__LALBA__no_interaction	phosphoribosyl amino__AMH__no_interaction	phosphoribosyl amino__SOD 1__no_interaction	phosphoribosyl amino__GSR__no_interaction	phosphoribosyl amino__IGF-1__no_interaction	phosphoribosyl amino__synapsin 1__no_interaction	phosphoribosyl amino__IDH 1__no_interaction	phosphoribosyl amino__SYN 1__no_interaction	phosphoribosyl amino__PKM 2__no_interaction	phosphoribosyl amino__CASK__no_interaction	phosphoribosyl amino__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	phosphoribosyl amino__enolase 1 (alpha); G6PD__no_interaction	phosphoribosyl amino__ITPA__no_interaction	phosphoribosyl amino__PGM 3__no_interaction	phosphoribosyl amino__MDH 2__no_interaction	phosphoribosyl amino__ENO 1__no_interaction	phosphoribosyl amino__PAIS__no_interaction	phosphoribosyl amino__TPI__no_interaction	phosphoribosyl amino__LDHA__no_interaction	phosphoribosyl amino__LDHB__no_interaction	phosphoribosyl amino__LALBA__no_interaction	glutathione__AMH__no_interaction	glutathione__SOD 1__no_interaction	glutathione__GSR__no_interaction	glutathione__IGF-1__no_interaction	glutathione__synapsin 1__no_interaction	glutathione__IDH 1__no_interaction	glutathione__SYN 1__no_interaction	glutathione__PKM 2__no_interaction	glutathione__CASK__no_interaction	glutathione__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	glutathione__enolase 1 (alpha); G6PD__no_interaction	glutathione__ITPA__no_interaction	glutathione__PGM 3__no_interaction	glutathione__MDH 2__no_interaction	glutathione__ENO 1__no_interaction	glutathione__PAIS__no_interaction	glutathione__TPI__no_interaction	glutathione__LDHA__no_interaction	glutathione__LDHB__no_interaction	glutathione__LALBA__no_interaction	malate__AMH__no_interaction	malate__SOD 1__no_interaction	malate__GSR__no_interaction	malate__IGF-1__no_interaction	malate__synapsin 1__no_interaction	malate__IDH 1__no_interaction	malate__SYN 1__no_interaction	malate__PKM 2__no_interaction	malate__CASK__no_interaction	malate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	malate__enolase 1 (alpha); G6PD__no_interaction	malate__ITPA__no_interaction	malate__PGM 3__no_interaction	malate__MDH 2__no_interaction	malate__ENO 1__no_interaction	malate__PAIS__no_interaction	malate__TPI__no_interaction	malate__LDHA__no_interaction	malate__LDHB__no_interaction	malate__LALBA__no_interaction	gluconate__AMH__no_interaction	gluconate__SOD 1__no_interaction	gluconate__GSR__no_interaction	gluconate__IGF-1__no_interaction	gluconate__synapsin 1__no_interaction	gluconate__IDH 1__no_interaction	gluconate__SYN 1__no_interaction	gluconate__PKM 2__no_interaction	gluconate__CASK__no_interaction	gluconate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	gluconate__enolase 1 (alpha); G6PD__no_interaction	gluconate__ITPA__no_interaction	gluconate__PGM 3__no_interaction	gluconate__MDH 2__no_interaction	gluconate__ENO 1__no_interaction	gluconate__PAIS__no_interaction	gluconate__TPI__no_interaction	gluconate__LDHA__no_interaction	gluconate__LDHB__no_interaction	gluconate__LALBA__no_interaction	mannose__AMH__no_interaction	mannose__SOD 1__no_interaction	mannose__GSR__no_interaction	mannose__IGF-1__no_interaction	mannose__synapsin 1__no_interaction	mannose__IDH 1__no_interaction	mannose__SYN 1__no_interaction	mannose__PKM 2__no_interaction	mannose__CASK__no_interaction	mannose__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	mannose__enolase 1 (alpha); G6PD__no_interaction	mannose__ITPA__no_interaction	mannose__PGM 3__no_interaction	mannose__MDH 2__no_interaction	mannose__ENO 1__no_interaction	mannose__PAIS__no_interaction	mannose__TPI__no_interaction	mannose__LDHA__no_interaction	mannose__LDHB__no_interaction	mannose__LALBA__no_interaction	phosphate__AMH__no_interaction	phosphate__SOD 1__no_interaction	phosphate__GSR__no_interaction	phosphate__IGF-1__no_interaction	phosphate__synapsin 1__no_interaction	phosphate__IDH 1__no_interaction	phosphate__SYN 1__no_interaction	phosphate__PKM 2__no_interaction	phosphate__CASK__no_interaction	phosphate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	phosphate__enolase 1 (alpha); G6PD__no_interaction	phosphate__ITPA__no_interaction	phosphate__PGM 3__no_interaction	phosphate__MDH 2__no_interaction	phosphate__ENO 1__no_interaction	phosphate__PAIS__no_interaction	phosphate__TPI__no_interaction	phosphate__LDHA__no_interaction	phosphate__LDHB__no_interaction	phosphate__LALBA__no_interaction	lactate__AMH__no_interaction	lactate__SOD 1__no_interaction	lactate__GSR__no_interaction	lactate__IGF-1__no_interaction	lactate__synapsin 1__no_interaction	lactate__IDH 1__no_interaction	lactate__SYN 1__no_interaction	lactate__PKM 2__no_interaction	lactate__CASK__no_interaction	lactate__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	lactate__enolase 1 (alpha); G6PD__no_interaction	lactate__ITPA__no_interaction	lactate__PGM 3__no_interaction	lactate__MDH 2__no_interaction	lactate__ENO 1__no_interaction	lactate__PAIS__no_interaction	lactate__TPI__no_interaction	lactate__LDHA__no_interaction	lactate__LDHB__no_interaction	lactate__LALBA__no_interaction	imidazole__AMH__no_interaction	imidazole__SOD 1__no_interaction	imidazole__GSR__no_interaction	imidazole__IGF-1__no_interaction	imidazole__synapsin 1__no_interaction	imidazole__IDH 1__no_interaction	imidazole__SYN 1__no_interaction	imidazole__PKM 2__no_interaction	imidazole__CASK__no_interaction	imidazole__ACO 1: aconitase 1 (soluble); ADA: adenosine deaminase__no_interaction	imidazole__enolase 1 (alpha); G6PD__no_interaction	imidazole__ITPA__no_interaction	imidazole__PGM 3__no_interaction	imidazole__MDH 2__no_interaction	imidazole__ENO 1__no_interaction	imidazole__PAIS__no_interaction	imidazole__TPI__no_interaction	imidazole__LDHA__no_interaction	imidazole__LDHB__no_interaction	imidazole__LALBA__no_interaction
23118327-10	Predictions of CL based on kinetics from hydrolysis and <protein-id="Q9CQ62,Q4FJK0">NADPH</protein-id>-dependent pathways produced predicted hepatic CL values of 3.8, 3.0, 1.6, and 1.2 l/h⋅kg for compound 1, compound 2 [(E)-3,5-difluoro-N-(6-((4-(2-hydroxypropan-2-yl)<compound-id="8082">piperidin</compound-id>-1-yl)methyl)-1-((1s,4s)-4-(<compound-id="268118">isopropylcarbamoyl</compound-id>)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)<compound-id="2331">benzamide</compound-id>], compound 3 [(E)-<compound-id="97584">3-chloro-</compound-id>5-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)<compound-id="8082">piperidin</compound-id>-1-yl)methyl)-1-((1s,4s)-4-(<compound-id="268118">isopropylcarbamoyl</compound-id>)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)<compound-id="2331">benzamide</compound-id>], and compound 4 [(E)-N-(6-((4-(2-hydroxypropan-2-yl)<compound-id="8082">piperidin</compound-id>-1-yl)methyl)-1-((1s,4s)-4-(<compound-id="268118">isopropylcarbamoyl</compound-id>)cyclohexyl)-1H-benzo[d]imidazol-2(3H)-ylidene)-<compound-id="74535">3-(trifluoromethyl)benzamide</compound-id>], respectively.	3-chloro-__NADPH__no_interaction	benzamide__NADPH__no_interaction	3-(trifluoromethyl)benzamide__NADPH__no_interaction	piperidin__NADPH__no_interaction	isopropylcarbamoyl__NADPH__no_interaction
16789974-8	CHF patients are characterised by (i) decreased <compound-id="206,5793,64689,79025">glucose</compound-id> oxidation [<compound-id="206,5793,64689,79025">glucose</compound-id> oxidation (mg kg(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)): 1.25 +/- 0.09 (patients) vs. 1.55 +/- 0.09 (controls), P &lt; 0.01] and muscle <compound-id="206,5793,64689,79025">glucose</compound-id> uptake [a - v diff(<compound-id="206,5793,64689,79025">glucose</compound-id>) (micromol L(-1)): -10 +/- 25 (patients) vs. 70 +/- 22 (controls), P &lt; 0.01], (ii) elevated levels of free fatty acids (FFA) [FFA (mmol L(-1)): 0.72 +/- 0.05 (patients) vs. 0.48 +/- 0.03 (controls), P &lt; 0.01] and <compound-id="441">3-hydroxybutyrate</compound-id> and signs of elevated fat oxidation and muscle fat utilization [a - v diff(FFA) (mmol L(-1)): 0.12 +/- 0.02 (patients) vs. 0.05 +/- 0.01 (controls), P &lt; 0.05] and (iii) elevated protein turnover and protein breakdown [<compound-id="6140,71567,89654470,994">phenylalanine</compound-id> flux (micromol kg(-1) h(-1)): 36.4 +/- 1.5 (patients) vs. 29.6 +/- 1.3 (controls), P &lt; 0.01].	phenylalanine__min(-1__no_interaction	3-hydroxybutyrate__min(-1__no_interaction	glucose__min(-1__no_interaction
23240874-5	RESULTS: LILI upregulated cytochrome c oxidase subunit VIb polypeptide 2 (<protein-id="Q6YFQ2">COX6B2</protein-id>), <protein-id="P09669,A0A024R9B7">cytochrome c oxidase subunit VIc</protein-id> (<protein-id="P09669,A0A024R9B7">COX6C</protein-id>), and <protein-id="Q15181,V9HWB5">pyrophosphatase (inorganic) 1</protein-id> (<protein-id="Q15181,V9HWB5">PPA1</protein-id>) in diabetic wounded cells; <protein-id="P09669,A0A024R9B7">COX6C</protein-id>, ATP synthase, H+transporting, mitochondrial Fo complex, subunit B1 (<protein-id="P24539,Q08ET0">ATP5F1</protein-id>), <compound-id="5893">nicotinamide adenine dinucleotide</compound-id> (<compound-id="439153">NADH</compound-id>) dehydrogenase (ubiquinone) 1 alpha subcomplex, 11 (<protein-id="Q86Y39">NDUFA11</protein-id>), and <compound-id="439153">NADH</compound-id> dehydrogenase (ubiquinone) Fe-S protein 7 (<protein-id="O75251,Q7LD69,F5H5N1">NDUFS7</protein-id>) in wounded cells; and ATPase, H+/K+ exchanging, beta polypeptide (<protein-id="P51164">ATP4B</protein-id>), and ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) (<protein-id="Q06055">ATP5G2</protein-id>) in ischemic cells.	nicotinamide adenine dinucleotide__ATP4B__no_interaction	nicotinamide adenine dinucleotide__ATP5G2__no_interaction	nicotinamide adenine dinucleotide__pyrophosphatase (inorganic) 1__no_interaction	nicotinamide adenine dinucleotide__NDUFA11__no_interaction	nicotinamide adenine dinucleotide__PPA1__no_interaction	nicotinamide adenine dinucleotide__NDUFS7__no_interaction	nicotinamide adenine dinucleotide__COX6B2__no_interaction	nicotinamide adenine dinucleotide__cytochrome c oxidase subunit VIc__no_interaction	nicotinamide adenine dinucleotide__COX6C__no_interaction	nicotinamide adenine dinucleotide__ATP5F1__no_interaction	NADH__ATP4B__no_interaction	NADH__ATP5G2__no_interaction	NADH__pyrophosphatase (inorganic) 1__no_interaction	NADH__NDUFA11__no_interaction	NADH__PPA1__no_interaction	NADH__NDUFS7__no_interaction	NADH__COX6B2__no_interaction	NADH__cytochrome c oxidase subunit VIc__no_interaction	NADH__COX6C__no_interaction	NADH__ATP5F1__no_interaction
22195977-4	The genes most highly expressed early in infection, and thus classified as early, included <protein-id="Q98111">UL1</protein-id> (gL), <protein-id="Q98108">UL2</protein-id>, <protein-id="Q98107">UL3</protein-id>, <protein-id="Q98105">UL4</protein-id>, <protein-id="Q98104">UL5</protein-id>, <protein-id="Q9QP09">UL6</protein-id>, <protein-id="Q9QP10">UL7</protein-id>, <protein-id="Q9QP11">UL8</protein-id>, <protein-id="Q9QP16">UL13</protein-id>, UL14, <protein-id="Q9QP21">UL19</protein-id>, <protein-id="Q9QP22">UL20</protein-id>, <protein-id="P23983,Q71MU0">UL23</protein-id> (TK), UL25, <protein-id="G3CEZ2">UL28</protein-id>, <protein-id="Q9QH63">UL29</protein-id>, <protein-id="Q9QH61">UL31</protein-id>, <protein-id="Q9QH59">UL33</protein-id>, UL34, <protein-id="Q9QH54">UL38</protein-id>, <protein-id="Q9QH53">UL39</protein-id>, <protein-id="Q9QH52">UL40</protein-id>, <protein-id="Q9QH50">UL42</protein-id>, UL43, <protein-id="Q67628">UL44</protein-id> (gC), UL47, <protein-id="O56869">UL48</protein-id> (α-<compound-id="27873">TIF</compound-id>), <protein-id="O56868">UL49</protein-id>, <protein-id="Q69297">UL54</protein-id> (ICP27), US3 and US10.	TIF__UL8__no_interaction	TIF__UL2__no_interaction	TIF__UL3__no_interaction	TIF__UL1__no_interaction	TIF__UL6__no_interaction	TIF__UL7__no_interaction	TIF__UL4__no_interaction	TIF__UL5__no_interaction	TIF__UL54__no_interaction	TIF__UL38__no_interaction	TIF__UL39__no_interaction	TIF__UL19__no_interaction	TIF__UL33__no_interaction	TIF__UL31__no_interaction	TIF__UL13__no_interaction	TIF__UL42__no_interaction	TIF__UL40__no_interaction	TIF__UL20__no_interaction	TIF__UL23__no_interaction	TIF__UL44__no_interaction	TIF__UL49__no_interaction	TIF__UL48__no_interaction	TIF__UL29__no_interaction	TIF__UL28__no_interaction
12231375-7	In contrast, hearts stored in LYPS and Celsior had a LVDP x HR close to control hearts (31,349 +/- 1,847, 27,620 +/- 1,207, and 36,627 +/- 1,322 mm Hg/mn, respectively), whereas hearts stored in STH-1, <protein-id="P15709,A0A0G2JYC0">STH-2</protein-id>, UW-1, UW, <compound-id="71748654">HTK</compound-id>, and STF had intermediate functional response (14,278 +/- 2,176, 12,402 +/- 1,571, 11,428 +/- 1,629, 11,603 +/- 2,521, 7,045 +/- 537, and 7,086 +/- 1,206 mm Hg/mn, respectively).	HTK__STH-2__no_interaction
9428995-6	Prior to <compound-id="3440">furosemide</compound-id>, urinary EOLS excretion was found to correlate positively with diuresis (r = 0.80, p &lt; 0.01), <compound-id="5360545">sodium</compound-id> (r = 0.91, p &lt; 0.001), <compound-id="588">creatinine</compound-id> (r = 0.75, p &lt; 0.001), osmolar (r = 0.96, p &lt; 0.001), <protein-id="P05305,Q6FH53">ET-1</protein-id> (r = 0.90, p &lt; 0.001) and <protein-id="P01185,X5DQP6">AVP</protein-id> (r = 0.92, p &lt; 0.001) excretion.	creatinine__ET-1__no_interaction	creatinine__AVP__no_interaction	furosemide__ET-1__no_interaction	furosemide__AVP__no_interaction	sodium__ET-1__no_interaction	sodium__AVP__no_interaction
11599970-2	These complexes, which retain the <protein-id="Q9P2R6,B1AKN3,A0A024R4E9">Re=Re</protein-id> bonds of the parent dirhenium complexes, comprise the novel centrosymmetric complex [Re(2)Cl(3)(mu-dppE)(2)(CO)(2)(mu-NCS)](2)Pd(2)(mu-<compound-id="781">SCN</compound-id>)(mu-NCS)Cl(2) (9), and the trimetallic complexes Re(2)Cl(3)(mu-dppE)(2)(CO)(2)[(mu-NC)Ag(CN)] (10), Re(2)Cl(3)(mu-dppE)(2)(CO)(2)[(mu-NC)W(CO)(5)] (11), [Re(2)Cl(3)(mu-dppE)(2)(CO)(2)[(mu-NC)Pt(CN)(CN-t-Bu)(2)]]PF(6) (12), [Re(2)Cl(3)(mu-dppE)(2)(CO)(2)[(mu-N(CN)(2))Rh(CO)(PPh(3))(2)]]O(3)SCF(3) (13), and Re(2)Cl(3)(mu-<compound-id="74952">dppm</compound-id>)(2)(CO)(2)[(mu-NC)W(CO)(5)] (16).	SCN__Re=Re__no_interaction	dppm__Re=Re__no_interaction
23158422-6	The serum levels of <protein-id="Q8IWL2,A0A024QZP2,B4DNP6">SP-A</protein-id> were positively correlated with serum ferritin and <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) and negatively with percent <compound-id="281">carbon monoxide</compound-id> diffusing capacity (DLCO%) (r = -0.474, P &lt; 0.05), VC% (r = -0.404, P &lt; 0.05) while the serum levels of <protein-id="P35247">SP-D</protein-id> were negatively correlated with circulating CD3+T cells (r = -0.244, P &lt; 0.05) and CD4+T cells (r = -0.277, P &lt; 0.05) in PM/DM patients.	carbon monoxide__SP-D__no_interaction	carbon monoxide__C-reactive protein__no_interaction	carbon monoxide__CRP__no_interaction	carbon monoxide__SP-A__no_interaction
11120741-8	Compared with fibroblast adhesion to <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id>, <compound-id="44342165">laminin</compound-id>, or type I collagen, cell adhesion to <protein-id="O00622,Q6FI18">Cyr61</protein-id> or <protein-id="P29279,Q5M8T4">CTGF</protein-id> induces 1) more extensive and prolonged formation of filopodia and lamellipodia, concomitant with formation of integrin <protein-id="Q16558">alpha(6)beta(1</protein-id>)-containing focal complexes localized at leading edges of pseudopods; 2) activation of intracellular signaling molecules including focal adhesion kinase, <protein-id="P49023,F5GZ78">paxillin</protein-id>, and Rac with similar rapid kinetics; 3) sustained activation of <protein-id="P62333,A0A087X2I1">p42</protein-id>/<protein-id="P62333,A0A087X2I1">p44</protein-id> MAPKs lasting for at least 9 h; and 4) prolonged gene expression changes including up-regulation of <protein-id="P03956,Q53G95,B4DN15">MMP-1</protein-id> (collagenase-1) and <protein-id="P08254">MMP-3</protein-id> (<protein-id="P08254">stromelysin-1</protein-id>) mRNAs and proteins sustained for at least 24 h. Together, these results establish <protein-id="O00622,Q6FI18">Cyr61</protein-id> and <protein-id="P29279,Q5M8T4">CTGF</protein-id> as bona fide adhesive substrates with specific signaling capabilities, provide a molecular basis for their activities in fibroblasts through integrin <protein-id="Q16558">alpha(6)beta(1</protein-id>) and HSPG-mediated signaling during attachment and indicate that these proteins may function in matrix remodeling through the activation of metalloproteinases during angiogenesis and wound healing.	laminin__MMP-1__no_interaction	laminin__MMP-3__no_interaction	laminin__Cyr61__no_interaction	laminin__alpha(6)beta(1__no_interaction	laminin__CTGF__no_interaction	laminin__paxillin__no_interaction	laminin__fibronectin__no_interaction	laminin__p44__no_interaction	laminin__stromelysin-1__no_interaction	laminin__p42__no_interaction
11380499-12	In addition, the duration between the last dose of antenatal <compound-id="5743">dexamethasone</compound-id> and delivery significantly influenced the serum concentrations of <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = - 0.27, P &lt; 0.05), cortisol (r = 0.52, P &lt; 0.001), plasma ACTH (r = 0.28, P &lt; 0.05) and <protein-id="P01308,I3WAC9">insulin</protein-id>:<compound-id="206,5793,64689,79025">glucose</compound-id> ratio (r = - 0.27, P &lt; 0.05) on the first day of life.	glucose__leptin__no_interaction	glucose__insulin__no_interaction	dexamethasone__leptin__no_interaction	dexamethasone__insulin__no_interaction
19129589-1	The title complexes, catena-poly[[[diaquadiethanolmanganese(II)]-mu-1,4-<protein-id="O95817">bis</protein-id>(<compound-id="6327869">diphenylphosphinoyl</compound-id>)<compound-id="7843">butane</compound-id>-kappa(2)O:O'] dinitrate 1,4-<protein-id="O95817">bis</protein-id>(<compound-id="6327869">diphenylphosphinoyl</compound-id>)<compound-id="7843">butane</compound-id> solvate], {[Mn(C(2)H(6)O)(2)(C(28)H(28)O(2)P(2))(H(2)O)(2)](NO(3))(2).C(28)H(28)O(2)P(2)}(n), (I), and catena-poly[[[diaquadiethanolcobalt(II)]-mu-1,4-<protein-id="O95817">bis</protein-id>(<compound-id="6327869">diphenylphosphinoyl</compound-id>)<compound-id="7843">butane</compound-id>-kappa(2)O:O'] dinitrate 1,4-<protein-id="O95817">bis</protein-id>(<compound-id="6327869">diphenylphosphinoyl</compound-id>)<compound-id="7843">butane</compound-id> solvate], {[Co(C(2)H(6)O)(2)(C(28)H(28)O(2)P(2))(H(2)O)(2)](NO(3))(2).C(28)H(28)O(2)P(2)}(n), (II), are isostructural and centrosymmetric, with the M(II) ions at centres of inversion.	butane__bis__no_interaction	diphenylphosphinoyl__bis__no_interaction
22013582-9	These were characterized as (Z)-2-(2-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)-4-(4-hydroxy-1,2-<compound-id="66182">diphenylbut</compound-id>-1-enyl)<compound-id="996">phenol</compound-id> (III), (E)-2-(2-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)-4-(4-hydroxy-1,2-<compound-id="66182">diphenylbut</compound-id>-1-enyl)<compound-id="996">phenol</compound-id> (IV), (E)-4-(4-(2-(dimethylamino)ethoxy)phenyl)-3,4-<compound-id="66182">diphenylbut</compound-id>-3-en-1-ol (VII), (Z)-4-(4-(2-(dimethylamino)ethoxy)phenyl)-3,4-<compound-id="66182">diphenylbut</compound-id>-3-en-1-ol (<protein-id="P10176,Q53XN1">VIII</protein-id>), 2-(4-(10-(2-chloroethyl)<compound-id="995">phenanthren</compound-id>-9-yl)phenoxy)-<compound-id="12219">N-methylethanamine</compound-id> (XIV), and 2-(4-(10-(2-chloroethyl)<compound-id="995">phenanthren</compound-id>-9-yl)phenoxy)-N,N-dimethylethanamine (XV).	phenanthren__VIII__no_interaction	N-methylethanamine__VIII__no_interaction	diphenylbut__VIII__no_interaction	phenol__VIII__no_interaction	ethyl__VIII__no_interaction
20872251-7	No correlations were found between <compound-id="15950538">LGE</compound-id> and MR-proADM (r = 0.1; P = 0.5), CT-proET-1 (r = 0.07; P = 0.66), CT-proAVP (r = 0.16; P = 0.3), <protein-id="P14780">MMP-9</protein-id> (r = 0.01; P = 0.9), <protein-id="P01033,Q6FGX5,B4DJK3">TIMP-1</protein-id> (r = 0.02; P = 0.85), and <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (r = 0.02; P = 0.89).	LGE__MMP-9__no_interaction	LGE__TIMP-1__no_interaction	LGE__IL-8__no_interaction
9288551-4	After 8-10 weeks of complementary <protein-id="P01308,I3WAC9">insulin</protein-id> therapy, <compound-id="4998669">OHA</compound-id> patients (n = 33) improved both the glycemic control (HbA1c: 10.5 +/- 1.78% vs. 9.0 +/- 1.75%, p &lt; 0.001) and <compound-id="20484">fructosamine</compound-id>: 4.0 +/- 0.85 mmol/l vs. 3.5 +/- 0.76 mmol/l, p &lt; 0.001) and most of the lipid parameters (decreased serum triglyceride: 5.8 +/- 5.64 mmol/l vs. 3.6 +/- 4.69 mmol/l, p &lt; 0.001, total <compound-id="5997">cholesterol</compound-id>/HDL-<compound-id="5997">cholesterol</compound-id>: 6.8 +/- 3.13 vs. 5.6 +/- 2.23, p &lt; 0.01 and increased HDL-<compound-id="5997">cholesterol</compound-id>: 1.0 +/- 0.30 mmol/l vs. 1.2 +/- 0.30 mmol/l, p &lt; 0.001, <protein-id="P02647,A0A024R3E3">apo AI</protein-id>: 1.6 +/- 0.26 g/l vs. 1.8 +/- 0.28 g/l, p &lt; 0.001, LpAI particles: 0.6 +/- 0.1 g/l vs. 0.7 +/- 0.12 g/l, p &lt; 0.001 and LDL-<compound-id="5997">cholesterol</compound-id>/apo B: 2.1 +/- 0.67 vs. 2.7 +/- 0.67, p &lt; 0.001).	fructosamine__apo AI__no_interaction	fructosamine__insulin__no_interaction	OHA__apo AI__no_interaction	OHA__insulin__no_interaction	cholesterol__apo AI__no_interaction	cholesterol__insulin__no_interaction
9288551-5	In patients previously on INS 1-2x (n = 34), complementary <protein-id="P01308,I3WAC9">insulin</protein-id> therapy with reduced dose of <protein-id="P01308,I3WAC9">insulin</protein-id> per day (49.6 +/- 22.5 U/d vs. 36.6 +/- 13.3 U/d, p &lt; 0.001) did not further improve glycemic control but improved the number of proatherogenic and antiatherogenic lipoprotein particles (decreased apo B: 1.7 +/- 0.52 g/l vs. 1.5 +/- 0.94 g/l, p &lt; 0.01, <protein-id="P02647,A0A024R3E3">apo AI</protein-id>/Lp <compound-id="15942654">AI</compound-id>: 2.9 +/- 1.01 vs. 2.3 +/- 0.98, p &lt; 0.01 and increased Lp <compound-id="15942654">AI</compound-id> particles: 0.6 +/- 0.10 g/l vs. 0.7 +/- 0.12 g/l, p &lt; 0.0001); BMI also decreased (29.4 +/- 4.28 kg/m2 vs. 28.9 +/- 4.24 kg/m2, p &lt; 0.05).	AI__apo AI__no_interaction	AI__insulin__no_interaction
23569369-6	Moreover, there were correlations between MetS Z-score and body mass (r = 0.20), waist circumference (r = 0.26), waist-hip (r = 0.32) and waist-height ratio (r = 0.24), blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.24), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.24), homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.32), triglycerides (r = 0.39), tumor necrosis factor-α (r = 0.28), interferon-γ (r = 0.22), and inverse correlation with high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = -0.32).	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction
3122736-3	Among the series of 28 analogs, which had the amino acid at each position of <protein-id="P01286">hGRF</protein-id> (1-29)NH2, except <compound-id="45934207,750">glycine</compound-id> at position 15, substituted by the corresponding D-isomer, [D-Ala2]-, [D-Asp3]-, [D-Asn8]-, [D-Tyr10]-, [D-Asp25]-, [D-Met27]-, [D-Ser28]-, and [D-Arg29]<protein-id="P01286">hGRF</protein-id>(1-29)NH2 were as potent as <protein-id="P01286">hGRF</protein-id>(1-29)NH2, while [D-Ile5]-, [D-Phe6]-, [D-Thr7]-, and [D-Val13]<protein-id="P01286">hGRF</protein-id>(1-29)NH2 showed quite low potencies.	glycine__hGRF__no_interaction
19351176-1	The reactivity of the acido Ru(II) complexes cis-[RuCl(2)(LL)(2)], [RuCO(3)(LL)(2)], cis-[RuCO(3)-(bquin)(2)] (LL = 2,2'-bipyridine (bpy) and <compound-id="1318">1,10-phenanthroline</compound-id> (phen); bquin = <compound-id="8412">2,2'-biquinoline</compound-id>) and cyclometalated Ru(II) derivatives of <compound-id="13887">2-phenylpyridine</compound-id> and 4-(2-tolyl)pyridine [Ru(o-C(6)H(4)-2-py)(phen)(2)]PF(6) (1), [Ru(o-C(6)H(3)-p-R-2-py)(bpy)(<compound-id="6342">MeCN</compound-id>)(2)]PF(6) (2), and [Ru(o-C(6)H(3)-p-R-2-py)(phen)(<compound-id="6342">MeCN</compound-id>)(2)]PF(6) (3) (R = H (a), Me (b)) toward laccase from Coriolus hirsutus has been investigated by conventional UV-vis spectroscopy at <protein-id="Q9NXG6">pH 3-7</protein-id> and 25 degrees C. The acido and cyclometalated complexes are readily oxidized into the corresponding Ru(III) species, but the two types of complexes differ substantially in reactivity and obey different rate laws.	MeCN__pH 3-7__no_interaction	2,2'-biquinoline__pH 3-7__no_interaction	1,10-phenanthroline__pH 3-7__no_interaction	2-phenylpyridine__pH 3-7__no_interaction
12525256-7	There were significant differences between groups in the expression of IGF-IR (GrF(1-3)&gt; GrCmax and <compound-id="57149565">GrC</compound-id>(1-3) in ileum), IGF-IIR (<protein-id="E1BHY6">GrN</protein-id>&gt;<protein-id="Q863C3">GrP</protein-id> and <compound-id="57149565">GrC</compound-id>(1-3) in colon; <protein-id="E1BHY6">GrN</protein-id>&gt;<compound-id="57149565">GrC</compound-id>(1-3) in jejunum and total intestine), and IR (GrCmax&gt;GrF(1-3) in colon) and in the Bmax of IGF-IR (<protein-id="Q863C3">GrP</protein-id>&gt;<protein-id="E1BHY6">GrN</protein-id> in colon; GrCmax&gt;GrF(1-3) in jejunum), IGF-IIR (<protein-id="E1BHY6">GrN</protein-id>&gt;<protein-id="Q863C3">GrP</protein-id> in duodenum, ileum and total intestine; <protein-id="E1BHY6">GrN</protein-id>&gt;<compound-id="57149565">GrC</compound-id>(1-3) in duodenum, ileum, colon and total intestine) and IR (<protein-id="E1BHY6">GrN</protein-id>&gt;<protein-id="Q863C3">GrP</protein-id> in total intestine; <compound-id="57149565">GrC</compound-id>(1-3)&gt;<protein-id="E1BHY6">GrN</protein-id> in ileum and total intestine).	GrC__GrN__no_interaction	GrC__GrP__no_interaction
22224254-2	METHODS: The rat IEC-6 cell lines were divided into control group (C, cultured in <compound-id="152803">DEME</compound-id> medium containing 10% calf serum), burn control group (BC, cultured in <compound-id="152803">DEME</compound-id> medium containing 10% burn rat serum), burn serum + <protein-id="Q03191,A0A0G2JSY6">ITF</protein-id> group (B + I, cultured in <compound-id="152803">DEME</compound-id> medium containing 10% burn rat serum and 25 microg/mL <protein-id="Q03191,A0A0G2JSY6">ITF</protein-id>), burn serum + <protein-id="O35055">mucin</protein-id> group (B + M, cultured in <compound-id="152803">DEME</compound-id> medium containing 10% burn rat serum and 250 microg/mL <protein-id="O35055">mucin</protein-id>), and burn serum + <protein-id="Q03191,A0A0G2JSY6">ITF</protein-id> + <protein-id="O35055">mucin</protein-id> group (B + I + M, cultured in <compound-id="152803">DEME</compound-id> medium containing 10% burn rat serum, 25 microg/mL <protein-id="Q03191,A0A0G2JSY6">ITF</protein-id>, and 250 microg/mL <protein-id="O35055">mucin</protein-id>) according to the random number table.	DEME__ITF__no_interaction	DEME__mucin__no_interaction
9853015-1	We rapidly infused 234 +/- 3 mL of 5% human serum <protein-id="P02768">Albumin</protein-id> in eight men while measuring haematocrit, haemoglobin concentration, plasma volume (PV), <protein-id="P02768">Albumin</protein-id> concentration, total protein concentration, osmolality, <compound-id="5360545">sodium</compound-id> concentration, <protein-id="P00797">renin</protein-id> activity, <compound-id="5839">aldosterone</compound-id> concentration, and atrial natriuretic peptide concentration to test the hypotheses that plasma volume expansion and plasma <protein-id="P02768">Albumin</protein-id> content expansion will not persist for 24 h. Plasma volume and <protein-id="P02768">Albumin</protein-id> content were expanded for the first 6 h after infusion (44.3 +/- 1.9-47.2 +/- 2.0 mL kg-1 and 1.9 +/- 0.1-2.1 +/- 0.1 g kg-1 at pre-infusion and 1 h, respectively, P &lt; 0.05), but by 24 h plasma volume and <protein-id="P02768">Albumin</protein-id> content decreased significantly from 1 h post-infusion and were not different from pre-infusion (44.8 +/- 1.9 mL kg-1 and 1.9 +/- 0.1 g kg-1, respectively).	aldosterone__Albumin__no_interaction	aldosterone__renin__no_interaction	sodium__Albumin__no_interaction	sodium__renin__no_interaction
11304147-1	Treatment of the hydrosulfido-bridged <compound-id="23963">titanium</compound-id>-<compound-id="23950">ruthenium</compound-id> heterobimetallic complex [Cp2Ti(mu2-SH)2RuCl(eta5-C5Me5)] (1; Cp = eta5-C5H5) with an excess of <compound-id="8471">triethylamine</compound-id> followed by addition of [RuCl2(<protein-id="P60510,A0A024R625">PPh3</protein-id>)3] and [[(cod)M]2(mu2-Cl)2] (M = Rh, Ir; cod = <compound-id="5702534,82916">1,5-cyclooctadiene</compound-id>) led to the formation of the TiRu2 and TiRuM mixed-metal sulfido clusters [(CpTi)[(eta5-C5Me5)Ru][Ru(<protein-id="P60510,A0A024R625">PPh3</protein-id>)2](mu3-S)2(mu2-Cl)2] (3) and [(CpTi)[(eta5-C5Me5)Ru][M(cod)](mu3-S)2(mu2-Cl)] (M = Rh (<compound-id="69255155">4a</compound-id>), Ir (4b)), respectively.	ruthenium__PPh3__no_interaction	titanium__PPh3__no_interaction	4a__PPh3__no_interaction	triethylamine__PPh3__no_interaction	1,5-cyclooctadiene__PPh3__no_interaction
16324314-9	In the 3 <compound-id="5282199">teprenone</compound-id> groups, the ulcer index decreased (32.5, 23.0, and 23.0 vs. 44.5, all P &lt; 0.01), grade of histological lesions decreased (3.0, 3.0, and 1.5 vs. 5.5, all P &lt; 0.01), <protein-id="P22388">ET-1</protein-id> level decreased (299 pg/ml +/- 99 pg/ml, 284 pg/ml +/- 85 pg/ml, and 189 pg/ml +/- 32 pg/ml vs. 399 pg/ml +/- 74 pg/ml, P &lt; 0.05, P &lt; 0.01, and P &lt; 0.01), the No level increased (56 micromol/L +/- 16 micromol/L, 62 micromol/L +/- 12 micromol/L, and 83 micromol/L +/- 9 micromol/L vs. 27 micromol/L +/- 5 micromol/L, all P &lt; 0.01), and the PGE(2) level increased (190 pg/mg +/- 58 pg/mg, 196 pg/mg +/- 35 pg/mg, 241 pg/mg +/- 65 pg/mg vs. 154 pg/mg +/- 83 pg/mg, P &gt; 0.05, P &gt; 0.05, and P &lt; 0.05) compared with the model control group.	teprenone__ET-1__no_interaction
16226082-4	We modified these criteria and determined automated detection criteria as follows: type 1: STj&gt;or=0.2 mV and STj&gt;<protein-id="O00560,A0A024R7Z5">ST1</protein-id>&gt;<compound-id="446366">ST2</compound-id> and T&lt;0 mV; type 2: STj&gt;or=0.2 mV and STj&gt;STmin&gt;or=0.1 mV and T&gt;0 mV and T&lt;1.8xR' and S&lt;or=3.0 mV; type 3: STj&gt;or=0.2 mV and 0.1 mV&gt;STmin&gt;0 mV and T&gt;0 mV and T&lt;1.8xR' and S&gt;or=3.0 mV; STj, <protein-id="O00560,A0A024R7Z5">ST1</protein-id>, and <compound-id="446366">ST2</compound-id> are amplitude of the ST segment (STj: J point, <protein-id="O00560,A0A024R7Z5">ST1</protein-id>: J point +40 milliseconds, <compound-id="446366">ST2</compound-id>: J point +80 milliseconds).	ST2__ST1__no_interaction
15362134-1	The intermolecular interaction energies of the deprotonated <compound-id="783">hydrogen</compound-id>-bonded complexes F(-)(HF), F(-)(H(2)O), F(-)(NH(3)), Cl(-)(HF), SH(-)(HF), H(2)P(-)(HF), OH(-)(H(2)O), OH(-)(H(2)O)(2), OH(-)(NH(3)), Cl(-)(H(2)O), SH(-)(H(2)O), H(2)P(-)(H(2)O), Cl(-)(NH(3)), SH(-)(NH(3)), H(2)P(-)(NH(3)), Cl(-)(HCl), Cl(-)(H(2)S), Cl(-)(PH(3)), SH(-)(H(2)S), SH(-)(PH(3)), and H(2)P(-)(PH(3)) were calculated with correlation consistent basis sets at the <protein-id="P02689">MP2</protein-id>, MP4, QCISD(T), and CCSD(T) levels.	hydrogen__MP2__no_interaction
8961255-8	0.1 microM <protein-id="P14138,Q4FAT2">endothelin 3</protein-id> (<protein-id="P14138,Q4FAT2">ET3</protein-id>), 1 microM angiotensin II (<protein-id="Q96P20">AII</protein-id>), and 10 microM acetylcholine (<compound-id="187">Ach</compound-id>) significantly increased <protein-id="P01185,X5DQP6">AVP</protein-id> release; <protein-id="P14138,Q4FAT2">ET3</protein-id> (C 1.78 +/- 0.20 vs. <protein-id="P14138,Q4FAT2">ET3</protein-id> 6.85 +/- 1.86 pg/2 x 10(6) cells, N = 8, P &lt; 0.02); <protein-id="Q96P20">AII</protein-id> (C 1.29 +/- 0.38 vs. <protein-id="Q96P20">AII</protein-id> 27.80 +/- 7.09 pg/2 x 10(6) cells, N = 5, P &lt; 0.05) and <compound-id="187">Ach</compound-id> (C 1.14 +/- 0.33 vs. <compound-id="187">Ach</compound-id> 2.68 +/- 0.58 pg/2 x x10(6) cells, N = 6, P &lt; 0.05).	Ach__ET3__no_interaction	Ach__AII__no_interaction	Ach__AVP__no_interaction	Ach__endothelin 3__no_interaction
18475514-3	The results indicate that: (a) basal B but not <protein-id="P01193">ACTH</protein-id> plasma levels were significantly higher in female than in male mice; (b) <protein-id="Q9QUK6,L0CL36">LPS</protein-id> significantly increased both <protein-id="P01193">ACTH</protein-id> and B plasma levels over the baseline 2 h after injection, both hormone levels being higher in female than in male mice; (c) although plasma <protein-id="P01193">ACTH</protein-id> concentrations recovered the basal value at 72 h after <protein-id="Q9QUK6,L0CL36">LPS</protein-id> in animals of both sexes, plasma B levels returned to the baseline only at 120 h after treatment; (d) E plasma levels significantly increased 2 h after <protein-id="Q9QUK6,L0CL36">LPS</protein-id> and returned to the baseline at 72 h post-treatment, in both sexes; (e) at 2 h after <protein-id="Q9QUK6,L0CL36">LPS</protein-id>, <compound-id="6013">testosterone</compound-id> plasma levels significantly decreased in male mice and increased in female mice, recovering the baseline level at 120 and 72 h after <protein-id="Q9QUK6,L0CL36">LPS</protein-id>, respectively; (f) AP <protein-id="P01193">ACTH</protein-id> content was similar in both sexes in basal condition and it was significantly diminished 72 h post-treatment without sex difference; whereas AP <protein-id="P01193">ACTH</protein-id> returned to basal content 120 h after <protein-id="Q9QUK6,L0CL36">LPS</protein-id> in males, it remained significantly decreased in females; (g) basal adrenal B content was higher in female than in male mice, and it significantly increased in both sexes 2 h post-<protein-id="Q9QUK6,L0CL36">LPS</protein-id>, maintaining this sex difference.	testosterone__ACTH__no_interaction	testosterone__LPS__no_interaction
1802476-8	The increase in glomerular filtration rate was significantly correlated to the increase in <protein-id="P01275">glucagon</protein-id>, <compound-id="6306">isoleucine</compound-id>, and <compound-id="6287">valine</compound-id> (<protein-id="P01275">glucagon</protein-id> r = 0.71, p = 0.01, <compound-id="6306">isoleucine</compound-id> r = 0.59, p = 0.04, <compound-id="6287">valine</compound-id> r = 0.62, p = 0.03).	isoleucine__glucagon__no_interaction	valine__glucagon__no_interaction
15018649-3	RESULTS: Up to 200 unrelated German RA and JRA patients each and 300-400 healthy controls have been genotyped for <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">HLA-DRB1</protein-id>, <protein-id="P01375,Q5STB3">TNFa</protein-id>, <protein-id="P01375,Q5STB3">TNFa</protein-id> -<compound-id="15774">238a</compound-id>/g, <protein-id="P01375,Q5STB3">TNFa</protein-id> -308a/g, <protein-id="P01375,Q5STB3">TNFa</protein-id> -857c/t, <protein-id="P19438">TNFR1</protein-id> -609g/t, <protein-id="P19438">TNFR1</protein-id> P12P, <protein-id="P20333">TNFR2</protein-id> <compound-id="445801">del</compound-id> 15bp, <protein-id="Q9UBC1,A0A0A0MRT5,A8K778,Q5STV6">IKBL</protein-id> -332a/g, <protein-id="Q9UBC1,A0A0A0MRT5,A8K778,Q5STV6">IKBL</protein-id> -132t/a, <protein-id="Q9UBC1,A0A0A0MRT5,A8K778,Q5STV6">IKBL</protein-id> C224R, <protein-id="P16410">CTLA4</protein-id> -318c/t, <protein-id="P16410">CTLA4</protein-id> T17A, <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">PTPRC</protein-id> P57P, <protein-id="P14174,I4AY87">MIF</protein-id> -173g/c, the <protein-id="P14174,I4AY87">MIF</protein-id> and <protein-id="P01579">IFNG</protein-id> microsatellites as well as for D17S795, D17S807, D17S1821 by <compound-id="6579">polyacrylamide</compound-id> gel electrophoresis, single-strand conformation polymorphism analysis, restriction fragment length polymorphism analysis or allele specific hybridization.	238a__CTLA4__no_interaction	238a__IFNG__no_interaction	238a__HLA-DRB1__no_interaction	238a__MIF__no_interaction	238a__TNFR2__no_interaction	238a__TNFR1__no_interaction	238a__PTPRC__no_interaction	238a__TNFa__no_interaction	238a__IKBL__no_interaction	del__CTLA4__no_interaction	del__IFNG__no_interaction	del__HLA-DRB1__no_interaction	del__MIF__no_interaction	del__TNFR2__no_interaction	del__TNFR1__no_interaction	del__PTPRC__no_interaction	del__TNFa__no_interaction	del__IKBL__no_interaction	polyacrylamide__CTLA4__no_interaction	polyacrylamide__IFNG__no_interaction	polyacrylamide__HLA-DRB1__no_interaction	polyacrylamide__MIF__no_interaction	polyacrylamide__TNFR2__no_interaction	polyacrylamide__TNFR1__no_interaction	polyacrylamide__PTPRC__no_interaction	polyacrylamide__TNFa__no_interaction	polyacrylamide__IKBL__no_interaction
19370039-4	Correlations (all p &lt; 0.05) were observed between maximal <compound-id="977">oxygen</compound-id> consumption (L.<protein-id="P13987,Q6FHM9">min-1</protein-id>) and body mass (r = 0.53), body mass index (r = 0.39), waist circumference (r = 0.34), fat free mass (FFM; r = 0.68), fat mass (r = 0.33), the enzyme activity of cytochrome c oxidase (COX; r = 0.39), muscle type IIA (r = 0.40) and IIX (r = 0.50) fiber area, and the number of capillaries per type IIA (r = 0.39) and IIX (r = 0.37) fiber.	oxygen__min-1__no_interaction
24494519-6	The results showed that removal efficiency of the parameters such as <protein-id="P14678,Q66K91">COD</protein-id>, BOD5, TSS, <compound-id="943">NO3-</compound-id>N, NH3-N, <compound-id="1061">PO4</compound-id>-P, total coliform and fecal coliform was 74, 73, 84, 40, 36, 70, 33 and 38% in Cyperus alternifolius plant wetland, 44, 34, 77, 15, 0.3, 1, 17 and 26% in control wetland and 59, 54, 73, 6, 3, 10, 93 and 50 in Phragmites australis plant wetland, respectively.	PO4__COD__no_interaction	NO3-__COD__no_interaction
20203398-1	Four complexes containing the [UO(2)(<compound-id="5353370">oda</compound-id>)(2)](2-) anion (<compound-id="5353370">oda</compound-id> is oxydiacetate) are reported, namely dipyridinium dioxidobis(oxydiacetato)uranate(VI), (C(5)H(6)N)(2)[U(C(4)H(4)O(5))(2)O(2)], (I), <protein-id="O95817">bis</protein-id>(2-<compound-id="13597">methylpyridinium</compound-id>) dioxidobis(oxydiacetato)uranate(VI), (C(8)H(8)N)(2)[U(C(4)H(4)O(5))(2)O(2)], (II), <protein-id="O95817">bis</protein-id>(3-<compound-id="13597">methylpyridinium</compound-id>) dioxidobis(oxydiacetato)uranate(VI), (C(8)H(8)N)(2)[U(C(4)H(4)O(5))(2)O(2)], (III), and <protein-id="O95817">bis</protein-id>(<compound-id="7963">4-methylpyridinium</compound-id>) dioxidobis(oxydiacetato)uranate(VI), (C(8)H(8)N)(2)[U(C(4)H(4)O(5))(2)O(2)], (IV).	oda__bis__no_interaction	methylpyridinium__bis__no_interaction	4-methylpyridinium__bis__no_interaction
23592680-7	However, there was no correlation between the <protein-id="Q07820,C8YZ26,A0A087WT64">EAT</protein-id> and the LV ejection fraction (r = 0.0085, P = 0.37), right ventricular ejection fraction (r = 0.049, P = 0.6), LVRI (r = 0.116, P = 0.2) and the extent of <compound-id="15950538">LGE</compound-id> % (r = 0.189, P = 0.1).	LGE__EAT__no_interaction
9312396-5	Whereas serum 1,25(OH)2D (58.9 +/- 7.7 versus 51.6 +/- 7.4 pg/ml, P&lt; 0.01), serum phosphorus (4.5 +/- 0.1 versus 3.7 +/- 0.1 mg/dl, P &lt; 0.01), TRP (92.0 +/- 0.5 versus 87.8 +/- 0.7 mg/dl, P &lt; 0.005), TMP/<protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> (4.6 +/- 0.1 versus 3.5 +/- 0.2, P &lt; 0.005), and urinary <compound-id="22044544,5460341">calcium</compound-id> (602 +/- 49 versus 346 +/- 25 mg/day, P &lt; 0.001) increased significantly, serum <protein-id="P01270">PTH</protein-id> decreased significantly (19.9 +/- 1.9 versus 26.8 +/- 4.0 pg/ml, P &lt; 0.05) and serum <compound-id="22044544,5460341">calcium</compound-id> did not change when subjects received rhGH.	calcium__GFR__no_interaction	calcium__PTH__no_interaction
1913686-9	Tumor-associated ganglioside antigens (<compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4Glc beta 1-1'Cer, <compound-id="439197">NeuAc</compound-id> alpha 2-8NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1'Cer, <compound-id="35717">GalNAc</compound-id> beta 1-4 (<compound-id="439197">NeuAc</compound-id> alpha 2-3)Gal beta 1-4Glc beta 1-1'Cer, and <compound-id="35717">GalNAc</compound-id> beta 1-4(<compound-id="439197">NeuAc</compound-id> alpha 2-8NeuAc alpha 2-3)Gal beta 1-4Glc beta 1-1'Cer) HLA class I, HLA-DR, and <protein-id="P61769,H0YL18">beta 2-microglobulin</protein-id> on the cell surface of renal cancer lines were assessed by flow cytometry and radiometric binding assay.	GalNAc__beta 2-microglobulin__no_interaction	NeuAc__beta 2-microglobulin__no_interaction
8383673-4	By using the stereoisomers of <compound-id="5281888">MK-571</compound-id> ((+-)-3-(((3-(2-(<compound-id="521963">7-chloro-2-quinolinyl</compound-id>)<compound-id="123166">ethenyl</compound-id>)-phenyl)((3- (dimethylamino)-3-oxopropyl)-thio)methyl)-thio)propanoic acid), a potent <compound-id="3908,6435286">leukotriene D4</compound-id> receptor antagonist, we could show enantioselective activation of <protein-id="P23204,Q542P9">PPAR</protein-id>.	MK-571__PPAR__no_interaction	7-chloro-2-quinolinyl__PPAR__no_interaction	leukotriene D4__PPAR__no_interaction	ethenyl__PPAR__no_interaction
18084163-11	ABBREVIATIONS: 11beta-HSD: 11 Beta-Hydroxysteroid Dehydrogenase; Agc: Aggrecan; Aln: <compound-id="2088">Alendronate</compound-id>; <protein-id="Q9Y574">Asb- 4</protein-id>: Ankyrin Repeat and SOCS Box-Containing Protein 4; <protein-id="P18850,A8K383">Atf6</protein-id>: <protein-id="P18850,A8K383">Activating Transcription Factor6</protein-id>; BSP: Bisphosphonates; Calca: Calcitonin, Alpha Cdkn2a: Cyclin-Dependent <compound-id="53378893">Kinase Inhibitor</compound-id> 2A; Col1: Collagen 1; Col2: Collagen 2 Col10: Collagen 10; Dex: <compound-id="5743">Dexamethasone</compound-id>; <protein-id="P19419,A0A024R1A7,Q86SR6">Elk1</protein-id>: Member of ETS Oncogene Family; <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">Esr1: Estrogen Receptor 1 (Alpha</protein-id>); <protein-id="Q01543,A0A024R3K4,A0A024R3M5,A0A024R3N6">Fli1</protein-id>: Friend Leukemia Integration 1; Gabp: GA Repeat Binding Protein; GC: Glucocorticoids; Ghr: Growth Hormone Receptor; <protein-id="Q16665,D0VY79">Hif-1alpha</protein-id>: <protein-id="Q16665,D0VY79">Hypoxia-Inducible Factor 1 Alpha</protein-id>; hMSCs: Human Mesenchymal Stem Cells; Igf1: <protein-id="P05019,Q5U743,Q13429,Q59GC5">Insulin-Like Growth Factor 1</protein-id>; <protein-id="P08833">Igfbp1</protein-id>: <protein-id="P01308,I3WAC9">Insulin</protein-id>-Like Growth Factor Binding Protein 1; <protein-id="P08069,C9J5X1">Igf1r</protein-id>: <protein-id="P05019,Q5U743,Q13429,Q59GC5">Insulin-Like Growth Factor 1</protein-id>-Receptor; Igf2: <protein-id="P01308,I3WAC9">Insulin</protein-id>-Like Growth Factor 2; Igf2r: <protein-id="P01308,I3WAC9">Insulin</protein-id>-Like Growth Factor 2-Receptor; <protein-id="Q16236">Nfe2l2</protein-id>: Nuclear Factor, <compound-id="439574">Erythroid</compound-id> Derived 2, Like 2; <protein-id="Q16656,A0A024R770,A0A024R774">Nrf1</protein-id>: <protein-id="Q16656,A0A024R770,A0A024R774">Nuclear Respiratory Factor 1</protein-id>; Pam: <compound-id="4674">Pamidronate</compound-id>; <protein-id="Q92743">Prss11</protein-id>: <protein-id="Q92743">HtrA Serine Peptidase 1</protein-id>; PTU: <compound-id="657298">Propylthiouracil</compound-id>; Pycard: <compound-id="445779">PYD</compound-id> and <protein-id="P19793,F1D8Q5,Q6P3U7">CARD Domain Containing; Rxrg: Retinoid X Receptor</protein-id> Gamma; Tam: <compound-id="2733526">Tamoxifen</compound-id>. 	Pamidronate__Igfbp1__no_interaction	Pamidronate__Asb- 4__no_interaction	Pamidronate__Igf1r__no_interaction	Pamidronate__Prss11__no_interaction	Pamidronate__Nfe2l2__no_interaction	Pamidronate__Hif-1alpha__no_interaction	Pamidronate__Fli1__no_interaction	Pamidronate__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Pamidronate__Nrf1__no_interaction	Pamidronate__Insulin__no_interaction	Pamidronate__Elk1__no_interaction	Pamidronate__Insulin-Like Growth Factor 1__no_interaction	Pamidronate__HtrA Serine Peptidase 1__no_interaction	Pamidronate__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Pamidronate__Nuclear Respiratory Factor 1__no_interaction	Pamidronate__Atf6__no_interaction	Pamidronate__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Pamidronate__Activating Transcription Factor6__no_interaction	Alendronate__Igfbp1__no_interaction	Alendronate__Asb- 4__no_interaction	Alendronate__Igf1r__no_interaction	Alendronate__Prss11__no_interaction	Alendronate__Nfe2l2__no_interaction	Alendronate__Hif-1alpha__no_interaction	Alendronate__Fli1__no_interaction	Alendronate__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Alendronate__Nrf1__no_interaction	Alendronate__Insulin__no_interaction	Alendronate__Elk1__no_interaction	Alendronate__Insulin-Like Growth Factor 1__no_interaction	Alendronate__HtrA Serine Peptidase 1__no_interaction	Alendronate__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Alendronate__Nuclear Respiratory Factor 1__no_interaction	Alendronate__Atf6__no_interaction	Alendronate__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Alendronate__Activating Transcription Factor6__no_interaction	Erythroid__Igfbp1__no_interaction	Erythroid__Asb- 4__no_interaction	Erythroid__Igf1r__no_interaction	Erythroid__Prss11__no_interaction	Erythroid__Nfe2l2__no_interaction	Erythroid__Hif-1alpha__no_interaction	Erythroid__Fli1__no_interaction	Erythroid__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Erythroid__Nrf1__no_interaction	Erythroid__Insulin__no_interaction	Erythroid__Elk1__no_interaction	Erythroid__Insulin-Like Growth Factor 1__no_interaction	Erythroid__HtrA Serine Peptidase 1__no_interaction	Erythroid__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Erythroid__Nuclear Respiratory Factor 1__no_interaction	Erythroid__Atf6__no_interaction	Erythroid__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Erythroid__Activating Transcription Factor6__no_interaction	Kinase Inhibitor__Igfbp1__no_interaction	Kinase Inhibitor__Asb- 4__no_interaction	Kinase Inhibitor__Igf1r__no_interaction	Kinase Inhibitor__Prss11__no_interaction	Kinase Inhibitor__Nfe2l2__no_interaction	Kinase Inhibitor__Hif-1alpha__no_interaction	Kinase Inhibitor__Fli1__no_interaction	Kinase Inhibitor__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Kinase Inhibitor__Nrf1__no_interaction	Kinase Inhibitor__Insulin__no_interaction	Kinase Inhibitor__Elk1__no_interaction	Kinase Inhibitor__Insulin-Like Growth Factor 1__no_interaction	Kinase Inhibitor__HtrA Serine Peptidase 1__no_interaction	Kinase Inhibitor__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Kinase Inhibitor__Nuclear Respiratory Factor 1__no_interaction	Kinase Inhibitor__Atf6__no_interaction	Kinase Inhibitor__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Kinase Inhibitor__Activating Transcription Factor6__no_interaction	Propylthiouracil__Igfbp1__no_interaction	Propylthiouracil__Asb- 4__no_interaction	Propylthiouracil__Igf1r__no_interaction	Propylthiouracil__Prss11__no_interaction	Propylthiouracil__Nfe2l2__no_interaction	Propylthiouracil__Hif-1alpha__no_interaction	Propylthiouracil__Fli1__no_interaction	Propylthiouracil__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Propylthiouracil__Nrf1__no_interaction	Propylthiouracil__Insulin__no_interaction	Propylthiouracil__Elk1__no_interaction	Propylthiouracil__Insulin-Like Growth Factor 1__no_interaction	Propylthiouracil__HtrA Serine Peptidase 1__no_interaction	Propylthiouracil__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Propylthiouracil__Nuclear Respiratory Factor 1__no_interaction	Propylthiouracil__Atf6__no_interaction	Propylthiouracil__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Propylthiouracil__Activating Transcription Factor6__no_interaction	PYD__Igfbp1__no_interaction	PYD__Asb- 4__no_interaction	PYD__Igf1r__no_interaction	PYD__Prss11__no_interaction	PYD__Nfe2l2__no_interaction	PYD__Hif-1alpha__no_interaction	PYD__Fli1__no_interaction	PYD__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	PYD__Nrf1__no_interaction	PYD__Insulin__no_interaction	PYD__Elk1__no_interaction	PYD__Insulin-Like Growth Factor 1__no_interaction	PYD__HtrA Serine Peptidase 1__no_interaction	PYD__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	PYD__Nuclear Respiratory Factor 1__no_interaction	PYD__Atf6__no_interaction	PYD__Hypoxia-Inducible Factor 1 Alpha__no_interaction	PYD__Activating Transcription Factor6__no_interaction	Tamoxifen__Igfbp1__no_interaction	Tamoxifen__Asb- 4__no_interaction	Tamoxifen__Igf1r__no_interaction	Tamoxifen__Prss11__no_interaction	Tamoxifen__Nfe2l2__no_interaction	Tamoxifen__Hif-1alpha__no_interaction	Tamoxifen__Fli1__no_interaction	Tamoxifen__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Tamoxifen__Nrf1__no_interaction	Tamoxifen__Insulin__no_interaction	Tamoxifen__Elk1__no_interaction	Tamoxifen__Insulin-Like Growth Factor 1__no_interaction	Tamoxifen__HtrA Serine Peptidase 1__no_interaction	Tamoxifen__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Tamoxifen__Nuclear Respiratory Factor 1__no_interaction	Tamoxifen__Atf6__no_interaction	Tamoxifen__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Tamoxifen__Activating Transcription Factor6__no_interaction	Dexamethasone__Igfbp1__no_interaction	Dexamethasone__Asb- 4__no_interaction	Dexamethasone__Igf1r__no_interaction	Dexamethasone__Prss11__no_interaction	Dexamethasone__Nfe2l2__no_interaction	Dexamethasone__Hif-1alpha__no_interaction	Dexamethasone__Fli1__no_interaction	Dexamethasone__CARD Domain Containing; Rxrg: Retinoid X Receptor__no_interaction	Dexamethasone__Nrf1__no_interaction	Dexamethasone__Insulin__no_interaction	Dexamethasone__Elk1__no_interaction	Dexamethasone__Insulin-Like Growth Factor 1__no_interaction	Dexamethasone__HtrA Serine Peptidase 1__no_interaction	Dexamethasone__Esr1: Estrogen Receptor 1 (Alpha__no_interaction	Dexamethasone__Nuclear Respiratory Factor 1__no_interaction	Dexamethasone__Atf6__no_interaction	Dexamethasone__Hypoxia-Inducible Factor 1 Alpha__no_interaction	Dexamethasone__Activating Transcription Factor6__no_interaction
15634932-3	A(2A)AR activation reduces TCR-mediated production of <protein-id="P01580">IFN-gamma</protein-id> by 98% with a potency order of 4-{3-[6-amino-9-(5-ethylcarbamoyl-<compound-id="90803">3,4-dihydroxytetrahydrofuran</compound-id>-2-yl)-9H-<compound-id="1044">purin</compound-id>-2-yl]prop-2-ynyl}<compound-id="20748">cyclohexanecarboxylic acid methyl ester</compound-id> (ATL146e; EC(50) = 0.19 +/- 0.03 nM) &gt; <compound-id="59716279">4-{3-[6-amino-9-(5-cyclopropyl-carbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl]prop-2-ynyl}piperidine-1-carboxylic acid methyl ester</compound-id> (<compound-id="11627443">ATL313</compound-id>; 0.43 +/- 0.06 nM) &gt; <compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (3.5 +/- 0.77 nM) &gt; 2-[4-(2-carboxyethyl)phenethylamino]-<compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (<compound-id="3086599">CGS21680</compound-id>; 7.2 +/- 1.4 nM) &gt;&gt; N(6)-cyclohexyladenosine (110 +/- 33 nM) &gt; <compound-id="1800613">2-chloro</compound-id>-N(6)-(3-<compound-id="12098">iodobenzyl</compound-id>)-5'-N-methylcarboxamide (390 +/- 160 nM), similar to the potency order to compete for radioligand binding to the recombinant murine A(2A)AR but not the A(3)AR.	4-{3-[6-amino-9-(5-cyclopropyl-carbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl]prop-2-ynyl}piperidine-1-carboxylic acid methyl ester__IFN-gamma__no_interaction	CGS21680__IFN-gamma__no_interaction	ATL313__IFN-gamma__no_interaction	iodobenzyl__IFN-gamma__no_interaction	3,4-dihydroxytetrahydrofuran__IFN-gamma__no_interaction	purin__IFN-gamma__no_interaction	cyclohexanecarboxylic acid methyl ester__IFN-gamma__no_interaction	2-chloro__IFN-gamma__no_interaction	5'-N-ethylcarboxamidoadenosine__IFN-gamma__no_interaction
24235852-7	The significant multivariable prognostic characteristics for scrub typhus severity were increased body temperature (odds ratio [OR] = 0.58, 95% confidence interval [CI] = 0.45-0.74, P &lt; 0.001), increased pulse rate (OR = 1.03, 95% CI = 1.01-1.05, P &lt; 0.001), presence of crepitation (OR = 3.25, 95% CI = 1.52-6.96, P = 0.001), increased percentage of lymphocytes (OR = 0.97, 95% CI = 0.95-0.98, P = 0.001), increased <compound-id="5960">aspartate</compound-id> aminotransferase (every 10 IU/L) (OR = 1.04, 95% CI = 1.02-1.06, P &lt; 0.001), increased serum <protein-id="P02768">albumin</protein-id> (OR = 0.47, 95% CI = 0.27-0.80, P = 0.001), increased serum <compound-id="588">creatinine</compound-id> (OR = 1.83, 95% CI = 1.50-2.24, P &lt; 0.001), and increased levels of positive urine <protein-id="P02768">albumin</protein-id> (OR = 1.43, 95% CI = 1.17-1.75, P &lt; 0.001).	creatinine__albumin__no_interaction	aspartate__albumin__no_interaction
17531857-14	The following significant results were found: <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">HLA-DRB1</protein-id>*1501 positive patients had significantly lower <protein-id="P60983">GMF</protein-id> (0.493 vs 0.526, p &lt; 0.001), lower <compound-id="449429">BPF</compound-id> (0.784 vs 0.815, p = 0.018), and higher T1-LV (2.8 vs 0.7ml, p = 0.036); -<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0301 positive patients had significantly higher T2-LV (34.1 vs 0.7 ml, p = 0.041), and showed a trend for lower <compound-id="449429">BPF</compound-id> (0.790 vs 0.846, p = 0.064); -<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 positive patients had significantly lower T1-LV (2.4 vs 0.9 ml, p = 0.016); and -<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0602 positive patients had significantly lower <protein-id="P60983">GMF</protein-id> (0.492 vs 0.521, p = 0.007) and lower <compound-id="449429">BPF</compound-id> (0.781 vs 0.811, p = 0.023).	BPF__DQB1__no_interaction	BPF__HLA-DRB1__no_interaction	BPF__GMF__no_interaction
15819582-1	The metal-mediated coupling between coordinated EtCN in the <compound-id="23939">platinum</compound-id>(II) and <compound-id="23939">platinum</compound-id>(IV) complexes cis- and trans-[PtCl(2)(EtCN)(2)], trans-[PtCl(4)(EtCN)(2)], a mixture of cis/trans-[PtCl(4)(EtCN)(2)] or [Ph(3)PCH(2)Ph][PtCl(n)(EtCN)] (n = 3, 5), and dialkyl- and dibenzylhydroxylamines R(2)<compound-id="159652">NOH</compound-id> (R = Me, Et, CH(2)Ph, CH(2)C(6)H(4)<compound-id="312">Cl-</compound-id>p) proceeds smoothly in CH(2)Cl(2) at 20-25 degrees C and the subsequent workup allowed the isolation of new imino species [PtCl(n){NH=C(Et)ONR(2)}(2)] (n = 2, R = Me, <protein-id="Q9NSE2">cis-1</protein-id> and trans-1; Et, <protein-id="O14508,A0A024RBD2">cis-2</protein-id> and trans-2; CH(2)Ph, <protein-id="O14543,Q6FI39">cis-3</protein-id> and trans-3; CH(2)C(6)H(4)<compound-id="312">Cl-</compound-id>p, <protein-id="O14544,A0A024R379">cis-4</protein-id> and trans-4; n = 4, R = Me, trans-9; Et, trans-10; CH(2)Ph, trans-11; CH(2)C(6)H(4)<compound-id="312">Cl-</compound-id>p, trans-12) or [Ph(3)PCH(2)Ph][PtCl(n){NH=C(Et)ONR(2)}] (n = 3, R = Me, 5; Et, 6; CH(2)Ph, 7; CH(2)C(6)H(4)<compound-id="312">Cl-</compound-id>p, 8; n = 5, R = Me, 13; Et, 14; CH(2)Ph, 15; CH(2)C(6)H(4)<compound-id="312">Cl-</compound-id>p, 16) in excellent to good (95-80%) isolated yields.	platinum__cis-1__no_interaction	platinum__cis-3__no_interaction	platinum__cis-2__no_interaction	platinum__cis-4__no_interaction	Cl-__cis-1__no_interaction	Cl-__cis-3__no_interaction	Cl-__cis-2__no_interaction	Cl-__cis-4__no_interaction	NOH__cis-1__no_interaction	NOH__cis-3__no_interaction	NOH__cis-2__no_interaction	NOH__cis-4__no_interaction
14735511-1	Treatment of complex trans-[RuCl(2)(eta(2)-C(2)H(4))[kappa(3)-N,N,N-(R,R)-Ph-pybox]] [(R,R)-Ph-pybox = 2,6-bis[4'-(R)-<compound-id="244030">phenyloxazolin</compound-id>-2'-yl]pyridine] with phosphines or phosphites in <compound-id="6344">dichloromethane</compound-id> at 50 degrees C leads to the formation of novel <compound-id="23950">ruthenium</compound-id>(II)-pybox complexes trans-[RuCl(2)(L)[kappa(3)-N,N,N-(R,R)-Ph-pybox]] [L = <protein-id="P60510,A0A024R625">PPh(3</protein-id>) (1 a), <protein-id="P06733,A0A024R4F1,E2DRY6">PPh(2)Me</protein-id> (2 a), PPh(2)(C(3)H(5)) (3 a), PPh(2)(C(4)H(7)) (4 a), PMe(3) (5 a), PiPr(3) (6 a), P(OMe)(3) (7 a) and P(OPh)(3) (8 a)].	ruthenium__PPh(2)Me__no_interaction	ruthenium__PPh(3__no_interaction	phenyloxazolin__PPh(2)Me__no_interaction	phenyloxazolin__PPh(3__no_interaction	dichloromethane__PPh(2)Me__no_interaction	dichloromethane__PPh(3__no_interaction
1792157-7	The %ID in the blood at 60 min after the injection showed significant correlations with serum albumin levels (r = -0.741, p less than 0.0001), retention rates of <compound-id="6096882">ICG</compound-id> at 15 min (r = 0.855, p less than 0.0001), plasma disappearance rates of <compound-id="6096882">ICG</compound-id> (r = -0.760, p less than 0.0005), <protein-id="P00734">prothrombin</protein-id> times (r = -0.696, p less than 0.002), hepaplastin tests (r = -0.575, p less than 0.05), total <compound-id="5280352">bilirubin</compound-id> levels (r = 0.689, p less than 0.001) and Child Turcotte scores (r = 0.769, p less than 0.0001).	bilirubin__prothrombin__no_interaction	ICG__prothrombin__no_interaction
11694521-4	The pathway linking PLC-coupled receptors to PI 3-kinase was deduced to involve phosphoinositide hydrolysis and Ca2+-dependent <protein-id="P21860">ErbB3</protein-id> transactivation but not protein kinase C on the basis of the following evidence: (i) inhibition of <compound-id="2551">carbachol</compound-id> stimulated PLC by pretreatment with the <compound-id="22833501,27924,70702034">phorbol ester</compound-id> <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> concomitantly reduced PKB activity, whereas stimulation of other PLC-coupled receptors also activated PKB; (ii) Ca2+ ionophores and <compound-id="446378,49926">thapsigargin</compound-id> stimulated PKB activity in a <compound-id="312145">wortmannin</compound-id>-sensitive manner, whereas bis(2-<compound-id="5483936">aminophenoxy</compound-id>)<compound-id="6324">ethane</compound-id>-N,N,N',N'-tetraacetic acid blocked <compound-id="2551">carbachol</compound-id>-stimulated PKB activity; (iii) <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> alone did not activate PKB, whereas a protein kinase C inhibitor did not prevent the activation of PKB by <compound-id="2551">carbachol</compound-id>; and (iv) <compound-id="2551">carbachol</compound-id> stimulated <protein-id="P21860">ErbB3</protein-id>-<compound-id="6057,90983769">tyrosine</compound-id> phosphorylation and association with <protein-id="Q9BZL4">p85</protein-id>, and both these and PKB activity were blocked by tyrphostin <compound-id="2051">AG1478</compound-id>, an epidermal growth factor receptor-<compound-id="6057,90983769">tyrosine</compound-id> <compound-id="53378893">kinase inhibitor</compound-id>.	wortmannin__ErbB3__no_interaction	wortmannin__p85__no_interaction	thapsigargin__ErbB3__no_interaction	thapsigargin__p85__no_interaction	phorbol 12-myristate__ErbB3__no_interaction	phorbol 12-myristate__p85__no_interaction	aminophenoxy__ErbB3__no_interaction	aminophenoxy__p85__no_interaction	acetate__ErbB3__no_interaction	acetate__p85__no_interaction	kinase inhibitor__ErbB3__no_interaction	kinase inhibitor__p85__no_interaction	ethane__ErbB3__no_interaction	ethane__p85__no_interaction	carbachol__ErbB3__no_interaction	carbachol__p85__no_interaction	AG1478__ErbB3__no_interaction	AG1478__p85__no_interaction	phorbol ester__ErbB3__no_interaction	phorbol ester__p85__no_interaction	tyrosine__ErbB3__no_interaction	tyrosine__p85__no_interaction
19022862-2	Here we show a clear association between <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1501 carrier status and four domains of disease severity in an investigation of genotype-phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-<compound-id="5960">aspartate</compound-id> (NAA) concentration within normal appearing white matter (NAWM) via (1)HMR spectroscopy (P = 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm(3); P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1501+: 0.110 versus <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1501-: 0.048; P = 0.004).	aspartate__DRB1__no_interaction
7969053-2	Displacement of the selective <protein-id="P23979,Q8K1F4,E9QLC0">5-HT3</protein-id> receptor antagonist [3H]BRL 43694 by <compound-id="4780">phenylbiguanide</compound-id> (<compound-id="1021">PBG</compound-id>) derivatives revealed Ki values ranging from 3.4 x 10(-4) to 4.4 x 10(-10) M. The rank order of potency of agonists was 2,3,5-trichloro-<compound-id="1021">PBG</compound-id> &gt; 2,3-dichloro-<compound-id="1021">PBG</compound-id> = 2,5-dichloro-<compound-id="1021">PBG</compound-id> = 3,5-dichloro-<compound-id="1021">PBG</compound-id> &gt; 3,4-dichloro-<compound-id="1021">PBG</compound-id> = <compound-id="97584">3-chloro-</compound-id><compound-id="1021">PBG</compound-id> &gt; <compound-id="1800613">2-chloro</compound-id>-<compound-id="1021">PBG</compound-id> = 4-chloro-<compound-id="1021">PBG</compound-id> = 2-methyl-<compound-id="1021">PBG</compound-id> = 2,4-difluoro-<compound-id="1021">PBG</compound-id> &gt; <compound-id="1021">PBG</compound-id> = 2-trifluoro-5-chloro-<compound-id="1021">PBG</compound-id> &gt; 4-fluoro-<compound-id="1021">PBG</compound-id> = 3-<compound-id="6373">trifluoromethyl</compound-id>-<compound-id="1021">PBG</compound-id> &gt; 4-nitro-<compound-id="1021">PBG</compound-id> = 1,5-bis-4-chloro-<compound-id="1021">PBG</compound-id> = 3,5-ditrifluoromethyl-<compound-id="1021">PBG</compound-id> &gt; <compound-id="5709222">4-ethoxy</compound-id>-<compound-id="1021">PBG</compound-id> &gt;&gt; 4-<compound-id="104748,57190222">sulfonic acid</compound-id>-<compound-id="1021">PBG</compound-id>.	phenylbiguanide__5-HT3__no_interaction	4-ethoxy__5-HT3__no_interaction	PBG__5-HT3__no_interaction	sulfonic acid__5-HT3__no_interaction	2-chloro__5-HT3__no_interaction	3-chloro-__5-HT3__no_interaction	trifluoromethyl__5-HT3__no_interaction
21722101-5	RESULTS: There were no significant age-associated alterations in apo(a) levels, but there was a significant age-related decrease in activities of SOD (A&gt;C, B&gt;C: P &lt; 0·01), CAT (A&gt;C: P &lt; 0·05) and <compound-id="124886">GSH</compound-id>-Px (A&gt;C: P &lt; 0·05), accompanied by a significant increase in oxLDL (A&lt;C: P &lt; 0·001; B&lt;C: P &lt; 0·05), ADMA (A&lt;B: P &lt; 0·05; A&lt;C: P &lt; 0·001), MDA (A&lt;C, B&lt;C: P &lt; 0·01) and CD (A&lt;C, B&lt;C: P &lt; 0·01), and a significant decrease in <protein-id="P02765">fetuin A</protein-id> (A&gt;C: P &lt; 0·01; B&gt;C: P &lt; 0·05).	GSH__fetuin A__no_interaction
17028745-1	The first reported <compound-id="5360545">sodium</compound-id> alkyl(<protein-id="P54849,A0A024RAT0">TMP</protein-id>)<compound-id="114790">aluminate</compound-id> reagent to be synthesised and crystallographically characterised, [<compound-id="8037">TMEDA</compound-id>.Na(mu-<protein-id="P54849,A0A024RAT0">TMP</protein-id>)(mu-(I)Bu)Al((I)Bu)2], reacts as an amido base towards <compound-id="10821">phenylacetylene</compound-id> to form crystalline [(<compound-id="8037">TMEDA</compound-id>)2.Na(mu-CCPh)(mu-(I)Bu)Al((I)Bu)2]; whereas the congeneric <compound-id="8037">TMEDA</compound-id>-stabilised <compound-id="3028194">lithium</compound-id> (<protein-id="P54849,A0A024RAT0">TMP</protein-id>)<compound-id="114790">aluminate</compound-id> exhibits dual alkyl/amido basicity in its reaction with N,N-diisopropylbenzamide to form a novel heterobimetallic-heterotrianionic crystalline complex [{PhC(=O)N(iPr)2}.Li{2-[1-C(=O)N(iPr)2]C6H4}{Me2NCH2CH2N(Me)CH2}Al(iBu)2], which, in addition to having an ortho-deprotonated <compound-id="2331">benzamide</compound-id> ligand, also contains a methyl-deprotonated <compound-id="8037">TMEDA</compound-id> ligand and a neutral <compound-id="2331">benzamide</compound-id> molecule ligated to <compound-id="3028194">lithium</compound-id>.	sodium__TMP__no_interaction	aluminate__TMP__no_interaction	TMEDA__TMP__no_interaction	phenylacetylene__TMP__no_interaction	benzamide__TMP__no_interaction	lithium__TMP__no_interaction
17608470-1	To systematically explore the influence of the bulky aromatic ring skeleton with a large conjugated pi-system on the structures and properties of their complexes, six CuII, <protein-id="P00403,U5Z487,P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CoII</protein-id>, and NiII complexes with the <compound-id="8418">anthracene</compound-id>-based carboxylic ligand <compound-id="2201">anthracene-9-carboxylic acid</compound-id> (<protein-id="P07306,Q6FGQ5">HL1</protein-id>), were synthesized and characterized, sometimes incorporating different auxiliary ligands: [<compound-id="444924">Cu2</compound-id>(L1)4(CH3OH)2](CH3OH) (1), [Cu4(L1)6(L2)4](NO3)2(H2O)2 (2), {[<compound-id="444924">Cu2</compound-id>(L1)4(L3)](CH3OH)0.25}infinity (3), [<compound-id="280">Co2</compound-id>(L1)4(L4)2(micro-H2O)](CH3OH) (4), {[Co(L1)2(L5)(CH3OH)2]}infinity (5), and {[Ni(L1)2(L5)(CH3OH)2]}infinity (6) (L2 = 2,2'-bipyridine, L3 = <compound-id="558578">1,4-diazabicyclo[</compound-id>2.2.2]<compound-id="356">octane</compound-id>, L4 = 1,10-<compound-id="67473">phenanthroline</compound-id>, and L5 = <compound-id="11107">4,4'-bipyridine</compound-id>).	phenanthroline__CoII__no_interaction	phenanthroline__HL1__no_interaction	Co2__CoII__no_interaction	Co2__HL1__no_interaction	Cu2__CoII__no_interaction	Cu2__HL1__no_interaction	anthracene-9-carboxylic acid__CoII__no_interaction	anthracene-9-carboxylic acid__HL1__no_interaction	1,4-diazabicyclo[__CoII__no_interaction	1,4-diazabicyclo[__HL1__no_interaction	4,4'-bipyridine__CoII__no_interaction	4,4'-bipyridine__HL1__no_interaction	octane__CoII__no_interaction	octane__HL1__no_interaction	anthracene__CoII__no_interaction	anthracene__HL1__no_interaction
18755049-9	Serum <protein-id="P41159,A4D0Y8">leptin</protein-id> levels were significantly related to: sex (mean: girls 48.0 ng/ml, boys 34.4 ng/ml; P = 0.003); Tanner stage (mean: I-II 37.0 ng/ml, III-V 45.2 ng/ml; P = 0.035); systolic blood pressure (mean: normal 41.3 ng/ml, high 44.0 ng/ml; P = 0.009); BMI z-score (r 0.136; P = 0.010); <protein-id="P01308,I3WAC9">C-peptide</protein-id> (r 0.17; P = 0.002); <protein-id="P01308,I3WAC9">insulin</protein-id> (r 0.34; P &lt; 0.001); homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) (r 0.25; P &lt; 0.001) and <compound-id="5960">aspartate</compound-id> aminotransferase (r - 0.12; P = 0.023).	aspartate__leptin__no_interaction	aspartate__insulin__no_interaction	aspartate__C-peptide__no_interaction
2809224-4	Several lines of evidence suggest that complement activation was via the classical pathway: (1) complement activation was highly isotype-restricted with regard to the adsorbed Igs (human IgG1 and IgG3 as well as mouse IgM, IgG2a and IgG2b isotypes are strong activators in contrast to human IgG2, IgG4, IgA and mouse IgG1); (2) Ca2+ depletion, heat treatment (56 degrees C for 45 min), incubation with 0.5 M <compound-id="781">KSCN</compound-id> or heat-aggregated immunoglobulins (aggIgG) abrogated serum activity; (3) complement deficient sera (<protein-id="P02745,A0A024RAG6,P98086">C1q</protein-id> def', C2 def', C6 def' human sera; C2 def', C4 def' guinea pig sera) showed impaired deposition of the complement components that follow the missing component in the cascade of activation.	KSCN__C1q__no_interaction
21185730-1	The purpose of this study was to synthesize two new positron emission tomography (PET) probes, N-(4-(2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-<compound-id="333903,57417047">isoquinolinyl</compound-id>)<compound-id="23134249">ethyl</compound-id>)phenyl)-9,10-dihydro-5-[¹⁸F]fluoroethoxy-9-oxo-<compound-id="3025721">4-acridine carboxamide</compound-id> ([¹⁸F]3) and <compound-id="80971">quinoline-3-carboxylic acid</compound-id> [2-(4-{2-[7-(2-[¹⁸F]fluoroethoxy)-6-<compound-id="91066389">methoxy-</compound-id>3,4-dihydro-1H-isoquinolin-2-yl]<compound-id="23134249">ethyl</compound-id>}<compound-id="7671">phenylcarbamoyl</compound-id>)-4,5-dimethoxyphenyl]<compound-id="2826723">amide</compound-id> ([¹⁸F]4), and to evaluate the potential of these PET probes for assessing the function of two major drug efflux transporters, P-glycoprotein (P-gp) and <protein-id="Q7TMS5">breast cancer resistance protein</protein-id> (<protein-id="Q9UNQ0,A0A024RDD4">BCRP</protein-id>).	methoxy-__breast cancer resistance protein__no_interaction	methoxy-__BCRP__no_interaction	isoquinolinyl__breast cancer resistance protein__no_interaction	isoquinolinyl__BCRP__no_interaction	amide__breast cancer resistance protein__no_interaction	amide__BCRP__no_interaction	4-acridine carboxamide__breast cancer resistance protein__no_interaction	4-acridine carboxamide__BCRP__no_interaction	phenylcarbamoyl__breast cancer resistance protein__no_interaction	phenylcarbamoyl__BCRP__no_interaction	quinoline-3-carboxylic acid__breast cancer resistance protein__no_interaction	quinoline-3-carboxylic acid__BCRP__no_interaction	ethyl__breast cancer resistance protein__no_interaction	ethyl__BCRP__no_interaction
10413483-2	The results for neutral side chains with <protein-id="P06744,B4DE36">phi</protein-id>, psi angles approximately 180 degrees, approximately 180 degrees in ascending order, to an expected accuracy of +/-10 kJ mol(-)(1), are Asn 326; <compound-id="595">cystine</compound-id> 330; Asp 332; Gln 334; Trp 337; Arg 340; <compound-id="5962">Lys</compound-id> 340; Met 343; His 344; Phe 344; <compound-id="6057">Tyr</compound-id> 344; Leu 344; Ala 345; Cys 346; <compound-id="5951">Ser</compound-id> 349; Gly 350; Ile 351; Val 352; Glu 354; Thr 357; Pro-cis 358; Pro-trans 369.	Ser__phi__no_interaction	Tyr__phi__no_interaction	cystine__phi__no_interaction	Lys__phi__no_interaction
19273348-1	Class III multidrug resistance P-glycoproteins, <protein-id="P21440">mdr2</protein-id> in mice and <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> in human, are canalicular phospholipid translocators involved in biliary phospholipid (phosphatidylcholine) excretion.The role of a <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> (<protein-id="P21439">ABCB4</protein-id>) gene defect in liver disease has been initially proven in a subtype of progressive familial intrahepatic cholestasis called <protein-id="P21439">PFIC3</protein-id>, a severe pediatric liver disease that may require liver transplantation.Several <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> mutations have been identified in children with <protein-id="P21439">PFIC3</protein-id> and are associated to low level of phospholipids in bile leading to high biliary <compound-id="5997">cholesterol</compound-id> saturation index.<protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> mutations are associated to loss of canalicular <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> protein and /or to loss of protein function.There is evidence that biallelic or monoallelic <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> defect causes or predisposes to 6 human liver diseases (<protein-id="P21439">PFIC3</protein-id>, adult biliary cirrhosis, low phospholipid associated cholelithiasis syndrome, transient neonatal cholestasis, intrahepatic cholestasis of pregnancy, drug induced cholestasis).Some patients with <protein-id="P21439,P21447,Q9CVG4">MDR3</protein-id> deficiency may benefit from <compound-id="31401">ursodeoxycholic acid</compound-id> therapy and could be good candidates to a targeted pharmacological approach and/or to cell therapy in the future.	ursodeoxycholic acid__PFIC3__no_interaction	ursodeoxycholic acid__ABCB4__no_interaction	ursodeoxycholic acid__MDR3__no_interaction	ursodeoxycholic acid__mdr2__no_interaction	cholesterol__PFIC3__no_interaction	cholesterol__ABCB4__no_interaction	cholesterol__MDR3__no_interaction	cholesterol__mdr2__no_interaction
24010200-4	RESULTS: Compared with the <compound-id="679">DMSO</compound-id> control group, the low-, medium- and high-dose DEHP groups showed significantly upregulated expressions of <protein-id="P55213">Caspase-3</protein-id> mRNA (1.69 +/- 0.38 vs 3.82 +/- 0.39, 6.91 +/- 0.40 and 15.47 +/- 0.40, P &lt; 0.05), <protein-id="P55213">Caspase-3</protein-id> protein (0.18 +/- 0.0.09 vs 0.32 +/- 0.10, 0.61 +/- 0.08 and 0.89 +/- 0.09, P &lt; 0.05), <protein-id="Q9JHK1">Caspase-9</protein-id> mRNA (2.24 +/- 0.41 vs 5.16 +/- 0.43, 9.61 +/- 0.45 and 19.22 +/- 0.43, P &lt; 0.05) and <protein-id="Q9JHK1">Caspase-9</protein-id> protein (0.26 +/- 0.07 vs 0.40 +/- 0.08, 0.68 +/- 0.09 and 0.96 +/- 0.08, P &lt; 0.05), as well as increased apoptosis rate of Leydig cells (4.36 +/- 1.11 vs 7.52 +/- 1.09, 12.72 +/- 1.10 and 24.59 +/- 1.11, P &lt; 0.05), all in a dose-dependent manner.	DMSO__Caspase-9__no_interaction	DMSO__Caspase-3__no_interaction
18998651-5	Likewise, in addition to (kappa(1),<protein-id="Q9UNA4">eta(2</protein-id>)-CH(2)CC(6)H(4)Se)Mo(PMe(3))(4) and (kappa(1),<protein-id="Q9UNA4">eta(2</protein-id>)-CH(2)CHC(6)H(4)Se)Mo(PMe(3))(3)(<protein-id="Q9UNA4">eta(2</protein-id>)-CH(2)PMe(2)), which are counterparts of the species observed in the <compound-id="7221">benzothiophene</compound-id> reaction, the reaction of Mo(PMe(3))(6) with benzoselenophene yields products resulting from C-C coupling, namely [kappa(2),eta(4)-Se(C(6)H(4))(CH)(4)(C(6)H(4))Se]Mo(PMe(3))(2) and [mu-Se(C(6)H(4))(CH)C(CH)(2)(C(6)H(4))](mu-Se)[Mo(PMe(3))(2)][Mo(PMe(3))(2)H].	benzothiophene__eta(2__no_interaction
23123350-5	Pain-related behaviors were tested after incision in rats treated with intrathecal <protein-id="P07808,F2W8A6">NPY</protein-id>, Y(1) receptor antagonist (<compound-id="5311022">BIBO3304</compound-id>--Chemical Name: N-[(1R)-1-[[[[4-[[(Aminocarbonyl)amino]methyl]phenyl]methyl]amino]carbonyl]-4-[(aminoiminomethyl)amino]<compound-id="68006705">butyl</compound-id>]-α-phenyl-<compound-id="7680">benzeneacetamide</compound-id> ditrifluoroacetate), Y(2) receptor antagonist (<compound-id="5311024">BIIE0246</compound-id>--Chemical Name: N-[(1S)-4-[(Aminoiminomethyl)amino]-1-[[[2-(3,5-dioxo-1,2-diphenyl-<compound-id="5231543">1,2,4-triazolidin</compound-id>-4-yl)<compound-id="23134249">ethyl</compound-id>]amino]carbonyl]<compound-id="68006705">butyl</compound-id>]-1-[2-[4-(6,11-dihydro-6-oxo-5H-dibenz[b,e]<compound-id="21672373">azepin</compound-id>-11-yl)-1-piperazinyl]-2-oxoethyl]-<compound-id="18425633">cyclopentaneacetamide</compound-id>), combined <protein-id="P07808,F2W8A6">NPY</protein-id>+antagonists, <compound-id="5288826">morphine</compound-id>, or vehicle.	BIBO3304__NPY__no_interaction	morphine__NPY__no_interaction	1,2,4-triazolidin__NPY__no_interaction	cyclopentaneacetamide__NPY__no_interaction	butyl__NPY__no_interaction	BIIE0246__NPY__no_interaction	azepin__NPY__no_interaction	benzeneacetamide__NPY__no_interaction	ethyl__NPY__no_interaction
20870683-5	RESULTS: There were significant inverse relationships between <protein-id="Q14524,K4DIA1,Q86V90,E9PG18,H9KVD2,E9PHB6">IVF</protein-id> embryo number and follicular fluid L-<compound-id="6322,90867653">arginine</compound-id> (r = -0.507, P &lt; 0.001), ADMA (r = -0.356, P &lt; 0.024), SDMA (r = -0.347, P &lt; 0.028), MMA (r = -0.449, P &lt; 0.004) and to L-<compound-id="6322,90867653">arginine</compound-id>/ADMA ratio (r = -0.328, P &lt; 0.031).	arginine__IVF__no_interaction
16326710-1	Mice that lack the mitochondrial form of <compound-id="5359597">superoxide</compound-id> dismutase (<protein-id="P09671,Q4FJX9">SOD2</protein-id>) incur severe pathologies and mitochondrial deficiencies, including major depletion of complex II, as a consequence of buildup of endogenous reactive <compound-id="977">oxygen</compound-id> species (Melov, S., Coskun, P., Patel, M., Tuinstra, R., Cottrell, B., <protein-id="P05627,Q52L79">Jun</protein-id>, A. S., Zastawny, T. H., Dizdaroglu, M., Goodman, S. I., Huang, T. T., Miziorko, H., Epstein, C. J., and Wallace, D. C. (1999) Proc.	oxygen__Jun__no_interaction	oxygen__SOD2__no_interaction	superoxide__Jun__no_interaction	superoxide__SOD2__no_interaction
18766955-5	RESULTS: After treatment with <compound-id="5833">spironolactone</compound-id>, flow-mediated vasodilation (FMD) improved from 3.18 +/- 0.46% to 3.95 +/- 0.49% (p &lt; 0.001) whereas there was no significant change in endothelium-independent vasodilation with <compound-id="4510">nitroglycerin</compound-id> and baseline diameter (18.4 +/- 1.15% vs. 18.3 +/- 1.13%, p = 0.046, and 3.5 +/- 0.1 vs. 3.52 +/- 0.1 mm, p = 0.952, respectively); serum <compound-id="946">nitrite</compound-id> concentration was reduced significantly from 6.9 +/- 0.34 to 6.8 +/- 0.33 micromol/L (p &lt; 0.001), ESR from 59.90 +/- 4.86 to 51.22+/-4.26 mm in the first hour (p &lt; 0.001), and <protein-id="P02741">CRP</protein-id> level from 15.2+/-3.8 to 9.4+/-2.6 mg/dL (p = 0.019).	spironolactone__CRP__no_interaction	nitrite__CRP__no_interaction	nitroglycerin__CRP__no_interaction
10891872-2	In addition to the reverse transcriptase and protease step, various other events in the HIV replicative cycle are potential targets for chemotherapeutic intervention: (i) viral adsorption, through binding to the viral envelope glycoprotein <protein-id="Q14624,B7ZKJ8,B2RMS9">gp120</protein-id> (polysulphates, polysulphonates, polyoxometalates, <compound-id="16129728">zintevir</compound-id>, negatively charged albumins); (ii) viral entry, through blockade of the viral coreceptors <protein-id="P61073">CXCR4</protein-id> and <protein-id="P51681,Q38L21">CCR5</protein-id> [bicyclams (<compound-id="65015">AMD3100</compound-id>), polyphemusins (T22), <protein-id="P50750,A0A024R880">TAK</protein-id>-779]; (iii) virus-cell fusion, through binding to the viral glycoprotein gp41 [T-20 (DP-178), siamycins, betulinic acid derivatives]; (iv) viral assembly and disassembly, through NCp7 <compound-id="23994">zinc</compound-id> finger-targeted agents [2,2'-dithiobisbenzamides (DIBAs), azadicarbonamide (ADA)]; (v) proviral DNA integration, through integrase inhibitors such as L-<compound-id="5134221,5281764,5470299,6450976">chicoric acid</compound-id>; (vi) viral mRNA transcription, through inhibitors of the transcription (transactivation) process (peptoid <compound-id="462369">CGP64222</compound-id>, <compound-id="11094963">fluoroquinolone</compound-id> K-12, Streptomyces product <compound-id="475358">EM2487</compound-id>).	fluoroquinolone__TAK__no_interaction	fluoroquinolone__CCR5__no_interaction	fluoroquinolone__gp120__no_interaction	fluoroquinolone__CXCR4__no_interaction	chicoric acid__TAK__no_interaction	chicoric acid__CCR5__no_interaction	chicoric acid__gp120__no_interaction	chicoric acid__CXCR4__no_interaction	zintevir__TAK__no_interaction	zintevir__CCR5__no_interaction	zintevir__gp120__no_interaction	zintevir__CXCR4__no_interaction	AMD3100__TAK__no_interaction	AMD3100__CCR5__no_interaction	AMD3100__gp120__no_interaction	AMD3100__CXCR4__no_interaction	EM2487__TAK__no_interaction	EM2487__CCR5__no_interaction	EM2487__gp120__no_interaction	EM2487__CXCR4__no_interaction	zinc__TAK__no_interaction	zinc__CCR5__no_interaction	zinc__gp120__no_interaction	zinc__CXCR4__no_interaction	CGP64222__TAK__no_interaction	CGP64222__CCR5__no_interaction	CGP64222__gp120__no_interaction	CGP64222__CXCR4__no_interaction
10715149-13	On the other hand, four dicyclic (1, 1'-5/4-10) analogues met this criterion: dicyclo(1, 1'-5/4-10)[Ac-Asp(1)(Gly),<compound-id="4933">DCpa</compound-id>(2),DTrp(3),Asp(4),<compound-id="81184">Dbu</compound-id>(5 ), DNal(6), Dpr(10)]<protein-id="P07490">GnRH</protein-id> (32, K(i) = 0.22 nM), dicyclo(1, 1'-5/4-10)[Ac-Asp(1)(Gly),<compound-id="4933">DCpa</compound-id>(2),DNal(3),Asp(4),<compound-id="81184">Dbu</compound-id>(5 ), DNal(6), Dpr(10)]<protein-id="P07490">GnRH</protein-id> (34, K(i) = 0.38 nM), dicyclo(1, 1'-5/4-10)[Ac-Asp(1)(betaAla),<compound-id="4933">DCpa</compound-id>(2), DTrp(3),Asp(4),<compound-id="81184">Dbu</compound-id>(5),DNal(6), Dpr(10)]<protein-id="P07490">GnRH</protein-id> (40, K(i) = 0.15 nM), and dicyclo(1, 1'-5/4-10)[Ac-Glu(1)(Gly), <compound-id="4933">DCpa</compound-id>(2),DTrp(3),Asp(4),<compound-id="81184">Dbu</compound-id>(5),DNal(6), Dpr(10)]<protein-id="P07490">GnRH</protein-id> (41, K(i) = 0.24 nM).	DCpa__GnRH__no_interaction	Dbu__GnRH__no_interaction
15665139-9	The uptake by <protein-id="Q9NPD5,B3KP78">OATP1B3</protein-id> and hence the vectorial transport of <compound-id="16219094">CCK-8</compound-id> was inhibited by cyclosporin A (K(i) 1.2 microM) and by MK571 [(3-(3-(2-(<compound-id="521963">7-chloro-2-quinolinyl</compound-id>)<compound-id="123166">ethenyl</compound-id>)phenyl) ((3-dimethylamino-3-oxopropyl)thio)methyl)thiopropanoic acid] (K(i) 0.6 microM); the respective K(i) values for the <protein-id="Q92887">ABCC2</protein-id>-mediated transport were 24 and 8.5 microM.	7-chloro-2-quinolinyl__ABCC2__no_interaction	7-chloro-2-quinolinyl__OATP1B3__no_interaction	CCK-8__ABCC2__no_interaction	CCK-8__OATP1B3__no_interaction	ethenyl__ABCC2__no_interaction	ethenyl__OATP1B3__no_interaction
8719791-2	This study investigated the effect of the recently described non-peptide <protein-id="O70526">bradykinin B2 receptor</protein-id> antagonist, WIN 64338 ([[4-[[2- [[bis(cyclohexylamino)<compound-id="123164">methylene</compound-id>]amino]-3-(2-naphthalenyl)-1-oxopropyl] amino]phenyl]methyl]tributylphosphoniumchloride <compound-id="20254264">monohydrochloride</compound-id>), in experimental models of bradykinin-evoked sensory nerve stimulation.	monohydrochloride__bradykinin B2 receptor__no_interaction	methylene__bradykinin B2 receptor__no_interaction
23037574-1	Four new dinuclear complexes [Ni(μ-L)(μ-OAc)Ni(H2O)2]<protein-id="P41271,A0A087WTY6">NO3</protein-id> (1), Ni(μ-L)(μ-OBz)Ni(H2O)(<compound-id="887">MeOH</compound-id>)]<protein-id="P41271,A0A087WTY6">NO3</protein-id>·3MeOH (2), [Ni(μ-L)(μ-9-An)Ni(H2O)(<compound-id="887">MeOH</compound-id>)]<protein-id="P41271,A0A087WTY6">NO3</protein-id> (3) and [Ni(μ-L)(μ-OAc)Ni(H2O)(N3)]·CH3OH (4) have been prepared from the compartmental ligand N,N′,N′′-<compound-id="4245325">trimethyl-</compound-id>N,N′′-bis(<compound-id="97257">2-hydroxy-</compound-id>3-<compound-id="10351751">methoxy-5-methylbenzyl</compound-id>)<compound-id="8111">diethylenetriamine</compound-id> (H2L) and different carboxylate ligands (OBz = <compound-id="243">benzoate</compound-id> and 9-An = <compound-id="2201">9-anthracenecarboxylate</compound-id>), and then magnetically and structurally characterized.	methoxy-5-methylbenzyl__NO3__no_interaction	diethylenetriamine__NO3__no_interaction	trimethyl-__NO3__no_interaction	benzoate__NO3__no_interaction	MeOH__NO3__no_interaction	9-anthracenecarboxylate__NO3__no_interaction	2-hydroxy-__NO3__no_interaction
18592338-5	These assumptions are based on the following facts: 1) in estrogen-supplemented animals, <compound-id="5994">progesterone</compound-id> has been shown to reactivate the growth of regressed tumour xenograft obtained from breast cancer cell lines, expressing both estrogen and <compound-id="5994">progesterone</compound-id> receptor; 2) antiprogestin has been revealed to suppress the reactivation of the growth of tumour xenograft and to fully suppress the development of breast cancer in an animal model for <protein-id="P38398,A0A024R1V0">BRCA1</protein-id> gene mutation; 3) metabolites of <compound-id="5994">progesterone</compound-id> have been recognised as potent regulators of cell proliferation, cell detachment and apoptosis; 4) <compound-id="5994">progesterone</compound-id> has been shown to inhibit, in a dose-dependent manner, apoptosis in breast cancer cell lines and apoptosis induced by <compound-id="31703">doxorubicin</compound-id> and 5-fluorouracyl (drugs used in breast cancer treatment); 5) an association between breast cancer and HRT was suspected upon the addition of progestin on a regular basis for the prevention of endometrial cancer; 6) in a randomised placebo-controlled trial on HRT an increased risk of breast cancer was shown for the combination of estrogen and progestin, but not for estrogen alone; 7) in epidemiological studies on POC the recognition of an increased breast cancer risk was most probably impeded due to previously unrecognised systematic selection bias; 8) in a large epidemiological study on the risk of early-onset breast cancer in association with COC an increased risk was detected for COC use up to 1975, but no increased, even a slightly decreased, risk was shown for users of low-dose COC, applied since 1976; 9) a considerably higher number of breast cancer cases have been reported from Germany on POC than on the widespread used COC [corrected] (111 versus 12); 10) the big resemblance among the breast cancers reported for POC and their similarity with breast malignancies diagnosed in pregnancy suggest the existence of a pattern rather than pure coincidence [corrected]	doxorubicin__BRCA1__no_interaction	progesterone__BRCA1__no_interaction
11540419-1	Time to exhaustion at 87-91% of peak VO2 was measured in 5 untrained men (age: 31 +/- 8 years, body mass: 74.20 +/- 16.50 kg, body surface area: 1.90 +/- 0.24 m2, peak VO2: 2.87 +/- 0.40 l <protein-id="P13987,Q6FHM9">min-1</protein-id>, plasma volume: 3.21 +/- 0.88 l; means +/-SD) after consuming nothing (N) or two fluid formulations (10 ml kg-1, 743 +/- 161 ml): Performance 1 (P1), a multi-ionic carbohydrate drink, containing 55 mEq l-1 Na+, 4.16 g l-1 <compound-id="17938267">citrate</compound-id>, 20.49 g l-1 <compound-id="206,5793,64689,79025">glucose</compound-id>, and 365 mOsm kg-<compound-id="491852">1 H2O</compound-id>, and AstroAde (AA), a <compound-id="5234">sodium chloride</compound-id>-<compound-id="311,20541035">sodium citrate</compound-id> hyperhydration drink, containing 164 mEq l-1 Na+, 8.54 g l-1 <compound-id="17938267">citrate</compound-id>, &lt;5 mg l-1 <compound-id="206,5793,64689,79025">glucose</compound-id>, and 253 mOsm kg-<compound-id="491852">1 H2O</compound-id>.	sodium chloride__min-1__no_interaction	1 H2O__min-1__no_interaction	sodium citrate__min-1__no_interaction	citrate__min-1__no_interaction	glucose__min-1__no_interaction
17720993-3	<protein-id="Q96RP3">UCN2</protein-id> increased cardiac output (CO) (mean peak increments +/- <compound-id="5289348">SEM</compound-id>; placebo 0.3 +/- 0.1; LD 1.0 +/- 0.3; HD 2.0 +/- 0.2 L/min; P &lt; 0.001) and LVEF (0.0 +/- 1.5; LD 5.9 +/- 2.1; HD 14.1 +/- 2.7%; P = 0.001) and decreased mean arterial pressure (placebo 6.7 +/- 1.3; LD 11.4 +/- 1.7; HD 19.4 +/- 3.3 mmHg; P = 0.001), systemic vascular resistance (SVR) (placebo 104 +/- 37; LD 281 +/- 64; HD 476 +/- 79 dynes s/cm(5); P &lt; 0.003), and cardiac work (CW) (placebo 48 +/- 12; LD 66 +/- 22; HD 94 +/- 13 mmHg/L/min; P &lt; 0.001).	SEM__UCN2__no_interaction
22013105-8	After a single injection of <compound-id="45588096,53396299,56927919">exenatide</compound-id>, there was a reduction by 20 ± 7% in free fatty acids, 19 ± 7% in reactive <compound-id="977">oxygen</compound-id> species generation, 39 ± 11% in nuclear factor-κB binding, 18 ± 9% in TNFα expression, 26 ± 7% in IL-1β expression, 18 ± 7% in <protein-id="P45983,A1L4K2">JNK-1</protein-id> expression, 24 ± 12% in <protein-id="O00206">TLR-4</protein-id> expression, and 23 ± 11% in <protein-id="O14543,Q6FI39">SOCS-3</protein-id> expression (P &lt; 0.05 for all).	oxygen__JNK-1__no_interaction	oxygen__TLR-4__no_interaction	oxygen__SOCS-3__no_interaction	exenatide__JNK-1__no_interaction	exenatide__TLR-4__no_interaction	exenatide__SOCS-3__no_interaction
8263160-8	When all patients were analyzed together, serum <compound-id="5920">T3</compound-id> was negatively correlated to serum <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = -0.56; P &lt; 0.001), <compound-id="5280352">bilirubin</compound-id>/<protein-id="P02768">albumin</protein-id> ratio (r = -0.29; P = 0.004), and FFA/<protein-id="P02768">albumin</protein-id> ratio (r = -0.21; P = 0.03), but not with <compound-id="588">creatinine</compound-id> (r = -0.16; P = 0.11).	bilirubin__IL-6__no_interaction	bilirubin__albumin__no_interaction	creatinine__IL-6__no_interaction	creatinine__albumin__no_interaction	T3__IL-6__no_interaction	T3__albumin__no_interaction
2918240-3	The lipid classes, as percentages of the total lipid synthesized, were found by <protein-id="P31025,A0A024R8D7">TLC</protein-id> to be <compound-id="5997">cholesterol</compound-id> 12.3 +/- 2.0, mono-glycerides 7.5 +/- 1.5, 1,2 di-glycerides 3.0 +/- 0.9, 1,3 di-glycerides 3.5 +/- 0.5, tri-glycerides 28.4 +/- 1.8, free fatty acids 2.0 +/- 0.4, <compound-id="5313988">lysolecithin</compound-id> 15.4 +/- 3.9, sphingomyelin 9.9 +/- 4.3, phosphatidyl-<compound-id="305,57080826">choline</compound-id> 8.4 +/- 0.4, phosphatidyl-<compound-id="700">ethanolamine</compound-id> -<compound-id="892">inositol</compound-id> and -<compound-id="5951">serine</compound-id> 1.8 +/- 0.1, phosphatidic acid and <compound-id="449005">cardiolipin</compound-id> 3.3 +/- 0.5, and unidentified 3.3 +/- 0.5 (mean +/- <compound-id="5289348">sem</compound-id>, n = 5).	lysolecithin__TLC__no_interaction	choline__TLC__no_interaction	cholesterol__TLC__no_interaction	sem__TLC__no_interaction	ethanolamine__TLC__no_interaction	inositol__TLC__no_interaction	serine__TLC__no_interaction	cardiolipin__TLC__no_interaction
21210652-1	New hydrazone o-HO-phenylhydrazo-β-diketones (OHADB), R(1)<compound-id="15942664">NHN</compound-id>═CR(2)R(3) [R(1) = HO-2-C(6)H(4), R(2) = R(3) = COMe (H(2)L(1), 1), R(2)R(3) = <protein-id="O43405">COCH</protein-id>(2)C(Me)(2)CH(2)CO (H(2)L(2), 2), R(2) = COMe, R(3) = COOEt (H(2)L(4), 4); R(1) = HO-2-O(2)N-4-C(6)H(3), R(2)R(3) = <protein-id="O43405">COCH</protein-id>(2)C(Me)(2)CH(2)CO (H(2)L(3), 3), R(2) = COMe, R(3) = COOEt (H(2)L(5), 5), R(2)R(3) = COMe (H(2)L(6), 6A)], and their Cu(II) complexes [Cu(2)(CH(3)OH)(2)(μ-L(1))(2)] 7, [Cu(2)(H(2)O)(2)(μ-L(2))(2)] 8, [Cu(H(2)O)(L(3))] 9, [Cu(2)(μ-L(4))(2)](n) 10, [Cu(H(2)O)(L(5))] 11, [Cu(2)(H(2)O)(2)(μ-L(6))(2)] 12A and [Cu(H(2)O)(2)(L(6))] 12B were synthesized and fully characterized, namely, by X-ray analysis (4, 5, 7-12B).	NHN__COCH__no_interaction
20852754-1	A-3309, Abobotulinumtoxin A, Adalimumab, AIDSVAX gp120 B/E, ALVAC E120TMG, <compound-id="60823">Atorvastatin calcium</compound-id>; <compound-id="2351">Bepridil</compound-id>, Bevacizumab; <compound-id="2540">Candesartan cilexetil</compound-id>, <compound-id="60953">Capecitabine</compound-id>, Cetuximab, Clopidogrel; <compound-id="9887712">Dapagliflozin</compound-id>, <compound-id="3062316">Dasatinib</compound-id>, Denosumab, <compound-id="5311068">Dexmedetomidine hydrochloride</compound-id>, <compound-id="5462328">Diacetylmorphine</compound-id>, Diannexin, <compound-id="148124,54277830">Docetaxel</compound-id>, <compound-id="6918296">Dutasteride</compound-id>; <compound-id="153941">Entecavir</compound-id>, <compound-id="443872">Eplerenone</compound-id>, <compound-id="176870">Erlotinib hydrochloride</compound-id>, <compound-id="146570">Escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, Everolimus, <compound-id="150311">Ezetimibe</compound-id>; <compound-id="6918558">Fesoterodine fumarate</compound-id>, Flagellin.HuM2e, Fluzone; <compound-id="24848073">Glimepiride/rosiglitazone maleate</compound-id>; <compound-id="24728612,24759,3084050,453618">Hyaluronic acid</compound-id>-<compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id> bioconjugate; <compound-id="108161">IDX</compound-id>-184, <compound-id="5291">Imatinib mesylate</compound-id>, Infliximab, <protein-id="P01308,I3WAC9">Insulin</protein-id> <compound-id="44146714">glargine</compound-id>, <compound-id="3749">Irbesartan</compound-id>; JX-594; <compound-id="114905">Landiolol</compound-id>, <compound-id="14504487,25215545,3892,5352046,56928133">Latrunculin B</compound-id>, <compound-id="1549000">Levocetirizine dihydrochloride</compound-id>, Liraglutide, Lyprinol; <compound-id="4091">Metformin</compound-id>, <compound-id="4173">Metronidazole</compound-id>/<compound-id="54675776,54682538,54685734,54677640">tetracycline hydrochloride</compound-id>/<compound-id="5359367">bismuth</compound-id> biskalcitrate, <compound-id="44564108">Mipomersen sodium</compound-id>, <compound-id="446541">Mycophenolic acid sodium salt</compound-id>; <compound-id="6445230">Nalfurafine</compound-id> hydrochloride, <compound-id="644241">Nilotinib hydrochloride</compound-id> <compound-id="1488787">monohydrate</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> poliglumex, Peginterferon alfa-2a, Peginterferon alfa-2b, <compound-id="115368">Perospirone hydrochloride</compound-id>, <compound-id="10071196">Pimavanserin tartrate</compound-id>, <compound-id="40632">Pirfenidone</compound-id>, <compound-id="5282452">Pitavastatin</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">Prasterone</compound-id>, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, Ranibizumab, <compound-id="57504764,9867812">Remimazolam</compound-id>, <compound-id="5245">Risedronate</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">Rosuvastatin calcium</compound-id>; <compound-id="5312125">Silodosin</compound-id>, <compound-id="1549163,16211710,3086637,31553,5213">Silybin</compound-id> phosphatidylcholine complex, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting stent, <compound-id="4369359">Sitagliptin phosphate</compound-id> <compound-id="1488787">monohydrate</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="129211">Tamsulosin</compound-id> hydrochloride, Technosphere/<protein-id="P01308,I3WAC9">Insulin</protein-id>, <compound-id="65999">Telmisartan</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">Temsirolimus</compound-id>, Teriparatide, <compound-id="16130571">Thymalfasin</compound-id>, <compound-id="9871419">Ticagrelor</compound-id>, Toltedorine-XR, <compound-id="33741">Tramadol</compound-id>-XR, <compound-id="5957">Triphosadenine</compound-id>, <compound-id="5596">Trospium</compound-id>-XR; Val8-GLP-1(7-37)OH, <compound-id="60846">Valsartan</compound-id>, <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>, <compound-id="170362,46783232,53486179,6918678,9906942">Varenicline tartrate</compound-id>, Velaglucerase alfa; <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	Ticagrelor__Insulin__no_interaction	Erlotinib hydrochloride__Insulin__no_interaction	Zoledronic acid monohydrate__Insulin__no_interaction	IDX__Insulin__no_interaction	Vardenafil hydrochloride hydrate__Insulin__no_interaction	Silodosin__Insulin__no_interaction	Diacetylmorphine__Insulin__no_interaction	Pimavanserin tartrate__Insulin__no_interaction	Sirolimus__Insulin__no_interaction	Dutasteride__Insulin__no_interaction	Tramadol__Insulin__no_interaction	Metronidazole__Insulin__no_interaction	Pregabalin__Insulin__no_interaction	Metformin__Insulin__no_interaction	Trospium__Insulin__no_interaction	Pirfenidone__Insulin__no_interaction	Capecitabine__Insulin__no_interaction	Telmisartan__Insulin__no_interaction	Dasatinib__Insulin__no_interaction	Triphosadenine__Insulin__no_interaction	Atorvastatin calcium__Insulin__no_interaction	Remimazolam__Insulin__no_interaction	Hyaluronic acid__Insulin__no_interaction	Levocetirizine dihydrochloride__Insulin__no_interaction	Ezetimibe__Insulin__no_interaction	Sunitinib malate__Insulin__no_interaction	Entecavir__Insulin__no_interaction	Thymalfasin__Insulin__no_interaction	oxalate__Insulin__no_interaction	Fesoterodine fumarate__Insulin__no_interaction	Temsirolimus__Insulin__no_interaction	Latrunculin B__Insulin__no_interaction	Docetaxel__Insulin__no_interaction	Prasterone__Insulin__no_interaction	Imatinib mesylate__Insulin__no_interaction	Nilotinib hydrochloride__Insulin__no_interaction	monohydrate__Insulin__no_interaction	glargine__Insulin__no_interaction	Bepridil__Insulin__no_interaction	Perospirone hydrochloride__Insulin__no_interaction	Varenicline tartrate__Insulin__no_interaction	Sorafenib__Insulin__no_interaction	Tamsulosin__Insulin__no_interaction	Paclitaxel__Insulin__no_interaction	tetracycline hydrochloride__Insulin__no_interaction	Mycophenolic acid sodium salt__Insulin__no_interaction	Ranelic acid distrontium salt__Insulin__no_interaction	Sitagliptin phosphate__Insulin__no_interaction	Risedronate__Insulin__no_interaction	Prasugrel__Insulin__no_interaction	Dapagliflozin__Insulin__no_interaction	Eplerenone__Insulin__no_interaction	Escitalopram__Insulin__no_interaction	bismuth__Insulin__no_interaction	Glimepiride/rosiglitazone maleate__Insulin__no_interaction	Silybin__Insulin__no_interaction	Pitavastatin__Insulin__no_interaction	paclitaxel__Insulin__no_interaction	Nalfurafine__Insulin__no_interaction	Landiolol__Insulin__no_interaction	Candesartan cilexetil__Insulin__no_interaction	Valsartan__Insulin__no_interaction	calcium__Insulin__no_interaction	Rosuvastatin calcium__Insulin__no_interaction	Irbesartan__Insulin__no_interaction	Tadalafil__Insulin__no_interaction	Dexmedetomidine hydrochloride__Insulin__no_interaction	Mipomersen sodium__Insulin__no_interaction
22619573-6	RESULTS: Flow cytometry and <compound-id="64966">MTT</compound-id> analysis revealed that <protein-id="O60235,B4DL57">hAT</protein-id>-MSCs exhibited a higher resistance toward H(2)O(2)-induced apoptosis (n = 3, hBM-<protein-id="O60235,B4DL57">hAT</protein-id> viability H(2)O(2)  58.43 ± 1.24-73.02 ± 1.44, P &lt; 0.02) and to serum-deprivation-induced apoptosis at days 1 and 4 than the hBM-MSCs (n = 3, <protein-id="O60235,B4DL57">hAT</protein-id>-hBM absorbance, resp., day 1: 0.305 ± 0.027-0.234 ± 0.015, P = 0.029, day 4: 0.355 ± 0.003-0.318 ± 0.007, P = 0.001, and day 7: 0.400 ± 0.017-0.356 ± 0.008, P = 0.672).	MTT__hAT__no_interaction
22617833-5	<compound-id="638015">Retinal</compound-id> macula thickness was significantly associated with the concentrations of the epidermal growth factor (P = 0.005; ρ = 0.45), <protein-id="P05362">ICAM-1</protein-id> (P &lt; 0.001; ρ = 0.65), <protein-id="P08700">IL-3</protein-id> (P = 0.002; ρ = 0.48), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (P = 0.003; ρ = 0.47), <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (P &lt; 0.001; ρ = 0.71), <protein-id="P13500">monocyte chemoattractant protein-1</protein-id> (P = 0.001; ρ = 0.53), <protein-id="Q07325">monokine induced by interferon gamma</protein-id> (P &lt; 0.001; ρ = 0.57), <protein-id="P14780">matrix metalloproteinase 9</protein-id> (P &lt; 0.001; ρ = 0.61), tissue growth factor beta (P = 0.01; ρ = 0.42), placenta growth factor (P = 0.004; ρ = 0.46), vascular cell adhesion molecule (P = 0.006; ρ = 0.44), and <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">vascular endothelial growth factor</protein-id> (P = 0.01; ρ = 0.42).	Retinal__IL-8__no_interaction	Retinal__IL-6__no_interaction	Retinal__IL-3__no_interaction	Retinal__vascular endothelial growth factor__no_interaction	Retinal__monocyte chemoattractant protein-1__no_interaction	Retinal__monokine induced by interferon gamma__no_interaction	Retinal__matrix metalloproteinase 9__no_interaction	Retinal__ICAM-1__no_interaction
7654199-1	The <compound-id="208,447096,65127">mannose 6-phosphate</compound-id> (Man6P)-dependent pathway for routing lysosomal enzymes was characterized in the hepatopancreas of the estuary crab Chasmagnatus granulata: (a) an acid alpha-L-fucosidase was purified to homogeneity from the above-mentioned organ and was shown to contain <compound-id="206">mannose</compound-id>-linked <compound-id="1061,167704,644102">phosphate</compound-id> residues; (b) high-<compound-id="206">mannose</compound-id>-type oligosaccharides isolated from a protein fraction enriched in acid hydrolases were found to contain acid-labile <compound-id="11861101,899">N-acetylglucosamine</compound-id> (<compound-id="24139">GlcNAc</compound-id>) residues; (c) a membrane-bound <compound-id="445675">UDP-GlcNAc</compound-id>:lysosomal enzyme <compound-id="24139">GlcNAc</compound-id>-1-phosphotransferase was detected that phosphorylated the estuary-crab alpha-L-fucosidase and bovine <protein-id="G3M8V1">uteroferrin</protein-id> but not bovine pancreas ribonuclease B; (d) a <compound-id="24139">GlcNAc</compound-id>-1-phosphodiester alpha-N-acetylglucosaminidase that released <compound-id="24139">GlcNAc</compound-id> units from <compound-id="24139">GlcNAc</compound-id> alpha 1-P6Man alpha 1-methyl was detected in microsomal membranes of the hepatopancreas; (e) two detergent-solubilized microsomal proteins having molecular masses of 205 and 215 kDa that were retained by a Man6P-rich <compound-id="870">mannan</compound-id>-<compound-id="11966311">Sepharose</compound-id> column, from where they were eluted with Man6P but not with <compound-id="5958">glucose 6-phosphate</compound-id>, were recognized by antisera raised against bovine large (215 kDa) and small (46 kDa) Man6P receptors.	UDP-GlcNAc__uteroferrin__no_interaction	mannan__uteroferrin__no_interaction	GlcNAc__uteroferrin__no_interaction	N-acetylglucosamine__uteroferrin__no_interaction	mannose__uteroferrin__no_interaction	phosphate__uteroferrin__no_interaction	glucose 6-phosphate__uteroferrin__no_interaction	mannose 6-phosphate__uteroferrin__no_interaction	Sepharose__uteroferrin__no_interaction
1333302-1	This study characterizes a congenital hemorrhagic disorder caused by a platelet function defect with the following features: (1) severely impaired platelet aggregation and fibrinogen or <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>) binding induced by <compound-id="6022">adenosine diphosphate</compound-id> (ADP); (2) defective aggregation, release reaction, and fibrinogen or <protein-id="P04275">vWF</protein-id> binding induced by other agonists; (3) normal aggregation and release reaction induced by high concentrations of <compound-id="90470996">thrombin</compound-id> or collagen; (4) no further inhibition by ADP scavengers of aggregation, release reaction, and fibrinogen or <protein-id="P04275">vWF</protein-id> binding, comparable with those observed for normal platelets in the presence of ADP scavengers; (5) normal membrane glycoprotein (GP) composition and normal binding of the anti-GP IIb/IIIa monoclonal antibody 10E5; (6) no acceleration by ADP of binding of the anti-GP IIb/IIIa monoclonal antibody 7E3; (7) normal platelet-fibrin clot retraction if induced by <compound-id="90470996">thrombin</compound-id> or reptilase plus <compound-id="5816">epinephrine</compound-id>, absent if induced by reptilase plus ADP; (8) no inhibition by ADP of the <compound-id="5280723">prostaglandin E1</compound-id>-induced increase in platelet cyclic <compound-id="6083">adenosine monophosphate</compound-id>, but normal inhibition by <compound-id="5816">epinephrine</compound-id>; (9) defective mobilization of cytoplasmic Ca2+ by ADP; (10) normal binding of 14C-ADP to fresh platelets, but defective binding of [2-3H]-ADP to <compound-id="712">formalin</compound-id>-fixed platelets.	formalin__von Willebrand factor__no_interaction	formalin__vWF__no_interaction	adenosine diphosphate__von Willebrand factor__no_interaction	adenosine diphosphate__vWF__no_interaction	prostaglandin E1__von Willebrand factor__no_interaction	prostaglandin E1__vWF__no_interaction	adenosine monophosphate__von Willebrand factor__no_interaction	adenosine monophosphate__vWF__no_interaction	thrombin__von Willebrand factor__no_interaction	thrombin__vWF__no_interaction	epinephrine__von Willebrand factor__no_interaction	epinephrine__vWF__no_interaction
23747344-6	Summarizing, the experimental data showed that (i) <compound-id="4369270">Dtx</compound-id> A and B exert potent antiproliferative activity in the micromolar and <compound-id="4369270">Dtx</compound-id> E in the nanomolar range in KB-3-1, A549, CaCo-2, and especially in HCT116 colon cancer cells, (ii) all three <compound-id="4369270">Dtx</compound-id> derivatives cause imbalance of cell cycle distribution, (iii) their cytostatic/cytotoxic effects are widely <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>-independent but reduced by <protein-id="P42857,B2R5R8">p21</protein-id>- and bax-deletion, respectively, (iv) cytotoxicity is based on intrinsic apoptosis induction and associated with <compound-id="16738692">phosphoinositide</compound-id>-3-kinase (PI3K)/Akt pathway inhibition, (v) anticancer activity of <compound-id="4369270">Dtx</compound-id> E but not <compound-id="4369270">Dtx</compound-id> A and B involves disturbance of the intracellular redox balance, (vi) <compound-id="4369270">Dtx</compound-id> inhibit the migration and tube formation of human endothelial cells indicating antiangiogenic potential, and (vii) all three <compound-id="4369270">Dtx</compound-id> derivatives possess ionophoric properties not differing in conductivity, ion selectivity and single channel kinetics.	Dtx__p21__no_interaction	Dtx__p53__no_interaction	phosphoinositide__p21__no_interaction	phosphoinositide__p53__no_interaction
22490197-6	RESULTS: After intervention, BMI ((25.53 ± 2.77) kg/m(2)), WHR (0.82 ± 0.03), TC ((4.60 ± 0.98) mmol/L), TG ((1.26 ± 0.88) mmol/L) in the intervention group were decreased significantly compared to the levels of BMI ((26.60 ± 3.18) kg/m(2)), WHR (0.93 ± 0.05), TC ((4.97 ± 1.02) mmol/L), TG ((1.98 ± 1.11) mmol/L) in the control group (all P values &lt; 0.05); while HDL-C ((1.34 ± 0.26) mmol/L) in the intervention group was increased significantly compared to the level of HDL-C ((1.18 ± 0.17) mmol/L) in the control group (P &lt; 0.05); After intervention, levels of T-AOC (19.52 ± 0.81), <protein-id="P00441,V9HWC9">SOD</protein-id> ((85.42 ± 21.65) U/ml) and <compound-id="124886">GSH</compound-id>-Px ((128.26 ± 33.65) µmol/L) were increased significantly compared to the levels of T-AOC (11.11 ± 1.30), <protein-id="P00441,V9HWC9">SOD</protein-id> ((78.68 ± 30.48) U/ml) and <compound-id="124886">GSH</compound-id>-Px ((118.48 ± 24.19) µmol/L) in the control group (all P values &lt; 0.05); while MDA ((1.78 ± 1.16) nmol/ml) decreased significantly compared to the level of MDA ((2.12 ± 1.37) nmol/ml in the control group (P &lt; 0.05); Pearson product moment correlation analysis showed that: T-AOC with TC, TG, BMI showed a negative correlation (r values were -0.258, -0.266, -0.230, respectively, all P values &lt; 0.05), while with HDL-C was a positive correlation (r values was 0.194, P &lt; 0.05); <protein-id="P00441,V9HWC9">SOD</protein-id> with TC, TG, BMI showed a negative correlation (r values were -0.282, -0.311, -0.217, respectively, all P values &lt; 0.05), while with HDL-C was a positive correlation (r values was 0.169, P &lt; 0.05).	GSH__SOD__no_interaction
24122953-7	A multivariate <protein-id="P10176,Q53XN1">Cox</protein-id> proportional hazards analysis was conducted and total <compound-id="5280352">bilirubin</compound-id> (P &lt; 0.001, hazard ratio [HR] = 2.09, 95% confidence interval [CI] = 1.35-3.21), international normalized ratio (INR) (P &lt; 0.001, HR = 9.83, 95% CI = 4.51-21.45), serum <compound-id="5360545">sodium</compound-id> levels (P = 0.03, HR = 0.96, 95% CI = 0.92-0.99), ascites (P = 0.001, HR = 2.59, 95% CI = 1.44-4.64), and categorized age (0-1 versus ≥ 1 year old) (P = 0.025, HR = 2.33, 95% CI = 1.11-4.86) were independently associated with risk of death in 90 days.	bilirubin__Cox__no_interaction	sodium__Cox__no_interaction
24338217-6	In patients bearing 2-4 genotypes of <protein-id="P42898,Q8IU67,Q59GJ6">MTHFR</protein-id> 677C/C, <protein-id="P42898,Q8IU67,Q59GJ6">MTHFR</protein-id> 1298 A/C or C/C, <protein-id="Q9UNQ0,A0A024RDD4">ABCG2</protein-id> <compound-id="1151030">34G</compound-id>/G, and <protein-id="Q9UNQ0,A0A024RDD4">ABCG2</protein-id> 421C/A or A/A, those who received oxaliplatin-based chemotherapy achieved a higher RR (41.7 vs. 18.8 %, P = 0.027) and longer median PFS (mPFS) than <compound-id="60838">irinotecan</compound-id>-based therapy [8.9 vs. 7.1 m, <compound-id="56842117">FOLFIRI</compound-id>: hazard ratio (HR) = 1.722, 95 % confidence interval (CI) 1.026-2.892, P = 0.040, compared with <compound-id="56842121">FOLFOX</compound-id>/XELOX]; on the contrary, patients carrying 0 or 1 above genotype exhibited better outcomes after receiving <compound-id="56842117">FOLFIRI</compound-id> chemotherapy (mPFS: 9.3 vs. 6.4 m, <compound-id="56842117">FOLFIRI</compound-id>: HR = 0.422, 95 % CI 0.205-0.870, P = 0.019, compared with <compound-id="56842121">FOLFOX</compound-id>/XELOX).	FOLFOX__MTHFR__no_interaction	FOLFOX__ABCG2__no_interaction	irinotecan__MTHFR__no_interaction	irinotecan__ABCG2__no_interaction	34G__MTHFR__no_interaction	34G__ABCG2__no_interaction	FOLFIRI__MTHFR__no_interaction	FOLFIRI__ABCG2__no_interaction
21699193-1	We report the first insertion step at a metal center for the catalytic dehydropolymerization of <protein-id="P68431">H(3)B</protein-id>·<compound-id="192942">NMeH</compound-id>(2) to form the simplest oligomeric species, <protein-id="P68431">H(3)B</protein-id>·NMeHBH(2)·<compound-id="192942">NMeH</compound-id>(2), by the addition of 1 equiv of <protein-id="P68431">H(3)B</protein-id>·<compound-id="192942">NMeH</compound-id>(2) to [Ir(<compound-id="5289124">PCy</compound-id>(3))(2)(H)(2)(η(2)-<protein-id="P68431">H(3)B</protein-id>·<compound-id="192942">NMeH</compound-id>(2))][BAr(F)(4)] to give [Ir(<compound-id="5289124">PCy</compound-id>(3))(2)(H)(2)(η(2)-<protein-id="P68431">H(3)B</protein-id>·NMeHBH(2)·<compound-id="192942">NMeH</compound-id>(2))][BAr(F)(4)].	PCy__H(3)B__no_interaction	NMeH__H(3)B__no_interaction
23582092-5	With multivariate <protein-id="P10176,Q53XN1">Cox</protein-id> regression analysis, New York Heart Association functional class ≥III (hazard ratio [HR] 9.36, 95% confidence interval [CI] 2.11-41.4; P = .003), <compound-id="2724385">digoxin</compound-id> use (HR 6.36, 95% CI 2.18-18.6; P = .0010), FMD (HR 0.703, 95% CI 0.547-0.904; P = .006), PSR (HR 1.01, 95% CI 1.005-1.022; P = .001), <compound-id="44232355">FVD</compound-id> (HR 1.04, 95% CI 1.00-1.06; P = .02), and nFMD (HR 0.535, 95% CI 0.39-0.74; P = .0001) were predictors of unfavorable outcome.	FVD__Cox__no_interaction	digoxin__Cox__no_interaction
11456544-0	Characterization of the O(2)-evolving reaction catalyzed by [(<compound-id="70848">terpy</compound-id>)(H2O)Mn(III)(O)2Mn(IV)(OH2)(<compound-id="70848">terpy</compound-id>)](<protein-id="P41271,A0A087WTY6">NO3)3</protein-id> (<compound-id="70848">terpy</compound-id> = 2,2':6,2"-terpyridine).	terpy__NO3)3__no_interaction
9973219-7	The results revealed that: (a) CENU-<compound-id="4571095">lex</compound-id> preferentially induces N3-Alkyl-A at specific <compound-id="4571095">lex</compound-id> equilibrium binding sites, the formations of which are strongly inhibited by <compound-id="3115">distamycin</compound-id>; (b) reactivity toward Gs is still present, albeit to a lesser extent when compared to <compound-id="3041706">N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea</compound-id> and to CENU; (c) 91% of the 49 CENU-<compound-id="4571095">lex</compound-id> <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> mutations (45 of 49) were bp substitutions, 29 of which were GC--&gt;AT transitions, mainly at 5' purine G sites; (d) all AT-targeted mutations but one were AT--&gt;TA transversions; (e) the distribution of the CENU-<compound-id="4571095">lex</compound-id> mutations along the <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> cDNA was not random, with position 273 (codon 91), where only GC--&gt;AT transitions were observed, being a real (n = 3, P &lt; 0.0002) CENU-<compound-id="4571095">lex</compound-id> mutation hot spot; and (f) a shift in DNA alkylation sites between lesion spectra induced by CENU-<compound-id="4571095">lex</compound-id> and N-(2-chloroethyl-N-<compound-id="160550">cyclohexyl-N-nitrosourea</compound-id> was associated with an increased lethality and a decreased mutagenicity, whereas no dramatic change in mutational specificity was observed.	lex__p53__no_interaction	distamycin__p53__no_interaction	cyclohexyl-N-nitrosourea__p53__no_interaction	N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea__p53__no_interaction
22790974-1	A (3, 4, 14)-connected framework with complicated distorted triangular magnetic lattices, {[Co(7)(H(2)O)(4)(trz)(8)(sip)(2)]·3H(2)O}(n) (trz = 1,2,4-triazolate, sip = 5-<compound-id="15279310">sulfoisophthalate</compound-id>), exhibits continuous field-induced metamagnetic transition from an antiferromagnetic ordering to a ferrimagnetic state at 15 kOe, <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> competition at 26 kOe and <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> reorientation at 50 kOe, respectively.	sulfoisophthalate__spin__no_interaction
21956531-6	However, women without <protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id> gene polymorphism at position -786T&gt;C (TT genotype) and Intron 4b/a (bb genotype) presented a better reduction of total <compound-id="5997">cholesterol</compound-id> levels (-786T&gt;C: before = 213 ± 12.1, after = 159.8 ± 14.4, Δ = -24.9% and Intron 4b/a: before = 211.8 ± 7.4, after = 180.12 ± 6.4 mg/dL, Δ = -15%), and LDL <compound-id="5997">cholesterol</compound-id> (-786T&gt;C: before = 146.1 ± 13.3, after = 82.8 ± 9.2, Δ = -43.3% and Intron 4b/a: before = 143.2 ± 8, after = 102.7 ± 5.8 mg/dL, Δ = -28.3%) in response to ET compared to those who carried the mutant allele.	cholesterol__eNOS__no_interaction
9088856-4	Basal serum <protein-id="P41159,A4D0Y8">leptin</protein-id> concentration correlated positively with body mass index (r = 0.42, P &lt; 0.05), serum cortisol concentration (r = 0.70, P &lt; 0.001) and the rise in muscle <compound-id="439177">glycogen</compound-id> content during the clamp (r = 0.43, P &lt; 0.05) and inversely with serum <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> concentration (r = -0.43, P &lt; 0.05).	glycogen__leptin__no_interaction	glycogen__growth hormone__no_interaction
19767812-5	Results showed that, following <compound-id="2519,57106085">caffeine</compound-id> ingestion: (i) both systolic and diastolic blood pressure (SBP and <protein-id="Q10586">DBP</protein-id>, respectively) increased significantly (p &lt; 0.05) in the older women (SBP, 128.4 +/- 14.2 vs. 132.1 +/- 13.0 mm Hg (3%); <protein-id="Q10586">DBP</protein-id>, 80.2 +/- 6.9 vs. 83.4 +/- 7.5 mm Hg (4%), whereas only <protein-id="Q10586">DBP</protein-id> increased in the younger women (67.1 +/- 4.7 vs. 69.9 +/- 5.4 mm Hg (4.2%); p &lt; 0.05); (ii) heart rate decreased significantly (Y, 59.2 +/- 8.7 to 53.9 +/- 10.6 beats.<protein-id="P13987,Q6FHM9">min-1</protein-id> (p &lt; 0.05); O, 61.9 +/- 9.2 to 59.2 +/- 8.4 beats.<protein-id="P13987,Q6FHM9">min-1</protein-id> (p &lt; 0.05)) in both groups; and (iii) self-reported feelings of tension and vigor increased and feelings of fatigue decreased (p &lt; 0.05) in younger women, whereas depression decreased (p &lt; or = 0.05) in older women.	caffeine__DBP__no_interaction	caffeine__min-1__no_interaction
20799741-4	Complexes [Pd(C,N-C(6)H(4)CH(2)NR(2)-2)(mu-Cl)](2) (R = Me, H) react (i) with [Tl(2){S(2)C=C{C(O)Me}(2)}] and [PPN]Cl (0.5:1:1, PPN = Ph(3)P=N=<protein-id="P60510,A0A024R625,P06733,A0A024R4F1,E2DRY6">PPh(3</protein-id>)) to form PPN[Pd(C,N-C(6)H(4)CH(2)NR(2)-2){S,S-S(2)C=C{C(O)Me}(2)}] [R = H (5a), Me (<compound-id="18445697">5b</compound-id>)], or (ii) with [Tl(2){S(2)C=C{C(O)Me}(2)}] (1:1) to form [{Pd(C,N-C(6)H(4)CH(2)NR(2)-2)}(2){mu-S,S,O-S(2)C=C{C(O)Me}(2)}] [R = H (6a), Me (6b)].	5b__PPh(3__no_interaction
8720536-4	RESULTS: NIDDM patients without ICA showed higher BP (140/86 +/- 2/1 mmHg vs. 128/79 +/- 3/2 mmHg; P &lt; 0.05), total <compound-id="5997">cholesterol</compound-id> (6.10 +/- 0.11 vs. 5.09 +/- 0.29 mmol/l; P &lt; 0.01), LDL-to-<protein-id="P28845,X5D2L1">HDL</protein-id> ratio (3.85 +/- 0.14 vs. 2.49 +/- 0.18; P &lt; 0.001), and triglycerides (2.58 +/- 0.24 vs. 0.90 +/- 0.06 mmol/l; P &lt; 0.001), lower <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (1.08 +/- 0.03 vs. 1.40 +/- 0.08 mmol/l; P &lt; 0.001), and higher urinary <protein-id="P02768">albumin</protein-id> excretion (0.16 +/- 0.06 vs. 0.01 +/- 0.01 g/24 h; P &lt; 0.05) than NIDDM patients with ICA.	cholesterol__albumin__no_interaction	cholesterol__HDL__no_interaction
7932532-5	This information was used to aid in the design of a series of novel, <compound-id="8871">pyridone</compound-id>-containing, non-peptidic <protein-id="P08246">HLE</protein-id> inhibitors such as 2-[3-[[(benzyloxy)carbonyl]amino]-2-oxo- 1,2-dihydro-1-pyridyl]-N-(3,3,3-trifluoro-1-<compound-id="6334">isopropyl</compound-id>-2-oxopropyl)ace tam ide (<compound-id="18445697">5b</compound-id>) (Ki = 280 +/- 78 nM).	pyridone__HLE__no_interaction	isopropyl__HLE__no_interaction	5b__HLE__no_interaction
16254868-5	RESULTS: Individuals who recovered from a bulimic-type eating disorder had significantly lower activation in the right anterior cingulate cortex (<protein-id="Q13085,B2ZZ90,A0A024R0Y2,Q7Z5W8">ACC</protein-id>; Montreal Neurological Institute [<compound-id="15959255">MNI</compound-id>] coordinates x = 8, y = 22, z = 28; cluster size = 18 voxels, T = 5.11, Z-score = 3.78) and in the left cuneus (occipital cortex; <compound-id="15959255">MNI</compound-id> coordinates x = -12, y = -78, z = 10; cluster size = 21 voxels, T = 4.27, Z-score = 3.36), when <compound-id="206,64689">glucose</compound-id> was compared with artificial saliva.	MNI__ACC__no_interaction	glucose__ACC__no_interaction
18672196-5	Compared with <protein-id="P19429,Q6FGX2">cTnI</protein-id>- patients, the hearts of <protein-id="P19429,Q6FGX2">cTnI</protein-id>+ patients (<protein-id="P19429,Q6FGX2">cTnI</protein-id> &gt; or = 0.01 ng/mL, n = 19) were significantly more dilated (left ventricular end-diastolic diameter 67 vs 61 mm, P &lt; .05; left ventricular end-systolic dimension, 55 vs 49 mm, P &lt; .01; echocardiography) and demonstrated greater intracardiac volumes (left ventricular end-diastolic volume 161 vs 132 mL, P = .060; left ventricular end-systolic volume 112 vs 82 mL, P &lt; .05; gated single photon emission computed tomography), more disturbed systolic (ejection fraction 27 vs 33%, P &lt; .05; gated single photon emission computed tomography) and cardiac sympathetic (<compound-id="105140">123I</compound-id>-<compound-id="60860">metaiodobenzylguanidine</compound-id> washout: 41% vs 34%; P &lt; .05) function, and higher levels of vasoactive peptides (N-terminal proatrial natriuretic peptide 1030 vs 558 pmol/L, P &lt; .05; N-terminal pro-B type natriuretic peptide 337 vs 115 pmol/L, P &lt; .05).	123I__cTnI__no_interaction	metaiodobenzylguanidine__cTnI__no_interaction
21047927-4	RESEARCH DESIGN AND METHODS: A 4-h 2200 KJ-liquid meal test was performed in 10 healthy Caucasian males without family history of diabetes [age, 24 ± 3 yr (mean ± sd); body mass index, 24 ± 2 kg/m(2); fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id>, 4.9 ± 0.3 mm; hemoglobin A(1)c, 5.4 ± 0.1%] before and after intervention using high-calorie diet, relative physical inactivity, and administration of <compound-id="5755">prednisolone</compound-id> (37.5 mg/d) for 12 d. RESULTS: The intervention resulted in <protein-id="P01308,I3WAC9">insulin</protein-id> resistance according to the homeostatic model assessment [1.1 ± 0.3 vs. 2.3 (mean ± <compound-id="5289348">SEM</compound-id>) ± 1.3; P = 0.02] and increased postprandial <compound-id="206,5793,64689,79025">glucose</compound-id> excursions [area under curve (AUC), 51 ± 28 vs. 161 ± 32 mm · 4 h; P = 0.045], fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (36 ± 3 vs. 61 ± 6 pm; P = 0.02), and postprandial <protein-id="P01308,I3WAC9">insulin</protein-id> responses (AUC, 22 ± 6 vs. 43 ± 13 nm · 4 h; P = 0.03).	SEM__insulin__no_interaction	prednisolone__insulin__no_interaction	glucose__insulin__no_interaction
21047927-5	This disruption of <compound-id="206,5793,64689,79025">glucose</compound-id> homeostasis had no impact on postprandial <protein-id="P01275">GLP-1</protein-id> responses (AUC, 1.5 ± 0.7 vs. 2.0 ± 0.5 nm · 4 h; P = 0.56), but resulted in exaggerated postprandial <protein-id="P09681">GIP</protein-id> (6.2 ± 1.0 vs. 10.0 ± 1.3 nm · 4 h; P = 0.003) and glucagon responses (1.6 ± 1.5 vs. 2.4 ± 3.2; P = 0.007).	glucose__GLP-1__no_interaction	glucose__GIP__no_interaction
9368509-9	Significant positive correlations were evident between <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> and alkaline phosphatase up to term (r = 0.051, P &lt; 0.001) and between <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> and <compound-id="5280453">calcitriol</compound-id> (r = 0.46, P &lt; 0.001), <protein-id="P02818">osteocalcin</protein-id> (r = 0.23, P &lt; 0.05) and <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> (r = 0.41, P &lt; 0.05) during pregnancy.	calcitriol__prolactin__no_interaction	calcitriol__osteocalcin__no_interaction	calcitriol__PTHrP__no_interaction
2375957-2	Interspecific comparisons including human (HS) blood data revealed unusual rheological properties of seal blood relative to that from pigs or man: 1) RBC aggregation extent, rate and sedimentation were lower for seals (<compound-id="15942654">AI</compound-id> = 0, ZSR = .40, <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR</protein-id> = 0 for <compound-id="7021454">RS</compound-id> blood) relative to humans; 2) Viscous (n') and elastic (n") components of complex viscosity (OCRD) were lower for both seal species relative to SS blood, but only at shear rates less than or equal to 10 sec-1 (P less than 0.05), while n"/n' ratios for <compound-id="7021454">RS</compound-id> blood were lower than HS blood at all shear rates (P less than 0.01); 3) Blood viscosity measurements for <compound-id="7021454">RS</compound-id> and SS blood from rotational viscometry (Contraves) were consistent with OCRD data; 4) Seal plasma fibrinogen levels were low compared to pigs or humans (<compound-id="7021454">RS</compound-id> fibrinogen = -43% v. HS and -57% v. SS; ES fibrinogen = -58% v. HS and -69% v. SS).	AI__ESR__no_interaction	RS__ESR__no_interaction
19701972-5	sICAM-l in IBD patients was found to be closely related to the levels of <protein-id="P14920,A0A024RBI1">DAO</protein-id> and <compound-id="61503">D-lactate</compound-id> (212.94 +/- 69.89 vs 6.35 +/- 2.35, P = 0.000), <protein-id="P14920,A0A024RBI1">DAO</protein-id> 212.94 +/- 69.89 vs 8.65 +/- 3.54, P = 0.000) and WBC (212.94 +/- 69.89 vs 7.40 +/- 2.61, P = 0.000), but no significant difference was observed between patients with ulcerative colitis and patients with Crohn's disease.	D-lactate__DAO__no_interaction
22377712-3	To examine the association of type 2 diabetes susceptibility loci and visceral fat accumulation, we genotyped 1279 Japanese subjects (556 men and 723 women), who underwent computed tomography for measurements of visceral fat area (VFA) and subcutaneous fat area (SFA) for the following single-nucleotide polymorphisms (SNPs): <protein-id="Q04721,Q6IQ50,Q9UFD5">NOTCH2</protein-id> rs10923931, <protein-id="Q6YHU6">THADA</protein-id> rs7578597, <protein-id="P37231,D2KUA6,E9PFX5">PPARG</protein-id> rs1801282, <protein-id="Q9P2N4">ADAMTS9</protein-id> rs4607103, <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">IGF2BP2</protein-id> rs1470579, <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGFA</protein-id> rs9472138, <protein-id="Q86VZ6">JAZF1</protein-id> rs864745, <protein-id="Q8N726,P42771,K7PML8,G3XAG3">CDKN2A</protein-id>/<protein-id="P42772,K7PPU3">CDKN2B</protein-id> rs564398 and rs10811661, <protein-id="Q03014">HHEX</protein-id> rs1111875 and rs5015480, <protein-id="Q9NQB0,C6ZRK5,E2GH26,C6ZRJ7,Q6FHW4,C6ZRJ9,A0A0D9SGH8,E2GH16,C6ZRK1,A0A0A0MTL7,E2GH18,E2GH13,C6ZRK2">TCF7L2</protein-id> rs7901695, <protein-id="P51787,Q96AI9">KCNQ1</protein-id> rs2237892, <protein-id="Q14654,B2RC52">KCNJ11</protein-id> rs5215 and rs5219, <protein-id="Q93063,D3DR24">EXT2</protein-id> rs1113132, rs11037909, and rs3740878, <protein-id="P49286">MTNR1B</protein-id> rs10830963, <compound-id="8987">DCD</compound-id> rs1153188, <protein-id="P19075">TSPAN8</protein-id>/<protein-id="O75473,A0A0A8K8C7">LGR5</protein-id> rs7961581, and <protein-id="Q9C0B1,B3KU60,Q99770">FTO</protein-id> rs8050136 and rs9939609.	DCD__CDKN2B__no_interaction	DCD__LGR5__no_interaction	DCD__KCNJ11__no_interaction	DCD__CDKN2A__no_interaction	DCD__EXT2__no_interaction	DCD__ADAMTS9__no_interaction	DCD__JAZF1__no_interaction	DCD__NOTCH2__no_interaction	DCD__KCNQ1__no_interaction	DCD__PPARG__no_interaction	DCD__HHEX__no_interaction	DCD__VEGFA__no_interaction	DCD__TCF7L2__no_interaction	DCD__MTNR1B__no_interaction	DCD__TSPAN8__no_interaction	DCD__IGF2BP2__no_interaction	DCD__THADA__no_interaction	DCD__FTO__no_interaction
12051750-5	Using this assay system, we have identified a novel synthetic small molecule, APC0576, <compound-id="10200597">5-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)-2-(4-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)phenoxy)pyridine</compound-id>, as an inhibitor of <protein-id="P01583">IL-1</protein-id>-induced NF-kappaB-dependent gene activation without any adverse effects on the cell viability.	5-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)-2-(4-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)phenoxy)pyridine__IL-1__no_interaction
23511720-1	A monoanionic amido-imino ligand system [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)](-) was successfully employed for the synthesis of monomeric dichloro [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)]LnCl2(<compound-id="8028">THF</compound-id>)2 (Ln = Y, 2Y; Lu, 2Lu) and <protein-id="O95817">bis</protein-id>(alkyl) [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)]Ln(CH2SiMe3)2(<compound-id="8028">THF</compound-id>) (Ln = Y, 4Y; Lu, 4Lu) species of <compound-id="23993">yttrium</compound-id> and <compound-id="23929">lutetium</compound-id>.	THF__bis__no_interaction	yttrium__bis__no_interaction	lutetium__bis__no_interaction
18937451-1	The magnetic properties and results from X-ray structure analysis for a new pair of <compound-id="23925,67172434">iron</compound-id>(II) <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-crossover complexes [FeL1(meim) 2](meim) ( 1(meim)) and [Fe <compound-id="73441667">2L2</compound-id>(meim) 4](meim) 4 ( 2(meim) 4), with L1 being a tetradentate N 2O 2 (2-) coordinating Schiff-base-like ligand [([3,3']-[<compound-id="13256786">1,2-phenylenebis</compound-id>(iminomethylidyne)]bis(2,4-<compound-id="8003">pentane</compound-id>-dionato)(2-)N,N',O (2),O (2)'], L2 being an octadentate, dinucleating N 2O 2 (2-) coordinating Schiff-base-like ligand [3,3',3'',3''']-[1,2,4,5-phenylenetetra(iminomethylidyne)]tetra(2,4-pentanedionato)(2-) N, N', N'', N''', O (2), O (2) ', O (2) '', O (2) '''], and meim being <compound-id="1390">N-methylimidazole</compound-id>, are discussed in this work.	N-methylimidazole__spin__no_interaction	pentane__spin__no_interaction	1,2-phenylenebis__spin__no_interaction	iron__spin__no_interaction	2L2__spin__no_interaction
12081587-4	RESULTS: The increase in <protein-id="P02768">albumin</protein-id> synthesis on feeding was impaired in <compound-id="124226">HHD</compound-id> patients (fasting 15.0 +/- 1.5 vs. fed 17.7 +/- 2.9%, P = NS) compared to <compound-id="440334,4481">NHD</compound-id> (fasting 13.7 +/- 0.9 vs. fed 17.4 +/- 1.0%, P &lt; 0.05) and controls (fasting 12.9 +/- 0.6 vs. fed 15.2 +/- 0.6%, P &lt; 0.05).	NHD__albumin__no_interaction	HHD__albumin__no_interaction
19352535-1	The complexes [(eta-C(5)Me(5))(ON)<compound-id="70678409">LMn</compound-id>(micro-CN)M(CO)(RC[triple bond, length as m-dash]CR)Tp'](+) (L = CNXyl, M = Mo; L = CNBu(t), M = Mo or W, R = Ph or Me) and trans- or cis-[(<compound-id="74952">dppm</compound-id>){(<protein-id="Q06455,W8FW32,A0A087WWT6,B2R6I9,A0A0A0MSU1">EtO</protein-id>)(3)P}(OC)(2)Mn(micro-CN)M(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](+), and their linkage isomers [(eta-C(5)Me(5))(ON)<compound-id="70678409">LMn</compound-id>(micro-NC)M(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](+) and trans- or cis-[(<compound-id="74952">dppm</compound-id>){(<protein-id="Q06455,W8FW32,A0A087WWT6,B2R6I9,A0A0A0MSU1">EtO</protein-id>)(3)P}(OC)(2)Mn(micro-NC)M(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](+), undergo two one-electron oxidations.	dppm__EtO__no_interaction	LMn__EtO__no_interaction
19352535-6	Significantly longer Mn-P bond distances in trans-[(<compound-id="74952">dppm</compound-id>){(<protein-id="Q06455,W8FW32,A0A087WWT6,B2R6I9,A0A0A0MSU1">EtO</protein-id>)(3)P}(OC)(2)Mn(micro-NC)Mo(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](2+) than in trans-[(<compound-id="74952">dppm</compound-id>){(<protein-id="Q06455,W8FW32,A0A087WWT6,B2R6I9,A0A0A0MSU1">EtO</protein-id>)(3)P}(OC)(2)Mn(micro-NC)Mo(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](+) are consistent with one-electron oxidation first at Mn(I); the alignment of the (CN)Mn(CO)(2){P(<compound-id="6324">OEt</compound-id>)(3)}(<compound-id="74952">dppm</compound-id>) fragment relative to the alkyne in trans-[(<compound-id="74952">dppm</compound-id>){(<protein-id="Q06455,W8FW32,A0A087WWT6,B2R6I9,A0A0A0MSU1">EtO</protein-id>)(3)P}(OC)(2)Mn(micro-NC)Mo(CO)(PhC[triple bond, length as m-dash]CPh)Tp'](+) suggests it acts as a pi-acceptor, in contrast to related species such as trans-(NC)Mn(CO)(2){P(<compound-id="6324">OEt</compound-id>)(3)}(<compound-id="74952">dppm</compound-id>) and (NC)Mn(NO){P(OPh)(3)}(pi-C(5)H(4)Me) which behave as simple N-donors.	dppm__EtO__no_interaction	OEt__EtO__no_interaction
14685303-3	This issue focuses on the following selection of drugs: <compound-id="16131215">Abarelix</compound-id>, <compound-id="449200">ABX</compound-id>-EGF, <compound-id="34756">ademetionine</compound-id>, <compound-id="82148">agomelatine</compound-id>, AMGN-0007, <compound-id="72402">9-aminocamptothecin</compound-id>, AN-9, <compound-id="111332">anecortave</compound-id> <compound-id="176">acetate</compound-id>, <compound-id="166548">anidulafungin</compound-id>, <compound-id="71300630">AOD-9604</compound-id>, apolizumab, apomate, L-<compound-id="90867653">arginine</compound-id> hydrochloride, <compound-id="179337">arzoxifene</compound-id> hydrochloride; Bevacizumab, BP-897, BufferGel; <compound-id="1783">Capravirine</compound-id>, <compound-id="108144">carboxyamidotriazole</compound-id>, <compound-id="439224">carnosine</compound-id>, CC-4047, CEP-701, <compound-id="446156">cerivastatin sodium</compound-id>, <compound-id="119182">clofarabine</compound-id>, <compound-id="151171">conivaptan hydrochloride</compound-id>, <compound-id="6445782">CP-461</compound-id>, CS-003; <compound-id="16129629,16129688,16134395,21585658,25246315,46930993,57011757,57336511,71311849">Daptomycin</compound-id>, <compound-id="444031">darifenacin</compound-id>, <compound-id="451668">decitabine</compound-id>, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="60835">duloxetine</compound-id> hydrochloride; <compound-id="72051">Eberconazole</compound-id>, <compound-id="176885">Ecyd</compound-id>, efalizumab, <compound-id="213056">eglumegad hydrate</compound-id>, EMD-72000, (-)-epigallocatechin gallate, <compound-id="151115">exatecan mesilate</compound-id>, <compound-id="45588096,53396299,56927919">exenatide</compound-id>; <compound-id="1727">Fampridine</compound-id>, <compound-id="5288209">fenretinide</compound-id>, ferumoxtran-10; <compound-id="9919137">Gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="124093">garenoxacin mesilate</compound-id>, <compound-id="5280961">genistein</compound-id>, <compound-id="5961">glutamine</compound-id>, <compound-id="3038498">GPI-15715</compound-id>; Hexyl <protein-id="P01308,I3WAC9">insulin</protein-id> M2, human <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="445659">HYB</compound-id>-165; <compound-id="216468">Indisulam</compound-id>, <compound-id="148189">irofulven</compound-id>; KRN-5500, L-796568, <compound-id="42981">laurocapram</compound-id>, <compound-id="9911821">lidocaine/prilocaine</compound-id>, <compound-id="148195">lonafarnib</compound-id>, <compound-id="80274">lotrafiban</compound-id>; <compound-id="183797">Melagatran</compound-id>, <compound-id="896">melatonin</compound-id>, <compound-id="66414">2-methoxyestradiol</compound-id>, metreleptin, motexafin gadoliniu, <compound-id="151071">motexafin lutetium</compound-id>; Natalizumab, <compound-id="3011155">nelarabine</compound-id>, <compound-id="9818919">NO-aspirin</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; <compound-id="100594">ONO-6126</compound-id>; <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, pexelizumab, <compound-id="40632">pirfenidone</compound-id>, PncCRM9, polyglutamate <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id>, <compound-id="16132446">pramlintide acetate</compound-id> <compound-id="5486971">pregabalin</compound-id>, <compound-id="8420">PRO-2000</compound-id>; <compound-id="447458">Ragaglitazar</compound-id>, <compound-id="208902">ramelteon</compound-id>, <compound-id="3052776">rasagiline</compound-id> mesilate, rDNA <protein-id="P01308,I3WAC9">insulin</protein-id>, recombinant <compound-id="16133831">glucagon-like peptide-1 (7-36) amide</compound-id>, recombinant human parathyroid hormone (1-84), reolysin RG228, <compound-id="449193">roflumilast</compound-id>, <compound-id="177230">roxifiban acetate</compound-id>, RPI-4610, <compound-id="472335">rubitecan</compound-id>; <compound-id="131682">Safinamide mesilate</compound-id>, <compound-id="154059">solifenacin</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="446313">SRL</compound-id>-172; T-138067, <compound-id="115358">tafenoquine succinate</compound-id>, <compound-id="158795">tecadenoson</compound-id>, TER-286, <compound-id="208901">tesaglitazar</compound-id>, tetrathiomolybdate, <compound-id="151174">tezosentan disodium</compound-id>, TheraCIM, <compound-id="54686904">tigecycline</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="216237">tolvaptan</compound-id>, <compound-id="108150">trabectedin</compound-id>, <compound-id="6050">tributyrin</compound-id>, <compound-id="68926">trimegestone</compound-id>, <compound-id="151173,454194">troxacitabine</compound-id>; UCN-01, urokinase alfa; <compound-id="10629256,157688,6918295">Vinflunine</compound-id>, viscum fraxini 2; Xcellerated T cells, <compound-id="46783262,5478933,656635,71433741,9574101">ximelagatran</compound-id>.	lonafarnib__insulin__no_interaction	Ragaglitazar__insulin__no_interaction	HYB__insulin__no_interaction	rubitecan__insulin__no_interaction	eglumegad hydrate__insulin__no_interaction	PRO-2000__insulin__no_interaction	agomelatine__insulin__no_interaction	deferasirox__insulin__no_interaction	NSC-683864__insulin__no_interaction	acetate__insulin__no_interaction	Capravirine__insulin__no_interaction	troxacitabine__insulin__no_interaction	ONO-6126__insulin__no_interaction	cerivastatin sodium__insulin__no_interaction	Ecyd__insulin__no_interaction	trabectedin__insulin__no_interaction	melatonin__insulin__no_interaction	exatecan mesilate__insulin__no_interaction	ademetionine__insulin__no_interaction	ximelagatran__insulin__no_interaction	motexafin lutetium__insulin__no_interaction	conivaptan hydrochloride__insulin__no_interaction	rasagiline__insulin__no_interaction	tolvaptan__insulin__no_interaction	lotrafiban__insulin__no_interaction	sodium__insulin__no_interaction	GPI-15715__insulin__no_interaction	tecadenoson__insulin__no_interaction	nelarabine__insulin__no_interaction	anidulafungin__insulin__no_interaction	Safinamide mesilate__insulin__no_interaction	genistein__insulin__no_interaction	Eberconazole__insulin__no_interaction	ramelteon__insulin__no_interaction	exenatide__insulin__no_interaction	glutamine__insulin__no_interaction	garenoxacin mesilate__insulin__no_interaction	tigecycline__insulin__no_interaction	Melagatran__insulin__no_interaction	pregabalin__insulin__no_interaction	Pemetrexed disodium__insulin__no_interaction	pirfenidone__insulin__no_interaction	solifenacin__insulin__no_interaction	roxifiban acetate__insulin__no_interaction	darifenacin__insulin__no_interaction	Abarelix__insulin__no_interaction	anecortave__insulin__no_interaction	clofarabine__insulin__no_interaction	tipifarnib__insulin__no_interaction	roflumilast__insulin__no_interaction	tesaglitazar__insulin__no_interaction	arginine__insulin__no_interaction	SRL__insulin__no_interaction	pramlintide acetate__insulin__no_interaction	irofulven__insulin__no_interaction	lidocaine/prilocaine__insulin__no_interaction	ABX__insulin__no_interaction	carboxyamidotriazole__insulin__no_interaction	CP-461__insulin__no_interaction	fenretinide__insulin__no_interaction	glucagon-like peptide-1 (7-36) amide__insulin__no_interaction	tezosentan disodium__insulin__no_interaction	AOD-9604__insulin__no_interaction	Daptomycin__insulin__no_interaction	9-aminocamptothecin__insulin__no_interaction	trimegestone__insulin__no_interaction	Vinflunine__insulin__no_interaction	paclitaxel__insulin__no_interaction	tributyrin__insulin__no_interaction	Indisulam__insulin__no_interaction	tafenoquine succinate__insulin__no_interaction	2-methoxyestradiol__insulin__no_interaction	arzoxifene__insulin__no_interaction	laurocapram__insulin__no_interaction	NO-aspirin__insulin__no_interaction	carnosine__insulin__no_interaction	decitabine__insulin__no_interaction	Fampridine__insulin__no_interaction	succinate__insulin__no_interaction	Gadofosveset__insulin__no_interaction	duloxetine__insulin__no_interaction
21905260-7	DAS28 (mean ± SD 3.6 ± 1.2 versus 3.9 ± 1.5; P &lt; 0.02), ESR (mean ± SD 24 ± 18 versus 29 ± 24 mm/hour; P = 0.05), and <protein-id="P02741">CRP</protein-id> level (mean ± SD 1.2 ± 1.3 versus 1.6 ± 1.5 mg/dl; P &lt; 0.03) were lower in the high-adherence group compared to those with low <compound-id="126941">MTX</compound-id> adherence.	MTX__CRP__no_interaction
19217535-3	The validation results were shown as follows: (1) in specificity study, <compound-id="18950,206">mannose</compound-id>, <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and ClDG could be completely separated and the retention times of these were 6.2, 11.1 and 13.5 min, respectively, with a total run time of 20 min; (2) the intraday repeatable precision expressed with the CV% in six successive analysis was 0.52% (for <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id>) and 0.83% (for ClDG); (3) the interday variability precision expressed with the CV% value of the repeatable precision of 3 days was 0.99%, 0.52% and 0.58% for <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and 0.71%, 0.83% and 1.24% for ClDG; both the CV% of intraday and interday reproducibilities of <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and ClDG were better than 1.5%; (4) the accuracy and recovery of <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and ClDG expressed with the percentage of mean value of three successive analysis were 99.75% (for <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id>) and 100.68% (for ClDG) which were all greater than 95%; (5) under optimum conditions, the limit of detection of <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and ClDG was 0.41 and 0.68 microg/ml, and the limit of quantization of <protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id> and ClDG was 1.24 and 2.04 microg/ml; (6) the correlation coefficient (r) value of linearity is over 0.999 by 5-50 microg/ml ranges of both compounds, respectively; (7) no interference peak effects by composition of mobile phase or increasing/decreasing flow rate or change of temperature was observed.	mannose__FDG__no_interaction
22871402-3	A segment of thoracic duct of rats was adopted for isolated lymphatics after HS, then the HS 0.5-hour and 2-hour lymphatics were incubated combined or respectively with K(<compound-id="5957">ATP</compound-id>) inhibitor <compound-id="3488">glibenclamide</compound-id> (Gli), opener of K(<compound-id="5957">ATP</compound-id>) pinacidil (Pin), NO donor L-<compound-id="6322,90867653">arginine</compound-id> (<protein-id="Q5BMA6">L-Arg</protein-id>), protein kinase A (PKA) inhibitor H-89, PKA donor 8-bromine-cyclic <compound-id="6083">adenosine monophosphate</compound-id> (<compound-id="32014">8-Br-cAMP</compound-id>), nitricoxide synthase (NOS) inhibitor N-nitro-<compound-id="550788">L-arginine methyl ester</compound-id> (<compound-id="39836">L-NAME</compound-id>), soluble guanylyl cyclase (sGC) inhibitor 1 h-[1,2,4]-oxadiazole-[4,3-a]- quinoxalin-1-one (<compound-id="1456">ODQ</compound-id>), protein kinase G (PKG) inhibitor KT-5823 (named as HS 0.5 h, HS 0.5 h + <protein-id="Q5BMA6">L-Arg</protein-id>, HS 0.5 h + <protein-id="Q5BMA6">L-Arg</protein-id> + H-89, HS 0.5 h + <protein-id="Q5BMA6">L-Arg</protein-id> + Gli, HS 0.5 h + <compound-id="32014">8-Br-cAMP</compound-id>, HS 0.5 h + <compound-id="32014">8-Br-cAMP</compound-id> + Gli and HS 2 h, HS 2 h + <compound-id="39836">L-NAME</compound-id>, HS 2 h + <compound-id="39836">L-NAME</compound-id> + Pin, HS 2 h + <compound-id="1456">ODQ</compound-id>, HS 2 h + <compound-id="1456">ODQ</compound-id> + Pin, HS 2 h + KT-5823, HS 2 h + KT-5823 + Pin, n=6).	L-NAME__L-Arg__no_interaction	glibenclamide__L-Arg__no_interaction	ODQ__L-Arg__no_interaction	L-arginine methyl ester__L-Arg__no_interaction	adenosine monophosphate__L-Arg__no_interaction	arginine__L-Arg__no_interaction	ATP__L-Arg__no_interaction	8-Br-cAMP__L-Arg__no_interaction
24592408-7	RESULTS: Three mg/kg pioglitazone significantly improved <protein-id="P06306">insulin</protein-id> sensitivity (geometric mean [95% CI] 0.90 [0.64-1.28] to 2.03 [1.49-2.78] min⁻¹pmol⁻¹L; P = .0014 versus change with placebo), reduced <protein-id="P06306">insulin</protein-id> area under the curve during IVGTT (geometric mean [range] 27 [9-64] to 18 [6-54] min∙nmol/L; P = .0031 versus change with placebo), and lowered serum triglyceride (geometric mean [range] 71 [29-271] to 48 [27-75] mg/dL; P = .047 versus change with placebo) and <compound-id="5997">cholesterol</compound-id> (geometric mean [range] 187 [133-294] to 162 [107-249] mg/dL; P = .0042 versus change with placebo) concentrations in the obese cats.	cholesterol__insulin__no_interaction
2240206-2	Forearm <compound-id="5950,602">alanine</compound-id> and <compound-id="612">lactate</compound-id> fractional extraction averaged 37 +/- 3 and 27 +/- 2%, respectively; muscle <compound-id="5950,602">alanine</compound-id> release (2.94 +/- 0.27 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>) accounted for approximately 70% of its systemic appearance (4.18 +/- 0.31 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>); muscle <compound-id="612">lactate</compound-id> release (5.51 +/- 0.42 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>) accounted for approximately 40% of its systemic appearance (12.66 +/- 0.77 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>); muscle <compound-id="5950,602">alanine</compound-id> and <compound-id="612">lactate</compound-id> uptake (1.60 +/- 0.7 and 3.29 +/- 0.36 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>, respectively) accounted for approximately 30% of their overall disappearance from plasma, whereas <compound-id="5950,602">alanine</compound-id> and <compound-id="612">lactate</compound-id> incorporation into plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (1.83 +/- 0.20 and 4.24 +/- 0.44 mumol.kg body wt-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>, respectively) accounted for approximately 50% of their disappearance from plasma.	glucose__min-1__no_interaction	alanine__min-1__no_interaction	lactate__min-1__no_interaction
16363863-1	Reactions of [Cu(CH(3)CN)(4)]X (X = PF(6), BF(4)) with <protein-id="O95817">bis</protein-id>(<compound-id="70017">diphenylphosphino</compound-id>)<compound-id="297">methane</compound-id> (<compound-id="74952">dppm</compound-id> = Ph(2)PCH(2)PPh(2)) and <compound-id="223">ammonium</compound-id> dialkyldithiophosphates, (NH(4))[S(2)P(OR)(2)] (R = Et, (i)Pr), yield a series of novel Cu(I) polynuclear complexes, trinuclear [Cu(3)(mu-<compound-id="74952">dppm</compound-id>)(3)(mu(3)-Cl){S(2)P(<compound-id="6324">OEt</compound-id>)(2)}] (PF(6)) 1 and [Cu(3)(mu-<compound-id="74952">dppm</compound-id>)(2){S(2)P(OR)(2)}(2)](PF(6)) (R = Et, 2; (i)Pr, 3), tetranuclear [Cu(4)(mu-<compound-id="74952">dppm</compound-id>)(2) {S(2)P(<compound-id="6324">OEt</compound-id>)(2)}(4)] 4, and hexanuclear [Cu(6)(mu-<compound-id="74952">dppm</compound-id>)(2)(mu(4)-Cl){S(2)P(O(i)()Pr)(2)}(4)](BF(4)) 5.	diphenylphosphino__bis__no_interaction	ammonium__bis__no_interaction	dppm__bis__no_interaction	OEt__bis__no_interaction	methane__bis__no_interaction
12414867-10	<protein-id="P41159,A4D0Y8">leptin</protein-id> levels were negatively and significantly correlated with free <compound-id="6013">testosterone</compound-id> and total <compound-id="6013">testosterone</compound-id> levels both before (r = -0.656, P = 0.011; and r = -0.639, P = 0.014, respectively) and after (r = -0.537, P = 0.048; and r = -0.563, P = 0.036, respectively) gonadotropin administration.	testosterone__leptin__no_interaction
19217461-5	Univariate regression analysis showed that serum levels of sRAGE were associated with body mass index (r = -0.313, P &lt; .0001), waist (r = -0.214, P &lt; .0001), <compound-id="5950,602">alanine</compound-id> aminotransferase (r = -0.172, P = .005), <protein-id="Q9BX51,D3DW46">gamma-glutamyltranspeptidase</protein-id> (r = -0.213, P &lt; .0001), 24-hour <compound-id="588">creatinine</compound-id> clearance (r = -0.348, P &lt; .0001), B-type natriuretic peptide (r = 0.138, P = .027), <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (r = 0.138, P = .002), and <compound-id="10982484,702">alcohol</compound-id> intake (r = -0.155, P = .010).	creatinine__tumor necrosis factor-alpha__no_interaction	creatinine__gamma-glutamyltranspeptidase__no_interaction	alanine__tumor necrosis factor-alpha__no_interaction	alanine__gamma-glutamyltranspeptidase__no_interaction	alcohol__tumor necrosis factor-alpha__no_interaction	alcohol__gamma-glutamyltranspeptidase__no_interaction
16446059-8	We found statistically significant correlations between: i) TDR and number of <protein-id="Q13326">MAM</protein-id> in genes (r = 0.118, p = 0.02), ii) SINE-TDR and proportion of CpG --&gt; TpG (r = 0.11, p = 0.03); limited to MIR elements only (r = 0.14, p = 0.006), and iii) LINE-TDR and proportion of CpT --&gt; <compound-id="70848">TpT</compound-id> (r = 0.166, p = 0.04).	TpT__MAM__no_interaction
18455923-1	<compound-id="114789">Carbon-11</compound-id> labeled <compound-id="931">naphthalene</compound-id>-sulfonamides, N-(4-(N-(4-[(11)C]methoxyphenyl)sulfamoyl)<compound-id="931">naphthalene</compound-id>-1-<compound-id="53357478">yl)benzamide</compound-id> ([(11)C]5a), N-(4-(N-(4-[(11)C]methoxyphenyl)sulfamoyl)<compound-id="931">naphthalene</compound-id>-1-yl)-2-<compound-id="11954">methylbenzamide</compound-id> ([(11)C]<compound-id="18445697">5b</compound-id>), N-(4-(N-(4-[(11)C]methoxyphenyl)sulfamoyl)<compound-id="931">naphthalene</compound-id>-1-yl)-<compound-id="69253">3-methylbenzamide</compound-id> ([(11)C]5c), N-[(11)C]methyl-N-methyl-4-(4-benzamidonaphthalene-1-sulfonamido)<compound-id="72887">piperidine-1-carboxamide</compound-id> ([(11)C]9a) and N-[(11)C]methyl-N-methyl-4-(4-(2-<compound-id="10704">methylbenzamido</compound-id>)<compound-id="931">naphthalene</compound-id>-1-sulfonamido)<compound-id="72887">piperidine-1-carboxamide</compound-id> ([(11)C]9b), have been synthesized as new potential positron emission tomography (PET) agents for imaging of human <protein-id="P51685">CCR8</protein-id>.	yl)benzamide__CCR8__no_interaction	methylbenzamide__CCR8__no_interaction	3-methylbenzamide__CCR8__no_interaction	piperidine-1-carboxamide__CCR8__no_interaction	methylbenzamido__CCR8__no_interaction	Carbon-11__CCR8__no_interaction	naphthalene__CCR8__no_interaction	5b__CCR8__no_interaction
9253349-7	In the second study, fasting levels of <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id>, apolipoprotein A1, and lipoprotein(a) were also measured, and then circulating triglyceride and total <compound-id="5997">cholesterol</compound-id> concentrations were measured over 24 h. Fasting concentrations of triglyceride (mean +/- <compound-id="5289348">SEM</compound-id>, 1.73 +/- 0.22 vs. 1.11 +/- 0.09 mmol/L; P = 0.0025), total <compound-id="5997">cholesterol</compound-id> (6.45 +/- 0.25 vs. 5.59 +/- 0.21 mmol/L; P = 0.002), LDL <compound-id="5997">cholesterol</compound-id> (4.58 +/- 0.24 vs. 3.80 +/- 0.19 mmol/L; P = 0.007), and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (135 +/- 10 vs. 111 +/- 9 mg/dL; P = 0.048) were elevated in hypopituitary compared to control women.	SEM__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
18952838-4	RESULTS: ZDF rats compared with ZCL rats have lower hepatic GK activity (11.6 +/- 1.9 vs. 32.5 +/- 3.2 mU/mg protein), marked hyperglycemia (23.9 +/- 1.2 vs. 7.4 +/- 0.3 mmol/l), higher endogenous <compound-id="206,5793,64689,79025">glucose</compound-id> production (80 +/- 3 vs. 38 +/- 3 micromol x kg(-1) x min(-1)), increased <protein-id="P43428">glucose-6-phosphatase</protein-id> flux (150 +/- 11 vs. 58 +/- 8 micromol x kg(-1) x min(-1)), and during a hyperglycemic clamp, a failure to suppress endogenous <compound-id="206,5793,64689,79025">glucose</compound-id> production (80 +/- 7 vs. -7 +/- 4 micromol x kg(-1) x min(-1)) and promote <compound-id="206,5793,64689,79025">glucose</compound-id> incorporation into <compound-id="439177">glycogen</compound-id> (15 +/- 5 vs. 43 +/- 3 micromol/g liver).	glycogen__glucose-6-phosphatase__no_interaction	glucose__glucose-6-phosphatase__no_interaction
21624251-6	There was positive correlation between <protein-id="Q9NS23">RASSF1A</protein-id> deletion and gene hypermethylation or between H3 <compound-id="57449,5962,866">lysine</compound-id> 9 methylation of <protein-id="Q9NS23">RASSF1A</protein-id> gene promoter and DNA methylation in laryngeal carcinoma tissue(r = 0.816, P &lt; 0.05), but there was negative correlation between H3 <compound-id="57449,5962,866">lysine</compound-id> 4 methylation of <protein-id="Q9NS23">RASSF1A</protein-id> gene promoter and DNA methylation (r = -0.837, P &lt; 0.05) and no correlation between H3 <compound-id="57449,5962,866">lysine</compound-id> 9 acetylation and DNA methylation (r = -0.383, P &gt; 0.05).	lysine__RASSF1A__no_interaction
9083002-8	The <compound-id="15741980">A4V</compound-id> mutation is both the most commonly detected of FALS-associated <protein-id="P00441,V9HWC9">SOD1</protein-id> mutations and among the most clinically severe (Rosen, D. R., Bowling, A. C., Patterson, D., Usdin, T. B., <compound-id="24451">Sapp</compound-id>, P., Mezey, E., McKenna-Yasek, D., O'Regan, J. P., Rahmani, Z., Ferrante, R. J., Brownstein, M. J., Kowall, N. W., Beal, M. F., Horvitz, H. R., and Brown, R. H., Jr. (1994) Hum.	A4V__SOD1__no_interaction	Sapp__SOD1__no_interaction
8320913-5	Plasma concentrations (mmol/liter) of <compound-id="588">creatinine</compound-id> (1.12 +/- 0.27 vs 0.97 +/- 0.11, P &lt; 0.01) and <compound-id="1061,167704,644102">phosphate</compound-id> (2.58 +/- 0.47 vs. 1.92 +/- 0.31, P &lt; 0.001) were higher, whereas plasma levels of <compound-id="767">bicarbonate</compound-id> (14.2 +/- 3.9 vs 22.5 +/- 4.2, P &lt; 0.001) and <compound-id="22044544,5460341">calcium</compound-id> (1.85 +/- 0.24 vs. 2.27 +/- 0.15, P &lt; 0.001) were lower in LR than in ER group, as were hemoglobin (7.1 +/- 1.1 vs. 9.4 +/- 0.9 g/dl, P &lt; 0.001) and serum <protein-id="P02768">albumin</protein-id> levels (35.3 +/- 4.8 vs. 39.7 +/- 3.4, P &lt; 0.01).	calcium__albumin__no_interaction	creatinine__albumin__no_interaction	phosphate__albumin__no_interaction	bicarbonate__albumin__no_interaction
24624092-10	Direct <protein-id="P00797">renin</protein-id> was higher and <protein-id="P01185,X5DQP6">vasopressin</protein-id> and Δ <compound-id="5839">aldosterone</compound-id> tended to be higher in blacks (BL, direct <protein-id="P00797">renin</protein-id>: 12.1 ± 5.0 vs. 14.4 ± 3.7 pg/ml, p &lt; 0.05; BL, <protein-id="P01185,X5DQP6">vasopressin</protein-id>: 0.4 ± 0.0 vs. 1.6 ± 3.6 pg/ml, p = 0.065; Δ <compound-id="5839">aldosterone</compound-id>: -0.9 ± 5.1 vs. 3.8 ± 7.5 ng/ml; p = 0.069).	aldosterone__vasopressin__no_interaction	aldosterone__renin__no_interaction
8729307-11	After a short hypovolemic shock period lasting a 12 hours, a hyperdynamic shock occured which increased until the 5th day, with an increased cardiac index (6.9 +/- 0.4 at h120 vs 2.9 +/- 0.3 L.<protein-id="P13987,Q6FHM9">min-1</protein-id>.m-2 at h6, P &lt; 0.05), increased <compound-id="977">oxygen</compound-id> transport and consumption (respectively 880 +/- 77 at h72 vs 543 +/- 58 mL.<protein-id="P13987,Q6FHM9">min-1</protein-id> at <protein-id="P16403">h12</protein-id>, P &lt; 0.05 and, 203 +/- 15 at h72 vs 129 +/- 25 mL.<protein-id="P13987,Q6FHM9">min-1</protein-id> at h6, P &lt; 0.05) and markedly decreased systemic vascular resistances (1,002 +/- 118 at <compound-id="72725796">h36</compound-id> vs 2,330 +/- 328 dyn.s.cm-5.m2 at h6, P &lt; 0.05).	h36__h12__no_interaction	h36__min-1__no_interaction	oxygen__h12__no_interaction	oxygen__min-1__no_interaction
23537255-6	<protein-id="P10914,Q6FHN8,X5D3F6">MAR</protein-id> compared to <compound-id="25021189">SLR</compound-id>: 1) AMS severity at 4300 was lower (p&lt;0.05) at 12 h (0.50±0.69 vs. 1.48±1.28), 24 h (0.15±0.19 vs. 1.39±1.19), 48 h (0.10±0.18 vs. 1.37±1.49) and 72 h (0.08±0.12 vs. 0.69±0.70); 2) AMS prevalence at 4300 was lower (p&lt;0.05) at 12 h (22% vs. 72%), 24 h (0% vs. 56%), 48 h (0% vs. 56%), and 72 h (0% vs. 45%); 3) resting Sao2 (%) was lower (p&lt;0.05) at baseline (95±1 vs. 99±1) but higher (p&lt;0.05) at 4300 at 24 h (86±2 vs. 81±5), 48 h (88±3 vs. 83±6), and 72 h (88±2 vs. 83±5); and 4) PV (%) did not differ at 72 h at 4300 m in the <protein-id="P10914,Q6FHN8,X5D3F6">MAR</protein-id> (4.5±6.7) but was reduced for the <compound-id="25021189">SLR</compound-id> (-8.1±10.4).	SLR__MAR__no_interaction
19375109-3	With respect to the <compound-id="5202">serotonin</compound-id> transporter gene-linked polymorphic region we analyzed the data under the 3 models of 1) dominant S model (S/S + S/L(A) + S/L(G) + L(G)/L(G) + L(A)/L(G) vs L(A)/L(A)), 2) dominant L model (L(A)/L(A) + L(A)/L(G) + S/L(A) vs S/S + <protein-id="Q96PQ1,Q5T5C0">S/L(G) + L(G)/L(G)) and 3</protein-id>) genotype model (S/S + L(G)/L(G) + S/L(G) vs S/L(A) + L(A)/L(G) vs L(A)/L(A)).	serotonin__S/L(G) + L(G)/L(G)) and 3__no_interaction
16829167-2	The complexes with different modes of the carboxylate binding, from chelating, through bridging (<protein-id="P06241">syn</protein-id>-<protein-id="P06241">syn</protein-id>, <protein-id="P06241">syn</protein-id>-anti, monatomic), ionic to monodentate were used for the study, namely [Zn(C6H5CHCHCOO)2(H2O)2] (I) with chelating carboxylate group (C6H5CHCHCOO=<compound-id="8784,444539">cinnamate</compound-id>), [Zn2(C6H5COO)4(pap)2] (II) with <protein-id="P06241">syn</protein-id>-<protein-id="P06241">syn</protein-id> bridging carboxylate (C6H5COO=<compound-id="243">benzoate</compound-id>; pap=<compound-id="4680">papaverine</compound-id>), [Zn(C6H5CHCHCOO)2(mpcm)]n (III) with <protein-id="P06241">syn</protein-id>-anti carboxylate bridge (mpcm=methyl-3-<compound-id="21979604">pyridylcarbamate</compound-id>), [Zn(C5H4NCOO)2(H2O)4] (IV) with ionic carboxylate group (C5H4NCOO=<compound-id="938">nicotinate</compound-id>), [Zn(C6H5COO)2(pcb)2]n (V) with monodentate carboxylate coordination (pcb=<compound-id="7510">3-pyridylcarbinol</compound-id>) and [<compound-id="4655929">Zn3</compound-id>(C6H5COO)6(nia)2] (VI) with <protein-id="P06241">syn</protein-id>-<protein-id="P06241">syn</protein-id> and monatomic carboxylate bridges (nia=<compound-id="936">nicotinamide</compound-id>).	nicotinamide__syn__no_interaction	nicotinate__syn__no_interaction	cinnamate__syn__no_interaction	benzoate__syn__no_interaction	Zn3__syn__no_interaction	3-pyridylcarbinol__syn__no_interaction	pyridylcarbamate__syn__no_interaction	papaverine__syn__no_interaction
16575927-1	A family of <protein-id="Q9Y657,A0A024R297">spin</protein-id>-crossover (SC) complexes, [<compound-id="27284">Fe(II)</compound-id>H(3)L(Me)]Cl.X (X(-) = PF(6) (-), AsF(6) (-), SbF(6) (-), CF(3)SO(3) (-)), 1-4, has been synthesized, in which H(3)L(Me) denotes the hexadentate N(6) tripod-like ligand <compound-id="91594283">tris[2-{[(2-methylimidazol-4-yl)methylidene]amino}ethyl]amine</compound-id>, containing three <compound-id="795">imidazole</compound-id> groups, with a view to establishing the effect of the counter anion on the SC behavior.	imidazole__spin__no_interaction	Fe(II)__spin__no_interaction	tris[2-{[(2-methylimidazol-4-yl)methylidene]amino}ethyl]amine__spin__no_interaction
11419027-4	To understand the biologic significance of RAS-induced up-regulation of these ligands in both RAS-induced PAK activation and malignant transformation, we have conducted the following studies, based on the previous observations that (1) the N-terminal SH3 domain of <protein-id="Q9ES28">PIX</protein-id> selectively binds a Pro-rich domain of 18 amino acids of PAKs, <protein-id="P60766">CDC42</protein-id>/Rac-dependent <compound-id="5951">Ser</compound-id>/Thr kinase family, and (2) this specific interaction is essential for both PAK activation and membrane ruffling RESULTS: Using four distinct, cell-permeable, and highly specific inhibitors, namely WR-PAK18, which blocks the PAK-<protein-id="Q9ES28">PIX</protein-id> interaction; AG 1478, which inhibits ErbB1 kinase activity; and <compound-id="6091659">AG 825</compound-id> or AG 879, which inhibits <protein-id="P70424">ErbB2</protein-id> kinase activity, we demonstrate that (1) the PAK-<protein-id="Q9ES28">PIX</protein-id> interaction is essential for v-Ha-RAS-induced malignant transformation; (2) v-Ha-RAS requires not only ErbB1 but also <protein-id="P70424">ErbB2</protein-id>, which are activated through two independent autocrine pathways to induce both the <protein-id="Q9ES28">PIX</protein-id>/Rac/<protein-id="P60766">CDC42</protein-id>-dependent PAK activation and malignant transformation in vitro; and (3) a combination of AG 879 and the Src family kinase-specific inhibitor <protein-id="P63087,Q6ZWM8">PP1</protein-id> suppresses almost completely the growth of RAS-induced sarcomas in nude mice.	AG 825__PIX__no_interaction	AG 825__ErbB2__no_interaction	AG 825__PP1__no_interaction	AG 825__CDC42__no_interaction	Ser__PIX__no_interaction	Ser__ErbB2__no_interaction	Ser__PP1__no_interaction	Ser__CDC42__no_interaction
7775625-4	In all subjects, PAi activity levels were significantly and positively correlated with body mass index (r = 0.20, P &lt; 0.05), triglycerides (r = 0.38, P &lt; 0.0001), and <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.27, P &lt; 0.005) and were negatively correlated with <compound-id="6013">testosterone</compound-id> (r = -0.28, P &lt; 0.005) and TEBG (r = -0.42, P &lt; 0.001).	testosterone__insulin__no_interaction
23633321-19	Meta-analysis of hormone and lipid data showed that the mean effect was 0.26 ng/ml/hr (95% CI: 0.17 to 0.36, I (2)=70%) for plasma <protein-id="P00797">renin</protein-id> activity, 73.20 pmol/l (95% CI: 44.92 to 101.48, I (2)=62%) for <compound-id="5839">aldosterone</compound-id>, 31.67 pg/ml (95% CI: 6.57 to 56.77, I (2)=5%) for noradrenaline, 6.70 pg/ml (95% CI: -0.25 to 13.64, I (2)=12%) for <compound-id="5816">adrenaline</compound-id>, 0.05 mmol/l (95% CI: -0.02 to 0.11, I (2)=0%) for <compound-id="5997">cholesterol</compound-id>, 0.05 mmol/l (95% CI: -0.01 to 0.12, I (2)=0%) for LDL, -0.02 mmol/l (95% CI: -0.06 to 0.01, I (2)=16%) for HDL, and 0.04 mmol/l (95% CI: -0.02 to 0.09, I (2)=0%) for triglycerides.	cholesterol__renin__no_interaction	adrenaline__renin__no_interaction	aldosterone__renin__no_interaction
8480681-3	In diabetics (placebo-treated vs <compound-id="14985,1548900,1742129,2116">vitamin E</compound-id>-supplemented subjects, respectively) <compound-id="14985,1548900,1742129,2116">vitamin E</compound-id> supplementation reduced <compound-id="206,5793,64689,79025">glucose</compound-id> area under the curve (614 +/- 129 vs 544 +/- 98 mmol.L-1 x min-1; P &lt; 0.03) and increased <compound-id="206,5793,64689,79025">glucose</compound-id> disappearance (19.4 +/- 0.4 vs 26.4 +/- 0.7 mumol.kg lean body <protein-id="Q8WXG9">mass-1</protein-id>.min-1; P &lt; 0.03), total <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (19.0 +/- 0.7 vs 28.1 +/- 0.4 mumol.kg lean body <protein-id="Q8WXG9">mass-1</protein-id> x min-1; P &lt; 0.02), and nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism (8.5 +/- 0.3 vs 13.9 +/- 0.3 mumol.kg lean body <protein-id="Q8WXG9">mass-1</protein-id> x min-1; P &lt; 0.02).	vitamin E__mass-1__no_interaction	glucose__mass-1__no_interaction
3832077-2	We have found, employing analogs in which each <compound-id="57476835,60961">adenosine</compound-id> residue has been sequentially replaced by <compound-id="57476835,60961">adenosine</compound-id> (viz, ppp5'I2'p5'A2'p5'I, ppp5'A2'p5'I2'p5'A, ppp5'A2'p5'A2'p5'I) that the N6 amino group of the first (or 5'-terminal) <compound-id="57476835,60961">adenosine</compound-id> residue of <compound-id="107918">2-5A</compound-id> trimer is critical in <protein-id="Q05921,B2RQP1,Q3T9T6">RNase L</protein-id> binding whereas the N6 amino moiety of the third (or 2'-terminal) <compound-id="57476835,60961">adenosine</compound-id> residue of <compound-id="107918">2-5A</compound-id> is crucial for the activation of <protein-id="Q05921,B2RQP1,Q3T9T6">RNase L</protein-id>.	2-5A__RNase L__no_interaction	adenosine__RNase L__no_interaction
17956948-9	The percent change in liver fat correlated with the percent decrease in HbA 1c (r = 0.53, P = 0.06), <protein-id="P01308,I3WAC9">insulin</protein-id> dose (r = 0.66, P = 0.014), and suppression of endogenous <compound-id="206,5793,64689,79025">glucose</compound-id> production (r = 0.76, P = 0.003).	glucose__insulin__no_interaction
22490404-10	Both anaerobic threshold <compound-id="977">oxygen</compound-id> consumption (VO(2)AT) and peak <compound-id="977">oxygen</compound-id> consumption (VO(2)peak) were significantly lower in patients with PE, while CO(2) equivalent ventilation (VE/VCO(2) slope) was higher; VO(2)AT (9.44 ± 3.82) ml×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>) vs. (14.62 ± 2.93) ml×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>) (P &lt; 0.01) and VO2peak (12.26 ± 4.06) ml×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>) vs. (23.46 ± 6.15) ml×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>) (P &lt; 0.01) and VE/VCO(2) slope 35.47 ± 6.66 vs. 26.94 ± 3.16 (P &lt; 0.01).	oxygen__min(-1__no_interaction
11828128-1	The crystal structures of [(Z)-2-methylbut-1-en-1-yl][4-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]<compound-id="3715291">iodonium</compound-id> <compound-id="62406">trifluoromethanesulfonate</compound-id>, C(12)H(13)F(3)I(+).CF(3)O(3)S(-), (I), (3,5-<compound-id="57417436">dichlorophenyl</compound-id>)[(Z)-2-methylbut-1-en-1-yl]<compound-id="3715291">iodonium</compound-id> <compound-id="62406">trifluoromethanesulfonate</compound-id>, C(11)H(12)Cl(2)I(+).CF(3)O(3)S(-), (II), and <protein-id="O95817">bis</protein-id>[[3,5-<protein-id="O95817">bis</protein-id>(<compound-id="6373">trifluoromethyl</compound-id>)phenyl][(Z)-2-methylbut-1-en-1-yl]<compound-id="3715291">iodonium</compound-id>] <protein-id="O95817">bis</protein-id>(<compound-id="62406">trifluoromethanesulfonate</compound-id>) <compound-id="6344">dichloromethane</compound-id> solvate, 2C(13)H(12)F(6)I(+).<compound-id="46224514">2CF</compound-id>(3)O(3)S(-).CH(2)Cl(2), (III), are described.	dichloromethane__bis__no_interaction	dichlorophenyl__bis__no_interaction	trifluoromethanesulfonate__bis__no_interaction	iodonium__bis__no_interaction	2CF__bis__no_interaction	trifluoromethyl__bis__no_interaction
12616707-3	This issue focuses on the following selection of drugs: <compound-id="441300">Abacavir sulfate</compound-id>, <compound-id="16131215">abarelix</compound-id>, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, AdGVVEGF121.10, <compound-id="2187">anastrozole</compound-id>, <compound-id="111332">anecortave acetate</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="107924">asulacrine isethionate</compound-id>, <compound-id="148192">atazanavir</compound-id>, <compound-id="9952916">ATL-962</compound-id>, <compound-id="6445540">16-Aza-epothilone B</compound-id>; Bevacizumab, <compound-id="2375">bicalutamide</compound-id>, <compound-id="125564">blonanserin</compound-id>, BMS-188667, <compound-id="104865">bosentan</compound-id>; <compound-id="2662">Celecoxib</compound-id>, celmoleukin, cetuximab, <compound-id="151170">cilomilast</compound-id>, <compound-id="156419">cinacalcet hydrochloride</compound-id>, CNTF(Ax15), <compound-id="160051">colesevelam hydrochloride</compound-id>; Daclizumab, <compound-id="5625">delavirdine</compound-id> mesilate, <compound-id="40973">desogestrel</compound-id>, <compound-id="447865,6918680">desoxyepothilone B</compound-id>, <compound-id="154101">dexmethylphenidate hydrochloride</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>; Ecogramostim, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="1549120">epalrestat</compound-id>, <compound-id="146570">escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, <compound-id="6918297">examorelin</compound-id>, exendin-4, <compound-id="150311">ezetimibe</compound-id>; <compound-id="160024">Fidarestat</compound-id>, <compound-id="77992">frovatriptan</compound-id>; HIV-1 Immunogen; <compound-id="71360">Iloperidone</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> lispro, <compound-id="60838">irinotecan hydrochloride</compound-id>; Keratinocyte growth factor; <compound-id="216416">Lasofoxifene tartrate</compound-id>, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="35805">levormeloxifene</compound-id>, <compound-id="3033825">levosimendan</compound-id>, <compound-id="151166">lumiracoxib</compound-id>, LY-307161 SR; <compound-id="4054">Memantine hydrochloride</compound-id>, <compound-id="46233105">MEN-10755</compound-id>, <compound-id="4091">metformin hydrochloride</compound-id>, metreleptin, <compound-id="151071">motexafin gadolinium</compound-id>; <compound-id="4440">Naratriptan hydrochloride</compound-id>, natalizumab, nesiritide, <compound-id="157672">nicotine</compound-id>, <compound-id="16134956">NN-2211</compound-id>, NN-414; <compound-id="4585">Olanzapine</compound-id>, omalizumab; <compound-id="56603655">Pegaptanib</compound-id> <compound-id="5360545">sodium</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="40632">pirfenidone</compound-id>, <compound-id="16132446">pramlintide acetate</compound-id> <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; <compound-id="5002">Quetiapine fumarate</compound-id>; <compound-id="5029">Rabeprazole sodium</compound-id>, <compound-id="5035">raloxifene hydrochloride</compound-id>, <compound-id="104758">raltitrexed</compound-id>, rDNA <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P13109">rFGF-2</protein-id>, <compound-id="5245">risedronate sodium</compound-id>, <compound-id="5090">rofecoxib</compound-id>, <compound-id="449193">roflumilast</compound-id>, <compound-id="77999">rosiglitazone maleate</compound-id>; SN-22995; <compound-id="445643,90726579">Tacrolimus</compound-id>, <compound-id="110635">tadalafil</compound-id>, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="15057856,3086655,49800038,5487427">tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="54841">tomoxetine</compound-id> hydrochloride, trastuzumab, <compound-id="68926">trimegestone</compound-id>; <compound-id="444020">Voglibose</compound-id>, <compound-id="71616">Voriconazole</compound-id>; <compound-id="60854">Ziprasidone hydrochloride</compound-id>.	NN-2211__rFGF-2__no_interaction	NN-2211__insulin__no_interaction	escitalopram__rFGF-2__no_interaction	escitalopram__insulin__no_interaction	nicotine__rFGF-2__no_interaction	nicotine__insulin__no_interaction	Fidarestat__rFGF-2__no_interaction	Fidarestat__insulin__no_interaction	risedronate sodium__rFGF-2__no_interaction	risedronate sodium__insulin__no_interaction	trimegestone__rFGF-2__no_interaction	trimegestone__insulin__no_interaction	epalrestat__rFGF-2__no_interaction	epalrestat__insulin__no_interaction	metformin hydrochloride__rFGF-2__no_interaction	metformin hydrochloride__insulin__no_interaction	delavirdine__rFGF-2__no_interaction	delavirdine__insulin__no_interaction	bosentan__rFGF-2__no_interaction	bosentan__insulin__no_interaction	desogestrel__rFGF-2__no_interaction	desogestrel__insulin__no_interaction	Voglibose__rFGF-2__no_interaction	Voglibose__insulin__no_interaction	tomoxetine__rFGF-2__no_interaction	tomoxetine__insulin__no_interaction	tadalafil__rFGF-2__no_interaction	tadalafil__insulin__no_interaction	16-Aza-epothilone B__rFGF-2__no_interaction	16-Aza-epothilone B__insulin__no_interaction	examorelin__rFGF-2__no_interaction	examorelin__insulin__no_interaction	pimecrolimus__rFGF-2__no_interaction	pimecrolimus__insulin__no_interaction	Rabeprazole sodium__rFGF-2__no_interaction	Rabeprazole sodium__insulin__no_interaction	frovatriptan__rFGF-2__no_interaction	frovatriptan__insulin__no_interaction	anecortave acetate__rFGF-2__no_interaction	anecortave acetate__insulin__no_interaction	rofecoxib__rFGF-2__no_interaction	rofecoxib__insulin__no_interaction	Naratriptan hydrochloride__rFGF-2__no_interaction	Naratriptan hydrochloride__insulin__no_interaction	tiotropium__rFGF-2__no_interaction	tiotropium__insulin__no_interaction	cinacalcet hydrochloride__rFGF-2__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	raltitrexed__rFGF-2__no_interaction	raltitrexed__insulin__no_interaction	bromide__rFGF-2__no_interaction	bromide__insulin__no_interaction	Celecoxib__rFGF-2__no_interaction	Celecoxib__insulin__no_interaction	Pegaptanib__rFGF-2__no_interaction	Pegaptanib__insulin__no_interaction	pramlintide acetate__rFGF-2__no_interaction	pramlintide acetate__insulin__no_interaction	pregabalin__rFGF-2__no_interaction	pregabalin__insulin__no_interaction	bicalutamide__rFGF-2__no_interaction	bicalutamide__insulin__no_interaction	atazanavir__rFGF-2__no_interaction	atazanavir__insulin__no_interaction	dexmethylphenidate hydrochloride__rFGF-2__no_interaction	dexmethylphenidate hydrochloride__insulin__no_interaction	oxalate__rFGF-2__no_interaction	oxalate__insulin__no_interaction	ATL-962__rFGF-2__no_interaction	ATL-962__insulin__no_interaction	anastrozole__rFGF-2__no_interaction	anastrozole__insulin__no_interaction	duloxetine hydrochloride__rFGF-2__no_interaction	duloxetine hydrochloride__insulin__no_interaction	motexafin gadolinium__rFGF-2__no_interaction	motexafin gadolinium__insulin__no_interaction	cilomilast__rFGF-2__no_interaction	cilomilast__insulin__no_interaction	emtricitabine__rFGF-2__no_interaction	emtricitabine__insulin__no_interaction	irinotecan hydrochloride__rFGF-2__no_interaction	irinotecan hydrochloride__insulin__no_interaction	roflumilast__rFGF-2__no_interaction	roflumilast__insulin__no_interaction	ezetimibe__rFGF-2__no_interaction	ezetimibe__insulin__no_interaction	levetiracetam__rFGF-2__no_interaction	levetiracetam__insulin__no_interaction	Tacrolimus__rFGF-2__no_interaction	Tacrolimus__insulin__no_interaction	Quetiapine fumarate__rFGF-2__no_interaction	Quetiapine fumarate__insulin__no_interaction	tegaserod maleate__rFGF-2__no_interaction	tegaserod maleate__insulin__no_interaction	colesevelam hydrochloride__rFGF-2__no_interaction	colesevelam hydrochloride__insulin__no_interaction	raloxifene hydrochloride__rFGF-2__no_interaction	raloxifene hydrochloride__insulin__no_interaction	blonanserin__rFGF-2__no_interaction	blonanserin__insulin__no_interaction	Ziprasidone hydrochloride__rFGF-2__no_interaction	Ziprasidone hydrochloride__insulin__no_interaction	Olanzapine__rFGF-2__no_interaction	Olanzapine__insulin__no_interaction	Memantine hydrochloride__rFGF-2__no_interaction	Memantine hydrochloride__insulin__no_interaction	prasterone__rFGF-2__no_interaction	prasterone__insulin__no_interaction	abarelix__rFGF-2__no_interaction	abarelix__insulin__no_interaction	MEN-10755__rFGF-2__no_interaction	MEN-10755__insulin__no_interaction	sodium__rFGF-2__no_interaction	sodium__insulin__no_interaction	lumiracoxib__rFGF-2__no_interaction	lumiracoxib__insulin__no_interaction	rosiglitazone maleate__rFGF-2__no_interaction	rosiglitazone maleate__insulin__no_interaction	Voriconazole__rFGF-2__no_interaction	Voriconazole__insulin__no_interaction	Abacavir sulfate__rFGF-2__no_interaction	Abacavir sulfate__insulin__no_interaction	desoxyepothilone B__rFGF-2__no_interaction	desoxyepothilone B__insulin__no_interaction	adefovir dipivoxil__rFGF-2__no_interaction	adefovir dipivoxil__insulin__no_interaction	pirfenidone__rFGF-2__no_interaction	pirfenidone__insulin__no_interaction	aripiprazole__rFGF-2__no_interaction	aripiprazole__insulin__no_interaction	Lasofoxifene tartrate__rFGF-2__no_interaction	Lasofoxifene tartrate__insulin__no_interaction	Iloperidone__rFGF-2__no_interaction	Iloperidone__insulin__no_interaction	levosimendan__rFGF-2__no_interaction	levosimendan__insulin__no_interaction	asulacrine isethionate__rFGF-2__no_interaction	asulacrine isethionate__insulin__no_interaction	levormeloxifene__rFGF-2__no_interaction	levormeloxifene__insulin__no_interaction
19462275-8	There were significant associations between <protein-id="P13805">TnT</protein-id> levels and duration of disease (r = 0.29, p = 0.01), <compound-id="588">creatinine</compound-id> (r = 0.30, p = 0.01), GFR (r = -0.55, p &lt; 0.0001), and LVEF (r = -0.39, p = 0.001).	creatinine__TnT__no_interaction
16823088-14	These genes are categorized as control and regulatory genes for metabolic pathways involving the cell cycle (cyclin-dependent kinases), apoptosis, cytokine expression, Na+/K+ ATPase, stress responses, G-protein signal transduction, transcription factors, DNA repair as well as metal-regulatory transcription factor 1, MTF1 HGNC, <protein-id="O95196,B7Z2E0,A0A087WUT8">chondroitin sulfate proteoglycan 5</protein-id> (neuroglycan C), ATP-binding cassette, sub-family G (WHITE), cytochrome b-561 family protein, <protein-id="P49759">CDC-like kinase 1</protein-id> (CLK1 HGNC) (protein <compound-id="6057,90983769">tyrosine</compound-id> kinase STY), Na+/H+ exchanger regulatory factor (NHERF HGNC), <protein-id="Q12809,A0A090N7W1,A0A090N8Q0,A0A090N7X5,Q15BH2">potassium voltage-gated channel subfamily H member 2</protein-id> (<protein-id="Q12809,A0A090N7W1,A0A090N8Q0,A0A090N7X5,Q15BH2">KCNH2</protein-id>), putative MAPK activating protein (PM20, PM21), ras homolog gene family, polymerase (DNA directed), delta regulatory subunit (50 kDa), <compound-id="90470904">leptin</compound-id> receptor involved in hematopoietin/interferon-class (D200- domain) cytokine receptor activity and <compound-id="5789">thymidine</compound-id> kinase 2, mitochondrial TK2 HGNC and related genes.	leptin__potassium voltage-gated channel subfamily H member 2__no_interaction	leptin__CDC-like kinase 1__no_interaction	leptin__chondroitin sulfate proteoglycan 5__no_interaction	leptin__KCNH2__no_interaction	thymidine__potassium voltage-gated channel subfamily H member 2__no_interaction	thymidine__CDC-like kinase 1__no_interaction	thymidine__chondroitin sulfate proteoglycan 5__no_interaction	thymidine__KCNH2__no_interaction	tyrosine__potassium voltage-gated channel subfamily H member 2__no_interaction	tyrosine__CDC-like kinase 1__no_interaction	tyrosine__chondroitin sulfate proteoglycan 5__no_interaction	tyrosine__KCNH2__no_interaction
15510294-1	The reaction of <compound-id="2724394">AlMe</compound-id>(3) and [((t)Bu)(2)Al(micro-<protein-id="P13798,A0A024R2U9">OPh</protein-id>)](2) with <compound-id="9261">pyrazine</compound-id> (pyz), <compound-id="11107">4,4'-bipyridine</compound-id> (4-4'-<compound-id="1474">bipy</compound-id>), <compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id> (bpetha) and <compound-id="776222">1,2-bis(4-pyridyl)ethylene</compound-id> (bpethe) yields (Me(3)Al)(2)(micro-pyz)(1), (Me(3)Al)(2)(micro-4,4'-<compound-id="1474">bipy</compound-id>)(2), (Me(3)Al)(2)(micro-bpetha)(3), (Me(3)Al)(2)(micro-bipethe)(4), Al((t)Bu)(2)(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)(pyz)(5), [((t)Bu)(2)Al(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)](2)(micro-4,4-<compound-id="1474">bipy</compound-id>)(6a), [((t)Bu)(2)Al(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)](2)(micro-bpetha)(7a), [((t)Bu)(2)Al(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)](2)(micro-bipethe)(8a).	AlMe__OPh__no_interaction	1,2-bis(4-pyridyl)ethane__OPh__no_interaction	bipy__OPh__no_interaction	4,4'-bipyridine__OPh__no_interaction	pyrazine__OPh__no_interaction	1,2-bis(4-pyridyl)ethylene__OPh__no_interaction
15510294-4	In contrast, the solution equilibria for compounds 5-8a are sufficiently slow such that the mono-<compound-id="5359268">aluminium</compound-id> compounds may be observed by (1)H NMR spectroscopy: Al((t)Bu)(2)(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)(4,4-<compound-id="1474">bipy</compound-id>)(6b), Al((t)Bu)(2)(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)(bpetha)(7b) and Al((t)Bu)(2)(<protein-id="P13798,A0A024R2U9">OPh</protein-id>)(bpethe)(8b).	aluminium__OPh__no_interaction	bipy__OPh__no_interaction
24020500-1	Achiral [Ru2(μ-O2CR)4(<compound-id="887">MeOH</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (R = CH3 or C6H5) reacts with the chiral diphosphines R,R- and S,S-Chiraphos (two chiral centers on ligand between the coordinating P atoms) and R-<compound-id="3289">Prophos</compound-id> (one chiral center on ligand between the coordinating P atoms) leading to a disassembly of the paddlewheel core and the highly diastereoselective production of Λ-[Ru(η(2)-O2CC6H5)(η(2)-R,R-Chiraphos)2](<protein-id="Q6Q759">PF6</protein-id>) (Λ-R,R-III), Δ-[Ru(η(2)-O2CC6H5)(η(2)-S,S-Chiraphos)2](<protein-id="Q6Q759">PF6</protein-id>) (Δ-S,S-III) (the R = CH3 complexes of Chiraphos were reported in a earlier communication in this journal), and Λ-[Ru(η(2)-O2CCH3)(η(2)-R-<compound-id="3289">Prophos</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (Λ-R,R-VI), respectively, in high yield and purity.	Prophos__PF6__no_interaction	MeOH__PF6__no_interaction
24020500-2	Reactions of the same starting material with R,R- and S,S-o-tolyl-<compound-id="11419748">Dipamp</compound-id> (chiral centers are the coordinating P-atoms) lead to an inversion in the chirality-at-metal producing Λ-[Ru(η(2)-O2CC6H5)(η(2)-S,S-o-tolyl-<compound-id="11419748">Dipamp</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (Λ-S,S-IV), Δ-[Ru(η(2)-O2CC6H5)(η(2)-R,R-o-tolyl-<compound-id="11419748">Dipamp</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (Δ-R,R-IV), Λ-[Ru(η(2)-O2CCH3)(η(2)-S,S-o-tolyl-<compound-id="11419748">Dipamp</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (Λ-S,S-V), and Δ-[Ru(η(2)-O2CCH3)(η(2)-R,R-o-tolyl-<compound-id="11419748">Dipamp</compound-id>)2](<protein-id="Q6Q759">PF6</protein-id>) (Δ-R,R-V).	Dipamp__PF6__no_interaction
12059098-2	Thirty Type 2 diabetic subjects (18 women and 12 men) living in nursing homes, aged 77 +/- 3 yr, mean systolic pressure 147 +/- 6 and diastolic 82 +/- 4 mmHg, body mass index 27.5 +/- 2 kg/m2, known diabetes duration 10.1+/- 0.7 yr, mean HbA1c 8.5 +/- 0.8%, fasting C-peptide 1.3 +/- 0.5 ng/ml, treated with intensive (4 <protein-id="P01308,I3WAC9">insulin</protein-id> injections per day) therapy, mean <protein-id="P01308,I3WAC9">insulin</protein-id> need 45 +/- 7 IU per day, with 2.0 +/- 0.6 hypoglycaemic (blood <compound-id="206,5793,64689,79025">glucose</compound-id> level below 60 mg/dl) and 13 +/- 4 hyperglycaemic episodes (blood <compound-id="206,5793,64689,79025">glucose</compound-id> level over 250 mg/dl) per wk, were studied.	glucose__insulin__no_interaction
8080047-4	We examined three human macrophage precursor cell lines (THP-1, U-937, and HL-60), before and after differentiation with <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> or 1 alpha,25-dihydroxy-vitamin D3, for apoSAA messenger (m)-RNA expression and found that: 1) induction of steady-state apoSAA mRNA by <compound-id="11970143">lipopolysaccharide</compound-id>, <protein-id="P01583">interleukin-1</protein-id>, or <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> required the presence of the synthetic glucocorticoid <compound-id="5743">dexamethasone</compound-id>; 2) the three known active genes, apoSAA1, apoSAA2, and apoSAA4, were induced in THP-1 cells, whereas the pseudogene apoSAA3 was not; 3) differentiated and undifferentiated THP-1 cells expressed apoSAA mRNA, but U-937 cells expressed apoSAA mRNA (low levels) only after <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> differentiation and HL-60 cells did not express apoSAA mRNA whether differentiated or not; 4) apoSAA protein was detectable immunologically at a low level in lyophilized medium from induced THP-1 cells.	lipopolysaccharide__interleukin-1__no_interaction	lipopolysaccharide__interleukin-6__no_interaction	phorbol 12-myristate__interleukin-1__no_interaction	phorbol 12-myristate__interleukin-6__no_interaction	acetate__interleukin-1__no_interaction	acetate__interleukin-6__no_interaction	dexamethasone__interleukin-1__no_interaction	dexamethasone__interleukin-6__no_interaction
23967743-12	Both hepatic OPN and <protein-id="P04202,Q3UNK5">TGF-beta1</protein-id> showed significantly increasing trends in mRNA and protein expressions from weeks 5-8 (OPN mRNA: 1.83 +/- 0.25, 2.94 +/- 0.19, 3.45 +/- 0.31, and 5.99 +/- 0.17 (F= 476.27, P &lt; 0.001); OPN protein: 0.52 +/- 0.06, 1.02 +/- 0.10, 1.52 +/- 0.11 and 1.50 +/- 0.08 (F= 298.03, P&lt; 0.001); <protein-id="P04202,Q3UNK5">TGF-beta1</protein-id> mRNA: 13.19 +/- 0.40, 3.31 +/- 0.28, 1.58 +/- 0.18 and 2.08 +/- 0.26 (F= 85.55, P &lt; 0.001); TGF-<compound-id="9974420">P31</compound-id> protein: 1.26 +/- 0.16, 0.96 +/- 0.12, 1.09 +/- 0.25 and 1.10 +/- 0.20 (F = 43.64, P &lt; 0.001).	P31__TGF-beta1__no_interaction
10436588-8	Dose accumulated of fentanyl total (5732.7 +/- 5114.91 vs 624.2 +/- 591.2 mcg, p &lt; 0.005), dose daily of fentanyl (98.54 +/- 6.12 vs 36.23 +/- 23.42 mcg/Kg/<protein-id="O60879">dia</protein-id>, p &lt; 0.005), velocity of infusion of the fentayl (4.09 +/- 2.75 vs 1.5 +/- 0.95 mcg/Kg/hora, p &lt; 0.005), time of use of the fentanyl (10.2 +/- 5.1 vs 3.16 +/- 1.09 days, p &lt; 0.005), dose accumulated of <compound-id="4192">midazolam</compound-id> total (118.8 +/- 86.97 vs 20.03 +/- 14.79 mg, p &lt; 0.005), dose daily of <compound-id="4192">midazolam</compound-id> (2.32 +/- 0.86 vs 1.21 +/- 0.68 mg/Kg/<protein-id="O60879">dia</protein-id>, p &lt; 0.005), velocity of <compound-id="4192">midazolam</compound-id> infusion (0.13 +/- 0.16 vs 0.05 +/- 0.02 mg/Kg/hora, p &lt; 0.005) and time of use of the <compound-id="4192">midazolam</compound-id> (9.20 +/- 4.67 vs 2.55 +/- 1.54 days, p &lt; 0.005) they were considered significant.	midazolam__dia__no_interaction
10723491-2	MATERIALS AND METHODS: 10 cadaver wrist specimens were imaged with 12 MR sequences (SE: 400 ms/20 ms, TSE: 3000 ms/119 ms/17 ms, fatsat (FS) TSE: 3000 ms/17 ms and 3000 ms/45 ms, STIR: 2619 ms/29 ms/160 ms, DESS 3D: 43.7 ms/9 ms/35 degrees FS and 25.4 ms/9 ms/35 degrees <compound-id="962">water</compound-id> excitation (WE), <protein-id="O75462">CISS</protein-id> 3D: 12.2 ms/5.9 ms/40 degrees and FLASH-sequences: 53 ms/11 ms/40 degrees FS, 23 ms/11 ms/40 degrees WE and 45 ms/11 ms/30 degrees FS) at 1.5 T. Slice thickness was 3 mm, FOV 80 x 70 mm (pixel size 0.31 x 0.31 mm).	water__CISS__no_interaction
12578538-2	Corpora lutea were collected on days 4, 7, 10, 13 and 15 or 16 of the oestrous cycle, enzyme dissociated and the luteal cells were cultured for 24 h in Medium 199 with <protein-id="P16545,G9BFS9,A0A0G2KBD1,F1SRJ7,G9BFS5,Q45QB4,I3LBI3">IGF-I</protein-id> (0-100 ng ml(-1)), long R(3)-<protein-id="P16545,G9BFS9,A0A0G2KBD1,F1SRJ7,G9BFS5,Q45QB4,I3LBI3">IGF-I</protein-id> (0-100 ng ml(-1)), anti-<protein-id="P16545,G9BFS9,A0A0G2KBD1,F1SRJ7,G9BFS5,Q45QB4,I3LBI3">IGF-I</protein-id> (Sm 1.2B; 0-10 microg ml(-1)), anti-IGF-IR (alphaIR3; 0-2 microg ml(-1)), or <protein-id="P16545,G9BFS9,A0A0G2KBD1,F1SRJ7,G9BFS5,Q45QB4,I3LBI3">IGF-I</protein-id> signal transduction pathway inhibitors (<compound-id="16738692,53477912">phosphatidylinositol</compound-id> (PI)-3-kinase: 100 nmol <compound-id="312145">Wortmannin</compound-id> l(-1) and 10 micromol LY 294002 l(-1); MAP kinase: 50 micromol <compound-id="4713">PD 98059</compound-id> l(-1)) to investigate their effects on <protein-id="P16545,G9BFS9,A0A0G2KBD1,F1SRJ7,G9BFS5,Q45QB4,I3LBI3">IGF-I</protein-id> (100 ng ml(-1)) stimulated <compound-id="5994">progesterone</compound-id> secretion.	Wortmannin__IGF-I__no_interaction	progesterone__IGF-I__no_interaction	phosphatidylinositol__IGF-I__no_interaction	PD 98059__IGF-I__no_interaction
11349921-2	Thus, oxidation of 1 with Hg(SCN)2, Hg(C6F5)2/HOdpp (HOdpp = 2,6-<compound-id="13538462">diphenylphenol</compound-id>), TlCp (Cp = C5H5 or CH3C5H4), Tl(Ph2pz) (Ph2pz = <compound-id="91228503">3,5-diphenylpyrazolate</compound-id>) and CCl3CCl3 in <compound-id="8028">THF</compound-id> yielded the <compound-id="23992">ytterbium</compound-id>(II) complexes [Yb(NCS)3(<compound-id="8028">thf</compound-id>)4] (3), [Yb-(<protein-id="Q2VPK5">NCS)2</protein-id>(Odpp)(<compound-id="8028">thf</compound-id>)3](4), [Yb(NCS)<compound-id="445337,449598">2Cp</compound-id>-(<compound-id="8028">thf</compound-id>)3] (Cp = C5H5 (5), CH3C5H4 (6)), [Yb(<protein-id="Q2VPK5">NCS)2</protein-id>(Ph2pz)(<compound-id="8028">thf</compound-id>)4] (7) and [Yb(NCS)2Cl(<compound-id="8028">thf</compound-id>)4] (8).	ytterbium__NCS)2__no_interaction	2Cp__NCS)2__no_interaction	3,5-diphenylpyrazolate__NCS)2__no_interaction	thf__NCS)2__no_interaction	THF__NCS)2__no_interaction	diphenylphenol__NCS)2__no_interaction
21972524-8	The micronuclear rates in C and H group mice exposed to <compound-id="241">benzene</compound-id>(500 mg/kg C group, F5 and <protein-id="O88947,Q3TBR2,Q3U3V1,Q80Y26">F10</protein-id> mice; 1000 mg/kg C group, F5 and <protein-id="O88947,Q3TBR2,Q3U3V1,Q80Y26">F10</protein-id> mice; 500 mg/kg H group, F5 and <protein-id="O88947,Q3TBR2,Q3U3V1,Q80Y26">F10</protein-id> mice; 1000 mg/kg C group, F5 and <protein-id="O88947,Q3TBR2,Q3U3V1,Q80Y26">F10</protein-id> mice) were 5.88 per thousand +/- 4.55 per thousand, 8.25 per thousand +/- 2.06 per thousand, 7.50 per thousand +/- 6.99 per thousand, 10.67 per thousand +/- 1.16 per thousand, 7.88 per thousand +/- 3.09 per thousand, 9.20 per thousand +/- 1.30 per thousand, 9.63 per thousand +/- 4.34 per thousand and 13.33 per thousand +/- 2.08 per thousand, respectively, which were significantly higher than those (1.13 per thousand +/- 0.35 per thousand, 1.20 per thousand +/- 0.82 per thousand, 1.25 per thousand +/- 0.46 per thousand, 1.33 per thousand +/- 1.03 per thousand) in the solvent control group (P&lt;0.05 or P&lt;0.01).	benzene__F10__no_interaction
22062353-3	<compound-id="1548943">Capsaicin</compound-id> induced dose-dependent relaxation responses in <compound-id="2551">carbachol</compound-id>-contracted SHAM trachea (e.g., 10 μM <compound-id="1548943">capsaicin</compound-id> produced 66 ± 4% relaxation; n = 11), which were significantly inhibited by <compound-id="2733484">capsazepine</compound-id> [<protein-id="Q704Y3,Q3V318">transient receptor potential vanilloid type 1</protein-id> (<protein-id="Q704Y3,Q3V318">TRPV1</protein-id>) antagonist], (2S,<compound-id="21439199">3S</compound-id>)-3-{[3,5-bis(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]methoxy}-2-<compound-id="20038">phenylpiperidine</compound-id> hydrochloride (L-733,060) [neurokinin 1 (NK₁) receptor antagonist], <compound-id="3715">indomethacin</compound-id> [cyclooxygenase (COX) inhibitor], and the combination of 6-isopropoxy-<compound-id="473472">9-oxoxanthene-2-carboxylic acid</compound-id> (<compound-id="119461">AH6809</compound-id>) and 7-[5α-([1S,1α(Z)-biphenyl]-4-ylmethoxy)-2β-(4-morpholinyl)-3-<compound-id="8452">oxocyclopentyl</compound-id>]-<compound-id="3016291">4-heptenoic acid</compound-id>, <compound-id="22044544,5460341">calcium</compound-id> salt, hydrate (<compound-id="6435402">AH23848</compound-id>) [E-prostanoid (EP)₂ and EP₄ receptor antagonists, respectively], indicating that <compound-id="2548">capsaicin-</compound-id>induced relaxation involved the <protein-id="Q704Y3,Q3V318">TRPV1</protein-id>-mediated release of <protein-id="P41539,B7ZMQ2,Q149W7">substance P</protein-id> (SP), activation of epithelial NK₁ receptors, and production of COX products capable of activating relaxant EP₂/EP₄ receptors.	capsaicin-__TRPV1__no_interaction	capsaicin-__transient receptor potential vanilloid type 1__no_interaction	capsaicin-__substance P__no_interaction	4-heptenoic acid__TRPV1__no_interaction	4-heptenoic acid__transient receptor potential vanilloid type 1__no_interaction	4-heptenoic acid__substance P__no_interaction	capsaicin__TRPV1__no_interaction	capsaicin__transient receptor potential vanilloid type 1__no_interaction	capsaicin__substance P__no_interaction	oxocyclopentyl__TRPV1__no_interaction	oxocyclopentyl__transient receptor potential vanilloid type 1__no_interaction	oxocyclopentyl__substance P__no_interaction	9-oxoxanthene-2-carboxylic acid__TRPV1__no_interaction	9-oxoxanthene-2-carboxylic acid__transient receptor potential vanilloid type 1__no_interaction	9-oxoxanthene-2-carboxylic acid__substance P__no_interaction	3S__TRPV1__no_interaction	3S__transient receptor potential vanilloid type 1__no_interaction	3S__substance P__no_interaction	AH6809__TRPV1__no_interaction	AH6809__transient receptor potential vanilloid type 1__no_interaction	AH6809__substance P__no_interaction	AH23848__TRPV1__no_interaction	AH23848__transient receptor potential vanilloid type 1__no_interaction	AH23848__substance P__no_interaction	capsazepine__TRPV1__no_interaction	capsazepine__transient receptor potential vanilloid type 1__no_interaction	capsazepine__substance P__no_interaction	calcium__TRPV1__no_interaction	calcium__transient receptor potential vanilloid type 1__no_interaction	calcium__substance P__no_interaction	carbachol__TRPV1__no_interaction	carbachol__transient receptor potential vanilloid type 1__no_interaction	carbachol__substance P__no_interaction	Capsaicin__TRPV1__no_interaction	Capsaicin__transient receptor potential vanilloid type 1__no_interaction	Capsaicin__substance P__no_interaction	trifluoromethyl__TRPV1__no_interaction	trifluoromethyl__transient receptor potential vanilloid type 1__no_interaction	trifluoromethyl__substance P__no_interaction	phenylpiperidine__TRPV1__no_interaction	phenylpiperidine__transient receptor potential vanilloid type 1__no_interaction	phenylpiperidine__substance P__no_interaction	indomethacin__TRPV1__no_interaction	indomethacin__transient receptor potential vanilloid type 1__no_interaction	indomethacin__substance P__no_interaction
18560631-3	This issue focuses on the following selection of drugs: 131-I-<compound-id="86278273">Chlorotoxin</compound-id>, 423557; Abatacept, Ad.Egr.TNF.<compound-id="122016">11D</compound-id>, Adalimumab, AE-941, <compound-id="6918493">Ambrisentan</compound-id>, AMR-001, <compound-id="11556427">Anacetrapib</compound-id>, <compound-id="90470007">Anakinra</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, <compound-id="148192">Atazanavir sulfate</compound-id>; BAY-639044, Bazedoxifene <compound-id="176">acetate</compound-id>, Belimumab, Bevacizumab, <compound-id="387447">Bortezomib</compound-id>, Botulinum toxin type B, <compound-id="9837243">Brivaracetam</compound-id>, <compound-id="51045">Bucindolol</compound-id> hydrochloride; <compound-id="11556711">Carfilzomib</compound-id>, <compound-id="6918474">Carisbamate</compound-id>, CCX-282, CD20Bi, <compound-id="12993649,6918430">Ceftobiprole</compound-id>, Certolizumab pegol, CF-101, <compound-id="156419">Cinacalcet</compound-id> hydrochloride, <compound-id="9962928">Cypher</compound-id>; <compound-id="444031">Darifenacin hydrobromide</compound-id>, <compound-id="16136245">Degarelix acetate</compound-id>, Denosumab, <compound-id="125017">Desvenlafaxine</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="9578005">Dexlansoprazole</compound-id>, <compound-id="65808">Dexverapamil</compound-id>, Drotrecogin alfa (activated), <compound-id="60835">Duloxetine</compound-id> hydrochloride, <compound-id="6918296">Dutasteride</compound-id>; Efalizumab, EPs-7630, <compound-id="146570">Escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, <compound-id="123619">Etoricoxib</compound-id>; <compound-id="24847878,9854489">Fluticasone furoate</compound-id>, <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="3038498">Fospropofol disodium</compound-id>; <compound-id="19018347">Hexadecyloxypropyl</compound-id>-<compound-id="60613">cidofovir</compound-id>, HIV <protein-id="Q14624,B7ZKJ8,B2RMS9">gp120</protein-id>/NefTat/AS02A, HPV-6/11/16/18; INCB-18424, Incyclinide, <compound-id="57006608">Inhalable</compound-id> human <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir; KNS-760704, KW-0761; <compound-id="219078">Lacosamide</compound-id>, <compound-id="216326">Lenalidomide</compound-id>, <compound-id="5284583">Levetiracetam</compound-id>, <compound-id="133021">Licofelone</compound-id>, <compound-id="3676">Lidocaine</compound-id>/<compound-id="4906">prilocaine</compound-id>; mAb 216, MEDI-528, Men ACWY, Meningococcal C-CRM197 vaccine, <compound-id="5361918">Methylnaltrexone bromide</compound-id>; <compound-id="6918348">Nemifitide ditriflutate</compound-id>, <compound-id="157672">Nicotine</compound-id> conjugate vaccine, Nilotinib <compound-id="21885828">hydrochloride monohydrate</compound-id>; <protein-id="P01270">Octaparin; Parathyroid hormone</protein-id> (human recombinant), <compound-id="158786">Pegaptanib octasodium</compound-id>, Pitrakinra, <compound-id="16759247,5881,6432532,76,9814492,9860744">Prasterone</compound-id>, <compound-id="5486971">Pregabalin</compound-id>; <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, <compound-id="3052776">Rasagiline mesilate</compound-id>, <compound-id="121892">Retigabine</compound-id>, <compound-id="104850">Rimonabant</compound-id>, RTS,S/AS02D; <compound-id="1088">Sarcosine</compound-id>, <compound-id="216235">Sitaxentan sodium</compound-id>, <compound-id="154059">Solifenacin succinate</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="11226090">Taranabant</compound-id>, Taxus, <compound-id="16139605">Teduglutide</compound-id>, Teriparatide, <compound-id="9871419">Ticagrelor</compound-id>, <compound-id="5282226">Travoprost</compound-id>, TRU-015; USlipristal <compound-id="176">acetate</compound-id>, <protein-id="Q96RP3">Urocortin 2</protein-id>; <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>; <compound-id="10126189">YM-155</compound-id>, <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; Zanolimumab, <compound-id="68740">Zoledronic acid monohydrate</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">Zotarolimus</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">Zotarolimus</compound-id>-eluting stent.	YM-155__Urocortin 2__no_interaction	YM-155__Octaparin; Parathyroid hormone__no_interaction	YM-155__gp120__no_interaction	YM-155__insulin__no_interaction	Teduglutide__Urocortin 2__no_interaction	Teduglutide__Octaparin; Parathyroid hormone__no_interaction	Teduglutide__gp120__no_interaction	Teduglutide__insulin__no_interaction	Fospropofol disodium__Urocortin 2__no_interaction	Fospropofol disodium__Octaparin; Parathyroid hormone__no_interaction	Fospropofol disodium__gp120__no_interaction	Fospropofol disodium__insulin__no_interaction	Degarelix acetate__Urocortin 2__no_interaction	Degarelix acetate__Octaparin; Parathyroid hormone__no_interaction	Degarelix acetate__gp120__no_interaction	Degarelix acetate__insulin__no_interaction	Vardenafil hydrochloride hydrate__Urocortin 2__no_interaction	Vardenafil hydrochloride hydrate__Octaparin; Parathyroid hormone__no_interaction	Vardenafil hydrochloride hydrate__gp120__no_interaction	Vardenafil hydrochloride hydrate__insulin__no_interaction	Travoprost__Urocortin 2__no_interaction	Travoprost__Octaparin; Parathyroid hormone__no_interaction	Travoprost__gp120__no_interaction	Travoprost__insulin__no_interaction	Licofelone__Urocortin 2__no_interaction	Licofelone__Octaparin; Parathyroid hormone__no_interaction	Licofelone__gp120__no_interaction	Licofelone__insulin__no_interaction	Fondaparinux sodium__Urocortin 2__no_interaction	Fondaparinux sodium__Octaparin; Parathyroid hormone__no_interaction	Fondaparinux sodium__gp120__no_interaction	Fondaparinux sodium__insulin__no_interaction	acetate__Urocortin 2__no_interaction	acetate__Octaparin; Parathyroid hormone__no_interaction	acetate__gp120__no_interaction	acetate__insulin__no_interaction	Dutasteride__Urocortin 2__no_interaction	Dutasteride__Octaparin; Parathyroid hormone__no_interaction	Dutasteride__gp120__no_interaction	Dutasteride__insulin__no_interaction	Bucindolol__Urocortin 2__no_interaction	Bucindolol__Octaparin; Parathyroid hormone__no_interaction	Bucindolol__gp120__no_interaction	Bucindolol__insulin__no_interaction	Pregabalin__Urocortin 2__no_interaction	Pregabalin__Octaparin; Parathyroid hormone__no_interaction	Pregabalin__gp120__no_interaction	Pregabalin__insulin__no_interaction	Sitaxentan sodium__Urocortin 2__no_interaction	Sitaxentan sodium__Octaparin; Parathyroid hormone__no_interaction	Sitaxentan sodium__gp120__no_interaction	Sitaxentan sodium__insulin__no_interaction	Chlorotoxin__Urocortin 2__no_interaction	Chlorotoxin__Octaparin; Parathyroid hormone__no_interaction	Chlorotoxin__gp120__no_interaction	Chlorotoxin__insulin__no_interaction	Levetiracetam__Urocortin 2__no_interaction	Levetiracetam__Octaparin; Parathyroid hormone__no_interaction	Levetiracetam__gp120__no_interaction	Levetiracetam__insulin__no_interaction	Yttrium__Urocortin 2__no_interaction	Yttrium__Octaparin; Parathyroid hormone__no_interaction	Yttrium__gp120__no_interaction	Yttrium__insulin__no_interaction	Nemifitide ditriflutate__Urocortin 2__no_interaction	Nemifitide ditriflutate__Octaparin; Parathyroid hormone__no_interaction	Nemifitide ditriflutate__gp120__no_interaction	Nemifitide ditriflutate__insulin__no_interaction	Cinacalcet__Urocortin 2__no_interaction	Cinacalcet__Octaparin; Parathyroid hormone__no_interaction	Cinacalcet__gp120__no_interaction	Cinacalcet__insulin__no_interaction	Atazanavir sulfate__Urocortin 2__no_interaction	Atazanavir sulfate__Octaparin; Parathyroid hormone__no_interaction	Atazanavir sulfate__gp120__no_interaction	Atazanavir sulfate__insulin__no_interaction	Pegaptanib octasodium__Urocortin 2__no_interaction	Pegaptanib octasodium__Octaparin; Parathyroid hormone__no_interaction	Pegaptanib octasodium__gp120__no_interaction	Pegaptanib octasodium__insulin__no_interaction	Sunitinib malate__Urocortin 2__no_interaction	Sunitinib malate__Octaparin; Parathyroid hormone__no_interaction	Sunitinib malate__gp120__no_interaction	Sunitinib malate__insulin__no_interaction	oxalate__Urocortin 2__no_interaction	oxalate__Octaparin; Parathyroid hormone__no_interaction	oxalate__gp120__no_interaction	oxalate__insulin__no_interaction	Solifenacin succinate__Urocortin 2__no_interaction	Solifenacin succinate__Octaparin; Parathyroid hormone__no_interaction	Solifenacin succinate__gp120__no_interaction	Solifenacin succinate__insulin__no_interaction	Lacosamide__Urocortin 2__no_interaction	Lacosamide__Octaparin; Parathyroid hormone__no_interaction	Lacosamide__gp120__no_interaction	Lacosamide__insulin__no_interaction	Hexadecyloxypropyl__Urocortin 2__no_interaction	Hexadecyloxypropyl__Octaparin; Parathyroid hormone__no_interaction	Hexadecyloxypropyl__gp120__no_interaction	Hexadecyloxypropyl__insulin__no_interaction	Ticagrelor__Urocortin 2__no_interaction	Ticagrelor__Octaparin; Parathyroid hormone__no_interaction	Ticagrelor__gp120__no_interaction	Ticagrelor__insulin__no_interaction	Inhalable__Urocortin 2__no_interaction	Inhalable__Octaparin; Parathyroid hormone__no_interaction	Inhalable__gp120__no_interaction	Inhalable__insulin__no_interaction	Fluticasone furoate__Urocortin 2__no_interaction	Fluticasone furoate__Octaparin; Parathyroid hormone__no_interaction	Fluticasone furoate__gp120__no_interaction	Fluticasone furoate__insulin__no_interaction	Cypher__Urocortin 2__no_interaction	Cypher__Octaparin; Parathyroid hormone__no_interaction	Cypher__gp120__no_interaction	Cypher__insulin__no_interaction	Rasagiline mesilate__Urocortin 2__no_interaction	Rasagiline mesilate__Octaparin; Parathyroid hormone__no_interaction	Rasagiline mesilate__gp120__no_interaction	Rasagiline mesilate__insulin__no_interaction	Anacetrapib__Urocortin 2__no_interaction	Anacetrapib__Octaparin; Parathyroid hormone__no_interaction	Anacetrapib__gp120__no_interaction	Anacetrapib__insulin__no_interaction	Dexlansoprazole__Urocortin 2__no_interaction	Dexlansoprazole__Octaparin; Parathyroid hormone__no_interaction	Dexlansoprazole__gp120__no_interaction	Dexlansoprazole__insulin__no_interaction	Lenalidomide__Urocortin 2__no_interaction	Lenalidomide__Octaparin; Parathyroid hormone__no_interaction	Lenalidomide__gp120__no_interaction	Lenalidomide__insulin__no_interaction	Ambrisentan__Urocortin 2__no_interaction	Ambrisentan__Octaparin; Parathyroid hormone__no_interaction	Ambrisentan__gp120__no_interaction	Ambrisentan__insulin__no_interaction	ibritumomab tiuxetan__Urocortin 2__no_interaction	ibritumomab tiuxetan__Octaparin; Parathyroid hormone__no_interaction	ibritumomab tiuxetan__gp120__no_interaction	ibritumomab tiuxetan__insulin__no_interaction	90Y__Urocortin 2__no_interaction	90Y__Octaparin; Parathyroid hormone__no_interaction	90Y__gp120__no_interaction	90Y__insulin__no_interaction	Desvenlafaxine__Urocortin 2__no_interaction	Desvenlafaxine__Octaparin; Parathyroid hormone__no_interaction	Desvenlafaxine__gp120__no_interaction	Desvenlafaxine__insulin__no_interaction	Aripiprazole__Urocortin 2__no_interaction	Aripiprazole__Octaparin; Parathyroid hormone__no_interaction	Aripiprazole__gp120__no_interaction	Aripiprazole__insulin__no_interaction	Anakinra__Urocortin 2__no_interaction	Anakinra__Octaparin; Parathyroid hormone__no_interaction	Anakinra__gp120__no_interaction	Anakinra__insulin__no_interaction	Lidocaine__Urocortin 2__no_interaction	Lidocaine__Octaparin; Parathyroid hormone__no_interaction	Lidocaine__gp120__no_interaction	Lidocaine__insulin__no_interaction	Ranelic acid distrontium salt__Urocortin 2__no_interaction	Ranelic acid distrontium salt__Octaparin; Parathyroid hormone__no_interaction	Ranelic acid distrontium salt__gp120__no_interaction	Ranelic acid distrontium salt__insulin__no_interaction	prilocaine__Urocortin 2__no_interaction	prilocaine__Octaparin; Parathyroid hormone__no_interaction	prilocaine__gp120__no_interaction	prilocaine__insulin__no_interaction	Brivaracetam__Urocortin 2__no_interaction	Brivaracetam__Octaparin; Parathyroid hormone__no_interaction	Brivaracetam__gp120__no_interaction	Brivaracetam__insulin__no_interaction	Duloxetine__Urocortin 2__no_interaction	Duloxetine__Octaparin; Parathyroid hormone__no_interaction	Duloxetine__gp120__no_interaction	Duloxetine__insulin__no_interaction	Retigabine__Urocortin 2__no_interaction	Retigabine__Octaparin; Parathyroid hormone__no_interaction	Retigabine__gp120__no_interaction	Retigabine__insulin__no_interaction	11D__Urocortin 2__no_interaction	11D__Octaparin; Parathyroid hormone__no_interaction	11D__gp120__no_interaction	11D__insulin__no_interaction	Escitalopram__Urocortin 2__no_interaction	Escitalopram__Octaparin; Parathyroid hormone__no_interaction	Escitalopram__gp120__no_interaction	Escitalopram__insulin__no_interaction	Nicotine__Urocortin 2__no_interaction	Nicotine__Octaparin; Parathyroid hormone__no_interaction	Nicotine__gp120__no_interaction	Nicotine__insulin__no_interaction	Zoledronic acid monohydrate__Urocortin 2__no_interaction	Zoledronic acid monohydrate__Octaparin; Parathyroid hormone__no_interaction	Zoledronic acid monohydrate__gp120__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	Darifenacin hydrobromide__Urocortin 2__no_interaction	Darifenacin hydrobromide__Octaparin; Parathyroid hormone__no_interaction	Darifenacin hydrobromide__gp120__no_interaction	Darifenacin hydrobromide__insulin__no_interaction	Rimonabant__Urocortin 2__no_interaction	Rimonabant__Octaparin; Parathyroid hormone__no_interaction	Rimonabant__gp120__no_interaction	Rimonabant__insulin__no_interaction	Bortezomib__Urocortin 2__no_interaction	Bortezomib__Octaparin; Parathyroid hormone__no_interaction	Bortezomib__gp120__no_interaction	Bortezomib__insulin__no_interaction	Ceftobiprole__Urocortin 2__no_interaction	Ceftobiprole__Octaparin; Parathyroid hormone__no_interaction	Ceftobiprole__gp120__no_interaction	Ceftobiprole__insulin__no_interaction	Dexverapamil__Urocortin 2__no_interaction	Dexverapamil__Octaparin; Parathyroid hormone__no_interaction	Dexverapamil__gp120__no_interaction	Dexverapamil__insulin__no_interaction	Sarcosine__Urocortin 2__no_interaction	Sarcosine__Octaparin; Parathyroid hormone__no_interaction	Sarcosine__gp120__no_interaction	Sarcosine__insulin__no_interaction	cidofovir__Urocortin 2__no_interaction	cidofovir__Octaparin; Parathyroid hormone__no_interaction	cidofovir__gp120__no_interaction	cidofovir__insulin__no_interaction	Carisbamate__Urocortin 2__no_interaction	Carisbamate__Octaparin; Parathyroid hormone__no_interaction	Carisbamate__gp120__no_interaction	Carisbamate__insulin__no_interaction	Taranabant__Urocortin 2__no_interaction	Taranabant__Octaparin; Parathyroid hormone__no_interaction	Taranabant__gp120__no_interaction	Taranabant__insulin__no_interaction	hydrochloride monohydrate__Urocortin 2__no_interaction	hydrochloride monohydrate__Octaparin; Parathyroid hormone__no_interaction	hydrochloride monohydrate__gp120__no_interaction	hydrochloride monohydrate__insulin__no_interaction	Carfilzomib__Urocortin 2__no_interaction	Carfilzomib__Octaparin; Parathyroid hormone__no_interaction	Carfilzomib__gp120__no_interaction	Carfilzomib__insulin__no_interaction	Etoricoxib__Urocortin 2__no_interaction	Etoricoxib__Octaparin; Parathyroid hormone__no_interaction	Etoricoxib__gp120__no_interaction	Etoricoxib__insulin__no_interaction	Prasterone__Urocortin 2__no_interaction	Prasterone__Octaparin; Parathyroid hormone__no_interaction	Prasterone__gp120__no_interaction	Prasterone__insulin__no_interaction	succinate__Urocortin 2__no_interaction	succinate__Octaparin; Parathyroid hormone__no_interaction	succinate__gp120__no_interaction	succinate__insulin__no_interaction	Methylnaltrexone bromide__Urocortin 2__no_interaction	Methylnaltrexone bromide__Octaparin; Parathyroid hormone__no_interaction	Methylnaltrexone bromide__gp120__no_interaction	Methylnaltrexone bromide__insulin__no_interaction	Zotarolimus__Urocortin 2__no_interaction	Zotarolimus__Octaparin; Parathyroid hormone__no_interaction	Zotarolimus__gp120__no_interaction	Zotarolimus__insulin__no_interaction
20508517-1	BACKGROUND: This study sought to examine whether circulatory levels of endothelial dysfunction biomarkers [vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1), sE-<compound-id="4929">selectin</compound-id>, <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>), <protein-id="P00750">tissue plasminogen activator</protein-id> (<protein-id="P00750">t-PA</protein-id>) and plasminogen activator inhibitor (<protein-id="P05121,A0A024QYT5">PAI-1</protein-id>)] are associated with occurrence of late or very late stent thrombosis (ST) after percutaneous coronary intervention with <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">sirolimus</compound-id>-eluting stent implantation, and to assess the possible influence of genetic variants of these proteins on ST. METHODS: Serum levels of sVCAM-1, sICAM-1, sE-<compound-id="4929">selectin</compound-id>, <protein-id="P04275">vWF</protein-id>, <protein-id="P00750">t-PA</protein-id> and <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> were measured, and polymorphisms of <protein-id="P04275">vWF</protein-id> (-1234C/T, -1185A/G and -1051G/A), <protein-id="P00750">t-PA</protein-id> (insertion/deletion) and <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> genes (4G/5G) were determined in 41 patients who experienced at least one episode of late or very late ST. Eighty-two patients without ST randomly selected from the same study period served as controls.	sirolimus__von Willebrand factor__no_interaction	sirolimus__vWF__no_interaction	sirolimus__t-PA__no_interaction	sirolimus__PAI-1__no_interaction	sirolimus__tissue plasminogen activator__no_interaction	selectin__von Willebrand factor__no_interaction	selectin__vWF__no_interaction	selectin__t-PA__no_interaction	selectin__PAI-1__no_interaction	selectin__tissue plasminogen activator__no_interaction
16325771-2	This supposition is based on the following results: (i) microfluorimetry in <protein-id="Q15717">HUA</protein-id> smooth muscle cells in situ showed that a Ca(2+)-free extracellular solution diminished intracellular Ca(2+) ([Ca(2+)](i)), and <compound-id="4534086">KB-R7943</compound-id> (5microM), a specific inhibitor of the Ca(2+) entry mode of the exchanger, also decreased [Ca(2+)](i) (40.6+/-4.5% of Ca(2+)-free effect); (ii) <compound-id="4534086">KB-R7943</compound-id> produced the relaxation of <protein-id="Q15717">HUA</protein-id> rings (-24.7+/-7.3gF/gW, n=8, p&lt;0.05); (iii) stimulation of the NCX by lowering extracellular Na(+) increases basal [Ca(2+)](i) proportionally to Na(+) reduction (Delta fluorescence ratio=0.593+/-0.141 for Na(+)-free solution, n=8) and <protein-id="Q15717">HUA</protein-id> rings' contraction (peak force=181.5+/-39.7 for 130mM reduction, n=8), both inhibited by <compound-id="4534086">KB-R7943</compound-id> and a Ca(2+)-free extracellular solution.	KB-R7943__HUA__no_interaction
11344215-6	Analysis of <protein-id="P16220,Q53X93,Q5U0J5">CREB</protein-id> and <protein-id="Q03060,J3KQC0">ICER</protein-id> I/II messenger RNA revealed that the levels of both transcripts were higher in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(+) than in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(-) tumors (<protein-id="P16220,Q53X93,Q5U0J5">CREB</protein-id>/<compound-id="439168,446381">glyceraldehyde-3-phosphate</compound-id> dehydrogenase (<protein-id="P04406,V9HVZ4">GAPDH</protein-id>) mean optical density +/- SE, 2.34 +/- 0.36 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(+) vs. 0.99 +/- 0.22 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(-), P = 0.003; <protein-id="Q03060,J3KQC0">ICER</protein-id> I/<protein-id="P04406,V9HVZ4">GAPDH</protein-id>, 0.53 +/- 0.15 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(+) vs. 0.14 +/- 0.07 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(-), P = 0.01; <protein-id="Q03060,J3KQC0">ICER</protein-id> II/<protein-id="P04406,V9HVZ4">GAPDH</protein-id>, 1.5 +/- 0.21 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(+) vs. 0.83 +/- 0.13 in <protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">gsp</protein-id>(-), P = 0.01), although a few cases in both groups did not display this pattern of expression.	glyceraldehyde-3-phosphate__ICER__no_interaction	glyceraldehyde-3-phosphate__CREB__no_interaction	glyceraldehyde-3-phosphate__GAPDH__no_interaction	glyceraldehyde-3-phosphate__gsp__no_interaction
14636463-5	RESULTS: The RT-PCR showed that the levels of STAT1mRNA expression of the lung tissue in H1 1.25 +/- 0.12, <compound-id="783">H2</compound-id> 2.28 +/- 0.15 and H3 1.27 +/- 0.12 were significantly higher than that in the healthy control group 0.61 +/- 0.07 (P &lt; 0.01); the levels of STAT2mRNA expression in H1 0.54 +/- 0.06, <compound-id="783">H2</compound-id> 1.01 +/- 0.08 and H3 1.36 +/- 0.09 were significantly higher than that in control group 0.30 +/- 0.03 (P &lt; 0.01); the mRNA expressions of <protein-id="P52631">STAT3</protein-id> in H1 0.74 +/- 0.11, <compound-id="783">H2</compound-id> 1.19 +/- 0.13 and H3 0.80 +/- 0.08 were significantly higher than that in control group 0.26 +/- 0.10 (P &lt; 0.01); and the mRNA expressions of <protein-id="Q62771">STAT5</protein-id> in H1 0.92 +/- 0.10, <compound-id="783">H2</compound-id> 1.23 +/- 0.10 and H3 1.03 +/- 0.11 were significantly higher than that in control group 0.60 +/- 0.11 (P &lt; 0.01).	H2__STAT5__no_interaction	H2__STAT3__no_interaction
12875368-4	We now demonstrate that the 2 pathways exhibit distinctive susceptibilities to inhibitors: 1) The anionic amphiphile <compound-id="3028194">lithium</compound-id> <compound-id="8778">dodecyl sulfate</compound-id>, an activator of the canonical pathway, has the opposite effect (inhibition) on oxidase activation by prenylated Rac and <protein-id="P19878">p67phox</protein-id>; 2) <compound-id="8977">GDP</compound-id> and, paradoxically, <compound-id="6830">GTP</compound-id> (but not <compound-id="6804">GMP</compound-id>, <compound-id="5957">ATP</compound-id>, <compound-id="6022">ADP</compound-id>, and <protein-id="P07741">AMP</protein-id>) prevent oxidase activation by the <protein-id="P14598">p47phox</protein-id> and amphiphile-independent pathway but do not affect activation by the canonical pathway; 3) The Rac-binding domain of <protein-id="P42857,B2R5R8">p21</protein-id>-activated kinase is a potent inhibitor of activation by the <protein-id="P14598">p47phox</protein-id> and amphiphile-independent pathway while exerting a milder inhibitory effect on the canonical pathway; 4) The C-terminal polybasic <protein-id="P63000,A4D2P0,A4D2P1">Rac1</protein-id> peptide 177-191 and the cationic antibiotic <compound-id="8378,4454,45356930,5702092,62404,6602486,71463901">neomycin sulfate</compound-id> inhibit activation by the canonical pathway but do not affect activation by the <protein-id="P14598">p47phox</protein-id> and amphiphile-independent pathway; 5) Binding of prenylated <protein-id="P63000,A4D2P0,A4D2P1">Rac1</protein-id> to membrane-mimicking phospholipid vesicles is, nevertheless, enhanced when these contain negatively charged lipids.	GDP__AMP__no_interaction	GDP__Rac1__no_interaction	GDP__p21__no_interaction	GDP__p47phox__no_interaction	GDP__p67phox__no_interaction	neomycin sulfate__AMP__no_interaction	neomycin sulfate__Rac1__no_interaction	neomycin sulfate__p21__no_interaction	neomycin sulfate__p47phox__no_interaction	neomycin sulfate__p67phox__no_interaction	lithium__AMP__no_interaction	lithium__Rac1__no_interaction	lithium__p21__no_interaction	lithium__p47phox__no_interaction	lithium__p67phox__no_interaction	ADP__AMP__no_interaction	ADP__Rac1__no_interaction	ADP__p21__no_interaction	ADP__p47phox__no_interaction	ADP__p67phox__no_interaction	GTP__AMP__no_interaction	GTP__Rac1__no_interaction	GTP__p21__no_interaction	GTP__p47phox__no_interaction	GTP__p67phox__no_interaction	ATP__AMP__no_interaction	ATP__Rac1__no_interaction	ATP__p21__no_interaction	ATP__p47phox__no_interaction	ATP__p67phox__no_interaction	dodecyl sulfate__AMP__no_interaction	dodecyl sulfate__Rac1__no_interaction	dodecyl sulfate__p21__no_interaction	dodecyl sulfate__p47phox__no_interaction	dodecyl sulfate__p67phox__no_interaction	GMP__AMP__no_interaction	GMP__Rac1__no_interaction	GMP__p21__no_interaction	GMP__p47phox__no_interaction	GMP__p67phox__no_interaction
17333272-5	When compared with children in the lowest tertile, children in the highest tertile of saturated fat consumption had significantly higher mean levels of total <compound-id="5997">cholesterol</compound-id> (206.3 mg/dl vs. 151.8 mg/dl), LDL <compound-id="5997">cholesterol</compound-id> (140.6 mg/dl vs. 95.1 mg/dl) and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (99.2 mg/dl vs. 64.3 mg/dl) and lower mean levels of HDL <compound-id="5997">cholesterol</compound-id> (53.5 mg/dl vs. 57.5 mg/dl), whereas children in the highest tertile of monounsaturated fat consumption had significantly higher mean levels of HDL <compound-id="5997">cholesterol</compound-id> (56.5 mg/dl vs. 51.8 mg/dl) and lower levels of total <compound-id="5997">cholesterol</compound-id> (133.2 mg/dl vs. 201.6 mg/dl), LDL <compound-id="5997">cholesterol</compound-id> (93.1 mg/dl vs. 137.5 mg/dl) and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (68.6 mg/dl vs. 94.9 mg/dl) than children in the lowest tertile.	cholesterol__apolipoprotein B__no_interaction
17291104-2	The reactions of cluster 2 with [M(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)4] (M = Pd, Pt) give rise to the formation of a new family of nona- or decanuclear mixed-metal sulfide clusters, [{(Cp*Mo)3(mu3-S)4Ru}2(mu3-S)2{Pd(S)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)}][PF6]2 (3), [{(Cp*Mo)3(mu3-S)4Ru}2(mu3-S)2{(Pd(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>))2(mu2-S)}][PF6]2 (4), and [{(Cp*Mo)3(mu3-S)4Ru}2(mu3-S)2{Pt(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2}][PF6]2 (5), with two RuMo3S4 <compound-id="136090">cubane</compound-id> units, the structures of which have been determined by X-ray diffraction studies.	cubane__PPh3__no_interaction
10923829-1	Six new <compound-id="24816235">furostanol</compound-id>-type steroid saponins called trigoneosides Xa, Xb, <protein-id="P49184">XIb</protein-id>, XIIa, XIIb, and XIIIa were isolated from the seeds of Egyptian Trigonella foenum-graecum L. (Leguminosae) together with six known <compound-id="24816235">furostanol</compound-id>-type steroid saponins: trigoneosides Ia, Ib, and Va, glycoside D, <compound-id="441899">trigonelloside C</compound-id>, and <compound-id="11524144">compound C</compound-id>. The structures of trigoneosides Xa, Xb, Xlb, XIIa, Xllb, and XIIIa were determined on the basis of chemical and physicochemical evidence as 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>-(<compound-id="76936801">25S</compound-id>)-5alpha-<compound-id="53740100">furostane</compound-id>-2alpha+ ++,3beta,22xi,26-tetraol 3-O-<compound-id="13455857">alpha-L-rhamnopyranosyl</compound-id>(1--&gt;2)-,beta-<compound-id="5793">D-glucopyranoside</compound-id>, 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>-(25R)-5alpha-<compound-id="53740100">furostane</compound-id>-2 alpha,beta,22xi,26tetraol 3-O-<compound-id="13455857">alpha-L-rhamnopyranosyl</compound-id>(l --&gt;2)-beta-<compound-id="5793">D-glucopyranoside</compound-id>, 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>-(25R)-5alpha-furostane2alpha++ +,beta,22xi,26-tetraol 3-O-beta-<compound-id="446875">D-xylopyranosyl</compound-id>(l --&gt;4)-beta-<compound-id="5793">D-glucopyranoside</compound-id>, 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>-(<compound-id="76936801">25S</compound-id>)-furost-4-ene-3beta,22xi,26- triol 3-O-Ca-L-<compound-id="22787886">rhamnopyranosyl</compound-id>(1--&gt;2)-beta-<compound-id="5793">D-glucopyranoside</compound-id>, 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>-(25R)-furost-4-ene-3beta,22xi+ ++,26-triol 3-O-<compound-id="13455857">alpha-L-rhamnopyranosyl</compound-id>(1--&gt;2)-beta-<compound-id="5793">D-glucopyranoside</compound-id>, and 26-O-beta-D-<compound-id="64960">glucopyranosyl</compound-id>(<compound-id="76936801">25S</compound-id>)-furost-5-ene-3beta,22xi,26-t riol 3-O-<compound-id="13455857">alpha-L-rhamnopyranosyl</compound-id>(1--&gt;2)-beta-D-<compound-id="64960">glucopyranosyl</compound-id> (1--&gt;3)-beta-D-<compound-id="64960">glucopyranosyl</compound-id>(1--4)]-beta-<compound-id="5793">D-glucopyranoside</compound-id>, respectively.	furostanol__XIb__no_interaction	D-glucopyranoside__XIb__no_interaction	alpha-L-rhamnopyranosyl__XIb__no_interaction	trigonelloside C__XIb__no_interaction	furostane__XIb__no_interaction	D-xylopyranosyl__XIb__no_interaction	rhamnopyranosyl__XIb__no_interaction	glucopyranosyl__XIb__no_interaction	25S__XIb__no_interaction	compound C__XIb__no_interaction
19388868-5	She presented with hypokalemia (<compound-id="5462222">potassium</compound-id> level, 1.7 mEq/L), increased urinary excretion of <compound-id="5462222">potassium</compound-id> (fractional excretion of K, 21.2%), abnormalities on an electrocardiogram (flat T waves in II, III, AVF, and V1-6), rhabdomyolysis (<compound-id="586">creatine</compound-id> kinase level, 28,376 U/L), myopathy, metabolic alkalosis with respiratory compensation (O(2) flow rate, 2 L/min; pH, 7.473; pco(2), 61.0 mm Hg; po(2), 78.0 mm Hg; HCO(3), 44.1 mmol/L), hypertension (174/93 mm Hg), hyperglycemia (blood <compound-id="206,5793,64689,79025">glucose</compound-id> level, 200-300 mg/dL), frequent urination, suppressed plasma <protein-id="P00797">renin</protein-id> activity (0.1 ng/mL/hour), decreased <compound-id="5839">aldosterone</compound-id> levels (2.6 ng/dL), and increased urinary <compound-id="5754">cortisol</compound-id> levels (600.6 microg/day; reference range, 26.0-187.0 microg/day).	potassium__renin__no_interaction	glucose__renin__no_interaction	aldosterone__renin__no_interaction	cortisol__renin__no_interaction	creatine__renin__no_interaction
17924548-5	Pretreatment, all patients were <compound-id="5280795,5283711">vitamin D</compound-id> deficient with a mean 25(OH)D level of 11.6 [corrected] +/- 4 [corrected] ng/ml, had low BMD at the lumbar spine (L-spine), 0.87 +/- 0.11 g/cm(2) (mean Z-score of -2.6 3 +/- 0.71 SD and T score of -2.31 +/- 0.75 SD), femoral neck, 0.8 +/- 0.18 g/cm(2) (mean Z-score -1.36 +/- 0.84, T-score -1.14 +/- 0.75), and the distal radius and ulna, 0.6 +/- 0.17 g/cm(2) (mean Z-score -1.18 +/- 0.79, T-score -1.01 +/- 0.74) and had elevated <protein-id="Q02318">CTx</protein-id> (0.87 +/- 0.5 ng/ml) and <protein-id="P02818">osteocalcin</protein-id> levels (12.3 +/- 3.7 ng/mul).	vitamin D__osteocalcin__no_interaction	vitamin D__CTx__no_interaction
7958155-7	Furthermore, there was a significant positive relationship between <protein-id="P05305,Q6FH53">ET-1</protein-id> excretion and urine flow rate (r = 0.67, P &lt; 0.0001), CCR (r = 0.40, P &lt; 0.0025), Cosm (r = 0.58, P &lt; 0.001), <compound-id="5360545">sodium</compound-id> (r = 0.56, P &lt; 0.001) and <compound-id="5462222">potassium</compound-id> excretion (r = 0.42, P &lt; 0.001).	potassium__ET-1__no_interaction	sodium__ET-1__no_interaction
8520591-5	RESULTS--Basal and peak values (mean +/- SD) of <protein-id="P01189,Q6FHC8">ACTH</protein-id> and <compound-id="5754">cortisol</compound-id> for both tests were: cosyntropin test (AIDS x NS): basal <compound-id="5754">cortisol</compound-id> 22.5 +/- 7.1 x 10.6 +/- 3.6 (p &lt; 0.01), peak 36.0 +/- 12.8 x 28.3 +/- 7.6 (p &lt; 0.05); oCRH test: basal <protein-id="P01189,Q6FHC8">ACTH</protein-id> 42.2 +/- 33.5 x 28.9 +/- 12.7 (NS), peak 104.7 +/- 62.2 x 59.3 +/- 17.6 (p &lt; 0.05); basal <compound-id="5754">cortisol</compound-id> 19.7 +/- 9.0 x 10.1 +/- 3.4 (p &lt; 0.01), peak 27.5 +/- 8.9 x 18.3 +/- 5.1 (p &lt; 0.05).	cortisol__ACTH__no_interaction
16204370-9	RESULTS: In the cross-sectional study, <compound-id="5994">progesterone</compound-id> levels were positively related to concentrations of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.41; P &lt; 0.001), <protein-id="P02741">C-reactive protein</protein-id> (r = 0.37; P = 0.007), soluble <protein-id="P19320">vascular cell adhesion molecule 1</protein-id> (r = 0.28; P = 0.02), <protein-id="P16581">E-selectin</protein-id> (r = 0.45; P &lt; 0.001), <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.42; P &lt; 0.001), neutrophils (r = 0.62; P &lt; 0.001), and serum protein fractions <protein-id="P25100,B0ZBE0">alpha-1</protein-id> (r = 0.44; P &lt; 0.001) and alpha-2 (r = 0.36; P = 0.002).	progesterone__E-selectin__no_interaction	progesterone__vascular cell adhesion molecule 1__no_interaction	progesterone__IL-6__no_interaction	progesterone__leptin__no_interaction	progesterone__C-reactive protein__no_interaction	progesterone__alpha-1__no_interaction
22265835-4	It was found that <compound-id="86573619">Schiff base</compound-id> <compound-id="23978">copper</compound-id>(II) complexes, namely [Cu(C(15)H(13)BrNO(2))(2)]·2(C(6)H(7)N) (1), [Cu(C(15)H(12)Br(2)NO(2))(2)]·2(DMF) (2), Cu(C(19)H(16)NO(2))(2) (3) and Cu(C(19)H(16)NO)(2) (5), showed strong inhibitory activity against jack <protein-id="Q3B7T3">bean</protein-id> urease (IC(50)=1.45-3.59 μM), while <compound-id="86573619">Schiff base</compound-id> <compound-id="935">nickel</compound-id>(II) complex, [Ni(C(19)H(16)NO(2))(2)]·2(DMF) (4), exhibited weak inhibitory activity (IC(50)&gt;50 μM).	Schiff base__bean__no_interaction	nickel__bean__no_interaction	copper__bean__no_interaction
19381406-2	The reaction of derivative [cis-Pt(R(F))(2)(PPh(2)C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)] (R(F) = C(6)F(5)) with the solvate complex [cis-Pt(R(F))(2)(<compound-id="8028">thf</compound-id>)(2)] leads to the formation of an asymmetrical heteronuclear diplatinum complex [{Pt(R(F))(2)(mu-1kappaP:2eta(2)-PPh(2)C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)}Pt(R(F))(2)] having the "cis-Pt(R(F))(2)" fragment coordinated to the triple bonds of both ferrocenylethynylphosphine units, while treatment of [cis-Pt(C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)(PPh(2)C[triple bond]CR)(2)] (R = Fc , Ph , tBu ) with the same solvate [cis-Pt(R(F))(2)(<compound-id="8028">thf</compound-id>)(2)], affords double ferrocenylacetylide-bridged diplatinum systems [{Pt(PPh(2)C[triple bond]CR)(2)(mu-eta(1):eta(2)-C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)}Pt(R(F))(2)] .	thf__CFc__no_interaction
19381406-3	The solid-state structures of [cis/trans-Pt(R(F))(2)(PPh(2)C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)] /, [cis-Pt(R(F))(2)(PPh(2)C[triple bond]<protein-id="Q06124">CFc</protein-id>)(tht)] (tht = <compound-id="1127">tetrahydrothiophene</compound-id>), [{Pt(R(F))(2)(mu-1kappaP:2eta(2)-PPh(2)C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)}Pt(R(F))(2)] and [{Pt(PPh(2)C[triple bond]CtBu)(2)(mu-eta(1):eta(2)-C[triple bond]<protein-id="Q06124">CFc</protein-id>)(2)}Pt(R(F))(2)] have been determined by X-ray diffraction methods.	tetrahydrothiophene__CFc__no_interaction
17029391-4	The reaction between 2 and [{Pd(mu-Cl)(L(NC))}2] (5, L(NC) = 2-{(dimethylamino)methyl-kappaN}phenyl-kappaC(1)) gave the bridge-cleavage product [<compound-id="3035662">PdCl</compound-id>(L(NC))(2-kappaP)] (6) while the reaction with [Pd(L(NC))(<compound-id="6342">MeCN</compound-id>)2]ClO4 (7) yielded the cationic bis(chelate) [Pd(L(NC))(2-<protein-id="Q9UNA4">eta2</protein-id>:kappaP)]ClO4 (8).	PdCl__eta2__no_interaction	MeCN__eta2__no_interaction
10401706-10	In particular, in childhood onset GH deficient patients after 3 months <protein-id="P02818">osteocalcin</protein-id> increased from 2.5+/-1.3 to 7.9+/-2.1 mcg/l, p&lt;0.001 aminoterminal propeptide of type-III from 273+/-49 to 359+/-15 U/I p&lt;0.001; serum carboxyterminal telopeptide of <protein-id="P08123">type-I procollagen</protein-id> from 105+/-48 to 201+/-45 mcg/l, p&lt;0.001; urinary <compound-id="269023,5810">hydroxyproline</compound-id>/<compound-id="588">creatinine</compound-id> from 0.19+/-0.16 to 0.81+/-0.17 mmol/mol, p&lt;0.001; urinary <compound-id="3034763">deoxypyridinoline</compound-id>/<compound-id="588">creatinine</compound-id> from 21 +/-10 to 54+/-20 mcmol/mol, p&lt;0.001; while in adulthood onset GH deficient patients after 6 months <protein-id="P02818">osteocalcin</protein-id> increased from 4.2+/-3.6 to 6.5+/-1.9 mcg/l, p&lt;0.05; aminoterminal propeptide of type- III from 440+/-41 to 484+/-37 U/I, p&lt;0.05; serum carboxyterminal telopeptide of <protein-id="P08123">type-I procollagen</protein-id> from 125+/-40 to 152+/-22 mcg/l, p&lt;0.05; urinary <compound-id="269023,5810">hydroxyproline</compound-id>/<compound-id="588">creatinine</compound-id> from 0.24+/-0.12 to 0.54+/-0.06 mmol/mol, p&lt;0.001; urinary <compound-id="3034763">deoxypyridinoline</compound-id>/<compound-id="588">creatinine</compound-id> from 23+/-8 to 42+/-5 mcmol/mol, p&lt;0.001.	deoxypyridinoline__type-I procollagen__no_interaction	deoxypyridinoline__osteocalcin__no_interaction	creatinine__type-I procollagen__no_interaction	creatinine__osteocalcin__no_interaction	hydroxyproline__type-I procollagen__no_interaction	hydroxyproline__osteocalcin__no_interaction
24948904-1	Ni(II) and Zn(II) complexes were synthesized from tridentate 3-formyl chromone Schiff bases such as 3-((2-hydroxyphenylimino)methyl)-4H-<compound-id="10286">chromen-4-one</compound-id> (<protein-id="P07306,Q6FGQ5">HL1</protein-id>), 2-((4-oxo-4H-<compound-id="136068">chromen</compound-id>-3-yl)methylneamino)<compound-id="243">benzoic acid</compound-id> (<protein-id="P07307,Q7Z4G9">HL2</protein-id>), 3-((3-hydroxypyridin-2-ylimino)methyl)-4H-<compound-id="10286">chromen-4-one</compound-id> (<protein-id="Q14204">HL3</protein-id>), and 3-((2-mercaptophenylimino)methyl)-4H-<compound-id="10286">chromen-4-one</compound-id> (<compound-id="10130163">HL4</compound-id>).	chromen-4-one__HL3__no_interaction	chromen-4-one__HL2__no_interaction	chromen-4-one__HL1__no_interaction	chromen__HL3__no_interaction	chromen__HL2__no_interaction	chromen__HL1__no_interaction	HL4__HL3__no_interaction	HL4__HL2__no_interaction	HL4__HL1__no_interaction	benzoic acid__HL3__no_interaction	benzoic acid__HL2__no_interaction	benzoic acid__HL1__no_interaction
18096673-3	During studies to examine drug-interaction potential of compounds in cultured human hepatocytes, exposure with (S)-1-[(1S,<compound-id="21439199">3S</compound-id>,4S)-4-[(S)-2-(3-benzyl-2-oxo-<compound-id="449488">imidazolidin</compound-id>-1-yl)-3,3-dimethyl-<compound-id="10927">butyrylamino</compound-id>]-3-hydroxy-5-phenyl-1-(4-pyridin-2-yl-benzyl)-<compound-id="16217248">pentylcarbamoyl</compound-id>]-2,2-dimethyl-propyl-<compound-id="11722">carbamic acid methyl ester</compound-id> (A-792611), a novel HIV protease inhibitor (PI) previously under investigation for the treatment of HIV infection, resulted in significant down-regulation of constitutive <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> expression.	3S__CYP3A4__no_interaction	carbamic acid methyl ester__CYP3A4__no_interaction	butyrylamino__CYP3A4__no_interaction	pentylcarbamoyl__CYP3A4__no_interaction	imidazolidin__CYP3A4__no_interaction
19013291-9	There was a positive correlation between <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and <compound-id="24316">cyclic guanosine monophosphate</compound-id> (r = 0.73, P &lt; .0001), <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and reactive hyperemia (r = 0.63, P &lt; .0001), and <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and Arg/ADMA ratio (r = 0.44, P &lt; .01).	cyclic guanosine monophosphate__IGF-1__no_interaction
3542647-3	At a clamp plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> concentration of 10 microU/ml, <compound-id="206,64689,79025">glucose</compound-id> disposal rates did not change after weight loss; at approximately 100 microU/ml, <compound-id="206,64689,79025">glucose</compound-id> disposal rates increased by 21% [from 4.3 +/- 0.2 to 5.3 +/- 0.4 mg X min-1 X kg-1 of fat-free mass (FFM), P less than .01] mostly due to increased carbohydrate oxidation rates (2.0 +/- 0.3 to 2.8 +/- 0.3 mg X min-1 X kg-1 FFM, P less than .02); at 2400 microU/ml, <compound-id="206,64689,79025">glucose</compound-id> disposal rates increased by 37% (11.4 +/- 0.6 to 15.6 +/- 1.4 mg X min-1 X kg-1 FFM, P less than .02) mostly due to increased nonoxidative carbohydrate disposal rates or storage (7.5 +/- 0.6 to 10.9 +/- 1.3 mg X min-1 X kg-1 FFM, P less than .04).	glucose__Insulin__no_interaction
16892169-3	Our results showed that (1) all five MM cell lines (<compound-id="447084">OPM</compound-id>-2, RPMI-8226, U-266, KMS-12-BM, MOLP-8) expressed surface <protein-id="P08887,A0N0L5,A0A087WTB5">IL-6R</protein-id> and gp130, the B cell lymphomas (WSU-1, DOHH-2, U-698) expressed only gp130; (2) exogenous <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> markedly up-regulated the expression of membrane <protein-id="P08887,A0N0L5,A0A087WTB5">IL-6R</protein-id> (up to 186%) and down-regulated the gp130 receptor (down to 4%) in MM cell lines, the membrane expression of gp130 in B cell lymphomas was not altered; (3) <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> markedly increased the spontaneous proliferation (up to 151%) in all MM cell lines, that of B cell lymphomas was not affected; (4) <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> increased the DNA synthesis in the S cell cycle phase of MM cells and arrested the stage G2/M, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> was ineffective in any cell cycle phase of B cell lymphoma; (5) <protein-id="P08887,A0N0L5,A0A087WTB5">IL-6RA</protein-id> inhibited the membrane <protein-id="P08887,A0N0L5,A0A087WTB5">IL-6R</protein-id> partially, the proliferation was decreased only slightly; and (6) although gp130A inhibited the membrane gp130 completely, the proliferation was decreased 81-78% in MM and B cell lymphoma cell lines.	OPM__IL-6__no_interaction	OPM__IL-6R__no_interaction	OPM__IL-6RA__no_interaction
17961191-11	The population mean (and between-subject variability, CV%) for clearance and volume of distribution of the central compartment (V(C)) for <compound-id="60750">gemcitabine</compound-id> were 2.7 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (31%) and 15 l (39%), respectively, and 0.04 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (35%) and 46 l (15%), respectively, for dFdU.	gemcitabine__min(-1__no_interaction
18018381-9	RESULTS: Patients in group I demonstrated a significantly higher <compound-id="8376">TnT</compound-id> and CK-MB (1.39 +/-1.3 vs 0.83 +/-0.74 ng/ml, p &lt;0.05; 139.6 +/-178.5 vs 57.48+/-52.1 IU/I p &lt;0.05, respectively), higher concentrations of <protein-id="P02741">CRP</protein-id> (12.06 +/-14.3 vs 3.59 +/-4.1mg/l, p &lt;0.05) <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (4.59 +/-1.93 vs 3.62 +/-1.36 g/l, p &lt;0.05), sVCAM-1 (1393.4 +/-865.4 vs 863.9+/-425.2 ng/ml, p &lt;0.05) and sICAM-1 (735.1+/-316.3 vs 573.3 +/-226.1 ng/ml, p &lt;0.05), higher leucocytosis (11,430 +/-3680 vs 9750+/-3100/microl, p &lt;0.05) and lower <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> concentrations (5.8 +/-5.2 vs 8.3 +/-2.9 8 microg/ml, p &lt;0.05) as compared to the control group.	TnT__CRP__no_interaction	TnT__fibrinogen__no_interaction	TnT__adiponectin__no_interaction
22588750-0	Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (<compound-id="17754242">CFQ</compound-id>), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (<compound-id="44517638">FSS</compound-id>), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (<protein-id="O75444,H3BP11">MAF</protein-id>), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (<protein-id="Q96P53">ProF</protein-id>), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (<compound-id="6323535">VAS</compound-id>).	VAS__ProF__no_interaction	VAS__MAF__no_interaction	FSS__ProF__no_interaction	FSS__MAF__no_interaction	CFQ__ProF__no_interaction	CFQ__MAF__no_interaction
17351274-7	A1C showed a significant association with BMI (beta = 0.017, P &lt; 0.001), systolic (beta = 0.002, P = 0.028) and diastolic (beta = 0.202, P = 0.017) blood pressure, waist circumference (beta = 0.007, P &lt; 0.001), serum <compound-id="5997">cholesterol</compound-id> (beta = 0.002, P &lt; 0.001), triglycerides (beta = 0.001, P &lt; 0.001), LDL <compound-id="5997">cholesterol</compound-id> (beta = 0.002, P &lt; 0.001), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (beta = 0.009, P &lt; 0.001), and homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (beta = 0.047, P &lt; 0.001) after adjusting for age and sex.	cholesterol__insulin__no_interaction
10708717-1	The ability of the selective <compound-id="5202">serotonin</compound-id> reuptake inhibitor, fluoxetine, to modify the effects of <compound-id="5288826">morphine</compound-id>, N-((S)-2-<compound-id="123147">benzyl</compound-id>-3[(S) 2-amino-4-methylthio)butyldithio-]-1-oxopropyl)-L-<compound-id="5950,602">alanine</compound-id> benzylester (RB 120; mixed inhibitor of <compound-id="461776">enkephalin</compound-id> metabolism), and 4-¿[2-[[3-(1H-indol-3-yl))-2-methyl-1-oxo-2-[[(tricyclo[3,3,1,1] <protein-id="Q9C0J9,Q8TAT1,A0A024RAV8">dec-2</protein-id>-yloxy) carbonyl] amino¿ propyl] amino]-<compound-id="137551">1-phenylethyl</compound-id>] amino¿-4-oxo-[R-(R*,R*)]-<compound-id="264">butanoate</compound-id> N-methyl-D-<compound-id="10266">glucamine</compound-id> (CI 988; <compound-id="16129670">cholecystokinin</compound-id> receptor subtype [CCK(2)] antagonist), was assessed using conditioned place preference.	butanoate__dec-2__no_interaction	alanine__dec-2__no_interaction	morphine__dec-2__no_interaction	glucamine__dec-2__no_interaction	enkephalin__dec-2__no_interaction	serotonin__dec-2__no_interaction	1-phenylethyl__dec-2__no_interaction	benzyl__dec-2__no_interaction	cholecystokinin__dec-2__no_interaction
12087878-3	This issue focuses on the following selection of drugs: Abiciximab, <compound-id="187">acetylcholine chloride</compound-id>, <compound-id="12035">acetylcysteine</compound-id>, alefacept, alemtuzumab, <compound-id="16197724">alicaforsen</compound-id>, alteplase, <compound-id="169371,2154">aminopterin</compound-id>, <compound-id="33613,2171,28094872">amoxicillin sodium</compound-id>, <compound-id="5280965">amphotericin B</compound-id>, <compound-id="2187">anastrozole</compound-id>, <compound-id="152951,2232,440542,445156,92722">argatroban</compound-id> <compound-id="1488787">monohydrate</compound-id>, <compound-id="5359596">arsenic</compound-id> trioxide, <compound-id="2244">aspirin</compound-id>, <compound-id="148192">atazanavir</compound-id>, <compound-id="60823">atorvastatin</compound-id>, <compound-id="71587613">augmerosen</compound-id>, <compound-id="2265">azathioprine</compound-id>; <compound-id="5904">Benzylpenicillin</compound-id>, BMS-284756, botulinum toxin type A, botulinum toxin type B, <compound-id="16219006,443289,52943236">BQ-123</compound-id>, <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id>, <compound-id="130165">BXT-51072</compound-id>; <compound-id="6006">Calcium folinate</compound-id>, <compound-id="2554">carbamazepine</compound-id>, <compound-id="2568">carboplatin</compound-id>, <compound-id="2578">carmustine</compound-id>, <compound-id="5479530,11957492,12971801,5361919,2657,5896995,6398678">ceftriaxone sodium</compound-id>, <compound-id="13371699,3379942,47419,5361467,6321416">cefuroxime axetil</compound-id>, chorionic gonadotropin (human), <compound-id="2756">cimetidine</compound-id>, <compound-id="2764">ciprofloxacin hydrochloride</compound-id>, cisplatin, <compound-id="2771">citalopram hydrobromide</compound-id>, <compound-id="20279">cladribine</compound-id>, <compound-id="84029">clarithromycin</compound-id>, <compound-id="5280980">clavulanic acid</compound-id>, <compound-id="119182">clofarabine</compound-id>, <compound-id="2806,60606">clopidogrel hydrogensulfate</compound-id>, <compound-id="2812">clotrimazole</compound-id>, <compound-id="5353536">CNI</compound-id>-1493, <compound-id="160051">colesevelam</compound-id> hydrochloride, <compound-id="2907">cyclophosphamide</compound-id>, <compound-id="6253">cytarabine</compound-id>; <compound-id="25244226">Dalteparin sodium</compound-id>, <compound-id="16129629,16129688,16134395,21585658,25246315,46930993,57011757,57336511,71311849">daptomycin</compound-id>, darbepoetin alfa, <compound-id="2966">debrisoquine sulfate</compound-id>, <compound-id="71384">dexrazoxane</compound-id>, <compound-id="42616">diaziquone</compound-id>, <compound-id="50599">didanosine</compound-id>, <compound-id="148124,54277830">docetaxel</compound-id>, donezepil, <compound-id="31703">doxorubicin hydrochloride</compound-id> liposome injection, <compound-id="122129">DX-9065a</compound-id>; <compound-id="72051">Eberconazole</compound-id>, ecogramostim, <compound-id="77993">eletriptan</compound-id>, <compound-id="57199466,772">enoxaparin</compound-id> <compound-id="5360545">sodium</compound-id>, epoetin, <compound-id="5282411">epoprostenol sodium</compound-id>, erlizumab, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="1727">Fampridine</compound-id>, <compound-id="3339">fenofibrate</compound-id>, filgrastim, <compound-id="3365">fluconazole</compound-id>, <compound-id="30751">fludarabine phosphate</compound-id>, <compound-id="3385">fluorouracil</compound-id>, 5-<compound-id="3385">fluorouracil</compound-id>/<compound-id="5816">epinephrine</compound-id>, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>, <compound-id="3410,3034756,3083544,9862958">formoterol fumarate</compound-id>; <compound-id="3446">Gabapentin</compound-id>, <compound-id="60750">gemcitabine</compound-id>, <compound-id="3463">gemfibrozil</compound-id>, <compound-id="65370">glatiramer</compound-id>; Heparin <compound-id="5360545">sodium</compound-id>, <compound-id="285033">homoharringtonine</compound-id>; <compound-id="3672">Ibuprofen</compound-id>, <compound-id="10937300,5311181,53394043,53486260,6435378,6443959">iloprost</compound-id>, <compound-id="5291">imatinib</compound-id> mesilate, <compound-id="57469">imiquimod</compound-id>, interferon alpha-2b, interferon alpha-2c, <protein-id="P01574">interferon-beta</protein-id>; <compound-id="5311037">KW-6002</compound-id>; <compound-id="3878">Lamotrigine</compound-id>, lanoteplase, <compound-id="70045976">metoprolol tartrate</compound-id>, <compound-id="4212">mitoxantrone</compound-id> hydrochloride; <compound-id="156391">Naproxen sodium</compound-id>, <compound-id="4440">naratriptan</compound-id>, Natalizumab, <compound-id="64143">nelfinavir mesilate</compound-id>, <compound-id="4463">nevirapine</compound-id>, <compound-id="4485">nifedipine</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; Oral heparin; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>, peginterferon alfa-2b, <compound-id="1775">phenytoin</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="43672">piperacillin</compound-id>, <compound-id="1684">pleconaril</compound-id>, <compound-id="4885,119570,59868">pramipexole hydrochloride</compound-id>, <compound-id="5865">prednisone</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="5994">progesterone</compound-id>; Rasburicase, <compound-id="467825">ravuconazole</compound-id>, reteplase, <compound-id="37542">ribavirin</compound-id>, rituximab, <compound-id="5078">rizatriptan</compound-id>, <compound-id="77999">rosiglitazone maleate</compound-id>, <compound-id="59227">rotigotine</compound-id>; <compound-id="5329098">Semaxanib</compound-id>, <compound-id="5212">sildenafil citrate</compound-id>, <compound-id="54454">simvastatin</compound-id>, <compound-id="18283">stavudine</compound-id>, <compound-id="5358">sumatriptan</compound-id>; <compound-id="445643,90726579">Tacrolimus</compound-id>, <compound-id="2733525">tamoxifen citrate</compound-id>, <compound-id="12001323,177347,6918336">tanomastat</compound-id>, <compound-id="123630">tazobactam</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, tenecteplase, <compound-id="65990">tolafentrine</compound-id>, <compound-id="443879">tolterodine tartrate</compound-id>, <compound-id="6436">triamcinolone acetonide</compound-id>, <compound-id="21109">trimetazidine</compound-id>, <compound-id="151173,454194">troxacitabine</compound-id>; <compound-id="3121">Valproic acid</compound-id>, <compound-id="14969,14971,16051955,5651,71752911,73357372">vancomycin hydrochloride</compound-id>, <compound-id="5978">vincristine</compound-id>, <compound-id="71616">voriconazole</compound-id>, <compound-id="54678486">Warfarin sodium</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>, <compound-id="35370">Zidovudine</compound-id>, <compound-id="60857">zolmitriptan</compound-id>.	didanosine__interferon-beta__no_interaction	ertapenem sodium__interferon-beta__no_interaction	epinephrine__interferon-beta__no_interaction	alicaforsen__interferon-beta__no_interaction	cefuroxime axetil__interferon-beta__no_interaction	Semaxanib__interferon-beta__no_interaction	argatroban__interferon-beta__no_interaction	sodium__interferon-beta__no_interaction	metoprolol tartrate__interferon-beta__no_interaction	aminopterin__interferon-beta__no_interaction	fludarabine phosphate__interferon-beta__no_interaction	Warfarin sodium__interferon-beta__no_interaction	fluorouracil__interferon-beta__no_interaction	gemcitabine__interferon-beta__no_interaction	epoprostenol sodium__interferon-beta__no_interaction	triamcinolone acetonide__interferon-beta__no_interaction	KW-6002__interferon-beta__no_interaction	ezetimibe__interferon-beta__no_interaction	tazobactam__interferon-beta__no_interaction	zolmitriptan__interferon-beta__no_interaction	Tacrolimus__interferon-beta__no_interaction	simvastatin__interferon-beta__no_interaction	clotrimazole__interferon-beta__no_interaction	enoxaparin__interferon-beta__no_interaction	vincristine__interferon-beta__no_interaction	atazanavir__interferon-beta__no_interaction	Benzylpenicillin__interferon-beta__no_interaction	sildenafil citrate__interferon-beta__no_interaction	ceftriaxone sodium__interferon-beta__no_interaction	acetylcholine chloride__interferon-beta__no_interaction	rizatriptan__interferon-beta__no_interaction	nevirapine__interferon-beta__no_interaction	imatinib__interferon-beta__no_interaction	progesterone__interferon-beta__no_interaction	tamoxifen citrate__interferon-beta__no_interaction	rosiglitazone maleate__interferon-beta__no_interaction	Eberconazole__interferon-beta__no_interaction	amphotericin B__interferon-beta__no_interaction	fluconazole__interferon-beta__no_interaction	stavudine__interferon-beta__no_interaction	cladribine__interferon-beta__no_interaction	monohydrate__interferon-beta__no_interaction	clofarabine__interferon-beta__no_interaction	voriconazole__interferon-beta__no_interaction	piperacillin__interferon-beta__no_interaction	pleconaril__interferon-beta__no_interaction	carboplatin__interferon-beta__no_interaction	debrisoquine sulfate__interferon-beta__no_interaction	Valproic acid__interferon-beta__no_interaction	Gabapentin__interferon-beta__no_interaction	Ximelagatran__interferon-beta__no_interaction	telithromycin__interferon-beta__no_interaction	tolterodine tartrate__interferon-beta__no_interaction	vancomycin hydrochloride__interferon-beta__no_interaction	fenofibrate__interferon-beta__no_interaction	carmustine__interferon-beta__no_interaction	BXT-51072__interferon-beta__no_interaction	homoharringtonine__interferon-beta__no_interaction	clarithromycin__interferon-beta__no_interaction	naratriptan__interferon-beta__no_interaction	ciprofloxacin hydrochloride__interferon-beta__no_interaction	cyclophosphamide__interferon-beta__no_interaction	NSC-683864__interferon-beta__no_interaction	troxacitabine__interferon-beta__no_interaction	colesevelam__interferon-beta__no_interaction	arsenic__interferon-beta__no_interaction	imiquimod__interferon-beta__no_interaction	tolafentrine__interferon-beta__no_interaction	dexrazoxane__interferon-beta__no_interaction	ravuconazole__interferon-beta__no_interaction	iloprost__interferon-beta__no_interaction	clavulanic acid__interferon-beta__no_interaction	pregabalin__interferon-beta__no_interaction	Lamotrigine__interferon-beta__no_interaction	gemfibrozil__interferon-beta__no_interaction	aspirin__interferon-beta__no_interaction	Calcium folinate__interferon-beta__no_interaction	anastrozole__interferon-beta__no_interaction	carbamazepine__interferon-beta__no_interaction	formoterol fumarate__interferon-beta__no_interaction	Zidovudine__interferon-beta__no_interaction	docetaxel__interferon-beta__no_interaction	DX-9065a__interferon-beta__no_interaction	Ibuprofen__interferon-beta__no_interaction	Dalteparin sodium__interferon-beta__no_interaction	nifedipine__interferon-beta__no_interaction	azathioprine__interferon-beta__no_interaction	daptomycin__interferon-beta__no_interaction	phenytoin__interferon-beta__no_interaction	cytarabine__interferon-beta__no_interaction	pramipexole hydrochloride__interferon-beta__no_interaction	BQ-123__interferon-beta__no_interaction	cimetidine__interferon-beta__no_interaction	atorvastatin__interferon-beta__no_interaction	amoxicillin sodium__interferon-beta__no_interaction	augmerosen__interferon-beta__no_interaction	ribavirin__interferon-beta__no_interaction	clopidogrel hydrogensulfate__interferon-beta__no_interaction	diaziquone__interferon-beta__no_interaction	trimetazidine__interferon-beta__no_interaction	fondaparinux sodium__interferon-beta__no_interaction	rotigotine__interferon-beta__no_interaction	Naproxen sodium__interferon-beta__no_interaction	tanomastat__interferon-beta__no_interaction	prednisone__interferon-beta__no_interaction	budesonide__interferon-beta__no_interaction	Paclitaxel__interferon-beta__no_interaction	glatiramer__interferon-beta__no_interaction	acetylcysteine__interferon-beta__no_interaction	sumatriptan__interferon-beta__no_interaction	pimecrolimus__interferon-beta__no_interaction	nelfinavir mesilate__interferon-beta__no_interaction	CNI__interferon-beta__no_interaction	doxorubicin hydrochloride__interferon-beta__no_interaction	mitoxantrone__interferon-beta__no_interaction	Fampridine__interferon-beta__no_interaction	eletriptan__interferon-beta__no_interaction	citalopram hydrobromide__interferon-beta__no_interaction
19255312-2	PATIENTS AND METHODS: Patients were assigned to one of nine cohorts: cohort 1, <compound-id="5280352">bilirubin</compound-id> &lt; or = upper limit of normal (ULN) and <protein-id="Q9NRA2">AST</protein-id> &lt; or = ULN and <compound-id="588">creatinine</compound-id> clearance (CC) &gt; or = 60 mL/min; cohort 2, <compound-id="5280352">bilirubin</compound-id> more than ULN but &lt; or = 1.5x ULN and/or <protein-id="Q9NRA2">AST</protein-id> more than ULN; cohort 3, CC between 40 and 59 mL/min; cohort 4, <compound-id="5280352">bilirubin</compound-id> more than 1.5x ULN to &lt; or = 3x ULN (any <protein-id="Q9NRA2">AST</protein-id>); cohort 5, CC between 20 and 39 mL/min; cohort 6, <compound-id="5280352">bilirubin</compound-id> more than 3x ULN to <compound-id="60210992">10x</compound-id> ULN (any <protein-id="Q9NRA2">AST</protein-id>); cohort 7, CC less than 20 mL/min; cohort 8, albumin less than 2.5 mg/dL (any <compound-id="5280352">bilirubin</compound-id>/<protein-id="Q9NRA2">AST</protein-id>); and cohort 9, hemodialysis.	bilirubin__AST__no_interaction	creatinine__AST__no_interaction	10x__AST__no_interaction
19712087-4	RESULTS: More activated <compound-id="449278">GEP</compound-id>-score correlated with longer corrected QT (QTc)-interval (r = 0.377, p = 0.001, n = 63), longer QRS duration (r = 0.231, p = 0.03, n = 66), higher heart rate (r = 0.221, p = 0.037, n = 66), higher serum <compound-id="588">creatinine</compound-id> (r = 0.26, p = 0.01, n = 75), higher <protein-id="P19440">gamma-glutamyl transferase</protein-id> (GGT) GGT (r = 0.266, p = 0.037, n = 46), lower pulmonary artery <compound-id="977">oxygen</compound-id> saturation (r = -0.313, p = 0.003, n = 76), lower platelet count (r = -0.372, p = 0.001, n = 74), lower monocyte count (r = -0.208, p = 0.040, n = 72), and lower high-density lipoprotein (HDL) HDL level (r = -0.242, p = 0.041, n = 53).	creatinine__gamma-glutamyl transferase__no_interaction	GEP__gamma-glutamyl transferase__no_interaction	oxygen__gamma-glutamyl transferase__no_interaction
2404842-2	Immunological analysis involved standard fluorescence flow cytometry and utilized 31 monoclonal antibodies to known myeloid antigens (of CD groups 11b, 11c, 13, 14, 15, 16, w17, 31, <compound-id="70789250">w32</compound-id>, 33, 34, 35 and 36), a number of relatively less well studied antibodies with potential specificity for AML, and a series of control antibodies to T and B lymphocytes, platelets, erythrocytes and of widespread distribution (<protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>, leucocyte common; HLA-DR).	w32__CD45__no_interaction
21867721-3	The target tracers, (S)-N-(<compound-id="2735900">4-cyano</compound-id>-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-<compound-id="97257">2-hydroxy-</compound-id>3-(2-[(11)C]methoxyphenoxy)-<compound-id="68424">2-methylpropanamide</compound-id> ([(11)C]8a), (S)-<compound-id="97257">2-hydroxy-</compound-id>3-(2-[(11)C]methoxyphenoxy)-2-methyl-N-(4-nitro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)<compound-id="6578">propanamide</compound-id> ([(11)C]8 e), (S)-N-(<compound-id="2735900">4-cyano</compound-id>-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-<compound-id="97257">2-hydroxy-</compound-id>3-(4-[(11)C]methoxyphenoxy)-<compound-id="68424">2-methylpropanamide</compound-id> ([(11)C]8c) and (S)-<compound-id="97257">2-hydroxy-</compound-id>3-(4-[(11)C]methoxyphenoxy)-2-methyl-N-(4-nitro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)<compound-id="6578">propanamide</compound-id> ([(11)C]8 g), were prepared by O-[(11)C]methylation of their corresponding precursors, (S)-N-(<compound-id="2735900">4-cyano</compound-id>-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-2-hydroxy-<compound-id="43312348">3-(2-hydroxyphenoxy)-2-methylpropanamide</compound-id> (9a), (S)-<compound-id="97257">2-hydroxy-</compound-id>3-(2-hydroxyphenoxy)-2-methyl-N-(4-nitro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)<compound-id="6578">propanamide</compound-id> (9b), (S)-N-(<compound-id="2735900">4-cyano</compound-id>-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-2-hydroxy-<compound-id="43312347">3-(4-hydroxyphenoxy)-2-methylpropanamide</compound-id> (9 c) and (S)-<compound-id="97257">2-hydroxy-</compound-id>3-(4-hydroxyphenoxy)-2-methyl-N-(4-nitro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)<compound-id="6578">propanamide</compound-id> (9 d), with [(11)C]CH(3)OTf under basic conditions and isolated by a simplified <protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C-18</protein-id> solid-phase extraction (SPE) method in 55 ± 5% (n = 5) radiochemical yields based on [(11)C]CO(2) and decay corrected to end of bombardment (<compound-id="9547937">EOB</compound-id>).	EOB__C-18__no_interaction	propanamide__C-18__no_interaction	4-cyano__C-18__no_interaction	2-methylpropanamide__C-18__no_interaction	3-(4-hydroxyphenoxy)-2-methylpropanamide__C-18__no_interaction	3-(2-hydroxyphenoxy)-2-methylpropanamide__C-18__no_interaction	2-hydroxy-__C-18__no_interaction	trifluoromethyl__C-18__no_interaction
23656816-10	By Western Blot hybridization, grayscale ratio of <protein-id="P70564">maspin</protein-id> and β-actin was 0.912 ± 0.023 in control group, 0.607 ± 0.030, 0.476 ± 0.019, 0.416 ± 0.017 in <compound-id="11527397">AFH</compound-id> 1-3 groups, respectively, with a statistically significant difference within the four groups (F = 281.91, P &lt; 0.05); While grayscale ratio of IKKα and β-actin was 0.624 ± 0.012 in control group, 0.739 ± 0.020, 0.778 ± 0.010, 0.927 ± 0.017, respectively, in <compound-id="11527397">AFH</compound-id> 1-3 groups; with a statistically significant difference within the four groups(F = 200.91, P &lt; 0.05).	AFH__maspin__no_interaction
12824380-3	MHCPred implements robust statistical models for both Class I alleles (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0101, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0201, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0202, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0203, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0206, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0301, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*1101, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*3301, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*6801, <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*6802 and <protein-id="P01889,P30460,Q5SS57,E5FQ95">HLA-B</protein-id>*3501) and Class II alleles (HLA-<compound-id="3165,5894,59910845,6610267">DRB</compound-id>*0401, HLA-<compound-id="3165,5894,59910845,6610267">DRB</compound-id>*0401 and HLA-<compound-id="3165,5894,59910845,6610267">DRB</compound-id>*0701).	DRB__HLA-B__no_interaction	DRB__HLA-A__no_interaction
9283699-6	Determination by immunoassay of <protein-id="P14095">cytokine-induced neutrophil chemoattractant (CINC)-1, -2 alpha, -2 beta and -3</protein-id> in the conditioned medium at 4 h revealed that <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> (64 nM) and <compound-id="122634,22833501">TPA</compound-id> (49 nM) strongly stimulated the production of <protein-id="P30348">CINC-3</protein-id> (<compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, 133.0 +/- 3.8; <compound-id="122634,22833501">TPA</compound-id>, 26.7 +/- 1.0; control, 0.32 +/- 0.01 ng ml-1, means +/- s.e.mean from four samples) compared to <protein-id="P14095">CINC-1</protein-id> (<compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, 55.0 +/- 1.2; <compound-id="122634,22833501">TPA</compound-id>, 12.2 +/- 0.3; control, 0.56 +/- 0.01 ng ml-1), and <compound-id="23994">CINC</compound-id>-2 alpha (<compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, 1.09 +/- 0.03; <compound-id="122634,22833501">TPA</compound-id>, 0.90 +/- 0.02; control, &lt; 0.10 ng ml-1).	staurosporine__cytokine-induced neutrophil chemoattractant (CINC)-1, -2 alpha, -2 beta and -3__no_interaction	staurosporine__CINC-1__no_interaction	staurosporine__CINC-3__no_interaction	CINC__cytokine-induced neutrophil chemoattractant (CINC)-1, -2 alpha, -2 beta and -3__no_interaction	CINC__CINC-1__no_interaction	CINC__CINC-3__no_interaction	TPA__cytokine-induced neutrophil chemoattractant (CINC)-1, -2 alpha, -2 beta and -3__no_interaction	TPA__CINC-1__no_interaction	TPA__CINC-3__no_interaction
8773862-6	RESULTS: <compound-id="3763">Isoflurane</compound-id> at both doses caused equal decreases in mitral inflow A(atrial systole) velocity (control: 43 +/- 12.3 cm.sec-1 vs <protein-id="P11215">MAC 1</protein-id>: 31 +/- 6.0 cm.sec-1 and <protein-id="P17931,A0A024R693">MAC 1.5</protein-id>: 31.3 +/- 7.9 cm.sec-1 P &lt; 0.01), the deceleration time of the mitral inflow E (early) velocity (control: 178 +/- 31.7 msec versus <protein-id="P11215">MAC 1</protein-id>: 127 +/- 38.3 msec and <protein-id="P17931,A0A024R693">MAC 1.5</protein-id>: 137 +/- 28.4 msec, P &lt; 0.01), and mean blood pressure (control: 91.1 +/- 15.4 mmHg versus <protein-id="P11215">MAC 1</protein-id>: 76.1 +/- 8.8 mmHg and <protein-id="P17931,A0A024R693">MAC 1.5</protein-id>: 71.9 +/- 6.2 mmHg, P &lt; 0.002).	Isoflurane__MAC 1.5__no_interaction	Isoflurane__MAC 1__no_interaction
10431761-7	Our results demonstrated that: (1) injection of LPS caused a significant fall in blood pressure and a severe vascular hyporeactivity to NA in the anaesthetised rat, (2) the relaxation induced by the K(+)channel opener <compound-id="71191,93504">cromakalim</compound-id> was greater in rings obtained from endotoxaemic rats and this enhanced relaxation was partially inhibited by pretreatment of these rings with <compound-id="54245772">1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin</compound-id>-1-one (ODQ), an inhibitor of the NO/cGMP pathway, (3) endotoxaemia for 4 h was also associated with a profound vascular hyporeactivity to NA ex vivo and this vascular hyporesponsiveness was partially inhibited by ODQ, <compound-id="5413">tetraethylammonium</compound-id> (TEA, a non-selective inhibitor of K(+)-channels) and charybdotoxin [CTX, a selective inhibitor of large conductance <compound-id="22044544,5460341">calcium</compound-id>-activated K(+)- channels (<protein-id="Q62976">BK(Ca</protein-id>))], but not by <compound-id="16129677,16218850,56928162,57043712">apamin</compound-id>, and (4) the combination of TEA or CTX with ODQ completely restored that vascular responsiveness to normal.	calcium__BK(Ca__no_interaction	apamin__BK(Ca__no_interaction	tetraethylammonium__BK(Ca__no_interaction	cromakalim__BK(Ca__no_interaction	1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin__BK(Ca__no_interaction
7862024-2	In hyperandrogenemic patients we found significantly higher mean concentrations of total <compound-id="6013">testosterone</compound-id> when compared to the controls (n = 192; 3.5 + 1.9 vs n = 76; 1.9 = 0.9; P &lt; 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> (n = 95; 23.2 = 15.1; vs n = 33; 9.9 = 4.8; p &lt; 0.001) <protein-id="Q06520,A8K015">DHEA-S</protein-id> (n = 70; 6.2 = 1.6 vs n = 27; 3.6 = 1.9; p &lt; 0.001), FAI (n = 65; 27 = 32.9 vs n = 33; 3.9 = 2.1; p &lt; 0.001) while the levels of <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> in hyperandrogenemics were significantly lower than in the controls (n = 67; 24.6 = 15.9 vs n = 33; 52.8 = 19.3; p &lt; 0.001).	testosterone__SHBG__no_interaction	testosterone__DHEA-S__no_interaction	testosterone__insulin__no_interaction
22996231-3	Specifically, we aimed to optimize the therapeutic efficacy of Flt3L/TK treatment in the <compound-id="86287491">RG2</compound-id> model by overexpressing the following genes within the brain tumor microenvironment: 1) a TK mutant with enhanced cytotoxicity (SR39 mutant TK), 2) Flt3L-IgG fusion protein that has a longer half-life, 3) <protein-id="Q9Z2V2">CD40L</protein-id> to stimulate DC maturation, 4) T helper cell type 1 polarizing dendritic cell cytokines interleukin-12 or C-X-C motif ligand 10 chemokine (CXCL)-10, 5) <protein-id="P14844">C-C motif ligand 2 chemokine</protein-id> (<protein-id="P14844">CCL2</protein-id>) or <protein-id="P50229">C-C motif ligand 3 chemokine</protein-id> (<protein-id="P50229">CCL3</protein-id>) to enhance dendritic cell recruitment into the tumor microenvironment, 6) T helper cell type 1 cytokines interferon-γ or <protein-id="P17108">interleukin-2</protein-id> to enhance effector T-cell functions, and 7) IκBα or p65RHD (<protein-id="F1LQH2">nuclear factor kappa-B</protein-id> [NF-κB] inhibitors) to suppress the function of <protein-id="D4Q8I2,D3ZKI1">Foxp3</protein-id>+ Tregs and enhanced effector T-cell functions.	RG2__CCL2__no_interaction	RG2__CCL3__no_interaction	RG2__nuclear factor kappa-B__no_interaction	RG2__Foxp3__no_interaction	RG2__interleukin-2__no_interaction	RG2__C-C motif ligand 3 chemokine__no_interaction	RG2__CD40L__no_interaction	RG2__C-C motif ligand 2 chemokine__no_interaction
11272137-7	Labeled <compound-id="206,5793,64689,79025">glucose</compound-id> and <compound-id="6106">leucine</compound-id> were infused to assess whole-body <compound-id="206,5793,64689,79025">glucose</compound-id> and protein turnover in 1) 6 type 1 diabetic patients with full function after intraportal islet transplantation (FF group; C-peptide &gt; 0.6 nmol/l; daily <protein-id="P01308,I3WAC9">insulin</protein-id> dosage 0.03 +/- 0.02 U x kg(-1) body wt x day(-1); fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> &lt; 7.7 mmol/l; HbA1c &lt; or = 6.5%), 2) 17 patients with partial function (PF group; C-peptide &gt; 0.16 nmol/l; <protein-id="P01308,I3WAC9">insulin</protein-id> dosage &lt; 0.4 U x kg(-1) body wt x day(-1)), 3) 9 patients with no function (NF group; C-peptide &lt; 0.16 nmol/l; <protein-id="P01308,I3WAC9">insulin</protein-id> dosage &gt; 0.4 U x kg(-1) body wt x day(-1)), and 4) 6 patients with chronic uveitis as control subjects (CU group).	leucine__insulin__no_interaction	glucose__insulin__no_interaction
15166654-13	The overall <compound-id="10982484,702">alcohol</compound-id>-induced relative changes in <protein-id="Q06520,A8K015">DHEAS</protein-id>, <compound-id="6013">testosterone</compound-id>, and <compound-id="5757">estradiol</compound-id> correlated positively with the relative increase in high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (adjusted for the relative change in body weight); however, findings were only borderline significant for <protein-id="Q06520,A8K015">DHEAS</protein-id> and <compound-id="5757">estradiol</compound-id> (r = 0.44, p = 0.08; r = 0.32, p = 0.21; and r = 0.46, p = 0.06, respectively).	cholesterol__DHEAS__no_interaction	alcohol__DHEAS__no_interaction	estradiol__DHEAS__no_interaction	testosterone__DHEAS__no_interaction
18034069-3	The present study compared intra- arthicular bupivacaine with intra-arthricular morphine for postoperative analgesia in 56 patients (21 women, 35 men) (age 20-70, mean 39.8) undergoing knee joint arthroscopy.&lt;br /&gt; Intraoperatively, the patients received anaesthesia spinaly (0.5 % <compound-id="2474">Marcaine</compound-id> spinal ASTRA) and immediately following surgery received 10 ml intra-arthricular injection consisting either of 0.5 % bupivacaine (group I), 5 mg morphine + 0.9 % saline (group II).Postoperative analgesia was supporeted by intravenous doses of proefferalgan.&lt;br /&gt; In all patients the visual analogue pain score (<compound-id="6323535">VAS</compound-id>), PaO2, systolic blood preassure (<protein-id="P12273">SABP</protein-id>), diastolic blood preassure (<compound-id="56842224">DABP</compound-id>), heart rate (HR), respiratory rate (f), supplemented analgesia and possible side effects were monitored postoperatively.&lt;br /&gt; Results.	VAS__SABP__no_interaction	Marcaine__SABP__no_interaction	DABP__SABP__no_interaction
16431115-2	In particular, 3-(3,4-<compound-id="25493">dichlorobenzyloxy</compound-id>)-2-aminobicyclo[3.1.0]<compound-id="12614059">hexane-2,6-dicarboxylic acid</compound-id> (15ae), (1R,2S,5R,6R)-2-amino-3-(<compound-id="118986">3,4-dichlorobenzylthio</compound-id>)-<compound-id="22634786">6-fluorobicyclo[3.1.0]hexane</compound-id>-2,6-<compound-id="11229316,91179806">carboxylic acid</compound-id> (15at), and (1R,2S,5R,6R)-2-amino-3-(N-(3,4-<compound-id="12720694">dichlorobenzylamino</compound-id>))-<compound-id="22634786">6-fluorobicyclo[3.1.0]hexane</compound-id>-2,6-carboxylic (15ba) showed high affinity for the <protein-id="P23819,G5E8H1,Q4LG64,E9QKC0">mGluR2</protein-id> receptor (15ae: K(i) = 2.51 nM, 15at: K(i) = 1.96 nM, and 15ba: K(i) = 3.29 nM) and potent antagonist activity for <protein-id="P23819,G5E8H1,Q4LG64,E9QKC0">mGluR2</protein-id> (15ae; IC50 = 34.21 nM, 15at; IC50 = 13.34 nM, and 15ba; IC50 = 35.96 nM).	hexane-2,6-dicarboxylic acid__mGluR2__no_interaction	3,4-dichlorobenzylthio__mGluR2__no_interaction	dichlorobenzyloxy__mGluR2__no_interaction	6-fluorobicyclo[3.1.0]hexane__mGluR2__no_interaction	carboxylic acid__mGluR2__no_interaction	dichlorobenzylamino__mGluR2__no_interaction
22440459-3	RESULTS: Significant differences were as follows: a) Syringe I vs II: pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), base excess (BE), total hemoglobin (tHb), <compound-id="5360545">sodium</compound-id> (Na(+)), <compound-id="5462222">potassium</compound-id> (K(+)), <compound-id="22044544,5460341">calcium</compound-id> (Ca(2+)), <compound-id="206,5793,64689,79025">glucose</compound-id> (Glu), <compound-id="612">lactate</compound-id> (Lac), O(2) Hb and <protein-id="P25942,Q6P2H9">p 50</protein-id>; b) Syringe I vs III: pH, pO(2), cHCO(3)(-), ctCO(2), BE, Na(+), Glu, Lac and <protein-id="P25942,Q6P2H9">p 50</protein-id>; c) Syringe I vs IV: pH, pO(2), sO(2), pCO(2)(t), BE, Na(+), K(+), Ca(2+), Glu, Lac and O(2) Hb; d) Syringe II vs III: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), <compound-id="444514">ctO</compound-id>(2), tHb, Na(+), K(+), Ca(2+), Lac and <protein-id="P25942,Q6P2H9">p 50</protein-id>; e) Syringe II vs IV: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), BE, tHb, Na(+), K(+), Ca(2+), Lac, O(2) Hb and <protein-id="P25942,Q6P2H9">p 50</protein-id>; f) Syringe III vs IV: pH, pO(2), sO(2), cHCO(3)(-), ctCO(2), <compound-id="444514">ctO</compound-id>(2), BE, Na(+), K(+), Ca(2+), O(2) Hb and <protein-id="P25942,Q6P2H9">p 50</protein-id>.	sodium__p 50__no_interaction	potassium__p 50__no_interaction	calcium__p 50__no_interaction	lactate__p 50__no_interaction	ctO__p 50__no_interaction	glucose__p 50__no_interaction
15146530-1	A variety of hexaorganotellurium compounds, Ar(6-n)(CH3)<compound-id="53352194">nTe</compound-id> [Ar=4-CF3C6H4, n=0 (1a), n=1 (<compound-id="2981881,91293124">3a</compound-id>), n=2 (trans-<compound-id="69255155">4a</compound-id> and cis-<compound-id="69255155">4a</compound-id>), n=3 (mer-5a), n=4 (trans-6a); Ph, n=0 (1b), n=1 (3b), n=2 (trans-4b); 4-CH3C6H4, n=0 (1c), n=1 (3c), n=2 (trans-4c), n=4 (trans-6c); 4-BrC6H4, n=0 (1d)] and Ar5(R)Te [Ar=4-CF3C6H4, R=4-CH3OC6H4 (8); Ar=4-CF3C6H4, R=vinyl (9), Ar=Ph, R=vinyl (10), Ar=4-CF3C6H4, R=PhSCH2 (11), Ar=Ph, R=PhSCH2 (12), Ar=4-CF3C6H4, R=nBu (13)] and pentaorganotellurium halides, Ar5TeX [Ar=4-CF3C6H4, X=Cl (2a-Cl), <protein-id="Q13127">X=Br</protein-id> (2a-Br); Ar=Ph, X=Cl (2b-Cl), <protein-id="Q13127">X=Br</protein-id> (2b-Br); Ar=4-CH3C6H4, X=Cl (2c-Cl), <protein-id="Q13127">X=Br</protein-id> (2c-Br); Ar=4-BrC6H4, <protein-id="Q13127">X=Br</protein-id> (2d-Br)] and (4-CF3C6H4)4(CH3)TeX [X=Cl (trans-7a-Cl) and <protein-id="Q13127">X=Br</protein-id> (trans-7a-Br)] were synthesized by the following methods: 1) one-pot synthesis of 1 a, 2) the reaction of <compound-id="24648">SO2Cl2</compound-id> or <compound-id="24408">Br2</compound-id> with Ar5Te(-)Li+ generated from TeCl4 or TeBr4 with five equivalents of ArLi, 3) reductive cleavage of Ar(6-m)(CH3)(m)Te (m=0 or 2) with KC8 followed by treatment with CH3I, 4) valence expansion reaction from low-valent <compound-id="6327182">tellurium</compound-id> compounds by treatment with KC8 followed by reaction with CH3I, 5) nucleophilic substitution of Ar(6-y-z)(CH3)zTeX(y-z) (X=Cl, Br, OTf; z=0, 1; y=1, 2) with organolithium reagents.	SO2Cl2__X=Br__no_interaction	Br2__X=Br__no_interaction	tellurium__X=Br__no_interaction	3a__X=Br__no_interaction	nTe__X=Br__no_interaction	4a__X=Br__no_interaction
23257405-8	Although there were no significant differences in the systolic blood pressure (control versus <compound-id="5493444">aliskiren</compound-id>-treated: 127.20 ± 4.44 mmHg versus 103.80 ± 7.40 mmHg, p &gt; 0.05) and heart rate (control versus <compound-id="5493444">aliskiren</compound-id>-treated: 680.50 ± 11.71 versus 647.80 ± 13.90, p &gt; 0.05) of both groups after eight weeks, there was significant reduction of inflammatory cytokines (transforming growth factor-beta1, regulated on activation normal T cell expressed, <protein-id="P10148,Q5SVU3">monocyte chemoattractant protein-1</protein-id> and <protein-id="P10923,Q547B5,F8WIP8,Q3UBR1">osteopontin</protein-id>, p &lt; 0.05), reduction of innate immunity (<protein-id="P58681,Q548J0,Q599W9">toll-like receptor 7</protein-id>, p &lt; 0.05), as well as a reduction of glomerular proliferation and inflammation (<compound-id="6035">BrdU</compound-id>-, <protein-id="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0">CD45</protein-id>-, CD3- and F4/80-positive glomerular cells, p &lt; 0.01) after <compound-id="5493444">aliskiren</compound-id> infusion, which might translate into an improvement in proteinuria (control versus <compound-id="5493444">aliskiren</compound-id>-treated: 493.7 versus 843.7 mg/g, p &lt; 0.01) or weight gain (control versus <compound-id="5493444">aliskiren</compound-id>-treated: 5.65 ± 1.61 versus 8.67 ± 0.97%, p &lt; 0.05).	BrdU__CD45__no_interaction	BrdU__osteopontin__no_interaction	BrdU__toll-like receptor 7__no_interaction	BrdU__monocyte chemoattractant protein-1__no_interaction	aliskiren__CD45__no_interaction	aliskiren__osteopontin__no_interaction	aliskiren__toll-like receptor 7__no_interaction	aliskiren__monocyte chemoattractant protein-1__no_interaction
18923064-1	A library of robust <protein-id="Q92847">ghrelin receptor</protein-id> mutants with single substitutions at 22 positions in the main ligand-binding pocket was employed to map binding sites for six different agonists: two peptides (the 28-amino-acid octanoylated endogenous ligand <compound-id="44576256">ghrelin</compound-id> and the hexapeptide growth hormone secretagogue <compound-id="4345065">GHRP-6</compound-id>) plus four nonpeptide agonists-the original <compound-id="11126234">benzolactam</compound-id> L-692,429 [<compound-id="121879">3-amino-3-methyl-N-(2,3,4,5-tetrahydro-2-oxo-1-([2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl)-1H-1-benzazepin-3(R)-yl)-butanamide</compound-id>], the spiroindoline sulfonamide <compound-id="178024">MK-677</compound-id> [N-[1(R)-1, 2-dihydro-1-ethanesulfonylspiro-<compound-id="3083560">3H-indole</compound-id>-3,4'-<compound-id="8082">piperidin</compound-id>)-1'-yl]carbonyl-2-(phenylmethoxy)-<compound-id="23134249">ethyl</compound-id>-<compound-id="6453783">2-amino-2-methylpropanamide</compound-id>], and two novel <compound-id="321710">oxindole</compound-id> derivatives, SM-130686 [(+)-6-carbamoyl-3-(2-chlorophenyl)-(2-diethylaminoethyl)-4-trifluoromethyloxindole] and SM-157740 [(+/-)-6-carbamoyl-3-(2, 4-<compound-id="57417436">dichlorophenyl</compound-id>)-(2-diethylaminoethyl)-4-trifluoromethyloxindole)].	GHRP-6__ghrelin receptor__no_interaction	MK-677__ghrelin receptor__no_interaction	2-amino-2-methylpropanamide__ghrelin receptor__no_interaction	dichlorophenyl__ghrelin receptor__no_interaction	benzolactam__ghrelin receptor__no_interaction	piperidin__ghrelin receptor__no_interaction	oxindole__ghrelin receptor__no_interaction	ghrelin__ghrelin receptor__no_interaction	3H-indole__ghrelin receptor__no_interaction	3-amino-3-methyl-N-(2,3,4,5-tetrahydro-2-oxo-1-([2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl]methyl)-1H-1-benzazepin-3(R)-yl)-butanamide__ghrelin receptor__no_interaction	ethyl__ghrelin receptor__no_interaction
22398419-6	iPTH levels after treatment correlated with age (r = -0.51, P =   0.031), mean <compound-id="156419">cinacalcet</compound-id> dose (r = 0.65, P = 0.004), as well as baseline <compound-id="22044544,5460341">calcium</compound-id> (r = 0.65 P = 0.003), iPTH (r = 0.59, P = 0.01), <protein-id="P16581">E-selectin</protein-id> (r = 0.56, P = 0.016), and <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = -0.49, P = 0.039).	cinacalcet__E-selectin__no_interaction	cinacalcet__leptin__no_interaction	calcium__E-selectin__no_interaction	calcium__leptin__no_interaction
14763430-3	RESULTS: <compound-id="5212">sildenafil citrate</compound-id> 50 <protein-id="Q9NZI5">mgr</protein-id> after a single oral dose: 1) improved the ecg findings in some patients, worsening the basal ecg in none of the studied patients; 2) significantly reduced systolic and diastolic arterial blood pressure being such reduction very strong in those with basal high level 3) significantly improved left ventricular systolic function in those patients with basal reduced function and 4) Right ventricular diastolic function evaluation: <compound-id="5212">Sildenafil citrate</compound-id> 50 <protein-id="Q9NZI5">mgr</protein-id> significantly modified to normal pattern the E/A basal altered ratio in those patients with the inverted pattern as well as in those with restrictive pattern of tricupid diastolic influx to the right ventricle during the echo-duplex interrogation (p &lt; 0.0001) 5) Left ventricular diastolic function evaluation: <compound-id="5212">Sildenafil citrate</compound-id> 50 <protein-id="Q9NZI5">mgr</protein-id> significantly modified to normal pattern the E/A basal altered ratio in those patients with the inverted pattern as well as in those with restrictive pattern of mitral diastolic influx to the left ventricle, during the echo-duplex interrogation (p 0 &lt;.0001).	Sildenafil citrate__mgr__no_interaction	sildenafil citrate__mgr__no_interaction
24437975-4	The homometallic hexanuclear metallomacrocycles [{M2(μ-4-<compound-id="6912535">Spy</compound-id>)2(cod)2}2{M(cod)}2](BF4)2 (M = Rh [(1a)2], Ir [(2b)2]) and the heterometallic hexanuclear metallomacrocycles [{<protein-id="Q02094,Q96E98">Rh2</protein-id>(μ-4-<compound-id="6912535">Spy</compound-id>)2(cod)2}2{Ir(cod)}2](BF4)2 [(1b)2], [{<protein-id="Q02094,Q96E98">Rh2</protein-id>(μ-4-<compound-id="6912535">Spy</compound-id>)2(cod)2}2{M'(<compound-id="81219">dppp</compound-id>)}2](<protein-id="Q01860,D2IYK3,F2Z381,M1S623">OTf)4</protein-id> (M' = Pd [(1c)2], Pt [(1d)2]), and [{Ir2(μ-4-<compound-id="6912535">Spy</compound-id>)2(cod)2}2{M'(<compound-id="81219">dppp</compound-id>)}2](<protein-id="Q01860,D2IYK3,F2Z381,M1S623">OTf)4</protein-id> (M' = Pd [(2c)2], Pt [(2d)2]) were obtained.	dppp__OTf)4__no_interaction	dppp__Rh2__no_interaction	Spy__OTf)4__no_interaction	Spy__Rh2__no_interaction
17875554-6	Structures of these oligosaccharides were determined by a combination of exoglycosidase digestions and two-dimensional HPLC sugar mapping to be the biantennary complex-type structures with two <protein-id="P22083">Lewis x</protein-id> epitopes: (Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>)(0,1,2)-{Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>(Fuc <protein-id="Q6U1J5">alpha1</protein-id>-3)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id> beta1-2Man <protein-id="Q6U1J5">alpha1</protein-id>-6[Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>(Fuc <protein-id="Q6U1J5">alpha1</protein-id>-3)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id> beta1-2Man <protein-id="Q6U1J5">alpha1</protein-id>-3]}Man beta1-4GlcNAc, and (Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>)(0,1)-{Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>(Fuc <protein-id="Q6U1J5">alpha1</protein-id>-3)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id> beta1-2Man <protein-id="Q6U1J5">alpha1</protein-id>-6[Gal <protein-id="Q13509,Q53G92">beta1-4</protein-id>(Fuc <protein-id="Q6U1J5">alpha1</protein-id>-3)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id> beta1-2Man <protein-id="Q6U1J5">alpha1</protein-id>-3]} Man beta1-4GlcNAc beta1-4GlcNAc.	GlcNAc__Lewis x__no_interaction	GlcNAc__alpha1__no_interaction	GlcNAc__beta1-4__no_interaction
8385622-4	Specific binding of [125I][Lys5,<compound-id="6057">Tyr</compound-id>(I2)7,MeLeu9,Nle10]<protein-id="P20366,Q9Y494">NKA</protein-id>-(4-10) was inhibited by <compound-id="16132172">neuropeptide gamma</compound-id> SR 48968 &gt; or = <protein-id="P20366,Q9Y494">neurokinin A</protein-id> (<protein-id="P20366,Q9Y494">NKA</protein-id>) &gt; or = [Lys5,MeLeu9,Nle10]<protein-id="P20366,Q9Y494">NKA</protein-id>-(4-10) &gt; [Lys5,Tyr7,MeLeu9,Nle10] <protein-id="P20366,Q9Y494">NKA</protein-id>-(4-10) &gt; neuropeptide K &gt; [Lys5,<compound-id="6057">Tyr</compound-id>(I2)7,MeLeu9,Nle10]<protein-id="P20366,Q9Y494">NKA</protein-id>-(4-10) &gt; MDL 29,913 &gt; [127I]- Bolton-Hunter-<protein-id="P20366,Q9Y494">NKA</protein-id> &gt; <protein-id="Q9UHF0,A0A024RB97,A0A024RB47">neurokinin B</protein-id> &gt; <protein-id="P20366,Q9Y494">substance P</protein-id> (SP) &gt;&gt; <compound-id="25079030">MEN 10207</compound-id> &gt; [Sar9,Met(O2)11]SP &gt;&gt; <compound-id="108147,5079497">senktide</compound-id>, indicating binding to NK2 receptors.	neuropeptide gamma__substance P__no_interaction	neuropeptide gamma__NKA__no_interaction	neuropeptide gamma__neurokinin B__no_interaction	neuropeptide gamma__neurokinin A__no_interaction	MEN 10207__substance P__no_interaction	MEN 10207__NKA__no_interaction	MEN 10207__neurokinin B__no_interaction	MEN 10207__neurokinin A__no_interaction	Tyr__substance P__no_interaction	Tyr__NKA__no_interaction	Tyr__neurokinin B__no_interaction	Tyr__neurokinin A__no_interaction	senktide__substance P__no_interaction	senktide__NKA__no_interaction	senktide__neurokinin B__no_interaction	senktide__neurokinin A__no_interaction
2670764-8	Central infusion of <protein-id="P01015">angiotensin II</protein-id> had no significant effect on mean arterial pressure in <compound-id="44093">captopril</compound-id> or control SHR (<compound-id="44093">captopril</compound-id>-<protein-id="P01015">angiotensin II</protein-id> 125 +/- 4 vs. <compound-id="44093">captopril</compound-id>-vehicle 121 +/- 2; control-<protein-id="P01015">angiotensin II</protein-id> 169 +/- 5 vs. control-vehicle 173 +/- 7 mm Hg), but it produced a significant rise in basal heart rate (<compound-id="44093">captopril</compound-id>-<protein-id="P01015">angiotensin II</protein-id> 371 +/- 10 vs. <compound-id="44093">captopril</compound-id>-vehicle 323 +/- 8, p less than 0.0002; control-<protein-id="P01015">angiotensin II</protein-id> 338 +/- 7 vs. control-vehicle 312 +/- 8 beats/min, p less than 0.0183) and in daily <compound-id="962">water</compound-id> intake (<compound-id="44093">captopril</compound-id>-<protein-id="P01015">angiotensin II</protein-id> 20.7 +/- 2.2 vs. <compound-id="44093">captopril</compound-id>-vehicle 9.8 +/- 0.7, p less than 0.0426; control-<protein-id="P01015">angiotensin II</protein-id> 33.1 +/- 3.8 vs. control-vehicle 9.0 +/- 0.6 ml/100 g body wt, p less than 0.0001).	water__angiotensin II__no_interaction	captopril__angiotensin II__no_interaction
24507391-11	The content of <compound-id="269023,5810">hydroxyproline</compound-id> and the mRNA levels of collagen1α1, α-SMA, <protein-id="P27467">Wnt3a</protein-id>, <protein-id="P22724,Q3ZB23">Wnt4</protein-id>, <protein-id="P24383">Wnt7a</protein-id> in the treatment group at 28 d were 0.67 ± 0.14, 1.66 ± 0.34, 1.37 ± 0.41, 1.43 ± 0.27, 1.29 ± 0.19, 1.18 ± 0.20, respectively, all of which were significantly lower than those in the model group (1.10 ± 0.16, 3.50 ± 0.74, 2.68 ± 0.61, 2.60 ± 0.58, 2.23 ± 0.45, 1.93 ± 0.36, respectively).	hydroxyproline__Wnt3a__no_interaction	hydroxyproline__Wnt7a__no_interaction	hydroxyproline__Wnt4__no_interaction
8813545-1	The effects of the <protein-id="O02835">neuropeptide Y Y1 receptor</protein-id> antagonist <compound-id="5312150">SR 120107A</compound-id> (1-[2-[2-(2-naphtylsulfamoyl)-3-phenylpropionamido]-3-[4-[N- [4- (dimethylaminomethyl)-cis-cyclohexylmethyl]<compound-id="68047">amidino</compound-id>]phenyl]propiony l] <compound-id="31268">pyrrolidine</compound-id>, (S,R) stereoisomer) on sympathetic non-adrenergic vasoconstriction in a variety, of vascular beds were studied in reserpinized anesthetized pigs in vivo.	pyrrolidine__neuropeptide Y Y1 receptor__no_interaction	amidino__neuropeptide Y Y1 receptor__no_interaction	SR 120107A__neuropeptide Y Y1 receptor__no_interaction
22490832-8	Compared with the NC group (28.3 ± 1.8; 23.1 ± 3.4; 8.0 ± 1.8), the MMSE, <protein-id="Q8IZD9">MoCA</protein-id> and CDT scores were significantly lower in the <compound-id="11825097">SID</compound-id> (26.7 ± 2.5; 20.0 ± 4.0; 2.0 ± 2.7) and SIVD (26.8 ± 1.9; 20.7 ± 3.0; 6.1 ± 2.1) groups (P &lt; 0.05).	SID__MoCA__no_interaction
16409860-11	(2) The latency period decreased significantly along with the test days in all groups except in the <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia group (P &lt; 0.05 or 0.01), significantly longer in the ischemia and <compound-id="3676">lidocaine</compound-id> groups than in the corresponding control groups (P &lt; 0.05 or 0.01), significantly longer in the C57 <compound-id="3676">lidocaine</compound-id> group than in the C57 ischemia group on the 3 rd day of test [73.1 (22.1-120.1) s vs. 40.2 (28.4-91.1) s], and in the <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia group than in the C57 ischemia group on the 3 rd and 4 th days of test [88.2 (41.0-120.1) s vs. 40.2 (28.4-91.1) s, and 78.2 (32.9-120.1) s vs. 46.3 (11.6-81.9) s] (P &lt; 0.05 or 0.01), and, however, significantly shorter in the <protein-id="P08226,Q3TXU4">apoE</protein-id> <compound-id="3676">lidocaine</compound-id> group than in the C57 <compound-id="3676">lidocaine</compound-id> group on the 3rd day of test [39.0 (15.5-103.5) s vs. 73.1 (22.1-120.1) s], and in the <protein-id="P08226,Q3TXU4">apoE</protein-id> <compound-id="3676">lidocaine</compound-id> group than in the <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia group from the 3 rd to the 5 th days of test [39.0 (15.5-103.5) s vs. 88.2 (41.0-120.1) s, 24.9 (11.8-68.0) s vs. 78.2 (32.9-120.1) s, and 29.1 (6.6-57.2) s vs. 66.3 (14.2-97.0) s respectively] (P &lt; 0.05 or 0.01).	lidocaine__apoE__no_interaction
16409860-12	(3) The percentage of effective search strategy increased significantly along with the test day in all groups except in the C57 <compound-id="3676">lidocaine</compound-id> and <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia groups (P &lt; 0.05 or 0.01), significantly lower in the ischemia and <compound-id="3676">lidocaine</compound-id> groups than in the corresponding control groups (P &lt; 0.05 or 0.01), significantly lower in the C57 <compound-id="3676">lidocaine</compound-id> group than in the C57 ischemia group on the 4 th and 5 th days of test [25 (0-50)% vs. 50 (25-75)% and 37.5 (0-75)% vs. 50 (50-100)%], and in the <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia group than in the C57 ischemia group from the 3 rd to the 5th days of test [25 (0-25)% vs. 50 (25-75)%, 25 (0-25)% vs. 50 (25-75)%, and 25 (0-50)% vs. 50 (50-100)% respectively] (P &lt; 0.05 or 0.01), and, however, significantly higher in the <protein-id="P08226,Q3TXU4">apoE</protein-id> <compound-id="3676">lidocaine</compound-id> group than in the C57 <compound-id="3676">lidocaine</compound-id> group [50 (0-75)% vs. 25 (0-50)% and 50 (25-100)% vs. 37.5 (0-75)%], and in the <protein-id="P08226,Q3TXU4">apoE</protein-id> <compound-id="3676">lidocaine</compound-id> group than in <protein-id="P08226,Q3TXU4">apoE</protein-id> ischemia group [50 (0-75)% vs. 25 (0-25)% and 50 (25-100)% vs. 25 (0-50)%] on the 4 th and 5 th days of test (all P &lt; 0.05).	lidocaine__apoE__no_interaction
21427621-5	RESULTS: <compound-id="199">Agmatine</compound-id> therapy in rats significantly attenuated TBI-induced motor function deficits (62° vs. 52° maximal angle) and cerebral infarction (88 mm vs. 216 mm), significantly reduced TBI-induced neuronal (9 NeuN-TUNEL double positive cells vs. 60 NeuN-TUNEL double positive cells) and glial (2 <protein-id="P47819">GFAP</protein-id>-TUNEL double positive cells vs. 20 <protein-id="P47819">GFAP</protein-id>-TUNEL double positive cells) apoptosis (increased TUNEL-positive and <protein-id="P55213">caspase-3</protein-id>-positive cells), neuronal loss (82 NeuN-positive cells vs. 60 NeuN-positive cells), gliosis (35 <protein-id="P47819">GFAP</protein-id>-positive cells vs. 72 <protein-id="P47819">GFAP</protein-id>-positive cells; 60 Iba1-positive cells vs. 90 Iba1-positive cells), and neurotoxicity (30 n-NOS-positive cells vs. 90 n-NOS-positive cells; 35 3-NT-positive cells vs. 90 3-NT-positive cells), and significantly promoted angiogenesis (3 <compound-id="6035">BrdU</compound-id>/endothelial cells vs. 0.5 <compound-id="6035">BrdU</compound-id>/endothelial cells; 50 vascular endothelial growth factor positive cells vs. 20 vascular endothelial growth factor-positive cells) and neurogenesis (27 <compound-id="6035">BrdU</compound-id>/NeuN positive cells vs. 15 <compound-id="6035">BrdU</compound-id>/NeuN positive cells).	BrdU__caspase-3__no_interaction	BrdU__GFAP__no_interaction	Agmatine__caspase-3__no_interaction	Agmatine__GFAP__no_interaction
19427425-5	Residual platelet reactivity was significantly higher in women (220 +/- 82 vs 200 +/- 77 <protein-id="Q9H244,A8K7T1">P2Y12</protein-id> reaction units [PRU]; p = 0.041), non-Caucasians (229 +/- 79 vs 202 +/- 78 PRU; p = 0.047), patients with diabetes mellitus (220 +/- 73 vs 196 +/- 80 PRU; p = 0.005), and those treated with nitrates (233 +/- 70 vs 200 +/- 80 PRU; p = 0.018) or <compound-id="1038,5460653">proton</compound-id>-pump inhibitors (218 +/- 79 vs 198 +/- 78 PRU; p = 0.02), whereas residual platelet reactivity was significantly lower in active smokers (168 +/- 82 vs 208 +/- 77 PRU; p = 0.006).	proton__P2Y12__no_interaction
2913298-5	The 16 new analogues are (1) d(CH2)5[<compound-id="71098">D-Tyr</compound-id>(Me)2]<protein-id="P01186">AVP</protein-id>, (2) d(CH2)5[<compound-id="71098">D-Tyr</compound-id>(Me)2, Val4,delta 3-Pro7]<protein-id="P01186">AVP</protein-id>, (3) d(CH2)5[<compound-id="71098">D-Tyr</compound-id>-(Et)2, Val4,Lys8]VP, (4) d(CH2)5[<compound-id="71098">D-Tyr</compound-id>(Et)2,Val4,Cit8]VP, (5) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2]<compound-id="86289556">AVT</compound-id>, (6) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Lys8]VT, (7) dP[<compound-id="6057">Tyr</compound-id>(Me)2]<compound-id="86289556">AVT</compound-id>, (8) dP[<compound-id="6057">Tyr</compound-id>(Me)2,Val4]<compound-id="86289556">AVT</compound-id>, (9) d(CH2)5[<compound-id="71098">D-Tyr</compound-id>(Me)2, Val4]<compound-id="86289556">AVT</compound-id>, (10) d(CH2)5[D-Phe2,Val4]<compound-id="86289556">AVT</compound-id>, (11) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4]OVT, (12) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4,Ala-NH2(9)]OVT, (13) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4,Leu-NH2(9)]OVT, (14) d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4,<compound-id="2234">Arg-NH2</compound-id>(9)]OVT, (15) desGly-NH2(9),d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4]OVT, (16) desGly9,d(CH2)5[<compound-id="6057">Tyr</compound-id>(Me)2,Thr4]OVT.	AVT__AVP__no_interaction	Arg-NH2__AVP__no_interaction	D-Tyr__AVP__no_interaction	Tyr__AVP__no_interaction
2262972-2	These methods are (1) determination of serum <compound-id="5754">cortisol</compound-id> by HPLC with a BSA-ODS column (<protein-id="Q8WUA8,A0A024R5J8,B3KRF9">TSK</protein-id>) and serum sample direct injection, (2) determination of fluorescently derivatized serum <compound-id="5754">cortisol</compound-id> with sulfuric acid and <compound-id="702">ethanol</compound-id> by column switching HPLC, (3) determination of urinary 17-KS with no need of previous hydrolysis of the conjugated forms, (4) HPLC of conjugated 17-KS fluorescently prelabelled with <compound-id="94442">dansyl hydrazine</compound-id>, (5) HPLC of urinary free catecholamines (CA) with on-line extraction using a cation exchange column and on-line fluorescent derivatization with 1,2-<compound-id="110695">diphenylethylenediamine</compound-id>, (6) ion pair HPLC of urinary free CA with on-line extraction using a hard <compound-id="3016474">boric acid gel</compound-id> column and postcolumn <compound-id="193645">trihydroxyindole</compound-id> derivatization, and (7) HPLC of urinary free CA with on-line extraction and solid-phase derivatization using a <compound-id="3016474">boric acid gel</compound-id> column, <compound-id="4807">o-phthalaldehyde</compound-id> and 2-<compound-id="1567">mercaptoethanol</compound-id>, have achieved no previous or simple sample extraction, more rapid, accurate and higher sensitive determination comparison with ordinary methods for these substances and furthermore, some methods have enabled fully automated analysis.	diphenylethylenediamine__TSK__no_interaction	cortisol__TSK__no_interaction	dansyl hydrazine__TSK__no_interaction	o-phthalaldehyde__TSK__no_interaction	boric acid gel__TSK__no_interaction	ethanol__TSK__no_interaction	trihydroxyindole__TSK__no_interaction	mercaptoethanol__TSK__no_interaction
9283798-5	Mononuclear cell binding to ECV 304 cells correlated significantly with fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.52, P &lt; 0.01), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.51, P &lt; 0.01), triglyceride (r = 0.54, P &lt; 0.01), and VLDL (r = 0.54, P &lt; 0.01) and HDL <compound-id="5997">cholesterol</compound-id> (r = -0.45, P &lt; 0.05) levels, but not with either total or LDL <compound-id="5997">cholesterol</compound-id> levels or blood pressure.	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction
9832389-2	An <compound-id="44284481">endothelin</compound-id> ET(A) receptor antagonist (R)2-[(R)-2-[(S)-2-[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl]amino-4-me thyl-pentanoyl]amino-3-[3-(1-methyl-1H-indolyl)]propionyl]amino-3-(2-pyr idyl)<compound-id="1032">propionic acid</compound-id> (<compound-id="107810">FR139317</compound-id>, 1 microg/kg per min) attenuated the <protein-id="P29560">endothelin-1</protein-id> (1 ng/kg per min)-induced renal responses.	propionic acid__endothelin-1__no_interaction	endothelin__endothelin-1__no_interaction	1H-azepinyl__endothelin-1__no_interaction	FR139317__endothelin-1__no_interaction
8055870-5	These include: (i) identifying in vivo substrates for kinases (protein kinase C activated by <compound-id="22833501,27924,4792">phorbol myristate acetate</compound-id>), (ii) investigating cytokine signaling pathways (tumor necrosis factor and interleukin-1), (iii) investigating the effects of drugs on signaling pathways (<compound-id="11953808,42628599,446512,45356271,4584,5468826,57059112,6102351,6426933,6476659,6917781,90479758">okadaic acid</compound-id>, <compound-id="4055">menadione</compound-id> and cyclooxygenase inhibitors), (iv) characterization of specific phosphoproteins (heat-shock protein <protein-id="P04792,V9HW43">Hsp27</protein-id> and <protein-id="P16949">stathmin</protein-id>), (v) comparing normal and transformed cells (MRC-5 human lung fibroblasts and their SV-40-transformed counterparts, MRC-5 <compound-id="70699405">SV1</compound-id> cells), (vi) purifying phosphoproteins, (vii) investigating the relationship of protein phosphorylation to stages in the cell cycle (<protein-id="P16949">stathmin</protein-id>), (viii) investigating protein/protein interactions, (ix) mapping in vitro kinase substrates (protein kinase C, protein kinase A, and <protein-id="P49137">mitogen activated protein kinase activated protein kinase 2</protein-id>), and (x) locating and identifying cellular phosphatases (<protein-id="P04792,V9HW43">Hsp27</protein-id> phosphatase).	menadione__Hsp27__no_interaction	menadione__mitogen activated protein kinase activated protein kinase 2__no_interaction	menadione__stathmin__no_interaction	phorbol myristate acetate__Hsp27__no_interaction	phorbol myristate acetate__mitogen activated protein kinase activated protein kinase 2__no_interaction	phorbol myristate acetate__stathmin__no_interaction	okadaic acid__Hsp27__no_interaction	okadaic acid__mitogen activated protein kinase activated protein kinase 2__no_interaction	okadaic acid__stathmin__no_interaction	SV1__Hsp27__no_interaction	SV1__mitogen activated protein kinase activated protein kinase 2__no_interaction	SV1__stathmin__no_interaction
19339706-4	Serum <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> correlated positively with serum HDL-<compound-id="5997">cholesterol</compound-id> (r = 0.33; P &lt; 0.0001), plasma <compound-id="5994">progesterone</compound-id> (r = 0.17; P = 0.007), and dietary intake of <compound-id="6857447">beta-tocopherol</compound-id> (r = 0.17; P = 0.006), and negatively with that of fructose (r = -0.13; P = 0.04).	beta-tocopherol__SHBG__no_interaction	progesterone__SHBG__no_interaction	cholesterol__SHBG__no_interaction
18283269-7	<protein-id="P01189,Q6FHC8">ACTH</protein-id> levels increased with weight (r = 0.13, p = 0.02), systolic blood pressure (r = 0.21, p = 0.002), diastolic blood pressure (r = 0.17, p = 0.01), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.17, p = 0.01).	glucose__ACTH__no_interaction
19745772-6	Differences were also found for <compound-id="206,64689,79025">glucose</compound-id> (5.24 +/- 0.37 vs 5.05 +/- 0.42 mmol/L, respectively; P = 0.003), <protein-id="P01308,I3WAC9">insulin</protein-id> resistance as estimated by homeostasis model assessment HOMA-2-IR (2.01 +/- 0.53 vs 1.10 +/- 0.27, respectively; P &lt; 0.001), weight (72.6 +/- 8.0 vs 69.9 +/- 7.1 kg, respectively; P = 0.023), body mass index (28.3 +/- 2.3 vs 27.2 +/- 2.3 kg/m2, respectively; P = 0.003), and waist circumference (89.8 +/- 5.8 vs 86.0 +/- 6.5 cm, respectively; P &lt; 0.001).	glucose__insulin__no_interaction
19820031-7	RESULTS: <protein-id="P10912,A0A087X0H5,A0A087X162">GHR</protein-id> blockade significantly suppressed circulating free fatty acids (1226 +/- 83 vs. 1074 +/- 65 micromol/liter; P = 0.03) and <compound-id="4348752">ketone</compound-id> bodies (3080 +/- 271 vs. 2015 +/- 235 micromol/liter; P &lt;or= 0.01), as well as forearm uptake of free fatty acids (0.341 +/- 0.150 vs. 0.004 +/- 0.119 micromol/100 ml x min; P &lt; 0.01) and lipid oxidation (1.3 +/- 0.1 vs. 1.2 +/- 0.1 mg/kg x min; P = 0.03) in the basal period.	ketone__GHR__no_interaction
15372629-3	Here, we show (1) nontoxic concentrations of <protein-id="P01137">TGF-beta1</protein-id> up-regulates <protein-id="Q96NZ9,A6XND8">uPA</protein-id> expression in HRA and SKOV-3 human ovarian cancer cells, (2) <protein-id="P01137">TGF-beta1</protein-id> activates Smads (phosphorylation of <protein-id="Q15796,B7Z5N5,Q53XR6">Smad2</protein-id> and nuclear translocation of <protein-id="P84022,A0A024R5Z3,Q9P0T0">Smad3</protein-id>) and subsequently up-regulates <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> expression in HRA cells, whereas <protein-id="P01137">TGF-beta1</protein-id> neither activates Smads nor up-regulates <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> in SKOV-3 cells, (3) pharmacological Src inhibitor <compound-id="4878">PP2</compound-id> or antisense (AS) c-Src oligodeoxynucleotide (<compound-id="78673848">ODN</compound-id>) treatment significantly induces <protein-id="P01137">TGF-beta1</protein-id>-dependent activation of Smads, leading to <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> synthesis, compared with controls, in SKOV-3 cells, (4) combination of <protein-id="P01137">TGF-beta1</protein-id> and <compound-id="4878">PP2</compound-id>, which activates <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> expression and reduces <protein-id="Q96NZ9,A6XND8">uPA</protein-id> expression in SKOV-3, results in decreased invasiveness, (5) pharmacological inhibitors for mitogen-activated protein kinase (MAPK) (<compound-id="4713">PD98059</compound-id>) and <compound-id="16738692">phosphoinositide</compound-id>-3-kinase (PI3K) (<compound-id="3973">LY294002</compound-id> and <compound-id="312145">wortmannin</compound-id>) or AS-PI3K <compound-id="78673848">ODN</compound-id> transfection do not affect <protein-id="P01137">TGF-beta1</protein-id>-induced Smad signaling and up-regulation of <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> expression in SKOV-3 cells pretreated with <compound-id="4878">PP2</compound-id>, and (6) the induction of <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> protein was partially inhibited by an inhibitor of <protein-id="P08047">Sp1</protein-id>-DNA binding, <compound-id="163659">mithramycin</compound-id>, implicating, at least in part, <protein-id="P08047">Sp1</protein-id> in the regulation of this gene by <protein-id="P01137">TGF-beta1</protein-id>.	PD98059__TGF-beta1__no_interaction	PD98059__Sp1__no_interaction	PD98059__Smad2__no_interaction	PD98059__Smad3__no_interaction	PD98059__uPA__no_interaction	PD98059__PAI-1__no_interaction	wortmannin__TGF-beta1__no_interaction	wortmannin__Sp1__no_interaction	wortmannin__Smad2__no_interaction	wortmannin__Smad3__no_interaction	wortmannin__uPA__no_interaction	wortmannin__PAI-1__no_interaction	mithramycin__TGF-beta1__no_interaction	mithramycin__Sp1__no_interaction	mithramycin__Smad2__no_interaction	mithramycin__Smad3__no_interaction	mithramycin__uPA__no_interaction	mithramycin__PAI-1__no_interaction	LY294002__TGF-beta1__no_interaction	LY294002__Sp1__no_interaction	LY294002__Smad2__no_interaction	LY294002__Smad3__no_interaction	LY294002__uPA__no_interaction	LY294002__PAI-1__no_interaction	PP2__TGF-beta1__no_interaction	PP2__Sp1__no_interaction	PP2__Smad2__no_interaction	PP2__Smad3__no_interaction	PP2__uPA__no_interaction	PP2__PAI-1__no_interaction	phosphoinositide__TGF-beta1__no_interaction	phosphoinositide__Sp1__no_interaction	phosphoinositide__Smad2__no_interaction	phosphoinositide__Smad3__no_interaction	phosphoinositide__uPA__no_interaction	phosphoinositide__PAI-1__no_interaction	ODN__TGF-beta1__no_interaction	ODN__Sp1__no_interaction	ODN__Smad2__no_interaction	ODN__Smad3__no_interaction	ODN__uPA__no_interaction	ODN__PAI-1__no_interaction
18710200-5	The ionization energy connects the dissociation energies of the neutral and cation, leading to greatly improved 0 K bond dissociation energies for the neutrals: D0(Pt-C) = 5.95 +/- 0.07 eV, D0(Pt-O) = 4.30 +/- 0.12 eV, and D0(OPt-O) = 4.41 +/- 0.13 eV, as well as enthalpies of formation for the gas-phase molecules DeltaH(0)(f,0)(<protein-id="Q13635,Q59FG5">PtC</protein-id>(g)) = 701 +/- 7 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, DeltaH(0)(f,0)(PtO(g)) = 396 +/- 12 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, and DeltaH(0)(f,0)(<compound-id="345198">PtO2</compound-id>(g)) = 218 +/- 11 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>.	PtO2__PtC__no_interaction	PtO2__mol__no_interaction
11530969-6	Operated patients had higher systolic blood pressure (<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>; 130 [126-133] vs. 125 [125-125] mmHg; p &lt; 0.01), serum total <compound-id="5997">cholesterol</compound-id> (6.1 [5.9-6.3] vs. 5.7 [5.7-5.7] mmol/l; p &lt; 0.0001), serum triglyceride (1.4 [1.3-1.6] vs. 1.1 [1.1-1.1] mmol/l; p &lt; 0.0001), serum <compound-id="23327,33032,611">glutamic acid</compound-id> transferase (0.46 [0.40-0.53] vs. 0.40 [0.40-0.41] microkat/l; p &lt; 0.05), and plasma fibrinogen (3.77 [3.42-4.16] vs. 3.35 [3.30-3.41] mmol/l; p &lt; 0.05) levels, a lower 120-min insulin/<compound-id="206,5793,64689,79025">glucose</compound-id> ratio at an oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test (OGTT; 0.48 [0.38-0.58] vs. 0.60 [0.59-0.61]; p &lt; 0.05) and forced vital lung capacity (3.7 [3.6-3.9] vs. 3.9 [3.9-4.0] l/min; p &lt; 0.05), and a higher prevalence of smoking at screening (68% vs. 45%; p &lt; 0.0001).	glucose__SBP__no_interaction	glutamic acid__SBP__no_interaction	cholesterol__SBP__no_interaction
22744429-8	<protein-id="Q92847">ghrelin receptor</protein-id> and <protein-id="P12872">motilin</protein-id> expression tended to increase (<compound-id="44576256">ghrelin</compound-id>: 0.7 ± 0.4 vs 2.0 ± 0.4 and 1.2 ± 0.2 respectively; p = 0.04 and p = 0.2; <protein-id="P12872">motilin</protein-id>: 0.7 ± 0.5 vs 2.2 ± 0.5 and 2.0 ± 0.7; p = 0.06 and p = 0.16).	ghrelin__ghrelin receptor__no_interaction	ghrelin__motilin__no_interaction
18310472-0	<protein-id="Q6GUQ6">CYP2C75</protein-id>-involved autoinduction of metabolism in rhesus monkeys of <compound-id="16102897">methyl 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-carboxylate</compound-id> (MK-0686), a bradykinin B1 receptor antagonist.	methyl 3-chloro-3'-fluoro-4'-{(1R)-1-[({1-[(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1'-biphenyl-2-carboxylate__CYP2C75__no_interaction
18006447-9	S-NO-HSA restored the NO level to 825 +/- 20 nmol/L, shifted favourably the [NO]/[ONOO(-)] balance (a marker of <protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id> uncoupling) from 1.36 +/- 0.06 (ischaemia) to 3.59 +/- 0.18, significantly improved CF (65 +/- 10 vs. control, 43 +/- 5 mL/min, P &lt; 0.05), MAP (57 +/- 5 vs. 39 +/- 3 mm Hg, P &lt; 0.01), LVSP (106 +/- 5 vs. 81 +/- 4 mm Hg, P &lt; 0.01) and <compound-id="587,9548602">phosphocreatine</compound-id> (PCr) content (41.5 +/- 7.3 vs. 18.0 +/- 5.6 micromol/g protein; P &lt; 0.01) at 150 min of reperfusion.	phosphocreatine__eNOS__no_interaction
19140844-7	In univariate analysis, age (r = 0.301, P = 0.001), serum <protein-id="P02768">albumin</protein-id> (r = -0.219, P = 0.01), <compound-id="22044544,5460341">calcium</compound-id> (r = 0.205, P = 0.02), high sensitivity <protein-id="P02741">C-reactive protein</protein-id> (r = 0.209, P = 0.02), and <protein-id="P61769,H0YL18">beta(2)-microglobulin</protein-id> (r = 0.206, P = 0.02) significantly correlated with the number of calcified valves.	calcium__C-reactive protein__no_interaction	calcium__albumin__no_interaction	calcium__beta(2)-microglobulin__no_interaction
20959528-4	In this study, we examined whether increased sensitivity to stress-induced reproductive dysfunction is associated with elevated adrenal axis activity by measuring 1) the diurnal release of <protein-id="P01189,Q6FHC8">ACTH</protein-id> and cortisol, 2) <protein-id="P01189,Q6FHC8">ACTH</protein-id> and cortisol in response to an acute psychological stress, 3) the percent suppression of cortisol in response to <compound-id="5743">dexamethasone</compound-id> negative feedback, 4) the diurnal release of <protein-id="P01189,Q6FHC8">ACTH</protein-id> and cortisol following exposure to mild psychosocial and metabolic stress, 5) the concentration of cortisol in hair, and 6) adrenal weight.	dexamethasone__ACTH__no_interaction
21741445-4	For example, Ca(2+)-stimulated adenylyl cyclase (AC) isoforms AC3 and <protein-id="P40146">AC8</protein-id>, PKCδ and CaMKIIα, the voltage-gated <compound-id="5360545">sodium</compound-id> channel β1 and β4, and <compound-id="5462222">potassium</compound-id> channels K(v)1.1, K(v)3.2, K(v)4.1, K(v)9.1, K(v)9.3, K(ir)3.4, K(ir)7.1, K(2P)1.1/TWIK-1 had significantly higher mRNA expression in adult rat DRG neurons, while Ca(2+)-inhibited AC5 and AC6, <compound-id="5360545">sodium</compound-id> channel Na(v)1.3 α subunit, <compound-id="5462222">potassium</compound-id> channels K(ir)6.1, K(2P)10.1/<protein-id="Q9JIS4">TREK-2</protein-id>, <compound-id="22044544,5460341">calcium</compound-id> channel Ca(v)2.2 α1 subunit, and its auxiliary subunits β1 and β3 were conversely down regulated in adult neurons.	calcium__TREK-2__no_interaction	calcium__AC8__no_interaction	potassium__TREK-2__no_interaction	potassium__AC8__no_interaction	sodium__TREK-2__no_interaction	sodium__AC8__no_interaction
16386762-6	At the 20th week of life, the arterial blood pressure values of the different groups of rats were: <protein-id="P41542">tap</protein-id> <compound-id="962">water</compound-id> (SBP = 219.5 +/- 5.7, DBP = 167 +/- 3.7), non-treated egg white (SBP = 206.4 +/- 1.43, DBP = 166.4 +/- 4.9), <compound-id="44093">captopril</compound-id> (SBP = 131.7 +/- 2.74, DBP = 91.5 +/- 1.62), HEW 0.5 g/kg/day (SBP = 182.9 +/- 4.64, DBP = 127.5 +/- 2.1) and HEW 1 g/kg/day (SBP = 177.7 +/- 4.72, DBP = 120.1 +/- 2.4).	water__tap__no_interaction	captopril__tap__no_interaction
21969368-2	<compound-id="16720766,56603703,71729979,73014187">MLN4924</compound-id> is an <compound-id="57476835,60961">adenosine</compound-id> <compound-id="177700">sulfamate</compound-id> analogue that was identified as a selective, mechanism-based inhibitor of <protein-id="Q15843">NEDD8-activating enzyme (NAE), another E1 enzyme</protein-id>, by forming a <protein-id="Q15843">NEDD8</protein-id>-<compound-id="16720766,56603703,71729979,73014187">MLN4924</compound-id> adduct that tightly binds at the active site of NAE, a novel mechanism termed substrate-assisted inhibition (Brownell, J. E., Sintchak, M. D., Gavin, J. M., Liao, H., Bruzzese, F. J., <compound-id="3034171">Bump</compound-id>, N. J., Soucy, T. A., Milhollen, M. A., Yang, X., Burkhardt, A. L., Ma, J., Loke, H. K., Lingaraj, T., Wu, D., Hamman, K. B., Spelman, J. J., Cullis, C. A., Langston, S. P., Vyskocil, S., Sells, T. B., Mallender, W. D., Visiers, I., Li, P., Claiborne, C. F., Rolfe, M., Bolen, J.	Bump__NEDD8-activating enzyme (NAE), another E1 enzyme__no_interaction	Bump__NEDD8__no_interaction	adenosine__NEDD8-activating enzyme (NAE), another E1 enzyme__no_interaction	adenosine__NEDD8__no_interaction	sulfamate__NEDD8-activating enzyme (NAE), another E1 enzyme__no_interaction	sulfamate__NEDD8__no_interaction	MLN4924__NEDD8-activating enzyme (NAE), another E1 enzyme__no_interaction	MLN4924__NEDD8__no_interaction
19190259-3	Six healthy young subjects (23 +/- 3 yr, BMI 25 +/- 2 kg/m(-2); means +/- SE), eight older subjects (59 +/- 4 yr, BMI 28 +/- 2 kg/m(-2)), and eight subjects with T2D (62 +/- 4 yr, BMI 27 +/- 2 kg/m(-2)) received a 6-h 2DG infusion (prime 10 mg/kg, 6 mg.kg(-1).h(-1)) and <protein-id="P31939,V9HWH7">AICAR</protein-id> (10 or 20 mg.kg(-1).h(-1)) from 3 to 6 h. Quadriceps biopsies were taken at 0, 3, and 6 h. We determined 1) 2DG uptake, 2) total AMPKalpha activity, AMPK, <compound-id="444493">acetyl-CoA</compound-id> carboxylase (ACC), and <protein-id="O60343">AS160</protein-id> phosphorylation, and 3) <protein-id="P28482,Q1HBJ4,Q499G7">ERK1/2</protein-id> phosphorylation.	acetyl-CoA__AS160__no_interaction	acetyl-CoA__ERK1/2__no_interaction	acetyl-CoA__AICAR__no_interaction
18684840-0	The <protein-id="P13945,A8KAG8">beta3-adrenoceptor</protein-id> agonist 4-[[(<compound-id="8102">Hexylamino</compound-id>)carbonyl]amino]-N-[4-[2-[[(2S)-<compound-id="97257">2-hydroxy-</compound-id>3-(4-hydroxyphenoxy)propyl]amino]<compound-id="23134249">ethyl</compound-id>]-phenyl]-<compound-id="7370">benzenesulfonamide</compound-id> (<compound-id="9829836">L755507</compound-id>) and antagonist (S)-N-[4-[2-[[3-[3-(<compound-id="6582">acetamidomethyl</compound-id>)phenoxy]-2-hydroxypropyl]amino]-<compound-id="23134249">ethyl</compound-id>]phenyl]<compound-id="7370">benzenesulfonamide</compound-id> (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human <protein-id="P13945,A8KAG8">beta3-adrenoceptor</protein-id>.	Hexylamino__beta3-adrenoceptor__no_interaction	benzenesulfonamide__beta3-adrenoceptor__no_interaction	L755507__beta3-adrenoceptor__no_interaction	2-hydroxy-__beta3-adrenoceptor__no_interaction	ethyl__beta3-adrenoceptor__no_interaction	acetamidomethyl__beta3-adrenoceptor__no_interaction
2328843-7	Our conclusion that PKC is an essential component in the regulation of myoblast fusion is based in part on the following evidence: (1) an activator of PKC, the tumor promoter <compound-id="27924">12-O-tetradecanoylphorbol-13-acetate</compound-id> (<compound-id="122634,22833501">TPA</compound-id>), at low concentration and for a brief exposure period, induces precocious fusion and stimulates <protein-id="P07630">Ca2</protein-id>+ influx; (2) 4 alpha-<compound-id="442070">phorbol</compound-id>-12,13-didecanoate, an inactive analog of <compound-id="122634,22833501">TPA</compound-id>, has no discernible effect on fusion or <protein-id="P07630">Ca2</protein-id>+ influx; (3) 1-oleoyl-<compound-id="641349">2-acetyl glycerol</compound-id>, an analog of endogenous <compound-id="6026790">diacylglycerol</compound-id> (DAG) which activates PKC, promotes precocious fusion, as does the DAG <compound-id="53378893">kinase inhibitor</compound-id> <compound-id="3012">R59022</compound-id> (6-[2-[4-[(4-<compound-id="10008">fluorophenyl</compound-id>)phenylmethylene]-1-piperidinyl]<compound-id="23134249">ethyl</compound-id>]-7- methyl-5H-thiazole-[3,2 alpha]-<compound-id="565855">pyrimidin-5-one</compound-id>) which raises the level of endogenous DAG by inhibiting its catabolism; (4) 1-(5-<compound-id="57047419">isoquinolinesulfonyl</compound-id>)-<compound-id="66057">2-methylpiperazine</compound-id> (H-7), a highly potent PKC inhibitor, reversibly blocks myogenesis at a point between alignment and fusion; and (5) H-7 also blocks the normal increase in <protein-id="P07630">Ca2</protein-id>+ influx preceding fusion.	R59022__Ca2__no_interaction	2-methylpiperazine__Ca2__no_interaction	12-O-tetradecanoylphorbol-13-acetate__Ca2__no_interaction	fluorophenyl__Ca2__no_interaction	TPA__Ca2__no_interaction	pyrimidin-5-one__Ca2__no_interaction	isoquinolinesulfonyl__Ca2__no_interaction	kinase inhibitor__Ca2__no_interaction	phorbol__Ca2__no_interaction	diacylglycerol__Ca2__no_interaction	2-acetyl glycerol__Ca2__no_interaction	ethyl__Ca2__no_interaction
18852398-8	In addition, <compound-id="160051">colesevelam</compound-id> significantly (1) lowered fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (-13.9 mg/dL P = .01), <compound-id="20484">fructosamine</compound-id> (-23.2 micromol/L; P &lt; .001), total <compound-id="5997">cholesterol</compound-id> (TC) (-7.2%; P &lt; .001), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (-15.9%; P &lt; .001), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (-7.9%; P &lt; .001), non-high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) (-10.3%; P &lt; .001), and high-sensitivity C-reactive protein (-14.4%; P = .02) levels and (2) improved other measures of glycemic response, as well as TC/HDL-C, <protein-id="Q14746,B1ALW7">LDL-C</protein-id>/HDL-C, non-HDL-C/HDL-C, and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id>/<protein-id="P02647,A0A024R3E3">apolipoprotein A-I</protein-id> ratios (P &lt; .003 for all).	fructosamine__low-density lipoprotein cholesterol__no_interaction	fructosamine__apolipoprotein B__no_interaction	fructosamine__apolipoprotein A-I__no_interaction	fructosamine__LDL-C__no_interaction	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein A-I__no_interaction	cholesterol__LDL-C__no_interaction	colesevelam__low-density lipoprotein cholesterol__no_interaction	colesevelam__apolipoprotein B__no_interaction	colesevelam__apolipoprotein A-I__no_interaction	colesevelam__LDL-C__no_interaction	glucose__low-density lipoprotein cholesterol__no_interaction	glucose__apolipoprotein B__no_interaction	glucose__apolipoprotein A-I__no_interaction	glucose__LDL-C__no_interaction
11579176-8	The exercise-induced increase in interstitial <compound-id="24759880,753">glycerol</compound-id> concentration in subcutaneous adipose tissue was significantly lower in SCI compared with healthy subjects (SCI: 25 +/- 12 % (Cl), 36 +/- 20 % (Um); healthy: 60 +/- 17 % (Cl), 147 +/- 45 % (Um)) and the increase in ATBF was significantly lower (Cl) or similar (Um) in SCI compared with healthy subjects (SCI: 1.2 +/- 0.3 ml (100 g)(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (Cl), 1.0 +/- 0.3 ml (100 g)(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (Um); healthy: 2.8 +/- 0.7 ml (100 g)(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (Cl), 0.6 +/- 0.3 ml (100 g)(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (Um)).	glycerol__min(-1__no_interaction
20931854-2	METHOD: The HMC were divided into normal <compound-id="206,5793,64689,79025">glucose</compound-id> group (NG group, 5.5 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id>), normal <compound-id="206,5793,64689,79025">glucose</compound-id> +low DP group (NG + <protein-id="Q9Y646,A0A024R9B8">LDP</protein-id> group, 5.5 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id> +7.5 micromol x L(-1) DP), normal <compound-id="206,5793,64689,79025">glucose</compound-id> +high DP group (NG + HDP group, 5.5 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id> + 15 micromol x L(-1) DP), high <compound-id="206,5793,64689,79025">glucose</compound-id> group (HG group,25 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id>), high <compound-id="206,5793,64689,79025">glucose</compound-id> +low DP group (HG + <protein-id="Q9Y646,A0A024R9B8">LDP</protein-id> group, 25 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id> + 7.5 micromol x L(-1) DP)and high <compound-id="206,5793,64689,79025">glucose</compound-id> +high DP group (HG +HDP group, 25 mmol x L(-1) D-<compound-id="206,5793,64689,79025">glucose</compound-id> + 15 micromol x L(-1) DP).	glucose__LDP__no_interaction
23591727-6	RESULTS: Lymphocyte subpopulation counts and ratios including <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>:μL (P=0.005), CD3:μL (P=0.02), CD4DR:μL (P=0.002), <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>:μL (P=0.01), and CD8DR:μL (P=0.005) T cells; <protein-id="P01730,B4DT49,B0AZV7">CD4DR:CD4</protein-id> (P=0.009) and <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8DR:CD8</protein-id> (P=0.0004) ratios; DR cells:μL (P=0.003); CD19 B lymphocytes:μL (P=0.001); and plasma levels of <compound-id="444632,4455,448839">neopterin</compound-id> (P&lt;;0.0001), soluble <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> (P&lt;;0.0001), IL-8 (P=0.0001), and tumor necrosis factor-α (P=0.008) were significantly decreased after PP as compared with before PP.	neopterin__CD45__no_interaction	neopterin__interleukin-1 receptor antagonist__no_interaction	neopterin__CD8__no_interaction	neopterin__CD4DR:CD4__no_interaction	neopterin__CD8DR:CD8__no_interaction
8549869-2	Several of these characteristics are emphasized: a high-capacity system for <compound-id="206,5793,64689,79025">glucose</compound-id> transport; <compound-id="206,5793,64689,79025">glucose</compound-id> phosphorylation by the high-Km <protein-id="P35557,Q53Y25">glucokinase</protein-id> (GK), which is rate-limiting for <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism and determines physiologically the <compound-id="206,5793,64689,79025">glucose</compound-id> dependency curves of many processes in beta-cell intermediary and energy metabolism and of insulin release and is therefore viewed as <compound-id="206,5793,64689,79025">glucose</compound-id> sensor; remarkably low activity of <compound-id="612">lactate</compound-id> dehydrogenase and the presence of effective <compound-id="783">hydrogen</compound-id> shuttles to allow virtually quantitative oxidation of glycolytic <compound-id="439153">NADH</compound-id>; the near absence of <compound-id="439177">glycogen</compound-id> and fatty acid synthesis and of gluconeogenesis, such that intermediary metabolism is primarily catabolic; a crucial role of mitochondrial processes, including the <compound-id="311">citric acid</compound-id> cycle, electron transport, and oxidative phosphorylation with FoF1 ATPase governing the <compound-id="206,5793,64689,79025">glucose</compound-id>-dependent increase of the <compound-id="5957">ATP</compound-id> mass-action ratio; a Ca(2+)-independent <compound-id="206,5793,64689,79025">glucose</compound-id>-induced respiratory burst and increased <compound-id="5957">ATP</compound-id> production in beta-cells as striking manifestations of crucial mitochondrial reactions; control of the membrane potential by the mass-action ratio of <compound-id="5957">ATP</compound-id> and voltage-dependent Ca2+ influx as signal for insulin release; accumulation of <compound-id="644066">malonyl-CoA</compound-id>, acyl-<compound-id="44246472,447444,448506,46936280">CoA</compound-id>, and <compound-id="6026790">diacylglycerol</compound-id> as essential or auxiliary metabolic coupling factors; and amplification of the <compound-id="190,57060554">adenine</compound-id> nucleotide, lipid-related, and Ca2+ signals to recruit many auxiliary processes to maximize insulin biosynthesis and release.	malonyl-CoA__glucokinase__no_interaction	NADH__glucokinase__no_interaction	glycogen__glucokinase__no_interaction	adenine__glucokinase__no_interaction	CoA__glucokinase__no_interaction	citric acid__glucokinase__no_interaction	ATP__glucokinase__no_interaction	lactate__glucokinase__no_interaction	diacylglycerol__glucokinase__no_interaction	hydrogen__glucokinase__no_interaction	glucose__glucokinase__no_interaction
11739021-5	Islets from S5 hamsters released significantly more <protein-id="P01308,I3WAC9">insulin</protein-id> than C5 islets in the presence of low and high <compound-id="206,5793,64689,79025">glucose</compound-id> (3.3 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 0.77+/-0.04 vs 0.20+/-0.06 pg/ng DNA/min, P&lt;0.001; 16.7 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 2.77+/-0.12 vs 0.85+/-0.06 pg/ng DNA/min, P&lt;0.001) and produced significantly higher amounts of (14)CO(2) and (3)H(2)O at both <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations ((14)CO(2): 3.3 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 0.27+/-0.01 vs 0.18+/-0.01, P&lt;0.001; 16.7 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 1.44+/-0.15 vs 0.96+/-0.08, P&lt;0.02; (3)H(2)O: 3.3 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 0.31+/-0.02 vs 0.15+/-0.01, P&lt;0.001; 16.7 mM <compound-id="206,5793,64689,79025">glucose</compound-id>: 1.46+/-0.20 vs 0.76+/-0.05 pmol <compound-id="206,5793,64689,79025">glucose</compound-id>/ng DNA/min, P&lt;0.005).	glucose__insulin__no_interaction
24249745-6	RESULTS: Of 68 evaluable markers, 11 were statistically significantly associated with lung cancer risk (P trend across marker categories &lt; .05), including acute-phase proteins (<protein-id="P02741">C-reactive protein [CRP], serum amyloid A</protein-id> [SAA]), proinflammatory cytokines (soluble <protein-id="P20333">tumor necrosis factor receptor 2</protein-id> [sTNFRII]), anti-inflammatory cytokines (<protein-id="P18510,A0A024R528">interleukin 1 receptor antagonist [IL-1RA</protein-id>]), lymphoid differentiation cytokines (interleukin 7 [<protein-id="P13232,Q5FBX5,A0A0A0MTG5,A8K673">IL-7</protein-id>]), growth factors (transforming growth factor alpha [TGF-A]), and chemokines (epithelial neutrophil-activating <compound-id="3081257">peptide 78</compound-id> [<protein-id="P42830,Q6I9S7">ENA 78</protein-id>/<protein-id="P42830,Q6I9S7">CXCL5</protein-id>], <protein-id="Q07325">monokine induced by gamma interferon</protein-id> [MIG/<protein-id="O43927,Q53X90">CXCL9], B cell-attracting chemokine 1</protein-id> [<protein-id="O43927,Q53X90">BCA-1</protein-id>/<protein-id="O43927,Q53X90">CXCL13</protein-id>], thymus activation regulated chemokine [<protein-id="Q92583">TARC</protein-id>/<protein-id="Q92583">CCL17</protein-id>], <protein-id="O00626">macrophage-derived chemokine</protein-id> [<protein-id="O00626">MDC</protein-id>/<protein-id="O00626">CCL22</protein-id>]).	peptide 78__C-reactive protein [CRP], serum amyloid A__no_interaction	peptide 78__BCA-1__no_interaction	peptide 78__CXCL5__no_interaction	peptide 78__CXCL9], B cell-attracting chemokine 1__no_interaction	peptide 78__interleukin 1 receptor antagonist [IL-1RA__no_interaction	peptide 78__TARC__no_interaction	peptide 78__MDC__no_interaction	peptide 78__IL-7__no_interaction	peptide 78__tumor necrosis factor receptor 2__no_interaction	peptide 78__ENA 78__no_interaction	peptide 78__CCL17__no_interaction	peptide 78__macrophage-derived chemokine__no_interaction	peptide 78__CXCL13__no_interaction	peptide 78__CCL22__no_interaction	peptide 78__monokine induced by gamma interferon__no_interaction
10067872-7	The results are summarized as follows: 1) exposing the cells to a low Ca2+ (20 nM) buffer solution suppressed <protein-id="P55247,F6S1S9">LHRH</protein-id> release, whereas exposure to a normal Ca2+ solution (1.25 mM) maintained pulsatile <protein-id="P55247,F6S1S9">LHRH</protein-id> release; 2) <protein-id="P55247,F6S1S9">LHRH</protein-id> release from cultured <protein-id="P55247,F6S1S9">LHRH</protein-id> cells was stimulated by the voltage-sensitive L-type Ca2+ channel agonist, Bay K 8644 (10 microM), whereas it was suppressed by the L-type Ca2+ channel blocker, <compound-id="4485">nifedipine</compound-id> (1 microM), but not by the N-type channel blocker, <compound-id="16132374">omega-conotoxin GVIA</compound-id> (1 microM); 3) the intracellular Ca2+ stimulant, <compound-id="11317883,27439,441753,5114,6326656">ryanodine</compound-id> (1 microM), stimulated <protein-id="P55247,F6S1S9">LHRH</protein-id> release, whereas the intracellular Ca2+ transporting <compound-id="57476835,60961">adenosine</compound-id> triphosphatase antagonist, <compound-id="446378,49926">thapsigargin</compound-id> (1 and 10 microM), did not yield consistent results; and 4) <compound-id="57248046">carbonyl cyanide p-trifluoromethoxyphenyl-hydrazone</compound-id> (1 microM), a mitochondrial Ca2+ mobilizer, stimulated <protein-id="P55247,F6S1S9">LHRH</protein-id> release, whereas <compound-id="23950">ruthenium</compound-id> red, a mitochondrial Ca2+ uptake inhibitor, did not induce consistent results.	carbonyl cyanide p-trifluoromethoxyphenyl-hydrazone__LHRH__no_interaction	nifedipine__LHRH__no_interaction	thapsigargin__LHRH__no_interaction	omega-conotoxin GVIA__LHRH__no_interaction	ruthenium__LHRH__no_interaction	ryanodine__LHRH__no_interaction	adenosine__LHRH__no_interaction
20814065-7	This effect of <compound-id="44576256">ghrelin</compound-id> was blocked when the bath solution contained 1,4-<compound-id="76988">diamino</compound-id>-<compound-id="91008609">2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene</compound-id> (<compound-id="3006531,5354033,9951825">U0126</compound-id>), 4-amino-5-(4-methylphenyl)-7-(t-<compound-id="68006705">butyl</compound-id>) pyrazolo[3,4-d] pyrimidine (<compound-id="4878">PP2</compound-id>), D-609, 2-[<compound-id="88721">1-(3-dimethylaminopropyl)indol-3-yl</compound-id>]-3-(indol-3-yl) <compound-id="10935">maleimide</compound-id> (<compound-id="2396">GF109203x</compound-id>), pertussis toxin, <compound-id="57481262">2-aminoethyl</compound-id> <compound-id="17498">diphenylborinate</compound-id> (<compound-id="1598">2-APB</compound-id>), <compound-id="3715">indomethacin</compound-id>, (5Z,13E)-(9S,11S,15R)-9,15,Dihydroxy-11-fluoro-15-(2-<compound-id="57417021">indanyl</compound-id>)-16,17,18,19,20,pentanor-5,13-<compound-id="54199810">prostadienoic acid</compound-id> (AL-8810) - a non-selective prostanoid receptor antagonist, <compound-id="1519421">5-(4-Chlorophenyl)-1-(</compound-id>4-methoxyphenyl)-3-<compound-id="6373">trifluoromethyl</compound-id> pyrazolo (<compound-id="4306515">SC-560</compound-id>) - a selective <protein-id="P23219,A0A087X296">cyclooxygenase 1</protein-id> inhibitor, <compound-id="5282440">ozagrel</compound-id> - a selective <compound-id="114873">thromboxane</compound-id> A(2) synthase inhibitor or T prostanoid receptor antagonist GR32191B.	2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene__cyclooxygenase 1__no_interaction	U0126__cyclooxygenase 1__no_interaction	indanyl__cyclooxygenase 1__no_interaction	2-aminoethyl__cyclooxygenase 1__no_interaction	thromboxane__cyclooxygenase 1__no_interaction	diamino__cyclooxygenase 1__no_interaction	2-APB__cyclooxygenase 1__no_interaction	1-(3-dimethylaminopropyl)indol-3-yl__cyclooxygenase 1__no_interaction	SC-560__cyclooxygenase 1__no_interaction	PP2__cyclooxygenase 1__no_interaction	maleimide__cyclooxygenase 1__no_interaction	butyl__cyclooxygenase 1__no_interaction	ghrelin__cyclooxygenase 1__no_interaction	5-(4-Chlorophenyl)-1-(__cyclooxygenase 1__no_interaction	prostadienoic acid__cyclooxygenase 1__no_interaction	trifluoromethyl__cyclooxygenase 1__no_interaction	diphenylborinate__cyclooxygenase 1__no_interaction	indomethacin__cyclooxygenase 1__no_interaction	ozagrel__cyclooxygenase 1__no_interaction	GF109203x__cyclooxygenase 1__no_interaction
8680988-12	Leg <compound-id="206,5793,64689,79025">glucose</compound-id> clearance rates increased (p &lt; .05) with training and was similar in aged men (<protein-id="P06729,Q53F96">T: 1 +/- 1, 8</protein-id> +/- 1, 21 +/- 2, and 24 +/- 2; UT: 1 +/- 1, 6 +/- 1, 14 +/- 2, and 20 +/- 2 ml.<protein-id="P13987,Q6FHM9">min-1</protein-id>.kg leg-1) and young men (T: 1 +/- 1, 12 +/- 3, 23 +/- 3, and 26 +/- 3; UT: 1 +/- 1, 8 +/- 2, 17 +/- 2, and 21 +/- 2 ml.<protein-id="P13987,Q6FHM9">min-1</protein-id>.kg leg-1).	glucose__T: 1 +/- 1, 8__no_interaction	glucose__min-1__no_interaction
20598466-12	Comparison of the transfusion requirements at heart transplantation of 35 <protein-id="P08172,A4D1Q0,Q86SJ1,Q6SL56,Q6SL59">HM II</protein-id> patients with 62 HeartMate <compound-id="53313334">XVE</compound-id> patients demonstrated twice the transfusion requirements in <protein-id="P08172,A4D1Q0,Q86SJ1,Q6SL56,Q6SL59">HM II</protein-id> patients (packed red blood cells, 6.3 ± 0.8 U vs. 3.8 ± 0.5 U; platelets, 12.5 ± 5.4 U vs. 8.6 ± 6.4 U; fresh frozen plasma, 9.6 ± 4.9 U vs. 4.9 ± 3.6 U; and cryoprecipitate, 4.3 ± 3.6 U vs. 2.2 ± 3.5 U; p &lt; 0.05 for all).	XVE__HM II__no_interaction
10757572-7	RESULTS: After 24 h of study treatment goup A showed a significant increase in cardiac index (2.2+/-0.4 1 <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) to 2.7+/-0.51 <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2); P&lt;0.005), a decrease in systemic vascular resistance (1,427+/-609 dyn x s x cm(-5) to 951+/-184 dyn x s x cm(-5); P&lt;0.005), required lower doses of <compound-id="36811">dobutamine</compound-id> (5.9+/-4.2 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) to 2.2+/-3.3 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P&lt;0.02), but showed a tendency for higher vasoconstrictor (0.14+/-0.16 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) to 0.29+/-0.43 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P=n.s.	dobutamine__min(-1__no_interaction
14606846-1	The hydrothermal reactions of AgNO(3), 4,4'-<compound-id="1474">bipy</compound-id>, and carboxylate ligands gave rise to three supramolecular architectures, namely [Ag(<compound-id="1474">bipy</compound-id>)].H(2)<protein-id="Q96FS4">SIPA.1</protein-id>/2bipy.H(2)O (1), [Ag(<compound-id="1474">bipy</compound-id>)].1/2H(2)btec.H(2)O (2), and [Ag(<compound-id="1474">bipy</compound-id>)](2).H(2)dpstc.2H(2)O (3) (H(3)SIPA = <compound-id="80714">5-sulfoisophthalic acid</compound-id>, <compound-id="1474">bipy</compound-id> = <compound-id="11107">4,4'-bipyridine</compound-id>, H(4)btec = <compound-id="6961">1,2,4,5-benzenetetracarboxylic acid</compound-id>, H(4)dpstc = 3,3',4,4'-tetracarboxydiphenyl sulfone).	4,4'-bipyridine__SIPA.1__no_interaction	1,2,4,5-benzenetetracarboxylic acid__SIPA.1__no_interaction	bipy__SIPA.1__no_interaction	5-sulfoisophthalic acid__SIPA.1__no_interaction
11896713-3	The one-pot reaction of DmpLi with 1 equiv of YbCl(3) in <compound-id="86079">tetrahydrofuran at</compound-id> room temperature followed by addition of 1 equiv of KO(t)Bu produces the heterobimetallic monoalkoxide complex DmpYb(<compound-id="8028">THF</compound-id>)(O(t)Bu)(mu-Cl)(2)Li(<compound-id="8028">THF</compound-id>)(2) (4), which was crystallized from <compound-id="1140">toluene</compound-id>/tetrahydrofuran (20:1) at -30 degrees C. Crystal data for 1: monoclinic, <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n; T = 203 K; a = 10.178(3) A; b = 15.468(3) A; c = 20.132(5) A; beta = 101.85(3) degrees; V = 3102.0(17) A(3); Z' = 4; D(calcd) = 1.228 g cm(-3); R(1) = 5.89%.	THF__P2(1__no_interaction	tetrahydrofuran at__P2(1__no_interaction	toluene__P2(1__no_interaction
1930830-1	[Cu(H2O)4](<compound-id="139646">ClO3</compound-id>)2, Mr = 302.51, orthorhombic, Pbca, lambda (<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71069 A, Z = 4, F(000) = 604; T = 296 K, a = 12.924 (3), b = 9.502 (2), c = 7.233 (1) A, V = 888.3 (3) A3, D chi = 2.26 g cm-3, mu = 31.04 cm-1, R = 0.041 for 1174 unique reflections with I greater than sigma (I); T = 223 K, a = 12.853 (2), b = 9.492 (2), c = 7.216 (2) A, V = 880.4 (3) A3, D chi = 2.28 g cm-3, mu = 31.28 cm-1, R = 0.033 for 1279 unique reflections with I greater than sigma (I).	ClO3__Mo K alpha__no_interaction
16513445-7	RESULTS: Up-regulation of intestinal P-gp, <protein-id="Q92887">MRP2</protein-id>, and <protein-id="P22309,Q5DT03">UGT1A1</protein-id> (but not of <protein-id="Q9UHC9,A0A0C4DFX6">NPC1L1</protein-id>) by <compound-id="24871024,5702112,57032154,6243627,6842115,6913622">rifampin</compound-id> was associated with markedly decreased areas under the curve of <compound-id="150311">ezetimibe</compound-id> and its <compound-id="5281877">glucuronide</compound-id> (116 +/- 78.1 ng.h/mL versus 49.9 +/- 31.0 ng.h/mL and 635 +/- 302 ng.h/mL versus 225 +/- 86.4 ng.h/mL, respectively; both P = .002) and increased intestinal clearances (2400 +/- 1560 mL/min versus 5500 +/- 4610 mL/min [P = .003] and 76.6 +/- 113 mL/min versus 316 +/- 457 mL/min [P = .010], respectively) and nearly abolished sterol-lowering effects.	rifampin__MRP2__no_interaction	rifampin__UGT1A1__no_interaction	rifampin__NPC1L1__no_interaction	glucuronide__MRP2__no_interaction	glucuronide__UGT1A1__no_interaction	glucuronide__NPC1L1__no_interaction	ezetimibe__MRP2__no_interaction	ezetimibe__UGT1A1__no_interaction	ezetimibe__NPC1L1__no_interaction
11405462-1	The thermolysis of the <compound-id="6432095">phosphinidene</compound-id> complex [Cp*P[W(CO)5]2] (1) in <compound-id="1140">toluene</compound-id> in the presence of tBuC(triple bond)CMe leads to the four-membered ring complexes [[[<protein-id="Q9UNA4">eta2</protein-id>-C(Me)C(tBu)]Cp*(CO)W(mu3-P)[W(CO)3]][eta4:<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>:<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-P[W(CO)5]WCp*(CO)C(Me)C(tBu)]] (4) as the major product and [[W[Cp*(CO)2]W(CO)2WCp*(CO)[<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>:<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-C(Me)C(tBu)]](mu,eta3:<protein-id="Q9UNA4">eta2</protein-id>:<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-P2[W(CO)5]] (5).	phosphinidene__eta1__no_interaction	phosphinidene__eta2__no_interaction	toluene__eta1__no_interaction	toluene__eta2__no_interaction
11507101-5	These studies revealed that: (i) LTC(4) labels sites in the NH(2)- and COOH-proximal halves of <protein-id="P33527">MRP1</protein-id>, (ii) labeling of the NH(2)-half of <protein-id="P33527">MRP1</protein-id> is localized to a region encompassing membrane-spanning domain (MSD) 2 and nucleotide binding domain (NBD) 1, (iii) labeling of this region is dependent on the presence of all or part of the cytoplasmic loop (CL3) linking MSD1 and MSD2, but not on the presence of MSD1, (iv) labeling of the NH(2)-proximal site is preferentially inhibited by <compound-id="115260">S-methyl GSH</compound-id>, (v) labeling of the COOH-proximal half of the protein occurs in a region encompassing transmembrane helices 14-17 and appears not to require NBD2 or the cytoplasmic COOH-terminal region of the protein, (vi) labeling of intact <protein-id="P33527">MRP1</protein-id> by LTC(4) is strongly attenuated in the presence of ATP and vanadate, and this decrease in labeling is attributable to a marked reduction in LTC(4) binding to the NH(2)-proximal site, and (vii) the attenuation of LTC(4) binding to the NH(2)-proximal site is a consequence of ATP hydrolysis and trapping of Vi-<compound-id="6022">ADP</compound-id> exclusively at NBD2.	ADP__MRP1__no_interaction	S-methyl GSH__MRP1__no_interaction
10972686-11	For all patients, VLDL1 apoCII, <protein-id="P02656,A3KPE2">apoCIII</protein-id>, and <protein-id="P02649">apoE</protein-id> contents per particle were related to particle size (apoCII, r2 = 61.5%, P &lt; 0.001; <protein-id="P02656,A3KPE2">apoCIII</protein-id>, r2 = 75.8%, P &lt; 0.001; <protein-id="P02649">apoE</protein-id>, r2 = 58.2%, P &lt; 0.001) and inversely to the free <compound-id="5997">cholesterol</compound-id> to phospholipid ratio (apoCII, r2 = 41.6%, P &lt; 0.001; <protein-id="P02656,A3KPE2">apoCIII</protein-id>, r2 = 38.8%, P &lt; 0.001; <protein-id="P02649">apoE</protein-id>, r2 = 11.7%, P &lt; 0.05).	cholesterol__apoCIII__no_interaction	cholesterol__apoE__no_interaction
24194755-3	Cd-SiO2NPs induced mortality (about 50%) at 1  μ g/mL, <compound-id="24947">CdCl2</compound-id> at 25  μ g/mL; (ii) <compound-id="4126474">calcein-AM</compound-id>/PI staining: decrease in cell viability, noticeable at 25  μ g/mL, enhanced markedly at 50 and 100  μ g/mL, after 24 h. Cd-SiO2NPs induced higher mortality than <compound-id="24947">CdCl2</compound-id> (25% versus 4%, resp., at 25  μ g/mL) with further exacerbation after 48h; (iii) clonogenic assay: exposure for longer period (10 days) compromised the A549 proliferative capacity at very low dose (0.05  μ g/mL); (iv) a progressive activation of <protein-id="P42574">caspase-3</protein-id> immunolabelling was detected already at 1  μ g/mL; (v) <compound-id="124886">GSH</compound-id> intracellular level was modified by all compounds.	GSH__caspase-3__no_interaction	calcein-AM__caspase-3__no_interaction	CdCl2__caspase-3__no_interaction
19702302-4	<protein-id="P50052">At 2</protein-id> degrees C their rank ordering is: P &lt;&lt; G &lt; H &lt; C, T, N &lt; S &lt; Y, F, W &lt; V, D &lt; K &lt; Q &lt; I &lt; R, M &lt; L &lt; E &lt; A; at 60 degrees C the rank becomes: H, P &lt; G &lt; C &lt; R, K &lt; T, Y, F &lt; N, V &lt; S &lt; Q &lt; W, D &lt; I, M &lt; E &lt; A &lt; L. The DeltaDeltaG values, kcal/mol, relative to <compound-id="5950">alanine</compound-id>, for the cluster T, N, S, Y, F, W, V, D, Q, imply that <protein-id="P50052">At 2</protein-id> degrees C all are strong breakers: DeltaDeltaG(mean) = +0.63 +/- 0.11, but at 60 degrees C their breaking tendencies are dramatically attenuated and converge toward the mean: DeltaDeltaG(mean) = +0.25 +/- 0.07.	alanine__At 2__no_interaction
7955441-7	RESULTS: In the rhGH treated group there was a significant fall in serum <compound-id="5997">cholesterol</compound-id> (P &lt; 0.01) (6.44 +/- 0.49 to 5.71 +/- 0.48 mmol/l), LDL <compound-id="5997">cholesterol</compound-id> (P &lt; 0.02) (4.29 +/- 0.49 to 3.62 +/- 0.44 mmol/l), LDL <compound-id="5997">cholesterol</compound-id>/<protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> ratio (P &lt; 0.02) (3.99 +/- 0.62 to 3.26 +/- 0.39), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (P &lt; 0.01 (1.30 +/- 0.11 to 1.15 +/- 0.11 g/l) and <compound-id="439230">mevalonic acid</compound-id> (P &lt; 0.05) (13.4 +/- 10.96 to 6.21 +/- 1.91 micrograms/l).	mevalonic acid__HDL__no_interaction	mevalonic acid__apolipoprotein B__no_interaction	cholesterol__HDL__no_interaction	cholesterol__apolipoprotein B__no_interaction
10559845-7	The administration of Asc extract increased <compound-id="5884">NADPH</compound-id> diaphorase activity (2 days: control = 0, <protein-id="P41251">BCG</protein-id> = 7%, <protein-id="P41251">BCG</protein-id> + Asc = 13%, and Asc = 4%; 7 days: control = 4, <protein-id="P41251">BCG</protein-id> = 13%, <protein-id="P41251">BCG</protein-id> + Asc = 21%, and Asc = 4.5%) and <protein-id="P06804,Q3U593">TNF-alpha</protein-id> levels (mean +/- SD; 2 days: control = 0, <protein-id="P41251">BCG</protein-id> = 169 +/- 13, <protein-id="P41251">BCG</protein-id> + Asc = 202 +/- 37, and Asc = 0; 7 days: control = 0, <protein-id="P41251">BCG</protein-id> = 545 +/- 15.5, <protein-id="P41251">BCG</protein-id> + Asc = 2206 +/- 160.6, and Asc = 126 +/- 26; 14 days: control = 10 +/- 1.45, <protein-id="P41251">BCG</protein-id> = 9 +/- 1.15, <protein-id="P41251">BCG</protein-id> + Asc = 126 +/- 18, and Asc = 880 +/- 47.67 pg/ml) in the early phase of <protein-id="P41251">BCG</protein-id> infection.	NADPH__TNF-alpha__no_interaction	NADPH__BCG__no_interaction
15224175-5	bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists <compound-id="3378093">SB224289</compound-id> (300 microg/kg; <protein-id="P79250">5-HT1B</protein-id>), <compound-id="3654103">BRL15572</compound-id> (300 microg/kg; <protein-id="P11614">5-HT1D</protein-id>), <compound-id="643606">rauwolscine</compound-id> (300 microg/kg; alpha2), <compound-id="3378093">SB224289</compound-id> + <compound-id="3654103">BRL15572</compound-id> (300 microg/kg each), <compound-id="3378093">SB224289</compound-id> + <compound-id="643606">rauwolscine</compound-id> (300 microg/kg each), <compound-id="3654103">BRL15572</compound-id> + <compound-id="643606">rauwolscine</compound-id> (300 microg/kg each), <compound-id="643606">rauwolscine</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg; alpha1), <compound-id="3378093">SB224289</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg), <compound-id="3378093">SB224289</compound-id> (300 microg/kg) + <compound-id="643606">rauwolscine</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg), <compound-id="3378093">SB224289</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg) + <compound-id="121850">BRL44408</compound-id> (1,000 microg/kg; alpha2A), <compound-id="3378093">SB224289</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg)+ <compound-id="133621">imiloxan</compound-id> (1,000 microg/kg; alpha2B), or <compound-id="3378093">SB224289</compound-id> (300 microg/kg) + <compound-id="4893">prazosin</compound-id> (100 microg/kg) + <compound-id="5311298">MK912</compound-id> (300 microg/kg; alpha2C).	prazosin__5-HT1D__no_interaction	prazosin__5-HT1B__no_interaction	imiloxan__5-HT1D__no_interaction	imiloxan__5-HT1B__no_interaction	SB224289__5-HT1D__no_interaction	SB224289__5-HT1B__no_interaction	BRL15572__5-HT1D__no_interaction	BRL15572__5-HT1B__no_interaction	MK912__5-HT1D__no_interaction	MK912__5-HT1B__no_interaction	BRL44408__5-HT1D__no_interaction	BRL44408__5-HT1B__no_interaction	rauwolscine__5-HT1D__no_interaction	rauwolscine__5-HT1B__no_interaction
19303967-7	In univariate analysis, <protein-id="P02753">RBP4</protein-id> was associated with follicle-stimulating hormone (r = 0.37, P = .0004), luteinizing hormone (r = 0.3, P = .005), and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex hormone-binding globulin</protein-id> (r = -0.24, P = .03) and trended to significance with <compound-id="5757">estradiol</compound-id> (P = .09) but not with free <compound-id="6013">testosterone</compound-id> or <compound-id="12594">dehydroepiandrosterone sulfate</compound-id>.	dehydroepiandrosterone sulfate__sex hormone-binding globulin__no_interaction	dehydroepiandrosterone sulfate__RBP4__no_interaction	testosterone__sex hormone-binding globulin__no_interaction	testosterone__RBP4__no_interaction	estradiol__sex hormone-binding globulin__no_interaction	estradiol__RBP4__no_interaction
24524399-13	(2) Compared with before the analgesia, the white blood cell count (WBC), neutrophil percentage (N), platelet count (PLT), <compound-id="5960">aspartate</compound-id> transaminase (AST), <compound-id="588">creatinine</compound-id> (Cr), arterial partial pressure of <compound-id="280">carbon dioxide</compound-id> (PaCO(2)), blood <compound-id="612">lactic acid</compound-id>, blood sugar, <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) were markedly reduced after <compound-id="41693">sufentanil</compound-id> analgesia (WBC: 10.8 ± 4.2 ×10(9)/L vs. 14.2 ± 11.5×10(9)/L, F=49.879, P&lt;0.001; N: 0.806 ± 0.104 vs. 0.815 ± 0.128, F=5.768, P=0.017; PLT: 160.4 ± 77.0 ×10(9)/L vs. 166.1 ± 89.0×10(9)/L, F=6.568, P=0.011; AST: 61.3 ± 10.1 U/L vs. 90.9 ± 26.9 U/L, F=6.706, P=0.010; Cr: 86.7 ± 71.8 μmol/L vs. 119.6 ± 56.0 μmol/L, F=30.303, P&lt;0.001; PaCO(2): 39.4 ± 7.2 mmHg vs. 41.7 ± 22.6 mmHg, F=4.389, P=0.037; blood <compound-id="612">lactic acid</compound-id>: 1.9 ± 1.2 mmol/L vs. 2.7 ± 2.5 mmol/L, F=4.883, P=0.028; blood sugar: 8.0 ± 5.4 mmol/L vs. 9.7 ± 7.6 mmol/L, F=9.724, P=0.002; <protein-id="P02741">CRP</protein-id>: 64.8 ± 20.7 mg/L vs. 114.0 ± 55.9 mg/L, F=4.883, P=0.028).	carbon dioxide__C-reactive protein__no_interaction	carbon dioxide__CRP__no_interaction	creatinine__C-reactive protein__no_interaction	creatinine__CRP__no_interaction	aspartate__C-reactive protein__no_interaction	aspartate__CRP__no_interaction	lactic acid__C-reactive protein__no_interaction	lactic acid__CRP__no_interaction	sufentanil__C-reactive protein__no_interaction	sufentanil__CRP__no_interaction
19808895-5	RESULTS: The vasodilatatory effect of the purinergic system was 50% lower in the diabetic group as exemplified by an <compound-id="479">LBF</compound-id> increase of 274 +/- 37 vs. 143 +/- 26 ml/micromol ATP x kg, 494 +/- 80 vs. 234 +/- 39 ml/micromol UTP x kg, and 14.9 +/- 2.7 vs. 7.5 +/- 0.6 ml/micromol <protein-id="Q96SZ5,B3KXN9">ADO</protein-id> x kg in control and diabetic subjects, respectively, thus making the vasodilator potency as follows: UTP control subjects (100) &gt; ATP control subjects (55) &gt; UTP diabetic subjects (47) &gt; ATP diabetic subjects (29) &gt; <protein-id="Q96SZ5,B3KXN9">ADO</protein-id> control subjects (3) &gt; <protein-id="Q96SZ5,B3KXN9">ADO</protein-id> diabetic subjects (1.5).	LBF__ADO__no_interaction
22810216-2	This review finds evidence of many parallels between the two, including: (1) microtubule degeneration, specifically large, long-range axon degeneration with subsequent abortive axonal sprouting (short, thin axons); (2) dentritic overgrowth; (3) neuroinflammation; (4) microglial/astrocytic activation; (5) brain immune response activation; (6) elevated glial fibrillary acidic protein; (7) oxidative stress and lipid peroxidation; (8) decreased <compound-id="124886">reduced glutathione</compound-id> levels and elevated <compound-id="65359">oxidized glutathione</compound-id>; (9) mitochondrial dysfunction; (10) disruption in <compound-id="22044544,5460341">calcium</compound-id> homeostasis and signaling; (11) inhibition of <compound-id="23327,33032,611">glutamic acid</compound-id> decarboxylase (GAD) activity; (12) disruption of GABAergic and glutamatergic homeostasis; (13) inhibition of IGF-1 and <protein-id="Q99707">methionine synthase</protein-id> activity; (14) impairment in methylation; (15) vascular endothelial cell dysfunction and pathological changes of the blood vessels; (16) decreased cerebral/cerebellar blood flow; (17) increased amyloid precursor protein; (18) loss of granule and Purkinje neurons in the cerebellum; (19) increased pro-inflammatory cytokine levels in the brain (TNF-α, IFN-γ, IL-1β, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>); and (20) aberrant nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB).	calcium__IL-8__no_interaction	calcium__methionine synthase__no_interaction	oxidized glutathione__IL-8__no_interaction	oxidized glutathione__methionine synthase__no_interaction	reduced glutathione__IL-8__no_interaction	reduced glutathione__methionine synthase__no_interaction	glutamic acid__IL-8__no_interaction	glutamic acid__methionine synthase__no_interaction
19203563-11	<protein-id="P22301,Q6FGW4">IL-10</protein-id> was higher in Group B at any postoperative time (<protein-id="P22301,Q6FGW4">IL-10</protein-id>: T1 80.74 vs 143.3, p &lt; 0.001, T2 165.7 vs 377.4, p &lt; 0.001, <compound-id="5920">T3</compound-id> 203.4 vs 443.5, p &lt; 0,001, T4 251.8 vs 437.1, p &lt; 0.001), whereas <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id> and <protein-id="P01579">IFN-gamma</protein-id> proved higher in Group A at all time-points (<protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id>: T1 45.9 vs 31.2, p = 0.008, T2 67.2 vs 39.7, p &lt; 0.001, <compound-id="5920">T3</compound-id> 77.9 vs 39.2, p &lt; 0.001, T4 102.9 vs 42.2, p &lt; 0.001.	T3__IL-4__no_interaction	T3__IFN-gamma__no_interaction	T3__IL-10__no_interaction
12915650-4	There were significant decreases in mean values of N-telopeptide [mean (SD), -13.4 (13.4) vs. 1.2 (23.8) nmol bone collagen equivalents (BCE)/mmol <compound-id="588">creatinine</compound-id> (Cr); P = 0.001] and <compound-id="3034763">deoxypyridinoline</compound-id> [-1.2 (2.9) vs. -0.5 (1.5) nmol <compound-id="3034763">deoxypyridinoline</compound-id>/mmol Cr; P = 0.021] as well as significant decreases in bone specific alkaline phosphatase [-5.1 (3.5) vs. 0.4 (3.1) ng/ml; P &lt; 0.001], <protein-id="P02818">osteocalcin</protein-id> [-5.9 (3.6) vs. -2.9 (3.7); P = 0.016], and procollagen of type I propeptide [-35.2 (44.6) vs. -0.2 (30.0) ng/ml; P = 0.025], but not <protein-id="O00300">osteoprotegerin</protein-id> [0.39 (1.46) vs. -0.2 (0.49) pmol/liter; P = 0.397] in the <compound-id="5289019">NGM</compound-id>/EE vs. placebo group.	deoxypyridinoline__osteocalcin__no_interaction	deoxypyridinoline__osteoprotegerin__no_interaction	NGM__osteocalcin__no_interaction	NGM__osteoprotegerin__no_interaction	creatinine__osteocalcin__no_interaction	creatinine__osteoprotegerin__no_interaction
7946162-5	Obese hypertensives, subdivided by high (n = 11) and low (n = 11) <protein-id="P01308,I3WAC9">insulin</protein-id> areas-under-the-curve (AUCs) in response to oral <compound-id="206,5793,64689,79025">glucose</compound-id>, and lean hypertensives maintained higher ambulatory blood pressure than lean normotensives (130 +/- 3/74 +/- 1, 136 +/- 4/78 +/- 2, 132 +/- 5/77 +/- 3 v 118 +/- 4/65 +/- 2 mm Hg, respectively, P &lt; .05).	glucose__insulin__no_interaction
16464117-1	The new dibranched, heterocyclic "push-pull" chromophores <protein-id="O95817">bis</protein-id>{1-(pyridin-4-yl)-2-[2-(N-<compound-id="12489">methylpyrrol</compound-id>-5-yl)]<compound-id="6324">ethane</compound-id>}<compound-id="297">methane</compound-id> (1), <compound-id="71381479">1-(pyrid-4-yl)-2-(N-methyl-5-formylpyrrol-2-yl)ethylene</compound-id> (2), {1-(<compound-id="13597">N-methylpyridinium</compound-id>-4-yl)-2-[2-(N-<compound-id="12489">methylpyrrol</compound-id>-5-yl)]<compound-id="6324">ethane</compound-id>}{(1-(pyridin-4-yl)-2-[2-(N-<compound-id="12489">methylpyrrol</compound-id>-5-yl)]<compound-id="6324">ethane</compound-id>}<compound-id="297">methane</compound-id> (3), N-methyl-2-[1-(N-methylpyrid-4-yl)ethen-2-yl]-5-[pyrid-4-yl]ethen-2-yl]pyrrole <compound-id="105054,30165">iodide</compound-id> (4), <protein-id="O95817">bis</protein-id>{1-(N-methyl-4-pyridinio)-2-[2-(N-<compound-id="12489">methylpyrrol</compound-id>-5-yl)]<compound-id="6324">ethane</compound-id>}<compound-id="297">methane</compound-id> <compound-id="105054,30165">iodide</compound-id> (5), and N-methyl-2,5-[1-(N-methylpyrid-4-yl)ethen-2-yl]pyrrole <compound-id="105054,30165">iodide</compound-id> (6) have been synthesized and characterized.	methylpyrrol__bis__no_interaction	N-methylpyridinium__bis__no_interaction	ethane__bis__no_interaction	iodide__bis__no_interaction	1-(pyrid-4-yl)-2-(N-methyl-5-formylpyrrol-2-yl)ethylene__bis__no_interaction	methane__bis__no_interaction
11422000-8	RESULTS: Administration of <compound-id="2187">anastrozole</compound-id> resulted in no clinically significant changes in the pharmacokinetics of either R- or S-<compound-id="54678486">warfarin</compound-id> compared with placebo for AUC (ng ml-1 h) (glsmean, R-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 93619.9, placebo 91127.91, 95%CI 0.988-1.068; S-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 57129.21, placebo 55676.34, 95%CI 0.979-1.076), <protein-id="O75462">CL/F</protein-id> (ml <protein-id="P13987,Q6FHM9">min-1</protein-id>) (glsmean, R-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 2.23, placebo 2.29, 95%CI 0.937-1.012; S-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 3.65, placebo 3.74, 95%CI 0.929-1.021) and t1/2 (h) (lsmean, R-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 55.40, placebo 55.15, 95%CI-2.083-2.592; S-<compound-id="54678486">warfarin</compound-id>; <compound-id="2187">anastrozole</compound-id> 39.38, placebo 40.98, 95%CI-6.189-2.996).	anastrozole__CL/F__no_interaction	anastrozole__min-1__no_interaction	warfarin__CL/F__no_interaction	warfarin__min-1__no_interaction
10198381-2	Plasma <compound-id="5997">cholesterol</compound-id> levels were higher in both <protein-id="P08226,Q3TXU4">apoE</protein-id> -/- and <protein-id="P08226,Q3TXU4">apoE</protein-id> + LDLR -/- compared with normal mice on normal and high-<compound-id="5997">cholesterol</compound-id> diets (normal chow: normal 110 +/- 5 mg/dl, <protein-id="P08226,Q3TXU4">apoE</protein-id> -/- 680 +/- 40 mg/dl, <protein-id="P08226,Q3TXU4">apoE</protein-id> + LDLR -/- 810 +/- 40 mg/dl; high-<compound-id="5997">cholesterol</compound-id> chow: normal 280 +/- 60 mg/dl, <protein-id="P08226,Q3TXU4">apoE</protein-id> -/- 2,490 +/- 310 mg/dl, <protein-id="P08226,Q3TXU4">apoE</protein-id> + LDLR -/- 3,660 +/- 290 mg/dl).	cholesterol__apoE__no_interaction
17720772-4	Anesthetized rats were randomly assigned to the following groups with 30 min of regional ischemia and 3 h reperfusion: 1) control with saline; 2) vehicle (<compound-id="679">DMSO</compound-id>); 3) PAR-2 AP, 1 mg/kg given intravenously 5 min before reperfusion; 4) scrambled peptide (SP), 1 mg/kg; 5) the <protein-id="P21708,P63086">ERK1/2</protein-id> inhibitor PD-98059 (PD), 0.3 mg/kg given 10 min before reperfusion; 6) the <compound-id="16738692,53477912">phosphatidylinositol</compound-id> 3-<compound-id="53378893">kinase inhibitor</compound-id> <compound-id="3973">LY-294002</compound-id> (LY), 0.3 mg/kg given 10 min before reperfusion; 7) PD + PAR-2 AP, 0.3 mg/kg PD given 5 min before PAR-2 AP; 8) LY + PAR-2 AP, 0.3 mg/kg LY given 5 min before PAR-2 AP; 9) <compound-id="2703,411938">chelerythrine</compound-id> (Chel) alone, 5 mg/kg given 10 min before reperfusion; and 10) Chel + PAR-2 AP, Chel was given 5 min before PAR-2 AP (10 min before reperfusion).	kinase inhibitor__ERK1/2__no_interaction	LY-294002__ERK1/2__no_interaction	DMSO__ERK1/2__no_interaction	phosphatidylinositol__ERK1/2__no_interaction	chelerythrine__ERK1/2__no_interaction
1898744-3	This resulted in substantial reductions in serum concentrations of <compound-id="6013">testosterone</compound-id> (from 1.72 +/- 0.29 nmol/L on day -56 to 0.32 +/- 0.09 nmol/L on day 0), non-<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id>-bound <compound-id="6013">testosterone</compound-id> (from 104 +/- 16 pmol/L on day -56 to 19 +/- 5 pmol/L on day 0), <compound-id="6128">androstenedione</compound-id> (from 7.25 +/- 1.65 nmol/L on day -56 to 2.78 +/- 0.94 nmol/L on day 0), <compound-id="5870">estrone</compound-id> (from 371 +/- 71 pmol/L on day -56 to 156 +/- 29 pmol/L on day 0), <compound-id="5757">estradiol</compound-id> (from 235 +/- 26 pmol/L on day -56 to 90 +/- 24 pmol/L on day 0), and <compound-id="5994">progesterone</compound-id> (from 0.28 +/- 0.12 nmol/L on day -56 to 0.08 +/- 0.02 nmol/L on day 0).	estrone__SHBG__no_interaction	progesterone__SHBG__no_interaction	testosterone__SHBG__no_interaction	estradiol__SHBG__no_interaction	androstenedione__SHBG__no_interaction
20822156-2	The corresponding <compound-id="23978">copper</compound-id>(I) complexes, [(L(<protein-id="P17405,Q59EN6">ASM</protein-id>))Cu(I)](+) (1a) and [(L(<compound-id="14254830">EOE</compound-id>))Cu(I)](+) (<compound-id="2981881,91293124">3a</compound-id>), were studied as were the related compound [(L(<compound-id="10549">ESE</compound-id>))Cu(I)](+) (2a, L(<compound-id="10549">ESE</compound-id>) = (2-ethylthio-N,N-bis((pyridin-2-yl)methyl)<compound-id="6341">ethanamine</compound-id>).	copper__ASM__no_interaction	3a__ASM__no_interaction	ethanamine__ASM__no_interaction	ESE__ASM__no_interaction	EOE__ASM__no_interaction
20822156-7	Oxygenation of 1a at reduced temperature gives a characteristic deep blue intermediate [{(L(<protein-id="P17405,Q59EN6">ASM</protein-id>))Cu(II)}(2)(O(2)(2-))](2+) (1b(P)) with absorption features at 442 (1,500 M(-1) cm(-1)), 530 (8,600 M(-1) cm(-1)), and 605 nm (10,400 M(-1) cm(-1)); these values compare well to the ligand-to-metal charge-transfer (LMCT) transitions previously reported for [{(L(<compound-id="10549">ESE</compound-id>))Cu(II)}(2)(O(2)(2-))](2+) (2b(P)).	ESE__ASM__no_interaction
8641120-6	Albuminuria correlated with mean arterial pressure (r = 0.31, p &lt; 0.001), triglyceride (r = 0.36, p &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (r = 0.28, p = 0.001), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (<protein-id="P04114,Q7Z7Q0,Q59HB3">apo B</protein-id>) (r = 0.25, p = 0.003), and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.25, p &lt; 0.002).	cholesterol__apo B__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__insulin__no_interaction
20415700-8	RESULTS: Respect to controls and to <protein-id="Q00325,A0A024RBE8,A0A024RBH9,Q6MZF9">PHC</protein-id>, FH had significantly higher (P &lt; 0.001) beta-index (5.22 +/- 1.13 vs. 3.13 +/- 0.74 and 3.60 +/- 1.02), PWV (4.72 +/- 0.72 m s(-1) vs. 3.66 +/- 0.55 m s(-1) and 4.10 +/- 0.67 m s(-1)), <compound-id="6914605">AIx</compound-id> (3.55 +/- 3.97% vs. -4.43 +/- 4.09% and 0.61 +/- 2.39%) and E(p) (64.4 +/- 19.6 kPa vs. 36.2 +/- 11.3 kPa and 42.9 +/- 13.1), whereas AC (1.25 +/- 0.48 mm(2) kPa(-1) vs. 1.9 +/- 0.43 mm(2) kPa(-1) and 1.62 +/- 0.43 mm(2) kPa(-1)) was lower (P &lt; 0.001).	AIx__PHC__no_interaction
11483385-2	In addition, the chemopreventive potentials of these extracts to induce <compound-id="5893">NAD</compound-id>(P)H:<compound-id="4650">quinone</compound-id> oxidoreductase (QR) and <compound-id="124886,20725278">glutathione</compound-id> S-transferase (GST) activities and <compound-id="124886,20725278">glutathione</compound-id> (GSH) level extracts from the filtrate of the cultured broth of P. linteus, polysaccharide extracts from the cultured broth (PI I) and mycelia (<protein-id="Q9D154">PI II</protein-id>) and <compound-id="962">water</compound-id> extract of fruiting bodies (<protein-id="Q9D154">PI II</protein-id>) of P. igniarius, and polysaccharide extracts from the cultured broth (AC I) and mycelia (AC II) of A. cylindracea showed inhibitory effects on the mutagenic activities induced by the direct-acting mutagens, NPD and NaN(3), and the indirect-acting mutagens, 2-AF and B[a]P. QR was induced with PI I, <protein-id="Q9D154">PI II</protein-id>, AC I, and AC II, and GST activity was induced with PL I, <compound-id="3035653">PL II</compound-id>, PI I, <protein-id="Q9D154">PI II</protein-id>, PI III and AC I in murine Hepa1c1c7 cell culture.	water__PI II__no_interaction	quinone__PI II__no_interaction	glutathione__PI II__no_interaction	PL II__PI II__no_interaction	NAD__PI II__no_interaction
8163664-4	During protocol II, <protein-id="P01308,I3WAC9">insulin</protein-id> infusion decreased fetal <compound-id="6106">leucine</compound-id> concentration (222 +/- 22 vs. 175 +/- 22), decreased fetal <compound-id="6106">leucine</compound-id> disposal (11.63 +/- 0.89 vs. 12.55 +/- 0.89 mumol/kg per min), increased <compound-id="6106">leucine</compound-id> clearance (48.0 +/- 4.2 vs. 57.6 +/- 6.5 ml/kg per min), decreased <compound-id="6106">leucine</compound-id> decarboxylation (1.77 +/- 0.17 vs. 2.04 +/- 0.21 mumol/kg per min), decreased nonoxidative <compound-id="6106">leucine</compound-id> disposal (9.81 +/- 0.78 vs. 10.51 +/- 0.74 mumol/kg per min), decreased release of <compound-id="6106">leucine</compound-id> from fetal protein (7.43 +/- 1.08 vs. 8.38 +/- 0.84 mumol/kg per min), but did not change the accretion of <compound-id="6106">leucine</compound-id> into protein.	leucine__insulin__no_interaction
16883174-3	RESULTS: Significant (P &lt; 0.05) differences were noted between functional versus nonfunctional adenomas (percent aneuploidy, percent S phase, <protein-id="P46527,Q6I9V6">p27Kip1</protein-id> labeling indices [LI], male sex, tumor size, and frequency of visual disturbance); Cushing's versus silent <compound-id="16132265">adrenocorticotropin</compound-id> adenomas (percent hypertetraploidy, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, tumor size, visual disturbance, and resectability); untreated versus medically treated prolactin cell adenomas (<protein-id="Q86YT6">MIB-1</protein-id> LI, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, and resectability); untreated versus medically treated growth hormone-containing adenomas (percent diploidy, percent S phase, <protein-id="Q86YT6">MIB-1</protein-id> LI, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, and <protein-id="O00399">p27</protein-id> LI); untreated prolactin cell adenomas versus premetastatic tumors (percent hypertetraploidy, <protein-id="P12004">PCNA</protein-id> LI, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, invasiveness, and resectability); untreated growth hormone-containing adenomas versus premetastatic tumors (percent diploidy, percent S phase, <protein-id="P12004">PCNA</protein-id> LI, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, invasiveness, and resectability); Cushing's adenomas versus premetastatic tumors (percent diploidy, percent hypertetraploidy, percent S phase, <protein-id="Q86YT6">MIB-1</protein-id> LI, <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, tumor size, invasiveness, visual disturbance, and resectability); Nelson's adenomas versus premetastatic tumors (<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI, tumor size, invasiveness, and resectability); silent adenomas as a whole versus nonfunctional adenomas (percent nondiploid, percent S phase, invasiveness, and respectability); silent <compound-id="16132265">adrenocorticotropin</compound-id> adenomas I and II versus silent adenoma Subtype III (invasiveness); silent <compound-id="16132265">adrenocorticotropin</compound-id> adenoma Subtypes I and II versus premetastatic tumors (<protein-id="Q86YT6">MIB-1</protein-id> LI and invasiveness); silent adenoma Subtype III versus premetastatic tumors (<protein-id="P12004">PCNA</protein-id> and <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> LI); and premetastatic tumors versus metastatic pituitary carcinomas (<protein-id="Q86YT6">MIB-1</protein-id> LI).	adrenocorticotropin__PCNA__no_interaction	adrenocorticotropin__p27__no_interaction	adrenocorticotropin__p53__no_interaction	adrenocorticotropin__MIB-1__no_interaction	adrenocorticotropin__p27Kip1__no_interaction
8709132-2	Affinity was determined in radioligand binding assays at rat brain A1 and <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A2A</protein-id> receptors using [3H]-(R)-PIA [[3H]-(R)-N6-(phenylisopropyl)<compound-id="57476835,60961">adenosine</compound-id>] and [3H]<compound-id="3086599">CGS 21680</compound-id> [[3H]-2-[[4-(2-carboxyethyl)phenyl]<compound-id="6341">ethylamino</compound-id>]-5'-(N-ethylcarbamoyl++ +) <compound-id="57476835,60961">adenosine</compound-id>], respectively.	ethylamino__A2A__no_interaction	CGS 21680__A2A__no_interaction	adenosine__A2A__no_interaction
15562389-3	Pretreatment, the bottom and top <protein-id="P01308,I3WAC9">insulin</protein-id>-resistant quintile groups differed by median weight (84 vs 121 kg), <protein-id="P01308,I3WAC9">insulin</protein-id> (7.8 vs 40.5 I(1/4) U/mL), IR (1.62 vs 9.28), homeostasis model assessment <protein-id="P01308,I3WAC9">insulin</protein-id> secretion (131 vs 416), <compound-id="206,5793,64689,79025">glucose</compound-id> (82 vs 98 mg/dL), sex hormone-binding globulin (40 vs 15 nmol/L), (all P &lt; .0001), free androgen index (2.76 vs 10.8) ( P &lt; .001), triglyceride (92 vs 131 mg/dL), high-density lipoprotein (46 vs 39 mg/dL), systolic blood pressure (116 vs 128 mm Hg), and diastolic blood pressure (76 vs 84 mm Hg), (all P &lt; .01).	glucose__insulin__no_interaction
17313257-7	Linear regression demonstrated significant relationships between the PHIIR sport simulation distance and running velocity attained at a blood <compound-id="612">lactate</compound-id> concentration of 4 mmol x L(-1) (LT) (r = 0.77, p &lt; 0.05), 5 x 6-second repeated cycle sprint work (r = 0.56, p &lt; 0.05), 30-second Wingate test (r = 0.61, p &lt; 0.05), peak aerobic running velocity (Vmax) (r = 0.69, p &lt; 0.05), and Yo-Yo Intermittent Recovery Test (Yo-Yo <protein-id="Q9Y2I1">IR1</protein-id>) distance (r = 0.50, p &lt; 0.05), respectively.	lactate__IR1__no_interaction
11211574-10	) respectively for various indices which were significantly different were fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (100.2 +/- 5.58 mg/dl vs 116.2 +/- 11.6 mg/dl), area under 2-h plasma <compound-id="206,5793,64689,79025">glucose</compound-id> curve (245.9 +/- 15.13 mg.dl-1.h vs 280.8 +/- 37.09 mg.dl-1.h), <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (53.2 +/- 4.56 mg/dl vs 42.7 +/- 7.17 mg/dl), LDL <compound-id="5997">cholesterol</compound-id> (82.4 +/- 8.80 mg/dl vs 98.26 +/- 12.07 mg/dl), LDL/<protein-id="P28845,X5D2L1">HDL</protein-id> ratio (1.56 +/- 0.28 vs 2.38 +/- 0.63).	cholesterol__HDL__no_interaction	glucose__HDL__no_interaction
19592055-6	Changes in serum levels of <protein-id="P78380,A0A024RAU0">sLOX-1</protein-id> were positively correlated with changes in body weight (r = 0.54, P = .003), body mass index (r = 0.57, P = .001), body fat mass (r = 0.57, P = .002), total <compound-id="5997">cholesterol</compound-id> (r = 0.41, P = .03), subcutaneous fat area (r = 0.50, P = .007), high-sensitivity <protein-id="P02741">C-reactive protein</protein-id> (r = 0.56, P = .002), <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.47, P = .01), and <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (r = 0.32, P = .09); but no correlations were observed with fasting glycemic-related factors (blood <compound-id="206,5793,64689,79025">glucose</compound-id>, hemoglobin A(1c), and <protein-id="P01308,I3WAC9">insulin</protein-id>).	glucose__sLOX-1__no_interaction	glucose__C-reactive protein__no_interaction	glucose__insulin__no_interaction	glucose__leptin__no_interaction	glucose__tumor necrosis factor-alpha__no_interaction	cholesterol__sLOX-1__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction	cholesterol__leptin__no_interaction	cholesterol__tumor necrosis factor-alpha__no_interaction
10642126-5	In group I, the following values of electrophysiological parameters of the atrium indicated that AF was more likely to be induced during <compound-id="439710">RAA</compound-id> pacing than <protein-id="Q15582">CSd</protein-id> pacing: atrial effective refractory period (<compound-id="439710">RAA</compound-id> vs <protein-id="Q15582">CSd</protein-id>: 201 +/- 28 ms vs 240 +/- 35 ms, P &lt; 0.001), RAF zone (16 +/- 25 ms vs 0 +/- 0 ms, P &lt; 0.03), FAA zone (38 +/- 37 ms vs 5 +/- 19 ms, P &lt; 0.01), maximum interatrial conduction time (144 +/- 19 ms vs 93 +/- 19 ms, P &lt; 0.0001) and CD zone (53 +/- 21 ms vs 9 +/- 18 ms, P &lt; 0.0001).	RAA__CSd__no_interaction
15044047-2	Concentration-response (E/[A]) curves to noradrenaline were apparently monophasic (pEC(50) 6.47) but became biphasic in the presence of the selective <protein-id="P43140">alpha(1A)-adrenoceptor</protein-id> antagonist (+/-)-1,3,5-<compound-id="4245325">trimethyl-</compound-id>6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-<compound-id="136071">1,4-benzodioxin-5-yl</compound-id>)-1-piperazinyl]propyl]amino]-<compound-id="1174">2,4(1H,3H)-pyrimidinedione</compound-id> (B8805-033).	1,4-benzodioxin-5-yl__alpha(1A)-adrenoceptor__no_interaction	2,4(1H,3H)-pyrimidinedione__alpha(1A)-adrenoceptor__no_interaction	trimethyl-__alpha(1A)-adrenoceptor__no_interaction
2180759-2	In the postabsorptive state, the deep tissues of the forearm (mostly skeletal muscle) took up <compound-id="206,5793,64689,79025">glucose</compound-id> (mean +/- SE 1.09 +/- 0.17 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1 forearm vol), <compound-id="441">beta-hydroxybutyrate</compound-id> (0.267 +/- 0.130 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), and O2 (9.96 +/- 1.02 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1) and released <compound-id="612">lactate</compound-id> (0.284 +/- 0.098 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), <compound-id="24759880,753">glycerol</compound-id> (0.029 +/- 0.012 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), <compound-id="311,17938267">citrate</compound-id> (0.091 +/- 0.030 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), <compound-id="5950,602">alanine</compound-id> (0.184 +/- 0.044 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> (7.36 +/- 0.97 mumol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1), and protons (12.1 +/- 1.4 pmol.<protein-id="P13987,Q6FHM9">min-1</protein-id>.dl-1).	alanine__CO2__no_interaction	alanine__min-1__no_interaction	beta-hydroxybutyrate__CO2__no_interaction	beta-hydroxybutyrate__min-1__no_interaction	glycerol__CO2__no_interaction	glycerol__min-1__no_interaction	lactate__CO2__no_interaction	lactate__min-1__no_interaction	citrate__CO2__no_interaction	citrate__min-1__no_interaction	glucose__CO2__no_interaction	glucose__min-1__no_interaction
1932158-7	Pharmacokinetic parameters (area under curve = 1.8 +/- 0.26 microgram h <protein-id="Q9NTI2">ml-1</protein-id>, tmax = 1.5 +/- 0.5 h, Cmax = 734 +/- 82 ng <protein-id="Q9NTI2">ml-1</protein-id> and terminal half-life = 0.88 +/- 0.52 h) determined from the plasma decay of <compound-id="3033">diclofenac</compound-id> in three healthy subjects given a single oral dose of <compound-id="3033">diclofenac</compound-id> were in good agreement with those reported in the literature.	diclofenac__ml-1__no_interaction
12590984-5	Strong linkage disequilibria were also observed between the <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id> and <protein-id="P01889,P30460,Q5SS57,E5FQ95">HLA-B</protein-id> gene-<protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*00201-<compound-id="5355150">B58</compound-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*004-<compound-id="11505398">B44</compound-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*00701-<protein-id="Q8TCY5">B27</protein-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*00801-<compound-id="44475970">B60</compound-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*00901-<compound-id="57340899">B51</compound-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*010-<compound-id="44475972">B62</compound-id>, <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*012-<compound-id="44373851">B54</compound-id>, and <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id>*027-<protein-id="P20827">B61</protein-id>.	B44__B27__no_interaction	B44__HLA-B__no_interaction	B44__B61__no_interaction	B44__MICA__no_interaction	B58__B27__no_interaction	B58__HLA-B__no_interaction	B58__B61__no_interaction	B58__MICA__no_interaction	B60__B27__no_interaction	B60__HLA-B__no_interaction	B60__B61__no_interaction	B60__MICA__no_interaction	B62__B27__no_interaction	B62__HLA-B__no_interaction	B62__B61__no_interaction	B62__MICA__no_interaction	B51__B27__no_interaction	B51__HLA-B__no_interaction	B51__B61__no_interaction	B51__MICA__no_interaction	B54__B27__no_interaction	B54__HLA-B__no_interaction	B54__B61__no_interaction	B54__MICA__no_interaction
15609886-5	Group VTC (n = 17)--mean 24 hour <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> 150.6 +/- 5.2 mmHg, <protein-id="Q10586">DBP</protein-id> 86.1 +/- 3.3 mmHg, low density lipoprotein 158.1 +/- 24.5 mg/dl--received vitamin C 500 mg per day; Group ATR (n = 15)--mean 24 hour <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> 153.1 +/- 4.8 mmHg, <protein-id="Q10586">DBP</protein-id> 87.1 +/- 6.7 mmHg, LDL 162.6 +/- 13.6 mg/dl--received <compound-id="60823">atorvastatin</compound-id> 20 mg/day; and Group PLA (n = 16)--mean 24 hour <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> 151.1 +/- 7.4 mmHg, <protein-id="Q10586">DBP</protein-id> 84.8 +/- 5.9 mmHg, LDL 156.7 +/- 26.1 mg/dl--received a placebo.	atorvastatin__DBP__no_interaction	atorvastatin__SBP__no_interaction
11780780-5	The outcome of the experimental data is: 1) in contrast to unglycosylated 23 kDa rat <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id>, intra-chain S-S bridging is not affected in 26kDa rat <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id>, neither by transiting through a thiol gradient nor in sequential nonreducing/reducing SDS-PAGE; 2) the conformational availability of Asp residues involved in the endoproteinase <protein-id="Q5XIH1">Asp-N</protein-id> attack is the same in 23- and 26 kDa rat <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id>; the glycan moiety apparently does not cause steric hindrance at this level; 3) no glycosidic N-linkage could be detected, only O-linkage(s); 4) 26 kDa rat <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id> is no glycosyl-phosphaditylinositol-anchored protein; 5) in O-profiling an oligosaccharide chain of Mr +/- 1.4 kDa was recorded; 6) the monosaccharide composition obtained in FACE is peculiar in the sense that next to Fuc, Man, <compound-id="35717">GalNac</compound-id>, <compound-id="11861101,24139,439174,899">GlcNac</compound-id> and <compound-id="439197">NeuAc</compound-id> also Rib was determined; 7) HPAE-<compound-id="19805081,5492869">PAD</compound-id> analysis identified <compound-id="439197">NeuAc</compound-id> subtypes; 8) in vitro, glycosylation of rat <protein-id="P01237,B5DEM6,B2RYT1">prolactin</protein-id> modulates immune recognition through steric hindrance of the access to the epitope sites.	GlcNac__prolactin__no_interaction	GlcNac__Asp-N__no_interaction	GalNac__prolactin__no_interaction	GalNac__Asp-N__no_interaction	NeuAc__prolactin__no_interaction	NeuAc__Asp-N__no_interaction	PAD__prolactin__no_interaction	PAD__Asp-N__no_interaction
17360804-3	We now report that: (1) the CC chemokine, macrophage inflammatory protein-1alpha (<protein-id="P10855,Q5QNW0">MIP-1alpha</protein-id>/<protein-id="P10855,Q5QNW0">CCL3</protein-id>) synergizes with <compound-id="65015">AMD3100</compound-id> (an antagonist of the binding of <protein-id="P40224,H7BX38">SDF-1</protein-id>/<protein-id="P40224,H7BX38">CXCL12</protein-id> to <protein-id="P70658">CXCR4</protein-id>) to rapidly mobilize <compound-id="521017">HPCs</compound-id> to the blood of mice; moreover, the combination of granulocyte colony-stimulating factor (G-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id>) with <compound-id="65015">AMD3100</compound-id> and <protein-id="P10855,Q5QNW0">MIP-1alpha</protein-id>/<protein-id="P10855,Q5QNW0">CCL3</protein-id>, given in a specific sequence, mobilizes the greatest number of <compound-id="521017">HPCs</compound-id> compared to any combination of two of these mobilizing agents; (2) pretreatment of recipient mice with <compound-id="3107,94701">Diprotin A</compound-id>, an inhibitor of <protein-id="P28843,Q3TR43">CD26</protein-id>/Dipeptidylpeptidase IV (<protein-id="P28843,Q3TR43">DPPIV</protein-id>), enhances the competitive HSCs repopulating capacity of untreated donor cells; (3) the survival-enhancing effects of <protein-id="P40224,H7BX38">SDF-1</protein-id>/<protein-id="P40224,H7BX38">CXCL12</protein-id> on <compound-id="521017">HPCs</compound-id> subjected in vitro to delayed addition of growth factors (GFs) are mediated in part through the cell cycle-related proteins <protein-id="P39689,Q564P6">p21</protein-id>(<protein-id="P39689,Q564P6">cip1</protein-id>/<protein-id="P39689,Q564P6">waf1</protein-id>) (as assessed using <protein-id="P39689,Q564P6">p21</protein-id>(<protein-id="P39689,Q564P6">cip1</protein-id>/<protein-id="P39689,Q564P6">waf1</protein-id>) -/- and +/+ mice) and <protein-id="Q8QZV2">Mad2</protein-id> (using <protein-id="Q8QZV2">Mad2</protein-id> +/- and +/+ mice); and (4) deletion of <protein-id="P28843,Q3TR43">CD26</protein-id>/<protein-id="P28843,Q3TR43">DPPIV</protein-id> on mouse bone marrow cells increases the survival-enhancing effects of <protein-id="P40224,H7BX38">SDF-1</protein-id>/<protein-id="P40224,H7BX38">CXCL12</protein-id> on <compound-id="521017">HPCs</compound-id>.	Diprotin A__CCL3__no_interaction	Diprotin A__cip1__no_interaction	Diprotin A__waf1__no_interaction	Diprotin A__CD26__no_interaction	Diprotin A__SDF-1__no_interaction	Diprotin A__p21__no_interaction	Diprotin A__MIP-1alpha__no_interaction	Diprotin A__CXCR4__no_interaction	Diprotin A__Mad2__no_interaction	Diprotin A__CXCL12__no_interaction	Diprotin A__DPPIV__no_interaction	CSF__CCL3__no_interaction	CSF__cip1__no_interaction	CSF__waf1__no_interaction	CSF__CD26__no_interaction	CSF__SDF-1__no_interaction	CSF__p21__no_interaction	CSF__MIP-1alpha__no_interaction	CSF__CXCR4__no_interaction	CSF__Mad2__no_interaction	CSF__CXCL12__no_interaction	CSF__DPPIV__no_interaction	AMD3100__CCL3__no_interaction	AMD3100__cip1__no_interaction	AMD3100__waf1__no_interaction	AMD3100__CD26__no_interaction	AMD3100__SDF-1__no_interaction	AMD3100__p21__no_interaction	AMD3100__MIP-1alpha__no_interaction	AMD3100__CXCR4__no_interaction	AMD3100__Mad2__no_interaction	AMD3100__CXCL12__no_interaction	AMD3100__DPPIV__no_interaction	HPCs__CCL3__no_interaction	HPCs__cip1__no_interaction	HPCs__waf1__no_interaction	HPCs__CD26__no_interaction	HPCs__SDF-1__no_interaction	HPCs__p21__no_interaction	HPCs__MIP-1alpha__no_interaction	HPCs__CXCR4__no_interaction	HPCs__Mad2__no_interaction	HPCs__CXCL12__no_interaction	HPCs__DPPIV__no_interaction
15514005-5	Our results indicated that (1) the expression of <protein-id="P41212">TEL</protein-id>-<protein-id="P22607,Q0IJ44,X5D2G8">FGFR3</protein-id> but not DeltaHLH-<protein-id="P41212">TEL</protein-id>-<protein-id="P22607,Q0IJ44,X5D2G8">FGFR3</protein-id> resulted in efficient focus formation in NIH/3T3 cells and conferred <protein-id="P01586,Q5SX77">interleukin 3</protein-id> independence to Ba/F3 cells by a constitutive <compound-id="6057,90983769">tyrosine</compound-id> kinase activity probably through oligomerization by the HLH domain of <protein-id="P41212">TEL</protein-id>; (2) although effector proteins including classical mitogen-activated protein kinase (MAPK), p38 MAPK, <compound-id="16738692,53477912">phosphatidylinositol</compound-id> 3-kinase (PI3-K), mammalian target or <compound-id="16760631,478951,49652385,5040,5284616,5358081,53627520,5374464,5460439,5497196,60150249,70789198,71296106,86583604,9854380,9962928">rapamycin</compound-id> (mTOR), <protein-id="P40763">signal transducer and activator of transcription 3</protein-id> (<protein-id="P40763">STAT-3</protein-id>) and <protein-id="P42229,Q59GY7,A8K6I5,K7EK35">STAT-5</protein-id> were activated in <protein-id="P41212">TEL</protein-id>-<protein-id="P22607,Q0IJ44,X5D2G8">FGFR3</protein-id> transformants, the growth of the transformants was inhibited by <compound-id="5289418">SU5402</compound-id> (concentration that inhibits 50% [IC5)]=5 microM) and the PI3-K inhibitor, <compound-id="3973">LY294002</compound-id> (IC5)=10 microM) and <compound-id="312145">wortmannin</compound-id> (IC50=5 microM), but not by <compound-id="3006531,5354033,9951825">U0126</compound-id>, <compound-id="176155">SB203580</compound-id>, or <compound-id="16760631,478951,49652385,5040,5284616,5358081,53627520,5374464,5460439,5497196,60150249,70789198,71296106,86583604,9854380,9962928">rapamycin</compound-id>; and (3) injection of <protein-id="P41212">TEL</protein-id>-<protein-id="P22607,Q0IJ44,X5D2G8">FGFR3</protein-id> transformants induced lethal leukemia into syngeneic mice.	wortmannin__TEL__no_interaction	wortmannin__STAT-3__no_interaction	wortmannin__signal transducer and activator of transcription 3__no_interaction	wortmannin__STAT-5__no_interaction	wortmannin__interleukin 3__no_interaction	wortmannin__FGFR3__no_interaction	rapamycin__TEL__no_interaction	rapamycin__STAT-3__no_interaction	rapamycin__signal transducer and activator of transcription 3__no_interaction	rapamycin__STAT-5__no_interaction	rapamycin__interleukin 3__no_interaction	rapamycin__FGFR3__no_interaction	U0126__TEL__no_interaction	U0126__STAT-3__no_interaction	U0126__signal transducer and activator of transcription 3__no_interaction	U0126__STAT-5__no_interaction	U0126__interleukin 3__no_interaction	U0126__FGFR3__no_interaction	LY294002__TEL__no_interaction	LY294002__STAT-3__no_interaction	LY294002__signal transducer and activator of transcription 3__no_interaction	LY294002__STAT-5__no_interaction	LY294002__interleukin 3__no_interaction	LY294002__FGFR3__no_interaction	SB203580__TEL__no_interaction	SB203580__STAT-3__no_interaction	SB203580__signal transducer and activator of transcription 3__no_interaction	SB203580__STAT-5__no_interaction	SB203580__interleukin 3__no_interaction	SB203580__FGFR3__no_interaction	SU5402__TEL__no_interaction	SU5402__STAT-3__no_interaction	SU5402__signal transducer and activator of transcription 3__no_interaction	SU5402__STAT-5__no_interaction	SU5402__interleukin 3__no_interaction	SU5402__FGFR3__no_interaction	phosphatidylinositol__TEL__no_interaction	phosphatidylinositol__STAT-3__no_interaction	phosphatidylinositol__signal transducer and activator of transcription 3__no_interaction	phosphatidylinositol__STAT-5__no_interaction	phosphatidylinositol__interleukin 3__no_interaction	phosphatidylinositol__FGFR3__no_interaction	tyrosine__TEL__no_interaction	tyrosine__STAT-3__no_interaction	tyrosine__signal transducer and activator of transcription 3__no_interaction	tyrosine__STAT-5__no_interaction	tyrosine__interleukin 3__no_interaction	tyrosine__FGFR3__no_interaction
18837052-3	The results showed the following: (1) ATP at a concentration of 0.3 mM induced spinal <compound-id="56846361">LTP</compound-id> of C-fiber-evoked field potentials, lasting for at least 5 h; (2) spinal application of 2',<compound-id="90895110">3'-O-(2,4,6-trinitrophenyl)adenosine</compound-id>-5-triphosphate (TNP-ATP; an antagonist of <protein-id="Q99571">P2X(1-4</protein-id>) receptors), but not pyridoxal-<compound-id="1061,167704,644102">phosphate</compound-id>-6-<compound-id="141902">azophenyl</compound-id>-2',4'-disulphonic acid (<compound-id="6093163">PPADS</compound-id>; an antagonist of P2X(1,2,3,5,7) receptors), 30 min before ATP blocked ATP-induced <compound-id="56846361">LTP</compound-id>, indicating that ATP may induce spinal <compound-id="56846361">LTP</compound-id> by activation of <protein-id="Q99571">P2X(4</protein-id>) receptors; (3) at 60 min after <compound-id="56846361">LTP</compound-id> induction the level of phospho-<protein-id="P46108,L7RT18">p38</protein-id> mitogen-activated protein kinase (p-<protein-id="P46108,L7RT18">p38</protein-id> MAPK) was significantly elevated and at 180 min after <compound-id="56846361">LTP</compound-id> the number of <protein-id="Q99571">P2X(4</protein-id>) receptors increased significantly; both p-<protein-id="P46108,L7RT18">p38</protein-id> and <protein-id="Q99571">P2X(4</protein-id>) receptors were exclusively co-located with the microglia marker, but not with neuronal or astrocyte marker; (4) spinal application of TNP-ATP but not <compound-id="6093163">PPADS</compound-id> prevented <protein-id="P46108,L7RT18">p38</protein-id> activation; (5) spinal application of <compound-id="176155">SB203580</compound-id>, a <protein-id="P46108,L7RT18">p38</protein-id> MAPK inhibitor, prevented both spinal <compound-id="56846361">LTP</compound-id> and the upregulation of <protein-id="Q99571">P2X(4</protein-id>) receptors.	LTP__p38__no_interaction	LTP__P2X(1-4__no_interaction	LTP__P2X(4__no_interaction	PPADS__p38__no_interaction	PPADS__P2X(1-4__no_interaction	PPADS__P2X(4__no_interaction	3'-O-(2,4,6-trinitrophenyl)adenosine__p38__no_interaction	3'-O-(2,4,6-trinitrophenyl)adenosine__P2X(1-4__no_interaction	3'-O-(2,4,6-trinitrophenyl)adenosine__P2X(4__no_interaction	azophenyl__p38__no_interaction	azophenyl__P2X(1-4__no_interaction	azophenyl__P2X(4__no_interaction	phosphate__p38__no_interaction	phosphate__P2X(1-4__no_interaction	phosphate__P2X(4__no_interaction	SB203580__p38__no_interaction	SB203580__P2X(1-4__no_interaction	SB203580__P2X(4__no_interaction
23599396-11	<protein-id="P16671,A4D1B1,E9PLT1,B7Z6C3">Fat</protein-id> utilization during exercise correlated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.57, P = 0.05), <compound-id="206,5793,64689,79025">glucose</compound-id> intolerance severity z-score (r = 0.66, P = 0.01), and nonesterified fatty acids (trend; r = 0.55, P = 0.08).	glucose__Fat__no_interaction
10566601-5	A significant increase in DRB1*0402-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (RR = 16.18, p &lt; 0.05), DRB1*0405-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (RR = 16.12, p &lt; 0.05), DRB1*0301-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0501-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0201 (RR = 4.58, p &lt; 0.00005) and DRB1*0401-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (RR = 4.36, p &lt; 0.005) was apparent in the diabetic group, while the DRB1*1501-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0102-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0602 and DRB1*1401-<compound-id="439351">DQA</compound-id> *0104-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*05031 protective haplotypes (RR = 0.17 and 0.09, p &lt; 0.0005 and 0.05, respectively) were significantly lower in patients.	DQA__DQB1__no_interaction	DQA__DQA1__no_interaction
15907122-2	Reactions of [Os(VI)tBu-salch)O2] (1a) and [Os(VI)(Br-salch)O2] (1b) with <protein-id="P60510,A0A024R625">PPh(3</protein-id>), p-X-arylamines (X = NO2, CN), N2H4 x H2O, Ph2NNH2, <compound-id="24386">SOCl2</compound-id>, CF3CO2H, <compound-id="24408">Br2</compound-id>, and I2 under reducing conditions gave [Os(II)(Br-salch)(OPPh3)2] (2), [Os(IV)(Br-salch)(p-X-C6H4NH)2] (3), [mu-O-{Os(IV)(tBu-salch)(p-NO2C6H4NH)}2] (4), [Os(II)(Br-salch)(N2)(H2O)] (5), [Os(IV)(tBu-salch)(OH)(Cl)] (6), [Os(IV)(tBu-salch)(OH)2] (7), [Os(IV)(tBu-salch)<compound-id="24526">Cl2</compound-id>] (8), [Os(IV)(tBu-salch)(CF3CO2)2] (9), [Os(IV)(tBu-salch)<compound-id="24408">Br2</compound-id>] (10), and [Os(IV)(tBu-salch)I2] (11), respectively.	SOCl2__PPh(3__no_interaction	Br2__PPh(3__no_interaction	Cl2__PPh(3__no_interaction
12707790-5	Indexed LVM were: MRI: 107+/-6 g/m(2) (A), 79+/-7 g/m(2) (U); <protein-id="P51690,B7Z1M0,A1L484,F5GYY5,B7Z6V4,F5H324">ASE</protein-id>: 170+/-20 g/m(2) (A), 119+/-14 g/m(2) (U); DEV: 134+/-16 g/m(2) (A), 95+/-11 g/m(2) (U); TRO: 134+/-16 g/m(2) (A), 92+/-12 g/m(2) (U); TEI: 115+/-10 g/m(2) (A), 91+/-8 g/m(2) (U); <compound-id="54765324">REI</compound-id>: 114+/-14 g/m(2) (A), 89+/-11 g/m(2) (U); DIC: 110+/-14 g/m(2) (A); 80+/-9 g/m(2) (U).	REI__ASE__no_interaction
17083219-1	A series of mononuclear <compound-id="5462311,90760767">boron</compound-id> halides of the type LBX(2) [LH = <compound-id="72779345">N-phenyl-3,5-di-tert-butylsalicylaldimine</compound-id>, X = Cl (2), Br (3)] and LBX [<protein-id="O00469">LH2</protein-id> = <compound-id="6743255">N-(2-hydroxyphenyl)-3,5-di-tert-butylsalicylaldimine</compound-id>, X = Cl (7), Br (8); <protein-id="O00469">LH2</protein-id> = <compound-id="44185710">N-(2-hydroxyethyl)-3,5-di-tert-butylsalicylaldimine</compound-id>, X = Cl (9), Br (10); and <protein-id="O00469">LH2</protein-id> = <compound-id="91425344">N-(3-hydroxypropyl)-3,5-di-tert-butylsalicylaldimine</compound-id>, X = Cl (11), Br (12)] were synthesized from their <compound-id="26574">borate</compound-id> precursors LB(OMe)2 (1) (LH = <compound-id="72779345">N-phenyl-3,5-di-tert-butylsalicylaldimine</compound-id>) and LB(OMe) [<protein-id="O00469">LH2</protein-id> = <compound-id="6743255">N-(2-hydroxyphenyl)-3,5-di-tert-butylsalicylaldimine</compound-id> (4), <compound-id="44185710">N-(2-hydroxyethyl)-3,5-di-tert-butylsalicylaldimine</compound-id> (5), <compound-id="91425344">N-(3-hydroxypropyl)-3,5-di-tert-butylsalicylaldimine</compound-id> (6)].	N-(2-hydroxyethyl)-3,5-di-tert-butylsalicylaldimine__LH2__no_interaction	N-(2-hydroxyphenyl)-3,5-di-tert-butylsalicylaldimine__LH2__no_interaction	N-phenyl-3,5-di-tert-butylsalicylaldimine__LH2__no_interaction	N-(3-hydroxypropyl)-3,5-di-tert-butylsalicylaldimine__LH2__no_interaction	borate__LH2__no_interaction	boron__LH2__no_interaction
11890808-7	When a <protein-id="Q6Q759">PF(6</protein-id>)(-) monoanion instead of AF(6)(2)(-) dianions was used as the framework-regulator with another co-counteranion (coexistent anions), porous coordination polymers with various types of frameworks, ([Cu(2)(4,4'-bpy)(5)(H(2)O)(4)].anions.2H(2)O.4EtOH)(n)(anions = 4PF(6)(-) (3.2H(2)O.4EtOH), <compound-id="46224504">2PF</compound-id>(6)(-) + <compound-id="11473003">2ClO</compound-id>(4)(-) (4.2H(2)O.4EtOH)) (2-D Double-Layer), ([Cu(2)(<protein-id="Q6Q759">PF(6</protein-id>))(NO(3))(4,4'-bpy)(4)].<compound-id="46224504">2PF</compound-id>(6).2H(2)O)(n)(5.<compound-id="46224504">2PF</compound-id>(6).2H(2)O) (3-D Undulated Grid), ([Cu(<protein-id="Q6Q759">PF(6</protein-id>))(4,4'-bpy)(2)(<compound-id="6342">MeCN</compound-id>)].<protein-id="Q6Q759">PF(6</protein-id>).2MeCN)(n)(6.2MeCN) (2-D Grid), and ([Cu(4,4'-bpy)(2)(H(2)O)(2)].<protein-id="Q6Q759">PF(6</protein-id>).BF(4))(n) (7) (2-D Grid), were obtained, where the three modes of <protein-id="Q6Q759">PF(6</protein-id>)(-) anions are observed.	2ClO__PF(6__no_interaction	MeCN__PF(6__no_interaction	2PF__PF(6__no_interaction
16166271-5	These prejunctional receptors, involved in both positive and negative feedback mechanisms regulating cholinergic transmission, have been characterized by means of three highly selective 5-HT antagonists for 5-HT(4), 5-HT(7), and <protein-id="P08908,Q5ZGX3,A8K5W4">5-HT(1A</protein-id>) receptors, namely GR113808A ([1-[2-[(-<compound-id="57476620">methylsulphonyl</compound-id>) amino] <compound-id="23134249">ethyl</compound-id>]4-piperinidyl]methyl1-methyl-1H-<compound-id="69867">indole-3-carboxylate</compound-id> <compound-id="1110">succinate</compound-id>), SB269970 [(R)-3-(2-(2-(<compound-id="69381">4-methylpiperidin</compound-id>-1-yl)<compound-id="23134249">ethyl</compound-id>)<compound-id="31268">pyrrolidine</compound-id>-1-sulfonyl)phenol hydrochloride], and <compound-id="5684">WAY100635</compound-id> [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)<compound-id="23134249">ethyl</compound-id>)-N-(2-pyridyl)-<compound-id="14283">cyclohexane-carboxamide</compound-id> trichloride].	4-methylpiperidin__5-HT(1A__no_interaction	indole-3-carboxylate__5-HT(1A__no_interaction	pyrrolidine__5-HT(1A__no_interaction	cyclohexane-carboxamide__5-HT(1A__no_interaction	methylsulphonyl__5-HT(1A__no_interaction	WAY100635__5-HT(1A__no_interaction	succinate__5-HT(1A__no_interaction	ethyl__5-HT(1A__no_interaction
15049324-3	The skin disease know at that time are studied under the following topics: Cüderi (Ciçek, Variola, Small-pox); Hasbe (Kizamik, Rubeola, Measles); Cüzzam (Lepra, Leprosy, Hansen's disease); Demregü (Temriye, Dermatophtosis, Tinea coproris); Behak (There are two types: the white and the black; the black is Addison's disease ); Baras (Ala, Vitilio); Nemle (Isirga, <protein-id="P20794,F8VBW7">Mak</protein-id>ül); Ateş paresi (Nar-i farisi, frunculosis); Cemre (Kara kabarcik, Sirpenşe, Karbonkül, Carbuncle); Caversiye (Kabarcik hastaliği, blisters disease); Sivilceler (Various types of pimples; Humre: Yilancik, Erizipel, Erysipelas, St. Anthony's fire; Başbert: Ciban, Fronkül, Boil, Fruncle; Dümmel: <compound-id="6032">Kan</compound-id> çibani, Abse, Abscess); Abile (Kabarcik, Bule); Seretan (Kanser, Cancer); Hanaziz (Siraca, Scrofuloderma); Akile (Yinürbaş, Gangren); Kurdeşen (Urtiker, Urticeria); Uyuz (Gale, Scabies); Giciyik (Kaşinti, Prutitus); Sa'fe (Konak, Seboreik dermatit, Scurf); <protein-id="P23276,A0A077QP03">Kel</protein-id> (Aloposi, Favus); Evram (Sişler, Urlar, Tumours); Yara (Karha, Cerahat, Wound).	Kan__Mak__no_interaction	Kan__Kel__no_interaction
16258596-3	This issue focuses on the following selection of drugs: AAV-NGFbeta, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="54841">atomoxetine hydrochloride</compound-id>; <compound-id="9809743">beta-Methyl-6-chloromelatonin</compound-id>, <compound-id="448545">BMS-214662</compound-id>, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, CEA-TRICOM, cetuximab, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="119182">clofarabine</compound-id>, <compound-id="9962928">Cypher</compound-id>; Dalbavancin, darbepoetin alfa, <compound-id="444031">darifenacin hydrobromide</compound-id>, <compound-id="124087">desloratadine</compound-id>, Dexamet, <compound-id="68873">drospirenone</compound-id>, <compound-id="68873">drospirenone</compound-id>/<compound-id="5991">ethinylestradiol</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride, <compound-id="6918296">dutasteride</compound-id>; Ecogramostim, efalizumab, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="146570">escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, <compound-id="969472">eszopiclone</compound-id>; <compound-id="5288209">Fenretinide</compound-id>; <compound-id="123631">Gefitinib</compound-id>, <compound-id="3033968">gestodene</compound-id>, <compound-id="44576256">ghrelin</compound-id> (human); <protein-id="Q12791,Q59FH2,A0A0A0MRR0,B7ZMF5,S4R453,D5MRH1,A0A087WZL8">hMaxi-K</protein-id>, human papillomavirus vaccine; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="6450813">indiplon</compound-id>, <compound-id="807">iodine</compound-id> (i131) tositumomab, irofulven, ISS-1018; <compound-id="216416">Lasofoxifene tartrate</compound-id>, <compound-id="6047">levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>; <compound-id="6918348">Nemifitide ditriflutate</compound-id>, nesiritide; Omalizumab; Pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, phVEGF-<compound-id="3314467">A165</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="16132446">pramlintide acetate</compound-id>; Rasburicase, <compound-id="104850">rimonabant</compound-id> hydrochloride; <compound-id="6918220">Satraplatin</compound-id>, St. John's Wort extract, <compound-id="3086686,5329102">sunitinib</compound-id> <compound-id="525">malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="4369524">tanaproget</compound-id>, Taxus, <compound-id="15057856,3086655,49800038,5487427">tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="60490">Zileuton</compound-id>.	Imatinib mesylate__hMaxi-K__no_interaction	escitalopram__hMaxi-K__no_interaction	Ximelagatran__hMaxi-K__no_interaction	iodine__hMaxi-K__no_interaction	darifenacin hydrobromide__hMaxi-K__no_interaction	rimonabant__hMaxi-K__no_interaction	BMS-214662__hMaxi-K__no_interaction	bortezomib__hMaxi-K__no_interaction	sunitinib__hMaxi-K__no_interaction	Valdecoxib__hMaxi-K__no_interaction	bosentan__hMaxi-K__no_interaction	ghrelin__hMaxi-K__no_interaction	aprepitant__hMaxi-K__no_interaction	ciclesonide__hMaxi-K__no_interaction	pimecrolimus__hMaxi-K__no_interaction	Satraplatin__hMaxi-K__no_interaction	ertapenem sodium__hMaxi-K__no_interaction	doxorubicin__hMaxi-K__no_interaction	tanaproget__hMaxi-K__no_interaction	Gefitinib__hMaxi-K__no_interaction	levodopa__hMaxi-K__no_interaction	indiplon__hMaxi-K__no_interaction	drospirenone__hMaxi-K__no_interaction	dutasteride__hMaxi-K__no_interaction	oxalate__hMaxi-K__no_interaction	Fenretinide__hMaxi-K__no_interaction	eszopiclone__hMaxi-K__no_interaction	Cypher__hMaxi-K__no_interaction	Calcipotriol/betamethasone dipropionate__hMaxi-K__no_interaction	clofarabine__hMaxi-K__no_interaction	entacapone__hMaxi-K__no_interaction	gestodene__hMaxi-K__no_interaction	pramlintide acetate__hMaxi-K__no_interaction	A165__hMaxi-K__no_interaction	ethinylestradiol__hMaxi-K__no_interaction	tiotropium__hMaxi-K__no_interaction	beta-Methyl-6-chloromelatonin__hMaxi-K__no_interaction	atomoxetine hydrochloride__hMaxi-K__no_interaction	treprostinil sodium__hMaxi-K__no_interaction	Nemifitide ditriflutate__hMaxi-K__no_interaction	malate__hMaxi-K__no_interaction	Lasofoxifene tartrate__hMaxi-K__no_interaction	desloratadine__hMaxi-K__no_interaction	vardenafil hydrochloride__hMaxi-K__no_interaction	aripiprazole__hMaxi-K__no_interaction	bromide__hMaxi-K__no_interaction	Zileuton__hMaxi-K__no_interaction	Tadalafil__hMaxi-K__no_interaction	duloxetine__hMaxi-K__no_interaction
18521450-1	A series of mixed-ligand coordination complexes, namely [Zn(CA)(2)(<protein-id="P13645">BIE</protein-id>)] (1), [Zn(OX)(<protein-id="P13645">BIE</protein-id>)].H(2)O (2), [Zn(2)(m-<compound-id="446612">BDC</compound-id>)(2)(<protein-id="P13645">BIE</protein-id>)(2)] (3), [Cd(m-<compound-id="446612">BDC</compound-id>)(<protein-id="P13645">BIE</protein-id>)] (4), [Cd(5-<compound-id="11427">OH-m</compound-id>-<compound-id="446612">BDC</compound-id>)(<protein-id="P13645">BIE</protein-id>)] (5), [Zn(5-<compound-id="11427">OH-m</compound-id>-<compound-id="446612">BDC</compound-id>)(<protein-id="P13645">BIE</protein-id>)] (6), [Zn(2)(p-<compound-id="446612">BDC</compound-id>)(2)(<protein-id="P13645">BIE</protein-id>)(2)].2.5H(2)O (7), [Cd(3)(p-<compound-id="446612">BDC</compound-id>)(3)(<protein-id="P13645">BIE</protein-id>)] (8), [Cd(3)(BTC)(2)(<protein-id="P13645">BIE</protein-id>)(2)].0.5H(2)O (9) and [Zn(BTCA)(0.5)(<protein-id="P13645">BIE</protein-id>)] (10), where CA = <compound-id="8784,444539">cinnamate</compound-id> anion, OX = <compound-id="971">oxalate</compound-id> anion, m-<compound-id="446612">BDC</compound-id> = <compound-id="8496">1,3-benzenedicarboxylate</compound-id> anion, 5-<compound-id="11427">OH-m</compound-id>-<compound-id="446612">BDC</compound-id> = 5-OH-<compound-id="8496">1,3-benzenedicarboxylate</compound-id> anion, p-<compound-id="446612">BDC</compound-id> = <compound-id="7489">1,4-benzenedicarboxylate</compound-id> anion, BTC = 1,3,5-benzenetricarboxylate anion, BTCA = 1,2,3,4-<compound-id="19902429">butanetetracarboxylate</compound-id> anion, and <protein-id="P13645">BIE</protein-id> = 2,2'-bis(1H-imidazolyl)ether, were synthesized under hydrothermal conditions.	1,4-benzenedicarboxylate__BIE__no_interaction	BDC__BIE__no_interaction	OH-m__BIE__no_interaction	butanetetracarboxylate__BIE__no_interaction	oxalate__BIE__no_interaction	cinnamate__BIE__no_interaction	1,3-benzenedicarboxylate__BIE__no_interaction
8803843-3	Basing on the different mechanisms of the tracer uptake, cerebral supratentorial tumors could be distinguished in three groups: 1) cerebral tumors presenting 201T1 very high uptake (201T1 index &gt; 1.5) and homogeneous and high retention of 99mTc-HM-PAO (CBI &gt; or = 1.05) (meningiomas, <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> adenoma); histologically these neoplasms presented very rich neoformed capillary network; 2) cerebral neoplasms with 201T1 high uptake (201T1 index &gt; 1.5) and with inhomogeneous retention of <compound-id="26476">99Tc</compound-id>-HM-PAO (high grade gliomas amd metastasis); microscopically these tumors presented vascular proliferation, necrosis and high cellularity; 3) cerebral neoplasms characterized by 201T1 low uptake (201T1 index &lt; 1.5) and lower retention of <compound-id="26476">99Tc</compound-id>-HM-PAO than cerebellum (low grade gliomas); at microscopic examination these neoplasms were characterized by absence of vascular proliferation and necrosis.	99Tc__PRL__no_interaction
1399624-2	With CF defined as above, a kinetic model for the adsorption of <compound-id="24857">radon</compound-id> gas on charcoal in humid air predicts that CF (in m3) can be written for CR in Bq m-3, A in cpm, and E in cpm Bq-1 as CF = alpha[1-<protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-delta t)] + beta[1 - <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-delta t)]M(t), where alpha, beta, and delta are free parameters, t is the canister exposure time in hours, and M(t) is the canister <compound-id="962">water</compound-id> mass gain in grams in time t. For CF data for the U.S. Environmental Protection Agency's open-faced canisters in an active (with respect to air flow) environmental chamber, delta = (0.046 +/- 0.002)h-1, and <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-delta t) much less than 1 for t greater than or equal to 3 d. Also, alpha = (0.342 +/- 0.002)m3, and beta = -(0.0123 +/- 0.0001)<compound-id="16217590">m3g</compound-id>-1.	water__exp__no_interaction	m3g__exp__no_interaction	radon__exp__no_interaction
11526493-7	To assess the role of <protein-id="Q15370">elongin B</protein-id>/C, <protein-id="P62877">Rbx1</protein-id> and <protein-id="Q16665,D0VY79">HIF-1alpha</protein-id> in RCC tumorigenesis we (a) mapped the genes to chromosomes 8q(cen) (elongin C), 16p13.3 (<protein-id="Q15370">elongin B</protein-id>) and 22q11.2 (<protein-id="P62877">Rbx1</protein-id>) by FISH, monochromosomal somatic cell hybrid panel screening and in silico GenBank homology searching; (b) determined the genomic organisation of elongin C (by direct sequencing of PAC clones), <protein-id="P62877">Rbx1</protein-id> and <protein-id="Q15370">elongin B</protein-id> (by GenBank homology searching); and (c) performed mutation analysis of exons comprising the coding regions of elongins B, C and <protein-id="P62877">Rbx1</protein-id> and the <compound-id="977">oxygen</compound-id>-dependent degradation domain of <protein-id="Q16665,D0VY79">HIF-1alpha</protein-id> by SSCP screening and direct sequencing in 35 sporadic clear cell RCC samples without <protein-id="P40337,A0A024R2F2">VHL</protein-id> gene inactivation and in 13 individuals with familial non-<protein-id="P40337,A0A024R2F2">VHL</protein-id> clear cell RCC.	oxygen__Rbx1__no_interaction	oxygen__HIF-1alpha__no_interaction	oxygen__elongin B__no_interaction	oxygen__VHL__no_interaction
12457042-6	<compound-id="44576256">Ghrelin</compound-id> (10, 100 and 1,000 nM) stimulated the release of both <protein-id="P06850">corticotropin-releasing hormone</protein-id> (<protein-id="P06850">CRH</protein-id>) (100 nM: 6.0 +/- 0.8 vs. basal 4.2 +/- 0.5 pmol/explant, n = 49, p &lt; 0.05) and <protein-id="P01185,X5DQP6">arginine vasopressin</protein-id> (<protein-id="P01185,X5DQP6">AVP</protein-id>) (100 nM: 49.2 +/- 5.9 vs. basal 35.0 +/- 3.3 fmol/explant, n = 48, p &lt; 0.05), whilst <compound-id="44576256">ghrelin</compound-id> (100 and 1,000 nM) also stimulated the release of <protein-id="P01303,A4D158">neuropeptide Y</protein-id> (<protein-id="P01303,A4D158">NPY</protein-id>) (100 nM: 111.4 +/- 25.0 vs. basal 54.4 +/- 9.0 fmol/explant, n = 26, p &lt; 0.05) from hypothalamic explants in vitro.	ghrelin__neuropeptide Y__no_interaction	ghrelin__AVP__no_interaction	ghrelin__arginine vasopressin__no_interaction	ghrelin__NPY__no_interaction	ghrelin__CRH__no_interaction	ghrelin__corticotropin-releasing hormone__no_interaction	Ghrelin__neuropeptide Y__no_interaction	Ghrelin__AVP__no_interaction	Ghrelin__arginine vasopressin__no_interaction	Ghrelin__NPY__no_interaction	Ghrelin__CRH__no_interaction	Ghrelin__corticotropin-releasing hormone__no_interaction
7976417-3	In ear arteries, endothelium removal or treatment with the <compound-id="145068">nitric oxide</compound-id> synthase inhibitor NG-nitro-<compound-id="550788">L-arginine methyl ester</compound-id> (<compound-id="39836">L-NAME</compound-id>, 10(-5) M) did not affect the contraction to <compound-id="774">histamine</compound-id> at 37 degrees C, but it reversed the decreased contraction at 24 degrees C. In femoral arteries, endothelium removal or <compound-id="39836">L-NAME</compound-id> (10(-5) M) did not affect the response to <compound-id="774">histamine</compound-id> at 37 and 24 degrees C. Ear and femoral arteries precontracted with <protein-id="P29560">endothelin-1</protein-id> (10(-8)-10(-7) M) and pretreated with <compound-id="2725">chlorpheniramine</compound-id> (10(-5) M) relaxed to <compound-id="774">histamine</compound-id> (10(-7)-10(-4) M), and the sensitivity of this relaxation in ear arteries, but not in femoral arteries, increased at 24 degrees C. The relaxation of ear and femoral arteries to <compound-id="774">histamine</compound-id> was not modified by endothelium removal, <compound-id="39836">L-NAME</compound-id> (10(-5) M) or <compound-id="4037">meclofenamate</compound-id> (10(-5) M), but it was blocked by <compound-id="2756">cimetidine</compound-id> (10(-6) M) at 37 degrees C and 24 degrees C. These results suggest: (1) ear and femoral arteries have contracting H1 and relaxing <compound-id="783">H2</compound-id> receptors, probably located on smooth musculature, and (2) cooling reduces the contraction and increases the relaxation of cutaneous arteries to <compound-id="774">histamine</compound-id>: the reduction of this contraction could be caused by an augmented availability of endothelial <compound-id="145068">nitric oxide</compound-id>, and the increment of this relaxation could be caused by an augmented sensitivity of <compound-id="783">H2</compound-id> receptors of smooth musculature induced by cooling.	L-NAME__endothelin-1__no_interaction	H2__endothelin-1__no_interaction	L-arginine methyl ester__endothelin-1__no_interaction	meclofenamate__endothelin-1__no_interaction	cimetidine__endothelin-1__no_interaction	chlorpheniramine__endothelin-1__no_interaction	nitric oxide__endothelin-1__no_interaction	histamine__endothelin-1__no_interaction
2002021-2	This conclusion was supported by the following results: (a) the PGN- and <protein-id="Q9QUK6,L0CL36">LPS</protein-id>-binding proteins co-migrated following photoaffinity cross-linking and two-dimensional <compound-id="6579">polyacrylamide</compound-id> gel electrophoresis; (b) cross-linking of PGN to this 70-kDa protein was competitively inhibited by <protein-id="Q9QUK6,L0CL36">LPS</protein-id> (IC50 = 7.3 microM), <protein-id="Q9QUK6,L0CL36">LPS</protein-id> from a deep rough mutant (IC50 = 6.9 microM), and <compound-id="9877306">lipid A</compound-id> (IC50 = 18-72 microM); (c) cross-linking of <protein-id="Q9QUK6,L0CL36">LPS</protein-id> to this 70-kDa protein was competitively inhibited by polymeric soluble PGN (IC50 = 0.09 microM) and sonicated high Mr PGN (IC50 = 0.6 microM); (d) cross-linking of both PGN and <protein-id="Q9QUK6,L0CL36">LPS</protein-id> to this 70-kDa protein was also competitively inhibited by <compound-id="4125253,5460037">dextran</compound-id> <compound-id="1117">sulfate</compound-id> (IC50 = 115-124 microM); (e) cross-linking of both PGN and <protein-id="Q9QUK6,L0CL36">LPS</protein-id> to this 70-kDa protein was inhibited by a (<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>)2-specific lectin; and (f) peptide maps of the 70-kDa proteins digested with chymotrypsin, subtilisin, staphylococcal protease V, or papain were identical for PGN- and <protein-id="Q9QUK6,L0CL36">LPS</protein-id>-binding proteins and unique for each enzyme.	dextran__LPS__no_interaction	GlcNAc__LPS__no_interaction	polyacrylamide__LPS__no_interaction	lipid A__LPS__no_interaction	sulfate__LPS__no_interaction
15382499-2	<compound-id="5125">Tribufos</compound-id>, 0.47 kg <protein-id="Q15323">ha(-1</protein-id>) and <compound-id="5125">tribufos</compound-id>, 0.235 kg <protein-id="Q15323">ha(-1</protein-id>) + <compound-id="40087">thidiazuron</compound-id>, 0.125 kg <protein-id="Q15323">ha(-1</protein-id>) exhibited a slightly toxic effect to boll weevil, while <compound-id="5125">tribufos</compound-id>, 0.47 kg <protein-id="Q15323">ha(-1</protein-id>) + <compound-id="5281873,6440557,71464055">lambda-cyhalothrin</compound-id>, 0.019 kg <protein-id="Q15323">ha(-1</protein-id>), <compound-id="5125">tribufos</compound-id>, 0.47 kg <protein-id="Q15323">ha(-1</protein-id>) + <compound-id="2268">azinphos</compound-id>-methyl, 0.14 kg <protein-id="Q15323">ha(-1</protein-id>), and <compound-id="5125">tribufos</compound-id>, 0.235 kg <protein-id="Q15323">ha(-1</protein-id>) + <compound-id="40087">thidiazuron</compound-id>, 0.125 kg <protein-id="Q15323">ha(-1</protein-id>) + <compound-id="2268">azinphos</compound-id>-methyl, 0.14 kg ha(-l), provided control of boll weevil as good as or better than full-rate <compound-id="2268">azinphos</compound-id>-methyl or <compound-id="5281873,6440557,71464055">lambda-cyhalothrin</compound-id> alone owing to synergistic effects.	Tribufos__ha(-1__no_interaction	tribufos__ha(-1__no_interaction	thidiazuron__ha(-1__no_interaction	azinphos__ha(-1__no_interaction	lambda-cyhalothrin__ha(-1__no_interaction
15706870-3	RESULT: Seven compounds were obtained and identified as (20S,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha, 17beta-cevanine-6beta-hydroxy-3-one (hupehenirine, ZF1), (20S,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha, 17beta-cevanine-3beta-hydroxy-6-one (hupehenizine, <protein-id="Q96GC6,A0A0A0MR47">ZF2</protein-id>), (<compound-id="66610004">20R</compound-id>,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha-cevanine-3beta,20beta-dihydroxy-6-one (<compound-id="167691">peiminine</compound-id>, verticinone, ZF3), (20S,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha, 17beta-cevanine-3beta, 6beta-dihydroxy (<compound-id="14240934">hupehenine</compound-id>, ZF4), (<compound-id="66610004">20R</compound-id>,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha-cevanine-3beta, 6beta, 20beta-trihydroxy (isoverticine, <protein-id="O43829,B2R850">ZF5</protein-id>), (<compound-id="66610004">20R</compound-id>,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha-cevanine-3beta, 6alpha, 20beta-trihydroxy (<compound-id="131900">peimine</compound-id>, verticine, <protein-id="Q96SQ5">ZF6</protein-id>), (20S,<compound-id="76936801">25S</compound-id>)5alpha, 14alpha, 17beta-evanine-6beta-hydroxy-3beta-O-beta-D-glucoside (<compound-id="127202">hupeheninoside</compound-id>, ZF7).	20R__ZF2__no_interaction	20R__ZF6__no_interaction	20R__ZF5__no_interaction	peimine__ZF2__no_interaction	peimine__ZF6__no_interaction	peimine__ZF5__no_interaction	peiminine__ZF2__no_interaction	peiminine__ZF6__no_interaction	peiminine__ZF5__no_interaction	hupeheninoside__ZF2__no_interaction	hupeheninoside__ZF6__no_interaction	hupeheninoside__ZF5__no_interaction	hupehenine__ZF2__no_interaction	hupehenine__ZF6__no_interaction	hupehenine__ZF5__no_interaction	25S__ZF2__no_interaction	25S__ZF6__no_interaction	25S__ZF5__no_interaction
17693666-4	While there was no evidence of associations between <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">BAX</protein-id> (-248 G&gt;A), <protein-id="P10415,A0A024R2B3,A0A024R2C4">BCL2</protein-id> (-938 C&gt;A) or <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">TP53</protein-id> codon 72 SNPs and SCCHN risk in single-locus analyses, further analyses showed that, among <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">TP53</protein-id> heterozygotes after adjustment for age, sex and smoking and <compound-id="10982484,702">alcohol</compound-id> status, the <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">BAX</protein-id> AA genotype was associated with an elevated risk of SCCHN [odds ratio (OR) = 6.60, 95% confidence interval (CI) = 1.38-31.50 compared with the <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">BAX</protein-id> GG genotype or OR = 6.58, 95% CI = 1.38-31.49 compared with the combined genotypes (GG + AG)], whereas <protein-id="P10415,A0A024R2B3,A0A024R2C4">BCL2</protein-id> A variant genotypes were associated with a decreased risk of SCCHN (adjusted OR = 0.68, 95% CI = 0.47-0.98 for CA vs CC and OR = 0.67, 95% CI = 0.48-0.95 for AA vs CA+CC).	alcohol__TP53__no_interaction	alcohol__BAX__no_interaction	alcohol__BCL2__no_interaction
8646253-6	Furthermore, delta-mean satiety correlated to delta-AUC for plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.92, p &lt; 0.01), <compound-id="612">lactate</compound-id> (r = 0.98, p &lt; 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.95, p&lt; 0.01), noradrenaline (r = 0.97, p &lt; 0.01), gastric inhibitory polypeptide (r = 0.93), p &lt; 0.01) and net carbohydrate oxidation (r = 0.86, p &lt; 0.05).	lactate__insulin__no_interaction	glucose__insulin__no_interaction
20853680-11	The phosphorylation level of <protein-id="P21708,P63086">ERK1/2</protein-id> in Sch-B 1 on 3rd, 7th, 14th and 21st (0.974 +/- 0.169, 0.987 +/- 0.149, 0.920 +/- 0.092 and 0.884 +/- 0.078) and Sch-B 2 on 14th, 21st and 28th (1.012 +/- 0.050, 1.167 +/- 0.083 and 1.002 +/- 0.060) were significantly lower than in <compound-id="24261">silica</compound-id> groups P &lt; 0.05 or P &lt; 0.01); The phosphorylation level of JNK1 in Sch-B 1 reached its summit on 7th day (P &lt; 0.01 ), and that in Sch-B 2 on 14th, 21st and 28th (0.882 +/- 0.064, 0.802 +/- 0.061, 0.792 +/- 0.015) was lower than <compound-id="24261">Silica</compound-id> groups at every time points (P &lt; 0.01); The phosphorylation level of p-p38 in Sch-B 1 was higher than <compound-id="24261">silica</compound-id> group on 3rd day (0.309 +/- 0.045) and lower on 7th, 14th and 21st day, but that in Sch-B 2 were lower and lower.	Silica__ERK1/2__no_interaction	silica__ERK1/2__no_interaction
15446888-1	The <compound-id="768">isocyanide</compound-id> ligand forms complexes with <compound-id="23950">ruthenium</compound-id>(II) bis-bipyridine of the type [Ru(bpy)(2)(<protein-id="P27824">CNx</protein-id>)Cl](CF(3)SO(3)) (1), [Ru(bpy)(2)(<protein-id="P27824">CNx</protein-id>)(py)](PF(6))(2) (2), and [Ru(bpy)(2)(<protein-id="P27824">CNx</protein-id>)(2)](PF(6))(2) (3) (bpy = 2,2'-bipyridine, py = pyridine, and <protein-id="P27824">CNx</protein-id> = 2,6-dimethylphenylisocyanide).	isocyanide__CNx__no_interaction	ruthenium__CNx__no_interaction
18572354-8	Thus, increased <compound-id="315411,445226,68196650">FDG</compound-id> uptake was correlated with higher densities of inflammatory infiltrates (r = +0.87, P &lt; .01) and macrophage and T-cell infiltrations (r = +0.95, P &lt; .01 and r = +0.66, P &lt; .05), with higher <protein-id="P14780">MMP-9</protein-id> expressions (r = +0.86; P &lt; .01), and with reduction of collagen fiber (r = -0.76; P &lt; .01) and VSMCs (r = -0.71; P &lt; .01).	FDG__MMP-9__no_interaction
3905736-3	Concentrations of <protein-id="P01308,I3WAC9">Insulin</protein-id> and <compound-id="206,5793,64689,79025">glucose</compound-id> were determined in jugular venous serum obtained from blood samples collected at 60, 45, 30, 15 and 1 min before and at 2.5, 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 210 and 240 min after <compound-id="206,5793,64689,79025">glucose</compound-id>.	glucose__Insulin__no_interaction
11012906-9	No significant differences in sex, age (56 +/- 8 vs. 53 +/- 10 years, mean SD), body mass index (30 +/- 4 vs. 31 +/- 8 kg/m2), known duration of diabetes (6 +/- 6 vs. 4 +/- 3 years), <protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> (95 +/- 29 vs. 89 +/- 31 mL/min/1.73 m2), albuminuria (1304 +/- 169 to 4731 vs. 1050 +/- 181 to 5176 mg/24 hours), blood pressure (150/87 +/- 16/9 vs. 145/89 +/- 16/9 mm Hg), prevalence of hypertension (89 vs. 100%), hemoglobin A1c (8.2 +/- 1.6% vs. 9.0 +/- 2.5%), and serum total <compound-id="5997">cholesterol</compound-id> (7.1 +/- 2.4 vs. 6.3 +/- 1.6 mmol/L) were found between patients with and without diabetic glomerulopathy.	cholesterol__GFR__no_interaction
3511947-5	Based on recent reports that PMN do not express ABH antigens and on the data presented here, the occurrence of major RBC antigens on leucocytes may be defined as follows: (1) lymphocytes express A, B. Lea and <protein-id="P98088">Leb</protein-id> antigens, depending on the ABH secretor (Se) status of the donor; (2) ABH and Lewis antigens cannot be detected on monocytes and PMN regardless of Se status; (3) D, E, e, C, c, <compound-id="444490">Fya</compound-id>, <protein-id="O15117,Q05DE9">Fyb</protein-id>, Fy5, Jka, Jkb, Jk, K, k, M, N, S, s, U, <protein-id="B2RUZ4,M4WDD3">Vel</protein-id>, <compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">Coa</compound-id>, <protein-id="P98153,B7Z3T5,Q8IWC8,Q5CZ70">Lan</protein-id>, Jk3Yta, Dib, Ge, <protein-id="Q9Y242,A0A0G2JIJ7,D2IYK5">Sc:1</protein-id> or Lub antigens were not detected on lymphocytes, monocytes and PMN; (4) lymphocytes, monocytes and PMN all express I, i, P and P1 antigens.	Coa__Fyb__no_interaction	Coa__Sc:1__no_interaction	Coa__Leb__no_interaction	Coa__Vel__no_interaction	Coa__Lan__no_interaction	Fya__Fyb__no_interaction	Fya__Sc:1__no_interaction	Fya__Leb__no_interaction	Fya__Vel__no_interaction	Fya__Lan__no_interaction
10537142-6	The rank order of displacement of [125I]Tyr11-<protein-id="P61278">SST</protein-id> binding to hsst1 was: <protein-id="P61278">SST</protein-id> (IC50, 0.5 nM) &gt;&gt; DOTALAN (IC50, 154 nM) &gt; <compound-id="71349">lanreotide</compound-id> (LAN) approximate to Tyr3-<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> (TOCT) approximate to <compound-id="121841">DOTA</compound-id>-Tyr3-<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> (DOTATOCT) approximate to <compound-id="121841">DOTA</compound-id>-<compound-id="45588099,5311370,57214391,70689318,71306">vapreotide</compound-id> (DOTAVAP; IC50, &gt;1000 nM); that to <protein-id="O00204">hsst2</protein-id> was: DOTATOCT approximate to TOCT approximate to DOTALAN approximate to <protein-id="P61278">SST</protein-id> approximately LAN approximate to DOTAVAP (IC50, 1.4 nM); that to <protein-id="O95803">hsst3</protein-id> was: <protein-id="P61278">SST</protein-id> (IC50, 1.2 nM) &gt; DOTALAN = LAN (IC50, 15 nM) approximate to TOCT (IC50, 20 nM) approximate to DOTAVAP (IC50, 28 nM) &gt; DOTATOCT (IC50, 73 nM); that to hsst4 was: <protein-id="P61278">SST</protein-id> (IC50, 1.8 nM) approximate to DOTALAN (IC50, 2.5 nM) &gt; LAN (IC50, 22 nM) &gt;&gt; DOTATOCT approximate to DOTAVAP approximate to TOCT (IC50, &gt;500 nM); and that to hsst5 was: DOTALAN (IC50, 0.45 nM) &gt; <protein-id="P61278">SST</protein-id> (IC50, 0.9 nM) &gt; TOCT (IC50, 1.5 nM) &gt; DOTAVAP (IC50, 5.4 nM) &gt;&gt; LAN (IC50, 21 nM) &gt; DOTATOCT (IC50 260 nM).	DOTA__hsst3__no_interaction	DOTA__SST__no_interaction	DOTA__hsst2__no_interaction	lanreotide__hsst3__no_interaction	lanreotide__SST__no_interaction	lanreotide__hsst2__no_interaction	vapreotide__hsst3__no_interaction	vapreotide__SST__no_interaction	vapreotide__hsst2__no_interaction	octreotide__hsst3__no_interaction	octreotide__SST__no_interaction	octreotide__hsst2__no_interaction
15892618-11	Other promising new drugs currently under preclinical and clinical evaluation, are <protein-id="P35968,A0A024RD88">VEGFR2</protein-id> inhibitor PTK787/ZK 222584, thalidomide, farnesyl transferase inhibitor R115777 (tipifarnib, <compound-id="159324">Zarnestra</compound-id>(TM)), matrix metalloproteinase inhibitors, proteasome inhibitor bortezomib (<compound-id="387447,93860">Velcade</compound-id>(TM)), <protein-id="P42345">mammalian target of rapamycin</protein-id> (mTOR) inhibitors, <protein-id="P35354">cyclooxygenase-2</protein-id> (COX-2) inhibitors, platelet derived growth factor receptor (PDGF-R) inhibitors, protein kinase C (PKC) inhibitors, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitors, Rous sarcoma virus transforming oncogene (SRC) kinase inhibitors, histondeacetylase (HDAC) inhibitors, small hypoxia-inducible factor (HIF) inhibitors, aurora kinase inhibitors, hedgehog inhibitors, and TGF-beta signalling inhibitors.	Zarnestra__mammalian target of rapamycin__no_interaction	Zarnestra__VEGFR2__no_interaction	Zarnestra__cyclooxygenase-2__no_interaction	Velcade__mammalian target of rapamycin__no_interaction	Velcade__VEGFR2__no_interaction	Velcade__cyclooxygenase-2__no_interaction
24504097-2	We sought to use isometric tension measurements in ex vivo airways to determine whether short-term pharmacological activation of <protein-id="Q9HBA0">TRPV4</protein-id> with the potent agonist GSK1016790 [N-((1S)-1-{[4-((2S)-2-{[(2,4-<compound-id="57417436">dichlorophenyl</compound-id>)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-<compound-id="237073">benzothiophene-2-carboxamide</compound-id>] would constrict human bronchial tissue.	dichlorophenyl__TRPV4__no_interaction	benzothiophene-2-carboxamide__TRPV4__no_interaction
11329262-2	<compound-id="2016">Flavin</compound-id> reduction potentials are similar in the isolated domains (<compound-id="643975">FAD</compound-id> domain E(1) [oxidized/semiquinone] = -286 +/- 6 mV, E(2) [semiquinone/reduced] = -371 +/- 7 mV; <protein-id="Q68DA7,H0YM30">FMN</protein-id> domain E(1) = -43 +/- 7 mV, E(2) = -280 +/- 8 mV) and the soluble diflavin reductase (E(1) [<protein-id="Q68DA7,H0YM30">FMN</protein-id>] = -66 +/- 8 mV, E(2) [<protein-id="Q68DA7,H0YM30">FMN</protein-id>] = -269 +/- 10 mV; E(1) [<compound-id="643975">FAD</compound-id>] = -283 +/- 5 mV, E(2) [<compound-id="643975">FAD</compound-id>] = -382 +/- 8 mV).	Flavin__FMN__no_interaction	FAD__FMN__no_interaction
22538807-2	Results show that these apoptotic body-like liposomes carrying PA (ABL/PA) (i) are more efficiently internalized by human macrophages than by nonprofessional phagocytes, (ii) induce cytosolic Ca(2+) influx, (iii) promote Ca(2+)-dependent maturation of phagolysosomes containing Mycobacterium tuberculosis (MTB), (iv) induce Ca(2+)-dependent reactive <compound-id="977">oxygen</compound-id> species (ROS) production, (v) inhibit intracellular mycobacterial growth in differentiated THP-1 cells as well as in type-1 and -2 human macrophages, and (vi) down-regulate tumor necrosis factor (TNF)-α, interleukin (IL)-12, IL-1β, <protein-id="Q14116,A0A024R3E0">IL-18</protein-id>, and <protein-id="Q9NPF7">IL-23</protein-id> and up-regulate transforming growth factor (TGF)-β without altering <protein-id="P22301,Q6FGW4">IL-10</protein-id>, <protein-id="Q8NEV9">IL-27</protein-id>, and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> mRNA expression.	oxygen__IL-23__no_interaction	oxygen__IL-6__no_interaction	oxygen__IL-27__no_interaction	oxygen__IL-10__no_interaction	oxygen__IL-18__no_interaction
22611311-10	RESULTS: <compound-id="213604">AGM</compound-id> markedly reduced Evan's blue dye extravasation (3.58 ± 0.975 μg/stomach vs 1.175 ± 0.374 μg/stomach, P &lt; 0.05), <protein-id="P16612,Q541S7,A0A0G2K6Z7,B5DEK7">VEGF</protein-id> (36.87 ± 2.71 pg/100 mg protein vs 48.4 ± 6.53 pg/100 mg protein, P &lt; 0.05) and <protein-id="P14844">MCP-1</protein-id> tissue level (29.5 ± 7 pg/100 mg protein vs 41.17 ± 10.4 pg/100 mg protein, P &lt; 0.01).	AGM__VEGF__no_interaction	AGM__MCP-1__no_interaction
24528483-2	RESULTS: In PNS, the 10 up (↑)- or down (↓)-regulated proteins exhibiting the largest morphine-induced change were selected, excised manually from the gel and identified by MALDI-TOF MS/MS: 1-(gi|148747414, <compound-id="764">Guanine</compound-id> deaminase), ↑2.5×; 2-(gi|17105370, Vacuolar-type <compound-id="1038,5460653">proton</compound-id> <compound-id="5957">ATP</compound-id> subunit B, brain isoform), ↑2.6×; 3-(gi|1352384, <protein-id="P11598,P04785">Protein disulfide-isomerase A3</protein-id>), ↑3.4×; 4-(gi|40254595, <protein-id="P47942">Dihydropyrimidinase-related protein 2</protein-id>), ↑3.6×; 5-(gi|149054470, N-ethylmaleimide sensitive fusion protein, isoform CRAa), ↑2.0×; 6-(gi|42476181, <compound-id="525">Malate</compound-id> dehydrogenase, mitochondrial precursor), ↑1.4×; 7-(gi|62653546, <compound-id="439168,446381">Glyceraldehyde-3-phosphate</compound-id> dehydrogenase), ↑1.6×; 8-(gi|202837, Aldolase A), ↑1.3×; 9-(gi|31542401, <compound-id="586">Creatine</compound-id> kinase B-type), ↓0.86×; 10-(gi|40538860, <compound-id="309,444212">Aconitate</compound-id> hydratase, mitochondrial precursor), ↑1.3×.	Glyceraldehyde-3-phosphate__Protein disulfide-isomerase A3__no_interaction	Glyceraldehyde-3-phosphate__Dihydropyrimidinase-related protein 2__no_interaction	Aconitate__Protein disulfide-isomerase A3__no_interaction	Aconitate__Dihydropyrimidinase-related protein 2__no_interaction	Creatine__Protein disulfide-isomerase A3__no_interaction	Creatine__Dihydropyrimidinase-related protein 2__no_interaction	Malate__Protein disulfide-isomerase A3__no_interaction	Malate__Dihydropyrimidinase-related protein 2__no_interaction	proton__Protein disulfide-isomerase A3__no_interaction	proton__Dihydropyrimidinase-related protein 2__no_interaction	Guanine__Protein disulfide-isomerase A3__no_interaction	Guanine__Dihydropyrimidinase-related protein 2__no_interaction	ATP__Protein disulfide-isomerase A3__no_interaction	ATP__Dihydropyrimidinase-related protein 2__no_interaction
24528483-4	The 4 out of 9 up-regulated proteins (4, 6, 7, 10) were described as functionally related to oxidative stress; the 2 proteins participate in genesis of apoptotic cell death.In PM, the 18 up (↑)- or down (↓)-regulated proteins were identified by LC-MS/MS and were of plasma membrane [Brain acid soluble protein, ↓2.1×; trimeric Gβ subunit, ↓2.0x], myelin membrane [MBP, ↓2.5×], cytoplasmic [Internexin, ↑5.2×; DPYL2, ↑4.9×; Ubiquitin hydrolase, ↓2.0×; 60S ribosomal protein, ↑2.7×; KCRB, ↓2.6×; Sirtuin-2, ↑2.5×; Peroxiredoxin-2, ↑2.2×; <protein-id="B3GNI6">Septin-11</protein-id>, ↑2.2×; TERA, ↑2.1×; SYUA, ↑2.0×; <protein-id="Q91ZN1">Coronin-1A</protein-id>, ↓5.4×] and mitochondrial [<protein-id="P10860">Glutamate dehydrogenase 1</protein-id>, ↑2.7×; SCOT1, ↑2.2×; Prohibitin, ↑2.2×; <compound-id="5960">Aspartate</compound-id> aminotransferase, ↓2.2×] origin.	Aspartate__Septin-11__no_interaction	Aspartate__Glutamate dehydrogenase 1__no_interaction	Aspartate__Coronin-1A__no_interaction
11759203-5	RESULTS: Results of investigation showed that RR in AML was: for A2 = 1.144, for A3 = 1.038, for A29 = 1.814, for <compound-id="51058789">A34</compound-id> = 2.69, for B7 = 1.06, for <protein-id="P56556">B14</protein-id> = 1.74, for <protein-id="Q9NYP3">B17</protein-id> = 1.65 and for <protein-id="Q15438,B7Z9W0">B21</protein-id> = 2.49 and <compound-id="42628075">B35</compound-id> = 1.77 with value of chi 2 test of 4.62 and 4.63; that RR in ALL was: for A1 = 1.61, for A2 = 1.1, for A10 = 1.23, for A11 = 1.57, for <compound-id="51058787">A30</compound-id> = 1.4, for A32 = 2.2, for B7 = 2.81 with value of chi 2 test 4.39; that RR in CML was: for A2 = 1.21, for A32 = 1.89, for B7 = 1.52, for <protein-id="O43676,A0A024R413">B12</protein-id> = 1.2 and for <protein-id="O95168">B15</protein-id> = 3.28 with value of chi 2 test of 5.89; and that RR in CLL was: for A1 = 1.35 with value of chi 2 test of 3.973, RR for A2 = 1.02, for A28 = 1.97, for A32 = 1.25, for B5 = 1.44, for B8 = 1.27, for <protein-id="Q16718,A0A024R745,A0A087X1G1,A0A087WXR5">B13</protein-id> = 1.91 without statistically significant differences of frequencies except for A1.	B35__B21__no_interaction	B35__B17__no_interaction	B35__B14__no_interaction	B35__B15__no_interaction	B35__B12__no_interaction	B35__B13__no_interaction	A30__B21__no_interaction	A30__B17__no_interaction	A30__B14__no_interaction	A30__B15__no_interaction	A30__B12__no_interaction	A30__B13__no_interaction	A34__B21__no_interaction	A34__B17__no_interaction	A34__B14__no_interaction	A34__B15__no_interaction	A34__B12__no_interaction	A34__B13__no_interaction
16875425-9	There were significant correlations between fetal weight and HbAlc (r = -0.60, p &lt; 0.05), triglyceride levels (r = -0.63, p &lt; 0.01), and the number of pregnancies (r = -0.62, p &lt; 0.01), as well as between APGAR score and <compound-id="94214">MBG</compound-id> (r = -0.52, p &lt; 0.05) and <compound-id="5997">cholesterol</compound-id> levels (r = -0.65, p &lt; 0,01) before a portable <protein-id="P01308,I3WAC9">insulin</protein-id> pump was applicated.	MBG__insulin__no_interaction	cholesterol__insulin__no_interaction
21950195-6	A decrease of <protein-id="Q62600">eNOS</protein-id> was found in soleus muscle (20.6 +/- 1.4 vs. 30.3 +/- 1.2, p&lt;0.00001); of <protein-id="P29476,D3ZEW7">nNOS</protein-id> (soleus 16.8 +/- 1.4 vs. 20.7 +/- 1.8, p&lt; 0.05; EDL 13.6 +/- 1.3 vs. 21.9 +/- 1.8, p&lt;.005) and <compound-id="946">nitrite</compound-id> in EDL (5.8 +/- 0.3 vs. 7.1 +/- 0.5, p&lt;0.026).There was a positive correlation between <protein-id="P16599">TNF-alpha</protein-id> vs. nitrotyrosine in soleus (r=0.798; p&lt;0.031) and a tendency in EDL (r=0.739; p=0.059); <protein-id="Q06518">iNOS</protein-id> vs. nitrotyrosine (soleus: r=0.908; p&lt;0.0001; EDL: r=0.707; p&lt;0.01), a tendency between <protein-id="P16599">TNF-alpha</protein-id> and <protein-id="Q06518">iNOS</protein-id> (EDL: r=0.736; p&lt;0.059); and a negative correlation between <protein-id="Q62600">eNOS</protein-id> vs. nitrotyrosine in soleus muscle (r=-0.816; p&lt;0.0012).	nitrite__TNF-alpha__no_interaction	nitrite__eNOS__no_interaction	nitrite__nNOS__no_interaction	nitrite__iNOS__no_interaction
24004329-1	A series of mononuclear <compound-id="935">nickel</compound-id>(II) <compound-id="5047209">thiolate</compound-id> complexes (Et4N)Ni(X-pyS)3 (Et4N = tetraethylammonium; X = 5-<protein-id="Q02539">H (1a</protein-id>), 5-Cl (1b), 5-CF3 (1c), 6-CH3 (1d); pyS = <compound-id="2723698">pyridine-2-thiolate</compound-id>), Ni(pySH)4(NO3)2 (2), (Et4N)Ni(4,6-Y2-pymS)3 (Y = <protein-id="P68431">H (3a</protein-id>), CH3 (3b); pymS = <compound-id="1550489">pyrimidine-2-thiolate</compound-id>), and Ni(4,4'-Z-2,2'-bpy)(pyS)2 (Z = H (<compound-id="69255155">4a</compound-id>), CH3 (4b), OCH3 (4c); bpy = bipyridine) have been synthesized in high yield and characterized.	thiolate__H (3a__no_interaction	thiolate__H (1a__no_interaction	4a__H (3a__no_interaction	4a__H (1a__no_interaction	nickel__H (3a__no_interaction	nickel__H (1a__no_interaction	pyridine-2-thiolate__H (3a__no_interaction	pyridine-2-thiolate__H (1a__no_interaction	pyrimidine-2-thiolate__H (3a__no_interaction	pyrimidine-2-thiolate__H (1a__no_interaction
19011782-6	Values for absolute and relative <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> reactivity in insulintreated patients were lower than those in the other three groups (absolute <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> reactivity [means +/- SD]: control, 3.1 +/- 0.6 cm.s(-1).mmHg(-1), diet, 3.8 +/- 1.4 cm.s(-1) x mmHg(-1); oral antidiabetic drug 3.2 +/- 0.9 cm x s(-1) x mmHg(-1); <protein-id="P01308,I3WAC9">insulin</protein-id>, 1.1 +/- 0.6 cm x s(-1) x mmHg(-1); P = 0.002).The present study shows that <protein-id="P01308,I3WAC9">insulin</protein-id>-treated diabetic patients probably have lower cerebrovascular <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> reactivity under <compound-id="4943">propofol</compound-id> anesthesia than control patients or diabetics treated with dietary therapy or oral hypoglycemics.	propofol__CO2__no_interaction	propofol__insulin__no_interaction
16421165-12	In dialysis patients, the number of steps taken positively correlated with body <compound-id="962">water</compound-id> (R = 0.28, P = 0.03), fat mass (r = 0.29, P = 0.04), BMI (R = 0.25, P = 0.04), lean body mass (R = 0.26, P = 0.04), intracellular <compound-id="962">water</compound-id> (r = 0.30, P&lt;0.01), phase angle (R = 0.40, P = 0.002), serum <protein-id="P02768">albumin</protein-id> (R = 0.32, P = 0.01), haematocrit (R = 0.46, P = 0.001) and haemoglobin (R = 0.44, P = 0.001).	water__albumin__no_interaction
20815907-17	The following variables were significantly (p &lt; 0.05) lower following the <protein-id="Q14296,A0A090N8Z7,A0A090N8I0">Fast</protein-id> as compared to before the <protein-id="Q14296,A0A090N8Z7,A0A090N8I0">Fast</protein-id>: white blood cell count (5.68 ± 0.24 vs. 4.99 ± 0.19 103.μL-1), blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (13.07 ± 0.58 vs. 10.14 ± 0.59 mg.dL-1), blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id>/<compound-id="588">creatinine</compound-id> (14.74 ± 0.59 vs. 11.67 ± 0.68), protein (6.95 ± 0.07 vs. 6.77 ± 0.06 g.dL-1), total <compound-id="5997">cholesterol</compound-id> (171.07 ± 4.57 vs. 138.69 ± 4.39 mg.dL-1), LDL-C (98.38 ± 3.89 vs. 76.07 ± 3.53 mg.dL-1), HDL-C (55.65 ± 2.50 vs. 47.58 ± 2.19 mg.dL-1), SBP (114.65 ± 2.34 vs. 105.93 ± 2.12 mmHg), and DBP (72.23 ± 1.59 vs. 67.00 ± 1.43 mmHg).	creatinine__Fast__no_interaction	urea__Fast__no_interaction	nitrogen__Fast__no_interaction	cholesterol__Fast__no_interaction
12889972-1	The synthesis of a new series of mixed phenylene-<compound-id="8030">thiophene</compound-id> oligomers is reported; <compound-id="12067690">2,5-bis(4-n-hexylphenyl)thiophene</compound-id> (dH-<protein-id="P05451,A8K7G6">PTP</protein-id>, 1), <compound-id="12067691">5,5'-bis(4-n-hexylphenyl)-2,2'-bithiophene</compound-id> (dH-PTTP, 2), 5,5' '-bis(4-n-<compound-id="14109">hexylphenyl</compound-id>)-2,2':5',2' '-terthiophene (dH-PT(3)P, 3), 5,5' "-bis(4-n-<compound-id="14109">hexylphenyl</compound-id>)-2,2':5',2' ':5' ',2' "-quaterthiophene (dH-PT(4)P, 4), <compound-id="12067694">1,4-bis[5-(4-n-hexylphenyl)-2-thienyl]benzene</compound-id> (dH-PTPTP, 5), and <compound-id="12067695">2,5-bis[4(4'-n-hexylphenyl)phenyl]thiophene</compound-id> (dH-PPTPP, 6) were characterized by (1)H NMR, elemental analysis, UV-visible spectroscopy, differential scanning calorimetry, and thermogravimetric analysis.	1,4-bis[5-(4-n-hexylphenyl)-2-thienyl]benzene__PTP__no_interaction	5,5'-bis(4-n-hexylphenyl)-2,2'-bithiophene__PTP__no_interaction	thiophene__PTP__no_interaction	2,5-bis(4-n-hexylphenyl)thiophene__PTP__no_interaction	hexylphenyl__PTP__no_interaction	2,5-bis[4(4'-n-hexylphenyl)phenyl]thiophene__PTP__no_interaction
15319333-6	Formation of <compound-id="32414">normeperidine</compound-id> significantly correlated with <protein-id="P20813">CYP2B6</protein-id>-selective S-<compound-id="4060">mephenytoin</compound-id> N-demethylation (r = 0.88, p &lt; 0.0001 at 75 &gt; microM <compound-id="4058">meperidine</compound-id>, and r = 0.89, p &lt; 0.0001 at 350 microM <compound-id="4058">meperidine</compound-id>, n = 21) and <protein-id="P08684,Q6GRK0">CYP3A4</protein-id>-selective <compound-id="4192">midazolam</compound-id> 1'-hydroxylation (r = 0.59, p &lt; 0.01 at 75 microM <compound-id="4058">meperidine</compound-id>, and r = 0.55, p &lt; 0.01 at 350 microM <compound-id="4058">meperidine</compound-id>, n = 23).	meperidine__CYP3A4__no_interaction	meperidine__CYP2B6__no_interaction	mephenytoin__CYP3A4__no_interaction	mephenytoin__CYP2B6__no_interaction	midazolam__CYP3A4__no_interaction	midazolam__CYP2B6__no_interaction	normeperidine__CYP3A4__no_interaction	normeperidine__CYP2B6__no_interaction
15319333-7	No significant correlation was observed with <protein-id="P33261">CYP2C19</protein-id>-selective S-<compound-id="4060">mephenytoin</compound-id> 4'-hydroxylation (r = 0.36, p = 0.2 at 75 microM <compound-id="4058">meperidine</compound-id>, and r = 0.02, p = 0.9 at 350 microM <compound-id="4058">meperidine</compound-id>, n = 13).	meperidine__CYP2C19__no_interaction	mephenytoin__CYP2C19__no_interaction
19455266-1	ABT-869, <compound-id="17513">Acadesine</compound-id>, <compound-id="2244">Acetylsalicylic acid</compound-id>/<compound-id="4594">omeprazole</compound-id>, <compound-id="60172">Adefovir</compound-id>, <compound-id="60871">Adefovir dipivoxil</compound-id>, AEG-35156, Agatolimod <compound-id="5360545">sodium</compound-id>, Albiglutide, Alemtuzumab, Alipogene tiparvovec, <compound-id="11450633">Alogliptin benzoate</compound-id>, <compound-id="76935">AMG</compound-id>-386, <compound-id="3035016">Amrubicin</compound-id> hydrochloride, <compound-id="11561674">Apremilast</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, <compound-id="9577221">Asoprisnil</compound-id>, <compound-id="60823">Atorvastatin</compound-id>/<compound-id="3339">fenofibrate</compound-id>, <compound-id="56955939">AVN</compound-id>-944, <compound-id="6450551">Axitinib</compound-id>; <compound-id="6918638">Belinostat</compound-id>, Bevacizumab, BHT-3021, <compound-id="11364421">BI-2536</compound-id>, <compound-id="71340">Biapenem</compound-id>, <compound-id="185460">Bilastine</compound-id>, Biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, Blinatumomab, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>; Catumaxomab, CD-NP, <compound-id="9933475">Cediranib</compound-id>, Certolizumab pegol, Cetuximab, <compound-id="64929">Choline fenofibrate</compound-id>, <compound-id="6918155">Ciclesonide</compound-id>, <compound-id="11689883">CK-1827452</compound-id>,<compound-id="73115">Clevudine</compound-id>, <compound-id="119182">Clofarabine</compound-id>, CSL-360, <compound-id="11351021">CYT-997</compound-id>; <compound-id="9887712">Dapagliflozin</compound-id>, <compound-id="11683005">Darinaparsin</compound-id>, Denosumab, Densiron 68, <compound-id="124087">Desloratadine</compound-id>, Dulanermin; <compound-id="10280735">Edoxaban tosilate</compound-id>, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="153941">Entecavir</compound-id>, <compound-id="176870">Erlotinib hydrochloride</compound-id>, Everolimus, <compound-id="45588096,53396299,56927919">Exenatide</compound-id>, <compound-id="150311">Ezetimibe</compound-id>, <compound-id="9832423">Ezetimibe/simvastatin</compound-id>; Fidaxomicintiacumiv, <compound-id="104741">Fulvestrant</compound-id>; G-207, GCR-8015, <compound-id="123631">Gefitinib</compound-id>, <compound-id="44576256">Ghrelin</compound-id> (human), <compound-id="123628">Glufosfamide</compound-id>; HPV16L1E7CVLP; <compound-id="178024">Ibutamoren</compound-id> mesilate, <compound-id="5291">Imatinib mesylate</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine, <compound-id="807">Iodine</compound-id> (I131) tositumomab, <compound-id="9841834">Istaroxime</compound-id>, <compound-id="11285588,56841889,71717295">ITMN-191</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; <compound-id="44588310">JZP</compound-id>-4, <compound-id="216326">Lenalidomide</compound-id>; <compound-id="5284583">Levetiracetam</compound-id>, <compound-id="16158208">Linaclotide</compound-id> <compound-id="176">acetate</compound-id>, Liposomal <compound-id="6253">cytarabine</compound-id>/<compound-id="30323">daunorubicin</compound-id>, Liposomal <compound-id="31703">doxorubicin</compound-id>, Liraglutide, <compound-id="9909438">LY-518674</compound-id>; Milatuzumab, MMR-V, <compound-id="11667893">Motesanib</compound-id> diphosphate, <compound-id="4272">Mycophenolic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt; <compound-id="938">Niacin</compound-id>/<compound-id="54454">simvastatin</compound-id>; <compound-id="11404337,11244031,46930997,45356963,66751253">Obatoclax mesylate</compound-id>, <compound-id="10152654">Odanacatib</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>-eluting stent, <compound-id="65957">Pazufloxacin</compound-id>, PBT-2, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/<compound-id="37542">ribavirin</compound-id>, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, <compound-id="9924495">Perampanel</compound-id>, PfCP2.9, <compound-id="5282452">Pitavastatin</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, Poly I:CLC, <compound-id="134780">Pomalidomide</compound-id>, <compound-id="148121">Pralatrexate</compound-id>, <compound-id="16132446">Pramlintide acetate</compound-id>, <compound-id="3052762">Prucalopride</compound-id>; rhGAD65, <compound-id="449193">Roflumilast</compound-id>; RTS,S/AS02D; SCH-530348, <compound-id="9843750">Semagacestat</compound-id>, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting coronary stent, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-Eluting Stent, <compound-id="49800092,449592">SIR</compound-id>-Spheres, <compound-id="107706">Sivelestat</compound-id> <compound-id="14798">sodium hydrate</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="9868491">Tafluprost</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, <compound-id="16139605">Teduglutide</compound-id>, <compound-id="3010818">Telaprevir</compound-id>, <compound-id="159269">Telbivudine</compound-id>, <compound-id="5481350">Tenofovir disoproxil fumarate</compound-id>, <compound-id="15057856,3086655,49800038,5487427">Tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="24873435,66576988">TMC-435350</compound-id>, Tositumomab/<compound-id="807">iodine</compound-id> (I131) tositumomab, <compound-id="5282226">Travoprost</compound-id>/<compound-id="33624">timolol</compound-id>, <compound-id="43860">Triciribine phosphate</compound-id>; <compound-id="3081361">Vandetanib</compound-id>, VIA-2291, <compound-id="10629256,157688,6918295">Vinflunine</compound-id>, <compound-id="5311">Vorinostat</compound-id>; XL-019; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>.	Ciclesonide__insulin__no_interaction	Pralatrexate__insulin__no_interaction	Clevudine__insulin__no_interaction	SIR__insulin__no_interaction	Odanacatib__insulin__no_interaction	daunorubicin__insulin__no_interaction	Bilastine__insulin__no_interaction	Linaclotide__insulin__no_interaction	Levetiracetam__insulin__no_interaction	sodium__insulin__no_interaction	Sunitinib malate__insulin__no_interaction	Dapagliflozin__insulin__no_interaction	timolol__insulin__no_interaction	Desloratadine__insulin__no_interaction	Telaprevir__insulin__no_interaction	Vandetanib__insulin__no_interaction	simvastatin__insulin__no_interaction	Pitavastatin__insulin__no_interaction	Travoprost__insulin__no_interaction	Cediranib__insulin__no_interaction	Bosentan__insulin__no_interaction	Tadalafil__insulin__no_interaction	Pazufloxacin__insulin__no_interaction	Fulvestrant__insulin__no_interaction	Niacin__insulin__no_interaction	90Y__insulin__no_interaction	Tiotropium__insulin__no_interaction	ribavirin__insulin__no_interaction	Apremilast__insulin__no_interaction	Yttrium__insulin__no_interaction	Clofarabine__insulin__no_interaction	Emtricitabine__insulin__no_interaction	Gefitinib__insulin__no_interaction	Roflumilast__insulin__no_interaction	AMG__insulin__no_interaction	Ixabepilone__insulin__no_interaction	CYT-997__insulin__no_interaction	omeprazole__insulin__no_interaction	BI-2536__insulin__no_interaction	Triciribine phosphate__insulin__no_interaction	Sorafenib__insulin__no_interaction	Motesanib__insulin__no_interaction	Adefovir dipivoxil__insulin__no_interaction	Mycophenolic acid__insulin__no_interaction	LY-518674__insulin__no_interaction	TMC-435350__insulin__no_interaction	fenofibrate__insulin__no_interaction	AVN__insulin__no_interaction	Atorvastatin__insulin__no_interaction	Pomalidomide__insulin__no_interaction	Erlotinib hydrochloride__insulin__no_interaction	Teduglutide__insulin__no_interaction	Acetylsalicylic acid__insulin__no_interaction	Prucalopride__insulin__no_interaction	Adefovir__insulin__no_interaction	sodium hydrate__insulin__no_interaction	Pramlintide acetate__insulin__no_interaction	Darinaparsin__insulin__no_interaction	Telbivudine__insulin__no_interaction	ITMN-191__insulin__no_interaction	Ezetimibe__insulin__no_interaction	bromide__insulin__no_interaction	Tanespimycin__insulin__no_interaction	Imatinib mesylate__insulin__no_interaction	Semagacestat__insulin__no_interaction	Lenalidomide__insulin__no_interaction	Ezetimibe/simvastatin__insulin__no_interaction	Tafluprost__insulin__no_interaction	JZP__insulin__no_interaction	Sirolimus__insulin__no_interaction	Pemetrexed disodium__insulin__no_interaction	CK-1827452__insulin__no_interaction	calcium__insulin__no_interaction	Ghrelin__insulin__no_interaction	Obatoclax mesylate__insulin__no_interaction	Sivelestat__insulin__no_interaction	iodine__insulin__no_interaction	Acadesine__insulin__no_interaction	cytarabine__insulin__no_interaction	Vorinostat__insulin__no_interaction	acetate__insulin__no_interaction	Ibutamoren__insulin__no_interaction	Biapenem__insulin__no_interaction	Axitinib__insulin__no_interaction	Glufosfamide__insulin__no_interaction	Entecavir__insulin__no_interaction	Choline fenofibrate__insulin__no_interaction	Asoprisnil__insulin__no_interaction	Istaroxime__insulin__no_interaction	Alogliptin benzoate__insulin__no_interaction	doxorubicin__insulin__no_interaction	Paclitaxel__insulin__no_interaction	Tenofovir disoproxil fumarate__insulin__no_interaction	Perampanel__insulin__no_interaction	Aripiprazole__insulin__no_interaction	Amrubicin__insulin__no_interaction	Belinostat__insulin__no_interaction	Edoxaban tosilate__insulin__no_interaction	ibritumomab tiuxetan__insulin__no_interaction	Iodine__insulin__no_interaction	Vinflunine__insulin__no_interaction	Bortezomib__insulin__no_interaction	Exenatide__insulin__no_interaction
16678546-4	RESULTS: ERBT results were faster in women versus men (3.53% +/- 1.15% <compound-id="5462310">carbon</compound-id> 14 [14C] excreted/h versus 2.59% +/- 0.99% 14C excreted/h, respectively; <protein-id="Q9UNW9">ANOVA</protein-id>, P &lt; .002), faster in frail versus nonfrail patients (3.58% +/- 1.2% 14C excreted/h versus 2.81% +/- 1.06% (14)C excreted/h, respectively; <protein-id="Q9UNW9">ANOVA</protein-id>, P = .01), and faster in those receiving cytochrome P450 (CYP) <compound-id="2981881,91293124">3A</compound-id> inducers versus those without inducers (5.02% +/- 0.89% 14C excreted/h versus 3.02% +/- 1.08% 14C excreted/h, respectively; <protein-id="Q9UNW9">ANOVA</protein-id>, P = .0007).	carbon__ANOVA__no_interaction	3A__ANOVA__no_interaction
7685031-11	In this study, we demonstrated that 1) myocyte stretching maximally activated a kinase activity toward <protein-id="P02688,Q5XFW1,I7FKL4">myelin basic protein</protein-id> (<protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id>) at 10 min after stretching, and the kinase activity returned to the control level at 30 min after stretching; 2) kinase assays in <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id>-containing gel, after <compound-id="5360545">sodium</compound-id> <compound-id="8778">dodecyl sulfate</compound-id>-<compound-id="6579">polyacrylamide</compound-id> gel electrophoresis, revealed that stretch-induced <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id> kinase activity mainly migrated at 42 kDa in the immunoprecipitated fraction of anti-MAP kinase antibody, suggesting that the stretching mainly increased the 42-kDa MAP kinase activity in cardiac myocytes; 3) phosphorylation of MAP kinase was induced after stretching cardiac myocytes; 4) when protein kinase C was depleted by preincubating myocytes with 100 nM <compound-id="107854">12-O-tetradecanoyl-phorbol</compound-id>-13-<compound-id="176">acetate</compound-id> for 24 h or 2 nM <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> for 30 min, stretch-induced <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id> kinase activity was decreased by approximately 60-70% as compared with the kinase activity in myocytes without protein kinase C depletion; 5) although the receptor <compound-id="6057,90983769">tyrosine</compound-id> kinases were depleted by preincubating myocytes with 50 microM tyrphostin or 20 microM <compound-id="5280961">genistein</compound-id> for 30 min, there was no change in the stretch-induced <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id> kinase activity; 6) stretch-induced <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id> kinase activity was partially dependent on transsarcolemmal influx of Ca2+; 7) myocyte stretching also increased S6 peptide (RRLSSLRA) kinase activity in the anti-<protein-id="P67999">S6 kinase</protein-id> II antibody immunoprecipitates.	staurosporine__S6 kinase__no_interaction	staurosporine__MBP__no_interaction	staurosporine__myelin basic protein__no_interaction	sodium__S6 kinase__no_interaction	sodium__MBP__no_interaction	sodium__myelin basic protein__no_interaction	acetate__S6 kinase__no_interaction	acetate__MBP__no_interaction	acetate__myelin basic protein__no_interaction	genistein__S6 kinase__no_interaction	genistein__MBP__no_interaction	genistein__myelin basic protein__no_interaction	12-O-tetradecanoyl-phorbol__S6 kinase__no_interaction	12-O-tetradecanoyl-phorbol__MBP__no_interaction	12-O-tetradecanoyl-phorbol__myelin basic protein__no_interaction	dodecyl sulfate__S6 kinase__no_interaction	dodecyl sulfate__MBP__no_interaction	dodecyl sulfate__myelin basic protein__no_interaction	polyacrylamide__S6 kinase__no_interaction	polyacrylamide__MBP__no_interaction	polyacrylamide__myelin basic protein__no_interaction	tyrosine__S6 kinase__no_interaction	tyrosine__MBP__no_interaction	tyrosine__myelin basic protein__no_interaction
12856829-3	The following groups of cultured <protein-id="P29477">iNOS</protein-id> gene-knockout (<protein-id="P29477">iNOS</protein-id>-/-), and its respective wild-type (wt) mice myocytes subjected to simulated ischemia (SI) at 20 h were studied: (a) wt + SI: with ischemia alone; (b) <protein-id="P29477">iNOS</protein-id>-/- + SI: with ischemia alone; (c) <protein-id="P29477">iNOS</protein-id>-/- + heat shock (HS): <protein-id="P29477">iNOS</protein-id>-/- and HS; (d) <protein-id="P29477">iNOS</protein-id>-/- + sub-lethal simulated ischemia (SSI): <protein-id="P29477">iNOS</protein-id>-/- and SSI; (e) <protein-id="P29477">iNOS</protein-id>-/- + <protein-id="Q60612,Q8CAH1,Q6AXD8,Q3URG8,Q3UYG0">A1AR</protein-id> agonist <compound-id="123807">2-chloro-N6-cyclopentyladenosine</compound-id> (<compound-id="1547,23581816,23818609">CCPA</compound-id>): <protein-id="P29477">iNOS-/- and 1</protein-id> microM <compound-id="1547,23581816,23818609">CCPA</compound-id>; (f) <protein-id="P29477">iNOS</protein-id>-/- + <protein-id="Q60612,Q8CAH1,Q6AXD8,Q3URG8,Q3UYG0">A1AR</protein-id> agonist (2S)-N6-[2-endo-norbomyl]<compound-id="57476835,60961">adenosine</compound-id> (S-ENBA): <protein-id="P29477">iNOS-/- and 1</protein-id> nM S-ENBA; (g) <protein-id="P29477">iNOS</protein-id>-/- + K(<compound-id="5957">ATP</compound-id>) channel opener <compound-id="4826">pinacidil</compound-id> (Pin): <protein-id="P29477">iNOS-/- and 0</protein-id>.05 microM Pin, and (h) <protein-id="P29477">iNOS</protein-id>-/- + mitochondrial K(<compound-id="5957">ATP</compound-id>) channel opener <compound-id="3019">diazoxide</compound-id> (Diazo): <protein-id="P29477">iNOS</protein-id>-/- and 100 microM Diazo.	2-chloro-N6-cyclopentyladenosine__iNOS-/- and 1__no_interaction	2-chloro-N6-cyclopentyladenosine__iNOS-/- and 0__no_interaction	2-chloro-N6-cyclopentyladenosine__A1AR__no_interaction	2-chloro-N6-cyclopentyladenosine__iNOS__no_interaction	diazoxide__iNOS-/- and 1__no_interaction	diazoxide__iNOS-/- and 0__no_interaction	diazoxide__A1AR__no_interaction	diazoxide__iNOS__no_interaction	CCPA__iNOS-/- and 1__no_interaction	CCPA__iNOS-/- and 0__no_interaction	CCPA__A1AR__no_interaction	CCPA__iNOS__no_interaction	ATP__iNOS-/- and 1__no_interaction	ATP__iNOS-/- and 0__no_interaction	ATP__A1AR__no_interaction	ATP__iNOS__no_interaction	adenosine__iNOS-/- and 1__no_interaction	adenosine__iNOS-/- and 0__no_interaction	adenosine__A1AR__no_interaction	adenosine__iNOS__no_interaction	pinacidil__iNOS-/- and 1__no_interaction	pinacidil__iNOS-/- and 0__no_interaction	pinacidil__A1AR__no_interaction	pinacidil__iNOS__no_interaction
12856829-5	The cellular resistance was acquired by <protein-id="P29477">iNOS</protein-id>-/- mice myocytes due to HS, SSI, <compound-id="1547,23581816,23818609">CCPA</compound-id>, S-ENBA, <compound-id="4826">pinacidil</compound-id> and <compound-id="3019">diazoxide</compound-id> treatment, which was evidenced by reduction of LDH (U/L) release from 51.14 +/- 1.35 (<protein-id="P29477">iNOS</protein-id>-/-) to 42.20 +/- 1.01 (<protein-id="P29477">iNOS</protein-id>-/- + HS); 45.57 +/- 0.75 (<protein-id="P29477">iNOS</protein-id>-/- + SSI); 42.87 +/- 0.87 (<protein-id="P29477">iNOS</protein-id>-/- + <compound-id="1547,23581816,23818609">CCPA</compound-id>); 43.21 +/- 0.70 (<protein-id="P29477">iNOS</protein-id>-/- + S-ENBA); 37.81 +/- 0.99 (<protein-id="P29477">iNOS</protein-id>-/- + Pin) and 36.79 +/- 0.68 (<protein-id="P29477">iNOS</protein-id>-/- + Diazo), p &lt; 0.01.	pinacidil__iNOS__no_interaction	diazoxide__iNOS__no_interaction	CCPA__iNOS__no_interaction
8883421-10	The following observations may be drawn from data analysis: (1) plasma <compound-id="10313259,943">nitrate</compound-id> + <compound-id="946">nitrite</compound-id> significantly raised during treatment (P = 0.0226 for t0 vs <compound-id="5920">t3</compound-id>), but statistical significance was retained only when cycles administered with <protein-id="P60568,Q0GK43">IL-2</protein-id> 18 MIU m-2 day-1 are considered (P = 0.0329 for t0 vs <compound-id="5920">t3</compound-id>; P = 0.0354 for t0 vs t2 vs t4) (dose-dependent pattern); (2) during subsequent cycles a significant trend toward a progressive increase of plasma <compound-id="10313259,943">nitrate</compound-id> + <compound-id="946">nitrite</compound-id> levels, with increasing cumulative dose of <protein-id="P60568,Q0GK43">IL-2</protein-id>, was observed (linear regression coefficient r = 0.62, P = 0.0141 for t0; r = 0.80, P = 0.0003 for t1; r = 0.62, P = 0.013 for t2; r = 0.69, P = 0.045 for <compound-id="5920">t3</compound-id>); (3) plasma <compound-id="10313259,943">nitrate</compound-id> + <compound-id="946">nitrite</compound-id> levels peaked earlier in subsequent cycles than in the first cycle; (4) all patients experienced hypotension.	nitrate__IL-2__no_interaction	nitrite__IL-2__no_interaction	t3__IL-2__no_interaction
15692314-8	Partial correlation analyses adjusted for visceral AT showed that EE6-9 was significantly associated with systolic blood pressure (r = -0.22, P &lt; 0.05), plasma concentrations of HDL-<compound-id="5997">cholesterol</compound-id> (chol) (r = 0.23, P &lt; 0.05), <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id>-chol (r = 0.22, P &lt; 0.05), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.24, P &lt; 0.05), and fasting C-peptide (r = -0.24, P = or &lt;0.05).	glucose__HDL2__no_interaction	cholesterol__HDL2__no_interaction
1481882-3	Four weeks post-ablation, renal blood flow (RBF), was significantly higher in rats fed a standard protein (SP) diet (n = 16) compared with low-protein-fed (LP) rats (n = 7) (6.2 +/- 0.6 vs. 3.7 +/- 0.5 ml/min; P &lt; 0.01), autoregulation was impaired in SP rats [autoregulation index (<compound-id="15942654">AI</compound-id>) 1.0 +/- 0.1 (SP) vs. 0.2 +/- 0.1 (LP); P &lt; 0.05], and <protein-id="P08424">renin</protein-id> secretory rates were significantly increased in SP rats both during the basal state [24 +/- 7 (SP) vs. 2 +/- 1 (LP) ng.ml-1 x h-1 x min-1; P &lt; 0.05] and after reduction in renal perfusion pressure [110 +/- 29 (SP) vs. 16 +/- 7 (LP); P &lt; 0.05].	AI__renin__no_interaction
20435455-5	Compared to the CO group, the following was observed: only the βI group showed a decrease in the mean number of visible hepatocyte nodules (P&lt;.05); βI and GOH groups had reduced mean number of persistent preneoplastic lesions (pPNLs) (P&lt;.05), but no differences regarding number of remodeling PNL (rPNLs) were observed; only the βI group exhibited smaller rPNL size and percentage of liver sections occupied by pPNLs (P&lt;.05), whereas the GOH group displayed a smaller percentage of liver sections occupied by rPNLs (P&lt;.05); a trend was observed in the βI group, which showed reduced cell proliferation of pPNLs (P&lt;.10), and the GOH group had increased apoptosis in pPNLs and rPNLs (P&lt;.05); only the βI group displayed reduced total plasma <compound-id="5997">cholesterol</compound-id> concentrations (P&lt;.05) and increased hepatic <compound-id="15983954">3-hydroxy-3-methylglutaryl coenzyme A</compound-id> (<protein-id="P51639">HMGCoA) reductase</protein-id> mRNA levels (P&lt;.05); only the GOH group had lower hepatic membrane RhoA protein levels (P&lt;.05); both the βI- and GOH-treated groups had higher hepatic concentrations of βI and GOH, respectively (P&lt;.05).	3-hydroxy-3-methylglutaryl coenzyme A__HMGCoA) reductase__no_interaction	cholesterol__HMGCoA) reductase__no_interaction
14567379-3	The skin diseases known at that time are studied under the following topics: Cüderi (Ciçek, Variola, Small-pox); Hasbe (Kizamik, Rubeola, Measles); Cüzzam (Lepra, Leprosy, Hansen's disease); Demregü (Temriye, Dermatophtosis, Tinea corporis); Behak (There are two types: the white and the black; the black is Addison's disease); Baras (Ala, Vitilio); Nemle (Isirga, <protein-id="P20794,F8VBW7">Mak</protein-id>ül); Ateş paresi (Nar-l farisi, frunculosis); Cemre (Kara kabarcik, Sirpençe, Karbonkül, Carbuncle); Caversiye (Kabarcik hastaliği, blisters disease); Sivilceler (Various types of pimples; Humre: Yilancik, Erizipel, Erysipelas, St. Anthony's fire; Başbert: Ciban, Fronkül, Boil, Fruncle; Dümmel: <compound-id="6032">Kan</compound-id> çibani, Abse, Abscess); Abile (Kabarcik, Bule); Seretan (kanser, Cancer); Hanazir (Siraca, Scrofuloderma); Akile (Yinürbaş, Gangren); Kurdeşen (Urtiker, Urticeria); Uyuz (Gale, Scabies); Giciyik (Kaşinti, Pruritus); Sa'fe (Konak, Seboreik dermatit, Scurf); <protein-id="P23276,A0A077QP03">Kel</protein-id> (Alopesi, Favus); Evram (Sişler, Urlar, Tumours); Yara (Karha, Cerahat, Wound).	Kan__Mak__no_interaction	Kan__Kel__no_interaction
1885239-4	Using an uncoated adsorbent charcoal cartridge, we "regenerated" the UF obtained in PFD, eliminating the small (except for <compound-id="1176">urea</compound-id>, which was later eliminated by diffusion in the dialyzing section of the PFD system) and the medium-to-large molecules (vit <protein-id="O43676,A0A024R413">B12</protein-id> and <protein-id="P02144">myoglobin</protein-id> in vitro and <protein-id="P61769,H0YL18">beta-2-microglobulin</protein-id> (<protein-id="P61769,H0YL18">B2m</protein-id>) and (hANP) in vivo), but not the electrolytes and the endogenous bicarbonate, so as to verify its possible use as R. This technique, experimentally performed in 12 patients under HDF treatment with standard PFD, with a total mean UF of 9650 +/- 875 ml and the use of 130 g of uncoated charcoal, produced a solution with the following composition: Na+ 135.4 +/- 2.4 mmol/l, K+ 3.4 +/- 1.23 mmol/l, Ca++ 1.18 +/- 0.14 mmol/l, HCO3- 26.7 +/- 2.3 mmol/l, phosphates 2.88 +/- 0.81 mg/dl, <compound-id="1176">urea</compound-id> 63 +/- 14 mg/dl, <compound-id="588">creatinine</compound-id> 0.08 +/- 0.02 mg/dl, <compound-id="1175">uric acid</compound-id> 0.05 +/- 0.0 mg/dl, <protein-id="P61769,H0YL18">beta-2 microglobulin</protein-id> 0.5 +/- 0.5 mg/l, and hANP 4.15 +/- 5 pg/l.	creatinine__beta-2-microglobulin__no_interaction	creatinine__B2m__no_interaction	creatinine__beta-2 microglobulin__no_interaction	creatinine__B12__no_interaction	creatinine__myoglobin__no_interaction	urea__beta-2-microglobulin__no_interaction	urea__B2m__no_interaction	urea__beta-2 microglobulin__no_interaction	urea__B12__no_interaction	urea__myoglobin__no_interaction	uric acid__beta-2-microglobulin__no_interaction	uric acid__B2m__no_interaction	uric acid__beta-2 microglobulin__no_interaction	uric acid__B12__no_interaction	uric acid__myoglobin__no_interaction
17890245-6	Monthly mean outdoor temperature was inversely correlated with serum concentrations of <compound-id="5360545">sodium</compound-id> (r = -0.712, P &lt; 0.001), <compound-id="5462222">potassium</compound-id> (r = -0.697, P &lt; 0.001), <compound-id="767">bicarbonate</compound-id> (r = -0.642, P &lt; 0.001), BUN (r = -0.654, P &lt; 0.001), <protein-id="P02768">albumin</protein-id> (r = -0.496, P = 0.012), peritoneal ultrafiltration volume (r = -0.723, P = 0.001) and body weight (r = -0.623, P &lt; 0.001).	potassium__albumin__no_interaction	bicarbonate__albumin__no_interaction	sodium__albumin__no_interaction
25272490-7	According to the PCA results, the comprehensive scores of <compound-id="323">coumarin</compound-id> and volatile compounds in Angelica Dahuricae Radix herbs processed with different methods in the order from high to low were that unpeeled and dried by <compound-id="14778">quicklime</compound-id> embedding &gt; unpeeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 100 degrees C &gt; unpeeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 40 degrees C &gt; peeled and infrared-dried &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 60 degrees C &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 40 degrees C &gt; peeled and sun-dried &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 60 degrees C &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 100 degrees C &gt; peeled and microwave-dried &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 80 degrees C &gt; unpeeled and sun-dried &gt; unpeeled and dried with <compound-id="402">sulfur</compound-id>-fumigation &gt; peeled and dried with <compound-id="402">sulfur</compound-id>-fumigation &gt; unpeeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 120 degrees C &gt; unpeeled and freeze-dried &gt; unpeeled and infrared-dried &gt; peeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 120 degrees C &gt; peeled and freeze-dried &gt; peeled and dried by <compound-id="14778">quicklime</compound-id> embedding &gt; unpeeled and dried with <protein-id="Q8IWW8">hot</protein-id>-air at 80 degrees C &gt; peeled and shade-dried &gt; unpeeled and shade-dried &gt; unpeeled and microwave-dried.	coumarin__hot__no_interaction	sulfur__hot__no_interaction	quicklime__hot__no_interaction
21459966-8	When <compound-id="71588332">INCB9471</compound-id> was compared with three <protein-id="P51681,Q38L21">CCR5</protein-id> antagonists that had been tested in clinical trials, the potency of <compound-id="71588332">INCB9471</compound-id> in blocking <protein-id="P51681,Q38L21">CCR5</protein-id> ligand binding was similar to those of 4,6-dimethyl-5-{[4-methyl-4-((<compound-id="21439199">3S</compound-id>)-3-methyl-4-{(<compound-id="71560296">1R0</compound-id>-2-(<compound-id="123146">methyloxy</compound-id>)-1-[4-(<compound-id="6373">trifluoromethyl</compound-id>) phenyl]<compound-id="23134249">ethyl</compound-id>}-1-piperazingyl)-1-piperidinyl]carbonyl}pyrimidine (<compound-id="3009355">SCH-D</compound-id>; vicriviroc), 4-{[4-({(3R)-1-<compound-id="68006705">butyl</compound-id>-3-[(R)-cyclohexyl(hydroxyl)methyl]-2, 5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenyl]oxy}benzoic acid hydrochloride (873140; <compound-id="3001322">aplaviroc</compound-id>), and 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-<compound-id="275736">methylethyl</compound-id>)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenylpropyl)<compound-id="14283">cyclohexanecarboxamide</compound-id> (UK427857; <compound-id="3002977">maraviroc</compound-id>).	cyclohexanecarboxamide__CCR5__no_interaction	3S__CCR5__no_interaction	1R0__CCR5__no_interaction	INCB9471__CCR5__no_interaction	butyl__CCR5__no_interaction	methylethyl__CCR5__no_interaction	maraviroc__CCR5__no_interaction	methyloxy__CCR5__no_interaction	trifluoromethyl__CCR5__no_interaction	SCH-D__CCR5__no_interaction	aplaviroc__CCR5__no_interaction	ethyl__CCR5__no_interaction
15674846-6	Four types of effects were observed: (1) treatment with beta-carotene alone either reversed (cardiac <compound-id="65359">glutathione disulfide</compound-id>) or elevated (cardiac <compound-id="20725278">glutathione</compound-id>, hepatic <compound-id="20725278">glutathione</compound-id> peroxidase activity) levels seen in diabetic animals; (2) beta-carotene alone produced no effect, but pycnogenol both alone and in combinations elevated (renal <compound-id="20725278">glutathione</compound-id> peroxidase and <protein-id="F1LRE1">glutathione reductase</protein-id> activities, hepatic <protein-id="F1LRE1">glutathione reductase</protein-id> activity and <compound-id="65359">glutathione disulfide</compound-id>) or depressed (cardiac <compound-id="65359">glutathione disulfide</compound-id>) levels seen in untreated diabetic animals; (3) all treatments with antioxidants, either alone or in combination, either normalized (lipid peroxidation in all tissues), elevated (hepatic <compound-id="124886">GSH</compound-id>, cardiac <compound-id="20725278">glutathione</compound-id> peroxidase activity), or had no effect on (activities of hepatic catalase and <compound-id="5359597">superoxide</compound-id> dismutase in all tissues) levels seen in diabetic animals; (4) in only one case (cardiac <protein-id="F1LRE1">glutathione reductase</protein-id> activity) levels in diabetic animals treated with combinations of antioxidants were normal, but elevated in animals treated with either antioxidant alone.	GSH__glutathione reductase__no_interaction	glutathione__glutathione reductase__no_interaction	glutathione disulfide__glutathione reductase__no_interaction	superoxide__glutathione reductase__no_interaction
6630222-3	The following <compound-id="107918">2-5A</compound-id> isomers thus were prepared: <protein-id="P53041,A0A024R0Q7">ppp5</protein-id>'A2'p5'A3'p5'A, <protein-id="P53041,A0A024R0Q7">ppp5</protein-id>'A3'p5'A2'p5'A, <protein-id="P53041,A0A024R0Q7">ppp5</protein-id>'A3'p5'A3'p5'A("3-5A"), <protein-id="P53041,A0A024R0Q7">ppp5</protein-id>'A2'p5'A3'p5'A2'p5'A,and <protein-id="P53041,A0A024R0Q7">ppp5</protein-id>'A3'p5'A2'p5'-A2'p5'A.	2-5A__ppp5__no_interaction
9333133-6	Highly significant correlations were present between bone formation measured by <compound-id="22044544,5460341">calcium</compound-id> kinetics (Vo+) and serum levels of bone biochemical markers (OC, r = 0.82, p = 0.001; <protein-id="P05187,B2R7C7">ALP</protein-id>, r = 0.92, p = 0.001; and BAP, r = 0.90, p = 0.001) and between bone resorption measured by <compound-id="22044544,5460341">calcium</compound-id> kinetics (Vo-) and fasting serum levels and urine <compound-id="588">creatinine</compound-id> ratios of biochemical markers (TRAP, r = 0.77, p &lt; 0.001; OHP/Cr, r = 0.79, p &lt; 0.001; and NTx/Cr, r = 0.70, p &lt; 0.001).	calcium__ALP__no_interaction	creatinine__ALP__no_interaction
21309732-5	A significant correlation between the studied parameters and combined null <protein-id="P09488,X5D932,X5DR03">GSTM1</protein-id>/null <protein-id="P30711,A0A0G2JRN4,Q4W251,A0A0G2JRQ5,Q4GZS9">GSTT1</protein-id> (<compound-id="124886">GSH</compound-id>-px: P &lt; .001, GR: P = .026, CAT: P = .018, GST: P = .022, TAS: P = .046), His113His <protein-id="P07099,R4SBI6">EPHX1</protein-id>/null <protein-id="P09488,X5D932,X5DR03">GSTM1</protein-id> (<compound-id="124886">GSH</compound-id>-px: P = .001, GST: P = .0012, TAS: P = .013), His113His <protein-id="P07099,R4SBI6">EPHX1</protein-id>/Val105Val <protein-id="P09211,V9HWE9">GSTP1</protein-id> (<compound-id="124886">GSH</compound-id>-px: P = .048, CAT: P = .026, GST: P = .031), and null <protein-id="P09488,X5D932,X5DR03">GSTM1</protein-id>/Val105Val <protein-id="P09211,V9HWE9">GSTP1</protein-id> (<compound-id="124886">GSH</compound-id>-px: P = .011, GR: P = .0028, GST: P = .0054, TAS: P = .032) was found in patients.	GSH__GSTM1__no_interaction	GSH__GSTP1__no_interaction	GSH__GSTT1__no_interaction	GSH__EPHX1__no_interaction
15578855-1	<protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">Spin</protein-id>-frustrated polyoxometalates, K(11)H[(VO)(3)(<compound-id="72193922">SbW</compound-id>(9)O(33))(2)].27H(2)O (1) and K(12)[(VO)(3)(<compound-id="10435195">BiW</compound-id>(9)O(33))(2)].<compound-id="12132313">29H</compound-id>(2)O (2), containing approximately equilateral and isosceles (VO)(3)(6+)-triangles (V(IV)...V(IV) separation of 5.4-5.5 A) sandwiched by two diamagnetic alpha-B nonatungstate ligands ([<compound-id="72193922">SbW</compound-id>(9)O(33)](9)(-) and [<compound-id="10435195">BiW</compound-id>(9)O(33)](9)(-)) with approximate D(3)(h) symmetry, are found to show magnetization jumps with distinct hysteresis for the S = (1)/(2) &lt;--&gt; S = (3)/(2) level crossing under fast sweeping pulsed magnetic fields (approximately 10(3) T/s) at T &lt; or = 0.5 K. This unusual phenomenon is attributed to the theoretical prediction of half step magnetization, which is expected for an antiferromagnetic <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">Spin</protein-id> triangle with antisymmetrical Dzyaloshinky-Moriya interaction.	BiW__Spin__no_interaction	SbW__Spin__no_interaction	29H__Spin__no_interaction
23613693-4	RESULTS: Plasma CNP and <compound-id="586">creatine</compound-id> kinase myoglobin band (CK-MB) concentrations were significantly increased in the SPT (+) group relative to the SPT (-) group (CNP, 5.268±1.800 pg/mL vs. 3.342±1.150 pg/mL, p=0.002; CK-MB, 2.54±1.03 ng/dL vs. 1.86±0.96 ng/dL, p=0.019, respectively) while plasma high sensitivity C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT pro-<protein-id="P16860">BNP</protein-id>) concentrations were not significantly different between the SPT (-) group and SPT (+) group (hs-CRP, 2.76±4.99 mg/L vs. 3.13±4.88 mg/L, p=0.789; NT pro-<protein-id="P16860">BNP</protein-id>, 49±47 pg/mL vs. 57±63 pg/mL, p=0.818, respectively).	creatine__BNP__no_interaction
12582218-5	RESULTS: Pearson's correlation coefficients indicated a significant association between NC and body mass index (men, r = 0.71; women, r = 0.81; each, p &lt; 0.0001), waist circumference (men, r = 0.75; women, r = 0.79; each, p &lt; 0.0001), waist-to-<protein-id="Q06141,Q53S56">hip</protein-id> ratio (men, r = 0.56; women, r = 0.63; each, p &lt; 0.0001), total <compound-id="5997">cholesterol</compound-id> (men, r = 0.50; women, r = 0.66; each, p &lt; 0.0001), low-density lipoprotein-<compound-id="5997">cholesterol</compound-id> (men, r = 0.42; women, r = 0.60; each, p &lt; 0.0001), triglycerides (men, r = 0.48; women, r = 0.49; each, p &lt; 0.0001), <compound-id="206,5793,64689,79025">glucose</compound-id> (men, r = 0.21, p &lt; 0.001; women, r = 0.44; p &lt; 0.0001), <compound-id="1175">uric acid</compound-id> (men, r = 0.50, p &lt; 0.0001; women, r = 0.60, p &lt; 0.001), and systolic (men, r = 0.53; women, r = 0.69; each, p &lt; 0.0001), and diastolic (men, r = 0.55; women, r = 0.65; each, p &lt; 0.0001) blood pressure.	glucose__hip__no_interaction	uric acid__hip__no_interaction	cholesterol__hip__no_interaction
16954476-8	Stabilization of cyclin D1 protein by <compound-id="387447">bortezomib</compound-id> treatment further amplified the cyclin D1-dependent repression of <protein-id="P40763">STAT3</protein-id> in vitro and slowed tumor growth in vivo (week 7: untreated mean = 185.7 mm3 versus treated mean = 136.2 mm3, difference = 49.5 mm3, 95% confidence interval [CI] = 18 to 81 mm3, P = .007; week 8: untreated mean = 240.2 mm3 versus treated mean = 157.3 mm3, difference = 82.9 mm3, 95% CI = 9.1 to 156.7 mm3, P = .0014; and week 9: untreated mean = 256.4 mm3 versus treated mean = 170.2 mm3, difference = 86.2 mm3, 95% CI = 22.8 to 149.6 mm3, P = .006) and increased apoptosis (untreated mean = 19% versus treated mean = 54%, difference = 35%, 95% CI = 24.7% to 45.4%; P = .013) of xenograft tumors.	bortezomib__STAT3__no_interaction
19426539-7	<compound-id="107873">8-isoprostane</compound-id> correlated with 10 year cardiac risk (r = 0.55, p &lt; 0.001), VCAM with <compound-id="447041">IMT</compound-id> (r = 0.37, p = 0.012) and <protein-id="P16581">E-selectin</protein-id> with rheumatoid factor titre (r = 0.43, p = 0.003) in RA patients.	IMT__E-selectin__no_interaction	8-isoprostane__E-selectin__no_interaction
11882914-6	The <protein-id="P14600">NK1 receptor</protein-id> antagonist <compound-id="108167">SR 140333</compound-id> (10(-7) M), the <protein-id="P16610">NK2 receptor</protein-id> antagonist <compound-id="104974">SR 48968</compound-id> (10(-6) M), the <protein-id="P16177">NK3 receptor</protein-id> antagonist <compound-id="219077">SR 142801</compound-id> (10(-7) M), <compound-id="174174">atropine</compound-id> (10(-6) M), <compound-id="3604">hexamethonium</compound-id> (10(-4) M), <compound-id="5775">phentolamine</compound-id> (10(-6) M) plus propranolol (10(-6) M), N(G)-nitro- <compound-id="550788">L-arginine methyl ester</compound-id> ( <compound-id="39836">L-NAME</compound-id> 3 x 10(-4) M), <compound-id="16129677,16218850,56928162,57043712">apamin</compound-id> (10(-7) M), <compound-id="9681">methysergide</compound-id> (10(-6) M), the <protein-id="P01256,P01257,A0A0G2JSX2">calcitonin gene-related peptide</protein-id> (<protein-id="P01256,P01257,A0A0G2JSX2">CGRP</protein-id>) antagonist hCGRP 8-37 (1.5 x 10(-6) M), the <protein-id="P01283,A0A090BZQ0,B0BNF3">VIP</protein-id> antagonist hGRF 1-29 (10(-5) M) did not modify the inhibitory effect of <compound-id="2733484">capsazepine</compound-id>.	SR 48968__NK3 receptor__no_interaction	SR 48968__calcitonin gene-related peptide__no_interaction	SR 48968__VIP__no_interaction	SR 48968__NK1 receptor__no_interaction	SR 48968__CGRP__no_interaction	SR 48968__NK2 receptor__no_interaction	hexamethonium__NK3 receptor__no_interaction	hexamethonium__calcitonin gene-related peptide__no_interaction	hexamethonium__VIP__no_interaction	hexamethonium__NK1 receptor__no_interaction	hexamethonium__CGRP__no_interaction	hexamethonium__NK2 receptor__no_interaction	phentolamine__NK3 receptor__no_interaction	phentolamine__calcitonin gene-related peptide__no_interaction	phentolamine__VIP__no_interaction	phentolamine__NK1 receptor__no_interaction	phentolamine__CGRP__no_interaction	phentolamine__NK2 receptor__no_interaction	L-arginine methyl ester__NK3 receptor__no_interaction	L-arginine methyl ester__calcitonin gene-related peptide__no_interaction	L-arginine methyl ester__VIP__no_interaction	L-arginine methyl ester__NK1 receptor__no_interaction	L-arginine methyl ester__CGRP__no_interaction	L-arginine methyl ester__NK2 receptor__no_interaction	SR 142801__NK3 receptor__no_interaction	SR 142801__calcitonin gene-related peptide__no_interaction	SR 142801__VIP__no_interaction	SR 142801__NK1 receptor__no_interaction	SR 142801__CGRP__no_interaction	SR 142801__NK2 receptor__no_interaction	capsazepine__NK3 receptor__no_interaction	capsazepine__calcitonin gene-related peptide__no_interaction	capsazepine__VIP__no_interaction	capsazepine__NK1 receptor__no_interaction	capsazepine__CGRP__no_interaction	capsazepine__NK2 receptor__no_interaction	atropine__NK3 receptor__no_interaction	atropine__calcitonin gene-related peptide__no_interaction	atropine__VIP__no_interaction	atropine__NK1 receptor__no_interaction	atropine__CGRP__no_interaction	atropine__NK2 receptor__no_interaction	SR 140333__NK3 receptor__no_interaction	SR 140333__calcitonin gene-related peptide__no_interaction	SR 140333__VIP__no_interaction	SR 140333__NK1 receptor__no_interaction	SR 140333__CGRP__no_interaction	SR 140333__NK2 receptor__no_interaction	L-NAME__NK3 receptor__no_interaction	L-NAME__calcitonin gene-related peptide__no_interaction	L-NAME__VIP__no_interaction	L-NAME__NK1 receptor__no_interaction	L-NAME__CGRP__no_interaction	L-NAME__NK2 receptor__no_interaction	apamin__NK3 receptor__no_interaction	apamin__calcitonin gene-related peptide__no_interaction	apamin__VIP__no_interaction	apamin__NK1 receptor__no_interaction	apamin__CGRP__no_interaction	apamin__NK2 receptor__no_interaction	methysergide__NK3 receptor__no_interaction	methysergide__calcitonin gene-related peptide__no_interaction	methysergide__VIP__no_interaction	methysergide__NK1 receptor__no_interaction	methysergide__CGRP__no_interaction	methysergide__NK2 receptor__no_interaction
9164359-4	RESULTS: For PHA-stimulated PBMNCs in the <compound-id="439501">ouabain</compound-id>-treated group (n = 10 subjects), the mean (+/-STD) % uptake (% 3H thymidine uptake in absence of <compound-id="439501">ouabain</compound-id>) was 80.5 +/- 6.0 at 10(-12) M <compound-id="439501">ouabain</compound-id>, 73.1 +/- 8.4 at 10(-10) M, 47.89 +/- 13.1 at 10(-8) M, 6.9 +/- 3.2 at 10(-6) M, and 3.4 +/- 1.6 at 10(-4) M. For PHA-stimulated cells in the <compound-id="2724385">digoxin</compound-id>-treated group (n = 9 subjects), the mean (+/-STD) % uptake (% 3H thymidine uptake in absence of <compound-id="2724385">digoxin</compound-id>) was 89.8 +/- 9.8 at 10(-9) M <compound-id="2724385">digoxin</compound-id>, 92.6 +/- 8.2 at 10(-8) M, 54.3 +/- 19.8 at 10(-7) M, and 1.0 +/- 2.4 at 10(-6) M. Repeated measures <protein-id="Q9UNW9">ANOVA</protein-id> demonstrated a significant effect of concentration of both glycosides on PBMNC proliferation (P &lt; .01).	digoxin__ANOVA__no_interaction	ouabain__ANOVA__no_interaction
16966829-6	In univariate linear regression analysis, serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were positively correlated with serum <compound-id="588">creatinine</compound-id> (r = 0.648, P&lt;0.0001), urinary albumin (r = 0.583, P&lt;0.0001), urinary <protein-id="P54802">NAG</protein-id> (r = 0.406, P&lt;0.01), urinary <protein-id="P13500">MCP-1</protein-id> (r = 0.514, P&lt;0.0001), and urinary <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (r = 0.691, P&lt;0.0001) levels in all diabetic patients.	creatinine__MCP-1__no_interaction	creatinine__NAG__no_interaction	creatinine__adiponectin__no_interaction
16966829-7	Urinary <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were also positively correlated with serum <compound-id="588">creatinine</compound-id> (r = 0.729, P&lt;0.0001), urinary albumin (r = 0.799, P&lt;0.0001), urinary <protein-id="P54802">NAG</protein-id> (r = 0.701, P&lt;0.0001), and urinary <protein-id="P13500">MCP-1</protein-id> (r = 0.801, P&lt;0.0001) levels in all diabetic patients.	creatinine__MCP-1__no_interaction	creatinine__NAG__no_interaction	creatinine__adiponectin__no_interaction
21426695-6	RESULT: Compared to ordinary diet group, the rat's liver weight (g) (16.92 ± 2.49 vs. 12.16 ± 0.82), hepatic exponent (0.034 ± 0.004 vs. 0.026 ± 0.002), serum <compound-id="5950,602">alanine</compound-id> aminotransferase (U/L) (45.43 ± 9.73 vs. 29.42 ± 6.73), triglyceride (mmol/L) (1.22 ± 0.24 vs. 0.85 ± 0.19), <compound-id="5997">cholesterol</compound-id> (mmol/L) (2.00 ± 0.37 vs. 1.49 ± 0.33), lipoprotein(a) (mmol/L) (743.86 ± 32.19 vs. 648.42 ± 78.87), low-density lipoprotein (mmol/L) (1.31 ± 0.35 vs. 0.65 ± 0.22), insulin (mmol/L) (22.16 ± 5.16 vs. 16.86 ± 5.35), insulin resistance index(5.10 ± 1.45 vs. 3.59 ± 0.99), free fatty acid (mEq/L) (0.57 ± 0.10 vs. 0.35 ± 0.07), <protein-id="P14423">sPLA2</protein-id> [µmol/(min·ml)] (0.130 ± 0.016 vs. 0.098 ± 0.024), <compound-id="5311265">lysophosphatidylcholine</compound-id> (µmol/L) (707.26 ± 92.48 vs. 508.87 ± 96.50), <protein-id="P50596">leptin</protein-id> (pg/ml (80.08 ± 17.73 vs. 65.11 ± 14.09), liver triglyceride (mg/g) (13.57 ± 0.65 vs. 12.03 ± 1.14), <compound-id="5997">cholesterol</compound-id> (mg/g) (2.19 ± 0.15 vs. 1.94 ± 0.12) (P &lt; 0.05) were significantly increased in high-fat diet group.	lysophosphatidylcholine__leptin__no_interaction	lysophosphatidylcholine__sPLA2__no_interaction	alanine__leptin__no_interaction	alanine__sPLA2__no_interaction	cholesterol__leptin__no_interaction	cholesterol__sPLA2__no_interaction
21426695-8	Secondly, in comparison with high-fat diet group, early <compound-id="4091">metformin</compound-id> treatment significantly reduced the rat's body weight (g) (394.40 ± 33.10 vs. 491.86 ± 26.45), liver weight (g) (13.24 ± 1.16 vs. 16.92 ± 2.49), serum <compound-id="5950,602">alanine</compound-id> aminotransferase (U/L) (30.40 ± 4.50 vs. 45.43 ± 9.73), triglyceride (mmol/L) (0.75 ± 0.19 vs. 1.22 ± 0.24), <compound-id="5997">cholesterol</compound-id> (mmol/L) (1.61 ± 0.38 vs. 2.00 ± 0.37), insulin (mmol/L) (16.96 ± 5.60 vs. 22.16 ± 5.16), insulin resistance index (3.75 ± 1.41 vs. 5.10 ± 1.45), <protein-id="P14423">sPLA2</protein-id> [µmol/(min·ml)] (0.101 ± 0.009 vs. 0.130 ± 0.016), <compound-id="5311265">lysophosphatidylcholine</compound-id> (µmol/L) (549.92 ± 90.78 vs. 707.26 ± 92.48), liver triglyceride (mg/g) (11.23 ± 1.70 vs. 13.57 ± 0.65), <compound-id="5997">cholesterol</compound-id> (mg/g) (1.97 ± 0.20 vs. 2.19 ± 0.15) (P &lt; 0.05).	lysophosphatidylcholine__sPLA2__no_interaction	alanine__sPLA2__no_interaction	metformin__sPLA2__no_interaction	cholesterol__sPLA2__no_interaction
19809735-1	Homoleptic group 10 complexes of ditellurido <protein-id="P00491,V9HWH6">PNP</protein-id> (<protein-id="P00491,V9HWH6">PNP</protein-id> = imidodiphosphinate), heterodichalcogenido <protein-id="P00491,V9HWH6">PNP</protein-id> and monotellurido <protein-id="P00491,V9HWH6">PNP</protein-id> ligands, M[(TeP(i)<compound-id="445481">Pr2</compound-id>)2N]2 (1: M = Pd; 2: M = Pt), M[(EP(i)<compound-id="445481">Pr2</compound-id>)(TeP(i)<compound-id="445481">Pr2</compound-id>)N]2 (3: M = Pd, E = Se; 4: M = Pt, E = Se; 5: M = Pd, E = S; 6: M = Pt, E = S) and M[(P(i)<compound-id="445481">Pr2</compound-id>)(TeP(i)<compound-id="445481">Pr2</compound-id>)N]2 (7: M = Pd; 8: M = Pt), respectively, were prepared by metathesis between alkali-metal derivatives of the appropriate ligand and MCl2(COD) in <compound-id="8028">THF</compound-id>.	THF__PNP__no_interaction	Pr2__PNP__no_interaction
12826739-3	We found a significant relationship between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> and plasma levels of ACT (r = 0.4, p &lt; 0.001), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.74, p &lt; 0.001), <protein-id="P13500">MCP-1</protein-id> (r = 0.71, p &lt; 0.001), and a borderline relationship between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> and plasma oxLDL (r = 0.22, p &lt; 0.05).	CSF__IL-6__no_interaction	CSF__MCP-1__no_interaction
11456250-3	Antibodies against the following antigens were used: epidermal growth factor (EGF), <protein-id="P00533">EGF receptor</protein-id> (<protein-id="P00533">EGF-R</protein-id>), fibroblast growth factor (FGF), <protein-id="P21802,D3DRD5,D2CGD1,S4R381">FGF receptor</protein-id> (FGF-R), transforming growth factor (TGF)-beta, <protein-id="P37173,A3QNQ0,D2JYI1">TGF-beta receptor II</protein-id> (<protein-id="P37173,A3QNQ0,D2JYI1">TGF-beta -RII</protein-id>), insulin-like growth factor (<protein-id="P01344,E3UN46">IGF)II</protein-id>, platelet derived growth factor (PDGF)-AB, interleukin (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL)-6</protein-id>, IL-1 receptor II, <protein-id="P01375,Q5STB3">tumor necrosis factor (TNF)-alpha</protein-id>, <protein-id="P00750">tissue plasminogen activator</protein-id> (<protein-id="P00750">TPA</protein-id>), <compound-id="285703,6145931">prostaglandin</compound-id> (PG) E2, plasminogen activator inhibitor (<protein-id="P05121,A0A024QYT5">PAI)-1</protein-id>, alpha smooth muscle actin (alpha-SMA), keratin, <protein-id="P08670,V9HWE1">vimentin</protein-id>, <protein-id="Q7Z406,A1L2Z2,B3KWH4">myosin</protein-id>, <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id>, <compound-id="44342165">laminin</compound-id>, types I, II, III, IV, V and VI collagen (Col), and lens epithelial cells (LECs).	laminin__TPA__no_interaction	laminin__TGF-beta receptor II__no_interaction	laminin__tissue plasminogen activator__no_interaction	laminin__TGF-beta -RII__no_interaction	laminin__EGF-R__no_interaction	laminin__myosin__no_interaction	laminin__IL)-6__no_interaction	laminin__EGF receptor__no_interaction	laminin__IGF)II__no_interaction	laminin__fibronectin__no_interaction	laminin__vimentin__no_interaction	laminin__FGF receptor__no_interaction	laminin__tumor necrosis factor (TNF)-alpha__no_interaction	laminin__PAI)-1__no_interaction	prostaglandin__TPA__no_interaction	prostaglandin__TGF-beta receptor II__no_interaction	prostaglandin__tissue plasminogen activator__no_interaction	prostaglandin__TGF-beta -RII__no_interaction	prostaglandin__EGF-R__no_interaction	prostaglandin__myosin__no_interaction	prostaglandin__IL)-6__no_interaction	prostaglandin__EGF receptor__no_interaction	prostaglandin__IGF)II__no_interaction	prostaglandin__fibronectin__no_interaction	prostaglandin__vimentin__no_interaction	prostaglandin__FGF receptor__no_interaction	prostaglandin__tumor necrosis factor (TNF)-alpha__no_interaction	prostaglandin__PAI)-1__no_interaction
21784176-10	Alkaline phosphatase activity and <protein-id="P02818">osteocalcin</protein-id> concentration correlated with HA content (alkaline <compound-id="1061,167704,644102">phosphate</compound-id> activity in expansion medium and osteogenic medium for 40, 50, and 60 wt.% HA, 256.1 ± 71.8%, 304.0 ± 128.7%, and 500.2 ± 89.9%, and 358.4 ± 124.1%, 653.7 ± 216.5%, and 814.4 ± 68.8%, respectively; <protein-id="P02818">osteocalcin</protein-id> concentration in expansion medium and osteogenic medium for 40, 50, and 60 wt.% HA, 236.9 ± 7.8%, 253.0 ± 7.5%, and 285.2 ± 11.4%, and 265.8 ± 15.0%, 288.3 ± 17.9%, and 717.3 ± 38.7%, respectively).	phosphate__osteocalcin__no_interaction
9093548-4	Changes in <compound-id="445354">vitamin A</compound-id> status correlated positively and significantly with changes in serum <compound-id="23925,67172434">iron</compound-id> (r = 0.37; P = 0.0001) <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (r = 0.27; P = 0.004) and haemoglobin (r = 0.21; P = 0.03), but negatively with serum ferritin (r = -0.28; P = 0.003).	vitamin A__transferrin__no_interaction	iron__transferrin__no_interaction
10048132-4	Support for the TCDD-<protein-id="G3V6M2">AhR</protein-id>-mediated increases in ACTH concentrations is provided by the following observations: (1) ANF inhibited both the 1.3- to 2-fold TCDD-induced increase in basal medium and intracellular ACTH concentrations and the 30% TCDD-induced decrease in medium ACTH levels and the 1.2-fold increase in intracellular ACTH levels in <protein-id="P01143">corticotropin-releasing hormone</protein-id> (<protein-id="P01143">CRH</protein-id>)-stimulated cells, (2) <compound-id="80654">BNF</compound-id> increased basal medium (1.7-fold) and intracellular (1.3-fold) ACTH concentrations, (3) <compound-id="80654">BNF</compound-id> + TCDD demonstrated additivity by increasing basal medium (2.4-fold) and intracellular (1.7-fold) ACTH concentrations, (4) PCB increased basal medium (1.8- to 2.1-fold) and intracellular (1.3- to 1.8-fold) ACTH concentrations and inhibited medium ACTH secretion in <protein-id="P01143">CRH</protein-id> stimulated cells by 24-43%, and (5) HCB did not effect basal or <protein-id="P01143">CRH</protein-id> stimulated medium and intracellular ACTH concentrations.	BNF__AhR__no_interaction	BNF__CRH__no_interaction	BNF__corticotropin-releasing hormone__no_interaction
15307058-1	<compound-id="23948">Rhodium</compound-id>-103 chemical shifts are reported for 62 compounds, namely [Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] [X = Cl, N3, NCO, NCS, N(CN)2, NCBPh3, CNBPh3, CN] and derivatives formed by replacement of a <compound-id="24404">phosphine</compound-id> by CO, <compound-id="4212184">xylyl isocyanide</compound-id> (XNC) and <compound-id="1049">pyridine</compound-id> and/or by oxidative addition of H2 or O2 to give trans-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(CO)] (delta in the range -816 to -368 ppm) trans-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(XNC)] (delta -817 to -250 ppm), cis-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (the trans isomer is formed with X = CN, CNBPh3) (delta -233 to 170 ppm), [Rh(X)(H)2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] (delta -611 to 119), trans-[Rh(X)(H)2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (delta -30 to 566 ppm), [Rh(X)(O2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] (delta 1393 to 3273 ppm) and cis-[Rh(X)(O2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (delta 1949 to 3374 ppm).	phosphine__PPh3__no_interaction	xylyl isocyanide__PPh3__no_interaction	pyridine__PPh3__no_interaction	Rhodium__PPh3__no_interaction
24719803-7	It was directly correlated with HDL-<compound-id="5997">cholesterol</compound-id> (r = 0.599, P &lt; 0.001) and serum <compound-id="588">creatinine</compound-id> levels (r = 0.675, P &lt; 0.001) and inversely correlated with glomerular filtration rate (GFR) (r = -0.570, P &lt; 0.001), body mass index (BMI) (r = -0.318, P = 0.04), <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = -0.548, P &lt; 0.001) and fasting blood sugar (FBS) (r = -0.640, P &lt; 0.001) in CKD patients.	creatinine__C-reactive protein__no_interaction	creatinine__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__CRP__no_interaction
10754344-3	PDT was significantly correlated with <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.41, p = 0.009), intracellular <compound-id="5462224">magnesium</compound-id> levels (r = -0.46, p = 0.003) fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.47, p = 0.002), and total <compound-id="5997">cholesterol</compound-id> (r = 0.43, p = 0.006).	cholesterol__apolipoprotein B__no_interaction	magnesium__apolipoprotein B__no_interaction	glucose__apolipoprotein B__no_interaction
1671419-2	Compounds [R-(R*,S*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-3- phenylpropyl]-amino]-<compound-id="5314579,74088">4-oxo-2-butenoic acid</compound-id>, [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-oxy)carbonyl]amino]propyl]amino]-1- phenylethyl]amino]-<compound-id="5314579,74088">4-oxo-2-butenoic acid</compound-id>, and [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-1- phenylethyl]amino]-<compound-id="1112">4-oxobutanoic acid</compound-id> (<compound-id="21155395">29d</compound-id>) have <protein-id="P01355">CCK</protein-id>-B binding affinities of IC50 = 0.8, 0.7, and 1.7 nM with a <protein-id="P01355">CCK</protein-id>-A/<protein-id="P01355">CCK</protein-id>-B ratio of 550, 1100, and 2500, respectively.	4-oxo-2-butenoic acid__CCK__no_interaction	29d__CCK__no_interaction	4-oxobutanoic acid__CCK__no_interaction
18332235-7	This effect appeared specific for <compound-id="5288811">MLK</compound-id>, as the analog (E)-3-[[[3-[2-(<compound-id="521963">7-chloro-2-quinolinyl</compound-id>)<compound-id="123166">ethenyl</compound-id>]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]methyl]thio]-<compound-id="1032">propanoic acid, sodium salt</compound-id>, had no significant effect on eosinophil adhesion to <protein-id="P19320">VCAM-1</protein-id>.	propanoic acid, sodium salt__VCAM-1__no_interaction	MLK__VCAM-1__no_interaction	7-chloro-2-quinolinyl__VCAM-1__no_interaction	ethenyl__VCAM-1__no_interaction
11463578-9	Michaelis-Menten constants measured for <protein-id="P14060">3beta-HSD</protein-id> substrate (<compound-id="5881">dehydroepiandrosterone</compound-id>) utilization by the purified cytosolic enzyme (K(m)=4.5 microM, V(max)=53 nmol/min per mg) and the pure wild-type enzyme (K(m)=3.7 microM, V(max)=43 nmol/min per mg), for isomerase substrate (<compound-id="160531">5-androstene-3,17-dione</compound-id>) conversion by the purified cytosolic (K(m)=25 microM, V(max)=576 nmol/min per mg) and wild-type (K(m)=28 microM, V(max)=598 nmol/min per mg) enzymes, and for <compound-id="5893">NAD</compound-id>(+) reduction by the <protein-id="P14060">3beta-HSD</protein-id> activities of the cytosolic (K(m)=35 microM, V(max)=51 nmol/min per mg) and wild-type (K(m)=34 microM, V(max)=46 nmol/min per mg) enzymes are nearly identical.	5-androstene-3,17-dione__3beta-HSD__no_interaction	dehydroepiandrosterone__3beta-HSD__no_interaction	NAD__3beta-HSD__no_interaction
19833271-7	MAIN RESULTS: <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> levels were significantly lower at the 24th hour (14.66 +/- 4.40 pg/mL vs. 21.21 +/- 11.37 pg/mL, respectively) and at the 48th hour (21.25 +/- 15.85 pg/mL vs. 46.55 +/- 35.99 pg/mL, respectively) in Group D. <protein-id="P01583">IL-1</protein-id> levels were significantly lower at the 24th hour (5.03 +/- 0.15 pg/mL vs. 6.23 +/- 2.09 pg/mL, respectively) and the 48th hour (5.01 +/- 0.37 pg/mL vs. 6.42 +/- 2.76 pg/mL, respectively) in Group D. <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> levels were significantly lower at the 24th hour (253.1 +/- 303.6 pg/mL and 511.3 +/- 374.8 pg/mL, respectively) and at the 48th hour (343.5 +/- 393.4 pg/mL and 503.7 +/- 306.4 pg/mL, respectively) in Group D. Intraabdominal pressure also was significantly lower at the 24th hour (12.35 +/- 5.84 mmHg vs. 18.1 +/- 2.84 mmHg, respectively) and the 48th hour (13.9 +/- 6.15 mmHg vs. 18.7 +/- 3.46 mmHg, respectively) in Group D. CONCLUSION: <compound-id="5311068">Dexmedetomidine</compound-id> infusion decreases <protein-id="P01375,Q5STB3">TNF-a</protein-id>, <protein-id="P01583">IL-1</protein-id>, and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> levels and IAP more than a <compound-id="4943">propofol</compound-id> infusion. 	Dexmedetomidine__TNF-alpha__no_interaction	Dexmedetomidine__TNF-a__no_interaction	Dexmedetomidine__IL-1__no_interaction	Dexmedetomidine__IL-6__no_interaction	propofol__TNF-alpha__no_interaction	propofol__TNF-a__no_interaction	propofol__IL-1__no_interaction	propofol__IL-6__no_interaction
12915627-7	CRP was significantly correlated with prepregnancy BMI (r = 0.38, P &lt; 0.0001), followed by fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.27, P = 0.0002) and fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.18, P = 0.016).	glucose__insulin__no_interaction
11996197-3	The more recent trials indicate that: (1) diuretics and beta-blockers appear to be as effective in reducing overall morbidity/ mortality as other agents (Swedish Trial in Old Patients with Hypertension [STOP-2], United Kingdom Prospective Diabetes Study [UKPDS], Intervention as a Goal in Hypertension Treatment [INSIGHT], Nordic <compound-id="39186">diltiazem</compound-id> [NORDIL]); (2) the use of an a-blocker results in more cardiovascular events, especially congestive heart failure, when compared with a diuretic (Antihypertensive Therapy and Lipid Lowering Heart Attack Trial [ALLHAT]); (3)the use of an angiotensin-converting enzyme (ACE) inhibitor results in fewer myocardial infarctions and episodes of heart failure than <compound-id="22044544,5460341">calcium</compound-id> channel blockers in the elderly and in diabetic patients (<compound-id="3420,55891,6708482,9601226">Fosinopril</compound-id> vs. <compound-id="2162">Amlodipine</compound-id> Cardiovascular Events Randomized Trial [FACET], Appropriate Blood Pressure Control in Diabetes [ABCD], STOP-2) - other data (<compound-id="44093">Captopril</compound-id> Prevention Project [CAPPP]) suggest that the use of an ACE inhibitor is preferred in diabetic patients; (4) overall cardiovascular events are similar with <compound-id="22044544,5460341">calcium</compound-id> channel blockers compared with a diuretic - however, there are fewer strokes with non-dihydropyridine <compound-id="22044544,5460341">calcium</compound-id> channel blockers (NORDIL) and a trend towards an increase in heart failure and myocardial infarctions with either a dihydropyridine or non-dihydropyridine <compound-id="22044544,5460341">calcium</compound-id> channel blockers compared with a diuretic (INSIGHT, NORDIL); (5) angiotensin receptor blockers (ARBs) will decrease proteinuria and slow progression of renal disease in type 2 diabetic patients when compared with regimens that do not include an <protein-id="O76090,B7Z1N8,B7Z375,A0A0C4DGE9">ARB</protein-id> or an ACE inhibitor (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist <compound-id="3961">Losartan</compound-id> [RENAAL], <compound-id="3749">Irbesartan</compound-id> Type II Diabetic Nephropathy Trial [IDNT], <compound-id="3749">Irbesartan</compound-id> Type II Diabetes with Microalbuminuria [IRMA Il]).	Losartan__ARB__no_interaction	diltiazem__ARB__no_interaction	Fosinopril__ARB__no_interaction	Amlodipine__ARB__no_interaction	calcium__ARB__no_interaction	Irbesartan__ARB__no_interaction	Captopril__ARB__no_interaction
8937476-4	This conclusion is based on several lines of evidence: (a) <compound-id="15625">TCDD</compound-id> caused activation of protein <compound-id="6057,90983769">tyrosine</compound-id> kinase activity when administered directly to purified <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate; (b) this stimulatory effect of <compound-id="15625">TCDD</compound-id> was abolished when the cytosol was immunodepleted of c-Src protein or <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> protein by preincubating with anti-c-Src or anti-<protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> antibody, followed by the addition of <compound-id="15625">TCDD</compound-id> to the remaining portions of cytosol; (c) when <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate was incubated with <compound-id="15625">TCDD</compound-id>, and the kinase(s) released to the supernatant was analyzed on autoradiography of two-dimensional (2D) electrophoresis, 32P-labeled c-Src protein was recognized; (d) the same 32P-labeled-phosphoprotein with M(r) = 60 kDa and pl = 6.1 was found in the immunoprecipitate with anti-c-Src antibody on 2D autoradiograms; (e) this same phosphoprotein disappeared when the supernatant of the <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate was immunodepleted of c-Src protein by anti-c-Src antibody; and (f) a structure-activity relationship study with <compound-id="15625">TCDD</compound-id> and three dioxin-congeners revealed a rank order for their potency in activation of <protein-id="P41241">c-Src kinase</protein-id> activity to be identical to that of previously determined toxicity indices: i.e., <compound-id="15625">TCDD</compound-id> &gt; <compound-id="38439">1,2,3,7,8-pentachlorodibenzo-p-dioxin</compound-id> (1,2,3,7,8-PCDD) &gt; <compound-id="42836">1,2,4,7,8-pentachlorodibenzo-p-dioxin</compound-id> (1,2,4,7,8-PCDD) &gt; <compound-id="36613">2,7-dichlorodibenzo-p-dioxin</compound-id> (2,7-DCDD).	1,2,3,7,8-pentachlorodibenzo-p-dioxin__Ah-receptor__no_interaction	1,2,3,7,8-pentachlorodibenzo-p-dioxin__c-Src kinase__no_interaction	TCDD__Ah-receptor__no_interaction	TCDD__c-Src kinase__no_interaction	1,2,4,7,8-pentachlorodibenzo-p-dioxin__Ah-receptor__no_interaction	1,2,4,7,8-pentachlorodibenzo-p-dioxin__c-Src kinase__no_interaction	2,7-dichlorodibenzo-p-dioxin__Ah-receptor__no_interaction	2,7-dichlorodibenzo-p-dioxin__c-Src kinase__no_interaction	tyrosine__Ah-receptor__no_interaction	tyrosine__c-Src kinase__no_interaction
22497081-5	Comparative analysis of changes in the status of expression of genes in the heart of rats induced by <protein-id="P05943,B3Y9H3">P-11</protein-id> against the simulated in vivo arrhythmia identified 16 genes that reproducibly alter the level of expression.These genes encode the extracellular matrix proteins (<protein-id="P35053">glypican 1</protein-id>, <protein-id="P35053">Gpc1</protein-id>; <protein-id="P30121">tissue inhibitor of metalloproteinase 2, 3</protein-id>, <protein-id="P30121">Timp2</protein-id>, <protein-id="Q4V8L0">Timp 3</protein-id>); intracellular signaling molecules (<protein-id="G3V7H1">rho GTPase activating protein 7</protein-id>, <protein-id="G3V7H1">Dlc1</protein-id>; protein <compound-id="6057,90983769">tyrosine</compound-id> phosphatase <compound-id="16770253">4a1</compound-id>, <protein-id="Q78EG7">Ptp4a1; phosphodiesterase 4D</protein-id>, <protein-id="P14270">PDE4D</protein-id>; <protein-id="Q63787,M0RC47">PI3-kinase regulatory subunit alpha</protein-id>, <protein-id="Q63787,M0RC47">PIK3R1</protein-id>; <compound-id="764">guanine</compound-id> nucleotide binding protein alpha 12, <protein-id="Q63210,Q45QM2">Gna12</protein-id>) and protein of intermediate junctions (junction plakoglobin, <protein-id="Q6P0K8">Jup</protein-id>), proteins involved in glycolysis (phosphofructokinase I, Pfk1) and hemostasis (tissue plasminogen activator, <protein-id="P19637">Plat</protein-id>), plasma membrane transporters (Solute carrier family 16, member 1, <protein-id="P53987">Slc16a1</protein-id>; ATPase, Na+/K+ transporting, Atp1a), and ets.	4a1__Timp 3__no_interaction	4a1__Timp2__no_interaction	4a1__tissue inhibitor of metalloproteinase 2, 3__no_interaction	4a1__Slc16a1__no_interaction	4a1__PDE4D__no_interaction	4a1__rho GTPase activating protein 7__no_interaction	4a1__P-11__no_interaction	4a1__Plat__no_interaction	4a1__Gpc1__no_interaction	4a1__Jup__no_interaction	4a1__PI3-kinase regulatory subunit alpha__no_interaction	4a1__Gna12__no_interaction	4a1__Ptp4a1; phosphodiesterase 4D__no_interaction	4a1__PIK3R1__no_interaction	4a1__glypican 1__no_interaction	4a1__Dlc1__no_interaction	guanine__Timp 3__no_interaction	guanine__Timp2__no_interaction	guanine__tissue inhibitor of metalloproteinase 2, 3__no_interaction	guanine__Slc16a1__no_interaction	guanine__PDE4D__no_interaction	guanine__rho GTPase activating protein 7__no_interaction	guanine__P-11__no_interaction	guanine__Plat__no_interaction	guanine__Gpc1__no_interaction	guanine__Jup__no_interaction	guanine__PI3-kinase regulatory subunit alpha__no_interaction	guanine__Gna12__no_interaction	guanine__Ptp4a1; phosphodiesterase 4D__no_interaction	guanine__PIK3R1__no_interaction	guanine__glypican 1__no_interaction	guanine__Dlc1__no_interaction	tyrosine__Timp 3__no_interaction	tyrosine__Timp2__no_interaction	tyrosine__tissue inhibitor of metalloproteinase 2, 3__no_interaction	tyrosine__Slc16a1__no_interaction	tyrosine__PDE4D__no_interaction	tyrosine__rho GTPase activating protein 7__no_interaction	tyrosine__P-11__no_interaction	tyrosine__Plat__no_interaction	tyrosine__Gpc1__no_interaction	tyrosine__Jup__no_interaction	tyrosine__PI3-kinase regulatory subunit alpha__no_interaction	tyrosine__Gna12__no_interaction	tyrosine__Ptp4a1; phosphodiesterase 4D__no_interaction	tyrosine__PIK3R1__no_interaction	tyrosine__glypican 1__no_interaction	tyrosine__Dlc1__no_interaction
16120716-5	Carotid <compound-id="447041">IMT</compound-id> was significantly correlated with serum levels of <protein-id="P02741">CRP</protein-id> (r = 0.61, p = 0.0001), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.41, p = 0.01), and <protein-id="Q14116,A0A024R3E0">IL-18</protein-id> (r = 0.45, p = 0.005), duration of OSA-related hypoxia (r = 0.60, p = 0.0001), and severity of OSA (r = 0.50, p = 0.002).	IMT__CRP__no_interaction	IMT__IL-6__no_interaction	IMT__IL-18__no_interaction
21789900-8	In <compound-id="667639">astringinin</compound-id>-treated (0.3 mg/kg) rats subjected to trauma-hemorrhage, there were significant improvements in liver <protein-id="D3ZGE2,A0A0G2K1A2">myeloperoxidase</protein-id> (<protein-id="D3ZGE2,A0A0G2K1A2">MPO</protein-id>) activity (237.80 +/- 45.89 vs. 495.95 +/- 70.64 U/mg protein, P &lt; 0.05), <protein-id="P20607">interleukin-6</protein-id> (<protein-id="P20607">IL-6</protein-id>) levels (218.54 +/- 34.52 vs. 478.60 +/- 76.21 pg/mg protein, P &lt; 0.05), cytokine-induced neutrophil chemoattractant (<compound-id="23994">CINC</compound-id>)-1 (88.32 +/- 20.33 vs. 200.70 +/- 32.68 pg/mg protein, P &lt; 0.05), <protein-id="P30348">CINC-3</protein-id> (110.83 +/- 26.63 vs. 290.14 +/- 76.82 pg/mg protein, P &lt; 0.05) and <protein-id="Q00238">intercellular adhesion molecule (ICAM)-1</protein-id> concentrations (1,868.5 +/- 211.5 vs. 3,645.0 +/- 709.2 pg/mg protein, P &lt; 0.05), as well as in histology.	astringinin__intercellular adhesion molecule (ICAM)-1__no_interaction	astringinin__MPO__no_interaction	astringinin__IL-6__no_interaction	astringinin__myeloperoxidase__no_interaction	astringinin__interleukin-6__no_interaction	astringinin__CINC-3__no_interaction	CINC__intercellular adhesion molecule (ICAM)-1__no_interaction	CINC__MPO__no_interaction	CINC__IL-6__no_interaction	CINC__myeloperoxidase__no_interaction	CINC__interleukin-6__no_interaction	CINC__CINC-3__no_interaction
8683352-5	<compound-id="947">Nitrogen</compound-id> intake was significantly negatively correlated with urinary 4-PA excretion (r = -0.619, P &lt; 0.001) and plasma <protein-id="Q96GD0,A0A024R1I3">PLP</protein-id> concentration (r = -0.549, P &lt; 0.01), and positively correlated with erythrocyte <compound-id="5950,602">alanine</compound-id> aminotransferase percentage stimulation (r = 0.418, P &lt; 0.05) and urinary post-<compound-id="57175189,6305">tryptophan</compound-id> load excretion of <compound-id="5699">xanthurenic acid</compound-id> (r = 0.535, P &lt; 0.05), <compound-id="3845">kynurenic acid</compound-id> (r = 0.563, P &lt; 0.05) and VA (r = 0.626, P &lt; 0.01).	xanthurenic acid__PLP__no_interaction	tryptophan__PLP__no_interaction	alanine__PLP__no_interaction	Nitrogen__PLP__no_interaction	kynurenic acid__PLP__no_interaction
11532695-8	This protection was mediated via <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>) AR activation because the <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>)-selective AR agonist [4-((N-<compound-id="23134249">ethyl</compound-id>-5'-carbamoyadenos-2-yl)-aminoethyl)-<compound-id="107">phenylpropionic acid</compound-id> (<compound-id="3086599">CGS-21680</compound-id>)] mimics <compound-id="57476835,60961">adenosine</compound-id>-induced renal protection, and the <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>)-selective AR antagonist [<compound-id="5353365">8-(3-chlorostyryl)caffeine</compound-id> (CSC)] blocks <compound-id="57476835,60961">adenosine</compound-id>-induced renal protection.	CGS-21680__A(2a__no_interaction	adenosine__A(2a__no_interaction	phenylpropionic acid__A(2a__no_interaction	8-(3-chlorostyryl)caffeine__A(2a__no_interaction	ethyl__A(2a__no_interaction
15071612-3	This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-<protein-id="P29965">CD154</protein-id>, Adeno-Interferon gamma, alemtuzumab, APC-8024, <compound-id="72402">9-aminocamptothecin</compound-id>, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, l-<compound-id="6322,90867653">arginine</compound-id> hydrochloride, <compound-id="60795">aripiprazole</compound-id>, <compound-id="5359596">arsenic</compound-id> trioxide, <compound-id="179340">asimadoline</compound-id>; <compound-id="4578">O6-Benzylguanine</compound-id>, bevacizumab, Bi-20, <compound-id="9576912">binodenoson</compound-id>, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, bivatuzumab, <compound-id="161105">186Re</compound-id>-bivatuzumab, BMS-181176, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="16219006,52943236">BQ-123</compound-id>, <compound-id="16760328,22524140,433902,44277532,5280757,5458769,5477635,6435419,6473739">bryostatin 1</compound-id>; Carboxy- amidotriazole, <compound-id="5486792,2826718,66577042,71295847">caspofungin acetate</compound-id>, <compound-id="89105">CB-1954</compound-id>, CC-4047, <compound-id="6132">CDP</compound-id>-860, <compound-id="446156">cerivastatin sodium</compound-id>, <compound-id="153994">clevidipine</compound-id>, CTL-102; <compound-id="5918">3,4-DAP</compound-id>, darbepoetin alfa, <compound-id="451668">decitabine</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="6918473">DHA-paclitaxel</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>; Efalizumab, EGF vaccine, <compound-id="77993">eletriptan</compound-id>, <compound-id="43157">eniluracil</compound-id>, ENMD-0997, <compound-id="443872">eplerenone</compound-id>, <compound-id="54381650,5486684,5493160">eplivanserin</compound-id>, <compound-id="219078">erlosamide</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="4594,9568614">esomeprazole magnesium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="151115">exatecan</compound-id> mesilate, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="5352062">FR-901228</compound-id>, <compound-id="5288267">FTY</compound-id>-720; <compound-id="123631">Gefitinib</compound-id>, gemtuzumab <compound-id="9942071">ozogamicin</compound-id>, <compound-id="55191">gepirone</compound-id> hydrochloride; Hexyl <protein-id="P01308,I3WAC9">insulin</protein-id> M2, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> <compound-id="44146714">glargine</compound-id>, <compound-id="807">iodine</compound-id> (I131) tositumomab, ISV-205, <compound-id="132999">ivabradine hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; <compound-id="5284583">Levetiracetam</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="441401">linezolid</compound-id>, liposomal NDDP, <compound-id="148195">lonafarnib</compound-id>, <compound-id="92727">lopinavir</compound-id>, <compound-id="219018">LY-156735</compound-id>; <compound-id="9908997">Mafosfamide cyclohexylamine salt</compound-id>, <compound-id="24083">magnesium sulfate</compound-id>, <compound-id="6398761">maxacalcitol</compound-id>, <compound-id="119192">meclinertant</compound-id>, <compound-id="183797">melagatran</compound-id>, <compound-id="896">melatonin</compound-id>, <protein-id="Q9BUN1">MENT</protein-id>, <compound-id="56603701">mepolizumab</compound-id>, <compound-id="477468,6602291">micafungin sodium</compound-id>, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="151071">motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; Nesiritide, NS-1209, NSC-601316, <compound-id="54608508,6918289">NSC-683864</compound-id>; <compound-id="219077">Osanetant</compound-id>; <compound-id="6337614">Palonosetron</compound-id> hydrochloride, <compound-id="119828">parecoxib</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="56603655">pegaptanib</compound-id> <compound-id="5360545">sodium</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="10819">perillyl alcohol</compound-id>, <compound-id="7975">picoplatin</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="134019">pixantrone maleate</compound-id>, <compound-id="213022">plevitrexed</compound-id>, polyglutamate <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id>, posurdex, <compound-id="16132446">pramlintide acetate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; Rasburicase, <compound-id="104850">rimonabant</compound-id> hydrochloride, <compound-id="56841693,6918321,71306999">rostaporfin</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">rosuvastatin calcium</compound-id>; <compound-id="65015">SDZ-SID-791</compound-id>, sibrotuzumab, <compound-id="216239">sorafenib</compound-id>, SU-11248; <compound-id="110635">Tadalafil</compound-id>, <compound-id="132862">targinine</compound-id>, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, TheraCIM, <compound-id="54686904">tigecycline</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="92400">Zofenopril calcium</compound-id>, <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	escitalopram oxalate__MENT__no_interaction	escitalopram oxalate__CD154__no_interaction	escitalopram oxalate__insulin__no_interaction	eplerenone__MENT__no_interaction	eplerenone__CD154__no_interaction	eplerenone__insulin__no_interaction	rimonabant__MENT__no_interaction	rimonabant__CD154__no_interaction	rimonabant__insulin__no_interaction	ertapenem sodium__MENT__no_interaction	ertapenem sodium__CD154__no_interaction	ertapenem sodium__insulin__no_interaction	Valdecoxib__MENT__no_interaction	Valdecoxib__CD154__no_interaction	Valdecoxib__insulin__no_interaction	gadolinium__MENT__no_interaction	gadolinium__CD154__no_interaction	gadolinium__insulin__no_interaction	Fondaparinux sodium__MENT__no_interaction	Fondaparinux sodium__CD154__no_interaction	Fondaparinux sodium__insulin__no_interaction	Levetiracetam__MENT__no_interaction	Levetiracetam__CD154__no_interaction	Levetiracetam__insulin__no_interaction	sodium__MENT__no_interaction	sodium__CD154__no_interaction	sodium__insulin__no_interaction	asimadoline__MENT__no_interaction	asimadoline__CD154__no_interaction	asimadoline__insulin__no_interaction	exatecan__MENT__no_interaction	exatecan__CD154__no_interaction	exatecan__insulin__no_interaction	ezetimibe__MENT__no_interaction	ezetimibe__CD154__no_interaction	ezetimibe__insulin__no_interaction	3,4-DAP__MENT__no_interaction	3,4-DAP__CD154__no_interaction	3,4-DAP__insulin__no_interaction	eniluracil__MENT__no_interaction	eniluracil__CD154__no_interaction	eniluracil__insulin__no_interaction	pegaptanib__MENT__no_interaction	pegaptanib__CD154__no_interaction	pegaptanib__insulin__no_interaction	Zoledronic acid monohydrate__MENT__no_interaction	Zoledronic acid monohydrate__CD154__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	paclitaxel__MENT__no_interaction	paclitaxel__CD154__no_interaction	paclitaxel__insulin__no_interaction	bryostatin 1__MENT__no_interaction	bryostatin 1__CD154__no_interaction	bryostatin 1__insulin__no_interaction	plevitrexed__MENT__no_interaction	plevitrexed__CD154__no_interaction	plevitrexed__insulin__no_interaction	levocetirizine__MENT__no_interaction	levocetirizine__CD154__no_interaction	levocetirizine__insulin__no_interaction	lopinavir__MENT__no_interaction	lopinavir__CD154__no_interaction	lopinavir__insulin__no_interaction	Tadalafil__MENT__no_interaction	Tadalafil__CD154__no_interaction	Tadalafil__insulin__no_interaction	maxacalcitol__MENT__no_interaction	maxacalcitol__CD154__no_interaction	maxacalcitol__insulin__no_interaction	Vardenafil hydrochloride hydrate__MENT__no_interaction	Vardenafil hydrochloride hydrate__CD154__no_interaction	Vardenafil hydrochloride hydrate__insulin__no_interaction	erlosamide__MENT__no_interaction	erlosamide__CD154__no_interaction	erlosamide__insulin__no_interaction	Palonosetron__MENT__no_interaction	Palonosetron__CD154__no_interaction	Palonosetron__insulin__no_interaction	tigecycline__MENT__no_interaction	tigecycline__CD154__no_interaction	tigecycline__insulin__no_interaction	FR-901228__MENT__no_interaction	FR-901228__CD154__no_interaction	FR-901228__insulin__no_interaction	Gefitinib__MENT__no_interaction	Gefitinib__CD154__no_interaction	Gefitinib__insulin__no_interaction	rostaporfin__MENT__no_interaction	rostaporfin__CD154__no_interaction	rostaporfin__insulin__no_interaction	ivabradine hydrochloride__MENT__no_interaction	ivabradine hydrochloride__CD154__no_interaction	ivabradine hydrochloride__insulin__no_interaction	perillyl alcohol__MENT__no_interaction	perillyl alcohol__CD154__no_interaction	perillyl alcohol__insulin__no_interaction	CDP__MENT__no_interaction	CDP__CD154__no_interaction	CDP__insulin__no_interaction	eszopiclone__MENT__no_interaction	eszopiclone__CD154__no_interaction	eszopiclone__insulin__no_interaction	FTY__MENT__no_interaction	FTY__CD154__no_interaction	FTY__insulin__no_interaction	pramlintide acetate__MENT__no_interaction	pramlintide acetate__CD154__no_interaction	pramlintide acetate__insulin__no_interaction	targinine__MENT__no_interaction	targinine__CD154__no_interaction	targinine__insulin__no_interaction	ixabepilone__MENT__no_interaction	ixabepilone__CD154__no_interaction	ixabepilone__insulin__no_interaction	binodenoson__MENT__no_interaction	binodenoson__CD154__no_interaction	binodenoson__insulin__no_interaction	melagatran__MENT__no_interaction	melagatran__CD154__no_interaction	melagatran__insulin__no_interaction	pemetrexed disodium__MENT__no_interaction	pemetrexed disodium__CD154__no_interaction	pemetrexed disodium__insulin__no_interaction	mepolizumab__MENT__no_interaction	mepolizumab__CD154__no_interaction	mepolizumab__insulin__no_interaction	gepirone__MENT__no_interaction	gepirone__CD154__no_interaction	gepirone__insulin__no_interaction	Ximelagatran__MENT__no_interaction	Ximelagatran__CD154__no_interaction	Ximelagatran__insulin__no_interaction	9-aminocamptothecin__MENT__no_interaction	9-aminocamptothecin__CD154__no_interaction	9-aminocamptothecin__insulin__no_interaction	midostaurin__MENT__no_interaction	midostaurin__CD154__no_interaction	midostaurin__insulin__no_interaction	magnesium sulfate__MENT__no_interaction	magnesium sulfate__CD154__no_interaction	magnesium sulfate__insulin__no_interaction	picoplatin__MENT__no_interaction	picoplatin__CD154__no_interaction	picoplatin__insulin__no_interaction	caspofungin acetate__MENT__no_interaction	caspofungin acetate__CD154__no_interaction	caspofungin acetate__insulin__no_interaction	Zofenopril calcium__MENT__no_interaction	Zofenopril calcium__CD154__no_interaction	Zofenopril calcium__insulin__no_interaction	lonafarnib__MENT__no_interaction	lonafarnib__CD154__no_interaction	lonafarnib__insulin__no_interaction	Valganciclovir hydrochloride__MENT__no_interaction	Valganciclovir hydrochloride__CD154__no_interaction	Valganciclovir hydrochloride__insulin__no_interaction	186Re__MENT__no_interaction	186Re__CD154__no_interaction	186Re__insulin__no_interaction	bosentan__MENT__no_interaction	bosentan__CD154__no_interaction	bosentan__insulin__no_interaction	arsenic__MENT__no_interaction	arsenic__CD154__no_interaction	arsenic__insulin__no_interaction	aprepitant__MENT__no_interaction	aprepitant__CD154__no_interaction	aprepitant__insulin__no_interaction	exenatide__MENT__no_interaction	exenatide__CD154__no_interaction	exenatide__insulin__no_interaction	LY-156735__MENT__no_interaction	LY-156735__CD154__no_interaction	LY-156735__insulin__no_interaction	meclinertant__MENT__no_interaction	meclinertant__CD154__no_interaction	meclinertant__insulin__no_interaction	pixantrone maleate__MENT__no_interaction	pixantrone maleate__CD154__no_interaction	pixantrone maleate__insulin__no_interaction	Imatinib mesylate__MENT__no_interaction	Imatinib mesylate__CD154__no_interaction	Imatinib mesylate__insulin__no_interaction	tirapazamine__MENT__no_interaction	tirapazamine__CD154__no_interaction	tirapazamine__insulin__no_interaction	esomeprazole magnesium__MENT__no_interaction	esomeprazole magnesium__CD154__no_interaction	esomeprazole magnesium__insulin__no_interaction	CB-1954__MENT__no_interaction	CB-1954__CD154__no_interaction	CB-1954__insulin__no_interaction	tipifarnib__MENT__no_interaction	tipifarnib__CD154__no_interaction	tipifarnib__insulin__no_interaction	eplivanserin__MENT__no_interaction	eplivanserin__CD154__no_interaction	eplivanserin__insulin__no_interaction	arginine__MENT__no_interaction	arginine__CD154__no_interaction	arginine__insulin__no_interaction	Mafosfamide cyclohexylamine salt__MENT__no_interaction	Mafosfamide cyclohexylamine salt__CD154__no_interaction	Mafosfamide cyclohexylamine salt__insulin__no_interaction	prasterone__MENT__no_interaction	prasterone__CD154__no_interaction	prasterone__insulin__no_interaction	pregabalin__MENT__no_interaction	pregabalin__CD154__no_interaction	pregabalin__insulin__no_interaction	telithromycin__MENT__no_interaction	telithromycin__CD154__no_interaction	telithromycin__insulin__no_interaction	motexafin__MENT__no_interaction	motexafin__CD154__no_interaction	motexafin__insulin__no_interaction	desloratadine__MENT__no_interaction	desloratadine__CD154__no_interaction	desloratadine__insulin__no_interaction	ozogamicin__MENT__no_interaction	ozogamicin__CD154__no_interaction	ozogamicin__insulin__no_interaction	aripiprazole__MENT__no_interaction	aripiprazole__CD154__no_interaction	aripiprazole__insulin__no_interaction	micafungin sodium__MENT__no_interaction	micafungin sodium__CD154__no_interaction	micafungin sodium__insulin__no_interaction	decitabine__MENT__no_interaction	decitabine__CD154__no_interaction	decitabine__insulin__no_interaction	NSC-683864__MENT__no_interaction	NSC-683864__CD154__no_interaction	NSC-683864__insulin__no_interaction	iodine__MENT__no_interaction	iodine__CD154__no_interaction	iodine__insulin__no_interaction	SDZ-SID-791__MENT__no_interaction	SDZ-SID-791__CD154__no_interaction	SDZ-SID-791__insulin__no_interaction	parecoxib__MENT__no_interaction	parecoxib__CD154__no_interaction	parecoxib__insulin__no_interaction	BQ-123__MENT__no_interaction	BQ-123__CD154__no_interaction	BQ-123__insulin__no_interaction	cerivastatin sodium__MENT__no_interaction	cerivastatin sodium__CD154__no_interaction	cerivastatin sodium__insulin__no_interaction	melatonin__MENT__no_interaction	melatonin__CD154__no_interaction	melatonin__insulin__no_interaction	tiotropium bromide__MENT__no_interaction	tiotropium bromide__CD154__no_interaction	tiotropium bromide__insulin__no_interaction	duloxetine hydrochloride__MENT__no_interaction	duloxetine hydrochloride__CD154__no_interaction	duloxetine hydrochloride__insulin__no_interaction	glargine__MENT__no_interaction	glargine__CD154__no_interaction	glargine__insulin__no_interaction	O6-Benzylguanine__MENT__no_interaction	O6-Benzylguanine__CD154__no_interaction	O6-Benzylguanine__insulin__no_interaction	DHA-paclitaxel__MENT__no_interaction	DHA-paclitaxel__CD154__no_interaction	DHA-paclitaxel__insulin__no_interaction	linezolid__MENT__no_interaction	linezolid__CD154__no_interaction	linezolid__insulin__no_interaction	tegaserod maleate__MENT__no_interaction	tegaserod maleate__CD154__no_interaction	tegaserod maleate__insulin__no_interaction	pimecrolimus__MENT__no_interaction	pimecrolimus__CD154__no_interaction	pimecrolimus__insulin__no_interaction	clevidipine__MENT__no_interaction	clevidipine__CD154__no_interaction	clevidipine__insulin__no_interaction	treprostinil sodium__MENT__no_interaction	treprostinil sodium__CD154__no_interaction	treprostinil sodium__insulin__no_interaction	Osanetant__MENT__no_interaction	Osanetant__CD154__no_interaction	Osanetant__insulin__no_interaction	sorafenib__MENT__no_interaction	sorafenib__CD154__no_interaction	sorafenib__insulin__no_interaction	rosuvastatin calcium__MENT__no_interaction	rosuvastatin calcium__CD154__no_interaction	rosuvastatin calcium__insulin__no_interaction	eletriptan__MENT__no_interaction	eletriptan__CD154__no_interaction	eletriptan__insulin__no_interaction
20345144-5	The predicted total rate constants for (1)CH(2) + N(2) at 760 Torr Ar pressure can be represented by the expressions s-k(total) = 9.67 x 10(+7) x T (-6.88) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id> (-1345/T) cm(3) molecule(-1) s(-1) at T = 300-2400 K and 3.15 x 10(-229) x T (+56.18) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id> (128 000/T) cm(3) molecule(-1) s(-1) at T = 2400-3000 K. The branching ratios of the primary channels for (1)CH(2) + N(2) are predicted: k(1) for forming singlet s-CH(2)N(2)-a (<compound-id="9550">diazomethane</compound-id>) accounts for 0.97-0.01, k(2) + k(4) for producing HCNN-a + H accounts for 0.00-0.69, k(3) for forming singlet s-CH(2)N(2)-b (<compound-id="78958">3H-diazirine</compound-id>) accounts for 0.03-0.00, k(5) for producing HCN + NH accounts for 0.00-0.18, and k(6) for producing CNNH + H accounts for 0.00-0.11 in the temperature range of 300-3000 K. The rate constant predicted for the unimoclecular decomposition of <compound-id="9550">diazomethane</compound-id> producing (1)CH(2) + N(2) agrees closely with experimental results.	diazomethane__exp__no_interaction	3H-diazirine__exp__no_interaction
11912547-5	The obese children presented the following characteristics in comparison to the non-obese group: significantly high levels of <protein-id="P01308,I3WAC9">insulin</protein-id> (8.2 +/- 0.52 v 6.12 +/- 0.34 microU/mL), triglycerides (TG) (0.79 +/- 0.04 v 0.60 +/- 0.02 mmol/L), <compound-id="1175">uric acid</compound-id> (0.24 +/- 0.005 v 0.21 +/- 0.004 mmol/L), systolic (<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>) (94.59 +/- 1.06 v 88.85 +/- 1.2 mm Hg) and diastolic (56.49 +/- 1.07 v 52.21 +/- 1.06 mm Hg) blood pressure (<protein-id="Q10586">DBP</protein-id>), and low levels of high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) (1.30 +/- 0.04 v 1.46 +/- 0.03 mmol/L), and nonesterified fatty acids (0.407 +/- 0.02 v 0.505 +/- 0.02 mmol/L).	uric acid__DBP__no_interaction	uric acid__SBP__no_interaction	uric acid__insulin__no_interaction	cholesterol__DBP__no_interaction	cholesterol__SBP__no_interaction	cholesterol__insulin__no_interaction
16175401-7	Assessment of glutamatergic agents indicated that the mGlu1 receptor antagonist <compound-id="9926999">LY456236</compound-id> (10-30 mg/kg), mGlu5 receptor antagonist <compound-id="3025961">MPEP</compound-id> (10-30 mg/kg), mGlu2/3 receptor agonist <compound-id="213056">LY354740</compound-id> (3-10 mg/kg), mGlu2 receptor potentiator LY566332 (30 and 100 mg/kg), mGlu8 receptor agonist (S)-<compound-id="16202239">3,4-dicarboxyphenylglycine</compound-id> (30-60 mg/kg), competitive NMDA receptor antagonist <compound-id="131938">LY235959</compound-id> (1 mg/kg), AMPA receptor antagonist GYKI-52466 (10-20 mg/kg), and <compound-id="45934207,750">glycine</compound-id> transporter-1 (<protein-id="P28571">GlyT-1</protein-id>) inhibitor <compound-id="6604909">ALX-5407</compound-id> (3-10 mg/kg) dose-dependently attenuated stress-induced hyperthermia.	LY235959__GlyT-1__no_interaction	3,4-dicarboxyphenylglycine__GlyT-1__no_interaction	LY354740__GlyT-1__no_interaction	glycine__GlyT-1__no_interaction	ALX-5407__GlyT-1__no_interaction	LY456236__GlyT-1__no_interaction	MPEP__GlyT-1__no_interaction
16061781-6	RESULTS: There was univariate association (P &lt; .01) between WC and height (r = 0.73), BMI (r = 0.96), Tanner stage (r = 0.67), age (r = 0.56), systolic BP (r = 0.64), diastolic BP (r = 0.61), high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level (r = 0.45), triglyceride level (r = 0.28), <protein-id="P01308,I3WAC9">proinsulin</protein-id> level (r = 0.59), and HOMA-IR (r = 0.59).	cholesterol__proinsulin__no_interaction
17031383-4	KEY RESULTS: OLETF rats exhibited (vs. age-matched LETO rats): (1) greater potentiation of high-K(+)-induced contraction by 10 microM LPC - a potentiation attenuated by 10 microM <compound-id="5280961">genistein</compound-id>, protein <compound-id="6057,90983769">tyrosine</compound-id> kinase (PTK) inhibitor, (2) greater potentiation of UK14,304 (10 approximately 100 nM)-induced contractions by LPC (1 microM approximately 10 microM) - a potentiation attenuated by 10 microM <compound-id="5280961">genistein</compound-id>, 50 microM <compound-id="2052">tyrphostin A23</compound-id> (PTK inhibitor) or 10 microM <compound-id="4713">PD98059</compound-id> (<protein-id="P36506">MEK 1/2</protein-id> inhibitor), (3) greater basal and LPC (1 microM)-induced ERK activities, (4) greater basal and 100 nM UK14,304-stimulated <protein-id="P63086">ERK2</protein-id> activities in both the absence and presence of 10 microM LPC, (5) greater SOV (10 microM approximately 3 mM)-induced contractions, (6) greater potentiation of SOV-induced contractions by 10 microM LPC - a potentiation suppressed by 10 microM <compound-id="4713">PD98059</compound-id> or 10 microM <compound-id="5280961">genistein</compound-id>, (7) upregulation of <protein-id="Q4KLH9">GPR4</protein-id> mRNA.	PD98059__ERK2__no_interaction	PD98059__MEK 1/2__no_interaction	PD98059__GPR4__no_interaction	tyrphostin A23__ERK2__no_interaction	tyrphostin A23__MEK 1/2__no_interaction	tyrphostin A23__GPR4__no_interaction	tyrosine__ERK2__no_interaction	tyrosine__MEK 1/2__no_interaction	tyrosine__GPR4__no_interaction	genistein__ERK2__no_interaction	genistein__MEK 1/2__no_interaction	genistein__GPR4__no_interaction
20108767-5	RESULTS: The number of peripheral <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ T cells in group pre-HAART was decreased compared with group HAART (P &lt; 0.01); the frequency of CD3+ <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ T cells in group pre-HAART were decreased compared with group HAART (P &lt; 0.01), the frequency of <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P13612">CD49d</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P14151,A0A024R8Z0">CD62L</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+ CD45RO , <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+ CD45RO- ,<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ CD45RO+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ CD45RO- T cells in group pre-HAART were significantly decreased compared with group HAART (P &lt; 0.001); the frequency of CD3+ <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P14151,A0A024R8Z0">CD62L</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ T cells in group HAART were significantly decreased compared with group HIV-<compound-id="11118411">neg</compound-id> (P &lt; 0.05).	neg__CD4__no_interaction	neg__CCR9__no_interaction	neg__CD62L__no_interaction	neg__CCR5__no_interaction	neg__CD49d__no_interaction
1852119-3	In 21-day-old SHR fed 0.1 vs. 3.6% Ca diet for 14 days, increasing dietary Ca had no significant effects on basal [704 +/- 50 in 0.1% Ca vs. 784 +/- 61 ng angiotensin I (<compound-id="44299732">ANG I</compound-id>).mg-1.h-1 in 3.6% Ca, P = not significant (NS)], <compound-id="3779">isoproterenol</compound-id>-stimulated (1,057 +/- 52 in 0.1% Ca vs. 1,104 +/- 59 ng <compound-id="44299732">ANG I</compound-id>.mg-1.h-1 in 3.6% Ca, P = NS), or <protein-id="P01015">angiotensin II</protein-id> (<protein-id="Q5GAM5">ANG II</protein-id>)-inhibited (370 +/- 50 in 0.1% Ca vs. 411 +/- 39 ng <compound-id="44299732">ANG I</compound-id>.mg-1.h-1 in 3.6% Ca, P = NS) renal superficial cortical slice renin release.	isoproterenol__angiotensin II__no_interaction	isoproterenol__ANG II__no_interaction	ANG I__angiotensin II__no_interaction	ANG I__ANG II__no_interaction
15148527-3	This issue focuses on the following selection of drugs: ABI-007, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, alefacept, alemtuzumab, <compound-id="9571836">3-AP</compound-id>, AP-12009, APC-8015, <compound-id="6322">L-Arginine hydrochloride</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="208925">arundic acid</compound-id>, <compound-id="166558">avasimibe</compound-id>; Bevacizumab, bivatuzumab, <compound-id="101524">BMS-181176</compound-id>, BMS-184476, BMS-188797, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="16219006,443289,52943236">BQ-123</compound-id>, BRL-55730, <compound-id="16760328,22524140,433902,44277532,5458769,5477635,6435419">bryostatin 1</compound-id>; <compound-id="56603757">CEP-1347</compound-id>, cetuximab, <compound-id="156419">cinacalcet hydrochloride</compound-id>, <compound-id="6445782">CP-461</compound-id>, CpG-7909; D-003, <compound-id="216249">dabuzalgron</compound-id> hydrochloride, darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="447865,6440032,6918680">desoxyepothilone B</compound-id>, <compound-id="154101">dexmethylphenidate hydrochloride</compound-id>, <compound-id="6918473">DHA-paclitaxel</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="5280453">DN-101</compound-id>, <compound-id="9810955">DP-b99</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride, duramycin; Eculizumab, Efalizumab, <compound-id="6445562">EKB-569</compound-id>, <compound-id="108059">elcometrine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="443872">eplerenone</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="151115">exatecan</compound-id> mesilate, <compound-id="150311">ezetimibe</compound-id>; <compound-id="5288209">Fenretinide</compound-id>, <compound-id="131536">fosamprenavir calcium</compound-id>, <compound-id="77992">frovatriptan</compound-id>; GD2L-KLH conjugate vaccine, <compound-id="123631">gefitinib</compound-id>, <compound-id="123628">glufosfamide</compound-id>, <compound-id="56842148">GTI-2040</compound-id>; Hexyl <protein-id="P01308,I3WAC9">insulin</protein-id> M2, human <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="785,91156575">hydroquinone</compound-id>, gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>; <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id>(38-37)-PE38KDEL, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="216468">indisulam</compound-id>, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="6445540">ixabepilone</compound-id>; KRN-5500; <compound-id="56603730">LY-544344</compound-id>; MDX-210, <compound-id="896">melatonin</compound-id>, <compound-id="56603701">mepolizumab</compound-id>, <compound-id="151071">motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; Natalizumab, <compound-id="6505803">NSC-330507</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; 1-<compound-id="57024563,957">Octanol</compound-id>, omalizumab, <compound-id="6918412">ortataxel</compound-id>; <compound-id="131664">Pagoclone</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="219100">phenoxodiol</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="213022">plevitrexed</compound-id>, polyphenon E, <compound-id="16132446">pramlintide acetate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="219104">PX-12</compound-id>; <compound-id="60866">QS-21</compound-id>; <compound-id="447458">Ragaglitazar</compound-id>, <compound-id="3052774">ranelic acid distrontium salt</compound-id>, <compound-id="124970">RDP</compound-id>-58, recombinant glucagon-like peptide-1 (7-36) <compound-id="2826723">amide</compound-id>, <compound-id="198757">repinotan</compound-id> hydrochloride, rhEndostatin, rh-Lactoferrin, (R)-<compound-id="160355">roscovitine</compound-id>; S-8184, <compound-id="5329098">semaxanib</compound-id>, <compound-id="461399">sitafloxacin hydrate</compound-id>, sitaxsentan <compound-id="5360545">sodium</compound-id>, <compound-id="216239">sorafenib</compound-id>, <compound-id="9895066">synthadotin</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="108092">tesmilifene hydrochloride</compound-id>, theratope, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="219022">topixantrone hydrochloride</compound-id>, <compound-id="108150">trabectedin</compound-id>, <compound-id="219101">traxoprodil</compound-id>, <compound-id="5538">Tri-Luma</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">valganciclovir hydrochloride</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="16135415">Ziconotide</compound-id>.	eplerenone__IL-4__no_interaction	eplerenone__insulin__no_interaction	NSC-683864__IL-4__no_interaction	NSC-683864__insulin__no_interaction	LY-544344__IL-4__no_interaction	LY-544344__insulin__no_interaction	QS-21__IL-4__no_interaction	QS-21__insulin__no_interaction	avasimibe__IL-4__no_interaction	avasimibe__insulin__no_interaction	Ragaglitazar__IL-4__no_interaction	Ragaglitazar__insulin__no_interaction	ertapenem sodium__IL-4__no_interaction	ertapenem sodium__insulin__no_interaction	bortezomib__IL-4__no_interaction	bortezomib__insulin__no_interaction	NSC-330507__IL-4__no_interaction	NSC-330507__insulin__no_interaction	Ximelagatran__IL-4__no_interaction	Ximelagatran__insulin__no_interaction	desloratadine__IL-4__no_interaction	desloratadine__insulin__no_interaction	BQ-123__IL-4__no_interaction	BQ-123__insulin__no_interaction	Valdecoxib__IL-4__no_interaction	Valdecoxib__insulin__no_interaction	bosentan__IL-4__no_interaction	bosentan__insulin__no_interaction	gadolinium__IL-4__no_interaction	gadolinium__insulin__no_interaction	DN-101__IL-4__no_interaction	DN-101__insulin__no_interaction	trabectedin__IL-4__no_interaction	trabectedin__insulin__no_interaction	ezetimibe__IL-4__no_interaction	ezetimibe__insulin__no_interaction	topixantrone hydrochloride__IL-4__no_interaction	topixantrone hydrochloride__insulin__no_interaction	melatonin__IL-4__no_interaction	melatonin__insulin__no_interaction	CEP-1347__IL-4__no_interaction	CEP-1347__insulin__no_interaction	vinflunine__IL-4__no_interaction	vinflunine__insulin__no_interaction	erlotinib hydrochloride__IL-4__no_interaction	erlotinib hydrochloride__insulin__no_interaction	roscovitine__IL-4__no_interaction	roscovitine__insulin__no_interaction	elcometrine__IL-4__no_interaction	elcometrine__insulin__no_interaction	sodium__IL-4__no_interaction	sodium__insulin__no_interaction	ortataxel__IL-4__no_interaction	ortataxel__insulin__no_interaction	cinacalcet hydrochloride__IL-4__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	repinotan__IL-4__no_interaction	repinotan__insulin__no_interaction	PX-12__IL-4__no_interaction	PX-12__insulin__no_interaction	phenoxodiol__IL-4__no_interaction	phenoxodiol__insulin__no_interaction	Tri-Luma__IL-4__no_interaction	Tri-Luma__insulin__no_interaction	semaxanib__IL-4__no_interaction	semaxanib__insulin__no_interaction	pramlintide acetate__IL-4__no_interaction	pramlintide acetate__insulin__no_interaction	pregabalin__IL-4__no_interaction	pregabalin__insulin__no_interaction	Fenretinide__IL-4__no_interaction	Fenretinide__insulin__no_interaction	Octanol__IL-4__no_interaction	Octanol__insulin__no_interaction	dexmethylphenidate hydrochloride__IL-4__no_interaction	dexmethylphenidate hydrochloride__insulin__no_interaction	eszopiclone__IL-4__no_interaction	eszopiclone__insulin__no_interaction	exatecan__IL-4__no_interaction	exatecan__insulin__no_interaction	3-AP__IL-4__no_interaction	3-AP__insulin__no_interaction	RDP__IL-4__no_interaction	RDP__insulin__no_interaction	pimecrolimus__IL-4__no_interaction	pimecrolimus__insulin__no_interaction	indisulam__IL-4__no_interaction	indisulam__insulin__no_interaction	tipifarnib__IL-4__no_interaction	tipifarnib__insulin__no_interaction	valganciclovir hydrochloride__IL-4__no_interaction	valganciclovir hydrochloride__insulin__no_interaction	Ziconotide__IL-4__no_interaction	Ziconotide__insulin__no_interaction	arundic acid__IL-4__no_interaction	arundic acid__insulin__no_interaction	gefitinib__IL-4__no_interaction	gefitinib__insulin__no_interaction	glufosfamide__IL-4__no_interaction	glufosfamide__insulin__no_interaction	DHA-paclitaxel__IL-4__no_interaction	DHA-paclitaxel__insulin__no_interaction	tesmilifene hydrochloride__IL-4__no_interaction	tesmilifene hydrochloride__insulin__no_interaction	ixabepilone__IL-4__no_interaction	ixabepilone__insulin__no_interaction	L-Arginine hydrochloride__IL-4__no_interaction	L-Arginine hydrochloride__insulin__no_interaction	synthadotin__IL-4__no_interaction	synthadotin__insulin__no_interaction	traxoprodil__IL-4__no_interaction	traxoprodil__insulin__no_interaction	dabuzalgron__IL-4__no_interaction	dabuzalgron__insulin__no_interaction	DP-b99__IL-4__no_interaction	DP-b99__insulin__no_interaction	tirapazamine__IL-4__no_interaction	tirapazamine__insulin__no_interaction	CP-461__IL-4__no_interaction	CP-461__insulin__no_interaction	pemetrexed disodium__IL-4__no_interaction	pemetrexed disodium__insulin__no_interaction	mepolizumab__IL-4__no_interaction	mepolizumab__insulin__no_interaction	prasterone__IL-4__no_interaction	prasterone__insulin__no_interaction	imatinib mesylate__IL-4__no_interaction	imatinib mesylate__insulin__no_interaction	Tadalafil__IL-4__no_interaction	Tadalafil__insulin__no_interaction	frovatriptan__IL-4__no_interaction	frovatriptan__insulin__no_interaction	motexafin__IL-4__no_interaction	motexafin__insulin__no_interaction	amide__IL-4__no_interaction	amide__insulin__no_interaction	GTI-2040__IL-4__no_interaction	GTI-2040__insulin__no_interaction	bryostatin 1__IL-4__no_interaction	bryostatin 1__insulin__no_interaction	diflomotecan__IL-4__no_interaction	diflomotecan__insulin__no_interaction	fosamprenavir calcium__IL-4__no_interaction	fosamprenavir calcium__insulin__no_interaction	sitafloxacin hydrate__IL-4__no_interaction	sitafloxacin hydrate__insulin__no_interaction	plevitrexed__IL-4__no_interaction	plevitrexed__insulin__no_interaction	sorafenib__IL-4__no_interaction	sorafenib__insulin__no_interaction	desoxyepothilone B__IL-4__no_interaction	desoxyepothilone B__insulin__no_interaction	adefovir dipivoxil__IL-4__no_interaction	adefovir dipivoxil__insulin__no_interaction	Pagoclone__IL-4__no_interaction	Pagoclone__insulin__no_interaction	enfuvirtide__IL-4__no_interaction	enfuvirtide__insulin__no_interaction	aripiprazole__IL-4__no_interaction	aripiprazole__insulin__no_interaction	BMS-181176__IL-4__no_interaction	BMS-181176__insulin__no_interaction	ranelic acid distrontium salt__IL-4__no_interaction	ranelic acid distrontium salt__insulin__no_interaction	hydroquinone__IL-4__no_interaction	hydroquinone__insulin__no_interaction	EKB-569__IL-4__no_interaction	EKB-569__insulin__no_interaction	duloxetine__IL-4__no_interaction	duloxetine__insulin__no_interaction
18307903-4	RESULTS: (1) Compared with patients with a negative family history of diabetes mellitus, for women with a positive family history, WHR (0.99 +/- 0.10 vs 0.79 +/- 0.08) and score of hirsutism (1.9 +/- 1.2 vs 1.8 +/- 1.2) were increased, the duration of menstruation was longer [(108 +/- 10) vs (92 +/- 19) days]; A [(11 +/- 6) vs (8 +/- 5) nmol/L], homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR, 3.5 +/- 2.0 vs 2.7 +/- 1.6), area under curve (AUC) <compound-id="206,64689,79025">glucose</compound-id> [(836 +/- 245) vs (748 +/- 139) nmol.L(-1).min(-1)], AUC <protein-id="P01308,I3WAC9">insulin</protein-id> [(9670 +/- 4582) vs (7330 +/- 4311) mIU.L(-1).min(-1)], fasting <compound-id="206,64689,79025">glucose</compound-id> [(5.0 +/- 1.1) vs (4.8 +/- 0.5) mmol/L] and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> [(15 +/- 8) vs (11 +/- 8) mIU/L] were increased, while early <protein-id="P01308,I3WAC9">insulin</protein-id> secretion function index (DeltaI60/DeltaG60, 32 +/- 22 vs 52 +/- 30), <protein-id="P01308,I3WAC9">insulin</protein-id> sensitive index (ISI, 0.019 +/- 0.011 vs 0.033 +/- 0.014) and disposition index (DI, 18 +/- 10 vs 30 +/- 22; P &lt; 0.05) were decreased.	glucose__insulin__no_interaction
22311497-5	DN0: UAER &lt; 30 mg/24 h, DN1: UAER 30-300 mg/24 h and DN2: UAER &gt; 300 mg/24 h. RESULTS: Statistics showed: (1) Genotype frequencies and allele frequencies in <protein-id="O15123">Ang-2</protein-id> <compound-id="6440895">1233A</compound-id>/G had significant difference but not <protein-id="O15123">Ang-2</protein-id> 759T/G and 1078A/G; (2) Comparing with those with genotype AA, the relative risk of genotype (AG+ GG) suffered from T2DM and DN were 2.265 fold (OR= 2.265, 95% CI: 1.223-1.402, P= 0.031), 1.789 fold (OR= 1.789, 95% CI: 0.889-1.021, P= 0.012), respectively; (3) The onset of DN was related to <protein-id="O15123">Ang-2</protein-id> <compound-id="6440895">1233A</compound-id>/G allele G (r= 1.321, OR= 1.427, 95% CI: 2.324-4.177, P= 0.034).	1233A__Ang-2__no_interaction
7684452-3	Example compounds such as [1R-[1 alpha[R*(R*)],2 beta]]-4-[[2-[[3-(1H-indol-3-yl)- 2-methyl-2-[[[(2-methylcyclohexyl)oxy]carbonyl]amino]-1- oxopropyl]-amino]-<compound-id="137551">1-phenylethyl</compound-id>]amino]-<compound-id="1112">4-oxo-butanoic acid</compound-id> (24c), (1R-trans)-N-[alpha-methyl-N-[[(2-methylcyclohexyl)oxy] carbonyl]-D-<compound-id="17962040">tryptophyl</compound-id>]-L-3-(<compound-id="123147">phenylmethyl</compound-id>)-<compound-id="20275471">beta-alanine</compound-id> (28i), and N-[alpha-methyl-N-[(tricyclo[3.3.1.1]dec-2-yloxy) carbonyl]-D-tryptophanyl]-L-3-(<compound-id="123147">phenylmethyl</compound-id>)-<compound-id="20275471">beta-alanine</compound-id> (30m) are <protein-id="P01355">CCK</protein-id>-B selective compounds having <protein-id="P01355">CCK</protein-id>-B binding affinities of IC50 = 3.9, 0.34, and 0.15 nM with a <protein-id="P01355">CCK</protein-id>-A/<protein-id="P01355">CCK</protein-id>-B ratio of 464, 53, and 170, respectively.	4-oxo-butanoic acid__CCK__no_interaction	1-phenylethyl__CCK__no_interaction	tryptophyl__CCK__no_interaction	beta-alanine__CCK__no_interaction	phenylmethyl__CCK__no_interaction
18158437-10	RESULTS: Key recommendations, listed by category, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for <compound-id="439260">norepinephrine</compound-id> or <compound-id="681">dopamine</compound-id> to maintain an initial target of mean arterial pressure &gt; or = 65 mm Hg (1C); <compound-id="36811">dobutamine</compound-id> inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated <protein-id="P04070">protein C</protein-id> in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients).	norepinephrine__protein C__no_interaction	dobutamine__protein C__no_interaction	dopamine__protein C__no_interaction
15340100-2	Investigational antiobesity agents consist of 1) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (<compound-id="444">bupropion</compound-id>), selective <compound-id="5202">serotonin</compound-id> 2c receptor agonists, antiseizure agents (<compound-id="5284627">topiramate</compound-id>, <compound-id="5734">zonisamide</compound-id>), some <compound-id="681">dopamine</compound-id> antagonists, and cannabinoid-1 receptor antagonists (<compound-id="104850">rimonabant</compound-id>); 2) <compound-id="90470904">leptin</compound-id>/<protein-id="P01308,I3WAC9">insulin</protein-id>/central nervous system pathway agents, including <compound-id="90470904">leptin</compound-id> analogues, <compound-id="90470904">leptin</compound-id> transport and/or <compound-id="90470904">leptin</compound-id> receptor promoters, ciliary neurotrophic factor (Axokine), neuropeptide Y and agouti-related peptide antagonists, <protein-id="P01189,Q6FHC8">proopiomelanocortin</protein-id> and <compound-id="446220">cocaine</compound-id> and <compound-id="3007">amphetamine</compound-id> regulated transcript promoters, alpha-melanocyte-stimulating hormone analogues, melanocortin-4 receptor agonists, and agents that affect <protein-id="P01308,I3WAC9">insulin</protein-id> metabolism/activity, which include protein-<compound-id="6057,90983769">tyrosine</compound-id> phosphatase-1B inhibitors, peroxisome proliferator activated receptor-gamma receptor antagonists, short-acting bromocriptine (ergoset), somatostatin agonists (<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id>), and adiponectin; 3) gastrointestinal-neural pathway agents, including those that increase <compound-id="16129670">cholecystokinin</compound-id> activity, increase glucagon-like peptide-1 activity (extendin 4, liraglutide, dipeptidyl peptidase IV inhibitors), and increase protein YY3-36 activity and those that decrease <compound-id="44576256">ghrelin</compound-id> activity, as well as amylin analogues (pramlintide); 4) agents that may increase resting metabolic rate ("selective" beta-3 stimulators/agonist, uncoupling protein homologues, and thyroid receptor agonists); and 5) other more diverse agents, including <compound-id="6325610">melanin</compound-id> concentrating hormone antagonists, phytostanol analogues, functional oils, <protein-id="P49918">P57</protein-id>, amylase inhibitors, growth hormone fragments, synthetic analogues of <compound-id="12594">dehydroepiandrosterone sulfate</compound-id>, antagonists of adipocyte 11B-hydroxysteroid dehydrogenase type 1 activity, corticotropin-releasing hormone agonists, inhibitors of fatty acid synthesis, carboxypeptidase inhibitors, indanones/indanols, aminosterols, and other gastrointestinal <compound-id="5474737">lipase</compound-id> inhibitors (<compound-id="9952916">ATL962</compound-id>).	tyrosine__P57__no_interaction	tyrosine__proopiomelanocortin__no_interaction	tyrosine__insulin__no_interaction	leptin__P57__no_interaction	leptin__proopiomelanocortin__no_interaction	leptin__insulin__no_interaction	ATL962__P57__no_interaction	ATL962__proopiomelanocortin__no_interaction	ATL962__insulin__no_interaction	rimonabant__P57__no_interaction	rimonabant__proopiomelanocortin__no_interaction	rimonabant__insulin__no_interaction	melanin__P57__no_interaction	melanin__proopiomelanocortin__no_interaction	melanin__insulin__no_interaction	serotonin__P57__no_interaction	serotonin__proopiomelanocortin__no_interaction	serotonin__insulin__no_interaction	dehydroepiandrosterone sulfate__P57__no_interaction	dehydroepiandrosterone sulfate__proopiomelanocortin__no_interaction	dehydroepiandrosterone sulfate__insulin__no_interaction	zonisamide__P57__no_interaction	zonisamide__proopiomelanocortin__no_interaction	zonisamide__insulin__no_interaction	topiramate__P57__no_interaction	topiramate__proopiomelanocortin__no_interaction	topiramate__insulin__no_interaction	octreotide__P57__no_interaction	octreotide__proopiomelanocortin__no_interaction	octreotide__insulin__no_interaction	dopamine__P57__no_interaction	dopamine__proopiomelanocortin__no_interaction	dopamine__insulin__no_interaction	ghrelin__P57__no_interaction	ghrelin__proopiomelanocortin__no_interaction	ghrelin__insulin__no_interaction	cocaine__P57__no_interaction	cocaine__proopiomelanocortin__no_interaction	cocaine__insulin__no_interaction	amphetamine__P57__no_interaction	amphetamine__proopiomelanocortin__no_interaction	amphetamine__insulin__no_interaction	cholecystokinin__P57__no_interaction	cholecystokinin__proopiomelanocortin__no_interaction	cholecystokinin__insulin__no_interaction	lipase__P57__no_interaction	lipase__proopiomelanocortin__no_interaction	lipase__insulin__no_interaction	bupropion__P57__no_interaction	bupropion__proopiomelanocortin__no_interaction	bupropion__insulin__no_interaction
11926545-5	<protein-id="O95999">Carmen</protein-id> contained the following 8 <compound-id="8030">thiophene</compound-id> compounds: <compound-id="70813">5-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (<compound-id="446505">BBT</compound-id>), <compound-id="3083681">5'-methyl-5-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (MeBBT), <compound-id="15737449">5-(1-pentynyl)-2,2'-bithienyl</compound-id> (PBT), <compound-id="440357">5-(4-hydroxy-1-butynyl)-2,2'-bithienyl</compound-id> (BBTOH), 2,2',5,2"-terthienyl (<compound-id="6278">alpha-T</compound-id>), <compound-id="440356">5-(4-acetoxy-1-butynyl)-2,2'-bithienyl</compound-id> (BBTOAc), <compound-id="90928524">5-methylaceto-5'-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (AcOCH2BBT), and <compound-id="440404">5-(3,4-diacetoxy-1-butynyl)-2,2'-bithienyl</compound-id> (<compound-id="446505">BBT</compound-id>(OAc)2).	5-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	5'-methyl-5-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	5-(1-pentynyl)-2,2'-bithienyl__Carmen__no_interaction	thiophene__Carmen__no_interaction	5-(3,4-diacetoxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	5-(4-hydroxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	5-methylaceto-5'-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	alpha-T__Carmen__no_interaction	5-(4-acetoxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	BBT__Carmen__no_interaction
10417506-6	RESULTS: The mean concentrations of <compound-id="33741">tramadol</compound-id> during the postsurgery phase were 470+/-323 ng <protein-id="Q9NTI2">ml-1</protein-id>, 590+/-410 ng <protein-id="Q9NTI2">ml-1</protein-id> and 771+/-451 ng <protein-id="Q9NTI2">ml-1</protein-id> in the (+)-, racemate- and (-)-group, respectively ((+) vs (-), P&lt;0.05); the mean concentrations of the metabolite M1 were 57+/-18 ng <protein-id="Q9NTI2">ml-1</protein-id>, 84+/-34 ng <protein-id="Q9NTI2">ml-1</protein-id> and 96+/-41 ng <protein-id="Q9NTI2">ml-1</protein-id> in the (+)-, racemate- and (-)-group, respectively ((+) vs (-) and (+) vs racemate, P&lt;0.05).	tramadol__ml-1__no_interaction
7555001-3	Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, <protein-id="P51812,B7ZB17,B4DG22">Cls</protein-id>/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p &gt; 0.05) effect of <compound-id="3016">diazepam</compound-id> on quinidine disposition kinetics.	diazepam__Cls__no_interaction
24222953-11	When comparing <protein-id="P35639,Q3V405">CHOP</protein-id>(-/-) mice and WT mice, we observed that <protein-id="P35639,Q3V405">CHOP</protein-id>-deficient mice had greater increases in serum TNF-α (214.40 ± 19.52 pg/mL vs 150.40 ± 16.70 pg/mL; P = 0.037), amylase (4236.40 ± 646.32 U/L vs 2535.30 ± 81.83 U/L; P = 0.041), <compound-id="5474737">lipase</compound-id> (1678.20 ± 170.57 U/L vs 1046.21 ± 35.37 U/L; P = 0.008), and <protein-id="P08505,A2RTD1">IL-6</protein-id> (2054.44 ± 293.81 pg/mL vs 1316.10 ± 108.74 pg/mL; P = 0.046) than WT mice.	lipase__CHOP__no_interaction	lipase__IL-6__no_interaction
18793405-7	Although there were no significant treatment differentials between the age groups for these efficacy measures, the age groups themselves, regardless of treatment, were significantly different for ADHD-<compound-id="7021454">RS</compound-id> total (younger: <protein-id="Q13822">ATX</protein-id> = -14.2 [13.8], PBO = -4.6 [10.4]; older: <protein-id="Q13822">ATX</protein-id> = -15.4 [13.2], PBO = -7.3 [12.0]; p = .001), total T (younger: <protein-id="Q13822">ATX</protein-id> = -15.2 [14.8], PBO = -4.9 [11.2]; older: <protein-id="Q13822">ATX</protein-id> = -16.4 [14.6], PBO = -7.9 [13.1]; p = .003), and subscale scores (Inattentive: younger: <protein-id="Q13822">ATX</protein-id> = -7.2 [7.5], PBO = -2.4 [5.7]; older: <protein-id="Q13822">ATX</protein-id> = -8.0 [7.4], PBO = -3.9 [6.7]; p = .043; Hyperactive/Impulsive: younger: <protein-id="Q13822">ATX</protein-id> = -7.0 [7.2], PBO = -2.1 [5.4]; older: <protein-id="Q13822">ATX</protein-id> = -7.3 [7.0], PBO = -3.4 [6.3]; p &lt; .001), as well as the CGI-ADHD-S score (younger: <protein-id="Q13822">ATX</protein-id> = -1.2 [1.3], PBO = -0.5 [0.9]; older: <protein-id="Q13822">ATX</protein-id> = -1.4 [1.3], PBO = -0.7 [1.1]; p = .010).	RS__ATX__no_interaction
15968308-9	In univariate prognostic analysis model, the OS was higher in <protein-id="P17927,E9PDY4">CR1</protein-id> group pre-HSCT than that in non-<protein-id="P17927,E9PDY4">CR1</protein-id> group (74.50% vs 22.22%, P=0.0046), <compound-id="76871876">LFS</compound-id> was higher (49.06% vs 11.11%, P=0.0057), RI was lower (44.80% vs 84.76%, P=0.0157); the OS was higher in M(<protein-id="P11274">BCR/ABL</protein-id>) group than that in m(<protein-id="P11274">BCR/ABL</protein-id>) group (100% vs 40.91%, P=0.0318), <compound-id="76871876">LFS</compound-id> was higher (75% vs 17.72%, P=0.0057), RI was lower (25% vs 77.88, P=0.0116); OS was similar in HLA MM RD group to that in HLA identical group (52.65% vs 55.56%, P=0.6247), <compound-id="76871876">LFS</compound-id> was similar (45.12% vs 30.00%, P=0.8315), and RI was also similar (50.77% vs 60.62%, P=0.8217).	LFS__BCR/ABL__no_interaction	LFS__CR1__no_interaction
21560328-8	RESULTS: (1) The results determined by dry-weight method indicated that <compound-id="962">water</compound-id> content of rats brain increased markedly after rats were exposed to a simulated altitude at 6 000 m, 8 000 m. (2) The results determined by microscopy indicated that during the rats exposed to hypoxia, nerve cells, vascular endothelial cells and astrocyte foot processes swelled lightly, transudate occurred in tissues at 4 000 m. The swelling of vascular endothelial cell (<compound-id="2735038">VEC</compound-id>) and astrocyte foot processes aggravated, interspace between vessels and tissues enlarged, and transudate in tissue increased at 6 000 m. The swelling of <compound-id="2735038">VEC</compound-id> and astrocyte foot processes went from bad to worse, interspace between vessels and tissues enlarged further, and transudate in tissue increased evidently at 8 000 m. (3) During hypoxic encephaledema, the expression of <protein-id="P16612,Q541S7,A0A0G2K6Z7,B5DEK7">VEGF</protein-id>, <protein-id="P29975">AQP1</protein-id> and <protein-id="P47863,A0A0G2K4I1,A0A0H2UHZ1">AQP4</protein-id> mRNA increased, <protein-id="P29975">AQP1</protein-id> was abnormally expressed on the surface of <compound-id="2735038">VEC</compound-id>, and the expressive level of <protein-id="P16612,Q541S7,A0A0G2K6Z7,B5DEK7">VEGF</protein-id> and <protein-id="P29975">AQP1</protein-id> on <compound-id="2735038">VEC</compound-id> and <protein-id="P47863,A0A0G2K4I1,A0A0H2UHZ1">AQP4</protein-id> on astrocyte foot processes increased.	water__AQP4__no_interaction	water__VEGF__no_interaction	water__AQP1__no_interaction	VEC__AQP4__no_interaction	VEC__VEGF__no_interaction	VEC__AQP1__no_interaction
21154263-7	RESULTS: There were significant differences between three-vessel CAD patients and control groups with respect to the serum levels of: hsCRP (2.8 vs 1.4 mg/L, p = 0.01), HDL-<compound-id="5997">cholesterol</compound-id> (45 vs 54 mg/dL, p = 0.04), LDL-<compound-id="5997">cholesterol</compound-id> (102 vs 95 mg/dL, p = 0.04), NT-proBNP (392 vs 151 pg/mL, p = 0.008) and a marker of angiogenetic activity, <protein-id="P03950,W0UV28">angiogenin</protein-id> (414 vs 275 ng/mL, p = 0.02), However, no significant differences were found between three-vessel CAD and the control group with respect to the serum level of <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (8.08 vs 7.82 μg/mL), <protein-id="Q9HD89">resistin</protein-id> (17.5 vs 21 ng/mL), <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (20.7 vs 26.8 pg/mL) and <protein-id="P01375,Q5STB3">TNF-a</protein-id> (4.1 vs 4.3 pg/mL).	cholesterol__angiogenin__no_interaction	cholesterol__resistin__no_interaction	cholesterol__IL-8__no_interaction	cholesterol__TNF-a__no_interaction	cholesterol__adiponectin__no_interaction
10348797-4	Evidence that human hepatic <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> and 2D6 catalyze the formation of tam catechol from <compound-id="449459">4-OH-tam</compound-id> and supportive data that the catechol is proximate to the reactive intermediate, was obtained: 1) There was a good correlation (r = 0.82; p &lt;/=.0004) between steroidal 6beta-hydroxylase (CYP3A activity) and ortho hydroxylation of <compound-id="449459">4-OH-tam</compound-id> in human liver microsomes; 2) monospecific antibodies against <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> strongly inhibited catechol formation from <compound-id="449459">4-OH-tam</compound-id> and its covalent binding to proteins in human liver microsomes; 3) low levels of <compound-id="3823,456201,47576,5702077">ketoconazole</compound-id> inhibited catechol tam accumulation and covalent binding of <compound-id="449459">4-OH-tam</compound-id> to human liver proteins; 4) among human P-450s expressed in insect cells (supersomes), only <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> and 2D6 noticeably catalyzed catechol formation, and <protein-id="P00167">cytochrome b5</protein-id> markedly stimulated the <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> catalysis; and 5) human livers with high CYP3A and low or high <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> activity exhibited high catechol formation and those with low <compound-id="2981881,91293124">3A</compound-id> and 2D6 activities formed only little catechol.	4-OH-tam__CYP3A4__no_interaction	4-OH-tam__cytochrome b5__no_interaction	4-OH-tam__CYP2D6__no_interaction	3A__CYP3A4__no_interaction	3A__cytochrome b5__no_interaction	3A__CYP2D6__no_interaction	ketoconazole__CYP3A4__no_interaction	ketoconazole__cytochrome b5__no_interaction	ketoconazole__CYP2D6__no_interaction
10396370-13	In men, E1-FA levels also correlated with systolic blood pressure (r = 0.59, P = 0.01), total triglycerides (r = 0.63, P = 0.003), VLDL-triglycerides (r = 0.62, P = 0.004) and VLDL-<compound-id="5997">cholesterol</compound-id> (r = 0.48, P = 0.03), but not with diastolic blood pressure, serum total or LDL-<compound-id="5997">cholesterol</compound-id>, or total and <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> and HDL3 subfractions of HDL <compound-id="5997">cholesterol</compound-id>.	cholesterol__HDL2__no_interaction
10396370-15	In women, E1-FA levels correlated with total triglycerides (r = 0.66, P = 0.001), VLDL-triglycerides (r = 0.65, P = 0.001), VLDL-<compound-id="5997">cholesterol</compound-id> (r = 0.63, P = 0.002), LDL-<compound-id="5997">cholesterol</compound-id> (r = 0.57, P = 0.005) and total and <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> and HDL3 subfractions of HDL <compound-id="5997">cholesterol</compound-id> (r = -0.58, -0.48, -0.61, P = 0.004, 0.02 and 0.002, respectively), but not with systolic or diastolic blood pressure or total <compound-id="5997">cholesterol</compound-id>.	cholesterol__HDL2__no_interaction
10587445-2	It reveals that (i) D1-D2-Cyt b(559) complexes either in solubilized form or incorporated into liposomes contain only one type of Cyt b(559) with E(m) values of 60 +/- 5 and 100 +/- 10 mV, respectively, at pH 6.8; (ii) in <compound-id="977">oxygen</compound-id>-evolving solubilized <protein-id="P49810,E5RG63">PS II</protein-id> core complexes Cyt b(559) exists predominantly (&gt;85%) as an LP form with an E(m,7) of 125 +/- 10 mV and a minor fraction with an E(m,7) of -150 +/- 15 mV; (iii) in <compound-id="977">oxygen</compound-id>-evolving <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments three different redox forms are discernible with E(m) values of 390 +/- 15 mV (HP form), 230 +/- 20 mV (IP form), and 105 +/- 25 mV (LP form) and relative amplitudes of 58, 24, and 18%, respectively, at pH 7.3; (iv) the E(m) values are almost pH-independent between pH 6 and 9.5 in all sample types except D1-D2-Cyt b(559) complexes incorporated into liposomes with a slope of -29 mV/pH unit, when the pH increases from 6 to 9.5 (IP and LP form in <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments possibly within a restricted range from pH 6.5 to 8); (v) at pH &gt;8 the HP Cyt b(559) progressively converts to the IP form with increasing pH; (vi) the reduced-minus-oxidized optical difference spectra of Cyt b(559) are very similar in the lambda range of 360-700 nm for all types except for the HP form which exhibits pronounced differences in the Soret band; and (vii) <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments and core complexes are inferred to contain about two Cyt b(559) hemes per <protein-id="P49810,E5RG63">PS II</protein-id>.	oxygen__PS II__no_interaction
23505173-4	Thyroid stimulating hormone (TSH) correlated with BMI (r = 0.46; P = 0.02), both visceral (r = 0.58; P = 0.02) and subcutaneous adipose tissue volumes (r = 0.43; P = 0.03) and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (inverse relationship with <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity-<compound-id="206,5793,64689,79025">glucose</compound-id> uptake: r = -0.40; P = 0.04).	glucose__insulin__no_interaction
23074401-31	The following conclusions were drawn from the entire body of evidence: There is a lack of external validation to support the reliability of Oncotype-DX; however, the current available evidence derived from internal industry validation studies suggests that Oncotype-DX is reliable (i.e., Oncotype-DX is repeatable and reproducible).Current available evidence suggests a moderate failure rate of Oncotype-DX testing; however, the failure rate observed across clinical trials included in this review is likely inflated; the current Ontario experience suggests an acceptably lower rate of test failure.In women with newly diagnosed early breast cancer (stage I-II) that is estrogen-receptor positive and/or <compound-id="5994">progesterone</compound-id>-receptor positive and lymph-node negative:There is low quality evidence that Oncotype-DX has prognostic value in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id> or <compound-id="2187">anastrozole</compound-id> (the latter for postmenopausal women only),There is very low quality evidence that Oncotype-DX can predict which women will benefit from adjuvant CMF/MF chemotherapy in women being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id>.In postmenopausal women with newly diagnosed early breast cancer that is estrogen-receptor positive and/or <compound-id="5994">progesterone</compound-id>-receptor positive and lymph-node positive:There is low quality evidence that Oncotype-DX has limited prognostic value in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id> or <compound-id="2187">anastrozole</compound-id>,There is very low quality evidence that Oncotype-DX has limited predictive value for predicting which women will benefit from adjuvant <protein-id="Q92831">CAF</protein-id> chemotherapy in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id>.There are methodological and statistical limitations that affect both the generalizability of the current available evidence, as well as the magnitude and statistical strength of the observed effect sizes; in particular:Of the major predictive trials, Oncotype-DX scores were only produced for a small subset of women (&lt;40% of the original randomized population) potentially disabling the effects of treatment randomization and opening the possibility of selection bias;Data is not specific to <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">HER-2</protein-id>/<protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">neu</protein-id>-negative women;There were limitations with multivariate statistical analyses.Additional trials of observational design may provide further validation of the prognostic and predictive value of Oncotype-DX; however, it is unlikely that prospective or randomized data will become available in the near future due to ethical, time and resource considerations.There is currently insufficient evidence investigating how Oncoytpe-DX compares to other known prognostic estimators of risk, such as Adjuvant!	anastrozole__HER-2__no_interaction	anastrozole__neu__no_interaction	anastrozole__CAF__no_interaction	tamoxifen__HER-2__no_interaction	tamoxifen__neu__no_interaction	tamoxifen__CAF__no_interaction	progesterone__HER-2__no_interaction	progesterone__neu__no_interaction	progesterone__CAF__no_interaction
12168506-3	This issue focuses on the following selection of drugs: <compound-id="441300">Abacavir sulfate</compound-id>, <compound-id="16131215">abarelix</compound-id>, abciximab, <compound-id="16197724">alicaforsen sodium</compound-id>, <compound-id="123606">almotriptan</compound-id>, alteplase, <compound-id="2162">amlodipine</compound-id>, <compound-id="33613">amoxicillin trihydrate</compound-id>, <compound-id="65016">amprenavir</compound-id>, <compound-id="152951,2232,440542,445156,92722">argatroban</compound-id> <compound-id="1488787">monohydrate</compound-id>, <compound-id="2244">aspirin</compound-id>, <compound-id="60823">atorvastatin calcium</compound-id>, <compound-id="2265">azathioprine</compound-id>; <compound-id="2284">Baclofen</compound-id>, <compound-id="656668">benidipine</compound-id> hydrochloride, <compound-id="2327">benserazide</compound-id>, <compound-id="448545">BMS-214662</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B; <compound-id="2540">Candesartan cilexetil</compound-id>, <compound-id="2554">carbamazepine</compound-id>, carbidopa, <compound-id="2568">carboplatin</compound-id>, <compound-id="5479530,11957492,12971801,5361919,2657,5896995,6398678">ceftriaxone sodium</compound-id>, <compound-id="2662">celecoxib</compound-id>, <compound-id="2678">cetirizine hydrochloride</compound-id>, <compound-id="84029">clarithromycin</compound-id>, <compound-id="5280980">clavulanate potassium</compound-id>, <compound-id="2806,60606">clopidogrel hydrogensulfate</compound-id>, <compound-id="2818">clozapine</compound-id>, <compound-id="151118">CPI-1189</compound-id>, <compound-id="2907">cyclophosphamide</compound-id>, <compound-id="6253">cytarabine</compound-id>; Darbepoetin alfa, denileukin diftitox, <compound-id="5743">dexamethasone</compound-id>, <compound-id="3108">dipyridamole</compound-id>, <compound-id="3168">droperidol</compound-id>, DW-166HC; <compound-id="3191">Ebastine</compound-id>, efalizumab, <compound-id="64139">efavirenz</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="5388962">enalapril</compound-id> <compound-id="444266">maleate</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="57199466,772">enoxaparin</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="178103">enrasentan</compound-id>, <compound-id="5281081">entacapone</compound-id>, <protein-id="P01588,G9JKG7">epoetin</protein-id>, <compound-id="5281037">eprosartan mesilate</compound-id>, etanercept, <compound-id="123619">etoricoxib</compound-id>; Fenofibratefexofenadine hydrochloride, filgrastim, <compound-id="30751">fludarabine phosphate</compound-id>, <compound-id="3386">fluoxetine hydrochloride</compound-id> <compound-id="5324346">fluvoxamine maleate</compound-id>, <compound-id="77992">frovatriptan</compound-id>, <compound-id="3440">furosemide</compound-id>; <compound-id="3446">Gabapentin</compound-id>, <compound-id="9651">galantamine hydrobromide</compound-id>, <compound-id="5379">gatifloxacin</compound-id>, <compound-id="123631">gefitinib</compound-id>, <compound-id="44576256">ghrelin</compound-id> (human), <compound-id="3081884">glatiramer acetate</compound-id>; <compound-id="3559">Haloperidol</compound-id>; <compound-id="3672">Ibuprofen</compound-id>, <compound-id="3672">ibuprofen</compound-id>, <compound-id="460">guaiacol</compound-id> ester, <compound-id="42890">idarubicin hydrochloride</compound-id>, <compound-id="3696">imipramine hydrochloride</compound-id>, <compound-id="57469">imiquimod</compound-id>, <protein-id="P01574">interferon beta</protein-id>, <protein-id="P01574">interferon beta</protein-id>-1a, <protein-id="P01574">interferon beta</protein-id>-1b, interferon omega, <compound-id="3749">irbesartan</compound-id>, <compound-id="55283">itraconazole</compound-id>; Ketorolac, <compound-id="3826">ketorolac tromethamine</compound-id>; <compound-id="3038484">Lamifiban</compound-id>, <compound-id="3878">lamotrigine</compound-id>, lanoteplase, <compound-id="3883">lansoprazole</compound-id>, <compound-id="3899">leflunomide</compound-id>, <compound-id="657181">leuprorelin acetate</compound-id>, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="6047">levodopa</compound-id>, <compound-id="5362119">lisinopril</compound-id>, <compound-id="3957">loratadine</compound-id>; <compound-id="4008">Manidipine</compound-id>, <compound-id="6741">methylprednisolone</compound-id>, <compound-id="4173">metronidazole</compound-id>, <compound-id="4205">mirtazapine</compound-id>, <compound-id="65906">mizolastine</compound-id>, modafinil, <compound-id="5288826">morphine sulfate</compound-id>; <compound-id="156391">Naproxen sodium</compound-id>, <compound-id="4440">naratriptan hydrochloride</compound-id>, <compound-id="4485">nifedipine</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; <compound-id="4583">Ofloxacin</compound-id>, <compound-id="4585">olanzapine</compound-id>, omalizumab, <compound-id="656629">omapatrilat</compound-id>, <compound-id="4595">ondansetron hydrochloride</compound-id>, <compound-id="34312">oxcarbazepine</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>, <compound-id="119828">parecoxib sodium</compound-id>, <compound-id="43815">paroxetine hydrochloride</compound-id>, <compound-id="1775">phenytoin sodium</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="4885,119570,59868">pramipexole hydrochloride</compound-id>, <compound-id="54687">pravastatin</compound-id>, <compound-id="5865">prednisone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; <compound-id="5002">Quetiapine fumarate</compound-id>; <compound-id="3001055">Ranitidine hydrochloride</compound-id>, rasburicase, <compound-id="392622">ritonavir</compound-id>, <compound-id="14254240,6918078,71296087,77990">rivastigmine tartrate</compound-id>, <compound-id="77997">rizatriptan benzoate</compound-id>, <compound-id="5090">rofecoxib</compound-id>; <compound-id="441243">Saquinavir mesilate</compound-id>, <compound-id="68617">sertraline</compound-id>, <compound-id="5212">sildenafil citrate</compound-id>, <compound-id="54454">simvastatin</compound-id>, <compound-id="5358">sumatriptan succinate</compound-id>; <compound-id="445643,90726579">Tacrolimus</compound-id>, <compound-id="60648">tiagabine hydrochloride</compound-id>, <compound-id="5472">ticlopidine hydrochloride</compound-id>, <compound-id="60947">tirofiban hydrochloride</compound-id>, <compound-id="216237">tolvaptan</compound-id>, <compound-id="5284627">topiramate</compound-id>, <compound-id="444795">tretinoin</compound-id>; <compound-id="3121">Valproic acid</compound-id>, <compound-id="60846">valsartan</compound-id>, <compound-id="5656">venlafaxine hydrochloride</compound-id>, <compound-id="2520">verapamil</compound-id>; <compound-id="54678486">Warfarin</compound-id> <compound-id="5360545">sodium</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="60855">Zanamivir</compound-id>, <compound-id="16135415">ziconotide</compound-id>, <compound-id="60857">zolmitriptan</compound-id>, <compound-id="5734">zonisamide</compound-id>.	BMS-214662__epoetin__no_interaction	BMS-214662__interferon beta__no_interaction	sertraline__epoetin__no_interaction	sertraline__interferon beta__no_interaction	Lamifiban__epoetin__no_interaction	Lamifiban__interferon beta__no_interaction	dipyridamole__epoetin__no_interaction	dipyridamole__interferon beta__no_interaction	fluoxetine hydrochloride__epoetin__no_interaction	fluoxetine hydrochloride__interferon beta__no_interaction	argatroban__epoetin__no_interaction	argatroban__interferon beta__no_interaction	sodium__epoetin__no_interaction	sodium__interferon beta__no_interaction	Ofloxacin__epoetin__no_interaction	Ofloxacin__interferon beta__no_interaction	fludarabine phosphate__epoetin__no_interaction	fludarabine phosphate__interferon beta__no_interaction	idarubicin hydrochloride__epoetin__no_interaction	idarubicin hydrochloride__interferon beta__no_interaction	Zanamivir__epoetin__no_interaction	Zanamivir__interferon beta__no_interaction	atorvastatin calcium__epoetin__no_interaction	atorvastatin calcium__interferon beta__no_interaction	Warfarin__epoetin__no_interaction	Warfarin__interferon beta__no_interaction	Valproic acid__epoetin__no_interaction	Valproic acid__interferon beta__no_interaction	zolmitriptan__epoetin__no_interaction	zolmitriptan__interferon beta__no_interaction	Tacrolimus__epoetin__no_interaction	Tacrolimus__interferon beta__no_interaction	celecoxib__epoetin__no_interaction	celecoxib__interferon beta__no_interaction	galantamine hydrobromide__epoetin__no_interaction	galantamine hydrobromide__interferon beta__no_interaction	morphine sulfate__epoetin__no_interaction	morphine sulfate__interferon beta__no_interaction	abarelix__epoetin__no_interaction	abarelix__interferon beta__no_interaction	enoxaparin__epoetin__no_interaction	enoxaparin__interferon beta__no_interaction	ziconotide__epoetin__no_interaction	ziconotide__interferon beta__no_interaction	rizatriptan benzoate__epoetin__no_interaction	rizatriptan benzoate__interferon beta__no_interaction	Candesartan cilexetil__epoetin__no_interaction	Candesartan cilexetil__interferon beta__no_interaction	levocetirizine__epoetin__no_interaction	levocetirizine__interferon beta__no_interaction	sildenafil citrate__epoetin__no_interaction	sildenafil citrate__interferon beta__no_interaction	ceftriaxone sodium__epoetin__no_interaction	ceftriaxone sodium__interferon beta__no_interaction	enrasentan__epoetin__no_interaction	enrasentan__interferon beta__no_interaction	fluvoxamine maleate__epoetin__no_interaction	fluvoxamine maleate__interferon beta__no_interaction	furosemide__epoetin__no_interaction	furosemide__interferon beta__no_interaction	valsartan__epoetin__no_interaction	valsartan__interferon beta__no_interaction	alicaforsen sodium__epoetin__no_interaction	alicaforsen sodium__interferon beta__no_interaction	oxcarbazepine__epoetin__no_interaction	oxcarbazepine__interferon beta__no_interaction	ibuprofen__epoetin__no_interaction	ibuprofen__interferon beta__no_interaction	clozapine__epoetin__no_interaction	clozapine__interferon beta__no_interaction	tirofiban hydrochloride__epoetin__no_interaction	tirofiban hydrochloride__interferon beta__no_interaction	rofecoxib__epoetin__no_interaction	rofecoxib__interferon beta__no_interaction	pravastatin__epoetin__no_interaction	pravastatin__interferon beta__no_interaction	verapamil__epoetin__no_interaction	verapamil__interferon beta__no_interaction	Paclitaxel__epoetin__no_interaction	Paclitaxel__interferon beta__no_interaction	itraconazole__epoetin__no_interaction	itraconazole__interferon beta__no_interaction	lisinopril__epoetin__no_interaction	lisinopril__interferon beta__no_interaction	venlafaxine hydrochloride__epoetin__no_interaction	venlafaxine hydrochloride__interferon beta__no_interaction	benidipine__epoetin__no_interaction	benidipine__interferon beta__no_interaction	benserazide__epoetin__no_interaction	benserazide__interferon beta__no_interaction	monohydrate__epoetin__no_interaction	monohydrate__interferon beta__no_interaction	leflunomide__epoetin__no_interaction	leflunomide__interferon beta__no_interaction	gefitinib__epoetin__no_interaction	gefitinib__interferon beta__no_interaction	carboplatin__epoetin__no_interaction	carboplatin__interferon beta__no_interaction	leuprorelin acetate__epoetin__no_interaction	leuprorelin acetate__interferon beta__no_interaction	topiramate__epoetin__no_interaction	topiramate__interferon beta__no_interaction	clarithromycin__epoetin__no_interaction	clarithromycin__interferon beta__no_interaction	phenytoin sodium__epoetin__no_interaction	phenytoin sodium__interferon beta__no_interaction	tiagabine hydrochloride__epoetin__no_interaction	tiagabine hydrochloride__interferon beta__no_interaction	loratadine__epoetin__no_interaction	loratadine__interferon beta__no_interaction	Gabapentin__epoetin__no_interaction	Gabapentin__interferon beta__no_interaction	droperidol__epoetin__no_interaction	droperidol__interferon beta__no_interaction	ticlopidine hydrochloride__epoetin__no_interaction	ticlopidine hydrochloride__interferon beta__no_interaction	Ximelagatran__epoetin__no_interaction	Ximelagatran__interferon beta__no_interaction	efavirenz__epoetin__no_interaction	efavirenz__interferon beta__no_interaction	rivastigmine tartrate__epoetin__no_interaction	rivastigmine tartrate__interferon beta__no_interaction	glatiramer acetate__epoetin__no_interaction	glatiramer acetate__interferon beta__no_interaction	imipramine hydrochloride__epoetin__no_interaction	imipramine hydrochloride__interferon beta__no_interaction	cyclophosphamide__epoetin__no_interaction	cyclophosphamide__interferon beta__no_interaction	NSC-683864__epoetin__no_interaction	NSC-683864__interferon beta__no_interaction	bosentan__epoetin__no_interaction	bosentan__interferon beta__no_interaction	amoxicillin trihydrate__epoetin__no_interaction	amoxicillin trihydrate__interferon beta__no_interaction	etoricoxib__epoetin__no_interaction	etoricoxib__interferon beta__no_interaction	imiquimod__epoetin__no_interaction	imiquimod__interferon beta__no_interaction	Baclofen__epoetin__no_interaction	Baclofen__interferon beta__no_interaction	ketorolac tromethamine__epoetin__no_interaction	ketorolac tromethamine__interferon beta__no_interaction	frovatriptan__epoetin__no_interaction	frovatriptan__interferon beta__no_interaction	Ranitidine hydrochloride__epoetin__no_interaction	Ranitidine hydrochloride__interferon beta__no_interaction	zonisamide__epoetin__no_interaction	zonisamide__interferon beta__no_interaction	metronidazole__epoetin__no_interaction	metronidazole__interferon beta__no_interaction	dexamethasone__epoetin__no_interaction	dexamethasone__interferon beta__no_interaction	enfuvirtide__epoetin__no_interaction	enfuvirtide__interferon beta__no_interaction	aspirin__epoetin__no_interaction	aspirin__interferon beta__no_interaction	maleate__epoetin__no_interaction	maleate__interferon beta__no_interaction	methylprednisolone__epoetin__no_interaction	methylprednisolone__interferon beta__no_interaction	tolvaptan__epoetin__no_interaction	tolvaptan__interferon beta__no_interaction	clavulanate potassium__epoetin__no_interaction	clavulanate potassium__interferon beta__no_interaction	entacapone__epoetin__no_interaction	entacapone__interferon beta__no_interaction	ritonavir__epoetin__no_interaction	ritonavir__interferon beta__no_interaction	carbamazepine__epoetin__no_interaction	carbamazepine__interferon beta__no_interaction	amlodipine__epoetin__no_interaction	amlodipine__interferon beta__no_interaction	lamotrigine__epoetin__no_interaction	lamotrigine__interferon beta__no_interaction	CPI-1189__epoetin__no_interaction	CPI-1189__interferon beta__no_interaction	Haloperidol__epoetin__no_interaction	Haloperidol__interferon beta__no_interaction	pregabalin__epoetin__no_interaction	pregabalin__interferon beta__no_interaction	enalapril__epoetin__no_interaction	enalapril__interferon beta__no_interaction	almotriptan__epoetin__no_interaction	almotriptan__interferon beta__no_interaction	Manidipine__epoetin__no_interaction	Manidipine__interferon beta__no_interaction	eprosartan mesilate__epoetin__no_interaction	eprosartan mesilate__interferon beta__no_interaction	Ibuprofen__epoetin__no_interaction	Ibuprofen__interferon beta__no_interaction	ghrelin__epoetin__no_interaction	ghrelin__interferon beta__no_interaction	levetiracetam__epoetin__no_interaction	levetiracetam__interferon beta__no_interaction	omapatrilat__epoetin__no_interaction	omapatrilat__interferon beta__no_interaction	mirtazapine__epoetin__no_interaction	mirtazapine__interferon beta__no_interaction	nifedipine__epoetin__no_interaction	nifedipine__interferon beta__no_interaction	azathioprine__epoetin__no_interaction	azathioprine__interferon beta__no_interaction	cytarabine__epoetin__no_interaction	cytarabine__interferon beta__no_interaction	pramipexole hydrochloride__epoetin__no_interaction	pramipexole hydrochloride__interferon beta__no_interaction	irbesartan__epoetin__no_interaction	irbesartan__interferon beta__no_interaction	mizolastine__epoetin__no_interaction	mizolastine__interferon beta__no_interaction	tretinoin__epoetin__no_interaction	tretinoin__interferon beta__no_interaction	lansoprazole__epoetin__no_interaction	lansoprazole__interferon beta__no_interaction	ondansetron hydrochloride__epoetin__no_interaction	ondansetron hydrochloride__interferon beta__no_interaction	clopidogrel hydrogensulfate__epoetin__no_interaction	clopidogrel hydrogensulfate__interferon beta__no_interaction	Saquinavir mesilate__epoetin__no_interaction	Saquinavir mesilate__interferon beta__no_interaction	simvastatin__epoetin__no_interaction	simvastatin__interferon beta__no_interaction	Naproxen sodium__epoetin__no_interaction	Naproxen sodium__interferon beta__no_interaction	cetirizine hydrochloride__epoetin__no_interaction	cetirizine hydrochloride__interferon beta__no_interaction	prednisone__epoetin__no_interaction	prednisone__interferon beta__no_interaction	amprenavir__epoetin__no_interaction	amprenavir__interferon beta__no_interaction	sumatriptan succinate__epoetin__no_interaction	sumatriptan succinate__interferon beta__no_interaction	naratriptan hydrochloride__epoetin__no_interaction	naratriptan hydrochloride__interferon beta__no_interaction	gatifloxacin__epoetin__no_interaction	gatifloxacin__interferon beta__no_interaction	Quetiapine fumarate__epoetin__no_interaction	Quetiapine fumarate__interferon beta__no_interaction	paroxetine hydrochloride__epoetin__no_interaction	paroxetine hydrochloride__interferon beta__no_interaction	pimecrolimus__epoetin__no_interaction	pimecrolimus__interferon beta__no_interaction	olanzapine__epoetin__no_interaction	olanzapine__interferon beta__no_interaction	parecoxib sodium__epoetin__no_interaction	parecoxib sodium__interferon beta__no_interaction	Abacavir sulfate__epoetin__no_interaction	Abacavir sulfate__interferon beta__no_interaction	levodopa__epoetin__no_interaction	levodopa__interferon beta__no_interaction	Ebastine__epoetin__no_interaction	Ebastine__interferon beta__no_interaction	guaiacol__epoetin__no_interaction	guaiacol__interferon beta__no_interaction	eletriptan__epoetin__no_interaction	eletriptan__interferon beta__no_interaction
20353389-8	Total hydroperoxide significantly correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> serum levels in the HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>+ (r = 0.47, p &lt; 0.05) and HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>- groups (r = 0.29, p &lt; 0.05), while <compound-id="170717">AOPP</compound-id> significantly correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> serum levels in the HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>+ (r = 0.73, p &lt; 0.05) and HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>- (r = 0.54, p &lt; 0.05) groups.	AOPP__insulin__no_interaction	AOPP__LIPO__no_interaction
1838064-7	In Type 2 diabetic patients, HbA1c correlated positively with triglycerides (r = 0.70, p less than 0.001), <compound-id="5997">cholesterol</compound-id> (r = 0.60, p less than 0.001), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.77, p less than 0.001), and <protein-id="P02656,A3KPE2">apolipoprotein CIII</protein-id> (r = 0.55, p less than 0.001) and negatively with apolipoprotein <compound-id="15942654">AI</compound-id> (r = -0.49, p less than 0.001).	AI__apolipoprotein B__no_interaction	AI__apolipoprotein CIII__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein CIII__no_interaction
22641140-1	Six 3D architectures based on lanthanide-substituted polyoxometalosilicates, KLn[(H(2)O)(6)Ln](2)[(H(2)O)(4)LnSiW(11)O(39)](2)·nH(2)O (Ln = La 1, n = 42; <protein-id="O00748,A0A024R6X1">Ce 2</protein-id>, n = 40), H[(H(2)O)(6)Nd](2)[(H(2)O)(7)Nd][(H(2)O)(4)NdSiW(11)O(39)][(H(2)O)(3)NdSiW(11)O(39)]·13H(2)O (3), H(2)K(2)[(Hpic)(H(2)O)(5)Ln](2)[(H(2)O)(4)LnSiW(11)O(39)](2)·nH(2)O (Ln = <compound-id="78933">La 4</compound-id>, n = 18.5; Ce 5, n = 35; Nd 6, n = 36; Hpic = <compound-id="5922">4-picolinic acid</compound-id>), have been synthesized and characterized by elemental analysis, IR and UV-vis spectroscopy, TG analysis, powder X-ray diffraction and single crystal X-ray diffraction.	4-picolinic acid__Ce 2__no_interaction	La 4__Ce 2__no_interaction
12587046-11	<protein-id="P16860">BNP</protein-id> correlated with LVEDP (r = 0.50, p &lt;0.02), SVR (r =0.49, p &lt;0.03) and inversely with 6MWT (r =-0.60, p &lt;0.009), LVEF (r = -0.49, p &lt;0.004) and <compound-id="5360545">sodium</compound-id> (r = -0.36, p = 0.04).	sodium__BNP__no_interaction
15483716-1	The complexes, [VO(O(2))(pa)(2)]ClO(4).3H(2)O (1), [VO(O(2))(pa)(2)][VO(O(2))(2)(pa)].3H(2)O (2), [VO(O(2))(pa)(2)][VO(O(2))(ada)].2H(2)O (3) and [VO(O(2))(pa)(<protein-id="Q9Y5Y0,B2RB38">pca</protein-id>)].H(2)O (4)[pa = <compound-id="15070">picolinamide</compound-id>, ada = carbamoylmethyliminodiacetate(2-) and <protein-id="Q9Y5Y0,B2RB38">pca</protein-id> = <compound-id="1047">2-pyrazinecarboxylate</compound-id>(1-)], were synthesized.	2-pyrazinecarboxylate__pca__no_interaction	picolinamide__pca__no_interaction
18156400-8	<compound-id="185679">RLP</compound-id>-C concentration was positively associated (P &lt; 0.01) with the plasma concentrations of triacylglycerols (Kendall's correlation coefficient or r = 0.46), <compound-id="11146">triacylglycerol</compound-id>:HDL <compound-id="5997">cholesterol</compound-id> (HDL-C) (r = 0.44), total <compound-id="5997">cholesterol</compound-id>:HDL-C (r = 0.26), <protein-id="P04114,Q7Z7Q0,Q59HB3">Apo B</protein-id> (r = 0.22), C III (r = 0.41), and E (r = 0.17), and 18:1(n-9) (r = 0.32); it was negatively associated (P &lt; 0.05) with plasma concentrations of DHA (r = -0.32), EPA (r = -0.25), HDL-C (r = -0.21), LDL <compound-id="5997">cholesterol</compound-id>:<protein-id="P04114,Q7Z7Q0,Q59HB3">Apo B</protein-id> (r = -0.30), and HDL-C:Apo A (r = -0.25).	RLP__Apo B__no_interaction	triacylglycerol__Apo B__no_interaction	cholesterol__Apo B__no_interaction
15851913-6	Although similar in age, weight, and racial composition, HIV-infected women demonstrated higher CRP (4.6 +/- 0.7 vs. 2.3 +/- 0.4 mg/L, P = 0.007), IL-6 (2.7 +/- 0.2 vs. 1.8 +/- 0.1 pg/mL, P = 0.02), triglyceride (1.84 +/- 0.21 vs. 0.85 +/- 0.05 mM, P = 0.0002), 2-hour <compound-id="206,5793,64689,79025">glucose</compound-id> after oral <compound-id="206,5793,64689,79025">glucose</compound-id> challenge (6.88 +/- 0.22 vs. 5.72 +/- 0.17 mM, P = 0.0003), and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (81 +/- 8 vs. 45 +/- 2 pM, P = 0.0002) and lower high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (1.17 +/- 0.03 vs. 1.45 +/- 0.05 mM, P &lt; 0.0001) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (5.4 +/- 0.3 vs. 7.6 +/- 0.5 mg/L, P = 0.0001) levels compared with the control population.	cholesterol__insulin__no_interaction	cholesterol__adiponectin__no_interaction	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
10444633-2	To determine the extent to which <protein-id="P01321">insulin</protein-id>, <protein-id="P29794">glucagon</protein-id>, and selective (alpha/beta)-adrenergic activation mediate the increment in <compound-id="206,5793,64689,79025">glucose</compound-id> metabolic clearance rate (MCR) and <compound-id="206,5793,64689,79025">glucose</compound-id> production (R(a)), we used five groups of normal mongrel dogs: 1) pancreatic clamp (PC; n = 7) with peripheral somatostatin (0.8 microg x kg(-1) x min(-1)) and intraportal replacement of <protein-id="P01321">insulin</protein-id> (1,482 +/- 84 pmol x kg(-1) x min(-1)) and <protein-id="P29794">glucagon</protein-id> (0.65 ng x kg(-1) x min(-1)) infusions; 2) PC plus combined alpha (<compound-id="5775">phentolamine</compound-id>)- and beta (<compound-id="4946">propranolol</compound-id>)-blockade (7 and 5 microg x kg(-1) x min(-1), respectively; alpha+beta; n = 5); 3) PC plus alpha-blockade (alpha; n = 6); 4) PC plus beta-blockade (beta; n = 5); and 5) a <compound-id="2551">carbachol</compound-id> control group without PC (Con; n = 10).	carbachol__glucagon__no_interaction	carbachol__insulin__no_interaction	propranolol__glucagon__no_interaction	propranolol__insulin__no_interaction	phentolamine__glucagon__no_interaction	phentolamine__insulin__no_interaction	glucose__glucagon__no_interaction	glucose__insulin__no_interaction
11254486-4	Our results also suggested that the SO/OH(-) and Cl(-)/OH(-) exchange processes in Caco-2 cells are distinct based on the following: 1) the SO/OH(-) exchange was highly sensitive to inhibition by DIDS compared with Cl(-)/OH(-) exchange activity (K(i) for DIDS of 0.3 +/- 0.1 mM); 2) Cl(-) competitively inhibited the SO/OH(-) exchange activity with a high K(i) compared with the K(m) for SO, indicating a lower affinity for Cl(-); 3) DIDS competitively inhibited the Cl(-)/OH(-) exchange process, whereas it inhibited the SO/OH(-) exchange activity in a mixed-type manner; and 4) utilizing the RNase protection assay, our results showed that 24-h incubation with 100 nM of <compound-id="853">thyroxine</compound-id> significantly decreased the relative abundance of <protein-id="P40879">DRA</protein-id> mRNA along with the SO/OH(-) exchange activity but without any change in Cl(-)/OH(-) exchange process.	thyroxine__DRA__no_interaction
8652567-4	Simultaneous (global) analysis of the time courses of d(T5(2-AP)T4(2-AP)T5) (100 nM) binding to a range of <protein-id="A7XPK1">Rep</protein-id> monomer concentrations (25-400 nM) yields the following rate constants: k1 = (3.3 +/- 0.5) x 10(7) M-1 s-1; k-1 = 1.4 +/- 0.4 s-1; k2 = 2.7 +/- 0.9 s-1; k-2 = 0.21 +/- 0.06 s-1; k3 = (4.5 +/- 0.3) x 10(5) M-1 s-1; k-3 = 0.0027 +/- 0.0008 s-1 [20 mM Tris-HCl, pH 7.5, 6 mM NaCl, 5 mM MgCl2, 5 mM 2-<compound-id="1567">mercaptoethanol</compound-id>, and 10% (v/v) <compound-id="24759880,753">glycerol</compound-id>, 4.0 degrees C].	glycerol__Rep__no_interaction	mercaptoethanol__Rep__no_interaction
9477208-3	Clusterings of the following eight markers of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance were recorded as the main outcome measures: 1) at least one first-degree relative with non-<protein-id="P01308,I3WAC9">insulin</protein-id>-dependent diabetes (NIDDM); 2) obesity: body mass index (BMI) &gt; or = 30 kg/m2; 3) central adiposity: waist-to-hip ratio (WHR) &gt; or = 1.00 in men and &gt; or = 0.88 in women; 4) hypertension: systolic blood pressure &gt; or = 160 mmHg or diastolic blood pressure &gt; or = 95 mmHg, or receiving drug treatment for hypertension; 5) hypertriglyceridaemia &gt; or = 1.70 mmol/l; 6) low high-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id>: &lt; 1.0 mmol/l in men and &lt; 1.20 mmol/l in women; 7) abnormal <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism according to WHO criteria and 8) hyperinsulinaemia: fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> &gt; or = 13.0 mU/l.	glucose__insulin__no_interaction	cholesterol__insulin__no_interaction
10992093-5	RESULTS: The results are as follow:--the joint space of the <protein-id="Q06141,Q53S56">hip</protein-id> (JS/H): cranial part (cranial joint space: CJS/H): 5.5 mm +/- 0.5; medial part (medial joint space: MJS/H): 7 mm+/-0.5; --the bony roofingless part of the femoral head (BR/FH): 1-6 years: 1-3 mm; 7-13 years: 4-5 mm; 14-16 years: 6 mm; --the neck shaft angle of the femur (NSA/F); 1-6 years: 150 degrees-140 degrees; 7-16 years: 135 degrees; --the horizontal and the vertical diameters of the femoral head (HD/FH; VD/FH); x being the age of the children, the HD/FH grows according to a linear regression function as Ydh = 2x + 13+/-2 and the VD/FH as Ych = 2x + 18+/-2; --the centre acetabular edge index (<compound-id="5326781">CEI</compound-id>): the <compound-id="5326781">CEI</compound-id> decreases from 1 to 16 years: medium: 2.75-1.77; maximum: 2.31-1.67; minimum: 3.62-1.91; --the centre-acetabular cartilage index (CCI)): the CCI grows from 1 to 16 years: medium: 0.57-0.70; maximum: 0.62-0.73; minimum: 0.5-0.68.	CEI__hip__no_interaction
23675008-5	To test the hypothesis that dietary <compound-id="969516">curcumin</compound-id> prolongs lifespan, groups of 30 male D. melanogaster were cultured on media containing 1) no additive; 2) 0.5 mg of <compound-id="969516">curcumin</compound-id>/gram of media; 3) 1.0 mg of curumin/gram of media; 4) 1.0μg of the <compound-id="5359597">superoxide</compound-id> dismutase inhibitor, <compound-id="3117">disulfiram</compound-id>/gram of media; 5) 10 g of <compound-id="3117">disulfiram</compound-id>/gram of media; 6) 0.5 mg <compound-id="969516">curcumin</compound-id> and 1.0 g <compound-id="3117">disulfiram</compound-id>/ gram of media; 7) 1.0 mg <compound-id="969516">curcumin</compound-id> and 1.0 g <compound-id="3117">disulfiram</compound-id>/ gram of media; 8) 0.5 mg <compound-id="969516">curcumin</compound-id> and 10 g <compound-id="3117">disulfiram</compound-id>/gram of <protein-id="O62609,Q8IMG6">media; or 9</protein-id>) 1.0 mg <compound-id="969516">curcumin</compound-id> and 10 g <compound-id="3117">disulfiram</compound-id>/gram of media.	curcumin__media; or 9__no_interaction	disulfiram__media; or 9__no_interaction	superoxide__media; or 9__no_interaction
16011149-2	On <protein-id="O75888,B3KR02,Q2QBA2">April</protein-id> 10, one-year-old larch seedlings, after their roots washed and sterilized, were transplanted into a plastic pot (diameter 30 cm, height 27 cm) containing sterilized and washed quartz sand, and supplied with complete nutrient solution (4 mmol NH4NO3 x L(-1), 1 mmol <compound-id="516951">KH2PO4</compound-id> x L(-1), 1 mmol KCl x L(-1), 1 mmol <compound-id="5284359">CaCl2</compound-id> x L(-1), 0.6 mmol MgS4 x L(-1), 0.02 mmol <compound-id="24380">FeCl3</compound-id> x L(-1), 6 micromol MnC2 x L(-1), 0.016 mmol H3BO3 x L(-1), 0.3 micromol <compound-id="3007855">ZnCl2</compound-id> x L(-1), 0.3 micromol <compound-id="24014">CuCl2</compound-id> x L(-1), and 0.3 micromol NaMoO4 x L(-1)).	KH2PO4__April__no_interaction	CaCl2__April__no_interaction	ZnCl2__April__no_interaction	FeCl3__April__no_interaction	CuCl2__April__no_interaction
1433218-1	We have synthesized four guanidinophenyl-substituted <compound-id="5460631">protio</compound-id> enol and iodo enol lactones (3-(4-guanidinophenyl)-6-methylidenetetrahydro-<compound-id="68154">2-pyranone</compound-id> (1), 3-(4-guanidinophenyl)-6-(E)-(iodomethylidene)tetrahydro-2-pyran one (2), 4-(4-guanidinophenyl)-6-methylidenetetrahydro-<compound-id="68154">2-pyranone</compound-id>+ ++ (3), and 4-(4-guanidinophenyl)-6-(E)-(iodomethylidene)tetrahydro-2-pyran one (4)) and tested them for inhibitory activity against some trypsin-like enzymes, namely trypsin, urokinase, tissue plasminogen activator (<protein-id="P00750">t-PA</protein-id>), <protein-id="P00747,Q5TEH5">plasmin</protein-id>, and <compound-id="90470996">thrombin</compound-id>, as well as alpha-chymotrypsin and <protein-id="P08246">human neutrophil elastase</protein-id> (<protein-id="P08246">HNE</protein-id>).	2-pyranone__HNE__no_interaction	2-pyranone__human neutrophil elastase__no_interaction	2-pyranone__t-PA__no_interaction	2-pyranone__plasmin__no_interaction	protio__HNE__no_interaction	protio__human neutrophil elastase__no_interaction	protio__t-PA__no_interaction	protio__plasmin__no_interaction	thrombin__HNE__no_interaction	thrombin__human neutrophil elastase__no_interaction	thrombin__t-PA__no_interaction	thrombin__plasmin__no_interaction
21732435-1	Five <compound-id="23924">iridium</compound-id> <protein-id="O95817">bis</protein-id>(carbene) complexes, [Ir(pmi)(2)(pypz)] (1), [Ir(mpmi)(2)(pypz)] (2), [Ir(fpmi)(2)(pypz)] (3), [Ir(fpmi)(2)(pyim)] (4), and [Ir(fpmi)(2)(tfpypz)] (5) (pmi=1-phenyl-3-methylimdazolin-2-ylidene-C,C(2'); fpmi=1-(4-fluorophenyl)-3-methylimdazolin-2-ylidene-C,C(2'); mpmi=1-(4-methyl-phenyl)-3-methylimdazolin-2-ylidene-C,C(2'); pypz=2-(<compound-id="1048">1H-pyrazol</compound-id>-5-yl)pyridinato; pyim=2-(<compound-id="795">1H-imidazol</compound-id>-2-yl)pyridinato; and tfpypz=2-(3-(<compound-id="6373">trifluoromethyl</compound-id>)-<compound-id="1048">1H-pyrazol</compound-id>-5-yl)pyridinato), were synthesized and their structures were characterized by NMR spectroscopy, mass spectroscopy and X-ray diffraction.	iridium__bis__no_interaction	1H-pyrazol__bis__no_interaction	trifluoromethyl__bis__no_interaction	1H-imidazol__bis__no_interaction
21082856-3	Thus, the anionic heteroleptic cis-configured [cis-Pt(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2-) and [Pt(bzq)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](-) (Fc = ferrocenyl) complexes react with Tl(+) to form discrete octanuclear (PPh(3)Me)(2)[{trans,cis,cis-PtTl(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)}(2)] (1), [PtTl(bzq)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2) (5; bzq = <compound-id="427890">benzoquinolate</compound-id>), and decanuclear [trans,cis,cis-PtTl(2)(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2) (3) derivatives, stabilized by both Pt(II)···Tl(I) and Tl(I)···η(2)(alkynyl) bonds.	benzoquinolate__CFc__no_interaction
19007763-7	The most potent inhibitors of <protein-id="Q04828">AKR1C1</protein-id> were the <compound-id="24204674">pyrimidine derivative</compound-id> <compound-id="16656629">N-benzyl-2-(2-(4-methoxybenzyl)-6-oxo-1,6-dihydropyrimidin-4-yl)acetamide</compound-id> (K(i)=17 microM) and the <compound-id="227">anthranilic acid</compound-id> derivative <compound-id="16656630">2-(((2',3-dichlorobiphenyl-4-yl)carbonyl)(methyl)amino)benzoic acid</compound-id> (K(i)=33 microM), both of which are non-competitive inhibitors.	anthranilic acid__AKR1C1__no_interaction	2-(((2',3-dichlorobiphenyl-4-yl)carbonyl)(methyl)amino)benzoic acid__AKR1C1__no_interaction	pyrimidine derivative__AKR1C1__no_interaction	N-benzyl-2-(2-(4-methoxybenzyl)-6-oxo-1,6-dihydropyrimidin-4-yl)acetamide__AKR1C1__no_interaction
18185017-4	RESULTS: Serum total LDH activity in the NEPHR group was increased compared with the NON-NEPHR and CONTR groups (p &lt; 0.001) and correlated with serum total protein (r = -0.549, p &lt; 0.001), serum <protein-id="P02768">albumin</protein-id> (r = -0.596, p &lt; 0.001), proteinuria (r = 0.456, p &lt; 0.001) and serum total <compound-id="5997">cholesterol</compound-id> (r = 0.523, p &lt; 0.001).	cholesterol__albumin__no_interaction
18185017-7	Serum LDH-2 activity correlated with serum total protein (r = -0.665, p &lt; 0.001), serum <protein-id="P02768">albumin</protein-id> (r = -0.615, p &lt; 0.001), proteinuria (r = 0.694, p &lt; 0.001), and serum total <compound-id="5997">cholesterol</compound-id> (r = 0.723, p &lt; 0.001).	cholesterol__albumin__no_interaction
9480587-11	LV diastolic filling returned to normal limits: (E/A ratio: 0.62 +/- 0.34 vs. 1.3 +/- 0.8; p &lt; 0.05); <compound-id="3905118">Peak E</compound-id> velocity: 0.51 +/- 0.34 vs. 0.88 +/- 0.28 m/sec, p &lt; 0.05; Peak A velocity: 0.81 +/- 0.36 vs. 0.72 +/- 0.42 m/sec, ns; E deceleration velocity: 299 +/- 328 vs. 582 +/- 294 cm/<protein-id="Q10981,A8K2L2">sec2</protein-id>, p &lt; 0.05; Isovolumic relaxation time: 134 +/- 40 vs. 83 +/- 38 m/sec, p &lt; 0.05).	Peak E__sec2__no_interaction
19054567-1	Three doubly-bridged, trinuclear <compound-id="23978">copper</compound-id>(II) compounds with hydroxo and carboxylato bridges, (infinity)(1)[Cu(3)(L1)(2)(mu-OH)(2)(mu-propionato)(2)](1), [Cu(3)(L2)(2)(mu-OH)(2)(mu-propionato)(2)(DMF)(2)] (2) and (infinity)(1){[Cu(3)(L3)(2)(mu-OH)(2)(mu-propionato)(2)]} [Cu(3)(L3)(2)(mu-OH)(2)(mu-propionato)(2)(DMF)(2)]} (3) [HL1=N-(pyrid-2-ylmethyl)benzenesulfonylamide, <protein-id="P07307,Q7Z4G9">HL2</protein-id>=N-(pyrid-2-ylmethyl)toluenesulfonylamide, HL3=N-(pyrid-2-ylmethyl)naphthalenesulfonylamide], have been synthesized and characterized.	copper__HL2__no_interaction
12182214-8	The O group lost more <protein-id="Q9UBC3">ICF</protein-id> (p &lt; 0.05) (N: Y = -510.4 +/- 86.8 mL, O = -631.7 +/- 115.1 mL; H: Y = -529.3 +/- 118.0 mL, O = -928.6 +/- 118.9 mL) and less <compound-id="447834">ISF</compound-id> (p &lt; 0.05) (N: Y = -295.5 +/- 101.1 mL, O = 15.8 +/- 77.6 mL; H: Y = -684.6 +/- 134.5 mL, O = -397.9 +/- 165.5 mL) in both conditions.	ISF__ICF__no_interaction
8067427-2	<compound-id="57476835,60961">Adenosine</compound-id> and its analogues, <compound-id="8974">2-chloroadenosine</compound-id> (CAD), <compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (NECA), R-N6-(2-phenylisopropyl)<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="114854">R-PIA</compound-id>), <compound-id="104968,11957498,14426724,4402">N6-cyclopentyladenosine</compound-id> (CPA), N6-[2-(<compound-id="57420036">3,5-dimethoxyphenyl</compound-id>)-2-(2-methylphenyl)]<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="10391971,122246,24042201">DPMA</compound-id>), <compound-id="11957666,122170,12997926,1585,6917803">2-phenylaminoadenosine</compound-id> (CV-1808), 2-[m-(carboxyethyl)<compound-id="137550">phenylamino</compound-id>]-<compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (CGS-22988), 2-[(2-cyclohexylethyl)amino]<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="130199,44320650">CGS-22492</compound-id>), 2-[(p-amino)phenethylamino]<compound-id="57476835,60961">adenosine</compound-id> (APE), and 2-(1-octynyl)<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="171185">YT</compound-id>-146) (10 nM-100 microM), produced concentration-dependent relaxations in endothelium-intact and -denuded arterial ring segments contracted with 30 mM KCl, 10 nM <protein-id="P09558">endothelin-1</protein-id>, or 10 microM <compound-id="5280363">prostaglandin F2</compound-id> alpha.	3,5-dimethoxyphenyl__endothelin-1__no_interaction	N6-cyclopentyladenosine__endothelin-1__no_interaction	CGS-22492__endothelin-1__no_interaction	Adenosine__endothelin-1__no_interaction	DPMA__endothelin-1__no_interaction	YT__endothelin-1__no_interaction	phenylamino__endothelin-1__no_interaction	adenosine__endothelin-1__no_interaction	R-PIA__endothelin-1__no_interaction	2-phenylaminoadenosine__endothelin-1__no_interaction	5'-N-ethylcarboxamidoadenosine__endothelin-1__no_interaction	prostaglandin F2__endothelin-1__no_interaction	2-chloroadenosine__endothelin-1__no_interaction
15104796-5	RESULTS: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum <compound-id="5997">cholesterol</compound-id> (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of <compound-id="53232">Lovastatin</compound-id> therapy.	Lovastatin__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
23338999-9	<protein-id="Q15848,A8K660,B2R773">Adiponectin</protein-id> negatively correlated with weight (r = -0.34, p 〈 0.01), BMI (r = -0.37, p 〈 0.01), FN BMD (r = -0.26, p 〈 0.05), TH BMD (r = -0.33, p 〈 0.01), and did not correlate with <compound-id="40539">QUS</compound-id> result.	QUS__Adiponectin__no_interaction
22580336-5	A broad range of both proinflammatory and anti-inflammatory lipid mediators was detected, including PGE2, <protein-id="P41222,A0A024R8G3">PGD2</protein-id>, <compound-id="5283137,5461">TXB2</compound-id>, <compound-id="5280492">LTB4</compound-id>, <compound-id="5283128">6-trans-LTB4</compound-id>, <compound-id="5280745">20-OH-LTB4</compound-id>, <compound-id="133471,5280877">20-COOH-LTB4</compound-id>, <compound-id="5283157">20-HETE</compound-id>, <compound-id="5280724,5312986,5353283,9966861">15-HETE</compound-id>, <compound-id="1406,14123410,5312981,5312982,5353268">11-HETE</compound-id>, <compound-id="13786989,5283155,5312983,5312984,5353272">12-HETE</compound-id>, <compound-id="11976122,1898,5283154,5312975">8-HETE</compound-id>, <compound-id="1926">9-HETE</compound-id>, <compound-id="5280733,5353348">5-HETE</compound-id>, EpETrEs, diols, <compound-id="10473088">resolvin E1</compound-id>, <compound-id="5311211">15-deoxy-PGJ2</compound-id>, and <compound-id="16760543">LXA4</compound-id>.	resolvin E1__PGD2__no_interaction	6-trans-LTB4__PGD2__no_interaction	LTB4__PGD2__no_interaction	20-COOH-LTB4__PGD2__no_interaction	11-HETE__PGD2__no_interaction	15-HETE__PGD2__no_interaction	15-deoxy-PGJ2__PGD2__no_interaction	20-HETE__PGD2__no_interaction	8-HETE__PGD2__no_interaction	20-OH-LTB4__PGD2__no_interaction	12-HETE__PGD2__no_interaction	5-HETE__PGD2__no_interaction	9-HETE__PGD2__no_interaction	LXA4__PGD2__no_interaction	TXB2__PGD2__no_interaction
20814094-1	We report the synthesis of the <compound-id="90901057">2,2'-[2,5-bis(carboxymethoxy)-1,4-phenylene]diacetic acid</compound-id> (<protein-id="P37837">TALH</protein-id>(4)) ligand and the structures of its adducts with <compound-id="223">ammonium</compound-id>, namely diammonium <compound-id="60207171">2,2'-[2,5-bis(carboxymethyl)-1,4-phenylenedioxy]diacetate</compound-id>, <compound-id="447474">2NH</compound-id>(4)(+).C(14)H(12)O(10)(2-), (I), <compound-id="23926">lanthanum</compound-id>, namely poly[[aquabis[mu(4)-2,2'-(2-carboxylatomethyl-5-carboxymethyl-1,4-phenylenedioxy)diacetato]dilanthanum(III)] <compound-id="1488787">monohydrate</compound-id>], {[La(2)(C(14)H(11)O(10))(2)(H(2)O)].H(2)O}(n), (II), and <compound-id="23994">zinc</compound-id> cations, namely poly[[{mu(4)-2,2'-[<compound-id="5483205">2,5-bis(</compound-id>carboxymethyl)-1,4-phenylenedioxy]diacetato}<compound-id="23994">zinc</compound-id>(II)] trihydrate], {[Zn(C(14)H(12)O(10))].3H(2)O}(n), (III), and poly[[diaqua(mu(2)-<compound-id="11107">4,4'-bipyridyl</compound-id>){mu(4)-2,2'-[<compound-id="5483205">2,5-bis(</compound-id>carboxymethyl)-1,4-phenylenedioxy]diacetato}<compound-id="16722164">dizinc</compound-id>(II)] <compound-id="3039108">dihydrate</compound-id>], {[Zn(2)(C(14)H(10)O(10))(C(10)H(8)N(2))(H(2)O)(2)].2H(2)O}(n), (IV), the formation of all four being associated with deprotonation of <protein-id="P37837">TALH</protein-id>(4).	2,5-bis(__TALH__no_interaction	4,4'-bipyridyl__TALH__no_interaction	2NH__TALH__no_interaction	monohydrate__TALH__no_interaction	lanthanum__TALH__no_interaction	2,2'-[2,5-bis(carboxymethyl)-1,4-phenylenedioxy]diacetate__TALH__no_interaction	2,2'-[2,5-bis(carboxymethoxy)-1,4-phenylene]diacetic acid__TALH__no_interaction	ammonium__TALH__no_interaction	zinc__TALH__no_interaction	dizinc__TALH__no_interaction	dihydrate__TALH__no_interaction
10090866-8	18 for female versus male siblings), triglycerides (r = 0.56 versus r = 0.05), and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.72 versus r = 0.31); they were also higher between female siblings than between mixed-sex siblings for measures of adiposity (r = 0.46 versus r = 0.19) and total <compound-id="5997">cholesterol</compound-id> (r = 0.74 versus r = 0.27).	cholesterol__apolipoprotein B__no_interaction
8001634-4	Furthermore, pretreatment with <compound-id="60846">valsartan</compound-id> ((S)-N-valeryl-N-([2'-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)biphenyl-4-yl]-methyl)-val <compound-id="1649">ine</compound-id>), a new selective angiotensin AT1 receptor antagonist, antagonized the effects of <protein-id="P01015">angiotensin II</protein-id> on <compound-id="6041">phenylephrine</compound-id>-mediated pressor responses, whereas the administration of the selective angiotensin AT2 receptor antagonist, <compound-id="5311345">PD 123319</compound-id> (1-[[4-(dimethylamino)-3-methylphenyl]-methyl]-5-(<compound-id="13696">diphenylacetyl</compound-id>)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]-<compound-id="1049">pyridine</compound-id>-6-<compound-id="11229316,91179806">carboxylic acid</compound-id>, ditriflouroacetate, <compound-id="1488787">monohydrate</compound-id>), injected in bolus doses of 100 micrograms/kg, did not antagonize the enhancing effect of <protein-id="P01015">angiotensin II</protein-id>.	diphenylacetyl__angiotensin II__no_interaction	pyridine__angiotensin II__no_interaction	valsartan__angiotensin II__no_interaction	phenylephrine__angiotensin II__no_interaction	PD 123319__angiotensin II__no_interaction	ine__angiotensin II__no_interaction	carboxylic acid__angiotensin II__no_interaction	1H-tetrazol__angiotensin II__no_interaction	monohydrate__angiotensin II__no_interaction
16517693-6	Antagonist studies revealed that a <protein-id="P41595">5-HT2B</protein-id>-selective antagonist, <compound-id="7021454">RS</compound-id>-127445 [<compound-id="196968">2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine</compound-id>] (Ki = 0.13 nM), was significantly more effective at inhibiting 5-HT-induced activity than a <protein-id="P28223">5-HT2A</protein-id> antagonist, M-100907 (R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)<compound-id="23134249">ethyl</compound-id>]-<compound-id="420771">4-piperidinemethanol</compound-id>]) (Ki= 914 nM) and the <protein-id="P28335,K9J958">5-HT2C</protein-id> antagonists <compound-id="3693566">RS-102221</compound-id> (8-[5-(2,4-dimethoxy-5-(4-trifluoromethylsulfo-amido)phenyl-5-oxopentyl]-<compound-id="120989">1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride</compound-id>) (Ki = 2.5 microM) and SB-242084 (6-chloro-5-methyl-1-[6-92-methylpyridin-3-yloxy) <compound-id="1049">pyridine-</compound-id>3-ylcarbamoyl] <compound-id="10328">indoline</compound-id>) (Ki = 42.4 nM) in the HUSMC PI turnover assays.	indoline__5-HT2B__no_interaction	indoline__5-HT2C__no_interaction	indoline__5-HT2A__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2B__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2C__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2A__no_interaction	RS__5-HT2B__no_interaction	RS__5-HT2C__no_interaction	RS__5-HT2A__no_interaction	pyridine-__5-HT2B__no_interaction	pyridine-__5-HT2C__no_interaction	pyridine-__5-HT2A__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2B__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2C__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2A__no_interaction	ethyl__5-HT2B__no_interaction	ethyl__5-HT2C__no_interaction	ethyl__5-HT2A__no_interaction	4-piperidinemethanol__5-HT2B__no_interaction	4-piperidinemethanol__5-HT2C__no_interaction	4-piperidinemethanol__5-HT2A__no_interaction	RS-102221__5-HT2B__no_interaction	RS-102221__5-HT2C__no_interaction	RS-102221__5-HT2A__no_interaction
15526717-9	Serum <protein-id="P41159,A4D0Y8">leptin</protein-id> (30.8 +/- 18.3 vs 8.1 +/- 5.9 ng/ml), A (841.8 +/- 471.1 vs 522.5 +/- 317.2 pg/ml), <protein-id="Q06520,A8K015">DHEAS</protein-id> (0.53 +/- 0.44 vs 0.31 +/- 0.39 microg/ml), G (88.4 +/- 8.8 vs 80.2 +/- 8.1 mg/dl), I (13.5 +/- 7.7 vs 5.1 +/- 3.7 microU/ml) and total <compound-id="5997">cholesterol</compound-id> (TC) (180.5 +/- 30.9 vs 161.8 +/- 29.5 mg/dl) levels were greater in the OB than in the <compound-id="11473">nOB</compound-id> group.	nOB__DHEAS__no_interaction	nOB__leptin__no_interaction	cholesterol__DHEAS__no_interaction	cholesterol__leptin__no_interaction
17011056-3	The results showed that microinjection of <protein-id="P01186">AVP</protein-id> into PAG increased pain threshold, whereas microinjection of V2 receptor antagonist-d(CH2)5[d-Ile2, Ile4, Ala9-NH2]<protein-id="P01186">AVP</protein-id> into PAG decreased pain threshold in a dose-dependent manner, but local administration of V1 receptor antagonist-d(CH2)5Tyr(Me)<protein-id="P01186">AVP</protein-id> did not change pain threshold; Pain stimulation elevated <protein-id="P01186">AVP</protein-id>, <compound-id="6106">Leucine</compound-id>-<protein-id="P04094">enkephalin</protein-id> (L-Ek), <compound-id="6137,84815,876">Methionine</compound-id>-<protein-id="P04094">enkephalin</protein-id> (M-Ek) and beta-endorphin (beta-Ep), not <compound-id="25075996">dynorphinA</compound-id>(1-13) (DynA(1-13)) concentrations in PAG perfuse liquid; PAG pre-treatment with <compound-id="5284596">naloxone</compound-id>, an opiate receptor antagonist or V2 receptor antagonist completely reversed <protein-id="P01186">AVP</protein-id>-induced increase in pain threshold, however, PAG pre-treatment with V1 receptor antagonist did not influence this effect of <protein-id="P01186">AVP</protein-id> administration.	naloxone__AVP__no_interaction	naloxone__enkephalin__no_interaction	Leucine__AVP__no_interaction	Leucine__enkephalin__no_interaction	Methionine__AVP__no_interaction	Methionine__enkephalin__no_interaction	dynorphinA__AVP__no_interaction	dynorphinA__enkephalin__no_interaction
20397460-5	The order of the mean increasing percentage in the hypothalamic <protein-id="P07490">GnRH</protein-id> neuron electric activity was: the Gallbladder Channel &gt; the Spleen Channel &gt; the Stomach Channel/the Bladder Channel/the Conception Vessel &gt; the Liver Channel &gt; the Kidney Channel &gt; the Governor Vessel; for different acupoints, it was: Guanyuan (CV 4) &gt; Sanyinjiao (<protein-id="D3ZT88">SP 6</protein-id>) &gt; Zusanli (ST 36) &gt; Daimai (GB 26)/Yanglingquan (GB 34) &gt; Shenshu (BL 23) &gt; Weizhong (BL 40) &gt; Yaoyangguan (GV 3)/Liangmen (ST 21)/Fujie (SP 14) &gt; Qimen (LR 14)/Yingu (KI 10) &gt; Tangzhong (CV 17)/Zhiyang (GV 9); for different positions, it was: the lower abdominal part/the lower limb part &gt; the thoracodorsal part; for the extra-ordinary points, it was: Zigong (EX-CA1) &gt; Dannang (EX-LE6)/Yaoyan (EX-B7) &gt; Baichongwo (EX-LE3)/Qianzheng &gt; Jingbi/Bizhong/Taiyang (EX-<compound-id="44228987">HN5</compound-id>) &gt; Erbai (EX-UE2)/ Dingchun; and for the distribution sites of the extra-ordinary points: lower abdominal region &gt; the lower limb region &gt; the craniofacial region &gt; the upper limb region/the thoracodorsal region.	HN5__SP 6__no_interaction	HN5__GnRH__no_interaction
19100860-6	Twenty-one genes exhibited a distinct dose-dependent increase in expression at 4h for both carcinogens [<protein-id="Q07813,Q544Z6">Bax</protein-id>, <protein-id="Q04211,Q3TF68">Btg2</protein-id>, <protein-id="P51945,Q5NC86,Q5D0F7">Ccng1</protein-id>, <protein-id="P39689,Q564P6">Cdkn1a</protein-id>, <protein-id="O88833">Cyp4a10</protein-id>, <protein-id="P03940,Q3UJ92">Cyp21a1</protein-id>, <protein-id="P01101">Fos</protein-id>, <protein-id="P22339">Gadd45b</protein-id>, <protein-id="Q9Z0J7">Gdf15</protein-id>, <protein-id="P14901,Q3U5U6">Hmox1</protein-id>, <protein-id="P14602,Q545F4">Hspb1</protein-id>, <protein-id="Q9CZI9">Isg20l1</protein-id>, Jun, <protein-id="Q9Z2E2">Mbd1</protein-id>, <protein-id="P23804">Mdm2</protein-id>, Myc, <protein-id="Q9Z206,Q3USZ7">Net1</protein-id>, <protein-id="P53351,Q548A9,Q3TV29">Plk2</protein-id>, <protein-id="Q7TMB3">Ppp1r3c</protein-id>, <protein-id="Q9JHG6,Q542V6,Q7TNY3">Rcan1</protein-id> and <protein-id="P68372">Tubb2c</protein-id>], although the increase in gene expression due to <compound-id="12967">ENU</compound-id> was generally weaker than that due to DEN.	ENU__Plk2__no_interaction	ENU__Ppp1r3c__no_interaction	ENU__Btg2__no_interaction	ENU__Fos__no_interaction	ENU__Rcan1__no_interaction	ENU__Gadd45b__no_interaction	ENU__Cyp21a1__no_interaction	ENU__Hspb1__no_interaction	ENU__Hmox1__no_interaction	ENU__Bax__no_interaction	ENU__Ccng1__no_interaction	ENU__Tubb2c__no_interaction	ENU__Mbd1__no_interaction	ENU__Isg20l1__no_interaction	ENU__Mdm2__no_interaction	ENU__Gdf15__no_interaction	ENU__Cdkn1a__no_interaction	ENU__Net1__no_interaction	ENU__Cyp4a10__no_interaction
8977961-4	The <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id> genotype relative risks (and 95% CIs) for RA were: *0404,5,8/*0404,5,8 = 36.2 (15-87), *0401/*0404,5,8 = 31.3 (18-55), *401/*0401 = 18.8 (11-35), *0101,2/*0404,5,8 = 6.0 (2-14), *0101,2/*0401 = 6.4 (3-12), *0101,2/*0101,2 = 1.3 (0.3-6), *10/*0404,5,8 = 27.8 (5-148), *10/*0401 = 20.8 (5-89), *10/*0101,2 = 22.3 (5-96), *0404,5,8/<compound-id="16122567">DRX</compound-id> = 5.0 (3-8), *0401/<compound-id="16122567">DRX</compound-id> = 4.7 (3-7), *0101,2/<compound-id="16122567">DRX</compound-id> = 2.3 (1.4-4), *10/<compound-id="16122567">DRX</compound-id> = 3.4 (0.8-14).	DRX__DRB1__no_interaction
10067789-4	<protein-id="P35318">Adrenomedullin</protein-id> significantly decreased the order parameter for 5-<compound-id="787">nitroxide</compound-id> <compound-id="5281">stearate</compound-id> and peak height ratio for 16-<compound-id="787">nitroxide</compound-id> <compound-id="5281">stearate</compound-id> obtained from electron paramagnetic resonance spectra of erythrocyte membranes in normotensive volunteers (mean +/- <compound-id="5289348">SEM</compound-id> order parameter value: control, 0.718 +/- 0.003, n = 16; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-9) mol/l, 0.692 +/- 0.004, n = 16, P &lt; 0.05; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-8) mol/l, 0.690 +/- 0.004, n = 16, P &lt; 0.05; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-7) mol/l, 0.683 +/- 0.004, n = 16, P &lt; 0.05).	nitroxide__Adrenomedullin__no_interaction	SEM__Adrenomedullin__no_interaction	stearate__Adrenomedullin__no_interaction
19603104-6	In RA patients, log-OPN was related to log-C-reactive protein (log-CRP) (r = 0.30, P &lt; 0.05), age (r = 0.38, P &lt; 0.01), Health Assessment Questionnaire (HAQ) (r = 0.58, P &lt; 0.0001), and inversely related to total <compound-id="5997">cholesterol</compound-id> (r = -0.33, P &lt; 0.05) and apolipoprotein A (apoA) (r = -0.58, P &lt; 0.001), but not to oxidative stress markers and <protein-id="P05305,Q6FH53">ET-1</protein-id>.	cholesterol__ET-1__no_interaction
1769029-6	Hemodynamic parameters were significantly changed after the first <compound-id="4510">nitroglycerin</compound-id> patch application: particularly, mean systemic arterial (MAP), right atrial (<protein-id="P30533">RAP</protein-id>) and pulmonary wedge pressures (PWP) declined from 96 +/- 10, 8.9 +/- 1.8 and 20.1 +/- 5 to 81 +/- 6, 4.7 +/- 1.5 and 12.2 +/- 3 mmHg (-15.6, -47.2 and -59.3%, respectively); systemic vascular resistance (SVR) and heart rate (HR) were reduced from 1645 +/- 121 to 1288 +/- 89 dyne.s.cm-5 and from 85 +/- 7 to 81 +/- 7 b/min; lastly, cardiac index (CI), stroke volume (SVI) and stroke work index (SWI) increased from 2.3 +/- 0.3, 28.2 +/- 5 and 28.7 +/- 9 to 2.7 +/- 0.3 l/min/m2, 33.3 +/- 5 ml/min/m2 and 31.5 +/- 8 g.m/m2 (+17.4, 18.1 and 9.7%).	nitroglycerin__RAP__no_interaction
11923045-9	RESULTS: In <protein-id="P12272,Q53XY9,A0A024RB29">HHM</protein-id>, decreased contents (micromol/g wet weight) in <compound-id="57476835,60961">adenosine</compound-id> triphosphate (ATP) (control: 4.17 +/- 0.26; <protein-id="P12272,Q53XY9,A0A024RB29">HHM</protein-id>: 1.72 +/- 0.25; p &lt; 0.001), <compound-id="9548602">creatine phosphate</compound-id> (5.67 +/- 0.70 vs. 0.84 +/- 0.13; p &lt; 0.001) and <compound-id="586">creatine</compound-id> (27.6 +/- 3.19 vs. 11.2 +/- 1.56; p &lt; 0.0001) were found, but contents in <compound-id="612">lactate</compound-id> (2.22 +/- 0.26 vs. 25.38 +/- 3.53; p &lt; 0.001), purine bases (0.58 +/- 0.09 vs. 1.26 +/- 0.13; p &lt; 0.001) and protons (pH units: 7.199 +/- 0.01 vs. 6.59 +/- 0.07; p &lt; 0.001) were increased.	lactate__HHM__no_interaction	creatine phosphate__HHM__no_interaction	creatine__HHM__no_interaction	adenosine__HHM__no_interaction
10844099-5	Under pretreatment with an <compound-id="44284481">endothelin</compound-id> ET(A) receptor antagonist (R)-2-[(R)-2-[(S)-2-[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl]amino-4-m eth ylpentanoyl]amino-3-(2-pyridyl) <compound-id="1032">propionic acid</compound-id> (<compound-id="107810">FR139317</compound-id>) (1 microg/kg/min), <protein-id="P13206">endothelin-1</protein-id> suppressed the 1- and 3- Hz nerve stimulation-induced catecholamine response in a dose-dependent manner.	propionic acid__endothelin-1__no_interaction	endothelin__endothelin-1__no_interaction	1H-azepinyl__endothelin-1__no_interaction	FR139317__endothelin-1__no_interaction
12059220-8	The butatrienerhodium(I) compounds trans-[RhCl[eta(2)-H(2)C[double bond]C[double bond]C[double bond]C(R)R'](PiPr(3))(2)] (28-31) were prepared from 1, 20, and trans-[RhCl[[double bond]C[double bond]C[double bond]C(Ph)R](PiPr(3))(2)] [R = CF(3) (26), tBu (27)] and <compound-id="9550">diazomethane</compound-id>; with the exception of 30 (R = CF(3), R' = Ph), they thermally rearrange to the isomers trans-[RhCl[eta(2)-H(2)C[double bond]C[double bond]C[double bond]C(R)R'](PiPr(3))(2)] (32, 33, and <protein-id="P06241">syn</protein-id>/anti-34).	diazomethane__syn__no_interaction
3558354-5	Analysis of the spectra recorded during titrations of Zn7-MT 2 with <protein-id="P08921">Cd2</protein-id>+ suggests: (i) that <protein-id="P08921">Cd2</protein-id>+ replaces Zn2+ in Zn7-MT isomorphously; (ii) that <compound-id="23973">cadmium</compound-id> binds in a nonspecific, "distributed" manner across both domains; (iii) that cluster formation in the alpha domain only occurs after 4 mol eq of <compound-id="23973">cadmium</compound-id> have been added and is indicated by the presence of a cluster-sensitive, CD spectral feature; (iv) that the characteristic derivative CD spectrum of native <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT is only obtained from "synthetic" <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT following a treatment cycle that allows the redistribution of <compound-id="23973">cadmium</compound-id> into the alpha domain; warming the synthetic "native," <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT, to 65 degrees C results in <compound-id="23973">cadmium</compound-id> being preferentially bound in the alpha domain; and (v) Zn7-MT will bind <protein-id="P08921">Cd2</protein-id>+ quite normally at up to 65 degrees C but with greater specificity for the alpha domain compared with titrations carried out at 25 degrees C. These results suggest that the initial presence of <compound-id="23994">zinc</compound-id> in both domains is an important factor in the lack of any domain specificity during <compound-id="23973">cadmium</compound-id> binding to Zn-MT which contrasts the domain specific manner observed for <compound-id="23973">cadmium</compound-id> binding to apo-MT.	Zn3__Cd4__no_interaction	Zn3__Cd2__no_interaction	cadmium__Cd4__no_interaction	cadmium__Cd2__no_interaction	zinc__Cd4__no_interaction	zinc__Cd2__no_interaction
17477522-1	New homo- and heterometallic, hexa- and pentanuclear complexes of formula {[<compound-id="444924">Cu2</compound-id>(<compound-id="12277">mpba</compound-id>)2(H2O)F][Cu(Me5dien)]4}(<protein-id="Q6Q759">PF6</protein-id>)(3).5H2O (1), {[<compound-id="444924">Cu2</compound-id>(Me3mpba)2(H2O)2][Cu(Me5dien)]4}(ClO4)(4).12H2O (2), {[<compound-id="444924">Cu2</compound-id>(<compound-id="513615">ppba</compound-id>)2][Cu(Me5dien)]4}(ClO4)4 (3), and [Ni(<compound-id="64964">cyclam</compound-id>)]{[<compound-id="444924">Cu2</compound-id>(<compound-id="12277">mpba</compound-id>)2][Ni(<compound-id="64964">cyclam</compound-id>)]3}(ClO4)(4).6H2O (4) [<compound-id="12277">mpba</compound-id>=<compound-id="22395425,517764,91539310">1,3-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), Me3mpba=2,4,6-trimethyl-<compound-id="22395425,517764,91539310">1,3-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), <compound-id="513615">ppba</compound-id>=<compound-id="136813,13902,141623,15274144,22395417,22395423,22395427,57004341,684351,90706559,90760131,90828198,90832537">1,4-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), Me5dien=N,N,N'N' ',N' '-pentamethyldiethylenetriamine, and <compound-id="64964">cyclam</compound-id>=1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>] have been synthesized through the use of the "complex-as-ligand/complex-as-metal" strategy.	ppba__PF6__no_interaction	Cu2__PF6__no_interaction	oxamate__PF6__no_interaction	1,4-phenylenebis__PF6__no_interaction	mpba__PF6__no_interaction	cyclam__PF6__no_interaction	tetraazacyclotetradecane__PF6__no_interaction	1,3-phenylenebis__PF6__no_interaction
15225067-1	A series of [(R-iso-<compound-id="1474">BIPY</compound-id>)Pt(CH(3))L ](+)X(-) complexes [R-iso-<compound-id="1474">BIPY</compound-id> = N-(2-pyridyl)-R-pyridine-2-ylidene; (R = 4-H, 1; 4-<compound-id="90937099">tert-butyl</compound-id>, 2; 4-dimethylamino, 3; 5-dimethylamino, 4); L = <protein-id="P62304">SMe</protein-id>(2), b; <compound-id="679">dimethyl sulfoxide</compound-id> (DMSO), c; <compound-id="281">carbon monoxide</compound-id> (CO), d; X = OTf(-) = <compound-id="62406">trifluoromethanesulfonate</compound-id> and/or [BPh(4)](-)] were synthesized by cyclometalation of the [R-iso-<compound-id="1474">BIPY</compound-id>-H](+)[OTF](-) salts 1a-<compound-id="69255155">4a</compound-id> ([R-iso-<compound-id="1474">BIPY</compound-id>-H](+) = N-(2-pyridyl)-R-<compound-id="1049">pyridinium</compound-id>) with dimethylplatinum-micro-<compound-id="1068">dimethyl sulfide</compound-id> dimer.	dimethyl sulfide__SMe__no_interaction	dimethyl sulfoxide__SMe__no_interaction	pyridinium__SMe__no_interaction	BIPY__SMe__no_interaction	tert-butyl__SMe__no_interaction	trifluoromethanesulfonate__SMe__no_interaction	carbon monoxide__SMe__no_interaction	4a__SMe__no_interaction
2973508-3	Macrophages isolated from CBA mice bearing 21-day intraperitoneal Ehrlich ascites tumors (EAT) or C3H/HeJ mice bearing 21-day subcutaneous T58 mammary adenocarcinomas were added (+/- 10(-5) M <compound-id="3715">indomethacin</compound-id>, or a monoclonal anti-PGE2 ab) to syngeneic splenic lymphocytes to examine the effects on 1) polyclonal activation (3-d 3H-thymidine [3H-TdR] uptake) with concanavalin A (Con A); 2) one-way (CBA alpha BALB/C or C3H alpha BALBC) <protein-id="A3KN90">MLR</protein-id> (5-d 3H-TdR uptake) and subsequent CTL generation (tested against <compound-id="104786">51Cr</compound-id>-labeled Con A blasts of the stimulator phenotype); 3) NK activity (after 24-h co-culture) against <protein-id="Q60935,Q545U9">YAC-1</protein-id> targets; 4) generation of LAK cell activity (in the presence of 200 or 2,000 units recombinant <protein-id="P04351">IL-2</protein-id> for 3 or 5 days), tested against NK-sensitive and NK-resistant targets.	indomethacin__MLR__no_interaction	indomethacin__YAC-1__no_interaction	indomethacin__IL-2__no_interaction	51Cr__MLR__no_interaction	51Cr__YAC-1__no_interaction	51Cr__IL-2__no_interaction
19572728-1	The reactions between the redox-active <compound-id="71357708">4-(2-tetrathiafulvalenyl-ethenyl)pyridine</compound-id> ligand (<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py) and the <compound-id="6503">tris</compound-id>(1,1,1,5,5,5-hexafluoroacetylacetonate)Ln(III) (Ln = La and Nd) lead to the formation of compounds with the formulas {[La(<compound-id="73706">hfac</compound-id>)(5)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))](2)} (1), {[Nd(<compound-id="73706">hfac</compound-id>)(4)(H(2)O)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))]}(2) (2), and {[Nd(<compound-id="73706">hfac</compound-id>)(4)(H(2)O)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))]}(2)(H(2)O)(C(6)H(14))(0.5) (3) (<compound-id="73706">hfac</compound-id>(-) = 1,1,1,5,5,5-hexafluoroacetylacetonate anion).	hfac__TTF__no_interaction	tris__TTF__no_interaction	4-(2-tetrathiafulvalenyl-ethenyl)pyridine__TTF__no_interaction
19424605-5	The Chi-square test, multivariable logistic regression analysis with adjustment for covariates, as well as a stepwise forward selection procedure revealed that ten different polymorphisms were associated (P&lt;0.05) with the prevalence of CKD in high- or low-risk subjects: the -519Aright curved arrow G polymorphism of <protein-id="P03956,Q53G95,B4DN15">MMP1</protein-id>, the 1061Aright curved arrow G (Ile405Val) polymorphism of <protein-id="P11597,B4DMZ5">CETP</protein-id>, the Aright curved arrow G (Lys45Glu) polymorphism of <protein-id="P08254">MMP3</protein-id>, the -219Gright curved arrow T polymorphism of <protein-id="P02649">APOE</protein-id>, the Aright curved arrow G (Ile1205Val) polymorphism of <protein-id="P02461">COL3A1</protein-id>, the -863Cright curved arrow A polymorphism of TNF, and the 1454Cright curved arrow G (Leu125Val) polymorphism of <protein-id="P16284,A0A075B738">PECAM1</protein-id> in high-risk subjects; and the 1167Cright curved arrow T (Asn389Asn) polymorphism of <protein-id="P37173,A3QNQ0,D2JYI1">TGFBR2</protein-id>, the 2386Aright curved arrow G (Ile796Val) polymorphism of <protein-id="Q12770">SCAP</protein-id>, and the TAAAright curved arrow <compound-id="445801">del</compound-id> polymorphism of <protein-id="Q08499">PDE4D</protein-id> in low-risk subjects.	del__PECAM1__no_interaction	del__APOE__no_interaction	del__CETP__no_interaction	del__TGFBR2__no_interaction	del__SCAP__no_interaction	del__COL3A1__no_interaction	del__PDE4D__no_interaction	del__MMP3__no_interaction	del__MMP1__no_interaction
1837268-1	The substrate specificity of rat liver cytosolic neutral alpha-D-mannosidase was investigated by in vitro incubation with a crude cytosolic fraction of oligomannosyl oligosaccharides <compound-id="3081561">Man9GlcNAc</compound-id>, Man7GlcNAc, <compound-id="90475786">Man5GlcNAc</compound-id> I and II isomers and Man4GlcNAc having the following structures: <compound-id="3081561">Man9GlcNAc</compound-id>, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)[Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P78318">alpha 1-6</protein-id>)]Man(<protein-id="P78318">alpha 1-6</protein-id>) [Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)]Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; <compound-id="90475786">Man5GlcNAc</compound-id> I, Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)[Man(<protein-id="P78318">alpha 1-6</protein-id>)]-Man(<protein-id="P78318">alpha 1-6</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)] Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; <compound-id="90475786">Man5GlcNAc</compound-id> II, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>) [Man(<protein-id="P78318">alpha 1-6</protein-id>)]Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; Man4GlcNAc, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>.	Man9GlcNAc__alpha 1-6__no_interaction	Man9GlcNAc__alpha 1-3__no_interaction	Man9GlcNAc__alpha 1-2__no_interaction	Man9GlcNAc__beta 1-4__no_interaction	GlcNAc__alpha 1-6__no_interaction	GlcNAc__alpha 1-3__no_interaction	GlcNAc__alpha 1-2__no_interaction	GlcNAc__beta 1-4__no_interaction	Man5GlcNAc__alpha 1-6__no_interaction	Man5GlcNAc__alpha 1-3__no_interaction	Man5GlcNAc__alpha 1-2__no_interaction	Man5GlcNAc__beta 1-4__no_interaction
12630871-3	Addition of ligands L (L = <compound-id="53675528,6325">ethylene</compound-id>, <compound-id="8252">propylene</compound-id>, <compound-id="6335">propyne</compound-id>, <compound-id="10419">2-butyne</compound-id>, CO, <compound-id="10821">phenylacetylene</compound-id>, <compound-id="10037">allene</compound-id>, 1-hexene, <protein-id="O14508,A0A024RBD2">cis-2</protein-id>-<compound-id="7844">butene</compound-id>) to 1 in CD2Cl2 at -89 degrees C results in reversible formation of %@mt;sys@%Cp%@/xs;55;%lnwidth@%'%@/xs;63;(%lnwidth-<compound-id="44201390">x55</compound-id>)@%%@mh;-<compound-id="57519663">x63</compound-id>@%%@sb@%2%@sbx@%%@/hd@%Zr%@/hd@%%@fn;(;vis;full;auto@%O%@ital@%%@ex@%t%@<compound-id="9942150">rsf</compound-id>@%%@<compound-id="73437605">exx</compound-id>@%%@/hd@%Bu%@fnx;);vis;full@%%@/hd@%%@fn;(;vis;full;auto@%L%@fnx;);vis;full@%%@ex@%+%@<compound-id="73437605">exx</compound-id>@%%@mx@% adducts.	ethylene__cis-2__no_interaction	x55__cis-2__no_interaction	x63__cis-2__no_interaction	phenylacetylene__cis-2__no_interaction	propyne__cis-2__no_interaction	2-butyne__cis-2__no_interaction	propylene__cis-2__no_interaction	allene__cis-2__no_interaction	butene__cis-2__no_interaction	rsf__cis-2__no_interaction	exx__cis-2__no_interaction
14521722-3	RESULTS: The blood <compound-id="206,5793,64689,79025">glucose</compound-id> and serum <compound-id="5997">cholesterol</compound-id> levels were all normal in the OB group but the serum FFA and triglyceride concentrations were elevated compared with those of the controls (FFA: 888 microM/l +/- 158 microM/l vs 508 microM/l +/- 137 microM/l, P &lt; 0.05; TG: 1.8 mM/l +/- 0.6 mM/l vs 1.1 mM/l +/- 0.5 mM/l, P &lt; 0.05) The GDR in steady-state was 6.7 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) +/- 1.4 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) in the OB group, significantly lower than that of the controls (12.2 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) +/- 3.1 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1), P &lt; 0.05).	cholesterol__min(-1__no_interaction	glucose__min(-1__no_interaction
12029081-2	Two human ElaC variants were recently associated with cancer (Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., <protein-id="P49913,J3KNB4">Camp</protein-id>, N. J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M., Frank, D., Frye, C., Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N., Laity, K. E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F., Skolnick, M. H., Neuhausen, S., Rommens, J., and <compound-id="3050747">Cannon</compound-id>-Albright, L. A.	Cannon__Camp__no_interaction
8985819-12	The levels of PIIINP correlated significantly with <compound-id="5280352">bilirubin</compound-id> (r = 0.43, P &lt; 0.006), while hyaluronan was correlated with age (r = 0.33, P &lt; 0.015), pruritus (r = 0.32, P &lt; 0.02), fatigue (r = 0.41, P &lt; 0.003), hepatomegaly (r = -0.46, P &lt; 0.0008), the presence of oesophageal varices (r = 0.34, P &lt; 0.002), weight loss (r = 0.29, P &lt; 0.05), <compound-id="5280352">bilirubin</compound-id> (r = 0.54, P &lt; 0.0001), <protein-id="P02768">albumin</protein-id> (r = -0.30, P &lt; 0.04), extent of fat excretion (r = 0.53, P &lt; 0.009) and length of symptomatic period before diagnosis of PBC (r = 0.43, P &lt; 0.002).	bilirubin__albumin__no_interaction
10634414-4	The following novel features of cellular adhesion of ITMC to thyrocytes in the regulation of the thyrocyte function in GD were observed: 1) GD-ITMC expressed lymphocyte function-associated antigen (<protein-id="P20701,B2RAL6">LFA)-1</protein-id>, which became an active adhesive configuration much higher than peripheral blood mononuclear cells (PBMC) from normal volunteers and GD patients; 2) GD-thyrocytes expressed a high quantity of intercellular adhesion molecule (<protein-id="P05362">ICAM)-1</protein-id>; 3) GD-ITMC adhered to GD-thyrocytes, whereas normal PBMC required activation stimuli by <compound-id="442070">phorbol</compound-id> myriacetate, a pharmacological integrin-trigger, to adhere to GD- thyrocytes; 4) monoclonal antibody-blocking studies showed that the adhesion of the activated PBMC and ITMC to thyrocytes was mainly mediated by the <protein-id="P20701,B2RAL6">LFA-1</protein-id>/<protein-id="P05362">ICAM-1</protein-id> pathway; 5) the adhesion of GD-thyrocytes to the activated-PBMC or ITMC induced the proliferation of the thyrocytes, which was blocked by the addition of <protein-id="P05362">ICAM-1</protein-id> and/or <protein-id="P20701,B2RAL6">LFA-1</protein-id> monoclonal antibodies; and 6) in GD thyrocytes of early cultures, <protein-id="P05362">ICAM-1</protein-id> expression on GD-thyrocytes and its adhesion to <protein-id="P20701,B2RAL6">LFA-1</protein-id> on <compound-id="442070">phorbol</compound-id> myriacetate-activated PBMC or ITMC were not modulated by the addition of <protein-id="P01584">interleukin-1beta</protein-id> or <protein-id="P01579">interferon-gamma</protein-id>, and proliferation of thyrocytes by the cellular adhesion via the <protein-id="P05362">ICAM-1</protein-id>/<protein-id="P20701,B2RAL6">LFA-1</protein-id> pathway was independent of the proliferative response of these cytokines.	phorbol__LFA)-1__no_interaction	phorbol__ICAM)-1__no_interaction	phorbol__interleukin-1beta__no_interaction	phorbol__ICAM-1__no_interaction	phorbol__LFA-1__no_interaction	phorbol__interferon-gamma__no_interaction
20033681-5	RESULTS: The GM [90% confidence interval (CI)] of the <compound-id="148192">atazanavir</compound-id> C(min), C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), and AUC of patients taking the <compound-id="4095">methadone</compound-id> oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking <compound-id="4095">methadone</compound-id> oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [<protein-id="P15509">GM ratio</protein-id> (<protein-id="P15509">GMR</protein-id>) = 0.61, p = 0.229]; C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (<protein-id="P15509">GMR</protein-id> = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (<protein-id="P15509">GMR</protein-id> = 0.62, p = 0.074).	atazanavir__max__no_interaction	atazanavir__GMR__no_interaction	atazanavir__GM ratio__no_interaction	methadone__max__no_interaction	methadone__GMR__no_interaction	methadone__GM ratio__no_interaction
16923367-12	Low or high dose L-<compound-id="6322,90867653">arginine</compound-id> treatment increased significantly the IGF-I levels from 0.789 +/- 0.062 ng/mg (Model group) to 0.937 +/- 0.067 ng/mg (low dose group) or 0.858 +/- 0.077 ng/mg (high dose group), the <protein-id="P01346,A0A0G2JTA6,M9NW49">IGF-II</protein-id> levels from 0.270 +/- 0.020 ng/mg (Model group) to 0.318 +/- 0.018 ng/mg (low dose group) or 0.354 +/- 0.021 ng/mg (high dose group) and the IGF-I mRNA expression from (13.12 +/- 1.39) x 10(4) cps/mug RNA (Model group) to (19.24 +/- 2.48) x 10(4) cps/mug RNA (low dose group) or (17.35 +/- 2.30) x 10(4) cps/mug RNA (high dose group) (P &lt; 0.01).	arginine__IGF-II__no_interaction
3297770-2	Gastrin, <compound-id="123946">xenopsin</compound-id>, <protein-id="P06307,Q6FG82">cholecystokinin</protein-id> (<protein-id="P06307,Q6FG82">CCK</protein-id>), <protein-id="P61278">somatostatin</protein-id>, <protein-id="P12872">motilin</protein-id>, <protein-id="P09683">secretin</protein-id>, GIP (gastric inhibitory polypeptide), <protein-id="P30990,Q6FH20">neurotensin</protein-id>, glicentin/glucagon-37 and <protein-id="P10082">PYY</protein-id> (peptide <compound-id="6057,90983769">tyrosine</compound-id> <compound-id="6057,90983769">tyrosine</compound-id>) are the main products of gastrointestinal endocrine cells; glucagon, CRF (corticotropin releasing factor), <protein-id="P61278">somatostatin</protein-id>, PP (<protein-id="P01298">pancreatic polypeptide</protein-id>) and GRF (growth hormone releasing factor), in addition to insulin, are produced in pancreatic islet cells; <protein-id="P07492">bombesin</protein-id>-related peptides are the main markers of pulmonary endocrine cells; calcitonin and <protein-id="P06881,P01258">CGRP</protein-id> (<protein-id="P06881,P01258">calcitonin gene-related peptide</protein-id>) occur in thyroid and extrathyroid C cells; <protein-id="P01189,Q6FHC8">ACTH</protein-id> and endorphins in anterior and intermediate lobe pituitary cells, <protein-id="P01189,Q6FHC8">alpha-MSH</protein-id> and <protein-id="P01189,Q6FHC8">CLIP</protein-id> (<protein-id="P01189,Q6FHC8">corticotropin-like intermediate lobe peptide</protein-id>) in intermediate lobe cells; met- and leu-enkephalins and related peptides in adrenal medullary and paraganglionic cells as well as in some gut (enterochromaffin) cells; <protein-id="P01303,A4D158">NPY</protein-id> (<protein-id="P01303,A4D158">neuropeptide Y</protein-id>) in <compound-id="5816">adrenaline</compound-id>-type adrenal medullary cells, etc..	xenopsin__neuropeptide Y__no_interaction	xenopsin__PYY__no_interaction	xenopsin__alpha-MSH__no_interaction	xenopsin__neurotensin__no_interaction	xenopsin__CLIP__no_interaction	xenopsin__pancreatic polypeptide__no_interaction	xenopsin__ACTH__no_interaction	xenopsin__calcitonin gene-related peptide__no_interaction	xenopsin__corticotropin-like intermediate lobe peptide__no_interaction	xenopsin__somatostatin__no_interaction	xenopsin__motilin__no_interaction	xenopsin__NPY__no_interaction	xenopsin__CCK__no_interaction	xenopsin__bombesin__no_interaction	xenopsin__secretin__no_interaction	xenopsin__CGRP__no_interaction	xenopsin__cholecystokinin__no_interaction	adrenaline__neuropeptide Y__no_interaction	adrenaline__PYY__no_interaction	adrenaline__alpha-MSH__no_interaction	adrenaline__neurotensin__no_interaction	adrenaline__CLIP__no_interaction	adrenaline__pancreatic polypeptide__no_interaction	adrenaline__ACTH__no_interaction	adrenaline__calcitonin gene-related peptide__no_interaction	adrenaline__corticotropin-like intermediate lobe peptide__no_interaction	adrenaline__somatostatin__no_interaction	adrenaline__motilin__no_interaction	adrenaline__NPY__no_interaction	adrenaline__CCK__no_interaction	adrenaline__bombesin__no_interaction	adrenaline__secretin__no_interaction	adrenaline__CGRP__no_interaction	adrenaline__cholecystokinin__no_interaction	tyrosine__neuropeptide Y__no_interaction	tyrosine__PYY__no_interaction	tyrosine__alpha-MSH__no_interaction	tyrosine__neurotensin__no_interaction	tyrosine__CLIP__no_interaction	tyrosine__pancreatic polypeptide__no_interaction	tyrosine__ACTH__no_interaction	tyrosine__calcitonin gene-related peptide__no_interaction	tyrosine__corticotropin-like intermediate lobe peptide__no_interaction	tyrosine__somatostatin__no_interaction	tyrosine__motilin__no_interaction	tyrosine__NPY__no_interaction	tyrosine__CCK__no_interaction	tyrosine__bombesin__no_interaction	tyrosine__secretin__no_interaction	tyrosine__CGRP__no_interaction	tyrosine__cholecystokinin__no_interaction
18788218-9	When compared to standard CPB, the Synergy showed lower levels of the monocyte-platelet adhesion index at T2 (0.023 +/- 0.005 vs 0.063 +/- 0.013, P = 0.0092) and T4 (0.031 +/- 0.003 vs 0.055 +/- 0.005, P = 0.0017), TAT complexes at T2 (27.175 +/- 5.967 vs 86.592 +/- 5.415, P = 0.0005) and <compound-id="5920">T3</compound-id> (26.977 +/- 2.468 vs 45.146 +/- 4.365, P = 0.0041), <protein-id="P00748,Q8IZZ5">F1+2</protein-id> fragments at T2 (2.222 +/- 0.226 vs 4.249 +/- 0.292, P = 0.0009), and sP-<compound-id="4929">selectin</compound-id> at <compound-id="5920">T3</compound-id> (115.17 +/- 19.623 vs 169.554 +/- 19.709, P = 0.0703) and T4 (108.542 +/- 6.429 vs 140.799 +/- 14.771, P = 0.0833).	T3__F1+2__no_interaction	selectin__F1+2__no_interaction
3185288-2	After 14 days of <compound-id="5865">prednisone</compound-id>, there was a significant increase in levels (mg/dL) of very low density lipoprotein-triglyceride (VLDL-TG) (51 +/- 9 v 92 +/- 11, P less than .01), very low density lipoprotein-<compound-id="5997">cholesterol</compound-id> (VLDL-C) (19 +/- 2 v 28 +/- 3, P less than .01), high density lipoprotein-<compound-id="5997">cholesterol</compound-id> (<protein-id="P28845,X5D2L1">HDL</protein-id>-C) (39 +/- 1 v 50 +/- 4, P less than .05), <protein-id="P02647,A0A024R3E3">apolipoprotein (apo) AI</protein-id> (124 +/- 7 v 147 +/- 8, P less than .01), and apo E (3.1 +/- 0.4 v 4.1 +/- 0.4, P less than .01).	prednisone__HDL__no_interaction	prednisone__apolipoprotein (apo) AI__no_interaction	cholesterol__HDL__no_interaction	cholesterol__apolipoprotein (apo) AI__no_interaction
24441276-15	Mänga faktorer <compound-id="6032">kan</compound-id> ha påverkat resultatet <protein-id="Q8TE85">som</protein-id> tex patientens motivation, <compound-id="4594">andra</compound-id> psyko-sociala omstandigheter och arbetsterapeutemas beslut att endast använda sig av två stycken av ett flertal arbetsprov.Konklusiionen ar att en bedörning av patientens arbetskapacitet skall utföras prospektivt och bör ta i beräknng de krav arbetet ställer enligt DOT och därefter bör rätt arbetsprov väijas för den individuella patienten.	kan__som__no_interaction	andra__som__no_interaction
23086471-2	Oxidative addition of {SeC5H3(3-R)N}2 (R = H or Me) to [Pd(P∩P)2] (P∩P = dppe, dppp) gave either a mononuclear complex, [Pd{2-Se-C5H3(3-R)N}2(P∩P)] (for P∩P/R: dppe/H or Me; dppp/H) or a cationic binuclear complex, [<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>{μ-SeC5H3(3-Me)N}2(dppp)2]2+ (4b) (R = Me) whereas reactions involving the <compound-id="6327182">tellurium</compound-id> analogue exclusively afforded trinuclear complexes, [<compound-id="25011744">Pd3</compound-id>(μ-Te)2(P∩P)3]<compound-id="24526">Cl2</compound-id> (P∩P = dppe (2) or dppp (6)).	Pd3__Pd2__no_interaction	Cl2__Pd2__no_interaction	tellurium__Pd2__no_interaction
19364123-3	The organic bridging/chelating ligands are discussed separately as follows: (i) pyridyl alkoxides [the anions of <compound-id="11474">2-(hydroxymethyl)pyridine</compound-id> (<protein-id="Q03014">hmpH</protein-id>), <compound-id="70957">2,6-pyridinedimethanol</compound-id> (pdmH(2)), and the gem-diol form of <compound-id="88065">di-2-pyridyl ketone</compound-id> (dpkdH(2))]; (ii) non-pyridyl alkoxides [the anions of 1,1,1-<compound-id="6503">tris</compound-id>(hydroxymethyl)<compound-id="6324">ethane</compound-id> (thmeH(3)), <compound-id="7618">triethanolamine</compound-id> (<compound-id="8471">teaH</compound-id>(3)), and <compound-id="7767">N-methyldiethanolamine</compound-id> (mdaH(2))]; (iii) other alcohols [the anions of 2,6-<compound-id="79015">dihydroxymethyl</compound-id>-<compound-id="2879">4-methylphenol</compound-id> (LH(3)) and Schiff bases]; (iv) pyridyl monoximes/dioximes [the anions of <compound-id="51040923">methyl-2-pyridyl ketone</compound-id> <compound-id="6350">oxime</compound-id> (mpkoH), <compound-id="53973492">phenyl-2-pyridyl ketone</compound-id> <compound-id="6350">oxime</compound-id> (ppkoH), and <compound-id="90827264">2,6-diacetylpyridine dioxime</compound-id> (dapdoH(2))]; (v) non-pyridyl oximes [the anions of <compound-id="5324608,5359280,6740756">salicylaldoxime</compound-id> (saoH(2)) and its derivatives R-saoH(2)].	4-methylphenol__hmpH__no_interaction	2,6-diacetylpyridine dioxime__hmpH__no_interaction	ethane__hmpH__no_interaction	2,6-pyridinedimethanol__hmpH__no_interaction	methyl-2-pyridyl ketone__hmpH__no_interaction	dihydroxymethyl__hmpH__no_interaction	salicylaldoxime__hmpH__no_interaction	di-2-pyridyl ketone__hmpH__no_interaction	oxime__hmpH__no_interaction	teaH__hmpH__no_interaction	triethanolamine__hmpH__no_interaction	N-methyldiethanolamine__hmpH__no_interaction	2-(hydroxymethyl)pyridine__hmpH__no_interaction	phenyl-2-pyridyl ketone__hmpH__no_interaction	tris__hmpH__no_interaction
10090936-2	Further analysis of patient <compound-id="7009630">LE</compound-id>, with the highest inhibitor titer, showed that (1) plasma or polyclonal IgG antibodies prepared from <compound-id="7009630">LE</compound-id> plasma inhibited the activity of allogeneic (wild-type) but not of self FVIII; (2) the presence of <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>) increased by over 10-fold the inhibitory activity on wild-type FVIII; (3) the kinetics of FVIII inhibition followed a type II pattern, but in contrast to previously described type II inhibitors, <compound-id="7009630">LE</compound-id> IgG was potentiated by the presence of <protein-id="P04275">vWF</protein-id> instead of being in competition with it; (4) polyclonal <compound-id="7009630">LE</compound-id> IgG recognized the FVIII light chain in enzyme-linked immunosorbent assay and the recombinant A3-C1 domains in an immunoprecipitation assay, indicating that at least part of <compound-id="7009630">LE</compound-id> antibodies reacted with the FVIII domain encompassing the mutation site; and (5) <compound-id="7009630">LE</compound-id> IgG inhibited FVIII activity by decreasing the rate of FVIIIa release from <protein-id="P04275">vWF</protein-id>, but <compound-id="7009630">LE</compound-id> IgG recognized an epitope distinct from ESH8, a murine monoclonal antibody exhibiting the same property.	LE__von Willebrand factor__no_interaction	LE__vWF__no_interaction
15332825-8	The reactions of the Cu(I) complexes with dioxygen in <compound-id="887">MeOH</compound-id> at -75 degrees C have given the trans-micro-1,2 peroxo dinuclear Cu(II) complexes formulated as [((<compound-id="80083">tapa</compound-id>)Cu)(2)(O(2))](2+) (1c), [((bapa)Cu)(2)(O(2))](2+) (2c), and [((mapa)Cu)(2)(O(2))](2+) (3c), whose characterizations were confirmed by UV-vis, <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR</protein-id>, and resonance Raman spectroscopies.	tapa__ESR__no_interaction	MeOH__ESR__no_interaction
22246377-9	RESULTS: CI increased at 3 and 6 h by 0.4 ± 0.1 (23%) and 0.33 ± 0.1 (17%) l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) m(-2), during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs -0.02 ± 0.1 (-1%) and -0.08 ± 0.1 (-5%) l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) m(-2) during placebo (p = 0.003); and heart rate (HR) increased at 1, 3 and 6 h by 8 ± 3 (11%), 15 ± 4 (21%) and 21 ± 5 (29%) beats per min (bpm), during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs -1 ± 2 (-2%), 1 ± 1 (2%) and 6 ± 2 (8%) bpm, during placebo (p = 0.006); and PCWP decreased at 1, 3 and 6 h by -1.3 ± 0.8 (-8%), -1.2 ± 1 (-8%) and -2.2 ± 0.9 (-15%) mmHg, during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs 0.3 ± 0.5 (2%), 1 ± 0.6 (6%) and 1.4 ± 0.7 (8%) mmHg, during placebo (p = 0.001).	exenatide__min(-1__no_interaction
16156617-4	[<compound-id="199">Ag2</compound-id>(L9)](SO3CF3)2 (1) (triclinic, P; a =10.292(4), b = 10.794(4), c = 11.399(5) A; alpha = 98.894(5), beta = 102.360(6), gamma = 90.319(5) degrees ; Z = 2), [Ag(L9)]SbF6 (2) (orthorhombic, Cmca; a = 19.059(9), b = 12.922(6), c = 15.609(7) A; Z = 8), [Ag(L9)]BF4 (3) (orthorhombic, Cmca; a = 19.128(3), b = 12.6042(18), c = 28.003(4) A; Z = 16), [Ag(L9)]ClO4 (4) (monoclinic, P2(1)/c; a = 8.5153(16), b = 19.722(4), c = 10.320(2) A; beta = 105.307(3) degrees ; Z = 4), [Ag(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)]SO3CF3 (5) (triclinic, P; a = 9.0605(13), b = 10.4956(15), c = 10.8085(16) A; alpha = 101.666(2), beta = 109.269(2), gamma = 100.944(2) degrees ; Z = 2), [Ag(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)(H2O)(0.5)]BF4.0.5H2O (6) (monoclinic, C2/m; a = 32.180(6), b = 17.027(3), c = 8.1453(15) A; beta = 102.541(3) degrees ; Z = 8), and {[<compound-id="199">Ag2</compound-id>(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)2(H2O)](ClO4)2}.o-<compound-id="7237">xylene</compound-id> (7) (monoclinic, P2(1)/c; a = 8.1460(10), b = 17.326(2), c = 30.345(4) A; beta = 97.71 degrees ; Z = 4) were obtained by the combination of L9 and <protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id> with various Ag(I) salts in a <compound-id="241">benzene</compound-id>/<compound-id="6344">methylene chloride</compound-id> mixed solvent system.	benzene__L10__no_interaction	xylene__L10__no_interaction	Ag2__L10__no_interaction	methylene chloride__L10__no_interaction
22384252-7	<protein-id="P30531,A0A024R2G0">GAT1</protein-id> blockade resulted in increases in mean (± SD) [(11)C]<compound-id="3373">flumazenil</compound-id> VT in Group II in association cortices (6.8 ± 0.8 mL g-1 vs. 7.3 ± 0.4 mL g-1;p = 0.03), sensory cortices (6.7 ± 0.8 mL g-1 vs. 7.3 ± 0.5 mL g-1;p = 0.02) and limbic regions (5.2 ± 0.6 mL g-1 vs. 5.7 ± 0.3 mL g-1;p = 0.03).	flumazenil__GAT1__no_interaction
25125317-16	The studies were conducted in hospital settings in low, middle and high income countries.Blood lossWe found significant reductions in blood loss with the following interventions: vaginal <compound-id="5282381">misoprostol</compound-id> (2 RCTs, 89 women: MD -97.88 ml, 95% CI -125.52 to -70.24; I(2) = 43%; moderate-quality evidence); intramyometrial <protein-id="P01185,X5DQP6">vasopressin</protein-id> (3 RCTs, 128 women: MD -245.87 ml, 95% CI -434.58 to -57.16; I(2) = 98%; moderate-quality evidence); intramyometrial bupivacaine plus <compound-id="5816">epinephrine</compound-id> (1 RCT, 60 women: MD -68.60 ml, 95% CI -93.69 to -43.51; low-quality evidence); intravenous <compound-id="5526">tranexamic acid</compound-id> (1 RCT, 100 women: MD -243 ml, 95% CI -460.02 to -25.98; low-quality evidence); gelatin-<compound-id="90470996">thrombin</compound-id> matrix (1 RCT, 50 women: MD -545.00 ml, 95% CI -593.26 to -496.74; low-quality evidence); intravenous <compound-id="54670067">ascorbic acid</compound-id> (1 RCT, 102 women: MD -411.46 ml, 95% CI -502.58 to -320.34; low-quality evidence); vaginal <compound-id="5280360">dinoprostone</compound-id> (1 RCT, 108 women: MD -131.60 ml, 95% CI -253.42 to -9.78; low-quality evidence); loop ligation of the myoma pseudocapsule (1 RCT, 70 women: MD -305.01 ml, 95% CI -354.83 to -255.19; low-quality evidence); and a fibrin sealant patch (1 RCT, 70 women: MD -26.50 ml, 95% CI -44.47 to -8.53; low-quality evidence).	ascorbic acid__vasopressin__no_interaction	dinoprostone__vasopressin__no_interaction	thrombin__vasopressin__no_interaction	epinephrine__vasopressin__no_interaction	misoprostol__vasopressin__no_interaction	tranexamic acid__vasopressin__no_interaction
19916849-6	RESULTS: In ischemic events, <compound-id="5754">cortisol</compound-id> level at third and seventh days, and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> level at the first day were correlated with lesion volumes (r = 0.5, p = .02; r = 0.4, p = .02; r = 0.5, p = .005, respectively).	cortisol__fibrinogen__no_interaction
7956938-4	During the steady-state phase of the experiment, <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-I</protein-id> dose dependently reduced plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (pmol/liter: A, 718 +/- 58; B, 613 +/- 35, NS vs. A; C, 408 +/- 21, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0001), plasma <protein-id="P12969">amylin</protein-id> (pmol/liter: A, 10.2 +/- 0.6; B, 8.8 +/- 0.5, NS vs. A; C, 5.8 +/- 0.4, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0001), and net <compound-id="206,5793,64689,79025">glucose</compound-id> uptake (mumol/kg.min: A, 188 +/- 12; B, 160 +/- 12, NS vs. A; C, 134 +/- 7, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0025).	glucose__amylin__no_interaction	glucose__IGF-I__no_interaction	glucose__insulin__no_interaction
16425287-8	In addition, serum ferritin, serum <compound-id="23925,67172434">iron</compound-id> and <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation were all inversely associated with colon cancer risk specifically (OR = 0.2, 95% CI = 0.1-0.7, p trend = 0.02; OR = 0.2, 95% CI = 0.1-0.9, p trend = 0.05; OR = 0.1, 95% CI = 0.02-0.5, p trend = 0.003, respectively), whereas serum unsaturated <compound-id="23925,67172434">iron</compound-id> binding capacity was positively associated with colon cancer risk (OR = 4.7, 95% CI = 1.4-15.1, p trend = 0.009).	iron__transferrin__no_interaction
7544886-2	Here we report that: (i) L-dT is selectively phosphorylated in vivo to L-dTMP by HSV-1 TK and L-dTMP is further phosphorylated to the di- and triphosphate forms by non-stereospecific cellular kinases; (ii) <compound-id="472333">L-dTTP</compound-id> not only inhibits HSV-1 DNA polymerase in vitro, but also human <protein-id="P28340,M0R2B7,A0A024R4F4,Q308M6,Q59FA0">DNA polymerase alpha, gamma, delta and epsilon</protein-id>, human immunodeficiency virus reverse transcriptase (HIV-1 RT), Escherichia coli DNA polymerase 1 and calf thymus terminal transferase, although <protein-id="Q27958">DNA polymerase beta</protein-id> was resistant; (iii) whereas <protein-id="Q27958">DNA polymerase beta</protein-id>, gamma, delta and epsilon are unable to utilize <compound-id="472333">L-dTTP</compound-id> as a substrate, the other DNA polymerases clearly incorporate at least one L-dTMP residue, with DNA polymerase alpha and HIV-1 RT able to further elongate the DNA chain by catalyzing the formation of the phosphodiester bond between the incorporated L-dTMP and an incoming <compound-id="472333">L-dTTP</compound-id>; (iv) incorporated L-nucleotides at the 3'-OH terminus make DNA more resistant to 3'--&gt;5' exonucleases.	L-dTTP__DNA polymerase alpha, gamma, delta and epsilon__no_interaction	L-dTTP__DNA polymerase beta__no_interaction
9248636-4	With the exception of <compound-id="5816">adrenaline</compound-id>, there were significant positive correlations between <protein-id="P01185,X5DQP6">vasopressin</protein-id> (r = 0.707, p &lt; 0.0001), plasma <protein-id="P00797">renin</protein-id> activity (r = 0.721, P &lt; 0.0001), <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin II</protein-id> (r = 0.512, P = 0.002), aldosterone (r = 0.620, P &lt; 0.0001), noradrenaline (r = 0.430, P = 0.0189), <compound-id="681">dopamine</compound-id> (r = 0.627, P = 0.0024) and percentage burn surface area, and a negative correlation between atrial natriuretic peptide (r = 0.548, P = 0.0008) and burn surface area.	adrenaline__angiotensin II__no_interaction	adrenaline__vasopressin__no_interaction	adrenaline__renin__no_interaction	dopamine__angiotensin II__no_interaction	dopamine__vasopressin__no_interaction	dopamine__renin__no_interaction
9683948-9	Plasma viscosity was significantly correlated with <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.63, p &lt; 0.001), systolic blood pressure (r = 0.33, p = 0.03) and <compound-id="5997">cholesterol</compound-id> (r = 0.32, p = 0.04), while <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id> was correlated with Lp(a) levels (r = 0.38, p = 0.03).	cholesterol__fibrinogen__no_interaction	cholesterol__P-selectin__no_interaction
9546612-2	Alpha-<compound-id="90470996">thrombin</compound-id> activated Factor XIII more efficiently (Km = 0.83 +/- 0.08 x 10(-7) M; V/K = 14.90 +/- 3.20 x 10(-3) min(-1)) than beta-<compound-id="90470996">thrombin</compound-id> (Km = 6.14 +/- 1.26 x 10(-7) M; V/K = 3.30 +/- 1.00 x 10(-3) <protein-id="P13987,Q6FHM9">min(-1)) or gamma-thrombin</protein-id> (Km = 6.25 +/- 1.15 x 10(-7) M; V/K = 3.00 +/- 0.80 x 10(-3) min(-1)).	thrombin__min(-1)) or gamma-thrombin__no_interaction
10690853-3	After ovarian stimulation (mean +/- SE of mean): free T4 decreased, 14.4 +/- 0.2 vs. 12.9 +/- 0.2 pmol/L (P &lt; 0.0001); thyroid-stimulating hormone increased, 2.3 +/- 0.3 vs. 3.0 +/- 0.4 mU/L (P &lt; 0.0001); <protein-id="P05543">T4-binding globulin</protein-id> increased, 25.2 +/- 0.7 vs. 33.9 +/- 0.9 mg/L (P &lt; 0.0001); total T4 increased, 98.1 +/- 2.3 vs. 114.6 +/- 2.5 nmol/L (P &lt; 0.0001); total <compound-id="5920">T3</compound-id> increased, 2.0 +/- 0.04 vs. 2.3 +/- 0.07 nmol/L (P &lt; 0.0001); <protein-id="P07202,Q6P534,Q502Y3">TPO</protein-id> antibodies decreased, 370 +/- 233 U/mL vs. 355 +/- 224 U/mL (P &lt; 0.0001); LH decreased, 8.1 +/- 1.1 vs. 0.4 +/-0.1 U/L (P &lt; 0.0001); FSH did not change, 6.5 +/- 0.6 vs. 7.9 +/- 0.9 U/L (P = 0.08); human CG increased, &lt;2 +/- 0.0 vs. 195 +/- 16 U/L (P &lt; 0.0001); <compound-id="5757">estradiol</compound-id> increased, 359.3 +/- 25.9 pmol/L vs. 3491.8 +/-298.3 pmol/L (P &lt; 0.0001); and <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> increased, 0.23 +/- 0.02 vs. 0.95 +/- 0.06 U/L (P &lt; 0.0001).	T3__TPO__no_interaction	T3__PRL__no_interaction	T3__T4-binding globulin__no_interaction	estradiol__TPO__no_interaction	estradiol__PRL__no_interaction	estradiol__T4-binding globulin__no_interaction
12639121-1	The nuclear magnetic transverse relaxation time of <compound-id="10197601">oxygen-17</compound-id> in aqueous <compound-id="23665763">sodium bisulfite</compound-id> solutions in the pH range from 2.5 to 5 was measured over a range of temperatures, pH, and S(IV) concentrations at an ionic strength of 1.0 m. From these data the rate law for <compound-id="977">oxygen</compound-id> exchange between bisulfite ion and <compound-id="962">water</compound-id> was determined and found to be consistent with <compound-id="977">oxygen</compound-id> exchange occurring via the reactions <protein-id="Q5BIV9">SHO</protein-id>(3)(-) + H(+) SO(2) + H(2)O, SO(3)H(-) + <protein-id="Q5BIV9">SHO</protein-id>(3-) SO(3)(2-) + SO(2) + H(2)O, and SO(3)H(-) + <protein-id="Q5BIV9">SHO</protein-id>(3-) S(2)O(5)(2-) + H(2)O, where the symbol <protein-id="Q5BIV9">SHO</protein-id>(3-) refers to both isomeric forms of bisulfite ion, one in which the <compound-id="783">hydrogen</compound-id> is bonded to the <compound-id="402">sulfur</compound-id> (denoted HSO(3-)) and another in which the <compound-id="783">hydrogen</compound-id> is bonded to an <compound-id="977">oxygen</compound-id> atom (denoted SO(3)H(-)).	oxygen__SHO__no_interaction	oxygen-17__SHO__no_interaction	sodium bisulfite__SHO__no_interaction	water__SHO__no_interaction	sulfur__SHO__no_interaction	hydrogen__SHO__no_interaction
9794743-8	However, the changes in resting systolic (r = 0.32, P &lt; 0.025) and diastolic (r = 0.36, P &lt; 0.01) blood pressures and in 24 h systolic (r = 0.28, P &lt; 0.05) blood pressure after <compound-id="5360545">sodium</compound-id> loading were all positive functions of individual resting end-tidal partial pressures of <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id>.	sodium__CO2__no_interaction
8238456-4	As occurs in animals, durations of nocturnal periods of active <compound-id="896">melatonin</compound-id> secretion (11.9 +/- 1.6 vs. 10.3 +/- 1.3 h, df = 14, t = 4.583, P &lt; 0.0005, paired t test), high <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> secretion (12.9 +/- 2.1 vs. 9.9 +/- 2.2 h, df = 11, t = 2.917, P &lt; 0.01), and sleep (10.6 +/- 0.8 vs. 7.6 +/- 0.4 h, df = 14, t = 17.122, P &lt; 0.0005) were longer after exposure to long nights than after short ones.	melatonin__prolactin__no_interaction
11993410-4	Obese women demonstrated higher concentrations of TG (2.03 +/- 0.78 vs. 0.99 +/- 0.37 mmol/l; p &lt; 0.05), <compound-id="91474">7-ketocholesterol</compound-id> (7-K) (89.85 +/- 63.03 vs. 41.90 +/- 17.33 ng/ml; p &lt; 0.05) and <compound-id="473141">7-hydroxycholesterol</compound-id> (7-OH) (456.04 +/- 199.22 vs. 132.37 +/- 53.96 ng/ml; p &lt; 0.05), and lower <protein-id="P28845,X5D2L1">HDL</protein-id>-<compound-id="5997">cholesterol</compound-id> level (0.74 +/- 0.10 vs. 1.30 +/- +/- 0.17 mmol/l; p &lt; 0.05) compared to the control group, while there were no significant differences between the two groups in concentrations of TC, LDL-<compound-id="5997">cholesterol</compound-id> and <compound-id="1548900,1742129,2116">vitamin E</compound-id>. Plasma <compound-id="1548900,1742129,2116">vitamin E</compound-id>/(TC + TG) ratio was lower in obese women (6.42 +/- 2.61 vs. 10.76 +/- 4.57 mumol/mmol; p &lt; 0.05).	7-ketocholesterol__HDL__no_interaction	7-hydroxycholesterol__HDL__no_interaction	vitamin E__HDL__no_interaction	cholesterol__HDL__no_interaction
9540779-4	There was only a trend toward higher values of TAT and <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> for AF patients, while subjects with previous stroke (irrespective of AF) had increased levels of the markers of <compound-id="90470996">thrombin</compound-id> generation (TAT stroke+ 18.95 +/- 5.15 vs TAT stroke- 8.34 +/- 2.41; <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> stroke+ 2.22 +/- 0.29 vs <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> stroke- 1.32 +/- 0.12).	thrombin__F1 + 2__no_interaction
14728846-8	LH, T, free <compound-id="6013">testosterone</compound-id> (FT) were significant decreased from (13.9 +/- 5.9) IU/L, (2.1 +/- 0.8) nmol/L and (2.8 +/- 2.3) nmol/L respectively to (5.8 +/- 2.2) IU/L, (1.2 +/- 0.4) nmol/L and (0.8 +/- 0.5) nmol/L respectively and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> was significant increased from (99 +/- 42) nmol/L to (187 +/- 64) nmol/L in group A3, when compared with LH, T and FT from (13.8 +/- 7.6) IU/L, (2.2 +/- 1.1) nmol/L and (2.5 +/- 1.9) nmol/L respectively to (11.8 +/- 6.5) IU/L, (1.8 +/- 0.8) nmol/L and (1.7 +/- 1.0) nmol/L respectively and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> from (99 +/- 40) nmol/L to (120 +/- 51) nmol/L in group A2 (P &lt; 0.05 approximately 0.001).	testosterone__SHBG__no_interaction
15701011-1	High molecular weight, soluble, air- and moisture-stable, highly metallized (&gt;25 wt% metal) polyferrocenylsilanes (PFS) [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){<compound-id="280">Co2</compound-id>(CO)6C2Ph}]n (Co-PFS), [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){Mo2-<protein-id="P00450,A5PL27">Cp2</protein-id>(CO)4C2Ph}]n (Mo-PFS), and [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){Ni2Cp2C2Ph}]n (Ni-PFS) containing pendant <compound-id="104730">cobalt</compound-id>, <compound-id="23932">molybdenum</compound-id>, and <compound-id="935">nickel</compound-id> clusters, respectively, have been prepared via macromolecular clusterization of an acetylide-substituted PFS [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me)C(triple bond)CPh]n with [Co(2)(CO)8], [{MoCp(CO)(2)}2], or [{NiCp(CO)}2].	Co2__Cp2__no_interaction	nickel__Cp2__no_interaction	2Si__Cp2__no_interaction	molybdenum__Cp2__no_interaction	cobalt__Cp2__no_interaction
8957217-3	Pre-treatments with tachykinin NK1 receptor antagonists (<compound-id="108167,5311450">SR140333</compound-id>, (S)1-¿2-[3-(3.4-<compound-id="57417436">dichlorophenyl</compound-id>) -1-(3-isopropoxyphenylacetyl)<compound-id="8082">piperidin</compound-id>-n-3-yl]<compound-id="23134249">ethyl</compound-id>¿-4-ph eny l-1-azoniabicyclo [2,2,2]octane <compound-id="312">chloride</compound-id>; GR82334, <compound-id="159907">pGlu-Ala</compound-id>- <compound-id="170612">Asp-Pro</compound-id>-Asn-<compound-id="151410,3459978">Lys-Phe</compound-id>-<compound-id="6057">Tyr</compound-id>-(S-S)<compound-id="3527720">Pro-Leu</compound-id>(spiro-gamma-lactam)-Trp-NH2) reduced the <protein-id="P20366,Q9Y494">substance P</protein-id>-induced increases in the respiratory frequency but the tachykinin <protein-id="P21452">NK2 receptor</protein-id> antagonist (<compound-id="104974">SR48968</compound-id>, ((S)-N-methyl-N-[4-<compound-id="15886675">4-acetylamino-4-phenylpiperidine</compound-id>)-2-(3,4-dichlorop hen yl) <compound-id="68006705">butyl</compound-id>]<compound-id="2331">benzamide</compound-id>); MEN 10376, <compound-id="152455">Asp-Tyr</compound-id>-D-<compound-id="19816756,7009658">Trp-Val</compound-id>-<compound-id="9060">D-Trp</compound-id>-<compound-id="5962">Lys</compound-id>-NH2) had no effect; the increase in the respiratory frequency induced by the tachykinin <protein-id="P16177">NK3 receptor</protein-id> agonist was not affected by a pre-treatment with tachykinin NK1 and <protein-id="P21452">NK2 receptor</protein-id> antagonists.	Trp-Val__NK3 receptor__no_interaction	Trp-Val__substance P__no_interaction	Trp-Val__NK2 receptor__no_interaction	D-Trp__NK3 receptor__no_interaction	D-Trp__substance P__no_interaction	D-Trp__NK2 receptor__no_interaction	dichlorophenyl__NK3 receptor__no_interaction	dichlorophenyl__substance P__no_interaction	dichlorophenyl__NK2 receptor__no_interaction	Lys__NK3 receptor__no_interaction	Lys__substance P__no_interaction	Lys__NK2 receptor__no_interaction	SR140333__NK3 receptor__no_interaction	SR140333__substance P__no_interaction	SR140333__NK2 receptor__no_interaction	piperidin__NK3 receptor__no_interaction	piperidin__substance P__no_interaction	piperidin__NK2 receptor__no_interaction	Asp-Pro__NK3 receptor__no_interaction	Asp-Pro__substance P__no_interaction	Asp-Pro__NK2 receptor__no_interaction	4-acetylamino-4-phenylpiperidine__NK3 receptor__no_interaction	4-acetylamino-4-phenylpiperidine__substance P__no_interaction	4-acetylamino-4-phenylpiperidine__NK2 receptor__no_interaction	Lys-Phe__NK3 receptor__no_interaction	Lys-Phe__substance P__no_interaction	Lys-Phe__NK2 receptor__no_interaction	butyl__NK3 receptor__no_interaction	butyl__substance P__no_interaction	butyl__NK2 receptor__no_interaction	Asp-Tyr__NK3 receptor__no_interaction	Asp-Tyr__substance P__no_interaction	Asp-Tyr__NK2 receptor__no_interaction	SR48968__NK3 receptor__no_interaction	SR48968__substance P__no_interaction	SR48968__NK2 receptor__no_interaction	pGlu-Ala__NK3 receptor__no_interaction	pGlu-Ala__substance P__no_interaction	pGlu-Ala__NK2 receptor__no_interaction	benzamide__NK3 receptor__no_interaction	benzamide__substance P__no_interaction	benzamide__NK2 receptor__no_interaction	Pro-Leu__NK3 receptor__no_interaction	Pro-Leu__substance P__no_interaction	Pro-Leu__NK2 receptor__no_interaction	chloride__NK3 receptor__no_interaction	chloride__substance P__no_interaction	chloride__NK2 receptor__no_interaction	Tyr__NK3 receptor__no_interaction	Tyr__substance P__no_interaction	Tyr__NK2 receptor__no_interaction	ethyl__NK3 receptor__no_interaction	ethyl__substance P__no_interaction	ethyl__NK2 receptor__no_interaction
17942567-6	<compound-id="444266">Maleate</compound-id> toxicity reproduced critical characteristics of the hypoxia/ATP depletion-induced injury cascade: 1) <compound-id="20725278">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) conferred protection, but due to its <compound-id="45934207,750">glycine</compound-id>, not <compound-id="5862,90793998">cysteine</compound-id> (antioxidant), content; 2) ATP reductions reflected decreased production, not Na-K-ATPase-driven increased consumption; 3) cell death was completely blocked by extracellular acidosis (pH 6.6); 4) intracellular Ca(2+) chelation (<compound-id="104751">BAPTA</compound-id>) mitigated cell death; 5) <compound-id="444266">maleate</compound-id> and hypoxia each caused plasma membrane <compound-id="5997">cholesterol</compound-id> shedding and in both instances, this was completely <compound-id="45934207,750">glycine</compound-id> suppressible; <compound-id="40467203">6) maleate</compound-id> + hypoxia caused neither additive NEFA accumulation nor LDH release, implying shared pathogenic pathways; and 7) <compound-id="444266">maleate</compound-id>, like ischemia, induced renal cortical <compound-id="5997">cholesterol</compound-id> loading; increased HMG <compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> reductase (HMGCR) activity (statin inhibitable), increased HMGCR mRNA levels, and increased <protein-id="P46279,C6SWZ3">RNA polymerase II</protein-id> recruitment to the HMGCR locus (chromatin immunoprecipitation, ChIP, assay) were involved.	Maleate__RNA polymerase II__no_interaction	glutathione__RNA polymerase II__no_interaction	glycine__RNA polymerase II__no_interaction	6) maleate__RNA polymerase II__no_interaction	maleate__RNA polymerase II__no_interaction	CoA__RNA polymerase II__no_interaction	cysteine__RNA polymerase II__no_interaction	BAPTA__RNA polymerase II__no_interaction	cholesterol__RNA polymerase II__no_interaction	GSH__RNA polymerase II__no_interaction
12474259-1	This study is concerned with the development and application of kinetic locking-on and auxiliary tactics for bioaffinity purification of <compound-id="5886">NADP</compound-id>(+)-dependent dehydrogenases, specifically (1) the synthesis and characterization of highly substituted N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives using a rapid solid-phase modular approach; (2) the evaluation of the N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives for use with the kinetic locking-on strategy for bioaffinity purification of <compound-id="5886">NADP</compound-id>(+)-dependent dehydrogenases: Model bioaffinity chromatographic studies with <compound-id="23327,33032,611,57109091">glutamate</compound-id> dehydrogenase from bovine liver (<protein-id="P00367,E9KL48">GDH</protein-id> with dual <compound-id="108194">cofactor</compound-id> specificity, EC 1.4.1.3) and <compound-id="23327,33032,611,57109091">glutamate</compound-id> dehydrogenase from Candida utilis (<protein-id="P00367,E9KL48">GDH</protein-id> which is <compound-id="5886">NADP</compound-id>(+)-specific, EC 1.4.1.4); (3) the selection of an effective "stripping ligand" for <compound-id="5886">NADP</compound-id>(+)-dehydrogenase bioaffinity purifications using N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives in the locking-on mode; and (4) the application of the developed bioaffinity chromatographic system to the purification of C. utilis <protein-id="P00367,E9KL48">GDH</protein-id> from a crude cellular extract.	NADP__GDH__no_interaction	glutamate__GDH__no_interaction	cofactor__GDH__no_interaction
12629086-6	Serum IGF-I was positively correlated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.10, P = 0.06) and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.19, P = 0.0001) concentrations and blood pressure (systolic and diastolic r = 0.10, P &lt;/= 0.05) and inversely with percentage body fat (r = -0.13, P = 0.01) and waist circumference (r = -0.11, P = 0.03).	glucose__fibrinogen__no_interaction
15644495-3	Although (Z)-(4-<compound-id="7961">bromophenyl</compound-id>){1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-<compound-id="23092063">methyl-1,4'-bipiperidin-4-yl</compound-id>}methanone O-ethyloxime (Sch-C; SCH 351125), 4,6-dimethyl-5-{[4-methyl-4-((<compound-id="21439199">3S</compound-id>)-3-methyl-4-{(1R)-2-(<compound-id="123146">methyloxy</compound-id>)-1-[4-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]<compound-id="23134249">ethyl</compound-id>}-1-piperazinyl)-1-piperidinyl]carbonyl}pyrimidine (<compound-id="3009355">Sch-D</compound-id>; SCH 417,690), 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-<compound-id="275736">methylethyl</compound-id>)-4H-<compound-id="9257">1,2,4-triazol</compound-id>-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenyl-propyl)<compound-id="14283">cyclohexanecarboxamide</compound-id> (<compound-id="3002977">UK-427,857</compound-id>), and N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclo-<compound-id="11610">hepten</compound-id>-8-yl]carbonyl]amino]benzyl]<compound-id="8894">tetrahydro-2H-pyran</compound-id>-4-aminium <compound-id="312">chloride</compound-id> (<compound-id="183790">TAK779</compound-id>) blocked the binding of both chemokines (125)I-<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id> (also known as (125)I-<protein-id="P10147,A0N0R1">CCL3</protein-id>, (125)I-LD78) and (125)I-<protein-id="P13501,D0EI67">RANTES</protein-id> ((125)I-<protein-id="P13501,D0EI67">CCL5</protein-id>), 873140 was an ineffectual antagonist of (125)I-<protein-id="P13501,D0EI67">RANTES</protein-id> (regulated on activation normal T cell expressed and secreted) binding (but did block binding of (125)I-<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id>).	bromophenyl__CCL3__no_interaction	bromophenyl__RANTES__no_interaction	bromophenyl__MIP-1alpha__no_interaction	bromophenyl__CCL5__no_interaction	TAK779__CCL3__no_interaction	TAK779__RANTES__no_interaction	TAK779__MIP-1alpha__no_interaction	TAK779__CCL5__no_interaction	3S__CCL3__no_interaction	3S__RANTES__no_interaction	3S__MIP-1alpha__no_interaction	3S__CCL5__no_interaction	chloride__CCL3__no_interaction	chloride__RANTES__no_interaction	chloride__MIP-1alpha__no_interaction	chloride__CCL5__no_interaction	1,2,4-triazol__CCL3__no_interaction	1,2,4-triazol__RANTES__no_interaction	1,2,4-triazol__MIP-1alpha__no_interaction	1,2,4-triazol__CCL5__no_interaction	tetrahydro-2H-pyran__CCL3__no_interaction	tetrahydro-2H-pyran__RANTES__no_interaction	tetrahydro-2H-pyran__MIP-1alpha__no_interaction	tetrahydro-2H-pyran__CCL5__no_interaction	UK-427,857__CCL3__no_interaction	UK-427,857__RANTES__no_interaction	UK-427,857__MIP-1alpha__no_interaction	UK-427,857__CCL5__no_interaction	cyclohexanecarboxamide__CCL3__no_interaction	cyclohexanecarboxamide__RANTES__no_interaction	cyclohexanecarboxamide__MIP-1alpha__no_interaction	cyclohexanecarboxamide__CCL5__no_interaction	methylethyl__CCL3__no_interaction	methylethyl__RANTES__no_interaction	methylethyl__MIP-1alpha__no_interaction	methylethyl__CCL5__no_interaction	methyloxy__CCL3__no_interaction	methyloxy__RANTES__no_interaction	methyloxy__MIP-1alpha__no_interaction	methyloxy__CCL5__no_interaction	trifluoromethyl__CCL3__no_interaction	trifluoromethyl__RANTES__no_interaction	trifluoromethyl__MIP-1alpha__no_interaction	trifluoromethyl__CCL5__no_interaction	methyl-1,4'-bipiperidin-4-yl__CCL3__no_interaction	methyl-1,4'-bipiperidin-4-yl__RANTES__no_interaction	methyl-1,4'-bipiperidin-4-yl__MIP-1alpha__no_interaction	methyl-1,4'-bipiperidin-4-yl__CCL5__no_interaction	Sch-D__CCL3__no_interaction	Sch-D__RANTES__no_interaction	Sch-D__MIP-1alpha__no_interaction	Sch-D__CCL5__no_interaction	hepten__CCL3__no_interaction	hepten__RANTES__no_interaction	hepten__MIP-1alpha__no_interaction	hepten__CCL5__no_interaction	ethyl__CCL3__no_interaction	ethyl__RANTES__no_interaction	ethyl__MIP-1alpha__no_interaction	ethyl__CCL5__no_interaction
16988209-6	Pharmacokinetic parameters for <compound-id="132999">ivabradine</compound-id> did not vary significantly after <compound-id="4594">omeprazole</compound-id> (C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or <compound-id="3883">lansoprazole</compound-id> administration (C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).	lansoprazole__max__no_interaction	omeprazole__max__no_interaction	ivabradine__max__no_interaction
3390203-1	Early after administration of <protein-id="Q9ER65">CS2</protein-id> to untreated, <compound-id="4763">phenobarbital</compound-id> (PB)-and <compound-id="1674">3-methylcholanthrene</compound-id> (3-MC)-pretreated C57BL/6 Cr mice: (1) the loss of cytochrome P-450 was enhanced by pretreatment with both inducers, but to a greater extent with 3-MC; (2) the decrease in <compound-id="3294">7-ethoxyresorufin</compound-id> (ER) O-deethylation activity was much greater than that of cytochrome P-450 in untreated and PB-pretreated mice, but both paralleled values in 3-MC-pretreated mice, in which ER O-deethylation activity was induced markedly, (3) the peak of the <compound-id="281">carbon monoxide</compound-id>-difference spectrum of microsomal reduced cytochrome P-450 (about 448 nm) in 3-MC-pretreated mice shifted toward 450 nm after administration of increasing doses of <protein-id="Q9ER65">CS2</protein-id>; (4) similar tendencies were observed in vitro in items (1) to (3); (5) electrophoresis of microsomal proteins revealed a loss of each protein band induced by PB and 3-MC following <protein-id="Q9ER65">CS2</protein-id> administration; (6) in the reconstituted monooxygenase system using partially purified cytochrome P-450 and <protein-id="P04799">P-448</protein-id> forms from PB- and 3-MC-treated rats, <protein-id="Q9ER65">CS2</protein-id> suppressed the drug-metabolizing activities exhibited by the <protein-id="P04799">P-448</protein-id> form but had little or no effect on those by the P-450 form; and (7) in <compound-id="8143">n-octylamine</compound-id> difference spectra of microsomes, loss of the 3-MC-induced high spin form of cytochrome P-450 was evident.	3-methylcholanthrene__P-448__no_interaction	3-methylcholanthrene__CS2__no_interaction	n-octylamine__P-448__no_interaction	n-octylamine__CS2__no_interaction	7-ethoxyresorufin__P-448__no_interaction	7-ethoxyresorufin__CS2__no_interaction	phenobarbital__P-448__no_interaction	phenobarbital__CS2__no_interaction	carbon monoxide__P-448__no_interaction	carbon monoxide__CS2__no_interaction
12360930-1	An in-depth analysis of a set of 21 layered structures of metallic pseudopolymorphs of general formulation, beta''-(<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>)(4) x (guest)(n) x [Re(6)Q(6)Cl(8)], (<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>=bis-<compound-id="11822531">ethylenedithiotetrathiafulvalene</compound-id>; Q = S, Se; guest = H(2)O, <compound-id="31275">1,4-dioxane</compound-id>, THF, <protein-id="P13236">CCl(4</protein-id>), C(2)H(5)OH, <compound-id="6432229">CHCl</compound-id>(3), CH(2)ClI, CH(2)ClBr, CH(2)Cl(2), CH(2)OH-CH(2)OH, C(5)H(5)N, CH(3)COCH(3), <compound-id="93002">2-hydroxy-tetrahydrofuran</compound-id>, CH(3)CN, CS(2), C(6)H(6)), with diverse low-temperature behaviors, which differ solely by the nature of the cosolvent molecule selectively included during the electrocrystallization process, reveals a precise set of weak HO-H...<compound-id="312">Cl-</compound-id>mu-Re, (C-H)(<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>)...<compound-id="312">Cl-</compound-id>mu-Re, C-H...O(guest), (C-H)(guest)...<compound-id="312">Cl-</compound-id>mu-Re <compound-id="783">hydrogen</compound-id> bonds at the organic-inorganic interface, none of which dominates any of the others and whose balance is adjusted upon substitution of one guest molecule by another.	Cl-__BEDT-TTF__no_interaction	Cl-__CCl(4__no_interaction	CHCl__BEDT-TTF__no_interaction	CHCl__CCl(4__no_interaction	2-hydroxy-tetrahydrofuran__BEDT-TTF__no_interaction	2-hydroxy-tetrahydrofuran__CCl(4__no_interaction	ethylenedithiotetrathiafulvalene__BEDT-TTF__no_interaction	ethylenedithiotetrathiafulvalene__CCl(4__no_interaction	hydrogen__BEDT-TTF__no_interaction	hydrogen__CCl(4__no_interaction	1,4-dioxane__BEDT-TTF__no_interaction	1,4-dioxane__CCl(4__no_interaction
21751803-6	Herein, we report the photophysical properties of a series of 2-R-pyrenes {R = C(3)H(6)CO(2)H (1), Bpin (2; <protein-id="P63167,Q6FGH9">pin</protein-id> = OCMe(2)CMe(2)O), OC(3)H(6)CO(2)H (3), O(CH(2))(12)Br (4), C≡CPh (5), C(6)H(4)-4-CO(2)Me (6), C(6)H(4)-4-B(Mes)(2) (7), B(Mes)(2) (8)} and 2,7-R(2)-pyrenes {R = Bpin (9), OH (10), C≡C(<compound-id="54117399">TMS</compound-id>) (11), C≡CPh (12), C≡C-C(6)H(4)-4-B(Mes)(2) (13), C≡C-C(6)H(4)-4-NMe(2) (14), C(6)H(4)-4-CO(2)C(8)H(17) (15), N(Ph)-C(6)H(4)-4-OMe (16)} whose syntheses are reported elsewhere.	TMS__pin__no_interaction
19782655-4	Here, we describe comparative experiments (involving also cisplatin) revealing: (i) improved cytotoxicity (3.4-5.4-fold) of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in human tumor ovarian cell lines; (ii) enhanced cellular uptake (approximately 1.5-fold) of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)]; (iii) somewhat enhanced rate of reactions of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] with <compound-id="124886,20725278,745">glutathione</compound-id> (approximately 1.5-fold), but a similar rate of reactions with metallothionenin-2; (iv) enhanced rate of DNA binding of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in cell-free media (approximately 2-fold); (v) similar sequence preference of DNA binding of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in cell-free media; (vi) identical DNA interstrand cross-linking efficiency (6%); (vii) similar bending (32 degrees) and enhanced local unwinding (approximately 1.5-fold) induced in DNA by the major 1,2-GG-intrastrand cross-link; (viii) markedly enhanced inhibiting effects of DNA adducts of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] on processivity of DNA polymerase; and (ix) a slightly lower efficiency of DNA repair systems to remove the adducts of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] from DNA.	glutathione__cis-1__no_interaction
20537417-4	Genomic polymorphism of angiotensin converting enzyme (ACE I/D), <protein-id="P01019,B0ZBE2,B2R5S1">angiotensinogen</protein-id> (<protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id>, c.704C&gt;T), <protein-id="P30556,D3DNG8,A0A0A0MSE3,Q53YY0,Q6NUP5">angiotensin II receptor type 1</protein-id> (<protein-id="P30556,D3DNG8,A0A0A0MSE3,Q53YY0,Q6NUP5">AGTR1</protein-id>, c.1166A&gt;C), <protein-id="P19099">aldosterone synthase</protein-id> (<protein-id="P19099">CYP11B2</protein-id>, c.-344C&gt;T), <protein-id="P05305,Q6FH53">endothelin 1</protein-id> (<protein-id="P05305,Q6FH53">EDN1</protein-id>, <protein-id="P05305,Q6FH53">EDN1</protein-id>/ex5-c.5665G&gt;T), G protein (<protein-id="P16520,F1T0G5,E9PCP0">GNB3</protein-id>, c.825C&gt;T), <protein-id="P32298">G protein-coupled receptor kinase 4</protein-id> (<protein-id="P32298">GRK4</protein-id>, c.679C&gt;T), <protein-id="P35555">fibrillin 1</protein-id> (<protein-id="P35555">FBN1</protein-id>, VNTR(TAAA)) and two polymorphisms each of the ß1 adrenoreceptor (<protein-id="P08588">ADRB1</protein-id>, c.145G&gt;A and c.1165C&gt;G), ß2 adrenoreceptor (<protein-id="P07550">ADRB2</protein-id>, c.<compound-id="15658026">46A</compound-id>&gt;G and c.79C&gt;G), and endothelial NO synthase (<protein-id="P29474,A0A0A0MTA6,A0S0A6">NOS3</protein-id>, intron 4 I/D and <protein-id="P29474,A0A0A0MTA6,A0S0A6">NOS3</protein-id>, c.894G&gt;T) were determined by PCR amplification and fragment length analysis.	46A__G protein-coupled receptor kinase 4__no_interaction	46A__NOS3__no_interaction	46A__endothelin 1__no_interaction	46A__angiotensinogen__no_interaction	46A__angiotensin II receptor type 1__no_interaction	46A__GNB3__no_interaction	46A__FBN1__no_interaction	46A__ADRB1__no_interaction	46A__ADRB2__no_interaction	46A__fibrillin 1__no_interaction	46A__EDN1__no_interaction	46A__CYP11B2__no_interaction	46A__AGTR1__no_interaction	46A__AGT__no_interaction	46A__GRK4__no_interaction	46A__aldosterone synthase__no_interaction
15216418-3	These puzzling observations have now been explored in greater detail, with the following major findings: a) the large inward <compound-id="54730402">TRK</compound-id> currents are not carried by influx of either K(+) or H(+), but rather by an efflux of <compound-id="312">chloride</compound-id> ions; b) with normal expression levels for <protein-id="P12685">Trk1p</protein-id> and <protein-id="P28584">Trk2p</protein-id> in <compound-id="5462222">potassium</compound-id>-replete cells, the inward <compound-id="54730402">TRK</compound-id> currents are contributed approximately half by <protein-id="P12685">Trk1p</protein-id> and half by <protein-id="P28584">Trk2p</protein-id>; but c) strain background strongly influences the absolute magnitude of these currents, which are nearly twice as large in W303-derived spheroplasts as in S288c-derived cells (same cell-size and identical recording conditions); d) incorporation of mutations that increase cell size (deletion of the Golgi <compound-id="22044544,5460341">calcium</compound-id> pump, <protein-id="P13586">Pmr1p</protein-id>) or that upregulate the TRK2 promoter, can further substantially increase the <compound-id="54730402">TRK</compound-id> currents; e) removal of intracellular <compound-id="312">chloride</compound-id> (e.g., replacement by <compound-id="1117">sulfate</compound-id> or <compound-id="10690">gluconate</compound-id>) reveals small inward currents that are K(+)-dependent and can be enhanced by K(+) starvation; and f) finally, the latter currents display two saturating kinetic components, with preliminary estimates of K(0.5) at 46 micro M [K(+)](out) and 6.8 m M [K(+)](out), and saturating fluxes of approximately 5 m M/min and approximately 10 m M/min (referred to intracellular <compound-id="962">water</compound-id>).	TRK__Trk1p__no_interaction	TRK__Trk2p__no_interaction	TRK__Pmr1p__no_interaction	potassium__Trk1p__no_interaction	potassium__Trk2p__no_interaction	potassium__Pmr1p__no_interaction	sulfate__Trk1p__no_interaction	sulfate__Trk2p__no_interaction	sulfate__Pmr1p__no_interaction	gluconate__Trk1p__no_interaction	gluconate__Trk2p__no_interaction	gluconate__Pmr1p__no_interaction	water__Trk1p__no_interaction	water__Trk2p__no_interaction	water__Pmr1p__no_interaction	calcium__Trk1p__no_interaction	calcium__Trk2p__no_interaction	calcium__Pmr1p__no_interaction	chloride__Trk1p__no_interaction	chloride__Trk2p__no_interaction	chloride__Pmr1p__no_interaction
16633845-7	<protein-id="P02741">CRP</protein-id> was positively correlated with <compound-id="447041">IMT</compound-id> (r = 0.49, p = 0.001), IEM (r = 0.24, p = 0.05), DWS (r = 0.58, p &lt; 0.001), and body mass index (BMI) (r = 0.28, p = 0.05).	IMT__CRP__no_interaction
22235146-4	Here, we investigated whether a novel class of peptide <compound-id="449520">epoxyketone</compound-id>-based PIs, including <compound-id="11556711">carfilzomib</compound-id>, N-((S)-<compound-id="13516411">3-methoxy</compound-id>-1-(((S)-<compound-id="13516411">3-methoxy</compound-id>-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-<compound-id="23322366">methylthiazole-5-carboxamide</compound-id> (<compound-id="25067547">ONX0912</compound-id>), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(<compound-id="667910">2-morpholinoacetamido</compound-id>)propanamido)<compound-id="6578">propanamide</compound-id> (<compound-id="23642227">ONX0914</compound-id>), might escape two established BTZ-resistance mechanisms: 1) mutations in the proteasome β5 subunit (<protein-id="P28074">PSMB5</protein-id>) targeted by these <protein-id="P30740,V9HWH1">PIs, and 2</protein-id>) drug efflux mediated by <compound-id="5957">ATP</compound-id>-binding cassette transporters.	ONX0912__PSMB5__no_interaction	ONX0912__PIs, and 2__no_interaction	propanamide__PSMB5__no_interaction	propanamide__PIs, and 2__no_interaction	epoxyketone__PSMB5__no_interaction	epoxyketone__PIs, and 2__no_interaction	ONX0914__PSMB5__no_interaction	ONX0914__PIs, and 2__no_interaction	3-methoxy__PSMB5__no_interaction	3-methoxy__PIs, and 2__no_interaction	ATP__PSMB5__no_interaction	ATP__PIs, and 2__no_interaction	2-morpholinoacetamido__PSMB5__no_interaction	2-morpholinoacetamido__PIs, and 2__no_interaction	carfilzomib__PSMB5__no_interaction	carfilzomib__PIs, and 2__no_interaction	methylthiazole-5-carboxamide__PSMB5__no_interaction	methylthiazole-5-carboxamide__PIs, and 2__no_interaction
12831519-6	) were compared, the thrombocytopenic patients were found not only to be generally older than the non-thrombocytopenic [25.3 (1.1) v. 21.3 (0.18) years; P &lt; 0.001] but also to have presented with higher serum concentrations of <compound-id="5960">aspartate</compound-id> aminotransferase [77.6 (16.6) v. 32.3 (7.4) U/litre; P &lt; 0.0001], <compound-id="5950,602">alanine</compound-id> aminotransferase [96.7 (19.0) v. 44.7 (12.0) U/litre; P = 0.0001], <protein-id="P01583">interleukin-1</protein-id> [49.9 (7.4) v. 23.7 (5.1) pg/ml; P &lt; 0.001], <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> [174.9 (26.4) v. 57.3 (14.6) pg/ml; P = 0.001], <protein-id="P22301,Q6FGW4">interleukin-10</protein-id> [308.2 (39.6) v. 137.9 (23.1) pg/ml; P &lt; 0.002] and transforming growth factor-beta [1134.3 (387.5) v. 416.6 (183.8) pg/ml; P &lt; 0.0001], and higher levels of parasitaemia [4345.7 (966.6) v. 1443.8 (222.7) parasites/microl; P = 0.03).	alanine__interleukin-1__no_interaction	alanine__interleukin-10__no_interaction	alanine__interleukin-6__no_interaction	aspartate__interleukin-1__no_interaction	aspartate__interleukin-10__no_interaction	aspartate__interleukin-6__no_interaction
10484572-5	High plasma estradiol concentration lowered the P(<protein-id="P13725,B5MCX1">osm</protein-id>) threshold for <protein-id="P01185,X5DQP6">AVP</protein-id> release during the luteal phase and during OC E + P [x-intercepts, 282 +/- 2, 278 +/- 2, 276 +/- 2, and 280 +/- 2 mosmol/kgH(2)O, for follicular, luteal (combined means), OC E + P, and OC P, respectively; P &lt; 0.05, luteal phase and OC E + P vs. follicular phase] during exercise dehydration, and <compound-id="56981346,5757">17beta-estradiol</compound-id> administration lowered the P(<protein-id="P13725,B5MCX1">osm</protein-id>) threshold for thirst stimulation [x-intercepts, 280 +/- 2, 279 +/- 2, 276 +/- 2, and 280 +/- 2 mosmol/kgH(2)O for follicular, luteal, OC E + P, and OC P, respectively; P &lt; 0.05, OC E + P vs. follicular phase], without affecting body fluid balance.	17beta-estradiol__AVP__no_interaction	17beta-estradiol__osm__no_interaction
24083877-10	RESULT(S): Averages of times in the general population were: t2 = 27.9 hours, <compound-id="5920">t3</compound-id> = 38.2 hours, t4 = 40.7 hours, t5 = 51.0 hours, t6 = 54.1 hours, t7 = 56.7 hours, t8 = 59.1 hours, tM = 86.6 hours, tB = 104.1 hours, <compound-id="54736423">cc2</compound-id> = 10.3 hours, <protein-id="Q16627">cc3</protein-id> = 12.8 hours, s2 = 2.7 hours, and s3 = 9.9 hours.	t3__cc3__no_interaction	cc2__cc3__no_interaction
20561675-8	FINDINGS: In the first 3000 cases (n=2337, 78%, with ischaemic stroke; n=663, 22%, with intracerebral haemorrhagic stroke) and 3000 controls, significant risk factors for all stroke were: history of hypertension (OR 2.64, 99% CI 2.26-3.08; PAR 34.6%, 99% CI 30.4-39.1); current smoking (2.09, 1.75-2.51; 18.9%, 15.3-23.1); waist-to-<protein-id="Q06141,Q53S56">hip</protein-id> ratio (1.65, 1.36-1.99 for highest vs lowest tertile; 26.5%, 18.8-36.0); diet risk score (1.35, 1.11-1.64 for highest vs lowest tertile; 18.8%, 11.2-29.7); regular physical activity (0.69, 0.53-0.90; 28.5%, 14.5-48.5); diabetes mellitus (1.36, 1.10-1.68; 5.0%, 2.6-9.5); <compound-id="10982484,702">alcohol</compound-id> intake (1.51, 1.18-1.92 for more than 30 drinks per month or binge drinking; 3.8%, 0.9-14.4); psychosocial stress (1.30, 1.06-1.60; 4.6%, 2.1-9.6) and depression (1.35, 1.10-1.66; 5.2%, 2.7-9.8); cardiac causes (2.38, 1.77-3.20; 6.7%, 4.8-9.1); and ratio of apolipoproteins B to A1 (1.89, 1.49-2.40 for highest vs lowest tertile; 24.9%, 15.7-37.1).	alcohol__hip__no_interaction
20143470-10	Compared with model group, <compound-id="248">betaine</compound-id> feeding resulted in significant decreases of ALT (64.93 +/- 6.06 U/L vs 159.41 +/- 7.74 U/L, P &lt; 0.0001), AST (188.73 +/- 1.11 U/L vs 248.25 +/- 1.40 U/L, P &lt; 0.0001), endotoxin (61.80 +/- 12.56 ng/L vs 135.37 +/- 30.17 ng/L, P &lt; 0.0001), <protein-id="P16599">TNF-alpha</protein-id> (9.79 +/- 1.32 pg/mL vs 20.81 +/- 8.58 pg/mL, P = 0.0003), <protein-id="P01581">IFN-gamma</protein-id> (18.02 +/- 5.96 pg/mL vs 30.18 +/- 7.60 pg/mL, P = 0.0008) and <protein-id="P97636">IL-18</protein-id> (18.23 +/- 7.01 pg/mL vs 40.99 +/- 8.25 pg/mL, P &lt; 0.0001).	betaine__IFN-gamma__no_interaction	betaine__TNF-alpha__no_interaction	betaine__IL-18__no_interaction
17102647-8	Significant correlation was also observed between ELISA D-dimer and cardiac medications including beta-blocker (r = 0.22, P = 0.01), <compound-id="2244">aspirin</compound-id> (r = 0.18, P = 0.04), <compound-id="10313259,943">nitrate</compound-id> (r = 0.20, P = 0.002), acute phase reactants fibrinogen (r = 0.45, P = 0.0001) and <protein-id="P02741">C-reactive protein</protein-id> (r = 0.29, P = 0.004), ischemic electrocardiographic changes (r = 0.21, P = 0.02) and length of stay (r = 0.29, P = 0.001).	nitrate__C-reactive protein__no_interaction	aspirin__C-reactive protein__no_interaction
18855385-7	Complexes 6a and b participate in a series of successive equilibria in solution, involving the dissociation of <compound-id="11403475">phosphine ligands</compound-id> and the exchange of [M(<compound-id="5289124">PCy</compound-id> 3)] (+) units to give 2a or 3b and the corresponding disilver derivatives [Ag 2{[SC=( t-Bu-fy)] 2S}(<protein-id="P24158">PR 3</protein-id>) 2] [R = Ph ( 8a), To ( 8b)], followed by <compound-id="140368">thioketene</compound-id>-exchange reactions to give [AgCu{[SC=( t-Bu-fy)] <compound-id="21439199">3S</compound-id>}(<protein-id="P24158">PR 3</protein-id>) 2] [R = Ph ( 9a), To ( 9b)].	3S__PR 3__no_interaction	phosphine ligands__PR 3__no_interaction	thioketene__PR 3__no_interaction	PCy__PR 3__no_interaction
17941003-1	Naturally occurring cyclic tetrapeptides (CTPs) such as <compound-id="5281143,6442695,91592">tentoxin</compound-id> (Halloin et al., Plant Physiol 1970, 45, 310-314; Saad, Phytopathology 1970, 60, 415-418), ampicidin (Darkin-Rattray, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1996, 93, 13143-13147), <compound-id="107864">HC-toxin</compound-id> (Walton, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1987, 84, 8444-8447), and <compound-id="395803">trapoxin</compound-id> (Yoshida and Sugita, <compound-id="16220126">Jpn</compound-id> J Cancer Res 1992, 83, 324-328; Itazaki et al., J Antibiot (Tokyo) 1990, 43, 1524-1532) have a wide range of biological activity and potential use ranging from herbicides (Walton, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1987, 84, 8444-8447; Judson, J Agric Food Chem 1987, 35, 451-456) to therapeutics (Loiseau, Biopolymers 2003, 69, 363-385) for malaria (Darkin-Rattray, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1996, 93, 13143-13147) and cancer (Yoshida and Sugita, <compound-id="16220126">Jpn</compound-id> J Cancer Res 1992, 83, 324-328).	trapoxin__Proc__no_interaction	tentoxin__Proc__no_interaction	HC-toxin__Proc__no_interaction	Jpn__Proc__no_interaction
22095243-1	Substitution reactions of <compound-id="23939">platinum</compound-id> complexes bearing <compound-id="7965">cyclohexylamine</compound-id>/diamine moieties viz., [Pt(H(2)O)(N,N-bis(<compound-id="7975">2-pyridylmethyl</compound-id>)<compound-id="7965">cyclohexylamine</compound-id>)](CF(3)SO(3))(2), bpcHna; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="18374">trans-1,4-cyclohexyldiamine</compound-id>)](CF(3)SO(3))(4), <protein-id="P15882">cHn</protein-id> and [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-4,4'-<compound-id="177095">dicyclohexylmethanediamine</compound-id>)](CF(3)SO(3))(4), dcHnm and <compound-id="6115">phenylamine</compound-id>/diamine moieties viz., ([Pt(H(2)O)N,N-bis(<compound-id="7975">2-pyridylmethyl</compound-id>)<compound-id="6115">phenylamine</compound-id>)](CF(3)SO(3))(2), bpPha; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-1,3-phenyldiamine)](CF(3)SO(3))(4), mPh; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-1,4-phenyldiamine)](CF(3)SO(3))(4), pPh and [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7577">4,4'-diphenylmethanediamine</compound-id>)](CF(3)SO(3))(4)), dPhm with <compound-id="2723790">thiourea</compound-id> nucleophiles were studied in acidified 0.01 M LiCF(3)SO(3) aqueous medium under pseudo-first-order conditions using stopped-flow and UV-visible spectrophotometric techniques.	platinum__cHn__no_interaction	phenylamine__cHn__no_interaction	dicyclohexylmethanediamine__cHn__no_interaction	trans-1,4-cyclohexyldiamine__cHn__no_interaction	thiourea__cHn__no_interaction	4,4'-diphenylmethanediamine__cHn__no_interaction	2-pyridylmethyl__cHn__no_interaction	cyclohexylamine__cHn__no_interaction
16497181-6	In contrast, plasma <protein-id="P22388">Endothelin-1</protein-id> concentration (0.58 +/- 0.04 vs. 1.05 +/- 0.01 femtomol mL(-1); P &lt; 0.01), renal papillary ET-1 concentration (68 +/- 5 vs. 478 +/- 62 fmol mg(-1) protein; P &lt; 0.01) and preproET-1/<protein-id="O35077">GPDH</protein-id> mRNA ratio (0.65 +/- 0.09 vs. 0.88 +/- 0.05; P &lt; 0.05) as well as total <compound-id="44284481">endothelin</compound-id> receptor number in renal papilla (B(max) 5.3 +/- 0.4 vs. and 9.0 +/- 1.2 pmol mg(-1) protein; P &lt; 0.05) were markedly lower in <compound-id="7009630">LE</compound-id> than in WKY rats.	endothelin__Endothelin-1__no_interaction	endothelin__GPDH__no_interaction	LE__Endothelin-1__no_interaction	LE__GPDH__no_interaction
24508213-2	The aim of this study was to produce the multipurpose, bivalent [DUPA-6-<compound-id="448563">Ahx</compound-id>-((64)Cu-NODAGA)-5-<compound-id="16070004">Ava</compound-id>-BBN(7-14)NH2] radioligand for prostate cancer imaging, where DUPA = (2-[3-(1,3-<compound-id="11756">dicarboxypropyl</compound-id>)-ureido]<compound-id="743">pentanedioic acid</compound-id>), a small-molecule, <protein-id="Q04609">PSMA</protein-id>-targeting probe, 6Ahx = <compound-id="564">6-aminohexanoic acid</compound-id>, 5-<compound-id="16070004">Ava</compound-id> = <compound-id="138">5-aminovaleric acid</compound-id>, NODAGA = [2-(4,7-biscarboxymethyl)-1,4,7-(<compound-id="21896526">triazonan-1-yl</compound-id>)<compound-id="743">pentanedioic acid</compound-id>] (a derivative of <compound-id="124326">NOTA</compound-id> (<compound-id="188318">1,4,7-triazacyclononane</compound-id>-1,4,7-<compound-id="5459844">triacetic acid</compound-id>)), and BBN(7-14)NH2 = <protein-id="P07492">bombesin</protein-id>, a GRPr-specific peptide targeting probe.	triacetic acid__PSMA__no_interaction	triacetic acid__bombesin__no_interaction	dicarboxypropyl__PSMA__no_interaction	dicarboxypropyl__bombesin__no_interaction	6-aminohexanoic acid__PSMA__no_interaction	6-aminohexanoic acid__bombesin__no_interaction	triazonan-1-yl__PSMA__no_interaction	triazonan-1-yl__bombesin__no_interaction	pentanedioic acid__PSMA__no_interaction	pentanedioic acid__bombesin__no_interaction	NOTA__PSMA__no_interaction	NOTA__bombesin__no_interaction	1,4,7-triazacyclononane__PSMA__no_interaction	1,4,7-triazacyclononane__bombesin__no_interaction	5-aminovaleric acid__PSMA__no_interaction	5-aminovaleric acid__bombesin__no_interaction	Ahx__PSMA__no_interaction	Ahx__bombesin__no_interaction	Ava__PSMA__no_interaction	Ava__bombesin__no_interaction
2450260-2	The <protein-id="Q5BJP4">RRM</protein-id>-salt was characterized by: (1) increased endogenous "<compound-id="56840973">digitalis</compound-id>-like" compounds in plasma [cross reactivity with <compound-id="2724385">digoxin</compound-id>-antibodies (57.5 +/- 5.0 vs. 42.1 +/- 3.8 pg/ml, p less than 0.02); inhibition of kidney Na+, K+-ATPase activity (135 +/- 5 vs. 154 +/- 5 mumol/mg/h, p less than 0.01); and inhibition of Na+ extrusion from normal erythrocytes (5.96 +/- 0.40 vs. 7.68 +/- 0.34 mmol/L cells/h, p less than 0.01)]; (2) reduced Na+, K+-pump activity (7.34 +/- 0.29 vs. 10.88 +/- 0.41 mmol/L cells/h, p less than 0.001) and increased Na+ content (4.66 +/- .08 vs. 4.16 +/- 0.11 mmol/L cells, p less than 0.01) in erythrocytes; and (3) low plasma <protein-id="P08424">renin</protein-id> activity (2.1 +/- 0.9 vs. 12.6 +/- 1.6 ng/ml/h).	digitalis__RRM__no_interaction	digitalis__renin__no_interaction	digoxin__RRM__no_interaction	digoxin__renin__no_interaction
21606177-4	Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [(3)H]1-methyl-4-<compound-id="3734524">phenylpyridinium</compound-id> (MPP(+)) (<protein-id="O15245">OCT1</protein-id>-3), [(14)C]<compound-id="5413">tetraethylammonium bromide</compound-id> (TEA(+)) (<protein-id="O15245">OCT1</protein-id>-3 and <protein-id="Q9H015,Q9R141">OCTN1</protein-id>/2), [(3)H]<compound-id="3037043">ergothioneine</compound-id> (<protein-id="Q9H015,Q9R141">OCTN1</protein-id>), and [(3)H]l-carnitine (<protein-id="O70594">OCTN2</protein-id>).	tetraethylammonium bromide__OCTN1__no_interaction	tetraethylammonium bromide__OCTN2__no_interaction	tetraethylammonium bromide__OCT1__no_interaction	phenylpyridinium__OCTN1__no_interaction	phenylpyridinium__OCTN2__no_interaction	phenylpyridinium__OCT1__no_interaction	ergothioneine__OCTN1__no_interaction	ergothioneine__OCTN2__no_interaction	ergothioneine__OCT1__no_interaction
20817554-6	The multivariate logistic regression identified, after adjusting for demographic and socioeconomic variables, factors associated with short sleep duration: more television viewing during weekdays (<protein-id="Q8NGE0">OR=1.21</protein-id>, p=0.004), more frequent computer/internet using (<protein-id="Q8NGY2">OR=1.17</protein-id>, p=0.006), earlier school starting time (OR=1.10, p=0.020), more time on homework during weekdays (OR=1.66, p&lt;0.001) and weekends (OR=1.14, p=0.001), poor bedtime hygiene (e.g., having drinks with <compound-id="2519,57106085">caffeine</compound-id> after 6:00PM [<protein-id="Q8NGY5">OR=1.22</protein-id>, p&lt;0.001], doing exciting activities during bedtime [OR=1.16, p&lt;0.001], and irregular bedtime [<protein-id="Q96R27">OR=1.55</protein-id>, p&lt;0.001]), and shorter sleep duration of parents (mother: OR=1.31, p&lt;0.001 for sleep duration &lt;6h and OR=1.24, p=0.006 for 6-8h; father: OR=1.52, p&lt;0.001 for &lt;6h and OR=1.19, p&lt;0.001 for 6-8h).	caffeine__OR=1.21__no_interaction	caffeine__OR=1.17__no_interaction	caffeine__OR=1.55__no_interaction	caffeine__OR=1.22__no_interaction
23711224-5	The NEAT score was also negatively correlated with waist circumference (r = -0.509, P &lt; 0.05) and positively correlated with high-density lipoprotein-<compound-id="5997">cholesterol</compound-id> levels (r = 0.494, P &lt; 0.05) in women, and negatively associated with serum <protein-id="P01308,I3WAC9">insulin</protein-id> levels (r = -0.732, p &lt; 0.005), systolic (r = -0.482, P &lt; 0.05) and diastolic blood pressure (r = -0.538, P &lt; 0.05) in patients with abdominal obesity.	cholesterol__insulin__no_interaction
1325615-2	After 4 months of intravenous <compound-id="5280453">calcitriol</compound-id>, serum ionized <compound-id="22044544,5460341">calcium</compound-id> increased from 1.28 +/- 0.08 to 1.37 +/- 0.11 mmol/l (P less than 0.001), serum <compound-id="1061,167704,644102">phosphate</compound-id> from 1.54 +/- 0.18 to 1.79 +/- 0.4 mmol/l (P NS), serum <compound-id="5280453">calcitriol</compound-id> from 16.7 +/- 9.9 to 34.3 +/- 6.4 pg/ml (P less than 0.001), while alkaline phosphatase decreased from 366 +/- 340 to 226 +/- 180 IU/l (P less than 0.05), <protein-id="P02818">osteocalcin</protein-id> from 46.4 +/- 20 to 34.5 +/- 15.3 ng/ml (P less than 0.05), and basal intact <protein-id="P01270">PTH</protein-id> from 1069 +/- 700 to 305 +/- 270 (P less than 0.01).	calcitriol__osteocalcin__no_interaction	calcitriol__PTH__no_interaction	calcium__osteocalcin__no_interaction	calcium__PTH__no_interaction	phosphate__osteocalcin__no_interaction	phosphate__PTH__no_interaction
23070078-3	Presently investigated MOFs for MMMs include [Cu(SiF(6))(4,4'-<compound-id="1474">BIPY</compound-id>)(2)], [Cu(3)(<protein-id="P35070">BTC</protein-id>)(2)(H(2)O)(3)] (HKUST-1, Cu-<protein-id="P35070">BTC</protein-id>), [Cu(<compound-id="446612">BDC</compound-id>)(DMF)], [Zn(4)O(<compound-id="446612">BDC</compound-id>)(3)] (MOF-5), [Zn(<compound-id="23037044">2-methylimidazolate</compound-id>)(2)] (ZIF-8), [Zn(<compound-id="57058588">purinate</compound-id>)(2)] (ZIF-20), [Zn(2-carboxyaldehyde <compound-id="574321">imidazolate</compound-id>)(2)] (ZIF-90), Mn(HCOO)(2), [Al(<compound-id="446612">BDC</compound-id>)(μ-OH)] (MIL-53(Al)), [Al(NH(2)-<compound-id="446612">BDC</compound-id>)(μ-OH)] (NH(2)-MIL-53(Al)) and [Cr(3)O(<compound-id="446612">BDC</compound-id>)(3)(F,OH)(H(2)O)(2)] (MIL-101) (4,4'-<compound-id="1474">BIPY</compound-id> = <compound-id="11107">4,4'-bipyridine</compound-id>, <protein-id="P35070">BTC</protein-id> = <compound-id="11138">benzene-1,3,5-tricarboxylate</compound-id>, <compound-id="446612">BDC</compound-id> = <compound-id="241">benzene</compound-id>-1,4-dicarboxylate, <compound-id="7489">terephthalate</compound-id>).	benzene__BTC__no_interaction	benzene-1,3,5-tricarboxylate__BTC__no_interaction	purinate__BTC__no_interaction	BDC__BTC__no_interaction	imidazolate__BTC__no_interaction	BIPY__BTC__no_interaction	2-methylimidazolate__BTC__no_interaction	4,4'-bipyridine__BTC__no_interaction	terephthalate__BTC__no_interaction
15936556-10	These included local failure: <protein-id="Q15935">pT0-2</protein-id>: 5% vs. pT3-4: 19%, p = 0.007; <compound-id="466151">pN0</compound-id>: 7% vs. <compound-id="448911">pN1</compound-id>-3: 26%, p = 0.002; TRG1-2: 2% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 17%, p = 0.013; metastasis-free survival: <protein-id="Q15935">pT0-2</protein-id>: 86% vs. pT3-4: 62%, p = 0.005; pN-: 86% vs. pN*: 42%, p &lt; 0.001; TRG1-2: 91% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 66%, p = 0.004; disease-free survival: <protein-id="Q15935">pT0-2</protein-id>: 83% vs. pT3-4: 54%, p = 0.001; <compound-id="466151">pN0</compound-id>: 80% vs. <compound-id="448911">pN1</compound-id>-3: 39%, p &lt; 0.001; TRG1-2: 91% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 58%, p &lt; 0.001; and overall survival: <protein-id="Q15935">pT0-2</protein-id>: 85% vs. pT3-4: 65%, p = 0.007; <compound-id="466151">pN0</compound-id>: 86% vs. <compound-id="448911">pN1</compound-id>-3: 45%, p &lt; 0.001; TRG1-2: 89% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 68%, p = 0.004.	pN1__TRG3-5__no_interaction	pN1__pT0-2__no_interaction	pN0__TRG3-5__no_interaction	pN0__pT0-2__no_interaction
9024276-3	Compared to the men with normal <compound-id="5462314">PTT</compound-id> (mean +/- <compound-id="5289348">SEM</compound-id>, 19.8 +/- 0.7 nmol/L), the men with low <compound-id="5462314">PTT</compound-id> (10.1 +/- 0.3 nmol/L) had a significantly higher body mass index (P &lt; 0.01), waist/<protein-id="P47914">hip</protein-id> ratio (P &lt; 0.001), systolic blood pressure (P &lt; 0.05), fasting and 2-h plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (P &lt; 0.04 and P &lt; 0.02 respectively), serum triglycerides (P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (P &lt; 0.04), low density lipoprotein <compound-id="5997">cholesterol</compound-id> (P &lt; 0.01), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (P &lt; 0.01), fasting and 2-h plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (both P &lt; 0.0001), and lower values of serum high density lipoprotein <compound-id="5997">cholesterol</compound-id> (P &lt; 0.01) and apolipoprotein <compound-id="15942654">AI</compound-id> (P &lt; 0.05).	cholesterol__hip__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__insulin__no_interaction	AI__hip__no_interaction	AI__apolipoprotein B__no_interaction	AI__insulin__no_interaction	SEM__hip__no_interaction	SEM__apolipoprotein B__no_interaction	SEM__insulin__no_interaction	PTT__hip__no_interaction	PTT__apolipoprotein B__no_interaction	PTT__insulin__no_interaction	glucose__hip__no_interaction	glucose__apolipoprotein B__no_interaction	glucose__insulin__no_interaction
15189767-3	In addition, the <protein-id="Q60484,A0A0C3SFY8">5-HT1D receptor</protein-id>-preferring antagonists, 1-[2-[4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>)-3,6-dihydro-2H-pyridin-1-yl]-<compound-id="23134249">ethyl</compound-id>]-3-pyridin-4-yl-methyl-<compound-id="74615">tetrahydro-pyrimidin-2-one</compound-id> (LY367642), (R)-1-[2-(4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>-)-3,6-dihydro-1(2H)-pyridinyl)<compound-id="23134249">ethyl</compound-id>]-3,4-<compound-id="53681010">dihydro-1H-2-benzopyran-6-carboxamide</compound-id> (LY456219), (S)-1-[2-(4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>-)-3,6-dihydro-1(2H)-pyridinyl)<compound-id="23134249">ethyl</compound-id>]-3,4-<compound-id="53681010">dihydro-1H-2-benzopyran-6-carboxamide</compound-id> (LY456220) and 1-[2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-<compound-id="23134249">ethyl</compound-id>]-3,3-dimethyl-1,2-dihydro-<compound-id="17904787">indol-2-one</compound-id> (<compound-id="4282258">LY310762</compound-id>), potentiated [3H]<compound-id="5202">5-HT</compound-id> outflow from this preparation with potencies (EC50 values=31-140 nM) in the same range as their affinities for the guinea pig <protein-id="Q60484,A0A0C3SFY8">5-HT1D receptor</protein-id> (Ki values=100-333 nM).	tetrahydro-pyrimidin-2-one__5-HT1D receptor__no_interaction	LY310762__5-HT1D receptor__no_interaction	fluoro-1H-indol-3-yl__5-HT1D receptor__no_interaction	indol-2-one__5-HT1D receptor__no_interaction	dihydro-1H-2-benzopyran-6-carboxamide__5-HT1D receptor__no_interaction	5-HT__5-HT1D receptor__no_interaction	ethyl__5-HT1D receptor__no_interaction
15722644-10	Significant correlations were demonstrated between the Whole and the intact <protein-id="P01270">PTH</protein-id> assays, and as expected between the 2 intact assays ('Whole'/'Intact', r = 0.92, p &lt; 0.0001, 'Whole'/'Total', r = 0.94, p &lt; 0.0001, 'Intact'/'Total', r = 0.97, p &lt; 0.0001) with no influence of the two <compound-id="5280795,5283711">vitamin D</compound-id> analogs administered.	vitamin D__PTH__no_interaction
22306220-11	In the striatum, when compared with the deep hypothermic circulatory arrest group, the <protein-id="P09919,Q6FH65,Q8N4W3">granulocyte-colony stimulating factor</protein-id> group had higher levels of <protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> (50.3 ± 7.4 vs 31.8 ± 3.8, P = .01), serine/<compound-id="194239,6288">threonine</compound-id>-specific protein kinase (132.7 ± 12.3 vs 14 ± 1.34, P = 2.3 × 10(6)), and Janus protein <protein-id="P29597,A0A024R7E4">tyrosine kinase 2</protein-id> (126 ± 17.4 vs 77.9 ± 13.6, P = .011), and lower levels of <protein-id="P42574">Caspase-3</protein-id> (12.8 ± 5.0 vs 32.2 ± 11.5, P = .033), Fas (390 ± 31 vs 581 ± 74, P = .038), <protein-id="P48023,Q53ZZ1">Fas ligand</protein-id> (20.5 ± 11.5 vs 57.8 ± 15.6, P = .04), and <protein-id="O75509,A0A024RD71">death receptor 6</protein-id> (57.4 ± 4.4 vs 108.8 ± 13.4, P = .007).	threonine__Caspase-3__no_interaction	threonine__tyrosine kinase 2__no_interaction	threonine__Fas ligand__no_interaction	threonine__death receptor 6__no_interaction	threonine__granulocyte-colony stimulating factor__no_interaction	threonine__Bcl-2__no_interaction
11952363-3	Subsequent treatment with AgOTf (OTf = <compound-id="62406">triflate</compound-id>) generates the bis(<compound-id="62406">triflate</compound-id>) analogues IrR(CO)(dppe)(OTf)(2) (R = CH(3) (2a) and CF(3) (2b)), which undergo clean metathesis with <compound-id="2778201">NaBARF</compound-id> (BARF = B(3,5-(CF(3))(2)C(6)H(3))(4)(-)) in the presence of 1,2-<compound-id="11994">diiodobenzene</compound-id> (DIB) forming the dicationic halocarbon adducts [IrR(CO)(dppe)(DIB)][BARF](2) (R = CH(3) (<compound-id="2981881,91293124">3a</compound-id>) and <protein-id="P00751">CF(3) (3b</protein-id>)).	3a__CF(3) (3b__no_interaction	triflate__CF(3) (3b__no_interaction	diiodobenzene__CF(3) (3b__no_interaction	NaBARF__CF(3) (3b__no_interaction
15112212-1	Polynuclear <compound-id="23978">copper</compound-id>(I) complexes with bridging <protein-id="O95817">bis</protein-id>(<compound-id="13239">dicyclohexylphosphino</compound-id>)<compound-id="297">methane</compound-id> (<compound-id="11155">dcpm</compound-id>) and <compound-id="105054,30165">iodide</compound-id> ligands, [Cu(2)(<compound-id="11155">dcpm</compound-id>)(2)(CH(3)CN)(2)](BF(4))(2) (1), [Cu(2)(<compound-id="11155">dcpm</compound-id>)(2)](BF(4))(2) (2), [(CuI)(3)(<compound-id="11155">dcpm</compound-id>)(2)] (3), [(CuI)(4)(<compound-id="11155">dcpm</compound-id>)(2)] (4), and [(CuI)(2)(<compound-id="11155">dcpm</compound-id>)(2)] (5) were prepared and their structures determined by X-ray crystal analysis.	dicyclohexylphosphino__bis__no_interaction	copper__bis__no_interaction	iodide__bis__no_interaction	dcpm__bis__no_interaction	methane__bis__no_interaction
17221285-6	The relative risk was significantly increased concerning: (1) male over female pts (RR: 1.95, p&lt;0.01), (2) diabetic vs. non diabetic pts (RR: 2.09, p&lt;0.001), (3) patients with SHP over pts with iPTH values&lt;250 pg/ml (RR: 2.16, p&lt;0.001), (4) hypertensive vs. non hypertensive pts (RR: 2.26, p=0.002), (5) smokers vs. non smokers (RR: 1.69, p&lt;0.05), (6) pts with HOC over pts with normal <compound-id="778,91552">homocysteine</compound-id> values (RR: 2.09, p&lt;0.05), (7) pts with increased <protein-id="P02741">CRP</protein-id> levels over pts with normal <protein-id="P02741">CRP</protein-id> levels (RR: 1.8, p&lt;0.01), (8) pts undergoing HD for 36 vs. 12 months (RR: 1.71, p=0.03), (9) between pts with inadequate or adequate HD (RR: 1.73, p=0.02).	homocysteine__CRP__no_interaction
15090974-6	RESULTS: Key recommendations, listed by category and not by hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; early administration of broad-spectrum antibiotic therapy; reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; a usual 7-10 days of antibiotic therapy guided by clinical response; source control with attention to the method that balances risks and benefits; equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for <compound-id="439260">norepinephrine</compound-id> and <compound-id="681">dopamine</compound-id>; cautious use of <protein-id="P01185,X5DQP6">vasopressin</protein-id> pending further studies; avoiding low-dose <compound-id="681">dopamine</compound-id> administration for renal protection; consideration of <compound-id="36811">dobutamine</compound-id> inotropic therapy in some clinical situations; avoidance of supranormal <compound-id="977">oxygen</compound-id> delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recombinant activated protein C in patients with severe sepsis and high risk for death; with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; a semirecumbent bed position unless contraindicated; protocols for weaning and sedation/analgesia, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; avoidance of neuromuscular blockers, if at all possible; maintenance of blood <compound-id="206,5793,64689,79025">glucose</compound-id> &lt;150 mg/dL after initial stabilization; equivalence of continuous veno-veno hemofiltration and intermittent hemodialysis; lack of utility of <compound-id="767">bicarbonate</compound-id> use for pH &gt; or =7.15; use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate.	oxygen__vasopressin__no_interaction	bicarbonate__vasopressin__no_interaction	dobutamine__vasopressin__no_interaction	norepinephrine__vasopressin__no_interaction	dopamine__vasopressin__no_interaction	glucose__vasopressin__no_interaction
16759126-2	Using a relative kinetic method rate coefficients (in units of cm3 molecule(-1) s(-1)) of (7.79 +/- 1.71) x 10(-11), (9.73 +/- 1.94) x 10(-11) and (1.13 +/- 0.31) x 10(-10) have been obtained for the reaction of OH with EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively, (1.40 +/- 0.35) x 10(-12), (1.85 +/- 0.53) x 10(-12) and (2.10 +/- 0.54) x 10(-12) for the reaction of <protein-id="P41271,A0A087WTY6">NO3</protein-id> with EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively, and (2.06 +/- 0.42) x 10(-16), (2.34 +/- 0.48) x 10(-16) and (2.59 +/- 0.52) x 10(-16) for the ozonolysis of EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively.	PVE__NO3__no_interaction
12322823-11	The underdialyzed group contained fewer women (39.5% vs 60.2%, p &lt; 0.001) and more patients with anuria (35.0% vs 8.8%, p &lt; 0.001), and had higher serum <compound-id="1176">urea</compound-id> (20.7 +/- 6.9 vs 18.2 +/- 5.3 mmol/L, p = 0.001) and serum <compound-id="588">creatinine</compound-id> (974 +/- 283 vs 734 +/- 275 micromol/L, p &lt; 0.001), marginally lower serum <protein-id="P02768">albumin</protein-id> (35.8 +/- 5.2 vs 37.2 +/- 6.4 g/L, p = 0.082), lower <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> excretion (5778 +/- 2290 vs 7085 +/- 2238 mg/24 hr, p &lt; 0.001) and indices derived from <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> excretion (protein <compound-id="947">nitrogen</compound-id> appearance and normalized protein <compound-id="947">nitrogen</compound-id> appearance), and lower <compound-id="588">creatinine</compound-id> excretion (1034 +/- 349 vs 1217 +/- 432 mg/24 hr, p &lt; 0.001) and indices derived from <compound-id="588">creatinine</compound-id> excretion (lean body mass normalized to actual or desired weight) than the adequately dialyzed group.	creatinine__albumin__no_interaction	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
11096257-4	These major HLA factors produced 6 haplotypes extending across the class I and class II regions: A*01-Cw*04-B* 4501-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1503-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0602 (A1-Cw4-B12- DR15 - <compound-id="57325589">DQ6</compound-id>), A * 01 - Cw * 04 - B * 4901 -<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id> * 1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604 (A1-Cw4-<compound-id="776315">B21</compound-id>-DR13-<compound-id="57325589">DQ6</compound-id>), A*30 - Cw*04 - B*15 - <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1101 - <protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0301 (A19-Cw4-B15-<protein-id="Q9BZH6,Q659C9">DR11</protein-id>-<compound-id="56964577">DQ7</compound-id>), A*68-Cw*07-B* 4901-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604(A28-<compound-id="57345898">Cw7</compound-id>-<compound-id="776315">B21</compound-id>- DR13 - <compound-id="57325589">DQ6</compound-id>), A*30 - Cw*07 - B*5703 - <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>* 1303-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0301(A19 - <compound-id="57345898">Cw7</compound-id> - <protein-id="Q9NYP3">B17</protein-id> - DR13 - <compound-id="56964577">DQ7</compound-id>), and A*74-Cw*07-B*4901-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>* 0604 (A19-<compound-id="57345898">Cw7</compound-id>-<compound-id="776315">B21</compound-id>-DR13-<compound-id="57325589">DQ6</compound-id>), respectively.	DQ6__B17__no_interaction	DQ6__DQB1__no_interaction	DQ6__DR11__no_interaction	DQ6__DRB1__no_interaction	DQ7__B17__no_interaction	DQ7__DQB1__no_interaction	DQ7__DR11__no_interaction	DQ7__DRB1__no_interaction	Cw7__B17__no_interaction	Cw7__DQB1__no_interaction	Cw7__DR11__no_interaction	Cw7__DRB1__no_interaction	B21__B17__no_interaction	B21__DQB1__no_interaction	B21__DR11__no_interaction	B21__DRB1__no_interaction
12460707-3	Despite equivalent effects on BP (<protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>: -19 +/- 4/-15 +/- 2 mm Hg; <compound-id="5326781">CEI</compound-id>: -12 +/- 3/-13 +/- 2 mm Hg; ARB: -10 +/- 3/-12 +/- 2 mm Hg; and BBl: -14 +/- 3/-12 +/- 2 mm Hg; P &lt;.005 for each drug v pretreatment), <protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>, <compound-id="5326781">CEI</compound-id>, and ARB significantly increased arterial compliance (<protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>: %deltaC1 = 30.0 +/- 5.8, %Delta C2 = 43.7 +/- 23.3; <compound-id="5326781">CEI</compound-id>: %deltaC1 = 32.7 +/- 5.4, %deltaC2 = 26.7 +/- 7.1; ARB: %deltaC1 = 36.3 +/- 11.8, %deltaC2 = 43.6 +/- 23.1; P &lt;.01 for <protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>, <compound-id="5326781">CEI</compound-id>, and ARB v pretreatment), but BBl did not (%deltaC1 = -3.9 +/- 7.6, %deltaC2 = -7.0 +/- 11.5, P = not significant v pretreatment, sig = 0.01 v other drugs).	CEI__CaBl__no_interaction
9695142-5	Human <compound-id="90470996">thrombin</compound-id> (0.1-10 U/ml), LPS (0.3-10 ng/ml) and the <compound-id="22833501,70702034">phorbol ester</compound-id>, <compound-id="71308525">phorbol 12-myristate</compound-id>-13-<compound-id="176">acetate</compound-id> (0.1 nM-1 microM), significantly increased ir-ET release, whereas <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (0.1-10 ng/ml), <protein-id="P13501,D0EI67">RANTES</protein-id> (0.1-100 nM), IL-1 (0.01-10 ng/ml), <protein-id="P01042">bradykinin</protein-id> (1 nM-10 microM), <protein-id="P06881,P01258">CGRP</protein-id> (0.01 nM-1 microM), PDGF (0.1-3 ng/ml), Sar9, Met(O2)11-Sub P, Nle10-<compound-id="5311311">NKA</compound-id> 4-10 and <compound-id="108147,5079497">senktide</compound-id> (selective <protein-id="P25103">NK-1</protein-id>, <protein-id="P20366,Q9Y494">NK-2</protein-id> and <protein-id="P29371">NK-3 receptor</protein-id> agonists, respectively; 1 nM-10 microM), <compound-id="52640,6435286">LTD4</compound-id> (1 nM-10 microM) or major basic protein (10 nM-1 microM) were without stimulatory effect.	NKA__bradykinin__no_interaction	NKA__CGRP__no_interaction	NKA__NK-3 receptor__no_interaction	NKA__TNF-alpha__no_interaction	NKA__RANTES__no_interaction	NKA__NK-2__no_interaction	NKA__NK-1__no_interaction	phorbol 12-myristate__bradykinin__no_interaction	phorbol 12-myristate__CGRP__no_interaction	phorbol 12-myristate__NK-3 receptor__no_interaction	phorbol 12-myristate__TNF-alpha__no_interaction	phorbol 12-myristate__RANTES__no_interaction	phorbol 12-myristate__NK-2__no_interaction	phorbol 12-myristate__NK-1__no_interaction	thrombin__bradykinin__no_interaction	thrombin__CGRP__no_interaction	thrombin__NK-3 receptor__no_interaction	thrombin__TNF-alpha__no_interaction	thrombin__RANTES__no_interaction	thrombin__NK-2__no_interaction	thrombin__NK-1__no_interaction	LTD4__bradykinin__no_interaction	LTD4__CGRP__no_interaction	LTD4__NK-3 receptor__no_interaction	LTD4__TNF-alpha__no_interaction	LTD4__RANTES__no_interaction	LTD4__NK-2__no_interaction	LTD4__NK-1__no_interaction	acetate__bradykinin__no_interaction	acetate__CGRP__no_interaction	acetate__NK-3 receptor__no_interaction	acetate__TNF-alpha__no_interaction	acetate__RANTES__no_interaction	acetate__NK-2__no_interaction	acetate__NK-1__no_interaction	senktide__bradykinin__no_interaction	senktide__CGRP__no_interaction	senktide__NK-3 receptor__no_interaction	senktide__TNF-alpha__no_interaction	senktide__RANTES__no_interaction	senktide__NK-2__no_interaction	senktide__NK-1__no_interaction	phorbol ester__bradykinin__no_interaction	phorbol ester__CGRP__no_interaction	phorbol ester__NK-3 receptor__no_interaction	phorbol ester__TNF-alpha__no_interaction	phorbol ester__RANTES__no_interaction	phorbol ester__NK-2__no_interaction	phorbol ester__NK-1__no_interaction
1319339-2	Human alveolar macrophages harvested by bronchoalveolar lavage were stimulated by opsonised <compound-id="64689">zymosan</compound-id> 1 mg/ml in the presence of N6,2'0-<compound-id="22840750">dibutyryladenosine</compound-id> 3':5' cyclic monophosphate (<compound-id="9687">dibutyryl cyclic AMP</compound-id>) 5 x 10(-6) to 5 x 10(-3) M,8-<compound-id="254688,96544">bromoadenosine</compound-id> 3':5'-cyclic monophosphate (8-bromo cyclic AMP) 5 x 10(-6) to 5 x 10(-3) M, 5'-(N-ethylcarboxamido)-<compound-id="57476835,60961">adenosine</compound-id> (NECA) 10(-7) to 10(-4) M, <compound-id="57476835,60961">adenosine</compound-id> 10(-7) to 10(-4) M, <compound-id="2153">theophylline</compound-id> 5 x 10(-6) to 5 x 10(-3) M and <compound-id="1676">enprofylline</compound-id> 5 x 10(-8) to 5 x 10(-4) M. The subsequent release of <compound-id="114873">thromboxane</compound-id> B2 (<compound-id="5283137,5461">TXB2</compound-id>) and <protein-id="P54802">N-acetyl-beta-D-glucosaminidase</protein-id> (<protein-id="P54802">NAG</protein-id>) activity was monitored.	zymosan__N-acetyl-beta-D-glucosaminidase__no_interaction	zymosan__NAG__no_interaction	TXB2__N-acetyl-beta-D-glucosaminidase__no_interaction	TXB2__NAG__no_interaction	theophylline__N-acetyl-beta-D-glucosaminidase__no_interaction	theophylline__NAG__no_interaction	thromboxane__N-acetyl-beta-D-glucosaminidase__no_interaction	thromboxane__NAG__no_interaction	bromoadenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	bromoadenosine__NAG__no_interaction	dibutyryl cyclic AMP__N-acetyl-beta-D-glucosaminidase__no_interaction	dibutyryl cyclic AMP__NAG__no_interaction	enprofylline__N-acetyl-beta-D-glucosaminidase__no_interaction	enprofylline__NAG__no_interaction	adenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	adenosine__NAG__no_interaction	dibutyryladenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	dibutyryladenosine__NAG__no_interaction
21925493-9	<compound-id="10951331">CORM-2</compound-id> inhibited <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>-induced apoptosis (% annexin-V positive cells: <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> = 60 ± 4% vs. <compound-id="10951331">CORM-2</compound-id> 10 μM = 48 ± 4%, <compound-id="10951331">CORM-2</compound-id> 25 μM=42 ± 5%, <compound-id="10951331">CORM-2</compound-id> 50 μM = 40 ± 4% and <compound-id="10951331">CORM-2</compound-id> 100 μM = 38 ± 2%, mean ± S.D., P&lt;0.001; <protein-id="Q08DY9">caspase-3</protein-id> activity: <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>=92 ± 15 RFUs vs. <compound-id="10951331">CORM-2</compound-id> 50 μM=60 ± 14 RFUs, mean ± S.D.	CORM-2__caspase-3__no_interaction	staurosporine__caspase-3__no_interaction
17180193-0	Interplay between covalent and aurophilic interactions in a series of isostructural 3D Hoffman-like frameworks containing <compound-id="123444">bipyrimidine</compound-id> and <compound-id="161098">dicyanoaurate</compound-id> bridges. X-Ray structure and magnetic properties of {(mu-Au(CN)(2)](2)[(M(NH(3))(2))(2)(mu-bpym)]}[Au(CN)(2)](2) (M = Ni(II), <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co(II</protein-id>) and Cu(II)).	dicyanoaurate__Co(II__no_interaction	bipyrimidine__Co(II__no_interaction
19400559-4	Analogously, the Rh(I) compounds [{Rh(eta(2),eta(2)-NBD)(<compound-id="5289124">PCy</compound-id>(3))(2)}{BAr(F)}] (NBD = <compound-id="8473">norbornadiene</compound-id>) and [{Rh(eta(2),eta(2)-COD)(2)}{BAr(F)}] ({BAr(F)}= B{[C(6)H(3)(CF(3))(2)](4)) yield the complexes [{Rh(eta(2),eta(2)-NBD)(<compound-id="5289124">PCy</compound-id>(3))(GaCp*)(2)}{BAr(F)}] (4), [{Rh(eta(2),eta(2)-COD)(GaCp*)(3)}{BAr(F)}] (5), and [{Rh(eta(2),eta(2)-COD)(AlCp*)(3)}{BAr(F)]}] (6) upon reaction with the appropriate <protein-id="P12724">ECp</protein-id>* ligand (E = Al, Ga).	PCy__ECp__no_interaction	norbornadiene__ECp__no_interaction
23214495-1	Reactions of [8,8,8-(H)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)-9-(Py)-nido-8,7-RhSB(9)H(9)] (1), [1,1-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)-3-(Py)-closo-1,2-RhSB(9)H(8)] (2), and [1,1-(CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-3-(Py)-closo-1,2-RhSB(9)H(8)] (4), where Py = Pyridine, with HCl to give the <compound-id="312">Cl-</compound-id>ligated clusters, [8,8-(Cl)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-9-(Py)-nido-8,7-RhSB(9)H(9)] (3) and [8,8,8-(Cl)(CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-9-(Py)-nido-8,7-RhSB(9)H(8)] (5), have recently demonstrated the remarkable nido-to-closo redox flexibility and bifunctional character of this class of 11-vertex rhodathiaboranes.	Cl-__PPh(3__no_interaction
24187469-5	The results showed that probiotic therapy signiﬁcantly decreased <compound-id="5950">alanine</compound-id> aminotransferase (ALT), <compound-id="5960">aspartate</compound-id> transaminase (AST), total-<compound-id="5997">cholesterol</compound-id> (T-chol), high density lipoprotein (HDL), tumor necrosis factor (TNF)-α and homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) [ALT: weighted mean difference (WMD) -23.71, 95%CI: -33.46--13.95, P &lt; 0.00001; AST: WMD -19.77, 95%CI: -32.55--7.00, P = 0.002; T-chol: WMD -0.28, 95%CI: -0.55--0.01, P = 0.04; HDL: WMD -0.09, 95%CI: -0.16-0.01, P = 0.03; TNF-α: WMD -0.32, 95%CI: -0.48--0.17, P &lt; 0.0001; HOMA-IR: WMD -0.46, 95%CI: -0.73--0.19, P = 0.0008].	alanine__insulin__no_interaction	aspartate__insulin__no_interaction	cholesterol__insulin__no_interaction
23619195-8	In non-diabetic subjects, circulating <protein-id="Q8NAU1">irisin</protein-id> was correlated with age (r = 0.398, p &lt; 0.01), BMI (r = 0.387, p &lt; 0.01), total <compound-id="5997">cholesterol</compound-id> (r = 0.341, p &lt; 0.01), total triglycerides (r = 0.299, p &lt; 0.05), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.430, p &lt; 0.01) and diastolic blood pressure (r = 0.306, p &lt; 0.05).	glucose__irisin__no_interaction	cholesterol__irisin__no_interaction
1820200-3	The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG alpha</protein-id> comprised monosialylated 'monoantenary' <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (<protein-id="O43805,A0A024R8G6">N1-4</protein-id>'), disialylated diantennary <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[<compound-id="439197">NeuAc</compound-id> alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG alpha</protein-id> carried N2 and <protein-id="O43805,A0A024R8G6">N1-4</protein-id>' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of <protein-id="P01233,A0A0F7RQP8">hCG beta</protein-id> contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the <compound-id="11861101,439174">N-acetylglucosamine</compound-id> linked to Asn-13 and Asn-30, respectively.	NeuAc__hCG beta__no_interaction	NeuAc__hCG alpha__no_interaction	NeuAc__N1-4__no_interaction	N-acetylglucosamine__hCG beta__no_interaction	N-acetylglucosamine__hCG alpha__no_interaction	N-acetylglucosamine__N1-4__no_interaction
7558154-5	There were significant positive correlations between the increase in RL to <compound-id="187">acetylcholine</compound-id> and the numbers of CD25+ (r = 0.92, P &lt; 0.001), CD4+ (r = 0.77, P &lt; 0.05), CD8+ (r = 0.71, P &lt; 0.05) and <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id>+ (r = 0.72, P &lt; 0.03) cells in the OVA-sensitized and exposed group, but not in saline-exposed or naive animals.	acetylcholine__MBP__no_interaction
17982548-1	This study evaluated the bond strength (push-out method) and Knoop hardness of Z250 composite resin, photoactivated with XL 2500 curing unit, using different protocols: continuous mode (700 mW/cm(2) for 20s) (CO); soft-start (50 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">SS1</protein-id>); soft-start (100 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="637516">SS2</compound-id>); soft-start (150 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15s) (SS3); soft-start (200 mW/cm(2) for 5s, followed by 700 mW/cm(2) for 15s) (<compound-id="16122642">SS4</compound-id>); soft-start (250 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="16122641">SS5</compound-id>); soft-start (300 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="42608444">SS6</compound-id>).	SS5__SS1__no_interaction	SS4__SS1__no_interaction	SS6__SS1__no_interaction	SS2__SS1__no_interaction
18767076-9	Further treatment of 7 S with dimethyl <compound-id="371">acetylenedicarboxylate</compound-id> at ambient temperature affords two B-disubstituted complexes at the carborane cage in the positions of the B3 and B6 sites, that is, [CpCo(S2C2-B10H8){(MeO2C)C=CH(CO2Me)}2] (9S) and [CpCo(S2C2B10H8){(MeO2C)-<protein-id="Q00610,A0A087WVQ6">CHC</protein-id>(CO2Me)}{(MeO2C)C=CH-(CO2Me)}] (10S).	acetylenedicarboxylate__CHC__no_interaction
23021775-9	After adjustment for BMI, smoking, drinking, and metabolic syndrome status, age was positively correlated with LDL-<compound-id="5997">cholesterol</compound-id> (r = 0.095, P &lt; 0.001), oxidized LDL (r = 0.305, P &lt; 0.001), hs-<protein-id="P02741">CRP</protein-id> (r = 0.150, P &lt; 0.001), TNF-α (r = 0.171, P &lt; 0.001) and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.294, P &lt; 0.001) and negatively with LDL particle size (r = -0.239, P &lt; 0.001).	cholesterol__CRP__no_interaction	cholesterol__IL-6__no_interaction
23585283-3	DESIGN AND METHODS: In a cross-sectional sample of 929 70-year-old individuals (50% women) of the Prospective Investigation of the Vasculature in Uppsala Seniors study, relations between serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> and oxidative stress [conjugated dienes (CD), <compound-id="778,91552">homocysteine</compound-id>, total antioxidant capacity, oxidized low-density lipoprotein (OxLDL), OxLDL antibodies, baseline CD of LDL, <compound-id="124886,20725278">glutathione</compound-id> (GSH), total <compound-id="124886,20725278">glutathione</compound-id> (TGSH), <compound-id="65359">glutathione disulfide</compound-id>], circulation interleukins (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>), other cytokines [tumor necrosis factor α, <protein-id="P13500">monocyte chemotactic protein-1</protein-id> (<protein-id="P13500">MCP-1</protein-id>), epidermal growth factor (EGF), vascular endothelial growth factor], cell adhesion molecules (<protein-id="P05362">vascular cell adhesion molecule-1, intercellular adhesion molecule-1</protein-id>, <protein-id="P16581">E-selectin</protein-id>, <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id>, <protein-id="P14151,A0A024R8Z0">L-selectin</protein-id>), and systemic inflammatory markers [<protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>), leukocyte count] in separate models were investigated.	homocysteine__E-selectin__no_interaction	homocysteine__CRP__no_interaction	homocysteine__IL-8__no_interaction	homocysteine__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	homocysteine__IL-6__no_interaction	homocysteine__C-reactive protein__no_interaction	homocysteine__monocyte chemotactic protein-1__no_interaction	homocysteine__L-selectin__no_interaction	homocysteine__adiponectin__no_interaction	homocysteine__P-selectin__no_interaction	homocysteine__MCP-1__no_interaction	glutathione disulfide__E-selectin__no_interaction	glutathione disulfide__CRP__no_interaction	glutathione disulfide__IL-8__no_interaction	glutathione disulfide__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	glutathione disulfide__IL-6__no_interaction	glutathione disulfide__C-reactive protein__no_interaction	glutathione disulfide__monocyte chemotactic protein-1__no_interaction	glutathione disulfide__L-selectin__no_interaction	glutathione disulfide__adiponectin__no_interaction	glutathione disulfide__P-selectin__no_interaction	glutathione disulfide__MCP-1__no_interaction	glutathione__E-selectin__no_interaction	glutathione__CRP__no_interaction	glutathione__IL-8__no_interaction	glutathione__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	glutathione__IL-6__no_interaction	glutathione__C-reactive protein__no_interaction	glutathione__monocyte chemotactic protein-1__no_interaction	glutathione__L-selectin__no_interaction	glutathione__adiponectin__no_interaction	glutathione__P-selectin__no_interaction	glutathione__MCP-1__no_interaction
12955681-7	Although no correlation was observed with nutrient intake (protein, fat, saturated fat, or carbohydrate), both serum CML and MG levels correlated with blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (r = 0.2; P = 0.03 and r = 0.2; P = 0.02, respectively) and serum <protein-id="P02768">albumin</protein-id> levels (r = 0.16; P = 0.04 and r = 0.18; P = 0.02, respectively).	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
23969412-1	Three trimeric polyoxovanadate based on 1:13 anions [MnV13O38](7-) with lanthanide cations Ln(3+) (Ln = La, Ce and Nd) and <compound-id="938">pyridine-3-carboxylic acid</compound-id>: <protein-id="P52790,A0A024R7R1">HK3</protein-id>{[Ln(H2O)4]6[MnV13O38]3(SO4)2}·3(C6H6NO2)·nH2O (Ln = La 1, Nd 3; n = 33 for 1, 20 for 3), H(2.5)K(1.5){[Ce(H2O)4]6[MnV13O38]3(SO4)2}·3(C6H6NO2)·20.5H2O (2) (C6H5NO2 = <compound-id="938">pyridine-3-carboxylic acid</compound-id>) have been synthesized and characterized by elemental analysis, IR spectroscopy, UV spectroscopy, TG analysis, XPRD, electrochemical analyses, magnetism and single-crystal X-ray diffraction.	pyridine-3-carboxylic acid__HK3__no_interaction
16273137-3	This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (Z)-4-hydroxytamoxifen; Ad.muIFN-beta AD-237, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, agalsidase alfa, alemtuzumab, <compound-id="123606">almotriptan</compound-id>, ALVAC vCP1452, <compound-id="5488548">alvimopan hydrate</compound-id>, <compound-id="6918493">ambrisentan</compound-id>, <compound-id="90470007">anakinra</compound-id>, anti-<protein-id="P07353,A9QXB7">IFN-gamma</protein-id> MAb; <compound-id="5311027">Bimatoprost</compound-id>, <compound-id="6918494">BMS-188797</compound-id>, <compound-id="448545">BMS-214662</compound-id>, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, bovine <protein-id="P24627,B9VPZ5">lactoferrin</protein-id>; <compound-id="2519,57106085">Caffeine</compound-id>, <compound-id="156414">canertinib dihydrochloride</compound-id>, <compound-id="5312109">canfosfamide hydrochloride</compound-id>, <compound-id="644019">cannabidiol</compound-id>, <compound-id="5486792,2826718,66577042,71295847">caspofungin acetate</compound-id>, cetuximab, cH36, ChimeriVax-JE, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="6918107">cilansetron</compound-id>, <compound-id="156419">cinacalcet</compound-id> hydrochloride, <compound-id="60606">clopidogrel</compound-id>, CpG-7909, <compound-id="9962928">Cypher</compound-id>; <compound-id="16129629,16129688,16134395,21585658,25246315,46930993,57011757,57336511,71311849">Daptomycin</compound-id>, darbepoetin alfa, <compound-id="444031">darifenacin</compound-id> hydrobromide, <compound-id="451668">decitabine</compound-id>, <compound-id="9875516,192708,56841084">denufosol</compound-id> <compound-id="21226136">tetrasodium</compound-id>, Dexamet, <compound-id="3071">diindolemethane</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride, DX-9065a; E-7010, <compound-id="4021">edaravone</compound-id>, efalizumab, <compound-id="446284">eicosapentaenoic acid</compound-id>/<compound-id="3144,445580">docosahexaenoic acid</compound-id>, <compound-id="119373">elacridar</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="12043008,60877">emtricitabine</compound-id>, epratuzumab, <compound-id="176870">erlotinib</compound-id> hydrochloride, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="150311">ezetimibe</compound-id>; <compound-id="657237">Fludarabine</compound-id>, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>; gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="6450546">gavestinel sodium</compound-id>, <compound-id="123631">gefitinib</compound-id>, <compound-id="17572266,3510,5284566,86287410">granisetron</compound-id>-Biochronomer; Human Albumin, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="5291">Imatinib</compound-id> <compound-id="6395">mesylate</compound-id>, <compound-id="6450813">indiplon</compound-id>, <protein-id="P60568,Q0GK43">interleukin-2</protein-id> XL, <compound-id="72231">isatoribine</compound-id>, ISS-1018, i.v.	isatoribine__IFN-gamma__no_interaction	isatoribine__interleukin-2__no_interaction	isatoribine__insulin__no_interaction	isatoribine__lactoferrin__no_interaction	tetrasodium__IFN-gamma__no_interaction	tetrasodium__interleukin-2__no_interaction	tetrasodium__insulin__no_interaction	tetrasodium__lactoferrin__no_interaction	BMS-214662__IFN-gamma__no_interaction	BMS-214662__interleukin-2__no_interaction	BMS-214662__insulin__no_interaction	BMS-214662__lactoferrin__no_interaction	bortezomib__IFN-gamma__no_interaction	bortezomib__interleukin-2__no_interaction	bortezomib__insulin__no_interaction	bortezomib__lactoferrin__no_interaction	Caffeine__IFN-gamma__no_interaction	Caffeine__interleukin-2__no_interaction	Caffeine__insulin__no_interaction	Caffeine__lactoferrin__no_interaction	eicosapentaenoic acid__IFN-gamma__no_interaction	eicosapentaenoic acid__interleukin-2__no_interaction	eicosapentaenoic acid__insulin__no_interaction	eicosapentaenoic acid__lactoferrin__no_interaction	bosentan__IFN-gamma__no_interaction	bosentan__interleukin-2__no_interaction	bosentan__insulin__no_interaction	bosentan__lactoferrin__no_interaction	darifenacin__IFN-gamma__no_interaction	darifenacin__interleukin-2__no_interaction	darifenacin__insulin__no_interaction	darifenacin__lactoferrin__no_interaction	erlotinib__IFN-gamma__no_interaction	erlotinib__interleukin-2__no_interaction	erlotinib__insulin__no_interaction	erlotinib__lactoferrin__no_interaction	ciclesonide__IFN-gamma__no_interaction	ciclesonide__interleukin-2__no_interaction	ciclesonide__insulin__no_interaction	ciclesonide__lactoferrin__no_interaction	canfosfamide hydrochloride__IFN-gamma__no_interaction	canfosfamide hydrochloride__interleukin-2__no_interaction	canfosfamide hydrochloride__insulin__no_interaction	canfosfamide hydrochloride__lactoferrin__no_interaction	sodium__IFN-gamma__no_interaction	sodium__interleukin-2__no_interaction	sodium__insulin__no_interaction	sodium__lactoferrin__no_interaction	gavestinel sodium__IFN-gamma__no_interaction	gavestinel sodium__interleukin-2__no_interaction	gavestinel sodium__insulin__no_interaction	gavestinel sodium__lactoferrin__no_interaction	alvimopan hydrate__IFN-gamma__no_interaction	alvimopan hydrate__interleukin-2__no_interaction	alvimopan hydrate__insulin__no_interaction	alvimopan hydrate__lactoferrin__no_interaction	Fludarabine__IFN-gamma__no_interaction	Fludarabine__interleukin-2__no_interaction	Fludarabine__insulin__no_interaction	Fludarabine__lactoferrin__no_interaction	indiplon__IFN-gamma__no_interaction	indiplon__interleukin-2__no_interaction	indiplon__insulin__no_interaction	indiplon__lactoferrin__no_interaction	ertapenem sodium__IFN-gamma__no_interaction	ertapenem sodium__interleukin-2__no_interaction	ertapenem sodium__insulin__no_interaction	ertapenem sodium__lactoferrin__no_interaction	diindolemethane__IFN-gamma__no_interaction	diindolemethane__interleukin-2__no_interaction	diindolemethane__insulin__no_interaction	diindolemethane__lactoferrin__no_interaction	BMS-188797__IFN-gamma__no_interaction	BMS-188797__interleukin-2__no_interaction	BMS-188797__insulin__no_interaction	BMS-188797__lactoferrin__no_interaction	caspofungin acetate__IFN-gamma__no_interaction	caspofungin acetate__interleukin-2__no_interaction	caspofungin acetate__insulin__no_interaction	caspofungin acetate__lactoferrin__no_interaction	eszopiclone__IFN-gamma__no_interaction	eszopiclone__interleukin-2__no_interaction	eszopiclone__insulin__no_interaction	eszopiclone__lactoferrin__no_interaction	mesylate__IFN-gamma__no_interaction	mesylate__interleukin-2__no_interaction	mesylate__insulin__no_interaction	mesylate__lactoferrin__no_interaction	Cypher__IFN-gamma__no_interaction	Cypher__interleukin-2__no_interaction	Cypher__insulin__no_interaction	Cypher__lactoferrin__no_interaction	clopidogrel__IFN-gamma__no_interaction	clopidogrel__interleukin-2__no_interaction	clopidogrel__insulin__no_interaction	clopidogrel__lactoferrin__no_interaction	docosahexaenoic acid__IFN-gamma__no_interaction	docosahexaenoic acid__interleukin-2__no_interaction	docosahexaenoic acid__insulin__no_interaction	docosahexaenoic acid__lactoferrin__no_interaction	cilansetron__IFN-gamma__no_interaction	cilansetron__interleukin-2__no_interaction	cilansetron__insulin__no_interaction	cilansetron__lactoferrin__no_interaction	cinacalcet__IFN-gamma__no_interaction	cinacalcet__interleukin-2__no_interaction	cinacalcet__insulin__no_interaction	cinacalcet__lactoferrin__no_interaction	fondaparinux sodium__IFN-gamma__no_interaction	fondaparinux sodium__interleukin-2__no_interaction	fondaparinux sodium__insulin__no_interaction	fondaparinux sodium__lactoferrin__no_interaction	gefitinib__IFN-gamma__no_interaction	gefitinib__interleukin-2__no_interaction	gefitinib__insulin__no_interaction	gefitinib__lactoferrin__no_interaction	Bimatoprost__IFN-gamma__no_interaction	Bimatoprost__interleukin-2__no_interaction	Bimatoprost__insulin__no_interaction	Bimatoprost__lactoferrin__no_interaction	ezetimibe__IFN-gamma__no_interaction	ezetimibe__interleukin-2__no_interaction	ezetimibe__insulin__no_interaction	ezetimibe__lactoferrin__no_interaction	denufosol__IFN-gamma__no_interaction	denufosol__interleukin-2__no_interaction	denufosol__insulin__no_interaction	denufosol__lactoferrin__no_interaction	elacridar__IFN-gamma__no_interaction	elacridar__interleukin-2__no_interaction	elacridar__insulin__no_interaction	elacridar__lactoferrin__no_interaction	decitabine__IFN-gamma__no_interaction	decitabine__interleukin-2__no_interaction	decitabine__insulin__no_interaction	decitabine__lactoferrin__no_interaction	emtricitabine__IFN-gamma__no_interaction	emtricitabine__interleukin-2__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__lactoferrin__no_interaction	Daptomycin__IFN-gamma__no_interaction	Daptomycin__interleukin-2__no_interaction	Daptomycin__insulin__no_interaction	Daptomycin__lactoferrin__no_interaction	edaravone__IFN-gamma__no_interaction	edaravone__interleukin-2__no_interaction	edaravone__insulin__no_interaction	edaravone__lactoferrin__no_interaction	granisetron__IFN-gamma__no_interaction	granisetron__interleukin-2__no_interaction	granisetron__insulin__no_interaction	granisetron__lactoferrin__no_interaction	almotriptan__IFN-gamma__no_interaction	almotriptan__interleukin-2__no_interaction	almotriptan__insulin__no_interaction	almotriptan__lactoferrin__no_interaction	ambrisentan__IFN-gamma__no_interaction	ambrisentan__interleukin-2__no_interaction	ambrisentan__insulin__no_interaction	ambrisentan__lactoferrin__no_interaction	Imatinib__IFN-gamma__no_interaction	Imatinib__interleukin-2__no_interaction	Imatinib__insulin__no_interaction	Imatinib__lactoferrin__no_interaction	adefovir dipivoxil__IFN-gamma__no_interaction	adefovir dipivoxil__interleukin-2__no_interaction	adefovir dipivoxil__insulin__no_interaction	adefovir dipivoxil__lactoferrin__no_interaction	cannabidiol__IFN-gamma__no_interaction	cannabidiol__interleukin-2__no_interaction	cannabidiol__insulin__no_interaction	cannabidiol__lactoferrin__no_interaction	anakinra__IFN-gamma__no_interaction	anakinra__interleukin-2__no_interaction	anakinra__insulin__no_interaction	anakinra__lactoferrin__no_interaction	canertinib dihydrochloride__IFN-gamma__no_interaction	canertinib dihydrochloride__interleukin-2__no_interaction	canertinib dihydrochloride__insulin__no_interaction	canertinib dihydrochloride__lactoferrin__no_interaction	eletriptan__IFN-gamma__no_interaction	eletriptan__interleukin-2__no_interaction	eletriptan__insulin__no_interaction	eletriptan__lactoferrin__no_interaction	duloxetine__IFN-gamma__no_interaction	duloxetine__interleukin-2__no_interaction	duloxetine__insulin__no_interaction	duloxetine__lactoferrin__no_interaction
2112071-2	All patients were clinically euthyroid and there were no significant differences between circulating levels (mean +/- SD) of T4 (114.7 +/- 26.8 vs 129.9 +/- 28.3 nmol/l), FT4 (16.6 +/- 4.5 vs 18.4 +/- 3.8 pmol/l), <compound-id="5920">T3</compound-id> (1.61 +/- 0.29 vs 1.86 +/- 0.33 pmol/l), TSH (2.7 +/- 1.3 vs 2.4 +/- 1.4 mU/l), <protein-id="P05543">TBG</protein-id> (26.7 +/- 5.5 vs 27.6 +/- 4.9 mg/l), T4/<compound-id="5920">T3</compound-id> (84.3 +/- 18.4 vs 82.1 +/- 15.3), and FT4/FT3 (0.28 +/- 0.05 vs 0.33 +/- 0.08).	T3__TBG__no_interaction
7718893-5	U-HL-60 cells contain 17.76 +/- 6.01 pmol actin per 10(6) cells (<compound-id="27873">TIF</compound-id>, 5.3 +/- 1.5; TSF, 2.17 +/- 0.37; G, 10.3 +/- 5.7; n = 5) and 0.073 pmol <protein-id="P06396,A0A0A0MS51,A0A0A0MT01,B7Z4U6">gelsolin</protein-id> per 10(6) cells (<compound-id="27873">TIF</compound-id>, 0; TSF, 0.002 +/- 0.005; G, 0.07 +/- 0.01; n = 3), representing molar actin to <protein-id="P06396,A0A0A0MS51,A0A0A0MT01,B7Z4U6">gelsolin</protein-id> (A:G) ratios of 1,085:1 for TSF and 147:1 for G. After myeloid differentiation, the actin content increases 1.80-fold (31.94 +/- 6.14 pmol/10(6) cells) equally in each actin pool (<compound-id="27873">TIF</compound-id>, 9.36 +/- 2.35; TSF, 3.29 +/- 0.62; G, 19.29 +/- 4.83).	TIF__gelsolin__no_interaction
8701397-5	FVII:C correlated with <compound-id="5997">cholesterol</compound-id> (r = 0.51, p &lt; 0.0005), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.36, p = 0.002), triglycerides (r = 0.34, p = 0.001), age (r = 0.23, p &lt; 0.005) and body mass index (r = 0.23, p &lt; 0.05).	cholesterol__insulin__no_interaction
9289451-4	The following parameters of amniotic fluid were measured: 1) total protein, 2) <protein-id="P02768">albumin</protein-id>, 3) beta-lipoprotein, 4) <compound-id="5997">cholesterol</compound-id>, 5) <compound-id="1175">uric acid</compound-id>, 6) <compound-id="1176">urea</compound-id>, 7) <compound-id="588">creatinine</compound-id>.	creatinine__albumin__no_interaction	urea__albumin__no_interaction	uric acid__albumin__no_interaction	cholesterol__albumin__no_interaction
19921058-2	of <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> in <compound-id="6344">dichloromethane</compound-id> to afford octanuclear <compound-id="23978">copper</compound-id>(I) complexes, [Cu(8)(mu-X)(8)(mu-dpmppm)(2)] (X = Cl (1a), Br (1b), I (1c)), which involve a ladder-type {Cu(8)(mu-X)(2)(mu(3)-X)(6)} core supported by two dpmppm ligands in anti arrangement.	copper__CuX__no_interaction	dichloromethane__CuX__no_interaction
16452471-7	Under optimal conditions (150 mm NaCl and 500 mm <compound-id="5462222">potassium</compound-id> <compound-id="1061,167704,644102">phosphate</compound-id>, 37 degrees C, and pH 7.5), no cofactors are required, and the lyase had a Km(PCB) = 2.7 and 2.3 microm, and a kcat = 1.7 x 10(-5) and 1.1 x 10(-5) s(-1) for PCB attachment to CpcB (C155I) and PecB (C155I), respectively; (b) Reconstitution products had absorption maxima at 619 and 602 nm and fluorescence emission maxima at 643 and 629 nm, respectively; and (c) PCB-CpcB(C155I) and PCB-PecB(C155I), with the same absorption and fluorescence maxima, were also biosynthesized heterologously in vivo, when <protein-id="Q7NLD4">cpeS</protein-id> was introduced into E. coli with cpcB(C155I) or pecB(C155I), respectively, together with genes ho1 (encoding <compound-id="4971">heme</compound-id> oxygenase) and pcyA (encoding PCB:ferredoxin oxidoreductase), thereby further proving the lyase function of <protein-id="Q7NLD4">cpeS</protein-id>.	potassium__cpeS__no_interaction	phosphate__cpeS__no_interaction	heme__cpeS__no_interaction
15672194-2	Using a variety of synthetic routes complexes [Mn(O2CPh)2{(py)2CNOH}2].0.25H2O (1.0.25H2O), Mn4(O2CPh)2{(py)2CO2}2{(py)2CNO}2Br2].MeCN (2.MeCN), [Mn4(O2CPh)2{(py)2CO2}2{(py)2CNO}2Cl(2)].2MeCN (3.2MeCN), [Mn4(O2CMe)2{(py)2CO2}2{(py)2CNO}2Br2].2MeCN (4.2MeCN), [Mn4(O2CMe)2{(py)2CO2}2{(py)2CNO}2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2].MeCN.H2O (5.MeCN.H2O) and [Mn2(O2CCF3)2(<compound-id="73706">hfac</compound-id>)2{(py)2CNOH}2] (6) have been isolated in good yields.	hfac__NO3__no_interaction
16156630-1	Monometallic [Pt{S-S2C2(NR)2H}2] (S-S2C2(NR)2H = kappa2-S,S-S2C2(NR)2H = bis-dialkyl-dithioxamidate, R = methyl, <compound-id="6556">isoamyl</compound-id>, <compound-id="123147">benzyl</compound-id>) and binuclear and trinuclear heterobimetallic complexes [Pt{S-S2C2(NR)2H}{mu-S2C2(NR)2}<protein-id="P12872">MLn</protein-id>] (mu-S2C2(NR)2 = kappa2-S,S(Pt)-kappa2-N,N(M)-S2C2(NR)2) and [Pt{ {mu-S2C2(NR)2}<protein-id="P12872">MLn</protein-id>}2] (<protein-id="P12872">MLn</protein-id>+ = [(eta3-<compound-id="8252">allyl</compound-id>)<compound-id="23938">palladium</compound-id>]+, [bis-(2-phenylpyridine)<compound-id="23948">rhodium</compound-id>]+, [(eta6-p-<compound-id="7463">cymene</compound-id>)(chloro)<compound-id="23950">ruthenium</compound-id>]+, [(<compound-id="5367363">1,4-cyclooctadiene</compound-id>)<compound-id="23948">rhodium</compound-id>]+, [(<compound-id="142539">pentamethylcyclopentadienyl</compound-id>)(chloro)<compound-id="23948">rhodium</compound-id>]+) have been prepared and characterized.	isoamyl__MLn__no_interaction	allyl__MLn__no_interaction	ruthenium__MLn__no_interaction	cymene__MLn__no_interaction	pentamethylcyclopentadienyl__MLn__no_interaction	1,4-cyclooctadiene__MLn__no_interaction	benzyl__MLn__no_interaction	palladium__MLn__no_interaction	rhodium__MLn__no_interaction
24015718-9	Women in the highest quintile of <compound-id="94789">HEI</compound-id> had the lowest mean values of systolic blood pressure and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (mean ± SD = 112.7 ± 20.2, 112.6 ± 20.5, 110.6 ± 19.5 mmHg; p = 0.001 and mean ± SD = 99.3 ± 26.0, 100.1 ± 26.6, 97.7 ± 23.1 (mg/dL); p = 0.04, respectively).	HEI__apolipoprotein B__no_interaction
8580890-4	When administered to ovariectomized rats <protein-id="P01015">ANG II</protein-id> induced comparable amounts of <compound-id="962">water</compound-id> intake (4.0 +/- 0.5, 4.8 +/- 0.6, 6.9 +/- 0.7, 9.6 +/- 0.8, and 10.9 +/- 1.2 ml/120 min, respectively) (N = 43) but there was a significant decrease of 3% NaCl solution ingestion (0.3 +/- 0.1, 0.4 +/- 0.1, 0.8 +/- 0.2, 0.7 +/- 0.2, and 0.6 +/- 0.2 ml/120 min, respectively) (N = 44).	water__ANG II__no_interaction
11566978-8	We did, however, identify four types of <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id> mutations or strain genotypes that selectively disrupted substrate translocation or T-pilus production: (i) <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>/<protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>* merodiploid strains expressing all class II and III dominant alleles were strongly suppressed for T-DNA translocation but efficiently mobilized an IncQ plasmid to agrobacterial recipients and also elaborated abundant levels of T pilus; (ii) strains synthesizing two class III mutant proteins, <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>, V258G and <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>.I265T, efficiently transferred both DNA substrates but produced low and undetectable levels of T pilus, respectively; (iii) a strain synthesizing the class II mutant protein <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>.I103T/M301L efficiently exported VirE2 but produced undetectable levels of T pilus; (iv) strains synthesizing three <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id> derivatives with a four-residue (HMVD) insertion (<compound-id="5481481">L75</compound-id>.i4, C168.i4, and <compound-id="14716343">L302</compound-id>.i4) neither transferred T-DNA nor produced detectable levels of T pilus but efficiently transferred VirE2 to plants and the IncQ plasmid to agrobacterial recipient cells.	L302__VirB11__no_interaction	L75__VirB11__no_interaction
8882615-11	<protein-id="G3V9Z3">MAO-A</protein-id> inhibition during HS intake was found to produce a 47-68% decrease in Na+ excretion (from 39.1 +/- 0.7 to 15.1 +/- 2.5 mmol kg-1 day-1, n = 4; P &lt; 0.02) and urine volume (from 160.4 +/- 3.3 to 43.8 +/- 9.0 ml kg-1 day-1, n = 4; P &lt; 0.02) without changes in K+ (from 11.1 +/- 0.5 to 9.2 +/- 0.6 mmol kg-1 day-1, n = 4) and <compound-id="588">creatinine</compound-id> (from 29.1 +/- 2.3 to 28.4 +/- 2.1 mg kg-1 day-1) excretion; urine osmolality increased 2 fold (from 936.3 +/- 40.3 to 2210.7 +/- 157.4 mOsm kg-<compound-id="491852">1 H2O</compound-id>, n = 4; P &lt; 0.02).	1 H2O__MAO-A__no_interaction	creatinine__MAO-A__no_interaction
8855152-2	Serum concentrations of apo A-I, LpA-I, LpA-I:A-II, apo C-III, and LpC-III significantly (P &lt;/= 0.01) increased with <compound-id="10982484">alcohol</compound-id> intake (mean +/- SE in low drinkers vs in alcoholics)--1.45 +/- 0.03 vs 1.78 +/- 0.05 g/L; 0.45 +/- 0.02 vs 0.56 +/- 0.02 g/L; 0.99 +/- 0.02 vs 1.22 +/- 0.04 g/L; 27.6 +/- 1.5 vs 39.7 +/- 1.7 mg/L; and 8.4 +/- 0.9 vs 24.7 +/- 1.7 mg/L, respectively-whereas <protein-id="P04114,Q7Z7Q0,Q59HB3">apo B</protein-id> and LpC-III:B concentrations tended to decrease--1.20 +/- 0.04 vs 1.06 +/- 0.04 g/L and 19.3 +/- 1.2 vs 14.9 +/- 1.0 mg/L, respectively.	alcohol__apo B__no_interaction
10705501-9	The partial solubility parameters obtained, expressed as <protein-id="Q96PP9">MPa1/2</protein-id>, were delta d = 17.6, delta p = 28.7, delta h = 19, delta a = 14.5, delta b = 12.4, delta T = 32.8 for <compound-id="294">lactose</compound-id>, delta d = 16.2, delta p = 24.5, delta h = 14.6, delta a = 8.7, delta b = 12.2, delta T = 32.8 for <compound-id="6251">mannitol</compound-id> and delta d = 17.1, delta p = 18.5, delta h = 13, delta a = 11.3, delta b = 7.6, delta T = 28.4 for <compound-id="5988">saccharose</compound-id>.	lactose__MPa1/2__no_interaction	mannitol__MPa1/2__no_interaction	saccharose__MPa1/2__no_interaction
15175802-3	SLC was in univariate analysis positively correlated with <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> activity (r = 0.35, p &lt;0.01), <compound-id="122634,22833501">tPA</compound-id> antigen (r = 0.38, p &lt;0.01), <protein-id="P04275">von Willebrand factor</protein-id> (r = 0.25, p &lt;0.05), protein S (r = 0.26, p &lt;0.05), and C (r = 0.30, p &lt;0.01), and negatively associated with <compound-id="122634,22833501">tPA</compound-id> activity(r = -0.28, p &lt;0.01).	tPA__von Willebrand factor__no_interaction	tPA__PAI-1__no_interaction
6146116-3	Comparative enzyme activities were as follows (mumol/h/g wet wt): <protein-id="P00367,E9KL48">glutamic acid dehydrogenase</protein-id> (<protein-id="P00367,E9KL48">GDH</protein-id>)--spiking 135.77 +/- 10.22 (mean +/- <compound-id="5289348">SEM</compound-id>), nonspiking 118.58 +/- 9.42 (p less than 0.001, N = 17); glutamic acid decarboxylase--spiking 10.63 +/- 0.95, nonspiking 9.96 +/- 1.10 (NS, N = 13); <protein-id="P80404,X5D8S1">GABA-aminotransferase</protein-id>--spiking 36.49 +/- 1.05, nonspiking 36.46 +/- 1.48 (NS, N = 12); <compound-id="5961">glutamine</compound-id> synthetase--spiking 96.94 +/- 3.81, nonspiking 96.52 +/- 4.10 (NS, N = 20); and <protein-id="P07101,P78428">tyrosine hydroxylase</protein-id> (TH; nmol/h/g)--spiking 16.23 +/- 2.39, nonspiking 10.67 +/- 1.95 (p less than 0.001, N = 14).	SEM__GDH__no_interaction	SEM__GABA-aminotransferase__no_interaction	SEM__glutamic acid dehydrogenase__no_interaction	SEM__tyrosine hydroxylase__no_interaction	glutamine__GDH__no_interaction	glutamine__GABA-aminotransferase__no_interaction	glutamine__glutamic acid dehydrogenase__no_interaction	glutamine__tyrosine hydroxylase__no_interaction
22357517-9	In the rat cerebral cortex and hippocampus, there were the negative correlation (r = -0.927, P &lt; 0.01; r = -0.934, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="P49950">Bcl-2</protein-id>, the positive correlation (r = 0.858, P &lt; 0.01; r = 0.847, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="Q9JKL3,G3V8T9">Bax</protein-id> and the negative correlation (r = -0.939, P &lt; 0.01; r = -0.942, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="P49950">Bcl-2</protein-id>/<protein-id="Q9JKL3,G3V8T9">Bax</protein-id>.	AI__Bcl-2__no_interaction	AI__Bax__no_interaction
3470275-1	Orally active 1-(alkyl substituted <compound-id="15984456">cyclohexyloxycarbonyloxy</compound-id>)alkyl ester prodrugs (9b-h) of 7 beta-[2-(2-<compound-id="2155">aminothiazol</compound-id>-4-yl)<compound-id="178">acetamido</compound-id>]-3- [[[1-(2-dimethylaminoethyl)-<compound-id="67519">1H-tetrazol</compound-id>-5-yl]thio]-methyl]ceph+ ++-3- em-4-<compound-id="11229316,91179806">carboxylic acid</compound-id> (<compound-id="43708">cefotiam</compound-id>, <protein-id="Q9Z109">CTM</protein-id>) have been studied as well as the thia (9i) and aza (9j) analogs.	cefotiam__CTM__no_interaction	cyclohexyloxycarbonyloxy__CTM__no_interaction	acetamido__CTM__no_interaction	aminothiazol__CTM__no_interaction	carboxylic acid__CTM__no_interaction	1H-tetrazol__CTM__no_interaction
21431217-1	A novel class of cyclometalated macrocycles [(Cp*Ir)(2)(R-N=C-C(6)H(2)-C=N-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (<compound-id="69255155">4a</compound-id>), p-MeOC(6)H(4) (4b), p-MeC(6)H(4) (4c), p-ClC(6)H(4) (4d), Me (4e)]; [(Cp*Rh)(2)(R-N=C-C(6)H(2)-C=N-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (<compound-id="69255155">4a</compound-id>'), p-MeOC(6)H(4) (4b'), p-MeC(6)H(4) (4c')] and [(Cp*Ir)(2)(R-C=N-C(6)H(4)-N=C-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (5a), p-MeOC(6)H(4) (<compound-id="18445697">5b</compound-id>)] was stepwise constructed through the double-site C-H activation of aromatic <protein-id="O95817">Bis</protein-id>-imine substrates.	5b__Bis__no_interaction	pyrazine__Bis__no_interaction	4a__Bis__no_interaction
21742997-3	In situ intravital microscopy of mouse cremaster vasculature was used to evaluate arteriolar reactivities to the vasoconstrictors <protein-id="Q3UTR7">angiotensin II</protein-id> (<protein-id="Q3UTR7">ANG II</protein-id>) and <compound-id="6041">phenylephrine</compound-id> (Phe) and the vasodilators <compound-id="187">acetylcholine</compound-id> (ACh) and <compound-id="57476835,60961">adenosine</compound-id> (Ado) in normal [+/+; wild type (WT)] and genetically immunodeficient (T(-)B(-)NK(+) or T(-)B(-)\NK(-)) C57BL/6 and BALB/c mice, strain backgrounds with differentially polarized T cell cytokine production.	phenylephrine__angiotensin II__no_interaction	phenylephrine__ANG II__no_interaction	acetylcholine__angiotensin II__no_interaction	acetylcholine__ANG II__no_interaction	adenosine__angiotensin II__no_interaction	adenosine__ANG II__no_interaction
12879253-4	RESULTS: In comparison with NGT, IGT were modestly <protein-id="P01308,I3WAC9">insulin</protein-id> resistant (M=29+/-2 vs 35+/-2 micromol x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(FFM)(-1), p=0.01); <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity of <compound-id="206,5793,64689,79025">glucose</compound-id> production also was reduced, in approximate proportion to M. Despite higher baseline <protein-id="P01308,I3WAC9">insulin</protein-id> secretion rates, IGT was characterized by a 50% reduction in <compound-id="206,5793,64689,79025">glucose</compound-id> sensitivity [53 (36) vs 102 (123) pmol x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) x mM(-1), median (interquartile range), p=0.001] and impaired potentiation [1.6 (0.8) vs 2.0 (1.5) units, p&lt;0.04] of <protein-id="P01308,I3WAC9">insulin</protein-id> release, whereas rate sensitivity [1.15 (1.15) vs 1.38 (1.28) nmol x m(-2) x mM(-1)] was not significantly reduced.	glucose__min(-1__no_interaction	glucose__insulin__no_interaction
22070200-1	The syntheses, crystal structures, and magnetochemical characterization are reported for the new mixed-valent Mn clusters [Mn(2)(II)Mn(III)(O(2)CMe)(2)(edteH(2))(2)](ClO(4)) (1), [Mn(II)(2)Mn(III)(2)(edteH(2))(2)(hmp)(2)Cl(2)](<compound-id="27854">Mn(II)</compound-id>Cl(4)) (2), [Mn(III)(6)O(2)(O(2)CBu(t))(6)(edteH)(2)(N(3))(2)] (3), [Na(2)Mn(III)(8)Mn(II)(2)O(4)(OMe)(2)(O(2)CEt)(6)(edte)(2)(N(3))(6)] (4), and (NEt(4))(2)[Mn(8)(III)Mn(2)(II)O(4)(OH)(2)-(O(2)CEt)(6)(edte)(2)(N(3))(6)](5), where edteH(4) is N,N,N',N'-tetrakis-(2-hydroxyethyl)<compound-id="17822391,3301">ethylenediamine</compound-id> and <protein-id="Q03014">hmpH</protein-id> is <compound-id="11474">2-(hydroxymethyl)pyridine</compound-id>.	ethylenediamine__hmpH__no_interaction	Mn(II)__hmpH__no_interaction	2-(hydroxymethyl)pyridine__hmpH__no_interaction
11102586-5	Known genes that were upregulated in waking and sleep deprivation can be grouped into the following categories: immediate early genes/transcription factors (<protein-id="Q63053">Arc</protein-id>, <protein-id="Q496Y7,Q62804">CHOP</protein-id>, IER5, <protein-id="P08154">NGFI-A</protein-id>, <protein-id="P22829">NGFI-B</protein-id>, <protein-id="Q04970">N-Ras</protein-id>, <protein-id="P52631">Stat3</protein-id>), genes related to energy metabolism (<compound-id="206,5793,64689,79025">glucose</compound-id> type I transporter Glut1, <compound-id="42627579">Vgf</compound-id>), growth factors/adhesion molecules (<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>, <protein-id="Q63604,A0A0G2K5X6">TrkB</protein-id>, F3 adhesion molecule), chaperones/heat shock proteins (<protein-id="P06761">BiP</protein-id>, <protein-id="P38659">ERP72</protein-id>, <protein-id="F1M953">GRP75</protein-id>, <protein-id="P63039">HSP60</protein-id>, HSP70), vesicle- and synapse-related genes (<protein-id="P10362,G3V7X2">chromogranin C</protein-id>, <protein-id="P50232">synaptotagmin IV</protein-id>), neurotransmitter/hormone receptors (<protein-id="P43140">adrenergic receptor alpha(1A</protein-id>) and beta(2), <compound-id="119">GABA</compound-id>(A) receptor beta(3), <compound-id="23327,33032,611,57109091">glutamate</compound-id> NMDA receptor 2A, <compound-id="23327,33032,611,57109091">glutamate</compound-id> AMPA receptor <protein-id="P19491">GluR2</protein-id> and <protein-id="P19492,G3V6Z5,G3V8Y9">GluR3</protein-id>, nicotinic <compound-id="187">acetylcholine</compound-id> receptor beta(2), thyroid hormone receptor TRbeta), neurotransmitter transporters (<compound-id="23327,33032,611,57109091">glutamate</compound-id>/<compound-id="5960">aspartate</compound-id> transporter <protein-id="P24942,A0A0G2JSU1,G3V846,A0A0G2KAS7,A0A0G2K611">GLAST</protein-id>, Na(+)/Cl(-) transporter <protein-id="P31662">NTT4</protein-id>/Rxt1), enzymes (aryl sulfotransferase, <protein-id="P49185">c-jun N-terminal kinase 1</protein-id>, serum/glucocorticoid-induced serine/<compound-id="194239,6288">threonine</compound-id> kinase), and a miscellaneous group (calmodulin, <protein-id="Q04827">cyclin D2</protein-id>, <protein-id="Q5PPG8">LMO-4</protein-id>, <protein-id="P37361">metallothionein 3</protein-id>).	acetylcholine__cyclin D2__no_interaction	acetylcholine__ERP72__no_interaction	acetylcholine__GRP75__no_interaction	acetylcholine__BDNF__no_interaction	acetylcholine__chromogranin C__no_interaction	acetylcholine__BiP__no_interaction	acetylcholine__LMO-4__no_interaction	acetylcholine__c-jun N-terminal kinase 1__no_interaction	acetylcholine__N-Ras__no_interaction	acetylcholine__metallothionein 3__no_interaction	acetylcholine__NGFI-B__no_interaction	acetylcholine__CHOP__no_interaction	acetylcholine__synaptotagmin IV__no_interaction	acetylcholine__NGFI-A__no_interaction	acetylcholine__Stat3__no_interaction	acetylcholine__TrkB__no_interaction	acetylcholine__adrenergic receptor alpha(1A__no_interaction	acetylcholine__HSP60__no_interaction	acetylcholine__GluR3__no_interaction	acetylcholine__GluR2__no_interaction	acetylcholine__Arc__no_interaction	acetylcholine__GLAST__no_interaction	acetylcholine__NTT4__no_interaction	Vgf__cyclin D2__no_interaction	Vgf__ERP72__no_interaction	Vgf__GRP75__no_interaction	Vgf__BDNF__no_interaction	Vgf__chromogranin C__no_interaction	Vgf__BiP__no_interaction	Vgf__LMO-4__no_interaction	Vgf__c-jun N-terminal kinase 1__no_interaction	Vgf__N-Ras__no_interaction	Vgf__metallothionein 3__no_interaction	Vgf__NGFI-B__no_interaction	Vgf__CHOP__no_interaction	Vgf__synaptotagmin IV__no_interaction	Vgf__NGFI-A__no_interaction	Vgf__Stat3__no_interaction	Vgf__TrkB__no_interaction	Vgf__adrenergic receptor alpha(1A__no_interaction	Vgf__HSP60__no_interaction	Vgf__GluR3__no_interaction	Vgf__GluR2__no_interaction	Vgf__Arc__no_interaction	Vgf__GLAST__no_interaction	Vgf__NTT4__no_interaction	aspartate__cyclin D2__no_interaction	aspartate__ERP72__no_interaction	aspartate__GRP75__no_interaction	aspartate__BDNF__no_interaction	aspartate__chromogranin C__no_interaction	aspartate__BiP__no_interaction	aspartate__LMO-4__no_interaction	aspartate__c-jun N-terminal kinase 1__no_interaction	aspartate__N-Ras__no_interaction	aspartate__metallothionein 3__no_interaction	aspartate__NGFI-B__no_interaction	aspartate__CHOP__no_interaction	aspartate__synaptotagmin IV__no_interaction	aspartate__NGFI-A__no_interaction	aspartate__Stat3__no_interaction	aspartate__TrkB__no_interaction	aspartate__adrenergic receptor alpha(1A__no_interaction	aspartate__HSP60__no_interaction	aspartate__GluR3__no_interaction	aspartate__GluR2__no_interaction	aspartate__Arc__no_interaction	aspartate__GLAST__no_interaction	aspartate__NTT4__no_interaction	glucose__cyclin D2__no_interaction	glucose__ERP72__no_interaction	glucose__GRP75__no_interaction	glucose__BDNF__no_interaction	glucose__chromogranin C__no_interaction	glucose__BiP__no_interaction	glucose__LMO-4__no_interaction	glucose__c-jun N-terminal kinase 1__no_interaction	glucose__N-Ras__no_interaction	glucose__metallothionein 3__no_interaction	glucose__NGFI-B__no_interaction	glucose__CHOP__no_interaction	glucose__synaptotagmin IV__no_interaction	glucose__NGFI-A__no_interaction	glucose__Stat3__no_interaction	glucose__TrkB__no_interaction	glucose__adrenergic receptor alpha(1A__no_interaction	glucose__HSP60__no_interaction	glucose__GluR3__no_interaction	glucose__GluR2__no_interaction	glucose__Arc__no_interaction	glucose__GLAST__no_interaction	glucose__NTT4__no_interaction	glutamate__cyclin D2__no_interaction	glutamate__ERP72__no_interaction	glutamate__GRP75__no_interaction	glutamate__BDNF__no_interaction	glutamate__chromogranin C__no_interaction	glutamate__BiP__no_interaction	glutamate__LMO-4__no_interaction	glutamate__c-jun N-terminal kinase 1__no_interaction	glutamate__N-Ras__no_interaction	glutamate__metallothionein 3__no_interaction	glutamate__NGFI-B__no_interaction	glutamate__CHOP__no_interaction	glutamate__synaptotagmin IV__no_interaction	glutamate__NGFI-A__no_interaction	glutamate__Stat3__no_interaction	glutamate__TrkB__no_interaction	glutamate__adrenergic receptor alpha(1A__no_interaction	glutamate__HSP60__no_interaction	glutamate__GluR3__no_interaction	glutamate__GluR2__no_interaction	glutamate__Arc__no_interaction	glutamate__GLAST__no_interaction	glutamate__NTT4__no_interaction	threonine__cyclin D2__no_interaction	threonine__ERP72__no_interaction	threonine__GRP75__no_interaction	threonine__BDNF__no_interaction	threonine__chromogranin C__no_interaction	threonine__BiP__no_interaction	threonine__LMO-4__no_interaction	threonine__c-jun N-terminal kinase 1__no_interaction	threonine__N-Ras__no_interaction	threonine__metallothionein 3__no_interaction	threonine__NGFI-B__no_interaction	threonine__CHOP__no_interaction	threonine__synaptotagmin IV__no_interaction	threonine__NGFI-A__no_interaction	threonine__Stat3__no_interaction	threonine__TrkB__no_interaction	threonine__adrenergic receptor alpha(1A__no_interaction	threonine__HSP60__no_interaction	threonine__GluR3__no_interaction	threonine__GluR2__no_interaction	threonine__Arc__no_interaction	threonine__GLAST__no_interaction	threonine__NTT4__no_interaction	GABA__cyclin D2__no_interaction	GABA__ERP72__no_interaction	GABA__GRP75__no_interaction	GABA__BDNF__no_interaction	GABA__chromogranin C__no_interaction	GABA__BiP__no_interaction	GABA__LMO-4__no_interaction	GABA__c-jun N-terminal kinase 1__no_interaction	GABA__N-Ras__no_interaction	GABA__metallothionein 3__no_interaction	GABA__NGFI-B__no_interaction	GABA__CHOP__no_interaction	GABA__synaptotagmin IV__no_interaction	GABA__NGFI-A__no_interaction	GABA__Stat3__no_interaction	GABA__TrkB__no_interaction	GABA__adrenergic receptor alpha(1A__no_interaction	GABA__HSP60__no_interaction	GABA__GluR3__no_interaction	GABA__GluR2__no_interaction	GABA__Arc__no_interaction	GABA__GLAST__no_interaction	GABA__NTT4__no_interaction
22155782-4	The major findings of this study are that TRPV1 is activated by some, but not all of the prototype PM materials evaluated, with rank-ordered responses of CFA1 &gt; diesel exhaust PM &gt; crystalline <compound-id="24261">silica</compound-id>; TRP melastatin-8 is also robustly activated by CFA1, whereas other TRP channels expressed by airway sensory neurons and lung epithelial cells that may also be activated by CFA1, including TRPs ankyrin 1 (A1), canonical 4α (C4α), M2, V2, V3, and V4, were either slightly (<protein-id="Q8BLA8,V5TCP9">TRPA1</protein-id>) or not activated by CFA1; activation of TRPV1 by CFA1 occurs via cell surface interactions between the solid components of CFA1 and specific amino acid residues of TRPV1 that are localized in the putative pore-loop region; and activation of TRPV1 by CFA1 is not exclusive in mouse lungs but represents a pathway by which CFA1 affects the expression of selected genes in lung epithelial cells and airway tissue.	silica__TRPA1__no_interaction
11229569-1	The reactions of potentially hexadentate H2bbpen (N,N'-bis(2-hydroxybenzyl)-N,N'-bis<compound-id="12677274">(2-pyridylmethyl)-ethylenediamine</compound-id>, H2L1), <compound-id="783">H2</compound-id>(Cl)bbpen (N,N'-bis(5-chloro-2-hydroxybenzyl)-<compound-id="300761">N,N'-bis(2-pyridylmethyl)ethylenediamine</compound-id>, H2L2), and <protein-id="P06899,A0A024RCJ2">H2(Br</protein-id>)bbpen (N,N'-bis(5-bromo-2-hydroxybenzyl)-<compound-id="300761">N,N'-bis(2-pyridylmethyl)ethylenediamine</compound-id>, H2L3) with Ln(III) ions in the presence of a base in <compound-id="11686950,887">methanol</compound-id> resulted in three types of complexes: neutral mononuclear ([LnL(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]), monocationic dinuclear ([Ln2L2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]+), and monocationic trinuclear ([Ln3L2(X)n(CH3OH)]+), where X = bridging (CH3COO-) and bidentate ligands (<protein-id="P41271,A0A087WTY6">NO3</protein-id>-, CH3COO-, ClO4-) and n is 4.	H2__NO3__no_interaction	H2__H2(Br__no_interaction	methanol__NO3__no_interaction	methanol__H2(Br__no_interaction	(2-pyridylmethyl)-ethylenediamine__NO3__no_interaction	(2-pyridylmethyl)-ethylenediamine__H2(Br__no_interaction	N,N'-bis(2-pyridylmethyl)ethylenediamine__NO3__no_interaction	N,N'-bis(2-pyridylmethyl)ethylenediamine__H2(Br__no_interaction
15808768-7	Quantification of myocardial TF messenger ribonucleic acid in DCM revealed a decrease in the TF/<compound-id="439168,446381">glyceraldehyde-3-phosphate</compound-id> dehydrogenase (<protein-id="P04406,V9HVZ4">GAPDH</protein-id>) ratio (1.76 x 10(-1) +/- 6.08 x 10(-2) for EF &gt; or =50% [n = 19] vs. 1.06 x 10(-1) +/- 5.26 x 10(-2) for EF &lt;50% [n = 27]; p &lt; 0.001) and asHTF/<protein-id="P04406,V9HVZ4">GAPDH</protein-id> ratio (13.91 x 10(-5) +/- 11.20 x 10(-5) for EF &gt; or =50% vs. 7.17 x 10(-5) +/- 3.82 x 10(-5) for EF &lt;50%; p = 0.014).	glyceraldehyde-3-phosphate__GAPDH__no_interaction
19381423-1	A series of novel cationic and neutral <compound-id="23948">rhodium</compound-id> and <compound-id="23924">iridium</compound-id> complexes containing bidentate <compound-id="57182093">phosphine-imidazolyl</compound-id> donor ligands of the general formulae [M(<compound-id="8582">ImP</compound-id>)(COD)]BPh(4) (M = Rh, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 3; ImP1a, <compound-id="69255155">4a</compound-id>; ImP1b, 4b and M = Ir, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 5; ImP1a, 6a and ImP1b, 6b), [Ir(<compound-id="8582">ImP</compound-id>)(CO)(2)]BPh(4) (<compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 7; ImP1a, 8a and ImP1b, 8b), [Rh(ImP1b)(CO)(2)]BPh(4) (10b) and [M(<compound-id="8582">ImP</compound-id>)(CO)Cl] (M = Rh, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 11; ImP1b,12 and M = Ir, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 13; ImP1b, 14 ) where COD = <compound-id="5702534,8135,82916">1,5-cyclooctadiene</compound-id>, <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id> = 1-methyl-2-[(2-(<compound-id="70017">diphenylphosphino</compound-id>)<compound-id="23134249">ethyl</compound-id>]<compound-id="795">imidazole</compound-id>, 1; ImP1a = <compound-id="10874611">1-methyl-2-[(diphenylphosphino)methyl]imidazole</compound-id>, 2a and ImP1b = <compound-id="15388202">2-[(diisopropylphosphino)methyl]-1-methylimidazole</compound-id>, 2b were successfully synthesised.	diphenylphosphino__ImP2__no_interaction	imidazole__ImP2__no_interaction	2-[(diisopropylphosphino)methyl]-1-methylimidazole__ImP2__no_interaction	ImP__ImP2__no_interaction	iridium__ImP2__no_interaction	phosphine-imidazolyl__ImP2__no_interaction	1-methyl-2-[(diphenylphosphino)methyl]imidazole__ImP2__no_interaction	1,5-cyclooctadiene__ImP2__no_interaction	ethyl__ImP2__no_interaction	rhodium__ImP2__no_interaction	4a__ImP2__no_interaction
22868212-2	Four experiments were conducted: (1) six steers were randomly assigned to receive intravenous (IV) bolus injections of 0, 0.2, 1.0, 12.5 and 50.0 μg/kg <compound-id="20832894,53481581,5486814">neuromedin C</compound-id> (NMC); (2) seven pre-weaned calves were IV injected with 1.0 μg/kg NMC; (3) six steers were IV injected with 2.5μg/kg bovine <protein-id="Q863C3">gastrin-releasing peptide</protein-id> (<protein-id="Q863C3">GRP</protein-id>), 1.0 μg/kg NMC combined with 20.0 μg/kg [d-<compound-id="5962">Lys</compound-id>(3)]-<compound-id="4345065">GHRP-6</compound-id> (an antagonist for the GH secretagogue receptor type 1a [GHS-R1a]), 1.0 μg/kg NMC combined with 20.0 μg/kg N-acetyl-<protein-id="Q863C3">GRP</protein-id>(20-26)-OCH(2)CH(3) (N-<protein-id="Q863C3">GRP</protein-id>-EE, an antagonist for the <protein-id="Q863C3">GRP</protein-id> receptor), 20.0 μg/kg N-<protein-id="Q863C3">GRP</protein-id>-EE alone, 1.0 μg/kg <protein-id="Q2T9U8">neuromedin B</protein-id> (<protein-id="Q2T9U8">NMB</protein-id>); and (4) four rats were IV injected 1.0 μg/kg NMC.	GHRP-6__gastrin-releasing peptide__no_interaction	GHRP-6__NMB__no_interaction	GHRP-6__neuromedin B__no_interaction	GHRP-6__GRP__no_interaction	Lys__gastrin-releasing peptide__no_interaction	Lys__NMB__no_interaction	Lys__neuromedin B__no_interaction	Lys__GRP__no_interaction	neuromedin C__gastrin-releasing peptide__no_interaction	neuromedin C__NMB__no_interaction	neuromedin C__neuromedin B__no_interaction	neuromedin C__GRP__no_interaction
6371116-3	The total <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="P01308,I3WAC9">insulin</protein-id> responses following the oral <compound-id="206,5793,64689,79025">glucose</compound-id> load were increased by 24% and 127% respectively in the elderly compared with the young (24,524 +/- 1,080 vs. 19,734 +/- 702 mg/dl X min and 24,289 +/- 3,401 vs. 10,700 +/- 1,209 microU/ml X min).	glucose__insulin__no_interaction
18082268-1	Six bipyridyl complexes of <compound-id="23939">platinum</compound-id>(II) with <compound-id="2723790">thiourea</compound-id>, with different substituents on <compound-id="2723790">thiourea</compound-id> moiety [Pt(bipy)(R,R'NCSNR'',R''')(2)]Cl(2) (bipy=<compound-id="1474">2,2'-bipyridine</compound-id>: R=R'=R''=R''' =H; R=Me, R'=R''=R'''=H; R=n-Bu, R'=R''=R'''=H; R=Et, R'=H, R''=Et, R'''=H; R=p-tolyl, R'=R''=R'''=H; R=phenyl, R'=H, R''=phenyl, R'''=H), rationally designed to intercalate into DNA, have been tested against a cisplatin (cDDP)-sensitive human ovarian carcinoma cell line (2008) and its -resistant variant (<protein-id="P31276">C13</protein-id>( *)).	platinum__C13__no_interaction	2,2'-bipyridine__C13__no_interaction	thiourea__C13__no_interaction
16335581-5	Patients reaching the composite outcome had predominantly proliferative lupus nephritis (WHO classes: 30% III, 32% IV, 18% V and 5% II, P &lt; 0.025) with higher activity index score (7 +/- 6 versus 5 +/- 5, P &lt; 0.05), chronicity index (CI) score (4 +/- 3 versus 2 +/- 2 unit, P &lt; 0.025), higher baseline mean arterial pressure (MAP) (111 +/- 21 versus 102 +/- 14 mmHg, P &lt; 0.025) and serum <compound-id="588">creatinine</compound-id> (1.9 +/- 1.3 versus 1.3 +/- 1.0 mg/dL, P &lt; 0.025), but lower baseline hematocrit (29 +/- 6 versus 31 + 5%, P &lt; 0.025) and <protein-id="P01024,V9HWA9,B4DR57">complement C3</protein-id> (54 +/- 26 versus 65 + 33 mg/dL, P &lt; 0.025) compared to controls.	creatinine__complement C3__no_interaction
23883066-5	Rate constants (25 °C) (k1 or k3) and activation parameters (ΔHk‡, kJ mol(-1); ΔSk‡, J K(-1) mol(-1)) from Eyring plots for entering nucleophiles as indicated are as follows: <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="12287">3-chloropyridine</compound-id>: (k1) 2.33 ± 0.01 M(-1) s(-1); 85.1 ± 0.6, 48 ± 2; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="1049">pyridine</compound-id>: (k1) 1.29 ± 0.02 M(-1) s(-1); 92 ± 2, 66 ± 7; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="7963">4-picoline</compound-id>: (k1) 1.27 ± 0.05 M(-1) s(-1); 88 ± 2, 53 ± 6; (k3) 3.9 ± 0.03 s(-1); 78 ± 8, 30 ± 27; (kf) 1.7 ± 0.02 M(-1) s(-1); 86 ± 2, 49 ± 6; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="14284">DMAP</compound-id> (k3) 1.15 ± 0.02 s(-1); 88 ± 2, 52 ± 7.	4-picoline__fac__no_interaction	3-chloropyridine__fac__no_interaction	pyridine__fac__no_interaction	DMAP__fac__no_interaction
25095655-5	There were direct correlations between all the examined biomarkers and the degree of uricemia (<compound-id="7021454">Rs</compound-id> = 0.453; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.411; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.322; p = 0.067; <compound-id="7021454">Rs</compound-id> = 0.537; p &lt; 0.001; and <compound-id="7021454">Rs</compound-id> = 0.318; p = 0.004, respectively) and between the markers of endothelial dysfunction and those of tubulointerstitial tissue lesion (<compound-id="7021454">Rs</compound-id> = 0.295 for <protein-id="P05305,Q6FH53">ET-1</protein-id> and <protein-id="P13500">MCP-1</protein-id>; p = 0.008; <compound-id="7021454">Rs</compound-id> = 0.399 for <protein-id="P05305,Q6FH53">ET-1</protein-id> and beta2-MG; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.462 for <compound-id="54688679,54720365">MAU</compound-id> and beta2-MG; p &lt; 0.001; and <compound-id="7021454">Rs</compound-id> = 0.188 for <compound-id="54688679,54720365">MAU</compound-id> and <protein-id="P13500">MCP-1</protein-id>; p = 0.094).	MAU__ET-1__no_interaction	MAU__MCP-1__no_interaction	Rs__ET-1__no_interaction	Rs__MCP-1__no_interaction
18453222-3	RESULTS: Under normoxia, the <protein-id="Q16665,D0VY79">HIF-1alpha</protein-id> mRNA and protein of HepG2(Tet-on-<protein-id="Q16665,D0VY79">HIF-1alpha</protein-id>) cells could be induced up to (5.899 +/- 2.176) and (2.179 +/- 0.742) folds by <compound-id="54671203">doxycycline</compound-id> (1 microg/ml); There were no difference of A(490 nm) between the Dox(+)and Dox(-) group in experiment detecting the proliferation activity (P &gt; 0.05); But in adhesive experiment, the A(490 nm) of Dox (+) group was 0.662 +/- 0.058, higher than the Dox(-) group 0.526 +/- 0.808 (P = 0.008); The invasive cell number of Dox(+) group was 37.611 +/- 8.424, but in the Dox(-) group, the number was 25.333 +/- 8.117 (P &lt; 0.01).	doxycycline__HIF-1alpha__no_interaction
12492336-5	Metathesis of these polyfluoroalkyl-substituted triazolium halides with other salts led to the formation of quaternary compounds, some of which comprise ionic liquids, namely, [R(R(f))-<compound-id="123630">Taz</compound-id>](+)Y(-) (Y = <compound-id="5326889">NTf</compound-id>(2), BF(4), <protein-id="Q6Q759">PF(6</protein-id>), and OTf), in good isolated yields without the need for further purification: N1-CH(3)-N4-(CH(2))(2)C(m)F(2)(m)( +) (1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 4, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1- C(7)H(15)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 4, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(10)H(21)-N4-(CH(2))(2)C(m)F(2)(m)(+1)-<compound-id="123630">Taz</compound-id> Y (n = 1, 4; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(n)H(2)(n )(+ 1)-N4-(CH(2))(2)F-<compound-id="123630">Taz</compound-id> Y (n = 7, 10; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(10)H(21)-N4-(CH(2))(2)F-TazY (Y = OTf), N1-C(7)H(15)-N4-(CH(2))(2)F-TazY (Y = BF(4)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m) (+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 4, 6; Y = <protein-id="Q6Q759">PF(6</protein-id>)), N1-C(7)H(15)-N4-(CH(2))(2)C(4)F(9)-<compound-id="123630">Taz</compound-id> Y (Y = <protein-id="Q6Q759">PF(6</protein-id>)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 4, 6; Y = OTf).	Taz__PF(6__no_interaction	NTf__PF(6__no_interaction
21923249-3	At the end of the study, the comparison between group A and group B showed significant differences in <protein-id="Q9NRA2">aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) (-80.9 versus -110.3; P &lt; 0.001), <compound-id="5950,602">alanine</compound-id> aminotransferase (-111.6 versus -134.7; P &lt; 0.001), Viremia (-3.26 versus -3.82; P &lt; 0.05), mental health (0 versus 11; P &lt; 0.001), physical functioning (-1 versus 8; P &lt; 0.001), role-physical (1 versus 13; P &lt; 0.001), bodily pain (1 versus 12; P &lt; 0.001), general health (3 versus 12; P &lt; 0.001), vitality (3 versus 13; P &lt; 0.001), social functioning (3 versus 10; P &lt; 0.001), physical fatigue (2.1 versus -5.4; P &lt; 0.001), mental fatigue (-0.7 versus -2.7; P &lt; 0.001), and fatigue severity scale (-3.4 versus -12; P &lt; 0.001).	alanine__aspartate aminotransferase__no_interaction	alanine__AST__no_interaction
22462581-7	RESULTS: We found <compound-id="61739">hypochlorite</compound-id>-oxidized <protein-id="P28845,X5D2L1">HDL</protein-id> dramatically promotes breast cancer cell pulmonary metastasis (133.4% increase at P &lt; 0.0 l for MDA-MB-231 by mammary fat <compound-id="19805081,5492869">pad</compound-id> injection; 164.3% increase at P &lt; 0.01 for MCF7 by tail vein injection) and hepatic metastasis (420% increase at P &lt; 0.0 l for MDA-MB-231 by mammary fat <compound-id="19805081,5492869">pad</compound-id> injection; 1840% fold increase at P &lt; 0.001 for MCF7 by tail vein injection) in nude mice, and stimulates higher cell invasion (85.1% increase at P &lt; 0.00 l for MDA-MB-231; 88.8% increase at P &lt; 0.00 l for MCF7;), TC-HUVEC adhesion (43.4% increase at P &lt; 0.00 l for MDA-MB-231; 35.2% increase at P &lt; 0.00 l for MCF7), and TC-<protein-id="Q13201">ECM</protein-id> attachment (41.0% increase at P &lt; 0.00 l for MDA-MB-231; 26.7% increase at P &lt; 0.05 for MCF7) in vitro compared with normal <protein-id="P28845,X5D2L1">HDL</protein-id>.	hypochlorite__ECM__no_interaction	hypochlorite__HDL__no_interaction	pad__ECM__no_interaction	pad__HDL__no_interaction
19950340-1	The preparation and characterization of a series of <compound-id="5462224">magnesium</compound-id>(II) <compound-id="105054,30165">iodide</compound-id> complexes incorporating beta-diketiminate ligands of varying steric bulk and denticity, namely, [(ArNCMe)(2)CH](-) (Ar=phenyl, ((Ph)Nacnac), mesityl ((Mes)Nacnac), or 2,6-<compound-id="11345">diisopropylphenyl</compound-id> (<protein-id="Q9JI46,B2KF67">Dipp</protein-id>, (<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)), [(DippNCtBu)(2)CH](-) ((tBu)Nacnac), and [(DippNCMe)(Me(2)<compound-id="445100">NCH</compound-id>(2)CH(2)NCMe)CH](-) ((Dmeda)Nacnac) are reported.	NCH__Dipp__no_interaction	diisopropylphenyl__Dipp__no_interaction	magnesium__Dipp__no_interaction	iodide__Dipp__no_interaction
19950340-2	The complexes [((Ph)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Mes)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Dmeda)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Mes)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="8028">thf</compound-id>)], [((<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="8028">thf</compound-id>)], [((tBu)Nacnac)<compound-id="11779786">MgI</compound-id>], and [((tBu)Nacnac)<compound-id="11779786">MgI</compound-id>(DMAP)] (DMAP=4-<compound-id="21885">dimethylaminopyridine</compound-id>) were shown to be monomeric by X-ray crystallography.	thf__Dipp__no_interaction	MgI__Dipp__no_interaction	dimethylaminopyridine__Dipp__no_interaction	OEt__Dipp__no_interaction
19950340-7	All attempts to form <compound-id="5460467">beryllium</compound-id>(I) or <compound-id="22044544,5460341">calcium</compound-id>(I) dimers by reductions of [((Mes)Nacnac)<compound-id="445303">BeI</compound-id>], [{((<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)CaI(<compound-id="6324">OEt</compound-id>(2))}(2)], or [{((tBu)Nacnac)CaI(<compound-id="8028">thf</compound-id>)}(2)] have so far been unsuccessful.	calcium__Dipp__no_interaction	BeI__Dipp__no_interaction	thf__Dipp__no_interaction	beryllium__Dipp__no_interaction	OEt__Dipp__no_interaction
22968548-1	Reaction of [Pt(2)(μ-S)(2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)] with the dialkylating agents ClCH(2)C(O)CH(2)Cl or ClCH(2)C(=NNHC(O)NH(2))CH(2)Cl gives the dicationic di-μ-<compound-id="5047209">thiolate</compound-id> complexes [Pt(2){μ-SCH(2)C(O)CH(2)S)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)](2+) or [Pt(2){μ-SCH(2)C(=NNHC(O)NH(2))CH(2)S}(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)](2+), isolated as BPh(4)(-) salts and characterised by ESI mass spectrometry, NMR spectroscopy and single-crystal X-ray crystallography.	thiolate__PPh(3__no_interaction
12443025-3	With this method new human milk oligosaccharides of previously unknown isomeric structures have been identified, e.g., the occurence of three isomeric fucosylated lacto-N-hexaoses could be determined precisely, which have not been described before: (1) Fuc (alpha1--&gt;2) <protein-id="P22466">Gal</protein-id> (beta1--&gt;3) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>, (2) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNAc</compound-id> [(alpha1--&gt;3) Fuc] (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>, (3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNAc</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> [(alpha1--&gt;3) Fuc] (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>.	GlcNAc__Gal__no_interaction	Glc__Gal__no_interaction	GlcNac__Gal__no_interaction
2458719-7	Ca2+ release was effected by <protein-id="Q08050,Q53Y49,A0A0D9SFF0,A8K591">Ins(1,4,5</protein-id>)P3, with half-maximal release at 0.5 +/- 0.14 microM-<protein-id="Q08050,Q53Y49,A0A0D9SFF0,A8K591">Ins(1,4,5</protein-id>)P3, <protein-id="P12235">t1/2 11.2</protein-id> +/- 1.1 s. GTP- and <compound-id="6802">guanosine</compound-id> 5'-[beta gamma-imido]triphosphate (p[NH]ppG)-promoted release of 45Ca2+ was demonstrated in this preparation, but the kinetics of release (half-maximal Ca2+ release at 5.4 +/- 0.7 microM, with <protein-id="P12235">t1/2 77.3</protein-id> +/- 6.9 s, and at 51.1 +/- 4.2 microM, with <protein-id="P12235">t1/2 19.0</protein-id> +/- 2.2 s, for GTP and p[NH]ppG respectively), and the ability of <compound-id="8378,4454,62404">neomycin sulphate</compound-id> to block p[NH]ppG-induced release only, are indicative of separate release mechanisms after treatment with these agents.	guanosine__t1/2 77.3__no_interaction	guanosine__t1/2 11.2__no_interaction	guanosine__t1/2 19.0__no_interaction	guanosine__Ins(1,4,5__no_interaction	neomycin sulphate__t1/2 77.3__no_interaction	neomycin sulphate__t1/2 11.2__no_interaction	neomycin sulphate__t1/2 19.0__no_interaction	neomycin sulphate__Ins(1,4,5__no_interaction
20886810-1	The syntheses, crystal structures, and the experimental and theoretical magnetochemical characterization for three tetrametallic Ni(II) clusters, namely, [Ni(4)(L)(4)(Cl)(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·4MeOH (1), [Ni(4)(L)(4)(N(3))(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·2MeOH (2), and [Ni(4)(L1)(4)(pyz)(2)(PhCOO)(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·7MeOH (3) (where HL and <protein-id="P07306,Q6FGQ5">HL1</protein-id> represent bipyridine-2-carboxamideoxime and <compound-id="51550622">pyrimidine-2-carboxamideoxime</compound-id>, respectively) are reported.	pyrimidine-2-carboxamideoxime__HL1__no_interaction	MeOH__HL1__no_interaction
12889996-8	In addition to the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401/0404-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302/(<protein-id="Q93038">DR3</protein-id>)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*05-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*02 genotype and <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*04-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 homozygous genotypes, heterozygous combinations <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302/(DR13)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604, approximately /(<compound-id="9547897">DR8</compound-id>)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*04, approximately /(DR9)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*03-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0303, approximately /(<protein-id="Q01658,Q658N3">DR1</protein-id>)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0501 and approximately /(DR7)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0201-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*02 were also disease-associated.	DR8__DR1__no_interaction	DR8__DQB1__no_interaction	DR8__DR3__no_interaction	DR8__DRB1__no_interaction	DR8__DQA1__no_interaction
16629137-6	with values of 9.97 micromol x g(-1) at 10 d to 3.67 micromol x g(-1) at 28 d. The LR50 values for H. azteca were intermediate and ranged from 2.25 micromol x g(-1) at 5 d to 0.56 micromol x g(-1) at 28 d. <compound-id="11855">Pentachlorobenzene</compound-id> LR50 values were less variable among species and ranged from 1.20 micromol x g(-1) at 4 d to 0.81 micromol x g(-1) at 10 d for C. tentans, 5.0 micromol x g(-1) at 20 d and 2.75 micromol x g(-1) at 28 d for Diporeia <protein-id="Q8TCT9,A0A0C4DGU3">spp</protein-id>., and 1.51 micromol x g(-1) at 4 d and 0.71 micromol x g(-1) at 28 d for H. azteca.	Pentachlorobenzene__spp__no_interaction
23485720-7	Patients who had developed HE had a significantly higher baseline Child-Turcotte-Pugh score (10.15 ±1.82 vs. 6.35 ± 1.60, p &lt; 0.05), <compound-id="5950,602">alanine</compound-id> aminotransferase (111.25 ± 91.62 vs. 48.32 ± 47.45, p &lt; 0.05), <compound-id="5960">aspartate</compound-id> aminotransferase (171.42 ± 142.68 vs. 46.33 ± 42.68, p &lt; 0.05), total <compound-id="5280352">bilirubin</compound-id> (73.44 ± 47.20 vs. 29.75 ± 22.08, p &lt; 0.05), serum albumin (24.65 ± 5.04 vs. 33.43 ± 6.49, p &lt; 0.05), plasma <protein-id="P00734">prothrombin</protein-id> time (22.18 ± 4.60 vs. 17.12 ± 4.62, p &lt; 0.05), and lower hemoglobin level (72.31 ± 15.15 vs. 87.45 ± 19.79, p &lt; 0.05) as compared to patients who did not develop HE.	bilirubin__prothrombin__no_interaction	alanine__prothrombin__no_interaction	aspartate__prothrombin__no_interaction
19026018-6	In Part 1 of this review we discuss the impact of exercise on CVD, and we highlight the effects of exercise on (i) endothelial function by regulation of endothelial genes mediating oxidative metabolism, inflammation, apoptosis, cellular growth and proliferation, increased <protein-id="P00441,V9HWC9">superoxide dismutase (SOD)-1</protein-id>, down-regulation of <protein-id="P19878">p67phox</protein-id>, changes in intracellular <compound-id="22044544,5460341">calcium</compound-id> level, increased vascular endothelial <compound-id="145068">nitric oxide</compound-id> synthase (<protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id>), expression and <protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id> <compound-id="5951">Ser</compound-id>-1177 phosphorylation; (ii) vascular smooth muscle function by either an increased affinity of the Ca2+ extrusion mechanism or an augmented Ca2+ buffering system by the superficial sarcoplasmic reticulum to increase Ca2+ sequestration, increase in K+ channel activity and/or expression, and increase in L-type Ca2+ current density; (iii) antioxidant systems by elevation of Mn-SOD, Cu/Zn-SOD and catalase, increases in <compound-id="124886,20725278,745">glutathione</compound-id> peroxidase activity and activation of vascular <compound-id="5886,929,44415116">nicotinamide adenine dinucleotide phosphate</compound-id> [(<compound-id="5893">NAD</compound-id>(P)H] oxidase and <protein-id="P13498,B4DT46,H3BNP7">p22phox</protein-id> expression; (iv) heat shock protein (HSP) expression by stimulating HSP70 expression in myocardium, skeletal muscle and even in human leucocytes, probably through heat shock transcription factor 1 activity; (v) inflammation by reducing serum inflammatory cytokines such as high-sensitivity C-reactive protein (<protein-id="P02741">hCRP</protein-id>), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin (IL)-6</protein-id>, <protein-id="Q14116,A0A024R3E0">IL-18</protein-id> and tumour necrosis factor-alpha and by regulating <protein-id="O00206">Toll-like receptor 4</protein-id> pathway.	glutathione__IL-18__no_interaction	glutathione__p67phox__no_interaction	glutathione__superoxide dismutase (SOD)-1__no_interaction	glutathione__eNOS__no_interaction	glutathione__Toll-like receptor 4__no_interaction	glutathione__interleukin (IL)-6__no_interaction	glutathione__hCRP__no_interaction	glutathione__p22phox__no_interaction	Ser__IL-18__no_interaction	Ser__p67phox__no_interaction	Ser__superoxide dismutase (SOD)-1__no_interaction	Ser__eNOS__no_interaction	Ser__Toll-like receptor 4__no_interaction	Ser__interleukin (IL)-6__no_interaction	Ser__hCRP__no_interaction	Ser__p22phox__no_interaction	NAD__IL-18__no_interaction	NAD__p67phox__no_interaction	NAD__superoxide dismutase (SOD)-1__no_interaction	NAD__eNOS__no_interaction	NAD__Toll-like receptor 4__no_interaction	NAD__interleukin (IL)-6__no_interaction	NAD__hCRP__no_interaction	NAD__p22phox__no_interaction	nicotinamide adenine dinucleotide phosphate__IL-18__no_interaction	nicotinamide adenine dinucleotide phosphate__p67phox__no_interaction	nicotinamide adenine dinucleotide phosphate__superoxide dismutase (SOD)-1__no_interaction	nicotinamide adenine dinucleotide phosphate__eNOS__no_interaction	nicotinamide adenine dinucleotide phosphate__Toll-like receptor 4__no_interaction	nicotinamide adenine dinucleotide phosphate__interleukin (IL)-6__no_interaction	nicotinamide adenine dinucleotide phosphate__hCRP__no_interaction	nicotinamide adenine dinucleotide phosphate__p22phox__no_interaction	calcium__IL-18__no_interaction	calcium__p67phox__no_interaction	calcium__superoxide dismutase (SOD)-1__no_interaction	calcium__eNOS__no_interaction	calcium__Toll-like receptor 4__no_interaction	calcium__interleukin (IL)-6__no_interaction	calcium__hCRP__no_interaction	calcium__p22phox__no_interaction	nitric oxide__IL-18__no_interaction	nitric oxide__p67phox__no_interaction	nitric oxide__superoxide dismutase (SOD)-1__no_interaction	nitric oxide__eNOS__no_interaction	nitric oxide__Toll-like receptor 4__no_interaction	nitric oxide__interleukin (IL)-6__no_interaction	nitric oxide__hCRP__no_interaction	nitric oxide__p22phox__no_interaction
21942464-1	The reaction of the neutral binuclear complexes [(R(F))(2)Pt(μ-PPh(2))(2)M(phen)] (phen = <compound-id="1318">1,10-phenanthroline</compound-id>, R(F) = C(6)F(5); M = Pt, 1; M = Pd, 2) with AgClO(4) or [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))] affords the trinuclear complexes [AgPt(2)(μ-PPh(2))(2)(R(F))(2)(phen)(<compound-id="5460593">OClO</compound-id>(3))] (7a) or [AgPtM(μ-PPh(2))(2)(R(F))(2)(phen)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))][ClO(4)] (M = Pt, 8; M = Pd, 9), which display an "open-book" type structure and two (7a) or one (8, 9) Pt-Ag bonds.	OClO__PPh(3__no_interaction	1,10-phenanthroline__PPh(3__no_interaction
21942464-3	The dppm Pt-Pt complex 3 reacts with [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))], affording a silver adduct 10 in which the Ag atom interacts with the Pt atoms, while the dppm Pt-Pd complex 4 reacts with [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))], forming a 1:1 mixture of [AgPdPt(μ-PPh(2))(2)(R(F))(2)(<compound-id="5460593">OClO</compound-id>(3))(dppm)] (11), in which the <compound-id="23954">silver atom</compound-id> is connected to the Pt-Pd moiety through Pd-(μ-PPh(2))-Ag and Ag-P(k(1)-dppm) interactions, and [AgPdPt(μ-PPh(2))(2)(R(F))(2)(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)][ClO(4)] (12).	OClO__PPh(3__no_interaction	silver atom__PPh(3__no_interaction
21942464-7	Finally, the oxidation of trinuclear derivatives [(R(F))(2)Pt(II)(μ-PPh(2))(2)Pt(II)(μ-PPh(2))(2)Pt(II)L(2)] (L(2) = phen, 15; L = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), 16) by AgClO(4) results in the formation of the unsaturated 46 <compound-id="2735038">VEC</compound-id> complexes [(R(F))(2)Pt(III)(μ-PPh(2))(2)Pt(III)(μ-PPh(2))(2)Pt(II)L(2)][ClO(4)](2) (17 and 18, respectively) which display Pt(III)-Pt(III) bonds.	VEC__PPh(3__no_interaction
12734394-0	Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(<compound-id="8082">4-piperidinyl</compound-id>)-2-[2-(<compound-id="8082">4-piperidinyl</compound-id>)<compound-id="23134249">ethyl</compound-id>] butanoyl]amino)acetyl]amino]<compound-id="1032">propanoic acid</compound-id> dihydrochloride (CRL42796), in combination with <compound-id="2244">aspirin</compound-id> and/or <compound-id="57199466,772">enoxaparin</compound-id>, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue <protein-id="F1Q421">plasminogen</protein-id> activator.	propanoic acid__plasminogen__no_interaction	aspirin__plasminogen__no_interaction	4-piperidinyl__plasminogen__no_interaction	enoxaparin__plasminogen__no_interaction	ethyl__plasminogen__no_interaction
16366633-2	Absolute values for <compound-id="781">SCN</compound-id>-, N3(-), and <protein-id="P28070">HN3</protein-id> were well-described over the temperature range of 9-81 degrees C by the equations log k5 = (12.03 +/- 0.12) - [(21.05 +/- 0.66 kJ mol(-1))/2.303RT], log <protein-id="P13645">k10</protein-id> = (12.75 +/- 0.21) - [(18.43 +/- 1.22 kJ mol(-1))/2.303RT], and log <protein-id="P19012,B3KVF5">k15</protein-id> = (11.59 +/- 0.12) - [(21.44 +/- 0.69 kJ mol(-1))/2.303RT], corresponding to room temperature (22 degrees C) rate constants of (2.07 +/- 0.03) x 10(8), (3.15 +/- 0.08) x 10(9), and (6.31 +/- 0.05) x 10(7) M(-1) s(-1) and activation energies for these chemicals of 21.05 +/- 0.66, 18.4 +/- 1.2, and 21.44 +/- 0.69 kJ mol(-1), respectively.	SCN__HN3__no_interaction	SCN__k10__no_interaction	SCN__k15__no_interaction
18966803-4	Potential measurements of the Mn(III) Mn(II) system in several azide aqueous buffers solutions: 1.0 x 10(-2) mol 1(-1) HN(3), (0.50-2.0 mol 1(-1)) N(-)(3) and 5.0 x 10(-2) mol 1(-1) Mn(II) and constant ionic strength 2.0 mol 1(-1), kept with <compound-id="522606">sodium perchlorate</compound-id>, leads to the conditional potential, E(0')x, in several azide concentrations at 25.0 +/- 0.1 degrees C. Considering the overall formation constants of Mn(II) N (-)(3), from former studies, and the potential, E(0')s = 1.063 V versus SCE, for Mn(III) Mn(II) system in non-complexing media, it was possible to calculate the Fronaeus function, F(0)(L), and the following overall formation constants: <protein-id="Q16558">beta(1) = 1.2</protein-id> x 10(5) M(-1), <protein-id="Q13562">beta(2) = 6.0</protein-id> x 10(8) M(-2), beta(3) = (2.4 +/- 0.7) x 10(11) M(-3), <protein-id="Q13509,Q53G92">beta(4) = (1.5 +/- 0.5</protein-id>) x 10(11) M(-4) and <protein-id="P04350">beta(5) = (9.6 +/- 0.8</protein-id>) x 10(11) M(-5) for the Mn(III) N (-)(3) complexes.	sodium perchlorate__beta(2) = 6.0__no_interaction	sodium perchlorate__beta(1) = 1.2__no_interaction	sodium perchlorate__beta(4) = (1.5 +/- 0.5__no_interaction	sodium perchlorate__beta(5) = (9.6 +/- 0.8__no_interaction
22150562-3	MATERIAL AND METHODS: SVF4 cells were stimulated with <protein-id="P21274">BMP2</protein-id>, and the following assays were carried out: (i) Wnt/β-catenin pathway activation assessed by western blotting, β-catenin/transcription factor (TCF) reporter assays and expression of the lymphoid enhancer-binding factor-1 (Lef1), transcription factor 7 (Tcf7), Wnt inhibitor factor 1 (Wif1) and Axin2 (Axin2) genes; and (ii) cementoblast/osteoblast differentiation assessed by mineralization in vitro, and by the mRNA levels of runt-related transcription factor 2 (<protein-id="Q08775,Q9Z2T9,F8WHN7,E0CZ12">Runx2</protein-id>), osterix (Osx), alkaline phosphatase (Alp), osteocalcin (<compound-id="3269217">Ocn</compound-id>) and bone sialoprotein (Bsp), determined by quantitative PCR after treatment with wingless-type MMTV integration site family, member <compound-id="2981881,91293124">3A</compound-id> (<protein-id="P27467">WNT3A</protein-id>) and knockdown of β-catenin.	3A__Runx2__no_interaction	3A__WNT3A__no_interaction	3A__BMP2__no_interaction	Ocn__Runx2__no_interaction	Ocn__WNT3A__no_interaction	Ocn__BMP2__no_interaction
15886816-3	We compared the uPA production, the presence of <protein-id="Q03405,M0R1I2">uPAR</protein-id>, AR, <protein-id="P00533">EGFR</protein-id> and <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id> with the chemotaxis and the Matrigel invasion in ten human PCa cell lines and observed that: (1) the levels of <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id>, but not of <protein-id="P00533">EGFR</protein-id>, as well as the uPA secretion, cell motility and Matrigel invasion were statistically higher in AR negative than in AR positive PCa cells; (2) the uPA secretion and uPA Rexpression were positively related to Matrigel invasion; (3) the EGF was able to stimulate chemotaxis and Matrigel invasion in a dose-dependent manner; (4) the EGF-induced cell migration was statistically higher inAR negative than in AR positive cells with a similar increase with respect to basal value (about 2.6 fold); (5) the Matrigel invasion was statistically higher in AR negative than in AR positive PCa cells also if the increment of Matrigel invasion after EGF treatment was statistically higher in AR positive respect to AR negative cells; (6) the EGF induced uPA secretion and its membrane uptake through the increment of <protein-id="Q03405,M0R1I2">uPAR</protein-id>; and (7) these effects were blocked by <protein-id="P00533">EGFR</protein-id>/<protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id> <compound-id="6057,90983769">tyrosine</compound-id> kinase inhibitors with IC(50) lower than those needed to inhibit cell proliferation and required <protein-id="P42336">PI3K</protein-id>/<protein-id="P31749,B0LPE5,B3KVH4">Akt</protein-id>, MAPK and <protein-id="P30101,V9HVY3">PI-PLC</protein-id> activities as verified by inhibition experiments.	tyrosine__PI3K__no_interaction	tyrosine__EGFR__no_interaction	tyrosine__Akt__no_interaction	tyrosine__uPAR__no_interaction	tyrosine__Her2__no_interaction	tyrosine__PI-PLC__no_interaction
2100278-2	Hypergonadotropism [luteinising hormone (LH), 18.7 +/- 7.3 IU/l; follicle-stimulating hormone (<protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>), 6.3 +/- 2.0 IU/l], low serum <compound-id="6013">testosterone</compound-id> (6.1 +/- 2.8 nmol/l), low serum <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex-hormone-binding globulin</protein-id> (<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id>; 13.2 +/- 2.0 nmol/l) and subnormal <compound-id="6013">testosterone</compound-id> response to human chorionic gonadotropin <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>; (30% increase in serum <compound-id="6013">testosterone</compound-id> following <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>) observed during the hypothyroid phase were restored to normal (LH, 7.2 +/- 2.0 IU/l; <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, 2.7 +/- 0.9 IU/l; <compound-id="6013">testosterone</compound-id>, 12.9 +/- 2.7 nmol/l; <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id>, 26.5 +/- 8.4 nmol/l, and 2-fold increase in serum <compound-id="6013">testosterone</compound-id> following <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>) with <compound-id="853">thyroxine</compound-id> substitution therapy.	thyroxine__FSH__no_interaction	thyroxine__SHBG__no_interaction	thyroxine__sex-hormone-binding globulin__no_interaction	thyroxine__hCG__no_interaction	testosterone__FSH__no_interaction	testosterone__SHBG__no_interaction	testosterone__sex-hormone-binding globulin__no_interaction	testosterone__hCG__no_interaction
8719263-3	Head-up tilt made thoracic electrical impedance (3.0 +/- 1.0 omega), mean arterial pressure (MAP, 86 +/- 4-93 +/- 4 mmHg), heart rate (HR, 63 +/- 3-99 +/- 10 beats <protein-id="P13987,Q6FHM9">min-1</protein-id>) and total peripheral resistance (TPR, 15 +/- 1-28 +/- 4 mmHg min L-1) increase, while central venous <compound-id="977">oxygen</compound-id> saturation (74 +/- 2-58 +/- 4%), cardiac output (5.7 +/- 0.1-3.1 +/- 0.3 L <protein-id="P13987,Q6FHM9">min-1</protein-id>), stroke volume (95 +/- 6-41 +/- 5 mL) and pulse pressure (55 +/- 4-49 +/- 4 mmHg) decreased (P &lt; 0.05).	oxygen__min-1__no_interaction
22199269-7	Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (<compound-id="57449,5962,866">lysine</compound-id>) acetyltransferase 5 (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>), <protein-id="Q13547,Q6IT96">HDAC1</protein-id>, <protein-id="O75164">KDM4A</protein-id>, <protein-id="O43463">SUV39H1</protein-id> and <protein-id="O15550,B7ZKN1,E1U0S6,Q59HG3,Q86TD1,B4E0L8,B7ZKN6,B7ZKN5">KDM6A</protein-id>)); <protein-id="Q9UKZ4,B7ZMH4">TNM</protein-id> stage (<protein-id="O43463">SUV39H1</protein-id>, K (<compound-id="57449,5962,866">lysine</compound-id>) acetyltransferase 2B (<protein-id="Q92831">KAT2B</protein-id>), <protein-id="O60341">lysine (K)-specific demethylase 1A</protein-id> (<protein-id="O60341">KDM1A</protein-id>), <protein-id="O75164">KDM4A</protein-id>, <compound-id="57449,5962,866">lysine</compound-id> (K)-specific demethylase 5C (<protein-id="Q9H7Z6">KDM5C), K (lysine) acetyltransferase 8</protein-id> (<protein-id="Q9H7Z6">KAT8</protein-id>), <protein-id="Q9UQL6">HDAC5</protein-id> and <protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>)); Nottingham Prognostic Index (<protein-id="P41229">KDM5C</protein-id>, myeloid/lymphoid or <protein-id="Q03164">mixed-lineage leukemia</protein-id> (<protein-id="Q03164">MLL</protein-id>), <protein-id="Q9H7Z6">KAT8</protein-id> and <protein-id="Q01105,A0A024R895,Q5VXV3,A0A0C4DFV9">SET and MYND domain containing 3</protein-id> (<protein-id="Q9H7B4,B3KN46">SMYD3</protein-id>)); receptor status (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>, <protein-id="Q9H7B4,B3KN46">SMYD3</protein-id> and <protein-id="O60341">KDM1A</protein-id>); histological type (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>, <protein-id="P41229">KDM5C</protein-id>, <protein-id="Q9H7Z6">KAT8</protein-id>, <protein-id="O75164">KDM4A</protein-id> and <protein-id="Q03164">MLL</protein-id>); disease-free survival (<protein-id="O43463">SUV39H1</protein-id>, <protein-id="Q9H7B4,B3KN46">SMYD3</protein-id>, <protein-id="Q9UQL6">HDAC5</protein-id>, <protein-id="O15550,B7ZKN1,E1U0S6,Q59HG3,Q86TD1,B4E0L8,B7ZKN6,B7ZKN5">KDM6A</protein-id>, <protein-id="Q13547,Q6IT96">HDAC1</protein-id>, <protein-id="O60341">KDM1A</protein-id>, <protein-id="O75164">KDM4A</protein-id>, <protein-id="Q9H7Z6">KAT8</protein-id>, <protein-id="P41229">KDM5C</protein-id>, <protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id> and <protein-id="Q03164">MLL</protein-id>) and overall survival (<protein-id="Q9H7Z6">KAT8</protein-id>).	lysine__HDAC1__no_interaction	lysine__KDM1A__no_interaction	lysine__lysine (K)-specific demethylase 1A__no_interaction	lysine__SUV39H1__no_interaction	lysine__KDM5C), K (lysine) acetyltransferase 8__no_interaction	lysine__SMYD3__no_interaction	lysine__KAT5__no_interaction	lysine__MLL__no_interaction	lysine__KAT2B__no_interaction	lysine__mixed-lineage leukemia__no_interaction	lysine__KDM4A__no_interaction	lysine__KDM6A__no_interaction	lysine__SET and MYND domain containing 3__no_interaction	lysine__KAT8__no_interaction	lysine__TNM__no_interaction	lysine__HDAC5__no_interaction	lysine__KDM5C__no_interaction
24029567-7	(3) Applying Logistic regression analysis, type 2 diabetes mellitus (OR = 35.784), essential hypertension (OR = 7.782), familial history of early coronary artery disease (OR = 4.613), <protein-id="Q14746,B1ALW7">low density lipoprotein cholesterol</protein-id> (OR = 2.496), smoking history (OR = 2.241), hemoglobin (OR = 1.042) and serum <compound-id="1175">uric acid</compound-id> (OR = 1.005) are independent risk factors (P &lt; 0.05) for young men with AMI, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (OR = 0.147, P &lt; 0.05) is a protective factor; <protein-id="Q14746,B1ALW7">low density lipoprotein cholesterol</protein-id> (OR = 2.095) and essential hypertension (OR = 1.042) are independent risk factors (P &lt; 0.05) for young men with multiple vessel lesions in AMI, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (OR = 0.071, P &lt; 0.05) is a protective factor.	uric acid__low density lipoprotein cholesterol__no_interaction	cholesterol__low density lipoprotein cholesterol__no_interaction
22329521-9	Only daily intake of <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.304, p = 0.002), duration of sun exposure (r = 0.268, p = 0.009), the level of <protein-id="P01270">PTH</protein-id> (r = -0.459, p &lt; 0.001), daily intake of <compound-id="22044544,5460341">calcium</compound-id> (r = 0.239, p = 0.018) and <protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> of more than 90 ml/min (OR = 1.208, CI 95% = 1.080-1.350, p = 0.033) had a correlation with serum <compound-id="5280795,5283711">vitamin D</compound-id> concentration.	calcium__GFR__no_interaction	calcium__PTH__no_interaction	vitamin D__GFR__no_interaction	vitamin D__PTH__no_interaction
11760372-9	RESULTS: ISH (systolic blood pressure, <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> &gt; or = 140 mmHg and diastolic blood pressure, <protein-id="Q10586">DBP</protein-id> &lt; or = 90 mmHg) incidence increased with age in general (men: 0 per 1,000 person-years at age 20-34 yr, 1.9 at age 35-49, 14.3 at age 50-64, 40.9 at age 65-74, and 73.3 at age 75+ yr; women: 0 per 1,000 person-yr at age 20-34 yr, 3.6 at age 35-49, 17.8 at age 50-64, 64.9 9 at age 65-74, and 33.5 at age 75+ yr), but peak incidence of <compound-id="5288605">IDH</compound-id> (<protein-id="Q10586">DBP</protein-id> &gt; or = 90 mmHg and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> &lt; or = 140 mmHg) occurred between 35 and 49 years (men: 8.9 per 1,000 person-yr at age 20-34 yr, 14.5 at age 35-49, 12.3 at age 50-64, 2.7 at age 65-74, and 0 at age 75+ yr; women: 1.7 per 1,000 person-yr at age 20-34, 4.2 at age 35-49, 3.7 at age 50-64, 0 at age 65-74, and 0 at age 75+ yr).	IDH__DBP__no_interaction	IDH__SBP__no_interaction
7951855-5	The <protein-id="P12004">PCNA</protein-id>-LIs of the <compound-id="11686950,887">methanol</compound-id>-fixed tissues were: normal liver 0.78 +/- 0.38%, chronic persistent hepatitis 1.06 +/- 0.86%, chronic aggressive hepatitis 2A 1.01 +/- 0.50%, chronic aggressive hepatitis 2B 4.20 +/- 1.79%, inactive cirrhosis 0.81 +/- 0.49%, active cirrhosis 1.96 +/- 0.93%, HCC of Edmondson's type I 4.83 +/- 1.98%, type II 6.65 +/- 1.69%, and type III 38.7 +/- 30.6%.	methanol__PCNA__no_interaction
8537340-3	These two significantly different 2Fe2S clusters were characterized with respect to their EPR spectra, electrochemical properties (Rieske-type cluster with gz = 2.025, gy = 1.91, <compound-id="87833">gx</compound-id> = 1.79, <compound-id="10128749">gav</compound-id> = 1.91, Em = -125 +/- 10 mV; <protein-id="Q9I6D2">ferredoxin</protein-id>-type center with gz = 2.05, gy = 1.96, <compound-id="87833">gx</compound-id> = 1.89, <compound-id="10128749">gav</compound-id> = 1.97, Em = -200 +/- 10 mV) and pH dependence thereof.	gav__ferredoxin__no_interaction	gx__ferredoxin__no_interaction
22724673-1	Structural features of <compound-id="783">hydrogen</compound-id> thioperoxide (oxadisulfane, H-S-O-H) and of alkanesulfenic acids (R-S-O-H; R = CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, <protein-id="P10147,A0N0R1">CCl3</protein-id>) and the mechanisms of their dehydrative cyclocondensation to the respective sulfinothioic acid (H-(S═O)-S-H) and alkyl alkanethiosulfinates (R-(S═O)-S-R) have been studied using coupled cluster theory with single and double and perturbative triple excitations [CCSD(T)] and quadratic configuration interaction with single and double and perturbative triple excitations [QCISD(T)] with the cc-pVDZ basis set and also using second-order Møller-Plesset perturbation theory (<protein-id="P02689">MP2</protein-id>) and the hybrid density functionals B3LYP, B3PW91, and PBE1PBE with the 6-311+G(d,p) basis set.	hydrogen__CCl3__no_interaction	hydrogen__MP2__no_interaction
15133757-4	RESULTS: Compared to control islets, freshly prepared type 1 diabetic islets released a significantly higher amount of cytokines (pg/mL) into the culture medium (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>: 112.9 +/- 5.6 vs 75.6 +/- 24.4; INF-gamma: 286.9 +/- 26.9 vs 58.6 +/- 6.2; <protein-id="P22301,Q6FGW4">IL-10</protein-id>: 41.8 +/- 4.3 vs 10.1 +/- 3.2; TGF-1 beta: 294.0 +/- 20.6 vs 45.1 +/- 3.5); had a significantly higher chemotactic index (1.9 +/- 0.2 vs 1.2 +/- 0.1); showed reduced <protein-id="P01308,I3WAC9">insulin</protein-id> release (% of <protein-id="P01308,I3WAC9">insulin</protein-id> content) in response to <compound-id="206,5793,64689,79025">glucose</compound-id> (2.8 +/- 0.7 vs 5.3 +/- 1.9), <compound-id="6322,90867653">arginine</compound-id> (3.0 +/- 0.6 vs 5.6 +/- 1.0), and <compound-id="3488">glibenclamide</compound-id> (2.9 +/- 0.7 vs 5.4 +/- 0.9); and exhibited decreased <compound-id="206,5793,64689,79025">glucose</compound-id> oxidation capability and diminished mRNA expression of <protein-id="P35557,Q53Y25">glucokinase</protein-id>, aldolase, <compound-id="1060">pyruvate</compound-id> kinase, and mitochondrial glycerolphosphate dehydrogenase.	glibenclamide__TNF-alpha__no_interaction	glibenclamide__glucokinase__no_interaction	glibenclamide__insulin__no_interaction	glibenclamide__IL-10__no_interaction	pyruvate__TNF-alpha__no_interaction	pyruvate__glucokinase__no_interaction	pyruvate__insulin__no_interaction	pyruvate__IL-10__no_interaction	arginine__TNF-alpha__no_interaction	arginine__glucokinase__no_interaction	arginine__insulin__no_interaction	arginine__IL-10__no_interaction	glucose__TNF-alpha__no_interaction	glucose__glucokinase__no_interaction	glucose__insulin__no_interaction	glucose__IL-10__no_interaction
20677555-4	METHODS: Firstly, six different cell culture medium which contained YTMLC Gejiu human lung squamous carcinoma cell, <protein-id="P98194,B4E2Q0,B4E295">SPC-A1</protein-id> human lung adenocarcinoma cell, AGZY low metastatic human lung adenocarcinoma, 973 high metastatic human lung adenocarcinoma cell, <compound-id="3034742,57288387,6971003">GLC</compound-id>-82 Gejiu human lung adenocarcinoma cell, and KMB17 human embryonic lung diploid fibroblast, respectively with equal cell density of 1 x 10(6)/mL and the same volume were prepared; secondly, the same radioactive dose of <compound-id="26476">99Tc</compound-id>(m) -N(<compound-id="9934363">NOEt</compound-id>)2 was added into each sample and then 300 microL mixed sample was taken out respectively and cultured in 37 degrees C culture box; Finally, 5 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min after cultivation, centrifuged each cultured sample and determined the intracellular radiocounts of each sample, calculated each cell sample's uptake rate of <compound-id="26476">99Tc</compound-id>(m) -N(<compound-id="9934363">NOEt</compound-id>)2 at different time.	99Tc__SPC-A1__no_interaction	GLC__SPC-A1__no_interaction	NOEt__SPC-A1__no_interaction
19787913-8	The equilibrium constant of the trapping reaction Al(Ti)x = Al(Ti)' + h* is evaluated as Ka = 1.9 x 10(23) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-1.04 eV/kT) cm(-3) and the mobility of trapped holes (Al(Ti)x) as u(x) approximately = 720 <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-1.04 eV/kT) cm2 V(-1) s(-1) as the upper bound while those of free electrons and holes as un = 0.044 + 0.010 cm2 V(-1) s(-1) and up approximately = 0.024 +/- 0.007 cm2 V(-1) s(-1), respectively, in the temperature range of 800 degrees C to 1100 degres C. The effect of hole-trapping on DC conductivity, chemical diffusivity and <compound-id="977">oxygen</compound-id> nonstoichiometry is exhaustively analyzed and further experiments are proposed that allow one to determine the trapping energy of acceptor impurities.	oxygen__exp__no_interaction
15366433-8	In patients with advanced heart failure and reduced pre-load reserve (LVEDP &gt; 16 mm Hg, n = 18), <protein-id="Q9NPH2">iNOS</protein-id> protein and nitrotyrosine formation correlated positively with LVSW/<compound-id="92304">EDP</compound-id> (r = 0.65, p = 0.03 and r = 0.64, p = 0.04, respectively), DT (r = 0.96, p &lt; 0.01 and r = 0.88, p &lt; 0.01, respectively) and inversely with E/A (r = -0.82, p &lt; 0.01 and r = -0.88, p &lt; 0.01, respectively).	EDP__iNOS__no_interaction
12793810-1	The two flexible multidentate ligands 1,3-<protein-id="O95817">bis</protein-id>(8-thioquinolyl)<compound-id="6334">propane</compound-id> (C3TQ) and 1,4-<protein-id="O95817">bis</protein-id>(8-thioquinolyl)<compound-id="7843">butane</compound-id> (C4TQ) were reacted with <protein-id="Q16222">AgX</protein-id> (X = CF(3)SO(3)(-) or ClO(4)(-)) to give four new complexes: ([Ag(C3TQ)](ClO(4)))(n)() 1, ([Ag(C3TQ)](CF(3)SO(3)))(n)() 2, ([Ag(2)(C4TQ)(CF(3)SO(3))(CH(3)CN)](CF(3)SO(3)))(n)() 3, and ([Ag(C4TQ)](ClO(4)))(n)() 4.	propane__bis__no_interaction	propane__AgX__no_interaction	butane__bis__no_interaction	butane__AgX__no_interaction
3079759-1	Equilibrium constants for reactions catalyzed by <protein-id="Q3MIF0,A0A0G2JW38">ribulose-5-phosphate 3-epimerase</protein-id>, [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P]/[sigma <compound-id="439184">ribulose-5-P</compound-id>] = 1.82, <protein-id="D4A7L6">ribose-5-phosphate isomerase</protein-id>, [sigma Rib-5-P]/[sigma <compound-id="439184">ribulose-5-P</compound-id>] = 1.20, <protein-id="Q9EQS0">transaldolase</protein-id>, [sigma <compound-id="122357">erythrose-4-P</compound-id>] [sigma <compound-id="69507">Fru-6-P</compound-id>]/[sigma <compound-id="165007">sedoheptulose-7-P</compound-id>] [sigma glyceraldehyde 3-P] = 0.37, and transketolase, [sigma <compound-id="69507">Fru-6-P</compound-id>] [sigma glyceraldehyde 3-P]/[sigma <compound-id="122357">erythrose-4-P</compound-id>] [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P] = 29.7 and [sigma Rib-5-P] [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P]/[sigma <compound-id="165007">sedoheptulose-7-P</compound-id>] [sigma glyceraldehyde 3-P] = 0.48, were redetermined under physiological conditions.	Fru-6-P__ribulose-5-phosphate 3-epimerase__no_interaction	Fru-6-P__transaldolase__no_interaction	Fru-6-P__ribose-5-phosphate isomerase__no_interaction	erythrose-4-P__ribulose-5-phosphate 3-epimerase__no_interaction	erythrose-4-P__transaldolase__no_interaction	erythrose-4-P__ribose-5-phosphate isomerase__no_interaction	xylulose__ribulose-5-phosphate 3-epimerase__no_interaction	xylulose__transaldolase__no_interaction	xylulose__ribose-5-phosphate isomerase__no_interaction	sedoheptulose-7-P__ribulose-5-phosphate 3-epimerase__no_interaction	sedoheptulose-7-P__transaldolase__no_interaction	sedoheptulose-7-P__ribose-5-phosphate isomerase__no_interaction	ribulose-5-P__ribulose-5-phosphate 3-epimerase__no_interaction	ribulose-5-P__transaldolase__no_interaction	ribulose-5-P__ribose-5-phosphate isomerase__no_interaction
12470401-10	The peak level of CK-MB correlated with donor age (r = 0.48, p = 0.02) and implantation time (r = 0.53, p = 0.02); and with recipient plasma <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.56, p = 0.02), allograft <compound-id="977">oxygen</compound-id> extraction (r = 0.56, p = 0.02), <compound-id="612">lactate</compound-id> release (r = 0.47, p = 0.02) and allograft arterial-coronary sinus (cs) pH (r = 0.47, p = 0.02) all during final cardioplegia before reperfusion.	oxygen__IL-6__no_interaction	lactate__IL-6__no_interaction
15543339-6	<compound-id="4552">NS1619</compound-id> significantly increased <compound-id="24316">cGMP</compound-id> levels which was inhibited by LNMMA, <compound-id="16132435">iberiotoxin</compound-id>, <compound-id="104751">BAPTA</compound-id>, 2-<protein-id="Q9H4A4">APB</protein-id>, reduction of extracellular Ca(2+), PD 98059, or <compound-id="3006531,5354033,9951825">U0126</compound-id> (<compound-id="24316">cGMP</compound-id> (pmol/mg protein): <compound-id="4552">NS1619</compound-id> 3.25 +/- 0.85; <compound-id="4552">NS1619</compound-id> + <compound-id="132862">L-NMMA</compound-id> 0.86 +/- 0.02; <compound-id="4552">NS1619</compound-id> + <compound-id="16132435">iberiotoxin</compound-id> 0.99 +/- 0.09; <compound-id="4552">NS1619</compound-id> + <compound-id="104751">BAPTA</compound-id> 0.93 +/- 0.29; <compound-id="4552">NS1619</compound-id> + 2-<protein-id="Q9H4A4">APB</protein-id> 0.99 +/- 0.31; <compound-id="4552">NS1619</compound-id> + Ca(2+)-reduction 1.17 +/- 0.06; <compound-id="4552">NS1619</compound-id> + <compound-id="4713">PD98059</compound-id> 1.06 +/- 0.49; <compound-id="4552">NS1619</compound-id> + <compound-id="3006531,5354033,9951825">U0126</compound-id> 1.10 +/- 0.24; n=10; p&lt;0.05).	PD98059__APB__no_interaction	cGMP__APB__no_interaction	U0126__APB__no_interaction	NS1619__APB__no_interaction	BAPTA__APB__no_interaction	L-NMMA__APB__no_interaction	iberiotoxin__APB__no_interaction
19149935-7	The levels of endotoxin (0.37 +/- 0.07 EU/mL), <protein-id="P20607">IL-6</protein-id> (289 +/- 49 ng/L) and <protein-id="P16599">TNF-alpha (1.87</protein-id> +/- 0.32 microg/L) as well as the expression of <protein-id="Q63691">CD14</protein-id> mRNA (0.39 +/- 0.05), TNF-alpha mRNA (0.47 +/- 0.03) in <compound-id="6540261">EIN</compound-id> + rhGH group were also obviously lower than those [(0.48 +/- 0.08) EU/mL, (364 +/- 53) ng/L, (2.50 +/- 0.48) microg/L, 0.67 +/- 0.06, 0.66 +/- 0.05, P &lt; 0.05 or P &lt; 0.01, respectively] in <compound-id="6540261">EIN</compound-id> group on 10 PSD (P &lt; 0.05 or P &lt; 0.01).	EIN__IL-6__no_interaction	EIN__CD14__no_interaction	EIN__TNF-alpha (1.87__no_interaction
19198542-3	The <compound-id="162282">polylysine</compound-id> homodendrimers of the third [(NH2)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2] (I), fourth [(NH2)32(<compound-id="5962">Lys</compound-id>)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2 (II) and fifth [(NH2)64(<compound-id="5962">Lys</compound-id>)32(<compound-id="5962">Lys</compound-id>)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2] (III) generations and the <compound-id="162282">polylysine</compound-id> homodendrimers of fifth generation--[(NH2)64(<compound-id="7010502">Lys-Glu</compound-id>)32(<compound-id="7010502">Lys-Glu</compound-id>)16(<compound-id="7010502">Lys-Glu</compound-id>)8(<compound-id="7010502">Lys-Glu</compound-id>)4(<compound-id="7010502">Lys-Glu</compound-id>)2Lys-Ala-<compound-id="7016106">Ala-Lys</compound-id> (<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-NH2] (IV), [(NH2)64(<compound-id="45122324,7010504">Lys-Ala</compound-id>)32(<compound-id="45122324,7010504">Lys-Ala</compound-id>)16(<compound-id="45122324,7010504">Lys-Ala</compound-id>)8(<compound-id="45122324,7010504">Lys-Ala</compound-id>)4(<compound-id="45122324,7010504">Lys-Ala</compound-id>)2Lys-<compound-id="7016106">Ala-Lys</compound-id>(<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-Ala-NH2] (V) and [(NH2)64(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)32(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)16(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)8(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)4(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)2 <compound-id="259320,7022320">Lys-Gly</compound-id>-<compound-id="3080576">Gly-Lys</compound-id>(<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-Ala-NH2] (VI) showed receptor-independent mechanism of heterotrimeric G-proteins activity, preferably of inhibitory type, interacting with C-terminal regions of their alpha-subunits.	Ala-Lys__ClAc__no_interaction	Lys__ClAc__no_interaction	polylysine__ClAc__no_interaction	Lys-Glu__ClAc__no_interaction	Gly-Lys__ClAc__no_interaction	Lys-Ala__ClAc__no_interaction	Lys-Gly__ClAc__no_interaction
12168501-3	First, macrophages were incubated with or without <compound-id="6326983">CSE</compound-id>, and the supernatants collected at different time points were used to measure the levels of <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) and sICAM-1 by enzyme-linked immunosorbent assay (ELISA); and second, HUVEC were cultured with <compound-id="6326983">CSE</compound-id>, a vehicle, or ANA-1 supernatants (collected at different time points) and the sICAM-1 levels in the supernatants were measured by ELISA at 24 h. The results showed that: i) <compound-id="6326983">CSE</compound-id> showed no effect on the production of sICAM-1 by HUVEC; ii) sICAM-1, in unstimulated or <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants collected at different time points, was under the detectable level; iii) <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants collected at 3 or 6 h showed no effect on sICAM-1 production in HUVEC, while those collected at 12 and 24 h significantly increased sICAM-1 production (p &lt; 0.02 and p &lt; 0.005, respectively); iv) no significant difference in <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> levels was detected between unstimulated and <compound-id="6326983">CSE</compound-id>-stimulated macrophage supernatants collected at 3 and 6 h, however, higher levels of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> were found in <compound-id="6326983">CSE</compound-id>-stimulated supernatants collected at 12 and 24 h (p &lt; 0.05 and p &lt; 0.002, respectively); and v) a significant correlation (r = 0.9693, p &lt; 0.001) was found between the levels of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> in <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants and those of related sICAM-1 production in HUVEC.	CSE__tumor necrosis factor-alpha__no_interaction	CSE__TNF-alpha__no_interaction
15655267-4	Plasma <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were correlated negatively with body mass index, triglyceride, total <compound-id="5997">cholesterol</compound-id>, hemoglobin A1c, and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> levels (r = -0.456, P &lt; 0.0001; r = -0.355, P &lt; 0.0001; r = -0.286, P = 0.002; r = -0.299, P &lt; 0.0001; r = -0.400, P &lt; 0.0001, respectively), but were not significantly correlated with high sensitivity <protein-id="P02741">C-reactive protein</protein-id> or low density lipoprotein levels (r = -0.088, P = 0.352; r = -0.167, P = 0.077, respectively).	cholesterol__C-reactive protein__no_interaction	cholesterol__fibrinogen__no_interaction	cholesterol__adiponectin__no_interaction
17605139-1	The major objective of this work was to explore the quantitative structure-activity relationship (QSAR) of hydroxyl-substituent Schiff bases in protecting human erythrocytes against <compound-id="10176833,10198824,122970,13864694,13955041,14048842,142347,14592126,15724735,17782191,179514,18332075,206038,21225683,21394077,21394085,21917678,21917682,21917686,432073,22149489,22326016,22418667,22450834,280938,53746083,53852030,6453657,67354174,85872172,88201,90752878,90813009,91537,93079,9794905,98836">2,2'-azobis</compound-id>(2-<compound-id="18182">amidinopropane</compound-id> hydrochloride) (AAPH)- induced hemolysis, in which 10 Schiff bases including <compound-id="5355326">4-phenyliminomethylphenol</compound-id> (PIH); <compound-id="5338977">4-((4-hydroxybenzylidene) amino)phenol</compound-id> (<compound-id="2148">PAH</compound-id>); <compound-id="6744469">2-methoxy-4-((4-hydroxyphenylimino)methyl)phenol</compound-id> (<compound-id="445008">PMH</compound-id>); 4-((furan-2-ylmethylene)amino) <compound-id="996">phenol</compound-id> (FAH); 4-((4-N,N-dimethylaminobenzylidene)amino)<compound-id="996">phenol</compound-id> (<protein-id="Q9P0J1,Q6P1N1,A0A024R9C0">PDH</protein-id>); 2-((4-N,N-dimethylaminobenzylidene)amino) <compound-id="996">phenol</compound-id> (<compound-id="2978966">ODH</compound-id>); <compound-id="6739368">2-(naphthalene-1-yliminomethyl)phenol</compound-id> (NAH); <compound-id="6738088">2-(benzyliminomethyl)phenol</compound-id> (BPH); <compound-id="5383316">1,4-di((2-hydroxyphenylimino) methyl)benzene</compound-id> (DOH); <compound-id="5383317">1,4-di((4-hydroxyphenylimino)methyl)benzene</compound-id> DPH, were available for this in vitro experimental system.	2-methoxy-4-((4-hydroxyphenylimino)methyl)phenol__PDH__no_interaction	4-((4-hydroxybenzylidene) amino)phenol__PDH__no_interaction	1,4-di((4-hydroxyphenylimino)methyl)benzene__PDH__no_interaction	2,2'-azobis__PDH__no_interaction	ODH__PDH__no_interaction	PAH__PDH__no_interaction	2-(naphthalene-1-yliminomethyl)phenol__PDH__no_interaction	2-(benzyliminomethyl)phenol__PDH__no_interaction	phenol__PDH__no_interaction	4-phenyliminomethylphenol__PDH__no_interaction	amidinopropane__PDH__no_interaction	1,4-di((2-hydroxyphenylimino) methyl)benzene__PDH__no_interaction	PMH__PDH__no_interaction
16388798-1	We investigated the effect of acidic pH, a condition that can be encountered during inflammation accompanying allergic reaction, on the binding properties of <compound-id="774">histamine</compound-id> H1 receptor antagonists, including levocetirizine ((2-(4-[(R)-(4-chlorophenyl)(phenyl)methyl]<compound-id="91216341">piperazin-1-yl</compound-id>)ethoxy)acetic acid; <compound-id="1549000">Xyzal</compound-id> ), fexofenadine (<protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl) <compound-id="8082">piperidin</compound-id>-1-yl]<compound-id="68006705">butyl</compound-id>]phenyl]-<compound-id="6590">2-methylpropionic acid</compound-id> hydrochloride; <compound-id="3348">Allegra</compound-id>) and <compound-id="124087">desloratadine</compound-id> (8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]<compound-id="9265">cyclohepta</compound-id>[1,2-b]pyridine; Clarinex ).	Allegra__rac-2__no_interaction	piperazin-1-yl__rac-2__no_interaction	Xyzal__rac-2__no_interaction	2-methylpropionic acid__rac-2__no_interaction	piperidin__rac-2__no_interaction	desloratadine__rac-2__no_interaction	butyl__rac-2__no_interaction	cyclohepta__rac-2__no_interaction	histamine__rac-2__no_interaction
14720373-6	RESULTS: (1) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP and prolongation of culture time, the morphology of HepG2 cells was changed from spindle shape to round; the ability of HepG2 cells adhering to wall were decreased; the ability of HepG2 cells in suspension were increased; and debris emitted around the cells; (2) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP, DNA ladder occurred; (3) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP and prolongation of culture time, the nuclei of HepG2 cells showed chromatin pyknosis, and clustered on the inner border of karyotheca, condensed cytoplasm with many vacuoles; (4) The <compound-id="64966">MTT</compound-id> values of HepG2 cells were decreased with the increasing concentration of <protein-id="P05109">cagA</protein-id>(+) HP (P&lt; 0.01); (5)The values of <compound-id="5950">alanine</compound-id> aminotransferase (ALT) and <compound-id="612">lactate</compound-id> dehydrogenase (LDH) in coculture supernatants of <protein-id="P05109">cagA</protein-id> (+) Hp and HepG2 were increased (P&lt; 0.01); (6) No influence of <protein-id="P05109">cagA</protein-id> (-) Hp on HepG2 was found.	alanine__cagA__no_interaction	MTT__cagA__no_interaction	lactate__cagA__no_interaction
7559427-7	Their structures were determined by chemical and enzymatic analyses and 1H NMR spectroscopy and found to be the following octa- and decasaccharide sequences attached to <compound-id="5951">Ser</compound-id> in a molar ratio of 1.1:2.3:1.0:1.3: delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1-4GlcN(NS,6S)alpha 1-4GlcA beta 1-4GlcNAc alpha 1-4- <compound-id="94715">GlcA</compound-id> beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (I), delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1- 4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc alpha 1-4GlcA beta 1- 3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (II), delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1- 4GlcN(NS,6S)alpha 1- 4IdoA alpha 1-4GlcNAc alpha 1-4GlcA beta 1-4GlcNAc-alpha 1- 4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (III), delta <protein-id="B1PK15">HexA</protein-id> alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc(6S)alpha 1- 4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (IV) (delta <protein-id="B1PK15">HexA</protein-id>, <compound-id="94715">GlcA</compound-id>, <compound-id="446102">IdoA</compound-id>, and GlcN represent 4,5-unsaturated <compound-id="50">hexuronic acid</compound-id>, D-glucuronic acid, <compound-id="441039,7140380">L-iduronic acid</compound-id>, and <compound-id="441477">D-glucosamine</compound-id>, whereas 2S, 6S, and NS stand for 2-<compound-id="1117">sulfate</compound-id>, 6-<compound-id="1117">sulfate</compound-id>, and N-<compound-id="1117">sulfate</compound-id>, respectively).	Ser__HexA__no_interaction	sulfate__HexA__no_interaction	D-glucosamine__HexA__no_interaction	IdoA__HexA__no_interaction	L-iduronic acid__HexA__no_interaction	hexuronic acid__HexA__no_interaction	GlcA__HexA__no_interaction
24301038-4	METHODS: The following immunological features were studied to understand how Candida induces immune responses in healthy subjects: (1) proliferative capacity of T-cells upon exposure to Candida through monocyte-derived human Langerhans cells (LCs) measured using alamarBlue, (2) cytokine (IL-1β, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>, <protein-id="P22301,Q6FGW4">IL-10</protein-id>, IL-12p40, IL-23Ap19, IFN-γ, and TNF- expression upon Candida stimulation of LCs by quantitative reverse transcription (qRT)-PCR and cytokine secretion by ELISA, (3) expression of pattern recognition receptors (PRRs) known to associate with Candida albicans (DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, <compound-id="18950,206">mannose</compound-id> receptor, Toll-like receptors 1, 2, 4, 6, and 9) on LCs by qRT-PCR, (4) role of dectin-1 in IL-12 production by antibody blocking, and (5) induction of Th1, Th2, and/or Th17 responses by intracellular cytokine staining of CD4 cells exposed to Candida pulsed LCs for IFN-γ, IL-4, and IL-17A.	mannose__IL-6__no_interaction	mannose__IL-8__no_interaction	mannose__IL-10__no_interaction
11246868-8	Compared with patients undergoing KA transplantation, patients undergoing KP transplantation showed lower values for HbA1c (KP = 6.2 +/- 0.1% vs. KA = 8.4 +/- 0.5%; P &lt; 0.01), fasting <compound-id="778,91552">homocysteine</compound-id> (KP = 14.0 +/- 0.7 mcromol/l vs. KA = 19.0 +/- 2.0 micromol/l; P = 0.02), <protein-id="P04275">von Willebrand factor</protein-id> levels (KP = 157.9 +/- 8.6% vs. KA = 212.5 +/- 16.2%; P &lt; 0.01), D-dimer fragments (KP = 0.29 +/- 0.02 microg/ml vs. KA = 0.73 +/- 0.11 microg/ml;P &lt; 0.01), fibrinogen (KP = 363.0 +/- 11.1 mg/dl vs. KA = 397.6 +/- 19.4 mg/dl; NS), triglycerides (KP = 122.7 +/- 8.6 mg/dl vs. KA = 187.0 +/- 30.1 mg/dl; P = 0.01), and urinary albumin excretion rate (KP = 13.5 +/- 1.9 mg/24 h vs. KA = 57.3 +/- 26.3 mg/24 h; P &lt; 0.01).	homocysteine__von Willebrand factor__no_interaction
19023279-5	In multivariate models including age, gender, and waist circumference, there were inverse correlations between changes in <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> and <protein-id="P19320">vascular cell adhesion molecule-1</protein-id> (<protein-id="P19320">VCAM-1</protein-id>) (r = -0.54, P &lt; 0.0001) and <protein-id="P05362">intercellular adhesion molecule-1</protein-id> (<protein-id="P05362">ICAM-1</protein-id>) (r = -0.57, P &lt; 0.0001), and <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = -0.40, P = 0.0041); <compound-id="11970143">lipopolysaccharide</compound-id> (LPS)-stimulated production of <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (r = -0.30, P = 0.035), <protein-id="P01584">interleukin (IL)-1beta</protein-id> (r = -0.44, P = 0.0016), <protein-id="P13500">monocyte chemotactic protein-1</protein-id> (<protein-id="P13500">MCP-1</protein-id>) (r = -0.46, P = 0.001), and <protein-id="P10147,A0N0R1">macrophage inflammatory protein-1alpha</protein-id> (<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id>) (r = -0.45, P = 0.0012).	lipopolysaccharide__macrophage inflammatory protein-1alpha__no_interaction	lipopolysaccharide__CRP__no_interaction	lipopolysaccharide__interleukin (IL)-1beta__no_interaction	lipopolysaccharide__tumor necrosis factor-alpha__no_interaction	lipopolysaccharide__MIP-1alpha__no_interaction	lipopolysaccharide__adiponectin__no_interaction	lipopolysaccharide__intercellular adhesion molecule-1__no_interaction	lipopolysaccharide__vascular cell adhesion molecule-1__no_interaction	lipopolysaccharide__C-reactive protein__no_interaction	lipopolysaccharide__VCAM-1__no_interaction	lipopolysaccharide__ICAM-1__no_interaction	lipopolysaccharide__monocyte chemotactic protein-1__no_interaction	lipopolysaccharide__TNF-alpha__no_interaction	lipopolysaccharide__MCP-1__no_interaction
24084430-5	<compound-id="53443082">MTSEA</compound-id> treatment resulted in a significant reduction in the binding of (125)I-<protein-id="O95399,A0AVP6">UII</protein-id> to <protein-id="P06753,A0A087WWU8,J3KN67,B4DQ80">TM3</protein-id> mutants L126C((3.28)), F127C((3.29)), F131C((3.33)) and M134C((3.36)) and TM4 mutants M184C((4.60)) and I188C((4.64)).	MTSEA__UII__no_interaction	MTSEA__TM3__no_interaction
11352071-6	Patients with generalized arteriosclerosis had higher plasma <protein-id="P02675,V9HVY1">fibrinogen</protein-id> concentrations than did those suffering from <compound-id="221493">CHD</compound-id> only (for men, control 2.65 +/- 0.51, <compound-id="221493">CHD</compound-id> 3.07 +/- 0.73, <compound-id="221493">CHD</compound-id> plus POAD 3.17 +/- 0.77 and <compound-id="221493">CHD</compound-id> plus POAD plus CVD 3.45 +/- 0.78 g/l; for women, control 2.69 +/- 0.44, <compound-id="221493">CHD</compound-id> 3.25 +/- 0.67, <compound-id="221493">CHD</compound-id> plus POAD 3.19 +/- 0.77, <compound-id="221493">CHD</compound-id> plus POAD plus CVD 3.60 +/- 0.84 g/l).	CHD__fibrinogen__no_interaction
22225958-5	The serum <protein-id="P55008,Q4V347,I3WTX1">AIF-1</protein-id> concentrations positively correlated with levels of fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.159, P =.0056), hemoglobin A(1c) (r = 0.169, P = .0032), triglycerides (r = 0.137, P = .0172), and <compound-id="1175">uric acid</compound-id> (r = 0.146, P = .0108) and with waist circumference (r = 0.221, P = .0001) and body mass index (r = 0.185, P = .0012), whereas the serum <protein-id="P55008,Q4V347,I3WTX1">AIF-1</protein-id> concentrations inversely correlated with high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level (r = -0.178, P = .0019).	cholesterol__AIF-1__no_interaction	uric acid__AIF-1__no_interaction	glucose__AIF-1__no_interaction
1889145-6	RESULTS: In the obese group an impaired <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> response to hypoglycaemia (mean area under the curve obese 54 U/l min, controls 155 U/l min; P = 0.0001) was inversely correlated to fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, r2 = 0.142, P = 0.03; relative <protein-id="P01308,I3WAC9">insulin</protein-id> resistance, r2 = 0.134, P = 0.03 and steady-state plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level, r2 = 0.345, P = 0.0004 whereas the impaired GH response (mean GH area under the curve obese 1.9 U/l min, controls 65.7 U/l min; P = 0.0001) was inversely correlated to steady-state plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level, r2 = 0.196, P = 0.01.	glucose__prolactin__no_interaction	glucose__insulin__no_interaction
8960832-7	<protein-id="P00450,A5PL27">CPII</protein-id> for 12 months resulted in: a slight and transient improvement in HbA1c (Time (T)0: 7.6 +/- 0.2%, <compound-id="5920">T3</compound-id>: 7.1 +/- 0.2%, T12: 7.5 +/- 0.2%, p &lt; 0.02), improvement in GHBP (T0: 10.2 +/- 0.8%, T12: 15.5 +/- 1.5, p &lt; 0.0001), near-normalization of <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> (T0: 89.4 +/- 8.8 ng/ml, T12: 146.9 +/- 15.6, p &lt; 0.002) and normalization of <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> (T0: 1974 +/- 121 ng/ml, T12: 3534 +/- 305, p &lt; 0.0001).	T3__CPII__no_interaction	T3__IGF-I__no_interaction	T3__IGFBP-3__no_interaction
8656502-9	RESULTS: Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued <compound-id="35370">zidovudine</compound-id> monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs -0.02 x 10(9)/L, respectively; P &lt; .001); log10 HIV-1 RNA as measured by the Roche assay (-0.96 vs -0.77 vs +0.07 copies/mL, respectively; P &lt; .001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0.59 vs -1.06 vs -0.02 copies/mL, respectively; P &lt; .011); and immune-complex dissociated (ICD) <protein-id="Q15363,Q6FHT8">p24</protein-id> antigen (-74% vs -68% vs +27%, respectively; P &lt; .001).	zidovudine__p24__no_interaction
8933293-3	The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (<protein-id="Q63118">ClR</protein-id>: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and <protein-id="Q63118">ClR</protein-id> (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of <compound-id="114759">DA-125</compound-id>.	DA-125__ClR__no_interaction
3383840-1	Eleven mutagenic heterocyclic amines, 3-amino-1,4-dimethyl-<compound-id="13347754">5H-pyrido</compound-id>[4,3-b]-<compound-id="798">indole</compound-id> (<compound-id="5284474">Trp-P-1</compound-id>), 3-amino-1-methyl-<compound-id="13347754">5H-pyrido</compound-id>[4,3]<compound-id="798">indole</compound-id> (<protein-id="O35245">Trp-P-2</protein-id>), 2-amino-6-methyl-dipyrido[1,2-a:3',2'-d]<compound-id="795">imidazole</compound-id> (<compound-id="49971">Glu-P-1</compound-id>), 2-aminodipyrido[1,2-a:3',2'-d]<compound-id="795">imidazole</compound-id> (Glu-P-2), <compound-id="62805">2-amino-9H-pyrido[2,3-b]indole</compound-id> (A alpha C), 2-amino-<compound-id="12596583">3-methyl-9H-pyrido[2,3-b]indole</compound-id> (MeA alpha C), <compound-id="53462">2-amino-3-methylimidazo[4,5-f]quinoline</compound-id> (IQ), 2-amino-<compound-id="151879">3,4-dimethylimidazo[4,5-f]quinoline</compound-id> (MeIQ), 2-amino-3,8-<compound-id="70259">dimethylimidazo</compound-id> [4,5-f]<compound-id="7047">quinoline</compound-id> (<compound-id="62275">MeIQX</compound-id>), 2-amino-3,4,8-<compound-id="69976">trimethylimidazo</compound-id>[4,5-f]<compound-id="7045">quinoxaline</compound-id> (4,8-diMeIQX), and <compound-id="104855">2-amino-3,7,8-trimethylimidazo[4,5-f]quinoxaline</compound-id> (7,8-diMeIQX), were studied for genotoxicity in the hepatocyte/DNA repair test employing hepatocytes of male rats, male and female mice, and male hamsters.	Glu-P-1__Trp-P-2__no_interaction	indole__Trp-P-2__no_interaction	quinoxaline__Trp-P-2__no_interaction	2-amino-9H-pyrido[2,3-b]indole__Trp-P-2__no_interaction	MeIQX__Trp-P-2__no_interaction	3-methyl-9H-pyrido[2,3-b]indole__Trp-P-2__no_interaction	dimethylimidazo__Trp-P-2__no_interaction	trimethylimidazo__Trp-P-2__no_interaction	2-amino-3-methylimidazo[4,5-f]quinoline__Trp-P-2__no_interaction	5H-pyrido__Trp-P-2__no_interaction	Trp-P-1__Trp-P-2__no_interaction	3,4-dimethylimidazo[4,5-f]quinoline__Trp-P-2__no_interaction	2-amino-3,7,8-trimethylimidazo[4,5-f]quinoxaline__Trp-P-2__no_interaction	quinoline__Trp-P-2__no_interaction	imidazole__Trp-P-2__no_interaction
8314584-4	By isozyme analysis and Southern hybridization, <protein-id="Q29443">transferrin</protein-id> (TF) and <protein-id="P00442">superoxide dismutase 1</protein-id> (<protein-id="P00442">SOD1</protein-id>), both in the bovine syntenic group U10, were assigned to sheep chromosome 1q; <protein-id="C5IJA8">adenylate kinase 1</protein-id> (<protein-id="C5IJA8">AK1</protein-id>), in the bovine syntenic group <compound-id="6914648">U16</compound-id>, to sheep chromosome 3p; <compound-id="612">lactate</compound-id> dehydrogenase B (LDHB) and <protein-id="W5Q2V2">phenylalanine hydroxylase</protein-id> (<protein-id="W5Q2V2">PAH</protein-id>) on bovine chromosome 5 (BTA5) to sheep chromosome 3q; phosphoglucomutase 2 (PGM2) (bovine syntenic group 15) to sheep chromosome 6 (<compound-id="56955962">t1q</compound-id>); avian myelocytomatosis viral oncogene homolog (MYC) and Moloney murine sarcoma viral oncogene homolog (MOS) (BTA 14) to sheep 9 (t2q); and <compound-id="124886,20725278,745">glutathione</compound-id> reductase (GSR) (bovine syntenic group U14) to sheep 24 (<compound-id="657023">t1p</compound-id>).	glutathione__SOD1__no_interaction	glutathione__AK1__no_interaction	glutathione__transferrin__no_interaction	glutathione__superoxide dismutase 1__no_interaction	glutathione__adenylate kinase 1__no_interaction	glutathione__phenylalanine hydroxylase__no_interaction	glutathione__PAH__no_interaction	lactate__SOD1__no_interaction	lactate__AK1__no_interaction	lactate__transferrin__no_interaction	lactate__superoxide dismutase 1__no_interaction	lactate__adenylate kinase 1__no_interaction	lactate__phenylalanine hydroxylase__no_interaction	lactate__PAH__no_interaction	t1p__SOD1__no_interaction	t1p__AK1__no_interaction	t1p__transferrin__no_interaction	t1p__superoxide dismutase 1__no_interaction	t1p__adenylate kinase 1__no_interaction	t1p__phenylalanine hydroxylase__no_interaction	t1p__PAH__no_interaction	t1q__SOD1__no_interaction	t1q__AK1__no_interaction	t1q__transferrin__no_interaction	t1q__superoxide dismutase 1__no_interaction	t1q__adenylate kinase 1__no_interaction	t1q__phenylalanine hydroxylase__no_interaction	t1q__PAH__no_interaction	U16__SOD1__no_interaction	U16__AK1__no_interaction	U16__transferrin__no_interaction	U16__superoxide dismutase 1__no_interaction	U16__adenylate kinase 1__no_interaction	U16__phenylalanine hydroxylase__no_interaction	U16__PAH__no_interaction
16088424-6	After I-R, nSTZ-rats showed increased plasma concentrations of LPO, NO, <protein-id="Q00238">ICAM-1</protein-id> (0.5141 +/- 0.083 vs 0.024 +/- 0.003, ICV; 0.574 +/- 0.075 vs 0.023 +/- 0.003, <compound-id="446034">SCV</compound-id>; 0.528 +/- 0.067 vs 0.027 +/- 0.003 PV; ng/ml), <protein-id="P16599">TNF-alpha</protein-id> (42.4 +/- 5.7 ICV, 248.4 +/- 28.2 <compound-id="446034">SCV</compound-id>, and 33.6 +/- 4.0 PV.	SCV__ICAM-1__no_interaction	SCV__TNF-alpha__no_interaction
22612619-1	The objective was to determine the cytochrome P450s (CYPs) responsible for the stereoselective and regiospecific hydroxylation of ketamine [(R,S)-<protein-id="Q9H3D4">Ket</protein-id>] to diastereomeric hydroxyketamines, (2S,6S;2R,6R)-HK (5a) and (2S,6R;2R,6S)-HK (<compound-id="18445697">5b</compound-id>) and norketamine [(R,S)-norKet] to hydroxynorketamines, (2S,6S;2R,6R)-HNK (<compound-id="69255155">4a</compound-id>), (2S,6R;2R,6S)-HNK (4b), (2S,5S;2R,5R)-HNK (4c), (2S,4S;2R,4R)-HNK (4d), (2S,4R;2R,4S)-HNK (4e), (2S,5R;2R,5S)-HNK (4f).	4a__Ket__no_interaction	5b__Ket__no_interaction
23562108-5	Positive DM family history was associated with elevated fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (98.6 ± 13.1 vs 96.5 ± 12.3 mg/dL), HbA1c (5.58% ± 0.49% vs 5.50% ± 0.46%), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (9.74 ± 4.20 vs 9.21 ± 3.63 μU/mL) and HOMA (2.43 ± 1.19 vs 2.24 ± 1.01) values, lower QUICKI (0.342 ± 0.025 vs 0.345 ± 0.023), Bennett (0.285 ± 0.081 vs 0.292 ± 0.078) and McAuley (6.73 ± 3.43 vs 6.95 ± 3.44) values, and higher IGH prevalence (45.3% vs 38.7%); P &lt; .01 for all comparisons.	glucose__insulin__no_interaction
11179725-3	Altogether, the following relationship between the space region and activity was found: Affinity for <protein-id="P11473,F1D8P8">vitamin D receptor</protein-id> (<protein-id="P11473,F1D8P8">VDR</protein-id>), EA &gt; A&gt; F &gt; G &gt; EG; Affinity for <protein-id="P02774">vitamin D binding protein</protein-id> (<protein-id="Q10586">DBP</protein-id>), A &gt;&gt; G,EA,EG; Target gene transactivation, EA &gt; F &gt; A &gt; EG &gt; or = G; Cell differentiation, EA &gt; F &gt; A &gt; EG &gt; or = G; Bone <compound-id="22044544,5460341">calcium</compound-id> mobilization, EA &gt; GA &gt; F &gt; or = EG; Intestinal <compound-id="22044544,5460341">calcium</compound-id> absorption, EA = A &gt; or = G &gt;&gt; EG.	calcium__DBP__no_interaction	calcium__VDR__no_interaction	calcium__vitamin D receptor__no_interaction	calcium__vitamin D binding protein__no_interaction
20465997-5	We verified that in LF cells, comparatively to HF cells: (1) uptake of [3H]folic acid is upregulated, via an increase in the Vmax of uptake; (2) uptake of [3H]<compound-id="53782692">deoxy-glucose</compound-id>, [3H]<compound-id="15173104">O-methyl-glucose</compound-id> and [3H]<compound-id="39484">1-methyl-4-phenylpyridinium</compound-id> (MPP+) is downregulated, via a decrease in the Vmax of uptake; additionally, a reduction in Km was observed for [3H]<compound-id="15173104">O-methyl-glucose</compound-id>; (3) uptake of [3H]5-hydroxytryptamine and [14C]<compound-id="264">butyrate</compound-id> is not changed; and (4) the steady-state mRNA levels of the folic acid transporters RFC (reduced <compound-id="6037">folate</compound-id> carrier), PCFT (<compound-id="1038,5460653">proton</compound-id>-coupled <compound-id="6037">folate</compound-id> transporter) and FRalpha (<compound-id="6037">folate</compound-id> receptor alpha), of the organic cation transporter <protein-id="O15245">OCT1</protein-id> (<protein-id="O15245">organic cation transporter type 1</protein-id>), of the <compound-id="206,5793,64689,79025">glucose</compound-id> transporter <protein-id="P11168,Q6PAU8">GLUT2</protein-id> (facilitative <protein-id="P11168,Q6PAU8">glucose transporter type 2</protein-id>) and of the <compound-id="264">butyrate</compound-id> transporter <protein-id="P53985,B4DKS0,A0A024R0H1">MCT1</protein-id> (<protein-id="P53985,B4DKS0,A0A024R0H1">monocarboxylate transporter type 1</protein-id>) were decreased.	proton__OCT1__no_interaction	proton__glucose transporter type 2__no_interaction	proton__monocarboxylate transporter type 1__no_interaction	proton__GLUT2__no_interaction	proton__organic cation transporter type 1__no_interaction	proton__MCT1__no_interaction	folate__OCT1__no_interaction	folate__glucose transporter type 2__no_interaction	folate__monocarboxylate transporter type 1__no_interaction	folate__GLUT2__no_interaction	folate__organic cation transporter type 1__no_interaction	folate__MCT1__no_interaction	butyrate__OCT1__no_interaction	butyrate__glucose transporter type 2__no_interaction	butyrate__monocarboxylate transporter type 1__no_interaction	butyrate__GLUT2__no_interaction	butyrate__organic cation transporter type 1__no_interaction	butyrate__MCT1__no_interaction	deoxy-glucose__OCT1__no_interaction	deoxy-glucose__glucose transporter type 2__no_interaction	deoxy-glucose__monocarboxylate transporter type 1__no_interaction	deoxy-glucose__GLUT2__no_interaction	deoxy-glucose__organic cation transporter type 1__no_interaction	deoxy-glucose__MCT1__no_interaction	O-methyl-glucose__OCT1__no_interaction	O-methyl-glucose__glucose transporter type 2__no_interaction	O-methyl-glucose__monocarboxylate transporter type 1__no_interaction	O-methyl-glucose__GLUT2__no_interaction	O-methyl-glucose__organic cation transporter type 1__no_interaction	O-methyl-glucose__MCT1__no_interaction	1-methyl-4-phenylpyridinium__OCT1__no_interaction	1-methyl-4-phenylpyridinium__glucose transporter type 2__no_interaction	1-methyl-4-phenylpyridinium__monocarboxylate transporter type 1__no_interaction	1-methyl-4-phenylpyridinium__GLUT2__no_interaction	1-methyl-4-phenylpyridinium__organic cation transporter type 1__no_interaction	1-methyl-4-phenylpyridinium__MCT1__no_interaction	glucose__OCT1__no_interaction	glucose__glucose transporter type 2__no_interaction	glucose__monocarboxylate transporter type 1__no_interaction	glucose__GLUT2__no_interaction	glucose__organic cation transporter type 1__no_interaction	glucose__MCT1__no_interaction
12839666-4	RESULTS: The results showed that the mineral deposit rate and bone contents of <compound-id="23994">zinc</compound-id>, phosphorus and <compound-id="269023,5810">hydroxyproline</compound-id>, and serum levels of <protein-id="P01256,P01257,A0A0G2JSX2">calcitonin</protein-id> and osteocalcin lowered significantly in ZD group, as compared with those in the control and pair-fed groups, with (3.26 +/- 0.34) micro m/d, (64.54 +/- 2.34) g/kg, (54.4 +/- 9.5) mg/kg, (9.28 +/- 1.62) g/kg, (41.2 +/- 13.5) micro g/L, (82 +/- 30) micro g/L in ZD group; (5.37 +/- 0.53) micro m/d, (69.01 +/- 4.05) g/kg, (117.4 +/- 8.0) mg/kg, (11.31 +/- 1.30) g/kg, (68.3 +/- 14.4) micro g/L, (131 +/- 46) micro g/L in the control group; and (5.45 +/- 0.30) micro m/d, (67.81 +/- 3.56) g/kg, (106.7 +/- 8.4) mg/kg, (10.88 +/- 1.47) g/kg, (63.7 +/- 12.0) micro g/L, (120 +/- 52) micro g/L in the pair-fed group, respectively.	hydroxyproline__calcitonin__no_interaction	zinc__calcitonin__no_interaction
22973371-7	Plasma acylated <compound-id="44576256">ghrelin</compound-id> concentrations in obese and lean men were negatively correlated to body weight (r= -0.50, r= -0.43, respectively), body fat percent (r = -0.53, r = -0.44, respectively), body mass index (r = -0.53, r = -0.49, respectively), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.42, r = -0.40, respectively) and HOMA-IR (r = -0.48, r = -0.45, respectively), and positively correlated to GH levels (r = 0.37, r = 0.31, respectively) and maximal <compound-id="977">oxygen</compound-id> uptake (r = 0.33, r = 0.31, respectively) (p &lt; 0.01).	ghrelin__insulin__no_interaction	oxygen__insulin__no_interaction
12805480-4	<compound-id="122634,22833501,4792">PMA</compound-id>/Io-stimulated <protein-id="P04351">interleukin-2</protein-id> production was inhibited by <compound-id="2543">cannabinol</compound-id>, <compound-id="644019">cannabidiol</compound-id>, and both <compound-id="5311501,5689">WIN 55212-2</compound-id> stereoisomers with a rank order potency of R-(+)-[<compound-id="3525223">2,3-dihydro-5-</compound-id>methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-<compound-id="15246252">1,4-benzoxazinyl</compound-id>]-(1-napthanlenyl) methanone <compound-id="6395">mesylate</compound-id> (<compound-id="5311501,5689">WIN 55212-2</compound-id>) approximately <compound-id="644019">cannabidiol</compound-id> &gt; S-(-)-[<compound-id="3525223">2,3-dihydro-5-</compound-id>methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-<compound-id="15246252">1,4-benzoxazinyl</compound-id>]-(1-napthanlenyl) methanone <compound-id="6395">mesylate</compound-id> (<compound-id="23616032">WIN 55212</compound-id>-3) approximately <compound-id="2543">cannabinol</compound-id>.	mesylate__interleukin-2__no_interaction	1,4-benzoxazinyl__interleukin-2__no_interaction	2,3-dihydro-5-__interleukin-2__no_interaction	WIN 55212__interleukin-2__no_interaction	cannabinol__interleukin-2__no_interaction	cannabidiol__interleukin-2__no_interaction	WIN 55212-2__interleukin-2__no_interaction	PMA__interleukin-2__no_interaction
16127505-6	Reactions of [Rh(acac)(L-L)](L-L = cod, (CO)2, (CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)) with 4 and the dendrimers G(1)SH-8, G(2)SH-16, and G(1)SH-12, gave microcrystalline solids of formulae [Rh3(MeSi[(CH2)<compound-id="21439199">3S</compound-id>]3)(L-L)3]n, [Si[(CH2)3SiMe{(CH2)3SRh(cod)}2]4]n([G(1)Rh(cod)-8]n), [Si[(CH2)3Si{(CH2)3SRh(cod)}3]4]n([G(1)Rh(cod)-12]n), etc., which presumably are tridimensional coordination polymers.	3S__PPh3__no_interaction
8458191-5	Univariate analysis showed that in diabetic patients systolic blood pressure was related to age (r = 0.17, p &lt; 0.05), BMI (r = 0.23, p &lt; 0.01) and plasma immunoreactive <protein-id="P01308,I3WAC9">insulin</protein-id> (fasting and post <compound-id="206,5793,64689,79025">glucose</compound-id>, r = approximately 0.25, p &lt; 0.01) but not to C-peptide concentrations; diastolic blood pressure to BMI (r = 0.35, p &lt; 0.001), waist-hip ratio (r = 0.23, p &lt; 0.01) and plasma immunoreactive <protein-id="P01308,I3WAC9">insulin</protein-id> (fasting r = 0.30, p &lt; 0.001, post <compound-id="206,5793,64689,79025">glucose</compound-id> r = approximately 0.20, p &lt; 0.05) but not to C-peptide concentrations.	glucose__insulin__no_interaction
8804889-2	These elements <protein-id="Q9Y4K1,B3KPT0,A0A0J9YWL0">aim 1</protein-id>) to diminish frequency and severity of acid challenge, 2) enhance salivary flow, 3) to enhance acid resistance, remineralization and rehardening by <compound-id="28179">fluoride</compound-id> application, 4) to offer chemical protection by buffering substances, 5) to minimize abrasion, 6) to offer mechanical protection.	fluoride__aim 1__no_interaction
22052298-3	Herein, we report a complete work including (i) effect of initial [<compound-id="4346576">APTS</compound-id>]/[Ru] molar ratio on both the size and the catalytic activity of <compound-id="23950">ruthenium</compound-id>(0) nanoparticles, (ii) collection of extensive kinetic data under non-MTL conditions depending on the substrate and catalyst concentrations to define the rate law of Ru(0)/<compound-id="4346576">APTS</compound-id>-catalyzed dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> at room temperature, (iii) determination of activation parameters (E(a), ΔH(#) and ΔS(#)) for Ru(0)/<compound-id="4346576">APTS</compound-id>-catalyzed dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id>; (iv) demonstration of the catalytic lifetime of Ru(0)/<compound-id="4346576">APTS</compound-id> nanoparticles in the dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> at room temperature, (v) testing the bottlability and reusability of Ru(0)/<compound-id="4346576">APTS</compound-id> nanocatalyst in the room-temperature dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id>, (vi) quantitative <compound-id="6348">carbon disulfide</compound-id> (CS(2)) poisoning experiments to find a corrected TTO and <protein-id="Q8TBJ5">TOF</protein-id> values on a per-active-<compound-id="23950">ruthenium</compound-id>-atom basis, (vii) a summary of extensive literature review for the catalysts tested in the catalytic dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> as part of the results and discussions.	APTS__TOF__no_interaction	ruthenium__TOF__no_interaction	carbon disulfide__TOF__no_interaction	borane__TOF__no_interaction
12919040-1	2-Halophenyl <compound-id="114522">ketones</compound-id> 1a-e (1a, o-IC(6)H(4)COCH(3)) undergo carbocyclization with alkyl propiolates (2a, CH(3)(CH(2))(4)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2b, TMSC[triple bond]<compound-id="446195">CCO</compound-id>(2)Et 2c, CH(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2d, CH(3)OCH(2)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2e, CH(3)(CH(2))(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2f, <protein-id="Q00325,A0A024RBE8,A0A024RBH9,Q6MZF9">PhC</protein-id>[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); and 2g, (CH(3))(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3)) in the presence of Ni(dppe)Br(2) and <compound-id="23994">zinc</compound-id> powder in acetonitrile at 80 degrees C to afford the corresponding <compound-id="316919">indenol</compound-id> derivatives <compound-id="2981881,91293124">3a</compound-id>-m with remarkable regioselectivity in good to excellent yields.	ketones__PhC__no_interaction	indenol__PhC__no_interaction	CCO__PhC__no_interaction	3a__PhC__no_interaction	zinc__PhC__no_interaction
22340657-5	ACC (acetyl <compound-id="317,44216777,44246472,444624,445126,447444,448506,46936280,5326877,6816,6914636,87642">coenzyme A</compound-id> carboxylase) and <protein-id="P56720,R9PXS1">SREBP-1</protein-id> mRNA expression, lowered plasma <protein-id="Q8K3R4">adiponectin</protein-id> (OLETF vs LETO: 8 weeks age, 2.38 ± 0.23 vs 3.1 ± 0.17, P &lt; 0.05; 32 weeks age, 1.51 ± 0.05 vs 2.84 ± 0.34, P &lt; 0.01; 40 weeks age, 1.24 ± 0.04 vs 2.64 ± 0.49 ng/ml, P &lt; 0.01) and liver tissue (8, 32 or 40 weeks age, 2.24 ± 0.18 vs 2.68 ± 0.13, 2.04 ± 0.19 vs 2.51 ± 0.14, 1.76 ± 0.12 vs 2.47 ± 0.21 µg/g respectively, P &lt; 0.05) as well as elevated triglyceride (TG) (40 weeks age, TG 1.88 ± 0.11 vs 0.51 ± 0.07 mmol/L, P &lt; 0.01) and <compound-id="5997">cholesterol</compound-id> (40 weeks age, total <compound-id="5997">cholesterol</compound-id> 0.94 ± 0.17 vs 0.69 ± 0.14 mmol/L, P &lt; 0.01) and lowered <protein-id="P35570">IRS-1</protein-id> (<protein-id="P35570">insulin receptor substrate 1</protein-id>) <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation in liver tissue in OLETF rats were observed.	coenzyme A__insulin receptor substrate 1__no_interaction	coenzyme A__adiponectin__no_interaction	coenzyme A__IRS-1__no_interaction	coenzyme A__SREBP-1__no_interaction	tyrosine__insulin receptor substrate 1__no_interaction	tyrosine__adiponectin__no_interaction	tyrosine__IRS-1__no_interaction	tyrosine__SREBP-1__no_interaction	cholesterol__insulin receptor substrate 1__no_interaction	cholesterol__adiponectin__no_interaction	cholesterol__IRS-1__no_interaction	cholesterol__SREBP-1__no_interaction
19159569-5	The specific lysis effects of <protein-id="P19544,Q6PI38">WT1</protein-id> peptide specific CTLs upon leukemic bone marrow CD34+ progenitor cells positively expressing <protein-id="P19544,Q6PI38">WT1</protein-id> (3 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+) and 3 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0201(-)), peripheral blood CD34+ cells from healthy persons (2 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+) and 1 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(-)), and leukemia cells of the lines of NB4 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+)/<protein-id="P19544,Q6PI38">WT1</protein-id>(+)), U937 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+)/<protein-id="P19544,Q6PI38">WT1</protein-id>(-)), and K562 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(-)/<protein-id="P19544,Q6PI38">WT1</protein-id>(+)) were measured by methyl <compound-id="57036910">thiazolyl tetrazolium</compound-id> (<compound-id="64966">MTT</compound-id>) chromatometry assay.	thiazolyl tetrazolium__WT1__no_interaction	thiazolyl tetrazolium__HLA-A__no_interaction	MTT__WT1__no_interaction	MTT__HLA-A__no_interaction
17003851-2	The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, <compound-id="57476835,60961">adenosine</compound-id> triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, <compound-id="90470007">anakinra</compound-id>, angiotensin-(1-7), <compound-id="166548">anidulafungin</compound-id>, <compound-id="176405">apomine</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="54841">atomoxetine hydrochloride</compound-id>, <compound-id="9869929">avanafil</compound-id>; <compound-id="6918606">BAL-8557</compound-id>, <compound-id="101524">becatecarin</compound-id>, bevacizumab, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, BMS-188797, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="446727">brivudine</compound-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">caspofungin acetate</compound-id>, catumaxomab, certolizumab pegol, cetuximab, CG-0070, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="156419">cinacalcet hydrochloride</compound-id>, <compound-id="10346039,32603,358642,443385,44629926,45356833,51064166">clindamycin phosphate</compound-id>/<compound-id="7187">benzoyl peroxide</compound-id>, <compound-id="76210638,9939639">cryptophycin 52</compound-id>, <compound-id="9962928">Cypher</compound-id>; <compound-id="213023,6445226,9578572">Dabigatran etexilate</compound-id>, <compound-id="9939609">darapladib</compound-id>, darbepoetin alfa, <compound-id="451668">decitabine</compound-id>, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="107778">dexanabinol</compound-id>, <compound-id="3008,5360696,5362449,6916184">dextromethorphan</compound-id>/<compound-id="1065,3036746,5748152,441074,5953">quinidine sulfate</compound-id>, DMF, drotrecogin alfa (activated), <compound-id="60835">duloxetine hydrochloride</compound-id>; E-7010, <compound-id="4021">edaravone</compound-id>, efalizumab, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="153941">entecavir</compound-id>, <compound-id="443872">eplerenone</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="13791">estradiol valerate</compound-id>/<compound-id="68861">dienogest</compound-id>, <compound-id="969472">eszopiclone</compound-id>, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="104741">fulvestrant</compound-id>; <compound-id="123631">Gefitinib</compound-id>, <compound-id="3033968">gestodene</compound-id>, <compound-id="154069">GYKI-16084</compound-id>; <compound-id="24728612,24759,3084050,453618">Hyaluronic acid</compound-id>, <compound-id="3637">hydralazine hydrochloride</compound-id>/<compound-id="6883">isosorbide dinitrate</compound-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="6450813">indiplon</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine; Juzen-taiho-to; <compound-id="60825">Lamivudine</compound-id>/<compound-id="35370">zidovudine</compound-id>/<compound-id="441300">abacavir sulfate</compound-id>, L-<compound-id="90867653">arginine</compound-id> hydrochloride, <compound-id="216416">lasofoxifene tartrate</compound-id>, L-<compound-id="15991548">BLP</compound-id>-25, <compound-id="216326">lenalidomide</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="6047">levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, lexatumumab, <compound-id="9911821">lidocaine/prilocaine</compound-id>, <compound-id="157920">lubiprostone</compound-id>, <compound-id="151166">lumiracoxib</compound-id>; MAb-14.18, <compound-id="71772">mitoquidone</compound-id>; Natalizumab, <compound-id="71237">neridronic acid</compound-id>, neuradiab; <compound-id="198716">Olpadronic acid sodium salt</compound-id>, omalizumab; <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="148178">perifosine</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="6918456">prasugrel</compound-id>, <protein-id="Q6PL18,A0A024R9G7">PRO-2000</protein-id>, Pseudostat; <compound-id="44462688">R24</compound-id>, rasburicase, RHAMM R3 peptide, rilonacept, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">rosuvastatin calcium</compound-id>, rotavirus vaccine, <compound-id="129228">rufinamide</compound-id>; <compound-id="151897,46233105">Sabarubicin</compound-id> hydrochloride, SHL-749, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498">sirolimus</compound-id>-eluting stent, SLx-2101, <compound-id="264">sodium butyrate</compound-id>, <compound-id="216239">sorafenib</compound-id>, SU-6668; TachoSil, <compound-id="110635">tadalafil</compound-id>, taxus, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="159269">telbivudine</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, teriparatide, <compound-id="14296">tetramethylpyrazine</compound-id>, <compound-id="70697627">teverelix</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="216237">tolvaptan</compound-id>, TransvaxTM hepatitis C vaccine, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="60846">valsartan</compound-id>/<compound-id="2162">amlodipine</compound-id>, <compound-id="3081361">vandetanib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate, <compound-id="151194">vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, veglin, <compound-id="71616">voriconazole</compound-id>; <compound-id="23993">Yttrium</compound-id> 90 (90Y) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; <compound-id="60490">Zileuton</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>-eluting stent.	escitalopram oxalate__PRO-2000__no_interaction	escitalopram oxalate__insulin__no_interaction	escitalopram oxalate__p53__no_interaction	eplerenone__PRO-2000__no_interaction	eplerenone__insulin__no_interaction	eplerenone__p53__no_interaction	anidulafungin__PRO-2000__no_interaction	anidulafungin__insulin__no_interaction	anidulafungin__p53__no_interaction	sodium butyrate__PRO-2000__no_interaction	sodium butyrate__insulin__no_interaction	sodium butyrate__p53__no_interaction	abacavir sulfate__PRO-2000__no_interaction	abacavir sulfate__insulin__no_interaction	abacavir sulfate__p53__no_interaction	tetramethylpyrazine__PRO-2000__no_interaction	tetramethylpyrazine__insulin__no_interaction	tetramethylpyrazine__p53__no_interaction	lubiprostone__PRO-2000__no_interaction	lubiprostone__insulin__no_interaction	lubiprostone__p53__no_interaction	Fondaparinux sodium__PRO-2000__no_interaction	Fondaparinux sodium__insulin__no_interaction	Fondaparinux sodium__p53__no_interaction	Lamivudine__PRO-2000__no_interaction	Lamivudine__insulin__no_interaction	Lamivudine__p53__no_interaction	ciclesonide__PRO-2000__no_interaction	ciclesonide__insulin__no_interaction	ciclesonide__p53__no_interaction	BAL-8557__PRO-2000__no_interaction	BAL-8557__insulin__no_interaction	BAL-8557__p53__no_interaction	indiplon__PRO-2000__no_interaction	indiplon__insulin__no_interaction	indiplon__p53__no_interaction	estradiol valerate__PRO-2000__no_interaction	estradiol valerate__insulin__no_interaction	estradiol valerate__p53__no_interaction	telbivudine__PRO-2000__no_interaction	telbivudine__insulin__no_interaction	telbivudine__p53__no_interaction	vatalanib__PRO-2000__no_interaction	vatalanib__insulin__no_interaction	vatalanib__p53__no_interaction	ezetimibe__PRO-2000__no_interaction	ezetimibe__insulin__no_interaction	ezetimibe__p53__no_interaction	Dabigatran etexilate__PRO-2000__no_interaction	Dabigatran etexilate__insulin__no_interaction	Dabigatran etexilate__p53__no_interaction	isosorbide dinitrate__PRO-2000__no_interaction	isosorbide dinitrate__insulin__no_interaction	isosorbide dinitrate__p53__no_interaction	atomoxetine hydrochloride__PRO-2000__no_interaction	atomoxetine hydrochloride__insulin__no_interaction	atomoxetine hydrochloride__p53__no_interaction	clindamycin phosphate__PRO-2000__no_interaction	clindamycin phosphate__insulin__no_interaction	clindamycin phosphate__p53__no_interaction	dextromethorphan__PRO-2000__no_interaction	dextromethorphan__insulin__no_interaction	dextromethorphan__p53__no_interaction	voriconazole__PRO-2000__no_interaction	voriconazole__insulin__no_interaction	voriconazole__p53__no_interaction	levocetirizine__PRO-2000__no_interaction	levocetirizine__insulin__no_interaction	levocetirizine__p53__no_interaction	edaravone__PRO-2000__no_interaction	edaravone__insulin__no_interaction	edaravone__p53__no_interaction	anakinra__PRO-2000__no_interaction	anakinra__insulin__no_interaction	anakinra__p53__no_interaction	lidocaine/prilocaine__PRO-2000__no_interaction	lidocaine/prilocaine__insulin__no_interaction	lidocaine/prilocaine__p53__no_interaction	prasugrel__PRO-2000__no_interaction	prasugrel__insulin__no_interaction	prasugrel__p53__no_interaction	bortezomib__PRO-2000__no_interaction	bortezomib__insulin__no_interaction	bortezomib__p53__no_interaction	valsartan__PRO-2000__no_interaction	valsartan__insulin__no_interaction	valsartan__p53__no_interaction	dexanabinol__PRO-2000__no_interaction	dexanabinol__insulin__no_interaction	dexanabinol__p53__no_interaction	Yttrium__PRO-2000__no_interaction	Yttrium__insulin__no_interaction	Yttrium__p53__no_interaction	Olpadronic acid sodium salt__PRO-2000__no_interaction	Olpadronic acid sodium salt__insulin__no_interaction	Olpadronic acid sodium salt__p53__no_interaction	zotarolimus__PRO-2000__no_interaction	zotarolimus__insulin__no_interaction	zotarolimus__p53__no_interaction	neridronic acid__PRO-2000__no_interaction	neridronic acid__insulin__no_interaction	neridronic acid__p53__no_interaction	eszopiclone__PRO-2000__no_interaction	eszopiclone__insulin__no_interaction	eszopiclone__p53__no_interaction	Cypher__PRO-2000__no_interaction	Cypher__insulin__no_interaction	Cypher__p53__no_interaction	dienogest__PRO-2000__no_interaction	dienogest__insulin__no_interaction	dienogest__p53__no_interaction	BLP__PRO-2000__no_interaction	BLP__insulin__no_interaction	BLP__p53__no_interaction	entecavir__PRO-2000__no_interaction	entecavir__insulin__no_interaction	entecavir__p53__no_interaction	erlotinib hydrochloride__PRO-2000__no_interaction	erlotinib hydrochloride__insulin__no_interaction	erlotinib hydrochloride__p53__no_interaction	teverelix__PRO-2000__no_interaction	teverelix__insulin__no_interaction	teverelix__p53__no_interaction	brivudine__PRO-2000__no_interaction	brivudine__insulin__no_interaction	brivudine__p53__no_interaction	pemetrexed disodium__PRO-2000__no_interaction	pemetrexed disodium__insulin__no_interaction	pemetrexed disodium__p53__no_interaction	becatecarin__PRO-2000__no_interaction	becatecarin__insulin__no_interaction	becatecarin__p53__no_interaction	Hyaluronic acid__PRO-2000__no_interaction	Hyaluronic acid__insulin__no_interaction	Hyaluronic acid__p53__no_interaction	caspofungin acetate__PRO-2000__no_interaction	caspofungin acetate__insulin__no_interaction	caspofungin acetate__p53__no_interaction	hydralazine hydrochloride__PRO-2000__no_interaction	hydralazine hydrochloride__insulin__no_interaction	hydralazine hydrochloride__p53__no_interaction	vandetanib__PRO-2000__no_interaction	vandetanib__insulin__no_interaction	vandetanib__p53__no_interaction	Valganciclovir hydrochloride__PRO-2000__no_interaction	Valganciclovir hydrochloride__insulin__no_interaction	Valganciclovir hydrochloride__p53__no_interaction	deferasirox__PRO-2000__no_interaction	deferasirox__insulin__no_interaction	deferasirox__p53__no_interaction	lasofoxifene tartrate__PRO-2000__no_interaction	lasofoxifene tartrate__insulin__no_interaction	lasofoxifene tartrate__p53__no_interaction	bosentan__PRO-2000__no_interaction	bosentan__insulin__no_interaction	bosentan__p53__no_interaction	Gefitinib__PRO-2000__no_interaction	Gefitinib__insulin__no_interaction	Gefitinib__p53__no_interaction	exenatide__PRO-2000__no_interaction	exenatide__insulin__no_interaction	exenatide__p53__no_interaction	benzoyl peroxide__PRO-2000__no_interaction	benzoyl peroxide__insulin__no_interaction	benzoyl peroxide__p53__no_interaction	cryptophycin 52__PRO-2000__no_interaction	cryptophycin 52__insulin__no_interaction	cryptophycin 52__p53__no_interaction	treprostinil sodium__PRO-2000__no_interaction	treprostinil sodium__insulin__no_interaction	treprostinil sodium__p53__no_interaction	Imatinib mesylate__PRO-2000__no_interaction	Imatinib mesylate__insulin__no_interaction	Imatinib mesylate__p53__no_interaction	tirapazamine__PRO-2000__no_interaction	tirapazamine__insulin__no_interaction	tirapazamine__p53__no_interaction	quinidine sulfate__PRO-2000__no_interaction	quinidine sulfate__insulin__no_interaction	quinidine sulfate__p53__no_interaction	GYKI-16084__PRO-2000__no_interaction	GYKI-16084__insulin__no_interaction	GYKI-16084__p53__no_interaction	tipifarnib__PRO-2000__no_interaction	tipifarnib__insulin__no_interaction	tipifarnib__p53__no_interaction	entacapone__PRO-2000__no_interaction	entacapone__insulin__no_interaction	entacapone__p53__no_interaction	arginine__PRO-2000__no_interaction	arginine__insulin__no_interaction	arginine__p53__no_interaction	amlodipine__PRO-2000__no_interaction	amlodipine__insulin__no_interaction	amlodipine__p53__no_interaction	Sabarubicin__PRO-2000__no_interaction	Sabarubicin__insulin__no_interaction	Sabarubicin__p53__no_interaction	prasterone__PRO-2000__no_interaction	prasterone__insulin__no_interaction	prasterone__p53__no_interaction	apomine__PRO-2000__no_interaction	apomine__insulin__no_interaction	apomine__p53__no_interaction	desloratadine__PRO-2000__no_interaction	desloratadine__insulin__no_interaction	desloratadine__p53__no_interaction	vardenafil hydrochloride__PRO-2000__no_interaction	vardenafil hydrochloride__insulin__no_interaction	vardenafil hydrochloride__p53__no_interaction	aripiprazole__PRO-2000__no_interaction	aripiprazole__insulin__no_interaction	aripiprazole__p53__no_interaction	adenosine__PRO-2000__no_interaction	adenosine__insulin__no_interaction	adenosine__p53__no_interaction	decitabine__PRO-2000__no_interaction	decitabine__insulin__no_interaction	decitabine__p53__no_interaction	rufinamide__PRO-2000__no_interaction	rufinamide__insulin__no_interaction	rufinamide__p53__no_interaction	tadalafil__PRO-2000__no_interaction	tadalafil__insulin__no_interaction	tadalafil__p53__no_interaction	fulvestrant__PRO-2000__no_interaction	fulvestrant__insulin__no_interaction	fulvestrant__p53__no_interaction	tolvaptan__PRO-2000__no_interaction	tolvaptan__insulin__no_interaction	tolvaptan__p53__no_interaction	tiotropium bromide__PRO-2000__no_interaction	tiotropium bromide__insulin__no_interaction	tiotropium bromide__p53__no_interaction	cinacalcet hydrochloride__PRO-2000__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	cinacalcet hydrochloride__p53__no_interaction	sirolimus__PRO-2000__no_interaction	sirolimus__insulin__no_interaction	sirolimus__p53__no_interaction	zidovudine__PRO-2000__no_interaction	zidovudine__insulin__no_interaction	zidovudine__p53__no_interaction	duloxetine hydrochloride__PRO-2000__no_interaction	duloxetine hydrochloride__insulin__no_interaction	duloxetine hydrochloride__p53__no_interaction	Calcipotriol/betamethasone dipropionate__PRO-2000__no_interaction	Calcipotriol/betamethasone dipropionate__insulin__no_interaction	Calcipotriol/betamethasone dipropionate__p53__no_interaction	emtricitabine__PRO-2000__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__p53__no_interaction	gestodene__PRO-2000__no_interaction	gestodene__insulin__no_interaction	gestodene__p53__no_interaction	tegaserod maleate__PRO-2000__no_interaction	tegaserod maleate__insulin__no_interaction	tegaserod maleate__p53__no_interaction	perifosine__PRO-2000__no_interaction	perifosine__insulin__no_interaction	perifosine__p53__no_interaction	pimecrolimus__PRO-2000__no_interaction	pimecrolimus__insulin__no_interaction	pimecrolimus__p53__no_interaction	mitoquidone__PRO-2000__no_interaction	mitoquidone__insulin__no_interaction	mitoquidone__p53__no_interaction	ibritumomab tiuxetan__PRO-2000__no_interaction	ibritumomab tiuxetan__insulin__no_interaction	ibritumomab tiuxetan__p53__no_interaction	succinate__PRO-2000__no_interaction	succinate__insulin__no_interaction	succinate__p53__no_interaction	avanafil__PRO-2000__no_interaction	avanafil__insulin__no_interaction	avanafil__p53__no_interaction	lenalidomide__PRO-2000__no_interaction	lenalidomide__insulin__no_interaction	lenalidomide__p53__no_interaction	lumiracoxib__PRO-2000__no_interaction	lumiracoxib__insulin__no_interaction	lumiracoxib__p53__no_interaction	tenofovir disoproxil fumarate__PRO-2000__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	tenofovir disoproxil fumarate__p53__no_interaction	sorafenib__PRO-2000__no_interaction	sorafenib__insulin__no_interaction	sorafenib__p53__no_interaction	levodopa__PRO-2000__no_interaction	levodopa__insulin__no_interaction	levodopa__p53__no_interaction	rosuvastatin calcium__PRO-2000__no_interaction	rosuvastatin calcium__insulin__no_interaction	rosuvastatin calcium__p53__no_interaction	darapladib__PRO-2000__no_interaction	darapladib__insulin__no_interaction	darapladib__p53__no_interaction	Zileuton__PRO-2000__no_interaction	Zileuton__insulin__no_interaction	Zileuton__p53__no_interaction	R24__PRO-2000__no_interaction	R24__insulin__no_interaction	R24__p53__no_interaction
11198869-2	<compound-id="23978">Copper</compound-id>(II) complexes of the ligands derived from <compound-id="6998">salicylaldehyde</compound-id> (L2), <compound-id="126">p-hydroxybenzaldehyde</compound-id> (L4), and <compound-id="12088">p-carboxybenzaldehyde</compound-id> (L5) were structurally characterized: [<protein-id="Q08DE9">CuL2</protein-id>](ClO4)2.3H2O (monoclinic, P2(1)/c, a = 11.915(6) A, b = 13.861(2) A, c = 17.065(8) A, beta = 102.14(2) degrees, Z = 4); [CuL4](ClO4)2 (monoclinic, P2(1)/n, a = 9.550(3) A, b = 17.977(2) A, c = 14.612(4) A, beta 96.76(1) degrees, Z = 4), and [CuL4](ClO4)2 (monoclinic, P2(1)/n, a = 9.286(2) A, b = 11.294(1) A, c = 23.609(8) A, beta 93.68(1) degrees, Z = 4).	Copper__CuL2__no_interaction	salicylaldehyde__CuL2__no_interaction	p-hydroxybenzaldehyde__CuL2__no_interaction	p-carboxybenzaldehyde__CuL2__no_interaction
3429789-5	Gonadotropin and <compound-id="896">melatonin</compound-id> excretions correlated positively (first 13 days <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, r = 0.828; <compound-id="7021454">rs</compound-id> = 0.815 and LH, r = 0.816; <compound-id="7021454">rs</compound-id> = 0.905, p less than 0.005 and subsequent 14 days <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, r = 0.607; <compound-id="7021454">rs</compound-id> = 0.685, p less than 0.025 and LH, r = 0.490, p less than 0.05; <compound-id="7021454">rs</compound-id> = 0.638, p less than 0.025).	melatonin__FSH__no_interaction	rs__FSH__no_interaction
22168209-1	A series of multinuclear <compound-id="23978">Copper</compound-id>(I) guanidinate complexes have been synthesized in a succession of reactions between <compound-id="62652">CuCl</compound-id> and the <compound-id="3028194">lithium</compound-id> guanidinate systems Li{L} (L = Me(2)NC((i)<protein-id="Q9H6Q4">PrN</protein-id>)(2) (1a), Me(2)NC(<compound-id="12358846,5316647,54610010">CyN</compound-id>)(2) (1b), Me(2)NC((t)BuN)(2)(1c), and Me(2)NC(<compound-id="40828">DipN</compound-id>)(2) (2d) ((i)Pr = iso-propyl, Cy = cyclohexyl, (t)Bu = <compound-id="6360,90937099">tert-butyl</compound-id>, and Dip = 2,6-disopropylphenyl) made in situ, and structurally characterized.	Copper__PrN__no_interaction	tert-butyl__PrN__no_interaction	CuCl__PrN__no_interaction	DipN__PrN__no_interaction	lithium__PrN__no_interaction	CyN__PrN__no_interaction
24455256-5	In the whole group NEADLS score was correlated with age (rho: -0.759, P &lt; 0.0001), clinical systolic blood pressure (rho: -0.212, P: 0.018), blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (rho: -0.516, P &lt; 0.0001), <compound-id="588">creatinine</compound-id> (rho: -0.501, P &lt; 0.0001), <compound-id="1175">uric acid</compound-id> (rho: -0.308, P &lt; 0.0001), <protein-id="P02768">albumin</protein-id> (rho: 0.382, P &lt; 0.0001), total <compound-id="5997">cholesterol</compound-id> (rho: -0.194, P: 0.022), LDL-<compound-id="5997">cholesterol</compound-id> (rho: -0.230, P: 0.008), hemoglobin (rho: 0.256, P: 0.002), <compound-id="588">creatinine</compound-id> clearance (rho: 0.565, P &lt; 0.0001), 24-hour urinary protein excretion (rho: -0.324, P &lt; 0.0001), and 24-hour urinary <protein-id="P02768">albumin</protein-id> excretion (UAE) (rho: -0.483, P &lt; 0.0001).	creatinine__albumin__no_interaction	urea__albumin__no_interaction	uric acid__albumin__no_interaction	nitrogen__albumin__no_interaction	cholesterol__albumin__no_interaction
11561214-5	For the hormones measured, differences (p &lt; 0.05) between conditions at rest were noted for plasma renin activity (PRA) (0.62 +/- 0.09 vs. 5.61 +/- 0.94 ng/ml/h), angiotensin I (<protein-id="Q15389">ANG 1</protein-id>) (0.26 +/- 0.03 vs. 0.56 +/- 0.08 ng/ml), <compound-id="5839">aldosterone</compound-id> (ALD) (143 +/- 14 vs. 1603 +/- 302 pg/ml), <protein-id="P01185,X5DQP6">arginine vasopressin</protein-id> (<protein-id="P01185,X5DQP6">AVP</protein-id>) (4.13 +/- 1.1 vs. 9.58 +/- 1.6 pg/ml) and atrial natriuretic peptide (alpha-ANP) (11.5 +/- 2.8 vs. 6.33 +/- 1.0 pg/ml).	aldosterone__AVP__no_interaction	aldosterone__arginine vasopressin__no_interaction	aldosterone__ANG 1__no_interaction
23598368-1	The reaction kinetics between <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> and <compound-id="21490611">trihexyl(tetradecyl)</compound-id><compound-id="5460504">phosphonium</compound-id> ([P66614])-based ionic liquids (ILs) with <compound-id="614">prolinate</compound-id> ([Pro]), 2-cyanopyrrolide ([2-CNpyr]), and 3-(<compound-id="6373">trifluoromethyl</compound-id>)pyrazolide ([3-CF3pyra]) anions are studied at temperatures from 22-60 °C.	trifluoromethyl__CO2__no_interaction	prolinate__CO2__no_interaction	trihexyl(tetradecyl)__CO2__no_interaction	phosphonium__CO2__no_interaction
22233423-8	PCOS women with <compound-id="445607">ATH</compound-id> had higher waist-to-hip ratio (WHR) (0·80 [0·75-0·88] vs 0·78 [0·73-0·85], P = 0·046), <compound-id="206,5793,64689,79025">glucose</compound-id> 2 h (5·28 [4·57-6·33] mmol/l vs 5·67 [4·68-6·78] mmol/l, P = 0·037), <protein-id="Q99250">HbA1c</protein-id> (5·2 [5·0-5·4]%vs 5·1 [5·0-5·3]%, P = 0·009), parathyroid hormone (3·72(2·91-4·86] pmol/l vs 3·61 [2·94-4·63] pmol/l, P = 0·030) and Ferriman-Gallwey-Scores (FG Scores) (7 [3-12] vs 4 [1-9], P = 0·002) and lower 25(OH)D levels (54·4 [35·2-80·6] nmol/l vs 68·4 [49·7-89·4] nmol/l, P &lt; 0·001) than PCOS women without <compound-id="445607">ATH</compound-id>.	ATH__HbA1c__no_interaction	glucose__HbA1c__no_interaction
19011165-3	In isometric rings of rabbit artery, the PKC inhibitors, Go-6983 (3-[1-[3-(dimethylamino)propyl]-5-<compound-id="41160">methoxy-1H-indol-3-yl</compound-id>]-<compound-id="9877762">4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione</compound-id>), <compound-id="2396">GF-109203X</compound-id> (2-[<compound-id="88721">1-(3-dimethylaminopropyl)indol-3-yl</compound-id>]-3-(indol-3-yl) <compound-id="10935">maleimide</compound-id>), and a cell-permeable (myristoylated) pseudosubstrate inhibitor of PKCzeta (PI(PKCzeta)) inhibited KCl-induced tonic F. A myristoylated pseudosubstrate inhibitor of <protein-id="P10102">PKCalpha</protein-id>/beta that inhibited <compound-id="37783">phorbol dibutyrate</compound-id>-induced F slightly potentiated KCl-induced tonic F and attenuated 30 mM KCl-induced F. Although the <compound-id="5711">ROCK inhibitor</compound-id>, H-1152 [(S)-(+)-2-methyl-1-[(4-methyl-5-<compound-id="333903,57417047">isoquinolinyl</compound-id>)-sulfonyl]-<compound-id="68163">hexahydro-1H-1,4-diazepine</compound-id> dihydrochloride], reduced basal phosphorylation of myosin light-chain phosphatase-targeting subunit at Thr853 (MYPT1-pT853), 3 and 10 muM <compound-id="2396">GF-109203X</compound-id> inhibited only KCl-stimulated phosphorylation, not basal MYPT1-pT853.	isoquinolinyl__PKCalpha__no_interaction	hexahydro-1H-1,4-diazepine__PKCalpha__no_interaction	ROCK inhibitor__PKCalpha__no_interaction	GF-109203X__PKCalpha__no_interaction	1-(3-dimethylaminopropyl)indol-3-yl__PKCalpha__no_interaction	maleimide__PKCalpha__no_interaction	methoxy-1H-indol-3-yl__PKCalpha__no_interaction	4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione__PKCalpha__no_interaction	phorbol dibutyrate__PKCalpha__no_interaction
23646232-12	In contrast, in group II, when compared with group III, there was a significant increase in serum <protein-id="P41159,A4D0Y8">leptin</protein-id> and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (35.17 ± 1.06 ng/mL vs 10.69 ± 0.84 ng/mL, P &lt; 0.001, and 436 ± 9.75 pg /mL vs 342.4 ± 44.48 pg/mL, P &lt; 0.05, respectively), while there was no significant difference between both groups regarding serum <compound-id="588">creatinine</compound-id> (0.83 ± 0.34 vs 0.89 ± 0.24, P &gt; 0.05).	creatinine__leptin__no_interaction	creatinine__adiponectin__no_interaction
21519277-8	As expected, compared to female sex, male sex showed higher total/HDL-<compound-id="5997">cholesterol</compound-id> ratio (3.642 ± 0.99 vs. 3.329 ± 0.89, P = 0.017) and lower HDL-<compound-id="5997">cholesterol</compound-id> (1.221 ± 0.24 vs. 1.343 ± 0.28 mmol/l, P = 0.001), <protein-id="P02647,A0A024R3E3">Apo A-I</protein-id> (1.390 ± 0.20 vs. 1.474 ± 0.23 g/l, P = 0.003) concentrations and <protein-id="P02647,A0A024R3E3">Apo A-I</protein-id>/Apo B ratio (1.632 ± 0.49 vs. 1.830 ± 0.66, P = 0.016).	cholesterol__Apo A-I__no_interaction
2011075-3	Mean fasting plasma high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) was significantly higher by 12% +/- 4% (0.97 +/- 0.08 v 0.89 +/- 0.08 mmol/L, P less than .01), whereas mean total <compound-id="5997">cholesterol</compound-id> (TC) was lower by 6.5% +/- 1.3% (5.7 +/- 0.3 v 6.1 +/- 0.3 mmol/L, P less than .001), mean <protein-id="Q14746,B1ALW7">low-density lipoprotein-cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) lower by 6.4% +/- 2.0% (4.5 +/- 0.2 v 4.8 +/- 0.2 mmol/L, P less than .02), mean total triglycerides (TG) lower by 23% +/- 5% (1.7 +/- 0.1 v 2.4 +/- 0.3 mmol/L, P less than .02), and mean high versus low protein diet.	cholesterol__low-density lipoprotein-cholesterol__no_interaction	cholesterol__LDL-C__no_interaction
16734562-3	In 40 Iranian healthy subjects, cytokine single nucleotide polymorphisms (SNPs) were used to determine allelic and genotypic frequencies for the following cytokine genes: <protein-id="P01583">interleukin-1alpha</protein-id> (<protein-id="P01583">IL-1alpha</protein-id>) (T/C -889), <protein-id="P01584">IL-1beta</protein-id> (C/T -511, T/C +3962), IL-12 ( C/A-1188), <protein-id="P01579">interferon-gamma (IFN-gamma</protein-id>) (A/T UTR 5644), transforming growth factor-beta (TGF-beta) (C/T codon 10, G/C codon 25), <protein-id="P01375,Q5STB3">tumor necrosis factor alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (G/A -308, G/A -238), <protein-id="P60568,Q0GK43">IL-2</protein-id> (T/G -330, G/T +166), <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id> (T/G -1089, T/C -590, T/C -33), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6 (G/C -174</protein-id>, G/A nt565), <protein-id="P22301,Q6FGW4">IL-10</protein-id> (G/A -1082, C/T -819, C/A -592), IL-1R (C/T pst11970), <protein-id="P14778,B8ZZW4">IL-1RA</protein-id> (T/C <compound-id="120308">mspa</compound-id> 111100), <protein-id="P24394,B2RBY1">IL-4RA</protein-id> (G/A +1902).	mspa__IL-6 (G/C -174__no_interaction	mspa__IL-4RA__no_interaction	mspa__IL-4__no_interaction	mspa__interleukin-1alpha__no_interaction	mspa__IL-2__no_interaction	mspa__interferon-gamma (IFN-gamma__no_interaction	mspa__IL-1beta__no_interaction	mspa__IL-10__no_interaction	mspa__IL-1alpha__no_interaction	mspa__tumor necrosis factor alpha__no_interaction	mspa__TNF-alpha__no_interaction	mspa__IL-1RA__no_interaction
21252482-9	No significant change of <compound-id="6013">testosterone</compound-id> (4.21 ± 1.49 vs. 4.00 ± 1.48 ng/ml, p = 0.46), free <compound-id="6013">testosterone</compound-id> (9.01 ± 3.64 vs. 8.85 ± 3.04 pg/ml, p = 0.83), <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> (38 ± 14.39 vs. 38.5 ± 17.23 nmol/l, p = 0.71), calculated free <compound-id="6013">testosterone</compound-id> (0.091 ± 0.13 vs. 0.067 ± 0.026, p = 0.563), and bioavailable <compound-id="6013">testosterone</compound-id> (1.89 ± 0.722 vs. 1.88 ± 0.53, p = 0.912) was observed.	testosterone__SHBG__no_interaction
17500540-8	Our estimated VIPs values calculated by G3 theory (in eV) are <protein-id="P01282">VIP</protein-id> ((E)-<compound-id="6432229">CHCl</compound-id>=CFCl) = 9.89, <protein-id="P01282">VIP</protein-id> ((Z)-<compound-id="6432229">CHCl</compound-id>=CFCl) = 9.90, <protein-id="P01282">VIP</protein-id> ((E)-CFCl=CHF)= 10.26, <protein-id="P01282">VIP</protein-id> ((Z)-CFCl=CHF) = 10.25, <protein-id="P01282">VIP</protein-id> ((E)-CFCl=CFCl) = 9.93, <protein-id="P01282">VIP</protein-id> ((Z)-CFCl=CFCl) = 9.96, <protein-id="P01282">VIP</protein-id> (<protein-id="P13500">CCl2</protein-id>=CFCl) = 9.71, <protein-id="P01282">VIP</protein-id> (<protein-id="Q15904,A0A0C4DGX8">CF2</protein-id>=<compound-id="6432229">CHCl</compound-id>) = 10.19, <protein-id="P01282">VIP</protein-id> (CHF=<protein-id="P13500">CCl2</protein-id>) = 9.96, <protein-id="P01282">VIP</protein-id> (CH2=CFCl) = 10.32, <protein-id="P01282">VIP</protein-id> ((Z)-<compound-id="6432229">CHCl</compound-id>=CHF) = 10.16, and <protein-id="P01282">VIP</protein-id> ((E)-<compound-id="6432229">CHCl</compound-id>=CHF) = 10.16.	CHCl__CCl2__no_interaction	CHCl__VIP__no_interaction	CHCl__CF2__no_interaction
16873605-5	In aorta, <protein-id="P80511">CGRP</protein-id>((8-37)), [N-alpha-benzoyl]human alpha-<protein-id="P80511">CGRP</protein-id>((8-37)) [<compound-id="9413">bzl</compound-id>-<protein-id="P80511">CGRP</protein-id>((8-37))], and [N-alpha-benzoyl-His(10)-benzyl]human alpha-<protein-id="P80511">CGRP</protein-id>((8-37)) [<compound-id="9413">bzl</compound-id>-bn-<protein-id="P80511">CGRP</protein-id>((8-37))] caused rightward shifts in the concentration-response relaxation curve for <protein-id="P80511">CGRP</protein-id> with K(B) values of 1000, 88, and 50 nM, respectively.	bzl__CGRP__no_interaction
21682757-9	RESULTS: Multiple of upper limit of normal (xULN) of <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> (0·23 (0·09-0·4) vs 0·71 (0·4-1·04), P &lt; 0·01), WHR (0·98 (0·86-1·04) vs 1·01 (0·86-1·05), P &lt; 0·05) and <compound-id="44576256">ghrelin</compound-id> levels [119·8 ng/l (67·7-266·6) vs 137 ng/l (67-289·5), P &lt; 0·05] were significantly higher, whereas fat mass (FM) [34·7% (20·4-49·2) vs 32·4% (16·7-48·5), P &lt; 0·05] and <protein-id="P41159,A4D0Y8">leptin</protein-id> [11·2 μg/l (3·3-55·7) vs 7·05 μg/l (2·4-54·3), P &lt; 0·05] were significantly lower at study end.	ghrelin__leptin__no_interaction	ghrelin__IGF-I__no_interaction
20576202-6	RESULTS: The urinary level of each <compound-id="962">water</compound-id>-soluble vitamin was correlated positively to its mean intake in the past 2-4 d (<compound-id="1130">vitamin B1</compound-id>: r = 0·42, P &lt; 0·001; <compound-id="493570">vitamin B2</compound-id>: r = 0·43, P &lt; 0·001; <compound-id="1054">vitamin B6</compound-id>: r = 0·49, P &lt; 0·001; <compound-id="938">niacin</compound-id>: r = 0·32, P &lt; 0·001; <compound-id="938">niacin</compound-id> equivalents: r = 0·32, P &lt; 0·001; pantothenic acid: r = 0·32, P &lt; 0·001; <compound-id="6037">folic acid</compound-id>: r = 0·27, P &lt; 0·01; <compound-id="54670067">vitamin C</compound-id>: r = 0·39, P &lt; 0.001), except for vitamin <protein-id="O43676,A0A024R413">B12</protein-id> (r = 0·10, P = NS).	niacin__B12__no_interaction	vitamin B2__B12__no_interaction	water__B12__no_interaction	vitamin B1__B12__no_interaction	vitamin B6__B12__no_interaction	vitamin C__B12__no_interaction	folic acid__B12__no_interaction
22362817-4	Treatment with the NO-donating <compound-id="60823">atorvastatin</compound-id> NCX 6560 (11.7 mg/kg) was significantly more effective than <compound-id="60823">atorvastatin</compound-id> (10 mg/kg) in reducing the following parameters: lipid-rich lesions in the aortic arch (surface covered: <compound-id="60823">atorvastatin</compound-id> = 24 ± 5%; NCX 6560 = 14.7 ± 3.9%; P&lt; 0.05); the production of radical <compound-id="977">oxygen</compound-id> species in the aorta (<compound-id="64944">dichlorofluorescein</compound-id> fluorescence intensity per milligram of protein: <compound-id="60823">atorvastatin</compound-id> = 2419 ± 136.7; NCX 6560 = 1766 ± 161.2; P&lt; 0.05); femoral artery intima/media thickness (<compound-id="60823">atorvastatin</compound-id> = 1.2 ± 0.11; NCX 6560 = 0.3 ± 0.14; P&lt; 0.05); circulating <protein-id="P08505,A2RTD1">interleukin-6</protein-id> (<compound-id="60823">atorvastatin</compound-id> = 34.3 ± 6.8 pg/mL; NCX 6560 = 17.7 ± 14.4 pg/mL; P&lt; 0.05); and <protein-id="P33434,Q3UG07">matrix metalloproteinase 2</protein-id> in the arterial wall (<compound-id="60823">atorvastatin</compound-id> = 55.2 ± 1.9 ng/µg of proteins; NCX 6560 = 45.8 ± 2.6 ng/µg of proteins; P &lt; 0.05).	atorvastatin__interleukin-6__no_interaction	atorvastatin__matrix metalloproteinase 2__no_interaction	dichlorofluorescein__interleukin-6__no_interaction	dichlorofluorescein__matrix metalloproteinase 2__no_interaction	oxygen__interleukin-6__no_interaction	oxygen__matrix metalloproteinase 2__no_interaction
8198931-7	) kinetic parameters for the N-demethylation and 2-hydroxylation of <compound-id="3696">imipramine</compound-id> derived from a two-enzyme kinetic analysis were: <compound-id="56643075">Km1</compound-id> = 1.1 +/- 0.4 and 1.6 +/- 0.6 microM, Vmax1 = 0.11 +/- 0.03 and 0.15 +/- 0.07 nmol <protein-id="Q9HC84">mg-1 min-1</protein-id>, and Vmax1/<compound-id="56643075">Km1</compound-id> = 0.10 +/- 0.02 and 0.09 +/- 0.04 ml <protein-id="Q9HC84">mg-1 min-1</protein-id>; Km2 = 214 +/- 84 and 257 +/- 148 microM, Vmax2 = 2.22 +/- 0.69 and 0.53 +/- 0.15 nmol <protein-id="Q9HC84">mg-1 min-1</protein-id>, and Vmax2/Km2 = 0.011 +/- 0.001 and 0.003 +/- 0.002 ml <protein-id="Q9HC84">mg-1 min-1</protein-id>.	imipramine__mg-1 min-1__no_interaction	Km1__mg-1 min-1__no_interaction
17217690-4	RESULTS: The levels of serum <protein-id="P14555,A0A024RA96">sPLA2</protein-id> [(68 +/- 17) U/ml], <protein-id="P10145,A0A024RDA5">IL-8</protein-id> [(182 +/- 80) pg/ml] and LPA [(2.85 +/- 0.36) micromol/L] were significantly higher in <compound-id="221493">CHD</compound-id> patients than those in controls [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (55 +/- 12) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (119 +/- 33) pg/ml; LPA: (2.34 +/- 0.36) micromol/L, all P &lt; 0.01], and <protein-id="P14555,A0A024RA96">sPLA2</protein-id> and <protein-id="P10145,A0A024RDA5">IL-8</protein-id> were also significantly higher in ACS patients [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (71 +/- 18) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (195 +/- 78) pg/ml] than those in <compound-id="3009355">SCHD</compound-id> patients [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (63 +/- 12) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (159 +/- 79) pg/ml, both P &lt; 0.01].	SCHD__sPLA2__no_interaction	SCHD__IL-8__no_interaction	CHD__sPLA2__no_interaction	CHD__IL-8__no_interaction
23220477-2	To investigate the mechanism of this adaptation, muscle biopsies obtained before and ∼72 h after the last training bout were analyzed for mRNA levels of <compound-id="285703,6145931">prostaglandin</compound-id> (PG)/cyclooxygenase pathway enzymes and receptors [<compound-id="444899">arachidonic acid</compound-id> synthesis: cytosolic phospholipase A(2) (cPLA(2)) and secreted phospholipase A(2) (sPLA(2)); PGF(2α) synthesis: PGF(2α) synthase and PGE(2) to PGF(2α) reductase; PGE(2) synthesis: PGE(2) synthase-1, -2, and -3; PGF(2α) receptor and PGE(2) receptor-4], cytokines and myokines involved in skeletal muscle adaptation (TNF-α, IL-1β, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>, <protein-id="P22301,Q6FGW4">IL-10</protein-id>), and regulators of muscle growth [myogenin, <protein-id="P23409">myogenic regulatory factor-4</protein-id> (<protein-id="P23409">MRF4</protein-id>), myostatin] and atrophy [<protein-id="O43524">Forkhead box O3A</protein-id> (<protein-id="O43524">FOXO3A</protein-id>), <protein-id="Q969Q1">atrogin-1, muscle RING finger protein 1</protein-id> (<protein-id="Q969Q1">MuRF-1</protein-id>), inhibitory κB kinase β (IKKβ)].	arachidonic acid__IL-8__no_interaction	arachidonic acid__Forkhead box O3A__no_interaction	arachidonic acid__atrogin-1, muscle RING finger protein 1__no_interaction	arachidonic acid__IL-6__no_interaction	arachidonic acid__IL-10__no_interaction	arachidonic acid__MuRF-1__no_interaction	arachidonic acid__FOXO3A__no_interaction	arachidonic acid__MRF4__no_interaction	arachidonic acid__myogenic regulatory factor-4__no_interaction	prostaglandin__IL-8__no_interaction	prostaglandin__Forkhead box O3A__no_interaction	prostaglandin__atrogin-1, muscle RING finger protein 1__no_interaction	prostaglandin__IL-6__no_interaction	prostaglandin__IL-10__no_interaction	prostaglandin__MuRF-1__no_interaction	prostaglandin__FOXO3A__no_interaction	prostaglandin__MRF4__no_interaction	prostaglandin__myogenic regulatory factor-4__no_interaction
23294625-6	RESULTS: We observed a positive correlation of <protein-id="P23142,Q8NBH6">fibulin-1</protein-id> levels with age (r = 0.38; p = 0.033), glycated hemoglobin (r = 0.80; p = 0.003), <compound-id="588">creatinine</compound-id> (r = 0.35; p = 0.045), and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.39; p = 0.027).	creatinine__fibrinogen__no_interaction	creatinine__fibulin-1__no_interaction
23246932-2	Optimum DLLME conditions (5 mL of <compound-id="962">water</compound-id> at pH=7.6, 20% (w/v) NaCl, 685 μL of CHCl₃ as extractant solvent, and 1250 μL of <protein-id="P35240,A0A024R1J9,A0A024R1J8,A0A024R1I0,A0A024R1F6,A0A024R1D9">ACN</protein-id> as disperser solvent) allowed the repeatable, accurate and selective determination of 11 sulfonamides (<compound-id="5333">sulfanilamide</compound-id>, <compound-id="23104500,5320">sulfacetamide</compound-id>, <compound-id="5215">sulfadiazine</compound-id>, <compound-id="5340">sulfathiazole</compound-id>, <compound-id="5327">sulfadimidin</compound-id>, <compound-id="5330">sulfamethoxypyridazine</compound-id>, <compound-id="17134">sulfadoxine</compound-id>, <compound-id="5329">sulfamethoxazole</compound-id>, <compound-id="5344">sulfisoxazole</compound-id>, <compound-id="5323">sulfadimethoxine</compound-id> and <compound-id="5338">sulfaquinoxaline</compound-id>) and 14 <compound-id="3036108">quinolones</compound-id> (<compound-id="4831">pipemidic acid</compound-id>, <compound-id="60651">marbofloxacin</compound-id>, <compound-id="3357">fleroxacin</compound-id>, <compound-id="149096">levofloxacin</compound-id>, <compound-id="51081">pefloxacin</compound-id>, <compound-id="2764">ciprofloxacin</compound-id>, <compound-id="3948">lomefloxacin</compound-id>, <compound-id="71335">danofloxacin</compound-id>, <compound-id="71188">enrofloxacin</compound-id>, <compound-id="56208">sarafloxacin</compound-id>, <compound-id="56206">difloxacin</compound-id>, <compound-id="152946">moxifloxacin</compound-id>, <compound-id="4628">oxolinic</compound-id> acid and <compound-id="3374">flumequine</compound-id>).	sulfathiazole__ACN__no_interaction	sarafloxacin__ACN__no_interaction	sulfadoxine__ACN__no_interaction	pipemidic acid__ACN__no_interaction	marbofloxacin__ACN__no_interaction	lomefloxacin__ACN__no_interaction	sulfamethoxazole__ACN__no_interaction	difloxacin__ACN__no_interaction	sulfamethoxypyridazine__ACN__no_interaction	sulfaquinoxaline__ACN__no_interaction	sulfadimethoxine__ACN__no_interaction	levofloxacin__ACN__no_interaction	enrofloxacin__ACN__no_interaction	sulfadiazine__ACN__no_interaction	pefloxacin__ACN__no_interaction	moxifloxacin__ACN__no_interaction	flumequine__ACN__no_interaction	danofloxacin__ACN__no_interaction	ciprofloxacin__ACN__no_interaction	water__ACN__no_interaction	fleroxacin__ACN__no_interaction	sulfisoxazole__ACN__no_interaction	sulfacetamide__ACN__no_interaction	oxolinic__ACN__no_interaction	sulfadimidin__ACN__no_interaction	sulfanilamide__ACN__no_interaction	quinolones__ACN__no_interaction
9309982-6	The numbers of <protein-id="P05113">IL-5</protein-id> mRNA copies relative to <protein-id="A5A3E0">beta-actin</protein-id> mRNA correlated with disease severity assessed by the Aas asthma score (r = 0.70, p = 0.01), baseline FEV1 (r = -0.94, p = 0.001), baseline peak expiratory flow rate (r = -0.77, p = 0.01), peak expiratory flow rate variability over 2 wk (r = 0.69, p = 0.028), and the <compound-id="774">histamine</compound-id> PC20 (r = -0.72, p = 0.018).	histamine__IL-5__no_interaction	histamine__beta-actin__no_interaction
17908053-6	The distribution of <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> genotypes in the Spanish population is the following: (a) Extensive Metabolizers (EM)(51.61%): *1/*1, 47.10%; and *1/*10, 4.52%; (b) Intermediate Metabolizers (IM)(32.26%): *1/*3, 1.95%; *1/*4, 17.42%; *1/*5, 3.87%; *1/*6, 2.58%; *1/*7, 0.75%; *10/*10, 1.30%; *4/*10, 3.23%; *6/*10, 0.65%; and *7/*10, 0.65%; (b) Poor Metabolizers (PM)(9.03%): *4/*4, 8.37%; and *5/*5, 0.65%; and (c) Ultrarapid Metabolizers (UM)(7.10%): *<compound-id="19935268">1xN</compound-id>/*1, 4.52%; *<compound-id="19935268">1xN</compound-id>/*4, 1.95%; and <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> gene duplications, 0.65%.	1xN__CYP2D6__no_interaction
1540242-1	The penetration of the <compound-id="57476835,60961">adenosine</compound-id> antagonists <compound-id="1917">8-cyclopentyl-1,3-dimethylxanthine</compound-id> (CPT), <compound-id="1329">8-cyclopentyl-1,3-dipropylxanthine</compound-id> (CPX), 8-(p-sulfophenyltheophylline (8-<protein-id="Q64692,Q53WR7,A0A087WRA0,Q6PAS1">PST</protein-id>), and 8-[4-[[[[(2-amino-<compound-id="23134249">ethyl</compound-id>)amino]carbonyl]methyl]oxy]phenyl]- <compound-id="169317">1,3-dipropylxanthine</compound-id> (<compound-id="5697">XAC</compound-id>) into mouse brain was determined using ex vivo binding and locomotor studies.	1,3-dipropylxanthine__PST__no_interaction	adenosine__PST__no_interaction	XAC__PST__no_interaction	8-cyclopentyl-1,3-dimethylxanthine__PST__no_interaction	8-cyclopentyl-1,3-dipropylxanthine__PST__no_interaction	ethyl__PST__no_interaction
6389747-6	Respective peak LH (micrograms/l) and <compound-id="6013">testosterone</compound-id> (nmol/l) responses to <protein-id="P01148">LHRH</protein-id> were as follows: 1 ng <protein-id="P01148">LHRH</protein-id> (3.0 +/- 0.7; 47.3 +/- 4.1); 5 ng <protein-id="P01148">LHRH</protein-id> (8.0 +/- 1.2; 52.8 +/- 6.2); 10 ng <protein-id="P01148">LHRH</protein-id> (11.1 +/- 2.3; 57.7 +/- 9.1); 50 ng <protein-id="P01148">LHRH</protein-id> (19.2 +/- 2.8; 47.9 +/- 8.6); 100 ng <protein-id="P01148">LHRH</protein-id> (19.1 +/- 4.7; 43.9 +/- 6.4).	testosterone__LHRH__no_interaction
16173912-8	Lifetime frequency of experienced violence was associated with higher basal <protein-id="Q10586">DBP</protein-id> (r = .33, p &lt; .05), HR (r = .33, p &lt; .05), and <compound-id="5754">cortisol</compound-id> (r = .53, p &lt; .00), and decreased <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> (beta = -.27, p &lt; .05) and <protein-id="Q10586">DBP</protein-id> (beta = -.31, p &lt; .05) reactivity.	cortisol__DBP__no_interaction	cortisol__SBP__no_interaction
18602884-8	On the contrary, PB C-glucuronidating activity was detected by <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id>((1-132))/<compound-id="71297183">1A8</compound-id>((133-286)), <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id>((1-212))/<compound-id="71297183">1A8</compound-id>((213-286)), <protein-id="O60656,Q5DSZ5">UGT1A8((1-68))/1A9</protein-id>((69-286)), and <protein-id="O60656,Q5DSZ5">UGT1A8((1-68))/1A9</protein-id>((69-132))/<compound-id="71297183">1A8</compound-id>((133-286)) chimeras.	1A8__UGT1A8((1-68))/1A9__no_interaction	1A8__UGT1A9__no_interaction
23817569-4	We identified 16 shared susceptibility loci with association P&lt;5×10(-8), including 8 loci previously associated with asthma, as well as 4p14 near <protein-id="Q15399">TLR1</protein-id>, <protein-id="Q9Y2C9,B2R933">TLR6</protein-id> and <protein-id="Q9BXR5,A0A024R9W4">TLR10</protein-id> (rs2101521, P=5.3×10(-21)); 6p21.33 near <protein-id="P10321,O19617,Q6R739,Q95HC2">HLA-C</protein-id> and <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id> (rs9266772, P=3.2×10(-12)); 5p13.1 near <protein-id="P35408,A0PJF5">PTGER4</protein-id> (rs7720838, P=8.2×10(-11)); 2q33.1 in <protein-id="Q15111">PLCL1</protein-id> (rs10497813, P=6.1×10(-10)), 3q28 in <compound-id="152192">LPP</compound-id> (rs9860547, P=1.2×10(-9)); 20q13.2 in <protein-id="Q13469,B5B2P4">NFATC2</protein-id> (rs6021270, P=6.9×10(-9)), 4q27 in <protein-id="Q96M93">ADAD1</protein-id> (rs17388568, P=3.9×10(-8)); and 14q21.1 near <protein-id="P55317">FOXA1</protein-id> and TTC6 (rs1998359, P=4.8×10(-8)).	LPP__FOXA1__no_interaction	LPP__NFATC2__no_interaction	LPP__HLA-C__no_interaction	LPP__PLCL1__no_interaction	LPP__TLR10__no_interaction	LPP__PTGER4__no_interaction	LPP__TLR1__no_interaction	LPP__TLR6__no_interaction	LPP__ADAD1__no_interaction	LPP__MICA__no_interaction
10671942-10	65, P &lt; 0.0001), fat mass (r = 0.51, P = 0.003), waist circumference (r = 0.64, P &lt; 0.0001), waist-to-hip ratio (r = 0.42, P = 0.01), <protein-id="P01308,I3WAC9">Insulin</protein-id> sensitivity (SI, r = - 0.61, P = 0.0001), <protein-id="P01308,I3WAC9">Insulin</protein-id> secretion (expressed as the acute <protein-id="P01308,I3WAC9">Insulin</protein-id> response to intravenous <compound-id="206,5793,64689,79025">glucose</compound-id>, AIRg) (r = 0.48, P = 0.006) and <protein-id="P41159,A4D0Y8">leptin</protein-id> concentration (r = 0.49, P = 0.004).	glucose__leptin__no_interaction	glucose__Insulin__no_interaction
14650355-5	Overweight adults with combined hyperlipidemia had significantly higher plasma levels of sICAM-1 (376.5 +/- 107.4 ng/mL vs 239.3 +/- 60.4 ng/mL; p &lt; 0.001), sE-<compound-id="4929">selectin</compound-id> (70.4 +/- 20.2 ng/mL vs 48.5 +/- 25.6 ng/mL; p = 0.005), sP-<compound-id="4929">selectin</compound-id> (228.2 +/- 88.6 ng/mL vs 123.1 +/- 45.3 ng/mL; p &lt; 0.001) and positive acute phase proteins <protein-id="P02763">ORM</protein-id> (0.82 +/- 0.16 g/L vs 0.64 +/- 0.20 g/L; p = 0.005), FBG (3.42 +/- 0.54 g/L vs 2.74 +/- 0.57 g/L; p = 0.037) and PAI-1 Ag (97.9 +/- 40.6 ng/mL vs 56.4 +/- 25.6 ng/mL; p &lt; 0.05), and a decrease of negative acute phase protein TRF (2.14 +/- 0.40 g/L vs 2.77 +/- 0.45 g/L; p &lt; 0.001) compared to the results in overweight non-hyperlipidemic controls.	selectin__ORM__no_interaction
15292311-8	We found no difference in hypercortisolemia or <protein-id="P01189,Q6FHC8">ACTH</protein-id> at diagnosis in males compared with females in the patients less than 18 yr of age [serum 0000 h cortisol, 510.5 +/- 75.2 vs. 415.6 +/- 63.7 nmol/liter (P = 0.52); plasma <protein-id="P01189,Q6FHC8">ACTH</protein-id>, 48.5 +/- 7.9 vs. 42.9 +/- 10.9 ng/liter (P = 0.54); percent suppression of serum cortisol during low dose <compound-id="5743">dexamethasone</compound-id> suppression test, 57.2 +/- 8.6% vs. 33.5 +/- 13.1% (P = 0.14); high dose <compound-id="5743">dexamethasone</compound-id> suppression test, 85.9 +/- 3.1% vs. 85.7 +/- 4.9% (P = 0.55); percent increase in cortisol after iv <protein-id="P06850">CRH</protein-id>, 180.3 +/- 15.3% vs. 189.9 +/- 20.3% (P = 0.67)].	dexamethasone__ACTH__no_interaction	dexamethasone__CRH__no_interaction
24034086-9	Compared with the saline treated EAE group, <protein-id="Q07456">UTI</protein-id> combined <compound-id="6741">methylprednisolone</compound-id> significantly increased expressions of <protein-id="P16330,Q3TYV5,Q3TYL9">CNP</protein-id> (1.14 ± 0.06 vs. 0.65 ± 0.04, P &lt; 0.001), <protein-id="P04370,Q5D096,Q542T4,Q3UGF3">MBP</protein-id> (1.28 ± 0.14 vs. 0.44 ± 0.17, P &lt; 0.001), and decreased expressions of proNGF (1.08 ± 0.10 vs. 2.32 ± 0.12, P &lt; 0.001), <protein-id="Q8CFT3">p75</protein-id> (1.13 ± 0.13 vs. 2.33 ± 0.17, P &lt; 0.001), and <protein-id="P29477">iNOS</protein-id> (1.05 ± 0.31 vs. 2.17 ± 0.13, P &lt; 0.001) proteins in EAE.	methylprednisolone__p75__no_interaction	methylprednisolone__UTI__no_interaction	methylprednisolone__MBP__no_interaction	methylprednisolone__CNP__no_interaction	methylprednisolone__iNOS__no_interaction
9175721-1	In this study, we determined whether the <protein-id="P30046,Q53Y51">DDT</protein-id> isomers p,p'-<protein-id="P30046,Q53Y51">DDT</protein-id> [1,1,1,-trichloro-<compound-id="19076">2,2-bis(p-chlorophenyl)ethane</compound-id>], o,p'-<protein-id="P30046,Q53Y51">DDT</protein-id> [1,1,1-trichloro-2(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="6324">ethane</compound-id>], and their metabolites p,p'-DDD [<compound-id="6294">1,1-dichloro-2,2-bis(p-chlorophenyl)ethane</compound-id>], <compound-id="4211">o,p'-DDD</compound-id> [1,1-dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="6324">ethane</compound-id>], p,p'-DDE [1,1,-dichloro-<compound-id="94775">2,2-bis(p-chlorophenyl)ethylene</compound-id>], <compound-id="246598">o,p'-DDE</compound-id> [1,1-dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="53675528,6325">ethylene</compound-id>], and p,p'-DDA [2,2-<compound-id="6730">bis(p-chlorophenyl)acetic acid</compound-id>], could bind to and transcriptionally activate the human <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor</protein-id> (hER).	ethylene__estrogen receptor__no_interaction	ethylene__DDT__no_interaction	bis(p-chlorophenyl)acetic acid__estrogen receptor__no_interaction	bis(p-chlorophenyl)acetic acid__DDT__no_interaction	1,1-dichloro-2,2-bis(p-chlorophenyl)ethane__estrogen receptor__no_interaction	1,1-dichloro-2,2-bis(p-chlorophenyl)ethane__DDT__no_interaction	2,2-bis(p-chlorophenyl)ethylene__estrogen receptor__no_interaction	2,2-bis(p-chlorophenyl)ethylene__DDT__no_interaction	2,2-bis(p-chlorophenyl)ethane__estrogen receptor__no_interaction	2,2-bis(p-chlorophenyl)ethane__DDT__no_interaction	ethane__estrogen receptor__no_interaction	ethane__DDT__no_interaction	o,p'-DDE__estrogen receptor__no_interaction	o,p'-DDE__DDT__no_interaction	o,p'-DDD__estrogen receptor__no_interaction	o,p'-DDD__DDT__no_interaction
15870635-4	RESULTS: 1) Pole force pattern with initial impact force peak and the following active force peak (<compound-id="70387">PPF</compound-id>) correlated to V85%, (r = 0.66, P &lt; 0.05); 2) active flexion-extension pattern in elbow, <protein-id="Q06141,Q53S56">hip</protein-id>, knee, and ankle joints with angle minima occurring around <compound-id="70387">PPF</compound-id>, correlated to <protein-id="Q06141,Q53S56">hip</protein-id> angle at pole plant (r = -0.89, P &lt; 0.01), minimum elbow angle (r = -0.71), and relative poling time (r = -0.72, P &lt; 0.05); 3) two different DP strategies (A and B), where strategy A (best skiers) was characterized by higher angular elbow- and <protein-id="Q06141,Q53S56">hip</protein-id>-flexion velocities, smaller minimum elbow (P &lt; 0.01) and <protein-id="Q06141,Q53S56">hip</protein-id> angles (P &lt; 0.05), and higher <compound-id="70387">PPF</compound-id> (P &lt; 0.05); 4) EMG activity in trunk and <protein-id="Q06141,Q53S56">hip</protein-id> flexors, shoulder, and elbow extensors, and several lower body muscles followed a specific sequential pattern with changing activation levels; and 5) EMG activity in lower body muscles showed DP requires more than upper body work.	PPF__hip__no_interaction
11126305-5	They also had a greater mean (+/- SD) difference between the lengths of their kidneys (29 +/- 10 vs 5 +/- 5 mm, P &lt; 0.001); greater systolic blood pressure (203 +/- 22 vs 174 +/- 25 mm Hg, P &lt; 0.005), plasma <protein-id="P00797">renin</protein-id> activity (17 +/- 19 vs 2 +/- 2 ng/mL/h, P = 0.005), and plasma aldosterone concentration (40 +/- 23 vs 11 +/- 10 ng/dL, P = 0.0001); and lower serum <compound-id="5462222">potassium</compound-id> levels (3.3 +/- 0.5 vs 3.8 +/- 0.5, P &lt;0.05).	potassium__renin__no_interaction
18247301-5	Although significant difference was not observed in the frequencies of <protein-id="P49789,A0A024R366">FHIT</protein-id> gene hypermethylation among patients with refractory anemia/refractory anemia with ringed sideroblasts (RA/RAS) (1/6, 16.7%), refractory anemia/refractory anemia with ringed sideroblasts (RCMD) and refractory cytopenia with multilineage dysplasia with ringed blasts (RCMD-<compound-id="7021454">RS</compound-id>) (6/19, 31.6%), refractory anemia with excess blasts-1 (RAEB-1) (7/11, 63.6%), refractory anemia with excess blasts-2 (RAEB-2) (4/7, 57.1%) and refractory anemia with excess blasts in transformation/acute myeloid leukemia (RAEBt/AML) (8/11, 72.7%)(chi-square=8.417, P=0.077), it was observed in patients in early stages (RA/RAS and RCMD) (7/25, 28.0%), advanced stages (RAEB-1 and RAEB-2)(11/18, 61.1%) and RAEBt/AML (8/11, 72.7%) (chi-square=7.938, P=0.019).	RS__FHIT__no_interaction
22564192-5	Treatment of 1 with <compound-id="23978">copper</compound-id> halides in 1:1 molar ratio resulted in the formation of one-dimensional (1D) coordination polymers, [(<protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id>){1,3-C(6)H(4){OP(μ-N(t)Bu)(2)PN(H)(t)Bu} }(2)](n) (7, X = Cl; 8, X = Br; 9, X = I), which showed the helical structure in solid state because of intramolecular <compound-id="783">hydrogen</compound-id> bonding, whereas similar reactions of 1 with 4 equiv of <compound-id="23978">copper</compound-id> halides also produced 1D-coordination polymers, [(Cu(2)X(2))(2){1,3-C(6)H(4){OP(μ-N(t)Bu)(2)PN(H)(t)Bu}(2)}](n) (10, X = Cl; 11, X = Br; 12, X = I), but containing Cu(2)X(2) rhomboids instead of <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> linkers.	copper__CuX__no_interaction	hydrogen__CuX__no_interaction
21785763-5	Interestingly, the [Fe(HL)(DBC)](+) and [Fe(<protein-id="Q14204">HL3</protein-id>)(HDBC)X] adducts, generated by adding ∼1 equivalent of <compound-id="8082">piperidine</compound-id> to solutions containing equimolar quantities of <compound-id="23925,67172434">iron</compound-id>(III) complexes 1-5 and H(2)DBC (<compound-id="66099">3,5-di-tert-butylcatechol</compound-id>), display two DBC(2-)→ <compound-id="23925,67172434">iron</compound-id>(III) LMCT bands (λ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 1, 577, 905; 2, 575,915; 3, 586, 920; 4, 563, 870; 5, 557, 856 nm; Δλ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), 299-340 nm); however, the bands are blue-shifted (λ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 1, 443, 700; 2, 425, 702; 3, 424, 684; 4, 431, 687; 5, 434, 685 nm; Δλ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), 251-277 nm) on adding 1 more equivalent of <compound-id="8082">piperidine</compound-id> to form the adducts [Fe(L)(DBC)] and [Fe(<protein-id="Q14204">HL3</protein-id>)(HDBC)X].	piperidine__max__no_interaction	piperidine__HL3__no_interaction	3,5-di-tert-butylcatechol__max__no_interaction	3,5-di-tert-butylcatechol__HL3__no_interaction	iron__max__no_interaction	iron__HL3__no_interaction
19787836-10	Furthermore, the levels of serum <protein-id="P17246">TGFbeta1</protein-id>, <protein-id="P16599">TNF-alpha</protein-id> and <protein-id="P20607">IL-6</protein-id> were strikingly reduced in the <compound-id="64982">baicalin</compound-id>-treated group compared with the model group, while the production of <protein-id="P29456">IL-10</protein-id> was up-regulated: (<protein-id="P17246">TGF-beta1</protein-id>: 260.21 +/- 31.01 pg/mL vs 375.49 +/- 57.47 pg/mL; <protein-id="P16599">TNF-alpha</protein-id>: 193.40 +/- 15.18 pg/mL vs 260.04 +/- 37.70 pg/mL; <protein-id="P20607">IL-6</protein-id>: 339.87 +/- 72.95 pg/mL vs 606.47 +/- 130.73 pg/mL; <protein-id="P29456">IL-10</protein-id>: 506.22 +/- 112.07 pg/mL vs 316.95 +/- 62.74 pg/mL, P &lt; 0.01).	baicalin__TNF-alpha__no_interaction	baicalin__TGF-beta1__no_interaction	baicalin__IL-10__no_interaction	baicalin__IL-6__no_interaction	baicalin__TGFbeta1__no_interaction
9640062-6	Median 24 l of blood (24-36) was processed collecting: 10.3 x 10(8)/kg (6.69-18.8) WBC, 9.9 x 10(8)/kg (5.87-16.02) MNC, 9.72 x 10(6)/kg (0.74-18.98) CD34+ cells, 242.5 x 10(6)/kg (77.9-422) T lymphocytes (<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ to <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>+ ratio was 1.5), 76 x 10(6)/kg (24-113) B lymphocytes, 33 x 10(6)/kg (14-88) NK cells and 168.8 x 104/kg (23.1-271.4) <compound-id="77620543">CFU</compound-id>-GM with 131.7 x 10(4)/kg (8.4-297.6) BFU-E. Engraftment times to a neutrophil count (ANC) &gt; 0.5 x 10(9)/l was achieved at a median of 15 days (range 10-23) in all patients whereas the platelet count &gt; 20 x 10(9)/l at a median of 14 days (9-19) in all but one patient who received the smallest dose of CD34+ cells.	CFU__CD4__no_interaction	CFU__CD8__no_interaction
8203337-3	Accordingly, we studied 36 patients with stable, moderate CHF in a double-blind, placebo-controlled, crossover fashion to evaluate by multiple discriminate regression analysis the pathophysiologic determinants of changes in blood pressure, glomerular filtration rate, and urinary <compound-id="5360545">sodium</compound-id> excretion after initial converting enzyme inhibition with <compound-id="44093">captopril</compound-id> 25 mg. A <compound-id="44093">captopril</compound-id>-mediated decrease in mean arterial pressure was predicted by 3 factors (r2 = 0.74): the decrease in serum <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin II</protein-id> (F ratio = 10.3, p &lt; 0.01), the decrease in plasma norepinephrine (F = 8, p = 0.02), and, inversely by pretreatment mean arterial pressure (F = 5.6, p = 0.04), patients with higher initial values exhibiting greater decreases in response to <compound-id="44093">captopril</compound-id>.	captopril__angiotensin II__no_interaction	sodium__angiotensin II__no_interaction
24753772-8	CA19-9 levels in the whole cohort were correlated with <protein-id="P05187,B2R7C7">ALP</protein-id> (r = 0.77, P &lt; 0.001), GGT (r = 0.83, P &lt; 0.001), <compound-id="5280352">bilirubin</compound-id> (r = 0.69, P &lt; 0.001), and CRP (r = 0.37, P = 0.004).	bilirubin__ALP__no_interaction
2173723-3	<compound-id="6371">Phosgene</compound-id> caused no increase in lung generation of cyclooxygenase metabolites and no elevation in pulmonary arterial pressure, but markedly increased transvascular fluid flux (delta W = 31 +/- 5 <compound-id="6371">phosgene</compound-id> vs. 8 +/- 1 g unexposed, P less than 0.001), permeability to <protein-id="P49065">albumin</protein-id> (125I-HSA) lung leak index 0.274 +/- 0.035 <compound-id="6371">phosgene</compound-id> vs. 0.019 +/- 0.001 unexposed, P less than 0.01; 125I-HSA lavage leak index 0.352 +/- 0.073 <compound-id="6371">phosgene</compound-id> vs. 0.008 +/- 0.001 unexposed, P less than 0.01), and lung <compound-id="10964">malondialdehyde</compound-id> (50 +/- 7 <compound-id="6371">phosgene</compound-id> vs. 24 +/- 0.7 mumol/g dry lung unexposed, P less than 0.01).	Phosgene__albumin__no_interaction	malondialdehyde__albumin__no_interaction	phosgene__albumin__no_interaction
11952361-3	X-ray crystal studies of these complexes 1-12, [Ca(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](PIC)(2).H(2)O (1), [Ca(HEEN)(PIC)](PIC) (2), Ba(<protein-id="Q86UF1">HPEN</protein-id>)(PIC)(2) (3), [Na(<protein-id="Q86UF1">HPEN</protein-id>)(PIC)](2) (4), Ca(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="8331">DNB</compound-id>)(2).H(2)O (5),Ca(HEEN)(H(2)O)](<compound-id="8331">DNB</compound-id>)(2).H(2)O (6), [Sr(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(3)](<compound-id="8331">DNB</compound-id>)(2) (7), [Ba(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="8331">DNB</compound-id>)(2).H(2)O](2) (8), [[Ba(HEEN)(H(2)O)(2)](ONB)(2)](2) (9), [[Sr(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="54058300,57080304,57201203">DNP</compound-id>)(2)](2) (10), [[Ba(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="54058300,57080304,57201203">DNP</compound-id>)(2)](2) (11), and [Ca(HEEN)(<compound-id="54058300,57080304,57201203">DNP</compound-id>)](<compound-id="54058300,57080304,57201203">DNP</compound-id>) (H(2)O) (12), have been carried out at room temperature.	DNP__HPEN__no_interaction	DNB__HPEN__no_interaction
10404042-6	The data demonstrated that: 1) bone marrow- and hepatic-derived stromal/adherent cells support preB cell growth and regulate apoptosis induced by DMBA or B[a]P; 2) B[a]P is more effective than DMBA when preB cells are maintained on Hepa-1c1c7 monolayers than when maintained on BMS2 monolayers; 3) DMBA is more effective than B[a]P when preB cells are cultured on BMS2 monolayers; 4) alpha-naphthoflavone, an <protein-id="P30561,Q3U5D9">AhR</protein-id> antagonist and cytochrome P-450 inhibitor, blocks preB cell apoptosis in both BU-11/Hepa-1c1c7 and BU-11/BMS2 cultures; 5) although preB cells grow well in Hepa-1c1c7 or BMS2 supernatants, addition of <compound-id="2148">PAH</compound-id> in the absence of hepatic- or bone marrow-derived adherent cells does not result in preB cell apoptosis; 6) preB cell apoptosis is dependent on <protein-id="P30561,Q3U5D9">AhR</protein-id> activity in adherent hepatic- or bone marrow-derived stromal cells; and 7) apoptosis is induced by DMBA when preB cells are maintained on primary bone marrow stromal cell monolayers from wildtype but not from <protein-id="P30561,Q3U5D9">AhR</protein-id>-/- mice.	PAH__AhR__no_interaction
17950096-7	No significant differences were seen in the blood levels of <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (7814 +/- 870 vs 8090 +/- 967 ng/mL), <protein-id="P41159,A4D0Y8">leptin</protein-id> (961 +/- 122 vs 965 +/- 147 pmol/L), <protein-id="Q9HD89">resistin</protein-id> (11.7 +/- 1.0 vs 11.3 +/- 0.7 ng/mL), <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor 1</protein-id> activity (23.9 +/- 2.2 vs 25.1 +/- 2.2 U/mL), tumor necrosis factor alpha (1.35 +/- 0.11 vs 1.72 +/- 0.28 pg/mL), and high-sensitivity C-reactive protein (3.09 +/- 0.84 vs 2.09 +/- 0.42 mg/L) between treatment with <compound-id="2162">amlodipine</compound-id> 10 mg or <compound-id="3961">losartan</compound-id> 100 mg + <compound-id="2162">amlodipine</compound-id> 5 mg, respectively.	amlodipine__plasminogen activator inhibitor 1__no_interaction	amlodipine__leptin__no_interaction	amlodipine__resistin__no_interaction	amlodipine__adiponectin__no_interaction	losartan__plasminogen activator inhibitor 1__no_interaction	losartan__leptin__no_interaction	losartan__resistin__no_interaction	losartan__adiponectin__no_interaction
22449109-9	High hs-<protein-id="P02741">CRP</protein-id> was an independent risk factor for all-cause death (HR, 6.48; 95% CI, 1.41 to 29.8; P= 0.016), as well as history of atrial fibrillation (HR, 5.24; 95% CI, 1.83 to 15.0; P= 0.002), no statin therapy during hospitalization (HR, 4.56; 95% CI, 2.18 to 9.55; P &lt; 0.001), high <compound-id="778,91552">homocysteine</compound-id> (&gt;15.1 mmol/L) (HR, 2.66; 95% CI, 1.26 to 5.60; P= 0.01); fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (&gt;6.1 mmol/L) (HR, 9.14; 95% CI, 3.34 to 25.0; P &lt; 0.001), NIHSS at admission (HR, 2.35; 95% CI, 1.35 to 4.09; P= 0.003) and history of coronary heart disease (<compound-id="221493">CHD</compound-id>) (HR, 2.34; 95% CI, 1.06 to 5.17; P= 0.035).	homocysteine__CRP__no_interaction	CHD__CRP__no_interaction	glucose__CRP__no_interaction
15206663-6	Consistent with previous reports, the correlation between total <compound-id="5073">risperidone</compound-id> level and <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> was very high (r = 0.92, df = 12, P &lt; 0.0001), but <compound-id="5073">risperidone</compound-id> did not appear to affect either <compound-id="6013">testosterone</compound-id> (r = 0.29, df = 5, P = 0.51) or free and weakly bound <compound-id="6013">testosterone</compound-id> (r = -0.11, df = 10, P = 0.72).	risperidone__PRL__no_interaction	testosterone__PRL__no_interaction
10711772-10	Age (r = 0.327, p &lt; 0.001), KITT (r = -0.201, p &lt; 0.01), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.187, p &lt; 0.01), LDL-chol (r = 0.201, p &lt; 0.01), smoking (r = 0.147, p &lt; 0.05), <protein-id="P02686,A0A024R384">MBP</protein-id> levels (r = 0.154, p &lt; 0.05), <compound-id="5997">cholesterol</compound-id> (r = 0.152, p &lt; 0.05) and HDL-chol (r = -0.159, p &lt; 0.05) were also significantly associated with <compound-id="447041">IMT</compound-id>.	cholesterol__MBP__no_interaction	IMT__MBP__no_interaction	glucose__MBP__no_interaction
23511286-6	<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin (IL)-6</protein-id> increased to a mean (± <compound-id="5289348">SEM</compound-id>) of 2.16 ± 0.61 to 3.81 ± 0.49 pg/mg (P &lt; .05), as did <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (3.32 ± 0.76 to 20.51 ± 6.65 pg/mg; P &lt; .05), IL-12 (6.23±0.98 to 8.11±0.95pg/mg; P=0.01), <protein-id="P35225">IL-13</protein-id> (3.86 ± 0.32 to 11.83 ± 1.47 pg/mg; P &lt; .05), <protein-id="P13500">monocyte chemoattractant protein-1</protein-id> (2.78 ± 2.61 to 6.5 ± 3.97 pg/mg; P &lt; .05), <protein-id="P05164">MPO</protein-id> (13.41 ± 1.40 to 24.52 ± 4.31 units/mg protein; P &lt; .05), and elastase (2.46 ± 0.38 to 5.08 ± 0.72 pg/mL; P &lt; .05).	SEM__Interleukin (IL)-6__no_interaction	SEM__MPO__no_interaction	SEM__IL-8__no_interaction	SEM__IL-13__no_interaction	SEM__monocyte chemoattractant protein-1__no_interaction
11168785-6	RESULTS: The mean common carotid artery intima-media thickness (<compound-id="447041">IMT</compound-id>), but not the common femoral <compound-id="447041">IMT</compound-id>, correlated significantly with <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rate (<compound-id="65911">GIR</compound-id>) (r = - 0.20, P &lt; 0.05), systolic blood pressure (r = 0.20, P &lt; 0.05), pulse pressure (r = 0.23 P &lt; 0.01), heart rate (r = 0.20, P &lt; 0.05), HDL <compound-id="5997">cholesterol</compound-id> (r = - 0.18, P &lt; 0.05), log triglycerides (r = 0.28, P &lt; 0.01), <protein-id="P02647,A0A024R3E3">apoA1</protein-id> (r = - 0.20, P &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (r = 0.21, P &lt; 0.05), LDL particle size (r = - 0.22, P &lt; 0.05) and plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> (r = 0.20, P &lt; 0.05).	cholesterol__apoB__no_interaction	cholesterol__apoA1__no_interaction	cholesterol__Insulin__no_interaction	IMT__apoB__no_interaction	IMT__apoA1__no_interaction	IMT__Insulin__no_interaction	GIR__apoB__no_interaction	GIR__apoA1__no_interaction	GIR__Insulin__no_interaction	glucose__apoB__no_interaction	glucose__apoA1__no_interaction	glucose__Insulin__no_interaction
1655340-4	Continuous intravenous infusion of two doses of synthetic rat <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id>, 300 ng/h per rat (0.10 pmol/h per rat) and 800 ng/h per rat (0.28 pmol/h per rat), attenuated the development of pulmonary hypertension in rats exposed to chronic hypoxia (fractional concentration of <compound-id="977">oxygen</compound-id> in inspired air = 10%) for 7 days: (i) the pulmonary artery pressure (mean +/- SD) in the vehicle-treated hypoxic group was 45 +/- 6 mmHg compared with 28 +/- 6 mmHg in the vehicle-treated normotoxic group (n = 8, P less than 0.001); (ii) treatment with <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id> in normoxia did not alter the pulmonary artery pressure, systemic blood pressure or heart rate; (iii) treatment with <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id> in hypoxia resulted in a lower pulmonary artery pressure in the group treated with 800 ng of <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id>/h per rat (38 +/- 8 mmHg, P less than 0.05 compared with the vehicle-treated hypoxic group) without affecting the systemic blood pressure or heart rate.	oxygen__atrial natriuretic peptide__no_interaction
23612925-1	A series of <compound-id="962">water</compound-id> soluble <compound-id="23978">copper</compound-id>(II) complexes of the types [Cu(L)Cl] 1-2, where LH is 2-(2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="535674">ethyliminomethyl</compound-id>)<compound-id="996">phenol</compound-id> (<protein-id="P07306,Q6FGQ5">H(L1</protein-id>)), and 2-(2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)-<compound-id="535674">ethyliminomethyl</compound-id>)-<compound-id="2879">4-methylphenol</compound-id> (<protein-id="Q9C0G6">H(L2</protein-id>)), and [Cu(L)<compound-id="24526">Cl2</compound-id>] 3-6, where L is (2-pyridin-2-yl-<compound-id="23134249">ethyl</compound-id>)pyridin-2-ylmethyleneamine (L3), 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="7523">ethylpyridin</compound-id>-2-yl-<compound-id="123139">methyleneamine</compound-id> (L4), 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="23134249">ethyl</compound-id>(<compound-id="795">1H-imidazol</compound-id>-2-ylmethylene)amine (L5), and 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="23134249">ethyl</compound-id>-(4,4a-<compound-id="5231402">dihydroquinolin</compound-id>-2-ylmethylene)amine (L6), have been isolated and characterized by elemental analysis, electronic absorption, ESI-MS and EPR spectral techniques and the electrochemical method.	copper__H(L1__no_interaction	copper__H(L2__no_interaction	4-methylphenol__H(L1__no_interaction	4-methylphenol__H(L2__no_interaction	ethylpyridin__H(L1__no_interaction	ethylpyridin__H(L2__no_interaction	1H-imidazol__H(L1__no_interaction	1H-imidazol__H(L2__no_interaction	dihydroquinolin__H(L1__no_interaction	dihydroquinolin__H(L2__no_interaction	water__H(L1__no_interaction	water__H(L2__no_interaction	1H-benzimidazol__H(L1__no_interaction	1H-benzimidazol__H(L2__no_interaction	methyleneamine__H(L1__no_interaction	methyleneamine__H(L2__no_interaction	phenol__H(L1__no_interaction	phenol__H(L2__no_interaction	ethyliminomethyl__H(L1__no_interaction	ethyliminomethyl__H(L2__no_interaction	Cl2__H(L1__no_interaction	Cl2__H(L2__no_interaction	ethyl__H(L1__no_interaction	ethyl__H(L2__no_interaction
12503477-5	RESULTS: Markers of endothelial cell damage and coagulation activation were significantly elevated in patients with lung injury compared with controls: <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>) 4.12 vs. 1.25 U/ml, p &lt; 0.0001; F VIII 4.40 vs. 1.88 U/ml, p = 0.0001; <protein-id="P00750">tissue-type plasminogen activator</protein-id> (<protein-id="P00750">tPA</protein-id>) 11.6 vs. 8.7 ng/ml, p = 0.02; <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor-1</protein-id> (<protein-id="P05121,A0A024QYT5">PAI</protein-id>) 48.9 vs. 14.6 ng/ml, p &lt; 0.0001; D-dimer 2.9 vs. 0.6 microgram/ml, p &lt; 0.0001; <compound-id="90470996">thrombin</compound-id>-antithrombin III complex (TAT) 7.9 vs. 2.2 ng/ml, p &lt; 0.0001 (median values; Mann-Whitney U-test).	thrombin__von Willebrand factor__no_interaction	thrombin__tPA__no_interaction	thrombin__plasminogen activator inhibitor-1__no_interaction	thrombin__tissue-type plasminogen activator__no_interaction	thrombin__PAI__no_interaction	thrombin__vWF__no_interaction
7532302-2	Isosmotic replacement of Na+ in the extracellular medium with the nonpermeant Na+ analogue choline+ or with <compound-id="206,5793,64689,79025">glucose</compound-id> led to a significant increase in anti-IgE- (1/5000: 43.7 +/- 7.3% in high Na+ vs 68.9 +/- 7.3% in low Na+, mean +/- <compound-id="5289348">SEM</compound-id>, n = 8, P &lt; 0.001), <protein-id="P21462">FMLP</protein-id>- (1 microM: 37.9 +/- 2.3% vs 49.5 +/- 4.3%, n = 8, P &lt; 0.01) and PMA-(160 nM: 12.7 +/- 0.9% vs 27.3 +/- 4.3%, n = 8, P &lt; 0.05) induced <compound-id="774">histamine</compound-id> release, whereas A23187-induced <compound-id="774">histamine</compound-id> release was reduced (1 microM: 90.4 +/- 2.4% vs 45.4 +/- 3.4%, n = 8, P &lt; 0.0001).	SEM__FMLP__no_interaction	histamine__FMLP__no_interaction	glucose__FMLP__no_interaction
15312156-9	The reductions in 24-h trough BP were more pronounced in <compound-id="2162">amlodipine</compound-id> compared with <compound-id="60846">valsartan</compound-id> group as well in office [SBP: -17.8 +/- 10.9 vs. -14.6 +/- 11.2, P = 0.025, <protein-id="Q10586">DBP</protein-id>: -12.7 +/- 7.2 vs. -10.9 +/- 7.8 mmHg, P = 0.06) as in ambulatory BP (SBP/<protein-id="Q10586">DBP</protein-id>: -13.0 +/- 13.7/-10.8 +/- 9.1 vs. -7.2 +/- 19.4/-4.9 +/- 13.4 mmHg, P &lt; 0.05).	amlodipine__DBP__no_interaction	valsartan__DBP__no_interaction
24107872-1	The treatment of the hydridorhodathiaboranes, [8,8,8-(H)(<protein-id="P24158">PR3</protein-id>)2-9-(Py)-nido-8,7-RhSB9H9], where <protein-id="P24158">PR3</protein-id> = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (2), PMePh2 (3), <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> and PMe2Ph (4), or <compound-id="68983">PMe3</compound-id> and <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (5), and [8,8,8-(H)(PMePh2)2-9-(PMePh2)-nido-8,7-RhSB9H9] (6), with <compound-id="62406">TfOH</compound-id> affords [8,8,8-(H)(<protein-id="P24158">PR3</protein-id>)2-9-(Py)-nido-8,7-RhSB9H10](+) cations, where <protein-id="P24158">PR3</protein-id> = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (12), PMePh2 (13), <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> and PMe2Ph (14), or <compound-id="68983">PMe3</compound-id> and <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (15), and [8,8,8-(H)(PMePh2)2-9-(PMePh2)-nido-8,7-RhSB9H10](+) (16).	PMe3__PR3__no_interaction	PMe3__PPh3__no_interaction	TfOH__PR3__no_interaction	TfOH__PPh3__no_interaction
1573640-1	This paper describes the chemical synthesis and <protein-id="P32239">CCK-B</protein-id> and <protein-id="P32238">CCK-A receptor</protein-id> binding affinities of a series of compounds in which the central <compound-id="2826723">amide</compound-id> bond of the <protein-id="P32239">CCK-B</protein-id> "dipeptoid" ligand tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,S*)]-[2-[[1-(hydroxymethyl)- 2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]carb amate (4) (<protein-id="P32239">CCK-B</protein-id> IC50 = 852 nM), and tricyclo[3.3.1.1(3,7)]dec-2-yl (R)-[1-(1H-indol-3-ylmethyl)-1-methyl- 2-oxo-2-[(2-phenylethyl)amino]<compound-id="23134249">ethyl</compound-id>]<compound-id="277">carbamate</compound-id> (23) (<protein-id="P32239">CCK-B</protein-id> IC50 = 32 nM) is replaced by 11 different <compound-id="2826723">amide</compound-id> replacements.	ethyl__CCK-B__no_interaction	ethyl__CCK-A receptor__no_interaction	carbamate__CCK-B__no_interaction	carbamate__CCK-A receptor__no_interaction	amide__CCK-B__no_interaction	amide__CCK-A receptor__no_interaction
24333775-3	In mice, C57Bl/6 males, intraplantar BoNT-B (1 U) given unilaterally into the hind paw had no effect upon survival or motor function, but ipsilaterally decreased: (1) intraplantar <compound-id="712">formalin</compound-id>-evoked flinching; (2) intraplantar <compound-id="2548">capsaicin-</compound-id>evoked plasma extravasation in the hind paw measured by <compound-id="5356750,6913958">Evans blue</compound-id> in the paw; (3) intraplantar <compound-id="712">formalin</compound-id>-evoked dorsal horn <protein-id="P41539,B7ZMQ2,Q149W7">substance P</protein-id> (SP) release (neurokinin 1 [NK1] receptor internalization); (4) intraplantar <compound-id="712">formalin</compound-id>-evoked dorsal horn neuronal activation (<protein-id="P01101">c-fos</protein-id>); (5) ipsilateral dorsal root ganglion (DRG) vesicle-associated membrane protein (<compound-id="90479729">VAMP</compound-id>); (6) ipsilateral SP release otherwise evoked bilaterally by intrathecal <compound-id="1548943">capsaicin</compound-id>; (7) ipsilateral activation of <protein-id="P01101">c-fos</protein-id> otherwise evoked bilaterally by intrathecal SP.	formalin__substance P__no_interaction	formalin__c-fos__no_interaction	capsaicin-__substance P__no_interaction	capsaicin-__c-fos__no_interaction	VAMP__substance P__no_interaction	VAMP__c-fos__no_interaction	capsaicin__substance P__no_interaction	capsaicin__c-fos__no_interaction	Evans blue__substance P__no_interaction	Evans blue__c-fos__no_interaction
12022998-12	The gallbladder responses were also greater when mice were treated with <protein-id="P57774">neuropeptide Y</protein-id> (10(-8) mol/L: 0.00 +/- 0.00 vs. 0.00 +/- 0.00, NS; 10(-7) mol/L: 0.12 +/- 0.02 vs. 0.05 +/- 0.01, P &lt; 0.01; 10(-6) mol/L: 0.26 +/- 0.08 vs. 0.06 +/- 0.01, P &lt; 0.01) and <compound-id="16129670">cholecystokinin</compound-id> (10(-10) mol/L: 0.27 +/- 0.04 vs. 0.13 +/- 0.02, P &lt; 0.01; 10(-9) mol/L: 0.59 +/- 0.08 vs. 0.27 +/- 0.04, P &lt; 0.01; 10(-8) mol/L: 0.80 +/- 0.11 vs. 0.37 +/- 0.05, P &lt; 0.01; 10(-7) mol/L: 0.86 +/- 0.11 vs. 0.44 +/- 0.06, P &lt; 0.01).	cholecystokinin__neuropeptide Y__no_interaction
22865637-1	A substituted <compound-id="5323619">2,6-bis(pyrazol-3-yl)pyridine</compound-id> (3-bpp) ligand, <protein-id="Q99525">H(4)L</protein-id>, created to facilitate intermolecular interactions in the solid, has been used to obtain four novel Fe(II) complexes: [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅2 CH(3)NO(2)⋅2 H(2)O, [Fe(<protein-id="Q99525">H(4)L</protein-id>)(H(2)<compound-id="479">LBF</compound-id>(2))](BF(4))⋅5 C(3)H(6)O (H(2)<compound-id="479">LBF</compound-id>(2) is an in situ modified version of <protein-id="Q99525">H(4)L</protein-id>), [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅2 C(3)H(7)OH and [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅4 C(2)H(5)OH.	2,6-bis(pyrazol-3-yl)pyridine__H(4)L__no_interaction	LBF__H(4)L__no_interaction
16423635-5	Serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> level was negatively correlated to HOMA-IR (r = -0.288, P = .005), BMI (r = -0.308, P = .002), diastolic blood pressure (r = -0.269, P = .012), and triglycerides (r = -0.338, P &lt; .001), and positively correlated to high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.300, P = .003) in our patients.	cholesterol__adiponectin__no_interaction
14600946-12	RESULTS: Compared to control, no statistical differences in the levels of <protein-id="P16581">E-selectin</protein-id> (C--44.4 +/- 11 ng/ml) and <protein-id="P14151,A0A024R8Z0">L-selectin</protein-id> (C--842 +/- 168.9 ng/ml) were observed before treatment in the patients with GD (E-<compound-id="68294">sel</compound-id>.--59.8 +/- 19.6 ng/ml; L-<compound-id="68294">sel</compound-id>.--1288.2 +/- 273.5 ng/ml) and with TNG (E-<compound-id="68294">sel</compound-id>.--61.5 +/- 18.4 ng/ml, L-<compound-id="68294">sel</compound-id>.--1247.0 +/- 273.5 ng/ml) as well as in the 6th week after I-131 administration; values in GD group were: E-<compound-id="68294">sel</compound-id>.--57.3 +/- 19.5 ng/ml, L-<compound-id="68294">sel</compound-id>.--1142.4 +/- 193.4 ng/ml; in TNG group: E-<compound-id="68294">sel</compound-id>.--62.1 +/- 20.6 ng/ml, L-<compound-id="68294">sel</compound-id>.--1113.5 +/- 236.3 ng/ml.	sel__E-selectin__no_interaction	sel__L-selectin__no_interaction
8039152-3	The randomized comparisons are: (1) <compound-id="2733526">tamoxifen</compound-id> 2 years versus 5 years in postmenopausal stage I-II patients, (2) sequential <compound-id="2733526">tamoxifen</compound-id>/<compound-id="19090">megestrol</compound-id> in alternating 3 months cycles for 2 years versus <compound-id="2733526">tamoxifen</compound-id> alone for 2 years in <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor</protein-id> (ER)-positive, postmenopausal stage I-II patients, (3) <compound-id="2733526">tamoxifen</compound-id> for 2 years versus <compound-id="2733526">tamoxifen</compound-id>+<protein-id="P01148">LHRH</protein-id>-analogue for 2 years versus <protein-id="P01148">LHRH</protein-id>-analogue alone versus control in premenopausal stage I-II patients, (4) CMF chemotherapy versus radiological castration in ER-positive, premenopausal stage II patients, (5) high-dose chemotherapy+autologous bone marrow transplantation versus conventional chemotherapy in high-risk (pN6+) stage II patients aged under 60 years, (6) postoperative radiotherapy to the breast versus control after breast-conserving surgery for invasive stage I-II breast cancer, (7) postoperative radiotherapy to the breast versus control after breast-conserving surgery for ductal carcinoma in situ (DCIS), and (8) CMF- or FEC-chemotherapy plus APD (<compound-id="4674">pamidronate</compound-id>) versus the same chemotherapy without APD.	pamidronate__LHRH__no_interaction	pamidronate__estrogen receptor__no_interaction	tamoxifen__LHRH__no_interaction	tamoxifen__estrogen receptor__no_interaction	megestrol__LHRH__no_interaction	megestrol__estrogen receptor__no_interaction
10463551-8	Among moderate-risk patients with and without IAIs, those with IAIs were more likely to have abdominal abrasions (5/22 vs 34/459, p = 0.008), an abnormal chest examination (11/22 vs 86/457, p = 0.01), higher mean serum concentrations of <compound-id="5960">aspartate</compound-id> aminotransferase (<protein-id="Q9NRA2">AST</protein-id>) (604 U/L vs 77 U/L, p &lt; 0.001) and <compound-id="5950,602">alanine</compound-id> aminotransferase (ALT) (276 U/L vs 39 U/L, p = 0.002), higher mean white blood cell (WBC) counts (16.3 K/mm3 vs 12.8 K/mm3, p &lt; 0.001), and a higher prevalence of &gt;5 RBCs/hpf on urinalysis (7/22 vs 54/427, p = 0.02).	alanine__AST__no_interaction	aspartate__AST__no_interaction
20812749-1	<protein-id="P07954">MCl</protein-id>(3) react with o-C(6)H(4)(EMe)(2) (E = S, Se) or o-C(6)H(4)(CH(2)ER)(2) (E = S, R = Me or Et; E = Se, R = Me) in anhydrous CH(2)Cl(2) or <compound-id="6342">MeCN</compound-id> to give the yellow (Bi) or white (Sb) complexes, [<protein-id="P07954">MCl</protein-id>(3){o-C(6)H(4)(EMe)(2)}], [(<protein-id="P07954">MCl</protein-id>(3))(2){o-C(6)H(4)(CH(2)SMe)(2)}(3)], [<protein-id="P07954">MCl</protein-id>(3){o-C(6)H(4)(CH(2)SEt)(2)}], and [(BiCl(3))(4){o-C(6)H(4)(CH(2)SeMe)(2)}(3)], which were characterized by IR/Raman, (1)H NMR spectroscopy, and microanalysis.	MeCN__MCl__no_interaction
2581959-3	This conclusion is based on the following data: 1) <compound-id="5280723">prostaglandin E1</compound-id> (PGE1) activated and alpha 2-adrenergic treatment inhibited <compound-id="6083">adenylate</compound-id> cyclase activation in PMN plasma membranes; <compound-id="443295">fMet-Leu-Phe</compound-id>, however, neither activated nor inhibited <compound-id="6083">adenylate</compound-id> cyclase in these membranes; 2) depletion of extracellular Ca2+ had no effect on <compound-id="3779">isoproterenol</compound-id> and PGE1 elicited <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact PMNs while peak <compound-id="443295">fMet-Leu-Phe</compound-id> and <compound-id="40486">A23187</compound-id>-induced responses were reduced by approximately 50 and 80%, respectively; 3) 8-(N,N-diethylamino)-octyl-<compound-id="8357">3,4,5-trimethoxybenzoate</compound-id>, a purported Ca2+ antagonist, caused almost complete inhibition of <compound-id="443295">fMet-Leu-Phe</compound-id> and ionophore-induced <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact cells but had no effect on PGE1 and <compound-id="3779">isoproterenol</compound-id>; 4) alpha 2-adrenergic agonists inhibited PGE1 but not chemoattractant- or <compound-id="40486">A23187</compound-id>-elicited <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact PMNs; and 5) pretreatment of cells with a phosphodiesterase inhibitor (isobutylmethylxanthine) greatly potentiated the PGE1 and <compound-id="3779">isoproterenol</compound-id> <protein-id="P49913,J3KNB4">cAMP</protein-id> responses but nearly abolished the peak <compound-id="443295">fMet-Leu-Phe</compound-id> response.	isoproterenol__cAMP__no_interaction	3,4,5-trimethoxybenzoate__cAMP__no_interaction	prostaglandin E1__cAMP__no_interaction	A23187__cAMP__no_interaction	adenylate__cAMP__no_interaction	fMet-Leu-Phe__cAMP__no_interaction
11601684-2	Reference intervals were established for three different times of the day: in morning samples (05.45-07.15) the limit of detection (LOD) was 2.10 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (82 women) and 2.86 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (37 men), and the reference interval was 3.6-29.1 micromol norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> and 2.3-52.8 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (119 women and men); in afternoon samples (15.30-18.30) the reference interval was 0.64-10.8 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (82 women), 1.20-11.2 micromol/<compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (36 men), 11.0-54.1 micromol/ norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> and LOD was 42.4 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (117 women and men); in evening samples (21.45-23.45) LOD was 8.66 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (81 women) and 7.99 micromol/<compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (36 men), the reference interval was 11.0-54.1 micromol norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id>, and LOD was 42.4 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (117 women and men).	creatinine__mol__no_interaction	epinephrine__mol__no_interaction	cortisol__mol__no_interaction
22174545-8	The number of the apoptotic colonic epithelial cells in <compound-id="5494424">HPM</compound-id>, MWM and SASP groups was largely reduced (61.5 ± 16.91 vs 15.5 ± 8.89, 14.8 ± 6.27 and 24.7 ± 9.68, respectively (P = 0.001); and the expression of <protein-id="Q6P6T5">occludin</protein-id>, <protein-id="P56745">claudin-1</protein-id> and <protein-id="F1M4A0">ZO-1</protein-id> in the MWM and <compound-id="5494424">HPM</compound-id> groups was significantly enhanced (0.48 ± 0.10, 0.64 ± 0.09 vs 0.18 ± 0.05 for <protein-id="Q6P6T5">occludin</protein-id>, 0.12 ± 0.02, 0.17 ± 0.03 vs 0.05 ± 0.01 for <protein-id="P56745">claudin-1</protein-id>, and 0.08 ± 0.01, 0.11 ± 0.01 vs 0.02 ± 0.01 for <protein-id="F1M4A0">ZO-1</protein-id>).	HPM__occludin__no_interaction	HPM__ZO-1__no_interaction	HPM__claudin-1__no_interaction
15345837-1	The structures of three compounds, namely <compound-id="91407687">7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C19H11F3N2O2, (Id), <compound-id="91084899">6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C19H11F3N2O2, (<compound-id="6540267">IId</compound-id>), and <compound-id="91255250">2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C16H13F3N2O2, (IIf), which are potent reversible type-B monoamine oxidase (<protein-id="P27338,B7Z242">MAO-B</protein-id>) inhibitors, are presented and discussed.	IId__MAO-B__no_interaction	2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction	6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction	7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction
17707803-7	In both male rats and mice, an increasing renal uptake was found: [(111)In-<compound-id="3053">DTPA</compound-id>]CCK8&lt;[(111)In-<compound-id="3053">DTPA</compound-id>-Pro(1),<compound-id="6057">Tyr</compound-id>(4)]bombesin approximately [(111)In-<compound-id="3053">DTPA</compound-id>]<protein-id="Q9D3P9">neurotensin</protein-id>&lt;[(111)In-<compound-id="3053">DTPA</compound-id>]<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id>&lt;&lt;[(111)In-<compound-id="3053">DTPA</compound-id>]MG0.	DTPA__neurotensin__no_interaction	Tyr__neurotensin__no_interaction	octreotide__neurotensin__no_interaction
16955257-3	The metabolites are products of: 1) monohydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 344, M20 and <compound-id="6431318">M21</compound-id>), <compound-id="798">indole</compound-id> ring (m/z 344, <compound-id="86287484">M17</compound-id> and <compound-id="24754814">M18</compound-id>), or the N-alkyl group (m/z 344, <compound-id="16044960">M14</compound-id>); 2) arene oxidation leading to dihydrodiols (m/z 362, M12 and <compound-id="16132126">M15</compound-id>); 3) dihydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 360, <compound-id="54884">M7</compound-id>) or <compound-id="798">indole</compound-id> ring (m/z 360, M13), resulting from a combination of monohydroxylations on both the <compound-id="931">naphthalene</compound-id> and <compound-id="798">indole</compound-id> rings (m/z 360, M16), or a combination of monohydroxylations on the <compound-id="931">naphthalene</compound-id> ring and on the N-propyl group (m/z 360, <compound-id="11400707">M9</compound-id>); 4) trihydroxylation (m/z 378, M1, M3, M4, M6, and <compound-id="76871900">M10</compound-id>); 5) N-dealkylation (m/z 286, <protein-id="Q9BRT2">M19</protein-id>); 6) N-dealkylation and monohydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 302, <compound-id="25021181">M11</compound-id>); 7) N-dealkylation and dihydrodiol formation from arene oxidation (m/z 320, M2 and M5); 8) dehydrogenation after monohydroxylation on the N-alkyl group (m/z 326, <compound-id="16045336">M22</compound-id>); 9) dehydrogenation and monohydroxylation on the <compound-id="798">indole</compound-id> ring (m/z 342, M8).	indole__M19__no_interaction	M21__M19__no_interaction	M22__M19__no_interaction	M11__M19__no_interaction	M10__M19__no_interaction	M7__M19__no_interaction	M15__M19__no_interaction	M14__M19__no_interaction	M17__M19__no_interaction	M18__M19__no_interaction	M9__M19__no_interaction	naphthalene__M19__no_interaction
1340881-4	Between 30 and 50 years of age, the prevalence of risk factors was greater in males than females; 27.3% of males vs 16.0 of females had CT &gt; or = 240 mg/dl (p &lt; 0.05), 30.5% vs 19.7%, had CLDL &gt; or = 160 mg/dl (p &lt; 0.05), 10.3% vs 5.9%, had <protein-id="Q86WJ1,B4DPN5,A0A0A0MRH8,A0A0A0MSH9,Q9H678">CHDL</protein-id> &lt; 35 mg/dl, 8.9% vs 4.2% had PS &gt; 145 mmHg, 9.0% vs 5.9%, had PD &gt; 90 mm Hg, 33.6% vs 23.4%, had <compound-id="118458">Cig</compound-id> &gt; or = 10/d (p &lt; 0.05), 26.0% vs 13.8% had TG &gt; 170 mg/dl (p &lt; 0.05), 30.5% vs 22.4%, had BMI &gt; 27 Kg/m2 (p &lt; 0.05) (Figs.	Cig__CHDL__no_interaction
20923925-13	Moreover, the cultured supernatant in CD-exposed cells contained significantly higher levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (4.09 ± 0.36 vs 2.73 ± 0.38 pg/mL, P &lt; 0.01, 24 h; 4.28 ± 0.32 vs 2.83 ± 0.32 pg/mL, P &lt; 0.01, 48 h) and tumour necrosis factor α (3.45 ± 0.79 vs 2.44 ± 0.39 pg/mL, P &lt; 0.05, 24 h; 4.60 ± 0.57 vs 2.50 ± 0.37 pg/mL, P &lt; 0.01, 48 h) than those of <compound-id="5459917,5280361">HPD</compound-id>.	HPD__interleukin-6__no_interaction
1495014-3	The cis-(2S,4R) isomer 2 was the most effective against rat <protein-id="Q64654">lanosterol 14 alpha-demethylase</protein-id>, (2S,4R)-2 greater than (2R,4S)-4 much greater than (2R,4R)-3 = (2S,4S)-5, and <compound-id="5994">progesterone</compound-id> 17 alpha,20-lyase, (2S,4R)-2 much greater than (2S,4S)-5 greater than (2R,4R)-3 = (2R,4S)-4, whereas the cis-(2R,4S) isomer 4 was more effective against <protein-id="P18125">cholesterol 7 alpha-hydroxylase</protein-id>, (2R,4S)-4 greater than (2S,4S)-5 greater than (2R,4R)-3, greater than (2S,4R)-2, and the trans-(2S,4S) isomer 5 was the most effective against aromatase, (2S,4R)-5 much greater than (2R,4R)-3 = (2R,4S)-4 greater than (2S,4R)-2.	progesterone__cholesterol 7 alpha-hydroxylase__no_interaction	progesterone__lanosterol 14 alpha-demethylase__no_interaction
10208256-2	In vitro -<protein-id="O00548">delta[HCO3-] x delta pH(-1</protein-id>) [nonbicarbonate buffer capacity (beta) of blood] was increased 7 days after descent [before 31.3 (<compound-id="5289348">SEM</compound-id> 0.4) mmol x kgH2O(-1), after 38.3 (<compound-id="5289348">SEM</compound-id> 3.9) mmol x kgH2O(-1); P&lt;0.05] resulting from an increased proportion of young erythrocytes; in additional experiments an augmented beta was found in young (low density cells) compared to old cells [&lt;1.097 g x ml(-1): 0.216 (<compound-id="5289348">SEM</compound-id> 0.028) mmol x gHb(-1), &gt;1.100 g x ml(-1): 0.145 (<compound-id="5289348">SEM</compound-id> 0.013) mmol x gHb(-1), where Hb is haemoglobin; P &lt; 0.02].	SEM__delta[HCO3-] x delta pH(-1__no_interaction
1750428-4	RESULTS: Compared with 78 control subjects, 70 offspring of essential hypertensive parents had similar age (mean +/- <compound-id="5289348">SEM</compound-id>: 24 +/- 1 versus 24 +/- 1 years, respectively) and body mass index (22.3 +/- 0.2 versus 22.4 +/- 0.2 kg/m2), a blood pressure of 127/77 +/- 1/1 versus 123/76 +/- 1/1 mm Hg (p less than 0.05 for systolic), and significantly elevated (p less than 0.01 to 0.001) fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> levels (9.9 +/- 0.3 versus 8.6 +/- 0.3 microU/mL), serum total triglycerides (1.03 +/- 0.06 versus 0.83 +/- 0.03 mmol/L), total <compound-id="5997">cholesterol</compound-id> (4.37 +/- 0.08 versus 3.93 +/- 0.07 mmol/L), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (2.45 +/- 0.08 versus 2.14 +/- 0.07 mmol/L), and total/high-density lipoprotein <compound-id="5997">cholesterol</compound-id> ratio (4.3 +/- 0.1 versus 3.7 +/- 0.1).	SEM__insulin__no_interaction	cholesterol__insulin__no_interaction
8720310-0	Effects of the novel <protein-id="P25102">histamine H2-receptor</protein-id> antagonist (+/-)-(E)-1-[<compound-id="97257">2-hydroxy-</compound-id>2-(4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]<compound-id="23134249">ethyl</compound-id>]-2-(methylsulfonyl) <compound-id="3520,87210844">guanidine</compound-id> on gastric secretion and gastroduodenal ulcers in rats.	2-hydroxy-__histamine H2-receptor__no_interaction	guanidine__histamine H2-receptor__no_interaction	ethyl__histamine H2-receptor__no_interaction
8720310-1	The effects of (+/-)-(E)-1-[<compound-id="97257">2-hydroxy-</compound-id>2-(4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]-3-[2- [[[5-(methylamino)methyl-2-furyl] methyl]thio]<compound-id="23134249">ethyl</compound-id>]-2-(methylsulfonyl)<compound-id="3520,87210844">guanidine</compound-id> (CAS 140695-21-2, T-593), a new <protein-id="P25102">histamine H2-receptor</protein-id> antagonist, on gastric secretion and experimental gastric and duodenal lesion/ulcer models in rats were examined.	2-hydroxy-__histamine H2-receptor__no_interaction	guanidine__histamine H2-receptor__no_interaction	ethyl__histamine H2-receptor__no_interaction
8684680-7	Nutritional (hemoglobin*: 13 +/- 0.2 g%, <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>*: 313 +/- 57 mg%, IGF-1: 187 +/- 15 ng/ml) and hormonal (LH*: 9.4 +/- 1 mUI/ml, FSH*: 15 +/- 1.3 mUI/ml, <compound-id="5920">T3</compound-id>: 1 +/- 1 ng/ml) parameters were significantly improved (*p &lt; 0.01, p &lt; 0.05) compared to those at admission (hemoglobin: 12 +/- 0.2 g%, <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>: 218 +/- 58 mg%, IGF-1: 154 +/- 21 ng/ml, LH: 5.6 +/- 0.8 mUI/ml, FSH: 9.5 +/- 1 mUI/ml, <compound-id="5920">T3</compound-id>: 0.8 +/- 1 ng/ml).	T3__transferrin__no_interaction
23640650-7	When we compared the survivor and non-survivor groups, it was found that mortality was associated with delayed presentation (6.8 vs 9.4 days), presence of hypotension (132/80 vs 112/70 mmHg), oliguria (300 vs 130 mL), anemia (8 vs 9.3 gm/dL), prolonged <protein-id="P00734">prothrombin</protein-id> time (15 vs 29 s) and activated partial <compound-id="90470996">thrombin</compound-id> time (38 vs 46 s), creatinine (7.8 vs 6.4 mg/dL), blood <compound-id="1176">urea</compound-id> (161 vs 135 mg/dL), higher D-dimer (1603 vs 2185), short hospital stay (27.9 vs 8.3 days), number of hemodialysis sessions (11.9 vs 6 times), need for vasopressors (14% vs 52%) and ventilator (7.2% vs 75%) and higher Sequential Organ Failure Assessment (SOFA) score (6.7 vs 11.4) (P &lt;0.05).	thrombin__prothrombin__no_interaction	urea__prothrombin__no_interaction
17622751-8	At peak aerobic test, the trained elderly, compared to the untrained subjects, achieved significantly (p &lt; 0.05) higher values of end diastolic volume (156.1 +/- 8.2 and 134.1 +/- 7.6 ml, respectively), stroke volume (123.0 +/- 7.9 and 96.0 +/- 4.8 ml, respectively), cardiac output (20.2 +/- 1.5 and 15.0 +/- 1.3 liters.<protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively) and <compound-id="977">oxygen</compound-id> uptake (42.1 +/- 2.1 and 31.1 +/- 2.4 ml.kg(-1).<protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively), while diastolic blood pressure (70.3 +/- 5.6 and 77.5 +/- 4.2 mm Hg, respectively) and total peripheral resistance [4.3 +/- 0.8 and 5.9 +/- 1.41 (dyn.s(-1).cm(-5)).10(-1), respectively], were significantly (p &lt; 0.05) lower.	oxygen__min(-1__no_interaction
15260886-7	RESULTS: The activity of MDA was increased (5.33 +/- 0.72 vs 2.55 +/- 0.22 nmol/mL; P &lt; 0.0001) while levels of <compound-id="5359597">superoxide</compound-id> dismutase (493.6 +/- 54.9 vs. 786.8 +/- 79.1 U/g Hb; P &lt; 0.0001), <protein-id="P04040">catalase</protein-id> (1.48 +/- 0.24 vs. 2.31 +/- 0.20 U/g Hb; P &lt; 0.0001) and <compound-id="124886">reduced glutathione</compound-id> (2.84 +/- 0.37 vs 6.42 +/- 0.23 Umol/g Hb, P &lt; 0.0001) were decreased in term SGA born to undernourished mothers as compared to term AGA born to healthy mothers.	reduced glutathione__catalase__no_interaction	superoxide__catalase__no_interaction
8534868-6	expression of <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> protein, <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">c-erbB-2</protein-id> protein, <protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id>, and cell kinetics; <compound-id="795">IMD</compound-id> was weakly associated only with histological grade (p = 0.053); ii) <compound-id="795">IMD</compound-id> remains a highly significant prognostic factor for RFS and OS (p &lt; 0.0001 and p = 0.018, respectively) in univariate analysis; iii) in multivariate analysis on RFS, <compound-id="795">IMD</compound-id> (likelihood ratio test (LRT) = 30.16; p &lt; 0.0001), <protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id> (LRT = 9.80; p = 0.0017), the <compound-id="795">IMD</compound-id>/<protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id> interaction (LRT = 8.62; p = 0.0033), tumor size (LRT = 8.56; p = 0.0034), and <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> protein (LRT = 4.96; p = 0.025) are significant and independent prognostic indicators.	IMD__c-erbB-2__no_interaction	IMD__67 kDa laminin receptor__no_interaction	IMD__p53__no_interaction
17317287-4	The ternary chelates were isolated in 1:1:1 (M:H(2)L(1):L(2)) ratios and have the general formulae [M(H(2)L(1))(L(2))(Cl)(n)(H(2)O)(m)].<compound-id="7020181">yH</compound-id>(2)O (M=Fe(III) (n=2, m=0, y=2), Co(II) (n=1, m=1, y=2) and Ni(II) (n=1, m=1, y=3)); [M(H(2)L(1))(L(2))](X)(z).<compound-id="7020181">yH</compound-id>(2)O (M=Cu(II) (X=<protein-id="Q9H2R5,Q6UBM2,M0R0D7">AcO</protein-id>, z=1, y=0), Zn(II) (X=<protein-id="Q9H2R5,Q6UBM2,M0R0D7">AcO</protein-id>, z=1, y=3) and UO(2)(II) (X=NO(3), z=1, y=2)).	yH__AcO__no_interaction
18297698-5	On the contrary, incubation with SK and QT at both concentrations (10 and 100 nM) produced a significant increase in the release of <protein-id="P10145,A0A024RDA5">IL-8</protein-id> as compared to other groups (4.19 +/- 0.82, SK-QT 10 nM; 3.83 +/- 1.17 SK-QT 100 nM, P &lt; 0.05 vs. baseline 1.00 +/- 0.10, <compound-id="65028">Tamiflu</compound-id> 100 nM 1.35 +/- 0.16, SK 10 nM 1.68 +/- 0.15 and SK 100 nM 1.80 +/- 0.48).	Tamiflu__IL-8__no_interaction
17082371-7	The amount of <compound-id="36811">dobutamine</compound-id> necessary to increase heart rate by 25 beats/min [men: 29.6 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 6.6) to 42.7 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 12.9) vs. women: 23.5 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 4.0) to 30.0 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 7.8); P &lt; 0.05] and contractility by 10 mmHg/cm2 [men: 20.9 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 5.1) to 37.0 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 11.5) vs. women: 22.6 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 6.4) to 30.7 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 7.2); P &lt; 0.05] was greater in both men and women postrace.	dobutamine__min(-1__no_interaction
8387897-5	Multivariate relationships between the: 1) independent polyinositol forms (3H-<compound-id="892">inositol</compound-id>, I1P, and I1,4,P2) and dependent I1,4,5,P3 existed for control (R2 = 0.71) and 20% BSA burn (R2 = 0.67) groups; 2) the independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent <protein-id="P49913,J3KNB4">cAMP</protein-id> for control (R2 = 0.73), 20% BSA (R2 = 0.99), and 50% BSA (R2 = 0.99) groups; 3) independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent 45Ca2+ for the control (R2 = 0.99), 20% BSA (R2 = 0.44), and 50% BSA (R2 = 0.82) groups; and 4) independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent active tension for 20% BSA (R2 = 0.97) and 50% BSA (R2 = 0.64) burn groups.	inositol__cAMP__no_interaction
21339629-6	Obese subjects had higher systolic (118.8 ± 1.5 vs 105.7 ± 2.0 mmHg, p &lt; 0.001) and diastolic blood pressure (71.61 ± 1.35 vs 64.53 ± 1.40 mmHg, p = 0.001), higher triglyceride (1.35 ± 0.13 vs 0.79 ± 0.05 mmol/l, p &lt; 0.001), lower high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) (1.43 ± 0.04 vs 1.62 ± 0.05 mmol/l, p = 0.003), higher hs-CRP (11.58 ± 1.88 vs 1.88 ± 0.35 mg/l, p &lt; 0.001), and lower <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (8.80 ± 0.43 vs 25.93 ± 0.40 μg/ml, p &lt; 0.001) compared to lean subjects.	cholesterol__adiponectin__no_interaction
8808636-5	Both sICAM-1 and sVCAM-1 correlated to serum levels of <compound-id="444632,4455">neopterin</compound-id> (r = 0.40, P &lt; 0.001; r = 0.46, P &lt;0.001, respectively) and <protein-id="P01375,Q5STB3">TNFalpha</protein-id> (r = 0.44, P &lt; 0.01; r = 0.49, P &lt; 0.001, respectively), while only sVCAM-1 correlated strongly to CD4+ lymphocyte count (r = -0.46, P &lt; 0.001).	neopterin__TNFalpha__no_interaction
17950106-11	The <protein-id="P11597,B4DMZ5">CETP</protein-id> activities correlated with HOMA-IR (r = 0.33, P &lt; .01), <compound-id="2723628">thiobarbituric acid</compound-id> reactive substances (r = 0.45, P &lt; .001), and <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.36, P &lt; .01) levels in univariate but not in multivariate models.	thiobarbituric acid__leptin__no_interaction	thiobarbituric acid__CETP__no_interaction
22426688-8	Higher serum <protein-id="P01034">cystatin C</protein-id> was positively correlated with higher serum levels of <compound-id="588">creatinine</compound-id> (r = 0.84; p &lt; 0.0001), β2-microglobulin (r = 0.72; p &lt; 0.0001), LDH (r = 0.43; p = 0.0003), white blood cell counts (r = 0.61; p &lt; 0.0001) and <compound-id="22044544,5460341">calcium</compound-id> (r = 0.29; p = 0.016), and negatively correlated with lower serum albumin levels (r = 0.44; p &lt; 0.0001) and hemoglobin levels (r = 0.31; p = 0.01).	calcium__cystatin C__no_interaction	creatinine__cystatin C__no_interaction
21924075-6	The serum concentration of total <compound-id="5997">cholesterol</compound-id> (TC), triglyceride (TG), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>), high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) and <compound-id="1175">uric acid</compound-id> in patient before and after treatment were (6.18 ± 2.47) mmol/L vs. (5.61 ± 1.84) mmol/L (P = 0.020), (11.17 ± 9.85) mmol/L vs. (6.81 ± 5.97) mmol/L (P = 0.010), (2.55 ± 1.27) mmol/L vs. (2.78 ± 1.07) mmol/L (P = 0.617), (0.98 ± 0.37) mmol/L vs. (0.96 ± 0.23) mmol/L (P = 0.005), (526.53 ± 127.09) µmol/L vs. (490.78 ± 129.79) µmol/L (P = 0.977), respectively.	uric acid__low-density lipoprotein cholesterol__no_interaction	uric acid__LDL-C__no_interaction	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__LDL-C__no_interaction
15252635-1	The pK(a)s and Zn2+, Cd2+ and Cu2+ complexation constants (K) for 1,4,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-phenylpropionate)]-1,4,7-triazacyclononane, 1, 1,4,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(1''-carboxy-3''-<compound-id="7668">phenylpropane</compound-id>)]-1,4,7-triazacyclononane, <protein-id="Q71DI3">H(3)2, 1,4</protein-id>,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-(<compound-id="43849">1H-3</compound-id>-indolyl)<compound-id="1032">propionate</compound-id>)]-1,4,7-triazacyclononane, 3, and 1,4,7,10-tetrakis[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-phenylpropionate)]-1,4,7,10-tetraazacyclododecane, 4, 1,4,7,10-tetrakis[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(1''-carboxy-3''-<compound-id="7668">phenylpropane</compound-id>)]-1,4,7,10-tetraazacyclododecane, H(4)5, in 20 : 80 v/v <compound-id="962">water</compound-id>-<compound-id="11686950,887">methanol</compound-id> solution are reported.	1H-3__H(3)2, 1,4__no_interaction	phenylpropane__H(3)2, 1,4__no_interaction	water__H(3)2, 1,4__no_interaction	methanol__H(3)2, 1,4__no_interaction	propionate__H(3)2, 1,4__no_interaction	acetamido__H(3)2, 1,4__no_interaction	tris__H(3)2, 1,4__no_interaction
15252635-5	The tricarboxylic acid <protein-id="Q71DI3">H(3)2</protein-id> generates a greater variety of complexes as exemplified by: [Zn(2)-] (10.68) [Zn(<compound-id="783">H2</compound-id>)] (6.60) [Zn(H(2)2)+] (5.15), [Cd(2)](-) (4.99), [Cd(<compound-id="783">H2</compound-id>)] (4.64), [Cd(<compound-id="783">H2</compound-id>(2))]+ (3.99), [Cd(<protein-id="Q71DI3">H(3)2</protein-id>)]2+ (3.55), [Cu(2)](-) (12.55) [Cu(<compound-id="783">H2</compound-id>)] (7.66), [Cu(H(2)2)]+ (5.54) and [Cu(2)2](4-) (3.23).	H2__H(3)2__no_interaction
19022445-4	RESULTS: Delivery of a SGA infant was associated with altered lipids [triglyceride median (IQR) mmol/l; control 0.64 (0.49-0.84); SGA 0.95 (0.67-0.95), p=0.012] [<compound-id="5997">cholesterol</compound-id>:<protein-id="P28845,X5D2L1">HDL</protein-id> ratio: control 2.64 (2.10-3.10); SGA 3.06 (2.65-3.89), p=0.013], systolic blood pressure [control mmHg: 110 (108-118); SGA 120 (110-130), p=0.031], subclinical inflammation [<protein-id="P02741">CRP</protein-id> mg/l: control 0.7 (0.3-2.1); SGA 2.2 (1.2-4.0), p=0.002] [<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> pg/ml: control 1.2 (0.8-1.4); SGA 1.5 (1.1-2.2), p=0.009] and endothelial activation [<protein-id="P05362">ICAM-1</protein-id> ng/ml: control 237.7 (210.0-279.4); SGA 283.1 (240.5-366.3), p=0.013], with differences robust to confounder adjustment.	cholesterol__ICAM-1__no_interaction	cholesterol__CRP__no_interaction	cholesterol__HDL__no_interaction	cholesterol__IL-6__no_interaction
20442503-1	The dinuclear Au(I) complex containing the 4,5-<protein-id="O95817">Bis</protein-id>(<compound-id="70017">diphenylphosphino</compound-id>)-9,9-<compound-id="606997">dimethylxanthene</compound-id> (xantphos) ligand and <compound-id="6422">trifluoroacetate</compound-id> anions exists in a solvent-free form, [<protein-id="O00189,C9IZL5,C9JC87">mu-4</protein-id>,5-<protein-id="O95817">Bis</protein-id>(<compound-id="70017">diphenylphosphino</compound-id>)-9,9-<compound-id="606997">dimethylxanthene</compound-id>]<protein-id="O95817">Bis</protein-id>[(trifluoroacetato)<compound-id="23985">gold</compound-id>(I)], [Au(2)(C(2)F(3)O(2))(2)(C(39)H(32)OP(2))], (I), and as a <compound-id="6344">dichloromethane</compound-id> solvate, [Au(2)(C(2)F(3)O(2))(2)(C(39)H(32)OP(2))].0.58CH(2)Cl(2), (II).	dimethylxanthene__mu-4__no_interaction	dimethylxanthene__Bis__no_interaction	diphenylphosphino__mu-4__no_interaction	diphenylphosphino__Bis__no_interaction	dichloromethane__mu-4__no_interaction	dichloromethane__Bis__no_interaction	gold__mu-4__no_interaction	gold__Bis__no_interaction	trifluoroacetate__mu-4__no_interaction	trifluoroacetate__Bis__no_interaction
19826741-2	Reactions of six amido-oxazolinate ligand precursors, <compound-id="5975">HNC</compound-id>(2)(Me)Oxa, <compound-id="5975">HNC</compound-id>(2)(OMe)Oxa, <compound-id="5975">HNC</compound-id>(2)(StBu)Oxa, HNPhOxa, HNPh(OMe)Oxa or HNPh(<protein-id="P62304">SMe</protein-id>)Oxa, with half molar equivalent of Mg(n)Bu(2) in <compound-id="8058">hexane</compound-id> yield the <compound-id="5462224">magnesium</compound-id> <protein-id="O95817">bis</protein-id>(amido-oxazolinate) complexes, (NC(2)(E)Oxa)(2)Mg [C(2)(E) = propyl, (NC(2)(Me)Oxa)(2)Mg (1); C(2)(E) = 2-methoxyethyl, (NC(2)(OMe)Oxa)(2)Mg (2); C(2)(E) = <compound-id="139723">2-tert-butylthioethyl</compound-id>, (NC(2)(StBu)Oxa)(2)Mg (3)], or <compound-id="5462224">magnesium</compound-id> <protein-id="O95817">bis</protein-id>(anilido-oxazolinate) complexes, (NArOxa)(2)Mg [Ar = phenyl, (NPhOxa)(2)Mg (4); Ar = 2-methoxyphenyl, (NPh(OMe)Oxa)(2)Mg (5); Ar = 2-methylthiophenyl, (NPh(<protein-id="P62304">SMe</protein-id>)Oxa)(2)Mg (6)], respectively.	2-tert-butylthioethyl__SMe__no_interaction	2-tert-butylthioethyl__bis__no_interaction	HNC__SMe__no_interaction	HNC__bis__no_interaction	hexane__SMe__no_interaction	hexane__bis__no_interaction	magnesium__SMe__no_interaction	magnesium__bis__no_interaction
20533433-2	Five kinds of neutral ligands (phen=<compound-id="1318">1,10-phenanthroline</compound-id>, <compound-id="1474">bipy</compound-id>=<compound-id="11107">4,4'-bipyridine</compound-id>, bpa=<compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>, bpe=<compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>, and bpp=<compound-id="87019">1,3-bis(4-pyridyl)propane</compound-id>) were selected, and a series of new Zn(II)/Co(II) dicarboxylates have been synthesized by slow diffusion, namely, [Zn(phen)(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(H(2)O)](2).CH(3)OH (1), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpe)].H(2)O}(n) (2), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(<compound-id="1474">bipy</compound-id>)].2H(2)O}(n) (3), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpa)](2).5H(2)O}(n) (4), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)](2).CH(3)OH}(n) (5), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)]}(n) (6), {[Co(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)(CH(3)OH)(H(2)O)].CH(3)OH2 H(2)O}(n) (7), and {[Co(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)]}(n) (8).	4,4'-bipyridine__ADC__no_interaction	1,2-bis(4-pyridyl)ethane__ADC__no_interaction	bipy__ADC__no_interaction	1,3-bis(4-pyridyl)propane__ADC__no_interaction	1,10-phenanthroline__ADC__no_interaction
8553999-5	Absolute changes from baseline were significantly different for the two forms of exertion: <compound-id="12388">TRD</compound-id> versus HG: BP = 11 +/- 9 versus 36 +/- 10 mm Hg, HR = 37 +/- 16 versus 16 +/- 9 beats/min, E = 11.6 +/- 11.3 versus -7.0 +/- 9.4 cm/sec, A = 29.9 +/- 14.5 versus 14 +/- 12 cm/sec, ACC = 164 +/- 151 versus -56 +/- 135 cm/<protein-id="Q10981,A8K2L2">sec2</protein-id>, Ti = 1.9 +/- 3.0 versus -1.7 +/- 1.7 cm, and IRT = -12 +/- 9 versus 9 +/- 10 msec, all p &lt; 0.0001 except for A, p &lt; 0.001).	TRD__sec2__no_interaction
1818062-1	A high-performance liquid chromatographic method with column switching was developed for the determination of the <protein-id="P08424">renin</protein-id> inhibitor <compound-id="5462340">Ro 42-5892</compound-id>/001, (S)-alpha-[(S)-alpha-[(tert.-<compound-id="12113170">butylsulphonyl</compound-id>)methyl]hydrocinnama mido]-N- [(1S,2R,<compound-id="21439199">3S</compound-id>)-1-(cyclohexylmethyl)-3-cylcopropyl-2, 3-<compound-id="134919">dihydroxypropyl</compound-id>]<compound-id="565498">imidazole-4-propionamide</compound-id> <compound-id="6395">methanesulphonate</compound-id> (1:1), in rat, marmoset and human plasma, using a Nucleosil C8 120 (3 microns) stationary phase.	butylsulphonyl__renin__no_interaction	3S__renin__no_interaction	dihydroxypropyl__renin__no_interaction	imidazole-4-propionamide__renin__no_interaction	Ro 42-5892__renin__no_interaction	methanesulphonate__renin__no_interaction
14988742-3	This issue focuses on the following selection of drugs: Abetimus <compound-id="5360545">sodium</compound-id>, Ad5-<protein-id="P08620">FGF4</protein-id>, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, <compound-id="16197724">alicaforsen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="123606">almotriptan</compound-id>, alpharadin, <compound-id="90470007">anakinra</compound-id>, anatumomab mafenatox, ANG-453, anti-<protein-id="P16410">CTLA-4</protein-id> Mab, AP-12009, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="5359596">arsenic</compound-id> trioxide, <compound-id="2247">astemizole</compound-id>, atlizumab, <compound-id="54841">atomoxetine hydrochloride</compound-id>; Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; <compound-id="2519,57106085">Caffeine</compound-id>, <compound-id="6132">CDP</compound-id>-870, cetuximab, <compound-id="151170">cilomilast</compound-id>, <compound-id="9853710">ciluprevir</compound-id>, <compound-id="119182">clofarabine</compound-id>, continuous erythropoiesis receptor activator, CP-461; Darbepoetin alfa, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="447865,6918680">desoxyepothilone B</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="3033818,3148,49800054,60654">dolasetron</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride; ED-71, efalizumab, efaproxiral <compound-id="5360545">sodium</compound-id>, <compound-id="25138225">EKB</compound-id>-569, <compound-id="77993">eletriptan</compound-id>, EMD-72000, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="123619">etoricoxib</compound-id>; <compound-id="1727">Fampridine</compound-id>, ferumoxytol, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>; <compound-id="9919137">Gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, gastrazole, <compound-id="123631">gefitinib</compound-id>, gemtuzumab <compound-id="9942071">ozogamicin</compound-id>, <compound-id="55191">gepirone</compound-id> hydrochloride <compound-id="5961">glutamine</compound-id>; hLM609, HSPPC-96, human <protein-id="P01308,I3WAC9">insulin</protein-id>; IDD-1, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="216468">indisulam</compound-id>, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="6445540">ixabepilone</compound-id>; Keratinocyte growth factor; <compound-id="208908">Lapatinib</compound-id>, <compound-id="54677946">laquinimod</compound-id>, LDP-02, <compound-id="7009630">LE</compound-id>-<compound-id="104842">SN38</compound-id>, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="3033825">levosimendan</compound-id>, <compound-id="133021">licofelone</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, liposomal NDDP, <compound-id="92727">lopinavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>, <compound-id="219018">LY-156735</compound-id>; <compound-id="5288826">Morphine hydrochloride</compound-id>, <compound-id="5360621">morphine-6-glucuronide</compound-id>, <compound-id="151071">motexafin gadolinium</compound-id>, <compound-id="4261">MS-27-275</compound-id>, MVA-5T4, MVA-Muc1-<protein-id="P60568,Q0GK43">IL-2</protein-id>; <compound-id="6918348">Nemifitide ditriflutate</compound-id>, <compound-id="71237">neridronic acid</compound-id> <compound-id="9884642">nitronaproxen</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>, NSC-703940, <compound-id="6918537">NVP-LAF-237</compound-id>; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="216456">ocinaplon</compound-id>, oncomyc-NG, <compound-id="219020">OPC-28326</compound-id>, <compound-id="6918412">ortataxel</compound-id>, <compound-id="3036505">ospemifene</compound-id>; Palonosetron hydrochloride, PEG-filgrastim peginterferon alfa-2(a), peginterferon alfa-2b, pegsunercept, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="4906">prilocaine</compound-id>, <compound-id="1052">pyridoxamine</compound-id>; <compound-id="124970">RDP</compound-id>-58, recombinant glucagon-like peptide-1 (7-36) <compound-id="2826723">amide</compound-id>, recombinant human <protein-id="P02647,A0A024R3E3">ApoA-I</protein-id> milano/phospholipid complex; <compound-id="6851740">SB-715992</compound-id>, <compound-id="24978490,6918315,70687327">soblidotin</compound-id>, <compound-id="6597">sodium dichloroacetate</compound-id>, St. John's Wort extract; TAS-102, <compound-id="5405">terfenadine</compound-id>, TG-1024, TG-5001, <compound-id="168566">4'-Thio-ara-C</compound-id>, <compound-id="54682461">tipranavir</compound-id>, <compound-id="219022">topixantrone hydrochloride</compound-id>, <compound-id="108150">trabectedin</compound-id>, transdermal <compound-id="26757">selegiline</compound-id>, <compound-id="5578">trimethoprim</compound-id>, <compound-id="151173,454194">troxacitabine</compound-id>, TT-232; <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="60854">Ziprasidone hydrochloride</compound-id>, <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	escitalopram oxalate__ApoA-I__no_interaction	escitalopram oxalate__FGF4__no_interaction	escitalopram oxalate__CTLA-4__no_interaction	escitalopram oxalate__IL-2__no_interaction	escitalopram oxalate__insulin__no_interaction	Morphine hydrochloride__ApoA-I__no_interaction	Morphine hydrochloride__FGF4__no_interaction	Morphine hydrochloride__CTLA-4__no_interaction	Morphine hydrochloride__IL-2__no_interaction	Morphine hydrochloride__insulin__no_interaction	NSC-683864__ApoA-I__no_interaction	NSC-683864__FGF4__no_interaction	NSC-683864__CTLA-4__no_interaction	NSC-683864__IL-2__no_interaction	NSC-683864__insulin__no_interaction	laquinimod__ApoA-I__no_interaction	laquinimod__FGF4__no_interaction	laquinimod__CTLA-4__no_interaction	laquinimod__IL-2__no_interaction	laquinimod__insulin__no_interaction	sodium dichloroacetate__ApoA-I__no_interaction	sodium dichloroacetate__FGF4__no_interaction	sodium dichloroacetate__CTLA-4__no_interaction	sodium dichloroacetate__IL-2__no_interaction	sodium dichloroacetate__insulin__no_interaction	4'-Thio-ara-C__ApoA-I__no_interaction	4'-Thio-ara-C__FGF4__no_interaction	4'-Thio-ara-C__CTLA-4__no_interaction	4'-Thio-ara-C__IL-2__no_interaction	4'-Thio-ara-C__insulin__no_interaction	lumiracoxib__ApoA-I__no_interaction	lumiracoxib__FGF4__no_interaction	lumiracoxib__CTLA-4__no_interaction	lumiracoxib__IL-2__no_interaction	lumiracoxib__insulin__no_interaction	deferasirox__ApoA-I__no_interaction	deferasirox__FGF4__no_interaction	deferasirox__CTLA-4__no_interaction	deferasirox__IL-2__no_interaction	deferasirox__insulin__no_interaction	NVP-LAF-237__ApoA-I__no_interaction	NVP-LAF-237__FGF4__no_interaction	NVP-LAF-237__CTLA-4__no_interaction	NVP-LAF-237__IL-2__no_interaction	NVP-LAF-237__insulin__no_interaction	astemizole__ApoA-I__no_interaction	astemizole__FGF4__no_interaction	astemizole__CTLA-4__no_interaction	astemizole__IL-2__no_interaction	astemizole__insulin__no_interaction	indisulam__ApoA-I__no_interaction	indisulam__FGF4__no_interaction	indisulam__CTLA-4__no_interaction	indisulam__IL-2__no_interaction	indisulam__insulin__no_interaction	troxacitabine__ApoA-I__no_interaction	troxacitabine__FGF4__no_interaction	troxacitabine__CTLA-4__no_interaction	troxacitabine__IL-2__no_interaction	troxacitabine__insulin__no_interaction	alicaforsen__ApoA-I__no_interaction	alicaforsen__FGF4__no_interaction	alicaforsen__CTLA-4__no_interaction	alicaforsen__IL-2__no_interaction	alicaforsen__insulin__no_interaction	morphine-6-glucuronide__ApoA-I__no_interaction	morphine-6-glucuronide__FGF4__no_interaction	morphine-6-glucuronide__CTLA-4__no_interaction	morphine-6-glucuronide__IL-2__no_interaction	morphine-6-glucuronide__insulin__no_interaction	EKB__ApoA-I__no_interaction	EKB__FGF4__no_interaction	EKB__CTLA-4__no_interaction	EKB__IL-2__no_interaction	EKB__insulin__no_interaction	SB-715992__ApoA-I__no_interaction	SB-715992__FGF4__no_interaction	SB-715992__CTLA-4__no_interaction	SB-715992__IL-2__no_interaction	SB-715992__insulin__no_interaction	trabectedin__ApoA-I__no_interaction	trabectedin__FGF4__no_interaction	trabectedin__CTLA-4__no_interaction	trabectedin__IL-2__no_interaction	trabectedin__insulin__no_interaction	arsenic__ApoA-I__no_interaction	arsenic__FGF4__no_interaction	arsenic__CTLA-4__no_interaction	arsenic__IL-2__no_interaction	arsenic__insulin__no_interaction	topixantrone hydrochloride__ApoA-I__no_interaction	topixantrone hydrochloride__FGF4__no_interaction	topixantrone hydrochloride__CTLA-4__no_interaction	topixantrone hydrochloride__IL-2__no_interaction	topixantrone hydrochloride__insulin__no_interaction	aprepitant__ApoA-I__no_interaction	aprepitant__FGF4__no_interaction	aprepitant__CTLA-4__no_interaction	aprepitant__IL-2__no_interaction	aprepitant__insulin__no_interaction	etoricoxib__ApoA-I__no_interaction	etoricoxib__FGF4__no_interaction	etoricoxib__CTLA-4__no_interaction	etoricoxib__IL-2__no_interaction	etoricoxib__insulin__no_interaction	MS-27-275__ApoA-I__no_interaction	MS-27-275__FGF4__no_interaction	MS-27-275__CTLA-4__no_interaction	MS-27-275__IL-2__no_interaction	MS-27-275__insulin__no_interaction	ocinaplon__ApoA-I__no_interaction	ocinaplon__FGF4__no_interaction	ocinaplon__CTLA-4__no_interaction	ocinaplon__IL-2__no_interaction	ocinaplon__insulin__no_interaction	erlotinib hydrochloride__ApoA-I__no_interaction	erlotinib hydrochloride__FGF4__no_interaction	erlotinib hydrochloride__CTLA-4__no_interaction	erlotinib hydrochloride__IL-2__no_interaction	erlotinib hydrochloride__insulin__no_interaction	ospemifene__ApoA-I__no_interaction	ospemifene__FGF4__no_interaction	ospemifene__CTLA-4__no_interaction	ospemifene__IL-2__no_interaction	ospemifene__insulin__no_interaction	Nemifitide ditriflutate__ApoA-I__no_interaction	Nemifitide ditriflutate__FGF4__no_interaction	Nemifitide ditriflutate__CTLA-4__no_interaction	Nemifitide ditriflutate__IL-2__no_interaction	Nemifitide ditriflutate__insulin__no_interaction	sodium__ApoA-I__no_interaction	sodium__FGF4__no_interaction	sodium__CTLA-4__no_interaction	sodium__IL-2__no_interaction	sodium__insulin__no_interaction	prilocaine__ApoA-I__no_interaction	prilocaine__FGF4__no_interaction	prilocaine__CTLA-4__no_interaction	prilocaine__IL-2__no_interaction	prilocaine__insulin__no_interaction	licofelone__ApoA-I__no_interaction	licofelone__FGF4__no_interaction	licofelone__CTLA-4__no_interaction	licofelone__IL-2__no_interaction	licofelone__insulin__no_interaction	clofarabine__ApoA-I__no_interaction	clofarabine__FGF4__no_interaction	clofarabine__CTLA-4__no_interaction	clofarabine__IL-2__no_interaction	clofarabine__insulin__no_interaction	trimethoprim__ApoA-I__no_interaction	trimethoprim__FGF4__no_interaction	trimethoprim__CTLA-4__no_interaction	trimethoprim__IL-2__no_interaction	trimethoprim__insulin__no_interaction	pyridoxamine__ApoA-I__no_interaction	pyridoxamine__FGF4__no_interaction	pyridoxamine__CTLA-4__no_interaction	pyridoxamine__IL-2__no_interaction	pyridoxamine__insulin__no_interaction	LY-156735__ApoA-I__no_interaction	LY-156735__FGF4__no_interaction	LY-156735__CTLA-4__no_interaction	LY-156735__IL-2__no_interaction	LY-156735__insulin__no_interaction	selegiline__ApoA-I__no_interaction	selegiline__FGF4__no_interaction	selegiline__CTLA-4__no_interaction	selegiline__IL-2__no_interaction	selegiline__insulin__no_interaction	fondaparinux sodium__ApoA-I__no_interaction	fondaparinux sodium__FGF4__no_interaction	fondaparinux sodium__CTLA-4__no_interaction	fondaparinux sodium__IL-2__no_interaction	fondaparinux sodium__insulin__no_interaction	ozogamicin__ApoA-I__no_interaction	ozogamicin__FGF4__no_interaction	ozogamicin__CTLA-4__no_interaction	ozogamicin__IL-2__no_interaction	ozogamicin__insulin__no_interaction	vinflunine__ApoA-I__no_interaction	vinflunine__FGF4__no_interaction	vinflunine__CTLA-4__no_interaction	vinflunine__IL-2__no_interaction	vinflunine__insulin__no_interaction	neridronic acid__ApoA-I__no_interaction	neridronic acid__FGF4__no_interaction	neridronic acid__CTLA-4__no_interaction	neridronic acid__IL-2__no_interaction	neridronic acid__insulin__no_interaction	Zoledronic acid monohydrate__ApoA-I__no_interaction	Zoledronic acid monohydrate__FGF4__no_interaction	Zoledronic acid monohydrate__CTLA-4__no_interaction	Zoledronic acid monohydrate__IL-2__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	ciluprevir__ApoA-I__no_interaction	ciluprevir__FGF4__no_interaction	ciluprevir__CTLA-4__no_interaction	ciluprevir__IL-2__no_interaction	ciluprevir__insulin__no_interaction	enfuvirtide__ApoA-I__no_interaction	enfuvirtide__FGF4__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__IL-2__no_interaction	enfuvirtide__insulin__no_interaction	levetiracetam__ApoA-I__no_interaction	levetiracetam__FGF4__no_interaction	levetiracetam__CTLA-4__no_interaction	levetiracetam__IL-2__no_interaction	levetiracetam__insulin__no_interaction	doxorubicin__ApoA-I__no_interaction	doxorubicin__FGF4__no_interaction	doxorubicin__CTLA-4__no_interaction	doxorubicin__IL-2__no_interaction	doxorubicin__insulin__no_interaction	dolasetron__ApoA-I__no_interaction	dolasetron__FGF4__no_interaction	dolasetron__CTLA-4__no_interaction	dolasetron__IL-2__no_interaction	dolasetron__insulin__no_interaction	OPC-28326__ApoA-I__no_interaction	OPC-28326__FGF4__no_interaction	OPC-28326__CTLA-4__no_interaction	OPC-28326__IL-2__no_interaction	OPC-28326__insulin__no_interaction	RDP__ApoA-I__no_interaction	RDP__FGF4__no_interaction	RDP__CTLA-4__no_interaction	RDP__IL-2__no_interaction	RDP__insulin__no_interaction	motexafin gadolinium__ApoA-I__no_interaction	motexafin gadolinium__FGF4__no_interaction	motexafin gadolinium__CTLA-4__no_interaction	motexafin gadolinium__IL-2__no_interaction	motexafin gadolinium__insulin__no_interaction	cilomilast__ApoA-I__no_interaction	cilomilast__FGF4__no_interaction	cilomilast__CTLA-4__no_interaction	cilomilast__IL-2__no_interaction	cilomilast__insulin__no_interaction	terfenadine__ApoA-I__no_interaction	terfenadine__FGF4__no_interaction	terfenadine__CTLA-4__no_interaction	terfenadine__IL-2__no_interaction	terfenadine__insulin__no_interaction	Lapatinib__ApoA-I__no_interaction	Lapatinib__FGF4__no_interaction	Lapatinib__CTLA-4__no_interaction	Lapatinib__IL-2__no_interaction	Lapatinib__insulin__no_interaction	glutamine__ApoA-I__no_interaction	glutamine__FGF4__no_interaction	glutamine__CTLA-4__no_interaction	glutamine__IL-2__no_interaction	glutamine__insulin__no_interaction	gefitinib__ApoA-I__no_interaction	gefitinib__FGF4__no_interaction	gefitinib__CTLA-4__no_interaction	gefitinib__IL-2__no_interaction	gefitinib__insulin__no_interaction	Ziprasidone hydrochloride__ApoA-I__no_interaction	Ziprasidone hydrochloride__FGF4__no_interaction	Ziprasidone hydrochloride__CTLA-4__no_interaction	Ziprasidone hydrochloride__IL-2__no_interaction	Ziprasidone hydrochloride__insulin__no_interaction	Caffeine__ApoA-I__no_interaction	Caffeine__FGF4__no_interaction	Caffeine__CTLA-4__no_interaction	Caffeine__IL-2__no_interaction	Caffeine__insulin__no_interaction	tipranavir__ApoA-I__no_interaction	tipranavir__FGF4__no_interaction	tipranavir__CTLA-4__no_interaction	tipranavir__IL-2__no_interaction	tipranavir__insulin__no_interaction	ixabepilone__ApoA-I__no_interaction	ixabepilone__FGF4__no_interaction	ixabepilone__CTLA-4__no_interaction	ixabepilone__IL-2__no_interaction	ixabepilone__insulin__no_interaction	ortataxel__ApoA-I__no_interaction	ortataxel__FGF4__no_interaction	ortataxel__CTLA-4__no_interaction	ortataxel__IL-2__no_interaction	ortataxel__insulin__no_interaction	LE__ApoA-I__no_interaction	LE__FGF4__no_interaction	LE__CTLA-4__no_interaction	LE__IL-2__no_interaction	LE__insulin__no_interaction	Oblimersen__ApoA-I__no_interaction	Oblimersen__FGF4__no_interaction	Oblimersen__CTLA-4__no_interaction	Oblimersen__IL-2__no_interaction	Oblimersen__insulin__no_interaction	Vatalanib__ApoA-I__no_interaction	Vatalanib__FGF4__no_interaction	Vatalanib__CTLA-4__no_interaction	Vatalanib__IL-2__no_interaction	Vatalanib__insulin__no_interaction	pemetrexed disodium__ApoA-I__no_interaction	pemetrexed disodium__FGF4__no_interaction	pemetrexed disodium__CTLA-4__no_interaction	pemetrexed disodium__IL-2__no_interaction	pemetrexed disodium__insulin__no_interaction	atomoxetine hydrochloride__ApoA-I__no_interaction	atomoxetine hydrochloride__FGF4__no_interaction	atomoxetine hydrochloride__CTLA-4__no_interaction	atomoxetine hydrochloride__IL-2__no_interaction	atomoxetine hydrochloride__insulin__no_interaction	Ximelagatran__ApoA-I__no_interaction	Ximelagatran__FGF4__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__IL-2__no_interaction	Ximelagatran__insulin__no_interaction	imatinib mesylate__ApoA-I__no_interaction	imatinib mesylate__FGF4__no_interaction	imatinib mesylate__CTLA-4__no_interaction	imatinib mesylate__IL-2__no_interaction	imatinib mesylate__insulin__no_interaction	gepirone__ApoA-I__no_interaction	gepirone__FGF4__no_interaction	gepirone__CTLA-4__no_interaction	gepirone__IL-2__no_interaction	gepirone__insulin__no_interaction	soblidotin__ApoA-I__no_interaction	soblidotin__FGF4__no_interaction	soblidotin__CTLA-4__no_interaction	soblidotin__IL-2__no_interaction	soblidotin__insulin__no_interaction	amide__ApoA-I__no_interaction	amide__FGF4__no_interaction	amide__CTLA-4__no_interaction	amide__IL-2__no_interaction	amide__insulin__no_interaction	succinate__ApoA-I__no_interaction	succinate__FGF4__no_interaction	succinate__CTLA-4__no_interaction	succinate__IL-2__no_interaction	succinate__insulin__no_interaction	diflomotecan__ApoA-I__no_interaction	diflomotecan__FGF4__no_interaction	diflomotecan__CTLA-4__no_interaction	diflomotecan__IL-2__no_interaction	diflomotecan__insulin__no_interaction	almotriptan__ApoA-I__no_interaction	almotriptan__FGF4__no_interaction	almotriptan__CTLA-4__no_interaction	almotriptan__IL-2__no_interaction	almotriptan__insulin__no_interaction	nitronaproxen__ApoA-I__no_interaction	nitronaproxen__FGF4__no_interaction	nitronaproxen__CTLA-4__no_interaction	nitronaproxen__IL-2__no_interaction	nitronaproxen__insulin__no_interaction	desoxyepothilone B__ApoA-I__no_interaction	desoxyepothilone B__FGF4__no_interaction	desoxyepothilone B__CTLA-4__no_interaction	desoxyepothilone B__IL-2__no_interaction	desoxyepothilone B__insulin__no_interaction	desloratadine__ApoA-I__no_interaction	desloratadine__FGF4__no_interaction	desloratadine__CTLA-4__no_interaction	desloratadine__IL-2__no_interaction	desloratadine__insulin__no_interaction	CDP__ApoA-I__no_interaction	CDP__FGF4__no_interaction	CDP__CTLA-4__no_interaction	CDP__IL-2__no_interaction	CDP__insulin__no_interaction	SN38__ApoA-I__no_interaction	SN38__FGF4__no_interaction	SN38__CTLA-4__no_interaction	SN38__IL-2__no_interaction	SN38__insulin__no_interaction	aripiprazole__ApoA-I__no_interaction	aripiprazole__FGF4__no_interaction	aripiprazole__CTLA-4__no_interaction	aripiprazole__IL-2__no_interaction	aripiprazole__insulin__no_interaction	anakinra__ApoA-I__no_interaction	anakinra__FGF4__no_interaction	anakinra__CTLA-4__no_interaction	anakinra__IL-2__no_interaction	anakinra__insulin__no_interaction	pregabalin__ApoA-I__no_interaction	pregabalin__FGF4__no_interaction	pregabalin__CTLA-4__no_interaction	pregabalin__IL-2__no_interaction	pregabalin__insulin__no_interaction	lopinavir__ApoA-I__no_interaction	lopinavir__FGF4__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__IL-2__no_interaction	lopinavir__insulin__no_interaction	Fampridine__ApoA-I__no_interaction	Fampridine__FGF4__no_interaction	Fampridine__CTLA-4__no_interaction	Fampridine__IL-2__no_interaction	Fampridine__insulin__no_interaction	eletriptan__ApoA-I__no_interaction	eletriptan__FGF4__no_interaction	eletriptan__CTLA-4__no_interaction	eletriptan__IL-2__no_interaction	eletriptan__insulin__no_interaction	levosimendan__ApoA-I__no_interaction	levosimendan__FGF4__no_interaction	levosimendan__CTLA-4__no_interaction	levosimendan__IL-2__no_interaction	levosimendan__insulin__no_interaction	Gadofosveset__ApoA-I__no_interaction	Gadofosveset__FGF4__no_interaction	Gadofosveset__CTLA-4__no_interaction	Gadofosveset__IL-2__no_interaction	Gadofosveset__insulin__no_interaction	duloxetine__ApoA-I__no_interaction	duloxetine__FGF4__no_interaction	duloxetine__CTLA-4__no_interaction	duloxetine__IL-2__no_interaction	duloxetine__insulin__no_interaction
14731357-11	Compared with control group, the levels of triglyceride, total <compound-id="5997">cholesterol</compound-id>, low density lipoprotein-<compound-id="5997">cholesterol</compound-id>, and <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id>(100) were higher, and those of high density lipoprotein-<compound-id="5997">cholesterol</compound-id>, <protein-id="P02647,A0A024R3E3">apoA I</protein-id> and <protein-id="P02649">apoE</protein-id> were lower in children with obesity [(1.68 +/- 0.50) mmol/L vs. (0.99 +/- 0.54) mmol/L, (4.47 +/- 0.91) mmol/L vs. (3.33 +/- 0.90) mmol/L, (2.23 +/- 0.71) mmol/L vs. (1.13 +/- 0.96) mmol/L, (94.48 +/- 9.97) mg/dl vs. (83.81 +/- 15.64) mg/dl, (1.47 +/- 0.39) mmol/L vs. (1.73 +/- 0.36) mmol/L, (112.71 +/- 27.86) mg/dl vs. (134.80 +/- 45.36) mg/dl, (24.50 +/- 10.92) mg/L vs.(35.07 +/- 9.79) mg/L, respectively, P &lt; 0.05].	cholesterol__apoA I__no_interaction	cholesterol__apoE__no_interaction	cholesterol__apoB__no_interaction
19572374-6	<protein-id="P21741">midkine</protein-id> significantly correlated with inflammatory indices: <protein-id="P02741">CRP</protein-id> (r = 0.49), erythrocyte sedimentation rate (r = 0.31), leukocytes (r = 0.48), platelets (r = 0.52), albumin (r = -0.49), <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> (r = -0.47), and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.54); hematological variables: hemoglobin (r = -0.38), hematocrit (r = -0.43), and <compound-id="23925,67172434">iron</compound-id> (r = -0.58); angiogenic factors: <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">vascular endothelial growth factor-A</protein-id> (r = 0.42), <protein-id="P09038">fibroblast growth factor-2</protein-id> (r = 0.54), and platelet-derived growth factor-BB (r = 0.57).	iron__CRP__no_interaction	iron__IL-6__no_interaction	iron__transferrin__no_interaction	iron__midkine__no_interaction	iron__vascular endothelial growth factor-A__no_interaction	iron__fibroblast growth factor-2__no_interaction
22339487-2	The complexes include the mononuclear species [(pbi)AuX(2)] (X = Cl, 1; OAc, 2), [(pbiH)<compound-id="5460531">AuCl</compound-id>] (3), [(pbiH)Au(PPh(3))][PF(6)] (4-PF(6)), and [(pbi)Au(L)] (L = PPh(3), 5; <protein-id="P00750">TPA</protein-id>, 6), and the binuclear <compound-id="23985">gold</compound-id>(I)/<compound-id="23985">gold</compound-id>(I) and <compound-id="23985">gold</compound-id>(I)/<compound-id="23985">gold</compound-id>(III) derivatives [(PPh(3))(2)Au(2)(μ(2)-pbi)][PF(6)] (10-PF(6)), [ClAu(μ(3)-pbi)<compound-id="5460531">AuCl</compound-id>(2)] (7),and [(PPh(3))Au(μ(3)-pbi)AuX(2)][PF(6)] (X = Cl, 8-PF(6); OAc, 9-PF(6)).	AuCl__TPA__no_interaction	gold__TPA__no_interaction
24351593-5	The data of preoperative <protein-id="P19429,Q6FGX2">cTnI</protein-id> showed no significant difference between two groups (P &gt; 0.05) .However, after CPB, significant intergroup difference existed in the level of <protein-id="P19429,Q6FGX2">cTnI</protein-id> (µg/L) <compound-id="4577">OnP</compound-id>-BH group vs CCABG group: (0.5 h after CPB: (0.132 ± 0.022) vs (0.265 ± 0.014) , 1 h after CPB: (0.341 ± 0.027) vs (0.572 ± 0.046) , 1 h after operation: (0.641 ± 0.036) vs (0.932 ± 0.047) , 6 h after operation: (1.212 ± 0.765) vs (1.627 ± 0.542) and 24 h after operation: (1.496 ± 0.263) vs (1.734 ± 0.328) , all P &lt; 0.05).	OnP__cTnI__no_interaction
23736006-5	With diet P and in genotype Trp64Trp, <compound-id="206,5793,64689,79025">glucose</compound-id> levels (-6.7 ± 12.1 vs. -1.2 ± 2.2 mg/dl; p &lt; 0.05), total <compound-id="5997">cholesterol</compound-id> (-11.2 ± 8.1 vs. -1.0 ± 7.1 mg/dl; p &lt; 0.05), low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> (-9.7 ± 10.1 vs. -2.2 ± 8.1 mg/dl; p &lt; 0.05), triglycerides (-11.7 ± 13.1 vs. +1.7 ± 10.3 mg/dl; p &lt; 0.05), homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-R; -0.7 ± 1.1 vs. -0.3 ± 2.1 units; p &lt; 0.05) and <protein-id="P01308,I3WAC9">insulin</protein-id> levels (-1.8 ± 4.6 vs. -1.0 ± 9.1 mIU/l; p &lt; 0.05) decreased.	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction
20619421-9	Within FEP patients, decreases in <compound-id="5754">cortisol</compound-id> and the <compound-id="5754">cortisol</compound-id>/<protein-id="Q06520,A8K015">DHEAS</protein-id> ratio over time were directly related to the improvement in depression (r = 0.45; p = 0.031, r = 0.52; p = 0.01), negative (r = 0.51; p = 0.006, r = 0.55; p = 0.008) and psychotic symptoms (<compound-id="5754">cortisol</compound-id> only, r = 0.53; p = 0.01).	cortisol__DHEAS__no_interaction
2061325-2	Kinetic studies revealed that (i) S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) was maximally released by the 3rd day, and this was associated with a proportionate decrease in hydrophobic FBPs; (ii) although <compound-id="6197">cycloheximide</compound-id> inhibited de novo synthesis of [35S]<compound-id="6137,84815,876">methionine</compound-id>-labeled hydrophobic FBPs and S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) by greater than 90%, unlabeled net S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) release was only inhibited by 50%; (iii) <compound-id="6049">EDTA</compound-id> markedly inhibited release of S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) which was accompanied by a proportionate increase in hydrophobic FBPs; (iv) <compound-id="6049">EDTA</compound-id> effects were completely reversed by 5-fold molar excesses of Mg2+ which led to a 50-fold greater release of S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) compared to <compound-id="6049">EDTA</compound-id> alone; (v) whereas Mg2+ alone stimulated S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) release 4-fold greater than basal conditions, addition of <compound-id="6197">cycloheximide</compound-id> to Mg2+ suppressed (by 4-fold) the expected increase observed with Mg2+ alone.	EDTA__FBP__no_interaction	methionine__FBP__no_interaction	cycloheximide__FBP__no_interaction
22364105-3	The distortion of the ligand--which stands in contrast to all other complexes of <compound-id="23989">uranium</compound-id> supported by the ((R)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>(3-) ligand, including 2-Ad--is most clearly seen in the structures of 2-t-Bu, [(((t-Bu)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>)U(VI)(O)(eq)]SbF(6), and 3-t-Bu, [(((t-Bu)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>)U(VI)(O)(eq)(OC(O)CF(3))(ax)].	uranium__ArO__no_interaction	tacn__ArO__no_interaction
16833708-2	Measured rate coefficients at T = 295 +/- 1 K (in units of M(-1) s(-1)) are as follows: Cl + <compound-id="679">DMSO</compound-id>, (6.3 +/- 0.6) x 10(9); <protein-id="O95490">Cl2</protein-id>(-) + <compound-id="679">DMSO</compound-id>, (1.6 +/- 0.8) x 10(7); Cl + DMSO2, (8.2 +/- 1.6) x 10(5); <protein-id="O95490">Cl2</protein-id>(-) + DMSO2, (8.2 +/- 5.5) x 10(3); <protein-id="O95490">Cl2</protein-id>(-) + MSI, (8.0 +/- 1.0) x 10(8); Cl + MS, (4.9 +/- 0.6) x 10(5); <protein-id="O95490">Cl2</protein-id>(-) + MS, (3.9 +/- 0.7) x 10(3).	DMSO__Cl2__no_interaction
11273911-7	SjO(2) correlated with plasma mAMj concentrations at preclamp (r = 0.79, P &lt; 0.01), postclamp (r = 0.71, P &lt; 0.05), and post-<protein-id="P15086">CPB</protein-id> (r = 0.72, P &lt; 0.05), as well as with <compound-id="8948">mAMa</compound-id> concentrations at preclamp (r = 0.79, P &lt; 0.01) and postclamp (r = 0.72, P &lt; 0.05).	mAMa__CPB__no_interaction
8049647-3	When PBMC from normal individuals were cultured with sera from <compound-id="9841438">ATL</compound-id> patients for 24 hrs, CD3 expression revealed by means of fluorescent intensity (MFI) was down-regulated by sera from <compound-id="9841438">ATL</compound-id> patients in Group A (MFI: <protein-id="Q15935">Pt.1</protein-id> = 51.6 +/- 4.5, Pt.2 = 48.0 +/- 6.9, Control = 96.5 +/- 6.6), not by sera from patients in Group B (MFI: <protein-id="P52742,Q8N9M3,B4DLZ7">Pt.3</protein-id> = 105.5 +/- 7.9, Pt.4 = 102.5 +/- 8.3, Control = 96.5 +/- 6.6).	ATL__Pt.3__no_interaction	ATL__Pt.1__no_interaction
19997015-6	Venoarterial [La-] difference ([La-]v-a) at 30 s of post-<compound-id="447029">IHG</compound-id> was the same across conditions (passive = 6.1 +/- 0.6 mmol x L(-1), active = 5.7 +/- 0.6 mmol x L(-1), massage = 5.5 +/- 0.6 mmol x L(-1), NS), whereas FBF was greater in passive (766 +/- 101 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) versus active (614 +/- 62 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P = 0.003) versus massage (540 +/- 60 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.0001).	IHG__min(-1__no_interaction
16913263-10	However, at 10 minutes, changes in <protein-id="P41222,A0A024R8G3">PGD2</protein-id>, tryptase, and <compound-id="774">histamine</compound-id> were not significant (46.8 +/- 9.2 pg/mL versus 68.6 +/- 9.2 pg/mL, p = 0.1; 9.5 +/- 2.7 ng/mL versus 16.6 +/- 2.9 ng/mL, p = 0.09; and 1.5 +/- 1.6 ng/mL versus 3.5 +/- 1.6 ng/mL, p = 0.4).	histamine__PGD2__no_interaction
8434787-5	Using the dual assay, kinetic constants determined for <protein-id="Q64133,Q3TPD9,Q3UJ53">MAO-A</protein-id> (mean +/- SD) were: Km,<compound-id="5202">5-HT</compound-id> = 39 +/- 7 microM, Vmax,<compound-id="5202">5-HT</compound-id> = 37.6 +/- 2.1 pmol/mg wet tissue/min, Km,MHBA = 341 +/- 75 microM, and Vmax,MHBA = 27.7 +/- 2.3 pmol/mg wet tissue/min; those for <protein-id="Q8BW75">MAO-B</protein-id> were: Km,MHBA = 108 +/- 11 microM, Vmax,MHBA = 44.3 +/- 1.2 pmol/mg wet tissue/min, Km,<compound-id="5202">5-HT</compound-id> = 1704 +/- 122 microM, and Vmax,<compound-id="5202">5-HT</compound-id> = 12.0 +/- 0.3 pmol/mg wet tissue/min.	5-HT__MAO-B__no_interaction	5-HT__MAO-A__no_interaction
20868439-13	(E/e'<protein-id="O43561,A0A024QZD6">lat</protein-id>)/LVDd was not reduced in athletes comparing to controls (<compound-id="962">water</compound-id> polo players 0.83 ± 0.39, wrestlers 0.73 ± 0.29, controls 0.70 ± 0.28; P = 0.52), but (E/e's)/<compound-id="56973415">RVe</compound-id>'<protein-id="O43561,A0A024QZD6">lat</protein-id> better distinguished examined groups (<compound-id="962">water</compound-id> polo players 0.48 ± 0.37, wrestlers 0.28 ± 0.15, controls 0.25 ± 0.16, P = 0.015) and it was the only index which predicted VO(2) max.	water__lat__no_interaction	RVe__lat__no_interaction
16676956-1	A new dealkylation reaction between organophosphate esters and <compound-id="5464119">Salen</compound-id> <compound-id="24409">aluminum bromide</compound-id> compounds has been used to prepare three new <compound-id="5359268">aluminum</compound-id> <compound-id="5464119">salen</compound-id> compounds <compound-id="5464119">salen</compound-id>((t)Bu)AlOP(O)<protein-id="Q8IXK0">Ph2</protein-id> (1) (<compound-id="5464119">salen</compound-id> = N,N'-ethylenebis(3,5-di-tert-butylsalicylideneimine)), [(<compound-id="887">MeOH</compound-id>)Alsalen((t)Bu)[OMePO2(O)]Alsalen((t)Bu)[OMePO2(O)]Alsalen((t)Bu)]Br (2), and [salpen((t)Bu)AlO]2[(BuO)2PO]2 (3) (salpen = N,N'-propylenebis(3,5-di-tert-butylsalicylideneimine)).	Salen__Ph2__no_interaction	salen__Ph2__no_interaction	aluminum__Ph2__no_interaction	aluminum bromide__Ph2__no_interaction	MeOH__Ph2__no_interaction
15648780-5	Serum <protein-id="P50591,Q6IBA9">TRAIL</protein-id> concentrations correlated significantlywithTBF (r = 0.31, p &lt; 0.05) and lean body mass (r = -0.26, p &lt;0.05) in men and <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.32, p &lt; 0.05) and total <compound-id="5997">cholesterol</compound-id> (r = 0.21, p &lt; 0.05) in women.	cholesterol__TRAIL__no_interaction	cholesterol__LDL-C__no_interaction
20029513-3	Mean RSA time (RSA(mean)) and RSA decrement were related to the physiological responses to HIT (blood <compound-id="612">lactate</compound-id> concentration ([La(-)]), r = 0.66 and 0.77; blood <compound-id="767">bicarbonate</compound-id> concentration ([HCO(3)-]), r = -0.71 and -0.75; and blood <compound-id="783">hydrogen</compound-id> ion concentration ([H(+)]), r = 0.61 and 0.73; all p &lt; 0.05), VO(2) (max) (r = -0.45 and -0.65, p &lt; 0.05), and time constant (<protein-id="P10636,A0A024R9Y0,A0A024RA17,A0A024R9Y1,A0A024RA19,B3KTM0">tau</protein-id>) in VO(2) kinetics (r = 0.62 and 0.62, p &lt; 0.05).	bicarbonate__tau__no_interaction	hydrogen__tau__no_interaction	lactate__tau__no_interaction
17921920-7	Presence of inflammation and malnutrition (in 44% of patients) was associated with older age (60.69 -/+ 12.46 vs. 54.52 -/+ 12.37, p = 0.0002), lower levels of Hb (99.53 -/+ 14.97 vs. 111.86 -/+ 10.38 g/l, p = 0.0000), <compound-id="588">creatinine</compound-id> (835.88 -/+ 179.84 vs. 1069.98 -/+ 821.23-/+mol/l, p = 0.0047), <protein-id="P02768">albumin</protein-id> (36.58 -/+ 3.41 vs.40.32 -/+ 2.82 g/l, p = 0.0000), <compound-id="5997">cholesterol</compound-id> (4.32 -/+ 1.04 vs. 4.75 -/+ 1.09 mmol/l, p = 0.0025) and higher levels of fibrinogen (4.94 -/+ 1.18 vs. 4.29-/+0.91g/l, p=0.0000) and <protein-id="P02741">CRP</protein-id> (30.42-/+29.47 vs. 5.24-/+4.89 mg/l, p=0.0000).	creatinine__CRP__no_interaction	creatinine__albumin__no_interaction	cholesterol__CRP__no_interaction	cholesterol__albumin__no_interaction
23675748-6	The activation parameters, which have been obtained from fitting the reaction rates at different temperatures to the Eyring equation for <compound-id="23950">ruthenium</compound-id> [ΔH(cis-trans)‡ = 122.8 ± 1.3; ΔH(trans-cis)‡ = 138.8 ± 1.0 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>; ΔS(cis-trans)‡ = -18.7 ± 3.6; ΔS(trans-cis)‡ = 31.8 ± 2.7 J/(<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>·K)] and <compound-id="23937">osmium</compound-id> [ΔH(cis-trans)‡ = 200.7 ± 0.7; ΔH(trans-cis)‡ = 168.2 ± 0.6 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>; ΔS(cis-trans)‡ = 142.7 ± 8.9; ΔS(trans-cis)‡ = 85.9 ± 3.9 J/(<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>·K)] reflect the inertness of these systems.	ruthenium__mol__no_interaction	osmium__mol__no_interaction
6510639-1	A new <compound-id="962">water</compound-id>-soluble nitrosourea derivative, methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-<compound-id="5793">D-glucopyranoside</compound-id> (MCNU), was tested for antitumor activity against murine tumors (L1210 and P388 leukemias, B16 melanoma, and Lewis lung carcinoma) and BC-47 rat bladder carcinoma, and the results were compared with those for four other nitrosourea derivatives; <compound-id="57130000">chlorozotocin</compound-id>, 1-(2-chloroethyl)-3-(beta-D-<compound-id="64960">glucopyranosyl</compound-id>)-<compound-id="105035">1-nitrosourea</compound-id> (<compound-id="99636,9972891">GANU</compound-id>), 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1- nitrosourea hydrochloride (ACNU), and 1-(2-chloroethyl)-<compound-id="91127918">3-(4-methylcyclohexyl)-1-nitrosourea</compound-id> (methyl-<protein-id="P0C242,B2RWG0">CCNU</protein-id>).	D-glucopyranoside__CCNU__no_interaction	GANU__CCNU__no_interaction	1-nitrosourea__CCNU__no_interaction	water__CCNU__no_interaction	glucopyranosyl__CCNU__no_interaction	3-(4-methylcyclohexyl)-1-nitrosourea__CCNU__no_interaction	chlorozotocin__CCNU__no_interaction
23197773-2	In the present studies, the effects of <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) agonists [(6aR,10aR)-3-(1-adamantyl)-<compound-id="44375198">6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol</compound-id> (AM411), 9β-(hydroxymethyl)-3-(1-adamantyl)-<compound-id="522237">hexahydrocannabinol</compound-id> (<compound-id="71661716">AM4054</compound-id>), <compound-id="54358654">R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate</compound-id> (WIN55,212.2), Δ(9)-<compound-id="16078">tetrahydrocannabinol</compound-id> (Δ(9)-THC), (R)-(+)-<compound-id="6438332">arachidonyl-1'-hydroxy-2'-propylamide</compound-id> (<compound-id="18346297,6321351,6610214">methanandamide</compound-id>)], <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) antagonists [<compound-id="1519421">5-(4-chlorophenyl)-1-(</compound-id>2,4-dichloro-phenyl)-<compound-id="67158791">4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide</compound-id> (<compound-id="104850">SR141716A</compound-id>), 5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-<compound-id="67158791">4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide</compound-id> (AM4113)], and <compound-id="681">dopamine</compound-id> (DA)-related [<compound-id="10836">methamphetamine</compound-id>, (±)-6-chloro-7,8-dihydroxy-3-<compound-id="8252">allyl</compound-id>-<compound-id="2870943">1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine</compound-id> hydrobromide (SKF82958), (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-<compound-id="1400243">2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride</compound-id> (<compound-id="5018">SCH23390</compound-id>), (6aR)-5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]<compound-id="7047">quinoline</compound-id>-10,11-diol (R-(-)-NPA), <compound-id="3559">haloperidol</compound-id>] and opioid (morphine, <compound-id="5360515">naltrexone</compound-id>) drugs on scheduled-controlled responding under a 30-response fixed ratio schedule of stimulus-shock termination in squirrel monkeys were compared before and during chronic treatment with the long-acting <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) agonist AM411 (1.0 mg/kg per day, i.m.).	methamphetamine__CB(1__no_interaction	1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine__CB(1__no_interaction	methanandamide__CB(1__no_interaction	SR141716A__CB(1__no_interaction	R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate__CB(1__no_interaction	dopamine__CB(1__no_interaction	SCH23390__CB(1__no_interaction	hexahydrocannabinol__CB(1__no_interaction	AM4054__CB(1__no_interaction	4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide__CB(1__no_interaction	6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol__CB(1__no_interaction	tetrahydrocannabinol__CB(1__no_interaction	5-(4-chlorophenyl)-1-(__CB(1__no_interaction	allyl__CB(1__no_interaction	2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride__CB(1__no_interaction	naltrexone__CB(1__no_interaction	quinoline__CB(1__no_interaction	haloperidol__CB(1__no_interaction	arachidonyl-1'-hydroxy-2'-propylamide__CB(1__no_interaction
2147141-1	The effect of acute volume expansion (2 liters of saline solution in 2 h) on plasma concentrations of <protein-id="P01160">atrial natriuretic factor</protein-id> (<protein-id="P01160">ANF</protein-id>), plasma aldosterone concentration (PAC), plasma <protein-id="P00797">renin</protein-id> activity (PRA) and their relationship to the renal excretion of urine, <compound-id="5360545">sodium</compound-id> and <compound-id="5462222">potassium</compound-id> were studied in 6 control subjects and 7 patients with essential hypertension (EH) WHO stage I. Saline infusion provoked comparable rise in plasma <protein-id="P01160">ANF</protein-id> in both groups (from 2.98 +/- 0.45 to 12.36 +/- 1.74 pmol/l in the control subjects and from 3.80 +/- 0.72 to 15.78 +/- 2.06 pmol/l in EH patients), significant drop in PRA (from 0.915 +/- 0.419 to 0.256 +/- 0.127 nmol/l/h in controls and from 1.711 +/- 0.324 to 0.714 +/- 0.128 nmol/l/h in EH) and in PAC (from 0.30 +/- 0.07 to 0.14 +/- 0.03 nmol/l in control subjects and from 0.53 +/- 0.13 to 0.24 +/- 0.07 nmol/l in EH).	potassium__ANF__no_interaction	potassium__atrial natriuretic factor__no_interaction	potassium__renin__no_interaction	sodium__ANF__no_interaction	sodium__atrial natriuretic factor__no_interaction	sodium__renin__no_interaction
8388858-1	To evaluate whether, in the forearm of hypertensive patients with different circulating <protein-id="P00797">renin</protein-id> profiles, local beta-adrenergic receptor-induced production of active <protein-id="P00797">renin</protein-id>, plasma <protein-id="P00797">renin</protein-id> activity, <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin I (Ang I</protein-id>), and angiotensin II (<protein-id="O15123">Ang II</protein-id>) was or was not related to the <protein-id="P00797">renin</protein-id> profile, we studied four groups of patients: 1) hypertensive patients with primary aldosteronism and suppressed circulating plasma <protein-id="P00797">renin</protein-id> activity values (0.15 +/- 0.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 7), 2) essential hypertensive patients with low (0.47 +/- 0.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 8) circulating plasma <protein-id="P00797">renin</protein-id> activity values, 3) essential hypertensive patients with normal (2.48 +/- 0.52 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 8) circulating plasma <protein-id="P00797">renin</protein-id> activity value, and 4) renovascular hypertensive patients with high circulating plasma <protein-id="P00797">renin</protein-id> activity values (4.16 +/- 2.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 10).	Ang I__angiotensin I (Ang I__no_interaction	Ang I__Ang II__no_interaction	Ang I__renin__no_interaction
17126448-6	Multivariate analysis identified <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (&gt;or=86 mg/dl), aa substitutions in HCV-CR (double-wild-type; <compound-id="6322,90867653">arginine</compound-id> at aa 70/<compound-id="6106">leucine</compound-id> at aa 91), <protein-id="Q9BX51,D3DW46">gamma-glutamyl transpeptidase</protein-id> (GGT) (&lt;109 IU/l), RBV dose (&gt;or=11.0mg/kg), and leukocyte count (&gt;or=4500/mm3) as significant determinants of EVR, and aa substitutions in HCV-CR (double-wild-type), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (&gt;or=86 mg/dl), male gender, <compound-id="6096882">ICG</compound-id> <compound-id="24856345">R15</compound-id> (&lt;10%), GGT (&lt;109 IU/l), and RBV dose (&gt;or=11.0 mg/kg) as determinants of SVR.	leucine__low-density lipoprotein cholesterol__no_interaction	leucine__LDL-C__no_interaction	leucine__gamma-glutamyl transpeptidase__no_interaction	R15__low-density lipoprotein cholesterol__no_interaction	R15__LDL-C__no_interaction	R15__gamma-glutamyl transpeptidase__no_interaction	ICG__low-density lipoprotein cholesterol__no_interaction	ICG__LDL-C__no_interaction	ICG__gamma-glutamyl transpeptidase__no_interaction	arginine__low-density lipoprotein cholesterol__no_interaction	arginine__LDL-C__no_interaction	arginine__gamma-glutamyl transpeptidase__no_interaction
15119638-10	Observed/predicted ratios for TBK in PD patients correlated with serum <compound-id="5462222">potassium</compound-id> (Boddy r = 0.355, p = 0.06; <protein-id="Q9NR09">Bruce</protein-id> r = 0.411, p &lt; 0.05; Burkinshaw r = 0.457, p &lt; 0.01; Leeds r = 0.412, p &lt; or = 0.05; Ellis r = 0.356, p = 0.06) and tended to correlate with <protein-id="P02768">serum albumin</protein-id> (<protein-id="Q9NR09">Bruce</protein-id> r = 0.343, p = 0.07; Burkinshaw r = 0.421, p &lt; 0.05; Leeds r = 0.357, p = 0.06; Ellis r = 0.310, p = NS).	potassium__Bruce__no_interaction	potassium__serum albumin__no_interaction
12005497-3	Crystal structures of the monosubstituted ortho-carborane, 1-[(N,N'((tert-butyloxy)carbonyl)hydrazino)]-1,2-dicarba-closo-dodecaborane (8) [a = 21.213(6) A, b = 10.498(3) A, c = 9.866(2) <protein-id="P28347,Q59EF3">A, alpha</protein-id> = gamma = 90 degrees, beta = 90.529(4) degrees ] and the bifunctional para-carborane 1-[(N,N'((tert-butyloxy)carbonyl)hydrazino)]-1,12-dicarba-closo-dodecaborane-12-<compound-id="11229316,91179806">carboxylic acid</compound-id> (3) [a = 12.744(10) A, b = 12.875(9) A, c = 14.767(9) <protein-id="P28347,Q59EF3">A, alpha</protein-id> = beta = gamma = 90 degrees ] were obtained.	carboxylic acid__A, alpha__no_interaction
24294778-7	We found a significant correlation between fibrosis stage and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.53; p &lt; 0.01), IL-6 (r = 0.62; p &lt; 0.01), the Knodell Histological Activity Index and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.58, p &lt; 0.05), IL-6 (r = 0.64; p &lt; 0.01), the results of 13C MBT and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = -0.72; p &lt; 0.01), IL-6 (r = -0.73; p &lt; 0.01), <compound-id="5950">alanine</compound-id> aminotransferase and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.61; p &lt; 0.01), IL-6 (r = 0.54; p &lt; 0.01), <compound-id="5960">aspartate</compound-id> aminotransferase and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.64; p &lt; 0.01), IL-6 (r = 0.65; p &lt; 0.01), <protein-id="Q9BX51,D3DW46">gamma-glutamyl transpeptidase</protein-id> and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.46; p &lt; 0.01), IL-6 (r = 0.48; p &lt; 0.01).	alanine__TNF-alpha__no_interaction	alanine__gamma-glutamyl transpeptidase__no_interaction	aspartate__TNF-alpha__no_interaction	aspartate__gamma-glutamyl transpeptidase__no_interaction
11960941-2	Several days of hypobaric hypoxemia reduced body weight (-2.1 +/- 0.4 kg), increased plasma osmolality (+5.3 +/- 1.4 mosmol/kgH(2)O), elevated blood pressure (+12 +/- 1 mmHg), reduced <compound-id="588">creatinine</compound-id> clearance (122 +/- 6 to 96 +/- 10 ml/min), inhibited the <protein-id="P00797">renin</protein-id> system (19.5 +/- 2.0 to 10.9 +/- 0.9 mU/l) and plasma <protein-id="P01185,X5DQP6">vasopressin</protein-id> (1.14 +/- 0.16 to 0.38 +/- 0.06 pg/ml), and doubled circulating levels of <compound-id="439260">norepinephrine</compound-id> (103 +/- 16 to 191 +/- 35 pg/ml) and <protein-id="P05305,Q6FH53">endothelin-1</protein-id> (3.0 +/- 0.2 to 6.3 +/- 0.6 pg/ml), whereas <compound-id="16132416">urodilatin</compound-id> excretion rate decreased from day 2 (all changes P &lt; 0.05 compared with sea level).	creatinine__endothelin-1__no_interaction	creatinine__vasopressin__no_interaction	creatinine__renin__no_interaction	urodilatin__endothelin-1__no_interaction	urodilatin__vasopressin__no_interaction	urodilatin__renin__no_interaction	norepinephrine__endothelin-1__no_interaction	norepinephrine__vasopressin__no_interaction	norepinephrine__renin__no_interaction
22227199-3	During the BAL trial, absolute power (F 107 ± 2 and UF 102 ± 2 W; P = 0.126), E(<compound-id="72792">req</compound-id>) (F 175 ± 5 and UF 176 ± 9 W m(-2); P = 0.855), steady-state whole-body sweat rate (F 0.44 ± 0.02 and UF 0.47 ± 0.02 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.385) and local sweat rate on the arm (F 0.29 ± 0.03 and UF 0.35 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.129) were not different between groups; however, local sweat rate on the forehead in UF (1.67 ± 0.20 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) was almost double (P = 0.002) that of F (0.87 ± 0.11 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)).	req__min(-1__no_interaction
22227199-6	At 60% (V(O2 max)), absolute power (F 174 ± 6 and UF 110 ± 5 W; P &lt; 0.001), E(<compound-id="72792">req</compound-id>) (F 291 ± 14 and UF 190 ± 17 W m(-2); P &lt; 0.001), steady-state whole-body sweat rate (F 0.84 ± 0.05 and UF 0.53 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt; 0.001) and local sweat rate on the arm (F 0.75 ± 0.04 and UF 0.35 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt; 0.001) and on the forehead (F 2.92 ± 0.42 and UF 1.68 ± 0.23 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.022) were all significantly greater in F compared with UF.	req__min(-1__no_interaction
19785958-5	RESULTS: Transaminase increased significantly only in 10 and 11-month- old (<protein-id="Q8VHK8">AST</protein-id>(TX10) = 218.3 U/L, <protein-id="Q8VHK8">AST</protein-id>(TX11) = 197.5 U/L, <protein-id="Q8VHK8">AST</protein-id>(DL10) = 171.5 U/L, <protein-id="Q8VHK8">AST</protein-id>(DL11) = 165.0 U/L, P(10) less than 0.001, P(11) = 0.022), but the <compound-id="23978">copper</compound-id> concentration of liver, brain and kidney was significantly increased during 7-12 month old (the average concentration of <compound-id="23978">copper</compound-id>, Liver(TX) = (750.0 +/- 85.5) mg/kg, Brain(TX) = (39.7 +/- 2.2)mg/kg, Kidney(TX) = (29.8 +/- 5.0) mg/kg, Liver(DL) = (11.6 +/- 1.5) mg/kg, Brain(DL) = (16.8 +/- 0.9) mg/kg, Kidney(DL) = (14.2 +/- 1.0) mg/kg, t = 21.16, 23.60, 7.47, for all these organs P less than 0.05).	copper__AST__no_interaction
22236368-7	The following markers were found to be of prognostic value on mortality in hip fracture patients: low haemoglobin (odds ratio, 2.78; 95% confidence interval, 2.17-3.55; P&lt;0.00001, 3148 subjects included), low total lymphocyte count, <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 2.60; 95% confidence interval, 1.61-4.20; P&lt;0.00001, 1689 subjects included), low albumin (odds ratio, 1.83; 95% confidence interval, 1.31-2.56; P=0.0004, 1680 subjects included), low albumin/low <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 3.00; 95% confidence interval, 1.81-4.99; P&lt;0.0001, 704 subjects included), low albumin/high <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 3.39; 95% confidence interval, 1.83-6.29; P=0.0001, 704 subjects included), high <compound-id="588">creatinine</compound-id> (odds ratio, 1.58; 95% confidence interval, 1.25-1.99; P=0.0001, 3761 subjects included), and high <protein-id="P01270">PTH</protein-id> (odds ratio, 15.43; 95% confidence interval, 3.60-66.14; P=0.0002, 525 subjects included).	creatinine__TLC__no_interaction	creatinine__PTH__no_interaction
8148775-3	The sum of blood <compound-id="206,64689,79025">glucose</compound-id> and plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> levels (0 + 1h + 2h) were compared in each of the following 5 groups of subjects: A--25 cases with IGT but without obesity (BMI: 23.2 +/- 2.6) and hyperlipidaemia (PL: 627 +/- 112; TG: 102 +/- 109 and CH: 208 +/- 35 mg/dl); B--35 cases with IGT and obesity (BMI: 31.2 +/- 2.6) but without hyperlipidaemia (PL: 807 +/- 109; TG: 136 +/- 31 and CH: 254 +/- 41 mg/dl); C--23 cases with IGT and hyperlipidaemia (PL: 1013 +/- 217; TG: 214 +/- 85 and CH: 311 +/- 52 mg/dl) but without obesity (BMI: 25.4 +/- 1.9); D--48 cases with IGT and both obesity (BMI: 30.9 +/- 2.8) and hyperlipidaemia (PL: 1457 +/- 155; TG: 597 +/- 188 and CH: 483 +/- 184 mg/dl); a control group of 49 cases without IGT, obesity (BMI: 26.2 +/- 1.9) or hyperlipidaemia (PL: 726 +/- 99 mg/dl).	glucose__Insulin__no_interaction
20816195-8	Gene-based analyses that included all available SNPs in each gene found associations (P &lt; .05) with both phenotypes for several genes: <protein-id="Q7Z3B1">neuronal growth regulator 1</protein-id> (<protein-id="Q7Z3B1">NEGR1</protein-id>); roundabout, axon guidance receptor, homolog 1 (<protein-id="Q9Y6N7,Q1RMC8">ROBO1</protein-id>); <protein-id="P49619">diacylglycerol kinase, gamma</protein-id> (<protein-id="P49619">DGKG</protein-id>); <protein-id="Q9BWQ8">Fas apoptotic inhibitory molecule 2</protein-id> (<protein-id="Q9BWQ8">FAIM2</protein-id>); fat mass and obesity associated (FTO); and carbohydrate (<compound-id="440552,57455154,84265,899">N-acetylgalactosamine</compound-id> 4-0) sulfotransferase 8 (<protein-id="Q9H2A9">CHST8</protein-id>) among the BMI GWAS genes; <protein-id="Q01638">interleukin 1 receptor-like 1</protein-id> / <protein-id="Q13478,B7ZKV7">interleukin 18 receptor 1</protein-id> (<protein-id="Q01638">IL1RL1</protein-id>/<protein-id="Q13478,B7ZKV7">IL18R1</protein-id>), <protein-id="Q8N608,B4DKB5,Q0GLB9,B2RCJ8,Q0GLB7">dipeptidyl-peptidase 10</protein-id> (<protein-id="Q8N608,B4DKB5,Q0GLB9,B2RCJ8,Q0GLB7">DPP10</protein-id>), <protein-id="Q08499">phosphodiesterase 4D</protein-id> (<protein-id="Q08499">PDE4D</protein-id>), V-<protein-id="P10242,Q708E9,Q14025">myb</protein-id> myeloblastosis viral oncogene homolog (<protein-id="P10242,Q708E9,Q14025">myb</protein-id>), <protein-id="Q9Y233">PDE10A</protein-id>, <protein-id="O95760">IL33</protein-id>, and especially protein <compound-id="6057,90983769">tyrosine</compound-id> phosphatase, receptor type D (PTPRD) among the asthma GWAS genes; and <protein-id="P17252,Q7Z727">protein kinase C, alpha</protein-id> (<protein-id="P17252,Q7Z727">PRKCA</protein-id>) among the BMI and asthma candidate genes.	N-acetylgalactosamine__FAIM2__no_interaction	N-acetylgalactosamine__DPP10__no_interaction	N-acetylgalactosamine__interleukin 1 receptor-like 1__no_interaction	N-acetylgalactosamine__dipeptidyl-peptidase 10__no_interaction	N-acetylgalactosamine__diacylglycerol kinase, gamma__no_interaction	N-acetylgalactosamine__CHST8__no_interaction	N-acetylgalactosamine__neuronal growth regulator 1__no_interaction	N-acetylgalactosamine__interleukin 18 receptor 1__no_interaction	N-acetylgalactosamine__Fas apoptotic inhibitory molecule 2__no_interaction	N-acetylgalactosamine__protein kinase C, alpha__no_interaction	N-acetylgalactosamine__IL18R1__no_interaction	N-acetylgalactosamine__NEGR1__no_interaction	N-acetylgalactosamine__ROBO1__no_interaction	N-acetylgalactosamine__PRKCA__no_interaction	N-acetylgalactosamine__IL33__no_interaction	N-acetylgalactosamine__PDE10A__no_interaction	N-acetylgalactosamine__myb__no_interaction	N-acetylgalactosamine__PDE4D__no_interaction	N-acetylgalactosamine__DGKG__no_interaction	N-acetylgalactosamine__phosphodiesterase 4D__no_interaction	N-acetylgalactosamine__IL1RL1__no_interaction	tyrosine__FAIM2__no_interaction	tyrosine__DPP10__no_interaction	tyrosine__interleukin 1 receptor-like 1__no_interaction	tyrosine__dipeptidyl-peptidase 10__no_interaction	tyrosine__diacylglycerol kinase, gamma__no_interaction	tyrosine__CHST8__no_interaction	tyrosine__neuronal growth regulator 1__no_interaction	tyrosine__interleukin 18 receptor 1__no_interaction	tyrosine__Fas apoptotic inhibitory molecule 2__no_interaction	tyrosine__protein kinase C, alpha__no_interaction	tyrosine__IL18R1__no_interaction	tyrosine__NEGR1__no_interaction	tyrosine__ROBO1__no_interaction	tyrosine__PRKCA__no_interaction	tyrosine__IL33__no_interaction	tyrosine__PDE10A__no_interaction	tyrosine__myb__no_interaction	tyrosine__PDE4D__no_interaction	tyrosine__DGKG__no_interaction	tyrosine__phosphodiesterase 4D__no_interaction	tyrosine__IL1RL1__no_interaction
11525238-3	The dissociation of <protein-id="P04792,V9HW43">Hsp27</protein-id> induced by exposure of U251 MG human glioma cells to metals (NaAsO2 and CdCl2), hypertonic stress (<compound-id="5780">sorbitol</compound-id> and NaCI), or <compound-id="253602">anisomycin</compound-id>, an activator of p38 mitogen-activated protein (MAP) kinase, was completely suppressed by the presence of <compound-id="176155">SB 203580</compound-id> or <compound-id="4712">PD 169316</compound-id>, inhibitors of <protein-id="Q16539,L7RSM2,B4E0K5,A0A024RD15">p38 MAP kinase</protein-id>, but not by PD 98059 and Uo 126, inhibitors of MAP kinase kinase (MEK), nor by <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, Go 6983, and <compound-id="2396">bisindolylmaleimide</compound-id> I, inhibitors of protein kinase C. <compound-id="27924,70702034">Phorbol ester</compound-id> (<compound-id="122634">PMA</compound-id>)-induced dissociation of <protein-id="P04792,V9HW43">Hsp27</protein-id> was completely suppressed by <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, Go 6983, or <compound-id="2396">bisindolylmaleimide</compound-id> I and partially suppressed by <compound-id="176155">SB 203580</compound-id>, or <compound-id="4712">PD 169316</compound-id> but not by PD 98059 or Uo 126, indicating mediation by 2 cascades.	bisindolylmaleimide__Hsp27__no_interaction	bisindolylmaleimide__p38 MAP kinase__no_interaction	staurosporine__Hsp27__no_interaction	staurosporine__p38 MAP kinase__no_interaction	PD 169316__Hsp27__no_interaction	PD 169316__p38 MAP kinase__no_interaction	anisomycin__Hsp27__no_interaction	anisomycin__p38 MAP kinase__no_interaction	SB 203580__Hsp27__no_interaction	SB 203580__p38 MAP kinase__no_interaction	PMA__Hsp27__no_interaction	PMA__p38 MAP kinase__no_interaction	sorbitol__Hsp27__no_interaction	sorbitol__p38 MAP kinase__no_interaction	Phorbol ester__Hsp27__no_interaction	Phorbol ester__p38 MAP kinase__no_interaction
23364602-1	Twelve lanthanide coordination polymers associated with the organic ligand 5-(2′-carboxylphenyl) <compound-id="938">nicotinic acid</compound-id> (H2cpna): {[Ln(Hcpna)(cpna)(phen)]·H2O}n (Ln = Sm (1), Tb (2), Ho (3), phen = 1,10-<compound-id="67473">phenanthroline</compound-id>), {[Sm(Hcpna)(cpna)(phen)]·2H2O}n (4), {[Ln2(cpna)3(H2O)3]·<compound-id="70679364">4H2O</compound-id>}n (Ln = Y (5), Tb(6), Dy (7), Ho (8)), [Lu2(cpna)3(H2O)2]n (9), {[Y2(cpna)3(phen)2(H2O)]·H2O}n (10), and [Ln(cpna)(phen)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]n (Ln = Tm (11), Lu (12)) have been prepared by hydrothermal methods and structurally characterized.	phenanthroline__NO3__no_interaction	nicotinic acid__NO3__no_interaction	4H2O__NO3__no_interaction
18820136-6	The effects of (-)-<compound-id="3779">isoproterenol</compound-id> were surmountably antagonized by the <protein-id="P18762">beta(2)-AR</protein-id>-selective antagonist ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-<compound-id="7219">inden</compound-id>-4-yl)oxy]-3-[(1-<compound-id="275736">methylethyl</compound-id>)amino]-2-<compound-id="12721311,263">butanol</compound-id>] (pK(B) = 9.28) but not affected by the <protein-id="P34971">beta(1)-AR</protein-id>-selective antagonist CGP 20712 [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)<compound-id="6341">ethylamino</compound-id>]-3-[4-(1-methyl-4-<compound-id="6373">trifluoromethyl</compound-id>-2-imidazolyl)phenoxy]-<compound-id="3776">2-propanol</compound-id>] and <protein-id="P13945,A8KAG8">beta(3)-AR</protein-id>-selective L-748,337 [(S)-M-[4-[2-[3-[3-[<compound-id="6582">acetamidomethyl</compound-id>)phenoxy)-2-hydroxypropyl]-amino]-<compound-id="23134249">ethyl</compound-id>]-phenylbenzsulfonamide)], suggesting involvement of <protein-id="P18762">beta(2)-AR</protein-id> only.	isoproterenol__beta(3)-AR__no_interaction	isoproterenol__beta(2)-AR__no_interaction	isoproterenol__beta(1)-AR__no_interaction	ethylamino__beta(3)-AR__no_interaction	ethylamino__beta(2)-AR__no_interaction	ethylamino__beta(1)-AR__no_interaction	2-propanol__beta(3)-AR__no_interaction	2-propanol__beta(2)-AR__no_interaction	2-propanol__beta(1)-AR__no_interaction	methylethyl__beta(3)-AR__no_interaction	methylethyl__beta(2)-AR__no_interaction	methylethyl__beta(1)-AR__no_interaction	inden__beta(3)-AR__no_interaction	inden__beta(2)-AR__no_interaction	inden__beta(1)-AR__no_interaction	butanol__beta(3)-AR__no_interaction	butanol__beta(2)-AR__no_interaction	butanol__beta(1)-AR__no_interaction	ethyl__beta(3)-AR__no_interaction	ethyl__beta(2)-AR__no_interaction	ethyl__beta(1)-AR__no_interaction	trifluoromethyl__beta(3)-AR__no_interaction	trifluoromethyl__beta(2)-AR__no_interaction	trifluoromethyl__beta(1)-AR__no_interaction	acetamidomethyl__beta(3)-AR__no_interaction	acetamidomethyl__beta(2)-AR__no_interaction	acetamidomethyl__beta(1)-AR__no_interaction
2472359-3	<protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> and galanin significantly inhibited the stimulation-evoked [3H]norepinephrine release in a dose-dependent manner (1 Hz: S2/S1 ratio (mean +/- <compound-id="5289348">SEM</compound-id>), control 0.947 +/- 0.040, n = 11, <protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> 1 x 10(-8) M 0.509 +/- 0.013, n = 8, p less than 0.01, <protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> 1 x 10(-7) M 0.283 +/- 0.021, n = 8, p less than 0.01; galanin 1 x 10(-7) M 0.448 +/- 0.026, n = 8, p less than 0.01, galanin 1 x 10(-6) M 0.261 +/- 0.023, n = 8, p less than 0.01).	SEM__Neuropeptide Y__no_interaction
17494790-9	Serum <protein-id="P20366,Q9Y494">substance P</protein-id> levels were negatively correlated with Epworth sleepiness scale score (r = - 0.253, p = 0.048), number of total apneas during the night (r = - 0.247, p = 0.036), number of respiratory events during the night (r = - 0.266, p = 0.024), apnea-hypopnea index (r = - 0.287, p = 0.015), respiratory arousal index (r = - 0.267, p = 0.026), time spent in apnea and hypopnea (r = - 0.307, p = 0.01), average <compound-id="977">oxygen</compound-id> desaturation (r = - 0.265, p = 0.026), and <compound-id="977">oxygen</compound-id> desaturation index (r = - 0.254, p = 0.031).	oxygen__substance P__no_interaction
16161752-6	In these surveillances spanning three years, the incidence rates of resistance in various species were as follows (2000.6-2001.3 --&gt; 2001.4-2002.3 --&gt; 2002.4-2003.3): <compound-id="6087">methicillin</compound-id>-resistant Staphylococcus aureus (39.3% --&gt; 43.9% --&gt; 47.3%), penicillin-intermediate Streptococcus pneumoniae (48.9% --&gt; 44.2% --&gt; 25.7%), penicillin-resistant S. pneumoniae (PRSP, 13.8% --&gt; 26.3% --&gt; 43.2%), extended-spectrum <protein-id="Q48435,Q6A253">beta-lactamase</protein-id> (ESBL)-producing Escherichia coli (0.9% --&gt; 0% --&gt; 1.4%), ESBL-producing Klebsiella pneumoniae (3.4% --&gt; 1.3% --&gt; 3.1%), <protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-producing Haemophilus influenzae (19.2% --&gt; 8.9% --&gt; 42.9%), <protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-negative <compound-id="6249">ampicillin</compound-id>-resistant H. influenzae (BLNAR, 22.1% --&gt; 30.7% --&gt; 33.0%), and metallo-<protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-producing Pseudomonas aeruginosa (1.0% --&gt; 4.4% --&gt; 1.0%).	methicillin__beta-lactamase__no_interaction	ampicillin__beta-lactamase__no_interaction
16556241-4	A significant positive correlation emerged between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> values of <protein-id="P39905">GDNF</protein-id> and those of <protein-id="P61278">somatostatin</protein-id> in CM (r = 0.70, P &lt; 0.02), PCM + PAAH (r = 0.78, P &lt; 0.004), and PFMS patients (r = 0.68, P &lt; 0.008).	CSF__somatostatin__no_interaction	CSF__GDNF__no_interaction
10671946-13	Fasting <protein-id="P08833">IGFBP-1</protein-id> levels were doubled in hyperthyroid subjects compared to healthy controls and correlated positively with free T4 (r = 0.84, P &lt; 0.0001), with peak <compound-id="206,5793,64689,79025">glucose</compound-id> during the OGTT (r = 0.68, P &lt; 0.005) with peak <protein-id="P01308,I3WAC9">insulin</protein-id> during the IVGTT (r = 0.51, P &lt; 0.005) and negatively with <compound-id="206,5793,64689,79025">glucose</compound-id> disappearance constant (r = - 0.52, P &lt; 0.005).	glucose__IGFBP-1__no_interaction	glucose__insulin__no_interaction
20346637-5	After treatment with high-dose <compound-id="3440">furosemide</compound-id>+HSS compared to treatment with <compound-id="3440">furosemide</compound-id> alone we observed a significant lowering of <protein-id="P01160">ANP</protein-id> [96 (46.5-159.5) pg/ml vs 64 (21-150) pg/ml], <protein-id="P16860">BNP</protein-id> [215.5 (80.5-487) pg/ml vs 87 (66-141.5) pg/ml], TNF-α [389.5 (265-615.5) pg/ml vs 231.5 (156-373.5) pg/ml], IL-1β [8 (7-9) pg/ml vs 4 (3-7) pg/ml], IL-6 [5 (3-7.5) pg/ml vs 3 (2-4) pg/ml], plasma values and after an acute saline load, a lower percentage change of <protein-id="P01160">ANP</protein-id> (+18.6% vs +28.03% vs +25% vs +29%), <protein-id="P16860">BNP</protein-id> (+14.5% vs +29.2% vs +30% vs +29.6%) TNF-α (+10.8% vs +15.8% vs +17.8% vs +11.3%), IL-1β (+20% vs 34.4% vs 40% vs 34.4%) compared to control groups.	furosemide__BNP__no_interaction	furosemide__ANP__no_interaction
8706295-11	RESULTS: <compound-id="21885907,5464109,6918297">Hexarelin</compound-id> induced a significant increase in <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> levels in NS (median, range, delta peak <protein-id="Q03014">HEX</protein-id> vs placebo: 150 (-14-402) vs 10 (-34-24) mU/l; delta AUC <protein-id="Q03014">HEX</protein-id> vs placebo: 7710 (2,100-3 2540) vs 30 (-2,566-2,040) mU min/l, P &lt; 0.01) and in ACRO (190 (-10-496) vs 6 (-100-34) mU/l; 10,170 (-5,310-51,436) vs -82 (-6,030-1,410) mU min/l, P &lt; 0.02), but not in HPRL (10 (-180-80) vs 50 (-100-240) mU/l; -600 (-16,996-10,140) vs -1,950 (-8,540-14,160) mU min/l).	Hexarelin__PRL__no_interaction	Hexarelin__HEX__no_interaction
16464885-7	RESULTS: The following are the main findings for 2004 (post-K/DOQI): an increased use of dialysates with a Ca concentration of 2.5 mEq/l (27.2-50.9%, P&lt;0.001) and a reduced use of a dialysate <compound-id="22044544,5460341">calcium</compound-id> of 3.0 mEq/l (44.6-39.6%, P: NS) and 3.5 mEq/l (28-9.4%, P&lt;0.001); a reduced use of <compound-id="22044544,5460341">calcium</compound-id>-based <compound-id="1061,167704,644102">phosphate</compound-id> binders (891.9-565.5 mg Ca/day, P&lt;0.001) and increased use of <compound-id="159247">sevelamer hydrochloride</compound-id> (800 mg) (from 4.86 to 7.51 mg, tablets/day, P&lt;0.001) lower serum Ca levels (9.7-9.4 mg/dl, P&lt;0.01), and higher intact <protein-id="P01270">PTH</protein-id> levels (201.4-311.8 pg/ml, P&lt;0.001), without changes in serum P levels; an increased proportion of patients with serum Ca levels within the K/DOQI target range (38.7-46.6%, P&lt;0.01), resulting mainly from the reduced percentage of patients with hypercalcaemia (55-44.4%, P&lt;0.01); a decreased proportion of patients with <protein-id="P01270">PTH</protein-id>&lt;150 pg/ml (53.8-31.4%, P&lt;0.001) but an increased proportion of patients with <protein-id="P01270">PTH</protein-id>&gt;300 pg/ml, with no change in the proportion of patients with PTHs within the K/DOQI target range.	calcium__PTH__no_interaction	phosphate__PTH__no_interaction	sevelamer hydrochloride__PTH__no_interaction
19069643-7	Significant decreased <protein-id="P18887,B2RCY5,Q59HH7">XRCC1</protein-id> mRNA expression were observed at 10 micromol/L <compound-id="95170">PBDE-47</compound-id>, 5 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id>, and 10 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id> groups while significant increased <protein-id="O43542,Q53XC8">XRCC3</protein-id> mRNA expression were observed at 10 micromol/L <compound-id="95170">PBDE-47</compound-id> and 10 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id> compared to the control group (P &lt; 0.05).	PBDE-47__XRCC1__no_interaction	PBDE-47__XRCC3__no_interaction	PCB153__XRCC1__no_interaction	PCB153__XRCC3__no_interaction
23656591-7	<compound-id="5180215">Na5</compound-id>[B(SO4)4]-I: space group Pca21, a = 10.730(2) Å, b = 13.891(3) Å, c = 18.197(4) Å. <compound-id="5180215">Na5</compound-id>[B(SO4)4]-II: space group P212121, a = 8.624(2) Å, b = 9.275(2) Å, c = 16.671(3) Å. A3[B(SO4)3] (A = K, Rb) are isotypic with Ba3[B(<compound-id="1061">PO4</compound-id>)3] adopting space group Ibca [K3[B(SO4)3], a = 7.074(4) Å, b = 14.266(9) Å, c = 22.578(14) Å; <protein-id="Q9H169,E7EVN3">Rb3</protein-id>[B(SO4)3], a = 7.2759(5) Å, b = 14.7936(11) Å, c = 22.637(2) Å] with vierer chains of BO4tetrahedra based on two bridging and two terminal SO4 tetrahedra.	PO4__Rb3__no_interaction	Na5__Rb3__no_interaction
21741247-4	The most active compound when tested in intact HEK-293 transfected cells, namely (3α,5α)-3-{[trans-2,5-dimethyl-4-{[2-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl] sulfonyl}<compound-id="91216341">piperazin-1-yl</compound-id>]methyl}-<compound-id="225">3-hydroxyandrostan-17-one</compound-id> (<compound-id="447977">15b</compound-id>), shows an IC₅₀ value of 6 nM, this compound is thus eight times more active than our reference compound <protein-id="P55327">D-5-2</protein-id> (IC₅₀=51 nM).	trifluoromethyl__D-5-2__no_interaction	15b__D-5-2__no_interaction	piperazin-1-yl__D-5-2__no_interaction	3-hydroxyandrostan-17-one__D-5-2__no_interaction
23224921-7	Following ECG parameters correlated the most prominently with LVMI - RV5: r = 0.5 (p = 0.002), RV6: r = 0.61 (p = 0.0001), <compound-id="70699405">SV1</compound-id>+RV5, 6: r = 0.64 (p = 0.001), RaVL+SV3: r = 0.5 (p = 0.002), <protein-id="Q7L0J3,B4E000">SV2</protein-id>+RV5, 6: r = 0.71 (p = 0.0001), <protein-id="Q7L0J3,B4E000">SV2</protein-id>, 3+RV5, 6: r = 0.75 (p = 0.0001).	SV1__SV2__no_interaction
17698902-4	RESULTS: GH, but not placebo, increased <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> serum concentration (from 144 +/- 35 to 293 +/- 58 ng/ml; P &lt; 0.005) and improved New York Heart Association functional class (from 2.4 +/- 0.5 to 1.8 +/- 0.4; P &lt; 0.005), exercise duration (from 831 +/- 273 to 925 +/- 266 sec; P &lt; 0.005), peak power output (from 245 +/- 127 to 280 +/- 132 W; P &lt; 0.05), peak minute ventilation (from 52.5 +/- 16.1 to 61.3 +/- 17.3 liters/min; P &lt; 0.05), peak <compound-id="977">oxygen</compound-id> consumption (from 19.8 +/- 5.6 to 25.1 +/- 5.6 ml/kg.min; P &lt; 0.005), and anaerobic threshold (from 14.9 +/- 4.8 to 20.0 +/- 4.5 ml/kg.min; P &lt; 0.005) without affecting lung function parameters.	oxygen__IGF-I__no_interaction
16839062-4	The bimolecular rate coefficients of all three reactions are independent of the bath gas (He or N2) and pressure within the experimental range (1-6 Torr) and are found to depend on temperature as follows: k(<compound-id="5378701">CH2Cl</compound-id> + NO2) = (2.16 +/- 0.08) x 10(-11) (T/300 K)(-1.12+/-0.24) cm3 molecule(-1) s(-1) (220-363 K), k(<compound-id="123193">CHCl2</compound-id> + NO2) = (8.90 +/- 0.16) x 10(-12) (T/300 K)(-1.48+/-0.13) cm3 molecule(-1) s(-1) (220-363 K), and k(<protein-id="P10147,A0N0R1">CCl3</protein-id> + NO2) = (3.35 +/- 0.10) x 10(-12) (T/300 K)(-2.2+/-0.4) cm3 molecule(-1) s(-1) (298-363 K), with the uncertainties given as one-standard deviations.	CH2Cl__CCl3__no_interaction	CHCl2__CCl3__no_interaction
12920794-5	Significantly lower body weight (37.79 +/- 3.93 vs. 49.63 +/- 9.84 kg, p &lt; 0.05), body mass index (13.51 +/- 1.43 vs. 17.75 +/- 2.64 kg/m2, p &lt; 0.05),), body fat percentage (13.28 +/- 2.83 vs. 18.9 +/- 5.65%, p &lt; 0.05), serum <protein-id="P41159,A4D0Y8">Leptin</protein-id> (1.117 +/- 0.95 vs. 5.88 +/- 4.7 ng/ml, p &lt; 0.05) and <compound-id="5997">cholesterol</compound-id> levels (4.14 +/- 1.78 vs. 6.31 +/- 1.27 mmol/l, p &lt; 0.05) were found in patient with restrictive relative to purgative subtype of anorexia nervosa.	cholesterol__Leptin__no_interaction
22316010-1	We designed three novel positron emission tomography ligands, N-(4-(6-(isopropylamino)pyrimidin-4-yl)-1,3-<compound-id="9256">thiazol</compound-id>-2-yl)-4-[(11)C]<compound-id="569575">methoxy-N-methylbenzamide</compound-id> ([(11)C]6), 4-[(18)F]fluoroethoxy-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]-<compound-id="11954">N-methylbenzamide</compound-id> ([(18)F]7), and 4-[(18)F]<compound-id="68042">fluoropropoxy</compound-id>-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]-<compound-id="11954">N-methylbenzamide</compound-id> ([(18)F]8), for imaging metabotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptor type 1 (<protein-id="P23818,Q7TNB5,F6YNQ1">mGluR1</protein-id>) in rodent brain.	methoxy-N-methylbenzamide__mGluR1__no_interaction	N-methylbenzamide__mGluR1__no_interaction	glutamate__mGluR1__no_interaction	thiazol__mGluR1__no_interaction	fluoropropoxy__mGluR1__no_interaction
8742040-1	Exposure of rat hippocampal neurons to the peptide amyloid beta (A beta) (25-35) as well as A beta (1-40) peptides enhances phosphorylation of tau to a paired helical filament (PHF)-state through activation of tau protein kinase I (TPK I)/<compound-id="439177">glycogen</compound-id> synthase kinase-3 beta (<protein-id="P18266,A0A0G2JSH4,A0A0G2KB98">GSK-3 beta</protein-id>) [Busciglio, J., Lorenzo, A., Yeh, J. and Yankner, B.A., Neuron, 14 (1995) 879-888; Takashima, A., Ishiguro, K., Noguchi, K., Michel, G., Hoshi, M., Sato, K., Takahashi, M., Hoshino, T., Uchida, T. and Imahori, K., Neurosci.	glycogen__GSK-3 beta__no_interaction
19845099-15	The group conduction velocities and group nerve fibre diameters had the following pair-values at 35.5 degrees C: Spindle afferents: <protein-id="P08047">SP1</protein-id> (65 m/s / 13.1 microm), <protein-id="Q02086">SP2</protein-id> (51/12.1); touch afferents: T1 (47/11.1), T2 (39/10.1), <compound-id="5920">T3</compound-id> (27/9.1), T4 (19/8.1); urinary bladder afferents: S1 (41 m/s / -), ST (35/-); alpha-motoneurons: alpha 13 (-/14.4), alpha 12 (65 m/s /13.1 microm), alpha 11 (60?/12.1)[FF], alpha 2 (51/10.3)[FR], alpha 3 (41/8.2)[S]; gamma-motoneurons: gamma(beta) (27/7.1), gamma 1 (21/6.6), gamma 21 (16/5.8), gamma 22 (14/5.1); preganglionic parasympathetic motoneurons: (10 m/s / 3.7 microm).	T3__SP1__no_interaction	T3__SP2__no_interaction
24907224-3	METHODS: In the QUEST-2, phase 3 study, done at 76 sites in 14 countries (Europe, and North and South Americas), patients with confirmed chronic HCV genotype 1 infection and no history of HCV treatment were randomly assigned with a computer-generated allocation sequence in a ratio of 2:1 and stratified by HCV genotype 1 subtype and host <protein-id="Q8IZI9,A0A0C4DGW8">IL28B</protein-id> genotype to receive <compound-id="24873435,57956385,66576988,68266086,73425379">simeprevir</compound-id> (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight; 50 μg, 80 μg, 100 μg, 120 μg, or 150 μg once weekly, subcutaneous injection), plus <compound-id="37542">ribavirin</compound-id> (1000-1200 mg/day or 800-1400 mg/day, orally; <compound-id="24873435,57956385,66576988,68266086,73425379">simeprevir</compound-id> group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus <compound-id="37542">ribavirin</compound-id> (placebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus <compound-id="37542">ribavirin</compound-id>.	ribavirin__IL28B__no_interaction	simeprevir__IL28B__no_interaction
15607480-1	A new positron emission tomography (PET) radioligand for the <protein-id="P31652">serotonin transporter</protein-id> (SERT), [(11)C]2-[2-[[(dimethylamino)methyl]phenyl]thio]-5-(2-fluoroethyl)<compound-id="6115">phenylamine</compound-id> ([(11)C]AFE, 12), was synthesized and evaluated in vivo in rats and baboons.	phenylamine__serotonin transporter__no_interaction
19907722-3	This issue focuses on the following selection of drugs: AAV1/SERCA2a, <compound-id="441300">Abacavir sulfate</compound-id>/<compound-id="60825">lamivudine</compound-id>, Adalimumab, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="6918493">Ambrisentan</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, AT-7519, <compound-id="148192">Atazanavir sulfate</compound-id>, <compound-id="54841">Atomoxetine</compound-id> hydrochloride, <compound-id="9444">Azacitidine</compound-id>, <compound-id="54549244,65948">Azelnidipine</compound-id>; <compound-id="10178705">Besifloxacin hydrochloride</compound-id>, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">Budesonide</compound-id>/<compound-id="3410,3034756,3083544,9862958">formoterol fumarate</compound-id>; <protein-id="P22748">CAIV</protein-id>-T, <compound-id="6918474">Carisbamate</compound-id>, <compound-id="9917021">Casopitant mesylate</compound-id>, Certolizumab pegol, Cetuximab, <compound-id="6918155">Ciclesonide</compound-id>, <compound-id="2764">Ciprofloxacin</compound-id>/<compound-id="5743">dexamethasone</compound-id>, CTCE-9908; <compound-id="6918540">Dalcetrapib</compound-id>, <compound-id="213039">Darunavir</compound-id>, <compound-id="36687767,5493381,6098188">Deferasirox</compound-id>, <compound-id="124087">Desloratadine</compound-id>, <compound-id="90471248,9833838">Disitertide</compound-id>, Drotrecogin alfa (activated), DTA-H19, <compound-id="60835">Duloxetine</compound-id> hydrochloride, <compound-id="6918296">Dutasteride</compound-id>; Ecogramostim, Efalizumab, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="11354606">Eribulin mesilate</compound-id>, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="969472">Eszopiclone</compound-id>, EUR-1008, Everolimus-eluting coronary stent, <compound-id="45588096,53396299,56927919">Exenatide</compound-id>; <compound-id="1727">Fampridine</compound-id>, <compound-id="24847878,9854489">Fluticasone furoate</compound-id>, <compound-id="3410,3034756,3083544,9862958">Formoterol fumarate</compound-id>/<compound-id="444036">fluticasone propionate</compound-id>, <compound-id="131536">Fosamprenavir</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="104741">Fulvestrant</compound-id>; <compound-id="9883933">Gabapentin enacarbil</compound-id>, GS-7904L; HPV-6/11/16/18, <compound-id="16158474">Human Secretin</compound-id>, <compound-id="3637">Hydralazine hydrochloride</compound-id>/<compound-id="6883">isosorbide dinitrate</compound-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="68791">Imexon</compound-id>, Inalimarev/Falimarev, Indacaterol, <compound-id="6918554">Indacaterol maleate</compound-id>, <compound-id="57006608">Inhalable</compound-id> human <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> <compound-id="44146714">glargine</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; L-<compound-id="22128">Alanosine</compound-id>, <compound-id="208908">Lapatinib ditosylate</compound-id>, <compound-id="216326">Lenalidomide</compound-id>, <compound-id="1549000">Levocetirizine dihydrochloride</compound-id>, Liraglutide, <compound-id="11597698">Lisdexamfetamine mesilate</compound-id>, <compound-id="92727">Lopinavir</compound-id>, <compound-id="3957">Loratadine</compound-id>/<compound-id="5281040,60951">montelukast sodium</compound-id>, Lutropin alfa; MeNZB, <compound-id="56603701">Mepolizumab</compound-id>, <compound-id="477468,6602291">Micafungin sodium</compound-id>, <compound-id="5288826">Morphine hydrochloride</compound-id>; <compound-id="44148067">Nabiximols</compound-id>, <compound-id="456557,5458181">Nikkomycin Z</compound-id>; <compound-id="130881">Olmesartan medoxomil</compound-id>, Omalizumab; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, <compound-id="148178">Perifosine</compound-id>, <compound-id="11465695">PF-489791</compound-id>, <compound-id="44152164,56928089,9812534">Plitidepsin</compound-id>, <compound-id="468595">Posaconazole</compound-id>, <compound-id="5486971">Pregabalin</compound-id>; QAX-576; <compound-id="54671008">Raltegravir potassium</compound-id>, <compound-id="208902">Ramelteon</compound-id>, <compound-id="3052776">Rasagiline mesilate</compound-id>, Recombinant <compound-id="71300770">human relaxin</compound-id> <compound-id="783">H2</compound-id>, rhGAD65, <compound-id="9875401">Rivaroxaban</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>, <compound-id="59227">Rotigotine</compound-id>; <compound-id="11235729,11243969,44144606,44590597,66576989,71752157,78577434">Saxagliptin</compound-id>, <compound-id="10077130">SCH-530348</compound-id>, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting stent, SLIT-<compound-id="37768">amikacin</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="10296883">Sotrastaurin</compound-id>, SR-16234, <compound-id="5350">Sulforaphane</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, <compound-id="9838022">Tapentadol hydrochloride</compound-id>, Teriparatide, <compound-id="11370864">Tesofensine</compound-id>, <compound-id="15057856,3086655,49800038,5487427">Tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="33776">Tirapazamine</compound-id>, <compound-id="5388906">TMC-207</compound-id>, Tocilizumab, <compound-id="216237">Tolvaptan</compound-id>, <compound-id="15547703">Tosedostat</compound-id>, <compound-id="6918140,54786">Treprostinil sodium</compound-id>; <compound-id="121750">Ustekinumab</compound-id>; <compound-id="9886917">Varespladib methyl</compound-id>, <compound-id="3009355">Vicriviroc</compound-id>, <compound-id="11077541,24848920,6918537">Vildagliptin</compound-id>, <compound-id="11077541,24848920,6918537">Vildagliptin</compound-id>/<compound-id="4091">metformin hydrochloride</compound-id>, Volociximab, <compound-id="71616">Voriconazole</compound-id>; <compound-id="16135415">Ziconotide</compound-id>, <compound-id="60854">Ziprasidone hydrochloride</compound-id>.	Morphine hydrochloride__CAIV__no_interaction	Morphine hydrochloride__insulin__no_interaction	Ciclesonide__CAIV__no_interaction	Ciclesonide__insulin__no_interaction	Ciprofloxacin__CAIV__no_interaction	Ciprofloxacin__insulin__no_interaction	Sulforaphane__CAIV__no_interaction	Sulforaphane__insulin__no_interaction	Besifloxacin hydrochloride__CAIV__no_interaction	Besifloxacin hydrochloride__insulin__no_interaction	Aliskiren fumarate__CAIV__no_interaction	Aliskiren fumarate__insulin__no_interaction	Human Secretin__CAIV__no_interaction	Human Secretin__insulin__no_interaction	Rotigotine__CAIV__no_interaction	Rotigotine__insulin__no_interaction	Indacaterol maleate__CAIV__no_interaction	Indacaterol maleate__insulin__no_interaction	Tolvaptan__CAIV__no_interaction	Tolvaptan__insulin__no_interaction	Budesonide__CAIV__no_interaction	Budesonide__insulin__no_interaction	Levocetirizine dihydrochloride__CAIV__no_interaction	Levocetirizine dihydrochloride__insulin__no_interaction	Plitidepsin__CAIV__no_interaction	Plitidepsin__insulin__no_interaction	Fosamprenavir__CAIV__no_interaction	Fosamprenavir__insulin__no_interaction	Loratadine__CAIV__no_interaction	Loratadine__insulin__no_interaction	Atomoxetine__CAIV__no_interaction	Atomoxetine__insulin__no_interaction	Desloratadine__CAIV__no_interaction	Desloratadine__insulin__no_interaction	Rivaroxaban__CAIV__no_interaction	Rivaroxaban__insulin__no_interaction	Lopinavir__CAIV__no_interaction	Lopinavir__insulin__no_interaction	isosorbide dinitrate__CAIV__no_interaction	isosorbide dinitrate__insulin__no_interaction	Raltegravir potassium__CAIV__no_interaction	Raltegravir potassium__insulin__no_interaction	Tosedostat__CAIV__no_interaction	Tosedostat__insulin__no_interaction	Olmesartan medoxomil__CAIV__no_interaction	Olmesartan medoxomil__insulin__no_interaction	Carisbamate__CAIV__no_interaction	Carisbamate__insulin__no_interaction	Bosentan__CAIV__no_interaction	Bosentan__insulin__no_interaction	Alanosine__CAIV__no_interaction	Alanosine__insulin__no_interaction	Casopitant mesylate__CAIV__no_interaction	Casopitant mesylate__insulin__no_interaction	Tadalafil__CAIV__no_interaction	Tadalafil__insulin__no_interaction	Fulvestrant__CAIV__no_interaction	Fulvestrant__insulin__no_interaction	amikacin__CAIV__no_interaction	amikacin__insulin__no_interaction	Tiotropium__CAIV__no_interaction	Tiotropium__insulin__no_interaction	Ramelteon__CAIV__no_interaction	Ramelteon__insulin__no_interaction	montelukast sodium__CAIV__no_interaction	montelukast sodium__insulin__no_interaction	Pregabalin__CAIV__no_interaction	Pregabalin__insulin__no_interaction	Eszopiclone__CAIV__no_interaction	Eszopiclone__insulin__no_interaction	Azacitidine__CAIV__no_interaction	Azacitidine__insulin__no_interaction	Emtricitabine__CAIV__no_interaction	Emtricitabine__insulin__no_interaction	Lapatinib ditosylate__CAIV__no_interaction	Lapatinib ditosylate__insulin__no_interaction	Atazanavir sulfate__CAIV__no_interaction	Atazanavir sulfate__insulin__no_interaction	Ixabepilone__CAIV__no_interaction	Ixabepilone__insulin__no_interaction	Tesofensine__CAIV__no_interaction	Tesofensine__insulin__no_interaction	Mepolizumab__CAIV__no_interaction	Mepolizumab__insulin__no_interaction	Treprostinil sodium__CAIV__no_interaction	Treprostinil sodium__insulin__no_interaction	Darunavir__CAIV__no_interaction	Darunavir__insulin__no_interaction	Ziconotide__CAIV__no_interaction	Ziconotide__insulin__no_interaction	PF-489791__CAIV__no_interaction	PF-489791__insulin__no_interaction	Voriconazole__CAIV__no_interaction	Voriconazole__insulin__no_interaction	Sorafenib__CAIV__no_interaction	Sorafenib__insulin__no_interaction	Micafungin sodium__CAIV__no_interaction	Micafungin sodium__insulin__no_interaction	dexamethasone__CAIV__no_interaction	dexamethasone__insulin__no_interaction	Escitalopram oxalate__CAIV__no_interaction	Escitalopram oxalate__insulin__no_interaction	Nabiximols__CAIV__no_interaction	Nabiximols__insulin__no_interaction	H2__CAIV__no_interaction	H2__insulin__no_interaction	Deferasirox__CAIV__no_interaction	Deferasirox__insulin__no_interaction	Sotrastaurin__CAIV__no_interaction	Sotrastaurin__insulin__no_interaction	Aripiprazole__CAIV__no_interaction	Aripiprazole__insulin__no_interaction	Imexon__CAIV__no_interaction	Imexon__insulin__no_interaction	TMC-207__CAIV__no_interaction	TMC-207__insulin__no_interaction	Formoterol fumarate__CAIV__no_interaction	Formoterol fumarate__insulin__no_interaction	bromide__CAIV__no_interaction	bromide__insulin__no_interaction	Perifosine__CAIV__no_interaction	Perifosine__insulin__no_interaction	Tanespimycin__CAIV__no_interaction	Tanespimycin__insulin__no_interaction	human relaxin__CAIV__no_interaction	human relaxin__insulin__no_interaction	Imatinib mesylate__CAIV__no_interaction	Imatinib mesylate__insulin__no_interaction	Posaconazole__CAIV__no_interaction	Posaconazole__insulin__no_interaction	Lenalidomide__CAIV__no_interaction	Lenalidomide__insulin__no_interaction	Ambrisentan__CAIV__no_interaction	Ambrisentan__insulin__no_interaction	Dutasteride__CAIV__no_interaction	Dutasteride__insulin__no_interaction	formoterol fumarate__CAIV__no_interaction	formoterol fumarate__insulin__no_interaction	Rosuvastatin calcium__CAIV__no_interaction	Rosuvastatin calcium__insulin__no_interaction	Ziprasidone hydrochloride__CAIV__no_interaction	Ziprasidone hydrochloride__insulin__no_interaction	Duloxetine__CAIV__no_interaction	Duloxetine__insulin__no_interaction	Vicriviroc__CAIV__no_interaction	Vicriviroc__insulin__no_interaction	Varespladib methyl__CAIV__no_interaction	Varespladib methyl__insulin__no_interaction	calcium__CAIV__no_interaction	calcium__insulin__no_interaction	Saxagliptin__CAIV__no_interaction	Saxagliptin__insulin__no_interaction	Ustekinumab__CAIV__no_interaction	Ustekinumab__insulin__no_interaction	Disitertide__CAIV__no_interaction	Disitertide__insulin__no_interaction	Gabapentin enacarbil__CAIV__no_interaction	Gabapentin enacarbil__insulin__no_interaction	metformin hydrochloride__CAIV__no_interaction	metformin hydrochloride__insulin__no_interaction	Sirolimus__CAIV__no_interaction	Sirolimus__insulin__no_interaction	Tirapazamine__CAIV__no_interaction	Tirapazamine__insulin__no_interaction	Tipifarnib__CAIV__no_interaction	Tipifarnib__insulin__no_interaction	SCH-530348__CAIV__no_interaction	SCH-530348__insulin__no_interaction	Eribulin mesilate__CAIV__no_interaction	Eribulin mesilate__insulin__no_interaction	Lisdexamfetamine mesilate__CAIV__no_interaction	Lisdexamfetamine mesilate__insulin__no_interaction	Azelnidipine__CAIV__no_interaction	Azelnidipine__insulin__no_interaction	lamivudine__CAIV__no_interaction	lamivudine__insulin__no_interaction	Dalcetrapib__CAIV__no_interaction	Dalcetrapib__insulin__no_interaction	Inhalable__CAIV__no_interaction	Inhalable__insulin__no_interaction	Fluticasone furoate__CAIV__no_interaction	Fluticasone furoate__insulin__no_interaction	Rasagiline mesilate__CAIV__no_interaction	Rasagiline mesilate__insulin__no_interaction	glargine__CAIV__no_interaction	glargine__insulin__no_interaction	Paclitaxel__CAIV__no_interaction	Paclitaxel__insulin__no_interaction	Nikkomycin Z__CAIV__no_interaction	Nikkomycin Z__insulin__no_interaction	Hydralazine hydrochloride__CAIV__no_interaction	Hydralazine hydrochloride__insulin__no_interaction	Bortezomib__CAIV__no_interaction	Bortezomib__insulin__no_interaction	Vildagliptin__CAIV__no_interaction	Vildagliptin__insulin__no_interaction	Tapentadol hydrochloride__CAIV__no_interaction	Tapentadol hydrochloride__insulin__no_interaction	Abacavir sulfate__CAIV__no_interaction	Abacavir sulfate__insulin__no_interaction	Exenatide__CAIV__no_interaction	Exenatide__insulin__no_interaction	Fampridine__CAIV__no_interaction	Fampridine__insulin__no_interaction	fluticasone propionate__CAIV__no_interaction	fluticasone propionate__insulin__no_interaction
10512362-6	Furthermore, <protein-id="O35659">GLP-1R</protein-id>(-/-) islets exhibited: 1) reduced cAMP accumulation in the presence of 20 mmol/<compound-id="53782688">l glucose</compound-id> (knockout islets versus control islets, 12 +/- 1 vs. 27 +/- 3 fmol x islet(-1) x 15 min(-1); P &lt; 0.001) and exaggerated acceleration of cAMP production by 10 nmol/l <protein-id="P48756">glucose-dependent insulinotropic peptide</protein-id> (<protein-id="P48756">GIP</protein-id>) (increase over 20 mmol/<compound-id="53782688">l glucose</compound-id> by <protein-id="P48756">GIP</protein-id> in knockout islets versus control islets: 66 +/- 5 vs. 14 +/- 3 fmol x islet(-1) x 15 min(-1); P &lt; 0.001); 2) increased mean cytosolic [Ca2+] ([Ca2+]c) at 7, 10, and 15 mmol/<compound-id="53782688">l glucose</compound-id> in knockout islets versus control islets; and 3) signs of asynchrony of [Ca2+]c oscillations between different islet subregions.	l glucose__GIP__no_interaction	l glucose__GLP-1R__no_interaction	l glucose__glucose-dependent insulinotropic peptide__no_interaction
19345526-8	It is now possible to identify factors clearly favoring the formation of VC: <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (which stimulates cell necrosis/apoptosis), <protein-id="P02741">CRP</protein-id>, oxidized lipids, AGEs, <protein-id="P41159,A4D0Y8">leptin</protein-id>, inorganic <compound-id="1061,167704,644102">phosphate</compound-id>, high <compound-id="22044544,5460341">calcium</compound-id>-phosphorus product (CaxPO(4)), <compound-id="22044544,5460341">calcium</compound-id>, 1,25-OH(2)D(3) and <compound-id="5280795,5283711">Vitamin D</compound-id>(3), <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> (via an intracrine pathway), cyclic AMP, TGF-beta, <protein-id="P12643,C8C060">bone morphogenic protein 2</protein-id> (<protein-id="P12643,C8C060">BMP2</protein-id>) and factors protective against the formation of VC: <compound-id="5462224">magnesium</compound-id>, HDL, inorganic pyrophosphate, <protein-id="P02768">albumin</protein-id>, ahsg/fetuin A, <protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">osteopontin</protein-id> (OPN), <protein-id="O00300">osteoprotegerin</protein-id> (<protein-id="O00300">OPG</protein-id>), <protein-id="P09486">osteonectin</protein-id> (ON), <protein-id="P18075,A8K571">bone morphogenic protein 7</protein-id> (<protein-id="P18075,A8K571">BMP7</protein-id>), klotho, <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> (via a paracrine pathway), <protein-id="P08493,A0A024RAX0">matrix gla protein</protein-id> (<protein-id="P08493,A0A024RAX0">MGP</protein-id>), <protein-id="P01270">PTH</protein-id> (via <protein-id="P35548">Msx2</protein-id>) and <compound-id="5284607">vitamin K</compound-id>. In conclusion, until recently, neglected disorders of <compound-id="22044544,5460341">calcium</compound-id>-phosphorus metabolism are currently recognized as the main actors in the process leading to vascular mediacalcosis in patients with chronic kidney failure.	vitamin K__BMP7__no_interaction	vitamin K__bone morphogenic protein 2__no_interaction	vitamin K__BMP2__no_interaction	vitamin K__CRP__no_interaction	vitamin K__bone morphogenic protein 7__no_interaction	vitamin K__osteopontin__no_interaction	vitamin K__PTH__no_interaction	vitamin K__leptin__no_interaction	vitamin K__osteoprotegerin__no_interaction	vitamin K__PTHrP__no_interaction	vitamin K__OPG__no_interaction	vitamin K__matrix gla protein__no_interaction	vitamin K__osteonectin__no_interaction	vitamin K__MGP__no_interaction	vitamin K__TNF-alpha__no_interaction	vitamin K__albumin__no_interaction	vitamin K__Msx2__no_interaction	calcium__BMP7__no_interaction	calcium__bone morphogenic protein 2__no_interaction	calcium__BMP2__no_interaction	calcium__CRP__no_interaction	calcium__bone morphogenic protein 7__no_interaction	calcium__osteopontin__no_interaction	calcium__PTH__no_interaction	calcium__leptin__no_interaction	calcium__osteoprotegerin__no_interaction	calcium__PTHrP__no_interaction	calcium__OPG__no_interaction	calcium__matrix gla protein__no_interaction	calcium__osteonectin__no_interaction	calcium__MGP__no_interaction	calcium__TNF-alpha__no_interaction	calcium__albumin__no_interaction	calcium__Msx2__no_interaction	phosphate__BMP7__no_interaction	phosphate__bone morphogenic protein 2__no_interaction	phosphate__BMP2__no_interaction	phosphate__CRP__no_interaction	phosphate__bone morphogenic protein 7__no_interaction	phosphate__osteopontin__no_interaction	phosphate__PTH__no_interaction	phosphate__leptin__no_interaction	phosphate__osteoprotegerin__no_interaction	phosphate__PTHrP__no_interaction	phosphate__OPG__no_interaction	phosphate__matrix gla protein__no_interaction	phosphate__osteonectin__no_interaction	phosphate__MGP__no_interaction	phosphate__TNF-alpha__no_interaction	phosphate__albumin__no_interaction	phosphate__Msx2__no_interaction	magnesium__BMP7__no_interaction	magnesium__bone morphogenic protein 2__no_interaction	magnesium__BMP2__no_interaction	magnesium__CRP__no_interaction	magnesium__bone morphogenic protein 7__no_interaction	magnesium__osteopontin__no_interaction	magnesium__PTH__no_interaction	magnesium__leptin__no_interaction	magnesium__osteoprotegerin__no_interaction	magnesium__PTHrP__no_interaction	magnesium__OPG__no_interaction	magnesium__matrix gla protein__no_interaction	magnesium__osteonectin__no_interaction	magnesium__MGP__no_interaction	magnesium__TNF-alpha__no_interaction	magnesium__albumin__no_interaction	magnesium__Msx2__no_interaction	Vitamin D__BMP7__no_interaction	Vitamin D__bone morphogenic protein 2__no_interaction	Vitamin D__BMP2__no_interaction	Vitamin D__CRP__no_interaction	Vitamin D__bone morphogenic protein 7__no_interaction	Vitamin D__osteopontin__no_interaction	Vitamin D__PTH__no_interaction	Vitamin D__leptin__no_interaction	Vitamin D__osteoprotegerin__no_interaction	Vitamin D__PTHrP__no_interaction	Vitamin D__OPG__no_interaction	Vitamin D__matrix gla protein__no_interaction	Vitamin D__osteonectin__no_interaction	Vitamin D__MGP__no_interaction	Vitamin D__TNF-alpha__no_interaction	Vitamin D__albumin__no_interaction	Vitamin D__Msx2__no_interaction
11312752-1	The metathetical reactions of the <compound-id="3028194">lithium</compound-id> derivative of the monoanion [((t)BuN)(S)P(mu-N(t)Bu)(2)P(S)(NH(t)Bu)](-) (L) with <compound-id="62652">CuCl</compound-id>/PPh(3), NiCl(2)(PEt(3))(2), <protein-id="Q13371">PdCl</protein-id>(2)L'(2) (L' = PhCN, PPh(3)), and PtCl(2)(PEt(3))(2) produced the complexes (PPh(3))CuL (5), NiL(2) (6), <protein-id="Q13371">PdCl</protein-id>(L)(PPh(3)) (7), PdL(2) (8), and Pt(PEt(3))(2)[((t)BuN)(S)P(mu-N(t)Bu)(2)P(S)(N(t)Bu)] (9).	lithium__PdCl__no_interaction	CuCl__PdCl__no_interaction
21520919-3	A fourth complex, [NEt(4)][(Tp*)Mn(II)(η(2)-acac(3-CN))(η(1)-NC-acac)] (4), is obtained via treatment of Mn(acac(3-CN))(3) with <compound-id="446833">KTp</compound-id>* and [<protein-id="P62079">NEt(4)]CN, while</protein-id> [NEt(4)](2)[Mn(II)(CN)(4)] (5) was prepared from <compound-id="23930">manganese</compound-id>(II) <compound-id="62406">trifluoromethanesulfonate</compound-id> and excess [NEt(4)]CN.	trifluoromethanesulfonate__NEt(4)]CN, while__no_interaction	KTp__NEt(4)]CN, while__no_interaction	manganese__NEt(4)]CN, while__no_interaction
19760959-8	The serum prohepdicin levels were not significantly correlated with the ages (r = -0.041, p = 0.760), hemoglobin (r = 0.127, p = 0.346), <compound-id="5950,602">alanine</compound-id> aminotransferase (r = -0.032, p = 0.813), <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (r = 0.025, p = 0.862), ferritin levels (r = 0.211, p = 0.133) and hepatic inflammation grades (r = 0.153, p = 0.352) in CHC patients.	alanine__transferrin__no_interaction
19218528-2	This study focuses on the <compound-id="11527495">ibodutant</compound-id> pharmacodynamic profile at the human <protein-id="P21452">NK(2)R</protein-id> and compares it with two other antagonists, <compound-id="3086682">nepadutant</compound-id> (<compound-id="5311275">MEN11420</compound-id>, (cyclo-[[Asn(beta-<compound-id="1738118">D-GlcNAc</compound-id>)-<compound-id="7020001">Asp-Trp</compound-id>-Phe-Dpr-Leu]cyclo(2beta-5beta)]) and saredutant [<compound-id="104974">SR48968</compound-id>, (S)-N-methyl-N[4-(4-acetylamino-<compound-id="69873">4-phenylpiperidino</compound-id>)-2-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="68006705">butyl</compound-id>]<compound-id="2331">benzamide</compound-id>].	dichlorophenyl__NK(2)R__no_interaction	nepadutant__NK(2)R__no_interaction	SR48968__NK(2)R__no_interaction	4-phenylpiperidino__NK(2)R__no_interaction	ibodutant__NK(2)R__no_interaction	butyl__NK(2)R__no_interaction	Asp-Trp__NK(2)R__no_interaction	D-GlcNAc__NK(2)R__no_interaction	benzamide__NK(2)R__no_interaction	MEN11420__NK(2)R__no_interaction
8324419-8	<compound-id="2720">Thiazide</compound-id> users had lower serum levels of <protein-id="P01270">PTH</protein-id> (26.2 +/- 7.6 (SD) ng/l vs. 31.0 +/- 11.7 ng/l, P = 0.009) and <compound-id="5280453">1,25-dihydroxyvitamin D</compound-id> (60.8 +/- 16.2 pmol/l vs. 77.0 +/- 18.7 pmol/l, P &lt; 0.001) in the winter/spring and, in the subset measured, reduced levels of osteocalcin year round (summer/fall: 2.89 +/- 0.82 micrograms/l, n = 10, vs. 3.65 +/- 1.02, n = 82, P = 0.019; winter/spring: 2.54 +/- 0.80 micrograms/l vs. 3.47 +/- 1.07 micrograms/l, P = 0.005).	Thiazide__PTH__no_interaction	1,25-dihydroxyvitamin D__PTH__no_interaction
3688234-3	The maintenance period of chronic CDA, compared with control, was characterized by hypokalemic metabolic alkalosis (serum <compound-id="6857437">TCO2</compound-id> 31.9 +/- 0.6 vs. 23.1 +/- 0.5 meq/l, P less than 0.05), volume contraction (plasma volume 3.76 +/- 0.08 vs. 4.19 +/- 0.22 ml/100 g body wt, P less than 0.05), decreased GFR (838 +/- 84 vs. 1045 +/- 45 microliters.min-1.100 g body <protein-id="P49952,D3ZJ55">wt-1</protein-id>, P less than 0.05), increased plasma renin activity (PRA) (63 +/- 13 vs. 12 +/- 3 ng.ml-1.h-1, P less than 0.05), but unchanged plasma <compound-id="5839">aldosterone</compound-id> concentrations (PAC) (4.1 +/- 1.0 vs. 3.4 +/- 1.6 ng/dl, P = NS).	TCO2__wt-1__no_interaction	aldosterone__wt-1__no_interaction
2857145-4	Inclusion of <protein-id="P60042">somatostatin</protein-id> in the culture medium (1 X 10(-8) to 1 X 10(-4) M) resulted in significant inhibition of gastrin release at <protein-id="P60042">somatostatin</protein-id> concentrations of 1 X 10(-5) and 1 X 10(-4) M: both doses of <protein-id="P60042">somatostatin</protein-id> inhibited gastrin release by approximately 52% at 30 min and by 32% at 6 h. Gastrin release stimulated by dibutyryl cyclic <compound-id="6083">adenosine monophosphate</compound-id> was significantly inhibited by 1 X 10(-5) and 1 X 10(-4) M <protein-id="P60042">somatostatin</protein-id> to 133% and 121% at 30 min and 77% and 98% at 6 h, respectively.	adenosine monophosphate__somatostatin__no_interaction
19618904-1	One-dimensional (1D) coordination polymers of formula [Fe(NH(2)trz)(3)]A.nH(2)O, {A = <compound-id="27873">TiF</compound-id>(6)(2-), n = 0.5 (1) and n = 1 (2); A = ZrF(6)(2-), n = 0.5 (3) and n = 0 (4); A = SnF(6)(2-), n = 0.5 (5) and n = 1 (6); A = TaF(7)(2-), n = 3 (7) and n = 2.5 (8); A = <protein-id="Q92974,D3DVA5">GeF</protein-id>(6)(2-), n = 1 (9) and n = 0.5 (10), NH(2)trz = <compound-id="11432">4-amino-1,2,4-triazole</compound-id>} have been synthesized, fully characterized, and their <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover behavior carefully studied by SQUID magnetometry, Mossbauer spectroscopy, and differential scanning calorimetry.	TiF__spin__no_interaction	TiF__GeF__no_interaction	4-amino-1,2,4-triazole__spin__no_interaction	4-amino-1,2,4-triazole__GeF__no_interaction
17844660-1	The study of the reaction between the <compound-id="53675528,6325">ethylene</compound-id> [Pt(eta-H2C = CH2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] or alkyne [Pt(eta2-HC [triple bond] CR)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] (R = SiMe3 1, Bu(t) 2) complexes with [cis-Pt(C6F5)2(thf)2] (thf = tetrahydrofuran) has enabled us to observe the existence of competitive processes between the activation of a P-C(Ph) bond on the <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> ligand, to give the binuclear derivative [cis-(C6F5)2Pt(mu-Ph)(mu-PPh2)Pt(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)] 3, and the activation of a C-H bond of the unsaturated group, to give the corresponding (mu-<compound-id="166653">hydride</compound-id>)(mu-vinyl) [cis, cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-CH = CH2)Pt(C6F5)2] 4 or (mu-<compound-id="166653">hydride</compound-id>)(mu-alkynyl) [cis,cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-C [triple bond]CR)Pt(C6F5)2] (R = SiMe3 5, Bu(t) 6) compounds, respectively.	ethylene__PPh3__no_interaction	hydride__PPh3__no_interaction
24065527-5	We found that the urinary <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> level was positively correlated with hypertension (ρ = 0.28, P &lt; 0.01), urinary protein (r = 0.38, P &lt; 0.01), urinary <protein-id="O15123">Ang II</protein-id> (r = 0.29, P &lt; 0.05), urinary type IV collagen (Col IV) (r = 0.56, P &lt; 0.01), and was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.28, P &lt; 0.01), urinary <compound-id="5360545">sodium</compound-id> (r = -0.22, P &lt; 0.05) and serum <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> (r = -0.27, P &lt; 0.01).	sodium__AGT__no_interaction	sodium__Ang II__no_interaction
11839533-3	" This hypothesized mechanism is supported by the following experimental data: 1) <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulates the de novo synthesis of surfactant phospholipid by both fetal rat type II cells (400% x 100 ng(-1) x ml(-1) x 24 h(-1)) and adult human airway epithelial cells (85% x 100 ng(-1) x 24 h(-1)); 2) <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> is secreted by lipofibroblasts in amounts that stimulate type II cell surfactant phospholipid synthesis in vitro; 3) epithelial cell secretions such as <protein-id="P12272,Q53XY9,A0A024RB29">parathyroid hormone-related protein</protein-id> (<protein-id="P13085">PTHrP</protein-id>), PGE(2), and <compound-id="5743">dexamethasone</compound-id> stimulate <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> expression by fetal rat lung fibroblasts; 4) <protein-id="P13085">PTHrP</protein-id> or <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulate the de novo synthesis of surfactant phospholipid (2- to 2.5-fold/24 h) and the expression of <protein-id="P22355">surfactant protein B</protein-id> (<protein-id="P22355">SP-B</protein-id>; &gt;25-fold/24 h) by fetal rat lung explants, an effect that is blocked by a <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> antibody; and 5) a <protein-id="P13085">PTHrP</protein-id> receptor antagonist inhibits the expression of <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> mRNA by explants but does not inhibit <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> stimulation of surfactant phospholipid or <protein-id="P22355">SP-B</protein-id> expression, indicating that <protein-id="P13085">PTHrP</protein-id> paracrine stimulation of type II cell maturation requires <protein-id="P50596,P41159,A4D0Y8">Leptin</protein-id> expression by lipofibroblasts.	dexamethasone__SP-B__no_interaction	dexamethasone__Leptin__no_interaction	dexamethasone__surfactant protein B__no_interaction	dexamethasone__parathyroid hormone-related protein__no_interaction	dexamethasone__PTHrP__no_interaction
8606641-6	In NS, <compound-id="444913">ACX</compound-id> failed to significantly potentiate the GH response to either <protein-id="P01286">GHRH</protein-id> (1,371.9 +/- 425.2 v 1,001.8 +/- 229.0 micrograms/L x min) or <protein-id="P01286">GHRH</protein-id>+ARG (3558.4 +/- 1,513.7 v 3,045.9 +/- 441.8 micrograms/L x min), while in OB patients it increased the GH response to <protein-id="P01286">GHRH</protein-id> (797.6 +/- 277.3 v 353.8 +/- 136.7 micrograms/L x min, P&lt;.01) and did not modify the response to ARG+<protein-id="P01286">GHRH</protein-id> (1,010.5 +/- 253.1 v 821.1 +/- 222.0 micrograms/L x min).	ACX__GHRH__no_interaction
15651855-1	The reaction of (<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))<compound-id="5460531">AuCl</compound-id> with the low valent <compound-id="5360835">gallium</compound-id> compound Ga(<protein-id="O60220">DDP</protein-id>) (<protein-id="O60220">DDP</protein-id> = 2-((2,6-<compound-id="11345">diisopropylphenyl</compound-id>)amino-4-((2,6-diiso-<compound-id="7668">propylphenyl</compound-id>)imino)-<compound-id="5326160,5326161">2-pentene</compound-id>) yields the insertion products [{Ga(<protein-id="O60220">DDP</protein-id>)}Au{Ga(<protein-id="O60220">DDP</protein-id>)Cl}] (1) and [(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))Au{Ga(<protein-id="O60220">DDP</protein-id>)Cl}] (2), the first examples of molecular compounds with Au-Ga bonds.	propylphenyl__DDP__no_interaction	propylphenyl__PPh(3__no_interaction	AuCl__DDP__no_interaction	AuCl__PPh(3__no_interaction	gallium__DDP__no_interaction	gallium__PPh(3__no_interaction	diisopropylphenyl__DDP__no_interaction	diisopropylphenyl__PPh(3__no_interaction	2-pentene__DDP__no_interaction	2-pentene__PPh(3__no_interaction
10193650-3	Furthermore, the anxiolytic-like effect was antagonized by co-administration of the potent <protein-id="P07808,F2W8A6">neuropeptide Y</protein-id> Y1 receptor antagonist ((R)-N-[[4-(<compound-id="90777035">aminocarbonylaminomethyl</compound-id>)-phenyl]methyl]-N2-(diphen ylacetyl)-<compound-id="2234">argininamide</compound-id> <compound-id="6422">trifluoroacetate</compound-id>) 3304, but not with the inactive enantiomer ((R)-N-[[4-(<compound-id="90777035">aminocarbonylaminomethyl</compound-id>)-phenyl]methyl]-N2-(diphen ylacetyl)-<compound-id="2234">argininamide</compound-id> <compound-id="6422">trifluoroacetate</compound-id>) 3457.	aminocarbonylaminomethyl__neuropeptide Y__no_interaction	argininamide__neuropeptide Y__no_interaction	trifluoroacetate__neuropeptide Y__no_interaction
24513870-2	Here we describe the activity of a novel, inhaled, bifunctional, small molecule (R)-6-[(3-{[4-(5-{[<compound-id="97257">2-hydroxy-</compound-id>2-(8-hydroxy-2-oxo-1,2-<compound-id="5231402">dihydroquinolin</compound-id>-5-yl)<compound-id="23134249">ethyl</compound-id>]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-<compound-id="11910">8-methylquinoline</compound-id>-3-<compound-id="11960529">carboxamide</compound-id> (GS-5759), which has specific β(2) agonist and <protein-id="P27815">PDE4</protein-id> inhibitory activity.	2-hydroxy-__PDE4__no_interaction	carboxamide__PDE4__no_interaction	ethyl__PDE4__no_interaction	8-methylquinoline__PDE4__no_interaction	dihydroquinolin__PDE4__no_interaction
19192257-6	Other comparisons (mean +/- SD) between cryoprecipitate and FFP, respectively, were as follows: coagulation <protein-id="P00451">FVIII</protein-id> activity, 133 +/- 37 and 265 +/- 83 U per bag; <protein-id="P02675,V9HVY1">fibrinogen</protein-id> content (Clauss kinetic assay), 183 +/- 44 and 725 +/- 199 mg per bag; <protein-id="P04275">VWF</protein-id> antigen content, 181 +/- 53 and 218 +/- 70 U per bag; <protein-id="P04275">VWF</protein-id> ristocetin <compound-id="108194">cofactor</compound-id> activity, 168 +/- 34 and 221 +/- 65 U per bag; <protein-id="P04275">VWF</protein-id> collagen-binding activity, 164 +/- 40 and 208 +/- 71 U per bag; and fluid (plasma) volumes per bag, 21.3 +/- 2.7 and 245 +/- 29 mL.	cofactor__VWF__no_interaction	cofactor__fibrinogen__no_interaction	cofactor__FVIII__no_interaction
10912908-4	In the in vitro biological assays a remarkable agonist activity to the opiate receptor mu in guinea pig ileum (GPI) relative to Leu-<protein-id="P22005">ENK</protein-id> was shown by the following: Leu-<protein-id="P22005">ENK</protein-id>, 100; [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (I), 8.1; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (VI), 26.2; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (VII), 2.9; [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (VIII), 4.7; and [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (X), 5.6.	CH2OH__ENK__no_interaction	NOH__ENK__no_interaction	Tyr__ENK__no_interaction
10912908-8	The analogues: [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (I), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2H)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (II), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2Me)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (III), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CO2H)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (IV), [<compound-id="6057">Tyr</compound-id>(Me)(3'-CONH2)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (V), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (VI), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (VII), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=<compound-id="159652">NOH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (VIII), [<compound-id="6057">Tyr</compound-id>(Me)(3'-(E)-CH=NOMe)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (IX), [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OMe5]-<protein-id="P22005">ENK</protein-id> (X), [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-OH5]-<protein-id="P22005">ENK</protein-id> (XI) and [<compound-id="6057">Tyr</compound-id>(Me)(3'-<compound-id="137654">CH2OH</compound-id>)1, Leu-NH2(5)]-<protein-id="P22005">ENK</protein-id> (XII) under testing had no significant agonist activity to the enkephalinergic receptor in mouse <compound-id="6323535">vas</compound-id> deferens (MVD).	CH2OH__ENK__no_interaction	NOH__ENK__no_interaction	Tyr__ENK__no_interaction	vas__ENK__no_interaction
11555526-15	The mean (+/- SD) variables that were significantly different between desaturators (10 patients) and nondesaturators (3 patients) were FEV(1) (70.1 +/- 9.1% predicted vs 98.1 +/- 15.1% predicted, respectively; p = 0.002), resting PaO(2) (61.8 +/- 16.1 vs 90.3 +/- 2.3 mm Hg, respectively; p = 0.001), alveolar-arterial <compound-id="977">oxygen</compound-id> pressure difference (P[A-a]O(2)) (40.5 +/- 20.5 vs 12.2 +/- 7.2 mm Hg, respectively; p = 0.048), resting <protein-id="P22079">SpO</protein-id>(2) (91.6 +/- 5.4% vs 98.7 +/- 2.3%, respectively; p = 0.038), and walking <protein-id="P22079">SpO</protein-id>(2) (83.8 +/- 9.3% vs 95.3 +/- 1.2%, respectively; p = 0.002).	oxygen__SpO__no_interaction
16676966-2	Treatment of 1a with <compound-id="82050">LiBr</compound-id>/1,4-<compound-id="9261">pyrazine</compound-id> (1,4-pyz), pyridine (py), <compound-id="433294">LiCl</compound-id>/py, or <compound-id="11107">4,4'-bipyridine</compound-id> (4,4'-<compound-id="1474">bipy</compound-id>) and treatment of 1b with 4,4'-<compound-id="1474">bipy</compound-id> gave rise to a new set of W/Cu/S cluster-based compounds, [Li[((eta5-C5Me5)WS3Cu3(mu3-Br))2(mu-CN)3].C6H6]infinity (2), [(eta5-C5Me5)WS3Cu3(mu-CN)2(py)]infinity (3), [[<protein-id="O14649">PPh4</protein-id>][(eta5-C5Me5)WS3Cu3(mu3-Cl)(mu-CN)(CN)].py]infinity (4), [<protein-id="O14649">PPh4</protein-id>]2[(eta5-C5Me5)WS3Cu3(CN)2]2(mu-CN)2.	4,4'-bipyridine__PPh4__no_interaction	LiBr__PPh4__no_interaction	bipy__PPh4__no_interaction	LiCl__PPh4__no_interaction	pyrazine__PPh4__no_interaction
24900171-2	We report here the discovery of the first potent and selective inhibitor of <protein-id="Q02224">Centromere-Associated Protein E</protein-id> (<protein-id="Q02224">CENP-E</protein-id>) <compound-id="97584">3-chloro-</compound-id>N-{(1S)-2-[(N,N-<compound-id="10197622">dimethylglycyl</compound-id>)amino]-1-[(4-{<compound-id="91272666">8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl</compound-id>}phenyl)methyl]<compound-id="23134249">ethyl</compound-id>}-4-[(1-<compound-id="275736">methylethyl</compound-id>)oxy]<compound-id="2331">benzamide</compound-id> (<compound-id="46898058">GSK923295</compound-id>; 1), starting from a high-throughput screening hit, <compound-id="22597728">3-chloro-4-isopropoxybenzoic acid</compound-id> 2.	GSK923295__CENP-E__no_interaction	GSK923295__Centromere-Associated Protein E__no_interaction	dimethylglycyl__CENP-E__no_interaction	dimethylglycyl__Centromere-Associated Protein E__no_interaction	methylethyl__CENP-E__no_interaction	methylethyl__Centromere-Associated Protein E__no_interaction	8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl__CENP-E__no_interaction	8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl__Centromere-Associated Protein E__no_interaction	3-chloro-__CENP-E__no_interaction	3-chloro-__Centromere-Associated Protein E__no_interaction	benzamide__CENP-E__no_interaction	benzamide__Centromere-Associated Protein E__no_interaction	3-chloro-4-isopropoxybenzoic acid__CENP-E__no_interaction	3-chloro-4-isopropoxybenzoic acid__Centromere-Associated Protein E__no_interaction	ethyl__CENP-E__no_interaction	ethyl__Centromere-Associated Protein E__no_interaction
11867949-12	In rHuEPO-treated CAPD subjects <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and <protein-id="P08833">IGFBP-1</protein-id> correlated positively with serum CrossLaps (r = 0.61, p &lt; 0.05 and r = 0.64, p &lt; 0.05, respectively), whereas in hemodialyzed patients without rHuEPO a significant negative correlation between <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> and serum CrossLaps was found (r = --0.69, p &lt; 0.001) as well as between <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> and <compound-id="5359268">aluminium</compound-id> (r = 0.51, p &lt; 0.05), <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> and ICTP (r = --0.43, p &lt; 0.05).	aluminium__IGFBP-3__no_interaction	aluminium__IGF-1__no_interaction	aluminium__IGFBP-1__no_interaction
14689705-9	The stepwise regression analysis discovered correlation between plasmic ASUP and end-diastolic volume of the left ventricle (r = 0.62; p = 0.01), dopplerographic index (r = 0.52; p = 0.001), left ventricular ejection fraction (r = -0.66; p = 0.002), velocity of early diastolic filling (r = -0.84; p = 0.001), plasmic pool of norepinephrine (r = 0.66; p = 0.001), endotheline-1 (r = 0.70; p = 0.03) and <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin-II</protein-id> (r = 0.55; p = 0.02), daily dose of <compound-id="3440">furosemide</compound-id> (r = 0.80; p = 0.001), heart rate (r = 0.64; p = 0.02).	furosemide__angiotensin-II__no_interaction
9181456-3	The main observations were as follows: (a) The mean encapsulation efficiency, as determined by bioassays, was 49-79%, depending on the formulation, for <protein-id="P01587,Q5SX78">GM-CSF</protein-id>, and 48% for <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>; (b) some of the entrapped cytokine preparations displayed high stability at 4 degrees C, with &lt; 30% loss of biologic activity during a 4-month period; (c) release of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>, but not of <protein-id="P01587,Q5SX78">GM-CSF</protein-id>, from the liposomes was required for their biological activity in vitro; (d) plasma half-lives (t1/2 alpha, t1/2 beta) and the area under the curve (AUC) of the entrapped cytokines were 10-20 times greater than those of the soluble cytokines; (e) the toxicity of liposomal <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> was one-third and one-seventh that of soluble <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> in normal and tumor-bearing mice, respectively; (f) administration of liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> (5 x 10(4)-2 x 10(5) U, one to five times) to normal and <compound-id="3385">5-fluorouracil</compound-id>-treated mice led to a two- to fourfold increase in the absolute number of peritoneal and spleen leukocytes and of GM colony-forming cells in the spleen, as compared with the levels obtained using soluble <protein-id="P01587,Q5SX78">GM-CSF</protein-id>; and (g) under the experimental conditions used, neither free nor liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> significantly increased the absolute number of blood leukocytes, although liposomal <protein-id="P01587,Q5SX78">GM-CSF</protein-id> markedly (threefold) enhanced the level of blood granulocytes.	5-fluorouracil__TNF-alpha__no_interaction	5-fluorouracil__GM-CSF__no_interaction
14632755-4	Regardless of the total lymphocyte count the <compound-id="67184">NBS</compound-id> patients showed: (1) profound deficiency of CD4+ and CD3/CD8+ T cell subsets and up to fourfold increase in natural killer (NK) cells, almost lack of naive CD4+ T cells expressing CD45RA isoform, unchanged percentage of naive CD8+ cell subset (CD8/CD45RA+) but bearing the CD8 receptor of low density (CD8low); (2) normal expression of CD45RA isoform in the <protein-id="P13591,A0A087WWD4">CD56</protein-id>+ lymphocyte subset, profound decrease in alpha beta but up to threefold increase in gamma delta-T cell-receptor (TCR)-positive T cells; (3) shift towards the memory phenotype in both CD4+ and CD8+ lymphocyte subpopulations expressing CD45RO isoform (over-expression of CD45RO in terms of both the fluorescence intensity for CD45RO isoform and the number of positive cells); and (4) an increase in fluorescence intensity for the CD45RA isoform in NK cells population.	NBS__CD56__no_interaction
23598081-2	To explain the role of <compound-id="5951">Ser</compound-id>(1) and Pro(4) residues of <protein-id="Q9VIP4">Neb</protein-id>-colloostatin in the pro-apoptotic activity of this peptide, the synthesis of a series of analogs was performed, such as: [Ac-<compound-id="5951">Ser</compound-id>(1)]- (1), [d-<compound-id="5951">Ser</compound-id>(1)]- (2), [Thr(1)]- (3), [Asp(1)]- (4), [Glu(1)]- (5), [Gln(1)]- (6), [Ala(1)]- (7), [Val(1)]- (8), [<compound-id="8988">d-Pro</compound-id>(4)]-(9), [Hyp(4)]- (10), [Acp(4)]- (11), [<compound-id="187">Ach</compound-id>(4)]- (12), [Ala(4)]- (13), [Ile(4)]- (14), and [Val(4)]-colloostatin (15).	d-Pro__Neb__no_interaction	Ser__Neb__no_interaction	Ach__Neb__no_interaction
15975960-5	Number/cm(2) liver section, mean area (mm(2)) and percent liver section area occupied by total (persistent + remodeling) placental <compound-id="124886,20725278,745">glutathione</compound-id> S-transferase (<protein-id="P04906,B6DYQ7">GST-P</protein-id>) positive PNL was reduced (P &lt; 0.05) in AtRA (107 +/- 13; 0.12 +/- 0.06; 13.9 +/- 3.9), 9cRA (71 +/- 12; 0.12 +/- 0.06; 6.8 +/- 2.2), ROL (96 +/- 13; 0.11 +/- 0.22; 6.8 +/- 2.0) and betaC (106 +/- 13; 0.08 +/- 0.03; 10.8 +/- 2.5) groups compared with CO group (166 +/- 14; 0.18 +/- 0.09; 28.6 +/- 5.2).	glutathione__GST-P__no_interaction
23579233-1	DFT calculations of the mononuclear Fe(II) <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover complexes [Fe(L)](2+) (L = ({bis[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7852">3-aminopropyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine})), ({[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7852">3-aminopropyl</compound-id>][N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="57481262">2-aminoethyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine}) and ({bis[N-(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="57481262">2-aminoethyl</compound-id>](<compound-id="7975">2-pyridylmethyl</compound-id>)amine}) abbreviated as (66), (56) and (55) have been performed in order to explain the observed <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> transition temperature differences.	2-aminoethyl__spin__no_interaction	2-pyridylmethyl__spin__no_interaction	3-aminopropyl__spin__no_interaction
7923820-15	There was a significantly (P = 0.0014) greater increment of GH secretion after <compound-id="4991">pyridostigmine</compound-id> and <protein-id="P01286">GHRH</protein-id> analogue compared with <protein-id="P01286">GHRH</protein-id> analogue alone (difference in AUC of <compound-id="4991">pyridostigmine</compound-id>+<protein-id="P01286">GHRH</protein-id> analogue and <protein-id="P01286">GHRH</protein-id> analogue alone 6348 (696-12856) mU/l controls vs 542 (120-1340) mU/l in the irradiated group) and significantly (P = 0.033) greater suppression of GH secretion after <compound-id="4848">pirenzepine</compound-id> and <protein-id="P01286">GHRH</protein-id> analogue compared with <protein-id="P01286">GHRH</protein-id> analogue alone (difference in AUC of <protein-id="P01286">GHRH</protein-id> analogue alone and <compound-id="4848">pirenzepine</compound-id>+<protein-id="P01286">GHRH</protein-id> analogue 1644 (222-15205) mU/l in controls vs 479 (469-1623) mU/l in the irradiated group) in the control population compared with those who had received cranial irradiation in childhood.	pirenzepine__GHRH__no_interaction	pyridostigmine__GHRH__no_interaction
20142002-12	Vessel-wall <protein-id="Q5BKB0">IL-1 beta</protein-id> was reduced only in the <compound-id="54671203">DOXY</compound-id> group at 7 days (NaCl = 26 +/- 3, LMWH = 38 +/- 17, <compound-id="54671203">DOXY</compound-id> = 6 +/- 3 pg/mg protein, n = 4-6, p &lt; 0.05), as was the IT score versus controls (NaCl = 2.2 +/- 0.6, LMWH =1.7 +/- 0.3, <compound-id="54671203">DOXY</compound-id> = 0.8 +/- 0.20, n = 4-6, p &lt; 0.05).	DOXY__IL-1 beta__no_interaction
8127099-2	The mean maximum constrictor responses, expressed as percentage of maximum <compound-id="5462222">potassium</compound-id> depolarization, were as follows: <compound-id="114873">thromboxane</compound-id> analog <compound-id="5311493">U46619</compound-id>: native vein 147.0% +/- 10.5%, distended vein 251.2% +/- 29.1%, short-term graft 174.6% +/- 33.8%, long-term graft 220.9% +/- 21.7%; 5-hydroxytryptamine: native vein 115.6% +/- 6.1%, distended vein 129.9% +/- 13.3%, short-term graft 80.0% +/- 15.0%, long-term graft 95.1% +/- 12.1%; <protein-id="P05305,Q6FH53">endothelin-1</protein-id>: native vein 126.5% +/- 22.1%, distended vein 138.1% +/- 24.7%, short-term graft 120.7% +/- 43.3%, long-term graft 171.4% +/- 26.0%; <compound-id="3907,44563898,5280493,5283121">leukotriene C4</compound-id>: native vein 49.9% +/- 8.7%, distended vein 78.9% +/- 11.8%, short-term graft 90.8% +/- 39.1%, long-term graft 7.4% +/- 5.0%; and norepinephrine: native vein 127.0% +/- 9.3%, distended vein 155.0% +/- 17.8%, short-term graft 61.6% +/- 11.3%, long-term graft 80.1% +/- 7.7%.	potassium__endothelin-1__no_interaction	leukotriene C4__endothelin-1__no_interaction	thromboxane__endothelin-1__no_interaction	U46619__endothelin-1__no_interaction
21950243-3	All remaining compounds adopt the hexagonal ScAl(3)C(3)-type structure (Pearson symbol <protein-id="O95059">hP14</protein-id>, space group P6(3)/mmc, Z = 2; a = 4.1772(7)-4.1501(2) Å, c = 20.477(3)-20.357(1) Å for REZn(3)As(3) (RE = Ce, Pr, Nd, Sm); a = 4.4190(3)-4.3923(2) Å, c = 21.4407(13)-21.3004(8) Å for RECd(3)As(3) (RE = La-Pr)) in which [M(3)As(3)](3-) layers (M = Zn, Cd), formed by a triple stacking of nets of close-packed As atoms with M atoms occupying <compound-id="57180004">tetrahedral</compound-id> and trigonal planar sites, are separated by La(3+) cations.	tetrahedral__hP14__no_interaction
19545664-5	RESULTS: Compared with control livers, <protein-id="P01256,P01257,A0A0G2JSX2">CGRP</protein-id>-treated organs showed significantly decreased <compound-id="5950,602">alanine</compound-id> aminotransferase (ALT) and <compound-id="53776235">glutamate-lactate</compound-id> dehydrogenase (GLDH) leakage and portal venous pressure (2.0 +/- 0.3 vs 4.0 +/- 0.4 mmHg; P &lt; .01), with significantly increased bile production (8.56 +/- 0.76 vs 3.34 +/- 0.68 microL/g/45 min; P &lt; .01), <compound-id="977">oxygen</compound-id> consumption (5.14 +/- 0.4 vs 2.57 +/- 0.2 microL/g/min; P &lt; .01), and total <compound-id="190,57060554">adenine</compound-id> nucleotides (TAN) (11.1 +/- 0.71 vs 7.02 +/- 0.53 micromol/g; P &lt; .01) upon reperfusion as signs of recovered viability.	glutamate-lactate__CGRP__no_interaction	alanine__CGRP__no_interaction	oxygen__CGRP__no_interaction	adenine__CGRP__no_interaction
23268605-2	Analogous treatment of 2 and 3 with 1 equiv of pyridine, <compound-id="76009">2,6-dimethylphenylisocyanide</compound-id>, <compound-id="23577">tert-butylisocyanide</compound-id>, or <compound-id="11776">triphenylphosphane</compound-id> gives the ionic compounds [(L)M{(μ(3)-NH)(3)Ti(3)(η(5)-C(5)Me(5))(3)(μ(3)-N)}][O(3)SCF(3)] (L = py, M = Cu (6), Ag (7); L = CNAr, M = Cu (8), Ag (9); L = CNtBu, M = Cu (10), Ag (11); L = <protein-id="P60510,A0A024R625">PPh(3</protein-id>), M = Cu (12), Ag (13)).	2,6-dimethylphenylisocyanide__PPh(3__no_interaction	tert-butylisocyanide__PPh(3__no_interaction	triphenylphosphane__PPh(3__no_interaction
3499193-3	The results demonstrate that 1) increased release of <protein-id="P01587,Q5SX78">granulocyte-macrophage colony stimulating factor</protein-id> (<protein-id="P04141">GM-CSF</protein-id>) in vitro from pokeweed mitogen stimulated mouse spleen cells and from human mononuclear blood cells occurred at lowered O2 tension, and that human mononuclear blood leukocytes were more sensitive to the LF-induced suppression of <protein-id="P04141">GM-CSF</protein-id> release when cells were cultured at 5%, compared to 20%, O2 tension; 2) LF administered intravenously (IV) to mice pretreated with sublethal intraperitoneal dosages of <compound-id="2907,9554281">Cytoxan</compound-id> decreased the cycling status of marrow and spleen granulocyte-macrophage (<compound-id="77620543">CFU</compound-id>-GM), erythroid (BFU-E-2 and BFU-E-1) and multipotential (<compound-id="77620543">CFU</compound-id>-GEMM) progenitor cells and the absolute numbers of these progenitors; these effects were most noticeable if care was taken to deplete endotoxin from the LF samples prior to testing LF in vivo and if the control medium was endotoxin free; 3) endotoxin-depleted LF decreased the cycling status of marrow and spleen <compound-id="77620543">CFU</compound-id>-GM, BFU-E, and <compound-id="77620543">CFU</compound-id>-GEMM and the numbers of these progenitors in the marrows of mice previously untreated with <compound-id="2907,9554281">Cytoxan</compound-id>; these effects were most apparent when assessment of progenitor cells and their cycling rates were evaluated in vitro at lowered (5%) O2 tension; 4) purified natural human <protein-id="P09603,A0A024R0A1">CSF-1</protein-id> increased the absolute numbers of marrow <compound-id="77620543">CFU</compound-id>-GM and the cycling status of marrow <compound-id="77620543">CFU</compound-id>-GM and <compound-id="77620543">CFU</compound-id>-GEMM in mice pretreated with LF; and 5) purified recombinant murine <protein-id="P01586,Q5SX77">IL-3</protein-id> stimulated proliferation of day 8 and day 12 <compound-id="77620543">CFU</compound-id>-S (colony forming unit-spleen) in mice not previously treated with <compound-id="2907,9554281">Cytoxan</compound-id>.	CFU__CSF-1__no_interaction	CFU__granulocyte-macrophage colony stimulating factor__no_interaction	CFU__GM-CSF__no_interaction	CFU__IL-3__no_interaction	Cytoxan__CSF-1__no_interaction	Cytoxan__granulocyte-macrophage colony stimulating factor__no_interaction	Cytoxan__GM-CSF__no_interaction	Cytoxan__IL-3__no_interaction
3585175-7	During these tests, the expected <compound-id="24759880,753">glycerol</compound-id> appearance rates were successively 5.03 +/- 0.33, 7.48 +/- 0.39, 9.94 +/- 0.34, 7.48 +/- 0.39, and 5.03 +/- 0.33 mumol +/- kg-1 X <protein-id="P13987,Q6FHM9">min-1</protein-id>, whereas the corresponding isotopically determined appearance rates were 4.62 +/- 0.45, 6.95 +/- 0.56, 10.85 +/- 0.51, 7.35 +/- 0.34, and 5.28 +/- 0.12 mumol <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>.	glycerol__X kg-1 X min-1__no_interaction	glycerol__min-1__no_interaction
2848453-3	In contrast, there were several ligand-dependent differences in the mouse <protein-id="P30561,Q3U5D9">Ah receptor</protein-id> complexes formed after incubation in low salt buffer and these include: <compound-id="5988">sucrose</compound-id> density gradient analysis of the 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex gave a 9.5 S specifically bound peak and a 2.6 S nonspecifically bound peak whereas the corresponding 2,3,7,8-[3H]TCDD receptor complex gave a single 9.6 S specifically bound peak; <compound-id="5988">sucrose</compound-id> density gradient analysis of the two major peaks eluted from a Sephacryl S-300 column chromatographic separation of the 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex gave two specifically bound peaks at 9.2 and 5.1 S. The molecular properties of the rat hepatic cytosolic receptor complexes incubated in high salt (0.4 M KCl) buffer were ligand independent with one exception, namely the significant difference in the sedimentation coefficient of the specifically bound disaggregated 2,3,7,8-[3H]TCDD receptor complex (6.8 S) and the corresponding 2,3,7,8-[3H]<compound-id="39929">TCDF</compound-id> receptor complex (5.0 S).	TCDF__Ah receptor__no_interaction	sucrose__Ah receptor__no_interaction
22088246-6	RESULTS: Compared to control group, patients with SCF were younger [(57.8 +/- 10.7) years vs. (59.8 +/- 8.2) years], rate of smokers (59.3% vs. 46.4%) and diabetes mellitus (49.3% vs. 30.7%), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (FBG) level [(7.8 +/- 2.8) mmol/L vs. (6.2 +/- 2.0) mmol/L, P &lt; 0.05] and triglyceride (TG) level [(2.11 +/- 1.93) mmol/L vs. (1.67 +/- 1.01) mmol/L, P &lt; 0.05] were higher, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) level [(1.05 +/- 0.35) mmol/L vs. (1.42 +/- 0.74) mmol/L, P &lt; 0.01] and <protein-id="P02647,A0A024R3E3">apolipoprotein A1</protein-id> (<protein-id="P02647,A0A024R3E3">apoA1</protein-id>) level [(1.10 +/- 0.19) mmol/L vs. (1.31 +/- 0.31) mmol/L, P &lt; 0.01] were lower.	cholesterol__apolipoprotein A1__no_interaction	cholesterol__apoA1__no_interaction	glucose__apolipoprotein A1__no_interaction	glucose__apoA1__no_interaction
15130378-9	RESULTS: (1) The levels of serum LH (15.8 +/- 2.8) U/L, LH/FSH 2.8 +/- 0.6, T (4.3 +/- 0.9) nmol/L, FIN (25.2 +/- 3.8) mU/L and HOMA IR (1.56 +/- 0.25) in group A were significantly higher than those of group B (13.9 +/- 1.9) U/L, 2.3 +/- 0.4, (3.6 +/- 0.4) nmol/L, (13.4 +/- 3.8) mU/L, 0.87 +/- 0.28 and control group (7.3 +/- 2.1) U/L, 1.3 +/- 0.3, (0.9 +/- 0.2) nmol/L, (9.5 +/- 2.6) mU/L, 0.50 +/- 0.30 (all P &lt; 0.05); (2) The protein expression and <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="P35568,A0A024R499">IRS-1</protein-id> in group A (690 +/- 19 and 528 +/- 72 respectively) were significantly lower than those in group B (892 +/- 31, 801 +/- 64) and control group (988 +/- 29, 1139 +/- 124) (P &lt; 0.05, and P &lt; 0.01 respectively).	tyrosine__IRS-1__no_interaction
10792332-7	RESULTS: PHP patients had higher concentrations of <protein-id="P02763">ORM</protein-id> (0.80 +/- 0.25, vs. 0.61 +/- 0.20 g/l; P = 0.05), FBG (3.22 +/- 0.48, vs. 2.57 +/- 0.47 g/l; P = 0.001), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> Ag (97.12 +/- 33.23, vs. 44.11 +/- 21.40 microgram/l; P = 0.001), sE-<compound-id="4929">selectin</compound-id> (72.42 +/- 28.35, vs. 42.	selectin__ORM__no_interaction	selectin__PAI-1__no_interaction
10792332-9	After 12-month rhGH replacement the patients showed an increase of TRF (2.64 +/- 0.84 g/l, P = 0.037) and decrease of soluble adhesion molecules (sE-<compound-id="4929">selectin</compound-id> 57.98 +/- 27.04 microgram/l, P = 0.01, sP-<compound-id="4929">selectin</compound-id> 121.74 +/- 50.42 microgram/l, P = 0.007; and sICAM-1 279.95 +/- 88.32 microgram/l, P = 0.005), which then, similarly to the <protein-id="P02763">ORM</protein-id> (0.	selectin__ORM__no_interaction
22535877-6	Twenty genes were downregulated (↓) and two upregulated (↑), including angiogenic growth factors/receptors (↓placental growth factor), adhesion molecules (↓angiopoietin-like-3; ↓collagen-18A1; ↓endoglin), proteases/matrix proteins/inhibitors (↓<compound-id="188982,448397">alanyl</compound-id> aminopeptidase; ↓collagen-4A3; ↓heparanase; ↓plasminogen, ↑plasminogen activator urokinase; ↓platelet factor-4; ↓plexin domain containing-1; ↓tissue inhibitor of metalloproteinases-3), transcription/signaling molecules (↓heart and neural crest derivatives-2; ↓DNA-binding protein inhibitor; ↓NOTCH-4; ↓ribosomal protein-L13a1; ↓<protein-id="P05386,A0A024R608">ribosomal protein large-P1</protein-id>), cytokines/chemokines (↓interleukin-1B), and miscellaneous growth factors (↓<compound-id="90470904">leptin</compound-id>; ↓platelet-derived growth factor-α); ↓transforming growth factor (TGF-α; ↑TGF-β receptor-1).	leptin__ribosomal protein large-P1__no_interaction	alanyl__ribosomal protein large-P1__no_interaction
15788127-5	RESULTS: The content of <protein-id="P49913,J3KNB4">cAMP</protein-id>, <compound-id="5359597">superoxide</compound-id> dismutase (SOD), Zn and Cu in gastric mucosa, and the content of Zn and Cu in mitochondria decreased progressively in order of groups: healthy control (HC), spleen Qi deficiency without organic lesion (F-<compound-id="448048">SQD</compound-id>), spleen Yang deficiency without organic lesion (F-SyangD), disease without symptoms group, spleen Qi deficiency with organic lesion (G-<compound-id="448048">SQD</compound-id>), spleen Yang deficiency with organic lesion (G-SyangD), spleen Yin deficiency (SyinD) and spleen deficiency with Qi stagnation (SDQS), chronic spleen deficiency gastritis (<compound-id="15216946">CSG</compound-id>) and chronic atrophic gastritis (CAG); decreased in order of HC, intestinal metaplasia (IM)Ia, IMIb, IMIIa and IMIIb, P &lt; 0.05.	CSG__cAMP__no_interaction	superoxide__cAMP__no_interaction	SQD__cAMP__no_interaction
20193771-6	However, strains JGS1714 (enterotoxigenic genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), human food poisoning), JGS1936 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), bovine neonatal enteritis), JGS4142 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), bovine jejunal hemorrhage syndrome), JGS1473 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), chicken normal flora), JGS1070 (genotype C, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), porcine hemorrhagic enteritis), JGS1882 (genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), porcine neonatal enteritis), JGS1120 (ATCC 13124, genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), gas gangrene), JGS4151 (strain 13, genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(pos), canine), and JGS4303 (SM101, enterotoxigenic genotype A, <protein-id="Q96IY4,A0A087WSY5">cpb2</protein-id>(<compound-id="11118411">neg</compound-id>), human food poisoning) failed to produce disease.	neg__cpb2__no_interaction
17175269-9	Expression of <protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">osteopontin</protein-id> (22.5 +/- 2.6-fold <compound-id="8987">DCD</compound-id> vs 7.7 +/- 1.7 LD; P &lt; .001), chemokines (CCL4 4.4 +/- 0.7 vs 2.5 +/- 0.3; P &lt; .01), (CCL2 6.0 +/- 1.3 vs 2.8 +/- 0.5), <protein-id="P09341">CXCL1</protein-id> (9.5 +/- 0.4 vs 2.0 +/- 0.2), and <protein-id="P19875,A0A024RDD9">CXCL2</protein-id> (16.7 +/- 5.3 vs 4.8 +/- 1.3; P &lt; .05), adhesion molecule (ICAM-1 4.7 +/- 0.7 vs 2.5 +/- 0.4; P &lt; .05), and heat shock proteins (HSPA1L 6.7 +/- 0.7 vs 1.6 +/- 0.3, <protein-id="P0DMV8,P0DMV9,A8K5I0,B3KTT5">HSPA1A</protein-id> 17.7 +/- 2.6 vs 2.4 +/- 0.5, <protein-id="P0DMV8,P0DMV9,A8K5I0">HSPA1B</protein-id> 13.3 +/- 0.2 vs 3.0 +/- 0.7, <protein-id="P11021,V9HWB4">HSPA5</protein-id> 6.7 +/- 0.8 vs 3.2 +/- 0.3, <protein-id="P04792,V9HW43">HSPB1</protein-id> 2.9 +/- 0.2 vs 1.0 +/- 0.1, and <protein-id="Q92598,A0A024RDQ0,A0A024RDS1,B4DY72,A0A0A0MSM0">HSPH1</protein-id> 19.4 +/- 3.0 vs 5.9 +/- 1.1; P &lt; .001) were up-regulated in the kidneys from <compound-id="8987">DCD</compound-id>.	DCD__CXCL1__no_interaction	DCD__CXCL2__no_interaction	DCD__HSPH1__no_interaction	DCD__HSPA5__no_interaction	DCD__HSPB1__no_interaction	DCD__osteopontin__no_interaction	DCD__HSPA1B__no_interaction	DCD__HSPA1A__no_interaction
9145775-1	We have examined whether 4-<compound-id="6360">tert-butyl-</compound-id>N-[6-(<compound-id="97257">2-hydroxy-</compound-id>ethoxy)-2,2'-bipyrimidin-4-yl]-<compound-id="241">benzen</compound-id> esulfonamide (<compound-id="104865">bosentan</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(A/B) receptor antagonist) and (R)2-[(R)-2-[(S)-2-[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl] amino-4-methylpentanoil]amino-3-[3-(1-methyl-1H-indoyl)]prop ionyl]amino-3-(2-pyridyl) <compound-id="1032">propionic acid</compound-id> (<compound-id="107810">FR 139317</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(A) receptor antagonist) inhibit contractions of human airway smooth muscle induced by <protein-id="P05305,Q6FH53">endothelin-1</protein-id> or Suc-[Glu9,Ala(11,15)]enthothelin-1-(8-21) (<compound-id="16130933">IRL 1620</compound-id>; <compound-id="44284481">endothelin</compound-id> ET(B) receptor agonist).	1H-azepinyl__endothelin-1__no_interaction	propionic acid__endothelin-1__no_interaction	endothelin__endothelin-1__no_interaction	benzen__endothelin-1__no_interaction	bosentan__endothelin-1__no_interaction	tert-butyl-__endothelin-1__no_interaction	FR 139317__endothelin-1__no_interaction	2-hydroxy-__endothelin-1__no_interaction	IRL 1620__endothelin-1__no_interaction
14629173-1	Six supramolecular complexes incorporating <compound-id="8651">benzil</compound-id> as a guest, CMCR*<compound-id="1474">bipy</compound-id>*<compound-id="8651">benzil</compound-id> (<protein-id="P25100,B0ZBE0">alpha) 1</protein-id> (CMCR = <compound-id="3952517">C-methylcalix[4]resorcinarene</compound-id>), CMCR*<compound-id="1474">bipy</compound-id>*<compound-id="8651">benzil</compound-id> (beta) 2, CMCR*2bpe*<compound-id="8651">benzil</compound-id>*<compound-id="702">ethanol</compound-id> 3 (bpe = trans-1,4-bis(pyridyl)<compound-id="53675528,6325">ethylene</compound-id>), CMCR*2bpe*<compound-id="8651">benzil</compound-id>*2H2O 4, CMCR.2bpeh*<compound-id="8651">benzil</compound-id>*<compound-id="702">ethanol</compound-id> 5 (bpeh = bis-(1-pyridin-4-yl-<compound-id="59061983">ethylidene</compound-id>)-<compound-id="9321">hydrazine</compound-id>), and CECR*2bpe.<compound-id="8651">benzil</compound-id> 6 (CECR = C-ethylcalix[4]resorcinarene), have been synthesized by hydrothermal and conventional methods and characterized by X-ray diffraction.	ethylene__alpha) 1__no_interaction	benzil__alpha) 1__no_interaction	bipy__alpha) 1__no_interaction	ethylidene__alpha) 1__no_interaction	C-methylcalix[4]resorcinarene__alpha) 1__no_interaction	hydrazine__alpha) 1__no_interaction	ethanol__alpha) 1__no_interaction
6363874-6	At each increment of <protein-id="P01308,I3WAC9,P01315">insulin</protein-id> infused, steady-state <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rates for porcine <protein-id="P01308,I3WAC9,P01315">insulin</protein-id> were 1.12 +/- 0.22, 1.90 +/- 0.59, 4.28 +/- 0.61, and 9.37 +/- 0.66 mg/kg/min compared with 1.27 +/- 0.42, 2.38 +/- 0.20, 4.25 +/- 0.43, and 8.87 +/- 0.67 mg/kg/min for semisynthetic human <protein-id="P01308,I3WAC9,P01315">insulin</protein-id>.	glucose__insulin__no_interaction
2180818-4	It was specific, as the pressor effect induced by other unrelated peptides was similar during the infusion of either vehicle or kinin antagonist (angiotensin II, 25 +/- 4 vs. 26 +/- 2 mm Hg; <compound-id="5280360">prostaglandin E2</compound-id>, 48 +/- 3 vs. 47 +/- 8 mm Hg; <compound-id="439260">norepinephrine</compound-id>, 17 +/- 2 vs. 18 +/- 2 mm Hg; <compound-id="6106">leucine</compound-id>-enkephaline, 15 +/- 2 vs. 16 +/- 1 mm Hg; <protein-id="G3V6J4">neurotensin</protein-id>, 18 +/- 2 vs. 19 +/- 1 mm Hg; substance P, 19 +/- 2 vs. 19 +/- 2 mm Hg).	norepinephrine__neurotensin__no_interaction	leucine__neurotensin__no_interaction	prostaglandin E2__neurotensin__no_interaction
7572973-5	<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex hormone-binding globulin</protein-id> was significantly inversely correlated with body mass index (r = -0.53, p 0.001), glycosylated hemoglobin (r = -0.34, p &lt; 0.001), and diastolic blood pressure (r = -0.25, p &lt; 0.001), and positively correlated with high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL <compound-id="5997">cholesterol</compound-id>) (r = 0.31, p &lt; 0.001), and HDL <compound-id="5997">cholesterol</compound-id>/total <compound-id="5997">cholesterol</compound-id> (r = 0.31, p &lt; 0.001).	cholesterol__sex hormone-binding globulin__no_interaction
20825003-4	The results show that the pollutants concentration often exceeds state criterion except <compound-id="947">nitrogen</compound-id> oxides, O3 concentration in summer and autumn is higher, averaged hourly maximum concentration (O3-<protein-id="P61244,Q8TAX8,A0A024R682">Max</protein-id>) is (177.2 +/- 63.0) and (105.8 +/- 61.7) microg x m(-3), the concentrations of NO and NO2 are (4.5 +/- 4.0), (32.7 +/- 12.4) microg x m(-3) and (21.5 +/- 16.9), (60.5 +/- 16.9) microg x m(-3) respectively, SO2 concentration is (72.0 +/- 27.5) and (92.0 +/- 44.4) microg x m(-3), PM2.5 and PM10 concentrations reach to (102.3 +/- 47.6), (153.3 +/- 58.3) microg x m(-3) and (95.8 +/- 50.0), (147.4 +/- 67.0) microg x m(-3).	nitrogen__Max__no_interaction
16732984-5	Duration of diabetes [(66.09 +/- 72.51) months vs (143.71 +/- 93.27) months vs (174.30 +/- 81.91) months, P = 0.00], systolic blood pressure [(131.95 +/- 47.20) mmHg vs (138.71 +/- 21.36) mmHg vs (147.58 +/- 24.10) mmHg, P = 0.01], urine <protein-id="P02768">albumin</protein-id> [(32.79 +/- 122.29) mg/L vs (190.96 +/- 455.65) mg/L vs (362.00 +/- 552.51) mg/L, P = 0.00], glycated hemoglobin (HbA1c) [(8.68 +/- 2.26)% vs (9.42 +/- 1.84)% vs (9.42 +/- 1.96)%, P = 0.04], <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) [(3.19 +/- 7.37) mg/L vs (6.36 +/- 23.59) mg/L vs (3.02 +/- 4.34) mg/L, P = 0.03], high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) [(1.23 +/- 0.37) mmol/L vs (1.33 +/- 0.35) mmol/L vs (1.24 +/- 0.33) mmol/L, P = 0.01], <compound-id="1175">uric acid</compound-id> (UA) [(288.51 +/- 90.85) mmol/L vs (300.29 +/- 101.98) mmol/L vs (337.57 +/- 115.09) mmol/L, P = 0.00], <compound-id="588">creatinine</compound-id> (CREA) [(84.22 +/- 16.31) micromol/L vs (89.35 +/- 27.45) micromol/L vs (103.28 +/- 48.64) micromol/L, P = 0.00], blood urine <compound-id="947">nitrogen</compound-id> (BUN) [(5.62 +/- 1.62) mmol/L vs (6.55 +/- 2.74) mmol/L vs (8.11 +/- 3.60) mmol/L, P = 0.00] were statistically different among the three groups.	creatinine__C-reactive protein__no_interaction	creatinine__albumin__no_interaction	creatinine__CRP__no_interaction	uric acid__C-reactive protein__no_interaction	uric acid__albumin__no_interaction	uric acid__CRP__no_interaction	nitrogen__C-reactive protein__no_interaction	nitrogen__albumin__no_interaction	nitrogen__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__albumin__no_interaction	cholesterol__CRP__no_interaction
18357530-7	After 90 days in group A treated with ALC, we observed a significant decrease in <protein-id="P00734">prothrombin</protein-id> time (P &lt; 0.001), <compound-id="5280352">bilirubin</compound-id> serum levels (P &lt; 0.01), AST (P &lt; 0.001), fasting NH(4) serum levels (P &lt; 0.001), Trail Making Test-A (P &lt; 0.001) and Trail Making Test-B (P &lt; 0.001), and a significant increase in albumin serum levels (P &lt; 0.005), MMSE test (P &lt; 0.001), Symbol Digit Modalities Test (P &lt; 0.001), BDT (P &lt; 0.001), AVL long-term test (P &lt; 0.001) and AVL total test (P &lt; 0.001).	bilirubin__prothrombin__no_interaction
9773399-11	Low-density lipoprotein diameter correlated inversely with concentrations of serum triglyceride (r = -.61, P &lt; .0001), apo B (r = -.66, P &lt; .0001), <compound-id="5997">cholesterol</compound-id> (r = -.53, P &lt; .001), LDL <compound-id="5997">cholesterol</compound-id> (r = -.45, P &lt; .005), and <protein-id="P02647,A0A024R3E3">apo A-I</protein-id> (r = -.39, P &lt; .02).	cholesterol__apo A-I__no_interaction
15879357-4	RESULTS: The patients were androgen deficient compared with controls (median, range), <protein-id="Q06520,A8K015">dehydroepiandrosterone sulphate</protein-id> (<protein-id="Q06520,A8K015">DHEAS</protein-id>): 185 (99-7800) nmol/l vs 4400 (820-13,000) nmol/l, P=or&lt;0.001; <compound-id="6128">androstenedione</compound-id>: 0.5 (0.1-7.1) nmol/l vs 4.3 (1.6-8.8) nmol/l, P=or&lt;0.001; <compound-id="10635">dihydrotestosterone</compound-id> (DHT): 0.13 (0.09-0.54) nmol/l vs 0.55 (0.09-0.89) nmol/l, P=or&lt;0.001; <compound-id="6013">testosterone</compound-id>: 0.28 (0.09-1.56) nmol/l vs 1.1 (0.71-2.24) nmol/l, (P=or&lt;0.001); free <compound-id="6013">testosterone</compound-id>: 0.004 (0.001-0.030) nmol/l vs 0.016 (0.001-0.030) nmol/l, P=or&lt;0.001.	dihydrotestosterone__DHEAS__no_interaction	dihydrotestosterone__dehydroepiandrosterone sulphate__no_interaction	androstenedione__DHEAS__no_interaction	androstenedione__dehydroepiandrosterone sulphate__no_interaction	testosterone__DHEAS__no_interaction	testosterone__dehydroepiandrosterone sulphate__no_interaction
23383498-4	The chromatographic separation was achieved on a reverse-phase <protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C18</protein-id> column by gradient elution using 0.01 mol/L <compound-id="1004">phosphoric acid</compound-id> (adjusted to pH 3.6 by <compound-id="8471">triethylamine</compound-id>) and acetonitrile, detected with a diode array detector (DAD) at 228 nm for 2-amino-9H-pyrido [ 2,3-b] <compound-id="798">indole</compound-id> (AaC) and 2-amino-3-methyl-9H-pyrido [ 2,3-b] <compound-id="798">indole</compound-id> (MeAaC); 253 nm for 2-amino-<compound-id="97555">3-methylimidazo[4,5-f]quinoline</compound-id> (<compound-id="53462">IQ</compound-id>), 1-methyl-9H-pyrido[3, 4-b] <compound-id="798">indole</compound-id> (<compound-id="5281404">Harman</compound-id>), 9H-pyrido[3,4-b] <compound-id="798">indole</compound-id> (<compound-id="64961">Norharman</compound-id>); 263 nm for 2-amino-<compound-id="151877">3,8-dimethylimidazo[4,5-f]quinoxaline</compound-id> (<compound-id="62275">MeIQx</compound-id>), 2-amino-3,4,8-<compound-id="69976">trimethylimidazo</compound-id> [4,5-f] <compound-id="7045">quinoxaline</compound-id> (4, 8-DiMeIQx), 3-amino-1-methyl-<compound-id="13347754">5H-pyrido</compound-id> [4,3-b] <compound-id="798">indole</compound-id> (Trp-p-2); 321 nm for 2-amino-1-methyl-6-<compound-id="69591">phenylimidazo</compound-id> [4,5-b]pyridine (PhIP).	phenylimidazo__C18__no_interaction	indole__C18__no_interaction	quinoxaline__C18__no_interaction	trimethylimidazo__C18__no_interaction	IQ__C18__no_interaction	MeIQx__C18__no_interaction	phosphoric acid__C18__no_interaction	triethylamine__C18__no_interaction	Harman__C18__no_interaction	Norharman__C18__no_interaction	3,8-dimethylimidazo[4,5-f]quinoxaline__C18__no_interaction	5H-pyrido__C18__no_interaction	3-methylimidazo[4,5-f]quinoline__C18__no_interaction
18252895-7	The most susceptible haplotypes are the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0301-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0501-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0201 (odds ratio [OR] 3.64) and the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0405-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302, <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<compound-id="5326974">DQB</compound-id>*0302, and <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0402-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 haplotypes (ORs 11.37, 8.39, and 3.63), followed by the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0404-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0301-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 (OR 1.59) and the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0801-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0401-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0402 (OR 1.25) haplotypes.	DQB__DQB1__no_interaction	DQB__DRB1__no_interaction	DQB__DQA1__no_interaction
19875056-1	PURPOSE: The response of 2-amino-4-([(14)C]methylthio)<compound-id="264">butyric acid</compound-id> ([(14)C]Met) uptake and [(125)I]<compound-id="15284370">3-iodo-alpha-methyl-l-tyrosine</compound-id> ([(125)I]<compound-id="447041">IMT</compound-id>) uptake to radiotherapy of <protein-id="Q9NYD6,Q53XI4">C10</protein-id> glioma cells was compared to elucidate the intracellular reactions that affect the response of 2-amino-4-([(11)C]methylthio)<compound-id="264">butyric acid</compound-id> ([(11)C]Met) uptake to radiotherapy.	butyric acid__C10__no_interaction	3-iodo-alpha-methyl-l-tyrosine__C10__no_interaction	IMT__C10__no_interaction
20364816-4	Values for some of the more important parameters (r(g)/A; angle(alpha)/deg) of the C(s) form are r(C=C) = 1.337(21), <protein-id="Q9HC52">r(C1-C4</protein-id>) = 1.496(8), r(C2-C3) = 1.501(8), r(C3-C4) = 1.567(12), r(C1-O) = 1.318(12), r(C2-O) = 1.340(12), r(C3-F) = 1.375(4), r(C4-F) = 1.368(4), angle(<compound-id="16070039">ave</compound-id>)(C=C-C) = 94.4(4), angle(<compound-id="16070039">ave</compound-id>)(C=C-O) = 133.5(12), angle(<compound-id="16070039">ave</compound-id>)(C-O-C) = 119.6(13), and angle(<compound-id="16070039">ave</compound-id>)(F-C-F) = 104.4(7).	ave__r(C1-C4__no_interaction
14703492-7	The cDNA library contained oxidative metabolic genes in mitochondria (<compound-id="439168">triose phosphate</compound-id> dehydrogenase, NADH4, <compound-id="644102">pyrophosphate</compound-id> synthase, 16S rRNA ribosome, <compound-id="1110">succinate</compound-id>-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> ligase and <compound-id="5957">ATP</compound-id> synthase 6); transcriptional and translation genes poly (A) binding protein, t-RNA-<compound-id="764">guanine</compound-id> transglycoslase, <protein-id="P62831">ribosomal protein L23</protein-id>, ribosomal protein S15A, <compound-id="59918034">eukaryotic translation initiation factor 3</compound-id>, Rab interaction protein 5, splicing factor-<compound-id="54451667">arginine serine</compound-id> rich 5, and <compound-id="6022">ADP</compound-id>-ribosylation factor-like 6 interacting protein), <compound-id="190217">oxide</compound-id> stress related genes (ferritin high chain and <protein-id="P17741">high-mobility group protein 2</protein-id>); protein activating and signaling pathway related genes (casein kinase, serine kinase 2 and <compound-id="16738692,53477912">phosphatidylinositol</compound-id>-four-<compound-id="1061,167704">phosphate</compound-id> adaptor protein-1-associated protein); cell differentiation and apoptosis associated genes (NB4 cell apoptosis related protein and myeloid differentiation primary response protein) and five genes with unknown function (KIAA0092, CGI-147protein, GCI-35, nucleolar phosphoprotein Nopp34 and Mus muscular partial mRNA for hypothetical protein), as well as a novel gene unmatched to the sequence in GenBank.	pyrophosphate__high-mobility group protein 2__no_interaction	pyrophosphate__ribosomal protein L23__no_interaction	ADP__high-mobility group protein 2__no_interaction	ADP__ribosomal protein L23__no_interaction	triose phosphate__high-mobility group protein 2__no_interaction	triose phosphate__ribosomal protein L23__no_interaction	phosphatidylinositol__high-mobility group protein 2__no_interaction	phosphatidylinositol__ribosomal protein L23__no_interaction	arginine serine__high-mobility group protein 2__no_interaction	arginine serine__ribosomal protein L23__no_interaction	guanine__high-mobility group protein 2__no_interaction	guanine__ribosomal protein L23__no_interaction	eukaryotic translation initiation factor 3__high-mobility group protein 2__no_interaction	eukaryotic translation initiation factor 3__ribosomal protein L23__no_interaction	CoA__high-mobility group protein 2__no_interaction	CoA__ribosomal protein L23__no_interaction	oxide__high-mobility group protein 2__no_interaction	oxide__ribosomal protein L23__no_interaction	phosphate__high-mobility group protein 2__no_interaction	phosphate__ribosomal protein L23__no_interaction	ATP__high-mobility group protein 2__no_interaction	ATP__ribosomal protein L23__no_interaction	succinate__high-mobility group protein 2__no_interaction	succinate__ribosomal protein L23__no_interaction
20401425-1	The structures and magnetic properties of a family of new octanuclear heterometallic 3d-4f complexes [Mn(III)(4)Ln(III)(4)(mu(3)-OH)(4)(mu(2),eta(1)-X)(4)(O(2)CBu(t))(8)(t-bdea)(4)]·solv, where X = N(3)(-), Ln = Y (1), Eu (2), Gd (3), Tb (4), Dy (5), Ho (6); X = <protein-id="P02818">OCN</protein-id>(-), Ln = Dy (7); X = NO(3)(-), Ln = Gd (8), Tb (9), Dy (10), Ho (11), Er (12); solv = <compound-id="6342">MeCN</compound-id> or <compound-id="1140">toluene</compound-id>, are reported.	MeCN__OCN__no_interaction	toluene__OCN__no_interaction
22378230-1	Six inorganic-organic <compound-id="5359367">bismuth</compound-id> <compound-id="10367">2,6-pyridinedicarboxylate</compound-id> (pdc) compounds, [Bi(2,6-pdc)(3)]·3(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 1, [Bi(2,6-pdc)(3)]·3(<protein-id="Q31604,Q6ICR9">dma</protein-id>)·2(H(2)O), 2, [Bi(2,6-pdc)(2)(dmf)]·(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 3, Bi(2,6-pdc)(2,6-pdcme)(<compound-id="887">MeOH</compound-id>), 4, [LiBi(2,6-pdc)(3)(H(2)O)]·2(<protein-id="Q31604,Q6ICR9">dma</protein-id>), 5, and Li(5)Bi(2,6-pdc)(4)(H(2)O)(2), 6 (where <protein-id="Q31604,Q6ICR9">dma</protein-id> = dimethyl <compound-id="223">ammonium cation</compound-id>, dmf = dimethylformamide and 2,6-pdcme = 6-methyl-oxycarbonyl <compound-id="1049">pyridine</compound-id> 2-carboxylate) have been synthesized under solvothermal conditions and their structures determined by single crystal X-ray diffraction.	pyridine__dma__no_interaction	bismuth__dma__no_interaction	ammonium cation__dma__no_interaction	2,6-pyridinedicarboxylate__dma__no_interaction	MeOH__dma__no_interaction
19099859-8	Compared with the group treated with traditional medicines, plasma concentration of <protein-id="P16860">BNP</protein-id> [(403 +/- 216) ng/L vs. (219 +/- 87) ng/L] significantly decreased, the clinical symptom was significantly improved, cardio-thoracic ratio (CTR) (0.60 +/- 0.05 vs. 0.54 +/- 0.06) (P &lt; 0.05) and heart rate [(115 +/- 20) bpm vs. (90 +/- 14) bpm] (P &lt; 0.01) decreased, ejection fraction (EF) (46.6% +/- 13.4% vs. 54.5% +/- 12.9%), fractional shortening (21.6% +/- 8.1% vs. 24.1% +/- 7.5%), mean velocity of circumferential fiber shortening [(0.8 +/- 0.5) cir/s vs. (0.9 +/- 0.4) cir/s] were significantly increased (P &lt; 0.01), left ventricular end-systolic dimension [(34.0 +/- 8.6) mm vs. (32.2 +/- 9.1) mm] (P &lt; 0.05), left ventricular mass [(65.9 +/- 34.1) g vs. (65.9 +/- 34.1) g], interventricular septal thickness at end-systole [(6.0 +/- 1.0) mm vs (5.5 +/- 1.1) mm] were notably decreased (P &lt; 0.01) after treatment with <compound-id="2585">carvedilol</compound-id>.	carvedilol__BNP__no_interaction
22098258-5	Estimates for the enthalpy of vaporization of EMIM(+)Br(-) and, by comparison, <compound-id="2734162">1-butyl-3-methylimidazolium</compound-id> bromide (BMIM(+)Br(-)) from molecular dynamics calculations and their gas phase enthalpies of formation obtained by G4 calculations yield estimates for the ionic liquids' enthalpies of formation in the liquid phase: ΔH(vap)(298 K) (EMIM(+)Br(-)) = 168 ± 20 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, gas)(298 K) (EMIM(+)Br(-)) = 38.4 ± 10 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, <compound-id="15942667">liq</compound-id>)(298 K) (EMIM(+)Br(-)) = -130 ± 22 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, ΔH(f, gas)(298 K) (BMIM(+)Br(-)) = -5.6 ± 10 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>, and ΔH(f, <compound-id="15942667">liq</compound-id>)(298 K) (BMIM(+)Br(-)) = -180 ± 20 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>.	liq__mol__no_interaction	1-butyl-3-methylimidazolium__mol__no_interaction
9666933-5	In women, <compound-id="40539">QUS</compound-id> data correlated significantly with age (r = -0.297), body mass index (BMI) (r = 0.403), <compound-id="22044544,5460341">calcium</compound-id> (r = 0.220), <protein-id="P01270">PTH</protein-id> (r = -0.296), 25OHD (r = 0.298) and alkaline phosphatase (AP) (r = -0.170) for broadband ultrasound attenuation (BUA), and with age (r = -0.195), BMI (r = 0.208), <protein-id="P01270">PTH</protein-id> (r = -0.174), 25OHD (r = 0.140) and AP (r = -0.130) for speed of sound (SOS).	calcium__PTH__no_interaction	QUS__PTH__no_interaction
15883813-3	RESULTS: Here we show that (1) <compound-id="46173706">beta-glucan</compound-id> had cytotoxic effect against human ovarian cancer HRA cells, but not against murine Lewis lung cancer <compound-id="86580376">3LL</compound-id> cells, in vitro; (2) <compound-id="46173706">beta-glucan</compound-id> promotes p38 MAPK activity for suppressing HRA cell proliferation and amplifying the apoptosis cascade; (3) <compound-id="46173706">beta-glucan</compound-id> stimulates translocation of the proapoptotic protein, <protein-id="Q07813,Q544Z6">Bax</protein-id>, from the cytosol to mitochondria, cytochrome c release, and subsequent <protein-id="Q8C3Q9,A2AS93">caspase-9</protein-id> activation; (4) treatment with <compound-id="176155">SB203580</compound-id>, a p38 MAPK-specific inhibitor, suppresses <compound-id="46173706">beta-glucan</compound-id>-induced effects, indicating that activation of p38 MAPK is involved in the suppression of cell proliferation and mitochondrial activation-mediated cell death pathway; (5) in mice, oral supplementation with <compound-id="46173706">beta-glucan</compound-id> reduces pulmonary metastasis of <compound-id="86580376">3LL</compound-id> cells and peritoneal disseminated metastasis of HRA cells and inhibits the growth of these metastatic tumors in lung or peritoneal cavity, in part, by suppressing uPA expression; and (6) in an in vivo experimental metastasis assay, however, the oral supplementation with <compound-id="46173706">beta-glucan</compound-id> after i.v.	beta-glucan__caspase-9__no_interaction	beta-glucan__Bax__no_interaction	3LL__caspase-9__no_interaction	3LL__Bax__no_interaction	SB203580__caspase-9__no_interaction	SB203580__Bax__no_interaction
6616041-3	For cells treated with 3H-<compound-id="5789">thymidine</compound-id> at 01 h, T = 24.3 h, ts = 6 h, <protein-id="P21981">tG2</protein-id> min = 1.5 h, <protein-id="P21981">tG2</protein-id>+ 1/2 M = 2.9 h and <protein-id="P21981">tG1+/2</protein-id> M = 15.4 h; for those treated with 3H-<compound-id="5789">thymidine</compound-id> at 13 h, T = 25.6 h, ts = 8.4 h, <protein-id="P21981">tG2</protein-id> min = 1 h, <protein-id="P21981">tG2</protein-id>+ 1/2 M = 2.2 h, tG1+ 1/2 M = 15 h. Cells labeled at 01 h proliferated more actively for a long period of time as compared to those labeled at 13 h. The synchronism in undergoing several successive mitotic cycles was greater for cells labeled at the peak radioisotope index.	thymidine__tG2__no_interaction	thymidine__tG1+/2__no_interaction
8647820-3	Seven <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)-derived triple-helical peptides (<compound-id="41478">THPs</compound-id>) were synthesized based on charge clustering (<protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)256-270, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)385-396, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)406-417, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)415-423, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)448-456, <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)496-507, and <protein-id="P25100,B0ZBE0">alpha 1</protein-id>(I)526-537).	THPs__alpha 1__no_interaction
21917315-5	RESULTS: <protein-id="P00813,F5GWI4">ADA</protein-id> activity and <protein-id="P02778,A0A024RDA4">IP-10</protein-id>, IFN-γ, and <protein-id="P27487">DPP4</protein-id> levels were significantly higher in <compound-id="445181">TPE</compound-id> than in non-<compound-id="445181">TPE</compound-id> (88.9 ± 62.7 U/L vs 18.1 ± 16.2 U/L, P &lt; .05; 147.5 ± 117.3 ng/L vs 24.9 ± 19.7 ng/L, P &lt; .05; 627.2 ± 345.3 ng/L vs 152.6 ± 71.4 ng/L, P &lt; .05; and 560.6 ± 451.2 vs 56.8 ± 57.7, P &lt; .05, respectively).	TPE__IP-10__no_interaction	TPE__DPP4__no_interaction	TPE__ADA__no_interaction
22112436-8	These had a mean ± SD reduction in weight (6.8 ± 6.9 kg, P &lt; 0.001), waist circumference (6.1 ± 7.3 cm, P &lt; 0.001), <compound-id="206,5793,64689,79025">glucose</compound-id> (4.5 ± 29.6 mg/dL or 0.25 ± 1.64 mmol/L, P = 0.009), triglycerides (26.4 ± 58.5 mg/dL or 0.30 ± 0.66 mmol/L, P &lt; 0.001), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (LDL) (7.9 ± 25.1 mg/dL or 0.2 ± 0.65 mmol/L, P &lt; 0.001), hemoglobin A1c (HgbA1c) (0.20 ± 0.64%, P = 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> (3.8 ± 11 microU/ml or 26.6 ± 76.4 ρmol, P &lt; 0.001) and ultra sensitive <protein-id="P02741">C-reactive protein</protein-id> (US - <protein-id="P02741">CRP</protein-id>) (0.9 ± 4.8 mg/dL or 7.3 ± 40.2 nmol/L, P = 0.012), an increase in mean high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL) (3.7 ± 8.4 mg/dL or 0.1 ± 0.22, P &lt; 0.001), and decreased use of medications.	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction	cholesterol__CRP__no_interaction	glucose__C-reactive protein__no_interaction	glucose__insulin__no_interaction	glucose__CRP__no_interaction
18940877-9	RESULTS: After 12 wk <compound-id="60823">atorvastatin</compound-id>, there was a significant reduction (mean +/- <compound-id="5289348">sem</compound-id>) in total <compound-id="5997">cholesterol</compound-id> (4.6 +/- 0.2 vs. 3.4 +/- 0.2 mmol/liter, P &lt; 0.01), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (2.9 +/- 0.2 vs. 1.8 +/- 0.2 mmol/liter, P &lt; 0.01), triglycerides (1.34 +/- 0.08 vs. 1.08 +/- 0.13 mmol/liter, P &lt;0.01), high-sensitivity <protein-id="P02741">C-reactive protein</protein-id> (4.9 +/- 1.4 vs. 3.4 +/- 1.1 mg/liter, P = 0.04), free androgen index (13.4 +/- 0.6 vs. 8.7 +/- 0.4, P &lt; 0.01), <compound-id="6013">testosterone</compound-id> (4.1 +/- 0.2 vs. 2.9 +/- 0.1 nmol/liter, P &lt; 0.01) and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance as measured by homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) (3.3 +/- 0.4 vs. 2.7 +/- 0.4).	atorvastatin__C-reactive protein__no_interaction	atorvastatin__insulin__no_interaction	sem__C-reactive protein__no_interaction	sem__insulin__no_interaction	testosterone__C-reactive protein__no_interaction	testosterone__insulin__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction
21813378-3	RESULTS: 1) In SB vs. SF unstratified OM biomarkers were statistically unchanged, but the majority of patients was overweight; despite, in SB vs. SF urine pH, total and non-albumin protein concentration were elevated, fractional urinary <compound-id="1175">uric acid</compound-id> excretion and blood <compound-id="767">bicarbonate</compound-id> decreased, whereas urine volume, <compound-id="5360545">sodium</compound-id>, supersaturation with CaOx and CaPi (as <compound-id="14781">hydroxyapatite</compound-id>) were unchanged; 2) upon variation of OM markers (strata below and above median) numerous stone parameters differed significantly, among others urine volume, total protein, Ca/Pi ratio, pH, <compound-id="5360545">sodium</compound-id>, <compound-id="5462222">potassium</compound-id>, plasma Ca/Pi ratio and parathyroid hormone, blood pressure, renal excretion of non-albumin protein and other substances; 3) a significant shift from SF to SB patients occurred with increase of urine pH, decrease of blood <compound-id="767">bicarbonate</compound-id>, and increase of diastolic blood pressure, whereas increase of plasma <compound-id="1175">uric acid</compound-id> impacted only marginally; 4) in both SF and SB patients a strong curvilinear relationship links a rise of urine Ca/Pi to urine Ca/Pi divided by plasma Ca/Pi, but in SB urine Ca/Pi failed to correlate significantly with urine <compound-id="14781">hydroxyapatite</compound-id> supersaturation; 5) also in SB, plasma Ca/Pi and urinary <compound-id="10313259,943">nitrate</compound-id> were negatively correlated, whereas in SF plasma Ca/Pi ratio, <protein-id="P01270">PTH</protein-id> and body mass index correlated positively; 6) multivariate regression analysis revealed that <protein-id="P01270">PTH</protein-id>, body mass index and <compound-id="10313259,943">nitrate</compound-id> together could explain 22 (p = 0.002) and only 7 (p = 0.06) per cent of variation of plasma Ca/Pi in SF and SB, respectively.	sodium__PTH__no_interaction	potassium__PTH__no_interaction	bicarbonate__PTH__no_interaction	nitrate__PTH__no_interaction	hydroxyapatite__PTH__no_interaction	uric acid__PTH__no_interaction
21341784-4	The <compound-id="123195">diimine</compound-id> [(Me(2))(C(6)H(3))Xanthdim]H(2) was treated with CuOtBu in the presence of acetonitrile, <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), and PMe(3) to yield the corresponding complexes [(Me(2))(C(6)H(3))Xanthdim](Cu(L))(2) (L = CH(3)CN, 1, <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), 2, and PMe(3), 3) that proved to be stable and were fully characterized.	diimine__PPh(3__no_interaction
17893771-2	Reactions of or with <compound-id="180">acetone</compound-id> oxime , cyclic <compound-id="6350">nitrone</compound-id> (-)O(+)N = <protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>(2)CH(2)C[upper bond 1 end]Me(2) or N,N-<compound-id="19463">diethylhydroxylamine</compound-id> give access, in moderate to good yields, to the unsymmetric mixed ligand oxadiazoline and/or imine complexes trans-[PtCl(2)(oxadiazoline-a)(imine-a)] , trans-[PtCl(2)(oxadiazoline-a)(oxadiazoline-b)] [oxadiazoline-b = [upper bond 1 start]N[double bond, length as m-dash]C(CH(2)CO(2)Me)O[lower bond 1 start]NC[upper bond 1 end](H)CH(2)CH(2)C[lower bond 1 end]Me(2)], trans-[PtCl(2)(imine-a)(imine-b)] [imine-b = NH = C(CH(2)CO(2)Me)ONEt(2)] or trans-[PtCl(2)(imine-a)(oxadiazoline-b)] .	nitrone__CHCH__no_interaction	diethylhydroxylamine__CHCH__no_interaction	acetone__CHCH__no_interaction
18633161-5	Blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (BUN) in <protein-id="Q60760">Meg1</protein-id> Tg mice (19.6 +/- 1.2 mg/dl) was significantly lower than in controls (22.0 +/- 0.8 mg/dl), while plasma triglyceride, insulin, <protein-id="Q60994">adiponectin</protein-id>, and <protein-id="Q99P87,Q5BMX4">resistin</protein-id> levels were significantly higher (202.0 +/- 23.4 mg/dl vs 146.3 +/- 23.4 mg/dl, 152.4 +/- 16.3 pg/ml vs 88.1 +/- 16.9 pg/ml, 74.4 +/- 10.9 microg/ml vs 48.3 +/- 7.0 microg/ml, and 4.0 +/- 0.2 ng/ml vs 3.6 +/- 0.2 ng/ml, respectively).	urea__resistin__no_interaction	urea__Meg1__no_interaction	urea__adiponectin__no_interaction	nitrogen__resistin__no_interaction	nitrogen__Meg1__no_interaction	nitrogen__adiponectin__no_interaction
10588341-9	For the determination of a mixture of <compound-id="11568">3-aminophenol</compound-id>, <compound-id="7245">2-chlorophenol</compound-id>, <compound-id="6947">2-nitrophenol</compound-id>, <compound-id="980">4-nitrophenol</compound-id>, <compound-id="335">o-methylphenol</compound-id>, <compound-id="342">m-methylphenol</compound-id>, <compound-id="2879">p-methylphenol</compound-id>, <compound-id="8449">2,4-dichlorophenol</compound-id>, <compound-id="7771">2,4-dimethylphenol</compound-id>, 2,4-<compound-id="1493">dinitrophenol</compound-id>, 2,4,6-trichlorophenol, <compound-id="10698">2,4,6-trimethylphenol</compound-id>, <compound-id="7808">4-bromophenol</compound-id>, 3-methyl-<compound-id="4684">4-chlorophenol</compound-id>, <compound-id="992">pentachlorophenol</compound-id>, and unsubstituted <compound-id="996">phenol</compound-id>, the calibration graphs for most phenols were linear over the range of 10-1000 microg <protein-id="Q9NTI2">ml(-1</protein-id>) and the mass detection limits were in the ng range based on three times standard deviation of seven measurements of the lowest peak that could be detected.	p-methylphenol__ml(-1__no_interaction	2,4-dichlorophenol__ml(-1__no_interaction	dinitrophenol__ml(-1__no_interaction	2,4,6-trimethylphenol__ml(-1__no_interaction	2-chlorophenol__ml(-1__no_interaction	o-methylphenol__ml(-1__no_interaction	2-nitrophenol__ml(-1__no_interaction	m-methylphenol__ml(-1__no_interaction	phenol__ml(-1__no_interaction	4-chlorophenol__ml(-1__no_interaction	4-bromophenol__ml(-1__no_interaction	pentachlorophenol__ml(-1__no_interaction	3-aminophenol__ml(-1__no_interaction	2,4-dimethylphenol__ml(-1__no_interaction	4-nitrophenol__ml(-1__no_interaction
15374490-5	Our data show that <protein-id="P01308,I3WAC9">Insulin</protein-id> resistance calculated by the <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rate during a euglycemic hyperinsulinemic <compound-id="206,5793,64689,79025">glucose</compound-id> clamp procedure is significantly correlated with the <protein-id="P01308,I3WAC9">Insulin</protein-id>-mediated net decrease in erythrocyte Na+ content (r = 0.58, P &lt; 0.05), as well as with net increase in erythrocyte K+ (r = 0.64, P &lt; 0.05) and Mg2+ (r = 0.67, P &lt; 0.01) content and to basal diastolic blood pressure (r = -0.63, P &lt; 0.05).	glucose__Insulin__no_interaction
20531239-7	RESULTS: Adalimumab treatment significantly decreased serum amylase activity (AP, 2778.25 ± 298.80; AP + ADA, 2143.13 ± 221.69; control, 1541.00 ± 148.39; ADA, 1143.00 ± 256.30 U/L; P &lt; 0.001), <compound-id="612">lactate</compound-id> dehydrogenase activity (AP, 2978.37 ± 364.65; AP + ADA, 2582.75 ± 164.23; control 931.25 ± 135.93; ADA, 582.62 ± 99.37 U/L; P &lt; 0.001), <protein-id="D3ZGE2,A0A0G2K1A2">myeloperoxidase</protein-id> activity (AP, 1.44 ± 0.20; AP + ADA, 0.86 ± 0.01; control, 0.60 ± 0.17; ADA, 0.41 ± 0.00 U/g of wet tissue; P &lt; 0.001), <compound-id="10964">malondialdehyde</compound-id> activity (AP, 16.94 ± 3.98; AP + ADA, 7.66 ± 2.27; control, 9.07 ± 1.00; ADA, 3.58 ± 0.30 nmol/g; P &lt; 0.01), and total histopathologic scores (AP, 2.75 ± 0.16; AP + ADA, 1.50 ± 0.19; control, 0.00 ± 0.00; ADA, 0.00 ± 0.00; P &lt; 0.001).	malondialdehyde__myeloperoxidase__no_interaction	lactate__myeloperoxidase__no_interaction
9225998-5	In this article, we summarise recent studies demonstrating that (1) chronic HIV-1 infection of human myelomonoblastic <compound-id="5289162">PLB</compound-id>-985 cells leads to constitutive NF-kappa B activity, activated in part due to enhanced <protein-id="P25963">I kappa B alpha</protein-id> turnover and increased NF-kappa B/<protein-id="Q04864">Rel</protein-id> production; (2) HTLV-1 Tax protein physically associates with the <protein-id="P25963">I kappa B alpha</protein-id> protein in vivo and in vitro and also mediates a 20- to 40-fold stimulation of NF-kappa B DNA binding activity mediated via an enhancement of NF-kappa B dimer formation; (3) casein kinase II phosphorylates <protein-id="P25963">I kappa B alpha</protein-id> at multiple sites in the C-terminal PEST domains and regulates <protein-id="P25963">I kappa B alpha</protein-id> function; (4) transdominant forms of <protein-id="P25963">I kappa B alpha</protein-id>, mutated in critical <compound-id="5951">Ser</compound-id> or Thr residues required for inducer-mediated (S32A,S36A) and/or constitutive phosphorylation block HIV LTR trans-activation and also effectively inhibit HIV-1 multiplication in a single cycle infection model; and (5) the amino-terminal 55aa of <protein-id="P25963">I kappa B alpha</protein-id> (<compound-id="3250092">NIK</compound-id>) interacts with the human homologue of dynein light chain 1, a small 9-kDa human homologue of the dynein light chain protein involved in microtubule and cytoskeletal dynamics.	NIK__I kappa B alpha__no_interaction	NIK__Rel__no_interaction	PLB__I kappa B alpha__no_interaction	PLB__Rel__no_interaction	Ser__I kappa B alpha__no_interaction	Ser__Rel__no_interaction
24189104-3	Based on comprehensive surveys of the nine Cree Territory (Eeyou Istchee) communities in this region during the period 2002-2009, blood plasma concentrations are presented of <compound-id="38018">Aroclor 1260</compound-id>, <protein-id="P11498,A0A024R5C5">PCB</protein-id> congeners 28, 52, 99, 101, 105, 118, 128, 138, 153, 156, 163, 170, 180, 183, and 187, <compound-id="12310947,2087,222548,24860538,61103">Aldrin</compound-id>, ß-HCH, α-<compound-id="5993">Chlordane</compound-id>, γ-<compound-id="5993">Chlordane</compound-id>, oxy-<compound-id="12303020">Chlordane, trans-</compound-id><compound-id="23275328">Nonachlor</compound-id>, cis-<compound-id="23275328">Nonachlor</compound-id>, <compound-id="3036">p,p'-DDT</compound-id>, p,p'-<compound-id="3035">DDE</compound-id>, Hexachloro <compound-id="241">benzene</compound-id> (HCB), <compound-id="16945">Mirex</compound-id>, <compound-id="158629,5289112">PBB</compound-id> 153, PBDE 47, <compound-id="36159">PBDE 99</compound-id>, <compound-id="154083">PBDE 100</compound-id>, <compound-id="155166">PBDE 153</compound-id>, <compound-id="5284469">Toxaphene</compound-id> 26, and <compound-id="5284469">Toxaphene</compound-id> 50.	Chlordane, trans-__PCB__no_interaction	benzene__PCB__no_interaction	PBDE 100__PCB__no_interaction	PBDE 99__PCB__no_interaction	PBDE 153__PCB__no_interaction	PBB__PCB__no_interaction	p,p'-DDT__PCB__no_interaction	Toxaphene__PCB__no_interaction	Chlordane__PCB__no_interaction	DDE__PCB__no_interaction	Nonachlor__PCB__no_interaction	Mirex__PCB__no_interaction	Aroclor 1260__PCB__no_interaction	Aldrin__PCB__no_interaction
11783633-4	Measured rate constants (in cm3 molecule(-1) s(-1) units) are OH radical reactions [OTNE, (9.85 +/- 0.88) x 10(-11); <compound-id="157326,6440618">acetyl cedrene</compound-id>, (7.7 +/- 1.6) x 10(-11); <compound-id="91497">HHCB</compound-id>, (2.6 +/- 0.6) x 10(-11); and <compound-id="96266">isochroman</compound-id>, (3.7 +/- 0.6) x 10(-11)], <protein-id="P41271,A0A087WTY6">NO3</protein-id> radical reactions [OTNE, (1.71 +/- 0.19) x 10(-11) and <compound-id="157326,6440618">acetyl cedrene</compound-id>, (4.1 +/- 1.0) x 10(-15)], and O3 reactions [OTNE, (2.1 +/- 0.5) x 10(-18) and <compound-id="157326,6440618">acetyl cedrene</compound-id>, &lt;2.2 x 10(-18)] where the error limits are two least-squares standard deviations.	acetyl cedrene__NO3__no_interaction	isochroman__NO3__no_interaction	HHCB__NO3__no_interaction
11714907-3	([R-(R*,R*)]-4[[2-[[3-(1H-<compound-id="798">Indole</compound-id>-3-yl)-2-methyl-1-oxo-2-[[tricyclo[3.3.1.1(3,7)]- <protein-id="Q99PV5,Q6L8F5,D3Z2G6">dec-2</protein-id>-yloxy)carbonyl[amino]propyl]amino]-<compound-id="137551">1-phenylethyl</compound-id>]amino]-<compound-id="1112">4-oxobutanoic acid</compound-id>) (CI-988; 100 nM) inhibited the ability of 10 nM <protein-id="P09240,Q8R041">CCK</protein-id>-8 to elevate cytosolic Ca(2+) in 1-[2-(<compound-id="16340557">5-carboxyoxazol-2-yl</compound-id>)-<compound-id="19959504">6-aminobenzofuran</compound-id>-5-oxy]-2-(2'-amino-5'-methylphenoxy)-<compound-id="6324">ethane</compound-id>-N,N,N',N'-<compound-id="57175139">tetraacetic acid acetoxymethyl ester</compound-id>-loaded NCI-H209 cells.	Indole__dec-2__no_interaction	Indole__CCK__no_interaction	5-carboxyoxazol-2-yl__dec-2__no_interaction	5-carboxyoxazol-2-yl__CCK__no_interaction	tetraacetic acid acetoxymethyl ester__dec-2__no_interaction	tetraacetic acid acetoxymethyl ester__CCK__no_interaction	ethane__dec-2__no_interaction	ethane__CCK__no_interaction	6-aminobenzofuran__dec-2__no_interaction	6-aminobenzofuran__CCK__no_interaction	1-phenylethyl__dec-2__no_interaction	1-phenylethyl__CCK__no_interaction	4-oxobutanoic acid__dec-2__no_interaction	4-oxobutanoic acid__CCK__no_interaction
8970998-6	However, further analyses revealed that (i) the EHV-1 <compound-id="56671814">vhs</compound-id> homolog gene, <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id>, was transcribed and translated into a 58-kDa protein in infected cells; (ii) the <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> protein was packaged into viral particles in amounts detectable in Western blots (immunoblots) with monoclonal antibodies; (iii) in cotransfection <compound-id="56671814">vhs</compound-id> activity assays, transiently-expressed <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> protein had intrinsic <compound-id="56671814">vhs</compound-id> activity comparable to that of wild-type HSV-1 <compound-id="56671814">vhs</compound-id>; and (iv) this intrinsic <compound-id="56671814">vhs</compound-id> activity was ablated by in vitro site-directed mutations in which either the functionally inactive HSV-1 vhs1 UL41 mutation (Thr at position 214 replaced by Ile [Thr-214--&gt;Ile]) was recreated within <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> or two conserved residues within the putative poly(A) binding region of the <protein-id="P28957,P84398,L8AYE0">ORF19</protein-id> sequence were altered (<compound-id="6057">Tyr</compound-id>-190, 192--&gt;Phe).	Tyr__ORF19__no_interaction	vhs__ORF19__no_interaction
24648846-3	ASM cells from people with and without asthma were stimulated with IL-1 β , TNF- α , and/or IFN γ and treated with <compound-id="774">histamine</compound-id> (1-100  μ M) ± <compound-id="2725,716121">chlorpheniramine</compound-id> (<protein-id="P35367">H1R</protein-id> antagonist; 1  μ M) or <compound-id="3001055,9883333">ranitidine</compound-id> (<protein-id="P25021">H2R</protein-id> antagonist; 50  μ M) or tryptase (1 nM) ± <compound-id="3033938,3910,439527,5284408,72429">leupeptin</compound-id> (serine protease inhibitor; 50  μ M), heat-inactivated tryptase, or vehicle for 4 h or 24 h. Human lung mast cells (MC) were isolated and activated with IgE/anti-IgE and supernatants were collected after 2 h or 24 h. The supernatants were added to ASM cells for 48 h and ASM cell <protein-id="P02778,A0A024RDA4">CXCL10</protein-id> production detected using ELISA (protein) and real-time PCR (mRNA).	chlorpheniramine__CXCL10__no_interaction	chlorpheniramine__H1R__no_interaction	chlorpheniramine__H2R__no_interaction	leupeptin__CXCL10__no_interaction	leupeptin__H1R__no_interaction	leupeptin__H2R__no_interaction	histamine__CXCL10__no_interaction	histamine__H1R__no_interaction	histamine__H2R__no_interaction	ranitidine__CXCL10__no_interaction	ranitidine__H1R__no_interaction	ranitidine__H2R__no_interaction
12074830-10	The levels of AuAb-oxLDL in patients were found to correlate with TAS, total <compound-id="5997">cholesterol</compound-id>, <protein-id="Q14746,B1ALW7">LDL-C</protein-id>, lipid <compound-id="784">hydroperoxide</compound-id> and erythrocyte <protein-id="P00441,V9HWC9">SOD</protein-id> activities (r = -0.62, p &lt; 0.01; r = 0.64, p &lt; 0.01; r = 0.55, p &lt; 0.01; r = 0.81, p &lt; 0.01; r = -0.63, p &lt; 0.01, respectively).	hydroperoxide__LDL-C__no_interaction	hydroperoxide__SOD__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__SOD__no_interaction
16352707-4	Here, we address the issue of physical dependence by comparing the <protein-id="P62812,Q544F7,Q3URD4">GABA(A)-alpha1</protein-id> affinity-selective drug <compound-id="5732">zolpidem</compound-id>, the novel compounds 7-(1,1-dimethylethyl)-6-(2-methyl-2H-<compound-id="9257">1,2,4-triazol</compound-id>-3-ylmethoxy)-3-(2,5-<compound-id="9706">difluorophenyl</compound-id>)-<compound-id="577392">1,2,4-triazolo[4,3-b]pyridazine</compound-id> (L-838,417) and 6-fluoro-9-methyl-2-phenyl-4-(<compound-id="31268">pyrrolidin</compound-id>-1-yl-carbonyl)-2,9-dihydro-1H-pyridol[3,4-b]indol-1-one (<compound-id="9908378">SL651498</compound-id>) with functional selectivity for certain non-alpha(1) GABA(A) receptors, nonselective partial agonists [<compound-id="107926">bretazenil</compound-id>, 1-[1-[3-(3-pyridyl)phenyl]benzimidazol-5-yl]<compound-id="177">ethanone</compound-id> O-ethyloxime (NS2710), and 5-furan-3-yl-1-(3-imidazol-1-phenyl)-1H-<compound-id="5798">benzoimidazole</compound-id> (NS2664)], and nonselective full efficacy benzodiazepines, in a rapid precipitated withdrawal assay using the inverse agonist N-methyl-<compound-id="13129465">beta-carboline-3-carboxamide</compound-id> (FG-7142).	1,2,4-triazol__GABA(A)-alpha1__no_interaction	bretazenil__GABA(A)-alpha1__no_interaction	pyrrolidin__GABA(A)-alpha1__no_interaction	beta-carboline-3-carboxamide__GABA(A)-alpha1__no_interaction	benzoimidazole__GABA(A)-alpha1__no_interaction	difluorophenyl__GABA(A)-alpha1__no_interaction	SL651498__GABA(A)-alpha1__no_interaction	ethanone__GABA(A)-alpha1__no_interaction	zolpidem__GABA(A)-alpha1__no_interaction	1,2,4-triazolo[4,3-b]pyridazine__GABA(A)-alpha1__no_interaction
22967099-8	Increased LF was significantly associated with <compound-id="18283">d4T</compound-id> (P = 0.006) and didanosine (<compound-id="50599">ddI</compound-id>) use (P = 0.007), months on <compound-id="18283">d4T</compound-id> (P = 0.001) and on ARV (P = 0.025), duration of HIV (P &lt; 0.0001) and HCV infections (P &lt; 0.0001), higher HIV (P = 0.03) and HCV loads (P &lt; 0.0001), presence of lipodystrophy (P = 0.02), male gender (P = 0.02), older age (P = 0.04), low nadir (P = 0.02) and current CD4(+) T-cells (P &lt; 0.0001), low gain of CD4(+) T-cells after HAART (P = 0.01) and higher <protein-id="P08253,A0A024R6R4">MMP-2</protein-id> (P = 0.02) and <protein-id="P16035">TIMP-2</protein-id> serum levels (P = 0.02).	ddI__TIMP-2__no_interaction	ddI__MMP-2__no_interaction	d4T__TIMP-2__no_interaction	d4T__MMP-2__no_interaction
11927221-8	Patients with partially decompressed ventricles (n = 13, LVEDD = 4.8 +/- 1.0 cm) as compared to those with fully decompressed ventricles (n = 10, LVEDD = 3.0 +/- 0.3 cm) demonstrated significant improvements in: peak <compound-id="977">oxygen</compound-id> consumption (16.8 +/- 4.3 versus 12.8 +/- 3.0 ml/kg.min), native left ventricular index during exercise (2.5 +/- 1.4 versus 0.8 +/- 0.8 liters/min.m(2)); ability to exercise with the device weaned (10 of 13 versus 1 of 10 patients); resting myocardial blood flow (0.55 +/- 0.11 versus 0.21 +/- 0.13 ml/g.min); and myocardial <compound-id="977">oxygen</compound-id> consumption (0.04 +/- 0.01 versus 0.02 +/- 0.001 <protein-id="P13987,Q6FHM9">min-1</protein-id>) (all p &lt; 0.05).	oxygen__min-1__no_interaction
19489246-6	RESULTS: Compared with group C [size of area at risk (41.5 +/- 1.0)%, infarct size (45.5 +/- 1.0)%, expression of <protein-id="P55213">Caspase-3</protein-id> (5.87 +/- 0.29), percentage of apoptotic cardiomyocytes (26.8 +/- 1.3)%, level of phosphorylated Akt (10.8 +/- 1.9)%], <compound-id="4943">propofol</compound-id> 1 mg/kg and 2 mg/kg significantly reduced the size of area at risk and infarct size [size of area at risk (38.3 +/- 1.0)% and (37.3 +/- 1.2)%; infarct size (33.8 +/- 1.2)% and (30.2 +/- 1.7)%, P &lt; 0.05], inhibited the expression of <protein-id="P55213">Caspase-3</protein-id> (1.50 +/- 0.36 and 1.48 +/- 0.30, P &lt; 0.05), decreased the percentage of apoptotic cardiomyocytes [(16.3 +/- 1.2)% and (16.5 +/- 1.0)%, P &lt; 0.05] and promoted the phosphorylation of Akt [(68.7 +/- 4.0)% and (58.3 +/- 2.8)%, P &lt; 0.05].	propofol__Caspase-3__no_interaction
7991622-5	Antagonists [Ibu0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-28) <compound-id="213604">Agm</compound-id> (MZ-4-71), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-28) <compound-id="213604">Agm</compound-id> (MZ-4-243), [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]<protein-id="P01286">hGHRH</protein-id>-(1-29) NH2 (MZ-4-169), [Nac0-His1,D-Arg2,Phe(4-Cl)6,Abu15,Nle27]-hGH RH-(1-29)NH2 (MZ-4-181), and [Nac0,D-Arg2,Phe(4-Cl)6,Abu15,Nle27,Asp28]hGH RH-(1-28)<compound-id="213604">Agm</compound-id> (MZ-4-209) inhibited GH release at 3 x 10(-9) M. Among these peptides, MZ-4-243, MZ-4-169, and MZ-4-181 were also long acting in vitro.	Agm__hGHRH__no_interaction
20598432-6	No significant between-group differences were observed at the brachial, or axillary, artery for FMD (brachial: <protein-id="P49747">COMP</protein-id>: mean (SD) 6.2 (3.1)%, NONCOMP: 6.1 (3.5)%, p = 0.967, axillary: <protein-id="P49747">COMP</protein-id>: 8.0 (5.5)%, NONCOMP: 9.0 (3.6)%, p = 0.602), CADC (brachial: <protein-id="P49747">COMP</protein-id>: 10.4 (3.4)%, NONCOMP: 10.4 (5.4)%, p = 0.999, axillary: <protein-id="P49747">COMP</protein-id>: 9.6 (4.2)%, NONCOMP: 8.5 (3.2)%, p = 0.492), GTN-induced vasodilation (brachial: <protein-id="P49747">COMP</protein-id>: 17.9 (5.1)%, NONCOMP:14.1 (7.2)%, p = 0.173, axillary: <protein-id="P49747">COMP</protein-id>: 9.5 (4.3)%, NONCOMP: 7.7 (3.1)%, p = 0.302) or <compound-id="447041">IMT</compound-id> (brachial: p = 0.084, axillary: p = 0.581).	IMT__COMP__no_interaction
3887103-5	<compound-id="206,5793,64689,79025">Glucose</compound-id> uptake during the last 30 minutes of each clamp were consistently lower in uremic patients pre-dialysis than in controls (2.3 +/- 0.3 v 6.6 +/- 0.8 mg X kg-1 X min, 7.8 +/- 0.6 v 13.2 +/- 1.1 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id> and 9.6 +/- 0.7 v 15.5 +/- 1.0 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>, all P less than 0.001).	Glucose__X kg-1 X min-1__no_interaction
22247364-10	Age at onset of AS (p = 0.001), Bath AS Disease Activity Index (p = 0.002), AS Disease Activity Score (ASDAS) erythrocyte sedimentation rate (ESR; p = 0.047), ASDAS C-reactive protein (<protein-id="P02741">CRP</protein-id>; p = 0.012), Bath AS Functional Index (p = 0.008), global spine visual analog scale for pain (p = 0.000), Schober index (p = 0.039), Bath AS Metrology Index (p = 0.028), modified Stoke Ankylosing Spondylitis Spine Score (p = 0.035), and high ESR (p = 0.001) and <protein-id="P02741">CRP</protein-id> (p = 0.000) were correlated with high <compound-id="447041">IMT</compound-id> in patients with AS.	IMT__CRP__no_interaction
6349384-6	With the preprogrammed insulin infusions used to normalize plasma <compound-id="206,5793,64689,79025">glucose</compound-id> profiles to the intraduodenal <compound-id="206,5793,64689,79025">glucose</compound-id> load, all hormonal and metabolic responses were normalized during intraportal infusion (IRI, 72.5 +/- 4.2 microU/ml; <protein-id="P29794">glucagon</protein-id>, 66 +/- 10 pg/ml; <compound-id="612">lactate</compound-id>, 1.06 +/- 0.10 mmol/liter; <compound-id="5950">alanine</compound-id>, 0.251 +/- 0.042 mmol/liter; <compound-id="24759880,753">glycerol</compound-id>, 0.043 +/- 0.013 mmol/liter; NEFA, 0.24 +/- 0.03 mmol/liter; and <compound-id="441">3-hydroxybutyrate</compound-id>, 0.012 +/- 0.007 mmol/liter) but marked hyperinsulinemia (103.2 +/- 6.1 microU/ml) and depressed <compound-id="24759880,753">glycerol</compound-id>, NEFA, and <compound-id="441">3-hydroxybutyrate</compound-id> responses at 2 h (0.056 +/- 0.005, 0.52 +/- 0.10, and 0.019 +/- 0.010 mmol/liter, respectively) resulted during peripheral infusion.	lactate__glucagon__no_interaction	alanine__glucagon__no_interaction	glycerol__glucagon__no_interaction	3-hydroxybutyrate__glucagon__no_interaction	glucose__glucagon__no_interaction
1317517-4	Scatchard analysis of competitive inhibition of 125I <protein-id="P05305,Q6FH53">Et1</protein-id> binding gave the following results (m +/- <compound-id="5289348">SEM</compound-id>, n = 3): isolated glomeruli, Kd = 4.2 +/- 2.1 x 10(-10) M, Bmax = 8.1 +/- 1.2 x 10(10) sites/mg protein; mesangial cells, Kd = 5.2 +/- 1.5 x 10(-10) M, Bmax = 1.87 +/- 0.49 x 10(4) sites/cell; epithelial cells, Kd = 7.2 +/- 1.5 x 10(-10) M, Bmax = 2.46 +/- 0.15 x 10(4) sites/cell.	SEM__Et1__no_interaction
16318777-2	METHODS: Cultured HSC-T6 cells were randomly divided into 7 groups: Sham control group, <protein-id="P05305,Q6FH53">ET-1</protein-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id>), <compound-id="16219006,443289,52943236">BQ-123</compound-id> group [1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id>, a selective <protein-id="P25101">endothelin receptor A</protein-id> (<protein-id="P25101">ETRA</protein-id>) antagonist], <compound-id="5311032,44283453">BQ-788</compound-id> group [1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>, a selective <protein-id="P24530,A0A024R645,A0A024R638">endothelin receptor B</protein-id> (<protein-id="P24530,A0A024R645,A0A024R638">ETRB</protein-id>) antagonist], <protein-id="P05305,Q6FH53">ET-1</protein-id> + BQ123 group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id>), <protein-id="P05305,Q6FH53">ET-1</protein-id> + <compound-id="5311032,44283453">BQ-788</compound-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>) and <protein-id="P05305,Q6FH53">ET-1</protein-id> + <compound-id="5311032,44283453">BQ-788</compound-id> group (10 nmol/L <protein-id="P05305,Q6FH53">ET-1</protein-id> + 1 micromol/L <compound-id="16219006,443289,52943236">BQ-123</compound-id> + 1 micromol/L <compound-id="5311032,44283453">BQ-788</compound-id>).	BQ-788__endothelin receptor A__no_interaction	BQ-788__ET-1__no_interaction	BQ-788__endothelin receptor B__no_interaction	BQ-788__ETRA__no_interaction	BQ-788__ETRB__no_interaction	BQ-123__endothelin receptor A__no_interaction	BQ-123__ET-1__no_interaction	BQ-123__endothelin receptor B__no_interaction	BQ-123__ETRA__no_interaction	BQ-123__ETRB__no_interaction
1835351-4	MAIN RESULTS: 1) The relative wall thickness (h/r) shows a normal distribution: mean = 0.39; SD = 0.08; 1st quartile = 0.33; 3rd = 0.43; 2) The septal/posterior wall ratio (ST/PWT) shows also a normal distribution: mean = 1.14; SD = 0.24; 1st quartile = 1; 3rd = 1.3; 3) Among patients with LVH (Devereux's criteria, n = 65) the 6 patients with h/r less than or equal to 0.33 are significantly different from the 18 patients with h/r greater than or equal to 0.43 for age (44 +/- 8 vs 51 +/- 10; p less than 0.03), casual (146 +/- 7 vs 166 +/- 13 mmHg; p less than 0.05) and ambulatory <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> (135 +/- 19 vs 146 +/- 16 mmHg; p less than 0.05), peak systolic stress (280 +/- 15 vs 187 +/- 31 Dynes/cm2; p less than 0.001) and E/A ratio (1.17 +/- 0.01 vs 0.94 +/- 0.27; p less than 0.05) but not for <compound-id="3337">ponderal</compound-id> excess.	ponderal__SBP__no_interaction
16784955-4	In these patients, the serum <protein-id="P23560,A0A0E3SU01">BDNF</protein-id> level showed positive correlation with the body mass index (r = 0.535, P &lt; .01), the percentage of body fat (r = 0.552, P &lt; .01), the subcutaneous fat area based on computed tomography scan (r = 0.480, P &lt; .05), the triglyceride level (r = 0.470, P &lt; .05), the fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> level (r = 0.437, P &lt; .05), and the homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance score (r = 0.506, P &lt; .05), whereas it showed a negative correlation with age (r = -0.486, P &lt; .05).	glucose__BDNF__no_interaction	glucose__insulin__no_interaction
7768892-3	As <protein-id="P04638">apoA-II</protein-id> was progressively substituted for apoA-I in HDL3 (A-II:A-I+A-II percentage mass: 29.5, 47.6, 71.5, 97.4, and 98.9%), the rate of <compound-id="5997">cholesterol</compound-id> efflux from Fu5AH hepatoma gradually and significantly decreased after 2 or 4 h of incubation at 37 degrees C (<compound-id="5997">cholesterol</compound-id> efflux: 30.4 +/- 0.8, 24.1 +/- 1.0, 19.8 +/- 1.2, 15.7 +/- 1.4, and 13.4 +/- 1.3%/2h, respectively; 38.4 +/- 1.5, 29.2 +/- 0.9, 27.0 +/- 0.2, 20.4 +/- 0.4, and 17.5 +/- 1.0%/4h, respectively) (p &lt; 0.01 with all A-II-enriched HDL3 fractions as compared with non-enriched homologues).	cholesterol__apoA-II__no_interaction
18040531-1	(-)-Epigallocatechin gallate, [<compound-id="167082">188Re</compound-id>]-P2045, 12B75, 89-12; <compound-id="441300">Abacavir sulfate</compound-id>/<compound-id="60825">lamivudine</compound-id>, Abatacept, <compound-id="9821849">Abiraterone acetate</compound-id>, ABT-869, Adalimumab, Ad-rh Endostatin, <compound-id="15942654">AI</compound-id>-700, Alemtuzumab, <compound-id="5488548">Alvimopan hydrate</compound-id>, <compound-id="3035016">Amrubicin</compound-id> hydrochloride, AP-12009, <compound-id="72231">Apomab</compound-id> 7.3, <compound-id="3083544">Arformoterol tartrate</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, AS-1404, <compound-id="9444">Azacitidine</compound-id>, <compound-id="10302451">AZD-0530</compound-id>; Bevacizumab, BHT-3009, <compound-id="71340">Biapenem</compound-id>, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, <compound-id="9941379">Bremelanotide</compound-id>; <protein-id="Q16790">CA9</protein-id>-SCAN, Calcitonin gene-related peptide, <compound-id="156414">Canertinib dihydrochloride</compound-id>, Cannabidiol, <compound-id="108144">Carboxyamidotriazole</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">Caspofungin acetate</compound-id>, <compound-id="60734">Celgosivir</compound-id>, Certolizumab pegol, <compound-id="156419">Cinacalcet hydrochloride</compound-id>, <compound-id="73115">Clevudine</compound-id>, CP-751871, <compound-id="969516">Curcumin</compound-id>, Cx-401, <compound-id="9962928">Cypher</compound-id>; <compound-id="213039">Darunavir</compound-id>, <compound-id="451668">Decitabine</compound-id>, <compound-id="11520894,23724531,53486198,71296108,71752077,72734349,74787553,86289926">Deforolimus</compound-id>, Dexamet, <compound-id="3108">Dipyridamole</compound-id>/<compound-id="5755">prednisolone</compound-id>, <compound-id="68873">Drospirenone</compound-id>, <compound-id="68873">Drospirenone</compound-id>/<compound-id="5757">estradiol</compound-id>, DTPw-<compound-id="4177956">HepB</compound-id>-Hib, <compound-id="60835">Duloxetine</compound-id> hydrochloride; Efalizumab, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="176870">Erlotinib</compound-id> hydrochloride, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="969472">Eszopiclone</compound-id>; Ferumoxtran-10, Ferumoxytol, <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="219090">Fosaprepitant dimeglumine</compound-id>; gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">Gefitinib</compound-id>, <compound-id="5280961">Genistein</compound-id>, <compound-id="44576256">Ghrelin</compound-id> (human), <compound-id="9577124">Gimatecan</compound-id>, <protein-id="P04141">GM-CSF</protein-id> PMED, Golimumab, <protein-id="P40967">gp100</protein-id> PMED; <compound-id="5291">Imatinib mesylate</compound-id>, Immunoglobulin intravenous (human), IV Gamma-globulin; <compound-id="56842232">LA-419</compound-id>, <compound-id="9867642">Laropiprant</compound-id>, L-<compound-id="15991548">BLP</compound-id>-25, <compound-id="6047">Levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, <compound-id="9911821">Lidocaine/prilocaine</compound-id>, <compound-id="11980957">Lopinavir/ritonavir</compound-id>, <compound-id="151166">Lumiracoxib</compound-id>, LY-2076962; <compound-id="56603701">Mepolizumab</compound-id>, <compound-id="5361918">Methylnaltrexone</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="121891">Mitiglinide calcium hydrate</compound-id>, <compound-id="4272">Mycophenolic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt, <compound-id="531641">Myristyl nicotinate</compound-id>; Natalizumab, Nesiritide, <compound-id="53232">Niacin/lovastatin</compound-id>; <compound-id="71587613">Oblimersen sodium</compound-id>, <compound-id="6918251">Ofatumumab</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, Ozarelix; <compound-id="6337614">Palonosetron hydrochloride</compound-id>, <protein-id="P01270">Parathyroid hormone</protein-id> (human recombinant), <compound-id="10113978">Pazopanib hydrochloride</compound-id>, <compound-id="158786">Pegaptanib octasodium</compound-id>, Pegfilgrastim, Peginterferon alfa- 2a, Peginterferon alfa-2b, Pegvisomant, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, Pexelizumab, <compound-id="7975">Picoplatin</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="468595">Posaconazole</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, PRO-1762, <compound-id="12419,169870">Progesterone caproate</compound-id>, <compound-id="65947">Prulifloxacin</compound-id>; <compound-id="208902">Ramelteon</compound-id>, <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, <compound-id="9838712">Reparixin</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">Rosuvastatin calcium</compound-id>; <compound-id="59227">Rotigotine</compound-id>; <compound-id="6918220">Satraplatin</compound-id>, Sertraline, Sipuleucel-T, SLIT-cisplatin, <compound-id="4261">SNDX-275</compound-id>, <compound-id="154059">Solifenacin succinate</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="5311424">Talnetant</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, Taxus, <compound-id="5362436">Tegaserod maleate</compound-id>, <compound-id="65999">Telmisartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="5282497">Tenofovir disoproxil fumarate/emtricitabine</compound-id>, Teriparatide, tgAAC-94, <compound-id="5487427">Tiotropium bromide</compound-id>, Tocilizumab, <compound-id="216237">Tolvaptan</compound-id>, <compound-id="5578">Trimethoprim</compound-id>; <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>, <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="10629256,157688,6918295">Vinflunine</compound-id>, <compound-id="71616">Voriconazole</compound-id>, <compound-id="5494449">VX-680</compound-id>; XL-880; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>.	Clevudine__CA9__no_interaction	Clevudine__gp100__no_interaction	Clevudine__GM-CSF__no_interaction	Clevudine__Parathyroid hormone__no_interaction	Gefitinib__CA9__no_interaction	Gefitinib__gp100__no_interaction	Gefitinib__GM-CSF__no_interaction	Gefitinib__Parathyroid hormone__no_interaction	Cinacalcet hydrochloride__CA9__no_interaction	Cinacalcet hydrochloride__gp100__no_interaction	Cinacalcet hydrochloride__GM-CSF__no_interaction	Cinacalcet hydrochloride__Parathyroid hormone__no_interaction	Genistein__CA9__no_interaction	Genistein__gp100__no_interaction	Genistein__GM-CSF__no_interaction	Genistein__Parathyroid hormone__no_interaction	Fondaparinux sodium__CA9__no_interaction	Fondaparinux sodium__gp100__no_interaction	Fondaparinux sodium__GM-CSF__no_interaction	Fondaparinux sodium__Parathyroid hormone__no_interaction	Rotigotine__CA9__no_interaction	Rotigotine__gp100__no_interaction	Rotigotine__GM-CSF__no_interaction	Rotigotine__Parathyroid hormone__no_interaction	Ranelic acid distrontium salt__CA9__no_interaction	Ranelic acid distrontium salt__gp100__no_interaction	Ranelic acid distrontium salt__GM-CSF__no_interaction	Ranelic acid distrontium salt__Parathyroid hormone__no_interaction	Tolvaptan__CA9__no_interaction	Tolvaptan__gp100__no_interaction	Tolvaptan__GM-CSF__no_interaction	Tolvaptan__Parathyroid hormone__no_interaction	sodium__CA9__no_interaction	sodium__gp100__no_interaction	sodium__GM-CSF__no_interaction	sodium__Parathyroid hormone__no_interaction	Pegaptanib octasodium__CA9__no_interaction	Pegaptanib octasodium__gp100__no_interaction	Pegaptanib octasodium__GM-CSF__no_interaction	Pegaptanib octasodium__Parathyroid hormone__no_interaction	Sunitinib malate__CA9__no_interaction	Sunitinib malate__gp100__no_interaction	Sunitinib malate__GM-CSF__no_interaction	Sunitinib malate__Parathyroid hormone__no_interaction	Tegaserod maleate__CA9__no_interaction	Tegaserod maleate__gp100__no_interaction	Tegaserod maleate__GM-CSF__no_interaction	Tegaserod maleate__Parathyroid hormone__no_interaction	Niacin/lovastatin__CA9__no_interaction	Niacin/lovastatin__gp100__no_interaction	Niacin/lovastatin__GM-CSF__no_interaction	Niacin/lovastatin__Parathyroid hormone__no_interaction	prednisolone__CA9__no_interaction	prednisolone__gp100__no_interaction	prednisolone__GM-CSF__no_interaction	prednisolone__Parathyroid hormone__no_interaction	Levodopa__CA9__no_interaction	Levodopa__gp100__no_interaction	Levodopa__GM-CSF__no_interaction	Levodopa__Parathyroid hormone__no_interaction	Picoplatin__CA9__no_interaction	Picoplatin__gp100__no_interaction	Picoplatin__GM-CSF__no_interaction	Picoplatin__Parathyroid hormone__no_interaction	Drospirenone__CA9__no_interaction	Drospirenone__gp100__no_interaction	Drospirenone__GM-CSF__no_interaction	Drospirenone__Parathyroid hormone__no_interaction	Olmesartan medoxomil__CA9__no_interaction	Olmesartan medoxomil__gp100__no_interaction	Olmesartan medoxomil__GM-CSF__no_interaction	Olmesartan medoxomil__Parathyroid hormone__no_interaction	Bosentan__CA9__no_interaction	Bosentan__gp100__no_interaction	Bosentan__GM-CSF__no_interaction	Bosentan__Parathyroid hormone__no_interaction	Dipyridamole__CA9__no_interaction	Dipyridamole__gp100__no_interaction	Dipyridamole__GM-CSF__no_interaction	Dipyridamole__Parathyroid hormone__no_interaction	Tadalafil__CA9__no_interaction	Tadalafil__gp100__no_interaction	Tadalafil__GM-CSF__no_interaction	Tadalafil__Parathyroid hormone__no_interaction	Vardenafil hydrochloride hydrate__CA9__no_interaction	Vardenafil hydrochloride hydrate__gp100__no_interaction	Vardenafil hydrochloride hydrate__GM-CSF__no_interaction	Vardenafil hydrochloride hydrate__Parathyroid hormone__no_interaction	Satraplatin__CA9__no_interaction	Satraplatin__gp100__no_interaction	Satraplatin__GM-CSF__no_interaction	Satraplatin__Parathyroid hormone__no_interaction	90Y__CA9__no_interaction	90Y__gp100__no_interaction	90Y__GM-CSF__no_interaction	90Y__Parathyroid hormone__no_interaction	Tiotropium bromide__CA9__no_interaction	Tiotropium bromide__gp100__no_interaction	Tiotropium bromide__GM-CSF__no_interaction	Tiotropium bromide__Parathyroid hormone__no_interaction	HepB__CA9__no_interaction	HepB__gp100__no_interaction	HepB__GM-CSF__no_interaction	HepB__Parathyroid hormone__no_interaction	Ramelteon__CA9__no_interaction	Ramelteon__gp100__no_interaction	Ramelteon__GM-CSF__no_interaction	Ramelteon__Parathyroid hormone__no_interaction	Vatalanib__CA9__no_interaction	Vatalanib__gp100__no_interaction	Vatalanib__GM-CSF__no_interaction	Vatalanib__Parathyroid hormone__no_interaction	VX-680__CA9__no_interaction	VX-680__gp100__no_interaction	VX-680__GM-CSF__no_interaction	VX-680__Parathyroid hormone__no_interaction	Arformoterol tartrate__CA9__no_interaction	Arformoterol tartrate__gp100__no_interaction	Arformoterol tartrate__GM-CSF__no_interaction	Arformoterol tartrate__Parathyroid hormone__no_interaction	Pregabalin__CA9__no_interaction	Pregabalin__gp100__no_interaction	Pregabalin__GM-CSF__no_interaction	Pregabalin__Parathyroid hormone__no_interaction	Eszopiclone__CA9__no_interaction	Eszopiclone__gp100__no_interaction	Eszopiclone__GM-CSF__no_interaction	Eszopiclone__Parathyroid hormone__no_interaction	Azacitidine__CA9__no_interaction	Azacitidine__gp100__no_interaction	Azacitidine__GM-CSF__no_interaction	Azacitidine__Parathyroid hormone__no_interaction	Yttrium__CA9__no_interaction	Yttrium__gp100__no_interaction	Yttrium__GM-CSF__no_interaction	Yttrium__Parathyroid hormone__no_interaction	Prulifloxacin__CA9__no_interaction	Prulifloxacin__gp100__no_interaction	Prulifloxacin__GM-CSF__no_interaction	Prulifloxacin__Parathyroid hormone__no_interaction	Methylnaltrexone__CA9__no_interaction	Methylnaltrexone__gp100__no_interaction	Methylnaltrexone__GM-CSF__no_interaction	Methylnaltrexone__Parathyroid hormone__no_interaction	AZD-0530__CA9__no_interaction	AZD-0530__gp100__no_interaction	AZD-0530__GM-CSF__no_interaction	AZD-0530__Parathyroid hormone__no_interaction	SNDX-275__CA9__no_interaction	SNDX-275__gp100__no_interaction	SNDX-275__GM-CSF__no_interaction	SNDX-275__Parathyroid hormone__no_interaction	estradiol__CA9__no_interaction	estradiol__gp100__no_interaction	estradiol__GM-CSF__no_interaction	estradiol__Parathyroid hormone__no_interaction	Mepolizumab__CA9__no_interaction	Mepolizumab__gp100__no_interaction	Mepolizumab__GM-CSF__no_interaction	Mepolizumab__Parathyroid hormone__no_interaction	Cypher__CA9__no_interaction	Cypher__gp100__no_interaction	Cypher__GM-CSF__no_interaction	Cypher__Parathyroid hormone__no_interaction	Darunavir__CA9__no_interaction	Darunavir__gp100__no_interaction	Darunavir__GM-CSF__no_interaction	Darunavir__Parathyroid hormone__no_interaction	Lumiracoxib__CA9__no_interaction	Lumiracoxib__gp100__no_interaction	Lumiracoxib__GM-CSF__no_interaction	Lumiracoxib__Parathyroid hormone__no_interaction	BLP__CA9__no_interaction	BLP__gp100__no_interaction	BLP__GM-CSF__no_interaction	BLP__Parathyroid hormone__no_interaction	Voriconazole__CA9__no_interaction	Voriconazole__gp100__no_interaction	Voriconazole__GM-CSF__no_interaction	Voriconazole__Parathyroid hormone__no_interaction	Pazopanib hydrochloride__CA9__no_interaction	Pazopanib hydrochloride__gp100__no_interaction	Pazopanib hydrochloride__GM-CSF__no_interaction	Pazopanib hydrochloride__Parathyroid hormone__no_interaction	Caspofungin acetate__CA9__no_interaction	Caspofungin acetate__gp100__no_interaction	Caspofungin acetate__GM-CSF__no_interaction	Caspofungin acetate__Parathyroid hormone__no_interaction	Decitabine__CA9__no_interaction	Decitabine__gp100__no_interaction	Decitabine__GM-CSF__no_interaction	Decitabine__Parathyroid hormone__no_interaction	Escitalopram oxalate__CA9__no_interaction	Escitalopram oxalate__gp100__no_interaction	Escitalopram oxalate__GM-CSF__no_interaction	Escitalopram oxalate__Parathyroid hormone__no_interaction	Progesterone caproate__CA9__no_interaction	Progesterone caproate__gp100__no_interaction	Progesterone caproate__GM-CSF__no_interaction	Progesterone caproate__Parathyroid hormone__no_interaction	Curcumin__CA9__no_interaction	Curcumin__gp100__no_interaction	Curcumin__GM-CSF__no_interaction	Curcumin__Parathyroid hormone__no_interaction	succinate__CA9__no_interaction	succinate__gp100__no_interaction	succinate__GM-CSF__no_interaction	succinate__Parathyroid hormone__no_interaction	Alvimopan hydrate__CA9__no_interaction	Alvimopan hydrate__gp100__no_interaction	Alvimopan hydrate__GM-CSF__no_interaction	Alvimopan hydrate__Parathyroid hormone__no_interaction	188Re__CA9__no_interaction	188Re__gp100__no_interaction	188Re__GM-CSF__no_interaction	188Re__Parathyroid hormone__no_interaction	Fosaprepitant dimeglumine__CA9__no_interaction	Fosaprepitant dimeglumine__gp100__no_interaction	Fosaprepitant dimeglumine__GM-CSF__no_interaction	Fosaprepitant dimeglumine__Parathyroid hormone__no_interaction	Abiraterone acetate__CA9__no_interaction	Abiraterone acetate__gp100__no_interaction	Abiraterone acetate__GM-CSF__no_interaction	Abiraterone acetate__Parathyroid hormone__no_interaction	Amrubicin__CA9__no_interaction	Amrubicin__gp100__no_interaction	Amrubicin__GM-CSF__no_interaction	Amrubicin__Parathyroid hormone__no_interaction	Mycophenolic acid__CA9__no_interaction	Mycophenolic acid__gp100__no_interaction	Mycophenolic acid__GM-CSF__no_interaction	Mycophenolic acid__Parathyroid hormone__no_interaction	Gimatecan__CA9__no_interaction	Gimatecan__gp100__no_interaction	Gimatecan__GM-CSF__no_interaction	Gimatecan__Parathyroid hormone__no_interaction	Reparixin__CA9__no_interaction	Reparixin__gp100__no_interaction	Reparixin__GM-CSF__no_interaction	Reparixin__Parathyroid hormone__no_interaction	Myristyl nicotinate__CA9__no_interaction	Myristyl nicotinate__gp100__no_interaction	Myristyl nicotinate__GM-CSF__no_interaction	Myristyl nicotinate__Parathyroid hormone__no_interaction	Lopinavir/ritonavir__CA9__no_interaction	Lopinavir/ritonavir__gp100__no_interaction	Lopinavir/ritonavir__GM-CSF__no_interaction	Lopinavir/ritonavir__Parathyroid hormone__no_interaction	bromide__CA9__no_interaction	bromide__gp100__no_interaction	bromide__GM-CSF__no_interaction	bromide__Parathyroid hormone__no_interaction	Celgosivir__CA9__no_interaction	Celgosivir__gp100__no_interaction	Celgosivir__GM-CSF__no_interaction	Celgosivir__Parathyroid hormone__no_interaction	Deforolimus__CA9__no_interaction	Deforolimus__gp100__no_interaction	Deforolimus__GM-CSF__no_interaction	Deforolimus__Parathyroid hormone__no_interaction	Pemetrexed disodium__CA9__no_interaction	Pemetrexed disodium__gp100__no_interaction	Pemetrexed disodium__GM-CSF__no_interaction	Pemetrexed disodium__Parathyroid hormone__no_interaction	Imatinib mesylate__CA9__no_interaction	Imatinib mesylate__gp100__no_interaction	Imatinib mesylate__GM-CSF__no_interaction	Imatinib mesylate__Parathyroid hormone__no_interaction	Mitiglinide calcium hydrate__CA9__no_interaction	Mitiglinide calcium hydrate__gp100__no_interaction	Mitiglinide calcium hydrate__GM-CSF__no_interaction	Mitiglinide calcium hydrate__Parathyroid hormone__no_interaction	Posaconazole__CA9__no_interaction	Posaconazole__gp100__no_interaction	Posaconazole__GM-CSF__no_interaction	Posaconazole__Parathyroid hormone__no_interaction	Bremelanotide__CA9__no_interaction	Bremelanotide__gp100__no_interaction	Bremelanotide__GM-CSF__no_interaction	Bremelanotide__Parathyroid hormone__no_interaction	Rosuvastatin calcium__CA9__no_interaction	Rosuvastatin calcium__gp100__no_interaction	Rosuvastatin calcium__GM-CSF__no_interaction	Rosuvastatin calcium__Parathyroid hormone__no_interaction	Oblimersen sodium__CA9__no_interaction	Oblimersen sodium__gp100__no_interaction	Oblimersen sodium__GM-CSF__no_interaction	Oblimersen sodium__Parathyroid hormone__no_interaction	Canertinib dihydrochloride__CA9__no_interaction	Canertinib dihydrochloride__gp100__no_interaction	Canertinib dihydrochloride__GM-CSF__no_interaction	Canertinib dihydrochloride__Parathyroid hormone__no_interaction	Duloxetine__CA9__no_interaction	Duloxetine__gp100__no_interaction	Duloxetine__GM-CSF__no_interaction	Duloxetine__Parathyroid hormone__no_interaction	Pimecrolimus__CA9__no_interaction	Pimecrolimus__gp100__no_interaction	Pimecrolimus__GM-CSF__no_interaction	Pimecrolimus__Parathyroid hormone__no_interaction	Tanespimycin__CA9__no_interaction	Tanespimycin__gp100__no_interaction	Tanespimycin__GM-CSF__no_interaction	Tanespimycin__Parathyroid hormone__no_interaction	Talnetant__CA9__no_interaction	Talnetant__gp100__no_interaction	Talnetant__GM-CSF__no_interaction	Talnetant__Parathyroid hormone__no_interaction	Ghrelin__CA9__no_interaction	Ghrelin__gp100__no_interaction	Ghrelin__GM-CSF__no_interaction	Ghrelin__Parathyroid hormone__no_interaction	hydrochlorothiazide__CA9__no_interaction	hydrochlorothiazide__gp100__no_interaction	hydrochlorothiazide__GM-CSF__no_interaction	hydrochlorothiazide__Parathyroid hormone__no_interaction	Telmisartan__CA9__no_interaction	Telmisartan__gp100__no_interaction	Telmisartan__GM-CSF__no_interaction	Telmisartan__Parathyroid hormone__no_interaction	Solifenacin succinate__CA9__no_interaction	Solifenacin succinate__gp100__no_interaction	Solifenacin succinate__GM-CSF__no_interaction	Solifenacin succinate__Parathyroid hormone__no_interaction	Erlotinib__CA9__no_interaction	Erlotinib__gp100__no_interaction	Erlotinib__GM-CSF__no_interaction	Erlotinib__Parathyroid hormone__no_interaction	LA-419__CA9__no_interaction	LA-419__gp100__no_interaction	LA-419__GM-CSF__no_interaction	LA-419__Parathyroid hormone__no_interaction	Trimethoprim__CA9__no_interaction	Trimethoprim__gp100__no_interaction	Trimethoprim__GM-CSF__no_interaction	Trimethoprim__Parathyroid hormone__no_interaction	Laropiprant__CA9__no_interaction	Laropiprant__gp100__no_interaction	Laropiprant__GM-CSF__no_interaction	Laropiprant__Parathyroid hormone__no_interaction	Biapenem__CA9__no_interaction	Biapenem__gp100__no_interaction	Biapenem__GM-CSF__no_interaction	Biapenem__Parathyroid hormone__no_interaction	Palonosetron hydrochloride__CA9__no_interaction	Palonosetron hydrochloride__gp100__no_interaction	Palonosetron hydrochloride__GM-CSF__no_interaction	Palonosetron hydrochloride__Parathyroid hormone__no_interaction	lamivudine__CA9__no_interaction	lamivudine__gp100__no_interaction	lamivudine__GM-CSF__no_interaction	lamivudine__Parathyroid hormone__no_interaction	Carboxyamidotriazole__CA9__no_interaction	Carboxyamidotriazole__gp100__no_interaction	Carboxyamidotriazole__GM-CSF__no_interaction	Carboxyamidotriazole__Parathyroid hormone__no_interaction	entacapone__CA9__no_interaction	entacapone__gp100__no_interaction	entacapone__GM-CSF__no_interaction	entacapone__Parathyroid hormone__no_interaction	Apomab__CA9__no_interaction	Apomab__gp100__no_interaction	Apomab__GM-CSF__no_interaction	Apomab__Parathyroid hormone__no_interaction	Ofatumumab__CA9__no_interaction	Ofatumumab__gp100__no_interaction	Ofatumumab__GM-CSF__no_interaction	Ofatumumab__Parathyroid hormone__no_interaction	AI__CA9__no_interaction	AI__gp100__no_interaction	AI__GM-CSF__no_interaction	AI__Parathyroid hormone__no_interaction	Aripiprazole__CA9__no_interaction	Aripiprazole__gp100__no_interaction	Aripiprazole__GM-CSF__no_interaction	Aripiprazole__Parathyroid hormone__no_interaction	Lidocaine/prilocaine__CA9__no_interaction	Lidocaine/prilocaine__gp100__no_interaction	Lidocaine/prilocaine__GM-CSF__no_interaction	Lidocaine/prilocaine__Parathyroid hormone__no_interaction	ibritumomab tiuxetan__CA9__no_interaction	ibritumomab tiuxetan__gp100__no_interaction	ibritumomab tiuxetan__GM-CSF__no_interaction	ibritumomab tiuxetan__Parathyroid hormone__no_interaction	Vinflunine__CA9__no_interaction	Vinflunine__gp100__no_interaction	Vinflunine__GM-CSF__no_interaction	Vinflunine__Parathyroid hormone__no_interaction	Bortezomib__CA9__no_interaction	Bortezomib__gp100__no_interaction	Bortezomib__GM-CSF__no_interaction	Bortezomib__Parathyroid hormone__no_interaction	Abacavir sulfate__CA9__no_interaction	Abacavir sulfate__gp100__no_interaction	Abacavir sulfate__GM-CSF__no_interaction	Abacavir sulfate__Parathyroid hormone__no_interaction	Emtricitabine__CA9__no_interaction	Emtricitabine__gp100__no_interaction	Emtricitabine__GM-CSF__no_interaction	Emtricitabine__Parathyroid hormone__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__CA9__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__gp100__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__GM-CSF__no_interaction	Tenofovir disoproxil fumarate/emtricitabine__Parathyroid hormone__no_interaction
12895207-5	RESULTS: There was no significant difference observed in the allelic and genotypic distribution between the BPAD and control groups for cPLA2 (genotype: chi2 = 0.8, 2df, p = 0.6; allele chi2 = 0, <compound-id="15527939">1df</compound-id>, p = 0.9), <protein-id="O60733,B7Z6K3,A8K460">iPLA2</protein-id> (genotype: chi2 = 1.7, 2df, p = 0.4; allele: chi2 = 0.3, <compound-id="15527939">1df</compound-id>, p = 0.6), and <protein-id="P14555,A0A024RA96">sPLA2</protein-id> (allele: chi2 = 3.6, 6df, p = 0.8).	1df__sPLA2__no_interaction	1df__iPLA2__no_interaction
15319344-0	In vitro metabolism of <compound-id="151183">MK-0767</compound-id> [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-<compound-id="14114096">2-methoxy</compound-id>-N-[[(4-<compound-id="6373">trifluoromethyl</compound-id>) phenyl]methyl]<compound-id="2331">benzamide</compound-id>], a <protein-id="Q07869,F1D8S4">peroxisome proliferator-activated receptor alpha</protein-id>/gamma agonist. I. Role of cytochrome P450, methyltransferases, <compound-id="2016">flavin</compound-id> monooxygenases, and esterases.	2-methoxy__peroxisome proliferator-activated receptor alpha__no_interaction	flavin__peroxisome proliferator-activated receptor alpha__no_interaction	trifluoromethyl__peroxisome proliferator-activated receptor alpha__no_interaction	MK-0767__peroxisome proliferator-activated receptor alpha__no_interaction	benzamide__peroxisome proliferator-activated receptor alpha__no_interaction
15962959-1	The 1H NMR spectra of <compound-id="23925,67172434">iron</compound-id>(III) 5-ethynyl-10,15,20-tri(p-tolyl)porphyrin [(ETrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5-(phenylethynyl)-10,15,20-tri(p-tolyl)porphyrin [(PETrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5-(<compound-id="11355482">phenylbutadiynyl</compound-id>)-10,15,20-tri(p-tolyl)porphyrin [(PBTrTP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 5,10,15,20-tetra(phenylethynyl)porphyrin [(TPEP)Fe(III)X(n)], <compound-id="23925,67172434">iron</compound-id>(III) 1,4-bis-[10,15,20-tri(p-tolyl)porphyrin-5-yl]-1,3-<compound-id="9997">butadiyne</compound-id> {[(TrTP)Fe(III)X(n)]2 B}, and <compound-id="70653959">5,10,15-triphenylporphyrin</compound-id> [(TrPP)Fe(III)X(n)] have been studied to elucidate the impact of meso-ethynyl substitution on the electronic structure and <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> density distribution of high-<protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> (X = Cl-, n = 1) and low-<protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> (X = CN-, n = 2) derivatives.	5,10,15-triphenylporphyrin__spin__no_interaction	butadiyne__spin__no_interaction	iron__spin__no_interaction	phenylbutadiynyl__spin__no_interaction
17967187-4	RESULTS: Serum <compound-id="5950">alanine</compound-id> aminotransferase (ALT) and <protein-id="Q9NRA2">aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) were associated with <protein-id="P01308,I3WAC9">insulin</protein-id> resistance in univariate analysis (R = 0.54, p &lt; 0.0001 and R = 0.36, p = 0.001, respectively) and after adjustment for age, gender and waist circumference (partial R = 0.43, p = 0.0001 and partial R = 0.37, p = 0.001, respectively).	alanine__insulin__no_interaction	alanine__aspartate aminotransferase__no_interaction	alanine__AST__no_interaction
16580903-6	RESULTS: Oral <compound-id="4192">midazolam</compound-id> clearance decreased after pretreatment with <compound-id="3823,456201,47576,5702077">ketoconazole</compound-id> (from a geometric mean of 25 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 12-57 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)] to 2.7 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 1.2-8.5 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)], P &lt; .001) and increased after pretreatment with <compound-id="24871024,25141428,5381226,5458213,5702112,57032154,6243627,6913622">rifampin</compound-id> (to a geometric mean of 203 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) [range, 125-371 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1)], P &lt; .001).	rifampin__min(-1__no_interaction	midazolam__min(-1__no_interaction	ketoconazole__min(-1__no_interaction
23801867-10	Compared with the conventional group, <compound-id="5469318">FTS</compound-id> shortened the duration of flatus (79.03 ± 20.26 h vs 60.97 ± 24.40 h, P = 0.000) and duration of defecation (93.03 ± 27.95 h vs 68.00 ± 25.42 h, P = 0.000), accelerated the decrease in white blood cell count [P &lt; 0.05 on postoperative day (POD) 3 and 4], alleviated pain in patients after surgery (P &lt; 0.05 on <protein-id="O43680">POD 1, 2 and 3</protein-id>), reduced complications (P &lt; 0.05), shortened the duration of postoperative stay (7.10 ± 2.13 d vs 5.68 ± 1.22 d, P = 0.000), reduced the cost of hospitalization (43783.25 ± 8102.36 <compound-id="446491">RMB</compound-id> vs 39597.62 ± 7529.98 <compound-id="446491">RMB</compound-id>, P = 0.005), and promoted recovery of patients.	RMB__POD 1, 2 and 3__no_interaction	FTS__POD 1, 2 and 3__no_interaction
9727056-3	Using murine osteoclast-like cells (OCLs) or their mononuclear precursors (pOCs), generated in a coculture of bone marrow and osteoblastic MB1.8 cells, we show: (a) <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> upon ligation of beta3 integrins or adhesion of pOCs to serum, <protein-id="P29788">vitronectin</protein-id>, <protein-id="P10923,Q547B5,F8WIP8,Q3UBR1">osteopontin</protein-id>, or <protein-id="P11276,B9EHT6,A0A087WR50,A0A087WSN6,Q3UHL6,B7ZNJ1,Q3UZF9,Q3UGY5,Q3UHR1,A0A087WS56,Q3UH17,Q3TBB4">fibronectin</protein-id> but not to <compound-id="44342165">laminin</compound-id> or collagen; (b) coimmunoprecipitation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> and c-Src from OCLs; (c) <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> binding to the SH2 domains of Src; (d) marked reduction in <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation and kinase activity of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> in OCLs derived from Src (-/-) mice, which do not form actin rings and do not resorb bone; (e) <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> phosphorylation by exogeneous c-Src; (f) translocation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> to the <compound-id="5590">Triton X-100</compound-id> insoluble cytoskeletal fraction upon adhesion; (g) localization of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> in podosomes and the ring-like structures in OCLs plated on glass and in the sealing zone in OCLs plated on bone; and (h) activation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id>, in the presence of MB1.8 cells, parallels the formation of sealing zones and pit resorption in vitro and is reduced by echistatin or calcitonin and <compound-id="24978555,30956,5458428,5476249,60159013,6433799,71308181,71308557,71699760,90479773">cytochalasin D</compound-id>. Taken together, these findings suggest that Src-dependent <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation of <protein-id="Q9QVP9,K7QD41,Q3UDE9,E9Q2A6,P70600">PYK2</protein-id> is involved in the adhesion-induced formation of the sealing zone, required for osteoclastic bone resorption.	Triton X-100__osteopontin__no_interaction	Triton X-100__fibronectin__no_interaction	Triton X-100__vitronectin__no_interaction	Triton X-100__PYK2__no_interaction	laminin__osteopontin__no_interaction	laminin__fibronectin__no_interaction	laminin__vitronectin__no_interaction	laminin__PYK2__no_interaction	cytochalasin D__osteopontin__no_interaction	cytochalasin D__fibronectin__no_interaction	cytochalasin D__vitronectin__no_interaction	cytochalasin D__PYK2__no_interaction	tyrosine__osteopontin__no_interaction	tyrosine__fibronectin__no_interaction	tyrosine__vitronectin__no_interaction	tyrosine__PYK2__no_interaction
7657737-4	The mean (+/- SD) age (34.01 +/- 4.42 versus 34.81 +/- 4.00 years), mean total dosage of HMG (61.25 +/- 26.87 versus 56.17 +/- 25.18 ampoules), mean daily dosage of HMG (4.74 versus 4.94 ampoules), duration of HMG stimulation (12.91 +/- 3.68 versus 11.31 +/- 3.46 days) and <compound-id="5757">oestradiol</compound-id> concentration on the day of <protein-id="P01215,Q6I9S8,A0A087WYZ4">HCG</protein-id> (10,082 +/- 8007 versus 9440 +/- 7840 pmol/l) were similar in both groups but the mean total number of injections (GnRH and HMG) (13.55 +/- 3.35 versus 55.37 +/- 31.92) was significantly lower in group I.	oestradiol__HCG__no_interaction
12679161-5	RESULTS: Plasma Se (microg/L) levels were 47.11 +/- 11.61 in sg 1, 38.69 +/- 13.22 in sg 2, 43.53 +/- 11.73 in <protein-id="Q86UP2,A0A024R663">cg 1</protein-id>, and 48.71 +/- 9.39 in <protein-id="Q9H330">cg 2</protein-id>; plasma <compound-id="124886">GSH</compound-id>-Px (U/mL) levels, were 0.15 +/- 0.04, 0.14 +/- 0.04, 0.16 +/- 0.04, and 0.18 +/- 0.03, respectively; and erythrocyte <compound-id="124886">GSH</compound-id>-Px (U/g of hemoglobin) levels were 13.97 +/- 4.27, 13.16 +/- 3.85, 14.25 +/- 3.84, and 14.35 +/- 3.35, respectively.	GSH__cg 2__no_interaction	GSH__cg 1__no_interaction
16207394-4	The measured parameters included forced vital capacity (FVC), forced expiratory volume in one second (FEV(1)), FEV(1)/FVC, maximal ventilatory volume (MVV), residual volume (RV), total lung capacity (TLC), RV/TLC, inspiratory capacity (IC), thoracic gas volume (TGV), peak expiratory flow (PEF), total airway resistance (R(aw)total), diffusion capacity for CO of lung (D(L)CO), diffusion capacity for CO of lung/alveolar volume (D(L)CO/V(A)), 6 minute walk distance (6MWD), partial pressure of <compound-id="977">oxygen</compound-id> in arterial blood (PaO(2)), alveolar-artery <compound-id="977">oxygen</compound-id> gradient [P((A-a))O(2)], <compound-id="977">oxygen</compound-id> saturation in arterial blood (SaO(2)), partial pressure of <compound-id="280">carbon dioxide</compound-id> in arterial blood (PaCO(2)) and mean pulmonary arterial pressure (<protein-id="Q9QWY8,E9QMJ1,H3BKE6,H3BL41,Q3TXY1,Q3UJA5">mPAP</protein-id>).	carbon dioxide__mPAP__no_interaction	oxygen__mPAP__no_interaction
8548495-4	The individual values of the <protein-id="P38646">CSA</protein-id> of the left and right quadriceps femoris (QF) correlated (p &lt; .05-.001) with the individual values of maximal unilateral knee extension forces in M50 (r = .87 and r = .87), M70 (r = .61 and r = .80), W50 (r = .79 and r = .58), and <compound-id="73010356">W70</compound-id> (r = .56 and r = .54).	W70__CSA__no_interaction
20486179-6	RESULTS: At baseline, there was stronger correlation between sTfR and markers of hemolysis and erythropoietic drive, including hemoglobin (Spearman's r = -0.67, P &lt; or = 0.001) and reticulocyte count (Spearman's r = 0.59, P &lt; or = 0.001), than with markers of <compound-id="23925,67172434">iron</compound-id> metabolism, such as <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (TS; Spearman's r = 0.33, P = 0.02) and ferritin (Spearman's r = 0.17, P = 0.26).	iron__transferrin__no_interaction
12924877-4	Specifically, several new monoanionic <protein-id="O95817">Bis</protein-id>(<compound-id="139579">phosphino</compound-id>)borates are detailed: [Ph(2)B(CH(2)PPh(2))(2)] (25); [(p-MePh)(2)B(CH(2)PPh(2))(2)] (26); [(p-(t)BuPh)(2)B(CH(2)PPh(2))(2)] (27); [(p-MeOPh)(2)B(CH(2)PPh(2))(2)] (28); [(p-CF(3)Ph)(2)B(CH(2)PPh(2))(2)] (29); [Cy(2)B(CH(2)PPh(2))(2)] (30); [Ph(2)B(CH(2)P[p-(t)BuPh](2))(2)] (31); [(p-MeOPh)(2)B(CH(2)P[p-(t)BuPh](2))(2)] (32); [Ph(2)B(CH(2)P[p-CF(3)Ph](2))(2)] (33); [Ph(2)B(CH(2)P(BH(3))(Me)(2))(2)] (34); [Ph(2)B(CH(2)P(S)(Me)(2))(2)] (35); [Ph(2)B(CH(2)P(i)Pr(2))(2)] (36); [Ph(2)B(CH(2)P(t)Bu(2))(2)] (37); [(m,m-Me(2)Ph)(2)B(CH(2)P(t)Bu(2))(2)] (38).	phosphino__Bis__no_interaction
9061303-4	Suppression of <protein-id="P01308,I3WAC9">C-peptide</protein-id> during low-dose [2 pmol kg-1 min-1 (20 mU kg-1 h-1) for 90 min, plasma insulin approximately 120 pmol L-1 (20 mUL-1)] and high-dose [8 pmol kg-1 h-1 (80 mU kg-1 h-1) for 90 min, plasma insulin approximately 450 pmol L-1 (75 mU L-1)] insulin infusion under euglycaemic conditions [plasma <compound-id="206,5793,64689,79025">glucose</compound-id> 4.4-5.0 mmol L-1 (80-90 mg dL-1)] and during high-dose insulin infusion under hypoglycaemic conditions [<compound-id="206,5793,64689,79025">glucose</compound-id> 2-2.2 mmol L-1 (40-45 mg dL-1)] was evaluated by radioimmunoassay (RIA).	glucose__C-peptide__no_interaction
22976988-1	The acidity constants of twofold protonated, antivirally active, acyclic nucleoside phosphonates (ANPs), H(2)(PE)(±), where PE(2-)=<compound-id="60172">9-[2-(phosphonomethoxy)ethyl]adenine</compound-id> (PMEA(2-)), <compound-id="451477">2-amino-9-[2-(phosphonomethoxy)ethyl]purine</compound-id> (PME2AP(2-)), 2,6-<compound-id="76988">diamino</compound-id>-9-[2-(<compound-id="53689411">phosphonomethoxy</compound-id>)<compound-id="23134249">ethyl</compound-id>]purine (<compound-id="64988">PMEDAP</compound-id>(2-)), or 2-amino-6-(dimethylamino)-9-[2-(<compound-id="53689411">phosphonomethoxy</compound-id>)<compound-id="23134249">ethyl</compound-id>]purine (PME(2A6DMAP)(2-)), as well as the stability constants of the corresponding ternary Cu(<protein-id="P14550,V9HWI0">Arm</protein-id>)(H;PE)(+) and Cu(<protein-id="P14550,V9HWI0">Arm</protein-id>)(PE) complexes, where <protein-id="Q9UK76">Arm=2</protein-id>,2'-bipyridine (bpy) or 1,10-<compound-id="67473">phenanthroline</compound-id> (phen), are compared.	phosphonomethoxy__Arm=2__no_interaction	phosphonomethoxy__Arm__no_interaction	phenanthroline__Arm=2__no_interaction	phenanthroline__Arm__no_interaction	diamino__Arm=2__no_interaction	diamino__Arm__no_interaction	2-amino-9-[2-(phosphonomethoxy)ethyl]purine__Arm=2__no_interaction	2-amino-9-[2-(phosphonomethoxy)ethyl]purine__Arm__no_interaction	PMEDAP__Arm=2__no_interaction	PMEDAP__Arm__no_interaction	9-[2-(phosphonomethoxy)ethyl]adenine__Arm=2__no_interaction	9-[2-(phosphonomethoxy)ethyl]adenine__Arm__no_interaction	ethyl__Arm=2__no_interaction	ethyl__Arm__no_interaction
19050789-3	In the 1 : 1 molar ratio reactions, single C-O bond cleavage occurs, resulting in formation of alkyl <compound-id="312">chloride</compound-id> and of the complexes [upper bond 1 start]<protein-id="P07954">MCl</protein-id>(4)[O(R)CH(R')CH(2)O][upper bond 1 end] [M = Nb, R = Me, R' = H, <compound-id="2981881,91293124">3a</compound-id>; M = Ta, R = Me, R' = H, 3b; M = Nb, R = Et, R' = H, 5; M = Nb, R = R' = Me, 6; M = Nb, R = CH(2)Cl, R' = H, 7; M = Nb, R = (CH(2))(2)O(Me)NbCl(5), R' = H, 8], which have been characterized spectroscopically.	3a__MCl__no_interaction	chloride__MCl__no_interaction
20839916-5	In univariate analysis, <protein-id="Q15848,A8K660,B2R773">Adiponectin</protein-id> was inversely associated with <compound-id="447041">IMT</compound-id> (r = -0.16, P &lt; 0.0001) and directly with FMD (r = 0.12, P &lt; 0.0001) and carotid elasticity (r = 0.20, P &lt; 0.0001).	IMT__Adiponectin__no_interaction
12577838-3	RESULTS: <compound-id="3157">Tonocardin</compound-id> treatment lowered systolic BP (from 159 +/- 19.83 to 136.57 +/- 17.43 mm Hg; by 14.5%), diastolic BP (from 93.38 +/- 12.98 to 79.12 +/- 11.69 mm Hg; by 15.28%), fasting glycemia (from 9.32 +/- 1.61 to 7.05 +/- 1.51 mmole/l; by 24.36%), glycosylated hemoglobin <compound-id="15942654">Ai</compound-id> (from 9.63 +/- 1.86 to 8.59 +/- 0.98%; by 10.8%), total <compound-id="5997">cholesterol</compound-id> (from 6.09 +/- 0.57 to 5.4 +/- 0.4 mmole/l; by 11.4%), triglycerides (from 2.11 +/- 0.57 to 1.88 +/- 0.52 mmole/l; by 11%), glycemia after 30-min <protein-id="P01308,I3WAC9">insulin</protein-id> load (from 9.32 +/- 1.61 to 5.77 +/- 1.57; by 39% and from 7.05 +/- 1.51 to 4.2 +/- 1.25 mmole/l; by 44% at the beginning and end of the follow-up, respectively), <protein-id="P01308,I3WAC9">insulin</protein-id> resistance index (from 9.87 +/- 2.45 to 6.57 +/- 1.99; by 33.5%).	Ai__insulin__no_interaction	Tonocardin__insulin__no_interaction	cholesterol__insulin__no_interaction
15319815-3	This issue focuses on the following selection of drugs: <compound-id="3081349">101M</compound-id>; Adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, <compound-id="57476835,60961">adenosine</compound-id> triphosphate, albumin <compound-id="1345">interferon alfa</compound-id>, alefacept, alemtuzumab, <compound-id="6433083">aminolevulinic acid hexyl ester</compound-id>, autologous renal tumor vaccine, <compound-id="9571004">azimilide hydrochloride</compound-id>; <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, <protein-id="O14625">BR-1</protein-id>; C340, cantuzumab <compound-id="71301226">mertansine</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">caspofungin acetate</compound-id>, CGP-36742, CHAMPION everolimus-eluting coronary stent, <compound-id="9962928">cypher</compound-id>; Dalbavancin, darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>, <compound-id="6918296">dutasteride</compound-id>; Efalizumab, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="219078">erlosamide</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, everolimus, <compound-id="150311">ezetimibe</compound-id>; <compound-id="57347">Flesinoxan hydrochloride</compound-id>, <compound-id="131536">fosamprenavir calcium</compound-id>, <compound-id="5352062">FR-901228</compound-id>, <compound-id="77992">frovatriptan</compound-id>; <compound-id="9919137">Gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, gadomer-17, galiximab, gamma-hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">gefitinib</compound-id>; HuOKT3gamma1(Ala234-Ala235); <compound-id="12000240">IDN-6556</compound-id>, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="807">iodine</compound-id> (I131) tositumomab, <compound-id="16131103">iseganan hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; Keratinocyte growth factor; <compound-id="6480442">LB-80380</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, <compound-id="16760536,6917907">LMB</compound-id>-9, <compound-id="92727">lopinavir</compound-id>, <compound-id="92727">lopinavir</compound-id>/<compound-id="392622">ritonavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>, <compound-id="60956">lurtotecan</compound-id>; Mecasermin, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="5288826">morphine hydrochloride</compound-id>; Natalizumab, <compound-id="64143">nelfinavir</compound-id>, nesiritide, <compound-id="53232">niacin/lovastatin</compound-id>; <compound-id="6918509">Olcegepant</compound-id>, omalizumab, oregovomab; <compound-id="119828">Parecoxib sodium</compound-id>, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ <compound-id="37542">ribavirin</compound-id>, <compound-id="115368">perospirone</compound-id> hydrochloride, pexelizumab, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="466151">prinomastat</compound-id>; <compound-id="159603">Resiquimod</compound-id>, rhIGFBP-3, rhIGF-I/rhIGFBP-3, <compound-id="5074">ritanserin</compound-id>, ro-31-7453, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">rosuvastatin calcium</compound-id>; <compound-id="9871074">SCIO-469</compound-id>, <compound-id="65015">SDZ-SID-791</compound-id>, SU-11248, <compound-id="5311">suberanilohydroxamic acid</compound-id>; <compound-id="110635">Tadalafil</compound-id>, taxus, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, TER-286, <compound-id="151174">tezosentan disodium</compound-id>, TH-9507, <compound-id="159324">tipifarnib</compound-id>, <compound-id="54682461">tipranavir</compound-id>, <compound-id="216237">tolvaptan</compound-id>, <compound-id="33741">tramadol hydrochloride</compound-id>/<compound-id="1983">acetaminophen</compound-id>, <compound-id="5282226">travoprost</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>, <compound-id="55223">tucaresol</compound-id>; <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="6918726">val-mCyd</compound-id>, <compound-id="110634">vardenafil hydrochloride hydrate</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>, <compound-id="71616">voriconazole</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>, XTL-002; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>.	tramadol hydrochloride__BR-1__no_interaction	vinflunine__BR-1__no_interaction	erlosamide__BR-1__no_interaction	iodine__BR-1__no_interaction	voriconazole__BR-1__no_interaction	SDZ-SID-791__BR-1__no_interaction	ertapenem sodium__BR-1__no_interaction	90Y__BR-1__no_interaction	travoprost__BR-1__no_interaction	val-mCyd__BR-1__no_interaction	bosentan__BR-1__no_interaction	perospirone__BR-1__no_interaction	midostaurin__BR-1__no_interaction	Valganciclovir hydrochloride__BR-1__no_interaction	ribavirin__BR-1__no_interaction	FR-901228__BR-1__no_interaction	interferon alfa__BR-1__no_interaction	morphine hydrochloride__BR-1__no_interaction	IDN-6556__BR-1__no_interaction	pimecrolimus__BR-1__no_interaction	frovatriptan__BR-1__no_interaction	sodium__BR-1__no_interaction	desloratadine__BR-1__no_interaction	tezosentan disodium__BR-1__no_interaction	SCIO-469__BR-1__no_interaction	dutasteride__BR-1__no_interaction	suberanilohydroxamic acid__BR-1__no_interaction	acetaminophen__BR-1__no_interaction	azimilide hydrochloride__BR-1__no_interaction	aminolevulinic acid hexyl ester__BR-1__no_interaction	vardenafil hydrochloride hydrate__BR-1__no_interaction	enfuvirtide__BR-1__no_interaction	iseganan hydrochloride__BR-1__no_interaction	101M__BR-1__no_interaction	duloxetine hydrochloride__BR-1__no_interaction	mertansine__BR-1__no_interaction	tipifarnib__BR-1__no_interaction	tolvaptan__BR-1__no_interaction	lurtotecan__BR-1__no_interaction	Olcegepant__BR-1__no_interaction	emtricitabine__BR-1__no_interaction	Parecoxib sodium__BR-1__no_interaction	ritonavir__BR-1__no_interaction	gefitinib__BR-1__no_interaction	nelfinavir__BR-1__no_interaction	ezetimibe__BR-1__no_interaction	tipranavir__BR-1__no_interaction	ixabepilone__BR-1__no_interaction	Yttrium__BR-1__no_interaction	prinomastat__BR-1__no_interaction	ibritumomab tiuxetan__BR-1__no_interaction	niacin/lovastatin__BR-1__no_interaction	tucaresol__BR-1__no_interaction	treprostinil sodium__BR-1__no_interaction	imatinib mesylate__BR-1__no_interaction	Flesinoxan hydrochloride__BR-1__no_interaction	cypher__BR-1__no_interaction	Ximelagatran__BR-1__no_interaction	telithromycin__BR-1__no_interaction	Bortezomib__BR-1__no_interaction	lumiracoxib__BR-1__no_interaction	fosamprenavir calcium__BR-1__no_interaction	LB-80380__BR-1__no_interaction	tenofovir disoproxil fumarate__BR-1__no_interaction	levocetirizine__BR-1__no_interaction	doxorubicin__BR-1__no_interaction	adefovir dipivoxil__BR-1__no_interaction	rosuvastatin calcium__BR-1__no_interaction	Resiquimod__BR-1__no_interaction	caspofungin acetate__BR-1__no_interaction	adenosine__BR-1__no_interaction	lopinavir__BR-1__no_interaction	LMB__BR-1__no_interaction	Tadalafil__BR-1__no_interaction	Gadofosveset__BR-1__no_interaction	ritanserin__BR-1__no_interaction
16968464-11	Flow-mediated dilatation (FMD) was negatively related to hsCRP (r = -0.512, P = 0.015); <protein-id="P05305,Q6FH53">ET-1</protein-id> was positively related to free androgen index (r = 0.27, P = 0.05) and negatively to sex hormone-binding globulin (r = -0.465, P = 0.022); sVCAM-1 was positively related to total <compound-id="6013">testosterone</compound-id> (r = 0.431, P = 0.036); hsCRP was positively related to BMI (r = 0.647, P = 0.001), and negatively related to FMD (r = -0.512, P = 0.015), quantitative insulin sensitivity check index (QUICKI) (r = -0.499, P = 0.018), and MATSUDA index (r = -0.445, P = 0.038).	testosterone__ET-1__no_interaction
22791215-6	A binding preference for 9-ethylguanine (<compound-id="95189">9-EtG</compound-id>) compared with <compound-id="7">9-ethyladenine</compound-id> (9-<protein-id="P25101">EtA</protein-id>) was observed for [(η(6)-p-cym)Ru(bpm)Cl][PF(6)], [(η(6)-hmb)Ru(bpm)Cl](+), [(η(6)-ind)Ru(bpm)Cl](+), [(η(6)-thn)Ru(bpm)Cl](+), [(η(6)-p-cym)Ru(phen)Cl](+) and [(η(6)-p-cym)Ru(bathophen)Cl](+) in aqueous solution at 310 K. The X-ray crystal structure of the <compound-id="764">guanine</compound-id> complex [(η(6)-p-cym)Ru(bpm)(<compound-id="95189">9-EtG</compound-id>-N7)][PF(6)](2) shows multiple <compound-id="783">hydrogen</compound-id> bonding.	9-EtG__EtA__no_interaction	9-ethyladenine__EtA__no_interaction	hydrogen__EtA__no_interaction	guanine__EtA__no_interaction
22552303-1	Although it has not proved possible to crystallize the newly prepared <compound-id="64964">cyclam</compound-id>-methylimidazole ligand 1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id> (<protein-id="P48742,Q58F18">L(Im1</protein-id>)), the trans and cis isomers of an Ni(II) complex, namely trans-aqua{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>) <compound-id="1488787">monohydrate</compound-id>, [Ni(C(15)H(30)N(6))(H(2)O)](ClO(4))(2)·H(2)O, (1), and cis-aqua{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>), [Ni(C(15)H(30)N(6))(H(2)O)](ClO(4))(2), (2), have been prepared and structurally characterized.	nickel__L(Im1__no_interaction	monohydrate__L(Im1__no_interaction	1H-imidazol__L(Im1__no_interaction	perchlorate__L(Im1__no_interaction	cyclam__L(Im1__no_interaction	tetraazacyclotetradecane__L(Im1__no_interaction
22552303-2	At different stages of the crystallization and thermal treatment from which (1) and (2) were obtained, a further two compounds were isolated in crystalline form and their structures also analysed, namely trans-{1-[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}(perchlorato)<compound-id="26158">nickel(II) perchlorate</compound-id>, [Ni(ClO(4))(C(15)H(30)N(6))]ClO(4), (3), and <protein-id="Q9NSE2">cis-{1,8</protein-id>-bis[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>}<compound-id="935">nickel</compound-id>(II) bis(<compound-id="123351">perchlorate</compound-id>) 0.24-hydrate, [Ni(C(20)H(36)N(6))](ClO(4))(2)·0.24H(2)O, (4); the 1,8-bis[(1-methyl-<compound-id="795">1H-imidazol</compound-id>-2-yl)methyl]-1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id> ligand is a minor side product, probably formed in trace amounts in the synthesis of <protein-id="P48742,Q58F18">L(Im1</protein-id>).	nickel__cis-{1,8__no_interaction	nickel__L(Im1__no_interaction	nickel(II) perchlorate__cis-{1,8__no_interaction	nickel(II) perchlorate__L(Im1__no_interaction	tetraazacyclotetradecane__cis-{1,8__no_interaction	tetraazacyclotetradecane__L(Im1__no_interaction	perchlorate__cis-{1,8__no_interaction	perchlorate__L(Im1__no_interaction	1H-imidazol__cis-{1,8__no_interaction	1H-imidazol__L(Im1__no_interaction
15978869-6	The visible absorption spectra of Mn2+:glasses have shown a broad absorption band at 520 nm (6A1g(S) --&gt; 4T1g(G)); with <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>+ ions one absorption band at 605 nm (<compound-id="25165666">4A2</compound-id>(4F) --&gt; 4T1(4P)) and another at 1450 nm (<compound-id="25165666">4A2</compound-id>(4F) --&gt; 4T1(4F)); and for Ni2+:glasses three absorption bands at 420 nm (3A2g(F) --&gt; 3T1g(P)), 805 nm (3A2g(F) --&gt; <compound-id="72206629">1Eg</compound-id>(D)) and 880 nm (3A2g(F) --&gt; 3T1g(F)) have been observed.	1Eg__Co2__no_interaction	4A2__Co2__no_interaction
10463859-3	These studies demonstrated that (i) the quiescent state is characterized by the absence of cell-associated virus, capsids, and viral antigens; (ii) HS (43 degrees C, 3 h) efficiently activated virus from quiescently infected Nd-PC12 (QIF-PC12) cells; (iii) the rate of virus production was significantly greater following HS than <compound-id="47936">forskolin</compound-id> treatment, and the rates of both were dependent on MOI; (iv) <compound-id="47936">forskolin</compound-id> and HS appeared to affect pathways of viral activation from a quiescent state as they did not enhance viral growth in Nd-PC12 cells; (v) viral alpha4 gene and host <protein-id="P0DMW0,P0DMW1">HSP72</protein-id> gene transcription were rapidly induced in QIF-PC12 as soon as 3 h post-HS initiation; (vi) induction of the viral alpha27 gene followed that of representative beta and gamma genes, U(L)30 and U(L)18, respectively, and (vii) HS induced asynchronous HSV-1 replication from QIF-PC12 cells with 1:400 to 1:22000 positive foci detected as rapid as 24 h post-induction when established at MOIs of 30 and 3, respectively.	forskolin__HSP72__no_interaction
23353941-12	RESULTS: Key recommendations and suggestions, listed by category, include: early quantitative resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm a potential source of infection (UG); administration of broad-spectrum antimicrobials therapy within 1 hr of recognition of septic shock (1B) and severe sepsis without septic shock (1C) as the goal of therapy; reassessment of antimicrobial therapy daily for de-escalation, when appropriate (1B); infection source control with attention to the balance of risks and benefits of the chosen method within 12 hrs of diagnosis (1C); initial fluid resuscitation with crystalloid (1B) and consideration of the addition of <protein-id="P02768">albumin</protein-id> in patients who continue to require substantial amounts of crystalloid to maintain adequate mean arterial pressure (2C) and the avoidance of hetastarch formulations (1C); initial fluid challenge in patients with sepsis-induced tissue hypoperfusion and suspicion of hypovolemia to achieve a minimum of 30 mL/kg of crystalloids (more rapid administration and greater amounts of fluid may be needed in some patients) (1C); fluid challenge technique continued as long as hemodynamic improvement, as based on either dynamic or static variables (UG); <compound-id="439260">norepinephrine</compound-id> as the first-choice vasopressor to maintain mean arterial pressure ≥ 65 mm Hg (1B); <compound-id="5816">epinephrine</compound-id> when an additional agent is needed to maintain adequate blood pressure (2B); <protein-id="P01185,X5DQP6">vasopressin</protein-id> (0.03 U/min) can be added to <compound-id="439260">norepinephrine</compound-id> to either raise mean arterial pressure to target or to decrease <compound-id="439260">norepinephrine</compound-id> dose but should not be used as the initial vasopressor (UG); <compound-id="681">dopamine</compound-id> is not recommended except in highly selected circumstances (2C); <compound-id="36811">dobutamine</compound-id> infusion administered or added to vasopressor in the presence of a) myocardial dysfunction as suggested by elevated cardiac filling pressures and low cardiac output, or b) ongoing signs of hypoperfusion despite achieving adequate intravascular volume and adequate mean arterial pressure (1C); avoiding use of intravenous <compound-id="5754">hydrocortisone</compound-id> in adult septic shock patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stability (2C); hemoglobin target of 7-9 g/dL in the absence of tissue hypoperfusion, ischemic coronary artery disease, or acute hemorrhage (1B); low tidal volume (1A) and limitation of inspiratory plateau pressure (1B) for acute respiratory distress syndrome (ARDS); application of at least a minimal amount of positive end-expiratory pressure (PEEP) in ARDS (1B); higher rather than lower level of PEEP for patients with sepsis-induced moderate or severe ARDS (2C); recruitment maneuvers in sepsis patients with severe refractory hypoxemia due to ARDS (2C); prone positioning in sepsis-induced ARDS patients with a PaO2/FIO2 ratio of ≤ 100 mm Hg in facilities that have experience with such practices (2C); head-of-bed elevation in mechanically ventilated patients unless contraindicated (1B); a conservative fluid strategy for patients with established ARDS who do not have evidence of tissue hypoperfusion (1C); protocols for weaning and sedation (1A); minimizing use of either intermittent bolus sedation or continuous infusion sedation targeting specific titration endpoints (1B); avoidance of neuromuscular blockers if possible in the septic patient without ARDS (1C); a short course of neuromuscular blocker (no longer than 48 hrs) for patients with early ARDS and a Pao2/Fio2 &lt; 150 mm Hg (2C); a protocolized approach to blood <compound-id="206,5793,64689,79025">glucose</compound-id> management commencing insulin dosing when two consecutive blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels are &gt; 180 mg/dL, targeting an upper blood <compound-id="206,5793,64689,79025">glucose</compound-id> ≤ 180 mg/dL (1A); equivalency of continuous veno-venous hemofiltration or intermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylaxis to prevent upper gastrointestinal bleeding in patients with bleeding risk factors (1B); oral or enteral (if necessary) feedings, as tolerated, rather than either complete fasting or provision of only intravenous <compound-id="206,5793,64689,79025">glucose</compound-id> within the first 48 hrs after a diagnosis of severe sepsis/septic shock (2C); and addressing goals of care, including treatment plans and end-of-life planning (as appropriate) (1B), as early as feasible, but within 72 hrs of intensive care unit admission (2C).	epinephrine__albumin__no_interaction	epinephrine__vasopressin__no_interaction	dobutamine__albumin__no_interaction	dobutamine__vasopressin__no_interaction	hydrocortisone__albumin__no_interaction	hydrocortisone__vasopressin__no_interaction	norepinephrine__albumin__no_interaction	norepinephrine__vasopressin__no_interaction	dopamine__albumin__no_interaction	dopamine__vasopressin__no_interaction	glucose__albumin__no_interaction	glucose__vasopressin__no_interaction
15721346-4	The relative reactivities of OH-groups were determined by GC-MS as: Me alpha- and beta-Glcp, <protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;<protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;HO-6, Me alpha- and beta-<compound-id="16133813">Galp</compound-id>, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;HO-6, Me alpha-Manp, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>&gt;HO-4&gt;HO-6, Me beta-Manp, <protein-id="P49590,B4DDN8">HO-3</protein-id>&gt;HO-<compound-id="90684367">4HO</compound-id>-6&gt;<protein-id="P30519,A0A087WT44,B3KSE0">HO-2</protein-id>, Me alpha-Rhap, OH-3&gt;OH-2&gt;OH-4; Me alphabeta-Fucp, OH-2&gt;OH-3&gt;OH-4, and Me alphabeta-Xylp, OH-2&gt;OH-4&gt;OH-3.	4HO__HO-2__no_interaction	4HO__HO-3__no_interaction	Galp__HO-2__no_interaction	Galp__HO-3__no_interaction
24024772-10	RESULTS: Oatmeal, higher in fiber and protein but lower in sugar than the <compound-id="23931">RTEC</compound-id>, resulted in greater increase in fullness (AUC: p = 0.005 [120 minute: p = 0.0408, 180 minute: p = 0.0061, 240 minute: p = 0.0102]) and greater reduction in hunger (AUC: p = 0.0009 [120 minute: p = 0.0197, 180 minute: p = 0.0003, 240 minute: p = 0.0036]), desire to <protein-id="Q07820,C8YZ26,A0A087WT64">eat</protein-id> (AUC: p = 0.0002 [120 minute: p = 0.0168, 180 minute: p &lt; 0.0001, 240 minute: p = 0.0022]), and prospective intake (AUC: p = 0.0012 [120 minute: p = 0.0058, 180 minute: p = 0.006, 240 minute: p = 0.0047]) compared to the <compound-id="23931">RTEC</compound-id>.	RTEC__eat__no_interaction
23394103-10	There was a positive correlation between <compound-id="1175">uric acid</compound-id> and inflammatory markers, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.30, p = 0.01), <protein-id="P02741">CRP</protein-id> (r = 0.37, p = 0.003), TNF-α (r = 0.40, p = 0.001), <protein-id="P05362">ICAM-1</protein-id> (r = 0.53, p = 0.0001), and <protein-id="P19320">VCAM-1</protein-id> (r = 0.45, p = 0.0001).	uric acid__ICAM-1__no_interaction	uric acid__IL-6__no_interaction	uric acid__VCAM-1__no_interaction	uric acid__CRP__no_interaction
14762098-3	To target thrombosis in a new way, we have identified and optimized a phosphinic acid-containing inhibitor of <protein-id="P19223">CPB</protein-id>, EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxyphosphinoyl]methyl]<compound-id="8094">heptanoic acid</compound-id>] and determined both the pharmacological profile and pathophysiological role of <protein-id="P19223">CPB</protein-id> in rat thrombolysis.	heptanoic acid__CPB__no_interaction
15117561-1	This study included the following experiments: (1) effects of <compound-id="107526">dextrose solution</compound-id> (250 mL of <compound-id="962">water</compound-id> containing 75 g of dextrose) or honey solution (250 mL of <compound-id="962">water</compound-id> containing 75 g of natural honey) on plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level (PGL), plasma <protein-id="P01308,I3WAC9">insulin</protein-id>, and plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> (eight subjects); (2) effects of dextrose, honey, or artificial honey (250 mL of <compound-id="962">water</compound-id> containing 35 g of dextrose and 40 g of fructose) on <compound-id="5997">cholesterol</compound-id> and triglycerides (TG) (nine subjects); (3) effects of honey solution, administered for 15 days, on PGL, blood lipids, <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>), and <compound-id="91552">homocysteine</compound-id> (eight subjects); (4) effects of honey or artificial honey on <compound-id="5997">cholesterol</compound-id> and TG in six patients with hypercholesterolemia and five patients with hypertriglyceridemia; (5) effects of honey for 15 days on blood lipid and <protein-id="P02741">CRP</protein-id> in five patients with elevated <compound-id="5997">cholesterol</compound-id> and <protein-id="P02741">CRP</protein-id>; (6) effects of 70 g of dextrose or 90 g of honey on PGL in seven patients with type 2 diabetes mellitus; and (7) effects of 30 g of <compound-id="5988">sucrose</compound-id> or 30 g of honey on PGL, plasma <protein-id="P01308,I3WAC9">insulin</protein-id>, and plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> in five diabetic patients.	homocysteine__CRP__no_interaction	homocysteine__C-reactive protein__no_interaction	homocysteine__insulin__no_interaction	homocysteine__C-peptide__no_interaction	water__CRP__no_interaction	water__C-reactive protein__no_interaction	water__insulin__no_interaction	water__C-peptide__no_interaction	sucrose__CRP__no_interaction	sucrose__C-reactive protein__no_interaction	sucrose__insulin__no_interaction	sucrose__C-peptide__no_interaction	cholesterol__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__insulin__no_interaction	cholesterol__C-peptide__no_interaction	dextrose solution__CRP__no_interaction	dextrose solution__C-reactive protein__no_interaction	dextrose solution__insulin__no_interaction	dextrose solution__C-peptide__no_interaction	glucose__CRP__no_interaction	glucose__C-reactive protein__no_interaction	glucose__insulin__no_interaction	glucose__C-peptide__no_interaction
12165891-6	The results point out that well controlled and regulated HT does not reduce but increases the plasma levels of <compound-id="23327,33032,611,57109091">glutamate</compound-id> (means and SD; <protein-id="Q16518">RP 20</protein-id> +/- 8 micromol/l, HT I 34 +/- 11 micromol/l), <compound-id="5961">glutamine</compound-id> (RP 489 +/- 155 micromol/l, HT I 634 +/- 113 micromol/l) and BCAA (<compound-id="6287">valine</compound-id> RP 164 +/- 54 micro mol/l, HT I 283 +/- 58 micromol/l, <compound-id="6306">isoleucine</compound-id> <protein-id="Q86SQ9">RP 59</protein-id> +/- 20 micromol/l, HT I 101 +/- 24 micromol/l, <compound-id="6106">leucine</compound-id> RP 88 +/- 32 micromol/l, HT I 142 +/- 35 micro mol/l).	leucine__RP 20__no_interaction	leucine__RP 59__no_interaction	isoleucine__RP 20__no_interaction	isoleucine__RP 59__no_interaction	valine__RP 20__no_interaction	valine__RP 59__no_interaction	glutamate__RP 20__no_interaction	glutamate__RP 59__no_interaction	glutamine__RP 20__no_interaction	glutamine__RP 59__no_interaction
10210917-10	The following antigens were determined [cluster of definition (CD)]: <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">leukocyte common antigen</protein-id> (<protein-id="P09496,C9J8P9">LCA</protein-id>) (B220, T 200, Ly-5), <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>; LPS-R (<compound-id="11970143">lipopolysaccharide</compound-id> receptor), <protein-id="P08571">CD14</protein-id>; found on all T cells, CD3; <protein-id="P06729,Q53F96">LFA-2</protein-id> (<protein-id="P06729,Q53F96">lymphocyte function associated antigen, T 11</protein-id>), <protein-id="P06729,Q53F96">CD2</protein-id>; coreceptor for MHC class II molecules, found on helper T cells, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>; coreceptor for MHC class I molecules, found on suppressor/cytotoxic T cells, <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>; B4, found on all human B cells, <protein-id="P15391">CD19</protein-id>; <protein-id="P13591,A0A087WWD4">NCAM</protein-id> (neural cell adhesion molecule), <protein-id="P13591,A0A087WWD4">CD56</protein-id>; <protein-id="P05107,B4E0R1">integrin beta2</protein-id> subunit, associated with <protein-id="P20701,B2RAL6">CD11a</protein-id> (<protein-id="P05107,B4E0R1">CD11a/CD18</protein-id>, <protein-id="P05107,B4E0R1">LFA-1</protein-id>, alphaLbeta2) and <protein-id="P11215">CD11b</protein-id> (<protein-id="P05107,B4E0R1">CD11b/CD18</protein-id>, <protein-id="P05107,B4E0R1">Mac-1</protein-id>,CR3, alphaMbeta2), <protein-id="P05107,B4E0R1">CD18</protein-id>; alphaL, alpha subunit of integrin <protein-id="P05107,B4E0R1">LFA-1</protein-id> (alphaLbeta2, <protein-id="P05107,B4E0R1">CD11a/CD18</protein-id>), <protein-id="P20701,B2RAL6">CD11a; alphaM, alpha subunit of integrin Mac-1</protein-id> (CR3, alphaMbeta2, <protein-id="P05107,B4E0R1">CD11b/CD18</protein-id>), <protein-id="P11215">CD11b</protein-id>; <protein-id="P05362">ICAM-1</protein-id> (intercellular adhesion molecule), <protein-id="P05362">CD54</protein-id>; H-CAM, <protein-id="P16070">Hermes antigen</protein-id>, <protein-id="P16070">Pgp-1</protein-id>, <protein-id="P16070">CD44</protein-id>; AIM (activation inducer molecule), early activation antigen, <protein-id="Q07108,Q53ZX0">CD69</protein-id>; T-cell receptor gammadelta, TCR gammadelta.	lipopolysaccharide__CD56__no_interaction	lipopolysaccharide__CD54__no_interaction	lipopolysaccharide__integrin beta2__no_interaction	lipopolysaccharide__Hermes antigen__no_interaction	lipopolysaccharide__CD2__no_interaction	lipopolysaccharide__CD8__no_interaction	lipopolysaccharide__Pgp-1__no_interaction	lipopolysaccharide__NCAM__no_interaction	lipopolysaccharide__lymphocyte function associated antigen, T 11__no_interaction	lipopolysaccharide__CD45__no_interaction	lipopolysaccharide__CD44__no_interaction	lipopolysaccharide__Mac-1__no_interaction	lipopolysaccharide__CD69__no_interaction	lipopolysaccharide__CD11a/CD18__no_interaction	lipopolysaccharide__leukocyte common antigen__no_interaction	lipopolysaccharide__CD4__no_interaction	lipopolysaccharide__CD11b/CD18__no_interaction	lipopolysaccharide__CD14__no_interaction	lipopolysaccharide__CD11b__no_interaction	lipopolysaccharide__CD11a; alphaM, alpha subunit of integrin Mac-1__no_interaction	lipopolysaccharide__LCA__no_interaction	lipopolysaccharide__ICAM-1__no_interaction	lipopolysaccharide__LFA-2__no_interaction	lipopolysaccharide__LFA-1__no_interaction	lipopolysaccharide__CD11a__no_interaction	lipopolysaccharide__CD18__no_interaction	lipopolysaccharide__CD19__no_interaction
22738259-4	In the liver, we measured (i) <compound-id="5884">NADPH</compound-id> oxidase activity, and gene and protein expression; (ii) protein carbonyl groups, <compound-id="124886">GSH</compound-id> and TBARSs (<compound-id="2723628">thiobarbituric acid</compound-id>-reactive substances); (iii) catalase, <protein-id="P07632">CuZn-SOD</protein-id> (<compound-id="5359597">superoxide</compound-id> dismutase) and Mn-SOD expression; (iv) liver <compound-id="439177">glycogen</compound-id> and lipid content; (v) GK (glucokinase), <protein-id="P43428">G6Pase</protein-id> (<protein-id="P43428">glucose-6-phosphatase</protein-id>) and G6PDH (<protein-id="P05370">glucose-6-phosphate dehydrogenase</protein-id>) activities; (vi) FAS (fatty acid synthase), GPAT (<compound-id="24759880,753">glycerol</compound-id>-3-<compound-id="1061,167704,644102">phosphate</compound-id> acyltransferase), <protein-id="P43428">G6Pase</protein-id> and G6PDH, IL-1β (interleukin-1β), <protein-id="P20961">PAI-1</protein-id> (<protein-id="P20961">plasminogen-activator inhibitor-1</protein-id>) and TNFα (tumour necrosis factor α) gene expression; and (vii) IκBα (inhibitor of nuclear factor κB α) protein expression.	glycogen__glucose-6-phosphatase__no_interaction	glycogen__G6Pase__no_interaction	glycogen__plasminogen-activator inhibitor-1__no_interaction	glycogen__CuZn-SOD__no_interaction	glycogen__PAI-1__no_interaction	glycogen__glucose-6-phosphate dehydrogenase__no_interaction	thiobarbituric acid__glucose-6-phosphatase__no_interaction	thiobarbituric acid__G6Pase__no_interaction	thiobarbituric acid__plasminogen-activator inhibitor-1__no_interaction	thiobarbituric acid__CuZn-SOD__no_interaction	thiobarbituric acid__PAI-1__no_interaction	thiobarbituric acid__glucose-6-phosphate dehydrogenase__no_interaction	NADPH__glucose-6-phosphatase__no_interaction	NADPH__G6Pase__no_interaction	NADPH__plasminogen-activator inhibitor-1__no_interaction	NADPH__CuZn-SOD__no_interaction	NADPH__PAI-1__no_interaction	NADPH__glucose-6-phosphate dehydrogenase__no_interaction	phosphate__glucose-6-phosphatase__no_interaction	phosphate__G6Pase__no_interaction	phosphate__plasminogen-activator inhibitor-1__no_interaction	phosphate__CuZn-SOD__no_interaction	phosphate__PAI-1__no_interaction	phosphate__glucose-6-phosphate dehydrogenase__no_interaction	glycerol__glucose-6-phosphatase__no_interaction	glycerol__G6Pase__no_interaction	glycerol__plasminogen-activator inhibitor-1__no_interaction	glycerol__CuZn-SOD__no_interaction	glycerol__PAI-1__no_interaction	glycerol__glucose-6-phosphate dehydrogenase__no_interaction	GSH__glucose-6-phosphatase__no_interaction	GSH__G6Pase__no_interaction	GSH__plasminogen-activator inhibitor-1__no_interaction	GSH__CuZn-SOD__no_interaction	GSH__PAI-1__no_interaction	GSH__glucose-6-phosphate dehydrogenase__no_interaction	superoxide__glucose-6-phosphatase__no_interaction	superoxide__G6Pase__no_interaction	superoxide__plasminogen-activator inhibitor-1__no_interaction	superoxide__CuZn-SOD__no_interaction	superoxide__PAI-1__no_interaction	superoxide__glucose-6-phosphate dehydrogenase__no_interaction
11374224-5	Blood pressure was monitored for 24 hours with Spacelab tonometer (SBP: 161 +/- 29 mmHg, DBP: 98 +/- 12 mmHg versus SBP: 168 +/- 21 mmHg, DBP: 103 +/- 9 mmHg; plasma <protein-id="P00797">renin</protein-id> activity was 8.1 +/- 5.6 versus 0.3 +/- 0.4 ng.ml-1.h-1, p &lt; 0.001; recumbent plasma <compound-id="5839">aldosterone</compound-id> level was 98 +/- 31 versus 358 +/- 103 pg.ml-1, p &lt; 0.001, normal value till 150 pg/ml, serum <compound-id="5462222">potassium</compound-id> was 3.9 +/- 0.4 and 3.5 +/- 0.6 mmol/l).	potassium__renin__no_interaction	aldosterone__renin__no_interaction
17142315-4	The mechanism is now defined by binding of N-linked glycan having multiple <compound-id="24139,899">GlcNAc</compound-id> termini to GM3 through carbohydrate-to-carbohydrate interaction, based on the following data: (i) <protein-id="P00533">EGFR</protein-id> (molecular mass, approximately 170 kDa) has N-linked glycan with <compound-id="24139,899">GlcNAc</compound-id> termini, as probed by mAb (J1) or lectin (<protein-id="P51159,A2RU94">GS-II</protein-id>); (ii) <protein-id="P51159,A2RU94">GS-II</protein-id>-bound <protein-id="P00533">EGFR</protein-id> also bound to anti-<protein-id="P00533">EGFR</protein-id> Ab as well as to GM3-coated beads; (iii) GM3 inhibitory effect on <protein-id="P00533">EGFR</protein-id> <compound-id="6057,90983769">tyrosine</compound-id> kinase was abrogated in vitro by coincubation with glycan having multiple <compound-id="24139,899">GlcNAc</compound-id> termini and in cell culture in situ incubated with the same glycan; and (iv) cells treated with <compound-id="51683">swainsonine</compound-id>, which increased expression of complex-type and hybrid-type <compound-id="871">glycans</compound-id> with <compound-id="24139,899">GlcNAc</compound-id> termini, displayed higher inhibition of <protein-id="P00533">EGFR</protein-id> kinase by GM3 than <compound-id="51683">swainsonine</compound-id>-untreated control cells.	glycans__GS-II__no_interaction	glycans__EGFR__no_interaction	swainsonine__GS-II__no_interaction	swainsonine__EGFR__no_interaction	GlcNAc__GS-II__no_interaction	GlcNAc__EGFR__no_interaction	tyrosine__GS-II__no_interaction	tyrosine__EGFR__no_interaction
7565768-9	The following results suggest that JNK activation in rat liver epithelial cells is at least partially Ca(2+) dependent: (i) norepinephrine and vasopressin hormones that increase <compound-id="55310">inositol 1,4,5-triphosphate</compound-id> stimulated JNK; (ii) both <compound-id="49926">thapsigargin</compound-id>, a compound that produces an intracellular Ca(2+) signal, and Ca(2+) ionophores stimulated a dramatic increase in JNK activity (up to 200-fold); (iii) extracellular Ca(2+) chelation with <compound-id="174">ethylene glycol</compound-id> <compound-id="176">tetraacetic acid</compound-id> (<compound-id="6207">EGTA</compound-id>) inhibited JNK activation by ionophore and intracellular chelation with 1,2-bis-(o-<compound-id="5483936">aminophenoxy</compound-id>)-<compound-id="6324">ethane</compound-id>-N,N,N',N'-<compound-id="176">tetraacetic acid</compound-id> tetraacetoxymethyl-ester (<compound-id="2293">BAPTA-AM</compound-id>) partially inhibited JNK activation by <protein-id="P01015">Ang II</protein-id> or <compound-id="49926">thapsigargin</compound-id>; and (iv) JNK activation by <protein-id="P01015">Ang II</protein-id> was inhibited by pretreatment of cells with <compound-id="49926">thapsigargin</compound-id> and <compound-id="6207">EGTA</compound-id>, a procedure which depletes intracellular Ca(2+) stores.	EGTA__Ang II__no_interaction	thapsigargin__Ang II__no_interaction	aminophenoxy__Ang II__no_interaction	BAPTA-AM__Ang II__no_interaction	tetraacetic acid__Ang II__no_interaction	inositol 1,4,5-triphosphate__Ang II__no_interaction	ethane__Ang II__no_interaction	ethylene glycol__Ang II__no_interaction
8784086-6	No change was observed in other metabolic parameters, including <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity index (0.76 +/- 0.21 x 10(-5) <protein-id="P13987,Q6FHM9">min-1</protein-id>/pM on therapy; 0.76 +/- 0.19 x 10(-5) <protein-id="P13987,Q6FHM9">min-1</protein-id>/pM off therapy), acute <protein-id="P01308,I3WAC9">insulin</protein-id> response to <compound-id="6322,90867653">arginine</compound-id> (225 +/- 37 pmol/L on therapy; 225 +/- 40 pmol/L off therapy), acute <protein-id="P01308,I3WAC9">insulin</protein-id> response to <compound-id="206,5793,64689,79025">glucose</compound-id> (10 +/- 6 pmol/L on therapy; 5 +/- 4 pmol/L off therapy), <compound-id="206,5793,64689,79025">glucose</compound-id> effectiveness at zero <protein-id="P01308,I3WAC9">insulin</protein-id> (0.0127 +/- 0.0007 <protein-id="P13987,Q6FHM9">min-1</protein-id> on therapy; 0.0119 +/- 0.0009 <protein-id="P13987,Q6FHM9">min-1</protein-id> off therapy), and iv <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (0.85 +/- 0.05%/min on therapy; 0.71 +/- 0.07%/min off therapy).	arginine__insulin__no_interaction	arginine__min-1__no_interaction	glucose__insulin__no_interaction	glucose__min-1__no_interaction
14635503-25	Abbreviations' list: <compound-id="5920">T3</compound-id>--triiodothyronine, T4--<compound-id="853">thyroxine</compound-id>, FT4--free <compound-id="853">thyroxine</compound-id>, <compound-id="644280">rT3</compound-id>--revers triiodothyronine TSII--Thyroid Stimulating Hormone Type I lodothyronine 5'deiodinase = type I 5'deiodinase = 5'DI = DI Type II <compound-id="22833547">Iodothyronine</compound-id> 5'deiodinase = <protein-id="Q92813,Q9HCP7,A8K845">typeII 5'deiodinase</protein-id> = 5'DII = DII E.S.S.--Euthyroid Sick Syndrome, hDII = human type II <compound-id="22833547">iodothyronine</compound-id> deiodinase HDII-b, hDII-c = two novel splice variants SCC--Squamous Cell Cancer, A--adenocarcinoma, BMI--Body Mass Index BSA--Bovine Standard Albumin, <compound-id="439196,446094">DTT</compound-id>-1,4 Dithio-L-treitol, PTU--Propylothiouracil <compound-id="6421">TCA</compound-id>--Tricholoroacetic Acid, TNM--Tumour Nodule Metastases (class.	thyroxine__typeII 5'deiodinase__no_interaction	iodothyronine__typeII 5'deiodinase__no_interaction	T3__typeII 5'deiodinase__no_interaction	rT3__typeII 5'deiodinase__no_interaction	Iodothyronine__typeII 5'deiodinase__no_interaction	TCA__typeII 5'deiodinase__no_interaction	DTT__typeII 5'deiodinase__no_interaction
21043597-4	Our results indicate that: (a) the mean steady-state fluorescence polarization (p) of both <compound-id="15590,5376733">1,6-diphenyl-1,3,5-hexatriene</compound-id> (DPH) and 1-anilino-8-naphthalenesulphonate (ANS) in membranes from diabetic subjects were significantly greater than for control subjects, thus indicating reduced membrane lipid fluidity in diabetic platelets in various membrane regions; (b) the significantly higher [(3)H]NaBH(4) reduction, indicating the increased attachment of <compound-id="206,64689,79025">glucose</compound-id> to protein amino groups, was attributed to the proteins extracted from diabetic platelet membranes; (c) <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id>-positive resting platelets were not significantly more abundant in diabetic patients; (d) basically, unaltered amounts of PADGEM-140 membrane antigen (<protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id>) copies were detected in resting diabetic platelets; (e) significantly higher numbers of membrane glycoprotein β(3) were found in diabetic platelets; (f) <compound-id="90470996">thrombin</compound-id>-induced elevations in the expression of <protein-id="P05106">CD61</protein-id> (β(3)) and <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62</protein-id> (PADGEM-140) occurred to much higher extent in platelets of diabetic patients, thus pointing to more profound activation of diabetic platelets by <compound-id="90470996">thrombin</compound-id>; (g) the total amounts of platelet membrane glycoprotein β(3) was significantly reduced in platelet lysates from diabetic subjects.	thrombin__CD62__no_interaction	thrombin__CD61__no_interaction	1,6-diphenyl-1,3,5-hexatriene__CD62__no_interaction	1,6-diphenyl-1,3,5-hexatriene__CD61__no_interaction	glucose__CD62__no_interaction	glucose__CD61__no_interaction
8785138-9	The mean population pharmacokinetic values for <protein-id="Q9NSE2">cis</protein-id>-<compound-id="47319">atracurium</compound-id> were: volume of distribution (V) = 21,900 (<compound-id="5289348">SEM</compound-id> 416) ml; clearance (Cl) = 549 (79) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of <compound-id="47319">atracurium</compound-id> isomers were: <protein-id="Q9NSE2">cis</protein-id>-<protein-id="Q9NSE2">cis</protein-id>, V = 15,100 (720) ml, Cl = 449 (42) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 23.4 (1.2) min; <protein-id="Q9NSE2">cis</protein-id>-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml <protein-id="P13987,Q6FHM9">min-1</protein-id>, T1/2 = 5.8 (0.4) min.	SEM__cis__no_interaction	SEM__min-1__no_interaction	atracurium__cis__no_interaction	atracurium__min-1__no_interaction
21981776-13	<protein-id="Q99969,A0A090N7U9">chemerin</protein-id> mRNA expression in EAT was also positively correlated with BMI (r = 0.305, P &lt; 0.05), waist circumference (r = 0.384, P &lt; 0.01), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.334, P &lt; 0.05) and negatively correlated with <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> mRNA expression in EAT (r = -0.322, P &lt; 0.05).	glucose__chemerin__no_interaction	glucose__adiponectin__no_interaction
15072129-7	The significant results from the present study were: 1) serologically, a significant increase in HLA A2, A11, B40 and <compound-id="57345898">Cw7</compound-id>, while a decrease of A28, <protein-id="O43676,A0A024R413">B12</protein-id>, <protein-id="O95168">B15</protein-id> and Cw3 were observed among the leprosy patients when compared with the controls; 2) molecular subtyping in multibacillary leprosy patients revealed a significant increase in frequency of HLA A*0203, A*0206, A*1102, B*1801, B*4016, B*5110, Cw*0407 and Cw*0703 while a decrease in the frequency of HLA A*0101, A*0211, B*4006, Cw*03031, Cw*04011 and Cw*0602 leprosy patients was observed when compared with the controls; 3) further haplotypes A*1102-B*4006-Cw*1502; A*0203-B*4016-Cw*0703; A*11-B*40 was significantly increased among the multibacillary leprosy patients when compared with the controls.	Cw7__B15__no_interaction	Cw7__B12__no_interaction
8836619-5	The ultrapotent <compound-id="1548943">capsaicin</compound-id> analogue <compound-id="104826,44564218,5148108,5702546,57090162,6324660">resiniferatoxin</compound-id> (100 micrograms/kg s.c.) was discovered to be highly emetic and comparative studies showed that <compound-id="89594">nicotine</compound-id> and <compound-id="104826,44564218,5148108,5702546,57090162,6324660">resiniferatoxin</compound-id> induced the most intense responses with episodes (retches and a vomit) occurring every 10-15 s. The retching response to mechanical stimulation in the anaesthetised Suncus was not blocked by a 5-HT3 receptor antagonist (<compound-id="17572266,3510,5284566,86287410">granisetron</compound-id>, 1-5 mg/kg s.c.), a tachykinin NK1 receptor antagonist (<compound-id="105083">CP-99,994</compound-id> 20 mg/kg s.c. dihydrochloride salt (9+) -(2S,<compound-id="21439199">3S</compound-id>)-3-(<compound-id="81292">2-methoxybenzylamino</compound-id>)-<compound-id="103020">2-phenylpiperidine</compound-id>) or <compound-id="5288826">morphine</compound-id> (2 mg/kg s.c.) but was blocked by the <protein-id="Q6XXX9">5-HT1A receptor</protein-id> agonist 8-hydroxy-<compound-id="90285">2-(di-n-propylamino)tetralin</compound-id> (8-OH-DPAT 100 micrograms/kg s.c.).	2-phenylpiperidine__5-HT1A receptor__no_interaction	nicotine__5-HT1A receptor__no_interaction	capsaicin__5-HT1A receptor__no_interaction	3S__5-HT1A receptor__no_interaction	granisetron__5-HT1A receptor__no_interaction	2-(di-n-propylamino)tetralin__5-HT1A receptor__no_interaction	CP-99,994__5-HT1A receptor__no_interaction	resiniferatoxin__5-HT1A receptor__no_interaction	morphine__5-HT1A receptor__no_interaction	2-methoxybenzylamino__5-HT1A receptor__no_interaction
23961489-14	In newborns with <compound-id="56841631">VDD</compound-id>, serum <compound-id="22044544,5460341">calcium</compound-id> levels were correlated significantly with 25OHD (r = 0.597, P &lt; 0.001), Mg concentrations (r = 0.436, P &lt; 0.001) and negatively with <protein-id="P05187,B2R7C7">ALP</protein-id> concentrations (r = -0.451, P &lt; 0.001).	calcium__ALP__no_interaction	VDD__ALP__no_interaction
23961489-15	Serum <protein-id="P01270">PTH</protein-id> concentrations were correlated significantly with serum Mg (r = 0.78, P &lt; 0.0001) but not with serum <compound-id="22044544,5460341">calcium</compound-id> (r = -0.103, P = 0.3) or 25OHD (r = -0.03, P = 0.7) concentrations.	calcium__PTH__no_interaction
8684837-4	The genes include: (i) Scl-2 (mouse chromosome 4/human chromosome 9p; candidate Janus <compound-id="6057,90983769">tyrosine</compound-id> kinase 1) controlling a unique no lesion growth resistance phenotype to Leishmania mexicana; (ii) Scl-1 (distal mouse chromosome 11/human 17q; candidates <protein-id="P35228">Nos2</protein-id>, Sigje, <protein-id="P32246,Q5U003">MIP1 alpha</protein-id>, <protein-id="P13236">MIP1 beta</protein-id>) controlling healing versus non-healing responses to L. major; (iii) the 'T helper 2' cytokine gene cluster (proximal murine chromosome 11/human 5p; candidates IL4,5,9) controlling later phases of L. major infection; (iv) the major histocompatibility complex (MHC: H-2 in mouse, HLA in man: mouse chromosome 17/human 6p; candidates class II and class III including TNF alpha/beta genes); and (v) <protein-id="P49279,A0A024R474">Nramp1</protein-id>, the positionally cloned candidate for the murine macrophage resistance gene <protein-id="P41251">Ity</protein-id>/<protein-id="P41251">Lsh</protein-id>/<protein-id="P41251">Bcg</protein-id> (mouse chromosome 1/human 2q35).	tyrosine__Nramp1__no_interaction	tyrosine__Nos2__no_interaction	tyrosine__MIP1 beta__no_interaction	tyrosine__Bcg__no_interaction	tyrosine__Lsh__no_interaction	tyrosine__Ity__no_interaction	tyrosine__MIP1 alpha__no_interaction
9428458-6	Predialytic serum <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> was significantly correlated with serum <protein-id="P02768">albumin</protein-id> (r = -0.4, P = 0.006), cholinesterase (r = -0.51, P = 0.001), body weight change for 3 years (r = -0.48, P = 0.001) and <compound-id="8948">MAMA</compound-id> r = -0.39, P = 0.05).	MAMA__IL-6__no_interaction	MAMA__albumin__no_interaction
21063874-5	Serum <protein-id="P15090,E7DVW4">A-FABP</protein-id> at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.53, P &lt; 0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein <compound-id="5997">cholesterol</compound-id>, triglyceride, and CAVI.	cholesterol__A-FABP__no_interaction	cholesterol__insulin__no_interaction
23238775-1	A dinuclear <compound-id="23930">manganese</compound-id>(III) complex (1) of an N-(carboxymethyl)-N-[3,5-bis(α,α-dimethylbenzyl-2-hydroxybenzyl)]<compound-id="45934207,750">glycine</compound-id> (HDA) ligand (L) binds a <compound-id="23930">manganese</compound-id>(II) species through displacement of its solvating ligands by appropriately dispositioned carbonyl groups of a dinuclear complex {[Mn(2)(L)(2)(OH)(OCH(3))][Mn(H(2)O)(3)(CH(3)OH)(3)], 2, triclinic P1, a = 13.172(3) Å, b = 15.897(3) Å, c = 19.059(4) Å, V = 3461.9(13) Å(3)} leading to a trinuclear complex {3, monoclinic <protein-id="P38936,A0A024RCX5">P21</protein-id>/n, a = 11.7606(8) Å, b = 21.3505(8) Å, c = 26.7827(17) Å, V = 6722.7(7) Å(3)} with cyclization of two of the carboxy groups through the doubly-carboxy group coordinated Mn(2+) ion.	glycine__P21__no_interaction	manganese__P21__no_interaction
23214255-4	RESULTS: After 12 weeks of treatment, the IIEF-5 scores were significantly improved in both the trial and the control groups as compared with the baseline (19.5 +/- 4.1 vs 13.0 +/- 3.8 and 16.4 +/- 3.7 vs 13.7 +/- 3.5, P&lt;0.05), the level of serum <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> was remarkably decreased ([156.07 +/- 26.31] vs [478.35 +/- 62.28] mIU/L and [164.73 +/- 28.58] vs [445.26 +/- 57.83] mIU/L, P&lt;0.05), while the level of serum <compound-id="6013">testosterone</compound-id> was markedly increased ([15.34 +/- 5.27] vs [3.80 +/- 1.09] nmol/L and [12.02 +/- 2.36] vs [4.07 +/- 1.25] nmol/L, P&lt;0.05).	testosterone__prolactin__no_interaction
19482015-6	The different abnormalities of the alpha chain were located either in the G helix: Hb Bronovo alpha103(G10)His--&gt;Leu, Hb Sallanches alpha104(<protein-id="P49842">G11</protein-id>)Cys--&gt;<compound-id="6057">Tyr</compound-id>, Hb Oegstgeest alpha104(<protein-id="P49842">G11</protein-id>)Cys--&gt;<compound-id="5951">Ser</compound-id>, Hb Bleuland alpha108(G15)Thr--&gt;Asn, Hb Suan Dok alpha109(<compound-id="447467">G16</compound-id>)Leu--&gt;Arg and as yet undescribed alpha109(<compound-id="447467">G16</compound-id>)Leu--&gt;Gln, in the GH corner: Hb Foggia alpha117(<compound-id="163897">GH5</compound-id>)Phe--&gt;<compound-id="5951">Ser</compound-id>, or in the H helix: Hb Groene Hart alpha119(<compound-id="783">H2</compound-id>)Pro--&gt;<compound-id="5951">Ser</compound-id>, Hb <compound-id="71494">Diamant</compound-id> alpha119(<compound-id="783">H2</compound-id>)Pro--&gt;Leu, Hb Utrecht alpha129(<compound-id="448724">H12</compound-id>)Leu--&gt;Pro.	GH5__G11__no_interaction	Diamant__G11__no_interaction	H2__G11__no_interaction	H12__G11__no_interaction	G16__G11__no_interaction	Tyr__G11__no_interaction	Ser__G11__no_interaction
9439541-7	NE infusion produced approximately a threefold increase in plasma NE, associated with (1) a significant reduction in <compound-id="206,5793,64689,79025">glucose</compound-id> disposal ([KG] SAL v NE, 0.73 +/- 0.06 v 0.61 +/- 0.06 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05), (2) no reduction in Si (2.33 +/- 0.8 v 2.62 +/- 0.9 x 10(-4).<protein-id="P13987,Q6FHM9">min-1</protein-id>/mU/L, NS), (3) a reduced mean second-phase <protein-id="P01308,I3WAC9">insulin</protein-id> secretion rate (1.21 +/- 0.19 v 1.01 +/- 0.16 x 10(-3) pmol/kg/min per mmol/<compound-id="53782688">L glucose</compound-id>, P &lt; .05), (4) a significant increase in Sg (0.89 +/- 0.08 v 1.63 +/- 0.2 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05), and (5) a corresponding increase in <compound-id="206,5793,64689,79025">glucose</compound-id> effectiveness at zero <protein-id="P01308,I3WAC9">insulin</protein-id> ([GEZI] 0.55 +/- 0.13 v 1.30 +/- 0.33 x 10(-2).<protein-id="P13987,Q6FHM9">min-1</protein-id>, P &lt; .05).	L glucose__insulin__no_interaction	L glucose__min-1__no_interaction	glucose__insulin__no_interaction	glucose__min-1__no_interaction
16625256-1	The thioethers <compound-id="91407362">4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane</compound-id> (tBu-L3) and <compound-id="91407362">4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane</compound-id> (tBu-L4) react with <protein-id="Q8N4E4">PdCl2</protein-id>(NCMe)2 to give the dinuclear <compound-id="23938">palladium</compound-id> <compound-id="10909502">thiophenolate</compound-id> complexes [(L3)Pd2Cl2]+ (2) and [(L4Pd2(mu-Cl)]2+ (3) (HL3= <compound-id="91270987">2,6-bis((2-(dimethylamino)ethylimino)methyl)-4-tert-butylbenzenethiol</compound-id>, <compound-id="10130163">HL4</compound-id> = 2,6-bis((2-(dimethylamino)<compound-id="6341">ethylamino</compound-id>)methyl)-<compound-id="75454">4-tert-butylbenzenethiol</compound-id>).	2,6-bis((2-(dimethylamino)ethylimino)methyl)-4-tert-butylbenzenethiol__PdCl2__no_interaction	HL4__PdCl2__no_interaction	thiophenolate__PdCl2__no_interaction	4-tert-butyl-2,6-bis((2-(dimethylamino)ethylimino)methyl)phenyl(tert-butyl)sulfane__PdCl2__no_interaction	ethylamino__PdCl2__no_interaction	palladium__PdCl2__no_interaction	4-tert-butylbenzenethiol__PdCl2__no_interaction
16625256-2	The <compound-id="312">chloride</compound-id> ligands in could be replaced by neutral (NCMe) and anionic ligands (NCS-, N3-, CN-, OAc-) to give the diamagnetic Pd(II) complexes [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(NCMe)2]3+ (4), [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(NCS)2]+ (5), [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(N3)2]+ (6), [{(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(mu-CN)}2]4+ (7) and [(L3)<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>(OAc)]2+ (9).	chloride__Pd2__no_interaction
20525986-3	<protein-id="P17931,A0A024R693">Galectin-3</protein-id> levels were associated with older age (r = 0.26, P = 0.006), lower <compound-id="588">creatinine</compound-id> clearance (r = -0.42, P &lt; 0.001), and higher levels of N-terminal-proBNP (r = 0.39, P &lt; 0.001).	creatinine__Galectin-3__no_interaction
9352247-5	Urinary albumin excretion showed a significant positive correlation with systolic (r = 0.46, P &lt; 0.005) and mean blood pressure (r = 0.38, P &lt; 0.05), serum <compound-id="1175">uric acid</compound-id> (r = 0.43, P &lt; 0.005) and triglyceride values (r = 0.36, P &lt; 0.005), and a significant negative correlation with plasma <protein-id="P00797">renin</protein-id> activity (r = -0.34, P &lt; 0.05).	uric acid__renin__no_interaction
12969144-14	<protein-id="P27548,Q0VEI3">CD40L</protein-id> blockade significantly reduced tubulointerstitial injury as well [tubular diameter microm), group 3, 42.5 +/- 6.9 vs. group 2, 66.3 +/- 13.7, P &lt; 0.001; and group 1, 37.3 +/- 5.7, P &lt; 0.01; tubular cell height microm), group 3, 16.3 +/- 1.7 vs. group 2, 11 +/- 1.8, P &lt; 0.01; and group 1, 18.2 +/- 1.9, P &lt; 0.01; interstitial volume (%), group 3, 13.9 +/- 5.1 vs. group 2, 26.2 +/- 4.9, P &lt; 0.001; and group 1, 1.3 +/- 0.7, P &lt; 0.001; proteinuria (mg/24 hours), group 3, 1.8 +/- 0.6 vs. group 2, 4.3 +/- 0.8, P &lt; 0.001; and group 1, 0.7 +/- 0.2, P &lt; 0.05; and <compound-id="588">creatinine</compound-id> clearance microL/min), group 3, 75 +/- 4 vs. group 2, 35 +/- 2, P &lt; 0.001; and group 1, 82 +/- 4, P &lt; 0.01] were also improved by <protein-id="Q8HWB0">MR1</protein-id>.	creatinine__CD40L__no_interaction	creatinine__MR1__no_interaction
9524781-7	Simple regression analysis showed that LVMI was correlated with 48-hour pulse pressure (r = 0.52, p &lt; 0.00033), 48-hour systolic BP (r = 0.37, p &lt; 0.05), <protein-id="P01270">PTH</protein-id> (r = 0.31, p &lt; 0.04) and inversely with serum <compound-id="22044544,5460341">calcium</compound-id> (r = -0.29, p &lt; 0.05) and hemoglobin (r = -0.33, p &lt; 0.03).	calcium__PTH__no_interaction
19711899-7	When compound 2 was heated to reflux in an <compound-id="356">octane</compound-id> solution, it was converted to two new compounds: cis-Re(4)(CO)(16)(mu-BiPh(2))(2)(mu(4)-BiPhBiPh), <protein-id="O75159">cis-6</protein-id> and trans-Re(4)(CO)(16)(mu-BiPh(2))(2)(mu(4)-BiPhBiPh), trans-7 and a small amount of 1 (3% yield).	octane__cis-6__no_interaction
23806067-5	Eight genotypes of Hb variants were found, including Hb E [β26(B8)Glu→<compound-id="5962">Lys</compound-id>, GAG&gt;AAG; <compound-id="5792">HBB</compound-id>: c.79G&gt;A], Hb J-Bangkok [β56(D7)Gly→Asp (<compound-id="449471">GGC</compound-id>&gt;<protein-id="O94925,Q68D38">GAC</protein-id>); <compound-id="5792">HBB</compound-id>; c.170G&gt;A], Hb G-Coushatta [β22(4)Glu→Ala (GAA&gt;<protein-id="P28676,H7BXD5">GCA</protein-id>); <compound-id="5792">HBB</compound-id>: c.68A&gt;C], Hb Queens [α34(<protein-id="O95168">B15</protein-id>)Leu→Arg (CTG&gt;CGG) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.104T&gt;G (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)], Hb I [α16(A14)<compound-id="5962">Lys</compound-id>→Glu, AAG&gt;GAG (α1); <protein-id="P69905,D1MGQ2">HBA1</protein-id>: c.<compound-id="445535">49A</compound-id>&gt;G], Hb Beijing [α16(A14)<compound-id="5962">Lys</compound-id>→Asn (AAG&gt;AAC or AAT) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.51G&gt;C (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>) or 51G&gt;T (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)], Hb <compound-id="16125102">Ube</compound-id>-2 [α68(E17)Asn→Asp (AAC&gt;<protein-id="O94925,Q68D38">GAC</protein-id>) (α2 or α1); <protein-id="P69905,D1MGQ2">HBA2</protein-id>: c.205A&gt;G (or <protein-id="P69905,D1MGQ2">HBA1</protein-id>)] and Hb G-Taipei [β22(B4)Glu→Gly (GAA&gt;GGA); <compound-id="5792">HBB</compound-id>: c.68A&gt;G].	Ube__GCA__no_interaction	Ube__HBA1__no_interaction	Ube__B15__no_interaction	Ube__GAC__no_interaction	Ube__HBA2__no_interaction	HBB__GCA__no_interaction	HBB__HBA1__no_interaction	HBB__B15__no_interaction	HBB__GAC__no_interaction	HBB__HBA2__no_interaction	49A__GCA__no_interaction	49A__HBA1__no_interaction	49A__B15__no_interaction	49A__GAC__no_interaction	49A__HBA2__no_interaction	GGC__GCA__no_interaction	GGC__HBA1__no_interaction	GGC__B15__no_interaction	GGC__GAC__no_interaction	GGC__HBA2__no_interaction	Lys__GCA__no_interaction	Lys__HBA1__no_interaction	Lys__B15__no_interaction	Lys__GAC__no_interaction	Lys__HBA2__no_interaction
23329150-8	There was no correlation between iPTH and <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.04, P = 0.70) and AS progression was associated with <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.42, P = 0.009), but not with iPTH (R = 0.10, P = 0.55) in patients with normal <compound-id="5280795,5283711">vitamin D</compound-id> levels, whereas it was associated with iPTH (R = 0.47, P &lt; 0.001) and not with <protein-id="Q02318">CTX</protein-id>/<protein-id="P02818">osteocalcin</protein-id> (R = 0.04, P = 0.73) in those with low <compound-id="5280795,5283711">vitamin D</compound-id> levels, especially if mild renal insufficiency was present (R = 0.61, P &lt; 0.001).	vitamin D__osteocalcin__no_interaction	vitamin D__CTX__no_interaction
18540596-2	The subsequent rate of <compound-id="1038,5460653">proton</compound-id> transfer depends markedly on the nature of L. Stopped-flow kinetic studies show that <compound-id="1038,5460653">proton</compound-id> transfer from [pyrH] (+) to [Fe 4Y 4Cl 4] (2-) { (S) k 4 = (2.1 +/- 0.5) x 10 (4) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1); (Se) k 4 = (8.0 +/- 0.5) x 10 (3) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1)} is increased by prior binding of L = <protein-id="P10071">PhS</protein-id> (-) or Bu ( t )NC to form [Fe 4Y 4Cl 4(L)] (n-) ( (S) k 7 (L) approximately 1 x 10 (6) dm (3) <protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> (-1) s (-1)), but prior binding of L = I (-), Br (-), or EtS (-) to the clusters inhibits the rate of <compound-id="1038,5460653">proton</compound-id> transfer {e.g.	proton__PhS__no_interaction	proton__mol__no_interaction
7709007-7	RESULTS: The 95% confidence limits of means for the most important variables were as follows: estimated ELF content 0.42-0.74%; total cells in <protein-id="P43652">ALF</protein-id> 76.6-143.0 x 10(6) l-1; distribution of inflammatory cells on filter and CCF slides: macrophages 74.9-83.6 and 81.4-90.1%, lymphocytes 13.1-22.5 and 8.1-16.4%, and neutrophils 1.0-4.1 and 0.7-2.7%, respectively; distribution of lymphocyte subsets: CD3+<protein-id="P06729,Q53F96">CD2</protein-id> 85.6-90.6%, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id> 44.3-53.1%, <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id> 26.9-35.8%; concentration of solutes in <protein-id="P43652">ALF</protein-id>: total protein 44.8-61.3 mg l-1, <protein-id="P02768">albumin</protein-id> 15.4-22.2 mg l-1, IgA 1.8-3.4 mg l-1, IgG 3.1-6.1 mg l-1, IgM 0.05-0.26 mg l-1, <compound-id="24728612,24759,3084050,453618">hyaluronic acid</compound-id> 8.8-11.1 micrograms l-1, <protein-id="P12724">ECP</protein-id> 0.19-0.77 micrograms l-1, PCP 0.005-0.58 micrograms l-1, <protein-id="P61769,H0YL18">beta 2-microglobulin</protein-id> 62.2-81.5 micrograms l-1.	hyaluronic acid__ALF__no_interaction	hyaluronic acid__beta 2-microglobulin__no_interaction	hyaluronic acid__CD4__no_interaction	hyaluronic acid__CD2__no_interaction	hyaluronic acid__ECP__no_interaction	hyaluronic acid__albumin__no_interaction	hyaluronic acid__CD8__no_interaction
21619011-1	The work in this paper presents the syntheses, structures, and magnetic properties of three end-to-end (EE) azide/<compound-id="540">cyanate</compound-id>-bridged <compound-id="23978">copper</compound-id>(II) compounds [Cu(II)L(1)(μ(1,3)-NCO)](n)·<compound-id="447474">2nH</compound-id>(2)O (1), [Cu(II)L(1)(μ(1,3)-N(3))](n)·<compound-id="447474">2nH</compound-id>(2)O (2), and [Cu(II)L(2)(μ(1,3)-N(3))](n) (3), where the ligands used to achieve these species, <protein-id="P07306,Q6FGQ5">HL(1</protein-id>) and <protein-id="P07307,Q7Z4G9">HL(2</protein-id>), are the tridentate <compound-id="86573619">Schiff base</compound-id> ligands obtained from [1 + 1] condensations of <compound-id="6998">salicylaldehyde</compound-id> with 4-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8083">morpholine</compound-id> and <compound-id="13516411">3-methoxy</compound-id> <compound-id="6998">salicylaldehyde</compound-id> with 1-(<compound-id="57481262">2-aminoethyl</compound-id>)-<compound-id="8082">piperidine</compound-id>, respectively.	cyanate__HL(1__no_interaction	cyanate__HL(2__no_interaction	copper__HL(1__no_interaction	copper__HL(2__no_interaction	2nH__HL(1__no_interaction	2nH__HL(2__no_interaction	3-methoxy__HL(1__no_interaction	3-methoxy__HL(2__no_interaction	Schiff base__HL(1__no_interaction	Schiff base__HL(2__no_interaction	morpholine__HL(1__no_interaction	morpholine__HL(2__no_interaction	2-aminoethyl__HL(1__no_interaction	2-aminoethyl__HL(2__no_interaction	piperidine__HL(1__no_interaction	piperidine__HL(2__no_interaction	salicylaldehyde__HL(1__no_interaction	salicylaldehyde__HL(2__no_interaction
22944276-9	After a pretreatment of antibodies of <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">ErbB2</protein-id>, <protein-id="P21860">ErbB3</protein-id>, inhibitors of p38MAPK, <protein-id="P28482,Q1HBJ4,Q499G7">ERK1/2</protein-id>, <protein-id="O75582,Q9UG98">MSK1</protein-id> and antibody of <protein-id="P16220,Q53X93,Q5U0J5">CREB</protein-id> and a stimulation of <compound-id="440005">NRG</compound-id>-1β, the expression of <protein-id="P98088">MUC5AC</protein-id> decreased (0.221 ± 0.033, 0.238 ± 0.044, 0.386 ± 0.021, 0.352 ± 0.022, 0.294 ± 0.017, 0.252 ± 0.019) versus the <compound-id="440005">NRG</compound-id>-1β group (0.650 ± 0.134).	NRG__ErbB2__no_interaction	NRG__ErbB3__no_interaction	NRG__MSK1__no_interaction	NRG__ERK1/2__no_interaction	NRG__MUC5AC__no_interaction	NRG__CREB__no_interaction
12740739-6	Similarly, no significant effect of physical training was observed on studied parameters between these two groups during either follicular phase (TG: 1.96 +/- 1.00 nmol x mmol C -1; <compound-id="46943433">ETG</compound-id>: 1.97 +/- 0.70 nmol x mmol C -1; TG/<compound-id="46943433">ETG</compound-id> ratio: 0.66 +/- 0.05 and <protein-id="O75800">FLU</protein-id>: 11.31 +/- 3.73 nmol x mmol C -1) or luteal phase (TG: 1.93 +/- 0.86 nmol x mmol C -1; <compound-id="46943433">ETG</compound-id>: 3.19 +/- 1.23 nmol x mmol C -1; TG/<compound-id="46943433">ETG</compound-id> ratio: 0.69 +/- 0.33 and <protein-id="O75800">FLU</protein-id>: 9.52 +/- 3.86 nmol x mmol C -1).	ETG__FLU__no_interaction
10585525-1	The role of <compound-id="681">dopamine</compound-id> D(1) and D(2) receptors in the control of <compound-id="187">acetylcholine</compound-id> release in the dorsal striatum by endogenous <compound-id="681">dopamine</compound-id> was investigated by monitoring with microdialysis the effect of the separate or combined administration of the <protein-id="P21728">Dopamine D(1) receptor</protein-id> antagonist, <compound-id="107930">SCH 39166</compound-id> ¿(-)-trans-6,7,7a,8,9, 13b-exahydro-3-chloro-<compound-id="97257">2-hydroxy-</compound-id>N-methyl-5H-benzo-[d]-nap <compound-id="444397">hto</compound-id>-[2, 1b]-<compound-id="6451476">azepine</compound-id> hydrochloride¿ (50 microg/kg subcutaneous (s.c.)), of the <compound-id="681">dopamine</compound-id> D(2)/D(3) receptor agonist, quinpirole (trans-(-)-4aR, <compound-id="69255155">4a</compound-id>,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo-(3,4-g)-<compound-id="7047">quinoline hydrochloride</compound-id>) (5 and 10 microg/kg s.c.), and of the D(3) receptor selective agonist, PD 128,907 [S(+)-(4aR,10bR)-3,4,<compound-id="69255155">4a</compound-id>, 10b-tetrahydro-4-propyl-2H,<compound-id="22361982">5H-[1]benzopyrano</compound-id>-[4,3-b]-1,4-<compound-id="12313776">oxazin</compound-id> -9-ol hydrochloride] (50 microg/kg s.c.), on in vivo <compound-id="681">dopamine</compound-id> and <compound-id="187">acetylcholine</compound-id> release.	acetylcholine__Dopamine D(1) receptor__no_interaction	5H-[1]benzopyrano__Dopamine D(1) receptor__no_interaction	hto__Dopamine D(1) receptor__no_interaction	oxazin__Dopamine D(1) receptor__no_interaction	SCH 39166__Dopamine D(1) receptor__no_interaction	azepine__Dopamine D(1) receptor__no_interaction	dopamine__Dopamine D(1) receptor__no_interaction	2-hydroxy-__Dopamine D(1) receptor__no_interaction	quinoline hydrochloride__Dopamine D(1) receptor__no_interaction	4a__Dopamine D(1) receptor__no_interaction
17291221-1	We developed methods for prolonged (12 h), sterile, normothermic perfusion of rat kidneys and screened compounds for renal preservation including: mitochondrial transition pore inhibitor (<compound-id="2971">decylubiquinone</compound-id>); caspase inhibitor (Z-VAD); <protein-id="P37230">peroxisome proliferator-activated receptor-alpha</protein-id> (<protein-id="P37230">PPARalpha</protein-id>) agonists (<compound-id="3463">gemfibrozil</compound-id>, WY-14643); antioxidants (<compound-id="40634">trolox</compound-id>, <compound-id="5280445">luteolin</compound-id>, <compound-id="5280343">quercetin</compound-id>); growth factors (HGF, PDGF, EGF, <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-1</protein-id>, VEGF, <protein-id="P12346">transferrin</protein-id>); <protein-id="P27321,A0A0G2JSY2,D3ZL24,F1LPH1">calpain inhibitor</protein-id> (<compound-id="72430">Z-Val-Phe-CHO</compound-id>); calmodulin inhibitor (<compound-id="5681">W7</compound-id>); K(<compound-id="5957">ATP</compound-id>) opener (<compound-id="4201">minoxidil</compound-id>, <compound-id="4203">minoxidil sulfate</compound-id>); PARP inhibitor (<compound-id="1645">3-aminobenzamide</compound-id>); <compound-id="22044544,5460341">calcium</compound-id> channel blocker (<compound-id="2520">verapamil</compound-id>); V(2) agonist (<compound-id="27991">DDAVP</compound-id>); diuretics (<compound-id="1986">acetazolamide</compound-id>, <compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="3440">furosemide</compound-id>, <compound-id="6251">mannitol</compound-id>); peroxisome proliferator-activated receptor-beta agonist (L-165041); <compound-id="681">dopamine</compound-id> agonist (<compound-id="681">dopamine</compound-id>); essential fatty acid (<compound-id="5280934">linolenic acid</compound-id>); <compound-id="5893">beta-NAD</compound-id>; <compound-id="1176">urea</compound-id>; <compound-id="1175">uric acid</compound-id>; and <compound-id="5839">aldosterone</compound-id>.	minoxidil__calpain inhibitor__no_interaction	minoxidil__transferrin__no_interaction	minoxidil__peroxisome proliferator-activated receptor-alpha__no_interaction	minoxidil__PPARalpha__no_interaction	minoxidil__IGF-1__no_interaction	3-aminobenzamide__calpain inhibitor__no_interaction	3-aminobenzamide__transferrin__no_interaction	3-aminobenzamide__peroxisome proliferator-activated receptor-alpha__no_interaction	3-aminobenzamide__PPARalpha__no_interaction	3-aminobenzamide__IGF-1__no_interaction	luteolin__calpain inhibitor__no_interaction	luteolin__transferrin__no_interaction	luteolin__peroxisome proliferator-activated receptor-alpha__no_interaction	luteolin__PPARalpha__no_interaction	luteolin__IGF-1__no_interaction	furosemide__calpain inhibitor__no_interaction	furosemide__transferrin__no_interaction	furosemide__peroxisome proliferator-activated receptor-alpha__no_interaction	furosemide__PPARalpha__no_interaction	furosemide__IGF-1__no_interaction	trolox__calpain inhibitor__no_interaction	trolox__transferrin__no_interaction	trolox__peroxisome proliferator-activated receptor-alpha__no_interaction	trolox__PPARalpha__no_interaction	trolox__IGF-1__no_interaction	ATP__calpain inhibitor__no_interaction	ATP__transferrin__no_interaction	ATP__peroxisome proliferator-activated receptor-alpha__no_interaction	ATP__PPARalpha__no_interaction	ATP__IGF-1__no_interaction	dopamine__calpain inhibitor__no_interaction	dopamine__transferrin__no_interaction	dopamine__peroxisome proliferator-activated receptor-alpha__no_interaction	dopamine__PPARalpha__no_interaction	dopamine__IGF-1__no_interaction	acetazolamide__calpain inhibitor__no_interaction	acetazolamide__transferrin__no_interaction	acetazolamide__peroxisome proliferator-activated receptor-alpha__no_interaction	acetazolamide__PPARalpha__no_interaction	acetazolamide__IGF-1__no_interaction	linolenic acid__calpain inhibitor__no_interaction	linolenic acid__transferrin__no_interaction	linolenic acid__peroxisome proliferator-activated receptor-alpha__no_interaction	linolenic acid__PPARalpha__no_interaction	linolenic acid__IGF-1__no_interaction	gemfibrozil__calpain inhibitor__no_interaction	gemfibrozil__transferrin__no_interaction	gemfibrozil__peroxisome proliferator-activated receptor-alpha__no_interaction	gemfibrozil__PPARalpha__no_interaction	gemfibrozil__IGF-1__no_interaction	aldosterone__calpain inhibitor__no_interaction	aldosterone__transferrin__no_interaction	aldosterone__peroxisome proliferator-activated receptor-alpha__no_interaction	aldosterone__PPARalpha__no_interaction	aldosterone__IGF-1__no_interaction	Z-Val-Phe-CHO__calpain inhibitor__no_interaction	Z-Val-Phe-CHO__transferrin__no_interaction	Z-Val-Phe-CHO__peroxisome proliferator-activated receptor-alpha__no_interaction	Z-Val-Phe-CHO__PPARalpha__no_interaction	Z-Val-Phe-CHO__IGF-1__no_interaction	DDAVP__calpain inhibitor__no_interaction	DDAVP__transferrin__no_interaction	DDAVP__peroxisome proliferator-activated receptor-alpha__no_interaction	DDAVP__PPARalpha__no_interaction	DDAVP__IGF-1__no_interaction	urea__calpain inhibitor__no_interaction	urea__transferrin__no_interaction	urea__peroxisome proliferator-activated receptor-alpha__no_interaction	urea__PPARalpha__no_interaction	urea__IGF-1__no_interaction	verapamil__calpain inhibitor__no_interaction	verapamil__transferrin__no_interaction	verapamil__peroxisome proliferator-activated receptor-alpha__no_interaction	verapamil__PPARalpha__no_interaction	verapamil__IGF-1__no_interaction	minoxidil sulfate__calpain inhibitor__no_interaction	minoxidil sulfate__transferrin__no_interaction	minoxidil sulfate__peroxisome proliferator-activated receptor-alpha__no_interaction	minoxidil sulfate__PPARalpha__no_interaction	minoxidil sulfate__IGF-1__no_interaction	mannitol__calpain inhibitor__no_interaction	mannitol__transferrin__no_interaction	mannitol__peroxisome proliferator-activated receptor-alpha__no_interaction	mannitol__PPARalpha__no_interaction	mannitol__IGF-1__no_interaction	beta-NAD__calpain inhibitor__no_interaction	beta-NAD__transferrin__no_interaction	beta-NAD__peroxisome proliferator-activated receptor-alpha__no_interaction	beta-NAD__PPARalpha__no_interaction	beta-NAD__IGF-1__no_interaction	quercetin__calpain inhibitor__no_interaction	quercetin__transferrin__no_interaction	quercetin__peroxisome proliferator-activated receptor-alpha__no_interaction	quercetin__PPARalpha__no_interaction	quercetin__IGF-1__no_interaction	decylubiquinone__calpain inhibitor__no_interaction	decylubiquinone__transferrin__no_interaction	decylubiquinone__peroxisome proliferator-activated receptor-alpha__no_interaction	decylubiquinone__PPARalpha__no_interaction	decylubiquinone__IGF-1__no_interaction	W7__calpain inhibitor__no_interaction	W7__transferrin__no_interaction	W7__peroxisome proliferator-activated receptor-alpha__no_interaction	W7__PPARalpha__no_interaction	W7__IGF-1__no_interaction	calcium__calpain inhibitor__no_interaction	calcium__transferrin__no_interaction	calcium__peroxisome proliferator-activated receptor-alpha__no_interaction	calcium__PPARalpha__no_interaction	calcium__IGF-1__no_interaction	hydrochlorothiazide__calpain inhibitor__no_interaction	hydrochlorothiazide__transferrin__no_interaction	hydrochlorothiazide__peroxisome proliferator-activated receptor-alpha__no_interaction	hydrochlorothiazide__PPARalpha__no_interaction	hydrochlorothiazide__IGF-1__no_interaction	uric acid__calpain inhibitor__no_interaction	uric acid__transferrin__no_interaction	uric acid__peroxisome proliferator-activated receptor-alpha__no_interaction	uric acid__PPARalpha__no_interaction	uric acid__IGF-1__no_interaction
15539964-3	In a 24-week, open-label, multicenter trial, men and women aged &gt; or =18 years with fasting levels of total <compound-id="5997">cholesterol</compound-id> &gt; or =200 mg/dL, HDL <compound-id="5997">cholesterol</compound-id> &gt; or =45 mg/dL, triglycerides 200-800 mg/dL, and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> &gt; or =110 mg/dL were randomly assigned to one of four treatment groups: <compound-id="446157,656606">rosuvastatin</compound-id> 10-40 mg, ER <compound-id="938">niacin</compound-id> 0.5-2 g, <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg plus ER <compound-id="938">niacin</compound-id> 0.5-1 g, or <compound-id="446157,656606">rosuvastatin</compound-id> 10 mg plus ER <compound-id="938">niacin</compound-id> 0.5-2 g. Daily doses of <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg monotherapy reduced low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> and non-HDL <compound-id="5997">cholesterol</compound-id> levels significantly more than did either ER <compound-id="938">niacin</compound-id> 2 g monotherapy or <compound-id="446157,656606">rosuvastatin</compound-id> 10 mg combined with ER <compound-id="938">niacin</compound-id> 2 g. Addition of ER <compound-id="938">niacin</compound-id> 1 g to <compound-id="446157,656606">rosuvastatin</compound-id> 40 mg did not further reduce total or non-HDL <compound-id="5997">cholesterol</compound-id>.	niacin__apolipoprotein B__no_interaction	rosuvastatin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
18331609-8	Serum 25-OHD was negatively associated with %TBF (r = -0.28), <protein-id="Q96LC9">BMF</protein-id> (r = -0.36) and TBF (r = -0.33), all P &lt; 0.001, and positively associated with dietary <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.10) and pack years of smoking (r = 0.11), both P &lt; 0.01.	vitamin D__BMF__no_interaction
20738599-4	The basic diploid chromosome number (2n), in all mahseer species, was observed to be 100; however, the karyotype formula varied among the species, which were recorded as: 20m + 14sm + 22st + 44t (fundamental arm number, FN = 134) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> khudree; <compound-id="9547940">22m</compound-id> + 24sm + 24st + <compound-id="86346631">30t</compound-id> (FN = 146) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> mussullah; <compound-id="5225083">12m</compound-id> + 22sm + 14st + 52t (FN = 134) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> putitora; 20m + 24sm + 24st + <compound-id="25271551">32t</compound-id> (FN = 144) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id>; 20m + 30sm + 24st + <compound-id="77620531">26t</compound-id> (FN = 150) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> chelynoides; 20m + 20sm + 20st + 40t (FN = 140) in <protein-id="P51449,Q6I9R9,F1D8P6">Tor</protein-id> progeneius; and 20m + 18sm + 14st + <compound-id="70698415">48t</compound-id> (FN = 138) in Neolissochilus hexagonolepis.	22m__Tor__no_interaction	30t__Tor__no_interaction	12m__Tor__no_interaction	32t__Tor__no_interaction	26t__Tor__no_interaction	48t__Tor__no_interaction
16954340-4	All five acute interventions caused significant increases of PRC in both <protein-id="P00405,Q7JCZ1">COX-2</protein-id>+/+ and -/- mice, but the response was consistently less in <protein-id="P00405,Q7JCZ1">COX-2</protein-id>-deficient mice (e.g., DeltaPRC in ng <protein-id="Q3UTR7">ANG I</protein-id> x ml(-1) x h(-1) caused by <compound-id="3440">furosemide</compound-id>, <compound-id="3779">isoproterenol</compound-id>, <compound-id="3637">hydralazine</compound-id>, quinaprilate, or <compound-id="2541">candesartan</compound-id> 4,699 +/- 544, 3,534 +/- 957, 2,522 +/- 369, 9,453 +/- 1,705, 66,455 +/- 21,938 in 129J WT, and 201 +/- 78, 869 +/- 275, 140 +/- 71, 902 +/- 304, 2,660 +/- 954 in 129J <protein-id="P00405,Q7JCZ1">COX-2</protein-id>-/-).	isoproterenol__ANG I__no_interaction	isoproterenol__COX-2__no_interaction	furosemide__ANG I__no_interaction	furosemide__COX-2__no_interaction	hydralazine__ANG I__no_interaction	hydralazine__COX-2__no_interaction	candesartan__ANG I__no_interaction	candesartan__COX-2__no_interaction
19087721-2	METHODS: Human HSCs of the line HSC-T6 were cultured and randomly divided into 6 groups: negative control group, <protein-id="Q9UID3">Ang II</protein-id> group treated by Ang II10 micromol/L for 15 min, <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="3749">irbesartan</compound-id> (<protein-id="Q9UID3">Ang II</protein-id> receptor inhibitor) group, exposed to <compound-id="3749">irbesartan</compound-id> for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="448042">Y27632</compound-id> (<protein-id="Q13464">Rho kinase</protein-id> specific inhibitor) exposed to <compound-id="448042">Y27632</compound-id> for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, <protein-id="Q9UID3">Ang II</protein-id> + <protein-id="P16260,B4DPV4">ML-7</protein-id> (myosin light chain kinase specific inhibitor) + saturo (protein kinase C specific inhibitor) group exposed to stauro for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment, and <protein-id="Q9UID3">Ang II</protein-id> + <compound-id="448042">Y27632</compound-id> + <protein-id="P16260,B4DPV4">ML-7</protein-id> + stauro group, exposed to <compound-id="448042">Y27632</compound-id> and stauro for 60 min prior to <protein-id="Q9UID3">Ang II</protein-id> treatment.	Y27632__Rho kinase__no_interaction	Y27632__Ang II__no_interaction	Y27632__ML-7__no_interaction	irbesartan__Rho kinase__no_interaction	irbesartan__Ang II__no_interaction	irbesartan__ML-7__no_interaction
7512696-7	On guinea-pig isolated bronchi, the potency order of contractile agonists was: [Lys5,MeLeu9,Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; <compound-id="5311311">NKA</compound-id> &gt; or = NP gamma &gt; or = [Lys5,Tyr7,MeLeu9, Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; or = <compound-id="119137">septide</compound-id> = BHNKA &gt; or = [Lys5,<compound-id="6057">Tyr</compound-id>(I2)7,MeLeu9,Nle10]-<compound-id="5311311">NKA</compound-id>(4-10) &gt; or = [Sar9,Met(O2)11]-SP &gt; or = <protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> = [Pro9]-SP &gt; or = SP &gt;&gt; <compound-id="108147,5079497">senktide</compound-id>.	NKA__NKB__no_interaction	senktide__NKB__no_interaction	Tyr__NKB__no_interaction	septide__NKB__no_interaction
1844449-9	There were significant positive correlations between the LVMI and ASBP (r = 0.51, p &lt; 0.005), the SHI (r = 0.49, p &lt; 0.005), CSBP (r = 0.47, p &lt; 0.01) and RSBP (r = 0.41, p &lt; 0.05), however, there were no significant correlations between the LVMI and <compound-id="126488">ADBP</compound-id>, the <compound-id="114683">DHI</compound-id>, CDBP, <protein-id="P18615">RDBP</protein-id> and age.	ADBP__RDBP__no_interaction	DHI__RDBP__no_interaction
1844449-10	There were significant positive correlations between the A/R and <compound-id="126488">ADBP</compound-id> (r = 0.44, p &lt; 0.01), age (r = 0.40, p &lt; 0.02), CSBP (r = 0.38, p &lt; 0.05) and <protein-id="P18615">RDBP</protein-id> (r = 0.38, p &lt; 0.05), however, no significant correlations between the A/R and ASBP, the SHI, <compound-id="114683">DHI</compound-id>, RSBP and CDBP.	ADBP__RDBP__no_interaction	DHI__RDBP__no_interaction
2343775-3	During lactation the significant findings were (1) a selective reduction (7.1%, P less than 0.03) in BMD at the ultradistal site containing 60% trabecular bone, but not at two more proximal, chiefly cortical bone sites; (2) increased bone turnover affecting bone resorption [fasting <compound-id="269023,5810">hydroxyproline</compound-id> excretion, Lac 2.22 +/- 0.12 mumol/liter GF (mean +/- <compound-id="5289348">SEM</compound-id>), Con 1.19 +/- 0.04, P less than 0.001] and affecting bone formation (plasma alkaline phosphatase, Lac 81.9 +/- 2.5 IU/liter, Con 53.5 +/- 2.7, P less than 0.001, and serum <protein-id="P02818">osteocalcin</protein-id>, Lac 14.0 +/- 0.7 microgram/liter, Con 7.3 +/- 0.4, P less than 0.001); and (3) renal conservation in the fasting state of both Ca and inorganic <compound-id="1061,167704,644102">phosphate</compound-id> (Pi) with a resultant moderate increase in plasma Pi but not in plasma Ca (total or ionized).	SEM__osteocalcin__no_interaction	phosphate__osteocalcin__no_interaction	hydroxyproline__osteocalcin__no_interaction
18843972-3	RESULTS: 1) Serum <protein-id="P61769,H0YL18">beta2-microglobulin</protein-id> (beta2-MG) &gt; or = 3.5 mg/L was an independent adverse prognostic factor for overall survival (OS), and serum <protein-id="P02768">albumin</protein-id> &lt;35 g/L predicted for time to progression (<compound-id="64968">TTP</compound-id>), 2) In the 58 cases having cytogenetic data, chromosome 13 aberration (Delta 13) was the only independent adverse prognostic factor for OS; 3) Factors significantly related to serum beta2-MG were serum <compound-id="588">creatinine</compound-id>, 24h urinary protein,body mass index (BMI) and performance status (PS); and those related to serum <protein-id="P02768">albumin</protein-id> were hemoglobin level, percentage of bone marrow plasma cells, <compound-id="612">lactate</compound-id> dehydrogenase(<compound-id="45382306">LDN</compound-id>), fever, PS, class of <protein-id="P54296">M-protein</protein-id>, serum phosphorus and BMI; 4) All traditional prognostic factors had no statistical difference between ISS stage II and III excepting for serum beta2-MG and <compound-id="588">creatinine</compound-id>, and 5/6 Delta 13 patients were classified to ISS stage II; 5) The median OS of ISS stage I, II, III were 69, 23 and 26 months (m) respectively, being no statistical difference between stage II and III; for DS system, 89.5% of patients were classified in stage III, being no statistical difference for OS between the stage I/II and III; while for <compound-id="447607">IFM</compound-id> system, the median OS of low-, intermediate- and high-risk group were 69, 40 and 8 months respectively, being statistically different between high-risk and intermediate/ low-risk groups.	IFM__albumin__no_interaction	IFM__beta2-microglobulin__no_interaction	IFM__M-protein__no_interaction	creatinine__albumin__no_interaction	creatinine__beta2-microglobulin__no_interaction	creatinine__M-protein__no_interaction	TTP__albumin__no_interaction	TTP__beta2-microglobulin__no_interaction	TTP__M-protein__no_interaction	LDN__albumin__no_interaction	LDN__beta2-microglobulin__no_interaction	LDN__M-protein__no_interaction	lactate__albumin__no_interaction	lactate__beta2-microglobulin__no_interaction	lactate__M-protein__no_interaction
9826215-4	Compared with six normal-weight subjects (BMI, 21.0+/-0.9 kg/m2), all obese subjects exhibited basal hyperinsulinism (fasting plasma <protein-id="P01308,I3WAC9">Insulin</protein-id>, 16.0+/-1.4 v 9.8+/-1.3 microU/microL, P &lt; .001; fasting plasma C-peptide, 1.4+/-0.2 v 0.5+/-0.2 ng/mL, P &lt; .001), hypofibrinolysis (euglobulin lysis time [ELT], 378+/-29 v 222+/-31 minutes, P=.01; <protein-id="P00750">tissue plasminogen activator</protein-id> [<protein-id="P00750">tPA</protein-id>] antigen, 7.8+/-0.9 v 4.2+/-0.5 ng/mL, P=.04; <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor type 1</protein-id> [<protein-id="P05121,A0A024QYT5">PAI-1</protein-id>] activity, 22.2+/-2.5 v3.9+/-0.6 AU/mL, P=.004), and marked <protein-id="P01308,I3WAC9">Insulin</protein-id> resistance (M value, ie, the maximal <compound-id="206,5793,64689,79025">glucose</compound-id> disposal rate, 9.1+/-0.6 v 18.6+/-0.8 mg/(kg x min), P &lt; .001).	glucose__PAI-1__no_interaction	glucose__plasminogen activator inhibitor type 1__no_interaction	glucose__Insulin__no_interaction	glucose__tPA__no_interaction	glucose__tissue plasminogen activator__no_interaction
24171493-2	Here we present a series of 26 novel <compound-id="2155">2-aminothiazole</compound-id>-featured <compound-id="5694">pirinixic acid</compound-id> derivatives as dual <protein-id="P48999">5-LO</protein-id>/<protein-id="Q9JM51,Q8BNP8">mPGES-1</protein-id> inhibitors with improved potency (exemplified by <compound-id="46936266">compound 16</compound-id> (2-[(4-chloro-6-{[4-(<compound-id="931">naphthalen</compound-id>-2-yl)-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]amino}pyrimidin-2-yl)<compound-id="5460613">sulfanyl</compound-id>]<compound-id="379">octanoic acid</compound-id>) with IC50 = 0.3 and 0.4 μM, respectively) and bioactivity in vivo.	octanoic acid__5-LO__no_interaction	octanoic acid__mPGES-1__no_interaction	2-aminothiazole__5-LO__no_interaction	2-aminothiazole__mPGES-1__no_interaction	thiazol__5-LO__no_interaction	thiazol__mPGES-1__no_interaction	pirinixic acid__5-LO__no_interaction	pirinixic acid__mPGES-1__no_interaction	compound 16__5-LO__no_interaction	compound 16__mPGES-1__no_interaction	sulfanyl__5-LO__no_interaction	sulfanyl__mPGES-1__no_interaction	naphthalen__5-LO__no_interaction	naphthalen__mPGES-1__no_interaction
18211669-9	Moreover, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (R2 = 0.338, p = 0.001) and not <protein-id="P22301,Q6FGW4">IL-10</protein-id> was a predictor of low <compound-id="5920">T3</compound-id> levels with only a borderline significance for T4 (R2 = 0.082, p = 0.071).By subgroup analysis, the proportion of patients with subnormal <compound-id="5920">T3</compound-id>, T4, and TSH levels was highest in the MI patients (70%, 70%, and 72%, respectively) who displayed the greatest <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and <protein-id="P22301,Q6FGW4">IL-10</protein-id> concentrations (192.5 +/- 45.1 ng/L &amp; 122.95 +/- 46.1 ng/L, respectively) compared with CHF (82.95 +/- 28.9 ng/L &amp; 69.05 +/- 44.0 ng/L, respectively) and CRI patients (40.05 +/- 28.9 ng/L &amp; 30.4 +/- 10.6 ng/L, respectively).	T3__IL-6__no_interaction	T3__IL-10__no_interaction
9047091-6	Maximal plasma <compound-id="612">lactate</compound-id> levels during exercise (<compound-id="4091">metformin</compound-id>: 4.1 +/- 2.6 mmol l(-)1, placebo: 4.5 +/- 2.6 mmol (l-1)), areas under the plasma <compound-id="612">lactate</compound-id> curve (207 +/- 121 vs 222 +/- 133 mmol l(-1) h(-1), blood <compound-id="1060">pyruvate</compound-id> levels at the end of exercise (0.06 +/- 0.04 vs 0.07 +/- 0.04 mmol l(-1)), <compound-id="612">lactate</compound-id>/<compound-id="1060">pyruvate</compound-id> ratio (65 +/- 41 vs 60 +/- 36), serum <protein-id="P01308,I3WAC9">insulin</protein-id> (25.4 +/- 8.9 vs 32.3 +/- 13.0 pmol l(-1)), and plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (4.4 +/- 0.3 vs 4.5 +/- 0.3 mmol l(-1)) did not differ significantly between <compound-id="4091">metformin</compound-id> and placebo administration.	pyruvate__insulin__no_interaction	glucose__insulin__no_interaction	metformin__insulin__no_interaction	lactate__insulin__no_interaction
19951500-6	01); the level of <protein-id="P10145,A0A024RDA5">IL-8</protein-id> in sputum was significantly higher in severe asthmatics [2907.78 (331.67 - 3457.93) ng/L] than mild-moderate asthmatics [287.58 (130.75-656.84) ng/L] and healthy control subjects [179.2 (58.55-346.59) ng/L] (P &lt; 0.01); the percentages of neutrophilic apoptosis respectively cultured with <protein-id="O14896,G0Z349">LPS</protein-id> [(10.57 +/- 1.97)%], severe asthmatics supernatant [(11.82 +/- 2.96)%], <protein-id="P10145,A0A024RDA5">IL-8</protein-id> [(10.47 +/- 1.93)%], <compound-id="5743">dexamethasone</compound-id> [(9.93 +/- 1.95)%], severe asthma supernatant + <compound-id="55245">mifepristone</compound-id> [(12.15 +/- 2.86)%] in vitro were lower than that cultured with <protein-id="P30536,O76068">PBS</protein-id> [(17.98 +/- 2.27)%], healthy control supernatant [(17.37 +/- 2.50)%], mild-moderate asthmatics supernatant [(16.35 +/- 3.26)%], <compound-id="55245">mifepristone</compound-id> [(17.89 +/- 2.38)%], and <compound-id="5743">dexamethasone</compound-id> + <compound-id="55245">mifepristone</compound-id> [(17.06 +/- 2.59)%] (P &lt; 0.01).	mifepristone__LPS__no_interaction	mifepristone__IL-8__no_interaction	mifepristone__PBS__no_interaction	dexamethasone__LPS__no_interaction	dexamethasone__IL-8__no_interaction	dexamethasone__PBS__no_interaction
17519026-9	Correlations between inverse of <protein-id="P61769,H0YL18">B2M</protein-id> and CrC (r = 0.477) and between inverse of <protein-id="P61769,H0YL18">B2M</protein-id> and Schwartz (r = 0.697) were better than correlations between inverse of <protein-id="P01034">Cystatin C</protein-id> and CrC (r = 0.390) or Schwartz (r = 0.586) and better than correlations between inverse of <compound-id="588">creatinine</compound-id> and CrC (r = 0.104) or Schwartz (r = 0.442).	creatinine__B2M__no_interaction	creatinine__Cystatin C__no_interaction
19095599-6	<protein-id="P07225">PSA</protein-id> concentrations were positively related to age (r = 0.34, P&lt;.001), total <compound-id="6013">testosterone</compound-id> (r = 0.29, P&lt;.001), free <compound-id="6013">testosterone</compound-id> (r = 0.17, P = .02), and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex hormone-binding globulin</protein-id> (r = 0.22, P&lt;.001) and negatively related to body mass index (r = -0.28, P&lt;.001).	testosterone__PSA__no_interaction	testosterone__sex hormone-binding globulin__no_interaction
14635202-7	Plasma levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (8.27 +/- 0.74 [9.65, 0.90-13.32] pg/mL versus 2.64 +/- 0.66 [1.80, 0.10-11.86] pg/mL, P &lt; 0.001), <protein-id="P02741">CRP</protein-id> (45.57 +/- 9.92 [21.00, 1.34-330.00] mg/L versus 1.96 +/- 0.50 [1.05, 0.19-8.03] mg/L, P &lt; 0.001), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> (7.40 +/- 0.67 [5.57, 2.40-31.80] IU/mL versus 4.73 +/- 0.65 [3.60, 2.32-11.00] IU/mL, P &lt; 0.01), <compound-id="45480165">GFC</compound-id> score (1.90 +/- 0.02 [2, 1-3] versus 2.50 +/- 0.14 [3, 1-3], P &lt; 0.001) were increased compared with controls.	GFC__IL-6__no_interaction	GFC__CRP__no_interaction	GFC__PAI-1__no_interaction
23094669-2	These compounds, (Hbpi)[(UO(2))(H(2)O)(HL)]·H(2)O (<protein-id="P11684">UP-1</protein-id>), represents 1D structure, (Hbpi)[(UO(2))(H(2)O)(HL)] (<protein-id="O00526">UP-2</protein-id>), (H(2)dib)(0.5)[(UO(2))(H(2)O)(HL)] (UP-3), and [(UO(2))(H(2)O)(H(2)L)]·2H(2)O (UP-4) feature 2D architectures, (H(2)bipy){[(UO(2))(H(2)O)](2)[(UO(2))(H(2)O)(2)](L)(2)}·2H(2)O (UP-5), and (H(3)O)(2){[(UO(2))(H(2)O)](3)(L)(2)}·2H(2)O (UP-6) adopt 3D networks (bpi: 1-(biphenyl-4-yl)-<compound-id="795">1H-imidazole</compound-id>, dib: 1,4-di(1H-imidazol-1-yl)<compound-id="241">benzene</compound-id>, bipy: <compound-id="1474">2,2'-bipyridine</compound-id>).	benzene__UP-1__no_interaction	benzene__UP-2__no_interaction	2,2'-bipyridine__UP-1__no_interaction	2,2'-bipyridine__UP-2__no_interaction	1H-imidazole__UP-1__no_interaction	1H-imidazole__UP-2__no_interaction
23663343-5	RESULTS: Hypoxia significantly increased the expression of <protein-id="P04961">PCNA</protein-id> (0.528 ± 0.028), p-<protein-id="P21708">ERK1</protein-id>, 2 (1.12 ± 0.05, 0.91 ± 0.06), <compound-id="6035">BrdU</compound-id> incorporation (143.3 ± 4.2) and cell proliferation index (12.5 ± 0.9) (all P &lt; 0.05, versus control group, 0.243 ± 0.025, 0.47 ± 0.03, 0.40 ± 0.03, 100.0 ± 5.4, 7.5 ± 1.2).	BrdU__PCNA__no_interaction	BrdU__ERK1__no_interaction
1635058-4	Among the more active compounds synthesized are tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[2-[[2-[[(3-hydroxy-5-isoxazolyl)acetyl]-amino]-2- phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl+ ++]<compound-id="277">carbamate</compound-id> (15), tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[2-[(1-oxo- 3-sulfopropyl)amino]-2-phenylethyl]amino]-<compound-id="23134249">ethyl</compound-id>]<compound-id="277">carbamate</compound-id>, <compound-id="5360545">monosodium</compound-id> salt (27), and tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,R*)]-[1-(1H-indol-3-ylmethyl)-1- methyl-2-oxo-2-[[2-[[(1H-1,2,4-triazol-5-ylsulfinyl)acetyl]a mino]-2-phenylethyl]amino]<compound-id="23134249">ethyl</compound-id>]carbamic acid (34) which have <protein-id="P32239">CCK-B</protein-id> binding affinities of IC50 = 2.6, 1.3, and 1.7 nM, <protein-id="P32238">CCK-A</protein-id>/-B ratios of 650, 780, and 550 and pK(a) values of 6.5, less than 1, and 7.0, respectively.	monosodium__CCK-B__no_interaction	monosodium__CCK-A__no_interaction	ethyl__CCK-B__no_interaction	ethyl__CCK-A__no_interaction	carbamate__CCK-B__no_interaction	carbamate__CCK-A__no_interaction
17115712-7	In contrast, the <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id>-catalyzed hydrolysis of N-alpha-Z-<compound-id="71070">D-Arg</compound-id>-Gly-Arg-pNA.2HCl (S-2765) and H-D-Ile-<compound-id="151004">L-Pro-L-Arg</compound-id>-pNA.HCl (S-2288) is most consistent with two-<compound-id="1038,5460653">proton</compound-id> bridges forming at the transition state between Ser195 OgammaH and His57 N(epsilon)2 and His57 Ndelta1 and Asp102 COObeta- at the active site, with transition-state fractionation factors of <protein-id="Q96C90">phi1</protein-id> = phi2 = 0.57 +/- 0.07 and phiS = 0.78 +/- 0.16 for solvent rearrangement for S-2765 and <protein-id="Q96C90">phi1</protein-id> = phi2 = 0.674 +/- 0.001 for S-2288 under enzyme saturation with the substrate at pH 8.40 and 25.0 +/- 0.1 degrees C. The rate-determining step(s) in these reactions is most likely the cleavage of the C-N bond and departure of the leaving group.	proton__FXa__no_interaction	proton__phi1__no_interaction	L-Pro-L-Arg__FXa__no_interaction	L-Pro-L-Arg__phi1__no_interaction	D-Arg__FXa__no_interaction	D-Arg__phi1__no_interaction
2157439-8	With aldehyde as the varied substrate the specificity ratios were: <compound-id="5278">statil</compound-id> less than <compound-id="133677">ICI 105552</compound-id> less than <compound-id="2120">alrestatin</compound-id> less than <compound-id="53359">tolrestat</compound-id> less than <compound-id="5280343">quercetin</compound-id> less than CCA less than <compound-id="337359">sorbinil</compound-id> less than <compound-id="4763">phenobarbital</compound-id>, and with <protein-id="Q16698,A0A024R9D7">NADPH</protein-id> as the varied substrate, <compound-id="133677">ICI 105552</compound-id> less than <compound-id="5278">statil</compound-id> less than <compound-id="2120">alrestatin</compound-id> less than <compound-id="53359">tolrestat</compound-id> less than <compound-id="5280343">quercetin</compound-id> less than CCA less than <compound-id="337359">sorbinil</compound-id> less than <compound-id="4763">phenobarbital</compound-id>.	ICI 105552__NADPH__no_interaction	quercetin__NADPH__no_interaction	phenobarbital__NADPH__no_interaction	tolrestat__NADPH__no_interaction	sorbinil__NADPH__no_interaction	statil__NADPH__no_interaction	alrestatin__NADPH__no_interaction
16934042-5	RESULTS: <compound-id="36811">Dobutamine</compound-id> dose-dependently increased ventilation (placebo 6.7 +/- 0.5 vs. D2.5 7.8 +/- 0.4 vs. D7.5 8.7 +/- 0.4 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.005) during normoxia, enhanced the ventilatory (placebo 14.4 +/- 0.6 vs. D2.5 17.3 +/- 0.8 vs. D7.5 22.5 +/- 1.9 l <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.0001) and sympathetic (placebo + 215 +/- 31 vs. D2.5 + 285 +/- 19 vs. D7.5 + 395 +/- 50% of baseline, P &lt; 0.03) responses at the fifth minute of isocapnic hypoxia and enhanced the sympathetic response to apnoea performed after hypoxia (increase after 5 min of hypoxia: + 290 +/- 43% for placebo vs.+ 360 +/- 21% for D2.5 vs. 537 +/- 69% for D7.5, P &lt; 0.05).	Dobutamine__min(-1__no_interaction
1528982-1	Using the direct measurement of the photosensitized luminescence of singlet molecular <compound-id="977">oxygen</compound-id> (<compound-id="44593851">1O2</compound-id>) the rate constants (<compound-id="196305">kq</compound-id>) have been determined for <compound-id="44593851">1O2</compound-id> quenching by the monomeric molecules of the following phthalocyanines and naphthalocyanines in <compound-id="6212">chloroform</compound-id>: tetra-(4-<compound-id="90937099">tert-butyl</compound-id>) <compound-id="5282330">phthalocyanine</compound-id> (I); octa-(3,6-butoxy) <compound-id="5282330">phthalocyanine</compound-id> (II), tetra-(6-<compound-id="90937099">tert-butyl</compound-id>)-2,3 <compound-id="5748311">naphthalocyanine</compound-id> (III), <compound-id="5359268">aluminium</compound-id> tetra-(1-tert-phenyl)-2,3 <compound-id="5748311">naphthalocyanine</compound-id> (IV), tri-(n-hexyl-siloxy) derivatives of <compound-id="5461123,6329105">silicon</compound-id>- (V), <compound-id="5352426">tin</compound-id>- (VI), <compound-id="5359268">aluminium</compound-id>- (VII) and <compound-id="5360835">gallium</compound-id>- (<protein-id="P10176,Q53XN1">VIII</protein-id>) 2,3 <compound-id="5748311">naphthalocyanine</compound-id>.	phthalocyanine__VIII__no_interaction	aluminium__VIII__no_interaction	1O2__VIII__no_interaction	oxygen__VIII__no_interaction	gallium__VIII__no_interaction	chloroform__VIII__no_interaction	tert-butyl__VIII__no_interaction	tin__VIII__no_interaction	silicon__VIII__no_interaction	kq__VIII__no_interaction	naphthalocyanine__VIII__no_interaction
17256846-1	A series of protonated and methylated Anderson-type molybdoperiodates as well as the unprotonated [IMo6O24]5- have been synthesized and structurally characterized as <compound-id="16028">tetra-n-butylammonium</compound-id> salts: [(<compound-id="137616">n-C4H9</compound-id>)4N]5[IMo6O24] [monoclinic, space group C2/c, a = 33.6101(3) A, b = 15.2575(1) A, c = 24.0294(2) A, beta = 126.9569(3) degrees , Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]4[IMo6O23(OH)] [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/c, a = 9.5587(1) A, b = 24.1364(2) A, c = 18.2788(2) A, beta = 90.1562(5) degrees , Z = 2], [(<compound-id="137616">n-C4H9</compound-id>)4N]3[IMo6O22(OH)2].2DMF [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/a, a = 17.6105(4) A, b = 15.5432(5) A, c = 29.3316(9) A, beta = 91.475(3) degrees , Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]4[IMo6O23(OMe)].3H2O [orthorhombic, space group Pbca, a = 17.0679(4) A, b = 25.6998(6) A, c = 20.7428(4) A, Z = 4], [(<compound-id="137616">n-C4H9</compound-id>)4N]3[IMo6O22(OMe)2] [monoclinic, space group <protein-id="P38936,A0A024RCX5">P21</protein-id>/n, a = 10.4009(1) A, b = 14.6658(3) A, c = 23.5395(4) A, beta = 100.324(1) degrees , Z = 2].	n-C4H9__P21__no_interaction	tetra-n-butylammonium__P21__no_interaction
21122208-5	The hemodynamics after using ECMO was much improved than before ECMO [mean arterial pressure (mm Hg, 1 mm Hg=0.133 kPa): 78.13±8.01 vs. 47.75±5.21, central venous pressure ( mm Hg ): 11.03±3.21 vs. 19.36±4.51, cardiac output (L/min): 4.93±1.01 vs. 3.50±0.81, cardiac index (L×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2)): 2.71±0.51 vs. 1.91±0.40, pulmonary artery wedge pressure ( mm Hg ): 12.72±6.52 vs. 20.22±6.91, venous <compound-id="977">oxygen</compound-id> saturation: 0.66±0.13 vs. 0.54±0.07], and the amount of using inotropic drug was significantly reduced compared with that before ECMO [<compound-id="681">dopamine</compound-id> (μg×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)): 5.05±0.85 vs. 14.20±5.05, <compound-id="5816">epinephrine</compound-id> (μg×kg(-1) ×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)): 0.05±0.01 vs. 0.24±0.04, all P&lt;0.05].	epinephrine__min(-1__no_interaction	oxygen__min(-1__no_interaction	dopamine__min(-1__no_interaction
9855050-7	The levels of <compound-id="23978">copper</compound-id> were positively correlated with the C3C (r = 0.41, P &lt; 0.0005), C4 (r = 0.38, P &lt; 0.001) and <protein-id="P00450,A5PL27">ceruloplasmin</protein-id> (r = 0.44, P &lt; 0.0005), whereas <compound-id="23994">zinc</compound-id> was correlated with C3C (r = 0.32, P = 0.0005) and ANA (P = 0.01).	copper__ceruloplasmin__no_interaction	zinc__ceruloplasmin__no_interaction
7806089-6	No differences were observed in SEpo levels (pre-<protein-id="Q9UHK6">race</protein-id> = 19.8 +/- 4.1 U/L, 6-hour = 21.2 +/- 4.9 U/L and post-<protein-id="Q9UHK6">race</protein-id> = 21 +/- 4 U/L), but UEpo increased following the <protein-id="Q9UHK6">race</protein-id> (pre-<protein-id="Q9UHK6">race</protein-id> = 15.4 +/- 9.6 U/L, 6-hour = 26.1 +/- 6.2 U/L and post-<protein-id="Q9UHK6">race</protein-id> = 14.1 +/- 6.5 U/L) (p &lt; 0.0001) and this UEpo increase was related to urine <compound-id="588">creatinine</compound-id> changes (<compound-id="7021454">rs</compound-id> = 0.79, p &lt; 0.00001).	creatinine__race__no_interaction	rs__race__no_interaction
24066833-1	The complexes (BDI)<compound-id="10111">MgX</compound-id>(<compound-id="8028">THF</compound-id>), where X = Bu(n), <protein-id="Q05519">NEt2</protein-id>, and OBu(t), are shown to undergo <compound-id="8028">THF</compound-id> exchange at low added concentrations of <compound-id="8028">THF</compound-id> by a dissociative mechanism: X = Bu(n), ΔH(#) (kcal mol(-1)) = 13.4 ± 0.4 and ΔS(#) (cal mol(-1) K(-1)) = 6.3 ± 1.6; X = <protein-id="Q05519">NEt2</protein-id>, ΔH(#) (kcal mol(-1)) = 15.2 ± 0.5 and ΔS(#) (cal mol(-1) K(-1)) = 11.4 ± 2.3; X = OBu(t), ΔH(#) (kcal mol(-1)) = 16.4 ± 0.3 and ΔS(#) (cal mol(-1) K(-1)) = 9.5 ± 1.3.	THF__NEt2__no_interaction	MgX__NEt2__no_interaction
1515102-1	(III): [4 alpha,6 beta(E)]-(+-)-6-(2-[2-(4-Fluoro-3-methylphenyl)- 4,4,6,6-tetramethyl-1-<compound-id="8079">cyclohexen</compound-id>-1-yl]<compound-id="123166">ethenyl</compound-id>)-4-hydroxytetrahy <compound-id="25113117">dro</compound-id> <compound-id="68154">pyran-2-one</compound-id> (<compound-id="22451705,6436001">RG-12561</compound-id>) <compound-id="6344">dichloromethane</compound-id> solvate, 2C24H31FO3.CH2-<protein-id="O95490">Cl2</protein-id>, Mr = 857.94, triclinic, Pl, a = 11.7413 (5), b = 13.0279 (5), c = 16.2332 (9) A, alpha = 99.456 (4), beta = 94.217 (4), gamma = 101.893 (4) degrees, V = 2381.9 (4) A3, Z = 4 [four molecules of (III)+two molecules of solvent per unit cell], Dx = 1.195 g cm-3, Cu K alpha, lambda = 1.54178 A, mu = 16.69 cm-1, F(000) = 912, T = 293 K, final R = 0.053, wR = 0.060 for 4031 reflections with I greater than 3 sigma(I).	pyran-2-one__Cl2__no_interaction	dichloromethane__Cl2__no_interaction	cyclohexen__Cl2__no_interaction	RG-12561__Cl2__no_interaction	ethenyl__Cl2__no_interaction	dro__Cl2__no_interaction
11907637-14	Treatment with 40 mg/day <compound-id="3403,446155">fluvastatin</compound-id> caused a significant decrease in total <compound-id="5997">cholesterol</compound-id> (patients: 5.47 +/- 1.32 mmol/L vs. 7.30 +/- 1.83 mmol/L; controls: 4.69 +/- 0.64 mmol/L vs. 5.81 +/- 0.72 mmol/L), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (patients: 3.28 +/- 1.25 mmol/L vs. 5.00 +/- 1.85 mmol/L; controls: 2.58 +/- 0.63 mmol/L vs. 3.50 +/- 0.70 mmol/L), and triglycerides (patients: 1.99 +/- 0.77 mmol/L vs. 2.50 +/- 1.00 mmol/L; controls: 1.24 +/- 0.46 mmol/L vs. 1.72 +/- 0.67 mmol/L) in both study groups, whereas HDL-C was not significantly changed (patients: 1.29 +/- 0.35 mmol/L vs. 1.17 +/- 0.32 mmol/L; controls: 1.55 +/- 0.30 mmol/L vs. 1.53 +/- 0.26 mmol/L).	fluvastatin__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
24180413-6	We show that i) <protein-id="Q8N414">PGBD5</protein-id> was first domesticated in the common ancestor of the cephalochordate Branchiostoma floridae (<compound-id="5287660">aka</compound-id> lancelet or amphioxus) and vertebrates, and is conserved in all vertebrates including lamprey but cannot be found in more basal urochordates, hemichordates, or echinoderms; ii) the lancelet, lamprey, and human <protein-id="Q8N414">PGBD5</protein-id> genes are syntenic and orthologous; iii) no potentially mobile ancestral <protein-id="Q8N414">PGBD5</protein-id> elements can be identified in other more deeply rooted organisms; iv) although derived from an IS4-related transposase of the RNase H clan, <protein-id="Q8N414">PGBD5</protein-id> protein is unlikely to retain enzymatic activity because the catalytic DDD(D) motif is not conserved; v) <protein-id="Q8N414">PGBD5</protein-id> is preferentially expressed in certain granule cell lineages of the brain and in the central nervous system based on available mouse and human in situ hybridization data, and the tissue-specificity of documented mammalian EST and mRNA clones; vi) the human <protein-id="Q8N414">PGBD5</protein-id> promoter and gene region is rich in bound regulatory factors including the neuron-restrictive silencer factors <protein-id="Q13127">NRSF</protein-id>/<protein-id="Q13127">REST</protein-id> and <protein-id="Q9UKL0,J3KN32">CoREST</protein-id>, as well as SIN3, <protein-id="Q13263">KAP1</protein-id>, <protein-id="P40763">STAT3</protein-id>, and <protein-id="P49711">CTCF</protein-id>; and vii) despite preferential localization within the nucleus, <protein-id="Q8N414">PGBD5</protein-id> protein is unlikely to bind DNA or chromatin as neither DNase I digestion nor high salt extraction release <protein-id="Q8N414">PGBD5</protein-id> from fractionated mouse brain nuclei.	aka__PGBD5__no_interaction	aka__STAT3__no_interaction	aka__KAP1__no_interaction	aka__CoREST__no_interaction	aka__REST__no_interaction	aka__NRSF__no_interaction	aka__CTCF__no_interaction
19781220-2	METHODS: Human monocytic cell line (THP-1) was induced into macrophages by 160 nmol/L <compound-id="4792">phorbol myristate acetate</compound-id> (<compound-id="122634,22833501,27924">PMA</compound-id>) for 48 h, and were randomly allocated into four groups: negative control group (50 microg/ml LDL for 48 h); positive control group (50 microg/ml ox-LDL for 48 h); <protein-id="P15169">C.pn</protein-id> infection group (50 microg/ml LDL plus 1 x 10(5), 4 x 10(5), 5 x 10(5) and 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 48 h or 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 0, 24, 48 and 72 h); ACAT <compound-id="5327347">inhibitor 58</compound-id>-035 plus <protein-id="P15169">C.pn</protein-id> infection group (1, 5, 10 microg/ml ACAT <compound-id="5327347">inhibitor 58</compound-id>-035 pretreatment for 1 h, 50 microg/ml LDL and 1 x 10(6) IFU <protein-id="P15169">C.pn</protein-id> for 48 h).	inhibitor 58__C.pn__no_interaction	phorbol myristate acetate__C.pn__no_interaction	PMA__C.pn__no_interaction
18550542-6	Here we show that (i) upstream regulators, PIK and <protein-id="Q15118,B7Z7N6">PDK1</protein-id>, are not the target(s) of the <protein-id="P49913,J3KNB4">cAMP</protein-id> inhibitory action; (ii) constitutively active Akt and <compound-id="11029486,179202,2534,44338867,44351042,46936510,49786999,5459084,54608024">calyculin A</compound-id>-stimulated Akt are resistant to <protein-id="P49913,J3KNB4">cAMP</protein-id> inhibition, suggesting the action of a phosphatase; (iii) <protein-id="P49913,J3KNB4">cAMP</protein-id> increases the rate of Akt dephosphorylation, directly implicating an Akt-phosphatase; (iv) Epac- and protein kinase A (PKA)-specific analogs synergistically inhibit Akt, indicating the involvement of both <protein-id="P49913,J3KNB4">cAMP</protein-id>-dependent effector pathways; (v) H89 and dominant negative Epac 279E block <protein-id="P49913,J3KNB4">cAMP</protein-id>-inhibitory action; (vi) Epac associates in a complex with Akt and <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id>, and the associated-phosphatase activity is positively modulated by <protein-id="P49913,J3KNB4">cAMP</protein-id> in a PKA- and Rap1-dependent manner; (vii) like its action on Akt inhibition, PKA- and Epac-specific analogs synergistically activate Epac-associated <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id>; and (viii) dominant negative <protein-id="Q15257,B4DZF8,F6WIT2">PP2A</protein-id> blocks <protein-id="P49913,J3KNB4">cAMP</protein-id>-inhibitory action.	calyculin A__PDK1__no_interaction	calyculin A__cAMP__no_interaction	calyculin A__PP2A__no_interaction
23375594-8	Our results show that (i) MU-PH1 cells expresses the Müller cell markers Vimentin, S-100, <compound-id="5961">glutamine</compound-id> synthetase and the progenitor and stem cell markers Nestin, <protein-id="Q9UNQ0,A0A024RDD4">Abcg2</protein-id>, <protein-id="P50553">Ascl1</protein-id>, α-tubulin and β-III-tubulin, whereas lacks the expression of <protein-id="P12271">CRALBP</protein-id>, GFAP, <protein-id="P58304">Chx10</protein-id>, <protein-id="P26367,F1T0F8,Q66SS1,D1KF47">Pax6</protein-id> and <protein-id="P46531">Notch1</protein-id> markers; (ii) MU-PH1 cell line stably express the photoreceptor markers recoverin, transducin, <protein-id="P08100">rhodopsin</protein-id>, blue and red/green opsins and also melanopsin; (iii) the presence of opsins was confirmed by the recording of intracellular free <compound-id="22044544,5460341">calcium</compound-id> levels during light stimulation; (iv) MU-PH1 cell line also expresses the <compound-id="896">melatonin</compound-id> MT1 and <compound-id="25011735">MT2</compound-id> receptors; (v) MU-PH1 cells express <protein-id="O60603,B3KWR9">TLR1, 2, 4 and 6</protein-id> mRNA; (vi) MU-PH1 express <protein-id="O60603,B3KWR9">TLR2</protein-id> at cell surface level; (vii) Candida albicans increases <protein-id="O60603,B3KWR9">TLR2</protein-id> and TLR6 mRNA expression; (viii) C. albicans or TLR selective agonists (Pam(3)CysSK(4), LPS) did not elicit morphological changes nor TNF-α secretion; (ix) C. albicans and Pam(3)CysSK(4) augmented MU-PH1 neurospheres formation in a statistically significant manner.	MT2__Abcg2__no_interaction	MT2__Ascl1__no_interaction	MT2__Notch1__no_interaction	MT2__rhodopsin__no_interaction	MT2__TLR2__no_interaction	MT2__Pax6__no_interaction	MT2__CRALBP__no_interaction	MT2__Chx10__no_interaction	MT2__TLR1, 2, 4 and 6__no_interaction	calcium__Abcg2__no_interaction	calcium__Ascl1__no_interaction	calcium__Notch1__no_interaction	calcium__rhodopsin__no_interaction	calcium__TLR2__no_interaction	calcium__Pax6__no_interaction	calcium__CRALBP__no_interaction	calcium__Chx10__no_interaction	calcium__TLR1, 2, 4 and 6__no_interaction	melatonin__Abcg2__no_interaction	melatonin__Ascl1__no_interaction	melatonin__Notch1__no_interaction	melatonin__rhodopsin__no_interaction	melatonin__TLR2__no_interaction	melatonin__Pax6__no_interaction	melatonin__CRALBP__no_interaction	melatonin__Chx10__no_interaction	melatonin__TLR1, 2, 4 and 6__no_interaction	glutamine__Abcg2__no_interaction	glutamine__Ascl1__no_interaction	glutamine__Notch1__no_interaction	glutamine__rhodopsin__no_interaction	glutamine__TLR2__no_interaction	glutamine__Pax6__no_interaction	glutamine__CRALBP__no_interaction	glutamine__Chx10__no_interaction	glutamine__TLR1, 2, 4 and 6__no_interaction
22012979-1	Six assays were evaluated in this study to determine their suitability for the diagnosis of acute dengue infection using samples from 259 Sri Lankan patients with acute fevers (99 confirmed dengue cases and 160 patients with other confirmed acute febrile illnesses): (i) the <compound-id="84098">Merlin</compound-id> dengue fever IgG &amp; IgM combo device (<compound-id="84098">Merlin</compound-id>), (ii) the Standard Diagnostics Dengue <protein-id="O60229,C9IZQ6,J3QSW6">Duo</protein-id> nonstructural 1 (NS1) antigen and IgG/IgM combo device (Standard Diagnostics, South Korea), (iii) the Biosynex Immunoquick dengue fever IgG and IgM (Biosynex, France) assay, (iv) the Bio-Rad NS1 antigen strip (Bio-Rad, France), (v) the Panbio Dengue <protein-id="O60229,C9IZQ6,J3QSW6">Duo</protein-id> IgG/IgM Cassette (Inverness, Australia), and (vi) the Panbio dengue NS1 antigen strip (Inverness, Australia).	Merlin__Duo__no_interaction
10841001-8	Peak <protein-id="P01308,I3WAC9">insulin</protein-id> and <protein-id="P01308,I3WAC9">C-peptide</protein-id> concentrations were as follows (<protein-id="P01308,I3WAC9">C-peptide</protein-id> concentrations are given in parentheses): for patients (n = 12): meal, 277 +/- 42 pmol/l (2,181 +/- 261 pmol/l); <protein-id="P01275">GLP-1</protein-id> (2.5 nmol), 390 +/- 74 pmol/l (2,144 +/- 254 pmol/l); <protein-id="P01275">glucagon</protein-id>, 329 +/- 50 pmol/l (1,780 +/- 160 pmol/l); <compound-id="206,5793,64689,79025">glucose</compound-id> plus <protein-id="P01275">GLP-1</protein-id>, 465 +/- 87 pmol/l (2,384 +/- 299 pmol/l); for control subjects (n = 12): meal, 543 +/- 89 pmol/l (2,873 +/- 210 pmol/l); <protein-id="P01275">GLP-1</protein-id>, 356 +/- 51 pmol/l (2,001 +/- 130 pmol/l); <protein-id="P01275">glucagon</protein-id>, 420 +/- 61 pmol/l (1,995 +/- 99 pmol/l); <compound-id="206,5793,64689,79025">glucose</compound-id> plus <protein-id="P01275">GLP-1</protein-id>, 1,412 +/- 187 pmol/l (4,391 +/- 416 pmol/l).	glucose__GLP-1__no_interaction	glucose__glucagon__no_interaction	glucose__insulin__no_interaction	glucose__C-peptide__no_interaction
20045992-4	Twelve novel single nucleotide polymorphisms (SNPs) (<protein-id="P00492">HGPRT</protein-id>: IVS6-12C&gt;A (frequency:0.003); <protein-id="Q9BY32">ITPA</protein-id>: 569T&gt;C (Phe189Phe, 0.003); <protein-id="P20839,Q6ZNB1,B3KRZ3">IMPDH1</protein-id>: IVS8-<compound-id="46840165">15C</compound-id>&gt;A (0.003), IVS9+227A&gt;G (0.003), IVS17+115C&gt;T (0.003), and 930C&gt;T (Thr310Thr, 0.005); <protein-id="P12268">IMPDH2</protein-id>: IVS1+<compound-id="86277907">50G</compound-id>&gt;T (0.003), IVS2+<compound-id="66575094">15G</compound-id>&gt;A (0.010), IVS3-<compound-id="71815954">20G</compound-id>&gt;A (0.003), 609C&gt;T (Arg203Arg, 0.003), and 1534C&gt;T (Arg512Trp, 0.003); and <protein-id="P49915">GMPS</protein-id>: 1563T&gt;C (Gly521Gly, 0.003)) and 7 known SNPs (<protein-id="Q9BY32">ITPA</protein-id>: 94C&gt;A (Pro32Thr, 0.005), 138G&gt;A (Gln46Gln, 0.586), and 563G&gt;A (Glu187Glu, 0.433); <protein-id="P20839,Q6ZNB1,B3KRZ3">IMPDH1</protein-id>: 987G&gt;C (Leu329Leu, 0.113) and 1575A&gt;G (Ala525Ala, 0.620) and <protein-id="P49915">GMPS</protein-id>: IVS5-7T&gt;C (0.153), 993A&gt;G (Thr331Thr, 0.153)) were identified in 200 Japanese subjects.	50G__ITPA__no_interaction	50G__GMPS__no_interaction	50G__IMPDH1__no_interaction	50G__HGPRT__no_interaction	50G__IMPDH2__no_interaction	15C__ITPA__no_interaction	15C__GMPS__no_interaction	15C__IMPDH1__no_interaction	15C__HGPRT__no_interaction	15C__IMPDH2__no_interaction	20G__ITPA__no_interaction	20G__GMPS__no_interaction	20G__IMPDH1__no_interaction	20G__HGPRT__no_interaction	20G__IMPDH2__no_interaction	15G__ITPA__no_interaction	15G__GMPS__no_interaction	15G__IMPDH1__no_interaction	15G__HGPRT__no_interaction	15G__IMPDH2__no_interaction
11372388-5	(2) When graded concentrations of <compound-id="5717">zafirlukast</compound-id> (0, 10(-12) mol/L, 10(-10) mol/L, 10(-8) mol/L, 10(-6) mol/L) were added to the <compound-id="5280493">LTC4</compound-id> cultured 16-HBE and ASMC, a significant inhibition of <protein-id="P05305,Q6FH53">ET-1</protein-id> production was observed in both groups cultured with 10(-8) mol/L or more <compound-id="5717">zafirlukast</compound-id> [(12.7 +/- 1.3) ng/L vs (5.5 +/- 2.6) ng/L 16-HBE, t = 4.693, P = 0.019; (7.5 +/- 1.0) ng/L vs (4.4 +/- 0.9) ng/L ASMC (t = 5.003, P = 0.007)].	LTC4__ET-1__no_interaction	zafirlukast__ET-1__no_interaction
2909737-2	These peptides are as follows: 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>]-<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)<protein-id="P01185,X5DQP6">AVP</protein-id>), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)<protein-id="P01185,X5DQP6">AVP</protein-id>), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)DAVP), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)DAVP), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)VAVP), 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>]<compound-id="6322,90867653">arginine</compound-id>-<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)VAVP), 1-deamino[2-<compound-id="2723935,97118">O-methyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Me)<compound-id="171113">VDAVP</compound-id>), and 1-deamino[2-O-<compound-id="54028054">ethyltyrosine</compound-id>,<compound-id="22796635">4-valine</compound-id>,8-D-<compound-id="6322,90867653">arginine</compound-id>]<protein-id="P01185,X5DQP6">vasopressin</protein-id> (dTyr(Et)<compound-id="171113">VDAVP</compound-id>).	4-valine__AVP__no_interaction	4-valine__vasopressin__no_interaction	VDAVP__AVP__no_interaction	VDAVP__vasopressin__no_interaction	O-methyltyrosine__AVP__no_interaction	O-methyltyrosine__vasopressin__no_interaction	ethyltyrosine__AVP__no_interaction	ethyltyrosine__vasopressin__no_interaction	arginine__AVP__no_interaction	arginine__vasopressin__no_interaction
21891868-5	In fact, <protein-id="Q92692">Nectin-2</protein-id> (NC-2); <protein-id="P02649">apolipoprotein E</protein-id> (<protein-id="P02649">APOE</protein-id>); glycoprotein carcinoembryonic antigen related cell adhesion molecule-16 (<protein-id="Q2WEN9">CEACAM-16</protein-id>); <protein-id="P20749">B-cell lymphoma-3</protein-id> (<protein-id="P20749">Bcl-3</protein-id>); translocase of outer mitochondrial membrane 40 homolog (T0MM-40); complement receptor-1 (CR-l); <protein-id="P10909">APOJ</protein-id> or clusterin and C-type lectin domain A family-16 member (<protein-id="Q2KHT3">CLEC-16A</protein-id>); <compound-id="44134894">Phosphatidyl inositol</compound-id>- binding clathrin assembly protein gene (<protein-id="Q13492,A0A024R5P1,A0A024R5L7">PICALM</protein-id>); <compound-id="5957">ATP</compound-id>-bonding cassette, sub family A, member 7 (<protein-id="Q8IZY2,B3KUJ3">ABCA7</protein-id>); membrane spanning A4 (MSA4); <protein-id="Q9Y5K6">CD2 associated protein</protein-id> (<protein-id="Q9Y5K6">CD2AP</protein-id>); cluster of differentiation 33 (CD33); and <protein-id="P21709">ephrin receptor A1</protein-id> (<protein-id="P21709">EPHA1</protein-id>) result in a genetic signature that might affect individual brain susceptibility to infection by the herpes virus family during aging, leading to neuronal loss, inflammation, and amyloid deposition.	ATP__Nectin-2__no_interaction	ATP__B-cell lymphoma-3__no_interaction	ATP__apolipoprotein E__no_interaction	ATP__CLEC-16A__no_interaction	ATP__CD2 associated protein__no_interaction	ATP__APOJ__no_interaction	ATP__EPHA1__no_interaction	ATP__CEACAM-16__no_interaction	ATP__ABCA7__no_interaction	ATP__APOE__no_interaction	ATP__ephrin receptor A1__no_interaction	ATP__Bcl-3__no_interaction	ATP__CD2AP__no_interaction	ATP__PICALM__no_interaction	Phosphatidyl inositol__Nectin-2__no_interaction	Phosphatidyl inositol__B-cell lymphoma-3__no_interaction	Phosphatidyl inositol__apolipoprotein E__no_interaction	Phosphatidyl inositol__CLEC-16A__no_interaction	Phosphatidyl inositol__CD2 associated protein__no_interaction	Phosphatidyl inositol__APOJ__no_interaction	Phosphatidyl inositol__EPHA1__no_interaction	Phosphatidyl inositol__CEACAM-16__no_interaction	Phosphatidyl inositol__ABCA7__no_interaction	Phosphatidyl inositol__APOE__no_interaction	Phosphatidyl inositol__ephrin receptor A1__no_interaction	Phosphatidyl inositol__Bcl-3__no_interaction	Phosphatidyl inositol__CD2AP__no_interaction	Phosphatidyl inositol__PICALM__no_interaction
11372387-6	RESULTS: At 1, 2, 4, 6 h after therapy, FEV1% [(43 +/- +/- 5)%, (50 +/- 5)%, (57 +/- 5)%, (67 +/- 6)%], PEF% [(47 +/- 5)%, (55 +/- 6)%, (62 +/- 7)%, (69 +/- 7)%], clinical index (5.1 +/- 0.8, 4.3 +/- 0.6, 3.5 +/- 0.6, 2.5 +/- 0.4) in <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id> group and FEV1% [(42 +/- 5)%, (44 +/- 5)%, (45 +/- 5)%, (45 +/- 5)%], <protein-id="Q03431,A0A024R2Z8,Q0VGD7">PFE</protein-id>% [(46 +/- 5)%, (47 +/- 5)%, (49 +/- 6)%, (49 +/- 6)%], clinical index (5.3 +/- 0.7, 5.0 +/- 0.5, 4.9 +/- 0.7, 4.8 +/- 0.7) in control group were difference markedly compared with before therapy [<compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">budesonide</compound-id> group was (35 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.0, and control group was (33 +/- 5)%, (38 +/- 5)%, 8.3 +/- 1.1, respectively], all (P &lt; 0.01).	budesonide__PFE__no_interaction
9520478-1	In this study, we demonstrate that: (i) injection of an adenovirus (Ad) vector containing the <protein-id="P23363,A0A0G2K624,A0A0H2UI28">brain-derived neurotrophic factor</protein-id> (<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>) gene (Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>) into the vitreous chamber of adult rats results in selective transgene expression by Müller cells; (ii) in vitro, Müller cells infected with Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> secrete <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> that enhances neuronal survival; (iii) in vivo, Ad-mediated expression of functional <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> by Müller cells, temporarily extends the survival of axotomized <compound-id="638015">retinal</compound-id> ganglion cells (RGCs); 16 days after axotomy, injured retinas treated with Ad.<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> showed a 4.5-fold increase in surviving RGCs compared with control retinas; (iv) the transient expression of the <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> transgene, which lasted approximately 10 days, can be prolonged with immunosuppression for at least 30 days, and such Ad-mediated <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> remains biologically active, (v) persistent expression of <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id> by infected Müller cells does not further enhance the survival of injured RGCs, indicating that the effect of this neurotrophin on RGC survival is limited by changes induced by the lesion within 10-16 days after optic nerve transection rather than the availability of <protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>.	retinal__brain-derived neurotrophic factor__no_interaction	retinal__BDNF__no_interaction
11755153-5	Compared to other <protein-id="Q64077">tachykinin NK(1) and NK(2) receptor</protein-id> agonists, the order of potency was: <compound-id="108147,5079497">senktide</compound-id>&gt;<compound-id="5311312,55583">neurokinin B</compound-id>=[Sar(9),Met(O(2))(11)]substance P=[betaAla(8)]<compound-id="13561815,5311311,55582">neurokinin A</compound-id> (4-10)=[MePhe(7)]<compound-id="5311312,55583">neurokinin B</compound-id>&gt;<compound-id="13561815,5311311,55582">neurokinin A</compound-id>&gt;substance P. The potentiation by [MePhe(7)]<compound-id="5311312,55583">neurokinin B</compound-id> of <compound-id="774">histamine</compound-id>-induced microvascular leakage was abolished by the tachykinin NK(1) receptor antagonist <compound-id="108167,5311450">SR140333</compound-id> ([(S)1-(2-[3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)-1-(3-iso-propoxyphenylacetyl)<compound-id="8082">piperidin-3-yl</compound-id>]etyl)-<compound-id="142810">4-phenyl-1-azoniabicyclo[2.2.2]octane</compound-id>, <compound-id="312">chloride</compound-id>]) or the tachykinin NK(3) receptor antagonists <compound-id="219077">SR 142801</compound-id> ([(R)-(N)-(1-(3-(l-benzoyl-3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="8082">piperidin-3-yl</compound-id>) propyl)-<compound-id="69873">4-phenylpiperidin</compound-id>-4-yl)-<compound-id="6582">N-methylacetamide</compound-id>]) and SB 223412 ([(S)-(-)-N-(alpha-ethylbenzyl)-3-hydroxy-<compound-id="185680">2-phenylquinoline-4-carboxamide</compound-id>]).	4-phenylpiperidin__tachykinin NK(1) and NK(2) receptor__no_interaction	2-phenylquinoline-4-carboxamide__tachykinin NK(1) and NK(2) receptor__no_interaction	dichlorophenyl__tachykinin NK(1) and NK(2) receptor__no_interaction	piperidin-3-yl__tachykinin NK(1) and NK(2) receptor__no_interaction	senktide__tachykinin NK(1) and NK(2) receptor__no_interaction	SR 142801__tachykinin NK(1) and NK(2) receptor__no_interaction	chloride__tachykinin NK(1) and NK(2) receptor__no_interaction	N-methylacetamide__tachykinin NK(1) and NK(2) receptor__no_interaction	SR140333__tachykinin NK(1) and NK(2) receptor__no_interaction	neurokinin A__tachykinin NK(1) and NK(2) receptor__no_interaction	neurokinin B__tachykinin NK(1) and NK(2) receptor__no_interaction	4-phenyl-1-azoniabicyclo[2.2.2]octane__tachykinin NK(1) and NK(2) receptor__no_interaction	histamine__tachykinin NK(1) and NK(2) receptor__no_interaction
22229838-1	Three coordination polymers of [(NiL(1))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (1), [(NiL(2))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (2), and [(NiL(3))(3)(<protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>)(2)] (3) have been constructed using azamacrocyclic Ni(II) complexes [NiL(1)](ClO(4))(2)/[NiL(2)](ClO(4))(2)/[NiL(3)](ClO(4))(2) and <protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>(3-) as building blocks (L(1) = 3,10-bis(2-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12-<compound-id="11084806">hexaazacyclotetradecane</compound-id>; L(2) = 3,10-bis(3-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12-<compound-id="11084806">hexaazacyclotetradecane</compound-id>; L(3) = 3,10-bis(4-<compound-id="9591">fluorobenzyl</compound-id>)-1,3,5,8,10,12- <compound-id="11084806">hexaazacyclotetradecane</compound-id>; <protein-id="Q5VXU1,B0AZU5,B3KNZ0">TCBA</protein-id>(3-) = tri(4-carboxy-benzyl)amine).	hexaazacyclotetradecane__TCBA__no_interaction	fluorobenzyl__TCBA__no_interaction
15644641-6	MEASUREMENTS AND MAIN RESULTS: Baseline plasma levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id>, <protein-id="P10145,A0A024RDA5">interleukin-8</protein-id>, and <protein-id="P22301,Q6FGW4">interleukin-10</protein-id> were each associated with an increased risk of death in both logistic regression analyses controlling for ventilator group (odds ratio 1.63 per log-10 increment, 95% confidence interval 1.33-1.98; odds ratio 2.33 per log-10 increment, 95% confidence interval 1.79-3.03; odds ratio 2.02 per log-10 increment, 95% confidence interval 1.47-2.76, respectively) and multivariate analyses controlling for ventilation strategy, Acute Physiology and Chronic Health Evaluation III score, Pao2/Fio2 ratio, <compound-id="588">creatinine</compound-id>, platelet count, and vasopressor use (odds ratio 1.63 per log-10 increment, 95% confidence interval 0.93-1.49; odds ratio 1.73 per log-10 increment, 95% confidence interval 1.29-2.34; odds ratio 1.23 per log-10 increment, 95% confidence interval 0.86-1.76, respectively).	creatinine__interleukin-8__no_interaction	creatinine__interleukin-10__no_interaction	creatinine__interleukin-6__no_interaction
7589203-1	The effects of two new non-peptide angiotensin receptor antagonists, irbesartan (SR 47436/<compound-id="3749">BMS-186295</compound-id>, (2-n-<compound-id="68006705">butyl</compound-id>-4-spirocyclopentane-1-[((2'-tetrazol-5-yl)bipheny l-4-yl)methyl]2 - <compound-id="504">imidazolin-5-one</compound-id>) and SR 47155A (2-n-<compound-id="68006705">butyl</compound-id>-4-spirocyclopentane-1-[((2'-carboxy)biphenyl-4-yl)methy l]2- <compound-id="504">imidazolin-5-one</compound-id>, <compound-id="6422">trifluoroacetate</compound-id>), on <protein-id="P01015">angiotensin II</protein-id>-induced pressor responses were studied in the pithed rat in comparison to <compound-id="3961">losartan</compound-id>, EXP 3174 and [Sar1,Val5,Ala8]<protein-id="P01015">angiotensin II</protein-id>.	losartan__angiotensin II__no_interaction	imidazolin-5-one__angiotensin II__no_interaction	butyl__angiotensin II__no_interaction	BMS-186295__angiotensin II__no_interaction	trifluoroacetate__angiotensin II__no_interaction
2850820-2	Increasing dietary Na at the lower Ca intake caused significant (P less than 0.05) increases in <protein-id="P01270">parathyroid hormone (PTH) and 24</protein-id>-hour cyclic AMP excretion that were associated with significant (P less than 0.01) increases in erythrocyte intracellular <compound-id="22044544,5460341">calcium</compound-id> (from 5.4 +/- 0.7 to 11.1 +/- 3.7 microM), Ca-ATPase (from 37.2 +/- 2.4 to 42.2 +/- 2.1 pmol/min/10(6) cells) and intracellular <compound-id="5360545">sodium</compound-id> (from 220.5 +/- 7.4 to 262.0 +/- 8.3 micrograms/mL) and decreases (P less than 0.05) in Na/K-ATPase (from 1.90 +/- 0.55 to 1.48 +/- 0.47 pmol/min/10(6) cells) and intracellular <compound-id="5462224">magnesium</compound-id> (Mg) (from 52.4 +/- 3.5 to 43.8 +/- 2.4 micrograms/mL).	calcium__parathyroid hormone (PTH) and 24__no_interaction	magnesium__parathyroid hormone (PTH) and 24__no_interaction	sodium__parathyroid hormone (PTH) and 24__no_interaction
11598880-2	The glucan <protein-id="Q9UKR8">TM8</protein-id> in <compound-id="679">DMSO</compound-id> was fractionated by nonsolvent addition method into ten fractions, and the solution properties were studied by size exclusion chromatography combined with multiangle laser light scattering (SEC-MALLS) and viscometry in <compound-id="679">DMSO</compound-id> at 30 degrees C. The dependencies of intrinsic viscosity [eta] and radius of gyration [(s(2)(1/2)(z-2)] on weight-average molecular mass M(w) for this glucan were found to be [eta] = (9.24 +/- 0.2) x 10(-2)M(w)(0.51 +/- 0.02) (cm(3)g(-1)) and [(s(2)(1/2)(z-2)] = (3.67 +/- 0.3) x 10(-2)M(w)(0.56 +/- 0.02) (nm) in the range of M(w) from 1.07 x 10(4) to 77.4 x 10(4).	DMSO__TM8__no_interaction
24570606-5	There was no significant effect of measurement time on session-<protein-id="Q96AT9">RPE</protein-id> values following easy (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 1.3 ± 1.0 Arbitrary Unit (AU), %Heart Rate Reserve (HRR) = 49.5 ± 11.1, and ∆Blood <compound-id="612">lactate</compound-id> = -2.3 ± 16.3%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 1.7 ± 1.0 AU, %HRR = 51.3 ± 10.8, and ∆Blood <compound-id="612">lactate</compound-id> = 0.7 ± 25.2%), moderate (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 2.7 ± 1.6 AU, %HRR = 67.2 ± 10.8, and ∆Blood <compound-id="612">lactate</compound-id> = 2.2 ± 19%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 2.5 ± 0.9 AU, %HRR = 67.2 ± 5.9, and ∆Blood <compound-id="612">lactate</compound-id> = 24.5 ± 17.1%) and hard (10 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 5.7 ± 1.0 AU, %HRR = 88.1 ± 6.3, and ∆Blood <compound-id="612">lactate</compound-id> = 146.3 ± 87.9%; 30 minutes: session-<protein-id="Q96AT9">RPE</protein-id> = 5.8 ± 1.9 AU, %HRR&gt; = 83.3 ± 8.0, and ∆Blood <compound-id="612">lactate</compound-id> = 91.6 ± 39%) sessions.	lactate__RPE__no_interaction
2146429-4	Patients with AGN and NS had comparable edema (AGN 2.8 +/- 0.53 kg; NS 3.36 +/- 0.47 kg; SE) and urinary Na excretion (mean +/- <compound-id="5289348">SEM</compound-id>: AGN 0.97 +/- 0.11 mEq/hr; NS 1.06 +/- 0.16 mEq/hr), but AGN patients had five times higher <protein-id="P01160">ANF</protein-id> (AGN 27.2 +/- 4.06 fmol/ml; NS 5.51 +/- 1.02 fmol/ml; P less than 0.001) and six times lower PRA ng/liter.sec levels (AGN 0.187 +/- 0.047; NS 1.144 +/- 0.222; P less than 0.001) than NS patients.	SEM__ANF__no_interaction
14970995-6	RESULTS: To yield the best-fit weight formula for each fetal gender we employed step-wise regression analysis based on fractional polynomials with the biometric parameters biparietal diameter (BPD), head circumference (HC), transverse abdominal diameter (<compound-id="124886">TAD</compound-id>), abdominal circumference (AC) and femur length (FL): estimated fetal weight for girls (g) = - 4035.275 + 1.143 x BPD3 + 1159.878 x <protein-id="Q08828,C9J1J0,Q8NFM5,Q59FG4,Q08462,Q71UM8">AC1/2</protein-id> + 10.079 x FL3 - 81.277 x <compound-id="446134">FL2</compound-id> [in cm]; estimated fetal weight for boys (g) = 43576.579 + 1913.853 x log10BPD + 0.01323 x <compound-id="65094">HC3</compound-id> + 55.532 x AC2 - 13602.664 x <protein-id="Q08828,C9J1J0,Q8NFM5,Q59FG4,Q08462,Q71UM8">AC1/2</protein-id> - 0.721 x AC3 + 2.31 x FL3 [in cm].	TAD__AC1/2__no_interaction	HC3__AC1/2__no_interaction	FL2__AC1/2__no_interaction
21896912-7	The CYP2B6*6 allele, <protein-id="O15439,A8K2Q2">multidrug resistance-associated protein 4</protein-id> (<protein-id="O15439,A8K2Q2">MRP4</protein-id>) 1497C → T, and <protein-id="Q9BX51,D3DW46">gamma-glutamyltranspeptidase</protein-id> (GGT) were identified as major factors influencing the apparent <compound-id="64139">EFV</compound-id> oral clearance (CL/F), reducing the initial interindividual variability by 54.8%, according to the model CL/F = (12.2 - 0.00279 · GGT) · 0.602(CYP2B6*6 [G/T]) · 0.354(CYP2B6*6 [T/T]) · 0.793(<protein-id="O15439,A8K2Q2">MRP4</protein-id> 1497C → T), where CYP2B6*6 [G/T], CYP2B6*6 [T/T], and <protein-id="O15439,A8K2Q2">MRP4</protein-id> 1497C → T take values of 0 or 1 to indicate the absence or presence of polymorphisms.	EFV__multidrug resistance-associated protein 4__no_interaction	EFV__MRP4__no_interaction	EFV__gamma-glutamyltranspeptidase__no_interaction
8230672-6	The amounts of cyclic AMP produced by the stimulation of membranes with GTP, GTP+(l)-<compound-id="3779">isoproterenol</compound-id>, <compound-id="54215836">guanylimidodiphosphate</compound-id> (<compound-id="36735">Gpp(NH)p</compound-id>) or <compound-id="36735">Gpp(NH)p</compound-id>+(l)-<compound-id="3779">isoproterenol</compound-id> were significantly lower in 10 mM <compound-id="784">hydrogen peroxide</compound-id>-treated groups than those in controls (GTP: control 57.6 +/- 5.6 pmol <protein-id="G3V8S9">cAMP</protein-id>/mg protein/min vs H2O2 46.4 +/- 6.9, GTP+(l)-<compound-id="3779">isoproterenol</compound-id>: control 83.9 +/- 10.2 vs H2O2 67.7 +/- 10.3, <compound-id="36735">Gpp(NH)p</compound-id>: control 77.5 +/- 8.8 vs H2O2 61.0 +/- 8.6, <compound-id="36735">Gpp(NH)p</compound-id>+(l)-<compound-id="3779">isoproterenol</compound-id>: control 105.0 +/- 13.1 vs H2O2 83.9 +/- 12.2, <compound-id="47936">forskolin</compound-id>: control 223.2 +/- 13.8 vs H2O2 182.8 +/- 18.4).	isoproterenol__cAMP__no_interaction	Gpp(NH)p__cAMP__no_interaction	forskolin__cAMP__no_interaction	guanylimidodiphosphate__cAMP__no_interaction	hydrogen peroxide__cAMP__no_interaction
15579544-2	The present study demonstrated that regardless of whether pre-exercise muscle <compound-id="439177">glycogen</compound-id> content was at a habitual resting concentration (412 +/- 30 mmol (kg dry muscle)(-1)) or depleted (60 +/- 3 mmol (kg dry muscle)(-1)), the increase in PDC activation from its resting value (5.46 +/- 0.96 and 3.67 +/- 0.34 nmol <compound-id="444493">acetyl-CoA</compound-id> <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (mg protein)(-1), respectively) during 10 min of exercise at 75% of the maximum rate of <compound-id="977">oxygen</compound-id> consumption (VO2max) (delta12.82 +/- 1.72 and delta13.24 +/- 1.42 nmol <compound-id="444493">acetyl-CoA</compound-id> <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (mg protein)(-1), respectively) was the same, despite pyruvate accumulation during exercise being 3-fold lower in the <compound-id="439177">glycogen</compound-id> depleted state (delta0.34 +/- 0.04 and delta0.11 +/- 0.06 mmol (kg dry muscle)(-1), P &lt; 0.001).	oxygen__min(-1__no_interaction	acetyl-CoA__min(-1__no_interaction	glycogen__min(-1__no_interaction
7554525-5	After switching from <compound-id="25244226">Sandoparin</compound-id> to unfractionated heparin we observed significant decreases in total <compound-id="5997">cholesterol</compound-id> (from 168.6 +/- 42.2 to 154.4 +/- 41.9 mg/dl, p &lt; 0.02), LDL <compound-id="5997">cholesterol</compound-id> (from 106.4 +/- 35.2 to 89.9 +/- 32.3 mg/dl, p &lt; 0.005), triglycerides (from 148.7 +/- 85.0 to 121.4 +/- 88.8 mg/dl, p &lt; 0.05) and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (from 100.0 +/- 35.3 to 89.9 +/- 30.4 mg/dl, p &lt; 0.05) and a significant increase in HDL <compound-id="5997">cholesterol</compound-id> (from 32.8 +/- 12.5 to 37.7 +/- 17.5 mg/dl, p &lt; 0.02).	Sandoparin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
19274289-1	The new mononuclear [Cu(Hbdea)(2)].2Hdnba (), dinuclear [Cu(2)(mu-Hbdea)(2)(N(3))(2)] () and [Cu(2)(mu-Hbdea)(2)(pta)(2)].2H(2)O (), and 1D polymeric [Cu(2)(mu-Hbdea)(2)(mu-<compound-id="122634,22833501">tpa</compound-id>)](n).<compound-id="447474">2nH</compound-id>(2)O () <compound-id="23978">copper</compound-id>(II) compounds have been prepared by self-assembly, in aqueous alkali medium and at ambient conditions, from Cu(II) <compound-id="176">acetate</compound-id>, <compound-id="7620">N-butyldiethanolamine</compound-id> (H(2)bdea) and the corresponding auxiliary reagents, 3,5-dinitrobenzoic acid (Hdnba), <compound-id="33557">sodium azide</compound-id>, <compound-id="7470">p-toluic acid</compound-id> (<protein-id="P14210">Hpta</protein-id>) and <compound-id="7489">terephthalic acid</compound-id> (H(2)<compound-id="122634,22833501">tpa</compound-id>), respectively.	copper__Hpta__no_interaction	2nH__Hpta__no_interaction	tpa__Hpta__no_interaction	p-toluic acid__Hpta__no_interaction	N-butyldiethanolamine__Hpta__no_interaction	acetate__Hpta__no_interaction	sodium azide__Hpta__no_interaction	terephthalic acid__Hpta__no_interaction
18411413-1	In the present report, we evaluated the effect of the novel acid pump antagonist <compound-id="9833312">7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine</compound-id> (CS-526) and 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-<compound-id="5798">1H-benzimidazole</compound-id> (<compound-id="3883,9578006">lansoprazole</compound-id>) on rebound gastric acid secretion, using an intragastric dialysis membrane perfusion model and on the serum and <compound-id="35864">antral</compound-id> <protein-id="P04563">gastrin</protein-id> level after a 14-day treatment in rats.	lansoprazole__gastrin__no_interaction	antral__gastrin__no_interaction	7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine__gastrin__no_interaction	1H-benzimidazole__gastrin__no_interaction
19044958-6	Combining the VUV-<compound-id="54688400">PFI</compound-id>-PE and VUV-IR-PIRI measurements, 17 fundamental vibrational frequencies of trans-CH(2)[Double Bond]<protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>[Double Bond]CH(2) (+) have been determined, including nu(1) (+)=182+/-3, nu(2) (+)=300+/-3, nu(3) (+)=428+/-3, nu(4) (+)=514+/-3, nu(5) (+)=554+/-5, nu(6) (+)=901+/-3, nu(7) (+)=928+/-5, nu(8) (+)=994+/-3, nu(9) (+)=1008+/-5, nu(10) (+)=1094+/-5, nu(13) (+)=1258+/-3, nu(14) (+)=1293+/-3, nu(16) (+)=1479+/-3, nu(18) (+)=1620+/-3, nu(19) (+)=2985+/-10, nu(22) (+)=3030+/-10, and nu(23) (+)=3105+/-10 cm(-1).	PFI__CHCH__no_interaction
18036385-4	The calibration curves of analysed compounds are linear within the range of concentration: 45-825, 0.2-15, 16-225, 12-285, 0.1-32, 15-235, 0.1-12, 0.1-12, 10-205, 0.02-12, 0.1-24, 0.01-10 and 0.01-8 nmol mL(-1) for GLN, <compound-id="123895">NOHA</compound-id>, CIT, <protein-id="Q9P2R6,B1AKN3,A0A024R4E9">ARG</protein-id>, NMMA, <compound-id="232">HARG</compound-id>, ADMA, SDMA, ORN, PUT, <compound-id="213604">AGM</compound-id>, SPERMD and SPERM, respectively.	NOHA__ARG__no_interaction	HARG__ARG__no_interaction	AGM__ARG__no_interaction
15167345-10	Corrected <compound-id="588">creatinine</compound-id> clearance negatively correlated significantly with both <protein-id="P01034">cystatin C</protein-id> and <compound-id="588">creatinine</compound-id> levels (r = -0.622, P &lt; 0.001; r = -0.346, P = 0.045, respectively) before chemotherapy and also 1 month after chemotherapy (r = -0.577, P &lt; 0.001; r = -0.45, P = 0.009, respectively).	creatinine__cystatin C__no_interaction
23633364-19	<compound-id="44223986">FGS</compound-id> versus alpha-glucosidase inhibitors showed statistical significance in favour of <compound-id="44223986">FGS</compound-id> for adverse events (RR 0.63, 95% CI 0.52 to 0.76; P = 0.01; 2 trials; 246 participants; HRB) and for drop-outs due to adverse events (RR 0.28, 95% CI 0.12 to 0.67; P = 0.004; 2 trials; 246 participants; HRB).Second-generation sulphonylureas (SGS) versus <compound-id="4091">metformin</compound-id> (RR 0.98, 95% CI 0.61 to 1.58; P = 0.68; 6 trials; 3528 participants; HRB), thiazolidinediones (RR 0.92, 95% CI 0.60 to 1.41; P = 0.70; 7 trials; 4955 participants; HRB), <protein-id="P01308,I3WAC9">insulin</protein-id> (RR 0.96, 95% CI 0.79 to 1.18; P = 0.72; 4 trials; 1642 participants; HRB), <compound-id="3033769">meglitinides</compound-id> (RR 1.44, 95% CI 0.47 to 4.42; P = 0.52; 7 trials; 2038 participants; HRB), or incretin-based interventions (RR 1.39, 95% CI 0.52 to 3.68; P = 0.51; 2 trials; 1503 participants; HRB) showed no statistically significant effects regarding all-cause mortality in a random-effects model.	meglitinides__insulin__no_interaction	metformin__insulin__no_interaction	FGS__insulin__no_interaction
23270831-5	These compounds could be grouped as follows: alkaloids, 25.23% (<compound-id="5311218">TB1</compound-id>), 25.67% (<protein-id="Q00765">TB2</protein-id>), and 21.91% (TB3); phenols, 24.19% (<compound-id="5311218">TB1</compound-id>), 23.08% (<protein-id="Q00765">TB2</protein-id>), and 29.91% (TB3); <compound-id="947">nitrogen</compound-id>-compounds, 11.79% (<compound-id="5311218">TB1</compound-id>), 11.25% (<protein-id="Q00765">TB2</protein-id>), and 13.39% (TB3); hydrocarbons, 10.96% (<compound-id="5311218">TB1</compound-id>), 10.37% (<protein-id="Q00765">TB2</protein-id>), and 11.37% (TB3); <compound-id="114522">ketones</compound-id>, 10.34% (<compound-id="5311218">TB1</compound-id>), 6.58% (<protein-id="Q00765">TB2</protein-id>), and 8.22% (TB3); furan, 5.40% (<compound-id="5311218">TB1</compound-id>), 4.06% (<protein-id="Q00765">TB2</protein-id>), and 2.33% (TB3); <compound-id="10982484,702">alcohol</compound-id>, 3.30% (<compound-id="5311218">TB1</compound-id>), 4.16% (<protein-id="Q00765">TB2</protein-id>), and 3.34% (TB3); fatty acids, 2.80% (<compound-id="5311218">TB1</compound-id>), 4.03% (<protein-id="Q00765">TB2</protein-id>), and 1.42% (TB3); esters 2.17% (<compound-id="5311218">TB1</compound-id>), 0.99% (<protein-id="Q00765">TB2</protein-id>) and 2.35% (TB3); and amines 1.61% (<compound-id="5311218">TB1</compound-id>), 2.81% (<protein-id="Q00765">TB2</protein-id>), and 0.86% (TB3).	TB1__TB2__no_interaction	ketones__TB2__no_interaction	alcohol__TB2__no_interaction	nitrogen__TB2__no_interaction
11561072-6	The rank order of potency at <protein-id="P47824,Q9JIF8,B7U2F3">rP2X1</protein-id> was <compound-id="5957">ATP</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = Ap6G &gt; or = Ap5G, and rank order of efficacy was <compound-id="5957">ATP</compound-id> &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; Ap5G &gt; Ap6G, whereas at <protein-id="P49654,Q9R1K3">rP2X3</protein-id> the rank order of potency was <compound-id="5957">ATP</compound-id> &gt; Ap5G &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> &gt; or = <compound-id="123694">Ap6A</compound-id> &gt; or = Ap6G and the rank order of efficacy was <compound-id="5957">ATP</compound-id> approximately Ap5G &gt; or = <compound-id="2388,44237137,440210">Ap5A</compound-id> approximately <compound-id="123694">Ap6A</compound-id> &gt; or = Ap6G.	Ap6A__rP2X1__no_interaction	Ap6A__rP2X3__no_interaction	Ap5A__rP2X1__no_interaction	Ap5A__rP2X3__no_interaction	ATP__rP2X1__no_interaction	ATP__rP2X3__no_interaction
1592393-2	A large panel of antibodies was applied that included, for frozen tissue, Leu-6 (<protein-id="P06126">CD1</protein-id>), <protein-id="P06729,Q53F96">T11</protein-id> (<protein-id="P06729,Q53F96">CD2</protein-id>), Leu-<compound-id="2981881,91293124">3a</compound-id> (<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>), <protein-id="P06127">Leu-1</protein-id> (<protein-id="P06127">CD5</protein-id>), Leu-2a (<protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>), J5 (<protein-id="P08473">CD10</protein-id>), My7 (<protein-id="P15144,A0A024RC61,Q59E93">CD13</protein-id>), Leu-11 (<protein-id="P08637,M9MML0">CD16</protein-id>), B4 (<protein-id="P15391">CD19</protein-id>), B1 (<protein-id="P11836,A0A024R507">CD20</protein-id>), B2 (<protein-id="P20023">CD21</protein-id>), Tac (<protein-id="P01589,Q5W005">CD25</protein-id>), <compound-id="16741230">My9</compound-id> (<protein-id="P20138,Q546G0">CD33</protein-id>), <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">T200</protein-id> (<protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>), <compound-id="9362340">NKH</compound-id>-1 (<protein-id="P13591,A0A087WWD4">CD56</protein-id>), kappa and lambda chains, beta F1, Ki-67, HLA-DR, <protein-id="P14151,A0A024R8Z0">TQ1</protein-id>, and keratin, and for fixed tissue, leukocyte common antigen (<protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>), <protein-id="P61254">L26</protein-id> (<protein-id="P11836,A0A024R507">CD20</protein-id>), <protein-id="O14832">LN1</protein-id> (CDw75), LN2 (<protein-id="P04233">CD74</protein-id>), LN3, LN4, <compound-id="44176361">LN5</compound-id>, <protein-id="P11912">MB1</protein-id> (CD45R), <compound-id="74766010">MB2</compound-id>, <protein-id="P04731">MT1</protein-id> (<protein-id="P16150,A0A024R629">CD43</protein-id>), <protein-id="P49286">MT2</protein-id> (CD45R), <protein-id="P09936,V9HW74">UCHL1</protein-id> (CD45R0), <compound-id="444703">BM1</compound-id>, Ki-1 (<protein-id="P28908,A5D8T4">CD30</protein-id>), Leu-M1 (<protein-id="P22083">CD15</protein-id>), <protein-id="P61626,B2R4C5">lysozyme</protein-id>, KP1 (<protein-id="P34810">CD68</protein-id>), actin, S100, neuron-specific enolase, <protein-id="P08670,V9HWE1">vimentin</protein-id>, and keratin.	My9__CD74__no_interaction	My9__CD56__no_interaction	My9__CD30__no_interaction	My9__CD33__no_interaction	My9__CD4__no_interaction	My9__CD5__no_interaction	My9__CD1__no_interaction	My9__CD2__no_interaction	My9__CD8__no_interaction	My9__T11__no_interaction	My9__MT2__no_interaction	My9__MT1__no_interaction	My9__vimentin__no_interaction	My9__L26__no_interaction	My9__T200__no_interaction	My9__TQ1__no_interaction	My9__CD45__no_interaction	My9__CD21__no_interaction	My9__CD20__no_interaction	My9__LN1__no_interaction	My9__CD25__no_interaction	My9__CD68__no_interaction	My9__CD43__no_interaction	My9__Leu-1__no_interaction	My9__UCHL1__no_interaction	My9__MB1__no_interaction	My9__lysozyme__no_interaction	My9__CD16__no_interaction	My9__CD15__no_interaction	My9__CD13__no_interaction	My9__CD10__no_interaction	My9__CD19__no_interaction	NKH__CD74__no_interaction	NKH__CD56__no_interaction	NKH__CD30__no_interaction	NKH__CD33__no_interaction	NKH__CD4__no_interaction	NKH__CD5__no_interaction	NKH__CD1__no_interaction	NKH__CD2__no_interaction	NKH__CD8__no_interaction	NKH__T11__no_interaction	NKH__MT2__no_interaction	NKH__MT1__no_interaction	NKH__vimentin__no_interaction	NKH__L26__no_interaction	NKH__T200__no_interaction	NKH__TQ1__no_interaction	NKH__CD45__no_interaction	NKH__CD21__no_interaction	NKH__CD20__no_interaction	NKH__LN1__no_interaction	NKH__CD25__no_interaction	NKH__CD68__no_interaction	NKH__CD43__no_interaction	NKH__Leu-1__no_interaction	NKH__UCHL1__no_interaction	NKH__MB1__no_interaction	NKH__lysozyme__no_interaction	NKH__CD16__no_interaction	NKH__CD15__no_interaction	NKH__CD13__no_interaction	NKH__CD10__no_interaction	NKH__CD19__no_interaction	LN5__CD74__no_interaction	LN5__CD56__no_interaction	LN5__CD30__no_interaction	LN5__CD33__no_interaction	LN5__CD4__no_interaction	LN5__CD5__no_interaction	LN5__CD1__no_interaction	LN5__CD2__no_interaction	LN5__CD8__no_interaction	LN5__T11__no_interaction	LN5__MT2__no_interaction	LN5__MT1__no_interaction	LN5__vimentin__no_interaction	LN5__L26__no_interaction	LN5__T200__no_interaction	LN5__TQ1__no_interaction	LN5__CD45__no_interaction	LN5__CD21__no_interaction	LN5__CD20__no_interaction	LN5__LN1__no_interaction	LN5__CD25__no_interaction	LN5__CD68__no_interaction	LN5__CD43__no_interaction	LN5__Leu-1__no_interaction	LN5__UCHL1__no_interaction	LN5__MB1__no_interaction	LN5__lysozyme__no_interaction	LN5__CD16__no_interaction	LN5__CD15__no_interaction	LN5__CD13__no_interaction	LN5__CD10__no_interaction	LN5__CD19__no_interaction	BM1__CD74__no_interaction	BM1__CD56__no_interaction	BM1__CD30__no_interaction	BM1__CD33__no_interaction	BM1__CD4__no_interaction	BM1__CD5__no_interaction	BM1__CD1__no_interaction	BM1__CD2__no_interaction	BM1__CD8__no_interaction	BM1__T11__no_interaction	BM1__MT2__no_interaction	BM1__MT1__no_interaction	BM1__vimentin__no_interaction	BM1__L26__no_interaction	BM1__T200__no_interaction	BM1__TQ1__no_interaction	BM1__CD45__no_interaction	BM1__CD21__no_interaction	BM1__CD20__no_interaction	BM1__LN1__no_interaction	BM1__CD25__no_interaction	BM1__CD68__no_interaction	BM1__CD43__no_interaction	BM1__Leu-1__no_interaction	BM1__UCHL1__no_interaction	BM1__MB1__no_interaction	BM1__lysozyme__no_interaction	BM1__CD16__no_interaction	BM1__CD15__no_interaction	BM1__CD13__no_interaction	BM1__CD10__no_interaction	BM1__CD19__no_interaction	3a__CD74__no_interaction	3a__CD56__no_interaction	3a__CD30__no_interaction	3a__CD33__no_interaction	3a__CD4__no_interaction	3a__CD5__no_interaction	3a__CD1__no_interaction	3a__CD2__no_interaction	3a__CD8__no_interaction	3a__T11__no_interaction	3a__MT2__no_interaction	3a__MT1__no_interaction	3a__vimentin__no_interaction	3a__L26__no_interaction	3a__T200__no_interaction	3a__TQ1__no_interaction	3a__CD45__no_interaction	3a__CD21__no_interaction	3a__CD20__no_interaction	3a__LN1__no_interaction	3a__CD25__no_interaction	3a__CD68__no_interaction	3a__CD43__no_interaction	3a__Leu-1__no_interaction	3a__UCHL1__no_interaction	3a__MB1__no_interaction	3a__lysozyme__no_interaction	3a__CD16__no_interaction	3a__CD15__no_interaction	3a__CD13__no_interaction	3a__CD10__no_interaction	3a__CD19__no_interaction	MB2__CD74__no_interaction	MB2__CD56__no_interaction	MB2__CD30__no_interaction	MB2__CD33__no_interaction	MB2__CD4__no_interaction	MB2__CD5__no_interaction	MB2__CD1__no_interaction	MB2__CD2__no_interaction	MB2__CD8__no_interaction	MB2__T11__no_interaction	MB2__MT2__no_interaction	MB2__MT1__no_interaction	MB2__vimentin__no_interaction	MB2__L26__no_interaction	MB2__T200__no_interaction	MB2__TQ1__no_interaction	MB2__CD45__no_interaction	MB2__CD21__no_interaction	MB2__CD20__no_interaction	MB2__LN1__no_interaction	MB2__CD25__no_interaction	MB2__CD68__no_interaction	MB2__CD43__no_interaction	MB2__Leu-1__no_interaction	MB2__UCHL1__no_interaction	MB2__MB1__no_interaction	MB2__lysozyme__no_interaction	MB2__CD16__no_interaction	MB2__CD15__no_interaction	MB2__CD13__no_interaction	MB2__CD10__no_interaction	MB2__CD19__no_interaction
15809706-4	Our results showed that (i) treatment with <protein-id="P48023,Q53ZZ1">FasL</protein-id> increased <protein-id="Q14790,A0A024R3Z8">caspase-8</protein-id> activity (maximum at 4 h) and apoptosis (maximum at 8 h) in both <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) and <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (ii) <protein-id="P48023,Q53ZZ1">FasL</protein-id>-induced <protein-id="Q14790,A0A024R3Z8">caspase-8</protein-id> activity and apoptosis were significantly greater in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells compared with <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (iii) <protein-id="P48023,Q53ZZ1">FasL</protein-id> treatment increased cell surface expression of Fas receptor in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells to a greater extent compared with <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(-) cells, (iv) increased cell surface expression of Fas in <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells was not blocked by an inhibitor of protein synthesis (<compound-id="6197">cycloheximide</compound-id>), but was completely abrogated by <compound-id="24123450,2430,5351204,5353446,6364669,6436187,71308166">brefeldin A</compound-id>, an inhibitor of post-translational protein trafficking to the cell surface, and (v) <compound-id="24123450,2430,5351204,5353446,6364669,6436187,71308166">brefeldin A</compound-id> inhibited the increased sensitivity of <protein-id="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5">MUC1</protein-id>(+) cells to <protein-id="P48023,Q53ZZ1">FasL</protein-id>-induced apoptosis.	brefeldin A__caspase-8__no_interaction	brefeldin A__MUC1__no_interaction	brefeldin A__FasL__no_interaction	cycloheximide__caspase-8__no_interaction	cycloheximide__MUC1__no_interaction	cycloheximide__FasL__no_interaction
21059972-5	Compared with the control group, supervised exercise produced significant improvements (mean difference [95% confidence interval]) in physical fitness; HbA(1c) level (-0.30% [-0.49% to -0.10%]; P &lt; .001); systolic (-4.2 mm Hg [-6.9 to -1.6 mm Hg]; P = .002) and diastolic (-1.7 mm Hg [-3.3 to -1.1 mm Hg]; P = .03) blood pressure; high-density lipoprotein (3.7 mg/dL [2.2 to 5.3 mg/dL]; P &lt; .001) and low-density lipoprotein (-9.6 mg/dL [-15.9 to -3.3 mg/dL]; P = .003) <compound-id="5997">cholesterol</compound-id> level; waist circumference (-3.6 cm [-4.4 to -2.9 cm]; P &lt; .001); body mass index; <protein-id="P01308,I3WAC9">insulin</protein-id> resistance; inflammation; and risk scores.	cholesterol__insulin__no_interaction
1377308-5	After 3 months of treatment, we found (a) significant decreases in systolic (147 +/- 18 vs. 166 +/- 16 mm Hg, p less than 0.001) and diastolic blood pressure (90 +/- 8 vs. 107 +/- 8 mm Hg, p less than 0.0007), triglycerides (107 +/- 47 vs. 120 +/- 49 mg/dl, p less than 0.0007), and <compound-id="5997">cholesterol</compound-id> (236 +/- 4 vs. 257 +/- 44 mg/dl, p less than 0.00075) in blood, and in K excretion (50 +/- 19 vs. 46 +/- 19 mEq/g of <compound-id="588">creatinine</compound-id>, p less than 0.0007) and excreted fraction of K (49 +/- 6% vs. 8 +/- 5%, p less than 0.0012) in urine; (b) significant increases in <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> (65 +/- 13 vs. 58 +/- 13 mg/dl, p less than 0.001) in blood, and in Na (115 +/- 73 vs. 109 +/- 69 mEq/g of <compound-id="588">creatinine</compound-id>, p less than 0.0007) in urine; and (c) no significant change in the remaining biochemical parameters, or in heart rate.	creatinine__HDL__no_interaction	cholesterol__HDL__no_interaction
18520077-3	Among them, compounds with substituent at the 3-position on the central <compound-id="241">benzene</compound-id> ring represented by (N-{4-[1-(<compound-id="140746">acetimidoyl</compound-id>)<compound-id="79341">piperidin-4-yloxy</compound-id>]-3-chlorophenyl}-N-[(E)-3-(3-<compound-id="2332">amidinophenyl</compound-id>)-<compound-id="123136">2-propenyl</compound-id>]sulfamoyl)acetic acid dihydrochloride (<compound-id="42628077">45b</compound-id>) and (N-{4-[1-(<compound-id="140746">acetimidoyl</compound-id>)<compound-id="79341">piperidin-4-yloxy</compound-id>]-3-carbamoylphenyl}-N-[(E)-3-(3-<compound-id="2332">amidinophenyl</compound-id>)-<compound-id="123136">2-propenyl</compound-id>]sulfamoyl)acetic acid dihydrochloride (45j) exhibited potent <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id> inhibitory activities with IC(50) values of less than 10 nM in vitro.	benzene__FXa__no_interaction	piperidin-4-yloxy__FXa__no_interaction	2-propenyl__FXa__no_interaction	amidinophenyl__FXa__no_interaction	45b__FXa__no_interaction	acetimidoyl__FXa__no_interaction
9088909-1	Routine postmortem examinations and the pathobiological features revealed by systematically designed studies have shown several pathologic phenotypes that are often characteristic enough to differentiate among the various <compound-id="34756">SAM</compound-id> strains: senile amyloidosis in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, -P7, -P9, -<protein-id="P08207,Q3TC45">P10</protein-id>, and -P11; secondary amyloidosis in SAMP2 and -P6; contracted kidney in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, -<protein-id="P08207,Q3TC45">P10</protein-id>, and -P11; immunoblastic lymphoma in SAMR1 and -R4; histiocytic sarcoma in SAMR1 and -R4; ovarian cysts in SAMR1; impaired immune response in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>, -P2, and -P8; hyperinflation of the lungs in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>; hearing impairment in <protein-id="A2A8U2,Q8C397,Q8C9U2,Q3TXY3">SAMP1</protein-id>; degenerative temporomandibular joint disease in SAMP3; senile osteoporosis in SAMP6; deficits in learning and memory in SAMP8 and -<protein-id="P08207,Q3TC45">P10</protein-id>; emotional disorders in SAMP8 and -<protein-id="P08207,Q3TC45">P10</protein-id>; cataracts in SAMP9; and brain atrophy in SAMP10.	SAM__P10__no_interaction	SAM__SAMP1__no_interaction
10447673-5	Several properties clearly distinguish cdkX, and its associated HMG-I kinase, from known anti-PSTAIRE cross-reactive cdks: (a) cdkX migrates, in SDS/PAGE, in a position intermediate between prophase phosphorylated <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id> and metaphase dephosphorylated <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>; (b) in contrast with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>, cdkX and associated HMG-I kinase activity do not decrease following successive depletions on p9CKShs1-<compound-id="11966311">sepharose</compound-id>; (c) cdkX and associated HMG-I kinase activity, but not <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>, decrease following depletions on immobilized inhibitor; (d) cdkX is expressed during the early development of sea urchin embryos; in contrast with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id>/cyclin B kinase, the p15cdk-BP-bound HMG-I kinase is active throughout the cell cycle; compared with <protein-id="P06493,A0A024QZJ8,B7Z3D6,I6L9I5">cdk1</protein-id> it is active later in development; (e) p15cdk-BP-bound HMG-I kinase is essentially insensitive to powerful inhibitors of cdk such as <compound-id="448991">purvalanol</compound-id>, <compound-id="160355">roscovitine</compound-id>, <compound-id="4592">olomoucine</compound-id>, <protein-id="P38936,A0A024RCX5">p21cip1</protein-id> and <protein-id="Q8N726,P42771,K7PML8,G3XAG3">p16INK4A</protein-id>; HD is only moderately inhibitory.	olomoucine__cdk1__no_interaction	olomoucine__p16INK4A__no_interaction	olomoucine__p21cip1__no_interaction	roscovitine__cdk1__no_interaction	roscovitine__p16INK4A__no_interaction	roscovitine__p21cip1__no_interaction	purvalanol__cdk1__no_interaction	purvalanol__p16INK4A__no_interaction	purvalanol__p21cip1__no_interaction	sepharose__cdk1__no_interaction	sepharose__p16INK4A__no_interaction	sepharose__p21cip1__no_interaction
8006137-8	A decline in sperm motility from 0 to 4 h incubation was noted for all the <compound-id="4740">pentoxifylline</compound-id>-treated samples, under both test tube conditions (<protein-id="P18206,A0A024QZN4,V9HWK2,B3KXA2">VCL</protein-id>: 102.77 +/- 14.4 versus 73.16 +/- 4.6 microns/s, P &lt; 0.005; VSL: 27.2 +/- 10 versus 10.66 +/- 2.2 microns/s, P &lt; 0.005; LIN: 23.65 +/- 7.1 versus 11.86 +/- 1.8%, P &lt; 0.005) and HZA conditions (<protein-id="P18206,A0A024QZN4,V9HWK2,B3KXA2">VCL</protein-id>: 100.04 +/- 13.1 versus 76.00 +/- 7 microns/s, P &lt; 0.005; VSL: 26.40 +/- 8.7 versus 9.14 +/- 4.5 microns/s, P &lt; 0.005; LIN: 26.2 +/- 12 versus 11.05 +/- 4.3%, P &lt; 0.005).	pentoxifylline__VCL__no_interaction
17332736-5	<compound-id="3973">LY294002</compound-id> (a PI3K inhibitor) attenuated high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced cell cycle-dependent (G(0)/G(1) phase) hypertrophy at 72 h while attenuating high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced p21(WAF1) gene transcription and protein expression at 36-48 h. <compound-id="3973">LY294002</compound-id> also attenuated high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced binding of p21(WAF1) to the cyclin E/cdk2 complex, whereas attenuating high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced TGF-beta bioactivity, <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> phosphorylation, and <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> DNA-binding activity at 36-48 h. We concluded that PI3K is required for high <compound-id="206,5793,64689,79025">glucose</compound-id>-induced cell cycle-dependent hypertrophy, p21(WAF1) transcription and expression, p21(WAF1) binding to the cyclin E/cdk2 complex, TGF-beta bioactivity, and <protein-id="G9BWQ0,P84024">Smad2/3</protein-id> activity in LLC-PK1 cells.	LY294002__Smad2/3__no_interaction	glucose__Smad2/3__no_interaction
18426992-6	Renal medullary tissues of 2K1C rats showed greater levels of <protein-id="P08424">renin</protein-id> protein (CK: 1.4+/-0.2; <compound-id="24963056">NCK</compound-id>: 1.5+/-0.3), <protein-id="P08424">renin</protein-id> mRNA (CK: 5.8+/-2.0; <compound-id="24963056">NCK</compound-id>: 4.9+/-2.0), angiotensin I (CK: 120+/-18 pg/g; <compound-id="24963056">NCK</compound-id>: 129+/-13 pg/g versus sham: 67+/-6 pg/g), <protein-id="P01015">angiotensin II</protein-id> (CK: 150+/-32 pg/g; <compound-id="24963056">NCK</compound-id>: 123+/-21 pg/g versus sham: 91+/-12 pg/g; P&lt;0.05), and <protein-id="P08424">renin</protein-id> activity (CK: 8.6 microg of angiotensin I per microgram of protein; <compound-id="24963056">NCK</compound-id>: 8.3 microg of angiotensin I per microgram of protein; sham: 3.4 microg of angiotensin I per microgram of protein) than sham rats.	NCK__angiotensin II__no_interaction	NCK__renin__no_interaction
11510352-7	During the first 3 h of <protein-id="O15381,B4DF43">NVL</protein-id>, <compound-id="977">oxygen</compound-id> delivery increased from 371.3 +/- 84.9 to 443.9 +/- 92.7 gm/m2 and <compound-id="977">oxygen</compound-id> consumption from 123.9 +/- 35.9 to 173.5 +/- 34 m/m2, <compound-id="977">oxygen</compound-id> alveolar-arterial difference decreased from 400.8 +/- 165.3 to 210 +/- 57.5 mm Hg, pulmonary shunt from 41.8 +/- 11.9 to 19 +/- 7.9%, PaO2/FiO2 from 140.4 +/- 210 +/- 84.9, left-ventricular stroke index increased from 38.2 +/- 14.9 to 50.6 +/- 21.8 ml/m2, left-ventricular output index from 37 +/- 19.5 to 47.4 +/- 23.7 gm/m2, and heart rate decreased from 119.2 +/- 17.5 to 111.4 +/- 23.8 <protein-id="P13987,Q6FHM9">min-1</protein-id>.	oxygen__NVL__no_interaction	oxygen__min-1__no_interaction
10376199-8	For plaque size, univariate and multivariate analyses demonstrated that diabetes mellitus and hypercholesterolemia were independent predictors for greater plaque (13.5 +/- 5.72 versus 10.17 +/- 4.6 mm2, P = 0.015, for diabetic versus non-diabetic patients; 12.0 +/- 5.35 versus 9.03 +/- 3.76 mm2, P = 0.010, for hypercholesterolemic versus normocholesterolemic patients) and <compound-id="21313">EEM</compound-id> <protein-id="Q13216,B3KPW7,B4DGZ9">CSA</protein-id> (17.16 +/- 5.81 versus 14.3 +/- 5.1 mm2, P = 0.033, for diabetic versus non-diabetic patients; 16.57 +/- 5.49 versus 12.25 +/- 3.8 mm2, P = 0.001, for hypercholesterolemic versus normocholesterolemic patients) at the target lesion.	EEM__CSA__no_interaction
20979757-10	The level of plasma Hcy, and the content of <compound-id="5356750,6913958">Evans Blue</compound-id> leaked out brain tissue and the expression of <protein-id="P33436">MMP-2</protein-id> mRNA of the intervention group was significantly lower than those of the model group (12.5 +/- 1.4 vs 32.2 +/- 1.3, 3.42 +/- 0.45 vs 6.67 +/- 0.54, 0.118 +/- 0.052 vs 0.372 +/- 0.088, P &lt; 0.01).	Evans Blue__MMP-2__no_interaction
1518006-6	Anti-ZP3 titres developed in all treatment groups and correlated with carbohydrate content (peak per cent [125I]-labelled ZP3 binding by radioimmunoassay: SIZP 71.9 +/- 1.2, ZP3 70.0 +/- 2.5, <protein-id="Q07287">ZP3 alpha</protein-id>-EBGD 60.9 +/- 5.3, <protein-id="P42098">ZP3 beta</protein-id>-EBGD 56.4 +/- 5.0, <protein-id="Q07287">ZP3 alpha</protein-id>-DG 56.4 +/- 4.0, <protein-id="P42098">ZP3 beta</protein-id>-DG 53.5 +/- 4.3) (means +/- <compound-id="5289348">SEM</compound-id>).	SEM__ZP3 beta__no_interaction	SEM__ZP3 alpha__no_interaction
14605381-1	The title compounds, chlorotris(<compound-id="1068">dimethyl sulfide</compound-id>-kappaS)<compound-id="23939">platinum</compound-id>(II) <compound-id="9886">hexafluorophosphate</compound-id>, [PtCl(C(2)H(6)S)(3)]<protein-id="Q6Q759">PF(6</protein-id>), and bromotris(<compound-id="1068">dimethyl sulfide</compound-id>-kappaS)<compound-id="23939">platinum</compound-id>(II) <compound-id="9886">hexafluorophosphate</compound-id>, [PtBr(C(2)H(6)S)(3)]<protein-id="Q6Q759">PF(6</protein-id>), are isomorphous and are composed of [PtX(dms)(3)](+) complex cations (X = Cl and Br, and dms is <compound-id="1068">dimethyl sulfide</compound-id>) and <protein-id="Q6Q759">PF(6</protein-id>)(-) anions.	platinum__PF(6__no_interaction	dimethyl sulfide__PF(6__no_interaction	hexafluorophosphate__PF(6__no_interaction
8269792-8	RESULTS: Comparing data at the end of placebo and <compound-id="44093">captopril</compound-id> treatment, <compound-id="44093">captopril</compound-id> resulted in: lower blood pressure (systolic 154 +/- 2 vs. 163 +/- 3 mmHg and diastolic 93 +/- 2 vs. 101 +/- 2 mmHg); greater <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity in hyperglycemic conditions (total amount of <protein-id="P01308,I3WAC9">insulin</protein-id> infused and time of <protein-id="P01308,I3WAC9">insulin</protein-id> infusion required to reach euglycemia, 1.73 +/- 0.54 vs. 2.08 +/- 0.60 U and 58 +/- 8 vs. 70 +/- 11 min, <compound-id="44093">captopril</compound-id> and placebo, respectively, P &lt; 0.05); greater <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity in euglycemic conditions at liver level (hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> output 4.11 +/- 0.55 vs. 5.2 +/- 0.4 mumol.kg-1.min-1, step 1 of the clamp), muscle level (rates of <compound-id="206,5793,64689,79025">glucose</compound-id> disappearance 26.1 +/- 2.3 vs. 23.8 +/- 2.1 mumol.kg-1.min-1 step 2 of the clamp), primarily attributable to approximately 29% increase in nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism, and adipose tissue level (plasma free fatty acid 0.185 +/- 0.03 vs. 0.24 +/- 0.02 mM and lipid oxidation 1.9 +/- 0.3 vs. 2.21 +/- 0.04 mumol.kg-1.min-1 in step 1); and lower HbA1c (6.7 +/- 0.2 vs. 7.3 +/- 0.2%, P &lt; 0.05).	captopril__insulin__no_interaction	glucose__insulin__no_interaction
18799592-2	We describe two novel, potent <compound-id="242643">oxybenzylglycine</compound-id> <protein-id="Q07869,F1D8S4">PPARalpha</protein-id>-selective agonists, BMS-687453 [N-[[3-[[2-(4-chlorophenyl)-<compound-id="528411">5-methyl-4-oxazolyl</compound-id>]methoxy]phenyl]methyl]-N-(methoxycarbonyl)-<compound-id="45934207,750">glycine</compound-id>] and <compound-id="16727109">BMS-711939</compound-id> N-[[5-[[2-(4-chlorophenyl)-<compound-id="528411">5-methyl-4-oxazolyl</compound-id>]methoxy]-2-<compound-id="10008">fluorophenyl</compound-id>]methyl]-N-(methoxycarbonyl)-<compound-id="45934207,750">glycine</compound-id>], that robustly increase <protein-id="P02647,A0A024R3E3">apolipoprotein (Apo) A1</protein-id> and high-density lipoprotein <compound-id="5997">cholesterol</compound-id> in human <protein-id="P02647,A0A024R3E3">ApoA1</protein-id> transgenic mice and lower low-density lipoprotein-<compound-id="5997">cholesterol</compound-id> and triglycerides in fat-fed hamsters.	5-methyl-4-oxazolyl__apolipoprotein (Apo) A1__no_interaction	5-methyl-4-oxazolyl__ApoA1__no_interaction	5-methyl-4-oxazolyl__PPARalpha__no_interaction	fluorophenyl__apolipoprotein (Apo) A1__no_interaction	fluorophenyl__ApoA1__no_interaction	fluorophenyl__PPARalpha__no_interaction	glycine__apolipoprotein (Apo) A1__no_interaction	glycine__ApoA1__no_interaction	glycine__PPARalpha__no_interaction	BMS-711939__apolipoprotein (Apo) A1__no_interaction	BMS-711939__ApoA1__no_interaction	BMS-711939__PPARalpha__no_interaction	cholesterol__apolipoprotein (Apo) A1__no_interaction	cholesterol__ApoA1__no_interaction	cholesterol__PPARalpha__no_interaction	oxybenzylglycine__apolipoprotein (Apo) A1__no_interaction	oxybenzylglycine__ApoA1__no_interaction	oxybenzylglycine__PPARalpha__no_interaction
15945636-3	Results obtained using the CASSCF [multiconfigurational complete active space (SCF--self-consistent field)] method, with active spaces ranging from (9e/9o) to (15e/<compound-id="72201006">12o</compound-id>), followed by second-order perturbation theory [CASPT2 and MS-CASPT2 (MS--multistate)] with polarized 6-311G(d,p) and natural orbital (ANO-L) basis sets reveal the following: (i) both <protein-id="Q8N5C8">TAB3</protein-id>+ and TMB (D3h) have a quartet <compound-id="69255155">4A</compound-id>"1 ground state with doublet-quartet <compound-id="73010387">2B1</compound-id>-<compound-id="69255155">4A</compound-id>"1 energy gaps of 8.0+/-2.0 and 12.4+/-2.0 kcal/mol, respectively; (ii) in the neutral N series, the quartet state remains the electronic ground state, irrespective of the number of N atoms, but each with slightly reduced gap, 11 kcal/mol for C8H8N (<compound-id="69255155">4A</compound-id>"), 10 kcal/mol for C7H7N2 (<compound-id="25165666">4A2</compound-id>), and 9 kcal/mol for C6H6N3 (<compound-id="25165666">4A2</compound-id>); and (iii) the ground state of monoamino cation and <compound-id="76988">diamino</compound-id> dication is a low-spin doublet state (<compound-id="73010387">2B1</compound-id> for C8H9N+ and <compound-id="50937462">2A2</compound-id> for C7H9N2 2+) and lying well below the corresponding quartet state by 10 and 12 kcal/mol, respectively.	4A2__TAB3__no_interaction	diamino__TAB3__no_interaction	2B1__TAB3__no_interaction	12o__TAB3__no_interaction	2A2__TAB3__no_interaction	4A__TAB3__no_interaction
17003923-6	Variants of coagulation factors [factor V 1691G&gt;A (factor V Leiden), factor V 4070A&gt;G (factor V <compound-id="16220139">HR2</compound-id> haplotype), factor VII Arg353Gln, factor XIII Val34Leu, beta-fibrinogen -455G&gt;A, prothrombin 20210G&gt;A], coagulation inhibitors [<compound-id="38003">tissue factor pathway inhibitor</compound-id> 536C&gt;T, thrombomodulin 127G&gt;A], fibrinolytic factors [angiotensin converting enzyme intron 16 insertion/deletion, factor VII-activating protease 1601G&gt;A (FSAP Marburg I), plasminogen activator inhibitor 1-675 insertion/deletion (5G/4G), tissue plasminogen activator intron h deletion/insertion], and other factors implicated in influencing susceptibility to thromboembolic diseases [apolipoprotein E2/E3/E4, <protein-id="Q13201">glycoprotein Ia</protein-id> 807C&gt;T, <compound-id="21889576">methylenetetrahydrofolate</compound-id> reductase 677C&gt;T] were included.	methylenetetrahydrofolate__glycoprotein Ia__no_interaction	tissue factor pathway inhibitor__glycoprotein Ia__no_interaction	HR2__glycoprotein Ia__no_interaction
20100409-6	RESULTS: In elective and emergency aneurysm repair, D2max (26, standard deviation [SD] 3, mm v. 30.7 [SD 3] mm), D5a (16 [SD 4.7] mm v. 19.3 [SD 5] mm), D5b (15.3 [SD 4] mm v. 18.1 [SD 3.6] mm), H1 (25.6 [SD 8.6] mm v. 18 [SD 2] mm), H4a (173 [SD 22] mm v. 189.5 [SD 22] mm) and <protein-id="P62805,B2R4R0">H4b</protein-id> (174 [<compound-id="12631">SD 25</compound-id>] mm v. 190 [SD 14] mm) were significantly different between the 2 groups (p = 0.001, p = 0.006, p = 0.007, p &lt; 0.001, p = 0.05 and p = 0.01, respectively).	SD 25__H4b__no_interaction
16903746-1	New mono- and dinuclear <compound-id="23947">rhenium</compound-id>(I) tricarbonyls, of formulas [Re(bpy)(CO)3(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)]+ (1), [(bpy)(CO)<compound-id="49852675">3Re</compound-id>(I)(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)Re(I)(CO)3(bpy)]2+ (2), and [(bpy)(CO)<compound-id="49852675">3Re</compound-id>(I)(<protein-id="Q9Y5Y0,B2RB38">PCA</protein-id>)Ru(II)(NH3)5]3+ (3) (bpy = 2,2'-bipyridine, <protein-id="Q9Y5Y0,B2RB38">PCA</protein-id> = 4-pyridinecarboxaldehydeazine), have been synthesized as <protein-id="Q6Q759">PF6</protein-id>- salts and characterized by spectroscopic, electrochemical, and photophysical techniques.	rhenium__PCA__no_interaction	rhenium__PF6__no_interaction	3Re__PCA__no_interaction	3Re__PF6__no_interaction
23154546-4	RESULTS: Pathway activation mapping of NSCLC revealed distinct subgroups composed of epidermal growth factor receptor (ERBB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (<protein-id="P70424">ERBB2</protein-id>), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (<protein-id="Q61526">ERBB3</protein-id>), <protein-id="Q61527">v-erb-a erythroblastic leukemia viral oncogene homolog 4</protein-id> (<protein-id="Q61527">ERBB4</protein-id>), v-akt murine thymoma viral oncogene homolog 1- mammalian target of <compound-id="16760631,478951,49652385,5040,5284616,5358081,53627520,5374464,60150249,6436030,70789198,71296106,71308609,86583604,91454826,9854380">rapamycin</compound-id> (AKT-<protein-id="Q9JLN9">mTOR</protein-id>), protein kinase, AMP-activated, alpha 2 catalytic subunit (<protein-id="Q9Y478,A0A024RBN1">AMPK</protein-id>), and autophagy-related signaling, along with transforming growth factor-beta-signaling protein 1 (SMAD), <protein-id="P08069,C9J5X1">insulin-line growth factor receptor</protein-id> (<protein-id="P08069,C9J5X1">IGFR</protein-id>), <protein-id="P07949,Q9BTX6,A0A024R7T2">rearranged during transfection proto-oncogene</protein-id> (<protein-id="P07949,Q9BTX6,A0A024R7T2">RET</protein-id>), and activated CDC42-associated kinase (<compound-id="101812">ACK</compound-id>) activation.	ACK__ERBB2__no_interaction	ACK__ERBB3__no_interaction	ACK__ERBB4__no_interaction	ACK__AMPK__no_interaction	ACK__insulin-line growth factor receptor__no_interaction	ACK__v-erb-a erythroblastic leukemia viral oncogene homolog 4__no_interaction	ACK__RET__no_interaction	ACK__mTOR__no_interaction	ACK__IGFR__no_interaction	ACK__rearranged during transfection proto-oncogene__no_interaction	rapamycin__ERBB2__no_interaction	rapamycin__ERBB3__no_interaction	rapamycin__ERBB4__no_interaction	rapamycin__AMPK__no_interaction	rapamycin__insulin-line growth factor receptor__no_interaction	rapamycin__v-erb-a erythroblastic leukemia viral oncogene homolog 4__no_interaction	rapamycin__RET__no_interaction	rapamycin__mTOR__no_interaction	rapamycin__IGFR__no_interaction	rapamycin__rearranged during transfection proto-oncogene__no_interaction
22863558-7	In patients with ACS, there was a negative correlation among serum <compound-id="1176">urea</compound-id> (r = -0.377; p &lt; 0.001) and <compound-id="588">creatinine</compound-id> (r = -0.232; p = 0.024) levels and <protein-id="P02765">fetuin-A</protein-id>, and a negative correlation among WBC (r = -0.156; p = 0,132), ESR (r = -0.214; p = 0.037), hs-CRP (r = -0.220; p = 0.032) levels and <protein-id="P02765">fetuin-A</protein-id>.	creatinine__fetuin-A__no_interaction	urea__fetuin-A__no_interaction
20347721-6	<compound-id="16122568,16750043,4369303,448383">CSF</compound-id> Cbl levels were significantly higher (RR patients 27.9+/-9.7 pg/ml, p&lt;0.0001 vs. C; SP patients 25.4+/-8 pg/ml, p&lt;0.02 vs. C), and <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> and EGF levels significantly lower in the patients with the <protein-id="P01375,Q5STB3">RR (TNF-alpha</protein-id> 28.3+/-23.4 x 10(-3) pg/ml, p&lt;0.0001 vs. C; EGF 129.9+/-44.8 pg/ml, p&lt;0.02 vs. C) or SP (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id> 20.5+/-20.5 x 10(-3) pg/ml, p&lt;0.001 vs. C; EGF 116.5+/-24.8 pg/ml, p&lt;0.05 vs. C) clinical course than in controls (Cbl 21+/-4.6 pg/ml; <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> 75.6+/-34.7 x 10(-3) pg/ml; EGF 170.2+/-54.8 pg/ml).	CSF__TNF-alpha__no_interaction	CSF__RR (TNF-alpha__no_interaction
20079222-6	RESULTS: In the group NDM, ED and T-STD were prolonged [(546.04 +/- 103.78) s vs (617.52 +/- 106.96) s, P &lt; 0.05 and (378.64 +/- 92.34) s vs (436.84 +/- 91.25) s, P &lt; 0.05], STDmax was shortened [(2.06 +/- 0.37) mm vs (1.75 +/- 0.41) mm, P &lt; 0.01] and RPP was increased [(173.77 +/- 34.73) beatsxmin(-1)<compound-id="5289587">xmm</compound-id> Hg(-2) vs (199.23 +/- 37.07 beatsxmin(-1)<compound-id="5289587">xmm</compound-id> Hg(-2), P &lt; 0.05] as the parameters during EX2 were compared with those during <protein-id="Q96NE9">EX1</protein-id>.	xmm__EX1__no_interaction
19131510-3	Results are summarized: 1) E(2), the nuclear membrane-impermeable estrogen, estrogen-dendrimer conjugate, and the plasma membrane-impermeable estrogen, E(2)-BSA conjugate, all stimulated <protein-id="P01148">LHRH</protein-id> release within 10 min of exposure; 2) whereas the estrogen receptor antagonist, <compound-id="104741">ICI 182,780</compound-id>, did not block the E(2)-induced <protein-id="P01148">LHRH</protein-id> release, E(2) application to cells treated with pertussis toxin failed to induce <protein-id="P01148">LHRH</protein-id> release; 3) <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> mRNA was expressed in olfactory placode cultures, and <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> protein was expressed in a subset of <protein-id="P01148">LHRH</protein-id> neurons; 4) pertussis toxin treatment blocked the E(2)-induced increase in [Ca(2+)](i) oscillations; 5) knockdown of <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> in primate <protein-id="P01148">LHRH</protein-id> neurons by transfection with small interfering RNA (siRNA) for <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> completely abrogated the E(2)-induced changes in [Ca(2+)](i) oscillations, whereas transfection with control siRNA did not; 6) the estrogen-dendrimer conjugate-induced increase in [Ca(2+)](i) oscillations also did not occur in <protein-id="P01148">LHRH</protein-id> neurons transfected with <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> siRNA; and 7) G1, a <protein-id="Q99527,Q63ZY2,A0A024R849">GPR30</protein-id> agonist, resulted in changes in [Ca(2+)](i) oscillations, similar to those observed with E(2).	ICI 182,780__GPR30__no_interaction	ICI 182,780__LHRH__no_interaction
25005608-9	RESULTS: In <compound-id="1983">APAP</compound-id> group, <protein-id="Q8QZR5,Q566C3">ALT</protein-id>, hepatic MDA and the number of IL-12 and <protein-id="P70380,Q2PMY2">IL-18</protein-id> positive stained cells were significantly increased when compared to control group (1210.50 ± 533.86 vs 85.28 ± 28.27 U/L, 3.60 ± 1.50 vs 1.38 ± 0.15 nmol/mg protein, 12.18 ± 1.10 vs 1.84 ± 1.29%, and 13.26 ± 0.90 vs 2.54 ± 1.29%, P = 0.000, respectively), whereas hepatic <compound-id="124886">GSH</compound-id> was significantly decreased when compared to control group (5.98 ± 0.30 vs 11.65 ± 0.43 nmol/mg protein, P = 0.000).	GSH__ALT__no_interaction	GSH__IL-18__no_interaction	APAP__ALT__no_interaction	APAP__IL-18__no_interaction
25005608-10	The mean level of <protein-id="Q8QZR5,Q566C3">ALT</protein-id>, hepatic MDA, the number of IL-12 and <protein-id="P70380,Q2PMY2">IL-18</protein-id> positive stained cells, and hepatic <compound-id="124886">GSH</compound-id> in Aloe vera-treated group were improved as compared with <compound-id="1983">APAP</compound-id> group (606.38 ± 495.45 vs 1210.50 ± 533.86 U/L, P = 0.024; 1.49 ± 0.64 vs 3.60 ± 1.50 nmol/mg protein, P = 0.001; 5.56 ± 1.25 vs 12.18 ± 1.10%, P = 0.000; 6.23 ± 0.94 vs 13.26 ± 0.90%, P = 0.000; and 10.02 ± 0.20 vs 5.98 ± 0.30 nmol/mg protein, P = 0.000, respectively).	GSH__ALT__no_interaction	GSH__IL-18__no_interaction	APAP__ALT__no_interaction	APAP__IL-18__no_interaction
3516657-2	The mechanisms subserving this facilitative interaction included the following: 1) insulin's synergism with LDL was profoundly attenuated by covalent modification of <compound-id="6322,90867653">arginine</compound-id> residues in LDL by 1,2-<compound-id="13006">cyclohexanedione</compound-id> treatment; 2) insulin increased by 2- to 6-fold the number of specific high affinity LDL receptors on granulosa cells, with no change in apparent binding affinity; 3) insulin augmented rates of [125I]iodo-LDL internalization and degradation without enhancing nonspecific bulk fluid-phase pinocytosis (assessed with [125I]iodo-polyvinylpyrollidone); 4) insulin increased by 2.5- to 3-fold granulosa cell content of free and esterified <compound-id="5997">cholesterol</compound-id> (measured by fluorometry) in response to treatment with unlabeled LDL; 5) insulin stimulated the intracellular accumulation of free [3H]<compound-id="5997">cholesterol</compound-id> and [3H]cholesteryl ester, and amplified [3H]<compound-id="5994">progesterone</compound-id> secretion by granulosa cells exposed to [3H]<compound-id="227041,22833537,46936301,5287939,54100202,54609098,57314933,6379755,6538325">cholesteryl linoleate</compound-id>-labeled LDL; and 6) insulin action was specific in that it was not mimicked by desoctapeptide insulin, epidermal growth factor, fibroblast growth factor, or <protein-id="P01348">relaxin</protein-id>.	cholesteryl linoleate__relaxin__no_interaction	progesterone__relaxin__no_interaction	arginine__relaxin__no_interaction	cyclohexanedione__relaxin__no_interaction	cholesterol__relaxin__no_interaction
23534942-1	New <compound-id="23947">rhenium</compound-id>(VII or III) complexes [ReO3(PTA)2][ReO4] (1) (PTA = <compound-id="143061">1,3,5-triaza-7-phosphaadamantane</compound-id>), [ReO3(<compound-id="656710">mPTA</compound-id>)][ReO4]I (2) (<compound-id="656710">mPTA</compound-id> = N-methyl-<compound-id="143061">1,3,5-triaza-7-phosphaadamantane</compound-id> cation), [ReO3(HMT)2][ReO4] (3) (HMT = <compound-id="4101">hexamethylenetetramine</compound-id>), [ReO3(η(2)-Tpm)(PTA)][ReO4] (4) [Tpm = hydrotris(pyrazol-1-yl)<compound-id="297">methane</compound-id>, HC(pz)3, pz = <compound-id="1048">pyrazolyl</compound-id>], [ReO3(Hpz)(HMT)][ReO4] (5) (Hpz = pyrazole), [ReO(Tpms)(HMT)] (6) [Tpms = <compound-id="6503">tris</compound-id>(pyrazol-1-yl)<compound-id="6395">methanesulfonate</compound-id>, O3SC(pz)3(-)] and [ReCl2{<compound-id="5288874">N2C</compound-id>(O)Ph}(PTA)3] (7) have been prepared from the Re(VII) <compound-id="190217">oxide</compound-id> <compound-id="123106">Re2O7</compound-id> (1-6) or, in the case of 7, by ligand exchange from the benzoyldiazenido complex [ReCl2{<compound-id="5288874">N2C</compound-id>(O)Ph}(Hpz)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2], and characterized by IR and NMR spectroscopies, elemental analysis and electrochemical properties.	rhenium__PPh3__no_interaction	hexamethylenetetramine__PPh3__no_interaction	methanesulfonate__PPh3__no_interaction	N2C__PPh3__no_interaction	oxide__PPh3__no_interaction	mPTA__PPh3__no_interaction	pyrazolyl__PPh3__no_interaction	Re2O7__PPh3__no_interaction	1,3,5-triaza-7-phosphaadamantane__PPh3__no_interaction	tris__PPh3__no_interaction	methane__PPh3__no_interaction
19265213-1	The title complex, <protein-id="O95817">Bis</protein-id>[mu(3)-cis-N-(2-aminopropyl)-N'-(2-carboxylatophenyl)oxamidato(3-)]-1:2:4kappa(7)N,N',N'',O:O',O'':O''';2:3:4kappa(7)O''':N,N',N'',O:O',O''-<protein-id="O95817">Bis</protein-id>(2,2'-bipyridine)-2kappa(2)N,N';4kappa(2)N,N'-dichlorido-1kappaCl,3kappaCl-tetracopper(II) <compound-id="3039108">dihydrate</compound-id>, [Cu(4)(C(12)H(12)N(3)O(4))(2)Cl(2)(C(10)H(8)N(2))(2)].2H(2)O, consists of a neutral cyclic tetracopper(II) system having an embedded centre of inversion and two solvent <compound-id="962">water</compound-id> molecules.	water__Bis__no_interaction	dihydrate__Bis__no_interaction
18605990-8	Plasma <protein-id="P01160">ANP</protein-id> concentrations positively correlated significantly with pulmonary artery pressure (PAP) (r = 0.74, p &lt; 0.05) and <compound-id="656964">3DE</compound-id> measurements of cardiac volumes (right ventricular end-diastolic (r = 0.50, p &lt; 0.05) and end-systolic volume (r = 0.50, p &lt; 0.05) and negatively correlated with RVEF (r = -0.38, p &lt; 0.05).	3DE__ANP__no_interaction
18822124-6	In COPD with <compound-id="2148">PAH</compound-id>, linear regression analysis showed good correlation between <protein-id="P05305,Q6FH53">ET-1</protein-id> in <compound-id="368250">EBC</compound-id> and <compound-id="10214">PaPs</compound-id> (r = 0.621; p = 0.031), and between arterial levels of <protein-id="P05305,Q6FH53">ET-1</protein-id> and <compound-id="10214">PaPs</compound-id> (r = 0.648; p = 0.022), while arterial levels of <protein-id="P05305,Q6FH53">ET-1</protein-id> inversely correlated with FEV1%, (r = -0.59, p = 0.043), and <compound-id="10214">PaPs</compound-id> negatively correlated to PaO2 (r = -0.618; p = 0.032).	PAH__ET-1__no_interaction	PaPs__ET-1__no_interaction	EBC__ET-1__no_interaction
22218706-1	A series of germylene, stannylene and plumbylene complexes [η(2)(N,N)-Me(2)Si(DippN)(2)Ge:] (<compound-id="2981881,91293124">3a</compound-id>), [η(2)(N,N)-Ph(2)Si(DippN)(2)Ge:] (3b), [η(2)(N,N)-Me(2)Si(DippN)(2)Sn:] (4), [η(2)(N,N)-Me(2)Si(DippN)(2)Pb:](2) (5a), and [η(2)(N,N)-Ph(2)Si(DippN)(2)Pb:] (<compound-id="18445697">5b</compound-id>) (<compound-id="122669">Dipp</compound-id> = 2,6-iPr(2)C(6)H(3)) bearing bulky <protein-id="O95817">bis</protein-id>(amido)silane ligands were readily prepared either by the transamination of M[N(SiMe(3))(2)](2) (M = Sn, Pb) and [Me(2)Si(DippNH)(2)] or by the metathesis reaction of bislithium <protein-id="O95817">bis</protein-id>(amido)silane [η(1)(N),η(1)(N)-R(2)Si(DippNLi)(2)] (R = Me, Ph) with the corresponding metal halides GeCl(2)(<compound-id="31275">dioxane</compound-id>), SnCl(2), and PbCl(2), respectively.	Dipp__bis__no_interaction	3a__bis__no_interaction	dioxane__bis__no_interaction	5b__bis__no_interaction
20964312-2	X-ray diffraction data of these complexes indicate that (PPh(4))(2)[Fe(CN)(5)<compound-id="795">imidazole</compound-id>]·2H(2)O crystallizes in the triclinic space group P1 with a = 9.8108(15) Å, b = 11.1655(17) Å, c = 23.848(4) Å, α = 87.219(2)°, β = 85.573(2)°, γ = 70.729(2)°, and Z = 2, while its precursor Na(3)[Fe(CN)(5)(en)]·5H(2)O crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n with a = 8.3607(7) Å, b = 11.1624(9) Å, c = 17.4233(14) Å, β = 90.1293(9)°, and Z = 4.	imidazole__P2(1__no_interaction
16390154-7	The rates of photoisomerization of these complexes, [((Z)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-bpy)Ru(bpy)(2)](PF(6))(2) (2Z) and [((E)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-bpy)Ru(bpy)(2)](PF(6))(2) (2E), were compared to those of their untethered analogues, (Z)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-OTBS (1Z) and (E)-1,2-<protein-id="O95817">bis</protein-id>(biphenyl)<compound-id="6325">ethene</compound-id>-OTBS (1E), where <compound-id="23950">ruthenium</compound-id> sensitization occurred through an intermolecular pathway.	ruthenium__bis__no_interaction	ethene__bis__no_interaction
20383650-5	<compound-id="5997">Cholesterol</compound-id> 202.5 ± 37.6 mg/dl, HDL 51.4 ± 20.4 mg/dl, LDL 126.5 ± 36.0 mg/dl, triglyceride 146.2 ± 72.4 mg/dl, <protein-id="Q8TD31,Q769H0,M1T2K8,B0S7V6,M1TIV4,Q2TB68,D2IYK9">SBP</protein-id> 137.8 ± 14.2 mmHg, DBP 80.7 ± 10.8 mmHg, 10-year CV risk score 13.7 ± 9.1; 70.4% had no microangiopathy-i.e.	Cholesterol__SBP__no_interaction
20380714-4	RESULTS: Baseline circulating omentin-1 concentrations correlated negatively with BMI (r = -0.58, p &lt; 0.001), body weight (r = -0.35, p = 0.045), fat mass (r = -0.67, p &lt; 0.001), circulating <compound-id="90470904">leptin</compound-id> (r = -0.7, p &lt; 0.001) and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.37, p = 0.03).	leptin__insulin__no_interaction
12905763-5	Multivariate logistic regression analysis shows that diabetes family history, duration of diabetes (&gt; 5 years), and systolic blood pressure (&gt; 125 mmHg) are the risk factors for diabetic retinopathy; duration of diabetes (&gt; 5 years), systolic blood pressure (&gt; 125 mmHg), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (&gt; 3.12 mmol/L), and triglyceride (&gt; 1.70 mmol/L) are the risk factors for diabetic nephropathy; age (&gt; 45 years), duration of diabetes (&gt; 5 years), HbA1C (&gt; 7.0%), systolic blood pressure (&gt; 125 mmHg), and <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (&gt; 3.12 mmol/L), are the risk factors for <compound-id="221493">CHD</compound-id>; age (&gt; 45 years), duration of diabetes (&gt; 5 years), systolic blood pressure (&gt; 125 mmHg), and triglyceride (&gt; 1.70 mmol/L) are the risk factors for CVD.	CHD__LDL-C__no_interaction
22356715-4	RESULTS: In malignant transformation cells, the mRNA expression level (<protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 0.63 ± 0.04, <protein-id="P54274">TRF1</protein-id>: 0.36 ± 0.01) and the protein expression level (<protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 0.36 ± 0.05, <protein-id="P54274">TRF1</protein-id>: 0.09 ± 0.03) of <protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id> and <protein-id="P54274">TRF1</protein-id> was statistically significant decreased compared to that of BEAS-2B group (mRNA: <protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 1.00 ± 0.04, <protein-id="P54274">TRF1</protein-id>: 1.01 ± 0.16; protein: <protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 0.55 ± 0.07, <protein-id="P54274">TRF1</protein-id>: 0.27 ± 0.07) and <compound-id="679">DMSO</compound-id> group (mRNA: <protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 0.89 ± 0.12, <protein-id="P54274">TRF1</protein-id>: 0.90 ± 0.08; protein: <protein-id="Q9NUX5,Q5MJ33,A8MTK3,A0A024R739">POT1</protein-id>: 0.55 ± 0.10, <protein-id="P54274">TRF1</protein-id>: 0.26 ± 0.04) (P &lt; 0.05); mRNA expression level (1.45 ± 0.07) and the protein expression level (0.88 ± 0.06) of <protein-id="Q15554">TRF2</protein-id> was increased compared to that of BEAS-2B group (mRNA: 1.00 ± 0.07, protein: 0.48 ± 0.06) and <compound-id="679">DMSO</compound-id> group (mRNA: 1.00 ± 0.06, protein: 0.50 ± 0.06) (P &lt; 0.05).	DMSO__TRF1__no_interaction	DMSO__TRF2__no_interaction	DMSO__POT1__no_interaction
19860767-2	METHODS: Seventy-five unrelated AMD patients and 75 unrelated healthy, sex- and age-matched control patients were genotyped for the following 19 single nucleotide polymorphisms (SNPs) in 14 different genes: blood coagulation factor V (FV) R506Q, factor II (<protein-id="P00734">prothrombin</protein-id>) G20210A and factor XIII (FXIII) V34L; <compound-id="108194,439175,445117,884">5,10-methylenetetrahydrofolate</compound-id> reductase (<protein-id="P42898,Q8IU67,Q59GJ6">MTHFR</protein-id>) C677T, A1298C; <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor 1</protein-id> (<protein-id="P05121,A0A024QYT5">PAI-1) 4G/5G; endothelial protein C receptor</protein-id> (<protein-id="Q9UNN8">EPCR</protein-id>) 4600 A&gt;G (A3 haplotype), 4678 G&gt;C (A1 haplotype); <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (<protein-id="P04114,Q7Z7Q0,Q59HB3">ApoB</protein-id>) R3500Q; <protein-id="P02649">apolipoprotein E</protein-id> (<protein-id="P02649">ApoE</protein-id>) E2/E3/E4; β-fibrinogen -455 G&gt;A; human platelet antigen 1 (HPA1) a/b; angiotensin-converting enzyme (ACE) I/D; <protein-id="P29474,A0A0A0MTA6,A0S0A6">endothelial nitric oxide synthase</protein-id> (<protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id>) 786 T&gt;C, 894 G&gt;T; <protein-id="P01374,Q5ST95,Q6FG55,Q5STV3">lymphotoxin alpha</protein-id> (<protein-id="P01374,Q5ST95,Q6FG55,Q5STV3">LTA</protein-id>) 804 C&gt;A and 9p21 rs10757278.	5,10-methylenetetrahydrofolate__apolipoprotein B__no_interaction	5,10-methylenetetrahydrofolate__ApoB__no_interaction	5,10-methylenetetrahydrofolate__MTHFR__no_interaction	5,10-methylenetetrahydrofolate__lymphotoxin alpha__no_interaction	5,10-methylenetetrahydrofolate__EPCR__no_interaction	5,10-methylenetetrahydrofolate__prothrombin__no_interaction	5,10-methylenetetrahydrofolate__eNOS__no_interaction	5,10-methylenetetrahydrofolate__endothelial nitric oxide synthase__no_interaction	5,10-methylenetetrahydrofolate__LTA__no_interaction	5,10-methylenetetrahydrofolate__ApoE__no_interaction	5,10-methylenetetrahydrofolate__plasminogen activator inhibitor 1__no_interaction	5,10-methylenetetrahydrofolate__apolipoprotein E__no_interaction	5,10-methylenetetrahydrofolate__PAI-1) 4G/5G; endothelial protein C receptor__no_interaction
22445016-8	Jugular blood samples were then collected <protein-id="G5E6F7,P41361">at 1, 2, 3, 4, 5, 6, 7, 8, 9</protein-id>, 10, 13, 16, 19, 25 and 31 min after the injection to determine 15N <compound-id="5962">Lys</compound-id> enrichment.	Lys__at 1, 2, 3, 4, 5, 6, 7, 8, 9__no_interaction
18303271-5	RESULTS: 24 h after reperfusion, group A had higher levels of <compound-id="5950">alanine</compound-id> aminotransferase (70 +/- 12 IU/l vs. 51 +/- 5.9 IU/l; p &lt; 0.05), <compound-id="5950">alanine</compound-id> aminotransferase per gram of liver remnant (0.41 +/- 0.07 IU/l/g vs. 0.21 +/- 0.05 IU/l/g; p &lt; 0.05), <protein-id="Q19AZ8">prothrombin</protein-id> time (24.1 +/- 2.4 s vs. 14.3 +/- 2.9 s; p &lt; 0.05), international normalized ratio (2.11 +/- 0.15 vs. 1.29 +/- 0.28; p &lt; 0.05), hepatocyte necrosis scores and percentages of nuclei stained for proliferating cell nuclear antigen (52.57 +/- 8.9% vs. 36.71 +/- 6%; p &lt; 0.05) compared to group B.	alanine__prothrombin__no_interaction
23087862-8	For hsCRP: grade of ulcer (r = 0.236, P &lt; 0.002), BMI (r = -0.155, P &lt; 0.048), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = -0.174, P &lt; 0.026), triglycerides (r = -0.216, P &lt; 0.005), retinopathy (r = -0.165, P &lt; 0.037), nephropathy (r = -0.028, P &lt; 0.007), and smoking (r = -0.164, P &lt; 0.036), while total <compound-id="5997">cholesterol</compound-id> (r = -0.209, P &lt; 0.007) and neuropathy (r = 0.141, P &lt; 0.072) for TNF-α.	cholesterol__LDL-C__no_interaction
16720678-5	Although <protein-id="D3ZPX4">Sex</protein-id>-common QTLs were detected for BP [chromosome (chr) 1-144.3 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>; chr 1-208.8 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>], GIS (chr 1-208.8 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), and cardiac mass (<compound-id="6448119">chr 5</compound-id>-150.3 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), most QTLs across the three phenotypes studied are gender specific as follows: female QTLs for BP (chr 2-106.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 2-181.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, <compound-id="6448119">chr 5</compound-id>-113.9 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, <compound-id="6448119">chr 5</compound-id>-146.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 12-12.8 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), GIS (chr 15-59.6 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), and RHW (chr 2-31.5 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, <compound-id="6448119">chr 5</compound-id>-154.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, <compound-id="6448119">chr 5</compound-id>-110.9 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>); male QTLs for BP (chr 2-196.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 11-48.0 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 20-35.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), GIS (chr 6-3.3 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 20-40.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>), and RHW (chr 6-3.3 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>, chr 20-40.7 <protein-id="P02688,Q5XFW1,I7FKL4">Mbp</protein-id>).	chr 5__Mbp__no_interaction	chr 5__Sex__no_interaction
10959709-6	Our results showed that: (i) fucosylated <compound-id="53477707">chondroitin</compound-id> <compound-id="1117">sulfate</compound-id> had a strong inhibitory effect on SMC proliferation (IC50 =10 +/- 5 microg/ml) and (ii) no effect on HUVEC proliferation and migration assays, in the absence of exogenous FGF, while heparin had inhibitory effects; (iii) fucosylated <compound-id="53477707">chondroitin</compound-id> <compound-id="1117">sulfate</compound-id> (10 microg/ml) enhanced <protein-id="P05230,A8K147,Q16089">FGF-1</protein-id> and <protein-id="P09038">FGF-2</protein-id> induced HUVEC proliferation by 45% (145.4 +/- 7.2%) and 27% (126.9 +/- 4.2%), respectively; (iv) on FGF-induced HUVEC migration, fucosylated <compound-id="53477707">chondroitin</compound-id> <compound-id="1117">sulfate</compound-id> (10 microg/ml) had a strong enhancing effect with <protein-id="P05230,A8K147,Q16089">FGF-1</protein-id>, +122% (222.2 +/- 15.8%), three times higher than that of heparin, and a lower enhancing effect with <protein-id="P09038">FGF-2</protein-id>, +43% (142.7 +/- 4.6%), whereas heparin had no effect; (v) fucosylated <compound-id="53477707">chondroitin</compound-id> <compound-id="1117">sulfate</compound-id> stimulated <protein-id="P10646">TFPI</protein-id> release, mainly on the free form.	chondroitin__FGF-2__no_interaction	chondroitin__FGF-1__no_interaction	chondroitin__TFPI__no_interaction	sulfate__FGF-2__no_interaction	sulfate__FGF-1__no_interaction	sulfate__TFPI__no_interaction
23336224-5	RESULTS: After incubation with <compound-id="107985">triptolide</compound-id> at 10 µg/L, the levels of IFN-α, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and TNF-α in group 1 \[(451.32 ± 85.77) ng/L, (105.68 ± 23.85) ng/L and (135.78 ± 30.62) ng/L\] and group 2 \[(391.71 ± 72.49) ng/L, (84.73 ± 17.77) ng/L and (108.16 ± 23.21) ng/L\] were significantly higher than those in group 3 \[(335.51 ± 67.54) ng/L, (73.62 ± 21.82) ng/L and (95.58 ± 32.85) ng/L\] (all P &lt; 0.05); the levels of IFN-α, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and TNF-α in group 1 were significantly higher than those in group 2 (all P &lt; 0.05) in a dose-dependent manner (P &lt; 0.05).	triptolide__IL-6__no_interaction
16261995-4	The mean contents of each component were as follows: <compound-id="445354">vitamin A</compound-id>, 159.0 +/- 95.2 IU/100 mL; <compound-id="1548900,1742129,2116">vitamin E</compound-id>, 0.325 +/- 0.165 alpha-TE mg/100mL; vitamin D3 (<compound-id="10883523,22811020,2735,44281724,5283710,5283711,5353527,5363362,57484195,6221,6432644,9821465">cholecalciferol</compound-id>), 8.0 +/- 10.7 ng/100mL; <compound-id="1130">vitamin B1</compound-id> (thiamin), 12.3 +/- 3.2 microg/100 mL; vitamin B2, 38.4 +/- 12.7 microg/100 mL; <compound-id="1054">vitamin B6</compound-id>, 5.7 +/- 2.5 microg/100 mL; vitamin <protein-id="O43676,A0A024R413">B12</protein-id>, 0.04 +/- 0.02 microg/100 mL; vitamin C, 5.1 +/- 1.9 mg/100 mL; <compound-id="53700020">biotin</compound-id>, 0.50 +/- 0.23 microg/100 mL; <compound-id="305,57080826">choline</compound-id>, 9.2 +/- 1.8 mg/100 mL; <compound-id="6037">folic acid</compound-id>, 6.2 +/- 2.9 microg/100 mL; <compound-id="892">inositol</compound-id>, 12.6 +/- 3.6 mg/100 mL; <compound-id="938">niacin</compound-id> (<compound-id="936">nicotinamide</compound-id>), 32.9 +/- 20.4 microg/100 mL and pantothenic acid, 0.27 +/- 0.09 mg/100 mL.	niacin__B12__no_interaction	cholecalciferol__B12__no_interaction	vitamin A__B12__no_interaction	vitamin B1__B12__no_interaction	vitamin B6__B12__no_interaction	biotin__B12__no_interaction	vitamin E__B12__no_interaction	nicotinamide__B12__no_interaction	folic acid__B12__no_interaction	inositol__B12__no_interaction	choline__B12__no_interaction
21479653-2	Twenty-four untrained males (age, 22.7 ± 2.8 years; BMI, 24.38 ± 2.19 kg m(-2); body fat (%), 16 ± 2.2; VO(2max), 40.2 ± 6.5 ml kg(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) and 18 females (age, 22.4 ± 2.9 years; BMI, 21.68 ± 2.43 kg m(-2); body fat (%), 23% ± 1.8; VO(2max), 35.9 ± 2.8 ml kg(-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) walked at five different velocities (54, 67, 80, 94 and 107 m <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) on a treadmill in 5-min stages while wearing three types of pedometers: (a) HJ-720, (b) HJ-113, and (c) Yamax Digi-Walker SW-200 (<compound-id="24757941">YAM</compound-id>).	YAM__min(-1__no_interaction
10549460-2	Following Ethics Committee approval, patients were randomly assigned to one of the following four treatments: Group P (n = 17): <compound-id="4943">propofol</compound-id> infusion, 1 mg kg-1 min-1 intravenous for 2 min, followed by <compound-id="4943">propofol</compound-id> infusion, 200 micrograms kg-1 min-1, until skin incision; Group <protein-id="Q96QT6,C9J9G2">PF1</protein-id> (n = 17): fentanyl bolus, 1 microgram kg-1 intravenous + <compound-id="4943">propofol</compound-id> infusion as in Group P; Group PF2 (n = 17): fentanyl bolus, 2 micrograms kg-1 intravenous + <compound-id="4943">propofol</compound-id> infusion as in Group P; and Group <compound-id="62665">PF3</compound-id> (n = 17): fentanyl bolus, 3 micrograms kg-1 intravenous + <compound-id="4943">propofol</compound-id> infusion as in Group P. The bispectral index and 95% spectral edge frequency were monitored continuously and recorded prior to induction of anaesthesia (base-line) and at skin incision.	PF3__PF1__no_interaction	propofol__PF1__no_interaction
19526756-5	RESULTS: Compared with the control group, in the SMI group, WBC and neutrophil count were lower at T2 (P &lt; 0.01); percentages of CD3+ and <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ lower at T4 and T5 (P &lt; 0.05 or P &lt; 0.01); percentage of <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>+ higher at T2 to T5 (P &lt; 0.05 or P &lt; 0.01); <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+/<protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>+ ratio lower at <compound-id="5920">T3</compound-id> to T5 (P &lt; 0.05 or P &lt; 0.01); IgG lower at T2 (P &lt; 0.05); IgA higher at <compound-id="5920">T3</compound-id> (P &lt; 0.05); <protein-id="P29965">IgM</protein-id> higher at <compound-id="5920">T3</compound-id> to T5 (P &lt; 0.05); <protein-id="P10145,A0A024RDA5">IL-8</protein-id> lower at T2 to T4 (P &lt; 0.05); and <protein-id="P22301,Q6FGW4">IL-10</protein-id> higher at T2 (P &lt; 0.05).	T3__CD4__no_interaction	T3__IL-8__no_interaction	T3__IgM__no_interaction	T3__CD8__no_interaction	T3__IL-10__no_interaction
16625573-17	<compound-id="5853">Metrifonate</compound-id> at various doses, fixed and loading doses, was associated with significant cognitive improvement compared to placebo, except for weekly doses where there was no difference from placebo: MMSE (<compound-id="5853">metrifonate</compound-id> 60-80 mg/day with initial loading at 26 weeks; <compound-id="5853">metrifonate</compound-id> 50 mg/day fixed dose with no initial loading at 26 weeks MD 1.85, 95% CI 1.06 to 2.64, p&lt;0.00001); <protein-id="O00116,B7Z3Q4">ADAS-Cog</protein-id> (<compound-id="5853">metrifonate</compound-id> 60-80 mg/day with initial loading at 26 weeks MD -3.24, 95% CI -4.40 to -2.08, p&lt;0.00001)In most trials, there was improvement in clinical global impression: CIBIC-Plus (<compound-id="5853">metrifonate</compound-id> 30-55 mg/day, approximately 0.65 mg/kg body weight, with initial loading at 26 weeks MD -0.25, 95% CI -0.41 to -0.09 p=0.002; <compound-id="5853">metrifonate</compound-id> 50 mg/day fixed dose with no initial loading at 26 weeks MD -0.20, 95% CI -0.39 to -0.01, p=0.04).	Metrifonate__ADAS-Cog__no_interaction	metrifonate__ADAS-Cog__no_interaction
16433252-11	In addition, <compound-id="6013">testosterone</compound-id> levels showed positive correlations with albumin (r = 0.690, p = 0.019) and negative correlations with <compound-id="1175">uric acid</compound-id> (r = -0.630, p &lt; 0.001), HsCRP (r = -0.449, p = 0.003), <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = -0.508, p = 0.001), and white blood cells (r = -0.433, p = 0.005).	testosterone__fibrinogen__no_interaction	uric acid__fibrinogen__no_interaction
8144215-2	In the <compound-id="53782691">fructose-</compound-id>fed group, (1) fasting triglyceridemia increased from 35.3 +/- 0.63 to 91.9 +/- 11.55 mg/dL after 25 days (P &lt; .001); (2) fasting insulinemia increased from 19.0 +/- 1.9 to 58.9 +/- 7.22 microU/mL after 25 days (P &lt; .001); (3) <protein-id="P01321">insulin</protein-id> resistance, which was estimated by steady-state glycemia during an <protein-id="P01321">insulin</protein-id> suppression test, increased from 105.8 +/- 21.5 to 187.8 +/- 32.6 mg/dL after 15 days (P &lt; .001), whereas steady-state insulinemia did not change; (4) mean arterial pressure increased from 100.4 +/- 1.6 to 122.6 +/- 2.3 mm Hg after 28 days (P &lt; .01); and (5) cumulative <compound-id="5360545">sodium</compound-id> balance was increased on days 7 through 11 (111.60 +/- 4.44 mEq on day 8, P &lt; .01), returning to normal for the rest of the experiment.	fructose-__insulin__no_interaction	sodium__insulin__no_interaction
19190235-6	The Ca(2+) chelator <compound-id="1811074">1,2-bis(2-aminophenoxy)ethane</compound-id>-N,N,N',N'-<compound-id="176">tetraacetic acid</compound-id>-acetoxymethyl ester, the two protein kinase C (PKC) inhibitors 3-[1-[3-(dimethylaminopropyl]-1H-indol-3-yl]-<compound-id="9877762">4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione</compound-id> <compound-id="20254264">monohydrochloride</compound-id> (<compound-id="2396">GF109203X</compound-id>) and 2-[8-[(dimethylamino)methyl]-6,7,8,9-tetrahydropyridol[1,2-a]indol-3-yl]-3-(1-<compound-id="7224">methylindol</compound-id>-3-yl)maleimide (<compound-id="5084,127757">Ro-32-0432</compound-id>), and the <protein-id="P21708,P63086">extracellular signal-regulated kinase (ERK)1/2</protein-id> inhibitors <compound-id="4713">2'-amino-3'-methoxyflavone</compound-id> (PD98059) and 1,4-<compound-id="76988">diamino</compound-id>-2,3-dicyano-1,4-bis(methylthio)<compound-id="7845">butadiene</compound-id> (<compound-id="3006531,5354033,9951825">U0126</compound-id>) all blocked <compound-id="2551">carbachol</compound-id>-induced axonal outgrowth.	monohydrochloride__extracellular signal-regulated kinase (ERK)1/2__no_interaction	U0126__extracellular signal-regulated kinase (ERK)1/2__no_interaction	diamino__extracellular signal-regulated kinase (ERK)1/2__no_interaction	1,2-bis(2-aminophenoxy)ethane__extracellular signal-regulated kinase (ERK)1/2__no_interaction	butadiene__extracellular signal-regulated kinase (ERK)1/2__no_interaction	2'-amino-3'-methoxyflavone__extracellular signal-regulated kinase (ERK)1/2__no_interaction	tetraacetic acid__extracellular signal-regulated kinase (ERK)1/2__no_interaction	carbachol__extracellular signal-regulated kinase (ERK)1/2__no_interaction	4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione__extracellular signal-regulated kinase (ERK)1/2__no_interaction	methylindol__extracellular signal-regulated kinase (ERK)1/2__no_interaction	Ro-32-0432__extracellular signal-regulated kinase (ERK)1/2__no_interaction	GF109203X__extracellular signal-regulated kinase (ERK)1/2__no_interaction
20447562-1	PURPOSE: The compound (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy) pyridin-3-yl)vinyl)-<compound-id="7515">N-methylbenzenamine</compound-id> ([(18)F]<compound-id="24822371,57396865">AV-45</compound-id>) is a novel radiopharmaceutical capable of selectively binding to beta-amyloid (<protein-id="P05067,A0A0A0MRG2,B4DGD0,B4DJT9,E9PG40">A beta</protein-id>) plaques.	N-methylbenzenamine__A beta__no_interaction	AV-45__A beta__no_interaction
14656211-6	We have found that: (1) nuclear proteins from <compound-id="47936">forskolin</compound-id>-stimulated granulosa cells were specifically bound to an oligonucleotide containing the CLS sequence of the CYP19 ovarian promoter and one out of the two protein-DNA complexes formed was supershifted by an anti-<protein-id="Q03061,M0RCG1,A0A0G2K748,D3ZXY8,F1LNP3,A0A0G2JYV9">CREM</protein-id> antibody; (2) in granulosa cells, <compound-id="47936">forskolin</compound-id>-induced increases in P450(AROM) promoter luciferase reporter gene activity were prevented by the transient overexpression of <protein-id="Q03061,M0RCG1,A0A0G2K748,D3ZXY8,F1LNP3,A0A0G2JYV9">ICER</protein-id>; (3) similar results were obtained in <compound-id="32014">8-Br-cAMP</compound-id>-stimulated <compound-id="24794393">R2C</compound-id> cells, a Leydig tumor cell line routinely used for the study of P450(AROM) promoter activity; (4) both <protein-id="Q03061,M0RCG1,A0A0G2K748,D3ZXY8,F1LNP3,A0A0G2JYV9">ICER</protein-id> mRNA levels and P450(AROM) promoter-driven luciferase activity were elevated 6 and 12 h after stimulation of <compound-id="24794393">R2C</compound-id> cells with <compound-id="32014">8-Br-cAMP</compound-id> and were decreased 24 and 48 h later; (5) in an <compound-id="24794393">R2C</compound-id> polyclonal line overexpressing <protein-id="Q03061,M0RCG1,A0A0G2K748,D3ZXY8,F1LNP3,A0A0G2JYV9">ICER</protein-id>, the promoter activity at early stages of stimulation was completely attenuated, while 24 and 48 h downregulation was prevented in another <compound-id="24794393">R2C</compound-id> line stably transfected with an antisense <protein-id="Q03061,M0RCG1,A0A0G2K748,D3ZXY8,F1LNP3,A0A0G2JYV9">ICER</protein-id> construct.	R2C__ICER__no_interaction	R2C__CREM__no_interaction	forskolin__ICER__no_interaction	forskolin__CREM__no_interaction	8-Br-cAMP__ICER__no_interaction	8-Br-cAMP__CREM__no_interaction
15312180-5	The effects of both peptides could not be blocked by the <protein-id="P25095">AT1</protein-id> antagonist <compound-id="2541">candesartan</compound-id> (10 nm and 1 microm) nor by the AT2 antagonist S-(+)-1-([4-(dimethylamino)-3-methylphenyl]methyl)-5-(diphenyl-acetyl)-4,5,6,7-tetrahydro-1H-amidazo(4,5-c) pyridine-6-<compound-id="11229316,91179806">carboxylic acid</compound-id> (1 microm), suggesting that the observed effects are both <protein-id="P25095">AT1</protein-id> and AT2 independent.	carboxylic acid__AT1__no_interaction	candesartan__AT1__no_interaction
19466522-7	<protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> increase was +1.64% after 6 h with a decrease of -0.82% at 9 and 12 h. A significant sICAM-1, hsCRP, and sE-<compound-id="4929">selectin</compound-id> variation was observed after 6 and 9 h, while a significant sVCAM-1 change occurred after 3, 6, and 9 h. Soluble <protein-id="P05362">ICAM-1</protein-id> increase was +20.58% at 3 h, +34.10% at 6 h (P &lt; 0.05 vs 0) +25.94% at 9 h (P &lt; 0.01 vs 0), and +19.14% at 12 h; sVCAM-1 increase was +13.97% (P &lt; 0.05 vs 0) at 3 h, +18.55% at 6 h (P &lt; 0.01 vs 0), +12.02% at 9 h (P &lt; 0.05 vs 0), and +8.70% at 12 h. High-sensitivity CRP increase was +36.36% at 3 h, +90.91% at 6 h (P &lt; 0.01 vs 0), +63.64% at 9 h (P &lt; 0.05 vs 0), and +36.36% at 12 h. Soluble E-<compound-id="4929">selectin</compound-id> increase was +27.11% at 3 h, +51.90% at 6 h (P &lt; 0.05 vs 0), +45.19% at 9 h (P &lt; 0.01 vs 0), and +20.12% at 12 h. <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> increase was +61.11% at 3 h (P &lt; 0.05 vs 0), +83.33% at 6 h (P &lt; 0.001 vs 0), +55.56% at 9 h (P &lt; 0.01 vs 0), and +22.22% at 12 h. <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> increase was +42.86% at 3 h (P &lt; 0.05 vs 0), +71.43% at 6 h (P &lt; 0.01 vs 0), (+50.00% at 9 h (P &lt; 0.05 vs 0), and +28.57% at 12 h. We observed that the <compound-id="445155">OFL</compound-id> induces a complex and massive systemic inflammatory response that includes <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P01375,Q5STB3">TNF-alpha</protein-id>, hsCRP, and cell adhesion molecules, even before Tg significantly rises.	selectin__tumor necrosis factor-alpha__no_interaction	selectin__low-density lipoprotein cholesterol__no_interaction	selectin__IL-6__no_interaction	selectin__interleukin-6__no_interaction	selectin__ICAM-1__no_interaction	selectin__TNF-alpha__no_interaction	OFL__tumor necrosis factor-alpha__no_interaction	OFL__low-density lipoprotein cholesterol__no_interaction	OFL__IL-6__no_interaction	OFL__interleukin-6__no_interaction	OFL__ICAM-1__no_interaction	OFL__TNF-alpha__no_interaction
11825078-1	Five-coordinated trithiotungsten complexes (<protein-id="O14649">PPh(4</protein-id>))[(<compound-id="23737">dmsp</compound-id>)W(S)(3)] (1a) and (<protein-id="O14649">PPh(4</protein-id>))[(dpsp)W(S)(3)] (1b) (R(2)PCH(2)CH(2)S(-); R = Me (<compound-id="23737">dmsp</compound-id>-)), Ph (dpsp-))) were synthesized by addition of Hdmsp and Hdpsp to a <compound-id="8028">THF</compound-id> solution of (<protein-id="O14649">PPh(4</protein-id>))[(EtS)W(S)(3)].	THF__PPh(4__no_interaction	dmsp__PPh(4__no_interaction
20211058-8	The results of flow cytometry showed that: after SW480 cells were treated with 0, 20, 40, 80 microg/ml <compound-id="5280961">genistein</compound-id> for 48 h, the FI values of <protein-id="P12004">PCNA</protein-id> were 1.49 +/- 0.02, 1.28 +/- 0.04, 1.14 +/- 0.03, and 0.93 +/- 0.08; the FI values of VEGF were 1.75 +/- 0.02, 1.34 +/- 0.06, 1.32 +/- 0.04, and 1.23 +/- 0.04; the fluorescence index (FI) values of <protein-id="P38936,A0A024RCX5">p21</protein-id> were 1.26 +/- 0.05, 1.36 +/- 0.06, 1.61 +/- 0.03, and 1.73 +/- 0.03, respectively.	genistein__PCNA__no_interaction	genistein__p21__no_interaction
18686014-11	In preeclamptic patients, serum Hsp70 levels showed significant correlations with serum <protein-id="P02741">CRP</protein-id> levels (Spearman R = 0.32, p = 0.010), serum <compound-id="5960">aspartate</compound-id> aminotransferase (R = 0.32, p = 0.008) and LDH activities (R = 0.50, p &lt; 0.001), as well as with plasma <compound-id="10964">malondialdehyde</compound-id> levels (R = 0.25, p = 0.043).	aspartate__CRP__no_interaction	malondialdehyde__CRP__no_interaction
10678147-7	TMP (0.05, 0.5, 5, 50 mumol.L-1) dose-dependently decreased the release of PAF [(12.7 +/- 1.6), (8.9 +/- 1.2), (6.9 +/- 0.8), (5.5 +/- 1.0) micrograms.L-1 vs control (11.9 +/- 1.8) micrograms.L-1, P &lt; 0.01] from <compound-id="446492">PMO</compound-id> cultured with LPS (5 mg.L-1), reduced the <protein-id="P31482,V5TDK8">PLA2</protein-id> activity [(149.9 +/- 2.8), (117.5 +/- 2.0), (89.6 +/- 2.0), (75.0 +/- 2.8) U vs control (170.8 +/- 3.9) U, P &lt; 0.01] and <compound-id="444493">acetyl-CoA</compound-id>: lyso-PAF acetyltransferase activity [PAF (9.5 +/- 0.7), (5.2 +/- 0.7), (2.9 +/- 0.3), (2.5 +/- 0.3) micrograms.g-1 (protein).min-1 vs control (11.0 +/- 0.7) micrograms.g-1 (protein).min-1, P &lt; 0.01] of <compound-id="446492">PMO</compound-id> lysate.	PMO__PLA2__no_interaction	acetyl-CoA__PLA2__no_interaction
1516292-3	Mean fasting plasma <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> rose significantly by 17 +/- 3% (1.11 +/- 0.12 vs 0.95 +/- 0.11 mmol/L, p less than 0.005, n = 5), whereas total triglycerides fell by 23 +/- 2% (1.7 +/- 0.3 vs 2.2 +/- 0.3 mmol/L, p less than 0.005, n = 5), VLDL triglycerides fell by 28 +/- 5% (0.88 +/- 0.15 vs 1.18 +/- 0.19 mmol/L, p less than 0.02, n = 5), VLDL <compound-id="5997">cholesterol</compound-id> fell by 32 +/- 7% (0.39 +/- 0.08 vs 0.56 +/- 0.09 mmol/L, p less than 0.01, n = 5), the ratio of LDL <compound-id="5997">cholesterol</compound-id>: <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> by 19 +/- 5% (4.7 +/- 0.7 vs 5.7 +/- 0.7, p less than 0.05) and that of total <compound-id="5997">cholesterol</compound-id>: <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> by 16 +/- 5% (6.6 +/- 0.5 vs 8.0 +/- 0.7, p less than 0.05) on the high versus low protein diet.	cholesterol__HDL__no_interaction
21464197-3	Here we report the development and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(2,4-<compound-id="9706">difluorophenyl</compound-id>)-2-methyl-<compound-id="12586">1,3-dioxolan</compound-id>-4-yl)methoxy)phenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)<compound-id="177">ethanone</compound-id> (<compound-id="70789750">FLB</compound-id>-12)] that antagonizes the activated state of <protein-id="O54915,Q0P525">PXR</protein-id> with limited effects on other related nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor α, peroxisome proliferator-activated receptor γ, and mouse constitutive <compound-id="123412,6857536,94144">androstane</compound-id> receptor).	piperazin-1-yl__PXR__no_interaction	1,3-dioxolan__PXR__no_interaction	difluorophenyl__PXR__no_interaction	androstane__PXR__no_interaction	ethanone__PXR__no_interaction	FLB__PXR__no_interaction
8329287-5	Comparing (S)- and (R)-<compound-id="3672">ibuprofen</compound-id> within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P &lt; 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P &lt; 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P &lt; 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml <protein-id="P13987,Q6FHM9">min-1</protein-id>; P &lt; 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.	ibuprofen__min-1__no_interaction
1445696-2	Serum FA2 was positively correlated with <compound-id="853">thyroxine</compound-id> (T4) (<compound-id="7021454">Rs</compound-id> = 0.51; p &lt; 0.05), <compound-id="5920">triiodothyronine</compound-id> (T3) (<compound-id="7021454">Rs</compound-id> = 0.64; p &lt; 0.01), <protein-id="P02818">bone-Gla protein</protein-id> (<protein-id="P02818">BGP</protein-id>) (<compound-id="7021454">Rs</compound-id> = 0.70; p &lt; 0.01), total alkaline phosphatase (total-AP) (<compound-id="7021454">Rs</compound-id> = 0.62; p &lt; 0.01), bone isoenzyme alkaline phosphatase (bone-AP) (<compound-id="7021454">Rs</compound-id> = 0.63; p &lt; 0.01), N-terminal procollagen type III (PIIINP) (<compound-id="7021454">Rs</compound-id> = 0.65; p &lt; 0.01) and urine OH-<compound-id="145742,57240853,614,8988">proline</compound-id> (OHP) (<compound-id="7021454">Rs</compound-id> = 0.79; p &lt; 0.01).	proline__BGP__no_interaction	proline__bone-Gla protein__no_interaction	thyroxine__BGP__no_interaction	thyroxine__bone-Gla protein__no_interaction	triiodothyronine__BGP__no_interaction	triiodothyronine__bone-Gla protein__no_interaction	Rs__BGP__no_interaction	Rs__bone-Gla protein__no_interaction
8923850-4	According to a randomized, single blind, cross-over protocol, six healthy subjects, six obese subjects, and six elderly subjects received on 2 different days, with a 1-week interval, placebo or <compound-id="5310993">acipimox</compound-id> (250 mg, orally) at 0700 and 1100 h; <protein-id="P01286">GHRH</protein-id> [<protein-id="P01286">GHRH</protein-id>-(1-44)NH2; 50 micrograms in healthy subjects and in elderly subjects, 100 micrograms in obese subjects] was injected iv at 1300 h, and blood samples for evaluation of plasma FFA, blood <compound-id="206,5793,64689,79025">glucose</compound-id>, serum <protein-id="P01308,I3WAC9">insulin</protein-id> (IRI), and serum GH levels were taken from 1200 to 1500 h. Plasma FFA levels were always lower (P &lt; 0.05) after <compound-id="5310993">acipimox</compound-id> than after placebo (0.03 +/- 0.01 vs. 0.13 +/- 0.02 g/L in healthy subjects, 0.09 +/- 0.01 vs. 0.27 +/- 0.02 g/L in obese, 0.02 +/- 0.005 vs. 0.17 +/- 0.01 g/L in elderly subjects); serum IRI levels were also lower (P &lt; 0.05) after <compound-id="5310993">acipimox</compound-id> than after placebo in the three groups of subjects (16 +/- 3 vs. 30 +/- 5, 120 +/- 30 vs. 181 +/- 32, and 21 +/- 3 vs. 49 +/- 9 pmol/L); both FFA (P &lt; 0.05) and IRI levels (P &lt; 0.05) were higher in obese than in healthy or elderly subjects after placebo and <compound-id="5310993">acipimox</compound-id>.	acipimox__GHRH__no_interaction	acipimox__insulin__no_interaction	glucose__GHRH__no_interaction	glucose__insulin__no_interaction
19167646-11	Positive correlations were demonstrated between remnant lipoprotein <compound-id="5997">cholesterol</compound-id> and OxLDL (<compound-id="185679">RLP</compound-id>-C and MDA-LDL/<protein-id="Q14746,B1ALW7">LDL-C</protein-id>, r = 0.45, p = 0.0024, <compound-id="185679">RLP</compound-id>-C and OxPC, r = 0.51, p = 0.0005, RemL-C and MDA-LDL/<protein-id="Q14746,B1ALW7">LDL-C</protein-id>, r = 0.42, p = 0.0044, RemL-C and OxPC, r = 0.43, p = 0.0043).	RLP__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
21220125-3	METHODS: We incubated methyl 3β-(4-iodophenyl)<compound-id="637986">tropane</compound-id>-2β-carboxylate (β-<protein-id="O14578">CIT</protein-id>)/2-fluoroethyl 3β-(4-iodophenyl)<compound-id="637986">tropane</compound-id>-2β-carboxylate (FE@<protein-id="O14578">CIT</protein-id>), <compound-id="21474">methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate</compound-id> (<compound-id="2734010">MTO</compound-id>)/<compound-id="36339">ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate</compound-id> (ETO)/2-fluoroethyl <compound-id="9815351">1-(1-phenylethyl)-1H-imidazole</compound-id>-5-carboxylate (FETO), <compound-id="241865">ethyl 8</compound-id>-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo-[f]imidazo[1,5-a]-[1,4]<compound-id="166734">diazepine</compound-id>-3-carboxylate (FMZ)/2-fluoroethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo-[f]imidazo[1,5-a]-[1,4]<compound-id="166734">diazepine</compound-id>-3-carboxylate (FFMZ), methyl <compound-id="137551">1-phenylethyl</compound-id>-4-(N-propanoylanilino)<compound-id="3773">piperidine-4-carboxylate</compound-id> (CFN)/2-fluoroethyl <compound-id="137551">1-phenylethyl</compound-id>-4-(N-propanoylanilino)<compound-id="3773">piperidine-4-carboxylate</compound-id> (FE@CFN) and methyl 2,4-diethyl-3-<compound-id="638145">methylsulfanylcarbonyl</compound-id>-<compound-id="13887">6-phenylpyridine</compound-id>-5-carboxylate [(Me)(2)@SUPPY]/2-fluorethyl 2,4-diethyl-3-<compound-id="140799">ethylsulfanylcarbonyl</compound-id>-<compound-id="13887">6-phenylpyridine</compound-id>-5-carboxylate (FE@SUPPY) under physiological conditions.	ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate__CIT__no_interaction	1-(1-phenylethyl)-1H-imidazole__CIT__no_interaction	diazepine__CIT__no_interaction	tropane__CIT__no_interaction	methylsulfanylcarbonyl__CIT__no_interaction	ethylsulfanylcarbonyl__CIT__no_interaction	6-phenylpyridine__CIT__no_interaction	1-phenylethyl__CIT__no_interaction	ethyl 8__CIT__no_interaction	methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate__CIT__no_interaction	piperidine-4-carboxylate__CIT__no_interaction	MTO__CIT__no_interaction
11172452-14	Although <protein-id="P02647,A0A024R3E3">Apo-A1</protein-id> concentration was directly associated with HDL level (r = +0.39, P &lt;.01, n = 139), <protein-id="P04114,Q7Z7Q0,Q59HB3">Apo-B</protein-id> was inversely related to HDL level (r = -0.37, P &lt;.01, n = 138) and directly related to <compound-id="5997">cholesterol</compound-id> concentration (r = +0.71, P &lt;.01, n = 138), VLDL concentration (r = +0.87, P &lt;.01, n = 138), and triglyceride concentration (r = +0.81, P &lt;.01, n = 138).	cholesterol__Apo-B__no_interaction	cholesterol__Apo-A1__no_interaction
18597009-1	(-)-<compound-id="65064">Epigallocatechin gallate</compound-id>, (-)-Gossypol; Ad.<protein-id="P01574">hIFN-beta</protein-id>, AF-37702, Agatolimod <compound-id="5360545">sodium</compound-id>, <compound-id="82148">Agomelatine</compound-id>, <compound-id="5287969">Alvocidib hydrochloride</compound-id>, ARC-1779; Belimumab, <compound-id="10184653">BIBW-2992</compound-id>, <compound-id="9576912">Binodenoson</compound-id>, <compound-id="387447">Bortezomib</compound-id>, <compound-id="5328940">Bosutinib</compound-id>, <compound-id="9837243">Brivaracetam</compound-id>; <compound-id="9933475">Cediranib</compound-id>, <compound-id="153994">Clevidipine</compound-id>, CNTO-328, CP-751871, <compound-id="969516">Curcumin</compound-id>; <compound-id="9939609">Darapladib</compound-id>, <compound-id="11520894,23724531,53486198,71296108,71752077,72734349,74787553,86289926">Deforolimus</compound-id>, Denosumab, <compound-id="125017">Desvenlafaxine</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="3108">Dipyridamole</compound-id>/<compound-id="5755">prednisolone</compound-id>, <compound-id="208898">Dronedarone hydrochloride</compound-id>, DTPw-HBV/Hib 2.5; Ecogramostim, <compound-id="6438895">Elacytarabine</compound-id>, <compound-id="25181561,66583167,9846180">Eltrombopag</compound-id>, <compound-id="428573">Eprodisate sodium</compound-id>; <compound-id="389644,5469318">Farnesylthiosalicylic acid</compound-id>, <compound-id="134018">Febuxostat</compound-id>, <compound-id="5288209">Fenretinide</compound-id>, Ferumoxytol, FMP2.1/AS02A, <compound-id="444499">Forodesine hydrochloride</compound-id>, FP-0011; HuLuc-63, Human <protein-id="P05230,A8K147,Q16089">Fibroblast Growth Factor 1</protein-id>; <compound-id="57391680">Idraparinux sodium</compound-id>, <compound-id="5359967">Indium</compound-id> 111 (<compound-id="5462099">111In</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>, <protein-id="Q9HBE4">Interleukin-21</protein-id>, Ipilimumab, ISS-1018, <compound-id="214907">ITF</compound-id>-2357; <compound-id="9874248">Lapaquistat acetate</compound-id>, <compound-id="9867642">Laropiprant</compound-id>, Liposomal <compound-id="5978">vincristine</compound-id>, <compound-id="9909438">LY-518674</compound-id>; <compound-id="10074640">Masitinib</compound-id> <compound-id="6395">mesylate</compound-id>, MAXY-G34, <compound-id="9865515">MGCD-0103</compound-id>, <compound-id="16760627,24202429,71719722,9829523">Midostaurin</compound-id>, Mitumprotimut-T, MK-0343, MLN-1202, MM-093, <compound-id="151071">Motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; <compound-id="2815031">NB-001</compound-id>, NB-002, <compound-id="938">Niacin</compound-id>/<compound-id="9867642">laropiprant</compound-id>; <compound-id="71587613">Oblimersen sodium</compound-id>, Ocrelizumab, <compound-id="285033">Omacetaxine mepesuccinate</compound-id>; <compound-id="6918837">Panobinostat</compound-id>, <compound-id="448013">Patupilone</compound-id>, PBI-1402, <compound-id="148178">Perifosine</compound-id>, <compound-id="11442891">PHA-739358</compound-id>, <compound-id="65015">Plerixafor hydrochloride</compound-id>, <compound-id="6918456">Prasugrel</compound-id>; <compound-id="219024">Regadenoson</compound-id>, RHAMM R3 peptide, Rilonacept, <compound-id="9875401">Rivaroxaban</compound-id>, Romiplostim; <compound-id="131682">Safinamide mesilate</compound-id>, <compound-id="11347535">Salinosporamide A</compound-id>, <compound-id="24934">Selenite sodium</compound-id>, <compound-id="10296883">Sotrastaurin</compound-id>; <compound-id="90470996">Thrombin</compound-id> alfa, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="56603725,9930827">TRO-19622</compound-id>; <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="9930049">Vernakalant</compound-id> hydrochloride, VRC-WNVDNA017-00-VP; YM-155, <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; <compound-id="3036703">Zosuquidar</compound-id> trihydrochloride.	Niacin__hIFN-beta__no_interaction	Niacin__Interleukin-21__no_interaction	Niacin__Fibroblast Growth Factor 1__no_interaction	Selenite sodium__hIFN-beta__no_interaction	Selenite sodium__Interleukin-21__no_interaction	Selenite sodium__Fibroblast Growth Factor 1__no_interaction	Dronedarone hydrochloride__hIFN-beta__no_interaction	Dronedarone hydrochloride__Interleukin-21__no_interaction	Dronedarone hydrochloride__Fibroblast Growth Factor 1__no_interaction	Febuxostat__hIFN-beta__no_interaction	Febuxostat__Interleukin-21__no_interaction	Febuxostat__Fibroblast Growth Factor 1__no_interaction	Thrombin__hIFN-beta__no_interaction	Thrombin__Interleukin-21__no_interaction	Thrombin__Fibroblast Growth Factor 1__no_interaction	Lapaquistat acetate__hIFN-beta__no_interaction	Lapaquistat acetate__Interleukin-21__no_interaction	Lapaquistat acetate__Fibroblast Growth Factor 1__no_interaction	Vernakalant__hIFN-beta__no_interaction	Vernakalant__Interleukin-21__no_interaction	Vernakalant__Fibroblast Growth Factor 1__no_interaction	111In__hIFN-beta__no_interaction	111In__Interleukin-21__no_interaction	111In__Fibroblast Growth Factor 1__no_interaction	Rivaroxaban__hIFN-beta__no_interaction	Rivaroxaban__Interleukin-21__no_interaction	Rivaroxaban__Fibroblast Growth Factor 1__no_interaction	Bosutinib__hIFN-beta__no_interaction	Bosutinib__Interleukin-21__no_interaction	Bosutinib__Fibroblast Growth Factor 1__no_interaction	Vatalanib__hIFN-beta__no_interaction	Vatalanib__Interleukin-21__no_interaction	Vatalanib__Fibroblast Growth Factor 1__no_interaction	Laropiprant__hIFN-beta__no_interaction	Laropiprant__Interleukin-21__no_interaction	Laropiprant__Fibroblast Growth Factor 1__no_interaction	Elacytarabine__hIFN-beta__no_interaction	Elacytarabine__Interleukin-21__no_interaction	Elacytarabine__Fibroblast Growth Factor 1__no_interaction	Forodesine hydrochloride__hIFN-beta__no_interaction	Forodesine hydrochloride__Interleukin-21__no_interaction	Forodesine hydrochloride__Fibroblast Growth Factor 1__no_interaction	MGCD-0103__hIFN-beta__no_interaction	MGCD-0103__Interleukin-21__no_interaction	MGCD-0103__Fibroblast Growth Factor 1__no_interaction	Salinosporamide A__hIFN-beta__no_interaction	Salinosporamide A__Interleukin-21__no_interaction	Salinosporamide A__Fibroblast Growth Factor 1__no_interaction	Yttrium__hIFN-beta__no_interaction	Yttrium__Interleukin-21__no_interaction	Yttrium__Fibroblast Growth Factor 1__no_interaction	Plerixafor hydrochloride__hIFN-beta__no_interaction	Plerixafor hydrochloride__Interleukin-21__no_interaction	Plerixafor hydrochloride__Fibroblast Growth Factor 1__no_interaction	PHA-739358__hIFN-beta__no_interaction	PHA-739358__Interleukin-21__no_interaction	PHA-739358__Fibroblast Growth Factor 1__no_interaction	sodium__hIFN-beta__no_interaction	sodium__Interleukin-21__no_interaction	sodium__Fibroblast Growth Factor 1__no_interaction	Tipifarnib__hIFN-beta__no_interaction	Tipifarnib__Interleukin-21__no_interaction	Tipifarnib__Fibroblast Growth Factor 1__no_interaction	Safinamide mesilate__hIFN-beta__no_interaction	Safinamide mesilate__Interleukin-21__no_interaction	Safinamide mesilate__Fibroblast Growth Factor 1__no_interaction	Brivaracetam__hIFN-beta__no_interaction	Brivaracetam__Interleukin-21__no_interaction	Brivaracetam__Fibroblast Growth Factor 1__no_interaction	Zosuquidar__hIFN-beta__no_interaction	Zosuquidar__Interleukin-21__no_interaction	Zosuquidar__Fibroblast Growth Factor 1__no_interaction	laropiprant__hIFN-beta__no_interaction	laropiprant__Interleukin-21__no_interaction	laropiprant__Fibroblast Growth Factor 1__no_interaction	Perifosine__hIFN-beta__no_interaction	Perifosine__Interleukin-21__no_interaction	Perifosine__Fibroblast Growth Factor 1__no_interaction	Deforolimus__hIFN-beta__no_interaction	Deforolimus__Interleukin-21__no_interaction	Deforolimus__Fibroblast Growth Factor 1__no_interaction	Fenretinide__hIFN-beta__no_interaction	Fenretinide__Interleukin-21__no_interaction	Fenretinide__Fibroblast Growth Factor 1__no_interaction	Clevidipine__hIFN-beta__no_interaction	Clevidipine__Interleukin-21__no_interaction	Clevidipine__Fibroblast Growth Factor 1__no_interaction	Eprodisate sodium__hIFN-beta__no_interaction	Eprodisate sodium__Interleukin-21__no_interaction	Eprodisate sodium__Fibroblast Growth Factor 1__no_interaction	Eltrombopag__hIFN-beta__no_interaction	Eltrombopag__Interleukin-21__no_interaction	Eltrombopag__Fibroblast Growth Factor 1__no_interaction	mesylate__hIFN-beta__no_interaction	mesylate__Interleukin-21__no_interaction	mesylate__Fibroblast Growth Factor 1__no_interaction	90Y__hIFN-beta__no_interaction	90Y__Interleukin-21__no_interaction	90Y__Fibroblast Growth Factor 1__no_interaction	prednisolone__hIFN-beta__no_interaction	prednisolone__Interleukin-21__no_interaction	prednisolone__Fibroblast Growth Factor 1__no_interaction	Motexafin__hIFN-beta__no_interaction	Motexafin__Interleukin-21__no_interaction	Motexafin__Fibroblast Growth Factor 1__no_interaction	Midostaurin__hIFN-beta__no_interaction	Midostaurin__Interleukin-21__no_interaction	Midostaurin__Fibroblast Growth Factor 1__no_interaction	Patupilone__hIFN-beta__no_interaction	Patupilone__Interleukin-21__no_interaction	Patupilone__Fibroblast Growth Factor 1__no_interaction	ibritumomab tiuxetan__hIFN-beta__no_interaction	ibritumomab tiuxetan__Interleukin-21__no_interaction	ibritumomab tiuxetan__Fibroblast Growth Factor 1__no_interaction	Oblimersen sodium__hIFN-beta__no_interaction	Oblimersen sodium__Interleukin-21__no_interaction	Oblimersen sodium__Fibroblast Growth Factor 1__no_interaction	Desvenlafaxine__hIFN-beta__no_interaction	Desvenlafaxine__Interleukin-21__no_interaction	Desvenlafaxine__Fibroblast Growth Factor 1__no_interaction	Darapladib__hIFN-beta__no_interaction	Darapladib__Interleukin-21__no_interaction	Darapladib__Fibroblast Growth Factor 1__no_interaction	Farnesylthiosalicylic acid__hIFN-beta__no_interaction	Farnesylthiosalicylic acid__Interleukin-21__no_interaction	Farnesylthiosalicylic acid__Fibroblast Growth Factor 1__no_interaction	Binodenoson__hIFN-beta__no_interaction	Binodenoson__Interleukin-21__no_interaction	Binodenoson__Fibroblast Growth Factor 1__no_interaction	Indium__hIFN-beta__no_interaction	Indium__Interleukin-21__no_interaction	Indium__Fibroblast Growth Factor 1__no_interaction	Epigallocatechin gallate__hIFN-beta__no_interaction	Epigallocatechin gallate__Interleukin-21__no_interaction	Epigallocatechin gallate__Fibroblast Growth Factor 1__no_interaction	Prasugrel__hIFN-beta__no_interaction	Prasugrel__Interleukin-21__no_interaction	Prasugrel__Fibroblast Growth Factor 1__no_interaction	NB-001__hIFN-beta__no_interaction	NB-001__Interleukin-21__no_interaction	NB-001__Fibroblast Growth Factor 1__no_interaction	Bortezomib__hIFN-beta__no_interaction	Bortezomib__Interleukin-21__no_interaction	Bortezomib__Fibroblast Growth Factor 1__no_interaction	Alvocidib hydrochloride__hIFN-beta__no_interaction	Alvocidib hydrochloride__Interleukin-21__no_interaction	Alvocidib hydrochloride__Fibroblast Growth Factor 1__no_interaction	TRO-19622__hIFN-beta__no_interaction	TRO-19622__Interleukin-21__no_interaction	TRO-19622__Fibroblast Growth Factor 1__no_interaction	ITF__hIFN-beta__no_interaction	ITF__Interleukin-21__no_interaction	ITF__Fibroblast Growth Factor 1__no_interaction	Agomelatine__hIFN-beta__no_interaction	Agomelatine__Interleukin-21__no_interaction	Agomelatine__Fibroblast Growth Factor 1__no_interaction	Regadenoson__hIFN-beta__no_interaction	Regadenoson__Interleukin-21__no_interaction	Regadenoson__Fibroblast Growth Factor 1__no_interaction	Panobinostat__hIFN-beta__no_interaction	Panobinostat__Interleukin-21__no_interaction	Panobinostat__Fibroblast Growth Factor 1__no_interaction	vincristine__hIFN-beta__no_interaction	vincristine__Interleukin-21__no_interaction	vincristine__Fibroblast Growth Factor 1__no_interaction	Sotrastaurin__hIFN-beta__no_interaction	Sotrastaurin__Interleukin-21__no_interaction	Sotrastaurin__Fibroblast Growth Factor 1__no_interaction	Cediranib__hIFN-beta__no_interaction	Cediranib__Interleukin-21__no_interaction	Cediranib__Fibroblast Growth Factor 1__no_interaction	Masitinib__hIFN-beta__no_interaction	Masitinib__Interleukin-21__no_interaction	Masitinib__Fibroblast Growth Factor 1__no_interaction	Idraparinux sodium__hIFN-beta__no_interaction	Idraparinux sodium__Interleukin-21__no_interaction	Idraparinux sodium__Fibroblast Growth Factor 1__no_interaction	Dipyridamole__hIFN-beta__no_interaction	Dipyridamole__Interleukin-21__no_interaction	Dipyridamole__Fibroblast Growth Factor 1__no_interaction	BIBW-2992__hIFN-beta__no_interaction	BIBW-2992__Interleukin-21__no_interaction	BIBW-2992__Fibroblast Growth Factor 1__no_interaction	Curcumin__hIFN-beta__no_interaction	Curcumin__Interleukin-21__no_interaction	Curcumin__Fibroblast Growth Factor 1__no_interaction	Omacetaxine mepesuccinate__hIFN-beta__no_interaction	Omacetaxine mepesuccinate__Interleukin-21__no_interaction	Omacetaxine mepesuccinate__Fibroblast Growth Factor 1__no_interaction	succinate__hIFN-beta__no_interaction	succinate__Interleukin-21__no_interaction	succinate__Fibroblast Growth Factor 1__no_interaction	LY-518674__hIFN-beta__no_interaction	LY-518674__Interleukin-21__no_interaction	LY-518674__Fibroblast Growth Factor 1__no_interaction	gadolinium__hIFN-beta__no_interaction	gadolinium__Interleukin-21__no_interaction	gadolinium__Fibroblast Growth Factor 1__no_interaction
18026713-5	RESULTS: In comparison with healthy participants, type 2 diabetic patients on an NPD had similar ELF, reduced serum <protein-id="P02768">albumin</protein-id> (38 +/- 1.1 vs 42 +/- 0.8 g/l; p &lt; 0.05), similar fractional synthesis rates (<compound-id="72206646">FSR</compound-id>) and absolute synthesis rates (ASR) of <protein-id="P02768">albumin</protein-id>, and both increased plasma <protein-id="P02675,V9HVY1">fibrinogen</protein-id> concentration [10.7 +/- 0.6 vs 7.2 +/- 0.5 micromol/l (3.64 +/- 0.22 vs 2.45 +/- 0.18 g/l); p &lt; 0.05] and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> ASR [11.03 +/- 1.17 vs 6.0 +/- 1.8 micromol 1.73 m(-2) day(-1) (3.7 +/- 0.4 vs 1.9 +/- 0.3 g 1.73 m(-2) day(-1)); p &lt; 0.01].	FSR__fibrinogen__no_interaction	FSR__albumin__no_interaction
9313756-4	Although <compound-id="206,5793,64689,79025">glucose</compound-id> control was similar at the end of both periods (MDBG 8.3 +/- 0.3 vs. 7.9 +/- 0.3 mmol/l; HbA1c 7.4 +/- 0.3 vs. 7.0 +/- 0.2%, <protein-id="P01308,I3WAC9">Insulin</protein-id> versus <compound-id="3488">glibenclamide</compound-id>), <protein-id="P01308,I3WAC9">Insulin</protein-id> compared with <compound-id="3488">glibenclamide</compound-id> induced a significant reduction in plasma triglycerides (0.9 +/- 0.1 vs. 1.1 +/- 0.1 mmol/l, P &lt; 0.05), VLDL triglycerides (50.1 +/- 12.2 vs. 63.6 +/- 12.3 mg/dl, P &lt; 0.02), VLDL1 lipid concentration (24.9 +/- 7.5 vs. 39.9 +/- 9.5 mg/dl, P &lt; 0.006), and increased <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> <compound-id="5997">cholesterol</compound-id> (25.2 +/- 1.6 vs. 20.3 +/- 1.3 mg/dl, P &lt; 0.03).	cholesterol__Insulin__no_interaction	cholesterol__HDL2__no_interaction	glibenclamide__Insulin__no_interaction	glibenclamide__HDL2__no_interaction	glucose__Insulin__no_interaction	glucose__HDL2__no_interaction
11756164-4	Using novel canine-human chimeras dissecting the C-terminal flank, it is now demonstrated that (1) Phe201-Glu225 contains the epitope for AP1, an anti-<protein-id="P07359,L7UYB8">GPIb alpha</protein-id> monoclonal antibody that inhibits both ristocetin- and botrocetin-dependent <protein-id="P04275">vWF</protein-id> binding; (2) VM16d, an antibody that preferentially inhibits botrocetin-dependent <protein-id="P04275">vWF</protein-id> binding, recognizes the sequence Val226-Gly268, surrounding Cys248, which forms a disulfide-bond with Cys209; (3) <protein-id="P04275">vWF</protein-id> binding to chimeric <protein-id="P07359,L7UYB8">GPIb alpha</protein-id> is comparable to wild-type in 2 chimeras in which the sixth <compound-id="6106">leucine</compound-id>-rich repeat was of the same species as the first disulfide loop (Phe201-Cys248) of the C-terminal flank, suggesting an interaction between these domains may be important for optimal <protein-id="P04275">vWF</protein-id> binding; and (4) replacing the C-terminal flank second disulfide loop (Asp249-Gly268) in human <protein-id="P07359,L7UYB8">GPIb alpha</protein-id> with the corresponding canine sequence enhanced <protein-id="P04275">vWF</protein-id> binding under static and flow conditions, providing the first evidence for a gain-of-function phenotype associated with the second loop of the C-terminal flank.	leucine__vWF__no_interaction	leucine__GPIb alpha__no_interaction
11558844-9	Univariate analysis showed that patients with LV thrombus had a higher peak <compound-id="586">creatine</compound-id> kinase (CK) level (2,879 +/- 742 vs. 1,693 +/- 1,210 I/U, p = 0.001), higher peak <protein-id="P02741">CRP</protein-id> level (14.9 +/- 7.1 vs. 9.2 +/- 6.8 mg/dl, p = 0.001), higher wall motion score index (1.8 +/- 0.2 vs. 1.5 +/- 0.3, p = 0.002), higher apical wall motion score index (2.35 +/- 0.72 vs. 2.07 +/- 0.70, p = 0.001), larger end-diastolic volume (145.2 +/- 43.7 vs. 116.5 +/- 44.2 ml, p = 0.002), larger end-systolic volume (85.4 +/- 37.2 vs. 62.9 +/- 31.6 ml, p = 0.003), and lower ejection fraction (42.1 +/- 12 vs. 47.3 +/- 13, p = 0.04).	creatine__CRP__no_interaction
22014996-2	A total of thirty-two <compound-id="12210218">thieno[3,2-b]pyridine</compound-id> derivatives of two series: methyl 3-amino-6-(hetero)arylthieno[3,2-b]<compound-id="1049">pyridine-</compound-id>2-carboxylates (1a-1t) and methyl 3-amino-6-[(hetero)arylethynyl]<compound-id="12210218">thieno[3,2-b]pyridine</compound-id>-2-carboxylates (2a-2n), previously prepared by some of us, were evaluated as new potential anti-HCC agents by studying their in vitro cell growth inhibition on human HepG2 cells and hepatotoxicity using a porcine liver primary cell culture (<protein-id="P60201,A8K9L3,B4DI30">PLP1</protein-id>).	pyridine-__PLP1__no_interaction	thieno[3,2-b]pyridine__PLP1__no_interaction
21870121-6	At the end of the study period, between the 2 groups we observed a significant difference in Everyday Memory Questionnaire -23.9 vs 4.4 (p &lt; 0.001), Logical Memory (Paragraph recall) test 22.3 vs 0.7 (p &lt; 0.001), Trail Making Test A -7.5 vs -2.6 (p &lt; 0.001), Trail Making Test B -10.5 vs -3.1 (p &lt; 0.001), Controlled Oral Word Association Test 4.2 vs 0.5 (p &lt; 0.001), Hooper test 2.6 vs 0.1 (p &lt; 0.05), Judgement of line orientation 2.8 vs 0.3 (p &lt; 0.001), Digit Cancellation time -24.5 vs -2.4 (p &lt; 0.001), NH₄⁺ 30.5 vs 13.5 (p &lt; 0.001), <protein-id="P00734">prothrombin</protein-id> time 2 vs 2.4 (p &lt; 0.05), <compound-id="5950,602">alanine</compound-id> transaminase -10.7 vs -13.6 (p &lt; 0.001).	alanine__prothrombin__no_interaction
22367758-2	The stoichiometric reaction of the bis(phenols) 1,3-dithiapropanediyl-2,2'-bis(4,6-<compound-id="185594">di-tert-butylphenol</compound-id>), 1,3-dithiapropanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-propanediyl-1,4-dithiabutanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-butanediyl-1,4-dithiabutane diyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-hexanediyl-1,4-dithiabutanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], 1,3-dithiapropanediyl-2,2'-bis[6-(1-methylcyclohexyl)-<compound-id="2879">4-methylphenol</compound-id>] (C(1), R=1-methylcyclohexyl), and 1,4-dithiabutanediyl-2,2'-bis[6-(1-methylcyclohexyl)-<compound-id="2879">4-methylphenol</compound-id>] with rare-earth metal silylamido precursors [Ln{N(SiHMe(2))(2)(3)(thf)(x)] (Ln=Sc, x=1 or Ln=Y, x=2; thf=tetrahydrofuran) afforded the corresponding <compound-id="23952">scandium</compound-id> and <compound-id="23993">yttrium</compound-id> bis(<compound-id="996">phenolate</compound-id>) silylamido complexes [Ln(OSSO){N(SiHMe(2))(2)}(thf)] in moderate to good yields.	scandium__rac-2__no_interaction	phenolate__rac-2__no_interaction	4-methylphenol__rac-2__no_interaction	di-tert-butylphenol__rac-2__no_interaction	yttrium__rac-2__no_interaction
8605955-2	In radioligand binding assays, the dipeptoid <compound-id="9850711">PD 135666</compound-id> ((<compound-id="4775">benzenebutanoic acid</compound-id>, beta-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2- [[(tricyclo[3.3.1.1(3,7)]<protein-id="Q99PV5,Q6L8F5,D3Z2G6">dec-2</protein-id>-yloxy)carbonyl]amino]propyl] amino],-[R-(+*,S*)]) selectively inhibited [125I]Bolton Hunter <compound-id="16219094">CCK-8</compound-id> binding to CCKB receptors in mouse cerebral cortex (CCKB IC50 = 0.1 nM) but was weaker as an inhibitor of <protein-id="Q63931">CCKA receptor</protein-id> binding in the rat pancreas (IC50 = 26 nM).	CCK-8__dec-2__no_interaction	CCK-8__CCKA receptor__no_interaction	PD 135666__dec-2__no_interaction	PD 135666__CCKA receptor__no_interaction	benzenebutanoic acid__dec-2__no_interaction	benzenebutanoic acid__CCKA receptor__no_interaction
11422740-14	RESULTS: The anti-Thy-1.1 treated with 1,25(OH)2D3 group versus the anti-Thy-1.1 alone group showed a significant reduction in urinary protein (at day 7, 424 +/- 228 vs. 66 +/- 30 mg/mg urinary <compound-id="588">creatinine</compound-id>, P = 0.02) and <protein-id="P20607">interleukin-6</protein-id> excretion (at day 3, 537 +/- 360 pg/mL vs. 110 +/- 34 pg/mg urinary <compound-id="588">creatinine</compound-id>, P = 0.015), reduced glomerular diameters (at day 7, 283 +/- 38 vs. 261 +/- 48 microm, P &lt; 0.01), decreased neutrophil (at day 4, 20 +/- 12 His48-positive cells/glomerulus vs. 3.7 +/- 1.3 His48-positive cells/glomerulus, P &lt; 0.001), and monocyte accumulation (day 7, 4.9 +/- 2.9 ED1-positive cells/glomerulus vs. 2.8 +/- 2.9 ED1-positive cells/glomerulus, P &lt; 0.05), and attenuated glomerular cells proliferation (day 7, 13 +/- 3.2 <protein-id="P04961">PCNA</protein-id>-positive cells/glomerulus vs. 9.4 +/- 3 <protein-id="P04961">PCNA</protein-id>-positive cells/glomerulus, P &lt; 0.01).	creatinine__PCNA__no_interaction	creatinine__interleukin-6__no_interaction
21490074-8	Furthermore, hepatic <protein-id="P35557,Q53Y25">GCK</protein-id> mRNA expression is associated with lipogenic gene expression (fatty acid synthase, r = 0.49, P = 0.0003; <compound-id="6302">acetyl-coenzyme A</compound-id> carboxylase-α, r = 0.44, P = 0.0015, and <compound-id="6302">acetyl-coenzyme A</compound-id> carboxylase-β, r = 0.48, P = 0.0004) and the de novo lipogenesis index (r = 0.36, P = 0.01).	acetyl-coenzyme A__GCK__no_interaction
2210017-2	We investigated the changes in blood <compound-id="206,5793,64689,79025">glucose</compound-id>, plasma non-esterified fatty acids (NEFA), <compound-id="767">bicarbonate</compound-id> and glucagon after stopping <protein-id="P01308,I3WAC9">insulin</protein-id> infusion between 08.00 h. and 14.00 h. <protein-id="P01308,I3WAC9">insulin</protein-id> infusion cessation resulted in: 1) a similar increase in blood <compound-id="206,5793,64689,79025">glucose</compound-id> in both groups after 2 hours of interruption (group 1: 9.45 +/- 1.28 mmol/L versus basal levels of 6.94 +/- 0.96 mmol/L, p less than 0.05; group 2: 8.11 +/- 2.87 mmol/L versus 5.75 +/- 2.17 mmol/L, p less than 0.02) and a greater increase in blood <compound-id="206,5793,64689,79025">glucose</compound-id> in group 1 than group 2 after 4 hours (p less than 0.05) and after 6 hours (p less than 0.05); 2) a progressive increase in NEFA in group 1 throughout the study period (08.00 h.: 0.51 +/- 0.28 mmol/L; 14.00 h: 1.44 +/- 0.45 mmol/L, p less than 0.05) that was significant after 4 and 6 hours of <protein-id="P0DML3,B1A4H9,A6NIT4">CSII</protein-id> interruption; there were no changes in NEFA in group 2; 3) plasma level of IA correlated inversely with final glycemia (r = -0.67, p less than 0.01) and final NEFA (r = -0.56, p = 0.02).	bicarbonate__CSII__no_interaction	bicarbonate__insulin__no_interaction	glucose__CSII__no_interaction	glucose__insulin__no_interaction
19361602-6	Plasma <protein-id="P16860">BNP</protein-id> (F = 14.8, p = 001), <compound-id="10964">malondialdehyde</compound-id> (F = 9.4, p = 0.006), protein carbonyl (F = 9.2, p = 0.006), and nitrotyrosine (F = 4.4, p = 0.045) were significantly decreased, along with an increase in antioxidative <compound-id="124886,20725278">glutathione</compound-id> (F = 4.2, p = 0.049) after darbepoetin alfa treatment.	glutathione__BNP__no_interaction	malondialdehyde__BNP__no_interaction
16712667-9	<protein-id="O00300">OPG</protein-id> was negatively correlated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> and triglyceride levels (r = -0.18, P = 0.031 and r = -0.19, P = 0.02, respectively) and positively correlated with the QUICKI index (r = 0.17, P = 0.033), HDL <compound-id="5997">cholesterol</compound-id> (r = 0.21, P = 0.009) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (r = 0.27, P = 0.001).	cholesterol__OPG__no_interaction	cholesterol__adiponectin__no_interaction	glucose__OPG__no_interaction	glucose__adiponectin__no_interaction
16676992-1	Addition of [Mo(V)2O2S2(edt)2]2- (edt =1,2-ethanedithiolate) to <compound-id="6342">acetonitrile</compound-id> and/or <compound-id="11686950,887">methanol</compound-id> solutions of MnII containing bipyridines [<compound-id="87019">4,4'-trimethylenedipyridine</compound-id> (TDP), <compound-id="11107">4,4'-bipyridine</compound-id> (4,4'-bpy), <compound-id="1474">2,2'-bipyridine</compound-id> (2,2'-bpy)] or <compound-id="36336">15-crown-5</compound-id> produces three new heterometallic cluster coordination polymers, [Mn2[Mo2O2S2(edt)2]2(TDP)3(CH3OH)2(NCMe)2].3CH3OH.0.25MeCN (1), [Mn(TDP)2(H2O)2]2+[Mn[Mo2O2S2(edt)2)2(TDP)2]]2-.6CH3OH (2), [Mn[Mo2O2S2(edt)2](TDP)2(CH3OH)(H2O)].CH3OH (3), and three new multinuclear clusters, [Mn[Mo2O2S2(edt)2](4,4'-bpy)(CH3OH)4].0.5(4,4'-bpy) (4), [Mn[Mo2O2S2(edt)2](2,2'-bpy)2].2CH3OH (5), and (<protein-id="P62079">NEt4</protein-id>)2[Mn(<compound-id="36336">15-crown-5</compound-id>)[Mo2O2S2(edt)2]2] (6).	15-crown-5__NEt4__no_interaction	4,4'-trimethylenedipyridine__NEt4__no_interaction	4,4'-bipyridine__NEt4__no_interaction	methanol__NEt4__no_interaction	2,2'-bipyridine__NEt4__no_interaction	acetonitrile__NEt4__no_interaction
19099934-5	RESULTS: <compound-id="54687">Pravastatin</compound-id> dose-dependently upregulated <protein-id="P23242,Q8C4N2">Cx43</protein-id> proteins on membrane of myocardial cells (group A: 0.16 +/- 0.06, group B: 4.55 +/- 0.73 and group C: 5.21 +/- 0.42, P &lt; 0.01 vs. group A) and <protein-id="P23242,Q8C4N2">Cx43</protein-id> mRNA expression (group A: 1.000 +/- 0.127, group B: 1.320 +/- 0.096, group C: 1.550 +/- 0.126, P &lt; 0.05 vs. group A), <protein-id="P18893,Q3U879">IL-10</protein-id> mRNA expression (group A: 1.000 +/- 0.031, group B: 1.810 +/- 0.029, group C: 2.140 +/- 0.032, P &lt; 0.05 vs. group A) while down-regulated <protein-id="P01580">IFN-gamma</protein-id> mRNA (group A: 1.000 +/- 0.061, group B: 0.603 +/- 0.063, group C: 0.333 +/- 0.071, P &lt; 0.01 vs. group A).	Pravastatin__IFN-gamma__no_interaction	Pravastatin__Cx43__no_interaction	Pravastatin__IL-10__no_interaction
23522250-9	RESULTS: The relative expression level of the phosphorylation of <protein-id="G3V617,Q56A33">p38</protein-id> of SA-B group is 0.33+/-0.05,obviously lower than control group(q=7.08, P less than 0.01); SA-B+TGFb1 group is 0.46+/-0.04, obviously lower than TGF b1 group(q=10.45, P less than 0.01); The relative expression level of the phosphorylation of <protein-id="Q925D6">MKK3/6</protein-id> of SA-B group is 0.11+/-0.07, obviously lower than control group(q=3.944, P less than 0.05); SA-B+TGF b1 group is 0.28+/-0.07, obviously lower than TGFb1 group (q=7.91, P less than 0.01); The relative luciferase activity of MEF2 reporter of SA-B+TGFb1 group and <compound-id="176155">SB203580</compound-id>+TGF b1 group is 2.93+/-0.09 and 2.50+/-0.05 respectively, both obviously lower than TGFb1 group(q=35.35 and 37.2, P less than 0.01); The relative expression level of <protein-id="A0A096MJ23,A0A096MK88,A0A096MKI4,A0A096MJY4">MEF2C</protein-id> and <protein-id="Q2MJT0,A0A0G2JSZ4,M0R6R7">MEF2A</protein-id> of SA-B group is 15.82+/-0.97 and 13.00+/-0.40 respectively, obviously lower than control group(q is 5.18 and 13.32, both P less than 0.01); SA-B+TGF b1 group is 13.40+/-0.72 and 20.47+/-0.83 respectively, obviously lower than TGFb1 group(q is 43.93 and 12.52,both P less than 0.01); The relative expression level of a-SMA of SA-B+TGFb1 group is 8.76+/-0.44, obviously lower than TGFb1 group(q=20.35, P less than 0.01); SA-B+<compound-id="176155">SB203580</compound-id>+TGFb1 group is only 3.57+/-0.49, obviously lower than TGFb1 group(q=39.78, P less than 0.01); The relative luciferase activity of collagen a1(I) reporter of SA-B+TGF b1 group and <compound-id="176155">SB203580</compound-id>+TGFb1 group is 1.61+/-0.05 and 1.42+/-0.07 respectively, obviously lower than TGFb1 group(q=26.4 and 27.62, both P less than 0.01).	SB203580__MEF2C__no_interaction	SB203580__p38__no_interaction	SB203580__MEF2A__no_interaction	SB203580__MKK3/6__no_interaction
12122495-2	Thus, we determined, in isolated rings from human saphenous vein and human internal mammary artery, contractile responses to noradrenaline (10(-8)-10(-4) M) in the absence and presence of the alpha-adrenoceptor antagonists yohimbine (alpha(2)-adrenoceptor antagonist, 10(-8)-10(-6) M), <compound-id="4893">prazosin</compound-id> (alpha(1)-adrenoceptor antagonist, 10(-9)-10(-7) M), <compound-id="5640">5-methyl-urapidil</compound-id> (5-MU, <protein-id="P35348,B0ZBD3">alpha(1A)-adrenoceptor</protein-id> antagonist, 10(-8)-10(-6) M), <compound-id="2419">BMY 7378</compound-id> (<protein-id="P25100,B0ZBE0">alpha(1D)-adrenoceptor</protein-id> antagonist, 10(-7)-10(-6) M), and <compound-id="104973">chloroethylclonidine</compound-id> (CEC, irreversible <protein-id="P35368">alpha(1B)-adrenoceptor</protein-id> antagonist, 3x10(-5) M for 30 min).	chloroethylclonidine__alpha(1A)-adrenoceptor__no_interaction	chloroethylclonidine__alpha(1B)-adrenoceptor__no_interaction	chloroethylclonidine__alpha(1D)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1A)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1B)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1D)-adrenoceptor__no_interaction	prazosin__alpha(1A)-adrenoceptor__no_interaction	prazosin__alpha(1B)-adrenoceptor__no_interaction	prazosin__alpha(1D)-adrenoceptor__no_interaction	BMY 7378__alpha(1A)-adrenoceptor__no_interaction	BMY 7378__alpha(1B)-adrenoceptor__no_interaction	BMY 7378__alpha(1D)-adrenoceptor__no_interaction
9821173-3	In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant <compound-id="3385">5-fluorouracil</compound-id> (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; <compound-id="60750">gemcitabine</compound-id> has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> and TGF-beta; a <protein-id="P38936,A0A024RCX5">p21</protein-id>-adenovirus (rAD-<protein-id="P38936,A0A024RCX5">p21</protein-id>) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-<protein-id="P38936,A0A024RCX5">p21</protein-id>.	5-fluorouracil__p21__no_interaction	5-fluorouracil__p53__no_interaction	gemcitabine__p21__no_interaction	gemcitabine__p53__no_interaction
2824919-2	During the "fasting test" the following data expressed as mean basal plasma values +/- <compound-id="5289348">SEM</compound-id> vs. mean hypoglycemic values +/- <compound-id="5289348">SEM</compound-id> were obtained: <protein-id="P01308,I3WAC9">insulin</protein-id> (57.3 +/- 17.9 vs. 27.5 +/- 10.6 microU/ml), <protein-id="P01308,I3WAC9">C-peptide</protein-id> (4.9 +/- 1.1 vs. 3.5 +/- 0.9 ng/ml), free fatty acids (0.30 +/- 0.01 vs. 0.32 +/- 0.02 mmol/l), <compound-id="441">beta-hydroxybutyrate</compound-id> (less than 0.03 vs. 0.05 +/- 0.02 mmol/l), alanine (204.0 +/- 67.5 vs. 228.3 +/- 64.9 mumol/l), <compound-id="612">lactate</compound-id> (5.3 +/- 0.7 vs. 5.4 +/- 1.1 mg/dl), pyruvate (41.3 +/- 4.8 vs. 19.7 +/- 4.2 mg/dl).	SEM__insulin__no_interaction	SEM__C-peptide__no_interaction	beta-hydroxybutyrate__insulin__no_interaction	beta-hydroxybutyrate__C-peptide__no_interaction	lactate__insulin__no_interaction	lactate__C-peptide__no_interaction
19081404-7	The correlation of <compound-id="444185">GLS</compound-id> with <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>-EF (r = -0.69, P &lt; .0001) was comparable to that between 3D-EF and <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (r = 0.80, P &lt; .0001), and better than that between 2D-EF (r = 0.58, P &lt; .0001) or automated EF and <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (r = 0.62, P &lt; .0001).	GLS__MRI__no_interaction
19134409-5	RESULTS: Compared with the control group, the expression of p-<protein-id="P17252,Q7Z727">PKCalpha</protein-id> and <protein-id="P27361,L7RXH5,Q9BWJ1">ERK1</protein-id>/2, p-<protein-id="P27361,L7RXH5,Q9BWJ1">ERK1</protein-id>/2 protein increased, the expression of <protein-id="P12004">cyclinD1</protein-id>, P21(<protein-id="P38936,A0A024RCX5">cip1</protein-id>) protein increased correspondingly (the A value % control was 2.10 +/- 0.29, 1.67 +/- 0.19, 2.20 +/- 0.27, 1.99 +/- 0.22 and 3.11 +/- 0.29 respectively; q value was 9.87, 7.06, 10.57, 11.10 and 20.33 respectively; all P &lt; 0.05) in <compound-id="122634,22833501,27924,4792">PMA</compound-id> treated group, and cells proliferation [the percentage of cells in S phase was (30.3 +/- 2.4)%, A(490) value was 0.80 +/- 0.06] enhanced significantly compared with those [the percentage of cells in S phase was (13.9 +/- 2.6)%, A(490) value was 0.41 +/- 0.04] of the control group (q = 6.07, 12.63; all P &lt; 0.05).	PMA__ERK1__no_interaction	PMA__PKCalpha__no_interaction	PMA__cip1__no_interaction	PMA__cyclinD1__no_interaction
21726418-5	RESULTS: (i) CBD and <compound-id="34180,93147">tetrahydrocannabivarin</compound-id> (THCV) stimulated <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id>-mediated [Ca(2+)](i) with high efficacy (50-70% of the effect of <compound-id="25134244,3733,5353687,6434517,6912226">ionomycin</compound-id>) and potency (EC(50∼) 3.7 μm), whereas <compound-id="59444407">cannabigerovarin</compound-id> (CBGV) and cannabigerolic acid (<compound-id="6449999">CBGA</compound-id>) were significantly more efficacious at desensitizing this channel to the action of <compound-id="10364">carvacrol</compound-id> than at activating it; (ii) <compound-id="11601669,45783233">cannabidivarin</compound-id> and THCV stimulated <protein-id="Q9ERZ8">TRPV4</protein-id>-mediated [Ca(2+)](i) with moderate-high efficacy (30-60% of the effect of <compound-id="25134244,3733,5353687,6434517,6912226">ionomycin</compound-id>) and potency (EC(50) 0.9-6.4 μm), whereas <compound-id="6449999">CBGA</compound-id>, CBGV, <compound-id="2543">cannabinol</compound-id> and <compound-id="5315659">cannabigerol</compound-id> were significantly more efficacious at desensitizing this channel to the action of 4-α-<compound-id="16219908">phorbol 12,13-didecanoate</compound-id> (4α-<compound-id="452543,452544,537379,71308620">PDD</compound-id>) than at activating it; (iii) CBC reduced <protein-id="Q704Y3,Q3V318">TRPV1</protein-id>β, <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id> and <protein-id="Q9ERZ8">TRPV4</protein-id> mRNA in the jejunum, and <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id> and <protein-id="Q9ERZ8">TRPV4</protein-id> mRNA in the ileum of croton oil-treated mice.	phorbol 12,13-didecanoate__TRPV4__no_interaction	phorbol 12,13-didecanoate__TRPV1__no_interaction	phorbol 12,13-didecanoate__TRPV3__no_interaction	ionomycin__TRPV4__no_interaction	ionomycin__TRPV1__no_interaction	ionomycin__TRPV3__no_interaction	cannabinol__TRPV4__no_interaction	cannabinol__TRPV1__no_interaction	cannabinol__TRPV3__no_interaction	tetrahydrocannabivarin__TRPV4__no_interaction	tetrahydrocannabivarin__TRPV1__no_interaction	tetrahydrocannabivarin__TRPV3__no_interaction	cannabidivarin__TRPV4__no_interaction	cannabidivarin__TRPV1__no_interaction	cannabidivarin__TRPV3__no_interaction	carvacrol__TRPV4__no_interaction	carvacrol__TRPV1__no_interaction	carvacrol__TRPV3__no_interaction	CBGA__TRPV4__no_interaction	CBGA__TRPV1__no_interaction	CBGA__TRPV3__no_interaction	cannabigerol__TRPV4__no_interaction	cannabigerol__TRPV1__no_interaction	cannabigerol__TRPV3__no_interaction	PDD__TRPV4__no_interaction	PDD__TRPV1__no_interaction	PDD__TRPV3__no_interaction	cannabigerovarin__TRPV4__no_interaction	cannabigerovarin__TRPV1__no_interaction	cannabigerovarin__TRPV3__no_interaction
16471964-1	Reactions of <compound-id="23978">copper</compound-id>(I) halides with a series of <compound-id="9568512">thiosemicarbazone</compound-id> ligands (Htsc) in the presence of <compound-id="11776">triphenylphosphine</compound-id> (Ph(3)P) in <compound-id="6342">acetonitrile</compound-id> have yielded three types of complexes: (i) monomers, [CuX(<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-S-Htsc)(Ph3P)2] [X, Htsc = I (1), Br (2), <compound-id="5711036">benzaldehyde thiosemicarbazone</compound-id> (Hbtsc); I (5), Br (6), Cl (7), <compound-id="1638753,5354113">pyridine-2-carbaldehyde thiosemicarbazone</compound-id> (Hpytsc)], (ii) halogen-bridged dimers, [<compound-id="444924">Cu2</compound-id>(<protein-id="Q96CW1,E9PFW3,B4DNB9">mu2</protein-id>-X)2(<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-S-Htsc)2(Ph3P)2] [X, Htsc = Br (3), Hbtsc; I (8), <compound-id="699319">furan-2-carbaldehyde thiosemicarbazone</compound-id> (Hftsc); I (11), <compound-id="692778">thiophene-2-carbaldehyde thiosemicarbazone</compound-id> (Httsc)], and (iii) <compound-id="402">sulfur</compound-id>-bridged dimers, [Cu2X2(<protein-id="Q96CW1,E9PFW3,B4DNB9">mu2</protein-id>-S-Htsc)2(Ph3P)2] [X, Htsc = Cl (4), Hbtsc; Br (9), Cl (10), <compound-id="6746523">pyrrole-2-carbaldehyde thiosemicarbazone</compound-id> (Hptsc); Br (12), Httsc].	copper__eta1__no_interaction	copper__mu2__no_interaction	thiosemicarbazone__eta1__no_interaction	thiosemicarbazone__mu2__no_interaction	Cu2__eta1__no_interaction	Cu2__mu2__no_interaction	pyrrole-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	pyrrole-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	benzaldehyde thiosemicarbazone__eta1__no_interaction	benzaldehyde thiosemicarbazone__mu2__no_interaction	furan-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	furan-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	pyridine-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	pyridine-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	triphenylphosphine__eta1__no_interaction	triphenylphosphine__mu2__no_interaction	sulfur__eta1__no_interaction	sulfur__mu2__no_interaction	acetonitrile__eta1__no_interaction	acetonitrile__mu2__no_interaction	thiophene-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	thiophene-2-carbaldehyde thiosemicarbazone__mu2__no_interaction
22658637-9	Our data also demonstrated that <compound-id="54454">simvastatin</compound-id> reduced the expression and secretion of <protein-id="P13500">MCP-1</protein-id>, under baseline (770.4 ± 199.9 vs 312.7 ± 113.7 and 1.00 ± 0.14 vs 0.63 ± 0.13, p&lt;0.05, respectively) and inflammatory conditions (14945 ± 228.7 vs 7837.6 ± 847.4 and 24.16 ± 5.49 vs 14.97 ± 2.67, p&lt;0.05, p&lt;0.05, respectively).	simvastatin__MCP-1__no_interaction
17466660-5	RESULTS: Normonatremic runners (n = 33; 2001) with a mean 3% decrease in body weight showed a 40-fold increase in <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (66.6 +/- 11.9 pg/mL from 1.6 +/- 0.5 pg/mL, P = .001), which was significantly correlated with increases in <compound-id="586">creatine</compound-id> kinase (r = 0.88, P = &lt;.0001), <compound-id="5754">cortisol</compound-id> (r = 0.70, P = .0003), and <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> (r = 0.67, P &lt;.007), but not <compound-id="6322,90867653">arginine</compound-id> <protein-id="P01185,X5DQP6">vasopressin</protein-id> (r = 0.44, P = .07).	cortisol__prolactin__no_interaction	cortisol__vasopressin__no_interaction	cortisol__interleukin-6__no_interaction	arginine__prolactin__no_interaction	arginine__vasopressin__no_interaction	arginine__interleukin-6__no_interaction	creatine__prolactin__no_interaction	creatine__vasopressin__no_interaction	creatine__interleukin-6__no_interaction
22051955-1	The title polymeric compound, {(C(13)H(16)N(2))[Co(C(10)H(3)O(8))(C(13)H(14)N(2))(H(2)O)(2)](2)·5H(2)O}(n), is an ionic structure comprising an anionic two-dimensional mesh characterized by a {[Co(Hbtc)(<protein-id="O60687">bpp</protein-id>)(H(2)O)(2)](-)}(2) motif [Hbtc is 5-<compound-id="243">carboxybenzene</compound-id>-1,2,4-tricarboxylate and <protein-id="O60687">bpp</protein-id> is <compound-id="87019">1,3-bis(4-pyridyl)propane</compound-id>], with interspersed 4,4'-(<compound-id="6334">propane</compound-id>-1,3-diyl)dipyridinium cations, denoted (H(2)<protein-id="O60687">bpp</protein-id>)(2+), and <compound-id="962">water</compound-id> molecules providing the charge balance and structure stabilization.	propane__bpp__no_interaction	water__bpp__no_interaction	carboxybenzene__bpp__no_interaction	1,3-bis(4-pyridyl)propane__bpp__no_interaction
12162592-4	RESULTS: EV71 patients with both encephalitis and pulmonary oedema were found to have much higher levels of blood <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>) (947 +/- 1239 vs 4.9 +/- 3.1 pg/ml, p = 0.0003), <protein-id="P01375,Q5STB3">tumour necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (22.4 +/- 29.5 vs 5.3 +/- 1.0 pg/ml, p = 0.0035), interleukin Ibeta (<protein-id="P01584">IL-1beta</protein-id>) (48.4 +/- 85.2 vs 4.9 +/- 10.1 pg/ml, p = 0.01), white blood cell count (28.3 +/- 7.6 vs 15.5 +/- 6.8 10(9)/L, p &gt; or = 0.0001) and blood <compound-id="206,5793,64689,79025">glucose</compound-id> (501 +/- 186 vs 165 +/- 117 mg/dL, p = 0.0009) than patients with EV71 encephalitis alone.	glucose__IL-6__no_interaction	glucose__IL-1beta__no_interaction	glucose__tumour necrosis factor-alpha__no_interaction	glucose__TNF-alpha__no_interaction	glucose__interleukin-6__no_interaction
16216995-3	METHODS: The prevalence of high <protein-id="P02741">CRP</protein-id> levels in the third National Health and Nutrition Examination Survey (n = 15 341) was studied using <compound-id="221493">CHD</compound-id> risk-factor cut points designated as abnormal (total <compound-id="5997">cholesterol</compound-id> values, &gt;or=240 mg/dL [&gt;or=6.22 mmol/L]; fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels, &gt;or=126 mg/dL [&gt;or=6.99 mmol/L]; blood pressure, &gt;or=140/90 mm Hg; body mass index [BMI], &gt;or=30 kg/m(2); high-density lipoprotein <compound-id="5997">cholesterol</compound-id> values, &lt;40 mg/dL [&lt;1.04 mmol/L] for men and &lt;50 mg/dL [&lt;1.30 mmol/L] for women; triglyceride levels, &gt;or=200 mg/dL [&gt;or=2.26 mmol/L]; current smoking status) or borderline (total <compound-id="5997">cholesterol</compound-id> values, 200-239 mg/dL [5.18-6.19 mmol/L]; fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels, 100-125 mg/dL [5.55-6.94 mmol/L]; blood pressure, 120-139/80-89 mm Hg; BMI, 25.0-29.9 kg/m(2), and triglyceride values 150-199 mg/dL [1.70-2.25 mmol/L], former smoking status), or normal.	glucose__CRP__no_interaction	CHD__CRP__no_interaction	cholesterol__CRP__no_interaction
19902426-4	As a consequence of the changes we significantly improved the yield of proteomic data, identifying 26 mouse CYPs (<protein-id="P05177">CYP1A2</protein-id>, <compound-id="91623326">2a4</compound-id>, <compound-id="44626338">2a5</compound-id>, 2a12, 2b9, 2c29, 2c37, 2c39, 2c40, 2c50, 2c54, 2c70, <compound-id="6102789">2d9</compound-id>, 2d10, 2d26, <compound-id="6102788">2e1</compound-id>, 2f2, <compound-id="4167622">2j5</compound-id>, 3a11, 3a13, 3a25, 3a41, 4a14, <compound-id="78225217">4f14</compound-id>, 8b1 and 27a1) with an average sequence coverage of 30.1%, including some previously undetected highly homologous isoforms.	2j5__CYP1A2__no_interaction	2e1__CYP1A2__no_interaction	2d9__CYP1A2__no_interaction	4f14__CYP1A2__no_interaction	2a4__CYP1A2__no_interaction	2a5__CYP1A2__no_interaction
15974579-3	Competition binding in cells stably expressing the transfected human <protein-id="P31645,B2R7Y7">SERT</protein-id>, <protein-id="Q01959">dopamine transporter</protein-id> (<protein-id="Q01959">DAT</protein-id>), and <protein-id="P23975,H3BRE9,A0A024R6T9">norepinephrine transporter</protein-id> (<protein-id="P23975,H3BRE9,A0A024R6T9">NET</protein-id>) using [(3)H]<compound-id="2771">citalopram</compound-id>, [(3)H]<compound-id="105056">WIN 35,428</compound-id> or [(125)I]<compound-id="18618996">RTI-55</compound-id>, and [(3)H]<compound-id="4500">nisoxetine</compound-id>, respectively, demonstrated the following order of <protein-id="P31645,B2R7Y7">SERT</protein-id> affinity (K(i) (nM)): <compound-id="657007">14a</compound-id> (0.25) &gt; 16 (0.49) &gt; 20 (0.57) &gt; <compound-id="259834">14b</compound-id> (1.12) &gt; 13 (1.59) &gt; <compound-id="56940697">33b</compound-id> (1.94) = 35 (2.04) &gt;&gt; 23 (8.50) = 28 (8.55) &gt; 41 (15.11) &gt;&gt; 22 (51) &gt; <compound-id="10134160">33a</compound-id> (83.43) &gt; 27 (92).	citalopram__DAT__no_interaction	citalopram__SERT__no_interaction	citalopram__NET__no_interaction	citalopram__norepinephrine transporter__no_interaction	citalopram__dopamine transporter__no_interaction	RTI-55__DAT__no_interaction	RTI-55__SERT__no_interaction	RTI-55__NET__no_interaction	RTI-55__norepinephrine transporter__no_interaction	RTI-55__dopamine transporter__no_interaction	WIN 35,428__DAT__no_interaction	WIN 35,428__SERT__no_interaction	WIN 35,428__NET__no_interaction	WIN 35,428__norepinephrine transporter__no_interaction	WIN 35,428__dopamine transporter__no_interaction	14b__DAT__no_interaction	14b__SERT__no_interaction	14b__NET__no_interaction	14b__norepinephrine transporter__no_interaction	14b__dopamine transporter__no_interaction	14a__DAT__no_interaction	14a__SERT__no_interaction	14a__NET__no_interaction	14a__norepinephrine transporter__no_interaction	14a__dopamine transporter__no_interaction	nisoxetine__DAT__no_interaction	nisoxetine__SERT__no_interaction	nisoxetine__NET__no_interaction	nisoxetine__norepinephrine transporter__no_interaction	nisoxetine__dopamine transporter__no_interaction	33a__DAT__no_interaction	33a__SERT__no_interaction	33a__NET__no_interaction	33a__norepinephrine transporter__no_interaction	33a__dopamine transporter__no_interaction	33b__DAT__no_interaction	33b__SERT__no_interaction	33b__NET__no_interaction	33b__norepinephrine transporter__no_interaction	33b__dopamine transporter__no_interaction
15838260-3	We have made the following observations: (i)<protein-id="P29560">endothelin-1 and 5</protein-id>-hydroxytryptamine produced contraction in the normal Cl- Krebs-Henseleit bicarbonate solution (123 mM Cl-); (ii)inhibition of Na+-K+-2Cl- co-transporter with <compound-id="2471">bumetanide</compound-id> abolished the contractions; (iii) bicarbonate-free solution with <compound-id="23831">HEPES</compound-id> reduced contractions to 5-hydroxytryptamine and <protein-id="P29560">endothelin-1</protein-id>; (iv) substitution of extracellular Cl- with <compound-id="6395">methanesulfonate</compound-id> acid (MS- 113 mM, Cl- 10 mM) enhanced peak contraction to 5-hydroxytryptamine and <protein-id="P29560">endothelin-1</protein-id> and decreased plateau contraction to 5-hydroxytryptamine, but did not affect the plateau contraction to <protein-id="P29560">endothelin-1</protein-id> and KCl; and (v) blockade of Ca2+-dependent Cl- channel with <compound-id="4488">niflumic acid</compound-id> and non-selective Cl- channel with 5-nitro-2-(3-phenylpropylamino) <compound-id="243">benzoic acid</compound-id> and indanyloxyacetic acid-94, R- (+)-methylindazone (R- (+)-<compound-id="656717">IAA-94</compound-id>)decreased contractions to <protein-id="P29560">endothelin-1 and 5</protein-id>-hydroxytryptamine.However, removal of endothelium attenuated the effect of Cl-channel inhibitors.	HEPES__endothelin-1 and 5__no_interaction	HEPES__endothelin-1__no_interaction	niflumic acid__endothelin-1 and 5__no_interaction	niflumic acid__endothelin-1__no_interaction	methanesulfonate__endothelin-1 and 5__no_interaction	methanesulfonate__endothelin-1__no_interaction	benzoic acid__endothelin-1 and 5__no_interaction	benzoic acid__endothelin-1__no_interaction	IAA-94__endothelin-1 and 5__no_interaction	IAA-94__endothelin-1__no_interaction	bumetanide__endothelin-1 and 5__no_interaction	bumetanide__endothelin-1__no_interaction
22046326-2	The purpose of this study was to analyse the association of smoking status and smoking-related phenotypes (included <compound-id="942">nicotine</compound-id> dependence) with 17 candidate genetic variants: CYP2A6*1×2, CYP2A6*2 (1799T&gt;A) [rs1801272], CYP2A6*9 (-<compound-id="70698415">48T</compound-id>&gt;G) [rs28399433], CYP2A6*12, <protein-id="Q16696">CYP2A13</protein-id>*2 (3375C&gt;T) [rs8192789], <protein-id="Q16696">CYP2A13</protein-id>*3 (7520C&gt;G), <protein-id="Q16696">CYP2A13</protein-id>*4 (579G&gt;A), <protein-id="Q16696">CYP2A13</protein-id>*7 (578C&gt;T) [rs72552266], <protein-id="P20813">CYP2B6</protein-id>*4 (785A&gt;G), <protein-id="P20813">CYP2B6</protein-id>*9 (516G&gt;T), <protein-id="P32297">CHRNA3</protein-id> 546C&gt;T [rs578776], <protein-id="P30532,Q6EWN4,H0YM98">CHRNA5</protein-id> 1192G&gt;A [rs16969968], <protein-id="P21554,V5KA96,S5TLS4">CNR1</protein-id> 3764C&gt;G [rs6928499], <protein-id="P14416,A0A024R3C5,A0A024R3I6">DRD2</protein-id>-<protein-id="Q8NFD2">ANKK1</protein-id> 2137G&gt;A (Taq1A) [rs1800497], 5HTT LPR, <protein-id="P28223">HTR2A</protein-id> -1438A&gt;G [rs6311] and <protein-id="P35372,L0E130,G8XRH5,G8XRH4,B8K2Q5">OPRM1</protein-id> 118A&gt;G [rs1799971].	nicotine__CNR1__no_interaction	nicotine__CYP2A13__no_interaction	nicotine__DRD2__no_interaction	nicotine__CYP2B6__no_interaction	nicotine__CHRNA5__no_interaction	nicotine__OPRM1__no_interaction	nicotine__HTR2A__no_interaction	nicotine__CHRNA3__no_interaction	nicotine__ANKK1__no_interaction	48T__CNR1__no_interaction	48T__CYP2A13__no_interaction	48T__DRD2__no_interaction	48T__CYP2B6__no_interaction	48T__CHRNA5__no_interaction	48T__OPRM1__no_interaction	48T__HTR2A__no_interaction	48T__CHRNA3__no_interaction	48T__ANKK1__no_interaction
8567098-5	In addition, the total amounts of <compound-id="6013">testosterone</compound-id> and DHT were correlated with total activity of <protein-id="O43451,E7ER45">alpha-glucosidase</protein-id> (r = 0.49, p &lt; 0.001; r = 0.58, p &lt; 0.01), and gamma-glutamyltransferase (r = 0.49, p &lt; 0.001; r = 0.48, p &lt; 0.001) in seminal plasma.	testosterone__alpha-glucosidase__no_interaction
21059445-6	Adults with DS possessed lower <compound-id="447041">IMT</compound-id> (0.43 ± 0.07 vs 0.48 ± 0.09 mm, p &lt;0.001), systolic blood pressure (116 ± 15 vs 125 ± 17 mm Hg, p &lt;0.011), and diastolic blood pressure (59 ± 10 vs 73 ± 9 mm Hg, p &lt;0.001) and higher <protein-id="P02741">C-reactive protein</protein-id> (0.58 ± 0.55 vs 0.30 ± 0.42 mg/dl, p &lt;0.003), triglycerides (126.5 ± 55.2 vs 103.8 ± 53.2 mg/dl, p &lt;0.048), and total body fat (37.8 ± 10.2% vs 32.4 ± 11.2%, p &lt;0.002) than controls.	IMT__C-reactive protein__no_interaction
15036005-5	Also other <compound-id="54289232">aminophenyl-beta-carboline</compound-id> compounds, such as 9-(4'-amino-3'-methylphenyl)-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[<compound-id="91262462">amino-3'-methylphenylnorharman</compound-id> (3'-AMPNH)], 9-(4'-amino-2'-methylphenyl)-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id> [amino-2'-methylphenylnorharman (2'-AMPNH)], 9-(4'-aminophenyl)-1-methyl-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[<compound-id="90901259">aminophenylharman</compound-id> (APH)] and 9-(4'-amino-3'-methylphenyl)-1-methyl-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[amino-3'-methylphenylharman (<protein-id="P49418">AMPH</protein-id>)], have been found on reaction of norharman or <compound-id="5281404">harman</compound-id> with <compound-id="6115">aniline</compound-id> or toluidine isomers.	indole__AMPH__no_interaction	aminophenyl-beta-carboline__AMPH__no_interaction	aminophenylharman__AMPH__no_interaction	harman__AMPH__no_interaction	amino-3'-methylphenylnorharman__AMPH__no_interaction	aniline__AMPH__no_interaction
14763071-13	Patients with <protein-id="P02768">albumin</protein-id> &lt; 4 g/dL showed a lower <compound-id="122634,22833501">tPA</compound-id> ratio, lower <protein-id="P41271,A0A087WTY6">NO3</protein-id>, and a higher <protein-id="P02741">CRP</protein-id>, <protein-id="P01375,Q5STB3">TNF alpha</protein-id>, and Lp(a) than did patients with <protein-id="P02768">albumin</protein-id> &gt; 4 g/dL [<compound-id="122634,22833501">tPA</compound-id> ratio: 2.1 +/- 1.56 (n = 29) vs. 2.6 +/- 2.3 (n = 16), p &lt; 0.05; <protein-id="P41271,A0A087WTY6">NO3</protein-id>: 47 +/- 27 micrograms/mL vs. 69 +/- 33 micrograms/mL, p &lt; 0.05; <protein-id="P02741">CRP</protein-id>: 1.8 +/- 3 mg/dL vs. 1.1 +/- 1.6 mg/dL, p &lt; 0.05; <protein-id="P01375,Q5STB3">TNF alpha</protein-id>: 44.4 +/- 16 pg/mL vs. 36.6 +/- 21.4 pg/mL, p &lt; 0.05; Lp(a): 55 +/- 39 mg/dL vs. 33 +/- 21 mg/dL, p &lt; 0.05].	tPA__CRP__no_interaction	tPA__albumin__no_interaction	tPA__TNF alpha__no_interaction	tPA__NO3__no_interaction
23174241-10	In patients with overactive bladder the nerve growth factor-to-<compound-id="588">creatinine</compound-id> (mean ± SD 488.5 ± 591.8 vs 188.3 ± 290.2, p = 0.005) and <protein-id="P23560,A0A0E3SU01">brain-derived neurotrophic factor</protein-id>-to-<compound-id="588">creatinine</compound-id> (mean 628.1 ± 590.5 vs 110.4 ± 159.5, p &lt;0.001) ratios were significantly higher than in healthy women.	creatinine__brain-derived neurotrophic factor__no_interaction
16512757-6	Nine diallelic polymorphisms (gene and SNP descriptor) were studied in subjects: <protein-id="P16410">cytotoxic T-lymphocyte antigen-4</protein-id> (<protein-id="P16410">CTLA-4</protein-id>, 49 A&gt;G), human <protein-id="P60022">beta-defensin-1</protein-id> (DEFB1, 692 G&gt;A), intercellular adhesion molecule-1 (ICAM-1, 1548 A&gt;G), Fas ligand (fasL, -844 C&gt;T), inducible costimulator (ICOS, 3990 G&gt;T), interleukin-6 (IL-6, -174 G&gt;C), <compound-id="5862,90793998">cysteine</compound-id>-<compound-id="5862,90793998">cysteine</compound-id> chemokine receptor-5 (CCR5, 59653 C&gt;T), osteoprotegerin (OPG, 245 T&gt;G), and osteopontin (OPN, 707 C&gt;T).	cysteine__beta-defensin-1__no_interaction	cysteine__cytotoxic T-lymphocyte antigen-4__no_interaction	cysteine__CTLA-4__no_interaction
22858784-1	Two novel alkynyl-bridged symmetric bis-tridentate ligands 1,2-bis(1'-[4'-(2,2':6',2''-<compound-id="14938971">terpyridinyl</compound-id>)]ferrocenyl)<compound-id="6326">ethyne</compound-id> (<compound-id="2981881,91293124">3a</compound-id>; tpy-Fc-C[triple bond]C-Fc-tpy; Fc = ferrocenyl; tpy = terpyridyl) and 1,4-bis(1'-[4'-(2,2':6',2''-<compound-id="14938971">terpyridinyl</compound-id>)]ferrocenyl)-<compound-id="9997">1,3-butadiyne</compound-id> (3b; tpy-Fc-C[triple bond]C-C[triple bond]C-Fc-tpy) and their <protein-id="Q9UHG0">Ru(2+) complexes 6a and 6b</protein-id> have been synthesized and characterized by cyclic voltammetry, UV-vis and luminescence spectroscopy, and in the case of 3b by single-crystal X-ray diffraction.	ethyne__Ru(2+) complexes 6a and 6b__no_interaction	3a__Ru(2+) complexes 6a and 6b__no_interaction	terpyridinyl__Ru(2+) complexes 6a and 6b__no_interaction	1,3-butadiyne__Ru(2+) complexes 6a and 6b__no_interaction
15679405-2	Here L3- is the deprotonated form of 2,6-<protein-id="O95817">bis</protein-id>[{ {(2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L1), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-methyl-2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L2), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-<compound-id="6360">tert-butyl-</compound-id>2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L3), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-chloro-2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id>(H3L4), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-bromo-2-hydroxybenzyl)(N'N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L5), or 2,6-<protein-id="O95817">bis</protein-id>[{ {(<compound-id="12483497">5-methoxy-2-hydroxybenzyl</compound-id>)(N'N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L6).	4-methylphenol__bis__no_interaction	tert-butyl-__bis__no_interaction	5-methoxy-2-hydroxybenzyl__bis__no_interaction	ethyl__bis__no_interaction
21347968-4	Following the standard care programme, within-group analyses demonstrated a significant reduction in waist circumference, whereas following the supported exercise programme there were reductions in glycosylated haemoglobin (6.4 vs. 6.0%; P = 0.007), waist circumference (101.4 vs. 97.2 cm; P = 0.021), body mass (91.7 vs. 87.9 kg; P = 0.007), body mass index (30.0 vs. 28.7 kg · m(-2); P = 0.006), total <compound-id="5997">cholesterol</compound-id> (5.3 vs. 4.6 mmol · L(-1); P = 0.046), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (3.2 vs. 2.6 mmol · L(-1); P = 0.028), fasting β-cell responsiveness (11.5 × 10(-9) vs. 7.0 × 10(-9) pmol · kg(-1) · min(-1); P = 0.009), and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (3.0 vs. 2.1; P = 0.049).	cholesterol__insulin__no_interaction
24311446-5	In addition to dissociated cultures, incubation of optic nerves ex vivo with <compound-id="57476835,60961">adenosine</compound-id> and the A3 receptor agonist 2-<compound-id="3035850">CI-IB-MECA</compound-id>(1-[<compound-id="1800613">2-Chloro</compound-id>-6-[[(3-iodophenyl)methyl]amino]-9H-<compound-id="1044">purin</compound-id>-9-yl]-1-deoxy-N-methyl-b-D-<compound-id="53841601">ribofuranuronamide</compound-id>)-induced <protein-id="P55213">caspase-3</protein-id> activation, oligodendrocyte damage, and myelin loss, effects which were prevented by the presence of <compound-id="2519,57106085">caffeine</compound-id> and the A3 receptor antagonist MRS 1220 (N-[9-Chloro-2-(2-furanyl)[1,2,4]-triazolo [1,5-c]quinazolin-5-yl]<compound-id="241">benzene</compound-id> <compound-id="178">acetamide</compound-id>).	benzene__caspase-3__no_interaction	CI-IB-MECA__caspase-3__no_interaction	caffeine__caspase-3__no_interaction	purin__caspase-3__no_interaction	acetamide__caspase-3__no_interaction	adenosine__caspase-3__no_interaction	2-Chloro__caspase-3__no_interaction	ribofuranuronamide__caspase-3__no_interaction
19326849-4	The physiological essence of put forward positions will consist in the following: 1) <compound-id="760">glyoxylate</compound-id> cycle functioning in peroxysomes not only simbyotic microflorae of pre-stomaches (rumen), but also in bodies of ruminants, involves in a metabolism and synthesis of <compound-id="206,5793,64689,79025">glucose</compound-id>, as a product of a rumenal fermentation a <compound-id="612">lactic acid</compound-id> (through piruvate and <compound-id="181,6302">acetyl CoA</compound-id>), and <compound-id="176">acetate</compound-id> of rumenal origin and synthesized in reactions of lipids beta-oxidation; 2) In peroxysomes take place processes of beta-oxidation of fatt acids, which maximum activity in the period of the greatest activity of a metabolism and decrease of mitochondrial beta-oxidation of lipids; 3) one of key metabolites of peroxysomal reactions considers cisteamin, having expressed an antioxidant and radioprotector properties, and being simultaneously the negative endocellular messenger of <protein-id="P01308,I3WAC9">insulin</protein-id>; 4) Two-<compound-id="5462310">carbon</compound-id> fragments of peroxysomal reactions (glycolat and <compound-id="760">glyoxylate</compound-id>) are inhibitors of series reactions in a cells including <compound-id="311,17938267">citrate</compound-id> cycle, terminal oxidation, piruvatdehylrogenase and piruvatcarboxylase and strengthen a stream of metabolites in peroxysomales reactions; 5) formed in significant amounts in peroxysomes <compound-id="17887040">peroxide</compound-id> of <compound-id="783">hydrogen</compound-id>, having <protein-id="P01308,I3WAC9">insulin</protein-id>-like action, influences a number of processes in an organism, including utilisation of <compound-id="206,5793,64689,79025">glucose</compound-id> and synthesis of muscular fibers; 6) the close interrelation between peroxysomes and mitochondria is carried out at a level of coordination of processes making energy, biosynthetic and antioxidant processes.	lactic acid__insulin__no_interaction	acetate__insulin__no_interaction	peroxide__insulin__no_interaction	acetyl CoA__insulin__no_interaction	carbon__insulin__no_interaction	hydrogen__insulin__no_interaction	citrate__insulin__no_interaction	glyoxylate__insulin__no_interaction	glucose__insulin__no_interaction
23601524-6	RESULTS: After 12 weeks raise, among high dosage group, low dosage group, high fat diet group and normal control group, the weight was (32.8 ± 1.5), (40.4 ± 1.9), (40.7 ± 2.1) and (33.5 ± 1.3) g, respectively (F = 55.26, P &lt; 0.05); average food intake was (3.48 ± 0.56), (3.69 ± 0.76), (3.66 ± 0.81) and (3.54 ± 0.61) g/d respectively (F = 0.26, P &gt; 0.05); fasting blood-<compound-id="206,5793,64689,79025">glucose</compound-id> was (5.29 ± 1.59), (6.13 ± 1.75), (7.63 ± 1.09) and (4.24 ± 0.98) mmol/L respectively (F = 9.54, P &lt; 0.01); serum insulin level was (1.97 ± 0.10), (2.44 ± 0.24), (3.02 ± 0.36) and (1.48 ± 0.28) ng/ml respectively (F = 47.58, P &lt; 0.01); the area under blood <compound-id="206,5793,64689,79025">glucose</compound-id> concentration curve was (25.81 ± 1.44), (30.42 ± 2.01), (35.17 ± 1.20) and (21.03 ± 1.24) mmol×L(-1)×h(-1), respectively (F = 64.98, P &lt; 0.05); insulin resistance index was (9.84 ± 3.78), (13.69 ± 4.48), (21.54 ± 3.27) and (5.81 ± 1.59) respectively (F = 30.18, P &lt; 0.01); serum total <compound-id="5997">cholesterol</compound-id> (TC) level was (4.05 ± 0.88), (4.30 ± 0.48), (4.73 ± 0.66) and (3.37 ± 0.40) mmol/L respectively (F = 6.70, P &lt; 0.01); serum triglyceride (TG) level was (0.90 ± 0.09), (0.98 ± 0.09), (1.05 ± 0.06) and (0.76 ± 0.26) mmol/L respectively (F = 6.75, P &lt; 0.01); serum high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) level was (2.91 ± 0.59), (3.34 ± 0.46), (4.89 ± 0.42) and (3.24 ± 0.37) mmol/L respectively (F = 31.73, P &lt; 0.01); serum <protein-id="Q921L5">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q921L5">LDL-C</protein-id>) level was (0.25 ± 0.15), (0.42 ± 0.19), (0.72 ± 0.12) and (0.32 ± 0.11) mmol/L, respectively (F = 17.27, P &lt; 0.01); free fatty acids (FFA) level was (1.06 ± 0.03), (1.05 ± 0.05), (1.18 ± 0.32) and (1.04 ± 0.02) mmol/L, respectively (F = 1.36, P &gt; 0.05); HDL-C/<protein-id="Q921L5">LDL-C</protein-id> was (13.77 ± 5.51), (9.11 ± 3.53), (7.04 ± 1.65) and (11.21 ± 3.31), respectively (F = 5.24, P &lt; 0.01).	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__LDL-C__no_interaction	glucose__low-density lipoprotein cholesterol__no_interaction	glucose__LDL-C__no_interaction
22025778-6	Individuals with <protein-id="P51812,B7ZB17,B4DG22">CLS</protein-id> had greater VAT (3.7 ± 1.3 vs. 2.6 ± 1.6 L; P = 0.04), HFF (9.9 ± 7.3 vs. 5.8 ± 4.4%; P = 0.03), tumor necrosis factor-α (20.8 ± 4.8 vs. 16.2 ± 5.8 pg/mL; P = 0.01), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (20.9 ± 10.6 vs. 9.7 ± 6.6 mU/mL; P &lt; 0.001) and <compound-id="206,5793,64689,79025">glucose</compound-id> (94.4 ± 9.3 vs. 86.8 ± 5.3 mg/dL; P = 0.005), and lower DI (1,559 ± 984 vs. 2,024 ± 829 × 10(-4) min(-1); P = 0.03).	glucose__insulin__no_interaction	glucose__CLS__no_interaction
21215187-7	RESULTS: The concentrations of <compound-id="10918">carnitine</compound-id> (C(0)); short-chain acylcarnitines (SC-AC), including acetyl (C(2)), propionyl (<protein-id="P01024,V9HWA9,B4DR57">C(3</protein-id>)), malonyl (<protein-id="P01024,V9HWA9,B4DR57">C(3</protein-id>)DC), butyryl (C(4)), <compound-id="98735">methylmalonyl</compound-id> (C(4)DC), isovaleryl (C(5)), glutaryl (C(5)DC); middle-chain acylcarnitines (MC-AC), including hexanoyl (C(6)), <compound-id="147023">hexanediol</compound-id> (C(6)DC), octylenoyl (C(8:1)), octanoyl (C(8)), <compound-id="19360862">decadienoyl</compound-id> (C(10:2)), <compound-id="8175">decanoyl</compound-id> (C(10:1)), <compound-id="8175">decanoyl</compound-id> (C(10)); total <compound-id="10918">carnitine</compound-id> and acylcarnitines (TCAC)were lower in neonate, highest in 1-3 months of age, higher in 6-12 months of age, and kept at the same level between 2 and 15 years of age.	decadienoyl__C(3__no_interaction	hexanediol__C(3__no_interaction	carnitine__C(3__no_interaction	methylmalonyl__C(3__no_interaction	decanoyl__C(3__no_interaction
15303129-3	RESULTS: (1) <compound-id="64966">MTT</compound-id> conversion rates were higher in neurons pre and co  treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> than those of neurons with only Mg(2+)-free treatment in neurons cultured for 17 d, but not in neurons cultured for 6 d.(2) [Ca(2+)]i was lower in neurons pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> than those of neurons with only Mg(2+)-free treatment, either in neurons cultured for 6 d or in neurons cultured for 17 d, and the effects of <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> on [Ca(2+)]i change were different between neurons cultured for 6 d and neurons cultured for 17 d.(3) Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> NR1 mRNA expression increase induced by Mg(2+)-free treatment was decreased, either in neurons cultured for 6 d or neurons cultured for 17 d, and this effect showed no difference between neurons cultured for 6 d and 17 d; Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> <protein-id="Q00959">NR2A</protein-id> mRNA expression increase induced by Mg(2+)-free treatment in neurons cultured for 17 d was decreased, and <protein-id="Q00959">NR2A</protein-id> mRNA expression showed no difference between <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> group and age-matched control group, but have no effect on neurons cultured for 6 d; Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> have <protein-id="Q00960">NR2B</protein-id> mRNA expression increase induced by Mg(2+)-free treatment was not affected, either in neurons cultured for 6 d or neurons cultured for 17 d. CONCLUSION: Neuroprotection of <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> in seizure-induced injury is age-dependent.	MTT__NR2B__no_interaction	MTT__NR2A__no_interaction	MTT__IL-1ra__no_interaction
16857740-3	Here, we report that 1) <compound-id="10404739,104858,3514">GSNO</compound-id> is only one of a class of S-nitrosylating agents that, at low micromolar concentrations, increase DeltaF508 and wild-type CFTR expression and maturation; 2) NO itself (at these concentrations) and <compound-id="104767">8-bromocyclic GMP</compound-id> are minimally active on CFTR; 3) a novel agent, <compound-id="91016544">S-nitrosoglutathione diethyl ester</compound-id>, bypasses the need for <compound-id="10404739,104858,3514">GSNO</compound-id> bioactivation by <compound-id="193305">gamma-glutamyl</compound-id> transpeptidase to increase CFTR maturation; 4) surprisingly, expression-but not S-nitrosylation-of <compound-id="5862,90793998">cysteine</compound-id> string proteins (<protein-id="P53805,Q6FGP2,Q6ZMM3,V9GYW9,E9PDJ2">Csp) 1 and 2</protein-id> is increased by <compound-id="10404739,104858,3514">GSNO</compound-id>; 5) the effect of <compound-id="10404739,104858,3514">GSNO</compound-id> to increase full maturation of wild-type CFTR is inhibited by Csp silencing (si)RNA; 6) proteins relevant to CFTR trafficking are SNO-modified, and SNO proteins traffic through the endoplasmic reticulum (ER) and Golgi after <compound-id="10404739,104858,3514">GSNO</compound-id> exposure; and 7) <compound-id="10404739,104858,3514">GSNO</compound-id> alters the interactions of DeltaF508 CFTR with Csp and <protein-id="P11142,V9HW22,Q53HF2">Hsc70</protein-id> in the ER and Golgi.	S-nitrosoglutathione diethyl ester__Hsc70__no_interaction	S-nitrosoglutathione diethyl ester__Csp) 1 and 2__no_interaction	cysteine__Hsc70__no_interaction	cysteine__Csp) 1 and 2__no_interaction	gamma-glutamyl__Hsc70__no_interaction	gamma-glutamyl__Csp) 1 and 2__no_interaction	8-bromocyclic GMP__Hsc70__no_interaction	8-bromocyclic GMP__Csp) 1 and 2__no_interaction	GSNO__Hsc70__no_interaction	GSNO__Csp) 1 and 2__no_interaction
24444564-4	RESULTS: (1)The expression of mRNA of <protein-id="P40939,E9KL44">LCHAD</protein-id>: the level of mRNA of <protein-id="P40939,E9KL44">LCHAD</protein-id> in NP+DMEM, E-PE+DMEM, E-PE+<compound-id="5884">NADPH</compound-id>-I, E-PE+p38-I, L-PE+DMEM, L-PE+<compound-id="5884">NADPH</compound-id>-I, L-PE+p38-I and HELLP+DMEM, HELLP+<compound-id="5884">NADPH</compound-id>-I, HELLP+p38-I groups were 1.00 ± 0.03, 0.14 ± 0.08, 0.95 ± 0.20, 1.43 ± 1.02, 0.37 ± 0.18, 1.51 ± 0.36, 1.60 ± 0.31, 0.10 ± 0.04, 0.49 ± 0.10, 0.44 ± 0.21, respectively.	NADPH__LCHAD__no_interaction
24444564-7	(2) The expression of protein of <protein-id="P40939,E9KL44">LCHAD</protein-id>: the relative expressions of protein of <protein-id="P40939,E9KL44">LCHAD</protein-id> in NP+DMEM, E-PE+DMEM, E-PE+<compound-id="5884">NADPH</compound-id>-I, E-PE+p38-I, L-PE+DMEM, L-PE+<compound-id="5884">NADPH</compound-id>-I, L-PE+p38-I and HELLP+ DMEM, HELLP+<compound-id="5884">NADPH</compound-id>-I, HELLP+p38-I groups were 19.4 ± 2.2, 10.7 ± 1.1, 17.9 ± 3.3, 19.1 ± 2.9, 16.4 ± 2.3, 20.3 ± 2.3, 20.9 ± 4.3, 12.4 ± 2.3, 17.6 ± 2.6, 17.7 ± 2.0 respectively.	NADPH__LCHAD__no_interaction
10928972-4	The high-affinity GTPase activity was stimulated by the following compounds with a rank order of potency of (2S,2'R,3'R)-2-(2', 3'-dicarboxycyclopropyl) <compound-id="45934207,750">glycine</compound-id> (<compound-id="115114">DCG-IV</compound-id>) &gt; (2S,1'S, 2'S)-2-(carboxycyclopyropyl)<compound-id="45934207,750">glycine</compound-id> (<compound-id="1271">L-CCG-I</compound-id>) &gt; L-<compound-id="611,57109091">glutamate</compound-id> &gt; or = 2R, 4R-<compound-id="3331970">4-aminopyrrolidine-2,4-dicarboxylate</compound-id> [(2R,4R)-<compound-id="65351">APDC</compound-id>] &gt; 1S, 3R-<compound-id="1310">1-aminocyclopentane-1,3-dicarboxylate</compound-id> [(1S,3R)-ACPD] &gt; (S)-<compound-id="1297">4-carboxy-3-hydroxyphenylglycine</compound-id> [(S)-4C3HPG] &gt; (S)-3-carboxy-<compound-id="36143,89853,92143">4-hydroxyphenylglycine</compound-id> [(S)-3C4HPG] &gt; <compound-id="1233">ibotenate</compound-id>, but not by L-(+)-2-amino-4-<compound-id="2773805">phosphonobutyrate</compound-id> (<compound-id="179394">L-AP4</compound-id>), (<compound-id="7021454">RS</compound-id>)-3, 5-<compound-id="5310986">dihydroxyphenylglycine</compound-id> [(<compound-id="7021454">RS</compound-id>)-<compound-id="108001">3,5-DHPG</compound-id>], <compound-id="40539">quisqualate</compound-id>, or L-serine-<compound-id="1061">O-phosphate</compound-id> (<compound-id="68841">L-SOP</compound-id>), indicative of involvement of group II mGluRs, in particular <protein-id="Q14BI2,P23819,G5E8H1,Q4LG64,E9QKC0">mGluR2</protein-id>.	DCG-IV__mGluR2__no_interaction	1-aminocyclopentane-1,3-dicarboxylate__mGluR2__no_interaction	ibotenate__mGluR2__no_interaction	4-aminopyrrolidine-2,4-dicarboxylate__mGluR2__no_interaction	L-SOP__mGluR2__no_interaction	glycine__mGluR2__no_interaction	RS__mGluR2__no_interaction	3,5-DHPG__mGluR2__no_interaction	4-hydroxyphenylglycine__mGluR2__no_interaction	L-AP4__mGluR2__no_interaction	quisqualate__mGluR2__no_interaction	dihydroxyphenylglycine__mGluR2__no_interaction	APDC__mGluR2__no_interaction	O-phosphate__mGluR2__no_interaction	L-CCG-I__mGluR2__no_interaction	phosphonobutyrate__mGluR2__no_interaction	4-carboxy-3-hydroxyphenylglycine__mGluR2__no_interaction	glutamate__mGluR2__no_interaction
15677459-4	By using cell-free biochemical experiments, confocal laser immunofluorescence microscopy, and flow cytometry of tissues and cells from wild-type and knock-out mice, we find that (a) APP and <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> colocalize in perinuclear compartments of neuroblastoma cells, (b) <compound-id="53681531">ascorbate</compound-id>-triggered nitric oxidecatalyzed <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> autodegradation is <compound-id="32051">zinc ion</compound-id>-dependent in the same cells, (c) in cell-free experiments, APP but not <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> stimulates <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> autodegradation in the presence of both Cu(II) and Zn(II) ions, whereas the Cu(I) form of APP and the Cu(II) and Cu(I) forms of <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> inhibit autodegradation, (d) in primary cortical neurons from APP or <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> knock-out mice, there is an increased <compound-id="145068">nitric oxide</compound-id>-catalyzed degradation of heparan <compound-id="1117">sulfate</compound-id> compared with brain tissue and neurons from wild-type mice, and (e) in growth-quiescent fibroblasts from <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> knock-out mice, but not from APP knock-out mice, there is also an increased heparan <compound-id="1117">sulfate</compound-id> degradation.	nitric oxide__APLP2__no_interaction	nitric oxide__glypican-1__no_interaction	zinc ion__APLP2__no_interaction	zinc ion__glypican-1__no_interaction	sulfate__APLP2__no_interaction	sulfate__glypican-1__no_interaction	ascorbate__APLP2__no_interaction	ascorbate__glypican-1__no_interaction
23770842-8	After adjusting for potential confounders, strong associations existed between PN <protein-id="P01308,I3WAC9">insulin</protein-id> requirements and diabetes mellitus (DM) diagnosis (OR, 8.90; 95% CI, 4.98-15.90, P &lt; .001), overweight/obese status (body mass index ≥25.0 kg/m(2)) (OR, 2.12; 95% CI, 1.04-4.30, P = .04), intensive care unit (ICU) admission (OR, 1.79; 95% CI, 1.03-3.11, P = .04), blood <compound-id="206,5793,64689,79025">glucose</compound-id> (BG) on day of PN start &gt;120 mg/dL (OR, 2.32; 95% CI, 1.32-4.05, P = .003), mean BG &gt;180 mg/dL while receiving PN (OR, 6.10; 95% CI, 2.18-17.04, P = .001), and hemoglobin A1c (A1c) ≥5.7% (OR, 3.18; 95% CI, 1.84-5.50, P &lt; .001).	glucose__insulin__no_interaction
16214877-3	Forty-eight hours after the last drug injection, cholinergic receptors were measured by [(125)I]-(+/-)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]<compound-id="8900">heptane</compound-id> ([(125)I]IPH; <compound-id="10176670,105084,11031065,3073763,443366,44592968,854023">epibatidine</compound-id> analog), (125)I-<compound-id="44264212">alpha-bungarotoxin</compound-id> ((125)I-<protein-id="Q05941,Q5UMH9">BTX</protein-id>), [(3)H]<compound-id="4848">pirenzepine</compound-id> ([(3)H]<compound-id="32594">PRZ</compound-id>), and [(3)H]-5,11-dihydro-11-[((2-(2-((dipropylamino)methyl)-1-piperidinyl)<compound-id="23134249">ethyl</compound-id>)amino)carbonyl]-6H-pyrido(2,3-b)(1,4)-<compound-id="22114368">benzodiazepin-6-one</compound-id> <compound-id="6395">methanesulfonate</compound-id> ([(3)H]AFDX-384, or [(3)H]<compound-id="51346193">AFX</compound-id>) autoradiography.	epibatidine__BTX__no_interaction	methanesulfonate__BTX__no_interaction	AFX__BTX__no_interaction	alpha-bungarotoxin__BTX__no_interaction	benzodiazepin-6-one__BTX__no_interaction	pirenzepine__BTX__no_interaction	PRZ__BTX__no_interaction	heptane__BTX__no_interaction	ethyl__BTX__no_interaction
12625872-3	<compound-id="54090624">Phenoxypropanolamine</compound-id> derivatives, SWR-0334NA (([E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl] phenoxy]<compound-id="176">acetic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt), SWR-0335SA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl] phenoxy] <compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>), SWR-0342SA (S-(Z)-[4-[[1-[2-[(2-<compound-id="19871799">hydroxy-3-phenoxypropyl</compound-id>)]amino] <compound-id="23134249">ethyl</compound-id>]-1-propenyl]phenoxy] <compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>), SWR-0348SA-SITA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-<compound-id="57417590">hexene-3-yl</compound-id>] phenoxy]<compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>) and SWR-0361SA ((E)-N-methyl[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl]phenoxy]<compound-id="178">acetoamide</compound-id> <compound-id="971">ethanedioic acid</compound-id>) showed higher agonistic activity for the <protein-id="P13945,A8KAG8">Beta(3)-adrenoceptor</protein-id>.	hexene-3-yl__Beta(3)-adrenoceptor__no_interaction	hydroxy-3-phenoxypropyl__Beta(3)-adrenoceptor__no_interaction	Phenoxypropanolamine__Beta(3)-adrenoceptor__no_interaction	sodium__Beta(3)-adrenoceptor__no_interaction	ethanedioic acid__Beta(3)-adrenoceptor__no_interaction	2-pentene__Beta(3)-adrenoceptor__no_interaction	acetoamide__Beta(3)-adrenoceptor__no_interaction	acetic acid__Beta(3)-adrenoceptor__no_interaction	ethyl__Beta(3)-adrenoceptor__no_interaction
15112172-6	In a univariate analysis, age, central venous pressure (CVP), and serum <compound-id="588">creatinine</compound-id> and blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> levels were greater (P = 0.003, P = 0.006, P &lt; 0.001, and P &lt; 0.001, respectively), whereas mean arterial and diastolic blood pressures, 24-hour urinary output, arterial pH, <compound-id="767">bicarbonate</compound-id> level, thrombocyte count, <protein-id="P02768">albumin</protein-id> level, and <protein-id="P00734">prothrombin</protein-id> time were lower (P = 0.05, P = 0.004, P = 0.005, P = 0.03, P = 0.009, P = 0.037, P = 0.05, and P = 0.006, respectively) in the ARF group.	creatinine__albumin__no_interaction	creatinine__prothrombin__no_interaction	urea__albumin__no_interaction	urea__prothrombin__no_interaction	nitrogen__albumin__no_interaction	nitrogen__prothrombin__no_interaction	bicarbonate__albumin__no_interaction	bicarbonate__prothrombin__no_interaction
15454392-3	Diabetes was associated with an increase in urine albumin excretion (UAE; ND, 0.39 +/- 0.03; D, 5.9 +/- 0.8 mg/day; P &lt; 0.001), decrease in <compound-id="588">creatinine</compound-id> clearance (CrCl; ND, 0.69 +/- 0.03; D, 0.43 +/- 0.09 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x 100 g body wt(-1); P &lt; 0.05), increase in the index of glomerulosclerosis [GSI; ND, 0.01 +/- 0.01; D, 0.15 +/- 0.04 arbitrary units (AU); P &lt; 0.01], tubulointerstitial fibrosis (TIFI; ND, 0.04 +/- 0.04; D, 0.68 +/- 0.2 AU; P &lt; 0.01), and transforming growth factor-beta (TGF-beta) protein expression (ND, 0.61 +/- 0.02; D, 1.25 +/- 0.07 AU; P &lt; 0.01).	creatinine__min(-1__no_interaction
23455029-1	Four heteropoly blue complexes constructed from Keggin-type heteropoly blue <compound-id="23932">molybdenum</compound-id>-<compound-id="23964">tungsten</compound-id> clusters and Cu(II) ions as linkers, <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(PDA)2·H2O]2 (1), <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(<protein-id="Q68CQ4">DEF</protein-id>)3·H2O][Cu(<protein-id="Q68CQ4">DEF</protein-id>)2·2H2O]·6H2O (2), <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(DMF)3H2O]2·6H2O (3), and H4[α-SiW10Mo(V)2O40]2[CuK2(DMF)6][Na0.75K3.25(DMF)6] (4) [PDA = <compound-id="7911">propanediamide</compound-id>, <protein-id="Q68CQ4">DEF</protein-id> = <compound-id="12051">N,N-diethylformamide</compound-id> and DMF = N,N-dimethylformamide], have been synthesized by conventional reactions and characterized by single-crystal X-ray diffraction, elemental analysis, IR spectroscopy, thermogravimetry, X-ray powder diffraction (XRD) and UV spectra.	tungsten__DEF__no_interaction	H2__DEF__no_interaction	N,N-diethylformamide__DEF__no_interaction	propanediamide__DEF__no_interaction	molybdenum__DEF__no_interaction
17023528-4	The results were as follows: 1) treatment with estrogen increased phosphorylation and MgATPase activity and decreased NMM-II-B filamentation; 2) estrogen effects could be blocked by antisense nucleotides for the <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor-alpha</protein-id> and by ICI-182,780, <compound-id="2733526">tamoxifen</compound-id>, and the casein kinase-II (CK2) inhibitor, 5,6-dichloro-1-beta-(D)-<compound-id="24898154">ribofuranosylbenzimidazole</compound-id> and attenuated by <compound-id="2051">AG1478</compound-id> and <compound-id="4713">PD98059</compound-id> (inhibitors of epithelial growth factor receptor and ERK/MAPK) but not <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> [blocker of protein kinase C (PKC)]; 3) treatments with the PKC activator sn-1,2-dioctanoyl diglyceride induced biphasic effect on NMM-II-B MgATPase activity: an increase at 1 nm to 1 microM and a decrease in activity at more than 1 microM; 4) sn-1,2-dioctanoyl diglyceride also decreased NMM-II-B filamentation in a monophasic and saturable dose dependence (EC(50) 1-10 microM); 5) when coincubated directly with purified NMM-II-B filaments, both CK2 and PKC decreased filamentation and increased MgATPase activity; 6) assays done on disassembled NMM-II-B filaments showed MgATPase activity in filaments obtained from estrogen-treated cells but not estrogen-depleted cells; and 7) incubations in vitro with CK2, but not PKC, facilitated MgATPase activity, even in disassembled NMM-II-B filaments.	PD98059__estrogen receptor-alpha__no_interaction	tamoxifen__estrogen receptor-alpha__no_interaction	staurosporine__estrogen receptor-alpha__no_interaction	AG1478__estrogen receptor-alpha__no_interaction	ribofuranosylbenzimidazole__estrogen receptor-alpha__no_interaction
16182977-5	The plasma <protein-id="P01185,X5DQP6">vasopressin</protein-id> level at baseline was significantly lower for those who finally developed septic shock (septic shock group, 3.6 +/- 2.5 pg/mL; 95% confidence interval [CI], 3.0-4.2 pg/mL; severe sepsis group, 21.8 +/- 4.1 pg/mL, 95% CI, 20.7-22.9 pg/mL; sepsis group, 10.6 +/- 6.5 pg/mL, 95% CI, 8.8-12.4 pg/mL, P &lt; .001), whereas the <compound-id="439260">norepinephrine</compound-id> level was highest for the same group (septic shock group, 3650 +/- 980 pg/mL, 95% CI, 3420-3880 pg/mL; severe sepsis group, 3600 +/- 1000 pg/mL, 95% CI, 3330-3870 pg/mL; sepsis group, 1720 +/- 320 pg/mL, 95% CI, 1630-1810 pg/mL).	norepinephrine__vasopressin__no_interaction
9323928-6	Likewise, peak and average plasma TNF, serum <protein-id="Q8SPS7,K7GKE7">haptoglobin</protein-id>, and serum <compound-id="23994">zinc</compound-id> were correlated indicating a prolonged stress or pathogenic insult (r = 0.89, P &lt; 0.0001 for TNF; r = 0.67, P = 0.01 for <protein-id="Q8SPS7,K7GKE7">haptoglobin</protein-id>; r = 0.73, P = 0.005 for <compound-id="23994">zinc</compound-id>).	zinc__haptoglobin__no_interaction
21934202-9	Patients in group I, compared with group II, were older (35.5 ± 10.5 vs 27.9 ± 14.0 years, P &lt; 0.01), predominantly male (M: F, 10.8: 1 vs 4.8: 1, P = 0.035), obese (75.0% vs 23.4%, P P &lt; 0.01), with higher triglycerides (138.8 ± 62.1 vs 88.0 ± 27.9, P = 0.02), with higher <compound-id="5997">cholesterol</compound-id> (171.9 ± 43.5 vs 139.3 ± 37.6, P = 0.017), and with higher serum <protein-id="P01308,I3WAC9">insulin</protein-id> (13.1 ± 9.1 vs 9.1 ± 6.0, P &lt; .027) levels.	cholesterol__insulin__no_interaction
1516292-3	Mean fasting plasma <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> rose significantly by 17 +/- 3% (1.11 +/- 0.12 vs 0.95 +/- 0.11 mmol/L, p less than 0.005, n = 5), whereas total triglycerides fell by 23 +/- 2% (1.7 +/- 0.3 vs 2.2 +/- 0.3 mmol/L, p less than 0.005, n = 5), VLDL triglycerides fell by 28 +/- 5% (0.88 +/- 0.15 vs 1.18 +/- 0.19 mmol/L, p less than 0.02, n = 5), VLDL <compound-id="5997">cholesterol</compound-id> fell by 32 +/- 7% (0.39 +/- 0.08 vs 0.56 +/- 0.09 mmol/L, p less than 0.01, n = 5), the ratio of LDL <compound-id="5997">cholesterol</compound-id>: <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> by 19 +/- 5% (4.7 +/- 0.7 vs 5.7 +/- 0.7, p less than 0.05) and that of total <compound-id="5997">cholesterol</compound-id>: <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> by 16 +/- 5% (6.6 +/- 0.5 vs 8.0 +/- 0.7, p less than 0.05) on the high versus low protein diet.	cholesterol__HDL__no_interaction
21464197-3	Here we report the development and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(2,4-<compound-id="9706">difluorophenyl</compound-id>)-2-methyl-<compound-id="12586">1,3-dioxolan</compound-id>-4-yl)methoxy)phenyl)<compound-id="91216341">piperazin-1-yl</compound-id>)<compound-id="177">ethanone</compound-id> (<compound-id="70789750">FLB</compound-id>-12)] that antagonizes the activated state of <protein-id="O54915,Q0P525">PXR</protein-id> with limited effects on other related nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor α, peroxisome proliferator-activated receptor γ, and mouse constitutive <compound-id="123412,6857536,94144">androstane</compound-id> receptor).	piperazin-1-yl__PXR__no_interaction	1,3-dioxolan__PXR__no_interaction	difluorophenyl__PXR__no_interaction	androstane__PXR__no_interaction	ethanone__PXR__no_interaction	FLB__PXR__no_interaction
8329287-5	Comparing (S)- and (R)-<compound-id="3672">ibuprofen</compound-id> within the group receiving the racemate significantly higher Cmax (20.3 +/- 5.3 vs 17.7 +/- 4.4 micrograms ml-1; P &lt; 0.02; 95% confidence interval for differences (CI): 0.5-4.6), AUC (86.2 +/- 23.5 vs 67.6 +/- 26.6 micrograms ml-1 h; P &lt; 0.001; CI: 9.5-27.6), mean residence time (4.5 +/- 1.1 vs 4.1 +/- 1.2 h; P &lt; 0.01; CI: 0.1-0.6) and renal clearance (0.8 +/- 0.6 vs 0.0 +/- 0.0 ml <protein-id="P13987,Q6FHM9">min-1</protein-id>; P &lt; 0.001; CI: 0.5-1.0) values were observed for the (S)-enantiomer.	ibuprofen__min-1__no_interaction
1445696-2	Serum FA2 was positively correlated with <compound-id="853">thyroxine</compound-id> (T4) (<compound-id="7021454">Rs</compound-id> = 0.51; p &lt; 0.05), <compound-id="5920">triiodothyronine</compound-id> (T3) (<compound-id="7021454">Rs</compound-id> = 0.64; p &lt; 0.01), <protein-id="P02818">bone-Gla protein</protein-id> (<protein-id="P02818">BGP</protein-id>) (<compound-id="7021454">Rs</compound-id> = 0.70; p &lt; 0.01), total alkaline phosphatase (total-AP) (<compound-id="7021454">Rs</compound-id> = 0.62; p &lt; 0.01), bone isoenzyme alkaline phosphatase (bone-AP) (<compound-id="7021454">Rs</compound-id> = 0.63; p &lt; 0.01), N-terminal procollagen type III (PIIINP) (<compound-id="7021454">Rs</compound-id> = 0.65; p &lt; 0.01) and urine OH-<compound-id="145742,57240853,614,8988">proline</compound-id> (OHP) (<compound-id="7021454">Rs</compound-id> = 0.79; p &lt; 0.01).	proline__BGP__no_interaction	proline__bone-Gla protein__no_interaction	thyroxine__BGP__no_interaction	thyroxine__bone-Gla protein__no_interaction	triiodothyronine__BGP__no_interaction	triiodothyronine__bone-Gla protein__no_interaction	Rs__BGP__no_interaction	Rs__bone-Gla protein__no_interaction
8923850-4	According to a randomized, single blind, cross-over protocol, six healthy subjects, six obese subjects, and six elderly subjects received on 2 different days, with a 1-week interval, placebo or <compound-id="5310993">acipimox</compound-id> (250 mg, orally) at 0700 and 1100 h; <protein-id="P01286">GHRH</protein-id> [<protein-id="P01286">GHRH</protein-id>-(1-44)NH2; 50 micrograms in healthy subjects and in elderly subjects, 100 micrograms in obese subjects] was injected iv at 1300 h, and blood samples for evaluation of plasma FFA, blood <compound-id="206,5793,64689,79025">glucose</compound-id>, serum <protein-id="P01308,I3WAC9">insulin</protein-id> (IRI), and serum GH levels were taken from 1200 to 1500 h. Plasma FFA levels were always lower (P &lt; 0.05) after <compound-id="5310993">acipimox</compound-id> than after placebo (0.03 +/- 0.01 vs. 0.13 +/- 0.02 g/L in healthy subjects, 0.09 +/- 0.01 vs. 0.27 +/- 0.02 g/L in obese, 0.02 +/- 0.005 vs. 0.17 +/- 0.01 g/L in elderly subjects); serum IRI levels were also lower (P &lt; 0.05) after <compound-id="5310993">acipimox</compound-id> than after placebo in the three groups of subjects (16 +/- 3 vs. 30 +/- 5, 120 +/- 30 vs. 181 +/- 32, and 21 +/- 3 vs. 49 +/- 9 pmol/L); both FFA (P &lt; 0.05) and IRI levels (P &lt; 0.05) were higher in obese than in healthy or elderly subjects after placebo and <compound-id="5310993">acipimox</compound-id>.	acipimox__GHRH__no_interaction	acipimox__insulin__no_interaction	glucose__GHRH__no_interaction	glucose__insulin__no_interaction
19167646-11	Positive correlations were demonstrated between remnant lipoprotein <compound-id="5997">cholesterol</compound-id> and OxLDL (<compound-id="185679">RLP</compound-id>-C and MDA-LDL/<protein-id="Q14746,B1ALW7">LDL-C</protein-id>, r = 0.45, p = 0.0024, <compound-id="185679">RLP</compound-id>-C and OxPC, r = 0.51, p = 0.0005, RemL-C and MDA-LDL/<protein-id="Q14746,B1ALW7">LDL-C</protein-id>, r = 0.42, p = 0.0044, RemL-C and OxPC, r = 0.43, p = 0.0043).	RLP__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
21220125-3	METHODS: We incubated methyl 3β-(4-iodophenyl)<compound-id="637986">tropane</compound-id>-2β-carboxylate (β-<protein-id="O14578">CIT</protein-id>)/2-fluoroethyl 3β-(4-iodophenyl)<compound-id="637986">tropane</compound-id>-2β-carboxylate (FE@<protein-id="O14578">CIT</protein-id>), <compound-id="21474">methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate</compound-id> (<compound-id="2734010">MTO</compound-id>)/<compound-id="36339">ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate</compound-id> (ETO)/2-fluoroethyl <compound-id="9815351">1-(1-phenylethyl)-1H-imidazole</compound-id>-5-carboxylate (FETO), <compound-id="241865">ethyl 8</compound-id>-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo-[f]imidazo[1,5-a]-[1,4]<compound-id="166734">diazepine</compound-id>-3-carboxylate (FMZ)/2-fluoroethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo-[f]imidazo[1,5-a]-[1,4]<compound-id="166734">diazepine</compound-id>-3-carboxylate (FFMZ), methyl <compound-id="137551">1-phenylethyl</compound-id>-4-(N-propanoylanilino)<compound-id="3773">piperidine-4-carboxylate</compound-id> (CFN)/2-fluoroethyl <compound-id="137551">1-phenylethyl</compound-id>-4-(N-propanoylanilino)<compound-id="3773">piperidine-4-carboxylate</compound-id> (FE@CFN) and methyl 2,4-diethyl-3-<compound-id="638145">methylsulfanylcarbonyl</compound-id>-<compound-id="13887">6-phenylpyridine</compound-id>-5-carboxylate [(Me)(2)@SUPPY]/2-fluorethyl 2,4-diethyl-3-<compound-id="140799">ethylsulfanylcarbonyl</compound-id>-<compound-id="13887">6-phenylpyridine</compound-id>-5-carboxylate (FE@SUPPY) under physiological conditions.	ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate__CIT__no_interaction	1-(1-phenylethyl)-1H-imidazole__CIT__no_interaction	diazepine__CIT__no_interaction	tropane__CIT__no_interaction	methylsulfanylcarbonyl__CIT__no_interaction	ethylsulfanylcarbonyl__CIT__no_interaction	6-phenylpyridine__CIT__no_interaction	1-phenylethyl__CIT__no_interaction	ethyl 8__CIT__no_interaction	methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate__CIT__no_interaction	piperidine-4-carboxylate__CIT__no_interaction	MTO__CIT__no_interaction
11172452-14	Although <protein-id="P02647,A0A024R3E3">Apo-A1</protein-id> concentration was directly associated with HDL level (r = +0.39, P &lt;.01, n = 139), <protein-id="P04114,Q7Z7Q0,Q59HB3">Apo-B</protein-id> was inversely related to HDL level (r = -0.37, P &lt;.01, n = 138) and directly related to <compound-id="5997">cholesterol</compound-id> concentration (r = +0.71, P &lt;.01, n = 138), VLDL concentration (r = +0.87, P &lt;.01, n = 138), and triglyceride concentration (r = +0.81, P &lt;.01, n = 138).	cholesterol__Apo-B__no_interaction	cholesterol__Apo-A1__no_interaction
18597009-1	(-)-<compound-id="65064">Epigallocatechin gallate</compound-id>, (-)-Gossypol; Ad.<protein-id="P01574">hIFN-beta</protein-id>, AF-37702, Agatolimod <compound-id="5360545">sodium</compound-id>, <compound-id="82148">Agomelatine</compound-id>, <compound-id="5287969">Alvocidib hydrochloride</compound-id>, ARC-1779; Belimumab, <compound-id="10184653">BIBW-2992</compound-id>, <compound-id="9576912">Binodenoson</compound-id>, <compound-id="387447">Bortezomib</compound-id>, <compound-id="5328940">Bosutinib</compound-id>, <compound-id="9837243">Brivaracetam</compound-id>; <compound-id="9933475">Cediranib</compound-id>, <compound-id="153994">Clevidipine</compound-id>, CNTO-328, CP-751871, <compound-id="969516">Curcumin</compound-id>; <compound-id="9939609">Darapladib</compound-id>, <compound-id="11520894,23724531,53486198,71296108,71752077,72734349,74787553,86289926">Deforolimus</compound-id>, Denosumab, <compound-id="125017">Desvenlafaxine</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="3108">Dipyridamole</compound-id>/<compound-id="5755">prednisolone</compound-id>, <compound-id="208898">Dronedarone hydrochloride</compound-id>, DTPw-HBV/Hib 2.5; Ecogramostim, <compound-id="6438895">Elacytarabine</compound-id>, <compound-id="25181561,66583167,9846180">Eltrombopag</compound-id>, <compound-id="428573">Eprodisate sodium</compound-id>; <compound-id="389644,5469318">Farnesylthiosalicylic acid</compound-id>, <compound-id="134018">Febuxostat</compound-id>, <compound-id="5288209">Fenretinide</compound-id>, Ferumoxytol, FMP2.1/AS02A, <compound-id="444499">Forodesine hydrochloride</compound-id>, FP-0011; HuLuc-63, Human <protein-id="P05230,A8K147,Q16089">Fibroblast Growth Factor 1</protein-id>; <compound-id="57391680">Idraparinux sodium</compound-id>, <compound-id="5359967">Indium</compound-id> 111 (<compound-id="5462099">111In</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>, <protein-id="Q9HBE4">Interleukin-21</protein-id>, Ipilimumab, ISS-1018, <compound-id="214907">ITF</compound-id>-2357; <compound-id="9874248">Lapaquistat acetate</compound-id>, <compound-id="9867642">Laropiprant</compound-id>, Liposomal <compound-id="5978">vincristine</compound-id>, <compound-id="9909438">LY-518674</compound-id>; <compound-id="10074640">Masitinib</compound-id> <compound-id="6395">mesylate</compound-id>, MAXY-G34, <compound-id="9865515">MGCD-0103</compound-id>, <compound-id="16760627,24202429,71719722,9829523">Midostaurin</compound-id>, Mitumprotimut-T, MK-0343, MLN-1202, MM-093, <compound-id="151071">Motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; <compound-id="2815031">NB-001</compound-id>, NB-002, <compound-id="938">Niacin</compound-id>/<compound-id="9867642">laropiprant</compound-id>; <compound-id="71587613">Oblimersen sodium</compound-id>, Ocrelizumab, <compound-id="285033">Omacetaxine mepesuccinate</compound-id>; <compound-id="6918837">Panobinostat</compound-id>, <compound-id="448013">Patupilone</compound-id>, PBI-1402, <compound-id="148178">Perifosine</compound-id>, <compound-id="11442891">PHA-739358</compound-id>, <compound-id="65015">Plerixafor hydrochloride</compound-id>, <compound-id="6918456">Prasugrel</compound-id>; <compound-id="219024">Regadenoson</compound-id>, RHAMM R3 peptide, Rilonacept, <compound-id="9875401">Rivaroxaban</compound-id>, Romiplostim; <compound-id="131682">Safinamide mesilate</compound-id>, <compound-id="11347535">Salinosporamide A</compound-id>, <compound-id="24934">Selenite sodium</compound-id>, <compound-id="10296883">Sotrastaurin</compound-id>; <compound-id="90470996">Thrombin</compound-id> alfa, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="56603725,9930827">TRO-19622</compound-id>; <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="9930049">Vernakalant</compound-id> hydrochloride, VRC-WNVDNA017-00-VP; YM-155, <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; <compound-id="3036703">Zosuquidar</compound-id> trihydrochloride.	Niacin__hIFN-beta__no_interaction	Niacin__Interleukin-21__no_interaction	Niacin__Fibroblast Growth Factor 1__no_interaction	Selenite sodium__hIFN-beta__no_interaction	Selenite sodium__Interleukin-21__no_interaction	Selenite sodium__Fibroblast Growth Factor 1__no_interaction	Dronedarone hydrochloride__hIFN-beta__no_interaction	Dronedarone hydrochloride__Interleukin-21__no_interaction	Dronedarone hydrochloride__Fibroblast Growth Factor 1__no_interaction	Febuxostat__hIFN-beta__no_interaction	Febuxostat__Interleukin-21__no_interaction	Febuxostat__Fibroblast Growth Factor 1__no_interaction	Thrombin__hIFN-beta__no_interaction	Thrombin__Interleukin-21__no_interaction	Thrombin__Fibroblast Growth Factor 1__no_interaction	Lapaquistat acetate__hIFN-beta__no_interaction	Lapaquistat acetate__Interleukin-21__no_interaction	Lapaquistat acetate__Fibroblast Growth Factor 1__no_interaction	Vernakalant__hIFN-beta__no_interaction	Vernakalant__Interleukin-21__no_interaction	Vernakalant__Fibroblast Growth Factor 1__no_interaction	111In__hIFN-beta__no_interaction	111In__Interleukin-21__no_interaction	111In__Fibroblast Growth Factor 1__no_interaction	Rivaroxaban__hIFN-beta__no_interaction	Rivaroxaban__Interleukin-21__no_interaction	Rivaroxaban__Fibroblast Growth Factor 1__no_interaction	Bosutinib__hIFN-beta__no_interaction	Bosutinib__Interleukin-21__no_interaction	Bosutinib__Fibroblast Growth Factor 1__no_interaction	Vatalanib__hIFN-beta__no_interaction	Vatalanib__Interleukin-21__no_interaction	Vatalanib__Fibroblast Growth Factor 1__no_interaction	Laropiprant__hIFN-beta__no_interaction	Laropiprant__Interleukin-21__no_interaction	Laropiprant__Fibroblast Growth Factor 1__no_interaction	Elacytarabine__hIFN-beta__no_interaction	Elacytarabine__Interleukin-21__no_interaction	Elacytarabine__Fibroblast Growth Factor 1__no_interaction	Forodesine hydrochloride__hIFN-beta__no_interaction	Forodesine hydrochloride__Interleukin-21__no_interaction	Forodesine hydrochloride__Fibroblast Growth Factor 1__no_interaction	MGCD-0103__hIFN-beta__no_interaction	MGCD-0103__Interleukin-21__no_interaction	MGCD-0103__Fibroblast Growth Factor 1__no_interaction	Salinosporamide A__hIFN-beta__no_interaction	Salinosporamide A__Interleukin-21__no_interaction	Salinosporamide A__Fibroblast Growth Factor 1__no_interaction	Yttrium__hIFN-beta__no_interaction	Yttrium__Interleukin-21__no_interaction	Yttrium__Fibroblast Growth Factor 1__no_interaction	Plerixafor hydrochloride__hIFN-beta__no_interaction	Plerixafor hydrochloride__Interleukin-21__no_interaction	Plerixafor hydrochloride__Fibroblast Growth Factor 1__no_interaction	PHA-739358__hIFN-beta__no_interaction	PHA-739358__Interleukin-21__no_interaction	PHA-739358__Fibroblast Growth Factor 1__no_interaction	sodium__hIFN-beta__no_interaction	sodium__Interleukin-21__no_interaction	sodium__Fibroblast Growth Factor 1__no_interaction	Tipifarnib__hIFN-beta__no_interaction	Tipifarnib__Interleukin-21__no_interaction	Tipifarnib__Fibroblast Growth Factor 1__no_interaction	Safinamide mesilate__hIFN-beta__no_interaction	Safinamide mesilate__Interleukin-21__no_interaction	Safinamide mesilate__Fibroblast Growth Factor 1__no_interaction	Brivaracetam__hIFN-beta__no_interaction	Brivaracetam__Interleukin-21__no_interaction	Brivaracetam__Fibroblast Growth Factor 1__no_interaction	Zosuquidar__hIFN-beta__no_interaction	Zosuquidar__Interleukin-21__no_interaction	Zosuquidar__Fibroblast Growth Factor 1__no_interaction	laropiprant__hIFN-beta__no_interaction	laropiprant__Interleukin-21__no_interaction	laropiprant__Fibroblast Growth Factor 1__no_interaction	Perifosine__hIFN-beta__no_interaction	Perifosine__Interleukin-21__no_interaction	Perifosine__Fibroblast Growth Factor 1__no_interaction	Deforolimus__hIFN-beta__no_interaction	Deforolimus__Interleukin-21__no_interaction	Deforolimus__Fibroblast Growth Factor 1__no_interaction	Fenretinide__hIFN-beta__no_interaction	Fenretinide__Interleukin-21__no_interaction	Fenretinide__Fibroblast Growth Factor 1__no_interaction	Clevidipine__hIFN-beta__no_interaction	Clevidipine__Interleukin-21__no_interaction	Clevidipine__Fibroblast Growth Factor 1__no_interaction	Eprodisate sodium__hIFN-beta__no_interaction	Eprodisate sodium__Interleukin-21__no_interaction	Eprodisate sodium__Fibroblast Growth Factor 1__no_interaction	Eltrombopag__hIFN-beta__no_interaction	Eltrombopag__Interleukin-21__no_interaction	Eltrombopag__Fibroblast Growth Factor 1__no_interaction	mesylate__hIFN-beta__no_interaction	mesylate__Interleukin-21__no_interaction	mesylate__Fibroblast Growth Factor 1__no_interaction	90Y__hIFN-beta__no_interaction	90Y__Interleukin-21__no_interaction	90Y__Fibroblast Growth Factor 1__no_interaction	prednisolone__hIFN-beta__no_interaction	prednisolone__Interleukin-21__no_interaction	prednisolone__Fibroblast Growth Factor 1__no_interaction	Motexafin__hIFN-beta__no_interaction	Motexafin__Interleukin-21__no_interaction	Motexafin__Fibroblast Growth Factor 1__no_interaction	Midostaurin__hIFN-beta__no_interaction	Midostaurin__Interleukin-21__no_interaction	Midostaurin__Fibroblast Growth Factor 1__no_interaction	Patupilone__hIFN-beta__no_interaction	Patupilone__Interleukin-21__no_interaction	Patupilone__Fibroblast Growth Factor 1__no_interaction	ibritumomab tiuxetan__hIFN-beta__no_interaction	ibritumomab tiuxetan__Interleukin-21__no_interaction	ibritumomab tiuxetan__Fibroblast Growth Factor 1__no_interaction	Oblimersen sodium__hIFN-beta__no_interaction	Oblimersen sodium__Interleukin-21__no_interaction	Oblimersen sodium__Fibroblast Growth Factor 1__no_interaction	Desvenlafaxine__hIFN-beta__no_interaction	Desvenlafaxine__Interleukin-21__no_interaction	Desvenlafaxine__Fibroblast Growth Factor 1__no_interaction	Darapladib__hIFN-beta__no_interaction	Darapladib__Interleukin-21__no_interaction	Darapladib__Fibroblast Growth Factor 1__no_interaction	Farnesylthiosalicylic acid__hIFN-beta__no_interaction	Farnesylthiosalicylic acid__Interleukin-21__no_interaction	Farnesylthiosalicylic acid__Fibroblast Growth Factor 1__no_interaction	Binodenoson__hIFN-beta__no_interaction	Binodenoson__Interleukin-21__no_interaction	Binodenoson__Fibroblast Growth Factor 1__no_interaction	Indium__hIFN-beta__no_interaction	Indium__Interleukin-21__no_interaction	Indium__Fibroblast Growth Factor 1__no_interaction	Epigallocatechin gallate__hIFN-beta__no_interaction	Epigallocatechin gallate__Interleukin-21__no_interaction	Epigallocatechin gallate__Fibroblast Growth Factor 1__no_interaction	Prasugrel__hIFN-beta__no_interaction	Prasugrel__Interleukin-21__no_interaction	Prasugrel__Fibroblast Growth Factor 1__no_interaction	NB-001__hIFN-beta__no_interaction	NB-001__Interleukin-21__no_interaction	NB-001__Fibroblast Growth Factor 1__no_interaction	Bortezomib__hIFN-beta__no_interaction	Bortezomib__Interleukin-21__no_interaction	Bortezomib__Fibroblast Growth Factor 1__no_interaction	Alvocidib hydrochloride__hIFN-beta__no_interaction	Alvocidib hydrochloride__Interleukin-21__no_interaction	Alvocidib hydrochloride__Fibroblast Growth Factor 1__no_interaction	TRO-19622__hIFN-beta__no_interaction	TRO-19622__Interleukin-21__no_interaction	TRO-19622__Fibroblast Growth Factor 1__no_interaction	ITF__hIFN-beta__no_interaction	ITF__Interleukin-21__no_interaction	ITF__Fibroblast Growth Factor 1__no_interaction	Agomelatine__hIFN-beta__no_interaction	Agomelatine__Interleukin-21__no_interaction	Agomelatine__Fibroblast Growth Factor 1__no_interaction	Regadenoson__hIFN-beta__no_interaction	Regadenoson__Interleukin-21__no_interaction	Regadenoson__Fibroblast Growth Factor 1__no_interaction	Panobinostat__hIFN-beta__no_interaction	Panobinostat__Interleukin-21__no_interaction	Panobinostat__Fibroblast Growth Factor 1__no_interaction	vincristine__hIFN-beta__no_interaction	vincristine__Interleukin-21__no_interaction	vincristine__Fibroblast Growth Factor 1__no_interaction	Sotrastaurin__hIFN-beta__no_interaction	Sotrastaurin__Interleukin-21__no_interaction	Sotrastaurin__Fibroblast Growth Factor 1__no_interaction	Cediranib__hIFN-beta__no_interaction	Cediranib__Interleukin-21__no_interaction	Cediranib__Fibroblast Growth Factor 1__no_interaction	Masitinib__hIFN-beta__no_interaction	Masitinib__Interleukin-21__no_interaction	Masitinib__Fibroblast Growth Factor 1__no_interaction	Idraparinux sodium__hIFN-beta__no_interaction	Idraparinux sodium__Interleukin-21__no_interaction	Idraparinux sodium__Fibroblast Growth Factor 1__no_interaction	Dipyridamole__hIFN-beta__no_interaction	Dipyridamole__Interleukin-21__no_interaction	Dipyridamole__Fibroblast Growth Factor 1__no_interaction	BIBW-2992__hIFN-beta__no_interaction	BIBW-2992__Interleukin-21__no_interaction	BIBW-2992__Fibroblast Growth Factor 1__no_interaction	Curcumin__hIFN-beta__no_interaction	Curcumin__Interleukin-21__no_interaction	Curcumin__Fibroblast Growth Factor 1__no_interaction	Omacetaxine mepesuccinate__hIFN-beta__no_interaction	Omacetaxine mepesuccinate__Interleukin-21__no_interaction	Omacetaxine mepesuccinate__Fibroblast Growth Factor 1__no_interaction	succinate__hIFN-beta__no_interaction	succinate__Interleukin-21__no_interaction	succinate__Fibroblast Growth Factor 1__no_interaction	LY-518674__hIFN-beta__no_interaction	LY-518674__Interleukin-21__no_interaction	LY-518674__Fibroblast Growth Factor 1__no_interaction	gadolinium__hIFN-beta__no_interaction	gadolinium__Interleukin-21__no_interaction	gadolinium__Fibroblast Growth Factor 1__no_interaction
18026713-5	RESULTS: In comparison with healthy participants, type 2 diabetic patients on an NPD had similar ELF, reduced serum <protein-id="P02768">albumin</protein-id> (38 +/- 1.1 vs 42 +/- 0.8 g/l; p &lt; 0.05), similar fractional synthesis rates (<compound-id="72206646">FSR</compound-id>) and absolute synthesis rates (ASR) of <protein-id="P02768">albumin</protein-id>, and both increased plasma <protein-id="P02675,V9HVY1">fibrinogen</protein-id> concentration [10.7 +/- 0.6 vs 7.2 +/- 0.5 micromol/l (3.64 +/- 0.22 vs 2.45 +/- 0.18 g/l); p &lt; 0.05] and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> ASR [11.03 +/- 1.17 vs 6.0 +/- 1.8 micromol 1.73 m(-2) day(-1) (3.7 +/- 0.4 vs 1.9 +/- 0.3 g 1.73 m(-2) day(-1)); p &lt; 0.01].	FSR__fibrinogen__no_interaction	FSR__albumin__no_interaction
9313756-4	Although <compound-id="206,5793,64689,79025">glucose</compound-id> control was similar at the end of both periods (MDBG 8.3 +/- 0.3 vs. 7.9 +/- 0.3 mmol/l; HbA1c 7.4 +/- 0.3 vs. 7.0 +/- 0.2%, <protein-id="P01308,I3WAC9">Insulin</protein-id> versus <compound-id="3488">glibenclamide</compound-id>), <protein-id="P01308,I3WAC9">Insulin</protein-id> compared with <compound-id="3488">glibenclamide</compound-id> induced a significant reduction in plasma triglycerides (0.9 +/- 0.1 vs. 1.1 +/- 0.1 mmol/l, P &lt; 0.05), VLDL triglycerides (50.1 +/- 12.2 vs. 63.6 +/- 12.3 mg/dl, P &lt; 0.02), VLDL1 lipid concentration (24.9 +/- 7.5 vs. 39.9 +/- 9.5 mg/dl, P &lt; 0.006), and increased <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> <compound-id="5997">cholesterol</compound-id> (25.2 +/- 1.6 vs. 20.3 +/- 1.3 mg/dl, P &lt; 0.03).	cholesterol__Insulin__no_interaction	cholesterol__HDL2__no_interaction	glibenclamide__Insulin__no_interaction	glibenclamide__HDL2__no_interaction	glucose__Insulin__no_interaction	glucose__HDL2__no_interaction
11756164-4	Using novel canine-human chimeras dissecting the C-terminal flank, it is now demonstrated that (1) Phe201-Glu225 contains the epitope for AP1, an anti-<protein-id="P07359,L7UYB8">GPIb alpha</protein-id> monoclonal antibody that inhibits both ristocetin- and botrocetin-dependent <protein-id="P04275">vWF</protein-id> binding; (2) VM16d, an antibody that preferentially inhibits botrocetin-dependent <protein-id="P04275">vWF</protein-id> binding, recognizes the sequence Val226-Gly268, surrounding Cys248, which forms a disulfide-bond with Cys209; (3) <protein-id="P04275">vWF</protein-id> binding to chimeric <protein-id="P07359,L7UYB8">GPIb alpha</protein-id> is comparable to wild-type in 2 chimeras in which the sixth <compound-id="6106">leucine</compound-id>-rich repeat was of the same species as the first disulfide loop (Phe201-Cys248) of the C-terminal flank, suggesting an interaction between these domains may be important for optimal <protein-id="P04275">vWF</protein-id> binding; and (4) replacing the C-terminal flank second disulfide loop (Asp249-Gly268) in human <protein-id="P07359,L7UYB8">GPIb alpha</protein-id> with the corresponding canine sequence enhanced <protein-id="P04275">vWF</protein-id> binding under static and flow conditions, providing the first evidence for a gain-of-function phenotype associated with the second loop of the C-terminal flank.	leucine__vWF__no_interaction	leucine__GPIb alpha__no_interaction
11558844-9	Univariate analysis showed that patients with LV thrombus had a higher peak <compound-id="586">creatine</compound-id> kinase (CK) level (2,879 +/- 742 vs. 1,693 +/- 1,210 I/U, p = 0.001), higher peak <protein-id="P02741">CRP</protein-id> level (14.9 +/- 7.1 vs. 9.2 +/- 6.8 mg/dl, p = 0.001), higher wall motion score index (1.8 +/- 0.2 vs. 1.5 +/- 0.3, p = 0.002), higher apical wall motion score index (2.35 +/- 0.72 vs. 2.07 +/- 0.70, p = 0.001), larger end-diastolic volume (145.2 +/- 43.7 vs. 116.5 +/- 44.2 ml, p = 0.002), larger end-systolic volume (85.4 +/- 37.2 vs. 62.9 +/- 31.6 ml, p = 0.003), and lower ejection fraction (42.1 +/- 12 vs. 47.3 +/- 13, p = 0.04).	creatine__CRP__no_interaction
22014996-2	A total of thirty-two <compound-id="12210218">thieno[3,2-b]pyridine</compound-id> derivatives of two series: methyl 3-amino-6-(hetero)arylthieno[3,2-b]<compound-id="1049">pyridine-</compound-id>2-carboxylates (1a-1t) and methyl 3-amino-6-[(hetero)arylethynyl]<compound-id="12210218">thieno[3,2-b]pyridine</compound-id>-2-carboxylates (2a-2n), previously prepared by some of us, were evaluated as new potential anti-HCC agents by studying their in vitro cell growth inhibition on human HepG2 cells and hepatotoxicity using a porcine liver primary cell culture (<protein-id="P60201,A8K9L3,B4DI30">PLP1</protein-id>).	pyridine-__PLP1__no_interaction	thieno[3,2-b]pyridine__PLP1__no_interaction
21870121-6	At the end of the study period, between the 2 groups we observed a significant difference in Everyday Memory Questionnaire -23.9 vs 4.4 (p &lt; 0.001), Logical Memory (Paragraph recall) test 22.3 vs 0.7 (p &lt; 0.001), Trail Making Test A -7.5 vs -2.6 (p &lt; 0.001), Trail Making Test B -10.5 vs -3.1 (p &lt; 0.001), Controlled Oral Word Association Test 4.2 vs 0.5 (p &lt; 0.001), Hooper test 2.6 vs 0.1 (p &lt; 0.05), Judgement of line orientation 2.8 vs 0.3 (p &lt; 0.001), Digit Cancellation time -24.5 vs -2.4 (p &lt; 0.001), NH₄⁺ 30.5 vs 13.5 (p &lt; 0.001), <protein-id="P00734">prothrombin</protein-id> time 2 vs 2.4 (p &lt; 0.05), <compound-id="5950,602">alanine</compound-id> transaminase -10.7 vs -13.6 (p &lt; 0.001).	alanine__prothrombin__no_interaction
22367758-2	The stoichiometric reaction of the bis(phenols) 1,3-dithiapropanediyl-2,2'-bis(4,6-<compound-id="185594">di-tert-butylphenol</compound-id>), 1,3-dithiapropanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-propanediyl-1,4-dithiabutanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-butanediyl-1,4-dithiabutane diyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], <protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>,3-trans-hexanediyl-1,4-dithiabutanediyl-2,2'-bis[4,6-di(2-phenyl-2-propyl)phenol], 1,3-dithiapropanediyl-2,2'-bis[6-(1-methylcyclohexyl)-<compound-id="2879">4-methylphenol</compound-id>] (C(1), R=1-methylcyclohexyl), and 1,4-dithiabutanediyl-2,2'-bis[6-(1-methylcyclohexyl)-<compound-id="2879">4-methylphenol</compound-id>] with rare-earth metal silylamido precursors [Ln{N(SiHMe(2))(2)(3)(thf)(x)] (Ln=Sc, x=1 or Ln=Y, x=2; thf=tetrahydrofuran) afforded the corresponding <compound-id="23952">scandium</compound-id> and <compound-id="23993">yttrium</compound-id> bis(<compound-id="996">phenolate</compound-id>) silylamido complexes [Ln(OSSO){N(SiHMe(2))(2)}(thf)] in moderate to good yields.	scandium__rac-2__no_interaction	phenolate__rac-2__no_interaction	4-methylphenol__rac-2__no_interaction	di-tert-butylphenol__rac-2__no_interaction	yttrium__rac-2__no_interaction
8605955-2	In radioligand binding assays, the dipeptoid <compound-id="9850711">PD 135666</compound-id> ((<compound-id="4775">benzenebutanoic acid</compound-id>, beta-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2- [[(tricyclo[3.3.1.1(3,7)]<protein-id="Q99PV5,Q6L8F5,D3Z2G6">dec-2</protein-id>-yloxy)carbonyl]amino]propyl] amino],-[R-(+*,S*)]) selectively inhibited [125I]Bolton Hunter <compound-id="16219094">CCK-8</compound-id> binding to CCKB receptors in mouse cerebral cortex (CCKB IC50 = 0.1 nM) but was weaker as an inhibitor of <protein-id="Q63931">CCKA receptor</protein-id> binding in the rat pancreas (IC50 = 26 nM).	CCK-8__dec-2__no_interaction	CCK-8__CCKA receptor__no_interaction	PD 135666__dec-2__no_interaction	PD 135666__CCKA receptor__no_interaction	benzenebutanoic acid__dec-2__no_interaction	benzenebutanoic acid__CCKA receptor__no_interaction
11422740-14	RESULTS: The anti-Thy-1.1 treated with 1,25(OH)2D3 group versus the anti-Thy-1.1 alone group showed a significant reduction in urinary protein (at day 7, 424 +/- 228 vs. 66 +/- 30 mg/mg urinary <compound-id="588">creatinine</compound-id>, P = 0.02) and <protein-id="P20607">interleukin-6</protein-id> excretion (at day 3, 537 +/- 360 pg/mL vs. 110 +/- 34 pg/mg urinary <compound-id="588">creatinine</compound-id>, P = 0.015), reduced glomerular diameters (at day 7, 283 +/- 38 vs. 261 +/- 48 microm, P &lt; 0.01), decreased neutrophil (at day 4, 20 +/- 12 His48-positive cells/glomerulus vs. 3.7 +/- 1.3 His48-positive cells/glomerulus, P &lt; 0.001), and monocyte accumulation (day 7, 4.9 +/- 2.9 ED1-positive cells/glomerulus vs. 2.8 +/- 2.9 ED1-positive cells/glomerulus, P &lt; 0.05), and attenuated glomerular cells proliferation (day 7, 13 +/- 3.2 <protein-id="P04961">PCNA</protein-id>-positive cells/glomerulus vs. 9.4 +/- 3 <protein-id="P04961">PCNA</protein-id>-positive cells/glomerulus, P &lt; 0.01).	creatinine__PCNA__no_interaction	creatinine__interleukin-6__no_interaction
21490074-8	Furthermore, hepatic <protein-id="P35557,Q53Y25">GCK</protein-id> mRNA expression is associated with lipogenic gene expression (fatty acid synthase, r = 0.49, P = 0.0003; <compound-id="6302">acetyl-coenzyme A</compound-id> carboxylase-α, r = 0.44, P = 0.0015, and <compound-id="6302">acetyl-coenzyme A</compound-id> carboxylase-β, r = 0.48, P = 0.0004) and the de novo lipogenesis index (r = 0.36, P = 0.01).	acetyl-coenzyme A__GCK__no_interaction
2210017-2	We investigated the changes in blood <compound-id="206,5793,64689,79025">glucose</compound-id>, plasma non-esterified fatty acids (NEFA), <compound-id="767">bicarbonate</compound-id> and glucagon after stopping <protein-id="P01308,I3WAC9">insulin</protein-id> infusion between 08.00 h. and 14.00 h. <protein-id="P01308,I3WAC9">insulin</protein-id> infusion cessation resulted in: 1) a similar increase in blood <compound-id="206,5793,64689,79025">glucose</compound-id> in both groups after 2 hours of interruption (group 1: 9.45 +/- 1.28 mmol/L versus basal levels of 6.94 +/- 0.96 mmol/L, p less than 0.05; group 2: 8.11 +/- 2.87 mmol/L versus 5.75 +/- 2.17 mmol/L, p less than 0.02) and a greater increase in blood <compound-id="206,5793,64689,79025">glucose</compound-id> in group 1 than group 2 after 4 hours (p less than 0.05) and after 6 hours (p less than 0.05); 2) a progressive increase in NEFA in group 1 throughout the study period (08.00 h.: 0.51 +/- 0.28 mmol/L; 14.00 h: 1.44 +/- 0.45 mmol/L, p less than 0.05) that was significant after 4 and 6 hours of <protein-id="P0DML3,B1A4H9,A6NIT4">CSII</protein-id> interruption; there were no changes in NEFA in group 2; 3) plasma level of IA correlated inversely with final glycemia (r = -0.67, p less than 0.01) and final NEFA (r = -0.56, p = 0.02).	bicarbonate__CSII__no_interaction	bicarbonate__insulin__no_interaction	glucose__CSII__no_interaction	glucose__insulin__no_interaction
19361602-6	Plasma <protein-id="P16860">BNP</protein-id> (F = 14.8, p = 001), <compound-id="10964">malondialdehyde</compound-id> (F = 9.4, p = 0.006), protein carbonyl (F = 9.2, p = 0.006), and nitrotyrosine (F = 4.4, p = 0.045) were significantly decreased, along with an increase in antioxidative <compound-id="124886,20725278">glutathione</compound-id> (F = 4.2, p = 0.049) after darbepoetin alfa treatment.	glutathione__BNP__no_interaction	malondialdehyde__BNP__no_interaction
16712667-9	<protein-id="O00300">OPG</protein-id> was negatively correlated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> and triglyceride levels (r = -0.18, P = 0.031 and r = -0.19, P = 0.02, respectively) and positively correlated with the QUICKI index (r = 0.17, P = 0.033), HDL <compound-id="5997">cholesterol</compound-id> (r = 0.21, P = 0.009) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (r = 0.27, P = 0.001).	cholesterol__OPG__no_interaction	cholesterol__adiponectin__no_interaction	glucose__OPG__no_interaction	glucose__adiponectin__no_interaction
16676992-1	Addition of [Mo(V)2O2S2(edt)2]2- (edt =1,2-ethanedithiolate) to <compound-id="6342">acetonitrile</compound-id> and/or <compound-id="11686950,887">methanol</compound-id> solutions of MnII containing bipyridines [<compound-id="87019">4,4'-trimethylenedipyridine</compound-id> (TDP), <compound-id="11107">4,4'-bipyridine</compound-id> (4,4'-bpy), <compound-id="1474">2,2'-bipyridine</compound-id> (2,2'-bpy)] or <compound-id="36336">15-crown-5</compound-id> produces three new heterometallic cluster coordination polymers, [Mn2[Mo2O2S2(edt)2]2(TDP)3(CH3OH)2(NCMe)2].3CH3OH.0.25MeCN (1), [Mn(TDP)2(H2O)2]2+[Mn[Mo2O2S2(edt)2)2(TDP)2]]2-.6CH3OH (2), [Mn[Mo2O2S2(edt)2](TDP)2(CH3OH)(H2O)].CH3OH (3), and three new multinuclear clusters, [Mn[Mo2O2S2(edt)2](4,4'-bpy)(CH3OH)4].0.5(4,4'-bpy) (4), [Mn[Mo2O2S2(edt)2](2,2'-bpy)2].2CH3OH (5), and (<protein-id="P62079">NEt4</protein-id>)2[Mn(<compound-id="36336">15-crown-5</compound-id>)[Mo2O2S2(edt)2]2] (6).	15-crown-5__NEt4__no_interaction	4,4'-trimethylenedipyridine__NEt4__no_interaction	4,4'-bipyridine__NEt4__no_interaction	methanol__NEt4__no_interaction	2,2'-bipyridine__NEt4__no_interaction	acetonitrile__NEt4__no_interaction
19099934-5	RESULTS: <compound-id="54687">Pravastatin</compound-id> dose-dependently upregulated <protein-id="P23242,Q8C4N2">Cx43</protein-id> proteins on membrane of myocardial cells (group A: 0.16 +/- 0.06, group B: 4.55 +/- 0.73 and group C: 5.21 +/- 0.42, P &lt; 0.01 vs. group A) and <protein-id="P23242,Q8C4N2">Cx43</protein-id> mRNA expression (group A: 1.000 +/- 0.127, group B: 1.320 +/- 0.096, group C: 1.550 +/- 0.126, P &lt; 0.05 vs. group A), <protein-id="P18893,Q3U879">IL-10</protein-id> mRNA expression (group A: 1.000 +/- 0.031, group B: 1.810 +/- 0.029, group C: 2.140 +/- 0.032, P &lt; 0.05 vs. group A) while down-regulated <protein-id="P01580">IFN-gamma</protein-id> mRNA (group A: 1.000 +/- 0.061, group B: 0.603 +/- 0.063, group C: 0.333 +/- 0.071, P &lt; 0.01 vs. group A).	Pravastatin__IFN-gamma__no_interaction	Pravastatin__Cx43__no_interaction	Pravastatin__IL-10__no_interaction
23522250-9	RESULTS: The relative expression level of the phosphorylation of <protein-id="G3V617,Q56A33">p38</protein-id> of SA-B group is 0.33+/-0.05,obviously lower than control group(q=7.08, P less than 0.01); SA-B+TGFb1 group is 0.46+/-0.04, obviously lower than TGF b1 group(q=10.45, P less than 0.01); The relative expression level of the phosphorylation of <protein-id="Q925D6">MKK3/6</protein-id> of SA-B group is 0.11+/-0.07, obviously lower than control group(q=3.944, P less than 0.05); SA-B+TGF b1 group is 0.28+/-0.07, obviously lower than TGFb1 group (q=7.91, P less than 0.01); The relative luciferase activity of MEF2 reporter of SA-B+TGFb1 group and <compound-id="176155">SB203580</compound-id>+TGF b1 group is 2.93+/-0.09 and 2.50+/-0.05 respectively, both obviously lower than TGFb1 group(q=35.35 and 37.2, P less than 0.01); The relative expression level of <protein-id="A0A096MJ23,A0A096MK88,A0A096MKI4,A0A096MJY4">MEF2C</protein-id> and <protein-id="Q2MJT0,A0A0G2JSZ4,M0R6R7">MEF2A</protein-id> of SA-B group is 15.82+/-0.97 and 13.00+/-0.40 respectively, obviously lower than control group(q is 5.18 and 13.32, both P less than 0.01); SA-B+TGF b1 group is 13.40+/-0.72 and 20.47+/-0.83 respectively, obviously lower than TGFb1 group(q is 43.93 and 12.52,both P less than 0.01); The relative expression level of a-SMA of SA-B+TGFb1 group is 8.76+/-0.44, obviously lower than TGFb1 group(q=20.35, P less than 0.01); SA-B+<compound-id="176155">SB203580</compound-id>+TGFb1 group is only 3.57+/-0.49, obviously lower than TGFb1 group(q=39.78, P less than 0.01); The relative luciferase activity of collagen a1(I) reporter of SA-B+TGF b1 group and <compound-id="176155">SB203580</compound-id>+TGFb1 group is 1.61+/-0.05 and 1.42+/-0.07 respectively, obviously lower than TGFb1 group(q=26.4 and 27.62, both P less than 0.01).	SB203580__MEF2C__no_interaction	SB203580__p38__no_interaction	SB203580__MEF2A__no_interaction	SB203580__MKK3/6__no_interaction
12122495-2	Thus, we determined, in isolated rings from human saphenous vein and human internal mammary artery, contractile responses to noradrenaline (10(-8)-10(-4) M) in the absence and presence of the alpha-adrenoceptor antagonists yohimbine (alpha(2)-adrenoceptor antagonist, 10(-8)-10(-6) M), <compound-id="4893">prazosin</compound-id> (alpha(1)-adrenoceptor antagonist, 10(-9)-10(-7) M), <compound-id="5640">5-methyl-urapidil</compound-id> (5-MU, <protein-id="P35348,B0ZBD3">alpha(1A)-adrenoceptor</protein-id> antagonist, 10(-8)-10(-6) M), <compound-id="2419">BMY 7378</compound-id> (<protein-id="P25100,B0ZBE0">alpha(1D)-adrenoceptor</protein-id> antagonist, 10(-7)-10(-6) M), and <compound-id="104973">chloroethylclonidine</compound-id> (CEC, irreversible <protein-id="P35368">alpha(1B)-adrenoceptor</protein-id> antagonist, 3x10(-5) M for 30 min).	chloroethylclonidine__alpha(1A)-adrenoceptor__no_interaction	chloroethylclonidine__alpha(1B)-adrenoceptor__no_interaction	chloroethylclonidine__alpha(1D)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1A)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1B)-adrenoceptor__no_interaction	5-methyl-urapidil__alpha(1D)-adrenoceptor__no_interaction	prazosin__alpha(1A)-adrenoceptor__no_interaction	prazosin__alpha(1B)-adrenoceptor__no_interaction	prazosin__alpha(1D)-adrenoceptor__no_interaction	BMY 7378__alpha(1A)-adrenoceptor__no_interaction	BMY 7378__alpha(1B)-adrenoceptor__no_interaction	BMY 7378__alpha(1D)-adrenoceptor__no_interaction
9821173-3	In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant <compound-id="3385">5-fluorouracil</compound-id> (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; <compound-id="60750">gemcitabine</compound-id> has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> and TGF-beta; a <protein-id="P38936,A0A024RCX5">p21</protein-id>-adenovirus (rAD-<protein-id="P38936,A0A024RCX5">p21</protein-id>) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-<protein-id="P38936,A0A024RCX5">p21</protein-id>.	5-fluorouracil__p21__no_interaction	5-fluorouracil__p53__no_interaction	gemcitabine__p21__no_interaction	gemcitabine__p53__no_interaction
2824919-2	During the "fasting test" the following data expressed as mean basal plasma values +/- <compound-id="5289348">SEM</compound-id> vs. mean hypoglycemic values +/- <compound-id="5289348">SEM</compound-id> were obtained: <protein-id="P01308,I3WAC9">insulin</protein-id> (57.3 +/- 17.9 vs. 27.5 +/- 10.6 microU/ml), <protein-id="P01308,I3WAC9">C-peptide</protein-id> (4.9 +/- 1.1 vs. 3.5 +/- 0.9 ng/ml), free fatty acids (0.30 +/- 0.01 vs. 0.32 +/- 0.02 mmol/l), <compound-id="441">beta-hydroxybutyrate</compound-id> (less than 0.03 vs. 0.05 +/- 0.02 mmol/l), alanine (204.0 +/- 67.5 vs. 228.3 +/- 64.9 mumol/l), <compound-id="612">lactate</compound-id> (5.3 +/- 0.7 vs. 5.4 +/- 1.1 mg/dl), pyruvate (41.3 +/- 4.8 vs. 19.7 +/- 4.2 mg/dl).	SEM__insulin__no_interaction	SEM__C-peptide__no_interaction	beta-hydroxybutyrate__insulin__no_interaction	beta-hydroxybutyrate__C-peptide__no_interaction	lactate__insulin__no_interaction	lactate__C-peptide__no_interaction
19081404-7	The correlation of <compound-id="444185">GLS</compound-id> with <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>-EF (r = -0.69, P &lt; .0001) was comparable to that between 3D-EF and <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (r = 0.80, P &lt; .0001), and better than that between 2D-EF (r = 0.58, P &lt; .0001) or automated EF and <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (r = 0.62, P &lt; .0001).	GLS__MRI__no_interaction
19134409-5	RESULTS: Compared with the control group, the expression of p-<protein-id="P17252,Q7Z727">PKCalpha</protein-id> and <protein-id="P27361,L7RXH5,Q9BWJ1">ERK1</protein-id>/2, p-<protein-id="P27361,L7RXH5,Q9BWJ1">ERK1</protein-id>/2 protein increased, the expression of <protein-id="P12004">cyclinD1</protein-id>, P21(<protein-id="P38936,A0A024RCX5">cip1</protein-id>) protein increased correspondingly (the A value % control was 2.10 +/- 0.29, 1.67 +/- 0.19, 2.20 +/- 0.27, 1.99 +/- 0.22 and 3.11 +/- 0.29 respectively; q value was 9.87, 7.06, 10.57, 11.10 and 20.33 respectively; all P &lt; 0.05) in <compound-id="122634,22833501,27924,4792">PMA</compound-id> treated group, and cells proliferation [the percentage of cells in S phase was (30.3 +/- 2.4)%, A(490) value was 0.80 +/- 0.06] enhanced significantly compared with those [the percentage of cells in S phase was (13.9 +/- 2.6)%, A(490) value was 0.41 +/- 0.04] of the control group (q = 6.07, 12.63; all P &lt; 0.05).	PMA__ERK1__no_interaction	PMA__PKCalpha__no_interaction	PMA__cip1__no_interaction	PMA__cyclinD1__no_interaction
21726418-5	RESULTS: (i) CBD and <compound-id="34180,93147">tetrahydrocannabivarin</compound-id> (THCV) stimulated <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id>-mediated [Ca(2+)](i) with high efficacy (50-70% of the effect of <compound-id="25134244,3733,5353687,6434517,6912226">ionomycin</compound-id>) and potency (EC(50∼) 3.7 μm), whereas <compound-id="59444407">cannabigerovarin</compound-id> (CBGV) and cannabigerolic acid (<compound-id="6449999">CBGA</compound-id>) were significantly more efficacious at desensitizing this channel to the action of <compound-id="10364">carvacrol</compound-id> than at activating it; (ii) <compound-id="11601669,45783233">cannabidivarin</compound-id> and THCV stimulated <protein-id="Q9ERZ8">TRPV4</protein-id>-mediated [Ca(2+)](i) with moderate-high efficacy (30-60% of the effect of <compound-id="25134244,3733,5353687,6434517,6912226">ionomycin</compound-id>) and potency (EC(50) 0.9-6.4 μm), whereas <compound-id="6449999">CBGA</compound-id>, CBGV, <compound-id="2543">cannabinol</compound-id> and <compound-id="5315659">cannabigerol</compound-id> were significantly more efficacious at desensitizing this channel to the action of 4-α-<compound-id="16219908">phorbol 12,13-didecanoate</compound-id> (4α-<compound-id="452543,452544,537379,71308620">PDD</compound-id>) than at activating it; (iii) CBC reduced <protein-id="Q704Y3,Q3V318">TRPV1</protein-id>β, <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id> and <protein-id="Q9ERZ8">TRPV4</protein-id> mRNA in the jejunum, and <protein-id="Q8K424,Q32MT9,E9PU00">TRPV3</protein-id> and <protein-id="Q9ERZ8">TRPV4</protein-id> mRNA in the ileum of croton oil-treated mice.	phorbol 12,13-didecanoate__TRPV4__no_interaction	phorbol 12,13-didecanoate__TRPV1__no_interaction	phorbol 12,13-didecanoate__TRPV3__no_interaction	ionomycin__TRPV4__no_interaction	ionomycin__TRPV1__no_interaction	ionomycin__TRPV3__no_interaction	cannabinol__TRPV4__no_interaction	cannabinol__TRPV1__no_interaction	cannabinol__TRPV3__no_interaction	tetrahydrocannabivarin__TRPV4__no_interaction	tetrahydrocannabivarin__TRPV1__no_interaction	tetrahydrocannabivarin__TRPV3__no_interaction	cannabidivarin__TRPV4__no_interaction	cannabidivarin__TRPV1__no_interaction	cannabidivarin__TRPV3__no_interaction	carvacrol__TRPV4__no_interaction	carvacrol__TRPV1__no_interaction	carvacrol__TRPV3__no_interaction	CBGA__TRPV4__no_interaction	CBGA__TRPV1__no_interaction	CBGA__TRPV3__no_interaction	cannabigerol__TRPV4__no_interaction	cannabigerol__TRPV1__no_interaction	cannabigerol__TRPV3__no_interaction	PDD__TRPV4__no_interaction	PDD__TRPV1__no_interaction	PDD__TRPV3__no_interaction	cannabigerovarin__TRPV4__no_interaction	cannabigerovarin__TRPV1__no_interaction	cannabigerovarin__TRPV3__no_interaction
16471964-1	Reactions of <compound-id="23978">copper</compound-id>(I) halides with a series of <compound-id="9568512">thiosemicarbazone</compound-id> ligands (Htsc) in the presence of <compound-id="11776">triphenylphosphine</compound-id> (Ph(3)P) in <compound-id="6342">acetonitrile</compound-id> have yielded three types of complexes: (i) monomers, [CuX(<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-S-Htsc)(Ph3P)2] [X, Htsc = I (1), Br (2), <compound-id="5711036">benzaldehyde thiosemicarbazone</compound-id> (Hbtsc); I (5), Br (6), Cl (7), <compound-id="1638753,5354113">pyridine-2-carbaldehyde thiosemicarbazone</compound-id> (Hpytsc)], (ii) halogen-bridged dimers, [<compound-id="444924">Cu2</compound-id>(<protein-id="Q96CW1,E9PFW3,B4DNB9">mu2</protein-id>-X)2(<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-S-Htsc)2(Ph3P)2] [X, Htsc = Br (3), Hbtsc; I (8), <compound-id="699319">furan-2-carbaldehyde thiosemicarbazone</compound-id> (Hftsc); I (11), <compound-id="692778">thiophene-2-carbaldehyde thiosemicarbazone</compound-id> (Httsc)], and (iii) <compound-id="402">sulfur</compound-id>-bridged dimers, [Cu2X2(<protein-id="Q96CW1,E9PFW3,B4DNB9">mu2</protein-id>-S-Htsc)2(Ph3P)2] [X, Htsc = Cl (4), Hbtsc; Br (9), Cl (10), <compound-id="6746523">pyrrole-2-carbaldehyde thiosemicarbazone</compound-id> (Hptsc); Br (12), Httsc].	copper__eta1__no_interaction	copper__mu2__no_interaction	thiosemicarbazone__eta1__no_interaction	thiosemicarbazone__mu2__no_interaction	Cu2__eta1__no_interaction	Cu2__mu2__no_interaction	pyrrole-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	pyrrole-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	benzaldehyde thiosemicarbazone__eta1__no_interaction	benzaldehyde thiosemicarbazone__mu2__no_interaction	furan-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	furan-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	pyridine-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	pyridine-2-carbaldehyde thiosemicarbazone__mu2__no_interaction	triphenylphosphine__eta1__no_interaction	triphenylphosphine__mu2__no_interaction	sulfur__eta1__no_interaction	sulfur__mu2__no_interaction	acetonitrile__eta1__no_interaction	acetonitrile__mu2__no_interaction	thiophene-2-carbaldehyde thiosemicarbazone__eta1__no_interaction	thiophene-2-carbaldehyde thiosemicarbazone__mu2__no_interaction
22658637-9	Our data also demonstrated that <compound-id="54454">simvastatin</compound-id> reduced the expression and secretion of <protein-id="P13500">MCP-1</protein-id>, under baseline (770.4 ± 199.9 vs 312.7 ± 113.7 and 1.00 ± 0.14 vs 0.63 ± 0.13, p&lt;0.05, respectively) and inflammatory conditions (14945 ± 228.7 vs 7837.6 ± 847.4 and 24.16 ± 5.49 vs 14.97 ± 2.67, p&lt;0.05, p&lt;0.05, respectively).	simvastatin__MCP-1__no_interaction
17466660-5	RESULTS: Normonatremic runners (n = 33; 2001) with a mean 3% decrease in body weight showed a 40-fold increase in <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (66.6 +/- 11.9 pg/mL from 1.6 +/- 0.5 pg/mL, P = .001), which was significantly correlated with increases in <compound-id="586">creatine</compound-id> kinase (r = 0.88, P = &lt;.0001), <compound-id="5754">cortisol</compound-id> (r = 0.70, P = .0003), and <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> (r = 0.67, P &lt;.007), but not <compound-id="6322,90867653">arginine</compound-id> <protein-id="P01185,X5DQP6">vasopressin</protein-id> (r = 0.44, P = .07).	cortisol__prolactin__no_interaction	cortisol__vasopressin__no_interaction	cortisol__interleukin-6__no_interaction	arginine__prolactin__no_interaction	arginine__vasopressin__no_interaction	arginine__interleukin-6__no_interaction	creatine__prolactin__no_interaction	creatine__vasopressin__no_interaction	creatine__interleukin-6__no_interaction
22051955-1	The title polymeric compound, {(C(13)H(16)N(2))[Co(C(10)H(3)O(8))(C(13)H(14)N(2))(H(2)O)(2)](2)·5H(2)O}(n), is an ionic structure comprising an anionic two-dimensional mesh characterized by a {[Co(Hbtc)(<protein-id="O60687">bpp</protein-id>)(H(2)O)(2)](-)}(2) motif [Hbtc is 5-<compound-id="243">carboxybenzene</compound-id>-1,2,4-tricarboxylate and <protein-id="O60687">bpp</protein-id> is <compound-id="87019">1,3-bis(4-pyridyl)propane</compound-id>], with interspersed 4,4'-(<compound-id="6334">propane</compound-id>-1,3-diyl)dipyridinium cations, denoted (H(2)<protein-id="O60687">bpp</protein-id>)(2+), and <compound-id="962">water</compound-id> molecules providing the charge balance and structure stabilization.	propane__bpp__no_interaction	water__bpp__no_interaction	carboxybenzene__bpp__no_interaction	1,3-bis(4-pyridyl)propane__bpp__no_interaction
12162592-4	RESULTS: EV71 patients with both encephalitis and pulmonary oedema were found to have much higher levels of blood <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>) (947 +/- 1239 vs 4.9 +/- 3.1 pg/ml, p = 0.0003), <protein-id="P01375,Q5STB3">tumour necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (22.4 +/- 29.5 vs 5.3 +/- 1.0 pg/ml, p = 0.0035), interleukin Ibeta (<protein-id="P01584">IL-1beta</protein-id>) (48.4 +/- 85.2 vs 4.9 +/- 10.1 pg/ml, p = 0.01), white blood cell count (28.3 +/- 7.6 vs 15.5 +/- 6.8 10(9)/L, p &gt; or = 0.0001) and blood <compound-id="206,5793,64689,79025">glucose</compound-id> (501 +/- 186 vs 165 +/- 117 mg/dL, p = 0.0009) than patients with EV71 encephalitis alone.	glucose__IL-6__no_interaction	glucose__IL-1beta__no_interaction	glucose__tumour necrosis factor-alpha__no_interaction	glucose__TNF-alpha__no_interaction	glucose__interleukin-6__no_interaction
16216995-3	METHODS: The prevalence of high <protein-id="P02741">CRP</protein-id> levels in the third National Health and Nutrition Examination Survey (n = 15 341) was studied using <compound-id="221493">CHD</compound-id> risk-factor cut points designated as abnormal (total <compound-id="5997">cholesterol</compound-id> values, &gt;or=240 mg/dL [&gt;or=6.22 mmol/L]; fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels, &gt;or=126 mg/dL [&gt;or=6.99 mmol/L]; blood pressure, &gt;or=140/90 mm Hg; body mass index [BMI], &gt;or=30 kg/m(2); high-density lipoprotein <compound-id="5997">cholesterol</compound-id> values, &lt;40 mg/dL [&lt;1.04 mmol/L] for men and &lt;50 mg/dL [&lt;1.30 mmol/L] for women; triglyceride levels, &gt;or=200 mg/dL [&gt;or=2.26 mmol/L]; current smoking status) or borderline (total <compound-id="5997">cholesterol</compound-id> values, 200-239 mg/dL [5.18-6.19 mmol/L]; fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels, 100-125 mg/dL [5.55-6.94 mmol/L]; blood pressure, 120-139/80-89 mm Hg; BMI, 25.0-29.9 kg/m(2), and triglyceride values 150-199 mg/dL [1.70-2.25 mmol/L], former smoking status), or normal.	glucose__CRP__no_interaction	CHD__CRP__no_interaction	cholesterol__CRP__no_interaction
19902426-4	As a consequence of the changes we significantly improved the yield of proteomic data, identifying 26 mouse CYPs (<protein-id="P05177">CYP1A2</protein-id>, <compound-id="91623326">2a4</compound-id>, <compound-id="44626338">2a5</compound-id>, 2a12, 2b9, 2c29, 2c37, 2c39, 2c40, 2c50, 2c54, 2c70, <compound-id="6102789">2d9</compound-id>, 2d10, 2d26, <compound-id="6102788">2e1</compound-id>, 2f2, <compound-id="4167622">2j5</compound-id>, 3a11, 3a13, 3a25, 3a41, 4a14, <compound-id="78225217">4f14</compound-id>, 8b1 and 27a1) with an average sequence coverage of 30.1%, including some previously undetected highly homologous isoforms.	2j5__CYP1A2__no_interaction	2e1__CYP1A2__no_interaction	2d9__CYP1A2__no_interaction	4f14__CYP1A2__no_interaction	2a4__CYP1A2__no_interaction	2a5__CYP1A2__no_interaction
15974579-3	Competition binding in cells stably expressing the transfected human <protein-id="P31645,B2R7Y7">SERT</protein-id>, <protein-id="Q01959">dopamine transporter</protein-id> (<protein-id="Q01959">DAT</protein-id>), and <protein-id="P23975,H3BRE9,A0A024R6T9">norepinephrine transporter</protein-id> (<protein-id="P23975,H3BRE9,A0A024R6T9">NET</protein-id>) using [(3)H]<compound-id="2771">citalopram</compound-id>, [(3)H]<compound-id="105056">WIN 35,428</compound-id> or [(125)I]<compound-id="18618996">RTI-55</compound-id>, and [(3)H]<compound-id="4500">nisoxetine</compound-id>, respectively, demonstrated the following order of <protein-id="P31645,B2R7Y7">SERT</protein-id> affinity (K(i) (nM)): <compound-id="657007">14a</compound-id> (0.25) &gt; 16 (0.49) &gt; 20 (0.57) &gt; <compound-id="259834">14b</compound-id> (1.12) &gt; 13 (1.59) &gt; <compound-id="56940697">33b</compound-id> (1.94) = 35 (2.04) &gt;&gt; 23 (8.50) = 28 (8.55) &gt; 41 (15.11) &gt;&gt; 22 (51) &gt; <compound-id="10134160">33a</compound-id> (83.43) &gt; 27 (92).	citalopram__DAT__no_interaction	citalopram__SERT__no_interaction	citalopram__NET__no_interaction	citalopram__norepinephrine transporter__no_interaction	citalopram__dopamine transporter__no_interaction	RTI-55__DAT__no_interaction	RTI-55__SERT__no_interaction	RTI-55__NET__no_interaction	RTI-55__norepinephrine transporter__no_interaction	RTI-55__dopamine transporter__no_interaction	WIN 35,428__DAT__no_interaction	WIN 35,428__SERT__no_interaction	WIN 35,428__NET__no_interaction	WIN 35,428__norepinephrine transporter__no_interaction	WIN 35,428__dopamine transporter__no_interaction	14b__DAT__no_interaction	14b__SERT__no_interaction	14b__NET__no_interaction	14b__norepinephrine transporter__no_interaction	14b__dopamine transporter__no_interaction	14a__DAT__no_interaction	14a__SERT__no_interaction	14a__NET__no_interaction	14a__norepinephrine transporter__no_interaction	14a__dopamine transporter__no_interaction	nisoxetine__DAT__no_interaction	nisoxetine__SERT__no_interaction	nisoxetine__NET__no_interaction	nisoxetine__norepinephrine transporter__no_interaction	nisoxetine__dopamine transporter__no_interaction	33a__DAT__no_interaction	33a__SERT__no_interaction	33a__NET__no_interaction	33a__norepinephrine transporter__no_interaction	33a__dopamine transporter__no_interaction	33b__DAT__no_interaction	33b__SERT__no_interaction	33b__NET__no_interaction	33b__norepinephrine transporter__no_interaction	33b__dopamine transporter__no_interaction
15838260-3	We have made the following observations: (i)<protein-id="P29560">endothelin-1 and 5</protein-id>-hydroxytryptamine produced contraction in the normal Cl- Krebs-Henseleit bicarbonate solution (123 mM Cl-); (ii)inhibition of Na+-K+-2Cl- co-transporter with <compound-id="2471">bumetanide</compound-id> abolished the contractions; (iii) bicarbonate-free solution with <compound-id="23831">HEPES</compound-id> reduced contractions to 5-hydroxytryptamine and <protein-id="P29560">endothelin-1</protein-id>; (iv) substitution of extracellular Cl- with <compound-id="6395">methanesulfonate</compound-id> acid (MS- 113 mM, Cl- 10 mM) enhanced peak contraction to 5-hydroxytryptamine and <protein-id="P29560">endothelin-1</protein-id> and decreased plateau contraction to 5-hydroxytryptamine, but did not affect the plateau contraction to <protein-id="P29560">endothelin-1</protein-id> and KCl; and (v) blockade of Ca2+-dependent Cl- channel with <compound-id="4488">niflumic acid</compound-id> and non-selective Cl- channel with 5-nitro-2-(3-phenylpropylamino) <compound-id="243">benzoic acid</compound-id> and indanyloxyacetic acid-94, R- (+)-methylindazone (R- (+)-<compound-id="656717">IAA-94</compound-id>)decreased contractions to <protein-id="P29560">endothelin-1 and 5</protein-id>-hydroxytryptamine.However, removal of endothelium attenuated the effect of Cl-channel inhibitors.	HEPES__endothelin-1 and 5__no_interaction	HEPES__endothelin-1__no_interaction	niflumic acid__endothelin-1 and 5__no_interaction	niflumic acid__endothelin-1__no_interaction	methanesulfonate__endothelin-1 and 5__no_interaction	methanesulfonate__endothelin-1__no_interaction	benzoic acid__endothelin-1 and 5__no_interaction	benzoic acid__endothelin-1__no_interaction	IAA-94__endothelin-1 and 5__no_interaction	IAA-94__endothelin-1__no_interaction	bumetanide__endothelin-1 and 5__no_interaction	bumetanide__endothelin-1__no_interaction
22046326-2	The purpose of this study was to analyse the association of smoking status and smoking-related phenotypes (included <compound-id="942">nicotine</compound-id> dependence) with 17 candidate genetic variants: CYP2A6*1×2, CYP2A6*2 (1799T&gt;A) [rs1801272], CYP2A6*9 (-<compound-id="70698415">48T</compound-id>&gt;G) [rs28399433], CYP2A6*12, <protein-id="Q16696">CYP2A13</protein-id>*2 (3375C&gt;T) [rs8192789], <protein-id="Q16696">CYP2A13</protein-id>*3 (7520C&gt;G), <protein-id="Q16696">CYP2A13</protein-id>*4 (579G&gt;A), <protein-id="Q16696">CYP2A13</protein-id>*7 (578C&gt;T) [rs72552266], <protein-id="P20813">CYP2B6</protein-id>*4 (785A&gt;G), <protein-id="P20813">CYP2B6</protein-id>*9 (516G&gt;T), <protein-id="P32297">CHRNA3</protein-id> 546C&gt;T [rs578776], <protein-id="P30532,Q6EWN4,H0YM98">CHRNA5</protein-id> 1192G&gt;A [rs16969968], <protein-id="P21554,V5KA96,S5TLS4">CNR1</protein-id> 3764C&gt;G [rs6928499], <protein-id="P14416,A0A024R3C5,A0A024R3I6">DRD2</protein-id>-<protein-id="Q8NFD2">ANKK1</protein-id> 2137G&gt;A (Taq1A) [rs1800497], 5HTT LPR, <protein-id="P28223">HTR2A</protein-id> -1438A&gt;G [rs6311] and <protein-id="P35372,L0E130,G8XRH5,G8XRH4,B8K2Q5">OPRM1</protein-id> 118A&gt;G [rs1799971].	nicotine__CNR1__no_interaction	nicotine__CYP2A13__no_interaction	nicotine__DRD2__no_interaction	nicotine__CYP2B6__no_interaction	nicotine__CHRNA5__no_interaction	nicotine__OPRM1__no_interaction	nicotine__HTR2A__no_interaction	nicotine__CHRNA3__no_interaction	nicotine__ANKK1__no_interaction	48T__CNR1__no_interaction	48T__CYP2A13__no_interaction	48T__DRD2__no_interaction	48T__CYP2B6__no_interaction	48T__CHRNA5__no_interaction	48T__OPRM1__no_interaction	48T__HTR2A__no_interaction	48T__CHRNA3__no_interaction	48T__ANKK1__no_interaction
8567098-5	In addition, the total amounts of <compound-id="6013">testosterone</compound-id> and DHT were correlated with total activity of <protein-id="O43451,E7ER45">alpha-glucosidase</protein-id> (r = 0.49, p &lt; 0.001; r = 0.58, p &lt; 0.01), and gamma-glutamyltransferase (r = 0.49, p &lt; 0.001; r = 0.48, p &lt; 0.001) in seminal plasma.	testosterone__alpha-glucosidase__no_interaction
21059445-6	Adults with DS possessed lower <compound-id="447041">IMT</compound-id> (0.43 ± 0.07 vs 0.48 ± 0.09 mm, p &lt;0.001), systolic blood pressure (116 ± 15 vs 125 ± 17 mm Hg, p &lt;0.011), and diastolic blood pressure (59 ± 10 vs 73 ± 9 mm Hg, p &lt;0.001) and higher <protein-id="P02741">C-reactive protein</protein-id> (0.58 ± 0.55 vs 0.30 ± 0.42 mg/dl, p &lt;0.003), triglycerides (126.5 ± 55.2 vs 103.8 ± 53.2 mg/dl, p &lt;0.048), and total body fat (37.8 ± 10.2% vs 32.4 ± 11.2%, p &lt;0.002) than controls.	IMT__C-reactive protein__no_interaction
15036005-5	Also other <compound-id="54289232">aminophenyl-beta-carboline</compound-id> compounds, such as 9-(4'-amino-3'-methylphenyl)-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[<compound-id="91262462">amino-3'-methylphenylnorharman</compound-id> (3'-AMPNH)], 9-(4'-amino-2'-methylphenyl)-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id> [amino-2'-methylphenylnorharman (2'-AMPNH)], 9-(4'-aminophenyl)-1-methyl-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[<compound-id="90901259">aminophenylharman</compound-id> (APH)] and 9-(4'-amino-3'-methylphenyl)-1-methyl-9H-pyrido[3,4-b]<compound-id="798">indole</compound-id>[amino-3'-methylphenylharman (<protein-id="P49418">AMPH</protein-id>)], have been found on reaction of norharman or <compound-id="5281404">harman</compound-id> with <compound-id="6115">aniline</compound-id> or toluidine isomers.	indole__AMPH__no_interaction	aminophenyl-beta-carboline__AMPH__no_interaction	aminophenylharman__AMPH__no_interaction	harman__AMPH__no_interaction	amino-3'-methylphenylnorharman__AMPH__no_interaction	aniline__AMPH__no_interaction
14763071-13	Patients with <protein-id="P02768">albumin</protein-id> &lt; 4 g/dL showed a lower <compound-id="122634,22833501">tPA</compound-id> ratio, lower <protein-id="P41271,A0A087WTY6">NO3</protein-id>, and a higher <protein-id="P02741">CRP</protein-id>, <protein-id="P01375,Q5STB3">TNF alpha</protein-id>, and Lp(a) than did patients with <protein-id="P02768">albumin</protein-id> &gt; 4 g/dL [<compound-id="122634,22833501">tPA</compound-id> ratio: 2.1 +/- 1.56 (n = 29) vs. 2.6 +/- 2.3 (n = 16), p &lt; 0.05; <protein-id="P41271,A0A087WTY6">NO3</protein-id>: 47 +/- 27 micrograms/mL vs. 69 +/- 33 micrograms/mL, p &lt; 0.05; <protein-id="P02741">CRP</protein-id>: 1.8 +/- 3 mg/dL vs. 1.1 +/- 1.6 mg/dL, p &lt; 0.05; <protein-id="P01375,Q5STB3">TNF alpha</protein-id>: 44.4 +/- 16 pg/mL vs. 36.6 +/- 21.4 pg/mL, p &lt; 0.05; Lp(a): 55 +/- 39 mg/dL vs. 33 +/- 21 mg/dL, p &lt; 0.05].	tPA__CRP__no_interaction	tPA__albumin__no_interaction	tPA__TNF alpha__no_interaction	tPA__NO3__no_interaction
23174241-10	In patients with overactive bladder the nerve growth factor-to-<compound-id="588">creatinine</compound-id> (mean ± SD 488.5 ± 591.8 vs 188.3 ± 290.2, p = 0.005) and <protein-id="P23560,A0A0E3SU01">brain-derived neurotrophic factor</protein-id>-to-<compound-id="588">creatinine</compound-id> (mean 628.1 ± 590.5 vs 110.4 ± 159.5, p &lt;0.001) ratios were significantly higher than in healthy women.	creatinine__brain-derived neurotrophic factor__no_interaction
16512757-6	Nine diallelic polymorphisms (gene and SNP descriptor) were studied in subjects: <protein-id="P16410">cytotoxic T-lymphocyte antigen-4</protein-id> (<protein-id="P16410">CTLA-4</protein-id>, 49 A&gt;G), human <protein-id="P60022">beta-defensin-1</protein-id> (DEFB1, 692 G&gt;A), intercellular adhesion molecule-1 (ICAM-1, 1548 A&gt;G), Fas ligand (fasL, -844 C&gt;T), inducible costimulator (ICOS, 3990 G&gt;T), interleukin-6 (IL-6, -174 G&gt;C), <compound-id="5862,90793998">cysteine</compound-id>-<compound-id="5862,90793998">cysteine</compound-id> chemokine receptor-5 (CCR5, 59653 C&gt;T), osteoprotegerin (OPG, 245 T&gt;G), and osteopontin (OPN, 707 C&gt;T).	cysteine__beta-defensin-1__no_interaction	cysteine__cytotoxic T-lymphocyte antigen-4__no_interaction	cysteine__CTLA-4__no_interaction
22858784-1	Two novel alkynyl-bridged symmetric bis-tridentate ligands 1,2-bis(1'-[4'-(2,2':6',2''-<compound-id="14938971">terpyridinyl</compound-id>)]ferrocenyl)<compound-id="6326">ethyne</compound-id> (<compound-id="2981881,91293124">3a</compound-id>; tpy-Fc-C[triple bond]C-Fc-tpy; Fc = ferrocenyl; tpy = terpyridyl) and 1,4-bis(1'-[4'-(2,2':6',2''-<compound-id="14938971">terpyridinyl</compound-id>)]ferrocenyl)-<compound-id="9997">1,3-butadiyne</compound-id> (3b; tpy-Fc-C[triple bond]C-C[triple bond]C-Fc-tpy) and their <protein-id="Q9UHG0">Ru(2+) complexes 6a and 6b</protein-id> have been synthesized and characterized by cyclic voltammetry, UV-vis and luminescence spectroscopy, and in the case of 3b by single-crystal X-ray diffraction.	ethyne__Ru(2+) complexes 6a and 6b__no_interaction	3a__Ru(2+) complexes 6a and 6b__no_interaction	terpyridinyl__Ru(2+) complexes 6a and 6b__no_interaction	1,3-butadiyne__Ru(2+) complexes 6a and 6b__no_interaction
15679405-2	Here L3- is the deprotonated form of 2,6-<protein-id="O95817">bis</protein-id>[{ {(2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L1), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-methyl-2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L2), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-<compound-id="6360">tert-butyl-</compound-id>2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L3), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-chloro-2-hydroxybenzyl)(N',N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id>(H3L4), 2,6-<protein-id="O95817">bis</protein-id>[{ {(5-bromo-2-hydroxybenzyl)(N'N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}amino}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L5), or 2,6-<protein-id="O95817">bis</protein-id>[{ {(<compound-id="12483497">5-methoxy-2-hydroxybenzyl</compound-id>)(N'N'-(dimethylamino)<compound-id="23134249">ethyl</compound-id>)}methyl]-<compound-id="2879">4-methylphenol</compound-id> (H3L6).	4-methylphenol__bis__no_interaction	tert-butyl-__bis__no_interaction	5-methoxy-2-hydroxybenzyl__bis__no_interaction	ethyl__bis__no_interaction
21347968-4	Following the standard care programme, within-group analyses demonstrated a significant reduction in waist circumference, whereas following the supported exercise programme there were reductions in glycosylated haemoglobin (6.4 vs. 6.0%; P = 0.007), waist circumference (101.4 vs. 97.2 cm; P = 0.021), body mass (91.7 vs. 87.9 kg; P = 0.007), body mass index (30.0 vs. 28.7 kg · m(-2); P = 0.006), total <compound-id="5997">cholesterol</compound-id> (5.3 vs. 4.6 mmol · L(-1); P = 0.046), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (3.2 vs. 2.6 mmol · L(-1); P = 0.028), fasting β-cell responsiveness (11.5 × 10(-9) vs. 7.0 × 10(-9) pmol · kg(-1) · min(-1); P = 0.009), and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (3.0 vs. 2.1; P = 0.049).	cholesterol__insulin__no_interaction
24311446-5	In addition to dissociated cultures, incubation of optic nerves ex vivo with <compound-id="57476835,60961">adenosine</compound-id> and the A3 receptor agonist 2-<compound-id="3035850">CI-IB-MECA</compound-id>(1-[<compound-id="1800613">2-Chloro</compound-id>-6-[[(3-iodophenyl)methyl]amino]-9H-<compound-id="1044">purin</compound-id>-9-yl]-1-deoxy-N-methyl-b-D-<compound-id="53841601">ribofuranuronamide</compound-id>)-induced <protein-id="P55213">caspase-3</protein-id> activation, oligodendrocyte damage, and myelin loss, effects which were prevented by the presence of <compound-id="2519,57106085">caffeine</compound-id> and the A3 receptor antagonist MRS 1220 (N-[9-Chloro-2-(2-furanyl)[1,2,4]-triazolo [1,5-c]quinazolin-5-yl]<compound-id="241">benzene</compound-id> <compound-id="178">acetamide</compound-id>).	benzene__caspase-3__no_interaction	CI-IB-MECA__caspase-3__no_interaction	caffeine__caspase-3__no_interaction	purin__caspase-3__no_interaction	acetamide__caspase-3__no_interaction	adenosine__caspase-3__no_interaction	2-Chloro__caspase-3__no_interaction	ribofuranuronamide__caspase-3__no_interaction
19326849-4	The physiological essence of put forward positions will consist in the following: 1) <compound-id="760">glyoxylate</compound-id> cycle functioning in peroxysomes not only simbyotic microflorae of pre-stomaches (rumen), but also in bodies of ruminants, involves in a metabolism and synthesis of <compound-id="206,5793,64689,79025">glucose</compound-id>, as a product of a rumenal fermentation a <compound-id="612">lactic acid</compound-id> (through piruvate and <compound-id="181,6302">acetyl CoA</compound-id>), and <compound-id="176">acetate</compound-id> of rumenal origin and synthesized in reactions of lipids beta-oxidation; 2) In peroxysomes take place processes of beta-oxidation of fatt acids, which maximum activity in the period of the greatest activity of a metabolism and decrease of mitochondrial beta-oxidation of lipids; 3) one of key metabolites of peroxysomal reactions considers cisteamin, having expressed an antioxidant and radioprotector properties, and being simultaneously the negative endocellular messenger of <protein-id="P01308,I3WAC9">insulin</protein-id>; 4) Two-<compound-id="5462310">carbon</compound-id> fragments of peroxysomal reactions (glycolat and <compound-id="760">glyoxylate</compound-id>) are inhibitors of series reactions in a cells including <compound-id="311,17938267">citrate</compound-id> cycle, terminal oxidation, piruvatdehylrogenase and piruvatcarboxylase and strengthen a stream of metabolites in peroxysomales reactions; 5) formed in significant amounts in peroxysomes <compound-id="17887040">peroxide</compound-id> of <compound-id="783">hydrogen</compound-id>, having <protein-id="P01308,I3WAC9">insulin</protein-id>-like action, influences a number of processes in an organism, including utilisation of <compound-id="206,5793,64689,79025">glucose</compound-id> and synthesis of muscular fibers; 6) the close interrelation between peroxysomes and mitochondria is carried out at a level of coordination of processes making energy, biosynthetic and antioxidant processes.	lactic acid__insulin__no_interaction	acetate__insulin__no_interaction	peroxide__insulin__no_interaction	acetyl CoA__insulin__no_interaction	carbon__insulin__no_interaction	hydrogen__insulin__no_interaction	citrate__insulin__no_interaction	glyoxylate__insulin__no_interaction	glucose__insulin__no_interaction
23601524-6	RESULTS: After 12 weeks raise, among high dosage group, low dosage group, high fat diet group and normal control group, the weight was (32.8 ± 1.5), (40.4 ± 1.9), (40.7 ± 2.1) and (33.5 ± 1.3) g, respectively (F = 55.26, P &lt; 0.05); average food intake was (3.48 ± 0.56), (3.69 ± 0.76), (3.66 ± 0.81) and (3.54 ± 0.61) g/d respectively (F = 0.26, P &gt; 0.05); fasting blood-<compound-id="206,5793,64689,79025">glucose</compound-id> was (5.29 ± 1.59), (6.13 ± 1.75), (7.63 ± 1.09) and (4.24 ± 0.98) mmol/L respectively (F = 9.54, P &lt; 0.01); serum insulin level was (1.97 ± 0.10), (2.44 ± 0.24), (3.02 ± 0.36) and (1.48 ± 0.28) ng/ml respectively (F = 47.58, P &lt; 0.01); the area under blood <compound-id="206,5793,64689,79025">glucose</compound-id> concentration curve was (25.81 ± 1.44), (30.42 ± 2.01), (35.17 ± 1.20) and (21.03 ± 1.24) mmol×L(-1)×h(-1), respectively (F = 64.98, P &lt; 0.05); insulin resistance index was (9.84 ± 3.78), (13.69 ± 4.48), (21.54 ± 3.27) and (5.81 ± 1.59) respectively (F = 30.18, P &lt; 0.01); serum total <compound-id="5997">cholesterol</compound-id> (TC) level was (4.05 ± 0.88), (4.30 ± 0.48), (4.73 ± 0.66) and (3.37 ± 0.40) mmol/L respectively (F = 6.70, P &lt; 0.01); serum triglyceride (TG) level was (0.90 ± 0.09), (0.98 ± 0.09), (1.05 ± 0.06) and (0.76 ± 0.26) mmol/L respectively (F = 6.75, P &lt; 0.01); serum high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) level was (2.91 ± 0.59), (3.34 ± 0.46), (4.89 ± 0.42) and (3.24 ± 0.37) mmol/L respectively (F = 31.73, P &lt; 0.01); serum <protein-id="Q921L5">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q921L5">LDL-C</protein-id>) level was (0.25 ± 0.15), (0.42 ± 0.19), (0.72 ± 0.12) and (0.32 ± 0.11) mmol/L, respectively (F = 17.27, P &lt; 0.01); free fatty acids (FFA) level was (1.06 ± 0.03), (1.05 ± 0.05), (1.18 ± 0.32) and (1.04 ± 0.02) mmol/L, respectively (F = 1.36, P &gt; 0.05); HDL-C/<protein-id="Q921L5">LDL-C</protein-id> was (13.77 ± 5.51), (9.11 ± 3.53), (7.04 ± 1.65) and (11.21 ± 3.31), respectively (F = 5.24, P &lt; 0.01).	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__LDL-C__no_interaction	glucose__low-density lipoprotein cholesterol__no_interaction	glucose__LDL-C__no_interaction
22025778-6	Individuals with <protein-id="P51812,B7ZB17,B4DG22">CLS</protein-id> had greater VAT (3.7 ± 1.3 vs. 2.6 ± 1.6 L; P = 0.04), HFF (9.9 ± 7.3 vs. 5.8 ± 4.4%; P = 0.03), tumor necrosis factor-α (20.8 ± 4.8 vs. 16.2 ± 5.8 pg/mL; P = 0.01), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (20.9 ± 10.6 vs. 9.7 ± 6.6 mU/mL; P &lt; 0.001) and <compound-id="206,5793,64689,79025">glucose</compound-id> (94.4 ± 9.3 vs. 86.8 ± 5.3 mg/dL; P = 0.005), and lower DI (1,559 ± 984 vs. 2,024 ± 829 × 10(-4) min(-1); P = 0.03).	glucose__insulin__no_interaction	glucose__CLS__no_interaction
21215187-7	RESULTS: The concentrations of <compound-id="10918">carnitine</compound-id> (C(0)); short-chain acylcarnitines (SC-AC), including acetyl (C(2)), propionyl (<protein-id="P01024,V9HWA9,B4DR57">C(3</protein-id>)), malonyl (<protein-id="P01024,V9HWA9,B4DR57">C(3</protein-id>)DC), butyryl (C(4)), <compound-id="98735">methylmalonyl</compound-id> (C(4)DC), isovaleryl (C(5)), glutaryl (C(5)DC); middle-chain acylcarnitines (MC-AC), including hexanoyl (C(6)), <compound-id="147023">hexanediol</compound-id> (C(6)DC), octylenoyl (C(8:1)), octanoyl (C(8)), <compound-id="19360862">decadienoyl</compound-id> (C(10:2)), <compound-id="8175">decanoyl</compound-id> (C(10:1)), <compound-id="8175">decanoyl</compound-id> (C(10)); total <compound-id="10918">carnitine</compound-id> and acylcarnitines (TCAC)were lower in neonate, highest in 1-3 months of age, higher in 6-12 months of age, and kept at the same level between 2 and 15 years of age.	decadienoyl__C(3__no_interaction	hexanediol__C(3__no_interaction	carnitine__C(3__no_interaction	methylmalonyl__C(3__no_interaction	decanoyl__C(3__no_interaction
15303129-3	RESULTS: (1) <compound-id="64966">MTT</compound-id> conversion rates were higher in neurons pre and co  treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> than those of neurons with only Mg(2+)-free treatment in neurons cultured for 17 d, but not in neurons cultured for 6 d.(2) [Ca(2+)]i was lower in neurons pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> than those of neurons with only Mg(2+)-free treatment, either in neurons cultured for 6 d or in neurons cultured for 17 d, and the effects of <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> on [Ca(2+)]i change were different between neurons cultured for 6 d and neurons cultured for 17 d.(3) Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> NR1 mRNA expression increase induced by Mg(2+)-free treatment was decreased, either in neurons cultured for 6 d or neurons cultured for 17 d, and this effect showed no difference between neurons cultured for 6 d and 17 d; Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> <protein-id="Q00959">NR2A</protein-id> mRNA expression increase induced by Mg(2+)-free treatment in neurons cultured for 17 d was decreased, and <protein-id="Q00959">NR2A</protein-id> mRNA expression showed no difference between <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> group and age-matched control group, but have no effect on neurons cultured for 6 d; Pre and co-treated with 10 mg/L <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> have <protein-id="Q00960">NR2B</protein-id> mRNA expression increase induced by Mg(2+)-free treatment was not affected, either in neurons cultured for 6 d or neurons cultured for 17 d. CONCLUSION: Neuroprotection of <protein-id="P25086,A0A0H2UHE2">IL-1ra</protein-id> in seizure-induced injury is age-dependent.	MTT__NR2B__no_interaction	MTT__NR2A__no_interaction	MTT__IL-1ra__no_interaction
16857740-3	Here, we report that 1) <compound-id="10404739,104858,3514">GSNO</compound-id> is only one of a class of S-nitrosylating agents that, at low micromolar concentrations, increase DeltaF508 and wild-type CFTR expression and maturation; 2) NO itself (at these concentrations) and <compound-id="104767">8-bromocyclic GMP</compound-id> are minimally active on CFTR; 3) a novel agent, <compound-id="91016544">S-nitrosoglutathione diethyl ester</compound-id>, bypasses the need for <compound-id="10404739,104858,3514">GSNO</compound-id> bioactivation by <compound-id="193305">gamma-glutamyl</compound-id> transpeptidase to increase CFTR maturation; 4) surprisingly, expression-but not S-nitrosylation-of <compound-id="5862,90793998">cysteine</compound-id> string proteins (<protein-id="P53805,Q6FGP2,Q6ZMM3,V9GYW9,E9PDJ2">Csp) 1 and 2</protein-id> is increased by <compound-id="10404739,104858,3514">GSNO</compound-id>; 5) the effect of <compound-id="10404739,104858,3514">GSNO</compound-id> to increase full maturation of wild-type CFTR is inhibited by Csp silencing (si)RNA; 6) proteins relevant to CFTR trafficking are SNO-modified, and SNO proteins traffic through the endoplasmic reticulum (ER) and Golgi after <compound-id="10404739,104858,3514">GSNO</compound-id> exposure; and 7) <compound-id="10404739,104858,3514">GSNO</compound-id> alters the interactions of DeltaF508 CFTR with Csp and <protein-id="P11142,V9HW22,Q53HF2">Hsc70</protein-id> in the ER and Golgi.	S-nitrosoglutathione diethyl ester__Hsc70__no_interaction	S-nitrosoglutathione diethyl ester__Csp) 1 and 2__no_interaction	cysteine__Hsc70__no_interaction	cysteine__Csp) 1 and 2__no_interaction	gamma-glutamyl__Hsc70__no_interaction	gamma-glutamyl__Csp) 1 and 2__no_interaction	8-bromocyclic GMP__Hsc70__no_interaction	8-bromocyclic GMP__Csp) 1 and 2__no_interaction	GSNO__Hsc70__no_interaction	GSNO__Csp) 1 and 2__no_interaction
24444564-4	RESULTS: (1)The expression of mRNA of <protein-id="P40939,E9KL44">LCHAD</protein-id>: the level of mRNA of <protein-id="P40939,E9KL44">LCHAD</protein-id> in NP+DMEM, E-PE+DMEM, E-PE+<compound-id="5884">NADPH</compound-id>-I, E-PE+p38-I, L-PE+DMEM, L-PE+<compound-id="5884">NADPH</compound-id>-I, L-PE+p38-I and HELLP+DMEM, HELLP+<compound-id="5884">NADPH</compound-id>-I, HELLP+p38-I groups were 1.00 ± 0.03, 0.14 ± 0.08, 0.95 ± 0.20, 1.43 ± 1.02, 0.37 ± 0.18, 1.51 ± 0.36, 1.60 ± 0.31, 0.10 ± 0.04, 0.49 ± 0.10, 0.44 ± 0.21, respectively.	NADPH__LCHAD__no_interaction
24444564-7	(2) The expression of protein of <protein-id="P40939,E9KL44">LCHAD</protein-id>: the relative expressions of protein of <protein-id="P40939,E9KL44">LCHAD</protein-id> in NP+DMEM, E-PE+DMEM, E-PE+<compound-id="5884">NADPH</compound-id>-I, E-PE+p38-I, L-PE+DMEM, L-PE+<compound-id="5884">NADPH</compound-id>-I, L-PE+p38-I and HELLP+ DMEM, HELLP+<compound-id="5884">NADPH</compound-id>-I, HELLP+p38-I groups were 19.4 ± 2.2, 10.7 ± 1.1, 17.9 ± 3.3, 19.1 ± 2.9, 16.4 ± 2.3, 20.3 ± 2.3, 20.9 ± 4.3, 12.4 ± 2.3, 17.6 ± 2.6, 17.7 ± 2.0 respectively.	NADPH__LCHAD__no_interaction
10928972-4	The high-affinity GTPase activity was stimulated by the following compounds with a rank order of potency of (2S,2'R,3'R)-2-(2', 3'-dicarboxycyclopropyl) <compound-id="45934207,750">glycine</compound-id> (<compound-id="115114">DCG-IV</compound-id>) &gt; (2S,1'S, 2'S)-2-(carboxycyclopyropyl)<compound-id="45934207,750">glycine</compound-id> (<compound-id="1271">L-CCG-I</compound-id>) &gt; L-<compound-id="611,57109091">glutamate</compound-id> &gt; or = 2R, 4R-<compound-id="3331970">4-aminopyrrolidine-2,4-dicarboxylate</compound-id> [(2R,4R)-<compound-id="65351">APDC</compound-id>] &gt; 1S, 3R-<compound-id="1310">1-aminocyclopentane-1,3-dicarboxylate</compound-id> [(1S,3R)-ACPD] &gt; (S)-<compound-id="1297">4-carboxy-3-hydroxyphenylglycine</compound-id> [(S)-4C3HPG] &gt; (S)-3-carboxy-<compound-id="36143,89853,92143">4-hydroxyphenylglycine</compound-id> [(S)-3C4HPG] &gt; <compound-id="1233">ibotenate</compound-id>, but not by L-(+)-2-amino-4-<compound-id="2773805">phosphonobutyrate</compound-id> (<compound-id="179394">L-AP4</compound-id>), (<compound-id="7021454">RS</compound-id>)-3, 5-<compound-id="5310986">dihydroxyphenylglycine</compound-id> [(<compound-id="7021454">RS</compound-id>)-<compound-id="108001">3,5-DHPG</compound-id>], <compound-id="40539">quisqualate</compound-id>, or L-serine-<compound-id="1061">O-phosphate</compound-id> (<compound-id="68841">L-SOP</compound-id>), indicative of involvement of group II mGluRs, in particular <protein-id="Q14BI2,P23819,G5E8H1,Q4LG64,E9QKC0">mGluR2</protein-id>.	DCG-IV__mGluR2__no_interaction	1-aminocyclopentane-1,3-dicarboxylate__mGluR2__no_interaction	ibotenate__mGluR2__no_interaction	4-aminopyrrolidine-2,4-dicarboxylate__mGluR2__no_interaction	L-SOP__mGluR2__no_interaction	glycine__mGluR2__no_interaction	RS__mGluR2__no_interaction	3,5-DHPG__mGluR2__no_interaction	4-hydroxyphenylglycine__mGluR2__no_interaction	L-AP4__mGluR2__no_interaction	quisqualate__mGluR2__no_interaction	dihydroxyphenylglycine__mGluR2__no_interaction	APDC__mGluR2__no_interaction	O-phosphate__mGluR2__no_interaction	L-CCG-I__mGluR2__no_interaction	phosphonobutyrate__mGluR2__no_interaction	4-carboxy-3-hydroxyphenylglycine__mGluR2__no_interaction	glutamate__mGluR2__no_interaction
15677459-4	By using cell-free biochemical experiments, confocal laser immunofluorescence microscopy, and flow cytometry of tissues and cells from wild-type and knock-out mice, we find that (a) APP and <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> colocalize in perinuclear compartments of neuroblastoma cells, (b) <compound-id="53681531">ascorbate</compound-id>-triggered nitric oxidecatalyzed <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> autodegradation is <compound-id="32051">zinc ion</compound-id>-dependent in the same cells, (c) in cell-free experiments, APP but not <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> stimulates <protein-id="Q9QZF2,Q3U379">glypican-1</protein-id> autodegradation in the presence of both Cu(II) and Zn(II) ions, whereas the Cu(I) form of APP and the Cu(II) and Cu(I) forms of <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> inhibit autodegradation, (d) in primary cortical neurons from APP or <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> knock-out mice, there is an increased <compound-id="145068">nitric oxide</compound-id>-catalyzed degradation of heparan <compound-id="1117">sulfate</compound-id> compared with brain tissue and neurons from wild-type mice, and (e) in growth-quiescent fibroblasts from <protein-id="Q06335,Q60709,Q3UDL6,Q64348,Q61482,Q3TPZ7">APLP2</protein-id> knock-out mice, but not from APP knock-out mice, there is also an increased heparan <compound-id="1117">sulfate</compound-id> degradation.	nitric oxide__APLP2__no_interaction	nitric oxide__glypican-1__no_interaction	zinc ion__APLP2__no_interaction	zinc ion__glypican-1__no_interaction	sulfate__APLP2__no_interaction	sulfate__glypican-1__no_interaction	ascorbate__APLP2__no_interaction	ascorbate__glypican-1__no_interaction
23770842-8	After adjusting for potential confounders, strong associations existed between PN <protein-id="P01308,I3WAC9">insulin</protein-id> requirements and diabetes mellitus (DM) diagnosis (OR, 8.90; 95% CI, 4.98-15.90, P &lt; .001), overweight/obese status (body mass index ≥25.0 kg/m(2)) (OR, 2.12; 95% CI, 1.04-4.30, P = .04), intensive care unit (ICU) admission (OR, 1.79; 95% CI, 1.03-3.11, P = .04), blood <compound-id="206,5793,64689,79025">glucose</compound-id> (BG) on day of PN start &gt;120 mg/dL (OR, 2.32; 95% CI, 1.32-4.05, P = .003), mean BG &gt;180 mg/dL while receiving PN (OR, 6.10; 95% CI, 2.18-17.04, P = .001), and hemoglobin A1c (A1c) ≥5.7% (OR, 3.18; 95% CI, 1.84-5.50, P &lt; .001).	glucose__insulin__no_interaction
16214877-3	Forty-eight hours after the last drug injection, cholinergic receptors were measured by [(125)I]-(+/-)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]<compound-id="8900">heptane</compound-id> ([(125)I]IPH; <compound-id="10176670,105084,11031065,3073763,443366,44592968,854023">epibatidine</compound-id> analog), (125)I-<compound-id="44264212">alpha-bungarotoxin</compound-id> ((125)I-<protein-id="Q05941,Q5UMH9">BTX</protein-id>), [(3)H]<compound-id="4848">pirenzepine</compound-id> ([(3)H]<compound-id="32594">PRZ</compound-id>), and [(3)H]-5,11-dihydro-11-[((2-(2-((dipropylamino)methyl)-1-piperidinyl)<compound-id="23134249">ethyl</compound-id>)amino)carbonyl]-6H-pyrido(2,3-b)(1,4)-<compound-id="22114368">benzodiazepin-6-one</compound-id> <compound-id="6395">methanesulfonate</compound-id> ([(3)H]AFDX-384, or [(3)H]<compound-id="51346193">AFX</compound-id>) autoradiography.	epibatidine__BTX__no_interaction	methanesulfonate__BTX__no_interaction	AFX__BTX__no_interaction	alpha-bungarotoxin__BTX__no_interaction	benzodiazepin-6-one__BTX__no_interaction	pirenzepine__BTX__no_interaction	PRZ__BTX__no_interaction	heptane__BTX__no_interaction	ethyl__BTX__no_interaction
12625872-3	<compound-id="54090624">Phenoxypropanolamine</compound-id> derivatives, SWR-0334NA (([E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl] phenoxy]<compound-id="176">acetic acid</compound-id> <compound-id="5360545">sodium</compound-id> salt), SWR-0335SA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl] phenoxy] <compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>), SWR-0342SA (S-(Z)-[4-[[1-[2-[(2-<compound-id="19871799">hydroxy-3-phenoxypropyl</compound-id>)]amino] <compound-id="23134249">ethyl</compound-id>]-1-propenyl]phenoxy] <compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>), SWR-0348SA-SITA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-<compound-id="57417590">hexene-3-yl</compound-id>] phenoxy]<compound-id="176">acetic acid</compound-id> <compound-id="971">ethanedioic acid</compound-id>) and SWR-0361SA ((E)-N-methyl[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-<compound-id="12585,5326160">2-pentene</compound-id>-3-yl]phenoxy]<compound-id="178">acetoamide</compound-id> <compound-id="971">ethanedioic acid</compound-id>) showed higher agonistic activity for the <protein-id="P13945,A8KAG8">Beta(3)-adrenoceptor</protein-id>.	hexene-3-yl__Beta(3)-adrenoceptor__no_interaction	hydroxy-3-phenoxypropyl__Beta(3)-adrenoceptor__no_interaction	Phenoxypropanolamine__Beta(3)-adrenoceptor__no_interaction	sodium__Beta(3)-adrenoceptor__no_interaction	ethanedioic acid__Beta(3)-adrenoceptor__no_interaction	2-pentene__Beta(3)-adrenoceptor__no_interaction	acetoamide__Beta(3)-adrenoceptor__no_interaction	acetic acid__Beta(3)-adrenoceptor__no_interaction	ethyl__Beta(3)-adrenoceptor__no_interaction
15112172-6	In a univariate analysis, age, central venous pressure (CVP), and serum <compound-id="588">creatinine</compound-id> and blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> levels were greater (P = 0.003, P = 0.006, P &lt; 0.001, and P &lt; 0.001, respectively), whereas mean arterial and diastolic blood pressures, 24-hour urinary output, arterial pH, <compound-id="767">bicarbonate</compound-id> level, thrombocyte count, <protein-id="P02768">albumin</protein-id> level, and <protein-id="P00734">prothrombin</protein-id> time were lower (P = 0.05, P = 0.004, P = 0.005, P = 0.03, P = 0.009, P = 0.037, P = 0.05, and P = 0.006, respectively) in the ARF group.	creatinine__albumin__no_interaction	creatinine__prothrombin__no_interaction	urea__albumin__no_interaction	urea__prothrombin__no_interaction	nitrogen__albumin__no_interaction	nitrogen__prothrombin__no_interaction	bicarbonate__albumin__no_interaction	bicarbonate__prothrombin__no_interaction
15454392-3	Diabetes was associated with an increase in urine albumin excretion (UAE; ND, 0.39 +/- 0.03; D, 5.9 +/- 0.8 mg/day; P &lt; 0.001), decrease in <compound-id="588">creatinine</compound-id> clearance (CrCl; ND, 0.69 +/- 0.03; D, 0.43 +/- 0.09 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x 100 g body wt(-1); P &lt; 0.05), increase in the index of glomerulosclerosis [GSI; ND, 0.01 +/- 0.01; D, 0.15 +/- 0.04 arbitrary units (AU); P &lt; 0.01], tubulointerstitial fibrosis (TIFI; ND, 0.04 +/- 0.04; D, 0.68 +/- 0.2 AU; P &lt; 0.01), and transforming growth factor-beta (TGF-beta) protein expression (ND, 0.61 +/- 0.02; D, 1.25 +/- 0.07 AU; P &lt; 0.01).	creatinine__min(-1__no_interaction
23455029-1	Four heteropoly blue complexes constructed from Keggin-type heteropoly blue <compound-id="23932">molybdenum</compound-id>-<compound-id="23964">tungsten</compound-id> clusters and Cu(II) ions as linkers, <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(PDA)2·H2O]2 (1), <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(<protein-id="Q68CQ4">DEF</protein-id>)3·H2O][Cu(<protein-id="Q68CQ4">DEF</protein-id>)2·2H2O]·6H2O (2), <compound-id="783">H2</compound-id>[α-SiW10Mo(V)2O40][Cu(DMF)3H2O]2·6H2O (3), and H4[α-SiW10Mo(V)2O40]2[CuK2(DMF)6][Na0.75K3.25(DMF)6] (4) [PDA = <compound-id="7911">propanediamide</compound-id>, <protein-id="Q68CQ4">DEF</protein-id> = <compound-id="12051">N,N-diethylformamide</compound-id> and DMF = N,N-dimethylformamide], have been synthesized by conventional reactions and characterized by single-crystal X-ray diffraction, elemental analysis, IR spectroscopy, thermogravimetry, X-ray powder diffraction (XRD) and UV spectra.	tungsten__DEF__no_interaction	H2__DEF__no_interaction	N,N-diethylformamide__DEF__no_interaction	propanediamide__DEF__no_interaction	molybdenum__DEF__no_interaction
17023528-4	The results were as follows: 1) treatment with estrogen increased phosphorylation and MgATPase activity and decreased NMM-II-B filamentation; 2) estrogen effects could be blocked by antisense nucleotides for the <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor-alpha</protein-id> and by ICI-182,780, <compound-id="2733526">tamoxifen</compound-id>, and the casein kinase-II (CK2) inhibitor, 5,6-dichloro-1-beta-(D)-<compound-id="24898154">ribofuranosylbenzimidazole</compound-id> and attenuated by <compound-id="2051">AG1478</compound-id> and <compound-id="4713">PD98059</compound-id> (inhibitors of epithelial growth factor receptor and ERK/MAPK) but not <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> [blocker of protein kinase C (PKC)]; 3) treatments with the PKC activator sn-1,2-dioctanoyl diglyceride induced biphasic effect on NMM-II-B MgATPase activity: an increase at 1 nm to 1 microM and a decrease in activity at more than 1 microM; 4) sn-1,2-dioctanoyl diglyceride also decreased NMM-II-B filamentation in a monophasic and saturable dose dependence (EC(50) 1-10 microM); 5) when coincubated directly with purified NMM-II-B filaments, both CK2 and PKC decreased filamentation and increased MgATPase activity; 6) assays done on disassembled NMM-II-B filaments showed MgATPase activity in filaments obtained from estrogen-treated cells but not estrogen-depleted cells; and 7) incubations in vitro with CK2, but not PKC, facilitated MgATPase activity, even in disassembled NMM-II-B filaments.	PD98059__estrogen receptor-alpha__no_interaction	tamoxifen__estrogen receptor-alpha__no_interaction	staurosporine__estrogen receptor-alpha__no_interaction	AG1478__estrogen receptor-alpha__no_interaction	ribofuranosylbenzimidazole__estrogen receptor-alpha__no_interaction
16182977-5	The plasma <protein-id="P01185,X5DQP6">vasopressin</protein-id> level at baseline was significantly lower for those who finally developed septic shock (septic shock group, 3.6 +/- 2.5 pg/mL; 95% confidence interval [CI], 3.0-4.2 pg/mL; severe sepsis group, 21.8 +/- 4.1 pg/mL, 95% CI, 20.7-22.9 pg/mL; sepsis group, 10.6 +/- 6.5 pg/mL, 95% CI, 8.8-12.4 pg/mL, P &lt; .001), whereas the <compound-id="439260">norepinephrine</compound-id> level was highest for the same group (septic shock group, 3650 +/- 980 pg/mL, 95% CI, 3420-3880 pg/mL; severe sepsis group, 3600 +/- 1000 pg/mL, 95% CI, 3330-3870 pg/mL; sepsis group, 1720 +/- 320 pg/mL, 95% CI, 1630-1810 pg/mL).	norepinephrine__vasopressin__no_interaction
9323928-6	Likewise, peak and average plasma TNF, serum <protein-id="Q8SPS7,K7GKE7">haptoglobin</protein-id>, and serum <compound-id="23994">zinc</compound-id> were correlated indicating a prolonged stress or pathogenic insult (r = 0.89, P &lt; 0.0001 for TNF; r = 0.67, P = 0.01 for <protein-id="Q8SPS7,K7GKE7">haptoglobin</protein-id>; r = 0.73, P = 0.005 for <compound-id="23994">zinc</compound-id>).	zinc__haptoglobin__no_interaction
21934202-9	Patients in group I, compared with group II, were older (35.5 ± 10.5 vs 27.9 ± 14.0 years, P &lt; 0.01), predominantly male (M: F, 10.8: 1 vs 4.8: 1, P = 0.035), obese (75.0% vs 23.4%, P P &lt; 0.01), with higher triglycerides (138.8 ± 62.1 vs 88.0 ± 27.9, P = 0.02), with higher <compound-id="5997">cholesterol</compound-id> (171.9 ± 43.5 vs 139.3 ± 37.6, P = 0.017), and with higher serum <protein-id="P01308,I3WAC9">insulin</protein-id> (13.1 ± 9.1 vs 9.1 ± 6.0, P &lt; .027) levels.	cholesterol__insulin__no_interaction
7542815-7	There were no significant differences in pre- vs. post-<compound-id="445643">FK506</compound-id> treatment values of plasma <compound-id="206,5793,64689,79025">glucose</compound-id> during the hyperglycemic clamp mean acute <protein-id="P01308,I3WAC9">insulin</protein-id> response to <compound-id="206,5793,64689,79025">glucose</compound-id> (AIRG) 164 +/- 38 pmol/L vs. 148 +/- 46 pmol/L (P &gt; 0.1); mean incremental area under the <protein-id="P01308,I3WAC9">insulin</protein-id> curve (IAUC) during the first 10 min of the study, 473 +/- 109 pmol/L vs. 443 +/- 146 pmol/L (P &gt; 0.1); total area under the <protein-id="P01308,I3WAC9">insulin</protein-id> curve (TAUC) during the first 10 min of the study, 786 +/- 152 pmol/L vs. 781 +/- 18 pmol/L (P &gt; 0.1); mean <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rate (<compound-id="65911">GIR</compound-id>) 37.7 +/- 5.0 mumol/kg/min vs. 33.3 +/- 4.4 mumol/kg/min (P &gt; 0.1); or mean <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity index (ISI), 3.05 +/- 0.4 vs. 3.13 +/- 0.5 (P &gt; 0.1).	FK506__insulin__no_interaction	GIR__insulin__no_interaction	glucose__insulin__no_interaction
22419314-17	There was evidence of a positive effect of <protein-id="P06276,D3DNN4">Cholinesterase</protein-id> inhibitors on the Mini-Mental State Examination (MMSE) in patients with <compound-id="16219908,452543,452544,537379,71308620">PDD</compound-id> (WMD 1.09, 95% CI 0.45 to 1.73, P = 0.0008) and in the single <compound-id="16219908,452543,452544,537379,71308620">PDD</compound-id> and CIND-PD trial (WMD 1.05, 95% CI 0.42 to 1.68, P = 0.01) but not in the single DLB trial.For behavioural disturbance, analysis of the pooled continuous data relating to behavioural disturbance rating scales favoured treatment with <protein-id="P06276,D3DNN4">Cholinesterase</protein-id> inhibitors (SMD -0.20, 95% CI -0.36 to -0.04, P = 0.01).For activities of daily living, combined data for the ADCS and the Unified Parkinson's Disease Rating Scale (UPDRS) activities of daily living rating scales favoured treatment with <protein-id="P06276,D3DNN4">Cholinesterase</protein-id> inhibitors (SMD -0.20, 95% CI -0.38 to -0.02, P = 0.03).For safety and tolerability, those taking a <protein-id="P06276,D3DNN4">Cholinesterase</protein-id> inhibitor were more likely to experience an adverse event (318/452 versus 668/842; odds ratio (OR) 1.64, 95% CI 1.26 to 2.15, P = 0.0003) and to drop out (128/465 versus 45/279; OR 1.94, 95% CI 1.33 to 2.84, P = 0.0006).	PDD__Cholinesterase__no_interaction
8612422-12	Twenty-four hours after decannulation, ventilator settings and arterial blood <protein-id="Q9BTK6">gas</protein-id> measurements were as follows: FIO2 0.42 +/- 0.14, <compound-id="51049645">IMV</compound-id> 27.4 +/- 13.5 breaths/min, positive end-expiratory pressure 5.2 +/- 1.6 cm H2O, mean airway pressure 12.0 +/- 3.4 cm H2O, peak inspiratory pressure 31.1 +/- 6.5 cm H2O, PaO2 77.0 +/- 16.9 torr (10.3 +/- 2.3 kPa), PaCO2 44.9 +/- 8.4 torr (6.0 +/- 1.1 kPa), and pH 7.40 +/- 0.07.	IMV__gas__no_interaction
8855783-9	In the subjects with untreated primary hyperparathyroidism, serum levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> correlated strongly with those of intact <protein-id="P01270">PTH</protein-id> (r = 0.47, P = 0.003) and biochemical markers of bone resorption: serum <compound-id="3034763">deoxypyridinoline</compound-id> (r = 0.93, P &lt; 0.001), serum type I collagen carboxyterminal telopeptide (r = 0.87, P &lt; 0.001), urinary pyridinoline (r = 0.81, P &lt; 0.001), and urinary <compound-id="3034763">deoxypyridinoline</compound-id> (r = 0.63, P = 0.005).	deoxypyridinoline__interleukin-6__no_interaction	deoxypyridinoline__PTH__no_interaction
8855783-10	Levels of <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> correlated less strongly with the same variables: <protein-id="P01270">PTH</protein-id> (r = 0.41, P = 0.01), serum <compound-id="3034763">deoxypyridinoline</compound-id> (r = 0.48, P = 0.002), serum type I collagen carboxyterminal telopeptide (r = 0.46, P = 0.004), urinary pyridinoline (r = 0.61, P = 0.008), and urinary <compound-id="3034763">deoxypyridinoline</compound-id> (r = 0.61, P = 0.007).	deoxypyridinoline__tumor necrosis factor-alpha__no_interaction	deoxypyridinoline__PTH__no_interaction
22204062-3	The median plasma biochemistry values were as follows: hematocrit = 21%, <compound-id="588">creatinine</compound-id> kinase = 2,100 U/L, <compound-id="612">lactate</compound-id> dehydrogenase = 97 U/L, <compound-id="5960">aspartate</compound-id> aminotransferase = 88 U/L, <compound-id="602">alanine</compound-id> aminotransferase = 51 U/L, alkaline phosphatase 3,939 U/L, gamma-<compound-id="129297">glutamyl</compound-id> transpeptidase = 1 U/L, amylase = 40 U/L, blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> = &lt; 11 mg/dl, <compound-id="206,5793,64689,79025">glucose</compound-id> = 21 mg/dl, <compound-id="22044544,5460341">calcium</compound-id> = 12.5 mg/dl, triglyceride = 206 mg/dl, <compound-id="588">creatinine</compound-id> = 0.1 mg/dl, <compound-id="5997">cholesterol</compound-id> = 334 mg/dl, total <compound-id="5280352">bilirubin</compound-id> = &lt; 0.1 mg/dl, phosphorus = 6.5 mg/dl, total protein = 4.2 g/dl, <protein-id="P02768">albumin</protein-id> = 1.5 g/dl, globulin = 2.7 g/dl, <protein-id="P02768">albumin</protein-id>/ globulin ratio = 0.6, <compound-id="5360545">sodium</compound-id> = 185 mmol/L, <compound-id="5462222">potassium</compound-id> = 3.7 mmol/L, and <compound-id="312">chloride</compound-id> = 175 mmol/L.	urea__albumin__no_interaction	sodium__albumin__no_interaction	bilirubin__albumin__no_interaction	potassium__albumin__no_interaction	cholesterol__albumin__no_interaction	calcium__albumin__no_interaction	glutamyl__albumin__no_interaction	alanine__albumin__no_interaction	aspartate__albumin__no_interaction	nitrogen__albumin__no_interaction	lactate__albumin__no_interaction	creatinine__albumin__no_interaction	chloride__albumin__no_interaction	glucose__albumin__no_interaction
17187127-9	There was a significant reduction of the hormonal level in the animals that received <compound-id="4168">metoclopramide</compound-id> as compared to controls (<protein-id="Q8K211">CTR1</protein-id>: <compound-id="5757">estradiol</compound-id> = 156.6 +/- 42.2 pg/ml; <compound-id="5994">progesterone</compound-id> = 39.4 +/- 5.1 ng/ml; <protein-id="Q3TT66,Q9CPQ2">prolactin</protein-id> = 130.4 +/- 26.2 ng/ml; <protein-id="P13864,Q3UWN4,Q3UHZ3,J3QNW0">MET1</protein-id>: <compound-id="5757">estradiol</compound-id> = 108.0 +/- 33.1 pg/ml; <compound-id="5994">progesterone</compound-id> = 28.0 +/- 6.4 ng/ml; <protein-id="Q3TT66,Q9CPQ2">prolactin</protein-id> = 551.5 +/- 23.3 ng/ml; <protein-id="Q9CPU9,Q4KL43,Q9D524">CTR2</protein-id>: <compound-id="5757">estradiol</compound-id> = 354.0 +/- 56.0 pg/ml; <compound-id="5994">progesterone</compound-id> = 251.0 +/- 56.0 ng/ml; <protein-id="Q3TT66,Q9CPQ2">prolactin</protein-id> = 423.2 +/- 28.1 ng/ml; MET2: <compound-id="5757">estradiol</compound-id> = 293.0 +/- 43.0 pg/ml; <compound-id="5994">progesterone</compound-id> = 184.0 +/- 33.0 ng/ml; <protein-id="Q3TT66,Q9CPQ2">prolactin</protein-id> = 823.1 +/- 51.1 ng/ml).	progesterone__prolactin__no_interaction	progesterone__CTR1__no_interaction	progesterone__MET1__no_interaction	progesterone__CTR2__no_interaction	estradiol__prolactin__no_interaction	estradiol__CTR1__no_interaction	estradiol__MET1__no_interaction	estradiol__CTR2__no_interaction	metoclopramide__prolactin__no_interaction	metoclopramide__CTR1__no_interaction	metoclopramide__MET1__no_interaction	metoclopramide__CTR2__no_interaction
21141840-4	Analogously, the addition of <protein-id="P06733,A0A024R4F1,E2DRY6">PPh(2)Et</protein-id>, CO or <compound-id="1049">pyridine</compound-id> to 2 affords the 46e complexes of general formula [(L)(C(6)F(5))(2)Pt(2)(μ-P(2)Ph(2))Pd(μ-PPh(2))(μ-Ph(2)P(4)-P(3)Ph(2))Pt(1)(C(6)F(5))(2)] (L = <protein-id="P06733,A0A024R4F1,E2DRY6">PPh(2)Et</protein-id>, 4; L = CO, 6; L = <compound-id="1049">pyridine</compound-id>, 7).	pyridine__PPh(2)Et__no_interaction
20127289-7	RESULTS: Among the variables included to the stepwise regression analysis, plasma high-density lipoprotein (HDL)-<compound-id="5997">cholesterol</compound-id> (r = 0.38; p = 0.0004) and total <compound-id="5997">cholesterol</compound-id> (r = 0.16; p = 0.0541) levels were the only two (out of 12) independent variables retained as predictive of <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> omental AT mRNA levels, whereas BMI (r = 0.35; p = 0.0039), plasma HDL-<compound-id="5997">cholesterol</compound-id> concentrations (r = -0.31; p = 0.0375), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> omental AT mRNA levels (r = 0.19; p = 0.0532) and <protein-id="P05121,A0A024QYT5">PAI-1</protein-id>-844G/A (p = 0.0023), and rs6092 (p.A15T; p = 0.0358) polymorphisms contributed independently to plasma <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> concentrations.	cholesterol__PAI-1__no_interaction
24469870-5	There were no differences between both groups in the mean values of the <protein-id="P16233">PTL</protein-id> tests measured 30 days after PCI (PUFA vs. C ASPI: 18.5 ± 17 vs. 27 ± 29 U, COL: 30.4 ± 14.3 vs. 30.3 ± 13.4 U, <compound-id="6022">ADP</compound-id>: 25.4 ± 16.1 vs. 20 ± 10.7 U, TRAP: 65.8 ± 25.6 vs. 57.1 ± 20.4 U, p = NS).	ADP__PTL__no_interaction
19967103-1	[<compound-id="91066389">Methoxy-</compound-id>11c]PD-153035; <compound-id="16197727">Afamelanotide</compound-id>, Agalsidase beta, Alemtuzumab, Alkaline phosphatase, <compound-id="2162">Amlodipine</compound-id>, <compound-id="111332">Anecortave</compound-id> <compound-id="176">acetate</compound-id>, <compound-id="10182969">Apixaban</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, <compound-id="54841">Atomoxetine</compound-id> hydrochloride; Bevacizumab, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, Botulinum toxin type B, <compound-id="11387895">Brimonidine tartrate/timolol maleate</compound-id>, <compound-id="446727">Brivudine</compound-id>; Canakinumab, Cetuximab, <compound-id="86278273">Chlorotoxin</compound-id>, <compound-id="9808022">Cinaciguat</compound-id>; <compound-id="9887712">Dapagliflozin</compound-id>, <compound-id="451668">Decitabine</compound-id>, <compound-id="60835">Duloxetine hydrochloride</compound-id>; <compound-id="11250647">Elagolix sodium</compound-id>, <compound-id="443872">Eplerenone</compound-id>, <compound-id="6912404">Eritoran</compound-id> <compound-id="21226136">tetrasodium</compound-id>, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="123619">Etoricoxib</compound-id>, <compound-id="150311">Ezetimibe</compound-id>; <compound-id="3038498">Fospropofol disodium</compound-id>; G-207, <compound-id="9883933">Gabapentin enacarbil</compound-id>, <compound-id="123631">Gefitinib</compound-id>, Golimumab; Human plasmin; Inotuzumab <compound-id="9942071">ozogamicin</compound-id>, <protein-id="P01308,I3WAC9">Insulin</protein-id> glargine, <protein-id="P01308,I3WAC9">Insulin</protein-id> glulisine, <compound-id="9841834">Istaroxime</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; KLH; <compound-id="6047">Levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>; <compound-id="51634">Miglustat</compound-id>, Mitumprotimut-T, MP-470; <compound-id="71587613">Oblimersen sodium</compound-id>, <compound-id="130881">Olmesartan medoxomil</compound-id>; <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">P53</protein-id>-SLP, <compound-id="9571836">PAN-811</compound-id>, <compound-id="448013">Patupilone</compound-id>, <compound-id="10113978">Pazopanib</compound-id> hydrochloride, PC-515, Peginterferon alfa-2a, Pegylated <compound-id="6322,90867653">arginine</compound-id> deiminase 20000, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, <compound-id="44152164,56928089,9812534">Plitidepsin</compound-id>, <compound-id="5486971">Pregabalin</compound-id>; <compound-id="3052776">Rasagiline</compound-id> mesilate, <compound-id="59227">Rotigotine</compound-id>; SCH-697243, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting stent, <compound-id="5358">Sumatriptan succinate</compound-id>/<compound-id="156391">naproxen sodium</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, Tapentadol hydrochloride, <compound-id="5388906">TMC-207</compound-id>; V-211, <compound-id="64147">Valganciclovir hydrochloride</compound-id>; <compound-id="18004026,24720996,57487">Zolpidem tartrate</compound-id>.	Fospropofol disodium__Insulin__no_interaction	Fospropofol disodium__P53__no_interaction	Gabapentin enacarbil__Insulin__no_interaction	Gabapentin enacarbil__P53__no_interaction	tetrasodium__Insulin__no_interaction	tetrasodium__P53__no_interaction	acetate__Insulin__no_interaction	acetate__P53__no_interaction	Sirolimus__Insulin__no_interaction	Sirolimus__P53__no_interaction	Miglustat__Insulin__no_interaction	Miglustat__P53__no_interaction	Valganciclovir hydrochloride__Insulin__no_interaction	Valganciclovir hydrochloride__P53__no_interaction	Rotigotine__Insulin__no_interaction	Rotigotine__P53__no_interaction	PAN-811__Insulin__no_interaction	PAN-811__P53__no_interaction	Chlorotoxin__Insulin__no_interaction	Chlorotoxin__P53__no_interaction	Brimonidine tartrate/timolol maleate__Insulin__no_interaction	Brimonidine tartrate/timolol maleate__P53__no_interaction	Methoxy-__Insulin__no_interaction	Methoxy-__P53__no_interaction	Duloxetine hydrochloride__Insulin__no_interaction	Duloxetine hydrochloride__P53__no_interaction	Pregabalin__Insulin__no_interaction	Pregabalin__P53__no_interaction	Anecortave__Insulin__no_interaction	Anecortave__P53__no_interaction	Sunitinib malate__Insulin__no_interaction	Sunitinib malate__P53__no_interaction	Apixaban__Insulin__no_interaction	Apixaban__P53__no_interaction	Gefitinib__Insulin__no_interaction	Gefitinib__P53__no_interaction	TMC-207__Insulin__no_interaction	TMC-207__P53__no_interaction	Ezetimibe__Insulin__no_interaction	Ezetimibe__P53__no_interaction	Amlodipine__Insulin__no_interaction	Amlodipine__P53__no_interaction	Ixabepilone__Insulin__no_interaction	Ixabepilone__P53__no_interaction	Plitidepsin__Insulin__no_interaction	Plitidepsin__P53__no_interaction	Rasagiline__Insulin__no_interaction	Rasagiline__P53__no_interaction	Pemetrexed disodium__Insulin__no_interaction	Pemetrexed disodium__P53__no_interaction	Istaroxime__Insulin__no_interaction	Istaroxime__P53__no_interaction	Cinaciguat__Insulin__no_interaction	Cinaciguat__P53__no_interaction	Zolpidem tartrate__Insulin__no_interaction	Zolpidem tartrate__P53__no_interaction	Eritoran__Insulin__no_interaction	Eritoran__P53__no_interaction	Atomoxetine__Insulin__no_interaction	Atomoxetine__P53__no_interaction	Elagolix sodium__Insulin__no_interaction	Elagolix sodium__P53__no_interaction	Patupilone__Insulin__no_interaction	Patupilone__P53__no_interaction	Levodopa__Insulin__no_interaction	Levodopa__P53__no_interaction	Oblimersen sodium__Insulin__no_interaction	Oblimersen sodium__P53__no_interaction	Afamelanotide__Insulin__no_interaction	Afamelanotide__P53__no_interaction	Aripiprazole__Insulin__no_interaction	Aripiprazole__P53__no_interaction	Brivudine__Insulin__no_interaction	Brivudine__P53__no_interaction	Decitabine__Insulin__no_interaction	Decitabine__P53__no_interaction	naproxen sodium__Insulin__no_interaction	naproxen sodium__P53__no_interaction	Dapagliflozin__Insulin__no_interaction	Dapagliflozin__P53__no_interaction	Escitalopram oxalate__Insulin__no_interaction	Escitalopram oxalate__P53__no_interaction	Eplerenone__Insulin__no_interaction	Eplerenone__P53__no_interaction	Bortezomib__Insulin__no_interaction	Bortezomib__P53__no_interaction	Olmesartan medoxomil__Insulin__no_interaction	Olmesartan medoxomil__P53__no_interaction	Sumatriptan succinate__Insulin__no_interaction	Sumatriptan succinate__P53__no_interaction	Bosentan__Insulin__no_interaction	Bosentan__P53__no_interaction	ozogamicin__Insulin__no_interaction	ozogamicin__P53__no_interaction	arginine__Insulin__no_interaction	arginine__P53__no_interaction	Etoricoxib__Insulin__no_interaction	Etoricoxib__P53__no_interaction	Tadalafil__Insulin__no_interaction	Tadalafil__P53__no_interaction	entacapone__Insulin__no_interaction	entacapone__P53__no_interaction	Pazopanib__Insulin__no_interaction	Pazopanib__P53__no_interaction
12368510-3	Platelet activation was less following <protein-id="Q9Y3T9">NIR</protein-id> implantation as indicated by reduced aggregation to 5  mol <compound-id="6022">adenosine diphosphate</compound-id> at 30 days (32.3   6.1% versus 94.5   18.9%; p = 0.02) and reduced expression of multiple surface markers (log mean fluorescence intensity): at 2 hours, CD 107a (22   13 versus 18   5; p = 0.045); at 24 hours, <protein-id="P16284,A0A075B738">CD 31</protein-id> (136   48 versus 110   48; p = 0.04), CD 151 (104   45 versus 91   31; p = 0.048), platelet leukocyte aggregates (95   40 versus 77   24; p = 0.018), and CD 107a (24   12 versus 17   4; p = 0.03); and at 30 days, CD 151 (99   33 versus 81   32; p = 0.03), platelet leukocyte aggregates (84   35 versus 72   31; p = 0.045) and <protein-id="P41586,A0A090N8F8">PAC-1</protein-id> (88   91 versus 72   30; p = 0.025).	adenosine diphosphate__NIR__no_interaction	adenosine diphosphate__PAC-1__no_interaction	adenosine diphosphate__CD 31__no_interaction
21762298-6	The risk factors associated with GC included older age (69 years vs. 57 years; P= 0.001), diabetes (19% vs. 10%; P= 0.049), temperature of &gt;38 °C (36% vs. 16%; P &lt; 0.001), tachycardia (31% vs. 15%; P= 0.002), detection of muscle rigidity on examination (27% vs. 12%; P= 0.01) and greater elevations in white cell count (<compound-id="6411762">WCC</compound-id>) (13.4 × 10⁹/l vs. 10.7 × 10⁹/l; P &lt; 0.001), <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (94 mg/l vs. 17 mg/l; P= 0.001), <compound-id="5280352">bilirubin</compound-id> (19 µmol/l vs. 17 µmol/l; P= 0.029), <compound-id="1176">urea</compound-id> (5.3 mmol/l vs. 4.7 mmol/l; P= 0.016) and <compound-id="588">creatinine</compound-id> (82 µmol/l vs. 74 µmol/l; P= 0.001).	bilirubin__C-reactive protein__no_interaction	bilirubin__CRP__no_interaction	WCC__C-reactive protein__no_interaction	WCC__CRP__no_interaction	urea__C-reactive protein__no_interaction	urea__CRP__no_interaction	creatinine__C-reactive protein__no_interaction	creatinine__CRP__no_interaction
15738009-10	Data are as follows (mean +/- standard error of the mean): <protein-id="P01178,X5D7M6">oxytocin</protein-id> dose-<compound-id="5280360">dinoprostone</compound-id> 10,929 +/- 219 mU, <compound-id="5282381">misoprostol</compound-id> 6,081 +/- 170 mU, P = .008; <protein-id="P01178,X5D7M6">oxytocin</protein-id> time-<compound-id="5280360">dinoprostone</compound-id> 798 +/- 11 minutes, <compound-id="5282381">misoprostol</compound-id> 531 +/- 11 minutes, P = .009; dose intensity-<compound-id="5280360">dinoprostone</compound-id> 11.3 +/- 0.1 mU/min, <compound-id="5282381">misoprostol</compound-id> 7.4 +/- 0.2 mU/min, P = .003.	dinoprostone__oxytocin__no_interaction	misoprostol__oxytocin__no_interaction
11181914-3	The results showed that 1) the chimeric SMA41 could degrade in serum-containing medium (t(1/2) of approximately 30 min) to generate, as predicted, the free inhibitor SMA52 as the most abundant metabolite (approximately 81% yield); 2) in contrast to SMA52 alone, the chimeric SMA41 and TEM induced significant DNA damage in A431 cells after 30-min or 2-h drug exposures, as confirmed by alkaline single-cell gel microelectrophoresis (comet) assay; 3) SMA41 showed 5-fold greater affinity for the <compound-id="5957">ATP</compound-id> binding site of <protein-id="P00533">EGFR</protein-id> than independently synthesized SMA52 in an enzyme assay and blocked EGF-induced <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation and <protein-id="P00533">EGFR</protein-id> autophosphorylation in A431 cells in a dose-dependent manner; 4) these mixed targeting properties of SMA41, combined with its ability to be converted to another potent <protein-id="P00533">EGFR</protein-id> TK inhibitor (e.g., SMA52) by hydrolytic cleavage, translated into over 8-fold greater antiproliferative activity than TEM, which showed no <protein-id="P00533">EGFR</protein-id> targeting properties (IC(50) competitive binding &gt;100 microM); 5) under continuous drug exposure (3-6-day sulforhodamine and clonogenic assays), SMA41 was almost equipotent with SMA52; however, in a short 2-h drug exposure followed by incubation in drug-free media, SMA52 showed an almost complete loss of antiproliferative activity over the whole dose range.	ATP__EGFR__no_interaction	tyrosine__EGFR__no_interaction
17999490-1	By using the neutral bidentate <compound-id="947">nitrogen</compound-id>-containing ligand, <compound-id="12074516">bis(3,5-diisopropyl-1-pyrazolyl)methane</compound-id> (L1' '), the <compound-id="23978">copper</compound-id>(I) complexes [Cu(L1' ')2](<compound-id="24014">CuCl2</compound-id>) (1CuCl2), [Cu(L1' ')2](ClO4) (1ClO4), [Cu(L1' ')]2(ClO4)2 (2ClO4), [Cu(L1' ')]2(BF4)2 (2BF4), [Cu(L1' ')(NCMe)](<protein-id="Q6Q759">PF6</protein-id>) (3PF6), [Cu(L1' ')(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)](ClO4) (4ClO4), [Cu(L1' ')(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)](<protein-id="Q6Q759">PF6</protein-id>) (4PF6), [{Cu(L1' ')(CO)}2(mu-ClO4)](ClO4) (5ClO4), and the <compound-id="23978">copper</compound-id>(II) complexes [{Cu(L1' ')}2(mu-OH)2(mu-ClO4)2] (6), and [Cu(L1' ')<compound-id="24526">Cl2</compound-id>] (7) were systematically synthesized and fully characterized by X-ray crystallography and by IR and 1H NMR spectroscopy.	bis(3,5-diisopropyl-1-pyrazolyl)methane__PPh3__no_interaction	bis(3,5-diisopropyl-1-pyrazolyl)methane__PF6__no_interaction	copper__PPh3__no_interaction	copper__PF6__no_interaction	CuCl2__PPh3__no_interaction	CuCl2__PF6__no_interaction	Cl2__PPh3__no_interaction	Cl2__PF6__no_interaction	nitrogen__PPh3__no_interaction	nitrogen__PF6__no_interaction
10570049-4	The multidrug resistance-reversing agents cyclosporin A (CsA) and 2-[4-(<compound-id="7580">diphenylmethyl</compound-id>)-1-piperazinyl]-5-(trans-4,6-dimethyl-1,3, 2-<compound-id="57183225">dioxaphosphorinan</compound-id>-2-yl)-2, 6-dimethyl-4-(3-nitrophenyl)-<compound-id="938">3-pyridinecarboxylate</compound-id> P-<compound-id="190217">oxide</compound-id> (<compound-id="131368">PAK-104P</compound-id>) almost completely reversed the resistance to VCR, <compound-id="104842">7-ethyl-10-hydroxy-camptothecin</compound-id>, and cisplatin of LLC/<protein-id="Q92887">cMOAT</protein-id>-1 cells; and <compound-id="2724716">DL-buthionine</compound-id>-(S,R)-<compound-id="139610">sulfoximine</compound-id>, (3'-oxo-4-butenyl-4-<compound-id="7010355">methyl-threonine</compound-id>(1), (<compound-id="6287">valine</compound-id>(2)) cyclosporin (<compound-id="5281884">PSC833</compound-id>), and 3-([(3-(2-[<compound-id="521963">7-chloro-2-quinolinyl</compound-id>]<compound-id="123166">ethenyl</compound-id>)phenyl)-((3-dimethylamino-3- oxopropyl)-thio)-methyl]thio)<compound-id="1032">propanoic acid</compound-id> (MK571) partially reversed the resistance to these drugs.	7-chloro-2-quinolinyl__cMOAT__no_interaction	3-pyridinecarboxylate__cMOAT__no_interaction	PSC833__cMOAT__no_interaction	PAK-104P__cMOAT__no_interaction	methyl-threonine__cMOAT__no_interaction	propanoic acid__cMOAT__no_interaction	oxide__cMOAT__no_interaction	ethenyl__cMOAT__no_interaction	sulfoximine__cMOAT__no_interaction	valine__cMOAT__no_interaction	dioxaphosphorinan__cMOAT__no_interaction	DL-buthionine__cMOAT__no_interaction	diphenylmethyl__cMOAT__no_interaction	7-ethyl-10-hydroxy-camptothecin__cMOAT__no_interaction
20392126-4	The reactions of the cations [(<protein-id="P16435">por</protein-id>)Fe(<compound-id="8028">THF</compound-id>)(2)]ClO(4) (<protein-id="P16435">por</protein-id> = TPP, <protein-id="P26651,M0QY76">TTP</protein-id>, <compound-id="472095">OEP</compound-id>) with dialkylnitrosamines (R(2)<compound-id="146119">NNO</compound-id>; R(2) = Me(2), Et(2), (cyclo-CH(2))(4), (cyclo-CH(2))(5), (PhCH(2))(2)) in <compound-id="1140">toluene</compound-id> generate the six-coordinate high-spin (S = 5/2) [(<protein-id="P16435">por</protein-id>)Fe(ONNR(2))(2)]ClO(4) compounds and a five-coordinate intermediate-spin (S = 3/2) [(<compound-id="472095">OEP</compound-id>)Fe(ONNMe(2))]ClO(4) derivative in 57-72% yields (TPP = 5,10,15,20-tetraphenylporphyrinato dianion, <protein-id="P26651,M0QY76">TTP</protein-id> = 5,10,15,20-tetra-p-tolylporphyrinato dianion, <compound-id="472095">OEP</compound-id> = 2,3,7,8,12,13,17,18-octaethylporphyrinato dianion).	NNO__TTP__no_interaction	NNO__por__no_interaction	THF__TTP__no_interaction	THF__por__no_interaction	OEP__TTP__no_interaction	OEP__por__no_interaction	toluene__TTP__no_interaction	toluene__por__no_interaction
1513103-4	No differences were seen between the two diabetic groups in respect to body weight, food intake, blood <compound-id="206,5793,64689,79025">glucose</compound-id> levels, urinary <compound-id="206,5793,64689,79025">glucose</compound-id> output, hemoglobin A1C(HbA1C), <compound-id="20484">fructosamine</compound-id>, serum growth hormone (rGH) or <compound-id="588">creatinine</compound-id> clearance, but kidney weight (896 +/- 36 vs. 1000 +/- 24 mg, P less than 0.02), UAE (417 +/- 131 vs. 1098 +/- 187 micrograms/24 hr, P less than 0.02), kidney <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">insulin-like growth factor I</protein-id> (<protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-I</protein-id>) (167 +/- 16 vs. 239 +/- 17 ng/g, P less than 0.01) and serum <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-I</protein-id> (301 +/- 26 vs. 407 +/- 17 micrograms/liter, P less than 0.01) were all reduced in the <protein-id="Q3MIE9">SMS</protein-id>-treated diabetic animals when compared to the untreated diabetic group.	fructosamine__SMS__no_interaction	fructosamine__insulin-like growth factor I__no_interaction	fructosamine__IGF-I__no_interaction	creatinine__SMS__no_interaction	creatinine__insulin-like growth factor I__no_interaction	creatinine__IGF-I__no_interaction	glucose__SMS__no_interaction	glucose__insulin-like growth factor I__no_interaction	glucose__IGF-I__no_interaction
10341862-7	Serum <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> correlated with serum <compound-id="5994">progesterone</compound-id> concentrations in the luteal phase (r = 0.85, P &lt; 0.001), with serum <compound-id="5757">oestradiol</compound-id> concentrations in the early follicular (r = 0.67, P = 0.009), pre-ovulatory (r = 0.57, P = 0.03) and luteal phases (r = 0.68, P &lt; 0.005) and with serum <compound-id="6013">testosterone</compound-id> in the early follicular phase (r = 0.63, P = 0.01).	oestradiol__VEGF__no_interaction	testosterone__VEGF__no_interaction	progesterone__VEGF__no_interaction
21941738-2	From the south to the north along the precipitation and thermal gradient, weather varied from cool and humid to warm and semi-arid, and the maximum net photosynthetic rate (Pn max) and light saturation point (<compound-id="6602471">Lsp</compound-id>) of Q. wutaishanica leaves reduced obviously from 13.34 to 6.99 micromol <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> x m(-2) x s(-1) and from 1489.9 to 1055.6 micromol x m(-2) x s(-1), dark respiration rate (Rd) and light compensation point (Lcp) increased evidently from 0.313 to 1.080 micromol <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> x m(-2) x s(-1) and from 7.49 to 31.96 micromol x m(-2) x s(-1), the minimum fluorescence (F0) and coefficient of non-photochemical quenching (NPQ) displayed an increasing trend, and actual photochemical quantum yield of PS II (phiPS II), apparent electron transport rates (ETR), and coefficient of photochemical quenching (qP) reduced obviously.	Lsp__CO2__no_interaction
21702310-4	RESULTS: H2-rich saline significantly decreased the incidence of DCS from 67.57 to 35.14% and partially counteracted the increases in the total concentration of protein in the bronchoalveolar lavage from 0.33 +/- 0.05 to 0.14 +/- 0.01 mg x ml(-1) (mean +/- SD; P &lt; 0.05), <protein-id="D3ZGE2,A0A0G2K1A2">myeloperoxidase</protein-id> activity from 0.86 +/- 0.16 to 0.44 +/- 0.13 U/g, levels of <compound-id="10964">malondialdehyde</compound-id> (MDA) from 0.80 +/- 0.10 to 0.48 +/- 0.05 nmol x mg(-1), <compound-id="73318">8-hydroxydeoxyguanosine</compound-id> from 253.7 +/- 9.3 to 191.2 +/- 4.8 pg x mg(-1) in the lungs, and MDA level from 1.77 +/- 0.20 to 0.87 +/- 0.23 nmol x mg(-1) in the spinal cord in rat DCS models.	8-hydroxydeoxyguanosine__myeloperoxidase__no_interaction	malondialdehyde__myeloperoxidase__no_interaction
21799254-2	Studies on this locus in my and several other laboratories during the past four decades have revealed that (i) this locus is developmentally active, (ii) it is a member of the heat shock gene family but selectively inducible by amides, (iii) the 93D or heat shock RNA omega (hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>) gene produces multiple nuclear and cytoplasmic large non-coding RNAs (hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-n, hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-pre-c and hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-c), (iv) a variety of RNA-processing proteins, especially the hnRNPs, associate with its &gt; 10 kb nuclear (hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-n) transcript to form the nucleoplasmic omega speckles, (v) its genomic architecture and hnRNP-binding properties with the nuclear transcript are conserved in different species although the primary base sequence has diverged rapidly, (vi) heat shock causes the omega speckles to disappear and all the omega speckle associated proteins and the hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-n transcript to accumulate at the 93D locus, (vii) the hsr <protein-id="Q95RL2,Q5U156,A0A0B4KER0">row</protein-id>-n transcript directly or indirectly affects the localization/ stability/activity of a variety of proteins including hnRNPs, <protein-id="P19339,M9PGK6,E6PBY4,M9PHB3,M9PGW6,F0JAP9,M9PJB1">Sxl</protein-id>, <protein-id="P02828,M9PBL3">Hsp83</protein-id>, <protein-id="O96676,Q7KVU4,M9PHB8">CBP</protein-id>, <protein-id="Q24306,M9PI74">DIAP1</protein-id>, JNK-signalling members, proteasome constituents, lamin C, <protein-id="Q24368">ISWI</protein-id>, <protein-id="P05205">HP1</protein-id> and poly(<compound-id="6022">ADP</compound-id>)-<compound-id="9996708">ribose</compound-id> polymerase and (viii) a balanced level of its transcripts is essential for the orderly relocation of various proteins, including hnRNPs, RNA pol II and <protein-id="P05205">HP1</protein-id>, to developmentally active chromosome regions during recovery from heat stress.	ribose__ISWI__no_interaction	ribose__HP1__no_interaction	ribose__Sxl__no_interaction	ribose__CBP__no_interaction	ribose__Hsp83__no_interaction	ribose__DIAP1__no_interaction	ribose__row__no_interaction	ADP__ISWI__no_interaction	ADP__HP1__no_interaction	ADP__Sxl__no_interaction	ADP__CBP__no_interaction	ADP__Hsp83__no_interaction	ADP__DIAP1__no_interaction	ADP__row__no_interaction
21319821-1	We have studied <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-dependent charge transfer dynamics in wirelike donor-bridge-acceptor (<protein-id="P39019,B0ZBD0">D-B-A</protein-id>) molecules comprising a <compound-id="7108">phenothiazine</compound-id> (PTZ) donor, an oligo(2,7-<compound-id="6853">fluorene</compound-id>) (FL(n)) bridge, and a <compound-id="9142">perylene</compound-id>-3,4:9,10-bis(dicarboximide) (PDI) acceptor, PTZ-FL(3)-PDI (1) and PTZ-FL(4)-PDI (2), dissolved in the magnetic field-aligned nematic phase of <compound-id="2735900">4-cyano</compound-id>-4'-<compound-id="19378343">n-pentylbiphenyl</compound-id> (<compound-id="92319">5CB</compound-id>) at 295 K. Time-resolved EPR spectroscopy using both continuous wave and pulsed microwaves shows that the photogenerated radical pairs (RPs), PTZ(+•)-FL(3)-PDI(-•) and PTZ(+•)-FL(4)-PDI(-•), recombine much faster from the singlet RP manifold than the triplet RP manifold.	fluorene__spin__no_interaction	fluorene__D-B-A__no_interaction	4-cyano__spin__no_interaction	4-cyano__D-B-A__no_interaction	phenothiazine__spin__no_interaction	phenothiazine__D-B-A__no_interaction	n-pentylbiphenyl__spin__no_interaction	n-pentylbiphenyl__D-B-A__no_interaction	5CB__spin__no_interaction	5CB__D-B-A__no_interaction	perylene__spin__no_interaction	perylene__D-B-A__no_interaction
7530803-2	The present series of experiments indicate differences in the rank-order of potency of sigma ligands [DTG; <compound-id="3559">haloperidol</compound-id> (HAL)], SP analogs [SP; <protein-id="Q62252,Q545M2">SP(1-7</protein-id>); SP(5-11); [D-Pro2, <compound-id="92432">D-Phe7</compound-id>]-<protein-id="Q62252,Q545M2">SP(1-7</protein-id>) (D-<protein-id="Q62252,Q545M2">SP(1-7</protein-id>))] and miscellaneous compounds [morphine (MOR), <compound-id="5284596">naloxone</compound-id> (NAL)] at competing for [3H]-DTG binding sites in the mouse brain and spinal cord in vitro: Brain; DTG = HAL &gt;&gt; SP = MOR = NAL &gt;&gt; <protein-id="Q62252,Q545M2">SP(1-7</protein-id>) &gt;&gt; D-<protein-id="Q62252,Q545M2">SP(1-7</protein-id>) &gt;&gt; SP(5-11): Spinal cord; DTG = HAL &gt;&gt; <protein-id="Q62252,Q545M2">SP(1-7</protein-id>) = MOR = NAL &gt;&gt; SP &gt;&gt; D-<protein-id="Q62252,Q545M2">SP(1-7</protein-id>) = SP(5-11).	haloperidol__SP(1-7__no_interaction	D-Phe7__SP(1-7__no_interaction	naloxone__SP(1-7__no_interaction
23251661-6	Salient findings include a nonsynonymous SNP (rs1056513) in <protein-id="Q8NI35">INADL</protein-id> (p = 1.2E-07) for weight; an intronic variant in <protein-id="P49286">MTNR1B</protein-id> associated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (p = 3.7E-08); variants in the <protein-id="Q6Q788,A0A0B4RUS7">APOA5</protein-id>-<protein-id="O75312">ZNF259</protein-id> region associated with triglycerides (p = 2.5-4.8E-08); an intronic variant in <protein-id="P16519">PCSK2</protein-id> associated with total antioxidants (p = 7.6E-08); a block of 23 SNPs in <protein-id="P23025">XPA</protein-id>/<protein-id="O00358">FOXE1</protein-id> (<protein-id="Q9UNY4,A0A024R0F1">TTF-2</protein-id>) associated with serum TSH (p = 5.5E-08 to 1.0E-09); a nonsynonymous SNP (p = 1.3E-21), an intronic SNP (p = 3.6E-13) in <protein-id="Q16570,Q5Y7A1,Q5Y7A2">DARC</protein-id> identified for <protein-id="P13500">MCP-1</protein-id>; an intronic variant in <protein-id="Q6P4F7">ARHGAP11A</protein-id> associated with sleep duration (p = 5.0E-08); and, after adjusting for body weight, variants in <protein-id="P42679,F1T0G6">MATK</protein-id> for total energy expenditure (p = 2.7E-08) and in <protein-id="P32297">CHRNA3</protein-id> for sleeping energy expenditure (p = 6.0E-08).	glucose__ZNF259__no_interaction	glucose__PCSK2__no_interaction	glucose__XPA__no_interaction	glucose__FOXE1__no_interaction	glucose__DARC__no_interaction	glucose__TTF-2__no_interaction	glucose__INADL__no_interaction	glucose__ARHGAP11A__no_interaction	glucose__CHRNA3__no_interaction	glucose__MTNR1B__no_interaction	glucose__APOA5__no_interaction	glucose__MATK__no_interaction	glucose__MCP-1__no_interaction
12110539-3	Compared with controls, HLS patients had lower fat mass (15.9 +/- 1.3 vs. 22.3 +/- 1.7 kg, P &lt; 0.05) but higher plasma <compound-id="24759880,753">glycerol</compound-id> rate of appearance (R(a)), an index of total lipolysis (964.71 +/- 103.33 vs. 611.08 +/- 63.38 micromol x kg <protein-id="Q14517">fat(-1</protein-id>) x h(-1), P &lt; 0.05), R(a) <compound-id="985">palmitate</compound-id>, an index of net lipolysis (731.49 +/- 72.36 vs. 419.72 +/- 33.78 micromol x kg <protein-id="Q14517">fat(-1</protein-id>) x h(-1), P &lt; 0.01), R(a) free fatty acids (2,094.74 +/- 182.18 vs. 1,470.87 +/- 202.80 micromol x kg <protein-id="Q14517">fat(-1</protein-id>) x h(-1), P &lt; 0.05), and rates of intra-adipocyte (799.40 +/- 157.69 vs. 362.36 +/- 74.87 micromol x kg <protein-id="Q14517">fat(-1</protein-id>) x h(-1), P &lt; 0.01) and intrahepatic fatty acid reesterification (1,352.08 +/- 123.90 vs. 955.56 +/- 124.09 micromol x kg <protein-id="Q14517">fat(-1</protein-id>) x h(-1), P &lt; 0.05).	palmitate__fat(-1__no_interaction	glycerol__fat(-1__no_interaction
9434704-7	Mitochondrial <compound-id="5359597">superoxide</compound-id> dismutase, mitochondrial and cytosolic <protein-id="F1LRE1">glutathione reductase</protein-id> activity, and cytosolic <compound-id="124886">reduced glutathione</compound-id> were significantly lower in the cyanotic group than in the control group at end-ischemia (<compound-id="5359597">superoxide</compound-id> dismutase, 3.7 +/- 1.3 vs 5.9 +/- 1.5 units/mg protein, p = 0.012; mitochondrial <protein-id="F1LRE1">glutathione reductase</protein-id>, 43.7 +/- 14.0 vs 71.0 +/- 30.3 munits/mg protein, p = 0.039; cytosolic <protein-id="F1LRE1">glutathione reductase</protein-id>, 13.7 +/- 2.0 vs 23.2 +/- 4.2 munits/mg protein, p &lt; 0.001; and <compound-id="124886">reduced glutathione</compound-id>, 0.69 +/- 0.10 vs 0.91 +/- 0.24 microgram/mg protein, p = 0.037).	reduced glutathione__glutathione reductase__no_interaction	superoxide__glutathione reductase__no_interaction
9674176-3	RESULTS: The LL of the indirect exercise intensity prescription showed VO2 and HR values significantly higher than VO2 and HR values measured at AT (4 mph = 34.4 +/- 4.5 vs 19.6 +/- 4.6 and 5 mph = 28.9 +/- 2 vs 18.9 +/- 5.4, and <protein-id="Q16549">LPC</protein-id> = 32.0 +/- 4.1 vs 17.2 +/- 2.8 and MPC = 31.6 +/- 4.9 vs 21.1 +/- 5.7 mlO2.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>) and (4 mph = 128.9 +/- 7.8 vs 113.1 +/- 15.6 and 5 mph = 130.3 +/- 5.2 vs 114.1 +/- 18.9, and <protein-id="Q16549">LPC</protein-id> = 127.6 +/- 7.2 vs 109.3 +/- 13.2 and MPC = 131.2 +/- 5.7 vs 117.4 +/- 19.2 bpm) The UL of the indirect exercise intensity prescription in 4 mph and <protein-id="Q16549">LPC</protein-id> group showed VO2 values significantly higher than those measured at <compound-id="449097">RCP</compound-id> (40.1 +/- 5.3 vs 32.2 +/- 4.3 and 37.4 +/- 4.8 vs 30.6 +/- 2.5 mlO2.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>, respectively), but similar HR values to those obtained at <compound-id="449097">RCP</compound-id>.	RCP__LPC__no_interaction	RCP__min-1__no_interaction
12489071-6	Univariate regression analysis showed that <protein-id="P02741">CRP</protein-id> value was positively correlated to age (r = 0.218, P =.012), BMI (r = 0.239, P =.006), HOMA-IR (r = 0.397, P &lt;.0001), triglycerides (r= 0.310, P &lt;.005), LDL <compound-id="5997">cholesterol</compound-id> (r= 0.179, P =.038), and fibrinogen (r = 0.371, P &lt;.0001) levels and inversely correlated to HDL <compound-id="5997">cholesterol</compound-id> (r = 0.174, P =.044) level in our diabetic patients.	cholesterol__CRP__no_interaction
22318754-7	However, among menthol smokers, the AUC ratios of metabolite/<compound-id="444">bupropion</compound-id> were lower in the nonsmoking phase compared with the smoking phase (hydro/<protein-id="Q9UBI1">bup</protein-id> = 31.49 ± 18.84 vs. 22.95 ± 13.27, p = .04; erythro/<protein-id="Q9UBI1">bup</protein-id> = 1.99 ± 1.02 vs. 1.76 ± 0.75, p = .016; threo/<protein-id="Q9UBI1">bup</protein-id> = 11.77 ± 8.90 vs. 10.44 ± 5.63, p = .034).	bupropion__bup__no_interaction
17088962-2	Furthermore, the binuclear cobalt(III) complex O[CH(2)CH(2)(eta(5)-C(5)H(4))<compound-id="521823">Co(CO)</compound-id>I(2)](2) and insoluble polynuclear <compound-id="23948">rhodium</compound-id>(III) complex {O[CH(2)CH(2)(eta(5)-C(5)H(4))RhI(2)](2)}(n) were obtained from reactions of with the corresponding metal fragments and they react easily with <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>) to give binuclear metal complexes, O[CH(2)CH(2)(eta(5)-C(5)H(4))Co(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))I(2)](2) and O[CH(2)CH(2)(eta(5)-C(5)H(4))Rh(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))I(2)](2), respectively.	rhodium__PPh(3__no_interaction	Co(CO)__PPh(3__no_interaction
17088962-3	Complexes react with bidentate dilithium dichalcogenolato ortho-carborane to give eight binuclear half-sandwich ortho-carboranedichalcogenolato cobalt(III) and <compound-id="23948">rhodium</compound-id>(III) complexes O[CH(2)CH(2)(eta(5)-C(5)H(4))Co(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(E(2)C(2)B(10)H(10))](2) (E = S and Se), O[CH(2)CH(2)(eta(5)-C(5)H(4))](2)Co(2)(E(2)C(2)B(10)H(10)) (E = S and Se), O[CH(2)CH(2)(eta(5)-C(5)H(4))Co(E(2)C(2)B(10)H(10))](2) (E = S and Se and O[CH(2)CH(2)(eta(5)-C(5)H(4))Rh(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(E(2)C(2)B(10)H(10))](2) (E = S and Se).	rhodium__PPh(3__no_interaction
24187023-4	In accordance with rule 18f of the International Code of Nomenclature of Bacteria the following type strains are designated for these species: strain Cm a14(T) ( = DSM 14605(T) = JCM 12615(T)) as the type strain of Chondromyces apiculatus, strain Cm c5(T) ( = DSM 14714(T) = JCM 12616(T)) as the type strain of Chondromyces crocatus, strain <compound-id="7021866">Sy</compound-id> t2(T) ( = DSM 14631(T) = JCM 12617(T)) as the type strain of Chondromyces lanuginosus, strain Cm <protein-id="Q9H3D4">p51</protein-id>(T) ( = DSM 14607(T) = JCM 12618(T)) as the type strain of Chondromyces pediculatus, strain Me b8(T) ( = DSM 14713(T) = JCM 12633(T)) as the type strain of Melittangium boletus, strain Pl <compound-id="122099">s12</compound-id>(T) ( = DSM 14670(T) = JCM 12637(T)) as the type strain of Polyangium sorediatum and strain Pl <compound-id="24875312">sm5</compound-id>(T) ( = DSM 14734(T) = JCM 12638(T)) as the type strain of Polyangium spumosum.	s12__p51__no_interaction	Sy__p51__no_interaction	sm5__p51__no_interaction
12213868-8	There were significant increases in surrogate markers of bone turnover in subjects with AN compared with controls as assessed by <protein-id="P02818">osteocalcin</protein-id> (AN, 0.9 +/- 0.4 micro g/liter.month, vs. control, -1.1 +/- 0.4 micro g/liter.month; P = 0.0007), bone-specific alkaline phosphatase (AN, 0.6 +/- 0.5 U/liter.month, vs. control, -1.5 +/- 0.4 U/liter.month; P = 0.002), <compound-id="3034763">deoxypyridinoline</compound-id> [AN, 0.1 +/- 0.1 nmol/mmol <compound-id="588">creatinine</compound-id> (cr).month, vs. control, -0.4 +/- 0.1 nmol/mmol cr.month; P = 0.005], and N-telopeptide (AN, 4 +/- 4 nmol BCE/mmol cr/month, vs. control, -9 +/- 4 nmol BCE/mmol cr/month; P = 0.01).	deoxypyridinoline__osteocalcin__no_interaction	creatinine__osteocalcin__no_interaction
16532712-7	Evaluating lipid profile changes, a significant (p&lt;0.0001) reduction was noted in total <compound-id="5997">cholesterol</compound-id> (TC: from 220 +/- 39 to 216 +/- 36 mg/dL), low density lipoprotein <compound-id="5997">cholesterol</compound-id> (LDL: from 146 +/- 35 to 141 +/- 33 mg/dL), ratio of TC to high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL) (from 4.80 +/- 1.35 to 4.64 +/- 1.25), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein (Apo) B</protein-id> (from 129 +/- 32 to 124 +/- 28 mg/dL), and triglyceride levels (from 130 +/- 63 to 128 +/- 61 mg/dL, p=0.015), while <protein-id="P02647,A0A024R3E3">ApoA1</protein-id> and lipoprotein(a) levels were not significantly affected (149 +/- 23 vs. 149 +/- 22 and 24.9 +/- 26.3 vs. 24.7 +/- 26.4 mg/ dL, respectively, p=NS).	cholesterol__apolipoprotein (Apo) B__no_interaction	cholesterol__ApoA1__no_interaction
19050602-9	The following recommendations for <compound-id="152951,2232,440542,445156,92722">argatroban</compound-id> dosing during CRRT could be determined: a loading dose of 100 microg/kg followed by a maintenance infusion rate (microg/kg/min), which can be calculated from the scores as follows: for APACHE II: 2.15-0.06 x APACHE II (r = -.81, p &lt; 0.001); for <protein-id="O75170">SAPS II</protein-id>: 2.06-0.03 x <protein-id="O75170">SAPS II</protein-id> (r = -.8, p &lt; 0.001); and for ICG-PDR: -0.35 + 0.08 x ICG-PDR (r = .89, p &lt; 0.001).	argatroban__SAPS II__no_interaction
23242524-5	Results of the present study indicates that selective inhibition of <protein-id="P43116">PTGER2</protein-id>- and <protein-id="P35408,A0PJF5">PTGER4</protein-id>-mediated PGE2 signaling 1) decreases the expression and/or activity of specific integrin receptor subunits Itgb1 (<protein-id="Q16558">beta1</protein-id>) and <protein-id="P05106">Itgb3</protein-id> (<protein-id="Q8NFJ8,B4DF88">beta3</protein-id>) but not <protein-id="P18084,L7RT22">Itgb5</protein-id> (<protein-id="P04350">beta5</protein-id>), Itga1 (alpha1), Itga2 (alpha2), Itga5 (alpha5), and Itgav (alphav); 2) decreases integrin-signaling components focal adhesion kinase or protein kinase 2 (PTK2) and talin proteins; 3) inhibits interactions between Itgb1/<protein-id="P05106">Itgb3</protein-id> subunits, PTK2, and talin and <protein-id="P43116">PTGER2</protein-id>/<protein-id="P35408,A0PJF5">PTGER4</protein-id> proteins through <protein-id="P49407,B7Z1Q3">beta-arrestin-1</protein-id> and Src kinase protein complex in human endometriotic epithelial cells <compound-id="66553067">12Z</compound-id> and stromal cells 22B; and 4) decreases adhesion of <compound-id="66553067">12Z</compound-id> and 22B cells to ECM collagen I, collagen IV, <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id>, and <protein-id="P04004,D9ZGG2">vitronectin</protein-id> in a substrate-specific manner.	12Z__Itgb3__no_interaction	12Z__Itgb5__no_interaction	12Z__PTGER4__no_interaction	12Z__fibronectin__no_interaction	12Z__PTGER2__no_interaction	12Z__beta5__no_interaction	12Z__beta3__no_interaction	12Z__beta1__no_interaction	12Z__beta-arrestin-1__no_interaction	12Z__vitronectin__no_interaction
12228793-3	METHODS: In a prospective study design, 15 patients with active acromegaly (AA group; mean age-adjusted serum <protein-id="P05019,Q5U743,Q13429,Q59GC5">insuline-like growth factor-I</protein-id> [<protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id>] level, 420 +/- 170 ng/mL, mean growth hormone nadir during 75-g oral <compound-id="206,5793,64689,79025">glucose</compound-id> load, 12.3 +/- 30.1 microg/L), 18 patients with cured (n = 14, mean <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> level 205 +/- 115 ng/mL, mean growth hormone nadir during <compound-id="206,5793,64689,79025">glucose</compound-id> load 0.72 +/- 0.34 microg/L) or well-controlled (n = 4, normal age-adjusted ranges of <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> levels with medication with somatostatin analogues 354 +/- 88 ng/mL) acromegaly (CA group), and 24 control subjects (control group) underwent 2-dimensional/Doppler echocardiographic measurements, including assessment of the Tei index (isovolumic contraction time and isovolumic relaxation time divided by ejection time).	glucose__insuline-like growth factor-I__no_interaction	glucose__IGF-I__no_interaction
23157862-14	Logistic regression analysis showed that age (taking 35 - 44 years old as reference, 45 - 54 years old: OR = 1.45, 95%CI: 1.07 - 1.95; 55 - 64 years old: OR = 2.08, 95%CI: 1.53 - 2.84; 65 years old and over: OR = 1.85, 95%CI: 1.25 - 2.75), family history of diabetes (OR = 2.83, 95%CI: 1.70 - 4.72), overweight or obesity (overweight: OR = 1.36, 95%CI: 1.05 - 1.78; obesity: OR = 2.11, 95%CI: 1.47 - 3.01), central obesity (OR = 1.84, 95%CI: 1.39 - 2.44), abnormal triglyceride (OR = 1.54, 95%CI: 1.21 - 1.97), abnormal total <compound-id="5997">cholesterol</compound-id> (OR = 1.40, 95%CI: 1.11 - 1.77) and abnormal <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (OR = 1.82, 95%CI: 1.19 - 2.79) increased the risk of type 2 diabetes, and regular physical activity (OR = 0.57, 95%CI: 0.45 - 0.72) was the protective factor of type 2 diabetes.	cholesterol__LDL-C__no_interaction
16288434-5	With n = 3 patients in high flux HD at blood flow 450, 400, 350 and 250 ml/min we found remarkably high clearance for <compound-id="1176">urea</compound-id> (347 +/- 4%, 305 +/- 0%, 288 +/- 5%, 230 +/- 3%, for Rexeed-<compound-id="72187586">18A</compound-id> and 361 +/- 3%, 329 +/- 0%, 313 +/- 1%, 234 +/- 3%for Rexeed-<compound-id="449135">25A</compound-id>),<compound-id="588">creatinine</compound-id> (282 +/- 10%, 234 +/- 0%, 221 +/- 8%, 174 +/- 8%, for Rexeed-<compound-id="72187586">18A</compound-id> and 276 +/- 6%, 245 +/- 0%, 226 +/- 9%, 172 +/- 13% for Rexeed-<compound-id="449135">25A</compound-id>),<compound-id="1061,167704,644102">phosphate</compound-id> (347 +/- 0%, 316 +/- 0%, 275 +/- 4%, 202 +/- 16%, for Rexeed-<compound-id="72187586">18A</compound-id> and 364 +/- 3%, 365 +/- 0%,286 +/- 3%, 224 +/- 2% for Rexeed-<compound-id="449135">25A</compound-id>)and <protein-id="P17693,Q5RJ85,Q31611,Q6DU14">b2-microglobulin</protein-id> (133 +/- 21%, 124 +/- 0%,118 +/- 12%, 98 +/- 11%, for Rexeed-<compound-id="72187586">18A</compound-id> and 159 +/- 8%, 169 +/- 0%,157 +/- 8%, 129 +/- 7% for Rexeed-<compound-id="449135">25A</compound-id>) With n = 2 patients in HDF at blood flow 300 ml/min we found remarkably high clearance for <compound-id="1176">urea</compound-id> (268 +/- 2%, for Rexeed-<compound-id="72187586">18A</compound-id> and 283 +/- 2% for Rexeed-<compound-id="449135">25A</compound-id>),<compound-id="588">creatinine</compound-id> (183 +/- 6%for Rexeed-<compound-id="72187586">18A</compound-id> and 205 +/- 9% for Rexeed-<compound-id="449135">25A</compound-id>),<compound-id="1061,167704,644102">phosphate</compound-id> (245 +/- 3%, for Rexeed-<compound-id="72187586">18A</compound-id> and 270 +/- 2% for Rexeed-<compound-id="449135">25A</compound-id>)and <protein-id="P17693,Q5RJ85,Q31611,Q6DU14">b2-microglobulin</protein-id> (166 +/- 12%, for Rexeed-<compound-id="72187586">18A</compound-id> and 192 +/- 4% for Rexeed-<compound-id="449135">25A</compound-id>).	phosphate__b2-microglobulin__no_interaction	25A__b2-microglobulin__no_interaction	18A__b2-microglobulin__no_interaction	urea__b2-microglobulin__no_interaction	creatinine__b2-microglobulin__no_interaction
21160213-6	Thyroid volume correlated positively with body mass index (r = 0.48, p = 0.04), <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.1, p = 0.03), and thyroid-stimulating hormone (r = 0.43, p = 0.001) levels, while there was a negative correlation between thyroid volume and urinary <compound-id="807">iodine</compound-id> (r = -0.38, p = 0.04) and urinary <compound-id="807">iodine</compound-id>/<compound-id="588">creatinine</compound-id> ratio (r = -0.25, p = 0.045) in obese women.	creatinine__leptin__no_interaction	iodine__leptin__no_interaction
19219061-6	Omental adipocyte adiponectin release was significantly and negatively correlated with total body fat mass (r = -0.47, P &lt; 0.01), visceral adipose tissue area (r = -0.50, P &lt; 0.01), omental adipocyte diameter (r = -0.43, P &lt; 0.01), triglyceride levels (r = -0.32, P &lt; or = 0.05), <compound-id="5997">cholesterol</compound-id>/high-density lipoprotein (HDL)-<compound-id="5997">cholesterol</compound-id> (r = -0.31, P &lt; or = 0.05), fasting <compound-id="206,64689,79025">glucose</compound-id> (r = -0.39, P &lt; or = 0.01), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.36, P &lt; or = 0.05), homeostasis model assessment index (r = -0.39, P &lt; or = 0.01), and positively associated with HDL-<compound-id="5997">cholesterol</compound-id> concentrations (r = 0.33, P &lt; or = 0.05).	glucose__insulin__no_interaction	cholesterol__insulin__no_interaction
9178615-2	Following hypotonic exposure (50% osmolarity) there is: (i) no increase in cellular Ins(1,4,5)P3 content, as measured in extracts from [2-3H]<compound-id="892">myoinositol</compound-id>-labeled cells, a finding at variance with earlier reports from our group; (ii) no evidence of <protein-id="P27139">Ca2</protein-id>+-signaling recorded in a suspension of <compound-id="57054">fura-2</compound-id>-loaded cells; (iii) <protein-id="P27139">Ca2</protein-id>+-signaling in only about 6% of the single, <compound-id="57054">fura-2</compound-id>-loaded cells at 1-mm <protein-id="P27139">Ca2</protein-id>+ (1% only at 0.1-mM <protein-id="P27139">Ca2</protein-id>+ and in <protein-id="P27139">Ca2</protein-id>+-free medium), as monitored by fluorescence-ratio imaging; (iv) no effect of removing external <protein-id="P27139">Ca2</protein-id>+ upon the volume-induced K+ loss; (v) no significant inhibition of the <compound-id="46934007">RVD</compound-id> response in cells loaded with the <protein-id="P27139">Ca2</protein-id>+ chelator <compound-id="104751">BAPTA</compound-id> when the <compound-id="104751">BAPTA</compound-id>-loading is performed in K+ equilibrium medium; (vi) an inhibition of the swelling-induced K+ loss (about 50%) at 1-mM Ba2+, but almost no effect of charybdotoxin (100 nm) or of <compound-id="2812">clotrimazole</compound-id> (10 microM), reported inhibitors of the K+ loss induced by <protein-id="P27139">Ca2</protein-id>+-mobilizing agonists.	RVD__Ca2__no_interaction	clotrimazole__Ca2__no_interaction	myoinositol__Ca2__no_interaction	BAPTA__Ca2__no_interaction	fura-2__Ca2__no_interaction
16432806-2	By internal acylation of <compound-id="5962">Lys</compound-id>, Orn, L-1,4-diaminobutyric acid (Dab), <protein-id="Q9QX67">L-1,3-diaminopropionic acid (Dap</protein-id>) at position 4 with the C-terminal Gly of the peptide tail, we prepared cyclo-(4-9)-[<compound-id="5962">Lys</compound-id>(4), Gly(9)]-PA (pA(2) = 8.77 +/- 0.27), 1, and cyclo-(4-9)-[Orn(4), Gly(9)]-PA (pA(2) = 8.81 +/- 0.25), 3, which are equipotent with PA (pA(2) = 8.68 +/- 0.18) in the rat uterotonic assay and cyclo-(4-9)-[Dab(4), Gly(9)]-PA, 4, cyclo-(4-9)-[Dap(4), Gly(9)]-PA, 5, and cyclo-(4-9)-[Pmp(1), <compound-id="5962">Lys</compound-id>(4), Gly(9)]-PA, 2, which were weaker OTAs.	Lys__L-1,3-diaminopropionic acid (Dap__no_interaction
12823020-1	A series of sulfido-bridged <compound-id="23964">tungsten</compound-id>-<compound-id="23950">ruthenium</compound-id> dinuclear complexes Cp*W(mu-S)(3)<compound-id="72725778">RuX</compound-id>(PPh(3))(2) (<compound-id="69255155">4a</compound-id>; X = Cl, 4b; X = H), Cp*W(O)(mu-S)(2)<compound-id="72725778">RuX</compound-id>(PPh(3))(2) (5a; X = Cl, <compound-id="18445697">5b</compound-id>; X = H), and Cp*W(NPh)(mu-S)(2)<compound-id="72725778">RuX</compound-id>(PPh(3))(2) (6a; X = Cl, 6b; X = H) have been synthesized by the reactions of (<protein-id="O14649">PPh(4</protein-id>))[Cp*W(S)(3)] (1), (<protein-id="O14649">PPh(4</protein-id>))[Cp*W(O)(S)(2)] (2), and (<protein-id="O14649">PPh(4</protein-id>))[Cp*W(NPh)(S)(2)] (3), with RuClX(PPh(3))(3) (X = Cl, H).	tungsten__PPh(4__no_interaction	ruthenium__PPh(4__no_interaction	RuX__PPh(4__no_interaction	5b__PPh(4__no_interaction	4a__PPh(4__no_interaction
7867683-4	The mean values of AUC (0-4 h), Cmax and Tmax for <compound-id="5362124">benazepril</compound-id> given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.ml-1, and 0.5 vs 0.6 h. The mean values of AUC (0-24 h), Cmax and Tmax for <compound-id="5463984">benazeprilat</compound-id> after <compound-id="5362124">benazepril</compound-id> given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.ml-1, and 1.7 vs 1.5 h. The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.ml-1, and 8.3 vs 9.0 h. The differences in these pharmacokinetic parameters between the combination and monotherapy treatments were not statistically significant based on <protein-id="Q9UNW9">ANOVA</protein-id>.	benazeprilat__ANOVA__no_interaction	benazepril__ANOVA__no_interaction
20664824-1	[¹¹C]RAC; (18)F-<compound-id="92242">Fluoromisonidazole</compound-id>; 89-12; 9-[¹⁸F]<compound-id="9998">Fluoropropyl</compound-id>-(+)-<compound-id="123836,14580381">dihydrotetrabenazine</compound-id>; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod <compound-id="5360545">sodium</compound-id>, AGS-004, Alglucosidase alfa, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="5287969">Alvocidib hydrochloride</compound-id>, <compound-id="76935">AMG</compound-id>-108, <compound-id="76935">AMG</compound-id>-853, <compound-id="10182969">Apixaban</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, <compound-id="9690109">Armodafinil</compound-id>, <compound-id="148192">Atazanavir sulfate</compound-id>, <compound-id="54841">Atomoxetine hydrochloride</compound-id>; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>; <compound-id="5486792,2826718,66577042,71295847">Caspofungin acetate</compound-id>, <compound-id="9933475">Cediranib</compound-id>, Cetuximab, ChimeriVax-Dengue, Choriogonadotropin alfa, <compound-id="156419">Cinacalcet</compound-id> hydrochloride, <compound-id="132411">Cizolirtine citrate</compound-id>, <compound-id="119182">Clofarabine</compound-id>, <compound-id="446220">Cocaine</compound-id> conjugate vaccine, CX-717; Darbepoetin alfa, <compound-id="3062316">Dasatinib</compound-id>, <compound-id="451668">Decitabine</compound-id>, Denosumab, <compound-id="125017">Desvenlafaxine</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="9400">Dexamethasone sodium phosphate</compound-id>, <compound-id="68861">Dienogest</compound-id>, <compound-id="65057">Diphencyprone</compound-id>, <compound-id="73303">Doripenem</compound-id>, DTaP-<compound-id="4177956">HepB</compound-id>-IPV, <compound-id="6918296">Dutasteride</compound-id>; E-7010, Ecallantide, <compound-id="1615">Ecstasy</compound-id>, <compound-id="446284">Eicosapentaenoic acid</compound-id>/<compound-id="3144,445580">docosahexaenoic acid</compound-id>, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="16130199">Enfuvirtide</compound-id>, <compound-id="176870">Erlotinib</compound-id> hydrochloride, <compound-id="969472">Eszopiclone</compound-id>, <compound-id="6917715">Etonogestrel</compound-id>/<compound-id="5991">ethinyl estradiol</compound-id>, <compound-id="123619">Etoricoxib</compound-id>, Everolimus, Everolimus-eluting coronary stent EVT-201, <compound-id="150311">Ezetimibe</compound-id>, <compound-id="9832423">Ezetimibe/simvastatin</compound-id>; Ferumoxytol, <compound-id="6918558">Fesoterodine</compound-id> fumavate, <compound-id="6917781">Figitumumab</compound-id>, Filgrastim, <compound-id="107970">Fingolimod</compound-id> hydrochloride, <compound-id="24847878,9854489">Fluticasone furoate</compound-id>, <compound-id="3386">Fluval</compound-id> P, Fluzone, <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="104741">Fulvestrant</compound-id>, <compound-id="5282200">Fungichromin</compound-id>; Gamma-hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="123631">Gefitinib</compound-id>, GHB-01L1, GLY-230, GSK-1349572; Hib-MenCY-TT, Hib-TT, HPV-6/11/16/18, <compound-id="20831824">Hydrocodone bitartrate</compound-id>; IC-51, <compound-id="6918173">Icatibant acetate</compound-id>, <compound-id="5291">Imatinib mesylate</compound-id>, Immunoglobulin intravenous (human), Indetanib, Influenza A (H1N1) 2009 Monovalent Vaccine, <compound-id="57006608">Inhalable</compound-id> human <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine, <protein-id="P01308,I3WAC9">insulin</protein-id> glulisine, <protein-id="P01574">Interferon-beta</protein-id>, <compound-id="6851740">Ispinesib mesylate</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; <compound-id="3081349">Laromustine</compound-id>, <compound-id="5311221">Latanoprost</compound-id>/<compound-id="168613,33624">timolol maleate</compound-id>, L-Citrulline, <compound-id="216326">Lenalidomide</compound-id>, Lexatumumab, <compound-id="441401">Linezolid</compound-id>, <compound-id="11980957">Lopinavir/ritonavir</compound-id>, Lutropin alfa; Mapatumumab, MDX-066, MDX-1388, <compound-id="56603701">Mepolizumab</compound-id>, Methoxy polyethylene <compound-id="174">glycol</compound-id>-epoetin-beta, Metreleptin, <compound-id="477468,6602291">Micafungin sodium</compound-id>, <compound-id="441336">Mometasone furoate</compound-id>/<compound-id="4636">oxymetazoline hydrochloride</compound-id>, Mx-dnG1, <compound-id="446541">Mycophenolic acid sodium salt</compound-id>; <compound-id="44148067">Nabiximols</compound-id>, Natalizumab, <compound-id="11993740">Nemonoxacin</compound-id>, <compound-id="13752005,62930,6537152,91454290,9568628">Norelgestromin</compound-id>/<compound-id="5991">ethinyl estradiol</compound-id>; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, Ocriplasmin, <compound-id="130881">Olmesartan medoxomil</compound-id>, <compound-id="285033">Omacetaxine mepesuccinate</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>-eluting stent, <compound-id="131664">Pagoclone</compound-id>, <compound-id="115237">Paliperidone</compound-id>, Panitumumab, <compound-id="10113978">Pazopanib hydrochloride</compound-id>, PCV7, <compound-id="158786">Pegaptanib octasodium</compound-id>, Peginterferon alfa-2a, Peginterferon alfa-2b/ <compound-id="37542">ribavirin</compound-id>, Pegvisomant, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, <compound-id="148178">Perifosine</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="5282452">Pitavastatin</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="65015">Plerixafor hydrochloride</compound-id>, <compound-id="44152164,56928089,9812534">Plitidepsin</compound-id>, <compound-id="468595">Posaconazole</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, <compound-id="5994">Progesterone</compound-id> capriate; <compound-id="54671008">Raltegravir potassium</compound-id>, Ramucirumab, <compound-id="3052774">Ranelic acid distrontium salt</compound-id>, Rasburicase, Recombinant Bet V1, Recombinant human <protein-id="P01308,I3WAC9">insulin</protein-id>, rhFSH, <compound-id="64627">Rolofylline</compound-id>, <compound-id="5352062">Romidepsin</compound-id>, Romiplostim, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">Rosuvastatin calcium</compound-id>; <compound-id="153970">Sapacitabine</compound-id>, <compound-id="3085017">Sevelamer</compound-id> carbonate, Sinecatechins, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting stent, <compound-id="4369359">Sitagliptin phosphate</compound-id> <compound-id="1488787">monohydrate</compound-id>, SN-29244, <compound-id="216239">Sorafenib</compound-id>, <compound-id="6918585,70693550">Sugammadex</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="115358">Tafenoquine</compound-id>, <compound-id="5311424">Talnetant</compound-id>, Tanezumab, <compound-id="9838022">Tapentadol hydrochloride</compound-id>, <compound-id="10174505">Tasocitinib citrate</compound-id>, Technosphere/<protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="11319053">Telcagepant</compound-id>, <compound-id="5481350">Tenofovir disoproxil fumarate</compound-id>, Teriparatide, <compound-id="9871419">Ticagrelor</compound-id>, <compound-id="54686904">Tigecycline</compound-id>, <compound-id="5487427">Tiotropium bromide</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, Tocilizumab, TS-041; <compound-id="13559282">Ulipristal acetate</compound-id>, Urtoxazumab, <compound-id="121750">Ustekinumab</compound-id>; <compound-id="3081361">Vandetanib</compound-id>, <compound-id="170362,46783232,53486179,6918678,9906942">Varenicline tartrate</compound-id>, <compound-id="3009355">Vicriviroc</compound-id>, <compound-id="71616">Voriconazole</compound-id>, <compound-id="5311">Vorinostat</compound-id>, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP; <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	Icatibant acetate__insulin__no_interaction	Icatibant acetate__Interferon-beta__no_interaction	Laromustine__insulin__no_interaction	Laromustine__Interferon-beta__no_interaction	Varenicline tartrate__insulin__no_interaction	Varenicline tartrate__Interferon-beta__no_interaction	Aliskiren fumarate__insulin__no_interaction	Aliskiren fumarate__Interferon-beta__no_interaction	Fondaparinux sodium__insulin__no_interaction	Fondaparinux sodium__Interferon-beta__no_interaction	Diphencyprone__insulin__no_interaction	Diphencyprone__Interferon-beta__no_interaction	Vandetanib__insulin__no_interaction	Vandetanib__Interferon-beta__no_interaction	Pegaptanib octasodium__insulin__no_interaction	Pegaptanib octasodium__Interferon-beta__no_interaction	Sunitinib malate__insulin__no_interaction	Sunitinib malate__Interferon-beta__no_interaction	Plitidepsin__insulin__no_interaction	Plitidepsin__Interferon-beta__no_interaction	Pimecrolimus__insulin__no_interaction	Pimecrolimus__Interferon-beta__no_interaction	Sapacitabine__insulin__no_interaction	Sapacitabine__Interferon-beta__no_interaction	Raltegravir potassium__insulin__no_interaction	Raltegravir potassium__Interferon-beta__no_interaction	Nemonoxacin__insulin__no_interaction	Nemonoxacin__Interferon-beta__no_interaction	Fungichromin__insulin__no_interaction	Fungichromin__Interferon-beta__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	Zoledronic acid monohydrate__Interferon-beta__no_interaction	dihydrotetrabenazine__insulin__no_interaction	dihydrotetrabenazine__Interferon-beta__no_interaction	Pitavastatin__insulin__no_interaction	Pitavastatin__Interferon-beta__no_interaction	Tigecycline__insulin__no_interaction	Tigecycline__Interferon-beta__no_interaction	Eicosapentaenoic acid__insulin__no_interaction	Eicosapentaenoic acid__Interferon-beta__no_interaction	Olmesartan medoxomil__insulin__no_interaction	Olmesartan medoxomil__Interferon-beta__no_interaction	Bosentan__insulin__no_interaction	Bosentan__Interferon-beta__no_interaction	Fesoterodine__insulin__no_interaction	Fesoterodine__Interferon-beta__no_interaction	Doripenem__insulin__no_interaction	Doripenem__Interferon-beta__no_interaction	glycol__insulin__no_interaction	glycol__Interferon-beta__no_interaction	Tadalafil__insulin__no_interaction	Tadalafil__Interferon-beta__no_interaction	Fulvestrant__insulin__no_interaction	Fulvestrant__Interferon-beta__no_interaction	ethinyl estradiol__insulin__no_interaction	ethinyl estradiol__Interferon-beta__no_interaction	Fluoropropyl__insulin__no_interaction	Fluoropropyl__Interferon-beta__no_interaction	Tiotropium bromide__insulin__no_interaction	Tiotropium bromide__Interferon-beta__no_interaction	HepB__insulin__no_interaction	HepB__Interferon-beta__no_interaction	oxymetazoline hydrochloride__insulin__no_interaction	oxymetazoline hydrochloride__Interferon-beta__no_interaction	Cizolirtine citrate__insulin__no_interaction	Cizolirtine citrate__Interferon-beta__no_interaction	ribavirin__insulin__no_interaction	ribavirin__Interferon-beta__no_interaction	Eszopiclone__insulin__no_interaction	Eszopiclone__Interferon-beta__no_interaction	Cediranib__insulin__no_interaction	Cediranib__Interferon-beta__no_interaction	Ulipristal acetate__insulin__no_interaction	Ulipristal acetate__Interferon-beta__no_interaction	Clofarabine__insulin__no_interaction	Clofarabine__Interferon-beta__no_interaction	Apixaban__insulin__no_interaction	Apixaban__Interferon-beta__no_interaction	Emtricitabine__insulin__no_interaction	Emtricitabine__Interferon-beta__no_interaction	Atazanavir sulfate__insulin__no_interaction	Atazanavir sulfate__Interferon-beta__no_interaction	Gefitinib__insulin__no_interaction	Gefitinib__Interferon-beta__no_interaction	AMG__insulin__no_interaction	AMG__Interferon-beta__no_interaction	Latanoprost__insulin__no_interaction	Latanoprost__Interferon-beta__no_interaction	Ixabepilone__insulin__no_interaction	Ixabepilone__Interferon-beta__no_interaction	Mepolizumab__insulin__no_interaction	Mepolizumab__Interferon-beta__no_interaction	monohydrate__insulin__no_interaction	monohydrate__Interferon-beta__no_interaction	docosahexaenoic acid__insulin__no_interaction	docosahexaenoic acid__Interferon-beta__no_interaction	Mometasone furoate__insulin__no_interaction	Mometasone furoate__Interferon-beta__no_interaction	Voriconazole__insulin__no_interaction	Voriconazole__Interferon-beta__no_interaction	Nabiximols__insulin__no_interaction	Nabiximols__Interferon-beta__no_interaction	Pazopanib hydrochloride__insulin__no_interaction	Pazopanib hydrochloride__Interferon-beta__no_interaction	Caspofungin acetate__insulin__no_interaction	Caspofungin acetate__Interferon-beta__no_interaction	Oblimersen__insulin__no_interaction	Oblimersen__Interferon-beta__no_interaction	Micafungin sodium__insulin__no_interaction	Micafungin sodium__Interferon-beta__no_interaction	Decitabine__insulin__no_interaction	Decitabine__Interferon-beta__no_interaction	Tenofovir disoproxil fumarate__insulin__no_interaction	Tenofovir disoproxil fumarate__Interferon-beta__no_interaction	Etoricoxib__insulin__no_interaction	Etoricoxib__Interferon-beta__no_interaction	Fluoromisonidazole__insulin__no_interaction	Fluoromisonidazole__Interferon-beta__no_interaction	Sorafenib__insulin__no_interaction	Sorafenib__Interferon-beta__no_interaction	Norelgestromin__insulin__no_interaction	Norelgestromin__Interferon-beta__no_interaction	sodium__insulin__no_interaction	sodium__Interferon-beta__no_interaction	Fluval__insulin__no_interaction	Fluval__Interferon-beta__no_interaction	succinate__insulin__no_interaction	succinate__Interferon-beta__no_interaction	Paliperidone__insulin__no_interaction	Paliperidone__Interferon-beta__no_interaction	Sevelamer__insulin__no_interaction	Sevelamer__Interferon-beta__no_interaction	Sugammadex__insulin__no_interaction	Sugammadex__Interferon-beta__no_interaction	Enfuvirtide__insulin__no_interaction	Enfuvirtide__Interferon-beta__no_interaction	Dasatinib__insulin__no_interaction	Dasatinib__Interferon-beta__no_interaction	Ispinesib mesylate__insulin__no_interaction	Ispinesib mesylate__Interferon-beta__no_interaction	Cinacalcet__insulin__no_interaction	Cinacalcet__Interferon-beta__no_interaction	Armodafinil__insulin__no_interaction	Armodafinil__Interferon-beta__no_interaction	Ezetimibe__insulin__no_interaction	Ezetimibe__Interferon-beta__no_interaction	Lopinavir/ritonavir__insulin__no_interaction	Lopinavir/ritonavir__Interferon-beta__no_interaction	Perifosine__insulin__no_interaction	Perifosine__Interferon-beta__no_interaction	Pemetrexed disodium__insulin__no_interaction	Pemetrexed disodium__Interferon-beta__no_interaction	Imatinib mesylate__insulin__no_interaction	Imatinib mesylate__Interferon-beta__no_interaction	Posaconazole__insulin__no_interaction	Posaconazole__Interferon-beta__no_interaction	Lenalidomide__insulin__no_interaction	Lenalidomide__Interferon-beta__no_interaction	Dutasteride__insulin__no_interaction	Dutasteride__Interferon-beta__no_interaction	Romidepsin__insulin__no_interaction	Romidepsin__Interferon-beta__no_interaction	Rosuvastatin calcium__insulin__no_interaction	Rosuvastatin calcium__Interferon-beta__no_interaction	Desvenlafaxine__insulin__no_interaction	Desvenlafaxine__Interferon-beta__no_interaction	Mycophenolic acid sodium salt__insulin__no_interaction	Mycophenolic acid sodium salt__Interferon-beta__no_interaction	Ranelic acid distrontium salt__insulin__no_interaction	Ranelic acid distrontium salt__Interferon-beta__no_interaction	Ezetimibe/simvastatin__insulin__no_interaction	Ezetimibe/simvastatin__Interferon-beta__no_interaction	Ecstasy__insulin__no_interaction	Ecstasy__Interferon-beta__no_interaction	Vicriviroc__insulin__no_interaction	Vicriviroc__Interferon-beta__no_interaction	Alvocidib hydrochloride__insulin__no_interaction	Alvocidib hydrochloride__Interferon-beta__no_interaction	Hydrocodone bitartrate__insulin__no_interaction	Hydrocodone bitartrate__Interferon-beta__no_interaction	Fingolimod__insulin__no_interaction	Fingolimod__Interferon-beta__no_interaction	Talnetant__insulin__no_interaction	Talnetant__Interferon-beta__no_interaction	calcium__insulin__no_interaction	calcium__Interferon-beta__no_interaction	Ustekinumab__insulin__no_interaction	Ustekinumab__Interferon-beta__no_interaction	Erlotinib__insulin__no_interaction	Erlotinib__Interferon-beta__no_interaction	Figitumumab__insulin__no_interaction	Figitumumab__Interferon-beta__no_interaction	Vorinostat__insulin__no_interaction	Vorinostat__Interferon-beta__no_interaction	Sitagliptin phosphate__insulin__no_interaction	Sitagliptin phosphate__Interferon-beta__no_interaction	Sirolimus__insulin__no_interaction	Sirolimus__Interferon-beta__no_interaction	Pregabalin__insulin__no_interaction	Pregabalin__Interferon-beta__no_interaction	Tipifarnib__insulin__no_interaction	Tipifarnib__Interferon-beta__no_interaction	Dienogest__insulin__no_interaction	Dienogest__Interferon-beta__no_interaction	Linezolid__insulin__no_interaction	Linezolid__Interferon-beta__no_interaction	Tafenoquine__insulin__no_interaction	Tafenoquine__Interferon-beta__no_interaction	Atomoxetine hydrochloride__insulin__no_interaction	Atomoxetine hydrochloride__Interferon-beta__no_interaction	Ticagrelor__insulin__no_interaction	Ticagrelor__Interferon-beta__no_interaction	Inhalable__insulin__no_interaction	Inhalable__Interferon-beta__no_interaction	Fluticasone furoate__insulin__no_interaction	Fluticasone furoate__Interferon-beta__no_interaction	Plerixafor hydrochloride__insulin__no_interaction	Plerixafor hydrochloride__Interferon-beta__no_interaction	Tasocitinib citrate__insulin__no_interaction	Tasocitinib citrate__Interferon-beta__no_interaction	Paclitaxel__insulin__no_interaction	Paclitaxel__Interferon-beta__no_interaction	Progesterone__insulin__no_interaction	Progesterone__Interferon-beta__no_interaction	Aripiprazole__insulin__no_interaction	Aripiprazole__Interferon-beta__no_interaction	Etonogestrel__insulin__no_interaction	Etonogestrel__Interferon-beta__no_interaction	Telcagepant__insulin__no_interaction	Telcagepant__Interferon-beta__no_interaction	Dexamethasone sodium phosphate__insulin__no_interaction	Dexamethasone sodium phosphate__Interferon-beta__no_interaction	Cocaine__insulin__no_interaction	Cocaine__Interferon-beta__no_interaction	Bortezomib__insulin__no_interaction	Bortezomib__Interferon-beta__no_interaction	Tapentadol hydrochloride__insulin__no_interaction	Tapentadol hydrochloride__Interferon-beta__no_interaction	Pagoclone__insulin__no_interaction	Pagoclone__Interferon-beta__no_interaction	Rolofylline__insulin__no_interaction	Rolofylline__Interferon-beta__no_interaction	timolol maleate__insulin__no_interaction	timolol maleate__Interferon-beta__no_interaction	Omacetaxine mepesuccinate__insulin__no_interaction	Omacetaxine mepesuccinate__Interferon-beta__no_interaction
8222295-10	RESULTS: During the short-term treatment mean (+/- <compound-id="5289348">SEM</compound-id>) serum <compound-id="22044544,5460341">calcium</compound-id> decreased significantly (on days 6 and 8, 2.21 +/- 0.08 and 2.15 +/- 0.09 mmol/l, respectively vs basal level, 2.38 +/- 0.08 mmol/l), whereas significant increments were seen in mean serum <protein-id="P01270">PTH</protein-id> (on day 14, 36 +/- 4 vs basal, 24 +/- 3 ng/l; ng/l divided by 9.425 = pmol/l), mean serum 1,25(OH)2 Vit D (on day 8, 112 +/- 7 vs basal 96 +/- 8 pmol/l), and 'free 1,25(OH)2 Vit D-index', i.e.	calcium__PTH__no_interaction	SEM__PTH__no_interaction
17136234-3	This issues focuses on the following selection of drugs: (-)-<compound-id="65064">Epigallocatechin gallate</compound-id>, (-)-<compound-id="3503">gossypol</compound-id>, <compound-id="108223">2-deoxyglucose</compound-id>, <compound-id="5918">3,4-DAP</compound-id>, 7-monohydroxyethylrutoside; Ad5CMV-<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, <protein-id="P07327">ADH-1</protein-id>, alemtuzumab, <compound-id="5493444">aliskiren fumarate</compound-id>, <compound-id="5287969">alvocidib hydrochloride</compound-id>, <compound-id="137">aminolevulinic acid hydrochloride</compound-id>, <compound-id="157922">aminolevulinic acid methyl ester</compound-id>, <compound-id="3035016">amrubicin hydrochloride</compound-id>, AN-152, <compound-id="90470007">anakinra</compound-id>, <compound-id="111332">anecortave</compound-id> <compound-id="176">acetate</compound-id>, antiasthma herbal medicine intervention, AP-12009, <compound-id="11520894,74787553">AP-23573</compound-id>, <compound-id="5813717">apaziquone</compound-id>, <compound-id="71587701">aprinocarsen sodium</compound-id>, AR-C126532, AR-H065522, <compound-id="60795">aripiprazole</compound-id>, <compound-id="9690109">armodafinil</compound-id>, <compound-id="179337">arzoxifene</compound-id> hydrochloride, <compound-id="148192">atazanavir sulfate</compound-id>, <compound-id="72734326">atilmotin</compound-id>, <compound-id="54841">atomoxetine hydrochloride</compound-id>, <compound-id="60823">atorvastatin</compound-id>, <compound-id="9869929">avanafil</compound-id>, <compound-id="9571004">azimilide hydrochloride</compound-id>; Bevacizumab, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, <compound-id="448545">BMS-214662</compound-id>, <compound-id="5287541">BN-83495</compound-id>, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B; <compound-id="5486792,2826718,468682,66577042,71295847">Caspofungin acetate</compound-id>, cetuximab, <compound-id="5281607">chrysin</compound-id>, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="73115">clevudine</compound-id>, <compound-id="119182">clofarabine</compound-id>, <compound-id="60606">clopidogrel</compound-id>, CNF-1010, CNTO-328, CP-751871, CX-717, <compound-id="9962928">Cypher</compound-id>; <compound-id="71353">Dapoxetine</compound-id> hydrochloride, <compound-id="444031">darifenacin hydrobromide</compound-id>, <compound-id="3062316">dasatinib</compound-id>, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="204105">dextofisopam</compound-id>, <compound-id="3008,5360696,5362449,6916184">dextromethorphan</compound-id>/<compound-id="1065,3036746,5748152,441074,5953">quinidine sulfate</compound-id>, <compound-id="3033">diclofenac</compound-id>, <compound-id="208898">dronedarone hydrochloride</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine hydrochloride</compound-id>, <compound-id="6918296">dutasteride</compound-id>; <compound-id="4021">Edaravone</compound-id>, <compound-id="122335">efaproxiral sodium</compound-id>, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="153941">entecavir</compound-id>, <compound-id="443872">eplerenone</compound-id>, epratuzumab, <compound-id="176870">erlotinib</compound-id> hydrochloride, <compound-id="146570">escitalopram</compound-id> <compound-id="971">oxalate</compound-id>, <compound-id="123619">etoricoxib</compound-id>, <compound-id="150311">ezetimibe</compound-id>, <compound-id="9832423">ezetimibe/simvastatin</compound-id>; <compound-id="216220">Finrozole</compound-id>, <compound-id="213041">fipamezole hydrochloride</compound-id>, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>, <compound-id="104741">fulvestrant</compound-id>; <compound-id="9883933">Gabapentin enacarbil</compound-id>, <compound-id="3448">gaboxadol</compound-id>, <compound-id="123631">gefitinib</compound-id>, <compound-id="3033968">gestodene</compound-id>, <compound-id="44576256">ghrelin</compound-id> (human); Human <protein-id="P01308,I3WAC9">insulin</protein-id>, human papillomavirus vaccine; <compound-id="5291">Imatinib</compound-id> <compound-id="6395">mesylate</compound-id>, immunoglobulin intravenous (human), <compound-id="6450813">indiplon</compound-id>, <protein-id="P01308,I3WAC9">insulin detemir, insulin glargine, insulin glulisine, intranasal insulin</protein-id>, <compound-id="5311037">istradefylline</compound-id>, i.v.	eplerenone__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	eplerenone__ADH-1__no_interaction	eplerenone__insulin__no_interaction	eplerenone__p53__no_interaction	escitalopram__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	escitalopram__ADH-1__no_interaction	escitalopram__insulin__no_interaction	escitalopram__p53__no_interaction	Gabapentin enacarbil__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Gabapentin enacarbil__ADH-1__no_interaction	Gabapentin enacarbil__insulin__no_interaction	Gabapentin enacarbil__p53__no_interaction	alvocidib hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	alvocidib hydrochloride__ADH-1__no_interaction	alvocidib hydrochloride__insulin__no_interaction	alvocidib hydrochloride__p53__no_interaction	BMS-214662__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	BMS-214662__ADH-1__no_interaction	BMS-214662__insulin__no_interaction	BMS-214662__p53__no_interaction	bortezomib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	bortezomib__ADH-1__no_interaction	bortezomib__insulin__no_interaction	bortezomib__p53__no_interaction	dutasteride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	dutasteride__ADH-1__no_interaction	dutasteride__insulin__no_interaction	dutasteride__p53__no_interaction	deferasirox__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	deferasirox__ADH-1__no_interaction	deferasirox__insulin__no_interaction	deferasirox__p53__no_interaction	amrubicin hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	amrubicin hydrochloride__ADH-1__no_interaction	amrubicin hydrochloride__insulin__no_interaction	amrubicin hydrochloride__p53__no_interaction	acetate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	acetate__ADH-1__no_interaction	acetate__insulin__no_interaction	acetate__p53__no_interaction	gaboxadol__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	gaboxadol__ADH-1__no_interaction	gaboxadol__insulin__no_interaction	gaboxadol__p53__no_interaction	bosentan__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	bosentan__ADH-1__no_interaction	bosentan__insulin__no_interaction	bosentan__p53__no_interaction	chrysin__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	chrysin__ADH-1__no_interaction	chrysin__insulin__no_interaction	chrysin__p53__no_interaction	diclofenac__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	diclofenac__ADH-1__no_interaction	diclofenac__insulin__no_interaction	diclofenac__p53__no_interaction	atorvastatin__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	atorvastatin__ADH-1__no_interaction	atorvastatin__insulin__no_interaction	atorvastatin__p53__no_interaction	etoricoxib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	etoricoxib__ADH-1__no_interaction	etoricoxib__insulin__no_interaction	etoricoxib__p53__no_interaction	indiplon__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	indiplon__ADH-1__no_interaction	indiplon__insulin__no_interaction	indiplon__p53__no_interaction	fulvestrant__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	fulvestrant__ADH-1__no_interaction	fulvestrant__insulin__no_interaction	fulvestrant__p53__no_interaction	2-deoxyglucose__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	2-deoxyglucose__ADH-1__no_interaction	2-deoxyglucose__insulin__no_interaction	2-deoxyglucose__p53__no_interaction	quinidine sulfate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	quinidine sulfate__ADH-1__no_interaction	quinidine sulfate__insulin__no_interaction	quinidine sulfate__p53__no_interaction	mesylate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	mesylate__ADH-1__no_interaction	mesylate__insulin__no_interaction	mesylate__p53__no_interaction	ciclesonide__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	ciclesonide__ADH-1__no_interaction	ciclesonide__insulin__no_interaction	ciclesonide__p53__no_interaction	darifenacin hydrobromide__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	darifenacin hydrobromide__ADH-1__no_interaction	darifenacin hydrobromide__insulin__no_interaction	darifenacin hydrobromide__p53__no_interaction	clevudine__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	clevudine__ADH-1__no_interaction	clevudine__insulin__no_interaction	clevudine__p53__no_interaction	BN-83495__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	BN-83495__ADH-1__no_interaction	BN-83495__insulin__no_interaction	BN-83495__p53__no_interaction	efaproxiral sodium__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	efaproxiral sodium__ADH-1__no_interaction	efaproxiral sodium__insulin__no_interaction	efaproxiral sodium__p53__no_interaction	duloxetine hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	duloxetine hydrochloride__ADH-1__no_interaction	duloxetine hydrochloride__insulin__no_interaction	duloxetine hydrochloride__p53__no_interaction	Dapoxetine__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Dapoxetine__ADH-1__no_interaction	Dapoxetine__insulin__no_interaction	Dapoxetine__p53__no_interaction	gestodene__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	gestodene__ADH-1__no_interaction	gestodene__insulin__no_interaction	gestodene__p53__no_interaction	Edaravone__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Edaravone__ADH-1__no_interaction	Edaravone__insulin__no_interaction	Edaravone__p53__no_interaction	aliskiren fumarate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	aliskiren fumarate__ADH-1__no_interaction	aliskiren fumarate__insulin__no_interaction	aliskiren fumarate__p53__no_interaction	oxalate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	oxalate__ADH-1__no_interaction	oxalate__insulin__no_interaction	oxalate__p53__no_interaction	Cypher__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Cypher__ADH-1__no_interaction	Cypher__insulin__no_interaction	Cypher__p53__no_interaction	emtricitabine__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	emtricitabine__ADH-1__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__p53__no_interaction	azimilide hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	azimilide hydrochloride__ADH-1__no_interaction	azimilide hydrochloride__insulin__no_interaction	azimilide hydrochloride__p53__no_interaction	erlotinib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	erlotinib__ADH-1__no_interaction	erlotinib__insulin__no_interaction	erlotinib__p53__no_interaction	dasatinib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	dasatinib__ADH-1__no_interaction	dasatinib__insulin__no_interaction	dasatinib__p53__no_interaction	fondaparinux sodium__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	fondaparinux sodium__ADH-1__no_interaction	fondaparinux sodium__insulin__no_interaction	fondaparinux sodium__p53__no_interaction	apaziquone__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	apaziquone__ADH-1__no_interaction	apaziquone__insulin__no_interaction	apaziquone__p53__no_interaction	gossypol__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	gossypol__ADH-1__no_interaction	gossypol__insulin__no_interaction	gossypol__p53__no_interaction	armodafinil__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	armodafinil__ADH-1__no_interaction	armodafinil__insulin__no_interaction	armodafinil__p53__no_interaction	clopidogrel__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	clopidogrel__ADH-1__no_interaction	clopidogrel__insulin__no_interaction	clopidogrel__p53__no_interaction	anecortave__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	anecortave__ADH-1__no_interaction	anecortave__insulin__no_interaction	anecortave__p53__no_interaction	clofarabine__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	clofarabine__ADH-1__no_interaction	clofarabine__insulin__no_interaction	clofarabine__p53__no_interaction	atilmotin__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	atilmotin__ADH-1__no_interaction	atilmotin__insulin__no_interaction	atilmotin__p53__no_interaction	dextofisopam__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	dextofisopam__ADH-1__no_interaction	dextofisopam__insulin__no_interaction	dextofisopam__p53__no_interaction	atazanavir sulfate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	atazanavir sulfate__ADH-1__no_interaction	atazanavir sulfate__insulin__no_interaction	atazanavir sulfate__p53__no_interaction	gefitinib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	gefitinib__ADH-1__no_interaction	gefitinib__insulin__no_interaction	gefitinib__p53__no_interaction	ezetimibe__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	ezetimibe__ADH-1__no_interaction	ezetimibe__insulin__no_interaction	ezetimibe__p53__no_interaction	aprinocarsen sodium__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	aprinocarsen sodium__ADH-1__no_interaction	aprinocarsen sodium__insulin__no_interaction	aprinocarsen sodium__p53__no_interaction	entecavir__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	entecavir__ADH-1__no_interaction	entecavir__insulin__no_interaction	entecavir__p53__no_interaction	aminolevulinic acid hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	aminolevulinic acid hydrochloride__ADH-1__no_interaction	aminolevulinic acid hydrochloride__insulin__no_interaction	aminolevulinic acid hydrochloride__p53__no_interaction	3,4-DAP__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	3,4-DAP__ADH-1__no_interaction	3,4-DAP__insulin__no_interaction	3,4-DAP__p53__no_interaction	Caspofungin acetate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Caspofungin acetate__ADH-1__no_interaction	Caspofungin acetate__insulin__no_interaction	Caspofungin acetate__p53__no_interaction	AP-23573__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	AP-23573__ADH-1__no_interaction	AP-23573__insulin__no_interaction	AP-23573__p53__no_interaction	atomoxetine hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	atomoxetine hydrochloride__ADH-1__no_interaction	atomoxetine hydrochloride__insulin__no_interaction	atomoxetine hydrochloride__p53__no_interaction	Finrozole__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Finrozole__ADH-1__no_interaction	Finrozole__insulin__no_interaction	Finrozole__p53__no_interaction	aminolevulinic acid methyl ester__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	aminolevulinic acid methyl ester__ADH-1__no_interaction	aminolevulinic acid methyl ester__insulin__no_interaction	aminolevulinic acid methyl ester__p53__no_interaction	dronedarone hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	dronedarone hydrochloride__ADH-1__no_interaction	dronedarone hydrochloride__insulin__no_interaction	dronedarone hydrochloride__p53__no_interaction	avanafil__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	avanafil__ADH-1__no_interaction	avanafil__insulin__no_interaction	avanafil__p53__no_interaction	dextromethorphan__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	dextromethorphan__ADH-1__no_interaction	dextromethorphan__insulin__no_interaction	dextromethorphan__p53__no_interaction	adefovir dipivoxil__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	adefovir dipivoxil__ADH-1__no_interaction	adefovir dipivoxil__insulin__no_interaction	adefovir dipivoxil__p53__no_interaction	arzoxifene__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	arzoxifene__ADH-1__no_interaction	arzoxifene__insulin__no_interaction	arzoxifene__p53__no_interaction	Imatinib__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Imatinib__ADH-1__no_interaction	Imatinib__insulin__no_interaction	Imatinib__p53__no_interaction	aripiprazole__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	aripiprazole__ADH-1__no_interaction	aripiprazole__insulin__no_interaction	aripiprazole__p53__no_interaction	anakinra__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	anakinra__ADH-1__no_interaction	anakinra__insulin__no_interaction	anakinra__p53__no_interaction	ghrelin__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	ghrelin__ADH-1__no_interaction	ghrelin__insulin__no_interaction	ghrelin__p53__no_interaction	Epigallocatechin gallate__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	Epigallocatechin gallate__ADH-1__no_interaction	Epigallocatechin gallate__insulin__no_interaction	Epigallocatechin gallate__p53__no_interaction	ezetimibe/simvastatin__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	ezetimibe/simvastatin__ADH-1__no_interaction	ezetimibe/simvastatin__insulin__no_interaction	ezetimibe/simvastatin__p53__no_interaction	istradefylline__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	istradefylline__ADH-1__no_interaction	istradefylline__insulin__no_interaction	istradefylline__p53__no_interaction	fipamezole hydrochloride__insulin detemir, insulin glargine, insulin glulisine, intranasal insulin__no_interaction	fipamezole hydrochloride__ADH-1__no_interaction	fipamezole hydrochloride__insulin__no_interaction	fipamezole hydrochloride__p53__no_interaction
17136234-4	gamma-globulin, <compound-id="132999">ivabradine hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; LA-419, <compound-id="219078">lacosamide</compound-id>, <compound-id="114905">landiolol</compound-id>, <compound-id="23926">lanthanum</compound-id> carbonate, <compound-id="9911821">lidocaine/prilocaine</compound-id>, liposomal cisplatin, lutropin alfa; Matuzumab, MBP(82-98), mecasermin, MGCD-0103, MMR-V, <compound-id="5288826">morphine hydrochloride</compound-id>, <compound-id="446541">mycophenolic acid sodium salt</compound-id>; Natalizumab, <compound-id="119032">NCX-4016</compound-id>, <compound-id="71237">neridronic acid</compound-id>, nesiritide, <compound-id="644241">nilotinib</compound-id>, <compound-id="6505803">NSC-330507</compound-id>; <compound-id="4578">O6-benzylguanine</compound-id>, <compound-id="4585">olanzapine</compound-id>/<compound-id="3386">fluoxetine hydrochloride</compound-id>, omalizumab; Panitumumab, parathyroid hormone (human recombinant), <compound-id="119828">parecoxib sodium</compound-id>, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="115368">perospirone</compound-id> hydrochloride, pexelizumab, <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id>, pneumococcal 7-valent conjugate vaccine, <compound-id="468595">posaconazole</compound-id>, <compound-id="3013050">pramiconazole</compound-id>, <compound-id="6918456">prasugrel</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="4906">prilocaine</compound-id>; rAAV-GAD65, <compound-id="3033769">raclopride</compound-id>, <compound-id="3052776">rasagiline</compound-id> mesilate, <compound-id="6918462">retapamulin</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133">rosuvastatin calcium</compound-id>, <compound-id="59227">rotigotine</compound-id>, <compound-id="129228">rufinamide</compound-id>; SarCNU, <compound-id="22345245">SB-743921</compound-id>, SHL-749, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498">sirolimus</compound-id>-eluting stent, <compound-id="216235">sitaxsentan sodium</compound-id>, <compound-id="216239">sorafenib</compound-id>; TachoSil, <compound-id="110635">tadalafil</compound-id>, <compound-id="164509">talampanel</compound-id>, Taxus, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, <compound-id="65999">telmisartan</compound-id>/<compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">temsirolimus</compound-id>, <compound-id="636411">tenatoprazole</compound-id>, <compound-id="54684141">teriflunomide</compound-id>, tetrathiomolybdate, ticilimumab, <compound-id="9811664">timcodar dimesilate</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, TPI, <compound-id="1646">tramiprosate</compound-id>, <compound-id="6256">trifluridine</compound-id>/TPI, <compound-id="5578">trimethoprim</compound-id>; <compound-id="16132416">Ularitide</compound-id>, <protein-id="Q96RP3">Urocortin 2</protein-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">valganciclovir hydrochloride</compound-id>, <compound-id="3121">valproate</compound-id> <compound-id="5462224">magnesium</compound-id>, <compound-id="5281884">valspodar</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate, vitespen, <compound-id="6918331">vofopitant</compound-id> hydrochloride, volociximab, <compound-id="5311">vorinostat</compound-id>; <compound-id="23993">Yttrium</compound-id> 90 (<compound-id="104760">90Y</compound-id>) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; <compound-id="60854">Ziprasidone hydrochloride</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>-eluting stent.	parecoxib sodium__Urocortin 2__no_interaction	vorinostat__Urocortin 2__no_interaction	tenatoprazole__Urocortin 2__no_interaction	telmisartan__Urocortin 2__no_interaction	teriflunomide__Urocortin 2__no_interaction	90Y__Urocortin 2__no_interaction	landiolol__Urocortin 2__no_interaction	acetate__Urocortin 2__no_interaction	pramiconazole__Urocortin 2__no_interaction	Valdecoxib__Urocortin 2__no_interaction	perospirone__Urocortin 2__no_interaction	NSC-330507__Urocortin 2__no_interaction	rufinamide__Urocortin 2__no_interaction	fluoxetine hydrochloride__Urocortin 2__no_interaction	zotarolimus__Urocortin 2__no_interaction	SB-743921__Urocortin 2__no_interaction	morphine hydrochloride__Urocortin 2__no_interaction	tadalafil__Urocortin 2__no_interaction	valganciclovir hydrochloride__Urocortin 2__no_interaction	nilotinib__Urocortin 2__no_interaction	prilocaine__Urocortin 2__no_interaction	sitaxsentan sodium__Urocortin 2__no_interaction	trimethoprim__Urocortin 2__no_interaction	O6-benzylguanine__Urocortin 2__no_interaction	trifluridine__Urocortin 2__no_interaction	sirolimus__Urocortin 2__no_interaction	ivabradine hydrochloride__Urocortin 2__no_interaction	vofopitant__Urocortin 2__no_interaction	vardenafil hydrochloride__Urocortin 2__no_interaction	rotigotine__Urocortin 2__no_interaction	neridronic acid__Urocortin 2__no_interaction	talampanel__Urocortin 2__no_interaction	tirapazamine__Urocortin 2__no_interaction	Ularitide__Urocortin 2__no_interaction	phorbol 12-myristate__Urocortin 2__no_interaction	valproate__Urocortin 2__no_interaction	raclopride__Urocortin 2__no_interaction	tipifarnib__Urocortin 2__no_interaction	valspodar__Urocortin 2__no_interaction	retapamulin__Urocortin 2__no_interaction	ixabepilone__Urocortin 2__no_interaction	Yttrium__Urocortin 2__no_interaction	tegaserod maleate__Urocortin 2__no_interaction	NCX-4016__Urocortin 2__no_interaction	lidocaine/prilocaine__Urocortin 2__no_interaction	Ziprasidone hydrochloride__Urocortin 2__no_interaction	rasagiline__Urocortin 2__no_interaction	pemetrexed disodium__Urocortin 2__no_interaction	ibritumomab tiuxetan__Urocortin 2__no_interaction	pregabalin__Urocortin 2__no_interaction	telithromycin__Urocortin 2__no_interaction	lanthanum__Urocortin 2__no_interaction	posaconazole__Urocortin 2__no_interaction	tramiprosate__Urocortin 2__no_interaction	sorafenib__Urocortin 2__no_interaction	rosuvastatin calcium__Urocortin 2__no_interaction	timcodar dimesilate__Urocortin 2__no_interaction	magnesium__Urocortin 2__no_interaction	hydrochlorothiazide__Urocortin 2__no_interaction	mycophenolic acid sodium salt__Urocortin 2__no_interaction	olanzapine__Urocortin 2__no_interaction	lacosamide__Urocortin 2__no_interaction	prasugrel__Urocortin 2__no_interaction	temsirolimus__Urocortin 2__no_interaction
22764645-8	There were significant correlations at three months between changes in <protein-id="P02647,A0A024R3E3">Apo A1</protein-id> and A2 (r = .559, P &lt; .001), <protein-id="P02649">Apo E</protein-id> and total <compound-id="5997">cholesterol</compound-id> (r = .746, P &lt; .001), between A1c and FPG (r = .563, P = .001) and BMI and body weight (r = .732, P &lt; .001).	cholesterol__Apo A1__no_interaction	cholesterol__Apo E__no_interaction
22421784-1	A 55-year-old male had complained of melena.Colonoscopy revealed a type 2 tumor at the rectum.CT demonstrated hepatic lymph nodes and multiple liver metastases(stage IV).Low anterior resection was performed(tub2, RsRa, circ, type 2, pSS, <protein-id="P07093,A0A024R451,A0A024R498">pN1</protein-id>, sH3, <protein-id="P15882">cHN1</protein-id>, <compound-id="2742752">sP0</compound-id>, cM0: fstage IV).The patient was treated with mFOLFOX6 and sLV5FU2 after operation.CT revealed a partial response after 14 courses of systemic chemotherapy.sLV5 <compound-id="5288269">FU2</compound-id> therapy was converted to <compound-id="60953">capecitabine</compound-id> because he experienced bone marrow suppression.CT showed that the liver metastases had enlarged but the hepatic lymph nodes disappeared.Right portal vein embolization was performed.After 4 weeks, right hepatectomy and hepatic lymph node dissection were performed.Preoperative chemotherapy with mFOLFOX6 seems beneficial as a neoadjuvant chemotherapy for hepatic lymph node-positive advanced colorectal cancer.	sP0__pN1__no_interaction	sP0__cHN1__no_interaction	capecitabine__pN1__no_interaction	capecitabine__cHN1__no_interaction	FU2__pN1__no_interaction	FU2__cHN1__no_interaction
10618482-3	<compound-id="114873">Thromboxane</compound-id> production was increased by the bisindolylmaleimide derivative, 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimi de (<compound-id="2396">GF 109203X</compound-id>), unchanged by the inhibitors 12-(2-cyanoethyl)-6,7, 12,13-tetrahydro-13-methyl-5-oxo-5H-indolo (2,3-a) pyrrolo (3, 4-c)-<compound-id="6854">carbazole</compound-id> (Gö 6976) and 5,21:12,17-dimetheno-<compound-id="73254836">18H</compound-id>-dibenzo[i, o]pyrrolo[3,4-l][1,8]diazacyclohexadecine-18,20(<compound-id="70680244">19H</compound-id>)-dione, 8-[(dimethylamino)methyl]-6,7,8,9,10,11-hexahydro-, monomethanesulfonate (379196), the latter of which is protein kinase C beta-selective, and decreased by 1-[6-[(3-acetyl-2,4, 6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2, 2-dimethyl-2H-1-<compound-id="9211">benzopyran</compound-id>-8-yl]-<compound-id="307">3-phenyl-2-propen-1-one</compound-id> (<compound-id="5281847">rottlerin</compound-id>), an inhibitor selective for <protein-id="Q05655,A0A024R328">protein kinase C delta</protein-id>.	GF 109203X__protein kinase C delta__no_interaction	Thromboxane__protein kinase C delta__no_interaction	carbazole__protein kinase C delta__no_interaction	18H__protein kinase C delta__no_interaction	3-phenyl-2-propen-1-one__protein kinase C delta__no_interaction	19H__protein kinase C delta__no_interaction	rottlerin__protein kinase C delta__no_interaction	benzopyran__protein kinase C delta__no_interaction
22689503-3	We synthesized, purified, and applied the first <compound-id="24824">tritium-</compound-id>labeled allosteric modulator of the human chemokine receptor <protein-id="P49682">CXCR3</protein-id> (RAMX3, [(3) H]N-{1-[3-(4-<compound-id="7674">ethoxyphenyl</compound-id>)-4-oxo-3,4-<compound-id="13347754">dihydropyrido</compound-id>[2,3-d]pyrimidin-2-yl]<compound-id="23134249">ethyl</compound-id>}-2-[4-fluoro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]-<compound-id="23391806">N-[(1-methylpiperidin-4-yl)methyl]acetamide</compound-id>).	dihydropyrido__CXCR3__no_interaction	tritium-__CXCR3__no_interaction	ethoxyphenyl__CXCR3__no_interaction	N-[(1-methylpiperidin-4-yl)methyl]acetamide__CXCR3__no_interaction	trifluoromethyl__CXCR3__no_interaction	ethyl__CXCR3__no_interaction
15644578-4	Compared with 64 control women, <compound-id="16850">NAFL</compound-id> had a significant increase in the variables of the metabolic syndrome, other hepatic enzymes and <protein-id="P41159,A4D0Y8">leptin</protein-id> levels, while a reduction in AST/ALT ratio and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> before (mean +/- SE: 7.2 +/- 0.5 vs 9.0 +/- 0.4 microg/ml, p &lt; 0.005) and after adjustment for body fat mass (0.24 +/- 0.02 vs 0.34 +/- 0.02, p &lt; 0.0001), atherogenic Index [(total <compound-id="5997">cholesterol</compound-id> - HDLC)/HDLC: 3.2 +/- 0.3 vs 4.6 +/- 0.3, p &lt; 0.005] or calculated insulin resistance (HOMA-R) (6.6 +/- 1.9 vs 8.6 +/- 0.9, p &lt; 0.005).	NAFL__leptin__no_interaction	NAFL__adiponectin__no_interaction	cholesterol__leptin__no_interaction	cholesterol__adiponectin__no_interaction
18523766-9	Table 1 Results according to each different method Patient Sex Side <protein-id="P00915,V9HWE3">CA1</protein-id> <protein-id="Q8ND90">MA1</protein-id> <protein-id="Q9Y624,Q6FIB4">PAM1</protein-id> R2 D2 PAM2 R3 D3 PAM3 1 M R 738 19.1 2.58 15.1 13.4 2.45 16 14 2.6 2 M R 462.6 30.5 6.59 11.9 9.7 4.83 16 10 12.97 3 F L 359 24.5 6.82 17 11.8 9.86 11.8 17 9.86 4 M L 522 59.4 11.37 12.7 9.1 8.95 16 10 12.97 5 M L 670 93.1 13.89 13.6 7.6 16.84 16 9 16.31 6 M R 659 137.5 20.8 14.3 7.1 20.10 20 8 25.23 7 M L 520 137 26.34 11.6 5.1 23.49 16 8 19.55 <compound-id="446250">AVG</compound-id> 12.63 12.36 14.21 SD 8.46 7.92 7.20 <protein-id="P00915,V9HWE3">CA1</protein-id> Area of circle directly measured by MPR software, <protein-id="Q8ND90">MA1</protein-id> missing area of circle measured by MPR software, <protein-id="Q9Y624,Q6FIB4">PAM1</protein-id> calculated (100 x <protein-id="Q8ND90">MA1</protein-id>/<protein-id="P00915,V9HWE3">CA1</protein-id>) percentage area missing for method 1, R2 radius of the circle measured by MPR software, D2 depth from the missing edge to the center of the circle measured by MPR software, PAM2 calculated Percentage area missing from R2 and D2 using the function "q" (Appendix), R3 radius of the circle measured with a femoral gauge, D3 depth from the missing edge to the center of the circle measured with a femoral gauge, PAM3 calculated Percentage area missing from R3 and D3 using the function "q" (Appendix), <compound-id="446250">AVG</compound-id> average, SD standard deviation CONCLUSION: Using this simple method and the function provided, the eroded area of the anterior part of the glenoid in anterior glenohumeral instability can be calculated preoperatively using a 3D CT reconstruction of the glenoid with "subtraction" of the humeral head, obviating the need for sophisticated software to obtain this critical information for preoperative decision making. 	AVG__MA1__no_interaction	AVG__CA1__no_interaction	AVG__PAM1__no_interaction
11393096-7	The 5-day storage significantly increased the mean proportion of platelets expressing <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62P</protein-id> (25.00% vs 15.02%, p = 0.008), mean PO2 (116.34 mm Hg vs 98.07 mm Hg, p = 0.002), and mean concentrations of K+ (3.30 mmol/L vs 3.06 mmol/L, p &lt; 0.001), <compound-id="612">lactate</compound-id> (15.12 mmol/L vs 3.23 mmol/L, p &lt; 0.001), <protein-id="P01584">IL-1 beta</protein-id> (52.75 pg/mL vs 29.73 pg/mL, p = 0.001), and <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (13.07 pg/mL vs 3.62 pg/mL, p &lt; 0.001).	lactate__IL-1 beta__no_interaction	lactate__IL-8__no_interaction	lactate__CD62P__no_interaction
19565884-12	Results from Univariate analysis demonstrated that 24 parameters were correlated with an adverse 14-day clinical outcomes, which include palpation, syncope, panic, cyanosis, respiratory rate &gt; or = 30/min, pulse &gt; or = 110/min, jugular vein, accentuation of P2, murmurs in tricuspid area, time interval from onset, <compound-id="586">creatine</compound-id> phosphokinase (CPK), <compound-id="612">lactate</compound-id> dehydrogenase (LDH), alveolar-arterial PO2 difference (PA-<compound-id="448288">aO2</compound-id>), white blood cell (WBC) &lt; 4.0 x 10(9)/L or &gt;10.0 x 10(9)/L, platelet, thrombus on TTE, RV/LV &gt; 1.1, TRPG &gt;30 mm Hg, IVCmin &lt;8 mm, <compound-id="46934007">RVD</compound-id>, RVED/LVED &gt; 0.6, <protein-id="Q13113">SPAP</protein-id> &gt;60 mm Hg, RVWM, PTE range larger than two lobes or seven segments on <compound-id="130577">CTPA</compound-id>.	CTPA__SPAP__no_interaction	RVD__SPAP__no_interaction	lactate__SPAP__no_interaction	aO2__SPAP__no_interaction	creatine__SPAP__no_interaction
11315931-8	RESULTS: Activation of PMN by <protein-id="P05164">MPO</protein-id>-ANCA-positive IgG preparations compared with <protein-id="P24158">PR3-ANCA</protein-id>-positive IgG preparations resulted in greater generation of <compound-id="5359597">superoxide</compound-id> anions (<protein-id="P05164">MPO</protein-id>-ANCA-positive IgG preparations 9.13 +/- 0.39 nmoles [mean +/- <compound-id="5289348">SEM</compound-id>], <protein-id="P24158">PR3-ANCA</protein-id>-positive IgG preparations 6.32 +/- 0.35 nmoles; P &lt; 0.001), Ca2+ fluxes (<protein-id="P05164">MPO</protein-id>-ANCA-positive IgG preparations 0.735 +/- 0.10, <protein-id="P24158">PR3-ANCA</protein-id>-positive IgG preparations 0.33 +/- 0.098; P &lt; 0.01), and <protein-id="P05164">MPO</protein-id> degranulation (<protein-id="P05164">MPO</protein-id>-ANCA-positive IgG preparations 251.98 +/- 26.7 ng, <protein-id="P24158">PR3-ANCA</protein-id>-positive IgG preparations 145.19 +/- 19.4 ng; P &lt; 0.001).	SEM__MPO__no_interaction	SEM__PR3-ANCA__no_interaction	superoxide__MPO__no_interaction	superoxide__PR3-ANCA__no_interaction
24414551-13	Total and free <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> levels during cycle 1 Cycle 1 Total <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> (pg/mL) Mean ± SD Free <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> (pg/mL) Mean ± SD D1 80 ± 70 51 ± 47 <compound-id="51063198">D29</compound-id> 150 ± 62 103 ± 35 D29H4 10 ± 12 2 ± 5 <compound-id="5288018">D42</compound-id> 177 ± 34 97 ± 18 CONCLUSIONS: Subclinical MAHA was seen despite using sequential <compound-id="3086686,5329102">sunitinib</compound-id> with low-dose bevacizumab, and this combination was not feasible for further development.	D29__VEGF__no_interaction	D42__VEGF__no_interaction	sunitinib__VEGF__no_interaction
21215776-2	The results indicated that: (1) SKNBE neuroblastoma cells treated with <compound-id="24934">sodium selenite</compound-id>, <compound-id="25960">sodium selenate</compound-id> and seleno-<compound-id="6137,84815,876">methionine</compound-id> (0.1, 0.5 and 0.5 μM, respectively) for 24h exhibited a viability decrease, unlike kidney or prostatic cells; (2) the PARP (poly-<compound-id="192,44415180,445794">ADP-ribose</compound-id>-polymerase) degradation and caspase activation detected by Western blot and flow cytometry fluorimetric examination showed induction of apoptosis; (3) during selenium treatment, a <protein-id="P08922">ROS</protein-id>/RNS increase occurred despite the GSH increment, as revealed by fluorimetric analysis; (4) the RNS production could be blocked by a <compound-id="104806">peroxynitrite</compound-id> scavenger; (5) after exposure to <compound-id="6326970">selenium compounds</compound-id>, the concentration of <compound-id="145068">nitric oxide</compound-id> synthase, <protein-id="P04179,A0A0C4DFU1,A0A0C4DFU2">manganese superoxide dismutase</protein-id> (<protein-id="P04179,A0A0C4DFU1,A0A0C4DFU2">SOD2</protein-id>), P-NF-kB (phospho nuclear factor kB), <compound-id="124886,20725278,745">glutathione</compound-id> reductase and <compound-id="124886,20725278,745">glutathione</compound-id> peroxidase increased, whereas that of <protein-id="Q9NZJ5">P-ERK</protein-id> (phospho extracellular signal-regulated kinase) decreased; (6) selenium presence induced <compound-id="23978">copper</compound-id>/<compound-id="14809">zinc superoxide</compound-id> dismutase (<protein-id="P00441,V9HWC9">SOD1</protein-id>) translocation into mitochondria, in a way similar to what is observed in amyotrophic lateral sclerosis (ALS).	selenium compounds__manganese superoxide dismutase__no_interaction	selenium compounds__P-ERK__no_interaction	selenium compounds__ROS__no_interaction	selenium compounds__SOD2__no_interaction	selenium compounds__SOD1__no_interaction	copper__manganese superoxide dismutase__no_interaction	copper__P-ERK__no_interaction	copper__ROS__no_interaction	copper__SOD2__no_interaction	copper__SOD1__no_interaction	glutathione__manganese superoxide dismutase__no_interaction	glutathione__P-ERK__no_interaction	glutathione__ROS__no_interaction	glutathione__SOD2__no_interaction	glutathione__SOD1__no_interaction	peroxynitrite__manganese superoxide dismutase__no_interaction	peroxynitrite__P-ERK__no_interaction	peroxynitrite__ROS__no_interaction	peroxynitrite__SOD2__no_interaction	peroxynitrite__SOD1__no_interaction	zinc superoxide__manganese superoxide dismutase__no_interaction	zinc superoxide__P-ERK__no_interaction	zinc superoxide__ROS__no_interaction	zinc superoxide__SOD2__no_interaction	zinc superoxide__SOD1__no_interaction	methionine__manganese superoxide dismutase__no_interaction	methionine__P-ERK__no_interaction	methionine__ROS__no_interaction	methionine__SOD2__no_interaction	methionine__SOD1__no_interaction	sodium selenate__manganese superoxide dismutase__no_interaction	sodium selenate__P-ERK__no_interaction	sodium selenate__ROS__no_interaction	sodium selenate__SOD2__no_interaction	sodium selenate__SOD1__no_interaction	nitric oxide__manganese superoxide dismutase__no_interaction	nitric oxide__P-ERK__no_interaction	nitric oxide__ROS__no_interaction	nitric oxide__SOD2__no_interaction	nitric oxide__SOD1__no_interaction	ADP-ribose__manganese superoxide dismutase__no_interaction	ADP-ribose__P-ERK__no_interaction	ADP-ribose__ROS__no_interaction	ADP-ribose__SOD2__no_interaction	ADP-ribose__SOD1__no_interaction	sodium selenite__manganese superoxide dismutase__no_interaction	sodium selenite__P-ERK__no_interaction	sodium selenite__ROS__no_interaction	sodium selenite__SOD2__no_interaction	sodium selenite__SOD1__no_interaction
16282559-5	RESULTS: Simple sex-stratified correlations demonstrated that, in men, body mass index-adjusted handgrip strength correlated positively with physical activity (r = 0.321; p &lt; .001), muscle area (r = 0.420; p &lt; .001), muscle density (r = 0.263; p = .001), plasma <protein-id="P02768">albumin</protein-id> (r = 0.156; p = .001), <protein-id="P05019,Q5U743,Q13429,Q59GC5">Insulin-like growth factor-1</protein-id> (r = 0.258; p &lt; .001), <compound-id="22044544,5460341">calcium</compound-id> (r = 0.140; p = .006), and <compound-id="6013">testosterone</compound-id> (r = 0.325; p &lt; .001) concentrations, whereas a negative association was found for age (r = -0.659; p &lt; .001) and <protein-id="P02144">myoglobin</protein-id> plasma levels (r = -0.164; p =.001).	calcium__Insulin-like growth factor-1__no_interaction	calcium__albumin__no_interaction	calcium__myoglobin__no_interaction	testosterone__Insulin-like growth factor-1__no_interaction	testosterone__albumin__no_interaction	testosterone__myoglobin__no_interaction
19633067-7	Although known substrates of <protein-id="Q9UNQ0,A0A024RDD4">ABCG2</protein-id> such as <compound-id="4212">mitoxantrone</compound-id> or <compound-id="60700">topotecan</compound-id> were not identified, we characterized three novel substrates-<compound-id="5360588">5-hydroxypicolinaldehyde thiosemicarbazone</compound-id> (<compound-id="5494303">NSC107392</compound-id>), (E)-<compound-id="319853">N-(1-decylsulfanyl-3-hydroxypropan-2-yl)-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide</compound-id> (<compound-id="5351281">NSC265473</compound-id>), and <compound-id="609635,72377">1,2,3,4,7-pentahydroxy-1,3,4,4a,5,11b-hexahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one</compound-id> [<compound-id="441597">NSC349156</compound-id> (pancratistatin)]-and four compounds that inhibited transporter function-2-[methyl(2-pyridin-2-ylethyl)-amino]<compound-id="10241">fluoren-9-one</compound-id> hydroiodide (NSC24048), <compound-id="53696623">5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic acid</compound-id>, <compound-id="13468584">methyl ester</compound-id> (<compound-id="5351544">NSC45384</compound-id>), (17beta)-2,4-dibromo-<compound-id="9811784">estra-1,3,5(10)-triene-3,17-diol</compound-id> (<compound-id="266051">NSC103054</compound-id>), and <compound-id="3000602">methyl N-(pyridine-4-carbonylamino)carbamodithioate</compound-id> (NSC636795).	N-(1-decylsulfanyl-3-hydroxypropan-2-yl)-3-(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)prop-2-enamide__ABCG2__no_interaction	NSC265473__ABCG2__no_interaction	NSC107392__ABCG2__no_interaction	fluoren-9-one__ABCG2__no_interaction	NSC103054__ABCG2__no_interaction	NSC349156__ABCG2__no_interaction	mitoxantrone__ABCG2__no_interaction	topotecan__ABCG2__no_interaction	1,2,3,4,7-pentahydroxy-1,3,4,4a,5,11b-hexahydro[1,3]dioxolo[4,5-j]phenanthridin-6(2H)-one__ABCG2__no_interaction	5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic acid__ABCG2__no_interaction	estra-1,3,5(10)-triene-3,17-diol__ABCG2__no_interaction	5-hydroxypicolinaldehyde thiosemicarbazone__ABCG2__no_interaction	NSC45384__ABCG2__no_interaction	methyl N-(pyridine-4-carbonylamino)carbamodithioate__ABCG2__no_interaction	methyl ester__ABCG2__no_interaction
18345622-2	This intriguing reaction provided us with a convenient entry into a series of mononuclear <compound-id="23932">molybdenum</compound-id> trisulfido complexes, [<protein-id="O14649">PPh 4</protein-id>][MoS 3X] ( 4, X = Cp*; 6a, X = S (t) Bu; 6b, X = SPh; 6c, X = SMes (Mes = mesityl); 6d, X = <protein-id="Q6IA86">STip</protein-id> (Tip = 2,4,6-<compound-id="13880201">triisopropylphenyl</compound-id>); 6e, X = <compound-id="94924">SDmp</compound-id> (Dmp = <compound-id="4137109">2,6-dimesitylphenyl</compound-id>); 7, X = <protein-id="O95156">NPh 2</protein-id>; 8a, X = O (t) Bu; 8b, X = OPh; 8c, X = OC(CH 2) (t) Bu; 8d, X = OC(CH 2)Ph), which were obtained by the reactions of 2 with the corresponding <compound-id="5462222">potassium</compound-id> salts.	triisopropylphenyl__PPh 4__no_interaction	triisopropylphenyl__STip__no_interaction	triisopropylphenyl__NPh 2__no_interaction	potassium__PPh 4__no_interaction	potassium__STip__no_interaction	potassium__NPh 2__no_interaction	2,6-dimesitylphenyl__PPh 4__no_interaction	2,6-dimesitylphenyl__STip__no_interaction	2,6-dimesitylphenyl__NPh 2__no_interaction	SDmp__PPh 4__no_interaction	SDmp__STip__no_interaction	SDmp__NPh 2__no_interaction	molybdenum__PPh 4__no_interaction	molybdenum__STip__no_interaction	molybdenum__NPh 2__no_interaction
20023994-1	A series of symmetric and unsymmetric N,N-bis(diarylphosphino)amine ('<protein-id="P00491,V9HWH6">PNP</protein-id>') ligands (Ar2PN(R)PNAr'2: R = Me, Ar2 = o-anisyl, Ar'2 = Ph, 1, R = Me, Ar2 = o-tolyl, Ar'2 = Ph, 2, R = Me, Ar2 = Ph(o-<compound-id="23134249">ethyl</compound-id>), Ar'2 = Ph, 3, R = Me, Ar2 = Ar'2 = o-anisyl, 4, R = iPr, Ar2 = Ar'2 = Ph, 5) and symmetric N,N'-bis(diarylphosphino)<compound-id="5976">dimethylhydrazine</compound-id> ('PNNP') ligands (Ar2PN(Me)N(Me)PAr2: Ar2 = o-tolyl, 6, Ar2 = o-anisyl, 7) have been synthesised.	dimethylhydrazine__PNP__no_interaction	ethyl__PNP__no_interaction
16499375-2	The following new classes of bam complexes have been structurally characterized: heterobimetallic spirocycles {(L)mu-Li[<protein-id="P35232,A8K401,Q53FV0">PhB</protein-id>(mu-NtBu)2]}2M (6a,b, M = Mg, L = Et2O, <compound-id="8028">THF</compound-id>; 6c, M = Zn, L = Et(2)O); bis(organomagnesium) complexes {[<protein-id="P35232,A8K401,Q53FV0">PhB</protein-id>(mu3-NtBu)2](MgtBu)2(mu3-Cl)Li(OEt2)3} (8) and {[<protein-id="P35232,A8K401,Q53FV0">PhB</protein-id>(mu3-NtBu)2](MgR)2(<compound-id="8028">THF</compound-id>)2} (9a, R = iPr; 9b, R = Ph); mononuclear complex {[<protein-id="P35232,A8K401,Q53FV0">PhB</protein-id>(mu-NDipp)2]Mg(OEt2)2} (10).	THF__PhB__no_interaction
7798908-3	The rank order potency of drugs competing with [3H]<compound-id="443408">diprenorphine</compound-id> was as follows: <compound-id="5359272">levorphanol</compound-id> (Ki = 0.6 +/- 0.2 nM) approximately beta-endorphin (Ki = 0.7 +/- 0.05 nM) approximately morphine (Ki = 0.8 +/- 0.5 nM) approximately [D-Ala2, N-Me-Phe4,Gly-ol5]-<protein-id="P04094">enkephalin</protein-id> (DAMGO; Ki = 1.6 +/- 0.5 nM) uch much greater than <compound-id="3036289">U50,488</compound-id> (Ki = 910 +/- 0.78 nM) &gt; [D-Pen2,5]- <protein-id="P04094">enkephalin</protein-id> (Ki = 3,170 +/- 98 nM) &gt; <compound-id="3918,5360697">dextrorphan</compound-id> (Ki = 4,100 +/- 68 nM).	dextrorphan__enkephalin__no_interaction	U50,488__enkephalin__no_interaction	diprenorphine__enkephalin__no_interaction	levorphanol__enkephalin__no_interaction
1563746-5	The phenotypic profile of the BZSLL clonal cell population studied by the immunoperoxidase method and by single- and double-labeling flow cytometric analyses (SIg+, <protein-id="P15391">CD19</protein-id>+, <protein-id="P11836,A0A024R507">CD20</protein-id>+, <protein-id="P20023">CD21</protein-id>+, <protein-id="P20273,Q0EAF5">CD22</protein-id>+, <protein-id="P25063,B6EC88,A0A087WYI6">CD24</protein-id>+, <protein-id="P17927,E9PDY4">CD35</protein-id>+, <protein-id="P11049">CD37</protein-id>+, <protein-id="P04233">CD74</protein-id>+, <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45</protein-id>+, <protein-id="P08575,A0A0A0MT22,M9MML4,X6R433">CD45R</protein-id>+, MB2+, HLA-DR+, Leu-8+, <protein-id="P21926,B4DK09,A6NNI4">CD9</protein-id>+/-, CDw75+/-, <protein-id="P06127">CD5</protein-id>-/+, <protein-id="P06734,K3W4U1">CD23</protein-id>-/+, CD10-, FMC7-, PCA-1-, <protein-id="P01589,Q5W005">CD25</protein-id>-, <protein-id="P28907">CD38</protein-id>-, CD43-, CD3-) appeared to be fairly homogeneous and sufficiently distinct from that of ILL/<compound-id="9820664">MZL</compound-id>, based on the absence of FMC7 and <protein-id="P28907">CD38</protein-id> molecules, and from that of <protein-id="Q8TB61">SLL/CLL</protein-id> due to significantly stronger expression of SIgs (P less than .05), the higher reactivity with anti-<protein-id="P21926,B4DK09,A6NNI4">CD9</protein-id> and -<protein-id="P20273,Q0EAF5">CD22</protein-id> antibodies (P less than .05), the lower reactivity with anti-<protein-id="P06127">CD5</protein-id> and -<protein-id="P06734,K3W4U1">CD23</protein-id> antibodies (P less than .05), and the absence of <protein-id="P01589,Q5W005">CD25</protein-id> determinants.	MZL__CD74__no_interaction	MZL__CD38__no_interaction	MZL__SLL/CLL__no_interaction	MZL__CD45__no_interaction	MZL__CD22__no_interaction	MZL__CD21__no_interaction	MZL__CD20__no_interaction	MZL__CD35__no_interaction	MZL__CD25__no_interaction	MZL__CD24__no_interaction	MZL__CD5__no_interaction	MZL__CD23__no_interaction	MZL__CD45R__no_interaction	MZL__CD37__no_interaction	MZL__CD9__no_interaction	MZL__CD19__no_interaction
12402308-4	Our study indicates that (i) <protein-id="P16070">CD44</protein-id> stimulation by fragmented HA upregulates expression of <protein-id="P00749,A0A024QZM9,Q59GZ8">uPA</protein-id> and <protein-id="Q03405,M0R1I2">uPAR</protein-id> mRNA and protein but does not affect MMPs secretion or <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> mRNA expression; (ii) the effects of HA fragments are critically HA size dependent: high molecular weight HA is inactive, but lower molecular weight fragmented HA (Mr 3.5 kDa) is active; (iii) cells can bind avidly Mr 3.5 kDa fragmented HA through a <protein-id="P16070">CD44</protein-id> molecule, whereas cells do not effectively bind higher Mr HA; (iv) a fragmented HA induces phosphorylation of MAP kinase proteins (<protein-id="P36507,B3KS97">MEK1/2</protein-id>, <protein-id="P28482,Q1HBJ4,Q499G7">ERK1/2</protein-id> and c-Jun) within 30 min; (v) <protein-id="P16070">CD44</protein-id> is critical for the response (activation of MAP kinase and upregulation of <protein-id="P00749,A0A024QZM9,Q59GZ8">uPA</protein-id> and <protein-id="Q03405,M0R1I2">uPAR</protein-id> expression); and (vi) cell invasion induced by <protein-id="P16070">CD44</protein-id> stimulation with a fragmented HA is inhibited by anti-<protein-id="P16070">CD44</protein-id> mAb, MAP kinase inhibitors, neutralizing anti-<protein-id="Q03405,M0R1I2">uPAR</protein-id> pAb, anti-catalytic anti-<protein-id="P00749,A0A024QZM9,Q59GZ8">uPA</protein-id> mAb or <compound-id="16231">amiloride</compound-id>.	amiloride__CD44__no_interaction	amiloride__uPA__no_interaction	amiloride__uPAR__no_interaction	amiloride__MEK1/2__no_interaction	amiloride__ERK1/2__no_interaction	amiloride__PAI-1__no_interaction
23808436-5	There was a difference in total triglycerides (95 ± 29 mg/dL and 60 ± 10 mg/dL) which were correlated with a decrease in serum ferritin levels (r = 0,926, p = 0.008), UIBC (r = 0.910, p = 0.01), total <compound-id="5997">cholesterol</compound-id> (r = 0,918, p = 0.01) and <protein-id="Q14746,B1ALW7">LDL-c</protein-id> fraction (r = 0.830, p = 0.04), with an increase in HDL-c fraction (r = 0,807, p = 0.05).	cholesterol__LDL-c__no_interaction
21875366-9	There was a significant positive correlation of fT3 with milk concentrations of PCB138, <compound-id="37034">PCB153</compound-id>, Σ<protein-id="P11498,A0A024R5C5">PCB</protein-id>, and dibutylphthalate (respectively r = 0.31, p = 0.016, r = 0.28, p = 0.029; r = 0.34, p = 0.0079 and r = 0.272, p = 0.0295), with a trend for PCB180 (r = 0.259, p = 0.061).	PCB153__PCB__no_interaction
19938192-8	After the <compound-id="448882">MGC</compound-id>-803 cells were treated with rhMIF for 24 h, the expression of <protein-id="P24385,Q6FI00">cyclin D1</protein-id> was significantly up-regulated compared with the cells not treated with rhMIF at both mRNA and protein levels (0.97 +/- 0.02 vs 0.74 +/- 0.01, P = 0.002; 0.98 +/- 0.05 vs 0.69 +/- 0.04, P = 0.003).	MGC__cyclin D1__no_interaction
10385599-3	Treatment of adherent ASMC with <protein-id="Q0V8R6">beta-hexosaminidase A</protein-id> (<protein-id="P06865">Hex A</protein-id>, 50 nM), an endogenous mannosyl-rich glycoprotein, resulted in a late-onset (30-min) activation of <protein-id="P62333,A0A087X2I1">p44</protein-id>/42(MAPK) that lasted for 4 h. Activation of <protein-id="P62333,A0A087X2I1">p44</protein-id>/42(MAPK) induced by <protein-id="P06865">Hex A</protein-id> was inhibited by an 18-mer phosphorothioate-derivatized antisense oligonucleotide (1-5 microM) directed to human <protein-id="P62333,A0A087X2I1">p44</protein-id>(MAPK); the mitogen-activated protein kinase kinase (<protein-id="Q02750,A4QPA9,B4DFY5">MEK1</protein-id>) inhibitor <compound-id="4713">PD98059</compound-id> (5 microM); the <protein-id="P62333,A0A087X2I1">p42</protein-id>(MAPK) inhibitor Tyrphostin <compound-id="2046">AG-126</compound-id> (0.2 microM); the farnesyl transferase inhibitors SCH-56582 (10 microM) and <compound-id="3000505">FPT</compound-id> III (10 miroM), which inhibit <protein-id="E1BMX0,P01112,X5D945">p21Ras</protein-id> activation; and <compound-id="2533">Calphostin C</compound-id> (0.2 microM), an inhibitor of protein kinase C. These agents also inhibited <protein-id="P06865">Hex A</protein-id>-induced cell proliferation in bovine ASMC.	PD98059__Hex A__no_interaction	PD98059__p42__no_interaction	PD98059__MEK1__no_interaction	PD98059__p21Ras__no_interaction	PD98059__p44__no_interaction	PD98059__beta-hexosaminidase A__no_interaction	FPT__Hex A__no_interaction	FPT__p42__no_interaction	FPT__MEK1__no_interaction	FPT__p21Ras__no_interaction	FPT__p44__no_interaction	FPT__beta-hexosaminidase A__no_interaction	AG-126__Hex A__no_interaction	AG-126__p42__no_interaction	AG-126__MEK1__no_interaction	AG-126__p21Ras__no_interaction	AG-126__p44__no_interaction	AG-126__beta-hexosaminidase A__no_interaction	Calphostin C__Hex A__no_interaction	Calphostin C__p42__no_interaction	Calphostin C__MEK1__no_interaction	Calphostin C__p21Ras__no_interaction	Calphostin C__p44__no_interaction	Calphostin C__beta-hexosaminidase A__no_interaction
18414750-1	The first <compound-id="24404">phosphane</compound-id> complexes of <compound-id="10130040">germanium(iv) fluoride</compound-id>, trans-[<protein-id="Q9NR80,Q9NTG0">GeF(4</protein-id>)(PR(3))(2)] (R = Me or Ph) and cis-[<protein-id="Q9NR80,Q9NTG0">GeF(4</protein-id>)(<compound-id="139283">diphosphane</compound-id>)] (<compound-id="139283">diphosphane</compound-id> = R(2)P(CH(2))(2)PR(2), R = Me, Et, Ph or Cy; o-C(6)H(4)(PR(2))(2), R = Me or Ph) have been prepared from [<protein-id="Q9NR80,Q9NTG0">GeF(4</protein-id>)(<compound-id="6342">MeCN</compound-id>)(2)] and the ligands in dry CH(2)Cl(2) and characterised by microanalysis, IR, Raman, (1)H, (19)F{(1)H} and (31)P{(1)H} NMR spectroscopy.	phosphane__GeF(4__no_interaction	diphosphane__GeF(4__no_interaction	MeCN__GeF(4__no_interaction	germanium(iv) fluoride__GeF(4__no_interaction
11777908-3	Our results showed the following novel findings: (a) the standard form of <protein-id="P16070">CD44</protein-id> (<protein-id="P16070">CD44s</protein-id>; 85 kDa) is expressed in both unstimulated and <compound-id="122634,22833501,27924">PMA</compound-id>-stimulated cells, while CD44v isoforms containing epitope v9 (110 kDa) are strongly up-regulated in response to treatment with <compound-id="122634,22833501,27924">PMA</compound-id>; (b) CD44v isoforms containing epitope v9 present on the same cell exclusively form aggregates in stimulated cells; (c) induction of <protein-id="P00749,A0A024QZM9,Q59GZ8">uPA</protein-id> mRNA expression could be achieved by using a second cross-linker antibody to cross-link Fab monomers of anti-<protein-id="P16070">CD44</protein-id>; (d) co-treatment of stimulated cells with anti-<protein-id="P16070">CD44</protein-id> mAb alone or anti-CD44v9 mAb alone suppresses <compound-id="122634,22833501,27924">PMA</compound-id>-induced clustering of <protein-id="P16070">CD44</protein-id>, which results in inhibition of <protein-id="P00749,A0A024QZM9,Q59GZ8">uPA</protein-id> overexpression; (e) <protein-id="P02760">bikunin</protein-id> efficiently disrupts <compound-id="122634,22833501,27924">PMA</compound-id>-induced clustering of <protein-id="P16070">CD44</protein-id>, but does not prevent <compound-id="122634,22833501,27924">PMA</compound-id>-induced up-regulation of CD44v isoforms containing epitope v9; and (f) after exposure to <compound-id="736299">bik</compound-id>, approximately 150-kDa band is mainly detected with immunoprecipitation and this band is shown to be a heterodimer composed of the 110-kDa v9-containing CD44v isoforms and a 45-kDa <compound-id="736299">bik</compound-id> receptor (<compound-id="736299">bik</compound-id>-R).	PMA__CD44__no_interaction	PMA__uPA__no_interaction	PMA__bikunin__no_interaction	PMA__CD44s__no_interaction	bik__CD44__no_interaction	bik__uPA__no_interaction	bik__bikunin__no_interaction	bik__CD44s__no_interaction
22206689-4	RESULTS: Complement factor-3 correlated directly with body mass index (r = 0.23417, P = 0.0032), body fat mass (bioelectrical impedance analysis; r = 0.33407, P &lt; 0.0001), percentage of body fat (bioelectrical impedance analysis; r = 0.26873, P = 0.0007), waist circumference (r = 0.21266, P = 0.0075), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.26152, P = 0.0009), homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (r = 0.24831, P = 0.0017), total <compound-id="5997">cholesterol</compound-id> (r = 0.23335, P = 0.0033), triacylglycerols (r = 0.38435, P &lt; 0.0001), and other outcome measurements.	cholesterol__insulin__no_interaction
18473419-9	To further explore the mechanism of <compound-id="77999">rosiglitazone</compound-id> action, we found that <compound-id="77999">rosiglitazone</compound-id> can significantly increase the expression of <protein-id="P37238,Q6GU14,M1VPI1">PPAR gamma</protein-id> [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P &lt; 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P &lt; 0.05), and lower the serum level of <protein-id="P06804,Q3U593">TNF-alpha</protein-id> (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P &lt; 0.05) and <protein-id="P08505,A2RTD1">IL-6</protein-id> (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P &lt; 0.05) in mice with liver fibrosis.	rosiglitazone__PPAR gamma__no_interaction	rosiglitazone__TNF-alpha__no_interaction	rosiglitazone__IL-6__no_interaction
20707314-8	Our results showed that (1) MRSA PK is an allosteric enzyme with homotetramer architecture activated by AMP or <compound-id="77982">ribose 5-phosphate</compound-id> (<compound-id="448888">R5P</compound-id>), but not by <protein-id="P09467,Q2TU34">fructose 1,6-bisphosphate</protein-id> (<protein-id="P09467,Q2TU34">FBP</protein-id>), which suggests a different mode of allosteric regulation when compared with human isozymes, (2) the CT domain is not required for the tetramerization of the enzyme; homotetramerization occurred in a truncated PK lacking the domain, (3) truncated enzyme exhibited high affinity toward both PEP and <compound-id="6022">ADP</compound-id> and exhibited hyperbolic kinetics toward PEP in the presence of activators (AMP and <compound-id="448888">R5P</compound-id>) consistent with kinetic properties of full-length enzyme, indicating that the CT domain is not required for substrate binding or allosteric regulation observed in the holoenzyme, (4) the kinetic efficiency (k(cat)/S(0.5)) of truncated enzyme was decreased by 24- and 16-fold, in ligand-free state, toward PEP and <compound-id="6022">ADP</compound-id>, respectively, but was restored by 3-fold in AMP-bound state, suggesting that the sequence containing the CT domain (Gly(473)-Leu(585)) plays a substantial role in enzyme activity and comformational stability, and (5) full-length MRSA PK activity was stimulated at low concentrations of <compound-id="5957">ATP</compound-id> (e.g., 1 mM) and inhibited by inorganic <compound-id="1061,167704,644102">phosphate</compound-id> and high concentrations of <protein-id="P09467,Q2TU34">FBP</protein-id> (10 mM) and <compound-id="5957">ATP</compound-id> (e.g., &gt;2.5 mM), whereas for truncated enzyme, stimulation at low concentrations of <compound-id="5957">ATP</compound-id> was lost.	ribose 5-phosphate__fructose 1,6-bisphosphate__no_interaction	ribose 5-phosphate__FBP__no_interaction	R5P__fructose 1,6-bisphosphate__no_interaction	R5P__FBP__no_interaction	phosphate__fructose 1,6-bisphosphate__no_interaction	phosphate__FBP__no_interaction	ATP__fructose 1,6-bisphosphate__no_interaction	ATP__FBP__no_interaction	ADP__fructose 1,6-bisphosphate__no_interaction	ADP__FBP__no_interaction
9434257-1	The pharmacological properties of 2-<compound-id="68006705">butyl</compound-id>-4-(methylthio)-1-[[2'-[[[(propylamino)carbonyl] amino]sulfonyl](1,1'-biphenyl)-4-yl]methyl]-<compound-id="14080">1H-imidazole-5-carboxylate</compound-id> (HR720), a novel non-peptide angiotensin (<protein-id="O15123">Ang) II</protein-id> type I (AT1) receptor antagonist, were characterized in both in vitro and in vivo systems.	butyl__Ang) II__no_interaction	1H-imidazole-5-carboxylate__Ang) II__no_interaction
1663819-3	In contrast, 1-h infusions of 3, 10, or 30 pmol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id> of human atrial natriuretic peptide lowered blood pressure by -3 +/- 4, -9 +/- 4, and -27 +/- 3 mmHg (1 mmHg = 133.322 Pa), increased cyclic <compound-id="24755530">guanosine monophosphate</compound-id> excretion from 78 +/- 11 to 90 +/- 6, 216 +/- 33, and 531 +/- 41 pmol/min, and raised plasma atrial natriuretic peptide from 7.2 +/- 0.7 to 21 +/- 4, 62 +/- 12, and 192 +/- 35 fmol/mL without affecting <compound-id="5360545">sodium</compound-id> excretion.	guanosine monophosphate__min-1__no_interaction	sodium__min-1__no_interaction
19195505-9	Importantly, serum <protein-id="P07711,Q9HBQ7,A0A024R276">cathepsin L</protein-id> associated positively with number of coronary branch luminal narrowings (R = 0.38, p &lt;0.001), Gensini scores (R = 0.44, p &lt;0.001), high-sensitivity <protein-id="P02741">C-reactive protein</protein-id> (R = 0.32, p &lt;0.001), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (R = 0.16, p &lt;0.03), and cigarette smokers (R = 0.27, p &lt;0.001), but inversely with high-density lipoprotein (R = -0.23, p = 0.002) and apolipoprotein A1 (R = -0.19, p = 0.01) in all subjects.	glucose__C-reactive protein__no_interaction	glucose__cathepsin L__no_interaction
8397979-1	Chloro(<compound-id="17822391,3301">ethylenediamine</compound-id>)[(-)-2,3,5,6-tetrahydro-6-<compound-id="69591">phenylimidazo</compound-id>[2, 1-b]thiazole]<compound-id="2770">platinum(II) chloride</compound-id>, [PtCl(C2H8N2)(C11H12N2S)]Cl, M(r) = 530.39, orthorhombic, P2(1)2(1)2(1), a = 31.676 (11), b = 8.190 (2), c = 6.6242 (6) A, V = 1718.5 (7) A3, Z = 4, Dx = 2.050 g cm-3, lambda (<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71069 A, mu = 86.8 cm-1, F(000) = 1016, T = 296 K, final R = 0.030 for 1646 unique observed reflections [F &gt; 4 sigma (F)].	phenylimidazo__Mo K alpha__no_interaction	platinum(II) chloride__Mo K alpha__no_interaction	ethylenediamine__Mo K alpha__no_interaction
9439715-5	Results presented here demonstrate that (1) exposure of primary bone marrow cultures to DMBA results in preB cell death by apoptosis; (2) notably low doses of DMBA (&gt; or = 10(-8) M) induce preB cell apoptosis; (3) in long-term cultures, bone marrow stromal cells, but not preB cells, express <protein-id="P30561,Q3U5D9">AhR</protein-id> mRNA and protein as determined by in situ hybridization, RT-PCR, and immunoblotting; (4) freshly isolated unfractionated bone marrow cells, but not purified bone marrow B cells, express <protein-id="P30561,Q3U5D9">AhR</protein-id> protein as assessed by immunohistochemistry; (5) <compound-id="11790">alpha-naphthoflavone</compound-id>, a competitive <protein-id="P30561,Q3U5D9">AhR</protein-id> inhibitor and cytochrome P450 antagonist, completely blocks DMBA-induced preB cell apoptosis in primary bone marrow cultures; and (6) DMBA or benzo[a]<compound-id="31423">pyrene</compound-id> injection in vivo results in bone marrow cell apoptosis consistent with the death of hematopoietic cells clustered around stromal elements.	alpha-naphthoflavone__AhR__no_interaction	pyrene__AhR__no_interaction
23064465-5	Admission 25-OH-D levels correlated with 1,25-(OH)(2)-D (R = 0.61, p = 0.001), Simplified Acute Physiology Score (<protein-id="O75170">SAPS-II</protein-id>) (R = -0.3, p = 0.01), Acute Physiology and Chronic Health Evaluation (APACHE-II) scores (R = -0.2, p = 0.05), but not <compound-id="22044544,5460341">calcium</compound-id> (R = 0.16, p = 0.11) or <protein-id="P01270">PTH</protein-id> (R = -0.11, p = 0.31) levels.	calcium__SAPS-II__no_interaction	calcium__PTH__no_interaction
23243034-7	RESULTS: Seven patients (12%) died in-hospital, of whom 5 were Child-Turcotte-Pugh class B and 2 class C. Comparing survivors vs non-survivors, univariate analysis revealed that variables associated with short-term outcome were international normalized ratio (1.5 ± 0.24 vs 2.2 ± 0.11, P &lt; 0.0001), presurgery platelet count (171 ± 87 vs 113 ± 52 l nl(-1), P = 0.031), presurgery haemoglobin count (11.8 ± 1.8 vs 10.2 ± 1.4 g dl(-1), P = 0.021), total need for erythrocyte concentrates (2 ± 3.4 vs 8.5 ± 8 units, P &lt; 0.0001), <protein-id="Q9NWM0">PaO</protein-id>(2)/FiO(2) at 12 h after ICU admission (327 ± 84 vs 257 ± 78, P = 0.04), initial central venous pressure (11 ± 3 vs 16 ± 4 mmHg, P = 0.02) and arterial blood <compound-id="612">lactate</compound-id> concentration 24 h after admission (1.8 ± 0.5 vs 2.5 ± 1.3 mmol l(-1), P = 0.019).	lactate__PaO__no_interaction
10909980-1	With the aim of investigating <compound-id="206,5793,64689,79025">glucose</compound-id>-mediated <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (<compound-id="206,5793,64689,79025">glucose</compound-id> effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 diabetes (<protein-id="P62633">DM2</protein-id>), and 15 age-, sex-, and BMI-matched control subjects without a family history of <protein-id="P62633">DM2</protein-id>, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with <protein-id="P61278">somatostatin</protein-id> (360 microg/h), insulin (0.25 mU x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)), glucagon (0.5 ng x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)), growth hormone (6 ng x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)), and tritiated <compound-id="206,5793,64689,79025">glucose</compound-id> infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at hyperglycemia (approximately 12 mmol/l) over the last 2 h. Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P &lt; 0.04), whereas plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l).	glucose__somatostatin__no_interaction	glucose__DM2__no_interaction	glucose__min(-1__no_interaction
10909980-2	At the end (i.e., 4.5-5.0 h) of the euglycemic clamp (PG, 6.1 +/- 0.4 vs. 5.6 +/- 0.1 mmol/l; PI, 78 +/- 5 vs. 73 +/-6 pmol/l), peripheral <compound-id="206,5793,64689,79025">glucose</compound-id> uptake (Rd(euglycemia)) was decreased in the relatives (2.93 +/- 0.08 vs. 3.70 +/-0.23 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) fat free mass [FFM], P &lt; 0.005), due to a decreased nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (0.83 +/-0.21 vs. 1.62 +/- 0.19 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM, P &lt; 0.01), but hepatic <compound-id="206,5793,64689,79025">glucose</compound-id> production (<compound-id="448530">HGP</compound-id>) was increased (1.97 +/-0.19 vs. 1.50 +/- 0.13 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM, P &lt; 0.05).	HGP__min(-1__no_interaction	glucose__min(-1__no_interaction
10909980-3	At the matched end of the hyperglycemic clamp (PG, 12.7 +/-0.2 vs. 12.6 +/- 0.2 mmol/l; PI, 87 +/- 5 vs. 78 +/- 7 pmol/l), peripheral <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (Rd(hyperglycemia)) (5.52 +/- 0.22 vs. 5.92 +/- 0.29 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM, NS), nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> disposal (2.93 +/- 0.18 vs. 2.78 +/- 0.25 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM, NS), and <compound-id="448530">HGP</compound-id>(hyperglycemia) (1.20 +/- 0.09 vs. 1.37 +/-0.23 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM, NS) were all identical.	HGP__min(-1__no_interaction	glucose__min(-1__no_interaction
10909980-4	When the effectiveness of <compound-id="206,5793,64689,79025">glucose</compound-id> itself on <compound-id="206,5793,64689,79025">glucose</compound-id> uptake and production [(Rd(hyperglycemia) - Rd(euglycemia))/deltaPG and (<compound-id="448530">HGP</compound-id>(euglycemia)- <compound-id="448530">HGP</compound-id>(hyperglycemia))/deltaPG] was calculated, the relatives had a 22% increase in peripheral uptake (0.022 +/- 0.002 vs. 0.018 +/- 0.002 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM per mg/dl), due to a significantly increased nonoxidative <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism and enhanced suppression of <compound-id="448530">HGP</compound-id> (0.0076 +/- 0.0021 vs. 0.0011 +/- 0.0022 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) FFM per mg/dl, P &lt; 0.05).	HGP__min(-1__no_interaction	glucose__min(-1__no_interaction
16696336-5	Both of the concentrations of <compound-id="24083">magnesium sulfate</compound-id> in high and low agents group are higher than the <protein-id="Q6P6U0">FGR</protein-id> group (P &lt; 0.01); the weight of the placenta and fetal rat in high agent group are higher than the <protein-id="Q6P6U0">FGR</protein-id> group (P &lt; 0.05 and P &lt; 0.01); the expression of mRNA and protein of <protein-id="P55213">caspase-3</protein-id> in the two agent group is higher than the <protein-id="Q6P6U0">FGR</protein-id> group (P &lt; 0.05 respectively); concentration of <compound-id="24083">magnesium sulfate</compound-id> in the maternal rat blood correlate to the weight of fetal rat (r = 0.899, P = 0.038) and the expression of <protein-id="P55213">caspase-3</protein-id> in the placenta of maternal rat (r = -0.747, P = 0.033; r = - 0.915, P = 0.001).	magnesium sulfate__caspase-3__no_interaction	magnesium sulfate__FGR__no_interaction
12667703-1	The synthesis, spectroscopic (IR, 1H and 13C NMR, UV-Vis-<protein-id="Q9Y3T9">NIR</protein-id>, EPR), magnetic measurements and biological studies of a number of complexes of Co(II), Ni(II), Cu(II), Zn(II), Cd(II), Au(III) and Hg(II) of the <compound-id="86573619">Schiff base</compound-id> derived from the 1:2 condensation of <compound-id="81744">2,6-diformyl-4-methylphenol</compound-id> and <compound-id="13611">5-aminouracil</compound-id>, ((5-[[(3-[[(2,4-dioxopyrimidin-5(1H,3H)-yl)imino]methyl]-<compound-id="97257">2-hydroxy-</compound-id>5-methylphenyl)<compound-id="123164">methylene</compound-id>]amino]pyrimidine-2,4(1H,3H)-dione, hereafter denoted as BDF5AU) are reported.	2-hydroxy-__NIR__no_interaction	Schiff base__NIR__no_interaction	5-aminouracil__NIR__no_interaction	methylene__NIR__no_interaction	2,6-diformyl-4-methylphenol__NIR__no_interaction
23238233-1	Four new <compound-id="9548714">dammarane</compound-id>-type triterpenoid saponins such as chikusetsusaponin <compound-id="71464711">LM3</compound-id> (1), chikusetsusaponin <compound-id="71464710">LM4</compound-id> (2), chikusetsusaponin <compound-id="45480579">LM5</compound-id> (3), chikusetsusaponin LM6 (4), and twenty known triterpenoid saponins such as <compound-id="441923">ginsenoside</compound-id> <protein-id="Q9H169,E7EVN3">Rb3</protein-id> (5), <compound-id="100018,12855889">ginsenoside Rc</compound-id> (6), <compound-id="441923">ginsenoside</compound-id> Rd (7), <compound-id="432449,441921,73149">ginsenoside Re</compound-id> (8), <compound-id="441923">ginsenoside</compound-id> Rg1 (9), <compound-id="46887678">ginsenoside F3</compound-id> (10), <compound-id="46224647">ginsenoside F5</compound-id> (11), <compound-id="441923">ginsenoside</compound-id> F6 (12), <compound-id="13909684,3080813,49771253">chikusetsusaponin IVa</compound-id> (13), <compound-id="160238">chikusetsusaponin V</compound-id> (14), chikusetsusaponin L5 (15), chikusetsusaponin L9a (16), chikusetsusaponin L9bc (17), chikusetsusaponin <protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id> (18), chikusetsusaponin FK2 (19), chikusetsusaponin FK6 (20), chikusetsusaponin FK7 (21), chikusetsusaponin <protein-id="Q9H8T0,A0A024R6T5,A0A024R6S6">FT1</protein-id> (22), chikusetsusaponin <compound-id="73427346">LM1</compound-id> (23), and chikusetsusaponin <compound-id="448829">LM2</compound-id> (24), were isolated from the leaves of Panax japonicus C. A. MEYER collected in Miyazaki prefecture, Japan.	ginsenoside Re__FT1__no_interaction	ginsenoside Re__L10__no_interaction	ginsenoside Re__Rb3__no_interaction	ginsenoside Rc__FT1__no_interaction	ginsenoside Rc__L10__no_interaction	ginsenoside Rc__Rb3__no_interaction	LM1__FT1__no_interaction	LM1__L10__no_interaction	LM1__Rb3__no_interaction	LM2__FT1__no_interaction	LM2__L10__no_interaction	LM2__Rb3__no_interaction	LM3__FT1__no_interaction	LM3__L10__no_interaction	LM3__Rb3__no_interaction	LM4__FT1__no_interaction	LM4__L10__no_interaction	LM4__Rb3__no_interaction	LM5__FT1__no_interaction	LM5__L10__no_interaction	LM5__Rb3__no_interaction	chikusetsusaponin IVa__FT1__no_interaction	chikusetsusaponin IVa__L10__no_interaction	chikusetsusaponin IVa__Rb3__no_interaction	ginsenoside__FT1__no_interaction	ginsenoside__L10__no_interaction	ginsenoside__Rb3__no_interaction	chikusetsusaponin V__FT1__no_interaction	chikusetsusaponin V__L10__no_interaction	chikusetsusaponin V__Rb3__no_interaction	ginsenoside F3__FT1__no_interaction	ginsenoside F3__L10__no_interaction	ginsenoside F3__Rb3__no_interaction	ginsenoside F5__FT1__no_interaction	ginsenoside F5__L10__no_interaction	ginsenoside F5__Rb3__no_interaction	dammarane__FT1__no_interaction	dammarane__L10__no_interaction	dammarane__Rb3__no_interaction
18981938-3	METHODS: Fourteen males with MetS (waist circumference (WC) = 110.2 +/- 10.9 cm; triglycerides (TG) = 217 +/- 84 mg dL(-1); fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> = 105 +/- 7 mg dL(-1); high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) = 44 +/- 7 mg dL(-1); systolic blood pressure (SBP) = 120 +/- 12 mm Hg; diastolic blood pressure (DBP) = 76 +/- 10 mm Hg) completed a control condition consisting of a high-fat meal and blood sampling at 2 h intervals for 6 h. Next, participants completed the following exercise conditions: 1) continuous moderate-intensity (<protein-id="P83916,Q6IBN6">MOD-1</protein-id>), 2) continuous low-intensity (LOW-1), and 3) two accumulated moderate-intensity sessions (<protein-id="Q13185,B8ZZ43,A4D177">MOD-2</protein-id>).	cholesterol__MOD-2__no_interaction	cholesterol__MOD-1__no_interaction	glucose__MOD-2__no_interaction	glucose__MOD-1__no_interaction
23021803-4	By comparing [C(8)MIM] [PF(6)] with <compound-id="2734175">1-hexyl-3-methylimidazolium hexafluorophosphate</compound-id> ([C(6)MIM] [<protein-id="Q6Q759,Q96QT6,C9J9G2">PF(6)]) and 1</protein-id>-<compound-id="17841391">butyl-3-methylimidazolium</compound-id> <compound-id="9886">hexafluorophosphate</compound-id> ([C(4)MIM] [PF(6)]) as extraction solvents, it was observed that when using [C(8)MIM] [PF(6)] the cloudy solution was formed more readily than when using [C(6)MIM] [PF(6)] or [C(4)MIM] [PF(6)].	1-hexyl-3-methylimidazolium hexafluorophosphate__PF(6)]) and 1__no_interaction	butyl-3-methylimidazolium__PF(6)]) and 1__no_interaction	hexafluorophosphate__PF(6)]) and 1__no_interaction
12175214-1	In the presence of Co(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2I2, <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>, <compound-id="962">water</compound-id>, and <compound-id="23994">zinc</compound-id> powder, the reaction of alkynes (R1CCR2: R1 = Ph, R2 = Me (1a); R1 = Ph, R2 = Ph (1b); R1 = Et, R2 = Et (1c); R1 = Ph, R2 = (CH2)3OH (1d); R1 = CO2Et, R2 = Ph (1e); R1 = CO2Me, R2 = (CH2)4CH3 (1f); R1 = CO2Et, R2 = SiMe3 (1g)) with alkenes having an electron-withdrawing substituent (CH2=CHR: R = CO2Bu (2a), CN (2b), SO2Ph (2c) and CO2Me (2d)) proceeded smoothly in acetonitrile to give the corresponding reductive coupling products (R1HC=CR2CH2CH2R, <compound-id="2981881,91293124">3a</compound-id>-j) in fair to excellent yields.	water__PPh3__no_interaction	3a__PPh3__no_interaction	zinc__PPh3__no_interaction
20435794-6	Mean +/- SD values in the entire population were as follows: A1C 7.5 +/- 0.5%, fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (FPG) 8.6 +/- 1.3 mmol/l, fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (FPI) 148 +/- 74 pmol/l, MMSE 24.9 +/- 2.4, TMT-A 61.6 +/- 42.0, TMT-B 162.8 +/- 78.7, the difference between TMT-B and TMT-A [DIFFBA] 101.2 +/- 58.1, and RAVLT 24.3 +/- 2.1.	glucose__insulin__no_interaction
10370672-6	The weight of resected liver (r = 0.821, p &lt; 0.0001), maximum diameter of tumor (r = 0.782, p &lt; 0.0001) and operation time (r = 0.748, p &lt; 0.0001) were the most highly correlated with intra-operative blood loss, followed by pre-operative total <compound-id="5280352">bilirubin</compound-id> (r = 0.605, p = 0.0038), <protein-id="Q9NRC9">FDP</protein-id> level (r = 0.576, p = 0.0068) and intra-operative blood transfusion (r = 0.561, p = 0.0089).	bilirubin__FDP__no_interaction
9844122-11	The production of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> was inhibited by <compound-id="5280453">calcitriol</compound-id> in a dose-dependent manner [LPS + Vit.D3 100 ng, 2.9 +/- 2.1 in N, 3.7 +/- 1.9 in CRF and 3.4 +/- 1.7 in HD; LPS + Vit.D3 50 ng, 263 +/- 296 (N), 6.73 +/- 11 (CRF), 38 +/- 28 (HD); LPS + Vit.D3 25 ng = 873 +/- 583 (N), 325 +/- 483 (CRF), 588 +/- 507 (HD); LPS + Vit.D3 12.5 ng, 954 +/- 483 (N), 912 +/- 510 (CRF), 875 +/- 527 (HD)].	calcitriol__TNF-alpha__no_interaction
15649789-1	Equilibria for the formation of supramolecular complexes of [60]<compound-id="123591">fullerene</compound-id> with a series of mono O-substituted calix[6]arenes, namely: (i) 37-<compound-id="91066389">methoxy-</compound-id>38,39,40,41,42-pentahydroxy-5,11,17,23,29,35-hexa(4-<compound-id="90937099">tert-butyl</compound-id>)<compound-id="2724885">calix[6]arene</compound-id> (1), (ii) 37-<compound-id="8252">allyl</compound-id>-38,39,40,41,42-pentahydroxy-5,11,17,23,29,35-hexa(4-<compound-id="90937099">tert-butyl</compound-id>)<compound-id="2724885">calix[6]arene</compound-id> (2), (iii) 37-phenacyl-38,39,40,41,42-pentahydroxy-5,11,17,23,29,35-hexa(4-<compound-id="90937099">tert-butyl</compound-id>)<compound-id="2724885">calix[6]arene</compound-id> (3), (iv) 37-ethylester-38,39,40,41,42-pentahydroxy-5,11,17,23,29,35-hexa(4-<compound-id="90937099">tert-butyl</compound-id>)<compound-id="2724885">calix[6]arene</compound-id> (4) and (v) 37-benzyl-38,39,40,41,42-pentahydroxy-5,11,17,23,29,35-hexa(4-<compound-id="90937099">tert-butyl</compound-id>)<compound-id="2724885">calix[6]arene</compound-id> (5) have been studied in <protein-id="P13236">CCl4</protein-id> medium by absorption spectroscopic technique.	fullerene__CCl4__no_interaction	allyl__CCl4__no_interaction	calix[6]arene__CCl4__no_interaction	tert-butyl__CCl4__no_interaction	methoxy-__CCl4__no_interaction
6602637-1	In the process of evaluating roles for purified preparations of <protein-id="P08071">lactoferrin</protein-id>, <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> and acidic isoferritins in the regulation of myelopoiesis, it was found that: (1) values reported for <protein-id="P08071">lactoferrin</protein-id> in the serum and plasma of normal donors are in most cases an over-estimation, (2) <protein-id="P08071">lactoferrin</protein-id> suppresses the production/release of granulocyte-macrophage colony stimulatory factors (GM-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id>) from monocytes in the absence of T-lymphocytes and also suppresses the production/release of acidic isoferritin-inhibitory activity from monocytes, (3) <protein-id="P08071">lactoferrin</protein-id>, <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> and acidic isoferritins act on their specific target cells which express Ia-like antigens, (4) <protein-id="P08071">lactoferrin</protein-id> and <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> act in vivo to suppress rebound myelopoiesis in mice recovering from sublethal dosages of <compound-id="2907,9554281">Cytoxan</compound-id>, with preliminary observations suggesting that <protein-id="P08071">lactoferrin</protein-id> has a greater apparent effect on the bone marrow and <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> has a greater apparent effect on the spleen, (5) active <protein-id="P08071">lactoferrin</protein-id> derives from Fc receptor positive subpopulations of PMN from patients with CML as well as from normal donors, but the percentage of Fc receptor containing PMN is lower in CML, as is the amount of active <protein-id="P08071">lactoferrin</protein-id> found in their PMN, and (6) <protein-id="P08071">lactoferrin</protein-id>, <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> and acidic isoferritins suppress the colony formation of U937 clonogenic cells, with <protein-id="P08071">lactoferrin</protein-id> and <protein-id="P02787,Q06AH7,A0PJA6,Q921I1">transferrin</protein-id> decreasing the release of growth factors from U937 cells which are needed to stimulate U937 colony formation, and <protein-id="P08071">lactoferrin</protein-id> and acidic isoferritins suppress the colony formation of WEHI-3 cells, with <protein-id="P08071">lactoferrin</protein-id> decreasing the release of growth factors from WEHI-3 cells which are needed to stimulate WEHI-3 colony formation.	CSF__transferrin__no_interaction	CSF__lactoferrin__no_interaction	Cytoxan__transferrin__no_interaction	Cytoxan__lactoferrin__no_interaction
16278342-5	We showed that 1) after 1 h of reoxygenation, fluorescence had risen and that ROS production was inhibited by <compound-id="2995">desipramine</compound-id>, an inhibitor of sphingomyelinase, an enzyme responsible for ceramide production (126 +/- 7% vs. 48 +/- 12%, P &lt; 0.05); 2) administration of ceramide (<compound-id="5497136">N-acetylsphingosine</compound-id>) per se (i.e., in the absence of H/R) induced ROS production (65 +/- 3%), which was inhibited by complex III inhibitor: <compound-id="12550,14957,16218979,6420045">antimycin A</compound-id> (24 +/- 3%, P &lt; 0.0001), or <compound-id="447884,5353970,6435507">stigmatellin</compound-id> (31 +/- 2%, P &lt; 0.0001); 3) hypoxia/reoxygenation-induced ROS production was not affected by either ceramide-activated protein <compound-id="53378893">kinase inhibitor</compound-id> <compound-id="53759493">dimethyl aminopurine</compound-id> or mitochondrial permeability transition inhibitor cyclosporin A but was significantly inhibited by the antiapoptotic protein <protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> (82 +/- 8%, P &lt; 0.05); 4) ceramide-induced ROS production was also inhibited by <protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> (41 +/- 4%, P &lt; 0.0001).	N-acetylsphingosine__Bcl-2__no_interaction	dimethyl aminopurine__Bcl-2__no_interaction	stigmatellin__Bcl-2__no_interaction	antimycin A__Bcl-2__no_interaction	kinase inhibitor__Bcl-2__no_interaction	desipramine__Bcl-2__no_interaction
8402760-10	Analysis of a total of 42 measurements obtained during the therapeutic course in the CHF group revealed a correlation of P[v-a]<protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> with cardiac index (r = -0.3, p &lt; 0.05), OER (r = 0.57, p &lt; 0.001), SvO2 (r = -0.56, p &lt; 0.001) and <compound-id="612">lactate</compound-id> (r = 0.62, p &lt; 0.001).	lactate__CO2__no_interaction
18398545-2	A range of new <compound-id="23950">ruthenium</compound-id> complexes were synthesised using these and related ligands, namely: [{RuCl(PhPNO)}2Cl] (4), [Ru(PhPNO)2] (5), [RuCl(PhPNXR)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)]<compound-id="1125">BPh4</compound-id> [X = O, R = Me (6); X = O, R = Ph (7); X = S, R = Me (8)], [{RuCl(PhPNX'R)}2Cl]X [X' = O, R = Me, X = Cl(-) (9); X' = S, R = Me, X = <compound-id="1125">BPh4</compound-id>(-) or PF6(-) (10)], and [RuCl(PhPNO-eta 6C6H5)]<compound-id="1125">BPh4</compound-id> (11).	ruthenium__PPh3__no_interaction	BPh4__PPh3__no_interaction
17226891-1	The crystal-state conformations of the hexapeptide <compound-id="2826723">amide</compound-id> Pht-(Aib)(6)-NH-C(CH(3))(2)-O-OtBu (7), the hexapeptide Ac-L-aIle-(Aib)(5)-OtBu (6), the pentapeptide Z-(Aib)(3)-<compound-id="33032">L-Glu</compound-id>(OtBu)-Aib-O-(CH(2))(2)-(1)Nap (5), the tetrapeptides Z-(Aib)(2)-<compound-id="6274">L-His</compound-id>(N(tau)-<compound-id="446308">Trt</compound-id>)-Aib-OMe (4 I) and Z-(Aib)(2)-L-<compound-id="824">Nva</compound-id>-Aib-OtBu (4 II), the tripeptide Pyr-(Aib)(3)-OtBu (3 I), the dipeptide amides Pyr-(Aib)(2)-(4)NH-TEMPO (3 II) and Piv-(Aib)(2)-NH-C(CH(3))(2)-O-OtBu (3 III), and the dipeptides Pht-Aib-betaAc(6)c-OtBu (2 I), Pht-Aib-NH-C(CH(3))(2)-O-OtBu (2 II) and <protein-id="Q9BWV1,Q96DN7">Boc</protein-id>-gGly-mAib-OH (2 III) have been determined by X-ray diffraction analyses.	L-Glu__Boc__no_interaction	Nva__Boc__no_interaction	Trt__Boc__no_interaction	L-His__Boc__no_interaction	amide__Boc__no_interaction
12377060-4	Crystal data with <protein-id="Q6PIJ6,Q6AZE0">Mo Kalpha</protein-id> (lambda = 0.710 73 A) are as follows: Mg[NDiip(SiMe(3))](2), 1, a = 9.4687(6) A, b = 9.6818(6) A, c = 17.9296(1) A, alpha = 96.487(1) degrees, beta = 94.537(1) degrees, gamma = 89.222(1) degrees, V = 1608.8(2) A(3), Z = 2 (two independent molecules), triclinic, space group P(-)1, R1 (all data) = 0.0508; (n)()BuMg[NDiip(SiMe(3))]<compound-id="8028">THF</compound-id>(2), 2, a = 9.5413(1) A, b = 16.493(2) A, c = 9.8218(1) A, beta = 108.149(2) degrees, V = 1468.7(4) A(3), Z = 2, monoclinic, space group P2(1), R1(all data) = 0.1232; Ca[NDiip(SiMe(3))](2)<compound-id="8028">THF</compound-id>(2), 4, a = 9.7074(1) A, b = 20.9466(4) A, c = 21.6242(3) A, alpha = 73.573(1) degrees, beta = 78.632(1) degrees, gamma = 89.621(1) degrees, V = 4129.1(1) A(3), Z = 4 (two independent molecules), triclinic, space group P(-)1, R1 (all data) = 0.0902; Sr[NDiip(SiMe(3))](2)<compound-id="8028">THF</compound-id>(2), 5, a = 20.5874(5) A, b = 9.8785(2) A, c = 20.8522(5) A, beta = 102.035(2) degrees, V = 4147.6(2) A(3), Z = 4 (two independent molecules), monoclinic, space group P2/n, R1 (all data) = 0.0756; Ba[NDiip(SiMe(3))](2)<compound-id="8028">THF</compound-id>(2), 6, a = 20.5476(2) A, b = 10.0353(2) A, c = 20.9020(4) A, beta = 101.657(1) degrees, V = 4221.0(1) A(3), Z = 4 (two independent molecules), monoclinic, space group P2/n, R1 (all data) = 0.0573.	THF__Mo Kalpha__no_interaction
23095175-5	Higher levels of <protein-id="P13500">MCP-1</protein-id> were associated with increased <compound-id="22044544,5460341">calcium</compound-id> (r = 0.47, p = 0.004), NC (r = 0.38, p = 0.02) and less fibrous tissue components (r = -0.34, p = 0.03), whereas <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id> had an inverse correlation with both <compound-id="22044544,5460341">calcium</compound-id> components (r = -0.37, p = 0.02) and NC (r = -0.34, p = 0.036) but was strongly associated with increased fibrous components (r = 0.47, p = 0.003).	calcium__VEGF__no_interaction	calcium__MCP-1__no_interaction
15450171-4	Cell entry by ricin involves the following steps: (i) binding to cell-surface glycolipids and glycoproteins bearing <protein-id="Q16558,Q13509,Q53G92">beta-1,4</protein-id>-linked <compound-id="206,439353,59083882,6036">galactose</compound-id> residues through the lectin activity of the B-chain (RTB); (ii) uptake by endocytosis and entry into early endosomes; (iii) transfer by vesicular transport to the trans-Golgi network; (iv) retrograde vesicular transport through the Golgi complex and into the endoplasmic reticulum (ER); (v) reduction of the disulfide bond connecting the A- and B-chains; (vi) a partial unfolding of the A-chain (<protein-id="O43251">RTA</protein-id>) to enable it to translocate across the ER membrane via the <protein-id="P61619,B3KME8,B3KNF6">Sec61p</protein-id> translocon using the pathway normally followed by misfolded ER proteins for targeting to the ER-associated degradation (ERAD) machinery; (vi) refolding in the cytosol into a protease-resistant, enzymatically active structure; (vii) interaction with the sarcin-ricin domain (SRD) of the large ribosome subunit RNA followed by cleavage of a single N-glycosidic bond in the RNA to generate a depurinated, inactive ribosome.	galactose__RTA__no_interaction	galactose__beta-1,4__no_interaction	galactose__Sec61p__no_interaction
23241214-5	Functional deficits of <compound-id="6013">testosterone</compound-id> reduced expression of <protein-id="Q9JMB7">MIWI</protein-id>, the 5-methyl cap binding RNA-binding protein (PIWIlike murine homologue of the Drosophila protein <protein-id="Q9VKM1,X2J7U0">PIWI</protein-id>/P-element induced wimpy testis) containing a PAZ/<protein-id="Q9VKM1,X2J7U0">PIWI</protein-id>-Argonaut-Zwille domain and levels of <protein-id="Q94517">histone deacetylase1</protein-id> (<protein-id="Q94517">HDAC1</protein-id>), ubiquitin ligating enzyme (URE-B1/E3), 20S proteasome α1 concomitant with reduced expression of ubiquitin activating enzyme (ube1), conjugating enzyme (ube2d2), chromodomain Y like protein (cdyl), bromodomain testis specific protein (brdt), <protein-id="Q9XYX1,Q8IR38,Q8IR37,Q86NK9,M9NGF7,M9NEH6,M9PJN5">hdac6</protein-id> (<protein-id="Q9XYX1,Q8IR38,Q8IR37,Q86NK9,M9NGF7,M9NEH6,M9PJN5">histone deacetylase6</protein-id>), androgen-dependent homeobox placentae embryonic protein (pem/RhoX5), histones h2b and <compound-id="3378216">th3</compound-id> (testis-specific h3).	th3__HDAC1__no_interaction	th3__hdac6__no_interaction	th3__histone deacetylase1__no_interaction	th3__histone deacetylase6__no_interaction	th3__PIWI__no_interaction	th3__MIWI__no_interaction	testosterone__HDAC1__no_interaction	testosterone__hdac6__no_interaction	testosterone__histone deacetylase1__no_interaction	testosterone__histone deacetylase6__no_interaction	testosterone__PIWI__no_interaction	testosterone__MIWI__no_interaction
21418998-6	Moreover, the expression levels of <protein-id="Q15399">TLR1</protein-id>, <protein-id="O60603,B3KWR9">TLR2</protein-id>, <protein-id="O00206">TLR4</protein-id>, <protein-id="O60602">TLR5</protein-id>, <protein-id="Q9Y2C9,B2R933">TLR6</protein-id>, <protein-id="Q9NR97">TLR8</protein-id> and <protein-id="Q9BXR5,A0A024R9W4">TLR10</protein-id> in the experimental group were significantly higher than those in <compound-id="86322">HK-2</compound-id> cell line [(4.40 ± 0.19) × 10(-2), (1.77 ± 0.24) × 10(-2), (5.03 ± 0.62) × 10(-2), (3.93 ± 0.86) × 10(-2), (6.11 ± 0.48) × 10(-2), (1.89 ± 0.47) × 10(-2), (2.84 ± 0.57) × 10(-2) vs (0.84 ± 0.27) × 10(-2), (0.40 ± 0.04) × 10(-2), (0.95 ± 0.73) × 10(-2), (0.56 ± 0.25) × 10(-2), (0.49 ± 0.16) × 10(-2), (0.20 ± 0.07) × 10(-2), (0.27 ± 0.08) × 10(-2), P &lt; 0.01].	HK-2__TLR10__no_interaction	HK-2__TLR2__no_interaction	HK-2__TLR1__no_interaction	HK-2__TLR6__no_interaction	HK-2__TLR4__no_interaction	HK-2__TLR5__no_interaction	HK-2__TLR8__no_interaction
2143899-4	Moreover, while BBM Na(+)-dependent Pi transport is significantly reduced in <protein-id="P70669,Q3TYM9">Hyp</protein-id> mice (249 +/- 54 vs 465 +/- 82 pmol/mg protein/6s), genotype differences in (1) Na(+)-dependent PFA binding (1020 +/- 115 vs 1009 +/- 97 pmol/mg protein/30 min), (2) Pi-displaceable Na(+)-dependent PFA binding (605 +/- 82 vs 624 +/- 65 pmol/mg protein/6s), and (3) <compound-id="1061,167704,644102">phosphate</compound-id> uptake at Na(+)-equilibrium (67 +/- 10 vs 54 +/- 7 pmol/mg protein/6s) are not apparent.	phosphate__Hyp__no_interaction
8810043-4	Five putative ORF products show similarity to known proteins: the <compound-id="6106">leucine</compound-id> zipper-containing ABC transporter L1313p to the yeast Ycflp metal resistance protein, to the yeast putative <compound-id="5957">ATP</compound-id>-dependent permease Yhd5p, to the yeast putative proteins Yk83p and Yk84p, to the human <protein-id="P13569,A0A024R730">cystic fibrosis transmembrane conductance regulator</protein-id> protein (hCFTR) and to the human multidrug resistance-associated protein hMRP1; L1325p to the Drosophila melanogaster Pumilio protein, to the putative yeast regulatory protein Yg13p and to the yeast protein <protein-id="P39016">Mpt5p</protein-id>/Htrlp; L1329p to human <compound-id="5474737">lipase</compound-id> A and <protein-id="P07098">gastric lipase</protein-id>, to rat lingual <compound-id="5474737">lipase</compound-id> and to the putative yeast triglyceride <compound-id="5474737">lipase</compound-id> Tg11p; L1341p to the putative yeast protein Yhg4p; and the <compound-id="6106">leucine</compound-id> zipper-containing L1361p to the two yeast proteins 00953p and Ym8156.08p and to the Arabidopsis thaliana protein <protein-id="Q8GUH7,F4J116,A0A097NUP6">HYP1</protein-id>.	leucine__HYP1__no_interaction	leucine__cystic fibrosis transmembrane conductance regulator__no_interaction	leucine__gastric lipase__no_interaction	leucine__Mpt5p__no_interaction	lipase__HYP1__no_interaction	lipase__cystic fibrosis transmembrane conductance regulator__no_interaction	lipase__gastric lipase__no_interaction	lipase__Mpt5p__no_interaction	ATP__HYP1__no_interaction	ATP__cystic fibrosis transmembrane conductance regulator__no_interaction	ATP__gastric lipase__no_interaction	ATP__Mpt5p__no_interaction
15796547-1	Olefin complexes (silox)(3)M(ole) (silox = (t)Bu(3)SiO; M = Nb (1-ole), Ta (2-ole); ole = C(2)H(4), C(2)H(3)Me, C(2)H(3)Et, C(2)H(3)C(6)H(4)-p-X (X = OMe, H, CF(3)), C(2)H(3)(t)Bu, (c)C(5)H(8), (c)C(6)H(10), (c)C(7)H(10) (<compound-id="10352">norbornene</compound-id>)) rearrange to alkylidene isomers (silox)(3)M(<protein-id="Q9UM73,B6D4Y2">alk</protein-id>) (M = Nb (1=<protein-id="Q9UM73,B6D4Y2">alk</protein-id>), Ta (2=<protein-id="Q9UM73,B6D4Y2">alk</protein-id>); <protein-id="Q9UM73,B6D4Y2">alk</protein-id> = CHMe, CHEt, CH(n)Pr, <protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>(2)C(6)H(4)-p-X (X = OMe, H, CF(3) (Ta only)), <protein-id="Q8WUH1,A0A024R6B7">CHCH</protein-id>(2)(t)Bu, (c)C(5)H(8), (c)C(6)H(10), (c)C(7)H(10) (norbornylidene)).	norbornene__CHCH__no_interaction	norbornene__alk__no_interaction
15113225-4	The CCl(3)(+), <protein-id="O75828,V9HW40">CBr(3</protein-id>)(+), CBr(OTeF(5))(2)(+), C(OTeF(5))(3)(+), and Br(OTeF(5))(2)(+) cations and C(OTeF(5))(4) have been characterized in SO(2)<protein-id="O75462">ClF</protein-id> solution by (13)C and/or (19)F NMR spectroscopy at -78 degrees C. The X-ray crystal structures of the CCl(3)(+), <protein-id="O75828,V9HW40">CBr(3</protein-id>)(+), and C(OTeF(5))(3)(+) cations have been determined in [CCl(3)][Sb(OTeF(5))(6)], [<protein-id="O75828,V9HW40">CBr(3</protein-id>)][Sb(OTeF(5))(6)].SO(2)<protein-id="O75462">ClF</protein-id>, and [C(OTeF(5))(3)][Sb(OTeF(5))(6)].<compound-id="86208093">3SO</compound-id>(2)<protein-id="O75462">ClF</protein-id> at -173 degrees C. The CCl(3)(+) and <protein-id="O75828,V9HW40">CBr(3</protein-id>)(+) salts were stable at room temperature, whereas the CBr(n)(OTeF(5))(3-n)(+) salts were stable at 0 degrees C for several hours.	3SO__ClF__no_interaction	3SO__CBr(3__no_interaction
18768398-4	We found that (1) although <protein-id="P25095">AT(1)R</protein-id> expression in the RVLM was upregulated, the <protein-id="P35351,B1WBL8">AT(2)R</protein-id> was significantly downregulated (CHF: 0.06+/-0.02 versus sham: 0.15+/-0.02, P&lt;0.05); (2) simultaneously stimulating RVLM <protein-id="P25095">AT(1)R</protein-id> and <protein-id="P35351,B1WBL8">AT(2)R</protein-id> by <protein-id="P01015">angiotensin II</protein-id> evoked sympathoexcitation, hypertension, and tachycardia in both sham and CHF rats with greater responses in CHF; (3) stimulating RVLM <protein-id="P25095">AT1R</protein-id> with <protein-id="P01015">angiotensin II</protein-id> plus the specific <protein-id="P35351,B1WBL8">AT(2)R</protein-id> antagonist <compound-id="5311345">PD123319</compound-id> induced a larger sympathoexcitatory response than simultaneously stimulating <protein-id="P25095">AT(1)R</protein-id> and <protein-id="P35351,B1WBL8">AT(2)R</protein-id> in sham rats, but not in CHF; (4) activating RVLM <protein-id="P35351,B1WBL8">AT(2)R</protein-id> with <compound-id="123794">CGP42112</compound-id> induced a sympathoinhibition, hypotension, and bradycardia only in sham rats (renal sympathetic nerve activity: 36.4+/-5.1% of baseline versus 102+/-3.9% of baseline in artificial cerebrospinal fluid, P&lt;0.05); (5) pretreatment with <compound-id="1780">5,8,11,14-eicosatetraynoic acid</compound-id>, a general inhibitor of <compound-id="444899">arachidonic acid</compound-id> metabolism, into the RVLM attenuates the <compound-id="123794">CGP42112</compound-id>-induced sympathoinhibition.	CGP42112__AT1R__no_interaction	CGP42112__angiotensin II__no_interaction	CGP42112__AT(1)R__no_interaction	CGP42112__AT(2)R__no_interaction	5,8,11,14-eicosatetraynoic acid__AT1R__no_interaction	5,8,11,14-eicosatetraynoic acid__angiotensin II__no_interaction	5,8,11,14-eicosatetraynoic acid__AT(1)R__no_interaction	5,8,11,14-eicosatetraynoic acid__AT(2)R__no_interaction	PD123319__AT1R__no_interaction	PD123319__angiotensin II__no_interaction	PD123319__AT(1)R__no_interaction	PD123319__AT(2)R__no_interaction	arachidonic acid__AT1R__no_interaction	arachidonic acid__angiotensin II__no_interaction	arachidonic acid__AT(1)R__no_interaction	arachidonic acid__AT(2)R__no_interaction
9565403-4	The permeability sequence for <protein-id="P35524">rClC-1</protein-id>, <compound-id="781">SCN</compound-id>- approximately ClO4- &gt; Cl- &gt; Br- &gt; NO3- approximately ClO3- &gt; I- &gt;&gt; BrO3- &gt; HCO3- &gt;&gt; <compound-id="6395">methanesulfonate</compound-id> approximately <compound-id="7533">cyclamate</compound-id> approximately <compound-id="23327,33032,611,57109091">glutamate</compound-id>, was different from the sequence determined for blocking potency and ability to shift the Popen curve, <compound-id="781">SCN</compound-id>- approximately ClO4- &gt; I- &gt; NO3- approximately ClO3- approximately <compound-id="6395">methanesulfonate</compound-id> &gt; Br- &gt; <compound-id="7533">cyclamate</compound-id> &gt; BrO3- &gt; HCO3- &gt; <compound-id="23327,33032,611,57109091">glutamate</compound-id>, implying that the regulatory binding site that opens the channel is different from the selectivity center and situated closer to the external side.	cyclamate__rClC-1__no_interaction	SCN__rClC-1__no_interaction	methanesulfonate__rClC-1__no_interaction	glutamate__rClC-1__no_interaction
1415417-11	RESULTS: (1) <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> was present in all amniotic fluid samples; (2) amniotic fluid contains the highest <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> concentrations detected in any biologic fluid to date; (3) amniotic fluid <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> concentrations were not increased in women with preterm labor and intraamniotic infection in spite of dramatically elevated concentrations of <protein-id="P01583">Interleukin-1 alpha</protein-id> and <protein-id="P01584">interleukin-1 beta</protein-id> in the same fluid (median 22 ng/ml and range 0.16 to 70 for preterm labor with negative amniotic fluid culture vs median 30 ng/ml and range 6 to 70 for preterm labor with positive amniotic fluid culture; p &gt; 0.05); (4) <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> reduced <protein-id="P01584">interleukin-1 beta</protein-id>-induced <compound-id="5280360">prostaglandin E2</compound-id> production by amnion and chorion in a dose-dependent manner; (5) <protein-id="P18510,A0A024R528">interleukin-1 receptor antagonist</protein-id> by itself did not stimulate <compound-id="5280360">prostaglandin E2</compound-id> release by amnion and chorion when used in concentrations ranging from 0.1 to 1000 ng/ml.	prostaglandin E2__interleukin-1 beta__no_interaction	prostaglandin E2__Interleukin-1 alpha__no_interaction	prostaglandin E2__interleukin-1 receptor antagonist__no_interaction
23893995-8	Correlation analysis indicated that the IMF content in the LM was highly correlated with mRNA levels of <protein-id="Q9TUM6,F1N1N6,F1MHI1">PLIN2</protein-id> (r = 0.70, P &lt; 0.001), <compound-id="57476835,60961">adenosine</compound-id> triphosphatase (ATPase), H(+)-transporting, lysosomal 42 kDa, V1 subunit C1 (<protein-id="P21282">ATP6V1C1</protein-id>: r = 0.66, P &lt; 0.001), and cytochrome c oxidase assembly homolog 11 (<protein-id="A3KMZ6">COX11</protein-id>: r = 0.72, P &lt; 0.001) genes in a pooled animal group of steers plus bulls, and significant correlations in the steer-alone group were maintained in the 3 genes, <protein-id="Q9TUM6,F1N1N6,F1MHI1">PLIN2</protein-id> (r = 0.47, P &lt; 0.05), <protein-id="P21282">ATP6V1C1</protein-id> (r = 0.50, P &lt; 0.05), and <protein-id="A3KMZ6">COX11</protein-id> (r = 0.60, P &lt; 0.01).	adenosine__COX11__no_interaction	adenosine__ATP6V1C1__no_interaction	adenosine__PLIN2__no_interaction
23074487-16	THE TECHNOLOGY BEING REVIEWED: The following energy-based techniques were considered for assessment: transurethral electrovaporization of the prostate (TUVP)transurethral electrovapor resection of the prostate (TUVRP)transurethral electrovaporization of the prostate using bipolar energy (plasmakinetic vaporization of the prostate [PKVP])visual laser ablation of the prostate (VLAP)transurethral ultrasound guided laser incision prostatectomy (<compound-id="60823">TULIP</compound-id>)contact laser vaporization of the prostate (CLV)interstitial laser coagulation (<protein-id="Q9Y4X3,Q5VZ77">ILC</protein-id>)<compound-id="23988">holmium</compound-id> laser resection of the prostate (HoLRP)<compound-id="23988">holmium</compound-id> laser enucleation of the prostate (HoLEP)<compound-id="23988">holmium</compound-id> laser ablation of the prostate (HoLAP)<compound-id="159454">potassium titanyl phosphate</compound-id> (<compound-id="446833">KTP</compound-id>) lasertransurethral microwave thermotherapy (TUMT)transurethral needle ablation (TUNA) REVIEW STRATEGY: A search of electronic databases (OVID MEDLINE, MEDLINE In-Process &amp; Other Non-Indexed Citations, EMBASE, The Cochrane Library, and the International Agency for Health Technology Assessment [INAHTA] database) was undertaken to identify evidence published from January 1, 2000 to June 21, 2006.	TULIP__ILC__no_interaction	potassium titanyl phosphate__ILC__no_interaction	KTP__ILC__no_interaction	holmium__ILC__no_interaction
23074487-23	Two of the three RCTs on VLAP have shown that patients undergoing VLAP had a significantly lesser improvement in urinary symptom scores compared with patients undergoing TURP.RCTs showed that the time to catheter removal was significantly longer in patients undergoing VLAP compared with patients undergoing TURP.Meta-analysis of the rate of reoperation showed that patients undergoing VLAP had a significantly higher rate of reoperation compared with patients undergoing TURP.Meta-analysis showed that patients undergoing CLV had a significantly lesser improvement in urinary symptom scores compared with TURP at 2 years and at 3 or more years of follow-up.Two RCTs with 6-month and 2-year follow-up showed similar improvement in symptom scores for <protein-id="Q9Y4X3,Q5VZ77">ILC</protein-id> and TURP.Time to catheter removal was significantly longer in patients undergoing <protein-id="Q9Y4X3,Q5VZ77">ILC</protein-id> compared with patients undergoing TURP.The results of RCTs on HoLEP with 1-year follow-up showed excellent clinical outcomes with regard to the urinary symptom score and peak urinary flow.Meta-analysis showed that at 1-year follow-up, patients undergoing HoLEP had a significantly greater improvement in urinary symptom scores and peak flow rate compared with patients undergoing TURP.Procedural time is significantly longer in HoLEP compared with TURP.The results of one RCT with 4-year follow-up showed that HoLRP and TURP provided equivalent improvement in urinary symptom scores.The results of one RCT with 1-year follow-up showed that patients undergoing <compound-id="446833">KTP</compound-id> had a lesser improvement in urinary symptom scores than did patients undergoing TURP.	KTP__ILC__no_interaction
16750036-5	RESULTS: The <protein-id="P06850">CRH</protein-id> concentration [(1.66 +/- 0.34), (4.96 +/- 0.98) mmol/L before and after sleep] and <compound-id="5754">cortisol</compound-id> content [(152.93 +/- 136.15), (445.53 +/- 123.09) microg/L before and after sleep] in the OSAHS group were significantly higher than those of the control group [<protein-id="P06850">CRH</protein-id> was (0.67 +/- 0.42), (2.27 +/- 1.10) mmol/L, <compound-id="5754">cortisol</compound-id> concentration was (68.94 +/- 20.13), (146.05 +/- 30.48) microg/L, before and after sleep, respectively, all P &lt; 0.01]; <protein-id="P01286">GHRH</protein-id> significantly decreased in the OSAHS group [(1.42 +/- 0.07), (1.01 +/- 0.05) mmol/L before and after sleep] compared with the control group [(1.99 +/- 0.34), (1.58 +/- 0.15) mmol/L, respectively; all P &lt; 0.01]; but there was no difference in <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id>.	cortisol__CRH__no_interaction	cortisol__GHRH__no_interaction	cortisol__growth hormone__no_interaction
21312133-4	Table 1 Summary of Adhesion Molecules Group CD number Name Expressed on Ligand Integrins CD <compound-id="445535">49a</compound-id> <protein-id="P56199">VLA-1</protein-id> T lymphocytes, fibroblasts, basement membrane <compound-id="44342165">Laminin</compound-id>, collagen B1 very late antigens CD 49b <protein-id="P17301">VLA-2</protein-id> Activated T lymphocytes, platelets, fibroblasts, endothelium, epithelium Collagen, <compound-id="44342165">laminin</compound-id> CD <compound-id="86277905">49c</compound-id> VLA-3 Epithelium, fibroblasts <compound-id="44342165">Laminin</compound-id>, collagen, <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id> CD 49d VLA-4 Leukocytes, fibroblasts <protein-id="P19320">VCAM-1</protein-id>, <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id> CD 49e VLA-5 Leukocytes, platelets, epithelium <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id> CD 49f VLA-6 T lymphocytes, platelets <compound-id="44342165">Laminin</compound-id> B2 leukocyte integrins CD 11a <protein-id="P05107,B4E0R1">LFA-1</protein-id> Leukocytes <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P13598,Q6FHE2">ICAM-2</protein-id>, ICAM-3 CD 11b Mac-1 Macrophages, monocytes, granulocytes <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P02675,V9HVY1">fibrinogen</protein-id>, C3bi CD 11c p150.95 Macrophages, monocytes, granulocytes <protein-id="P02675,V9HVY1">fibrinogen</protein-id>, C3bi IG Supergene family CD 54 <protein-id="P05362">ICAM-1</protein-id> Endothelium, leukocytes, epithelium <protein-id="P05107,B4E0R1">LFA-1</protein-id> Mac-1 CD 102 <protein-id="P13598,Q6FHE2">ICAM-2</protein-id> Endothelium, leukocytes <protein-id="P05107,B4E0R1">LFA-1</protein-id> CD 106 <protein-id="P19320">VCAM-1</protein-id> Endothelium, dendritic cells, tissue macrophages VLA-4 Selectins CD 62E E <compound-id="4929">selectin</compound-id> Endothelium <compound-id="11828886">Sialyl Lewis x</compound-id> CD <compound-id="6420118">62P</compound-id> P <compound-id="4929">selectin</compound-id> Platelets, endothelium <compound-id="11828886">Sialyl Lewis x</compound-id> CD 62L L <compound-id="4929">selectin</compound-id> Leukocytes <compound-id="18950,206">Mannose</compound-id>-6-P, <compound-id="69507">fructose-6-P</compound-id>.	fructose-6-P__VCAM-1__no_interaction	fructose-6-P__fibrinogen__no_interaction	fructose-6-P__VLA-1__no_interaction	fructose-6-P__fibronectin__no_interaction	fructose-6-P__VLA-2__no_interaction	fructose-6-P__ICAM-2__no_interaction	fructose-6-P__ICAM-1__no_interaction	fructose-6-P__LFA-1__no_interaction	62P__VCAM-1__no_interaction	62P__fibrinogen__no_interaction	62P__VLA-1__no_interaction	62P__fibronectin__no_interaction	62P__VLA-2__no_interaction	62P__ICAM-2__no_interaction	62P__ICAM-1__no_interaction	62P__LFA-1__no_interaction	selectin__VCAM-1__no_interaction	selectin__fibrinogen__no_interaction	selectin__VLA-1__no_interaction	selectin__fibronectin__no_interaction	selectin__VLA-2__no_interaction	selectin__ICAM-2__no_interaction	selectin__ICAM-1__no_interaction	selectin__LFA-1__no_interaction	Laminin__VCAM-1__no_interaction	Laminin__fibrinogen__no_interaction	Laminin__VLA-1__no_interaction	Laminin__fibronectin__no_interaction	Laminin__VLA-2__no_interaction	Laminin__ICAM-2__no_interaction	Laminin__ICAM-1__no_interaction	Laminin__LFA-1__no_interaction	49a__VCAM-1__no_interaction	49a__fibrinogen__no_interaction	49a__VLA-1__no_interaction	49a__fibronectin__no_interaction	49a__VLA-2__no_interaction	49a__ICAM-2__no_interaction	49a__ICAM-1__no_interaction	49a__LFA-1__no_interaction	49c__VCAM-1__no_interaction	49c__fibrinogen__no_interaction	49c__VLA-1__no_interaction	49c__fibronectin__no_interaction	49c__VLA-2__no_interaction	49c__ICAM-2__no_interaction	49c__ICAM-1__no_interaction	49c__LFA-1__no_interaction	Mannose__VCAM-1__no_interaction	Mannose__fibrinogen__no_interaction	Mannose__VLA-1__no_interaction	Mannose__fibronectin__no_interaction	Mannose__VLA-2__no_interaction	Mannose__ICAM-2__no_interaction	Mannose__ICAM-1__no_interaction	Mannose__LFA-1__no_interaction	laminin__VCAM-1__no_interaction	laminin__fibrinogen__no_interaction	laminin__VLA-1__no_interaction	laminin__fibronectin__no_interaction	laminin__VLA-2__no_interaction	laminin__ICAM-2__no_interaction	laminin__ICAM-1__no_interaction	laminin__LFA-1__no_interaction	Sialyl Lewis x__VCAM-1__no_interaction	Sialyl Lewis x__fibrinogen__no_interaction	Sialyl Lewis x__VLA-1__no_interaction	Sialyl Lewis x__fibronectin__no_interaction	Sialyl Lewis x__VLA-2__no_interaction	Sialyl Lewis x__ICAM-2__no_interaction	Sialyl Lewis x__ICAM-1__no_interaction	Sialyl Lewis x__LFA-1__no_interaction
10487686-7	Plasma <protein-id="P08185">CBG</protein-id> correlated positively with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> levels (r = 0.49; P = 0.002), hemoglobin A1c levels (r = 0.35; P = 0.03), and area under the curve of <compound-id="206,5793,64689,79025">glucose</compound-id> after an oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test (r = 0.45; P = 0.005) and correlated negatively with the <protein-id="P01308,I3WAC9">insulin</protein-id> response to i.v.	glucose__CBG__no_interaction	glucose__insulin__no_interaction
14971196-5	But there was no significant difference of the levels of plasma ROS[(10,987.235 +/- 469.340)/(U.<protein-id="Q9NTI2">ml-1</protein-id>), (10,081.53 +/- 488.409)/(U.<protein-id="Q9NTI2">ml-1</protein-id>), (12,085.044 +/- 564.721)/(U.<protein-id="Q9NTI2">ml-1</protein-id>)], <protein-id="P00441,V9HWC9">SOD</protein-id>[(79.517 +/- 20.368)/(NU.<protein-id="Q9NTI2">ml-1</protein-id>), (67.975 +/- 24.202)/(NU.<protein-id="Q9NTI2">ml-1</protein-id>), (58.692 +/- 29.946)/(NU.<protein-id="Q9NTI2">ml-1</protein-id>)] and <compound-id="124886">GSH</compound-id>-PX[(101.362 +/- 59.859)/AU, (89.338 +/- 42.259)/AU, (101.890 +/- 33.559)/AU] in different pathological kinds of NPC.	GSH__ml-1__no_interaction	GSH__SOD__no_interaction
20959919-1	Several <compound-id="3776">titanium isopropoxide</compound-id> complexes [N,N'-bis(2-oxo-3-R(1)-5-R(2)-<compound-id="123147">phenylmethyl</compound-id>)-N,N'-bis(<compound-id="123164">methylene</compound-id>-p-R(3)-C(6)H(4))-<compound-id="17822391,3301">ethylenediamine</compound-id>]Ti(O(i)Pr)(2) [R(1) = t-Bu, R(2) = Me, <protein-id="P16401">R(3) = H (1b</protein-id>); R(1) = R(2) = t-Bu, <protein-id="Q16778">R(3) = H, (2b</protein-id>); R(1) = R(2) = Cl, <protein-id="P68431">R(3) = H, (3b</protein-id>), R(1) = t-Bu, R(2) = Me, R(3) = Cl (4b); R(1) = R(2) = t-Bu, R(3) = Cl, (<compound-id="18445697">5b</compound-id>); R(1) = R(2) = R(3) = Cl, (6b)] supported over sterically demanding aryloxy based [N(2)O(2)]H(2) ligands have been designed as precatalysts for the <compound-id="53675528,6325">ethylene</compound-id> polymerization.	ethylene__R(3) = H (1b__no_interaction	ethylene__R(3) = H, (2b__no_interaction	ethylene__R(3) = H, (3b__no_interaction	phenylmethyl__R(3) = H (1b__no_interaction	phenylmethyl__R(3) = H, (2b__no_interaction	phenylmethyl__R(3) = H, (3b__no_interaction	titanium isopropoxide__R(3) = H (1b__no_interaction	titanium isopropoxide__R(3) = H, (2b__no_interaction	titanium isopropoxide__R(3) = H, (3b__no_interaction	ethylenediamine__R(3) = H (1b__no_interaction	ethylenediamine__R(3) = H, (2b__no_interaction	ethylenediamine__R(3) = H, (3b__no_interaction	methylene__R(3) = H (1b__no_interaction	methylene__R(3) = H, (2b__no_interaction	methylene__R(3) = H, (3b__no_interaction	5b__R(3) = H (1b__no_interaction	5b__R(3) = H, (2b__no_interaction	5b__R(3) = H, (3b__no_interaction
18777500-17	<protein-id="P02753">RBP-4</protein-id> correlated with fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.40, p = 0.025), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.41, p = 0.02) and HOMA (r = 0.43, p = 0.015), but not with IRI (r = 0.19, p = 0.31).	glucose__RBP-4__no_interaction	glucose__insulin__no_interaction
7589883-1	We measured the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 (VLDL apoB) using a stable isotope gas-chromatography mass-spectrometry method in six patients with non-insulin-dependent diabetes mellitus (NIDDM) (four males, two females, age 57.5 +/- 2.2 years (mean +/- <compound-id="5289348">SEM</compound-id>), weight 88.2 +/- 5.5 kg, glycated haemoglobin (<protein-id="P69905,D1MGQ2">HbA1</protein-id>) 8.5 +/- 0.5%, plasma total <compound-id="5997">cholesterol</compound-id> concentration 5.7 +/- 0.5 mmol/l, triglyceride 3.8 +/- 0.9 mmol/l, high-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id> 1.0 +/- 0.1 mmol/l) and six non-diabetic subjects matched for age, sex and weight (four males, two females, age 55.7 +/- 2.8 years, weight 85.8 +/- 5.6 kg, <protein-id="P69905,D1MGQ2">HbA1</protein-id> 6.5 +/- 0.1%, plasma total <compound-id="5997">cholesterol</compound-id> concentration 5.7 +/- 0.5 mmol/l, triglyceride 1.2 +/- 0.1 mmol/l, HDL <compound-id="5997">cholesterol</compound-id> 1.4 +/- 0.1 mmol/l).	SEM__HbA1__no_interaction	cholesterol__HbA1__no_interaction
3286157-3	As compared to normal subjects, patients with chronic pancreatitis showed: (1) significantly higher plasma <compound-id="206,5793,64689,79025">glucose</compound-id> levels after oral <compound-id="206,5793,64689,79025">glucose</compound-id> load (area under the plasma <compound-id="206,5793,64689,79025">glucose</compound-id> curve 1708 +/- 142 vs 1208 +/- 47 mmol/liter X 240 min, P less than 0.005); (2) plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> levels significantly higher at fasting (0.11 +/- 0.008 vs 0.08 +/- 0.005 nmol/liter, P less than 0.01) but not after oral <compound-id="206,5793,64689,79025">glucose</compound-id> administration (area under the plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> curve 79 +/- 12 vs 88 +/- 16 nmol/liter X 240 min); (3) significantly lower plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> concentrations both in the fasting state (0.15 +/- 0.01 vs 0.54 +/- 0.05 nmol/liter, P less than 0.001) and after oral <compound-id="206,5793,64689,79025">glucose</compound-id> load (area under the plasma <protein-id="P01308,I3WAC9">C-peptide</protein-id> curve 211 +/- 30 vs 325 +/- 37 nmol/liter X 240 min, P less than 0.05).	glucose__Insulin__no_interaction	glucose__C-peptide__no_interaction
24509840-2	Fenamates such as FFA (<compound-id="3371">flufenamic acid</compound-id>; 2-{[3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]amino}<compound-id="243">benzoic acid</compound-id>), MFA [<compound-id="4044">mefenamic acid</compound-id>; 2-(2,3-dimethylphenyl)<compound-id="227">aminobenzoic acid</compound-id>], NFA [<compound-id="4488">niflumic acid</compound-id>; 2-{[3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]amino}<compound-id="938">nicotinic acid</compound-id>], and <compound-id="3033">diclofenac</compound-id> [2-(2-(<compound-id="11846">2,6-dichlorophenylamino</compound-id>)phenyl)<compound-id="176">acetic acid</compound-id>] and the related experimental drug <compound-id="16078951">BL-1249</compound-id> [(5,6,7,8-tetrahydro-<compound-id="931">naphthalen</compound-id>-1-yl)-[2-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)-phenyl]-amine] enhance the activity of <protein-id="O95069,Q6ZW95,U3N6F0,U3N834">TREK1</protein-id> currents, and we show that <compound-id="16078951">BL-1249</compound-id> is the most potent of these compounds.	BL-1249__TREK1__no_interaction	niflumic acid__TREK1__no_interaction	mefenamic acid__TREK1__no_interaction	2,6-dichlorophenylamino__TREK1__no_interaction	nicotinic acid__TREK1__no_interaction	aminobenzoic acid__TREK1__no_interaction	flufenamic acid__TREK1__no_interaction	benzoic acid__TREK1__no_interaction	diclofenac__TREK1__no_interaction	trifluoromethyl__TREK1__no_interaction	naphthalen__TREK1__no_interaction	1H-tetrazol__TREK1__no_interaction	acetic acid__TREK1__no_interaction
15591785-4	The binding affinity of Morniga M for ligands can be ranked in decreasing order as follows: gps carrying multiple N-<compound-id="871">glycans</compound-id> with oligomannosyl residues &gt;&gt; N-glycopeptide with a single trimannosyl core &gt; Tri-Man oligomer [Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;6(Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;3) Man], Penta-Man oligomer [Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;6(Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;3)Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;6(Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;3) Man] &gt; or = Man <protein-id="P25100,B0ZBE0">alpha1</protein-id>--&gt;2, 3 or 6 Man &gt; Man &gt; <compound-id="11861101,24139,439174,899">GlcNAc</compound-id>, <compound-id="3034742,57288387,6971003">Glc</compound-id> &gt;&gt; L-Fuc, Gal, <compound-id="35717">GalNAc</compound-id> (inactive), demonstrating the unique specificity of this lectin that may not only assist in our understanding of cell surface carbohydrate ligand-lectin recognition, but also provide informative guidelines for the application of this structural probe in biotechnological and clinical regimens, especially in the detection and purification of N-linked <compound-id="871">glycans</compound-id>.	glycans__alpha1__no_interaction	GalNAc__alpha1__no_interaction	Glc__alpha1__no_interaction	GlcNAc__alpha1__no_interaction
17652183-5	A series of 29 mutations targeting 25 amino acids broadly distributed in the minor and major ligand-binding pockets of <protein-id="P51685">CCR8</protein-id> uncovered that the binding of LMD-009 and of four analogs [2-(1-(<compound-id="611753">3-(2-methoxyphenoxy)benzyl</compound-id>)-<compound-id="79341">4-hydroxypiperidin</compound-id>-4-yl)<compound-id="243">benzoic acid</compound-id> (LMD-584), N-<compound-id="23134249">ethyl</compound-id>-2-<compound-id="70789">4-methoxybenzenesulfonamide</compound-id> (LMD-902), <compound-id="60016664">N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-2-phenyl-4-(pyrrolidin-1yl)butanamide</compound-id> (LMD-268), and <compound-id="60016644">N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-1,2,3,4-tetrahydro-2-oxoquinoline-4-carboxamide</compound-id> (LMD-174)] included several key-residues for nonpeptide antagonists targeting <protein-id="P32246,Q5U003">CCR1</protein-id>, -2, and -5.	3-(2-methoxyphenoxy)benzyl__CCR8__no_interaction	3-(2-methoxyphenoxy)benzyl__CCR1__no_interaction	benzoic acid__CCR8__no_interaction	benzoic acid__CCR1__no_interaction	4-methoxybenzenesulfonamide__CCR8__no_interaction	4-methoxybenzenesulfonamide__CCR1__no_interaction	N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-2-phenyl-4-(pyrrolidin-1yl)butanamide__CCR8__no_interaction	N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-2-phenyl-4-(pyrrolidin-1yl)butanamide__CCR1__no_interaction	4-hydroxypiperidin__CCR8__no_interaction	4-hydroxypiperidin__CCR1__no_interaction	N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-1,2,3,4-tetrahydro-2-oxoquinoline-4-carboxamide__CCR8__no_interaction	N-(1-(3-(2-methoxyphenoxy)benzyl)piperidin-4-yl)-1,2,3,4-tetrahydro-2-oxoquinoline-4-carboxamide__CCR1__no_interaction	ethyl__CCR8__no_interaction	ethyl__CCR1__no_interaction
20054162-4	RESULTS: pp TG response had positive associations with BMI (r = 0.24; p &lt; 0.05), fat mass (r = 0.28; p &lt; 0.01), waist circumference (r = 0.33; p &lt; 0.01), systolic blood pressure (r = 0.21; p &lt; 0.05), fasting (r = 0.29; p &lt; 0.01) and pp <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.40; p &lt; 0.001), fasting (r = 0.38; p &lt; 0.001) and pp <protein-id="P01308,I3WAC9">insulin</protein-id> levels (r = 0.46; p &lt; 0.001), and inverse associations with HDL-C (r = -0.43; p &lt; 0.001) and intake of dietary fibre (r = -0.31; p &lt; 0.05).	glucose__insulin__no_interaction
19499560-4	Substances 1-3 are good starting materials for further Cu(I) chemistry, and the reaction of 1-3 with the weak Lewis base <compound-id="66348">cyclooctasulfur</compound-id> gave the first Cu(I)-<compound-id="402">sulfur</compound-id> complexes of type [Cu(<compound-id="122099">S12</compound-id>)(S8)](+)[Al{OC(CF3)3}4]- (4), [Cu(CH2Cl2)(<compound-id="122099">S12</compound-id>)](+)[Al{OC(CF3)3}4]- (5), [A1Cu(1,5-<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>,<protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">eta1</protein-id>-S8)CuA1] (6; A1=[Al{OC(CH3)(CF3)2}4]-), and a Cu(I)-S8 1D coordination polymer with [<compound-id="444924">Cu2</compound-id>(S8)2A(2)(2)] (7; A2=[Al{OCH(CF3)2}4]-), as a monomeric repeat unit.	sulfur__eta1__no_interaction	S12__eta1__no_interaction	Cu2__eta1__no_interaction	cyclooctasulfur__eta1__no_interaction
24092995-6	Body mass index (BMI) was 31.43 ± 5.94 and 32.33 ± 6.54, systolic blood pressure was 117.15 ± 18.16 mmHg and 126.15 ± 20.26 mmHg, diastolic blood pressure was 81.11 ± 10.55 mmHg and 82.77 ± 10.85 mmHg, HbA1c was 7.2 ± 1.1 and 8.19 ± 1.95, serum total <compound-id="5997">cholesterol</compound-id> was 6.61 ± 1.11 and 4.11 ± 0.31, serum triglycerides were 3.52 ± 0.89 and 3.42 ± 0.79, serum low-density lipoprotein (LDL) was 2.12 ± 0.10 and 2.42 ± 0.15, high-density lipoprotein (HDL) was 2.66 ± 0.30 and 2.55 ± 0.21, <protein-id="P00441,V9HWC9">SOD</protein-id> was 3.12 ± 0.87 and 1.53 ± 0.14, GPx was 11.14 ± 2.21 and 8.2 ± 1.84, CAT was 26.43 ± 3.34 and 9.60 ± 2.14, for DR(-) and DR(+) patients, respectively.	cholesterol__SOD__no_interaction
10520704-8	RESULTS: Good correlation was observed between the total hepatic 99mTc-<protein-id="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2">GSA</protein-id> clearance and conventional hepatic function tests: plasma retention rate of iodocyanine green (<compound-id="6096882">ICG</compound-id>) at 15 min (<compound-id="6096882">ICG</compound-id> <compound-id="24856345">R15</compound-id>), r = -0.600, P &lt; 0.0001, n = 94; plasma disappearance rate of <compound-id="6096882">ICG</compound-id> (K <compound-id="6096882">ICG</compound-id>), r = 0.670, P &lt; 0.0001, n = 83; cholinesterase, r = 0.539, P &lt; 0.0001, n = 121; serum <protein-id="P02768">albumin</protein-id>, r = 0.421, P = 0.0001, n = 123; and hepaplastin test, r = 0.456, P &lt; 0.0001, n = 120.	R15__GSA__no_interaction	R15__albumin__no_interaction	ICG__GSA__no_interaction	ICG__albumin__no_interaction
22746383-5	METHODS: OVID MEDLINE and ISI Web of Science databases were searched using the terms "GHB," "gamma-hydroxybutyrate," "gamma-hydroxybutyric acid," "<compound-id="54075612">4-hydroxybutanoic acid</compound-id>," "<compound-id="10413">sodium oxybate</compound-id>," "<compound-id="7302">gamma-butyrolactone</compound-id>," "<protein-id="Q9BVC4">GBL</protein-id>," "<compound-id="8064,88748">1,4-butanediol</compound-id>," and "1,4-BD" alone and in combination with the keywords "pharmacokinetics," "kinetics," "poisoning," "poison," "toxicity," "ingestion," "adverse effects," "overdose," and "intoxication.	1,4-butanediol__GBL__no_interaction	sodium oxybate__GBL__no_interaction	4-hydroxybutanoic acid__GBL__no_interaction	gamma-butyrolactone__GBL__no_interaction
19332690-11	CBF = cerebral blood flow; DBP = diastolic blood pressure; DEFUSE = Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution; DWI = diffusion-weighted imaging; EPITHET = Echoplanar Imaging Thrombolytic Evaluation Trial; FOV = field of view; ICA = internal carotid artery; IQR = interquartile range; MCA = middle cerebral artery; <compound-id="64966">MTT</compound-id> = mean transit time; NIHSS = NIH Stroke Scale; PWI = perfusion-weighted imaging; PWI-MRI = magnetic resonance perfusion-weighted imaging; ROC = receiver operating characteristic; ROI = region of interest; <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> = systolic blood pressure; SVD = singular value decomposition; Xe-CT = <compound-id="23991">xenon</compound-id> CT. 	MTT__SBP__no_interaction	xenon__SBP__no_interaction
21127805-1	The CX3(+) salts [<protein-id="P10147,A0N0R1">CCl(3</protein-id>)](+)[Al(OR(F))(4)](-)1, [<protein-id="P10147,A0N0R1">CCl(3</protein-id>)](+)[(R(F)O)(3)Al-F-Al(OR(F))(3)](-)2, [<protein-id="O75828,V9HW40">CBr(3</protein-id>)](+)[Al(OR(F))(4)](-)3, [<protein-id="O75828,V9HW40">CBr(3</protein-id>)](+)[(R(F)O)(3)Al-F-Al(OR(F))(3)](-)4 (R(F) = C(CF(3))(3)) were prepared in 56 to 85% yield from CX(4) (X = Cl, Br) and the corresponding <compound-id="23954">silver</compound-id> salts (weight balance, NMR, IR, X-ray structure of 1).	silver__CCl(3__no_interaction	silver__CBr(3__no_interaction
23506284-3	<protein-id="Q9WVC6,E9Q8C1,E9Q1B0">SGK1</protein-id> sensitive functions include activation of ion channels (including epithelial Na(+) channel ENaC, voltage gated Na(+) channel SCN5A transient receptor potential channels TRPV4 - 6, Ca(2+) release activated Ca(2+) channel <protein-id="Q8BWG9,A3KCG1">Orai1</protein-id>/<protein-id="P70302">STIM1</protein-id>, renal outer medullary K(+) channel <protein-id="O88335,G3UWE7">ROMK</protein-id>, voltage gated K(+) channels <protein-id="P23299,Q545H6">KCNE1</protein-id>/<protein-id="P97414">KCNQ1</protein-id>, <compound-id="10255">kainate</compound-id> receptor GluR6, cystic fibrosis transmembrane regulator CFTR), carriers (including Na(+),Cl(-) symport NCC, Na(+),K(+),2Cl(-) symport NKCC, Na(+)/H(+) exchangers <protein-id="Q61165,Q3UDC9,Q3TN68">NHE1</protein-id> and <protein-id="G3X939">NHE3</protein-id>, Na(+), <compound-id="206,5793,64689,79025">glucose</compound-id> symport <protein-id="Q8C3K6,Q9QXI6,Q8CCA7">SGLT1</protein-id>, several amino acid transporters), and Na(+)/K(+)-ATPase.	kainate__STIM1__no_interaction	kainate__KCNE1__no_interaction	kainate__SGK1__no_interaction	kainate__KCNQ1__no_interaction	kainate__Orai1__no_interaction	kainate__SGLT1__no_interaction	kainate__NHE1__no_interaction	kainate__ROMK__no_interaction	kainate__NHE3__no_interaction	glucose__STIM1__no_interaction	glucose__KCNE1__no_interaction	glucose__SGK1__no_interaction	glucose__KCNQ1__no_interaction	glucose__Orai1__no_interaction	glucose__SGLT1__no_interaction	glucose__NHE1__no_interaction	glucose__ROMK__no_interaction	glucose__NHE3__no_interaction
21824757-6	<compound-id="129891">LTL</compound-id> resulted inversely correlated with family history of CVD (t = 2.70; p = 0.009), age (r = -0.238; p = 0.032), waist circumference (r = -0.256; p = 0.02), triglycerides (r = -0.218; p = 0.049), <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> (r = -0.288; p = 0.009) and directly correlated with HDL-<compound-id="5997">cholesterol</compound-id> (r = 0.316; p = 0.004) and EPC number (r = 0.358; p = 0.002).	cholesterol__PAI-1__no_interaction	LTL__PAI-1__no_interaction
19882211-3	The following alleles and genotypes were significantly (P &lt; 0.01 after correction for multiple testing) more frequent among patients: the <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id> -1098G allele and GG genotype (OR = 3.12 and 105.00, respectively), <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id> -<compound-id="44160268">33T</compound-id> allele and TT genotype (OR = 2.52 and 118.83, respectively), <protein-id="P22301,Q6FGW4">IL-10</protein-id> -1082G allele and GG genotype (OR = 2.16 and 6.40, respectively), <protein-id="P22301,Q6FGW4">IL-10</protein-id> -819T allele, TC and TT genotype (OR = 2.60, 3.68 and 6.76, respectively), <protein-id="P22301,Q6FGW4">IL-10</protein-id> -592A allele, AC and AA genotype (OR = 2.41, 2.89 and 5.68, respectively), <protein-id="P01137">TGF-beta</protein-id> +869C allele and CC genotype (OR = 2.24 and 6.21, respectively), and <protein-id="P01137">TGF-beta</protein-id> +915C allele, CG and CC genotype (OR = 7.81, 11.80 and 20.40, respectively).	33T__IL-4__no_interaction	33T__TGF-beta__no_interaction	33T__IL-10__no_interaction
23026737-12	After rewarming, the recovery of high-energy phosphates and <protein-id="E0Y441">pHi</protein-id> was much slower in Group I (PCr: 55.7 ± 9.1 vs 78.4 ± 5.1% of the baseline, P = 0.046; <compound-id="57476835,60961">adenosine</compound-id> triphosphate: 26.6 ± 10.6 vs 64.8 ± 4.6% of the baseline, P = 0.007; <protein-id="E0Y441">pHi</protein-id>: 6.5 ± 0.4 vs 7.1 ± 0.1, P = 0.021 at 30-min normothermic perfusion after rewarming).	adenosine__pHi__no_interaction
23399960-5	<compound-id="3446">Gabapentin</compound-id> produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of <protein-id="P29456">IL-10</protein-id> (TNF-α, 316.0 ± 69.7 pg/mL vs 88.8 ± 24.4 pg/mL; IL-1β, 1,212.9 ± 104.5 vs 577.4 ± 97.1 pg/mL; <protein-id="P20607">IL-6</protein-id>, 254.0 ± 64.8 pg/mL vs 125.5 ± 44.1 pg/mL; <protein-id="P29456">IL-10</protein-id>, 532.1 ± 78.7 pg/mL vs 918.9 ± 63.1 pg/mL).	Gabapentin__IL-6__no_interaction	Gabapentin__IL-10__no_interaction
8217018-1	[Cu(C6H18N4)(C10H10N2)](ClO4)2, (1-<compound-id="77918">benzylimidazole</compound-id>)[<compound-id="77731">N,N-bis(2-aminoethyl)-1,2-ethanediamine</compound-id>]<compound-id="23978">copper</compound-id>(II) diperchlorate (1), M(r) = 566.88, monoclinic, P2(1)/c, a = 10.549 (1), b = 9.2465 (9), c = 25.256 (2) A, beta = 101.42 (1) degrees, V = 2415 (1) A3, Z = 4, Dm = 1.54 (1), Dx = 1.559 Mg m-3, lambda (<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, mu = 1.18 mm-1, F(000) = 1172, T = 296 (1) K, R = 0.048, wR = 0.069 for 3063 reflections.	benzylimidazole__Mo K alpha__no_interaction	copper__Mo K alpha__no_interaction	N,N-bis(2-aminoethyl)-1,2-ethanediamine__Mo K alpha__no_interaction
8217018-2	[Zn0.99Cu0.01(C6H18N4)(C10H10N2)](ClO4)2, 1% CuII-doped (1-<compound-id="77918">benzylimidazole</compound-id>)[<compound-id="77731">N,N-bis(2-aminoethyl)-1,2-ethanediamine</compound-id>]<compound-id="23994">zinc</compound-id>(II) diperchlorate (2), M(r) = 568.72, monoclinic, P2(1)/c, a = 10.708 (1), b = 9.229 (2), c = 25.205 (2) A, beta = 101.867 (8) degrees, V = 2438 (1) A3, Z = 4, Dm = 1.54 (1), Dx = 1.549, lambda (<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, mu = 1.30 mm-1, F(000) = 1176, T = 295 (1) K, R = 0.041, wR = 0.055 for 3282 reflections.	benzylimidazole__Mo K alpha__no_interaction	zinc__Mo K alpha__no_interaction	N,N-bis(2-aminoethyl)-1,2-ethanediamine__Mo K alpha__no_interaction
23517875-6	Using the continuous-flow calibration device, lab-based sampling rates were determined for all the target compounds (RSBPA = 0.0326 L/d; RScisADT = 0.0800 L/d, <protein-id="Q15393,A8K6V3">RSE1</protein-id> = 0.0398 L/d, RSEQ = 0.0516 L/d, RSTT = 0.0745 L/d, RSE2 = 0.0585 L/d, RSEE2 = 0.0406 L/d, RSNT = 0.0846 L/d, RSPG = 0.0478 L/d and RSE3 = 0.1468 L/d), except for <protein-id="P17661,Q53SB5">DES</protein-id>, MeEE2, 4tOP, <compound-id="6560291">4OP</compound-id>, 4NPs, where the uptake after 14 days POCIS exposure was found to be insignificant or indicated a no linear behaviour.	4OP__RSE1__no_interaction	4OP__DES__no_interaction
17587396-9	<compound-id="4829,53942694">Pioglitazone</compound-id> caused an improvement in lipid profile in both ethnic groups, with a reduction in mean values of atherogenic fractions (triglyceride: Caucasian -0.5 mmol/l, p &lt; 0.001 vs. Maori-Polynesian -0.3 mmol/l, p = 0.05; very low-density lipoprotein (VLDL)-<compound-id="5997">cholesterol</compound-id>: Caucasian -0.11 mmol/l, p = 0.001 vs. Maori-Polynesian -0.04 mmol/l, p = 0.85; VLDL-triglyceride: Caucasian -0.36 mmol/l, p &lt; 0.001 vs. Maori-Polynesian -0.22 mmol/l, p = 0.14; <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id>: Caucasian -0.09 mmol/l, p = 0.03 vs. Maori-Polynesian -0.08 mmol/l, p = 0.18).	Pioglitazone__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
19699018-10	<protein-id="P01375,Q5STB3">Tumor necrosis factor alpha</protein-id> level was the strongest correlate of sCD14 level (r = +0.24; P &lt; 0.001), followed by <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin 6</protein-id> level (r = +0.18; P = 0.002), serum ferritin level (r = +0.21; P &lt; 0.001), total <compound-id="23925,67172434">iron</compound-id>-binding capacity (r = -0.19; P &lt; 0.001), body mass index (r = -0.15; P = 0.008), vintage (r = +0.14; P = 0.01), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> level (r = +0.13; P = 0.03), and body fat (r = -0.11; P = 0.06).	iron__Tumor necrosis factor alpha__no_interaction	iron__interleukin 6__no_interaction	cholesterol__Tumor necrosis factor alpha__no_interaction	cholesterol__interleukin 6__no_interaction
2964324-6	Moreover, the activities of <protein-id="P11413">glucose-6-phosphate dehydrogenase</protein-id> (0.25 +/- 0.03 vs 0.13 +/- 0.01 U/g wet weight) and malic enzyme (0.15 +/- 0.01 vs 0.05 +/- 0.01 U/g wet weight), necessary for lipid synthesis, were significantly increased (both p less than 0.001) in the diabetic patients while the glycolytic enzymes, hexokinase (0.65 +/- 0.09 vs 1.82 +/- 0.11 U/g wet weight), <compound-id="1060">pyruvate</compound-id> kinase (7.3 +/- 0.9 vs 13.2 +/- 0.9 U/g wet weight), phosphofructokinase (1.3 +/- 0.2 vs 2.6 +/- 0.2 U/g wet weight), and <compound-id="439162">alpha-glycerophosphate</compound-id> dehydrogenase (7.3 +/- 0.5 vs 12.5 +/- 0.7 U/g wet weight) were decreased (all p less than 0.001).	alpha-glycerophosphate__glucose-6-phosphate dehydrogenase__no_interaction	pyruvate__glucose-6-phosphate dehydrogenase__no_interaction
10908083-7	<protein-id="P01160">ANP</protein-id> levels at baseline were inversely related to LVEF (r = -0.39; P = .0001), exercise duration (r = -0.19; P = .0001), and peak <compound-id="977">oxygen</compound-id> consumption (r = -0.27; P = .008) and directly related to LV (r = 0.23; P = .0006) and right ventricular dilatation (r = 0.23; P = .0008).	oxygen__ANP__no_interaction
20580031-7	Corresponding to the number of MetS RF, baPWV (1306 ± 17, 1364 ± 16, and 1420 ± 33 cm/s; P &lt; .001) and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (1.5 ± 0.1, 1.9 ± 0.1, and 2.7 ± 0.2; P &lt; .001) gradually increased after adjustment for age, body mass index, smoking, and drinking, whereas serum <compound-id="446925">lycopene</compound-id> among antioxidants and LDL particle size gradually decreased (0.036 ± 0.001, 0.031 ± 0.001, and 0.028 ± 0.001 mmol/L; P = .004 and 23.9 ± 0.1, 23.7 ± 0.1, and 23.3 ± 0.1 nm; P &lt; .001, respectively).	lycopene__insulin__no_interaction
3009799-3	Several lines of evidence, however, demonstrated that deglycosylation produced significant modifications in the <protein-id="P42098">ZP3</protein-id> macromolecule which profoundly altered its antigenicity: 125I-radiolabelling procedures using <compound-id="31388">chloramine-T</compound-id> consistently resulted in 125I-labelled <protein-id="P42098">ZP3</protein-id> with a higher specific activity than 125I-labelled DG-<protein-id="P42098">ZP3</protein-id>; in competitive binding radioimmunoassays (RIAs) using an 125I-labelled-<protein-id="P42098">ZP3</protein-id> vs anti-<protein-id="P42098">ZP3</protein-id> system, unlabelled DG-<protein-id="P42098">ZP3</protein-id> successfully displaced <protein-id="P42098">ZP3</protein-id> in a dose-related manner; in direct binding RIAs comparing the reaction of labelled <protein-id="P42098">ZP3</protein-id> and DG-<protein-id="P42098">ZP3</protein-id> versus 5 different zona antisera, higher titres were consistently achieved with 125I-labelled <protein-id="P42098">ZP3</protein-id>; as compared to <protein-id="P42098">ZP3</protein-id>, 2-dimensional immunoelectrophoresis using DG-<protein-id="P42098">ZP3</protein-id> as antigen yielded significantly modified precipitin arc patterns; with electrophoretic blotting procedures, antisera to <protein-id="P42098">ZP3</protein-id> or DG-<protein-id="P42098">ZP3</protein-id> cross-reacted with the heterologous antigen; treatment of pig zonae with anti-DG-<protein-id="P42098">ZP3</protein-id> serum produced a dense precipitation layer on the zona surface.	chloramine-T__ZP3__no_interaction
24552493-11	Within the <protein-id="P49913,J3KNB4">Camp</protein-id> Lejeune cohort, monotonic categorical cumulative exposure trends were observed for kidney cancer and total contaminants (HR, high cumulative exposure = 1.54, 95% CI: 0.63, 3.75; log10 β = 0.06, 95% CI: -0.05, 0.17), Hodgkin lymphoma and <compound-id="6575">trichloroethylene</compound-id> (HR, high cumulative exposure = 1.97, 95% CI: 0.55, 7.03; β = 0.00005, 95% CI: -0.00003, 0.00013) and <compound-id="241">benzene</compound-id> (HR, high cumulative exposure = 1.94, 95% CI: 0.54, 6.95; β = 0.00203, 95% CI: -0.00339, 0.00745).	benzene__Camp__no_interaction	trichloroethylene__Camp__no_interaction
23467616-1	With diverse multi-dentate N-heterocyclic/diamine molecules as the cations, the reactions between Cd(2+) and <compound-id="781">SCN</compound-id>(-) in C2H5OH/H2O solution acidified by <compound-id="1118">H2SO4</compound-id> created five new thiocyanatocadmates [<compound-id="783">H2</compound-id>(bim)][Cd(<compound-id="781">SCN</compound-id>)2(H2O)2]SO4 (bim = 2,2'-<compound-id="101463">biimidazole</compound-id>) 1, [<compound-id="783">H2</compound-id>(pympip)]2[<protein-id="P06729,Q53F96">Cd2</protein-id>(<compound-id="781">SCN</compound-id>)4(SO4)2(H2O)4]·2H2O (pympip = <compound-id="88747">1-(2-pyrimidyl)piperazine</compound-id>) 2, [<compound-id="783">H2</compound-id>(tdpy)]2[Cd3(<compound-id="781">SCN</compound-id>)10] (tdpy = <compound-id="604650">4,4'-thiodipyridine</compound-id>) 3, [<compound-id="783">H2</compound-id>(badpm)][Cd(<compound-id="781">SCN</compound-id>)4] (badpm = 4,4'-biaminodiphenylmethane) 4 and [<compound-id="783">H2</compound-id>(pdma)][<protein-id="P06729,Q53F96">Cd2</protein-id>(<compound-id="781">SCN</compound-id>)4(SO4)] (pdma = <compound-id="68315">1,4-phenylenedimethanamine</compound-id>) 5.	1-(2-pyrimidyl)piperazine__Cd2__no_interaction	H2__Cd2__no_interaction	H2SO4__Cd2__no_interaction	SCN__Cd2__no_interaction	4,4'-thiodipyridine__Cd2__no_interaction	biimidazole__Cd2__no_interaction	1,4-phenylenedimethanamine__Cd2__no_interaction
18227124-5	<protein-id="P01375,Q5STB3">TNF-alpha</protein-id> significantly increased HTSMC-neutrophil adhesions, and this effect was associated with increased expression of <protein-id="P19320">VCAM-1</protein-id> on the HTSMCs and was blocked by the selective inhibitors of Src [4-amino-5-(4-methylphenyl)-7-(t-<compound-id="68006705">butyl</compound-id>)pyrazolo[3,4-d]-pyrimidine (<protein-id="Q15181,V9HWB5">PP1</protein-id>)], <protein-id="P00533">epidermal growth factor receptor</protein-id> [<protein-id="P00533">EGFR</protein-id>; 4-(3'-<compound-id="258030">chloroanilino</compound-id>)-6,7-dimethoxy-<compound-id="9210">quinazoline</compound-id>, (<compound-id="2051">AG1478</compound-id>)], <compound-id="16738692,53477912">phosphatidylinositol</compound-id> 3-kinase (PI3K) [<compound-id="3973">2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride</compound-id>(LY294002) and <compound-id="312145">wortmannin</compound-id>],<compound-id="22044544,5460341">calcium</compound-id>[1,2-bis(2-<compound-id="5483936">aminophenoxy</compound-id>) <compound-id="6324">ethane</compound-id>-N,N,N',N'-<compound-id="176">tetraacetic acid</compound-id>-acetoxymethyl ester; BAPTA-AM], <compound-id="16738692,53477912">phosphatidylinositol</compound-id>-phospholipase C (PLC) [<compound-id="91182329">1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione</compound-id> (<compound-id="104794">U73122</compound-id>)], protein kinase C (PKC) [12-(2-cyanoethyl)-6,7,12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-<compound-id="6854">carbazole</compound-id> (Gö6976), <compound-id="5281847">rottlerin</compound-id>, and 3-1-[3-(amidinothio)<compound-id="261162">propyl-1H-indol-3-yl</compound-id>]-3-(1-methyl-1H-indol-3-yl) maleimide (<compound-id="2396">bisindolylmaleimide</compound-id> IX) (<compound-id="214797">Ro 31</compound-id>-8220)], CaM (<compound-id="2531">calmidazolium chloride</compound-id>), CaM kinase II [(8R(*),9S(*),11S(*))-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-14-n-propoxy-2,3,9, 10-tetrahydro-8,11-<compound-id="160438,18783669">epoxy</compound-id>, 1H,8H, <compound-id="66534">11H</compound-id>-2,7b,11a-triazadibenzo[a,g]<compound-id="9266">cycloocta</compound-id>[cde]trinden-1-one (KT5926) and <compound-id="5312126">1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine</compound-id> (KN62)], <protein-id="Q09472,Q7Z6C1">p300</protein-id> (<compound-id="969516">curcumin</compound-id>), and HDAC (<compound-id="444732">trichostatin A</compound-id>) or transfection with short interfering RNAs for Src, <protein-id="P31749,B0LPE5,B3KVH4">Akt</protein-id>, <protein-id="P17252,Q7Z727">PKCalpha</protein-id>, <protein-id="Q15139,F8WBA3">PKCmu</protein-id>, and <protein-id="P56524">HDAC4</protein-id>.	bisindolylmaleimide__PKCmu__no_interaction	bisindolylmaleimide__HDAC4__no_interaction	bisindolylmaleimide__EGFR__no_interaction	bisindolylmaleimide__PKCalpha__no_interaction	bisindolylmaleimide__Akt__no_interaction	bisindolylmaleimide__PP1__no_interaction	bisindolylmaleimide__VCAM-1__no_interaction	bisindolylmaleimide__epidermal growth factor receptor__no_interaction	bisindolylmaleimide__TNF-alpha__no_interaction	bisindolylmaleimide__p300__no_interaction	tetraacetic acid__PKCmu__no_interaction	tetraacetic acid__HDAC4__no_interaction	tetraacetic acid__EGFR__no_interaction	tetraacetic acid__PKCalpha__no_interaction	tetraacetic acid__Akt__no_interaction	tetraacetic acid__PP1__no_interaction	tetraacetic acid__VCAM-1__no_interaction	tetraacetic acid__epidermal growth factor receptor__no_interaction	tetraacetic acid__TNF-alpha__no_interaction	tetraacetic acid__p300__no_interaction	trichostatin A__PKCmu__no_interaction	trichostatin A__HDAC4__no_interaction	trichostatin A__EGFR__no_interaction	trichostatin A__PKCalpha__no_interaction	trichostatin A__Akt__no_interaction	trichostatin A__PP1__no_interaction	trichostatin A__VCAM-1__no_interaction	trichostatin A__epidermal growth factor receptor__no_interaction	trichostatin A__TNF-alpha__no_interaction	trichostatin A__p300__no_interaction	U73122__PKCmu__no_interaction	U73122__HDAC4__no_interaction	U73122__EGFR__no_interaction	U73122__PKCalpha__no_interaction	U73122__Akt__no_interaction	U73122__PP1__no_interaction	U73122__VCAM-1__no_interaction	U73122__epidermal growth factor receptor__no_interaction	U73122__TNF-alpha__no_interaction	U73122__p300__no_interaction	quinazoline__PKCmu__no_interaction	quinazoline__HDAC4__no_interaction	quinazoline__EGFR__no_interaction	quinazoline__PKCalpha__no_interaction	quinazoline__Akt__no_interaction	quinazoline__PP1__no_interaction	quinazoline__VCAM-1__no_interaction	quinazoline__epidermal growth factor receptor__no_interaction	quinazoline__TNF-alpha__no_interaction	quinazoline__p300__no_interaction	curcumin__PKCmu__no_interaction	curcumin__HDAC4__no_interaction	curcumin__EGFR__no_interaction	curcumin__PKCalpha__no_interaction	curcumin__Akt__no_interaction	curcumin__PP1__no_interaction	curcumin__VCAM-1__no_interaction	curcumin__epidermal growth factor receptor__no_interaction	curcumin__TNF-alpha__no_interaction	curcumin__p300__no_interaction	wortmannin__PKCmu__no_interaction	wortmannin__HDAC4__no_interaction	wortmannin__EGFR__no_interaction	wortmannin__PKCalpha__no_interaction	wortmannin__Akt__no_interaction	wortmannin__PP1__no_interaction	wortmannin__VCAM-1__no_interaction	wortmannin__epidermal growth factor receptor__no_interaction	wortmannin__TNF-alpha__no_interaction	wortmannin__p300__no_interaction	aminophenoxy__PKCmu__no_interaction	aminophenoxy__HDAC4__no_interaction	aminophenoxy__EGFR__no_interaction	aminophenoxy__PKCalpha__no_interaction	aminophenoxy__Akt__no_interaction	aminophenoxy__PP1__no_interaction	aminophenoxy__VCAM-1__no_interaction	aminophenoxy__epidermal growth factor receptor__no_interaction	aminophenoxy__TNF-alpha__no_interaction	aminophenoxy__p300__no_interaction	carbazole__PKCmu__no_interaction	carbazole__HDAC4__no_interaction	carbazole__EGFR__no_interaction	carbazole__PKCalpha__no_interaction	carbazole__Akt__no_interaction	carbazole__PP1__no_interaction	carbazole__VCAM-1__no_interaction	carbazole__epidermal growth factor receptor__no_interaction	carbazole__TNF-alpha__no_interaction	carbazole__p300__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__PKCmu__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__HDAC4__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__EGFR__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__PKCalpha__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__Akt__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__PP1__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__VCAM-1__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__epidermal growth factor receptor__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__TNF-alpha__no_interaction	1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine__p300__no_interaction	butyl__PKCmu__no_interaction	butyl__HDAC4__no_interaction	butyl__EGFR__no_interaction	butyl__PKCalpha__no_interaction	butyl__Akt__no_interaction	butyl__PP1__no_interaction	butyl__VCAM-1__no_interaction	butyl__epidermal growth factor receptor__no_interaction	butyl__TNF-alpha__no_interaction	butyl__p300__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__PKCmu__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__HDAC4__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__EGFR__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__PKCalpha__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__Akt__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__PP1__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__VCAM-1__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__epidermal growth factor receptor__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__TNF-alpha__no_interaction	2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride__p300__no_interaction	cycloocta__PKCmu__no_interaction	cycloocta__HDAC4__no_interaction	cycloocta__EGFR__no_interaction	cycloocta__PKCalpha__no_interaction	cycloocta__Akt__no_interaction	cycloocta__PP1__no_interaction	cycloocta__VCAM-1__no_interaction	cycloocta__epidermal growth factor receptor__no_interaction	cycloocta__TNF-alpha__no_interaction	cycloocta__p300__no_interaction	AG1478__PKCmu__no_interaction	AG1478__HDAC4__no_interaction	AG1478__EGFR__no_interaction	AG1478__PKCalpha__no_interaction	AG1478__Akt__no_interaction	AG1478__PP1__no_interaction	AG1478__VCAM-1__no_interaction	AG1478__epidermal growth factor receptor__no_interaction	AG1478__TNF-alpha__no_interaction	AG1478__p300__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__PKCmu__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__HDAC4__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__EGFR__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__PKCalpha__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__Akt__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__PP1__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__VCAM-1__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__epidermal growth factor receptor__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__TNF-alpha__no_interaction	1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione__p300__no_interaction	propyl-1H-indol-3-yl__PKCmu__no_interaction	propyl-1H-indol-3-yl__HDAC4__no_interaction	propyl-1H-indol-3-yl__EGFR__no_interaction	propyl-1H-indol-3-yl__PKCalpha__no_interaction	propyl-1H-indol-3-yl__Akt__no_interaction	propyl-1H-indol-3-yl__PP1__no_interaction	propyl-1H-indol-3-yl__VCAM-1__no_interaction	propyl-1H-indol-3-yl__epidermal growth factor receptor__no_interaction	propyl-1H-indol-3-yl__TNF-alpha__no_interaction	propyl-1H-indol-3-yl__p300__no_interaction	phosphatidylinositol__PKCmu__no_interaction	phosphatidylinositol__HDAC4__no_interaction	phosphatidylinositol__EGFR__no_interaction	phosphatidylinositol__PKCalpha__no_interaction	phosphatidylinositol__Akt__no_interaction	phosphatidylinositol__PP1__no_interaction	phosphatidylinositol__VCAM-1__no_interaction	phosphatidylinositol__epidermal growth factor receptor__no_interaction	phosphatidylinositol__TNF-alpha__no_interaction	phosphatidylinositol__p300__no_interaction	calmidazolium chloride__PKCmu__no_interaction	calmidazolium chloride__HDAC4__no_interaction	calmidazolium chloride__EGFR__no_interaction	calmidazolium chloride__PKCalpha__no_interaction	calmidazolium chloride__Akt__no_interaction	calmidazolium chloride__PP1__no_interaction	calmidazolium chloride__VCAM-1__no_interaction	calmidazolium chloride__epidermal growth factor receptor__no_interaction	calmidazolium chloride__TNF-alpha__no_interaction	calmidazolium chloride__p300__no_interaction	Ro 31__PKCmu__no_interaction	Ro 31__HDAC4__no_interaction	Ro 31__EGFR__no_interaction	Ro 31__PKCalpha__no_interaction	Ro 31__Akt__no_interaction	Ro 31__PP1__no_interaction	Ro 31__VCAM-1__no_interaction	Ro 31__epidermal growth factor receptor__no_interaction	Ro 31__TNF-alpha__no_interaction	Ro 31__p300__no_interaction	11H__PKCmu__no_interaction	11H__HDAC4__no_interaction	11H__EGFR__no_interaction	11H__PKCalpha__no_interaction	11H__Akt__no_interaction	11H__PP1__no_interaction	11H__VCAM-1__no_interaction	11H__epidermal growth factor receptor__no_interaction	11H__TNF-alpha__no_interaction	11H__p300__no_interaction	calcium__PKCmu__no_interaction	calcium__HDAC4__no_interaction	calcium__EGFR__no_interaction	calcium__PKCalpha__no_interaction	calcium__Akt__no_interaction	calcium__PP1__no_interaction	calcium__VCAM-1__no_interaction	calcium__epidermal growth factor receptor__no_interaction	calcium__TNF-alpha__no_interaction	calcium__p300__no_interaction	ethane__PKCmu__no_interaction	ethane__HDAC4__no_interaction	ethane__EGFR__no_interaction	ethane__PKCalpha__no_interaction	ethane__Akt__no_interaction	ethane__PP1__no_interaction	ethane__VCAM-1__no_interaction	ethane__epidermal growth factor receptor__no_interaction	ethane__TNF-alpha__no_interaction	ethane__p300__no_interaction	epoxy__PKCmu__no_interaction	epoxy__HDAC4__no_interaction	epoxy__EGFR__no_interaction	epoxy__PKCalpha__no_interaction	epoxy__Akt__no_interaction	epoxy__PP1__no_interaction	epoxy__VCAM-1__no_interaction	epoxy__epidermal growth factor receptor__no_interaction	epoxy__TNF-alpha__no_interaction	epoxy__p300__no_interaction	rottlerin__PKCmu__no_interaction	rottlerin__HDAC4__no_interaction	rottlerin__EGFR__no_interaction	rottlerin__PKCalpha__no_interaction	rottlerin__Akt__no_interaction	rottlerin__PP1__no_interaction	rottlerin__VCAM-1__no_interaction	rottlerin__epidermal growth factor receptor__no_interaction	rottlerin__TNF-alpha__no_interaction	rottlerin__p300__no_interaction	chloroanilino__PKCmu__no_interaction	chloroanilino__HDAC4__no_interaction	chloroanilino__EGFR__no_interaction	chloroanilino__PKCalpha__no_interaction	chloroanilino__Akt__no_interaction	chloroanilino__PP1__no_interaction	chloroanilino__VCAM-1__no_interaction	chloroanilino__epidermal growth factor receptor__no_interaction	chloroanilino__TNF-alpha__no_interaction	chloroanilino__p300__no_interaction
15181043-5	<protein-id="O15123">Ang II</protein-id> caused an increase in <compound-id="702">ethanol</compound-id> outflow/inflow ratio, compared with baseline values both in adipose tissue (average of both groups, Ang 1.0 nM: 0.03 +/- 0.01, P = 0.02; Ang 1.0 microM: 0.05 +/- 0.01, P &lt; 0.01) and muscle (average of both groups, Ang 1.0 nM: 0.02 +/- 0.01, P = 0.09; Ang 1.0 microM: 0.04 +/- 0.01, P = 0.01), indicating a decrease in local blood flow.	ethanol__Ang II__no_interaction
22222007-2	METHODS: Urinary concentrations of nine <compound-id="1017">phthalate</compound-id> metabolites: monoethyl (<protein-id="P07711,Q9HBQ7,A0A024R276">MEP</protein-id>); mono-n-<compound-id="68006705">butyl</compound-id> (<protein-id="P02686,A0A024R384">MBP</protein-id>); mono-(3-carboxypropyl) (<compound-id="7153">MCPP</compound-id>); monobenzyl (MBzP); mono-isobutyl (<protein-id="Q9NPI5">MiBP</protein-id>); mono-(2-ethylhexyl) (<compound-id="20393">MEHP</compound-id>); mono-(2-<compound-id="23134249">ethyl</compound-id>-5-oxohexyl) (<compound-id="119096">MEOHP</compound-id>); mono-(2-<compound-id="23134249">ethyl</compound-id>-<compound-id="8892">5-carboxypentyl</compound-id>) (<compound-id="160264">MECPP</compound-id>); and mono-(2-<compound-id="23134249">ethyl</compound-id>-5-hydroxyhexyl) <compound-id="1017">phthalate</compound-id> (MEHHP) and the molar sum of the low molecular-weight <compound-id="1017">phthalate</compound-id> metabolites (low <compound-id="12285325">MWP</compound-id>: <protein-id="P07711,Q9HBQ7,A0A024R276">MEP</protein-id>, <protein-id="P02686,A0A024R384">MBP</protein-id> and <protein-id="Q9NPI5">MiBP</protein-id>) and high molecular-weight <compound-id="1017">phthalate</compound-id> metabolites (high <compound-id="12285325">MWP</compound-id>: <compound-id="160264">MECPP</compound-id>, MEHHP, <compound-id="119096">MEOHP</compound-id>, <compound-id="20393">MEHP</compound-id> and MBzP) and of four <compound-id="57359488">di-(2-ethylhexyl) phthalate</compound-id> (DEHP) metabolites (ΣDEHP: <compound-id="20393">MEHP</compound-id>, MEHHP, <compound-id="119096">MEOHP</compound-id>, <compound-id="160264">MECPP</compound-id>) and anthropometry, including body mass index and waist circumference were measured among 387 Hispanic and Black, New York City children who were between six and eight years at cohort enrollment (2004-2007).	MCPP__MiBP__no_interaction	MCPP__MBP__no_interaction	MCPP__MEP__no_interaction	MWP__MiBP__no_interaction	MWP__MBP__no_interaction	MWP__MEP__no_interaction	di-(2-ethylhexyl) phthalate__MiBP__no_interaction	di-(2-ethylhexyl) phthalate__MBP__no_interaction	di-(2-ethylhexyl) phthalate__MEP__no_interaction	MECPP__MiBP__no_interaction	MECPP__MBP__no_interaction	MECPP__MEP__no_interaction	MEOHP__MiBP__no_interaction	MEOHP__MBP__no_interaction	MEOHP__MEP__no_interaction	5-carboxypentyl__MiBP__no_interaction	5-carboxypentyl__MBP__no_interaction	5-carboxypentyl__MEP__no_interaction	butyl__MiBP__no_interaction	butyl__MBP__no_interaction	butyl__MEP__no_interaction	phthalate__MiBP__no_interaction	phthalate__MBP__no_interaction	phthalate__MEP__no_interaction	MEHP__MiBP__no_interaction	MEHP__MBP__no_interaction	MEHP__MEP__no_interaction	ethyl__MiBP__no_interaction	ethyl__MBP__no_interaction	ethyl__MEP__no_interaction
24356416-6	mGFR had a stronger linear relationship with inverse <protein-id="P01034">cystatin C</protein-id> before (r = 0.28, p = 0.09) and after (r = 0.38, p = 0.02) surgery compared to the inverse of <compound-id="588">creatinine</compound-id> (before: r = 0.26, p = 0.13; after: r = 0.11, p = 0.51).	creatinine__cystatin C__no_interaction
1501406-4	The level of [Ca2+]i in the PMNL of CRF rats (149 +/- 2.7 nM) was significantly (P less than 0.01) higher and the <compound-id="5957">ATP</compound-id> content (4.2 +/- 0.17 nmol/5 x 10(6) PMNL) significantly lower (P less than 0.01) than in normal (108 +/- 2.4 nM; 9.5 +/- 0.15 nmol/5 x 10(6) PMNL), CRF-PTX (103 +/- 2.9 nM; 9.2 +/- 0.19 nmol/5 x 10(6) PMNL), CRF-V (107 +/- 2.2 nM; 9.0 +/- 0.2 nmol/5 x 10(6) PMNL) and normal-V (106 +/- 1.8 nM; 9.2 +/- 0.2 nmol/5 x 10(6) PMNL), despite sustained elevation in blood <protein-id="P04089">PTH</protein-id> in the CRF-V group.	ATP__PTH__no_interaction
20016375-10	PUGNAc attenuated the trauma-hemorrhage-induced increase in serum <protein-id="P20607">interleukin-6</protein-id> (sham surgery: 8 +/- 6, control: 181 +/- 36, PUGNAc: 42 +/- 22 pg/mL, p &lt; .05), <compound-id="5950">alanine</compound-id> transaminase (sham surgery: 95 +/- 14, control: 297 +/- 56, PUGNAc: 126 +/- 21 IU, p &lt; .05), <compound-id="5960">aspartate</compound-id> transaminase (sham surgery: 536 +/- 110, control: 1661 +/- 215, PUGNAc: 897 +/- 155 IU, p &lt; .05), and <compound-id="612">lactate</compound-id> dehydrogenase (sham surgery: 160 +/- 18, control: 1499 +/- 311, PUGNAc: 357 +/- 99 IU, p &lt; .05); however, <compound-id="121837,18897,439213,441477,445621,45933887">glucosamine</compound-id> had no effect on these serum parameters.	alanine__interleukin-6__no_interaction	aspartate__interleukin-6__no_interaction	glucosamine__interleukin-6__no_interaction	lactate__interleukin-6__no_interaction
19342030-9	Compared with nonresponders, responders were more obese (BMI: 37.0 +/- 1.6 vs. 31.7 +/- 1.8 kg/m(2)); had higher <protein-id="P41159,A4D0Y8">leptin</protein-id> (28.9 +/- 1.7 vs. 24.1 +/- 1.1 ng/mL), and lower <protein-id="Q06520,A8K015">DHEAS</protein-id> (133 +/- 12 vs. 236 +/- 32 ng/mL), higher <compound-id="206,5793,64689,79025">glucose</compound-id> at 1 h of OGTT (195 +/- 13 vs. 131 +/- 12 mg/dL), higher area under the curve (AUC)(<compound-id="206,5793,64689,79025">Glucose</compound-id>) (332 +/- 20 vs. 265 +/- 17 mg/dL), higher AUC(<protein-id="P01308,I3WAC9">insulin</protein-id>) (244 +/- 50 vs. 125 +/- 30 <compound-id="15947593">muU</compound-id>/mL), and lower nadir <compound-id="206,5793,64689,79025">glucose</compound-id> (61 +/- 2 vs. 70 +/- 2 mg/dL).	muU__DHEAS__no_interaction	muU__leptin__no_interaction	muU__insulin__no_interaction	Glucose__DHEAS__no_interaction	Glucose__leptin__no_interaction	Glucose__insulin__no_interaction	glucose__DHEAS__no_interaction	glucose__leptin__no_interaction	glucose__insulin__no_interaction
22340787-10	The expressions of cyclin E mRNA in LC, MC, and HC groups decreased along with an increase in <compound-id="896">melatonin</compound-id> concentration, which were lower than that in C group (1.58 ± 0.21, 0.90 ± 0.20, and 0.24 ± 0.12 vs. 2.90 ± 0.30, F = 266.79, P &lt; 0.05), while the expressions of <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> mRNA and Fas mRNA showed opposite tendency (with F value respectively 10.11, 12.03, P values all below 0.05).	melatonin__p53__no_interaction
16451866-9	However, mEP and mBP showed positive correlations with <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> (r = 0.323, p = 0.002 and r = 0.272, p = 0.01, respectively); mMP, mEP, and mBP with LH:free <compound-id="6013">testosterone</compound-id> ratio (r = 0.21-0.323, p = 0.002-0.044) and miNP with luteinizing hormone (r = 0.243, p = 0.019).	testosterone__SHBG__no_interaction
9535544-9	The levels of <protein-id="P16599">TNF-alpha</protein-id>, <compound-id="23994">CINC</compound-id>/GRO and NO increased remarkably in both blood and ascites at 8-48 h after the surgical trauma (p &lt; 0.01): <protein-id="P16599">TNF-alpha</protein-id> increased from 194 +/- 9 (the mean +/- SD, n = 4) and 183 +/- 12 pg/ml (preoperation) to 797 +/- 28 and 1045 +/- 137 pg/ml at 24 h in blood and ascites, respectively; <compound-id="23994">CINC</compound-id>/GRO increased from 0.1 +/- 0 and 0.1 +/- 0 ng/ml (pre-operation) to 66.4 +/- 4.5 and 60.3 +/- 17.9 ng/ml at 8 h in blood and ascites, respectively; NO increased from 2.4 +/- 1.0 and 4.2 +/- 1.1 microM (pre-operation) to 11.9 +/- 0.7 and 36.9 +/- 2.1 microM in blood and ascites at 24 h and 48 h in blood and ascites, respectively.	CINC__TNF-alpha__no_interaction
10953048-3	Binding experiments, with (125)I-[MePhe(7)]-<protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> binding to HEK 293 cell membranes transiently expressing the <protein-id="P29371">hNK-3R</protein-id> (HEK 293-<protein-id="P29371">hNK-3R</protein-id>) or NK-4R (HEK 293-NK-4R), and functional studies (Ca(2+) mobilization in the same cells) revealed a similar profile of sensitivity to tachykinin agonists and antagonists for both receptors; i.e., in binding studies with the <protein-id="P29371">hNK-3R</protein-id>, MePhe(7)-<protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> &gt; <protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> &gt; <compound-id="108147,5079497">senktide</compound-id> &gt;&gt; <protein-id="P20366,Q9Y494">NKA</protein-id> = <protein-id="P20366,Q9Y494">Substance P</protein-id>; with the NK-4R, MePhe(7)-<protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> &gt; <protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id> = <compound-id="108147,5079497">senktide</compound-id> &gt;&gt; <protein-id="P20366,Q9Y494">Substance P</protein-id> = <protein-id="P20366,Q9Y494">NKA</protein-id>; and with antagonists, <compound-id="133090,5311424">SB 223412</compound-id> = <compound-id="219077">SR 142801</compound-id> &gt; <compound-id="6604009">SB 222200</compound-id> &gt;&gt; SR 48968 &gt;&gt; <compound-id="105083">CP 99994</compound-id> for both <protein-id="P29371">hNK-3R</protein-id> and NK-4R.	SB 222200__NKA__no_interaction	SB 222200__NKB__no_interaction	SB 222200__Substance P__no_interaction	SB 222200__hNK-3R__no_interaction	senktide__NKA__no_interaction	senktide__NKB__no_interaction	senktide__Substance P__no_interaction	senktide__hNK-3R__no_interaction	SB 223412__NKA__no_interaction	SB 223412__NKB__no_interaction	SB 223412__Substance P__no_interaction	SB 223412__hNK-3R__no_interaction	CP 99994__NKA__no_interaction	CP 99994__NKB__no_interaction	CP 99994__Substance P__no_interaction	CP 99994__hNK-3R__no_interaction	SR 142801__NKA__no_interaction	SR 142801__NKB__no_interaction	SR 142801__Substance P__no_interaction	SR 142801__hNK-3R__no_interaction
15044401-5	In the cases with PCO compared to (i) the controls and (ii) the cases without PCO, body mass index (P = 0.026 and P = 0.011), ovarian volume [right P = 0.001, left P = 0.208 (non-significant) and right P &lt; 0.001, left P = 0.022], mean follicle number (P &lt; 0.001 and P &lt; 0.001), <compound-id="6013">testosterone</compound-id> (P = 0.063 and P = 0.029), free androgen index (P = 0.007 and P = 0.013) and <protein-id="P01308,I3WAC9">insulin</protein-id> (P = 0.033 and P = 0.040) were higher, and sex hormone-binding globulin (P = 0.039 and P = 0.068) and <compound-id="206,5793,64689,79025">glucose</compound-id>:<protein-id="P01308,I3WAC9">insulin</protein-id> ratio (P = 0.060 and P = 0.054) lower.	testosterone__insulin__no_interaction	glucose__insulin__no_interaction
16608943-9	Furthermore, <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id> correlated with AHI (r = 0.32, p &lt; 0.001), respiratory arousal index (r = 0.27, p = 0.002), and nadir of <compound-id="977">oxygen</compound-id> saturation as measured by pulse oximetry (r = - 0.19, p = 0.038).	oxygen__P-selectin__no_interaction
8765819-14	In mite-sensitive patients both Der p 1 and <protein-id="Q9H3K2">Der p 2</protein-id> in beds significantly correlated with BHR (PD20: r = -0.49, <compound-id="24755475">DRR</compound-id>, r = 0.49; PD20: r = -0.46, <compound-id="24755475">DRR</compound-id>: r = 0.43) and amplitude percent mean PEFR (r = 0.38, r = 0.41) for Der p 1 and <protein-id="Q9H3K2">Der p 2</protein-id>, respectively.	DRR__Der p 2__no_interaction
23593534-5	RESULTS: Data showed that: (1) high TF mass was inversely correlated with low BMD both at lumbar (P &lt; 0.001) and <protein-id="Q06141,Q53S56">hip</protein-id> (P &lt; 0.01) sites and with serum <compound-id="5280795,5283711">vitamin D</compound-id> (P &lt; 0.0005), OSCA (P &lt; 0.0001) and <protein-id="P05019,Q5U743,Q13429,Q59GC5">insulin-like growth factor-1</protein-id> (<protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id>; P &lt; 0.0001) levels; (2) a positive correlation was found between TF and HOMA-IR (P &lt; 0.01), fibrinogen (P &lt; 0.0001) and erythrocyte sedimentation rate (P &lt; 0.0001); (3) <compound-id="5280795,5283711">vitamin D</compound-id> levels were directly correlated with <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id> (P &lt; 0.0005), lumbar (P &lt; 0.006) and <protein-id="Q06141,Q53S56">hip</protein-id> (P &lt; 0.01) BMD; and (4) inversely with HOMA-IR (P &lt; 0.001) and fibrinogen (P &lt; 0.0005).Multivariate analysis demonstrated that only <compound-id="5280795,5283711">vitamin D</compound-id> was independent of TF variable.	vitamin D__hip__no_interaction	vitamin D__insulin-like growth factor-1__no_interaction	vitamin D__IGF-1__no_interaction
24947443-6	RESULTS: At 24 weeks, greater improvements in adjusted mean change from baseline HbA1c (difference vs placebo [95% CI], -0.33% [-0.50%, -0.17%], [-4 (-5.5, -1.9) mmol/mol], P&lt;0.0001), FPG (-0.41 [-0.78, -0.03] mmol/L, P=0.03), PPG AUC0-180 (-168 [-245, -91.8] mmol min/L, P&lt;0.0001), <protein-id="P01308,I3WAC9">C-peptide</protein-id> AUC0-180 (19.7 [5.2, 34.2] nmol min/L, P=0.008), insulinogenic index (0.06% [0.02%, 0.09%], P=0.002), and greater suppression of <protein-id="P01275">glucagon</protein-id> secretion (<protein-id="P01275">glucagon</protein-id> AUC0-180, -322 [-493.6, -150.7] pmol min/L, P=0.0003) were observed with <compound-id="11235729,11243969,44144606,44590597,66576989,71752157,78577434">saxagliptin</compound-id> versus placebo.	saxagliptin__glucagon__no_interaction	saxagliptin__C-peptide__no_interaction
20339360-11	LOOH levels were negatively related to <protein-id="P78363,Q6AI28">FFM</protein-id>% (R = -0.413, P &lt; 0.05) and positively to FM%, <protein-id="P40933">IL-15</protein-id>, TNF-α, <protein-id="P01308,I3WAC9">insulin</protein-id>, total <compound-id="5997">cholesterol</compound-id>, low-density lipoprotein <compound-id="5997">cholesterol</compound-id>, and triglycerides (R = 0.408, R = 0.502, R = 0.341, R = 0.412, R = 0.4036, R = 0.405, R = 0.405, respectively, P &lt; 0.05).	cholesterol__FFM__no_interaction	cholesterol__IL-15__no_interaction	cholesterol__insulin__no_interaction
17403286-3	RESULTS: There were significant differences in the following parameters (malignant tumor of the body and tail vs those of the head) between the two tumors: (1) the complaints of pain (0.74:41, chi(2) = 37.035, P &lt; 0.01) and jaundice (0.04:0.75, chi(2) = 155.509, P &lt; 0.01); (2) serum SGPT [(27.33 +/- 3.98) U/L: (118.60 +/- 4.59) U/L, F = 89.351, P &lt; 0.01], total <compound-id="5280352">bilirubin</compound-id> [(1.46 +/- 0.46) mg/dl: (14.11 +/- 0.60) mg/dl, F = 105.341, P &lt; 0.01] and <protein-id="P02768">albumin</protein-id> [(4.20 +/- 0.45) g/L: (3.91 +/- 0.03) g/L, F = 26.642, P &lt; 0.001]; (3) CEA (0.40:0.24, chi(2) = 6.148, P = 0.046) and CA-19-9 positive rate (0.57:0.86, chi(2) = 24.132, P &lt; 0.01); (4) the concomitant total metastasis (0.38:0.20, chi(2) = 14.266, P &lt; 0.01), including liver metastasis (0.30:0.17, chi(2) = 9.003, P &lt; 0.01).	bilirubin__albumin__no_interaction
10487493-6	PLTP activity correlated significantly (P&lt;0.001) with body mass index (r = 0.22), serum total <compound-id="5997">cholesterol</compound-id> (r = 0.17), the ratio of HDL-<compound-id="5997">cholesterol</compound-id>/total <compound-id="5997">cholesterol</compound-id> (r = -0.20), triglycerides (r = 0.20), apo <protein-id="Q96P20">A-II</protein-id> (r = 0.20), and gamma <compound-id="129297">glutamyl</compound-id> transferase (r = 0.22) values.	glutamyl__A-II__no_interaction	cholesterol__A-II__no_interaction
22427875-3	METHODOLOGY/PRINCIPAL FINDINGS: In 595 GAD-negative, drug naïve patients (mean ± SD; age: 58.5 ± 10.2 yrs; BMI: 29.9 ± 5 kg/m(2), HbA1c: 7.0±1.3) with newly diagnosed type 2 diabetes we: 1. genotyped 10 tag SNPs in <protein-id="Q15878,Q59FG1,F8W9Z1">CACNA1E</protein-id> region reportedly covering ∼93% of <protein-id="Q15878,Q59FG1,F8W9Z1">CACNA1E</protein-id> common variability: rs558994, rs679931, rs2184945, rs10797728, rs3905011, rs12071300, rs175338, rs3753737, rs2253388 and rs4652679; 2. assessed clinical phenotypes, <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity by the euglycemic <protein-id="P01308,I3WAC9">insulin</protein-id> clamp and beta cell function by state-of-art modelling of <compound-id="206,5793,64689,79025">glucose</compound-id>/C-peptide curves during OGTT.	glucose__CACNA1E__no_interaction	glucose__insulin__no_interaction
8289207-3	They show high nanomolar affinity for <protein-id="P08908,Q5ZGX3,A8K5W4">5-HT1A</protein-id>, moderate affinity for D-2, and low affinity for 5-HT2 receptors, and in particular, two compounds, 4-[3-(1,2-dihydro-6-methoxynaphthalen-4-yl)-n-propyl]-1-(2- methoxyphenyl)<compound-id="4837">piperazine</compound-id> (8) and 4-[3-(1,2-dihydro-8-methoxynaphthalen-4-yl)-n-propyl]-1-(2- pyridyl)<compound-id="4837">piperazine</compound-id> (15), show values (nM) of IC50 = 2.0 and 1.4 for <protein-id="P08908,Q5ZGX3,A8K5W4">5-HT1A</protein-id> and IC50 = 90.6 and 119.3 for D-2, respectively.	piperazine__5-HT1A__no_interaction
11678583-10	Multivariate analysis revealed correlation between menopause and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> (r = -0.3904, p &lt; 0.05), D5 (r = -0.500, p &lt; 0.001), TC (r = 0.3137, p &lt;0.05), <compound-id="5281">stearic acid</compound-id> (r = 03564, p &lt; 0.05) and <compound-id="445639">oleic acid</compound-id> (r = 0.2954, p &lt; 0.05).	oleic acid__SHBG__no_interaction	stearic acid__SHBG__no_interaction
15375168-3	The following data obtained in control denuded oocytes are consistent with this view: (i) reverse transcription-PCR revealed that the oocyte expresses two transcripts for the <protein-id="Q28662">NCX1</protein-id> and NCX3 isoforms; (ii) immunofluorescence experiments showed that native <protein-id="Q28662">NCX1</protein-id> and InsP3Rs are largely codistributed in discrete areas of the plasma membrane in close apposition to the cortical endoplasmic reticulum shell; (iii) when stimulated by rabbit serum, which elevates intracellular Ca2+ mediated by InsP3, voltage-clamped oocytes display a large and transient inward Ca2+ -activated <compound-id="312">chloride</compound-id> current, IClCa, as a result of the Ca2+ rise at the inner surface membrane; (iv) this current is significantly enhanced by <compound-id="4534086">KB-R7943</compound-id> and by an extracellular <compound-id="5360545">sodium</compound-id>-depleted medium, two maneuvers that prevent "Ca2+ extrusion" via NCX; and (v) blocking NCX enhanced the IClCa elicited by InsP3 but not by Ca2+ photolysis in oocytes injected with the respective caged compounds.	KB-R7943__NCX1__no_interaction	chloride__NCX1__no_interaction	sodium__NCX1__no_interaction
17702855-8	RESULTS: Serum concentrations of <protein-id="Q8NBP7">PCSK9</protein-id> ranged from 11 to 115 microg/L and were directly correlated with serum concentrations of LDLC (r = 0.45, P = 0.001) and total <compound-id="5997">cholesterol</compound-id> (r = 0.50, P = 0.0003), but not with triglycerides (r = 0.15, P = 0.28) or <protein-id="P28845,X5D2L1">HDL</protein-id> <compound-id="5997">cholesterol</compound-id> concentrations (r = 0.13, P = 0.36).	cholesterol__PCSK9__no_interaction	cholesterol__HDL__no_interaction
10733873-5	336 nm due to <compound-id="104858">GSNO</compound-id>) was established as rate = -d[<compound-id="104858">GSNO</compound-id>](t)/dt = ((k(a)[H(+)](2) + k(b)[H(+)]K(1) + k(c)K(1)K(2))/([H(+)](2) + K(1)[H(+)] + K(1)K(2)))[<compound-id="104858">GSNO</compound-id>](t)[<protein-id="Q16777">H(2)A</protein-id>](t).	GSNO__H(2)A__no_interaction
15962926-10	Accordingly, the following mechanism is proposed (constants for 5 degrees C): HOCl = H+ + OCl-, pK1 = 7.47; <compound-id="595">cystine</compound-id>(0) = <compound-id="595">cystine</compound-id>(1-) + H+, <protein-id="Q9HC23">pK2</protein-id> = 8.15; <compound-id="595">cystine</compound-id>(1-) = <compound-id="595">cystine</compound-id>(2-) + H+, <protein-id="P14618,B4DNK4,A0A024R5Z9,V9HWB8">pK3</protein-id> = 9.00; <compound-id="595">cystine</compound-id>(1-) + HOCl --&gt; NCC(1-) + H2O, k4 = 4.3(2) x 10(6) M(-1) s(-1); <compound-id="595">cystine</compound-id>(2-) + HOCl --&gt; NCC(2)(-) + H2O, k5 = 1.6(2) x 10(7) M(-1) s(-1); NCC(1-) --&gt; NCC(2-) + H+, k6 = fast; NCC(2-) + HOCl --&gt; NDC(2-) + H2O, k7 = fast.	cystine__pK2__no_interaction	cystine__pK3__no_interaction
9263209-4	Dual in situ hybridization using <compound-id="15478">digoxigenin</compound-id>-labeled <protein-id="P07490">GnRH</protein-id> cRNA probes and 35S-labeled <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptor subunit probes, followed by autoradiography and image analysis were used to measure the KA2 or <protein-id="Q00959">NMDAR2A</protein-id> mRNA content in <protein-id="P07490">GnRH</protein-id> neurons in 20- to 50-day-old female rats which were sacrificed at 08.00 or 17.00 h. The results show that: (a) the KA2 mRNA content of <protein-id="P07490">GnRH</protein-id> neurons and the number of <protein-id="P07490">GnRH</protein-id> neurons expressing KA2 mRNA increase progressively in the morning hours between postnatal days 20 and 40; (b) the diurnal pattern of KA2 mRNA levels in <protein-id="P07490">GnRH</protein-id> neurons changes between days 40 and 50 from high KA2 levels in the morning hours before day 40 to high KA2 mRNA levels in the afternoon in 45- and 50-day-old animals; (c) while the high levels of KA2 mRNA in <protein-id="P07490">GnRH</protein-id> neurons in the morning hours of 20- to 40-day-old animals are paralleled by an overall increase in KA2 expression in the preoptic area, the rise in KA2 mRNA in <protein-id="P07490">GnRH</protein-id> neurons in the afternoon of 45- and 50-day-old animals appears to be specific for the <protein-id="P07490">GnRH</protein-id> neurons, and (d) no significant differences were detected for the <protein-id="Q00959">NMDAR2A</protein-id> mRNA content in <protein-id="P07490">GnRH</protein-id> neurons among the different age groups and the morning and afternoon values.	glutamate__NMDAR2A__no_interaction	glutamate__GnRH__no_interaction	digoxigenin__NMDAR2A__no_interaction	digoxigenin__GnRH__no_interaction
16423623-4	In LIPO, <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> correlated with clamp FFA (r = 0.67, P &lt; .01), clamp <compound-id="39042">LIPOX</compound-id> (r = 0.47, P &lt; .05), incremental FFA (r = 0.69, P &lt; .01), and incremental <compound-id="39042">LIPOX</compound-id> (r = 0.64, P &lt; .01), all of which, but not the clamp <compound-id="39042">LIPOX</compound-id> correlation (r = 0.29, P &gt; .05), remained significant after correction for <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity.	LIPOX__TNF-alpha__no_interaction	LIPOX__insulin__no_interaction
21687848-1	More usually thought of as a base, the <compound-id="5360545">sodium</compound-id> <compound-id="24424">zincate</compound-id> [(<compound-id="8037">TMEDA</compound-id>)·Na(μ-<protein-id="P54849,A0A024RAT0">TMP</protein-id>)(μ-(t)Bu)Zn((t)Bu)] 1 can undergo single electron transfer with TEMPO to give [(<compound-id="8037">TMEDA</compound-id>)·Na(μ-<protein-id="P54849,A0A024RAT0">TMP</protein-id>)(μ-TEMPO(-))Zn((t)Bu)] 2 and [(<compound-id="8037">TMEDA</compound-id>)·Na(μ-TEMPO(-))(2)Zn((t)Bu)] 3; and with <compound-id="637760">chalcone</compound-id> [PhCOCH=<compound-id="126085">CHPh</compound-id>] gives [{(<compound-id="8037">TMEDA</compound-id>)·Na(μ-<protein-id="P54849,A0A024RAT0">TMP</protein-id>)Zn((t)Bu)}(2)(μ-OCPhCH=CHPhCHPhCH=CPh-μ-O)] which contains two <compound-id="637760">chalcone</compound-id> units C-C coupled though their benzylic C atoms.	zincate__TMP__no_interaction	chalcone__TMP__no_interaction	CHPh__TMP__no_interaction	TMEDA__TMP__no_interaction	sodium__TMP__no_interaction
22804462-11	In the case of the more electron-rich ligand [(i)PrNP(i)Pr(2)](-), complexes with a 2:1 mixed donor ligand arrangement, in which one of the ligand arms has reversed orientation relative to the previous examples, are formed exclusively when [(i)PrNLiP(i)Pr(2)] (generated in situ) is treated with <protein-id="Q8WXI8">MCl</protein-id>(2) (M = Mn, Fe): (<compound-id="8028">THF</compound-id>)(3)<compound-id="433294">LiCl</compound-id>[Mn(N(i)PrP(i)Pr(2))(2)(P(i)Pr(2)N(i)Pr)MnCl] (8) and [Fe(N(i)PrP(i)Pr(2))(2)(P(i)Pr(2)N(i)Pr)FeCl] (9).	THF__MCl__no_interaction	LiCl__MCl__no_interaction
9024272-6	Serum free testosterone was correlated with total body and trochanter <protein-id="P11532,Q4G0X0,A7E212,A1L0U9,Q16484">BMD</protein-id> (r = 0.635; P = 0.048 and r = 0.629; P = 0.05), and serum free <compound-id="5757">estradiol</compound-id> was correlated with total body and trochanter <protein-id="P11532,Q4G0X0,A7E212,A1L0U9,Q16484">BMD</protein-id> (r = 0.641; P = 0.045 and r = 0.634; P = 0.048).	estradiol__BMD__no_interaction
20235627-4	Linear regression analysis showed that log(<protein-id="P01562,L0N195">IFN-alpha</protein-id> production) was positively correlated with log(triglyceride) (r = 0.088, P = 0.03) and <compound-id="1175">uric acid</compound-id> (r = 0.091, P = 0.03), and negatively correlated with age (r = -0.158, P = 0.0001) and FPG (r = -0.088, P = 0.03).	uric acid__IFN-alpha__no_interaction
10024085-4	In patients with eating disorder, logarithmic values for <protein-id="P41159,A4D0Y8">Leptin</protein-id> were significantly correlated with the body fat mass (r = .828, P &lt; .001), eating behavior score (r = .777, P &lt; .001), and LH (r = .465, P &lt; .001), FSH (r = .440, P &lt; .001), T3 (r = .572, P &lt; .001), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = .410, P &lt; .001), and <compound-id="5754">cortisol</compound-id> (r = -.389, P &lt; .001) levels.	cortisol__Leptin__no_interaction	cortisol__insulin__no_interaction
16612106-7	Circulating <compound-id="44576256">ghrelin</compound-id> levels significantly correlated with age (r = -0.26, p = 0.01), fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.21, p = 0.01), free <compound-id="5920">triiodothyronine</compound-id> (r = -0.18, p = 0.04), free <compound-id="5819,853">thyroxine</compound-id> (r = -0.23, p = 0.02) and thyroid stimulating hormone (r = 0.21, p = 0.04), but not with blood pressure, body mass index, lipid parameters, <protein-id="P01308,I3WAC9">insulin</protein-id> and homeostasis model assessment (p &gt; 0.05).	triiodothyronine__insulin__no_interaction	thyroxine__insulin__no_interaction	ghrelin__insulin__no_interaction	glucose__insulin__no_interaction
2360520-4	Compared with the control group, patients with SLE had significantly prolonged isovolumic relaxation time (62 +/- 12 vs 80 +/- 14 msec; p less than 0.01), reduced peak early diastolic flow velocity (<compound-id="3905118">peak E</compound-id>) (82 +/- 18 vs 76 +/- 16 cm/sec; p less than 0.05), increased peak late diastolic flow velocity (peak A) (45 +/- 7 vs 53 +/- 8 cm/sec; p less than 0.01), reduced E/A ratio (1.81 +/- 0.32 vs 1.46 +/- 0.29; p less than 0.001), and lower deceleration rate of early diastolic flow velocity (EF slope) (489 +/- 151 vs 361 +/- 185 cm/<protein-id="Q10981,A8K2L2">sec2</protein-id>; p less than 0.05).	peak E__sec2__no_interaction
22918042-4	In C57BL/6J mice on a high-fat diet the synthetic <protein-id="Q60641,Q3V1T8,D3YTT2">FXR</protein-id> agonists isopropyl <compound-id="66768645">3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate</compound-id> (<protein-id="Q60641,Q3V1T8,D3YTT2">FXR</protein-id>-450) and 4-[2-[<compound-id="1800613">2-chloro</compound-id>-4-[[5-cyclopropyl-3-(2,6-<compound-id="57417436">dichlorophenyl</compound-id>)-4-isoxazolyl]methoxy]phenyl]cyclopropyl]<compound-id="243">benzoic acid</compound-id> (PX20606) demonstrated potent plasma <compound-id="5997">cholesterol</compound-id>-lowering activity that affected all lipoprotein species, whereas 3-[2-[<compound-id="1800613">2-chloro</compound-id>-4-[[3-(2,6-<compound-id="57417436">dichlorophenyl</compound-id>)-5-(1-<compound-id="275736">methylethyl</compound-id>)-4-isoxazolyl]methoxy]phenyl]<compound-id="123166">ethenyl</compound-id>]<compound-id="243">benzoic acid</compound-id> (<compound-id="9893571">GW4064</compound-id>) and 6-<compound-id="23134249">ethyl</compound-id> <compound-id="10133">chenodeoxycholic acid</compound-id> (6-ECDCA) showed only limited effects.	chenodeoxycholic acid__FXR__no_interaction	dichlorophenyl__FXR__no_interaction	3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate__FXR__no_interaction	benzoic acid__FXR__no_interaction	ethenyl__FXR__no_interaction	methylethyl__FXR__no_interaction	cholesterol__FXR__no_interaction	2-chloro__FXR__no_interaction	GW4064__FXR__no_interaction	ethyl__FXR__no_interaction
23165627-1	Reaction of the <compound-id="5462222">potassium</compound-id> salt of N-thiophosphorylated <compound-id="2723790">thiourea</compound-id> 2-PyNHC(S)NHP(S)(OiPr)(2) (HL) with <protein-id="Q13371">PdCl</protein-id>(2) in aqueous <compound-id="887">MeOH</compound-id> leads to the formation of two mononuclear homoleptic complexes [Pd{2-PyNHC(S)NP(S)(OiPr)(2)-1,5-S,S'}(2)] ([Pd(L-1,5-S,S')(2)]) and [Pd{2-PyNHC(S)NP(S)(OiPr)(2)-1,5,7-N,N',S}(2)] ([Pd(L-1,5,7-N,N',S)(2)]), while the mechanically induced solid-state reaction of KL and <protein-id="Q13371">PdCl</protein-id>(2) leads to the exclusive formation of [Pd(L-1,5,7-N,N',S)(2)].	potassium__PdCl__no_interaction	MeOH__PdCl__no_interaction	thiourea__PdCl__no_interaction
16298496-8	The specific pathogenic pathways of MetSyn development include: (1) increased tissue and plasma levels of proinflammatory cytokines Interleukin-1(<protein-id="P01583">IL-1</protein-id>), Interleukin-6 (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> ) and <protein-id="P01375,Q5STB3">tumor necrosis factor - alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) caused by inflammatory and/or emotional distress; (2) increased plasma levels of <protein-id="P23560,A0A0E3SU01">neurotrophin</protein-id> - nerve growth factor (NGF) caused by the high <protein-id="P01583">IL-1</protein-id>, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> and <protein-id="P01375,Q5STB3">TNFalpha</protein-id> levels; (3) high plasma levels of NGF which enhance activation of: the autonomous nerve system--vegetodystonia (disbalance of neurotransmitters); <protein-id="P01303,A4D158">Neuropeptide Y</protein-id> (<protein-id="P01303,A4D158">NPY</protein-id>)--enhanced feeding, obesity and increased <compound-id="90470904">leptin</compound-id> plasma levels; hypothalamo-pituitary-adrenal axis--increased <protein-id="P06850">corticotropin-releasing hormone</protein-id> (<protein-id="P06850">CRH</protein-id>) and <compound-id="5754">cortisol</compound-id> (hormonal disbalance); immune cells--increased number and degranulation of mastocytes (MC)--immunological disbalance; (4) as a result of 1-3 insulin resistance is exhibited leading to diabetes mellitus.	leptin__TNFalpha__no_interaction	leptin__Neuropeptide Y__no_interaction	leptin__IL-6__no_interaction	leptin__IL-1__no_interaction	leptin__neurotrophin__no_interaction	leptin__tumor necrosis factor - alpha__no_interaction	leptin__NPY__no_interaction	leptin__TNF-alpha__no_interaction	leptin__corticotropin-releasing hormone__no_interaction	leptin__CRH__no_interaction	cortisol__TNFalpha__no_interaction	cortisol__Neuropeptide Y__no_interaction	cortisol__IL-6__no_interaction	cortisol__IL-1__no_interaction	cortisol__neurotrophin__no_interaction	cortisol__tumor necrosis factor - alpha__no_interaction	cortisol__NPY__no_interaction	cortisol__TNF-alpha__no_interaction	cortisol__corticotropin-releasing hormone__no_interaction	cortisol__CRH__no_interaction
23613693-4	RESULTS: Plasma CNP and <compound-id="586">creatine</compound-id> kinase myoglobin band (CK-MB) concentrations were significantly increased in the SPT (+) group relative to the SPT (-) group (CNP, 5.268±1.800 pg/mL vs. 3.342±1.150 pg/mL, p=0.002; CK-MB, 2.54±1.03 ng/dL vs. 1.86±0.96 ng/dL, p=0.019, respectively) while plasma high sensitivity C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT pro-<protein-id="P16860">BNP</protein-id>) concentrations were not significantly different between the SPT (-) group and SPT (+) group (hs-CRP, 2.76±4.99 mg/L vs. 3.13±4.88 mg/L, p=0.789; NT pro-<protein-id="P16860">BNP</protein-id>, 49±47 pg/mL vs. 57±63 pg/mL, p=0.818, respectively).	creatine__BNP__no_interaction
12582218-5	RESULTS: Pearson's correlation coefficients indicated a significant association between NC and body mass index (men, r = 0.71; women, r = 0.81; each, p &lt; 0.0001), waist circumference (men, r = 0.75; women, r = 0.79; each, p &lt; 0.0001), waist-to-<protein-id="Q06141,Q53S56">hip</protein-id> ratio (men, r = 0.56; women, r = 0.63; each, p &lt; 0.0001), total <compound-id="5997">cholesterol</compound-id> (men, r = 0.50; women, r = 0.66; each, p &lt; 0.0001), low-density lipoprotein-<compound-id="5997">cholesterol</compound-id> (men, r = 0.42; women, r = 0.60; each, p &lt; 0.0001), triglycerides (men, r = 0.48; women, r = 0.49; each, p &lt; 0.0001), <compound-id="206,5793,64689,79025">glucose</compound-id> (men, r = 0.21, p &lt; 0.001; women, r = 0.44; p &lt; 0.0001), <compound-id="1175">uric acid</compound-id> (men, r = 0.50, p &lt; 0.0001; women, r = 0.60, p &lt; 0.001), and systolic (men, r = 0.53; women, r = 0.69; each, p &lt; 0.0001), and diastolic (men, r = 0.55; women, r = 0.65; each, p &lt; 0.0001) blood pressure.	glucose__hip__no_interaction	uric acid__hip__no_interaction	cholesterol__hip__no_interaction
16954476-8	Stabilization of cyclin D1 protein by <compound-id="387447">bortezomib</compound-id> treatment further amplified the cyclin D1-dependent repression of <protein-id="P40763">STAT3</protein-id> in vitro and slowed tumor growth in vivo (week 7: untreated mean = 185.7 mm3 versus treated mean = 136.2 mm3, difference = 49.5 mm3, 95% confidence interval [CI] = 18 to 81 mm3, P = .007; week 8: untreated mean = 240.2 mm3 versus treated mean = 157.3 mm3, difference = 82.9 mm3, 95% CI = 9.1 to 156.7 mm3, P = .0014; and week 9: untreated mean = 256.4 mm3 versus treated mean = 170.2 mm3, difference = 86.2 mm3, 95% CI = 22.8 to 149.6 mm3, P = .006) and increased apoptosis (untreated mean = 19% versus treated mean = 54%, difference = 35%, 95% CI = 24.7% to 45.4%; P = .013) of xenograft tumors.	bortezomib__STAT3__no_interaction
19426539-7	<compound-id="107873">8-isoprostane</compound-id> correlated with 10 year cardiac risk (r = 0.55, p &lt; 0.001), VCAM with <compound-id="447041">IMT</compound-id> (r = 0.37, p = 0.012) and <protein-id="P16581">E-selectin</protein-id> with rheumatoid factor titre (r = 0.43, p = 0.003) in RA patients.	IMT__E-selectin__no_interaction	8-isoprostane__E-selectin__no_interaction
11882914-6	The <protein-id="P14600">NK1 receptor</protein-id> antagonist <compound-id="108167">SR 140333</compound-id> (10(-7) M), the <protein-id="P16610">NK2 receptor</protein-id> antagonist <compound-id="104974">SR 48968</compound-id> (10(-6) M), the <protein-id="P16177">NK3 receptor</protein-id> antagonist <compound-id="219077">SR 142801</compound-id> (10(-7) M), <compound-id="174174">atropine</compound-id> (10(-6) M), <compound-id="3604">hexamethonium</compound-id> (10(-4) M), <compound-id="5775">phentolamine</compound-id> (10(-6) M) plus propranolol (10(-6) M), N(G)-nitro- <compound-id="550788">L-arginine methyl ester</compound-id> ( <compound-id="39836">L-NAME</compound-id> 3 x 10(-4) M), <compound-id="16129677,16218850,56928162,57043712">apamin</compound-id> (10(-7) M), <compound-id="9681">methysergide</compound-id> (10(-6) M), the <protein-id="P01256,P01257,A0A0G2JSX2">calcitonin gene-related peptide</protein-id> (<protein-id="P01256,P01257,A0A0G2JSX2">CGRP</protein-id>) antagonist hCGRP 8-37 (1.5 x 10(-6) M), the <protein-id="P01283,A0A090BZQ0,B0BNF3">VIP</protein-id> antagonist hGRF 1-29 (10(-5) M) did not modify the inhibitory effect of <compound-id="2733484">capsazepine</compound-id>.	SR 48968__NK3 receptor__no_interaction	SR 48968__calcitonin gene-related peptide__no_interaction	SR 48968__VIP__no_interaction	SR 48968__NK1 receptor__no_interaction	SR 48968__CGRP__no_interaction	SR 48968__NK2 receptor__no_interaction	hexamethonium__NK3 receptor__no_interaction	hexamethonium__calcitonin gene-related peptide__no_interaction	hexamethonium__VIP__no_interaction	hexamethonium__NK1 receptor__no_interaction	hexamethonium__CGRP__no_interaction	hexamethonium__NK2 receptor__no_interaction	phentolamine__NK3 receptor__no_interaction	phentolamine__calcitonin gene-related peptide__no_interaction	phentolamine__VIP__no_interaction	phentolamine__NK1 receptor__no_interaction	phentolamine__CGRP__no_interaction	phentolamine__NK2 receptor__no_interaction	L-arginine methyl ester__NK3 receptor__no_interaction	L-arginine methyl ester__calcitonin gene-related peptide__no_interaction	L-arginine methyl ester__VIP__no_interaction	L-arginine methyl ester__NK1 receptor__no_interaction	L-arginine methyl ester__CGRP__no_interaction	L-arginine methyl ester__NK2 receptor__no_interaction	SR 142801__NK3 receptor__no_interaction	SR 142801__calcitonin gene-related peptide__no_interaction	SR 142801__VIP__no_interaction	SR 142801__NK1 receptor__no_interaction	SR 142801__CGRP__no_interaction	SR 142801__NK2 receptor__no_interaction	capsazepine__NK3 receptor__no_interaction	capsazepine__calcitonin gene-related peptide__no_interaction	capsazepine__VIP__no_interaction	capsazepine__NK1 receptor__no_interaction	capsazepine__CGRP__no_interaction	capsazepine__NK2 receptor__no_interaction	atropine__NK3 receptor__no_interaction	atropine__calcitonin gene-related peptide__no_interaction	atropine__VIP__no_interaction	atropine__NK1 receptor__no_interaction	atropine__CGRP__no_interaction	atropine__NK2 receptor__no_interaction	SR 140333__NK3 receptor__no_interaction	SR 140333__calcitonin gene-related peptide__no_interaction	SR 140333__VIP__no_interaction	SR 140333__NK1 receptor__no_interaction	SR 140333__CGRP__no_interaction	SR 140333__NK2 receptor__no_interaction	L-NAME__NK3 receptor__no_interaction	L-NAME__calcitonin gene-related peptide__no_interaction	L-NAME__VIP__no_interaction	L-NAME__NK1 receptor__no_interaction	L-NAME__CGRP__no_interaction	L-NAME__NK2 receptor__no_interaction	apamin__NK3 receptor__no_interaction	apamin__calcitonin gene-related peptide__no_interaction	apamin__VIP__no_interaction	apamin__NK1 receptor__no_interaction	apamin__CGRP__no_interaction	apamin__NK2 receptor__no_interaction	methysergide__NK3 receptor__no_interaction	methysergide__calcitonin gene-related peptide__no_interaction	methysergide__VIP__no_interaction	methysergide__NK1 receptor__no_interaction	methysergide__CGRP__no_interaction	methysergide__NK2 receptor__no_interaction
9164359-4	RESULTS: For PHA-stimulated PBMNCs in the <compound-id="439501">ouabain</compound-id>-treated group (n = 10 subjects), the mean (+/-STD) % uptake (% 3H thymidine uptake in absence of <compound-id="439501">ouabain</compound-id>) was 80.5 +/- 6.0 at 10(-12) M <compound-id="439501">ouabain</compound-id>, 73.1 +/- 8.4 at 10(-10) M, 47.89 +/- 13.1 at 10(-8) M, 6.9 +/- 3.2 at 10(-6) M, and 3.4 +/- 1.6 at 10(-4) M. For PHA-stimulated cells in the <compound-id="2724385">digoxin</compound-id>-treated group (n = 9 subjects), the mean (+/-STD) % uptake (% 3H thymidine uptake in absence of <compound-id="2724385">digoxin</compound-id>) was 89.8 +/- 9.8 at 10(-9) M <compound-id="2724385">digoxin</compound-id>, 92.6 +/- 8.2 at 10(-8) M, 54.3 +/- 19.8 at 10(-7) M, and 1.0 +/- 2.4 at 10(-6) M. Repeated measures <protein-id="Q9UNW9">ANOVA</protein-id> demonstrated a significant effect of concentration of both glycosides on PBMNC proliferation (P &lt; .01).	digoxin__ANOVA__no_interaction	ouabain__ANOVA__no_interaction
16966829-6	In univariate linear regression analysis, serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were positively correlated with serum <compound-id="588">creatinine</compound-id> (r = 0.648, P&lt;0.0001), urinary albumin (r = 0.583, P&lt;0.0001), urinary <protein-id="P54802">NAG</protein-id> (r = 0.406, P&lt;0.01), urinary <protein-id="P13500">MCP-1</protein-id> (r = 0.514, P&lt;0.0001), and urinary <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (r = 0.691, P&lt;0.0001) levels in all diabetic patients.	creatinine__MCP-1__no_interaction	creatinine__NAG__no_interaction	creatinine__adiponectin__no_interaction
16966829-7	Urinary <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were also positively correlated with serum <compound-id="588">creatinine</compound-id> (r = 0.729, P&lt;0.0001), urinary albumin (r = 0.799, P&lt;0.0001), urinary <protein-id="P54802">NAG</protein-id> (r = 0.701, P&lt;0.0001), and urinary <protein-id="P13500">MCP-1</protein-id> (r = 0.801, P&lt;0.0001) levels in all diabetic patients.	creatinine__MCP-1__no_interaction	creatinine__NAG__no_interaction	creatinine__adiponectin__no_interaction
21426695-6	RESULT: Compared to ordinary diet group, the rat's liver weight (g) (16.92 ± 2.49 vs. 12.16 ± 0.82), hepatic exponent (0.034 ± 0.004 vs. 0.026 ± 0.002), serum <compound-id="5950,602">alanine</compound-id> aminotransferase (U/L) (45.43 ± 9.73 vs. 29.42 ± 6.73), triglyceride (mmol/L) (1.22 ± 0.24 vs. 0.85 ± 0.19), <compound-id="5997">cholesterol</compound-id> (mmol/L) (2.00 ± 0.37 vs. 1.49 ± 0.33), lipoprotein(a) (mmol/L) (743.86 ± 32.19 vs. 648.42 ± 78.87), low-density lipoprotein (mmol/L) (1.31 ± 0.35 vs. 0.65 ± 0.22), insulin (mmol/L) (22.16 ± 5.16 vs. 16.86 ± 5.35), insulin resistance index(5.10 ± 1.45 vs. 3.59 ± 0.99), free fatty acid (mEq/L) (0.57 ± 0.10 vs. 0.35 ± 0.07), <protein-id="P14423">sPLA2</protein-id> [µmol/(min·ml)] (0.130 ± 0.016 vs. 0.098 ± 0.024), <compound-id="5311265">lysophosphatidylcholine</compound-id> (µmol/L) (707.26 ± 92.48 vs. 508.87 ± 96.50), <protein-id="P50596">leptin</protein-id> (pg/ml (80.08 ± 17.73 vs. 65.11 ± 14.09), liver triglyceride (mg/g) (13.57 ± 0.65 vs. 12.03 ± 1.14), <compound-id="5997">cholesterol</compound-id> (mg/g) (2.19 ± 0.15 vs. 1.94 ± 0.12) (P &lt; 0.05) were significantly increased in high-fat diet group.	lysophosphatidylcholine__leptin__no_interaction	lysophosphatidylcholine__sPLA2__no_interaction	alanine__leptin__no_interaction	alanine__sPLA2__no_interaction	cholesterol__leptin__no_interaction	cholesterol__sPLA2__no_interaction
21426695-8	Secondly, in comparison with high-fat diet group, early <compound-id="4091">metformin</compound-id> treatment significantly reduced the rat's body weight (g) (394.40 ± 33.10 vs. 491.86 ± 26.45), liver weight (g) (13.24 ± 1.16 vs. 16.92 ± 2.49), serum <compound-id="5950,602">alanine</compound-id> aminotransferase (U/L) (30.40 ± 4.50 vs. 45.43 ± 9.73), triglyceride (mmol/L) (0.75 ± 0.19 vs. 1.22 ± 0.24), <compound-id="5997">cholesterol</compound-id> (mmol/L) (1.61 ± 0.38 vs. 2.00 ± 0.37), insulin (mmol/L) (16.96 ± 5.60 vs. 22.16 ± 5.16), insulin resistance index (3.75 ± 1.41 vs. 5.10 ± 1.45), <protein-id="P14423">sPLA2</protein-id> [µmol/(min·ml)] (0.101 ± 0.009 vs. 0.130 ± 0.016), <compound-id="5311265">lysophosphatidylcholine</compound-id> (µmol/L) (549.92 ± 90.78 vs. 707.26 ± 92.48), liver triglyceride (mg/g) (11.23 ± 1.70 vs. 13.57 ± 0.65), <compound-id="5997">cholesterol</compound-id> (mg/g) (1.97 ± 0.20 vs. 2.19 ± 0.15) (P &lt; 0.05).	lysophosphatidylcholine__sPLA2__no_interaction	alanine__sPLA2__no_interaction	metformin__sPLA2__no_interaction	cholesterol__sPLA2__no_interaction
19809735-1	Homoleptic group 10 complexes of ditellurido <protein-id="P00491,V9HWH6">PNP</protein-id> (<protein-id="P00491,V9HWH6">PNP</protein-id> = imidodiphosphinate), heterodichalcogenido <protein-id="P00491,V9HWH6">PNP</protein-id> and monotellurido <protein-id="P00491,V9HWH6">PNP</protein-id> ligands, M[(TeP(i)<compound-id="445481">Pr2</compound-id>)2N]2 (1: M = Pd; 2: M = Pt), M[(EP(i)<compound-id="445481">Pr2</compound-id>)(TeP(i)<compound-id="445481">Pr2</compound-id>)N]2 (3: M = Pd, E = Se; 4: M = Pt, E = Se; 5: M = Pd, E = S; 6: M = Pt, E = S) and M[(P(i)<compound-id="445481">Pr2</compound-id>)(TeP(i)<compound-id="445481">Pr2</compound-id>)N]2 (7: M = Pd; 8: M = Pt), respectively, were prepared by metathesis between alkali-metal derivatives of the appropriate ligand and MCl2(COD) in <compound-id="8028">THF</compound-id>.	THF__PNP__no_interaction	Pr2__PNP__no_interaction
12826739-3	We found a significant relationship between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> and plasma levels of ACT (r = 0.4, p &lt; 0.001), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.74, p &lt; 0.001), <protein-id="P13500">MCP-1</protein-id> (r = 0.71, p &lt; 0.001), and a borderline relationship between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> and plasma oxLDL (r = 0.22, p &lt; 0.05).	CSF__IL-6__no_interaction	CSF__MCP-1__no_interaction
11456250-3	Antibodies against the following antigens were used: epidermal growth factor (EGF), <protein-id="P00533">EGF receptor</protein-id> (<protein-id="P00533">EGF-R</protein-id>), fibroblast growth factor (FGF), <protein-id="P21802,D3DRD5,D2CGD1,S4R381">FGF receptor</protein-id> (FGF-R), transforming growth factor (TGF)-beta, <protein-id="P37173,A3QNQ0,D2JYI1">TGF-beta receptor II</protein-id> (<protein-id="P37173,A3QNQ0,D2JYI1">TGF-beta -RII</protein-id>), insulin-like growth factor (<protein-id="P01344,E3UN46">IGF)II</protein-id>, platelet derived growth factor (PDGF)-AB, interleukin (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL)-6</protein-id>, IL-1 receptor II, <protein-id="P01375,Q5STB3">tumor necrosis factor (TNF)-alpha</protein-id>, <protein-id="P00750">tissue plasminogen activator</protein-id> (<protein-id="P00750">TPA</protein-id>), <compound-id="285703,6145931">prostaglandin</compound-id> (PG) E2, plasminogen activator inhibitor (<protein-id="P05121,A0A024QYT5">PAI)-1</protein-id>, alpha smooth muscle actin (alpha-SMA), keratin, <protein-id="P08670,V9HWE1">vimentin</protein-id>, <protein-id="Q7Z406,A1L2Z2,B3KWH4">myosin</protein-id>, <protein-id="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6">fibronectin</protein-id>, <compound-id="44342165">laminin</compound-id>, types I, II, III, IV, V and VI collagen (Col), and lens epithelial cells (LECs).	laminin__TPA__no_interaction	laminin__TGF-beta receptor II__no_interaction	laminin__tissue plasminogen activator__no_interaction	laminin__TGF-beta -RII__no_interaction	laminin__EGF-R__no_interaction	laminin__myosin__no_interaction	laminin__IL)-6__no_interaction	laminin__EGF receptor__no_interaction	laminin__IGF)II__no_interaction	laminin__fibronectin__no_interaction	laminin__vimentin__no_interaction	laminin__FGF receptor__no_interaction	laminin__tumor necrosis factor (TNF)-alpha__no_interaction	laminin__PAI)-1__no_interaction	prostaglandin__TPA__no_interaction	prostaglandin__TGF-beta receptor II__no_interaction	prostaglandin__tissue plasminogen activator__no_interaction	prostaglandin__TGF-beta -RII__no_interaction	prostaglandin__EGF-R__no_interaction	prostaglandin__myosin__no_interaction	prostaglandin__IL)-6__no_interaction	prostaglandin__EGF receptor__no_interaction	prostaglandin__IGF)II__no_interaction	prostaglandin__fibronectin__no_interaction	prostaglandin__vimentin__no_interaction	prostaglandin__FGF receptor__no_interaction	prostaglandin__tumor necrosis factor (TNF)-alpha__no_interaction	prostaglandin__PAI)-1__no_interaction
21784176-10	Alkaline phosphatase activity and <protein-id="P02818">osteocalcin</protein-id> concentration correlated with HA content (alkaline <compound-id="1061,167704,644102">phosphate</compound-id> activity in expansion medium and osteogenic medium for 40, 50, and 60 wt.% HA, 256.1 ± 71.8%, 304.0 ± 128.7%, and 500.2 ± 89.9%, and 358.4 ± 124.1%, 653.7 ± 216.5%, and 814.4 ± 68.8%, respectively; <protein-id="P02818">osteocalcin</protein-id> concentration in expansion medium and osteogenic medium for 40, 50, and 60 wt.% HA, 236.9 ± 7.8%, 253.0 ± 7.5%, and 285.2 ± 11.4%, and 265.8 ± 15.0%, 288.3 ± 17.9%, and 717.3 ± 38.7%, respectively).	phosphate__osteocalcin__no_interaction
9093548-4	Changes in <compound-id="445354">vitamin A</compound-id> status correlated positively and significantly with changes in serum <compound-id="23925,67172434">iron</compound-id> (r = 0.37; P = 0.0001) <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (r = 0.27; P = 0.004) and haemoglobin (r = 0.21; P = 0.03), but negatively with serum ferritin (r = -0.28; P = 0.003).	vitamin A__transferrin__no_interaction	iron__transferrin__no_interaction
10048132-4	Support for the TCDD-<protein-id="G3V6M2">AhR</protein-id>-mediated increases in ACTH concentrations is provided by the following observations: (1) ANF inhibited both the 1.3- to 2-fold TCDD-induced increase in basal medium and intracellular ACTH concentrations and the 30% TCDD-induced decrease in medium ACTH levels and the 1.2-fold increase in intracellular ACTH levels in <protein-id="P01143">corticotropin-releasing hormone</protein-id> (<protein-id="P01143">CRH</protein-id>)-stimulated cells, (2) <compound-id="80654">BNF</compound-id> increased basal medium (1.7-fold) and intracellular (1.3-fold) ACTH concentrations, (3) <compound-id="80654">BNF</compound-id> + TCDD demonstrated additivity by increasing basal medium (2.4-fold) and intracellular (1.7-fold) ACTH concentrations, (4) PCB increased basal medium (1.8- to 2.1-fold) and intracellular (1.3- to 1.8-fold) ACTH concentrations and inhibited medium ACTH secretion in <protein-id="P01143">CRH</protein-id> stimulated cells by 24-43%, and (5) HCB did not effect basal or <protein-id="P01143">CRH</protein-id> stimulated medium and intracellular ACTH concentrations.	BNF__AhR__no_interaction	BNF__CRH__no_interaction	BNF__corticotropin-releasing hormone__no_interaction
15307058-1	<compound-id="23948">Rhodium</compound-id>-103 chemical shifts are reported for 62 compounds, namely [Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] [X = Cl, N3, NCO, NCS, N(CN)2, NCBPh3, CNBPh3, CN] and derivatives formed by replacement of a <compound-id="24404">phosphine</compound-id> by CO, <compound-id="4212184">xylyl isocyanide</compound-id> (XNC) and <compound-id="1049">pyridine</compound-id> and/or by oxidative addition of H2 or O2 to give trans-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(CO)] (delta in the range -816 to -368 ppm) trans-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(XNC)] (delta -817 to -250 ppm), cis-[Rh(X)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (the trans isomer is formed with X = CN, CNBPh3) (delta -233 to 170 ppm), [Rh(X)(H)2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] (delta -611 to 119), trans-[Rh(X)(H)2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (delta -30 to 566 ppm), [Rh(X)(O2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] (delta 1393 to 3273 ppm) and cis-[Rh(X)(O2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(py)] (delta 1949 to 3374 ppm).	phosphine__PPh3__no_interaction	xylyl isocyanide__PPh3__no_interaction	pyridine__PPh3__no_interaction	Rhodium__PPh3__no_interaction
24719803-7	It was directly correlated with HDL-<compound-id="5997">cholesterol</compound-id> (r = 0.599, P &lt; 0.001) and serum <compound-id="588">creatinine</compound-id> levels (r = 0.675, P &lt; 0.001) and inversely correlated with glomerular filtration rate (GFR) (r = -0.570, P &lt; 0.001), body mass index (BMI) (r = -0.318, P = 0.04), <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = -0.548, P &lt; 0.001) and fasting blood sugar (FBS) (r = -0.640, P &lt; 0.001) in CKD patients.	creatinine__C-reactive protein__no_interaction	creatinine__CRP__no_interaction	cholesterol__C-reactive protein__no_interaction	cholesterol__CRP__no_interaction
10754344-3	PDT was significantly correlated with <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.41, p = 0.009), intracellular <compound-id="5462224">magnesium</compound-id> levels (r = -0.46, p = 0.003) fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.47, p = 0.002), and total <compound-id="5997">cholesterol</compound-id> (r = 0.43, p = 0.006).	cholesterol__apolipoprotein B__no_interaction	magnesium__apolipoprotein B__no_interaction	glucose__apolipoprotein B__no_interaction
1671419-2	Compounds [R-(R*,S*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-3- phenylpropyl]-amino]-<compound-id="5314579,74088">4-oxo-2-butenoic acid</compound-id>, [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-oxy)carbonyl]amino]propyl]amino]-1- phenylethyl]amino]-<compound-id="5314579,74088">4-oxo-2-butenoic acid</compound-id>, and [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-1- phenylethyl]amino]-<compound-id="1112">4-oxobutanoic acid</compound-id> (<compound-id="21155395">29d</compound-id>) have <protein-id="P01355">CCK</protein-id>-B binding affinities of IC50 = 0.8, 0.7, and 1.7 nM with a <protein-id="P01355">CCK</protein-id>-A/<protein-id="P01355">CCK</protein-id>-B ratio of 550, 1100, and 2500, respectively.	4-oxo-2-butenoic acid__CCK__no_interaction	29d__CCK__no_interaction	4-oxobutanoic acid__CCK__no_interaction
18332235-7	This effect appeared specific for <compound-id="5288811">MLK</compound-id>, as the analog (E)-3-[[[3-[2-(<compound-id="521963">7-chloro-2-quinolinyl</compound-id>)<compound-id="123166">ethenyl</compound-id>]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]methyl]thio]-<compound-id="1032">propanoic acid, sodium salt</compound-id>, had no significant effect on eosinophil adhesion to <protein-id="P19320">VCAM-1</protein-id>.	propanoic acid, sodium salt__VCAM-1__no_interaction	MLK__VCAM-1__no_interaction	7-chloro-2-quinolinyl__VCAM-1__no_interaction	ethenyl__VCAM-1__no_interaction
11463578-9	Michaelis-Menten constants measured for <protein-id="P14060">3beta-HSD</protein-id> substrate (<compound-id="5881">dehydroepiandrosterone</compound-id>) utilization by the purified cytosolic enzyme (K(m)=4.5 microM, V(max)=53 nmol/min per mg) and the pure wild-type enzyme (K(m)=3.7 microM, V(max)=43 nmol/min per mg), for isomerase substrate (<compound-id="160531">5-androstene-3,17-dione</compound-id>) conversion by the purified cytosolic (K(m)=25 microM, V(max)=576 nmol/min per mg) and wild-type (K(m)=28 microM, V(max)=598 nmol/min per mg) enzymes, and for <compound-id="5893">NAD</compound-id>(+) reduction by the <protein-id="P14060">3beta-HSD</protein-id> activities of the cytosolic (K(m)=35 microM, V(max)=51 nmol/min per mg) and wild-type (K(m)=34 microM, V(max)=46 nmol/min per mg) enzymes are nearly identical.	5-androstene-3,17-dione__3beta-HSD__no_interaction	dehydroepiandrosterone__3beta-HSD__no_interaction	NAD__3beta-HSD__no_interaction
19833271-7	MAIN RESULTS: <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> levels were significantly lower at the 24th hour (14.66 +/- 4.40 pg/mL vs. 21.21 +/- 11.37 pg/mL, respectively) and at the 48th hour (21.25 +/- 15.85 pg/mL vs. 46.55 +/- 35.99 pg/mL, respectively) in Group D. <protein-id="P01583">IL-1</protein-id> levels were significantly lower at the 24th hour (5.03 +/- 0.15 pg/mL vs. 6.23 +/- 2.09 pg/mL, respectively) and the 48th hour (5.01 +/- 0.37 pg/mL vs. 6.42 +/- 2.76 pg/mL, respectively) in Group D. <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> levels were significantly lower at the 24th hour (253.1 +/- 303.6 pg/mL and 511.3 +/- 374.8 pg/mL, respectively) and at the 48th hour (343.5 +/- 393.4 pg/mL and 503.7 +/- 306.4 pg/mL, respectively) in Group D. Intraabdominal pressure also was significantly lower at the 24th hour (12.35 +/- 5.84 mmHg vs. 18.1 +/- 2.84 mmHg, respectively) and the 48th hour (13.9 +/- 6.15 mmHg vs. 18.7 +/- 3.46 mmHg, respectively) in Group D. CONCLUSION: <compound-id="5311068">Dexmedetomidine</compound-id> infusion decreases <protein-id="P01375,Q5STB3">TNF-a</protein-id>, <protein-id="P01583">IL-1</protein-id>, and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> levels and IAP more than a <compound-id="4943">propofol</compound-id> infusion. 	Dexmedetomidine__TNF-alpha__no_interaction	Dexmedetomidine__TNF-a__no_interaction	Dexmedetomidine__IL-1__no_interaction	Dexmedetomidine__IL-6__no_interaction	propofol__TNF-alpha__no_interaction	propofol__TNF-a__no_interaction	propofol__IL-1__no_interaction	propofol__IL-6__no_interaction
12915627-7	CRP was significantly correlated with prepregnancy BMI (r = 0.38, P &lt; 0.0001), followed by fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.27, P = 0.0002) and fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.18, P = 0.016).	glucose__insulin__no_interaction
11996197-3	The more recent trials indicate that: (1) diuretics and beta-blockers appear to be as effective in reducing overall morbidity/ mortality as other agents (Swedish Trial in Old Patients with Hypertension [STOP-2], United Kingdom Prospective Diabetes Study [UKPDS], Intervention as a Goal in Hypertension Treatment [INSIGHT], Nordic <compound-id="39186">diltiazem</compound-id> [NORDIL]); (2) the use of an a-blocker results in more cardiovascular events, especially congestive heart failure, when compared with a diuretic (Antihypertensive Therapy and Lipid Lowering Heart Attack Trial [ALLHAT]); (3)the use of an angiotensin-converting enzyme (ACE) inhibitor results in fewer myocardial infarctions and episodes of heart failure than <compound-id="22044544,5460341">calcium</compound-id> channel blockers in the elderly and in diabetic patients (<compound-id="3420,55891,6708482,9601226">Fosinopril</compound-id> vs. <compound-id="2162">Amlodipine</compound-id> Cardiovascular Events Randomized Trial [FACET], Appropriate Blood Pressure Control in Diabetes [ABCD], STOP-2) - other data (<compound-id="44093">Captopril</compound-id> Prevention Project [CAPPP]) suggest that the use of an ACE inhibitor is preferred in diabetic patients; (4) overall cardiovascular events are similar with <compound-id="22044544,5460341">calcium</compound-id> channel blockers compared with a diuretic - however, there are fewer strokes with non-dihydropyridine <compound-id="22044544,5460341">calcium</compound-id> channel blockers (NORDIL) and a trend towards an increase in heart failure and myocardial infarctions with either a dihydropyridine or non-dihydropyridine <compound-id="22044544,5460341">calcium</compound-id> channel blockers compared with a diuretic (INSIGHT, NORDIL); (5) angiotensin receptor blockers (ARBs) will decrease proteinuria and slow progression of renal disease in type 2 diabetic patients when compared with regimens that do not include an <protein-id="O76090,B7Z1N8,B7Z375,A0A0C4DGE9">ARB</protein-id> or an ACE inhibitor (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist <compound-id="3961">Losartan</compound-id> [RENAAL], <compound-id="3749">Irbesartan</compound-id> Type II Diabetic Nephropathy Trial [IDNT], <compound-id="3749">Irbesartan</compound-id> Type II Diabetes with Microalbuminuria [IRMA Il]).	Losartan__ARB__no_interaction	diltiazem__ARB__no_interaction	Fosinopril__ARB__no_interaction	Amlodipine__ARB__no_interaction	calcium__ARB__no_interaction	Irbesartan__ARB__no_interaction	Captopril__ARB__no_interaction
8937476-4	This conclusion is based on several lines of evidence: (a) <compound-id="15625">TCDD</compound-id> caused activation of protein <compound-id="6057,90983769">tyrosine</compound-id> kinase activity when administered directly to purified <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate; (b) this stimulatory effect of <compound-id="15625">TCDD</compound-id> was abolished when the cytosol was immunodepleted of c-Src protein or <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> protein by preincubating with anti-c-Src or anti-<protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> antibody, followed by the addition of <compound-id="15625">TCDD</compound-id> to the remaining portions of cytosol; (c) when <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate was incubated with <compound-id="15625">TCDD</compound-id>, and the kinase(s) released to the supernatant was analyzed on autoradiography of two-dimensional (2D) electrophoresis, 32P-labeled c-Src protein was recognized; (d) the same 32P-labeled-phosphoprotein with M(r) = 60 kDa and pl = 6.1 was found in the immunoprecipitate with anti-c-Src antibody on 2D autoradiograms; (e) this same phosphoprotein disappeared when the supernatant of the <protein-id="P30561,Q3U5D9">Ah-receptor</protein-id> immunoprecipitate was immunodepleted of c-Src protein by anti-c-Src antibody; and (f) a structure-activity relationship study with <compound-id="15625">TCDD</compound-id> and three dioxin-congeners revealed a rank order for their potency in activation of <protein-id="P41241">c-Src kinase</protein-id> activity to be identical to that of previously determined toxicity indices: i.e., <compound-id="15625">TCDD</compound-id> &gt; <compound-id="38439">1,2,3,7,8-pentachlorodibenzo-p-dioxin</compound-id> (1,2,3,7,8-PCDD) &gt; <compound-id="42836">1,2,4,7,8-pentachlorodibenzo-p-dioxin</compound-id> (1,2,4,7,8-PCDD) &gt; <compound-id="36613">2,7-dichlorodibenzo-p-dioxin</compound-id> (2,7-DCDD).	1,2,3,7,8-pentachlorodibenzo-p-dioxin__Ah-receptor__no_interaction	1,2,3,7,8-pentachlorodibenzo-p-dioxin__c-Src kinase__no_interaction	TCDD__Ah-receptor__no_interaction	TCDD__c-Src kinase__no_interaction	1,2,4,7,8-pentachlorodibenzo-p-dioxin__Ah-receptor__no_interaction	1,2,4,7,8-pentachlorodibenzo-p-dioxin__c-Src kinase__no_interaction	2,7-dichlorodibenzo-p-dioxin__Ah-receptor__no_interaction	2,7-dichlorodibenzo-p-dioxin__c-Src kinase__no_interaction	tyrosine__Ah-receptor__no_interaction	tyrosine__c-Src kinase__no_interaction
22497081-5	Comparative analysis of changes in the status of expression of genes in the heart of rats induced by <protein-id="P05943,B3Y9H3">P-11</protein-id> against the simulated in vivo arrhythmia identified 16 genes that reproducibly alter the level of expression.These genes encode the extracellular matrix proteins (<protein-id="P35053">glypican 1</protein-id>, <protein-id="P35053">Gpc1</protein-id>; <protein-id="P30121">tissue inhibitor of metalloproteinase 2, 3</protein-id>, <protein-id="P30121">Timp2</protein-id>, <protein-id="Q4V8L0">Timp 3</protein-id>); intracellular signaling molecules (<protein-id="G3V7H1">rho GTPase activating protein 7</protein-id>, <protein-id="G3V7H1">Dlc1</protein-id>; protein <compound-id="6057,90983769">tyrosine</compound-id> phosphatase <compound-id="16770253">4a1</compound-id>, <protein-id="Q78EG7">Ptp4a1; phosphodiesterase 4D</protein-id>, <protein-id="P14270">PDE4D</protein-id>; <protein-id="Q63787,M0RC47">PI3-kinase regulatory subunit alpha</protein-id>, <protein-id="Q63787,M0RC47">PIK3R1</protein-id>; <compound-id="764">guanine</compound-id> nucleotide binding protein alpha 12, <protein-id="Q63210,Q45QM2">Gna12</protein-id>) and protein of intermediate junctions (junction plakoglobin, <protein-id="Q6P0K8">Jup</protein-id>), proteins involved in glycolysis (phosphofructokinase I, Pfk1) and hemostasis (tissue plasminogen activator, <protein-id="P19637">Plat</protein-id>), plasma membrane transporters (Solute carrier family 16, member 1, <protein-id="P53987">Slc16a1</protein-id>; ATPase, Na+/K+ transporting, Atp1a), and ets.	4a1__Timp 3__no_interaction	4a1__Timp2__no_interaction	4a1__tissue inhibitor of metalloproteinase 2, 3__no_interaction	4a1__Slc16a1__no_interaction	4a1__PDE4D__no_interaction	4a1__rho GTPase activating protein 7__no_interaction	4a1__P-11__no_interaction	4a1__Plat__no_interaction	4a1__Gpc1__no_interaction	4a1__Jup__no_interaction	4a1__PI3-kinase regulatory subunit alpha__no_interaction	4a1__Gna12__no_interaction	4a1__Ptp4a1; phosphodiesterase 4D__no_interaction	4a1__PIK3R1__no_interaction	4a1__glypican 1__no_interaction	4a1__Dlc1__no_interaction	guanine__Timp 3__no_interaction	guanine__Timp2__no_interaction	guanine__tissue inhibitor of metalloproteinase 2, 3__no_interaction	guanine__Slc16a1__no_interaction	guanine__PDE4D__no_interaction	guanine__rho GTPase activating protein 7__no_interaction	guanine__P-11__no_interaction	guanine__Plat__no_interaction	guanine__Gpc1__no_interaction	guanine__Jup__no_interaction	guanine__PI3-kinase regulatory subunit alpha__no_interaction	guanine__Gna12__no_interaction	guanine__Ptp4a1; phosphodiesterase 4D__no_interaction	guanine__PIK3R1__no_interaction	guanine__glypican 1__no_interaction	guanine__Dlc1__no_interaction	tyrosine__Timp 3__no_interaction	tyrosine__Timp2__no_interaction	tyrosine__tissue inhibitor of metalloproteinase 2, 3__no_interaction	tyrosine__Slc16a1__no_interaction	tyrosine__PDE4D__no_interaction	tyrosine__rho GTPase activating protein 7__no_interaction	tyrosine__P-11__no_interaction	tyrosine__Plat__no_interaction	tyrosine__Gpc1__no_interaction	tyrosine__Jup__no_interaction	tyrosine__PI3-kinase regulatory subunit alpha__no_interaction	tyrosine__Gna12__no_interaction	tyrosine__Ptp4a1; phosphodiesterase 4D__no_interaction	tyrosine__PIK3R1__no_interaction	tyrosine__glypican 1__no_interaction	tyrosine__Dlc1__no_interaction
16120716-5	Carotid <compound-id="447041">IMT</compound-id> was significantly correlated with serum levels of <protein-id="P02741">CRP</protein-id> (r = 0.61, p = 0.0001), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.41, p = 0.01), and <protein-id="Q14116,A0A024R3E0">IL-18</protein-id> (r = 0.45, p = 0.005), duration of OSA-related hypoxia (r = 0.60, p = 0.0001), and severity of OSA (r = 0.50, p = 0.002).	IMT__CRP__no_interaction	IMT__IL-6__no_interaction	IMT__IL-18__no_interaction
21789900-8	In <compound-id="667639">astringinin</compound-id>-treated (0.3 mg/kg) rats subjected to trauma-hemorrhage, there were significant improvements in liver <protein-id="D3ZGE2,A0A0G2K1A2">myeloperoxidase</protein-id> (<protein-id="D3ZGE2,A0A0G2K1A2">MPO</protein-id>) activity (237.80 +/- 45.89 vs. 495.95 +/- 70.64 U/mg protein, P &lt; 0.05), <protein-id="P20607">interleukin-6</protein-id> (<protein-id="P20607">IL-6</protein-id>) levels (218.54 +/- 34.52 vs. 478.60 +/- 76.21 pg/mg protein, P &lt; 0.05), cytokine-induced neutrophil chemoattractant (<compound-id="23994">CINC</compound-id>)-1 (88.32 +/- 20.33 vs. 200.70 +/- 32.68 pg/mg protein, P &lt; 0.05), <protein-id="P30348">CINC-3</protein-id> (110.83 +/- 26.63 vs. 290.14 +/- 76.82 pg/mg protein, P &lt; 0.05) and <protein-id="Q00238">intercellular adhesion molecule (ICAM)-1</protein-id> concentrations (1,868.5 +/- 211.5 vs. 3,645.0 +/- 709.2 pg/mg protein, P &lt; 0.05), as well as in histology.	astringinin__intercellular adhesion molecule (ICAM)-1__no_interaction	astringinin__MPO__no_interaction	astringinin__IL-6__no_interaction	astringinin__myeloperoxidase__no_interaction	astringinin__interleukin-6__no_interaction	astringinin__CINC-3__no_interaction	CINC__intercellular adhesion molecule (ICAM)-1__no_interaction	CINC__MPO__no_interaction	CINC__IL-6__no_interaction	CINC__myeloperoxidase__no_interaction	CINC__interleukin-6__no_interaction	CINC__CINC-3__no_interaction
8683352-5	<compound-id="947">Nitrogen</compound-id> intake was significantly negatively correlated with urinary 4-PA excretion (r = -0.619, P &lt; 0.001) and plasma <protein-id="Q96GD0,A0A024R1I3">PLP</protein-id> concentration (r = -0.549, P &lt; 0.01), and positively correlated with erythrocyte <compound-id="5950,602">alanine</compound-id> aminotransferase percentage stimulation (r = 0.418, P &lt; 0.05) and urinary post-<compound-id="57175189,6305">tryptophan</compound-id> load excretion of <compound-id="5699">xanthurenic acid</compound-id> (r = 0.535, P &lt; 0.05), <compound-id="3845">kynurenic acid</compound-id> (r = 0.563, P &lt; 0.05) and VA (r = 0.626, P &lt; 0.01).	xanthurenic acid__PLP__no_interaction	tryptophan__PLP__no_interaction	alanine__PLP__no_interaction	Nitrogen__PLP__no_interaction	kynurenic acid__PLP__no_interaction
11532695-8	This protection was mediated via <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>) AR activation because the <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>)-selective AR agonist [4-((N-<compound-id="23134249">ethyl</compound-id>-5'-carbamoyadenos-2-yl)-aminoethyl)-<compound-id="107">phenylpropionic acid</compound-id> (<compound-id="3086599">CGS-21680</compound-id>)] mimics <compound-id="57476835,60961">adenosine</compound-id>-induced renal protection, and the <protein-id="P16086,Q6IRK8,A0A0G2K1Y8">A(2a</protein-id>)-selective AR antagonist [<compound-id="5353365">8-(3-chlorostyryl)caffeine</compound-id> (CSC)] blocks <compound-id="57476835,60961">adenosine</compound-id>-induced renal protection.	CGS-21680__A(2a__no_interaction	adenosine__A(2a__no_interaction	phenylpropionic acid__A(2a__no_interaction	8-(3-chlorostyryl)caffeine__A(2a__no_interaction	ethyl__A(2a__no_interaction
15071612-3	This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-<protein-id="P29965">CD154</protein-id>, Adeno-Interferon gamma, alemtuzumab, APC-8024, <compound-id="72402">9-aminocamptothecin</compound-id>, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, l-<compound-id="6322,90867653">arginine</compound-id> hydrochloride, <compound-id="60795">aripiprazole</compound-id>, <compound-id="5359596">arsenic</compound-id> trioxide, <compound-id="179340">asimadoline</compound-id>; <compound-id="4578">O6-Benzylguanine</compound-id>, bevacizumab, Bi-20, <compound-id="9576912">binodenoson</compound-id>, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, bivatuzumab, <compound-id="161105">186Re</compound-id>-bivatuzumab, BMS-181176, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="16219006,52943236">BQ-123</compound-id>, <compound-id="16760328,22524140,433902,44277532,5280757,5458769,5477635,6435419,6473739">bryostatin 1</compound-id>; Carboxy- amidotriazole, <compound-id="5486792,2826718,66577042,71295847">caspofungin acetate</compound-id>, <compound-id="89105">CB-1954</compound-id>, CC-4047, <compound-id="6132">CDP</compound-id>-860, <compound-id="446156">cerivastatin sodium</compound-id>, <compound-id="153994">clevidipine</compound-id>, CTL-102; <compound-id="5918">3,4-DAP</compound-id>, darbepoetin alfa, <compound-id="451668">decitabine</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="6918473">DHA-paclitaxel</compound-id>, <compound-id="60835">duloxetine hydrochloride</compound-id>; Efalizumab, EGF vaccine, <compound-id="77993">eletriptan</compound-id>, <compound-id="43157">eniluracil</compound-id>, ENMD-0997, <compound-id="443872">eplerenone</compound-id>, <compound-id="54381650,5486684,5493160">eplivanserin</compound-id>, <compound-id="219078">erlosamide</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="4594,9568614">esomeprazole magnesium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="151115">exatecan</compound-id> mesilate, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="5352062">FR-901228</compound-id>, <compound-id="5288267">FTY</compound-id>-720; <compound-id="123631">Gefitinib</compound-id>, gemtuzumab <compound-id="9942071">ozogamicin</compound-id>, <compound-id="55191">gepirone</compound-id> hydrochloride; Hexyl <protein-id="P01308,I3WAC9">insulin</protein-id> M2, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> <compound-id="44146714">glargine</compound-id>, <compound-id="807">iodine</compound-id> (I131) tositumomab, ISV-205, <compound-id="132999">ivabradine hydrochloride</compound-id>, <compound-id="6445540">ixabepilone</compound-id>; <compound-id="5284583">Levetiracetam</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="441401">linezolid</compound-id>, liposomal NDDP, <compound-id="148195">lonafarnib</compound-id>, <compound-id="92727">lopinavir</compound-id>, <compound-id="219018">LY-156735</compound-id>; <compound-id="9908997">Mafosfamide cyclohexylamine salt</compound-id>, <compound-id="24083">magnesium sulfate</compound-id>, <compound-id="6398761">maxacalcitol</compound-id>, <compound-id="119192">meclinertant</compound-id>, <compound-id="183797">melagatran</compound-id>, <compound-id="896">melatonin</compound-id>, <protein-id="Q9BUN1">MENT</protein-id>, <compound-id="56603701">mepolizumab</compound-id>, <compound-id="477468,6602291">micafungin sodium</compound-id>, <compound-id="16760627,24202429,71719722,9829523">midostaurin</compound-id>, <compound-id="151071">motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; Nesiritide, NS-1209, NSC-601316, <compound-id="54608508,6918289">NSC-683864</compound-id>; <compound-id="219077">Osanetant</compound-id>; <compound-id="6337614">Palonosetron</compound-id> hydrochloride, <compound-id="119828">parecoxib</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="56603655">pegaptanib</compound-id> <compound-id="5360545">sodium</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="10819">perillyl alcohol</compound-id>, <compound-id="7975">picoplatin</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="134019">pixantrone maleate</compound-id>, <compound-id="213022">plevitrexed</compound-id>, polyglutamate <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">paclitaxel</compound-id>, posurdex, <compound-id="16132446">pramlintide acetate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; Rasburicase, <compound-id="104850">rimonabant</compound-id> hydrochloride, <compound-id="56841693,6918321,71306999">rostaporfin</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">rosuvastatin calcium</compound-id>; <compound-id="65015">SDZ-SID-791</compound-id>, sibrotuzumab, <compound-id="216239">sorafenib</compound-id>, SU-11248; <compound-id="110635">Tadalafil</compound-id>, <compound-id="132862">targinine</compound-id>, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="11693521,17753754,21881641,22525209,23958736,24847865,3002190,46783745,5462516,5496803,70789201,71306735,73658">telithromycin</compound-id>, TheraCIM, <compound-id="54686904">tigecycline</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="110634">Vardenafil hydrochloride hydrate</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="92400">Zofenopril calcium</compound-id>, <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	escitalopram oxalate__MENT__no_interaction	escitalopram oxalate__CD154__no_interaction	escitalopram oxalate__insulin__no_interaction	eplerenone__MENT__no_interaction	eplerenone__CD154__no_interaction	eplerenone__insulin__no_interaction	rimonabant__MENT__no_interaction	rimonabant__CD154__no_interaction	rimonabant__insulin__no_interaction	ertapenem sodium__MENT__no_interaction	ertapenem sodium__CD154__no_interaction	ertapenem sodium__insulin__no_interaction	Valdecoxib__MENT__no_interaction	Valdecoxib__CD154__no_interaction	Valdecoxib__insulin__no_interaction	gadolinium__MENT__no_interaction	gadolinium__CD154__no_interaction	gadolinium__insulin__no_interaction	Fondaparinux sodium__MENT__no_interaction	Fondaparinux sodium__CD154__no_interaction	Fondaparinux sodium__insulin__no_interaction	Levetiracetam__MENT__no_interaction	Levetiracetam__CD154__no_interaction	Levetiracetam__insulin__no_interaction	sodium__MENT__no_interaction	sodium__CD154__no_interaction	sodium__insulin__no_interaction	asimadoline__MENT__no_interaction	asimadoline__CD154__no_interaction	asimadoline__insulin__no_interaction	exatecan__MENT__no_interaction	exatecan__CD154__no_interaction	exatecan__insulin__no_interaction	ezetimibe__MENT__no_interaction	ezetimibe__CD154__no_interaction	ezetimibe__insulin__no_interaction	3,4-DAP__MENT__no_interaction	3,4-DAP__CD154__no_interaction	3,4-DAP__insulin__no_interaction	eniluracil__MENT__no_interaction	eniluracil__CD154__no_interaction	eniluracil__insulin__no_interaction	pegaptanib__MENT__no_interaction	pegaptanib__CD154__no_interaction	pegaptanib__insulin__no_interaction	Zoledronic acid monohydrate__MENT__no_interaction	Zoledronic acid monohydrate__CD154__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	paclitaxel__MENT__no_interaction	paclitaxel__CD154__no_interaction	paclitaxel__insulin__no_interaction	bryostatin 1__MENT__no_interaction	bryostatin 1__CD154__no_interaction	bryostatin 1__insulin__no_interaction	plevitrexed__MENT__no_interaction	plevitrexed__CD154__no_interaction	plevitrexed__insulin__no_interaction	levocetirizine__MENT__no_interaction	levocetirizine__CD154__no_interaction	levocetirizine__insulin__no_interaction	lopinavir__MENT__no_interaction	lopinavir__CD154__no_interaction	lopinavir__insulin__no_interaction	Tadalafil__MENT__no_interaction	Tadalafil__CD154__no_interaction	Tadalafil__insulin__no_interaction	maxacalcitol__MENT__no_interaction	maxacalcitol__CD154__no_interaction	maxacalcitol__insulin__no_interaction	Vardenafil hydrochloride hydrate__MENT__no_interaction	Vardenafil hydrochloride hydrate__CD154__no_interaction	Vardenafil hydrochloride hydrate__insulin__no_interaction	erlosamide__MENT__no_interaction	erlosamide__CD154__no_interaction	erlosamide__insulin__no_interaction	Palonosetron__MENT__no_interaction	Palonosetron__CD154__no_interaction	Palonosetron__insulin__no_interaction	tigecycline__MENT__no_interaction	tigecycline__CD154__no_interaction	tigecycline__insulin__no_interaction	FR-901228__MENT__no_interaction	FR-901228__CD154__no_interaction	FR-901228__insulin__no_interaction	Gefitinib__MENT__no_interaction	Gefitinib__CD154__no_interaction	Gefitinib__insulin__no_interaction	rostaporfin__MENT__no_interaction	rostaporfin__CD154__no_interaction	rostaporfin__insulin__no_interaction	ivabradine hydrochloride__MENT__no_interaction	ivabradine hydrochloride__CD154__no_interaction	ivabradine hydrochloride__insulin__no_interaction	perillyl alcohol__MENT__no_interaction	perillyl alcohol__CD154__no_interaction	perillyl alcohol__insulin__no_interaction	CDP__MENT__no_interaction	CDP__CD154__no_interaction	CDP__insulin__no_interaction	eszopiclone__MENT__no_interaction	eszopiclone__CD154__no_interaction	eszopiclone__insulin__no_interaction	FTY__MENT__no_interaction	FTY__CD154__no_interaction	FTY__insulin__no_interaction	pramlintide acetate__MENT__no_interaction	pramlintide acetate__CD154__no_interaction	pramlintide acetate__insulin__no_interaction	targinine__MENT__no_interaction	targinine__CD154__no_interaction	targinine__insulin__no_interaction	ixabepilone__MENT__no_interaction	ixabepilone__CD154__no_interaction	ixabepilone__insulin__no_interaction	binodenoson__MENT__no_interaction	binodenoson__CD154__no_interaction	binodenoson__insulin__no_interaction	melagatran__MENT__no_interaction	melagatran__CD154__no_interaction	melagatran__insulin__no_interaction	pemetrexed disodium__MENT__no_interaction	pemetrexed disodium__CD154__no_interaction	pemetrexed disodium__insulin__no_interaction	mepolizumab__MENT__no_interaction	mepolizumab__CD154__no_interaction	mepolizumab__insulin__no_interaction	gepirone__MENT__no_interaction	gepirone__CD154__no_interaction	gepirone__insulin__no_interaction	Ximelagatran__MENT__no_interaction	Ximelagatran__CD154__no_interaction	Ximelagatran__insulin__no_interaction	9-aminocamptothecin__MENT__no_interaction	9-aminocamptothecin__CD154__no_interaction	9-aminocamptothecin__insulin__no_interaction	midostaurin__MENT__no_interaction	midostaurin__CD154__no_interaction	midostaurin__insulin__no_interaction	magnesium sulfate__MENT__no_interaction	magnesium sulfate__CD154__no_interaction	magnesium sulfate__insulin__no_interaction	picoplatin__MENT__no_interaction	picoplatin__CD154__no_interaction	picoplatin__insulin__no_interaction	caspofungin acetate__MENT__no_interaction	caspofungin acetate__CD154__no_interaction	caspofungin acetate__insulin__no_interaction	Zofenopril calcium__MENT__no_interaction	Zofenopril calcium__CD154__no_interaction	Zofenopril calcium__insulin__no_interaction	lonafarnib__MENT__no_interaction	lonafarnib__CD154__no_interaction	lonafarnib__insulin__no_interaction	Valganciclovir hydrochloride__MENT__no_interaction	Valganciclovir hydrochloride__CD154__no_interaction	Valganciclovir hydrochloride__insulin__no_interaction	186Re__MENT__no_interaction	186Re__CD154__no_interaction	186Re__insulin__no_interaction	bosentan__MENT__no_interaction	bosentan__CD154__no_interaction	bosentan__insulin__no_interaction	arsenic__MENT__no_interaction	arsenic__CD154__no_interaction	arsenic__insulin__no_interaction	aprepitant__MENT__no_interaction	aprepitant__CD154__no_interaction	aprepitant__insulin__no_interaction	exenatide__MENT__no_interaction	exenatide__CD154__no_interaction	exenatide__insulin__no_interaction	LY-156735__MENT__no_interaction	LY-156735__CD154__no_interaction	LY-156735__insulin__no_interaction	meclinertant__MENT__no_interaction	meclinertant__CD154__no_interaction	meclinertant__insulin__no_interaction	pixantrone maleate__MENT__no_interaction	pixantrone maleate__CD154__no_interaction	pixantrone maleate__insulin__no_interaction	Imatinib mesylate__MENT__no_interaction	Imatinib mesylate__CD154__no_interaction	Imatinib mesylate__insulin__no_interaction	tirapazamine__MENT__no_interaction	tirapazamine__CD154__no_interaction	tirapazamine__insulin__no_interaction	esomeprazole magnesium__MENT__no_interaction	esomeprazole magnesium__CD154__no_interaction	esomeprazole magnesium__insulin__no_interaction	CB-1954__MENT__no_interaction	CB-1954__CD154__no_interaction	CB-1954__insulin__no_interaction	tipifarnib__MENT__no_interaction	tipifarnib__CD154__no_interaction	tipifarnib__insulin__no_interaction	eplivanserin__MENT__no_interaction	eplivanserin__CD154__no_interaction	eplivanserin__insulin__no_interaction	arginine__MENT__no_interaction	arginine__CD154__no_interaction	arginine__insulin__no_interaction	Mafosfamide cyclohexylamine salt__MENT__no_interaction	Mafosfamide cyclohexylamine salt__CD154__no_interaction	Mafosfamide cyclohexylamine salt__insulin__no_interaction	prasterone__MENT__no_interaction	prasterone__CD154__no_interaction	prasterone__insulin__no_interaction	pregabalin__MENT__no_interaction	pregabalin__CD154__no_interaction	pregabalin__insulin__no_interaction	telithromycin__MENT__no_interaction	telithromycin__CD154__no_interaction	telithromycin__insulin__no_interaction	motexafin__MENT__no_interaction	motexafin__CD154__no_interaction	motexafin__insulin__no_interaction	desloratadine__MENT__no_interaction	desloratadine__CD154__no_interaction	desloratadine__insulin__no_interaction	ozogamicin__MENT__no_interaction	ozogamicin__CD154__no_interaction	ozogamicin__insulin__no_interaction	aripiprazole__MENT__no_interaction	aripiprazole__CD154__no_interaction	aripiprazole__insulin__no_interaction	micafungin sodium__MENT__no_interaction	micafungin sodium__CD154__no_interaction	micafungin sodium__insulin__no_interaction	decitabine__MENT__no_interaction	decitabine__CD154__no_interaction	decitabine__insulin__no_interaction	NSC-683864__MENT__no_interaction	NSC-683864__CD154__no_interaction	NSC-683864__insulin__no_interaction	iodine__MENT__no_interaction	iodine__CD154__no_interaction	iodine__insulin__no_interaction	SDZ-SID-791__MENT__no_interaction	SDZ-SID-791__CD154__no_interaction	SDZ-SID-791__insulin__no_interaction	parecoxib__MENT__no_interaction	parecoxib__CD154__no_interaction	parecoxib__insulin__no_interaction	BQ-123__MENT__no_interaction	BQ-123__CD154__no_interaction	BQ-123__insulin__no_interaction	cerivastatin sodium__MENT__no_interaction	cerivastatin sodium__CD154__no_interaction	cerivastatin sodium__insulin__no_interaction	melatonin__MENT__no_interaction	melatonin__CD154__no_interaction	melatonin__insulin__no_interaction	tiotropium bromide__MENT__no_interaction	tiotropium bromide__CD154__no_interaction	tiotropium bromide__insulin__no_interaction	duloxetine hydrochloride__MENT__no_interaction	duloxetine hydrochloride__CD154__no_interaction	duloxetine hydrochloride__insulin__no_interaction	glargine__MENT__no_interaction	glargine__CD154__no_interaction	glargine__insulin__no_interaction	O6-Benzylguanine__MENT__no_interaction	O6-Benzylguanine__CD154__no_interaction	O6-Benzylguanine__insulin__no_interaction	DHA-paclitaxel__MENT__no_interaction	DHA-paclitaxel__CD154__no_interaction	DHA-paclitaxel__insulin__no_interaction	linezolid__MENT__no_interaction	linezolid__CD154__no_interaction	linezolid__insulin__no_interaction	tegaserod maleate__MENT__no_interaction	tegaserod maleate__CD154__no_interaction	tegaserod maleate__insulin__no_interaction	pimecrolimus__MENT__no_interaction	pimecrolimus__CD154__no_interaction	pimecrolimus__insulin__no_interaction	clevidipine__MENT__no_interaction	clevidipine__CD154__no_interaction	clevidipine__insulin__no_interaction	treprostinil sodium__MENT__no_interaction	treprostinil sodium__CD154__no_interaction	treprostinil sodium__insulin__no_interaction	Osanetant__MENT__no_interaction	Osanetant__CD154__no_interaction	Osanetant__insulin__no_interaction	sorafenib__MENT__no_interaction	sorafenib__CD154__no_interaction	sorafenib__insulin__no_interaction	rosuvastatin calcium__MENT__no_interaction	rosuvastatin calcium__CD154__no_interaction	rosuvastatin calcium__insulin__no_interaction	eletriptan__MENT__no_interaction	eletriptan__CD154__no_interaction	eletriptan__insulin__no_interaction
20345144-5	The predicted total rate constants for (1)CH(2) + N(2) at 760 Torr Ar pressure can be represented by the expressions s-k(total) = 9.67 x 10(+7) x T (-6.88) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id> (-1345/T) cm(3) molecule(-1) s(-1) at T = 300-2400 K and 3.15 x 10(-229) x T (+56.18) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id> (128 000/T) cm(3) molecule(-1) s(-1) at T = 2400-3000 K. The branching ratios of the primary channels for (1)CH(2) + N(2) are predicted: k(1) for forming singlet s-CH(2)N(2)-a (<compound-id="9550">diazomethane</compound-id>) accounts for 0.97-0.01, k(2) + k(4) for producing HCNN-a + H accounts for 0.00-0.69, k(3) for forming singlet s-CH(2)N(2)-b (<compound-id="78958">3H-diazirine</compound-id>) accounts for 0.03-0.00, k(5) for producing HCN + NH accounts for 0.00-0.18, and k(6) for producing CNNH + H accounts for 0.00-0.11 in the temperature range of 300-3000 K. The rate constant predicted for the unimoclecular decomposition of <compound-id="9550">diazomethane</compound-id> producing (1)CH(2) + N(2) agrees closely with experimental results.	diazomethane__exp__no_interaction	3H-diazirine__exp__no_interaction
11912547-5	The obese children presented the following characteristics in comparison to the non-obese group: significantly high levels of <protein-id="P01308,I3WAC9">insulin</protein-id> (8.2 +/- 0.52 v 6.12 +/- 0.34 microU/mL), triglycerides (TG) (0.79 +/- 0.04 v 0.60 +/- 0.02 mmol/L), <compound-id="1175">uric acid</compound-id> (0.24 +/- 0.005 v 0.21 +/- 0.004 mmol/L), systolic (<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>) (94.59 +/- 1.06 v 88.85 +/- 1.2 mm Hg) and diastolic (56.49 +/- 1.07 v 52.21 +/- 1.06 mm Hg) blood pressure (<protein-id="Q10586">DBP</protein-id>), and low levels of high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) (1.30 +/- 0.04 v 1.46 +/- 0.03 mmol/L), and nonesterified fatty acids (0.407 +/- 0.02 v 0.505 +/- 0.02 mmol/L).	uric acid__DBP__no_interaction	uric acid__SBP__no_interaction	uric acid__insulin__no_interaction	cholesterol__DBP__no_interaction	cholesterol__SBP__no_interaction	cholesterol__insulin__no_interaction
16175401-7	Assessment of glutamatergic agents indicated that the mGlu1 receptor antagonist <compound-id="9926999">LY456236</compound-id> (10-30 mg/kg), mGlu5 receptor antagonist <compound-id="3025961">MPEP</compound-id> (10-30 mg/kg), mGlu2/3 receptor agonist <compound-id="213056">LY354740</compound-id> (3-10 mg/kg), mGlu2 receptor potentiator LY566332 (30 and 100 mg/kg), mGlu8 receptor agonist (S)-<compound-id="16202239">3,4-dicarboxyphenylglycine</compound-id> (30-60 mg/kg), competitive NMDA receptor antagonist <compound-id="131938">LY235959</compound-id> (1 mg/kg), AMPA receptor antagonist GYKI-52466 (10-20 mg/kg), and <compound-id="45934207,750">glycine</compound-id> transporter-1 (<protein-id="P28571">GlyT-1</protein-id>) inhibitor <compound-id="6604909">ALX-5407</compound-id> (3-10 mg/kg) dose-dependently attenuated stress-induced hyperthermia.	LY235959__GlyT-1__no_interaction	3,4-dicarboxyphenylglycine__GlyT-1__no_interaction	LY354740__GlyT-1__no_interaction	glycine__GlyT-1__no_interaction	ALX-5407__GlyT-1__no_interaction	LY456236__GlyT-1__no_interaction	MPEP__GlyT-1__no_interaction
16061781-6	RESULTS: There was univariate association (P &lt; .01) between WC and height (r = 0.73), BMI (r = 0.96), Tanner stage (r = 0.67), age (r = 0.56), systolic BP (r = 0.64), diastolic BP (r = 0.61), high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level (r = 0.45), triglyceride level (r = 0.28), <protein-id="P01308,I3WAC9">proinsulin</protein-id> level (r = 0.59), and HOMA-IR (r = 0.59).	cholesterol__proinsulin__no_interaction
17031383-4	KEY RESULTS: OLETF rats exhibited (vs. age-matched LETO rats): (1) greater potentiation of high-K(+)-induced contraction by 10 microM LPC - a potentiation attenuated by 10 microM <compound-id="5280961">genistein</compound-id>, protein <compound-id="6057,90983769">tyrosine</compound-id> kinase (PTK) inhibitor, (2) greater potentiation of UK14,304 (10 approximately 100 nM)-induced contractions by LPC (1 microM approximately 10 microM) - a potentiation attenuated by 10 microM <compound-id="5280961">genistein</compound-id>, 50 microM <compound-id="2052">tyrphostin A23</compound-id> (PTK inhibitor) or 10 microM <compound-id="4713">PD98059</compound-id> (<protein-id="P36506">MEK 1/2</protein-id> inhibitor), (3) greater basal and LPC (1 microM)-induced ERK activities, (4) greater basal and 100 nM UK14,304-stimulated <protein-id="P63086">ERK2</protein-id> activities in both the absence and presence of 10 microM LPC, (5) greater SOV (10 microM approximately 3 mM)-induced contractions, (6) greater potentiation of SOV-induced contractions by 10 microM LPC - a potentiation suppressed by 10 microM <compound-id="4713">PD98059</compound-id> or 10 microM <compound-id="5280961">genistein</compound-id>, (7) upregulation of <protein-id="Q4KLH9">GPR4</protein-id> mRNA.	PD98059__ERK2__no_interaction	PD98059__MEK 1/2__no_interaction	PD98059__GPR4__no_interaction	tyrphostin A23__ERK2__no_interaction	tyrphostin A23__MEK 1/2__no_interaction	tyrphostin A23__GPR4__no_interaction	tyrosine__ERK2__no_interaction	tyrosine__MEK 1/2__no_interaction	tyrosine__GPR4__no_interaction	genistein__ERK2__no_interaction	genistein__MEK 1/2__no_interaction	genistein__GPR4__no_interaction
20108767-5	RESULTS: The number of peripheral <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ T cells in group pre-HAART was decreased compared with group HAART (P &lt; 0.01); the frequency of CD3+ <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ T cells in group pre-HAART were decreased compared with group HAART (P &lt; 0.01), the frequency of <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P13612">CD49d</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P14151,A0A024R8Z0">CD62L</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+ CD45RO , <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51686,B2R734">CCR9</protein-id>+ CD45RO- ,<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ CD45RO+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ CD45RO- T cells in group pre-HAART were significantly decreased compared with group HAART (P &lt; 0.001); the frequency of CD3+ <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P14151,A0A024R8Z0">CD62L</protein-id>+, <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ <protein-id="P51681,Q38L21">CCR5</protein-id>+ T cells in group HAART were significantly decreased compared with group HIV-<compound-id="11118411">neg</compound-id> (P &lt; 0.05).	neg__CD4__no_interaction	neg__CCR9__no_interaction	neg__CD62L__no_interaction	neg__CCR5__no_interaction	neg__CD49d__no_interaction
1852119-3	In 21-day-old SHR fed 0.1 vs. 3.6% Ca diet for 14 days, increasing dietary Ca had no significant effects on basal [704 +/- 50 in 0.1% Ca vs. 784 +/- 61 ng angiotensin I (<compound-id="44299732">ANG I</compound-id>).mg-1.h-1 in 3.6% Ca, P = not significant (NS)], <compound-id="3779">isoproterenol</compound-id>-stimulated (1,057 +/- 52 in 0.1% Ca vs. 1,104 +/- 59 ng <compound-id="44299732">ANG I</compound-id>.mg-1.h-1 in 3.6% Ca, P = NS), or <protein-id="P01015">angiotensin II</protein-id> (<protein-id="Q5GAM5">ANG II</protein-id>)-inhibited (370 +/- 50 in 0.1% Ca vs. 411 +/- 39 ng <compound-id="44299732">ANG I</compound-id>.mg-1.h-1 in 3.6% Ca, P = NS) renal superficial cortical slice renin release.	isoproterenol__angiotensin II__no_interaction	isoproterenol__ANG II__no_interaction	ANG I__angiotensin II__no_interaction	ANG I__ANG II__no_interaction
15148527-3	This issue focuses on the following selection of drugs: ABI-007, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, alefacept, alemtuzumab, <compound-id="9571836">3-AP</compound-id>, AP-12009, APC-8015, <compound-id="6322">L-Arginine hydrochloride</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="208925">arundic acid</compound-id>, <compound-id="166558">avasimibe</compound-id>; Bevacizumab, bivatuzumab, <compound-id="101524">BMS-181176</compound-id>, BMS-184476, BMS-188797, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="16219006,443289,52943236">BQ-123</compound-id>, BRL-55730, <compound-id="16760328,22524140,433902,44277532,5458769,5477635,6435419">bryostatin 1</compound-id>; <compound-id="56603757">CEP-1347</compound-id>, cetuximab, <compound-id="156419">cinacalcet hydrochloride</compound-id>, <compound-id="6445782">CP-461</compound-id>, CpG-7909; D-003, <compound-id="216249">dabuzalgron</compound-id> hydrochloride, darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="447865,6440032,6918680">desoxyepothilone B</compound-id>, <compound-id="154101">dexmethylphenidate hydrochloride</compound-id>, <compound-id="6918473">DHA-paclitaxel</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="5280453">DN-101</compound-id>, <compound-id="9810955">DP-b99</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride, duramycin; Eculizumab, Efalizumab, <compound-id="6445562">EKB-569</compound-id>, <compound-id="108059">elcometrine</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="443872">eplerenone</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="151115">exatecan</compound-id> mesilate, <compound-id="150311">ezetimibe</compound-id>; <compound-id="5288209">Fenretinide</compound-id>, <compound-id="131536">fosamprenavir calcium</compound-id>, <compound-id="77992">frovatriptan</compound-id>; GD2L-KLH conjugate vaccine, <compound-id="123631">gefitinib</compound-id>, <compound-id="123628">glufosfamide</compound-id>, <compound-id="56842148">GTI-2040</compound-id>; Hexyl <protein-id="P01308,I3WAC9">insulin</protein-id> M2, human <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="785,91156575">hydroquinone</compound-id>, gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>; <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id>(38-37)-PE38KDEL, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="216468">indisulam</compound-id>, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="6445540">ixabepilone</compound-id>; KRN-5500; <compound-id="56603730">LY-544344</compound-id>; MDX-210, <compound-id="896">melatonin</compound-id>, <compound-id="56603701">mepolizumab</compound-id>, <compound-id="151071">motexafin</compound-id> <compound-id="23982">gadolinium</compound-id>; Natalizumab, <compound-id="6505803">NSC-330507</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; 1-<compound-id="57024563,957">Octanol</compound-id>, omalizumab, <compound-id="6918412">ortataxel</compound-id>; <compound-id="131664">Pagoclone</compound-id>, peginterferon alfa-2a, peginterferon alfa-2b, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="219100">phenoxodiol</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="213022">plevitrexed</compound-id>, polyphenon E, <compound-id="16132446">pramlintide acetate</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="219104">PX-12</compound-id>; <compound-id="60866">QS-21</compound-id>; <compound-id="447458">Ragaglitazar</compound-id>, <compound-id="3052774">ranelic acid distrontium salt</compound-id>, <compound-id="124970">RDP</compound-id>-58, recombinant glucagon-like peptide-1 (7-36) <compound-id="2826723">amide</compound-id>, <compound-id="198757">repinotan</compound-id> hydrochloride, rhEndostatin, rh-Lactoferrin, (R)-<compound-id="160355">roscovitine</compound-id>; S-8184, <compound-id="5329098">semaxanib</compound-id>, <compound-id="461399">sitafloxacin hydrate</compound-id>, sitaxsentan <compound-id="5360545">sodium</compound-id>, <compound-id="216239">sorafenib</compound-id>, <compound-id="9895066">synthadotin</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="108092">tesmilifene hydrochloride</compound-id>, theratope, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="219022">topixantrone hydrochloride</compound-id>, <compound-id="108150">trabectedin</compound-id>, <compound-id="219101">traxoprodil</compound-id>, <compound-id="5538">Tri-Luma</compound-id>; <compound-id="119607">Valdecoxib</compound-id>, <compound-id="64147">valganciclovir hydrochloride</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="16135415">Ziconotide</compound-id>.	eplerenone__IL-4__no_interaction	eplerenone__insulin__no_interaction	NSC-683864__IL-4__no_interaction	NSC-683864__insulin__no_interaction	LY-544344__IL-4__no_interaction	LY-544344__insulin__no_interaction	QS-21__IL-4__no_interaction	QS-21__insulin__no_interaction	avasimibe__IL-4__no_interaction	avasimibe__insulin__no_interaction	Ragaglitazar__IL-4__no_interaction	Ragaglitazar__insulin__no_interaction	ertapenem sodium__IL-4__no_interaction	ertapenem sodium__insulin__no_interaction	bortezomib__IL-4__no_interaction	bortezomib__insulin__no_interaction	NSC-330507__IL-4__no_interaction	NSC-330507__insulin__no_interaction	Ximelagatran__IL-4__no_interaction	Ximelagatran__insulin__no_interaction	desloratadine__IL-4__no_interaction	desloratadine__insulin__no_interaction	BQ-123__IL-4__no_interaction	BQ-123__insulin__no_interaction	Valdecoxib__IL-4__no_interaction	Valdecoxib__insulin__no_interaction	bosentan__IL-4__no_interaction	bosentan__insulin__no_interaction	gadolinium__IL-4__no_interaction	gadolinium__insulin__no_interaction	DN-101__IL-4__no_interaction	DN-101__insulin__no_interaction	trabectedin__IL-4__no_interaction	trabectedin__insulin__no_interaction	ezetimibe__IL-4__no_interaction	ezetimibe__insulin__no_interaction	topixantrone hydrochloride__IL-4__no_interaction	topixantrone hydrochloride__insulin__no_interaction	melatonin__IL-4__no_interaction	melatonin__insulin__no_interaction	CEP-1347__IL-4__no_interaction	CEP-1347__insulin__no_interaction	vinflunine__IL-4__no_interaction	vinflunine__insulin__no_interaction	erlotinib hydrochloride__IL-4__no_interaction	erlotinib hydrochloride__insulin__no_interaction	roscovitine__IL-4__no_interaction	roscovitine__insulin__no_interaction	elcometrine__IL-4__no_interaction	elcometrine__insulin__no_interaction	sodium__IL-4__no_interaction	sodium__insulin__no_interaction	ortataxel__IL-4__no_interaction	ortataxel__insulin__no_interaction	cinacalcet hydrochloride__IL-4__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	repinotan__IL-4__no_interaction	repinotan__insulin__no_interaction	PX-12__IL-4__no_interaction	PX-12__insulin__no_interaction	phenoxodiol__IL-4__no_interaction	phenoxodiol__insulin__no_interaction	Tri-Luma__IL-4__no_interaction	Tri-Luma__insulin__no_interaction	semaxanib__IL-4__no_interaction	semaxanib__insulin__no_interaction	pramlintide acetate__IL-4__no_interaction	pramlintide acetate__insulin__no_interaction	pregabalin__IL-4__no_interaction	pregabalin__insulin__no_interaction	Fenretinide__IL-4__no_interaction	Fenretinide__insulin__no_interaction	Octanol__IL-4__no_interaction	Octanol__insulin__no_interaction	dexmethylphenidate hydrochloride__IL-4__no_interaction	dexmethylphenidate hydrochloride__insulin__no_interaction	eszopiclone__IL-4__no_interaction	eszopiclone__insulin__no_interaction	exatecan__IL-4__no_interaction	exatecan__insulin__no_interaction	3-AP__IL-4__no_interaction	3-AP__insulin__no_interaction	RDP__IL-4__no_interaction	RDP__insulin__no_interaction	pimecrolimus__IL-4__no_interaction	pimecrolimus__insulin__no_interaction	indisulam__IL-4__no_interaction	indisulam__insulin__no_interaction	tipifarnib__IL-4__no_interaction	tipifarnib__insulin__no_interaction	valganciclovir hydrochloride__IL-4__no_interaction	valganciclovir hydrochloride__insulin__no_interaction	Ziconotide__IL-4__no_interaction	Ziconotide__insulin__no_interaction	arundic acid__IL-4__no_interaction	arundic acid__insulin__no_interaction	gefitinib__IL-4__no_interaction	gefitinib__insulin__no_interaction	glufosfamide__IL-4__no_interaction	glufosfamide__insulin__no_interaction	DHA-paclitaxel__IL-4__no_interaction	DHA-paclitaxel__insulin__no_interaction	tesmilifene hydrochloride__IL-4__no_interaction	tesmilifene hydrochloride__insulin__no_interaction	ixabepilone__IL-4__no_interaction	ixabepilone__insulin__no_interaction	L-Arginine hydrochloride__IL-4__no_interaction	L-Arginine hydrochloride__insulin__no_interaction	synthadotin__IL-4__no_interaction	synthadotin__insulin__no_interaction	traxoprodil__IL-4__no_interaction	traxoprodil__insulin__no_interaction	dabuzalgron__IL-4__no_interaction	dabuzalgron__insulin__no_interaction	DP-b99__IL-4__no_interaction	DP-b99__insulin__no_interaction	tirapazamine__IL-4__no_interaction	tirapazamine__insulin__no_interaction	CP-461__IL-4__no_interaction	CP-461__insulin__no_interaction	pemetrexed disodium__IL-4__no_interaction	pemetrexed disodium__insulin__no_interaction	mepolizumab__IL-4__no_interaction	mepolizumab__insulin__no_interaction	prasterone__IL-4__no_interaction	prasterone__insulin__no_interaction	imatinib mesylate__IL-4__no_interaction	imatinib mesylate__insulin__no_interaction	Tadalafil__IL-4__no_interaction	Tadalafil__insulin__no_interaction	frovatriptan__IL-4__no_interaction	frovatriptan__insulin__no_interaction	motexafin__IL-4__no_interaction	motexafin__insulin__no_interaction	amide__IL-4__no_interaction	amide__insulin__no_interaction	GTI-2040__IL-4__no_interaction	GTI-2040__insulin__no_interaction	bryostatin 1__IL-4__no_interaction	bryostatin 1__insulin__no_interaction	diflomotecan__IL-4__no_interaction	diflomotecan__insulin__no_interaction	fosamprenavir calcium__IL-4__no_interaction	fosamprenavir calcium__insulin__no_interaction	sitafloxacin hydrate__IL-4__no_interaction	sitafloxacin hydrate__insulin__no_interaction	plevitrexed__IL-4__no_interaction	plevitrexed__insulin__no_interaction	sorafenib__IL-4__no_interaction	sorafenib__insulin__no_interaction	desoxyepothilone B__IL-4__no_interaction	desoxyepothilone B__insulin__no_interaction	adefovir dipivoxil__IL-4__no_interaction	adefovir dipivoxil__insulin__no_interaction	Pagoclone__IL-4__no_interaction	Pagoclone__insulin__no_interaction	enfuvirtide__IL-4__no_interaction	enfuvirtide__insulin__no_interaction	aripiprazole__IL-4__no_interaction	aripiprazole__insulin__no_interaction	BMS-181176__IL-4__no_interaction	BMS-181176__insulin__no_interaction	ranelic acid distrontium salt__IL-4__no_interaction	ranelic acid distrontium salt__insulin__no_interaction	hydroquinone__IL-4__no_interaction	hydroquinone__insulin__no_interaction	EKB-569__IL-4__no_interaction	EKB-569__insulin__no_interaction	duloxetine__IL-4__no_interaction	duloxetine__insulin__no_interaction
18307903-4	RESULTS: (1) Compared with patients with a negative family history of diabetes mellitus, for women with a positive family history, WHR (0.99 +/- 0.10 vs 0.79 +/- 0.08) and score of hirsutism (1.9 +/- 1.2 vs 1.8 +/- 1.2) were increased, the duration of menstruation was longer [(108 +/- 10) vs (92 +/- 19) days]; A [(11 +/- 6) vs (8 +/- 5) nmol/L], homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR, 3.5 +/- 2.0 vs 2.7 +/- 1.6), area under curve (AUC) <compound-id="206,64689,79025">glucose</compound-id> [(836 +/- 245) vs (748 +/- 139) nmol.L(-1).min(-1)], AUC <protein-id="P01308,I3WAC9">insulin</protein-id> [(9670 +/- 4582) vs (7330 +/- 4311) mIU.L(-1).min(-1)], fasting <compound-id="206,64689,79025">glucose</compound-id> [(5.0 +/- 1.1) vs (4.8 +/- 0.5) mmol/L] and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> [(15 +/- 8) vs (11 +/- 8) mIU/L] were increased, while early <protein-id="P01308,I3WAC9">insulin</protein-id> secretion function index (DeltaI60/DeltaG60, 32 +/- 22 vs 52 +/- 30), <protein-id="P01308,I3WAC9">insulin</protein-id> sensitive index (ISI, 0.019 +/- 0.011 vs 0.033 +/- 0.014) and disposition index (DI, 18 +/- 10 vs 30 +/- 22; P &lt; 0.05) were decreased.	glucose__insulin__no_interaction
22311497-5	DN0: UAER &lt; 30 mg/24 h, DN1: UAER 30-300 mg/24 h and DN2: UAER &gt; 300 mg/24 h. RESULTS: Statistics showed: (1) Genotype frequencies and allele frequencies in <protein-id="O15123">Ang-2</protein-id> <compound-id="6440895">1233A</compound-id>/G had significant difference but not <protein-id="O15123">Ang-2</protein-id> 759T/G and 1078A/G; (2) Comparing with those with genotype AA, the relative risk of genotype (AG+ GG) suffered from T2DM and DN were 2.265 fold (OR= 2.265, 95% CI: 1.223-1.402, P= 0.031), 1.789 fold (OR= 1.789, 95% CI: 0.889-1.021, P= 0.012), respectively; (3) The onset of DN was related to <protein-id="O15123">Ang-2</protein-id> <compound-id="6440895">1233A</compound-id>/G allele G (r= 1.321, OR= 1.427, 95% CI: 2.324-4.177, P= 0.034).	1233A__Ang-2__no_interaction
7684452-3	Example compounds such as [1R-[1 alpha[R*(R*)],2 beta]]-4-[[2-[[3-(1H-indol-3-yl)- 2-methyl-2-[[[(2-methylcyclohexyl)oxy]carbonyl]amino]-1- oxopropyl]-amino]-<compound-id="137551">1-phenylethyl</compound-id>]amino]-<compound-id="1112">4-oxo-butanoic acid</compound-id> (24c), (1R-trans)-N-[alpha-methyl-N-[[(2-methylcyclohexyl)oxy] carbonyl]-D-<compound-id="17962040">tryptophyl</compound-id>]-L-3-(<compound-id="123147">phenylmethyl</compound-id>)-<compound-id="20275471">beta-alanine</compound-id> (28i), and N-[alpha-methyl-N-[(tricyclo[3.3.1.1]dec-2-yloxy) carbonyl]-D-tryptophanyl]-L-3-(<compound-id="123147">phenylmethyl</compound-id>)-<compound-id="20275471">beta-alanine</compound-id> (30m) are <protein-id="P01355">CCK</protein-id>-B selective compounds having <protein-id="P01355">CCK</protein-id>-B binding affinities of IC50 = 3.9, 0.34, and 0.15 nM with a <protein-id="P01355">CCK</protein-id>-A/<protein-id="P01355">CCK</protein-id>-B ratio of 464, 53, and 170, respectively.	4-oxo-butanoic acid__CCK__no_interaction	1-phenylethyl__CCK__no_interaction	tryptophyl__CCK__no_interaction	beta-alanine__CCK__no_interaction	phenylmethyl__CCK__no_interaction
18158437-10	RESULTS: Key recommendations, listed by category, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition (1C); blood cultures before antibiotic therapy (1C); imaging studies performed promptly to confirm potential source of infection (1C); administration of broad-spectrum antibiotic therapy within 1 hr of diagnosis of septic shock (1B) and severe sepsis without septic shock (1D); reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate (1C); a usual 7-10 days of antibiotic therapy guided by clinical response (1D); source control with attention to the balance of risks and benefits of the chosen method (1C); administration of either crystalloid or colloid fluid resuscitation (1B); fluid challenge to restore mean circulating filling pressure (1C); reduction in rate of fluid administration with rising filing pressures and no improvement in tissue perfusion (1D); vasopressor preference for <compound-id="439260">norepinephrine</compound-id> or <compound-id="681">dopamine</compound-id> to maintain an initial target of mean arterial pressure &gt; or = 65 mm Hg (1C); <compound-id="36811">dobutamine</compound-id> inotropic therapy when cardiac output remains low despite fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy given only in septic shock after blood pressure is identified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated <protein-id="P04070">protein C</protein-id> in patients with severe sepsis and clinical assessment of high risk for death (2B except 2C for postoperative patients).	norepinephrine__protein C__no_interaction	dobutamine__protein C__no_interaction	dopamine__protein C__no_interaction
15340100-2	Investigational antiobesity agents consist of 1) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (<compound-id="444">bupropion</compound-id>), selective <compound-id="5202">serotonin</compound-id> 2c receptor agonists, antiseizure agents (<compound-id="5284627">topiramate</compound-id>, <compound-id="5734">zonisamide</compound-id>), some <compound-id="681">dopamine</compound-id> antagonists, and cannabinoid-1 receptor antagonists (<compound-id="104850">rimonabant</compound-id>); 2) <compound-id="90470904">leptin</compound-id>/<protein-id="P01308,I3WAC9">insulin</protein-id>/central nervous system pathway agents, including <compound-id="90470904">leptin</compound-id> analogues, <compound-id="90470904">leptin</compound-id> transport and/or <compound-id="90470904">leptin</compound-id> receptor promoters, ciliary neurotrophic factor (Axokine), neuropeptide Y and agouti-related peptide antagonists, <protein-id="P01189,Q6FHC8">proopiomelanocortin</protein-id> and <compound-id="446220">cocaine</compound-id> and <compound-id="3007">amphetamine</compound-id> regulated transcript promoters, alpha-melanocyte-stimulating hormone analogues, melanocortin-4 receptor agonists, and agents that affect <protein-id="P01308,I3WAC9">insulin</protein-id> metabolism/activity, which include protein-<compound-id="6057,90983769">tyrosine</compound-id> phosphatase-1B inhibitors, peroxisome proliferator activated receptor-gamma receptor antagonists, short-acting bromocriptine (ergoset), somatostatin agonists (<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id>), and adiponectin; 3) gastrointestinal-neural pathway agents, including those that increase <compound-id="16129670">cholecystokinin</compound-id> activity, increase glucagon-like peptide-1 activity (extendin 4, liraglutide, dipeptidyl peptidase IV inhibitors), and increase protein YY3-36 activity and those that decrease <compound-id="44576256">ghrelin</compound-id> activity, as well as amylin analogues (pramlintide); 4) agents that may increase resting metabolic rate ("selective" beta-3 stimulators/agonist, uncoupling protein homologues, and thyroid receptor agonists); and 5) other more diverse agents, including <compound-id="6325610">melanin</compound-id> concentrating hormone antagonists, phytostanol analogues, functional oils, <protein-id="P49918">P57</protein-id>, amylase inhibitors, growth hormone fragments, synthetic analogues of <compound-id="12594">dehydroepiandrosterone sulfate</compound-id>, antagonists of adipocyte 11B-hydroxysteroid dehydrogenase type 1 activity, corticotropin-releasing hormone agonists, inhibitors of fatty acid synthesis, carboxypeptidase inhibitors, indanones/indanols, aminosterols, and other gastrointestinal <compound-id="5474737">lipase</compound-id> inhibitors (<compound-id="9952916">ATL962</compound-id>).	tyrosine__P57__no_interaction	tyrosine__proopiomelanocortin__no_interaction	tyrosine__insulin__no_interaction	leptin__P57__no_interaction	leptin__proopiomelanocortin__no_interaction	leptin__insulin__no_interaction	ATL962__P57__no_interaction	ATL962__proopiomelanocortin__no_interaction	ATL962__insulin__no_interaction	rimonabant__P57__no_interaction	rimonabant__proopiomelanocortin__no_interaction	rimonabant__insulin__no_interaction	melanin__P57__no_interaction	melanin__proopiomelanocortin__no_interaction	melanin__insulin__no_interaction	serotonin__P57__no_interaction	serotonin__proopiomelanocortin__no_interaction	serotonin__insulin__no_interaction	dehydroepiandrosterone sulfate__P57__no_interaction	dehydroepiandrosterone sulfate__proopiomelanocortin__no_interaction	dehydroepiandrosterone sulfate__insulin__no_interaction	zonisamide__P57__no_interaction	zonisamide__proopiomelanocortin__no_interaction	zonisamide__insulin__no_interaction	topiramate__P57__no_interaction	topiramate__proopiomelanocortin__no_interaction	topiramate__insulin__no_interaction	octreotide__P57__no_interaction	octreotide__proopiomelanocortin__no_interaction	octreotide__insulin__no_interaction	dopamine__P57__no_interaction	dopamine__proopiomelanocortin__no_interaction	dopamine__insulin__no_interaction	ghrelin__P57__no_interaction	ghrelin__proopiomelanocortin__no_interaction	ghrelin__insulin__no_interaction	cocaine__P57__no_interaction	cocaine__proopiomelanocortin__no_interaction	cocaine__insulin__no_interaction	amphetamine__P57__no_interaction	amphetamine__proopiomelanocortin__no_interaction	amphetamine__insulin__no_interaction	cholecystokinin__P57__no_interaction	cholecystokinin__proopiomelanocortin__no_interaction	cholecystokinin__insulin__no_interaction	lipase__P57__no_interaction	lipase__proopiomelanocortin__no_interaction	lipase__insulin__no_interaction	bupropion__P57__no_interaction	bupropion__proopiomelanocortin__no_interaction	bupropion__insulin__no_interaction
11926545-5	<protein-id="O95999">Carmen</protein-id> contained the following 8 <compound-id="8030">thiophene</compound-id> compounds: <compound-id="70813">5-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (<compound-id="446505">BBT</compound-id>), <compound-id="3083681">5'-methyl-5-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (MeBBT), <compound-id="15737449">5-(1-pentynyl)-2,2'-bithienyl</compound-id> (PBT), <compound-id="440357">5-(4-hydroxy-1-butynyl)-2,2'-bithienyl</compound-id> (BBTOH), 2,2',5,2"-terthienyl (<compound-id="6278">alpha-T</compound-id>), <compound-id="440356">5-(4-acetoxy-1-butynyl)-2,2'-bithienyl</compound-id> (BBTOAc), <compound-id="90928524">5-methylaceto-5'-(3-buten-1-ynyl)-2,2'-bithienyl</compound-id> (AcOCH2BBT), and <compound-id="440404">5-(3,4-diacetoxy-1-butynyl)-2,2'-bithienyl</compound-id> (<compound-id="446505">BBT</compound-id>(OAc)2).	5-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	5'-methyl-5-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	5-(1-pentynyl)-2,2'-bithienyl__Carmen__no_interaction	thiophene__Carmen__no_interaction	5-(3,4-diacetoxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	5-(4-hydroxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	5-methylaceto-5'-(3-buten-1-ynyl)-2,2'-bithienyl__Carmen__no_interaction	alpha-T__Carmen__no_interaction	5-(4-acetoxy-1-butynyl)-2,2'-bithienyl__Carmen__no_interaction	BBT__Carmen__no_interaction
10417506-6	RESULTS: The mean concentrations of <compound-id="33741">tramadol</compound-id> during the postsurgery phase were 470+/-323 ng <protein-id="Q9NTI2">ml-1</protein-id>, 590+/-410 ng <protein-id="Q9NTI2">ml-1</protein-id> and 771+/-451 ng <protein-id="Q9NTI2">ml-1</protein-id> in the (+)-, racemate- and (-)-group, respectively ((+) vs (-), P&lt;0.05); the mean concentrations of the metabolite M1 were 57+/-18 ng <protein-id="Q9NTI2">ml-1</protein-id>, 84+/-34 ng <protein-id="Q9NTI2">ml-1</protein-id> and 96+/-41 ng <protein-id="Q9NTI2">ml-1</protein-id> in the (+)-, racemate- and (-)-group, respectively ((+) vs (-) and (+) vs racemate, P&lt;0.05).	tramadol__ml-1__no_interaction
7555001-3	Comparison of various pharmacokinetic parameters of quinidine (Cmax 2.165 +/- 0.457 vs 2.239 +/- 0.338 micrograms/ml, Tmax 2 +/- 0.71 vs 2.13 +/- 0.58 h, T1/2 7.004 +/- 1.302 vs 7.82 +/- 1.63 h, <protein-id="P51812,B7ZB17,B4DG22">Cls</protein-id>/f 153.63 +/- 45.65 vs 134.87 +/- 31 ml/h/kg, AUC0-alpha 22.131 +/- 6.118 vs 24.321 +/- 4.924 micrograms.h/ml) by means of a two tailed t-test revealed no significant (p &gt; 0.05) effect of <compound-id="3016">diazepam</compound-id> on quinidine disposition kinetics.	diazepam__Cls__no_interaction
24222953-11	When comparing <protein-id="P35639,Q3V405">CHOP</protein-id>(-/-) mice and WT mice, we observed that <protein-id="P35639,Q3V405">CHOP</protein-id>-deficient mice had greater increases in serum TNF-α (214.40 ± 19.52 pg/mL vs 150.40 ± 16.70 pg/mL; P = 0.037), amylase (4236.40 ± 646.32 U/L vs 2535.30 ± 81.83 U/L; P = 0.041), <compound-id="5474737">lipase</compound-id> (1678.20 ± 170.57 U/L vs 1046.21 ± 35.37 U/L; P = 0.008), and <protein-id="P08505,A2RTD1">IL-6</protein-id> (2054.44 ± 293.81 pg/mL vs 1316.10 ± 108.74 pg/mL; P = 0.046) than WT mice.	lipase__CHOP__no_interaction	lipase__IL-6__no_interaction
18793405-7	Although there were no significant treatment differentials between the age groups for these efficacy measures, the age groups themselves, regardless of treatment, were significantly different for ADHD-<compound-id="7021454">RS</compound-id> total (younger: <protein-id="Q13822">ATX</protein-id> = -14.2 [13.8], PBO = -4.6 [10.4]; older: <protein-id="Q13822">ATX</protein-id> = -15.4 [13.2], PBO = -7.3 [12.0]; p = .001), total T (younger: <protein-id="Q13822">ATX</protein-id> = -15.2 [14.8], PBO = -4.9 [11.2]; older: <protein-id="Q13822">ATX</protein-id> = -16.4 [14.6], PBO = -7.9 [13.1]; p = .003), and subscale scores (Inattentive: younger: <protein-id="Q13822">ATX</protein-id> = -7.2 [7.5], PBO = -2.4 [5.7]; older: <protein-id="Q13822">ATX</protein-id> = -8.0 [7.4], PBO = -3.9 [6.7]; p = .043; Hyperactive/Impulsive: younger: <protein-id="Q13822">ATX</protein-id> = -7.0 [7.2], PBO = -2.1 [5.4]; older: <protein-id="Q13822">ATX</protein-id> = -7.3 [7.0], PBO = -3.4 [6.3]; p &lt; .001), as well as the CGI-ADHD-S score (younger: <protein-id="Q13822">ATX</protein-id> = -1.2 [1.3], PBO = -0.5 [0.9]; older: <protein-id="Q13822">ATX</protein-id> = -1.4 [1.3], PBO = -0.7 [1.1]; p = .010).	RS__ATX__no_interaction
15968308-9	In univariate prognostic analysis model, the OS was higher in <protein-id="P17927,E9PDY4">CR1</protein-id> group pre-HSCT than that in non-<protein-id="P17927,E9PDY4">CR1</protein-id> group (74.50% vs 22.22%, P=0.0046), <compound-id="76871876">LFS</compound-id> was higher (49.06% vs 11.11%, P=0.0057), RI was lower (44.80% vs 84.76%, P=0.0157); the OS was higher in M(<protein-id="P11274">BCR/ABL</protein-id>) group than that in m(<protein-id="P11274">BCR/ABL</protein-id>) group (100% vs 40.91%, P=0.0318), <compound-id="76871876">LFS</compound-id> was higher (75% vs 17.72%, P=0.0057), RI was lower (25% vs 77.88, P=0.0116); OS was similar in HLA MM RD group to that in HLA identical group (52.65% vs 55.56%, P=0.6247), <compound-id="76871876">LFS</compound-id> was similar (45.12% vs 30.00%, P=0.8315), and RI was also similar (50.77% vs 60.62%, P=0.8217).	LFS__BCR/ABL__no_interaction	LFS__CR1__no_interaction
21560328-8	RESULTS: (1) The results determined by dry-weight method indicated that <compound-id="962">water</compound-id> content of rats brain increased markedly after rats were exposed to a simulated altitude at 6 000 m, 8 000 m. (2) The results determined by microscopy indicated that during the rats exposed to hypoxia, nerve cells, vascular endothelial cells and astrocyte foot processes swelled lightly, transudate occurred in tissues at 4 000 m. The swelling of vascular endothelial cell (<compound-id="2735038">VEC</compound-id>) and astrocyte foot processes aggravated, interspace between vessels and tissues enlarged, and transudate in tissue increased at 6 000 m. The swelling of <compound-id="2735038">VEC</compound-id> and astrocyte foot processes went from bad to worse, interspace between vessels and tissues enlarged further, and transudate in tissue increased evidently at 8 000 m. (3) During hypoxic encephaledema, the expression of <protein-id="P16612,Q541S7,A0A0G2K6Z7,B5DEK7">VEGF</protein-id>, <protein-id="P29975">AQP1</protein-id> and <protein-id="P47863,A0A0G2K4I1,A0A0H2UHZ1">AQP4</protein-id> mRNA increased, <protein-id="P29975">AQP1</protein-id> was abnormally expressed on the surface of <compound-id="2735038">VEC</compound-id>, and the expressive level of <protein-id="P16612,Q541S7,A0A0G2K6Z7,B5DEK7">VEGF</protein-id> and <protein-id="P29975">AQP1</protein-id> on <compound-id="2735038">VEC</compound-id> and <protein-id="P47863,A0A0G2K4I1,A0A0H2UHZ1">AQP4</protein-id> on astrocyte foot processes increased.	water__AQP4__no_interaction	water__VEGF__no_interaction	water__AQP1__no_interaction	VEC__AQP4__no_interaction	VEC__VEGF__no_interaction	VEC__AQP1__no_interaction
21154263-7	RESULTS: There were significant differences between three-vessel CAD patients and control groups with respect to the serum levels of: hsCRP (2.8 vs 1.4 mg/L, p = 0.01), HDL-<compound-id="5997">cholesterol</compound-id> (45 vs 54 mg/dL, p = 0.04), LDL-<compound-id="5997">cholesterol</compound-id> (102 vs 95 mg/dL, p = 0.04), NT-proBNP (392 vs 151 pg/mL, p = 0.008) and a marker of angiogenetic activity, <protein-id="P03950,W0UV28">angiogenin</protein-id> (414 vs 275 ng/mL, p = 0.02), However, no significant differences were found between three-vessel CAD and the control group with respect to the serum level of <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (8.08 vs 7.82 μg/mL), <protein-id="Q9HD89">resistin</protein-id> (17.5 vs 21 ng/mL), <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (20.7 vs 26.8 pg/mL) and <protein-id="P01375,Q5STB3">TNF-a</protein-id> (4.1 vs 4.3 pg/mL).	cholesterol__angiogenin__no_interaction	cholesterol__resistin__no_interaction	cholesterol__IL-8__no_interaction	cholesterol__TNF-a__no_interaction	cholesterol__adiponectin__no_interaction
10348797-4	Evidence that human hepatic <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> and 2D6 catalyze the formation of tam catechol from <compound-id="449459">4-OH-tam</compound-id> and supportive data that the catechol is proximate to the reactive intermediate, was obtained: 1) There was a good correlation (r = 0.82; p &lt;/=.0004) between steroidal 6beta-hydroxylase (CYP3A activity) and ortho hydroxylation of <compound-id="449459">4-OH-tam</compound-id> in human liver microsomes; 2) monospecific antibodies against <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> strongly inhibited catechol formation from <compound-id="449459">4-OH-tam</compound-id> and its covalent binding to proteins in human liver microsomes; 3) low levels of <compound-id="3823,456201,47576,5702077">ketoconazole</compound-id> inhibited catechol tam accumulation and covalent binding of <compound-id="449459">4-OH-tam</compound-id> to human liver proteins; 4) among human P-450s expressed in insect cells (supersomes), only <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> and 2D6 noticeably catalyzed catechol formation, and <protein-id="P00167">cytochrome b5</protein-id> markedly stimulated the <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> catalysis; and 5) human livers with high CYP3A and low or high <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> activity exhibited high catechol formation and those with low <compound-id="2981881,91293124">3A</compound-id> and 2D6 activities formed only little catechol.	4-OH-tam__CYP3A4__no_interaction	4-OH-tam__cytochrome b5__no_interaction	4-OH-tam__CYP2D6__no_interaction	3A__CYP3A4__no_interaction	3A__cytochrome b5__no_interaction	3A__CYP2D6__no_interaction	ketoconazole__CYP3A4__no_interaction	ketoconazole__cytochrome b5__no_interaction	ketoconazole__CYP2D6__no_interaction
10396370-13	In men, E1-FA levels also correlated with systolic blood pressure (r = 0.59, P = 0.01), total triglycerides (r = 0.63, P = 0.003), VLDL-triglycerides (r = 0.62, P = 0.004) and VLDL-<compound-id="5997">cholesterol</compound-id> (r = 0.48, P = 0.03), but not with diastolic blood pressure, serum total or LDL-<compound-id="5997">cholesterol</compound-id>, or total and <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> and HDL3 subfractions of HDL <compound-id="5997">cholesterol</compound-id>.	cholesterol__HDL2__no_interaction
10396370-15	In women, E1-FA levels correlated with total triglycerides (r = 0.66, P = 0.001), VLDL-triglycerides (r = 0.65, P = 0.001), VLDL-<compound-id="5997">cholesterol</compound-id> (r = 0.63, P = 0.002), LDL-<compound-id="5997">cholesterol</compound-id> (r = 0.57, P = 0.005) and total and <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL2</protein-id> and HDL3 subfractions of HDL <compound-id="5997">cholesterol</compound-id> (r = -0.58, -0.48, -0.61, P = 0.004, 0.02 and 0.002, respectively), but not with systolic or diastolic blood pressure or total <compound-id="5997">cholesterol</compound-id>.	cholesterol__HDL2__no_interaction
10587445-2	It reveals that (i) D1-D2-Cyt b(559) complexes either in solubilized form or incorporated into liposomes contain only one type of Cyt b(559) with E(m) values of 60 +/- 5 and 100 +/- 10 mV, respectively, at pH 6.8; (ii) in <compound-id="977">oxygen</compound-id>-evolving solubilized <protein-id="P49810,E5RG63">PS II</protein-id> core complexes Cyt b(559) exists predominantly (&gt;85%) as an LP form with an E(m,7) of 125 +/- 10 mV and a minor fraction with an E(m,7) of -150 +/- 15 mV; (iii) in <compound-id="977">oxygen</compound-id>-evolving <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments three different redox forms are discernible with E(m) values of 390 +/- 15 mV (HP form), 230 +/- 20 mV (IP form), and 105 +/- 25 mV (LP form) and relative amplitudes of 58, 24, and 18%, respectively, at pH 7.3; (iv) the E(m) values are almost pH-independent between pH 6 and 9.5 in all sample types except D1-D2-Cyt b(559) complexes incorporated into liposomes with a slope of -29 mV/pH unit, when the pH increases from 6 to 9.5 (IP and LP form in <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments possibly within a restricted range from pH 6.5 to 8); (v) at pH &gt;8 the HP Cyt b(559) progressively converts to the IP form with increasing pH; (vi) the reduced-minus-oxidized optical difference spectra of Cyt b(559) are very similar in the lambda range of 360-700 nm for all types except for the HP form which exhibits pronounced differences in the Soret band; and (vii) <protein-id="P49810,E5RG63">PS II</protein-id> membrane fragments and core complexes are inferred to contain about two Cyt b(559) hemes per <protein-id="P49810,E5RG63">PS II</protein-id>.	oxygen__PS II__no_interaction
23505173-4	Thyroid stimulating hormone (TSH) correlated with BMI (r = 0.46; P = 0.02), both visceral (r = 0.58; P = 0.02) and subcutaneous adipose tissue volumes (r = 0.43; P = 0.03) and <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (inverse relationship with <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity-<compound-id="206,5793,64689,79025">glucose</compound-id> uptake: r = -0.40; P = 0.04).	glucose__insulin__no_interaction
23074401-31	The following conclusions were drawn from the entire body of evidence: There is a lack of external validation to support the reliability of Oncotype-DX; however, the current available evidence derived from internal industry validation studies suggests that Oncotype-DX is reliable (i.e., Oncotype-DX is repeatable and reproducible).Current available evidence suggests a moderate failure rate of Oncotype-DX testing; however, the failure rate observed across clinical trials included in this review is likely inflated; the current Ontario experience suggests an acceptably lower rate of test failure.In women with newly diagnosed early breast cancer (stage I-II) that is estrogen-receptor positive and/or <compound-id="5994">progesterone</compound-id>-receptor positive and lymph-node negative:There is low quality evidence that Oncotype-DX has prognostic value in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id> or <compound-id="2187">anastrozole</compound-id> (the latter for postmenopausal women only),There is very low quality evidence that Oncotype-DX can predict which women will benefit from adjuvant CMF/MF chemotherapy in women being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id>.In postmenopausal women with newly diagnosed early breast cancer that is estrogen-receptor positive and/or <compound-id="5994">progesterone</compound-id>-receptor positive and lymph-node positive:There is low quality evidence that Oncotype-DX has limited prognostic value in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id> or <compound-id="2187">anastrozole</compound-id>,There is very low quality evidence that Oncotype-DX has limited predictive value for predicting which women will benefit from adjuvant <protein-id="Q92831">CAF</protein-id> chemotherapy in women who are being treated with adjuvant <compound-id="2733526">tamoxifen</compound-id>.There are methodological and statistical limitations that affect both the generalizability of the current available evidence, as well as the magnitude and statistical strength of the observed effect sizes; in particular:Of the major predictive trials, Oncotype-DX scores were only produced for a small subset of women (&lt;40% of the original randomized population) potentially disabling the effects of treatment randomization and opening the possibility of selection bias;Data is not specific to <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">HER-2</protein-id>/<protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">neu</protein-id>-negative women;There were limitations with multivariate statistical analyses.Additional trials of observational design may provide further validation of the prognostic and predictive value of Oncotype-DX; however, it is unlikely that prospective or randomized data will become available in the near future due to ethical, time and resource considerations.There is currently insufficient evidence investigating how Oncoytpe-DX compares to other known prognostic estimators of risk, such as Adjuvant!	anastrozole__HER-2__no_interaction	anastrozole__neu__no_interaction	anastrozole__CAF__no_interaction	tamoxifen__HER-2__no_interaction	tamoxifen__neu__no_interaction	tamoxifen__CAF__no_interaction	progesterone__HER-2__no_interaction	progesterone__neu__no_interaction	progesterone__CAF__no_interaction
12168506-3	This issue focuses on the following selection of drugs: <compound-id="441300">Abacavir sulfate</compound-id>, <compound-id="16131215">abarelix</compound-id>, abciximab, <compound-id="16197724">alicaforsen sodium</compound-id>, <compound-id="123606">almotriptan</compound-id>, alteplase, <compound-id="2162">amlodipine</compound-id>, <compound-id="33613">amoxicillin trihydrate</compound-id>, <compound-id="65016">amprenavir</compound-id>, <compound-id="152951,2232,440542,445156,92722">argatroban</compound-id> <compound-id="1488787">monohydrate</compound-id>, <compound-id="2244">aspirin</compound-id>, <compound-id="60823">atorvastatin calcium</compound-id>, <compound-id="2265">azathioprine</compound-id>; <compound-id="2284">Baclofen</compound-id>, <compound-id="656668">benidipine</compound-id> hydrochloride, <compound-id="2327">benserazide</compound-id>, <compound-id="448545">BMS-214662</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B; <compound-id="2540">Candesartan cilexetil</compound-id>, <compound-id="2554">carbamazepine</compound-id>, carbidopa, <compound-id="2568">carboplatin</compound-id>, <compound-id="5479530,11957492,12971801,5361919,2657,5896995,6398678">ceftriaxone sodium</compound-id>, <compound-id="2662">celecoxib</compound-id>, <compound-id="2678">cetirizine hydrochloride</compound-id>, <compound-id="84029">clarithromycin</compound-id>, <compound-id="5280980">clavulanate potassium</compound-id>, <compound-id="2806,60606">clopidogrel hydrogensulfate</compound-id>, <compound-id="2818">clozapine</compound-id>, <compound-id="151118">CPI-1189</compound-id>, <compound-id="2907">cyclophosphamide</compound-id>, <compound-id="6253">cytarabine</compound-id>; Darbepoetin alfa, denileukin diftitox, <compound-id="5743">dexamethasone</compound-id>, <compound-id="3108">dipyridamole</compound-id>, <compound-id="3168">droperidol</compound-id>, DW-166HC; <compound-id="3191">Ebastine</compound-id>, efalizumab, <compound-id="64139">efavirenz</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="5388962">enalapril</compound-id> <compound-id="444266">maleate</compound-id>, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="57199466,772">enoxaparin</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="178103">enrasentan</compound-id>, <compound-id="5281081">entacapone</compound-id>, <protein-id="P01588,G9JKG7">epoetin</protein-id>, <compound-id="5281037">eprosartan mesilate</compound-id>, etanercept, <compound-id="123619">etoricoxib</compound-id>; Fenofibratefexofenadine hydrochloride, filgrastim, <compound-id="30751">fludarabine phosphate</compound-id>, <compound-id="3386">fluoxetine hydrochloride</compound-id> <compound-id="5324346">fluvoxamine maleate</compound-id>, <compound-id="77992">frovatriptan</compound-id>, <compound-id="3440">furosemide</compound-id>; <compound-id="3446">Gabapentin</compound-id>, <compound-id="9651">galantamine hydrobromide</compound-id>, <compound-id="5379">gatifloxacin</compound-id>, <compound-id="123631">gefitinib</compound-id>, <compound-id="44576256">ghrelin</compound-id> (human), <compound-id="3081884">glatiramer acetate</compound-id>; <compound-id="3559">Haloperidol</compound-id>; <compound-id="3672">Ibuprofen</compound-id>, <compound-id="3672">ibuprofen</compound-id>, <compound-id="460">guaiacol</compound-id> ester, <compound-id="42890">idarubicin hydrochloride</compound-id>, <compound-id="3696">imipramine hydrochloride</compound-id>, <compound-id="57469">imiquimod</compound-id>, <protein-id="P01574">interferon beta</protein-id>, <protein-id="P01574">interferon beta</protein-id>-1a, <protein-id="P01574">interferon beta</protein-id>-1b, interferon omega, <compound-id="3749">irbesartan</compound-id>, <compound-id="55283">itraconazole</compound-id>; Ketorolac, <compound-id="3826">ketorolac tromethamine</compound-id>; <compound-id="3038484">Lamifiban</compound-id>, <compound-id="3878">lamotrigine</compound-id>, lanoteplase, <compound-id="3883">lansoprazole</compound-id>, <compound-id="3899">leflunomide</compound-id>, <compound-id="657181">leuprorelin acetate</compound-id>, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="6047">levodopa</compound-id>, <compound-id="5362119">lisinopril</compound-id>, <compound-id="3957">loratadine</compound-id>; <compound-id="4008">Manidipine</compound-id>, <compound-id="6741">methylprednisolone</compound-id>, <compound-id="4173">metronidazole</compound-id>, <compound-id="4205">mirtazapine</compound-id>, <compound-id="65906">mizolastine</compound-id>, modafinil, <compound-id="5288826">morphine sulfate</compound-id>; <compound-id="156391">Naproxen sodium</compound-id>, <compound-id="4440">naratriptan hydrochloride</compound-id>, <compound-id="4485">nifedipine</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>; <compound-id="4583">Ofloxacin</compound-id>, <compound-id="4585">olanzapine</compound-id>, omalizumab, <compound-id="656629">omapatrilat</compound-id>, <compound-id="4595">ondansetron hydrochloride</compound-id>, <compound-id="34312">oxcarbazepine</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>, <compound-id="119828">parecoxib sodium</compound-id>, <compound-id="43815">paroxetine hydrochloride</compound-id>, <compound-id="1775">phenytoin sodium</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="4885,119570,59868">pramipexole hydrochloride</compound-id>, <compound-id="54687">pravastatin</compound-id>, <compound-id="5865">prednisone</compound-id>, <compound-id="5486971">pregabalin</compound-id>; <compound-id="5002">Quetiapine fumarate</compound-id>; <compound-id="3001055">Ranitidine hydrochloride</compound-id>, rasburicase, <compound-id="392622">ritonavir</compound-id>, <compound-id="14254240,6918078,71296087,77990">rivastigmine tartrate</compound-id>, <compound-id="77997">rizatriptan benzoate</compound-id>, <compound-id="5090">rofecoxib</compound-id>; <compound-id="441243">Saquinavir mesilate</compound-id>, <compound-id="68617">sertraline</compound-id>, <compound-id="5212">sildenafil citrate</compound-id>, <compound-id="54454">simvastatin</compound-id>, <compound-id="5358">sumatriptan succinate</compound-id>; <compound-id="445643,90726579">Tacrolimus</compound-id>, <compound-id="60648">tiagabine hydrochloride</compound-id>, <compound-id="5472">ticlopidine hydrochloride</compound-id>, <compound-id="60947">tirofiban hydrochloride</compound-id>, <compound-id="216237">tolvaptan</compound-id>, <compound-id="5284627">topiramate</compound-id>, <compound-id="444795">tretinoin</compound-id>; <compound-id="3121">Valproic acid</compound-id>, <compound-id="60846">valsartan</compound-id>, <compound-id="5656">venlafaxine hydrochloride</compound-id>, <compound-id="2520">verapamil</compound-id>; <compound-id="54678486">Warfarin</compound-id> <compound-id="5360545">sodium</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="60855">Zanamivir</compound-id>, <compound-id="16135415">ziconotide</compound-id>, <compound-id="60857">zolmitriptan</compound-id>, <compound-id="5734">zonisamide</compound-id>.	BMS-214662__epoetin__no_interaction	BMS-214662__interferon beta__no_interaction	sertraline__epoetin__no_interaction	sertraline__interferon beta__no_interaction	Lamifiban__epoetin__no_interaction	Lamifiban__interferon beta__no_interaction	dipyridamole__epoetin__no_interaction	dipyridamole__interferon beta__no_interaction	fluoxetine hydrochloride__epoetin__no_interaction	fluoxetine hydrochloride__interferon beta__no_interaction	argatroban__epoetin__no_interaction	argatroban__interferon beta__no_interaction	sodium__epoetin__no_interaction	sodium__interferon beta__no_interaction	Ofloxacin__epoetin__no_interaction	Ofloxacin__interferon beta__no_interaction	fludarabine phosphate__epoetin__no_interaction	fludarabine phosphate__interferon beta__no_interaction	idarubicin hydrochloride__epoetin__no_interaction	idarubicin hydrochloride__interferon beta__no_interaction	Zanamivir__epoetin__no_interaction	Zanamivir__interferon beta__no_interaction	atorvastatin calcium__epoetin__no_interaction	atorvastatin calcium__interferon beta__no_interaction	Warfarin__epoetin__no_interaction	Warfarin__interferon beta__no_interaction	Valproic acid__epoetin__no_interaction	Valproic acid__interferon beta__no_interaction	zolmitriptan__epoetin__no_interaction	zolmitriptan__interferon beta__no_interaction	Tacrolimus__epoetin__no_interaction	Tacrolimus__interferon beta__no_interaction	celecoxib__epoetin__no_interaction	celecoxib__interferon beta__no_interaction	galantamine hydrobromide__epoetin__no_interaction	galantamine hydrobromide__interferon beta__no_interaction	morphine sulfate__epoetin__no_interaction	morphine sulfate__interferon beta__no_interaction	abarelix__epoetin__no_interaction	abarelix__interferon beta__no_interaction	enoxaparin__epoetin__no_interaction	enoxaparin__interferon beta__no_interaction	ziconotide__epoetin__no_interaction	ziconotide__interferon beta__no_interaction	rizatriptan benzoate__epoetin__no_interaction	rizatriptan benzoate__interferon beta__no_interaction	Candesartan cilexetil__epoetin__no_interaction	Candesartan cilexetil__interferon beta__no_interaction	levocetirizine__epoetin__no_interaction	levocetirizine__interferon beta__no_interaction	sildenafil citrate__epoetin__no_interaction	sildenafil citrate__interferon beta__no_interaction	ceftriaxone sodium__epoetin__no_interaction	ceftriaxone sodium__interferon beta__no_interaction	enrasentan__epoetin__no_interaction	enrasentan__interferon beta__no_interaction	fluvoxamine maleate__epoetin__no_interaction	fluvoxamine maleate__interferon beta__no_interaction	furosemide__epoetin__no_interaction	furosemide__interferon beta__no_interaction	valsartan__epoetin__no_interaction	valsartan__interferon beta__no_interaction	alicaforsen sodium__epoetin__no_interaction	alicaforsen sodium__interferon beta__no_interaction	oxcarbazepine__epoetin__no_interaction	oxcarbazepine__interferon beta__no_interaction	ibuprofen__epoetin__no_interaction	ibuprofen__interferon beta__no_interaction	clozapine__epoetin__no_interaction	clozapine__interferon beta__no_interaction	tirofiban hydrochloride__epoetin__no_interaction	tirofiban hydrochloride__interferon beta__no_interaction	rofecoxib__epoetin__no_interaction	rofecoxib__interferon beta__no_interaction	pravastatin__epoetin__no_interaction	pravastatin__interferon beta__no_interaction	verapamil__epoetin__no_interaction	verapamil__interferon beta__no_interaction	Paclitaxel__epoetin__no_interaction	Paclitaxel__interferon beta__no_interaction	itraconazole__epoetin__no_interaction	itraconazole__interferon beta__no_interaction	lisinopril__epoetin__no_interaction	lisinopril__interferon beta__no_interaction	venlafaxine hydrochloride__epoetin__no_interaction	venlafaxine hydrochloride__interferon beta__no_interaction	benidipine__epoetin__no_interaction	benidipine__interferon beta__no_interaction	benserazide__epoetin__no_interaction	benserazide__interferon beta__no_interaction	monohydrate__epoetin__no_interaction	monohydrate__interferon beta__no_interaction	leflunomide__epoetin__no_interaction	leflunomide__interferon beta__no_interaction	gefitinib__epoetin__no_interaction	gefitinib__interferon beta__no_interaction	carboplatin__epoetin__no_interaction	carboplatin__interferon beta__no_interaction	leuprorelin acetate__epoetin__no_interaction	leuprorelin acetate__interferon beta__no_interaction	topiramate__epoetin__no_interaction	topiramate__interferon beta__no_interaction	clarithromycin__epoetin__no_interaction	clarithromycin__interferon beta__no_interaction	phenytoin sodium__epoetin__no_interaction	phenytoin sodium__interferon beta__no_interaction	tiagabine hydrochloride__epoetin__no_interaction	tiagabine hydrochloride__interferon beta__no_interaction	loratadine__epoetin__no_interaction	loratadine__interferon beta__no_interaction	Gabapentin__epoetin__no_interaction	Gabapentin__interferon beta__no_interaction	droperidol__epoetin__no_interaction	droperidol__interferon beta__no_interaction	ticlopidine hydrochloride__epoetin__no_interaction	ticlopidine hydrochloride__interferon beta__no_interaction	Ximelagatran__epoetin__no_interaction	Ximelagatran__interferon beta__no_interaction	efavirenz__epoetin__no_interaction	efavirenz__interferon beta__no_interaction	rivastigmine tartrate__epoetin__no_interaction	rivastigmine tartrate__interferon beta__no_interaction	glatiramer acetate__epoetin__no_interaction	glatiramer acetate__interferon beta__no_interaction	imipramine hydrochloride__epoetin__no_interaction	imipramine hydrochloride__interferon beta__no_interaction	cyclophosphamide__epoetin__no_interaction	cyclophosphamide__interferon beta__no_interaction	NSC-683864__epoetin__no_interaction	NSC-683864__interferon beta__no_interaction	bosentan__epoetin__no_interaction	bosentan__interferon beta__no_interaction	amoxicillin trihydrate__epoetin__no_interaction	amoxicillin trihydrate__interferon beta__no_interaction	etoricoxib__epoetin__no_interaction	etoricoxib__interferon beta__no_interaction	imiquimod__epoetin__no_interaction	imiquimod__interferon beta__no_interaction	Baclofen__epoetin__no_interaction	Baclofen__interferon beta__no_interaction	ketorolac tromethamine__epoetin__no_interaction	ketorolac tromethamine__interferon beta__no_interaction	frovatriptan__epoetin__no_interaction	frovatriptan__interferon beta__no_interaction	Ranitidine hydrochloride__epoetin__no_interaction	Ranitidine hydrochloride__interferon beta__no_interaction	zonisamide__epoetin__no_interaction	zonisamide__interferon beta__no_interaction	metronidazole__epoetin__no_interaction	metronidazole__interferon beta__no_interaction	dexamethasone__epoetin__no_interaction	dexamethasone__interferon beta__no_interaction	enfuvirtide__epoetin__no_interaction	enfuvirtide__interferon beta__no_interaction	aspirin__epoetin__no_interaction	aspirin__interferon beta__no_interaction	maleate__epoetin__no_interaction	maleate__interferon beta__no_interaction	methylprednisolone__epoetin__no_interaction	methylprednisolone__interferon beta__no_interaction	tolvaptan__epoetin__no_interaction	tolvaptan__interferon beta__no_interaction	clavulanate potassium__epoetin__no_interaction	clavulanate potassium__interferon beta__no_interaction	entacapone__epoetin__no_interaction	entacapone__interferon beta__no_interaction	ritonavir__epoetin__no_interaction	ritonavir__interferon beta__no_interaction	carbamazepine__epoetin__no_interaction	carbamazepine__interferon beta__no_interaction	amlodipine__epoetin__no_interaction	amlodipine__interferon beta__no_interaction	lamotrigine__epoetin__no_interaction	lamotrigine__interferon beta__no_interaction	CPI-1189__epoetin__no_interaction	CPI-1189__interferon beta__no_interaction	Haloperidol__epoetin__no_interaction	Haloperidol__interferon beta__no_interaction	pregabalin__epoetin__no_interaction	pregabalin__interferon beta__no_interaction	enalapril__epoetin__no_interaction	enalapril__interferon beta__no_interaction	almotriptan__epoetin__no_interaction	almotriptan__interferon beta__no_interaction	Manidipine__epoetin__no_interaction	Manidipine__interferon beta__no_interaction	eprosartan mesilate__epoetin__no_interaction	eprosartan mesilate__interferon beta__no_interaction	Ibuprofen__epoetin__no_interaction	Ibuprofen__interferon beta__no_interaction	ghrelin__epoetin__no_interaction	ghrelin__interferon beta__no_interaction	levetiracetam__epoetin__no_interaction	levetiracetam__interferon beta__no_interaction	omapatrilat__epoetin__no_interaction	omapatrilat__interferon beta__no_interaction	mirtazapine__epoetin__no_interaction	mirtazapine__interferon beta__no_interaction	nifedipine__epoetin__no_interaction	nifedipine__interferon beta__no_interaction	azathioprine__epoetin__no_interaction	azathioprine__interferon beta__no_interaction	cytarabine__epoetin__no_interaction	cytarabine__interferon beta__no_interaction	pramipexole hydrochloride__epoetin__no_interaction	pramipexole hydrochloride__interferon beta__no_interaction	irbesartan__epoetin__no_interaction	irbesartan__interferon beta__no_interaction	mizolastine__epoetin__no_interaction	mizolastine__interferon beta__no_interaction	tretinoin__epoetin__no_interaction	tretinoin__interferon beta__no_interaction	lansoprazole__epoetin__no_interaction	lansoprazole__interferon beta__no_interaction	ondansetron hydrochloride__epoetin__no_interaction	ondansetron hydrochloride__interferon beta__no_interaction	clopidogrel hydrogensulfate__epoetin__no_interaction	clopidogrel hydrogensulfate__interferon beta__no_interaction	Saquinavir mesilate__epoetin__no_interaction	Saquinavir mesilate__interferon beta__no_interaction	simvastatin__epoetin__no_interaction	simvastatin__interferon beta__no_interaction	Naproxen sodium__epoetin__no_interaction	Naproxen sodium__interferon beta__no_interaction	cetirizine hydrochloride__epoetin__no_interaction	cetirizine hydrochloride__interferon beta__no_interaction	prednisone__epoetin__no_interaction	prednisone__interferon beta__no_interaction	amprenavir__epoetin__no_interaction	amprenavir__interferon beta__no_interaction	sumatriptan succinate__epoetin__no_interaction	sumatriptan succinate__interferon beta__no_interaction	naratriptan hydrochloride__epoetin__no_interaction	naratriptan hydrochloride__interferon beta__no_interaction	gatifloxacin__epoetin__no_interaction	gatifloxacin__interferon beta__no_interaction	Quetiapine fumarate__epoetin__no_interaction	Quetiapine fumarate__interferon beta__no_interaction	paroxetine hydrochloride__epoetin__no_interaction	paroxetine hydrochloride__interferon beta__no_interaction	pimecrolimus__epoetin__no_interaction	pimecrolimus__interferon beta__no_interaction	olanzapine__epoetin__no_interaction	olanzapine__interferon beta__no_interaction	parecoxib sodium__epoetin__no_interaction	parecoxib sodium__interferon beta__no_interaction	Abacavir sulfate__epoetin__no_interaction	Abacavir sulfate__interferon beta__no_interaction	levodopa__epoetin__no_interaction	levodopa__interferon beta__no_interaction	Ebastine__epoetin__no_interaction	Ebastine__interferon beta__no_interaction	guaiacol__epoetin__no_interaction	guaiacol__interferon beta__no_interaction	eletriptan__epoetin__no_interaction	eletriptan__interferon beta__no_interaction
20353389-8	Total hydroperoxide significantly correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> serum levels in the HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>+ (r = 0.47, p &lt; 0.05) and HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>- groups (r = 0.29, p &lt; 0.05), while <compound-id="170717">AOPP</compound-id> significantly correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> serum levels in the HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>+ (r = 0.73, p &lt; 0.05) and HIV+<protein-id="P52926,Q1M183,F5H2A4,F5H6H0">LIPO</protein-id>- (r = 0.54, p &lt; 0.05) groups.	AOPP__insulin__no_interaction	AOPP__LIPO__no_interaction
1838064-7	In Type 2 diabetic patients, HbA1c correlated positively with triglycerides (r = 0.70, p less than 0.001), <compound-id="5997">cholesterol</compound-id> (r = 0.60, p less than 0.001), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.77, p less than 0.001), and <protein-id="P02656,A3KPE2">apolipoprotein CIII</protein-id> (r = 0.55, p less than 0.001) and negatively with apolipoprotein <compound-id="15942654">AI</compound-id> (r = -0.49, p less than 0.001).	AI__apolipoprotein B__no_interaction	AI__apolipoprotein CIII__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein CIII__no_interaction
22641140-1	Six 3D architectures based on lanthanide-substituted polyoxometalosilicates, KLn[(H(2)O)(6)Ln](2)[(H(2)O)(4)LnSiW(11)O(39)](2)·nH(2)O (Ln = La 1, n = 42; <protein-id="O00748,A0A024R6X1">Ce 2</protein-id>, n = 40), H[(H(2)O)(6)Nd](2)[(H(2)O)(7)Nd][(H(2)O)(4)NdSiW(11)O(39)][(H(2)O)(3)NdSiW(11)O(39)]·13H(2)O (3), H(2)K(2)[(Hpic)(H(2)O)(5)Ln](2)[(H(2)O)(4)LnSiW(11)O(39)](2)·nH(2)O (Ln = <compound-id="78933">La 4</compound-id>, n = 18.5; Ce 5, n = 35; Nd 6, n = 36; Hpic = <compound-id="5922">4-picolinic acid</compound-id>), have been synthesized and characterized by elemental analysis, IR and UV-vis spectroscopy, TG analysis, powder X-ray diffraction and single crystal X-ray diffraction.	4-picolinic acid__Ce 2__no_interaction	La 4__Ce 2__no_interaction
12587046-11	<protein-id="P16860">BNP</protein-id> correlated with LVEDP (r = 0.50, p &lt;0.02), SVR (r =0.49, p &lt;0.03) and inversely with 6MWT (r =-0.60, p &lt;0.009), LVEF (r = -0.49, p &lt;0.004) and <compound-id="5360545">sodium</compound-id> (r = -0.36, p = 0.04).	sodium__BNP__no_interaction
15483716-1	The complexes, [VO(O(2))(pa)(2)]ClO(4).3H(2)O (1), [VO(O(2))(pa)(2)][VO(O(2))(2)(pa)].3H(2)O (2), [VO(O(2))(pa)(2)][VO(O(2))(ada)].2H(2)O (3) and [VO(O(2))(pa)(<protein-id="Q9Y5Y0,B2RB38">pca</protein-id>)].H(2)O (4)[pa = <compound-id="15070">picolinamide</compound-id>, ada = carbamoylmethyliminodiacetate(2-) and <protein-id="Q9Y5Y0,B2RB38">pca</protein-id> = <compound-id="1047">2-pyrazinecarboxylate</compound-id>(1-)], were synthesized.	2-pyrazinecarboxylate__pca__no_interaction	picolinamide__pca__no_interaction
18156400-8	<compound-id="185679">RLP</compound-id>-C concentration was positively associated (P &lt; 0.01) with the plasma concentrations of triacylglycerols (Kendall's correlation coefficient or r = 0.46), <compound-id="11146">triacylglycerol</compound-id>:HDL <compound-id="5997">cholesterol</compound-id> (HDL-C) (r = 0.44), total <compound-id="5997">cholesterol</compound-id>:HDL-C (r = 0.26), <protein-id="P04114,Q7Z7Q0,Q59HB3">Apo B</protein-id> (r = 0.22), C III (r = 0.41), and E (r = 0.17), and 18:1(n-9) (r = 0.32); it was negatively associated (P &lt; 0.05) with plasma concentrations of DHA (r = -0.32), EPA (r = -0.25), HDL-C (r = -0.21), LDL <compound-id="5997">cholesterol</compound-id>:<protein-id="P04114,Q7Z7Q0,Q59HB3">Apo B</protein-id> (r = -0.30), and HDL-C:Apo A (r = -0.25).	RLP__Apo B__no_interaction	triacylglycerol__Apo B__no_interaction	cholesterol__Apo B__no_interaction
15851913-6	Although similar in age, weight, and racial composition, HIV-infected women demonstrated higher CRP (4.6 +/- 0.7 vs. 2.3 +/- 0.4 mg/L, P = 0.007), IL-6 (2.7 +/- 0.2 vs. 1.8 +/- 0.1 pg/mL, P = 0.02), triglyceride (1.84 +/- 0.21 vs. 0.85 +/- 0.05 mM, P = 0.0002), 2-hour <compound-id="206,5793,64689,79025">glucose</compound-id> after oral <compound-id="206,5793,64689,79025">glucose</compound-id> challenge (6.88 +/- 0.22 vs. 5.72 +/- 0.17 mM, P = 0.0003), and fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (81 +/- 8 vs. 45 +/- 2 pM, P = 0.0002) and lower high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (1.17 +/- 0.03 vs. 1.45 +/- 0.05 mM, P &lt; 0.0001) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (5.4 +/- 0.3 vs. 7.6 +/- 0.5 mg/L, P = 0.0001) levels compared with the control population.	cholesterol__insulin__no_interaction	cholesterol__adiponectin__no_interaction	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
10444633-2	To determine the extent to which <protein-id="P01321">insulin</protein-id>, <protein-id="P29794">glucagon</protein-id>, and selective (alpha/beta)-adrenergic activation mediate the increment in <compound-id="206,5793,64689,79025">glucose</compound-id> metabolic clearance rate (MCR) and <compound-id="206,5793,64689,79025">glucose</compound-id> production (R(a)), we used five groups of normal mongrel dogs: 1) pancreatic clamp (PC; n = 7) with peripheral somatostatin (0.8 microg x kg(-1) x min(-1)) and intraportal replacement of <protein-id="P01321">insulin</protein-id> (1,482 +/- 84 pmol x kg(-1) x min(-1)) and <protein-id="P29794">glucagon</protein-id> (0.65 ng x kg(-1) x min(-1)) infusions; 2) PC plus combined alpha (<compound-id="5775">phentolamine</compound-id>)- and beta (<compound-id="4946">propranolol</compound-id>)-blockade (7 and 5 microg x kg(-1) x min(-1), respectively; alpha+beta; n = 5); 3) PC plus alpha-blockade (alpha; n = 6); 4) PC plus beta-blockade (beta; n = 5); and 5) a <compound-id="2551">carbachol</compound-id> control group without PC (Con; n = 10).	carbachol__glucagon__no_interaction	carbachol__insulin__no_interaction	propranolol__glucagon__no_interaction	propranolol__insulin__no_interaction	phentolamine__glucagon__no_interaction	phentolamine__insulin__no_interaction	glucose__glucagon__no_interaction	glucose__insulin__no_interaction
11254486-4	Our results also suggested that the SO/OH(-) and Cl(-)/OH(-) exchange processes in Caco-2 cells are distinct based on the following: 1) the SO/OH(-) exchange was highly sensitive to inhibition by DIDS compared with Cl(-)/OH(-) exchange activity (K(i) for DIDS of 0.3 +/- 0.1 mM); 2) Cl(-) competitively inhibited the SO/OH(-) exchange activity with a high K(i) compared with the K(m) for SO, indicating a lower affinity for Cl(-); 3) DIDS competitively inhibited the Cl(-)/OH(-) exchange process, whereas it inhibited the SO/OH(-) exchange activity in a mixed-type manner; and 4) utilizing the RNase protection assay, our results showed that 24-h incubation with 100 nM of <compound-id="853">thyroxine</compound-id> significantly decreased the relative abundance of <protein-id="P40879">DRA</protein-id> mRNA along with the SO/OH(-) exchange activity but without any change in Cl(-)/OH(-) exchange process.	thyroxine__DRA__no_interaction
8652567-4	Simultaneous (global) analysis of the time courses of d(T5(2-AP)T4(2-AP)T5) (100 nM) binding to a range of <protein-id="A7XPK1">Rep</protein-id> monomer concentrations (25-400 nM) yields the following rate constants: k1 = (3.3 +/- 0.5) x 10(7) M-1 s-1; k-1 = 1.4 +/- 0.4 s-1; k2 = 2.7 +/- 0.9 s-1; k-2 = 0.21 +/- 0.06 s-1; k3 = (4.5 +/- 0.3) x 10(5) M-1 s-1; k-3 = 0.0027 +/- 0.0008 s-1 [20 mM Tris-HCl, pH 7.5, 6 mM NaCl, 5 mM MgCl2, 5 mM 2-<compound-id="1567">mercaptoethanol</compound-id>, and 10% (v/v) <compound-id="24759880,753">glycerol</compound-id>, 4.0 degrees C].	glycerol__Rep__no_interaction	mercaptoethanol__Rep__no_interaction
9477208-3	Clusterings of the following eight markers of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance were recorded as the main outcome measures: 1) at least one first-degree relative with non-<protein-id="P01308,I3WAC9">insulin</protein-id>-dependent diabetes (NIDDM); 2) obesity: body mass index (BMI) &gt; or = 30 kg/m2; 3) central adiposity: waist-to-hip ratio (WHR) &gt; or = 1.00 in men and &gt; or = 0.88 in women; 4) hypertension: systolic blood pressure &gt; or = 160 mmHg or diastolic blood pressure &gt; or = 95 mmHg, or receiving drug treatment for hypertension; 5) hypertriglyceridaemia &gt; or = 1.70 mmol/l; 6) low high-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id>: &lt; 1.0 mmol/l in men and &lt; 1.20 mmol/l in women; 7) abnormal <compound-id="206,5793,64689,79025">glucose</compound-id> metabolism according to WHO criteria and 8) hyperinsulinaemia: fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> &gt; or = 13.0 mU/l.	glucose__insulin__no_interaction	cholesterol__insulin__no_interaction
10992093-5	RESULTS: The results are as follow:--the joint space of the <protein-id="Q06141,Q53S56">hip</protein-id> (JS/H): cranial part (cranial joint space: CJS/H): 5.5 mm +/- 0.5; medial part (medial joint space: MJS/H): 7 mm+/-0.5; --the bony roofingless part of the femoral head (BR/FH): 1-6 years: 1-3 mm; 7-13 years: 4-5 mm; 14-16 years: 6 mm; --the neck shaft angle of the femur (NSA/F); 1-6 years: 150 degrees-140 degrees; 7-16 years: 135 degrees; --the horizontal and the vertical diameters of the femoral head (HD/FH; VD/FH); x being the age of the children, the HD/FH grows according to a linear regression function as Ydh = 2x + 13+/-2 and the VD/FH as Ych = 2x + 18+/-2; --the centre acetabular edge index (<compound-id="5326781">CEI</compound-id>): the <compound-id="5326781">CEI</compound-id> decreases from 1 to 16 years: medium: 2.75-1.77; maximum: 2.31-1.67; minimum: 3.62-1.91; --the centre-acetabular cartilage index (CCI)): the CCI grows from 1 to 16 years: medium: 0.57-0.70; maximum: 0.62-0.73; minimum: 0.5-0.68.	CEI__hip__no_interaction
23675008-5	To test the hypothesis that dietary <compound-id="969516">curcumin</compound-id> prolongs lifespan, groups of 30 male D. melanogaster were cultured on media containing 1) no additive; 2) 0.5 mg of <compound-id="969516">curcumin</compound-id>/gram of media; 3) 1.0 mg of curumin/gram of media; 4) 1.0μg of the <compound-id="5359597">superoxide</compound-id> dismutase inhibitor, <compound-id="3117">disulfiram</compound-id>/gram of media; 5) 10 g of <compound-id="3117">disulfiram</compound-id>/gram of media; 6) 0.5 mg <compound-id="969516">curcumin</compound-id> and 1.0 g <compound-id="3117">disulfiram</compound-id>/ gram of media; 7) 1.0 mg <compound-id="969516">curcumin</compound-id> and 1.0 g <compound-id="3117">disulfiram</compound-id>/ gram of media; 8) 0.5 mg <compound-id="969516">curcumin</compound-id> and 10 g <compound-id="3117">disulfiram</compound-id>/gram of <protein-id="O62609,Q8IMG6">media; or 9</protein-id>) 1.0 mg <compound-id="969516">curcumin</compound-id> and 10 g <compound-id="3117">disulfiram</compound-id>/gram of media.	curcumin__media; or 9__no_interaction	disulfiram__media; or 9__no_interaction	superoxide__media; or 9__no_interaction
16011149-2	On <protein-id="O75888,B3KR02,Q2QBA2">April</protein-id> 10, one-year-old larch seedlings, after their roots washed and sterilized, were transplanted into a plastic pot (diameter 30 cm, height 27 cm) containing sterilized and washed quartz sand, and supplied with complete nutrient solution (4 mmol NH4NO3 x L(-1), 1 mmol <compound-id="516951">KH2PO4</compound-id> x L(-1), 1 mmol KCl x L(-1), 1 mmol <compound-id="5284359">CaCl2</compound-id> x L(-1), 0.6 mmol MgS4 x L(-1), 0.02 mmol <compound-id="24380">FeCl3</compound-id> x L(-1), 6 micromol MnC2 x L(-1), 0.016 mmol H3BO3 x L(-1), 0.3 micromol <compound-id="3007855">ZnCl2</compound-id> x L(-1), 0.3 micromol <compound-id="24014">CuCl2</compound-id> x L(-1), and 0.3 micromol NaMoO4 x L(-1)).	KH2PO4__April__no_interaction	CaCl2__April__no_interaction	ZnCl2__April__no_interaction	FeCl3__April__no_interaction	CuCl2__April__no_interaction
1433218-1	We have synthesized four guanidinophenyl-substituted <compound-id="5460631">protio</compound-id> enol and iodo enol lactones (3-(4-guanidinophenyl)-6-methylidenetetrahydro-<compound-id="68154">2-pyranone</compound-id> (1), 3-(4-guanidinophenyl)-6-(E)-(iodomethylidene)tetrahydro-2-pyran one (2), 4-(4-guanidinophenyl)-6-methylidenetetrahydro-<compound-id="68154">2-pyranone</compound-id>+ ++ (3), and 4-(4-guanidinophenyl)-6-(E)-(iodomethylidene)tetrahydro-2-pyran one (4)) and tested them for inhibitory activity against some trypsin-like enzymes, namely trypsin, urokinase, tissue plasminogen activator (<protein-id="P00750">t-PA</protein-id>), <protein-id="P00747,Q5TEH5">plasmin</protein-id>, and <compound-id="90470996">thrombin</compound-id>, as well as alpha-chymotrypsin and <protein-id="P08246">human neutrophil elastase</protein-id> (<protein-id="P08246">HNE</protein-id>).	2-pyranone__HNE__no_interaction	2-pyranone__human neutrophil elastase__no_interaction	2-pyranone__t-PA__no_interaction	2-pyranone__plasmin__no_interaction	protio__HNE__no_interaction	protio__human neutrophil elastase__no_interaction	protio__t-PA__no_interaction	protio__plasmin__no_interaction	thrombin__HNE__no_interaction	thrombin__human neutrophil elastase__no_interaction	thrombin__t-PA__no_interaction	thrombin__plasmin__no_interaction
21732435-1	Five <compound-id="23924">iridium</compound-id> <protein-id="O95817">bis</protein-id>(carbene) complexes, [Ir(pmi)(2)(pypz)] (1), [Ir(mpmi)(2)(pypz)] (2), [Ir(fpmi)(2)(pypz)] (3), [Ir(fpmi)(2)(pyim)] (4), and [Ir(fpmi)(2)(tfpypz)] (5) (pmi=1-phenyl-3-methylimdazolin-2-ylidene-C,C(2'); fpmi=1-(4-fluorophenyl)-3-methylimdazolin-2-ylidene-C,C(2'); mpmi=1-(4-methyl-phenyl)-3-methylimdazolin-2-ylidene-C,C(2'); pypz=2-(<compound-id="1048">1H-pyrazol</compound-id>-5-yl)pyridinato; pyim=2-(<compound-id="795">1H-imidazol</compound-id>-2-yl)pyridinato; and tfpypz=2-(3-(<compound-id="6373">trifluoromethyl</compound-id>)-<compound-id="1048">1H-pyrazol</compound-id>-5-yl)pyridinato), were synthesized and their structures were characterized by NMR spectroscopy, mass spectroscopy and X-ray diffraction.	iridium__bis__no_interaction	1H-pyrazol__bis__no_interaction	trifluoromethyl__bis__no_interaction	1H-imidazol__bis__no_interaction
21082856-3	Thus, the anionic heteroleptic cis-configured [cis-Pt(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2-) and [Pt(bzq)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](-) (Fc = ferrocenyl) complexes react with Tl(+) to form discrete octanuclear (PPh(3)Me)(2)[{trans,cis,cis-PtTl(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)}(2)] (1), [PtTl(bzq)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2) (5; bzq = <compound-id="427890">benzoquinolate</compound-id>), and decanuclear [trans,cis,cis-PtTl(2)(C(6)F(5))(2)(C≡<protein-id="Q06124">CFc</protein-id>)(2)](2) (3) derivatives, stabilized by both Pt(II)···Tl(I) and Tl(I)···η(2)(alkynyl) bonds.	benzoquinolate__CFc__no_interaction
19007763-7	The most potent inhibitors of <protein-id="Q04828">AKR1C1</protein-id> were the <compound-id="24204674">pyrimidine derivative</compound-id> <compound-id="16656629">N-benzyl-2-(2-(4-methoxybenzyl)-6-oxo-1,6-dihydropyrimidin-4-yl)acetamide</compound-id> (K(i)=17 microM) and the <compound-id="227">anthranilic acid</compound-id> derivative <compound-id="16656630">2-(((2',3-dichlorobiphenyl-4-yl)carbonyl)(methyl)amino)benzoic acid</compound-id> (K(i)=33 microM), both of which are non-competitive inhibitors.	anthranilic acid__AKR1C1__no_interaction	2-(((2',3-dichlorobiphenyl-4-yl)carbonyl)(methyl)amino)benzoic acid__AKR1C1__no_interaction	pyrimidine derivative__AKR1C1__no_interaction	N-benzyl-2-(2-(4-methoxybenzyl)-6-oxo-1,6-dihydropyrimidin-4-yl)acetamide__AKR1C1__no_interaction
18185017-4	RESULTS: Serum total LDH activity in the NEPHR group was increased compared with the NON-NEPHR and CONTR groups (p &lt; 0.001) and correlated with serum total protein (r = -0.549, p &lt; 0.001), serum <protein-id="P02768">albumin</protein-id> (r = -0.596, p &lt; 0.001), proteinuria (r = 0.456, p &lt; 0.001) and serum total <compound-id="5997">cholesterol</compound-id> (r = 0.523, p &lt; 0.001).	cholesterol__albumin__no_interaction
18185017-7	Serum LDH-2 activity correlated with serum total protein (r = -0.665, p &lt; 0.001), serum <protein-id="P02768">albumin</protein-id> (r = -0.615, p &lt; 0.001), proteinuria (r = 0.694, p &lt; 0.001), and serum total <compound-id="5997">cholesterol</compound-id> (r = 0.723, p &lt; 0.001).	cholesterol__albumin__no_interaction
9480587-11	LV diastolic filling returned to normal limits: (E/A ratio: 0.62 +/- 0.34 vs. 1.3 +/- 0.8; p &lt; 0.05); <compound-id="3905118">Peak E</compound-id> velocity: 0.51 +/- 0.34 vs. 0.88 +/- 0.28 m/sec, p &lt; 0.05; Peak A velocity: 0.81 +/- 0.36 vs. 0.72 +/- 0.42 m/sec, ns; E deceleration velocity: 299 +/- 328 vs. 582 +/- 294 cm/<protein-id="Q10981,A8K2L2">sec2</protein-id>, p &lt; 0.05; Isovolumic relaxation time: 134 +/- 40 vs. 83 +/- 38 m/sec, p &lt; 0.05).	Peak E__sec2__no_interaction
19054567-1	Three doubly-bridged, trinuclear <compound-id="23978">copper</compound-id>(II) compounds with hydroxo and carboxylato bridges, (infinity)(1)[Cu(3)(L1)(2)(mu-OH)(2)(mu-propionato)(2)](1), [Cu(3)(L2)(2)(mu-OH)(2)(mu-propionato)(2)(DMF)(2)] (2) and (infinity)(1){[Cu(3)(L3)(2)(mu-OH)(2)(mu-propionato)(2)]} [Cu(3)(L3)(2)(mu-OH)(2)(mu-propionato)(2)(DMF)(2)]} (3) [HL1=N-(pyrid-2-ylmethyl)benzenesulfonylamide, <protein-id="P07307,Q7Z4G9">HL2</protein-id>=N-(pyrid-2-ylmethyl)toluenesulfonylamide, HL3=N-(pyrid-2-ylmethyl)naphthalenesulfonylamide], have been synthesized and characterized.	copper__HL2__no_interaction
12182214-8	The O group lost more <protein-id="Q9UBC3">ICF</protein-id> (p &lt; 0.05) (N: Y = -510.4 +/- 86.8 mL, O = -631.7 +/- 115.1 mL; H: Y = -529.3 +/- 118.0 mL, O = -928.6 +/- 118.9 mL) and less <compound-id="447834">ISF</compound-id> (p &lt; 0.05) (N: Y = -295.5 +/- 101.1 mL, O = 15.8 +/- 77.6 mL; H: Y = -684.6 +/- 134.5 mL, O = -397.9 +/- 165.5 mL) in both conditions.	ISF__ICF__no_interaction
8067427-2	<compound-id="57476835,60961">Adenosine</compound-id> and its analogues, <compound-id="8974">2-chloroadenosine</compound-id> (CAD), <compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (NECA), R-N6-(2-phenylisopropyl)<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="114854">R-PIA</compound-id>), <compound-id="104968,11957498,14426724,4402">N6-cyclopentyladenosine</compound-id> (CPA), N6-[2-(<compound-id="57420036">3,5-dimethoxyphenyl</compound-id>)-2-(2-methylphenyl)]<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="10391971,122246,24042201">DPMA</compound-id>), <compound-id="11957666,122170,12997926,1585,6917803">2-phenylaminoadenosine</compound-id> (CV-1808), 2-[m-(carboxyethyl)<compound-id="137550">phenylamino</compound-id>]-<compound-id="104795,11957539,24867503,2868392,448222">5'-N-ethylcarboxamidoadenosine</compound-id> (CGS-22988), 2-[(2-cyclohexylethyl)amino]<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="130199,44320650">CGS-22492</compound-id>), 2-[(p-amino)phenethylamino]<compound-id="57476835,60961">adenosine</compound-id> (APE), and 2-(1-octynyl)<compound-id="57476835,60961">adenosine</compound-id> (<compound-id="171185">YT</compound-id>-146) (10 nM-100 microM), produced concentration-dependent relaxations in endothelium-intact and -denuded arterial ring segments contracted with 30 mM KCl, 10 nM <protein-id="P09558">endothelin-1</protein-id>, or 10 microM <compound-id="5280363">prostaglandin F2</compound-id> alpha.	3,5-dimethoxyphenyl__endothelin-1__no_interaction	N6-cyclopentyladenosine__endothelin-1__no_interaction	CGS-22492__endothelin-1__no_interaction	Adenosine__endothelin-1__no_interaction	DPMA__endothelin-1__no_interaction	YT__endothelin-1__no_interaction	phenylamino__endothelin-1__no_interaction	adenosine__endothelin-1__no_interaction	R-PIA__endothelin-1__no_interaction	2-phenylaminoadenosine__endothelin-1__no_interaction	5'-N-ethylcarboxamidoadenosine__endothelin-1__no_interaction	prostaglandin F2__endothelin-1__no_interaction	2-chloroadenosine__endothelin-1__no_interaction
15104796-5	RESULTS: Serum triglyceride (Tg) (213.7 +/- 112.4 mg/dl vs. 153.4 +/- 54.8 mg/dl p = 0.003), serum <compound-id="5997">cholesterol</compound-id> (C) (185.8 +/- 48.3 mg/dl vs. 149.3 +/- 37.8 mg/dl, p = 0.014), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (120.1 mg/dl +/- 48.9 vs. 84.8 +/- 43.7 mg/d, p = 0.001), VLDL-C (40.7 +/- 18.9 mg/dl vs. 30.7 +/- 10.9 mg/dl, p = 0.025), MDA (13.1 +/- 3.5 nmol/ml vs. 1.27 +/- 1 nmol/ml, p = 0.00), TA (0.98 +/- 0.17 mmol/l vs. 1.28 +/- 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 +/- 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of <compound-id="53232">Lovastatin</compound-id> therapy.	Lovastatin__LDL-C__no_interaction	cholesterol__LDL-C__no_interaction
23338999-9	<protein-id="Q15848,A8K660,B2R773">Adiponectin</protein-id> negatively correlated with weight (r = -0.34, p 〈 0.01), BMI (r = -0.37, p 〈 0.01), FN BMD (r = -0.26, p 〈 0.05), TH BMD (r = -0.33, p 〈 0.01), and did not correlate with <compound-id="40539">QUS</compound-id> result.	QUS__Adiponectin__no_interaction
22580336-5	A broad range of both proinflammatory and anti-inflammatory lipid mediators was detected, including PGE2, <protein-id="P41222,A0A024R8G3">PGD2</protein-id>, <compound-id="5283137,5461">TXB2</compound-id>, <compound-id="5280492">LTB4</compound-id>, <compound-id="5283128">6-trans-LTB4</compound-id>, <compound-id="5280745">20-OH-LTB4</compound-id>, <compound-id="133471,5280877">20-COOH-LTB4</compound-id>, <compound-id="5283157">20-HETE</compound-id>, <compound-id="5280724,5312986,5353283,9966861">15-HETE</compound-id>, <compound-id="1406,14123410,5312981,5312982,5353268">11-HETE</compound-id>, <compound-id="13786989,5283155,5312983,5312984,5353272">12-HETE</compound-id>, <compound-id="11976122,1898,5283154,5312975">8-HETE</compound-id>, <compound-id="1926">9-HETE</compound-id>, <compound-id="5280733,5353348">5-HETE</compound-id>, EpETrEs, diols, <compound-id="10473088">resolvin E1</compound-id>, <compound-id="5311211">15-deoxy-PGJ2</compound-id>, and <compound-id="16760543">LXA4</compound-id>.	resolvin E1__PGD2__no_interaction	6-trans-LTB4__PGD2__no_interaction	LTB4__PGD2__no_interaction	20-COOH-LTB4__PGD2__no_interaction	11-HETE__PGD2__no_interaction	15-HETE__PGD2__no_interaction	15-deoxy-PGJ2__PGD2__no_interaction	20-HETE__PGD2__no_interaction	8-HETE__PGD2__no_interaction	20-OH-LTB4__PGD2__no_interaction	12-HETE__PGD2__no_interaction	5-HETE__PGD2__no_interaction	9-HETE__PGD2__no_interaction	LXA4__PGD2__no_interaction	TXB2__PGD2__no_interaction
20814094-1	We report the synthesis of the <compound-id="90901057">2,2'-[2,5-bis(carboxymethoxy)-1,4-phenylene]diacetic acid</compound-id> (<protein-id="P37837">TALH</protein-id>(4)) ligand and the structures of its adducts with <compound-id="223">ammonium</compound-id>, namely diammonium <compound-id="60207171">2,2'-[2,5-bis(carboxymethyl)-1,4-phenylenedioxy]diacetate</compound-id>, <compound-id="447474">2NH</compound-id>(4)(+).C(14)H(12)O(10)(2-), (I), <compound-id="23926">lanthanum</compound-id>, namely poly[[aquabis[mu(4)-2,2'-(2-carboxylatomethyl-5-carboxymethyl-1,4-phenylenedioxy)diacetato]dilanthanum(III)] <compound-id="1488787">monohydrate</compound-id>], {[La(2)(C(14)H(11)O(10))(2)(H(2)O)].H(2)O}(n), (II), and <compound-id="23994">zinc</compound-id> cations, namely poly[[{mu(4)-2,2'-[<compound-id="5483205">2,5-bis(</compound-id>carboxymethyl)-1,4-phenylenedioxy]diacetato}<compound-id="23994">zinc</compound-id>(II)] trihydrate], {[Zn(C(14)H(12)O(10))].3H(2)O}(n), (III), and poly[[diaqua(mu(2)-<compound-id="11107">4,4'-bipyridyl</compound-id>){mu(4)-2,2'-[<compound-id="5483205">2,5-bis(</compound-id>carboxymethyl)-1,4-phenylenedioxy]diacetato}<compound-id="16722164">dizinc</compound-id>(II)] <compound-id="3039108">dihydrate</compound-id>], {[Zn(2)(C(14)H(10)O(10))(C(10)H(8)N(2))(H(2)O)(2)].2H(2)O}(n), (IV), the formation of all four being associated with deprotonation of <protein-id="P37837">TALH</protein-id>(4).	2,5-bis(__TALH__no_interaction	4,4'-bipyridyl__TALH__no_interaction	2NH__TALH__no_interaction	monohydrate__TALH__no_interaction	lanthanum__TALH__no_interaction	2,2'-[2,5-bis(carboxymethyl)-1,4-phenylenedioxy]diacetate__TALH__no_interaction	2,2'-[2,5-bis(carboxymethoxy)-1,4-phenylene]diacetic acid__TALH__no_interaction	ammonium__TALH__no_interaction	zinc__TALH__no_interaction	dizinc__TALH__no_interaction	dihydrate__TALH__no_interaction
10090866-8	18 for female versus male siblings), triglycerides (r = 0.56 versus r = 0.05), and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.72 versus r = 0.31); they were also higher between female siblings than between mixed-sex siblings for measures of adiposity (r = 0.46 versus r = 0.19) and total <compound-id="5997">cholesterol</compound-id> (r = 0.74 versus r = 0.27).	cholesterol__apolipoprotein B__no_interaction
8001634-4	Furthermore, pretreatment with <compound-id="60846">valsartan</compound-id> ((S)-N-valeryl-N-([2'-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)biphenyl-4-yl]-methyl)-val <compound-id="1649">ine</compound-id>), a new selective angiotensin AT1 receptor antagonist, antagonized the effects of <protein-id="P01015">angiotensin II</protein-id> on <compound-id="6041">phenylephrine</compound-id>-mediated pressor responses, whereas the administration of the selective angiotensin AT2 receptor antagonist, <compound-id="5311345">PD 123319</compound-id> (1-[[4-(dimethylamino)-3-methylphenyl]-methyl]-5-(<compound-id="13696">diphenylacetyl</compound-id>)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]-<compound-id="1049">pyridine</compound-id>-6-<compound-id="11229316,91179806">carboxylic acid</compound-id>, ditriflouroacetate, <compound-id="1488787">monohydrate</compound-id>), injected in bolus doses of 100 micrograms/kg, did not antagonize the enhancing effect of <protein-id="P01015">angiotensin II</protein-id>.	diphenylacetyl__angiotensin II__no_interaction	pyridine__angiotensin II__no_interaction	valsartan__angiotensin II__no_interaction	phenylephrine__angiotensin II__no_interaction	PD 123319__angiotensin II__no_interaction	ine__angiotensin II__no_interaction	carboxylic acid__angiotensin II__no_interaction	1H-tetrazol__angiotensin II__no_interaction	monohydrate__angiotensin II__no_interaction
16517693-6	Antagonist studies revealed that a <protein-id="P41595">5-HT2B</protein-id>-selective antagonist, <compound-id="7021454">RS</compound-id>-127445 [<compound-id="196968">2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine</compound-id>] (Ki = 0.13 nM), was significantly more effective at inhibiting 5-HT-induced activity than a <protein-id="P28223">5-HT2A</protein-id> antagonist, M-100907 (R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)<compound-id="23134249">ethyl</compound-id>]-<compound-id="420771">4-piperidinemethanol</compound-id>]) (Ki= 914 nM) and the <protein-id="P28335,K9J958">5-HT2C</protein-id> antagonists <compound-id="3693566">RS-102221</compound-id> (8-[5-(2,4-dimethoxy-5-(4-trifluoromethylsulfo-amido)phenyl-5-oxopentyl]-<compound-id="120989">1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride</compound-id>) (Ki = 2.5 microM) and SB-242084 (6-chloro-5-methyl-1-[6-92-methylpyridin-3-yloxy) <compound-id="1049">pyridine-</compound-id>3-ylcarbamoyl] <compound-id="10328">indoline</compound-id>) (Ki = 42.4 nM) in the HUSMC PI turnover assays.	indoline__5-HT2B__no_interaction	indoline__5-HT2C__no_interaction	indoline__5-HT2A__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2B__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2C__no_interaction	1,3,8-triazaspiro[4.5]decane-2,4-dione hydrochloride__5-HT2A__no_interaction	RS__5-HT2B__no_interaction	RS__5-HT2C__no_interaction	RS__5-HT2A__no_interaction	pyridine-__5-HT2B__no_interaction	pyridine-__5-HT2C__no_interaction	pyridine-__5-HT2A__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2B__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2C__no_interaction	2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine__5-HT2A__no_interaction	ethyl__5-HT2B__no_interaction	ethyl__5-HT2C__no_interaction	ethyl__5-HT2A__no_interaction	4-piperidinemethanol__5-HT2B__no_interaction	4-piperidinemethanol__5-HT2C__no_interaction	4-piperidinemethanol__5-HT2A__no_interaction	RS-102221__5-HT2B__no_interaction	RS-102221__5-HT2C__no_interaction	RS-102221__5-HT2A__no_interaction
15526717-9	Serum <protein-id="P41159,A4D0Y8">leptin</protein-id> (30.8 +/- 18.3 vs 8.1 +/- 5.9 ng/ml), A (841.8 +/- 471.1 vs 522.5 +/- 317.2 pg/ml), <protein-id="Q06520,A8K015">DHEAS</protein-id> (0.53 +/- 0.44 vs 0.31 +/- 0.39 microg/ml), G (88.4 +/- 8.8 vs 80.2 +/- 8.1 mg/dl), I (13.5 +/- 7.7 vs 5.1 +/- 3.7 microU/ml) and total <compound-id="5997">cholesterol</compound-id> (TC) (180.5 +/- 30.9 vs 161.8 +/- 29.5 mg/dl) levels were greater in the OB than in the <compound-id="11473">nOB</compound-id> group.	nOB__DHEAS__no_interaction	nOB__leptin__no_interaction	cholesterol__DHEAS__no_interaction	cholesterol__leptin__no_interaction
17011056-3	The results showed that microinjection of <protein-id="P01186">AVP</protein-id> into PAG increased pain threshold, whereas microinjection of V2 receptor antagonist-d(CH2)5[d-Ile2, Ile4, Ala9-NH2]<protein-id="P01186">AVP</protein-id> into PAG decreased pain threshold in a dose-dependent manner, but local administration of V1 receptor antagonist-d(CH2)5Tyr(Me)<protein-id="P01186">AVP</protein-id> did not change pain threshold; Pain stimulation elevated <protein-id="P01186">AVP</protein-id>, <compound-id="6106">Leucine</compound-id>-<protein-id="P04094">enkephalin</protein-id> (L-Ek), <compound-id="6137,84815,876">Methionine</compound-id>-<protein-id="P04094">enkephalin</protein-id> (M-Ek) and beta-endorphin (beta-Ep), not <compound-id="25075996">dynorphinA</compound-id>(1-13) (DynA(1-13)) concentrations in PAG perfuse liquid; PAG pre-treatment with <compound-id="5284596">naloxone</compound-id>, an opiate receptor antagonist or V2 receptor antagonist completely reversed <protein-id="P01186">AVP</protein-id>-induced increase in pain threshold, however, PAG pre-treatment with V1 receptor antagonist did not influence this effect of <protein-id="P01186">AVP</protein-id> administration.	naloxone__AVP__no_interaction	naloxone__enkephalin__no_interaction	Leucine__AVP__no_interaction	Leucine__enkephalin__no_interaction	Methionine__AVP__no_interaction	Methionine__enkephalin__no_interaction	dynorphinA__AVP__no_interaction	dynorphinA__enkephalin__no_interaction
20397460-5	The order of the mean increasing percentage in the hypothalamic <protein-id="P07490">GnRH</protein-id> neuron electric activity was: the Gallbladder Channel &gt; the Spleen Channel &gt; the Stomach Channel/the Bladder Channel/the Conception Vessel &gt; the Liver Channel &gt; the Kidney Channel &gt; the Governor Vessel; for different acupoints, it was: Guanyuan (CV 4) &gt; Sanyinjiao (<protein-id="D3ZT88">SP 6</protein-id>) &gt; Zusanli (ST 36) &gt; Daimai (GB 26)/Yanglingquan (GB 34) &gt; Shenshu (BL 23) &gt; Weizhong (BL 40) &gt; Yaoyangguan (GV 3)/Liangmen (ST 21)/Fujie (SP 14) &gt; Qimen (LR 14)/Yingu (KI 10) &gt; Tangzhong (CV 17)/Zhiyang (GV 9); for different positions, it was: the lower abdominal part/the lower limb part &gt; the thoracodorsal part; for the extra-ordinary points, it was: Zigong (EX-CA1) &gt; Dannang (EX-LE6)/Yaoyan (EX-B7) &gt; Baichongwo (EX-LE3)/Qianzheng &gt; Jingbi/Bizhong/Taiyang (EX-<compound-id="44228987">HN5</compound-id>) &gt; Erbai (EX-UE2)/ Dingchun; and for the distribution sites of the extra-ordinary points: lower abdominal region &gt; the lower limb region &gt; the craniofacial region &gt; the upper limb region/the thoracodorsal region.	HN5__SP 6__no_interaction	HN5__GnRH__no_interaction
19100860-6	Twenty-one genes exhibited a distinct dose-dependent increase in expression at 4h for both carcinogens [<protein-id="Q07813,Q544Z6">Bax</protein-id>, <protein-id="Q04211,Q3TF68">Btg2</protein-id>, <protein-id="P51945,Q5NC86,Q5D0F7">Ccng1</protein-id>, <protein-id="P39689,Q564P6">Cdkn1a</protein-id>, <protein-id="O88833">Cyp4a10</protein-id>, <protein-id="P03940,Q3UJ92">Cyp21a1</protein-id>, <protein-id="P01101">Fos</protein-id>, <protein-id="P22339">Gadd45b</protein-id>, <protein-id="Q9Z0J7">Gdf15</protein-id>, <protein-id="P14901,Q3U5U6">Hmox1</protein-id>, <protein-id="P14602,Q545F4">Hspb1</protein-id>, <protein-id="Q9CZI9">Isg20l1</protein-id>, Jun, <protein-id="Q9Z2E2">Mbd1</protein-id>, <protein-id="P23804">Mdm2</protein-id>, Myc, <protein-id="Q9Z206,Q3USZ7">Net1</protein-id>, <protein-id="P53351,Q548A9,Q3TV29">Plk2</protein-id>, <protein-id="Q7TMB3">Ppp1r3c</protein-id>, <protein-id="Q9JHG6,Q542V6,Q7TNY3">Rcan1</protein-id> and <protein-id="P68372">Tubb2c</protein-id>], although the increase in gene expression due to <compound-id="12967">ENU</compound-id> was generally weaker than that due to DEN.	ENU__Plk2__no_interaction	ENU__Ppp1r3c__no_interaction	ENU__Btg2__no_interaction	ENU__Fos__no_interaction	ENU__Rcan1__no_interaction	ENU__Gadd45b__no_interaction	ENU__Cyp21a1__no_interaction	ENU__Hspb1__no_interaction	ENU__Hmox1__no_interaction	ENU__Bax__no_interaction	ENU__Ccng1__no_interaction	ENU__Tubb2c__no_interaction	ENU__Mbd1__no_interaction	ENU__Isg20l1__no_interaction	ENU__Mdm2__no_interaction	ENU__Gdf15__no_interaction	ENU__Cdkn1a__no_interaction	ENU__Net1__no_interaction	ENU__Cyp4a10__no_interaction
8977961-4	The <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id> genotype relative risks (and 95% CIs) for RA were: *0404,5,8/*0404,5,8 = 36.2 (15-87), *0401/*0404,5,8 = 31.3 (18-55), *401/*0401 = 18.8 (11-35), *0101,2/*0404,5,8 = 6.0 (2-14), *0101,2/*0401 = 6.4 (3-12), *0101,2/*0101,2 = 1.3 (0.3-6), *10/*0404,5,8 = 27.8 (5-148), *10/*0401 = 20.8 (5-89), *10/*0101,2 = 22.3 (5-96), *0404,5,8/<compound-id="16122567">DRX</compound-id> = 5.0 (3-8), *0401/<compound-id="16122567">DRX</compound-id> = 4.7 (3-7), *0101,2/<compound-id="16122567">DRX</compound-id> = 2.3 (1.4-4), *10/<compound-id="16122567">DRX</compound-id> = 3.4 (0.8-14).	DRX__DRB1__no_interaction
10067789-4	<protein-id="P35318">Adrenomedullin</protein-id> significantly decreased the order parameter for 5-<compound-id="787">nitroxide</compound-id> <compound-id="5281">stearate</compound-id> and peak height ratio for 16-<compound-id="787">nitroxide</compound-id> <compound-id="5281">stearate</compound-id> obtained from electron paramagnetic resonance spectra of erythrocyte membranes in normotensive volunteers (mean +/- <compound-id="5289348">SEM</compound-id> order parameter value: control, 0.718 +/- 0.003, n = 16; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-9) mol/l, 0.692 +/- 0.004, n = 16, P &lt; 0.05; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-8) mol/l, 0.690 +/- 0.004, n = 16, P &lt; 0.05; <protein-id="P35318">Adrenomedullin</protein-id> at 10(-7) mol/l, 0.683 +/- 0.004, n = 16, P &lt; 0.05).	nitroxide__Adrenomedullin__no_interaction	SEM__Adrenomedullin__no_interaction	stearate__Adrenomedullin__no_interaction
19603104-6	In RA patients, log-OPN was related to log-C-reactive protein (log-CRP) (r = 0.30, P &lt; 0.05), age (r = 0.38, P &lt; 0.01), Health Assessment Questionnaire (HAQ) (r = 0.58, P &lt; 0.0001), and inversely related to total <compound-id="5997">cholesterol</compound-id> (r = -0.33, P &lt; 0.05) and apolipoprotein A (apoA) (r = -0.58, P &lt; 0.001), but not to oxidative stress markers and <protein-id="P05305,Q6FH53">ET-1</protein-id>.	cholesterol__ET-1__no_interaction
1769029-6	Hemodynamic parameters were significantly changed after the first <compound-id="4510">nitroglycerin</compound-id> patch application: particularly, mean systemic arterial (MAP), right atrial (<protein-id="P30533">RAP</protein-id>) and pulmonary wedge pressures (PWP) declined from 96 +/- 10, 8.9 +/- 1.8 and 20.1 +/- 5 to 81 +/- 6, 4.7 +/- 1.5 and 12.2 +/- 3 mmHg (-15.6, -47.2 and -59.3%, respectively); systemic vascular resistance (SVR) and heart rate (HR) were reduced from 1645 +/- 121 to 1288 +/- 89 dyne.s.cm-5 and from 85 +/- 7 to 81 +/- 7 b/min; lastly, cardiac index (CI), stroke volume (SVI) and stroke work index (SWI) increased from 2.3 +/- 0.3, 28.2 +/- 5 and 28.7 +/- 9 to 2.7 +/- 0.3 l/min/m2, 33.3 +/- 5 ml/min/m2 and 31.5 +/- 8 g.m/m2 (+17.4, 18.1 and 9.7%).	nitroglycerin__RAP__no_interaction
11923045-9	RESULTS: In <protein-id="P12272,Q53XY9,A0A024RB29">HHM</protein-id>, decreased contents (micromol/g wet weight) in <compound-id="57476835,60961">adenosine</compound-id> triphosphate (ATP) (control: 4.17 +/- 0.26; <protein-id="P12272,Q53XY9,A0A024RB29">HHM</protein-id>: 1.72 +/- 0.25; p &lt; 0.001), <compound-id="9548602">creatine phosphate</compound-id> (5.67 +/- 0.70 vs. 0.84 +/- 0.13; p &lt; 0.001) and <compound-id="586">creatine</compound-id> (27.6 +/- 3.19 vs. 11.2 +/- 1.56; p &lt; 0.0001) were found, but contents in <compound-id="612">lactate</compound-id> (2.22 +/- 0.26 vs. 25.38 +/- 3.53; p &lt; 0.001), purine bases (0.58 +/- 0.09 vs. 1.26 +/- 0.13; p &lt; 0.001) and protons (pH units: 7.199 +/- 0.01 vs. 6.59 +/- 0.07; p &lt; 0.001) were increased.	lactate__HHM__no_interaction	creatine phosphate__HHM__no_interaction	creatine__HHM__no_interaction	adenosine__HHM__no_interaction
10844099-5	Under pretreatment with an <compound-id="44284481">endothelin</compound-id> ET(A) receptor antagonist (R)-2-[(R)-2-[(S)-2-[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]carbonyl]amino-4-m eth ylpentanoyl]amino-3-(2-pyridyl) <compound-id="1032">propionic acid</compound-id> (<compound-id="107810">FR139317</compound-id>) (1 microg/kg/min), <protein-id="P13206">endothelin-1</protein-id> suppressed the 1- and 3- Hz nerve stimulation-induced catecholamine response in a dose-dependent manner.	propionic acid__endothelin-1__no_interaction	endothelin__endothelin-1__no_interaction	1H-azepinyl__endothelin-1__no_interaction	FR139317__endothelin-1__no_interaction
12059220-8	The butatrienerhodium(I) compounds trans-[RhCl[eta(2)-H(2)C[double bond]C[double bond]C[double bond]C(R)R'](PiPr(3))(2)] (28-31) were prepared from 1, 20, and trans-[RhCl[[double bond]C[double bond]C[double bond]C(Ph)R](PiPr(3))(2)] [R = CF(3) (26), tBu (27)] and <compound-id="9550">diazomethane</compound-id>; with the exception of 30 (R = CF(3), R' = Ph), they thermally rearrange to the isomers trans-[RhCl[eta(2)-H(2)C[double bond]C[double bond]C[double bond]C(R)R'](PiPr(3))(2)] (32, 33, and <protein-id="P06241">syn</protein-id>/anti-34).	diazomethane__syn__no_interaction
3558354-5	Analysis of the spectra recorded during titrations of Zn7-MT 2 with <protein-id="P08921">Cd2</protein-id>+ suggests: (i) that <protein-id="P08921">Cd2</protein-id>+ replaces Zn2+ in Zn7-MT isomorphously; (ii) that <compound-id="23973">cadmium</compound-id> binds in a nonspecific, "distributed" manner across both domains; (iii) that cluster formation in the alpha domain only occurs after 4 mol eq of <compound-id="23973">cadmium</compound-id> have been added and is indicated by the presence of a cluster-sensitive, CD spectral feature; (iv) that the characteristic derivative CD spectrum of native <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT is only obtained from "synthetic" <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT following a treatment cycle that allows the redistribution of <compound-id="23973">cadmium</compound-id> into the alpha domain; warming the synthetic "native," <protein-id="P05540">Cd4</protein-id>,<compound-id="4655929">Zn3</compound-id>-MT, to 65 degrees C results in <compound-id="23973">cadmium</compound-id> being preferentially bound in the alpha domain; and (v) Zn7-MT will bind <protein-id="P08921">Cd2</protein-id>+ quite normally at up to 65 degrees C but with greater specificity for the alpha domain compared with titrations carried out at 25 degrees C. These results suggest that the initial presence of <compound-id="23994">zinc</compound-id> in both domains is an important factor in the lack of any domain specificity during <compound-id="23973">cadmium</compound-id> binding to Zn-MT which contrasts the domain specific manner observed for <compound-id="23973">cadmium</compound-id> binding to apo-MT.	Zn3__Cd4__no_interaction	Zn3__Cd2__no_interaction	cadmium__Cd4__no_interaction	cadmium__Cd2__no_interaction	zinc__Cd4__no_interaction	zinc__Cd2__no_interaction
17477522-1	New homo- and heterometallic, hexa- and pentanuclear complexes of formula {[<compound-id="444924">Cu2</compound-id>(<compound-id="12277">mpba</compound-id>)2(H2O)F][Cu(Me5dien)]4}(<protein-id="Q6Q759">PF6</protein-id>)(3).5H2O (1), {[<compound-id="444924">Cu2</compound-id>(Me3mpba)2(H2O)2][Cu(Me5dien)]4}(ClO4)(4).12H2O (2), {[<compound-id="444924">Cu2</compound-id>(<compound-id="513615">ppba</compound-id>)2][Cu(Me5dien)]4}(ClO4)4 (3), and [Ni(<compound-id="64964">cyclam</compound-id>)]{[<compound-id="444924">Cu2</compound-id>(<compound-id="12277">mpba</compound-id>)2][Ni(<compound-id="64964">cyclam</compound-id>)]3}(ClO4)(4).6H2O (4) [<compound-id="12277">mpba</compound-id>=<compound-id="22395425,517764,91539310">1,3-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), Me3mpba=2,4,6-trimethyl-<compound-id="22395425,517764,91539310">1,3-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), <compound-id="513615">ppba</compound-id>=<compound-id="136813,13902,141623,15274144,22395417,22395423,22395427,57004341,684351,90706559,90760131,90828198,90832537">1,4-phenylenebis</compound-id>(<compound-id="974">oxamate</compound-id>), Me5dien=N,N,N'N' ',N' '-pentamethyldiethylenetriamine, and <compound-id="64964">cyclam</compound-id>=1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>] have been synthesized through the use of the "complex-as-ligand/complex-as-metal" strategy.	ppba__PF6__no_interaction	Cu2__PF6__no_interaction	oxamate__PF6__no_interaction	1,4-phenylenebis__PF6__no_interaction	mpba__PF6__no_interaction	cyclam__PF6__no_interaction	tetraazacyclotetradecane__PF6__no_interaction	1,3-phenylenebis__PF6__no_interaction
15225067-1	A series of [(R-iso-<compound-id="1474">BIPY</compound-id>)Pt(CH(3))L ](+)X(-) complexes [R-iso-<compound-id="1474">BIPY</compound-id> = N-(2-pyridyl)-R-pyridine-2-ylidene; (R = 4-H, 1; 4-<compound-id="90937099">tert-butyl</compound-id>, 2; 4-dimethylamino, 3; 5-dimethylamino, 4); L = <protein-id="P62304">SMe</protein-id>(2), b; <compound-id="679">dimethyl sulfoxide</compound-id> (DMSO), c; <compound-id="281">carbon monoxide</compound-id> (CO), d; X = OTf(-) = <compound-id="62406">trifluoromethanesulfonate</compound-id> and/or [BPh(4)](-)] were synthesized by cyclometalation of the [R-iso-<compound-id="1474">BIPY</compound-id>-H](+)[OTF](-) salts 1a-<compound-id="69255155">4a</compound-id> ([R-iso-<compound-id="1474">BIPY</compound-id>-H](+) = N-(2-pyridyl)-R-<compound-id="1049">pyridinium</compound-id>) with dimethylplatinum-micro-<compound-id="1068">dimethyl sulfide</compound-id> dimer.	dimethyl sulfide__SMe__no_interaction	dimethyl sulfoxide__SMe__no_interaction	pyridinium__SMe__no_interaction	BIPY__SMe__no_interaction	tert-butyl__SMe__no_interaction	trifluoromethanesulfonate__SMe__no_interaction	carbon monoxide__SMe__no_interaction	4a__SMe__no_interaction
2973508-3	Macrophages isolated from CBA mice bearing 21-day intraperitoneal Ehrlich ascites tumors (EAT) or C3H/HeJ mice bearing 21-day subcutaneous T58 mammary adenocarcinomas were added (+/- 10(-5) M <compound-id="3715">indomethacin</compound-id>, or a monoclonal anti-PGE2 ab) to syngeneic splenic lymphocytes to examine the effects on 1) polyclonal activation (3-d 3H-thymidine [3H-TdR] uptake) with concanavalin A (Con A); 2) one-way (CBA alpha BALB/C or C3H alpha BALBC) <protein-id="A3KN90">MLR</protein-id> (5-d 3H-TdR uptake) and subsequent CTL generation (tested against <compound-id="104786">51Cr</compound-id>-labeled Con A blasts of the stimulator phenotype); 3) NK activity (after 24-h co-culture) against <protein-id="Q60935,Q545U9">YAC-1</protein-id> targets; 4) generation of LAK cell activity (in the presence of 200 or 2,000 units recombinant <protein-id="P04351">IL-2</protein-id> for 3 or 5 days), tested against NK-sensitive and NK-resistant targets.	indomethacin__MLR__no_interaction	indomethacin__YAC-1__no_interaction	indomethacin__IL-2__no_interaction	51Cr__MLR__no_interaction	51Cr__YAC-1__no_interaction	51Cr__IL-2__no_interaction
19572728-1	The reactions between the redox-active <compound-id="71357708">4-(2-tetrathiafulvalenyl-ethenyl)pyridine</compound-id> ligand (<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py) and the <compound-id="6503">tris</compound-id>(1,1,1,5,5,5-hexafluoroacetylacetonate)Ln(III) (Ln = La and Nd) lead to the formation of compounds with the formulas {[La(<compound-id="73706">hfac</compound-id>)(5)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))](2)} (1), {[Nd(<compound-id="73706">hfac</compound-id>)(4)(H(2)O)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))]}(2) (2), and {[Nd(<compound-id="73706">hfac</compound-id>)(4)(H(2)O)][(<protein-id="Q15669,Q6ICP4">TTF</protein-id>-CH=CH-Py(*+))]}(2)(H(2)O)(C(6)H(14))(0.5) (3) (<compound-id="73706">hfac</compound-id>(-) = 1,1,1,5,5,5-hexafluoroacetylacetonate anion).	hfac__TTF__no_interaction	tris__TTF__no_interaction	4-(2-tetrathiafulvalenyl-ethenyl)pyridine__TTF__no_interaction
19424605-5	The Chi-square test, multivariable logistic regression analysis with adjustment for covariates, as well as a stepwise forward selection procedure revealed that ten different polymorphisms were associated (P&lt;0.05) with the prevalence of CKD in high- or low-risk subjects: the -519Aright curved arrow G polymorphism of <protein-id="P03956,Q53G95,B4DN15">MMP1</protein-id>, the 1061Aright curved arrow G (Ile405Val) polymorphism of <protein-id="P11597,B4DMZ5">CETP</protein-id>, the Aright curved arrow G (Lys45Glu) polymorphism of <protein-id="P08254">MMP3</protein-id>, the -219Gright curved arrow T polymorphism of <protein-id="P02649">APOE</protein-id>, the Aright curved arrow G (Ile1205Val) polymorphism of <protein-id="P02461">COL3A1</protein-id>, the -863Cright curved arrow A polymorphism of TNF, and the 1454Cright curved arrow G (Leu125Val) polymorphism of <protein-id="P16284,A0A075B738">PECAM1</protein-id> in high-risk subjects; and the 1167Cright curved arrow T (Asn389Asn) polymorphism of <protein-id="P37173,A3QNQ0,D2JYI1">TGFBR2</protein-id>, the 2386Aright curved arrow G (Ile796Val) polymorphism of <protein-id="Q12770">SCAP</protein-id>, and the TAAAright curved arrow <compound-id="445801">del</compound-id> polymorphism of <protein-id="Q08499">PDE4D</protein-id> in low-risk subjects.	del__PECAM1__no_interaction	del__APOE__no_interaction	del__CETP__no_interaction	del__TGFBR2__no_interaction	del__SCAP__no_interaction	del__COL3A1__no_interaction	del__PDE4D__no_interaction	del__MMP3__no_interaction	del__MMP1__no_interaction
1837268-1	The substrate specificity of rat liver cytosolic neutral alpha-D-mannosidase was investigated by in vitro incubation with a crude cytosolic fraction of oligomannosyl oligosaccharides <compound-id="3081561">Man9GlcNAc</compound-id>, Man7GlcNAc, <compound-id="90475786">Man5GlcNAc</compound-id> I and II isomers and Man4GlcNAc having the following structures: <compound-id="3081561">Man9GlcNAc</compound-id>, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)[Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P78318">alpha 1-6</protein-id>)]Man(<protein-id="P78318">alpha 1-6</protein-id>) [Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)]Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; <compound-id="90475786">Man5GlcNAc</compound-id> I, Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)[Man(<protein-id="P78318">alpha 1-6</protein-id>)]-Man(<protein-id="P78318">alpha 1-6</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)] Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; <compound-id="90475786">Man5GlcNAc</compound-id> II, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>) [Man(<protein-id="P78318">alpha 1-6</protein-id>)]Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>; Man4GlcNAc, Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-2</protein-id>)Man(<protein-id="P25100,B0ZBE0">alpha 1-3</protein-id>)Man(<protein-id="Q13509,Q53G92">beta 1-4</protein-id>)<compound-id="11861101,24139,439174,899">GlcNAc</compound-id>.	Man9GlcNAc__alpha 1-6__no_interaction	Man9GlcNAc__alpha 1-3__no_interaction	Man9GlcNAc__alpha 1-2__no_interaction	Man9GlcNAc__beta 1-4__no_interaction	GlcNAc__alpha 1-6__no_interaction	GlcNAc__alpha 1-3__no_interaction	GlcNAc__alpha 1-2__no_interaction	GlcNAc__beta 1-4__no_interaction	Man5GlcNAc__alpha 1-6__no_interaction	Man5GlcNAc__alpha 1-3__no_interaction	Man5GlcNAc__alpha 1-2__no_interaction	Man5GlcNAc__beta 1-4__no_interaction
12630871-3	Addition of ligands L (L = <compound-id="53675528,6325">ethylene</compound-id>, <compound-id="8252">propylene</compound-id>, <compound-id="6335">propyne</compound-id>, <compound-id="10419">2-butyne</compound-id>, CO, <compound-id="10821">phenylacetylene</compound-id>, <compound-id="10037">allene</compound-id>, 1-hexene, <protein-id="O14508,A0A024RBD2">cis-2</protein-id>-<compound-id="7844">butene</compound-id>) to 1 in CD2Cl2 at -89 degrees C results in reversible formation of %@mt;sys@%Cp%@/xs;55;%lnwidth@%'%@/xs;63;(%lnwidth-<compound-id="44201390">x55</compound-id>)@%%@mh;-<compound-id="57519663">x63</compound-id>@%%@sb@%2%@sbx@%%@/hd@%Zr%@/hd@%%@fn;(;vis;full;auto@%O%@ital@%%@ex@%t%@<compound-id="9942150">rsf</compound-id>@%%@<compound-id="73437605">exx</compound-id>@%%@/hd@%Bu%@fnx;);vis;full@%%@/hd@%%@fn;(;vis;full;auto@%L%@fnx;);vis;full@%%@ex@%+%@<compound-id="73437605">exx</compound-id>@%%@mx@% adducts.	ethylene__cis-2__no_interaction	x55__cis-2__no_interaction	x63__cis-2__no_interaction	phenylacetylene__cis-2__no_interaction	propyne__cis-2__no_interaction	2-butyne__cis-2__no_interaction	propylene__cis-2__no_interaction	allene__cis-2__no_interaction	butene__cis-2__no_interaction	rsf__cis-2__no_interaction	exx__cis-2__no_interaction
14521722-3	RESULTS: The blood <compound-id="206,5793,64689,79025">glucose</compound-id> and serum <compound-id="5997">cholesterol</compound-id> levels were all normal in the OB group but the serum FFA and triglyceride concentrations were elevated compared with those of the controls (FFA: 888 microM/l +/- 158 microM/l vs 508 microM/l +/- 137 microM/l, P &lt; 0.05; TG: 1.8 mM/l +/- 0.6 mM/l vs 1.1 mM/l +/- 0.5 mM/l, P &lt; 0.05) The GDR in steady-state was 6.7 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) +/- 1.4 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) in the OB group, significantly lower than that of the controls (12.2 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1) +/- 3.1 mg x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(-1), P &lt; 0.05).	cholesterol__min(-1__no_interaction	glucose__min(-1__no_interaction
12029081-2	Two human ElaC variants were recently associated with cancer (Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., <protein-id="P49913,J3KNB4">Camp</protein-id>, N. J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M., Frank, D., Frye, C., Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N., Laity, K. E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F., Skolnick, M. H., Neuhausen, S., Rommens, J., and <compound-id="3050747">Cannon</compound-id>-Albright, L. A.	Cannon__Camp__no_interaction
8985819-12	The levels of PIIINP correlated significantly with <compound-id="5280352">bilirubin</compound-id> (r = 0.43, P &lt; 0.006), while hyaluronan was correlated with age (r = 0.33, P &lt; 0.015), pruritus (r = 0.32, P &lt; 0.02), fatigue (r = 0.41, P &lt; 0.003), hepatomegaly (r = -0.46, P &lt; 0.0008), the presence of oesophageal varices (r = 0.34, P &lt; 0.002), weight loss (r = 0.29, P &lt; 0.05), <compound-id="5280352">bilirubin</compound-id> (r = 0.54, P &lt; 0.0001), <protein-id="P02768">albumin</protein-id> (r = -0.30, P &lt; 0.04), extent of fat excretion (r = 0.53, P &lt; 0.009) and length of symptomatic period before diagnosis of PBC (r = 0.43, P &lt; 0.002).	bilirubin__albumin__no_interaction
10634414-4	The following novel features of cellular adhesion of ITMC to thyrocytes in the regulation of the thyrocyte function in GD were observed: 1) GD-ITMC expressed lymphocyte function-associated antigen (<protein-id="P20701,B2RAL6">LFA)-1</protein-id>, which became an active adhesive configuration much higher than peripheral blood mononuclear cells (PBMC) from normal volunteers and GD patients; 2) GD-thyrocytes expressed a high quantity of intercellular adhesion molecule (<protein-id="P05362">ICAM)-1</protein-id>; 3) GD-ITMC adhered to GD-thyrocytes, whereas normal PBMC required activation stimuli by <compound-id="442070">phorbol</compound-id> myriacetate, a pharmacological integrin-trigger, to adhere to GD- thyrocytes; 4) monoclonal antibody-blocking studies showed that the adhesion of the activated PBMC and ITMC to thyrocytes was mainly mediated by the <protein-id="P20701,B2RAL6">LFA-1</protein-id>/<protein-id="P05362">ICAM-1</protein-id> pathway; 5) the adhesion of GD-thyrocytes to the activated-PBMC or ITMC induced the proliferation of the thyrocytes, which was blocked by the addition of <protein-id="P05362">ICAM-1</protein-id> and/or <protein-id="P20701,B2RAL6">LFA-1</protein-id> monoclonal antibodies; and 6) in GD thyrocytes of early cultures, <protein-id="P05362">ICAM-1</protein-id> expression on GD-thyrocytes and its adhesion to <protein-id="P20701,B2RAL6">LFA-1</protein-id> on <compound-id="442070">phorbol</compound-id> myriacetate-activated PBMC or ITMC were not modulated by the addition of <protein-id="P01584">interleukin-1beta</protein-id> or <protein-id="P01579">interferon-gamma</protein-id>, and proliferation of thyrocytes by the cellular adhesion via the <protein-id="P05362">ICAM-1</protein-id>/<protein-id="P20701,B2RAL6">LFA-1</protein-id> pathway was independent of the proliferative response of these cytokines.	phorbol__LFA)-1__no_interaction	phorbol__ICAM)-1__no_interaction	phorbol__interleukin-1beta__no_interaction	phorbol__ICAM-1__no_interaction	phorbol__LFA-1__no_interaction	phorbol__interferon-gamma__no_interaction
20033681-5	RESULTS: The GM [90% confidence interval (CI)] of the <compound-id="148192">atazanavir</compound-id> C(min), C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), and AUC of patients taking the <compound-id="4095">methadone</compound-id> oral solution at doses of 20-175 mg/day simultaneously with antiretroviral therapy were impaired compared to patients not taking <compound-id="4095">methadone</compound-id> oral solution: C(min) = 315 (range 197-448) vs. 519 (279-793) ng/mL [<protein-id="P15509">GM ratio</protein-id> (<protein-id="P15509">GMR</protein-id>) = 0.61, p = 0.229]; C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) = 1714 (1238-2262) vs. 3190 (2412-4076) ng/mL (<protein-id="P15509">GMR</protein-id> = 0.54, p = 0.018); AUC = 21,987 (15,870-29,327) vs. 35,572 (26,211-46,728) ng h/mL (<protein-id="P15509">GMR</protein-id> = 0.62, p = 0.074).	atazanavir__max__no_interaction	atazanavir__GMR__no_interaction	atazanavir__GM ratio__no_interaction	methadone__max__no_interaction	methadone__GMR__no_interaction	methadone__GM ratio__no_interaction
16923367-12	Low or high dose L-<compound-id="6322,90867653">arginine</compound-id> treatment increased significantly the IGF-I levels from 0.789 +/- 0.062 ng/mg (Model group) to 0.937 +/- 0.067 ng/mg (low dose group) or 0.858 +/- 0.077 ng/mg (high dose group), the <protein-id="P01346,A0A0G2JTA6,M9NW49">IGF-II</protein-id> levels from 0.270 +/- 0.020 ng/mg (Model group) to 0.318 +/- 0.018 ng/mg (low dose group) or 0.354 +/- 0.021 ng/mg (high dose group) and the IGF-I mRNA expression from (13.12 +/- 1.39) x 10(4) cps/mug RNA (Model group) to (19.24 +/- 2.48) x 10(4) cps/mug RNA (low dose group) or (17.35 +/- 2.30) x 10(4) cps/mug RNA (high dose group) (P &lt; 0.01).	arginine__IGF-II__no_interaction
3297770-2	Gastrin, <compound-id="123946">xenopsin</compound-id>, <protein-id="P06307,Q6FG82">cholecystokinin</protein-id> (<protein-id="P06307,Q6FG82">CCK</protein-id>), <protein-id="P61278">somatostatin</protein-id>, <protein-id="P12872">motilin</protein-id>, <protein-id="P09683">secretin</protein-id>, GIP (gastric inhibitory polypeptide), <protein-id="P30990,Q6FH20">neurotensin</protein-id>, glicentin/glucagon-37 and <protein-id="P10082">PYY</protein-id> (peptide <compound-id="6057,90983769">tyrosine</compound-id> <compound-id="6057,90983769">tyrosine</compound-id>) are the main products of gastrointestinal endocrine cells; glucagon, CRF (corticotropin releasing factor), <protein-id="P61278">somatostatin</protein-id>, PP (<protein-id="P01298">pancreatic polypeptide</protein-id>) and GRF (growth hormone releasing factor), in addition to insulin, are produced in pancreatic islet cells; <protein-id="P07492">bombesin</protein-id>-related peptides are the main markers of pulmonary endocrine cells; calcitonin and <protein-id="P06881,P01258">CGRP</protein-id> (<protein-id="P06881,P01258">calcitonin gene-related peptide</protein-id>) occur in thyroid and extrathyroid C cells; <protein-id="P01189,Q6FHC8">ACTH</protein-id> and endorphins in anterior and intermediate lobe pituitary cells, <protein-id="P01189,Q6FHC8">alpha-MSH</protein-id> and <protein-id="P01189,Q6FHC8">CLIP</protein-id> (<protein-id="P01189,Q6FHC8">corticotropin-like intermediate lobe peptide</protein-id>) in intermediate lobe cells; met- and leu-enkephalins and related peptides in adrenal medullary and paraganglionic cells as well as in some gut (enterochromaffin) cells; <protein-id="P01303,A4D158">NPY</protein-id> (<protein-id="P01303,A4D158">neuropeptide Y</protein-id>) in <compound-id="5816">adrenaline</compound-id>-type adrenal medullary cells, etc..	xenopsin__neuropeptide Y__no_interaction	xenopsin__PYY__no_interaction	xenopsin__alpha-MSH__no_interaction	xenopsin__neurotensin__no_interaction	xenopsin__CLIP__no_interaction	xenopsin__pancreatic polypeptide__no_interaction	xenopsin__ACTH__no_interaction	xenopsin__calcitonin gene-related peptide__no_interaction	xenopsin__corticotropin-like intermediate lobe peptide__no_interaction	xenopsin__somatostatin__no_interaction	xenopsin__motilin__no_interaction	xenopsin__NPY__no_interaction	xenopsin__CCK__no_interaction	xenopsin__bombesin__no_interaction	xenopsin__secretin__no_interaction	xenopsin__CGRP__no_interaction	xenopsin__cholecystokinin__no_interaction	adrenaline__neuropeptide Y__no_interaction	adrenaline__PYY__no_interaction	adrenaline__alpha-MSH__no_interaction	adrenaline__neurotensin__no_interaction	adrenaline__CLIP__no_interaction	adrenaline__pancreatic polypeptide__no_interaction	adrenaline__ACTH__no_interaction	adrenaline__calcitonin gene-related peptide__no_interaction	adrenaline__corticotropin-like intermediate lobe peptide__no_interaction	adrenaline__somatostatin__no_interaction	adrenaline__motilin__no_interaction	adrenaline__NPY__no_interaction	adrenaline__CCK__no_interaction	adrenaline__bombesin__no_interaction	adrenaline__secretin__no_interaction	adrenaline__CGRP__no_interaction	adrenaline__cholecystokinin__no_interaction	tyrosine__neuropeptide Y__no_interaction	tyrosine__PYY__no_interaction	tyrosine__alpha-MSH__no_interaction	tyrosine__neurotensin__no_interaction	tyrosine__CLIP__no_interaction	tyrosine__pancreatic polypeptide__no_interaction	tyrosine__ACTH__no_interaction	tyrosine__calcitonin gene-related peptide__no_interaction	tyrosine__corticotropin-like intermediate lobe peptide__no_interaction	tyrosine__somatostatin__no_interaction	tyrosine__motilin__no_interaction	tyrosine__NPY__no_interaction	tyrosine__CCK__no_interaction	tyrosine__bombesin__no_interaction	tyrosine__secretin__no_interaction	tyrosine__CGRP__no_interaction	tyrosine__cholecystokinin__no_interaction
18788218-9	When compared to standard CPB, the Synergy showed lower levels of the monocyte-platelet adhesion index at T2 (0.023 +/- 0.005 vs 0.063 +/- 0.013, P = 0.0092) and T4 (0.031 +/- 0.003 vs 0.055 +/- 0.005, P = 0.0017), TAT complexes at T2 (27.175 +/- 5.967 vs 86.592 +/- 5.415, P = 0.0005) and <compound-id="5920">T3</compound-id> (26.977 +/- 2.468 vs 45.146 +/- 4.365, P = 0.0041), <protein-id="P00748,Q8IZZ5">F1+2</protein-id> fragments at T2 (2.222 +/- 0.226 vs 4.249 +/- 0.292, P = 0.0009), and sP-<compound-id="4929">selectin</compound-id> at <compound-id="5920">T3</compound-id> (115.17 +/- 19.623 vs 169.554 +/- 19.709, P = 0.0703) and T4 (108.542 +/- 6.429 vs 140.799 +/- 14.771, P = 0.0833).	T3__F1+2__no_interaction	selectin__F1+2__no_interaction
3185288-2	After 14 days of <compound-id="5865">prednisone</compound-id>, there was a significant increase in levels (mg/dL) of very low density lipoprotein-triglyceride (VLDL-TG) (51 +/- 9 v 92 +/- 11, P less than .01), very low density lipoprotein-<compound-id="5997">cholesterol</compound-id> (VLDL-C) (19 +/- 2 v 28 +/- 3, P less than .01), high density lipoprotein-<compound-id="5997">cholesterol</compound-id> (<protein-id="P28845,X5D2L1">HDL</protein-id>-C) (39 +/- 1 v 50 +/- 4, P less than .05), <protein-id="P02647,A0A024R3E3">apolipoprotein (apo) AI</protein-id> (124 +/- 7 v 147 +/- 8, P less than .01), and apo E (3.1 +/- 0.4 v 4.1 +/- 0.4, P less than .01).	prednisone__HDL__no_interaction	prednisone__apolipoprotein (apo) AI__no_interaction	cholesterol__HDL__no_interaction	cholesterol__apolipoprotein (apo) AI__no_interaction
24441276-15	Mänga faktorer <compound-id="6032">kan</compound-id> ha påverkat resultatet <protein-id="Q8TE85">som</protein-id> tex patientens motivation, <compound-id="4594">andra</compound-id> psyko-sociala omstandigheter och arbetsterapeutemas beslut att endast använda sig av två stycken av ett flertal arbetsprov.Konklusiionen ar att en bedörning av patientens arbetskapacitet skall utföras prospektivt och bör ta i beräknng de krav arbetet ställer enligt DOT och därefter bör rätt arbetsprov väijas för den individuella patienten.	kan__som__no_interaction	andra__som__no_interaction
23086471-2	Oxidative addition of {SeC5H3(3-R)N}2 (R = H or Me) to [Pd(P∩P)2] (P∩P = dppe, dppp) gave either a mononuclear complex, [Pd{2-Se-C5H3(3-R)N}2(P∩P)] (for P∩P/R: dppe/H or Me; dppp/H) or a cationic binuclear complex, [<protein-id="Q8N7H5,A0A024R0H6">Pd2</protein-id>{μ-SeC5H3(3-Me)N}2(dppp)2]2+ (4b) (R = Me) whereas reactions involving the <compound-id="6327182">tellurium</compound-id> analogue exclusively afforded trinuclear complexes, [<compound-id="25011744">Pd3</compound-id>(μ-Te)2(P∩P)3]<compound-id="24526">Cl2</compound-id> (P∩P = dppe (2) or dppp (6)).	Pd3__Pd2__no_interaction	Cl2__Pd2__no_interaction	tellurium__Pd2__no_interaction
19364123-3	The organic bridging/chelating ligands are discussed separately as follows: (i) pyridyl alkoxides [the anions of <compound-id="11474">2-(hydroxymethyl)pyridine</compound-id> (<protein-id="Q03014">hmpH</protein-id>), <compound-id="70957">2,6-pyridinedimethanol</compound-id> (pdmH(2)), and the gem-diol form of <compound-id="88065">di-2-pyridyl ketone</compound-id> (dpkdH(2))]; (ii) non-pyridyl alkoxides [the anions of 1,1,1-<compound-id="6503">tris</compound-id>(hydroxymethyl)<compound-id="6324">ethane</compound-id> (thmeH(3)), <compound-id="7618">triethanolamine</compound-id> (<compound-id="8471">teaH</compound-id>(3)), and <compound-id="7767">N-methyldiethanolamine</compound-id> (mdaH(2))]; (iii) other alcohols [the anions of 2,6-<compound-id="79015">dihydroxymethyl</compound-id>-<compound-id="2879">4-methylphenol</compound-id> (LH(3)) and Schiff bases]; (iv) pyridyl monoximes/dioximes [the anions of <compound-id="51040923">methyl-2-pyridyl ketone</compound-id> <compound-id="6350">oxime</compound-id> (mpkoH), <compound-id="53973492">phenyl-2-pyridyl ketone</compound-id> <compound-id="6350">oxime</compound-id> (ppkoH), and <compound-id="90827264">2,6-diacetylpyridine dioxime</compound-id> (dapdoH(2))]; (v) non-pyridyl oximes [the anions of <compound-id="5324608,5359280,6740756">salicylaldoxime</compound-id> (saoH(2)) and its derivatives R-saoH(2)].	4-methylphenol__hmpH__no_interaction	2,6-diacetylpyridine dioxime__hmpH__no_interaction	ethane__hmpH__no_interaction	2,6-pyridinedimethanol__hmpH__no_interaction	methyl-2-pyridyl ketone__hmpH__no_interaction	dihydroxymethyl__hmpH__no_interaction	salicylaldoxime__hmpH__no_interaction	di-2-pyridyl ketone__hmpH__no_interaction	oxime__hmpH__no_interaction	teaH__hmpH__no_interaction	triethanolamine__hmpH__no_interaction	N-methyldiethanolamine__hmpH__no_interaction	2-(hydroxymethyl)pyridine__hmpH__no_interaction	phenyl-2-pyridyl ketone__hmpH__no_interaction	tris__hmpH__no_interaction
10090936-2	Further analysis of patient <compound-id="7009630">LE</compound-id>, with the highest inhibitor titer, showed that (1) plasma or polyclonal IgG antibodies prepared from <compound-id="7009630">LE</compound-id> plasma inhibited the activity of allogeneic (wild-type) but not of self FVIII; (2) the presence of <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>) increased by over 10-fold the inhibitory activity on wild-type FVIII; (3) the kinetics of FVIII inhibition followed a type II pattern, but in contrast to previously described type II inhibitors, <compound-id="7009630">LE</compound-id> IgG was potentiated by the presence of <protein-id="P04275">vWF</protein-id> instead of being in competition with it; (4) polyclonal <compound-id="7009630">LE</compound-id> IgG recognized the FVIII light chain in enzyme-linked immunosorbent assay and the recombinant A3-C1 domains in an immunoprecipitation assay, indicating that at least part of <compound-id="7009630">LE</compound-id> antibodies reacted with the FVIII domain encompassing the mutation site; and (5) <compound-id="7009630">LE</compound-id> IgG inhibited FVIII activity by decreasing the rate of FVIIIa release from <protein-id="P04275">vWF</protein-id>, but <compound-id="7009630">LE</compound-id> IgG recognized an epitope distinct from ESH8, a murine monoclonal antibody exhibiting the same property.	LE__von Willebrand factor__no_interaction	LE__vWF__no_interaction
15332825-8	The reactions of the Cu(I) complexes with dioxygen in <compound-id="887">MeOH</compound-id> at -75 degrees C have given the trans-micro-1,2 peroxo dinuclear Cu(II) complexes formulated as [((<compound-id="80083">tapa</compound-id>)Cu)(2)(O(2))](2+) (1c), [((bapa)Cu)(2)(O(2))](2+) (2c), and [((mapa)Cu)(2)(O(2))](2+) (3c), whose characterizations were confirmed by UV-vis, <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR</protein-id>, and resonance Raman spectroscopies.	tapa__ESR__no_interaction	MeOH__ESR__no_interaction
22246377-9	RESULTS: CI increased at 3 and 6 h by 0.4 ± 0.1 (23%) and 0.33 ± 0.1 (17%) l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) m(-2), during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs -0.02 ± 0.1 (-1%) and -0.08 ± 0.1 (-5%) l <protein-id="P13987,Q6FHM9">min(-1</protein-id>) m(-2) during placebo (p = 0.003); and heart rate (HR) increased at 1, 3 and 6 h by 8 ± 3 (11%), 15 ± 4 (21%) and 21 ± 5 (29%) beats per min (bpm), during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs -1 ± 2 (-2%), 1 ± 1 (2%) and 6 ± 2 (8%) bpm, during placebo (p = 0.006); and PCWP decreased at 1, 3 and 6 h by -1.3 ± 0.8 (-8%), -1.2 ± 1 (-8%) and -2.2 ± 0.9 (-15%) mmHg, during <compound-id="45588096,53396299,56927919">exenatide</compound-id> infusion vs 0.3 ± 0.5 (2%), 1 ± 0.6 (6%) and 1.4 ± 0.7 (8%) mmHg, during placebo (p = 0.001).	exenatide__min(-1__no_interaction
16156617-4	[<compound-id="199">Ag2</compound-id>(L9)](SO3CF3)2 (1) (triclinic, P; a =10.292(4), b = 10.794(4), c = 11.399(5) A; alpha = 98.894(5), beta = 102.360(6), gamma = 90.319(5) degrees ; Z = 2), [Ag(L9)]SbF6 (2) (orthorhombic, Cmca; a = 19.059(9), b = 12.922(6), c = 15.609(7) A; Z = 8), [Ag(L9)]BF4 (3) (orthorhombic, Cmca; a = 19.128(3), b = 12.6042(18), c = 28.003(4) A; Z = 16), [Ag(L9)]ClO4 (4) (monoclinic, P2(1)/c; a = 8.5153(16), b = 19.722(4), c = 10.320(2) A; beta = 105.307(3) degrees ; Z = 4), [Ag(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)]SO3CF3 (5) (triclinic, P; a = 9.0605(13), b = 10.4956(15), c = 10.8085(16) A; alpha = 101.666(2), beta = 109.269(2), gamma = 100.944(2) degrees ; Z = 2), [Ag(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)(H2O)(0.5)]BF4.0.5H2O (6) (monoclinic, C2/m; a = 32.180(6), b = 17.027(3), c = 8.1453(15) A; beta = 102.541(3) degrees ; Z = 8), and {[<compound-id="199">Ag2</compound-id>(<protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id>)2(H2O)](ClO4)2}.o-<compound-id="7237">xylene</compound-id> (7) (monoclinic, P2(1)/c; a = 8.1460(10), b = 17.326(2), c = 30.345(4) A; beta = 97.71 degrees ; Z = 4) were obtained by the combination of L9 and <protein-id="P27635,X5D2T3,A0A087WV22">L10</protein-id> with various Ag(I) salts in a <compound-id="241">benzene</compound-id>/<compound-id="6344">methylene chloride</compound-id> mixed solvent system.	benzene__L10__no_interaction	xylene__L10__no_interaction	Ag2__L10__no_interaction	methylene chloride__L10__no_interaction
22384252-7	<protein-id="P30531,A0A024R2G0">GAT1</protein-id> blockade resulted in increases in mean (± SD) [(11)C]<compound-id="3373">flumazenil</compound-id> VT in Group II in association cortices (6.8 ± 0.8 mL g-1 vs. 7.3 ± 0.4 mL g-1;p = 0.03), sensory cortices (6.7 ± 0.8 mL g-1 vs. 7.3 ± 0.5 mL g-1;p = 0.02) and limbic regions (5.2 ± 0.6 mL g-1 vs. 5.7 ± 0.3 mL g-1;p = 0.03).	flumazenil__GAT1__no_interaction
25125317-16	The studies were conducted in hospital settings in low, middle and high income countries.Blood lossWe found significant reductions in blood loss with the following interventions: vaginal <compound-id="5282381">misoprostol</compound-id> (2 RCTs, 89 women: MD -97.88 ml, 95% CI -125.52 to -70.24; I(2) = 43%; moderate-quality evidence); intramyometrial <protein-id="P01185,X5DQP6">vasopressin</protein-id> (3 RCTs, 128 women: MD -245.87 ml, 95% CI -434.58 to -57.16; I(2) = 98%; moderate-quality evidence); intramyometrial bupivacaine plus <compound-id="5816">epinephrine</compound-id> (1 RCT, 60 women: MD -68.60 ml, 95% CI -93.69 to -43.51; low-quality evidence); intravenous <compound-id="5526">tranexamic acid</compound-id> (1 RCT, 100 women: MD -243 ml, 95% CI -460.02 to -25.98; low-quality evidence); gelatin-<compound-id="90470996">thrombin</compound-id> matrix (1 RCT, 50 women: MD -545.00 ml, 95% CI -593.26 to -496.74; low-quality evidence); intravenous <compound-id="54670067">ascorbic acid</compound-id> (1 RCT, 102 women: MD -411.46 ml, 95% CI -502.58 to -320.34; low-quality evidence); vaginal <compound-id="5280360">dinoprostone</compound-id> (1 RCT, 108 women: MD -131.60 ml, 95% CI -253.42 to -9.78; low-quality evidence); loop ligation of the myoma pseudocapsule (1 RCT, 70 women: MD -305.01 ml, 95% CI -354.83 to -255.19; low-quality evidence); and a fibrin sealant patch (1 RCT, 70 women: MD -26.50 ml, 95% CI -44.47 to -8.53; low-quality evidence).	ascorbic acid__vasopressin__no_interaction	dinoprostone__vasopressin__no_interaction	thrombin__vasopressin__no_interaction	epinephrine__vasopressin__no_interaction	misoprostol__vasopressin__no_interaction	tranexamic acid__vasopressin__no_interaction
19916849-6	RESULTS: In ischemic events, <compound-id="5754">cortisol</compound-id> level at third and seventh days, and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> level at the first day were correlated with lesion volumes (r = 0.5, p = .02; r = 0.4, p = .02; r = 0.5, p = .005, respectively).	cortisol__fibrinogen__no_interaction
7956938-4	During the steady-state phase of the experiment, <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF-I</protein-id> dose dependently reduced plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (pmol/liter: A, 718 +/- 58; B, 613 +/- 35, NS vs. A; C, 408 +/- 21, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0001), plasma <protein-id="P12969">amylin</protein-id> (pmol/liter: A, 10.2 +/- 0.6; B, 8.8 +/- 0.5, NS vs. A; C, 5.8 +/- 0.4, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0001), and net <compound-id="206,5793,64689,79025">glucose</compound-id> uptake (mumol/kg.min: A, 188 +/- 12; B, 160 +/- 12, NS vs. A; C, 134 +/- 7, P &lt; 0.01 vs. A; dose-response effect: P &lt; 0.0025).	glucose__amylin__no_interaction	glucose__IGF-I__no_interaction	glucose__insulin__no_interaction
16425287-8	In addition, serum ferritin, serum <compound-id="23925,67172434">iron</compound-id> and <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation were all inversely associated with colon cancer risk specifically (OR = 0.2, 95% CI = 0.1-0.7, p trend = 0.02; OR = 0.2, 95% CI = 0.1-0.9, p trend = 0.05; OR = 0.1, 95% CI = 0.02-0.5, p trend = 0.003, respectively), whereas serum unsaturated <compound-id="23925,67172434">iron</compound-id> binding capacity was positively associated with colon cancer risk (OR = 4.7, 95% CI = 1.4-15.1, p trend = 0.009).	iron__transferrin__no_interaction
7544886-2	Here we report that: (i) L-dT is selectively phosphorylated in vivo to L-dTMP by HSV-1 TK and L-dTMP is further phosphorylated to the di- and triphosphate forms by non-stereospecific cellular kinases; (ii) <compound-id="472333">L-dTTP</compound-id> not only inhibits HSV-1 DNA polymerase in vitro, but also human <protein-id="P28340,M0R2B7,A0A024R4F4,Q308M6,Q59FA0">DNA polymerase alpha, gamma, delta and epsilon</protein-id>, human immunodeficiency virus reverse transcriptase (HIV-1 RT), Escherichia coli DNA polymerase 1 and calf thymus terminal transferase, although <protein-id="Q27958">DNA polymerase beta</protein-id> was resistant; (iii) whereas <protein-id="Q27958">DNA polymerase beta</protein-id>, gamma, delta and epsilon are unable to utilize <compound-id="472333">L-dTTP</compound-id> as a substrate, the other DNA polymerases clearly incorporate at least one L-dTMP residue, with DNA polymerase alpha and HIV-1 RT able to further elongate the DNA chain by catalyzing the formation of the phosphodiester bond between the incorporated L-dTMP and an incoming <compound-id="472333">L-dTTP</compound-id>; (iv) incorporated L-nucleotides at the 3'-OH terminus make DNA more resistant to 3'--&gt;5' exonucleases.	L-dTTP__DNA polymerase alpha, gamma, delta and epsilon__no_interaction	L-dTTP__DNA polymerase beta__no_interaction
9248636-4	With the exception of <compound-id="5816">adrenaline</compound-id>, there were significant positive correlations between <protein-id="P01185,X5DQP6">vasopressin</protein-id> (r = 0.707, p &lt; 0.0001), plasma <protein-id="P00797">renin</protein-id> activity (r = 0.721, P &lt; 0.0001), <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin II</protein-id> (r = 0.512, P = 0.002), aldosterone (r = 0.620, P &lt; 0.0001), noradrenaline (r = 0.430, P = 0.0189), <compound-id="681">dopamine</compound-id> (r = 0.627, P = 0.0024) and percentage burn surface area, and a negative correlation between atrial natriuretic peptide (r = 0.548, P = 0.0008) and burn surface area.	adrenaline__angiotensin II__no_interaction	adrenaline__vasopressin__no_interaction	adrenaline__renin__no_interaction	dopamine__angiotensin II__no_interaction	dopamine__vasopressin__no_interaction	dopamine__renin__no_interaction
9683948-9	Plasma viscosity was significantly correlated with <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.63, p &lt; 0.001), systolic blood pressure (r = 0.33, p = 0.03) and <compound-id="5997">cholesterol</compound-id> (r = 0.32, p = 0.04), while <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id> was correlated with Lp(a) levels (r = 0.38, p = 0.03).	cholesterol__fibrinogen__no_interaction	cholesterol__P-selectin__no_interaction
9546612-2	Alpha-<compound-id="90470996">thrombin</compound-id> activated Factor XIII more efficiently (Km = 0.83 +/- 0.08 x 10(-7) M; V/K = 14.90 +/- 3.20 x 10(-3) min(-1)) than beta-<compound-id="90470996">thrombin</compound-id> (Km = 6.14 +/- 1.26 x 10(-7) M; V/K = 3.30 +/- 1.00 x 10(-3) <protein-id="P13987,Q6FHM9">min(-1)) or gamma-thrombin</protein-id> (Km = 6.25 +/- 1.15 x 10(-7) M; V/K = 3.00 +/- 0.80 x 10(-3) min(-1)).	thrombin__min(-1)) or gamma-thrombin__no_interaction
10690853-3	After ovarian stimulation (mean +/- SE of mean): free T4 decreased, 14.4 +/- 0.2 vs. 12.9 +/- 0.2 pmol/L (P &lt; 0.0001); thyroid-stimulating hormone increased, 2.3 +/- 0.3 vs. 3.0 +/- 0.4 mU/L (P &lt; 0.0001); <protein-id="P05543">T4-binding globulin</protein-id> increased, 25.2 +/- 0.7 vs. 33.9 +/- 0.9 mg/L (P &lt; 0.0001); total T4 increased, 98.1 +/- 2.3 vs. 114.6 +/- 2.5 nmol/L (P &lt; 0.0001); total <compound-id="5920">T3</compound-id> increased, 2.0 +/- 0.04 vs. 2.3 +/- 0.07 nmol/L (P &lt; 0.0001); <protein-id="P07202,Q6P534,Q502Y3">TPO</protein-id> antibodies decreased, 370 +/- 233 U/mL vs. 355 +/- 224 U/mL (P &lt; 0.0001); LH decreased, 8.1 +/- 1.1 vs. 0.4 +/-0.1 U/L (P &lt; 0.0001); FSH did not change, 6.5 +/- 0.6 vs. 7.9 +/- 0.9 U/L (P = 0.08); human CG increased, &lt;2 +/- 0.0 vs. 195 +/- 16 U/L (P &lt; 0.0001); <compound-id="5757">estradiol</compound-id> increased, 359.3 +/- 25.9 pmol/L vs. 3491.8 +/-298.3 pmol/L (P &lt; 0.0001); and <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> increased, 0.23 +/- 0.02 vs. 0.95 +/- 0.06 U/L (P &lt; 0.0001).	T3__TPO__no_interaction	T3__PRL__no_interaction	T3__T4-binding globulin__no_interaction	estradiol__TPO__no_interaction	estradiol__PRL__no_interaction	estradiol__T4-binding globulin__no_interaction
12639121-1	The nuclear magnetic transverse relaxation time of <compound-id="10197601">oxygen-17</compound-id> in aqueous <compound-id="23665763">sodium bisulfite</compound-id> solutions in the pH range from 2.5 to 5 was measured over a range of temperatures, pH, and S(IV) concentrations at an ionic strength of 1.0 m. From these data the rate law for <compound-id="977">oxygen</compound-id> exchange between bisulfite ion and <compound-id="962">water</compound-id> was determined and found to be consistent with <compound-id="977">oxygen</compound-id> exchange occurring via the reactions <protein-id="Q5BIV9">SHO</protein-id>(3)(-) + H(+) SO(2) + H(2)O, SO(3)H(-) + <protein-id="Q5BIV9">SHO</protein-id>(3-) SO(3)(2-) + SO(2) + H(2)O, and SO(3)H(-) + <protein-id="Q5BIV9">SHO</protein-id>(3-) S(2)O(5)(2-) + H(2)O, where the symbol <protein-id="Q5BIV9">SHO</protein-id>(3-) refers to both isomeric forms of bisulfite ion, one in which the <compound-id="783">hydrogen</compound-id> is bonded to the <compound-id="402">sulfur</compound-id> (denoted HSO(3-)) and another in which the <compound-id="783">hydrogen</compound-id> is bonded to an <compound-id="977">oxygen</compound-id> atom (denoted SO(3)H(-)).	oxygen__SHO__no_interaction	oxygen-17__SHO__no_interaction	sodium bisulfite__SHO__no_interaction	water__SHO__no_interaction	sulfur__SHO__no_interaction	hydrogen__SHO__no_interaction
9794743-8	However, the changes in resting systolic (r = 0.32, P &lt; 0.025) and diastolic (r = 0.36, P &lt; 0.01) blood pressures and in 24 h systolic (r = 0.28, P &lt; 0.05) blood pressure after <compound-id="5360545">sodium</compound-id> loading were all positive functions of individual resting end-tidal partial pressures of <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id>.	sodium__CO2__no_interaction
8238456-4	As occurs in animals, durations of nocturnal periods of active <compound-id="896">melatonin</compound-id> secretion (11.9 +/- 1.6 vs. 10.3 +/- 1.3 h, df = 14, t = 4.583, P &lt; 0.0005, paired t test), high <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> secretion (12.9 +/- 2.1 vs. 9.9 +/- 2.2 h, df = 11, t = 2.917, P &lt; 0.01), and sleep (10.6 +/- 0.8 vs. 7.6 +/- 0.4 h, df = 14, t = 17.122, P &lt; 0.0005) were longer after exposure to long nights than after short ones.	melatonin__prolactin__no_interaction
11993410-4	Obese women demonstrated higher concentrations of TG (2.03 +/- 0.78 vs. 0.99 +/- 0.37 mmol/l; p &lt; 0.05), <compound-id="91474">7-ketocholesterol</compound-id> (7-K) (89.85 +/- 63.03 vs. 41.90 +/- 17.33 ng/ml; p &lt; 0.05) and <compound-id="473141">7-hydroxycholesterol</compound-id> (7-OH) (456.04 +/- 199.22 vs. 132.37 +/- 53.96 ng/ml; p &lt; 0.05), and lower <protein-id="P28845,X5D2L1">HDL</protein-id>-<compound-id="5997">cholesterol</compound-id> level (0.74 +/- 0.10 vs. 1.30 +/- +/- 0.17 mmol/l; p &lt; 0.05) compared to the control group, while there were no significant differences between the two groups in concentrations of TC, LDL-<compound-id="5997">cholesterol</compound-id> and <compound-id="1548900,1742129,2116">vitamin E</compound-id>. Plasma <compound-id="1548900,1742129,2116">vitamin E</compound-id>/(TC + TG) ratio was lower in obese women (6.42 +/- 2.61 vs. 10.76 +/- 4.57 mumol/mmol; p &lt; 0.05).	7-ketocholesterol__HDL__no_interaction	7-hydroxycholesterol__HDL__no_interaction	vitamin E__HDL__no_interaction	cholesterol__HDL__no_interaction
9540779-4	There was only a trend toward higher values of TAT and <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> for AF patients, while subjects with previous stroke (irrespective of AF) had increased levels of the markers of <compound-id="90470996">thrombin</compound-id> generation (TAT stroke+ 18.95 +/- 5.15 vs TAT stroke- 8.34 +/- 2.41; <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> stroke+ 2.22 +/- 0.29 vs <protein-id="P00748,Q8IZZ5">F1 + 2</protein-id> stroke- 1.32 +/- 0.12).	thrombin__F1 + 2__no_interaction
14728846-8	LH, T, free <compound-id="6013">testosterone</compound-id> (FT) were significant decreased from (13.9 +/- 5.9) IU/L, (2.1 +/- 0.8) nmol/L and (2.8 +/- 2.3) nmol/L respectively to (5.8 +/- 2.2) IU/L, (1.2 +/- 0.4) nmol/L and (0.8 +/- 0.5) nmol/L respectively and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> was significant increased from (99 +/- 42) nmol/L to (187 +/- 64) nmol/L in group A3, when compared with LH, T and FT from (13.8 +/- 7.6) IU/L, (2.2 +/- 1.1) nmol/L and (2.5 +/- 1.9) nmol/L respectively to (11.8 +/- 6.5) IU/L, (1.8 +/- 0.8) nmol/L and (1.7 +/- 1.0) nmol/L respectively and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> from (99 +/- 40) nmol/L to (120 +/- 51) nmol/L in group A2 (P &lt; 0.05 approximately 0.001).	testosterone__SHBG__no_interaction
15701011-1	High molecular weight, soluble, air- and moisture-stable, highly metallized (&gt;25 wt% metal) polyferrocenylsilanes (PFS) [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){<compound-id="280">Co2</compound-id>(CO)6C2Ph}]n (Co-PFS), [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){Mo2-<protein-id="P00450,A5PL27">Cp2</protein-id>(CO)4C2Ph}]n (Mo-PFS), and [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me){Ni2Cp2C2Ph}]n (Ni-PFS) containing pendant <compound-id="104730">cobalt</compound-id>, <compound-id="23932">molybdenum</compound-id>, and <compound-id="935">nickel</compound-id> clusters, respectively, have been prepared via macromolecular clusterization of an acetylide-substituted PFS [Fe(eta-C5H4)<compound-id="444390">2Si</compound-id>(Me)C(triple bond)CPh]n with [Co(2)(CO)8], [{MoCp(CO)(2)}2], or [{NiCp(CO)}2].	Co2__Cp2__no_interaction	nickel__Cp2__no_interaction	2Si__Cp2__no_interaction	molybdenum__Cp2__no_interaction	cobalt__Cp2__no_interaction
8957217-3	Pre-treatments with tachykinin NK1 receptor antagonists (<compound-id="108167,5311450">SR140333</compound-id>, (S)1-¿2-[3-(3.4-<compound-id="57417436">dichlorophenyl</compound-id>) -1-(3-isopropoxyphenylacetyl)<compound-id="8082">piperidin</compound-id>-n-3-yl]<compound-id="23134249">ethyl</compound-id>¿-4-ph eny l-1-azoniabicyclo [2,2,2]octane <compound-id="312">chloride</compound-id>; GR82334, <compound-id="159907">pGlu-Ala</compound-id>- <compound-id="170612">Asp-Pro</compound-id>-Asn-<compound-id="151410,3459978">Lys-Phe</compound-id>-<compound-id="6057">Tyr</compound-id>-(S-S)<compound-id="3527720">Pro-Leu</compound-id>(spiro-gamma-lactam)-Trp-NH2) reduced the <protein-id="P20366,Q9Y494">substance P</protein-id>-induced increases in the respiratory frequency but the tachykinin <protein-id="P21452">NK2 receptor</protein-id> antagonist (<compound-id="104974">SR48968</compound-id>, ((S)-N-methyl-N-[4-<compound-id="15886675">4-acetylamino-4-phenylpiperidine</compound-id>)-2-(3,4-dichlorop hen yl) <compound-id="68006705">butyl</compound-id>]<compound-id="2331">benzamide</compound-id>); MEN 10376, <compound-id="152455">Asp-Tyr</compound-id>-D-<compound-id="19816756,7009658">Trp-Val</compound-id>-<compound-id="9060">D-Trp</compound-id>-<compound-id="5962">Lys</compound-id>-NH2) had no effect; the increase in the respiratory frequency induced by the tachykinin <protein-id="P16177">NK3 receptor</protein-id> agonist was not affected by a pre-treatment with tachykinin NK1 and <protein-id="P21452">NK2 receptor</protein-id> antagonists.	Trp-Val__NK3 receptor__no_interaction	Trp-Val__substance P__no_interaction	Trp-Val__NK2 receptor__no_interaction	D-Trp__NK3 receptor__no_interaction	D-Trp__substance P__no_interaction	D-Trp__NK2 receptor__no_interaction	dichlorophenyl__NK3 receptor__no_interaction	dichlorophenyl__substance P__no_interaction	dichlorophenyl__NK2 receptor__no_interaction	Lys__NK3 receptor__no_interaction	Lys__substance P__no_interaction	Lys__NK2 receptor__no_interaction	SR140333__NK3 receptor__no_interaction	SR140333__substance P__no_interaction	SR140333__NK2 receptor__no_interaction	piperidin__NK3 receptor__no_interaction	piperidin__substance P__no_interaction	piperidin__NK2 receptor__no_interaction	Asp-Pro__NK3 receptor__no_interaction	Asp-Pro__substance P__no_interaction	Asp-Pro__NK2 receptor__no_interaction	4-acetylamino-4-phenylpiperidine__NK3 receptor__no_interaction	4-acetylamino-4-phenylpiperidine__substance P__no_interaction	4-acetylamino-4-phenylpiperidine__NK2 receptor__no_interaction	Lys-Phe__NK3 receptor__no_interaction	Lys-Phe__substance P__no_interaction	Lys-Phe__NK2 receptor__no_interaction	butyl__NK3 receptor__no_interaction	butyl__substance P__no_interaction	butyl__NK2 receptor__no_interaction	Asp-Tyr__NK3 receptor__no_interaction	Asp-Tyr__substance P__no_interaction	Asp-Tyr__NK2 receptor__no_interaction	SR48968__NK3 receptor__no_interaction	SR48968__substance P__no_interaction	SR48968__NK2 receptor__no_interaction	pGlu-Ala__NK3 receptor__no_interaction	pGlu-Ala__substance P__no_interaction	pGlu-Ala__NK2 receptor__no_interaction	benzamide__NK3 receptor__no_interaction	benzamide__substance P__no_interaction	benzamide__NK2 receptor__no_interaction	Pro-Leu__NK3 receptor__no_interaction	Pro-Leu__substance P__no_interaction	Pro-Leu__NK2 receptor__no_interaction	chloride__NK3 receptor__no_interaction	chloride__substance P__no_interaction	chloride__NK2 receptor__no_interaction	Tyr__NK3 receptor__no_interaction	Tyr__substance P__no_interaction	Tyr__NK2 receptor__no_interaction	ethyl__NK3 receptor__no_interaction	ethyl__substance P__no_interaction	ethyl__NK2 receptor__no_interaction
17942567-6	<compound-id="444266">Maleate</compound-id> toxicity reproduced critical characteristics of the hypoxia/ATP depletion-induced injury cascade: 1) <compound-id="20725278">glutathione</compound-id> (<compound-id="124886">GSH</compound-id>) conferred protection, but due to its <compound-id="45934207,750">glycine</compound-id>, not <compound-id="5862,90793998">cysteine</compound-id> (antioxidant), content; 2) ATP reductions reflected decreased production, not Na-K-ATPase-driven increased consumption; 3) cell death was completely blocked by extracellular acidosis (pH 6.6); 4) intracellular Ca(2+) chelation (<compound-id="104751">BAPTA</compound-id>) mitigated cell death; 5) <compound-id="444266">maleate</compound-id> and hypoxia each caused plasma membrane <compound-id="5997">cholesterol</compound-id> shedding and in both instances, this was completely <compound-id="45934207,750">glycine</compound-id> suppressible; <compound-id="40467203">6) maleate</compound-id> + hypoxia caused neither additive NEFA accumulation nor LDH release, implying shared pathogenic pathways; and 7) <compound-id="444266">maleate</compound-id>, like ischemia, induced renal cortical <compound-id="5997">cholesterol</compound-id> loading; increased HMG <compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> reductase (HMGCR) activity (statin inhibitable), increased HMGCR mRNA levels, and increased <protein-id="P46279,C6SWZ3">RNA polymerase II</protein-id> recruitment to the HMGCR locus (chromatin immunoprecipitation, ChIP, assay) were involved.	Maleate__RNA polymerase II__no_interaction	glutathione__RNA polymerase II__no_interaction	glycine__RNA polymerase II__no_interaction	6) maleate__RNA polymerase II__no_interaction	maleate__RNA polymerase II__no_interaction	CoA__RNA polymerase II__no_interaction	cysteine__RNA polymerase II__no_interaction	BAPTA__RNA polymerase II__no_interaction	cholesterol__RNA polymerase II__no_interaction	GSH__RNA polymerase II__no_interaction
12474259-1	This study is concerned with the development and application of kinetic locking-on and auxiliary tactics for bioaffinity purification of <compound-id="5886">NADP</compound-id>(+)-dependent dehydrogenases, specifically (1) the synthesis and characterization of highly substituted N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives using a rapid solid-phase modular approach; (2) the evaluation of the N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives for use with the kinetic locking-on strategy for bioaffinity purification of <compound-id="5886">NADP</compound-id>(+)-dependent dehydrogenases: Model bioaffinity chromatographic studies with <compound-id="23327,33032,611,57109091">glutamate</compound-id> dehydrogenase from bovine liver (<protein-id="P00367,E9KL48">GDH</protein-id> with dual <compound-id="108194">cofactor</compound-id> specificity, EC 1.4.1.3) and <compound-id="23327,33032,611,57109091">glutamate</compound-id> dehydrogenase from Candida utilis (<protein-id="P00367,E9KL48">GDH</protein-id> which is <compound-id="5886">NADP</compound-id>(+)-specific, EC 1.4.1.4); (3) the selection of an effective "stripping ligand" for <compound-id="5886">NADP</compound-id>(+)-dehydrogenase bioaffinity purifications using N(6)-linked immobilized <compound-id="5886">NADP</compound-id>(+) derivatives in the locking-on mode; and (4) the application of the developed bioaffinity chromatographic system to the purification of C. utilis <protein-id="P00367,E9KL48">GDH</protein-id> from a crude cellular extract.	NADP__GDH__no_interaction	glutamate__GDH__no_interaction	cofactor__GDH__no_interaction
12629086-6	Serum IGF-I was positively correlated with fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.10, P = 0.06) and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.19, P = 0.0001) concentrations and blood pressure (systolic and diastolic r = 0.10, P &lt;/= 0.05) and inversely with percentage body fat (r = -0.13, P = 0.01) and waist circumference (r = -0.11, P = 0.03).	glucose__fibrinogen__no_interaction
15644495-3	Although (Z)-(4-<compound-id="7961">bromophenyl</compound-id>){1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-<compound-id="23092063">methyl-1,4'-bipiperidin-4-yl</compound-id>}methanone O-ethyloxime (Sch-C; SCH 351125), 4,6-dimethyl-5-{[4-methyl-4-((<compound-id="21439199">3S</compound-id>)-3-methyl-4-{(1R)-2-(<compound-id="123146">methyloxy</compound-id>)-1-[4-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]<compound-id="23134249">ethyl</compound-id>}-1-piperazinyl)-1-piperidinyl]carbonyl}pyrimidine (<compound-id="3009355">Sch-D</compound-id>; SCH 417,690), 4,4-difluoro-N-((1S)-3-{(3-endo)-3-[3-methyl-5-(1-<compound-id="275736">methylethyl</compound-id>)-4H-<compound-id="9257">1,2,4-triazol</compound-id>-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-1-phenyl-propyl)<compound-id="14283">cyclohexanecarboxamide</compound-id> (<compound-id="3002977">UK-427,857</compound-id>), and N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclo-<compound-id="11610">hepten</compound-id>-8-yl]carbonyl]amino]benzyl]<compound-id="8894">tetrahydro-2H-pyran</compound-id>-4-aminium <compound-id="312">chloride</compound-id> (<compound-id="183790">TAK779</compound-id>) blocked the binding of both chemokines (125)I-<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id> (also known as (125)I-<protein-id="P10147,A0N0R1">CCL3</protein-id>, (125)I-LD78) and (125)I-<protein-id="P13501,D0EI67">RANTES</protein-id> ((125)I-<protein-id="P13501,D0EI67">CCL5</protein-id>), 873140 was an ineffectual antagonist of (125)I-<protein-id="P13501,D0EI67">RANTES</protein-id> (regulated on activation normal T cell expressed and secreted) binding (but did block binding of (125)I-<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id>).	bromophenyl__CCL3__no_interaction	bromophenyl__RANTES__no_interaction	bromophenyl__MIP-1alpha__no_interaction	bromophenyl__CCL5__no_interaction	TAK779__CCL3__no_interaction	TAK779__RANTES__no_interaction	TAK779__MIP-1alpha__no_interaction	TAK779__CCL5__no_interaction	3S__CCL3__no_interaction	3S__RANTES__no_interaction	3S__MIP-1alpha__no_interaction	3S__CCL5__no_interaction	chloride__CCL3__no_interaction	chloride__RANTES__no_interaction	chloride__MIP-1alpha__no_interaction	chloride__CCL5__no_interaction	1,2,4-triazol__CCL3__no_interaction	1,2,4-triazol__RANTES__no_interaction	1,2,4-triazol__MIP-1alpha__no_interaction	1,2,4-triazol__CCL5__no_interaction	tetrahydro-2H-pyran__CCL3__no_interaction	tetrahydro-2H-pyran__RANTES__no_interaction	tetrahydro-2H-pyran__MIP-1alpha__no_interaction	tetrahydro-2H-pyran__CCL5__no_interaction	UK-427,857__CCL3__no_interaction	UK-427,857__RANTES__no_interaction	UK-427,857__MIP-1alpha__no_interaction	UK-427,857__CCL5__no_interaction	cyclohexanecarboxamide__CCL3__no_interaction	cyclohexanecarboxamide__RANTES__no_interaction	cyclohexanecarboxamide__MIP-1alpha__no_interaction	cyclohexanecarboxamide__CCL5__no_interaction	methylethyl__CCL3__no_interaction	methylethyl__RANTES__no_interaction	methylethyl__MIP-1alpha__no_interaction	methylethyl__CCL5__no_interaction	methyloxy__CCL3__no_interaction	methyloxy__RANTES__no_interaction	methyloxy__MIP-1alpha__no_interaction	methyloxy__CCL5__no_interaction	trifluoromethyl__CCL3__no_interaction	trifluoromethyl__RANTES__no_interaction	trifluoromethyl__MIP-1alpha__no_interaction	trifluoromethyl__CCL5__no_interaction	methyl-1,4'-bipiperidin-4-yl__CCL3__no_interaction	methyl-1,4'-bipiperidin-4-yl__RANTES__no_interaction	methyl-1,4'-bipiperidin-4-yl__MIP-1alpha__no_interaction	methyl-1,4'-bipiperidin-4-yl__CCL5__no_interaction	Sch-D__CCL3__no_interaction	Sch-D__RANTES__no_interaction	Sch-D__MIP-1alpha__no_interaction	Sch-D__CCL5__no_interaction	hepten__CCL3__no_interaction	hepten__RANTES__no_interaction	hepten__MIP-1alpha__no_interaction	hepten__CCL5__no_interaction	ethyl__CCL3__no_interaction	ethyl__RANTES__no_interaction	ethyl__MIP-1alpha__no_interaction	ethyl__CCL5__no_interaction
16988209-6	Pharmacokinetic parameters for <compound-id="132999">ivabradine</compound-id> did not vary significantly after <compound-id="4594">omeprazole</compound-id> (C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 45.0 +/- 36.6 vs 42.7 +/- 27.6 ng/mL, P = .98; AUC: 128 +/- 87 vs 126 +/- 63 ng/mL, P = .82) or <compound-id="3883">lansoprazole</compound-id> administration (C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 45.0 +/- 36.6 vs 41.3 +/- 29.4 ng/mL, P = .70; AUC: 128 +/- 87 vs 123 +/- 50, P = .73).	lansoprazole__max__no_interaction	omeprazole__max__no_interaction	ivabradine__max__no_interaction
3390203-1	Early after administration of <protein-id="Q9ER65">CS2</protein-id> to untreated, <compound-id="4763">phenobarbital</compound-id> (PB)-and <compound-id="1674">3-methylcholanthrene</compound-id> (3-MC)-pretreated C57BL/6 Cr mice: (1) the loss of cytochrome P-450 was enhanced by pretreatment with both inducers, but to a greater extent with 3-MC; (2) the decrease in <compound-id="3294">7-ethoxyresorufin</compound-id> (ER) O-deethylation activity was much greater than that of cytochrome P-450 in untreated and PB-pretreated mice, but both paralleled values in 3-MC-pretreated mice, in which ER O-deethylation activity was induced markedly, (3) the peak of the <compound-id="281">carbon monoxide</compound-id>-difference spectrum of microsomal reduced cytochrome P-450 (about 448 nm) in 3-MC-pretreated mice shifted toward 450 nm after administration of increasing doses of <protein-id="Q9ER65">CS2</protein-id>; (4) similar tendencies were observed in vitro in items (1) to (3); (5) electrophoresis of microsomal proteins revealed a loss of each protein band induced by PB and 3-MC following <protein-id="Q9ER65">CS2</protein-id> administration; (6) in the reconstituted monooxygenase system using partially purified cytochrome P-450 and <protein-id="P04799">P-448</protein-id> forms from PB- and 3-MC-treated rats, <protein-id="Q9ER65">CS2</protein-id> suppressed the drug-metabolizing activities exhibited by the <protein-id="P04799">P-448</protein-id> form but had little or no effect on those by the P-450 form; and (7) in <compound-id="8143">n-octylamine</compound-id> difference spectra of microsomes, loss of the 3-MC-induced high spin form of cytochrome P-450 was evident.	3-methylcholanthrene__P-448__no_interaction	3-methylcholanthrene__CS2__no_interaction	n-octylamine__P-448__no_interaction	n-octylamine__CS2__no_interaction	7-ethoxyresorufin__P-448__no_interaction	7-ethoxyresorufin__CS2__no_interaction	phenobarbital__P-448__no_interaction	phenobarbital__CS2__no_interaction	carbon monoxide__P-448__no_interaction	carbon monoxide__CS2__no_interaction
12360930-1	An in-depth analysis of a set of 21 layered structures of metallic pseudopolymorphs of general formulation, beta''-(<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>)(4) x (guest)(n) x [Re(6)Q(6)Cl(8)], (<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>=bis-<compound-id="11822531">ethylenedithiotetrathiafulvalene</compound-id>; Q = S, Se; guest = H(2)O, <compound-id="31275">1,4-dioxane</compound-id>, THF, <protein-id="P13236">CCl(4</protein-id>), C(2)H(5)OH, <compound-id="6432229">CHCl</compound-id>(3), CH(2)ClI, CH(2)ClBr, CH(2)Cl(2), CH(2)OH-CH(2)OH, C(5)H(5)N, CH(3)COCH(3), <compound-id="93002">2-hydroxy-tetrahydrofuran</compound-id>, CH(3)CN, CS(2), C(6)H(6)), with diverse low-temperature behaviors, which differ solely by the nature of the cosolvent molecule selectively included during the electrocrystallization process, reveals a precise set of weak HO-H...<compound-id="312">Cl-</compound-id>mu-Re, (C-H)(<protein-id="Q15669,Q6ICP4">BEDT-TTF</protein-id>)...<compound-id="312">Cl-</compound-id>mu-Re, C-H...O(guest), (C-H)(guest)...<compound-id="312">Cl-</compound-id>mu-Re <compound-id="783">hydrogen</compound-id> bonds at the organic-inorganic interface, none of which dominates any of the others and whose balance is adjusted upon substitution of one guest molecule by another.	Cl-__BEDT-TTF__no_interaction	Cl-__CCl(4__no_interaction	CHCl__BEDT-TTF__no_interaction	CHCl__CCl(4__no_interaction	2-hydroxy-tetrahydrofuran__BEDT-TTF__no_interaction	2-hydroxy-tetrahydrofuran__CCl(4__no_interaction	ethylenedithiotetrathiafulvalene__BEDT-TTF__no_interaction	ethylenedithiotetrathiafulvalene__CCl(4__no_interaction	hydrogen__BEDT-TTF__no_interaction	hydrogen__CCl(4__no_interaction	1,4-dioxane__BEDT-TTF__no_interaction	1,4-dioxane__CCl(4__no_interaction
21751803-6	Herein, we report the photophysical properties of a series of 2-R-pyrenes {R = C(3)H(6)CO(2)H (1), Bpin (2; <protein-id="P63167,Q6FGH9">pin</protein-id> = OCMe(2)CMe(2)O), OC(3)H(6)CO(2)H (3), O(CH(2))(12)Br (4), C≡CPh (5), C(6)H(4)-4-CO(2)Me (6), C(6)H(4)-4-B(Mes)(2) (7), B(Mes)(2) (8)} and 2,7-R(2)-pyrenes {R = Bpin (9), OH (10), C≡C(<compound-id="54117399">TMS</compound-id>) (11), C≡CPh (12), C≡C-C(6)H(4)-4-B(Mes)(2) (13), C≡C-C(6)H(4)-4-NMe(2) (14), C(6)H(4)-4-CO(2)C(8)H(17) (15), N(Ph)-C(6)H(4)-4-OMe (16)} whose syntheses are reported elsewhere.	TMS__pin__no_interaction
19782655-4	Here, we describe comparative experiments (involving also cisplatin) revealing: (i) improved cytotoxicity (3.4-5.4-fold) of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in human tumor ovarian cell lines; (ii) enhanced cellular uptake (approximately 1.5-fold) of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)]; (iii) somewhat enhanced rate of reactions of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] with <compound-id="124886,20725278,745">glutathione</compound-id> (approximately 1.5-fold), but a similar rate of reactions with metallothionenin-2; (iv) enhanced rate of DNA binding of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in cell-free media (approximately 2-fold); (v) similar sequence preference of DNA binding of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] in cell-free media; (vi) identical DNA interstrand cross-linking efficiency (6%); (vii) similar bending (32 degrees) and enhanced local unwinding (approximately 1.5-fold) induced in DNA by the major 1,2-GG-intrastrand cross-link; (viii) markedly enhanced inhibiting effects of DNA adducts of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] on processivity of DNA polymerase; and (ix) a slightly lower efficiency of DNA repair systems to remove the adducts of [PtCl(2)(<protein-id="Q9NSE2">cis-1</protein-id>,4-DACH)] from DNA.	glutathione__cis-1__no_interaction
20537417-4	Genomic polymorphism of angiotensin converting enzyme (ACE I/D), <protein-id="P01019,B0ZBE2,B2R5S1">angiotensinogen</protein-id> (<protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id>, c.704C&gt;T), <protein-id="P30556,D3DNG8,A0A0A0MSE3,Q53YY0,Q6NUP5">angiotensin II receptor type 1</protein-id> (<protein-id="P30556,D3DNG8,A0A0A0MSE3,Q53YY0,Q6NUP5">AGTR1</protein-id>, c.1166A&gt;C), <protein-id="P19099">aldosterone synthase</protein-id> (<protein-id="P19099">CYP11B2</protein-id>, c.-344C&gt;T), <protein-id="P05305,Q6FH53">endothelin 1</protein-id> (<protein-id="P05305,Q6FH53">EDN1</protein-id>, <protein-id="P05305,Q6FH53">EDN1</protein-id>/ex5-c.5665G&gt;T), G protein (<protein-id="P16520,F1T0G5,E9PCP0">GNB3</protein-id>, c.825C&gt;T), <protein-id="P32298">G protein-coupled receptor kinase 4</protein-id> (<protein-id="P32298">GRK4</protein-id>, c.679C&gt;T), <protein-id="P35555">fibrillin 1</protein-id> (<protein-id="P35555">FBN1</protein-id>, VNTR(TAAA)) and two polymorphisms each of the ß1 adrenoreceptor (<protein-id="P08588">ADRB1</protein-id>, c.145G&gt;A and c.1165C&gt;G), ß2 adrenoreceptor (<protein-id="P07550">ADRB2</protein-id>, c.<compound-id="15658026">46A</compound-id>&gt;G and c.79C&gt;G), and endothelial NO synthase (<protein-id="P29474,A0A0A0MTA6,A0S0A6">NOS3</protein-id>, intron 4 I/D and <protein-id="P29474,A0A0A0MTA6,A0S0A6">NOS3</protein-id>, c.894G&gt;T) were determined by PCR amplification and fragment length analysis.	46A__G protein-coupled receptor kinase 4__no_interaction	46A__NOS3__no_interaction	46A__endothelin 1__no_interaction	46A__angiotensinogen__no_interaction	46A__angiotensin II receptor type 1__no_interaction	46A__GNB3__no_interaction	46A__FBN1__no_interaction	46A__ADRB1__no_interaction	46A__ADRB2__no_interaction	46A__fibrillin 1__no_interaction	46A__EDN1__no_interaction	46A__CYP11B2__no_interaction	46A__AGTR1__no_interaction	46A__AGT__no_interaction	46A__GRK4__no_interaction	46A__aldosterone synthase__no_interaction
15216418-3	These puzzling observations have now been explored in greater detail, with the following major findings: a) the large inward <compound-id="54730402">TRK</compound-id> currents are not carried by influx of either K(+) or H(+), but rather by an efflux of <compound-id="312">chloride</compound-id> ions; b) with normal expression levels for <protein-id="P12685">Trk1p</protein-id> and <protein-id="P28584">Trk2p</protein-id> in <compound-id="5462222">potassium</compound-id>-replete cells, the inward <compound-id="54730402">TRK</compound-id> currents are contributed approximately half by <protein-id="P12685">Trk1p</protein-id> and half by <protein-id="P28584">Trk2p</protein-id>; but c) strain background strongly influences the absolute magnitude of these currents, which are nearly twice as large in W303-derived spheroplasts as in S288c-derived cells (same cell-size and identical recording conditions); d) incorporation of mutations that increase cell size (deletion of the Golgi <compound-id="22044544,5460341">calcium</compound-id> pump, <protein-id="P13586">Pmr1p</protein-id>) or that upregulate the TRK2 promoter, can further substantially increase the <compound-id="54730402">TRK</compound-id> currents; e) removal of intracellular <compound-id="312">chloride</compound-id> (e.g., replacement by <compound-id="1117">sulfate</compound-id> or <compound-id="10690">gluconate</compound-id>) reveals small inward currents that are K(+)-dependent and can be enhanced by K(+) starvation; and f) finally, the latter currents display two saturating kinetic components, with preliminary estimates of K(0.5) at 46 micro M [K(+)](out) and 6.8 m M [K(+)](out), and saturating fluxes of approximately 5 m M/min and approximately 10 m M/min (referred to intracellular <compound-id="962">water</compound-id>).	TRK__Trk1p__no_interaction	TRK__Trk2p__no_interaction	TRK__Pmr1p__no_interaction	potassium__Trk1p__no_interaction	potassium__Trk2p__no_interaction	potassium__Pmr1p__no_interaction	sulfate__Trk1p__no_interaction	sulfate__Trk2p__no_interaction	sulfate__Pmr1p__no_interaction	gluconate__Trk1p__no_interaction	gluconate__Trk2p__no_interaction	gluconate__Pmr1p__no_interaction	water__Trk1p__no_interaction	water__Trk2p__no_interaction	water__Pmr1p__no_interaction	calcium__Trk1p__no_interaction	calcium__Trk2p__no_interaction	calcium__Pmr1p__no_interaction	chloride__Trk1p__no_interaction	chloride__Trk2p__no_interaction	chloride__Pmr1p__no_interaction
16633845-7	<protein-id="P02741">CRP</protein-id> was positively correlated with <compound-id="447041">IMT</compound-id> (r = 0.49, p = 0.001), IEM (r = 0.24, p = 0.05), DWS (r = 0.58, p &lt; 0.001), and body mass index (BMI) (r = 0.28, p = 0.05).	IMT__CRP__no_interaction
22235146-4	Here, we investigated whether a novel class of peptide <compound-id="449520">epoxyketone</compound-id>-based PIs, including <compound-id="11556711">carfilzomib</compound-id>, N-((S)-<compound-id="13516411">3-methoxy</compound-id>-1-(((S)-<compound-id="13516411">3-methoxy</compound-id>-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-<compound-id="23322366">methylthiazole-5-carboxamide</compound-id> (<compound-id="25067547">ONX0912</compound-id>), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(<compound-id="667910">2-morpholinoacetamido</compound-id>)propanamido)<compound-id="6578">propanamide</compound-id> (<compound-id="23642227">ONX0914</compound-id>), might escape two established BTZ-resistance mechanisms: 1) mutations in the proteasome β5 subunit (<protein-id="P28074">PSMB5</protein-id>) targeted by these <protein-id="P30740,V9HWH1">PIs, and 2</protein-id>) drug efflux mediated by <compound-id="5957">ATP</compound-id>-binding cassette transporters.	ONX0912__PSMB5__no_interaction	ONX0912__PIs, and 2__no_interaction	propanamide__PSMB5__no_interaction	propanamide__PIs, and 2__no_interaction	epoxyketone__PSMB5__no_interaction	epoxyketone__PIs, and 2__no_interaction	ONX0914__PSMB5__no_interaction	ONX0914__PIs, and 2__no_interaction	3-methoxy__PSMB5__no_interaction	3-methoxy__PIs, and 2__no_interaction	ATP__PSMB5__no_interaction	ATP__PIs, and 2__no_interaction	2-morpholinoacetamido__PSMB5__no_interaction	2-morpholinoacetamido__PIs, and 2__no_interaction	carfilzomib__PSMB5__no_interaction	carfilzomib__PIs, and 2__no_interaction	methylthiazole-5-carboxamide__PSMB5__no_interaction	methylthiazole-5-carboxamide__PIs, and 2__no_interaction
12831519-6	) were compared, the thrombocytopenic patients were found not only to be generally older than the non-thrombocytopenic [25.3 (1.1) v. 21.3 (0.18) years; P &lt; 0.001] but also to have presented with higher serum concentrations of <compound-id="5960">aspartate</compound-id> aminotransferase [77.6 (16.6) v. 32.3 (7.4) U/litre; P &lt; 0.0001], <compound-id="5950,602">alanine</compound-id> aminotransferase [96.7 (19.0) v. 44.7 (12.0) U/litre; P = 0.0001], <protein-id="P01583">interleukin-1</protein-id> [49.9 (7.4) v. 23.7 (5.1) pg/ml; P &lt; 0.001], <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> [174.9 (26.4) v. 57.3 (14.6) pg/ml; P = 0.001], <protein-id="P22301,Q6FGW4">interleukin-10</protein-id> [308.2 (39.6) v. 137.9 (23.1) pg/ml; P &lt; 0.002] and transforming growth factor-beta [1134.3 (387.5) v. 416.6 (183.8) pg/ml; P &lt; 0.0001], and higher levels of parasitaemia [4345.7 (966.6) v. 1443.8 (222.7) parasites/microl; P = 0.03).	alanine__interleukin-1__no_interaction	alanine__interleukin-10__no_interaction	alanine__interleukin-6__no_interaction	aspartate__interleukin-1__no_interaction	aspartate__interleukin-10__no_interaction	aspartate__interleukin-6__no_interaction
10484572-5	High plasma estradiol concentration lowered the P(<protein-id="P13725,B5MCX1">osm</protein-id>) threshold for <protein-id="P01185,X5DQP6">AVP</protein-id> release during the luteal phase and during OC E + P [x-intercepts, 282 +/- 2, 278 +/- 2, 276 +/- 2, and 280 +/- 2 mosmol/kgH(2)O, for follicular, luteal (combined means), OC E + P, and OC P, respectively; P &lt; 0.05, luteal phase and OC E + P vs. follicular phase] during exercise dehydration, and <compound-id="56981346,5757">17beta-estradiol</compound-id> administration lowered the P(<protein-id="P13725,B5MCX1">osm</protein-id>) threshold for thirst stimulation [x-intercepts, 280 +/- 2, 279 +/- 2, 276 +/- 2, and 280 +/- 2 mosmol/kgH(2)O for follicular, luteal, OC E + P, and OC P, respectively; P &lt; 0.05, OC E + P vs. follicular phase], without affecting body fluid balance.	17beta-estradiol__AVP__no_interaction	17beta-estradiol__osm__no_interaction
24083877-10	RESULT(S): Averages of times in the general population were: t2 = 27.9 hours, <compound-id="5920">t3</compound-id> = 38.2 hours, t4 = 40.7 hours, t5 = 51.0 hours, t6 = 54.1 hours, t7 = 56.7 hours, t8 = 59.1 hours, tM = 86.6 hours, tB = 104.1 hours, <compound-id="54736423">cc2</compound-id> = 10.3 hours, <protein-id="Q16627">cc3</protein-id> = 12.8 hours, s2 = 2.7 hours, and s3 = 9.9 hours.	t3__cc3__no_interaction	cc2__cc3__no_interaction
20561675-8	FINDINGS: In the first 3000 cases (n=2337, 78%, with ischaemic stroke; n=663, 22%, with intracerebral haemorrhagic stroke) and 3000 controls, significant risk factors for all stroke were: history of hypertension (OR 2.64, 99% CI 2.26-3.08; PAR 34.6%, 99% CI 30.4-39.1); current smoking (2.09, 1.75-2.51; 18.9%, 15.3-23.1); waist-to-<protein-id="Q06141,Q53S56">hip</protein-id> ratio (1.65, 1.36-1.99 for highest vs lowest tertile; 26.5%, 18.8-36.0); diet risk score (1.35, 1.11-1.64 for highest vs lowest tertile; 18.8%, 11.2-29.7); regular physical activity (0.69, 0.53-0.90; 28.5%, 14.5-48.5); diabetes mellitus (1.36, 1.10-1.68; 5.0%, 2.6-9.5); <compound-id="10982484,702">alcohol</compound-id> intake (1.51, 1.18-1.92 for more than 30 drinks per month or binge drinking; 3.8%, 0.9-14.4); psychosocial stress (1.30, 1.06-1.60; 4.6%, 2.1-9.6) and depression (1.35, 1.10-1.66; 5.2%, 2.7-9.8); cardiac causes (2.38, 1.77-3.20; 6.7%, 4.8-9.1); and ratio of apolipoproteins B to A1 (1.89, 1.49-2.40 for highest vs lowest tertile; 24.9%, 15.7-37.1).	alcohol__hip__no_interaction
20143470-10	Compared with model group, <compound-id="248">betaine</compound-id> feeding resulted in significant decreases of ALT (64.93 +/- 6.06 U/L vs 159.41 +/- 7.74 U/L, P &lt; 0.0001), AST (188.73 +/- 1.11 U/L vs 248.25 +/- 1.40 U/L, P &lt; 0.0001), endotoxin (61.80 +/- 12.56 ng/L vs 135.37 +/- 30.17 ng/L, P &lt; 0.0001), <protein-id="P16599">TNF-alpha</protein-id> (9.79 +/- 1.32 pg/mL vs 20.81 +/- 8.58 pg/mL, P = 0.0003), <protein-id="P01581">IFN-gamma</protein-id> (18.02 +/- 5.96 pg/mL vs 30.18 +/- 7.60 pg/mL, P = 0.0008) and <protein-id="P97636">IL-18</protein-id> (18.23 +/- 7.01 pg/mL vs 40.99 +/- 8.25 pg/mL, P &lt; 0.0001).	betaine__IFN-gamma__no_interaction	betaine__TNF-alpha__no_interaction	betaine__IL-18__no_interaction
17102647-8	Significant correlation was also observed between ELISA D-dimer and cardiac medications including beta-blocker (r = 0.22, P = 0.01), <compound-id="2244">aspirin</compound-id> (r = 0.18, P = 0.04), <compound-id="10313259,943">nitrate</compound-id> (r = 0.20, P = 0.002), acute phase reactants fibrinogen (r = 0.45, P = 0.0001) and <protein-id="P02741">C-reactive protein</protein-id> (r = 0.29, P = 0.004), ischemic electrocardiographic changes (r = 0.21, P = 0.02) and length of stay (r = 0.29, P = 0.001).	nitrate__C-reactive protein__no_interaction	aspirin__C-reactive protein__no_interaction
18855385-7	Complexes 6a and b participate in a series of successive equilibria in solution, involving the dissociation of <compound-id="11403475">phosphine ligands</compound-id> and the exchange of [M(<compound-id="5289124">PCy</compound-id> 3)] (+) units to give 2a or 3b and the corresponding disilver derivatives [Ag 2{[SC=( t-Bu-fy)] 2S}(<protein-id="P24158">PR 3</protein-id>) 2] [R = Ph ( 8a), To ( 8b)], followed by <compound-id="140368">thioketene</compound-id>-exchange reactions to give [AgCu{[SC=( t-Bu-fy)] <compound-id="21439199">3S</compound-id>}(<protein-id="P24158">PR 3</protein-id>) 2] [R = Ph ( 9a), To ( 9b)].	3S__PR 3__no_interaction	phosphine ligands__PR 3__no_interaction	thioketene__PR 3__no_interaction	PCy__PR 3__no_interaction
17941003-1	Naturally occurring cyclic tetrapeptides (CTPs) such as <compound-id="5281143,6442695,91592">tentoxin</compound-id> (Halloin et al., Plant Physiol 1970, 45, 310-314; Saad, Phytopathology 1970, 60, 415-418), ampicidin (Darkin-Rattray, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1996, 93, 13143-13147), <compound-id="107864">HC-toxin</compound-id> (Walton, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1987, 84, 8444-8447), and <compound-id="395803">trapoxin</compound-id> (Yoshida and Sugita, <compound-id="16220126">Jpn</compound-id> J Cancer Res 1992, 83, 324-328; Itazaki et al., J Antibiot (Tokyo) 1990, 43, 1524-1532) have a wide range of biological activity and potential use ranging from herbicides (Walton, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1987, 84, 8444-8447; Judson, J Agric Food Chem 1987, 35, 451-456) to therapeutics (Loiseau, Biopolymers 2003, 69, 363-385) for malaria (Darkin-Rattray, <protein-id="P04070">Proc</protein-id> Natl Acad Sci USA 1996, 93, 13143-13147) and cancer (Yoshida and Sugita, <compound-id="16220126">Jpn</compound-id> J Cancer Res 1992, 83, 324-328).	trapoxin__Proc__no_interaction	tentoxin__Proc__no_interaction	HC-toxin__Proc__no_interaction	Jpn__Proc__no_interaction
22095243-1	Substitution reactions of <compound-id="23939">platinum</compound-id> complexes bearing <compound-id="7965">cyclohexylamine</compound-id>/diamine moieties viz., [Pt(H(2)O)(N,N-bis(<compound-id="7975">2-pyridylmethyl</compound-id>)<compound-id="7965">cyclohexylamine</compound-id>)](CF(3)SO(3))(2), bpcHna; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="18374">trans-1,4-cyclohexyldiamine</compound-id>)](CF(3)SO(3))(4), <protein-id="P15882">cHn</protein-id> and [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-4,4'-<compound-id="177095">dicyclohexylmethanediamine</compound-id>)](CF(3)SO(3))(4), dcHnm and <compound-id="6115">phenylamine</compound-id>/diamine moieties viz., ([Pt(H(2)O)N,N-bis(<compound-id="7975">2-pyridylmethyl</compound-id>)<compound-id="6115">phenylamine</compound-id>)](CF(3)SO(3))(2), bpPha; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-1,3-phenyldiamine)](CF(3)SO(3))(4), mPh; [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-1,4-phenyldiamine)](CF(3)SO(3))(4), pPh and [{Pt(H(2)O)}(2)(N,N,N',N'-tetrakis(<compound-id="7975">2-pyridylmethyl</compound-id>)-<compound-id="7577">4,4'-diphenylmethanediamine</compound-id>)](CF(3)SO(3))(4)), dPhm with <compound-id="2723790">thiourea</compound-id> nucleophiles were studied in acidified 0.01 M LiCF(3)SO(3) aqueous medium under pseudo-first-order conditions using stopped-flow and UV-visible spectrophotometric techniques.	platinum__cHn__no_interaction	phenylamine__cHn__no_interaction	dicyclohexylmethanediamine__cHn__no_interaction	trans-1,4-cyclohexyldiamine__cHn__no_interaction	thiourea__cHn__no_interaction	4,4'-diphenylmethanediamine__cHn__no_interaction	2-pyridylmethyl__cHn__no_interaction	cyclohexylamine__cHn__no_interaction
16497181-6	In contrast, plasma <protein-id="P22388">Endothelin-1</protein-id> concentration (0.58 +/- 0.04 vs. 1.05 +/- 0.01 femtomol mL(-1); P &lt; 0.01), renal papillary ET-1 concentration (68 +/- 5 vs. 478 +/- 62 fmol mg(-1) protein; P &lt; 0.01) and preproET-1/<protein-id="O35077">GPDH</protein-id> mRNA ratio (0.65 +/- 0.09 vs. 0.88 +/- 0.05; P &lt; 0.05) as well as total <compound-id="44284481">endothelin</compound-id> receptor number in renal papilla (B(max) 5.3 +/- 0.4 vs. and 9.0 +/- 1.2 pmol mg(-1) protein; P &lt; 0.05) were markedly lower in <compound-id="7009630">LE</compound-id> than in WKY rats.	endothelin__Endothelin-1__no_interaction	endothelin__GPDH__no_interaction	LE__Endothelin-1__no_interaction	LE__GPDH__no_interaction
24508213-2	The aim of this study was to produce the multipurpose, bivalent [DUPA-6-<compound-id="448563">Ahx</compound-id>-((64)Cu-NODAGA)-5-<compound-id="16070004">Ava</compound-id>-BBN(7-14)NH2] radioligand for prostate cancer imaging, where DUPA = (2-[3-(1,3-<compound-id="11756">dicarboxypropyl</compound-id>)-ureido]<compound-id="743">pentanedioic acid</compound-id>), a small-molecule, <protein-id="Q04609">PSMA</protein-id>-targeting probe, 6Ahx = <compound-id="564">6-aminohexanoic acid</compound-id>, 5-<compound-id="16070004">Ava</compound-id> = <compound-id="138">5-aminovaleric acid</compound-id>, NODAGA = [2-(4,7-biscarboxymethyl)-1,4,7-(<compound-id="21896526">triazonan-1-yl</compound-id>)<compound-id="743">pentanedioic acid</compound-id>] (a derivative of <compound-id="124326">NOTA</compound-id> (<compound-id="188318">1,4,7-triazacyclononane</compound-id>-1,4,7-<compound-id="5459844">triacetic acid</compound-id>)), and BBN(7-14)NH2 = <protein-id="P07492">bombesin</protein-id>, a GRPr-specific peptide targeting probe.	triacetic acid__PSMA__no_interaction	triacetic acid__bombesin__no_interaction	dicarboxypropyl__PSMA__no_interaction	dicarboxypropyl__bombesin__no_interaction	6-aminohexanoic acid__PSMA__no_interaction	6-aminohexanoic acid__bombesin__no_interaction	triazonan-1-yl__PSMA__no_interaction	triazonan-1-yl__bombesin__no_interaction	pentanedioic acid__PSMA__no_interaction	pentanedioic acid__bombesin__no_interaction	NOTA__PSMA__no_interaction	NOTA__bombesin__no_interaction	1,4,7-triazacyclononane__PSMA__no_interaction	1,4,7-triazacyclononane__bombesin__no_interaction	5-aminovaleric acid__PSMA__no_interaction	5-aminovaleric acid__bombesin__no_interaction	Ahx__PSMA__no_interaction	Ahx__bombesin__no_interaction	Ava__PSMA__no_interaction	Ava__bombesin__no_interaction
2450260-2	The <protein-id="Q5BJP4">RRM</protein-id>-salt was characterized by: (1) increased endogenous "<compound-id="56840973">digitalis</compound-id>-like" compounds in plasma [cross reactivity with <compound-id="2724385">digoxin</compound-id>-antibodies (57.5 +/- 5.0 vs. 42.1 +/- 3.8 pg/ml, p less than 0.02); inhibition of kidney Na+, K+-ATPase activity (135 +/- 5 vs. 154 +/- 5 mumol/mg/h, p less than 0.01); and inhibition of Na+ extrusion from normal erythrocytes (5.96 +/- 0.40 vs. 7.68 +/- 0.34 mmol/L cells/h, p less than 0.01)]; (2) reduced Na+, K+-pump activity (7.34 +/- 0.29 vs. 10.88 +/- 0.41 mmol/L cells/h, p less than 0.001) and increased Na+ content (4.66 +/- .08 vs. 4.16 +/- 0.11 mmol/L cells, p less than 0.01) in erythrocytes; and (3) low plasma <protein-id="P08424">renin</protein-id> activity (2.1 +/- 0.9 vs. 12.6 +/- 1.6 ng/ml/h).	digitalis__RRM__no_interaction	digitalis__renin__no_interaction	digoxin__RRM__no_interaction	digoxin__renin__no_interaction
21606177-4	Levels of mRNA and functional activities of rat (r)Octns and rOcts in rat DRG tissue and primary cultures were characterized using reverse transcription-polymerase chain reaction and uptake of model OCT/OCTN substrates, including [(3)H]1-methyl-4-<compound-id="3734524">phenylpyridinium</compound-id> (MPP(+)) (<protein-id="O15245">OCT1</protein-id>-3), [(14)C]<compound-id="5413">tetraethylammonium bromide</compound-id> (TEA(+)) (<protein-id="O15245">OCT1</protein-id>-3 and <protein-id="Q9H015,Q9R141">OCTN1</protein-id>/2), [(3)H]<compound-id="3037043">ergothioneine</compound-id> (<protein-id="Q9H015,Q9R141">OCTN1</protein-id>), and [(3)H]l-carnitine (<protein-id="O70594">OCTN2</protein-id>).	tetraethylammonium bromide__OCTN1__no_interaction	tetraethylammonium bromide__OCTN2__no_interaction	tetraethylammonium bromide__OCT1__no_interaction	phenylpyridinium__OCTN1__no_interaction	phenylpyridinium__OCTN2__no_interaction	phenylpyridinium__OCT1__no_interaction	ergothioneine__OCTN1__no_interaction	ergothioneine__OCTN2__no_interaction	ergothioneine__OCT1__no_interaction
20817554-6	The multivariate logistic regression identified, after adjusting for demographic and socioeconomic variables, factors associated with short sleep duration: more television viewing during weekdays (<protein-id="Q8NGE0">OR=1.21</protein-id>, p=0.004), more frequent computer/internet using (<protein-id="Q8NGY2">OR=1.17</protein-id>, p=0.006), earlier school starting time (OR=1.10, p=0.020), more time on homework during weekdays (OR=1.66, p&lt;0.001) and weekends (OR=1.14, p=0.001), poor bedtime hygiene (e.g., having drinks with <compound-id="2519,57106085">caffeine</compound-id> after 6:00PM [<protein-id="Q8NGY5">OR=1.22</protein-id>, p&lt;0.001], doing exciting activities during bedtime [OR=1.16, p&lt;0.001], and irregular bedtime [<protein-id="Q96R27">OR=1.55</protein-id>, p&lt;0.001]), and shorter sleep duration of parents (mother: OR=1.31, p&lt;0.001 for sleep duration &lt;6h and OR=1.24, p=0.006 for 6-8h; father: OR=1.52, p&lt;0.001 for &lt;6h and OR=1.19, p&lt;0.001 for 6-8h).	caffeine__OR=1.21__no_interaction	caffeine__OR=1.17__no_interaction	caffeine__OR=1.55__no_interaction	caffeine__OR=1.22__no_interaction
23711224-5	The NEAT score was also negatively correlated with waist circumference (r = -0.509, P &lt; 0.05) and positively correlated with high-density lipoprotein-<compound-id="5997">cholesterol</compound-id> levels (r = 0.494, P &lt; 0.05) in women, and negatively associated with serum <protein-id="P01308,I3WAC9">insulin</protein-id> levels (r = -0.732, p &lt; 0.005), systolic (r = -0.482, P &lt; 0.05) and diastolic blood pressure (r = -0.538, P &lt; 0.05) in patients with abdominal obesity.	cholesterol__insulin__no_interaction
1325615-2	After 4 months of intravenous <compound-id="5280453">calcitriol</compound-id>, serum ionized <compound-id="22044544,5460341">calcium</compound-id> increased from 1.28 +/- 0.08 to 1.37 +/- 0.11 mmol/l (P less than 0.001), serum <compound-id="1061,167704,644102">phosphate</compound-id> from 1.54 +/- 0.18 to 1.79 +/- 0.4 mmol/l (P NS), serum <compound-id="5280453">calcitriol</compound-id> from 16.7 +/- 9.9 to 34.3 +/- 6.4 pg/ml (P less than 0.001), while alkaline phosphatase decreased from 366 +/- 340 to 226 +/- 180 IU/l (P less than 0.05), <protein-id="P02818">osteocalcin</protein-id> from 46.4 +/- 20 to 34.5 +/- 15.3 ng/ml (P less than 0.05), and basal intact <protein-id="P01270">PTH</protein-id> from 1069 +/- 700 to 305 +/- 270 (P less than 0.01).	calcitriol__osteocalcin__no_interaction	calcitriol__PTH__no_interaction	calcium__osteocalcin__no_interaction	calcium__PTH__no_interaction	phosphate__osteocalcin__no_interaction	phosphate__PTH__no_interaction
23070078-3	Presently investigated MOFs for MMMs include [Cu(SiF(6))(4,4'-<compound-id="1474">BIPY</compound-id>)(2)], [Cu(3)(<protein-id="P35070">BTC</protein-id>)(2)(H(2)O)(3)] (HKUST-1, Cu-<protein-id="P35070">BTC</protein-id>), [Cu(<compound-id="446612">BDC</compound-id>)(DMF)], [Zn(4)O(<compound-id="446612">BDC</compound-id>)(3)] (MOF-5), [Zn(<compound-id="23037044">2-methylimidazolate</compound-id>)(2)] (ZIF-8), [Zn(<compound-id="57058588">purinate</compound-id>)(2)] (ZIF-20), [Zn(2-carboxyaldehyde <compound-id="574321">imidazolate</compound-id>)(2)] (ZIF-90), Mn(HCOO)(2), [Al(<compound-id="446612">BDC</compound-id>)(μ-OH)] (MIL-53(Al)), [Al(NH(2)-<compound-id="446612">BDC</compound-id>)(μ-OH)] (NH(2)-MIL-53(Al)) and [Cr(3)O(<compound-id="446612">BDC</compound-id>)(3)(F,OH)(H(2)O)(2)] (MIL-101) (4,4'-<compound-id="1474">BIPY</compound-id> = <compound-id="11107">4,4'-bipyridine</compound-id>, <protein-id="P35070">BTC</protein-id> = <compound-id="11138">benzene-1,3,5-tricarboxylate</compound-id>, <compound-id="446612">BDC</compound-id> = <compound-id="241">benzene</compound-id>-1,4-dicarboxylate, <compound-id="7489">terephthalate</compound-id>).	benzene__BTC__no_interaction	benzene-1,3,5-tricarboxylate__BTC__no_interaction	purinate__BTC__no_interaction	BDC__BTC__no_interaction	imidazolate__BTC__no_interaction	BIPY__BTC__no_interaction	2-methylimidazolate__BTC__no_interaction	4,4'-bipyridine__BTC__no_interaction	terephthalate__BTC__no_interaction
15936556-10	These included local failure: <protein-id="Q15935">pT0-2</protein-id>: 5% vs. pT3-4: 19%, p = 0.007; <compound-id="466151">pN0</compound-id>: 7% vs. <compound-id="448911">pN1</compound-id>-3: 26%, p = 0.002; TRG1-2: 2% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 17%, p = 0.013; metastasis-free survival: <protein-id="Q15935">pT0-2</protein-id>: 86% vs. pT3-4: 62%, p = 0.005; pN-: 86% vs. pN*: 42%, p &lt; 0.001; TRG1-2: 91% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 66%, p = 0.004; disease-free survival: <protein-id="Q15935">pT0-2</protein-id>: 83% vs. pT3-4: 54%, p = 0.001; <compound-id="466151">pN0</compound-id>: 80% vs. <compound-id="448911">pN1</compound-id>-3: 39%, p &lt; 0.001; TRG1-2: 91% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 58%, p &lt; 0.001; and overall survival: <protein-id="Q15935">pT0-2</protein-id>: 85% vs. pT3-4: 65%, p = 0.007; <compound-id="466151">pN0</compound-id>: 86% vs. <compound-id="448911">pN1</compound-id>-3: 45%, p &lt; 0.001; TRG1-2: 89% vs. <protein-id="P07195,Q5U077">TRG3-5</protein-id>: 68%, p = 0.004.	pN1__TRG3-5__no_interaction	pN1__pT0-2__no_interaction	pN0__TRG3-5__no_interaction	pN0__pT0-2__no_interaction
9024276-3	Compared to the men with normal <compound-id="5462314">PTT</compound-id> (mean +/- <compound-id="5289348">SEM</compound-id>, 19.8 +/- 0.7 nmol/L), the men with low <compound-id="5462314">PTT</compound-id> (10.1 +/- 0.3 nmol/L) had a significantly higher body mass index (P &lt; 0.01), waist/<protein-id="P47914">hip</protein-id> ratio (P &lt; 0.001), systolic blood pressure (P &lt; 0.05), fasting and 2-h plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (P &lt; 0.04 and P &lt; 0.02 respectively), serum triglycerides (P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (P &lt; 0.04), low density lipoprotein <compound-id="5997">cholesterol</compound-id> (P &lt; 0.01), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (P &lt; 0.01), fasting and 2-h plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (both P &lt; 0.0001), and lower values of serum high density lipoprotein <compound-id="5997">cholesterol</compound-id> (P &lt; 0.01) and apolipoprotein <compound-id="15942654">AI</compound-id> (P &lt; 0.05).	cholesterol__hip__no_interaction	cholesterol__apolipoprotein B__no_interaction	cholesterol__insulin__no_interaction	AI__hip__no_interaction	AI__apolipoprotein B__no_interaction	AI__insulin__no_interaction	SEM__hip__no_interaction	SEM__apolipoprotein B__no_interaction	SEM__insulin__no_interaction	PTT__hip__no_interaction	PTT__apolipoprotein B__no_interaction	PTT__insulin__no_interaction	glucose__hip__no_interaction	glucose__apolipoprotein B__no_interaction	glucose__insulin__no_interaction
15189767-3	In addition, the <protein-id="Q60484,A0A0C3SFY8">5-HT1D receptor</protein-id>-preferring antagonists, 1-[2-[4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>)-3,6-dihydro-2H-pyridin-1-yl]-<compound-id="23134249">ethyl</compound-id>]-3-pyridin-4-yl-methyl-<compound-id="74615">tetrahydro-pyrimidin-2-one</compound-id> (LY367642), (R)-1-[2-(4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>-)-3,6-dihydro-1(2H)-pyridinyl)<compound-id="23134249">ethyl</compound-id>]-3,4-<compound-id="53681010">dihydro-1H-2-benzopyran-6-carboxamide</compound-id> (LY456219), (S)-1-[2-(4-(6-<compound-id="18669466">fluoro-1H-indol-3-yl</compound-id>-)-3,6-dihydro-1(2H)-pyridinyl)<compound-id="23134249">ethyl</compound-id>]-3,4-<compound-id="53681010">dihydro-1H-2-benzopyran-6-carboxamide</compound-id> (LY456220) and 1-[2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-<compound-id="23134249">ethyl</compound-id>]-3,3-dimethyl-1,2-dihydro-<compound-id="17904787">indol-2-one</compound-id> (<compound-id="4282258">LY310762</compound-id>), potentiated [3H]<compound-id="5202">5-HT</compound-id> outflow from this preparation with potencies (EC50 values=31-140 nM) in the same range as their affinities for the guinea pig <protein-id="Q60484,A0A0C3SFY8">5-HT1D receptor</protein-id> (Ki values=100-333 nM).	tetrahydro-pyrimidin-2-one__5-HT1D receptor__no_interaction	LY310762__5-HT1D receptor__no_interaction	fluoro-1H-indol-3-yl__5-HT1D receptor__no_interaction	indol-2-one__5-HT1D receptor__no_interaction	dihydro-1H-2-benzopyran-6-carboxamide__5-HT1D receptor__no_interaction	5-HT__5-HT1D receptor__no_interaction	ethyl__5-HT1D receptor__no_interaction
15722644-10	Significant correlations were demonstrated between the Whole and the intact <protein-id="P01270">PTH</protein-id> assays, and as expected between the 2 intact assays ('Whole'/'Intact', r = 0.92, p &lt; 0.0001, 'Whole'/'Total', r = 0.94, p &lt; 0.0001, 'Intact'/'Total', r = 0.97, p &lt; 0.0001) with no influence of the two <compound-id="5280795,5283711">vitamin D</compound-id> analogs administered.	vitamin D__PTH__no_interaction
22306220-11	In the striatum, when compared with the deep hypothermic circulatory arrest group, the <protein-id="P09919,Q6FH65,Q8N4W3">granulocyte-colony stimulating factor</protein-id> group had higher levels of <protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> (50.3 ± 7.4 vs 31.8 ± 3.8, P = .01), serine/<compound-id="194239,6288">threonine</compound-id>-specific protein kinase (132.7 ± 12.3 vs 14 ± 1.34, P = 2.3 × 10(6)), and Janus protein <protein-id="P29597,A0A024R7E4">tyrosine kinase 2</protein-id> (126 ± 17.4 vs 77.9 ± 13.6, P = .011), and lower levels of <protein-id="P42574">Caspase-3</protein-id> (12.8 ± 5.0 vs 32.2 ± 11.5, P = .033), Fas (390 ± 31 vs 581 ± 74, P = .038), <protein-id="P48023,Q53ZZ1">Fas ligand</protein-id> (20.5 ± 11.5 vs 57.8 ± 15.6, P = .04), and <protein-id="O75509,A0A024RD71">death receptor 6</protein-id> (57.4 ± 4.4 vs 108.8 ± 13.4, P = .007).	threonine__Caspase-3__no_interaction	threonine__tyrosine kinase 2__no_interaction	threonine__Fas ligand__no_interaction	threonine__death receptor 6__no_interaction	threonine__granulocyte-colony stimulating factor__no_interaction	threonine__Bcl-2__no_interaction
11952363-3	Subsequent treatment with AgOTf (OTf = <compound-id="62406">triflate</compound-id>) generates the bis(<compound-id="62406">triflate</compound-id>) analogues IrR(CO)(dppe)(OTf)(2) (R = CH(3) (2a) and CF(3) (2b)), which undergo clean metathesis with <compound-id="2778201">NaBARF</compound-id> (BARF = B(3,5-(CF(3))(2)C(6)H(3))(4)(-)) in the presence of 1,2-<compound-id="11994">diiodobenzene</compound-id> (DIB) forming the dicationic halocarbon adducts [IrR(CO)(dppe)(DIB)][BARF](2) (R = CH(3) (<compound-id="2981881,91293124">3a</compound-id>) and <protein-id="P00751">CF(3) (3b</protein-id>)).	3a__CF(3) (3b__no_interaction	triflate__CF(3) (3b__no_interaction	diiodobenzene__CF(3) (3b__no_interaction	NaBARF__CF(3) (3b__no_interaction
15112212-1	Polynuclear <compound-id="23978">copper</compound-id>(I) complexes with bridging <protein-id="O95817">bis</protein-id>(<compound-id="13239">dicyclohexylphosphino</compound-id>)<compound-id="297">methane</compound-id> (<compound-id="11155">dcpm</compound-id>) and <compound-id="105054,30165">iodide</compound-id> ligands, [Cu(2)(<compound-id="11155">dcpm</compound-id>)(2)(CH(3)CN)(2)](BF(4))(2) (1), [Cu(2)(<compound-id="11155">dcpm</compound-id>)(2)](BF(4))(2) (2), [(CuI)(3)(<compound-id="11155">dcpm</compound-id>)(2)] (3), [(CuI)(4)(<compound-id="11155">dcpm</compound-id>)(2)] (4), and [(CuI)(2)(<compound-id="11155">dcpm</compound-id>)(2)] (5) were prepared and their structures determined by X-ray crystal analysis.	dicyclohexylphosphino__bis__no_interaction	copper__bis__no_interaction	iodide__bis__no_interaction	dcpm__bis__no_interaction	methane__bis__no_interaction
17221285-6	The relative risk was significantly increased concerning: (1) male over female pts (RR: 1.95, p&lt;0.01), (2) diabetic vs. non diabetic pts (RR: 2.09, p&lt;0.001), (3) patients with SHP over pts with iPTH values&lt;250 pg/ml (RR: 2.16, p&lt;0.001), (4) hypertensive vs. non hypertensive pts (RR: 2.26, p=0.002), (5) smokers vs. non smokers (RR: 1.69, p&lt;0.05), (6) pts with HOC over pts with normal <compound-id="778,91552">homocysteine</compound-id> values (RR: 2.09, p&lt;0.05), (7) pts with increased <protein-id="P02741">CRP</protein-id> levels over pts with normal <protein-id="P02741">CRP</protein-id> levels (RR: 1.8, p&lt;0.01), (8) pts undergoing HD for 36 vs. 12 months (RR: 1.71, p=0.03), (9) between pts with inadequate or adequate HD (RR: 1.73, p=0.02).	homocysteine__CRP__no_interaction
15090974-6	RESULTS: Key recommendations, listed by category and not by hierarchy, include early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; early administration of broad-spectrum antibiotic therapy; reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; a usual 7-10 days of antibiotic therapy guided by clinical response; source control with attention to the method that balances risks and benefits; equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; vasopressor preference for <compound-id="439260">norepinephrine</compound-id> and <compound-id="681">dopamine</compound-id>; cautious use of <protein-id="P01185,X5DQP6">vasopressin</protein-id> pending further studies; avoiding low-dose <compound-id="681">dopamine</compound-id> administration for renal protection; consideration of <compound-id="36811">dobutamine</compound-id> inotropic therapy in some clinical situations; avoidance of supranormal <compound-id="977">oxygen</compound-id> delivery as a goal of therapy; stress-dose steroid therapy for septic shock; use of recombinant activated protein C in patients with severe sepsis and high risk for death; with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; appropriate use of fresh frozen plasma and platelets; a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; a semirecumbent bed position unless contraindicated; protocols for weaning and sedation/analgesia, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; avoidance of neuromuscular blockers, if at all possible; maintenance of blood <compound-id="206,5793,64689,79025">glucose</compound-id> &lt;150 mg/dL after initial stabilization; equivalence of continuous veno-veno hemofiltration and intermittent hemodialysis; lack of utility of <compound-id="767">bicarbonate</compound-id> use for pH &gt; or =7.15; use of deep vein thrombosis/stress ulcer prophylaxis; and consideration of limitation of support where appropriate.	oxygen__vasopressin__no_interaction	bicarbonate__vasopressin__no_interaction	dobutamine__vasopressin__no_interaction	norepinephrine__vasopressin__no_interaction	dopamine__vasopressin__no_interaction	glucose__vasopressin__no_interaction
16759126-2	Using a relative kinetic method rate coefficients (in units of cm3 molecule(-1) s(-1)) of (7.79 +/- 1.71) x 10(-11), (9.73 +/- 1.94) x 10(-11) and (1.13 +/- 0.31) x 10(-10) have been obtained for the reaction of OH with EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively, (1.40 +/- 0.35) x 10(-12), (1.85 +/- 0.53) x 10(-12) and (2.10 +/- 0.54) x 10(-12) for the reaction of <protein-id="P41271,A0A087WTY6">NO3</protein-id> with EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively, and (2.06 +/- 0.42) x 10(-16), (2.34 +/- 0.48) x 10(-16) and (2.59 +/- 0.52) x 10(-16) for the ozonolysis of EVE, <compound-id="25246321">PVE</compound-id> and BVE, respectively.	PVE__NO3__no_interaction
12322823-11	The underdialyzed group contained fewer women (39.5% vs 60.2%, p &lt; 0.001) and more patients with anuria (35.0% vs 8.8%, p &lt; 0.001), and had higher serum <compound-id="1176">urea</compound-id> (20.7 +/- 6.9 vs 18.2 +/- 5.3 mmol/L, p = 0.001) and serum <compound-id="588">creatinine</compound-id> (974 +/- 283 vs 734 +/- 275 micromol/L, p &lt; 0.001), marginally lower serum <protein-id="P02768">albumin</protein-id> (35.8 +/- 5.2 vs 37.2 +/- 6.4 g/L, p = 0.082), lower <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> excretion (5778 +/- 2290 vs 7085 +/- 2238 mg/24 hr, p &lt; 0.001) and indices derived from <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> excretion (protein <compound-id="947">nitrogen</compound-id> appearance and normalized protein <compound-id="947">nitrogen</compound-id> appearance), and lower <compound-id="588">creatinine</compound-id> excretion (1034 +/- 349 vs 1217 +/- 432 mg/24 hr, p &lt; 0.001) and indices derived from <compound-id="588">creatinine</compound-id> excretion (lean body mass normalized to actual or desired weight) than the adequately dialyzed group.	creatinine__albumin__no_interaction	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
11096257-4	These major HLA factors produced 6 haplotypes extending across the class I and class II regions: A*01-Cw*04-B* 4501-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1503-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0602 (A1-Cw4-B12- DR15 - <compound-id="57325589">DQ6</compound-id>), A * 01 - Cw * 04 - B * 4901 -<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id> * 1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604 (A1-Cw4-<compound-id="776315">B21</compound-id>-DR13-<compound-id="57325589">DQ6</compound-id>), A*30 - Cw*04 - B*15 - <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1101 - <protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0301 (A19-Cw4-B15-<protein-id="Q9BZH6,Q659C9">DR11</protein-id>-<compound-id="56964577">DQ7</compound-id>), A*68-Cw*07-B* 4901-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604(A28-<compound-id="57345898">Cw7</compound-id>-<compound-id="776315">B21</compound-id>- DR13 - <compound-id="57325589">DQ6</compound-id>), A*30 - Cw*07 - B*5703 - <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>* 1303-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0301(A19 - <compound-id="57345898">Cw7</compound-id> - <protein-id="Q9NYP3">B17</protein-id> - DR13 - <compound-id="56964577">DQ7</compound-id>), and A*74-Cw*07-B*4901-<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*1302-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>* 0604 (A19-<compound-id="57345898">Cw7</compound-id>-<compound-id="776315">B21</compound-id>-DR13-<compound-id="57325589">DQ6</compound-id>), respectively.	DQ6__B17__no_interaction	DQ6__DQB1__no_interaction	DQ6__DR11__no_interaction	DQ6__DRB1__no_interaction	DQ7__B17__no_interaction	DQ7__DQB1__no_interaction	DQ7__DR11__no_interaction	DQ7__DRB1__no_interaction	Cw7__B17__no_interaction	Cw7__DQB1__no_interaction	Cw7__DR11__no_interaction	Cw7__DRB1__no_interaction	B21__B17__no_interaction	B21__DQB1__no_interaction	B21__DR11__no_interaction	B21__DRB1__no_interaction
12460707-3	Despite equivalent effects on BP (<protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>: -19 +/- 4/-15 +/- 2 mm Hg; <compound-id="5326781">CEI</compound-id>: -12 +/- 3/-13 +/- 2 mm Hg; ARB: -10 +/- 3/-12 +/- 2 mm Hg; and BBl: -14 +/- 3/-12 +/- 2 mm Hg; P &lt;.005 for each drug v pretreatment), <protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>, <compound-id="5326781">CEI</compound-id>, and ARB significantly increased arterial compliance (<protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>: %deltaC1 = 30.0 +/- 5.8, %Delta C2 = 43.7 +/- 23.3; <compound-id="5326781">CEI</compound-id>: %deltaC1 = 32.7 +/- 5.4, %deltaC2 = 26.7 +/- 7.1; ARB: %deltaC1 = 36.3 +/- 11.8, %deltaC2 = 43.6 +/- 23.1; P &lt;.01 for <protein-id="P00519,Q59FK4,A0A024R8E2">CaBl</protein-id>, <compound-id="5326781">CEI</compound-id>, and ARB v pretreatment), but BBl did not (%deltaC1 = -3.9 +/- 7.6, %deltaC2 = -7.0 +/- 11.5, P = not significant v pretreatment, sig = 0.01 v other drugs).	CEI__CaBl__no_interaction
9695142-5	Human <compound-id="90470996">thrombin</compound-id> (0.1-10 U/ml), LPS (0.3-10 ng/ml) and the <compound-id="22833501,70702034">phorbol ester</compound-id>, <compound-id="71308525">phorbol 12-myristate</compound-id>-13-<compound-id="176">acetate</compound-id> (0.1 nM-1 microM), significantly increased ir-ET release, whereas <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (0.1-10 ng/ml), <protein-id="P13501,D0EI67">RANTES</protein-id> (0.1-100 nM), IL-1 (0.01-10 ng/ml), <protein-id="P01042">bradykinin</protein-id> (1 nM-10 microM), <protein-id="P06881,P01258">CGRP</protein-id> (0.01 nM-1 microM), PDGF (0.1-3 ng/ml), Sar9, Met(O2)11-Sub P, Nle10-<compound-id="5311311">NKA</compound-id> 4-10 and <compound-id="108147,5079497">senktide</compound-id> (selective <protein-id="P25103">NK-1</protein-id>, <protein-id="P20366,Q9Y494">NK-2</protein-id> and <protein-id="P29371">NK-3 receptor</protein-id> agonists, respectively; 1 nM-10 microM), <compound-id="52640,6435286">LTD4</compound-id> (1 nM-10 microM) or major basic protein (10 nM-1 microM) were without stimulatory effect.	NKA__bradykinin__no_interaction	NKA__CGRP__no_interaction	NKA__NK-3 receptor__no_interaction	NKA__TNF-alpha__no_interaction	NKA__RANTES__no_interaction	NKA__NK-2__no_interaction	NKA__NK-1__no_interaction	phorbol 12-myristate__bradykinin__no_interaction	phorbol 12-myristate__CGRP__no_interaction	phorbol 12-myristate__NK-3 receptor__no_interaction	phorbol 12-myristate__TNF-alpha__no_interaction	phorbol 12-myristate__RANTES__no_interaction	phorbol 12-myristate__NK-2__no_interaction	phorbol 12-myristate__NK-1__no_interaction	thrombin__bradykinin__no_interaction	thrombin__CGRP__no_interaction	thrombin__NK-3 receptor__no_interaction	thrombin__TNF-alpha__no_interaction	thrombin__RANTES__no_interaction	thrombin__NK-2__no_interaction	thrombin__NK-1__no_interaction	LTD4__bradykinin__no_interaction	LTD4__CGRP__no_interaction	LTD4__NK-3 receptor__no_interaction	LTD4__TNF-alpha__no_interaction	LTD4__RANTES__no_interaction	LTD4__NK-2__no_interaction	LTD4__NK-1__no_interaction	acetate__bradykinin__no_interaction	acetate__CGRP__no_interaction	acetate__NK-3 receptor__no_interaction	acetate__TNF-alpha__no_interaction	acetate__RANTES__no_interaction	acetate__NK-2__no_interaction	acetate__NK-1__no_interaction	senktide__bradykinin__no_interaction	senktide__CGRP__no_interaction	senktide__NK-3 receptor__no_interaction	senktide__TNF-alpha__no_interaction	senktide__RANTES__no_interaction	senktide__NK-2__no_interaction	senktide__NK-1__no_interaction	phorbol ester__bradykinin__no_interaction	phorbol ester__CGRP__no_interaction	phorbol ester__NK-3 receptor__no_interaction	phorbol ester__TNF-alpha__no_interaction	phorbol ester__RANTES__no_interaction	phorbol ester__NK-2__no_interaction	phorbol ester__NK-1__no_interaction
1319339-2	Human alveolar macrophages harvested by bronchoalveolar lavage were stimulated by opsonised <compound-id="64689">zymosan</compound-id> 1 mg/ml in the presence of N6,2'0-<compound-id="22840750">dibutyryladenosine</compound-id> 3':5' cyclic monophosphate (<compound-id="9687">dibutyryl cyclic AMP</compound-id>) 5 x 10(-6) to 5 x 10(-3) M,8-<compound-id="254688,96544">bromoadenosine</compound-id> 3':5'-cyclic monophosphate (8-bromo cyclic AMP) 5 x 10(-6) to 5 x 10(-3) M, 5'-(N-ethylcarboxamido)-<compound-id="57476835,60961">adenosine</compound-id> (NECA) 10(-7) to 10(-4) M, <compound-id="57476835,60961">adenosine</compound-id> 10(-7) to 10(-4) M, <compound-id="2153">theophylline</compound-id> 5 x 10(-6) to 5 x 10(-3) M and <compound-id="1676">enprofylline</compound-id> 5 x 10(-8) to 5 x 10(-4) M. The subsequent release of <compound-id="114873">thromboxane</compound-id> B2 (<compound-id="5283137,5461">TXB2</compound-id>) and <protein-id="P54802">N-acetyl-beta-D-glucosaminidase</protein-id> (<protein-id="P54802">NAG</protein-id>) activity was monitored.	zymosan__N-acetyl-beta-D-glucosaminidase__no_interaction	zymosan__NAG__no_interaction	TXB2__N-acetyl-beta-D-glucosaminidase__no_interaction	TXB2__NAG__no_interaction	theophylline__N-acetyl-beta-D-glucosaminidase__no_interaction	theophylline__NAG__no_interaction	thromboxane__N-acetyl-beta-D-glucosaminidase__no_interaction	thromboxane__NAG__no_interaction	bromoadenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	bromoadenosine__NAG__no_interaction	dibutyryl cyclic AMP__N-acetyl-beta-D-glucosaminidase__no_interaction	dibutyryl cyclic AMP__NAG__no_interaction	enprofylline__N-acetyl-beta-D-glucosaminidase__no_interaction	enprofylline__NAG__no_interaction	adenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	adenosine__NAG__no_interaction	dibutyryladenosine__N-acetyl-beta-D-glucosaminidase__no_interaction	dibutyryladenosine__NAG__no_interaction
21925493-9	<compound-id="10951331">CORM-2</compound-id> inhibited <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>-induced apoptosis (% annexin-V positive cells: <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id> = 60 ± 4% vs. <compound-id="10951331">CORM-2</compound-id> 10 μM = 48 ± 4%, <compound-id="10951331">CORM-2</compound-id> 25 μM=42 ± 5%, <compound-id="10951331">CORM-2</compound-id> 50 μM = 40 ± 4% and <compound-id="10951331">CORM-2</compound-id> 100 μM = 38 ± 2%, mean ± S.D., P&lt;0.001; <protein-id="Q08DY9">caspase-3</protein-id> activity: <compound-id="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>=92 ± 15 RFUs vs. <compound-id="10951331">CORM-2</compound-id> 50 μM=60 ± 14 RFUs, mean ± S.D.	CORM-2__caspase-3__no_interaction	staurosporine__caspase-3__no_interaction
17180193-0	Interplay between covalent and aurophilic interactions in a series of isostructural 3D Hoffman-like frameworks containing <compound-id="123444">bipyrimidine</compound-id> and <compound-id="161098">dicyanoaurate</compound-id> bridges. X-Ray structure and magnetic properties of {(mu-Au(CN)(2)](2)[(M(NH(3))(2))(2)(mu-bpym)]}[Au(CN)(2)](2) (M = Ni(II), <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co(II</protein-id>) and Cu(II)).	dicyanoaurate__Co(II__no_interaction	bipyrimidine__Co(II__no_interaction
19400559-4	Analogously, the Rh(I) compounds [{Rh(eta(2),eta(2)-NBD)(<compound-id="5289124">PCy</compound-id>(3))(2)}{BAr(F)}] (NBD = <compound-id="8473">norbornadiene</compound-id>) and [{Rh(eta(2),eta(2)-COD)(2)}{BAr(F)}] ({BAr(F)}= B{[C(6)H(3)(CF(3))(2)](4)) yield the complexes [{Rh(eta(2),eta(2)-NBD)(<compound-id="5289124">PCy</compound-id>(3))(GaCp*)(2)}{BAr(F)}] (4), [{Rh(eta(2),eta(2)-COD)(GaCp*)(3)}{BAr(F)}] (5), and [{Rh(eta(2),eta(2)-COD)(AlCp*)(3)}{BAr(F)]}] (6) upon reaction with the appropriate <protein-id="P12724">ECp</protein-id>* ligand (E = Al, Ga).	PCy__ECp__no_interaction	norbornadiene__ECp__no_interaction
23214495-1	Reactions of [8,8,8-(H)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)-9-(Py)-nido-8,7-RhSB(9)H(9)] (1), [1,1-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)-3-(Py)-closo-1,2-RhSB(9)H(8)] (2), and [1,1-(CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-3-(Py)-closo-1,2-RhSB(9)H(8)] (4), where Py = Pyridine, with HCl to give the <compound-id="312">Cl-</compound-id>ligated clusters, [8,8-(Cl)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-9-(Py)-nido-8,7-RhSB(9)H(9)] (3) and [8,8,8-(Cl)(CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))-9-(Py)-nido-8,7-RhSB(9)H(8)] (5), have recently demonstrated the remarkable nido-to-closo redox flexibility and bifunctional character of this class of 11-vertex rhodathiaboranes.	Cl-__PPh(3__no_interaction
24187469-5	The results showed that probiotic therapy signiﬁcantly decreased <compound-id="5950">alanine</compound-id> aminotransferase (ALT), <compound-id="5960">aspartate</compound-id> transaminase (AST), total-<compound-id="5997">cholesterol</compound-id> (T-chol), high density lipoprotein (HDL), tumor necrosis factor (TNF)-α and homeostasis model assessment of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-IR) [ALT: weighted mean difference (WMD) -23.71, 95%CI: -33.46--13.95, P &lt; 0.00001; AST: WMD -19.77, 95%CI: -32.55--7.00, P = 0.002; T-chol: WMD -0.28, 95%CI: -0.55--0.01, P = 0.04; HDL: WMD -0.09, 95%CI: -0.16-0.01, P = 0.03; TNF-α: WMD -0.32, 95%CI: -0.48--0.17, P &lt; 0.0001; HOMA-IR: WMD -0.46, 95%CI: -0.73--0.19, P = 0.0008].	alanine__insulin__no_interaction	aspartate__insulin__no_interaction	cholesterol__insulin__no_interaction
23619195-8	In non-diabetic subjects, circulating <protein-id="Q8NAU1">irisin</protein-id> was correlated with age (r = 0.398, p &lt; 0.01), BMI (r = 0.387, p &lt; 0.01), total <compound-id="5997">cholesterol</compound-id> (r = 0.341, p &lt; 0.01), total triglycerides (r = 0.299, p &lt; 0.05), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.430, p &lt; 0.01) and diastolic blood pressure (r = 0.306, p &lt; 0.05).	glucose__irisin__no_interaction	cholesterol__irisin__no_interaction
1820200-3	The results are summarized as follows: (i) oligosaccharides attached to Asn-52 of <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG alpha</protein-id> comprised monosialylated 'monoantenary' <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (<protein-id="O43805,A0A024R8G6">N1-4</protein-id>'), disialylated diantennary <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[<compound-id="439197">NeuAc</compound-id> alpha 2-3-Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N2), and the monosialylated hybrid-type structures <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-A) and <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal-beta 1-4GlcNAc beta 1-2Man alpha 1-3[Man alpha 1-3(Man alpha 1-6)Man alpha 1-6]Man beta 1-4GlcNAc beta 1-4GlcNAc (N1-AB) in a ratio approaching 5:2:2:1; (ii) Asn-78 of <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG alpha</protein-id> carried N2 and <protein-id="O43805,A0A024R8G6">N1-4</protein-id>' almost exclusively (ratio approximately 3:2); (iii) both N-glycosylation sites of <protein-id="P01233,A0A0F7RQP8">hCG beta</protein-id> contained predominantly component N2, partially (approximately 25%) and completely alpha 1-6-fucosylated at the <compound-id="11861101,439174">N-acetylglucosamine</compound-id> linked to Asn-13 and Asn-30, respectively.	NeuAc__hCG beta__no_interaction	NeuAc__hCG alpha__no_interaction	NeuAc__N1-4__no_interaction	N-acetylglucosamine__hCG beta__no_interaction	N-acetylglucosamine__hCG alpha__no_interaction	N-acetylglucosamine__N1-4__no_interaction
7558154-5	There were significant positive correlations between the increase in RL to <compound-id="187">acetylcholine</compound-id> and the numbers of CD25+ (r = 0.92, P &lt; 0.001), CD4+ (r = 0.77, P &lt; 0.05), CD8+ (r = 0.71, P &lt; 0.05) and <protein-id="P02688,Q5XFW1,I7FKL4">MBP</protein-id>+ (r = 0.72, P &lt; 0.03) cells in the OVA-sensitized and exposed group, but not in saline-exposed or naive animals.	acetylcholine__MBP__no_interaction
17982548-1	This study evaluated the bond strength (push-out method) and Knoop hardness of Z250 composite resin, photoactivated with XL 2500 curing unit, using different protocols: continuous mode (700 mW/cm(2) for 20s) (CO); soft-start (50 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">SS1</protein-id>); soft-start (100 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="637516">SS2</compound-id>); soft-start (150 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15s) (SS3); soft-start (200 mW/cm(2) for 5s, followed by 700 mW/cm(2) for 15s) (<compound-id="16122642">SS4</compound-id>); soft-start (250 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="16122641">SS5</compound-id>); soft-start (300 mW/cm(2) for 5 s, followed by 700 mW/cm(2) for 15 s) (<compound-id="42608444">SS6</compound-id>).	SS5__SS1__no_interaction	SS4__SS1__no_interaction	SS6__SS1__no_interaction	SS2__SS1__no_interaction
18767076-9	Further treatment of 7 S with dimethyl <compound-id="371">acetylenedicarboxylate</compound-id> at ambient temperature affords two B-disubstituted complexes at the carborane cage in the positions of the B3 and B6 sites, that is, [CpCo(S2C2-B10H8){(MeO2C)C=CH(CO2Me)}2] (9S) and [CpCo(S2C2B10H8){(MeO2C)-<protein-id="Q00610,A0A087WVQ6">CHC</protein-id>(CO2Me)}{(MeO2C)C=CH-(CO2Me)}] (10S).	acetylenedicarboxylate__CHC__no_interaction
23021775-9	After adjustment for BMI, smoking, drinking, and metabolic syndrome status, age was positively correlated with LDL-<compound-id="5997">cholesterol</compound-id> (r = 0.095, P &lt; 0.001), oxidized LDL (r = 0.305, P &lt; 0.001), hs-<protein-id="P02741">CRP</protein-id> (r = 0.150, P &lt; 0.001), TNF-α (r = 0.171, P &lt; 0.001) and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.294, P &lt; 0.001) and negatively with LDL particle size (r = -0.239, P &lt; 0.001).	cholesterol__CRP__no_interaction	cholesterol__IL-6__no_interaction
23585283-3	DESIGN AND METHODS: In a cross-sectional sample of 929 70-year-old individuals (50% women) of the Prospective Investigation of the Vasculature in Uppsala Seniors study, relations between serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> and oxidative stress [conjugated dienes (CD), <compound-id="778,91552">homocysteine</compound-id>, total antioxidant capacity, oxidized low-density lipoprotein (OxLDL), OxLDL antibodies, baseline CD of LDL, <compound-id="124886,20725278">glutathione</compound-id> (GSH), total <compound-id="124886,20725278">glutathione</compound-id> (TGSH), <compound-id="65359">glutathione disulfide</compound-id>], circulation interleukins (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>), other cytokines [tumor necrosis factor α, <protein-id="P13500">monocyte chemotactic protein-1</protein-id> (<protein-id="P13500">MCP-1</protein-id>), epidermal growth factor (EGF), vascular endothelial growth factor], cell adhesion molecules (<protein-id="P05362">vascular cell adhesion molecule-1, intercellular adhesion molecule-1</protein-id>, <protein-id="P16581">E-selectin</protein-id>, <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id>, <protein-id="P14151,A0A024R8Z0">L-selectin</protein-id>), and systemic inflammatory markers [<protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>), leukocyte count] in separate models were investigated.	homocysteine__E-selectin__no_interaction	homocysteine__CRP__no_interaction	homocysteine__IL-8__no_interaction	homocysteine__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	homocysteine__IL-6__no_interaction	homocysteine__C-reactive protein__no_interaction	homocysteine__monocyte chemotactic protein-1__no_interaction	homocysteine__L-selectin__no_interaction	homocysteine__adiponectin__no_interaction	homocysteine__P-selectin__no_interaction	homocysteine__MCP-1__no_interaction	glutathione disulfide__E-selectin__no_interaction	glutathione disulfide__CRP__no_interaction	glutathione disulfide__IL-8__no_interaction	glutathione disulfide__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	glutathione disulfide__IL-6__no_interaction	glutathione disulfide__C-reactive protein__no_interaction	glutathione disulfide__monocyte chemotactic protein-1__no_interaction	glutathione disulfide__L-selectin__no_interaction	glutathione disulfide__adiponectin__no_interaction	glutathione disulfide__P-selectin__no_interaction	glutathione disulfide__MCP-1__no_interaction	glutathione__E-selectin__no_interaction	glutathione__CRP__no_interaction	glutathione__IL-8__no_interaction	glutathione__vascular cell adhesion molecule-1, intercellular adhesion molecule-1__no_interaction	glutathione__IL-6__no_interaction	glutathione__C-reactive protein__no_interaction	glutathione__monocyte chemotactic protein-1__no_interaction	glutathione__L-selectin__no_interaction	glutathione__adiponectin__no_interaction	glutathione__P-selectin__no_interaction	glutathione__MCP-1__no_interaction
12955681-7	Although no correlation was observed with nutrient intake (protein, fat, saturated fat, or carbohydrate), both serum CML and MG levels correlated with blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (r = 0.2; P = 0.03 and r = 0.2; P = 0.02, respectively) and serum <protein-id="P02768">albumin</protein-id> levels (r = 0.16; P = 0.04 and r = 0.18; P = 0.02, respectively).	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
23969412-1	Three trimeric polyoxovanadate based on 1:13 anions [MnV13O38](7-) with lanthanide cations Ln(3+) (Ln = La, Ce and Nd) and <compound-id="938">pyridine-3-carboxylic acid</compound-id>: <protein-id="P52790,A0A024R7R1">HK3</protein-id>{[Ln(H2O)4]6[MnV13O38]3(SO4)2}·3(C6H6NO2)·nH2O (Ln = La 1, Nd 3; n = 33 for 1, 20 for 3), H(2.5)K(1.5){[Ce(H2O)4]6[MnV13O38]3(SO4)2}·3(C6H6NO2)·20.5H2O (2) (C6H5NO2 = <compound-id="938">pyridine-3-carboxylic acid</compound-id>) have been synthesized and characterized by elemental analysis, IR spectroscopy, UV spectroscopy, TG analysis, XPRD, electrochemical analyses, magnetism and single-crystal X-ray diffraction.	pyridine-3-carboxylic acid__HK3__no_interaction
16273137-3	This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate, (Z)-4-hydroxytamoxifen; Ad.muIFN-beta AD-237, adalimumab, <compound-id="60871">adefovir dipivoxil</compound-id>, agalsidase alfa, alemtuzumab, <compound-id="123606">almotriptan</compound-id>, ALVAC vCP1452, <compound-id="5488548">alvimopan hydrate</compound-id>, <compound-id="6918493">ambrisentan</compound-id>, <compound-id="90470007">anakinra</compound-id>, anti-<protein-id="P07353,A9QXB7">IFN-gamma</protein-id> MAb; <compound-id="5311027">Bimatoprost</compound-id>, <compound-id="6918494">BMS-188797</compound-id>, <compound-id="448545">BMS-214662</compound-id>, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, bovine <protein-id="P24627,B9VPZ5">lactoferrin</protein-id>; <compound-id="2519,57106085">Caffeine</compound-id>, <compound-id="156414">canertinib dihydrochloride</compound-id>, <compound-id="5312109">canfosfamide hydrochloride</compound-id>, <compound-id="644019">cannabidiol</compound-id>, <compound-id="5486792,2826718,66577042,71295847">caspofungin acetate</compound-id>, cetuximab, cH36, ChimeriVax-JE, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="6918107">cilansetron</compound-id>, <compound-id="156419">cinacalcet</compound-id> hydrochloride, <compound-id="60606">clopidogrel</compound-id>, CpG-7909, <compound-id="9962928">Cypher</compound-id>; <compound-id="16129629,16129688,16134395,21585658,25246315,46930993,57011757,57336511,71311849">Daptomycin</compound-id>, darbepoetin alfa, <compound-id="444031">darifenacin</compound-id> hydrobromide, <compound-id="451668">decitabine</compound-id>, <compound-id="9875516,192708,56841084">denufosol</compound-id> <compound-id="21226136">tetrasodium</compound-id>, Dexamet, <compound-id="3071">diindolemethane</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride, DX-9065a; E-7010, <compound-id="4021">edaravone</compound-id>, efalizumab, <compound-id="446284">eicosapentaenoic acid</compound-id>/<compound-id="3144,445580">docosahexaenoic acid</compound-id>, <compound-id="119373">elacridar</compound-id>, <compound-id="77993">eletriptan</compound-id>, <compound-id="12043008,60877">emtricitabine</compound-id>, epratuzumab, <compound-id="176870">erlotinib</compound-id> hydrochloride, <compound-id="150610">ertapenem sodium</compound-id>, <compound-id="969472">eszopiclone</compound-id>, everolimus, <compound-id="150311">ezetimibe</compound-id>; <compound-id="657237">Fludarabine</compound-id>, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>; gamma-Hydroxybutyrate <compound-id="5360545">sodium</compound-id>, <compound-id="6450546">gavestinel sodium</compound-id>, <compound-id="123631">gefitinib</compound-id>, <compound-id="17572266,3510,5284566,86287410">granisetron</compound-id>-Biochronomer; Human Albumin, human <protein-id="P01308,I3WAC9">insulin</protein-id>; <compound-id="5291">Imatinib</compound-id> <compound-id="6395">mesylate</compound-id>, <compound-id="6450813">indiplon</compound-id>, <protein-id="P60568,Q0GK43">interleukin-2</protein-id> XL, <compound-id="72231">isatoribine</compound-id>, ISS-1018, i.v.	isatoribine__IFN-gamma__no_interaction	isatoribine__interleukin-2__no_interaction	isatoribine__insulin__no_interaction	isatoribine__lactoferrin__no_interaction	tetrasodium__IFN-gamma__no_interaction	tetrasodium__interleukin-2__no_interaction	tetrasodium__insulin__no_interaction	tetrasodium__lactoferrin__no_interaction	BMS-214662__IFN-gamma__no_interaction	BMS-214662__interleukin-2__no_interaction	BMS-214662__insulin__no_interaction	BMS-214662__lactoferrin__no_interaction	bortezomib__IFN-gamma__no_interaction	bortezomib__interleukin-2__no_interaction	bortezomib__insulin__no_interaction	bortezomib__lactoferrin__no_interaction	Caffeine__IFN-gamma__no_interaction	Caffeine__interleukin-2__no_interaction	Caffeine__insulin__no_interaction	Caffeine__lactoferrin__no_interaction	eicosapentaenoic acid__IFN-gamma__no_interaction	eicosapentaenoic acid__interleukin-2__no_interaction	eicosapentaenoic acid__insulin__no_interaction	eicosapentaenoic acid__lactoferrin__no_interaction	bosentan__IFN-gamma__no_interaction	bosentan__interleukin-2__no_interaction	bosentan__insulin__no_interaction	bosentan__lactoferrin__no_interaction	darifenacin__IFN-gamma__no_interaction	darifenacin__interleukin-2__no_interaction	darifenacin__insulin__no_interaction	darifenacin__lactoferrin__no_interaction	erlotinib__IFN-gamma__no_interaction	erlotinib__interleukin-2__no_interaction	erlotinib__insulin__no_interaction	erlotinib__lactoferrin__no_interaction	ciclesonide__IFN-gamma__no_interaction	ciclesonide__interleukin-2__no_interaction	ciclesonide__insulin__no_interaction	ciclesonide__lactoferrin__no_interaction	canfosfamide hydrochloride__IFN-gamma__no_interaction	canfosfamide hydrochloride__interleukin-2__no_interaction	canfosfamide hydrochloride__insulin__no_interaction	canfosfamide hydrochloride__lactoferrin__no_interaction	sodium__IFN-gamma__no_interaction	sodium__interleukin-2__no_interaction	sodium__insulin__no_interaction	sodium__lactoferrin__no_interaction	gavestinel sodium__IFN-gamma__no_interaction	gavestinel sodium__interleukin-2__no_interaction	gavestinel sodium__insulin__no_interaction	gavestinel sodium__lactoferrin__no_interaction	alvimopan hydrate__IFN-gamma__no_interaction	alvimopan hydrate__interleukin-2__no_interaction	alvimopan hydrate__insulin__no_interaction	alvimopan hydrate__lactoferrin__no_interaction	Fludarabine__IFN-gamma__no_interaction	Fludarabine__interleukin-2__no_interaction	Fludarabine__insulin__no_interaction	Fludarabine__lactoferrin__no_interaction	indiplon__IFN-gamma__no_interaction	indiplon__interleukin-2__no_interaction	indiplon__insulin__no_interaction	indiplon__lactoferrin__no_interaction	ertapenem sodium__IFN-gamma__no_interaction	ertapenem sodium__interleukin-2__no_interaction	ertapenem sodium__insulin__no_interaction	ertapenem sodium__lactoferrin__no_interaction	diindolemethane__IFN-gamma__no_interaction	diindolemethane__interleukin-2__no_interaction	diindolemethane__insulin__no_interaction	diindolemethane__lactoferrin__no_interaction	BMS-188797__IFN-gamma__no_interaction	BMS-188797__interleukin-2__no_interaction	BMS-188797__insulin__no_interaction	BMS-188797__lactoferrin__no_interaction	caspofungin acetate__IFN-gamma__no_interaction	caspofungin acetate__interleukin-2__no_interaction	caspofungin acetate__insulin__no_interaction	caspofungin acetate__lactoferrin__no_interaction	eszopiclone__IFN-gamma__no_interaction	eszopiclone__interleukin-2__no_interaction	eszopiclone__insulin__no_interaction	eszopiclone__lactoferrin__no_interaction	mesylate__IFN-gamma__no_interaction	mesylate__interleukin-2__no_interaction	mesylate__insulin__no_interaction	mesylate__lactoferrin__no_interaction	Cypher__IFN-gamma__no_interaction	Cypher__interleukin-2__no_interaction	Cypher__insulin__no_interaction	Cypher__lactoferrin__no_interaction	clopidogrel__IFN-gamma__no_interaction	clopidogrel__interleukin-2__no_interaction	clopidogrel__insulin__no_interaction	clopidogrel__lactoferrin__no_interaction	docosahexaenoic acid__IFN-gamma__no_interaction	docosahexaenoic acid__interleukin-2__no_interaction	docosahexaenoic acid__insulin__no_interaction	docosahexaenoic acid__lactoferrin__no_interaction	cilansetron__IFN-gamma__no_interaction	cilansetron__interleukin-2__no_interaction	cilansetron__insulin__no_interaction	cilansetron__lactoferrin__no_interaction	cinacalcet__IFN-gamma__no_interaction	cinacalcet__interleukin-2__no_interaction	cinacalcet__insulin__no_interaction	cinacalcet__lactoferrin__no_interaction	fondaparinux sodium__IFN-gamma__no_interaction	fondaparinux sodium__interleukin-2__no_interaction	fondaparinux sodium__insulin__no_interaction	fondaparinux sodium__lactoferrin__no_interaction	gefitinib__IFN-gamma__no_interaction	gefitinib__interleukin-2__no_interaction	gefitinib__insulin__no_interaction	gefitinib__lactoferrin__no_interaction	Bimatoprost__IFN-gamma__no_interaction	Bimatoprost__interleukin-2__no_interaction	Bimatoprost__insulin__no_interaction	Bimatoprost__lactoferrin__no_interaction	ezetimibe__IFN-gamma__no_interaction	ezetimibe__interleukin-2__no_interaction	ezetimibe__insulin__no_interaction	ezetimibe__lactoferrin__no_interaction	denufosol__IFN-gamma__no_interaction	denufosol__interleukin-2__no_interaction	denufosol__insulin__no_interaction	denufosol__lactoferrin__no_interaction	elacridar__IFN-gamma__no_interaction	elacridar__interleukin-2__no_interaction	elacridar__insulin__no_interaction	elacridar__lactoferrin__no_interaction	decitabine__IFN-gamma__no_interaction	decitabine__interleukin-2__no_interaction	decitabine__insulin__no_interaction	decitabine__lactoferrin__no_interaction	emtricitabine__IFN-gamma__no_interaction	emtricitabine__interleukin-2__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__lactoferrin__no_interaction	Daptomycin__IFN-gamma__no_interaction	Daptomycin__interleukin-2__no_interaction	Daptomycin__insulin__no_interaction	Daptomycin__lactoferrin__no_interaction	edaravone__IFN-gamma__no_interaction	edaravone__interleukin-2__no_interaction	edaravone__insulin__no_interaction	edaravone__lactoferrin__no_interaction	granisetron__IFN-gamma__no_interaction	granisetron__interleukin-2__no_interaction	granisetron__insulin__no_interaction	granisetron__lactoferrin__no_interaction	almotriptan__IFN-gamma__no_interaction	almotriptan__interleukin-2__no_interaction	almotriptan__insulin__no_interaction	almotriptan__lactoferrin__no_interaction	ambrisentan__IFN-gamma__no_interaction	ambrisentan__interleukin-2__no_interaction	ambrisentan__insulin__no_interaction	ambrisentan__lactoferrin__no_interaction	Imatinib__IFN-gamma__no_interaction	Imatinib__interleukin-2__no_interaction	Imatinib__insulin__no_interaction	Imatinib__lactoferrin__no_interaction	adefovir dipivoxil__IFN-gamma__no_interaction	adefovir dipivoxil__interleukin-2__no_interaction	adefovir dipivoxil__insulin__no_interaction	adefovir dipivoxil__lactoferrin__no_interaction	cannabidiol__IFN-gamma__no_interaction	cannabidiol__interleukin-2__no_interaction	cannabidiol__insulin__no_interaction	cannabidiol__lactoferrin__no_interaction	anakinra__IFN-gamma__no_interaction	anakinra__interleukin-2__no_interaction	anakinra__insulin__no_interaction	anakinra__lactoferrin__no_interaction	canertinib dihydrochloride__IFN-gamma__no_interaction	canertinib dihydrochloride__interleukin-2__no_interaction	canertinib dihydrochloride__insulin__no_interaction	canertinib dihydrochloride__lactoferrin__no_interaction	eletriptan__IFN-gamma__no_interaction	eletriptan__interleukin-2__no_interaction	eletriptan__insulin__no_interaction	eletriptan__lactoferrin__no_interaction	duloxetine__IFN-gamma__no_interaction	duloxetine__interleukin-2__no_interaction	duloxetine__insulin__no_interaction	duloxetine__lactoferrin__no_interaction
2112071-2	All patients were clinically euthyroid and there were no significant differences between circulating levels (mean +/- SD) of T4 (114.7 +/- 26.8 vs 129.9 +/- 28.3 nmol/l), FT4 (16.6 +/- 4.5 vs 18.4 +/- 3.8 pmol/l), <compound-id="5920">T3</compound-id> (1.61 +/- 0.29 vs 1.86 +/- 0.33 pmol/l), TSH (2.7 +/- 1.3 vs 2.4 +/- 1.4 mU/l), <protein-id="P05543">TBG</protein-id> (26.7 +/- 5.5 vs 27.6 +/- 4.9 mg/l), T4/<compound-id="5920">T3</compound-id> (84.3 +/- 18.4 vs 82.1 +/- 15.3), and FT4/FT3 (0.28 +/- 0.05 vs 0.33 +/- 0.08).	T3__TBG__no_interaction
7718893-5	U-HL-60 cells contain 17.76 +/- 6.01 pmol actin per 10(6) cells (<compound-id="27873">TIF</compound-id>, 5.3 +/- 1.5; TSF, 2.17 +/- 0.37; G, 10.3 +/- 5.7; n = 5) and 0.073 pmol <protein-id="P06396,A0A0A0MS51,A0A0A0MT01,B7Z4U6">gelsolin</protein-id> per 10(6) cells (<compound-id="27873">TIF</compound-id>, 0; TSF, 0.002 +/- 0.005; G, 0.07 +/- 0.01; n = 3), representing molar actin to <protein-id="P06396,A0A0A0MS51,A0A0A0MT01,B7Z4U6">gelsolin</protein-id> (A:G) ratios of 1,085:1 for TSF and 147:1 for G. After myeloid differentiation, the actin content increases 1.80-fold (31.94 +/- 6.14 pmol/10(6) cells) equally in each actin pool (<compound-id="27873">TIF</compound-id>, 9.36 +/- 2.35; TSF, 3.29 +/- 0.62; G, 19.29 +/- 4.83).	TIF__gelsolin__no_interaction
8701397-5	FVII:C correlated with <compound-id="5997">cholesterol</compound-id> (r = 0.51, p &lt; 0.0005), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.36, p = 0.002), triglycerides (r = 0.34, p = 0.001), age (r = 0.23, p &lt; 0.005) and body mass index (r = 0.23, p &lt; 0.05).	cholesterol__insulin__no_interaction
9289451-4	The following parameters of amniotic fluid were measured: 1) total protein, 2) <protein-id="P02768">albumin</protein-id>, 3) beta-lipoprotein, 4) <compound-id="5997">cholesterol</compound-id>, 5) <compound-id="1175">uric acid</compound-id>, 6) <compound-id="1176">urea</compound-id>, 7) <compound-id="588">creatinine</compound-id>.	creatinine__albumin__no_interaction	urea__albumin__no_interaction	uric acid__albumin__no_interaction	cholesterol__albumin__no_interaction
19921058-2	of <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> in <compound-id="6344">dichloromethane</compound-id> to afford octanuclear <compound-id="23978">copper</compound-id>(I) complexes, [Cu(8)(mu-X)(8)(mu-dpmppm)(2)] (X = Cl (1a), Br (1b), I (1c)), which involve a ladder-type {Cu(8)(mu-X)(2)(mu(3)-X)(6)} core supported by two dpmppm ligands in anti arrangement.	copper__CuX__no_interaction	dichloromethane__CuX__no_interaction
16452471-7	Under optimal conditions (150 mm NaCl and 500 mm <compound-id="5462222">potassium</compound-id> <compound-id="1061,167704,644102">phosphate</compound-id>, 37 degrees C, and pH 7.5), no cofactors are required, and the lyase had a Km(PCB) = 2.7 and 2.3 microm, and a kcat = 1.7 x 10(-5) and 1.1 x 10(-5) s(-1) for PCB attachment to CpcB (C155I) and PecB (C155I), respectively; (b) Reconstitution products had absorption maxima at 619 and 602 nm and fluorescence emission maxima at 643 and 629 nm, respectively; and (c) PCB-CpcB(C155I) and PCB-PecB(C155I), with the same absorption and fluorescence maxima, were also biosynthesized heterologously in vivo, when <protein-id="Q7NLD4">cpeS</protein-id> was introduced into E. coli with cpcB(C155I) or pecB(C155I), respectively, together with genes ho1 (encoding <compound-id="4971">heme</compound-id> oxygenase) and pcyA (encoding PCB:ferredoxin oxidoreductase), thereby further proving the lyase function of <protein-id="Q7NLD4">cpeS</protein-id>.	potassium__cpeS__no_interaction	phosphate__cpeS__no_interaction	heme__cpeS__no_interaction
15672194-2	Using a variety of synthetic routes complexes [Mn(O2CPh)2{(py)2CNOH}2].0.25H2O (1.0.25H2O), Mn4(O2CPh)2{(py)2CO2}2{(py)2CNO}2Br2].MeCN (2.MeCN), [Mn4(O2CPh)2{(py)2CO2}2{(py)2CNO}2Cl(2)].2MeCN (3.2MeCN), [Mn4(O2CMe)2{(py)2CO2}2{(py)2CNO}2Br2].2MeCN (4.2MeCN), [Mn4(O2CMe)2{(py)2CO2}2{(py)2CNO}2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2].MeCN.H2O (5.MeCN.H2O) and [Mn2(O2CCF3)2(<compound-id="73706">hfac</compound-id>)2{(py)2CNOH}2] (6) have been isolated in good yields.	hfac__NO3__no_interaction
16156630-1	Monometallic [Pt{S-S2C2(NR)2H}2] (S-S2C2(NR)2H = kappa2-S,S-S2C2(NR)2H = bis-dialkyl-dithioxamidate, R = methyl, <compound-id="6556">isoamyl</compound-id>, <compound-id="123147">benzyl</compound-id>) and binuclear and trinuclear heterobimetallic complexes [Pt{S-S2C2(NR)2H}{mu-S2C2(NR)2}<protein-id="P12872">MLn</protein-id>] (mu-S2C2(NR)2 = kappa2-S,S(Pt)-kappa2-N,N(M)-S2C2(NR)2) and [Pt{ {mu-S2C2(NR)2}<protein-id="P12872">MLn</protein-id>}2] (<protein-id="P12872">MLn</protein-id>+ = [(eta3-<compound-id="8252">allyl</compound-id>)<compound-id="23938">palladium</compound-id>]+, [bis-(2-phenylpyridine)<compound-id="23948">rhodium</compound-id>]+, [(eta6-p-<compound-id="7463">cymene</compound-id>)(chloro)<compound-id="23950">ruthenium</compound-id>]+, [(<compound-id="5367363">1,4-cyclooctadiene</compound-id>)<compound-id="23948">rhodium</compound-id>]+, [(<compound-id="142539">pentamethylcyclopentadienyl</compound-id>)(chloro)<compound-id="23948">rhodium</compound-id>]+) have been prepared and characterized.	isoamyl__MLn__no_interaction	allyl__MLn__no_interaction	ruthenium__MLn__no_interaction	cymene__MLn__no_interaction	pentamethylcyclopentadienyl__MLn__no_interaction	1,4-cyclooctadiene__MLn__no_interaction	benzyl__MLn__no_interaction	palladium__MLn__no_interaction	rhodium__MLn__no_interaction
24015718-9	Women in the highest quintile of <compound-id="94789">HEI</compound-id> had the lowest mean values of systolic blood pressure and <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (mean ± SD = 112.7 ± 20.2, 112.6 ± 20.5, 110.6 ± 19.5 mmHg; p = 0.001 and mean ± SD = 99.3 ± 26.0, 100.1 ± 26.6, 97.7 ± 23.1 (mg/dL); p = 0.04, respectively).	HEI__apolipoprotein B__no_interaction
8580890-4	When administered to ovariectomized rats <protein-id="P01015">ANG II</protein-id> induced comparable amounts of <compound-id="962">water</compound-id> intake (4.0 +/- 0.5, 4.8 +/- 0.6, 6.9 +/- 0.7, 9.6 +/- 0.8, and 10.9 +/- 1.2 ml/120 min, respectively) (N = 43) but there was a significant decrease of 3% NaCl solution ingestion (0.3 +/- 0.1, 0.4 +/- 0.1, 0.8 +/- 0.2, 0.7 +/- 0.2, and 0.6 +/- 0.2 ml/120 min, respectively) (N = 44).	water__ANG II__no_interaction
11566978-8	We did, however, identify four types of <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id> mutations or strain genotypes that selectively disrupted substrate translocation or T-pilus production: (i) <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>/<protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>* merodiploid strains expressing all class II and III dominant alleles were strongly suppressed for T-DNA translocation but efficiently mobilized an IncQ plasmid to agrobacterial recipients and also elaborated abundant levels of T pilus; (ii) strains synthesizing two class III mutant proteins, <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>, V258G and <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>.I265T, efficiently transferred both DNA substrates but produced low and undetectable levels of T pilus, respectively; (iii) a strain synthesizing the class II mutant protein <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id>.I103T/M301L efficiently exported VirE2 but produced undetectable levels of T pilus; (iv) strains synthesizing three <protein-id="P0A3F9,P0A3F8,Q7BLP8">VirB11</protein-id> derivatives with a four-residue (HMVD) insertion (<compound-id="5481481">L75</compound-id>.i4, C168.i4, and <compound-id="14716343">L302</compound-id>.i4) neither transferred T-DNA nor produced detectable levels of T pilus but efficiently transferred VirE2 to plants and the IncQ plasmid to agrobacterial recipient cells.	L302__VirB11__no_interaction	L75__VirB11__no_interaction
8882615-11	<protein-id="G3V9Z3">MAO-A</protein-id> inhibition during HS intake was found to produce a 47-68% decrease in Na+ excretion (from 39.1 +/- 0.7 to 15.1 +/- 2.5 mmol kg-1 day-1, n = 4; P &lt; 0.02) and urine volume (from 160.4 +/- 3.3 to 43.8 +/- 9.0 ml kg-1 day-1, n = 4; P &lt; 0.02) without changes in K+ (from 11.1 +/- 0.5 to 9.2 +/- 0.6 mmol kg-1 day-1, n = 4) and <compound-id="588">creatinine</compound-id> (from 29.1 +/- 2.3 to 28.4 +/- 2.1 mg kg-1 day-1) excretion; urine osmolality increased 2 fold (from 936.3 +/- 40.3 to 2210.7 +/- 157.4 mOsm kg-<compound-id="491852">1 H2O</compound-id>, n = 4; P &lt; 0.02).	1 H2O__MAO-A__no_interaction	creatinine__MAO-A__no_interaction
8855152-2	Serum concentrations of apo A-I, LpA-I, LpA-I:A-II, apo C-III, and LpC-III significantly (P &lt;/= 0.01) increased with <compound-id="10982484">alcohol</compound-id> intake (mean +/- SE in low drinkers vs in alcoholics)--1.45 +/- 0.03 vs 1.78 +/- 0.05 g/L; 0.45 +/- 0.02 vs 0.56 +/- 0.02 g/L; 0.99 +/- 0.02 vs 1.22 +/- 0.04 g/L; 27.6 +/- 1.5 vs 39.7 +/- 1.7 mg/L; and 8.4 +/- 0.9 vs 24.7 +/- 1.7 mg/L, respectively-whereas <protein-id="P04114,Q7Z7Q0,Q59HB3">apo B</protein-id> and LpC-III:B concentrations tended to decrease--1.20 +/- 0.04 vs 1.06 +/- 0.04 g/L and 19.3 +/- 1.2 vs 14.9 +/- 1.0 mg/L, respectively.	alcohol__apo B__no_interaction
10705501-9	The partial solubility parameters obtained, expressed as <protein-id="Q96PP9">MPa1/2</protein-id>, were delta d = 17.6, delta p = 28.7, delta h = 19, delta a = 14.5, delta b = 12.4, delta T = 32.8 for <compound-id="294">lactose</compound-id>, delta d = 16.2, delta p = 24.5, delta h = 14.6, delta a = 8.7, delta b = 12.2, delta T = 32.8 for <compound-id="6251">mannitol</compound-id> and delta d = 17.1, delta p = 18.5, delta h = 13, delta a = 11.3, delta b = 7.6, delta T = 28.4 for <compound-id="5988">saccharose</compound-id>.	lactose__MPa1/2__no_interaction	mannitol__MPa1/2__no_interaction	saccharose__MPa1/2__no_interaction
15175802-3	SLC was in univariate analysis positively correlated with <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> activity (r = 0.35, p &lt;0.01), <compound-id="122634,22833501">tPA</compound-id> antigen (r = 0.38, p &lt;0.01), <protein-id="P04275">von Willebrand factor</protein-id> (r = 0.25, p &lt;0.05), protein S (r = 0.26, p &lt;0.05), and C (r = 0.30, p &lt;0.01), and negatively associated with <compound-id="122634,22833501">tPA</compound-id> activity(r = -0.28, p &lt;0.01).	tPA__von Willebrand factor__no_interaction	tPA__PAI-1__no_interaction
6146116-3	Comparative enzyme activities were as follows (mumol/h/g wet wt): <protein-id="P00367,E9KL48">glutamic acid dehydrogenase</protein-id> (<protein-id="P00367,E9KL48">GDH</protein-id>)--spiking 135.77 +/- 10.22 (mean +/- <compound-id="5289348">SEM</compound-id>), nonspiking 118.58 +/- 9.42 (p less than 0.001, N = 17); glutamic acid decarboxylase--spiking 10.63 +/- 0.95, nonspiking 9.96 +/- 1.10 (NS, N = 13); <protein-id="P80404,X5D8S1">GABA-aminotransferase</protein-id>--spiking 36.49 +/- 1.05, nonspiking 36.46 +/- 1.48 (NS, N = 12); <compound-id="5961">glutamine</compound-id> synthetase--spiking 96.94 +/- 3.81, nonspiking 96.52 +/- 4.10 (NS, N = 20); and <protein-id="P07101,P78428">tyrosine hydroxylase</protein-id> (TH; nmol/h/g)--spiking 16.23 +/- 2.39, nonspiking 10.67 +/- 1.95 (p less than 0.001, N = 14).	SEM__GDH__no_interaction	SEM__GABA-aminotransferase__no_interaction	SEM__glutamic acid dehydrogenase__no_interaction	SEM__tyrosine hydroxylase__no_interaction	glutamine__GDH__no_interaction	glutamine__GABA-aminotransferase__no_interaction	glutamine__glutamic acid dehydrogenase__no_interaction	glutamine__tyrosine hydroxylase__no_interaction
22357517-9	In the rat cerebral cortex and hippocampus, there were the negative correlation (r = -0.927, P &lt; 0.01; r = -0.934, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="P49950">Bcl-2</protein-id>, the positive correlation (r = 0.858, P &lt; 0.01; r = 0.847, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="Q9JKL3,G3V8T9">Bax</protein-id> and the negative correlation (r = -0.939, P &lt; 0.01; r = -0.942, P &lt; 0.01) between <compound-id="15942654">AI</compound-id> and <protein-id="P49950">Bcl-2</protein-id>/<protein-id="Q9JKL3,G3V8T9">Bax</protein-id>.	AI__Bcl-2__no_interaction	AI__Bax__no_interaction
3470275-1	Orally active 1-(alkyl substituted <compound-id="15984456">cyclohexyloxycarbonyloxy</compound-id>)alkyl ester prodrugs (9b-h) of 7 beta-[2-(2-<compound-id="2155">aminothiazol</compound-id>-4-yl)<compound-id="178">acetamido</compound-id>]-3- [[[1-(2-dimethylaminoethyl)-<compound-id="67519">1H-tetrazol</compound-id>-5-yl]thio]-methyl]ceph+ ++-3- em-4-<compound-id="11229316,91179806">carboxylic acid</compound-id> (<compound-id="43708">cefotiam</compound-id>, <protein-id="Q9Z109">CTM</protein-id>) have been studied as well as the thia (9i) and aza (9j) analogs.	cefotiam__CTM__no_interaction	cyclohexyloxycarbonyloxy__CTM__no_interaction	acetamido__CTM__no_interaction	aminothiazol__CTM__no_interaction	carboxylic acid__CTM__no_interaction	1H-tetrazol__CTM__no_interaction
21431217-1	A novel class of cyclometalated macrocycles [(Cp*Ir)(2)(R-N=C-C(6)H(2)-C=N-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (<compound-id="69255155">4a</compound-id>), p-MeOC(6)H(4) (4b), p-MeC(6)H(4) (4c), p-ClC(6)H(4) (4d), Me (4e)]; [(Cp*Rh)(2)(R-N=C-C(6)H(2)-C=N-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (<compound-id="69255155">4a</compound-id>'), p-MeOC(6)H(4) (4b'), p-MeC(6)H(4) (4c')] and [(Cp*Ir)(2)(R-C=N-C(6)H(4)-N=C-R)(2)](2)(<compound-id="9261">pyrazine</compound-id>)(2)·(OTf)(4) [R = Ph (5a), p-MeOC(6)H(4) (<compound-id="18445697">5b</compound-id>)] was stepwise constructed through the double-site C-H activation of aromatic <protein-id="O95817">Bis</protein-id>-imine substrates.	5b__Bis__no_interaction	pyrazine__Bis__no_interaction	4a__Bis__no_interaction
21742997-3	In situ intravital microscopy of mouse cremaster vasculature was used to evaluate arteriolar reactivities to the vasoconstrictors <protein-id="Q3UTR7">angiotensin II</protein-id> (<protein-id="Q3UTR7">ANG II</protein-id>) and <compound-id="6041">phenylephrine</compound-id> (Phe) and the vasodilators <compound-id="187">acetylcholine</compound-id> (ACh) and <compound-id="57476835,60961">adenosine</compound-id> (Ado) in normal [+/+; wild type (WT)] and genetically immunodeficient (T(-)B(-)NK(+) or T(-)B(-)\NK(-)) C57BL/6 and BALB/c mice, strain backgrounds with differentially polarized T cell cytokine production.	phenylephrine__angiotensin II__no_interaction	phenylephrine__ANG II__no_interaction	acetylcholine__angiotensin II__no_interaction	acetylcholine__ANG II__no_interaction	adenosine__angiotensin II__no_interaction	adenosine__ANG II__no_interaction
12879253-4	RESULTS: In comparison with NGT, IGT were modestly <protein-id="P01308,I3WAC9">insulin</protein-id> resistant (M=29+/-2 vs 35+/-2 micromol x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x kg(FFM)(-1), p=0.01); <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity of <compound-id="206,5793,64689,79025">glucose</compound-id> production also was reduced, in approximate proportion to M. Despite higher baseline <protein-id="P01308,I3WAC9">insulin</protein-id> secretion rates, IGT was characterized by a 50% reduction in <compound-id="206,5793,64689,79025">glucose</compound-id> sensitivity [53 (36) vs 102 (123) pmol x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) x mM(-1), median (interquartile range), p=0.001] and impaired potentiation [1.6 (0.8) vs 2.0 (1.5) units, p&lt;0.04] of <protein-id="P01308,I3WAC9">insulin</protein-id> release, whereas rate sensitivity [1.15 (1.15) vs 1.38 (1.28) nmol x m(-2) x mM(-1)] was not significantly reduced.	glucose__min(-1__no_interaction	glucose__insulin__no_interaction
22070200-1	The syntheses, crystal structures, and magnetochemical characterization are reported for the new mixed-valent Mn clusters [Mn(2)(II)Mn(III)(O(2)CMe)(2)(edteH(2))(2)](ClO(4)) (1), [Mn(II)(2)Mn(III)(2)(edteH(2))(2)(hmp)(2)Cl(2)](<compound-id="27854">Mn(II)</compound-id>Cl(4)) (2), [Mn(III)(6)O(2)(O(2)CBu(t))(6)(edteH)(2)(N(3))(2)] (3), [Na(2)Mn(III)(8)Mn(II)(2)O(4)(OMe)(2)(O(2)CEt)(6)(edte)(2)(N(3))(6)] (4), and (NEt(4))(2)[Mn(8)(III)Mn(2)(II)O(4)(OH)(2)-(O(2)CEt)(6)(edte)(2)(N(3))(6)](5), where edteH(4) is N,N,N',N'-tetrakis-(2-hydroxyethyl)<compound-id="17822391,3301">ethylenediamine</compound-id> and <protein-id="Q03014">hmpH</protein-id> is <compound-id="11474">2-(hydroxymethyl)pyridine</compound-id>.	ethylenediamine__hmpH__no_interaction	Mn(II)__hmpH__no_interaction	2-(hydroxymethyl)pyridine__hmpH__no_interaction
11102586-5	Known genes that were upregulated in waking and sleep deprivation can be grouped into the following categories: immediate early genes/transcription factors (<protein-id="Q63053">Arc</protein-id>, <protein-id="Q496Y7,Q62804">CHOP</protein-id>, IER5, <protein-id="P08154">NGFI-A</protein-id>, <protein-id="P22829">NGFI-B</protein-id>, <protein-id="Q04970">N-Ras</protein-id>, <protein-id="P52631">Stat3</protein-id>), genes related to energy metabolism (<compound-id="206,5793,64689,79025">glucose</compound-id> type I transporter Glut1, <compound-id="42627579">Vgf</compound-id>), growth factors/adhesion molecules (<protein-id="P23363,A0A0G2K624,A0A0H2UI28">BDNF</protein-id>, <protein-id="Q63604,A0A0G2K5X6">TrkB</protein-id>, F3 adhesion molecule), chaperones/heat shock proteins (<protein-id="P06761">BiP</protein-id>, <protein-id="P38659">ERP72</protein-id>, <protein-id="F1M953">GRP75</protein-id>, <protein-id="P63039">HSP60</protein-id>, HSP70), vesicle- and synapse-related genes (<protein-id="P10362,G3V7X2">chromogranin C</protein-id>, <protein-id="P50232">synaptotagmin IV</protein-id>), neurotransmitter/hormone receptors (<protein-id="P43140">adrenergic receptor alpha(1A</protein-id>) and beta(2), <compound-id="119">GABA</compound-id>(A) receptor beta(3), <compound-id="23327,33032,611,57109091">glutamate</compound-id> NMDA receptor 2A, <compound-id="23327,33032,611,57109091">glutamate</compound-id> AMPA receptor <protein-id="P19491">GluR2</protein-id> and <protein-id="P19492,G3V6Z5,G3V8Y9">GluR3</protein-id>, nicotinic <compound-id="187">acetylcholine</compound-id> receptor beta(2), thyroid hormone receptor TRbeta), neurotransmitter transporters (<compound-id="23327,33032,611,57109091">glutamate</compound-id>/<compound-id="5960">aspartate</compound-id> transporter <protein-id="P24942,A0A0G2JSU1,G3V846,A0A0G2KAS7,A0A0G2K611">GLAST</protein-id>, Na(+)/Cl(-) transporter <protein-id="P31662">NTT4</protein-id>/Rxt1), enzymes (aryl sulfotransferase, <protein-id="P49185">c-jun N-terminal kinase 1</protein-id>, serum/glucocorticoid-induced serine/<compound-id="194239,6288">threonine</compound-id> kinase), and a miscellaneous group (calmodulin, <protein-id="Q04827">cyclin D2</protein-id>, <protein-id="Q5PPG8">LMO-4</protein-id>, <protein-id="P37361">metallothionein 3</protein-id>).	acetylcholine__cyclin D2__no_interaction	acetylcholine__ERP72__no_interaction	acetylcholine__GRP75__no_interaction	acetylcholine__BDNF__no_interaction	acetylcholine__chromogranin C__no_interaction	acetylcholine__BiP__no_interaction	acetylcholine__LMO-4__no_interaction	acetylcholine__c-jun N-terminal kinase 1__no_interaction	acetylcholine__N-Ras__no_interaction	acetylcholine__metallothionein 3__no_interaction	acetylcholine__NGFI-B__no_interaction	acetylcholine__CHOP__no_interaction	acetylcholine__synaptotagmin IV__no_interaction	acetylcholine__NGFI-A__no_interaction	acetylcholine__Stat3__no_interaction	acetylcholine__TrkB__no_interaction	acetylcholine__adrenergic receptor alpha(1A__no_interaction	acetylcholine__HSP60__no_interaction	acetylcholine__GluR3__no_interaction	acetylcholine__GluR2__no_interaction	acetylcholine__Arc__no_interaction	acetylcholine__GLAST__no_interaction	acetylcholine__NTT4__no_interaction	Vgf__cyclin D2__no_interaction	Vgf__ERP72__no_interaction	Vgf__GRP75__no_interaction	Vgf__BDNF__no_interaction	Vgf__chromogranin C__no_interaction	Vgf__BiP__no_interaction	Vgf__LMO-4__no_interaction	Vgf__c-jun N-terminal kinase 1__no_interaction	Vgf__N-Ras__no_interaction	Vgf__metallothionein 3__no_interaction	Vgf__NGFI-B__no_interaction	Vgf__CHOP__no_interaction	Vgf__synaptotagmin IV__no_interaction	Vgf__NGFI-A__no_interaction	Vgf__Stat3__no_interaction	Vgf__TrkB__no_interaction	Vgf__adrenergic receptor alpha(1A__no_interaction	Vgf__HSP60__no_interaction	Vgf__GluR3__no_interaction	Vgf__GluR2__no_interaction	Vgf__Arc__no_interaction	Vgf__GLAST__no_interaction	Vgf__NTT4__no_interaction	aspartate__cyclin D2__no_interaction	aspartate__ERP72__no_interaction	aspartate__GRP75__no_interaction	aspartate__BDNF__no_interaction	aspartate__chromogranin C__no_interaction	aspartate__BiP__no_interaction	aspartate__LMO-4__no_interaction	aspartate__c-jun N-terminal kinase 1__no_interaction	aspartate__N-Ras__no_interaction	aspartate__metallothionein 3__no_interaction	aspartate__NGFI-B__no_interaction	aspartate__CHOP__no_interaction	aspartate__synaptotagmin IV__no_interaction	aspartate__NGFI-A__no_interaction	aspartate__Stat3__no_interaction	aspartate__TrkB__no_interaction	aspartate__adrenergic receptor alpha(1A__no_interaction	aspartate__HSP60__no_interaction	aspartate__GluR3__no_interaction	aspartate__GluR2__no_interaction	aspartate__Arc__no_interaction	aspartate__GLAST__no_interaction	aspartate__NTT4__no_interaction	glucose__cyclin D2__no_interaction	glucose__ERP72__no_interaction	glucose__GRP75__no_interaction	glucose__BDNF__no_interaction	glucose__chromogranin C__no_interaction	glucose__BiP__no_interaction	glucose__LMO-4__no_interaction	glucose__c-jun N-terminal kinase 1__no_interaction	glucose__N-Ras__no_interaction	glucose__metallothionein 3__no_interaction	glucose__NGFI-B__no_interaction	glucose__CHOP__no_interaction	glucose__synaptotagmin IV__no_interaction	glucose__NGFI-A__no_interaction	glucose__Stat3__no_interaction	glucose__TrkB__no_interaction	glucose__adrenergic receptor alpha(1A__no_interaction	glucose__HSP60__no_interaction	glucose__GluR3__no_interaction	glucose__GluR2__no_interaction	glucose__Arc__no_interaction	glucose__GLAST__no_interaction	glucose__NTT4__no_interaction	glutamate__cyclin D2__no_interaction	glutamate__ERP72__no_interaction	glutamate__GRP75__no_interaction	glutamate__BDNF__no_interaction	glutamate__chromogranin C__no_interaction	glutamate__BiP__no_interaction	glutamate__LMO-4__no_interaction	glutamate__c-jun N-terminal kinase 1__no_interaction	glutamate__N-Ras__no_interaction	glutamate__metallothionein 3__no_interaction	glutamate__NGFI-B__no_interaction	glutamate__CHOP__no_interaction	glutamate__synaptotagmin IV__no_interaction	glutamate__NGFI-A__no_interaction	glutamate__Stat3__no_interaction	glutamate__TrkB__no_interaction	glutamate__adrenergic receptor alpha(1A__no_interaction	glutamate__HSP60__no_interaction	glutamate__GluR3__no_interaction	glutamate__GluR2__no_interaction	glutamate__Arc__no_interaction	glutamate__GLAST__no_interaction	glutamate__NTT4__no_interaction	threonine__cyclin D2__no_interaction	threonine__ERP72__no_interaction	threonine__GRP75__no_interaction	threonine__BDNF__no_interaction	threonine__chromogranin C__no_interaction	threonine__BiP__no_interaction	threonine__LMO-4__no_interaction	threonine__c-jun N-terminal kinase 1__no_interaction	threonine__N-Ras__no_interaction	threonine__metallothionein 3__no_interaction	threonine__NGFI-B__no_interaction	threonine__CHOP__no_interaction	threonine__synaptotagmin IV__no_interaction	threonine__NGFI-A__no_interaction	threonine__Stat3__no_interaction	threonine__TrkB__no_interaction	threonine__adrenergic receptor alpha(1A__no_interaction	threonine__HSP60__no_interaction	threonine__GluR3__no_interaction	threonine__GluR2__no_interaction	threonine__Arc__no_interaction	threonine__GLAST__no_interaction	threonine__NTT4__no_interaction	GABA__cyclin D2__no_interaction	GABA__ERP72__no_interaction	GABA__GRP75__no_interaction	GABA__BDNF__no_interaction	GABA__chromogranin C__no_interaction	GABA__BiP__no_interaction	GABA__LMO-4__no_interaction	GABA__c-jun N-terminal kinase 1__no_interaction	GABA__N-Ras__no_interaction	GABA__metallothionein 3__no_interaction	GABA__NGFI-B__no_interaction	GABA__CHOP__no_interaction	GABA__synaptotagmin IV__no_interaction	GABA__NGFI-A__no_interaction	GABA__Stat3__no_interaction	GABA__TrkB__no_interaction	GABA__adrenergic receptor alpha(1A__no_interaction	GABA__HSP60__no_interaction	GABA__GluR3__no_interaction	GABA__GluR2__no_interaction	GABA__Arc__no_interaction	GABA__GLAST__no_interaction	GABA__NTT4__no_interaction
22155782-4	The major findings of this study are that TRPV1 is activated by some, but not all of the prototype PM materials evaluated, with rank-ordered responses of CFA1 &gt; diesel exhaust PM &gt; crystalline <compound-id="24261">silica</compound-id>; TRP melastatin-8 is also robustly activated by CFA1, whereas other TRP channels expressed by airway sensory neurons and lung epithelial cells that may also be activated by CFA1, including TRPs ankyrin 1 (A1), canonical 4α (C4α), M2, V2, V3, and V4, were either slightly (<protein-id="Q8BLA8,V5TCP9">TRPA1</protein-id>) or not activated by CFA1; activation of TRPV1 by CFA1 occurs via cell surface interactions between the solid components of CFA1 and specific amino acid residues of TRPV1 that are localized in the putative pore-loop region; and activation of TRPV1 by CFA1 is not exclusive in mouse lungs but represents a pathway by which CFA1 affects the expression of selected genes in lung epithelial cells and airway tissue.	silica__TRPA1__no_interaction
11229569-1	The reactions of potentially hexadentate H2bbpen (N,N'-bis(2-hydroxybenzyl)-N,N'-bis<compound-id="12677274">(2-pyridylmethyl)-ethylenediamine</compound-id>, H2L1), <compound-id="783">H2</compound-id>(Cl)bbpen (N,N'-bis(5-chloro-2-hydroxybenzyl)-<compound-id="300761">N,N'-bis(2-pyridylmethyl)ethylenediamine</compound-id>, H2L2), and <protein-id="P06899,A0A024RCJ2">H2(Br</protein-id>)bbpen (N,N'-bis(5-bromo-2-hydroxybenzyl)-<compound-id="300761">N,N'-bis(2-pyridylmethyl)ethylenediamine</compound-id>, H2L3) with Ln(III) ions in the presence of a base in <compound-id="11686950,887">methanol</compound-id> resulted in three types of complexes: neutral mononuclear ([LnL(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]), monocationic dinuclear ([Ln2L2(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]+), and monocationic trinuclear ([Ln3L2(X)n(CH3OH)]+), where X = bridging (CH3COO-) and bidentate ligands (<protein-id="P41271,A0A087WTY6">NO3</protein-id>-, CH3COO-, ClO4-) and n is 4.	H2__NO3__no_interaction	H2__H2(Br__no_interaction	methanol__NO3__no_interaction	methanol__H2(Br__no_interaction	(2-pyridylmethyl)-ethylenediamine__NO3__no_interaction	(2-pyridylmethyl)-ethylenediamine__H2(Br__no_interaction	N,N'-bis(2-pyridylmethyl)ethylenediamine__NO3__no_interaction	N,N'-bis(2-pyridylmethyl)ethylenediamine__H2(Br__no_interaction
15808768-7	Quantification of myocardial TF messenger ribonucleic acid in DCM revealed a decrease in the TF/<compound-id="439168,446381">glyceraldehyde-3-phosphate</compound-id> dehydrogenase (<protein-id="P04406,V9HVZ4">GAPDH</protein-id>) ratio (1.76 x 10(-1) +/- 6.08 x 10(-2) for EF &gt; or =50% [n = 19] vs. 1.06 x 10(-1) +/- 5.26 x 10(-2) for EF &lt;50% [n = 27]; p &lt; 0.001) and asHTF/<protein-id="P04406,V9HVZ4">GAPDH</protein-id> ratio (13.91 x 10(-5) +/- 11.20 x 10(-5) for EF &gt; or =50% vs. 7.17 x 10(-5) +/- 3.82 x 10(-5) for EF &lt;50%; p = 0.014).	glyceraldehyde-3-phosphate__GAPDH__no_interaction
19381423-1	A series of novel cationic and neutral <compound-id="23948">rhodium</compound-id> and <compound-id="23924">iridium</compound-id> complexes containing bidentate <compound-id="57182093">phosphine-imidazolyl</compound-id> donor ligands of the general formulae [M(<compound-id="8582">ImP</compound-id>)(COD)]BPh(4) (M = Rh, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 3; ImP1a, <compound-id="69255155">4a</compound-id>; ImP1b, 4b and M = Ir, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 5; ImP1a, 6a and ImP1b, 6b), [Ir(<compound-id="8582">ImP</compound-id>)(CO)(2)]BPh(4) (<compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 7; ImP1a, 8a and ImP1b, 8b), [Rh(ImP1b)(CO)(2)]BPh(4) (10b) and [M(<compound-id="8582">ImP</compound-id>)(CO)Cl] (M = Rh, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 11; ImP1b,12 and M = Ir, <compound-id="8582">ImP</compound-id> = <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id>, 13; ImP1b, 14 ) where COD = <compound-id="5702534,8135,82916">1,5-cyclooctadiene</compound-id>, <protein-id="Q9Y6M1,B3FTN5,F8W930,B4DKT5">ImP2</protein-id> = 1-methyl-2-[(2-(<compound-id="70017">diphenylphosphino</compound-id>)<compound-id="23134249">ethyl</compound-id>]<compound-id="795">imidazole</compound-id>, 1; ImP1a = <compound-id="10874611">1-methyl-2-[(diphenylphosphino)methyl]imidazole</compound-id>, 2a and ImP1b = <compound-id="15388202">2-[(diisopropylphosphino)methyl]-1-methylimidazole</compound-id>, 2b were successfully synthesised.	diphenylphosphino__ImP2__no_interaction	imidazole__ImP2__no_interaction	2-[(diisopropylphosphino)methyl]-1-methylimidazole__ImP2__no_interaction	ImP__ImP2__no_interaction	iridium__ImP2__no_interaction	phosphine-imidazolyl__ImP2__no_interaction	1-methyl-2-[(diphenylphosphino)methyl]imidazole__ImP2__no_interaction	1,5-cyclooctadiene__ImP2__no_interaction	ethyl__ImP2__no_interaction	rhodium__ImP2__no_interaction	4a__ImP2__no_interaction
22868212-2	Four experiments were conducted: (1) six steers were randomly assigned to receive intravenous (IV) bolus injections of 0, 0.2, 1.0, 12.5 and 50.0 μg/kg <compound-id="20832894,53481581,5486814">neuromedin C</compound-id> (NMC); (2) seven pre-weaned calves were IV injected with 1.0 μg/kg NMC; (3) six steers were IV injected with 2.5μg/kg bovine <protein-id="Q863C3">gastrin-releasing peptide</protein-id> (<protein-id="Q863C3">GRP</protein-id>), 1.0 μg/kg NMC combined with 20.0 μg/kg [d-<compound-id="5962">Lys</compound-id>(3)]-<compound-id="4345065">GHRP-6</compound-id> (an antagonist for the GH secretagogue receptor type 1a [GHS-R1a]), 1.0 μg/kg NMC combined with 20.0 μg/kg N-acetyl-<protein-id="Q863C3">GRP</protein-id>(20-26)-OCH(2)CH(3) (N-<protein-id="Q863C3">GRP</protein-id>-EE, an antagonist for the <protein-id="Q863C3">GRP</protein-id> receptor), 20.0 μg/kg N-<protein-id="Q863C3">GRP</protein-id>-EE alone, 1.0 μg/kg <protein-id="Q2T9U8">neuromedin B</protein-id> (<protein-id="Q2T9U8">NMB</protein-id>); and (4) four rats were IV injected 1.0 μg/kg NMC.	GHRP-6__gastrin-releasing peptide__no_interaction	GHRP-6__NMB__no_interaction	GHRP-6__neuromedin B__no_interaction	GHRP-6__GRP__no_interaction	Lys__gastrin-releasing peptide__no_interaction	Lys__NMB__no_interaction	Lys__neuromedin B__no_interaction	Lys__GRP__no_interaction	neuromedin C__gastrin-releasing peptide__no_interaction	neuromedin C__NMB__no_interaction	neuromedin C__neuromedin B__no_interaction	neuromedin C__GRP__no_interaction
6371116-3	The total <compound-id="206,5793,64689,79025">glucose</compound-id> and <protein-id="P01308,I3WAC9">insulin</protein-id> responses following the oral <compound-id="206,5793,64689,79025">glucose</compound-id> load were increased by 24% and 127% respectively in the elderly compared with the young (24,524 +/- 1,080 vs. 19,734 +/- 702 mg/dl X min and 24,289 +/- 3,401 vs. 10,700 +/- 1,209 microU/ml X min).	glucose__insulin__no_interaction
18082268-1	Six bipyridyl complexes of <compound-id="23939">platinum</compound-id>(II) with <compound-id="2723790">thiourea</compound-id>, with different substituents on <compound-id="2723790">thiourea</compound-id> moiety [Pt(bipy)(R,R'NCSNR'',R''')(2)]Cl(2) (bipy=<compound-id="1474">2,2'-bipyridine</compound-id>: R=R'=R''=R''' =H; R=Me, R'=R''=R'''=H; R=n-Bu, R'=R''=R'''=H; R=Et, R'=H, R''=Et, R'''=H; R=p-tolyl, R'=R''=R'''=H; R=phenyl, R'=H, R''=phenyl, R'''=H), rationally designed to intercalate into DNA, have been tested against a cisplatin (cDDP)-sensitive human ovarian carcinoma cell line (2008) and its -resistant variant (<protein-id="P31276">C13</protein-id>( *)).	platinum__C13__no_interaction	2,2'-bipyridine__C13__no_interaction	thiourea__C13__no_interaction
16335581-5	Patients reaching the composite outcome had predominantly proliferative lupus nephritis (WHO classes: 30% III, 32% IV, 18% V and 5% II, P &lt; 0.025) with higher activity index score (7 +/- 6 versus 5 +/- 5, P &lt; 0.05), chronicity index (CI) score (4 +/- 3 versus 2 +/- 2 unit, P &lt; 0.025), higher baseline mean arterial pressure (MAP) (111 +/- 21 versus 102 +/- 14 mmHg, P &lt; 0.025) and serum <compound-id="588">creatinine</compound-id> (1.9 +/- 1.3 versus 1.3 +/- 1.0 mg/dL, P &lt; 0.025), but lower baseline hematocrit (29 +/- 6 versus 31 + 5%, P &lt; 0.025) and <protein-id="P01024,V9HWA9,B4DR57">complement C3</protein-id> (54 +/- 26 versus 65 + 33 mg/dL, P &lt; 0.025) compared to controls.	creatinine__complement C3__no_interaction
23883066-5	Rate constants (25 °C) (k1 or k3) and activation parameters (ΔHk‡, kJ mol(-1); ΔSk‡, J K(-1) mol(-1)) from Eyring plots for entering nucleophiles as indicated are as follows: <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="12287">3-chloropyridine</compound-id>: (k1) 2.33 ± 0.01 M(-1) s(-1); 85.1 ± 0.6, 48 ± 2; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="1049">pyridine</compound-id>: (k1) 1.29 ± 0.02 M(-1) s(-1); 92 ± 2, 66 ± 7; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="7963">4-picoline</compound-id>: (k1) 1.27 ± 0.05 M(-1) s(-1); 88 ± 2, 53 ± 6; (k3) 3.9 ± 0.03 s(-1); 78 ± 8, 30 ± 27; (kf) 1.7 ± 0.02 M(-1) s(-1); 86 ± 2, 49 ± 6; <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(Sal-mTol)(CO)3(HOCH3)] <compound-id="14284">DMAP</compound-id> (k3) 1.15 ± 0.02 s(-1); 88 ± 2, 52 ± 7.	4-picoline__fac__no_interaction	3-chloropyridine__fac__no_interaction	pyridine__fac__no_interaction	DMAP__fac__no_interaction
25095655-5	There were direct correlations between all the examined biomarkers and the degree of uricemia (<compound-id="7021454">Rs</compound-id> = 0.453; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.411; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.322; p = 0.067; <compound-id="7021454">Rs</compound-id> = 0.537; p &lt; 0.001; and <compound-id="7021454">Rs</compound-id> = 0.318; p = 0.004, respectively) and between the markers of endothelial dysfunction and those of tubulointerstitial tissue lesion (<compound-id="7021454">Rs</compound-id> = 0.295 for <protein-id="P05305,Q6FH53">ET-1</protein-id> and <protein-id="P13500">MCP-1</protein-id>; p = 0.008; <compound-id="7021454">Rs</compound-id> = 0.399 for <protein-id="P05305,Q6FH53">ET-1</protein-id> and beta2-MG; p &lt; 0.001; <compound-id="7021454">Rs</compound-id> = 0.462 for <compound-id="54688679,54720365">MAU</compound-id> and beta2-MG; p &lt; 0.001; and <compound-id="7021454">Rs</compound-id> = 0.188 for <compound-id="54688679,54720365">MAU</compound-id> and <protein-id="P13500">MCP-1</protein-id>; p = 0.094).	MAU__ET-1__no_interaction	MAU__MCP-1__no_interaction	Rs__ET-1__no_interaction	Rs__MCP-1__no_interaction
18453222-3	RESULTS: Under normoxia, the <protein-id="Q16665,D0VY79">HIF-1alpha</protein-id> mRNA and protein of HepG2(Tet-on-<protein-id="Q16665,D0VY79">HIF-1alpha</protein-id>) cells could be induced up to (5.899 +/- 2.176) and (2.179 +/- 0.742) folds by <compound-id="54671203">doxycycline</compound-id> (1 microg/ml); There were no difference of A(490 nm) between the Dox(+)and Dox(-) group in experiment detecting the proliferation activity (P &gt; 0.05); But in adhesive experiment, the A(490 nm) of Dox (+) group was 0.662 +/- 0.058, higher than the Dox(-) group 0.526 +/- 0.808 (P = 0.008); The invasive cell number of Dox(+) group was 37.611 +/- 8.424, but in the Dox(-) group, the number was 25.333 +/- 8.117 (P &lt; 0.01).	doxycycline__HIF-1alpha__no_interaction
12492336-5	Metathesis of these polyfluoroalkyl-substituted triazolium halides with other salts led to the formation of quaternary compounds, some of which comprise ionic liquids, namely, [R(R(f))-<compound-id="123630">Taz</compound-id>](+)Y(-) (Y = <compound-id="5326889">NTf</compound-id>(2), BF(4), <protein-id="Q6Q759">PF(6</protein-id>), and OTf), in good isolated yields without the need for further purification: N1-CH(3)-N4-(CH(2))(2)C(m)F(2)(m)( +) (1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 4, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1- C(7)H(15)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 1, 4, 6; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(10)H(21)-N4-(CH(2))(2)C(m)F(2)(m)(+1)-<compound-id="123630">Taz</compound-id> Y (n = 1, 4; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(n)H(2)(n )(+ 1)-N4-(CH(2))(2)F-<compound-id="123630">Taz</compound-id> Y (n = 7, 10; Y = <compound-id="5326889">NTf</compound-id>(2)), N1-C(10)H(21)-N4-(CH(2))(2)F-TazY (Y = OTf), N1-C(7)H(15)-N4-(CH(2))(2)F-TazY (Y = BF(4)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m) (+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 4, 6; Y = <protein-id="Q6Q759">PF(6</protein-id>)), N1-C(7)H(15)-N4-(CH(2))(2)C(4)F(9)-<compound-id="123630">Taz</compound-id> Y (Y = <protein-id="Q6Q759">PF(6</protein-id>)), N1-C(4)H(9)-N4-(CH(2))(2)C(m)F(2)(m)(+ 1)-<compound-id="123630">Taz</compound-id> Y (m = 4, 6; Y = OTf).	Taz__PF(6__no_interaction	NTf__PF(6__no_interaction
21923249-3	At the end of the study, the comparison between group A and group B showed significant differences in <protein-id="Q9NRA2">aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) (-80.9 versus -110.3; P &lt; 0.001), <compound-id="5950,602">alanine</compound-id> aminotransferase (-111.6 versus -134.7; P &lt; 0.001), Viremia (-3.26 versus -3.82; P &lt; 0.05), mental health (0 versus 11; P &lt; 0.001), physical functioning (-1 versus 8; P &lt; 0.001), role-physical (1 versus 13; P &lt; 0.001), bodily pain (1 versus 12; P &lt; 0.001), general health (3 versus 12; P &lt; 0.001), vitality (3 versus 13; P &lt; 0.001), social functioning (3 versus 10; P &lt; 0.001), physical fatigue (2.1 versus -5.4; P &lt; 0.001), mental fatigue (-0.7 versus -2.7; P &lt; 0.001), and fatigue severity scale (-3.4 versus -12; P &lt; 0.001).	alanine__aspartate aminotransferase__no_interaction	alanine__AST__no_interaction
22462581-7	RESULTS: We found <compound-id="61739">hypochlorite</compound-id>-oxidized <protein-id="P28845,X5D2L1">HDL</protein-id> dramatically promotes breast cancer cell pulmonary metastasis (133.4% increase at P &lt; 0.0 l for MDA-MB-231 by mammary fat <compound-id="19805081,5492869">pad</compound-id> injection; 164.3% increase at P &lt; 0.01 for MCF7 by tail vein injection) and hepatic metastasis (420% increase at P &lt; 0.0 l for MDA-MB-231 by mammary fat <compound-id="19805081,5492869">pad</compound-id> injection; 1840% fold increase at P &lt; 0.001 for MCF7 by tail vein injection) in nude mice, and stimulates higher cell invasion (85.1% increase at P &lt; 0.00 l for MDA-MB-231; 88.8% increase at P &lt; 0.00 l for MCF7;), TC-HUVEC adhesion (43.4% increase at P &lt; 0.00 l for MDA-MB-231; 35.2% increase at P &lt; 0.00 l for MCF7), and TC-<protein-id="Q13201">ECM</protein-id> attachment (41.0% increase at P &lt; 0.00 l for MDA-MB-231; 26.7% increase at P &lt; 0.05 for MCF7) in vitro compared with normal <protein-id="P28845,X5D2L1">HDL</protein-id>.	hypochlorite__ECM__no_interaction	hypochlorite__HDL__no_interaction	pad__ECM__no_interaction	pad__HDL__no_interaction
19950340-1	The preparation and characterization of a series of <compound-id="5462224">magnesium</compound-id>(II) <compound-id="105054,30165">iodide</compound-id> complexes incorporating beta-diketiminate ligands of varying steric bulk and denticity, namely, [(ArNCMe)(2)CH](-) (Ar=phenyl, ((Ph)Nacnac), mesityl ((Mes)Nacnac), or 2,6-<compound-id="11345">diisopropylphenyl</compound-id> (<protein-id="Q9JI46,B2KF67">Dipp</protein-id>, (<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)), [(DippNCtBu)(2)CH](-) ((tBu)Nacnac), and [(DippNCMe)(Me(2)<compound-id="445100">NCH</compound-id>(2)CH(2)NCMe)CH](-) ((Dmeda)Nacnac) are reported.	NCH__Dipp__no_interaction	diisopropylphenyl__Dipp__no_interaction	magnesium__Dipp__no_interaction	iodide__Dipp__no_interaction
19950340-2	The complexes [((Ph)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Mes)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Dmeda)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="6324">OEt</compound-id>(2))], [((Mes)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="8028">thf</compound-id>)], [((<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)<compound-id="11779786">MgI</compound-id>(<compound-id="8028">thf</compound-id>)], [((tBu)Nacnac)<compound-id="11779786">MgI</compound-id>], and [((tBu)Nacnac)<compound-id="11779786">MgI</compound-id>(DMAP)] (DMAP=4-<compound-id="21885">dimethylaminopyridine</compound-id>) were shown to be monomeric by X-ray crystallography.	thf__Dipp__no_interaction	MgI__Dipp__no_interaction	dimethylaminopyridine__Dipp__no_interaction	OEt__Dipp__no_interaction
19950340-7	All attempts to form <compound-id="5460467">beryllium</compound-id>(I) or <compound-id="22044544,5460341">calcium</compound-id>(I) dimers by reductions of [((Mes)Nacnac)<compound-id="445303">BeI</compound-id>], [{((<protein-id="Q9JI46,B2KF67">Dipp</protein-id>)Nacnac)CaI(<compound-id="6324">OEt</compound-id>(2))}(2)], or [{((tBu)Nacnac)CaI(<compound-id="8028">thf</compound-id>)}(2)] have so far been unsuccessful.	calcium__Dipp__no_interaction	BeI__Dipp__no_interaction	thf__Dipp__no_interaction	beryllium__Dipp__no_interaction	OEt__Dipp__no_interaction
22968548-1	Reaction of [Pt(2)(μ-S)(2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)] with the dialkylating agents ClCH(2)C(O)CH(2)Cl or ClCH(2)C(=NNHC(O)NH(2))CH(2)Cl gives the dicationic di-μ-<compound-id="5047209">thiolate</compound-id> complexes [Pt(2){μ-SCH(2)C(O)CH(2)S)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)](2+) or [Pt(2){μ-SCH(2)C(=NNHC(O)NH(2))CH(2)S}(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(4)](2+), isolated as BPh(4)(-) salts and characterised by ESI mass spectrometry, NMR spectroscopy and single-crystal X-ray crystallography.	thiolate__PPh(3__no_interaction
12443025-3	With this method new human milk oligosaccharides of previously unknown isomeric structures have been identified, e.g., the occurence of three isomeric fucosylated lacto-N-hexaoses could be determined precisely, which have not been described before: (1) Fuc (alpha1--&gt;2) <protein-id="P22466">Gal</protein-id> (beta1--&gt;3) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>, (2) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNAc</compound-id> [(alpha1--&gt;3) Fuc] (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>, (3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNAc</compound-id> (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="11861101,24139,439174,899">GlcNac</compound-id> [(alpha1--&gt;3) Fuc] (beta1--&gt;3) <protein-id="P22466">Gal</protein-id> (beta1--&gt;4) <compound-id="3034742,57288387,6971003">Glc</compound-id>.	GlcNAc__Gal__no_interaction	Glc__Gal__no_interaction	GlcNac__Gal__no_interaction
2458719-7	Ca2+ release was effected by <protein-id="Q08050,Q53Y49,A0A0D9SFF0,A8K591">Ins(1,4,5</protein-id>)P3, with half-maximal release at 0.5 +/- 0.14 microM-<protein-id="Q08050,Q53Y49,A0A0D9SFF0,A8K591">Ins(1,4,5</protein-id>)P3, <protein-id="P12235">t1/2 11.2</protein-id> +/- 1.1 s. GTP- and <compound-id="6802">guanosine</compound-id> 5'-[beta gamma-imido]triphosphate (p[NH]ppG)-promoted release of 45Ca2+ was demonstrated in this preparation, but the kinetics of release (half-maximal Ca2+ release at 5.4 +/- 0.7 microM, with <protein-id="P12235">t1/2 77.3</protein-id> +/- 6.9 s, and at 51.1 +/- 4.2 microM, with <protein-id="P12235">t1/2 19.0</protein-id> +/- 2.2 s, for GTP and p[NH]ppG respectively), and the ability of <compound-id="8378,4454,62404">neomycin sulphate</compound-id> to block p[NH]ppG-induced release only, are indicative of separate release mechanisms after treatment with these agents.	guanosine__t1/2 77.3__no_interaction	guanosine__t1/2 11.2__no_interaction	guanosine__t1/2 19.0__no_interaction	guanosine__Ins(1,4,5__no_interaction	neomycin sulphate__t1/2 77.3__no_interaction	neomycin sulphate__t1/2 11.2__no_interaction	neomycin sulphate__t1/2 19.0__no_interaction	neomycin sulphate__Ins(1,4,5__no_interaction
20886810-1	The syntheses, crystal structures, and the experimental and theoretical magnetochemical characterization for three tetrametallic Ni(II) clusters, namely, [Ni(4)(L)(4)(Cl)(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·4MeOH (1), [Ni(4)(L)(4)(N(3))(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·2MeOH (2), and [Ni(4)(L1)(4)(pyz)(2)(PhCOO)(2)(<compound-id="887">MeOH</compound-id>)(2)](ClO(4))(2)·7MeOH (3) (where HL and <protein-id="P07306,Q6FGQ5">HL1</protein-id> represent bipyridine-2-carboxamideoxime and <compound-id="51550622">pyrimidine-2-carboxamideoxime</compound-id>, respectively) are reported.	pyrimidine-2-carboxamideoxime__HL1__no_interaction	MeOH__HL1__no_interaction
12889996-8	In addition to the <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401/0404-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302/(<protein-id="Q93038">DR3</protein-id>)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*05-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*02 genotype and <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*04-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302 homozygous genotypes, heterozygous combinations <protein-id="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0">DRB1</protein-id>*0401-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0302/(DR13)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0604, approximately /(<compound-id="9547897">DR8</compound-id>)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*04, approximately /(DR9)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*03-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0303, approximately /(<protein-id="Q01658,Q658N3">DR1</protein-id>)-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*0501 and approximately /(DR7)-<protein-id="P01909,Q5Y7H0,L8E864,Q5Y7D2,Q30063,Q08AS3,Q8MH44">DQA1</protein-id>*0201-<protein-id="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3">DQB1</protein-id>*02 were also disease-associated.	DR8__DR1__no_interaction	DR8__DQB1__no_interaction	DR8__DR3__no_interaction	DR8__DRB1__no_interaction	DR8__DQA1__no_interaction
16629137-6	with values of 9.97 micromol x g(-1) at 10 d to 3.67 micromol x g(-1) at 28 d. The LR50 values for H. azteca were intermediate and ranged from 2.25 micromol x g(-1) at 5 d to 0.56 micromol x g(-1) at 28 d. <compound-id="11855">Pentachlorobenzene</compound-id> LR50 values were less variable among species and ranged from 1.20 micromol x g(-1) at 4 d to 0.81 micromol x g(-1) at 10 d for C. tentans, 5.0 micromol x g(-1) at 20 d and 2.75 micromol x g(-1) at 28 d for Diporeia <protein-id="Q8TCT9,A0A0C4DGU3">spp</protein-id>., and 1.51 micromol x g(-1) at 4 d and 0.71 micromol x g(-1) at 28 d for H. azteca.	Pentachlorobenzene__spp__no_interaction
23485720-7	Patients who had developed HE had a significantly higher baseline Child-Turcotte-Pugh score (10.15 ±1.82 vs. 6.35 ± 1.60, p &lt; 0.05), <compound-id="5950,602">alanine</compound-id> aminotransferase (111.25 ± 91.62 vs. 48.32 ± 47.45, p &lt; 0.05), <compound-id="5960">aspartate</compound-id> aminotransferase (171.42 ± 142.68 vs. 46.33 ± 42.68, p &lt; 0.05), total <compound-id="5280352">bilirubin</compound-id> (73.44 ± 47.20 vs. 29.75 ± 22.08, p &lt; 0.05), serum albumin (24.65 ± 5.04 vs. 33.43 ± 6.49, p &lt; 0.05), plasma <protein-id="P00734">prothrombin</protein-id> time (22.18 ± 4.60 vs. 17.12 ± 4.62, p &lt; 0.05), and lower hemoglobin level (72.31 ± 15.15 vs. 87.45 ± 19.79, p &lt; 0.05) as compared to patients who did not develop HE.	bilirubin__prothrombin__no_interaction	alanine__prothrombin__no_interaction	aspartate__prothrombin__no_interaction
19026018-6	In Part 1 of this review we discuss the impact of exercise on CVD, and we highlight the effects of exercise on (i) endothelial function by regulation of endothelial genes mediating oxidative metabolism, inflammation, apoptosis, cellular growth and proliferation, increased <protein-id="P00441,V9HWC9">superoxide dismutase (SOD)-1</protein-id>, down-regulation of <protein-id="P19878">p67phox</protein-id>, changes in intracellular <compound-id="22044544,5460341">calcium</compound-id> level, increased vascular endothelial <compound-id="145068">nitric oxide</compound-id> synthase (<protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id>), expression and <protein-id="P29474,A0A0A0MTA6,A0S0A6">eNOS</protein-id> <compound-id="5951">Ser</compound-id>-1177 phosphorylation; (ii) vascular smooth muscle function by either an increased affinity of the Ca2+ extrusion mechanism or an augmented Ca2+ buffering system by the superficial sarcoplasmic reticulum to increase Ca2+ sequestration, increase in K+ channel activity and/or expression, and increase in L-type Ca2+ current density; (iii) antioxidant systems by elevation of Mn-SOD, Cu/Zn-SOD and catalase, increases in <compound-id="124886,20725278,745">glutathione</compound-id> peroxidase activity and activation of vascular <compound-id="5886,929,44415116">nicotinamide adenine dinucleotide phosphate</compound-id> [(<compound-id="5893">NAD</compound-id>(P)H] oxidase and <protein-id="P13498,B4DT46,H3BNP7">p22phox</protein-id> expression; (iv) heat shock protein (HSP) expression by stimulating HSP70 expression in myocardium, skeletal muscle and even in human leucocytes, probably through heat shock transcription factor 1 activity; (v) inflammation by reducing serum inflammatory cytokines such as high-sensitivity C-reactive protein (<protein-id="P02741">hCRP</protein-id>), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin (IL)-6</protein-id>, <protein-id="Q14116,A0A024R3E0">IL-18</protein-id> and tumour necrosis factor-alpha and by regulating <protein-id="O00206">Toll-like receptor 4</protein-id> pathway.	glutathione__IL-18__no_interaction	glutathione__p67phox__no_interaction	glutathione__superoxide dismutase (SOD)-1__no_interaction	glutathione__eNOS__no_interaction	glutathione__Toll-like receptor 4__no_interaction	glutathione__interleukin (IL)-6__no_interaction	glutathione__hCRP__no_interaction	glutathione__p22phox__no_interaction	Ser__IL-18__no_interaction	Ser__p67phox__no_interaction	Ser__superoxide dismutase (SOD)-1__no_interaction	Ser__eNOS__no_interaction	Ser__Toll-like receptor 4__no_interaction	Ser__interleukin (IL)-6__no_interaction	Ser__hCRP__no_interaction	Ser__p22phox__no_interaction	NAD__IL-18__no_interaction	NAD__p67phox__no_interaction	NAD__superoxide dismutase (SOD)-1__no_interaction	NAD__eNOS__no_interaction	NAD__Toll-like receptor 4__no_interaction	NAD__interleukin (IL)-6__no_interaction	NAD__hCRP__no_interaction	NAD__p22phox__no_interaction	nicotinamide adenine dinucleotide phosphate__IL-18__no_interaction	nicotinamide adenine dinucleotide phosphate__p67phox__no_interaction	nicotinamide adenine dinucleotide phosphate__superoxide dismutase (SOD)-1__no_interaction	nicotinamide adenine dinucleotide phosphate__eNOS__no_interaction	nicotinamide adenine dinucleotide phosphate__Toll-like receptor 4__no_interaction	nicotinamide adenine dinucleotide phosphate__interleukin (IL)-6__no_interaction	nicotinamide adenine dinucleotide phosphate__hCRP__no_interaction	nicotinamide adenine dinucleotide phosphate__p22phox__no_interaction	calcium__IL-18__no_interaction	calcium__p67phox__no_interaction	calcium__superoxide dismutase (SOD)-1__no_interaction	calcium__eNOS__no_interaction	calcium__Toll-like receptor 4__no_interaction	calcium__interleukin (IL)-6__no_interaction	calcium__hCRP__no_interaction	calcium__p22phox__no_interaction	nitric oxide__IL-18__no_interaction	nitric oxide__p67phox__no_interaction	nitric oxide__superoxide dismutase (SOD)-1__no_interaction	nitric oxide__eNOS__no_interaction	nitric oxide__Toll-like receptor 4__no_interaction	nitric oxide__interleukin (IL)-6__no_interaction	nitric oxide__hCRP__no_interaction	nitric oxide__p22phox__no_interaction
21942464-1	The reaction of the neutral binuclear complexes [(R(F))(2)Pt(μ-PPh(2))(2)M(phen)] (phen = <compound-id="1318">1,10-phenanthroline</compound-id>, R(F) = C(6)F(5); M = Pt, 1; M = Pd, 2) with AgClO(4) or [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))] affords the trinuclear complexes [AgPt(2)(μ-PPh(2))(2)(R(F))(2)(phen)(<compound-id="5460593">OClO</compound-id>(3))] (7a) or [AgPtM(μ-PPh(2))(2)(R(F))(2)(phen)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))][ClO(4)] (M = Pt, 8; M = Pd, 9), which display an "open-book" type structure and two (7a) or one (8, 9) Pt-Ag bonds.	OClO__PPh(3__no_interaction	1,10-phenanthroline__PPh(3__no_interaction
21942464-3	The dppm Pt-Pt complex 3 reacts with [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))], affording a silver adduct 10 in which the Ag atom interacts with the Pt atoms, while the dppm Pt-Pd complex 4 reacts with [Ag(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))], forming a 1:1 mixture of [AgPdPt(μ-PPh(2))(2)(R(F))(2)(<compound-id="5460593">OClO</compound-id>(3))(dppm)] (11), in which the <compound-id="23954">silver atom</compound-id> is connected to the Pt-Pd moiety through Pd-(μ-PPh(2))-Ag and Ag-P(k(1)-dppm) interactions, and [AgPdPt(μ-PPh(2))(2)(R(F))(2)(<compound-id="5460593">OClO</compound-id>(3))(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>))(2)][ClO(4)] (12).	OClO__PPh(3__no_interaction	silver atom__PPh(3__no_interaction
21942464-7	Finally, the oxidation of trinuclear derivatives [(R(F))(2)Pt(II)(μ-PPh(2))(2)Pt(II)(μ-PPh(2))(2)Pt(II)L(2)] (L(2) = phen, 15; L = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh(3</protein-id>), 16) by AgClO(4) results in the formation of the unsaturated 46 <compound-id="2735038">VEC</compound-id> complexes [(R(F))(2)Pt(III)(μ-PPh(2))(2)Pt(III)(μ-PPh(2))(2)Pt(II)L(2)][ClO(4)](2) (17 and 18, respectively) which display Pt(III)-Pt(III) bonds.	VEC__PPh(3__no_interaction
12734394-0	Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(<compound-id="8082">4-piperidinyl</compound-id>)-2-[2-(<compound-id="8082">4-piperidinyl</compound-id>)<compound-id="23134249">ethyl</compound-id>] butanoyl]amino)acetyl]amino]<compound-id="1032">propanoic acid</compound-id> dihydrochloride (CRL42796), in combination with <compound-id="2244">aspirin</compound-id> and/or <compound-id="57199466,772">enoxaparin</compound-id>, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue <protein-id="F1Q421">plasminogen</protein-id> activator.	propanoic acid__plasminogen__no_interaction	aspirin__plasminogen__no_interaction	4-piperidinyl__plasminogen__no_interaction	enoxaparin__plasminogen__no_interaction	ethyl__plasminogen__no_interaction
16366633-2	Absolute values for <compound-id="781">SCN</compound-id>-, N3(-), and <protein-id="P28070">HN3</protein-id> were well-described over the temperature range of 9-81 degrees C by the equations log k5 = (12.03 +/- 0.12) - [(21.05 +/- 0.66 kJ mol(-1))/2.303RT], log <protein-id="P13645">k10</protein-id> = (12.75 +/- 0.21) - [(18.43 +/- 1.22 kJ mol(-1))/2.303RT], and log <protein-id="P19012,B3KVF5">k15</protein-id> = (11.59 +/- 0.12) - [(21.44 +/- 0.69 kJ mol(-1))/2.303RT], corresponding to room temperature (22 degrees C) rate constants of (2.07 +/- 0.03) x 10(8), (3.15 +/- 0.08) x 10(9), and (6.31 +/- 0.05) x 10(7) M(-1) s(-1) and activation energies for these chemicals of 21.05 +/- 0.66, 18.4 +/- 1.2, and 21.44 +/- 0.69 kJ mol(-1), respectively.	SCN__HN3__no_interaction	SCN__k10__no_interaction	SCN__k15__no_interaction
18966803-4	Potential measurements of the Mn(III) Mn(II) system in several azide aqueous buffers solutions: 1.0 x 10(-2) mol 1(-1) HN(3), (0.50-2.0 mol 1(-1)) N(-)(3) and 5.0 x 10(-2) mol 1(-1) Mn(II) and constant ionic strength 2.0 mol 1(-1), kept with <compound-id="522606">sodium perchlorate</compound-id>, leads to the conditional potential, E(0')x, in several azide concentrations at 25.0 +/- 0.1 degrees C. Considering the overall formation constants of Mn(II) N (-)(3), from former studies, and the potential, E(0')s = 1.063 V versus SCE, for Mn(III) Mn(II) system in non-complexing media, it was possible to calculate the Fronaeus function, F(0)(L), and the following overall formation constants: <protein-id="Q16558">beta(1) = 1.2</protein-id> x 10(5) M(-1), <protein-id="Q13562">beta(2) = 6.0</protein-id> x 10(8) M(-2), beta(3) = (2.4 +/- 0.7) x 10(11) M(-3), <protein-id="Q13509,Q53G92">beta(4) = (1.5 +/- 0.5</protein-id>) x 10(11) M(-4) and <protein-id="P04350">beta(5) = (9.6 +/- 0.8</protein-id>) x 10(11) M(-5) for the Mn(III) N (-)(3) complexes.	sodium perchlorate__beta(2) = 6.0__no_interaction	sodium perchlorate__beta(1) = 1.2__no_interaction	sodium perchlorate__beta(4) = (1.5 +/- 0.5__no_interaction	sodium perchlorate__beta(5) = (9.6 +/- 0.8__no_interaction
22150562-3	MATERIAL AND METHODS: SVF4 cells were stimulated with <protein-id="P21274">BMP2</protein-id>, and the following assays were carried out: (i) Wnt/β-catenin pathway activation assessed by western blotting, β-catenin/transcription factor (TCF) reporter assays and expression of the lymphoid enhancer-binding factor-1 (Lef1), transcription factor 7 (Tcf7), Wnt inhibitor factor 1 (Wif1) and Axin2 (Axin2) genes; and (ii) cementoblast/osteoblast differentiation assessed by mineralization in vitro, and by the mRNA levels of runt-related transcription factor 2 (<protein-id="Q08775,Q9Z2T9,F8WHN7,E0CZ12">Runx2</protein-id>), osterix (Osx), alkaline phosphatase (Alp), osteocalcin (<compound-id="3269217">Ocn</compound-id>) and bone sialoprotein (Bsp), determined by quantitative PCR after treatment with wingless-type MMTV integration site family, member <compound-id="2981881,91293124">3A</compound-id> (<protein-id="P27467">WNT3A</protein-id>) and knockdown of β-catenin.	3A__Runx2__no_interaction	3A__WNT3A__no_interaction	3A__BMP2__no_interaction	Ocn__Runx2__no_interaction	Ocn__WNT3A__no_interaction	Ocn__BMP2__no_interaction
15886816-3	We compared the uPA production, the presence of <protein-id="Q03405,M0R1I2">uPAR</protein-id>, AR, <protein-id="P00533">EGFR</protein-id> and <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id> with the chemotaxis and the Matrigel invasion in ten human PCa cell lines and observed that: (1) the levels of <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id>, but not of <protein-id="P00533">EGFR</protein-id>, as well as the uPA secretion, cell motility and Matrigel invasion were statistically higher in AR negative than in AR positive PCa cells; (2) the uPA secretion and uPA Rexpression were positively related to Matrigel invasion; (3) the EGF was able to stimulate chemotaxis and Matrigel invasion in a dose-dependent manner; (4) the EGF-induced cell migration was statistically higher inAR negative than in AR positive cells with a similar increase with respect to basal value (about 2.6 fold); (5) the Matrigel invasion was statistically higher in AR negative than in AR positive PCa cells also if the increment of Matrigel invasion after EGF treatment was statistically higher in AR positive respect to AR negative cells; (6) the EGF induced uPA secretion and its membrane uptake through the increment of <protein-id="Q03405,M0R1I2">uPAR</protein-id>; and (7) these effects were blocked by <protein-id="P00533">EGFR</protein-id>/<protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">Her2</protein-id> <compound-id="6057,90983769">tyrosine</compound-id> kinase inhibitors with IC(50) lower than those needed to inhibit cell proliferation and required <protein-id="P42336">PI3K</protein-id>/<protein-id="P31749,B0LPE5,B3KVH4">Akt</protein-id>, MAPK and <protein-id="P30101,V9HVY3">PI-PLC</protein-id> activities as verified by inhibition experiments.	tyrosine__PI3K__no_interaction	tyrosine__EGFR__no_interaction	tyrosine__Akt__no_interaction	tyrosine__uPAR__no_interaction	tyrosine__Her2__no_interaction	tyrosine__PI-PLC__no_interaction
2100278-2	Hypergonadotropism [luteinising hormone (LH), 18.7 +/- 7.3 IU/l; follicle-stimulating hormone (<protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>), 6.3 +/- 2.0 IU/l], low serum <compound-id="6013">testosterone</compound-id> (6.1 +/- 2.8 nmol/l), low serum <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">sex-hormone-binding globulin</protein-id> (<protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id>; 13.2 +/- 2.0 nmol/l) and subnormal <compound-id="6013">testosterone</compound-id> response to human chorionic gonadotropin <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>; (30% increase in serum <compound-id="6013">testosterone</compound-id> following <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>) observed during the hypothyroid phase were restored to normal (LH, 7.2 +/- 2.0 IU/l; <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, 2.7 +/- 0.9 IU/l; <compound-id="6013">testosterone</compound-id>, 12.9 +/- 2.7 nmol/l; <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id>, 26.5 +/- 8.4 nmol/l, and 2-fold increase in serum <compound-id="6013">testosterone</compound-id> following <protein-id="P01215,Q6I9S8,A0A087WYZ4">hCG</protein-id>) with <compound-id="853">thyroxine</compound-id> substitution therapy.	thyroxine__FSH__no_interaction	thyroxine__SHBG__no_interaction	thyroxine__sex-hormone-binding globulin__no_interaction	thyroxine__hCG__no_interaction	testosterone__FSH__no_interaction	testosterone__SHBG__no_interaction	testosterone__sex-hormone-binding globulin__no_interaction	testosterone__hCG__no_interaction
8719263-3	Head-up tilt made thoracic electrical impedance (3.0 +/- 1.0 omega), mean arterial pressure (MAP, 86 +/- 4-93 +/- 4 mmHg), heart rate (HR, 63 +/- 3-99 +/- 10 beats <protein-id="P13987,Q6FHM9">min-1</protein-id>) and total peripheral resistance (TPR, 15 +/- 1-28 +/- 4 mmHg min L-1) increase, while central venous <compound-id="977">oxygen</compound-id> saturation (74 +/- 2-58 +/- 4%), cardiac output (5.7 +/- 0.1-3.1 +/- 0.3 L <protein-id="P13987,Q6FHM9">min-1</protein-id>), stroke volume (95 +/- 6-41 +/- 5 mL) and pulse pressure (55 +/- 4-49 +/- 4 mmHg) decreased (P &lt; 0.05).	oxygen__min-1__no_interaction
22199269-7	Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (<compound-id="57449,5962,866">lysine</compound-id>) acetyltransferase 5 (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>), <protein-id="Q13547,Q6IT96">HDAC1</protein-id>, <protein-id="O75164">KDM4A</protein-id>, <protein-id="O43463">SUV39H1</protein-id> and <protein-id="O15550,B7ZKN1,E1U0S6,Q59HG3,Q86TD1,B4E0L8,B7ZKN6,B7ZKN5">KDM6A</protein-id>)); <protein-id="Q9UKZ4,B7ZMH4">TNM</protein-id> stage (<protein-id="O43463">SUV39H1</protein-id>, K (<compound-id="57449,5962,866">lysine</compound-id>) acetyltransferase 2B (<protein-id="Q92831">KAT2B</protein-id>), <protein-id="O60341">lysine (K)-specific demethylase 1A</protein-id> (<protein-id="O60341">KDM1A</protein-id>), <protein-id="O75164">KDM4A</protein-id>, <compound-id="57449,5962,866">lysine</compound-id> (K)-specific demethylase 5C (<protein-id="Q9H7Z6">KDM5C), K (lysine) acetyltransferase 8</protein-id> (<protein-id="Q9H7Z6">KAT8</protein-id>), <protein-id="Q9UQL6">HDAC5</protein-id> and <protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>)); Nottingham Prognostic Index (<protein-id="P41229">KDM5C</protein-id>, myeloid/lymphoid or <protein-id="Q03164">mixed-lineage leukemia</protein-id> (<protein-id="Q03164">MLL</protein-id>), <protein-id="Q9H7Z6">KAT8</protein-id> and <protein-id="Q01105,A0A024R895,Q5VXV3,A0A0C4DFV9">SET and MYND domain containing 3</protein-id> (<protein-id="Q9H7B4,B3KN46">SMYD3</protein-id>)); receptor status (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>, <protein-id="Q9H7B4,B3KN46">SMYD3</protein-id> and <protein-id="O60341">KDM1A</protein-id>); histological type (<protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id>, <protein-id="P41229">KDM5C</protein-id>, <protein-id="Q9H7Z6">KAT8</protein-id>, <protein-id="O75164">KDM4A</protein-id> and <protein-id="Q03164">MLL</protein-id>); disease-free survival (<protein-id="O43463">SUV39H1</protein-id>, <protein-id="Q9H7B4,B3KN46">SMYD3</protein-id>, <protein-id="Q9UQL6">HDAC5</protein-id>, <protein-id="O15550,B7ZKN1,E1U0S6,Q59HG3,Q86TD1,B4E0L8,B7ZKN6,B7ZKN5">KDM6A</protein-id>, <protein-id="Q13547,Q6IT96">HDAC1</protein-id>, <protein-id="O60341">KDM1A</protein-id>, <protein-id="O75164">KDM4A</protein-id>, <protein-id="Q9H7Z6">KAT8</protein-id>, <protein-id="P41229">KDM5C</protein-id>, <protein-id="Q92993,A0A024R597,A0A024R5E8">KAT5</protein-id> and <protein-id="Q03164">MLL</protein-id>) and overall survival (<protein-id="Q9H7Z6">KAT8</protein-id>).	lysine__HDAC1__no_interaction	lysine__KDM1A__no_interaction	lysine__lysine (K)-specific demethylase 1A__no_interaction	lysine__SUV39H1__no_interaction	lysine__KDM5C), K (lysine) acetyltransferase 8__no_interaction	lysine__SMYD3__no_interaction	lysine__KAT5__no_interaction	lysine__MLL__no_interaction	lysine__KAT2B__no_interaction	lysine__mixed-lineage leukemia__no_interaction	lysine__KDM4A__no_interaction	lysine__KDM6A__no_interaction	lysine__SET and MYND domain containing 3__no_interaction	lysine__KAT8__no_interaction	lysine__TNM__no_interaction	lysine__HDAC5__no_interaction	lysine__KDM5C__no_interaction
24029567-7	(3) Applying Logistic regression analysis, type 2 diabetes mellitus (OR = 35.784), essential hypertension (OR = 7.782), familial history of early coronary artery disease (OR = 4.613), <protein-id="Q14746,B1ALW7">low density lipoprotein cholesterol</protein-id> (OR = 2.496), smoking history (OR = 2.241), hemoglobin (OR = 1.042) and serum <compound-id="1175">uric acid</compound-id> (OR = 1.005) are independent risk factors (P &lt; 0.05) for young men with AMI, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (OR = 0.147, P &lt; 0.05) is a protective factor; <protein-id="Q14746,B1ALW7">low density lipoprotein cholesterol</protein-id> (OR = 2.095) and essential hypertension (OR = 1.042) are independent risk factors (P &lt; 0.05) for young men with multiple vessel lesions in AMI, while high density lipoprotein <compound-id="5997">cholesterol</compound-id> (OR = 0.071, P &lt; 0.05) is a protective factor.	uric acid__low density lipoprotein cholesterol__no_interaction	cholesterol__low density lipoprotein cholesterol__no_interaction
22329521-9	Only daily intake of <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.304, p = 0.002), duration of sun exposure (r = 0.268, p = 0.009), the level of <protein-id="P01270">PTH</protein-id> (r = -0.459, p &lt; 0.001), daily intake of <compound-id="22044544,5460341">calcium</compound-id> (r = 0.239, p = 0.018) and <protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id> of more than 90 ml/min (OR = 1.208, CI 95% = 1.080-1.350, p = 0.033) had a correlation with serum <compound-id="5280795,5283711">vitamin D</compound-id> concentration.	calcium__GFR__no_interaction	calcium__PTH__no_interaction	vitamin D__GFR__no_interaction	vitamin D__PTH__no_interaction
11760372-9	RESULTS: ISH (systolic blood pressure, <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> &gt; or = 140 mmHg and diastolic blood pressure, <protein-id="Q10586">DBP</protein-id> &lt; or = 90 mmHg) incidence increased with age in general (men: 0 per 1,000 person-years at age 20-34 yr, 1.9 at age 35-49, 14.3 at age 50-64, 40.9 at age 65-74, and 73.3 at age 75+ yr; women: 0 per 1,000 person-yr at age 20-34 yr, 3.6 at age 35-49, 17.8 at age 50-64, 64.9 9 at age 65-74, and 33.5 at age 75+ yr), but peak incidence of <compound-id="5288605">IDH</compound-id> (<protein-id="Q10586">DBP</protein-id> &gt; or = 90 mmHg and <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> &lt; or = 140 mmHg) occurred between 35 and 49 years (men: 8.9 per 1,000 person-yr at age 20-34 yr, 14.5 at age 35-49, 12.3 at age 50-64, 2.7 at age 65-74, and 0 at age 75+ yr; women: 1.7 per 1,000 person-yr at age 20-34, 4.2 at age 35-49, 3.7 at age 50-64, 0 at age 65-74, and 0 at age 75+ yr).	IDH__DBP__no_interaction	IDH__SBP__no_interaction
7951855-5	The <protein-id="P12004">PCNA</protein-id>-LIs of the <compound-id="11686950,887">methanol</compound-id>-fixed tissues were: normal liver 0.78 +/- 0.38%, chronic persistent hepatitis 1.06 +/- 0.86%, chronic aggressive hepatitis 2A 1.01 +/- 0.50%, chronic aggressive hepatitis 2B 4.20 +/- 1.79%, inactive cirrhosis 0.81 +/- 0.49%, active cirrhosis 1.96 +/- 0.93%, HCC of Edmondson's type I 4.83 +/- 1.98%, type II 6.65 +/- 1.69%, and type III 38.7 +/- 30.6%.	methanol__PCNA__no_interaction
8537340-3	These two significantly different 2Fe2S clusters were characterized with respect to their EPR spectra, electrochemical properties (Rieske-type cluster with gz = 2.025, gy = 1.91, <compound-id="87833">gx</compound-id> = 1.79, <compound-id="10128749">gav</compound-id> = 1.91, Em = -125 +/- 10 mV; <protein-id="Q9I6D2">ferredoxin</protein-id>-type center with gz = 2.05, gy = 1.96, <compound-id="87833">gx</compound-id> = 1.89, <compound-id="10128749">gav</compound-id> = 1.97, Em = -200 +/- 10 mV) and pH dependence thereof.	gav__ferredoxin__no_interaction	gx__ferredoxin__no_interaction
22724673-1	Structural features of <compound-id="783">hydrogen</compound-id> thioperoxide (oxadisulfane, H-S-O-H) and of alkanesulfenic acids (R-S-O-H; R = CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, CF3, <protein-id="P10147,A0N0R1">CCl3</protein-id>) and the mechanisms of their dehydrative cyclocondensation to the respective sulfinothioic acid (H-(S═O)-S-H) and alkyl alkanethiosulfinates (R-(S═O)-S-R) have been studied using coupled cluster theory with single and double and perturbative triple excitations [CCSD(T)] and quadratic configuration interaction with single and double and perturbative triple excitations [QCISD(T)] with the cc-pVDZ basis set and also using second-order Møller-Plesset perturbation theory (<protein-id="P02689">MP2</protein-id>) and the hybrid density functionals B3LYP, B3PW91, and PBE1PBE with the 6-311+G(d,p) basis set.	hydrogen__CCl3__no_interaction	hydrogen__MP2__no_interaction
15133757-4	RESULTS: Compared to control islets, freshly prepared type 1 diabetic islets released a significantly higher amount of cytokines (pg/mL) into the culture medium (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>: 112.9 +/- 5.6 vs 75.6 +/- 24.4; INF-gamma: 286.9 +/- 26.9 vs 58.6 +/- 6.2; <protein-id="P22301,Q6FGW4">IL-10</protein-id>: 41.8 +/- 4.3 vs 10.1 +/- 3.2; TGF-1 beta: 294.0 +/- 20.6 vs 45.1 +/- 3.5); had a significantly higher chemotactic index (1.9 +/- 0.2 vs 1.2 +/- 0.1); showed reduced <protein-id="P01308,I3WAC9">insulin</protein-id> release (% of <protein-id="P01308,I3WAC9">insulin</protein-id> content) in response to <compound-id="206,5793,64689,79025">glucose</compound-id> (2.8 +/- 0.7 vs 5.3 +/- 1.9), <compound-id="6322,90867653">arginine</compound-id> (3.0 +/- 0.6 vs 5.6 +/- 1.0), and <compound-id="3488">glibenclamide</compound-id> (2.9 +/- 0.7 vs 5.4 +/- 0.9); and exhibited decreased <compound-id="206,5793,64689,79025">glucose</compound-id> oxidation capability and diminished mRNA expression of <protein-id="P35557,Q53Y25">glucokinase</protein-id>, aldolase, <compound-id="1060">pyruvate</compound-id> kinase, and mitochondrial glycerolphosphate dehydrogenase.	glibenclamide__TNF-alpha__no_interaction	glibenclamide__glucokinase__no_interaction	glibenclamide__insulin__no_interaction	glibenclamide__IL-10__no_interaction	pyruvate__TNF-alpha__no_interaction	pyruvate__glucokinase__no_interaction	pyruvate__insulin__no_interaction	pyruvate__IL-10__no_interaction	arginine__TNF-alpha__no_interaction	arginine__glucokinase__no_interaction	arginine__insulin__no_interaction	arginine__IL-10__no_interaction	glucose__TNF-alpha__no_interaction	glucose__glucokinase__no_interaction	glucose__insulin__no_interaction	glucose__IL-10__no_interaction
20677555-4	METHODS: Firstly, six different cell culture medium which contained YTMLC Gejiu human lung squamous carcinoma cell, <protein-id="P98194,B4E2Q0,B4E295">SPC-A1</protein-id> human lung adenocarcinoma cell, AGZY low metastatic human lung adenocarcinoma, 973 high metastatic human lung adenocarcinoma cell, <compound-id="3034742,57288387,6971003">GLC</compound-id>-82 Gejiu human lung adenocarcinoma cell, and KMB17 human embryonic lung diploid fibroblast, respectively with equal cell density of 1 x 10(6)/mL and the same volume were prepared; secondly, the same radioactive dose of <compound-id="26476">99Tc</compound-id>(m) -N(<compound-id="9934363">NOEt</compound-id>)2 was added into each sample and then 300 microL mixed sample was taken out respectively and cultured in 37 degrees C culture box; Finally, 5 min, 15 min, 30 min, 45 min, 60 min, 75 min, 90 min after cultivation, centrifuged each cultured sample and determined the intracellular radiocounts of each sample, calculated each cell sample's uptake rate of <compound-id="26476">99Tc</compound-id>(m) -N(<compound-id="9934363">NOEt</compound-id>)2 at different time.	99Tc__SPC-A1__no_interaction	GLC__SPC-A1__no_interaction	NOEt__SPC-A1__no_interaction
19787913-8	The equilibrium constant of the trapping reaction Al(Ti)x = Al(Ti)' + h* is evaluated as Ka = 1.9 x 10(23) <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-1.04 eV/kT) cm(-3) and the mobility of trapped holes (Al(Ti)x) as u(x) approximately = 720 <protein-id="Q9NR56,Q86VM6,A0A0A0MQX8">exp</protein-id>(-1.04 eV/kT) cm2 V(-1) s(-1) as the upper bound while those of free electrons and holes as un = 0.044 + 0.010 cm2 V(-1) s(-1) and up approximately = 0.024 +/- 0.007 cm2 V(-1) s(-1), respectively, in the temperature range of 800 degrees C to 1100 degres C. The effect of hole-trapping on DC conductivity, chemical diffusivity and <compound-id="977">oxygen</compound-id> nonstoichiometry is exhaustively analyzed and further experiments are proposed that allow one to determine the trapping energy of acceptor impurities.	oxygen__exp__no_interaction
15366433-8	In patients with advanced heart failure and reduced pre-load reserve (LVEDP &gt; 16 mm Hg, n = 18), <protein-id="Q9NPH2">iNOS</protein-id> protein and nitrotyrosine formation correlated positively with LVSW/<compound-id="92304">EDP</compound-id> (r = 0.65, p = 0.03 and r = 0.64, p = 0.04, respectively), DT (r = 0.96, p &lt; 0.01 and r = 0.88, p &lt; 0.01, respectively) and inversely with E/A (r = -0.82, p &lt; 0.01 and r = -0.88, p &lt; 0.01, respectively).	EDP__iNOS__no_interaction
12793810-1	The two flexible multidentate ligands 1,3-<protein-id="O95817">bis</protein-id>(8-thioquinolyl)<compound-id="6334">propane</compound-id> (C3TQ) and 1,4-<protein-id="O95817">bis</protein-id>(8-thioquinolyl)<compound-id="7843">butane</compound-id> (C4TQ) were reacted with <protein-id="Q16222">AgX</protein-id> (X = CF(3)SO(3)(-) or ClO(4)(-)) to give four new complexes: ([Ag(C3TQ)](ClO(4)))(n)() 1, ([Ag(C3TQ)](CF(3)SO(3)))(n)() 2, ([Ag(2)(C4TQ)(CF(3)SO(3))(CH(3)CN)](CF(3)SO(3)))(n)() 3, and ([Ag(C4TQ)](ClO(4)))(n)() 4.	propane__bis__no_interaction	propane__AgX__no_interaction	butane__bis__no_interaction	butane__AgX__no_interaction
3079759-1	Equilibrium constants for reactions catalyzed by <protein-id="Q3MIF0,A0A0G2JW38">ribulose-5-phosphate 3-epimerase</protein-id>, [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P]/[sigma <compound-id="439184">ribulose-5-P</compound-id>] = 1.82, <protein-id="D4A7L6">ribose-5-phosphate isomerase</protein-id>, [sigma Rib-5-P]/[sigma <compound-id="439184">ribulose-5-P</compound-id>] = 1.20, <protein-id="Q9EQS0">transaldolase</protein-id>, [sigma <compound-id="122357">erythrose-4-P</compound-id>] [sigma <compound-id="69507">Fru-6-P</compound-id>]/[sigma <compound-id="165007">sedoheptulose-7-P</compound-id>] [sigma glyceraldehyde 3-P] = 0.37, and transketolase, [sigma <compound-id="69507">Fru-6-P</compound-id>] [sigma glyceraldehyde 3-P]/[sigma <compound-id="122357">erythrose-4-P</compound-id>] [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P] = 29.7 and [sigma Rib-5-P] [sigma <compound-id="22253,5289590,619">xylulose</compound-id>-5-P]/[sigma <compound-id="165007">sedoheptulose-7-P</compound-id>] [sigma glyceraldehyde 3-P] = 0.48, were redetermined under physiological conditions.	Fru-6-P__ribulose-5-phosphate 3-epimerase__no_interaction	Fru-6-P__transaldolase__no_interaction	Fru-6-P__ribose-5-phosphate isomerase__no_interaction	erythrose-4-P__ribulose-5-phosphate 3-epimerase__no_interaction	erythrose-4-P__transaldolase__no_interaction	erythrose-4-P__ribose-5-phosphate isomerase__no_interaction	xylulose__ribulose-5-phosphate 3-epimerase__no_interaction	xylulose__transaldolase__no_interaction	xylulose__ribose-5-phosphate isomerase__no_interaction	sedoheptulose-7-P__ribulose-5-phosphate 3-epimerase__no_interaction	sedoheptulose-7-P__transaldolase__no_interaction	sedoheptulose-7-P__ribose-5-phosphate isomerase__no_interaction	ribulose-5-P__ribulose-5-phosphate 3-epimerase__no_interaction	ribulose-5-P__transaldolase__no_interaction	ribulose-5-P__ribose-5-phosphate isomerase__no_interaction
12470401-10	The peak level of CK-MB correlated with donor age (r = 0.48, p = 0.02) and implantation time (r = 0.53, p = 0.02); and with recipient plasma <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.56, p = 0.02), allograft <compound-id="977">oxygen</compound-id> extraction (r = 0.56, p = 0.02), <compound-id="612">lactate</compound-id> release (r = 0.47, p = 0.02) and allograft arterial-coronary sinus (cs) pH (r = 0.47, p = 0.02) all during final cardioplegia before reperfusion.	oxygen__IL-6__no_interaction	lactate__IL-6__no_interaction
15543339-6	<compound-id="4552">NS1619</compound-id> significantly increased <compound-id="24316">cGMP</compound-id> levels which was inhibited by LNMMA, <compound-id="16132435">iberiotoxin</compound-id>, <compound-id="104751">BAPTA</compound-id>, 2-<protein-id="Q9H4A4">APB</protein-id>, reduction of extracellular Ca(2+), PD 98059, or <compound-id="3006531,5354033,9951825">U0126</compound-id> (<compound-id="24316">cGMP</compound-id> (pmol/mg protein): <compound-id="4552">NS1619</compound-id> 3.25 +/- 0.85; <compound-id="4552">NS1619</compound-id> + <compound-id="132862">L-NMMA</compound-id> 0.86 +/- 0.02; <compound-id="4552">NS1619</compound-id> + <compound-id="16132435">iberiotoxin</compound-id> 0.99 +/- 0.09; <compound-id="4552">NS1619</compound-id> + <compound-id="104751">BAPTA</compound-id> 0.93 +/- 0.29; <compound-id="4552">NS1619</compound-id> + 2-<protein-id="Q9H4A4">APB</protein-id> 0.99 +/- 0.31; <compound-id="4552">NS1619</compound-id> + Ca(2+)-reduction 1.17 +/- 0.06; <compound-id="4552">NS1619</compound-id> + <compound-id="4713">PD98059</compound-id> 1.06 +/- 0.49; <compound-id="4552">NS1619</compound-id> + <compound-id="3006531,5354033,9951825">U0126</compound-id> 1.10 +/- 0.24; n=10; p&lt;0.05).	PD98059__APB__no_interaction	cGMP__APB__no_interaction	U0126__APB__no_interaction	NS1619__APB__no_interaction	BAPTA__APB__no_interaction	L-NMMA__APB__no_interaction	iberiotoxin__APB__no_interaction
19149935-7	The levels of endotoxin (0.37 +/- 0.07 EU/mL), <protein-id="P20607">IL-6</protein-id> (289 +/- 49 ng/L) and <protein-id="P16599">TNF-alpha (1.87</protein-id> +/- 0.32 microg/L) as well as the expression of <protein-id="Q63691">CD14</protein-id> mRNA (0.39 +/- 0.05), TNF-alpha mRNA (0.47 +/- 0.03) in <compound-id="6540261">EIN</compound-id> + rhGH group were also obviously lower than those [(0.48 +/- 0.08) EU/mL, (364 +/- 53) ng/L, (2.50 +/- 0.48) microg/L, 0.67 +/- 0.06, 0.66 +/- 0.05, P &lt; 0.05 or P &lt; 0.01, respectively] in <compound-id="6540261">EIN</compound-id> group on 10 PSD (P &lt; 0.05 or P &lt; 0.01).	EIN__IL-6__no_interaction	EIN__CD14__no_interaction	EIN__TNF-alpha (1.87__no_interaction
19198542-3	The <compound-id="162282">polylysine</compound-id> homodendrimers of the third [(NH2)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2] (I), fourth [(NH2)32(<compound-id="5962">Lys</compound-id>)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2 (II) and fifth [(NH2)64(<compound-id="5962">Lys</compound-id>)32(<compound-id="5962">Lys</compound-id>)16(<compound-id="5962">Lys</compound-id>)8(<compound-id="5962">Lys</compound-id>)4(<compound-id="5962">Lys</compound-id>)2Lys-Ala-NH2] (III) generations and the <compound-id="162282">polylysine</compound-id> homodendrimers of fifth generation--[(NH2)64(<compound-id="7010502">Lys-Glu</compound-id>)32(<compound-id="7010502">Lys-Glu</compound-id>)16(<compound-id="7010502">Lys-Glu</compound-id>)8(<compound-id="7010502">Lys-Glu</compound-id>)4(<compound-id="7010502">Lys-Glu</compound-id>)2Lys-Ala-<compound-id="7016106">Ala-Lys</compound-id> (<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-NH2] (IV), [(NH2)64(<compound-id="45122324,7010504">Lys-Ala</compound-id>)32(<compound-id="45122324,7010504">Lys-Ala</compound-id>)16(<compound-id="45122324,7010504">Lys-Ala</compound-id>)8(<compound-id="45122324,7010504">Lys-Ala</compound-id>)4(<compound-id="45122324,7010504">Lys-Ala</compound-id>)2Lys-<compound-id="7016106">Ala-Lys</compound-id>(<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-Ala-NH2] (V) and [(NH2)64(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)32(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)16(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)8(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)4(<compound-id="259320,7022320">Lys-Gly</compound-id>-Gly)2 <compound-id="259320,7022320">Lys-Gly</compound-id>-<compound-id="3080576">Gly-Lys</compound-id>(<protein-id="Q9BXS0,A8MWQ5">ClAc</protein-id>)-Ala-Ala-NH2] (VI) showed receptor-independent mechanism of heterotrimeric G-proteins activity, preferably of inhibitory type, interacting with C-terminal regions of their alpha-subunits.	Ala-Lys__ClAc__no_interaction	Lys__ClAc__no_interaction	polylysine__ClAc__no_interaction	Lys-Glu__ClAc__no_interaction	Gly-Lys__ClAc__no_interaction	Lys-Ala__ClAc__no_interaction	Lys-Gly__ClAc__no_interaction
12168501-3	First, macrophages were incubated with or without <compound-id="6326983">CSE</compound-id>, and the supernatants collected at different time points were used to measure the levels of <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) and sICAM-1 by enzyme-linked immunosorbent assay (ELISA); and second, HUVEC were cultured with <compound-id="6326983">CSE</compound-id>, a vehicle, or ANA-1 supernatants (collected at different time points) and the sICAM-1 levels in the supernatants were measured by ELISA at 24 h. The results showed that: i) <compound-id="6326983">CSE</compound-id> showed no effect on the production of sICAM-1 by HUVEC; ii) sICAM-1, in unstimulated or <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants collected at different time points, was under the detectable level; iii) <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants collected at 3 or 6 h showed no effect on sICAM-1 production in HUVEC, while those collected at 12 and 24 h significantly increased sICAM-1 production (p &lt; 0.02 and p &lt; 0.005, respectively); iv) no significant difference in <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> levels was detected between unstimulated and <compound-id="6326983">CSE</compound-id>-stimulated macrophage supernatants collected at 3 and 6 h, however, higher levels of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> were found in <compound-id="6326983">CSE</compound-id>-stimulated supernatants collected at 12 and 24 h (p &lt; 0.05 and p &lt; 0.002, respectively); and v) a significant correlation (r = 0.9693, p &lt; 0.001) was found between the levels of <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> in <compound-id="6326983">CSE</compound-id>-stimulated ANA-1 supernatants and those of related sICAM-1 production in HUVEC.	CSE__tumor necrosis factor-alpha__no_interaction	CSE__TNF-alpha__no_interaction
15655267-4	Plasma <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels were correlated negatively with body mass index, triglyceride, total <compound-id="5997">cholesterol</compound-id>, hemoglobin A1c, and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> levels (r = -0.456, P &lt; 0.0001; r = -0.355, P &lt; 0.0001; r = -0.286, P = 0.002; r = -0.299, P &lt; 0.0001; r = -0.400, P &lt; 0.0001, respectively), but were not significantly correlated with high sensitivity <protein-id="P02741">C-reactive protein</protein-id> or low density lipoprotein levels (r = -0.088, P = 0.352; r = -0.167, P = 0.077, respectively).	cholesterol__C-reactive protein__no_interaction	cholesterol__fibrinogen__no_interaction	cholesterol__adiponectin__no_interaction
17605139-1	The major objective of this work was to explore the quantitative structure-activity relationship (QSAR) of hydroxyl-substituent Schiff bases in protecting human erythrocytes against <compound-id="10176833,10198824,122970,13864694,13955041,14048842,142347,14592126,15724735,17782191,179514,18332075,206038,21225683,21394077,21394085,21917678,21917682,21917686,432073,22149489,22326016,22418667,22450834,280938,53746083,53852030,6453657,67354174,85872172,88201,90752878,90813009,91537,93079,9794905,98836">2,2'-azobis</compound-id>(2-<compound-id="18182">amidinopropane</compound-id> hydrochloride) (AAPH)- induced hemolysis, in which 10 Schiff bases including <compound-id="5355326">4-phenyliminomethylphenol</compound-id> (PIH); <compound-id="5338977">4-((4-hydroxybenzylidene) amino)phenol</compound-id> (<compound-id="2148">PAH</compound-id>); <compound-id="6744469">2-methoxy-4-((4-hydroxyphenylimino)methyl)phenol</compound-id> (<compound-id="445008">PMH</compound-id>); 4-((furan-2-ylmethylene)amino) <compound-id="996">phenol</compound-id> (FAH); 4-((4-N,N-dimethylaminobenzylidene)amino)<compound-id="996">phenol</compound-id> (<protein-id="Q9P0J1,Q6P1N1,A0A024R9C0">PDH</protein-id>); 2-((4-N,N-dimethylaminobenzylidene)amino) <compound-id="996">phenol</compound-id> (<compound-id="2978966">ODH</compound-id>); <compound-id="6739368">2-(naphthalene-1-yliminomethyl)phenol</compound-id> (NAH); <compound-id="6738088">2-(benzyliminomethyl)phenol</compound-id> (BPH); <compound-id="5383316">1,4-di((2-hydroxyphenylimino) methyl)benzene</compound-id> (DOH); <compound-id="5383317">1,4-di((4-hydroxyphenylimino)methyl)benzene</compound-id> DPH, were available for this in vitro experimental system.	2-methoxy-4-((4-hydroxyphenylimino)methyl)phenol__PDH__no_interaction	4-((4-hydroxybenzylidene) amino)phenol__PDH__no_interaction	1,4-di((4-hydroxyphenylimino)methyl)benzene__PDH__no_interaction	2,2'-azobis__PDH__no_interaction	ODH__PDH__no_interaction	PAH__PDH__no_interaction	2-(naphthalene-1-yliminomethyl)phenol__PDH__no_interaction	2-(benzyliminomethyl)phenol__PDH__no_interaction	phenol__PDH__no_interaction	4-phenyliminomethylphenol__PDH__no_interaction	amidinopropane__PDH__no_interaction	1,4-di((2-hydroxyphenylimino) methyl)benzene__PDH__no_interaction	PMH__PDH__no_interaction
16388798-1	We investigated the effect of acidic pH, a condition that can be encountered during inflammation accompanying allergic reaction, on the binding properties of <compound-id="774">histamine</compound-id> H1 receptor antagonists, including levocetirizine ((2-(4-[(R)-(4-chlorophenyl)(phenyl)methyl]<compound-id="91216341">piperazin-1-yl</compound-id>)ethoxy)acetic acid; <compound-id="1549000">Xyzal</compound-id> ), fexofenadine (<protein-id="P15153,A0A024R1P2,V9H0H7">rac-2</protein-id>-[4-[1-Hydroxy-4-[4-(hydroxydiphenylmethyl) <compound-id="8082">piperidin</compound-id>-1-yl]<compound-id="68006705">butyl</compound-id>]phenyl]-<compound-id="6590">2-methylpropionic acid</compound-id> hydrochloride; <compound-id="3348">Allegra</compound-id>) and <compound-id="124087">desloratadine</compound-id> (8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]<compound-id="9265">cyclohepta</compound-id>[1,2-b]pyridine; Clarinex ).	Allegra__rac-2__no_interaction	piperazin-1-yl__rac-2__no_interaction	Xyzal__rac-2__no_interaction	2-methylpropionic acid__rac-2__no_interaction	piperidin__rac-2__no_interaction	desloratadine__rac-2__no_interaction	butyl__rac-2__no_interaction	cyclohepta__rac-2__no_interaction	histamine__rac-2__no_interaction
14720373-6	RESULTS: (1) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP and prolongation of culture time, the morphology of HepG2 cells was changed from spindle shape to round; the ability of HepG2 cells adhering to wall were decreased; the ability of HepG2 cells in suspension were increased; and debris emitted around the cells; (2) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP, DNA ladder occurred; (3) With the increasing concentrations of <protein-id="P05109">cagA</protein-id> (+) HP and prolongation of culture time, the nuclei of HepG2 cells showed chromatin pyknosis, and clustered on the inner border of karyotheca, condensed cytoplasm with many vacuoles; (4) The <compound-id="64966">MTT</compound-id> values of HepG2 cells were decreased with the increasing concentration of <protein-id="P05109">cagA</protein-id>(+) HP (P&lt; 0.01); (5)The values of <compound-id="5950">alanine</compound-id> aminotransferase (ALT) and <compound-id="612">lactate</compound-id> dehydrogenase (LDH) in coculture supernatants of <protein-id="P05109">cagA</protein-id> (+) Hp and HepG2 were increased (P&lt; 0.01); (6) No influence of <protein-id="P05109">cagA</protein-id> (-) Hp on HepG2 was found.	alanine__cagA__no_interaction	MTT__cagA__no_interaction	lactate__cagA__no_interaction
7559427-7	Their structures were determined by chemical and enzymatic analyses and 1H NMR spectroscopy and found to be the following octa- and decasaccharide sequences attached to <compound-id="5951">Ser</compound-id> in a molar ratio of 1.1:2.3:1.0:1.3: delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1-4GlcN(NS,6S)alpha 1-4GlcA beta 1-4GlcNAc alpha 1-4- <compound-id="94715">GlcA</compound-id> beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (I), delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1- 4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc alpha 1-4GlcA beta 1- 3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (II), delta <protein-id="B1PK15">HexA</protein-id>(2S)alpha 1- 4GlcN(NS,6S)alpha 1- 4IdoA alpha 1-4GlcNAc alpha 1-4GlcA beta 1-4GlcNAc-alpha 1- 4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (III), delta <protein-id="B1PK15">HexA</protein-id> alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc(6S)alpha 1- 4GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-<compound-id="5951">Ser</compound-id> (IV) (delta <protein-id="B1PK15">HexA</protein-id>, <compound-id="94715">GlcA</compound-id>, <compound-id="446102">IdoA</compound-id>, and GlcN represent 4,5-unsaturated <compound-id="50">hexuronic acid</compound-id>, D-glucuronic acid, <compound-id="441039,7140380">L-iduronic acid</compound-id>, and <compound-id="441477">D-glucosamine</compound-id>, whereas 2S, 6S, and NS stand for 2-<compound-id="1117">sulfate</compound-id>, 6-<compound-id="1117">sulfate</compound-id>, and N-<compound-id="1117">sulfate</compound-id>, respectively).	Ser__HexA__no_interaction	sulfate__HexA__no_interaction	D-glucosamine__HexA__no_interaction	IdoA__HexA__no_interaction	L-iduronic acid__HexA__no_interaction	hexuronic acid__HexA__no_interaction	GlcA__HexA__no_interaction
24301038-4	METHODS: The following immunological features were studied to understand how Candida induces immune responses in healthy subjects: (1) proliferative capacity of T-cells upon exposure to Candida through monocyte-derived human Langerhans cells (LCs) measured using alamarBlue, (2) cytokine (IL-1β, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>, <protein-id="P22301,Q6FGW4">IL-10</protein-id>, IL-12p40, IL-23Ap19, IFN-γ, and TNF- expression upon Candida stimulation of LCs by quantitative reverse transcription (qRT)-PCR and cytokine secretion by ELISA, (3) expression of pattern recognition receptors (PRRs) known to associate with Candida albicans (DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, <compound-id="18950,206">mannose</compound-id> receptor, Toll-like receptors 1, 2, 4, 6, and 9) on LCs by qRT-PCR, (4) role of dectin-1 in IL-12 production by antibody blocking, and (5) induction of Th1, Th2, and/or Th17 responses by intracellular cytokine staining of CD4 cells exposed to Candida pulsed LCs for IFN-γ, IL-4, and IL-17A.	mannose__IL-6__no_interaction	mannose__IL-8__no_interaction	mannose__IL-10__no_interaction
11246868-8	Compared with patients undergoing KA transplantation, patients undergoing KP transplantation showed lower values for HbA1c (KP = 6.2 +/- 0.1% vs. KA = 8.4 +/- 0.5%; P &lt; 0.01), fasting <compound-id="778,91552">homocysteine</compound-id> (KP = 14.0 +/- 0.7 mcromol/l vs. KA = 19.0 +/- 2.0 micromol/l; P = 0.02), <protein-id="P04275">von Willebrand factor</protein-id> levels (KP = 157.9 +/- 8.6% vs. KA = 212.5 +/- 16.2%; P &lt; 0.01), D-dimer fragments (KP = 0.29 +/- 0.02 microg/ml vs. KA = 0.73 +/- 0.11 microg/ml;P &lt; 0.01), fibrinogen (KP = 363.0 +/- 11.1 mg/dl vs. KA = 397.6 +/- 19.4 mg/dl; NS), triglycerides (KP = 122.7 +/- 8.6 mg/dl vs. KA = 187.0 +/- 30.1 mg/dl; P = 0.01), and urinary albumin excretion rate (KP = 13.5 +/- 1.9 mg/24 h vs. KA = 57.3 +/- 26.3 mg/24 h; P &lt; 0.01).	homocysteine__von Willebrand factor__no_interaction
19023279-5	In multivariate models including age, gender, and waist circumference, there were inverse correlations between changes in <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> and <protein-id="P19320">vascular cell adhesion molecule-1</protein-id> (<protein-id="P19320">VCAM-1</protein-id>) (r = -0.54, P &lt; 0.0001) and <protein-id="P05362">intercellular adhesion molecule-1</protein-id> (<protein-id="P05362">ICAM-1</protein-id>) (r = -0.57, P &lt; 0.0001), and <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = -0.40, P = 0.0041); <compound-id="11970143">lipopolysaccharide</compound-id> (LPS)-stimulated production of <protein-id="P01375,Q5STB3">tumor necrosis factor-alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (r = -0.30, P = 0.035), <protein-id="P01584">interleukin (IL)-1beta</protein-id> (r = -0.44, P = 0.0016), <protein-id="P13500">monocyte chemotactic protein-1</protein-id> (<protein-id="P13500">MCP-1</protein-id>) (r = -0.46, P = 0.001), and <protein-id="P10147,A0N0R1">macrophage inflammatory protein-1alpha</protein-id> (<protein-id="P10147,A0N0R1">MIP-1alpha</protein-id>) (r = -0.45, P = 0.0012).	lipopolysaccharide__macrophage inflammatory protein-1alpha__no_interaction	lipopolysaccharide__CRP__no_interaction	lipopolysaccharide__interleukin (IL)-1beta__no_interaction	lipopolysaccharide__tumor necrosis factor-alpha__no_interaction	lipopolysaccharide__MIP-1alpha__no_interaction	lipopolysaccharide__adiponectin__no_interaction	lipopolysaccharide__intercellular adhesion molecule-1__no_interaction	lipopolysaccharide__vascular cell adhesion molecule-1__no_interaction	lipopolysaccharide__C-reactive protein__no_interaction	lipopolysaccharide__VCAM-1__no_interaction	lipopolysaccharide__ICAM-1__no_interaction	lipopolysaccharide__monocyte chemotactic protein-1__no_interaction	lipopolysaccharide__TNF-alpha__no_interaction	lipopolysaccharide__MCP-1__no_interaction
24084430-5	<compound-id="53443082">MTSEA</compound-id> treatment resulted in a significant reduction in the binding of (125)I-<protein-id="O95399,A0AVP6">UII</protein-id> to <protein-id="P06753,A0A087WWU8,J3KN67,B4DQ80">TM3</protein-id> mutants L126C((3.28)), F127C((3.29)), F131C((3.33)) and M134C((3.36)) and TM4 mutants M184C((4.60)) and I188C((4.64)).	MTSEA__UII__no_interaction	MTSEA__TM3__no_interaction
11352071-6	Patients with generalized arteriosclerosis had higher plasma <protein-id="P02675,V9HVY1">fibrinogen</protein-id> concentrations than did those suffering from <compound-id="221493">CHD</compound-id> only (for men, control 2.65 +/- 0.51, <compound-id="221493">CHD</compound-id> 3.07 +/- 0.73, <compound-id="221493">CHD</compound-id> plus POAD 3.17 +/- 0.77 and <compound-id="221493">CHD</compound-id> plus POAD plus CVD 3.45 +/- 0.78 g/l; for women, control 2.69 +/- 0.44, <compound-id="221493">CHD</compound-id> 3.25 +/- 0.67, <compound-id="221493">CHD</compound-id> plus POAD 3.19 +/- 0.77, <compound-id="221493">CHD</compound-id> plus POAD plus CVD 3.60 +/- 0.84 g/l).	CHD__fibrinogen__no_interaction
22225958-5	The serum <protein-id="P55008,Q4V347,I3WTX1">AIF-1</protein-id> concentrations positively correlated with levels of fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.159, P =.0056), hemoglobin A(1c) (r = 0.169, P = .0032), triglycerides (r = 0.137, P = .0172), and <compound-id="1175">uric acid</compound-id> (r = 0.146, P = .0108) and with waist circumference (r = 0.221, P = .0001) and body mass index (r = 0.185, P = .0012), whereas the serum <protein-id="P55008,Q4V347,I3WTX1">AIF-1</protein-id> concentrations inversely correlated with high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level (r = -0.178, P = .0019).	cholesterol__AIF-1__no_interaction	uric acid__AIF-1__no_interaction	glucose__AIF-1__no_interaction
1889145-6	RESULTS: In the obese group an impaired <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> response to hypoglycaemia (mean area under the curve obese 54 U/l min, controls 155 U/l min; P = 0.0001) was inversely correlated to fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, r2 = 0.142, P = 0.03; relative <protein-id="P01308,I3WAC9">insulin</protein-id> resistance, r2 = 0.134, P = 0.03 and steady-state plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level, r2 = 0.345, P = 0.0004 whereas the impaired GH response (mean GH area under the curve obese 1.9 U/l min, controls 65.7 U/l min; P = 0.0001) was inversely correlated to steady-state plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level, r2 = 0.196, P = 0.01.	glucose__prolactin__no_interaction	glucose__insulin__no_interaction
8960832-7	<protein-id="P00450,A5PL27">CPII</protein-id> for 12 months resulted in: a slight and transient improvement in HbA1c (Time (T)0: 7.6 +/- 0.2%, <compound-id="5920">T3</compound-id>: 7.1 +/- 0.2%, T12: 7.5 +/- 0.2%, p &lt; 0.02), improvement in GHBP (T0: 10.2 +/- 0.8%, T12: 15.5 +/- 1.5, p &lt; 0.0001), near-normalization of <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> (T0: 89.4 +/- 8.8 ng/ml, T12: 146.9 +/- 15.6, p &lt; 0.002) and normalization of <protein-id="P17936,B3KPF0">IGFBP-3</protein-id> (T0: 1974 +/- 121 ng/ml, T12: 3534 +/- 305, p &lt; 0.0001).	T3__CPII__no_interaction	T3__IGF-I__no_interaction	T3__IGFBP-3__no_interaction
8656502-9	RESULTS: Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued <compound-id="35370">zidovudine</compound-id> monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs -0.02 x 10(9)/L, respectively; P &lt; .001); log10 HIV-1 RNA as measured by the Roche assay (-0.96 vs -0.77 vs +0.07 copies/mL, respectively; P &lt; .001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0.59 vs -1.06 vs -0.02 copies/mL, respectively; P &lt; .011); and immune-complex dissociated (ICD) <protein-id="Q15363,Q6FHT8">p24</protein-id> antigen (-74% vs -68% vs +27%, respectively; P &lt; .001).	zidovudine__p24__no_interaction
8933293-3	The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (<protein-id="Q63118">ClR</protein-id>: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and <protein-id="Q63118">ClR</protein-id> (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of <compound-id="114759">DA-125</compound-id>.	DA-125__ClR__no_interaction
3383840-1	Eleven mutagenic heterocyclic amines, 3-amino-1,4-dimethyl-<compound-id="13347754">5H-pyrido</compound-id>[4,3-b]-<compound-id="798">indole</compound-id> (<compound-id="5284474">Trp-P-1</compound-id>), 3-amino-1-methyl-<compound-id="13347754">5H-pyrido</compound-id>[4,3]<compound-id="798">indole</compound-id> (<protein-id="O35245">Trp-P-2</protein-id>), 2-amino-6-methyl-dipyrido[1,2-a:3',2'-d]<compound-id="795">imidazole</compound-id> (<compound-id="49971">Glu-P-1</compound-id>), 2-aminodipyrido[1,2-a:3',2'-d]<compound-id="795">imidazole</compound-id> (Glu-P-2), <compound-id="62805">2-amino-9H-pyrido[2,3-b]indole</compound-id> (A alpha C), 2-amino-<compound-id="12596583">3-methyl-9H-pyrido[2,3-b]indole</compound-id> (MeA alpha C), <compound-id="53462">2-amino-3-methylimidazo[4,5-f]quinoline</compound-id> (IQ), 2-amino-<compound-id="151879">3,4-dimethylimidazo[4,5-f]quinoline</compound-id> (MeIQ), 2-amino-3,8-<compound-id="70259">dimethylimidazo</compound-id> [4,5-f]<compound-id="7047">quinoline</compound-id> (<compound-id="62275">MeIQX</compound-id>), 2-amino-3,4,8-<compound-id="69976">trimethylimidazo</compound-id>[4,5-f]<compound-id="7045">quinoxaline</compound-id> (4,8-diMeIQX), and <compound-id="104855">2-amino-3,7,8-trimethylimidazo[4,5-f]quinoxaline</compound-id> (7,8-diMeIQX), were studied for genotoxicity in the hepatocyte/DNA repair test employing hepatocytes of male rats, male and female mice, and male hamsters.	Glu-P-1__Trp-P-2__no_interaction	indole__Trp-P-2__no_interaction	quinoxaline__Trp-P-2__no_interaction	2-amino-9H-pyrido[2,3-b]indole__Trp-P-2__no_interaction	MeIQX__Trp-P-2__no_interaction	3-methyl-9H-pyrido[2,3-b]indole__Trp-P-2__no_interaction	dimethylimidazo__Trp-P-2__no_interaction	trimethylimidazo__Trp-P-2__no_interaction	2-amino-3-methylimidazo[4,5-f]quinoline__Trp-P-2__no_interaction	5H-pyrido__Trp-P-2__no_interaction	Trp-P-1__Trp-P-2__no_interaction	3,4-dimethylimidazo[4,5-f]quinoline__Trp-P-2__no_interaction	2-amino-3,7,8-trimethylimidazo[4,5-f]quinoxaline__Trp-P-2__no_interaction	quinoline__Trp-P-2__no_interaction	imidazole__Trp-P-2__no_interaction
8314584-4	By isozyme analysis and Southern hybridization, <protein-id="Q29443">transferrin</protein-id> (TF) and <protein-id="P00442">superoxide dismutase 1</protein-id> (<protein-id="P00442">SOD1</protein-id>), both in the bovine syntenic group U10, were assigned to sheep chromosome 1q; <protein-id="C5IJA8">adenylate kinase 1</protein-id> (<protein-id="C5IJA8">AK1</protein-id>), in the bovine syntenic group <compound-id="6914648">U16</compound-id>, to sheep chromosome 3p; <compound-id="612">lactate</compound-id> dehydrogenase B (LDHB) and <protein-id="W5Q2V2">phenylalanine hydroxylase</protein-id> (<protein-id="W5Q2V2">PAH</protein-id>) on bovine chromosome 5 (BTA5) to sheep chromosome 3q; phosphoglucomutase 2 (PGM2) (bovine syntenic group 15) to sheep chromosome 6 (<compound-id="56955962">t1q</compound-id>); avian myelocytomatosis viral oncogene homolog (MYC) and Moloney murine sarcoma viral oncogene homolog (MOS) (BTA 14) to sheep 9 (t2q); and <compound-id="124886,20725278,745">glutathione</compound-id> reductase (GSR) (bovine syntenic group U14) to sheep 24 (<compound-id="657023">t1p</compound-id>).	glutathione__SOD1__no_interaction	glutathione__AK1__no_interaction	glutathione__transferrin__no_interaction	glutathione__superoxide dismutase 1__no_interaction	glutathione__adenylate kinase 1__no_interaction	glutathione__phenylalanine hydroxylase__no_interaction	glutathione__PAH__no_interaction	lactate__SOD1__no_interaction	lactate__AK1__no_interaction	lactate__transferrin__no_interaction	lactate__superoxide dismutase 1__no_interaction	lactate__adenylate kinase 1__no_interaction	lactate__phenylalanine hydroxylase__no_interaction	lactate__PAH__no_interaction	t1p__SOD1__no_interaction	t1p__AK1__no_interaction	t1p__transferrin__no_interaction	t1p__superoxide dismutase 1__no_interaction	t1p__adenylate kinase 1__no_interaction	t1p__phenylalanine hydroxylase__no_interaction	t1p__PAH__no_interaction	t1q__SOD1__no_interaction	t1q__AK1__no_interaction	t1q__transferrin__no_interaction	t1q__superoxide dismutase 1__no_interaction	t1q__adenylate kinase 1__no_interaction	t1q__phenylalanine hydroxylase__no_interaction	t1q__PAH__no_interaction	U16__SOD1__no_interaction	U16__AK1__no_interaction	U16__transferrin__no_interaction	U16__superoxide dismutase 1__no_interaction	U16__adenylate kinase 1__no_interaction	U16__phenylalanine hydroxylase__no_interaction	U16__PAH__no_interaction
16088424-6	After I-R, nSTZ-rats showed increased plasma concentrations of LPO, NO, <protein-id="Q00238">ICAM-1</protein-id> (0.5141 +/- 0.083 vs 0.024 +/- 0.003, ICV; 0.574 +/- 0.075 vs 0.023 +/- 0.003, <compound-id="446034">SCV</compound-id>; 0.528 +/- 0.067 vs 0.027 +/- 0.003 PV; ng/ml), <protein-id="P16599">TNF-alpha</protein-id> (42.4 +/- 5.7 ICV, 248.4 +/- 28.2 <compound-id="446034">SCV</compound-id>, and 33.6 +/- 4.0 PV.	SCV__ICAM-1__no_interaction	SCV__TNF-alpha__no_interaction
22612619-1	The objective was to determine the cytochrome P450s (CYPs) responsible for the stereoselective and regiospecific hydroxylation of ketamine [(R,S)-<protein-id="Q9H3D4">Ket</protein-id>] to diastereomeric hydroxyketamines, (2S,6S;2R,6R)-HK (5a) and (2S,6R;2R,6S)-HK (<compound-id="18445697">5b</compound-id>) and norketamine [(R,S)-norKet] to hydroxynorketamines, (2S,6S;2R,6R)-HNK (<compound-id="69255155">4a</compound-id>), (2S,6R;2R,6S)-HNK (4b), (2S,5S;2R,5R)-HNK (4c), (2S,4S;2R,4R)-HNK (4d), (2S,4R;2R,4S)-HNK (4e), (2S,5R;2R,5S)-HNK (4f).	4a__Ket__no_interaction	5b__Ket__no_interaction
23562108-5	Positive DM family history was associated with elevated fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (98.6 ± 13.1 vs 96.5 ± 12.3 mg/dL), HbA1c (5.58% ± 0.49% vs 5.50% ± 0.46%), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (9.74 ± 4.20 vs 9.21 ± 3.63 μU/mL) and HOMA (2.43 ± 1.19 vs 2.24 ± 1.01) values, lower QUICKI (0.342 ± 0.025 vs 0.345 ± 0.023), Bennett (0.285 ± 0.081 vs 0.292 ± 0.078) and McAuley (6.73 ± 3.43 vs 6.95 ± 3.44) values, and higher IGH prevalence (45.3% vs 38.7%); P &lt; .01 for all comparisons.	glucose__insulin__no_interaction
11179725-3	Altogether, the following relationship between the space region and activity was found: Affinity for <protein-id="P11473,F1D8P8">vitamin D receptor</protein-id> (<protein-id="P11473,F1D8P8">VDR</protein-id>), EA &gt; A&gt; F &gt; G &gt; EG; Affinity for <protein-id="P02774">vitamin D binding protein</protein-id> (<protein-id="Q10586">DBP</protein-id>), A &gt;&gt; G,EA,EG; Target gene transactivation, EA &gt; F &gt; A &gt; EG &gt; or = G; Cell differentiation, EA &gt; F &gt; A &gt; EG &gt; or = G; Bone <compound-id="22044544,5460341">calcium</compound-id> mobilization, EA &gt; GA &gt; F &gt; or = EG; Intestinal <compound-id="22044544,5460341">calcium</compound-id> absorption, EA = A &gt; or = G &gt;&gt; EG.	calcium__DBP__no_interaction	calcium__VDR__no_interaction	calcium__vitamin D receptor__no_interaction	calcium__vitamin D binding protein__no_interaction
20465997-5	We verified that in LF cells, comparatively to HF cells: (1) uptake of [3H]folic acid is upregulated, via an increase in the Vmax of uptake; (2) uptake of [3H]<compound-id="53782692">deoxy-glucose</compound-id>, [3H]<compound-id="15173104">O-methyl-glucose</compound-id> and [3H]<compound-id="39484">1-methyl-4-phenylpyridinium</compound-id> (MPP+) is downregulated, via a decrease in the Vmax of uptake; additionally, a reduction in Km was observed for [3H]<compound-id="15173104">O-methyl-glucose</compound-id>; (3) uptake of [3H]5-hydroxytryptamine and [14C]<compound-id="264">butyrate</compound-id> is not changed; and (4) the steady-state mRNA levels of the folic acid transporters RFC (reduced <compound-id="6037">folate</compound-id> carrier), PCFT (<compound-id="1038,5460653">proton</compound-id>-coupled <compound-id="6037">folate</compound-id> transporter) and FRalpha (<compound-id="6037">folate</compound-id> receptor alpha), of the organic cation transporter <protein-id="O15245">OCT1</protein-id> (<protein-id="O15245">organic cation transporter type 1</protein-id>), of the <compound-id="206,5793,64689,79025">glucose</compound-id> transporter <protein-id="P11168,Q6PAU8">GLUT2</protein-id> (facilitative <protein-id="P11168,Q6PAU8">glucose transporter type 2</protein-id>) and of the <compound-id="264">butyrate</compound-id> transporter <protein-id="P53985,B4DKS0,A0A024R0H1">MCT1</protein-id> (<protein-id="P53985,B4DKS0,A0A024R0H1">monocarboxylate transporter type 1</protein-id>) were decreased.	proton__OCT1__no_interaction	proton__glucose transporter type 2__no_interaction	proton__monocarboxylate transporter type 1__no_interaction	proton__GLUT2__no_interaction	proton__organic cation transporter type 1__no_interaction	proton__MCT1__no_interaction	folate__OCT1__no_interaction	folate__glucose transporter type 2__no_interaction	folate__monocarboxylate transporter type 1__no_interaction	folate__GLUT2__no_interaction	folate__organic cation transporter type 1__no_interaction	folate__MCT1__no_interaction	butyrate__OCT1__no_interaction	butyrate__glucose transporter type 2__no_interaction	butyrate__monocarboxylate transporter type 1__no_interaction	butyrate__GLUT2__no_interaction	butyrate__organic cation transporter type 1__no_interaction	butyrate__MCT1__no_interaction	deoxy-glucose__OCT1__no_interaction	deoxy-glucose__glucose transporter type 2__no_interaction	deoxy-glucose__monocarboxylate transporter type 1__no_interaction	deoxy-glucose__GLUT2__no_interaction	deoxy-glucose__organic cation transporter type 1__no_interaction	deoxy-glucose__MCT1__no_interaction	O-methyl-glucose__OCT1__no_interaction	O-methyl-glucose__glucose transporter type 2__no_interaction	O-methyl-glucose__monocarboxylate transporter type 1__no_interaction	O-methyl-glucose__GLUT2__no_interaction	O-methyl-glucose__organic cation transporter type 1__no_interaction	O-methyl-glucose__MCT1__no_interaction	1-methyl-4-phenylpyridinium__OCT1__no_interaction	1-methyl-4-phenylpyridinium__glucose transporter type 2__no_interaction	1-methyl-4-phenylpyridinium__monocarboxylate transporter type 1__no_interaction	1-methyl-4-phenylpyridinium__GLUT2__no_interaction	1-methyl-4-phenylpyridinium__organic cation transporter type 1__no_interaction	1-methyl-4-phenylpyridinium__MCT1__no_interaction	glucose__OCT1__no_interaction	glucose__glucose transporter type 2__no_interaction	glucose__monocarboxylate transporter type 1__no_interaction	glucose__GLUT2__no_interaction	glucose__organic cation transporter type 1__no_interaction	glucose__MCT1__no_interaction
12839666-4	RESULTS: The results showed that the mineral deposit rate and bone contents of <compound-id="23994">zinc</compound-id>, phosphorus and <compound-id="269023,5810">hydroxyproline</compound-id>, and serum levels of <protein-id="P01256,P01257,A0A0G2JSX2">calcitonin</protein-id> and osteocalcin lowered significantly in ZD group, as compared with those in the control and pair-fed groups, with (3.26 +/- 0.34) micro m/d, (64.54 +/- 2.34) g/kg, (54.4 +/- 9.5) mg/kg, (9.28 +/- 1.62) g/kg, (41.2 +/- 13.5) micro g/L, (82 +/- 30) micro g/L in ZD group; (5.37 +/- 0.53) micro m/d, (69.01 +/- 4.05) g/kg, (117.4 +/- 8.0) mg/kg, (11.31 +/- 1.30) g/kg, (68.3 +/- 14.4) micro g/L, (131 +/- 46) micro g/L in the control group; and (5.45 +/- 0.30) micro m/d, (67.81 +/- 3.56) g/kg, (106.7 +/- 8.4) mg/kg, (10.88 +/- 1.47) g/kg, (63.7 +/- 12.0) micro g/L, (120 +/- 52) micro g/L in the pair-fed group, respectively.	hydroxyproline__calcitonin__no_interaction	zinc__calcitonin__no_interaction
22973371-7	Plasma acylated <compound-id="44576256">ghrelin</compound-id> concentrations in obese and lean men were negatively correlated to body weight (r= -0.50, r= -0.43, respectively), body fat percent (r = -0.53, r = -0.44, respectively), body mass index (r = -0.53, r = -0.49, respectively), <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.42, r = -0.40, respectively) and HOMA-IR (r = -0.48, r = -0.45, respectively), and positively correlated to GH levels (r = 0.37, r = 0.31, respectively) and maximal <compound-id="977">oxygen</compound-id> uptake (r = 0.33, r = 0.31, respectively) (p &lt; 0.01).	ghrelin__insulin__no_interaction	oxygen__insulin__no_interaction
12805480-4	<compound-id="122634,22833501,4792">PMA</compound-id>/Io-stimulated <protein-id="P04351">interleukin-2</protein-id> production was inhibited by <compound-id="2543">cannabinol</compound-id>, <compound-id="644019">cannabidiol</compound-id>, and both <compound-id="5311501,5689">WIN 55212-2</compound-id> stereoisomers with a rank order potency of R-(+)-[<compound-id="3525223">2,3-dihydro-5-</compound-id>methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-<compound-id="15246252">1,4-benzoxazinyl</compound-id>]-(1-napthanlenyl) methanone <compound-id="6395">mesylate</compound-id> (<compound-id="5311501,5689">WIN 55212-2</compound-id>) approximately <compound-id="644019">cannabidiol</compound-id> &gt; S-(-)-[<compound-id="3525223">2,3-dihydro-5-</compound-id>methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-<compound-id="15246252">1,4-benzoxazinyl</compound-id>]-(1-napthanlenyl) methanone <compound-id="6395">mesylate</compound-id> (<compound-id="23616032">WIN 55212</compound-id>-3) approximately <compound-id="2543">cannabinol</compound-id>.	mesylate__interleukin-2__no_interaction	1,4-benzoxazinyl__interleukin-2__no_interaction	2,3-dihydro-5-__interleukin-2__no_interaction	WIN 55212__interleukin-2__no_interaction	cannabinol__interleukin-2__no_interaction	cannabidiol__interleukin-2__no_interaction	WIN 55212-2__interleukin-2__no_interaction	PMA__interleukin-2__no_interaction
16127505-6	Reactions of [Rh(acac)(L-L)](L-L = cod, (CO)2, (CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)) with 4 and the dendrimers G(1)SH-8, G(2)SH-16, and G(1)SH-12, gave microcrystalline solids of formulae [Rh3(MeSi[(CH2)<compound-id="21439199">3S</compound-id>]3)(L-L)3]n, [Si[(CH2)3SiMe{(CH2)3SRh(cod)}2]4]n([G(1)Rh(cod)-8]n), [Si[(CH2)3Si{(CH2)3SRh(cod)}3]4]n([G(1)Rh(cod)-12]n), etc., which presumably are tridimensional coordination polymers.	3S__PPh3__no_interaction
8458191-5	Univariate analysis showed that in diabetic patients systolic blood pressure was related to age (r = 0.17, p &lt; 0.05), BMI (r = 0.23, p &lt; 0.01) and plasma immunoreactive <protein-id="P01308,I3WAC9">insulin</protein-id> (fasting and post <compound-id="206,5793,64689,79025">glucose</compound-id>, r = approximately 0.25, p &lt; 0.01) but not to C-peptide concentrations; diastolic blood pressure to BMI (r = 0.35, p &lt; 0.001), waist-hip ratio (r = 0.23, p &lt; 0.01) and plasma immunoreactive <protein-id="P01308,I3WAC9">insulin</protein-id> (fasting r = 0.30, p &lt; 0.001, post <compound-id="206,5793,64689,79025">glucose</compound-id> r = approximately 0.20, p &lt; 0.05) but not to C-peptide concentrations.	glucose__insulin__no_interaction
8804889-2	These elements <protein-id="Q9Y4K1,B3KPT0,A0A0J9YWL0">aim 1</protein-id>) to diminish frequency and severity of acid challenge, 2) enhance salivary flow, 3) to enhance acid resistance, remineralization and rehardening by <compound-id="28179">fluoride</compound-id> application, 4) to offer chemical protection by buffering substances, 5) to minimize abrasion, 6) to offer mechanical protection.	fluoride__aim 1__no_interaction
22052298-3	Herein, we report a complete work including (i) effect of initial [<compound-id="4346576">APTS</compound-id>]/[Ru] molar ratio on both the size and the catalytic activity of <compound-id="23950">ruthenium</compound-id>(0) nanoparticles, (ii) collection of extensive kinetic data under non-MTL conditions depending on the substrate and catalyst concentrations to define the rate law of Ru(0)/<compound-id="4346576">APTS</compound-id>-catalyzed dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> at room temperature, (iii) determination of activation parameters (E(a), ΔH(#) and ΔS(#)) for Ru(0)/<compound-id="4346576">APTS</compound-id>-catalyzed dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id>; (iv) demonstration of the catalytic lifetime of Ru(0)/<compound-id="4346576">APTS</compound-id> nanoparticles in the dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> at room temperature, (v) testing the bottlability and reusability of Ru(0)/<compound-id="4346576">APTS</compound-id> nanocatalyst in the room-temperature dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id>, (vi) quantitative <compound-id="6348">carbon disulfide</compound-id> (CS(2)) poisoning experiments to find a corrected TTO and <protein-id="Q8TBJ5">TOF</protein-id> values on a per-active-<compound-id="23950">ruthenium</compound-id>-atom basis, (vii) a summary of extensive literature review for the catalysts tested in the catalytic dehydrogenation of dimethylamine-<compound-id="5462311">borane</compound-id> as part of the results and discussions.	APTS__TOF__no_interaction	ruthenium__TOF__no_interaction	carbon disulfide__TOF__no_interaction	borane__TOF__no_interaction
12919040-1	2-Halophenyl <compound-id="114522">ketones</compound-id> 1a-e (1a, o-IC(6)H(4)COCH(3)) undergo carbocyclization with alkyl propiolates (2a, CH(3)(CH(2))(4)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2b, TMSC[triple bond]<compound-id="446195">CCO</compound-id>(2)Et 2c, CH(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2d, CH(3)OCH(2)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2e, CH(3)(CH(2))(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); 2f, <protein-id="Q00325,A0A024RBE8,A0A024RBH9,Q6MZF9">PhC</protein-id>[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3); and 2g, (CH(3))(3)C[triple bond]<compound-id="446195">CCO</compound-id>(2)CH(3)) in the presence of Ni(dppe)Br(2) and <compound-id="23994">zinc</compound-id> powder in acetonitrile at 80 degrees C to afford the corresponding <compound-id="316919">indenol</compound-id> derivatives <compound-id="2981881,91293124">3a</compound-id>-m with remarkable regioselectivity in good to excellent yields.	ketones__PhC__no_interaction	indenol__PhC__no_interaction	CCO__PhC__no_interaction	3a__PhC__no_interaction	zinc__PhC__no_interaction
22340657-5	ACC (acetyl <compound-id="317,44216777,44246472,444624,445126,447444,448506,46936280,5326877,6816,6914636,87642">coenzyme A</compound-id> carboxylase) and <protein-id="P56720,R9PXS1">SREBP-1</protein-id> mRNA expression, lowered plasma <protein-id="Q8K3R4">adiponectin</protein-id> (OLETF vs LETO: 8 weeks age, 2.38 ± 0.23 vs 3.1 ± 0.17, P &lt; 0.05; 32 weeks age, 1.51 ± 0.05 vs 2.84 ± 0.34, P &lt; 0.01; 40 weeks age, 1.24 ± 0.04 vs 2.64 ± 0.49 ng/ml, P &lt; 0.01) and liver tissue (8, 32 or 40 weeks age, 2.24 ± 0.18 vs 2.68 ± 0.13, 2.04 ± 0.19 vs 2.51 ± 0.14, 1.76 ± 0.12 vs 2.47 ± 0.21 µg/g respectively, P &lt; 0.05) as well as elevated triglyceride (TG) (40 weeks age, TG 1.88 ± 0.11 vs 0.51 ± 0.07 mmol/L, P &lt; 0.01) and <compound-id="5997">cholesterol</compound-id> (40 weeks age, total <compound-id="5997">cholesterol</compound-id> 0.94 ± 0.17 vs 0.69 ± 0.14 mmol/L, P &lt; 0.01) and lowered <protein-id="P35570">IRS-1</protein-id> (<protein-id="P35570">insulin receptor substrate 1</protein-id>) <compound-id="6057,90983769">tyrosine</compound-id> phosphorylation in liver tissue in OLETF rats were observed.	coenzyme A__insulin receptor substrate 1__no_interaction	coenzyme A__adiponectin__no_interaction	coenzyme A__IRS-1__no_interaction	coenzyme A__SREBP-1__no_interaction	tyrosine__insulin receptor substrate 1__no_interaction	tyrosine__adiponectin__no_interaction	tyrosine__IRS-1__no_interaction	tyrosine__SREBP-1__no_interaction	cholesterol__insulin receptor substrate 1__no_interaction	cholesterol__adiponectin__no_interaction	cholesterol__IRS-1__no_interaction	cholesterol__SREBP-1__no_interaction
19159569-5	The specific lysis effects of <protein-id="P19544,Q6PI38">WT1</protein-id> peptide specific CTLs upon leukemic bone marrow CD34+ progenitor cells positively expressing <protein-id="P19544,Q6PI38">WT1</protein-id> (3 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+) and 3 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id>*0201(-)), peripheral blood CD34+ cells from healthy persons (2 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+) and 1 being <protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(-)), and leukemia cells of the lines of NB4 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+)/<protein-id="P19544,Q6PI38">WT1</protein-id>(+)), U937 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(+)/<protein-id="P19544,Q6PI38">WT1</protein-id>(-)), and K562 (<protein-id="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126">HLA-A</protein-id> * 0201(-)/<protein-id="P19544,Q6PI38">WT1</protein-id>(+)) were measured by methyl <compound-id="57036910">thiazolyl tetrazolium</compound-id> (<compound-id="64966">MTT</compound-id>) chromatometry assay.	thiazolyl tetrazolium__WT1__no_interaction	thiazolyl tetrazolium__HLA-A__no_interaction	MTT__WT1__no_interaction	MTT__HLA-A__no_interaction
17003851-2	The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, <compound-id="57476835,60961">adenosine</compound-id> triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, <compound-id="90470007">anakinra</compound-id>, angiotensin-(1-7), <compound-id="166548">anidulafungin</compound-id>, <compound-id="176405">apomine</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="54841">atomoxetine hydrochloride</compound-id>, <compound-id="9869929">avanafil</compound-id>; <compound-id="6918606">BAL-8557</compound-id>, <compound-id="101524">becatecarin</compound-id>, bevacizumab, biphasic <protein-id="P01308,I3WAC9">insulin</protein-id> aspart, BMS-188797, <compound-id="387447">bortezomib</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, <compound-id="446727">brivudine</compound-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="5486792,2826718,468682,66577042,71295847">caspofungin acetate</compound-id>, catumaxomab, certolizumab pegol, cetuximab, CG-0070, <compound-id="6918155">ciclesonide</compound-id>, <compound-id="156419">cinacalcet hydrochloride</compound-id>, <compound-id="10346039,32603,358642,443385,44629926,45356833,51064166">clindamycin phosphate</compound-id>/<compound-id="7187">benzoyl peroxide</compound-id>, <compound-id="76210638,9939639">cryptophycin 52</compound-id>, <compound-id="9962928">Cypher</compound-id>; <compound-id="213023,6445226,9578572">Dabigatran etexilate</compound-id>, <compound-id="9939609">darapladib</compound-id>, darbepoetin alfa, <compound-id="451668">decitabine</compound-id>, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="107778">dexanabinol</compound-id>, <compound-id="3008,5360696,5362449,6916184">dextromethorphan</compound-id>/<compound-id="1065,3036746,5748152,441074,5953">quinidine sulfate</compound-id>, DMF, drotrecogin alfa (activated), <compound-id="60835">duloxetine hydrochloride</compound-id>; E-7010, <compound-id="4021">edaravone</compound-id>, efalizumab, <compound-id="12043008,60877">emtricitabine</compound-id>, <compound-id="153941">entecavir</compound-id>, <compound-id="443872">eplerenone</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="13791">estradiol valerate</compound-id>/<compound-id="68861">dienogest</compound-id>, <compound-id="969472">eszopiclone</compound-id>, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="150311">ezetimibe</compound-id>; <compound-id="3035403,17854871,5282448,71316924">Fondaparinux sodium</compound-id>, <compound-id="104741">fulvestrant</compound-id>; <compound-id="123631">Gefitinib</compound-id>, <compound-id="3033968">gestodene</compound-id>, <compound-id="154069">GYKI-16084</compound-id>; <compound-id="24728612,24759,3084050,453618">Hyaluronic acid</compound-id>, <compound-id="3637">hydralazine hydrochloride</compound-id>/<compound-id="6883">isosorbide dinitrate</compound-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="6450813">indiplon</compound-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> glargine; Juzen-taiho-to; <compound-id="60825">Lamivudine</compound-id>/<compound-id="35370">zidovudine</compound-id>/<compound-id="441300">abacavir sulfate</compound-id>, L-<compound-id="90867653">arginine</compound-id> hydrochloride, <compound-id="216416">lasofoxifene tartrate</compound-id>, L-<compound-id="15991548">BLP</compound-id>-25, <compound-id="216326">lenalidomide</compound-id>, <compound-id="1549000">levocetirizine</compound-id>, <compound-id="6047">levodopa</compound-id>/carbidopa/<compound-id="5281081">entacapone</compound-id>, lexatumumab, <compound-id="9911821">lidocaine/prilocaine</compound-id>, <compound-id="157920">lubiprostone</compound-id>, <compound-id="151166">lumiracoxib</compound-id>; MAb-14.18, <compound-id="71772">mitoquidone</compound-id>; Natalizumab, <compound-id="71237">neridronic acid</compound-id>, neuradiab; <compound-id="198716">Olpadronic acid sodium salt</compound-id>, omalizumab; <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="148178">perifosine</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">pimecrolimus</compound-id>, <compound-id="16759247,5881,6432532,76,9814492,9860744">prasterone</compound-id>, <compound-id="6918456">prasugrel</compound-id>, <protein-id="Q6PL18,A0A024R9G7">PRO-2000</protein-id>, Pseudostat; <compound-id="44462688">R24</compound-id>, rasburicase, RHAMM R3 peptide, rilonacept, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">rosuvastatin calcium</compound-id>, rotavirus vaccine, <compound-id="129228">rufinamide</compound-id>; <compound-id="151897,46233105">Sabarubicin</compound-id> hydrochloride, SHL-749, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498">sirolimus</compound-id>-eluting stent, SLx-2101, <compound-id="264">sodium butyrate</compound-id>, <compound-id="216239">sorafenib</compound-id>, SU-6668; TachoSil, <compound-id="110635">tadalafil</compound-id>, taxus, <compound-id="5362436">tegaserod maleate</compound-id>, <compound-id="159269">telbivudine</compound-id>, <compound-id="5481350">tenofovir disoproxil fumarate</compound-id>, teriparatide, <compound-id="14296">tetramethylpyrazine</compound-id>, <compound-id="70697627">teverelix</compound-id>, <compound-id="5487427">tiotropium bromide</compound-id>, <compound-id="159324">tipifarnib</compound-id>, <compound-id="33776">tirapazamine</compound-id>, <compound-id="216237">tolvaptan</compound-id>, TransvaxTM hepatitis C vaccine, <compound-id="6918140,54786">treprostinil sodium</compound-id>; <compound-id="64147">Valganciclovir hydrochloride</compound-id>, <compound-id="60846">valsartan</compound-id>/<compound-id="2162">amlodipine</compound-id>, <compound-id="3081361">vandetanib</compound-id>, <compound-id="110634">vardenafil hydrochloride</compound-id> hydrate, <compound-id="151194">vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, veglin, <compound-id="71616">voriconazole</compound-id>; <compound-id="23993">Yttrium</compound-id> 90 (90Y) <compound-id="74890578">ibritumomab tiuxetan</compound-id>; <compound-id="60490">Zileuton</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>, <compound-id="23375907,52945214,53398674,91450784,9876378">zotarolimus</compound-id>-eluting stent.	escitalopram oxalate__PRO-2000__no_interaction	escitalopram oxalate__insulin__no_interaction	escitalopram oxalate__p53__no_interaction	eplerenone__PRO-2000__no_interaction	eplerenone__insulin__no_interaction	eplerenone__p53__no_interaction	anidulafungin__PRO-2000__no_interaction	anidulafungin__insulin__no_interaction	anidulafungin__p53__no_interaction	sodium butyrate__PRO-2000__no_interaction	sodium butyrate__insulin__no_interaction	sodium butyrate__p53__no_interaction	abacavir sulfate__PRO-2000__no_interaction	abacavir sulfate__insulin__no_interaction	abacavir sulfate__p53__no_interaction	tetramethylpyrazine__PRO-2000__no_interaction	tetramethylpyrazine__insulin__no_interaction	tetramethylpyrazine__p53__no_interaction	lubiprostone__PRO-2000__no_interaction	lubiprostone__insulin__no_interaction	lubiprostone__p53__no_interaction	Fondaparinux sodium__PRO-2000__no_interaction	Fondaparinux sodium__insulin__no_interaction	Fondaparinux sodium__p53__no_interaction	Lamivudine__PRO-2000__no_interaction	Lamivudine__insulin__no_interaction	Lamivudine__p53__no_interaction	ciclesonide__PRO-2000__no_interaction	ciclesonide__insulin__no_interaction	ciclesonide__p53__no_interaction	BAL-8557__PRO-2000__no_interaction	BAL-8557__insulin__no_interaction	BAL-8557__p53__no_interaction	indiplon__PRO-2000__no_interaction	indiplon__insulin__no_interaction	indiplon__p53__no_interaction	estradiol valerate__PRO-2000__no_interaction	estradiol valerate__insulin__no_interaction	estradiol valerate__p53__no_interaction	telbivudine__PRO-2000__no_interaction	telbivudine__insulin__no_interaction	telbivudine__p53__no_interaction	vatalanib__PRO-2000__no_interaction	vatalanib__insulin__no_interaction	vatalanib__p53__no_interaction	ezetimibe__PRO-2000__no_interaction	ezetimibe__insulin__no_interaction	ezetimibe__p53__no_interaction	Dabigatran etexilate__PRO-2000__no_interaction	Dabigatran etexilate__insulin__no_interaction	Dabigatran etexilate__p53__no_interaction	isosorbide dinitrate__PRO-2000__no_interaction	isosorbide dinitrate__insulin__no_interaction	isosorbide dinitrate__p53__no_interaction	atomoxetine hydrochloride__PRO-2000__no_interaction	atomoxetine hydrochloride__insulin__no_interaction	atomoxetine hydrochloride__p53__no_interaction	clindamycin phosphate__PRO-2000__no_interaction	clindamycin phosphate__insulin__no_interaction	clindamycin phosphate__p53__no_interaction	dextromethorphan__PRO-2000__no_interaction	dextromethorphan__insulin__no_interaction	dextromethorphan__p53__no_interaction	voriconazole__PRO-2000__no_interaction	voriconazole__insulin__no_interaction	voriconazole__p53__no_interaction	levocetirizine__PRO-2000__no_interaction	levocetirizine__insulin__no_interaction	levocetirizine__p53__no_interaction	edaravone__PRO-2000__no_interaction	edaravone__insulin__no_interaction	edaravone__p53__no_interaction	anakinra__PRO-2000__no_interaction	anakinra__insulin__no_interaction	anakinra__p53__no_interaction	lidocaine/prilocaine__PRO-2000__no_interaction	lidocaine/prilocaine__insulin__no_interaction	lidocaine/prilocaine__p53__no_interaction	prasugrel__PRO-2000__no_interaction	prasugrel__insulin__no_interaction	prasugrel__p53__no_interaction	bortezomib__PRO-2000__no_interaction	bortezomib__insulin__no_interaction	bortezomib__p53__no_interaction	valsartan__PRO-2000__no_interaction	valsartan__insulin__no_interaction	valsartan__p53__no_interaction	dexanabinol__PRO-2000__no_interaction	dexanabinol__insulin__no_interaction	dexanabinol__p53__no_interaction	Yttrium__PRO-2000__no_interaction	Yttrium__insulin__no_interaction	Yttrium__p53__no_interaction	Olpadronic acid sodium salt__PRO-2000__no_interaction	Olpadronic acid sodium salt__insulin__no_interaction	Olpadronic acid sodium salt__p53__no_interaction	zotarolimus__PRO-2000__no_interaction	zotarolimus__insulin__no_interaction	zotarolimus__p53__no_interaction	neridronic acid__PRO-2000__no_interaction	neridronic acid__insulin__no_interaction	neridronic acid__p53__no_interaction	eszopiclone__PRO-2000__no_interaction	eszopiclone__insulin__no_interaction	eszopiclone__p53__no_interaction	Cypher__PRO-2000__no_interaction	Cypher__insulin__no_interaction	Cypher__p53__no_interaction	dienogest__PRO-2000__no_interaction	dienogest__insulin__no_interaction	dienogest__p53__no_interaction	BLP__PRO-2000__no_interaction	BLP__insulin__no_interaction	BLP__p53__no_interaction	entecavir__PRO-2000__no_interaction	entecavir__insulin__no_interaction	entecavir__p53__no_interaction	erlotinib hydrochloride__PRO-2000__no_interaction	erlotinib hydrochloride__insulin__no_interaction	erlotinib hydrochloride__p53__no_interaction	teverelix__PRO-2000__no_interaction	teverelix__insulin__no_interaction	teverelix__p53__no_interaction	brivudine__PRO-2000__no_interaction	brivudine__insulin__no_interaction	brivudine__p53__no_interaction	pemetrexed disodium__PRO-2000__no_interaction	pemetrexed disodium__insulin__no_interaction	pemetrexed disodium__p53__no_interaction	becatecarin__PRO-2000__no_interaction	becatecarin__insulin__no_interaction	becatecarin__p53__no_interaction	Hyaluronic acid__PRO-2000__no_interaction	Hyaluronic acid__insulin__no_interaction	Hyaluronic acid__p53__no_interaction	caspofungin acetate__PRO-2000__no_interaction	caspofungin acetate__insulin__no_interaction	caspofungin acetate__p53__no_interaction	hydralazine hydrochloride__PRO-2000__no_interaction	hydralazine hydrochloride__insulin__no_interaction	hydralazine hydrochloride__p53__no_interaction	vandetanib__PRO-2000__no_interaction	vandetanib__insulin__no_interaction	vandetanib__p53__no_interaction	Valganciclovir hydrochloride__PRO-2000__no_interaction	Valganciclovir hydrochloride__insulin__no_interaction	Valganciclovir hydrochloride__p53__no_interaction	deferasirox__PRO-2000__no_interaction	deferasirox__insulin__no_interaction	deferasirox__p53__no_interaction	lasofoxifene tartrate__PRO-2000__no_interaction	lasofoxifene tartrate__insulin__no_interaction	lasofoxifene tartrate__p53__no_interaction	bosentan__PRO-2000__no_interaction	bosentan__insulin__no_interaction	bosentan__p53__no_interaction	Gefitinib__PRO-2000__no_interaction	Gefitinib__insulin__no_interaction	Gefitinib__p53__no_interaction	exenatide__PRO-2000__no_interaction	exenatide__insulin__no_interaction	exenatide__p53__no_interaction	benzoyl peroxide__PRO-2000__no_interaction	benzoyl peroxide__insulin__no_interaction	benzoyl peroxide__p53__no_interaction	cryptophycin 52__PRO-2000__no_interaction	cryptophycin 52__insulin__no_interaction	cryptophycin 52__p53__no_interaction	treprostinil sodium__PRO-2000__no_interaction	treprostinil sodium__insulin__no_interaction	treprostinil sodium__p53__no_interaction	Imatinib mesylate__PRO-2000__no_interaction	Imatinib mesylate__insulin__no_interaction	Imatinib mesylate__p53__no_interaction	tirapazamine__PRO-2000__no_interaction	tirapazamine__insulin__no_interaction	tirapazamine__p53__no_interaction	quinidine sulfate__PRO-2000__no_interaction	quinidine sulfate__insulin__no_interaction	quinidine sulfate__p53__no_interaction	GYKI-16084__PRO-2000__no_interaction	GYKI-16084__insulin__no_interaction	GYKI-16084__p53__no_interaction	tipifarnib__PRO-2000__no_interaction	tipifarnib__insulin__no_interaction	tipifarnib__p53__no_interaction	entacapone__PRO-2000__no_interaction	entacapone__insulin__no_interaction	entacapone__p53__no_interaction	arginine__PRO-2000__no_interaction	arginine__insulin__no_interaction	arginine__p53__no_interaction	amlodipine__PRO-2000__no_interaction	amlodipine__insulin__no_interaction	amlodipine__p53__no_interaction	Sabarubicin__PRO-2000__no_interaction	Sabarubicin__insulin__no_interaction	Sabarubicin__p53__no_interaction	prasterone__PRO-2000__no_interaction	prasterone__insulin__no_interaction	prasterone__p53__no_interaction	apomine__PRO-2000__no_interaction	apomine__insulin__no_interaction	apomine__p53__no_interaction	desloratadine__PRO-2000__no_interaction	desloratadine__insulin__no_interaction	desloratadine__p53__no_interaction	vardenafil hydrochloride__PRO-2000__no_interaction	vardenafil hydrochloride__insulin__no_interaction	vardenafil hydrochloride__p53__no_interaction	aripiprazole__PRO-2000__no_interaction	aripiprazole__insulin__no_interaction	aripiprazole__p53__no_interaction	adenosine__PRO-2000__no_interaction	adenosine__insulin__no_interaction	adenosine__p53__no_interaction	decitabine__PRO-2000__no_interaction	decitabine__insulin__no_interaction	decitabine__p53__no_interaction	rufinamide__PRO-2000__no_interaction	rufinamide__insulin__no_interaction	rufinamide__p53__no_interaction	tadalafil__PRO-2000__no_interaction	tadalafil__insulin__no_interaction	tadalafil__p53__no_interaction	fulvestrant__PRO-2000__no_interaction	fulvestrant__insulin__no_interaction	fulvestrant__p53__no_interaction	tolvaptan__PRO-2000__no_interaction	tolvaptan__insulin__no_interaction	tolvaptan__p53__no_interaction	tiotropium bromide__PRO-2000__no_interaction	tiotropium bromide__insulin__no_interaction	tiotropium bromide__p53__no_interaction	cinacalcet hydrochloride__PRO-2000__no_interaction	cinacalcet hydrochloride__insulin__no_interaction	cinacalcet hydrochloride__p53__no_interaction	sirolimus__PRO-2000__no_interaction	sirolimus__insulin__no_interaction	sirolimus__p53__no_interaction	zidovudine__PRO-2000__no_interaction	zidovudine__insulin__no_interaction	zidovudine__p53__no_interaction	duloxetine hydrochloride__PRO-2000__no_interaction	duloxetine hydrochloride__insulin__no_interaction	duloxetine hydrochloride__p53__no_interaction	Calcipotriol/betamethasone dipropionate__PRO-2000__no_interaction	Calcipotriol/betamethasone dipropionate__insulin__no_interaction	Calcipotriol/betamethasone dipropionate__p53__no_interaction	emtricitabine__PRO-2000__no_interaction	emtricitabine__insulin__no_interaction	emtricitabine__p53__no_interaction	gestodene__PRO-2000__no_interaction	gestodene__insulin__no_interaction	gestodene__p53__no_interaction	tegaserod maleate__PRO-2000__no_interaction	tegaserod maleate__insulin__no_interaction	tegaserod maleate__p53__no_interaction	perifosine__PRO-2000__no_interaction	perifosine__insulin__no_interaction	perifosine__p53__no_interaction	pimecrolimus__PRO-2000__no_interaction	pimecrolimus__insulin__no_interaction	pimecrolimus__p53__no_interaction	mitoquidone__PRO-2000__no_interaction	mitoquidone__insulin__no_interaction	mitoquidone__p53__no_interaction	ibritumomab tiuxetan__PRO-2000__no_interaction	ibritumomab tiuxetan__insulin__no_interaction	ibritumomab tiuxetan__p53__no_interaction	succinate__PRO-2000__no_interaction	succinate__insulin__no_interaction	succinate__p53__no_interaction	avanafil__PRO-2000__no_interaction	avanafil__insulin__no_interaction	avanafil__p53__no_interaction	lenalidomide__PRO-2000__no_interaction	lenalidomide__insulin__no_interaction	lenalidomide__p53__no_interaction	lumiracoxib__PRO-2000__no_interaction	lumiracoxib__insulin__no_interaction	lumiracoxib__p53__no_interaction	tenofovir disoproxil fumarate__PRO-2000__no_interaction	tenofovir disoproxil fumarate__insulin__no_interaction	tenofovir disoproxil fumarate__p53__no_interaction	sorafenib__PRO-2000__no_interaction	sorafenib__insulin__no_interaction	sorafenib__p53__no_interaction	levodopa__PRO-2000__no_interaction	levodopa__insulin__no_interaction	levodopa__p53__no_interaction	rosuvastatin calcium__PRO-2000__no_interaction	rosuvastatin calcium__insulin__no_interaction	rosuvastatin calcium__p53__no_interaction	darapladib__PRO-2000__no_interaction	darapladib__insulin__no_interaction	darapladib__p53__no_interaction	Zileuton__PRO-2000__no_interaction	Zileuton__insulin__no_interaction	Zileuton__p53__no_interaction	R24__PRO-2000__no_interaction	R24__insulin__no_interaction	R24__p53__no_interaction
11198869-2	<compound-id="23978">Copper</compound-id>(II) complexes of the ligands derived from <compound-id="6998">salicylaldehyde</compound-id> (L2), <compound-id="126">p-hydroxybenzaldehyde</compound-id> (L4), and <compound-id="12088">p-carboxybenzaldehyde</compound-id> (L5) were structurally characterized: [<protein-id="Q08DE9">CuL2</protein-id>](ClO4)2.3H2O (monoclinic, P2(1)/c, a = 11.915(6) A, b = 13.861(2) A, c = 17.065(8) A, beta = 102.14(2) degrees, Z = 4); [CuL4](ClO4)2 (monoclinic, P2(1)/n, a = 9.550(3) A, b = 17.977(2) A, c = 14.612(4) A, beta 96.76(1) degrees, Z = 4), and [CuL4](ClO4)2 (monoclinic, P2(1)/n, a = 9.286(2) A, b = 11.294(1) A, c = 23.609(8) A, beta 93.68(1) degrees, Z = 4).	Copper__CuL2__no_interaction	salicylaldehyde__CuL2__no_interaction	p-hydroxybenzaldehyde__CuL2__no_interaction	p-carboxybenzaldehyde__CuL2__no_interaction
3429789-5	Gonadotropin and <compound-id="896">melatonin</compound-id> excretions correlated positively (first 13 days <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, r = 0.828; <compound-id="7021454">rs</compound-id> = 0.815 and LH, r = 0.816; <compound-id="7021454">rs</compound-id> = 0.905, p less than 0.005 and subsequent 14 days <protein-id="P25440,X5CF57,A0A024RCR5">FSH</protein-id>, r = 0.607; <compound-id="7021454">rs</compound-id> = 0.685, p less than 0.025 and LH, r = 0.490, p less than 0.05; <compound-id="7021454">rs</compound-id> = 0.638, p less than 0.025).	melatonin__FSH__no_interaction	rs__FSH__no_interaction
22168209-1	A series of multinuclear <compound-id="23978">Copper</compound-id>(I) guanidinate complexes have been synthesized in a succession of reactions between <compound-id="62652">CuCl</compound-id> and the <compound-id="3028194">lithium</compound-id> guanidinate systems Li{L} (L = Me(2)NC((i)<protein-id="Q9H6Q4">PrN</protein-id>)(2) (1a), Me(2)NC(<compound-id="12358846,5316647,54610010">CyN</compound-id>)(2) (1b), Me(2)NC((t)BuN)(2)(1c), and Me(2)NC(<compound-id="40828">DipN</compound-id>)(2) (2d) ((i)Pr = iso-propyl, Cy = cyclohexyl, (t)Bu = <compound-id="6360,90937099">tert-butyl</compound-id>, and Dip = 2,6-disopropylphenyl) made in situ, and structurally characterized.	Copper__PrN__no_interaction	tert-butyl__PrN__no_interaction	CuCl__PrN__no_interaction	DipN__PrN__no_interaction	lithium__PrN__no_interaction	CyN__PrN__no_interaction
24455256-5	In the whole group NEADLS score was correlated with age (rho: -0.759, P &lt; 0.0001), clinical systolic blood pressure (rho: -0.212, P: 0.018), blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (rho: -0.516, P &lt; 0.0001), <compound-id="588">creatinine</compound-id> (rho: -0.501, P &lt; 0.0001), <compound-id="1175">uric acid</compound-id> (rho: -0.308, P &lt; 0.0001), <protein-id="P02768">albumin</protein-id> (rho: 0.382, P &lt; 0.0001), total <compound-id="5997">cholesterol</compound-id> (rho: -0.194, P: 0.022), LDL-<compound-id="5997">cholesterol</compound-id> (rho: -0.230, P: 0.008), hemoglobin (rho: 0.256, P: 0.002), <compound-id="588">creatinine</compound-id> clearance (rho: 0.565, P &lt; 0.0001), 24-hour urinary protein excretion (rho: -0.324, P &lt; 0.0001), and 24-hour urinary <protein-id="P02768">albumin</protein-id> excretion (UAE) (rho: -0.483, P &lt; 0.0001).	creatinine__albumin__no_interaction	urea__albumin__no_interaction	uric acid__albumin__no_interaction	nitrogen__albumin__no_interaction	cholesterol__albumin__no_interaction
11561214-5	For the hormones measured, differences (p &lt; 0.05) between conditions at rest were noted for plasma renin activity (PRA) (0.62 +/- 0.09 vs. 5.61 +/- 0.94 ng/ml/h), angiotensin I (<protein-id="Q15389">ANG 1</protein-id>) (0.26 +/- 0.03 vs. 0.56 +/- 0.08 ng/ml), <compound-id="5839">aldosterone</compound-id> (ALD) (143 +/- 14 vs. 1603 +/- 302 pg/ml), <protein-id="P01185,X5DQP6">arginine vasopressin</protein-id> (<protein-id="P01185,X5DQP6">AVP</protein-id>) (4.13 +/- 1.1 vs. 9.58 +/- 1.6 pg/ml) and atrial natriuretic peptide (alpha-ANP) (11.5 +/- 2.8 vs. 6.33 +/- 1.0 pg/ml).	aldosterone__AVP__no_interaction	aldosterone__arginine vasopressin__no_interaction	aldosterone__ANG 1__no_interaction
23598368-1	The reaction kinetics between <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> and <compound-id="21490611">trihexyl(tetradecyl)</compound-id><compound-id="5460504">phosphonium</compound-id> ([P66614])-based ionic liquids (ILs) with <compound-id="614">prolinate</compound-id> ([Pro]), 2-cyanopyrrolide ([2-CNpyr]), and 3-(<compound-id="6373">trifluoromethyl</compound-id>)pyrazolide ([3-CF3pyra]) anions are studied at temperatures from 22-60 °C.	trifluoromethyl__CO2__no_interaction	prolinate__CO2__no_interaction	trihexyl(tetradecyl)__CO2__no_interaction	phosphonium__CO2__no_interaction
22233423-8	PCOS women with <compound-id="445607">ATH</compound-id> had higher waist-to-hip ratio (WHR) (0·80 [0·75-0·88] vs 0·78 [0·73-0·85], P = 0·046), <compound-id="206,5793,64689,79025">glucose</compound-id> 2 h (5·28 [4·57-6·33] mmol/l vs 5·67 [4·68-6·78] mmol/l, P = 0·037), <protein-id="Q99250">HbA1c</protein-id> (5·2 [5·0-5·4]%vs 5·1 [5·0-5·3]%, P = 0·009), parathyroid hormone (3·72(2·91-4·86] pmol/l vs 3·61 [2·94-4·63] pmol/l, P = 0·030) and Ferriman-Gallwey-Scores (FG Scores) (7 [3-12] vs 4 [1-9], P = 0·002) and lower 25(OH)D levels (54·4 [35·2-80·6] nmol/l vs 68·4 [49·7-89·4] nmol/l, P &lt; 0·001) than PCOS women without <compound-id="445607">ATH</compound-id>.	ATH__HbA1c__no_interaction	glucose__HbA1c__no_interaction
19011165-3	In isometric rings of rabbit artery, the PKC inhibitors, Go-6983 (3-[1-[3-(dimethylamino)propyl]-5-<compound-id="41160">methoxy-1H-indol-3-yl</compound-id>]-<compound-id="9877762">4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione</compound-id>), <compound-id="2396">GF-109203X</compound-id> (2-[<compound-id="88721">1-(3-dimethylaminopropyl)indol-3-yl</compound-id>]-3-(indol-3-yl) <compound-id="10935">maleimide</compound-id>), and a cell-permeable (myristoylated) pseudosubstrate inhibitor of PKCzeta (PI(PKCzeta)) inhibited KCl-induced tonic F. A myristoylated pseudosubstrate inhibitor of <protein-id="P10102">PKCalpha</protein-id>/beta that inhibited <compound-id="37783">phorbol dibutyrate</compound-id>-induced F slightly potentiated KCl-induced tonic F and attenuated 30 mM KCl-induced F. Although the <compound-id="5711">ROCK inhibitor</compound-id>, H-1152 [(S)-(+)-2-methyl-1-[(4-methyl-5-<compound-id="333903,57417047">isoquinolinyl</compound-id>)-sulfonyl]-<compound-id="68163">hexahydro-1H-1,4-diazepine</compound-id> dihydrochloride], reduced basal phosphorylation of myosin light-chain phosphatase-targeting subunit at Thr853 (MYPT1-pT853), 3 and 10 muM <compound-id="2396">GF-109203X</compound-id> inhibited only KCl-stimulated phosphorylation, not basal MYPT1-pT853.	isoquinolinyl__PKCalpha__no_interaction	hexahydro-1H-1,4-diazepine__PKCalpha__no_interaction	ROCK inhibitor__PKCalpha__no_interaction	GF-109203X__PKCalpha__no_interaction	1-(3-dimethylaminopropyl)indol-3-yl__PKCalpha__no_interaction	maleimide__PKCalpha__no_interaction	methoxy-1H-indol-3-yl__PKCalpha__no_interaction	4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione__PKCalpha__no_interaction	phorbol dibutyrate__PKCalpha__no_interaction
23646232-12	In contrast, in group II, when compared with group III, there was a significant increase in serum <protein-id="P41159,A4D0Y8">leptin</protein-id> and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (35.17 ± 1.06 ng/mL vs 10.69 ± 0.84 ng/mL, P &lt; 0.001, and 436 ± 9.75 pg /mL vs 342.4 ± 44.48 pg/mL, P &lt; 0.05, respectively), while there was no significant difference between both groups regarding serum <compound-id="588">creatinine</compound-id> (0.83 ± 0.34 vs 0.89 ± 0.24, P &gt; 0.05).	creatinine__leptin__no_interaction	creatinine__adiponectin__no_interaction
21519277-8	As expected, compared to female sex, male sex showed higher total/HDL-<compound-id="5997">cholesterol</compound-id> ratio (3.642 ± 0.99 vs. 3.329 ± 0.89, P = 0.017) and lower HDL-<compound-id="5997">cholesterol</compound-id> (1.221 ± 0.24 vs. 1.343 ± 0.28 mmol/l, P = 0.001), <protein-id="P02647,A0A024R3E3">Apo A-I</protein-id> (1.390 ± 0.20 vs. 1.474 ± 0.23 g/l, P = 0.003) concentrations and <protein-id="P02647,A0A024R3E3">Apo A-I</protein-id>/Apo B ratio (1.632 ± 0.49 vs. 1.830 ± 0.66, P = 0.016).	cholesterol__Apo A-I__no_interaction
2011075-3	Mean fasting plasma high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) was significantly higher by 12% +/- 4% (0.97 +/- 0.08 v 0.89 +/- 0.08 mmol/L, P less than .01), whereas mean total <compound-id="5997">cholesterol</compound-id> (TC) was lower by 6.5% +/- 1.3% (5.7 +/- 0.3 v 6.1 +/- 0.3 mmol/L, P less than .001), mean <protein-id="Q14746,B1ALW7">low-density lipoprotein-cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) lower by 6.4% +/- 2.0% (4.5 +/- 0.2 v 4.8 +/- 0.2 mmol/L, P less than .02), mean total triglycerides (TG) lower by 23% +/- 5% (1.7 +/- 0.1 v 2.4 +/- 0.3 mmol/L, P less than .02), and mean high versus low protein diet.	cholesterol__low-density lipoprotein-cholesterol__no_interaction	cholesterol__LDL-C__no_interaction
16734562-3	In 40 Iranian healthy subjects, cytokine single nucleotide polymorphisms (SNPs) were used to determine allelic and genotypic frequencies for the following cytokine genes: <protein-id="P01583">interleukin-1alpha</protein-id> (<protein-id="P01583">IL-1alpha</protein-id>) (T/C -889), <protein-id="P01584">IL-1beta</protein-id> (C/T -511, T/C +3962), IL-12 ( C/A-1188), <protein-id="P01579">interferon-gamma (IFN-gamma</protein-id>) (A/T UTR 5644), transforming growth factor-beta (TGF-beta) (C/T codon 10, G/C codon 25), <protein-id="P01375,Q5STB3">tumor necrosis factor alpha</protein-id> (<protein-id="P01375,Q5STB3">TNF-alpha</protein-id>) (G/A -308, G/A -238), <protein-id="P60568,Q0GK43">IL-2</protein-id> (T/G -330, G/T +166), <protein-id="P05112,D4HNR6,Q5FC01">IL-4</protein-id> (T/G -1089, T/C -590, T/C -33), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6 (G/C -174</protein-id>, G/A nt565), <protein-id="P22301,Q6FGW4">IL-10</protein-id> (G/A -1082, C/T -819, C/A -592), IL-1R (C/T pst11970), <protein-id="P14778,B8ZZW4">IL-1RA</protein-id> (T/C <compound-id="120308">mspa</compound-id> 111100), <protein-id="P24394,B2RBY1">IL-4RA</protein-id> (G/A +1902).	mspa__IL-6 (G/C -174__no_interaction	mspa__IL-4RA__no_interaction	mspa__IL-4__no_interaction	mspa__interleukin-1alpha__no_interaction	mspa__IL-2__no_interaction	mspa__interferon-gamma (IFN-gamma__no_interaction	mspa__IL-1beta__no_interaction	mspa__IL-10__no_interaction	mspa__IL-1alpha__no_interaction	mspa__tumor necrosis factor alpha__no_interaction	mspa__TNF-alpha__no_interaction	mspa__IL-1RA__no_interaction
21252482-9	No significant change of <compound-id="6013">testosterone</compound-id> (4.21 ± 1.49 vs. 4.00 ± 1.48 ng/ml, p = 0.46), free <compound-id="6013">testosterone</compound-id> (9.01 ± 3.64 vs. 8.85 ± 3.04 pg/ml, p = 0.83), <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SHBG</protein-id> (38 ± 14.39 vs. 38.5 ± 17.23 nmol/l, p = 0.71), calculated free <compound-id="6013">testosterone</compound-id> (0.091 ± 0.13 vs. 0.067 ± 0.026, p = 0.563), and bioavailable <compound-id="6013">testosterone</compound-id> (1.89 ± 0.722 vs. 1.88 ± 0.53, p = 0.912) was observed.	testosterone__SHBG__no_interaction
17500540-8	Our estimated VIPs values calculated by G3 theory (in eV) are <protein-id="P01282">VIP</protein-id> ((E)-<compound-id="6432229">CHCl</compound-id>=CFCl) = 9.89, <protein-id="P01282">VIP</protein-id> ((Z)-<compound-id="6432229">CHCl</compound-id>=CFCl) = 9.90, <protein-id="P01282">VIP</protein-id> ((E)-CFCl=CHF)= 10.26, <protein-id="P01282">VIP</protein-id> ((Z)-CFCl=CHF) = 10.25, <protein-id="P01282">VIP</protein-id> ((E)-CFCl=CFCl) = 9.93, <protein-id="P01282">VIP</protein-id> ((Z)-CFCl=CFCl) = 9.96, <protein-id="P01282">VIP</protein-id> (<protein-id="P13500">CCl2</protein-id>=CFCl) = 9.71, <protein-id="P01282">VIP</protein-id> (<protein-id="Q15904,A0A0C4DGX8">CF2</protein-id>=<compound-id="6432229">CHCl</compound-id>) = 10.19, <protein-id="P01282">VIP</protein-id> (CHF=<protein-id="P13500">CCl2</protein-id>) = 9.96, <protein-id="P01282">VIP</protein-id> (CH2=CFCl) = 10.32, <protein-id="P01282">VIP</protein-id> ((Z)-<compound-id="6432229">CHCl</compound-id>=CHF) = 10.16, and <protein-id="P01282">VIP</protein-id> ((E)-<compound-id="6432229">CHCl</compound-id>=CHF) = 10.16.	CHCl__CCl2__no_interaction	CHCl__VIP__no_interaction	CHCl__CF2__no_interaction
16873605-5	In aorta, <protein-id="P80511">CGRP</protein-id>((8-37)), [N-alpha-benzoyl]human alpha-<protein-id="P80511">CGRP</protein-id>((8-37)) [<compound-id="9413">bzl</compound-id>-<protein-id="P80511">CGRP</protein-id>((8-37))], and [N-alpha-benzoyl-His(10)-benzyl]human alpha-<protein-id="P80511">CGRP</protein-id>((8-37)) [<compound-id="9413">bzl</compound-id>-bn-<protein-id="P80511">CGRP</protein-id>((8-37))] caused rightward shifts in the concentration-response relaxation curve for <protein-id="P80511">CGRP</protein-id> with K(B) values of 1000, 88, and 50 nM, respectively.	bzl__CGRP__no_interaction
21682757-9	RESULTS: Multiple of upper limit of normal (xULN) of <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> (0·23 (0·09-0·4) vs 0·71 (0·4-1·04), P &lt; 0·01), WHR (0·98 (0·86-1·04) vs 1·01 (0·86-1·05), P &lt; 0·05) and <compound-id="44576256">ghrelin</compound-id> levels [119·8 ng/l (67·7-266·6) vs 137 ng/l (67-289·5), P &lt; 0·05] were significantly higher, whereas fat mass (FM) [34·7% (20·4-49·2) vs 32·4% (16·7-48·5), P &lt; 0·05] and <protein-id="P41159,A4D0Y8">leptin</protein-id> [11·2 μg/l (3·3-55·7) vs 7·05 μg/l (2·4-54·3), P &lt; 0·05] were significantly lower at study end.	ghrelin__leptin__no_interaction	ghrelin__IGF-I__no_interaction
20576202-6	RESULTS: The urinary level of each <compound-id="962">water</compound-id>-soluble vitamin was correlated positively to its mean intake in the past 2-4 d (<compound-id="1130">vitamin B1</compound-id>: r = 0·42, P &lt; 0·001; <compound-id="493570">vitamin B2</compound-id>: r = 0·43, P &lt; 0·001; <compound-id="1054">vitamin B6</compound-id>: r = 0·49, P &lt; 0·001; <compound-id="938">niacin</compound-id>: r = 0·32, P &lt; 0·001; <compound-id="938">niacin</compound-id> equivalents: r = 0·32, P &lt; 0·001; pantothenic acid: r = 0·32, P &lt; 0·001; <compound-id="6037">folic acid</compound-id>: r = 0·27, P &lt; 0·01; <compound-id="54670067">vitamin C</compound-id>: r = 0·39, P &lt; 0.001), except for vitamin <protein-id="O43676,A0A024R413">B12</protein-id> (r = 0·10, P = NS).	niacin__B12__no_interaction	vitamin B2__B12__no_interaction	water__B12__no_interaction	vitamin B1__B12__no_interaction	vitamin B6__B12__no_interaction	vitamin C__B12__no_interaction	folic acid__B12__no_interaction
22362817-4	Treatment with the NO-donating <compound-id="60823">atorvastatin</compound-id> NCX 6560 (11.7 mg/kg) was significantly more effective than <compound-id="60823">atorvastatin</compound-id> (10 mg/kg) in reducing the following parameters: lipid-rich lesions in the aortic arch (surface covered: <compound-id="60823">atorvastatin</compound-id> = 24 ± 5%; NCX 6560 = 14.7 ± 3.9%; P&lt; 0.05); the production of radical <compound-id="977">oxygen</compound-id> species in the aorta (<compound-id="64944">dichlorofluorescein</compound-id> fluorescence intensity per milligram of protein: <compound-id="60823">atorvastatin</compound-id> = 2419 ± 136.7; NCX 6560 = 1766 ± 161.2; P&lt; 0.05); femoral artery intima/media thickness (<compound-id="60823">atorvastatin</compound-id> = 1.2 ± 0.11; NCX 6560 = 0.3 ± 0.14; P&lt; 0.05); circulating <protein-id="P08505,A2RTD1">interleukin-6</protein-id> (<compound-id="60823">atorvastatin</compound-id> = 34.3 ± 6.8 pg/mL; NCX 6560 = 17.7 ± 14.4 pg/mL; P&lt; 0.05); and <protein-id="P33434,Q3UG07">matrix metalloproteinase 2</protein-id> in the arterial wall (<compound-id="60823">atorvastatin</compound-id> = 55.2 ± 1.9 ng/µg of proteins; NCX 6560 = 45.8 ± 2.6 ng/µg of proteins; P &lt; 0.05).	atorvastatin__interleukin-6__no_interaction	atorvastatin__matrix metalloproteinase 2__no_interaction	dichlorofluorescein__interleukin-6__no_interaction	dichlorofluorescein__matrix metalloproteinase 2__no_interaction	oxygen__interleukin-6__no_interaction	oxygen__matrix metalloproteinase 2__no_interaction
8198931-7	) kinetic parameters for the N-demethylation and 2-hydroxylation of <compound-id="3696">imipramine</compound-id> derived from a two-enzyme kinetic analysis were: <compound-id="56643075">Km1</compound-id> = 1.1 +/- 0.4 and 1.6 +/- 0.6 microM, Vmax1 = 0.11 +/- 0.03 and 0.15 +/- 0.07 nmol <protein-id="Q9HC84">mg-1 min-1</protein-id>, and Vmax1/<compound-id="56643075">Km1</compound-id> = 0.10 +/- 0.02 and 0.09 +/- 0.04 ml <protein-id="Q9HC84">mg-1 min-1</protein-id>; Km2 = 214 +/- 84 and 257 +/- 148 microM, Vmax2 = 2.22 +/- 0.69 and 0.53 +/- 0.15 nmol <protein-id="Q9HC84">mg-1 min-1</protein-id>, and Vmax2/Km2 = 0.011 +/- 0.001 and 0.003 +/- 0.002 ml <protein-id="Q9HC84">mg-1 min-1</protein-id>.	imipramine__mg-1 min-1__no_interaction	Km1__mg-1 min-1__no_interaction
17217690-4	RESULTS: The levels of serum <protein-id="P14555,A0A024RA96">sPLA2</protein-id> [(68 +/- 17) U/ml], <protein-id="P10145,A0A024RDA5">IL-8</protein-id> [(182 +/- 80) pg/ml] and LPA [(2.85 +/- 0.36) micromol/L] were significantly higher in <compound-id="221493">CHD</compound-id> patients than those in controls [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (55 +/- 12) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (119 +/- 33) pg/ml; LPA: (2.34 +/- 0.36) micromol/L, all P &lt; 0.01], and <protein-id="P14555,A0A024RA96">sPLA2</protein-id> and <protein-id="P10145,A0A024RDA5">IL-8</protein-id> were also significantly higher in ACS patients [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (71 +/- 18) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (195 +/- 78) pg/ml] than those in <compound-id="3009355">SCHD</compound-id> patients [<protein-id="P14555,A0A024RA96">sPLA2</protein-id>: (63 +/- 12) U/ml; <protein-id="P10145,A0A024RDA5">IL-8</protein-id>: (159 +/- 79) pg/ml, both P &lt; 0.01].	SCHD__sPLA2__no_interaction	SCHD__IL-8__no_interaction	CHD__sPLA2__no_interaction	CHD__IL-8__no_interaction
23220477-2	To investigate the mechanism of this adaptation, muscle biopsies obtained before and ∼72 h after the last training bout were analyzed for mRNA levels of <compound-id="285703,6145931">prostaglandin</compound-id> (PG)/cyclooxygenase pathway enzymes and receptors [<compound-id="444899">arachidonic acid</compound-id> synthesis: cytosolic phospholipase A(2) (cPLA(2)) and secreted phospholipase A(2) (sPLA(2)); PGF(2α) synthesis: PGF(2α) synthase and PGE(2) to PGF(2α) reductase; PGE(2) synthesis: PGE(2) synthase-1, -2, and -3; PGF(2α) receptor and PGE(2) receptor-4], cytokines and myokines involved in skeletal muscle adaptation (TNF-α, IL-1β, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>, <protein-id="P10145,A0A024RDA5">IL-8</protein-id>, <protein-id="P22301,Q6FGW4">IL-10</protein-id>), and regulators of muscle growth [myogenin, <protein-id="P23409">myogenic regulatory factor-4</protein-id> (<protein-id="P23409">MRF4</protein-id>), myostatin] and atrophy [<protein-id="O43524">Forkhead box O3A</protein-id> (<protein-id="O43524">FOXO3A</protein-id>), <protein-id="Q969Q1">atrogin-1, muscle RING finger protein 1</protein-id> (<protein-id="Q969Q1">MuRF-1</protein-id>), inhibitory κB kinase β (IKKβ)].	arachidonic acid__IL-8__no_interaction	arachidonic acid__Forkhead box O3A__no_interaction	arachidonic acid__atrogin-1, muscle RING finger protein 1__no_interaction	arachidonic acid__IL-6__no_interaction	arachidonic acid__IL-10__no_interaction	arachidonic acid__MuRF-1__no_interaction	arachidonic acid__FOXO3A__no_interaction	arachidonic acid__MRF4__no_interaction	arachidonic acid__myogenic regulatory factor-4__no_interaction	prostaglandin__IL-8__no_interaction	prostaglandin__Forkhead box O3A__no_interaction	prostaglandin__atrogin-1, muscle RING finger protein 1__no_interaction	prostaglandin__IL-6__no_interaction	prostaglandin__IL-10__no_interaction	prostaglandin__MuRF-1__no_interaction	prostaglandin__FOXO3A__no_interaction	prostaglandin__MRF4__no_interaction	prostaglandin__myogenic regulatory factor-4__no_interaction
23294625-6	RESULTS: We observed a positive correlation of <protein-id="P23142,Q8NBH6">fibulin-1</protein-id> levels with age (r = 0.38; p = 0.033), glycated hemoglobin (r = 0.80; p = 0.003), <compound-id="588">creatinine</compound-id> (r = 0.35; p = 0.045), and <protein-id="P02675,V9HVY1">fibrinogen</protein-id> (r = 0.39; p = 0.027).	creatinine__fibrinogen__no_interaction	creatinine__fibulin-1__no_interaction
23246932-2	Optimum DLLME conditions (5 mL of <compound-id="962">water</compound-id> at pH=7.6, 20% (w/v) NaCl, 685 μL of CHCl₃ as extractant solvent, and 1250 μL of <protein-id="P35240,A0A024R1J9,A0A024R1J8,A0A024R1I0,A0A024R1F6,A0A024R1D9">ACN</protein-id> as disperser solvent) allowed the repeatable, accurate and selective determination of 11 sulfonamides (<compound-id="5333">sulfanilamide</compound-id>, <compound-id="23104500,5320">sulfacetamide</compound-id>, <compound-id="5215">sulfadiazine</compound-id>, <compound-id="5340">sulfathiazole</compound-id>, <compound-id="5327">sulfadimidin</compound-id>, <compound-id="5330">sulfamethoxypyridazine</compound-id>, <compound-id="17134">sulfadoxine</compound-id>, <compound-id="5329">sulfamethoxazole</compound-id>, <compound-id="5344">sulfisoxazole</compound-id>, <compound-id="5323">sulfadimethoxine</compound-id> and <compound-id="5338">sulfaquinoxaline</compound-id>) and 14 <compound-id="3036108">quinolones</compound-id> (<compound-id="4831">pipemidic acid</compound-id>, <compound-id="60651">marbofloxacin</compound-id>, <compound-id="3357">fleroxacin</compound-id>, <compound-id="149096">levofloxacin</compound-id>, <compound-id="51081">pefloxacin</compound-id>, <compound-id="2764">ciprofloxacin</compound-id>, <compound-id="3948">lomefloxacin</compound-id>, <compound-id="71335">danofloxacin</compound-id>, <compound-id="71188">enrofloxacin</compound-id>, <compound-id="56208">sarafloxacin</compound-id>, <compound-id="56206">difloxacin</compound-id>, <compound-id="152946">moxifloxacin</compound-id>, <compound-id="4628">oxolinic</compound-id> acid and <compound-id="3374">flumequine</compound-id>).	sulfathiazole__ACN__no_interaction	sarafloxacin__ACN__no_interaction	sulfadoxine__ACN__no_interaction	pipemidic acid__ACN__no_interaction	marbofloxacin__ACN__no_interaction	lomefloxacin__ACN__no_interaction	sulfamethoxazole__ACN__no_interaction	difloxacin__ACN__no_interaction	sulfamethoxypyridazine__ACN__no_interaction	sulfaquinoxaline__ACN__no_interaction	sulfadimethoxine__ACN__no_interaction	levofloxacin__ACN__no_interaction	enrofloxacin__ACN__no_interaction	sulfadiazine__ACN__no_interaction	pefloxacin__ACN__no_interaction	moxifloxacin__ACN__no_interaction	flumequine__ACN__no_interaction	danofloxacin__ACN__no_interaction	ciprofloxacin__ACN__no_interaction	water__ACN__no_interaction	fleroxacin__ACN__no_interaction	sulfisoxazole__ACN__no_interaction	sulfacetamide__ACN__no_interaction	oxolinic__ACN__no_interaction	sulfadimidin__ACN__no_interaction	sulfanilamide__ACN__no_interaction	quinolones__ACN__no_interaction
9309982-6	The numbers of <protein-id="P05113">IL-5</protein-id> mRNA copies relative to <protein-id="A5A3E0">beta-actin</protein-id> mRNA correlated with disease severity assessed by the Aas asthma score (r = 0.70, p = 0.01), baseline FEV1 (r = -0.94, p = 0.001), baseline peak expiratory flow rate (r = -0.77, p = 0.01), peak expiratory flow rate variability over 2 wk (r = 0.69, p = 0.028), and the <compound-id="774">histamine</compound-id> PC20 (r = -0.72, p = 0.018).	histamine__IL-5__no_interaction	histamine__beta-actin__no_interaction
17908053-6	The distribution of <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> genotypes in the Spanish population is the following: (a) Extensive Metabolizers (EM)(51.61%): *1/*1, 47.10%; and *1/*10, 4.52%; (b) Intermediate Metabolizers (IM)(32.26%): *1/*3, 1.95%; *1/*4, 17.42%; *1/*5, 3.87%; *1/*6, 2.58%; *1/*7, 0.75%; *10/*10, 1.30%; *4/*10, 3.23%; *6/*10, 0.65%; and *7/*10, 0.65%; (b) Poor Metabolizers (PM)(9.03%): *4/*4, 8.37%; and *5/*5, 0.65%; and (c) Ultrarapid Metabolizers (UM)(7.10%): *<compound-id="19935268">1xN</compound-id>/*1, 4.52%; *<compound-id="19935268">1xN</compound-id>/*4, 1.95%; and <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> gene duplications, 0.65%.	1xN__CYP2D6__no_interaction
1540242-1	The penetration of the <compound-id="57476835,60961">adenosine</compound-id> antagonists <compound-id="1917">8-cyclopentyl-1,3-dimethylxanthine</compound-id> (CPT), <compound-id="1329">8-cyclopentyl-1,3-dipropylxanthine</compound-id> (CPX), 8-(p-sulfophenyltheophylline (8-<protein-id="Q64692,Q53WR7,A0A087WRA0,Q6PAS1">PST</protein-id>), and 8-[4-[[[[(2-amino-<compound-id="23134249">ethyl</compound-id>)amino]carbonyl]methyl]oxy]phenyl]- <compound-id="169317">1,3-dipropylxanthine</compound-id> (<compound-id="5697">XAC</compound-id>) into mouse brain was determined using ex vivo binding and locomotor studies.	1,3-dipropylxanthine__PST__no_interaction	adenosine__PST__no_interaction	XAC__PST__no_interaction	8-cyclopentyl-1,3-dimethylxanthine__PST__no_interaction	8-cyclopentyl-1,3-dipropylxanthine__PST__no_interaction	ethyl__PST__no_interaction
6389747-6	Respective peak LH (micrograms/l) and <compound-id="6013">testosterone</compound-id> (nmol/l) responses to <protein-id="P01148">LHRH</protein-id> were as follows: 1 ng <protein-id="P01148">LHRH</protein-id> (3.0 +/- 0.7; 47.3 +/- 4.1); 5 ng <protein-id="P01148">LHRH</protein-id> (8.0 +/- 1.2; 52.8 +/- 6.2); 10 ng <protein-id="P01148">LHRH</protein-id> (11.1 +/- 2.3; 57.7 +/- 9.1); 50 ng <protein-id="P01148">LHRH</protein-id> (19.2 +/- 2.8; 47.9 +/- 8.6); 100 ng <protein-id="P01148">LHRH</protein-id> (19.1 +/- 4.7; 43.9 +/- 6.4).	testosterone__LHRH__no_interaction
16173912-8	Lifetime frequency of experienced violence was associated with higher basal <protein-id="Q10586">DBP</protein-id> (r = .33, p &lt; .05), HR (r = .33, p &lt; .05), and <compound-id="5754">cortisol</compound-id> (r = .53, p &lt; .00), and decreased <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id> (beta = -.27, p &lt; .05) and <protein-id="Q10586">DBP</protein-id> (beta = -.31, p &lt; .05) reactivity.	cortisol__DBP__no_interaction	cortisol__SBP__no_interaction
18602884-8	On the contrary, PB C-glucuronidating activity was detected by <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id>((1-132))/<compound-id="71297183">1A8</compound-id>((133-286)), <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id>((1-212))/<compound-id="71297183">1A8</compound-id>((213-286)), <protein-id="O60656,Q5DSZ5">UGT1A8((1-68))/1A9</protein-id>((69-286)), and <protein-id="O60656,Q5DSZ5">UGT1A8((1-68))/1A9</protein-id>((69-132))/<compound-id="71297183">1A8</compound-id>((133-286)) chimeras.	1A8__UGT1A8((1-68))/1A9__no_interaction	1A8__UGT1A9__no_interaction
23817569-4	We identified 16 shared susceptibility loci with association P&lt;5×10(-8), including 8 loci previously associated with asthma, as well as 4p14 near <protein-id="Q15399">TLR1</protein-id>, <protein-id="Q9Y2C9,B2R933">TLR6</protein-id> and <protein-id="Q9BXR5,A0A024R9W4">TLR10</protein-id> (rs2101521, P=5.3×10(-21)); 6p21.33 near <protein-id="P10321,O19617,Q6R739,Q95HC2">HLA-C</protein-id> and <protein-id="Q29983,A0A0G2JJ55,Q96QC4,A0A024RCL3">MICA</protein-id> (rs9266772, P=3.2×10(-12)); 5p13.1 near <protein-id="P35408,A0PJF5">PTGER4</protein-id> (rs7720838, P=8.2×10(-11)); 2q33.1 in <protein-id="Q15111">PLCL1</protein-id> (rs10497813, P=6.1×10(-10)), 3q28 in <compound-id="152192">LPP</compound-id> (rs9860547, P=1.2×10(-9)); 20q13.2 in <protein-id="Q13469,B5B2P4">NFATC2</protein-id> (rs6021270, P=6.9×10(-9)), 4q27 in <protein-id="Q96M93">ADAD1</protein-id> (rs17388568, P=3.9×10(-8)); and 14q21.1 near <protein-id="P55317">FOXA1</protein-id> and TTC6 (rs1998359, P=4.8×10(-8)).	LPP__FOXA1__no_interaction	LPP__NFATC2__no_interaction	LPP__HLA-C__no_interaction	LPP__PLCL1__no_interaction	LPP__TLR10__no_interaction	LPP__PTGER4__no_interaction	LPP__TLR1__no_interaction	LPP__TLR6__no_interaction	LPP__ADAD1__no_interaction	LPP__MICA__no_interaction
10671942-10	65, P &lt; 0.0001), fat mass (r = 0.51, P = 0.003), waist circumference (r = 0.64, P &lt; 0.0001), waist-to-hip ratio (r = 0.42, P = 0.01), <protein-id="P01308,I3WAC9">Insulin</protein-id> sensitivity (SI, r = - 0.61, P = 0.0001), <protein-id="P01308,I3WAC9">Insulin</protein-id> secretion (expressed as the acute <protein-id="P01308,I3WAC9">Insulin</protein-id> response to intravenous <compound-id="206,5793,64689,79025">glucose</compound-id>, AIRg) (r = 0.48, P = 0.006) and <protein-id="P41159,A4D0Y8">leptin</protein-id> concentration (r = 0.49, P = 0.004).	glucose__leptin__no_interaction	glucose__Insulin__no_interaction
14650355-5	Overweight adults with combined hyperlipidemia had significantly higher plasma levels of sICAM-1 (376.5 +/- 107.4 ng/mL vs 239.3 +/- 60.4 ng/mL; p &lt; 0.001), sE-<compound-id="4929">selectin</compound-id> (70.4 +/- 20.2 ng/mL vs 48.5 +/- 25.6 ng/mL; p = 0.005), sP-<compound-id="4929">selectin</compound-id> (228.2 +/- 88.6 ng/mL vs 123.1 +/- 45.3 ng/mL; p &lt; 0.001) and positive acute phase proteins <protein-id="P02763">ORM</protein-id> (0.82 +/- 0.16 g/L vs 0.64 +/- 0.20 g/L; p = 0.005), FBG (3.42 +/- 0.54 g/L vs 2.74 +/- 0.57 g/L; p = 0.037) and PAI-1 Ag (97.9 +/- 40.6 ng/mL vs 56.4 +/- 25.6 ng/mL; p &lt; 0.05), and a decrease of negative acute phase protein TRF (2.14 +/- 0.40 g/L vs 2.77 +/- 0.45 g/L; p &lt; 0.001) compared to the results in overweight non-hyperlipidemic controls.	selectin__ORM__no_interaction
15292311-8	We found no difference in hypercortisolemia or <protein-id="P01189,Q6FHC8">ACTH</protein-id> at diagnosis in males compared with females in the patients less than 18 yr of age [serum 0000 h cortisol, 510.5 +/- 75.2 vs. 415.6 +/- 63.7 nmol/liter (P = 0.52); plasma <protein-id="P01189,Q6FHC8">ACTH</protein-id>, 48.5 +/- 7.9 vs. 42.9 +/- 10.9 ng/liter (P = 0.54); percent suppression of serum cortisol during low dose <compound-id="5743">dexamethasone</compound-id> suppression test, 57.2 +/- 8.6% vs. 33.5 +/- 13.1% (P = 0.14); high dose <compound-id="5743">dexamethasone</compound-id> suppression test, 85.9 +/- 3.1% vs. 85.7 +/- 4.9% (P = 0.55); percent increase in cortisol after iv <protein-id="P06850">CRH</protein-id>, 180.3 +/- 15.3% vs. 189.9 +/- 20.3% (P = 0.67)].	dexamethasone__ACTH__no_interaction	dexamethasone__CRH__no_interaction
24034086-9	Compared with the saline treated EAE group, <protein-id="Q07456">UTI</protein-id> combined <compound-id="6741">methylprednisolone</compound-id> significantly increased expressions of <protein-id="P16330,Q3TYV5,Q3TYL9">CNP</protein-id> (1.14 ± 0.06 vs. 0.65 ± 0.04, P &lt; 0.001), <protein-id="P04370,Q5D096,Q542T4,Q3UGF3">MBP</protein-id> (1.28 ± 0.14 vs. 0.44 ± 0.17, P &lt; 0.001), and decreased expressions of proNGF (1.08 ± 0.10 vs. 2.32 ± 0.12, P &lt; 0.001), <protein-id="Q8CFT3">p75</protein-id> (1.13 ± 0.13 vs. 2.33 ± 0.17, P &lt; 0.001), and <protein-id="P29477">iNOS</protein-id> (1.05 ± 0.31 vs. 2.17 ± 0.13, P &lt; 0.001) proteins in EAE.	methylprednisolone__p75__no_interaction	methylprednisolone__UTI__no_interaction	methylprednisolone__MBP__no_interaction	methylprednisolone__CNP__no_interaction	methylprednisolone__iNOS__no_interaction
9175721-1	In this study, we determined whether the <protein-id="P30046,Q53Y51">DDT</protein-id> isomers p,p'-<protein-id="P30046,Q53Y51">DDT</protein-id> [1,1,1,-trichloro-<compound-id="19076">2,2-bis(p-chlorophenyl)ethane</compound-id>], o,p'-<protein-id="P30046,Q53Y51">DDT</protein-id> [1,1,1-trichloro-2(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="6324">ethane</compound-id>], and their metabolites p,p'-DDD [<compound-id="6294">1,1-dichloro-2,2-bis(p-chlorophenyl)ethane</compound-id>], <compound-id="4211">o,p'-DDD</compound-id> [1,1-dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="6324">ethane</compound-id>], p,p'-DDE [1,1,-dichloro-<compound-id="94775">2,2-bis(p-chlorophenyl)ethylene</compound-id>], <compound-id="246598">o,p'-DDE</compound-id> [1,1-dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)<compound-id="53675528,6325">ethylene</compound-id>], and p,p'-DDA [2,2-<compound-id="6730">bis(p-chlorophenyl)acetic acid</compound-id>], could bind to and transcriptionally activate the human <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor</protein-id> (hER).	ethylene__estrogen receptor__no_interaction	ethylene__DDT__no_interaction	bis(p-chlorophenyl)acetic acid__estrogen receptor__no_interaction	bis(p-chlorophenyl)acetic acid__DDT__no_interaction	1,1-dichloro-2,2-bis(p-chlorophenyl)ethane__estrogen receptor__no_interaction	1,1-dichloro-2,2-bis(p-chlorophenyl)ethane__DDT__no_interaction	2,2-bis(p-chlorophenyl)ethylene__estrogen receptor__no_interaction	2,2-bis(p-chlorophenyl)ethylene__DDT__no_interaction	2,2-bis(p-chlorophenyl)ethane__estrogen receptor__no_interaction	2,2-bis(p-chlorophenyl)ethane__DDT__no_interaction	ethane__estrogen receptor__no_interaction	ethane__DDT__no_interaction	o,p'-DDE__estrogen receptor__no_interaction	o,p'-DDE__DDT__no_interaction	o,p'-DDD__estrogen receptor__no_interaction	o,p'-DDD__DDT__no_interaction
15870635-4	RESULTS: 1) Pole force pattern with initial impact force peak and the following active force peak (<compound-id="70387">PPF</compound-id>) correlated to V85%, (r = 0.66, P &lt; 0.05); 2) active flexion-extension pattern in elbow, <protein-id="Q06141,Q53S56">hip</protein-id>, knee, and ankle joints with angle minima occurring around <compound-id="70387">PPF</compound-id>, correlated to <protein-id="Q06141,Q53S56">hip</protein-id> angle at pole plant (r = -0.89, P &lt; 0.01), minimum elbow angle (r = -0.71), and relative poling time (r = -0.72, P &lt; 0.05); 3) two different DP strategies (A and B), where strategy A (best skiers) was characterized by higher angular elbow- and <protein-id="Q06141,Q53S56">hip</protein-id>-flexion velocities, smaller minimum elbow (P &lt; 0.01) and <protein-id="Q06141,Q53S56">hip</protein-id> angles (P &lt; 0.05), and higher <compound-id="70387">PPF</compound-id> (P &lt; 0.05); 4) EMG activity in trunk and <protein-id="Q06141,Q53S56">hip</protein-id> flexors, shoulder, and elbow extensors, and several lower body muscles followed a specific sequential pattern with changing activation levels; and 5) EMG activity in lower body muscles showed DP requires more than upper body work.	PPF__hip__no_interaction
11126305-5	They also had a greater mean (+/- SD) difference between the lengths of their kidneys (29 +/- 10 vs 5 +/- 5 mm, P &lt; 0.001); greater systolic blood pressure (203 +/- 22 vs 174 +/- 25 mm Hg, P &lt; 0.005), plasma <protein-id="P00797">renin</protein-id> activity (17 +/- 19 vs 2 +/- 2 ng/mL/h, P = 0.005), and plasma aldosterone concentration (40 +/- 23 vs 11 +/- 10 ng/dL, P = 0.0001); and lower serum <compound-id="5462222">potassium</compound-id> levels (3.3 +/- 0.5 vs 3.8 +/- 0.5, P &lt;0.05).	potassium__renin__no_interaction
18247301-5	Although significant difference was not observed in the frequencies of <protein-id="P49789,A0A024R366">FHIT</protein-id> gene hypermethylation among patients with refractory anemia/refractory anemia with ringed sideroblasts (RA/RAS) (1/6, 16.7%), refractory anemia/refractory anemia with ringed sideroblasts (RCMD) and refractory cytopenia with multilineage dysplasia with ringed blasts (RCMD-<compound-id="7021454">RS</compound-id>) (6/19, 31.6%), refractory anemia with excess blasts-1 (RAEB-1) (7/11, 63.6%), refractory anemia with excess blasts-2 (RAEB-2) (4/7, 57.1%) and refractory anemia with excess blasts in transformation/acute myeloid leukemia (RAEBt/AML) (8/11, 72.7%)(chi-square=8.417, P=0.077), it was observed in patients in early stages (RA/RAS and RCMD) (7/25, 28.0%), advanced stages (RAEB-1 and RAEB-2)(11/18, 61.1%) and RAEBt/AML (8/11, 72.7%) (chi-square=7.938, P=0.019).	RS__FHIT__no_interaction
22564192-5	Treatment of 1 with <compound-id="23978">copper</compound-id> halides in 1:1 molar ratio resulted in the formation of one-dimensional (1D) coordination polymers, [(<protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id>){1,3-C(6)H(4){OP(μ-N(t)Bu)(2)PN(H)(t)Bu} }(2)](n) (7, X = Cl; 8, X = Br; 9, X = I), which showed the helical structure in solid state because of intramolecular <compound-id="783">hydrogen</compound-id> bonding, whereas similar reactions of 1 with 4 equiv of <compound-id="23978">copper</compound-id> halides also produced 1D-coordination polymers, [(Cu(2)X(2))(2){1,3-C(6)H(4){OP(μ-N(t)Bu)(2)PN(H)(t)Bu}(2)}](n) (10, X = Cl; 11, X = Br; 12, X = I), but containing Cu(2)X(2) rhomboids instead of <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> linkers.	copper__CuX__no_interaction	hydrogen__CuX__no_interaction
21785763-5	Interestingly, the [Fe(HL)(DBC)](+) and [Fe(<protein-id="Q14204">HL3</protein-id>)(HDBC)X] adducts, generated by adding ∼1 equivalent of <compound-id="8082">piperidine</compound-id> to solutions containing equimolar quantities of <compound-id="23925,67172434">iron</compound-id>(III) complexes 1-5 and H(2)DBC (<compound-id="66099">3,5-di-tert-butylcatechol</compound-id>), display two DBC(2-)→ <compound-id="23925,67172434">iron</compound-id>(III) LMCT bands (λ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 1, 577, 905; 2, 575,915; 3, 586, 920; 4, 563, 870; 5, 557, 856 nm; Δλ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), 299-340 nm); however, the bands are blue-shifted (λ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>): 1, 443, 700; 2, 425, 702; 3, 424, 684; 4, 431, 687; 5, 434, 685 nm; Δλ(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>), 251-277 nm) on adding 1 more equivalent of <compound-id="8082">piperidine</compound-id> to form the adducts [Fe(L)(DBC)] and [Fe(<protein-id="Q14204">HL3</protein-id>)(HDBC)X].	piperidine__max__no_interaction	piperidine__HL3__no_interaction	3,5-di-tert-butylcatechol__max__no_interaction	3,5-di-tert-butylcatechol__HL3__no_interaction	iron__max__no_interaction	iron__HL3__no_interaction
19787836-10	Furthermore, the levels of serum <protein-id="P17246">TGFbeta1</protein-id>, <protein-id="P16599">TNF-alpha</protein-id> and <protein-id="P20607">IL-6</protein-id> were strikingly reduced in the <compound-id="64982">baicalin</compound-id>-treated group compared with the model group, while the production of <protein-id="P29456">IL-10</protein-id> was up-regulated: (<protein-id="P17246">TGF-beta1</protein-id>: 260.21 +/- 31.01 pg/mL vs 375.49 +/- 57.47 pg/mL; <protein-id="P16599">TNF-alpha</protein-id>: 193.40 +/- 15.18 pg/mL vs 260.04 +/- 37.70 pg/mL; <protein-id="P20607">IL-6</protein-id>: 339.87 +/- 72.95 pg/mL vs 606.47 +/- 130.73 pg/mL; <protein-id="P29456">IL-10</protein-id>: 506.22 +/- 112.07 pg/mL vs 316.95 +/- 62.74 pg/mL, P &lt; 0.01).	baicalin__TNF-alpha__no_interaction	baicalin__TGF-beta1__no_interaction	baicalin__IL-10__no_interaction	baicalin__IL-6__no_interaction	baicalin__TGFbeta1__no_interaction
9640062-6	Median 24 l of blood (24-36) was processed collecting: 10.3 x 10(8)/kg (6.69-18.8) WBC, 9.9 x 10(8)/kg (5.87-16.02) MNC, 9.72 x 10(6)/kg (0.74-18.98) CD34+ cells, 242.5 x 10(6)/kg (77.9-422) T lymphocytes (<protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>+ to <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>+ ratio was 1.5), 76 x 10(6)/kg (24-113) B lymphocytes, 33 x 10(6)/kg (14-88) NK cells and 168.8 x 104/kg (23.1-271.4) <compound-id="77620543">CFU</compound-id>-GM with 131.7 x 10(4)/kg (8.4-297.6) BFU-E. Engraftment times to a neutrophil count (ANC) &gt; 0.5 x 10(9)/l was achieved at a median of 15 days (range 10-23) in all patients whereas the platelet count &gt; 20 x 10(9)/l at a median of 14 days (9-19) in all but one patient who received the smallest dose of CD34+ cells.	CFU__CD4__no_interaction	CFU__CD8__no_interaction
8203337-3	Accordingly, we studied 36 patients with stable, moderate CHF in a double-blind, placebo-controlled, crossover fashion to evaluate by multiple discriminate regression analysis the pathophysiologic determinants of changes in blood pressure, glomerular filtration rate, and urinary <compound-id="5360545">sodium</compound-id> excretion after initial converting enzyme inhibition with <compound-id="44093">captopril</compound-id> 25 mg. A <compound-id="44093">captopril</compound-id>-mediated decrease in mean arterial pressure was predicted by 3 factors (r2 = 0.74): the decrease in serum <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin II</protein-id> (F ratio = 10.3, p &lt; 0.01), the decrease in plasma norepinephrine (F = 8, p = 0.02), and, inversely by pretreatment mean arterial pressure (F = 5.6, p = 0.04), patients with higher initial values exhibiting greater decreases in response to <compound-id="44093">captopril</compound-id>.	captopril__angiotensin II__no_interaction	sodium__angiotensin II__no_interaction
24753772-8	CA19-9 levels in the whole cohort were correlated with <protein-id="P05187,B2R7C7">ALP</protein-id> (r = 0.77, P &lt; 0.001), GGT (r = 0.83, P &lt; 0.001), <compound-id="5280352">bilirubin</compound-id> (r = 0.69, P &lt; 0.001), and CRP (r = 0.37, P = 0.004).	bilirubin__ALP__no_interaction
2173723-3	<compound-id="6371">Phosgene</compound-id> caused no increase in lung generation of cyclooxygenase metabolites and no elevation in pulmonary arterial pressure, but markedly increased transvascular fluid flux (delta W = 31 +/- 5 <compound-id="6371">phosgene</compound-id> vs. 8 +/- 1 g unexposed, P less than 0.001), permeability to <protein-id="P49065">albumin</protein-id> (125I-HSA) lung leak index 0.274 +/- 0.035 <compound-id="6371">phosgene</compound-id> vs. 0.019 +/- 0.001 unexposed, P less than 0.01; 125I-HSA lavage leak index 0.352 +/- 0.073 <compound-id="6371">phosgene</compound-id> vs. 0.008 +/- 0.001 unexposed, P less than 0.01), and lung <compound-id="10964">malondialdehyde</compound-id> (50 +/- 7 <compound-id="6371">phosgene</compound-id> vs. 24 +/- 0.7 mumol/g dry lung unexposed, P less than 0.01).	Phosgene__albumin__no_interaction	malondialdehyde__albumin__no_interaction	phosgene__albumin__no_interaction
11952361-3	X-ray crystal studies of these complexes 1-12, [Ca(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](PIC)(2).H(2)O (1), [Ca(HEEN)(PIC)](PIC) (2), Ba(<protein-id="Q86UF1">HPEN</protein-id>)(PIC)(2) (3), [Na(<protein-id="Q86UF1">HPEN</protein-id>)(PIC)](2) (4), Ca(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="8331">DNB</compound-id>)(2).H(2)O (5),Ca(HEEN)(H(2)O)](<compound-id="8331">DNB</compound-id>)(2).H(2)O (6), [Sr(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(3)](<compound-id="8331">DNB</compound-id>)(2) (7), [Ba(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="8331">DNB</compound-id>)(2).H(2)O](2) (8), [[Ba(HEEN)(H(2)O)(2)](ONB)(2)](2) (9), [[Sr(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="54058300,57080304,57201203">DNP</compound-id>)(2)](2) (10), [[Ba(<protein-id="Q86UF1">HPEN</protein-id>)(H(2)O)(2)](<compound-id="54058300,57080304,57201203">DNP</compound-id>)(2)](2) (11), and [Ca(HEEN)(<compound-id="54058300,57080304,57201203">DNP</compound-id>)](<compound-id="54058300,57080304,57201203">DNP</compound-id>) (H(2)O) (12), have been carried out at room temperature.	DNP__HPEN__no_interaction	DNB__HPEN__no_interaction
10404042-6	The data demonstrated that: 1) bone marrow- and hepatic-derived stromal/adherent cells support preB cell growth and regulate apoptosis induced by DMBA or B[a]P; 2) B[a]P is more effective than DMBA when preB cells are maintained on Hepa-1c1c7 monolayers than when maintained on BMS2 monolayers; 3) DMBA is more effective than B[a]P when preB cells are cultured on BMS2 monolayers; 4) alpha-naphthoflavone, an <protein-id="P30561,Q3U5D9">AhR</protein-id> antagonist and cytochrome P-450 inhibitor, blocks preB cell apoptosis in both BU-11/Hepa-1c1c7 and BU-11/BMS2 cultures; 5) although preB cells grow well in Hepa-1c1c7 or BMS2 supernatants, addition of <compound-id="2148">PAH</compound-id> in the absence of hepatic- or bone marrow-derived adherent cells does not result in preB cell apoptosis; 6) preB cell apoptosis is dependent on <protein-id="P30561,Q3U5D9">AhR</protein-id> activity in adherent hepatic- or bone marrow-derived stromal cells; and 7) apoptosis is induced by DMBA when preB cells are maintained on primary bone marrow stromal cell monolayers from wildtype but not from <protein-id="P30561,Q3U5D9">AhR</protein-id>-/- mice.	PAH__AhR__no_interaction
17950096-7	No significant differences were seen in the blood levels of <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (7814 +/- 870 vs 8090 +/- 967 ng/mL), <protein-id="P41159,A4D0Y8">leptin</protein-id> (961 +/- 122 vs 965 +/- 147 pmol/L), <protein-id="Q9HD89">resistin</protein-id> (11.7 +/- 1.0 vs 11.3 +/- 0.7 ng/mL), <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor 1</protein-id> activity (23.9 +/- 2.2 vs 25.1 +/- 2.2 U/mL), tumor necrosis factor alpha (1.35 +/- 0.11 vs 1.72 +/- 0.28 pg/mL), and high-sensitivity C-reactive protein (3.09 +/- 0.84 vs 2.09 +/- 0.42 mg/L) between treatment with <compound-id="2162">amlodipine</compound-id> 10 mg or <compound-id="3961">losartan</compound-id> 100 mg + <compound-id="2162">amlodipine</compound-id> 5 mg, respectively.	amlodipine__plasminogen activator inhibitor 1__no_interaction	amlodipine__leptin__no_interaction	amlodipine__resistin__no_interaction	amlodipine__adiponectin__no_interaction	losartan__plasminogen activator inhibitor 1__no_interaction	losartan__leptin__no_interaction	losartan__resistin__no_interaction	losartan__adiponectin__no_interaction
22449109-9	High hs-<protein-id="P02741">CRP</protein-id> was an independent risk factor for all-cause death (HR, 6.48; 95% CI, 1.41 to 29.8; P= 0.016), as well as history of atrial fibrillation (HR, 5.24; 95% CI, 1.83 to 15.0; P= 0.002), no statin therapy during hospitalization (HR, 4.56; 95% CI, 2.18 to 9.55; P &lt; 0.001), high <compound-id="778,91552">homocysteine</compound-id> (&gt;15.1 mmol/L) (HR, 2.66; 95% CI, 1.26 to 5.60; P= 0.01); fasting <compound-id="206,5793,64689,79025">glucose</compound-id> (&gt;6.1 mmol/L) (HR, 9.14; 95% CI, 3.34 to 25.0; P &lt; 0.001), NIHSS at admission (HR, 2.35; 95% CI, 1.35 to 4.09; P= 0.003) and history of coronary heart disease (<compound-id="221493">CHD</compound-id>) (HR, 2.34; 95% CI, 1.06 to 5.17; P= 0.035).	homocysteine__CRP__no_interaction	CHD__CRP__no_interaction	glucose__CRP__no_interaction
15206663-6	Consistent with previous reports, the correlation between total <compound-id="5073">risperidone</compound-id> level and <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> was very high (r = 0.92, df = 12, P &lt; 0.0001), but <compound-id="5073">risperidone</compound-id> did not appear to affect either <compound-id="6013">testosterone</compound-id> (r = 0.29, df = 5, P = 0.51) or free and weakly bound <compound-id="6013">testosterone</compound-id> (r = -0.11, df = 10, P = 0.72).	risperidone__PRL__no_interaction	testosterone__PRL__no_interaction
10711772-10	Age (r = 0.327, p &lt; 0.001), KITT (r = -0.201, p &lt; 0.01), fasting blood <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.187, p &lt; 0.01), LDL-chol (r = 0.201, p &lt; 0.01), smoking (r = 0.147, p &lt; 0.05), <protein-id="P02686,A0A024R384">MBP</protein-id> levels (r = 0.154, p &lt; 0.05), <compound-id="5997">cholesterol</compound-id> (r = 0.152, p &lt; 0.05) and HDL-chol (r = -0.159, p &lt; 0.05) were also significantly associated with <compound-id="447041">IMT</compound-id>.	cholesterol__MBP__no_interaction	IMT__MBP__no_interaction	glucose__MBP__no_interaction
23511286-6	<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin (IL)-6</protein-id> increased to a mean (± <compound-id="5289348">SEM</compound-id>) of 2.16 ± 0.61 to 3.81 ± 0.49 pg/mg (P &lt; .05), as did <protein-id="P10145,A0A024RDA5">IL-8</protein-id> (3.32 ± 0.76 to 20.51 ± 6.65 pg/mg; P &lt; .05), IL-12 (6.23±0.98 to 8.11±0.95pg/mg; P=0.01), <protein-id="P35225">IL-13</protein-id> (3.86 ± 0.32 to 11.83 ± 1.47 pg/mg; P &lt; .05), <protein-id="P13500">monocyte chemoattractant protein-1</protein-id> (2.78 ± 2.61 to 6.5 ± 3.97 pg/mg; P &lt; .05), <protein-id="P05164">MPO</protein-id> (13.41 ± 1.40 to 24.52 ± 4.31 units/mg protein; P &lt; .05), and elastase (2.46 ± 0.38 to 5.08 ± 0.72 pg/mL; P &lt; .05).	SEM__Interleukin (IL)-6__no_interaction	SEM__MPO__no_interaction	SEM__IL-8__no_interaction	SEM__IL-13__no_interaction	SEM__monocyte chemoattractant protein-1__no_interaction
11168785-6	RESULTS: The mean common carotid artery intima-media thickness (<compound-id="447041">IMT</compound-id>), but not the common femoral <compound-id="447041">IMT</compound-id>, correlated significantly with <compound-id="206,5793,64689,79025">glucose</compound-id> infusion rate (<compound-id="65911">GIR</compound-id>) (r = - 0.20, P &lt; 0.05), systolic blood pressure (r = 0.20, P &lt; 0.05), pulse pressure (r = 0.23 P &lt; 0.01), heart rate (r = 0.20, P &lt; 0.05), HDL <compound-id="5997">cholesterol</compound-id> (r = - 0.18, P &lt; 0.05), log triglycerides (r = 0.28, P &lt; 0.01), <protein-id="P02647,A0A024R3E3">apoA1</protein-id> (r = - 0.20, P &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (r = 0.21, P &lt; 0.05), LDL particle size (r = - 0.22, P &lt; 0.05) and plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> (r = 0.20, P &lt; 0.05).	cholesterol__apoB__no_interaction	cholesterol__apoA1__no_interaction	cholesterol__Insulin__no_interaction	IMT__apoB__no_interaction	IMT__apoA1__no_interaction	IMT__Insulin__no_interaction	GIR__apoB__no_interaction	GIR__apoA1__no_interaction	GIR__Insulin__no_interaction	glucose__apoB__no_interaction	glucose__apoA1__no_interaction	glucose__Insulin__no_interaction
1655340-4	Continuous intravenous infusion of two doses of synthetic rat <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id>, 300 ng/h per rat (0.10 pmol/h per rat) and 800 ng/h per rat (0.28 pmol/h per rat), attenuated the development of pulmonary hypertension in rats exposed to chronic hypoxia (fractional concentration of <compound-id="977">oxygen</compound-id> in inspired air = 10%) for 7 days: (i) the pulmonary artery pressure (mean +/- SD) in the vehicle-treated hypoxic group was 45 +/- 6 mmHg compared with 28 +/- 6 mmHg in the vehicle-treated normotoxic group (n = 8, P less than 0.001); (ii) treatment with <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id> in normoxia did not alter the pulmonary artery pressure, systemic blood pressure or heart rate; (iii) treatment with <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id> in hypoxia resulted in a lower pulmonary artery pressure in the group treated with 800 ng of <protein-id="P01161,B0BMW5">atrial natriuretic peptide</protein-id>/h per rat (38 +/- 8 mmHg, P less than 0.05 compared with the vehicle-treated hypoxic group) without affecting the systemic blood pressure or heart rate.	oxygen__atrial natriuretic peptide__no_interaction
23612925-1	A series of <compound-id="962">water</compound-id> soluble <compound-id="23978">copper</compound-id>(II) complexes of the types [Cu(L)Cl] 1-2, where LH is 2-(2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="535674">ethyliminomethyl</compound-id>)<compound-id="996">phenol</compound-id> (<protein-id="P07306,Q6FGQ5">H(L1</protein-id>)), and 2-(2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)-<compound-id="535674">ethyliminomethyl</compound-id>)-<compound-id="2879">4-methylphenol</compound-id> (<protein-id="Q9C0G6">H(L2</protein-id>)), and [Cu(L)<compound-id="24526">Cl2</compound-id>] 3-6, where L is (2-pyridin-2-yl-<compound-id="23134249">ethyl</compound-id>)pyridin-2-ylmethyleneamine (L3), 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="7523">ethylpyridin</compound-id>-2-yl-<compound-id="123139">methyleneamine</compound-id> (L4), 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="23134249">ethyl</compound-id>(<compound-id="795">1H-imidazol</compound-id>-2-ylmethylene)amine (L5), and 2-(<compound-id="5798">1H-benzimidazol</compound-id>-2-yl)<compound-id="23134249">ethyl</compound-id>-(4,4a-<compound-id="5231402">dihydroquinolin</compound-id>-2-ylmethylene)amine (L6), have been isolated and characterized by elemental analysis, electronic absorption, ESI-MS and EPR spectral techniques and the electrochemical method.	copper__H(L1__no_interaction	copper__H(L2__no_interaction	4-methylphenol__H(L1__no_interaction	4-methylphenol__H(L2__no_interaction	ethylpyridin__H(L1__no_interaction	ethylpyridin__H(L2__no_interaction	1H-imidazol__H(L1__no_interaction	1H-imidazol__H(L2__no_interaction	dihydroquinolin__H(L1__no_interaction	dihydroquinolin__H(L2__no_interaction	water__H(L1__no_interaction	water__H(L2__no_interaction	1H-benzimidazol__H(L1__no_interaction	1H-benzimidazol__H(L2__no_interaction	methyleneamine__H(L1__no_interaction	methyleneamine__H(L2__no_interaction	phenol__H(L1__no_interaction	phenol__H(L2__no_interaction	ethyliminomethyl__H(L1__no_interaction	ethyliminomethyl__H(L2__no_interaction	Cl2__H(L1__no_interaction	Cl2__H(L2__no_interaction	ethyl__H(L1__no_interaction	ethyl__H(L2__no_interaction
12503477-5	RESULTS: Markers of endothelial cell damage and coagulation activation were significantly elevated in patients with lung injury compared with controls: <protein-id="P04275">von Willebrand factor</protein-id> (<protein-id="P04275">vWF</protein-id>) 4.12 vs. 1.25 U/ml, p &lt; 0.0001; F VIII 4.40 vs. 1.88 U/ml, p = 0.0001; <protein-id="P00750">tissue-type plasminogen activator</protein-id> (<protein-id="P00750">tPA</protein-id>) 11.6 vs. 8.7 ng/ml, p = 0.02; <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor-1</protein-id> (<protein-id="P05121,A0A024QYT5">PAI</protein-id>) 48.9 vs. 14.6 ng/ml, p &lt; 0.0001; D-dimer 2.9 vs. 0.6 microgram/ml, p &lt; 0.0001; <compound-id="90470996">thrombin</compound-id>-antithrombin III complex (TAT) 7.9 vs. 2.2 ng/ml, p &lt; 0.0001 (median values; Mann-Whitney U-test).	thrombin__von Willebrand factor__no_interaction	thrombin__tPA__no_interaction	thrombin__plasminogen activator inhibitor-1__no_interaction	thrombin__tissue-type plasminogen activator__no_interaction	thrombin__PAI__no_interaction	thrombin__vWF__no_interaction
7532302-2	Isosmotic replacement of Na+ in the extracellular medium with the nonpermeant Na+ analogue choline+ or with <compound-id="206,5793,64689,79025">glucose</compound-id> led to a significant increase in anti-IgE- (1/5000: 43.7 +/- 7.3% in high Na+ vs 68.9 +/- 7.3% in low Na+, mean +/- <compound-id="5289348">SEM</compound-id>, n = 8, P &lt; 0.001), <protein-id="P21462">FMLP</protein-id>- (1 microM: 37.9 +/- 2.3% vs 49.5 +/- 4.3%, n = 8, P &lt; 0.01) and PMA-(160 nM: 12.7 +/- 0.9% vs 27.3 +/- 4.3%, n = 8, P &lt; 0.05) induced <compound-id="774">histamine</compound-id> release, whereas A23187-induced <compound-id="774">histamine</compound-id> release was reduced (1 microM: 90.4 +/- 2.4% vs 45.4 +/- 3.4%, n = 8, P &lt; 0.0001).	SEM__FMLP__no_interaction	histamine__FMLP__no_interaction	glucose__FMLP__no_interaction
15312156-9	The reductions in 24-h trough BP were more pronounced in <compound-id="2162">amlodipine</compound-id> compared with <compound-id="60846">valsartan</compound-id> group as well in office [SBP: -17.8 +/- 10.9 vs. -14.6 +/- 11.2, P = 0.025, <protein-id="Q10586">DBP</protein-id>: -12.7 +/- 7.2 vs. -10.9 +/- 7.8 mmHg, P = 0.06) as in ambulatory BP (SBP/<protein-id="Q10586">DBP</protein-id>: -13.0 +/- 13.7/-10.8 +/- 9.1 vs. -7.2 +/- 19.4/-4.9 +/- 13.4 mmHg, P &lt; 0.05).	amlodipine__DBP__no_interaction	valsartan__DBP__no_interaction
24107872-1	The treatment of the hydridorhodathiaboranes, [8,8,8-(H)(<protein-id="P24158">PR3</protein-id>)2-9-(Py)-nido-8,7-RhSB9H9], where <protein-id="P24158">PR3</protein-id> = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (2), PMePh2 (3), <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> and PMe2Ph (4), or <compound-id="68983">PMe3</compound-id> and <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (5), and [8,8,8-(H)(PMePh2)2-9-(PMePh2)-nido-8,7-RhSB9H9] (6), with <compound-id="62406">TfOH</compound-id> affords [8,8,8-(H)(<protein-id="P24158">PR3</protein-id>)2-9-(Py)-nido-8,7-RhSB9H10](+) cations, where <protein-id="P24158">PR3</protein-id> = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (12), PMePh2 (13), <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> and PMe2Ph (14), or <compound-id="68983">PMe3</compound-id> and <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> (15), and [8,8,8-(H)(PMePh2)2-9-(PMePh2)-nido-8,7-RhSB9H10](+) (16).	PMe3__PR3__no_interaction	PMe3__PPh3__no_interaction	TfOH__PR3__no_interaction	TfOH__PPh3__no_interaction
1573640-1	This paper describes the chemical synthesis and <protein-id="P32239">CCK-B</protein-id> and <protein-id="P32238">CCK-A receptor</protein-id> binding affinities of a series of compounds in which the central <compound-id="2826723">amide</compound-id> bond of the <protein-id="P32239">CCK-B</protein-id> "dipeptoid" ligand tricyclo[3.3.1.1(3,7)]dec-2-yl [R-(R*,S*)]-[2-[[1-(hydroxymethyl)- 2-phenylethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]carb amate (4) (<protein-id="P32239">CCK-B</protein-id> IC50 = 852 nM), and tricyclo[3.3.1.1(3,7)]dec-2-yl (R)-[1-(1H-indol-3-ylmethyl)-1-methyl- 2-oxo-2-[(2-phenylethyl)amino]<compound-id="23134249">ethyl</compound-id>]<compound-id="277">carbamate</compound-id> (23) (<protein-id="P32239">CCK-B</protein-id> IC50 = 32 nM) is replaced by 11 different <compound-id="2826723">amide</compound-id> replacements.	ethyl__CCK-B__no_interaction	ethyl__CCK-A receptor__no_interaction	carbamate__CCK-B__no_interaction	carbamate__CCK-A receptor__no_interaction	amide__CCK-B__no_interaction	amide__CCK-A receptor__no_interaction
24333775-3	In mice, C57Bl/6 males, intraplantar BoNT-B (1 U) given unilaterally into the hind paw had no effect upon survival or motor function, but ipsilaterally decreased: (1) intraplantar <compound-id="712">formalin</compound-id>-evoked flinching; (2) intraplantar <compound-id="2548">capsaicin-</compound-id>evoked plasma extravasation in the hind paw measured by <compound-id="5356750,6913958">Evans blue</compound-id> in the paw; (3) intraplantar <compound-id="712">formalin</compound-id>-evoked dorsal horn <protein-id="P41539,B7ZMQ2,Q149W7">substance P</protein-id> (SP) release (neurokinin 1 [NK1] receptor internalization); (4) intraplantar <compound-id="712">formalin</compound-id>-evoked dorsal horn neuronal activation (<protein-id="P01101">c-fos</protein-id>); (5) ipsilateral dorsal root ganglion (DRG) vesicle-associated membrane protein (<compound-id="90479729">VAMP</compound-id>); (6) ipsilateral SP release otherwise evoked bilaterally by intrathecal <compound-id="1548943">capsaicin</compound-id>; (7) ipsilateral activation of <protein-id="P01101">c-fos</protein-id> otherwise evoked bilaterally by intrathecal SP.	formalin__substance P__no_interaction	formalin__c-fos__no_interaction	capsaicin-__substance P__no_interaction	capsaicin-__c-fos__no_interaction	VAMP__substance P__no_interaction	VAMP__c-fos__no_interaction	capsaicin__substance P__no_interaction	capsaicin__c-fos__no_interaction	Evans blue__substance P__no_interaction	Evans blue__c-fos__no_interaction
12022998-12	The gallbladder responses were also greater when mice were treated with <protein-id="P57774">neuropeptide Y</protein-id> (10(-8) mol/L: 0.00 +/- 0.00 vs. 0.00 +/- 0.00, NS; 10(-7) mol/L: 0.12 +/- 0.02 vs. 0.05 +/- 0.01, P &lt; 0.01; 10(-6) mol/L: 0.26 +/- 0.08 vs. 0.06 +/- 0.01, P &lt; 0.01) and <compound-id="16129670">cholecystokinin</compound-id> (10(-10) mol/L: 0.27 +/- 0.04 vs. 0.13 +/- 0.02, P &lt; 0.01; 10(-9) mol/L: 0.59 +/- 0.08 vs. 0.27 +/- 0.04, P &lt; 0.01; 10(-8) mol/L: 0.80 +/- 0.11 vs. 0.37 +/- 0.05, P &lt; 0.01; 10(-7) mol/L: 0.86 +/- 0.11 vs. 0.44 +/- 0.06, P &lt; 0.01).	cholecystokinin__neuropeptide Y__no_interaction
22865637-1	A substituted <compound-id="5323619">2,6-bis(pyrazol-3-yl)pyridine</compound-id> (3-bpp) ligand, <protein-id="Q99525">H(4)L</protein-id>, created to facilitate intermolecular interactions in the solid, has been used to obtain four novel Fe(II) complexes: [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅2 CH(3)NO(2)⋅2 H(2)O, [Fe(<protein-id="Q99525">H(4)L</protein-id>)(H(2)<compound-id="479">LBF</compound-id>(2))](BF(4))⋅5 C(3)H(6)O (H(2)<compound-id="479">LBF</compound-id>(2) is an in situ modified version of <protein-id="Q99525">H(4)L</protein-id>), [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅2 C(3)H(7)OH and [Fe(<protein-id="Q99525">H(4)L</protein-id>)(2)](ClO(4))(2)⋅4 C(2)H(5)OH.	2,6-bis(pyrazol-3-yl)pyridine__H(4)L__no_interaction	LBF__H(4)L__no_interaction
16423635-5	Serum <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> level was negatively correlated to HOMA-IR (r = -0.288, P = .005), BMI (r = -0.308, P = .002), diastolic blood pressure (r = -0.269, P = .012), and triglycerides (r = -0.338, P &lt; .001), and positively correlated to high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.300, P = .003) in our patients.	cholesterol__adiponectin__no_interaction
14600946-12	RESULTS: Compared to control, no statistical differences in the levels of <protein-id="P16581">E-selectin</protein-id> (C--44.4 +/- 11 ng/ml) and <protein-id="P14151,A0A024R8Z0">L-selectin</protein-id> (C--842 +/- 168.9 ng/ml) were observed before treatment in the patients with GD (E-<compound-id="68294">sel</compound-id>.--59.8 +/- 19.6 ng/ml; L-<compound-id="68294">sel</compound-id>.--1288.2 +/- 273.5 ng/ml) and with TNG (E-<compound-id="68294">sel</compound-id>.--61.5 +/- 18.4 ng/ml, L-<compound-id="68294">sel</compound-id>.--1247.0 +/- 273.5 ng/ml) as well as in the 6th week after I-131 administration; values in GD group were: E-<compound-id="68294">sel</compound-id>.--57.3 +/- 19.5 ng/ml, L-<compound-id="68294">sel</compound-id>.--1142.4 +/- 193.4 ng/ml; in TNG group: E-<compound-id="68294">sel</compound-id>.--62.1 +/- 20.6 ng/ml, L-<compound-id="68294">sel</compound-id>.--1113.5 +/- 236.3 ng/ml.	sel__E-selectin__no_interaction	sel__L-selectin__no_interaction
8039152-3	The randomized comparisons are: (1) <compound-id="2733526">tamoxifen</compound-id> 2 years versus 5 years in postmenopausal stage I-II patients, (2) sequential <compound-id="2733526">tamoxifen</compound-id>/<compound-id="19090">megestrol</compound-id> in alternating 3 months cycles for 2 years versus <compound-id="2733526">tamoxifen</compound-id> alone for 2 years in <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor</protein-id> (ER)-positive, postmenopausal stage I-II patients, (3) <compound-id="2733526">tamoxifen</compound-id> for 2 years versus <compound-id="2733526">tamoxifen</compound-id>+<protein-id="P01148">LHRH</protein-id>-analogue for 2 years versus <protein-id="P01148">LHRH</protein-id>-analogue alone versus control in premenopausal stage I-II patients, (4) CMF chemotherapy versus radiological castration in ER-positive, premenopausal stage II patients, (5) high-dose chemotherapy+autologous bone marrow transplantation versus conventional chemotherapy in high-risk (pN6+) stage II patients aged under 60 years, (6) postoperative radiotherapy to the breast versus control after breast-conserving surgery for invasive stage I-II breast cancer, (7) postoperative radiotherapy to the breast versus control after breast-conserving surgery for ductal carcinoma in situ (DCIS), and (8) CMF- or FEC-chemotherapy plus APD (<compound-id="4674">pamidronate</compound-id>) versus the same chemotherapy without APD.	pamidronate__LHRH__no_interaction	pamidronate__estrogen receptor__no_interaction	tamoxifen__LHRH__no_interaction	tamoxifen__estrogen receptor__no_interaction	megestrol__LHRH__no_interaction	megestrol__estrogen receptor__no_interaction
10463551-8	Among moderate-risk patients with and without IAIs, those with IAIs were more likely to have abdominal abrasions (5/22 vs 34/459, p = 0.008), an abnormal chest examination (11/22 vs 86/457, p = 0.01), higher mean serum concentrations of <compound-id="5960">aspartate</compound-id> aminotransferase (<protein-id="Q9NRA2">AST</protein-id>) (604 U/L vs 77 U/L, p &lt; 0.001) and <compound-id="5950,602">alanine</compound-id> aminotransferase (ALT) (276 U/L vs 39 U/L, p = 0.002), higher mean white blood cell (WBC) counts (16.3 K/mm3 vs 12.8 K/mm3, p &lt; 0.001), and a higher prevalence of &gt;5 RBCs/hpf on urinalysis (7/22 vs 54/427, p = 0.02).	alanine__AST__no_interaction	aspartate__AST__no_interaction
20812749-1	<protein-id="P07954">MCl</protein-id>(3) react with o-C(6)H(4)(EMe)(2) (E = S, Se) or o-C(6)H(4)(CH(2)ER)(2) (E = S, R = Me or Et; E = Se, R = Me) in anhydrous CH(2)Cl(2) or <compound-id="6342">MeCN</compound-id> to give the yellow (Bi) or white (Sb) complexes, [<protein-id="P07954">MCl</protein-id>(3){o-C(6)H(4)(EMe)(2)}], [(<protein-id="P07954">MCl</protein-id>(3))(2){o-C(6)H(4)(CH(2)SMe)(2)}(3)], [<protein-id="P07954">MCl</protein-id>(3){o-C(6)H(4)(CH(2)SEt)(2)}], and [(BiCl(3))(4){o-C(6)H(4)(CH(2)SeMe)(2)}(3)], which were characterized by IR/Raman, (1)H NMR spectroscopy, and microanalysis.	MeCN__MCl__no_interaction
2581959-3	This conclusion is based on the following data: 1) <compound-id="5280723">prostaglandin E1</compound-id> (PGE1) activated and alpha 2-adrenergic treatment inhibited <compound-id="6083">adenylate</compound-id> cyclase activation in PMN plasma membranes; <compound-id="443295">fMet-Leu-Phe</compound-id>, however, neither activated nor inhibited <compound-id="6083">adenylate</compound-id> cyclase in these membranes; 2) depletion of extracellular Ca2+ had no effect on <compound-id="3779">isoproterenol</compound-id> and PGE1 elicited <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact PMNs while peak <compound-id="443295">fMet-Leu-Phe</compound-id> and <compound-id="40486">A23187</compound-id>-induced responses were reduced by approximately 50 and 80%, respectively; 3) 8-(N,N-diethylamino)-octyl-<compound-id="8357">3,4,5-trimethoxybenzoate</compound-id>, a purported Ca2+ antagonist, caused almost complete inhibition of <compound-id="443295">fMet-Leu-Phe</compound-id> and ionophore-induced <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact cells but had no effect on PGE1 and <compound-id="3779">isoproterenol</compound-id>; 4) alpha 2-adrenergic agonists inhibited PGE1 but not chemoattractant- or <compound-id="40486">A23187</compound-id>-elicited <protein-id="P49913,J3KNB4">cAMP</protein-id> responses in intact PMNs; and 5) pretreatment of cells with a phosphodiesterase inhibitor (isobutylmethylxanthine) greatly potentiated the PGE1 and <compound-id="3779">isoproterenol</compound-id> <protein-id="P49913,J3KNB4">cAMP</protein-id> responses but nearly abolished the peak <compound-id="443295">fMet-Leu-Phe</compound-id> response.	isoproterenol__cAMP__no_interaction	3,4,5-trimethoxybenzoate__cAMP__no_interaction	prostaglandin E1__cAMP__no_interaction	A23187__cAMP__no_interaction	adenylate__cAMP__no_interaction	fMet-Leu-Phe__cAMP__no_interaction
11601684-2	Reference intervals were established for three different times of the day: in morning samples (05.45-07.15) the limit of detection (LOD) was 2.10 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (82 women) and 2.86 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (37 men), and the reference interval was 3.6-29.1 micromol norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> and 2.3-52.8 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (119 women and men); in afternoon samples (15.30-18.30) the reference interval was 0.64-10.8 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (82 women), 1.20-11.2 micromol/<compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (36 men), 11.0-54.1 micromol/ norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> and LOD was 42.4 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (117 women and men); in evening samples (21.45-23.45) LOD was 8.66 micromol <compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (81 women) and 7.99 micromol/<compound-id="5816">epinephrine</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (36 men), the reference interval was 11.0-54.1 micromol norepinephrine/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id>, and LOD was 42.4 micromol <compound-id="5754">cortisol</compound-id>/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id> <compound-id="588">creatinine</compound-id> (117 women and men).	creatinine__mol__no_interaction	epinephrine__mol__no_interaction	cortisol__mol__no_interaction
22174545-8	The number of the apoptotic colonic epithelial cells in <compound-id="5494424">HPM</compound-id>, MWM and SASP groups was largely reduced (61.5 ± 16.91 vs 15.5 ± 8.89, 14.8 ± 6.27 and 24.7 ± 9.68, respectively (P = 0.001); and the expression of <protein-id="Q6P6T5">occludin</protein-id>, <protein-id="P56745">claudin-1</protein-id> and <protein-id="F1M4A0">ZO-1</protein-id> in the MWM and <compound-id="5494424">HPM</compound-id> groups was significantly enhanced (0.48 ± 0.10, 0.64 ± 0.09 vs 0.18 ± 0.05 for <protein-id="Q6P6T5">occludin</protein-id>, 0.12 ± 0.02, 0.17 ± 0.03 vs 0.05 ± 0.01 for <protein-id="P56745">claudin-1</protein-id>, and 0.08 ± 0.01, 0.11 ± 0.01 vs 0.02 ± 0.01 for <protein-id="F1M4A0">ZO-1</protein-id>).	HPM__occludin__no_interaction	HPM__ZO-1__no_interaction	HPM__claudin-1__no_interaction
15345837-1	The structures of three compounds, namely <compound-id="91407687">7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C19H11F3N2O2, (Id), <compound-id="91084899">6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C19H11F3N2O2, (<compound-id="6540267">IId</compound-id>), and <compound-id="91255250">2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one</compound-id>, C16H13F3N2O2, (IIf), which are potent reversible type-B monoamine oxidase (<protein-id="P27338,B7Z242">MAO-B</protein-id>) inhibitors, are presented and discussed.	IId__MAO-B__no_interaction	2-methyl-6-(4,4,4-trifluorobutoxy)-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction	6-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction	7-methoxy-2-[3-(trifluoromethyl)phenyl]-9H-indeno[1,2-c]pyridazin-9-one__MAO-B__no_interaction
17707803-7	In both male rats and mice, an increasing renal uptake was found: [(111)In-<compound-id="3053">DTPA</compound-id>]CCK8&lt;[(111)In-<compound-id="3053">DTPA</compound-id>-Pro(1),<compound-id="6057">Tyr</compound-id>(4)]bombesin approximately [(111)In-<compound-id="3053">DTPA</compound-id>]<protein-id="Q9D3P9">neurotensin</protein-id>&lt;[(111)In-<compound-id="3053">DTPA</compound-id>]<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id>&lt;&lt;[(111)In-<compound-id="3053">DTPA</compound-id>]MG0.	DTPA__neurotensin__no_interaction	Tyr__neurotensin__no_interaction	octreotide__neurotensin__no_interaction
16955257-3	The metabolites are products of: 1) monohydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 344, M20 and <compound-id="6431318">M21</compound-id>), <compound-id="798">indole</compound-id> ring (m/z 344, <compound-id="86287484">M17</compound-id> and <compound-id="24754814">M18</compound-id>), or the N-alkyl group (m/z 344, <compound-id="16044960">M14</compound-id>); 2) arene oxidation leading to dihydrodiols (m/z 362, M12 and <compound-id="16132126">M15</compound-id>); 3) dihydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 360, <compound-id="54884">M7</compound-id>) or <compound-id="798">indole</compound-id> ring (m/z 360, M13), resulting from a combination of monohydroxylations on both the <compound-id="931">naphthalene</compound-id> and <compound-id="798">indole</compound-id> rings (m/z 360, M16), or a combination of monohydroxylations on the <compound-id="931">naphthalene</compound-id> ring and on the N-propyl group (m/z 360, <compound-id="11400707">M9</compound-id>); 4) trihydroxylation (m/z 378, M1, M3, M4, M6, and <compound-id="76871900">M10</compound-id>); 5) N-dealkylation (m/z 286, <protein-id="Q9BRT2">M19</protein-id>); 6) N-dealkylation and monohydroxylation on the <compound-id="931">naphthalene</compound-id> ring (m/z 302, <compound-id="25021181">M11</compound-id>); 7) N-dealkylation and dihydrodiol formation from arene oxidation (m/z 320, M2 and M5); 8) dehydrogenation after monohydroxylation on the N-alkyl group (m/z 326, <compound-id="16045336">M22</compound-id>); 9) dehydrogenation and monohydroxylation on the <compound-id="798">indole</compound-id> ring (m/z 342, M8).	indole__M19__no_interaction	M21__M19__no_interaction	M22__M19__no_interaction	M11__M19__no_interaction	M10__M19__no_interaction	M7__M19__no_interaction	M15__M19__no_interaction	M14__M19__no_interaction	M17__M19__no_interaction	M18__M19__no_interaction	M9__M19__no_interaction	naphthalene__M19__no_interaction
1340881-4	Between 30 and 50 years of age, the prevalence of risk factors was greater in males than females; 27.3% of males vs 16.0 of females had CT &gt; or = 240 mg/dl (p &lt; 0.05), 30.5% vs 19.7%, had CLDL &gt; or = 160 mg/dl (p &lt; 0.05), 10.3% vs 5.9%, had <protein-id="Q86WJ1,B4DPN5,A0A0A0MRH8,A0A0A0MSH9,Q9H678">CHDL</protein-id> &lt; 35 mg/dl, 8.9% vs 4.2% had PS &gt; 145 mmHg, 9.0% vs 5.9%, had PD &gt; 90 mm Hg, 33.6% vs 23.4%, had <compound-id="118458">Cig</compound-id> &gt; or = 10/d (p &lt; 0.05), 26.0% vs 13.8% had TG &gt; 170 mg/dl (p &lt; 0.05), 30.5% vs 22.4%, had BMI &gt; 27 Kg/m2 (p &lt; 0.05) (Figs.	Cig__CHDL__no_interaction
20923925-13	Moreover, the cultured supernatant in CD-exposed cells contained significantly higher levels of <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">interleukin-6</protein-id> (4.09 ± 0.36 vs 2.73 ± 0.38 pg/mL, P &lt; 0.01, 24 h; 4.28 ± 0.32 vs 2.83 ± 0.32 pg/mL, P &lt; 0.01, 48 h) and tumour necrosis factor α (3.45 ± 0.79 vs 2.44 ± 0.39 pg/mL, P &lt; 0.05, 24 h; 4.60 ± 0.57 vs 2.50 ± 0.37 pg/mL, P &lt; 0.01, 48 h) than those of <compound-id="5459917,5280361">HPD</compound-id>.	HPD__interleukin-6__no_interaction
1495014-3	The cis-(2S,4R) isomer 2 was the most effective against rat <protein-id="Q64654">lanosterol 14 alpha-demethylase</protein-id>, (2S,4R)-2 greater than (2R,4S)-4 much greater than (2R,4R)-3 = (2S,4S)-5, and <compound-id="5994">progesterone</compound-id> 17 alpha,20-lyase, (2S,4R)-2 much greater than (2S,4S)-5 greater than (2R,4R)-3 = (2R,4S)-4, whereas the cis-(2R,4S) isomer 4 was more effective against <protein-id="P18125">cholesterol 7 alpha-hydroxylase</protein-id>, (2R,4S)-4 greater than (2S,4S)-5 greater than (2R,4R)-3, greater than (2S,4R)-2, and the trans-(2S,4S) isomer 5 was the most effective against aromatase, (2S,4R)-5 much greater than (2R,4R)-3 = (2R,4S)-4 greater than (2S,4R)-2.	progesterone__cholesterol 7 alpha-hydroxylase__no_interaction	progesterone__lanosterol 14 alpha-demethylase__no_interaction
10208256-2	In vitro -<protein-id="O00548">delta[HCO3-] x delta pH(-1</protein-id>) [nonbicarbonate buffer capacity (beta) of blood] was increased 7 days after descent [before 31.3 (<compound-id="5289348">SEM</compound-id> 0.4) mmol x kgH2O(-1), after 38.3 (<compound-id="5289348">SEM</compound-id> 3.9) mmol x kgH2O(-1); P&lt;0.05] resulting from an increased proportion of young erythrocytes; in additional experiments an augmented beta was found in young (low density cells) compared to old cells [&lt;1.097 g x ml(-1): 0.216 (<compound-id="5289348">SEM</compound-id> 0.028) mmol x gHb(-1), &gt;1.100 g x ml(-1): 0.145 (<compound-id="5289348">SEM</compound-id> 0.013) mmol x gHb(-1), where Hb is haemoglobin; P &lt; 0.02].	SEM__delta[HCO3-] x delta pH(-1__no_interaction
1750428-4	RESULTS: Compared with 78 control subjects, 70 offspring of essential hypertensive parents had similar age (mean +/- <compound-id="5289348">SEM</compound-id>: 24 +/- 1 versus 24 +/- 1 years, respectively) and body mass index (22.3 +/- 0.2 versus 22.4 +/- 0.2 kg/m2), a blood pressure of 127/77 +/- 1/1 versus 123/76 +/- 1/1 mm Hg (p less than 0.05 for systolic), and significantly elevated (p less than 0.01 to 0.001) fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> levels (9.9 +/- 0.3 versus 8.6 +/- 0.3 microU/mL), serum total triglycerides (1.03 +/- 0.06 versus 0.83 +/- 0.03 mmol/L), total <compound-id="5997">cholesterol</compound-id> (4.37 +/- 0.08 versus 3.93 +/- 0.07 mmol/L), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (2.45 +/- 0.08 versus 2.14 +/- 0.07 mmol/L), and total/high-density lipoprotein <compound-id="5997">cholesterol</compound-id> ratio (4.3 +/- 0.1 versus 3.7 +/- 0.1).	SEM__insulin__no_interaction	cholesterol__insulin__no_interaction
8720310-0	Effects of the novel <protein-id="P25102">histamine H2-receptor</protein-id> antagonist (+/-)-(E)-1-[<compound-id="97257">2-hydroxy-</compound-id>2-(4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]<compound-id="23134249">ethyl</compound-id>]-2-(methylsulfonyl) <compound-id="3520,87210844">guanidine</compound-id> on gastric secretion and gastroduodenal ulcers in rats.	2-hydroxy-__histamine H2-receptor__no_interaction	guanidine__histamine H2-receptor__no_interaction	ethyl__histamine H2-receptor__no_interaction
8720310-1	The effects of (+/-)-(E)-1-[<compound-id="97257">2-hydroxy-</compound-id>2-(4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]-3-[2- [[[5-(methylamino)methyl-2-furyl] methyl]thio]<compound-id="23134249">ethyl</compound-id>]-2-(methylsulfonyl)<compound-id="3520,87210844">guanidine</compound-id> (CAS 140695-21-2, T-593), a new <protein-id="P25102">histamine H2-receptor</protein-id> antagonist, on gastric secretion and experimental gastric and duodenal lesion/ulcer models in rats were examined.	2-hydroxy-__histamine H2-receptor__no_interaction	guanidine__histamine H2-receptor__no_interaction	ethyl__histamine H2-receptor__no_interaction
8684680-7	Nutritional (hemoglobin*: 13 +/- 0.2 g%, <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>*: 313 +/- 57 mg%, IGF-1: 187 +/- 15 ng/ml) and hormonal (LH*: 9.4 +/- 1 mUI/ml, FSH*: 15 +/- 1.3 mUI/ml, <compound-id="5920">T3</compound-id>: 1 +/- 1 ng/ml) parameters were significantly improved (*p &lt; 0.01, p &lt; 0.05) compared to those at admission (hemoglobin: 12 +/- 0.2 g%, <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>: 218 +/- 58 mg%, IGF-1: 154 +/- 21 ng/ml, LH: 5.6 +/- 0.8 mUI/ml, FSH: 9.5 +/- 1 mUI/ml, <compound-id="5920">T3</compound-id>: 0.8 +/- 1 ng/ml).	T3__transferrin__no_interaction
23640650-7	When we compared the survivor and non-survivor groups, it was found that mortality was associated with delayed presentation (6.8 vs 9.4 days), presence of hypotension (132/80 vs 112/70 mmHg), oliguria (300 vs 130 mL), anemia (8 vs 9.3 gm/dL), prolonged <protein-id="P00734">prothrombin</protein-id> time (15 vs 29 s) and activated partial <compound-id="90470996">thrombin</compound-id> time (38 vs 46 s), creatinine (7.8 vs 6.4 mg/dL), blood <compound-id="1176">urea</compound-id> (161 vs 135 mg/dL), higher D-dimer (1603 vs 2185), short hospital stay (27.9 vs 8.3 days), number of hemodialysis sessions (11.9 vs 6 times), need for vasopressors (14% vs 52%) and ventilator (7.2% vs 75%) and higher Sequential Organ Failure Assessment (SOFA) score (6.7 vs 11.4) (P &lt;0.05).	thrombin__prothrombin__no_interaction	urea__prothrombin__no_interaction
17622751-8	At peak aerobic test, the trained elderly, compared to the untrained subjects, achieved significantly (p &lt; 0.05) higher values of end diastolic volume (156.1 +/- 8.2 and 134.1 +/- 7.6 ml, respectively), stroke volume (123.0 +/- 7.9 and 96.0 +/- 4.8 ml, respectively), cardiac output (20.2 +/- 1.5 and 15.0 +/- 1.3 liters.<protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively) and <compound-id="977">oxygen</compound-id> uptake (42.1 +/- 2.1 and 31.1 +/- 2.4 ml.kg(-1).<protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively), while diastolic blood pressure (70.3 +/- 5.6 and 77.5 +/- 4.2 mm Hg, respectively) and total peripheral resistance [4.3 +/- 0.8 and 5.9 +/- 1.41 (dyn.s(-1).cm(-5)).10(-1), respectively], were significantly (p &lt; 0.05) lower.	oxygen__min(-1__no_interaction
15260886-7	RESULTS: The activity of MDA was increased (5.33 +/- 0.72 vs 2.55 +/- 0.22 nmol/mL; P &lt; 0.0001) while levels of <compound-id="5359597">superoxide</compound-id> dismutase (493.6 +/- 54.9 vs. 786.8 +/- 79.1 U/g Hb; P &lt; 0.0001), <protein-id="P04040">catalase</protein-id> (1.48 +/- 0.24 vs. 2.31 +/- 0.20 U/g Hb; P &lt; 0.0001) and <compound-id="124886">reduced glutathione</compound-id> (2.84 +/- 0.37 vs 6.42 +/- 0.23 Umol/g Hb, P &lt; 0.0001) were decreased in term SGA born to undernourished mothers as compared to term AGA born to healthy mothers.	reduced glutathione__catalase__no_interaction	superoxide__catalase__no_interaction
8534868-6	expression of <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> protein, <protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">c-erbB-2</protein-id> protein, <protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id>, and cell kinetics; <compound-id="795">IMD</compound-id> was weakly associated only with histological grade (p = 0.053); ii) <compound-id="795">IMD</compound-id> remains a highly significant prognostic factor for RFS and OS (p &lt; 0.0001 and p = 0.018, respectively) in univariate analysis; iii) in multivariate analysis on RFS, <compound-id="795">IMD</compound-id> (likelihood ratio test (LRT) = 30.16; p &lt; 0.0001), <protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id> (LRT = 9.80; p = 0.0017), the <compound-id="795">IMD</compound-id>/<protein-id="P08865,A0A0C4DG17,A0A024R2P0">67 kDa laminin receptor</protein-id> interaction (LRT = 8.62; p = 0.0033), tumor size (LRT = 8.56; p = 0.0034), and <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> protein (LRT = 4.96; p = 0.025) are significant and independent prognostic indicators.	IMD__c-erbB-2__no_interaction	IMD__67 kDa laminin receptor__no_interaction	IMD__p53__no_interaction
17317287-4	The ternary chelates were isolated in 1:1:1 (M:H(2)L(1):L(2)) ratios and have the general formulae [M(H(2)L(1))(L(2))(Cl)(n)(H(2)O)(m)].<compound-id="7020181">yH</compound-id>(2)O (M=Fe(III) (n=2, m=0, y=2), Co(II) (n=1, m=1, y=2) and Ni(II) (n=1, m=1, y=3)); [M(H(2)L(1))(L(2))](X)(z).<compound-id="7020181">yH</compound-id>(2)O (M=Cu(II) (X=<protein-id="Q9H2R5,Q6UBM2,M0R0D7">AcO</protein-id>, z=1, y=0), Zn(II) (X=<protein-id="Q9H2R5,Q6UBM2,M0R0D7">AcO</protein-id>, z=1, y=3) and UO(2)(II) (X=NO(3), z=1, y=2)).	yH__AcO__no_interaction
18297698-5	On the contrary, incubation with SK and QT at both concentrations (10 and 100 nM) produced a significant increase in the release of <protein-id="P10145,A0A024RDA5">IL-8</protein-id> as compared to other groups (4.19 +/- 0.82, SK-QT 10 nM; 3.83 +/- 1.17 SK-QT 100 nM, P &lt; 0.05 vs. baseline 1.00 +/- 0.10, <compound-id="65028">Tamiflu</compound-id> 100 nM 1.35 +/- 0.16, SK 10 nM 1.68 +/- 0.15 and SK 100 nM 1.80 +/- 0.48).	Tamiflu__IL-8__no_interaction
17082371-7	The amount of <compound-id="36811">dobutamine</compound-id> necessary to increase heart rate by 25 beats/min [men: 29.6 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 6.6) to 42.7 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 12.9) vs. women: 23.5 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 4.0) to 30.0 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 7.8); P &lt; 0.05] and contractility by 10 mmHg/cm2 [men: 20.9 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 5.1) to 37.0 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 11.5) vs. women: 22.6 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 6.4) to 30.7 microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (SD 7.2); P &lt; 0.05] was greater in both men and women postrace.	dobutamine__min(-1__no_interaction
8387897-5	Multivariate relationships between the: 1) independent polyinositol forms (3H-<compound-id="892">inositol</compound-id>, I1P, and I1,4,P2) and dependent I1,4,5,P3 existed for control (R2 = 0.71) and 20% BSA burn (R2 = 0.67) groups; 2) the independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent <protein-id="P49913,J3KNB4">cAMP</protein-id> for control (R2 = 0.73), 20% BSA (R2 = 0.99), and 50% BSA (R2 = 0.99) groups; 3) independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent 45Ca2+ for the control (R2 = 0.99), 20% BSA (R2 = 0.44), and 50% BSA (R2 = 0.82) groups; and 4) independent polyinositol forms (I1P, I1,4,P2, and I1,4,5,P3) and dependent active tension for 20% BSA (R2 = 0.97) and 50% BSA (R2 = 0.64) burn groups.	inositol__cAMP__no_interaction
21339629-6	Obese subjects had higher systolic (118.8 ± 1.5 vs 105.7 ± 2.0 mmHg, p &lt; 0.001) and diastolic blood pressure (71.61 ± 1.35 vs 64.53 ± 1.40 mmHg, p = 0.001), higher triglyceride (1.35 ± 0.13 vs 0.79 ± 0.05 mmol/l, p &lt; 0.001), lower high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) (1.43 ± 0.04 vs 1.62 ± 0.05 mmol/l, p = 0.003), higher hs-CRP (11.58 ± 1.88 vs 1.88 ± 0.35 mg/l, p &lt; 0.001), and lower <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> levels (8.80 ± 0.43 vs 25.93 ± 0.40 μg/ml, p &lt; 0.001) compared to lean subjects.	cholesterol__adiponectin__no_interaction
8808636-5	Both sICAM-1 and sVCAM-1 correlated to serum levels of <compound-id="444632,4455">neopterin</compound-id> (r = 0.40, P &lt; 0.001; r = 0.46, P &lt;0.001, respectively) and <protein-id="P01375,Q5STB3">TNFalpha</protein-id> (r = 0.44, P &lt; 0.01; r = 0.49, P &lt; 0.001, respectively), while only sVCAM-1 correlated strongly to CD4+ lymphocyte count (r = -0.46, P &lt; 0.001).	neopterin__TNFalpha__no_interaction
17950106-11	The <protein-id="P11597,B4DMZ5">CETP</protein-id> activities correlated with HOMA-IR (r = 0.33, P &lt; .01), <compound-id="2723628">thiobarbituric acid</compound-id> reactive substances (r = 0.45, P &lt; .001), and <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.36, P &lt; .01) levels in univariate but not in multivariate models.	thiobarbituric acid__leptin__no_interaction	thiobarbituric acid__CETP__no_interaction
22426688-8	Higher serum <protein-id="P01034">cystatin C</protein-id> was positively correlated with higher serum levels of <compound-id="588">creatinine</compound-id> (r = 0.84; p &lt; 0.0001), β2-microglobulin (r = 0.72; p &lt; 0.0001), LDH (r = 0.43; p = 0.0003), white blood cell counts (r = 0.61; p &lt; 0.0001) and <compound-id="22044544,5460341">calcium</compound-id> (r = 0.29; p = 0.016), and negatively correlated with lower serum albumin levels (r = 0.44; p &lt; 0.0001) and hemoglobin levels (r = 0.31; p = 0.01).	calcium__cystatin C__no_interaction	creatinine__cystatin C__no_interaction
21924075-6	The serum concentration of total <compound-id="5997">cholesterol</compound-id> (TC), triglyceride (TG), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>), high density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) and <compound-id="1175">uric acid</compound-id> in patient before and after treatment were (6.18 ± 2.47) mmol/L vs. (5.61 ± 1.84) mmol/L (P = 0.020), (11.17 ± 9.85) mmol/L vs. (6.81 ± 5.97) mmol/L (P = 0.010), (2.55 ± 1.27) mmol/L vs. (2.78 ± 1.07) mmol/L (P = 0.617), (0.98 ± 0.37) mmol/L vs. (0.96 ± 0.23) mmol/L (P = 0.005), (526.53 ± 127.09) µmol/L vs. (490.78 ± 129.79) µmol/L (P = 0.977), respectively.	uric acid__low-density lipoprotein cholesterol__no_interaction	uric acid__LDL-C__no_interaction	cholesterol__low-density lipoprotein cholesterol__no_interaction	cholesterol__LDL-C__no_interaction
15252635-1	The pK(a)s and Zn2+, Cd2+ and Cu2+ complexation constants (K) for 1,4,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-phenylpropionate)]-1,4,7-triazacyclononane, 1, 1,4,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(1''-carboxy-3''-<compound-id="7668">phenylpropane</compound-id>)]-1,4,7-triazacyclononane, <protein-id="Q71DI3">H(3)2, 1,4</protein-id>,7-<compound-id="6503">tris</compound-id>[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-(<compound-id="43849">1H-3</compound-id>-indolyl)<compound-id="1032">propionate</compound-id>)]-1,4,7-triazacyclononane, 3, and 1,4,7,10-tetrakis[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(methyl-3''-phenylpropionate)]-1,4,7,10-tetraazacyclododecane, 4, 1,4,7,10-tetrakis[(2''S)-<compound-id="178">acetamido</compound-id>-2''-(1''-carboxy-3''-<compound-id="7668">phenylpropane</compound-id>)]-1,4,7,10-tetraazacyclododecane, H(4)5, in 20 : 80 v/v <compound-id="962">water</compound-id>-<compound-id="11686950,887">methanol</compound-id> solution are reported.	1H-3__H(3)2, 1,4__no_interaction	phenylpropane__H(3)2, 1,4__no_interaction	water__H(3)2, 1,4__no_interaction	methanol__H(3)2, 1,4__no_interaction	propionate__H(3)2, 1,4__no_interaction	acetamido__H(3)2, 1,4__no_interaction	tris__H(3)2, 1,4__no_interaction
15252635-5	The tricarboxylic acid <protein-id="Q71DI3">H(3)2</protein-id> generates a greater variety of complexes as exemplified by: [Zn(2)-] (10.68) [Zn(<compound-id="783">H2</compound-id>)] (6.60) [Zn(H(2)2)+] (5.15), [Cd(2)](-) (4.99), [Cd(<compound-id="783">H2</compound-id>)] (4.64), [Cd(<compound-id="783">H2</compound-id>(2))]+ (3.99), [Cd(<protein-id="Q71DI3">H(3)2</protein-id>)]2+ (3.55), [Cu(2)](-) (12.55) [Cu(<compound-id="783">H2</compound-id>)] (7.66), [Cu(H(2)2)]+ (5.54) and [Cu(2)2](4-) (3.23).	H2__H(3)2__no_interaction
19022445-4	RESULTS: Delivery of a SGA infant was associated with altered lipids [triglyceride median (IQR) mmol/l; control 0.64 (0.49-0.84); SGA 0.95 (0.67-0.95), p=0.012] [<compound-id="5997">cholesterol</compound-id>:<protein-id="P28845,X5D2L1">HDL</protein-id> ratio: control 2.64 (2.10-3.10); SGA 3.06 (2.65-3.89), p=0.013], systolic blood pressure [control mmHg: 110 (108-118); SGA 120 (110-130), p=0.031], subclinical inflammation [<protein-id="P02741">CRP</protein-id> mg/l: control 0.7 (0.3-2.1); SGA 2.2 (1.2-4.0), p=0.002] [<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> pg/ml: control 1.2 (0.8-1.4); SGA 1.5 (1.1-2.2), p=0.009] and endothelial activation [<protein-id="P05362">ICAM-1</protein-id> ng/ml: control 237.7 (210.0-279.4); SGA 283.1 (240.5-366.3), p=0.013], with differences robust to confounder adjustment.	cholesterol__ICAM-1__no_interaction	cholesterol__CRP__no_interaction	cholesterol__HDL__no_interaction	cholesterol__IL-6__no_interaction
20442503-1	The dinuclear Au(I) complex containing the 4,5-<protein-id="O95817">Bis</protein-id>(<compound-id="70017">diphenylphosphino</compound-id>)-9,9-<compound-id="606997">dimethylxanthene</compound-id> (xantphos) ligand and <compound-id="6422">trifluoroacetate</compound-id> anions exists in a solvent-free form, [<protein-id="O00189,C9IZL5,C9JC87">mu-4</protein-id>,5-<protein-id="O95817">Bis</protein-id>(<compound-id="70017">diphenylphosphino</compound-id>)-9,9-<compound-id="606997">dimethylxanthene</compound-id>]<protein-id="O95817">Bis</protein-id>[(trifluoroacetato)<compound-id="23985">gold</compound-id>(I)], [Au(2)(C(2)F(3)O(2))(2)(C(39)H(32)OP(2))], (I), and as a <compound-id="6344">dichloromethane</compound-id> solvate, [Au(2)(C(2)F(3)O(2))(2)(C(39)H(32)OP(2))].0.58CH(2)Cl(2), (II).	dimethylxanthene__mu-4__no_interaction	dimethylxanthene__Bis__no_interaction	diphenylphosphino__mu-4__no_interaction	diphenylphosphino__Bis__no_interaction	dichloromethane__mu-4__no_interaction	dichloromethane__Bis__no_interaction	gold__mu-4__no_interaction	gold__Bis__no_interaction	trifluoroacetate__mu-4__no_interaction	trifluoroacetate__Bis__no_interaction
19826741-2	Reactions of six amido-oxazolinate ligand precursors, <compound-id="5975">HNC</compound-id>(2)(Me)Oxa, <compound-id="5975">HNC</compound-id>(2)(OMe)Oxa, <compound-id="5975">HNC</compound-id>(2)(StBu)Oxa, HNPhOxa, HNPh(OMe)Oxa or HNPh(<protein-id="P62304">SMe</protein-id>)Oxa, with half molar equivalent of Mg(n)Bu(2) in <compound-id="8058">hexane</compound-id> yield the <compound-id="5462224">magnesium</compound-id> <protein-id="O95817">bis</protein-id>(amido-oxazolinate) complexes, (NC(2)(E)Oxa)(2)Mg [C(2)(E) = propyl, (NC(2)(Me)Oxa)(2)Mg (1); C(2)(E) = 2-methoxyethyl, (NC(2)(OMe)Oxa)(2)Mg (2); C(2)(E) = <compound-id="139723">2-tert-butylthioethyl</compound-id>, (NC(2)(StBu)Oxa)(2)Mg (3)], or <compound-id="5462224">magnesium</compound-id> <protein-id="O95817">bis</protein-id>(anilido-oxazolinate) complexes, (NArOxa)(2)Mg [Ar = phenyl, (NPhOxa)(2)Mg (4); Ar = 2-methoxyphenyl, (NPh(OMe)Oxa)(2)Mg (5); Ar = 2-methylthiophenyl, (NPh(<protein-id="P62304">SMe</protein-id>)Oxa)(2)Mg (6)], respectively.	2-tert-butylthioethyl__SMe__no_interaction	2-tert-butylthioethyl__bis__no_interaction	HNC__SMe__no_interaction	HNC__bis__no_interaction	hexane__SMe__no_interaction	hexane__bis__no_interaction	magnesium__SMe__no_interaction	magnesium__bis__no_interaction
20533433-2	Five kinds of neutral ligands (phen=<compound-id="1318">1,10-phenanthroline</compound-id>, <compound-id="1474">bipy</compound-id>=<compound-id="11107">4,4'-bipyridine</compound-id>, bpa=<compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>, bpe=<compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>, and bpp=<compound-id="87019">1,3-bis(4-pyridyl)propane</compound-id>) were selected, and a series of new Zn(II)/Co(II) dicarboxylates have been synthesized by slow diffusion, namely, [Zn(phen)(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(H(2)O)](2).CH(3)OH (1), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpe)].H(2)O}(n) (2), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(<compound-id="1474">bipy</compound-id>)].2H(2)O}(n) (3), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpa)](2).5H(2)O}(n) (4), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)](2).CH(3)OH}(n) (5), {[Zn(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)]}(n) (6), {[Co(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)(CH(3)OH)(H(2)O)].CH(3)OH2 H(2)O}(n) (7), and {[Co(<protein-id="Q96A70,D3DPR0,B3KV62">ADC</protein-id>)(bpp)]}(n) (8).	4,4'-bipyridine__ADC__no_interaction	1,2-bis(4-pyridyl)ethane__ADC__no_interaction	bipy__ADC__no_interaction	1,3-bis(4-pyridyl)propane__ADC__no_interaction	1,10-phenanthroline__ADC__no_interaction
8553999-5	Absolute changes from baseline were significantly different for the two forms of exertion: <compound-id="12388">TRD</compound-id> versus HG: BP = 11 +/- 9 versus 36 +/- 10 mm Hg, HR = 37 +/- 16 versus 16 +/- 9 beats/min, E = 11.6 +/- 11.3 versus -7.0 +/- 9.4 cm/sec, A = 29.9 +/- 14.5 versus 14 +/- 12 cm/sec, ACC = 164 +/- 151 versus -56 +/- 135 cm/<protein-id="Q10981,A8K2L2">sec2</protein-id>, Ti = 1.9 +/- 3.0 versus -1.7 +/- 1.7 cm, and IRT = -12 +/- 9 versus 9 +/- 10 msec, all p &lt; 0.0001 except for A, p &lt; 0.001).	TRD__sec2__no_interaction
1818062-1	A high-performance liquid chromatographic method with column switching was developed for the determination of the <protein-id="P08424">renin</protein-id> inhibitor <compound-id="5462340">Ro 42-5892</compound-id>/001, (S)-alpha-[(S)-alpha-[(tert.-<compound-id="12113170">butylsulphonyl</compound-id>)methyl]hydrocinnama mido]-N- [(1S,2R,<compound-id="21439199">3S</compound-id>)-1-(cyclohexylmethyl)-3-cylcopropyl-2, 3-<compound-id="134919">dihydroxypropyl</compound-id>]<compound-id="565498">imidazole-4-propionamide</compound-id> <compound-id="6395">methanesulphonate</compound-id> (1:1), in rat, marmoset and human plasma, using a Nucleosil C8 120 (3 microns) stationary phase.	butylsulphonyl__renin__no_interaction	3S__renin__no_interaction	dihydroxypropyl__renin__no_interaction	imidazole-4-propionamide__renin__no_interaction	Ro 42-5892__renin__no_interaction	methanesulphonate__renin__no_interaction
14988742-3	This issue focuses on the following selection of drugs: Abetimus <compound-id="5360545">sodium</compound-id>, Ad5-<protein-id="P08620">FGF4</protein-id>, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, <compound-id="16197724">alicaforsen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="123606">almotriptan</compound-id>, alpharadin, <compound-id="90470007">anakinra</compound-id>, anatumomab mafenatox, ANG-453, anti-<protein-id="P16410">CTLA-4</protein-id> Mab, AP-12009, <compound-id="151165,21923359,53660666,6918365">aprepitant</compound-id>, <compound-id="60795">aripiprazole</compound-id>, <compound-id="5359596">arsenic</compound-id> trioxide, <compound-id="2247">astemizole</compound-id>, atlizumab, <compound-id="54841">atomoxetine hydrochloride</compound-id>; Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; <compound-id="2519,57106085">Caffeine</compound-id>, <compound-id="6132">CDP</compound-id>-870, cetuximab, <compound-id="151170">cilomilast</compound-id>, <compound-id="9853710">ciluprevir</compound-id>, <compound-id="119182">clofarabine</compound-id>, continuous erythropoiesis receptor activator, CP-461; Darbepoetin alfa, <compound-id="36687767,5493381,6098188">deferasirox</compound-id>, <compound-id="124087">desloratadine</compound-id>, <compound-id="447865,6918680">desoxyepothilone B</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="3033818,3148,49800054,60654">dolasetron</compound-id>, drotrecogin alfa (activated), <compound-id="60835">duloxetine</compound-id> hydrochloride; ED-71, efalizumab, efaproxiral <compound-id="5360545">sodium</compound-id>, <compound-id="25138225">EKB</compound-id>-569, <compound-id="77993">eletriptan</compound-id>, EMD-72000, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="176870">erlotinib hydrochloride</compound-id>, <compound-id="146570">escitalopram oxalate</compound-id>, <compound-id="123619">etoricoxib</compound-id>; <compound-id="1727">Fampridine</compound-id>, ferumoxytol, <compound-id="3035403,17854871,5282448,71316924">fondaparinux sodium</compound-id>; <compound-id="9919137">Gadofosveset</compound-id> <compound-id="5360545">sodium</compound-id>, gastrazole, <compound-id="123631">gefitinib</compound-id>, gemtuzumab <compound-id="9942071">ozogamicin</compound-id>, <compound-id="55191">gepirone</compound-id> hydrochloride <compound-id="5961">glutamine</compound-id>; hLM609, HSPPC-96, human <protein-id="P01308,I3WAC9">insulin</protein-id>; IDD-1, <compound-id="5291">imatinib mesylate</compound-id>, <compound-id="216468">indisulam</compound-id>, inhaled <protein-id="P01308,I3WAC9">insulin</protein-id>, <compound-id="6445540">ixabepilone</compound-id>; Keratinocyte growth factor; <compound-id="208908">Lapatinib</compound-id>, <compound-id="54677946">laquinimod</compound-id>, LDP-02, <compound-id="7009630">LE</compound-id>-<compound-id="104842">SN38</compound-id>, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="3033825">levosimendan</compound-id>, <compound-id="133021">licofelone</compound-id>, liposomal <compound-id="31703">doxorubicin</compound-id>, liposomal NDDP, <compound-id="92727">lopinavir</compound-id>, <compound-id="151166">lumiracoxib</compound-id>, <compound-id="219018">LY-156735</compound-id>; <compound-id="5288826">Morphine hydrochloride</compound-id>, <compound-id="5360621">morphine-6-glucuronide</compound-id>, <compound-id="151071">motexafin gadolinium</compound-id>, <compound-id="4261">MS-27-275</compound-id>, MVA-5T4, MVA-Muc1-<protein-id="P60568,Q0GK43">IL-2</protein-id>; <compound-id="6918348">Nemifitide ditriflutate</compound-id>, <compound-id="71237">neridronic acid</compound-id> <compound-id="9884642">nitronaproxen</compound-id>, <compound-id="54608508,6918289">NSC-683864</compound-id>, NSC-703940, <compound-id="6918537">NVP-LAF-237</compound-id>; <compound-id="71587613">Oblimersen</compound-id> <compound-id="5360545">sodium</compound-id>, <compound-id="216456">ocinaplon</compound-id>, oncomyc-NG, <compound-id="219020">OPC-28326</compound-id>, <compound-id="6918412">ortataxel</compound-id>, <compound-id="3036505">ospemifene</compound-id>; Palonosetron hydrochloride, PEG-filgrastim peginterferon alfa-2(a), peginterferon alfa-2b, pegsunercept, <compound-id="60843,394493,446556">pemetrexed disodium</compound-id>, <compound-id="5486971">pregabalin</compound-id>, <compound-id="4906">prilocaine</compound-id>, <compound-id="1052">pyridoxamine</compound-id>; <compound-id="124970">RDP</compound-id>-58, recombinant glucagon-like peptide-1 (7-36) <compound-id="2826723">amide</compound-id>, recombinant human <protein-id="P02647,A0A024R3E3">ApoA-I</protein-id> milano/phospholipid complex; <compound-id="6851740">SB-715992</compound-id>, <compound-id="24978490,6918315,70687327">soblidotin</compound-id>, <compound-id="6597">sodium dichloroacetate</compound-id>, St. John's Wort extract; TAS-102, <compound-id="5405">terfenadine</compound-id>, TG-1024, TG-5001, <compound-id="168566">4'-Thio-ara-C</compound-id>, <compound-id="54682461">tipranavir</compound-id>, <compound-id="219022">topixantrone hydrochloride</compound-id>, <compound-id="108150">trabectedin</compound-id>, transdermal <compound-id="26757">selegiline</compound-id>, <compound-id="5578">trimethoprim</compound-id>, <compound-id="151173,454194">troxacitabine</compound-id>, TT-232; <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, <compound-id="10629256,157688,6918295">vinflunine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; <compound-id="60854">Ziprasidone hydrochloride</compound-id>, <compound-id="68740">Zoledronic acid monohydrate</compound-id>.	escitalopram oxalate__ApoA-I__no_interaction	escitalopram oxalate__FGF4__no_interaction	escitalopram oxalate__CTLA-4__no_interaction	escitalopram oxalate__IL-2__no_interaction	escitalopram oxalate__insulin__no_interaction	Morphine hydrochloride__ApoA-I__no_interaction	Morphine hydrochloride__FGF4__no_interaction	Morphine hydrochloride__CTLA-4__no_interaction	Morphine hydrochloride__IL-2__no_interaction	Morphine hydrochloride__insulin__no_interaction	NSC-683864__ApoA-I__no_interaction	NSC-683864__FGF4__no_interaction	NSC-683864__CTLA-4__no_interaction	NSC-683864__IL-2__no_interaction	NSC-683864__insulin__no_interaction	laquinimod__ApoA-I__no_interaction	laquinimod__FGF4__no_interaction	laquinimod__CTLA-4__no_interaction	laquinimod__IL-2__no_interaction	laquinimod__insulin__no_interaction	sodium dichloroacetate__ApoA-I__no_interaction	sodium dichloroacetate__FGF4__no_interaction	sodium dichloroacetate__CTLA-4__no_interaction	sodium dichloroacetate__IL-2__no_interaction	sodium dichloroacetate__insulin__no_interaction	4'-Thio-ara-C__ApoA-I__no_interaction	4'-Thio-ara-C__FGF4__no_interaction	4'-Thio-ara-C__CTLA-4__no_interaction	4'-Thio-ara-C__IL-2__no_interaction	4'-Thio-ara-C__insulin__no_interaction	lumiracoxib__ApoA-I__no_interaction	lumiracoxib__FGF4__no_interaction	lumiracoxib__CTLA-4__no_interaction	lumiracoxib__IL-2__no_interaction	lumiracoxib__insulin__no_interaction	deferasirox__ApoA-I__no_interaction	deferasirox__FGF4__no_interaction	deferasirox__CTLA-4__no_interaction	deferasirox__IL-2__no_interaction	deferasirox__insulin__no_interaction	NVP-LAF-237__ApoA-I__no_interaction	NVP-LAF-237__FGF4__no_interaction	NVP-LAF-237__CTLA-4__no_interaction	NVP-LAF-237__IL-2__no_interaction	NVP-LAF-237__insulin__no_interaction	astemizole__ApoA-I__no_interaction	astemizole__FGF4__no_interaction	astemizole__CTLA-4__no_interaction	astemizole__IL-2__no_interaction	astemizole__insulin__no_interaction	indisulam__ApoA-I__no_interaction	indisulam__FGF4__no_interaction	indisulam__CTLA-4__no_interaction	indisulam__IL-2__no_interaction	indisulam__insulin__no_interaction	troxacitabine__ApoA-I__no_interaction	troxacitabine__FGF4__no_interaction	troxacitabine__CTLA-4__no_interaction	troxacitabine__IL-2__no_interaction	troxacitabine__insulin__no_interaction	alicaforsen__ApoA-I__no_interaction	alicaforsen__FGF4__no_interaction	alicaforsen__CTLA-4__no_interaction	alicaforsen__IL-2__no_interaction	alicaforsen__insulin__no_interaction	morphine-6-glucuronide__ApoA-I__no_interaction	morphine-6-glucuronide__FGF4__no_interaction	morphine-6-glucuronide__CTLA-4__no_interaction	morphine-6-glucuronide__IL-2__no_interaction	morphine-6-glucuronide__insulin__no_interaction	EKB__ApoA-I__no_interaction	EKB__FGF4__no_interaction	EKB__CTLA-4__no_interaction	EKB__IL-2__no_interaction	EKB__insulin__no_interaction	SB-715992__ApoA-I__no_interaction	SB-715992__FGF4__no_interaction	SB-715992__CTLA-4__no_interaction	SB-715992__IL-2__no_interaction	SB-715992__insulin__no_interaction	trabectedin__ApoA-I__no_interaction	trabectedin__FGF4__no_interaction	trabectedin__CTLA-4__no_interaction	trabectedin__IL-2__no_interaction	trabectedin__insulin__no_interaction	arsenic__ApoA-I__no_interaction	arsenic__FGF4__no_interaction	arsenic__CTLA-4__no_interaction	arsenic__IL-2__no_interaction	arsenic__insulin__no_interaction	topixantrone hydrochloride__ApoA-I__no_interaction	topixantrone hydrochloride__FGF4__no_interaction	topixantrone hydrochloride__CTLA-4__no_interaction	topixantrone hydrochloride__IL-2__no_interaction	topixantrone hydrochloride__insulin__no_interaction	aprepitant__ApoA-I__no_interaction	aprepitant__FGF4__no_interaction	aprepitant__CTLA-4__no_interaction	aprepitant__IL-2__no_interaction	aprepitant__insulin__no_interaction	etoricoxib__ApoA-I__no_interaction	etoricoxib__FGF4__no_interaction	etoricoxib__CTLA-4__no_interaction	etoricoxib__IL-2__no_interaction	etoricoxib__insulin__no_interaction	MS-27-275__ApoA-I__no_interaction	MS-27-275__FGF4__no_interaction	MS-27-275__CTLA-4__no_interaction	MS-27-275__IL-2__no_interaction	MS-27-275__insulin__no_interaction	ocinaplon__ApoA-I__no_interaction	ocinaplon__FGF4__no_interaction	ocinaplon__CTLA-4__no_interaction	ocinaplon__IL-2__no_interaction	ocinaplon__insulin__no_interaction	erlotinib hydrochloride__ApoA-I__no_interaction	erlotinib hydrochloride__FGF4__no_interaction	erlotinib hydrochloride__CTLA-4__no_interaction	erlotinib hydrochloride__IL-2__no_interaction	erlotinib hydrochloride__insulin__no_interaction	ospemifene__ApoA-I__no_interaction	ospemifene__FGF4__no_interaction	ospemifene__CTLA-4__no_interaction	ospemifene__IL-2__no_interaction	ospemifene__insulin__no_interaction	Nemifitide ditriflutate__ApoA-I__no_interaction	Nemifitide ditriflutate__FGF4__no_interaction	Nemifitide ditriflutate__CTLA-4__no_interaction	Nemifitide ditriflutate__IL-2__no_interaction	Nemifitide ditriflutate__insulin__no_interaction	sodium__ApoA-I__no_interaction	sodium__FGF4__no_interaction	sodium__CTLA-4__no_interaction	sodium__IL-2__no_interaction	sodium__insulin__no_interaction	prilocaine__ApoA-I__no_interaction	prilocaine__FGF4__no_interaction	prilocaine__CTLA-4__no_interaction	prilocaine__IL-2__no_interaction	prilocaine__insulin__no_interaction	licofelone__ApoA-I__no_interaction	licofelone__FGF4__no_interaction	licofelone__CTLA-4__no_interaction	licofelone__IL-2__no_interaction	licofelone__insulin__no_interaction	clofarabine__ApoA-I__no_interaction	clofarabine__FGF4__no_interaction	clofarabine__CTLA-4__no_interaction	clofarabine__IL-2__no_interaction	clofarabine__insulin__no_interaction	trimethoprim__ApoA-I__no_interaction	trimethoprim__FGF4__no_interaction	trimethoprim__CTLA-4__no_interaction	trimethoprim__IL-2__no_interaction	trimethoprim__insulin__no_interaction	pyridoxamine__ApoA-I__no_interaction	pyridoxamine__FGF4__no_interaction	pyridoxamine__CTLA-4__no_interaction	pyridoxamine__IL-2__no_interaction	pyridoxamine__insulin__no_interaction	LY-156735__ApoA-I__no_interaction	LY-156735__FGF4__no_interaction	LY-156735__CTLA-4__no_interaction	LY-156735__IL-2__no_interaction	LY-156735__insulin__no_interaction	selegiline__ApoA-I__no_interaction	selegiline__FGF4__no_interaction	selegiline__CTLA-4__no_interaction	selegiline__IL-2__no_interaction	selegiline__insulin__no_interaction	fondaparinux sodium__ApoA-I__no_interaction	fondaparinux sodium__FGF4__no_interaction	fondaparinux sodium__CTLA-4__no_interaction	fondaparinux sodium__IL-2__no_interaction	fondaparinux sodium__insulin__no_interaction	ozogamicin__ApoA-I__no_interaction	ozogamicin__FGF4__no_interaction	ozogamicin__CTLA-4__no_interaction	ozogamicin__IL-2__no_interaction	ozogamicin__insulin__no_interaction	vinflunine__ApoA-I__no_interaction	vinflunine__FGF4__no_interaction	vinflunine__CTLA-4__no_interaction	vinflunine__IL-2__no_interaction	vinflunine__insulin__no_interaction	neridronic acid__ApoA-I__no_interaction	neridronic acid__FGF4__no_interaction	neridronic acid__CTLA-4__no_interaction	neridronic acid__IL-2__no_interaction	neridronic acid__insulin__no_interaction	Zoledronic acid monohydrate__ApoA-I__no_interaction	Zoledronic acid monohydrate__FGF4__no_interaction	Zoledronic acid monohydrate__CTLA-4__no_interaction	Zoledronic acid monohydrate__IL-2__no_interaction	Zoledronic acid monohydrate__insulin__no_interaction	ciluprevir__ApoA-I__no_interaction	ciluprevir__FGF4__no_interaction	ciluprevir__CTLA-4__no_interaction	ciluprevir__IL-2__no_interaction	ciluprevir__insulin__no_interaction	enfuvirtide__ApoA-I__no_interaction	enfuvirtide__FGF4__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__IL-2__no_interaction	enfuvirtide__insulin__no_interaction	levetiracetam__ApoA-I__no_interaction	levetiracetam__FGF4__no_interaction	levetiracetam__CTLA-4__no_interaction	levetiracetam__IL-2__no_interaction	levetiracetam__insulin__no_interaction	doxorubicin__ApoA-I__no_interaction	doxorubicin__FGF4__no_interaction	doxorubicin__CTLA-4__no_interaction	doxorubicin__IL-2__no_interaction	doxorubicin__insulin__no_interaction	dolasetron__ApoA-I__no_interaction	dolasetron__FGF4__no_interaction	dolasetron__CTLA-4__no_interaction	dolasetron__IL-2__no_interaction	dolasetron__insulin__no_interaction	OPC-28326__ApoA-I__no_interaction	OPC-28326__FGF4__no_interaction	OPC-28326__CTLA-4__no_interaction	OPC-28326__IL-2__no_interaction	OPC-28326__insulin__no_interaction	RDP__ApoA-I__no_interaction	RDP__FGF4__no_interaction	RDP__CTLA-4__no_interaction	RDP__IL-2__no_interaction	RDP__insulin__no_interaction	motexafin gadolinium__ApoA-I__no_interaction	motexafin gadolinium__FGF4__no_interaction	motexafin gadolinium__CTLA-4__no_interaction	motexafin gadolinium__IL-2__no_interaction	motexafin gadolinium__insulin__no_interaction	cilomilast__ApoA-I__no_interaction	cilomilast__FGF4__no_interaction	cilomilast__CTLA-4__no_interaction	cilomilast__IL-2__no_interaction	cilomilast__insulin__no_interaction	terfenadine__ApoA-I__no_interaction	terfenadine__FGF4__no_interaction	terfenadine__CTLA-4__no_interaction	terfenadine__IL-2__no_interaction	terfenadine__insulin__no_interaction	Lapatinib__ApoA-I__no_interaction	Lapatinib__FGF4__no_interaction	Lapatinib__CTLA-4__no_interaction	Lapatinib__IL-2__no_interaction	Lapatinib__insulin__no_interaction	glutamine__ApoA-I__no_interaction	glutamine__FGF4__no_interaction	glutamine__CTLA-4__no_interaction	glutamine__IL-2__no_interaction	glutamine__insulin__no_interaction	gefitinib__ApoA-I__no_interaction	gefitinib__FGF4__no_interaction	gefitinib__CTLA-4__no_interaction	gefitinib__IL-2__no_interaction	gefitinib__insulin__no_interaction	Ziprasidone hydrochloride__ApoA-I__no_interaction	Ziprasidone hydrochloride__FGF4__no_interaction	Ziprasidone hydrochloride__CTLA-4__no_interaction	Ziprasidone hydrochloride__IL-2__no_interaction	Ziprasidone hydrochloride__insulin__no_interaction	Caffeine__ApoA-I__no_interaction	Caffeine__FGF4__no_interaction	Caffeine__CTLA-4__no_interaction	Caffeine__IL-2__no_interaction	Caffeine__insulin__no_interaction	tipranavir__ApoA-I__no_interaction	tipranavir__FGF4__no_interaction	tipranavir__CTLA-4__no_interaction	tipranavir__IL-2__no_interaction	tipranavir__insulin__no_interaction	ixabepilone__ApoA-I__no_interaction	ixabepilone__FGF4__no_interaction	ixabepilone__CTLA-4__no_interaction	ixabepilone__IL-2__no_interaction	ixabepilone__insulin__no_interaction	ortataxel__ApoA-I__no_interaction	ortataxel__FGF4__no_interaction	ortataxel__CTLA-4__no_interaction	ortataxel__IL-2__no_interaction	ortataxel__insulin__no_interaction	LE__ApoA-I__no_interaction	LE__FGF4__no_interaction	LE__CTLA-4__no_interaction	LE__IL-2__no_interaction	LE__insulin__no_interaction	Oblimersen__ApoA-I__no_interaction	Oblimersen__FGF4__no_interaction	Oblimersen__CTLA-4__no_interaction	Oblimersen__IL-2__no_interaction	Oblimersen__insulin__no_interaction	Vatalanib__ApoA-I__no_interaction	Vatalanib__FGF4__no_interaction	Vatalanib__CTLA-4__no_interaction	Vatalanib__IL-2__no_interaction	Vatalanib__insulin__no_interaction	pemetrexed disodium__ApoA-I__no_interaction	pemetrexed disodium__FGF4__no_interaction	pemetrexed disodium__CTLA-4__no_interaction	pemetrexed disodium__IL-2__no_interaction	pemetrexed disodium__insulin__no_interaction	atomoxetine hydrochloride__ApoA-I__no_interaction	atomoxetine hydrochloride__FGF4__no_interaction	atomoxetine hydrochloride__CTLA-4__no_interaction	atomoxetine hydrochloride__IL-2__no_interaction	atomoxetine hydrochloride__insulin__no_interaction	Ximelagatran__ApoA-I__no_interaction	Ximelagatran__FGF4__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__IL-2__no_interaction	Ximelagatran__insulin__no_interaction	imatinib mesylate__ApoA-I__no_interaction	imatinib mesylate__FGF4__no_interaction	imatinib mesylate__CTLA-4__no_interaction	imatinib mesylate__IL-2__no_interaction	imatinib mesylate__insulin__no_interaction	gepirone__ApoA-I__no_interaction	gepirone__FGF4__no_interaction	gepirone__CTLA-4__no_interaction	gepirone__IL-2__no_interaction	gepirone__insulin__no_interaction	soblidotin__ApoA-I__no_interaction	soblidotin__FGF4__no_interaction	soblidotin__CTLA-4__no_interaction	soblidotin__IL-2__no_interaction	soblidotin__insulin__no_interaction	amide__ApoA-I__no_interaction	amide__FGF4__no_interaction	amide__CTLA-4__no_interaction	amide__IL-2__no_interaction	amide__insulin__no_interaction	succinate__ApoA-I__no_interaction	succinate__FGF4__no_interaction	succinate__CTLA-4__no_interaction	succinate__IL-2__no_interaction	succinate__insulin__no_interaction	diflomotecan__ApoA-I__no_interaction	diflomotecan__FGF4__no_interaction	diflomotecan__CTLA-4__no_interaction	diflomotecan__IL-2__no_interaction	diflomotecan__insulin__no_interaction	almotriptan__ApoA-I__no_interaction	almotriptan__FGF4__no_interaction	almotriptan__CTLA-4__no_interaction	almotriptan__IL-2__no_interaction	almotriptan__insulin__no_interaction	nitronaproxen__ApoA-I__no_interaction	nitronaproxen__FGF4__no_interaction	nitronaproxen__CTLA-4__no_interaction	nitronaproxen__IL-2__no_interaction	nitronaproxen__insulin__no_interaction	desoxyepothilone B__ApoA-I__no_interaction	desoxyepothilone B__FGF4__no_interaction	desoxyepothilone B__CTLA-4__no_interaction	desoxyepothilone B__IL-2__no_interaction	desoxyepothilone B__insulin__no_interaction	desloratadine__ApoA-I__no_interaction	desloratadine__FGF4__no_interaction	desloratadine__CTLA-4__no_interaction	desloratadine__IL-2__no_interaction	desloratadine__insulin__no_interaction	CDP__ApoA-I__no_interaction	CDP__FGF4__no_interaction	CDP__CTLA-4__no_interaction	CDP__IL-2__no_interaction	CDP__insulin__no_interaction	SN38__ApoA-I__no_interaction	SN38__FGF4__no_interaction	SN38__CTLA-4__no_interaction	SN38__IL-2__no_interaction	SN38__insulin__no_interaction	aripiprazole__ApoA-I__no_interaction	aripiprazole__FGF4__no_interaction	aripiprazole__CTLA-4__no_interaction	aripiprazole__IL-2__no_interaction	aripiprazole__insulin__no_interaction	anakinra__ApoA-I__no_interaction	anakinra__FGF4__no_interaction	anakinra__CTLA-4__no_interaction	anakinra__IL-2__no_interaction	anakinra__insulin__no_interaction	pregabalin__ApoA-I__no_interaction	pregabalin__FGF4__no_interaction	pregabalin__CTLA-4__no_interaction	pregabalin__IL-2__no_interaction	pregabalin__insulin__no_interaction	lopinavir__ApoA-I__no_interaction	lopinavir__FGF4__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__IL-2__no_interaction	lopinavir__insulin__no_interaction	Fampridine__ApoA-I__no_interaction	Fampridine__FGF4__no_interaction	Fampridine__CTLA-4__no_interaction	Fampridine__IL-2__no_interaction	Fampridine__insulin__no_interaction	eletriptan__ApoA-I__no_interaction	eletriptan__FGF4__no_interaction	eletriptan__CTLA-4__no_interaction	eletriptan__IL-2__no_interaction	eletriptan__insulin__no_interaction	levosimendan__ApoA-I__no_interaction	levosimendan__FGF4__no_interaction	levosimendan__CTLA-4__no_interaction	levosimendan__IL-2__no_interaction	levosimendan__insulin__no_interaction	Gadofosveset__ApoA-I__no_interaction	Gadofosveset__FGF4__no_interaction	Gadofosveset__CTLA-4__no_interaction	Gadofosveset__IL-2__no_interaction	Gadofosveset__insulin__no_interaction	duloxetine__ApoA-I__no_interaction	duloxetine__FGF4__no_interaction	duloxetine__CTLA-4__no_interaction	duloxetine__IL-2__no_interaction	duloxetine__insulin__no_interaction
14731357-11	Compared with control group, the levels of triglyceride, total <compound-id="5997">cholesterol</compound-id>, low density lipoprotein-<compound-id="5997">cholesterol</compound-id>, and <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id>(100) were higher, and those of high density lipoprotein-<compound-id="5997">cholesterol</compound-id>, <protein-id="P02647,A0A024R3E3">apoA I</protein-id> and <protein-id="P02649">apoE</protein-id> were lower in children with obesity [(1.68 +/- 0.50) mmol/L vs. (0.99 +/- 0.54) mmol/L, (4.47 +/- 0.91) mmol/L vs. (3.33 +/- 0.90) mmol/L, (2.23 +/- 0.71) mmol/L vs. (1.13 +/- 0.96) mmol/L, (94.48 +/- 9.97) mg/dl vs. (83.81 +/- 15.64) mg/dl, (1.47 +/- 0.39) mmol/L vs. (1.73 +/- 0.36) mmol/L, (112.71 +/- 27.86) mg/dl vs. (134.80 +/- 45.36) mg/dl, (24.50 +/- 10.92) mg/L vs.(35.07 +/- 9.79) mg/L, respectively, P &lt; 0.05].	cholesterol__apoA I__no_interaction	cholesterol__apoE__no_interaction	cholesterol__apoB__no_interaction
19572374-6	<protein-id="P21741">midkine</protein-id> significantly correlated with inflammatory indices: <protein-id="P02741">CRP</protein-id> (r = 0.49), erythrocyte sedimentation rate (r = 0.31), leukocytes (r = 0.48), platelets (r = 0.52), albumin (r = -0.49), <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> (r = -0.47), and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id> (r = 0.54); hematological variables: hemoglobin (r = -0.38), hematocrit (r = -0.43), and <compound-id="23925,67172434">iron</compound-id> (r = -0.58); angiogenic factors: <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">vascular endothelial growth factor-A</protein-id> (r = 0.42), <protein-id="P09038">fibroblast growth factor-2</protein-id> (r = 0.54), and platelet-derived growth factor-BB (r = 0.57).	iron__CRP__no_interaction	iron__IL-6__no_interaction	iron__transferrin__no_interaction	iron__midkine__no_interaction	iron__vascular endothelial growth factor-A__no_interaction	iron__fibroblast growth factor-2__no_interaction
22339487-2	The complexes include the mononuclear species [(pbi)AuX(2)] (X = Cl, 1; OAc, 2), [(pbiH)<compound-id="5460531">AuCl</compound-id>] (3), [(pbiH)Au(PPh(3))][PF(6)] (4-PF(6)), and [(pbi)Au(L)] (L = PPh(3), 5; <protein-id="P00750">TPA</protein-id>, 6), and the binuclear <compound-id="23985">gold</compound-id>(I)/<compound-id="23985">gold</compound-id>(I) and <compound-id="23985">gold</compound-id>(I)/<compound-id="23985">gold</compound-id>(III) derivatives [(PPh(3))(2)Au(2)(μ(2)-pbi)][PF(6)] (10-PF(6)), [ClAu(μ(3)-pbi)<compound-id="5460531">AuCl</compound-id>(2)] (7),and [(PPh(3))Au(μ(3)-pbi)AuX(2)][PF(6)] (X = Cl, 8-PF(6); OAc, 9-PF(6)).	AuCl__TPA__no_interaction	gold__TPA__no_interaction
24351593-5	The data of preoperative <protein-id="P19429,Q6FGX2">cTnI</protein-id> showed no significant difference between two groups (P &gt; 0.05) .However, after CPB, significant intergroup difference existed in the level of <protein-id="P19429,Q6FGX2">cTnI</protein-id> (µg/L) <compound-id="4577">OnP</compound-id>-BH group vs CCABG group: (0.5 h after CPB: (0.132 ± 0.022) vs (0.265 ± 0.014) , 1 h after CPB: (0.341 ± 0.027) vs (0.572 ± 0.046) , 1 h after operation: (0.641 ± 0.036) vs (0.932 ± 0.047) , 6 h after operation: (1.212 ± 0.765) vs (1.627 ± 0.542) and 24 h after operation: (1.496 ± 0.263) vs (1.734 ± 0.328) , all P &lt; 0.05).	OnP__cTnI__no_interaction
23736006-5	With diet P and in genotype Trp64Trp, <compound-id="206,5793,64689,79025">glucose</compound-id> levels (-6.7 ± 12.1 vs. -1.2 ± 2.2 mg/dl; p &lt; 0.05), total <compound-id="5997">cholesterol</compound-id> (-11.2 ± 8.1 vs. -1.0 ± 7.1 mg/dl; p &lt; 0.05), low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> (-9.7 ± 10.1 vs. -2.2 ± 8.1 mg/dl; p &lt; 0.05), triglycerides (-11.7 ± 13.1 vs. +1.7 ± 10.3 mg/dl; p &lt; 0.05), homeostasis model assessment for <protein-id="P01308,I3WAC9">insulin</protein-id> resistance (HOMA-R; -0.7 ± 1.1 vs. -0.3 ± 2.1 units; p &lt; 0.05) and <protein-id="P01308,I3WAC9">insulin</protein-id> levels (-1.8 ± 4.6 vs. -1.0 ± 9.1 mIU/l; p &lt; 0.05) decreased.	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction
20619421-9	Within FEP patients, decreases in <compound-id="5754">cortisol</compound-id> and the <compound-id="5754">cortisol</compound-id>/<protein-id="Q06520,A8K015">DHEAS</protein-id> ratio over time were directly related to the improvement in depression (r = 0.45; p = 0.031, r = 0.52; p = 0.01), negative (r = 0.51; p = 0.006, r = 0.55; p = 0.008) and psychotic symptoms (<compound-id="5754">cortisol</compound-id> only, r = 0.53; p = 0.01).	cortisol__DHEAS__no_interaction
2061325-2	Kinetic studies revealed that (i) S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) was maximally released by the 3rd day, and this was associated with a proportionate decrease in hydrophobic FBPs; (ii) although <compound-id="6197">cycloheximide</compound-id> inhibited de novo synthesis of [35S]<compound-id="6137,84815,876">methionine</compound-id>-labeled hydrophobic FBPs and S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) by greater than 90%, unlabeled net S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) release was only inhibited by 50%; (iii) <compound-id="6049">EDTA</compound-id> markedly inhibited release of S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) which was accompanied by a proportionate increase in hydrophobic FBPs; (iv) <compound-id="6049">EDTA</compound-id> effects were completely reversed by 5-fold molar excesses of Mg2+ which led to a 50-fold greater release of S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) compared to <compound-id="6049">EDTA</compound-id> alone; (v) whereas Mg2+ alone stimulated S-<protein-id="P15328,A0A024R5H1">FBP</protein-id>(PCM) release 4-fold greater than basal conditions, addition of <compound-id="6197">cycloheximide</compound-id> to Mg2+ suppressed (by 4-fold) the expected increase observed with Mg2+ alone.	EDTA__FBP__no_interaction	methionine__FBP__no_interaction	cycloheximide__FBP__no_interaction
22364105-3	The distortion of the ligand--which stands in contrast to all other complexes of <compound-id="23989">uranium</compound-id> supported by the ((R)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>(3-) ligand, including 2-Ad--is most clearly seen in the structures of 2-t-Bu, [(((t-Bu)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>)U(VI)(O)(eq)]SbF(6), and 3-t-Bu, [(((t-Bu)<protein-id="P11511,A0A024R5S8,Q05CU4,A8K6W3,Q8TCA4,Q8IYG4">ArO</protein-id>)(3)<compound-id="188318">tacn</compound-id>)U(VI)(O)(eq)(OC(O)CF(3))(ax)].	uranium__ArO__no_interaction	tacn__ArO__no_interaction
16833708-2	Measured rate coefficients at T = 295 +/- 1 K (in units of M(-1) s(-1)) are as follows: Cl + <compound-id="679">DMSO</compound-id>, (6.3 +/- 0.6) x 10(9); <protein-id="O95490">Cl2</protein-id>(-) + <compound-id="679">DMSO</compound-id>, (1.6 +/- 0.8) x 10(7); Cl + DMSO2, (8.2 +/- 1.6) x 10(5); <protein-id="O95490">Cl2</protein-id>(-) + DMSO2, (8.2 +/- 5.5) x 10(3); <protein-id="O95490">Cl2</protein-id>(-) + MSI, (8.0 +/- 1.0) x 10(8); Cl + MS, (4.9 +/- 0.6) x 10(5); <protein-id="O95490">Cl2</protein-id>(-) + MS, (3.9 +/- 0.7) x 10(3).	DMSO__Cl2__no_interaction
11273911-7	SjO(2) correlated with plasma mAMj concentrations at preclamp (r = 0.79, P &lt; 0.01), postclamp (r = 0.71, P &lt; 0.05), and post-<protein-id="P15086">CPB</protein-id> (r = 0.72, P &lt; 0.05), as well as with <compound-id="8948">mAMa</compound-id> concentrations at preclamp (r = 0.79, P &lt; 0.01) and postclamp (r = 0.72, P &lt; 0.05).	mAMa__CPB__no_interaction
8049647-3	When PBMC from normal individuals were cultured with sera from <compound-id="9841438">ATL</compound-id> patients for 24 hrs, CD3 expression revealed by means of fluorescent intensity (MFI) was down-regulated by sera from <compound-id="9841438">ATL</compound-id> patients in Group A (MFI: <protein-id="Q15935">Pt.1</protein-id> = 51.6 +/- 4.5, Pt.2 = 48.0 +/- 6.9, Control = 96.5 +/- 6.6), not by sera from patients in Group B (MFI: <protein-id="P52742,Q8N9M3,B4DLZ7">Pt.3</protein-id> = 105.5 +/- 7.9, Pt.4 = 102.5 +/- 8.3, Control = 96.5 +/- 6.6).	ATL__Pt.3__no_interaction	ATL__Pt.1__no_interaction
19997015-6	Venoarterial [La-] difference ([La-]v-a) at 30 s of post-<compound-id="447029">IHG</compound-id> was the same across conditions (passive = 6.1 +/- 0.6 mmol x L(-1), active = 5.7 +/- 0.6 mmol x L(-1), massage = 5.5 +/- 0.6 mmol x L(-1), NS), whereas FBF was greater in passive (766 +/- 101 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) versus active (614 +/- 62 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P = 0.003) versus massage (540 +/- 60 mL x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), P &lt; 0.0001).	IHG__min(-1__no_interaction
16913263-10	However, at 10 minutes, changes in <protein-id="P41222,A0A024R8G3">PGD2</protein-id>, tryptase, and <compound-id="774">histamine</compound-id> were not significant (46.8 +/- 9.2 pg/mL versus 68.6 +/- 9.2 pg/mL, p = 0.1; 9.5 +/- 2.7 ng/mL versus 16.6 +/- 2.9 ng/mL, p = 0.09; and 1.5 +/- 1.6 ng/mL versus 3.5 +/- 1.6 ng/mL, p = 0.4).	histamine__PGD2__no_interaction
8434787-5	Using the dual assay, kinetic constants determined for <protein-id="Q64133,Q3TPD9,Q3UJ53">MAO-A</protein-id> (mean +/- SD) were: Km,<compound-id="5202">5-HT</compound-id> = 39 +/- 7 microM, Vmax,<compound-id="5202">5-HT</compound-id> = 37.6 +/- 2.1 pmol/mg wet tissue/min, Km,MHBA = 341 +/- 75 microM, and Vmax,MHBA = 27.7 +/- 2.3 pmol/mg wet tissue/min; those for <protein-id="Q8BW75">MAO-B</protein-id> were: Km,MHBA = 108 +/- 11 microM, Vmax,MHBA = 44.3 +/- 1.2 pmol/mg wet tissue/min, Km,<compound-id="5202">5-HT</compound-id> = 1704 +/- 122 microM, and Vmax,<compound-id="5202">5-HT</compound-id> = 12.0 +/- 0.3 pmol/mg wet tissue/min.	5-HT__MAO-B__no_interaction	5-HT__MAO-A__no_interaction
20868439-13	(E/e'<protein-id="O43561,A0A024QZD6">lat</protein-id>)/LVDd was not reduced in athletes comparing to controls (<compound-id="962">water</compound-id> polo players 0.83 ± 0.39, wrestlers 0.73 ± 0.29, controls 0.70 ± 0.28; P = 0.52), but (E/e's)/<compound-id="56973415">RVe</compound-id>'<protein-id="O43561,A0A024QZD6">lat</protein-id> better distinguished examined groups (<compound-id="962">water</compound-id> polo players 0.48 ± 0.37, wrestlers 0.28 ± 0.15, controls 0.25 ± 0.16, P = 0.015) and it was the only index which predicted VO(2) max.	water__lat__no_interaction	RVe__lat__no_interaction
16676956-1	A new dealkylation reaction between organophosphate esters and <compound-id="5464119">Salen</compound-id> <compound-id="24409">aluminum bromide</compound-id> compounds has been used to prepare three new <compound-id="5359268">aluminum</compound-id> <compound-id="5464119">salen</compound-id> compounds <compound-id="5464119">salen</compound-id>((t)Bu)AlOP(O)<protein-id="Q8IXK0">Ph2</protein-id> (1) (<compound-id="5464119">salen</compound-id> = N,N'-ethylenebis(3,5-di-tert-butylsalicylideneimine)), [(<compound-id="887">MeOH</compound-id>)Alsalen((t)Bu)[OMePO2(O)]Alsalen((t)Bu)[OMePO2(O)]Alsalen((t)Bu)]Br (2), and [salpen((t)Bu)AlO]2[(BuO)2PO]2 (3) (salpen = N,N'-propylenebis(3,5-di-tert-butylsalicylideneimine)).	Salen__Ph2__no_interaction	salen__Ph2__no_interaction	aluminum__Ph2__no_interaction	aluminum bromide__Ph2__no_interaction	MeOH__Ph2__no_interaction
15648780-5	Serum <protein-id="P50591,Q6IBA9">TRAIL</protein-id> concentrations correlated significantlywithTBF (r = 0.31, p &lt; 0.05) and lean body mass (r = -0.26, p &lt;0.05) in men and <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.32, p &lt; 0.05) and total <compound-id="5997">cholesterol</compound-id> (r = 0.21, p &lt; 0.05) in women.	cholesterol__TRAIL__no_interaction	cholesterol__LDL-C__no_interaction
20029513-3	Mean RSA time (RSA(mean)) and RSA decrement were related to the physiological responses to HIT (blood <compound-id="612">lactate</compound-id> concentration ([La(-)]), r = 0.66 and 0.77; blood <compound-id="767">bicarbonate</compound-id> concentration ([HCO(3)-]), r = -0.71 and -0.75; and blood <compound-id="783">hydrogen</compound-id> ion concentration ([H(+)]), r = 0.61 and 0.73; all p &lt; 0.05), VO(2) (max) (r = -0.45 and -0.65, p &lt; 0.05), and time constant (<protein-id="P10636,A0A024R9Y0,A0A024RA17,A0A024R9Y1,A0A024RA19,B3KTM0">tau</protein-id>) in VO(2) kinetics (r = 0.62 and 0.62, p &lt; 0.05).	bicarbonate__tau__no_interaction	hydrogen__tau__no_interaction	lactate__tau__no_interaction
17921920-7	Presence of inflammation and malnutrition (in 44% of patients) was associated with older age (60.69 -/+ 12.46 vs. 54.52 -/+ 12.37, p = 0.0002), lower levels of Hb (99.53 -/+ 14.97 vs. 111.86 -/+ 10.38 g/l, p = 0.0000), <compound-id="588">creatinine</compound-id> (835.88 -/+ 179.84 vs. 1069.98 -/+ 821.23-/+mol/l, p = 0.0047), <protein-id="P02768">albumin</protein-id> (36.58 -/+ 3.41 vs.40.32 -/+ 2.82 g/l, p = 0.0000), <compound-id="5997">cholesterol</compound-id> (4.32 -/+ 1.04 vs. 4.75 -/+ 1.09 mmol/l, p = 0.0025) and higher levels of fibrinogen (4.94 -/+ 1.18 vs. 4.29-/+0.91g/l, p=0.0000) and <protein-id="P02741">CRP</protein-id> (30.42-/+29.47 vs. 5.24-/+4.89 mg/l, p=0.0000).	creatinine__CRP__no_interaction	creatinine__albumin__no_interaction	cholesterol__CRP__no_interaction	cholesterol__albumin__no_interaction
23675748-6	The activation parameters, which have been obtained from fitting the reaction rates at different temperatures to the Eyring equation for <compound-id="23950">ruthenium</compound-id> [ΔH(cis-trans)‡ = 122.8 ± 1.3; ΔH(trans-cis)‡ = 138.8 ± 1.0 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>; ΔS(cis-trans)‡ = -18.7 ± 3.6; ΔS(trans-cis)‡ = 31.8 ± 2.7 J/(<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>·K)] and <compound-id="23937">osmium</compound-id> [ΔH(cis-trans)‡ = 200.7 ± 0.7; ΔH(trans-cis)‡ = 168.2 ± 0.6 kJ/<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>; ΔS(cis-trans)‡ = 142.7 ± 8.9; ΔS(trans-cis)‡ = 85.9 ± 3.9 J/(<protein-id="Q1HG43,B5M0B8,B5M0C0,A8K9Q6,B5M0B7">mol</protein-id>·K)] reflect the inertness of these systems.	ruthenium__mol__no_interaction	osmium__mol__no_interaction
6510639-1	A new <compound-id="962">water</compound-id>-soluble nitrosourea derivative, methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-<compound-id="5793">D-glucopyranoside</compound-id> (MCNU), was tested for antitumor activity against murine tumors (L1210 and P388 leukemias, B16 melanoma, and Lewis lung carcinoma) and BC-47 rat bladder carcinoma, and the results were compared with those for four other nitrosourea derivatives; <compound-id="57130000">chlorozotocin</compound-id>, 1-(2-chloroethyl)-3-(beta-D-<compound-id="64960">glucopyranosyl</compound-id>)-<compound-id="105035">1-nitrosourea</compound-id> (<compound-id="99636,9972891">GANU</compound-id>), 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1- nitrosourea hydrochloride (ACNU), and 1-(2-chloroethyl)-<compound-id="91127918">3-(4-methylcyclohexyl)-1-nitrosourea</compound-id> (methyl-<protein-id="P0C242,B2RWG0">CCNU</protein-id>).	D-glucopyranoside__CCNU__no_interaction	GANU__CCNU__no_interaction	1-nitrosourea__CCNU__no_interaction	water__CCNU__no_interaction	glucopyranosyl__CCNU__no_interaction	3-(4-methylcyclohexyl)-1-nitrosourea__CCNU__no_interaction	chlorozotocin__CCNU__no_interaction
23197773-2	In the present studies, the effects of <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) agonists [(6aR,10aR)-3-(1-adamantyl)-<compound-id="44375198">6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol</compound-id> (AM411), 9β-(hydroxymethyl)-3-(1-adamantyl)-<compound-id="522237">hexahydrocannabinol</compound-id> (<compound-id="71661716">AM4054</compound-id>), <compound-id="54358654">R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate</compound-id> (WIN55,212.2), Δ(9)-<compound-id="16078">tetrahydrocannabinol</compound-id> (Δ(9)-THC), (R)-(+)-<compound-id="6438332">arachidonyl-1'-hydroxy-2'-propylamide</compound-id> (<compound-id="18346297,6321351,6610214">methanandamide</compound-id>)], <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) antagonists [<compound-id="1519421">5-(4-chlorophenyl)-1-(</compound-id>2,4-dichloro-phenyl)-<compound-id="67158791">4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide</compound-id> (<compound-id="104850">SR141716A</compound-id>), 5-(4-alkylphenyl)-1-(2,4-dichlorophenyl)-<compound-id="67158791">4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide</compound-id> (AM4113)], and <compound-id="681">dopamine</compound-id> (DA)-related [<compound-id="10836">methamphetamine</compound-id>, (±)-6-chloro-7,8-dihydroxy-3-<compound-id="8252">allyl</compound-id>-<compound-id="2870943">1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine</compound-id> hydrobromide (SKF82958), (R)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-<compound-id="1400243">2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride</compound-id> (<compound-id="5018">SCH23390</compound-id>), (6aR)-5,6,6a,7-tetrahydro-6-propyl-4H-dibenzo[de,g]<compound-id="7047">quinoline</compound-id>-10,11-diol (R-(-)-NPA), <compound-id="3559">haloperidol</compound-id>] and opioid (morphine, <compound-id="5360515">naltrexone</compound-id>) drugs on scheduled-controlled responding under a 30-response fixed ratio schedule of stimulus-shock termination in squirrel monkeys were compared before and during chronic treatment with the long-acting <protein-id="P21554,V5KA96,S5TLS4">CB(1</protein-id>) agonist AM411 (1.0 mg/kg per day, i.m.).	methamphetamine__CB(1__no_interaction	1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine__CB(1__no_interaction	methanandamide__CB(1__no_interaction	SR141716A__CB(1__no_interaction	R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate__CB(1__no_interaction	dopamine__CB(1__no_interaction	SCH23390__CB(1__no_interaction	hexahydrocannabinol__CB(1__no_interaction	AM4054__CB(1__no_interaction	4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide__CB(1__no_interaction	6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol__CB(1__no_interaction	tetrahydrocannabinol__CB(1__no_interaction	5-(4-chlorophenyl)-1-(__CB(1__no_interaction	allyl__CB(1__no_interaction	2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride__CB(1__no_interaction	naltrexone__CB(1__no_interaction	quinoline__CB(1__no_interaction	haloperidol__CB(1__no_interaction	arachidonyl-1'-hydroxy-2'-propylamide__CB(1__no_interaction
2147141-1	The effect of acute volume expansion (2 liters of saline solution in 2 h) on plasma concentrations of <protein-id="P01160">atrial natriuretic factor</protein-id> (<protein-id="P01160">ANF</protein-id>), plasma aldosterone concentration (PAC), plasma <protein-id="P00797">renin</protein-id> activity (PRA) and their relationship to the renal excretion of urine, <compound-id="5360545">sodium</compound-id> and <compound-id="5462222">potassium</compound-id> were studied in 6 control subjects and 7 patients with essential hypertension (EH) WHO stage I. Saline infusion provoked comparable rise in plasma <protein-id="P01160">ANF</protein-id> in both groups (from 2.98 +/- 0.45 to 12.36 +/- 1.74 pmol/l in the control subjects and from 3.80 +/- 0.72 to 15.78 +/- 2.06 pmol/l in EH patients), significant drop in PRA (from 0.915 +/- 0.419 to 0.256 +/- 0.127 nmol/l/h in controls and from 1.711 +/- 0.324 to 0.714 +/- 0.128 nmol/l/h in EH) and in PAC (from 0.30 +/- 0.07 to 0.14 +/- 0.03 nmol/l in control subjects and from 0.53 +/- 0.13 to 0.24 +/- 0.07 nmol/l in EH).	potassium__ANF__no_interaction	potassium__atrial natriuretic factor__no_interaction	potassium__renin__no_interaction	sodium__ANF__no_interaction	sodium__atrial natriuretic factor__no_interaction	sodium__renin__no_interaction
8388858-1	To evaluate whether, in the forearm of hypertensive patients with different circulating <protein-id="P00797">renin</protein-id> profiles, local beta-adrenergic receptor-induced production of active <protein-id="P00797">renin</protein-id>, plasma <protein-id="P00797">renin</protein-id> activity, <protein-id="P01019,B0ZBE2,B2R5S1">angiotensin I (Ang I</protein-id>), and angiotensin II (<protein-id="O15123">Ang II</protein-id>) was or was not related to the <protein-id="P00797">renin</protein-id> profile, we studied four groups of patients: 1) hypertensive patients with primary aldosteronism and suppressed circulating plasma <protein-id="P00797">renin</protein-id> activity values (0.15 +/- 0.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 7), 2) essential hypertensive patients with low (0.47 +/- 0.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 8) circulating plasma <protein-id="P00797">renin</protein-id> activity values, 3) essential hypertensive patients with normal (2.48 +/- 0.52 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 8) circulating plasma <protein-id="P00797">renin</protein-id> activity value, and 4) renovascular hypertensive patients with high circulating plasma <protein-id="P00797">renin</protein-id> activity values (4.16 +/- 2.1 ng <compound-id="44299732">Ang I</compound-id>/mL per hour; n = 10).	Ang I__angiotensin I (Ang I__no_interaction	Ang I__Ang II__no_interaction	Ang I__renin__no_interaction
17126448-6	Multivariate analysis identified <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (&gt;or=86 mg/dl), aa substitutions in HCV-CR (double-wild-type; <compound-id="6322,90867653">arginine</compound-id> at aa 70/<compound-id="6106">leucine</compound-id> at aa 91), <protein-id="Q9BX51,D3DW46">gamma-glutamyl transpeptidase</protein-id> (GGT) (&lt;109 IU/l), RBV dose (&gt;or=11.0mg/kg), and leukocyte count (&gt;or=4500/mm3) as significant determinants of EVR, and aa substitutions in HCV-CR (double-wild-type), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (&gt;or=86 mg/dl), male gender, <compound-id="6096882">ICG</compound-id> <compound-id="24856345">R15</compound-id> (&lt;10%), GGT (&lt;109 IU/l), and RBV dose (&gt;or=11.0 mg/kg) as determinants of SVR.	leucine__low-density lipoprotein cholesterol__no_interaction	leucine__LDL-C__no_interaction	leucine__gamma-glutamyl transpeptidase__no_interaction	R15__low-density lipoprotein cholesterol__no_interaction	R15__LDL-C__no_interaction	R15__gamma-glutamyl transpeptidase__no_interaction	ICG__low-density lipoprotein cholesterol__no_interaction	ICG__LDL-C__no_interaction	ICG__gamma-glutamyl transpeptidase__no_interaction	arginine__low-density lipoprotein cholesterol__no_interaction	arginine__LDL-C__no_interaction	arginine__gamma-glutamyl transpeptidase__no_interaction
15119638-10	Observed/predicted ratios for TBK in PD patients correlated with serum <compound-id="5462222">potassium</compound-id> (Boddy r = 0.355, p = 0.06; <protein-id="Q9NR09">Bruce</protein-id> r = 0.411, p &lt; 0.05; Burkinshaw r = 0.457, p &lt; 0.01; Leeds r = 0.412, p &lt; or = 0.05; Ellis r = 0.356, p = 0.06) and tended to correlate with <protein-id="P02768">serum albumin</protein-id> (<protein-id="Q9NR09">Bruce</protein-id> r = 0.343, p = 0.07; Burkinshaw r = 0.421, p &lt; 0.05; Leeds r = 0.357, p = 0.06; Ellis r = 0.310, p = NS).	potassium__Bruce__no_interaction	potassium__serum albumin__no_interaction
12005497-3	Crystal structures of the monosubstituted ortho-carborane, 1-[(N,N'((tert-butyloxy)carbonyl)hydrazino)]-1,2-dicarba-closo-dodecaborane (8) [a = 21.213(6) A, b = 10.498(3) A, c = 9.866(2) <protein-id="P28347,Q59EF3">A, alpha</protein-id> = gamma = 90 degrees, beta = 90.529(4) degrees ] and the bifunctional para-carborane 1-[(N,N'((tert-butyloxy)carbonyl)hydrazino)]-1,12-dicarba-closo-dodecaborane-12-<compound-id="11229316,91179806">carboxylic acid</compound-id> (3) [a = 12.744(10) A, b = 12.875(9) A, c = 14.767(9) <protein-id="P28347,Q59EF3">A, alpha</protein-id> = beta = gamma = 90 degrees ] were obtained.	carboxylic acid__A, alpha__no_interaction
24294778-7	We found a significant correlation between fibrosis stage and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.53; p &lt; 0.01), IL-6 (r = 0.62; p &lt; 0.01), the Knodell Histological Activity Index and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.58, p &lt; 0.05), IL-6 (r = 0.64; p &lt; 0.01), the results of 13C MBT and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = -0.72; p &lt; 0.01), IL-6 (r = -0.73; p &lt; 0.01), <compound-id="5950">alanine</compound-id> aminotransferase and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.61; p &lt; 0.01), IL-6 (r = 0.54; p &lt; 0.01), <compound-id="5960">aspartate</compound-id> aminotransferase and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.64; p &lt; 0.01), IL-6 (r = 0.65; p &lt; 0.01), <protein-id="Q9BX51,D3DW46">gamma-glutamyl transpeptidase</protein-id> and <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (r = 0.46; p &lt; 0.01), IL-6 (r = 0.48; p &lt; 0.01).	alanine__TNF-alpha__no_interaction	alanine__gamma-glutamyl transpeptidase__no_interaction	aspartate__TNF-alpha__no_interaction	aspartate__gamma-glutamyl transpeptidase__no_interaction
11960941-2	Several days of hypobaric hypoxemia reduced body weight (-2.1 +/- 0.4 kg), increased plasma osmolality (+5.3 +/- 1.4 mosmol/kgH(2)O), elevated blood pressure (+12 +/- 1 mmHg), reduced <compound-id="588">creatinine</compound-id> clearance (122 +/- 6 to 96 +/- 10 ml/min), inhibited the <protein-id="P00797">renin</protein-id> system (19.5 +/- 2.0 to 10.9 +/- 0.9 mU/l) and plasma <protein-id="P01185,X5DQP6">vasopressin</protein-id> (1.14 +/- 0.16 to 0.38 +/- 0.06 pg/ml), and doubled circulating levels of <compound-id="439260">norepinephrine</compound-id> (103 +/- 16 to 191 +/- 35 pg/ml) and <protein-id="P05305,Q6FH53">endothelin-1</protein-id> (3.0 +/- 0.2 to 6.3 +/- 0.6 pg/ml), whereas <compound-id="16132416">urodilatin</compound-id> excretion rate decreased from day 2 (all changes P &lt; 0.05 compared with sea level).	creatinine__endothelin-1__no_interaction	creatinine__vasopressin__no_interaction	creatinine__renin__no_interaction	urodilatin__endothelin-1__no_interaction	urodilatin__vasopressin__no_interaction	urodilatin__renin__no_interaction	norepinephrine__endothelin-1__no_interaction	norepinephrine__vasopressin__no_interaction	norepinephrine__renin__no_interaction
22227199-3	During the BAL trial, absolute power (F 107 ± 2 and UF 102 ± 2 W; P = 0.126), E(<compound-id="72792">req</compound-id>) (F 175 ± 5 and UF 176 ± 9 W m(-2); P = 0.855), steady-state whole-body sweat rate (F 0.44 ± 0.02 and UF 0.47 ± 0.02 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.385) and local sweat rate on the arm (F 0.29 ± 0.03 and UF 0.35 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.129) were not different between groups; however, local sweat rate on the forehead in UF (1.67 ± 0.20 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) was almost double (P = 0.002) that of F (0.87 ± 0.11 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)).	req__min(-1__no_interaction
22227199-6	At 60% (V(O2 max)), absolute power (F 174 ± 6 and UF 110 ± 5 W; P &lt; 0.001), E(<compound-id="72792">req</compound-id>) (F 291 ± 14 and UF 190 ± 17 W m(-2); P &lt; 0.001), steady-state whole-body sweat rate (F 0.84 ± 0.05 and UF 0.53 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt; 0.001) and local sweat rate on the arm (F 0.75 ± 0.04 and UF 0.35 ± 0.03 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt; 0.001) and on the forehead (F 2.92 ± 0.42 and UF 1.68 ± 0.23 mg cm(-2) <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P = 0.022) were all significantly greater in F compared with UF.	req__min(-1__no_interaction
19785958-5	RESULTS: Transaminase increased significantly only in 10 and 11-month- old (<protein-id="Q8VHK8">AST</protein-id>(TX10) = 218.3 U/L, <protein-id="Q8VHK8">AST</protein-id>(TX11) = 197.5 U/L, <protein-id="Q8VHK8">AST</protein-id>(DL10) = 171.5 U/L, <protein-id="Q8VHK8">AST</protein-id>(DL11) = 165.0 U/L, P(10) less than 0.001, P(11) = 0.022), but the <compound-id="23978">copper</compound-id> concentration of liver, brain and kidney was significantly increased during 7-12 month old (the average concentration of <compound-id="23978">copper</compound-id>, Liver(TX) = (750.0 +/- 85.5) mg/kg, Brain(TX) = (39.7 +/- 2.2)mg/kg, Kidney(TX) = (29.8 +/- 5.0) mg/kg, Liver(DL) = (11.6 +/- 1.5) mg/kg, Brain(DL) = (16.8 +/- 0.9) mg/kg, Kidney(DL) = (14.2 +/- 1.0) mg/kg, t = 21.16, 23.60, 7.47, for all these organs P less than 0.05).	copper__AST__no_interaction
22236368-7	The following markers were found to be of prognostic value on mortality in hip fracture patients: low haemoglobin (odds ratio, 2.78; 95% confidence interval, 2.17-3.55; P&lt;0.00001, 3148 subjects included), low total lymphocyte count, <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 2.60; 95% confidence interval, 1.61-4.20; P&lt;0.00001, 1689 subjects included), low albumin (odds ratio, 1.83; 95% confidence interval, 1.31-2.56; P=0.0004, 1680 subjects included), low albumin/low <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 3.00; 95% confidence interval, 1.81-4.99; P&lt;0.0001, 704 subjects included), low albumin/high <protein-id="P31025,A0A024R8D7">TLC</protein-id> (odds ratio, 3.39; 95% confidence interval, 1.83-6.29; P=0.0001, 704 subjects included), high <compound-id="588">creatinine</compound-id> (odds ratio, 1.58; 95% confidence interval, 1.25-1.99; P=0.0001, 3761 subjects included), and high <protein-id="P01270">PTH</protein-id> (odds ratio, 15.43; 95% confidence interval, 3.60-66.14; P=0.0002, 525 subjects included).	creatinine__TLC__no_interaction	creatinine__PTH__no_interaction
8148775-3	The sum of blood <compound-id="206,64689,79025">glucose</compound-id> and plasma <protein-id="P01308,I3WAC9">Insulin</protein-id> levels (0 + 1h + 2h) were compared in each of the following 5 groups of subjects: A--25 cases with IGT but without obesity (BMI: 23.2 +/- 2.6) and hyperlipidaemia (PL: 627 +/- 112; TG: 102 +/- 109 and CH: 208 +/- 35 mg/dl); B--35 cases with IGT and obesity (BMI: 31.2 +/- 2.6) but without hyperlipidaemia (PL: 807 +/- 109; TG: 136 +/- 31 and CH: 254 +/- 41 mg/dl); C--23 cases with IGT and hyperlipidaemia (PL: 1013 +/- 217; TG: 214 +/- 85 and CH: 311 +/- 52 mg/dl) but without obesity (BMI: 25.4 +/- 1.9); D--48 cases with IGT and both obesity (BMI: 30.9 +/- 2.8) and hyperlipidaemia (PL: 1457 +/- 155; TG: 597 +/- 188 and CH: 483 +/- 184 mg/dl); a control group of 49 cases without IGT, obesity (BMI: 26.2 +/- 1.9) or hyperlipidaemia (PL: 726 +/- 99 mg/dl).	glucose__Insulin__no_interaction
20816195-8	Gene-based analyses that included all available SNPs in each gene found associations (P &lt; .05) with both phenotypes for several genes: <protein-id="Q7Z3B1">neuronal growth regulator 1</protein-id> (<protein-id="Q7Z3B1">NEGR1</protein-id>); roundabout, axon guidance receptor, homolog 1 (<protein-id="Q9Y6N7,Q1RMC8">ROBO1</protein-id>); <protein-id="P49619">diacylglycerol kinase, gamma</protein-id> (<protein-id="P49619">DGKG</protein-id>); <protein-id="Q9BWQ8">Fas apoptotic inhibitory molecule 2</protein-id> (<protein-id="Q9BWQ8">FAIM2</protein-id>); fat mass and obesity associated (FTO); and carbohydrate (<compound-id="440552,57455154,84265,899">N-acetylgalactosamine</compound-id> 4-0) sulfotransferase 8 (<protein-id="Q9H2A9">CHST8</protein-id>) among the BMI GWAS genes; <protein-id="Q01638">interleukin 1 receptor-like 1</protein-id> / <protein-id="Q13478,B7ZKV7">interleukin 18 receptor 1</protein-id> (<protein-id="Q01638">IL1RL1</protein-id>/<protein-id="Q13478,B7ZKV7">IL18R1</protein-id>), <protein-id="Q8N608,B4DKB5,Q0GLB9,B2RCJ8,Q0GLB7">dipeptidyl-peptidase 10</protein-id> (<protein-id="Q8N608,B4DKB5,Q0GLB9,B2RCJ8,Q0GLB7">DPP10</protein-id>), <protein-id="Q08499">phosphodiesterase 4D</protein-id> (<protein-id="Q08499">PDE4D</protein-id>), V-<protein-id="P10242,Q708E9,Q14025">myb</protein-id> myeloblastosis viral oncogene homolog (<protein-id="P10242,Q708E9,Q14025">myb</protein-id>), <protein-id="Q9Y233">PDE10A</protein-id>, <protein-id="O95760">IL33</protein-id>, and especially protein <compound-id="6057,90983769">tyrosine</compound-id> phosphatase, receptor type D (PTPRD) among the asthma GWAS genes; and <protein-id="P17252,Q7Z727">protein kinase C, alpha</protein-id> (<protein-id="P17252,Q7Z727">PRKCA</protein-id>) among the BMI and asthma candidate genes.	N-acetylgalactosamine__FAIM2__no_interaction	N-acetylgalactosamine__DPP10__no_interaction	N-acetylgalactosamine__interleukin 1 receptor-like 1__no_interaction	N-acetylgalactosamine__dipeptidyl-peptidase 10__no_interaction	N-acetylgalactosamine__diacylglycerol kinase, gamma__no_interaction	N-acetylgalactosamine__CHST8__no_interaction	N-acetylgalactosamine__neuronal growth regulator 1__no_interaction	N-acetylgalactosamine__interleukin 18 receptor 1__no_interaction	N-acetylgalactosamine__Fas apoptotic inhibitory molecule 2__no_interaction	N-acetylgalactosamine__protein kinase C, alpha__no_interaction	N-acetylgalactosamine__IL18R1__no_interaction	N-acetylgalactosamine__NEGR1__no_interaction	N-acetylgalactosamine__ROBO1__no_interaction	N-acetylgalactosamine__PRKCA__no_interaction	N-acetylgalactosamine__IL33__no_interaction	N-acetylgalactosamine__PDE10A__no_interaction	N-acetylgalactosamine__myb__no_interaction	N-acetylgalactosamine__PDE4D__no_interaction	N-acetylgalactosamine__DGKG__no_interaction	N-acetylgalactosamine__phosphodiesterase 4D__no_interaction	N-acetylgalactosamine__IL1RL1__no_interaction	tyrosine__FAIM2__no_interaction	tyrosine__DPP10__no_interaction	tyrosine__interleukin 1 receptor-like 1__no_interaction	tyrosine__dipeptidyl-peptidase 10__no_interaction	tyrosine__diacylglycerol kinase, gamma__no_interaction	tyrosine__CHST8__no_interaction	tyrosine__neuronal growth regulator 1__no_interaction	tyrosine__interleukin 18 receptor 1__no_interaction	tyrosine__Fas apoptotic inhibitory molecule 2__no_interaction	tyrosine__protein kinase C, alpha__no_interaction	tyrosine__IL18R1__no_interaction	tyrosine__NEGR1__no_interaction	tyrosine__ROBO1__no_interaction	tyrosine__PRKCA__no_interaction	tyrosine__IL33__no_interaction	tyrosine__PDE10A__no_interaction	tyrosine__myb__no_interaction	tyrosine__PDE4D__no_interaction	tyrosine__DGKG__no_interaction	tyrosine__phosphodiesterase 4D__no_interaction	tyrosine__IL1RL1__no_interaction
11525238-3	The dissociation of <protein-id="P04792,V9HW43">Hsp27</protein-id> induced by exposure of U251 MG human glioma cells to metals (NaAsO2 and CdCl2), hypertonic stress (<compound-id="5780">sorbitol</compound-id> and NaCI), or <compound-id="253602">anisomycin</compound-id>, an activator of p38 mitogen-activated protein (MAP) kinase, was completely suppressed by the presence of <compound-id="176155">SB 203580</compound-id> or <compound-id="4712">PD 169316</compound-id>, inhibitors of <protein-id="Q16539,L7RSM2,B4E0K5,A0A024RD15">p38 MAP kinase</protein-id>, but not by PD 98059 and Uo 126, inhibitors of MAP kinase kinase (MEK), nor by <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, Go 6983, and <compound-id="2396">bisindolylmaleimide</compound-id> I, inhibitors of protein kinase C. <compound-id="27924,70702034">Phorbol ester</compound-id> (<compound-id="122634">PMA</compound-id>)-induced dissociation of <protein-id="P04792,V9HW43">Hsp27</protein-id> was completely suppressed by <compound-id="44120114,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178">staurosporine</compound-id>, Go 6983, or <compound-id="2396">bisindolylmaleimide</compound-id> I and partially suppressed by <compound-id="176155">SB 203580</compound-id>, or <compound-id="4712">PD 169316</compound-id> but not by PD 98059 or Uo 126, indicating mediation by 2 cascades.	bisindolylmaleimide__Hsp27__no_interaction	bisindolylmaleimide__p38 MAP kinase__no_interaction	staurosporine__Hsp27__no_interaction	staurosporine__p38 MAP kinase__no_interaction	PD 169316__Hsp27__no_interaction	PD 169316__p38 MAP kinase__no_interaction	anisomycin__Hsp27__no_interaction	anisomycin__p38 MAP kinase__no_interaction	SB 203580__Hsp27__no_interaction	SB 203580__p38 MAP kinase__no_interaction	PMA__Hsp27__no_interaction	PMA__p38 MAP kinase__no_interaction	sorbitol__Hsp27__no_interaction	sorbitol__p38 MAP kinase__no_interaction	Phorbol ester__Hsp27__no_interaction	Phorbol ester__p38 MAP kinase__no_interaction
23364602-1	Twelve lanthanide coordination polymers associated with the organic ligand 5-(2′-carboxylphenyl) <compound-id="938">nicotinic acid</compound-id> (H2cpna): {[Ln(Hcpna)(cpna)(phen)]·H2O}n (Ln = Sm (1), Tb (2), Ho (3), phen = 1,10-<compound-id="67473">phenanthroline</compound-id>), {[Sm(Hcpna)(cpna)(phen)]·2H2O}n (4), {[Ln2(cpna)3(H2O)3]·<compound-id="70679364">4H2O</compound-id>}n (Ln = Y (5), Tb(6), Dy (7), Ho (8)), [Lu2(cpna)3(H2O)2]n (9), {[Y2(cpna)3(phen)2(H2O)]·H2O}n (10), and [Ln(cpna)(phen)(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)]n (Ln = Tm (11), Lu (12)) have been prepared by hydrothermal methods and structurally characterized.	phenanthroline__NO3__no_interaction	nicotinic acid__NO3__no_interaction	4H2O__NO3__no_interaction
18820136-6	The effects of (-)-<compound-id="3779">isoproterenol</compound-id> were surmountably antagonized by the <protein-id="P18762">beta(2)-AR</protein-id>-selective antagonist ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-<compound-id="7219">inden</compound-id>-4-yl)oxy]-3-[(1-<compound-id="275736">methylethyl</compound-id>)amino]-2-<compound-id="12721311,263">butanol</compound-id>] (pK(B) = 9.28) but not affected by the <protein-id="P34971">beta(1)-AR</protein-id>-selective antagonist CGP 20712 [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)<compound-id="6341">ethylamino</compound-id>]-3-[4-(1-methyl-4-<compound-id="6373">trifluoromethyl</compound-id>-2-imidazolyl)phenoxy]-<compound-id="3776">2-propanol</compound-id>] and <protein-id="P13945,A8KAG8">beta(3)-AR</protein-id>-selective L-748,337 [(S)-M-[4-[2-[3-[3-[<compound-id="6582">acetamidomethyl</compound-id>)phenoxy)-2-hydroxypropyl]-amino]-<compound-id="23134249">ethyl</compound-id>]-phenylbenzsulfonamide)], suggesting involvement of <protein-id="P18762">beta(2)-AR</protein-id> only.	isoproterenol__beta(3)-AR__no_interaction	isoproterenol__beta(2)-AR__no_interaction	isoproterenol__beta(1)-AR__no_interaction	ethylamino__beta(3)-AR__no_interaction	ethylamino__beta(2)-AR__no_interaction	ethylamino__beta(1)-AR__no_interaction	2-propanol__beta(3)-AR__no_interaction	2-propanol__beta(2)-AR__no_interaction	2-propanol__beta(1)-AR__no_interaction	methylethyl__beta(3)-AR__no_interaction	methylethyl__beta(2)-AR__no_interaction	methylethyl__beta(1)-AR__no_interaction	inden__beta(3)-AR__no_interaction	inden__beta(2)-AR__no_interaction	inden__beta(1)-AR__no_interaction	butanol__beta(3)-AR__no_interaction	butanol__beta(2)-AR__no_interaction	butanol__beta(1)-AR__no_interaction	ethyl__beta(3)-AR__no_interaction	ethyl__beta(2)-AR__no_interaction	ethyl__beta(1)-AR__no_interaction	trifluoromethyl__beta(3)-AR__no_interaction	trifluoromethyl__beta(2)-AR__no_interaction	trifluoromethyl__beta(1)-AR__no_interaction	acetamidomethyl__beta(3)-AR__no_interaction	acetamidomethyl__beta(2)-AR__no_interaction	acetamidomethyl__beta(1)-AR__no_interaction
2472359-3	<protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> and galanin significantly inhibited the stimulation-evoked [3H]norepinephrine release in a dose-dependent manner (1 Hz: S2/S1 ratio (mean +/- <compound-id="5289348">SEM</compound-id>), control 0.947 +/- 0.040, n = 11, <protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> 1 x 10(-8) M 0.509 +/- 0.013, n = 8, p less than 0.01, <protein-id="P07808,F2W8A6">Neuropeptide Y</protein-id> 1 x 10(-7) M 0.283 +/- 0.021, n = 8, p less than 0.01; galanin 1 x 10(-7) M 0.448 +/- 0.026, n = 8, p less than 0.01, galanin 1 x 10(-6) M 0.261 +/- 0.023, n = 8, p less than 0.01).	SEM__Neuropeptide Y__no_interaction
17494790-9	Serum <protein-id="P20366,Q9Y494">substance P</protein-id> levels were negatively correlated with Epworth sleepiness scale score (r = - 0.253, p = 0.048), number of total apneas during the night (r = - 0.247, p = 0.036), number of respiratory events during the night (r = - 0.266, p = 0.024), apnea-hypopnea index (r = - 0.287, p = 0.015), respiratory arousal index (r = - 0.267, p = 0.026), time spent in apnea and hypopnea (r = - 0.307, p = 0.01), average <compound-id="977">oxygen</compound-id> desaturation (r = - 0.265, p = 0.026), and <compound-id="977">oxygen</compound-id> desaturation index (r = - 0.254, p = 0.031).	oxygen__substance P__no_interaction
16161752-6	In these surveillances spanning three years, the incidence rates of resistance in various species were as follows (2000.6-2001.3 --&gt; 2001.4-2002.3 --&gt; 2002.4-2003.3): <compound-id="6087">methicillin</compound-id>-resistant Staphylococcus aureus (39.3% --&gt; 43.9% --&gt; 47.3%), penicillin-intermediate Streptococcus pneumoniae (48.9% --&gt; 44.2% --&gt; 25.7%), penicillin-resistant S. pneumoniae (PRSP, 13.8% --&gt; 26.3% --&gt; 43.2%), extended-spectrum <protein-id="Q48435,Q6A253">beta-lactamase</protein-id> (ESBL)-producing Escherichia coli (0.9% --&gt; 0% --&gt; 1.4%), ESBL-producing Klebsiella pneumoniae (3.4% --&gt; 1.3% --&gt; 3.1%), <protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-producing Haemophilus influenzae (19.2% --&gt; 8.9% --&gt; 42.9%), <protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-negative <compound-id="6249">ampicillin</compound-id>-resistant H. influenzae (BLNAR, 22.1% --&gt; 30.7% --&gt; 33.0%), and metallo-<protein-id="Q48435,Q6A253">beta-lactamase</protein-id>-producing Pseudomonas aeruginosa (1.0% --&gt; 4.4% --&gt; 1.0%).	methicillin__beta-lactamase__no_interaction	ampicillin__beta-lactamase__no_interaction
16556241-4	A significant positive correlation emerged between <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> values of <protein-id="P39905">GDNF</protein-id> and those of <protein-id="P61278">somatostatin</protein-id> in CM (r = 0.70, P &lt; 0.02), PCM + PAAH (r = 0.78, P &lt; 0.004), and PFMS patients (r = 0.68, P &lt; 0.008).	CSF__somatostatin__no_interaction	CSF__GDNF__no_interaction
10671946-13	Fasting <protein-id="P08833">IGFBP-1</protein-id> levels were doubled in hyperthyroid subjects compared to healthy controls and correlated positively with free T4 (r = 0.84, P &lt; 0.0001), with peak <compound-id="206,5793,64689,79025">glucose</compound-id> during the OGTT (r = 0.68, P &lt; 0.005) with peak <protein-id="P01308,I3WAC9">insulin</protein-id> during the IVGTT (r = 0.51, P &lt; 0.005) and negatively with <compound-id="206,5793,64689,79025">glucose</compound-id> disappearance constant (r = - 0.52, P &lt; 0.005).	glucose__IGFBP-1__no_interaction	glucose__insulin__no_interaction
20346637-5	After treatment with high-dose <compound-id="3440">furosemide</compound-id>+HSS compared to treatment with <compound-id="3440">furosemide</compound-id> alone we observed a significant lowering of <protein-id="P01160">ANP</protein-id> [96 (46.5-159.5) pg/ml vs 64 (21-150) pg/ml], <protein-id="P16860">BNP</protein-id> [215.5 (80.5-487) pg/ml vs 87 (66-141.5) pg/ml], TNF-α [389.5 (265-615.5) pg/ml vs 231.5 (156-373.5) pg/ml], IL-1β [8 (7-9) pg/ml vs 4 (3-7) pg/ml], IL-6 [5 (3-7.5) pg/ml vs 3 (2-4) pg/ml], plasma values and after an acute saline load, a lower percentage change of <protein-id="P01160">ANP</protein-id> (+18.6% vs +28.03% vs +25% vs +29%), <protein-id="P16860">BNP</protein-id> (+14.5% vs +29.2% vs +30% vs +29.6%) TNF-α (+10.8% vs +15.8% vs +17.8% vs +11.3%), IL-1β (+20% vs 34.4% vs 40% vs 34.4%) compared to control groups.	furosemide__BNP__no_interaction	furosemide__ANP__no_interaction
8706295-11	RESULTS: <compound-id="21885907,5464109,6918297">Hexarelin</compound-id> induced a significant increase in <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> levels in NS (median, range, delta peak <protein-id="Q03014">HEX</protein-id> vs placebo: 150 (-14-402) vs 10 (-34-24) mU/l; delta AUC <protein-id="Q03014">HEX</protein-id> vs placebo: 7710 (2,100-3 2540) vs 30 (-2,566-2,040) mU min/l, P &lt; 0.01) and in ACRO (190 (-10-496) vs 6 (-100-34) mU/l; 10,170 (-5,310-51,436) vs -82 (-6,030-1,410) mU min/l, P &lt; 0.02), but not in HPRL (10 (-180-80) vs 50 (-100-240) mU/l; -600 (-16,996-10,140) vs -1,950 (-8,540-14,160) mU min/l).	Hexarelin__PRL__no_interaction	Hexarelin__HEX__no_interaction
16464885-7	RESULTS: The following are the main findings for 2004 (post-K/DOQI): an increased use of dialysates with a Ca concentration of 2.5 mEq/l (27.2-50.9%, P&lt;0.001) and a reduced use of a dialysate <compound-id="22044544,5460341">calcium</compound-id> of 3.0 mEq/l (44.6-39.6%, P: NS) and 3.5 mEq/l (28-9.4%, P&lt;0.001); a reduced use of <compound-id="22044544,5460341">calcium</compound-id>-based <compound-id="1061,167704,644102">phosphate</compound-id> binders (891.9-565.5 mg Ca/day, P&lt;0.001) and increased use of <compound-id="159247">sevelamer hydrochloride</compound-id> (800 mg) (from 4.86 to 7.51 mg, tablets/day, P&lt;0.001) lower serum Ca levels (9.7-9.4 mg/dl, P&lt;0.01), and higher intact <protein-id="P01270">PTH</protein-id> levels (201.4-311.8 pg/ml, P&lt;0.001), without changes in serum P levels; an increased proportion of patients with serum Ca levels within the K/DOQI target range (38.7-46.6%, P&lt;0.01), resulting mainly from the reduced percentage of patients with hypercalcaemia (55-44.4%, P&lt;0.01); a decreased proportion of patients with <protein-id="P01270">PTH</protein-id>&lt;150 pg/ml (53.8-31.4%, P&lt;0.001) but an increased proportion of patients with <protein-id="P01270">PTH</protein-id>&gt;300 pg/ml, with no change in the proportion of patients with PTHs within the K/DOQI target range.	calcium__PTH__no_interaction	phosphate__PTH__no_interaction	sevelamer hydrochloride__PTH__no_interaction
19069643-7	Significant decreased <protein-id="P18887,B2RCY5,Q59HH7">XRCC1</protein-id> mRNA expression were observed at 10 micromol/L <compound-id="95170">PBDE-47</compound-id>, 5 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id>, and 10 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id> groups while significant increased <protein-id="O43542,Q53XC8">XRCC3</protein-id> mRNA expression were observed at 10 micromol/L <compound-id="95170">PBDE-47</compound-id> and 10 micromol/L <compound-id="95170">PBDE-47</compound-id> + 5 micromol/L <compound-id="37034">PCB153</compound-id> compared to the control group (P &lt; 0.05).	PBDE-47__XRCC1__no_interaction	PBDE-47__XRCC3__no_interaction	PCB153__XRCC1__no_interaction	PCB153__XRCC3__no_interaction
23656591-7	<compound-id="5180215">Na5</compound-id>[B(SO4)4]-I: space group Pca21, a = 10.730(2) Å, b = 13.891(3) Å, c = 18.197(4) Å. <compound-id="5180215">Na5</compound-id>[B(SO4)4]-II: space group P212121, a = 8.624(2) Å, b = 9.275(2) Å, c = 16.671(3) Å. A3[B(SO4)3] (A = K, Rb) are isotypic with Ba3[B(<compound-id="1061">PO4</compound-id>)3] adopting space group Ibca [K3[B(SO4)3], a = 7.074(4) Å, b = 14.266(9) Å, c = 22.578(14) Å; <protein-id="Q9H169,E7EVN3">Rb3</protein-id>[B(SO4)3], a = 7.2759(5) Å, b = 14.7936(11) Å, c = 22.637(2) Å] with vierer chains of BO4tetrahedra based on two bridging and two terminal SO4 tetrahedra.	PO4__Rb3__no_interaction	Na5__Rb3__no_interaction
21741247-4	The most active compound when tested in intact HEK-293 transfected cells, namely (3α,5α)-3-{[trans-2,5-dimethyl-4-{[2-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl] sulfonyl}<compound-id="91216341">piperazin-1-yl</compound-id>]methyl}-<compound-id="225">3-hydroxyandrostan-17-one</compound-id> (<compound-id="447977">15b</compound-id>), shows an IC₅₀ value of 6 nM, this compound is thus eight times more active than our reference compound <protein-id="P55327">D-5-2</protein-id> (IC₅₀=51 nM).	trifluoromethyl__D-5-2__no_interaction	15b__D-5-2__no_interaction	piperazin-1-yl__D-5-2__no_interaction	3-hydroxyandrostan-17-one__D-5-2__no_interaction
23224921-7	Following ECG parameters correlated the most prominently with LVMI - RV5: r = 0.5 (p = 0.002), RV6: r = 0.61 (p = 0.0001), <compound-id="70699405">SV1</compound-id>+RV5, 6: r = 0.64 (p = 0.001), RaVL+SV3: r = 0.5 (p = 0.002), <protein-id="Q7L0J3,B4E000">SV2</protein-id>+RV5, 6: r = 0.71 (p = 0.0001), <protein-id="Q7L0J3,B4E000">SV2</protein-id>, 3+RV5, 6: r = 0.75 (p = 0.0001).	SV1__SV2__no_interaction
17698902-4	RESULTS: GH, but not placebo, increased <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> serum concentration (from 144 +/- 35 to 293 +/- 58 ng/ml; P &lt; 0.005) and improved New York Heart Association functional class (from 2.4 +/- 0.5 to 1.8 +/- 0.4; P &lt; 0.005), exercise duration (from 831 +/- 273 to 925 +/- 266 sec; P &lt; 0.005), peak power output (from 245 +/- 127 to 280 +/- 132 W; P &lt; 0.05), peak minute ventilation (from 52.5 +/- 16.1 to 61.3 +/- 17.3 liters/min; P &lt; 0.05), peak <compound-id="977">oxygen</compound-id> consumption (from 19.8 +/- 5.6 to 25.1 +/- 5.6 ml/kg.min; P &lt; 0.005), and anaerobic threshold (from 14.9 +/- 4.8 to 20.0 +/- 4.5 ml/kg.min; P &lt; 0.005) without affecting lung function parameters.	oxygen__IGF-I__no_interaction
16839062-4	The bimolecular rate coefficients of all three reactions are independent of the bath gas (He or N2) and pressure within the experimental range (1-6 Torr) and are found to depend on temperature as follows: k(<compound-id="5378701">CH2Cl</compound-id> + NO2) = (2.16 +/- 0.08) x 10(-11) (T/300 K)(-1.12+/-0.24) cm3 molecule(-1) s(-1) (220-363 K), k(<compound-id="123193">CHCl2</compound-id> + NO2) = (8.90 +/- 0.16) x 10(-12) (T/300 K)(-1.48+/-0.13) cm3 molecule(-1) s(-1) (220-363 K), and k(<protein-id="P10147,A0N0R1">CCl3</protein-id> + NO2) = (3.35 +/- 0.10) x 10(-12) (T/300 K)(-2.2+/-0.4) cm3 molecule(-1) s(-1) (298-363 K), with the uncertainties given as one-standard deviations.	CH2Cl__CCl3__no_interaction	CHCl2__CCl3__no_interaction
12920794-5	Significantly lower body weight (37.79 +/- 3.93 vs. 49.63 +/- 9.84 kg, p &lt; 0.05), body mass index (13.51 +/- 1.43 vs. 17.75 +/- 2.64 kg/m2, p &lt; 0.05),), body fat percentage (13.28 +/- 2.83 vs. 18.9 +/- 5.65%, p &lt; 0.05), serum <protein-id="P41159,A4D0Y8">Leptin</protein-id> (1.117 +/- 0.95 vs. 5.88 +/- 4.7 ng/ml, p &lt; 0.05) and <compound-id="5997">cholesterol</compound-id> levels (4.14 +/- 1.78 vs. 6.31 +/- 1.27 mmol/l, p &lt; 0.05) were found in patient with restrictive relative to purgative subtype of anorexia nervosa.	cholesterol__Leptin__no_interaction
22316010-1	We designed three novel positron emission tomography ligands, N-(4-(6-(isopropylamino)pyrimidin-4-yl)-1,3-<compound-id="9256">thiazol</compound-id>-2-yl)-4-[(11)C]<compound-id="569575">methoxy-N-methylbenzamide</compound-id> ([(11)C]6), 4-[(18)F]fluoroethoxy-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]-<compound-id="11954">N-methylbenzamide</compound-id> ([(18)F]7), and 4-[(18)F]<compound-id="68042">fluoropropoxy</compound-id>-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-<compound-id="9256">thiazol</compound-id>-2-yl]-<compound-id="11954">N-methylbenzamide</compound-id> ([(18)F]8), for imaging metabotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptor type 1 (<protein-id="P23818,Q7TNB5,F6YNQ1">mGluR1</protein-id>) in rodent brain.	methoxy-N-methylbenzamide__mGluR1__no_interaction	N-methylbenzamide__mGluR1__no_interaction	glutamate__mGluR1__no_interaction	thiazol__mGluR1__no_interaction	fluoropropoxy__mGluR1__no_interaction
8742040-1	Exposure of rat hippocampal neurons to the peptide amyloid beta (A beta) (25-35) as well as A beta (1-40) peptides enhances phosphorylation of tau to a paired helical filament (PHF)-state through activation of tau protein kinase I (TPK I)/<compound-id="439177">glycogen</compound-id> synthase kinase-3 beta (<protein-id="P18266,A0A0G2JSH4,A0A0G2KB98">GSK-3 beta</protein-id>) [Busciglio, J., Lorenzo, A., Yeh, J. and Yankner, B.A., Neuron, 14 (1995) 879-888; Takashima, A., Ishiguro, K., Noguchi, K., Michel, G., Hoshi, M., Sato, K., Takahashi, M., Hoshino, T., Uchida, T. and Imahori, K., Neurosci.	glycogen__GSK-3 beta__no_interaction
19845099-15	The group conduction velocities and group nerve fibre diameters had the following pair-values at 35.5 degrees C: Spindle afferents: <protein-id="P08047">SP1</protein-id> (65 m/s / 13.1 microm), <protein-id="Q02086">SP2</protein-id> (51/12.1); touch afferents: T1 (47/11.1), T2 (39/10.1), <compound-id="5920">T3</compound-id> (27/9.1), T4 (19/8.1); urinary bladder afferents: S1 (41 m/s / -), ST (35/-); alpha-motoneurons: alpha 13 (-/14.4), alpha 12 (65 m/s /13.1 microm), alpha 11 (60?/12.1)[FF], alpha 2 (51/10.3)[FR], alpha 3 (41/8.2)[S]; gamma-motoneurons: gamma(beta) (27/7.1), gamma 1 (21/6.6), gamma 21 (16/5.8), gamma 22 (14/5.1); preganglionic parasympathetic motoneurons: (10 m/s / 3.7 microm).	T3__SP1__no_interaction	T3__SP2__no_interaction
24907224-3	METHODS: In the QUEST-2, phase 3 study, done at 76 sites in 14 countries (Europe, and North and South Americas), patients with confirmed chronic HCV genotype 1 infection and no history of HCV treatment were randomly assigned with a computer-generated allocation sequence in a ratio of 2:1 and stratified by HCV genotype 1 subtype and host <protein-id="Q8IZI9,A0A0C4DGW8">IL28B</protein-id> genotype to receive <compound-id="24873435,57956385,66576988,68266086,73425379">simeprevir</compound-id> (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight; 50 μg, 80 μg, 100 μg, 120 μg, or 150 μg once weekly, subcutaneous injection), plus <compound-id="37542">ribavirin</compound-id> (1000-1200 mg/day or 800-1400 mg/day, orally; <compound-id="24873435,57956385,66576988,68266086,73425379">simeprevir</compound-id> group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus <compound-id="37542">ribavirin</compound-id> (placebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus <compound-id="37542">ribavirin</compound-id>.	ribavirin__IL28B__no_interaction	simeprevir__IL28B__no_interaction
15607480-1	A new positron emission tomography (PET) radioligand for the <protein-id="P31652">serotonin transporter</protein-id> (SERT), [(11)C]2-[2-[[(dimethylamino)methyl]phenyl]thio]-5-(2-fluoroethyl)<compound-id="6115">phenylamine</compound-id> ([(11)C]AFE, 12), was synthesized and evaluated in vivo in rats and baboons.	phenylamine__serotonin transporter__no_interaction
19907722-3	This issue focuses on the following selection of drugs: AAV1/SERCA2a, <compound-id="441300">Abacavir sulfate</compound-id>/<compound-id="60825">lamivudine</compound-id>, Adalimumab, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="6918493">Ambrisentan</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, AT-7519, <compound-id="148192">Atazanavir sulfate</compound-id>, <compound-id="54841">Atomoxetine</compound-id> hydrochloride, <compound-id="9444">Azacitidine</compound-id>, <compound-id="54549244,65948">Azelnidipine</compound-id>; <compound-id="10178705">Besifloxacin hydrochloride</compound-id>, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, <compound-id="387447">Bortezomib</compound-id>, <compound-id="104865">Bosentan</compound-id>, <compound-id="2462,24867460,3033890,40000,46780910,5281004,5702148,63006">Budesonide</compound-id>/<compound-id="3410,3034756,3083544,9862958">formoterol fumarate</compound-id>; <protein-id="P22748">CAIV</protein-id>-T, <compound-id="6918474">Carisbamate</compound-id>, <compound-id="9917021">Casopitant mesylate</compound-id>, Certolizumab pegol, Cetuximab, <compound-id="6918155">Ciclesonide</compound-id>, <compound-id="2764">Ciprofloxacin</compound-id>/<compound-id="5743">dexamethasone</compound-id>, CTCE-9908; <compound-id="6918540">Dalcetrapib</compound-id>, <compound-id="213039">Darunavir</compound-id>, <compound-id="36687767,5493381,6098188">Deferasirox</compound-id>, <compound-id="124087">Desloratadine</compound-id>, <compound-id="90471248,9833838">Disitertide</compound-id>, Drotrecogin alfa (activated), DTA-H19, <compound-id="60835">Duloxetine</compound-id> hydrochloride, <compound-id="6918296">Dutasteride</compound-id>; Ecogramostim, Efalizumab, <compound-id="12043008,60877">Emtricitabine</compound-id>, <compound-id="11354606">Eribulin mesilate</compound-id>, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="969472">Eszopiclone</compound-id>, EUR-1008, Everolimus-eluting coronary stent, <compound-id="45588096,53396299,56927919">Exenatide</compound-id>; <compound-id="1727">Fampridine</compound-id>, <compound-id="24847878,9854489">Fluticasone furoate</compound-id>, <compound-id="3410,3034756,3083544,9862958">Formoterol fumarate</compound-id>/<compound-id="444036">fluticasone propionate</compound-id>, <compound-id="131536">Fosamprenavir</compound-id> <compound-id="22044544,5460341">calcium</compound-id>, <compound-id="104741">Fulvestrant</compound-id>; <compound-id="9883933">Gabapentin enacarbil</compound-id>, GS-7904L; HPV-6/11/16/18, <compound-id="16158474">Human Secretin</compound-id>, <compound-id="3637">Hydralazine hydrochloride</compound-id>/<compound-id="6883">isosorbide dinitrate</compound-id>; <compound-id="5291">Imatinib mesylate</compound-id>, <compound-id="68791">Imexon</compound-id>, Inalimarev/Falimarev, Indacaterol, <compound-id="6918554">Indacaterol maleate</compound-id>, <compound-id="57006608">Inhalable</compound-id> human <protein-id="P01308,I3WAC9">insulin</protein-id>, <protein-id="P01308,I3WAC9">insulin</protein-id> detemir, <protein-id="P01308,I3WAC9">insulin</protein-id> <compound-id="44146714">glargine</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; L-<compound-id="22128">Alanosine</compound-id>, <compound-id="208908">Lapatinib ditosylate</compound-id>, <compound-id="216326">Lenalidomide</compound-id>, <compound-id="1549000">Levocetirizine dihydrochloride</compound-id>, Liraglutide, <compound-id="11597698">Lisdexamfetamine mesilate</compound-id>, <compound-id="92727">Lopinavir</compound-id>, <compound-id="3957">Loratadine</compound-id>/<compound-id="5281040,60951">montelukast sodium</compound-id>, Lutropin alfa; MeNZB, <compound-id="56603701">Mepolizumab</compound-id>, <compound-id="477468,6602291">Micafungin sodium</compound-id>, <compound-id="5288826">Morphine hydrochloride</compound-id>; <compound-id="44148067">Nabiximols</compound-id>, <compound-id="456557,5458181">Nikkomycin Z</compound-id>; <compound-id="130881">Olmesartan medoxomil</compound-id>, Omalizumab; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id>-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, <compound-id="148178">Perifosine</compound-id>, <compound-id="11465695">PF-489791</compound-id>, <compound-id="44152164,56928089,9812534">Plitidepsin</compound-id>, <compound-id="468595">Posaconazole</compound-id>, <compound-id="5486971">Pregabalin</compound-id>; QAX-576; <compound-id="54671008">Raltegravir potassium</compound-id>, <compound-id="208902">Ramelteon</compound-id>, <compound-id="3052776">Rasagiline mesilate</compound-id>, Recombinant <compound-id="71300770">human relaxin</compound-id> <compound-id="783">H2</compound-id>, rhGAD65, <compound-id="9875401">Rivaroxaban</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>, <compound-id="59227">Rotigotine</compound-id>; <compound-id="11235729,11243969,44144606,44590597,66576989,71752157,78577434">Saxagliptin</compound-id>, <compound-id="10077130">SCH-530348</compound-id>, <compound-id="44634693,49652385,5284616,54600319,5460439,5497196,57312764,60148419,60150249,6436030,70789198,71308609,91534498,9962928">Sirolimus</compound-id>-eluting stent, SLIT-<compound-id="37768">amikacin</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="10296883">Sotrastaurin</compound-id>, SR-16234, <compound-id="5350">Sulforaphane</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, <compound-id="9838022">Tapentadol hydrochloride</compound-id>, Teriparatide, <compound-id="11370864">Tesofensine</compound-id>, <compound-id="15057856,3086655,49800038,5487427">Tiotropium</compound-id> <compound-id="259">bromide</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="33776">Tirapazamine</compound-id>, <compound-id="5388906">TMC-207</compound-id>, Tocilizumab, <compound-id="216237">Tolvaptan</compound-id>, <compound-id="15547703">Tosedostat</compound-id>, <compound-id="6918140,54786">Treprostinil sodium</compound-id>; <compound-id="121750">Ustekinumab</compound-id>; <compound-id="9886917">Varespladib methyl</compound-id>, <compound-id="3009355">Vicriviroc</compound-id>, <compound-id="11077541,24848920,6918537">Vildagliptin</compound-id>, <compound-id="11077541,24848920,6918537">Vildagliptin</compound-id>/<compound-id="4091">metformin hydrochloride</compound-id>, Volociximab, <compound-id="71616">Voriconazole</compound-id>; <compound-id="16135415">Ziconotide</compound-id>, <compound-id="60854">Ziprasidone hydrochloride</compound-id>.	Morphine hydrochloride__CAIV__no_interaction	Morphine hydrochloride__insulin__no_interaction	Ciclesonide__CAIV__no_interaction	Ciclesonide__insulin__no_interaction	Ciprofloxacin__CAIV__no_interaction	Ciprofloxacin__insulin__no_interaction	Sulforaphane__CAIV__no_interaction	Sulforaphane__insulin__no_interaction	Besifloxacin hydrochloride__CAIV__no_interaction	Besifloxacin hydrochloride__insulin__no_interaction	Aliskiren fumarate__CAIV__no_interaction	Aliskiren fumarate__insulin__no_interaction	Human Secretin__CAIV__no_interaction	Human Secretin__insulin__no_interaction	Rotigotine__CAIV__no_interaction	Rotigotine__insulin__no_interaction	Indacaterol maleate__CAIV__no_interaction	Indacaterol maleate__insulin__no_interaction	Tolvaptan__CAIV__no_interaction	Tolvaptan__insulin__no_interaction	Budesonide__CAIV__no_interaction	Budesonide__insulin__no_interaction	Levocetirizine dihydrochloride__CAIV__no_interaction	Levocetirizine dihydrochloride__insulin__no_interaction	Plitidepsin__CAIV__no_interaction	Plitidepsin__insulin__no_interaction	Fosamprenavir__CAIV__no_interaction	Fosamprenavir__insulin__no_interaction	Loratadine__CAIV__no_interaction	Loratadine__insulin__no_interaction	Atomoxetine__CAIV__no_interaction	Atomoxetine__insulin__no_interaction	Desloratadine__CAIV__no_interaction	Desloratadine__insulin__no_interaction	Rivaroxaban__CAIV__no_interaction	Rivaroxaban__insulin__no_interaction	Lopinavir__CAIV__no_interaction	Lopinavir__insulin__no_interaction	isosorbide dinitrate__CAIV__no_interaction	isosorbide dinitrate__insulin__no_interaction	Raltegravir potassium__CAIV__no_interaction	Raltegravir potassium__insulin__no_interaction	Tosedostat__CAIV__no_interaction	Tosedostat__insulin__no_interaction	Olmesartan medoxomil__CAIV__no_interaction	Olmesartan medoxomil__insulin__no_interaction	Carisbamate__CAIV__no_interaction	Carisbamate__insulin__no_interaction	Bosentan__CAIV__no_interaction	Bosentan__insulin__no_interaction	Alanosine__CAIV__no_interaction	Alanosine__insulin__no_interaction	Casopitant mesylate__CAIV__no_interaction	Casopitant mesylate__insulin__no_interaction	Tadalafil__CAIV__no_interaction	Tadalafil__insulin__no_interaction	Fulvestrant__CAIV__no_interaction	Fulvestrant__insulin__no_interaction	amikacin__CAIV__no_interaction	amikacin__insulin__no_interaction	Tiotropium__CAIV__no_interaction	Tiotropium__insulin__no_interaction	Ramelteon__CAIV__no_interaction	Ramelteon__insulin__no_interaction	montelukast sodium__CAIV__no_interaction	montelukast sodium__insulin__no_interaction	Pregabalin__CAIV__no_interaction	Pregabalin__insulin__no_interaction	Eszopiclone__CAIV__no_interaction	Eszopiclone__insulin__no_interaction	Azacitidine__CAIV__no_interaction	Azacitidine__insulin__no_interaction	Emtricitabine__CAIV__no_interaction	Emtricitabine__insulin__no_interaction	Lapatinib ditosylate__CAIV__no_interaction	Lapatinib ditosylate__insulin__no_interaction	Atazanavir sulfate__CAIV__no_interaction	Atazanavir sulfate__insulin__no_interaction	Ixabepilone__CAIV__no_interaction	Ixabepilone__insulin__no_interaction	Tesofensine__CAIV__no_interaction	Tesofensine__insulin__no_interaction	Mepolizumab__CAIV__no_interaction	Mepolizumab__insulin__no_interaction	Treprostinil sodium__CAIV__no_interaction	Treprostinil sodium__insulin__no_interaction	Darunavir__CAIV__no_interaction	Darunavir__insulin__no_interaction	Ziconotide__CAIV__no_interaction	Ziconotide__insulin__no_interaction	PF-489791__CAIV__no_interaction	PF-489791__insulin__no_interaction	Voriconazole__CAIV__no_interaction	Voriconazole__insulin__no_interaction	Sorafenib__CAIV__no_interaction	Sorafenib__insulin__no_interaction	Micafungin sodium__CAIV__no_interaction	Micafungin sodium__insulin__no_interaction	dexamethasone__CAIV__no_interaction	dexamethasone__insulin__no_interaction	Escitalopram oxalate__CAIV__no_interaction	Escitalopram oxalate__insulin__no_interaction	Nabiximols__CAIV__no_interaction	Nabiximols__insulin__no_interaction	H2__CAIV__no_interaction	H2__insulin__no_interaction	Deferasirox__CAIV__no_interaction	Deferasirox__insulin__no_interaction	Sotrastaurin__CAIV__no_interaction	Sotrastaurin__insulin__no_interaction	Aripiprazole__CAIV__no_interaction	Aripiprazole__insulin__no_interaction	Imexon__CAIV__no_interaction	Imexon__insulin__no_interaction	TMC-207__CAIV__no_interaction	TMC-207__insulin__no_interaction	Formoterol fumarate__CAIV__no_interaction	Formoterol fumarate__insulin__no_interaction	bromide__CAIV__no_interaction	bromide__insulin__no_interaction	Perifosine__CAIV__no_interaction	Perifosine__insulin__no_interaction	Tanespimycin__CAIV__no_interaction	Tanespimycin__insulin__no_interaction	human relaxin__CAIV__no_interaction	human relaxin__insulin__no_interaction	Imatinib mesylate__CAIV__no_interaction	Imatinib mesylate__insulin__no_interaction	Posaconazole__CAIV__no_interaction	Posaconazole__insulin__no_interaction	Lenalidomide__CAIV__no_interaction	Lenalidomide__insulin__no_interaction	Ambrisentan__CAIV__no_interaction	Ambrisentan__insulin__no_interaction	Dutasteride__CAIV__no_interaction	Dutasteride__insulin__no_interaction	formoterol fumarate__CAIV__no_interaction	formoterol fumarate__insulin__no_interaction	Rosuvastatin calcium__CAIV__no_interaction	Rosuvastatin calcium__insulin__no_interaction	Ziprasidone hydrochloride__CAIV__no_interaction	Ziprasidone hydrochloride__insulin__no_interaction	Duloxetine__CAIV__no_interaction	Duloxetine__insulin__no_interaction	Vicriviroc__CAIV__no_interaction	Vicriviroc__insulin__no_interaction	Varespladib methyl__CAIV__no_interaction	Varespladib methyl__insulin__no_interaction	calcium__CAIV__no_interaction	calcium__insulin__no_interaction	Saxagliptin__CAIV__no_interaction	Saxagliptin__insulin__no_interaction	Ustekinumab__CAIV__no_interaction	Ustekinumab__insulin__no_interaction	Disitertide__CAIV__no_interaction	Disitertide__insulin__no_interaction	Gabapentin enacarbil__CAIV__no_interaction	Gabapentin enacarbil__insulin__no_interaction	metformin hydrochloride__CAIV__no_interaction	metformin hydrochloride__insulin__no_interaction	Sirolimus__CAIV__no_interaction	Sirolimus__insulin__no_interaction	Tirapazamine__CAIV__no_interaction	Tirapazamine__insulin__no_interaction	Tipifarnib__CAIV__no_interaction	Tipifarnib__insulin__no_interaction	SCH-530348__CAIV__no_interaction	SCH-530348__insulin__no_interaction	Eribulin mesilate__CAIV__no_interaction	Eribulin mesilate__insulin__no_interaction	Lisdexamfetamine mesilate__CAIV__no_interaction	Lisdexamfetamine mesilate__insulin__no_interaction	Azelnidipine__CAIV__no_interaction	Azelnidipine__insulin__no_interaction	lamivudine__CAIV__no_interaction	lamivudine__insulin__no_interaction	Dalcetrapib__CAIV__no_interaction	Dalcetrapib__insulin__no_interaction	Inhalable__CAIV__no_interaction	Inhalable__insulin__no_interaction	Fluticasone furoate__CAIV__no_interaction	Fluticasone furoate__insulin__no_interaction	Rasagiline mesilate__CAIV__no_interaction	Rasagiline mesilate__insulin__no_interaction	glargine__CAIV__no_interaction	glargine__insulin__no_interaction	Paclitaxel__CAIV__no_interaction	Paclitaxel__insulin__no_interaction	Nikkomycin Z__CAIV__no_interaction	Nikkomycin Z__insulin__no_interaction	Hydralazine hydrochloride__CAIV__no_interaction	Hydralazine hydrochloride__insulin__no_interaction	Bortezomib__CAIV__no_interaction	Bortezomib__insulin__no_interaction	Vildagliptin__CAIV__no_interaction	Vildagliptin__insulin__no_interaction	Tapentadol hydrochloride__CAIV__no_interaction	Tapentadol hydrochloride__insulin__no_interaction	Abacavir sulfate__CAIV__no_interaction	Abacavir sulfate__insulin__no_interaction	Exenatide__CAIV__no_interaction	Exenatide__insulin__no_interaction	Fampridine__CAIV__no_interaction	Fampridine__insulin__no_interaction	fluticasone propionate__CAIV__no_interaction	fluticasone propionate__insulin__no_interaction
10512362-6	Furthermore, <protein-id="O35659">GLP-1R</protein-id>(-/-) islets exhibited: 1) reduced cAMP accumulation in the presence of 20 mmol/<compound-id="53782688">l glucose</compound-id> (knockout islets versus control islets, 12 +/- 1 vs. 27 +/- 3 fmol x islet(-1) x 15 min(-1); P &lt; 0.001) and exaggerated acceleration of cAMP production by 10 nmol/l <protein-id="P48756">glucose-dependent insulinotropic peptide</protein-id> (<protein-id="P48756">GIP</protein-id>) (increase over 20 mmol/<compound-id="53782688">l glucose</compound-id> by <protein-id="P48756">GIP</protein-id> in knockout islets versus control islets: 66 +/- 5 vs. 14 +/- 3 fmol x islet(-1) x 15 min(-1); P &lt; 0.001); 2) increased mean cytosolic [Ca2+] ([Ca2+]c) at 7, 10, and 15 mmol/<compound-id="53782688">l glucose</compound-id> in knockout islets versus control islets; and 3) signs of asynchrony of [Ca2+]c oscillations between different islet subregions.	l glucose__GIP__no_interaction	l glucose__GLP-1R__no_interaction	l glucose__glucose-dependent insulinotropic peptide__no_interaction
19345526-8	It is now possible to identify factors clearly favoring the formation of VC: <protein-id="P01375,Q5STB3">TNF-alpha</protein-id> (which stimulates cell necrosis/apoptosis), <protein-id="P02741">CRP</protein-id>, oxidized lipids, AGEs, <protein-id="P41159,A4D0Y8">leptin</protein-id>, inorganic <compound-id="1061,167704,644102">phosphate</compound-id>, high <compound-id="22044544,5460341">calcium</compound-id>-phosphorus product (CaxPO(4)), <compound-id="22044544,5460341">calcium</compound-id>, 1,25-OH(2)D(3) and <compound-id="5280795,5283711">Vitamin D</compound-id>(3), <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> (via an intracrine pathway), cyclic AMP, TGF-beta, <protein-id="P12643,C8C060">bone morphogenic protein 2</protein-id> (<protein-id="P12643,C8C060">BMP2</protein-id>) and factors protective against the formation of VC: <compound-id="5462224">magnesium</compound-id>, HDL, inorganic pyrophosphate, <protein-id="P02768">albumin</protein-id>, ahsg/fetuin A, <protein-id="P10451,A0A024RDE2,A0A024RDE6,B7Z351,A0A024RDJ0,Q3LGB0">osteopontin</protein-id> (OPN), <protein-id="O00300">osteoprotegerin</protein-id> (<protein-id="O00300">OPG</protein-id>), <protein-id="P09486">osteonectin</protein-id> (ON), <protein-id="P18075,A8K571">bone morphogenic protein 7</protein-id> (<protein-id="P18075,A8K571">BMP7</protein-id>), klotho, <protein-id="P12272,Q53XY9,A0A024RB29">PTHrP</protein-id> (via a paracrine pathway), <protein-id="P08493,A0A024RAX0">matrix gla protein</protein-id> (<protein-id="P08493,A0A024RAX0">MGP</protein-id>), <protein-id="P01270">PTH</protein-id> (via <protein-id="P35548">Msx2</protein-id>) and <compound-id="5284607">vitamin K</compound-id>. In conclusion, until recently, neglected disorders of <compound-id="22044544,5460341">calcium</compound-id>-phosphorus metabolism are currently recognized as the main actors in the process leading to vascular mediacalcosis in patients with chronic kidney failure.	vitamin K__BMP7__no_interaction	vitamin K__bone morphogenic protein 2__no_interaction	vitamin K__BMP2__no_interaction	vitamin K__CRP__no_interaction	vitamin K__bone morphogenic protein 7__no_interaction	vitamin K__osteopontin__no_interaction	vitamin K__PTH__no_interaction	vitamin K__leptin__no_interaction	vitamin K__osteoprotegerin__no_interaction	vitamin K__PTHrP__no_interaction	vitamin K__OPG__no_interaction	vitamin K__matrix gla protein__no_interaction	vitamin K__osteonectin__no_interaction	vitamin K__MGP__no_interaction	vitamin K__TNF-alpha__no_interaction	vitamin K__albumin__no_interaction	vitamin K__Msx2__no_interaction	calcium__BMP7__no_interaction	calcium__bone morphogenic protein 2__no_interaction	calcium__BMP2__no_interaction	calcium__CRP__no_interaction	calcium__bone morphogenic protein 7__no_interaction	calcium__osteopontin__no_interaction	calcium__PTH__no_interaction	calcium__leptin__no_interaction	calcium__osteoprotegerin__no_interaction	calcium__PTHrP__no_interaction	calcium__OPG__no_interaction	calcium__matrix gla protein__no_interaction	calcium__osteonectin__no_interaction	calcium__MGP__no_interaction	calcium__TNF-alpha__no_interaction	calcium__albumin__no_interaction	calcium__Msx2__no_interaction	phosphate__BMP7__no_interaction	phosphate__bone morphogenic protein 2__no_interaction	phosphate__BMP2__no_interaction	phosphate__CRP__no_interaction	phosphate__bone morphogenic protein 7__no_interaction	phosphate__osteopontin__no_interaction	phosphate__PTH__no_interaction	phosphate__leptin__no_interaction	phosphate__osteoprotegerin__no_interaction	phosphate__PTHrP__no_interaction	phosphate__OPG__no_interaction	phosphate__matrix gla protein__no_interaction	phosphate__osteonectin__no_interaction	phosphate__MGP__no_interaction	phosphate__TNF-alpha__no_interaction	phosphate__albumin__no_interaction	phosphate__Msx2__no_interaction	magnesium__BMP7__no_interaction	magnesium__bone morphogenic protein 2__no_interaction	magnesium__BMP2__no_interaction	magnesium__CRP__no_interaction	magnesium__bone morphogenic protein 7__no_interaction	magnesium__osteopontin__no_interaction	magnesium__PTH__no_interaction	magnesium__leptin__no_interaction	magnesium__osteoprotegerin__no_interaction	magnesium__PTHrP__no_interaction	magnesium__OPG__no_interaction	magnesium__matrix gla protein__no_interaction	magnesium__osteonectin__no_interaction	magnesium__MGP__no_interaction	magnesium__TNF-alpha__no_interaction	magnesium__albumin__no_interaction	magnesium__Msx2__no_interaction	Vitamin D__BMP7__no_interaction	Vitamin D__bone morphogenic protein 2__no_interaction	Vitamin D__BMP2__no_interaction	Vitamin D__CRP__no_interaction	Vitamin D__bone morphogenic protein 7__no_interaction	Vitamin D__osteopontin__no_interaction	Vitamin D__PTH__no_interaction	Vitamin D__leptin__no_interaction	Vitamin D__osteoprotegerin__no_interaction	Vitamin D__PTHrP__no_interaction	Vitamin D__OPG__no_interaction	Vitamin D__matrix gla protein__no_interaction	Vitamin D__osteonectin__no_interaction	Vitamin D__MGP__no_interaction	Vitamin D__TNF-alpha__no_interaction	Vitamin D__albumin__no_interaction	Vitamin D__Msx2__no_interaction
11312752-1	The metathetical reactions of the <compound-id="3028194">lithium</compound-id> derivative of the monoanion [((t)BuN)(S)P(mu-N(t)Bu)(2)P(S)(NH(t)Bu)](-) (L) with <compound-id="62652">CuCl</compound-id>/PPh(3), NiCl(2)(PEt(3))(2), <protein-id="Q13371">PdCl</protein-id>(2)L'(2) (L' = PhCN, PPh(3)), and PtCl(2)(PEt(3))(2) produced the complexes (PPh(3))CuL (5), NiL(2) (6), <protein-id="Q13371">PdCl</protein-id>(L)(PPh(3)) (7), PdL(2) (8), and Pt(PEt(3))(2)[((t)BuN)(S)P(mu-N(t)Bu)(2)P(S)(N(t)Bu)] (9).	lithium__PdCl__no_interaction	CuCl__PdCl__no_interaction
21520919-3	A fourth complex, [NEt(4)][(Tp*)Mn(II)(η(2)-acac(3-CN))(η(1)-NC-acac)] (4), is obtained via treatment of Mn(acac(3-CN))(3) with <compound-id="446833">KTp</compound-id>* and [<protein-id="P62079">NEt(4)]CN, while</protein-id> [NEt(4)](2)[Mn(II)(CN)(4)] (5) was prepared from <compound-id="23930">manganese</compound-id>(II) <compound-id="62406">trifluoromethanesulfonate</compound-id> and excess [NEt(4)]CN.	trifluoromethanesulfonate__NEt(4)]CN, while__no_interaction	KTp__NEt(4)]CN, while__no_interaction	manganese__NEt(4)]CN, while__no_interaction
19760959-8	The serum prohepdicin levels were not significantly correlated with the ages (r = -0.041, p = 0.760), hemoglobin (r = 0.127, p = 0.346), <compound-id="5950,602">alanine</compound-id> aminotransferase (r = -0.032, p = 0.813), <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (r = 0.025, p = 0.862), ferritin levels (r = 0.211, p = 0.133) and hepatic inflammation grades (r = 0.153, p = 0.352) in CHC patients.	alanine__transferrin__no_interaction
19218528-2	This study focuses on the <compound-id="11527495">ibodutant</compound-id> pharmacodynamic profile at the human <protein-id="P21452">NK(2)R</protein-id> and compares it with two other antagonists, <compound-id="3086682">nepadutant</compound-id> (<compound-id="5311275">MEN11420</compound-id>, (cyclo-[[Asn(beta-<compound-id="1738118">D-GlcNAc</compound-id>)-<compound-id="7020001">Asp-Trp</compound-id>-Phe-Dpr-Leu]cyclo(2beta-5beta)]) and saredutant [<compound-id="104974">SR48968</compound-id>, (S)-N-methyl-N[4-(4-acetylamino-<compound-id="69873">4-phenylpiperidino</compound-id>)-2-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="68006705">butyl</compound-id>]<compound-id="2331">benzamide</compound-id>].	dichlorophenyl__NK(2)R__no_interaction	nepadutant__NK(2)R__no_interaction	SR48968__NK(2)R__no_interaction	4-phenylpiperidino__NK(2)R__no_interaction	ibodutant__NK(2)R__no_interaction	butyl__NK(2)R__no_interaction	Asp-Trp__NK(2)R__no_interaction	D-GlcNAc__NK(2)R__no_interaction	benzamide__NK(2)R__no_interaction	MEN11420__NK(2)R__no_interaction
8324419-8	<compound-id="2720">Thiazide</compound-id> users had lower serum levels of <protein-id="P01270">PTH</protein-id> (26.2 +/- 7.6 (SD) ng/l vs. 31.0 +/- 11.7 ng/l, P = 0.009) and <compound-id="5280453">1,25-dihydroxyvitamin D</compound-id> (60.8 +/- 16.2 pmol/l vs. 77.0 +/- 18.7 pmol/l, P &lt; 0.001) in the winter/spring and, in the subset measured, reduced levels of osteocalcin year round (summer/fall: 2.89 +/- 0.82 micrograms/l, n = 10, vs. 3.65 +/- 1.02, n = 82, P = 0.019; winter/spring: 2.54 +/- 0.80 micrograms/l vs. 3.47 +/- 1.07 micrograms/l, P = 0.005).	Thiazide__PTH__no_interaction	1,25-dihydroxyvitamin D__PTH__no_interaction
3688234-3	The maintenance period of chronic CDA, compared with control, was characterized by hypokalemic metabolic alkalosis (serum <compound-id="6857437">TCO2</compound-id> 31.9 +/- 0.6 vs. 23.1 +/- 0.5 meq/l, P less than 0.05), volume contraction (plasma volume 3.76 +/- 0.08 vs. 4.19 +/- 0.22 ml/100 g body wt, P less than 0.05), decreased GFR (838 +/- 84 vs. 1045 +/- 45 microliters.min-1.100 g body <protein-id="P49952,D3ZJ55">wt-1</protein-id>, P less than 0.05), increased plasma renin activity (PRA) (63 +/- 13 vs. 12 +/- 3 ng.ml-1.h-1, P less than 0.05), but unchanged plasma <compound-id="5839">aldosterone</compound-id> concentrations (PAC) (4.1 +/- 1.0 vs. 3.4 +/- 1.6 ng/dl, P = NS).	TCO2__wt-1__no_interaction	aldosterone__wt-1__no_interaction
2857145-4	Inclusion of <protein-id="P60042">somatostatin</protein-id> in the culture medium (1 X 10(-8) to 1 X 10(-4) M) resulted in significant inhibition of gastrin release at <protein-id="P60042">somatostatin</protein-id> concentrations of 1 X 10(-5) and 1 X 10(-4) M: both doses of <protein-id="P60042">somatostatin</protein-id> inhibited gastrin release by approximately 52% at 30 min and by 32% at 6 h. Gastrin release stimulated by dibutyryl cyclic <compound-id="6083">adenosine monophosphate</compound-id> was significantly inhibited by 1 X 10(-5) and 1 X 10(-4) M <protein-id="P60042">somatostatin</protein-id> to 133% and 121% at 30 min and 77% and 98% at 6 h, respectively.	adenosine monophosphate__somatostatin__no_interaction
19618904-1	One-dimensional (1D) coordination polymers of formula [Fe(NH(2)trz)(3)]A.nH(2)O, {A = <compound-id="27873">TiF</compound-id>(6)(2-), n = 0.5 (1) and n = 1 (2); A = ZrF(6)(2-), n = 0.5 (3) and n = 0 (4); A = SnF(6)(2-), n = 0.5 (5) and n = 1 (6); A = TaF(7)(2-), n = 3 (7) and n = 2.5 (8); A = <protein-id="Q92974,D3DVA5">GeF</protein-id>(6)(2-), n = 1 (9) and n = 0.5 (10), NH(2)trz = <compound-id="11432">4-amino-1,2,4-triazole</compound-id>} have been synthesized, fully characterized, and their <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover behavior carefully studied by SQUID magnetometry, Mossbauer spectroscopy, and differential scanning calorimetry.	TiF__spin__no_interaction	TiF__GeF__no_interaction	4-amino-1,2,4-triazole__spin__no_interaction	4-amino-1,2,4-triazole__GeF__no_interaction
17844660-1	The study of the reaction between the <compound-id="53675528,6325">ethylene</compound-id> [Pt(eta-H2C = CH2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] or alkyne [Pt(eta2-HC [triple bond] CR)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] (R = SiMe3 1, Bu(t) 2) complexes with [cis-Pt(C6F5)2(thf)2] (thf = tetrahydrofuran) has enabled us to observe the existence of competitive processes between the activation of a P-C(Ph) bond on the <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> ligand, to give the binuclear derivative [cis-(C6F5)2Pt(mu-Ph)(mu-PPh2)Pt(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)] 3, and the activation of a C-H bond of the unsaturated group, to give the corresponding (mu-<compound-id="166653">hydride</compound-id>)(mu-vinyl) [cis, cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-CH = CH2)Pt(C6F5)2] 4 or (mu-<compound-id="166653">hydride</compound-id>)(mu-alkynyl) [cis,cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-C [triple bond]CR)Pt(C6F5)2] (R = SiMe3 5, Bu(t) 6) compounds, respectively.	ethylene__PPh3__no_interaction	hydride__PPh3__no_interaction
24065527-5	We found that the urinary <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> level was positively correlated with hypertension (ρ = 0.28, P &lt; 0.01), urinary protein (r = 0.38, P &lt; 0.01), urinary <protein-id="O15123">Ang II</protein-id> (r = 0.29, P &lt; 0.05), urinary type IV collagen (Col IV) (r = 0.56, P &lt; 0.01), and was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.28, P &lt; 0.01), urinary <compound-id="5360545">sodium</compound-id> (r = -0.22, P &lt; 0.05) and serum <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> (r = -0.27, P &lt; 0.01).	sodium__AGT__no_interaction	sodium__Ang II__no_interaction
9119530-1	We analyzed structural motifs of peptides bound to HLA-<protein-id="P13762,X5D2U9">DR4</protein-id> (DRB1*0405 and DRB1*0406) and DR9 (DRB1*0901) and found that: (a) AxxBxC motif where A, B, and C are hydrophobic, hydrophobic, and neutral, respectively, is important for binding to <protein-id="P13762,X5D2U9">DR4</protein-id>; (b) Gln (Q) or <compound-id="5951">Ser</compound-id> at position C allow high-affinity binding specific to DRB1*0406 which is strongly associated with <protein-id="P01308,I3WAC9">insulin</protein-id> autoimmune syndrome; (c) among human <protein-id="P01308,I3WAC9">insulin</protein-id>-derived peptide fragments, the TSICSLYQLE of the human <protein-id="P01308,I3WAC9">insulin</protein-id> alpha chain, which is exposed only under reducing conditions, has the highest affinity specific to DRB1*0406 by binding with the IxxLxQ motif; (d) a short-term human <protein-id="P01308,I3WAC9">insulin</protein-id>-specific T cell line recognizes a peptide fragment containing the IxxLxQ motif as a major T cell epitope; and (e) in the AxxB motif, where A and B need to be hydrophobic for binding to DR9, neutral <compound-id="5951">Ser</compound-id> is exceptionally allowed at position B.	Ser__DR4__no_interaction	Ser__insulin__no_interaction
24571702-6	Enamel loss (<compound-id="5289348">SEM</compound-id>) values for other European products and the reference control (active agents) were: <compound-id="23258">Meridol</compound-id>(®) : (1,400 ppm F as <protein-id="P06744,B4DE36">AmF</protein-id> + <protein-id="P51531,B1ALF6,F6T8Q0,B4DSC8,Q56A76,B4DNT1,Q8N9Q1">SnF2</protein-id> ) 12.0 μm (1.47); <compound-id="5564">Colgate</compound-id>(®) Cavity Protection: (1,450 ppm F as SMFP + NaF) 12.9 μm (1.66); Odol med 3(®) (1,400 ppm F as NaF) 14.2 μm (1.49); Elmex(®) (1,400 ppm F as <protein-id="P06744,B4DE36">AmF</protein-id>) 14.5 μm (1.76); <compound-id="5564">Colgate</compound-id>(®) Enamel Protect: (1,450 ppm F as NaF + KNO3 ) 16.3 μm (2.02); Lacalut(®) aktiv: (1,400 ppm F as AlF3 ) 18.5 μm (1.71); <compound-id="971">Sensodyne</compound-id>(®) ProNamel(™) : (1,450 ppm F as NaF + KNO3 ) 20.5 μm (1.26); Crest Cavity Protection (1,100 ppm F as NaF, reference control) 22.00 μm (2.04); and Mentadent(®) : (1,450 ppm F as NaF + Zn <compound-id="311,17938267">citrate</compound-id>) 22.3 μm (0.63).	Colgate__SnF2__no_interaction	Colgate__AmF__no_interaction	Meridol__SnF2__no_interaction	Meridol__AmF__no_interaction	SEM__SnF2__no_interaction	SEM__AmF__no_interaction	citrate__SnF2__no_interaction	citrate__AmF__no_interaction	Sensodyne__SnF2__no_interaction	Sensodyne__AmF__no_interaction
22387485-2	Interestingly, with similar five-member benzo-heterocycles, the two auxiliary acceptors of <compound-id="6809">phthalimide</compound-id> and <compound-id="7220">benzotriazole</compound-id> play exactly different roles in absorption and intramolecular charge transfer: (i) in contrast with WS-5 delocalized throughout the entire chromophore, the HOMO orbital of <protein-id="P05546,Q8IVC0">LS-2</protein-id> is mainly located at the donor part due to the twist conformation with the existence of two carbonyl groups in <compound-id="6809">phthalimide</compound-id>; (ii) the dihedral angles of "D-A" plane and "A-π" plane in <protein-id="P05546,Q8IVC0">LS-2</protein-id> further suggest that the incorporation of <compound-id="6809">phthalimide</compound-id> moiety results in curvature of electron delocalization over the whole molecule, in agreement with its blue-shifted, relatively narrow absorption spectra and low photocurrent density; (iii) in contrast with the beneficial charge transfer of <compound-id="7220">benzotriazole</compound-id> in WS-5, the <compound-id="6809">phthalimide</compound-id> unit in <protein-id="P05546,Q8IVC0">LS-2</protein-id> plays an oppositely negative contribution to the charge transfer, that is, blocking intramolecular electron transfer (ICT) from donor to acceptor to some extent; and (iv) in electrochemical impedance spectroscopy, the incorporated <compound-id="7220">benzotriazole</compound-id> unit enhances electron lifetime by 18.6-fold, the <compound-id="6809">phthalimide</compound-id> only increases electron lifetime by 5.0-fold.	benzotriazole__LS-2__no_interaction	phthalimide__LS-2__no_interaction
10774797-3	The vasorelaxant effects of substance P and the <protein-id="P30547,Q547C3,Q8R1R6">NK1 receptor</protein-id> agonist were abolished by the selective <protein-id="P30547,Q547C3,Q8R1R6">NK1 receptor</protein-id> antagonist <compound-id="107967">FK888</compound-id> (N2-[(4R)-4-hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-<compound-id="3323161">prolyl</compound-id>]-N-methy l-N-<compound-id="123147">phenylmethyl</compound-id>-3-(2-naphthyl)-L-<compound-id="350287,444939">alaninamide</compound-id>), whereas the selective <protein-id="Q64077">NK2 receptor</protein-id> antagonist <compound-id="104974">SR48968</compound-id> ((S)-N-methyl-N-[4-acetylamino-<compound-id="69873">4-phenylpiperidino</compound-id>)-2-(3,4-<compound-id="57417436">dichlorophenyl</compound-id> )-<compound-id="68006705">butyl</compound-id>] <compound-id="2331">benzamide</compound-id>) and the selective <protein-id="P30098">NK3 receptor</protein-id> antagonist SR142801 ((S)-(N)-( 1-(3-(1-benzoyl-3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="8082">piperidin-3-yl</compound-id>)propyl)4-p henylpiperidin-4-yl)-N-<compound-id="6582">methylacetamide</compound-id>) produced partial inhibition on their responses.	phenylmethyl__NK3 receptor__no_interaction	phenylmethyl__NK1 receptor__no_interaction	phenylmethyl__NK2 receptor__no_interaction	alaninamide__NK3 receptor__no_interaction	alaninamide__NK1 receptor__no_interaction	alaninamide__NK2 receptor__no_interaction	dichlorophenyl__NK3 receptor__no_interaction	dichlorophenyl__NK1 receptor__no_interaction	dichlorophenyl__NK2 receptor__no_interaction	piperidin-3-yl__NK3 receptor__no_interaction	piperidin-3-yl__NK1 receptor__no_interaction	piperidin-3-yl__NK2 receptor__no_interaction	SR48968__NK3 receptor__no_interaction	SR48968__NK1 receptor__no_interaction	SR48968__NK2 receptor__no_interaction	4-phenylpiperidino__NK3 receptor__no_interaction	4-phenylpiperidino__NK1 receptor__no_interaction	4-phenylpiperidino__NK2 receptor__no_interaction	methylacetamide__NK3 receptor__no_interaction	methylacetamide__NK1 receptor__no_interaction	methylacetamide__NK2 receptor__no_interaction	butyl__NK3 receptor__no_interaction	butyl__NK1 receptor__no_interaction	butyl__NK2 receptor__no_interaction	FK888__NK3 receptor__no_interaction	FK888__NK1 receptor__no_interaction	FK888__NK2 receptor__no_interaction	benzamide__NK3 receptor__no_interaction	benzamide__NK1 receptor__no_interaction	benzamide__NK2 receptor__no_interaction	prolyl__NK3 receptor__no_interaction	prolyl__NK1 receptor__no_interaction	prolyl__NK2 receptor__no_interaction
20233197-5	RESULTS: Concurrent <compound-id="392622">ritonavir</compound-id> administration resulted in about fourfold increases in both the C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) and AUC(T)[C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) 2.79 +/- 0.22 vs. 10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs. 220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P &lt; 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs. 2.71 +/- 0.09 l h(-1)) of quinine.	ritonavir__max__no_interaction
16919043-8	Fifty-four patients with (+) <protein-id="P08588">anti-beta(1)-AR</protein-id> had greater improvements than 42 patients with (-) <protein-id="P08588">anti-beta(1)-AR</protein-id> in LVEDD (left ventricular end-diastolic dimension) (P &lt; 0.01, from 69 +/- 0.8 to 58.0 +/- 0.5 mm vs. 69.0 +/- 0.8-63.6 +/- 0.9 mm) and LVESD (left ventricular end-systolic dimension) (P &lt; 0.01, from 57.1 +/- 1.4 to 43.9 +/- 0.8 mm vs. 56.2 +/- 0.9-48.6 +/- 1.0 mm), and LVEF (left ventricular ejection fraction) (P &lt; 0.01, from 35.4 +/- 1.3 to 49.8 +/- 0.6% vs. 34.4 +/- 1.0-44.3 +/- 1.1%) by <compound-id="4171">metoprolol</compound-id> therapy in combination with standard treatment regime for one year.	metoprolol__anti-beta(1)-AR__no_interaction
23221137-2	In severe sepsis and septic shock should be early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; -appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; -early administration of broad-spectrum antibiotic therapy; -reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; -a usual 7-10 days of antibiotic therapy guided by clinical response; -source control with attention to the method that balances risks and benefits; -equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; -vasopressor preference for <compound-id="439260">norepinephrine</compound-id> and <compound-id="681">dopamine</compound-id>; -cautious use of <protein-id="P01185,X5DQP6">vasopressin</protein-id> pending further studies; -avoiding low-dose <compound-id="681">dopamine</compound-id> administration for renal protection; consideration of <compound-id="36811">dobutamine</compound-id> inotropic therapy in some clinical situations; -stress-dose steroid therapy for septic shock; use of recombinant activated <protein-id="P04070">protein C</protein-id> in patients with severe sepsis and high risk for death; -with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; -a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; -application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; -protocols for weaning and sedation, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; -avoidance of neuromuscular blockers, if at all possible; -maintenance of blood <compound-id="206,5793,64689,79025">glucose</compound-id> &lt;150 mg/dL after initial stabilization.	norepinephrine__vasopressin__no_interaction	norepinephrine__protein C__no_interaction	glucose__vasopressin__no_interaction	glucose__protein C__no_interaction	dobutamine__vasopressin__no_interaction	dobutamine__protein C__no_interaction	dopamine__vasopressin__no_interaction	dopamine__protein C__no_interaction
20089735-4	Activity analyses of the resulting mutants, 910A [1A10((1-83))/<compound-id="71297182">1A9</compound-id>((84-285))], 910B [<compound-id="71297182">1A9</compound-id>((1-83))/1A10((84-147))/<compound-id="71297182">1A9</compound-id>((148-285))], 910C [<compound-id="71297182">1A9</compound-id>((1-147))/1A10((148-181))/<compound-id="71297182">1A9</compound-id>((182-285))], 910D [<compound-id="71297182">1A9</compound-id>((1-181))/1A10((182-235))/<compound-id="71297182">1A9</compound-id>((236-285))], and 910E [<compound-id="71297182">1A9</compound-id>((1-235))/1A10((236-285))] indicated that more than one residue is responsible for the differences between <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id> and <protein-id="Q9HAW8,Q5DT02">UGT1A10</protein-id>.	1A9__UGT1A9__no_interaction	1A9__UGT1A10__no_interaction
22248752-9	In group B, mean arterial pressure (MAP, mm Hg,1 mm Hg = 0.133 kPa) 24 hours and 72 hours after IABP, cardiac index [CI, L×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)× m(-2)] after 48 hours of IABP, and in 2 hours after termination of IABP, <compound-id="681">dopamine</compound-id> dosage [μg×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)] in 24, 48, 72 hours after IABP and 2 hours after termination were significantly improved than those in group A (MAP: 53.0 ± 6.3 vs. 52.1 ± 6.2, 65.6 ± 4.3 vs. 65.0 ± 2.1; CI: 3.40 ± 0.20 vs. 3.30 ± 0.50, 3.60 ± 0.30 vs. 3.60 ± 0.30; <compound-id="681">dopamine</compound-id> dosage: 17.5 ± 1.2 vs. 17.6 ± 1.3, 10.2 ± 1.3 vs. 12.8 ± 1.6, 5.8 ± 1.5 vs. 6.8 ± 1.7, 3.0 ± 0.7 vs. 4.1 ± 1.3, P &lt; 0.05 or P &lt; 0.01).	dopamine__min(-1__no_interaction
11590897-7	These results showed <compound-id="445014">ERI</compound-id> has a statistically significant correlation with <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (TS) (r = -0.327, p = 0.042), total weekly Kt/Vurea (r = -0.423, p = 0.018), serum <protein-id="P02768">albumin</protein-id> level (r = -0.458, p = 0.003), normalized protein catabolic rate (nPCR) (r = -0.479, p = 0.006), normalized protein equivalent of total <compound-id="947">nitrogen</compound-id> appearance (nPNA) (r = -0.488, p = 0.005) and serum <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = 0.332, p = 0.036).	ERI__albumin__no_interaction	ERI__C-reactive protein__no_interaction	ERI__transferrin__no_interaction	ERI__CRP__no_interaction	nitrogen__albumin__no_interaction	nitrogen__C-reactive protein__no_interaction	nitrogen__transferrin__no_interaction	nitrogen__CRP__no_interaction
22433825-5	These range from invasive monitoring by Eppendorf polarographic O(2) microelectrodes, positron electron tomography (PET) tracers based on 2-<compound-id="10701">nitroimidazole</compound-id> compounds [(18)F-labelled fluoro-<compound-id="26105">misonidazole</compound-id> ((18)F-MISO) or 1-(2-[((18))F]fluoro-1-[hydroxymethyl]ethoxy)<compound-id="21274">methyl-2-nitroimidazole</compound-id> (<compound-id="5494423">FRP</compound-id>-170)], (64)<compound-id="6409958">Cu-ATSM</compound-id> Cu-diacetyl-bis(N4-methylthiosemicarbazone) (<compound-id="6409958">Cu-ATSM</compound-id>) or (99m)Tc- and (68)Ga-labelled <compound-id="4173">metronidazole</compound-id> (MN) agents to advanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> methods, such as blood oxygenation level dependent (BOLD) <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>, <compound-id="977">oxygen</compound-id>-enhanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>, diffusion-weighted <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (DWI-<protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>), dynamic contrast-enhanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (DCE-<protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>) and (1)H-magnetic resonance spectroscopy.	oxygen__MRI__no_interaction	methyl-2-nitroimidazole__MRI__no_interaction	Cu-ATSM__MRI__no_interaction	metronidazole__MRI__no_interaction	FRP__MRI__no_interaction	misonidazole__MRI__no_interaction	nitroimidazole__MRI__no_interaction
18006567-5	When different stimulation strategies were compared, a strong correlation was noted for cytokine responses after <compound-id="11970143">lipopolysaccharide</compound-id> and S epidermidis exposure--that is, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL6</protein-id> (R = 0.431, 95% CI 0.29 to 0.55, p&lt;0.001, n = 161) and <protein-id="P22301,Q6FGW4">IL10</protein-id> (R = 0.332, 95% CI 0.18 to 0.47, p&lt;0.001, n = 161).	lipopolysaccharide__IL6__no_interaction	lipopolysaccharide__IL10__no_interaction
22891645-4	One exemplar, (R)-N-((1-(4-(but-3-en-1-ylamino)-6-(((<compound-id="547510">2-(thiophen-2-yl)thiazol-4-yl</compound-id>)methyl)amino)-1,3,5-<compound-id="7541">triazin</compound-id>-2-yl)<compound-id="31268">pyrrolidin</compound-id>-2-yl)methyl)-<compound-id="2265561">4-propylbenzenesulfonamide</compound-id> (8), inhibited <protein-id="Q9UNA0">ADAMTS-5</protein-id> with IC(50) = 30 nM, showing &gt;50-fold selectivity against <protein-id="O75173">ADAMTS-4</protein-id> and &gt;1000-fold selectivity against <protein-id="Q9UHI8,B2RB33">ADAMTS-1</protein-id>, <protein-id="Q76LX8">ADAMTS-13</protein-id>, <protein-id="P45452,Q53H33">MMP-13</protein-id>, and <protein-id="P78536,B2RNB2">TACE</protein-id>.	pyrrolidin__ADAMTS-5__no_interaction	pyrrolidin__ADAMTS-4__no_interaction	pyrrolidin__ADAMTS-1__no_interaction	pyrrolidin__MMP-13__no_interaction	pyrrolidin__TACE__no_interaction	pyrrolidin__ADAMTS-13__no_interaction	4-propylbenzenesulfonamide__ADAMTS-5__no_interaction	4-propylbenzenesulfonamide__ADAMTS-4__no_interaction	4-propylbenzenesulfonamide__ADAMTS-1__no_interaction	4-propylbenzenesulfonamide__MMP-13__no_interaction	4-propylbenzenesulfonamide__TACE__no_interaction	4-propylbenzenesulfonamide__ADAMTS-13__no_interaction	triazin__ADAMTS-5__no_interaction	triazin__ADAMTS-4__no_interaction	triazin__ADAMTS-1__no_interaction	triazin__MMP-13__no_interaction	triazin__TACE__no_interaction	triazin__ADAMTS-13__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-5__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-4__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-1__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__MMP-13__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__TACE__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-13__no_interaction
21664558-5	Similarly, plasma non-esterified fatty acids and triglycerides increased, while HDL <compound-id="5997">cholesterol</compound-id> decreased (P&lt;.05 to &lt;.001) from SL to 5300 m. Acylation-stimulating protein (SL 42.2 ± 40.2 nm; 4000 m 117.0 ± 69.6 nm; 4750 m 107.9 ± 44.5 nm; 5300 m 82.2 ± 20.2 nm; P=.019) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (SL 10.4 ± 6.5 ng/mL, 4000 m 13.9 ± 8.5 ng/mL, 4750 m 18.3 ± 8.3 ng/mL, 5300 m 14.7 ± 8.0 ng/mL; P=.015) increased, as did insulin and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>) levels (up to 71% and 168%, respectively; P&lt;.05) with no change in <protein-id="P41159,A4D0Y8">leptin</protein-id>, complement C3 (C3), high sensitivity C-reactive protein (hsCRP) or cortisol levels throughout the mountain ascent from SL to 5300 m. CONCLUSION: Acylation-stimulating protein and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> are increased during a 9-day period of high altitude (SL to 5300 m) exposure despite weight loss in healthy mountaineers. 	cholesterol__IL-6__no_interaction	cholesterol__leptin__no_interaction	cholesterol__Interleukin-6__no_interaction	cholesterol__adiponectin__no_interaction
22883217-5	Arterial <compound-id="222">ammonia</compound-id> (r = 0.72, p = 0.03), tumour necrosis factor alpha (r = 0.87, p = 0.02), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin-6</protein-id> (r = 0.50, p = 0.05), <protein-id="Q14116,A0A024R3E0">Interleukin-18</protein-id> (r = 0.76, p = 0.02) and serum endotoxin (r = 0.91, p = 0.01) correlated with higher grades of hepatic encephalopathy.	ammonia__Interleukin-18__no_interaction	ammonia__Interleukin-6__no_interaction
9605570-4	We studied the effect on neurogenic secretion in ferret trachea in vitro of the <protein-id="P18075,A8K571">OP1</protein-id> receptor (formerly known as delta opioid receptor) agonist [D-Pen2,5]<compound-id="461776">enkephalin</compound-id> (DPDPE), the <compound-id="12518745">OP2</compound-id> receptor (formely kappa) agonist <compound-id="68616">U-50,488H</compound-id>, the OP3 receptor (formerly micro) agonist [D-Ala2, <compound-id="6951135">N-Me-Phe</compound-id>, Gly-ol5]<compound-id="461776">enkephalin</compound-id> (<compound-id="5462471">DAMGO</compound-id>), the ATP-sensitive K+ (K(ATP)) channel inhibitor <compound-id="3488">glibenclamide</compound-id>, the large conductance <compound-id="22044544,5460341">calcium</compound-id> activated K+ (BK(Ca)) channel blocker <compound-id="16132435">iberiotoxin</compound-id>, the small conductance K(Ca) (SK(Ca)) channel blocker <compound-id="16129677,16218850,56928162,57043712">apamin</compound-id>, the K(ATP) channel opener <compound-id="93504">levcromakalim</compound-id>, a putative K(ATP) channel opener <compound-id="7021454">RS</compound-id> 91309, and the BK(Ca) channel opener <compound-id="4552">NS 1619</compound-id>.	DAMGO__OP1__no_interaction	levcromakalim__OP1__no_interaction	NS 1619__OP1__no_interaction	OP2__OP1__no_interaction	glibenclamide__OP1__no_interaction	RS__OP1__no_interaction	N-Me-Phe__OP1__no_interaction	enkephalin__OP1__no_interaction	calcium__OP1__no_interaction	iberiotoxin__OP1__no_interaction	U-50,488H__OP1__no_interaction	apamin__OP1__no_interaction
20721515-8	We observed levels of <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id> (pre-angioplasty: 14.23 ± 7.52 x 8.83 x 11.45 ± 7.65 ± 7.09; after angioplasty: 21.49 ± 23.82 x 4 37 ± 2.71 x 4.82 ± 4.47, ρ &lt; 0.01) and glycoprotein IIb/IIIa (pre-angioplasty: 98.97 ± 0.43 ± 1.25 x 98.79 x 99.21 ± 0.40 after angioplasty: 99.37 ± 0.29 ± 1.47 x 98.50 x 98.92 ± 0.88, ρ = 0.52), respectively, in the control, <compound-id="60823">atorvastatin</compound-id> and <compound-id="54454">simvastatin</compound-id> groups.	atorvastatin__P-selectin__no_interaction	simvastatin__P-selectin__no_interaction
15015153-7	Notably, both <compound-id="6106">leucine</compound-id> flux and nonoxidative <compound-id="6106">leucine</compound-id> R(d) (protein synthesis) increased with <protein-id="P01308,I3WAC9">insulin</protein-id> (2.36 +/- 0.06 to 2.81 +/- 0.10 and 1.79 +/- 0.05 to 2.18 +/- 0.10 micromol/kg fat-free mass (<protein-id="P78363,Q6AI28">FFM</protein-id>) x min, respectively; P &lt;.0005) while <compound-id="6106">leucine</compound-id> oxidation only tended to increase (P =.05) and endogenous <compound-id="6106">leucine</compound-id> R(a) (protein breakdown) decreased by 18% (2.36 +/- 0.06 to 1.94 +/- 0.09 micromol/kg <protein-id="P78363,Q6AI28">FFM</protein-id> x min; P &lt;.0005), resulting in a marked elevation of net protein synthesis (-0.57 +/- 0.02 to 0.24 +/- 0.02 micromol/kg <protein-id="P78363,Q6AI28">FFM</protein-id> x min; P &lt;.0000001).	leucine__FFM__no_interaction	leucine__insulin__no_interaction
18271677-2	Three-month administration of COC resulted in 1) significant increase of basal (454.0+/-125.0 to 860.9+/-179.7 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated serum <compound-id="5754">cortisol</compound-id> in 30th min (652.3+/-60.5 to 1374.1+/-240.6 nmol/l); 2) no significant change of basal (15.4+/-7.3 to 18.9+/-8.5 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated salivary <compound-id="5754">cortisol</compound-id> at the 30th min (32.4+/-8.8 to 32.9+/-9.0 nmol/l); 3) no significant change of basal serum <compound-id="222786">cortisone</compound-id> (38,8+/-7.68 to 45.2+/-24.2 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated <compound-id="222786">cortisone</compound-id> at the 30th (34.8+/-10.9 to 47.0+/-35.7 nmol/l); 4) significant increase of basal <protein-id="P01189,Q6FHC8">ACTH</protein-id> (17.2+/-9.0 to 38.2+/-29.4 ng/l), CBG (991.0+/-161.0 to 2332.0+/-428.0 nmol/l), and 5) no significant change of basal DHEA (24.6+/-15.7 to 22.6+/-11.7 micromol/l) and calculated basal value for free <compound-id="5754">cortisol</compound-id> (22.8+/-14.9 to 19.2+/-6.9 nmol/l).	cortisone__ACTH__no_interaction	cortisol__ACTH__no_interaction
1534954-8	<protein-id="P02675,V9HVY1">fibrinogen</protein-id> was lowered (in a comparison of the data prior to the first and following the second plasmapheresis) from 526.4 +/- 114 to 314.1 +/- 80.1 mg/dl (p less than 0.01), <compound-id="5997">cholesterol</compound-id> from 210.8 +/- 76.8 to 131.3 +/- 38.2 mg/dl (p less than 0.01), LDL from 125 +/- 53 mg/dl to 63.6 +/- 25.7 mg/dl (p less than 0.01), LP(a) from 26.2 +/- 13.2 to 12.0 +/- 9.5 mg/dl (p less than 0.01), HDL from 31.7 +/- 6.3 to 29.7 +/- 5.6 mg/dl (no significance), RCTT from 14.4 +/- 2.8 to 10.9 +/- 0.9 (p less than 0.01), whole blood viscosity (low shear rate) from 11.64 +/- 1.7 to 8.74 +/- 1.4 mPa/sec (p less than 0.01) and (high shear rate) from 5.38 +/- 0.58 to 4.28 +/- 0.83 mPa/sec (p less than 0.01).	cholesterol__fibrinogen__no_interaction
15146514-1	A general study of the regioselective hydroamination of terminal alkynes in the presence of [(eta5-Cp)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (1), [(eta5-CpEt)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (CpEt=<compound-id="528176">ethylcyclopentadienyl</compound-id>) (2), and [(eta5-Cp*)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (Cp*=<compound-id="142539">pentamethylcyclopentadienyl</compound-id>) (3) is presented.	ethylcyclopentadienyl__eta2__no_interaction	pentamethylcyclopentadienyl__eta2__no_interaction
23844086-5	In multivariate linear regression, after adjustment for gender, age, smoking and drinking, body mass index (BMI), systolic and diastolic blood pressure (<protein-id="Q8TD31,Q769H0,M1T2K8,B0S7V6,M1TIV4,Q2TB68,D2IYK9">SBP</protein-id>, <protein-id="Q10586">DBP</protein-id>), lipid profiles, logarithmic transformed C-reactive protein (log-CRP), estimated glomerular filtration rate (e-<protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id>), FPG and HbA1c, with a 1-mg/dl increment of <compound-id="5289420">SUA</compound-id>, 2-h PG increased by 5.04 ± 0.72 (P&lt;0.001), 3.06 ± 1.08 (P = 0.001), 5.40 ± 1.26 (P&lt;0.001), and 2.34 ± 2.16 mg/dl (P = 0.056) in all participants, in participants with normal <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (NGT), with impaired <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (IGT), and with 2-h newly diagnosed diabetes (2-h NDM, with 2-h PG ≥ 200 mg/dl), respectively.	SUA__GFR__no_interaction	SUA__DBP__no_interaction	SUA__SBP__no_interaction	glucose__GFR__no_interaction	glucose__DBP__no_interaction	glucose__SBP__no_interaction
10081703-8	A submaximal concentration of <protein-id="P01186">AVP</protein-id> (10(-10) M) induced cAMP accumulation of 48.6 +/- 2.5 pmol (mg protein)-1 (4 min)-1 (P &lt; 0.01 compared with basal level of 34.9 +/- 2.4 pmol (mg protein)-1 (4 min)-1, n = 10), which was blocked in the presence of a vasopressin V2 receptor antagonist (10(-7) M <compound-id="119369">OPC-31260</compound-id>) but not by the <protein-id="P70536">oxytocin receptor</protein-id> antagonist (10(-6) M [Pen1,pMePhe2, Thr4,Orn8]<compound-id="439302">oxytocin</compound-id>) (36.3 +/- 6.1 and 45.1 +/- 1.3 pmol (mg protein)-1 (4 min)-1 respectively, P &lt; 0.05, n = 10).	oxytocin__oxytocin receptor__no_interaction	oxytocin__AVP__no_interaction	OPC-31260__oxytocin receptor__no_interaction	OPC-31260__AVP__no_interaction
15193303-2	Incubation of 100 microM aminochrome with 100 microM <compound-id="54676038">dicoumarol</compound-id>, an inhibitor of <protein-id="P15559,B4DLR8">DT-diaphorase</protein-id> during 2 h, induces 56% cell death (P &lt; 0.001) with concomitant formation of (i) intracellular hydroperoxides (4.2-fold increase compared to control; P &lt; 0.001); (ii) <compound-id="961">hydroxyl radicals</compound-id>, detected with <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR</protein-id> and spin trapping agents (2.4-fold increase when cells were incubated with aminochrome in the presence of <compound-id="54676038">dicoumarol</compound-id> compared to aminochrome alone); (iii) intracellular edema, and cell membrane deterioration determined by transmission electron microscopy; (iv) absence of apoptosis, supported by using anexin-V with flow cytometry; (v) a strong decrease of mitochondrial membrane potential determined by the fluorescent dye 5,5',6,6'-<compound-id="5326109">tetrachloro-</compound-id>1,1',3,3'-tetraethylbenzimidazolylcarbocyanineiodide (P &lt; 0.01); (vi) swelling and disruption of outer and inner mitochondrial membranes determined by transmission electron microscopy.	hydroxyl radicals__ESR__no_interaction	hydroxyl radicals__DT-diaphorase__no_interaction	tetrachloro-__ESR__no_interaction	tetrachloro-__DT-diaphorase__no_interaction	dicoumarol__ESR__no_interaction	dicoumarol__DT-diaphorase__no_interaction
10734467-3	The SCSA measures, mean of <compound-id="6278">alpha-t</compound-id> (mean alpha t), standard deviation of <compound-id="6278">alpha-t</compound-id> (SD alpha t), and the <protein-id="P49747">COMP</protein-id> of <compound-id="6278">alpha-t</compound-id> (cells outside the main population)] were significantly correlated with the percentage seasonal pregnancy rate (SPR; mean alpha t, r = -0.24, P &lt; or = 0.05; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.27, P &lt; or = 0.05); percentage pregnant per first cycle (<compound-id="445951">FCP</compound-id>; SD alpha t, r = -0.30, P &lt; or = 0.01; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.42, P &lt; or = 0.0001); and the percentage pregnant per cycle (PC; mean alpha t, r = -0.31, P &lt; or = 0.01; SD alpha t, r = -0.32, P &lt; or = 0.01; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.41, P &lt; or = 0.0001).	alpha-t__COMP__no_interaction	FCP__COMP__no_interaction
15350062-1	The effect of adding an <compound-id="10982484,702">alcohol</compound-id> ethoxylate nonionic surfactant (<protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C(18</protein-id>)E(18)) to aqueous solutions of a cationic surfactant, <compound-id="53690099">erucyl</compound-id> bis(hydroxyethyl) <compound-id="6329">methylammonium</compound-id> chloride (EHAC,CH(3)(CH(2))(7)(CH)(2)(CH(2))(12)N(+)-(CH(2)CH(2)OH)(2)CH(3)Cl(-)), was studied using small-angle neutron scattering (SANS), steady-state rheology, and cryo-transmission electron microscopy (Cryo-TEM).	erucyl__C(18__no_interaction	methylammonium__C(18__no_interaction	alcohol__C(18__no_interaction
19088949-3	This issue focuses on the following selection of drugs: (+)-<compound-id="71353">Dapoxetine hydrochloride</compound-id>, (S)-<compound-id="636411">Tenatoprazole</compound-id> <compound-id="5360545">sodium</compound-id> salt <compound-id="1488787">monohydrate</compound-id> 19-<compound-id="25245141">28z</compound-id>, <compound-id="5282338">Acotiamide hydrochloride hydrate</compound-id>, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="3036780,163091">Asenapine maleate</compound-id>, <compound-id="6450551">Axitinib</compound-id>; Bavituximab, <compound-id="101524">Becatecarin</compound-id>, beta-1,3/1,6-Glucan, Bevacizumab, <compound-id="9941379">Bremelanotide</compound-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="9917021">Casopitant mesylate</compound-id>, Catumaxomab, CDX-110, <compound-id="9933475">Cediranib</compound-id>, CMD-193, <compound-id="148202">Cositecan</compound-id>; <compound-id="11683005">Darinaparsin</compound-id>, Denosumab, <compound-id="9810955">DP-b99</compound-id>, <compound-id="60835">Duloxetine hydrochloride</compound-id>; <compound-id="60138177">E75</compound-id>, Ecogramostim, <compound-id="6438895">Elacytarabine</compound-id>, EMD-273063, EndoTAG-1, <compound-id="176167">Enzastaurin hydrochloride</compound-id>, <compound-id="443872">Eplerenone</compound-id>, <compound-id="11354606">Eribulin mesilate</compound-id>, <compound-id="4594,9568614">Esomeprazole magnesium</compound-id>, <compound-id="193962">Etravirine</compound-id>, Everolimus, <compound-id="150311">Ezetimibe</compound-id>; <compound-id="6918218">Faropenem daloxate</compound-id>, <compound-id="134018">Febuxostat</compound-id>, <compound-id="5288209">Fenretinide</compound-id>; <compound-id="44576256">Ghrelin</compound-id> (human); I-131 ch-<compound-id="8376">TNT</compound-id>-1/B, I-131-<compound-id="86287509">3F8</compound-id>, <compound-id="213043">Iclaprim</compound-id>, <compound-id="124246">Iguratimod</compound-id>, <compound-id="71360">Iloperidone</compound-id>, <compound-id="5291">Imatinib mesylate</compound-id>, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, <compound-id="6851740">Ispinesib mesylate</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; <compound-id="208908">Lapatinib ditosylate</compound-id>, <compound-id="54677946">Laquinimod sodium</compound-id>, <compound-id="6918260,71749750">Larotaxel</compound-id> dehydrate, <compound-id="441401">Linezolid</compound-id>, LOR-2040; Mapatumumab, <compound-id="5327686">MKC-1</compound-id>, Motesanib <compound-id="644102">diphosphate</compound-id>, <compound-id="446541">Mycophenolic acid sodium salt</compound-id>; <compound-id="104842">NK-012</compound-id>; <compound-id="4585">Olanzapine</compound-id> pamoate, Oncolytic HSV, <compound-id="6918412">Ortataxel</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> poliglumex, <compound-id="115237">Paliperidone</compound-id> <compound-id="985">palmitate</compound-id>, Panitumumab, <compound-id="448013">Patupilone</compound-id>, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, <compound-id="7975">Picoplatin</compound-id>, <compound-id="10071196">Pimavanserin tartrate</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="65015">Plerixafor hydrochloride</compound-id>, <compound-id="9855343">PM-02734</compound-id>, Poly I:CLC, <compound-id="5326514">PR1</compound-id>, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, <compound-id="12419,169870">Progesterone caproate</compound-id>, <compound-id="3052762">Prucalopride</compound-id>, <compound-id="154104">Pumosetrag hydrochloride</compound-id>; RAV-12, RB-006, RB-007, Recombinant human <protein-id="P01588,G9JKG7">erythropoietin</protein-id> alfa, <compound-id="104850">Rimonabant</compound-id>, <compound-id="5352062">Romidepsin</compound-id>; SAR-109659, <compound-id="6918220">Satraplatin</compound-id>, <compound-id="264">Sodium butyrate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="164509">Talampanel</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, <compound-id="92337">Tarenflurbil</compound-id>, <compound-id="148201">Tariquidar</compound-id>, <compound-id="1123">Taurine</compound-id>, <compound-id="11485687,16124688,53488182">Tecovirimat</compound-id>, <compound-id="9808844">Telatinib</compound-id>, <compound-id="3081362,6918703">Telavancin hydrochloride</compound-id>, <compound-id="11319053">Telcagepant</compound-id>, <compound-id="476861">Terameprocol</compound-id>, <compound-id="11370864">Tesofensine</compound-id>, Tetrodotoxin, <compound-id="127894">Tezampanel</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="57339443">TPI-287</compound-id>, Tremelimumab; <compound-id="5281884">Valspodar</compound-id>, <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, VCL-CB01, vCP1452, <compound-id="5311">Vorinostat</compound-id>; XL-228; <compound-id="60854">Ziprasidone hydrochloride</compound-id>.	Progesterone caproate__erythropoietin__no_interaction	Aliskiren fumarate__erythropoietin__no_interaction	Ziprasidone hydrochloride__erythropoietin__no_interaction	E75__erythropoietin__no_interaction	Cositecan__erythropoietin__no_interaction	Duloxetine hydrochloride__erythropoietin__no_interaction	Vatalanib__erythropoietin__no_interaction	Valspodar__erythropoietin__no_interaction	Tariquidar__erythropoietin__no_interaction	Dapoxetine hydrochloride__erythropoietin__no_interaction	Pimecrolimus__erythropoietin__no_interaction	Tenatoprazole__erythropoietin__no_interaction	diphosphate__erythropoietin__no_interaction	Pumosetrag hydrochloride__erythropoietin__no_interaction	Picoplatin__erythropoietin__no_interaction	PR1__erythropoietin__no_interaction	Olanzapine__erythropoietin__no_interaction	Prasugrel__erythropoietin__no_interaction	Eplerenone__erythropoietin__no_interaction	Rimonabant__erythropoietin__no_interaction	Sodium butyrate__erythropoietin__no_interaction	Cediranib__erythropoietin__no_interaction	28z__erythropoietin__no_interaction	Casopitant mesylate__erythropoietin__no_interaction	Tadalafil__erythropoietin__no_interaction	TPI-287__erythropoietin__no_interaction	Satraplatin__erythropoietin__no_interaction	NK-012__erythropoietin__no_interaction	Pregabalin__erythropoietin__no_interaction	Iguratimod__erythropoietin__no_interaction	Lapatinib ditosylate__erythropoietin__no_interaction	Ixabepilone__erythropoietin__no_interaction	Tesofensine__erythropoietin__no_interaction	Acotiamide hydrochloride hydrate__erythropoietin__no_interaction	Iloperidone__erythropoietin__no_interaction	Becatecarin__erythropoietin__no_interaction	monohydrate__erythropoietin__no_interaction	Tarenflurbil__erythropoietin__no_interaction	Asenapine maleate__erythropoietin__no_interaction	Esomeprazole magnesium__erythropoietin__no_interaction	Patupilone__erythropoietin__no_interaction	Terameprocol__erythropoietin__no_interaction	Enzastaurin hydrochloride__erythropoietin__no_interaction	Laquinimod sodium__erythropoietin__no_interaction	sodium__erythropoietin__no_interaction	succinate__erythropoietin__no_interaction	Paliperidone__erythropoietin__no_interaction	Prucalopride__erythropoietin__no_interaction	Pimavanserin tartrate__erythropoietin__no_interaction	Taurine__erythropoietin__no_interaction	Elacytarabine__erythropoietin__no_interaction	Darinaparsin__erythropoietin__no_interaction	Etravirine__erythropoietin__no_interaction	Talampanel__erythropoietin__no_interaction	Ispinesib mesylate__erythropoietin__no_interaction	Ortataxel__erythropoietin__no_interaction	Ezetimibe__erythropoietin__no_interaction	Larotaxel__erythropoietin__no_interaction	Tanespimycin__erythropoietin__no_interaction	Imatinib mesylate__erythropoietin__no_interaction	PM-02734__erythropoietin__no_interaction	Bremelanotide__erythropoietin__no_interaction	Tezampanel__erythropoietin__no_interaction	Romidepsin__erythropoietin__no_interaction	Mycophenolic acid sodium salt__erythropoietin__no_interaction	MKC-1__erythropoietin__no_interaction	Iclaprim__erythropoietin__no_interaction	Telavancin hydrochloride__erythropoietin__no_interaction	Ghrelin__erythropoietin__no_interaction	Febuxostat__erythropoietin__no_interaction	Vorinostat__erythropoietin__no_interaction	palmitate__erythropoietin__no_interaction	Faropenem daloxate__erythropoietin__no_interaction	3F8__erythropoietin__no_interaction	Tipifarnib__erythropoietin__no_interaction	Axitinib__erythropoietin__no_interaction	Telatinib__erythropoietin__no_interaction	Linezolid__erythropoietin__no_interaction	Fenretinide__erythropoietin__no_interaction	TNT__erythropoietin__no_interaction	Calcipotriol/betamethasone dipropionate__erythropoietin__no_interaction	Plerixafor hydrochloride__erythropoietin__no_interaction	Paclitaxel__erythropoietin__no_interaction	Eribulin mesilate__erythropoietin__no_interaction	DP-b99__erythropoietin__no_interaction	Telcagepant__erythropoietin__no_interaction	Tecovirimat__erythropoietin__no_interaction
7895614-9	There was an excellent correlation between intestinal <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> protein level and catalytic activity (r = 0.86; p = 0.0001); however, neither parameter significantly correlated with hepatic <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> activity as measured by the <compound-id="12560">erythromycin</compound-id> breath test result (r = 0.27; p = 0.24 and r = 0.33; p = 0.15, respectively).	erythromycin__CYP3A4__no_interaction
23055444-1	The formation of the antimonato polyoxovanadates [V(14)Sb(8)(C(6)H(15)N(3))(4)O(42)(H(2)O)]·4H(2)O (1), (C(6)H(17)N(3))(2)[V(15)Sb(6)(C(6)H(15)N(3))(2)O(42)(H(2)O)]·2.5H(2)O (2), {C(6)H(15)N(3)}(4)[V(16)Sb(4)O(42)]2H(2)O (3) (C(6)H(15)N(3)=<compound-id="8795">1-(2-aminoethyl)piperazine</compound-id>, <protein-id="Q99538,Q53XC6,Q96CY7">AEP</protein-id>) has been studied under solvothermal conditions by using in situ energy dispersive X-ray diffraction (EDRXD).	1-(2-aminoethyl)piperazine__AEP__no_interaction
16296832-2	The [2,2,2-crypt-Na]4[Tl4Se8].en crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n, with Z = 2 and a = 14.768(3) angstroms, b = 16.635(3) angstroms, c = 21.254(4) angstroms, beta = 94.17(3) degrees at -123 degrees C, and the [2,2,2-crypt-Na]2[Tl2Se4]infinity1.en crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/c, with Z = 4 and a = 14.246(2) angstroms, b = 14.360(3) angstroms, c = 26.673(8) angstroms, beta = 99.87(3) degrees at -123 degrees C. The TlIII anions, Tl2Se6(6-) and Tl3Se7(5-), and the mixed oxidation state <compound-id="6432721">TlI</compound-id>/TlIII anion, Tl3Se6(5-), have been obtained by extraction of NaTl0.5Se and NaTlSe in en, in the presence of 2,2,2-crypt and/or in liquid NH3, and have been characterized in solution by low-temperature 77Se, 203Tl, and 205Tl NMR spectroscopy.	TlI__P2(1__no_interaction
16472384-11	Surprisingly, <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> was positively correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.293, p = 0.02) and HOMA-IR (r = 0.373, p = 0.003) while C3 was negatively correlated with <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.242, p = 0.022, <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.184, p = 0.05) and HOMA-IR.	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
21957267-5	The HK-1-stimulated PGE₂ release was inhibited by the tachykinin receptor antagonists (S)1-2-[3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)-1-(3-isopropoxyphenylacetyl)<compound-id="8082">piperidin-3-yl</compound-id>]<compound-id="23134249">ethyl</compound-id>-4-phenyl-l azonia-bicyclo[2.2.2]<compound-id="356">octane</compound-id> (<compound-id="108167,5311450">SR140333</compound-id>) [<protein-id="P20366,Q9Y494">neurokinin-1</protein-id> (NK₁)] and <compound-id="104974">N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide</compound-id> (SR48968) [<protein-id="P20366,Q9Y494">neurokinin-2</protein-id> (NK₂)] and was also inhibited by the <protein-id="P00403,U5Z487">cyclooxygenase (COX)-2</protein-id> inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)<compound-id="72879">methanesulfonamide</compound-id>) (NS-398) but not by the <protein-id="P00395,U5YWV7">COX-1</protein-id> inhibitor <compound-id="1519421">5-(4-chlorophenyl)-1-(</compound-id>4-methoxyphenyl)-3-<compound-id="1807034">trifluoromethylpyrazole</compound-id> (SC-560).	dichlorophenyl__COX-1__no_interaction	dichlorophenyl__neurokinin-2__no_interaction	dichlorophenyl__neurokinin-1__no_interaction	dichlorophenyl__cyclooxygenase (COX)-2__no_interaction	piperidin-3-yl__COX-1__no_interaction	piperidin-3-yl__neurokinin-2__no_interaction	piperidin-3-yl__neurokinin-1__no_interaction	piperidin-3-yl__cyclooxygenase (COX)-2__no_interaction	SR140333__COX-1__no_interaction	SR140333__neurokinin-2__no_interaction	SR140333__neurokinin-1__no_interaction	SR140333__cyclooxygenase (COX)-2__no_interaction	methanesulfonamide__COX-1__no_interaction	methanesulfonamide__neurokinin-2__no_interaction	methanesulfonamide__neurokinin-1__no_interaction	methanesulfonamide__cyclooxygenase (COX)-2__no_interaction	trifluoromethylpyrazole__COX-1__no_interaction	trifluoromethylpyrazole__neurokinin-2__no_interaction	trifluoromethylpyrazole__neurokinin-1__no_interaction	trifluoromethylpyrazole__cyclooxygenase (COX)-2__no_interaction	5-(4-chlorophenyl)-1-(__COX-1__no_interaction	5-(4-chlorophenyl)-1-(__neurokinin-2__no_interaction	5-(4-chlorophenyl)-1-(__neurokinin-1__no_interaction	5-(4-chlorophenyl)-1-(__cyclooxygenase (COX)-2__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__COX-1__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__neurokinin-2__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__neurokinin-1__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__cyclooxygenase (COX)-2__no_interaction	octane__COX-1__no_interaction	octane__neurokinin-2__no_interaction	octane__neurokinin-1__no_interaction	octane__cyclooxygenase (COX)-2__no_interaction	ethyl__COX-1__no_interaction	ethyl__neurokinin-2__no_interaction	ethyl__neurokinin-1__no_interaction	ethyl__cyclooxygenase (COX)-2__no_interaction
21960657-8	The <protein-id="E2RRC5">DBP</protein-id>, <protein-id="F1PJL8">MBP</protein-id>, and SBP RMSE values for 1/PAT were 9.8 ± 5.2, 10.4 ± 5.6, and 11.9 ± 6.1 mmHg, whereas the corresponding values for 1/<compound-id="5462314">PTT</compound-id> were 5.3 ± 1.2, 4.8 ± 1.0, and 7.5 ± 2.2 mmHg (P &lt; 0.05).	PTT__DBP__no_interaction	PTT__MBP__no_interaction
17639304-2	METHODS: We studied seven men with type 1 diabetes (mean +/- <compound-id="5289348">SEM</compound-id> diabetes duration 10 +/- 2 years, age 33 +/- 3 years, BMI 24 +/- 1 kg/m(2), HbA(1c) 8.1 +/- 0.2% and VO(2) peak 43 +/- 2 ml [kg lean body mass](-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) and five non-diabetic controls (mean +/- <compound-id="5289348">SEM</compound-id> age 30 +/- 3 years, BMI 22 +/- 1 kg/m(2), HbA(1c) 5.4 +/- 0.1% and VO(2) peak 52 +/- 4 ml [kg lean body mass](-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>), before and after a standardised breakfast and after three bouts (<protein-id="Q96NE9">EX1</protein-id>, EX2, EX3) of 40 min of cycling at 60% VO(2) peak.	SEM__min(-1__no_interaction	SEM__EX1__no_interaction
10933304-7	RESULTS: Visceral adipose tissue was significantly correlated with unfavorable levels of: <compound-id="11146">triacylglycerol</compound-id> (r = 0.27, p &lt; 0.05), total <compound-id="5997">cholesterol</compound-id> (r = 0.27, p &lt; 0.05), high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = -0.26, p &lt; 0.05), the ratio of total <compound-id="5997">cholesterol</compound-id>/high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.42, p &lt; 0.01), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.27, p &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.38, p &lt; 0.01), and systolic blood pressure (r = 0.30, p &lt; 0.01).	triacylglycerol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
6376034-3	The <protein-id="P01308,I3WAC9">insulin</protein-id>-resistant patients had fasting hyperinsulinemia (19 +/- 4 vs 11 +/- 1 microU/ml in nondiabetic subjects, P less than 0.05), decreased erythrocyte <protein-id="P06213">insulin receptor</protein-id> binding (4.8 +/- 0.4 vs 5.8 +/- 0.3%/1.6 X 10(9) cells in nondiabetic subjects, P less than 0.05), and impairment in both <protein-id="P01308,I3WAC9">insulin</protein-id>-induced suppression of <compound-id="206,5793,64689,79025">glucose</compound-id> production (Km 97 +/- 31 vs 21 +/- 7 microU/ml in nondiabetic subjects, P less than 0.05), and <protein-id="P01308,I3WAC9">insulin</protein-id>-induced stimulation of <compound-id="206,5793,64689,79025">glucose</compound-id> utilization (Km and Vmax 176 +/- 29 microU/ml and 5.8 +/- 0.7 mg/kg/min vs 50 +/- 2 microU/ml and 9.1 +/- 0.6 mg/kg/min in nondiabetic subjects, both P less than 0.05).	glucose__insulin receptor__no_interaction	glucose__insulin__no_interaction
19765079-12	Structured digital abstract: * <protein-id="Q96T58">MINT</protein-id>-7256467: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by circular dichroism (MI:0016) * <protein-id="Q96T58">MINT</protein-id>-7255686: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by biophysical (MI:0013) * <protein-id="Q96T58">MINT</protein-id>-7256439: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by fluorescence microscopy (MI:0416) * <protein-id="Q96T58">MINT</protein-id>-7256449: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by electron microscopy (MI:0040) * <protein-id="Q96T58">MINT</protein-id>-7256430: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by fluorescence technologies (MI:0051).	Dermaseptin__MINT__no_interaction
21134860-10	The collinearities between, 13C-NMR chemical shifts of C4, C5 and <protein-id="Q9Y2Y1">C11</protein-id> with KI-ls and NRL-ls, as well as with <compound-id="77890">TPSA</compound-id>, miLogP, Mr and V were also revealed (δ, ppm C4 vs. <compound-id="77890">TPSA</compound-id>, R = 0.9964; δ, ppm C4 vs. miLogP, R = 0.9487; δ, ppm C4 vs.Mr, R = 0.9629; δ, ppm C4 vs. KI-ls, R = 0.9461; δ, ppm C4 vs. NRL-ls, R = 0.9996; δ, ppm C5 vs. miLogP, R = 0.9994; δ, ppm C5 vs. KI-ls, R = 0.9990; δ, ppm C5 vs. NRL-ls, R = 0.9510; δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. <compound-id="77890">TPSA</compound-id>, R = -0,9958; δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. NRL-ls, R = -0.9994 and δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. KI-ls, R = -0.9481).	TPSA__C11__no_interaction
23827757-9	The recorded IC50 ranges were 3.29 µg/mL [against human knockout clones HCT116 (<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>(-/-)) colon cancer cells] to 14.32 µg/mL (against human liver hepatocellular carcinoma HepG2 cells) for the crude extract from Echinops giganteus, 4.17 µg/mL (against breast cancer cells transduced with control vector MDA-MB231 cells) to 19.45 µg/mL (against MDA-MB-231 BCRP cells) for that of Piper capense, 4.11 µg/mL (against leukemia CCRF-CEM cells) to 30.60 µg/mL (against leukemia HL60AR cells) for Xylopia aethiopica, 3.28 µg/mL [against HCT116 (<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>(-/-)) cells] to 33.43 µg/mL (against HepG2 cells) for Imperata cylindica and 0.11 µg/mL (against CCRF-CEM cells) to 132.47 µg/mL (against HL60AR cells) for <compound-id="31703">doxorubicin</compound-id>.	doxorubicin__p53__no_interaction
10912351-3	The following measured values were used for our analysis: <protein-id="P17516">c11</protein-id> = 19.5 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, c22 = 20.1 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P27701">c33</protein-id> = 30.9 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <compound-id="23657803">c44</compound-id> = 5.72 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, c55 = 5.17 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <compound-id="5287874">c66</compound-id> = 4.05 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P19338,B3KM80,A0A024R4A0">c23</protein-id> = 12.5 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>.	c44__c23__no_interaction	c44__c11__no_interaction	c44__GPa__no_interaction	c44__c33__no_interaction	c66__c23__no_interaction	c66__c11__no_interaction	c66__GPa__no_interaction	c66__c33__no_interaction
11216555-17	In protocol B, at completion of the study (week 9), D/P <compound-id="1176">urea</compound-id>, effluent <protein-id="Q64349">MAL</protein-id>, and AGEs were significantly higher in the experimental group as compared with the control groups [D/P: 0.67 +/- 0.04 (E) vs 0.46 +/- 0.07 (CP) vs 0.41 +/- 0.02 (CC), p &lt; 0.0002 and p &lt; 00001, respectively; <protein-id="Q64349">MAL</protein-id>: 336.8 +/- 63.30 microg/mL (E) vs 125.71 +/- 16.77 microg/mL (CP) vs 119.00 +/- 39.75 microg/mL (CC), p &lt; 0.008 and p &lt; 0.007, respectively; AGEs: 265.77 +/- 33.49 U/mg <compound-id="588">creatinine</compound-id> (E) vs 163.10 +/- 21.99 U/mg <compound-id="588">creatinine</compound-id> (CP) vs 83.17 +/- 22.66 U/mg <compound-id="588">creatinine</compound-id> (CC), p &lt; 0.02 and p &lt; 0.001, respectively].	creatinine__MAL__no_interaction	urea__MAL__no_interaction
17358053-1	Six new coordination polymers, namely [Zn1.5(<protein-id="P35070">BTC</protein-id>)(L1)(H2O)2].1.5H2O (1), [<compound-id="4655929">Zn3</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L2)3] (2), [<compound-id="4655929">Zn3</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L3)1.5(H2O)].H2O (3), [<compound-id="454063">Co6</compound-id>(<protein-id="P35070">BTC</protein-id>)4(L1)6(H2O)3].9H2O (4), [Co1.5(<protein-id="P35070">BTC</protein-id>)(L2)1.5].0.25H2O (5), and [<compound-id="447815">Co4</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L3)2(OH)2(H2O)].4.5H2O (6), where L1 = 1,2-bis(imidazol-1-ylmethyl)<compound-id="241">benzene</compound-id>, L2 = <compound-id="11228701">1,3-bis(imidazol-1-ylmethyl)benzene</compound-id>, L3 = 1,1'-(<compound-id="7843">1,4-butanediyl</compound-id>)bis(<compound-id="795">imidazole</compound-id>), and <protein-id="P35070">BTC</protein-id> = 1,3,5-benzenetricarboxylate anion, were synthesized under hydrothermal conditions.	benzene__BTC__no_interaction	Co4__BTC__no_interaction	Co6__BTC__no_interaction	1,4-butanediyl__BTC__no_interaction	Zn3__BTC__no_interaction	1,3-bis(imidazol-1-ylmethyl)benzene__BTC__no_interaction	imidazole__BTC__no_interaction
23155341-12	The HOMA index revealed a positive correlation with body mass index (BMI) (r = 0.378, P &lt; 0.001), waist circumference (r =0.356, P &lt; 0.001), percent body fat (r = 0.296, P &lt; 0.001), systolic blood pressure (r = 0.202, P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (r = 0.134, P &lt; 0.001), triglycerides (r = 0.292, P &lt; 0.001), <protein-id="P01034">cystatin C</protein-id> (r = 0.069, P &lt; 0.001) and <compound-id="1175">uric acid</compound-id> (r = 0.142, P &lt; 0.001).	uric acid__cystatin C__no_interaction	cholesterol__cystatin C__no_interaction
23155341-13	The QUICKI index revealed a negative correlation with BMI (r = -0.254, P &lt; 0.001), waist circumference (r = 0-0.243, P &lt; 0.001), percent body fat (r = -0.217, P &lt; 0.001), systolic blood pressure (r = -0.132, P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (r = -0.106, P &lt; 0.001), triglycerides (r = -0.205, P &lt; 0.001), <protein-id="P01034">cystatin C</protein-id> (r = -0.044, P &lt; 0.001) and <compound-id="1175">uric acid</compound-id> (r = -0.096, P &lt; 0.001).	uric acid__cystatin C__no_interaction	cholesterol__cystatin C__no_interaction
17484620-3	METHODS: We developed and validated a reverse-hybridization assay (Alpha-Globin StripAssay) for the rapid and simultaneous detection of 21 alpha-globin mutations: two single gene deletions (-alpha(3.7); -alpha(4.2)), five double gene deletions [--(MED); --(SEA); --(THAI); --(<compound-id="9578243">FIL</compound-id>); -(alpha)(20.5)], alpha alpha alpha(anti-3.7) gene triplication, two point mutations in the <protein-id="P25100,B0ZBE0">alpha1</protein-id> gene (cd 14 G&gt;A; Hb Adana) and 11 point mutations in the alpha2 gene (initiation cd T&gt;C; cd 19 -G; IVS1 -5nt; cd 59 G&gt;A; Hb Quong Sze; Hb Constant Spring; Hb Icaria; Hb Pakse; Hb Koya Dora; polyA-1; polyA-2).	FIL__alpha1__no_interaction
24589179-12	Compared with the CRI group, mice in the IPC-CRI group expressed lower <compound-id="5950,602">alanine</compound-id> transaminase activities (2 h: 839.2 ± 132.5 versus 384.2 ± 94.8, P &lt; 0.01; and 6 h: 680 ± 142.4 versus 342.3 ± 99.7, P &lt; 0.01) and lower <protein-id="P11247,Q6RFG4,Q571G0,Q7TMS4">myeloperoxidase</protein-id> levels (2 h: 7.1 ± 4.0 U/g versus 3.8 ± 1.6 U/g, P &lt; 0.05; and 6 h: 8.1 ± 1.3 U/g versus 5.2 ± 3.0 U/g, P &lt; 0.05).	alanine__myeloperoxidase__no_interaction
9389382-1	FK706, <compound-id="5360545">sodium</compound-id> 2-[4-[[(S)-1-[[(S)-2-[[(<compound-id="7021454">RS</compound-id>)-3, 3, 3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl]<compound-id="31268">pyrrolidin</compound-id> -1-yl]carbonyl]-2-<compound-id="7843">methylpropyl</compound-id>] aminocarbonyl] benzoylamino] <compound-id="176">acetate</compound-id>, C26H32F3N4NaO7, is a synthetic <compound-id="962">water</compound-id>-soluble inhibitor of human <protein-id="P08246">neutrophil elastase</protein-id>.	RS__neutrophil elastase__no_interaction	pyrrolidin__neutrophil elastase__no_interaction	sodium__neutrophil elastase__no_interaction	acetate__neutrophil elastase__no_interaction	water__neutrophil elastase__no_interaction	methylpropyl__neutrophil elastase__no_interaction
22990597-7	RESULTS: Intra- and interobserver kappa values for both readers (reader 1/reader 2; first reading/second reading) with 95 % confidence limits were: CE 0.54 (0.08-1.00)/ 0.75 (0.46-1.00); 0.73 (0.29-1.00)/ 0.45 (0.07-0.83), TD 0.53 (0.30-0.88)/ 0.86 (0.60-1.00); 0.56 (0.22-0.91)/ 0.67 (0.37-0.98), <protein-id="Q8TB61">SLL</protein-id> 0.59 (0.25-0.93)/ 0.66 (0.42-0.91); 0.31 (0.06-0.56)/ 0.49 (0.26-0.73), <compound-id="129891">LTL</compound-id> 0.83 (0.66-1.00)/ 0.68 (0.46-0.91); 0.90 (0.79-1.00)/ 0.48 (0.22-0.74); TFCC (0.72-1.00)/ (0.79-1.00); 0.65 (0.43-0.87)/ 0.59 (0.35-0.83), radius (scaphoid fossa) 0.45 (0.12-0.77)/ 0.64 (0.31-0.96); 0.58 (0.19-0.96)/ 0.38 (0.09-0.66), scaphoid 0.43 (0.12-0.74)/ 0.76 (0.55-0.96); 0.37 (0.00-0.75)/ 0.32 (0.04-0.59), radius (lunate fossa) 0.68 (0.36-1.00)/ 0.42 (0.00-0.86); 0.62 (0.29-0.96)/ 0.51 (0.12-0.91), and lunate 0.53 (0.16-0.90)/ 0.68 (0.44-0.91); 0.59 (0.29-0.88)/ 0.42 (0.00-0.84), respectively.	LTL__SLL__no_interaction
2610956-1	Bis[3-(5-chlorosalicylideneamino)propanolato-O,N,O']manganes e(IV) <compound-id="11686950,887">methanol</compound-id> solvate, [Mn(C10H10ClNO2)2].CH3OH, Mr = 510.3, monoclinic, P2(1)/c, a = 11.949 (2), b = 7.530 (2), c = 25.777 (6) A, beta = 105.75 (2) degrees, V = 2232.4 (8) A3, Z = 4, Dx = 1.518 g cm-3, lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.7107 A, mu = 7.98 cm-1, F(000) = 1502, T = 300 K, R = 0.0343, wR = 0.032 for 2113 unique reflections with (I) greater than 3 sigma(I).	methanol__Mo K alpha__no_interaction
23702795-5	Radiosyntheses of 2-[(18)F]fluoro-2-deoxy-<compound-id="79025">d-glucose</compound-id> ([(18)F]<protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id>), 1-[(18)F]fluoro-4-<compound-id="7416">nitrobenzene</compound-id> ([(18)F]FNB), and 2'-deoxy-2'-[(18)F]fluoro-1-β-d-arabinofuranosyl <compound-id="597">cytosine</compound-id> (d-[(18)F]FAC) were performed to validate the system and demonstrate its versatility.	d-glucose__FDG__no_interaction	nitrobenzene__FDG__no_interaction	cytosine__FDG__no_interaction
11456811-1	The electronic structures of the bis-<compound-id="795">imidazole</compound-id> complexes of <compound-id="23925,67172434">iron</compound-id>(III) tetraphenylporphyrin ([(TPP)Fe(<compound-id="444499">ImH</compound-id>)(2)](+)) and <compound-id="23925,67172434">iron</compound-id>(III) tetraphenylchlorin ([(<protein-id="Q16204,Q05CP8">TPC</protein-id>)Fe(<compound-id="444499">ImH</compound-id>)(2)](+)) in frozen glassy solutions have been studied by the pulsed electron nuclear double resonance (<compound-id="8620">ENDOR</compound-id>) technique of Mims and by electron <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-echo envelope modulation (ESEEM) spectroscopy.	ImH__spin__no_interaction	ImH__TPC__no_interaction	ENDOR__spin__no_interaction	ENDOR__TPC__no_interaction	iron__spin__no_interaction	iron__TPC__no_interaction	imidazole__spin__no_interaction	imidazole__TPC__no_interaction
12766180-7	Among HIV-infected subjects, muscle attenuation correlated significantly with FFA (r = -0.38; P = 0.02), visceral fat (r = -0.49; P = 0.002), <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.38; P = 0.02) and <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.60; P = 0.0001) response to a 75-g oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test.	glucose__insulin__no_interaction
16198506-9	RESULTS: A greater nPSA level and shorter T(nPSA) were associated with decreased <protein-id="P07225">PSA</protein-id>-DFS and DMFS in all patients and in all risk categories (low [Stage T1b, T1c, or <compound-id="25021197">T2a</compound-id>, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &lt; or =10 ng/mL], intermediate [Stage T1b, T1c, or <compound-id="25021197">T2a</compound-id>, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &gt;10 but &lt; or =20 ng/mL, or Stage <compound-id="71185540">T2b</compound-id> or T2c, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &lt; or =20 ng/mL, or Gleason score 7 and <protein-id="P07225">PSA</protein-id> level &lt; or =20 ng/mL], and high [Gleason score 8-10 or <protein-id="P07225">PSA</protein-id> level &gt;20 ng/mL]), regardless of RT dose.	T2a__PSA__no_interaction	T2b__PSA__no_interaction
24671708-8	These findings implicate JAK/<protein-id="P40763">STAT3</protein-id> signaling in the development of diaphragm muscle atrophy and dysfunction during CMV and suggest that the delayed extubation times associated with CMV can be prevented by inhibition of Janus kinase signaling.-Smith, I. J., Godinez, G. L., Singh, B. K., McCaughey, K. M., Alcantara, R. R., Gururaja, T., Ho, M. S., Nguyen, H. N., Friera, A. M., White, K. A., McLaughlin, J. R., Hansen, D., Romero, J. M., Baltgalvis, K. A., Claypool, M. D., Li, W., Lang, W., <compound-id="24757941">Yam</compound-id>, G. C., Gelman, M. S., Ding, R., Yung, S. L., Creger, D. P., Chen, Y., Singh, R., Smuder, A. J., Wiggs, M. P., Kwon, O.-S., Sollanek, K. J., Powers, S. K., Masuda, E. S., Taylor, V. C., Payan, D. G., Kinoshita, T., Kinsella, T. M. Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction. 	Yam__STAT3__no_interaction
15654200-2	Patients with isolated <compound-id="92108">CAE</compound-id> were detected to have significantly higher levels of plasma soluble <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P19320">VCAM-1</protein-id> and <protein-id="P16581">E-selectin</protein-id> in comparison with patients with obstructive coronary artery disease without <compound-id="92108">CAE</compound-id> (ICAM, 673 +/- 153 versus 381 +/- 106, respectively, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 1136 +/- 208, respectively, P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 61 +/- 18, respectively, P = 0.01) and subjects with normal coronary arteries (<protein-id="P05362">ICAM-1</protein-id>, 673 +/- 153 versus 303 +/- 131, respectively, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 729 +/- 231, respectively, P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 49 +/- 9, respectively, P &lt; 0.001), suggesting the presence of a more severe and extensive chronic inflammation in the coronary circulation in patients with isolated <compound-id="92108">CAE</compound-id>.	CAE__E-selectin__no_interaction	CAE__ICAM-1__no_interaction	CAE__VCAM-1__no_interaction
15654200-10	RESULTS: Patients with isolated <compound-id="92108">CAE</compound-id> were found to have significantly higher levels of plasma soluble <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P19320">VCAM-1</protein-id>, and <protein-id="P16581">E-selectin</protein-id> in comparison with patients with obstructive <protein-id="P27708,F8VPD4">CAD</protein-id> without <compound-id="92108">CAE</compound-id> (ICAM, 673 +/- 153 versus 381 +/- 106, respectively; P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 1136 +/- 208, respectively; P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 61+/-18, respectively; P = 0.01) and control subjects with normal coronary arteries (<protein-id="P05362">ICAM-1</protein-id>, 673 +/- 153 versus 303 +/- 131, respectively;, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 729 +/- 231, respectively; P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 49 +/- 9, respectively; P &lt; 0.001).	CAE__E-selectin__no_interaction	CAE__ICAM-1__no_interaction	CAE__VCAM-1__no_interaction	CAE__CAD__no_interaction
2139224-2	The consensus peptide for each is <protein-id="P08100">rhodopsin</protein-id> <compound-id="6057">Tyr</compound-id> Pro Pro Gln Gly <protein-id="P08247">synaptophysin</protein-id> <compound-id="6057">Tyr</compound-id> Gly Pro Gln Gly synexin <compound-id="6057">Tyr</compound-id> Pro Pro Pro Pro Gly <compound-id="17787981">gliadin</compound-id> <compound-id="6057">Tyr</compound-id> Pro Pro Pro Gln Pro RNA polymerase II <compound-id="6057">Tyr</compound-id> <compound-id="5951">Ser</compound-id> Pro Thr <compound-id="5951">Ser</compound-id> Pro <compound-id="5951">Ser</compound-id> hordein Phe Pro Gln Gln Pro Gln Gln Pro gluten <compound-id="6057">Tyr</compound-id> Pro Thr <compound-id="5951">Ser</compound-id> Pro Gln Gln Gly <compound-id="6057">Tyr</compound-id> Although there is obvious variation of sequence and of length, the penta- to nonapeptides share an initial <compound-id="6057">Tyr</compound-id> (or Phe) and have high Pro contents and abundant Gly, Gln, and <compound-id="5951">Ser</compound-id>.	Ser__synaptophysin__no_interaction	Ser__rhodopsin__no_interaction	Tyr__synaptophysin__no_interaction	Tyr__rhodopsin__no_interaction	gliadin__synaptophysin__no_interaction	gliadin__rhodopsin__no_interaction
12182215-8	Performance changes from day 2 or 3 to day 20 or 21 at ALT were as follows (values are means +/- SD): VO2max (ml x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)): DEF = +97 +/- 237, <compound-id="16500">ADQ</compound-id> = +159 +/- 156; L + C (s): DEF = -62 +/- 35*, <compound-id="16500">ADQ</compound-id> = -35 +/- 20* (*p &lt; 0.05; improved from day 3); arm flex (reps): DEF = -2 +/- 7, <compound-id="16500">ADQ</compound-id> = +2 +/- 8; AP endurance (min): DEF = +1.4 +/- 2, <compound-id="16500">ADQ</compound-id> = + 1.9 +/- 2; AP strength (kg): DEF = -0.7 +/- 4, <compound-id="16500">ADQ</compound-id> = -1.2 +/- 2.	ADQ__min(-1__no_interaction
18842111-4	Our investigation provided evidence that the development of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance/diabetic state in P. obesus is accompanied by (i) body weight gain and hyperlipidaemia; (ii) elevations of hepatic ACC-Ser79 phosphorylation and ACC protein levels; (iii) a rise in the gene expression of cytosolic <protein-id="Q13085,B2ZZ90,A0A024R0Y2,Q7Z5W8">ACC1</protein-id> concomitant with invariable mitochondrial <protein-id="Q16548">ACC2</protein-id>; (iv) an increase in hepatic AMPKalpha-Thr172 phosphorylation and protein expression without any modification in the calculated ratio of phospho-AMPKalpha to total AMPKalpha; (v) a stimulation in ACC activity despite increased AMPKalpha phosphorylation and protein expression; and (vi) a trend of increase in mRNA levels of key lipogenic enzymes [<protein-id="O00767">SCD-1</protein-id> (<protein-id="O00767">stearoyl-CoA desaturase-1</protein-id>), mGPAT (mitochondrial isoform of <compound-id="24759880,753">glycerol</compound-id>-3-<compound-id="1061,167704,644102">phosphate</compound-id> acyltransferase) and FAS (FA synthase)] and transcription factors [<protein-id="P36956,A8MTU8">SREBP-1</protein-id> (<protein-id="P36956,A8MTU8">sterol-regulatory-element-binding protein-1</protein-id>) and ChREBP (carbohydrate responsive element-binding protein)].	phosphate__stearoyl-CoA desaturase-1__no_interaction	phosphate__SCD-1__no_interaction	phosphate__sterol-regulatory-element-binding protein-1__no_interaction	phosphate__insulin__no_interaction	phosphate__ACC2__no_interaction	phosphate__ACC1__no_interaction	phosphate__SREBP-1__no_interaction	glycerol__stearoyl-CoA desaturase-1__no_interaction	glycerol__SCD-1__no_interaction	glycerol__sterol-regulatory-element-binding protein-1__no_interaction	glycerol__insulin__no_interaction	glycerol__ACC2__no_interaction	glycerol__ACC1__no_interaction	glycerol__SREBP-1__no_interaction
23695949-5	SM <compound-id="587,9548602">Phosphocreatine</compound-id> (20.2 ± 2.3 vs. 16.8 ± 2.3 μmol/g, control vs. <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm), p &lt; 0.05), ATP flux via CK (5.0 ± 0.9 vs. 3.1 ± 1.1 μmol/g/s, p &lt; 0.01), ATP synthesis from inorganic <compound-id="1061,167704,644102">phosphate</compound-id> (Pi → ATP) (0.58 ± 0.3 vs. 0.26 ± 0.2 μmol/g/s, p &lt; 0.05) and the free energy released from ATP hydrolysis (∆G ∼ATP) were significantly lower and [Pi] (2.8 ± 1.0 vs. 5.3 ± 2.0 μmol/g, control vs. <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm), p &lt; 0.05) markedly higher in <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm) than in control mice.	phosphate__IL10__no_interaction	Phosphocreatine__IL10__no_interaction
19858320-11	The increase in NTX correlated with reduction in BMI (r = 0.58; P = 0.009) and <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.45; P = 0.04) and the increase in serum 25-hydroxy <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.43; P = 0.05).	vitamin D__leptin__no_interaction
21358614-6	At the end of <compound-id="3033825">levosimendan</compound-id> therapy, <protein-id="P16860">BNP</protein-id> decreased (from 679.7 ± 512.1 pg/ml to 554.2 ± 407.6 pg/ml p = 0.03), and 6 MWT and LVEF improved (from 217.6 ± 97.7 m to 372.2 ± 90.4 m p = 0.0001; from 22.8 ± 9.1% to 25.4 ± 9.8% p = 0.05).	levosimendan__BNP__no_interaction
24403217-3	Complexes anti-[<compound-id="16214803">Au4</compound-id> (meso-dpmppm)2]X4 (X = <protein-id="Q6Q759">PF6</protein-id> (5 d), BF4 (5 e), TfO (5 f)) contain a linearly ordered <compound-id="16214803">Au4</compound-id> string and complexes <protein-id="P06241">syn</protein-id>-[<compound-id="16214803">Au4</compound-id> (rac-dpmppm)2X2]X'2 (X = Cl, X' = Cl (6 a), <protein-id="Q6Q759">PF6</protein-id> (6 b), BF4 (6 c)) and <protein-id="P06241">syn</protein-id>-[<compound-id="16214803">Au4</compound-id> (rac-dpmppm)2]X4 (X = <protein-id="Q6Q759">PF6</protein-id> (6 d), BF4 (6 e), TfO (6 f)) consist of a zigzag tetragold(I) chain supported by the two <protein-id="P06241">syn</protein-id>-arranged rac-dpmppm ligands.	Au4__syn__no_interaction	Au4__PF6__no_interaction
1433176-3	The minimum length of the backbone was investigated using the following truncated analogues [binding affinity (nM) for Y1 and <protein-id="P49146">Y2 receptor</protein-id> subtypes respectively are given in parentheses]: des-AA10-17[D-Ala9]<protein-id="P01303,A4D158">NPY</protein-id> (100, 0.9), des-<compound-id="9549196">AA7</compound-id>-23[D-Ala6]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 1.2), des-AA4-26[D-Ala3]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 120), cyclo(7,20)-des-AA10-17[Glu7,D- Ala9,D-Dpr20]<protein-id="P01303,A4D158">NPY</protein-id> (100, nd), cyclo(2,27)-des-<compound-id="9549196">AA7</compound-id>-23[Glu2,D-Ala6,D-Dpr27]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 3.6), cyclo(2,30)- des-<compound-id="9549196">AA7</compound-id>-23[Glu2,D-Ala6,-D-Dpr30]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, nd), cyclo(1,30)-des-AA4-26[Glu1,D-Ala3,D-Dpr30]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, &gt; 1000).	AA7__Y2 receptor__no_interaction	AA7__NPY__no_interaction
20331686-7	Following transplantation, serum levels of <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> and β-<compound-id="5757">estradiol</compound-id> decreased significantly (24.35 ± 11.62 vs. 13.93 ± 7.16 ng/mL, p = 0.027; 42.20 ± 15.04 vs. 17.7 ± 7.15 pg/mL, p = 0.000, respectively), whereas levels of <compound-id="6013">testosterone</compound-id> increased (3.07 ± 0.94 vs. 6.54 ± 3.14 ng/mL, p = 0.004).	testosterone__prolactin__no_interaction	estradiol__prolactin__no_interaction
12582948-6	After controlling for HRT status, VO2max was correlated with total <compound-id="5997">cholesterol</compound-id> (r = -0.51, p = 0.0001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = -0.52, p = 0.0001), HDL-C (r = 0.25, p = 0.055), <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL 2</protein-id> -C (r = 0.24, p = 0.08) and TG levels (r = -0.46, p = 0.0001).	cholesterol__LDL-C__no_interaction	cholesterol__HDL 2__no_interaction
12582948-7	After controlling for HRT status, % body fat was correlated with total <compound-id="5997">cholesterol</compound-id> (r = 0.43, p = 0.001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.38, p = 0.003), HDL-C (r = -0.29, p = 0.025), <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL 2</protein-id> -C (r = -0,26, p = 0.07) and TG levels (r = 0.40, p = 0.002).	cholesterol__LDL-C__no_interaction	cholesterol__HDL 2__no_interaction
15914118-2	METHODS: After 6-<compound-id="4624">hydroxydopamine</compound-id> (6-OHDA) pretreatment and a 20-min stabilization period, hearts were perfused at constant pressure for 20 min then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R, <protein-id="Q9ER05">Ctrl</protein-id>); exposed to 0.01 microM XA for 5 min with or without 10 microM <compound-id="2249">atenolol</compound-id> (ATE), a specific antagonist of beta1-AR, followed by a 15-min XA-free perfusion before I/R (PC, ATE-PC, respectively); treated during 20 min with either phosphoinositide (PI) 3-kinase inhibitors, <compound-id="3973">LY-294002</compound-id> (LY, 15 microM), or wortmaninn (WO, 0.1 microM); protein kinase C (PKC) inhibitor, GF-109203X (GF, 4 nM); or <protein-id="A1L1M0">protein kinase A</protein-id> (PKA) inhibitor, H89 (H89, 1 microM), with an infusion starting 3 min before XA (LY-PC, WO-PC, GF-PC, and H89-PC, respectively).	LY-294002__protein kinase A__no_interaction	LY-294002__Ctrl__no_interaction	atenolol__protein kinase A__no_interaction	atenolol__Ctrl__no_interaction	hydroxydopamine__protein kinase A__no_interaction	hydroxydopamine__Ctrl__no_interaction
20699417-5	RESULTS: Compared with a mean ± SE of 98 ± 5 mg/dl (5.4 ± 0.3 mmol/l) at 180 min during saline, mean plasma <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations declined to 58 ± 1 mg/dl (3.2 ± 0.1 mmol/l) (P &lt; 0.001) at 180 min during <compound-id="383414,44420813,448601,6400441,86289069">octreotide</compound-id> plus saline and were 104 ± 16 mg/dl (5.8 ± 0.9 mmol/l) (NS), 143 ± 13 mg/dl (7.9 ± 0.7 mmol/l) (P = 0.004), and 160 ± 15 mg/dl (8.9 ± 0.8 mmol/l) (P &lt; 0.001) at 180 min during <compound-id="383414,44420813,448601,6400441,86289069">octreotide</compound-id> plus <protein-id="P01275">Glucagon</protein-id> in doses of 0.5, 1.0, and 2.0 ng · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively.	octreotide__Glucagon__no_interaction	octreotide__min(-1__no_interaction	glucose__Glucagon__no_interaction	glucose__min(-1__no_interaction
17237312-8	Red meat, relative to control, resulted in: higher protein [5.3 (3.7, 6.9) % of energy], lower carbohydrate [-5.3 (-7.9, -2.7)% of energy], and higher <compound-id="23925,67172434">iron</compound-id> [3.2 (1.1, 5.4) mg/d] intakes; lower urinary F2-isoprostane excretion [-137 (-264, -9) pmol/mmol <compound-id="588">creatinine</compound-id>], lower leukocyte [-0.51 (-0.99, -0.02)x10(9)/L] counts, and a trend for lower serum C-reactive protein concentrations [-1.6 (-3.3, 0.0) mg/L, P=0.06]; and no differences in concentrations of plasma F2-isoprostanes [-12 (-122, 100) pmol/L], serum gamma-glytamyltransferase [-0.8 (-3.2, 1.5) U/L], <protein-id="P0DJI8">serum amyloid A protein [-1.4</protein-id> (-3.4, 0.5) mg/L], and plasma fibrinogen concentrations [-0.08 (-0.40.	creatinine__serum amyloid A protein [-1.4__no_interaction	iron__serum amyloid A protein [-1.4__no_interaction
8637441-2	Compared with the control subjects, the hemodialysis patients had significantly higher serum triglyceride and apolipoprotein B-associated apolipoprotein CIII concentrations (1.03 +/- 0.31 v 1.98 +/- 0.86 mmol/L and 0.004 +/- 0.002 v 0.011 +/- 0.005 g/L, respectively), lower serum high-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id> and apolipoprotein <compound-id="15942654">AI</compound-id> concentrations (1.33 +/- 0.37 v 0.95 +/- 0.31 mmol/L and 1.29 +/- 0.25 v 1.09 +/- 0.23 g/L, respectively), and lower postheparin plasma <protein-id="P11151">LPL</protein-id> activity (82 +/- 24 v 35 +/- 14 milliU/milliL).	AI__LPL__no_interaction	cholesterol__LPL__no_interaction
15786388-4	The following results were obtained: blood <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>: M (n=21) 1.78 +/- 0.57, V (n=96) 1.72 +/- 0.36 g/L (p=ns); blood <compound-id="23925,67172434">iron</compound-id>: M (n=22) 8.66 +/- 5.07, V (n=97) 10.50 +/- 4.57 mmol/L (p=ns); TIBC: M (n=21) 42.69 +/- 13.63, V (n=98) 40.36 +/- 10.33 mmol of <compound-id="23925,67172434">iron</compound-id>/L (p=ns); <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation: M (n=21) 22.10 +/- 13.07, V (n=96) 25.81 +/- 11.79% (p=ns); blood Hb: M (n=22) 107.55 +/-19.70, V (n=98) 111.02 +/- 14.68 g/L (p=ns); MCV: M (n=22) 94.58 +/- 7.35, V (n=98) 93.27 +/- 8.16 fL (p=ns); RDW: M (n=22) 16.60 +/- 1.51, V (n=98) 15.83 +/- 1.39 (p&lt;0.022); soluble <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> receptors: M (n=18) 1.85 +/- 0.90, V (n=90) 1.89 +/- 0.75 mg/L (p=ns); reticulocyte count: M (n=22) 91.38 +/- 34.69, V (n=98) 87.27 +/- 29.56 *10 9 /L (p=ns); CHR: M (n=22) 31.36 +/- 2.92, V (n=98) 31.46 +/- 3.08 pg (p=ns); <protein-id="Q969Q1">IRF</protein-id>: M (n=22) 24.81 +/- 7.55, V (n=98) 23.65 +/- 8.64 (p=ns); intravenous Fe+++ weekly supplementation: M (n=22) 45.45 +/- 26.81, V (n=98) 37.31 +/- 32.25 mg/week (p=ns); a-<protein-id="P01588,G9JKG7">EPO</protein-id> weekly supple-mentation: M (n=22) 9090.91 +/- 7824.92, V (n=97) 9030.93 +/- 8292.13 UI/week (p=ns).	iron__EPO__no_interaction	iron__transferrin__no_interaction	iron__IRF__no_interaction
18624404-2	They have been characterized by routine physicochemical techniques as well as by X-ray single-crystal structure analysis: [Cu 2(H <compound-id="73441667">2L2</compound-id> (2))(OH)(H 2O)(NO 3)](NO 3) 3.2H 2O ( 1), [Cu(<protein-id="P07306,Q6FGQ5">HL1</protein-id> (4))(H 2O)(NO 3)] 2(NO 3) 2.2H 2O ( 2), [Cu(L1 (1))(H 2O)(NO 3)] 2 ( 3), [Cu 2(L2 (3))(OH)(H 2O) 2](NO 3) 2, ( 4) and [Cu 2(L2 (1))(N 3) 3] ( 5) [L1 = 2-formyl-4-methyl-6R-iminomethyl-phenolato and L2 = 2,6-bis(R-iminomethyl)-4-methyl-phenolato; for L1 (1) and L2 (1), R = N-<compound-id="424975">propylmorpholine</compound-id>; for L2 (2), R = <compound-id="79196">N-ethylpiperazine</compound-id>; for L2 (3), R = N-<compound-id="81782">ethylpyrrolidine</compound-id>, and for L1 (4), R = N-<compound-id="7525">ethylmorpholine</compound-id>].	N-ethylpiperazine__HL1__no_interaction	ethylmorpholine__HL1__no_interaction	propylmorpholine__HL1__no_interaction	ethylpyrrolidine__HL1__no_interaction	2L2__HL1__no_interaction
16650737-10	Descending order of susceptibility of the spread monolayers of lipid mixtures to <protein-id="P02768">albumin</protein-id> destabilization was as follows: [(DPPC+PG, 7:3)=(DPPC+PG, 9:1)=(DPPC+<compound-id="5283485">POPC</compound-id>)]&gt;[(DPPC+PE)=(DPPC+CHOL)]&gt;[(DPPC+PA)=(DPPC)] The increase in minimum surface tension in presence of <protein-id="P02768">albumin</protein-id> and erythrocyte membranes was accompanied by sudden increases in compressibility at surface tensions of 15-30 mN/m.	POPC__albumin__no_interaction
15777867-2	Using both extracellular field potential and whole-cell patch-clamp recordings in brainstem parasagital slices of juvenile rat with the mandibular nerve attached, we show here that the induction of trigeminal primary afferent <compound-id="56846361">LTP</compound-id>: (1) does not require the activation of ionotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptors; (2) is dependent on extracellular Ca(2+) and the release of Ca(2+) from intracellular stores; (3) is specifically prevented by the metabotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptor subtype 5 (<protein-id="Q8C825,Q3UZT1,Q8BRT2,Q8BQZ0">mGluR5</protein-id>) antagonist 2-methyl-6-(phenylethynyl)pyridine but not the <protein-id="P23818,Q7TNB5,F6YNQ1">mGluR1</protein-id> antagonist <compound-id="5311261">LY367385</compound-id>, group II mGluR antagonist LY341495 or group III mGluR antagonist <protein-id="Q5M7W5,A0A0G2JW88">MAP4</protein-id>; (4) is mimicked by the bath-applied group I mGluR agonist (S)-<compound-id="108001">3,5-dihydroxyphenylglycine</compound-id> and <protein-id="Q8C825,Q3UZT1,Q8BRT2,Q8BQZ0">mGluR5</protein-id> agonist (<compound-id="7021454">RS</compound-id>)-<compound-id="1800613">2-chloro</compound-id>-5-<compound-id="20468917">hydroxyphenylglycine</compound-id>; (5) requires the activation of phospholipase C (PLC) and protein kinase C (PKC); and (6) is concomitantly with a decrease in paired-pulse depression.	LTP__mGluR5__no_interaction	LTP__mGluR1__no_interaction	LTP__MAP4__no_interaction	RS__mGluR5__no_interaction	RS__mGluR1__no_interaction	RS__MAP4__no_interaction	LY367385__mGluR5__no_interaction	LY367385__mGluR1__no_interaction	LY367385__MAP4__no_interaction	3,5-dihydroxyphenylglycine__mGluR5__no_interaction	3,5-dihydroxyphenylglycine__mGluR1__no_interaction	3,5-dihydroxyphenylglycine__MAP4__no_interaction	hydroxyphenylglycine__mGluR5__no_interaction	hydroxyphenylglycine__mGluR1__no_interaction	hydroxyphenylglycine__MAP4__no_interaction	2-chloro__mGluR5__no_interaction	2-chloro__mGluR1__no_interaction	2-chloro__MAP4__no_interaction	glutamate__mGluR5__no_interaction	glutamate__mGluR1__no_interaction	glutamate__MAP4__no_interaction
20625317-8	PARTICIPANTS: Participants were 110 hypertensive patients [male/female 46/64, age 66.3 ± 10.8 years, systolic blood pressure (SBP)/diastolic blood pressure (DBP) 161.8 ± 16.9/92.9 ± 12.4 mmHg, s-Cr 0.77 ± 0.32 mg/dl, plasma renin activity (PRA) 0.65 ± 0.63 ng/ml per h, angiotensin I (AngI) 70.5 ± 77.3 pg/ml, angiotensin II (<protein-id="O15123">AngII</protein-id>) 5.2 ± 3.9 pg/ml, plasma <compound-id="5839">aldosterone</compound-id> concentration (PAC) 76.3 ± 35.9 pg/ml, urinary albumin excretion (UAE) 108.1 ± 284.2 mg/<protein-id="P04150,E5KQF5,E5KQF6,F1D8N4,B7Z7I2">gCr</protein-id>].	aldosterone__gCr__no_interaction	aldosterone__AngII__no_interaction
20625317-12	RESULTS: Results were as follows (amlodipine vs. <compound-id="5282138">cilnidipine</compound-id>): SBP/DBP (mmHg): 135.2 ± 11.7/79.8 ± 9.6 vs. 136.7 ± 13.2/79.5 ± 10.9, P = 0.22/0.74; PRA (ng/ml per h): 1.16 ± 1.03 vs. 0.95 ± 0.78, P &lt; 0.01; AngI (pg/ml): 155.0 ± 306.4 vs. 101.8 ± 92.0, P &lt; 0.05; <protein-id="O15123">AngII</protein-id> (pg/ml): 12.0 ± 12.3 vs. 7.1 ± 4.5, P &lt; 0.001; PAC (pg/ml): 81.6 ± 37.9 vs. 74.3 ± 36.2, P &lt; 0.05; UAE (mg/<protein-id="P04150,E5KQF5,E5KQF6,F1D8N4,B7Z7I2">gCr</protein-id>): 145.4 ± 424.5 vs. 58.8 ± 125.1, P &lt; 0.05.	cilnidipine__gCr__no_interaction	cilnidipine__AngII__no_interaction
15364160-7	Serum <protein-id="P02656,A3KPE2">apo C III</protein-id> levels were found to be positively associated with plasma TG ( r = 0.527, P &lt; 0.001), TC (r = 0.424, P &lt; 0.001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.308, P &lt; 0.01) concentrations, and carotid <compound-id="447041">IMT</compound-id> (r =0.359, P &lt; 0.01 ).	IMT__LDL-C__no_interaction	IMT__apo C III__no_interaction
16869716-15	Using the intact assay only, <protein-id="Q9GZV9,Q9EPC2,Q3U1V5">FGF-23</protein-id> was significantly associated with serum <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.39, p &lt; 0.01), 24-h urinary <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.47, p &lt; 0.01), fractional excretion of <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.29, p &lt; 0.01), and 1,25-dihydroxyvitamin D (r = -0.30, p &lt; 0.01).	phosphate__FGF-23__no_interaction
23332241-6	However, the peak levels of ERK activation and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> expression in vascular smooth muscle cells were stimulated by combining SS and NE (ratio of phosphorylated ERK [pERK]/β-actin and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> positive rates, SS+NE [1.07 ± 0.04 and 73% ± 3%]; SS [0.83 ± 0.07 and 53% ± 2%]; NE [0.63 ± 0.11 and 42% ± 2%]), which could be partially inhibited by <compound-id="4893">prazosin</compound-id> (ratio of pERK/β-actin and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> positive rates, SS+NE+Praz [0.83 ± 0.08 and 40% ± 7% vs SS+NE; P &lt; .05], SS+Praz [0.60 ± 0.04 and 26% ± 2% vs SS; P &lt; .05], NE+Praz [0.32 ± 0.12 and 23% ± 2% vs NE; P &lt; .05]) or small interfering RNAs of α1B-ARs and α1D-ARs (P &lt; .05 vs siRNA control).	prazosin__Ki67__no_interaction
7313308-1	<protein-id="G3X8Q1,Q6PFH4,Q80X22">Cain</protein-id>'s <compound-id="7047">Quinolinium</compound-id>; <compound-id="7047">quinolinium</compound-id>, <compound-id="162282">6-amino-1-</compound-id>methyl-4[[[[[[(<compound-id="13597">1-methyl-pyridinium</compound-id>-4-yl)amino]phenyl]amino]carbonyl]phenyl]amino] (NSC 176319), is a chemotherapeutic agent, which is equally cytotoxic in vitro to both murine L1210 leukemia cells and bone marrow progenitor cells.	Quinolinium__Cain__no_interaction	6-amino-1-__Cain__no_interaction	1-methyl-pyridinium__Cain__no_interaction	quinolinium__Cain__no_interaction
19376108-4	In isolated rings of porcine pulmonary veins the typical alpha(1)-adrenoceptor agonist <compound-id="6041">phenylephrine</compound-id> caused a concentration-dependent contraction that was inhibited by the alpha(1B)-adrenoceptor selective antagonists <compound-id="9891980">1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one</compound-id> (Rec15/2615; pA(2) 8.96+/-0.13) and 4-amino-2-[4-[1-(<compound-id="7708">benzyloxycarbonyl</compound-id>)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-<compound-id="3031661">6,7-dimethoxyquinazoline</compound-id> (L-765,314; pA(2) 7.22+/-0.05), as well as the <protein-id="Q9TTM9">alpha(1D)-adrenoceptor</protein-id> selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]<compound-id="23134249">ethyl</compound-id>]-<compound-id="136843">8-azaspiro[4.5]decane-7,9-dione</compound-id> (BMY7378; pA(2) 8.29+/-0.15, slope of the Schild plot 0.75+/-0.09, significantly different from unity, P&lt;0.05), but not by the alpha(1A)-adrenoceptor selective antagonists (+/-)-1,3,5-<compound-id="4245325">trimethyl-</compound-id>6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-<compound-id="67490">benzodioxin-5-yl</compound-id>)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-<compound-id="1174">pyrimidinedione</compound-id> (B8805-033) and <compound-id="3894573">N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine</compound-id> (<compound-id="7021454">RS</compound-id>-17053).	benzyloxycarbonyl__alpha(1D)-adrenoceptor__no_interaction	RS__alpha(1D)-adrenoceptor__no_interaction	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one__alpha(1D)-adrenoceptor__no_interaction	N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine__alpha(1D)-adrenoceptor__no_interaction	trimethyl-__alpha(1D)-adrenoceptor__no_interaction	pyrimidinedione__alpha(1D)-adrenoceptor__no_interaction	phenylephrine__alpha(1D)-adrenoceptor__no_interaction	6,7-dimethoxyquinazoline__alpha(1D)-adrenoceptor__no_interaction	benzodioxin-5-yl__alpha(1D)-adrenoceptor__no_interaction	8-azaspiro[4.5]decane-7,9-dione__alpha(1D)-adrenoceptor__no_interaction	ethyl__alpha(1D)-adrenoceptor__no_interaction
2843998-5	The regional distribution of 125I-<compound-id="6057">Tyr</compound-id>(o)-ovine <protein-id="P01143">CRF</protein-id> binding (olfactory bulb greater than frontoparietal cortex approximately equal to cerebellum greater than hypothalamus greater than striatum greater than or equal to midbrain greater than hippocampus greater than or equal to spinal cord) did not correspond with the regional degree of <protein-id="P01143">CRF</protein-id> receptor-mediated stimulation of <compound-id="6083">adenylate</compound-id> cyclase (frontoparietal cortex greater than olfactory bulb greater than or equal to cerebellum greater than midbrain greater than or equal to hippocampus greater than striatum greater than or equal to hypothalamus greater than spinal cord).	adenylate__CRF__no_interaction	Tyr__CRF__no_interaction
24174496-4	Using site-directed mutagenesis complemented with in silico homology modeling, we report the binding modes of two high-affinity <protein-id="P49682">CXCR3</protein-id> antagonists of distinct chemotypes: VUF11211 [(S)-5-chloro-6-(4-(1-(4-chlorobenzyl)<compound-id="8082">piperidin-4-yl</compound-id>)-<compound-id="14094188">3-ethylpiperazin</compound-id>-1-yl)-<compound-id="78007">N-ethylnicotinamide</compound-id>] (<compound-id="15251992">piperazinyl-piperidine</compound-id>) with a rigid elongated structure containing two basic groups and <compound-id="10167713,45784923">NBI-74330</compound-id> [(R)-N-(1-(3-(4-<compound-id="7674">ethoxyphenyl</compound-id>)-4-oxo-3,4-<compound-id="13347754">dihydropyrido</compound-id>[2,3-d]pyrimidin-2-yl)<compound-id="23134249">ethyl</compound-id>)-2-(4-fluoro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-<compound-id="2735225">N-(pyridin-3-ylmethyl)acetamide</compound-id>] (8-azaquinazolinone) without any basic group.	piperidin-4-yl__CXCR3__no_interaction	dihydropyrido__CXCR3__no_interaction	3-ethylpiperazin__CXCR3__no_interaction	ethoxyphenyl__CXCR3__no_interaction	N-ethylnicotinamide__CXCR3__no_interaction	N-(pyridin-3-ylmethyl)acetamide__CXCR3__no_interaction	trifluoromethyl__CXCR3__no_interaction	piperazinyl-piperidine__CXCR3__no_interaction	NBI-74330__CXCR3__no_interaction	ethyl__CXCR3__no_interaction
11768247-4	Selected important clinical learning points include the following: (1) <compound-id="206,5793,64689,79025">glucose</compound-id> absorption mediated by <protein-id="P13866">SGLT1</protein-id> is controlled by mRNA abundance, as well as by posttranscriptional processes including protein trafficking; (2) inducers of cytochrome P-450 decrease <compound-id="206,5793,64689,79025">glucose</compound-id> and fructose absorption and increase <compound-id="206,5793,64689,79025">glucose</compound-id> consumption in the intestine; (3) the regulated release of nutrients from the stomach into the upper intestine ensures that the modest intestinal transport reserve capacity is not exceeded; (4) hepatocyte growth factor and short-chain fatty acids may enhance intestinal adaptation and prevent the atrophy seen when total parenteral nutrition is infused; (5) inhibitors of pancreatic <compound-id="5474737">lipase</compound-id> and phospholipase <compound-id="783">H2</compound-id> may be useful clinically to reduce absorption as part of a treatment program for obesity and hyperlipidemia; (6) several membrane-bound and cytosolic proteins have been identified in the enterocyte as well as in the hepatocyte and may be the target for the future therapeutic manipulation of bile acid metabolism and control of hyperlipidemia; (7) suspect bile acid malabsorption in the patient with otherwise unexplained chronic diarrhea; (8) a proportion of lipid absorption is protein-mediated, and this opens the way to targeting these proteins and thereby therapeutically modifying lipid absorption; (9) a high protein diet may be useful to increase the intestinal absorption of drugs transported by the H+/dipeptide cotransporter; (10) a metal transporter <protein-id="P49281">DCT1</protein-id> has been identified, and this may open the way to a better understanding of disorders of, for example, <compound-id="23925,67172434">iron</compound-id> and <compound-id="23994">zinc</compound-id> metabolism; (11) the nutrient transporters such as <protein-id="P13866">SGLT1</protein-id> are responsible for a portion of the intestinal absorption of <compound-id="962">water</compound-id>; (12) the influence of <compound-id="145068">nitric oxide</compound-id> on intestinal <compound-id="962">water</compound-id> absorption and secretion depends on its concentration; (13) a trial of bile acid-sequestering agent may prove useful in the treatment of the patient who experiences diarrhea while taking an enteral diet; (14) a proteolytic extract from pineapple stems may prove to be useful to treat diarrhea, although the mechanism of this effect remains to be established; and (15) the antisecretory effect of the new peptide, <compound-id="6904">sorbin</compound-id>, needs to be tested in a clinical situation on patients with diarrhea.	iron__DCT1__no_interaction	iron__SGLT1__no_interaction	H2__DCT1__no_interaction	H2__SGLT1__no_interaction	water__DCT1__no_interaction	water__SGLT1__no_interaction	sorbin__DCT1__no_interaction	sorbin__SGLT1__no_interaction	zinc__DCT1__no_interaction	zinc__SGLT1__no_interaction	nitric oxide__DCT1__no_interaction	nitric oxide__SGLT1__no_interaction	lipase__DCT1__no_interaction	lipase__SGLT1__no_interaction	glucose__DCT1__no_interaction	glucose__SGLT1__no_interaction
20617238-6	The addition of <compound-id="74260">N-(2-pyridinyl)acetoacetamide</compound-id> (paaH) to Mn(Y)2 x 4 H2O Y = <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) or ClO4(-) in <compound-id="887">MeOH</compound-id> gave a second divalent heptanuclear cluster with a 'disc'-like core of general formula [Mn7(paa)6(OMe)6][X]2 x solv (4) (X = <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) or ClO4(-)), whilst the addition of paaH to a mixture of Mn(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2 x 4 H2O, teaH3 and <protein-id="O60636,B1AKP1,B2RD31">NEt3</protein-id> in CH2Cl2-<compound-id="887">MeOH</compound-id> resulted in the formation of a mixed-valence Mn2(II)Mn2(III) tetranuclear 'butterfly' complex of formula [Mn4(paa)4(<compound-id="8471">teaH</compound-id>)2][<protein-id="P41271,A0A087WTY6">NO3</protein-id>]2 x 2 <compound-id="887">MeOH</compound-id> x 2 CH2Cl2 (5).	teaH__NEt3__no_interaction	teaH__NO3__no_interaction	MeOH__NEt3__no_interaction	MeOH__NO3__no_interaction	N-(2-pyridinyl)acetoacetamide__NEt3__no_interaction	N-(2-pyridinyl)acetoacetamide__NO3__no_interaction
17279246-1	Metalladichalcogenolate cluster complexes [Cp'Co{E(2)C(2)(B(10)H(10))}]{<protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>(CO)5} [Cp' = eta5-C5H5, E = S(<compound-id="2981881,91293124">3a</compound-id>), E = Se(3b); Cp' = eta5-C5(CH3)5, E = S(<compound-id="69255155">4a</compound-id>), E = Se(4b)], {CpCo[E(2)C(2)(B(10)H(10))]}(2)Mo(CO)2] [E = S(5a), Se(<compound-id="18445697">5b</compound-id>)], Cp*Co(micro2-CO)Mo(CO)(py)2[E(2)C(2)(B(10)H(10))] [E = S(6a), Se(6b)], Cp*Co[E(2)C(2)(B(10)H(10))]Mo(CO)2[E(2)C(2)(B(10)H(10))] [E = S(7a), Se(7b)], (Cp'Co[E(2)C(2)(B(10)H(10))]W(CO)2 [E(2)C(2)(B(10)H(10))] [Cp' = eta5-C5H5, E = S(8a), E = Se(8b); Cp' = eta5-C5(CH3)5, E = S(9a), E = Se(9b)], {CpCo[E(2)C(2)(B(10)H(10))]}(2)Ni [E = S(10a), Se(10b)] and 3,4-(PhCN(4)S)-3,1,2-[PhCN(4)<compound-id="446720">SCo</compound-id>(Cp)S(2)]-3,1,2-CoC(2)B(9)H(8) 12 were synthesized by the reaction of [Cp'CoE(2)C(2)(B(10)H(10))] [Cp' = eta5-C5H5, E = S(1a), E = Se(1b); Cp' = eta5-C5(CH3)5, E = S(2a), E = Se(2b)] with <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>(CO)8, M(CO)3(py)3 (M = Mo, W), <compound-id="82916">Ni(COD)2</compound-id>, [Rh(COD)Cl]2, and LiSCN4Ph respectively.	3a__Co2__no_interaction	5b__Co2__no_interaction	Ni(COD)2__Co2__no_interaction	SCo__Co2__no_interaction	4a__Co2__no_interaction
15252518-1	The reactions of four flexible tetradentate ligands, <compound-id="12836427">1,3-bis(2-pyridylthio)propane</compound-id> (L1), <compound-id="12140658">1,4-bis(2-pyridylthio)butane</compound-id> (L2), <compound-id="12140660">1,5-bis(2-pyridylthio)pentane</compound-id> (L3) and <compound-id="12140661">1,6-bis(2-pyridylthio)hexane</compound-id> (L4) with <protein-id="Q16222">AgX</protein-id> (X = BF4-, ClO4-, PF6-, or CF3SO3-) lead to the formation of seven new complexes: [AgL1(BF4)]2 (1), [[AgL2](ClO4)]infinity (2), [[AgL2(CH3CN)](PF6)]infinity (3), [[AgL3](BF4)(CHCl3)]2 (4), [[AgL3(CF3SO3)](CH3OH)(0.5)]infinity (5), [[Ag2L4(2)](BF4)2]infinity (6), and [[AgL4](PF6)]infinity (7), which have been characterized by elemental analyses, IR spectroscopy, and X-ray crystallography.	1,4-bis(2-pyridylthio)butane__AgX__no_interaction	1,6-bis(2-pyridylthio)hexane__AgX__no_interaction	1,3-bis(2-pyridylthio)propane__AgX__no_interaction	1,5-bis(2-pyridylthio)pentane__AgX__no_interaction
15943824-9	RESULTS: <compound-id="60823">Atorvastatin</compound-id> treatment compared to placebo resulted in a significant decrease in serum <compound-id="5997">cholesterol</compound-id> (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P &lt; 0.001), low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> (2.95 +/- 1.07 mmol/l vs. 1.82 +/- 0.92 mmol/l; P &lt; 0.001), very low-density lipoprotein (VLDL) <compound-id="5997">cholesterol</compound-id> (0.31 (0.21-0.47) mmol vs. 0.23 (0.13-0.30) mmol/l median (interquartile range); P &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (111 +/- 28 mg/dl vs. 80 +/- 18 mg/dl; P &lt; 0.001), and calculated coronary heart disease risk (6.8 (3.3-17.9) vs. 2.8 (1.5-5.7)% over next 10 years; P &lt; 0.01).	Atorvastatin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
12402618-17	Capacitance was directly correlated with body mass index (r = 0.35, p &lt; 0.05), <protein-id="P02768">albumin</protein-id> (r = 0.32, p &lt; 0.05), and blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (BUN) (r = 0.44, p &lt; 0.01), and inversely correlated with body weight (r = -0.51, p &lt; 0.0001).	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
10611907-7	The levels of lipid parameters were as follows: total <compound-id="5997">cholesterol</compound-id> for men was 4.22 +/- 1.00 mmol/l (mean arithmetic +/- SD), triglyceride 1.20 mmol/l (0.30-4.44) [geometric mean (range)], HDL-<compound-id="5997">cholesterol</compound-id> 0.88 +/- 0.22 mmol/l, LDL-<compound-id="5997">cholesterol</compound-id> 2.69 +/- 0.85 mmol/l, apolipoprotein A-I 1.26 +/- 0.22 mmol/l <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> 1.12 +/- 0.32 mmol/l, <protein-id="P02649">apolipoprotein E</protein-id> 0.037 +/- 0.012 mmol/l and lipoprotein(a) 0.25 g/l (0.03-2.75); total <compound-id="5997">cholesterol</compound-id> for women was 4.53 +/- 1.00 mmol/l, triglyceride 1.05 mmol/l (0.28-4.50), HDL-<compound-id="5997">cholesterol</compound-id> 1.08 +/- 0.26 mmol/l, LDL-<compound-id="5997">cholesterol</compound-id> 2.87 +/- 0.88 mmol/l, apolipoprotein A-I 1.45 +/- 0.25 mmol/l, <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> 1.11 +/- 0.31 mmol/l, <protein-id="P02649">apolipoprotein E</protein-id> 0.039 +/- 0.011 mmol/l and lipoprotein(a) 0.22 g/l (0.03 2.16).	cholesterol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein E__no_interaction
8324419-8	<compound-id="2720">Thiazide</compound-id> users had lower serum levels of <protein-id="P01270">PTH</protein-id> (26.2 +/- 7.6 (SD) ng/l vs. 31.0 +/- 11.7 ng/l, P = 0.009) and <compound-id="5280453">1,25-dihydroxyvitamin D</compound-id> (60.8 +/- 16.2 pmol/l vs. 77.0 +/- 18.7 pmol/l, P &lt; 0.001) in the winter/spring and, in the subset measured, reduced levels of osteocalcin year round (summer/fall: 2.89 +/- 0.82 micrograms/l, n = 10, vs. 3.65 +/- 1.02, n = 82, P = 0.019; winter/spring: 2.54 +/- 0.80 micrograms/l vs. 3.47 +/- 1.07 micrograms/l, P = 0.005).	Thiazide__PTH__no_interaction	1,25-dihydroxyvitamin D__PTH__no_interaction
3688234-3	The maintenance period of chronic CDA, compared with control, was characterized by hypokalemic metabolic alkalosis (serum <compound-id="6857437">TCO2</compound-id> 31.9 +/- 0.6 vs. 23.1 +/- 0.5 meq/l, P less than 0.05), volume contraction (plasma volume 3.76 +/- 0.08 vs. 4.19 +/- 0.22 ml/100 g body wt, P less than 0.05), decreased GFR (838 +/- 84 vs. 1045 +/- 45 microliters.min-1.100 g body <protein-id="P49952,D3ZJ55">wt-1</protein-id>, P less than 0.05), increased plasma renin activity (PRA) (63 +/- 13 vs. 12 +/- 3 ng.ml-1.h-1, P less than 0.05), but unchanged plasma <compound-id="5839">aldosterone</compound-id> concentrations (PAC) (4.1 +/- 1.0 vs. 3.4 +/- 1.6 ng/dl, P = NS).	TCO2__wt-1__no_interaction	aldosterone__wt-1__no_interaction
2857145-4	Inclusion of <protein-id="P60042">somatostatin</protein-id> in the culture medium (1 X 10(-8) to 1 X 10(-4) M) resulted in significant inhibition of gastrin release at <protein-id="P60042">somatostatin</protein-id> concentrations of 1 X 10(-5) and 1 X 10(-4) M: both doses of <protein-id="P60042">somatostatin</protein-id> inhibited gastrin release by approximately 52% at 30 min and by 32% at 6 h. Gastrin release stimulated by dibutyryl cyclic <compound-id="6083">adenosine monophosphate</compound-id> was significantly inhibited by 1 X 10(-5) and 1 X 10(-4) M <protein-id="P60042">somatostatin</protein-id> to 133% and 121% at 30 min and 77% and 98% at 6 h, respectively.	adenosine monophosphate__somatostatin__no_interaction
19618904-1	One-dimensional (1D) coordination polymers of formula [Fe(NH(2)trz)(3)]A.nH(2)O, {A = <compound-id="27873">TiF</compound-id>(6)(2-), n = 0.5 (1) and n = 1 (2); A = ZrF(6)(2-), n = 0.5 (3) and n = 0 (4); A = SnF(6)(2-), n = 0.5 (5) and n = 1 (6); A = TaF(7)(2-), n = 3 (7) and n = 2.5 (8); A = <protein-id="Q92974,D3DVA5">GeF</protein-id>(6)(2-), n = 1 (9) and n = 0.5 (10), NH(2)trz = <compound-id="11432">4-amino-1,2,4-triazole</compound-id>} have been synthesized, fully characterized, and their <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover behavior carefully studied by SQUID magnetometry, Mossbauer spectroscopy, and differential scanning calorimetry.	TiF__spin__no_interaction	TiF__GeF__no_interaction	4-amino-1,2,4-triazole__spin__no_interaction	4-amino-1,2,4-triazole__GeF__no_interaction
17844660-1	The study of the reaction between the <compound-id="53675528,6325">ethylene</compound-id> [Pt(eta-H2C = CH2)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] or alkyne [Pt(eta2-HC [triple bond] CR)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] (R = SiMe3 1, Bu(t) 2) complexes with [cis-Pt(C6F5)2(thf)2] (thf = tetrahydrofuran) has enabled us to observe the existence of competitive processes between the activation of a P-C(Ph) bond on the <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id> ligand, to give the binuclear derivative [cis-(C6F5)2Pt(mu-Ph)(mu-PPh2)Pt(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)] 3, and the activation of a C-H bond of the unsaturated group, to give the corresponding (mu-<compound-id="166653">hydride</compound-id>)(mu-vinyl) [cis, cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-CH = CH2)Pt(C6F5)2] 4 or (mu-<compound-id="166653">hydride</compound-id>)(mu-alkynyl) [cis,cis-(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2Pt(mu-H)(mu-1kappaC(alpha):eta2-C [triple bond]CR)Pt(C6F5)2] (R = SiMe3 5, Bu(t) 6) compounds, respectively.	ethylene__PPh3__no_interaction	hydride__PPh3__no_interaction
24065527-5	We found that the urinary <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> level was positively correlated with hypertension (ρ = 0.28, P &lt; 0.01), urinary protein (r = 0.38, P &lt; 0.01), urinary <protein-id="O15123">Ang II</protein-id> (r = 0.29, P &lt; 0.05), urinary type IV collagen (Col IV) (r = 0.56, P &lt; 0.01), and was negatively correlated with estimated glomerular filtration rate (eGFR) (r = -0.28, P &lt; 0.01), urinary <compound-id="5360545">sodium</compound-id> (r = -0.22, P &lt; 0.05) and serum <protein-id="P01019,B0ZBE2,B2R5S1">AGT</protein-id> (r = -0.27, P &lt; 0.01).	sodium__AGT__no_interaction	sodium__Ang II__no_interaction
9119530-1	We analyzed structural motifs of peptides bound to HLA-<protein-id="P13762,X5D2U9">DR4</protein-id> (DRB1*0405 and DRB1*0406) and DR9 (DRB1*0901) and found that: (a) AxxBxC motif where A, B, and C are hydrophobic, hydrophobic, and neutral, respectively, is important for binding to <protein-id="P13762,X5D2U9">DR4</protein-id>; (b) Gln (Q) or <compound-id="5951">Ser</compound-id> at position C allow high-affinity binding specific to DRB1*0406 which is strongly associated with <protein-id="P01308,I3WAC9">insulin</protein-id> autoimmune syndrome; (c) among human <protein-id="P01308,I3WAC9">insulin</protein-id>-derived peptide fragments, the TSICSLYQLE of the human <protein-id="P01308,I3WAC9">insulin</protein-id> alpha chain, which is exposed only under reducing conditions, has the highest affinity specific to DRB1*0406 by binding with the IxxLxQ motif; (d) a short-term human <protein-id="P01308,I3WAC9">insulin</protein-id>-specific T cell line recognizes a peptide fragment containing the IxxLxQ motif as a major T cell epitope; and (e) in the AxxB motif, where A and B need to be hydrophobic for binding to DR9, neutral <compound-id="5951">Ser</compound-id> is exceptionally allowed at position B.	Ser__DR4__no_interaction	Ser__insulin__no_interaction
24571702-6	Enamel loss (<compound-id="5289348">SEM</compound-id>) values for other European products and the reference control (active agents) were: <compound-id="23258">Meridol</compound-id>(®) : (1,400 ppm F as <protein-id="P06744,B4DE36">AmF</protein-id> + <protein-id="P51531,B1ALF6,F6T8Q0,B4DSC8,Q56A76,B4DNT1,Q8N9Q1">SnF2</protein-id> ) 12.0 μm (1.47); <compound-id="5564">Colgate</compound-id>(®) Cavity Protection: (1,450 ppm F as SMFP + NaF) 12.9 μm (1.66); Odol med 3(®) (1,400 ppm F as NaF) 14.2 μm (1.49); Elmex(®) (1,400 ppm F as <protein-id="P06744,B4DE36">AmF</protein-id>) 14.5 μm (1.76); <compound-id="5564">Colgate</compound-id>(®) Enamel Protect: (1,450 ppm F as NaF + KNO3 ) 16.3 μm (2.02); Lacalut(®) aktiv: (1,400 ppm F as AlF3 ) 18.5 μm (1.71); <compound-id="971">Sensodyne</compound-id>(®) ProNamel(™) : (1,450 ppm F as NaF + KNO3 ) 20.5 μm (1.26); Crest Cavity Protection (1,100 ppm F as NaF, reference control) 22.00 μm (2.04); and Mentadent(®) : (1,450 ppm F as NaF + Zn <compound-id="311,17938267">citrate</compound-id>) 22.3 μm (0.63).	Colgate__SnF2__no_interaction	Colgate__AmF__no_interaction	Meridol__SnF2__no_interaction	Meridol__AmF__no_interaction	SEM__SnF2__no_interaction	SEM__AmF__no_interaction	citrate__SnF2__no_interaction	citrate__AmF__no_interaction	Sensodyne__SnF2__no_interaction	Sensodyne__AmF__no_interaction
22387485-2	Interestingly, with similar five-member benzo-heterocycles, the two auxiliary acceptors of <compound-id="6809">phthalimide</compound-id> and <compound-id="7220">benzotriazole</compound-id> play exactly different roles in absorption and intramolecular charge transfer: (i) in contrast with WS-5 delocalized throughout the entire chromophore, the HOMO orbital of <protein-id="P05546,Q8IVC0">LS-2</protein-id> is mainly located at the donor part due to the twist conformation with the existence of two carbonyl groups in <compound-id="6809">phthalimide</compound-id>; (ii) the dihedral angles of "D-A" plane and "A-π" plane in <protein-id="P05546,Q8IVC0">LS-2</protein-id> further suggest that the incorporation of <compound-id="6809">phthalimide</compound-id> moiety results in curvature of electron delocalization over the whole molecule, in agreement with its blue-shifted, relatively narrow absorption spectra and low photocurrent density; (iii) in contrast with the beneficial charge transfer of <compound-id="7220">benzotriazole</compound-id> in WS-5, the <compound-id="6809">phthalimide</compound-id> unit in <protein-id="P05546,Q8IVC0">LS-2</protein-id> plays an oppositely negative contribution to the charge transfer, that is, blocking intramolecular electron transfer (ICT) from donor to acceptor to some extent; and (iv) in electrochemical impedance spectroscopy, the incorporated <compound-id="7220">benzotriazole</compound-id> unit enhances electron lifetime by 18.6-fold, the <compound-id="6809">phthalimide</compound-id> only increases electron lifetime by 5.0-fold.	benzotriazole__LS-2__no_interaction	phthalimide__LS-2__no_interaction
10774797-3	The vasorelaxant effects of substance P and the <protein-id="P30547,Q547C3,Q8R1R6">NK1 receptor</protein-id> agonist were abolished by the selective <protein-id="P30547,Q547C3,Q8R1R6">NK1 receptor</protein-id> antagonist <compound-id="107967">FK888</compound-id> (N2-[(4R)-4-hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-<compound-id="3323161">prolyl</compound-id>]-N-methy l-N-<compound-id="123147">phenylmethyl</compound-id>-3-(2-naphthyl)-L-<compound-id="350287,444939">alaninamide</compound-id>), whereas the selective <protein-id="Q64077">NK2 receptor</protein-id> antagonist <compound-id="104974">SR48968</compound-id> ((S)-N-methyl-N-[4-acetylamino-<compound-id="69873">4-phenylpiperidino</compound-id>)-2-(3,4-<compound-id="57417436">dichlorophenyl</compound-id> )-<compound-id="68006705">butyl</compound-id>] <compound-id="2331">benzamide</compound-id>) and the selective <protein-id="P30098">NK3 receptor</protein-id> antagonist SR142801 ((S)-(N)-( 1-(3-(1-benzoyl-3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)<compound-id="8082">piperidin-3-yl</compound-id>)propyl)4-p henylpiperidin-4-yl)-N-<compound-id="6582">methylacetamide</compound-id>) produced partial inhibition on their responses.	phenylmethyl__NK3 receptor__no_interaction	phenylmethyl__NK1 receptor__no_interaction	phenylmethyl__NK2 receptor__no_interaction	alaninamide__NK3 receptor__no_interaction	alaninamide__NK1 receptor__no_interaction	alaninamide__NK2 receptor__no_interaction	dichlorophenyl__NK3 receptor__no_interaction	dichlorophenyl__NK1 receptor__no_interaction	dichlorophenyl__NK2 receptor__no_interaction	piperidin-3-yl__NK3 receptor__no_interaction	piperidin-3-yl__NK1 receptor__no_interaction	piperidin-3-yl__NK2 receptor__no_interaction	SR48968__NK3 receptor__no_interaction	SR48968__NK1 receptor__no_interaction	SR48968__NK2 receptor__no_interaction	4-phenylpiperidino__NK3 receptor__no_interaction	4-phenylpiperidino__NK1 receptor__no_interaction	4-phenylpiperidino__NK2 receptor__no_interaction	methylacetamide__NK3 receptor__no_interaction	methylacetamide__NK1 receptor__no_interaction	methylacetamide__NK2 receptor__no_interaction	butyl__NK3 receptor__no_interaction	butyl__NK1 receptor__no_interaction	butyl__NK2 receptor__no_interaction	FK888__NK3 receptor__no_interaction	FK888__NK1 receptor__no_interaction	FK888__NK2 receptor__no_interaction	benzamide__NK3 receptor__no_interaction	benzamide__NK1 receptor__no_interaction	benzamide__NK2 receptor__no_interaction	prolyl__NK3 receptor__no_interaction	prolyl__NK1 receptor__no_interaction	prolyl__NK2 receptor__no_interaction
20233197-5	RESULTS: Concurrent <compound-id="392622">ritonavir</compound-id> administration resulted in about fourfold increases in both the C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) and AUC(T)[C(<protein-id="P61244,Q8TAX8,A0A024R682">max</protein-id>) 2.79 +/- 0.22 vs. 10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04; AUC 50.06 +/- 2.52 vs. 220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3], a significant increase (P &lt; 0.01) in the elimination half-life (11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77) and about a 4.5-fold decrease in CL/F (12.01 +/- 0.61 vs. 2.71 +/- 0.09 l h(-1)) of quinine.	ritonavir__max__no_interaction
16919043-8	Fifty-four patients with (+) <protein-id="P08588">anti-beta(1)-AR</protein-id> had greater improvements than 42 patients with (-) <protein-id="P08588">anti-beta(1)-AR</protein-id> in LVEDD (left ventricular end-diastolic dimension) (P &lt; 0.01, from 69 +/- 0.8 to 58.0 +/- 0.5 mm vs. 69.0 +/- 0.8-63.6 +/- 0.9 mm) and LVESD (left ventricular end-systolic dimension) (P &lt; 0.01, from 57.1 +/- 1.4 to 43.9 +/- 0.8 mm vs. 56.2 +/- 0.9-48.6 +/- 1.0 mm), and LVEF (left ventricular ejection fraction) (P &lt; 0.01, from 35.4 +/- 1.3 to 49.8 +/- 0.6% vs. 34.4 +/- 1.0-44.3 +/- 1.1%) by <compound-id="4171">metoprolol</compound-id> therapy in combination with standard treatment regime for one year.	metoprolol__anti-beta(1)-AR__no_interaction
23221137-2	In severe sepsis and septic shock should be early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; -appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; -early administration of broad-spectrum antibiotic therapy; -reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; -a usual 7-10 days of antibiotic therapy guided by clinical response; -source control with attention to the method that balances risks and benefits; -equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; -vasopressor preference for <compound-id="439260">norepinephrine</compound-id> and <compound-id="681">dopamine</compound-id>; -cautious use of <protein-id="P01185,X5DQP6">vasopressin</protein-id> pending further studies; -avoiding low-dose <compound-id="681">dopamine</compound-id> administration for renal protection; consideration of <compound-id="36811">dobutamine</compound-id> inotropic therapy in some clinical situations; -stress-dose steroid therapy for septic shock; use of recombinant activated <protein-id="P04070">protein C</protein-id> in patients with severe sepsis and high risk for death; -with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; -a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; -application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; -protocols for weaning and sedation, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; -avoidance of neuromuscular blockers, if at all possible; -maintenance of blood <compound-id="206,5793,64689,79025">glucose</compound-id> &lt;150 mg/dL after initial stabilization.	norepinephrine__vasopressin__no_interaction	norepinephrine__protein C__no_interaction	glucose__vasopressin__no_interaction	glucose__protein C__no_interaction	dobutamine__vasopressin__no_interaction	dobutamine__protein C__no_interaction	dopamine__vasopressin__no_interaction	dopamine__protein C__no_interaction
20089735-4	Activity analyses of the resulting mutants, 910A [1A10((1-83))/<compound-id="71297182">1A9</compound-id>((84-285))], 910B [<compound-id="71297182">1A9</compound-id>((1-83))/1A10((84-147))/<compound-id="71297182">1A9</compound-id>((148-285))], 910C [<compound-id="71297182">1A9</compound-id>((1-147))/1A10((148-181))/<compound-id="71297182">1A9</compound-id>((182-285))], 910D [<compound-id="71297182">1A9</compound-id>((1-181))/1A10((182-235))/<compound-id="71297182">1A9</compound-id>((236-285))], and 910E [<compound-id="71297182">1A9</compound-id>((1-235))/1A10((236-285))] indicated that more than one residue is responsible for the differences between <protein-id="O60656,Q5DSZ5">UGT1A9</protein-id> and <protein-id="Q9HAW8,Q5DT02">UGT1A10</protein-id>.	1A9__UGT1A9__no_interaction	1A9__UGT1A10__no_interaction
22248752-9	In group B, mean arterial pressure (MAP, mm Hg,1 mm Hg = 0.133 kPa) 24 hours and 72 hours after IABP, cardiac index [CI, L×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)× m(-2)] after 48 hours of IABP, and in 2 hours after termination of IABP, <compound-id="681">dopamine</compound-id> dosage [μg×kg(-1)×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)] in 24, 48, 72 hours after IABP and 2 hours after termination were significantly improved than those in group A (MAP: 53.0 ± 6.3 vs. 52.1 ± 6.2, 65.6 ± 4.3 vs. 65.0 ± 2.1; CI: 3.40 ± 0.20 vs. 3.30 ± 0.50, 3.60 ± 0.30 vs. 3.60 ± 0.30; <compound-id="681">dopamine</compound-id> dosage: 17.5 ± 1.2 vs. 17.6 ± 1.3, 10.2 ± 1.3 vs. 12.8 ± 1.6, 5.8 ± 1.5 vs. 6.8 ± 1.7, 3.0 ± 0.7 vs. 4.1 ± 1.3, P &lt; 0.05 or P &lt; 0.01).	dopamine__min(-1__no_interaction
11590897-7	These results showed <compound-id="445014">ERI</compound-id> has a statistically significant correlation with <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation (TS) (r = -0.327, p = 0.042), total weekly Kt/Vurea (r = -0.423, p = 0.018), serum <protein-id="P02768">albumin</protein-id> level (r = -0.458, p = 0.003), normalized protein catabolic rate (nPCR) (r = -0.479, p = 0.006), normalized protein equivalent of total <compound-id="947">nitrogen</compound-id> appearance (nPNA) (r = -0.488, p = 0.005) and serum <protein-id="P02741">C-reactive protein</protein-id> (<protein-id="P02741">CRP</protein-id>) (r = 0.332, p = 0.036).	ERI__albumin__no_interaction	ERI__C-reactive protein__no_interaction	ERI__transferrin__no_interaction	ERI__CRP__no_interaction	nitrogen__albumin__no_interaction	nitrogen__C-reactive protein__no_interaction	nitrogen__transferrin__no_interaction	nitrogen__CRP__no_interaction
22433825-5	These range from invasive monitoring by Eppendorf polarographic O(2) microelectrodes, positron electron tomography (PET) tracers based on 2-<compound-id="10701">nitroimidazole</compound-id> compounds [(18)F-labelled fluoro-<compound-id="26105">misonidazole</compound-id> ((18)F-MISO) or 1-(2-[((18))F]fluoro-1-[hydroxymethyl]ethoxy)<compound-id="21274">methyl-2-nitroimidazole</compound-id> (<compound-id="5494423">FRP</compound-id>-170)], (64)<compound-id="6409958">Cu-ATSM</compound-id> Cu-diacetyl-bis(N4-methylthiosemicarbazone) (<compound-id="6409958">Cu-ATSM</compound-id>) or (99m)Tc- and (68)Ga-labelled <compound-id="4173">metronidazole</compound-id> (MN) agents to advanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> methods, such as blood oxygenation level dependent (BOLD) <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>, <compound-id="977">oxygen</compound-id>-enhanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>, diffusion-weighted <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (DWI-<protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>), dynamic contrast-enhanced <protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id> (DCE-<protein-id="Q9BWK5,A0A024R780,A0A087WWQ8">MRI</protein-id>) and (1)H-magnetic resonance spectroscopy.	oxygen__MRI__no_interaction	methyl-2-nitroimidazole__MRI__no_interaction	Cu-ATSM__MRI__no_interaction	metronidazole__MRI__no_interaction	FRP__MRI__no_interaction	misonidazole__MRI__no_interaction	nitroimidazole__MRI__no_interaction
18006567-5	When different stimulation strategies were compared, a strong correlation was noted for cytokine responses after <compound-id="11970143">lipopolysaccharide</compound-id> and S epidermidis exposure--that is, <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL6</protein-id> (R = 0.431, 95% CI 0.29 to 0.55, p&lt;0.001, n = 161) and <protein-id="P22301,Q6FGW4">IL10</protein-id> (R = 0.332, 95% CI 0.18 to 0.47, p&lt;0.001, n = 161).	lipopolysaccharide__IL6__no_interaction	lipopolysaccharide__IL10__no_interaction
22891645-4	One exemplar, (R)-N-((1-(4-(but-3-en-1-ylamino)-6-(((<compound-id="547510">2-(thiophen-2-yl)thiazol-4-yl</compound-id>)methyl)amino)-1,3,5-<compound-id="7541">triazin</compound-id>-2-yl)<compound-id="31268">pyrrolidin</compound-id>-2-yl)methyl)-<compound-id="2265561">4-propylbenzenesulfonamide</compound-id> (8), inhibited <protein-id="Q9UNA0">ADAMTS-5</protein-id> with IC(50) = 30 nM, showing &gt;50-fold selectivity against <protein-id="O75173">ADAMTS-4</protein-id> and &gt;1000-fold selectivity against <protein-id="Q9UHI8,B2RB33">ADAMTS-1</protein-id>, <protein-id="Q76LX8">ADAMTS-13</protein-id>, <protein-id="P45452,Q53H33">MMP-13</protein-id>, and <protein-id="P78536,B2RNB2">TACE</protein-id>.	pyrrolidin__ADAMTS-5__no_interaction	pyrrolidin__ADAMTS-4__no_interaction	pyrrolidin__ADAMTS-1__no_interaction	pyrrolidin__MMP-13__no_interaction	pyrrolidin__TACE__no_interaction	pyrrolidin__ADAMTS-13__no_interaction	4-propylbenzenesulfonamide__ADAMTS-5__no_interaction	4-propylbenzenesulfonamide__ADAMTS-4__no_interaction	4-propylbenzenesulfonamide__ADAMTS-1__no_interaction	4-propylbenzenesulfonamide__MMP-13__no_interaction	4-propylbenzenesulfonamide__TACE__no_interaction	4-propylbenzenesulfonamide__ADAMTS-13__no_interaction	triazin__ADAMTS-5__no_interaction	triazin__ADAMTS-4__no_interaction	triazin__ADAMTS-1__no_interaction	triazin__MMP-13__no_interaction	triazin__TACE__no_interaction	triazin__ADAMTS-13__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-5__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-4__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-1__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__MMP-13__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__TACE__no_interaction	2-(thiophen-2-yl)thiazol-4-yl__ADAMTS-13__no_interaction
21664558-5	Similarly, plasma non-esterified fatty acids and triglycerides increased, while HDL <compound-id="5997">cholesterol</compound-id> decreased (P&lt;.05 to &lt;.001) from SL to 5300 m. Acylation-stimulating protein (SL 42.2 ± 40.2 nm; 4000 m 117.0 ± 69.6 nm; 4750 m 107.9 ± 44.5 nm; 5300 m 82.2 ± 20.2 nm; P=.019) and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (SL 10.4 ± 6.5 ng/mL, 4000 m 13.9 ± 8.5 ng/mL, 4750 m 18.3 ± 8.3 ng/mL, 5300 m 14.7 ± 8.0 ng/mL; P=.015) increased, as did insulin and <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin-6</protein-id> (<protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">IL-6</protein-id>) levels (up to 71% and 168%, respectively; P&lt;.05) with no change in <protein-id="P41159,A4D0Y8">leptin</protein-id>, complement C3 (C3), high sensitivity C-reactive protein (hsCRP) or cortisol levels throughout the mountain ascent from SL to 5300 m. CONCLUSION: Acylation-stimulating protein and <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> are increased during a 9-day period of high altitude (SL to 5300 m) exposure despite weight loss in healthy mountaineers. 	cholesterol__IL-6__no_interaction	cholesterol__leptin__no_interaction	cholesterol__Interleukin-6__no_interaction	cholesterol__adiponectin__no_interaction
22883217-5	Arterial <compound-id="222">ammonia</compound-id> (r = 0.72, p = 0.03), tumour necrosis factor alpha (r = 0.87, p = 0.02), <protein-id="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1">Interleukin-6</protein-id> (r = 0.50, p = 0.05), <protein-id="Q14116,A0A024R3E0">Interleukin-18</protein-id> (r = 0.76, p = 0.02) and serum endotoxin (r = 0.91, p = 0.01) correlated with higher grades of hepatic encephalopathy.	ammonia__Interleukin-18__no_interaction	ammonia__Interleukin-6__no_interaction
9605570-4	We studied the effect on neurogenic secretion in ferret trachea in vitro of the <protein-id="P18075,A8K571">OP1</protein-id> receptor (formerly known as delta opioid receptor) agonist [D-Pen2,5]<compound-id="461776">enkephalin</compound-id> (DPDPE), the <compound-id="12518745">OP2</compound-id> receptor (formely kappa) agonist <compound-id="68616">U-50,488H</compound-id>, the OP3 receptor (formerly micro) agonist [D-Ala2, <compound-id="6951135">N-Me-Phe</compound-id>, Gly-ol5]<compound-id="461776">enkephalin</compound-id> (<compound-id="5462471">DAMGO</compound-id>), the ATP-sensitive K+ (K(ATP)) channel inhibitor <compound-id="3488">glibenclamide</compound-id>, the large conductance <compound-id="22044544,5460341">calcium</compound-id> activated K+ (BK(Ca)) channel blocker <compound-id="16132435">iberiotoxin</compound-id>, the small conductance K(Ca) (SK(Ca)) channel blocker <compound-id="16129677,16218850,56928162,57043712">apamin</compound-id>, the K(ATP) channel opener <compound-id="93504">levcromakalim</compound-id>, a putative K(ATP) channel opener <compound-id="7021454">RS</compound-id> 91309, and the BK(Ca) channel opener <compound-id="4552">NS 1619</compound-id>.	DAMGO__OP1__no_interaction	levcromakalim__OP1__no_interaction	NS 1619__OP1__no_interaction	OP2__OP1__no_interaction	glibenclamide__OP1__no_interaction	RS__OP1__no_interaction	N-Me-Phe__OP1__no_interaction	enkephalin__OP1__no_interaction	calcium__OP1__no_interaction	iberiotoxin__OP1__no_interaction	U-50,488H__OP1__no_interaction	apamin__OP1__no_interaction
20721515-8	We observed levels of <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">P-selectin</protein-id> (pre-angioplasty: 14.23 ± 7.52 x 8.83 x 11.45 ± 7.65 ± 7.09; after angioplasty: 21.49 ± 23.82 x 4 37 ± 2.71 x 4.82 ± 4.47, ρ &lt; 0.01) and glycoprotein IIb/IIIa (pre-angioplasty: 98.97 ± 0.43 ± 1.25 x 98.79 x 99.21 ± 0.40 after angioplasty: 99.37 ± 0.29 ± 1.47 x 98.50 x 98.92 ± 0.88, ρ = 0.52), respectively, in the control, <compound-id="60823">atorvastatin</compound-id> and <compound-id="54454">simvastatin</compound-id> groups.	atorvastatin__P-selectin__no_interaction	simvastatin__P-selectin__no_interaction
15015153-7	Notably, both <compound-id="6106">leucine</compound-id> flux and nonoxidative <compound-id="6106">leucine</compound-id> R(d) (protein synthesis) increased with <protein-id="P01308,I3WAC9">insulin</protein-id> (2.36 +/- 0.06 to 2.81 +/- 0.10 and 1.79 +/- 0.05 to 2.18 +/- 0.10 micromol/kg fat-free mass (<protein-id="P78363,Q6AI28">FFM</protein-id>) x min, respectively; P &lt;.0005) while <compound-id="6106">leucine</compound-id> oxidation only tended to increase (P =.05) and endogenous <compound-id="6106">leucine</compound-id> R(a) (protein breakdown) decreased by 18% (2.36 +/- 0.06 to 1.94 +/- 0.09 micromol/kg <protein-id="P78363,Q6AI28">FFM</protein-id> x min; P &lt;.0005), resulting in a marked elevation of net protein synthesis (-0.57 +/- 0.02 to 0.24 +/- 0.02 micromol/kg <protein-id="P78363,Q6AI28">FFM</protein-id> x min; P &lt;.0000001).	leucine__FFM__no_interaction	leucine__insulin__no_interaction
18271677-2	Three-month administration of COC resulted in 1) significant increase of basal (454.0+/-125.0 to 860.9+/-179.7 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated serum <compound-id="5754">cortisol</compound-id> in 30th min (652.3+/-60.5 to 1374.1+/-240.6 nmol/l); 2) no significant change of basal (15.4+/-7.3 to 18.9+/-8.5 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated salivary <compound-id="5754">cortisol</compound-id> at the 30th min (32.4+/-8.8 to 32.9+/-9.0 nmol/l); 3) no significant change of basal serum <compound-id="222786">cortisone</compound-id> (38,8+/-7.68 to 45.2+/-24.2 nmol/l) and <protein-id="P01189,Q6FHC8">ACTH</protein-id>-stimulated <compound-id="222786">cortisone</compound-id> at the 30th (34.8+/-10.9 to 47.0+/-35.7 nmol/l); 4) significant increase of basal <protein-id="P01189,Q6FHC8">ACTH</protein-id> (17.2+/-9.0 to 38.2+/-29.4 ng/l), CBG (991.0+/-161.0 to 2332.0+/-428.0 nmol/l), and 5) no significant change of basal DHEA (24.6+/-15.7 to 22.6+/-11.7 micromol/l) and calculated basal value for free <compound-id="5754">cortisol</compound-id> (22.8+/-14.9 to 19.2+/-6.9 nmol/l).	cortisone__ACTH__no_interaction	cortisol__ACTH__no_interaction
1534954-8	<protein-id="P02675,V9HVY1">fibrinogen</protein-id> was lowered (in a comparison of the data prior to the first and following the second plasmapheresis) from 526.4 +/- 114 to 314.1 +/- 80.1 mg/dl (p less than 0.01), <compound-id="5997">cholesterol</compound-id> from 210.8 +/- 76.8 to 131.3 +/- 38.2 mg/dl (p less than 0.01), LDL from 125 +/- 53 mg/dl to 63.6 +/- 25.7 mg/dl (p less than 0.01), LP(a) from 26.2 +/- 13.2 to 12.0 +/- 9.5 mg/dl (p less than 0.01), HDL from 31.7 +/- 6.3 to 29.7 +/- 5.6 mg/dl (no significance), RCTT from 14.4 +/- 2.8 to 10.9 +/- 0.9 (p less than 0.01), whole blood viscosity (low shear rate) from 11.64 +/- 1.7 to 8.74 +/- 1.4 mPa/sec (p less than 0.01) and (high shear rate) from 5.38 +/- 0.58 to 4.28 +/- 0.83 mPa/sec (p less than 0.01).	cholesterol__fibrinogen__no_interaction
15146514-1	A general study of the regioselective hydroamination of terminal alkynes in the presence of [(eta5-Cp)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (1), [(eta5-CpEt)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (CpEt=<compound-id="528176">ethylcyclopentadienyl</compound-id>) (2), and [(eta5-Cp*)2Ti(<protein-id="Q9UNA4">eta2</protein-id>-Me3SiC2SiMe3)] (Cp*=<compound-id="142539">pentamethylcyclopentadienyl</compound-id>) (3) is presented.	ethylcyclopentadienyl__eta2__no_interaction	pentamethylcyclopentadienyl__eta2__no_interaction
23844086-5	In multivariate linear regression, after adjustment for gender, age, smoking and drinking, body mass index (BMI), systolic and diastolic blood pressure (<protein-id="Q8TD31,Q769H0,M1T2K8,B0S7V6,M1TIV4,Q2TB68,D2IYK9">SBP</protein-id>, <protein-id="Q10586">DBP</protein-id>), lipid profiles, logarithmic transformed C-reactive protein (log-CRP), estimated glomerular filtration rate (e-<protein-id="Q92565,A8MQ07,Q5JPD2">GFR</protein-id>), FPG and HbA1c, with a 1-mg/dl increment of <compound-id="5289420">SUA</compound-id>, 2-h PG increased by 5.04 ± 0.72 (P&lt;0.001), 3.06 ± 1.08 (P = 0.001), 5.40 ± 1.26 (P&lt;0.001), and 2.34 ± 2.16 mg/dl (P = 0.056) in all participants, in participants with normal <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (NGT), with impaired <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance (IGT), and with 2-h newly diagnosed diabetes (2-h NDM, with 2-h PG ≥ 200 mg/dl), respectively.	SUA__GFR__no_interaction	SUA__DBP__no_interaction	SUA__SBP__no_interaction	glucose__GFR__no_interaction	glucose__DBP__no_interaction	glucose__SBP__no_interaction
10081703-8	A submaximal concentration of <protein-id="P01186">AVP</protein-id> (10(-10) M) induced cAMP accumulation of 48.6 +/- 2.5 pmol (mg protein)-1 (4 min)-1 (P &lt; 0.01 compared with basal level of 34.9 +/- 2.4 pmol (mg protein)-1 (4 min)-1, n = 10), which was blocked in the presence of a vasopressin V2 receptor antagonist (10(-7) M <compound-id="119369">OPC-31260</compound-id>) but not by the <protein-id="P70536">oxytocin receptor</protein-id> antagonist (10(-6) M [Pen1,pMePhe2, Thr4,Orn8]<compound-id="439302">oxytocin</compound-id>) (36.3 +/- 6.1 and 45.1 +/- 1.3 pmol (mg protein)-1 (4 min)-1 respectively, P &lt; 0.05, n = 10).	oxytocin__oxytocin receptor__no_interaction	oxytocin__AVP__no_interaction	OPC-31260__oxytocin receptor__no_interaction	OPC-31260__AVP__no_interaction
15193303-2	Incubation of 100 microM aminochrome with 100 microM <compound-id="54676038">dicoumarol</compound-id>, an inhibitor of <protein-id="P15559,B4DLR8">DT-diaphorase</protein-id> during 2 h, induces 56% cell death (P &lt; 0.001) with concomitant formation of (i) intracellular hydroperoxides (4.2-fold increase compared to control; P &lt; 0.001); (ii) <compound-id="961">hydroxyl radicals</compound-id>, detected with <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR</protein-id> and spin trapping agents (2.4-fold increase when cells were incubated with aminochrome in the presence of <compound-id="54676038">dicoumarol</compound-id> compared to aminochrome alone); (iii) intracellular edema, and cell membrane deterioration determined by transmission electron microscopy; (iv) absence of apoptosis, supported by using anexin-V with flow cytometry; (v) a strong decrease of mitochondrial membrane potential determined by the fluorescent dye 5,5',6,6'-<compound-id="5326109">tetrachloro-</compound-id>1,1',3,3'-tetraethylbenzimidazolylcarbocyanineiodide (P &lt; 0.01); (vi) swelling and disruption of outer and inner mitochondrial membranes determined by transmission electron microscopy.	hydroxyl radicals__ESR__no_interaction	hydroxyl radicals__DT-diaphorase__no_interaction	tetrachloro-__ESR__no_interaction	tetrachloro-__DT-diaphorase__no_interaction	dicoumarol__ESR__no_interaction	dicoumarol__DT-diaphorase__no_interaction
10734467-3	The SCSA measures, mean of <compound-id="6278">alpha-t</compound-id> (mean alpha t), standard deviation of <compound-id="6278">alpha-t</compound-id> (SD alpha t), and the <protein-id="P49747">COMP</protein-id> of <compound-id="6278">alpha-t</compound-id> (cells outside the main population)] were significantly correlated with the percentage seasonal pregnancy rate (SPR; mean alpha t, r = -0.24, P &lt; or = 0.05; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.27, P &lt; or = 0.05); percentage pregnant per first cycle (<compound-id="445951">FCP</compound-id>; SD alpha t, r = -0.30, P &lt; or = 0.01; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.42, P &lt; or = 0.0001); and the percentage pregnant per cycle (PC; mean alpha t, r = -0.31, P &lt; or = 0.01; SD alpha t, r = -0.32, P &lt; or = 0.01; % <protein-id="P49747">COMP</protein-id> alpha t, r = -0.41, P &lt; or = 0.0001).	alpha-t__COMP__no_interaction	FCP__COMP__no_interaction
15350062-1	The effect of adding an <compound-id="10982484,702">alcohol</compound-id> ethoxylate nonionic surfactant (<protein-id="Q3SYG4,A0A090N7W2,A0A090N8P4">C(18</protein-id>)E(18)) to aqueous solutions of a cationic surfactant, <compound-id="53690099">erucyl</compound-id> bis(hydroxyethyl) <compound-id="6329">methylammonium</compound-id> chloride (EHAC,CH(3)(CH(2))(7)(CH)(2)(CH(2))(12)N(+)-(CH(2)CH(2)OH)(2)CH(3)Cl(-)), was studied using small-angle neutron scattering (SANS), steady-state rheology, and cryo-transmission electron microscopy (Cryo-TEM).	erucyl__C(18__no_interaction	methylammonium__C(18__no_interaction	alcohol__C(18__no_interaction
19088949-3	This issue focuses on the following selection of drugs: (+)-<compound-id="71353">Dapoxetine hydrochloride</compound-id>, (S)-<compound-id="636411">Tenatoprazole</compound-id> <compound-id="5360545">sodium</compound-id> salt <compound-id="1488787">monohydrate</compound-id> 19-<compound-id="25245141">28z</compound-id>, <compound-id="5282338">Acotiamide hydrochloride hydrate</compound-id>, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, <compound-id="5493444">Aliskiren fumarate</compound-id>, <compound-id="3036780,163091">Asenapine maleate</compound-id>, <compound-id="6450551">Axitinib</compound-id>; Bavituximab, <compound-id="101524">Becatecarin</compound-id>, beta-1,3/1,6-Glucan, Bevacizumab, <compound-id="9941379">Bremelanotide</compound-id>; <compound-id="9832804">Calcipotriol/betamethasone dipropionate</compound-id>, <compound-id="9917021">Casopitant mesylate</compound-id>, Catumaxomab, CDX-110, <compound-id="9933475">Cediranib</compound-id>, CMD-193, <compound-id="148202">Cositecan</compound-id>; <compound-id="11683005">Darinaparsin</compound-id>, Denosumab, <compound-id="9810955">DP-b99</compound-id>, <compound-id="60835">Duloxetine hydrochloride</compound-id>; <compound-id="60138177">E75</compound-id>, Ecogramostim, <compound-id="6438895">Elacytarabine</compound-id>, EMD-273063, EndoTAG-1, <compound-id="176167">Enzastaurin hydrochloride</compound-id>, <compound-id="443872">Eplerenone</compound-id>, <compound-id="11354606">Eribulin mesilate</compound-id>, <compound-id="4594,9568614">Esomeprazole magnesium</compound-id>, <compound-id="193962">Etravirine</compound-id>, Everolimus, <compound-id="150311">Ezetimibe</compound-id>; <compound-id="6918218">Faropenem daloxate</compound-id>, <compound-id="134018">Febuxostat</compound-id>, <compound-id="5288209">Fenretinide</compound-id>; <compound-id="44576256">Ghrelin</compound-id> (human); I-131 ch-<compound-id="8376">TNT</compound-id>-1/B, I-131-<compound-id="86287509">3F8</compound-id>, <compound-id="213043">Iclaprim</compound-id>, <compound-id="124246">Iguratimod</compound-id>, <compound-id="71360">Iloperidone</compound-id>, <compound-id="5291">Imatinib mesylate</compound-id>, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, <compound-id="6851740">Ispinesib mesylate</compound-id>, <compound-id="6445540">Ixabepilone</compound-id>; <compound-id="208908">Lapatinib ditosylate</compound-id>, <compound-id="54677946">Laquinimod sodium</compound-id>, <compound-id="6918260,71749750">Larotaxel</compound-id> dehydrate, <compound-id="441401">Linezolid</compound-id>, LOR-2040; Mapatumumab, <compound-id="5327686">MKC-1</compound-id>, Motesanib <compound-id="644102">diphosphate</compound-id>, <compound-id="446541">Mycophenolic acid sodium salt</compound-id>; <compound-id="104842">NK-012</compound-id>; <compound-id="4585">Olanzapine</compound-id> pamoate, Oncolytic HSV, <compound-id="6918412">Ortataxel</compound-id>; <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> poliglumex, <compound-id="115237">Paliperidone</compound-id> <compound-id="985">palmitate</compound-id>, Panitumumab, <compound-id="448013">Patupilone</compound-id>, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, <compound-id="7975">Picoplatin</compound-id>, <compound-id="10071196">Pimavanserin tartrate</compound-id>, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="65015">Plerixafor hydrochloride</compound-id>, <compound-id="9855343">PM-02734</compound-id>, Poly I:CLC, <compound-id="5326514">PR1</compound-id>, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5486971">Pregabalin</compound-id>, <compound-id="12419,169870">Progesterone caproate</compound-id>, <compound-id="3052762">Prucalopride</compound-id>, <compound-id="154104">Pumosetrag hydrochloride</compound-id>; RAV-12, RB-006, RB-007, Recombinant human <protein-id="P01588,G9JKG7">erythropoietin</protein-id> alfa, <compound-id="104850">Rimonabant</compound-id>, <compound-id="5352062">Romidepsin</compound-id>; SAR-109659, <compound-id="6918220">Satraplatin</compound-id>, <compound-id="264">Sodium butyrate</compound-id>; <compound-id="110635">Tadalafil</compound-id>, <compound-id="164509">Talampanel</compound-id>, <compound-id="6505803">Tanespimycin</compound-id>, <compound-id="92337">Tarenflurbil</compound-id>, <compound-id="148201">Tariquidar</compound-id>, <compound-id="1123">Taurine</compound-id>, <compound-id="11485687,16124688,53488182">Tecovirimat</compound-id>, <compound-id="9808844">Telatinib</compound-id>, <compound-id="3081362,6918703">Telavancin hydrochloride</compound-id>, <compound-id="11319053">Telcagepant</compound-id>, <compound-id="476861">Terameprocol</compound-id>, <compound-id="11370864">Tesofensine</compound-id>, Tetrodotoxin, <compound-id="127894">Tezampanel</compound-id>, <compound-id="159324">Tipifarnib</compound-id>, <compound-id="57339443">TPI-287</compound-id>, Tremelimumab; <compound-id="5281884">Valspodar</compound-id>, <compound-id="151194">Vatalanib</compound-id> <compound-id="1110">succinate</compound-id>, VCL-CB01, vCP1452, <compound-id="5311">Vorinostat</compound-id>; XL-228; <compound-id="60854">Ziprasidone hydrochloride</compound-id>.	Progesterone caproate__erythropoietin__no_interaction	Aliskiren fumarate__erythropoietin__no_interaction	Ziprasidone hydrochloride__erythropoietin__no_interaction	E75__erythropoietin__no_interaction	Cositecan__erythropoietin__no_interaction	Duloxetine hydrochloride__erythropoietin__no_interaction	Vatalanib__erythropoietin__no_interaction	Valspodar__erythropoietin__no_interaction	Tariquidar__erythropoietin__no_interaction	Dapoxetine hydrochloride__erythropoietin__no_interaction	Pimecrolimus__erythropoietin__no_interaction	Tenatoprazole__erythropoietin__no_interaction	diphosphate__erythropoietin__no_interaction	Pumosetrag hydrochloride__erythropoietin__no_interaction	Picoplatin__erythropoietin__no_interaction	PR1__erythropoietin__no_interaction	Olanzapine__erythropoietin__no_interaction	Prasugrel__erythropoietin__no_interaction	Eplerenone__erythropoietin__no_interaction	Rimonabant__erythropoietin__no_interaction	Sodium butyrate__erythropoietin__no_interaction	Cediranib__erythropoietin__no_interaction	28z__erythropoietin__no_interaction	Casopitant mesylate__erythropoietin__no_interaction	Tadalafil__erythropoietin__no_interaction	TPI-287__erythropoietin__no_interaction	Satraplatin__erythropoietin__no_interaction	NK-012__erythropoietin__no_interaction	Pregabalin__erythropoietin__no_interaction	Iguratimod__erythropoietin__no_interaction	Lapatinib ditosylate__erythropoietin__no_interaction	Ixabepilone__erythropoietin__no_interaction	Tesofensine__erythropoietin__no_interaction	Acotiamide hydrochloride hydrate__erythropoietin__no_interaction	Iloperidone__erythropoietin__no_interaction	Becatecarin__erythropoietin__no_interaction	monohydrate__erythropoietin__no_interaction	Tarenflurbil__erythropoietin__no_interaction	Asenapine maleate__erythropoietin__no_interaction	Esomeprazole magnesium__erythropoietin__no_interaction	Patupilone__erythropoietin__no_interaction	Terameprocol__erythropoietin__no_interaction	Enzastaurin hydrochloride__erythropoietin__no_interaction	Laquinimod sodium__erythropoietin__no_interaction	sodium__erythropoietin__no_interaction	succinate__erythropoietin__no_interaction	Paliperidone__erythropoietin__no_interaction	Prucalopride__erythropoietin__no_interaction	Pimavanserin tartrate__erythropoietin__no_interaction	Taurine__erythropoietin__no_interaction	Elacytarabine__erythropoietin__no_interaction	Darinaparsin__erythropoietin__no_interaction	Etravirine__erythropoietin__no_interaction	Talampanel__erythropoietin__no_interaction	Ispinesib mesylate__erythropoietin__no_interaction	Ortataxel__erythropoietin__no_interaction	Ezetimibe__erythropoietin__no_interaction	Larotaxel__erythropoietin__no_interaction	Tanespimycin__erythropoietin__no_interaction	Imatinib mesylate__erythropoietin__no_interaction	PM-02734__erythropoietin__no_interaction	Bremelanotide__erythropoietin__no_interaction	Tezampanel__erythropoietin__no_interaction	Romidepsin__erythropoietin__no_interaction	Mycophenolic acid sodium salt__erythropoietin__no_interaction	MKC-1__erythropoietin__no_interaction	Iclaprim__erythropoietin__no_interaction	Telavancin hydrochloride__erythropoietin__no_interaction	Ghrelin__erythropoietin__no_interaction	Febuxostat__erythropoietin__no_interaction	Vorinostat__erythropoietin__no_interaction	palmitate__erythropoietin__no_interaction	Faropenem daloxate__erythropoietin__no_interaction	3F8__erythropoietin__no_interaction	Tipifarnib__erythropoietin__no_interaction	Axitinib__erythropoietin__no_interaction	Telatinib__erythropoietin__no_interaction	Linezolid__erythropoietin__no_interaction	Fenretinide__erythropoietin__no_interaction	TNT__erythropoietin__no_interaction	Calcipotriol/betamethasone dipropionate__erythropoietin__no_interaction	Plerixafor hydrochloride__erythropoietin__no_interaction	Paclitaxel__erythropoietin__no_interaction	Eribulin mesilate__erythropoietin__no_interaction	DP-b99__erythropoietin__no_interaction	Telcagepant__erythropoietin__no_interaction	Tecovirimat__erythropoietin__no_interaction
7895614-9	There was an excellent correlation between intestinal <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> protein level and catalytic activity (r = 0.86; p = 0.0001); however, neither parameter significantly correlated with hepatic <protein-id="P08684,Q6GRK0">CYP3A4</protein-id> activity as measured by the <compound-id="12560">erythromycin</compound-id> breath test result (r = 0.27; p = 0.24 and r = 0.33; p = 0.15, respectively).	erythromycin__CYP3A4__no_interaction
23055444-1	The formation of the antimonato polyoxovanadates [V(14)Sb(8)(C(6)H(15)N(3))(4)O(42)(H(2)O)]·4H(2)O (1), (C(6)H(17)N(3))(2)[V(15)Sb(6)(C(6)H(15)N(3))(2)O(42)(H(2)O)]·2.5H(2)O (2), {C(6)H(15)N(3)}(4)[V(16)Sb(4)O(42)]2H(2)O (3) (C(6)H(15)N(3)=<compound-id="8795">1-(2-aminoethyl)piperazine</compound-id>, <protein-id="Q99538,Q53XC6,Q96CY7">AEP</protein-id>) has been studied under solvothermal conditions by using in situ energy dispersive X-ray diffraction (EDRXD).	1-(2-aminoethyl)piperazine__AEP__no_interaction
16296832-2	The [2,2,2-crypt-Na]4[Tl4Se8].en crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n, with Z = 2 and a = 14.768(3) angstroms, b = 16.635(3) angstroms, c = 21.254(4) angstroms, beta = 94.17(3) degrees at -123 degrees C, and the [2,2,2-crypt-Na]2[Tl2Se4]infinity1.en crystallizes in the monoclinic space group <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/c, with Z = 4 and a = 14.246(2) angstroms, b = 14.360(3) angstroms, c = 26.673(8) angstroms, beta = 99.87(3) degrees at -123 degrees C. The TlIII anions, Tl2Se6(6-) and Tl3Se7(5-), and the mixed oxidation state <compound-id="6432721">TlI</compound-id>/TlIII anion, Tl3Se6(5-), have been obtained by extraction of NaTl0.5Se and NaTlSe in en, in the presence of 2,2,2-crypt and/or in liquid NH3, and have been characterized in solution by low-temperature 77Se, 203Tl, and 205Tl NMR spectroscopy.	TlI__P2(1__no_interaction
16472384-11	Surprisingly, <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> was positively correlated with <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.293, p = 0.02) and HOMA-IR (r = 0.373, p = 0.003) while C3 was negatively correlated with <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.242, p = 0.022, <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.184, p = 0.05) and HOMA-IR.	glucose__insulin__no_interaction	glucose__adiponectin__no_interaction
21957267-5	The HK-1-stimulated PGE₂ release was inhibited by the tachykinin receptor antagonists (S)1-2-[3-(3,4-<compound-id="57417436">dichlorophenyl</compound-id>)-1-(3-isopropoxyphenylacetyl)<compound-id="8082">piperidin-3-yl</compound-id>]<compound-id="23134249">ethyl</compound-id>-4-phenyl-l azonia-bicyclo[2.2.2]<compound-id="356">octane</compound-id> (<compound-id="108167,5311450">SR140333</compound-id>) [<protein-id="P20366,Q9Y494">neurokinin-1</protein-id> (NK₁)] and <compound-id="104974">N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide</compound-id> (SR48968) [<protein-id="P20366,Q9Y494">neurokinin-2</protein-id> (NK₂)] and was also inhibited by the <protein-id="P00403,U5Z487">cyclooxygenase (COX)-2</protein-id> inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)<compound-id="72879">methanesulfonamide</compound-id>) (NS-398) but not by the <protein-id="P00395,U5YWV7">COX-1</protein-id> inhibitor <compound-id="1519421">5-(4-chlorophenyl)-1-(</compound-id>4-methoxyphenyl)-3-<compound-id="1807034">trifluoromethylpyrazole</compound-id> (SC-560).	dichlorophenyl__COX-1__no_interaction	dichlorophenyl__neurokinin-2__no_interaction	dichlorophenyl__neurokinin-1__no_interaction	dichlorophenyl__cyclooxygenase (COX)-2__no_interaction	piperidin-3-yl__COX-1__no_interaction	piperidin-3-yl__neurokinin-2__no_interaction	piperidin-3-yl__neurokinin-1__no_interaction	piperidin-3-yl__cyclooxygenase (COX)-2__no_interaction	SR140333__COX-1__no_interaction	SR140333__neurokinin-2__no_interaction	SR140333__neurokinin-1__no_interaction	SR140333__cyclooxygenase (COX)-2__no_interaction	methanesulfonamide__COX-1__no_interaction	methanesulfonamide__neurokinin-2__no_interaction	methanesulfonamide__neurokinin-1__no_interaction	methanesulfonamide__cyclooxygenase (COX)-2__no_interaction	trifluoromethylpyrazole__COX-1__no_interaction	trifluoromethylpyrazole__neurokinin-2__no_interaction	trifluoromethylpyrazole__neurokinin-1__no_interaction	trifluoromethylpyrazole__cyclooxygenase (COX)-2__no_interaction	5-(4-chlorophenyl)-1-(__COX-1__no_interaction	5-(4-chlorophenyl)-1-(__neurokinin-2__no_interaction	5-(4-chlorophenyl)-1-(__neurokinin-1__no_interaction	5-(4-chlorophenyl)-1-(__cyclooxygenase (COX)-2__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__COX-1__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__neurokinin-2__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__neurokinin-1__no_interaction	N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide__cyclooxygenase (COX)-2__no_interaction	octane__COX-1__no_interaction	octane__neurokinin-2__no_interaction	octane__neurokinin-1__no_interaction	octane__cyclooxygenase (COX)-2__no_interaction	ethyl__COX-1__no_interaction	ethyl__neurokinin-2__no_interaction	ethyl__neurokinin-1__no_interaction	ethyl__cyclooxygenase (COX)-2__no_interaction
21960657-8	The <protein-id="E2RRC5">DBP</protein-id>, <protein-id="F1PJL8">MBP</protein-id>, and SBP RMSE values for 1/PAT were 9.8 ± 5.2, 10.4 ± 5.6, and 11.9 ± 6.1 mmHg, whereas the corresponding values for 1/<compound-id="5462314">PTT</compound-id> were 5.3 ± 1.2, 4.8 ± 1.0, and 7.5 ± 2.2 mmHg (P &lt; 0.05).	PTT__DBP__no_interaction	PTT__MBP__no_interaction
17639304-2	METHODS: We studied seven men with type 1 diabetes (mean +/- <compound-id="5289348">SEM</compound-id> diabetes duration 10 +/- 2 years, age 33 +/- 3 years, BMI 24 +/- 1 kg/m(2), HbA(1c) 8.1 +/- 0.2% and VO(2) peak 43 +/- 2 ml [kg lean body mass](-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>)) and five non-diabetic controls (mean +/- <compound-id="5289348">SEM</compound-id> age 30 +/- 3 years, BMI 22 +/- 1 kg/m(2), HbA(1c) 5.4 +/- 0.1% and VO(2) peak 52 +/- 4 ml [kg lean body mass](-1) <protein-id="P13987,Q6FHM9">min(-1</protein-id>), before and after a standardised breakfast and after three bouts (<protein-id="Q96NE9">EX1</protein-id>, EX2, EX3) of 40 min of cycling at 60% VO(2) peak.	SEM__min(-1__no_interaction	SEM__EX1__no_interaction
10933304-7	RESULTS: Visceral adipose tissue was significantly correlated with unfavorable levels of: <compound-id="11146">triacylglycerol</compound-id> (r = 0.27, p &lt; 0.05), total <compound-id="5997">cholesterol</compound-id> (r = 0.27, p &lt; 0.05), high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = -0.26, p &lt; 0.05), the ratio of total <compound-id="5997">cholesterol</compound-id>/high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.42, p &lt; 0.01), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = 0.27, p &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (r = 0.38, p &lt; 0.01), and systolic blood pressure (r = 0.30, p &lt; 0.01).	triacylglycerol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
6376034-3	The <protein-id="P01308,I3WAC9">insulin</protein-id>-resistant patients had fasting hyperinsulinemia (19 +/- 4 vs 11 +/- 1 microU/ml in nondiabetic subjects, P less than 0.05), decreased erythrocyte <protein-id="P06213">insulin receptor</protein-id> binding (4.8 +/- 0.4 vs 5.8 +/- 0.3%/1.6 X 10(9) cells in nondiabetic subjects, P less than 0.05), and impairment in both <protein-id="P01308,I3WAC9">insulin</protein-id>-induced suppression of <compound-id="206,5793,64689,79025">glucose</compound-id> production (Km 97 +/- 31 vs 21 +/- 7 microU/ml in nondiabetic subjects, P less than 0.05), and <protein-id="P01308,I3WAC9">insulin</protein-id>-induced stimulation of <compound-id="206,5793,64689,79025">glucose</compound-id> utilization (Km and Vmax 176 +/- 29 microU/ml and 5.8 +/- 0.7 mg/kg/min vs 50 +/- 2 microU/ml and 9.1 +/- 0.6 mg/kg/min in nondiabetic subjects, both P less than 0.05).	glucose__insulin receptor__no_interaction	glucose__insulin__no_interaction
19765079-12	Structured digital abstract: * <protein-id="Q96T58">MINT</protein-id>-7256467: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by circular dichroism (MI:0016) * <protein-id="Q96T58">MINT</protein-id>-7255686: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by biophysical (MI:0013) * <protein-id="Q96T58">MINT</protein-id>-7256439: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by fluorescence microscopy (MI:0416) * <protein-id="Q96T58">MINT</protein-id>-7256449: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by electron microscopy (MI:0040) * <protein-id="Q96T58">MINT</protein-id>-7256430: <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) and <compound-id="16130489">Dermaseptin</compound-id> (uniprotkb:O93455) bind (MI:0407) by fluorescence technologies (MI:0051).	Dermaseptin__MINT__no_interaction
21134860-10	The collinearities between, 13C-NMR chemical shifts of C4, C5 and <protein-id="Q9Y2Y1">C11</protein-id> with KI-ls and NRL-ls, as well as with <compound-id="77890">TPSA</compound-id>, miLogP, Mr and V were also revealed (δ, ppm C4 vs. <compound-id="77890">TPSA</compound-id>, R = 0.9964; δ, ppm C4 vs. miLogP, R = 0.9487; δ, ppm C4 vs.Mr, R = 0.9629; δ, ppm C4 vs. KI-ls, R = 0.9461; δ, ppm C4 vs. NRL-ls, R = 0.9996; δ, ppm C5 vs. miLogP, R = 0.9994; δ, ppm C5 vs. KI-ls, R = 0.9990; δ, ppm C5 vs. NRL-ls, R = 0.9510; δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. <compound-id="77890">TPSA</compound-id>, R = -0,9958; δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. NRL-ls, R = -0.9994 and δ, ppm <protein-id="Q9Y2Y1">C11</protein-id> vs. KI-ls, R = -0.9481).	TPSA__C11__no_interaction
23827757-9	The recorded IC50 ranges were 3.29 µg/mL [against human knockout clones HCT116 (<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>(-/-)) colon cancer cells] to 14.32 µg/mL (against human liver hepatocellular carcinoma HepG2 cells) for the crude extract from Echinops giganteus, 4.17 µg/mL (against breast cancer cells transduced with control vector MDA-MB231 cells) to 19.45 µg/mL (against MDA-MB-231 BCRP cells) for that of Piper capense, 4.11 µg/mL (against leukemia CCRF-CEM cells) to 30.60 µg/mL (against leukemia HL60AR cells) for Xylopia aethiopica, 3.28 µg/mL [against HCT116 (<protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id>(-/-)) cells] to 33.43 µg/mL (against HepG2 cells) for Imperata cylindica and 0.11 µg/mL (against CCRF-CEM cells) to 132.47 µg/mL (against HL60AR cells) for <compound-id="31703">doxorubicin</compound-id>.	doxorubicin__p53__no_interaction
10912351-3	The following measured values were used for our analysis: <protein-id="P17516">c11</protein-id> = 19.5 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, c22 = 20.1 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P27701">c33</protein-id> = 30.9 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <compound-id="23657803">c44</compound-id> = 5.72 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, c55 = 5.17 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <compound-id="5287874">c66</compound-id> = 4.05 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>, <protein-id="P19338,B3KM80,A0A024R4A0">c23</protein-id> = 12.5 <protein-id="P02724,A0A0C4DFT7,E9PD10,Q14419">GPa</protein-id>.	c44__c23__no_interaction	c44__c11__no_interaction	c44__GPa__no_interaction	c44__c33__no_interaction	c66__c23__no_interaction	c66__c11__no_interaction	c66__GPa__no_interaction	c66__c33__no_interaction
11216555-17	In protocol B, at completion of the study (week 9), D/P <compound-id="1176">urea</compound-id>, effluent <protein-id="Q64349">MAL</protein-id>, and AGEs were significantly higher in the experimental group as compared with the control groups [D/P: 0.67 +/- 0.04 (E) vs 0.46 +/- 0.07 (CP) vs 0.41 +/- 0.02 (CC), p &lt; 0.0002 and p &lt; 00001, respectively; <protein-id="Q64349">MAL</protein-id>: 336.8 +/- 63.30 microg/mL (E) vs 125.71 +/- 16.77 microg/mL (CP) vs 119.00 +/- 39.75 microg/mL (CC), p &lt; 0.008 and p &lt; 0.007, respectively; AGEs: 265.77 +/- 33.49 U/mg <compound-id="588">creatinine</compound-id> (E) vs 163.10 +/- 21.99 U/mg <compound-id="588">creatinine</compound-id> (CP) vs 83.17 +/- 22.66 U/mg <compound-id="588">creatinine</compound-id> (CC), p &lt; 0.02 and p &lt; 0.001, respectively].	creatinine__MAL__no_interaction	urea__MAL__no_interaction
17358053-1	Six new coordination polymers, namely [Zn1.5(<protein-id="P35070">BTC</protein-id>)(L1)(H2O)2].1.5H2O (1), [<compound-id="4655929">Zn3</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L2)3] (2), [<compound-id="4655929">Zn3</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L3)1.5(H2O)].H2O (3), [<compound-id="454063">Co6</compound-id>(<protein-id="P35070">BTC</protein-id>)4(L1)6(H2O)3].9H2O (4), [Co1.5(<protein-id="P35070">BTC</protein-id>)(L2)1.5].0.25H2O (5), and [<compound-id="447815">Co4</compound-id>(<protein-id="P35070">BTC</protein-id>)2(L3)2(OH)2(H2O)].4.5H2O (6), where L1 = 1,2-bis(imidazol-1-ylmethyl)<compound-id="241">benzene</compound-id>, L2 = <compound-id="11228701">1,3-bis(imidazol-1-ylmethyl)benzene</compound-id>, L3 = 1,1'-(<compound-id="7843">1,4-butanediyl</compound-id>)bis(<compound-id="795">imidazole</compound-id>), and <protein-id="P35070">BTC</protein-id> = 1,3,5-benzenetricarboxylate anion, were synthesized under hydrothermal conditions.	benzene__BTC__no_interaction	Co4__BTC__no_interaction	Co6__BTC__no_interaction	1,4-butanediyl__BTC__no_interaction	Zn3__BTC__no_interaction	1,3-bis(imidazol-1-ylmethyl)benzene__BTC__no_interaction	imidazole__BTC__no_interaction
23155341-12	The HOMA index revealed a positive correlation with body mass index (BMI) (r = 0.378, P &lt; 0.001), waist circumference (r =0.356, P &lt; 0.001), percent body fat (r = 0.296, P &lt; 0.001), systolic blood pressure (r = 0.202, P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (r = 0.134, P &lt; 0.001), triglycerides (r = 0.292, P &lt; 0.001), <protein-id="P01034">cystatin C</protein-id> (r = 0.069, P &lt; 0.001) and <compound-id="1175">uric acid</compound-id> (r = 0.142, P &lt; 0.001).	uric acid__cystatin C__no_interaction	cholesterol__cystatin C__no_interaction
23155341-13	The QUICKI index revealed a negative correlation with BMI (r = -0.254, P &lt; 0.001), waist circumference (r = 0-0.243, P &lt; 0.001), percent body fat (r = -0.217, P &lt; 0.001), systolic blood pressure (r = -0.132, P &lt; 0.001), total <compound-id="5997">cholesterol</compound-id> (r = -0.106, P &lt; 0.001), triglycerides (r = -0.205, P &lt; 0.001), <protein-id="P01034">cystatin C</protein-id> (r = -0.044, P &lt; 0.001) and <compound-id="1175">uric acid</compound-id> (r = -0.096, P &lt; 0.001).	uric acid__cystatin C__no_interaction	cholesterol__cystatin C__no_interaction
17484620-3	METHODS: We developed and validated a reverse-hybridization assay (Alpha-Globin StripAssay) for the rapid and simultaneous detection of 21 alpha-globin mutations: two single gene deletions (-alpha(3.7); -alpha(4.2)), five double gene deletions [--(MED); --(SEA); --(THAI); --(<compound-id="9578243">FIL</compound-id>); -(alpha)(20.5)], alpha alpha alpha(anti-3.7) gene triplication, two point mutations in the <protein-id="P25100,B0ZBE0">alpha1</protein-id> gene (cd 14 G&gt;A; Hb Adana) and 11 point mutations in the alpha2 gene (initiation cd T&gt;C; cd 19 -G; IVS1 -5nt; cd 59 G&gt;A; Hb Quong Sze; Hb Constant Spring; Hb Icaria; Hb Pakse; Hb Koya Dora; polyA-1; polyA-2).	FIL__alpha1__no_interaction
24589179-12	Compared with the CRI group, mice in the IPC-CRI group expressed lower <compound-id="5950,602">alanine</compound-id> transaminase activities (2 h: 839.2 ± 132.5 versus 384.2 ± 94.8, P &lt; 0.01; and 6 h: 680 ± 142.4 versus 342.3 ± 99.7, P &lt; 0.01) and lower <protein-id="P11247,Q6RFG4,Q571G0,Q7TMS4">myeloperoxidase</protein-id> levels (2 h: 7.1 ± 4.0 U/g versus 3.8 ± 1.6 U/g, P &lt; 0.05; and 6 h: 8.1 ± 1.3 U/g versus 5.2 ± 3.0 U/g, P &lt; 0.05).	alanine__myeloperoxidase__no_interaction
9389382-1	FK706, <compound-id="5360545">sodium</compound-id> 2-[4-[[(S)-1-[[(S)-2-[[(<compound-id="7021454">RS</compound-id>)-3, 3, 3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl]<compound-id="31268">pyrrolidin</compound-id> -1-yl]carbonyl]-2-<compound-id="7843">methylpropyl</compound-id>] aminocarbonyl] benzoylamino] <compound-id="176">acetate</compound-id>, C26H32F3N4NaO7, is a synthetic <compound-id="962">water</compound-id>-soluble inhibitor of human <protein-id="P08246">neutrophil elastase</protein-id>.	RS__neutrophil elastase__no_interaction	pyrrolidin__neutrophil elastase__no_interaction	sodium__neutrophil elastase__no_interaction	acetate__neutrophil elastase__no_interaction	water__neutrophil elastase__no_interaction	methylpropyl__neutrophil elastase__no_interaction
22990597-7	RESULTS: Intra- and interobserver kappa values for both readers (reader 1/reader 2; first reading/second reading) with 95 % confidence limits were: CE 0.54 (0.08-1.00)/ 0.75 (0.46-1.00); 0.73 (0.29-1.00)/ 0.45 (0.07-0.83), TD 0.53 (0.30-0.88)/ 0.86 (0.60-1.00); 0.56 (0.22-0.91)/ 0.67 (0.37-0.98), <protein-id="Q8TB61">SLL</protein-id> 0.59 (0.25-0.93)/ 0.66 (0.42-0.91); 0.31 (0.06-0.56)/ 0.49 (0.26-0.73), <compound-id="129891">LTL</compound-id> 0.83 (0.66-1.00)/ 0.68 (0.46-0.91); 0.90 (0.79-1.00)/ 0.48 (0.22-0.74); TFCC (0.72-1.00)/ (0.79-1.00); 0.65 (0.43-0.87)/ 0.59 (0.35-0.83), radius (scaphoid fossa) 0.45 (0.12-0.77)/ 0.64 (0.31-0.96); 0.58 (0.19-0.96)/ 0.38 (0.09-0.66), scaphoid 0.43 (0.12-0.74)/ 0.76 (0.55-0.96); 0.37 (0.00-0.75)/ 0.32 (0.04-0.59), radius (lunate fossa) 0.68 (0.36-1.00)/ 0.42 (0.00-0.86); 0.62 (0.29-0.96)/ 0.51 (0.12-0.91), and lunate 0.53 (0.16-0.90)/ 0.68 (0.44-0.91); 0.59 (0.29-0.88)/ 0.42 (0.00-0.84), respectively.	LTL__SLL__no_interaction
2610956-1	Bis[3-(5-chlorosalicylideneamino)propanolato-O,N,O']manganes e(IV) <compound-id="11686950,887">methanol</compound-id> solvate, [Mn(C10H10ClNO2)2].CH3OH, Mr = 510.3, monoclinic, P2(1)/c, a = 11.949 (2), b = 7.530 (2), c = 25.777 (6) A, beta = 105.75 (2) degrees, V = 2232.4 (8) A3, Z = 4, Dx = 1.518 g cm-3, lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.7107 A, mu = 7.98 cm-1, F(000) = 1502, T = 300 K, R = 0.0343, wR = 0.032 for 2113 unique reflections with (I) greater than 3 sigma(I).	methanol__Mo K alpha__no_interaction
23702795-5	Radiosyntheses of 2-[(18)F]fluoro-2-deoxy-<compound-id="79025">d-glucose</compound-id> ([(18)F]<protein-id="Q53HV7,A0A024RAZ8">FDG</protein-id>), 1-[(18)F]fluoro-4-<compound-id="7416">nitrobenzene</compound-id> ([(18)F]FNB), and 2'-deoxy-2'-[(18)F]fluoro-1-β-d-arabinofuranosyl <compound-id="597">cytosine</compound-id> (d-[(18)F]FAC) were performed to validate the system and demonstrate its versatility.	d-glucose__FDG__no_interaction	nitrobenzene__FDG__no_interaction	cytosine__FDG__no_interaction
11456811-1	The electronic structures of the bis-<compound-id="795">imidazole</compound-id> complexes of <compound-id="23925,67172434">iron</compound-id>(III) tetraphenylporphyrin ([(TPP)Fe(<compound-id="444499">ImH</compound-id>)(2)](+)) and <compound-id="23925,67172434">iron</compound-id>(III) tetraphenylchlorin ([(<protein-id="Q16204,Q05CP8">TPC</protein-id>)Fe(<compound-id="444499">ImH</compound-id>)(2)](+)) in frozen glassy solutions have been studied by the pulsed electron nuclear double resonance (<compound-id="8620">ENDOR</compound-id>) technique of Mims and by electron <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id>-echo envelope modulation (ESEEM) spectroscopy.	ImH__spin__no_interaction	ImH__TPC__no_interaction	ENDOR__spin__no_interaction	ENDOR__TPC__no_interaction	iron__spin__no_interaction	iron__TPC__no_interaction	imidazole__spin__no_interaction	imidazole__TPC__no_interaction
12766180-7	Among HIV-infected subjects, muscle attenuation correlated significantly with FFA (r = -0.38; P = 0.02), visceral fat (r = -0.49; P = 0.002), <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.38; P = 0.02) and <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.60; P = 0.0001) response to a 75-g oral <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance test.	glucose__insulin__no_interaction
16198506-9	RESULTS: A greater nPSA level and shorter T(nPSA) were associated with decreased <protein-id="P07225">PSA</protein-id>-DFS and DMFS in all patients and in all risk categories (low [Stage T1b, T1c, or <compound-id="25021197">T2a</compound-id>, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &lt; or =10 ng/mL], intermediate [Stage T1b, T1c, or <compound-id="25021197">T2a</compound-id>, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &gt;10 but &lt; or =20 ng/mL, or Stage <compound-id="71185540">T2b</compound-id> or T2c, Gleason score &lt; or =6, and <protein-id="P07225">PSA</protein-id> level &lt; or =20 ng/mL, or Gleason score 7 and <protein-id="P07225">PSA</protein-id> level &lt; or =20 ng/mL], and high [Gleason score 8-10 or <protein-id="P07225">PSA</protein-id> level &gt;20 ng/mL]), regardless of RT dose.	T2a__PSA__no_interaction	T2b__PSA__no_interaction
24671708-8	These findings implicate JAK/<protein-id="P40763">STAT3</protein-id> signaling in the development of diaphragm muscle atrophy and dysfunction during CMV and suggest that the delayed extubation times associated with CMV can be prevented by inhibition of Janus kinase signaling.-Smith, I. J., Godinez, G. L., Singh, B. K., McCaughey, K. M., Alcantara, R. R., Gururaja, T., Ho, M. S., Nguyen, H. N., Friera, A. M., White, K. A., McLaughlin, J. R., Hansen, D., Romero, J. M., Baltgalvis, K. A., Claypool, M. D., Li, W., Lang, W., <compound-id="24757941">Yam</compound-id>, G. C., Gelman, M. S., Ding, R., Yung, S. L., Creger, D. P., Chen, Y., Singh, R., Smuder, A. J., Wiggs, M. P., Kwon, O.-S., Sollanek, K. J., Powers, S. K., Masuda, E. S., Taylor, V. C., Payan, D. G., Kinoshita, T., Kinsella, T. M. Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction. 	Yam__STAT3__no_interaction
15654200-2	Patients with isolated <compound-id="92108">CAE</compound-id> were detected to have significantly higher levels of plasma soluble <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P19320">VCAM-1</protein-id> and <protein-id="P16581">E-selectin</protein-id> in comparison with patients with obstructive coronary artery disease without <compound-id="92108">CAE</compound-id> (ICAM, 673 +/- 153 versus 381 +/- 106, respectively, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 1136 +/- 208, respectively, P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 61 +/- 18, respectively, P = 0.01) and subjects with normal coronary arteries (<protein-id="P05362">ICAM-1</protein-id>, 673 +/- 153 versus 303 +/- 131, respectively, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 729 +/- 231, respectively, P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 49 +/- 9, respectively, P &lt; 0.001), suggesting the presence of a more severe and extensive chronic inflammation in the coronary circulation in patients with isolated <compound-id="92108">CAE</compound-id>.	CAE__E-selectin__no_interaction	CAE__ICAM-1__no_interaction	CAE__VCAM-1__no_interaction
15654200-10	RESULTS: Patients with isolated <compound-id="92108">CAE</compound-id> were found to have significantly higher levels of plasma soluble <protein-id="P05362">ICAM-1</protein-id>, <protein-id="P19320">VCAM-1</protein-id>, and <protein-id="P16581">E-selectin</protein-id> in comparison with patients with obstructive <protein-id="P27708,F8VPD4">CAD</protein-id> without <compound-id="92108">CAE</compound-id> (ICAM, 673 +/- 153 versus 381 +/- 106, respectively; P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 1136 +/- 208, respectively; P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 61+/-18, respectively; P = 0.01) and control subjects with normal coronary arteries (<protein-id="P05362">ICAM-1</protein-id>, 673 +/- 153 versus 303 +/- 131, respectively;, P &lt; 0.001; <protein-id="P19320">VCAM-1</protein-id>, 2366 +/- 925 versus 729 +/- 231, respectively; P &lt; 0.001; <protein-id="P16581">E-selectin</protein-id>, 74 +/- 21 versus 49 +/- 9, respectively; P &lt; 0.001).	CAE__E-selectin__no_interaction	CAE__ICAM-1__no_interaction	CAE__VCAM-1__no_interaction	CAE__CAD__no_interaction
2139224-2	The consensus peptide for each is <protein-id="P08100">rhodopsin</protein-id> <compound-id="6057">Tyr</compound-id> Pro Pro Gln Gly <protein-id="P08247">synaptophysin</protein-id> <compound-id="6057">Tyr</compound-id> Gly Pro Gln Gly synexin <compound-id="6057">Tyr</compound-id> Pro Pro Pro Pro Gly <compound-id="17787981">gliadin</compound-id> <compound-id="6057">Tyr</compound-id> Pro Pro Pro Gln Pro RNA polymerase II <compound-id="6057">Tyr</compound-id> <compound-id="5951">Ser</compound-id> Pro Thr <compound-id="5951">Ser</compound-id> Pro <compound-id="5951">Ser</compound-id> hordein Phe Pro Gln Gln Pro Gln Gln Pro gluten <compound-id="6057">Tyr</compound-id> Pro Thr <compound-id="5951">Ser</compound-id> Pro Gln Gln Gly <compound-id="6057">Tyr</compound-id> Although there is obvious variation of sequence and of length, the penta- to nonapeptides share an initial <compound-id="6057">Tyr</compound-id> (or Phe) and have high Pro contents and abundant Gly, Gln, and <compound-id="5951">Ser</compound-id>.	Ser__synaptophysin__no_interaction	Ser__rhodopsin__no_interaction	Tyr__synaptophysin__no_interaction	Tyr__rhodopsin__no_interaction	gliadin__synaptophysin__no_interaction	gliadin__rhodopsin__no_interaction
12182215-8	Performance changes from day 2 or 3 to day 20 or 21 at ALT were as follows (values are means +/- SD): VO2max (ml x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)): DEF = +97 +/- 237, <compound-id="16500">ADQ</compound-id> = +159 +/- 156; L + C (s): DEF = -62 +/- 35*, <compound-id="16500">ADQ</compound-id> = -35 +/- 20* (*p &lt; 0.05; improved from day 3); arm flex (reps): DEF = -2 +/- 7, <compound-id="16500">ADQ</compound-id> = +2 +/- 8; AP endurance (min): DEF = +1.4 +/- 2, <compound-id="16500">ADQ</compound-id> = + 1.9 +/- 2; AP strength (kg): DEF = -0.7 +/- 4, <compound-id="16500">ADQ</compound-id> = -1.2 +/- 2.	ADQ__min(-1__no_interaction
18842111-4	Our investigation provided evidence that the development of <protein-id="P01308,I3WAC9">insulin</protein-id> resistance/diabetic state in P. obesus is accompanied by (i) body weight gain and hyperlipidaemia; (ii) elevations of hepatic ACC-Ser79 phosphorylation and ACC protein levels; (iii) a rise in the gene expression of cytosolic <protein-id="Q13085,B2ZZ90,A0A024R0Y2,Q7Z5W8">ACC1</protein-id> concomitant with invariable mitochondrial <protein-id="Q16548">ACC2</protein-id>; (iv) an increase in hepatic AMPKalpha-Thr172 phosphorylation and protein expression without any modification in the calculated ratio of phospho-AMPKalpha to total AMPKalpha; (v) a stimulation in ACC activity despite increased AMPKalpha phosphorylation and protein expression; and (vi) a trend of increase in mRNA levels of key lipogenic enzymes [<protein-id="O00767">SCD-1</protein-id> (<protein-id="O00767">stearoyl-CoA desaturase-1</protein-id>), mGPAT (mitochondrial isoform of <compound-id="24759880,753">glycerol</compound-id>-3-<compound-id="1061,167704,644102">phosphate</compound-id> acyltransferase) and FAS (FA synthase)] and transcription factors [<protein-id="P36956,A8MTU8">SREBP-1</protein-id> (<protein-id="P36956,A8MTU8">sterol-regulatory-element-binding protein-1</protein-id>) and ChREBP (carbohydrate responsive element-binding protein)].	phosphate__stearoyl-CoA desaturase-1__no_interaction	phosphate__SCD-1__no_interaction	phosphate__sterol-regulatory-element-binding protein-1__no_interaction	phosphate__insulin__no_interaction	phosphate__ACC2__no_interaction	phosphate__ACC1__no_interaction	phosphate__SREBP-1__no_interaction	glycerol__stearoyl-CoA desaturase-1__no_interaction	glycerol__SCD-1__no_interaction	glycerol__sterol-regulatory-element-binding protein-1__no_interaction	glycerol__insulin__no_interaction	glycerol__ACC2__no_interaction	glycerol__ACC1__no_interaction	glycerol__SREBP-1__no_interaction
23695949-5	SM <compound-id="587,9548602">Phosphocreatine</compound-id> (20.2 ± 2.3 vs. 16.8 ± 2.3 μmol/g, control vs. <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm), p &lt; 0.05), ATP flux via CK (5.0 ± 0.9 vs. 3.1 ± 1.1 μmol/g/s, p &lt; 0.01), ATP synthesis from inorganic <compound-id="1061,167704,644102">phosphate</compound-id> (Pi → ATP) (0.58 ± 0.3 vs. 0.26 ± 0.2 μmol/g/s, p &lt; 0.05) and the free energy released from ATP hydrolysis (∆G ∼ATP) were significantly lower and [Pi] (2.8 ± 1.0 vs. 5.3 ± 2.0 μmol/g, control vs. <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm), p &lt; 0.05) markedly higher in <protein-id="P18893,Q3U879">IL10</protein-id>(tm/tm) than in control mice.	phosphate__IL10__no_interaction	Phosphocreatine__IL10__no_interaction
19858320-11	The increase in NTX correlated with reduction in BMI (r = 0.58; P = 0.009) and <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.45; P = 0.04) and the increase in serum 25-hydroxy <compound-id="5280795,5283711">vitamin D</compound-id> (r = 0.43; P = 0.05).	vitamin D__leptin__no_interaction
21358614-6	At the end of <compound-id="3033825">levosimendan</compound-id> therapy, <protein-id="P16860">BNP</protein-id> decreased (from 679.7 ± 512.1 pg/ml to 554.2 ± 407.6 pg/ml p = 0.03), and 6 MWT and LVEF improved (from 217.6 ± 97.7 m to 372.2 ± 90.4 m p = 0.0001; from 22.8 ± 9.1% to 25.4 ± 9.8% p = 0.05).	levosimendan__BNP__no_interaction
24403217-3	Complexes anti-[<compound-id="16214803">Au4</compound-id> (meso-dpmppm)2]X4 (X = <protein-id="Q6Q759">PF6</protein-id> (5 d), BF4 (5 e), TfO (5 f)) contain a linearly ordered <compound-id="16214803">Au4</compound-id> string and complexes <protein-id="P06241">syn</protein-id>-[<compound-id="16214803">Au4</compound-id> (rac-dpmppm)2X2]X'2 (X = Cl, X' = Cl (6 a), <protein-id="Q6Q759">PF6</protein-id> (6 b), BF4 (6 c)) and <protein-id="P06241">syn</protein-id>-[<compound-id="16214803">Au4</compound-id> (rac-dpmppm)2]X4 (X = <protein-id="Q6Q759">PF6</protein-id> (6 d), BF4 (6 e), TfO (6 f)) consist of a zigzag tetragold(I) chain supported by the two <protein-id="P06241">syn</protein-id>-arranged rac-dpmppm ligands.	Au4__syn__no_interaction	Au4__PF6__no_interaction
1433176-3	The minimum length of the backbone was investigated using the following truncated analogues [binding affinity (nM) for Y1 and <protein-id="P49146">Y2 receptor</protein-id> subtypes respectively are given in parentheses]: des-AA10-17[D-Ala9]<protein-id="P01303,A4D158">NPY</protein-id> (100, 0.9), des-<compound-id="9549196">AA7</compound-id>-23[D-Ala6]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 1.2), des-AA4-26[D-Ala3]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 120), cyclo(7,20)-des-AA10-17[Glu7,D- Ala9,D-Dpr20]<protein-id="P01303,A4D158">NPY</protein-id> (100, nd), cyclo(2,27)-des-<compound-id="9549196">AA7</compound-id>-23[Glu2,D-Ala6,D-Dpr27]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, 3.6), cyclo(2,30)- des-<compound-id="9549196">AA7</compound-id>-23[Glu2,D-Ala6,-D-Dpr30]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, nd), cyclo(1,30)-des-AA4-26[Glu1,D-Ala3,D-Dpr30]<protein-id="P01303,A4D158">NPY</protein-id> (&gt; 1000, &gt; 1000).	AA7__Y2 receptor__no_interaction	AA7__NPY__no_interaction
20331686-7	Following transplantation, serum levels of <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> and β-<compound-id="5757">estradiol</compound-id> decreased significantly (24.35 ± 11.62 vs. 13.93 ± 7.16 ng/mL, p = 0.027; 42.20 ± 15.04 vs. 17.7 ± 7.15 pg/mL, p = 0.000, respectively), whereas levels of <compound-id="6013">testosterone</compound-id> increased (3.07 ± 0.94 vs. 6.54 ± 3.14 ng/mL, p = 0.004).	testosterone__prolactin__no_interaction	estradiol__prolactin__no_interaction
12582948-6	After controlling for HRT status, VO2max was correlated with total <compound-id="5997">cholesterol</compound-id> (r = -0.51, p = 0.0001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = -0.52, p = 0.0001), HDL-C (r = 0.25, p = 0.055), <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL 2</protein-id> -C (r = 0.24, p = 0.08) and TG levels (r = -0.46, p = 0.0001).	cholesterol__LDL-C__no_interaction	cholesterol__HDL 2__no_interaction
12582948-7	After controlling for HRT status, % body fat was correlated with total <compound-id="5997">cholesterol</compound-id> (r = 0.43, p = 0.001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.38, p = 0.003), HDL-C (r = -0.29, p = 0.025), <protein-id="Q8WXH2,F8W9A3,Q96HD8,B4DIC1">HDL 2</protein-id> -C (r = -0,26, p = 0.07) and TG levels (r = 0.40, p = 0.002).	cholesterol__LDL-C__no_interaction	cholesterol__HDL 2__no_interaction
15914118-2	METHODS: After 6-<compound-id="4624">hydroxydopamine</compound-id> (6-OHDA) pretreatment and a 20-min stabilization period, hearts were perfused at constant pressure for 20 min then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R, <protein-id="Q9ER05">Ctrl</protein-id>); exposed to 0.01 microM XA for 5 min with or without 10 microM <compound-id="2249">atenolol</compound-id> (ATE), a specific antagonist of beta1-AR, followed by a 15-min XA-free perfusion before I/R (PC, ATE-PC, respectively); treated during 20 min with either phosphoinositide (PI) 3-kinase inhibitors, <compound-id="3973">LY-294002</compound-id> (LY, 15 microM), or wortmaninn (WO, 0.1 microM); protein kinase C (PKC) inhibitor, GF-109203X (GF, 4 nM); or <protein-id="A1L1M0">protein kinase A</protein-id> (PKA) inhibitor, H89 (H89, 1 microM), with an infusion starting 3 min before XA (LY-PC, WO-PC, GF-PC, and H89-PC, respectively).	LY-294002__protein kinase A__no_interaction	LY-294002__Ctrl__no_interaction	atenolol__protein kinase A__no_interaction	atenolol__Ctrl__no_interaction	hydroxydopamine__protein kinase A__no_interaction	hydroxydopamine__Ctrl__no_interaction
20699417-5	RESULTS: Compared with a mean ± SE of 98 ± 5 mg/dl (5.4 ± 0.3 mmol/l) at 180 min during saline, mean plasma <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations declined to 58 ± 1 mg/dl (3.2 ± 0.1 mmol/l) (P &lt; 0.001) at 180 min during <compound-id="383414,44420813,448601,6400441,86289069">octreotide</compound-id> plus saline and were 104 ± 16 mg/dl (5.8 ± 0.9 mmol/l) (NS), 143 ± 13 mg/dl (7.9 ± 0.7 mmol/l) (P = 0.004), and 160 ± 15 mg/dl (8.9 ± 0.8 mmol/l) (P &lt; 0.001) at 180 min during <compound-id="383414,44420813,448601,6400441,86289069">octreotide</compound-id> plus <protein-id="P01275">Glucagon</protein-id> in doses of 0.5, 1.0, and 2.0 ng · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>), respectively.	octreotide__Glucagon__no_interaction	octreotide__min(-1__no_interaction	glucose__Glucagon__no_interaction	glucose__min(-1__no_interaction
17237312-8	Red meat, relative to control, resulted in: higher protein [5.3 (3.7, 6.9) % of energy], lower carbohydrate [-5.3 (-7.9, -2.7)% of energy], and higher <compound-id="23925,67172434">iron</compound-id> [3.2 (1.1, 5.4) mg/d] intakes; lower urinary F2-isoprostane excretion [-137 (-264, -9) pmol/mmol <compound-id="588">creatinine</compound-id>], lower leukocyte [-0.51 (-0.99, -0.02)x10(9)/L] counts, and a trend for lower serum C-reactive protein concentrations [-1.6 (-3.3, 0.0) mg/L, P=0.06]; and no differences in concentrations of plasma F2-isoprostanes [-12 (-122, 100) pmol/L], serum gamma-glytamyltransferase [-0.8 (-3.2, 1.5) U/L], <protein-id="P0DJI8">serum amyloid A protein [-1.4</protein-id> (-3.4, 0.5) mg/L], and plasma fibrinogen concentrations [-0.08 (-0.40.	creatinine__serum amyloid A protein [-1.4__no_interaction	iron__serum amyloid A protein [-1.4__no_interaction
8637441-2	Compared with the control subjects, the hemodialysis patients had significantly higher serum triglyceride and apolipoprotein B-associated apolipoprotein CIII concentrations (1.03 +/- 0.31 v 1.98 +/- 0.86 mmol/L and 0.004 +/- 0.002 v 0.011 +/- 0.005 g/L, respectively), lower serum high-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id> and apolipoprotein <compound-id="15942654">AI</compound-id> concentrations (1.33 +/- 0.37 v 0.95 +/- 0.31 mmol/L and 1.29 +/- 0.25 v 1.09 +/- 0.23 g/L, respectively), and lower postheparin plasma <protein-id="P11151">LPL</protein-id> activity (82 +/- 24 v 35 +/- 14 milliU/milliL).	AI__LPL__no_interaction	cholesterol__LPL__no_interaction
15786388-4	The following results were obtained: blood <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id>: M (n=21) 1.78 +/- 0.57, V (n=96) 1.72 +/- 0.36 g/L (p=ns); blood <compound-id="23925,67172434">iron</compound-id>: M (n=22) 8.66 +/- 5.07, V (n=97) 10.50 +/- 4.57 mmol/L (p=ns); TIBC: M (n=21) 42.69 +/- 13.63, V (n=98) 40.36 +/- 10.33 mmol of <compound-id="23925,67172434">iron</compound-id>/L (p=ns); <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> saturation: M (n=21) 22.10 +/- 13.07, V (n=96) 25.81 +/- 11.79% (p=ns); blood Hb: M (n=22) 107.55 +/-19.70, V (n=98) 111.02 +/- 14.68 g/L (p=ns); MCV: M (n=22) 94.58 +/- 7.35, V (n=98) 93.27 +/- 8.16 fL (p=ns); RDW: M (n=22) 16.60 +/- 1.51, V (n=98) 15.83 +/- 1.39 (p&lt;0.022); soluble <protein-id="P02787,Q06AH7,A0PJA6">transferrin</protein-id> receptors: M (n=18) 1.85 +/- 0.90, V (n=90) 1.89 +/- 0.75 mg/L (p=ns); reticulocyte count: M (n=22) 91.38 +/- 34.69, V (n=98) 87.27 +/- 29.56 *10 9 /L (p=ns); CHR: M (n=22) 31.36 +/- 2.92, V (n=98) 31.46 +/- 3.08 pg (p=ns); <protein-id="Q969Q1">IRF</protein-id>: M (n=22) 24.81 +/- 7.55, V (n=98) 23.65 +/- 8.64 (p=ns); intravenous Fe+++ weekly supplementation: M (n=22) 45.45 +/- 26.81, V (n=98) 37.31 +/- 32.25 mg/week (p=ns); a-<protein-id="P01588,G9JKG7">EPO</protein-id> weekly supple-mentation: M (n=22) 9090.91 +/- 7824.92, V (n=97) 9030.93 +/- 8292.13 UI/week (p=ns).	iron__EPO__no_interaction	iron__transferrin__no_interaction	iron__IRF__no_interaction
18624404-2	They have been characterized by routine physicochemical techniques as well as by X-ray single-crystal structure analysis: [Cu 2(H <compound-id="73441667">2L2</compound-id> (2))(OH)(H 2O)(NO 3)](NO 3) 3.2H 2O ( 1), [Cu(<protein-id="P07306,Q6FGQ5">HL1</protein-id> (4))(H 2O)(NO 3)] 2(NO 3) 2.2H 2O ( 2), [Cu(L1 (1))(H 2O)(NO 3)] 2 ( 3), [Cu 2(L2 (3))(OH)(H 2O) 2](NO 3) 2, ( 4) and [Cu 2(L2 (1))(N 3) 3] ( 5) [L1 = 2-formyl-4-methyl-6R-iminomethyl-phenolato and L2 = 2,6-bis(R-iminomethyl)-4-methyl-phenolato; for L1 (1) and L2 (1), R = N-<compound-id="424975">propylmorpholine</compound-id>; for L2 (2), R = <compound-id="79196">N-ethylpiperazine</compound-id>; for L2 (3), R = N-<compound-id="81782">ethylpyrrolidine</compound-id>, and for L1 (4), R = N-<compound-id="7525">ethylmorpholine</compound-id>].	N-ethylpiperazine__HL1__no_interaction	ethylmorpholine__HL1__no_interaction	propylmorpholine__HL1__no_interaction	ethylpyrrolidine__HL1__no_interaction	2L2__HL1__no_interaction
16650737-10	Descending order of susceptibility of the spread monolayers of lipid mixtures to <protein-id="P02768">albumin</protein-id> destabilization was as follows: [(DPPC+PG, 7:3)=(DPPC+PG, 9:1)=(DPPC+<compound-id="5283485">POPC</compound-id>)]&gt;[(DPPC+PE)=(DPPC+CHOL)]&gt;[(DPPC+PA)=(DPPC)] The increase in minimum surface tension in presence of <protein-id="P02768">albumin</protein-id> and erythrocyte membranes was accompanied by sudden increases in compressibility at surface tensions of 15-30 mN/m.	POPC__albumin__no_interaction
15777867-2	Using both extracellular field potential and whole-cell patch-clamp recordings in brainstem parasagital slices of juvenile rat with the mandibular nerve attached, we show here that the induction of trigeminal primary afferent <compound-id="56846361">LTP</compound-id>: (1) does not require the activation of ionotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptors; (2) is dependent on extracellular Ca(2+) and the release of Ca(2+) from intracellular stores; (3) is specifically prevented by the metabotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptor subtype 5 (<protein-id="Q8C825,Q3UZT1,Q8BRT2,Q8BQZ0">mGluR5</protein-id>) antagonist 2-methyl-6-(phenylethynyl)pyridine but not the <protein-id="P23818,Q7TNB5,F6YNQ1">mGluR1</protein-id> antagonist <compound-id="5311261">LY367385</compound-id>, group II mGluR antagonist LY341495 or group III mGluR antagonist <protein-id="Q5M7W5,A0A0G2JW88">MAP4</protein-id>; (4) is mimicked by the bath-applied group I mGluR agonist (S)-<compound-id="108001">3,5-dihydroxyphenylglycine</compound-id> and <protein-id="Q8C825,Q3UZT1,Q8BRT2,Q8BQZ0">mGluR5</protein-id> agonist (<compound-id="7021454">RS</compound-id>)-<compound-id="1800613">2-chloro</compound-id>-5-<compound-id="20468917">hydroxyphenylglycine</compound-id>; (5) requires the activation of phospholipase C (PLC) and protein kinase C (PKC); and (6) is concomitantly with a decrease in paired-pulse depression.	LTP__mGluR5__no_interaction	LTP__mGluR1__no_interaction	LTP__MAP4__no_interaction	RS__mGluR5__no_interaction	RS__mGluR1__no_interaction	RS__MAP4__no_interaction	LY367385__mGluR5__no_interaction	LY367385__mGluR1__no_interaction	LY367385__MAP4__no_interaction	3,5-dihydroxyphenylglycine__mGluR5__no_interaction	3,5-dihydroxyphenylglycine__mGluR1__no_interaction	3,5-dihydroxyphenylglycine__MAP4__no_interaction	hydroxyphenylglycine__mGluR5__no_interaction	hydroxyphenylglycine__mGluR1__no_interaction	hydroxyphenylglycine__MAP4__no_interaction	2-chloro__mGluR5__no_interaction	2-chloro__mGluR1__no_interaction	2-chloro__MAP4__no_interaction	glutamate__mGluR5__no_interaction	glutamate__mGluR1__no_interaction	glutamate__MAP4__no_interaction
20625317-8	PARTICIPANTS: Participants were 110 hypertensive patients [male/female 46/64, age 66.3 ± 10.8 years, systolic blood pressure (SBP)/diastolic blood pressure (DBP) 161.8 ± 16.9/92.9 ± 12.4 mmHg, s-Cr 0.77 ± 0.32 mg/dl, plasma renin activity (PRA) 0.65 ± 0.63 ng/ml per h, angiotensin I (AngI) 70.5 ± 77.3 pg/ml, angiotensin II (<protein-id="O15123">AngII</protein-id>) 5.2 ± 3.9 pg/ml, plasma <compound-id="5839">aldosterone</compound-id> concentration (PAC) 76.3 ± 35.9 pg/ml, urinary albumin excretion (UAE) 108.1 ± 284.2 mg/<protein-id="P04150,E5KQF5,E5KQF6,F1D8N4,B7Z7I2">gCr</protein-id>].	aldosterone__gCr__no_interaction	aldosterone__AngII__no_interaction
20625317-12	RESULTS: Results were as follows (amlodipine vs. <compound-id="5282138">cilnidipine</compound-id>): SBP/DBP (mmHg): 135.2 ± 11.7/79.8 ± 9.6 vs. 136.7 ± 13.2/79.5 ± 10.9, P = 0.22/0.74; PRA (ng/ml per h): 1.16 ± 1.03 vs. 0.95 ± 0.78, P &lt; 0.01; AngI (pg/ml): 155.0 ± 306.4 vs. 101.8 ± 92.0, P &lt; 0.05; <protein-id="O15123">AngII</protein-id> (pg/ml): 12.0 ± 12.3 vs. 7.1 ± 4.5, P &lt; 0.001; PAC (pg/ml): 81.6 ± 37.9 vs. 74.3 ± 36.2, P &lt; 0.05; UAE (mg/<protein-id="P04150,E5KQF5,E5KQF6,F1D8N4,B7Z7I2">gCr</protein-id>): 145.4 ± 424.5 vs. 58.8 ± 125.1, P &lt; 0.05.	cilnidipine__gCr__no_interaction	cilnidipine__AngII__no_interaction
15364160-7	Serum <protein-id="P02656,A3KPE2">apo C III</protein-id> levels were found to be positively associated with plasma TG ( r = 0.527, P &lt; 0.001), TC (r = 0.424, P &lt; 0.001), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (r = 0.308, P &lt; 0.01) concentrations, and carotid <compound-id="447041">IMT</compound-id> (r =0.359, P &lt; 0.01 ).	IMT__LDL-C__no_interaction	IMT__apo C III__no_interaction
16869716-15	Using the intact assay only, <protein-id="Q9GZV9,Q9EPC2,Q3U1V5">FGF-23</protein-id> was significantly associated with serum <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.39, p &lt; 0.01), 24-h urinary <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.47, p &lt; 0.01), fractional excretion of <compound-id="1061,167704,644102">phosphate</compound-id> (r = 0.29, p &lt; 0.01), and 1,25-dihydroxyvitamin D (r = -0.30, p &lt; 0.01).	phosphate__FGF-23__no_interaction
23332241-6	However, the peak levels of ERK activation and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> expression in vascular smooth muscle cells were stimulated by combining SS and NE (ratio of phosphorylated ERK [pERK]/β-actin and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> positive rates, SS+NE [1.07 ± 0.04 and 73% ± 3%]; SS [0.83 ± 0.07 and 53% ± 2%]; NE [0.63 ± 0.11 and 42% ± 2%]), which could be partially inhibited by <compound-id="4893">prazosin</compound-id> (ratio of pERK/β-actin and <protein-id="Q7TSF6,E9PVX6">Ki67</protein-id> positive rates, SS+NE+Praz [0.83 ± 0.08 and 40% ± 7% vs SS+NE; P &lt; .05], SS+Praz [0.60 ± 0.04 and 26% ± 2% vs SS; P &lt; .05], NE+Praz [0.32 ± 0.12 and 23% ± 2% vs NE; P &lt; .05]) or small interfering RNAs of α1B-ARs and α1D-ARs (P &lt; .05 vs siRNA control).	prazosin__Ki67__no_interaction
7313308-1	<protein-id="G3X8Q1,Q6PFH4,Q80X22">Cain</protein-id>'s <compound-id="7047">Quinolinium</compound-id>; <compound-id="7047">quinolinium</compound-id>, <compound-id="162282">6-amino-1-</compound-id>methyl-4[[[[[[(<compound-id="13597">1-methyl-pyridinium</compound-id>-4-yl)amino]phenyl]amino]carbonyl]phenyl]amino] (NSC 176319), is a chemotherapeutic agent, which is equally cytotoxic in vitro to both murine L1210 leukemia cells and bone marrow progenitor cells.	Quinolinium__Cain__no_interaction	6-amino-1-__Cain__no_interaction	1-methyl-pyridinium__Cain__no_interaction	quinolinium__Cain__no_interaction
19376108-4	In isolated rings of porcine pulmonary veins the typical alpha(1)-adrenoceptor agonist <compound-id="6041">phenylephrine</compound-id> caused a concentration-dependent contraction that was inhibited by the alpha(1B)-adrenoceptor selective antagonists <compound-id="9891980">1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one</compound-id> (Rec15/2615; pA(2) 8.96+/-0.13) and 4-amino-2-[4-[1-(<compound-id="7708">benzyloxycarbonyl</compound-id>)-2(S)-[[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-<compound-id="3031661">6,7-dimethoxyquinazoline</compound-id> (L-765,314; pA(2) 7.22+/-0.05), as well as the <protein-id="Q9TTM9">alpha(1D)-adrenoceptor</protein-id> selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]<compound-id="23134249">ethyl</compound-id>]-<compound-id="136843">8-azaspiro[4.5]decane-7,9-dione</compound-id> (BMY7378; pA(2) 8.29+/-0.15, slope of the Schild plot 0.75+/-0.09, significantly different from unity, P&lt;0.05), but not by the alpha(1A)-adrenoceptor selective antagonists (+/-)-1,3,5-<compound-id="4245325">trimethyl-</compound-id>6-[[3-[4-((2,3-dihydro-2-hydroxymethyl)-1,4-<compound-id="67490">benzodioxin-5-yl</compound-id>)-1-piperazinyl]propyl]amino]-2,4(1H,3H)-<compound-id="1174">pyrimidinedione</compound-id> (B8805-033) and <compound-id="3894573">N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine</compound-id> (<compound-id="7021454">RS</compound-id>-17053).	benzyloxycarbonyl__alpha(1D)-adrenoceptor__no_interaction	RS__alpha(1D)-adrenoceptor__no_interaction	1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-2-[2-(isopropyl)-6-methoxyphenoxy]ethan-1-one__alpha(1D)-adrenoceptor__no_interaction	N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H-indole-3-ethanamine__alpha(1D)-adrenoceptor__no_interaction	trimethyl-__alpha(1D)-adrenoceptor__no_interaction	pyrimidinedione__alpha(1D)-adrenoceptor__no_interaction	phenylephrine__alpha(1D)-adrenoceptor__no_interaction	6,7-dimethoxyquinazoline__alpha(1D)-adrenoceptor__no_interaction	benzodioxin-5-yl__alpha(1D)-adrenoceptor__no_interaction	8-azaspiro[4.5]decane-7,9-dione__alpha(1D)-adrenoceptor__no_interaction	ethyl__alpha(1D)-adrenoceptor__no_interaction
2843998-5	The regional distribution of 125I-<compound-id="6057">Tyr</compound-id>(o)-ovine <protein-id="P01143">CRF</protein-id> binding (olfactory bulb greater than frontoparietal cortex approximately equal to cerebellum greater than hypothalamus greater than striatum greater than or equal to midbrain greater than hippocampus greater than or equal to spinal cord) did not correspond with the regional degree of <protein-id="P01143">CRF</protein-id> receptor-mediated stimulation of <compound-id="6083">adenylate</compound-id> cyclase (frontoparietal cortex greater than olfactory bulb greater than or equal to cerebellum greater than midbrain greater than or equal to hippocampus greater than striatum greater than or equal to hypothalamus greater than spinal cord).	adenylate__CRF__no_interaction	Tyr__CRF__no_interaction
24174496-4	Using site-directed mutagenesis complemented with in silico homology modeling, we report the binding modes of two high-affinity <protein-id="P49682">CXCR3</protein-id> antagonists of distinct chemotypes: VUF11211 [(S)-5-chloro-6-(4-(1-(4-chlorobenzyl)<compound-id="8082">piperidin-4-yl</compound-id>)-<compound-id="14094188">3-ethylpiperazin</compound-id>-1-yl)-<compound-id="78007">N-ethylnicotinamide</compound-id>] (<compound-id="15251992">piperazinyl-piperidine</compound-id>) with a rigid elongated structure containing two basic groups and <compound-id="10167713,45784923">NBI-74330</compound-id> [(R)-N-(1-(3-(4-<compound-id="7674">ethoxyphenyl</compound-id>)-4-oxo-3,4-<compound-id="13347754">dihydropyrido</compound-id>[2,3-d]pyrimidin-2-yl)<compound-id="23134249">ethyl</compound-id>)-2-(4-fluoro-3-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl)-<compound-id="2735225">N-(pyridin-3-ylmethyl)acetamide</compound-id>] (8-azaquinazolinone) without any basic group.	piperidin-4-yl__CXCR3__no_interaction	dihydropyrido__CXCR3__no_interaction	3-ethylpiperazin__CXCR3__no_interaction	ethoxyphenyl__CXCR3__no_interaction	N-ethylnicotinamide__CXCR3__no_interaction	N-(pyridin-3-ylmethyl)acetamide__CXCR3__no_interaction	trifluoromethyl__CXCR3__no_interaction	piperazinyl-piperidine__CXCR3__no_interaction	NBI-74330__CXCR3__no_interaction	ethyl__CXCR3__no_interaction
11768247-4	Selected important clinical learning points include the following: (1) <compound-id="206,5793,64689,79025">glucose</compound-id> absorption mediated by <protein-id="P13866">SGLT1</protein-id> is controlled by mRNA abundance, as well as by posttranscriptional processes including protein trafficking; (2) inducers of cytochrome P-450 decrease <compound-id="206,5793,64689,79025">glucose</compound-id> and fructose absorption and increase <compound-id="206,5793,64689,79025">glucose</compound-id> consumption in the intestine; (3) the regulated release of nutrients from the stomach into the upper intestine ensures that the modest intestinal transport reserve capacity is not exceeded; (4) hepatocyte growth factor and short-chain fatty acids may enhance intestinal adaptation and prevent the atrophy seen when total parenteral nutrition is infused; (5) inhibitors of pancreatic <compound-id="5474737">lipase</compound-id> and phospholipase <compound-id="783">H2</compound-id> may be useful clinically to reduce absorption as part of a treatment program for obesity and hyperlipidemia; (6) several membrane-bound and cytosolic proteins have been identified in the enterocyte as well as in the hepatocyte and may be the target for the future therapeutic manipulation of bile acid metabolism and control of hyperlipidemia; (7) suspect bile acid malabsorption in the patient with otherwise unexplained chronic diarrhea; (8) a proportion of lipid absorption is protein-mediated, and this opens the way to targeting these proteins and thereby therapeutically modifying lipid absorption; (9) a high protein diet may be useful to increase the intestinal absorption of drugs transported by the H+/dipeptide cotransporter; (10) a metal transporter <protein-id="P49281">DCT1</protein-id> has been identified, and this may open the way to a better understanding of disorders of, for example, <compound-id="23925,67172434">iron</compound-id> and <compound-id="23994">zinc</compound-id> metabolism; (11) the nutrient transporters such as <protein-id="P13866">SGLT1</protein-id> are responsible for a portion of the intestinal absorption of <compound-id="962">water</compound-id>; (12) the influence of <compound-id="145068">nitric oxide</compound-id> on intestinal <compound-id="962">water</compound-id> absorption and secretion depends on its concentration; (13) a trial of bile acid-sequestering agent may prove useful in the treatment of the patient who experiences diarrhea while taking an enteral diet; (14) a proteolytic extract from pineapple stems may prove to be useful to treat diarrhea, although the mechanism of this effect remains to be established; and (15) the antisecretory effect of the new peptide, <compound-id="6904">sorbin</compound-id>, needs to be tested in a clinical situation on patients with diarrhea.	iron__DCT1__no_interaction	iron__SGLT1__no_interaction	H2__DCT1__no_interaction	H2__SGLT1__no_interaction	water__DCT1__no_interaction	water__SGLT1__no_interaction	sorbin__DCT1__no_interaction	sorbin__SGLT1__no_interaction	zinc__DCT1__no_interaction	zinc__SGLT1__no_interaction	nitric oxide__DCT1__no_interaction	nitric oxide__SGLT1__no_interaction	lipase__DCT1__no_interaction	lipase__SGLT1__no_interaction	glucose__DCT1__no_interaction	glucose__SGLT1__no_interaction
20617238-6	The addition of <compound-id="74260">N-(2-pyridinyl)acetoacetamide</compound-id> (paaH) to Mn(Y)2 x 4 H2O Y = <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) or ClO4(-) in <compound-id="887">MeOH</compound-id> gave a second divalent heptanuclear cluster with a 'disc'-like core of general formula [Mn7(paa)6(OMe)6][X]2 x solv (4) (X = <protein-id="P41271,A0A087WTY6">NO3</protein-id>(-) or ClO4(-)), whilst the addition of paaH to a mixture of Mn(<protein-id="P41271,A0A087WTY6">NO3</protein-id>)2 x 4 H2O, teaH3 and <protein-id="O60636,B1AKP1,B2RD31">NEt3</protein-id> in CH2Cl2-<compound-id="887">MeOH</compound-id> resulted in the formation of a mixed-valence Mn2(II)Mn2(III) tetranuclear 'butterfly' complex of formula [Mn4(paa)4(<compound-id="8471">teaH</compound-id>)2][<protein-id="P41271,A0A087WTY6">NO3</protein-id>]2 x 2 <compound-id="887">MeOH</compound-id> x 2 CH2Cl2 (5).	teaH__NEt3__no_interaction	teaH__NO3__no_interaction	MeOH__NEt3__no_interaction	MeOH__NO3__no_interaction	N-(2-pyridinyl)acetoacetamide__NEt3__no_interaction	N-(2-pyridinyl)acetoacetamide__NO3__no_interaction
17279246-1	Metalladichalcogenolate cluster complexes [Cp'Co{E(2)C(2)(B(10)H(10))}]{<protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>(CO)5} [Cp' = eta5-C5H5, E = S(<compound-id="2981881,91293124">3a</compound-id>), E = Se(3b); Cp' = eta5-C5(CH3)5, E = S(<compound-id="69255155">4a</compound-id>), E = Se(4b)], {CpCo[E(2)C(2)(B(10)H(10))]}(2)Mo(CO)2] [E = S(5a), Se(<compound-id="18445697">5b</compound-id>)], Cp*Co(micro2-CO)Mo(CO)(py)2[E(2)C(2)(B(10)H(10))] [E = S(6a), Se(6b)], Cp*Co[E(2)C(2)(B(10)H(10))]Mo(CO)2[E(2)C(2)(B(10)H(10))] [E = S(7a), Se(7b)], (Cp'Co[E(2)C(2)(B(10)H(10))]W(CO)2 [E(2)C(2)(B(10)H(10))] [Cp' = eta5-C5H5, E = S(8a), E = Se(8b); Cp' = eta5-C5(CH3)5, E = S(9a), E = Se(9b)], {CpCo[E(2)C(2)(B(10)H(10))]}(2)Ni [E = S(10a), Se(10b)] and 3,4-(PhCN(4)S)-3,1,2-[PhCN(4)<compound-id="446720">SCo</compound-id>(Cp)S(2)]-3,1,2-CoC(2)B(9)H(8) 12 were synthesized by the reaction of [Cp'CoE(2)C(2)(B(10)H(10))] [Cp' = eta5-C5H5, E = S(1a), E = Se(1b); Cp' = eta5-C5(CH3)5, E = S(2a), E = Se(2b)] with <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">Co2</protein-id>(CO)8, M(CO)3(py)3 (M = Mo, W), <compound-id="82916">Ni(COD)2</compound-id>, [Rh(COD)Cl]2, and LiSCN4Ph respectively.	3a__Co2__no_interaction	5b__Co2__no_interaction	Ni(COD)2__Co2__no_interaction	SCo__Co2__no_interaction	4a__Co2__no_interaction
15252518-1	The reactions of four flexible tetradentate ligands, <compound-id="12836427">1,3-bis(2-pyridylthio)propane</compound-id> (L1), <compound-id="12140658">1,4-bis(2-pyridylthio)butane</compound-id> (L2), <compound-id="12140660">1,5-bis(2-pyridylthio)pentane</compound-id> (L3) and <compound-id="12140661">1,6-bis(2-pyridylthio)hexane</compound-id> (L4) with <protein-id="Q16222">AgX</protein-id> (X = BF4-, ClO4-, PF6-, or CF3SO3-) lead to the formation of seven new complexes: [AgL1(BF4)]2 (1), [[AgL2](ClO4)]infinity (2), [[AgL2(CH3CN)](PF6)]infinity (3), [[AgL3](BF4)(CHCl3)]2 (4), [[AgL3(CF3SO3)](CH3OH)(0.5)]infinity (5), [[Ag2L4(2)](BF4)2]infinity (6), and [[AgL4](PF6)]infinity (7), which have been characterized by elemental analyses, IR spectroscopy, and X-ray crystallography.	1,4-bis(2-pyridylthio)butane__AgX__no_interaction	1,6-bis(2-pyridylthio)hexane__AgX__no_interaction	1,3-bis(2-pyridylthio)propane__AgX__no_interaction	1,5-bis(2-pyridylthio)pentane__AgX__no_interaction
15943824-9	RESULTS: <compound-id="60823">Atorvastatin</compound-id> treatment compared to placebo resulted in a significant decrease in serum <compound-id="5997">cholesterol</compound-id> (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P &lt; 0.001), low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> (2.95 +/- 1.07 mmol/l vs. 1.82 +/- 0.92 mmol/l; P &lt; 0.001), very low-density lipoprotein (VLDL) <compound-id="5997">cholesterol</compound-id> (0.31 (0.21-0.47) mmol vs. 0.23 (0.13-0.30) mmol/l median (interquartile range); P &lt; 0.05), <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> (111 +/- 28 mg/dl vs. 80 +/- 18 mg/dl; P &lt; 0.001), and calculated coronary heart disease risk (6.8 (3.3-17.9) vs. 2.8 (1.5-5.7)% over next 10 years; P &lt; 0.01).	Atorvastatin__apolipoprotein B__no_interaction	cholesterol__apolipoprotein B__no_interaction
12402618-17	Capacitance was directly correlated with body mass index (r = 0.35, p &lt; 0.05), <protein-id="P02768">albumin</protein-id> (r = 0.32, p &lt; 0.05), and blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> (BUN) (r = 0.44, p &lt; 0.01), and inversely correlated with body weight (r = -0.51, p &lt; 0.0001).	urea__albumin__no_interaction	nitrogen__albumin__no_interaction
10611907-7	The levels of lipid parameters were as follows: total <compound-id="5997">cholesterol</compound-id> for men was 4.22 +/- 1.00 mmol/l (mean arithmetic +/- SD), triglyceride 1.20 mmol/l (0.30-4.44) [geometric mean (range)], HDL-<compound-id="5997">cholesterol</compound-id> 0.88 +/- 0.22 mmol/l, LDL-<compound-id="5997">cholesterol</compound-id> 2.69 +/- 0.85 mmol/l, apolipoprotein A-I 1.26 +/- 0.22 mmol/l <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> 1.12 +/- 0.32 mmol/l, <protein-id="P02649">apolipoprotein E</protein-id> 0.037 +/- 0.012 mmol/l and lipoprotein(a) 0.25 g/l (0.03-2.75); total <compound-id="5997">cholesterol</compound-id> for women was 4.53 +/- 1.00 mmol/l, triglyceride 1.05 mmol/l (0.28-4.50), HDL-<compound-id="5997">cholesterol</compound-id> 1.08 +/- 0.26 mmol/l, LDL-<compound-id="5997">cholesterol</compound-id> 2.87 +/- 0.88 mmol/l, apolipoprotein A-I 1.45 +/- 0.25 mmol/l, <protein-id="P04114,Q7Z7Q0,Q59HB3">apolipoprotein B</protein-id> 1.11 +/- 0.31 mmol/l, <protein-id="P02649">apolipoprotein E</protein-id> 0.039 +/- 0.011 mmol/l and lipoprotein(a) 0.22 g/l (0.03 2.16).	cholesterol__apolipoprotein B__no_interaction	cholesterol__apolipoprotein E__no_interaction
20614913-2	The reaction of [<compound-id="5460531">AuCl</compound-id>(<protein-id="Q9Y2B0">CNPy-2</protein-id>)] (1) (Py = pyridyl) with the corresponding chiral primary amines afforded the chiral HBHC complexes (R)-[<compound-id="5460531">AuCl</compound-id>{C(NH(CHMePh))(NHPy-2)}] ((R)-2), and (S)-[<compound-id="5460531">AuCl</compound-id>{C(NH{CHMe(1-naphthyl)})(NHPy-2)}] ((S)-3), while the reaction of 2 equiv of 1 with diamines produced (S)-2,2'-bis[NH{C(<compound-id="5460531">AuCl</compound-id>)(NHPy-2)}](2)-<compound-id="11789">binaphthyl</compound-id> ((S)-4), (1R,2R)-1,2-bis[NH{C(<compound-id="5460531">AuCl</compound-id>)(NHPy-2)}]-<compound-id="7647">diphenylethane</compound-id> ((1R,2R)-5), and (1R,2R)-1,2-bis[NH{C(<compound-id="5460531">AuCl</compound-id>)(NHPy-2)}]-<compound-id="8078">cyclohexane</compound-id> ((1R,2R)-6).	diphenylethane__CNPy-2__no_interaction	binaphthyl__CNPy-2__no_interaction	AuCl__CNPy-2__no_interaction	cyclohexane__CNPy-2__no_interaction
11523906-4	In hyperthyroidism, in contrast, serum levels of ADIOLS (male 1.49 +/- 0.69, female 0.64 +/- 0.31 micromol/l), <protein-id="Q06520,A8K015">DHEAS</protein-id> (male 7.43 +/- 3.91, female 5.13 +/- 2.03 micromol/l), and <compound-id="105074">PREGS</compound-id> (male 1.13 +/- 0.58, female 1.07 +/- 0.85 micromol/l) were markedly increased, but serum concentrations of ADIOL and <compound-id="7641">DEHA</compound-id> were not significantly different from controls (ADIOLS male 0.36 +/- 0.33, female 0.14 +/- 0.09 micromol/l; <protein-id="Q06520,A8K015">DHEAS</protein-id> male 2.88 +/- 1.70, female 1.86 +/- l1.03pmol/l; <compound-id="105074">PREGS</compound-id> male 0.18 +/- 0.12, female 0.11 +/- 0.08 micromol/l; ADIOL male 3.76 +/- 1.35, female 1.91 +/- 1.17 nmol/l; DHEA male 9.23 +/- 3.49, female 13.5 +/- 10.8nmol/l).	DEHA__DHEAS__no_interaction	PREGS__DHEAS__no_interaction
20736253-8	On logistic regression analysis, serum <compound-id="23994">zinc</compound-id> levels were associated with serum <protein-id="P02768">albumin</protein-id> (F 20.36, β 0.174, CL 0.086-0.265, P &lt; 0.001) and dialysis vintage (F 8.1, β 0.008, CL 0.002-0.013, P = 0.005), <compound-id="23978">copper</compound-id> levels with log <protein-id="P02741">CRP</protein-id> (F 31.4, β 3.04, CL 0-1.97, P &lt; 0.001) and urine volume (F 5.1, β - 0.01, CL - 0.002-0, P = 0.024), and <compound-id="6326970">selenium</compound-id> levels with serum <protein-id="P02768">albumin</protein-id> (F 23.2, β 0.016, CL 0.02-0.1, P &lt; 0.001) and race (F 31.4, β 3.62, P = 0.032), with <compound-id="6326970">selenium</compound-id> levels being greater in non-Caucasoids (0.9 ± 0.02 vs 0.76 ± 0.02 μmol/L, P &lt; 0.01).	copper__CRP__no_interaction	copper__albumin__no_interaction	selenium__CRP__no_interaction	selenium__albumin__no_interaction	zinc__CRP__no_interaction	zinc__albumin__no_interaction
11735096-5	In diabetics, the metabolic clearance rates of <compound-id="206,5793,64689,79025">glucose</compound-id> at both <protein-id="P01308,I3WAC9">insulin</protein-id> levels (<protein-id="P08235,B0ZBF6,A0A0D9SFL9">MCR</protein-id>(glu)submax and <protein-id="P08235,B0ZBF6,A0A0D9SFL9">MCR</protein-id>(glu)max) were significantly reduced compared with HS (<protein-id="P08235,B0ZBF6,A0A0D9SFL9">MCR</protein-id>(glu)submax DMN, 5.35 +/- 2.7 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>), <protein-id="Q03001,Q6P0N6,B4DSS9,F8W9J4,E9PHM6,B4DGY0,E9PEB9,F6QMI7">DMH</protein-id>, 5.38 +/- 2.17 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); DMD, 5.48 +/- 2.35 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) v HS, 10.9 +/- 3.3 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt;.01; <protein-id="P08235,B0ZBF6,A0A0D9SFL9">MCR</protein-id>(glu)max DMN, 13.3 +/- 3.3 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); <protein-id="Q03001,Q6P0N6,B4DSS9,F8W9J4,E9PHM6,B4DGY0,E9PEB9,F6QMI7">DMH</protein-id>, 12.5 +/- 3.0 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); DMD, 13.3 +/- 3.0 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) v HS, 17.4 +/- 3.8 mL x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>); P &lt;.05).	glucose__DMH__no_interaction	glucose__min(-1__no_interaction	glucose__insulin__no_interaction	glucose__MCR__no_interaction
16512945-4	As compared with those fed with a normal chow diet (0.45 % Ca), CaDef pups developed significant hypocalcaemia (P &lt; 0.05), hypocalciuria (urinary Ca 76 (<compound-id="5289348">SEM</compound-id> 12) v. 17 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>) mg/l; P &lt; 0.005), hypophosphataemia (serum inorganic P 100 (<compound-id="5289348">SEM</compound-id> 6) v. 65 (<compound-id="5289348">SEM</compound-id> 4) mg/l; P &lt; 0.005), secondary hyperparathyroidism (SHPT) (serum intact parathyroid hormone human equivalent 18.2 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>.4) v. 125.0 (<compound-id="5289348">SEM</compound-id> 4.5) pg/ml; P &lt; 0.001) and elevated serum <compound-id="5280453">calcitriol</compound-id> levels (34.0 (<compound-id="5289348">SEM</compound-id> 3.9) v. 91.0 (<protein-id="P60896,Q6IBB7">SEM 1</protein-id>.0) pg/ml; P &lt; 0.005).	calcitriol__SEM 1__no_interaction	SEM__SEM 1__no_interaction
20572039-7	DNA was extracted, modified with <compound-id="23665763">sodium bisulfite</compound-id>, and subjected to real-time quantitative, methylation-specific polymerase chain reaction analysis for the following genes: adenomatous polyposis coli (APC); <protein-id="P12830">cadherin 1</protein-id>, type 1, <protein-id="P12830">E-cadherin</protein-id> (epithelial) (<protein-id="P12830">CDH1</protein-id>); <protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">estrogen receptor 1</protein-id> (<protein-id="P03372,Q9UBT1,G4XH65,A8KAF4">ESR1</protein-id>); cytokine <protein-id="Q96QR1">high in normal 1</protein-id> (<protein-id="Q96QR1">HIN1</protein-id>); <protein-id="Q9UIK5">hyperplastic polyposis protein 1</protein-id> (HPP1); <protein-id="P16455,B4DEE8">O-6 methylguanine-DNA methyltransferase</protein-id> (<protein-id="P16455,B4DEE8">MGMT</protein-id>); <protein-id="Q92832,K9UUD5,J3KNC5,B3KXR2,F5H6I3">neural epidermal growth factor-like 1</protein-id> (<protein-id="Q92832,K9UUD5,J3KNC5,B3KXR2,F5H6I3">NELL1</protein-id>); splicing factor 3B, 14-kDa subunit (p14); cyclin-dependent kinase (CDK) inhibitor 2B (inhibits <protein-id="P11802,A0A024RBB6">CDK4</protein-id>) (<protein-id="P42772,K7PPU3">p15</protein-id>); <protein-id="P10826,Q5QHG3,F1D8S6,Q86UC5,Q3SB16">retinoic acid receptor beta</protein-id> (RARβ); <protein-id="P61278">somatostatin</protein-id> (<protein-id="P61278">SST</protein-id>); <protein-id="P20366,Q9Y494">tachykinin, precursor 1</protein-id> (<protein-id="P20366,Q9Y494">TAC1</protein-id>); and <protein-id="P01033,Q6FGX5,B4DJK3">tissue inhibitor of metalloproteinase</protein-id> (<protein-id="P01033,Q6FGX5,B4DJK3">TIMP</protein-id>) <protein-id="P35625">metallopeptidase inhibitor 3</protein-id> (<protein-id="P35625">TIMP3</protein-id>).	sodium bisulfite__tissue inhibitor of metalloproteinase__no_interaction	sodium bisulfite__TIMP3__no_interaction	sodium bisulfite__TAC1__no_interaction	sodium bisulfite__neural epidermal growth factor-like 1__no_interaction	sodium bisulfite__cadherin 1__no_interaction	sodium bisulfite__E-cadherin__no_interaction	sodium bisulfite__somatostatin__no_interaction	sodium bisulfite__CDH1__no_interaction	sodium bisulfite__tachykinin, precursor 1__no_interaction	sodium bisulfite__estrogen receptor 1__no_interaction	sodium bisulfite__HIN1__no_interaction	sodium bisulfite__hyperplastic polyposis protein 1__no_interaction	sodium bisulfite__retinoic acid receptor beta__no_interaction	sodium bisulfite__O-6 methylguanine-DNA methyltransferase__no_interaction	sodium bisulfite__p15__no_interaction	sodium bisulfite__MGMT__no_interaction	sodium bisulfite__metallopeptidase inhibitor 3__no_interaction	sodium bisulfite__NELL1__no_interaction	sodium bisulfite__TIMP__no_interaction	sodium bisulfite__ESR1__no_interaction	sodium bisulfite__SST__no_interaction	sodium bisulfite__high in normal 1__no_interaction	sodium bisulfite__CDK4__no_interaction
2207443-4	Steroidal (acetyltriamcinolone, 2 mg/kg) and non-steroidal (<compound-id="3715">indomethacin</compound-id>, 25 mg/kg) [corrected] anti-inflammatory drugs markedly decreased this effect on 14-day old lesions induced by <compound-id="6433272">nistatin</compound-id> plus "non-activated" plasma (2.37 +/- 0.10 for acetyltriamcinolone treatment vs 8.15 +/- 1.22 for untreated animals; 3.34 +/- 0.41 for <compound-id="3715">indomethacin</compound-id> treatment vs 8.15 +/- 1.22 for untreated animals) and <protein-id="P70553,A0A0G2JZT3">BCG</protein-id> plus "non-activated" plasma (1.67 +/- 0.11 for acetyltriamcinolone treatment vs 10.27 +/- 0.52 for untreated animals; 5.87 +/- 0.35 for <compound-id="3715">indomethacin</compound-id> treatment vs 9.14 +/- 0.23 for untreated animals).	nistatin__BCG__no_interaction	indomethacin__BCG__no_interaction
19848323-8	RESULTS: Compared with control group, the abdominal fat content (0.74+/-0.63 vs. 1.36+/-0.65 g, P&lt;0.05) and abdominal fat index (0.44%+/-0.30% vs. 0.85%+/-0.30%, P&lt;0.01) as well as live lipid index (3.61%+/-0.65% vs. 11.33%+/-2.14%, P&lt;0.01) in model group significantly increased; the levels of serum <compound-id="1175">uric acid</compound-id> (210.61+/-94.76 vs. 304.25+/-141.94 micromol/L, P&lt;0.05), total <compound-id="5997">cholesterol</compound-id> (4.20+/-0.51 vs. 20.10+/-11.25 mmol/L, P&lt;0.01), <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (1.16+/-0.29 vs. 10.78+/-6.48 mmol/L, P&lt;0.01), and FFA (0.39+/-0.14 vs. 0.55+/-0.15 mmol/L, P&lt;0.01) in model group significantly increased; HDL-C (5.85+/-0.95 vs. 4.14+/-2.03 mmol/L, P&lt;0.05) significantly decreased; the levels of triglyceride and blood <compound-id="206,5793,64689,79025">glucose</compound-id> had no significant changes (P&gt;0.05); the activities of <protein-id="P00813,F5GWI4">ADA</protein-id> (9.71+/-3.05 vs. 17.19+/-5.10 U/ml, P&lt;0.01) and XOD (10.58+/-6.88 vs. 19.22+/-9.44 U/L, P&lt;0.01) in model group significantly increased; and FAS, <protein-id="P06858">LPL</protein-id>, HL had no significant changes (P&gt;0.05).	glucose__LPL__no_interaction	glucose__LDL-C__no_interaction	glucose__ADA__no_interaction	uric acid__LPL__no_interaction	uric acid__LDL-C__no_interaction	uric acid__ADA__no_interaction	cholesterol__LPL__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__ADA__no_interaction
15852124-1	The temperature dependence of the solution equilibrium constants for [((t)Bu)(2)Al(OPh)]2(<protein-id="O00189,C9IZL5,C9JC87">mu-4</protein-id>,4'-<compound-id="1474">bipy</compound-id>)(1a), [((t)Bu)<compound-id="6852197">2Al</compound-id>(OPh)](2)(mu-bipetha)(2a, bipetha = <compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>), and [((t)Bu)(2)Al(OPh)]2(mu-bipethe)(<compound-id="2981881,91293124">3a</compound-id>, bipethe =trans-1,2-<compound-id="10329984">bis(4-pyridyl)ethylene</compound-id>) in <compound-id="71601">C6D6</compound-id> and CDCl(3) allow for the determination of DeltaH and DeltaS for the dissociation of one Al(tBu)<compound-id="16122596">2OPh</compound-id> moiety from the bridging ligand, i.e., 2[(tBu)<compound-id="6852197">2AL</compound-id>(OPh)]2(mu-L)&lt;==&gt;(K1)<compound-id="6852197">2AL</compound-id>(OPh)(tBu)2(L)+[(tBu)<compound-id="6852197">2Al</compound-id>(mu-OPh)]2.	2AL__mu-4__no_interaction	bipy__mu-4__no_interaction	2OPh__mu-4__no_interaction	1,2-bis(4-pyridyl)ethane__mu-4__no_interaction	bis(4-pyridyl)ethylene__mu-4__no_interaction	C6D6__mu-4__no_interaction	3a__mu-4__no_interaction	2Al__mu-4__no_interaction
20692997-1	Toxic effects of 10 antiviral substances [9-(2-hydroxyethoxymethyl)-<compound-id="764">guanine</compound-id> (<protein-id="Q14643,B4DGH1,Q59H91,B4DER3">ACV</protein-id>), E-5-(2-bromovinyl)-2'-<compound-id="13712">deoxyuridine</compound-id> (BVDU), <compound-id="128986">5-(2-chloroethyl)-2'-deoxyuridine</compound-id> (<compound-id="514814">CEDU</compound-id>), 9-(1,3-dihydroxy-2-<compound-id="12660726">propoxymethyl</compound-id>) <compound-id="764">guanine</compound-id> (<compound-id="3454">DHPG</compound-id>), (S)-9-(3-hydroxy-<compound-id="91211259">2-phosphonylmethoxypropyl</compound-id>) <compound-id="190,57060554">adenine</compound-id> (<compound-id="72253">HPMPA</compound-id>), (S)-1-(3-hydroxy-<compound-id="91211259">2-phosphonylmethoxypropyl</compound-id>) <compound-id="597">cytosine</compound-id> (<compound-id="60613">HPMPC</compound-id>), <compound-id="56999026">5'-iodo-2'-deoxyuridine</compound-id> (IDU), <compound-id="3415">phosphonoformic acid</compound-id> (PFA), 9-(<compound-id="21095448">2-phosphonylmethoxyethyl</compound-id>) <compound-id="190,57060554">adenine</compound-id> (PMEA) and 5-<compound-id="54407723">trifluoromethyl-2'-deoxyuridine</compound-id> (TFT)] on uninfected human corneal cells were evaluated in two experimental models (undisturbed adherence and growth, and wound closure) under continuous drug exposure.	deoxyuridine__ACV__no_interaction	phosphonoformic acid__ACV__no_interaction	adenine__ACV__no_interaction	HPMPA__ACV__no_interaction	propoxymethyl__ACV__no_interaction	trifluoromethyl-2'-deoxyuridine__ACV__no_interaction	5-(2-chloroethyl)-2'-deoxyuridine__ACV__no_interaction	CEDU__ACV__no_interaction	HPMPC__ACV__no_interaction	2-phosphonylmethoxyethyl__ACV__no_interaction	guanine__ACV__no_interaction	2-phosphonylmethoxypropyl__ACV__no_interaction	DHPG__ACV__no_interaction	5'-iodo-2'-deoxyuridine__ACV__no_interaction	cytosine__ACV__no_interaction
22841193-4	Selected genes up-regulated before transplantation were: <protein-id="Q07011">TNFRSF9</protein-id> (tumor necrosis factor [TNF] receptor superfamily, member 9); <protein-id="P14784">IL2RB</protein-id> (<protein-id="P14784">interleukin-2 receptor beta</protein-id>); <protein-id="Q92843">BCL2L2</protein-id> (<protein-id="Q92843">BCL2-like 2</protein-id>); <protein-id="Q96PH1,A3QRJ0">NOX5</protein-id> (<protein-id="Q16698,A0A024R9D7">NADPH</protein-id>) oxidase, EF-hand <compound-id="22044544,5460341">calcium</compound-id> binding domain 5); <protein-id="P50542,B4E0T2,B4DR50">PEX5</protein-id> (<protein-id="P50542,B4E0T2,B4DR50">peroxisomal biogenesis factor 5</protein-id>); <protein-id="P37231,D2KUA6,E9PFX5">PPARG</protein-id> (<protein-id="P37231,D2KUA6,E9PFX5">peroxisome proliferator-activated receptor gamma</protein-id>); <protein-id="Q96Q05">NIBP</protein-id> (<protein-id="Q96Q05">IKK2 binding protein</protein-id>); <protein-id="Q9NYR9,A0A024R1Z4">NKIRAS2</protein-id> (<protein-id="Q9NYR9,A0A024R1Z4">NFKappaBeta inhibitor interacting Ras-like 2</protein-id>); <protein-id="P05112,D4HNR6,Q5FC01">IL4</protein-id> (<protein-id="P05112,D4HNR6,Q5FC01">interleukin-4</protein-id>); <protein-id="P24394,B2RBY1">IL-4R</protein-id> (<protein-id="P24394,B2RBY1">interleukin 4 receptor</protein-id>); <protein-id="P07327">ADH1A</protein-id> (<protein-id="P07327">alcohol dehydrogenase 1A</protein-id>, class 1); <protein-id="O75891,Q53H87">ALDH1L1</protein-id> (aldehyde dehydrogenase 1 family, member L1); <protein-id="P05164">MPO</protein-id> (<protein-id="P05164">myeloperoxidase</protein-id>); <protein-id="P01160">NPPA</protein-id> (<protein-id="P01160">natriuretic peptide precursor A</protein-id>); <protein-id="Q16548">BCL2A1</protein-id> (<protein-id="Q16548">BCL2-related protein A1</protein-id>); <protein-id="P24522,A5JUZ3">GADD45A</protein-id> (growth arrest and DNA-damage-inducible alpha); <protein-id="P55061,A0A024R0Z5">TEGT</protein-id> (<protein-id="P55061,A0A024R0Z5">Bax inhibitor 1</protein-id>); <protein-id="P42336">PIK3CA</protein-id> (<compound-id="16738692">phosphoinositide</compound-id>-3-kinase, catalytic, alpha polypeptide); <protein-id="P38484,A8K881,E7EUY1">IFNGR2</protein-id> (<protein-id="P38484,A8K881,E7EUY1">interferon gamma receptor 2</protein-id>); <protein-id="O60674">JAK2</protein-id> (<protein-id="O60674">Janus Kinase 2</protein-id>); FAS (Fas, TNF receptor superfamily, member 6); <protein-id="Q92844,Q6NW12,B2R7S3">TANK</protein-id> (<protein-id="Q92844,Q6NW12,B2R7S3">TRAF family member-associated NFKB activator</protein-id>); <protein-id="O95551">TTRAP</protein-id> (<protein-id="Q01362,A0A0B4J2E9">TRAF and TNF receptor-associated protein</protein-id>); and <protein-id="P08758,V9HWE0">ANXA5</protein-id> (<protein-id="P08758,V9HWE0">annexin A5</protein-id>).	calcium__BCL2L2__no_interaction	calcium__Janus Kinase 2__no_interaction	calcium__NOX5__no_interaction	calcium__IFNGR2__no_interaction	calcium__BCL2-like 2__no_interaction	calcium__alcohol dehydrogenase 1A__no_interaction	calcium__TANK__no_interaction	calcium__TTRAP__no_interaction	calcium__GADD45A__no_interaction	calcium__interleukin 4 receptor__no_interaction	calcium__natriuretic peptide precursor A__no_interaction	calcium__interferon gamma receptor 2__no_interaction	calcium__interleukin-4__no_interaction	calcium__TNFRSF9__no_interaction	calcium__JAK2__no_interaction	calcium__TRAF family member-associated NFKB activator__no_interaction	calcium__NPPA__no_interaction	calcium__ANXA5__no_interaction	calcium__Bax inhibitor 1__no_interaction	calcium__NADPH__no_interaction	calcium__PPARG__no_interaction	calcium__myeloperoxidase__no_interaction	calcium__TEGT__no_interaction	calcium__NIBP__no_interaction	calcium__peroxisome proliferator-activated receptor gamma__no_interaction	calcium__TRAF and TNF receptor-associated protein__no_interaction	calcium__BCL2-related protein A1__no_interaction	calcium__peroxisomal biogenesis factor 5__no_interaction	calcium__NKIRAS2__no_interaction	calcium__IL2RB__no_interaction	calcium__PEX5__no_interaction	calcium__BCL2A1__no_interaction	calcium__MPO__no_interaction	calcium__ALDH1L1__no_interaction	calcium__annexin A5__no_interaction	calcium__IL4__no_interaction	calcium__IL-4R__no_interaction	calcium__ADH1A__no_interaction	calcium__PIK3CA__no_interaction	calcium__NFKappaBeta inhibitor interacting Ras-like 2__no_interaction	calcium__IKK2 binding protein__no_interaction	calcium__interleukin-2 receptor beta__no_interaction	phosphoinositide__BCL2L2__no_interaction	phosphoinositide__Janus Kinase 2__no_interaction	phosphoinositide__NOX5__no_interaction	phosphoinositide__IFNGR2__no_interaction	phosphoinositide__BCL2-like 2__no_interaction	phosphoinositide__alcohol dehydrogenase 1A__no_interaction	phosphoinositide__TANK__no_interaction	phosphoinositide__TTRAP__no_interaction	phosphoinositide__GADD45A__no_interaction	phosphoinositide__interleukin 4 receptor__no_interaction	phosphoinositide__natriuretic peptide precursor A__no_interaction	phosphoinositide__interferon gamma receptor 2__no_interaction	phosphoinositide__interleukin-4__no_interaction	phosphoinositide__TNFRSF9__no_interaction	phosphoinositide__JAK2__no_interaction	phosphoinositide__TRAF family member-associated NFKB activator__no_interaction	phosphoinositide__NPPA__no_interaction	phosphoinositide__ANXA5__no_interaction	phosphoinositide__Bax inhibitor 1__no_interaction	phosphoinositide__NADPH__no_interaction	phosphoinositide__PPARG__no_interaction	phosphoinositide__myeloperoxidase__no_interaction	phosphoinositide__TEGT__no_interaction	phosphoinositide__NIBP__no_interaction	phosphoinositide__peroxisome proliferator-activated receptor gamma__no_interaction	phosphoinositide__TRAF and TNF receptor-associated protein__no_interaction	phosphoinositide__BCL2-related protein A1__no_interaction	phosphoinositide__peroxisomal biogenesis factor 5__no_interaction	phosphoinositide__NKIRAS2__no_interaction	phosphoinositide__IL2RB__no_interaction	phosphoinositide__PEX5__no_interaction	phosphoinositide__BCL2A1__no_interaction	phosphoinositide__MPO__no_interaction	phosphoinositide__ALDH1L1__no_interaction	phosphoinositide__annexin A5__no_interaction	phosphoinositide__IL4__no_interaction	phosphoinositide__IL-4R__no_interaction	phosphoinositide__ADH1A__no_interaction	phosphoinositide__PIK3CA__no_interaction	phosphoinositide__NFKappaBeta inhibitor interacting Ras-like 2__no_interaction	phosphoinositide__IKK2 binding protein__no_interaction	phosphoinositide__interleukin-2 receptor beta__no_interaction
22916707-4	The most potent compounds of the present series include 5-<compound-id="91066389">methoxy-</compound-id>3-(<compound-id="137549">2-methylbenzyl</compound-id>)-7-pentyl-<compound-id="323">2H-chromen-2-one</compound-id> (<compound-id="6096886">19a</compound-id>, <compound-id="448408">PSB</compound-id>-SB-1201), a selective CB(1)antagonist (K(i) CB(1) 0.022 μM), 5-<compound-id="91066389">methoxy-</compound-id>3-(2-<compound-id="5371073">methoxybenzyl</compound-id>)-7-pentyl-<compound-id="323">2H-chromen-2-one</compound-id> (<compound-id="71710918">21a</compound-id>, <compound-id="448408">PSB</compound-id>-SB-1202), a dual CB(1)/CB(2)agonist (CB(1)K(i) 0.032 μM, EC(50) 0.056 μM; CB(2)K(i) 0.049 μM, EC(50) 0.014 μM), 5-hydroxy-3-(2-hydroxybenzyl)-7-(2-methyloct-2-yl)-<compound-id="323">2H-chromen-2-one</compound-id> (<compound-id="44223996">25b</compound-id>, <compound-id="448408">PSB</compound-id>-SB-1203), a dual CB(1)/CB(2) ligand that blocks CB(1) but activates CB(2) receptors (CB(1)K(i) 0.244 μM; CB(2)K(i) 0.210 μM, EC(50) 0.054 μM), and 7-(<compound-id="16269">1-butylcyclopentyl</compound-id>)-5-hydroxy-3-(2-hydroxybenzyl)-<compound-id="323">2H-chromen-2-one</compound-id> (27b, <compound-id="448408">PSB</compound-id>-SB-1204), a selective <protein-id="P34972,A0A024RAH7">CB(2) receptor agonist</protein-id> (CB(1)K(i) 1.59 μM; CB(2)K(i) 0.068 μM, EC(50) 0.048 μM).	methoxy-__CB(2) receptor agonist__no_interaction	2-methylbenzyl__CB(2) receptor agonist__no_interaction	PSB__CB(2) receptor agonist__no_interaction	25b__CB(2) receptor agonist__no_interaction	2H-chromen-2-one__CB(2) receptor agonist__no_interaction	21a__CB(2) receptor agonist__no_interaction	methoxybenzyl__CB(2) receptor agonist__no_interaction	19a__CB(2) receptor agonist__no_interaction	1-butylcyclopentyl__CB(2) receptor agonist__no_interaction
2284332-3	It has been observed that: (i) <compound-id="977">oxygen</compound-id> saturation assures consistent and maximum sensitivity; (ii) <compound-id="11966311">agarose</compound-id> concentrations in the range 1.0-2.0% have no effect upon sensitivity; (iii) the initial G value is 150 Fe3+/100 eV for gels containing 0.5 mM Fe2+ ions; (iv) increasing NMR frequencies only causes a moderate increase in sensitivity; (v) the gel dosemeters are dose rate independent in the range 4.7-24.2 Gy <protein-id="P13987,Q6FHM9">min-1</protein-id>; (vi) sensitivity is pH dependent, being zero at pH 7; (vii) freshly prepared gels are slightly more sensitive than those more than 24 h old; and (ix) the diffusion coefficient for <compound-id="29936">ferric ions</compound-id> in a 1.0% <compound-id="11966311">agarose</compound-id> gel containing 0.0125 M <compound-id="1118">H2SO4</compound-id> is 1.83 x 10(-2) cm2 h-1, and this will require consideration for the NMR imaging of dose distributions.	H2SO4__min-1__no_interaction	agarose__min-1__no_interaction	ferric ions__min-1__no_interaction	oxygen__min-1__no_interaction
18609104-6	<protein-id="O95750">FGF-19</protein-id> correlated with <compound-id="206,5793,64689,79025">glucose</compound-id> (r = -0.35, p&lt;0.01), <protein-id="P28845,X5D2L1">HDL</protein-id> (r = 0.24, p = 0.045), triacylglycerols (r = -0.19, p = 0.05) and with a number of other risk factors for metabolic syndrome (r = -0.28, p = 0.01).	glucose__HDL__no_interaction	glucose__FGF-19__no_interaction
12425635-1	Infrared data in the nu(CO) region (1800-2150 cm(-1), in acetonitrile at 298 K) are reported for the ground (nu(gs)) and polypyridyl-based, metal-to-ligand charge-transfer (MLCT) excited (nu(es)) states of cis-[Os(pp)2(CO)(L)](n)(+) (pp = 1,10-<compound-id="67473">phenanthroline</compound-id> (phen) or <compound-id="1474">2,2'-bipyridine</compound-id> (bpy); L = <protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>, CH(3)CN, pyridine, Cl, or H) and fac-[Re(pp)(CO)3(4-Etpy)](+) (pp = phen, bpy, 4,4'-(CH3)<compound-id="444756">2bpy</compound-id>, 4,4'-(<compound-id="123146">CH3O</compound-id>)<compound-id="444756">2bpy</compound-id>, or 4,4'-(CO2Et)<compound-id="444756">2bpy</compound-id>; 4-Etpy = <compound-id="10822">4-ethylpyridine</compound-id>).	2,2'-bipyridine__PPh3__no_interaction	phenanthroline__PPh3__no_interaction	4-ethylpyridine__PPh3__no_interaction	CH3O__PPh3__no_interaction	2bpy__PPh3__no_interaction
20810618-2	A high-throughput screening (HTS) campaign using human osteosarcoma (U-2 OS) cells transiently transduced with <protein-id="Q05586,Q59GW0,Q5VSF9">NR1</protein-id>/<protein-id="Q12879,Q547U9,Q59EW6">NR2A</protein-id> NMDAR subunits, tested in a specifically designed fluorometric imaging plate reader (FLIPR)/Ca(2+) assay, identified <compound-id="4596756">sulfonamide derivative</compound-id> series, exemplified by <compound-id="97584">3-chloro-</compound-id>4-fluoro-N-[(4-{[2-(phenylcarbonyl)hydrazino]carbonyl}phenyl)methyl]<compound-id="7370">benzenesulfonamide</compound-id> (compound 1) and <compound-id="67518">thiodiazole</compound-id> derivative <compound-id="2608149">N-(cyclohexylmethyl)-2-({5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio)acetamide</compound-id> (compound 13) as novel <protein-id="Q05586,Q59GW0,Q5VSF9">NR1</protein-id>/<protein-id="Q12879,Q547U9,Q59EW6">NR2A</protein-id> receptor antagonists.	3-chloro-__NR1__no_interaction	3-chloro-__NR2A__no_interaction	sulfonamide derivative__NR1__no_interaction	sulfonamide derivative__NR2A__no_interaction	N-(cyclohexylmethyl)-2-({5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio)acetamide__NR1__no_interaction	N-(cyclohexylmethyl)-2-({5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio)acetamide__NR2A__no_interaction	thiodiazole__NR1__no_interaction	thiodiazole__NR2A__no_interaction	benzenesulfonamide__NR1__no_interaction	benzenesulfonamide__NR2A__no_interaction
2643752-8	The concentration of apoprotein A-I, <protein-id="Q96P20">A-II, and B</protein-id> averaged 104 +/- 17 v 89 +/- 16 mg/dL, 33 +/- 4 v 28 +/- 8 mg/dL, P less than 0.02, and 111 +/- 24 v 105 +/- 33 mg/dL after the diets with and without <compound-id="10982484,702">alcohol</compound-id>, respectively.	alcohol__A-II, and B__no_interaction
15562033-6	<compound-id="65911">GIR</compound-id> inversely correlated with fasting NEFAs (r = -0.47; P = 0.0002), <protein-id="P01308,I3WAC9">insulin</protein-id>-infused NEFAs (n = 38; r = -0.62; P &lt; 0.0001), low-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = -0.50; P &lt; 0.0001), non-high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (r = -0.52; P &lt; 0.0001), basal fat oxidation (r = -0.32; P = 0.03), <protein-id="P01308,I3WAC9">insulin</protein-id>-infused fat oxidation (r = -0.40; P = 0.02), SMT (r = -0.28; P &lt; 0.05), and central fat (percentage; r = -0.59; P &lt; 0.0001).	GIR__insulin__no_interaction	cholesterol__insulin__no_interaction
1680992-5	The pharmacokinetic parameters were as follows: <protein-id="Q99456">K12</protein-id> (microconstant) = 0.3455 +/- 0.5345 (mean +/- SD) h-1; <compound-id="1715">K21</compound-id> (microconstant) = 0.1691 +/- 0.1242 h-1; <protein-id="P13645">K10</protein-id> (microconstant) = 0.1320 +/- 0.1112 h-1; Vl (volume of distribution of central compartment) = 16.9057 +/- 5.9384 1; Vss (volume of distribution at steady state) = 38.8917 +/- 11.4540 1; V-beta (volume of distribution of elimination phase) = 46.3809 +/- 13.8742 1; alpha (distribution rate constant) = 0.5932 +/- 0.7090; and beta (excretion rate constant) = 0.0361 +/- 0.0141.	K21__K12__no_interaction	K21__K10__no_interaction
21429569-6	RESULTS: (1) ADMA decreased <protein-id="P00750">tPA</protein-id> antigen levels in time- and concentration-dependent manners, with the maximum effect of 30 μmol/L ADMA for 48h (control 109.01 ± 4.15 ng/ml vs ADMA 86.76 ± 5.95 ng/ml, p&lt;0.01); (2) 30 μmol/L ADMA elevated antigen levels of <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> in a time-dependent manner, with the maximum effect of 30 μmol/L ADMA for 48 h (control 2721.12 ± 278.02 ng/ml vs. ADMA 3435.78 ± 22.33ng/ml, p&lt;0.05); (3) ADMA reduced <protein-id="P00750">tPA</protein-id> mRNA levels and increased <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> mRNA levels; (4) L-<compound-id="6322,90867653">arginine</compound-id>, <compound-id="176155">SB203580</compound-id> (p38 MAPK inhibitor) and PDTC attenuated the effects of ADMA on <protein-id="P00750">tPA</protein-id> and <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> significantly.	arginine__PAI-1__no_interaction	arginine__tPA__no_interaction	SB203580__PAI-1__no_interaction	SB203580__tPA__no_interaction
20652473-7	(Normal mean reference values): oxLDL (63.23 +/- 16.23 U/L), (Male/Female 68.06 +/- 17.69/58.39 +/- 13.6 U/L), F(2)-isoprostanes (2.26 +/- 0.9 microg/g <compound-id="588">creatinine</compound-id>), PC (0.34 +/- 0.15 nmol/mg), 8-OHdG (23.27 +/- 10.58 ng/ml), <protein-id="P00441,V9HWC9">SOD</protein-id> (931.97 +/- 271.09 U/g Hb), GR (46.56 +/- 11.68 U/L), GPx (27.58 +/- 6.89 U/gHb (Male/Female 25.91 +/- 5.03/29.2 +/- 8.07 U/L)).	creatinine__SOD__no_interaction
8071515-6	In patients with PBC, serum <protein-id="P05187,B2R7C7">ALP</protein-id> levels were positively correlated with frequency of intake of fat/oil (r = 0.59, p &lt; 0.01) and meats (r = 0.46, p &lt; 0.05), whereas serum <protein-id="Q9NRA2">bilirubin (Bili) and aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) levels were significantly correlated with frequency of intake of dairy products (<compound-id="7021454">rs</compound-id> = 0.48 and 0.45, ps &lt; 0.05 for Bili and <protein-id="Q9NRA2">AST</protein-id>, respectively), meats (<compound-id="7021454">rs</compound-id> = 0.59 and 0.65, ps &lt; 0.01), and fat/oil (r = 0.54, p &lt; 0.02 and r = 0.48, p &lt; 0.05).	rs__bilirubin (Bili) and aspartate aminotransferase__no_interaction	rs__ALP__no_interaction	rs__AST__no_interaction
8994422-5	In the presence of <compound-id="36811">dobutamine</compound-id>, intracoronary <protein-id="P20366,Q9Y494">substance P</protein-id> caused a greater fall in left ventricular end-systolic pressure (transplantation control, -9 +/- 11 versus transplantation <compound-id="36811">dobutamine</compound-id>, -20 +/- 18 mm Hg [P &lt; .05]; cardiomyopathy control, -4 +/- 1 versus cardiomyopathy <compound-id="36811">dobutamine</compound-id>, -10 +/- 3 mm Hg [P &lt; .05]) and in left ventricular peak systolic pressure (transplantation control, -14 +/- 10 versus transplantation <compound-id="36811">dobutamine</compound-id>, -30 +/- 22 mm Hg [P &lt; .01]; cardiomyopathy control, -9 +/- 7 versus cardiomyopathy <compound-id="36811">dobutamine</compound-id>, -15 +/- 6 mm Hg [P = .1]).	dobutamine__substance P__no_interaction
16801331-6	Patients with <protein-id="P11226">MBL</protein-id>-low genotypes also presented higher mean values for total <compound-id="5997">cholesterol</compound-id> (228.6 vs 202.3 mg/dl, P = 0.017) and low-density lipoprotein (LDL) <compound-id="5997">cholesterol</compound-id> (139.9 vs 121.9 mg/dl, P = 0.045), a higher frequency of chronic renal failure (30 vs 4%, P = 0.001), vasculitis (30 vs 11%, P = 0.043), heart valve lesions (71 vs 32%, P = 0.026), cardiac valve dysfunction (57 vs 7%, P = 0.0004) and associated APS (39 vs 12%, P = 0.005), a higher mean Systemic Lupus International Collaborating Clinics score (2.09 vs 1.26, P = 0.029) and a lower prevalence of low C4 levels (43 vs 71%, P = 0.015).	cholesterol__MBL__no_interaction
14518092-4	The following differences were found between the respective groups: 1. the ultrasonographic examination of carotid arteries demonstrated sclerotic plates or carotid stenosis in 21.3% of patients with florid Cushing's syndrome and 41.4% in patients with corticolism having been cured-up against 11.7% in the relevant control group; 2. the examination of skin microcirculation by the laser-doppler method revealed a lower velocity of perfusion increase during examination of postocclusion hyperemia in patients with florid Cushing's syndrome and hypercortisolism having been cured-up against a control group (CUSH., P &lt; 0.04; previous cured-up, P &lt; 0.02) as well as thermally-induced hyperemia (CUSH., P &lt; 0.03; formerly cured-up, P &lt; 0.04); 3. the laboratory examination of patients with florid Cushing's syndrome revealed higher values of LDL-<compound-id="5997">cholesterol</compound-id> (P &lt; 0.05) and total <compound-id="5997">cholesterol</compound-id> (P &lt; 0.001), <compound-id="10964">malonyldialdehyde</compound-id> as an indicator of increased formation of <compound-id="977">oxygen</compound-id> radicals (P &lt; 0.05) and oromucoid, the protein of acute phase, signaling a chronic inflammation (P &lt; 0.05); 4. in patients who previously suffered from hypercortisolism increased levels of fibrinogen (P &lt; 0.03) and the cytoadhesive molecule <protein-id="P05362">ICAM-1</protein-id> (P &lt; 0.05) were accompanied by decreased levels of the growth factor of vascular endothelia (<protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGF</protein-id>) (P &lt; 0.05) against patients with florid Cushing's syndrome.	malonyldialdehyde__ICAM-1__no_interaction	malonyldialdehyde__VEGF__no_interaction	oxygen__ICAM-1__no_interaction	oxygen__VEGF__no_interaction	cholesterol__ICAM-1__no_interaction	cholesterol__VEGF__no_interaction
20168046-2	Since treatment with angiotensin II receptor blockers (ARBs) improves vasculopathies in type 2 diabetic patients, we asked whether the EDHF-type relaxation and its associated K(Ca) channels [small (SK(Ca))-, intermediate (IK(Ca))-, and large (<protein-id="Q62976">BK(Ca</protein-id>))-conductance channels] are abnormal in mesenteric arteries isolated from Goto-Kakizaki (GK) rats at the chronic stage of type 2 diabetes (34 - 38 weeks) and whether an ARBs (<compound-id="3961">losartan</compound-id>, 25 mg .	losartan__BK(Ca__no_interaction
24503482-4	Our study was able to identify potential ligand association for Class A Orphans and putative/unclassified Class A receptors with no cognate ligand information: <protein-id="Q99679,H9NIL4,B4DSD1">GPR21</protein-id> and <protein-id="Q9Y2T5,F2YGU0">GPR52</protein-id> with fatty acids; <protein-id="O95800">GPR75</protein-id> with <protein-id="P01303,A4D158">Neuropeptide Y</protein-id>; <protein-id="Q96P67">GPR82</protein-id>, <protein-id="Q14330,H9NIM1">GPR18</protein-id>, <protein-id="Q7Z602">GPR141</protein-id> with <compound-id="5283389">N-arachidonylglycine</compound-id>; <protein-id="Q14439,B4DZ23,H9NIL9,J3KNC6">GPR176</protein-id> with Free fatty acids, <protein-id="P49683,A5JUU5">GPR10</protein-id> with Tachykinin &amp; <protein-id="P01303,A4D158">Neuropeptide Y</protein-id>; <protein-id="P60893,A4D0T8,Q8NEN2">GPR85</protein-id> with <compound-id="5957">ATP</compound-id>, <compound-id="6022">ADP</compound-id> &amp; <compound-id="6031">UDP</compound-id> <compound-id="206,5793,64689,79025">glucose</compound-id>; <protein-id="Q8TDV0">GPR151</protein-id> with Galanin; <protein-id="Q6NV75,A0A0I9QQ03">GPR153</protein-id> and <protein-id="Q16538,A0A0I9QPQ8">GPR162</protein-id> with <compound-id="5816">Adrenalin</compound-id>, Noradrenalin; <protein-id="Q96CH1,A4D2Q3,B4DTD6">GPR146</protein-id>, <protein-id="Q6DWJ6">GPR139</protein-id>, <protein-id="Q7Z601">GPR142</protein-id> with Neuromedin, <compound-id="44576256">Ghrelin</compound-id>, Neuromedin U-25 &amp; Thyrotropin-releasing hormone; <protein-id="O14626">GPR171</protein-id> with <compound-id="5957">ATP</compound-id>, <compound-id="6022">ADP</compound-id> &amp; <compound-id="6031">UDP</compound-id> <compound-id="206,5793,64689,79025">Glucose</compound-id>; <protein-id="Q9GZN0">GPR88</protein-id>, <protein-id="Q8IZ08">GPR135</protein-id>, <protein-id="Q8N6U8,A0A0A0MQW8">GPR161</protein-id>, GPR101with 11-cis-<compound-id="638015">retinal</compound-id>; <protein-id="Q9NYM4,F5GZ43">GPR83</protein-id> with Tackykinin; <protein-id="Q8TDV2">GPR148</protein-id> with Prostanoids, <protein-id="P49019">GPR109b</protein-id>, <protein-id="Q9BXC0">GPR81</protein-id>, GPR31with <compound-id="5957">ATP</compound-id> &amp; <compound-id="6133">UTP</compound-id> and <protein-id="Q8NGU9,G4XH61">GPR150</protein-id> with <compound-id="16132914">GnRH I</compound-id> &amp; GnRHII.	UDP__GPR10__no_interaction	UDP__GPR18__no_interaction	UDP__GPR75__no_interaction	UDP__GPR52__no_interaction	UDP__GPR109b__no_interaction	UDP__GPR146__no_interaction	UDP__GPR141__no_interaction	UDP__GPR142__no_interaction	UDP__Neuropeptide Y__no_interaction	UDP__GPR148__no_interaction	UDP__GPR88__no_interaction	UDP__GPR162__no_interaction	UDP__GPR81__no_interaction	UDP__GPR82__no_interaction	UDP__GPR161__no_interaction	UDP__GPR85__no_interaction	UDP__GPR150__no_interaction	UDP__GPR21__no_interaction	UDP__GPR153__no_interaction	UDP__GPR151__no_interaction	UDP__GPR83__no_interaction	UDP__GPR135__no_interaction	UDP__GPR171__no_interaction	UDP__GPR139__no_interaction	UDP__GPR176__no_interaction	GnRH I__GPR10__no_interaction	GnRH I__GPR18__no_interaction	GnRH I__GPR75__no_interaction	GnRH I__GPR52__no_interaction	GnRH I__GPR109b__no_interaction	GnRH I__GPR146__no_interaction	GnRH I__GPR141__no_interaction	GnRH I__GPR142__no_interaction	GnRH I__Neuropeptide Y__no_interaction	GnRH I__GPR148__no_interaction	GnRH I__GPR88__no_interaction	GnRH I__GPR162__no_interaction	GnRH I__GPR81__no_interaction	GnRH I__GPR82__no_interaction	GnRH I__GPR161__no_interaction	GnRH I__GPR85__no_interaction	GnRH I__GPR150__no_interaction	GnRH I__GPR21__no_interaction	GnRH I__GPR153__no_interaction	GnRH I__GPR151__no_interaction	GnRH I__GPR83__no_interaction	GnRH I__GPR135__no_interaction	GnRH I__GPR171__no_interaction	GnRH I__GPR139__no_interaction	GnRH I__GPR176__no_interaction	ADP__GPR10__no_interaction	ADP__GPR18__no_interaction	ADP__GPR75__no_interaction	ADP__GPR52__no_interaction	ADP__GPR109b__no_interaction	ADP__GPR146__no_interaction	ADP__GPR141__no_interaction	ADP__GPR142__no_interaction	ADP__Neuropeptide Y__no_interaction	ADP__GPR148__no_interaction	ADP__GPR88__no_interaction	ADP__GPR162__no_interaction	ADP__GPR81__no_interaction	ADP__GPR82__no_interaction	ADP__GPR161__no_interaction	ADP__GPR85__no_interaction	ADP__GPR150__no_interaction	ADP__GPR21__no_interaction	ADP__GPR153__no_interaction	ADP__GPR151__no_interaction	ADP__GPR83__no_interaction	ADP__GPR135__no_interaction	ADP__GPR171__no_interaction	ADP__GPR139__no_interaction	ADP__GPR176__no_interaction	retinal__GPR10__no_interaction	retinal__GPR18__no_interaction	retinal__GPR75__no_interaction	retinal__GPR52__no_interaction	retinal__GPR109b__no_interaction	retinal__GPR146__no_interaction	retinal__GPR141__no_interaction	retinal__GPR142__no_interaction	retinal__Neuropeptide Y__no_interaction	retinal__GPR148__no_interaction	retinal__GPR88__no_interaction	retinal__GPR162__no_interaction	retinal__GPR81__no_interaction	retinal__GPR82__no_interaction	retinal__GPR161__no_interaction	retinal__GPR85__no_interaction	retinal__GPR150__no_interaction	retinal__GPR21__no_interaction	retinal__GPR153__no_interaction	retinal__GPR151__no_interaction	retinal__GPR83__no_interaction	retinal__GPR135__no_interaction	retinal__GPR171__no_interaction	retinal__GPR139__no_interaction	retinal__GPR176__no_interaction	UTP__GPR10__no_interaction	UTP__GPR18__no_interaction	UTP__GPR75__no_interaction	UTP__GPR52__no_interaction	UTP__GPR109b__no_interaction	UTP__GPR146__no_interaction	UTP__GPR141__no_interaction	UTP__GPR142__no_interaction	UTP__Neuropeptide Y__no_interaction	UTP__GPR148__no_interaction	UTP__GPR88__no_interaction	UTP__GPR162__no_interaction	UTP__GPR81__no_interaction	UTP__GPR82__no_interaction	UTP__GPR161__no_interaction	UTP__GPR85__no_interaction	UTP__GPR150__no_interaction	UTP__GPR21__no_interaction	UTP__GPR153__no_interaction	UTP__GPR151__no_interaction	UTP__GPR83__no_interaction	UTP__GPR135__no_interaction	UTP__GPR171__no_interaction	UTP__GPR139__no_interaction	UTP__GPR176__no_interaction	N-arachidonylglycine__GPR10__no_interaction	N-arachidonylglycine__GPR18__no_interaction	N-arachidonylglycine__GPR75__no_interaction	N-arachidonylglycine__GPR52__no_interaction	N-arachidonylglycine__GPR109b__no_interaction	N-arachidonylglycine__GPR146__no_interaction	N-arachidonylglycine__GPR141__no_interaction	N-arachidonylglycine__GPR142__no_interaction	N-arachidonylglycine__Neuropeptide Y__no_interaction	N-arachidonylglycine__GPR148__no_interaction	N-arachidonylglycine__GPR88__no_interaction	N-arachidonylglycine__GPR162__no_interaction	N-arachidonylglycine__GPR81__no_interaction	N-arachidonylglycine__GPR82__no_interaction	N-arachidonylglycine__GPR161__no_interaction	N-arachidonylglycine__GPR85__no_interaction	N-arachidonylglycine__GPR150__no_interaction	N-arachidonylglycine__GPR21__no_interaction	N-arachidonylglycine__GPR153__no_interaction	N-arachidonylglycine__GPR151__no_interaction	N-arachidonylglycine__GPR83__no_interaction	N-arachidonylglycine__GPR135__no_interaction	N-arachidonylglycine__GPR171__no_interaction	N-arachidonylglycine__GPR139__no_interaction	N-arachidonylglycine__GPR176__no_interaction	Ghrelin__GPR10__no_interaction	Ghrelin__GPR18__no_interaction	Ghrelin__GPR75__no_interaction	Ghrelin__GPR52__no_interaction	Ghrelin__GPR109b__no_interaction	Ghrelin__GPR146__no_interaction	Ghrelin__GPR141__no_interaction	Ghrelin__GPR142__no_interaction	Ghrelin__Neuropeptide Y__no_interaction	Ghrelin__GPR148__no_interaction	Ghrelin__GPR88__no_interaction	Ghrelin__GPR162__no_interaction	Ghrelin__GPR81__no_interaction	Ghrelin__GPR82__no_interaction	Ghrelin__GPR161__no_interaction	Ghrelin__GPR85__no_interaction	Ghrelin__GPR150__no_interaction	Ghrelin__GPR21__no_interaction	Ghrelin__GPR153__no_interaction	Ghrelin__GPR151__no_interaction	Ghrelin__GPR83__no_interaction	Ghrelin__GPR135__no_interaction	Ghrelin__GPR171__no_interaction	Ghrelin__GPR139__no_interaction	Ghrelin__GPR176__no_interaction	ATP__GPR10__no_interaction	ATP__GPR18__no_interaction	ATP__GPR75__no_interaction	ATP__GPR52__no_interaction	ATP__GPR109b__no_interaction	ATP__GPR146__no_interaction	ATP__GPR141__no_interaction	ATP__GPR142__no_interaction	ATP__Neuropeptide Y__no_interaction	ATP__GPR148__no_interaction	ATP__GPR88__no_interaction	ATP__GPR162__no_interaction	ATP__GPR81__no_interaction	ATP__GPR82__no_interaction	ATP__GPR161__no_interaction	ATP__GPR85__no_interaction	ATP__GPR150__no_interaction	ATP__GPR21__no_interaction	ATP__GPR153__no_interaction	ATP__GPR151__no_interaction	ATP__GPR83__no_interaction	ATP__GPR135__no_interaction	ATP__GPR171__no_interaction	ATP__GPR139__no_interaction	ATP__GPR176__no_interaction	Glucose__GPR10__no_interaction	Glucose__GPR18__no_interaction	Glucose__GPR75__no_interaction	Glucose__GPR52__no_interaction	Glucose__GPR109b__no_interaction	Glucose__GPR146__no_interaction	Glucose__GPR141__no_interaction	Glucose__GPR142__no_interaction	Glucose__Neuropeptide Y__no_interaction	Glucose__GPR148__no_interaction	Glucose__GPR88__no_interaction	Glucose__GPR162__no_interaction	Glucose__GPR81__no_interaction	Glucose__GPR82__no_interaction	Glucose__GPR161__no_interaction	Glucose__GPR85__no_interaction	Glucose__GPR150__no_interaction	Glucose__GPR21__no_interaction	Glucose__GPR153__no_interaction	Glucose__GPR151__no_interaction	Glucose__GPR83__no_interaction	Glucose__GPR135__no_interaction	Glucose__GPR171__no_interaction	Glucose__GPR139__no_interaction	Glucose__GPR176__no_interaction	Adrenalin__GPR10__no_interaction	Adrenalin__GPR18__no_interaction	Adrenalin__GPR75__no_interaction	Adrenalin__GPR52__no_interaction	Adrenalin__GPR109b__no_interaction	Adrenalin__GPR146__no_interaction	Adrenalin__GPR141__no_interaction	Adrenalin__GPR142__no_interaction	Adrenalin__Neuropeptide Y__no_interaction	Adrenalin__GPR148__no_interaction	Adrenalin__GPR88__no_interaction	Adrenalin__GPR162__no_interaction	Adrenalin__GPR81__no_interaction	Adrenalin__GPR82__no_interaction	Adrenalin__GPR161__no_interaction	Adrenalin__GPR85__no_interaction	Adrenalin__GPR150__no_interaction	Adrenalin__GPR21__no_interaction	Adrenalin__GPR153__no_interaction	Adrenalin__GPR151__no_interaction	Adrenalin__GPR83__no_interaction	Adrenalin__GPR135__no_interaction	Adrenalin__GPR171__no_interaction	Adrenalin__GPR139__no_interaction	Adrenalin__GPR176__no_interaction	glucose__GPR10__no_interaction	glucose__GPR18__no_interaction	glucose__GPR75__no_interaction	glucose__GPR52__no_interaction	glucose__GPR109b__no_interaction	glucose__GPR146__no_interaction	glucose__GPR141__no_interaction	glucose__GPR142__no_interaction	glucose__Neuropeptide Y__no_interaction	glucose__GPR148__no_interaction	glucose__GPR88__no_interaction	glucose__GPR162__no_interaction	glucose__GPR81__no_interaction	glucose__GPR82__no_interaction	glucose__GPR161__no_interaction	glucose__GPR85__no_interaction	glucose__GPR150__no_interaction	glucose__GPR21__no_interaction	glucose__GPR153__no_interaction	glucose__GPR151__no_interaction	glucose__GPR83__no_interaction	glucose__GPR135__no_interaction	glucose__GPR171__no_interaction	glucose__GPR139__no_interaction	glucose__GPR176__no_interaction
18349111-6	In lean individuals, <protein-id="Q9UBK2,A0A024R9Q9">PGC-1alpha</protein-id> protein correlated with <compound-id="311,17938267">citrate</compound-id> synthase (CS; r = 0.67) and rates of <compound-id="985">palmitate</compound-id> oxidation (r = 0.87), whereas <protein-id="Q86YN6,B7ZM40">PGC-1beta</protein-id> correlated with <protein-id="P37231,D2KUA6,E9PFX5">PPARgamma</protein-id> (r = 0.90), PPARdelta/beta (r = 0.63), and cytochrome c oxidase IV (COX-IV; r = 0.63).	palmitate__PPARgamma__no_interaction	palmitate__PGC-1alpha__no_interaction	palmitate__PGC-1beta__no_interaction	citrate__PPARgamma__no_interaction	citrate__PGC-1alpha__no_interaction	citrate__PGC-1beta__no_interaction
20657949-1	A series of seven metal-organic frameworks, namely, {[Zn(4)(bptc)(2)(<protein-id="O60687">bpp</protein-id>)(2)].3.5H(2)O}(n) (1), {[Zn(2)(bptc)(bix)].H(2)O}(n) (2), {[Zn(2)(bptc)(bpe)(1.5)(H(2)O)(3)].H(2)O}(n) (3), [Zn(2)(Hbptc)(mu(3)-OH)(4,4'-bpy)](n) (4), [Cd(2)(bptc)(<protein-id="Q03001,Q6P0N6,B4DSS9,F8W9J4,E9PHM6,B4DGY0,E9PEB9,F6QMI7">bpa</protein-id>)(2)(H(2)O)](n) (5), [Cd(2)(bptc)(<protein-id="O60687">bpp</protein-id>)(2)(H(2)O)(2)](n) (6), {[Cd(4)(bptc)(2)(bix)(2)(H(2)O)(2)].4.5H(2)O}(n) (7) (bptc = <compound-id="21888861">2,2',3,3'benzophenonetetracarboxylate</compound-id>), have been hydro(solvo)thermally synthesized through the reaction of 2,2',3,3'-<compound-id="3102">benzophenone</compound-id> tetracarboxylic dianhydride (2,2',3,3'-bptda) with divalent <compound-id="23994">zinc</compound-id> and <compound-id="23973">cadmium</compound-id> salts in the presence of ancillary <compound-id="947">nitrogen</compound-id> ligands (<protein-id="Q03001,Q6P0N6,B4DSS9,F8W9J4,E9PHM6,B4DGY0,E9PEB9,F6QMI7">bpa</protein-id> = <compound-id="78630">1,2-bis(4-pyridyl)ethane</compound-id>, bpe = <compound-id="83382">1,2-bis(4-pyridyl)ethene</compound-id>, <protein-id="O60687">bpp</protein-id> = <compound-id="87019">1,3-bi(4-pyridyl)propane</compound-id>, bix = <compound-id="1257389">1,4-bis(imidazol-1-ylmethyl)benzene</compound-id>, and bpy = 4,4'bipyridine).	benzophenone__bpa__no_interaction	benzophenone__bpp__no_interaction	zinc__bpa__no_interaction	zinc__bpp__no_interaction	2,2',3,3'benzophenonetetracarboxylate__bpa__no_interaction	2,2',3,3'benzophenonetetracarboxylate__bpp__no_interaction	1,3-bi(4-pyridyl)propane__bpa__no_interaction	1,3-bi(4-pyridyl)propane__bpp__no_interaction	1,2-bis(4-pyridyl)ethane__bpa__no_interaction	1,2-bis(4-pyridyl)ethane__bpp__no_interaction	cadmium__bpa__no_interaction	cadmium__bpp__no_interaction	1,2-bis(4-pyridyl)ethene__bpa__no_interaction	1,2-bis(4-pyridyl)ethene__bpp__no_interaction	nitrogen__bpa__no_interaction	nitrogen__bpp__no_interaction	1,4-bis(imidazol-1-ylmethyl)benzene__bpa__no_interaction	1,4-bis(imidazol-1-ylmethyl)benzene__bpp__no_interaction
20136836-2	EXPERIMENTAL APPROACH: The effect of the wide spectrum P2 receptor antagonist <compound-id="6093163">PPADS</compound-id>, the selective <protein-id="Q99572">P2X7</protein-id> receptor antagonist <compound-id="61364,5856033,6333920">Brilliant Blue G</compound-id> (BBG), the <protein-id="P51575">P2X1</protein-id> receptor antagonist (4,4',4'',4-[carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-<compound-id="7388">1,3-benzenedisulfonic acid</compound-id>, octasodium salt (NF449) and (8,8'-[carbonylbis(imino-3,1-phenylenecarbonylimino)]bis-1,3,5-<compound-id="11970435">naphthalene-trisulphonic acid</compound-id>, hexasodium salt (NF023), the <protein-id="Q9H244,A8K7T1">P2Y12</protein-id> receptor antagonist (<compound-id="6417">2,2-dimethyl-propionic acid</compound-id> 3-(<compound-id="1800613">2-chloro</compound-id>-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propylester (MRS2395), the selective <protein-id="P47900">P2Y1</protein-id> receptor agonist ([[(1R,2R,<compound-id="21439199">3S</compound-id>,4R,5S)-4-[6-amino-2-(methylthio)-9H-<compound-id="1044">purin</compound-id>-9-yl]-2,3-dihydroxybicyclo[3.1.0]<compound-id="6335158">hex-1</compound-id>-yl]methyl] <compound-id="1023">diphosphoric acid</compound-id> mono ester <compound-id="16219045">trisodium</compound-id> salt (<compound-id="73755044">MRS2365</compound-id>), the <protein-id="P41231">P2Y2</protein-id>/<protein-id="P51582">P2Y4</protein-id> agonist <compound-id="6133">uridine-5'-triphosphate</compound-id> (UTP), and the <protein-id="P51582">P2Y4</protein-id>/<protein-id="Q15077,A0A024R5I9">P2Y6</protein-id> agonist <compound-id="6101632">uridine-5'-diphosphate</compound-id> (<compound-id="6031">UDP</compound-id>) were examined on mechanical allodynia in the Seltzer model of neuropathic pain, on acute thermal nociception, and on the inflammatory pain and oedema induced by complete Freund's adjuvant (CFA).	UDP__P2Y1__no_interaction	UDP__P2X7__no_interaction	UDP__P2Y2__no_interaction	UDP__P2Y4__no_interaction	UDP__P2X1__no_interaction	UDP__P2Y12__no_interaction	UDP__P2Y6__no_interaction	PPADS__P2Y1__no_interaction	PPADS__P2X7__no_interaction	PPADS__P2Y2__no_interaction	PPADS__P2Y4__no_interaction	PPADS__P2X1__no_interaction	PPADS__P2Y12__no_interaction	PPADS__P2Y6__no_interaction	diphosphoric acid__P2Y1__no_interaction	diphosphoric acid__P2X7__no_interaction	diphosphoric acid__P2Y2__no_interaction	diphosphoric acid__P2Y4__no_interaction	diphosphoric acid__P2X1__no_interaction	diphosphoric acid__P2Y12__no_interaction	diphosphoric acid__P2Y6__no_interaction	1,3-benzenedisulfonic acid__P2Y1__no_interaction	1,3-benzenedisulfonic acid__P2X7__no_interaction	1,3-benzenedisulfonic acid__P2Y2__no_interaction	1,3-benzenedisulfonic acid__P2Y4__no_interaction	1,3-benzenedisulfonic acid__P2X1__no_interaction	1,3-benzenedisulfonic acid__P2Y12__no_interaction	1,3-benzenedisulfonic acid__P2Y6__no_interaction	3S__P2Y1__no_interaction	3S__P2X7__no_interaction	3S__P2Y2__no_interaction	3S__P2Y4__no_interaction	3S__P2X1__no_interaction	3S__P2Y12__no_interaction	3S__P2Y6__no_interaction	naphthalene-trisulphonic acid__P2Y1__no_interaction	naphthalene-trisulphonic acid__P2X7__no_interaction	naphthalene-trisulphonic acid__P2Y2__no_interaction	naphthalene-trisulphonic acid__P2Y4__no_interaction	naphthalene-trisulphonic acid__P2X1__no_interaction	naphthalene-trisulphonic acid__P2Y12__no_interaction	naphthalene-trisulphonic acid__P2Y6__no_interaction	trisodium__P2Y1__no_interaction	trisodium__P2X7__no_interaction	trisodium__P2Y2__no_interaction	trisodium__P2Y4__no_interaction	trisodium__P2X1__no_interaction	trisodium__P2Y12__no_interaction	trisodium__P2Y6__no_interaction	purin__P2Y1__no_interaction	purin__P2X7__no_interaction	purin__P2Y2__no_interaction	purin__P2Y4__no_interaction	purin__P2X1__no_interaction	purin__P2Y12__no_interaction	purin__P2Y6__no_interaction	hex-1__P2Y1__no_interaction	hex-1__P2X7__no_interaction	hex-1__P2Y2__no_interaction	hex-1__P2Y4__no_interaction	hex-1__P2X1__no_interaction	hex-1__P2Y12__no_interaction	hex-1__P2Y6__no_interaction	uridine-5'-diphosphate__P2Y1__no_interaction	uridine-5'-diphosphate__P2X7__no_interaction	uridine-5'-diphosphate__P2Y2__no_interaction	uridine-5'-diphosphate__P2Y4__no_interaction	uridine-5'-diphosphate__P2X1__no_interaction	uridine-5'-diphosphate__P2Y12__no_interaction	uridine-5'-diphosphate__P2Y6__no_interaction	2,2-dimethyl-propionic acid__P2Y1__no_interaction	2,2-dimethyl-propionic acid__P2X7__no_interaction	2,2-dimethyl-propionic acid__P2Y2__no_interaction	2,2-dimethyl-propionic acid__P2Y4__no_interaction	2,2-dimethyl-propionic acid__P2X1__no_interaction	2,2-dimethyl-propionic acid__P2Y12__no_interaction	2,2-dimethyl-propionic acid__P2Y6__no_interaction	2-chloro__P2Y1__no_interaction	2-chloro__P2X7__no_interaction	2-chloro__P2Y2__no_interaction	2-chloro__P2Y4__no_interaction	2-chloro__P2X1__no_interaction	2-chloro__P2Y12__no_interaction	2-chloro__P2Y6__no_interaction	uridine-5'-triphosphate__P2Y1__no_interaction	uridine-5'-triphosphate__P2X7__no_interaction	uridine-5'-triphosphate__P2Y2__no_interaction	uridine-5'-triphosphate__P2Y4__no_interaction	uridine-5'-triphosphate__P2X1__no_interaction	uridine-5'-triphosphate__P2Y12__no_interaction	uridine-5'-triphosphate__P2Y6__no_interaction	Brilliant Blue G__P2Y1__no_interaction	Brilliant Blue G__P2X7__no_interaction	Brilliant Blue G__P2Y2__no_interaction	Brilliant Blue G__P2Y4__no_interaction	Brilliant Blue G__P2X1__no_interaction	Brilliant Blue G__P2Y12__no_interaction	Brilliant Blue G__P2Y6__no_interaction	MRS2365__P2Y1__no_interaction	MRS2365__P2X7__no_interaction	MRS2365__P2Y2__no_interaction	MRS2365__P2Y4__no_interaction	MRS2365__P2X1__no_interaction	MRS2365__P2Y12__no_interaction	MRS2365__P2Y6__no_interaction
7925342-2	Using 1H-NMR spectroscopy, 25 reduced oligosaccharides deriving from keratan <compound-id="1117">sulphate</compound-id> were shown to have the following structures [<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol represents <compound-id="165206">N-acetylglucosaminitol</compound-id> 6-O-<compound-id="1117">sulphate</compound-id>]: Gal beta 1-4-<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1-4GlcNAc(6S)-ol, Gal(6S)beta 1-4GlcNAc(6S)-ol, Gal-(6S)beta 1-4GlcNAc(6S) beta 1-3Gal beta 1-4GlcNAc(6S)-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal(6S)beta 1-4GlcNAc(6S)-ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal(6S)1-4GlcNAc(6S)-ol, Gal beta 1-4(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol, Gal beta 1-4-(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)beta1-3Gal beta 1-4(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1-4(Fuc alpha 1-3)-<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol, Gal beta 1-4(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)beta 1-3Gal beta 1-4GlcNAc(6S)-ol, Gal(6S) beta 1-4GlcNAc-(6S)beta 1-3Gal beta 1-4(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)-ol, Gal beta 1-4(Fuc alpha 1-3)<compound-id="24139,899">GlcNAc</compound-id>(6S)beta 1-3Gal(6S)1-4GlcNAc(6S)-ol, Gal beta 1-4GlcNAc(6S)<protein-id="G3MZC5">beta 1-6</protein-id>(Gal beta 1-3)<compound-id="165880">GalNAc-ol</compound-id>, Gal beta 1-4GlcNAc(6S) beta1-6(NeuAc2-3Gal beta 1-3)Gal-NAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1-4GlcNAc(6S)<protein-id="G3MZC5">beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1</protein-id>-4GlcNAc(6S)<protein-id="G3MZC5">beta 1-6</protein-id>(NeuAc2-3Gal beta 1-3)-<compound-id="165880">GalNAc-ol</compound-id>, Gal(6S)beta 1-4GlcNAc(6S)<protein-id="G3MZC5">beta 1-6</protein-id>(<compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-3)<compound-id="165880">GalNAc-ol</compound-id>, Gal(6S) beta 1-4GlcNAc-(6S)beta 1-3Gal beta 1-4GlcNAc(6S)<protein-id="G3MZC5">beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1</protein-id>-4GlcNAc-(6S)<protein-id="G3MZC5">beta 1-6</protein-id>(<compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-3)<compound-id="165880">GalNAc-ol</compound-id>, <compound-id="439197">NeuAc</compound-id> alpha 2-6Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1-4GlcNAc(6S)-ol, <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1-4GlcNAc(6S)-ol, <compound-id="439197">NeuAc</compound-id> alpha 2-6Gal beta 1-4GlcNAc(6S)beta 1-3Gal-(6S)beta 1-4GlcNAc(6S)-ol, <compound-id="439197">NeuAc</compound-id> alpha 2-3Gal beta 1-4GlcNAc(6S)beta 1-3Gal(6S)beta 1-4GlcNAc(6S)-ol and Neu-Ac alpha 2-3Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal(6S beta)1-4GlcNAc(6S)-ol.	sulphate__beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	sulphate__beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	sulphate__beta 1-6__no_interaction	N-acetylglucosaminitol__beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	N-acetylglucosaminitol__beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	N-acetylglucosaminitol__beta 1-6__no_interaction	GlcNAc__beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	GlcNAc__beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	GlcNAc__beta 1-6__no_interaction	NeuAc__beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	NeuAc__beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	NeuAc__beta 1-6__no_interaction	GalNAc-ol__beta 1-6(Gal beta 1-3) GalNAc-ol, Gal(6S)beta 1-4GlcNAc-(6S)beta 1-6(Gal beta 1-3)GalNAc-ol, Gal beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	GalNAc-ol__beta 1-6(Gal beta 1-3)GalNAc- ol, Gal(6S)beta 1-4GlcNAc(6S)beta 1-3Gal beta 1__no_interaction	GalNAc-ol__beta 1-6__no_interaction
11955284-2	We found the following: (1) externally added <compound-id="61503">D-lactate</compound-id> causes <compound-id="977">oxygen</compound-id> uptake by mitochondria [P/O ratio (the ratio of mol of <compound-id="5957">ATP</compound-id> synthesized to mol of <compound-id="977">oxygen</compound-id> atoms reduced to <compound-id="962">water</compound-id> during oxidative phosphorylation)=2] and membrane potential (Delta(psi)) generation in processes that are rotenone-insensitive, but inhibited by <compound-id="12550,16218979,6420045">antimycin A</compound-id> and <compound-id="768">cyanide</compound-id>, and <compound-id="1038,5460653">proton</compound-id> release from coupled mitochondria inhibited by <compound-id="643159">alpha-cyanocinnamate</compound-id>, but not by <compound-id="95459">phenylsuccinate</compound-id>; (2) the activity of the putative flavoprotein (<protein-id="Q7TPJ4,A0A0G2K1W9">D-lactate dehydrogenase</protein-id>) was detected in inside-out submitochondrial particles, but not in mitochondria and mitoplasts, as it is localized in the matrix phase of the mitochondrial inner membrane; (3) three novel separate translocators exist to mediate <compound-id="61503">D-lactate</compound-id> traffic across the mitochondrial inner membrane: the <compound-id="61503">D-lactate</compound-id>/H(+) symporter, which was investigated by measuring fluorimetrically the rate of endogenous <compound-id="2016">flavin</compound-id> reduction, the <compound-id="61503">D-lactate</compound-id>/oxoacid antiporter (which mediates both the <compound-id="54149437">D-lactate/pyruvate</compound-id> and <compound-id="53819535">D-lactate/oxaloacetate</compound-id> exchanges) and D-<compound-id="22164561">lactate/malate</compound-id> antiporter studied by monitoring photometrically the appearance of the <compound-id="61503">D-lactate</compound-id> counteranions outside mitochondria.	lactate/malate__D-lactate dehydrogenase__no_interaction	oxygen__D-lactate dehydrogenase__no_interaction	D-lactate/pyruvate__D-lactate dehydrogenase__no_interaction	alpha-cyanocinnamate__D-lactate dehydrogenase__no_interaction	D-lactate/oxaloacetate__D-lactate dehydrogenase__no_interaction	proton__D-lactate dehydrogenase__no_interaction	water__D-lactate dehydrogenase__no_interaction	antimycin A__D-lactate dehydrogenase__no_interaction	phenylsuccinate__D-lactate dehydrogenase__no_interaction	ATP__D-lactate dehydrogenase__no_interaction	cyanide__D-lactate dehydrogenase__no_interaction	D-lactate__D-lactate dehydrogenase__no_interaction	flavin__D-lactate dehydrogenase__no_interaction
8596492-5	<protein-id="P01241,B1A4G6,B1A4G7">Growth hormone</protein-id> (GH) (0.39 +/- 0.10 v 0.78 +/- 0.23 mg/L, P &lt; .05), <protein-id="P05019,Q5U743,Q13429,Q59GC5">insulin-like growth factor-1</protein-id> (<protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-1</protein-id>) (127 +/- 17 v 157 +/- 21 mg/L, P &lt; .05), and nonesterified fatty acids (NEFA) (239 +/- 25 v 405 +/- 44 mmol/L, P &lt; .01) were lower following <compound-id="383414,44420813,448601,57181882,86289069">octreotide</compound-id> administration.	octreotide__insulin-like growth factor-1__no_interaction	octreotide__IGF-1__no_interaction	octreotide__Growth hormone__no_interaction
12846561-2	The obtained data revealed (i) the extent of light-induced formation of about one Q(A)(-*)per 230 chlorophylls (Chl) remains virtually invariant to dehydration down to the lowest values of relative humidity (6-8% RH); (ii) a decrease of the RH to 30% leads to severe blockage of the electron transfer from Q(A)(-*) to Q(B) and the progressive replacement of <compound-id="962">water</compound-id> oxidation by photooxidation of high potential (HP) cytochrome (Cyt) b559 in untreated <protein-id="P49810,E5RG63">PS II</protein-id> samples or accessory Chl and <compound-id="441664,5368396">carotenoid</compound-id> (Car) molecules in samples with preoxidized Cyt b559; (iii) photooxidation of Cyt b559 is followed by its photoreduction, concomitant with photooxidation of Chl and Car; (iv) in dry samples with preoxidized Cyt b559, not more than a half of total Cyt b559 can be photochemically reduced, independent of the extent of Cyt b559 in the HP form; (v) at low RH values, Cyt b559 photoreduction in samples with preoxidized <compound-id="4971">heme</compound-id> groups and photoaccumulation of Q(A)(-*) take place with biphasic kinetics with similar rate constants for both processes; (vi) Cyt b559 photoreduction in dry samples is <compound-id="3120">DCMU</compound-id> insensitive, while the dark rereduction of photooxidized Cyt b559 is inhibited by <compound-id="3120">DCMU</compound-id>; (vii) fast and slow kinetic phases of Cyt b559 photoreduction dramatically differ in their dependencies on the intensity of CW illumination and are associated with electron donation to Cyt b559 from Q(A)(-*) and <compound-id="21252250,5280352">pheophytin</compound-id>(-*), respectively.	water__PS II__no_interaction	DCMU__PS II__no_interaction	pheophytin__PS II__no_interaction	carotenoid__PS II__no_interaction	heme__PS II__no_interaction
10494889-3	The rank order of affinity of tachykinins to compete for [125I]-BH <compound-id="10486632">bufokinin</compound-id> binding revealed similarities with that of the mammalian <protein-id="P25103">NK1</protein-id> receptor, being <compound-id="10486632">bufokinin</compound-id> (IC50, 1.7 nM)&gt;<compound-id="14717795,17268">physalaemin</compound-id> (6.7 nM)&gt;<protein-id="P20366,Q9Y494">substance P</protein-id> (SP, 10.7 nM)&gt; or =<protein-id="P20366,Q9Y494">neuropeptide gamma</protein-id> (NPgamma, 12.4 nM)&gt; or =<compound-id="45749">kassinin</compound-id> (17.8 nM)&gt;<compound-id="147048">scyliorhinin I</compound-id> (35.3 nM)&gt; or =<compound-id="10328936,6242">eledoisin</compound-id> (40.6 nM)&gt; or =<compound-id="16132440">carassin</compound-id> (43.2 nM)&gt; or =<protein-id="P20366,Q9Y494">neurokinin A</protein-id> (<protein-id="P20366,Q9Y494">NKA</protein-id>, 57.8 nM)&gt; or =<compound-id="5311312,55583">neurokinin B</compound-id> (<protein-id="Q9UHF0,A0A024RB97,A0A024RB47">NKB</protein-id>, 77.5 nM)&gt;scyliorhinin II (338 nM).	carassin__NKA__no_interaction	carassin__NKB__no_interaction	carassin__substance P__no_interaction	carassin__NK1__no_interaction	carassin__neurokinin A__no_interaction	carassin__neuropeptide gamma__no_interaction	physalaemin__NKA__no_interaction	physalaemin__NKB__no_interaction	physalaemin__substance P__no_interaction	physalaemin__NK1__no_interaction	physalaemin__neurokinin A__no_interaction	physalaemin__neuropeptide gamma__no_interaction	scyliorhinin I__NKA__no_interaction	scyliorhinin I__NKB__no_interaction	scyliorhinin I__substance P__no_interaction	scyliorhinin I__NK1__no_interaction	scyliorhinin I__neurokinin A__no_interaction	scyliorhinin I__neuropeptide gamma__no_interaction	bufokinin__NKA__no_interaction	bufokinin__NKB__no_interaction	bufokinin__substance P__no_interaction	bufokinin__NK1__no_interaction	bufokinin__neurokinin A__no_interaction	bufokinin__neuropeptide gamma__no_interaction	neurokinin B__NKA__no_interaction	neurokinin B__NKB__no_interaction	neurokinin B__substance P__no_interaction	neurokinin B__NK1__no_interaction	neurokinin B__neurokinin A__no_interaction	neurokinin B__neuropeptide gamma__no_interaction	eledoisin__NKA__no_interaction	eledoisin__NKB__no_interaction	eledoisin__substance P__no_interaction	eledoisin__NK1__no_interaction	eledoisin__neurokinin A__no_interaction	eledoisin__neuropeptide gamma__no_interaction	kassinin__NKA__no_interaction	kassinin__NKB__no_interaction	kassinin__substance P__no_interaction	kassinin__NK1__no_interaction	kassinin__neurokinin A__no_interaction	kassinin__neuropeptide gamma__no_interaction
20537920-7	In univariate analysis, the following variables were associated with the composite endpoint of patient death or allograft loss: 1-year serum <protein-id="P02768">albumin</protein-id> (hazard ratio [HR] = 0.52, P = .0009), 1-year serum <protein-id="P02768">albumin</protein-id> &lt;4.0 g/dL (HR = 1.81, P = .02), 1-year serum <compound-id="588">creatinine</compound-id> (HR = 3.55, P &lt; .00001), angiotensin converting enzyme inhibitors or angiotensin receptor blockers use (HR = 1.61, P = .03), a history of previous transplant (HR = 1.54, P = .04), months of dialysis before transplant (HR = 1.01, P = .00003), type of transplant (deceased donor HR = 1.64, P = .02), and acute rejection (HR = 1.52, P = .0000003).	creatinine__albumin__no_interaction
24114923-2	The two iodido complexes, (S(Os),S(C))-[Os(η(6)-p-cym)(ImpyMe)I]<protein-id="Q6Q759">PF6</protein-id> (complex 2, (S)-ImpyMe: N-(2-pyridylmethylene)-(S)-<compound-id="7408">1-phenylethylamine</compound-id>) and (R(Os),R(C))-[Os(η(6)-p-cym)(ImpyMe)I]<protein-id="Q6Q759">PF6</protein-id> (complex 4, (R)-ImpyMe: N-(2-pyridylmethylene)-(R)-<compound-id="7408">1-phenylethylamine</compound-id>), showed higher anticancer activity (lower IC50 values) towards A2780 human ovarian cancer cells than cisplatin and were more active than the two chlorido derivatives, (S(Os),S(C))-[Os(η(6)-p-cym)(ImpyMe)Cl]<protein-id="Q6Q759">PF6</protein-id>, 1, and (R(Os),R(C))-[Os(η(6)-p-cym)(ImpyMe)Cl]<protein-id="Q6Q759">PF6</protein-id>, 3.	1-phenylethylamine__PF6__no_interaction
2285188-3	We have studied the changes in plasma lipids profile and plasma lipoprotein <compound-id="5997">cholesterol</compound-id> distribution in cord blood from 109 term newborn infants and 16 newborn infants have got higher plasma lipid concentrations than term newborn infants (total <compound-id="5997">cholesterol</compound-id>: 76.81 +/- 4.67 mg/dl (mean +/- <compound-id="5289348">SEM</compound-id>) vs 66.72 +/- 1.54 mg/dl, p less than 0.02; Phospholipids: 136.00 +/- 5.24 mg/dl vs 113.94 +/- 2.86 mg/dl, p less than 0.005) and a different <compound-id="5997">cholesterol</compound-id> lipoprotein distribution compared to normal full-term infants, standing out in premature babies, that <compound-id="5997">cholesterol</compound-id> is essentially joint with low density lipoproteins (<protein-id="Q14746,B1ALW7">LDLc</protein-id>: 42.40 +/- 3.62 mg/dl vs 28.76 +/- 1.16 mg/dl, p less than 0.01).	SEM__LDLc__no_interaction	cholesterol__LDLc__no_interaction
22776871-7	Levels were higher after cycling with <compound-id="3672">ibuprofen</compound-id> than after cycling without <compound-id="3672">ibuprofen</compound-id>, rest with <compound-id="3672">ibuprofen</compound-id>, or rest without <compound-id="3672">ibuprofen</compound-id> (peak <protein-id="P12104">I-FABP</protein-id>, 875 ± 137, 474 ± 74, 507 ± 103, and 352 ± 44 pg·mL, respectively, P &lt; 0.002).	ibuprofen__I-FABP__no_interaction
24196533-4	We found that 1) PP1γ, but not α or β isoform, enhanced the splicing of CaMKIIδ in HEK293T cells; 2) PP1γ promoted the function of ASF, evidenced by the existence of ASF-PP1γ association as well as the PP1γ overexpression- or silencing-mediated change in CaMKIIδ splicing in ASF-transfected HEK293T cells; 3) CaMKIIδ splicing was promoted by overexpression of PP1γ and impaired by application of PP1 inhibitor 1 (I1PP1) or pharmacological inhibitor <compound-id="128956,16759609,56996242,6439037">tautomycetin</compound-id> in primary cardiomyocytes; 4) CaMKIIδ splicing and enhancement of ASF-PP1γ association induced by <compound-id="977">oxygen</compound-id>-<compound-id="206,5793,64689,79025">glucose</compound-id> deprivation followed by reperfusion (<protein-id="P11362">OGD</protein-id>/R) were potentiated by overexpression of PP1γ and suppressed by inhibition of PP1γ with I1PP1 or <compound-id="128956,16759609,56996242,6439037">tautomycetin</compound-id> in primary cardiomyocytes; 5) functionally, overexpression and inhibition of PP1γ, respectively, potentiated or suppressed the apoptosis and <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">Bax</protein-id>/<protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> ratio, which were associated with the enhanced activity of CaMKII in <protein-id="P11362">OGD</protein-id>/R-stimulated cardiomyocytes; and 6) CaMKII was required for the <protein-id="P11362">OGD</protein-id>/R induced- and PP1γ exacerbated-apoptosis of cardiomyocytes, evidenced by a specific inhibitor of CaMKII <compound-id="5312122">KN93</compound-id>, but not its structural analog <compound-id="5353702">KN92</compound-id>, attenuating the apoptosis and <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">Bax</protein-id>/<protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl-2</protein-id> ratio in <protein-id="P11362">OGD</protein-id>/R and PP1γ-treated cells.	tautomycetin__OGD__no_interaction	tautomycetin__Bcl-2__no_interaction	tautomycetin__Bax__no_interaction	KN92__OGD__no_interaction	KN92__Bcl-2__no_interaction	KN92__Bax__no_interaction	KN93__OGD__no_interaction	KN93__Bcl-2__no_interaction	KN93__Bax__no_interaction	oxygen__OGD__no_interaction	oxygen__Bcl-2__no_interaction	oxygen__Bax__no_interaction	glucose__OGD__no_interaction	glucose__Bcl-2__no_interaction	glucose__Bax__no_interaction
20546490-3	" RESULTS: Twenty papers presented the following findings: (1) previous use of a removable prosthesis is a risk factor for resorption, with flabby tissues related to the severity of resorption; (2) implants in the reconstructed maxilla (&lt; or =5 mm) and supporting overdentures had a higher risk for bone loss based on the worse periimplant soft-tissue health observed; (3) bleeding on probing was found with pocket depths &gt; or =5 mm in half of the zygomatic implants; (4) prevalence of bone septa is higher in atrophic maxillae, and changes on nasopalatine canal can reduce up to 44.4% of the full length of buccal bone plates; (5) female patients have less medullar bone quantity and connectivity than male patients; (6) transectioning of nutrient vessels is easier and accelerates resorption; (7) stress does not concentrate on maxillary sinus base cortical bone contiguous to trabecular bone; (8) splinted implants receive nine times less load than nonsplinted implants even under oblique loading; (9) implant stability quotient (<compound-id="8405">ISQ</compound-id>) values for implants ranged between 60 and 65; (10) in vivo force transfer to implants is similar between fixed prostheses and overdentures; (11) inclined implants generate better biomechanical responses; (12) masticatory efficiency and bite forces improve in maxillectomized patients who receive obturators with milled <protein-id="P07550">bar</protein-id> attachments.	ISQ__bar__no_interaction
11147782-9	Regression analysis revealed a significant negative correlation between BMI (r = -0.676, P &lt; 0.0001), WHR (r = -0.631, P &lt; 0.0001), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -0.695, P &lt; 0.0001), HOMA-IR (r = -0.633, P &lt; 0.0001), and percent peak increase in FBF during <compound-id="187">ACh</compound-id> infusion.	ACh__insulin__no_interaction
20162392-7	Our results showed that (i) fluoxetine was potent in inhibiting both the uptake of [H(3)]DA (IC(50) = 0.21 +/- 0.032 mM, n = 3) and the [I(125)]<compound-id="18618996">RTI-55</compound-id> binding (IC(50) = 0.23 +/- 0.012 mM, n = 10); (ii) N-methyl amine substituted fluoxetine analogues, FD-2 and FD-4 were equally or more potent than fluoxetine itself in terms of inhibition of [H(3)]DA uptake (IC50 FD-2: 0.077 +/- 0.0032 mM (n = 3); FD-4: 0.26 +/- 0.13 mM (n = 3), inhibition of [I(125)]<compound-id="18618996">RTI-55</compound-id> binding, and reduction in <protein-id="Q01959">DA transporter</protein-id>-associated currents, suggesting that these analogues could be a new class of <compound-id="681">dopamine</compound-id> transporter inhibitors.	RTI-55__DA transporter__no_interaction	dopamine__DA transporter__no_interaction
22653268-1	Ionic complexes containing μ(2)-hydroxo-bonded (MgPc)(2)OH(-) <compound-id="5282330">phthalocyanine</compound-id> assemblies and C(60)(-) anions: {(MgPc)(2)OH(-)}(2)·(C(60)(-))(2)·(PMDAE(+))(4)·(C(6)H(5)CN)(4) (1); {(MgPc)(2)OH(-)}(2)·(C(60)(-))(2)·(<protein-id="P54849,A0A024RAT0">TMP</protein-id>(+))(4)·(C(6)H(5)CN)(3)·(C(6)H(4)Cl(2))(2.5) (2) (where PMDAE(+) is the cation of N,N,N',N',N'-pentamethyldiaminoethane and <protein-id="P54849,A0A024RAT0">TMP</protein-id>(+) is the N,N'N'-<compound-id="21683837">trimethylpiperazinium</compound-id> cation) have been obtained as single crystals.	phthalocyanine__TMP__no_interaction	trimethylpiperazinium__TMP__no_interaction
16602807-1	Complexes [PPh3Cu(Tr(<protein-id="Q9NXB0">Mes</protein-id>,Me))] (1), [PPh3Cu(Tr(Me,o-Py))] (2), and [PPh3Cu(Br(<protein-id="Q9NXB0">Mes</protein-id>)pz(o-Py))] (3) (Tr(<protein-id="Q9NXB0">Mes</protein-id>,Me) = <compound-id="91483995">hydrotris[1,4-dihydro-3-methyl-4-mesityl-5-thioxo-1,2,4-triazolyl]borate</compound-id>; Tr(Me,o-Py) = <compound-id="91287477">hydrotris[1,4-dihydro-4-methyl-3-(2-pyridyl)-5-thioxo-1,2,4-triazolyl]borate</compound-id>; Br(<protein-id="Q9NXB0">Mes</protein-id>)pz(o-Py) = <compound-id="90742644">hydro[bis(thioxotriazolyl)-3-(2-pyridyl)pyrazolyl]borate</compound-id>; <protein-id="P60510,A0A024R625">PPh3</protein-id> = triphenylphosphine) were synthesized by the reaction of dinuclear complexes [Cu(Tr(<protein-id="Q9NXB0">Mes</protein-id>,Me))]2, [Cu(Tr(Me,o-Py))]2, [Cu(Br(<protein-id="Q9NXB0">Mes</protein-id>)pz(o-Py))]2, and <protein-id="P60510,A0A024R625">PPh3</protein-id>.	hydrotris[1,4-dihydro-3-methyl-4-mesityl-5-thioxo-1,2,4-triazolyl]borate__Mes__no_interaction	hydrotris[1,4-dihydro-3-methyl-4-mesityl-5-thioxo-1,2,4-triazolyl]borate__PPh3__no_interaction	hydrotris[1,4-dihydro-4-methyl-3-(2-pyridyl)-5-thioxo-1,2,4-triazolyl]borate__Mes__no_interaction	hydrotris[1,4-dihydro-4-methyl-3-(2-pyridyl)-5-thioxo-1,2,4-triazolyl]borate__PPh3__no_interaction	hydro[bis(thioxotriazolyl)-3-(2-pyridyl)pyrazolyl]borate__Mes__no_interaction	hydro[bis(thioxotriazolyl)-3-(2-pyridyl)pyrazolyl]borate__PPh3__no_interaction
21149567-3	To analyze the mechanism of <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> recruitment, we manipulated the expression of mitochondrial fission and fusion proteins and demonstrated that (a) <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">mitochondrial fission factor</protein-id> (<protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id>) knockdown released the <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> foci from the <compound-id="5282188">MOM</compound-id> accompanied by network extension, whereas <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id> overexpression stimulated mitochondrial recruitment of <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> accompanied by mitochondrial fission; (b) <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id>-dependent mitochondrial fission proceeded independent of <protein-id="Q9Y3D6">Fis1</protein-id>; (c) a <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id> mutant with the plasma membrane-targeted CAAX motif directed <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> to the target membrane; (d) <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id> and <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> physically interacted in vitro and in vivo; (e) exogenous stimuli-induced mitochondrial fission and apoptosis were compromised by knockdown of <protein-id="Q14194,B3KT07,E9PD68,Q96I11,B3KV96,X5DNI1">Drp1</protein-id> and <protein-id="Q9GZY8,A0A024R491,A0A0A0MS29">Mff</protein-id> but not <protein-id="Q9Y3D6">Fis1</protein-id>; and (f) conditional knockout of <protein-id="Q9Y3D6">Fis1</protein-id> in colon carcinoma cells revealed that it is dispensable for mitochondrial fission.	MOM__mitochondrial fission factor__no_interaction	MOM__Drp1__no_interaction	MOM__Fis1__no_interaction	MOM__Mff__no_interaction
15388725-3	To evaluate this group of organisms, clinical reference isolates and the type strains of M. fortuitum third biovariant complex sorbitol-negative (n = 21), M. fortuitum third biovariant complex sorbitol-positive (n = 3), M. fortuitum (n = 3), Mycobacterium peregrinum (<compound-id="4831">pipemidic acid</compound-id>-susceptible) (n = 1), Mycobacterium porcinum (n = 1), Mycobacterium senegalense (n = 2) and Mycobacterium septicum (n = 1) were characterized by using conventional phenotypic (morphological, physiological and antimicrobial susceptibilities), chemotaxonomic (HPLC and cellular fatty acids) and genotypic [RFLP of the rRNA gene (ribotyping), PCR-RFLP of a 439 bp segment of the 65 kDa <protein-id="O53673">hsp</protein-id> gene (PCR restriction analysis) and 16S rRNA gene sequence] analysis, DNA G + C content and DNA-DNA relatedness analyses.	pipemidic acid__hsp__no_interaction
16814821-6	Factors associated with higher mortality in univariate analysis included male gender (relative risk (RR) 1.96, 95% CI 1.17-2.28), age &gt;40 years (RR 2.61, 95% CI 1.25-5.45), jaundice (RR 2.66, 95% CI 2.12-3.35), serum <protein-id="Q9NRA2">aspartate aminotransferase</protein-id> (<protein-id="Q9NRA2">AST</protein-id>) &gt;1200 IU/l (RR 1.84, 95% CI 1.23-2.74), <compound-id="5950,602">alanine</compound-id> aminotransferase &gt;1500 IU/l (RR 2.09, 95% CI 1.38-3.17), total <compound-id="5280352">bilirubin</compound-id> &gt;7.0mg/dl (RR 2.33, 95% CI 1.44-3.78), direct <compound-id="5280352">bilirubin</compound-id> &gt;5.0mg/dl (RR 2.29, 95% CI 1.33-3.94) and blood <compound-id="1176">urea</compound-id> <compound-id="947">nitrogen</compound-id> &gt;100mg/dl (RR 5.77, 95% CI 1.43-23.22).	bilirubin__aspartate aminotransferase__no_interaction	bilirubin__AST__no_interaction	urea__aspartate aminotransferase__no_interaction	urea__AST__no_interaction	alanine__aspartate aminotransferase__no_interaction	alanine__AST__no_interaction	nitrogen__aspartate aminotransferase__no_interaction	nitrogen__AST__no_interaction
10585175-11	Although serum <protein-id="P02768">albumin</protein-id> levels did not change throughout life, <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P02768">albumin</protein-id> levels and <compound-id="16122568,16750043,4369303,448383">CSF</compound-id>/serum <protein-id="P02768">albumin</protein-id> ratios increased gradually with age (r = 0.28, P = 0.052; r = 0.23, P = 0.114, respectively), but there was no significance.	CSF__albumin__no_interaction
20536218-2	Described herein is a catalyst system for <compound-id="241">benzene</compound-id> hydrogenation to <compound-id="8078">cyclohexane</compound-id> consisting of "weakly ligated/labile ligand" Ir(0) nanoparticles and aggregates plus dry-HCl formed in situ from commercially available [(1,5-<protein-id="P14678,Q66K91">COD</protein-id>)IrCl](2) plus 40 +/- 1 psig (approximately 2.7 atm) H(2) at 22 +/- 0.1 degrees C. Multiple control and other experiments reveal the following points: (i) that this catalyst system is quite active with a TOF (turnover frequency) of 25 h(-1) and TTO (total turnovers) of 5250; (ii) that the BF(4)(-) and PF(6)(-) <compound-id="23924">iridium</compound-id> salt precursors, [(1,5-<protein-id="P14678,Q66K91">COD</protein-id>)Ir(CH(3)CN)(2)]BF(4) and [(1,5-<protein-id="P14678,Q66K91">COD</protein-id>)Ir(CH(3)CN)(2)]PF(6), yield inferior catalysts; (iii) that <compound-id="23924">iridium</compound-id> black with or without added, preformed HCl cannot achieve the TOF of 25 h(-1) of the in situ formed Ir(0)/dry-HCl catalyst.	benzene__COD__no_interaction	cyclohexane__COD__no_interaction	iridium__COD__no_interaction
24152141-10	The use of hepatic cytochrome P450 (Cyp) reductase null (HRN) mice, in which <compound-id="5884">NADPH</compound-id>:Cyp oxidoreductase (<protein-id="P37040">Por</protein-id>) is deleted in hepatocytes, <protein-id="P00184,Q05A20">Cyp1a1</protein-id>((-/-)), <protein-id="P00186,B6VGH4">Cyp1a2</protein-id>((-/-)) single-knockout, <protein-id="P00184,Q05A20">Cyp1a1</protein-id>/1a2((-/-)) double-knockout and CYP1A-humanized mice revealed that mouse and human <protein-id="P00184,Q05A20">Cyp1a1</protein-id> and 1A2, besides mouse <compound-id="5893">NAD</compound-id>(P)H: <compound-id="4650">quinone</compound-id> oxidoreductase, were involved in the activation of AAI but <protein-id="P00184,Q05A20">Cyp1a1</protein-id> and 1A2 also oxidatively detoxified AAI. 	NADPH__Cyp1a1__no_interaction	NADPH__Cyp1a2__no_interaction	NADPH__Por__no_interaction	quinone__Cyp1a1__no_interaction	quinone__Cyp1a2__no_interaction	quinone__Por__no_interaction	NAD__Cyp1a1__no_interaction	NAD__Cyp1a2__no_interaction	NAD__Por__no_interaction
21126427-5	RESULTS: compared with the control group [<compound-id="119">GABA</compound-id>: (3.41 ± 0.12) micromol/g, Glu (14.00 ± 0.16) micromol/g, Gln (1.25 ± 0.19) micromol/g, <protein-id="P48320,Q548L4">GAD</protein-id> (13.50 ± 0.25) micromol × g(-1) × h(-1), <protein-id="P61922">GABA-T</protein-id> (25.51 ± 0.21) micromol × g(-1) × h(-1), GS(142.19 ± 1.31) U/mg pro], the level of <compound-id="119">GABA</compound-id> [(3.14 ± 0.14) micromol/g] was decreased (P &lt; 0.05), whereas the level of Glu [(17.54 ± 0.40) micromol/g] and Gln [(3.35 ± 0.27) micromol/g] were increased (P &lt; 0.05), the activity of <protein-id="P48320,Q548L4">GAD</protein-id> [(11.93 ± 0.15 micromol × g(-1) × h(-1)], <protein-id="P61922">GABA-T</protein-id> [(24.15 ± 0.22) micromol × g(-1) × h(-1)], GS [(140.75 ± 1.01) U/mg pro] was decreased (P &lt; 0.05) in acute intoxication group; Compared with the acute intoxication group, the level of <compound-id="119">GABA</compound-id> [(3.52 ± 0.30) micromol/g] was increased (P &lt; 0.05), whereas the level of Glu [(14.20 ± 0.32) micromol/g] and Gln [(1.32 ± 0.17) micromol/g] were decreased (P &lt; 0.05), the activity of <protein-id="P48320,Q548L4">GAD</protein-id> [(13.01 ± 0.45 micromol × g(-1) × h(-1)], <protein-id="P61922">GABA-T</protein-id> [(25.19 ± 0.26) micromol × g(-1) × h(-1), GS [(142.35 ± 1.20) U/mg pro] was increased (P &lt; 0.05); In contrast, the levels of <compound-id="119">GABA</compound-id>, Glu, Gln and the activity of <protein-id="P48320,Q548L4">GAD</protein-id>, <protein-id="P61922">GABA-T</protein-id>, and GS in Na-DMPS protection group were not significantly different in comparison with control group (P &gt; 0.05).	GABA__GAD__no_interaction	GABA__GABA-T__no_interaction
15736116-11	Univariate regression analysis showed that insulin resistance was positively correlated to <protein-id="P16581">E-selectin</protein-id> (r = 0.305, P = .003), BMI (r = 0.283, P = .006), <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = 0.296, P = .004), HbA1c (r = 0.241, P = .018), serum triglycerides (r = 0.385, P &lt; .001), serum total (r = 0.240, P = .019) and LDL <compound-id="5997">cholesterol</compound-id> (r = 0.254, P = .013) levels, and systolic (r = 0.247, P = .024) and diastolic (r = 0.305, P = .006) blood pressure.	cholesterol__E-selectin__no_interaction	cholesterol__leptin__no_interaction
1951733-4	We found that 1) platelets adhered to both types of protein-coated surfaces but not to uncoated glass; 2) platelets that adhered to <protein-id="P02675,V9HVY1">fibrinogen</protein-id> were nonoverlapping, clustering, and saturated at approximately 40 cells/1,000 microns 2 at 445 s-1 surface shear rate and at approximately 60 cells/1,000 microns 2 at 70 s-1 surface shear rate; 3) platelets that adhered to fibrin were nonoverlapping, random, and saturated at approximately 55 cells/1,000 microns 2 at 445 s-1 surface shear rate and at approximately 65 cells/1,000 microns 2 at 70 s-1 surface shear rate; 4) ethyleneglycol- bis(beta-aminoethylether)-N,N'-<compound-id="176">tetraacetic acid</compound-id>, the snake venom halysin (against glycoprotein IIb-IIIa complex), and monoclonal antibody <compound-id="29962">Ab-15</compound-id> (against glycoprotein IIIa) blocked platelet adhesion to both surfaces; 5) <compound-id="107775">Arg-Gly-Asp-Ser</compound-id> and monoclonal antibody LIBS-1 (against glycoprotein IIIa) partially inhibited platelet adhesion to <protein-id="P02675,V9HVY1">fibrinogen</protein-id>-coated surface but were almost ineffective in preventing platelet adhesion to fibrin-coated surface; and 6) monoclonal antibody Ab-144 (against glycoprotein Ib) was ineffective for platelet adhesion on both surfaces.	Arg-Gly-Asp-Ser__fibrinogen__no_interaction	Ab-15__fibrinogen__no_interaction	tetraacetic acid__fibrinogen__no_interaction
24163441-6	As <protein-id="P41220,A0A024R939">RGS2</protein-id> is a GTPase-activating protein that switches off Gαq, intracellular free <compound-id="22044544,5460341">calcium</compound-id> ([Ca(2+)]i) flux was used as a surrogate of responses induced by <compound-id="774">histamine</compound-id>, <compound-id="1993">methacholine</compound-id>, and the <compound-id="114873">thromboxane</compound-id> receptor agonist <compound-id="5311493">U46619</compound-id> [(Z)-7-[(1S,4R,5R,6S)-5-[(E,<compound-id="21439199">3S</compound-id>)-3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]<compound-id="8900">heptan</compound-id>-6-yl]<compound-id="44134911">hept-5-enoic acid</compound-id>].	hept-5-enoic acid__RGS2__no_interaction	thromboxane__RGS2__no_interaction	U46619__RGS2__no_interaction	3S__RGS2__no_interaction	heptan__RGS2__no_interaction	calcium__RGS2__no_interaction	methacholine__RGS2__no_interaction	histamine__RGS2__no_interaction
15476746-2	Intrathecal 5-HT suppressed both phases of behaviors produced by 5% <compound-id="712">formalin</compound-id>, and this was blocked by antagonists for <protein-id="P28564">5-HT(1B</protein-id>) (3-[3-(Dimethylamino)propyl]-4-hy-droxy-N-[4-(<compound-id="12594992">4-pyridinyl</compound-id>)phenyl]benzamide dihydrochloride, GR 55562), <protein-id="P08909,Q62842">5-HT(2C</protein-id>) (N-ormethylclozapine/8-Chloro-11-(1-piperazinyl)-5H-<compound-id="12524051">dibenzo[b,e][1,4]diazepine</compound-id>, D-MC), <protein-id="P35563,Q62999">5-HT3</protein-id> (<compound-id="3970">1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide maleate</compound-id>, LY-278,584) and 5-<compound-id="12306961">HT4</compound-id> receptors (4-Amino-5-chloro-2-metho-xy-<compound-id="243">benzoic acid</compound-id> 2-(diethylamino)<compound-id="23134249">ethyl</compound-id> ester hydrochloride, <compound-id="446129">SDZ</compound-id>-205,557), but not the 5-HT(1D) receptor antagonist <compound-id="11509723">3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride</compound-id> (<compound-id="3654103">BRL 15572</compound-id>).	formalin__5-HT(1B__no_interaction	formalin__5-HT(2C__no_interaction	formalin__5-HT3__no_interaction	dibenzo[b,e][1,4]diazepine__5-HT(1B__no_interaction	dibenzo[b,e][1,4]diazepine__5-HT(2C__no_interaction	dibenzo[b,e][1,4]diazepine__5-HT3__no_interaction	1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide maleate__5-HT(1B__no_interaction	1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide maleate__5-HT(2C__no_interaction	1-Methyl-N-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1H-indazole-3-carboxamide maleate__5-HT3__no_interaction	3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride__5-HT(1B__no_interaction	3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride__5-HT(2C__no_interaction	3-[4-(4-Chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol hydrochloride__5-HT3__no_interaction	SDZ__5-HT(1B__no_interaction	SDZ__5-HT(2C__no_interaction	SDZ__5-HT3__no_interaction	BRL 15572__5-HT(1B__no_interaction	BRL 15572__5-HT(2C__no_interaction	BRL 15572__5-HT3__no_interaction	benzoic acid__5-HT(1B__no_interaction	benzoic acid__5-HT(2C__no_interaction	benzoic acid__5-HT3__no_interaction	HT4__5-HT(1B__no_interaction	HT4__5-HT(2C__no_interaction	HT4__5-HT3__no_interaction	4-pyridinyl__5-HT(1B__no_interaction	4-pyridinyl__5-HT(2C__no_interaction	4-pyridinyl__5-HT3__no_interaction	ethyl__5-HT(1B__no_interaction	ethyl__5-HT(2C__no_interaction	ethyl__5-HT3__no_interaction
18806898-1	(+)-<compound-id="71353">Dapoxetine hydrochloride</compound-id>, (R)-<compound-id="3308">Etodolac</compound-id>; Abatacept, <compound-id="6918562">ABT-510</compound-id>, Adalimumab, Agatolimod <compound-id="5360545">sodium</compound-id>, Alemtuzumab, <compound-id="5287969">Alvocidib hydrochloride</compound-id>, <compound-id="157922">Aminolevulinic acid methyl ester</compound-id>, <compound-id="60795">Aripiprazole</compound-id>, AS01B, AS02B, AS02V, <compound-id="9444">Azacitidine</compound-id>; <compound-id="101524">Becatecarin</compound-id>, Bevacizumab, <compound-id="457928">Bevirimat</compound-id>, <compound-id="387447">Bortezomib</compound-id>, <compound-id="9941379">Bremelanotide</compound-id>; CAIV-T, <compound-id="5312109">Canfosfamide hydrochloride</compound-id>, CHR-2797, <compound-id="6918155">Ciclesonide</compound-id>, <compound-id="153994">Clevidipine</compound-id>; Darbepoetin alfa, <compound-id="451668">Decitabine</compound-id>, <compound-id="16136245,44151801,44398263">Degarelix</compound-id> <compound-id="176">acetate</compound-id>, Dendritic cell-based vaccine, Denosumab, <compound-id="124087">Desloratadine</compound-id>, <compound-id="5310985">DMXB-Anabaseine</compound-id>, <compound-id="60835">Duloxetine hydrochloride</compound-id>, <compound-id="6918296">Dutasteride</compound-id>; Ecogramostim, <compound-id="446284">Eicosapentaenoic acid</compound-id>/<compound-id="3144,445580">docosahexaenoic acid</compound-id>, <compound-id="77993">Eletriptan</compound-id>, <compound-id="176167">Enzastaurin</compound-id> hydrochloride, <compound-id="176870">Erlotinib hydrochloride</compound-id>, <compound-id="146570">Escitalopram oxalate</compound-id>, <compound-id="123619">Etoricoxib</compound-id>, Everolimus, <compound-id="150311">Ezetimibe</compound-id>, <compound-id="9832423">Ezetimibe/simvastatin</compound-id>; Ferumoxytol, <compound-id="6918558">Fesoterodine fumarate</compound-id>, <compound-id="104741">Fulvestrant</compound-id>; <compound-id="123631">Gefitinib</compound-id>, GM-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id> DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human <protein-id="P05230,A8K147,Q16089">Fibroblast Growth Factor 1</protein-id>, <compound-id="5281051">Hypericin</compound-id>-PVP; <compound-id="6918173">Icatibant acetate</compound-id>, <compound-id="213043">Iclaprim</compound-id>, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-<protein-id="P60568,Q0GK43">IL-2</protein-id>, Lapuleucel-T, <compound-id="9867642">Laropiprant</compound-id>, Liposomal <compound-id="31703">doxorubicin</compound-id>, <compound-id="15603282">LP-261</compound-id>, <compound-id="151166">Lumiracoxib</compound-id>, LY-518674; MDV-3100, <compound-id="9865515">MGCD-0103</compound-id>, <compound-id="9865528">Mirabegron</compound-id>, MyoCell; NASHA/Dx, <compound-id="938">Niacin</compound-id>/<compound-id="9867642">laropiprant</compound-id>; <compound-id="4578">O6-Benzylguanine</compound-id>, Ocrelizumab, <compound-id="130881">Olmesartan medoxomil</compound-id>, Omalizumab; P-276-00, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="36314,441276,44155032,4666,53313247,5352019,6713921,6915727">Paclitaxel</compound-id> nanoparticles, <compound-id="9809054">Padoporfin</compound-id>, <compound-id="115237">Paliperidone</compound-id>, <compound-id="9571836">PAN-811</compound-id>, <compound-id="158786">Pegaptanib octasodium</compound-id>, Pegfilgrastim, <compound-id="60843,394493,446556">Pemetrexed disodium</compound-id>, PF-00299804, <compound-id="16051947,17753757,24847863,3055172,53394893,53486290,6447131,6509979,71751667,91562575">Pimecrolimus</compound-id>, <compound-id="6918456">Prasugrel</compound-id>, <compound-id="5486971">Pregabalin</compound-id>; Reolysin, <compound-id="104850">Rimonabant</compound-id>, <compound-id="9875401">Rivaroxaban</compound-id>, <compound-id="12136802,6239562,4979943,446157,6436659,6439133,656606">Rosuvastatin calcium</compound-id>; <compound-id="6918220">Satraplatin</compound-id>, SCH-697243,<compound-id="24934">Selenite sodium</compound-id>, <compound-id="5312125">Silodosin</compound-id>, <compound-id="216239">Sorafenib</compound-id>, <compound-id="5329102">Sunitinib malate</compound-id>; <compound-id="9799888">Talarozole</compound-id>, Taxus, <compound-id="148191,18293306,23724530,24847874,53486199,54608508,6918289,71296107,71312019,71433778,86277830,86287409,9876533">Temsirolimus</compound-id>, Tocilizumab, Tolevamer <compound-id="16211683">potassium sodium</compound-id>, Tremelimumab, <compound-id="64968">TTP</compound-id>-889; <compound-id="1174,90983865">Uracil</compound-id>; V-260, <compound-id="60846">Valsartan</compound-id>/<compound-id="2162">amlodipine besylate</compound-id>, <compound-id="110634">Vardenafil hydrochloride</compound-id> hydrate, <compound-id="170362,46783232,53486179,6918678,9906942">Varenicline tartrate</compound-id>, <compound-id="155815">Varespladib</compound-id>, Vitespen, <compound-id="6918486">Voclosporin</compound-id>, <compound-id="39793">VX</compound-id>-001; <compound-id="71316700">Xience V</compound-id>; <compound-id="23375907,52945214,53398674,91450784,9876378">Zotarolimus</compound-id>-eluting stent.	Niacin__Fibroblast Growth Factor 1__no_interaction	Niacin__IL-2__no_interaction	Ciclesonide__Fibroblast Growth Factor 1__no_interaction	Ciclesonide__IL-2__no_interaction	Canfosfamide hydrochloride__Fibroblast Growth Factor 1__no_interaction	Canfosfamide hydrochloride__IL-2__no_interaction	Erlotinib hydrochloride__Fibroblast Growth Factor 1__no_interaction	Erlotinib hydrochloride__IL-2__no_interaction	Aminolevulinic acid methyl ester__Fibroblast Growth Factor 1__no_interaction	Aminolevulinic acid methyl ester__IL-2__no_interaction	Satraplatin__Fibroblast Growth Factor 1__no_interaction	Satraplatin__IL-2__no_interaction	Icatibant acetate__Fibroblast Growth Factor 1__no_interaction	Icatibant acetate__IL-2__no_interaction	LP-261__Fibroblast Growth Factor 1__no_interaction	LP-261__IL-2__no_interaction	Pegaptanib octasodium__Fibroblast Growth Factor 1__no_interaction	Pegaptanib octasodium__IL-2__no_interaction	Talarozole__Fibroblast Growth Factor 1__no_interaction	Talarozole__IL-2__no_interaction	amlodipine besylate__Fibroblast Growth Factor 1__no_interaction	amlodipine besylate__IL-2__no_interaction	acetate__Fibroblast Growth Factor 1__no_interaction	acetate__IL-2__no_interaction	VX__Fibroblast Growth Factor 1__no_interaction	VX__IL-2__no_interaction	Dutasteride__Fibroblast Growth Factor 1__no_interaction	Dutasteride__IL-2__no_interaction	Degarelix__Fibroblast Growth Factor 1__no_interaction	Degarelix__IL-2__no_interaction	Laropiprant__Fibroblast Growth Factor 1__no_interaction	Laropiprant__IL-2__no_interaction	MGCD-0103__Fibroblast Growth Factor 1__no_interaction	MGCD-0103__IL-2__no_interaction	PAN-811__Fibroblast Growth Factor 1__no_interaction	PAN-811__IL-2__no_interaction	potassium sodium__Fibroblast Growth Factor 1__no_interaction	potassium sodium__IL-2__no_interaction	Hypericin__Fibroblast Growth Factor 1__no_interaction	Hypericin__IL-2__no_interaction	Azacitidine__Fibroblast Growth Factor 1__no_interaction	Azacitidine__IL-2__no_interaction	Etodolac__Fibroblast Growth Factor 1__no_interaction	Etodolac__IL-2__no_interaction	Pregabalin__Fibroblast Growth Factor 1__no_interaction	Pregabalin__IL-2__no_interaction	sodium__Fibroblast Growth Factor 1__no_interaction	sodium__IL-2__no_interaction	Padoporfin__Fibroblast Growth Factor 1__no_interaction	Padoporfin__IL-2__no_interaction	TTP__Fibroblast Growth Factor 1__no_interaction	TTP__IL-2__no_interaction	Gefitinib__Fibroblast Growth Factor 1__no_interaction	Gefitinib__IL-2__no_interaction	Ezetimibe__Fibroblast Growth Factor 1__no_interaction	Ezetimibe__IL-2__no_interaction	Sunitinib malate__Fibroblast Growth Factor 1__no_interaction	Sunitinib malate__IL-2__no_interaction	Dapoxetine hydrochloride__Fibroblast Growth Factor 1__no_interaction	Dapoxetine hydrochloride__IL-2__no_interaction	Mirabegron__Fibroblast Growth Factor 1__no_interaction	Mirabegron__IL-2__no_interaction	ABT-510__Fibroblast Growth Factor 1__no_interaction	ABT-510__IL-2__no_interaction	Fesoterodine fumarate__Fibroblast Growth Factor 1__no_interaction	Fesoterodine fumarate__IL-2__no_interaction	DMXB-Anabaseine__Fibroblast Growth Factor 1__no_interaction	DMXB-Anabaseine__IL-2__no_interaction	Pimecrolimus__Fibroblast Growth Factor 1__no_interaction	Pimecrolimus__IL-2__no_interaction	Pemetrexed disodium__Fibroblast Growth Factor 1__no_interaction	Pemetrexed disodium__IL-2__no_interaction	Clevidipine__Fibroblast Growth Factor 1__no_interaction	Clevidipine__IL-2__no_interaction	laropiprant__Fibroblast Growth Factor 1__no_interaction	laropiprant__IL-2__no_interaction	Selenite sodium__Fibroblast Growth Factor 1__no_interaction	Selenite sodium__IL-2__no_interaction	Becatecarin__Fibroblast Growth Factor 1__no_interaction	Becatecarin__IL-2__no_interaction	Uracil__Fibroblast Growth Factor 1__no_interaction	Uracil__IL-2__no_interaction	docosahexaenoic acid__Fibroblast Growth Factor 1__no_interaction	docosahexaenoic acid__IL-2__no_interaction	Silodosin__Fibroblast Growth Factor 1__no_interaction	Silodosin__IL-2__no_interaction	Paclitaxel__Fibroblast Growth Factor 1__no_interaction	Paclitaxel__IL-2__no_interaction	CSF__Fibroblast Growth Factor 1__no_interaction	CSF__IL-2__no_interaction	Lumiracoxib__Fibroblast Growth Factor 1__no_interaction	Lumiracoxib__IL-2__no_interaction	O6-Benzylguanine__Fibroblast Growth Factor 1__no_interaction	O6-Benzylguanine__IL-2__no_interaction	Bremelanotide__Fibroblast Growth Factor 1__no_interaction	Bremelanotide__IL-2__no_interaction	Varenicline tartrate__Fibroblast Growth Factor 1__no_interaction	Varenicline tartrate__IL-2__no_interaction	Sorafenib__Fibroblast Growth Factor 1__no_interaction	Sorafenib__IL-2__no_interaction	Desloratadine__Fibroblast Growth Factor 1__no_interaction	Desloratadine__IL-2__no_interaction	Duloxetine hydrochloride__Fibroblast Growth Factor 1__no_interaction	Duloxetine hydrochloride__IL-2__no_interaction	Vardenafil hydrochloride__Fibroblast Growth Factor 1__no_interaction	Vardenafil hydrochloride__IL-2__no_interaction	Aripiprazole__Fibroblast Growth Factor 1__no_interaction	Aripiprazole__IL-2__no_interaction	Enzastaurin__Fibroblast Growth Factor 1__no_interaction	Enzastaurin__IL-2__no_interaction	Rivaroxaban__Fibroblast Growth Factor 1__no_interaction	Rivaroxaban__IL-2__no_interaction	Decitabine__Fibroblast Growth Factor 1__no_interaction	Decitabine__IL-2__no_interaction	Ezetimibe/simvastatin__Fibroblast Growth Factor 1__no_interaction	Ezetimibe/simvastatin__IL-2__no_interaction	Eletriptan__Fibroblast Growth Factor 1__no_interaction	Eletriptan__IL-2__no_interaction	Bevirimat__Fibroblast Growth Factor 1__no_interaction	Bevirimat__IL-2__no_interaction	Prasugrel__Fibroblast Growth Factor 1__no_interaction	Prasugrel__IL-2__no_interaction	Temsirolimus__Fibroblast Growth Factor 1__no_interaction	Temsirolimus__IL-2__no_interaction	Escitalopram oxalate__Fibroblast Growth Factor 1__no_interaction	Escitalopram oxalate__IL-2__no_interaction	Iclaprim__Fibroblast Growth Factor 1__no_interaction	Iclaprim__IL-2__no_interaction	Voclosporin__Fibroblast Growth Factor 1__no_interaction	Voclosporin__IL-2__no_interaction	Alvocidib hydrochloride__Fibroblast Growth Factor 1__no_interaction	Alvocidib hydrochloride__IL-2__no_interaction	Rimonabant__Fibroblast Growth Factor 1__no_interaction	Rimonabant__IL-2__no_interaction	Bortezomib__Fibroblast Growth Factor 1__no_interaction	Bortezomib__IL-2__no_interaction	Xience V__Fibroblast Growth Factor 1__no_interaction	Xience V__IL-2__no_interaction	Eicosapentaenoic acid__Fibroblast Growth Factor 1__no_interaction	Eicosapentaenoic acid__IL-2__no_interaction	Valsartan__Fibroblast Growth Factor 1__no_interaction	Valsartan__IL-2__no_interaction	Olmesartan medoxomil__Fibroblast Growth Factor 1__no_interaction	Olmesartan medoxomil__IL-2__no_interaction	doxorubicin__Fibroblast Growth Factor 1__no_interaction	doxorubicin__IL-2__no_interaction	Rosuvastatin calcium__Fibroblast Growth Factor 1__no_interaction	Rosuvastatin calcium__IL-2__no_interaction	Zotarolimus__Fibroblast Growth Factor 1__no_interaction	Zotarolimus__IL-2__no_interaction	Varespladib__Fibroblast Growth Factor 1__no_interaction	Varespladib__IL-2__no_interaction	Etoricoxib__Fibroblast Growth Factor 1__no_interaction	Etoricoxib__IL-2__no_interaction	Fulvestrant__Fibroblast Growth Factor 1__no_interaction	Fulvestrant__IL-2__no_interaction	Paliperidone__Fibroblast Growth Factor 1__no_interaction	Paliperidone__IL-2__no_interaction
2604378-7	Multiphasic chemistries at the time of leukoerythroblastosis were measured in five patients; abnormal values included <compound-id="22044544,5460341">calcium</compound-id> of 2.0 +/- 0.4 mmol per L, <compound-id="588">creatinine</compound-id> of 336 +/- 130 mumol per L, total protein of 45 +/- 17 g per L, <protein-id="P02768">albumin</protein-id> of 27 +/- 11 g per L, total <compound-id="5280352">bilirubin</compound-id> of 421 +/- 362 mumol per L, <compound-id="1175">uric acid</compound-id> of 499 +/- 264 mumol per L, triglycerides of 4.9 +/- 3.7 mmol per L, and alkaline phosphatase of 3.5 +/- 1.0 mu <compound-id="198256">kat</compound-id> per L.(ABSTRACT TRUNCATED AT 250 WORDS)	calcium__albumin__no_interaction	creatinine__albumin__no_interaction	kat__albumin__no_interaction	uric acid__albumin__no_interaction	bilirubin__albumin__no_interaction
15963498-5	The <compound-id="440005">NRG</compound-id> targets are FBJ murine osteosarcoma viral oncogene homolog B, <protein-id="P08046,Q544D6,Q8CAT6">Early growth response 1</protein-id>, v-jun avian sarcoma virus 17 oncogene homolog, <protein-id="Q60765,Q4FJW1">Activating transcription factor 3</protein-id>, Homo sapiens cDNA FLJ31636 <compound-id="449157">fis</compound-id>, <protein-id="P17275,Q5U079">Jun B</protein-id> proto-oncogene, <protein-id="Q12948,W6CJ52">Forkhead box C1</protein-id>, <protein-id="P16284,A0A075B738">Platelet/endothelial cell adhesion molecule 1</protein-id>, <protein-id="Q9BTZ2">NADPH-dependent retinol dehydrogenase/reductase</protein-id>, <protein-id="Q16690">Dual specificity phosphatase 5</protein-id>, NGF inducible protein <protein-id="P78543">TIS21</protein-id>, <protein-id="P29279,Q5M8T4">Connective tissue growth factor</protein-id>, Jun D proto-oncogene, Serum response factor, Cullin 1, v-myc avian myelocytomatosis viral oncogene, Transient receptor potential channel 1, <protein-id="P01130,A0A024R7D5">Low density lipoprotein receptor</protein-id>, <protein-id="P01137">Transforming growth factor beta 1</protein-id>, Nucleoporin 88 kDa, and Pleckstrin homology-like domain A1.	fis__Jun B__no_interaction	fis__Low density lipoprotein receptor__no_interaction	fis__Activating transcription factor 3__no_interaction	fis__Platelet/endothelial cell adhesion molecule 1__no_interaction	fis__Transforming growth factor beta 1__no_interaction	fis__Early growth response 1__no_interaction	fis__Dual specificity phosphatase 5__no_interaction	fis__Connective tissue growth factor__no_interaction	fis__TIS21__no_interaction	fis__NADPH-dependent retinol dehydrogenase/reductase__no_interaction	fis__Forkhead box C1__no_interaction	NRG__Jun B__no_interaction	NRG__Low density lipoprotein receptor__no_interaction	NRG__Activating transcription factor 3__no_interaction	NRG__Platelet/endothelial cell adhesion molecule 1__no_interaction	NRG__Transforming growth factor beta 1__no_interaction	NRG__Early growth response 1__no_interaction	NRG__Dual specificity phosphatase 5__no_interaction	NRG__Connective tissue growth factor__no_interaction	NRG__TIS21__no_interaction	NRG__NADPH-dependent retinol dehydrogenase/reductase__no_interaction	NRG__Forkhead box C1__no_interaction
2582343-4	The carbohydrate composition of CF <protein-id="P01023">alpha 2M</protein-id> expressed as mean mumol carbohydrate +/- SD per 100 mg protein was: <compound-id="17106,19466,439554,6713579,840">fucose</compound-id> 0.70 +/- 0.12; <compound-id="206">mannose</compound-id> 14.07 +/- 1.31; <compound-id="439353,439357,59083882,6036">galactose</compound-id> 6.72 +/- 0.65; <compound-id="121837,18897,439213,441477,445621,45933887">glucosamine</compound-id> 15.38 +/- 1.59; <compound-id="444885,445063,656387,906">sialic acid</compound-id> 5.52 +/- 0.33 while that of normal control <protein-id="P01023">alpha 2M</protein-id> was: <compound-id="17106,19466,439554,6713579,840">fucose</compound-id> 0.69 +/- 0.11; <compound-id="206">mannose</compound-id> 14.42 +/- 1.21; <compound-id="439353,439357,59083882,6036">galactose</compound-id> 6.91 +/- 0.52; <compound-id="121837,18897,439213,441477,445621,45933887">glucosamine</compound-id> 16.13 +/- 1.77; <compound-id="444885,445063,656387,906">sialic acid</compound-id> 5.58 +/- 0.31.	sialic acid__alpha 2M__no_interaction	mannose__alpha 2M__no_interaction	galactose__alpha 2M__no_interaction	glucosamine__alpha 2M__no_interaction	fucose__alpha 2M__no_interaction
15045499-6	RESULTS: Plasma clearance and <compound-id="5505">tolbutamide</compound-id> plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for <protein-id="P11712,S5RV20">CYP2C9</protein-id>*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.	tolbutamide__CYP2C9__no_interaction
24278961-2	MATERIALS AND METHODS: Ceramic and composite blocks (N = 30) were divided into six groups (n = 5) and subjected to the following conditioning procedures: G1: 9.6% <compound-id="14917">hydrofluoric acid</compound-id> (HF) for 20 s + silane (RelyX Ceramic Primer, 3M ESPE) + resin cement (Panavia F2.0, Kuraray) (control); G2: HF (20 s) + silane + heat treatment in furnace (<compound-id="6914579">HTF</compound-id>) (100°C, 2 min) + resin cement; G3: silane + <compound-id="6914579">HTF</compound-id> + resin cement; G4- HF (20 s) + silane + heat treatment with <protein-id="Q8IWW8">hot</protein-id> air (HTA) (50 ± 5°C for 1 min) + resin cement; G5: silane + HTA + resin cement; <compound-id="5473838">G6</compound-id>: silane + resin cement.	hydrofluoric acid__hot__no_interaction	HTF__hot__no_interaction	G6__hot__no_interaction
8159115-5	High-density lipoprotein (HDL) <compound-id="5997">cholesterol</compound-id> correlated inversely with fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -.26, P &lt; .05 in men; r = -.29, P &lt; .01 in women) and 2-hour <protein-id="P01308,I3WAC9">insulin</protein-id> (r = -.31, P &lt; .01 in men; r = -.39, P &lt; .001 in women) and positively with SI (r = .28, P = .05 in men; r = .43, P &lt; .001 in women).	cholesterol__insulin__no_interaction
11605647-4	We have investigated 1-arylsulfonyl-3-<compound-id="231360">piperazinone</compound-id> derivatives, containing a <compound-id="76002">4-(piperidino)pyridine</compound-id> group in place of <compound-id="3520">guanidino</compound-id> and/or <compound-id="68047">amidino</compound-id> groups, and discovered compound <compound-id="9826652">M55113</compound-id> (<compound-id="53338873">30a</compound-id>: <compound-id="446344">4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]piperazinone</compound-id>), as a potent inhibitor of <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id> (IC50=0.06 microM) with high selectivity for <protein-id="P00742,Q5JVE7,Q5JVE8">FXa</protein-id> over trypsin and <compound-id="90470996">thrombin</compound-id>.	piperazinone__FXa__no_interaction	amidino__FXa__no_interaction	4-[(6-Chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]piperazinone__FXa__no_interaction	thrombin__FXa__no_interaction	guanidino__FXa__no_interaction	30a__FXa__no_interaction	4-(piperidino)pyridine__FXa__no_interaction	M55113__FXa__no_interaction
21162227-7	After coincubation of frozen/thawed <compound-id="2735038">VEC</compound-id> with normal PMN, the adherence of frozen/thawed <compound-id="2735038">VEC</compound-id> to PMN increased from group control 0.204 +/- 0.025 to 0.363 +/- 0.022 (P &lt; 0.01), LDH activity in nutrient solution increased from group control 104.64 +/- 20.14 U/L to 162.33 +/- 27.88 U/L (P &lt; 0.01), monoclonal antibody against <protein-id="Q00238">ICAM-1</protein-id> (<protein-id="Q00238">ICAM-1</protein-id> Mab) could partially block the adherence of frozen/thawed <compound-id="2735038">VEC</compound-id> to PMN (0.270 +/- 0.021, P &lt; 0.01), and diminish LDH activity in nutrient solution (125.39 +/- 22.26 U/L, P &lt; 0.05).	VEC__ICAM-1__no_interaction
11818656-1	In the complexes [Ni(cyclam)(OCOR)2] (cyclam = 1,4,8,11-<compound-id="11084806">tetraazacyclotetradecane</compound-id>), where (RCOO)- is <compound-id="7123">2-naphthoate</compound-id> [bis-(2-naphthoato)-1,4,8,11-tetraazacyclotetradecanenickel(II), (I), monoclinic <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/c, Z' = 0.5], <compound-id="7433">3,5-dinitrobenzoate</compound-id> [bis-(3,5-dinitrobenzoato)-1,4,8,11-tetraazacyclotetradecanenickel(II), (II), triclinic P1, Z' = 0.5], <compound-id="6108">4-nitrobenzoate</compound-id> [bis-(4-nitrobenzoato)-1,4,8,11-tetraazacyclotetradecanenickel(II), (III), monoclinic <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/n, Z' = 0.5], <compound-id="7420">3-hydroxybenzoate</compound-id> [bis-(3-hydroxybenzoato)-1,4,8,11-tetraazacyclotetradecanenickel(II), (IV), monoclinic <protein-id="P38936,A0A024RCX5">P2(1</protein-id>)/c, Z' = 0.5] and <compound-id="978">4-aminobenzoate</compound-id> [bis-(4-aminobenzoato)-1,4,8,11-tetraazacyclotetradecanenickel(II), (V), monoclinic C2/c, Z' = 0.5], the Ni lies on a centre of inversion with monodentate carboxylato ligands occupying trans sites.	3-hydroxybenzoate__P2(1__no_interaction	4-nitrobenzoate__P2(1__no_interaction	3,5-dinitrobenzoate__P2(1__no_interaction	tetraazacyclotetradecane__P2(1__no_interaction	2-naphthoate__P2(1__no_interaction	4-aminobenzoate__P2(1__no_interaction
21786330-3	RESULTS: Protein-based detection assays include the conventional functional activated <protein-id="P04070">protein C</protein-id> resistance coagulation test and the recently reported antibody-mediated sensor detection; and DNA-based assays include approaches that use electrophoretic fractionation e.g., restriction fragment length polymorphism, denaturing gradient gel electrophoresis, and single-stranded conformational PCR analysis, DNA hybridization (e.g., microarrays), DNA polymerase-based assays, e.g., extension reactions, fluorescence polarization template-directed dye-terminator incorporation, PCR assays (e.g., amplification-refractory mutation system, melting curve analysis using real-time quantitative PCR, and helicase-dependent amplification), DNA sequencing (e.g., direct sequencing, pyrosequencing), cleavase-based <compound-id="6442259">Invader</compound-id> assay and ligase-based assays (e.g., oligonucleotide ligation assay and ligase-mediated rolling circle amplification).	Invader__protein C__no_interaction
19474786-4	Seventy-six patients on first-line <compound-id="64139">EFV</compound-id>-based regimens were genotyped for <protein-id="P20813">CYP2B6</protein-id> 516G&gt;T and <protein-id="P08183,A4D1D2">ABCB1</protein-id> 3435C&gt;T. There was a 37% increase (+0.32 mmol/l, P &lt; 0.001) in mean HDL-c level over 48 weeks, and this was univariately associated with gender (male +0.26 mmol/l, female +0.55 mmol/l; P = 0.03), <protein-id="P08183,A4D1D2">ABCB1</protein-id> 3435C&gt;T (CC +0.26 mmol/l, CT +0.16 mmol/l, TT +0.54 mmol/l; P(<protein-id="Q9UNW9">ANOVA</protein-id>) = 0.003) and <protein-id="P20813">CYP2B6</protein-id> 516 G&gt;T (GG +0.27 mmol/l, GT +0.29 mmol/l, TT +0.72 mmol/l; P(<protein-id="Q9UNW9">ANOVA</protein-id>) = 0.08).	EFV__ABCB1__no_interaction	EFV__CYP2B6__no_interaction	EFV__ANOVA__no_interaction
24719613-9	Compared with the control group, the fistuloclysis group showed greater improvements in liver function (Delta total <compound-id="5280352">bilirubin</compound-id> (TB): 20.3 ± 9.7 in the fistuloclysis group versus 15.6 ± 6.3 in the control group, P = 0.040; Delta direct <compound-id="5280352">bilirubin</compound-id> (DB): 12.5 ± 3.4 versus 10.0 ± 3.6, P = 0.011; Delta <protein-id="P05187,B2R7C7">alkaline phosphatase</protein-id> (<protein-id="P05187,B2R7C7">ALP</protein-id>): 98.4 ± 33.5 versus 57.6 ± 20.9, P &lt; 0.001); nutritional status (Delta total protein: 21.8 ± 8.7 versus 10.7 ± 2.1, P &lt; 0.001; Delta albumin: 11.3 ± 2.5 versus 4.2 ± 1.3, P &lt; 0.001).	bilirubin__alkaline phosphatase__no_interaction	bilirubin__ALP__no_interaction
2583381-2	Five categories of nondiabetic <compound-id="206,5793,64689,79025">glucose</compound-id> tolerance were defined according to fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (FPG) values (mM) and 1- and 2-h plasma <compound-id="206,5793,64689,79025">glucose</compound-id> values (PG1 and <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id>, respectively) after oral <compound-id="206,5793,64689,79025">glucose</compound-id> load: 1) normal by WHO and NDDG (FPG less than 6.4 mM, PG1 less than 11.1 mM, <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id> less than 7.8 mM), 2) Normal by WHO, nondiagnostic by NDDG (FPG 6.4-7.7 mM, PG1 less than 11.1 mM, <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id> less than 7.8 mM), 3) normal by WHO, nondiagnostic by NDDG (FPG less than 7.8 mM, PG1 greater than or equal to 11.1 mM, <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id> less than 7.8 mM), 4) IGT by WHO, nondiagnostic by NDDG (FPG less than 7.8 mM, PG1 less than 11.1 mM, <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id> 7.8-11.0 mM), and 5) IGT by WHO and NDDG (FPG less than 7.8 mM, PG1 greater than or equal to 11.1 mM, <protein-id="P80370,Q969Y6,A0A024R6L1">PG2</protein-id> 7.8-11.0 mM).	glucose__PG2__no_interaction
21359280-1	<protein-id="O95817">Bis</protein-id>(imino)<compound-id="8027">pyrrolyl</compound-id> <compound-id="23990">vanadium</compound-id>(III) complexes 2a-e [2,5-C(4)H(2)N(CH=NR)(2)]VCl(2)(THF)(2) [R = C(6)H(5) (2a), 2,6-Me(2)C(6)H(3) (2b), 2,6-(i)Pr(2)C(6)H(3) (2c), 2,4,6-Me(3)C(6)H(2) (2d), C(6)F(5) (2e)] and <protein-id="O95817">Bis</protein-id>(<compound-id="90911343">iminopyrrolyl</compound-id>) <compound-id="23990">vanadium</compound-id>(III) complex 4f [C(4)H(3)N(CH=N-2,6-(i)PrC(6)H(3))](2)VCl(THF) have been prepared in good yields from VCl(3)(THF)(3) by treating with 1.0 and 2.0 equivalent deprotonated ligands in tetrahydrofuran (THF), respectively.	iminopyrrolyl__Bis__no_interaction	vanadium__Bis__no_interaction	pyrrolyl__Bis__no_interaction
15888160-8	RESULTS: UVA1 produced negligible numbers of SBCs, relatively little <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> (Do-1) staining (mean +/- SD cell count per HPF 16 +/- 10), no <protein-id="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1">p53</protein-id> activation and very little evidence of p21 expression (mean +/- SD cell count per HPF 5.3 +/- 7), in contrast to TL-01 (mean +/- SD cell count per HPF of 11.83 +/- 2.1 SBCs, 146.3 +/- 38 for Do-1, 26.6 +/- 15 for <compound-id="5951">serine</compound-id> 15, 14.9 +/- 12 for <compound-id="5951">serine</compound-id> 392 and 77.9 +/- 30 for p21) or <compound-id="11347895">SSR</compound-id> irradiation (mean +/- SD cell count per HPF of 3.5 +/- 1.2 SBCs, 147.5 +/- 62 for Do-1, 54 +/- 50 for <compound-id="5951">serine</compound-id> 15, 38.9 +/- 18 for <compound-id="5951">serine</compound-id> 392 and 56.7 +/- 30 for p21).	serine__p53__no_interaction	SSR__p53__no_interaction
15084551-4	RESULTS: Plasma concentrations of <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> correlated negatively with body mass index (r = -0.18, p &lt; 0.05), serum triglyceride (r = -0.25, p &lt; 0.01), and fasting <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations (r = -0.21, p &lt; 0.05), but correlated positively with age (r = 0.26, p &lt; 0.01), high density lipoprotein <compound-id="5997">cholesterol</compound-id> concentrations (r = 0.35, p &lt; 0.01), and low density lipoprotein particle size (r = 0.37, p &lt; 0.01).	cholesterol__adiponectin__no_interaction	glucose__adiponectin__no_interaction
11325213-9	The C18:1/C18:0 delta9 desaturase activity index was negatively correlated to Z scores (r = -0.44, P&lt; 0.01 for Z score weight, r = -0.39, P &lt; 0.01 for Z score height), <protein-id="P02768">albumin</protein-id> (r = -0.82, P &lt; 0.01) and <compound-id="23994">zinc</compound-id> (r = -0.51, P&lt; 0.01) levels.	zinc__albumin__no_interaction
23364528-4	CommNTS lesions enhanced a 2 M NaCl intragastrically induced increase in the number of vasopressinergic neurons expressing <protein-id="P12841">c-Fos</protein-id> in the PVN (28 ± 1, vs. sham: 22 ± 2 <protein-id="P12841">c-Fos</protein-id>/AVP cells) and <protein-id="E9PTE1,F1MAQ7">SON</protein-id> (26 ± 4, vs. sham: 11 ± 1 <protein-id="P12841">c-Fos</protein-id>/AVP cells), plasma vasopressin levels (21 ± 8, vs. sham: 6.6 ± 1.3 pg/ml), pressor responses (25 ± 7 mmHg, vs. sham: 7 ± 2 mmHg), <compound-id="962">water</compound-id> intake (17.5 ± 0.8, vs. sham: 11.2 ± 1.8 ml/2 h), and natriuresis (4.9 ± 0.8, vs. sham: 1.4 ± 0.3 meq/1 h).	water__c-Fos__no_interaction	water__SON__no_interaction
23249209-1	Eight members of basketlike mixed-valent compounds, formulated as {H(3)O}(2){Fe(III)(2,2'-bpy)(3)}(6){Sr⊂P(6)Mo(V)(4)Mo(VI)(14)O(73)}(2)·9H(2)O (1), {H(2)(4,4'-bpy)}(5){[Ni(4,4'-bpy)(H(2)O)(3)](2)[Ni(H(2)O)(2)][Sr⊂P(6)Mo(V)(2)Mo(VI)(16)O(73)](2)}·12H(2)O (2), {Cu(2)(<protein-id="O43521,A0A0A0MRE7,A0A0C4DH20">bim</protein-id>)(4)(H(2)O)}(2){[Cu(<protein-id="O43521,A0A0A0MRE7,A0A0C4DH20">bim</protein-id>)(2)](2)[Cu(<protein-id="O43521,A0A0A0MRE7,A0A0C4DH20">bim</protein-id>)(H(2)O)](2)Cu(H(2)O)(2)[Sr⊂P(6)Mo(V)(3)Mo(VI)(15)O(73)](2)}·<compound-id="11080284">16H</compound-id>(2)O (3), {H(3)O}(4){[Cd(phen)(2)](2)Sr(H(2)O)(5)[Sr⊂P(6)Mo(V)(4)Mo(VI)(14)O(73)]}·H(2)O (4), {Cu(<protein-id="O43521,A0A0A0MRE7,A0A0C4DH20">bim</protein-id>)(2)} {[Cu(<protein-id="O43521,A0A0A0MRE7,A0A0C4DH20">bim</protein-id>)(2)](2)[Cu(Hbim)(H(2)O)(2)][Ca⊂P(6)Mo(V)(3)Mo(VI)(15)O(73)]}·9H(2)O (5), {[Cu(2,2'-bpy)(H(2)O)](4)[Ca⊂P(6)Mo(V)(2)Mo(VI)(16)O(73)]}·4H(2)O (6), {[Cu(2,2'-bpy)(H(2)O)](4)[Sr⊂P(6)Mo(V)(2)Mo(VI)(16)O(73)]}·8H(2)O (7), and {[Cu(2,2'-bpy)(H(2)O)](4)[Ba⊂P(6)Mo(V)(2)Mo(VI)(16)O(73)]}·8H(2)O (8), have been hydrothermally synthesized and structurally characterized via elemental analysis, thermogravimetry (TG), infrared (IR) spectroscopy, ultraviolet-visible light (UV-vis) spectroscopy, X-ray photoelectron spectroscopy (XPS), and single-crystal X-ray diffraction (XRD).	16H__bim__no_interaction
2850933-1	Pigeons, trained to discriminate between the presence or absence of delta 1-<compound-id="16078">tetrahydrocannabinol</compound-id> (THC) (I) (0.56 mg/kg), were tested with (1S,4R)-delta 2-THC (II) (1-17.5 mg/kg), with the C-1 epimers of (4R)-delta 2-THC <compound-id="176">acetate</compound-id>, namely (1S,4R)-delta 2-THC <compound-id="176">acetate</compound-id> (IIIA) (3-17.5 mg/kg) and (1R,4R)-delta 2-THC <compound-id="176">acetate</compound-id> (IIIB) (1-17.5 mg/kg) and with the enantiomers of <protein-id="Q9NYJ7">delta 3</protein-id>-THC <compound-id="176">acetate</compound-id>, namely (1S)-<protein-id="Q9NYJ7">delta 3</protein-id>-THC <compound-id="176">acetate</compound-id> (IVA) (1-10 mg/kg) and (1R)-<protein-id="Q9NYJ7">delta 3</protein-id>-THC <compound-id="176">acetate</compound-id> (IVB) (3-30 mg/kg).	acetate__delta 3__no_interaction	tetrahydrocannabinol__delta 3__no_interaction
21561895-8	<compound-id="90470996">Thrombin</compound-id> formation was enhanced in the low %HMWM group (<protein-id="P00748,Q8IZZ5">F1.2</protein-id>, 284.5 ± 63.7 vs 216.9 ± 62.5 pmol/l, p = 0.004; <compound-id="90470996">thrombin</compound-id>-antithrombin, 4.89 ± 1.3 vs 4.06 ± 0.9 μg/l, p = 0.02) and both markers showed inverse correlations with the percentage of <protein-id="P04275">vWF</protein-id> HMWM (r = -0.59, p = 0.002; r = -0.42, p = 0.03, respectively).	Thrombin__vWF__no_interaction	Thrombin__F1.2__no_interaction	thrombin__vWF__no_interaction	thrombin__F1.2__no_interaction
9453523-8	Among patients with cardioinhibitory syncope, norepinephrine concentration rose significantly from baseline to syncope (0.44 +/- 0.12 ng/ml versus 1.14 +/- 0.72 ng/ml; p &lt; 0.05), whereas no significant change was observed in <compound-id="5816">epinephrine</compound-id> (0.08 +/- 0.03 ng/ml versus 2.74 +/- 2.85 ng/ml; p = not significant [NS]), <protein-id="P00797">renin</protein-id> (5.68 +/- 3.03 pg/ml versus 19.58 +/- 11.47 pg/ml; p = NS), or <compound-id="5839">aldosterone</compound-id> concentration (66.60 +/- 16.10 ng/ml versus 109.00 +/- 44.70 ng/ml; p = NS).	epinephrine__renin__no_interaction	aldosterone__renin__no_interaction
19520444-7	Regional <compound-id="22044544,5460341">calcium</compound-id>-related parameters (RCaV 52.86 ± 58.39 vs 7.26 ± 15.27 mm(3), p&lt;0.001; RCaS 72.71 ± 78.4 vs 9.66 ± 20.2, p&lt;0.001; RCaEq 12.58 ± 12.97 vs 1.84 ± 3.716 mgCaHA, p&lt;0.001; %CaS/<protein-id="P0DML2,P0DML3,A8K6C2">CSA</protein-id> 53.9 ± 20.3 vs 30.4 ± 17.1%, p=0.009) in the occluded segment were higher and the occlusion length was longer (37.44 ± 27.48 vs 22.00 ± 18.04 mm, p&lt;0.021) in PCI-failure group compared to PCI-success group.	calcium__CSA__no_interaction
12564902-6	Using <compound-id="931">naphthalene</compound-id> as the reference compound, the values of (k(a)k(c)/k(b)) obtained for the <protein-id="P41271,A0A087WTY6">NO3</protein-id> radical reactions (in units of 10(-28) cm(6) molecule(-2) S(-1), indicated errors are two least-squares standard deviations) were as follows: 1-MN, 7.15 +/- 0.37; 2-MN, 10.2 +/- 1.0; 1-EN, 9.82 +/- 0.69; 2-EN, 7.99 +/- 0.99; 1,2-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 64.0 +/- 2.3; 1,3-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 21.3 +/- 1.2; 1,4-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 13.0 +/- 0.5; 1,5-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 14.1 +/- 1.3; 1,6-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 16.5 +/- 1.8; 1,7-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 13.5 +/- 0.7; 1,8-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 212 +/- 59; 2,3-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 15.2 +/- 0.5; 2,6-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 21.2 +/- 1.6; 2,7-<protein-id="O15061,A0A075B7B1">DMN</protein-id>, 21.0 +/- 1.5.	naphthalene__DMN__no_interaction	naphthalene__NO3__no_interaction
2882686-3	Plasma <compound-id="206,5793,64689,79025">glucose</compound-id> rate of decrease (0.052 +/- 0.003 vs. 0.06 +/- 0.003 mg <protein-id="P13987,Q6FHM9">X dl-1 X min-1</protein-id>), plasma <compound-id="206,5793,64689,79025">glucose</compound-id> nadir (49.8 +/- 1.2 vs. 50 +/- 1.0 mg/dl), initial suppression of <compound-id="206,5793,64689,79025">glucose</compound-id> production (0.22 +/- 0.01 vs. 0.23 +/- 0.01 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>), subsequent compensatory increase in <compound-id="206,5793,64689,79025">glucose</compound-id> production (0.54 +/- 0.05 vs. 0.48 +/- 0.04 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>), and the increase in <compound-id="206,5793,64689,79025">glucose</compound-id> utilization (0.45 +/- 0.05 vs. 0.42 +/- 0.05 mg <protein-id="P13987,Q6FHM9">X kg-1 X min-1</protein-id>) in <protein-id="Q06141,Q53S56">PAP</protein-id> clamp and control experiments, respectively, were not significantly different and were significantly correlated.	glucose__X kg-1 X min-1__no_interaction	glucose__PAP__no_interaction	glucose__X dl-1 X min-1__no_interaction
14577766-1	A new family of <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> crossover complexes, [<compound-id="27284">Fe(II)</compound-id>H(3)L(Me)](NO(3))(2).1.5H(2)O (1), [<compound-id="29936">Fe(III)</compound-id>L(Me)].3.5H(2)O (2), [<compound-id="27284">Fe(II)</compound-id>H(3)L(Me)][<compound-id="27284">Fe(II)</compound-id>L(Me)]NO(3) (3), and [<compound-id="27284">Fe(II)</compound-id>H(3)L(Me)][<compound-id="29936">Fe(III)</compound-id>L(Me)](NO(3))(2) (4), has been synthesized and characterized, where H(3)L(Me) denotes a hexadentate N(6) tripod ligand containing three <compound-id="795">imidazole</compound-id> groups, <compound-id="91594283">tris[2-(((2-methylimidazol-4-yl)methylidene)amino)ethyl]amine</compound-id>.	tris[2-(((2-methylimidazol-4-yl)methylidene)amino)ethyl]amine__spin__no_interaction	Fe(III)__spin__no_interaction	Fe(II)__spin__no_interaction	imidazole__spin__no_interaction
15127240-8	Innovative radiotracers for specific imaging of tumoural perfusion ([(15)O]H(2)O), <protein-id="P22736,A0A024R126,F5GXF0,Q6ZMM6">hormone receptor</protein-id> expression ([(18)F]FES), protein synthesis ([(11)C]<compound-id="6137,84815,876">methionine</compound-id>), proliferation rate ([(18)F]FLT) or bone mineralisation ([(18)F]<compound-id="28179">fluoride</compound-id>) may provide additional information compared with that provided by <compound-id="315411,445226,68196650">FDG</compound-id> PET.	fluoride__hormone receptor__no_interaction	methionine__hormone receptor__no_interaction	FDG__hormone receptor__no_interaction
7576398-7	In <compound-id="54892">quinapril</compound-id>-treated SHR compared with 36-week-old untreated SHR and age- and sex-matched Wistar-Kyoto (WKY) controls, we found 1) a lesser degree of LVH and a lesser level of blood pressure, 2) a lesser degree of interstitial fibrosis, represented by less interstitial collagen volume fraction (5.73 +/- 0.45% v 3.42 +/- 0.28%, P &lt; .05; WKY, 3.44 +/- 0.66%), 3) a lower <compound-id="269023,5810">hydroxyproline</compound-id> concentration (1.09 +/- 0.05 mumol/L/g dry weight/100 g body weight to 0.81 +/- 0.05 mumol/L/g dry weight/100 g body weight, P &lt; .05; WKY, 0.96 +/- 0.06 mumol/L/g dry weight/100 g body weight), 4) a lesser presence of collagen fibers, and 5) a lesser presence of collagen IV, <protein-id="F1LST1,A0A096P6L8">fibronectin</protein-id>, and <compound-id="44342165">laminin</compound-id>.	hydroxyproline__fibronectin__no_interaction	quinapril__fibronectin__no_interaction	laminin__fibronectin__no_interaction
9593065-5	LBNP induced a significant decrease in ERPF (534 +/- 28 to 457 +/- 26 ml/min; p &lt; 0.05), GFR (120 +/- 2.5 to 112 +/- 2.5 ml/min; p &lt; or = 0.01), in urine excretion (12 +/- 0.9 to 5.6 +/- 0.5 ml/min; p &lt; 0.001), in <compound-id="5360545">sodium</compound-id> excretion (0.36 +/- 0.03 to 0.30 +/- 0.02 mmol/min; p &lt; 0.05), and in plasma <protein-id="P01160">ANF</protein-id> (19 +/- 3 to 11 +/- 2 pg/ml; p = 0.001) concomitant with an increase in plasma <protein-id="P00797">renin</protein-id> activity (PRA; 0.48 +/- 0.09 to 0.87 +/- 0.16 ng/ml/h; p = 0.01) and of forearm vascular resistance (FVR; p &lt; 0.05).	sodium__ANF__no_interaction	sodium__renin__no_interaction
1707813-3	The monoclonal antibodies (1) specifically stained the cytoplasm of unfixed and <compound-id="712">formalin</compound-id>-fixed dog gastric parietal cells; (2) specifically reacted by ELISA with gastric tubulovesicular membranes; (3) recognised epitopes located on the luminal face of parietal cell tubulovesicular membranes, the site of the <protein-id="P50996">proton pump</protein-id>, by immunogold electron microscopy; (4) immunoblotted a 60-90-kDa molecule from tubulovesicular membranes and a 35-kDa component from peptide N-glycosidase-F-treated membrane extracts; (5) immunoblotted the 60-90-kDa parietal cell autoantigen associated with autoimmune gastritis and pernicious anemia, purified by chromatography on parietal cell autoantibody- or tomato-lectin-<compound-id="11966311">Sepharose</compound-id> 4B affinity columns, and the 35-kDa protein core of this autoantigen; this autoantigen has amino acid sequence similarity to the beta-subunit of the related Na+/K(+)-transporting <compound-id="57476835,60961">adenosine</compound-id> triphosphatase (Na+/K+ ATPase) [<compound-id="16122569">Toh</compound-id> et al.	formalin__proton pump__no_interaction	Toh__proton pump__no_interaction	Sepharose__proton pump__no_interaction	adenosine__proton pump__no_interaction
16906634-8	The goodness-of-fit evaluation model showed the coping and social support variables affected the psychological distress as mediator variables (df = 109, chi (2) = 209.75, <protein-id="P08651,B7Z4T6">NFI</protein-id> = 0.949, RFI = 0.929, IFI = 0.975, <compound-id="6432721">TLI</compound-id> = 0.964, RMSEA = 0.087).	TLI__NFI__no_interaction
9227812-10	In the subgroup of subjects who underwent IVGTT, the weighted HDL particle size score correlated positively with HDL <compound-id="5997">cholesterol</compound-id> level (r = 0.6, p &lt; 0.0005), LDL particle size (r = 0.47, p &lt; 0.001), and <protein-id="P01308,I3WAC9">Insulin</protein-id> sensitivity (r = 0.48, p &lt; 0.001), and negatively with plasma triglyceride level (r = 0.37, p &lt; 0.01).	cholesterol__Insulin__no_interaction
23585571-2	Recent preparation of <protein-id="Q9BZG9">LYNX1</protein-id> as an individual protein in the form of <compound-id="962">water</compound-id>-soluble domain lacking glycosylphosphatidylinositol anchor (ws-<protein-id="Q9BZG9">LYNX1</protein-id>; Lyukmanova, E. N., Shenkarev, Z. O., Shulepko, M. A., Mineev, K. S., D'Hoedt, D., Kasheverov, I. E., Filkin, S. Y., Krivolapova, A. P., Janickova, H., Dolezal, V., Dolgikh, D. A., Arseniev, A. S., Bertrand, D., Tsetlin, V. I., and Kirpichnikov, M. P. (2011) NMR structure and action on nicotinic <compound-id="187">acetylcholine</compound-id> receptors of <compound-id="962">water</compound-id>-soluble domain of human <protein-id="Q9BZG9">LYNX1</protein-id>.	water__LYNX1__no_interaction	acetylcholine__LYNX1__no_interaction
10871202-7	The extent of the reduction in plasma <protein-id="P05121,A0A024QYT5">PAI-1</protein-id> antigen concentrations in the diabetic patients after <compound-id="17756782,5591">troglitazone</compound-id> correlated with the reductions in fasting plasma <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.60, P &lt; 0.05), nonesterified fatty acid (r = 0.63, P &lt; 0.02), and <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations (r = 0.64, P &lt; 0.02) but not with the improvement in <compound-id="206,5793,64689,79025">glucose</compound-id> disposal rates during the <compound-id="206,5793,64689,79025">glucose</compound-id> clamps.	troglitazone__PAI-1__no_interaction	troglitazone__insulin__no_interaction	glucose__PAI-1__no_interaction	glucose__insulin__no_interaction
19100415-6	<protein-id="P16070">CD44</protein-id> was independently related to hsCRP (r = .37; P &lt; .01), ICAM (r = .23; P &lt; .05), eGFR (r = -.37; P &lt; .01), <protein-id="P07204">thrombomodulin</protein-id> (r = .43; P &lt; .001), VCAM (r = -.44; P &lt; .001), hemoglobin (r = -.26; P &lt; .01), red blood cell count (r = -.25; P &lt; .05), <compound-id="588">creatinine</compound-id> (r = .37; P &lt; .01), <protein-id="P43121,A0A024R3I5">CD146</protein-id> (r = .34; P &lt; .01), and <protein-id="P29965">CD40L</protein-id> (r = .23; P &lt; .05).	creatinine__CD44__no_interaction	creatinine__CD40L__no_interaction	creatinine__thrombomodulin__no_interaction	creatinine__CD146__no_interaction
10909997-7	Ex vivo by microcalorimetry, the heat produced after 1 hour by the enzyme-induced hydrolysis of <compound-id="57476835,60961">adenosine</compound-id> triphosphate (ATP), was measured in a thermostated microcalorimeter at 37 degrees C. The results showed that Na/K ATPase activity was significantly increased by insulin (12.4 +/- 0.5 v 15.4 +/- 0.9 mW/L RBCs, P &lt; .05, n = 23) but not by <protein-id="P01308,I3WAC9">C-peptide</protein-id> (11.9 +/- 0.7 v 12.9 +/- 0.9 mW/L RBCs, NS, P = .26, n = 12).	adenosine__C-peptide__no_interaction
22479352-5	The strongest evidence for association was observed with <protein-id="P01375,Q5STB3">TNF alpha</protein-id> and HbA1c (rs1052248; 0.04% increase per allele C; p-value = 4.4×10(-5)), <protein-id="Q9HD89">RETN</protein-id> and fasting plasma <compound-id="206,64689,79025">glucose</compound-id> (rs1423096; 0.7 mg/dl decrease per allele A; p-value = 1.1×10(-4)), <protein-id="P01583">IL8 and 1</protein-id> hr plasma <compound-id="206,64689,79025">glucose</compound-id> (rs2886920; 2.6 mg/dl decrease per allele T; p-value = 1.3×10(-4)), <protein-id="Q86V24">ADIPOR2</protein-id> and fasting <protein-id="P01308,I3WAC9">C-peptide</protein-id> (rs2041139; 0.55 ug/L decrease per allele A; p-value = 1.4×10(-4)), <protein-id="P48357,Q4G138">LEPR</protein-id> and 1-hour <protein-id="P01308,I3WAC9">C-peptide</protein-id> (rs1171278; 0.62 ug/L decrease per allele T; p-value = 2.4×10(-4)), and <protein-id="P01583">IL6 and 1</protein-id>-hour plasma <compound-id="206,64689,79025">glucose</compound-id> (rs6954897; -2.29 mg/dl decrease per allele G, p-value = 4.3×10(-4)).	glucose__ADIPOR2__no_interaction	glucose__TNF alpha__no_interaction	glucose__IL8 and 1__no_interaction	glucose__IL6 and 1__no_interaction	glucose__RETN__no_interaction	glucose__LEPR__no_interaction	glucose__C-peptide__no_interaction
22694956-5	This showed an association with the well-established AMD risk loci <protein-id="P0C7Q2">ARMS2</protein-id> (<protein-id="P0C7Q2">age-related maculopathy susceptibility 2</protein-id>)-<protein-id="Q92743">HTRA1</protein-id> (<protein-id="Q92743">HtrA serine peptidase 1</protein-id>) (P =2.7 × 10(-72)), <protein-id="P08603,A0A024R962,A0A0D9SG88">CFH</protein-id> (<protein-id="P08603,A0A024R962,A0A0D9SG88">complement factor H</protein-id>) (P =2.3 × 10(-47)), C2 (complement component 2)-<protein-id="P00751">CFB</protein-id> (<protein-id="P00751">complement factor B</protein-id>) (P =5.2 × 10(-9)), C3 (complement component 3) (P =2.2 × 10(-3)) and <compound-id="5231474">CFI</compound-id> (P =3.6 × 10(-3)) and with more recently reported risk loci at <protein-id="P15692,A0A024RD37,A0A024RD33,A2A2V4">VEGFA</protein-id> (P =1.2 × 10(-3)) and <protein-id="P11150,A6H8L5">LIPC</protein-id> (hepatic <compound-id="5474737">lipase</compound-id>) (P =0.04).	lipase__complement factor H__no_interaction	lipase__CFH__no_interaction	lipase__age-related maculopathy susceptibility 2__no_interaction	lipase__complement factor B__no_interaction	lipase__ARMS2__no_interaction	lipase__HtrA serine peptidase 1__no_interaction	lipase__LIPC__no_interaction	lipase__CFB__no_interaction	lipase__VEGFA__no_interaction	lipase__HTRA1__no_interaction	CFI__complement factor H__no_interaction	CFI__CFH__no_interaction	CFI__age-related maculopathy susceptibility 2__no_interaction	CFI__complement factor B__no_interaction	CFI__ARMS2__no_interaction	CFI__HtrA serine peptidase 1__no_interaction	CFI__LIPC__no_interaction	CFI__CFB__no_interaction	CFI__VEGFA__no_interaction	CFI__HTRA1__no_interaction
10640301-3	26 nM and a B(max) value of 1.44 pmol/mg protein; 2) the K(i) values for inhibition of (125)I-hPP binding by hPP, <protein-id="P10082">human peptide YY</protein-id> (<protein-id="P10082">hPYY</protein-id>), <protein-id="P01303,A4D158">human neuropeptide Y</protein-id> (<protein-id="P01303,A4D158">hNPY</protein-id>), and analogs were hPP (0.7 nM) &lt; rat PP (47 nM) &lt; <protein-id="P10082">hPYY</protein-id> (94 nM) &lt; h[Leu(31)-Pro(34)]NPY (124 nM) &lt;&lt; <protein-id="P01303,A4D158">hNPY</protein-id> = porcine NPY(13-36) = rat D-[Trp(32)]NPY (&gt;1 microM); 3) cross-linking experiments using (125)I-hPP identified a single M(r) 60,000 glycosylated Y4 receptor; and 4) the natural peptides hPP, <protein-id="P10082">hPYY</protein-id>, and <protein-id="P01303,A4D158">hNPY</protein-id> inhibited <compound-id="47936">forskolin</compound-id>-stimulated cAMP production in clone 29 cells with EC(50) values of 0.56 nM, 218 nM, and &gt;1 microM, respectively.	forskolin__human neuropeptide Y__no_interaction	forskolin__human peptide YY__no_interaction	forskolin__hNPY__no_interaction	forskolin__hPYY__no_interaction
23428137-1	Six uranyl phosphonates and sulfonates have been hydrothermally synthesized, namely, (H2tib)[(<compound-id="10916">UO2</compound-id>)3(PO3C6H5)4]·2H2O (UPhP-1), Zn(pi)2(<compound-id="10916">UO2</compound-id>)(PO3C6H5)2 (UPhP-2), Zn(dib)(<compound-id="10916">UO2</compound-id>)(PO3C6H5)2·2H2O (UPhP-3), (HTEA)[(<compound-id="10916">UO2</compound-id>)(5-SP)] (<protein-id="O94782">USP-1</protein-id>), (Hdib)2[(<compound-id="10916">UO2</compound-id>)2(OH)(O)(5-SP)] (<protein-id="O75604">USP-2</protein-id>), and Zn(phen)3(<compound-id="10916">UO2</compound-id>)2(3-SP)2 (<protein-id="Q9Y6I4">USP-3</protein-id>) (tib = 1,3,5-tri(1H-imidazol-1-yl)<compound-id="241">benzene</compound-id>, pi = <compound-id="81595">1-phenyl-1H-imidazole</compound-id>, dib = 1,4-di(1H-imidazol-1-yl)<compound-id="241">benzene</compound-id>, TEA = <compound-id="8471">triethylamine</compound-id>, phen = 1,10-<compound-id="67473">phenanthroline</compound-id>, 5-SP = <compound-id="80714">5-sulfoisophthalic acid</compound-id>, and 3-SP = 3-<compound-id="15279310">sulfoisophthalic acid</compound-id>).	benzene__USP-2__no_interaction	benzene__USP-3__no_interaction	benzene__USP-1__no_interaction	UO2__USP-2__no_interaction	UO2__USP-3__no_interaction	UO2__USP-1__no_interaction	phenanthroline__USP-2__no_interaction	phenanthroline__USP-3__no_interaction	phenanthroline__USP-1__no_interaction	1-phenyl-1H-imidazole__USP-2__no_interaction	1-phenyl-1H-imidazole__USP-3__no_interaction	1-phenyl-1H-imidazole__USP-1__no_interaction	triethylamine__USP-2__no_interaction	triethylamine__USP-3__no_interaction	triethylamine__USP-1__no_interaction	5-sulfoisophthalic acid__USP-2__no_interaction	5-sulfoisophthalic acid__USP-3__no_interaction	5-sulfoisophthalic acid__USP-1__no_interaction	sulfoisophthalic acid__USP-2__no_interaction	sulfoisophthalic acid__USP-3__no_interaction	sulfoisophthalic acid__USP-1__no_interaction
15133864-25	In the 18 refractory UC patients with platelet activation, after more than 4 wk of combined Kangshuanling and <compound-id="5353980,5359476,5384001">sulfasalazine</compound-id> therapy, 16 patients achieved clinical remission, with a highly significant statistical difference (P&lt;0.01) between pre-and post-treatment mean scores for all disease parameters: stool frequency (8.2/d vs 1.6/d), rectal bleeding (score 2.7 vs 0.3), colonoscopy (score 2.6 vs 1.1), histology (score 12.0 vs 5.0), general well being (score 4.0 vs 0.6) and <protein-id="P16109,Q5R341,A0A024R8Y9,Q6NUL9">CD62p</protein-id> (8.0+/-3.1% vs 4.1+/-1.8%), <protein-id="P08962,A0A024RB05">CD63</protein-id> (6.3+/-2.1% vs 3.2+/-1.6%), TXA2 (548+/-85 ng/L vs 390+/-67 ng/L), platelet aggregation rate (43.2+/-10.7% vs 34.8+/-8.1%), thrombosis length in vitro (2.3+/-0.6 cm vs 1.8+/-0.3 cm), <protein-id="P05362">CD54</protein-id> in blood (26.9+/-6.9% vs 14.4+/-5.1%), <protein-id="P05362">CD54</protein-id> in tissues (51.1+/-6.2% vs 23.1+/-4.1%), Pgp-170 in blood (18.9+/-3.9% vs 10.4+/-2.7%), Pgp-170 in tissues (16.5+/-3.2% vs 10.2+/-2.3%, P&lt;0.01 or 0.05).	sulfasalazine__CD63__no_interaction	sulfasalazine__CD54__no_interaction	sulfasalazine__CD62p__no_interaction
7749872-4	Mean concentrations for the high (n = 23), intermediate (n = 13), and normal (n = 2) <compound-id="5997">cholesterol</compound-id> level phenotypes at 4 months of age were TC, 316 +/- 62.2, 159 +/- 17.1, and 105 +/- 12 mg/dL; LDL <compound-id="5997">cholesterol</compound-id>, 275 +/- 63.1, 113 +/- 16.4, and 67 +/- 18.4 mg/dL; HDL-C, 35 +/- 6.1, 41 +/- 5.7, and 33 +/- 6.4 mg/dL; triglycerides, 48 +/- 10.8, 39 +/- 8.0, and 29 +/- 5.7 mg/dL; apoB, 152 +/- 32.5, 80 +/- 7.2, and 48 +/- 5.7 mg/dL; <protein-id="P27917">apoC-III</protein-id>, 10 +/- 4.2, 8 +/- 1.7, and 3 +/- 0.1 mg/dL; and <protein-id="P18650">apoE</protein-id>, 17 +/- 3.4, 7 +/- 1.7, and 5 +/- 0.7 mg/dL, respectively.	cholesterol__apoC-III__no_interaction	cholesterol__apoE__no_interaction
19444959-11	The highest correlations were reported between 48 h <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>/DBP with iHD or HD 24 h ABPM (r 2 = 0.95, P &lt; 0.001), while the lowest between 48 h <protein-id="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8">SBP</protein-id>/DBP and <compound-id="441161">OBP</compound-id> (r 2 = 0.40,P &lt; 0.01, r 2 = 0.12, P &lt; 0.01).	OBP__SBP__no_interaction
19228023-2	When the <compound-id="6326970">selenium</compound-id>-capped triiron carbonyl cluster [Et(4)N](2)[SeFe(3)(CO)(9)] was treated with 1-3 equiv of <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id> in tetrahydrofuran (THF) at low or room temperatures, <protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id>-incorporated SeFe(3) complexes [Et(4)N](2)[SeFe(3)(CO)(9)<protein-id="Q13948,P39880,Q3LIA3">CuX</protein-id>] (X = Cl, [Et(4)N](2)[1a]; Br, [Et(4)N](2)[1b]; I, [Et(4)N](2)[1c]), Cu(2)X(2)-incorporated SeFe(3) clusters [Et(4)N](2)[SeFe(3)(CO)(9)Cu(2)X(2)] (X = Cl, [Et(4)N](2)[2a]; Br, [Et(4)N](2)[2b]), and Cu(4)X(2)-linked di-SeFe(3) clusters [Et(4)N](2)[{SeFe(3)(CO)(9)}(2)Cu(4)X(2)] (X = Cl, [Et(4)N](2)[<compound-id="2981881,91293124">3a</compound-id>]; Br, [PPh(4)](2)[3b]) were obtained, respectively, in good yields.	3a__CuX__no_interaction	selenium__CuX__no_interaction
17874012-6	Compared to NT-NO, HT-NO showed higher <protein-id="P01308,I3WAC9">insulin</protein-id> levels before <compound-id="206,5793,64689,79025">glucose</compound-id> load (7.46 +/- 3.1 vs 4.32 +/- 2.1 microU/ml; p &lt; 0.05), higher HOMAr (1.59 +/- 0.72 vs 0.93 +/- 0.48 mmol x mU/l2; p = 0.006), higher <compound-id="90470904">leptin</compound-id> level (19.1 +/- 9.6 vs 7.4 +/- 3.5 ng/ml; p = 0.028), greater VF area (84.40 +/- 55.7 vs 37.50 +/- 23.0 cm2; p = 0.036), increased IVSTd (9.6 +/- 1.2 vs 8.2 +/- 1.7 mm; p &lt;0.05) and (<protein-id="Q15049,A0A024R4V4">LVM</protein-id>/height) (95.8 +/- 22.3 vs 78.4 +/- 15.5 g/m; p &lt; 0.05).	leptin__LVM__no_interaction	leptin__insulin__no_interaction	glucose__LVM__no_interaction	glucose__insulin__no_interaction
18165957-1	The <compound-id="23937">osmium</compound-id> compound trans,cis-[OsCl2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2(Pyme)] (1) (Pyme=1-(pyridin-2-yl)<compound-id="6329">methanamine</compound-id>), obtained from [OsCl2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] and Pyme, thermally isomerizes to cis,cis-[OsCl2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)(2)(Pyme)] (2) in <compound-id="7947">mesitylene</compound-id> at 150 degrees C. Reaction of [OsCl2(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)3] with Ph2P(CH2)(4)PPh2 (<compound-id="82124">dppb</compound-id>) and Pyme in <compound-id="7947">mesitylene</compound-id> (150 degrees C, 4 h) leads to a mixture of trans-[OsCl2(<compound-id="82124">dppb</compound-id>)(Pyme)] (3) and cis-[OsCl2(<compound-id="82124">dppb</compound-id>)(Pyme)] (4) in about an 1:3 molar ratio.	osmium__PPh3__no_interaction	dppb__PPh3__no_interaction	methanamine__PPh3__no_interaction	mesitylene__PPh3__no_interaction
18811147-5	Reaction of [Ru(S2CNC4H8NCS2)(dppm)2] with [Os(CH=CHC6H4Me-4)Cl(CO)(<compound-id="446725">BTD</compound-id>)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2] (<compound-id="446725">BTD</compound-id> = <compound-id="67502">2,1,3-benzothiadiazole</compound-id>), [Pd(C6H4CH2NMe2)Cl]2, [PtCl2(<compound-id="27365">PEt3</compound-id>)2], and [<compound-id="24385">NiCl2</compound-id>(dppp)] (dppp = 1,3-bis<compound-id="82100">(diphenylphosphino)propane</compound-id>) results in the heterobimetallic complexes [(dppm)<compound-id="24898133">2Ru</compound-id>(S2CNC4H8NCS2)ML(n))](m+) (ML(n) = Os(CH=CHC6H4Me-4)(CO)(<protein-id="Q03135,Q7Z4F3,A0A024R757,Q2TNI1,A9XTE5,Q59E85">PPh3</protein-id>)2](+), m = 1; ML(n) = Pd(C,N-C6H4CH2NMe2), m = 1; ML(n) = Pt(<compound-id="27365">PEt3</compound-id>)2, m = 2; ML(n) = Ni(dppp), m = 2).	NiCl2__PPh3__no_interaction	(diphenylphosphino)propane__PPh3__no_interaction	BTD__PPh3__no_interaction	PEt3__PPh3__no_interaction	2,1,3-benzothiadiazole__PPh3__no_interaction	2Ru__PPh3__no_interaction
15794943-6	PAO-induced [Ca2+]i elevation was significantly inhibited by 1-[6-[17beta-3-methoxyestra-1,3,5(10)-<compound-id="5565">trien</compound-id>-17-yl]amino]hexyl]-1H-<compound-id="10935">pyrrole-2,5-dione</compound-id> (U-73122), the inhibitor of phospholipase C-coupled processes, <compound-id="5280961">genistein</compound-id>, a general <compound-id="6057,90983769">tyrosine</compound-id> <compound-id="53378893">kinase inhibitor</compound-id>, <compound-id="71308525">phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> (<compound-id="122634,22833501,27924">PMA</compound-id>), a protein kinase C (PKC) activator, <compound-id="11029486,179202,2534,44338867,44351042,46936510,49786999,5459084,54608024">calyculin A</compound-id>, a cortical actin stabilizer, 2-(4-morpholinyl)-<compound-id="66909200">8-phenyl-4H-1-benzopyran-4-one</compound-id> (LY 294002), a <compound-id="16738692">phosphoinositide</compound-id> 3-<compound-id="53378893">kinase inhibitor</compound-id>, 1-[beta-[<compound-id="79406">3-(4-methoxyphenyl)propoxy</compound-id>]-<compound-id="73690">4-methoxyphenethyl</compound-id>]-<compound-id="795">1H-imidazole</compound-id> (SKF-96365), and cis-N-(2-<compound-id="136538">phenylcyclopentyl</compound-id>)azacyclotridec-1-en-2-amine (MDL-12,330A), the blockers of receptor-gated and store-operated Ca2+ channels, whereas there was no appreciable effect exerted by <compound-id="2236">aristolochic acid</compound-id>, a <protein-id="P04055">phospholipase A2</protein-id> inhibitor, 7-<compound-id="12333819">nitroindazole</compound-id> and N-(3-aminomethyl)benzylacetamidine (<compound-id="1433">1400W</compound-id>), the blockers of NO synthase, and by suspension in a Na+-deprived medium.	aristolochic acid__phospholipase A2__no_interaction	8-phenyl-4H-1-benzopyran-4-one__phospholipase A2__no_interaction	phorbol 12-myristate__phospholipase A2__no_interaction	4-methoxyphenethyl__phospholipase A2__no_interaction	nitroindazole__phospholipase A2__no_interaction	calyculin A__phospholipase A2__no_interaction	3-(4-methoxyphenyl)propoxy__phospholipase A2__no_interaction	acetate__phospholipase A2__no_interaction	genistein__phospholipase A2__no_interaction	kinase inhibitor__phospholipase A2__no_interaction	phosphoinositide__phospholipase A2__no_interaction	1H-imidazole__phospholipase A2__no_interaction	PMA__phospholipase A2__no_interaction	phenylcyclopentyl__phospholipase A2__no_interaction	trien__phospholipase A2__no_interaction	pyrrole-2,5-dione__phospholipase A2__no_interaction	1400W__phospholipase A2__no_interaction	tyrosine__phospholipase A2__no_interaction
18724387-5	The cannabinoid receptor type 1 (CB(1)) antagonist AM251 (N-(<compound-id="8082">piperidin</compound-id>-1-yl)-5-(4-iodophenyl)-<compound-id="60871732">1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole</compound-id>-3-<compound-id="11960529">carboxamide</compound-id>) and the <protein-id="P37230">peroxisome proliferator-activated receptor (PPAR)-alpha</protein-id> antagonist <compound-id="446738,71311842">GW6471</compound-id> ([(2S)-2-[[(1Z)-<compound-id="520404">1-methyl-3-</compound-id>oxo-3-[4-(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]-1-propenyl]amino]-3-[4-[2-(5-methyl-2-phenyl-4-oxa zolyl)ethoxy]phenyl]propyl]-<compound-id="277">carbamic acid</compound-id> <compound-id="23134249">ethyl</compound-id> ester) were used to investigate the roles of these receptors in mediating the effects of <compound-id="1383884">URB597</compound-id>.	carbamic acid__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	carboxamide__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	GW6471__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	piperidin__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	URB597__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	trifluoromethyl__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	1-methyl-3-__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction	ethyl__peroxisome proliferator-activated receptor (PPAR)-alpha__no_interaction
4021548-4	In responders, we recorded the following findings (mean +/- SD): urinary protein excretion decreased from 13.0 +/- 5.2 g/24 h to 7.2 +/- 3.5 g/24 h in 2 to 4 weeks and continued to decrease to 4.1 +/- 1.4 g/24 h at the time of the last follow-up study (median duration, 12 months; range, 6 to 36 months; P less than 0.01, 2 to 4 weeks versus later follow-up); the level of serum <protein-id="P02768">albumin</protein-id> increased from 1.9 +/- 0.5 g/dl to 2.9 +/- 0.7 g/dl (P less than 0.001) in 2 to 4 weeks; the level of serum <compound-id="5997">cholesterol</compound-id> decreased from 413 +/- 125 mg/dl to 346 +/- 114 mg/dl (P less than 0.005) at the time of the last follow-up examination; and renal function remained unchanged from the baseline study to the follow-up study (serum <compound-id="588">creatinine</compound-id> 1.5 +/- 0.5 mg/dl versus 1.6 +/- 0.4 mg/dl and glomerular filtration rate 60.5 +/- 29.2 ml/min per 1.7 m2 versus 64.1 +/- 25.5 ml/min per 1.7 m2).	creatinine__albumin__no_interaction	cholesterol__albumin__no_interaction
24149733-2	Forty five soldiers of the Brazilian <compound-id="5281872,6442842">brigade</compound-id> of special operations with at least one year of army training experience were divided into a control group (CG - n = 15, 20.18 ± 0.72 yrs, 1.74 ± 0.06 m, 66.7 ± 9.8 kg, and 1RM/weight ratio = 1.14 ± 0.12), a traditional periodization group (TG - n = 15, 20.11 ± 0.7 yrs, 1.72 ± 0.045 m, 63.1 ± 3.6 kg, and 1RM/weight ratio = 1.21 ± 0.16); and a maximum-power group (<protein-id="P29372,Q1W6H1">MPG</protein-id> - n = 15, 20.5 ± 0.6 yrs, 1.73 ± 0.049m, 67.3 ± 9.8 kg, 1RM/weight ratio = 1.20 ± 0.14).	brigade__MPG__no_interaction
22295849-3	RESULTS: The left testis volume, the right testis volume, and the levels of <protein-id="P01236,Q5I0G2,Q5THQ0">prolactin</protein-id> (<protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id>), follicle-stimulating hormone (FSH), luteinising hormone (LH), <compound-id="5757">estradiol</compound-id> (E2) and total <compound-id="6013">testosterone</compound-id> (T) in the non-sperm and sperm groups were (7.07 +/- 1.06) ml vs (11.75 +/- 1.38) ml, (7.37 +/- 1.37) ml vs (11.70 +/- 1.98) ml, (12.43 +/- 11.69) ng/ml vs (9.60 +/- 4.55) ng/ml, (15.77 +/- 10.84) mIU/ml vs (8.01 +/- 7.43) mIU/ml, (6.12 +/- 2.92) mIU/ml vs (8.11 +/- 20.11) mIU/ml, (119.36 +/- 43.52) pmol/L vs (141.12 +/- 48.33) pmol/L, and (11.43 +/- 4.05) nmol/L vs (12.46 +/- 4.60) nmol/L, respectively.	testosterone__prolactin__no_interaction	testosterone__PRL__no_interaction	estradiol__prolactin__no_interaction	estradiol__PRL__no_interaction
16270991-1	Reaction of the ditopic semirigid ligand <compound-id="90912056">1,2-bis(imidazolylmethyl)benzene</compound-id> (1,2-bImb) or the flexible ligand <compound-id="200005">1,4-bis(2-benzimidazolyl)butane</compound-id> (C4BIm) with <compound-id="44183922">AgX</compound-id> (X = ClO4-, BF4-, CF3CO2-) afforded five new complexes, namely, [<protein-id="A8IHN8">Ag2</protein-id>(1,2-bImb)2](ClO4)2 (1), [<protein-id="A8IHN8">Ag2</protein-id>(1,2-bImb)2](BF4)2 (2), [<protein-id="A8IHN8">Ag2</protein-id>(1,2-bImb)2](CF3CO2)2.2CH3OH (3.2CH3OH), [<protein-id="A8IHN8">Ag2</protein-id>(C4BIm)2](ClO4)2.2DMF (4.2DMF), and [<protein-id="A8IHN8">Ag2</protein-id>(C4BIm)2](CF3CO2)2.2H2O (5.2H2O), all of which contain a centrosymmetric, rectangular-shaped cationic disilver(I) metallacycle [<protein-id="A8IHN8">Ag2</protein-id>(L)2]2+.	AgX__Ag2__no_interaction	1,2-bis(imidazolylmethyl)benzene__Ag2__no_interaction	1,4-bis(2-benzimidazolyl)butane__Ag2__no_interaction
18602987-4	In order to clarify the nature of the BBB in the median eminence-arcuate nucleus complex, we have used immunohistochemistry and antisera to protein components of the BBB-(1) tight junctions, <protein-id="Q9JKD6">claudin-5</protein-id> and <protein-id="F1M4A0">zona occludens-1</protein-id> (<protein-id="F1M4A0">ZO-1</protein-id>); (2) endothelial cells: (a) all endothelial cells: rat endothelial cell antigen-1 (RECA-1), (b) endothelial cells at BBB: endothelial barrier antigen (EBA), <compound-id="206,5793,64689,79025">glucose</compound-id> transporter 1 (<protein-id="P11167">GLUT1</protein-id>) and <protein-id="G3V679">transferrin receptor</protein-id> (TfR), and (c) endothelial cells at CVOs: <protein-id="D4A6X1,A0A0G2K7B6">dysferlin</protein-id>; (3) basal lamina: <compound-id="44342165">laminin</compound-id>; (4) vascular smooth muscle cells: smooth muscle actin (SMA); (5) pericytes: <compound-id="53477707">chondroitin</compound-id> <compound-id="1117">sulfate</compound-id> proteoglycan (<protein-id="Q00657">NG2</protein-id>); (6) glial cells: (a) astrocytes: <protein-id="P47819">glial fibrillary acidic protein</protein-id> (<protein-id="P47819">GFAP</protein-id>), (b) tanycytes: <protein-id="Q6J4I0">dopamine- and cAMP-regulated phosphoprotein of 32kDA</protein-id> (<protein-id="Q6J4I0">DARPP-32</protein-id>), (c) microglia: <protein-id="Q9JI30">CD11b</protein-id>.	laminin__claudin-5__no_interaction	laminin__transferrin receptor__no_interaction	laminin__GFAP__no_interaction	laminin__DARPP-32__no_interaction	laminin__dopamine- and cAMP-regulated phosphoprotein of 32kDA__no_interaction	laminin__glial fibrillary acidic protein__no_interaction	laminin__CD11b__no_interaction	laminin__NG2__no_interaction	laminin__zona occludens-1__no_interaction	laminin__dysferlin__no_interaction	laminin__GLUT1__no_interaction	laminin__ZO-1__no_interaction	chondroitin__claudin-5__no_interaction	chondroitin__transferrin receptor__no_interaction	chondroitin__GFAP__no_interaction	chondroitin__DARPP-32__no_interaction	chondroitin__dopamine- and cAMP-regulated phosphoprotein of 32kDA__no_interaction	chondroitin__glial fibrillary acidic protein__no_interaction	chondroitin__CD11b__no_interaction	chondroitin__NG2__no_interaction	chondroitin__zona occludens-1__no_interaction	chondroitin__dysferlin__no_interaction	chondroitin__GLUT1__no_interaction	chondroitin__ZO-1__no_interaction	sulfate__claudin-5__no_interaction	sulfate__transferrin receptor__no_interaction	sulfate__GFAP__no_interaction	sulfate__DARPP-32__no_interaction	sulfate__dopamine- and cAMP-regulated phosphoprotein of 32kDA__no_interaction	sulfate__glial fibrillary acidic protein__no_interaction	sulfate__CD11b__no_interaction	sulfate__NG2__no_interaction	sulfate__zona occludens-1__no_interaction	sulfate__dysferlin__no_interaction	sulfate__GLUT1__no_interaction	sulfate__ZO-1__no_interaction	glucose__claudin-5__no_interaction	glucose__transferrin receptor__no_interaction	glucose__GFAP__no_interaction	glucose__DARPP-32__no_interaction	glucose__dopamine- and cAMP-regulated phosphoprotein of 32kDA__no_interaction	glucose__glial fibrillary acidic protein__no_interaction	glucose__CD11b__no_interaction	glucose__NG2__no_interaction	glucose__zona occludens-1__no_interaction	glucose__dysferlin__no_interaction	glucose__GLUT1__no_interaction	glucose__ZO-1__no_interaction
7586261-8	Among affected individuals, the QTonset-c was unusually prolonged in those individuals with mutations involving the cardiac <compound-id="5360545">sodium</compound-id> channel gene <protein-id="Q14524,K4DIA1,Q86V90,E9PG18,H9KVD2,E9PHB6">SCN5A</protein-id> on chromosome 3 (lead II QTonset-c [mean +/- SD]: chromosome 3, 341 +/- 42 ms; chromosome 7, 290 +/- 56 ms; chromosome 11, 243 +/- 73 ms; P &lt; .001); Tamplitude was generally quite small in the chromosome 7 genotype (lead II Tamplitude, mV: chromosome 3, 0.36 +/- 0.14; chromosome 7, 0.13 +/- 0.07; chromosome 11, 0.37 +/- 0.17; P &lt; .001); and Tduration was particularly long in the chromosome 11 genotype (lead II Tduration-c: chromosome 3, 187 +/- 33 ms; chromosome 7, 191 +/- 51 ms; chromosome 11, 262 +/- 65 ms; P &lt; .001).	sodium__SCN5A__no_interaction
20424477-7	Serum <protein-id="P80188">NGAL</protein-id> correlated strongly with residual renal function (r = -0.54, p &lt; 0.001), Kt/V (r = 0.41, p &lt; 0.001), <protein-id="P81172">hepcidin</protein-id> (r = -0.28, p &lt; 0.01), serum <compound-id="588">creatinine</compound-id> (r = 0.63, p &lt; 0.001), <compound-id="23925,67172434">iron</compound-id> (r = 0.25, p &lt; 0.01), TSAT (r = 0.30, p &lt; 0.001), ferritin (r = 0.33, p &lt; 0.001), hsCRP (r = 0.32, p &lt; 0.001).	creatinine__NGAL__no_interaction	creatinine__hepcidin__no_interaction	iron__NGAL__no_interaction	iron__hepcidin__no_interaction
23651969-7	RESULTS: Compared to NC siRNA and BC siRNA group (0.075 ± 0.021, 0.072 ± 0.019), the activity of <protein-id="P42574">caspase-3</protein-id> in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group (0.167 ± 0.012) was significantly increased (P &lt; 0.05); <protein-id="P10415,A0A024R2B3,A0A024R2C4">Bcl2</protein-id> mRNA and protein expression in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group (0.61 ± 0.06, 0.94 ± 0.11) were significantly downregulated compared with NC siRNA group (0.90 ± 0.070, 1.39 ± 0.15) and BC siRNA group (0.94 ± 0.087, 1.49 ± 0.20) (P &lt; 0.05); <protein-id="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0">Bax</protein-id> mRNA and protein expression in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group (1.05 ± 0.10, 1.25 ± 0.12) were markedly upregulated compared with NC siRNA group (0.72 ± 0.03, 0.99 ± 0.12) and BC siRNA group (0.64 ± 0.03, 0.92 ± 0.06), P &lt; 0.05; cytosolic cytochrome expression in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group (0.75 ± 0.14) was significantly upregulated compared with NC siRNA group (0.51 ± 0.06) and BC siRNA group (0.48 ± 0.07) (P &lt; 0.05); <compound-id="3801">JC-1</compound-id> monomer/polymer ratio in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group (0.163 ± 0.011) was significantly increased compared with NC siRNA group (0.092 ± 0.015) and BC siRNA group (0.072 ± 0.025) (P &lt; 0.05) indicating mitochondrial membrane potential was significantly reduced in <protein-id="Q06710,A0A024R524,A0A024R4X8,A0A024R531,R9W7C9">Pax-8</protein-id> siRNA group.	JC-1__Pax-8__no_interaction	JC-1__caspase-3__no_interaction	JC-1__Bax__no_interaction	JC-1__Bcl2__no_interaction
12131530-8	<compound-id="71300629">Catestatin</compound-id> correlated inversely with body mass index (r = -0.215, r(2) = 0.046, n = 276, P &lt; 0.001) and plasma <protein-id="P41159,A4D0Y8">leptin</protein-id> (r = -0.203, r(2) = 0.041, n = 212, P = 0.003), while body mass index and <protein-id="P41159,A4D0Y8">leptin</protein-id> correlated directly (r = 0.59, r(2) = 0.350, n = 212, P &lt; 0.001).	Catestatin__leptin__no_interaction
11095582-6	The involvement of <protein-id="P05177">CYP1A2</protein-id> in DMXAA metabolism by human livers was demonstrated by the following: 1) the potent inhibition of DMXAA metabolism by <compound-id="3433">furafylline</compound-id> (k(inact) = 0.23 +/- 0.04 min(-1), K'(app) = 15.6 +/- 6.7 microM) and <compound-id="11790">alpha-naphthoflavone</compound-id> (K(i) = 0.036 microM), but not by <compound-id="2756">cimetidine</compound-id>, <compound-id="3823,456201,47576,5702077">ketoconazole</compound-id>, <compound-id="5505">tolbutamide</compound-id>, <compound-id="441074">quinidine</compound-id>, <compound-id="2733">chlorzoxazone</compound-id>, <compound-id="8987">diethyldithiocarbamate</compound-id>, <compound-id="17675,202225,418931,45270772,5284630,5289436,6708521,6713914">troleandomycin</compound-id>, and <compound-id="5335">sulfaphenazole</compound-id>; 2) when incubated with human lymphoblastoid cell microsomes containing cDNA-expressed CYP isoenzymes, DMXAA was metabolized only by <protein-id="P05177">CYP1A2</protein-id>, with an apparent K(m) of 6.2 +/- 1.5 microM and V(max) of 0.014 +/- 0.001 nmol/min/mg, but not by <protein-id="P11509">CYP2A6</protein-id>, <protein-id="P20813">CYP2B6</protein-id>, <protein-id="P11712,S5RV20">CYP2C9</protein-id> (Arg(144)), <protein-id="P33261">CYP2C19</protein-id>, <protein-id="P10635,C1ID52,Q5Y7H2">CYP2D6</protein-id> (Val(374)), <protein-id="P05181">CYP2E1</protein-id>, and <protein-id="Q9HB55">CYP3A4; 3</protein-id>) a significant correlation (r = 0.90; P &lt;.001) between 6-methylhydroxylation of DMXAA and 7-<compound-id="3294">ethoxyresorufin</compound-id> O-deethylation; and 4) a significant correlation (r = 0.75; P &lt;.01) between the CYP1A protein level determined by Western blots and DMXAA 6-methylhydroxylation.	diethyldithiocarbamate__CYP2C9__no_interaction	diethyldithiocarbamate__CYP1A2__no_interaction	diethyldithiocarbamate__CYP2D6__no_interaction	diethyldithiocarbamate__CYP2B6__no_interaction	diethyldithiocarbamate__CYP2E1__no_interaction	diethyldithiocarbamate__CYP2C19__no_interaction	diethyldithiocarbamate__CYP2A6__no_interaction	diethyldithiocarbamate__CYP3A4; 3__no_interaction	troleandomycin__CYP2C9__no_interaction	troleandomycin__CYP1A2__no_interaction	troleandomycin__CYP2D6__no_interaction	troleandomycin__CYP2B6__no_interaction	troleandomycin__CYP2E1__no_interaction	troleandomycin__CYP2C19__no_interaction	troleandomycin__CYP2A6__no_interaction	troleandomycin__CYP3A4; 3__no_interaction	tolbutamide__CYP2C9__no_interaction	tolbutamide__CYP1A2__no_interaction	tolbutamide__CYP2D6__no_interaction	tolbutamide__CYP2B6__no_interaction	tolbutamide__CYP2E1__no_interaction	tolbutamide__CYP2C19__no_interaction	tolbutamide__CYP2A6__no_interaction	tolbutamide__CYP3A4; 3__no_interaction	quinidine__CYP2C9__no_interaction	quinidine__CYP1A2__no_interaction	quinidine__CYP2D6__no_interaction	quinidine__CYP2B6__no_interaction	quinidine__CYP2E1__no_interaction	quinidine__CYP2C19__no_interaction	quinidine__CYP2A6__no_interaction	quinidine__CYP3A4; 3__no_interaction	ethoxyresorufin__CYP2C9__no_interaction	ethoxyresorufin__CYP1A2__no_interaction	ethoxyresorufin__CYP2D6__no_interaction	ethoxyresorufin__CYP2B6__no_interaction	ethoxyresorufin__CYP2E1__no_interaction	ethoxyresorufin__CYP2C19__no_interaction	ethoxyresorufin__CYP2A6__no_interaction	ethoxyresorufin__CYP3A4; 3__no_interaction	furafylline__CYP2C9__no_interaction	furafylline__CYP1A2__no_interaction	furafylline__CYP2D6__no_interaction	furafylline__CYP2B6__no_interaction	furafylline__CYP2E1__no_interaction	furafylline__CYP2C19__no_interaction	furafylline__CYP2A6__no_interaction	furafylline__CYP3A4; 3__no_interaction	alpha-naphthoflavone__CYP2C9__no_interaction	alpha-naphthoflavone__CYP1A2__no_interaction	alpha-naphthoflavone__CYP2D6__no_interaction	alpha-naphthoflavone__CYP2B6__no_interaction	alpha-naphthoflavone__CYP2E1__no_interaction	alpha-naphthoflavone__CYP2C19__no_interaction	alpha-naphthoflavone__CYP2A6__no_interaction	alpha-naphthoflavone__CYP3A4; 3__no_interaction	sulfaphenazole__CYP2C9__no_interaction	sulfaphenazole__CYP1A2__no_interaction	sulfaphenazole__CYP2D6__no_interaction	sulfaphenazole__CYP2B6__no_interaction	sulfaphenazole__CYP2E1__no_interaction	sulfaphenazole__CYP2C19__no_interaction	sulfaphenazole__CYP2A6__no_interaction	sulfaphenazole__CYP3A4; 3__no_interaction	ketoconazole__CYP2C9__no_interaction	ketoconazole__CYP1A2__no_interaction	ketoconazole__CYP2D6__no_interaction	ketoconazole__CYP2B6__no_interaction	ketoconazole__CYP2E1__no_interaction	ketoconazole__CYP2C19__no_interaction	ketoconazole__CYP2A6__no_interaction	ketoconazole__CYP3A4; 3__no_interaction	cimetidine__CYP2C9__no_interaction	cimetidine__CYP1A2__no_interaction	cimetidine__CYP2D6__no_interaction	cimetidine__CYP2B6__no_interaction	cimetidine__CYP2E1__no_interaction	cimetidine__CYP2C19__no_interaction	cimetidine__CYP2A6__no_interaction	cimetidine__CYP3A4; 3__no_interaction	chlorzoxazone__CYP2C9__no_interaction	chlorzoxazone__CYP1A2__no_interaction	chlorzoxazone__CYP2D6__no_interaction	chlorzoxazone__CYP2B6__no_interaction	chlorzoxazone__CYP2E1__no_interaction	chlorzoxazone__CYP2C19__no_interaction	chlorzoxazone__CYP2A6__no_interaction	chlorzoxazone__CYP3A4; 3__no_interaction
19700700-12	Compared with BB calves, HF and EF calves had higher basal <compound-id="206,5793,64689,79025">glucose</compound-id> concentrations (4.40 +/- 0.16 vs. 5.70 +/- 0.35 and 5.81 +/- 0.13 mmol/L, respectively), <protein-id="A5PJB2">insulin</protein-id> peak concentrations (4.62 +/- 1.09 vs. 9.70 +/- 1.45 and 16.44 +/- 5.58 microU/mL, respectively), <protein-id="A5PJB2">insulin</protein-id> AUC (86.71 +/- 18.81 vs. 222.65 +/- 45.00 and 293.69 +/- 109.22 microU/mL.min, respectively), and <compound-id="206,5793,64689,79025">glucose</compound-id> AUC (256.22 +/- 17.53 vs. 335.66 +/- 18.74 and 321.03 +/- 10.05 mmol/L min, respectively).	glucose__insulin__no_interaction
22110271-7	RESULTS: Body weight, Lee's index, fasting plasma <compound-id="206,5793,64689,79025">glucose</compound-id> level, maltase activity in small intestinal mucosa, mucosa and apical <protein-id="Q68FZ1">GLUT2</protein-id>, <protein-id="Q68FZ1">GLUT2</protein-id> mRNA and protein expression levels were all significantly higher in the obese group than in the normal control group (605.61 ± 141.00 vs 378.54 ± 111.75, 337.61 ± 10.82 vs 318.73 ± 20.10, 8.60 ± 1.38 vs 7.33 ± 0.70, 156.01 ± 58.81 vs 50.43 ± 30.49, 390 744.2 ± 62 469.21 vs 170 546.50 ± 50 646.14, 26 740.18 ± 3809.60 vs 354.98 ± 57.19, 0.26 ± 0.11 vs 0.07 ± 0.02, and 2.08 ± 0.59 vs 1.27 ± 0.38, respectively, all P &lt; 0.01).	glucose__GLUT2__no_interaction
22110271-10	The intestinal mucosa and apical <protein-id="Q68FZ1">GLUT2</protein-id>, expression of <protein-id="Q68FZ1">GLUT2</protein-id> mRNA and protein were also significantly lower in the <compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> intervention group than in the obese group (269 975.2 ± 53 730.94 vs 390 744.2 ± 62 469.21, 3758.06 ±364.51 vs 26 740.18 ± 3809.60, 0.08 ± 0.02 vs 0.26 ±0.11, and 1.31 ± 0.27 vs 2.08 ± 0.59, respectively, all P &lt; 0.01).	octreotide__GLUT2__no_interaction
19257006-4	When H&lt;3/4 , the ergodicity breaking parameter E_{B}=[[delta;{2}[over ](x(t))];{2}-delta;{2}[over ](x(t));{2}]/delta;{2}[over ](x(t));{2} approximately k(H)Deltat;{-1} , when <protein-id="Q16695">H=3/4</protein-id> , E_{B} approximately (9/16)(<compound-id="440993">lnt</compound-id>)Deltat;{-1} , and when 3/4&lt;H&lt;1 , E_{B} approximately k(H)Delta;{4-4H}t;{4H-4} .	lnt__H=3/4__no_interaction
10651759-6	002), plasma triglycerides (r = 0.75, P &lt; 0.0001), VLDL-triglycerides (r = 0.59, P = 0.007), fasting FFA (r = 0.72, P = 0.002), <compound-id="1175">uric acid</compound-id> (r = 0.57 (P = 0.01) and <protein-id="P01308,I3WAC9">insulin</protein-id> sensitivity (SI, r = - 0.58, P = 0.008).	uric acid__insulin__no_interaction
10863894-4	We found that the means +/- <compound-id="5289348">SEM</compound-id> of free <protein-id="P05019,Q5U743,Q13429,Q59GC5">IGF-I</protein-id> in children with panhypopituitarism (PAN) and complete <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> deficiencies (cGHD) were significantly lower than those in sex and age matched normal children (0.02 +/- 0.01 vs 2.01 +/- 0.7 ng/ml, p = 0.0006 and 0.42 +/- 0.18 vs 1.72 +/- 0.27 ng/ml, p = 0.0007 respectively) but not in children with partial <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> deficiencies (pGHD) (0.91 +/- 0.3 vs 1.97 +/- 0.4 ng/ml, p = 0.27) and idiopathic short stature (ISS) (0.94 +/- 0.3 vs 1.95 +/- 0.6 ng/ml, p = 0.13).	SEM__IGF-I__no_interaction	SEM__growth hormone__no_interaction
14678286-6	SUBJECTS AND METHODS: In 15 male patients with OSAS [age, mean +/- <compound-id="5289348">SEM</compound-id> 43.5 +/- 1.6 years; body mass index (BMI) 39.2 +/- 3.1 kg/m2; apnoea/hypopnoea index, (AHI) 53.4 +/- 8.7], 15 male patients with simple obesity (OB, age 39.7 +/- 1.2 years; BMI 41.2 +/- 2.0 kg/m2; AHI 3.1 +/- 1.2 events/h of sleep) and in 15 normal lean male subjects (NS, age 38.2 +/- 1.4 years; BMI 21.2 +/- 0.8 kg/m2; AHI 1.9 +/- 0.8 events/h of sleep) we evaluated: (a) the <protein-id="P01189,Q6FHC8">ACTH</protein-id> and <compound-id="5754">cortisol</compound-id> responses to <protein-id="P06850">CRH</protein-id> [2 microg/kg intravenously (i.v.	SEM__ACTH__no_interaction	SEM__CRH__no_interaction	cortisol__ACTH__no_interaction	cortisol__CRH__no_interaction
15030406-2	Using electrophysiological and biochemical approaches in the hippocampal slices, we show here that <protein-id="P01308,I3WAC9">insulin</protein-id>-LTD (i) is specific to <compound-id="22559856">3-hydroxy-5-methylisoxazole-4-propionic acid</compound-id> (AMPA) receptor- but not NMDA receptor-mediated synaptic transmission; (ii) is induced and expressed postsynaptically but does not require the activation of ionotropic and metabotropic <compound-id="23327,33032,611,57109091">glutamate</compound-id> receptors; (iii) requires a concomitant Ca(2+) influx through l-type voltage-activated Ca(2+) channels (VACCs) and the release of Ca(2+) from intracellular stores; (iv) requires the series of protein kinases, including protein <compound-id="6057,90983769">tyrosine</compound-id> kinase (PTK), <compound-id="16738692,53477912">phosphatidylinositol</compound-id> 3-kinase (PI3K), and protein kinase C (PKC); (v) is mechanistically distinct from low-frequency stimulation-induced LTD (<compound-id="76871876">LFS</compound-id>-LTD) and independent on protein phosphatase 1/2 A (<protein-id="Q15181,V9HWB5">PP1/2 A</protein-id>) and PP2B activation; (vi) is dependent on a <compound-id="16760631,478951,5040,5358081,53627520,5374464,60150249,71296106,86583604,91454826,9854380">rapamycin</compound-id>-sensitive local translation of dendritic mRNA, and (vii) is associated with a persistent decrease in the surface expression of <protein-id="P42262">GluR2</protein-id> subunit.	rapamycin__PP1/2 A__no_interaction	rapamycin__insulin__no_interaction	rapamycin__GluR2__no_interaction	3-hydroxy-5-methylisoxazole-4-propionic acid__PP1/2 A__no_interaction	3-hydroxy-5-methylisoxazole-4-propionic acid__insulin__no_interaction	3-hydroxy-5-methylisoxazole-4-propionic acid__GluR2__no_interaction	LFS__PP1/2 A__no_interaction	LFS__insulin__no_interaction	LFS__GluR2__no_interaction	phosphatidylinositol__PP1/2 A__no_interaction	phosphatidylinositol__insulin__no_interaction	phosphatidylinositol__GluR2__no_interaction	glutamate__PP1/2 A__no_interaction	glutamate__insulin__no_interaction	glutamate__GluR2__no_interaction	tyrosine__PP1/2 A__no_interaction	tyrosine__insulin__no_interaction	tyrosine__GluR2__no_interaction
21978752-12	The high-fat diet decreased <compound-id="6083">5'-adenosine monophosphate</compound-id>-activated protein kinase (2561 ± 78 versus 1765 ± 65), glucokinase-3β (2.214 ± 34 versus 3356 ± 86), and <protein-id="Q923E4,Q3UNI1,Q3USJ2,A7MCT8,Q53Z05">SIRT1</protein-id> (2015 ± 76 versus 3567 ± 104) and increased tumor necrosis factor-α (3415 ± 112 versus 2042 ± 65), nuclear factor kappa B (5123 ± 201 versus 2562 ± 103), <protein-id="Q05769">cyclooxygenase-2</protein-id> (4230 ± 113 versus 2473 ± 98), <compound-id="5893">nicotinamide-adenine dinucleotide</compound-id> <compound-id="1061,167704,644102">phosphate</compound-id> oxidase (3501 ± 106 versus 1600 ± 69) and reactive <compound-id="977">oxygen</compound-id> species production (all P &lt; .001, obese mice versus lean mice).	phosphate__SIRT1__no_interaction	phosphate__cyclooxygenase-2__no_interaction	oxygen__SIRT1__no_interaction	oxygen__cyclooxygenase-2__no_interaction	5'-adenosine monophosphate__SIRT1__no_interaction	5'-adenosine monophosphate__cyclooxygenase-2__no_interaction	nicotinamide-adenine dinucleotide__SIRT1__no_interaction	nicotinamide-adenine dinucleotide__cyclooxygenase-2__no_interaction
12637241-13	For all the substrates except <compound-id="4594">omeprazole</compound-id>, a sex difference in their metabolism was observed in the dog (<compound-id="3008,5360696,5362449,6916184">dextromethorphan</compound-id> N-demethylation: female range = 0.7-0.9, male = 0.4-0.8 nmol mg(-1) protein <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (p &lt; 0.02); <compound-id="54688261">S-warfarin</compound-id> 7-hydroxylation: female = 9-15.5, male = 8-12 fmol mg(-1) protein <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (p &lt; 0.02); R-<compound-id="4060">mephenytoin</compound-id> 4'-hydroxylation: female = 16-35, male = 11.5-19 pmol mg(-1) protein <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (p &lt; 0.01); <compound-id="4594">omeprazole</compound-id> 5'-hydroxylation: female = 15-20, male 13-22 pmol mg(-1) protein <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (p &lt; 0.2)).	mephenytoin__min(-1__no_interaction	S-warfarin__min(-1__no_interaction	dextromethorphan__min(-1__no_interaction	omeprazole__min(-1__no_interaction
15056861-1	Two new (11)C-labelled ligands, <compound-id="85145780">N-(3-(4-hydroxyphenyl)propyl)-3-(4-methoxyphenyl)propylamine</compound-id> ([(11)C]2) and <compound-id="90916639">N-(3-(4-hydroxyphenyl)butyl)-3-(4-methoxyphenyl)butylamine</compound-id> ([(11)C]3) were designed based on bis(phenylalkyl)amines (1) which have been reported as polyamine site antagonists with high-selectivity for <protein-id="Q00960">NR1A/2B NMDA receptors</protein-id>, and radiolabelling of the corresponding <compound-id="996">phenol</compound-id> precursors with [(11)C]<compound-id="6328">methyl iodide</compound-id> was readily accomplished.	methyl iodide__NR1A/2B NMDA receptors__no_interaction	N-(3-(4-hydroxyphenyl)propyl)-3-(4-methoxyphenyl)propylamine__NR1A/2B NMDA receptors__no_interaction	phenol__NR1A/2B NMDA receptors__no_interaction	N-(3-(4-hydroxyphenyl)butyl)-3-(4-methoxyphenyl)butylamine__NR1A/2B NMDA receptors__no_interaction
19659999-7	After <compound-id="77999">rosiglitazone</compound-id> treatment for 12 consecutive weeks, we found that A allele carriers of <protein-id="P55851,A0A024R5N5">UCP2</protein-id> in the T2DM patients had smaller attenuated PINS (-3.82 +/- 13.2 vs.-42.1 +/- 30.7 mU l(-1), P &lt; 0.01) (9.45, 51.31 vs. 0.48, 11.88) and greater attenuated HbA(1c) (-1.85 +/- 1.62 vs.-0.61 +/- 0.80, P &lt; 0.05) (0.14, 1.37 vs. 1.10, 2.38) compared with GG genotypes, and <protein-id="P13945,A8KAG8">ADRB3</protein-id> Trp64Arg had greater attenuated serum TG (-3.88 +/- 2.77 vs.-0.24 +/- 1.16 mmol l(-1), P &lt; 0.05) (-0.19, 2.74 vs. 1.19, 1.45) and smaller attenuated LDL-<compound-id="5997">cholesterol</compound-id> (1.08 +/- 1.36 vs.-0.36 +/- 0.99, P &lt; 0.01) (-1.26, 0.78 vs.-1.26, 0.79) as well as reduced enhanced <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> (1.57 +/- 1.10 vs. 3.15 +/- 2.12 mmol l(-1), P &lt; 0.05) (1.68, 4.08 vs.-9.18, 11.40) compared with <protein-id="P13945,A8KAG8">ADRB3</protein-id> Trp64Trp.	rosiglitazone__UCP2__no_interaction	rosiglitazone__ADRB3__no_interaction	rosiglitazone__adiponectin__no_interaction	cholesterol__UCP2__no_interaction	cholesterol__ADRB3__no_interaction	cholesterol__adiponectin__no_interaction
20355242-10	Urinary <compound-id="3034763">deoxypyridinoline</compound-id>/<compound-id="588">creatinine</compound-id> (9.4 + or - 9.9 pmol/micromol vs 8.1 + or - 5.3 pmol/micromol, P = 0.51), urinary <compound-id="105069">pyridinoline</compound-id>/<compound-id="588">creatinine</compound-id> (51.3 + or - 66.6 pmol/micromol vs 29 + or - 25.8 pmol/micromol, P = 0.08), blood IL-1 level (3.4 + or - 8.8 pg/mL vs 1.6 + or - 3.5 pg/mL, P = 0.29), vitamin D3 level (18.6 + or - 13.3 microg/L vs 18.4 + or - 8.9 microg/L, P = 0.95), <compound-id="5754">cortisol</compound-id> level (11.1 + or - 4.8 microg/dL vs 12.6 + or - 4.3 microg/dL, P = 0.15) and <protein-id="P01270">PTH</protein-id> level (42.7 + or - 38 microg/dL vs 34.8 + or - 10.9 microg/dL, P = 0.27) were not significantly different.	deoxypyridinoline__PTH__no_interaction	creatinine__PTH__no_interaction	pyridinoline__PTH__no_interaction	cortisol__PTH__no_interaction
9579731-5	Schild regression analyses yielded affinity (mean <protein-id="P31749,B0LPE5,B3KVH4">pKb</protein-id>) estimates of 7.1, 6.2, 8.6, 8.6, 8.4, 9.3, 7.0, 7.4, 8.9, 10.0, 7.1 and 9.3, respectively, although deviations from unit Schild regression slope question the robustness of data for <compound-id="3894573">RS-17053</compound-id> and SNAP 5089.	RS-17053__pKb__no_interaction
24517070-10	RESULTS: At the end of the 6th week, statistical difference was shown in UF [(-3.3 +/- 14.2) mL] and [(-2.0 +/- 10.7) mL], <compound-id="75551">MTG</compound-id> [(18.1 +/- 0.8) mmol/kg] and [(16.1 +/- 1.2) mmol/kg], collagen fiber [(4 721.3 +/- 541.0)%] and [(6502.7 +/- 877.4)%], fibroblast [(0.087 +/- 0.010)/mm2] and [(0.131 +/- 0.042)/mm2], Col I [(187.5 +/- 36.9)%] and [(289.7 +/- 95.6)%], <protein-id="P30120">TIMP-1</protein-id> [(2.57 +/- 0.94)%] and [(3.63 +/- 0.29)%], and <protein-id="P17246">TGF-beta1</protein-id> [(104.0 +/- 20.7) ng/L] and [(108.2 +/- 17.5) ng/L] between Group C and Group E, when compared with the peritoneal dialysate group at the same concentration (P &lt; 0.05, P &lt; 0.01).	MTG__TIMP-1__no_interaction	MTG__TGF-beta1__no_interaction
12693380-4	<compound-id="2369">Betaxolol</compound-id> reduced the heart rate, the levels of atrial natriuretic peptide and <protein-id="P13205">brain natriuretic peptide</protein-id> mRNA expression and the atrial natriuretic peptide concentration [group N (normal rats), 367 +/- 4 beats/min, 100%, 100% and 78 +/- 7 pg/ml, respectively; group V, 391 +/- 9 beats/min, 761 +/- 68% versus group N, 317 +/- 42% versus group N and 4374 +/- 312 pg/ml, respectively; group 0.1, 387 +/- 10 beats/min, 621 +/- 78%, 288 +/- 41% and 2875 +/- 331 pg/ml, respectively; group 1, 323 +/- 9 beats/min, 442 +/- 84%, 148 +/- 12% and 884 +/- 51 pg/ml, respectively; and group 10, 312 +/- 8 beats/min, 97 +/- 18%, 92 + 9% and 453 +/- 53 pg/ml, respectively], and increased survival (group V, 62%; group 0.1, 69%; groups N, 1 and 10, 100%).	Betaxolol__brain natriuretic peptide__no_interaction
10901625-4	Fasting tHcy and <protein-id="P29590">PML</protein-id>-tHcy correlated with fasting <protein-id="P01308,I3WAC9">proinsulin</protein-id> (r = 0.395, p &lt; 0.05; r = 0.386, p&lt; 0.05) and <compound-id="588">creatinine</compound-id> (r = 0.489, p &lt; 0.01; r = 0.339, p &lt; 0.05), resp.	creatinine__PML__no_interaction	creatinine__proinsulin__no_interaction
19508594-6	Among HIV and non-HIV groups, peak GH was inversely associated with WC (rho = -0.44, P &lt; 0.0001; rho = -0.63, P &lt; 0.0001; HIV patients and controls, respectively), blood pressure (rho = -0.17, P = 0.02; rho = -0.36, P = 0.004), triglycerides (rho = -0.37, P &lt; 0.0001; rho = -0.43, P = 0.001), <compound-id="206,5793,64689,79025">glucose</compound-id> (rho = -0.34, P &lt; 0.0001; rho = -0.30, P = 0.02), <protein-id="P01308,I3WAC9">insulin</protein-id> (rho = -0.43, P &lt; 0.0001; rho = -0.60, P &lt; 0.0001) and <protein-id="P02741">CRP</protein-id> (rho= -0.29, P &lt; 0.0001; rho = -0.59, P &lt; 0.0001).	glucose__CRP__no_interaction	glucose__insulin__no_interaction
16157541-3	In addition, we compared the (99m)Tc-labeled peptides [(111)In-<compound-id="3053">diethylenetriaminepentaacetic acid</compound-id>(0)]<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> ([(111)In-DTPA]-OC) and [(111)In-<compound-id="121841">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</compound-id>(0),<compound-id="6057">Tyr</compound-id>(3),Thr(8)]<compound-id="383414,44420813,448601,57181882,6400441,86289069">octreotide</compound-id> ([(111)In-DOTA]-<compound-id="18526942">TATE</compound-id>) with regard to the rate of internalization and the biodistribution in AR4-2J (expressing the <protein-id="P30680">somatostatin receptor subtype 2</protein-id>) tumor-bearing rats.	diethylenetriaminepentaacetic acid__somatostatin receptor subtype 2__no_interaction	TATE__somatostatin receptor subtype 2__no_interaction	1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid__somatostatin receptor subtype 2__no_interaction	Tyr__somatostatin receptor subtype 2__no_interaction	octreotide__somatostatin receptor subtype 2__no_interaction
1566823-7	<compound-id="612">Lactate</compound-id> increased more during HG exercise (LG = 16 +/- 5, HG = 61 +/- 7 mmol/kg dry wt; P less than or equal to 0.001), whereas <protein-id="P29218,A0A024R830">IMP</protein-id> increased more during LG (LG = 2.8 +/- 0.6, HG = 0.9 +/- 0.2 mmol/kg dry wt; P less than or equal to 0.05).	Lactate__IMP__no_interaction
15943790-4	Karyotyping analyzes revealed that the chromosome numbers of the three cell systems ranged from 60 to 67 with 3n ploidies, and that there were many structural aberrations, such as <compound-id="445801">del</compound-id>(11)(q13), <compound-id="445801">del</compound-id>(22)(q13), add(2)(p11), add(7)(q22), extra copies for chromosomes 1, 2, 3, 5, 7, 9, 10, 11, 12, 16, 20, and 22, der(9)t(9;13)(p13;q12)add(9)(q34), and der(13;21)(q10;q10), which were shared by the three cell systems, while der(19)t(11;19)(q13;p13) was found in <protein-id="Q02410">MINT1</protein-id> and <protein-id="O96018">MINT3</protein-id>.	del__MINT1__no_interaction	del__MINT3__no_interaction
8181286-9	MEASUREMENTS AND MAIN RESULTS: Direct injection of gas samples collected in a bag from inspiratory and expiratory limbs of a breathing circuit into the arterial blood gas analyzer correlated very closely with mass spectrometer measurements for all variables (n = 32 sample measurements in 25 patients): fractional <compound-id="977">oxygen</compound-id> (r2 = .99, slope = 1.02, bias = 0.37%, precision = 0.54), fractional expired <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> (r2 = .90, slope = 0.86, bias = -0.10%, precision = 0.15), <compound-id="977">oxygen</compound-id> uptake (r2 = .87, slope = 0.99, bias = 21.6 mL/min, precision = 38.0), and <protein-id="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48">CO2</protein-id> production (r2 = .98, slope = 0.95, bias = 7.90 mL/min, precision = 15.3).	oxygen__CO2__no_interaction
2073375-1	N-(2-Iodophenyl)-N'-(tricyclo[3.3.1.1(3,7)]-<compound-id="15600">decan</compound-id>-1-yl) guanid inium <compound-id="312">chloride</compound-id>, C17H23ClIN3, Mr = 431.75, monoclinic, P2(1)/c, a = 11.696 (5), b = 20.120 (4), c = 7.754 (2) A, beta = 95.26 (3) degrees, V = 1817 (1) A3, Z = 4, Dx = 1.578 Mg m-3, lambda (<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71069 A, mu = 1.89 mm-1, F(000) = 864, T = 295 K, R = 0.071 for 1169 observed [I greater than or equal to 3 sigma(I)] reflections.	decan__Mo K alpha__no_interaction	chloride__Mo K alpha__no_interaction
15596634-5	Outcome measures were <protein-id="P05121,A0A024QYT5">plasminogen activator inhibitor type 1</protein-id> (<protein-id="P05121,A0A024QYT5">PAI-1</protein-id>), <compound-id="778,91552">homocysteine</compound-id>, <protein-id="P02675,V9HVY1">fibrinogen</protein-id>, fasting <compound-id="206,5793,64689,79025">glucose</compound-id>, blood pressure, high-density lipoprotein <compound-id="5997">cholesterol</compound-id>, triglycerides, low-density lipoprotein <compound-id="5997">cholesterol</compound-id>, and "lipid metabolic disorder" (LMD) (defined as systolic blood pressure &gt;/=140 mm Hg or diastolic blood pressure &gt;/=90 mm Hg); fasting <compound-id="206,5793,64689,79025">glucose</compound-id> &gt;/=126 mg/dL (&gt;/=7.0 mmol/L) or the use of diabetes medications; body mass index (calculated as weight in kilograms divided by the square of height in meters) &gt;/=30; triglycerides &gt;/=250 mg/dL (&gt;/=2.8 mmol/L), high-density lipoprotein <compound-id="5997">cholesterol</compound-id> &lt;40 mg/dL (&lt;1.0 mmol/L) in men and &lt;50 mg/dL (&lt;1.3 mmol/L) in women; and low-density lipoprotein <compound-id="5997">cholesterol</compound-id> level &gt;/=130 mg/dL (&gt;/=3.4 mmol/L).	cholesterol__fibrinogen__no_interaction	cholesterol__PAI-1__no_interaction	cholesterol__plasminogen activator inhibitor type 1__no_interaction	homocysteine__fibrinogen__no_interaction	homocysteine__PAI-1__no_interaction	homocysteine__plasminogen activator inhibitor type 1__no_interaction	glucose__fibrinogen__no_interaction	glucose__PAI-1__no_interaction	glucose__plasminogen activator inhibitor type 1__no_interaction
16919044-6	The <protein-id="P15090,E7DVW4">A-FABP</protein-id> serum level correlated with fasting levels of <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.34; P &lt; 0.01), <compound-id="206,5793,64689,79025">glucose</compound-id> (r = 0.21; P = 0.01), triglycerides (r = 0.4; P &lt; 0.01), BMI (r = 0.57; P &lt; 0.01) and waist circumference (r = 0.51; P &lt; 0.01), but negatively with HDL-c (r = -0.23; P &lt; 0.01) and Quicki (r = -0.32; P &lt; 0.01).	glucose__A-FABP__no_interaction	glucose__insulin__no_interaction
22816026-10	RESULTS: The mean weight (52.81 ± 8.04 kg vs 79.56 ± 9.91 kg; P &lt; 0.001), BMI (20.23 ± 3.05 kg/m(2)vs 32.19 ± 4.86 kg/m(2); P &lt; 0.001), <protein-id="P01308,I3WAC9">insulin</protein-id> (8.47 ± 3.24 μU/mL vs 14.67 ± 2.18 μU/mL; P &lt; 0.001), <compound-id="206,5793,64689,79025">glucose</compound-id> (97.44 ± 11.31 mg/dL vs 109.67 ± 8.02 mg/dL; P &lt; 0.001) and homeostasis model assessment index (2.01 ± 0.73 vs 3.96 ± 0.61; P &lt; 0.001) were significantly higher in postmenopausal obese women compared to postmenopausal non obese women.	glucose__insulin__no_interaction
19295002-15	The presence of heart failure was associated with significantly reduced MAMC (22.0 vs 23.6 cm2; P = 0.045), % AMM (28.5 vs 32.1; P = 0.021), % <protein-id="Q02223">BCM</protein-id> (33.0 vs 36.1% ; P = 0.034), BMM/<compound-id="783">H2</compound-id> (8.6 vs 9.4 kg/m2; P = 0.013), nPNA (1.17 vs 1.34 g/kg-d ; P = 0.047), serum <protein-id="P02768">albumin</protein-id> (39.7 vs 42.4 g/l; P = 0.010), serum <compound-id="588">creatinine</compound-id> (8.1 vs 9.4 mg/dl; P = 0.008) and Hb (10.5 vs 11.2 g/dl; P = 0.017).	H2__BCM__no_interaction	H2__albumin__no_interaction	creatinine__BCM__no_interaction	creatinine__albumin__no_interaction
22499471-1	A series of lanthanide <compound-id="2826723">amide</compound-id> complexes supported by bridged <protein-id="O95817">bis</protein-id>(amidinate) ligand L, LLnNHAr(1)(DME) (L = [Me(3)<compound-id="5748311">SiNC</compound-id>(Ph)N(CH(2))(3)NC(Ph)NSiMe(3)], Ar(1) = 2,6-(i)Pr(2)C(6)H(3), DME = dimethoxyethane, Ln = Y (1), Pr (2), Nd (3), Gd (4), Yb (5)), [Yb(μ(2)-NHPh)](2)(μ(2)-L)(2) (6) and [<compound-id="446553">LYb</compound-id>](2)(μ(2)-NHAr(2))(2) (7) (Ar(2) = (o-OMe)C(6)H(4)), were synthesized by reaction of LLnCl(<compound-id="8028">THF</compound-id>)(2) with the corresponding <compound-id="24532">lithium amide</compound-id> in good yields and structurally characterized by X-ray crystal structure analyses.	THF__bis__no_interaction	lithium amide__bis__no_interaction	SiNC__bis__no_interaction	LYb__bis__no_interaction	amide__bis__no_interaction
16221353-9	RESULTS: (1) At the 4(th) week, the serum <protein-id="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261">IGF1</protein-id> (724.0 +/- 153.5 ng/ml), <protein-id="P15473,A1A5Q9">IGFBP3</protein-id> (9.69 +/- 3.13 ng/ml), and VH (416.9 +/- 46.3 microm), <compound-id="135269">VSA</compound-id> (115.9 +/- 24.0 x 10(3) microm(2)), MT (583.9 +/- 68.5 microm) in the SH group were significantly higher than those of normal control group (539.4 +/- 198.4 ng/ml, 4.77 +/- 2.98 ng/ml and 322.1 +/- 25.8 microm, 85.8 +/- 17.8 x 10(3) microm(2), 480.0 +/- 61.5 microm) and IUGR control group (P &lt; 0.05).	VSA__IGFBP3__no_interaction	VSA__IGF1__no_interaction
19580248-3	Drawn were the following conclusions: (i) <compound-id="522391">Acetonitrile oxide</compound-id> (ACNO) is the compound responsible for the alkylating capacity of <compound-id="643460,5251">sorbate</compound-id>-<compound-id="946">nitrite</compound-id> mixtures; (ii) ACNO alkylates <protein-id="Q9H3D4">4-(p-nitrobenzyl)pyridine</protein-id> (<protein-id="Q9H3D4">NBP</protein-id>), a trap for alkylating agents with nucleophilic characteristics similar to those of DNA bases, forming an adduct (AD; epsilon = 1.4 x 10(4) M(-1) cm(-1); lambda = 519 nm); (iii) the <protein-id="Q9H3D4">NBP</protein-id> alkylation reaction complies with the rate equation, r = d[AD]/dt = k(alk)(ACNO)[ACNO][<protein-id="Q9H3D4">NBP</protein-id>]-k(hyd)(AD)[AD], k(alk)(ACNO) being the <protein-id="Q9H3D4">NBP</protein-id> alkylation rate constant for ACNO and k(hyd)(AD) the rate constant for the adduct hydrolysis reaction; (iv) the small fraction of ACNO forming the adduct with <protein-id="Q9H3D4">NBP</protein-id>, as well as the small magnitude of the quotient (k(alk) (ACNO)/k(hyd)(ACNO)) as compared with those reported for other alkylating agents, such as some lactones and N-alkyl-N-nitrosoureas, reveals the ACNO effective alkylating capacity to be less significant; (v) the low value of the <protein-id="Q9H3D4">NBP</protein-id>-ACNO adduct life (defined as the total amount of adduct present along the progression of the <protein-id="Q9H3D4">NBP</protein-id> alkylation per unit of alkylating agent concentration) points to the high instability of this adduct; and (vi) the obtained results are in accordance with the low carcinogenicity of ACNO.	nitrite__4-(p-nitrobenzyl)pyridine__no_interaction	nitrite__NBP__no_interaction	sorbate__4-(p-nitrobenzyl)pyridine__no_interaction	sorbate__NBP__no_interaction	Acetonitrile oxide__4-(p-nitrobenzyl)pyridine__no_interaction	Acetonitrile oxide__NBP__no_interaction
21491690-3	Dc magnetic susceptibility data for 1-6 in the temperature range 2-300 K have been analyzed through a "dimer-of-tetramers" model [H = - J(S(1A)·<protein-id="P61247,B7Z3M5">S(3A</protein-id>) + S(1A)·S(<compound-id="69255155">4A</compound-id>) + S(1A)·<protein-id="P55036,Q5VWC4">S(5A</protein-id>) + S(2B)·S(6B) + S(2B)·S(7B) + S(2B)·S(8B)) - J'S(1A)·S(2B), with S(1A) = S(2B) = S(M) and <protein-id="P61247,B7Z3M5">S(3A</protein-id>) = S(<compound-id="69255155">4A</compound-id>) = <protein-id="P55036,Q5VWC4">S(5A</protein-id>) = S(6B) = S(7B) = S(8B) = S(M')].	4A__S(3A__no_interaction	4A__S(5A__no_interaction
23468858-6	In the meta-analysis of 51,868 participants from 46 East Asian studies, 26 European studies and 19 studies of other ethnic groups, the -1131C allele was associated with higher fasting TC (weighted mean difference (WMD)  =  0.08 mmol/L, 95% CI  =  0.05, 0.10, P = 1.74×10(-9)), TG (WMD  =  0.30 mmol/L, 95% CI  =  0.26, 0.33, P =  1.87×10(-55)), LDL-<compound-id="5997">cholesterol</compound-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (WMD  =  0.04 mmol/L, 95% CI  =  0.02, 0.07, P = 0.002), and lower HDL-C (WMD  =  -0.05 mmol/L, 95% CI  =  -0.06,-0.04, P = 1.88×10(-21)), respectively.	cholesterol__LDL-C__no_interaction
17203585-4	The expression of <compound-id="871">glycans</compound-id> was examined by lectin-histochemistry using Vicia villosa lectin (VVL) for terminal alpha/beta <compound-id="35717,57455154,899">N-acetylgalactosamine</compound-id> (alpha/beta GalNAc); Galanthus nivalus lectin (GNL) for terminal <compound-id="18950">mannose</compound-id> <protein-id="P25100,B0ZBE0">alpha-1</protein-id>,3 (<protein-id="P25100,B0ZBE0">Man alpha-1,3</protein-id>); Peanut agglutinin (PNA) for <compound-id="206,439353,439357">galactose</compound-id> <protein-id="Q16558">beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc</protein-id>); Erythrina cristagalli lectin (ECL) for <compound-id="206,439353,439357">galactose</compound-id> <protein-id="Q16558">beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc</protein-id>); Sambucus nigra lectin (SNA) for <compound-id="444885,656387">sialic acid</compound-id> alpha-2.6 <compound-id="206,439353,439357">galactose</compound-id> (SA alpha-2,6 Gal); Maackia amurensis lectin II (<protein-id="Q969L2,A0A024R9E4">MAL II</protein-id>) for <compound-id="444885,656387">sialic acid</compound-id> alpha-2,3 (SA alpha-2,3); Wheat germ agglutinin (WGA) for terminal <compound-id="439174">N-acetylglucosamine</compound-id> with/ without <compound-id="444885,656387">sialic acid</compound-id> (<compound-id="11861101,24139">GlcNAc</compound-id> wo SA); succynilated WGA (sWGA) for terminal <compound-id="439174">N-acetylglucosamine</compound-id> without <compound-id="444885,656387">sialic acid</compound-id> (terminal <compound-id="11861101,24139">GlcNAc</compound-id> without SA); Griffonia simplicifolia lectin II (<compound-id="6420173">GSL</compound-id> II) for terminal alpha/beta <compound-id="439174">N-acetylglucosamine</compound-id> (alpha/beta <compound-id="11861101,24139">GlcNAc</compound-id> terminal); and Lotus tetragonolobus lectin (<compound-id="129891">LTL</compound-id>) alpha-<compound-id="19466,439554,6713579,71315513,840">fucose</compound-id>.	galactose__MAL II__no_interaction	galactose__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	galactose__Man alpha-1,3__no_interaction	galactose__alpha-1__no_interaction	galactose__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	glycans__MAL II__no_interaction	glycans__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	glycans__Man alpha-1,3__no_interaction	glycans__alpha-1__no_interaction	glycans__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	GlcNAc__MAL II__no_interaction	GlcNAc__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	GlcNAc__Man alpha-1,3__no_interaction	GlcNAc__alpha-1__no_interaction	GlcNAc__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	N-acetylglucosamine__MAL II__no_interaction	N-acetylglucosamine__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	N-acetylglucosamine__Man alpha-1,3__no_interaction	N-acetylglucosamine__alpha-1__no_interaction	N-acetylglucosamine__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	sialic acid__MAL II__no_interaction	sialic acid__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	sialic acid__Man alpha-1,3__no_interaction	sialic acid__alpha-1__no_interaction	sialic acid__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	mannose__MAL II__no_interaction	mannose__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	mannose__Man alpha-1,3__no_interaction	mannose__alpha-1__no_interaction	mannose__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	fucose__MAL II__no_interaction	fucose__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	fucose__Man alpha-1,3__no_interaction	fucose__alpha-1__no_interaction	fucose__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	GSL__MAL II__no_interaction	GSL__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	GSL__Man alpha-1,3__no_interaction	GSL__alpha-1__no_interaction	GSL__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	N-acetylgalactosamine__MAL II__no_interaction	N-acetylgalactosamine__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	N-acetylgalactosamine__Man alpha-1,3__no_interaction	N-acetylgalactosamine__alpha-1__no_interaction	N-acetylgalactosamine__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction	LTL__MAL II__no_interaction	LTL__beta-1,3N-acetylgalactosamine (Gal beta-1,3 GalNAc__no_interaction	LTL__Man alpha-1,3__no_interaction	LTL__alpha-1__no_interaction	LTL__beta-1,4 N-acetylglucosamine (Gal beta-1,4 GlcNAc__no_interaction
11243022-1	In order to evaluate the clinical characteristics of metabolic syndrome, a screening procedure was performed and in a cohort of middle-aged (40-60 years) hyperinsulinaemic (fasting plasma insulin &gt; 15 microU/ml) and/or postprandial [120 min after 75 g <compound-id="206,5793,64689,79025">glucose</compound-id> load] insulin &gt; 45 microU/ml) subjects (n = 91; men/women: 38/53; age mean +/- SD 47.6 +/- 4.3 years; body mass index: 34.6 +/- 4.9 kg/m2; waist-hip ratio: 0.92 +/- 0.07; actual blood pressure 146 +/- 16/87 +/- 9 mmHg; fasting insulin: 24.2 +/- 11.3 microU/ml; postprandial insulin 125.5 +/- 103.8 microU/ml; serum LDL-<compound-id="5997">cholesterol</compound-id>: 3.73 +/- 1.09 mmol/l; HDL-<compound-id="5997">cholesterol</compound-id>: 1.12 +/- 0.30 mmol/l; triglycerides: 2.97 +/- 2.38 mmol/l; <compound-id="1175">uric acid</compound-id> 279 +/- 79 mumol/l) plasma fasting <compound-id="91552">homocysteine</compound-id>, vitamin <protein-id="O43676,A0A024R413">B12</protein-id> and <compound-id="6037">folic acid</compound-id> levels were simultaneously determined.	homocysteine__B12__no_interaction	cholesterol__B12__no_interaction	folic acid__B12__no_interaction	uric acid__B12__no_interaction	glucose__B12__no_interaction
22239650-6	Next, a10 and a10' are predicted to decompose to C(9)H(7) (indenyl) + CO(2), 1,2-<protein-id="Q9NYD6,Q53XI4">C(10</protein-id>)H(6)O(2) (<compound-id="10667">1,2-naphthoquinone</compound-id>) + H, and 1-C(9)H(7)O (1-<compound-id="136068">benzopyranyl</compound-id>) + CO, whereas <protein-id="O14638,Q308M7">b10</protein-id> and <protein-id="O14638,Q308M7">b10</protein-id>' would dissociate to C(9)H(7) (indenyl) + CO(2), 2-C(9)H(7)O (<compound-id="9548822">2-benzopyranyl</compound-id>) + CO, and 1,2-<protein-id="Q9NYD6,Q53XI4">C(10</protein-id>)H(6)O(2) (<compound-id="10667">1,2-naphthoquinone</compound-id>) + H. On the basis of this, the 1-naphthyl + O(2) reaction is concluded to form the following products (with the overall reaction energies given in parentheses): 1-naphthoxy + O (-15.5 kcal/mol), indenyl + CO(2) (-123.9 kcal/mol), 1-<compound-id="136068">benzopyranyl</compound-id> + CO (-97.2 kcal/mol), and <compound-id="10667">1,2-naphthoquinone</compound-id> + H (-63.5 kcal/mol).	benzopyranyl__C(10__no_interaction	benzopyranyl__b10__no_interaction	2-benzopyranyl__C(10__no_interaction	2-benzopyranyl__b10__no_interaction	1,2-naphthoquinone__C(10__no_interaction	1,2-naphthoquinone__b10__no_interaction
19859595-1	A series of (mu-eta(2):eta(2)-disulfido)dinickel(II) complexes 2(n) have been synthesized by the reaction of Na(2)S(2) and <compound-id="935">nickel</compound-id>(II) complexes 1(n) supported by <compound-id="6503">tris</compound-id>[(pyridin-2-yl)methyl]amine (<compound-id="122634,22833501">TPA</compound-id>; 1(0)) [(6-methylpyridin-2-yl)methyl]<protein-id="O95817">bis</protein-id>[(pyridin-2-yl)methyl]amine (Me(1)<compound-id="122634,22833501">TPA</compound-id>; 1(1)), <protein-id="O95817">bis</protein-id>[(6-methylpyridin-2-yl)methyl][(pyridin-2-yl)methyl]amine (Me(2)<compound-id="122634,22833501">TPA</compound-id>; 1(2)) and <compound-id="11115050">tris[(6-methylpyridin-2-yl)methyl]amine</compound-id> (Me(3)<compound-id="122634,22833501">TPA</compound-id>; 1(3)), respectively, and characterised by UV-vis and resonance Raman spectroscopy.	nickel__bis__no_interaction	TPA__bis__no_interaction	tris__bis__no_interaction	tris[(6-methylpyridin-2-yl)methyl]amine__bis__no_interaction
25338341-3	METHOD: We performed an extensive MEDLINE search of articles from 1970 to January 2014 using the index word "calcinosis" and the co-indexing terms "treatment", "<compound-id="22044544,5460341">calcium</compound-id> channel blocker", "<compound-id="39186">diltiazem</compound-id>", "<compound-id="4485">nifedipine</compound-id>", "<compound-id="2520">verapamil</compound-id>", "<compound-id="2162">amlodipine</compound-id>", "anticoagulant", "<compound-id="54678486">warfarin</compound-id>", "bisphosphonate", "<compound-id="3305">etidronate</compound-id>", "<compound-id="4674">pamidronate</compound-id>", "<compound-id="2088">alendronate</compound-id>", "<compound-id="5245">risedronate</compound-id>", "<compound-id="5359268">aluminum</compound-id> hydroxide", "<compound-id="4911">probenecid</compound-id>", "antibiotic", "<compound-id="54675776">tetracycline</compound-id>", "<compound-id="54675783">minocycline</compound-id>", "<compound-id="5479530">ceftriaxone</compound-id>", "<compound-id="6167">colchicine</compound-id>", "intravenous immunoglobulin", "<compound-id="24477">sodium thiosulfate</compound-id>", "<protein-id="P01375,Q5STB3">TNF-alpha</protein-id> inhibitors", "infliximab", "rituximab", "<compound-id="5426">thalidomide</compound-id>", "corticosteroids", "stem cell transplantation".	nifedipine__TNF-alpha__no_interaction	tetracycline__TNF-alpha__no_interaction	minocycline__TNF-alpha__no_interaction	verapamil__TNF-alpha__no_interaction	colchicine__TNF-alpha__no_interaction	aluminum__TNF-alpha__no_interaction	etidronate__TNF-alpha__no_interaction	diltiazem__TNF-alpha__no_interaction	alendronate__TNF-alpha__no_interaction	thalidomide__TNF-alpha__no_interaction	warfarin__TNF-alpha__no_interaction	probenecid__TNF-alpha__no_interaction	amlodipine__TNF-alpha__no_interaction	calcium__TNF-alpha__no_interaction	sodium thiosulfate__TNF-alpha__no_interaction	pamidronate__TNF-alpha__no_interaction	risedronate__TNF-alpha__no_interaction	ceftriaxone__TNF-alpha__no_interaction
22441823-2	Our findings indicate that (1) recombinant PKCα, βII, δ, η and θ isoforms phosphorylate, in in vitro kinase assays, wild-type recombinant <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> protein expressed in E. coli and wild-type <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> protein immunoprecpitated from transfected HEK-293 cells but not the T198A mutant, (2) adoptive expressed PKCα and δ phosphorylate both transfected and endogenous <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> at T198 in HEK-293 cells, (3) T198 phosphorylation of transfected and endogenous <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> is increased by PKC activators [<compound-id="71308525">Phorbol 12-myristate</compound-id> 13-<compound-id="176">acetate</compound-id> (<compound-id="122634,22833501">PMA</compound-id>)] and suppressed by PKC inhibitors (<compound-id="5281847">Rottlerin</compound-id> A, G06976, <compound-id="2533">Calphostin C</compound-id>), (4) in parallel with increased T198 phosphorylation, <compound-id="122634,22833501">PMA</compound-id> induces stabilization of <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> protein in HeLa cells, whereas PKC inhibitors induce a decrease in <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> stability and, finally, (5) <compound-id="122634,22833501">PMA</compound-id>-induced <protein-id="P40305,A8K0H0,A0A087WZF8,Q7Z5R2">p27</protein-id> upregulation is necessary for growth arrest of HeLa and MCF-7 cells induced by PKC activation by <compound-id="122634,22833501">PMA</compound-id>.	Calphostin C__p27__no_interaction	Rottlerin__p27__no_interaction	Phorbol 12-myristate__p27__no_interaction	PMA__p27__no_interaction	acetate__p27__no_interaction
23538141-3	The results indicated that: 1) intracellular <protein-id="P01015">Ang II</protein-id> (10(-9) M) increased the total <compound-id="5462222">potassium</compound-id> current by 73% ± 2.6% (n = 22; P &lt; .05) within 5 minutes; 2) concurrently with the increment of <compound-id="5462222">potassium</compound-id> current, the resting potential was increased by 7 ± 1.5 mV (n = 23; P &lt; .05); 3) extracellular administration of <protein-id="P01015">Ang II</protein-id> (10(-9) M) reduced the total <compound-id="5462222">potassium</compound-id> current by 20% ± 1.6% (n = 21; P &lt; .05) within 5 minutes and depolarized the smooth muscle cells by 9 ± 2.3 mV (n = 26; P &lt; .05); 4) the effects of intracellular <protein-id="P01015">Ang II</protein-id> on <compound-id="5462222">potassium</compound-id> current and membrane potential were inhibited by dialyzing a PKA inhibitor (10(-9) M) inside the cell together with <protein-id="P01015">Ang II</protein-id> (10(-9) M; P &gt; .05); 5) <compound-id="60846">valsartan</compound-id> (10(-9) M) dialyzed into the cell together with <protein-id="P01015">Ang II</protein-id> (10(-9) M) abolished the effect of the peptide on <compound-id="5462222">potassium</compound-id> current and membrane potential.	potassium__Ang II__no_interaction	valsartan__Ang II__no_interaction
22251627-5	The positions of major pearl millet linkage group (LG) 2 DT-QTLs (reported from crosses H 77/833-2 × PRLT 2/89-33 and 841B × 863B) were added to the present consensus function map which identified 18 genes, coding for PSI reaction center subunit III, PHYC, actin, <compound-id="5950">alanine</compound-id> <compound-id="760">glyoxylate</compound-id> aminotransferase, <compound-id="6030">uridylate</compound-id> kinase, acyl-<compound-id="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642">CoA</compound-id> oxidase, <protein-id="P27487">dipeptidyl peptidase IV</protein-id>, MADS-box, <compound-id="5951">serine</compound-id>/<compound-id="194239,6288">threonine</compound-id> protein kinase, ubiquitin conjugating enzyme, <compound-id="23994">zinc</compound-id> finger C- × 8-C × 5-C × 3-H type, Hd3, <compound-id="181,6302">acetyl CoA</compound-id> carboxylase, chlorophyll a/b binding protein, photolyase, protein phosphatase1 regulatory subunit <protein-id="Q15435">SDS22</protein-id> and two hypothetical proteins, co-mapping in this DT-QTL interval.	alanine__SDS22__no_interaction	alanine__dipeptidyl peptidase IV__no_interaction	uridylate__SDS22__no_interaction	uridylate__dipeptidyl peptidase IV__no_interaction	CoA__SDS22__no_interaction	CoA__dipeptidyl peptidase IV__no_interaction	serine__SDS22__no_interaction	serine__dipeptidyl peptidase IV__no_interaction	zinc__SDS22__no_interaction	zinc__dipeptidyl peptidase IV__no_interaction	threonine__SDS22__no_interaction	threonine__dipeptidyl peptidase IV__no_interaction	glyoxylate__SDS22__no_interaction	glyoxylate__dipeptidyl peptidase IV__no_interaction	acetyl CoA__SDS22__no_interaction	acetyl CoA__dipeptidyl peptidase IV__no_interaction
22182581-2	Among these synthesized pyrimidine derivatives, 4-[<compound-id="97584">3-chloro-</compound-id>4-(<compound-id="68008">3-fluorobenzyloxy</compound-id>)anilino]-6-(3-acrylamidophenoxy)pyrimidine (6), 4-[<compound-id="97584">3-chloro-</compound-id>4-(<compound-id="68008">3-fluorobenzyloxy</compound-id>)anilino]-6-(3-cyanoacetamidophenoxy)pyrimidine (9), 4-[<compound-id="97584">3-chloro-</compound-id>4-(<compound-id="68008">3-fluorobenzyloxy</compound-id>)anilino]-6-{3-[6-(4-amino)pyrimidinyl]amino) phenoxy}pyrimidine (11) and 4-[<compound-id="97584">3-chloro-</compound-id>4-(<compound-id="68008">3-fluorobenzyloxy</compound-id>)anilino]-6-(3-phenoxyacetamidophenoxy)pyrimidine (14) could significantly inhibit dual <protein-id="P00533">EGFR</protein-id>/<protein-id="P04626,J3QLU9,F5H1T4,X5DNK3">ErbB-2</protein-id> kinase activities (IC(50)=37/29 nM, 48/38 nM, 61/42 nM, 65/79 nM, respectively).	3-chloro-__ErbB-2__no_interaction	3-chloro-__EGFR__no_interaction	3-fluorobenzyloxy__ErbB-2__no_interaction	3-fluorobenzyloxy__EGFR__no_interaction
7621900-3	Three antagonists, 6-propyl-7-oxo-4[[2'-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)biphenyl-4-yl]methyl]-4,7- <compound-id="90817999">dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid</compound-id> (SRL1080227), 2-ethoxy-1-[[2'-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-<compound-id="11229316,91179806">carboxylic acid</compound-id> (CV-11974) and 2-<compound-id="68006705">butyl</compound-id>-3-[[2'-(<compound-id="67519">1H-tetrazol</compound-id>-5-yl)biphenyl-4-yl]methyl]-3H-imidazo- [4,5-b]<compound-id="1049">pyridine</compound-id> (FK739), showed competitive antagonism when they were added simultaneously with [125I]<protein-id="P01015">angiotensin II</protein-id>, but <compound-id="2541">CV11974</compound-id> and SRL1080227 showed apparently noncompetitive antagonism when membranes were preincubated with each antagonist.	1H-tetrazol__angiotensin II__no_interaction	dihydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid__angiotensin II__no_interaction	butyl__angiotensin II__no_interaction	pyridine__angiotensin II__no_interaction	carboxylic acid__angiotensin II__no_interaction	CV11974__angiotensin II__no_interaction
22839727-1	Three bis-tetradentate acyclic amine ligands differing only in the arm length of the pyridine pendant arms attached to the 4,6-positions of the pyrimidine ring, namely, 4,6-bis[N,N-bis(2'-<compound-id="7523">pyridylethyl</compound-id>)aminomethyl]-2-<compound-id="593578">phenylpyrimidine</compound-id> (L(Et)), 4,6-bis[N,N-bis(2'-pyridylmethyl)aminomethyl]-2-<compound-id="593578">phenylpyrimidine</compound-id> (L(Me)), and 4,6-[(2'-pyridylmethyl)-2'-<compound-id="7523">pyridylethyl</compound-id>)aminomethyl]-2-<compound-id="593578">phenylpyrimidine</compound-id> (L(<protein-id="Q9H2W2,A0A024R3T7">Mix</protein-id>)) have been used to synthesize nine air-sensitive diiron(II) complexes: [Fe(II)(2)L(Et)(NCS)(4)]·MeOH·¾H(2)O (1·MeOH·¾H(2)O), [Fe(II)(2)L(Et)(NCSe)(4)]·H(2)O (2·H(2)O), [Fe(II)(2)L(Et)(NCBH(3))(4)]·(5/2)H(2)O (3·(5/2)H(2)O), [Fe(II)(2)L(Me)(NCS)(4)]·½H(2)O (4·½H(2)O), [Fe(II)(2)L(Me)(NCSe)(4)] (5), [Fe(II)(2)L(Me)(NCBH(3))(4)]·(3/2)H(2)O (6·(3/2)H(2)O), [Fe(II)(2)L(<protein-id="Q9H2W2,A0A024R3T7">Mix</protein-id>)(NCS)(4)]·½H(2)O (7·½H(2)O), [Fe(II)(2)L(<protein-id="Q9H2W2,A0A024R3T7">Mix</protein-id>)(NCSe)(4)]·(3/2)H(2)O (8·(3/2)H(2)O), and [Fe(II)(2)L(<protein-id="Q9H2W2,A0A024R3T7">Mix</protein-id>)(NCBH(3))(4)]·(3/2)H(2)O (9·(3/2)H(2)O).	phenylpyrimidine__Mix__no_interaction	pyridylethyl__Mix__no_interaction
12411107-6	TG, fasting <protein-id="P01308,I3WAC9">insulin</protein-id> and <compound-id="206,5793,64689,79025">glucose</compound-id>, 2-hour <protein-id="P01308,I3WAC9">insulin</protein-id> and <compound-id="206,5793,64689,79025">glucose</compound-id> levels were significantly elevated 1 month after castration (1.84 +/- 0.61 mmol/L vs 1.30 +/- 0.40 mmol/L, P &lt; 0.05; 18.16 +/- 5.57 mU/L vs 9.47 +/- 3.81 mU/L, P &lt; 0.05; 4.77 +/- 0.66 mmol/L vs 3.92 +/- 0.34 mmol/L, P &lt; 0.05; 65.52 +/- 14.78 mU/L vs 36.94 +/- 17.12 mU/L, P &lt; 0.01; 6.98 +/- 0.79 mmol/L vs 6.01 +/- 0.23 mmol/L, P = 0.001, respectively).	glucose__insulin__no_interaction
8389510-3	The AF <protein-id="O43766,Q6P5Q6,B4E0L7,A0A024R9W0">L/S</protein-id> ratio and EGF concentration increased linearly with increasing gestational age both before (r = 0.76, p &lt; 0.0001; r = 0.41, p &lt; 0.001, respectively) and after (r = 0.62, p &lt; 0.0001; r = 0.43, p &lt; 0.001 respectively) initiation of <compound-id="853">thyroxine</compound-id> treatment.	thyroxine__L/S__no_interaction
8239389-3	Tests were of 9 different types: 1) <compound-id="6322,90867653">arginine</compound-id> (n = 625); 2) <compound-id="2803">clonidine</compound-id> (n = 339); 3) <protein-id="P01308,I3WAC9">insulin</protein-id> (n = 198); 4) <compound-id="6262,91481091">ornithine</compound-id> (n = 162); 5) <protein-id="P01308,I3WAC9">insulin</protein-id> + <compound-id="6322,90867653">arginine</compound-id> (n = 203); 6) <compound-id="2803">clonidine</compound-id> + <compound-id="2369">betaxolol</compound-id> (n = 2,003); 7) L-dopa (n = 685); 8) glucagon = <compound-id="4946">propranolol</compound-id> (n = 443); 9) glucagon + <compound-id="2369">betaxolol</compound-id> (n = 815).	clonidine__insulin__no_interaction	betaxolol__insulin__no_interaction	propranolol__insulin__no_interaction	arginine__insulin__no_interaction	ornithine__insulin__no_interaction
17539299-4	RESULTS: Seven compounds were isolated as <compound-id="439514">scopolin</compound-id> (I), <compound-id="10470">octacosanoic acid</compound-id> (II), <compound-id="12411">tritriacontane</compound-id> (III), (2S,<compound-id="21439199">3S</compound-id>,4R,8E)-2-[(2'R)-2'-hydroxydocosanosylamino]-<compound-id="12697163">octadecane-1,3,4-triol</compound-id>(IV),(2S,<compound-id="21439199">3S</compound-id>,4R,8E)-2-[(2'R)-2'-hydroxytricosanosylamino]-<compound-id="12697163">octadecane-1,3,4-triol</compound-id>(V), (2S,<compound-id="21439199">3S</compound-id>,4R,8E)-2-[(2'R)-2'-hydroxytetracosanosylamino]-<compound-id="12697163">octadecane-1,3,4-triol</compound-id>(VI), (2S,<compound-id="21439199">3S</compound-id>,4R,8E)-2-[(2'R)-2'-hydroxypentacosanosylamino]-<compound-id="12697163">octadecane-1,3,4-triol</compound-id>(<protein-id="P10176,Q53XN1">VIII</protein-id>), (2S,<compound-id="21439199">3S</compound-id>,4R,8E)-2-[(2'R)-2'-hydroxyhexacosanosylamino]-<compound-id="12697163">octadecane-1,3,4-triol</compound-id>(<protein-id="P10176,Q53XN1">VIII</protein-id>).	3S__VIII__no_interaction	tritriacontane__VIII__no_interaction	octadecane-1,3,4-triol__VIII__no_interaction	octacosanoic acid__VIII__no_interaction	scopolin__VIII__no_interaction
12095139-5	<compound-id="681">Dopamine</compound-id> infusion [in cardiac surgery patients 4.2 (1.4-8.5) microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) (median, range) and in septic patients 4.0 (2.1-9.0) microg x kg(-1) x <protein-id="P13987,Q6FHM9">min(-1</protein-id>)] increased splanchnic blood flow in cardiac surgery patients from 0.61 (0.13) L x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) to 0.82 (0.13) L x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) [mean (standard deviation; SD); P = 0.018] and in septic patients from 0.91 (0.32) L x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) to 1.12 (0.40) L x <protein-id="P13987,Q6FHM9">min(-1</protein-id>) x m(-2) (P = 0.038).	Dopamine__min(-1__no_interaction
21590977-1	The synthesis of the 1st generation dendrimer 1,3,5-{trans-[Ru(C≡C-3,5-(trans-[Ru(C≡CPh)(dppe)(2) (C≡<protein-id="Q16795">CC(6</protein-id>) H(4) -4-(E)-CHCH)])(2) C(6) H(3) )(dppe)(2) (C≡<protein-id="Q16795">CC(6</protein-id>) H(4) -4-(E)-CHCH)]}(3) C(6) H(3) proceeds by a novel route that features Emmons-Horner-Wadsworth coupling of 1,3,5-C(6) H(3) (CH(2) PO(<compound-id="6324">OEt</compound-id>)(2) )(3) with trans-[Ru(C≡<protein-id="Q16795">CC(6</protein-id>) H(4) -4-CHO)Cl(dppe)(2) ] and 1-I-C(6) H(3) -3,5-(CH(2) PO(<compound-id="6324">OEt</compound-id>)(2) )(2) with trans-[Ru(C≡CPh)(C≡<protein-id="Q16795">CC(6</protein-id>) H(4) -4-CHO)(dppe)(2) ] as key steps.	OEt__CC(6__no_interaction
22464581-5	RESULTS: WBC [×10(9)/L], <protein-id="P02741">CRP</protein-id> (mg/L) and incidence of pulmonary infection in group C were significantly higher than those in group A and group B (WBC: 18.2 ± 8.7  vs.  13.2 ± 5.1, 14.5 ± 5.7; <protein-id="P02741">CRP</protein-id>: 32.9 ± 10.9  vs.  20.8 ± 9.8, 18.6 ± 8.5; incidence of pulmonary infection: 27.6%  vs.  8.6%, 10.5%, all P &lt; 0.05), but there were no statistical differences between group A and group B. ALT (U/L) in group B was significantly lower than that in group A and group C (49.0 ± 17.8  vs.  68.4 ± 16.9, 69.9 ± 13.8, both P &lt; 0.05), but there was no statistical difference between group A and group C. Incidence of hypoglycemia in group A was significantly higher than that in group B and group C (20.0%  vs.  2.6%, 3.4%, both P &lt; 0.05), but there was no statistical difference between group B and group C. There were no statistical differences in <compound-id="612">lactic acid</compound-id> (mmol/L), Cr (μmol/L) and the length of ICU stay (days) among group A, B, and C (<compound-id="612">lactic acid</compound-id>: 2.1 ± 0.8, 2.3 ± 0.5, 2.2 ± 0.7; Cr: 55.1 ± 13.4, 49.4 ± 15.7, 57.3 ± 11.6; the length of ICU stay: 3.5 ± 1.8, 3.2 ± 1.1, 3.6 ± 1.6, all P&gt;0.05).	lactic acid__CRP__no_interaction
16316811-2	METHOD: In the current prospective-randomized, placebo-controlled, double-blind study, PCOS patients (n = 116) were divided into six main groups according to <compound-id="206,5793,64689,79025">glucose</compound-id> to <protein-id="P01308,I3WAC9">insulin</protein-id> ratio (G-I ratio mg/10(-4) U) and body mass index (BMI kg/m2) as: Group 1: normoinsulinemic (G-I ratio &gt; or = 4.5 mg/10(-4) U), lean (BMI &lt; 25) (n = 37); Group 2: normoinsulinemic, overweight (BMI: 25-29.9) (n = 19); Group 3: normoinsulinemic, obese (BMI &gt; or = 30) (n = 18); Group 4: hyperinsulinemic (G-I ratio &lt; 4.5 mg/10(-4) U), lean (n = 28); Group 5: hyperinsulinemic, overweight (n = 17); Group 6: hyperinsulinemic, obese (n = 20).	glucose__insulin__no_interaction
15982585-1	The <protein-id="P14600">NK(1) receptor</protein-id> radioligands 1-[2-(3,5-bis-<compound-id="6373">trifluoromethyl</compound-id>-benzyloxy)-<compound-id="137551">1-phenyl-ethyl</compound-id>]-4-[(11)C]methyl-<compound-id="4837">piperazine</compound-id> ([(11)C]BMP, [(11)C]) and {4-[2-(3,5-bis-<compound-id="6373">trifluoromethyl</compound-id>-benzyloxy)-<compound-id="137551">1-phenyl-ethyl</compound-id>]-<compound-id="4837">piperazine</compound-id>-1-yl}-acetic acid [(11)C]<compound-id="13468584">methyl ester</compound-id> ([(11)C]BME, [(11)C]) were synthesized for evaluation as new potential PET imaging agents for brain NK(1) receptors.	methyl ester__NK(1) receptor__no_interaction	trifluoromethyl__NK(1) receptor__no_interaction	piperazine__NK(1) receptor__no_interaction	1-phenyl-ethyl__NK(1) receptor__no_interaction
8482423-2	GLP-1 7-36 <compound-id="2826723">amide</compound-id> and GLP-1 7-37 equipotently stimulated insulin secretion (integrated hormone response 0-60 min, 631 +/- 211 vs. 483 +/- 177 pmol/h x L-1) and C-peptide secretion (integrated hormone response 9064 +/- 1804 vs. 9954 +/- 2031 pmol/h x L-1) and equipotently lowered plasma <compound-id="206,5793,64689,79025">glucose</compound-id> (integrated decrease 48.3 +/- 5.7 vs. 46.2 +/- 8.4 mmol/h x L-1) and plasma <protein-id="P01275">glucagon</protein-id> (integrated decrease 80.4 +/- 24.3 vs. 156.0 +/- 34.6 pmol/h x L-1).	glucose__glucagon__no_interaction	amide__glucagon__no_interaction
23716997-6	RESULTS: Compared with normal mice, hyperlipidemic mice possessed significantly higher TC (3.50 ± 0.43 vs 2.89 ± 0.36, P &lt; 0.01), TG (1.76 ± 0.07 vs 1.10 ± 0.16, P &lt; 0.01), and <protein-id="Q921L5">LDL-C</protein-id> (1.72 ± 0.20 vs 0.82 ± 0.10, P&lt; 0.01) levels, resulting in an increase of atherogenic index (<compound-id="15942654">AI</compound-id>) (2.34 ± 1.60 vs 0.93 ± 0.55, P &lt; 0.05) and <protein-id="Q921L5">LDL-C</protein-id>/HDL-C ratio (1.43 ± 0.12 vs 0.51 ± 0.16, P &lt; 0.05).	AI__LDL-C__no_interaction
23458274-1	Syntheses of the heavy chalcogen-containing alumoxanes [(Me)LAl(<protein-id="P34913">SeH</protein-id>)]2(μ-O) (4) and ((Me)LAl)2(μ-Te)(μ-O) (7) were accomplished by the reaction of ((Me)LAlH)2(μ-O) (2; (Me)L = HC[(CMe)N(2,4,6-Me3C6H2)]2(-)) with either red <compound-id="6326970">selenium</compound-id> or metallic <compound-id="6327182">tellurium</compound-id>.	selenium__SeH__no_interaction	tellurium__SeH__no_interaction
23877573-4	The median concentrations of Σ7PCB (<compound-id="23448">PCB28</compound-id> + PCB52 + PCB101 + PCB118 + PCB138 + <compound-id="37034">PCB153</compound-id> + PCB180), Σ3HCH (α-HCH + β-HCH + γ-HCH) and Σ3pp'(<protein-id="P30046,Q53Y51">DDT</protein-id> + <compound-id="3035">DDE</compound-id> + <protein-id="P13647">DDD</protein-id>) were 1.60 ± 1.03, 0.22 ± 0.13 and 25.18 ± 82.70 μg kg(-1), respectively.	PCB153__DDD__no_interaction	PCB153__DDT__no_interaction	PCB28__DDD__no_interaction	PCB28__DDT__no_interaction	DDE__DDD__no_interaction	DDE__DDT__no_interaction
16324405-8	RESULTS: (1) When the platelets were incubated alone the <protein-id="P08758,V9HWE0">annexin V</protein-id> positive platelet ratio of the <compound-id="8583">ITP</compound-id> patients was 3.1% +/- 0.9%, not significantly different from that of the controls (3.2% +/- 1.1%, P &gt; 0.05); (2) When the platelets were co-incubated with CD 8(+) cells the <protein-id="P08758,V9HWE0">annexin V</protein-id> positive platelet ratio of the <compound-id="8583">ITP</compound-id> group (7.6% +/- 2.8%), significantly higher than that of the control group (3.6% +/- 0.9%, P &lt; 0.05); (3) When NK cells were used as effector cells, the <protein-id="P08758,V9HWE0">annexin V</protein-id> positive platelet ratio of the <compound-id="8583">ITP</compound-id> group was 3.5% +/- 1.1%), not significantly different from that of the control group (3.6% +/- 1.0%, P &gt; 0.05); (4) The expression rates of <protein-id="P48023,Q53ZZ1">FasL</protein-id> and <protein-id="P01375,Q5STB3">TNFalpha</protein-id> on CD 8(+) T cells of the <compound-id="8583">ITP</compound-id> group were 17.5% +/- 4.4% and 11.9% +/- 4.9% respectively, both significantly higher than those of the control group (8.9% +/- 1.5% and 6.4% +/- 2.1% respectively, both P &lt; 0.05), while the expression rate of <protein-id="P50591,Q6IBA9">TRAIL</protein-id> of the <compound-id="8583">ITP</compound-id> group was 16.1% +/- 3.8%, not significantly different from that of the control group (14.0% +/- 3.2%, P &gt; 0.05); (5) The mRNA levels of <protein-id="P10144,J3KQ52,Q67BC3">granzyme B</protein-id> and perforin in the CD 8(+) T cells of the <compound-id="8583">ITP</compound-id> group were 2.20% +/- 0.15% and 2.47% +/- 0.39% respectively, both significantly higher than those of the control group (1.63% +/- 0.22% and 1.80% +/- 0.31% respectively, both P &lt; 0.05).	ITP__TNFalpha__no_interaction	ITP__granzyme B__no_interaction	ITP__annexin V__no_interaction	ITP__FasL__no_interaction	ITP__TRAIL__no_interaction
19950722-11	The correlations were not observed between <protein-id="Q15848,A8K660,B2R773">adiponectin</protein-id> with total <compound-id="5997">cholesterol</compound-id> [(5.01 +/- 1.19) mmol/L] ( r(s) = -0.05, t(r) = -0.78, P = 0.44), high density lipoprotein-<compound-id="5997">cholesterol</compound-id> (HDL-C) [(1.21 +/- 0.32) mmol/L] (r(s) = 0.06, t(r) = 0.93, P = 0.36), systolic blood pressure [(131.40 +/- 14.93) mm Hg, 1 mm Hg = 0.133 kPa] (r(s) = -0.02, t(r) = -0.34, P = 0.73) and diastolic blood pressure [(86.77 +/- 9.14)mm Hg] (r(s) = -0.02, t(r) = -0.27, P = 0.78).	cholesterol__adiponectin__no_interaction
8951236-5	Six tripeptides, representing (a) phosphorylation by dimethyl phosphorothionates (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(S)(OMe)2]Ala-<compound-id="6324">OEt</compound-id>; 5), (b) phosphorylation by dimethyl phosphates (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(O)(OMe)2] Ala-<compound-id="6324">Oet</compound-id>; 6), (c) phosphorylation by O,S-dimethyl phosphorothiolates (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(O)(OMe)(<protein-id="P62304">SMe</protein-id>)]Ala-<compound-id="6324">OEt</compound-id>; 7), (d) aging following inhibition by dimethyl phosphorothionates (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(O)(OMe)(S-)]Ala-<compound-id="6324">OEt</compound-id>; 8), (e) aging following inhibition by dimethyl phosphates (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(O)(OMe)(O-)]Ala-<compound-id="6324">OEt</compound-id>; 9), and (f) phosphorylation by R/S)PSc-<compound-id="91529">isomalathion</compound-id> stereoisomers (N-CBZ-Glu-<compound-id="5951">Ser</compound-id>[O-P(O)(OMe)(SCH(CO2CO2Et)CH2-CO2Et)]Ala-<compound-id="6324">OEt</compound-id>; 10) have been synthesized.	Oet__SMe__no_interaction	Ser__SMe__no_interaction	isomalathion__SMe__no_interaction	OEt__SMe__no_interaction
8566099-1	We examined the effect of long-term <compound-id="145068">nitric oxide</compound-id> (NO) synthase inhibition on vascular and renal <protein-id="P22388">endothelin-1</protein-id> levels and evaluated the antihypertensive effect of <compound-id="44284481">endothelin</compound-id> <protein-id="P26684,A1Y2B8,A0A0G2JSX5">ETA</protein-id> receptor antagonist <compound-id="107810">FR139317</compound-id> ((R)2(-)[(R)-2(-)[(S)-2(-)[[1-(hexahydro-<compound-id="21672373">1H-azepinyl</compound-id>)]- carbonyl]amino-4-methyl-pentanoyl]amino-3(-)[3-(1-methyl-1H- indolyl)]propionyl]amino-3-(2-pyridyl) proprionic acid] on rats in which NO synthase was blocked.	nitric oxide__endothelin-1__no_interaction	nitric oxide__ETA__no_interaction	1H-azepinyl__endothelin-1__no_interaction	1H-azepinyl__ETA__no_interaction	FR139317__endothelin-1__no_interaction	FR139317__ETA__no_interaction	endothelin__endothelin-1__no_interaction	endothelin__ETA__no_interaction
12921858-6	Additionally, human calcitonin gene-related peptide alpha (<compound-id="44308929">hCGRPalpha</compound-id>), [Cys(Et)(2,7)]<compound-id="44308929">hCGRPalpha</compound-id> and [[R-(R,(R*,S*)]-N-[2-[[5-amino-1-[[4-(<compound-id="12594992">4-pyridinyl</compound-id>)-1-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-<compound-id="34264">dibromo-4-hydroxyphenyl</compound-id>)methyl]-2-oxoethyl]-4-(<compound-id="361199">1,4-dihydro-2</compound-id>-oxo-3(2H)-quinazolinyl)-,<compound-id="72887">1-Piperidinecarboxamide</compound-id>] (<compound-id="6918509">BIBN4096BS</compound-id>) competed against specific [125I]human <protein-id="P35318,P43145">adrenomedullin</protein-id>-(13-52) binding with profiles that were also best fitted to a two-site model.	BIBN4096BS__adrenomedullin__no_interaction	dibromo-4-hydroxyphenyl__adrenomedullin__no_interaction	1,4-dihydro-2__adrenomedullin__no_interaction	4-pyridinyl__adrenomedullin__no_interaction	hCGRPalpha__adrenomedullin__no_interaction	1-Piperidinecarboxamide__adrenomedullin__no_interaction
21745583-7	Furthermore, addition of GA (100 μg) inhibited: (1) spontaneous collagen degradation as assayed by CTX II enzyme-linked immunosorbent assay (ELISA) [mean CTX II (ng/g cartilage)] in control was 7.79 [95% confidence interval (CI) 2.57-13.02]-3.415 (95% CI 0.81-6.02) (P=0.0286); (2) spontaneous proMMP-13 secretion [mean <protein-id="P45452,Q53H33">MMP-13</protein-id> (ng/g cartilage)] in control was 16.98 (95% CI 7.739-26.23)-6.973 (95% CI 1.632-12.31) (P=0.0286); (3) production of IL-1β-induced inflammatory mediators such as <compound-id="145068">nitric oxide</compound-id> (NO) [mean NO (μM)] in IL-1 cultures was 11.47 (95% CI 7.10-15.83)-0.87 (95% CI 0.18-1.56) (P=0.0022); and (4) recombinant <protein-id="P45452,Q53H33">MMP-13</protein-id> in vitro activity (15-25%; P=0.004).	nitric oxide__MMP-13__no_interaction
22614629-1	Reactions of lithiated <compound-id="594591">cobalt bis</compound-id>(1,2-dicarbollide)(1(-)) anion (1(-)) in presence of <compound-id="712">paraformaldehyde</compound-id>, <compound-id="6354">ethylene oxide</compound-id> or <compound-id="10423">trimethylene oxide</compound-id> led to the substitution of 1(-) at the C-atoms resulting in the high yield formation of monosubstituted alkylhydroxy derivatives [(1-HO(CH(2))(n)-1,2-C(2)B(9)H(10))(1',2'-C(2)B(9)H(11))-3,3'-Co(III)](-) (n = 1-3) isolated as <compound-id="5354618">caesium</compound-id> salts (Cs2, <protein-id="Q8TDC0">Cs3</protein-id>, <compound-id="70701515">Cs4</compound-id>) along with disubstituted products of general formulation [(HO(CH(2))(n)-1,2-C(2)B(9)H(10))(2)-3,3'-Co(III)](-) (n = 1-3) (<compound-id="9808406,9916309">Cs5</compound-id>, Cs6 and <compound-id="11556254">Cs7</compound-id>).	ethylene oxide__Cs3__no_interaction	caesium__Cs3__no_interaction	cobalt bis__Cs3__no_interaction	trimethylene oxide__Cs3__no_interaction	Cs5__Cs3__no_interaction	Cs4__Cs3__no_interaction	Cs7__Cs3__no_interaction	paraformaldehyde__Cs3__no_interaction
1386885-2	I-<protein-id="P02743,V9HWP0">SAP</protein-id> antagonized <compound-id="5311175">I-BOP</compound-id> ([1S-(1 alpha, 2 beta(5Z),3 alpha(1E,3R*),4 alpha)]-7-[3-(3-hydroxy-4- (4'-<compound-id="10784">iodophenoxy</compound-id>)-1-butenyl)-7-oxabicyclo-[2.2.1]<compound-id="8900">heptan</compound-id>-2y l]-5'<compound-id="29373">heptenoic acid</compound-id>) and <compound-id="5311493">U46619</compound-id> [15S-hydroxy-11 alpha,9 alpha-(epoxymethano)-prosta-5Z,13E-dienoic acid)], two different TXA2/PGH2 mimetics, induced aggregation of washed human platelets in a similar manner (pA2 of 8.11 +/- 0.09, Kd = 7.8 nM, n = 3; pA2 = 8.01 +/- 0.05, Kd = 9.7 nM, n = 8, respectively).	I-BOP__SAP__no_interaction	heptenoic acid__SAP__no_interaction	U46619__SAP__no_interaction	heptan__SAP__no_interaction	iodophenoxy__SAP__no_interaction
1386885-3	I-<protein-id="P02743,V9HWP0">SAP</protein-id> also had agonistic activity, producing platelet shape change (EC50 = 9.7 nM +/- 0.6 nM at pH 7.4, n = 3) which was blocked by pretreatment of platelets with <compound-id="5311448,6437074">SQ29548</compound-id> ([1S-(1 alpha,2 beta(5Z),3 beta,4 alpha)]-7-[3-[[2- [(<compound-id="137550">phenylamino</compound-id>)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]<compound-id="64993">hept</compound-id>- 2-yl]-<compound-id="44134911">5-heptenoic acid</compound-id>), a TXA2/PGH2 receptor antagonist.	5-heptenoic acid__SAP__no_interaction	SQ29548__SAP__no_interaction	hept__SAP__no_interaction	phenylamino__SAP__no_interaction
21215125-8	The median of the ratio of <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>/<protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id> were 0.39, 0.51, 0.61, 0.65, 0.70, 0.73 and 0.76 in M3, M6, M12, <compound-id="24754814">M18</compound-id>, <compound-id="44517657">M24</compound-id>, M30 and M36, respectively which were significantly higher than that in D0 (0.19) (Z values were -5.158, -7.375, -9.078, -8.853, -8.373, -5.845 and -5.844 respectively, P &lt; 0.000).	M24__CD4__no_interaction	M24__CD8__no_interaction	M18__CD4__no_interaction	M18__CD8__no_interaction
21215125-10	In addition, the median of the absolute numbers of <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>(+)T lymphocytes in peripheral blood were 631, 813, 1050, 946, 1057, 1166 and 894 cells/mm(3) respectively in M3, M6, M12, <compound-id="24754814">M18</compound-id>, <compound-id="44517657">M24</compound-id>, M30 and M36, which were higher significantly than that of D0 (382 cells/mm(3)) (Z values were -3.318, -5.288, -6.661, -5.886, -5.801, -4.110 and -3.600 respectively, P &lt; 0.000).	M24__CD4__no_interaction	M18__CD4__no_interaction
15934750-1	The synthesis and characterization (X-ray crystallography, UV/vis spectroscopy, electrochemistry, ESI-MS, and (1)H, (13)C, and (59)Co NMR) of the complexes [Co(L)(O(2)CO)]ClO(4)xH(2)O (L = <protein-id="P00750">tpa</protein-id> (<protein-id="P00750">tpa</protein-id> = <compound-id="6503">tris</compound-id>(<compound-id="7975">2-pyridylmethyl</compound-id>)amine) (x = 1), <compound-id="60172">pmea</compound-id> (<compound-id="60172">pmea</compound-id> = bis((2-pyridyl)methyl)-2-((2-pyridyl)<compound-id="23134249">ethyl</compound-id>)amine) (x = 0), pmap (pmap = <compound-id="15502731">bis(2-(2-pyridyl)ethyl)(2-pyridylmethyl)amine</compound-id>) (x = 0), <compound-id="11016">tepa</compound-id> (<compound-id="11016">tepa</compound-id> = <compound-id="6503">tris</compound-id>(2-(2-pyridyl)<compound-id="23134249">ethyl</compound-id>)amine) (x = 0)) which contain tripodal tetradentate pyridyl ligands and chelated carbonate ligands are reported.	tris__tpa__no_interaction	pmea__tpa__no_interaction	tepa__tpa__no_interaction	2-pyridylmethyl__tpa__no_interaction	bis(2-(2-pyridyl)ethyl)(2-pyridylmethyl)amine__tpa__no_interaction	ethyl__tpa__no_interaction
20102380-6	RESULTS: Age was negatively associated with free <compound-id="6013">testosterone</compound-id> (r = -0.399, P &lt; 0.001 in 2002; r = -0.458, P &lt; 0.001 in 2007) and <protein-id="Q06520,A8K015">DHEA-S</protein-id> (r = -0.233, P = 0.02 in 2002; r = -0.336, P &lt; 0.01 in 2007) but not with total <compound-id="6013">testosterone</compound-id>, while the 5-year changes of free <compound-id="6013">testosterone</compound-id> and <protein-id="Q06520,A8K015">DHEA-S</protein-id> levels were not significant and showed no associations with major cardiovascular risk factors.	testosterone__DHEA-S__no_interaction
21627143-1	The interaction between CdSe nanocrystals (NCs) passivated with <compound-id="65577">trioctylphosphine oxide</compound-id> (TOPO) ligands and a series of Ru-polypyridine complexes-[Ru(bpy)(3)](PF(6))(2) (1), [Ru(bpy)(2)(mcb)](PF(6))(2) (2), [Ru(bpy)(mcb)(2)](BarF)(2) (3), and [Ru(tpby)(2)(dcb)](PF(6))(2) (4) (where bpy = 2,2'-bipyridine, mcb = 4-carboxy-<compound-id="11019291">4'-methyl-2,2'-bipyridine</compound-id>, tbpy = <compound-id="4249187">4,4'-di-tert-butyl-2,2'-bipyridine</compound-id>; dcb = 4,4'-<compound-id="20094891">dicarboxy-2,2'-bipyridine</compound-id>, and BarF = tetrakis[3,5-bis(<compound-id="6373">trifluoromethyl</compound-id>)phenyl]<compound-id="26574">borate</compound-id>)-was studied by attenuated total reflectance FTIR (<protein-id="Q13535">ATR-FTIR</protein-id>) and modeled using density functional theory (DFT).	trioctylphosphine oxide__ATR-FTIR__no_interaction	borate__ATR-FTIR__no_interaction	dicarboxy-2,2'-bipyridine__ATR-FTIR__no_interaction	4'-methyl-2,2'-bipyridine__ATR-FTIR__no_interaction	trifluoromethyl__ATR-FTIR__no_interaction	4,4'-di-tert-butyl-2,2'-bipyridine__ATR-FTIR__no_interaction
18985232-1	Subjecting furan to <compound-id="5360545">sodium</compound-id>-mediated magnesiation via the new heteroleptic alkyl-amido reagent [(<compound-id="8037">TMEDA</compound-id>).Na(CH(2)SiMe(3))(<protein-id="P54849,A0A024RAT0">TMP</protein-id>)Mg(<protein-id="P54849,A0A024RAT0">TMP</protein-id>)] produces the remarkable dodecasodium-hexamagnesium molecule [{(<compound-id="8037">TMEDA</compound-id>)(3)Na(6)Mg(3)(CH(2)SiMe(3))(2,5-C(4)H(2)O)(3)(2-C(4)H(3)O)(5)}(2)], built upon a bridge network of 10 monodeprotonated and 6 twofold-deprotonated furan ligands.	TMEDA__TMP__no_interaction	sodium__TMP__no_interaction
19082062-2	The ligand [2-((<compound-id="97257">2-hydroxy-</compound-id>3-(((2-hydroxyethyl)(pyridin-2-ylmethyl)amino)methyl)-<compound-id="137548">5-methylbenzyl</compound-id>)(pyridin-2-ylmethyl)amino)<compound-id="176">acetic acid</compound-id>] (H(3)L1) and two Zn(ii) complexes have been prepared and characterised as [Zn(2)(<protein-id="P07306,Q6FGQ5">HL1</protein-id>)(CH(3)COO)](PF(6)).H(2)O and Li[Zn(2)(<protein-id="P07306,Q6FGQ5">HL1</protein-id>)](4)(PO(4))(2)(PF(6))(3).(CH(3)OH).	2-hydroxy-__HL1__no_interaction	acetic acid__HL1__no_interaction	5-methylbenzyl__HL1__no_interaction
23438291-3	RESULTS: Serum <protein-id="P02765">fetuin-A</protein-id> levels were significantly associated with QT-d (r = 0.289, p = 0.044), P-d (r = 0.39, p = 0.005), total <compound-id="5997">cholesterol</compound-id> (r = 0.526, p = 0.000), <protein-id="Q14746,B1ALW7">low-density lipoprotein cholesterol</protein-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>) (r = 0.456, p = 0.00), triglyceride (r = 0.360, p = 0.011) and highly sensitive C-reactive protein (hsCRP) (r = -0.347, p = 0.030).	cholesterol__fetuin-A__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__low-density lipoprotein cholesterol__no_interaction
7756530-2	The fluorescence decay traces were analyzed with global compartmental analysis yielding the following values for the rate constants at room temperature in aqueous solution with <compound-id="104751">BAPTA</compound-id> as Ca2+ buffer: k01 = 1.2 x 10(9)s-1, <compound-id="1715">k21</compound-id> = 1.0 x 10(11) <protein-id="P09758">M-1 s-1</protein-id>, <compound-id="16122638">k02</compound-id> = 5.5 x 10(8) s-1, <protein-id="Q99456">k12</protein-id> = 2.2 x 10(7) s-1, and with <compound-id="6207">EGTA</compound-id> as Ca2+ buffer: k01 = 1.4 x 10(9) s-1, <compound-id="1715">k21</compound-id> = 5.0 x 10(10) <protein-id="P09758">M-1 s-1</protein-id>, <compound-id="16122638">k02</compound-id> = 5.5 x 10(8) s-1, <protein-id="Q99456">k12</protein-id> = 3.2 x 10(7) s-1.	EGTA__k12__no_interaction	EGTA__M-1 s-1__no_interaction	k02__k12__no_interaction	k02__M-1 s-1__no_interaction	k21__k12__no_interaction	k21__M-1 s-1__no_interaction	BAPTA__k12__no_interaction	BAPTA__M-1 s-1__no_interaction
8482332-1	The observation is reported that in low-passage human keratinocyte colonies cultured under conditions that allow full epidermal differentiation (i) the basement membrane protein <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein, identified by the mAb <protein-id="Q9NPC4">GB3</protein-id>, is codistributed with <compound-id="44342165">laminin</compound-id> and collagen type IV as well as with the bullous pemphigoid antigen in footprints deposited by growing and migrating colonies; (ii) the integrin heterodimer alpha 6 beta 4 is codistributed with the same molecules suggesting its spatial association with basement membrane components; (iii) the distribution pattern of alpha 6 beta 4 and <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein underneath individual cells is identical and is characterized by a typical "leopard skin" pattern complementary to the distribution of submembraneous F-actin microfilament network; (iv) a rabbit polyclonal antiserum to <compound-id="32518">kalinin</compound-id> (R4012) used in double-label immunofluorescence staining with mAb <protein-id="Q9NPC4">GB3</protein-id> shows that this protein has the same distribution as <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein and this suggests that they are identically located; and (v) immunoprecipitation with mAb <protein-id="Q9NPC4">GB3</protein-id> to <protein-id="Q16787,A0A0A0MTS5,A0A0A6YYF2,A0A0A0MSA0">BM-600</protein-id>/nicein and <compound-id="3352881">BM165</compound-id> to <compound-id="32518">kalinin</compound-id> shows identical bands suggesting that nicein and <compound-id="32518">kalinin</compound-id> represent the same molecular entity.	laminin__BM-600__no_interaction	laminin__GB3__no_interaction	BM165__BM-600__no_interaction	BM165__GB3__no_interaction	kalinin__BM-600__no_interaction	kalinin__GB3__no_interaction
8890720-5	Twenty patients had hyperPRL (serum <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> 331 (223-1120) mIU/l (median, range) in men and 932 (660-3927) mIU/l in women): urinary free cortisol excretion (p &lt; 0.03) and peak serum cortisol in response to IIH (p &lt; 0.02) were lower in hyperPRL than in normoPRL patients; peak serum cortisol after <protein-id="P06850">hCRF</protein-id> was not different between groups but occurred later in hyperPRL patients (at 60vs 30 min, p &lt; 0.03); urinary <compound-id="44626398">H4S</compound-id> excretion and <compound-id="6128">androstenedione</compound-id> response after <compound-id="4174">metyrapone</compound-id> were lower in hyperPRL than in normoPRL patients (p &lt; 0.05 for both): 60% of hyperPRL patients and 15% of normoPRL patients had an abnormal <compound-id="44626398">H4S</compound-id> response (p &lt; 0.025): central hypothyroidism (overt + subclinical) was present in 74% of hyperPRL and in 60% of normoPRL patients (NS); 78% of hyperPRL and 55% of normoPRL patients had gonadotrophin deficiency (NS): <protein-id="P01241,B1A4G6,B1A4G7">growth hormone</protein-id> (GH) deficiency was present in 83% of hyperPRL and in 89% of normoPRL patients (NS); 73.3% of 75 evaluable pituitary hormone axes were abnormal in hyperPRL patients compared to 53.8% of 78 hormone axes in normoPRL patients (by <compound-id="4174">metyrapone</compound-id> test to examine adrenal function, p &lt; 0.025); and no significant differences in tumour grade and stage distribution were found between hyperPRL and normoPRL patients.	metyrapone__PRL__no_interaction	metyrapone__hCRF__no_interaction	metyrapone__growth hormone__no_interaction	H4S__PRL__no_interaction	H4S__hCRF__no_interaction	H4S__growth hormone__no_interaction	androstenedione__PRL__no_interaction	androstenedione__hCRF__no_interaction	androstenedione__growth hormone__no_interaction
11196864-5	Reactions of <compound-id="123195">diazene</compound-id>-diazonium complexes 13-17 with the metal hydrides M2H2P'4 and M2'H(CO)5-nP"n afforded the heterobinuclear <protein-id="O95817">bis</protein-id>(aryldiazene) derivatives [M1(CO)<compound-id="86208116">3P2</compound-id>(mu-HN=NAr-<compound-id="449336">ArN</compound-id>=NH)M2HP'4](<compound-id="1125">BPh4</compound-id>)2 (ReFe, ReRu, ReOs, MnRu, MnOs) and [M1(CO)<compound-id="86208116">3P2</compound-id>(mu-HN=NAr-<compound-id="449336">ArN</compound-id>=NH)M2'(CO)5-nP"n](<compound-id="1125">BPh4</compound-id>)2 (ReMn, MnRe) [M1 = Re, Mn; M2 = Fe, Ru, Os; M2' = Mn, Re; P = PPh2OEt, PPh2OMe; P',P" = P(<compound-id="6324">OEt</compound-id>)3, PPh(<compound-id="6324">OEt</compound-id>)2; <compound-id="9549877">Ar-Ar</compound-id> = 4,4'-C6H4-C6H4, 4,4'-C6H4-CH2-C6H4; n = 1, 2].	Ar-Ar__bis__no_interaction	3P2__bis__no_interaction	BPh4__bis__no_interaction	OEt__bis__no_interaction	diazene__bis__no_interaction	ArN__bis__no_interaction
16422962-4	RESULTS: A statistically significant improvement in all eight parameters was observed as a result of <compound-id="5212">sildenafil</compound-id> administration: number of erections from 3.1 +/- 0.7 to 4.0 +/- 0.7 (P &lt; 0.05), erection time 22 +/- 3.5 to 34.2 +/- 5.9, minimal base tumescence 8.2 +/- 0.8 to 8.7 +/- 0.8, maximal base tumescence 12.1 +/- 0.7 to 14.2 +/- 0.7, base rigidity 75.6 +/- 3.1 to 81.6 +/- 3.6, <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> rigidity 70.6 +/- 1.5 to 75.9 +/- 3.1, minimal <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> tumescence 5.9 +/- 0.5 to 6.5 +/- 0.6, and maximal <protein-id="Q92993,A0A024R597,A0A024R5E8">tip</protein-id> tumescence 8.6 +/- 0.6 to 11.7 +/- 0.7 (P &lt; 0.0001 for each of the last seven parameters).	sildenafil__tip__no_interaction
2004445-2	The dialysis patients displayed a moderate hypertriglyceridemia (1.94 +/- 0.12 vs 1.09 +/- 0.11 mmol/L in controls, mean +/- <compound-id="5289348">SEM</compound-id>; P less than 0.001), <protein-id="P02656,A3KPE2">apo CIII</protein-id> concentrations were also increased (130.2 +/- 2.1 vs 108.4 +/- 0.7 mg/L; P less than 0.001), whereas apo CII (34.5 +/- 0.5 vs 36 +/- 0.5 mg/L; P less than 0.05), <protein-id="P02649">apo E</protein-id> (22.7 +/- 0.3 vs 27.9 +/- 0.2 mg/L; P less than 0.001), and <protein-id="P02647,A0A024R3E3">apo A-I</protein-id> (1.18 +/- 0.05 vs 1.31 +/- 0.04 g/L; P less than 0.05) were decreased.	SEM__apo CIII__no_interaction	SEM__apo A-I__no_interaction	SEM__apo E__no_interaction
21447733-6	Presented in the order of vector control, <protein-id="A6NDG6">P-gp</protein-id>, <protein-id="Q9UNQ0,A0A024RDD4">BCRP</protein-id>, and <protein-id="Q92887">MRP2</protein-id> knockdown Caco-2 cells, the P(app,B-A) values (×10(-6), cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for <compound-id="60823">atorvastatin</compound-id>; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for <compound-id="3403,446155">fluvastatin</compound-id>; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for <compound-id="446157,656606">rosuvastatin</compound-id>, respectively.	atorvastatin__BCRP__no_interaction	atorvastatin__P-gp__no_interaction	atorvastatin__MRP2__no_interaction	fluvastatin__BCRP__no_interaction	fluvastatin__P-gp__no_interaction	fluvastatin__MRP2__no_interaction	rosuvastatin__BCRP__no_interaction	rosuvastatin__P-gp__no_interaction	rosuvastatin__MRP2__no_interaction
8342613-8	A cross-reaction of <compound-id="27991">dDAVP</compound-id> with an <compound-id="439302">oxytocin</compound-id> (OT) receptor can be excluded since 1) the specific OT agonist [Thr4,Gly7]OT (10 nM) increased only slightly [Ca2+]i (delta-[Ca2+]i = 20 +/- 5 nM, n = 11); 2) the <compound-id="27991">dDAVP</compound-id> response was not altered by the specific OT antagonist [1-(beta-mercapto-beta,beta-cyclopentamethylene <compound-id="1032">propionic acid</compound-id>),2-(O-methyl)<compound-id="90983769">tyrosine</compound-id>,<compound-id="11094586">4-threonine</compound-id>, 8-<compound-id="6262,91481091">ornithine</compound-id>,9-tyrosylamide]<compound-id="24774,44285264,68649">vasotocin</compound-id> [d(CH2)5(1),O-Me-Tyr2,Thr4,<compound-id="6057">Tyr</compound-id>-NH2(9)]OVT; 3) it was insensitive to V1 antagonists but was totally blocked by the V1/V2 antagonist [d(CH2)5(1),O-Et-Tyr2,Val4]<protein-id="P01186">AVP</protein-id> ([delta[Ca2+]i = 18 +/- 4 nM, n = 6).	dDAVP__AVP__no_interaction	propionic acid__AVP__no_interaction	ornithine__AVP__no_interaction	4-threonine__AVP__no_interaction	oxytocin__AVP__no_interaction	vasotocin__AVP__no_interaction	Tyr__AVP__no_interaction	tyrosine__AVP__no_interaction
9182472-10	Responses to <compound-id="2585">carvedilol</compound-id> were greater than those to <compound-id="2249">atenolol</compound-id>, as follows: increase in total <compound-id="206,5793,64689,79025">glucose</compound-id> disposal, 9.54 mumol/kg of body weight per minute (95% CI, 7 to 11.9 mumol/kg per minute); decrease in plasma <compound-id="206,5793,64689,79025">glucose</compound-id> response to oral <compound-id="206,5793,64689,79025">glucose</compound-id>, 61 mmol/L x 180 minutes (CI, -101 to -21 mmol/L x 180 minutes); decrease in <protein-id="P01308,I3WAC9">insulin</protein-id> response to oral <compound-id="206,5793,64689,79025">glucose</compound-id>, 6.2 nmol/L x 180 minutes (CI, -9.8 to -2.6 nmol/L x 180 minutes); decrease in triglyceride level, 0.56 mmol/L (CI, -0.75 to -0.37 mmol/L; P &lt; 0.001); increase in high-density lipoprotein <compound-id="5997">cholesterol</compound-id> level, 0.13 mmol/L (CI, 0.09 to 0.17 mmol/L; P &lt; 0.001); and decrease in lipid peroxidation, 0.25 mumol/L (CI, -0.34 to -0.16 mumol/L).	cholesterol__insulin__no_interaction	glucose__insulin__no_interaction	atenolol__insulin__no_interaction	carvedilol__insulin__no_interaction
11229829-8	Principal results as mean differences (95% CI) between GO and placebo are: pulse, 2.9 beats/min (-0.8 to 6.7), P = 0.12; systolic BP, -4.5 mmHg (-10.8 to 1.9), P = 0.16; plasma total <compound-id="5997">cholesterol</compound-id>, 0.01 mmol/l (-0.34 to 0.37), P = 0.95; plasma triglycerides, -0.20 mmol/l (-0.43 to 0.03), P = 0.09; plasma TAS, 45 micromol <compound-id="40634">Trolox</compound-id> equivalent/l (-35 to 124), P = 0.26; LDL density, 0.0019 g/ml (-0.0005 to 0.0043), P = 0.12; LDL triglycerides/protein, -0.078 mg/mg (-0.149 to -0.007), P = 0.03; LDL <compound-id="5997">cholesterol</compound-id>/protein, -0.24 mg/mg (-0.69 to 0.22), P = 0.3; LDL TAS/triglycerides, 29 nmol/mg (11, 68), P = 0.15; <protein-id="P00734">prothrombin</protein-id> time, 0.99 s (-0.36 to 2.35), P = 0.14; partial thromboplastin time, 3.0 s (-1.0 to 7.1), P = 0.13.	Trolox__prothrombin__no_interaction	cholesterol__prothrombin__no_interaction
2441054-1	A series of pseudopeptide analogues of the C-terminal heptapeptide of <protein-id="P01355">cholecystokinin</protein-id> in which each peptide bond, one at a time, has been replaced by a CH2NH bond were synthesized: Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id>-Nle-Asp psi-(CH2NH)Phe-NH2 (1), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id>-Nle psi (CH2NH)<compound-id="7016047">Asp-Phe-NH2</compound-id> (2), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-<compound-id="102763">Gly-Trp</compound-id> psi-(CH2NH)Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (3), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle-Gly psi(CH2NH)Trp-Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (4), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Nle psi-(CH2NH)<compound-id="102763">Gly-Trp</compound-id>-Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (5), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id>-Nle-Asp psi (CH2NH)Phe-NH2 (6), Z-<compound-id="6057">Tyr</compound-id>-(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id>-Nle psi (CH2NH)<compound-id="7016047">Asp-Phe-NH2</compound-id> (7), Z-<compound-id="6057">Tyr</compound-id>(SO3-)-Met-<compound-id="102763">Gly-Trp</compound-id> psi (CH2NH)Nle-<compound-id="7016047">Asp-Phe-NH2</compound-id> (8).	Gly-Trp__cholecystokinin__no_interaction	Asp-Phe-NH2__cholecystokinin__no_interaction	Tyr__cholecystokinin__no_interaction
3271096-1	<compound-id="5413">Tetraethylammonium</compound-id> tribromo[2-(2- acetoxystyryl)<compound-id="7222">benzothiazole</compound-id>]platinate(II), [(C2H5)4N]-[PtBr3(C17H13NO2S)], Mr = 860.4 monoclinic, <protein-id="P38936,A0A024RCX5">P21</protein-id>/c, a = 11.230 (9), b = 19.333 (4), c = 13.685 (6) A, beta = 101.06 (4) degrees, V = 2916 (4) A3, Z = 4, D chi = 1.96 g cm-3, lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, mu = 90.3 cm-1, F(000) = 1648, T = 296 K, final R = 0.047 for 3384 unique observed reflections.	benzothiazole__P21__no_interaction	benzothiazole__Mo K alpha__no_interaction	Tetraethylammonium__P21__no_interaction	Tetraethylammonium__Mo K alpha__no_interaction
11194238-6	The mean values for NGT, IGT, and <compound-id="65103">DGT</compound-id>, respectively, and analysis of covariance P values, adjusted for age and sex, are as follows; intra-abdominal fat area by CT 69.7, 95.0, and 101.1 cm2 (P &lt; 0.0001); total CT fat area 437.7, 523.3, and 489.8 cm2 (P &lt; 0.0001); fasting triglycerides 1.40, 1.77, and 1.74 mmol/l (P = 0.002); fasting HDL <compound-id="5997">cholesterol</compound-id> 1.56, 1.50, and 1.49 mmol/l (P = 0.02); <protein-id="P01308,I3WAC9">C-peptide</protein-id> 0.80, 0.90, 0.95 nmol/l (P = 0.002); systolic BP 124.9, 132.4, and 136.9 mmHg (P = 0.0035); diastolic BP 74.8, 77.7, and 78.2 mmHg (P = 0.01).	DGT__C-peptide__no_interaction	cholesterol__C-peptide__no_interaction
17250655-3	Transiently expressing intact HEK293 cells, transfected with increasing amounts of <protein-id="Q01959">DAT</protein-id> cDNA, displayed increasing levels of surface <protein-id="Q01959">DAT</protein-id>, binding of the <compound-id="446220">cocaine</compound-id> analog [(3)H]<compound-id="6918292">2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane</compound-id> ([(3)H]CFT), and uptake of [(3)H]DA, [(3)H]N-<compound-id="39484">methyl-4-phenylpyridinium</compound-id> ([(3)H]<protein-id="P25189">MPP</protein-id>(+)), [(3)H]norepinephrine, and [(3)H]<compound-id="5202">serotonin</compound-id>.	serotonin__DAT__no_interaction	serotonin__MPP__no_interaction	cocaine__DAT__no_interaction	cocaine__MPP__no_interaction	2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane__DAT__no_interaction	2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane__MPP__no_interaction	methyl-4-phenylpyridinium__DAT__no_interaction	methyl-4-phenylpyridinium__MPP__no_interaction
10052021-5	Plasma vitamin C concentrations increased significantly (p &lt; 0.005) only in the group supplemented with vitamin C. Lipid peroxidation measured by breath <compound-id="8003">pentane</compound-id> output (BPO) (C: 7.5 +/- 1.4 vs P: 7.0 +/- 1.3 pmol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>) and plasma HPLC-separated <compound-id="10964">malondialdehyde</compound-id> (MDA) (C: 0.58 +/- 0.05 vs P: 0.47 +/- 0.05 nmol.ml-1) were not significantly different between the 2 groups at baseline and did not change after four weeks of vitamin C supplementation (BPO: C: 5.3 +/- 0.9 vs P: 5.5 +/- 0.9 pmol.kg-1.<protein-id="P13987,Q6FHM9">min-1</protein-id>; HPLC-MDA: C: 0.50 +/- 0.07 vs P: 0.42 +/- 0.07 nmol.ml-1).	pentane__min-1__no_interaction	malondialdehyde__min-1__no_interaction
15793560-2	The key cellular signaling pathways include 1) ER/coactivator interaction, 2) AR translocation into the nucleus, 3) ER/NO/sGC/<compound-id="24316">cGMP</compound-id>, 4) <protein-id="P62993,B0LPF3,Q14451">ER/Akt, 5) ER/Src, 6)ER/Src/Grb2, and 7</protein-id>) ER/Ca2+/CaM/CaMK pathways.	cGMP__ER/Akt, 5) ER/Src, 6)ER/Src/Grb2, and 7__no_interaction
11961081-2	We examined several small molecule inhibitors of alpha4beta1/<protein-id="P29533,Q3UPN1">VCAM-1</protein-id> interactions with in vitro potencies (IC(50) values) ranging from 0.52 nM (<compound-id="9828124">CP-664511</compound-id>; 3-[3-(1-[2-[<compound-id="13516411">3-methoxy</compound-id>-4-(3-O-tolyl-ureido)phenyl]-acetylamino]-3-methyl-<compound-id="68006705">butyl</compound-id>)<compound-id="11725766,25676">isoxazol</compound-id>-5-yl]-<compound-id="1032">propionic acid</compound-id>) to 38.5 nM (CP-609643; 3-[3-methyl-1-[2-[4-(3-O-tolyl-ureido)-phenyl]-acetylamino]-<compound-id="68006705">butyl</compound-id>)-<compound-id="11725766,25676">isoxazol</compound-id>-5-yl]-<compound-id="1032">propionic acid</compound-id>).	CP-664511__VCAM-1__no_interaction	3-methoxy__VCAM-1__no_interaction	butyl__VCAM-1__no_interaction	propionic acid__VCAM-1__no_interaction	isoxazol__VCAM-1__no_interaction
19175617-12	The concentrations of <protein-id="P01270">PTH</protein-id> and beta2-MG were significantly reduced by HPHD in comparison with <compound-id="221493">CHD</compound-id> (<protein-id="P01270">PTH</protein-id> 119.27 +/- 8.41 vs. 165.18 +/- 9.37 pmol/L, P = 0.01; beta2-MG 3.39 +/- 0.76 vs. 5.92+/- 1.58 g/mL, P = 0.012).	CHD__PTH__no_interaction
20601983-1	The directed assembly of N,N-<compound-id="5259992">bis(benzimidazol-2-yl-methyl)amine</compound-id> (BMA) with Cu(II), Mn(II), Ni(II) and Zn(II) salts based on <compound-id="80295">dicyanamide</compound-id> (<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca) and <compound-id="7489">terephthalate</compound-id> (mu-ta) linear bridging ligands, respectively, leads to four novel compounds: [Cu(BMA)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)(ClO(4))](n) (1), {[Mn(BMA)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)(CH(3)OH)] x ClO(4) x C(10)H(9)N(3)O x CH(3)OH}(n) (2), {[Ni(2)(BMA)(2)(mu-ta)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)] x ClO(4) x CH(3)OH x H(2)O}(n) (3), and {[Zn(2)(BMA)(2)(mu-ta)(<protein-id="P09488,X5D932,X5DR03">mu(1,5</protein-id>)-dca)] x ClO(4) x CH(3)OH}(n) (4), which were characterized by single-crystal X-ray diffraction, elemental analysis, IR, fluorescence spectroscopy, and magnetic measurement.	bis(benzimidazol-2-yl-methyl)amine__mu(1,5__no_interaction	dicyanamide__mu(1,5__no_interaction	terephthalate__mu(1,5__no_interaction
24383924-10	Baseline <compound-id="5950">alanine</compound-id> aminotransferase and <protein-id="P19440">gamma-glutamyl transferase</protein-id> (GGT) levels (71 ± 31 vs 47 ± 22, P &lt; 0.001 and 49 ± 39 vs 36 ± 28, P = 0.027, respectively), baseline mean fibrosis stage (2.2 ± 0.7 vs 1.9 ± 0.7, P = 0.018) and histologic activity index (6.3 ± 1.9 vs 4.3 ± 1.6, P &lt; 0.001) were higher in the TF group compared with the TN group.	alanine__gamma-glutamyl transferase__no_interaction
8006337-5	A distinct <protein-id="P01236,Q5I0G2,Q5THQ0">PRL</protein-id> episodic release was observed in all groups (follicular phase: 5.5 +/- 0.5, luteal phase: 6.5 +/- 0.6, postmenopause: 5 +/- 1, hyperprolactinemic women: 4.2 +/- 0.8, men: 4.8 +/- 0.4, agonadal before <compound-id="6013">testosterone</compound-id>: 6 +/- 1, agonadal during <compound-id="6013">testosterone</compound-id> administration: 5.3 +/- 0.3 peaks/6h), but mainly the computation of ISR allowed to demonstrate that the duration of the lactotropes secretory events was constant in all groups studied.	testosterone__PRL__no_interaction
15161652-4	The sequential infiltration and activation of effector cells correlated with the histopathological development of cutaneous GVHD and was accompanied by up-regulated expression of many chemokines and their receptors (CXCL-1, -2, -9, and -10; CCL-2, -5, -6, -7, -8, -9, -11, and -19; <protein-id="P51675,Q8BVW4,Q8BMH9">CCR-1</protein-id> and <protein-id="P51682">CCR-5</protein-id>), adhesion molecules (<protein-id="P13597,Q3U8M7">ICAM-1</protein-id>, <protein-id="P50284,B2RRV3,Q8BJV0">CD18</protein-id>, <protein-id="P26011">Ly69</protein-id>, <protein-id="Q3TA56,Q8C265">PSGL-1</protein-id>, <protein-id="P29533,Q3UPN1">VCAM-1</protein-id>), molecules involved in antigen processing and presentation (<protein-id="P21958,Q3TBA3,Q3U6V4">TAP1</protein-id> and <protein-id="P36371,Q792S7">TAP2</protein-id>, MHC class I and II, <protein-id="Q00609,Q549R2">CD80</protein-id>), regulators of apoptosis (<protein-id="P04187,Q3TZH4">granzyme B</protein-id>, <protein-id="P97864,Q4FJQ4">caspase 7</protein-id>, <protein-id="O08734">Bak1</protein-id>, <protein-id="Q07813,Q544Z6">Bax</protein-id>, and <protein-id="P10417,Q6NTH7">BclII</protein-id>), interferon-inducible genes (<protein-id="Q8C3V4,Q8CFQ1,Q99K94,A0A087WSP5,Q8C8M3,Q8C497">STAT1</protein-id>, <protein-id="P15314,Q5SX13,Q3U5M1">IRF-1</protein-id>, <protein-id="Q9QZ85,J7NNX8">IIGP</protein-id>, GTPI, <protein-id="Q9DCE9">IGTP</protein-id>, <protein-id="Q9R002">Ifi202A</protein-id>), stimulators of fibroblast proliferation and matrix synthesis (interleukin-1beta, transforming growth factor-beta1), and markers of keratinocyte proliferation (keratins 5 and 6), and differentiation (small <compound-id="145742,57240853,614,8988">proline</compound-id>-rich proteins 2E and 1B).	proline__TAP1__no_interaction	proline__TAP2__no_interaction	proline__caspase 7__no_interaction	proline__STAT1__no_interaction	proline__IIGP__no_interaction	proline__CD80__no_interaction	proline__PSGL-1__no_interaction	proline__CCR-5__no_interaction	proline__BclII__no_interaction	proline__Bax__no_interaction	proline__CCR-1__no_interaction	proline__granzyme B__no_interaction	proline__VCAM-1__no_interaction	proline__IGTP__no_interaction	proline__CD18__no_interaction	proline__Ifi202A__no_interaction	proline__ICAM-1__no_interaction	proline__Bak1__no_interaction	proline__IRF-1__no_interaction	proline__Ly69__no_interaction
2898330-2	By using GC/MS methodology and synthesized regioisomeric standards, we showed that three of the four possible monophenolic metabolites, alpha-[3-([2-(3,4-dimethoxyphenyl)<compound-id="23134249">ethyl</compound-id>]methyl-amino) propyl]-<compound-id="13516411">3-methoxy</compound-id>-4-hydroxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)<compound-id="8794">phenyl-acetonitrile</compound-id> (2), alpha-[3-([2-(3,4-methoxyphenyl)<compound-id="23134249">ethyl</compound-id>]methyl-amino) propyl]-3-hydroxy-4-methoxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)phenylaceto nitrile (3), and alpha-[3-([2-(<compound-id="13516411">3-methoxy</compound-id>-4-hydroxyphenyl)<compound-id="23134249">ethyl</compound-id>]methylamino) propyl]-3,4-dimethoxy-<protein-id="P25100,B0ZBE0">alpha-(1</protein-id>-<compound-id="275736">methylethyl</compound-id>)<compound-id="16227014,345685">phenylacetonitrile</compound-id> (4) were formed.	3-methoxy__alpha-(1__no_interaction	phenyl-acetonitrile__alpha-(1__no_interaction	phenylacetonitrile__alpha-(1__no_interaction	methylethyl__alpha-(1__no_interaction	ethyl__alpha-(1__no_interaction
12498906-3	In <protein-id="P08183,A4D1D2">MDR1</protein-id>-transfected Madin-Darby canine kidney, MDCKII, cell monolayers, <compound-id="2724385">digoxin</compound-id> secretion was reduced by the <protein-id="P08183,A4D1D2">MDR1</protein-id> inhibitor cyclosporin A, whereas no inhibition was seen in the presence of <compound-id="5281888">MK-571</compound-id>, 3-([(3-(2-[<compound-id="521963">7-chloro-2-quinolinyl</compound-id>]<compound-id="23134249">ethyl</compound-id>)phenyl]-[(3-dimethylamino-3-oxoprphyl)-thio)-methyl]-thio) <compound-id="1032">propanoic acid</compound-id>, a Multidrug Related Protein (MRP) inhibitor.	MK-571__MDR1__no_interaction	7-chloro-2-quinolinyl__MDR1__no_interaction	digoxin__MDR1__no_interaction	propanoic acid__MDR1__no_interaction	ethyl__MDR1__no_interaction
8174273-3	Analysis of the sugar chains by high performance liquid chromatography in combination with exoglycosidase digestion revealed an increase of a biantennary complex-type sugar chain with a fucosylated trimannosyl core; Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6(Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3) Man beta 1-4GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>(<protein-id="P04066,B5MDC5">Fuc alpha</protein-id> 1-6)GlcNAc in 7 of 13 cancer patients and an increase of a sugar chain with a fucosylated trimannosyl core and bisecting <compound-id="11861101,24139,439174,899">N-acetylglucosamine</compound-id>; Gal beta 1-4GlcNAc beta 1-2Man alpha 1-6(GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>) (Gal beta 1-4GlcNAc beta 1-2Man alpha 1-3)Man beta 1-4GlcNAc <protein-id="Q13509,Q53G92">beta 1-4</protein-id>(<protein-id="P04066,B5MDC5">Fuc alpha</protein-id> 1-6)GlcNAc in one of the 13 cancer patients.	N-acetylglucosamine__Fuc alpha__no_interaction	N-acetylglucosamine__beta 1-4__no_interaction
16106048-2	After adjustment for maternal polymorphisms, newborn <protein-id="P06858">LPL</protein-id>*S447X was associated with lower triglycerides (-21 +/- 9 mg/dl), lower LDL-<compound-id="5997">cholesterol</compound-id> (<protein-id="Q14746,B1ALW7">LDL-C</protein-id>; -12 +/- 5 mg/dl), lower <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (-14 +/- 4 mg/dl), higher HDL-C (5 +/- 2 mg/dl), and higher <protein-id="P02647,A0A024R3E3">apoA-I</protein-id> (9 +/- 4 mg/dl) in their mothers; newborn <protein-id="P06858">LPL</protein-id>*N291S was associated with higher maternal triglycerides (114 +/- 31 mg/dl); and newborn <protein-id="P02649">APOE</protein-id>*E2 (compared to E3E3) was associated with higher maternal <protein-id="Q14746,B1ALW7">LDL-C</protein-id> (14 +/- 6 mg/dl) and higher maternal <protein-id="P04114,Q7Z7Q0,Q59HB3">apoB</protein-id> (14 +/- 5 mg/dl).	cholesterol__APOE__no_interaction	cholesterol__LPL__no_interaction	cholesterol__apoB__no_interaction	cholesterol__LDL-C__no_interaction	cholesterol__apoA-I__no_interaction
18549246-1	Site-specific insertion of <compound-id="3081165">5-(3-aminopropyl)-2'-deoxyuridine</compound-id> (Z3dU) and 7-deaza-dG into the Dickerson-Drew dodecamers 5'-d(C (1)G (2)C (3)G (4)A (5)A (6)T (7)T (8)C (9) Z (10)C (11)G (12))-3'.5'-d(C (13)G (14)C (15)G (16)A (17)A (18)T (19)T (20)C (21) Z (22)C (23)G (24))-3' (named <protein-id="P13647">DDD</protein-id> (<compound-id="53301832">Z10</compound-id>)) and 5'-d(C (1)G (2)C (3)G (4)A (5)A (6)T (7) X (8)C (9) Z (10)C (11)G (12))-3'.5'-d(C (13)G (14)C (15)G (16)A (17)A (18)T (19) X (20)C (21) Z (22)C (23)G (24))-3' (named <protein-id="P13647">DDD</protein-id> (2+<compound-id="53301832">Z10</compound-id>)) (X = Z3dU; Z = 7-deaza-dG) suggests a mechanism underlying the formation of interstrand N+2 DNA cross-links by <compound-id="947">nitrogen</compound-id> mustards, e.g., <compound-id="460612">melphalan</compound-id> and <compound-id="4033">mechlorethamine</compound-id>.	melphalan__DDD__no_interaction	nitrogen__DDD__no_interaction	Z10__DDD__no_interaction	5-(3-aminopropyl)-2'-deoxyuridine__DDD__no_interaction	mechlorethamine__DDD__no_interaction
11015191-5	The presence of tertiary structure of purified ImmE1 in a solvent of mixed polarity, <compound-id="6212">chloroform</compound-id>/<compound-id="11686950,887">methanol</compound-id>/H(2)O (4:4:1) was demonstrated by (i) the constraints on <compound-id="6057">Tyr</compound-id> residues shown by the amplitude of near-UV circular dichroism spectra in the wavelength interval, 270-285 nm; (ii) the correlation between the near-UV <compound-id="6057">Tyr</compound-id> CD spectrum of single and double Cys-to-X mutants of the <protein-id="Q3ZU31">Imm</protein-id> protein and their in vivo activity; (iii) the upfield shift of methyl groups in a 1D NMR spectrum, a 2D- HSQC NMR spectrum of ImmE1 in the mixed polarity solvent mixture, and a broadening and disappearance of the <compound-id="798">indole</compound-id> (1)H <compound-id="1038,5460653">proton</compound-id> resonance from Trp94 in H3 by a spin label attached to Cys16 in the <compound-id="783">H2</compound-id> hydrophobic domain; (iv) near-UV circular dichroism spectra with a prominent ellipticity band centered at 290 nm from a single Trp inserted into the extended hydrophobic domains.	indole__Imm__no_interaction	H2__Imm__no_interaction	chloroform__Imm__no_interaction	proton__Imm__no_interaction	methanol__Imm__no_interaction	Tyr__Imm__no_interaction
16562956-2	[Cu(I)(R-PYAN)(<compound-id="6342">MeCN</compound-id>)n]B(C6F5)4 (R-PYAN = <compound-id="85985944">N-[2-(4-R-pyridin-2-yl)-ethyl]-N,N',N'-trimethyl-propane-1,3-diamine</compound-id>, R = <protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>, OMe, H, and Cl) (1R) vary over a narrow range in their Cu(II)/Cu(I) redox potentials (E(1/2) vs Fe(cp)2(+/0) = -0.40 V for 1(<protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>), -0.38 V for 1(OMe), -0.33 V for 1H, and -0.32 V for 1Cl) and in C-O stretching frequencies of their carbonyl adducts, 1R-CO: nu(C-O) = 2080, 2086, 2088, and 2090 cm(-1) for R = <protein-id="P22392,Q6FHN3,F6XY72">NMe2</protein-id>, OMe, H, and Cl, respectively.	MeCN__NMe2__no_interaction	N-[2-(4-R-pyridin-2-yl)-ethyl]-N,N',N'-trimethyl-propane-1,3-diamine__NMe2__no_interaction
10454466-1	The 5-hydroxytryptamine(1B/1D) (<protein-id="P28564">5-HT(1B</protein-id>/1D)) antagonist 2'-methyl-4'-(5-methyl-[1,2,4]<compound-id="10197612">oxadiazol</compound-id>-3-yl)-biphenyl-4-carboxyli <compound-id="8563">c acid</compound-id> [4-<compound-id="91066389">methoxy-</compound-id>3-(4-methyl-<compound-id="91216341">piperazin-1-yl</compound-id>)-phenyl]-<compound-id="2826723">amide</compound-id> (GR 127935) and <protein-id="P19327">5-HT(1A</protein-id>) antagonist N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)<compound-id="23134249">ethyl</compound-id>)-N-(2-pyridinyl)cyclohe xanecarboxamide (<compound-id="5684">WAY 100635</compound-id>) were used to assess whether hyperactivity induced by 3 mg/kg (+)-3, 4-<compound-id="1615">methylenedioxymethamphetamine</compound-id> [(+)-MDMA] is mediated by <protein-id="P28564">5-HT(1B</protein-id>/1D) and/or <protein-id="P19327">5-HT(1A</protein-id>) receptors.	methoxy-__5-HT(1B__no_interaction	methoxy-__5-HT(1A__no_interaction	piperazin-1-yl__5-HT(1B__no_interaction	piperazin-1-yl__5-HT(1A__no_interaction	amide__5-HT(1B__no_interaction	amide__5-HT(1A__no_interaction	c acid__5-HT(1B__no_interaction	c acid__5-HT(1A__no_interaction	oxadiazol__5-HT(1B__no_interaction	oxadiazol__5-HT(1A__no_interaction	WAY 100635__5-HT(1B__no_interaction	WAY 100635__5-HT(1A__no_interaction	methylenedioxymethamphetamine__5-HT(1B__no_interaction	methylenedioxymethamphetamine__5-HT(1A__no_interaction	ethyl__5-HT(1B__no_interaction	ethyl__5-HT(1A__no_interaction
9714526-4	When compared with placebo, <compound-id="4674">pamidronate</compound-id> treatment was associated with: (a) marked decreased osteoclastic resorption rate (0.86+/-0.59 microm/d vs. 5.7+/-5.0 microm/d, p=0.002), and diminished activation frequency (0.20+/-0.18 yr(-1) vs. 0.72+/-0.55 yr(-1), p=0.014); (b) compensatory reduced volume referent bone formation rate (0.17+/-0.21 yr(-1) vs. 0.71+/-0.54 yr(-1), p=0.007), but unaltered mineral appositional rate; (c) neutral (-0.66+/-5.6 mm) vs. negative (-2.15+/-2.2 microm, p=0.013) bone balance per remodelling cycle; (d) higher trabecular bone volume (21.0+/-6.2% vs. 13.0+/-3.7%, p=0.01); (e) suppressed urinary excretion and serum levels of some of the biochemical markers of bone metabolism; and (f) significant reduction of circulating soluble <protein-id="P08887,A0N0L5,A0A087WTB5">interleukin-6 receptor</protein-id> (IL-6sR) (25.9+/-4.1 ng/ml vs. 32.1+/-6.6 ng/ml, p=0.04), and (g) a uniform tendency of lower serum and marrow plasma levels of IL-6, <protein-id="P01584">IL-1beta</protein-id>, and <protein-id="P01375,Q5STB3">TNFalpha</protein-id>.	pamidronate__IL-1beta__no_interaction	pamidronate__TNFalpha__no_interaction	pamidronate__interleukin-6 receptor__no_interaction
15855434-10	RESULTS: <compound-id="54675783">Minocycline</compound-id>-treated macaques had less severe encephalitis (P = .02), reduced CNS expression of neuroinflammatory markers (major histocompatibility complex class II, P = .03; macrophage marker CD68 , P = .07; T-cell intracytoplasmic antigen 1, P = .03; <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P13500">monocyte chemoattractant protein 1</protein-id>, P = .001), reduced activation of <protein-id="Q16539,L7RSM2,B4E0K5,A0A024RD15">p38</protein-id> mitogen-activated protein kinase (P&lt;.001), less axonal degeneration (beta-amyloid precursor protein, P = .03), and lower CNS virus replication (viral RNA, P = .04; viral antigen, P = .04).	Minocycline__p38__no_interaction	Minocycline__monocyte chemoattractant protein 1__no_interaction	CSF__p38__no_interaction	CSF__monocyte chemoattractant protein 1__no_interaction
15907124-1	Coordination compounds with a <compound-id="11109901,23092711,87362681,87362782">4,4'-azobis</compound-id>(pyridine) (azpy) ligand, {[M2(azpy)6(H2O)5] x 4PF6 x azpy x H2O}n (M = Ni(II) (1) or Co(II) (2)) (0-dimensional (0-D) dimer), {[Zn(azpy)3(H2O)2] x 2PF6 x 2azpy x <compound-id="70679364">4H2O</compound-id>}n (3) (1-dimensional (1-D) fishbone-type chain), {[Ag(azpy)] x <protein-id="Q6Q759">PF6</protein-id>}n (4) (1-D linear chain), {[Mn(NCS)2(azpy)2] x azpy}n (5) (2-dimensional (2-D) grid sheet), and {[Ni(NCS)2(azpy)2] x 3toluene}n (6) (2-D grid sheet), were synthesized and structurally characterized.	4H2O__PF6__no_interaction	4,4'-azobis__PF6__no_interaction
21141136-9	The expressions of NF-kappaB protein (0.2315 +/- 0.0624, 0.3213 +/- 0.0740, 0.4729 +/- 0.0839) and mRNA (0.4370 +/- 0.0841, 0.5465 +/- 0.0503, 0.6443 +/- 0.0538) in all the lead exposed groups continuously increased compared with correspondent control groups; Group I was decreased obviously compared with group F. The expressions of FN protein (0.4243 +/- 0.0595, 0.4917 +/- 0.0891) and mRNA (0.8650 +/- 0.0880, 0.8714 +/- 0.0980) in group E and F increased compared with group B and C, but the expressions of FN protein in group I significantly decreased compared with group F; The expressions of FN mRNA in Group H and I significantly decreased compared with group E and F. CONCLUSION: The <compound-id="4875">potassium iodide</compound-id> can ameliorate renal ultrastructure and degrade expression of nuclear factor-kappaB and <protein-id="F1LST1,A0A096P6L8">fibronectin</protein-id> induced by lead. 	potassium iodide__fibronectin__no_interaction
8549614-4	The use of subtype selective muscarinic receptor antagonists (10(-7) to 10(-5) M), <compound-id="4848">pirenzepine</compound-id> (M1 &gt; M3 &gt; M2), AF-DX 116 (11-([2-[(diethylamino)-methyl]-1-piperidyl]acetyl)-5,11-dihydro-6H- pyridol[2,3-b][1,4]<compound-id="134664">benzodiazepine</compound-id>-6-one base; M2 &gt; M1 &gt; M3) and <compound-id="3602">HHSiD</compound-id> (p-fluorohexahydro-siladifenidol hydrochloride; M3 &gt; or = M1 &gt;&gt; M2) revealed that the negative inotropic effect of <compound-id="187">acetylcholine</compound-id> in atrial as well as the positive inotropic effect in ventricular trabeculae were best antagonized by AF-DX 116 and not by <compound-id="4848">pirenzepine</compound-id>, suggesting the involvement of the <protein-id="P08172,A4D1Q0,Q86SJ1,Q6SL56,Q6SL59">muscarinic M2 receptor</protein-id> subtype, possibly linked to different second messenger systems.	HHSiD__muscarinic M2 receptor__no_interaction	pirenzepine__muscarinic M2 receptor__no_interaction	acetylcholine__muscarinic M2 receptor__no_interaction	benzodiazepine__muscarinic M2 receptor__no_interaction
24049617-5	Pearson correlation coefficient between <protein-id="P02741">CRP</protein-id> and the other risk factors in case group showed that only ferritin, serum <compound-id="23925,67172434">iron</compound-id>, waist circumference, and <protein-id="Q14746,B1ALW7">LDL-c</protein-id> significantly correlated with <protein-id="P02741">CRP</protein-id> (r = 0.32 with P &lt; 0.001, r = 0.29 with P &lt; 0.05, r = 0.41 with P &lt; 0.01, and r = 0.36 with P &lt; 0.001, respectively).	iron__CRP__no_interaction	iron__LDL-c__no_interaction
9666272-5	<compound-id="446220">Cocaine</compound-id>'s in vitro effects on (a) permeability, (b) immune cell migration, (c) adhesion molecules, and (d) cytokine expression were investigated in a blood-brain barrier model constructed with brain microvascular endothelial cells and fetal astrocytes with the following results: (a) <compound-id="446220">cocaine</compound-id> and <protein-id="P16599">tumor necrosis factor-alpha</protein-id> (<protein-id="P16599">TNF-alpha</protein-id>) increased the model's permeability to <compound-id="18772499,24763">inulin</compound-id> similarly in a dose-responsive fashion; (b) <compound-id="446220">cocaine</compound-id> (10(-4) to 10(-8_ M) enhanced monocyte migration across the barrier with the maximum increase, approximately 100%, by 10(-5) M <compound-id="446220">cocaine</compound-id>; (c) <compound-id="446220">cocaine</compound-id> treatment also increased the expression of endothelial adhesion molecules, <protein-id="Q00238">intercellular adhesion molecule-1</protein-id> (<protein-id="Q00238">ICAM-1</protein-id>), <protein-id="P29534">vascular cell adhesion molecules-1</protein-id> (<protein-id="P29534">VCAM-1</protein-id>) and <protein-id="Q3SWT0">platelet/endothelial cell adhesion molecule-1</protein-id> (<protein-id="Q3SWT0">PECAM-1</protein-id>); (d) although the <compound-id="446220">cocaine</compound-id> in vitro effects on cytokine production by mononuclear cells have been difficult to assess due to a heterogeneity in the degree of responsiveness between individuals, the data suggest that mononuclear cells from <compound-id="446220">cocaine</compound-id> addicts are sensitized to in vitro <compound-id="446220">cocaine</compound-id> challenge with hypersecretion of inflammatory cytokines.	cocaine__platelet/endothelial cell adhesion molecule-1__no_interaction	cocaine__tumor necrosis factor-alpha__no_interaction	cocaine__vascular cell adhesion molecules-1__no_interaction	cocaine__PECAM-1__no_interaction	cocaine__intercellular adhesion molecule-1__no_interaction	cocaine__VCAM-1__no_interaction	cocaine__ICAM-1__no_interaction	cocaine__TNF-alpha__no_interaction	Cocaine__platelet/endothelial cell adhesion molecule-1__no_interaction	Cocaine__tumor necrosis factor-alpha__no_interaction	Cocaine__vascular cell adhesion molecules-1__no_interaction	Cocaine__PECAM-1__no_interaction	Cocaine__intercellular adhesion molecule-1__no_interaction	Cocaine__VCAM-1__no_interaction	Cocaine__ICAM-1__no_interaction	Cocaine__TNF-alpha__no_interaction	inulin__platelet/endothelial cell adhesion molecule-1__no_interaction	inulin__tumor necrosis factor-alpha__no_interaction	inulin__vascular cell adhesion molecules-1__no_interaction	inulin__PECAM-1__no_interaction	inulin__intercellular adhesion molecule-1__no_interaction	inulin__VCAM-1__no_interaction	inulin__ICAM-1__no_interaction	inulin__TNF-alpha__no_interaction
19143962-5	RESULTS: Serum hsCRP level was positively correlated with BMI (r = 0.512, P &lt; 0.01), RW (r = 0.438, P &lt; 0.05), systolic and diastolic BP (r = 0.498, P &lt; 0.01), serum <protein-id="P41159,A4D0Y8">leptin</protein-id> levels (r = 0.457, P &lt; 0.05), but not with serum lipid, <compound-id="206,5793,64689,79025">glucose</compound-id>, fasting <protein-id="P01308,I3WAC9">insulin</protein-id>, plasma hcy levels or <protein-id="P01308,I3WAC9">insulin</protein-id> resistance indexes.	glucose__leptin__no_interaction	glucose__insulin__no_interaction
23611092-10	Compared with control group, in "stage" group, <compound-id="612">lactic acid</compound-id> (Lac) was significantly lowered (1.50±1.08 mmol/L vs. 2.93±1.09 mmol/L), and pH, mixed venous <compound-id="977">oxygen</compound-id> saturation (SvO2), <compound-id="977">oxygen</compound-id> extraction ratio (O2ER), cardiac index (CI), <compound-id="977">oxygen</compound-id> delivery (<compound-id="160603">DO2</compound-id>) were significantly increased (pH:7.29±0.05 vs. 7.20±0.05, SvO2: 0.75±0.18 vs. 0.66±0.17, O2ER: 0.32±0.06 vs. 0.25±0.06, CI: 113.36±13.34 ml×s(-1)×m(-2) vs. 83.35±13.34 ml×s(-1)×m(-2), <compound-id="160603">DO2</compound-id>: 840±170 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2) vs. 630±171 ml×<protein-id="P13987,Q6FHM9">min(-1</protein-id>)×m(-2), all P&lt;0.01).	DO2__min(-1__no_interaction	lactic acid__min(-1__no_interaction	oxygen__min(-1__no_interaction
1388945-1	(1) 1,2-<compound-id="74971">Naphthalenedicarboxylic acid</compound-id>-<compound-id="3283">diethyl ether</compound-id>, C12H8O4.nC4H10O, M(r) = 216.19, tetragonal, I4(1)/a, a = 22.086 (3), c = 9.463 (3) A, V = 4616 (2) A3, Z = 16, F(000) = 1792 (without ether), F(000) = 1873 (with 2.7 molecules of ether per unit cell), Dx = 1.24 g cm-3 (without ether), Dx = 1.31 g cm-3 (with 2.7 molecules of ether per unit cell), lambda(<protein-id="Q6PIJ6,Q6AZE0">Mo K alpha</protein-id>) = 0.71073 A, T = 296 K, mu = 0.88 cm-1, R = 0.052 for 1130 unique reflections having I greater than 3 sigma I.	Naphthalenedicarboxylic acid__Mo K alpha__no_interaction	diethyl ether__Mo K alpha__no_interaction
15618238-12	In univariate analysis, DeltaCCA-<compound-id="447041">IMT</compound-id> correlated positively with age (R = 0.32, P = 0.03), BMI (R = 0.29, P = 0.05) and mean concentrations of <protein-id="P02741">CRP</protein-id> (R = 0.37, P = 0.01), <protein-id="P01375,Q5STB3">TNFalpha</protein-id> (0.52, P = 0.0002), but inversely with HDL-<compound-id="5997">cholesterol</compound-id> (R = -0.37, P = 0.01).	IMT__CRP__no_interaction	IMT__TNFalpha__no_interaction	cholesterol__CRP__no_interaction	cholesterol__TNFalpha__no_interaction
12025913-6	The results showed that plasma levels of <protein-id="P02741">CRP</protein-id> are significantly higher in patients with UA than those in patients with SA and control subjects (5.1 +/- 1.4 mg/L vs 1.7 +/- 0.4 mg/L and 1.3 +/- 0.2 mg/L, p&lt;0.01, respectively) with no difference between the latter two groups (p&gt;0.05); the total incidence of clinical events during in-hospital follow-up was higher in the group A (p&lt;0.01); the scores of coronary stenosis are significantly higher in patients with SA than those in patients with UA (4.9 +/- 2.1 vs 3.4 +/- 1.4, p&lt;0.05); there is no correlation between plasma levels of <protein-id="P02741">CRP</protein-id> and serum total <compound-id="5997">cholesterol</compound-id> (TC) as well as high-density lipoprotein <compound-id="5997">cholesterol</compound-id> (HDL-C) in both groups (p&gt;0.05 respectively); there was no correlation between plasma levels of <protein-id="P02741">CRP</protein-id> and severity of coronary stenosis was found in patients with UA (p&gt;0.05) but a significant positive association in patients with SA (p&lt;0.001); and the patients with persistent, severe, treatment-unresponsive UA had significantly higher <protein-id="P02741">CRP</protein-id> levels as well as incidence of clinical events than patients with treatment-responsive UA (7.4 +/- 1.8 mg/L vs 2.6 +/- 1.3 mg/L, p&lt;0.01; 0 vs 22.2%, p&lt;0.05).	cholesterol__CRP__no_interaction
20339887-2	In particular, log beta values for the formation of (VO)<compound-id="6914579">hTf</compound-id> (13.0 +/- 0.5), (VO)(2)<compound-id="6914579">hTf</compound-id> (25.5 +/- 0.5), (VO)HSA (9.1 +/- 1.0), (VO) (2) (d) HSA (20.9 +/- 1.0), cis-VO(<protein-id="Q12882">dhp</protein-id>)(2)(<compound-id="6914579">hTf</compound-id>) (25.5 +/- 0.6), cis-VO(<protein-id="Q12882">dhp</protein-id>)(2)(HSA) (25.9 +/- 0.6), (VO)<compound-id="6914579">hTf</compound-id>(lact) (14.5 +/- 0.8), (VO)(2)<compound-id="6914579">hTf</compound-id>(lact)(2) (28.5 +/- 0.8), (VO)<compound-id="6914579">hTf</compound-id>(pic) (15.6 +/- 0.8), and (VO)(2)<compound-id="6914579">hTf</compound-id>(pic)(2) (30.4 +/- 0.8) were determined.	hTf__dhp__no_interaction
23646229-22	Comparing patients with liver cirrhosis but without active <compound-id="10982484,702">alcohol</compound-id> consumption (n = 11), we also found significant lymphopenia (1.3 × 10(9)/L ± 0.6 × 10(9)/L vs 2.1 × 10(9)/L ± 0.5 × 10(9)/L, P &lt; 0.0001) and decreases in populations of CD3(+) (945.5 ± 547.4/mm(3) vs 1523.0 ± 364.6/mm(3), P = 0.003), <protein-id="P01730,B4DT49,B0AZV7">CD4</protein-id>(+) (745.2 ± 389.0/mm(3) vs 992.4 ± 274.7/mm(3), P = 0.032), <protein-id="P01732,Q8TAW8,Q6ZVS2">CD8</protein-id>(+) (233.9 ± 120.0/mm(3) vs 478.9 ± 164.6/mm(3), P &lt; 0.0001), and <protein-id="P15391">CD19</protein-id>(+) (150.8 ± 76.1/mm(3) vs 264.6 ± 88.0/mm(3), P = 0.001).	alcohol__CD4__no_interaction	alcohol__CD8__no_interaction	alcohol__CD19__no_interaction
17305237-7	Two methods of sample preparation, derivatization, and analysis were used on aqueous standard mixtures of, respectively, (i) eight beta-adrenoceptor ligands, including five beta-antagonists (<compound-id="1978">acebutolol</compound-id>, <compound-id="2119">alprenolol</compound-id>, <compound-id="2249">atenolol</compound-id>, <compound-id="4171">metoprolol</compound-id>, <compound-id="4828">pindolol</compound-id>) and three <protein-id="Q13562">beta2</protein-id>-agonists (<compound-id="2083">salbutamol</compound-id>, clenbuterol, terbutaline) and (ii) seventeen diuretic drugs (<compound-id="1986">acetazolamide</compound-id>, <compound-id="2122">althiazide</compound-id>, <compound-id="2315">bendroflumethiazide</compound-id>, <compound-id="2471">bumethanide</compound-id>, <compound-id="13789">canrenone</compound-id>, <compound-id="2720">chlorothiazide</compound-id>, <compound-id="2732">chlortalidone</compound-id>, <compound-id="2804">clopamide</compound-id>, ethacrinic acid, <compound-id="3440">furosemide</compound-id>, <compound-id="3639">hydrochlorothiazide</compound-id>, <compound-id="3647">hydroflumethiazide</compound-id>, <compound-id="3702">indapamide</compound-id>, <compound-id="3715">indomethacine</compound-id>, <compound-id="5833">spironolactone</compound-id>, <compound-id="5546">triamterene</compound-id>, <compound-id="5560">trichloromethiazide</compound-id>) and one masking agent (<compound-id="4911">probenecid</compound-id>).	canrenone__beta2__no_interaction	trichloromethiazide__beta2__no_interaction	indapamide__beta2__no_interaction	furosemide__beta2__no_interaction	probenecid__beta2__no_interaction	acebutolol__beta2__no_interaction	bumethanide__beta2__no_interaction	althiazide__beta2__no_interaction	acetazolamide__beta2__no_interaction	alprenolol__beta2__no_interaction	pindolol__beta2__no_interaction	atenolol__beta2__no_interaction	chlorothiazide__beta2__no_interaction	salbutamol__beta2__no_interaction	triamterene__beta2__no_interaction	clopamide__beta2__no_interaction	spironolactone__beta2__no_interaction	chlortalidone__beta2__no_interaction	bendroflumethiazide__beta2__no_interaction	hydrochlorothiazide__beta2__no_interaction	hydroflumethiazide__beta2__no_interaction	metoprolol__beta2__no_interaction	indomethacine__beta2__no_interaction
11511232-1	<compound-id="702">Ethanol</compound-id> adducts of <protein-id="O95817">bis</protein-id>(3-R-penta-2,4-dionato) <compound-id="935">nickel</compound-id>(II) have been prepared by recrystallization of the corresponding <compound-id="935">nickel</compound-id> bisacetylacetonate species from <compound-id="702">ethanol</compound-id>, and their crystal structures have been determined by X-ray diffraction: R = methyl, C16H30NiO6, a = 5.177(1), b = 9.326(1), c = 9.649(1), a = 95.39(1), beta = 100.04(1), gamma = 97.16(1), space group Ponebar, Z = 1; R = hex-5-enyl, C26H46NiO6, a = 5.176(1), b = 9.677(1), c = 14.458(1), a = 92.333(3), beta = 93.945(4), gamma = 96.011(6), space group Ponebar, Z = 1; R = phenyl, C26H34NiO6, a = 27.399(1), b = 5.349(1), c = 19.827(2), beta = 117.410(7), space group C2/c, Z = 4.	nickel__bis__no_interaction	ethanol__bis__no_interaction	Ethanol__bis__no_interaction
9809851-1	The aim was to study firstly, the motor effects of a new <protein-id="P19327">5-HT1A</protein-id> antagonist, <compound-id="6420188">NDL</compound-id>-249 [(R)-3-(<compound-id="12487536">N-cyclopentyl-N-propylamino</compound-id>)-8-fluoro-3,4-dihydro-2H-1-benzopyra n-5-<compound-id="11960529">carboxamide</compound-id> hydrochloride] and of the reference <protein-id="P19327">5-HT1A</protein-id> antagonist WAY-100 635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl))<compound-id="23134249">ethyl</compound-id>)-N-(2-pyridinyl) <compound-id="14283">cyclohexanecarboxamide</compound-id> trihydrochloride], in comparison to the <protein-id="P19327">5-HT1A</protein-id> agonist (+/-)-8-OH-DPAT [(8-hydroxy-2-(di-N-propylamino) <compound-id="8404">tetralin</compound-id>, hereafter 8-OH-DPAT], in rats acclimatised to the automated activity cages; secondly, to study whether the behavioural effects of <compound-id="6420188">NDL</compound-id>-249 and 8-OH-DPAT are sensitive to the <compound-id="5202">5-HT</compound-id> depleting effects of <compound-id="4652">p-chlorophenylalanine</compound-id> (PCPA); thirdly, to characterise the nature of the antagonist-induced activation seen in the automatic activity cages with the aid of a behavioural observation analysis; fourthly, to examine the interaction between the <protein-id="P19327">5-HT1A</protein-id> receptors mediating the behavioural effects and <compound-id="681">dopamine</compound-id> (DA) receptors.	carboxamide__5-HT1A__no_interaction	NDL__5-HT1A__no_interaction	5-HT__5-HT1A__no_interaction	cyclohexanecarboxamide__5-HT1A__no_interaction	p-chlorophenylalanine__5-HT1A__no_interaction	tetralin__5-HT1A__no_interaction	N-cyclopentyl-N-propylamino__5-HT1A__no_interaction	dopamine__5-HT1A__no_interaction	ethyl__5-HT1A__no_interaction
18070344-13	The 2 hour postoperative plasma <protein-id="P80188">NGAL</protein-id> levels strongly correlated with change in <compound-id="588">creatinine</compound-id> (r = 0.46, P &lt; 0.001), duration of AKI (r = 0.57, P &lt; 0.001), and length of hospital stay (r = 0.44, P &lt; 0.001).	creatinine__NGAL__no_interaction
15131536-4	Such trials included: the Belegian Netherlands Stent Study (BENESTENT) II, Optimal Coronary Balloon Angioplasty With Provisional Stenting Versus Primary Stent (OCBAS), Balloon Optimization vs Stent Study (BOSS), Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT), Optimum Percutaneous Transluminal Coronary Angioplasty Compared With Routine Stent Strategy (<compound-id="107901">OPUS</compound-id>-1), French Optimal Stenting Trial (FROST), Angioplasty or Stent (AS), and Doppler Endpoint Stenting International Investigation (DESTINI) trials for de novo coronary artery lesions; the Stent vs Percutaneous Angioplasty in Chronic Total Occlusion (SPACTO), Total Occlusion Study of Canada (TOSCA), Stent or Angioplasty after Recanalization of Chronic Coronary Occlusions (SARECCO), and Mayo-Japan Investigation for Chronic Total Occlusion (<compound-id="6440583">MAJIC</compound-id>) trials for coronary occlusions; the Primary Angioplasty Versus Stent Implantation in Acute Myocardial Infarction (<protein-id="A0A0A0MT80">PASTA</protein-id>), Gianturco-Roubin in Acute Myocardial Infarction (GRAMI), Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO), Immediate Coronary Angioplasty with Elective Wiktor Stent Implantation Compared with Conventional Balloon Angioplasty in Acute Myocardial Infarction (STENTUIM-2), Stent Primary Angioplasty in MI (Stent-PAMI), Zwolle, and Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (<compound-id="6468">CADILLAC</compound-id>) trials for acute ST-segment elevation myocardial infarction; and the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries (ISAR-SMART), Park, Stenting in Small Arteries (SISA), and Bestent in Small Arteries (BESMART) trials for small vessels.	OPUS__PASTA__no_interaction	MAJIC__PASTA__no_interaction	CADILLAC__PASTA__no_interaction
17333738-2	The mean <compound-id="16122568,16750043,4369303,448383">CSF</compound-id> <protein-id="P00813,F5GWI4">ADA</protein-id> values for the different groups were: 39.44 +/- 41.46, 13.00 +/- 7.43, 34.20 +/- 40.81, 3.17 +/- 4.82, 10.03 +/- 9.23, 8.67 +/- 13.60, and 2.58 +/- 2.90 U/I, respectively.	CSF__ADA__no_interaction
15118266-7	There were significant positive correlations between serum BPA and total <compound-id="6013">testosterone</compound-id> (r = 0.391, p&lt;0.001), free <compound-id="6013">testosterone</compound-id> (r = 0.504, p&lt;0.001), <compound-id="6128">androstenedione</compound-id> (r = 0.684, p&lt;0.001), and <protein-id="Q06520,A8K015">DHEAS</protein-id> (r = 0.514, p&lt;0.001) concentrations in all subjects.	testosterone__DHEAS__no_interaction	androstenedione__DHEAS__no_interaction
23990706-4	Afterwards, continuous infusion of <compound-id="36339,6338045">etomidate</compound-id> emulsion and <compound-id="60815">remifentanil</compound-id>, respectively (E1: 10 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.1 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>); E2: 15 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.2 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>); E3: 20 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>) and 0.2 μg · kg(-1) · <protein-id="P13987,Q6FHM9">min(-1</protein-id>)), and <compound-id="4943">propofol</compound-id> (P group: 6~10 mg · kg(-1) · h(-1)) were administered.	etomidate__min(-1__no_interaction	remifentanil__min(-1__no_interaction	propofol__min(-1__no_interaction
15137766-1	<compound-id="24523">Deuterium</compound-id> kinetic solvent isotope effects for the human alpha-<compound-id="90470996">thrombin</compound-id>-catalyzed hydrolysis of (1) substrates with selected P(1)-P(3) sites, Z-Pro-Arg-7-amido-<compound-id="11833">4-methylcoumarin</compound-id> (<compound-id="9920436">7-AMC</compound-id>), N-<compound-id="12623186,18362414,87576829">t-Boc</compound-id>-Val-Pro-Arg-<compound-id="9920436">7-AMC</compound-id>, <compound-id="23056">Bz</compound-id>-<compound-id="4096934">Phe-Val</compound-id>-Arg-4-<compound-id="61191">nitroanilide</compound-id> (pNA), and H-D-Phe-L-Pip-Arg-pNA, are (DOD)k(cat) = (2.8-3.3) +/- 0.1 and (DOD)(k(cat)/K(m)) = (0.8-2.1) +/- 0.1 and (2) internally fluorescence-quenched substrates (a) (AB)Val-<compound-id="133189">Phe-Pro-Arg</compound-id>-<compound-id="21285384">Ser-Phe</compound-id>-<compound-id="6992563">Arg-Leu</compound-id>-<compound-id="5962">Lys</compound-id>(<compound-id="54058300,57080304,57201203">DNP</compound-id>)-Asp-OH, an optimal sequence, and (b) (AB)<compound-id="139506">Val-Ser</compound-id>-Pro-Arg-<compound-id="21285384">Ser-Phe</compound-id>-Gln-<compound-id="5962">Lys</compound-id>(<compound-id="54058300,57080304,57201203">DNP</compound-id>)-Asp-OH, recognition sequence for factor <protein-id="P10176,Q53XN1">VIII</protein-id>, are (DOD)k(cat) = 2.2 +/- 0.2 and (DOD)(k(cat)/K(m)) = (0.8-0.9) +/- 0.1, at the pL (L = H, D) maximum, 8.4-9.0, and (25.0-26.0) +/- 0.1 degrees C. The most plausible models fitting the partial isotope effect (<compound-id="1038,5460653">proton</compound-id> inventory) data have been selected on the basis of lowest values of the reduced chi squared and consistency of fractionation factors at all substrate concentrations, assuming rate-determining acylation.	Phe-Val__VIII__no_interaction	Val-Ser__VIII__no_interaction	Lys__VIII__no_interaction	thrombin__VIII__no_interaction	proton__VIII__no_interaction	Deuterium__VIII__no_interaction	t-Boc__VIII__no_interaction	7-AMC__VIII__no_interaction	DNP__VIII__no_interaction	nitroanilide__VIII__no_interaction	Phe-Pro-Arg__VIII__no_interaction	4-methylcoumarin__VIII__no_interaction	Arg-Leu__VIII__no_interaction	Ser-Phe__VIII__no_interaction	Bz__VIII__no_interaction
11606774-5	Mesenteric arterioles of <protein-id="Q91WT9">CBS</protein-id>((-/+))/<protein-id="P11352">GPx-1((tg-)) mice</protein-id> showed vasoconstriction to superfusion with beta-<compound-id="1993">methacholine</compound-id> and bradykinin (P &lt; 0.001 vs. all other groups), whereas nonhyperhomocyst(e)inemic mice [<protein-id="Q91WT9">CBS</protein-id>((+/+))/<protein-id="P00435">GPx-1</protein-id>((tg-)) and <protein-id="Q91WT9">CBS</protein-id>((+/+))/<protein-id="P11352">GPx-1((tg+)) mice</protein-id>] demonstrated dose-dependent vasodilation in response to both agonists.	methacholine__GPx-1((tg-)) mice__no_interaction	methacholine__CBS__no_interaction	methacholine__GPx-1((tg+)) mice__no_interaction	methacholine__GPx-1__no_interaction
16295739-6	Among them 30 patients completed at least 6 months of therapy, majority (27 patients) showed improvement in liver function with decrease in serum ALT from mean (+/- SD) 118.8 +/- 106.5 to 50.2 +/- 57.1 U/L (p &lt; 0.001), decrease in serum <compound-id="5280352">bilirubin</compound-id> from 73.9 +/- 80.5 to 44.7 +/- 62.9 micromol/l (p = 0.129), increase in serum albumin from 26.2 +/- 4.2 to 33.2 +/- 3.4 g/l (p &lt; 0.05), decrease in <protein-id="P00734">prothrombin</protein-id> time from 8.3 +/- 4.0 to 3.9 +/- 2.9 seconds prolonged (p &lt; 0.05) and reduction in child pugh score from 11.0 +/- 1.7 to 7.0 +/- 1.3 (p &lt; 0.001).	bilirubin__prothrombin__no_interaction
15285676-1	The nature and dynamics of the lowest excited states of <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(I)(L)(CO)(3)(phen)](+) and <protein-id="Q00597,A0A024R9N2,B4E3W2,A0A087WW44">fac</protein-id>-[Re(I)(L)(CO)(3)(5-NO(2)-phen)](+) [L = Cl(-), 4-<compound-id="23134249">ethyl</compound-id>-<compound-id="1049">pyridine</compound-id> (4-Etpy), <compound-id="795">imidazole</compound-id> (<compound-id="444499">imH</compound-id>); phen = 1,10-<compound-id="67473">phenanthroline</compound-id>] have been investigated by picosecond visible and IR transient absorption spectroscopy in aqueous (L = <compound-id="444499">imH</compound-id>), acetonitrile (L = 4-Etpy, <compound-id="444499">imH</compound-id>), and <compound-id="887">MeOH</compound-id> (L = <compound-id="444499">imH</compound-id>) solutions.	phenanthroline__fac__no_interaction	imH__fac__no_interaction	pyridine__fac__no_interaction	MeOH__fac__no_interaction	ethyl__fac__no_interaction	imidazole__fac__no_interaction
14735233-3	This issue focuses on the following selection of drugs: Abetimus <compound-id="5360545">sodium</compound-id>, adalimumab, alefacept, alemtuzumab, <compound-id="123606">almotriptan</compound-id>, AMGN-0007, <compound-id="90470007">anakinra</compound-id>, anti-<protein-id="Q28090,Q71AW3">CTLA-4</protein-id> Mab, L-<compound-id="6322,90867653">arginine</compound-id> hydrochloride, <compound-id="179337">arzoxifene hydrochloride</compound-id>, <compound-id="2247">astemizole</compound-id>, <compound-id="148192">atazanavir sulfate</compound-id>, atlizumab; Belimumab, BG-9928, <compound-id="9576912">binodenoson</compound-id>, <compound-id="104865">bosentan</compound-id>, botulinum toxin type B, bovine <protein-id="P24627,B9VPZ5">lactoferrin</protein-id>, BufferGel; <compound-id="5486792,2826718,468682,66577042,71295847">Caspofungin acetate</compound-id>, <compound-id="6918155">ciclesonide</compound-id>,<compound-id="151170">cilomilast</compound-id>, <compound-id="9853710">ciluprevir</compound-id>, <compound-id="119182">clofarabine</compound-id>, CVT-3146; Darbepoetin alfa, <compound-id="124087">desloratadine</compound-id>, <compound-id="219023">diflomotecan</compound-id>, <compound-id="73303">doripenem</compound-id>, <compound-id="208898">dronedarone hydrochloride</compound-id>, drotrecogin alfa (activated), DT388-GM-<compound-id="16122568,16750043,4369303,448383">CSF</compound-id>, <compound-id="60835">duloxetine</compound-id> hydrochloride, E-5564, efalizumab, <compound-id="16130199">enfuvirtide</compound-id>, <compound-id="9568614">esomeprazole</compound-id> <compound-id="5462224">magnesium</compound-id>, <compound-id="157050">estradiol acetate</compound-id>, ETC-642, <compound-id="45588096,53396299,56927919">exenatide</compound-id>, <compound-id="5472495">exisulind</compound-id>, ezetimib; <compound-id="134018">Febuxostat</compound-id>; <compound-id="5360835">Gallium</compound-id> <compound-id="8369">maltolate</compound-id>, <compound-id="16130957,16130966">ganirelix acetate</compound-id>, <compound-id="124093">garenoxacin mesilate</compound-id>, <compound-id="123631">gefitinib</compound-id>; H11, HuMax; <protein-id="Q28028">IL-15</protein-id>, IDD-1, IGIV-C, <compound-id="5291">imatinib mesylate</compound-id>, ISIS-14803, <compound-id="216295">ITF-1697</compound-id>, <compound-id="132999">ivabradine hydrochloride</compound-id>; KRN-5500; L-365260, <compound-id="5284583">levetiracetam</compound-id>, <compound-id="3033825">levosimendan</compound-id>, <compound-id="133021">licofelone</compound-id>, <compound-id="441401">linezolid</compound-id>, <compound-id="3037609">LJP-1082</compound-id>, <compound-id="92727">lopinavir</compound-id> <compound-id="151166">lumiracoxib</compound-id>; MCC-478, <compound-id="896">melatonin</compound-id>, <compound-id="5288826">morphine hydrochloride</compound-id>, <compound-id="5360621">morphine-6-glucuronide</compound-id>, <compound-id="16760141,71312368,86287400,91506576,9571036,9604461,9832912">moxidectin</compound-id>; <compound-id="9903482">N-Acetylcarnosine</compound-id>, natalizumab, NM-702, <compound-id="5278688">NNC</compound-id>-05-1869, NSC-703940; <compound-id="216456">Ocinaplon</compound-id> OM-89, omalizumab, omeprazole/ <compound-id="767">sodium bicarbonate</compound-id>, <compound-id="219020">OPC-28326</compound-id>, <compound-id="3036505">ospemifene</compound-id>; PEG-filgrastim peginterferon alfa-2a, pegsunercept, <compound-id="40632">pirfenidone</compound-id>, <compound-id="6852372,6918245">pralmorelin</compound-id>, <compound-id="5486971">pregabalin</compound-id>; Recombinant <compound-id="16133831">glucagon-like peptide-1 (7-36) amide</compound-id>, repifermin, <compound-id="9930049">RSD-1235</compound-id>; S-8184, <compound-id="3082555">selodenoson</compound-id>, <compound-id="6597">sodium dichloroacetate</compound-id>, <compound-id="5311">suberanilohydroxamic acid</compound-id>; TAS-102, <compound-id="5405">terfenadine</compound-id>, teriparatide, <compound-id="54682461">tipranavir</compound-id> <compound-id="151173,454194">troxacitabine</compound-id>; <compound-id="46783262,5478933,656635,71433741,9574101">Ximelagatran</compound-id>; YM-337.	Ocinaplon__IL-15__no_interaction	Ocinaplon__CTLA-4__no_interaction	Ocinaplon__lactoferrin__no_interaction	ospemifene__IL-15__no_interaction	ospemifene__CTLA-4__no_interaction	ospemifene__lactoferrin__no_interaction	Febuxostat__IL-15__no_interaction	Febuxostat__CTLA-4__no_interaction	Febuxostat__lactoferrin__no_interaction	maltolate__IL-15__no_interaction	maltolate__CTLA-4__no_interaction	maltolate__lactoferrin__no_interaction	lumiracoxib__IL-15__no_interaction	lumiracoxib__CTLA-4__no_interaction	lumiracoxib__lactoferrin__no_interaction	glucagon-like peptide-1 (7-36) amide__IL-15__no_interaction	glucagon-like peptide-1 (7-36) amide__CTLA-4__no_interaction	glucagon-like peptide-1 (7-36) amide__lactoferrin__no_interaction	astemizole__IL-15__no_interaction	astemizole__CTLA-4__no_interaction	astemizole__lactoferrin__no_interaction	OPC-28326__IL-15__no_interaction	OPC-28326__CTLA-4__no_interaction	OPC-28326__lactoferrin__no_interaction	garenoxacin mesilate__IL-15__no_interaction	garenoxacin mesilate__CTLA-4__no_interaction	garenoxacin mesilate__lactoferrin__no_interaction	troxacitabine__IL-15__no_interaction	troxacitabine__CTLA-4__no_interaction	troxacitabine__lactoferrin__no_interaction	bosentan__IL-15__no_interaction	bosentan__CTLA-4__no_interaction	bosentan__lactoferrin__no_interaction	morphine-6-glucuronide__IL-15__no_interaction	morphine-6-glucuronide__CTLA-4__no_interaction	morphine-6-glucuronide__lactoferrin__no_interaction	lopinavir__IL-15__no_interaction	lopinavir__CTLA-4__no_interaction	lopinavir__lactoferrin__no_interaction	melatonin__IL-15__no_interaction	melatonin__CTLA-4__no_interaction	melatonin__lactoferrin__no_interaction	exenatide__IL-15__no_interaction	exenatide__CTLA-4__no_interaction	exenatide__lactoferrin__no_interaction	morphine hydrochloride__IL-15__no_interaction	morphine hydrochloride__CTLA-4__no_interaction	morphine hydrochloride__lactoferrin__no_interaction	ciclesonide__IL-15__no_interaction	ciclesonide__CTLA-4__no_interaction	ciclesonide__lactoferrin__no_interaction	ivabradine hydrochloride__IL-15__no_interaction	ivabradine hydrochloride__CTLA-4__no_interaction	ivabradine hydrochloride__lactoferrin__no_interaction	dronedarone hydrochloride__IL-15__no_interaction	dronedarone hydrochloride__CTLA-4__no_interaction	dronedarone hydrochloride__lactoferrin__no_interaction	sodium__IL-15__no_interaction	sodium__CTLA-4__no_interaction	sodium__lactoferrin__no_interaction	licofelone__IL-15__no_interaction	licofelone__CTLA-4__no_interaction	licofelone__lactoferrin__no_interaction	cilomilast__IL-15__no_interaction	cilomilast__CTLA-4__no_interaction	cilomilast__lactoferrin__no_interaction	NNC__IL-15__no_interaction	NNC__CTLA-4__no_interaction	NNC__lactoferrin__no_interaction	RSD-1235__IL-15__no_interaction	RSD-1235__CTLA-4__no_interaction	RSD-1235__lactoferrin__no_interaction	pirfenidone__IL-15__no_interaction	pirfenidone__CTLA-4__no_interaction	pirfenidone__lactoferrin__no_interaction	estradiol acetate__IL-15__no_interaction	estradiol acetate__CTLA-4__no_interaction	estradiol acetate__lactoferrin__no_interaction	esomeprazole__IL-15__no_interaction	esomeprazole__CTLA-4__no_interaction	esomeprazole__lactoferrin__no_interaction	suberanilohydroxamic acid__IL-15__no_interaction	suberanilohydroxamic acid__CTLA-4__no_interaction	suberanilohydroxamic acid__lactoferrin__no_interaction	pregabalin__IL-15__no_interaction	pregabalin__CTLA-4__no_interaction	pregabalin__lactoferrin__no_interaction	ciluprevir__IL-15__no_interaction	ciluprevir__CTLA-4__no_interaction	ciluprevir__lactoferrin__no_interaction	enfuvirtide__IL-15__no_interaction	enfuvirtide__CTLA-4__no_interaction	enfuvirtide__lactoferrin__no_interaction	ITF-1697__IL-15__no_interaction	ITF-1697__CTLA-4__no_interaction	ITF-1697__lactoferrin__no_interaction	sodium dichloroacetate__IL-15__no_interaction	sodium dichloroacetate__CTLA-4__no_interaction	sodium dichloroacetate__lactoferrin__no_interaction	CSF__IL-15__no_interaction	CSF__CTLA-4__no_interaction	CSF__lactoferrin__no_interaction	clofarabine__IL-15__no_interaction	clofarabine__CTLA-4__no_interaction	clofarabine__lactoferrin__no_interaction	terfenadine__IL-15__no_interaction	terfenadine__CTLA-4__no_interaction	terfenadine__lactoferrin__no_interaction	gefitinib__IL-15__no_interaction	gefitinib__CTLA-4__no_interaction	gefitinib__lactoferrin__no_interaction	LJP-1082__IL-15__no_interaction	LJP-1082__CTLA-4__no_interaction	LJP-1082__lactoferrin__no_interaction	atazanavir sulfate__IL-15__no_interaction	atazanavir sulfate__CTLA-4__no_interaction	atazanavir sulfate__lactoferrin__no_interaction	Gallium__IL-15__no_interaction	Gallium__CTLA-4__no_interaction	Gallium__lactoferrin__no_interaction	arginine__IL-15__no_interaction	arginine__CTLA-4__no_interaction	arginine__lactoferrin__no_interaction	selodenoson__IL-15__no_interaction	selodenoson__CTLA-4__no_interaction	selodenoson__lactoferrin__no_interaction	sodium bicarbonate__IL-15__no_interaction	sodium bicarbonate__CTLA-4__no_interaction	sodium bicarbonate__lactoferrin__no_interaction	tipranavir__IL-15__no_interaction	tipranavir__CTLA-4__no_interaction	tipranavir__lactoferrin__no_interaction	linezolid__IL-15__no_interaction	linezolid__CTLA-4__no_interaction	linezolid__lactoferrin__no_interaction	Caspofungin acetate__IL-15__no_interaction	Caspofungin acetate__CTLA-4__no_interaction	Caspofungin acetate__lactoferrin__no_interaction	arzoxifene hydrochloride__IL-15__no_interaction	arzoxifene hydrochloride__CTLA-4__no_interaction	arzoxifene hydrochloride__lactoferrin__no_interaction	ganirelix acetate__IL-15__no_interaction	ganirelix acetate__CTLA-4__no_interaction	ganirelix acetate__lactoferrin__no_interaction	N-Acetylcarnosine__IL-15__no_interaction	N-Acetylcarnosine__CTLA-4__no_interaction	N-Acetylcarnosine__lactoferrin__no_interaction	doripenem__IL-15__no_interaction	doripenem__CTLA-4__no_interaction	doripenem__lactoferrin__no_interaction	Ximelagatran__IL-15__no_interaction	Ximelagatran__CTLA-4__no_interaction	Ximelagatran__lactoferrin__no_interaction	imatinib mesylate__IL-15__no_interaction	imatinib mesylate__CTLA-4__no_interaction	imatinib mesylate__lactoferrin__no_interaction	exisulind__IL-15__no_interaction	exisulind__CTLA-4__no_interaction	exisulind__lactoferrin__no_interaction	moxidectin__IL-15__no_interaction	moxidectin__CTLA-4__no_interaction	moxidectin__lactoferrin__no_interaction	diflomotecan__IL-15__no_interaction	diflomotecan__CTLA-4__no_interaction	diflomotecan__lactoferrin__no_interaction	almotriptan__IL-15__no_interaction	almotriptan__CTLA-4__no_interaction	almotriptan__lactoferrin__no_interaction	desloratadine__IL-15__no_interaction	desloratadine__CTLA-4__no_interaction	desloratadine__lactoferrin__no_interaction	magnesium__IL-15__no_interaction	magnesium__CTLA-4__no_interaction	magnesium__lactoferrin__no_interaction	anakinra__IL-15__no_interaction	anakinra__CTLA-4__no_interaction	anakinra__lactoferrin__no_interaction	pralmorelin__IL-15__no_interaction	pralmorelin__CTLA-4__no_interaction	pralmorelin__lactoferrin__no_interaction	binodenoson__IL-15__no_interaction	binodenoson__CTLA-4__no_interaction	binodenoson__lactoferrin__no_interaction	levetiracetam__IL-15__no_interaction	levetiracetam__CTLA-4__no_interaction	levetiracetam__lactoferrin__no_interaction	levosimendan__IL-15__no_interaction	levosimendan__CTLA-4__no_interaction	levosimendan__lactoferrin__no_interaction	duloxetine__IL-15__no_interaction	duloxetine__CTLA-4__no_interaction	duloxetine__lactoferrin__no_interaction
22170388-7	<compound-id="702">Ethanol</compound-id> solvate 3 with a dimer motif shows field-induced single-molecule magnet like behavior below 2.5 K. The exchange coupling constant J within the dimer propagated by π-π interaction is -0.14 cm(-1) by fitting the susceptibility data χ(M) T (20-300 K) with the <protein-id="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5">spin</protein-id> Hamiltonian H = -2J S(A) S(B) + β(S((A)g(A)) + S((B)g(B)))H. The present studies open a new way to construct SCMs from anisotropic magnetic single-ion units through weak intermolecular interactions in the absence of bridging ligands.	Ethanol__spin__no_interaction
10565441-6	Mean concentrations (X(g) x DF) were as follows: <protein-id="P11182">E2beta</protein-id> (bpl) 31.1 (1.16), (spl) 24.2 (1.42) pg ml(-1); E1 (bpl) 143.3 (1.21), (spl) 117.7 (1.53) pg ml(-1); <compound-id="57336492">E1S</compound-id> (bpl) 157.3 (1.44), (spl) 2.92 (1.42) ng ml(-1); T (bpl) 570.6 (1.43), (spl) 23.1 (1.68) pg ml(-1); A (spl) 17.9 (1.39) pg ml(-1); DHEH (spl) 12.4 (1.51) pg ml(-1); 5alpha-DHT (spl) 9.7 (1.29) pg ml(-1).	E1S__E2beta__no_interaction
16990846-3	Our results are summarized as follows: (i) a recombinant HSV (M012) was constructed in which both copies of the gamma(1)34.5 gene were replaced with the bacterial CD gene, under the control of the cellular promoter <protein-id="P08046,Q544D6,Q8CAT6">Egr-1</protein-id>; (ii) M012-infected cells in vitro efficiently convert <compound-id="3366">5-fluorocytosine</compound-id> (5-FC) to 5-<compound-id="3385">fluorouracil</compound-id>, thereby enhancing cytotoxicity of neighboring, uninfected cells; (iii) both direct and bystander cytotoxicity of murine neuroblastoma and human glioma cell lines after infection with M012 were demonstrated; (iv) direct intracerebral inoculation of A/J mice demonstrated lack of neurotoxicity at doses similar to G207, a gamma(1)34.5-deleted HSV with demonstrated safety in human patient trials and (v) intratumoral injection of M012 into Neuro-2a flank tumors in combination with 5-FC administration significantly reduced tumor growth versus tumors treated with <compound-id="706845">R3659</compound-id> combined with 5-FC, or treated with M012 alone.	5-fluorocytosine__Egr-1__no_interaction	R3659__Egr-1__no_interaction	fluorouracil__Egr-1__no_interaction
2077810-11	5) When the bilateral vertebral arteries arising from the respective subclavian artery are found in the above 2), 3) and 4) "2" postfixed "C" and the prime mark "', as type G'2, type <compound-id="447253">C2G</compound-id>, type <protein-id="Q9H330">CG'2</protein-id>, type <compound-id="447253">C2G</compound-id>', type <compound-id="447253">C2G</compound-id>'2, type H'2, type C2H, type CH'2, type C2H', type C2H'2.	C2G__CG'2__no_interaction
17923273-5	<protein-id="P41159,A4D0Y8">leptin</protein-id> showed a positive correlation with BMI (r = 0.851, p &lt;0.0001), waist-to-hip ratio (r = 0.692, p &lt;0.0001), fasting <protein-id="P01308,I3WAC9">insulin</protein-id> (r = 0.441, p &lt;0.001), HOMA-IR (r = 0.412, p = 0.002), fibrinogen (r = 0.387, p = 0.004), <compound-id="1175">uric acid</compound-id> (r = 0.293, p = 0.033), hematocrit (r = 0.394, p = 0.003), systolic (r = 0.504, p &lt;0.0001), and diastolic blood pressure (r = 0.363, p = 0.008).	uric acid__leptin__no_interaction	uric acid__insulin__no_interaction
11149424-1	Evaluation of <compound-id="444795">retinoic acid</compound-id> receptor (RAR) subtype-selective alpha and gamma agonists and antagonists and a retinoid X receptor (RXR) class-selective agonist for efficacy at inhibiting both induction of <protein-id="P00860">ornithine decarboxylase</protein-id> (<protein-id="P00860">ODC</protein-id>) by the tumor promoter 12-<compound-id="18633279">O-tetradecanoylphorbol</compound-id>-13-<compound-id="176">acetate</compound-id> (<compound-id="122634,22833501">TPA</compound-id>) in mouse epidermis and rat tracheal epithelial cells and the appearance of papillomas in mouse epidermis treated in the 2-stage tumor initiation-promotion model indicated that (i) RXR class-selective transcriptional agonists, such as MM11246, were not involved in <protein-id="P00860">ODC</protein-id> inhibition; (ii) RAR-selective agonists that induce gene transcription from RA-responsive elements (RAREs) were active at low concentrations; (iii) RAR-selective antagonists that bind <protein-id="Q9D0I9">RARs</protein-id> and inhibit AP-1 activation on the collagenase promoter but do not activate RAREs to induce gene transcription were less effective inhibitors; and (iv) <protein-id="P18911">RARgamma</protein-id>-selective retinoid agonists were more effective inhibitors of <compound-id="122634,22833501">TPA</compound-id>-induced <protein-id="P00860">ODC</protein-id> activity than <protein-id="P11416,Q3U3R3,Q3U5E7">RARalpha</protein-id>-selective agonists.	O-tetradecanoylphorbol__ornithine decarboxylase__no_interaction	O-tetradecanoylphorbol__RARs__no_interaction	O-tetradecanoylphorbol__ODC__no_interaction	O-tetradecanoylphorbol__RARgamma__no_interaction	O-tetradecanoylphorbol__RARalpha__no_interaction	retinoic acid__ornithine decarboxylase__no_interaction	retinoic acid__RARs__no_interaction	retinoic acid__ODC__no_interaction	retinoic acid__RARgamma__no_interaction	retinoic acid__RARalpha__no_interaction	TPA__ornithine decarboxylase__no_interaction	TPA__RARs__no_interaction	TPA__ODC__no_interaction	TPA__RARgamma__no_interaction	TPA__RARalpha__no_interaction	acetate__ornithine decarboxylase__no_interaction	acetate__RARs__no_interaction	acetate__ODC__no_interaction	acetate__RARgamma__no_interaction	acetate__RARalpha__no_interaction
7769797-7	RAS activation was confirmed by 24-h urinary <compound-id="5360545">sodium</compound-id> excretion (screen, 142 +/- 74 mmol/24 h; prestudy, 66 +/- 33, 59 +/- 41, 78 +/- 4, 73 +/- 30 mmol/24 h) and increase in plasma <protein-id="P00797">renin</protein-id> activity (PRA) (screen, 0.8 +/- 0.3 ng <compound-id="15942654">AI</compound-id>/ml/h; before dosing, P, 6.5 +/- 3.1; 30 mg, 8.2 +/- 3; 100 mg, 9.4 +/- 5.7; 300 mg, 6.5 +/- 2.4; 600 mg, 5.2 +/- 2; 1,000 mg, 6.2 +/- 4.4 ng <compound-id="15942654">AI</compound-id>/ml/h).	AI__renin__no_interaction	sodium__renin__no_interaction
24005498-1	The reaction of <compound-id="9559">tetrapropylammonium</compound-id> bis(acetylacetonato)<compound-id="23985">gold</compound-id>(I) with alkyne derivatives of the <compound-id="5243808">tris(pyrazolyl)methane</compound-id> and 1,8-<compound-id="66491">naphthalimide</compound-id> functional groups yielded two new compounds, both bridged by the linear C[triple-bond]C-Au-C[triple-bond]C spacer, namely <compound-id="9559">tetrapropylammonium</compound-id> bis{3-[2,2,2-<compound-id="6503">tris</compound-id>(1H-pyrazol-1-yl)ethoxy]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-1-yl}aurate(I), (C16H28N)[Au(C14H13N6O)2], and <compound-id="9559">tetrapropylammonium</compound-id> {η(2)-μ-3-[2,4-dioxo-3-azatricyclo[7.3.1.0(5,13)]trideca-1(12),5,7,9(13),10-pentaen-3-yl]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-yl}bis{3-[2,4-dioxo-3-azatricyclo[7.3.1.0(5,13)]trideca-1(12),5,7,9(13),10-pentaen-3-yl]<protein-id="O75360,A0A0G2JQ02">prop-1</protein-id>-yn-1-yl}digold(I) <compound-id="71583">deuterochloroform</compound-id> disolvate, (C16H28N)[Au2(C15H8NO2)3]·2CDCl3.	tris(pyrazolyl)methane__prop-1__no_interaction	deuterochloroform__prop-1__no_interaction	tetrapropylammonium__prop-1__no_interaction	naphthalimide__prop-1__no_interaction	gold__prop-1__no_interaction	tris__prop-1__no_interaction
11894121-8	We found that: i) pretreatment with <compound-id="53232">lovastatin</compound-id> (5-30 microM) induces apoptosis in HT-29 cells significantly only at high concentrations (&gt; or = 20 microM) but not at low dose levels; ii) similarly, pretreatment with <compound-id="2662">celecoxib</compound-id> produced apoptosis in colon cancer cells at high concentrations only (&gt; or = 75 microM); iii) <protein-id="P42574">caspase-3</protein-id> protein expression was moderately altered by the treatment with <compound-id="53232">lovastatin</compound-id> or <compound-id="2662">celecoxib</compound-id> at lower concentrations; however, a significant increase (1.6 to 4-fold) in <protein-id="P42574">caspase-3</protein-id> expression and activity was found in HT-29 cells exposed with 20-25 microM <compound-id="53232">lovastatin</compound-id> and/or 5-125 microM <compound-id="2662">celecoxib</compound-id> and iv) importantly, in tumor cells exposed to low doses of (5 or 10 microM) <compound-id="53232">lovastatin</compound-id>, combined with 25-75 microM of <compound-id="2662">celecoxib</compound-id>, apoptosis induction rose 2.5 to 10-fold, <protein-id="P42574">caspase-3</protein-id> expression was 2.3 to 8-fold higher, and enzyme activities were 1.5 to 5.5-fold elevated.	lovastatin__caspase-3__no_interaction	celecoxib__caspase-3__no_interaction
16130178-3	As part of a program aimed at the design of selective agonists for the human V(1b) receptor, we recently reported the human V(1b), <protein-id="P30560">V(1a</protein-id>), V(2) and OT receptor affinities of the following position 4 substituted analogues of [deamino-Cys(1)] <protein-id="P01185,X5DQP6">arginine vasopressin</protein-id> (dAVP)-(1) d[Leu(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (2) d[Orn(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (3) d[<compound-id="5962">Lys</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (4) d[<compound-id="123895">Har</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (5) d[Arg(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (6) d[Val(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (7) d[Ala(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (8) d[Abu(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (9) d[<compound-id="824">Nva</compound-id>(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (10) d[Nle(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (11) d[Ile(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (12) d[Phe(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (13) d[Asn(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>, (14) d[Thr(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>: (15) d[Dap(4)]<protein-id="P01185,X5DQP6">AVP</protein-id>.	Har__V(1a__no_interaction	Har__arginine vasopressin__no_interaction	Har__AVP__no_interaction	Nva__V(1a__no_interaction	Nva__arginine vasopressin__no_interaction	Nva__AVP__no_interaction	Lys__V(1a__no_interaction	Lys__arginine vasopressin__no_interaction	Lys__AVP__no_interaction
